<SEC-DOCUMENT>0001829126-26-006917.txt : 20260626
<SEC-HEADER>0001829126-26-006917.hdr.sgml : 20260626
<ACCEPTANCE-DATETIME>20260626115055
ACCESSION NUMBER:		0001829126-26-006917
CONFORMED SUBMISSION TYPE:	S-4/A
PUBLIC DOCUMENT COUNT:		132
FILED AS OF DATE:		20260626
DATE AS OF CHANGE:		20260626

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			D. Boral ARC Acquisition I Corp.
		CENTRAL INDEX KEY:			0002065779
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-PREPACKAGED SOFTWARE [7372]
		ORGANIZATION NAME:           	06 Technology
		EIN:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-295869
		FILM NUMBER:		261125854

	BUSINESS ADDRESS:	
		STREET 1:		10 EAST 53RD STREET, SUITE 3001
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		332-266-7344

	MAIL ADDRESS:	
		STREET 1:		10 EAST 53RD STREET, SUITE 3001
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Exascale Labs Inc.
		CENTRAL INDEX KEY:			0002110790
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-PREPACKAGED SOFTWARE [7372]
		ORGANIZATION NAME:           	06 Technology
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-295869-01
		FILM NUMBER:		261125856

	BUSINESS ADDRESS:	
		STREET 1:		820 GESSNER RD
		STREET 2:		SUITE 332
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77024
		BUSINESS PHONE:		617-902-0530

	MAIL ADDRESS:	
		STREET 1:		820 GESSNER RD
		STREET 2:		SUITE 332
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77024

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			D. Boral ARC Merger Corp
		CENTRAL INDEX KEY:			0002109869
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-295869-02
		FILM NUMBER:		261125855

	BUSINESS ADDRESS:	
		STREET 1:		10 EAST 53RD STREET, SUITE 3001
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		(332) 266-7344

	MAIL ADDRESS:	
		STREET 1:		10 EAST 53RD STREET, SUITE 3001
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4/A
<SEQUENCE>1
<FILENAME>dboralarcacq_s4a.htm
<DESCRIPTION>S-4/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cik0002065779="http://cik0002065779/20260331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2025%2D(with%2DECD)_rempres -->
<!-- Field: Set; Name: xdx; ID: xdx_038_cik0002065779_cik0002065779_20260331 -->
<!-- Field: Set; Name: xdx; ID: xdx_041_20260101_20260331 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DAmendmentFlag_true -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0002065779 -->
<!-- Field: Set; Name: xdx; ID: xdx_07A_XDX_dboralarcacq__s4a.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Ratio_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000003" name="dei:AmendmentFlag">true</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000004" name="dei:EntityCentralIndexKey">0002065779</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-12-31" id="xdx2ixbrl0039" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-12-31" id="xdx2ixbrl0057" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-12-192025-12-31" id="xdx2ixbrl0065" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-18_us-gaap_CommonStockMember" id="xdx2ixbrl0077" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-18_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0078" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-18_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0079" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-18_custom_SubscriptionReceivableMember" id="xdx2ixbrl0080" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-18" id="xdx2ixbrl0081" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-18_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember" id="xdx2ixbrl0083" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee" contextRef="From2025-12-192025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0085" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee" contextRef="From2025-12-192025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0087" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee" contextRef="From2025-12-192025-12-31" id="xdx2ixbrl0089" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-12-192025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0093" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-12-192025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0094" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-12-192025-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0096" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0099" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-12-192025-12-31" id="xdx2ixbrl0117" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-12-192025-12-31" id="xdx2ixbrl0121" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-12-192025-12-31" id="xdx2ixbrl0125" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2025-12-192025-12-31" id="xdx2ixbrl0127" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-12-18" id="xdx2ixbrl0129" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-12-31" id="xdx2ixbrl0131" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:AmountDueToRelatedParty" contextRef="AsOf2025-12-31" id="xdx2ixbrl0197" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-12-31" id="xdx2ixbrl0209" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2026-03-31" id="xdx2ixbrl0210" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-12-31" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2026-03-31" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2026-01-01to2026-03-31" id="xdx2ixbrl0241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0252" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2026-01-012026-03-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2026-01-01to2026-03-31" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2026-01-01to2026-03-31" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2026-01-01to2026-03-31" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2026-01-01to2026-03-31" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-12-31" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2026-03-31" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-19_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-19_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-19_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-19_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-19_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-19_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-19_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0454" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-19_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0456" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ClassBOrdinarySharesIssuedToSponsor" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ClassBOrdinarySharesIssuedToSponsor" contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ClassBOrdinarySharesIssuedToSponsor" contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts" contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0470" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts" contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts" contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts" contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:IssuanceOfRepresentativeShares" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:IssuanceOfRepresentativeShares" contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:IssuanceOfRepresentativeShares" contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:AccretionInValueOfClassOrdinaryShares" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:AccretionInValueOfClassOrdinaryShares" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:AccretionInValueOfClassOrdinaryShares" contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ReverseOverallotmentOptionLiability" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ReverseOverallotmentOptionLiability" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ReverseOverallotmentOptionLiability" contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ForfeitureOfFounderShares" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ForfeitureOfFounderShares" contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ForfeitureOfFounderShares" contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ForfeitureOfFounderShares" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:AdjustmentOfAccruedOfferingCosts" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:AdjustmentOfAccruedOfferingCosts" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0516" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:AdjustmentOfAccruedOfferingCosts" contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0518" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:AdjustmentOfAccruedOfferingCosts" contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0519" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0522" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0524" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0526" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0531" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0533" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-03-19_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl0580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1070" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1071" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1121" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1122" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1139" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1142" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1148" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1150" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1182" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1184" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:AccretionInValueOfClassOrdinaryShares" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember62738953" id="xdx2ixbrl1191" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:AccretionInValueOfClassOrdinaryShares" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738953" id="xdx2ixbrl1192" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:AccretionInValueOfClassOrdinaryShares" contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1193" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:AccretionInValueOfClassOrdinaryShares" contextRef="From2026-01-012026-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1195" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember62738953" id="xdx2ixbrl1198" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738953" id="xdx2ixbrl1199" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1200" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2026-01-012026-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1202" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1207" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1209" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-19_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1216" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-19_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1217" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-19_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-19_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1219" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-19_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1220" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-19_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1221" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-19_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1223" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-19_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1225" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ClassBOrdinarySharesIssuedToSponsor" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember62738968" id="xdx2ixbrl1227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ClassBOrdinarySharesIssuedToSponsor" contextRef="From2025-03-202025-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ClassBOrdinarySharesIssuedToSponsor" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember62738968" id="xdx2ixbrl1236" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738984" id="xdx2ixbrl1237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-03-202025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-03-202025-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1240" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1250" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:PaymentOfExpensesThroughPromissoryNoteRelatedParty" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1265" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1273" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireRestrictedInvestments" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireRestrictedInvestments" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-03-19_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionInventoryAcquired1" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1491" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="xdx2ixbrl1493" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="xdx2ixbrl1848" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="xdx2ixbrl1849" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-07-012024-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl1883" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl1884" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl1888" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl1890" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-07-012025-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl1900" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl1901" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl1905" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl1907" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="xdx2ixbrl1995" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="xdx2ixbrl1996" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="xdx2ixbrl1998" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="xdx2ixbrl1999" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2098" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2217" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2221" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2227" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2231" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2235" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2244" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2248" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2258" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012024-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2272" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2278" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ConcentrationRiskPercentage" contextRef="From2023-07-012024-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2282" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ConcentrationRiskPercentage" contextRef="From2023-07-012024-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2286" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="xdx2ixbrl2470" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="xdx2ixbrl2471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_custom_SellingAndMarketingExpensesMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2508" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-06-30_custom_GeneralAndAdministrativeExpensesMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ShareBasedCompensations" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="xdx2ixbrl2606" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ShareBasedCompensation1" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="xdx2ixbrl2619" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="xdx2ixbrl2630" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="xdx2ixbrl2631" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:U.s.DollarCoin" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="xdx2ixbrl2692" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:PrepaidResearchAndDevelopmentExpenses" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="xdx2ixbrl2698" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl2708" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl2762" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-06-30_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2780" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-06-30_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2792" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl2863" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl2864" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl2865" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl2866" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2914" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2915" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2919" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2921" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2938" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-07-012025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2939" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2943" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2945" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2956" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2957" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2964" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2966" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:RedesignationOfAuthorizedOrdinaryShares" contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2971" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:RedesignationOfAuthorizedOrdinaryShares" contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2972" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:RedesignationOfAuthorizedOrdinaryShares" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl2973" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2981" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2982" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2983" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2984" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2988" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl2995" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3002" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3003" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3010" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3012" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:RedesignationOfAuthorizedOrdinaryShares" contextRef="From2025-07-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3017" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:RedesignationOfAuthorizedOrdinaryShares" contextRef="From2025-07-012026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3018" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:RedesignationOfAuthorizedOrdinaryShares" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3019" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3027" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-07-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3028" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-07-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3029" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-07-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3030" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3034" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3041" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3060" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3065" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3077" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ProceedsFromSaleOfDigitalAssetsAndUsdc" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3104" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3108" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:PaymentForDeferredOfferingCosts" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3116" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ProceedsFromSimpleAgreementsForFutureEquity" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3120" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3137" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3138" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3140" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3141" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesAssumed1" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3143" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LoansAssumed1" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3146" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3426" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3430" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3444" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3448" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3450" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3452" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3456" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3458" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3460" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3464" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3468" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3470" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3472" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3572" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3574" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3582" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3591" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3593" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3599" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3601" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetFairValue" contextRef="AsOf2025-06-30_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3611" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetFairValue" contextRef="AsOf2025-06-30_custom_USDCMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3613" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetFairValue" contextRef="AsOf2026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3627" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ShareBasedCompensations" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3876" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik0002065779:ShareBasedCompensations" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3878" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3905" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3906" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3907" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="xdx2ixbrl3908" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2026-01-012026-03-31_custom_OthersMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3959" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-07-012026-03-31_custom_OthersMember_custom_ExascaleLabsIncMember" id="xdx2ixbrl3963" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cik0002065779-20260331.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2026-01-01to2026-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassAOrdinarySharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassBOrdinarySharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassAOrdinarySharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassBOrdinarySharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassAOrdinarySharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassAOrdinarySharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassBOrdinarySharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassBOrdinarySharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-12-192025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-19</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-18_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-18_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-18_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-18_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-18_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralArcMergerCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralArcMergerCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-19_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-19_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-19_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-19_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-19_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-19_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-12-192025-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-19</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-12-192025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-19</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-12-192025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-19</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-12-192025-12-31_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-19</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-12-192025-12-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralArcMergerCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-19</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember62738953">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738953">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember62738968">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738984">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralArcMergerCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-01-11_custom_DBoralARCAcquisitionICorp.Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cik0002065779:DBoralARCAcquisitionICorp.Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-01-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-11_custom_DBoralARCAcquisitionICorp.Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cik0002065779:DBoralARCAcquisitionICorp.Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-12-192025-12-31_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-19</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember62742453">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-29</xbrli:startDate>
        <xbrli:endDate>2025-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-29</xbrli:startDate>
        <xbrli:endDate>2025-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-29</xbrli:startDate>
        <xbrli:endDate>2025-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:UnderwriterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-29</xbrli:startDate>
        <xbrli:endDate>2025-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-02</xbrli:startDate>
        <xbrli:endDate>2025-08-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-052025-09-09_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-05</xbrli:startDate>
        <xbrli:endDate>2025-09-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-29</xbrli:startDate>
        <xbrli:endDate>2025-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-12-31_custom_FounderSharesMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:FounderSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-292025-08-01_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-29</xbrli:startDate>
        <xbrli:endDate>2025-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_FounderSharesMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:FounderSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-022025-12-31_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-02</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-012025-03-25_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:FounderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-01</xbrli:startDate>
        <xbrli:endDate>2025-03-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-25_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:FounderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-12-31_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:FounderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_UnsecuredPromissoryNoteMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cik0002065779:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-12-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-12-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:FounderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-12-31_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-12-31_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:UnderwriterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:UnderwriterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-012025-03-25_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-01</xbrli:startDate>
        <xbrli:endDate>2025-03-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-25_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-012025-03-25_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:ClassAOrdinarySharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-01</xbrli:startDate>
        <xbrli:endDate>2025-03-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-11_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-12-31_custom_CommonStockClassBMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:CommonStockClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantsMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cik0002065779:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_ClassAOrdinaryShareMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassAOrdinaryShareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ConversionOfClassBToClassACommonStockMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cik0002065779:ConversionOfClassBToClassACommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_CommonStockClassBMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:CommonStockClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_WarrantsMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cik0002065779:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-01_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cik0002065779:PublicWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-292025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cik0002065779:PublicWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-29</xbrli:startDate>
        <xbrli:endDate>2025-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-01_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-01_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-12-012025-12-16_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:EvanaAlphaPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-01</xbrli:startDate>
        <xbrli:endDate>2025-12-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-08_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-08_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassAOrdinarySharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-08_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassBOrdinarySharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:ReservedCapacityArrangementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:ReservedCapacityArrangementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:OnDemandArrangementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:OnDemandArrangementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:ReservedCapacityArrangementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:ReservedCapacityArrangementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:ReservedCapacityArrangementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:ReservedCapacityArrangementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:OnDemandArrangementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:OnDemandArrangementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:OnDemandArrangementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:OnDemandArrangementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromComprehensiveDataCenterServicesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromComprehensiveDataCenterServicesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromComprehensiveDataCenterServicesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromComprehensiveDataCenterServicesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromComprehensiveDataCenterServicesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromComprehensiveDataCenterServicesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerGMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerGMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerHMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerHMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerIMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerIMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerGMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerHMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerIMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerIMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerIMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerIMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_PurchaseMember_custom_SupplierAMember_us-gaap_CustomerConcentrationRiskMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierFMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierFMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember62755093">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember62755109">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierFMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierFMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_custom_SupplierGMember_us-gaap_CustomerConcentrationRiskMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierGMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierGMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierGMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012025-06-30_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-06_us-gaap_SubsequentEventMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012026-03-31_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_DomesticCountryMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_DomesticCountryMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_StateAndLocalJurisdictionMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_StateAndLocalJurisdictionMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cik0002065779:EvanaAlphaPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:EmployeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_NonEmployeeMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:NonEmployeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_ThirdPartyServiceProviderMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:ThirdPartyServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_ThirdPartyServiceProviderMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:ThirdPartyServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-06_custom_EmployeeMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:EmployeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_EmployeeMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:EmployeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-02_custom_NonEmployeeMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:NonEmployeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_NonEmployeeMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:NonEmployeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_SellingAndMarketingExpensesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cik0002065779:IncomeStatementLocationsAxis">cik0002065779:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_SellingAndMarketingExpensesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cik0002065779:IncomeStatementLocationsAxis">cik0002065779:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_GeneralAndAdministrativeExpensesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cik0002065779:IncomeStatementLocationsAxis">cik0002065779:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_GeneralAndAdministrativeExpensesMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cik0002065779:IncomeStatementLocationsAxis">cik0002065779:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_country_SG_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_country_SG_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_country_US_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_country_US_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_country_CA_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_country_CA_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_country_HK_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_country_HK_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_country_GB_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_country_GB_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_OthersMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cik0002065779:OthersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_OthersMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cik0002065779:OthersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_country_US_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_country_US_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_country_US_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_country_US_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_country_CA_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_country_CA_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_country_CA_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_country_CA_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_country_SG_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_country_SG_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_country_SG_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_country_SG_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_country_HK_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_country_HK_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_country_HK_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_country_HK_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_country_GB_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_country_GB_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_country_GB_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_country_GB_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_OthersMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cik0002065779:OthersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_OthersMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cik0002065779:OthersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-03-31_custom_OthersMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cik0002065779:OthersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_OthersMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cik0002065779:OthersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-012026-02-11_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:EvanaAlphaPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-01</xbrli:startDate>
        <xbrli:endDate>2026-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-01-31_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:DigitalAssetsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_USDCMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:USDCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:DigitalAssetsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_USDCMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:USDCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:DigitalAssetsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_USDCMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:USDCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:DigitalAssetsAndUSDCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Ratio">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact001118" toRefs="Footnote001253"/>
  <ix:relationship fromRefs="Fact001119" toRefs="Footnote001253"/>
  <ix:relationship fromRefs="xdx2ixbrl1227" toRefs="Footnote001253"/>
  <ix:relationship fromRefs="Fact001228" toRefs="Footnote001253"/>
  <ix:relationship fromRefs="Fact001229" toRefs="Footnote001253"/>
  <ix:relationship fromRefs="xdx2ixbrl1230" toRefs="Footnote001253"/>
  <ix:relationship fromRefs="Fact001231" toRefs="Footnote001253"/>
  <ix:relationship fromRefs="xdx2ixbrl1232" toRefs="Footnote001253"/>
  <ix:relationship fromRefs="Fact002299" toRefs="Footnote002330"/>
  <ix:relationship fromRefs="xdx2ixbrl2301" toRefs="Footnote002330"/>
  <ix:relationship fromRefs="xdx2ixbrl2303" toRefs="Footnote002330"/>
  <ix:relationship fromRefs="Fact002305" toRefs="Footnote002330"/>
  <ix:relationship fromRefs="Fact002315" toRefs="Footnote002330"/>
  <ix:relationship fromRefs="xdx2ixbrl2317" toRefs="Footnote002330"/>
  <ix:relationship fromRefs="xdx2ixbrl2319" toRefs="Footnote002330"/>
  <ix:relationship fromRefs="Fact002321" toRefs="Footnote002330"/>
  <ix:relationship fromRefs="Fact002307" toRefs="Footnote002331"/>
  <ix:relationship fromRefs="xdx2ixbrl2309" toRefs="Footnote002331"/>
  <ix:relationship fromRefs="xdx2ixbrl2311" toRefs="Footnote002331"/>
  <ix:relationship fromRefs="Fact002313" toRefs="Footnote002331"/>
  <ix:relationship fromRefs="Fact002323" toRefs="Footnote002331"/>
  <ix:relationship fromRefs="xdx2ixbrl2325" toRefs="Footnote002331"/>
  <ix:relationship fromRefs="xdx2ixbrl2327" toRefs="Footnote002331"/>
  <ix:relationship fromRefs="Fact002329" toRefs="Footnote002331"/>
  <ix:relationship fromRefs="Fact002569" toRefs="Footnote002584"/>
  <ix:relationship fromRefs="Fact002571" toRefs="Footnote002584"/>
  <ix:relationship fromRefs="Fact002573" toRefs="Footnote002584"/>
  <ix:relationship fromRefs="Fact002575" toRefs="Footnote002584"/>
  <ix:relationship fromRefs="Fact003570" toRefs="Footnote003604"/>
  <ix:relationship fromRefs="xdx2ixbrl3572" toRefs="Footnote003604"/>
  <ix:relationship fromRefs="xdx2ixbrl3574" toRefs="Footnote003604"/>
  <ix:relationship fromRefs="Fact003576" toRefs="Footnote003604"/>
  <ix:relationship fromRefs="Fact003589" toRefs="Footnote003604"/>
  <ix:relationship fromRefs="xdx2ixbrl3591" toRefs="Footnote003604"/>
  <ix:relationship fromRefs="xdx2ixbrl3593" toRefs="Footnote003604"/>
  <ix:relationship fromRefs="Fact003595" toRefs="Footnote003604"/>
  <ix:relationship fromRefs="Fact003578" toRefs="Footnote003605"/>
  <ix:relationship fromRefs="xdx2ixbrl3580" toRefs="Footnote003605"/>
  <ix:relationship fromRefs="xdx2ixbrl3582" toRefs="Footnote003605"/>
  <ix:relationship fromRefs="Fact003584" toRefs="Footnote003605"/>
  <ix:relationship fromRefs="Fact003597" toRefs="Footnote003605"/>
  <ix:relationship fromRefs="xdx2ixbrl3599" toRefs="Footnote003605"/>
  <ix:relationship fromRefs="xdx2ixbrl3601" toRefs="Footnote003605"/>
  <ix:relationship fromRefs="Fact003603" toRefs="Footnote003605"/>
  <ix:relationship fromRefs="Fact003615" toRefs="Footnote003630"/>
  <ix:relationship fromRefs="Fact003617" toRefs="Footnote003630"/>
  <ix:relationship fromRefs="Fact003623" toRefs="Footnote003631"/>
  <ix:relationship fromRefs="Fact003625" toRefs="Footnote003631"/>
  <ix:relationship fromRefs="Fact003799" toRefs="Footnote003835"/>
  <ix:relationship fromRefs="Fact003801" toRefs="Footnote003835"/>
  <ix:relationship fromRefs="Fact003803" toRefs="Footnote003835"/>
  <ix:relationship fromRefs="Fact003805" toRefs="Footnote003835"/>
  <ix:relationship fromRefs="Fact003807" toRefs="Footnote003835"/>
  <ix:relationship fromRefs="Fact003809" toRefs="Footnote003835"/>
  <ix:relationship fromRefs="Fact003811" toRefs="Footnote003835"/>
  <ix:relationship fromRefs="Fact003813" toRefs="Footnote003835"/>
  <ix:relationship fromRefs="Fact003820" toRefs="Footnote003836"/>
  <ix:relationship fromRefs="Fact003822" toRefs="Footnote003836"/>
  <ix:relationship fromRefs="Fact003824" toRefs="Footnote003836"/>
  <ix:relationship fromRefs="Fact003826" toRefs="Footnote003836"/>
  <ix:relationship fromRefs="Fact003828" toRefs="Footnote003836"/>
  <ix:relationship fromRefs="Fact003830" toRefs="Footnote003836"/>
  <ix:relationship fromRefs="Fact003832" toRefs="Footnote003836"/>
  <ix:relationship fromRefs="Fact003834" toRefs="Footnote003836"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As filed
with the U.S. Securities and Exchange Commission on June&#160;11, 2026. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><b>Registration
No. 333-295869</b></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/>Washington,
D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b><span id="xdx_904_edei--AmendmentDescription_c20260101__20260331_zbdD7HpbRWH6"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000010" name="dei:AmendmentDescription">Amendment
No. 1</ix:nonNumeric></span> to</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b><br/> FORM <span id="xdx_902_edei--DocumentType_c20260101__20260331_zOBDpUjJJFoa"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000011" name="dei:DocumentType">S-4</ix:nonNumeric></span></b></span><b><br/></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>REGISTRATION STATEMENT<br/><i>UNDER<br/>THE SECURITIES
ACT OF 1933</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>D.
Boral ARC Merger Corporation*</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Exact name of registrant as specified in its charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span id="xdx_903_edei--EntityRegistrantName_c20260101__20260331_zrVyEvKSm3Wh" style="display: none"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000012" name="dei:EntityRegistrantName">D. Boral ARC Acquisition I Corp.&#160;</ix:nonNumeric></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20260101__20260331_zOeXcrK4npW4"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-size: 10pt"><b>6770</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 32%"><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20260101__20260331_zd8yIj77pGil"><b><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000014" name="dei:EntityTaxIdentificationNumber">42-3035215</ix:nonNumeric></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>(State or other jurisdiction of<br/> incorporation or
        organization)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>(Primary Standard Industrial<br/> Classification Code
        Number)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>(I.R.S. Employer<br/> Identification Number)</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20260101__20260331_zx0fuc0hvlmj"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000015" name="dei:EntityAddressAddressLine1">10 East 53rd Street</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressAddressLine2_c20260101__20260331_zQMVn05K697e"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 3001</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_907_edei--EntityAddressCityOrTown_c20260101__20260331_zBKmQ2a3WEDi"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000017" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressStateOrProvince_c20260101__20260331_zaSiBNHpRPre"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000018" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_90E_edei--EntityAddressPostalZipCode_c20260101__20260331_zUBCRUhBKGzf"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000019" name="dei:EntityAddressPostalZipCode">10022</ix:nonNumeric></span><br/>Tel. No. (<span id="xdx_90B_edei--CityAreaCode_c20260101__20260331_zDjVnsnqsogb"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000020" name="dei:CityAreaCode">332</ix:nonNumeric></span>) <span id="xdx_908_edei--LocalPhoneNumber_c20260101__20260331_zyXixzcCUg47"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000021" name="dei:LocalPhoneNumber">266-7344</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Address, including zip code, and telephone number,
including area code, of registrant&#8217;s principal executive offices)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>David Boral</b><br/><b>10 East 53rd Street, Suite
3001</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>New York, NY 10022<br/>Tel. No. (332) 266-7344</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Name, address, including zip code, and telephone
number, including area code, of agent for service)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><i>Copies to:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="text-align: center; vertical-align: top; width: 32%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Mitchell Nussbaum, Esq.</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>David Levine, Esq.</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Terry Bokosha, Esq.</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Loeb &amp; Loeb LLP<br/>
        345 Park Avenue<br/> New York, New York 10154<br/> Tel: (212) 407-4000</b></p></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="text-align: center; width: 32%"><b>Jose Santos<br/> Michael Doyle<br/> Forbes Hare<br/> Qwomar Building<br/> Road Town, Tortola<br/>
        British Virgin Islands<br/> Tel: (284) 542 1899</b></td>
    <td style="font-size: 10pt; text-align: center; width: 2%">&#160;</td>
    <td style="text-align: center; vertical-align: top; width: 32%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Kelvin Kesse, Esq.</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Kesse PLLC<br/> 845 Texas
        Ave, Suite 200<br/> Houston, Texas 77002<br/> Tel: (346) 348-0239</b></p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Approximate date of commencement of proposed sale
of the securities to the public: </b>As soon as practicable after this registration statement becomes effective and all other conditions
to the transactions contemplated by the Business Combination Agreement described in the included proxy statement/prospectus have been
satisfied or waived.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the securities being registered on this Form are
being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following
box.&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering.&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If this Form is a post-effective amendment filed pursuant
to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering.&#160;&#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 22%; text-align: justify; vertical-align: bottom">Large accelerated filer</td>
    <td style="width: 28%; text-align: justify; vertical-align: bottom">&#9744;</td>
    <td style="width: 25%; text-align: justify; vertical-align: bottom">Accelerated filer</td>
    <td style="width: 25%; text-align: justify; vertical-align: bottom">&#9744;</td> </tr>
  <tr>
    <td style="text-align: justify; vertical-align: bottom"><span id="xdx_90F_edei--EntityFilerCategory_c20260101__20260331_zTc3AP4XJkah"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" format="ixt-sec:entityfilercategoryen" id="Fact000022" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></td>
    <td style="text-align: justify; vertical-align: bottom">&#9746;</td>
    <td style="text-align: justify; vertical-align: bottom">Smaller reporting company</td>
    <td style="text-align: justify; vertical-align: bottom"><span id="xdx_90E_edei--EntitySmallBusiness_c20260101__20260331_zL9tmp2YPET4"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" format="ixt:booleantrue" id="Fact000023" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></td> </tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">Emerging growth company</td>
    <td style="text-align: justify; vertical-align: bottom"><span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20260101__20260331_zA34wDKfZGbf"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" format="ixt:booleantrue" id="Fact000024" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 7(a)(2)(B) of the Securities Act.&#160;<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_edei--EntityExTransitionPeriod_c20260101__20260331_ze2oLlaCdvWk"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" format="ixt:booleanfalse" id="Fact000025" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If applicable, place an X in the box to designate
the appropriate rule provision relied upon in conducting this transaction:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exchange Act Rule 13e-4(i) (Cross-Border Issuer
Tender Offer) <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exchange Act Rule 14d-1(d) (Cross-Border Third-Party
Tender Offer) <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>The registrant and co-registrant hereby amend this
registration statement on such date or dates as may be necessary to delay its effective date until the registrant and co-registrant shall
file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with
Section 8(a) of the Securities Act or until the registration statement shall become effective on such date as the SEC, acting pursuant
to said Section 8(a), may determine.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">*</td>
    <td style="text-align: justify">D. Boral ARC Acquisition I Corp. (&#8220;<b>BCAR</b>&#8221;), will merge with and into its wholly owned subsidiary,
        D. Boral ARC Merger Corporation, with D. Boral ARC Merger Corporation continuing as the surviving company (such surviving company, &#8220;<b>PubCo</b>&#8221;)
        and as a result of such merger, the jurisdiction of incorporation will be changed from the British Virgin Islands to the State of Delaware.
        All securities being registered will be issued by PubCo (after its domestication in Delaware, through the merger with BCAR). The surviving
        entity following such domestication will be renamed Exascale Labs Holdings Inc.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>TABLE OF CO-REGISTRANT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><b>Exact Name of Co-Registrant as
        Specified in its Charter<sup>(1)(2)</sup></b></td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">
        <p style="margin-top: 0; margin-bottom: 0">State or Other<br/> Jurisdiction&#160;of<br/> Incorporation&#160;or</p>
        <p style="margin-top: 0; margin-bottom: 0">Organization</p></td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Primary<br/> Standard<br/> Industrial<br/> Classification<br/>
        Code&#160;Number</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">I.R.S. Employer<br/> Identification<br/> Number</td>
    <td style="padding-bottom: 1pt">&#160;</td> </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Exascale Labs Inc.</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center"><b>Delaware</b></td>
    <td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; font-weight: bold; text-align: center">7372</td>
    <td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; font-weight: bold; text-align: center">88-2603290</td>
    <td style="width: 1%">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><sup>(1)</sup>&#160;</td>
    <td style="text-align: justify">The co-registrant has the following principal executive office address:</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">820 Gessner Road, Suite 332</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Houston, TX 77024</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><sup>(2)</sup>&#160;</td>
    <td style="text-align: justify">The agent for service for the co-registrant is:</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Exascale Labs Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Attn: Hoansoo Lee</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">820 Gessner Road, Suite 332</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Houston, TX 77024</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: Red">The information in this proxy
statement/prospectus is not complete and may be changed. D. Boral ARC Merger Corporation may not issue the securities offered by this
proxy statement/prospectus until the registration statement filed with the Securities and Exchange Commission, of which this proxy statement/prospectus
is a part, is declared effective. This proxy statement/prospectus does not constitute an offer to sell these securities and it is not
soliciting an offer to buy these securities in any jurisdiction where the offer or sale of these securities is not permitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="color: Red;"><b>PRELIMINARY
&#8212; SUBJECT TO COMPLETION, DATED JUNE&#160;11, 2026</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING
OF</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt"><b>D. BORAL ARC ACQUISITION
I CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(a British Virgin Islands business company)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FOR UP TO 60,456,000 SHARES OF CLASS A ORDINARY
COMMON STOCK,</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>30,744,000 SHARES OF CLASS B SUPER COMMON STOCK,
AND</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>14,100,000 WARRANTS TO PURCHASE SHARES OF CLASS
A ORDINARY COMMON STOCK</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(<i>For Issuance</i>)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>OF</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>D. BORAL ARC MERGER CORPORATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(to be renamed &#8220;Exascale Labs Holdings Inc.&#8221;
in connection with the Business Combination described herein)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 11, 2026, D. Boral ARC Acquisition
I Corp., a British Virgin Islands business company (&#8220;<b>BCAR</b>&#8221; or the &#8220;<b>Parent</b>&#8221;), entered into that certain
Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the &#8220;<b>Business Combination
Agreement</b>&#8221;), by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and a direct, wholly owned subsidiary
of BCAR (&#8220;<b>PubCo</b>&#8221;), D. Boral Arc Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary of BCAR
(&#8220;<b>Merger Sub</b>&#8221;), and Exascale Labs Inc., a Delaware corporation (the &#8220;<b>Company</b>&#8221; or &#8220;<b>Exascale</b>&#8221;).
Capitalized terms used but not defined herein shall have the meaning given to them in the Business Combination Agreement. A copy of the
Business Combination Agreement is attached to this proxy statement/prospectus as <i>Annex A.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale is a next-generation artificial intelligence
(&#8220;<b>AI</b>&#8221;) infrastructure provider operating an asset-light, software-defined graphics processing unit (&#8220;<b>GPU</b>&#8221;)
compute platform and related AI infrastructure solutions. Exascale&#8217;s core business includes GPU-as-a-Service (&#8220;<b>GaaS</b>&#8221;),
through which it provides reserved and on-demand access to high-performance GPU compute capacity sourced from third-party data centers
globally, as well as GPU cluster management and optimization services for AI data center (&#8220;<b>AIDC</b>&#8221;) operators. In addition,
Exascale has developed certain modular data center, high-density liquid cooling, high-voltage direct current (&#8220;<b>HVDC</b>&#8221;)
power and energy storage solutions that are designed to address deployment bottlenecks in AI infrastructure and that Exascale believes
are ready for commercial engagement, although these capabilities have not yet generated revenue as of the date of this proxy statement/prospectus.
The platform is purpose-built for large-scale AI workloads, including large language model (&#8220;<b>LLM</b>&#8221;) training, fine-tuning,
and high-concurrency inference. Additional information about Exascale is set forth in the section titled &#8220;<i>Information about Exascale</i>&#8221;
in this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Business Combination Agreement provides that,
among other things and upon the terms and subject to the conditions thereof, the following transactions will occur (together with the
other agreements and transactions contemplated by the Business Combination Agreement, the &#8220;<b>Business Combination</b>&#8221;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">(i)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Subject to the conditions of the Business Combination Agreement,
        BCAR shall continue out of the British Virgin Islands and into the State of Delaware so as to re-domicile as and become a Delaware corporation
        by means of a merger of BCAR with and into PubCo (the &#8220;<b>Domestication Merger</b>&#8221;), with PubCo continuing as the surviving
        company pursuant to the Business Companies Act, (Revised Edition 2020) as amended, of the British Virgin Islands and Section 388 and other
        applicable provisions of the General Corporation Law of the State of Delaware (the &#8220;<b>DGCL</b>&#8221;). Upon the Domestication
        Merger, PubCo shall change its name to &#8220;Exascale Labs Holdings Inc.&#8221;; and, thereafter</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">(ii)</td>
    <td style="text-align: justify">Merger Sub shall be merged with and into the Company, the separate corporate existence of Merger Sub shall
        thereupon cease, and the Company shall continue as the surviving corporation and become a wholly-owned subsidiary of PubCo (the &#8220;<b>Acquisition
        Merger</b>&#8221;).</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The BCAR Board has determined that the Business
Combination and the transactions contemplated thereby are fair to and in the best interests of BCAR and its shareholders because they
believe that Exascale is a company with strong revenue growth potential. In reaching its decision with respect to the Business Combination
and the transactions contemplated thereby, the BCAR Board reviewed various industry and financial data and the due diligence and evaluation
materials provided by Exascale, demonstrating that Exascale has a business plan dedicated to both near term cash flow as well as long
term growth. See <i>&#8220;The Business Combination Proposal &#8212; BCAR Board of Directors&#8217; Reasons for the Approval of the Business
Combination&#8221; on page&#160;130.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Consideration and Structure</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Business Combination Agreement, the
Merger Consideration is 50,000,000 shares of PubCo Common Stock to be issued at the closing of the Business Combination. Holders of shares
of Exascale Class A common stock and Exascale securities convertible or exchangeable for shares of Exascale Class A common stock (including
the Exascale Safeholders, the Base Camp Investor and the Exascale Equity Incentive Recipients) will receive shares of PubCo Class A Ordinary
Common Stock for such Exascale securities, and holders of Exascale Class B common stock will receive shares of PubCo Class B Super Common
Stock for such Exascale securities. Completion of the Business Combination is subject to the satisfaction or waiver, where permissible,
of various conditions to closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR&#8217;s
Units, Class A Ordinary Shares and Public Warrants are currently traded on the Global Market tier of the Nasdaq Stock Market LLC under
the symbols &#8220;BCARU,&#8221; &#8220;BCAR&#8221; and &#8220;BCARW,&#8221; respectively. BCAR has applied to have the PubCo Class A
Ordinary Common Stock (as defined below) and the PubCo Warrants (as defined below) listed on Nasdaq under the ticker symbols &#8220;XLAB&#8221;
and &#8220;XLABW,&#8221; respectively. It is a condition precedent to the consummation of the Business Combination that BCAR receive
confirmation from Nasdaq (or another nationally recognized securities exchange in the United States as may be agreed by BCAR and Exascale)
that the securities have been conditionally approved for listing on such exchange, but there can be no assurance such listing conditions
will be met or that BCAR will obtain such confirmation from such exchange.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summarizes the pro forma ownership
of PubCo&#8217;s Class A common stock, par value $0.0001 per share and having one (1) vote per share (&#8220;<b>PubCo Class A Ordinary
Common Stock</b>&#8221;), and PubCo&#8217;s Class B common stock, par value $0.0001 per share and having twenty (20) votes per share (&#8220;<b>PubCo
Class B Super Common Stock</b>&#8221;), immediately following the Business Combination across a range of varying redemption scenarios.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        No<br/> Redemption</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        50% of<br/> Maximum Redemption</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        100% of<br/> Maximum Redemption</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ownership<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Voting<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ownership<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Voting
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ownership<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Voting<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">PubCo
        Class A Ordinary Common Stock held by former Exascale Securityholders (including Exascale Class A common stockholders, the Exascale Safeholders,
        the Exascale Base Camp Investor, and the Exascale Equity Incentive Recipients)<sup>(1)</sup></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">19,256,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">21.1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">19,256,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">24.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">19,256,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30.5</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">PubCo
        Class B Super Common Stock held by former Exascale stockholders<sup>(2)</sup></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,744,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">33.7</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">91.1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,744,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">39.8</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">93.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,744,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">48.6</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">95.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt;">PubCo
    Class A Ordinary Common Stock held by Insiders<sup>(3)</sup></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">14.5</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">17.1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">20.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">PubCo
        Class A Ordinary Common Stock held by Non-Affiliated Public</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">28,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30.7</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">4.2</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">14,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">18.2</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
        pro forma PubCo Class A Ordinary Common Stock and PubCo Class B Super Common Stock</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">91,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">77,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">63,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">1.</td>
    <td style="text-align: justify">Consists of (i) 10,100,000 PubCo Class A Ordinary Common Stock to be issued
        to current holders of Exascale Class A common stock, (ii) 8,766,500 PubCo Class A Ordinary Common Stock to be issued to the Exascale Safeholders,
        (iii) 312,500 PubCo Class A Ordinary Common Stock to be issued to the Exascale Base Camp Investor, and (iv) 77,000 PubCo Class A Ordinary
        Common Stock to be issued to the Exascale Equity Incentive Recipients. For additional details, see &#8220;<i>Questions and Answers for
        Shareholders of BCAR&#8212;What will Exascale Securityholders receive in connection with the Business Combination?&#8221; Proposal No.
        1&#8212;The Business Combination Proposal&#8212;The Business Combination Agreement&#8212;Consideration&#8221; and &#8220;Unaudited Pro
        Forma Condensed Combined Financial Information&#8212;Description of the Transactions.</i>&#8221;</td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">2.</td>
    <td style="text-align: justify">Consists of 30,744,000 PubCo Class B Super Common Stock to be issued to
        current holders of Exascale Class B common stock. For additional details, see &#8220;<i>Questions and Answers for Shareholders of BCAR&#8212;What
        will Exascale Securityholders receive in connection with the Business Combination?&#8221; Proposal No. 1&#8212;The Business Combination
        Proposal&#8212;The Business Combination Agreement&#8212;Consideration&#8221; and &#8220;Unaudited Pro Forma Condensed Combined Financial
        Information&#8212;Description of the Transactions.</i>&#8221;</td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">3.</td>
    <td style="text-align: justify">Consists of 13,200,000 PubCo Class A Ordinary Common Stock to
    be issued in exchange for (i) 12,000,000 BCAR Class B Ordinary Shares held by the Sponsor, (ii) 200,000 BCAR Class A Ordinary Shares
    underlying the Private Units held by the Sponsor and (iii) 1,000,000 BCAR Class A Ordinary Shares (being the Representative Shares)
    held by BCAR&#8217;s Chairman and Chief Executive Officer.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stockholders will experience additional dilution to
the extent PubCo issues additional shares of PubCo Common Stock in connection with any Minimum Cash Financing and/or after the closing
of the Business Combination. The table above excludes any shares that will be issuable upon the exercise or settlement of: (i) the 100,000
Private Placement Warrants, and (ii) the 14,000,000 Public Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Dilution</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table illustrates varying ownership
levels in PubCo immediately following the consummation of the Business Combination based on the varying levels of redemptions by the Public
Shareholders, on a fully diluted basis, showing full exercise and conversion of all securities, including the Public Warrants and Private
Placement Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        No<br/> Redemption</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        50% of<br/> Maximum Redemption</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        100% of<br/> Maximum Redemption</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ownership<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Voting<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ownership<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Voting<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ownership<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Voting<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">PubCo
        Class A Ordinary Common Stock held by former Exascale Securityholders (including Exascale Class A common stockholders, the Exascale Safeholders,
        the Exascale Base Camp Investor, and the Exascale Equity Incentive Recipients)<sup>(1)</sup></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">19,256,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">18.3</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.8</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">19,256,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">22.8</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">19,256,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30.4</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">PubCo
        Class B Super Common Stock held by former Exascale stockholders<sup>(2)</sup></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,744,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">29.2</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">89.2</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,744,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">36.5</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">92.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,744,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">48.6</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">95.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt;">PubCo
    Class A Ordinary Common Stock held by Insiders<sup>(3)</sup></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,300,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">12.6</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,300,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">15.8</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,300,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">21.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">PubCo
        Class A Ordinary Common Stock held by Non-Affiliated Public</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">42,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">39.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">6.1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">21,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">24.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3.1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
        pro forma PubCo Class A Ordinary Common Stock and PubCo Class B Super Common Stock</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">105,300,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">84,300,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">63,300,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Consists
        of (i) 10,100,000 PubCo Class A Ordinary Common Stock to be issued to current holders of Exascale Class A common stock, (ii) 8,766,500
        PubCo Class A Ordinary Common Stock to be issued to the Exascale Safeholders, (iii) 312,500 PubCo Class A Ordinary Common Stock to be
        issued to the Exascale Base Camp Investor, and (iv) 77,000 PubCo Class A Ordinary Common Stock to be issued to the Exascale Equity Incentive
        Recipients. For additional details, see &#8220;<i>Questions and Answers for Shareholders of BCAR&#8212;What will Exascale Securityholders
        receive in connection with the Business Combination?&#8221; Proposal No. 1&#8212;The Business Combination Proposal&#8212;The Business
        Combination Agreement&#8212;Consideration&#8221; and &#8220;Unaudited Pro Forma Condensed Combined Financial Information&#8212;Description
        of the Transactions.</i>&#8221;</span></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">2.</td>
    <td style="text-align: justify">Consists of 30,744,000 PubCo Class B Super Common Stock to be issued to
        current holders of Exascale Class B common stock. For additional details, see &#8220;<i>Questions and Answers for Shareholders of BCAR&#8212;What
        will Exascale Securityholders receive in connection with the Business Combination?&#8221; Proposal No. 1&#8212;The Business Combination
        Proposal&#8212;The Business Combination Agreement&#8212;Consideration&#8221; and &#8220;Unaudited Pro Forma Condensed Combined Financial
        Information&#8212;Description of the Transactions.</i>&#8221;</td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">3.</td>
    <td style="text-align: justify">Consists of 13,300,000 PubCo Class A Ordinary Common Stock to
    be issued in exchange for (i) 12,000,000 BCAR Class B Ordinary Shares held by the Sponsor, (ii) 200,000 BCAR Class A Ordinary Shares
    underlying the Private Units held by the Sponsor, (iii) 100,000 BCAR Class A Ordinary Shares underlying Private Placement Warrants
    held by the Sponsor and (iv) 1,000,000 BCAR Class A Ordinary Shares (being the Representative Shares) held by BCAR&#8217;s Chairman
    and Chief Executive Officer.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although the PubCo Class A Ordinary Common Stock and
PubCo Class B Super Common Stock have identical economic rights, each holder of PubCo Class A Common Stock shall be entitled to one (1)
vote for each share of PubCo Class A Ordinary Common Stock held and twenty (20) votes for each PubCo share of PubCo Class B Super Common
Stock held.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For more information, please see the sections entitled
&#8220;<i>Questions and Answers for Shareholders of BCAR&#8212;What will Exascale Securityholders receive in connection with the Business
Combination?&#8221; Proposal No. 1&#8212;The Business Combination Proposal&#8212;The Business Combination Agreement&#8212;Consideration,&#8221;
&#8220;Unaudited Pro Forma Condensed Combined Financial Information&#8212;Description of the Transactions,</i>&#8221; &#8220;<i>Unaudited
Pro Forma Condensed Combined Financial Information</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the relative percentages above are for illustrative
purposes only and are based upon certain assumptions as described in the section entitled &#8220;<i>Unaudited Condensed Combined Pro Forma
Financial Information</i>&#8221;. For more information, including the ownership percentages giving effect to certain dilutive securities,
see the section entitled &#8220;<i>The Business Combination Proposal&#8212;Ownership of PubCo after the Closing</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Conflicts of interest</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain of BCAR&#8217;s directors and executive
officers may be deemed to have interests in the transactions contemplated by the Business Combination Agreement that are different from,
or in addition to, those of BCAR&#8217;s shareholders generally. These interests may present these individuals with certain potential
conflicts of interest. BCAR&#8217;s independent directors reviewed and considered these interests during their evaluation and negotiation
of the Business Combination and in unanimously approving, as members of the BCAR Board, the Business Combination Agreement and the transactions
contemplated therein, including the Business Combination. The BCAR Board concluded that the potential benefits that it expected BCAR and
its shareholders to achieve as a result of the Business Combination outweighed the potentially negative factors associated with the Business
Combination. When you consider the recommendation of the BCAR Board in favor of approval of the Business Combination, you should keep
in mind that BCAR&#8217;s directors and officers have interests in the Business Combination that are different from, or in addition to,
your interests as a shareholder, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify">If the proposed Business Combination is not consummated
        by February 1, 2027 (or May 1, 2027 if the Sponsor (as defined below) exercises its three-month extension option), then BCAR will be required
        to wind down its affairs and liquidate. In such event, the 12,000,000 BCAR Class B Ordinary Shares, which were acquired by BCAR&#8217;s
        sponsor, MFH 1, LLC (the &#8220;Sponsor&#8221;), prior to the IPO for an aggregate purchase price of $25,000, will be worthless. Such
        BCAR Class B Ordinary Shares had an aggregate market value of approximately $[_] based on the closing price of BCAR&#8217;s Public Shares
        of $[_] on Nasdaq as of [_], 2026. As a result of the nominal price of $0.002 per Class B Ordinary Share paid by the Sponsor compared
        to the recent market price of BCAR&#8217;s Class A Ordinary Shares, the Sponsor is likely to earn a positive rate of return on their investments
        in the Class B Ordinary Shares even if the holders of BCAR&#8217;s Class A Ordinary Shares experience a negative rate of return on their
        investments in the Class A Ordinary Shares.</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">If the proposed Business Combination is not consummated by February 1,
        2027 (or May 1, 2027 if the Sponsor exercises its three-month extension option), then 200,000 private placement units (the &#8220;<b>Private
        Units</b>&#8221;) purchased by the Sponsor for a total purchase price of $2,000,000, will be worthless. Such Private Units had an aggregate
        market value of approximately $[_] based on the closing price of BCAR Units of $[_] on Nasdaq as of [_], 2026.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Sponsor invested an aggregate of $2,025,000 in BCAR, comprised of the $25,000
        purchase price for the Founder Shares and $2,000,000 purchase price for the Private Units. The amount held in BCAR&#8217;s trust account
        was approximately $[_] on the Record Date, implying a value of $[_] per public share. Based on these assumptions, each PubCo Class A Common
        Stock would have an implied value of $[_] per share upon consummation of the Business Combination, representing a [_]% decrease from the
        initial implied value of $[_] per public share. While the implied value of $[_] per share upon consummation of the Business Combination
        would represent a dilution to our Public Shareholders, this would represent a significant increase in value for the Sponsor relative to
        the price it paid for each Founder Share. At approximately $[_] per share, the 12,200,000 PubCo Class A Common Stock that the Sponsor
        would own upon consummation of the Business Combination would have an aggregate implied value of $[_]. As a result, even if the trading
        price of PubCo Class A Common Stock significantly declines, the value of the PubCo Class A Common Stock held by the Sponsor will be significantly
        greater than the amount the Sponsor paid to purchase such shares. For more information, please see &#8220;<i>Risk Factors &#8211; The
        nominal purchase price paid by the Sponsor and directors and officers of BCAR for the Founder Shares may significantly dilute the implied
        value of the Public Shares in the event the parties complete an initial business combination. In addition, the value of the Founder Shares
        will be significantly greater than the amount the Sponsor and directors and officers of BCAR paid to purchase such shares in the event
        the parties complete an initial business combination, even if the Business Combination causes the trading price of the PubCo Class A Common
        Stock to materially decline.</i>&#8221;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0">If the proposed Business Combination is not consummated, then 1,000,000
        BCAR Class A Ordinary Shares (the &#8220;<b>Representative Shares</b>&#8221;) granted to D. Boral Capital LLC, the underwriter in the
        IPO, as compensation, which are held by David Boral, the CEO of D. Boral Capital LLC and BCAR&#8217;s Chairman and Chief Executive Officer,
        will be worthless. Such Representative Shares had an aggregate market value of approximately $[_] based on the closing price of BCAR Class
        A Ordinary Shares of $[_] on Nasdaq as of [_], 2026;</p></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">As of [_], 2026, BCAR has unsecured promissory
        notes in the aggregate principal amount of $[_] outstanding and BCAR has drawn down an aggregate of $[_] under the notes. The promissory
        notes were issued for working capital purposes. In the absence of shareholder approval for a further extension, if the proposed Business
        Combination is not consummated by February 1, 2027 (or May 1, 2027 if the Sponsor exercises its three-month extension option), then such
        loans may not be repaid.</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Unless BCAR consummates the Business Combination,
        its officers, directors and the Sponsor will not receive reimbursement for any out-of-pocket expenses incurred by them to the extent that
        such expenses exceeded the amount of its working capital. As of [_], 2026, $[_] of advances was paid by the Sponsor for expenses incurred
        on BCAR&#8217;s behalf and if the proposed Business Combination is not consummated by February 1, 2027 (or May 1, 2027 if the Sponsor
        exercises its three-month extension option), that amount would not be repaid. As a result, the financial interest of BCAR&#8217;s officers,
        directors and Initial Shareholders or their affiliates could influence its officers&#8217; and directors&#8217; motivation in selecting
        Exascale as a target and therefore there may be a conflict of interest when it determined that the Business Combination is in BCAR&#8217;s
        shareholders&#8217; best interest.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The exercise of BCAR&#8217;s directors&#8217;
        and officers&#8217; discretion in agreeing to changes or waivers in the terms of the Business Combination Agreement may result in a conflict
        of interest when determining whether such changes or waivers are appropriate and in our shareholders&#8217; best interest.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The continued indemnification of current directors and officers and the continuation
        of directors&#8217; and officers&#8217; liability insurance.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">BCAR&#8217;s Current Charter provides that BCAR renounces any interest or expectancy
        in, or in being offered an opportunity to participate in, any potential transaction or matter that may be a corporate opportunity for
        any member of BCAR&#8217;s management, on the one hand, and BCAR, on the other hand, or the participation in which would breach any existing
        legal obligation, under applicable law or otherwise, of a member of BCAR&#8217;s management to any other entity. BCAR is not aware of
        any such corporate opportunities not being offered to BCAR and does not believe that waiver of the corporate opportunities doctrine has
        materially affected BCAR&#8217;s search for an acquisition target or will materially affect BCAR&#8217;s ability to complete an initial
        business combination.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing interests may influence the officers
and directors of BCAR to support or approve the Business Combination. As such, the Sponsor and BCAR&#8217;s officers and directors may
be incentivized to complete an acquisition of a less favorable target company or on terms less favorable to BCAR&#8217;s shareholders
rather than liquidate. In considering the recommendations of the BCAR Board to vote for the proposals, BCAR&#8217;s shareholders should
consider these interests.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following
table sets forth the payments to be received by BCAR&#8217;s promoters and the Sponsor and its affiliates from BCAR prior to or in connection
with the completion of the Business Combination and the securities issued and to be issued by BCAR to the Sponsor or its affiliates. Since
the Insiders, and any other holders of BCAR&#8217;s Founder Shares may lose their entire investment in BCAR if the Business Combination
is not completed, a conflict of interest may arise in determining whether Exascale is appropriate for BCAR&#8217;s initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Entity/Individual</td>
    <td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
        <p style="text-align: center; margin-top: 0; margin-bottom: 0">Amount of Compensation to be<br/> Received or Securities Issued or to
        be Issued</p></td>
    <td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Consideration Paid or to be Paid</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 30%; text-align: left">MFH 1, LLC</td>
    <td style="text-align: left; width: 2%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 33%; text-align: left">12,000,000 Class B Ordinary Shares</td>
    <td style="text-align: left; width: 2%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 33%; text-align: left">$25,000</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">200,000 Private Units purchased simultaneously with the closing of the IPO</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">$2,000,000</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">$20,000 per month, commencing on July&#160;30, 2025</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">Office space, utilities and secretarial and administrative services</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">Up to $2,500,000 in working capital loans, which loans may be converted into Private Units
        of the post-business combination entity at the price of $10.00 per Private Unit</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">Working capital loans to finance transaction costs in connection with an initial business
        combination</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">MFH 1, LLC, BCAR&#8217;s officers, directors,
        advisor or BCAR&#8217;s or their affiliates</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">Reimbursement for any out-of-pocket expenses related to identifying, investigating and completing
        an initial business combination</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">Services in connection with identifying, investigating and completing an initial business
        combination</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">David Boral</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">1,000,000 Representative Shares</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">Underwriter compensation in connection with the IPO</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><b>For more information, please
see Section &#8211; &#8220;<i>Directors, Officers, Executive Compensation and Corporate Governance of BCAR Prior to the Business Combination
&#8211; Conflicts of interest</i>&#8221; on page&#160;208.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Business Combination Agreement,
BCAR agreed to cause PubCo to receive an amount of at least $5,000,000 in any combination of cash, cash in the trust account, a private
investment in public equity (&#8220;<b>PIPE</b>&#8221;), an equity line of credit, or third-party financing, net of any outstanding checks,
wire transfers, or similar items not yet cleared, and net of any cash distributions or transfers made in connection with or as a result
of the Business Combination (the &#8220;<b>Minimum Cash Financing</b>&#8221;). It is a condition precedent to Closing that PubCo receive
the Minimum Cash Financing. If the Minimum Cash Financing is not met, and such condition is not waived by Exascale under the terms of
the Business Combination Agreement, the proposed Business Combination will not be consummated. In the event that the Business Combination
will not be consummated, all Public Shares submitted for redemption will be returned to the holders thereof, and BCAR may instead search
for an alternate business combination or liquidate BCAR. As of the date hereof, neither BCAR nor Exascale has secured financing for the
Minimum Cash Financing. The management teams of BCAR and Exascale are continuing to analyze the available financing options based on cost,
amount available under any such facility and future effects that any financing would have on the capitalization of PubCo. BCAR, the Sponsor,
Exascale and their affiliates will have no prior relationships with any of the potential financing sources that will be considered in
connection with the Business Combination. Upon entry into a financing arrangement for the Business Combination, including any Minimum
Cash Financing, BCAR will disclose such arrangement (including the potential dilution) in accordance with the rules of the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time at or prior to the Extraordinary General
Meeting, during a period when they are not then aware of any material nonpublic information regarding BCAR or its securities, the Sponsor,
BCAR&#8217;s officers, BCAR&#8217;s directors and/or their affiliates, in compliance with the tender offer rules and other Exchange Act
limitations, including Rule 14e-5 thereunder, may purchase Public Shares from institutional and other investors, execute agreements to
purchase shares from such investors in the future, or they may enter into transactions, including non-redemption agreements, with such
investors and others to provide them with incentives to acquire shares of BCAR and/or not to redeem (or to validly rescind any redemption
requests). The Sponsor, BCAR&#8217;s officers, BCAR&#8217;s directors and/or their affiliates anticipate that they may identify such unaffiliated
third-party shareholders with whom the Sponsor, BCAR&#8217;s officers, BCAR&#8217;s directors or their affiliates may pursue privately
negotiated transactions by either the shareholders contacting BCAR directly or by BCAR&#8217;s receipt of redemption requests submitted
by shareholders following BCAR&#8217;s mailing of tender offer or proxy materials in connection with the Business Combination. To the
extent that the Sponsor, BCAR&#8217;s officers, BCAR&#8217;s directors, BCAR&#8217;s advisors or their affiliates enter into a private
transaction with an unaffiliated third party, they would identify and contact only potential selling or redeeming shareholders who have
expressed their election to redeem their shares for a pro rata share of the trust account, whether or not such shareholder has already
submitted a proxy with respect to the Business Combination but only if such shares have not already been voted at the Extraordinary General
Meeting related to the Business Combination. The Sponsor, BCAR&#8217;s officers, BCAR&#8217;s directors, BCAR&#8217;s advisors or their
affiliates will select which shareholders to purchase shares from based on the negotiated price and number of shares and any other factors
that they may deem relevant, and will be restricted from purchasing shares if such purchases do not comply with Regulation M under the
Exchange Act and the other federal securities laws. Any such privately negotiated transactions may be effected at purchase prices that
are no greater than the per share pro rata portion of the trust account. Such privately negotiated transactions may include a contractual
acknowledgement that such unaffiliated third-party shareholder, although still the record or beneficial holder of BCAR&#8217;s shares,
is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights. In the event that the Sponsor, BCAR&#8217;s
officers, BCAR&#8217;s directors and/or their affiliates purchase shares in privately negotiated transactions from unaffiliated third-party
shareholders who have already elected to exercise their redemption rights, such selling shareholders would be required to revoke their
prior elections to redeem their Public Shares. The purpose of such share purchases and other transactions would be to limit the number
of Public Shares electing to be redeemed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the SEC&#8217;s Compliance
and Disclosure Interpretation 166.01, any Public Shares purchased by the Sponsor, BCAR&#8217;s officers, BCAR&#8217;s directors and/or
their affiliates would not be voted in favor of approving the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as disclosed in this proxy statement/prospectus,
BCAR has not entered into any privately negotiated transactions with respect to its shares as of the date hereof. If they engage in such
privately negotiated transactions, the Sponsor, BCAR&#8217;s officers, BCAR&#8217;s directors and/or their affiliates will be restricted
from making any such purchases when they are in possession of any material non-public information not disclosed to the seller or if such
purchases are prohibited by Regulation M under the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sponsor, BCAR&#8217;s officers, BCAR&#8217;s
directors and/or their affiliates will be restricted from making purchases of shares if the purchases would violate Section 9(a)(2) of,
or Rule 10b-5 under, the Exchange Act. BCAR expects any such purchases would be reported by such person pursuant to Section 13 and Section
16 of the Exchange Act to the extent such purchasers are subject to such reporting requirements. Additionally, in the event the Sponsor,
BCAR&#8217;s directors, BCAR&#8217;s officers, BCAR&#8217;s advisors, or their affiliates were to purchase shares from Public Shareholders,
or if any third party investors are incentivized to acquire Public Shares by the Sponsor, BCAR&#8217;s directors, BCAR&#8217;s officers,
or their affiliates, such purchases would be structured in compliance with the requirements of Rule 14e-5 under the Exchange Act including,
in pertinent part, through adherence to the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">this proxy statement/prospectus would disclose the possibility that the Sponsor,
        BCAR&#8217;s directors, BCAR&#8217;s officers, BCAR&#8217;s advisors or any of their affiliates may purchase shares from Public Shareholders
        outside the redemption process, along with the purpose of such purchases;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">if the Sponsor, BCAR&#8217;s directors, BCAR&#8217;s officers, BCAR&#8217;s
        advisors or any of their affiliates were to purchase shares from Public Shareholders, they would do so at a price no higher than the price
        offered through BCAR&#8217;s redemption process;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any of BCAR&#8217;s shares purchased by the Sponsor, BCAR&#8217;s directors,
        BCAR&#8217;s officers, BCAR&#8217;s advisors or any of their affiliates would not be voted in favor of approving the Business Combination;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the Sponsor, BCAR&#8217;s directors, BCAR&#8217;s officers, BCAR&#8217;s advisors
        or any of their affiliates would not possess any redemption rights with respect to BCAR&#8217;s shares or, if they do acquire and possess
        redemption rights, they would waive such rights; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">BCAR would disclose in a Current Report on Form 8-K, before the Extraordinary
        General Meeting, the following material items:&#160;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the amount of BCAR&#8217;s shares purchased outside of the redemption offer
        by the Sponsor, BCAR&#8217;s directors, BCAR&#8217;s officers, BCAR&#8217;s advisors or any of their affiliates, along with the purchase
        price;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the purpose of the purchases by the Sponsor, BCAR&#8217;s directors, BCAR&#8217;s
        officers, BCAR&#8217;s advisors or any of their affiliates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the impact, if any, of the purchases by the Sponsor, BCAR&#8217;s directors,
        BCAR&#8217;s officers, BCAR&#8217;s advisors or any of their affiliates on the likelihood that the Business Combination will be approved;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the identities of BCAR&#8217;s security holders who sold to the Sponsor, BCAR&#8217;s
        directors, BCAR&#8217;s officers, BCAR&#8217;s advisors or any of their affiliates (if not purchased on the open market) or the nature
        of BCAR&#8217;s security holders (e.g., 5% security holders) who sold to the Sponsor, BCAR&#8217;s directors, BCAR&#8217;s officers, BCAR&#8217;s
        advisors or any of their affiliates; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the number of BCAR&#8217;s shares for which BCAR has received redemption requests
        pursuant to BCAR&#8217;s redemption offer.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of the funds in the trust account will be
used to purchase Public Shares in such transactions.</p>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Investing in PubCo&#8217;s
securities involves a high degree of risk. We encourage you to read this proxy statement/prospectus carefully. In particular, you should
review the matters discussed under the section entitled &#8220;Risk Factors.&#8221;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR will hold an Extraordinary General Meeting
of its shareholders (the &#8220;<b>Extraordinary General Meeting</b>&#8221;) to consider matters relating to the Business Combination
at 10:00 A.M., Eastern Time, on [_], 2026. The Extraordinary General Meeting will be a virtual meeting conducted via live webcast. For
the purposes of British Virgin Islands law and the Current Charter, the physical location of the meeting will be at the offices of Loeb
&amp; Loeb LLP, 345 Park Avenue, New York, NY 10154 on [_], 2026, at 10:00 A.M. Eastern Time and virtually using the following dial-in
information: Telephone number: __________________ Participant Passcode: __________________.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this proxy statement/prospectus,
there was approximately $[_] in BCAR&#8217;s trust account. On [_], 2026, the last sale price of BCAR Class A Ordinary Shares was $[_]
per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant
to BCAR&#8217;s existing amended and restated memorandum and articles of association (the &#8220;<b>Current Charter</b>&#8221;), BCAR
is providing its Public Shareholders with the opportunity to redeem all or a portion of their Public Shares at a per-share price, payable
in cash, equal to the aggregate amount then on deposit in BCAR&#8217;s trust account as of two business days prior to the consummation
of the Business Combination, including interest, less taxes payable, divided by the number of then outstanding Public Shares that were
sold as part of the BCAR Units in the IPO, subject to the limitations described herein. BCAR estimates that the per-share price at which
Public Shares may be redeemed from cash held in the trust account will be approximately $[_] at the time of the Extraordinary General
Meeting. BCAR&#8217;s Public Shareholders may elect to redeem their shares even if they vote for the Business Combination Proposal or
do not vote at all. BCAR has no specified maximum redemption threshold under BCAR&#8217;s Current Charter. Holders of outstanding BCAR
Warrants do not have redemption rights in connection with the Business Combination. Notwithstanding the foregoing redemption rights,
a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert
or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Exchange Act), will be restricted from redeeming its shares with
respect to more than an aggregate of 15% of the shares sold in the IPO without BCAR&#8217;s prior consent. However, BCAR will not restrict
shareholders&#8217; ability to vote all their shares (including all shares held by those shareholders that hold more than 15% of the
shares sold in the IPO) for or against the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On [_], 2026, the record date for the Extraordinary
General Meeting (the &#8220;<b>Record Date</b>&#8221;), the last sale price of BCAR Class A Ordinary Share was $[_].</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you have
any questions or need assistance voting your BCAR shares, please contact Advantage Proxy, Inc., BCAR&#8217;s proxy solicitor, by email
at karen@advantageproxy.com. Individuals may also call Advantage Proxy toll free at 877-870-8565; banks and brokers can call 206-870-8565.
The notice of the Extraordinary General Meeting and the proxy statement/prospectus relating to the Business Combination will be available
at <span style="text-decoration: underline">www.sec.gov</span> or https://www.cstproxy.com/[_].</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This document is (i) a prospectus related to the
issuance by PubCo of PubCo Common Stock and PubCo Warrants in the Business Combination and (ii) a proxy statement for BCAR to use in soliciting
proxies for the Extraordinary General Meeting. The Insiders, who own approximately 32.0% of BCAR&#8217;s outstanding ordinary shares as
of the Record Date, have agreed to vote all shares they own in favor of the Business Combination Proposal, and intend to vote for each
of the other proposals as well, although there is no agreement in place with respect to voting on those proposals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>This proxy statement/prospectus provides shareholders
of BCAR with detailed information about the Business Combination and other matters to be considered at the Extraordinary General Meeting
of BCAR. We encourage you to read this entire document, including the Annexes and other documents referred to herein, carefully and in
their entirety. You should also carefully consider the risk factors described under the heading &#8220;Risk Factors.&#8221;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>BCAR&#8217;s board of directors unanimously
recommends that BCAR shareholders vote &#8220;FOR&#8221; approval of each of the proposals.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NEITHER THE SECURITIES AND EXCHANGE COMMISSION
NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED IN THIS PROXY STATEMENT/PROSPECTUS,
PASSED UPON THE MERITS OR FAIRNESS OF THE PROPOSED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS PROXY
STATEMENT/PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>IF YOU RETURN YOUR PROXY CARD WITHOUT AN INDICATION
OF HOW YOU WISH TO VOTE, YOUR SHARES WILL BE VOTED IN FAVOR OF EACH OF THE PROPOSALS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>TO EXERCISE YOUR REDEMPTION RIGHTS, YOU MUST ELECT
TO HAVE BCAR REDEEM YOUR SHARES FOR A PRO RATA PORTION OF THE FUNDS HELD IN THE TRUST ACCOUNT AND TENDER YOUR SHARES TO BCAR&#8217;S TRANSFER
AGENT AT LEAST TWO BUSINESS DAYS PRIOR TO THE VOTE AT THE EXTRAORDINARY GENERAL MEETING. YOU MAY TENDER YOUR SHARES BY EITHER DELIVERING
YOUR SHARE CERTIFICATE TO THE TRANSFER AGENT OR BY DELIVERING YOUR SHARES ELECTRONICALLY USING THE DEPOSITORY TRUST COMPANY&#8217;S DWAC
(DEPOSIT AND WITHDRAWAL AT CUSTODIAN) SYSTEM. IF THE BUSINESS COMBINATION IS NOT COMPLETED, THEN THESE SHARES WILL NOT BE REDEEMED FOR
CASH. IF YOU HOLD THE SHARES IN STREET NAME, YOU WILL NEED TO INSTRUCT THE ACCOUNT EXECUTIVE AT YOUR BANK OR BROKER TO WITHDRAW THE SHARES
FROM YOUR ACCOUNT IN ORDER TO EXERCISE YOUR REDEMPTION RIGHTS. PLEASE SEE THE SECTION TITLED &#8220;<i>EXTRAORDINARY GENERAL MEETING OF
BCAR SHAREHOLDERS - REDEMPTION RIGHTS</i>&#8221; FOR MORE SPECIFIC INSTRUCTIONS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>D. BORAL ARC ACQUISITION I CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">British Virgin Islands Business Company</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Company Number WC-2172570)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">10 East 53rd Street, Suite 3001, New York, NY 10022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(332) 266-7344</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTICE OF EXTRAORDINARY GENERAL MEETING TO BE HELD
ON [_], 2026</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the Shareholders of D. Boral ARC Acquisition I
Corp.:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOTICE IS HEREBY GIVEN that an Extraordinary General
Meeting (the &#8220;<b>Extraordinary General Meeting</b>&#8221;) of D. Boral ARC Acquisition I Corp., a British Virgin Islands business
company (&#8220;<b>BCAR</b>&#8221; or the &#8220;<b>Parent</b>&#8221;), will be held at the offices of Loeb &amp; Loeb LLP, 345 Park Avenue,
New York, NY 10154 on [_], 2026, at 10:00 A.M. Eastern Time and virtually using the following dial-in information: Telephone number: __________________
Participant Passcode: __________________.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Capitalized terms used but not defined herein
shall have the meaning given to them in the accompanying proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the purposes of British Virgin Islands law and
the amended and restated memorandum and articles of association of BCAR (the &#8220;<b>Current Charter</b>&#8221;), the physical location
of the Extraordinary General Meeting will be at the offices of Loeb &amp; Loeb LLP, 345 Park Avenue, New York, NY 10154. You are cordially
invited to attend the Extraordinary General Meeting, which will be held for the following purposes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>(1) Proposal No. 1 &#8212; The Business
Combination Proposal </b>&#8212; To consider and vote upon a proposal to approve by way of an ordinary resolution and adopt the Agreement
and Plan of Merger, dated as of January 11, 2026 (the &#8220;<b>Business Combination Agreement</b>&#8221;), by and among BCAR, D. Boral
ARC Merger Corporation, a Delaware corporation and a direct, wholly owned subsidiary of BCAR (&#8220;<b>PubCo</b>&#8221;), D. Boral Arc
Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary of BCAR (&#8220;<b>Merger Sub</b>&#8221;), and Exascale
Labs Inc., a Delaware corporation (the &#8220;<b>Company</b>&#8221; or &#8220;<b>Exascale</b>&#8221;), pursuant to which, among other
things, following the closing of the Domestication Merger (as defined below), Merger Sub shall be merged with and into the Company, with
the Company surviving the merger as a wholly-owned subsidiary of PubCo (the &#8220;<b>Acquisition Merger</b>&#8221;), and approve the
Acquisition Merger and the other transactions contemplated by the Business Combination Agreement. The Acquisition Merger, together with
the Domestication Merger and the other agreements and transactions contemplated by the Business Combination Agreement, are referred to
herein as the &#8220;<b>Business Combination</b>.&#8221; We refer to this proposal as the &#8220;<b>Business Combination Proposal</b>.&#8221;
A copy of the Business Combination Agreement is attached to the accompanying proxy statement/prospectus as <i>Annex A</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>(2) Proposal No. 2 &#8212; The Domestication
Merger Proposal</b> &#8212; To consider and vote upon a proposal to approve by way of an ordinary resolution and adopt the domestication
of D. Boral ARC Acquisition I Corp., a British Virgin Islands business company (&#8220;<b>BCAR</b>&#8221; or the &#8220;<b>Parent</b>&#8221;)
pursuant to the Business Combination Agreement, and subject to the conditions of the Business Combination Agreement, pursuant to which
BCAR shall continue out of the British Virgin Islands and into the State of Delaware so as to re-domicile as and become a Delaware corporation
by means of a merger (the &#8220;<b>Domestication Merger</b>&#8221;) of BCAR with and into PubCo, with PubCo as the surviving company
pursuant to the Business Companies Act, (Revised Edition 2020) as amended, of the British Virgin Islands and Section 388 and other applicable
provisions of the General Corporation Law of the State of Delaware (the &#8220;<b>DGCL</b>&#8221;). Upon the Domestication Merger, PubCo
shall change its name to &#8220;Exascale Labs Holdings Inc.&#8221; We refer to this proposal as the &#8220;<b>Domestication Merger Proposal</b>.&#8221;
A copy of the Business Combination Agreement is attached to the accompanying proxy statement/prospectus as <i>Annex A.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>(3) Proposal No. 3 &#8212; Organizational
Documents Proposal </b>&#8212; To consider and vote upon a proposal to approve by way of an ordinary resolution the proposed amended and
restated certificate of incorporation (the &#8220;<b>Proposed Charter</b>&#8221;) and the proposed amended and restated bylaws (&#8220;<b>Proposed
Bylaws</b>&#8221; and, together with the Proposed Charter, the &#8220;<b>Proposed Organizational Documents</b>&#8221;) of PubCo (a corporation
incorporated in the State of Delaware), (the &#8220;<b>Organizational Documents Proposal</b>&#8221;). The forms of each of the Proposed
Charter and the Proposed Bylaws are attached to the accompanying proxy statement/prospectus as <i>Annex B-1 </i>and <i>Annex B-2</i>,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>(4) Proposal No. 4 &#8212; The Advisory
Organizational Documents Proposals </b>&#8212; To consider and vote upon the following six (6) separate proposals (collectively, the &#8220;<b>Advisory
Organizational Documents Proposals</b>&#8221;) to approve on an advisory non-binding basis by way of an ordinary resolution the following
material differences between the Current Charter and the Proposed Organizational Documents:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><b>(A) <i>Advisory Organizational Documents
Proposal 4A (Authorized Shares) </i></b>&#8212; authorize the amendment and redesignation of the authorized shares of BCAR from (a) 500,000,000
BCAR Class A Ordinary Shares, 50,000,000 BCAR Class B Ordinary Shares and 5,000,000 BCAR preference shares, in each case par value $0.0001
per share, to (b) 260,000,000 shares of PubCo Class A Ordinary Common Stock, 35,000,000 shares of PubCo Class B Super Common Stock, and
5,000,000 shares of PubCo Preferred Stock, in each case par value $0.0001 per share (&#8220;<b>Advisory Organizational Documents Proposal
4A</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><b>(B) <i>Advisory Organizational Documents
Proposal 4B (Change in Voting Rights) </i></b>&#8212; to change the voting rights of PubCo&#8217;s Common Stock such that, each PubCo
Class A Ordinary Common Stock will be entitled to one (1) vote per PubCo Class A Ordinary Common Stock on all matters submitted to a vote
of the stockholders of PubCo, and each PubCo Class B Super Common Stock will be entitled to twenty (20) votes per PubCo Class B Super
Common Stock on all matters submitted to a vote of the stockholders of PubCo, and that the PubCo Class A Ordinary Common Stock and PubCo
Class B Super Common Stock shall vote together on all matters except as explicitly required by the DGCL or as explicitly set forth in
the Proposed Charter (&#8220;<b>Advisory Organizational Documents Proposal 4B</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><b>(C) <i>Advisory Organizational Documents
Proposal 4C (Exclusive Forum Provision) </i></b>&#8212; to authorize adopting Delaware as the exclusive forum for certain stockholder
litigation and adopting the federal district courts of the United States as the exclusive forum for resolving complaints asserting a cause
of action under the Securities Act of 1933, as amended (the &#8220;<b>Securities Act</b>&#8221;) (&#8220;<b>Advisory Organizational Documents
Proposal 4C</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><b>(D)
<i>Advisory Organizational Documents Proposal 4D (Required Vote to Amend Charter) </i></b>&#8212; to approve provisions providing that
the affirmative vote of at least 66&#8532;% of the voting power of all the then outstanding shares of capital stock of PubCo entitled
to vote thereon, voting together as a single class, will be required to amend, alter, repeal or rescind any provision of Article FIFTH,
Article SIXTH, Article SEVENTH, Article EIGHTH, Article NINTH, Article TENTH or Article ELEVENTH of the Proposed Charter (&#8220;<b>Advisory
Organizational Documents Proposal 4D</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><b>(E) <i>Advisory Organizational Documents
Proposal 4E (Removal of Directors) </i></b>&#8212; to approve provisions permitting the removal of a director, but only for cause, and
then by the affirmative vote of at least 66&#8532;% of the voting power of all the then outstanding shares entitled to vote generally
in the election of directors, voting together as a single class (&#8220;<b>Advisory Organizational Documents Proposal 4E</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><b>(F) <i>Advisory Organizational Documents
Proposal 4F (Name Change) </i></b>&#8212; to approve the change of the name of PubCo to &#8220;Exascale Labs Holdings Inc.&#8221; (&#8220;<b>Advisory
Organizational Documents Proposal 4F</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>(5)
Proposal No. 5 &#8212; Directors Proposal</b> &#8212; A proposal to elect Hoansoo Lee, Wenying Jia, David Card, Shachar Kariv and Jaeyoung
Shin as the directors of PubCo, with Hoansoo Lee to serve until the 2029 annual meeting and until his successor has been duly elected
and qualified or until his earlier resignation, removal or death, with each of Wenying Jia and David Card to serve until the 2028 annual
meeting and until their respective successors have been duly elected and qualified or until their earlier resignation, removal or death,
and with each of Shachar Kariv and Jaeyoung Shin to serve until the 2027 annual meeting and until their respective successors have been
duly elected and qualified or until their earlier resignation, removal or death (the &#8220;<b>Directors Proposal</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>(6) Proposal No. 6 &#8212; The Equity
Incentive Plan Proposal </b>&#8212; To consider and vote upon a proposal to approve by an ordinary resolution the Equity Incentive Plan
(the &#8220;<b>Equity Incentive Plan Proposal</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>(7) Proposal No. 7 &#8212; The Nasdaq
Proposal</b> &#8212; To consider and vote upon a proposal to approve by an ordinary resolution, for purposes of complying with the applicable
provisions of Nasdaq Stock Exchange Listing Rule 5635, the issuance of PubCo Common Stock and PubCo Warrants in connection with the Business
Combination (the &#8220;<b>Nasdaq proposal</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>(8) Proposal No. 8 &#8212; The Adjournment
Proposal </b>&#8212; To consider and vote upon a proposal to approve by way of an ordinary resolution the adjournment of the Extraordinary
General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are
insufficient votes for the approval of one or more proposals at the Extraordinary General Meeting (the &#8220;<b>Adjournment Proposal</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each of Proposal Nos. 1, 2, 3, 5, 6 and 7 is cross-conditioned
on the approval of each other (the &#8220;<b>Condition Precedent Proposals</b>&#8221;). The Advisory Organizational Documents Proposal
4A-F and the Adjournment Proposal are not cross-conditioned upon the approval of any other proposal set forth in this proxy statement/prospectus.
Notwithstanding the order of the resolutions on this notice to the Extraordinary General Meeting, the Adjournment Proposal may be presented
first to the shareholders if, based on the tabulated vote collected at the time of the Extraordinary General Meeting, there are insufficient
votes for, or otherwise in connection with, the approval of the Condition Precedent Proposals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant
to BCAR&#8217;s existing amended and restated memorandum and articles of association (the &#8220;<b>Current Charter</b>&#8221;), BCAR
is providing its Public Shareholders with the opportunity to redeem all or a portion of their Public Shares at a per-share price, payable
in cash, equal to the aggregate amount then on deposit in BCAR&#8217;s trust account as of two business days prior to the consummation
of the Business Combination, including interest, less taxes payable, divided by the number of then outstanding Public Shares that were
sold as part of the BCAR Units in the IPO, subject to the limitations described herein. BCAR estimates that the per-share price at which
Public Shares may be redeemed from cash held in the trust account will be approximately $[_] at the time of the Extraordinary General
Meeting. BCAR&#8217;s Public Shareholders may elect to redeem their shares even if they vote for the Business Combination Proposal or
do not vote at all. BCAR has no specified maximum redemption threshold under BCAR&#8217;s Current Charter. Holders of outstanding BCAR
Warrants do not have redemption rights in connection with the Business Combination. Notwithstanding the foregoing redemption rights,
a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert
or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Exchange Act), will be restricted from redeeming its shares with
respect to more than an aggregate of 15% of the shares sold in the IPO without BCAR&#8217;s prior consent. However, BCAR will not restrict
shareholders&#8217; ability to vote all their shares (including all shares held by those shareholders that hold more than 15% of the
shares sold in the IPO) for or against the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Only holders of record of BCAR Ordinary Shares
at the close of business on [_], 2026 (the &#8220;<b>Record Date</b>&#8221;) are entitled to notice of and to vote at and to have their
votes counted at the Extraordinary General Meeting and any adjournment of the Extraordinary General Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This proxy statement/prospectus and accompanying proxy
card is being provided to BCAR&#8217;s shareholders in connection with the solicitation of proxies to be voted at the Extraordinary General
Meeting and at any adjournment of the Extraordinary General Meeting. <b>Whether or not you plan to attend the Extraordinary General Meeting,
all of BCAR&#8217;s shareholders are urged to read this proxy statement/prospectus, including the Annexes and the documents referred to
herein, carefully and in their entirety. You should also carefully consider the risk factors described under the heading &#8220;<i>Risk
Factors</i>&#8221; beginning on page&#160;54 of this proxy statement/prospectus.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>After careful consideration, the board of directors
of BCAR (the &#8220;BCAR Board&#8221;) has unanimously approved the Business Combination and unanimously recommends that shareholders
vote &#8220;FOR&#8221; the adoption of the Business Combination Agreement, and approval of the transactions contemplated thereby, including
the Business Combination Proposal, and &#8220;FOR&#8221; all other proposals presented to BCAR&#8217;s shareholders in this proxy statement/prospectus.
When you consider the recommendation of these proposals by the BCAR Board, you should keep in mind that BCAR&#8217;s directors and officers
have interests in the Business Combination that may conflict with your interests as a shareholder. Additionally, the Insiders have the
right to vote an aggregate of 13,200,000 shares, or approximately 32.0% of the issued and outstanding BCAR Ordinary Shares. See &#8220;<i>The
Business Combination Proposal &#8212; Certain Interests of BCAR&#8217;s Directors and Officers and Others in the Business Combination</i>&#8221;
for a further discussion of these considerations.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Business Combination Agreement is subject to the
satisfaction or waiver of customary closing conditions, including, among others: (i) approval of the Business Combination and related
agreements and transactions by the respective shareholders of BCAR and Exascale; and (ii) the effectiveness of the registration statement
on Form S-4 filed by BCAR of which the accompanying proxy statement/prospectus forms a part.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of
each of the Business Combination Proposal, the Domestication Merger Proposal, the Organizational Documents Proposal, the Advisory Organizational
Documents Proposals, the Directors Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal and the Adjournment Proposal requires
an ordinary resolution, being the affirmative vote of a simple majority of the votes cast by holders of BCAR Ordinary Shares, represented
in person or by proxy and entitled to vote thereon at the Extraordinary General Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Sponsor and each director and officer of BCAR
(collectively, the &#8220;<b>Insiders</b>&#8221;) have agreed to, among other things, vote in favor of the Business Combination. The Sponsor
together with each of the directors and officers of BCAR, own 13,200,000 BCAR Ordinary Shares, including (i) 12,000,000 Class B Ordinary
Shares held by the Sponsor, (ii) 200,000 Class A Ordinary Shares underlying the Private Units, and (iii) 1,000,000 Representative Shares.
As a result, as of the date of the accompanying proxy statement/prospectus, the Insiders own approximately 32.0% of the issued and outstanding
BCAR Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Your vote is very important. </i>Whether or
not you plan to attend the Extraordinary General Meeting, please vote as soon as possible by following the instructions in the accompanying
proxy statement/prospectus to make sure that your shares are represented at the Extraordinary General Meeting. If you hold your shares
in &#8220;street name&#8221; through a bank, broker or other nominee, you will need to follow the instructions provided to you by your
bank, broker or other nominee to ensure that your shares are represented and voted at the Extraordinary General Meeting. The transactions
contemplated by the Business Combination Agreement will be consummated only if the Condition Precedent Proposals are approved at the Extraordinary
General Meeting.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you sign, date and return your proxy card without
indicating how you wish to vote, your proxy will be voted &#8220;FOR&#8221; each of the proposals presented at the Extraordinary General
Meeting. If you fail to return your proxy card or fail to instruct your bank, broker or other nominee how to vote, and do not attend the
Extraordinary General Meeting in person, the effect will be that your shares will not be voted. An abstention or broker non-vote will
be counted towards the quorum requirement but will not count as a vote cast at the Extraordinary General Meeting and otherwise will have
no effect on a particular proposal because each proposal requires the affirmative vote of a particular number of votes cast and an abstention
or broker non-vote is not a vote cast. If you are a shareholder of record and you attend the Extraordinary General Meeting and wish to
vote in person, you may withdraw your proxy and vote in person.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Your attention
is directed to the proxy statement/prospectus accompanying this notice (including the Annexes and other documents referred to therein)
for a more complete description of the Business Combination and related transactions and each of the proposals. You are encouraged to
read the accompanying proxy statement/prospectus carefully and in its entirety, including the Annexes and other documents referred to
therein. If you have any questions or need assistance voting your BCAR Ordinary Shares, please contact Advantage Proxy, Inc., BCAR&#8217;s
proxy solicitor, by email at Karen@advantageproxy.com. Individuals may also call Advantage Proxy toll free at 877-870-8565; banks and
brokers can call 206-870-8565. This notice of Extraordinary General Meeting and the accompanying proxy statement/prospectus are available
at <span style="text-decoration: underline">www.sec.gov</span> or https://www.cstproxy.com/[_].</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thank you for your participation. We look forward
to your continued support.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">By Order of the Board of Directors of D. Boral ARC
Acquisition I Corp.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; text-align: left; width: 50%">&#160;</td>
    <td style="vertical-align: top; text-align: left; width: 50%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: top; text-align: left">David Boral</td>
    <td style="vertical-align: top; text-align: left">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: top; text-align: left">Chairman and Chief Executive Officer</td>
    <td style="vertical-align: top; text-align: left">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>IF YOU RETURN YOUR PROXY CARD WITHOUT AN INDICATION
OF HOW YOU WISH TO VOTE, YOUR SHARES WILL BE VOTED IN FAVOR OF EACH OF THE PROPOSALS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>TO EXERCISE YOUR REDEMPTION RIGHTS, YOU MUST
ELECT TO HAVE BCAR REDEEM YOUR SHARES FOR A PRO RATA PORTION OF THE FUNDS HELD IN THE TRUST ACCOUNT AND TENDER YOUR SHARES TO BCAR&#8217;S
TRANSFER AGENT AT LEAST TWO BUSINESS DAYS PRIOR TO THE VOTE AT THE EXTRAORDINARY GENERAL MEETING. YOU MAY TENDER YOUR SHARES BY EITHER
DELIVERING YOUR SHARE CERTIFICATE TO THE TRANSFER AGENT OR BY DELIVERING YOUR SHARES ELECTRONICALLY USING THE DEPOSITORY TRUST COMPANY&#8217;S
DWAC (DEPOSIT AND WITHDRAWAL AT CUSTODIAN) SYSTEM. IF THE BUSINESS COMBINATION IS NOT COMPLETED, THEN THESE SHARES WILL NOT BE REDEEMED
FOR CASH. IF YOU HOLD THE SHARES IN STREET NAME, YOU WILL NEED TO INSTRUCT THE ACCOUNT EXECUTIVE AT YOUR BANK OR BROKER TO WITHDRAW THE
SHARES FROM YOUR ACCOUNT IN ORDER TO EXERCISE YOUR REDEMPTION RIGHTS. PLEASE SEE THE SECTION TITLED &#8220;<i>EXTRAORDINARY GENERAL MEETING
OF BCAR SHAREHOLDERS - REDEMPTION RIGHTS</i>&#8221; FOR MORE SPECIFIC INSTRUCTIONS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying proxy statement/prospectus is dated
[_], 2026 and is first being mailed to shareholders on or about [_], 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="toc"></span>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top; width: 90%">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom; width: 9%"><b>Page</b></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_001">ABOUT THIS PROXY STATEMENT/PROSPECTUS</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">1</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_002">FREQUENTLY USED TERMS</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">2</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_003">MARKET AND INDUSTRY DATA</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">7</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_003a">TRADEMARKS, TRADE NAMES
        AND SERVICE MARKS</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">7</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_004">CAUTIONARY NOTE REGARDING
        FORWARD-LOOKING STATEMENTS</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">8</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_005">QUESTIONS AND ANSWERS FOR
        SHAREHOLDERS OF BCAR</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">11</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_006">SUMMARY OF THE PROXY STATEMENT/PROSPECTUS</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">33</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_007">MARKET PRICE AND DIVIDENDS
        OF SECURITIES</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">53</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_008">RISK FACTORS</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">54</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_009">PROPOSAL No. 1</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">120</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_010">THE BUSINESS COMBINATION
        PROPOSAL</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">120</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_011">PROPOSAL No. 2</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">146</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_012">THE DOMESTICATION MERGER
        PROPOSAL</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">146</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_013">PROPOSAL No. 3</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">150</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_014">THE ORGANIZATIONAL DOCUMENTS
        PROPOSAL</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">150</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_015">PROPOSAL No. 4</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">152</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_016">THE ADVISORY ORGANIZATIONAL
        DOCUMENTS PROPOSALS</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">152</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_017">PROPOSAL No. 5</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">159</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_018">THE DIRECTORS PROPOSAL</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">159</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_019">PROPOSAL No. 6</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">160</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_020">THE EQUITY INCENTIVE PLAN
        PROPOSAL</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">160</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_020a">PROPOSAL No. 7</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">165</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_020b">THE NASDAQ PROPOSAL</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">165</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_021">PROPOSAL No. 8</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">167</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_022">THE ADJOURNMENT PROPOSAL</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">167</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_023">CERTAIN MATERIAL U.S. FEDERAL
        INCOME TAX CONSIDERATIONS</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">168</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_024">UNAUDITED PRO FORMA CONDENSED
        COMBINED FINANCIAL INFORMATION</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">183</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_025">INFORMATION ABOUT PUBCO BEFORE
        THE BUSINESS COMBINATION</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">195</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_026">DIRECTORS, OFFICERS, EXECUTIVE
        COMPENSATION AND CORPORATE GOVERNANCE OF BCAR PRIOR TO THE BUSINESS COMBINATION</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">201</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_027">MANAGEMENT&#8217;S DISCUSSION
        AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF BCAR</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">212</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_028">INFORMATION ABOUT EXASCALE</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">216</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_029">MANAGEMENT&#8217;S DISCUSSION
        AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF EXASCALE</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">231</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_030">BENEFICIAL OWNERSHIP OF SECURITIES</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">264</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_031">CERTAIN RELATIONSHIPS AND
        RELATED PARTY TRANSACTIONS</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">267</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_032">COMPARISON OF CORPORATE GOVERNANCE
        AND SHAREHOLDER RIGHTS</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">270</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_033">SECURITIES ACT RESTRICTIONS
        ON RESALE OF PUBCO SECURITIES</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">307</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_034">STOCKHOLDER PROPOSALS AND
        DIRECTOR NOMINATIONS</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">308</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_035">SHAREHOLDER COMMUNICATIONS</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">309</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_036">LEGAL MATTERS</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">309</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_037">OTHER MATTERS</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">309</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_038">EXPERTS</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">309</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_039">DELIVERY OF DOCUMENTS TO
        SHAREHOLDERS</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">310</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_040">ENFORCEABILITY OF CIVIL LIABILITY</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">310</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_041">WHERE YOU CAN FIND MORE INFORMATION</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">311</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#a_042"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDEX
        TO FINANCIAL STATEMENTS</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">F-1</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top; width: 10%">ANNEX A</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#8211;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; width: 79%"><a href="#annex_a">BUSINESS COMBINATION
        AGREEMENT AND AMENDMENT</a></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; width: 9%">A-1</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">ANNEX B-1</td>
    <td style="vertical-align: bottom">&#8211;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><a href="#annex_b1">FORM OF THE AMENDED AND
        RESTATED CERTIFICATE OF INCORPORATION</a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">B-1-1</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">ANNEX B-2</td>
    <td style="vertical-align: bottom">&#8211;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><a href="#annex_b2">FORM OF THE AMENDED AND
        RESTATED BYLAWS</a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">B-2-1</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">ANNEX C</td>
    <td style="vertical-align: bottom">&#8211;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><a href="#annex_c">FORM OF THE EQUITY INCENTIVE
        PLAN</a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">C-1</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">ANNEX D</td>
    <td style="vertical-align: bottom">&#8211;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><a href="#annex_d">SPONSOR SUPPORT AGREEMENT</a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">D-1</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">ANNEX E</td>
    <td style="vertical-align: bottom">&#8211;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><a href="#annex_e">COMPANY SUPPORT AGREEMENT</a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">E-1</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">ANNEX F</td>
    <td style="vertical-align: bottom">&#8211;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><a href="#annex_f">FORM OF LOCK-UP AGREEMENT</a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">F-1</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 17; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_001"></span>ABOUT THIS PROXY STATEMENT/PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This proxy statement/prospectus, which forms part
of a registration statement on Form S-4 filed with the Securities and Exchange Commission (the &#8220;<b>SEC</b>&#8221;) by BCAR, constitutes
a prospectus of PubCo under Section 5 of the Securities Act, with respect to the PubCo Common Stock and PubCo Warrants to be issued to
BCAR shareholders and warrant holders and Exascale securityholders if the Business Combination described herein is consummated. This document
also constitutes a proxy statement of BCAR under Section 14(a) of the Exchange Act, and a notice of meeting with respect to the Extraordinary
General Meeting of BCAR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information contained
in this proxy statement/prospectus. BCAR and Exascale have not authorized anyone to provide you with information that is different from
that contained in this proxy statement/prospectus. This proxy statement/prospectus is dated [_], 2026 and you should not assume that the
information contained in this proxy statement/prospectus is accurate as of any date other than such date unless otherwise specifically
provided herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This proxy statement/prospectus does not constitute
an offer to sell, or a solicitation of an offer to buy, any securities, or the solicitation of a proxy, in any jurisdiction to or from
any person to whom it is unlawful to make any such offer or solicitation in such jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>This proxy statement/prospectus incorporates
important business and financial information about BCAR that is not included or delivered herewith. If you would like to receive additional
information or if you want additional copies of this document, agreements contained in the appendices or any other documents filed by
BCAR with the SEC, such information is available without charge upon written or oral request to BCAR&#8217;s Chief Executive Officer at
10 East 53rd Street, Suite 3001, New York, NY 10022; or to Advantage Proxy LLC, our proxy solicitor, by email at karen@advantageproxy.com.
Individuals may also call Advantage Proxy toll free at 877-870-8565; banks and brokers can call 206-870-8565.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>In order for you to receive timely delivery
of the documents in advance of the Extraordinary General Meeting of BCAR to be held on [_], 2026, you must request the information no
later than five business days prior to the date of the Extraordinary General Meeting, by [_], 2026.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 18; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_002"></span>FREQUENTLY USED TERMS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise stated or unless the context
otherwise requires, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Parent,&#8221; and &#8220;BCAR&#8221; refer
to D. Boral ARC Acquisition I Corp. (which prior to the Domestication Merger is a business company incorporated under the laws of the
British Virgin Islands, and in connection with the Domestication Merger, will merge with and into D. Boral ARC Merger Corporation, a Delaware
corporation). Following the Domestication Merger, D. Boral ARC Merger Corporation will be renamed &#8220;Exascale Labs Holdings Inc.&#8221;
D. Boral ARC Merger Corporation is referred to in this document as PubCo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In this document:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Acquisition Merger</b>&#8221; means
the statutory merger of Merger Sub with and into Exascale pursuant to the terms of the Business Combination Agreement with Exascale continuing
as the surviving entity and a wholly-owned subsidiary of PubCo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Adjournment Proposal</b>&#8221; means
the proposal to be considered at the Extraordinary General Meeting to adjourn the Extraordinary General Meeting to a later date or dates,
if necessary to permit further solicitation and vote of proxies if it is determined by BCAR that more time is necessary or appropriate
to approve one or more proposals at the Extraordinary General Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Advantage Proxy</b>&#8221; means Advantage
Proxy, Inc., proxy solicitor to BCAR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Advisory Organizational Documents Proposals</b>&#8221;
means the proposals to be considered at the Extraordinary General Meeting to approve, on a non-binding advisory basis and as required
by applicable SEC guidance, certain material differences between the Current Charter and the Proposed Organizational Documents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>AI</b>&#8221; means artificial intelligence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>AIDC</b>&#8221; means AI data center.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Base Camp Investment Agreement</b>&#8221;
means the Base Camp Investment Agreement dated May 9, 2023, by and between Exascale and the Base Camp Investor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Base Camp Investor</b>&#8221; means
Outlier Ventures Operations Ltd.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>BCAR</b>&#8221; means D. Boral ARC Acquisition
I Corp.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>BCAR Board</b>&#8221; means the board of
directors of BCAR prior to the Closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>BCAR Class A Ordinary Shares</b>&#8221;
means, prior to the Domestication Merger, the Class A ordinary shares of BCAR, par value $0.0001 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>BCAR Class B Ordinary Shares</b>&#8221;
means, prior to the Domestication Merger, the Class B ordinary shares of BCAR, par value $0.0001 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>BCAR Ordinary Shares</b>&#8221; means, collectively,
the BCAR Class A Ordinary Shares and the BCAR Class B Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>BCAR Units</b>&#8221; means the units
of BCAR issued in the IPO, consisting of one Public Share and one-half of one BCAR Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>BCAR Warrant</b>&#8221; means one whole
redeemable warrant exercisable for one BCAR Class A Ordinary Share at an exercise price of $11.50 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Business Combination</b>&#8221; means
the transactions contemplated by the Business Combination Agreement and the other agreements contemplated therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Business Combination Agreement</b>&#8221;
means the Agreement and Plan of Merger, dated as of January 11, 2026, by and among BCAR, Merger Sub, Exascale and D. Boral ARC Merger
Corporation, and as it may be further amended and/or restated from time to time. A copy of the Business Combination Agreement is attached
to this proxy statement/prospectus as <i>Annex A</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Business Combination Proposal</b>&#8221;
means the proposal to be considered at the Extraordinary General Meeting to approve the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Business Day</b>&#8221; means a day, other
than a Saturday or Sunday, on which commercial banks in New York, NY are open for the general transaction of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Current Charter</b>&#8221; means BCAR&#8217;s
Amended and Restated Memorandum and Articles of Association, as in effect on the date of this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Closing</b>&#8221; means the closing of
the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Closing Date</b>&#8221; means the date of
the Closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Code</b>&#8221; means the U.S. Internal
Revenue Code of 1986, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Companies Act</b>&#8221; refers to the Business
Companies Act, (Revised Edition 2020) as amended, of the British Virgin Islands.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Condition Precedent Proposals</b>&#8221;
mean the Business Combination Proposal, the Domestication Merger Proposal, the Organizational Documents Proposal, the Directors Proposal,
the Nasdaq Proposal and the Equity Incentive Plan Proposal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>DGCL</b>&#8221; means the General Corporation
Law of the State of Delaware.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Directors Proposal</b>&#8221; means
the proposal to be considered at the Extraordinary General Meeting to elect the directors of PubCo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Domestication Merger</b>&#8221; means the
merger of BCAR with and into D. Boral ARC Merger Corporation, a Delaware corporation and wholly owned subsidiary of BCAR, upon which the
separate existence of BCAR will cease and D. Boral ARC Merger Corporation will be the surviving corporation (such surviving company, &#8220;<b>PubCo</b>&#8221;)
in accordance with the DGCL, the Companies Act, the Certificate of Merger, which is filed as Exhibit 3.5 to this proxy statement/prospectus
(the &#8220;<b>Certificate of Merger</b>&#8221;), and the Current Charter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Domestication Merger Proposal</b>&#8221;
means the proposal to be considered at the Extraordinary General Meeting to approve the Domestication Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>DWAC</b>&#8221; means The Depository Trust
Company&#8217;s deposit/withdrawal at custodian system.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Effective Time</b>&#8221; means the effective
time of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Equity Incentive Plan</b>&#8221; means the
Exascale Labs Holdings Inc. 2026 Omnibus Equity Incentive Plan, which will become effective upon the Closing. A copy of the Equity Incentive
Plan is attached to this proxy statement/prospectus as <i>Annex C</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Equity Incentive Plan Proposal</b>&#8221;
means the proposal to be considered at the Extraordinary General Meeting to approve the Equity Incentive Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Exascale</b>&#8221; or the &#8220;<b>Company</b>&#8221;
means Exascale Labs Inc., a Delaware corporation, and, if the context requires, Exascale Labs Inc. together with its subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Exascale Board</b>&#8221; means the board
of directors of Exascale prior to the Closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Exascale Common Stock</b>&#8221; means the
common stock, par value $0.01 per share, of Exascale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Exascale Equity Incentive Recipients</b>&#8221;
means, collectively, the persons entitled to receive shares of Exascale Class A Common Stock pursuant to outstanding share-based compensation
awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Exascale Safeholder</b>&#8221; means
holder of a SAFE.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Exascale Securityholders</b>&#8221;
means, collectively, Exascale Stockholders, the Base Camp Investor, the Exascale Equity Incentive Recipients and Exascale Safeholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Exascale Stockholder</b>&#8221; means a
holder of shares of Exascale Common Stock prior to the Closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Exascale Support Agreement</b>&#8221; means
the support agreement, dated as of January&#160;11, 2026, entered by and among BCAR, Exascale and certain stockholders of Exascale, as
it may be amended and supplemented from time to time, pursuant to which such Exascale stockholders have agreed, among other things, to
vote in favor of the adoption and approval of the Business Combination. A copy of the Exascale Support Agreement is attached to this proxy
statement/prospectus as <i>Annex E</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Exchange Act</b>&#8221; means the U.S. Securities
Exchange Act of 1934, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;E<b>xtraordinary General Meeting</b>&#8221;
means the extraordinary general meeting of BCAR&#8217;s shareholders, to be held virtually and in person at 10:00 A.M., Eastern Time on
[_], 2026, at the offices of Loeb &amp; Loeb LLP, 345 Park Avenue, New York, NY 10154, and any adjournments or postponements thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Founder Shares</b>&#8221; means the
12,000,000 BCAR Class B Ordinary Shares acquired by the Sponsor prior to the IPO for the purchase price of $25,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>GaaS</b>&#8221; means GPU-as-a-Service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>GAAP</b>&#8221; means U.S. generally
accepted accounting principles.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>GPU</b>&#8221; means graphics processing
unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>HVDC</b>&#8221; means high-voltage direct
current.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Initial Shareholders</b>&#8221; means
the holders of BCAR Class B Ordinary shares prior to the IPO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Insiders</b>&#8221; means the Sponsor
and each director and officer of BCAR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>IPO</b>&#8221; means BCAR&#8217;s initial
public offering of 28,000,000 BCAR Units (each BCAR Unit consisting of one BCAR Class A Ordinary Share and one-half of one warrant to
purchase one BCAR Class A Ordinary Share at a price of $11.50 per share) pursuant to registration statements on Form S-1 declared effective
by the SEC on July 30, 2025. On August 1, 2025, BCAR completed its initial public offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>IRS</b>&#8221; means the U.S. Internal
Revenue Service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>LLM</b>&#8221; means large language
model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Merger Consideration</b>&#8221; means 50,000,000
shares of PubCo Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Merger Sub</b>&#8221; means D. Boral Arc
Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of BCAR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Nasdaq</b>&#8221; means The Nasdaq Stock
Market LLC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Nasdaq Global Market</b>&#8221; means
the Global Market tier of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Nasdaq Proposal</b>&#8221; means the
proposal to be considered at the Extraordinary General Meeting to approve the issuance of PubCo Common Stock and PubCo Warrants in connection
with the Business Combination, for purposes of complying with the applicable provisions of Nasdaq Stock Exchange Listing Rule 5635.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Organizational Documents Proposal</b>&#8221;
means the proposal to be considered at the Extraordinary General Meeting to approve by ordinary resolution the Proposed Charter and the
Proposed Bylaws. A copy of each of the Proposed Charter and the Proposed Bylaws is attached to this proxy statement/prospectus as <i>Annex
B-1 </i>and <i>Annex B-2</i>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Person</b>&#8221; means any individual,
firm, corporation, partnership, limited liability company, association, trust, joint venture, joint stock company, governmental authority
or instrumentality or other entity or organization of any other kind.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Private Placement Shares</b>&#8221;
or &#8220;<b>Private Shares</b>&#8221; means the BCAR Class A Ordinary Shares included in the Private Units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#8220;Private Placement Warrants</b>&#8221;
means the warrants included in the Private Units, each whole warrant exercisable for one BCAR Class A Ordinary Share at a price of $11.50
per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Private Units</b>&#8221; means the 200,000
units of BCAR, consisting of one BCAR Class A Ordinary Share and one-half of one warrant, issued in a private placement that closed concurrently
with the IPO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Proposed Bylaws</b>&#8221; mean the
proposed bylaws of PubCo to be in effect following the Domestication Merger and Business Combination, a form of which is attached to this
proxy statement/prospectus as <i>Annex B-2</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>Proposed Charter</b>&#8221; means the
proposed certificate of incorporation of PubCo to be in effect following the Domestication Merger and the Business Combination, a form
of which is attached to this proxy statement/prospectus as <i>Annex B-1</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Proposed Organizational Documents</b>&#8221;
means the Proposed Charter and the Proposed Bylaws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>PubCo</b>&#8221; means D. Boral ARC
Merger Corporation following its merger with BCAR (which will be renamed &#8220;Exascale Labs Holdings Inc.&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>PubCo Board</b>&#8221; means the board
of directors of PubCo subsequent to the Closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>PubCo Class A Ordinary Common Stock</b>&#8221;
means the Class A Ordinary Common Stock, par value $0.0001 per share, of PubCo, with each such share having one (1) vote per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>PubCo Class B Super Common Stock</b>&#8221;
means the Class B Common Stock, par value $0.0001 per share, of PubCo, with each such share having twenty (20) votes per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>PubCo Common Stock</b>&#8221; means
PubCo Class A Ordinary Common Stock and PubCo Class B Super Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>PubCo Preferred Stock</b>&#8221; means
the preferred stock of PubCo, par value $0.0001 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>PubCo Warrant</b>&#8221; means a BCAR Warrant
that will become exercisable for one share of PubCo Class A Ordinary Common Stock subsequent to the Closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Public Shareholders</b>&#8221; means the
holders of BCAR Class A Ordinary Shares that were sold in the IPO (whether they were purchased in the IPO or thereafter in the open market).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Public Shares</b>&#8221; means the BCAR
Class A Ordinary Shares sold in the IPO (whether they were purchased in the IPO as part of the BCAR Units or thereafter in the open market)
and, following the Domestication Merger, the shares of PubCo Class A Ordinary Common Stock received in connection with the Domestication
Merger upon conversion of such BCAR Class A Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Public Warrant Holders</b>&#8221; means
the holders of the Public Warrants of BCAR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Public Warrants</b>&#8221; means the BCAR
Warrants sold in the IPO (whether they were purchased in the IPO as part of the BCAR Units or thereafter in the open market).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Record Date</b>&#8221; means [_], 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Representative Shares</b>&#8221; means the
1,000,000 BCAR Class A Ordinary Shares granted to D. Boral Capital LLC, the underwriter in BCAR&#8217;s initial public offering, as compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>SAFE</b>&#8221; means the Simple Agreements
for Future Equity by and between Exascale and each Exascale Safeholder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Sarbanes-Oxley Act</b>&#8221; means the
Sarbanes-Oxley Act of 2002.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>SEC</b>&#8221; means the U.S. Securities
and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Securities Act</b>&#8221; means the U.S.
Securities Act of 1933, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Sponsor</b>&#8221; means MFH 1, LLC, a Delaware
limited liability company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Sponsor Support Agreement</b>&#8221; means
the Sponsor support agreement, dated as of January&#160;11, 2026, entered by and among BCAR, Exascale and the Sponsor, as it may be amended
and supplemented from time to time, pursuant to which the Sponsor has agreed, among other things, to vote in favor of the adoption and
approval of the Business Combination. A copy of the Sponsor Support Agreement is attached to this proxy statement/prospectus as <i>Annex
D</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Transfer Agent</b>&#8221; means Odyssey
Transfer and Trust Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Warrant Agreement</b>&#8221; means the Warrant
Agreement, dated as of July&#160;30, 2025, between BCAR and Odyssey Transfer and Trust Company, as warrant agent, which governs BCAR&#8217;s
outstanding warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>Working Capital Loan</b>&#8221; means any
financing provided by the Sponsor or an affiliate of the Sponsor, or BCAR&#8217;s officers and directors, as may occur, in order to finance
the transaction costs of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_003"></span>MARKET AND INDUSTRY DATA</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are responsible
for the disclosure contained in this proxy statement/prospectus. However, information contained in this proxy statement/prospectus concerning
the market and the industry in which Exascale competes, including its market position, general expectations of market opportunity, size
and growth rates, is based on information from various third-party sources, on assumptions made by Exascale based on such sources and
Exascale&#8217;s knowledge of the markets for its services and solutions. This information and any estimates provided herein involve numerous
assumptions and limitations, and third-party sources generally state that the information contained in such source has been obtained from
sources believed to be reliable. The industry in which Exascale operates is subject to a high degree of uncertainty and risk. As a result,
the estimates and market and industry information provided in this proxy statement/prospectus are subject to change based on various factors,
including those described in &#8220;<i>Cautionary Note Regarding Forward-Looking Statements</i>&#8221; and &#8220;<i>Risk Factors &#8212;
Risks Related to Exascale</i>&#8221; and elsewhere in this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_003a"></span>TRADEMARKS, TRADE NAMES
AND SERVICE MARKS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This proxy statement/prospectus contains references
to trademarks, trade names and service marks. Solely for convenience, trademarks, trade names and service marks referred to in this proxy
statement/prospectus may appear without the &#174; or &#8482; symbols, but such references are not intended to indicate, in any way, that
the applicable licensor will not assert, to the fullest extent under applicable law, its rights to such trademarks, trade names and service
marks. Neither BCAR nor Exascale intends the use or display of other entities&#8217; trade names, trademarks or service marks in this
proxy statement/prospectus to imply a relationship with, or endorsement or sponsorship of BCAR or Exascale by, any other entities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_004"></span>CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This proxy statement/prospectus contains forward-looking
statements. These forward-looking statements include, without limitation, statements relating to expectations for future financial performance,
business strategies or expectations for the businesses of BCAR, Exascale and PubCo, and the timing and ability of BCAR and Exascale to
complete the Business Combination. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees
of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used
in this proxy statement/prospectus, words such as &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;can&#8221;, &#8220;continue&#8221;,
&#8220;could&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;forecast&#8221;, &#8220;intend&#8221;, &#8220;may&#8221;, &#8220;might&#8221;,
&#8220;plan&#8221;, &#8220;possible&#8221;, &#8220;potential&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;seek&#8221;,
&#8220;should&#8221;, &#8220;strive&#8221;, &#8220;target&#8221;, &#8220;will&#8221;, &#8220;would&#8221; and similar expressions may
identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Forward-looking statements in this proxy statement/prospectus
and in any document incorporated by reference in this proxy statement/prospectus may include, for example, statements about:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the anticipated benefits of the
        Business Combination;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability to consummate the Business
        Combination, including meeting the Minimum Cash Financing condition;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the future financial performance
        of PubCo following the Business Combination;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the market for Exascale&#8217;s
        products and services;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s expected growth,
        scale, and market opportunity in AI infrastructure, GaaS, and enterprise AI compute markets;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the anticipated performance, capacity,
        utilization, availability, and economics of Exascale&#8217;s GPU compute platform;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expected demand for LLM training,
        fine-tuning, and high-concurrency inference workloads and Exascale&#8217;s ability to capture such demand;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s ability to execute
        its business strategy, expand customer relationships, enter into strategic partnerships, and compete effectively in the AI infrastructure
        market;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s ability to execute
        its growth strategy, manage growth and maintain its corporate culture as it grows;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expectations regarding Exascale
        existing contracts and agreements, including its memorandum of understanding;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">anticipated technology trends and
        developments and Exascale&#8217;s ability to address those trends and developments with its products and offerings;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s future regulatory,
        legal, and compliance environment, including matters related to data security, AI regulation, energy usage, and data center operations;
        and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#9679;</td>
    <td style="text-align: justify">expansion plans and opportunities.</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These forward-looking statements are based on information
available as of the date of this proxy statement/prospectus and BCAR&#8217;s and Exascale&#8217;s managements&#8217; current expectations,
forecasts and assumptions, and involve a number of judgments, known and unknown risks and uncertainties and other factors, many of which
are outside the control of BCAR, Exascale and their respective directors, officers and affiliates. Accordingly, forward-looking statements
should not be relied upon as representing BCAR&#8217;s or Exascale&#8217;s views as of any subsequent date. Neither BCAR nor Exascale
undertakes any obligation to update, add or to otherwise correct any forward-looking statements contained herein to reflect events or
circumstances after the date they were made, whether as a result of new information, future events, inaccuracies that become apparent
after the date hereof or otherwise, except as may be required under applicable securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should not place undue reliance on these forward-looking
statements in deciding how your vote should be cast or in voting your shares on the proposals set out in this proxy statement/prospectus.
Should one or more of a number of known and unknown risks and uncertainties materialize, or should any of BCAR&#8217;s and Exascale&#8217;s
assumptions prove incorrect, actual results or performance may be materially different from those expressed or implied by these forward-looking
statements. Some factors that could cause actual results to differ include, but are not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the occurrence of any event, change
        or other circumstances that could delay the Business Combination or give rise to the termination of the Business Combination Agreement;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">estimates and forecasts of financial
        and performance metrics and expectations and timing related to potential benefits, terms and timing of the Business Combination;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks relating to the uncertainty
        of the projected financial information with respect to Exascale and PubCo;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the outcome of any legal proceedings
        that may be instituted against Exascale or BCAR following announcement of the Business Combination and transactions contemplated thereby;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inability to complete the Business
        Combination due to the failure to obtain approval of the BCAR shareholders or the failure of BCAR or Exascale to meet the conditions to
        closing in the Business Combination Agreement;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo&#8217;s public securities&#8217;
        liquidity and trading;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the risk that the Business Combination
        disrupts current plans and operations;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability to recognize the anticipated
        benefits of the Business Combination, which may be affected by, among other things, competition, and the ability of PubCo to grow and
        manage growth profitably;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs related to the Business Combination;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s ability to obtain
        sufficient additional financing, on acceptable terms or at all, and ability to continue as a going concern;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of Exascale&#8217;s remaining
        indebtedness outstanding following the Business Combination;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the market in which Exascale
        competes, including with respect to its competitive landscape, technology evolution or changes in applicable laws or regulations;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demand uncertainty for AI compute
        services, including slower-than-anticipated adoption of LLMs, changes in customer workload requirements, budget constraints, or shifts
        toward alternative architectures or in-house compute solutions;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations in utilization rates
        of Exascale&#8217;s GPU capacity, which could negatively affect revenues, margins, and operating leverage;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">technological risks, including the
        performance, scalability, reliability, and security of Exascale&#8217;s platform, as well as the pace of innovation in AI hardware and
        software that could render Exascale&#8217;s offerings less competitive;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competitive pressures from hyperscalers,
        cloud service providers, vertically integrated AI infrastructure companies, and other GaaS providers with greater scale, resources, or
        pricing flexibility;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of macroeconomic events,
        such as inflation, recessions or depressions, and war or fears of war;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the vertical markets
        that Exascale targets;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of current or future
        government regulation and oversight, including the U.S. federal, state and local authorities;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability to launch new Exascale
        services and products or to profitably expand into new markets;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability to execute Exascale&#8217;s
        growth strategies, including identifying and executing acquisitions;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability to develop and maintain
        effective internal controls and procedures, correct or remediate the previously identified material weaknesses, or correct or remediate
        any future identified material weaknesses;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exposure to any liability, protracted
        and costly litigation or reputational damage relating to Exascale&#8217;s data security;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility that Exascale, PubCo
        or BCAR may be adversely affected by other economic, business, and/or competitive factors; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other risks and uncertainties indicated
        in this proxy statement/prospectus, including those set forth under &#8220;Risk Factors&#8221; in this proxy statement/prospectus.&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_005"></span>QUESTIONS AND ANSWERS FOR
SHAREHOLDERS OF BCAR</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The questions and answers below highlight only
selected information from this document and only briefly address some commonly asked questions about the proposals to be presented at
the Extraordinary General Meeting, including with respect to the Business Combination. The following questions and answers do not include
all the information that is important to BCAR&#8217;s shareholders. BCAR urges shareholders to read this proxy statement/prospectus, including
the Annexes and the other documents referred to herein, carefully and in their entirety to fully understand the Business Combination and
the voting procedures for the Extraordinary General Meeting, which will be held at 10:00 A.M., Eastern Time, on [_], 2026, at the offices
of Loeb &amp; Loeb LLP, 345 Park Avenue, New York, NY 10154. You may also attend the Extraordinary General Meeting virtually via telephone
at: </i>Telephone number: __________________ Participant Passcode: __________________. <i>For the purposes of British Virgin Islands law
and the Current Charter (as defined herein), the physical location of the Extraordinary General Meeting will be at the offices of Loeb
&amp; Loeb LLP, 345 Park Avenue, New York, NY 10154. If you hold your shares through a bank, broker or other nominee, you will need to
take additional steps to participate in the Extraordinary General Meeting, as described in this proxy statement/prospectus.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="text-align: left; padding-left: 0pt; vertical-align: top; width: 0.25in"><b><i>Q.</i></b></td>
    <td style="vertical-align: top; text-align: justify"><b><i>Why am I receiving this proxy statement/prospectus?</i></b></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0in"/>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">You are receiving this proxy statement/prospectus because you
        are a shareholder of BCAR and you are entitled to vote at the Extraordinary General Meeting to approve the matters set forth herein. This
        document serves as:</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a proxy statement of BCAR to solicit proxies for the Extraordinary
        General Meeting on the matters set forth herein; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a prospectus of PubCo to offer PubCo Common Stock and PubCo
        Warrants to the BCAR shareholders and warrant holders in the Domestication Merger and to the Exascale Securityholders in the Business
        Combination.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">BCAR shareholders are being asked to consider
and vote upon, among other proposals, a proposal to approve and adopt the Business Combination Agreement and approve the Business Combination.
The Business Combination Agreement provides for, among other things, (i) the Domestication Merger of BCAR and (ii) the merger of Merger
Sub with and into Exascale, with Exascale surviving the merger, in accordance with the terms and subject to the conditions of the Business
Combination Agreement, as more fully described elsewhere in this proxy statement/prospectus. See &#8220;<i>The Business Combination Proposal</i>&#8221;
and &#8220;<i>The Domestication Merger Proposal</i>&#8221; for more detail. The BCAR Board is soliciting your proxy to vote for the Business
Combination and other proposals at the Extraordinary General Meeting because you owned BCAR Class A Ordinary Shares at the close of business
on [_], 2026, the &#8220;Record Date&#8221; for the Extraordinary General Meeting, and are therefore entitled to vote at the meeting.
This proxy statement/prospectus summarizes the information that you need to know in order to cast your vote.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">A copy of the Business Combination Agreement
is attached to this proxy statement/prospectus as <i>Annex A </i>and you are encouraged to read it in its entirety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">THE VOTE OF PUBLIC SHAREHOLDERS IS IMPORTANT.
PUBLIC SHAREHOLDERS ARE ENCOURAGED TO VOTE AS SOON AS POSSIBLE AFTER CAREFULLY REVIEWING THIS PROXY STATEMENT/PROSPECTUS, INCLUDING THE
ANNEXES AND THE ACCOMPANYING FINANCIAL STATEMENTS OF BCAR AND EXASCALE.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0in"/>
    <td style="vertical-align: top; width: 0.25in"><b><i>Q.</i></b></td>
    <td style="vertical-align: top; text-align: justify"><b><i>What proposals are shareholders of BCAR being asked to vote upon?</i></b></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0in"/>
    <td style="vertical-align: top; width: 0.25in"><b><i>A.</i></b></td>
    <td style="vertical-align: top; text-align: justify">At the Extraordinary General Meeting, BCAR is asking holders of BCAR Ordinary Shares
        to consider and vote upon:</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">The Business Combination Proposal;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">The Domestication Merger Proposal;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">The Organizational Documents Proposal;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Advisory Organizational Documents Proposals;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td/>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right"/>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Directors Proposal;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Equity Incentive Plan Proposal;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td/>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right"/>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Nasdaq Proposal; and </span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">The Adjournment Proposal, if presented.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">If BCAR&#8217;s shareholders do not approve
each of the Condition Precedent Proposals, then unless certain conditions in the Business Combination Agreement are waived by the applicable
parties to the Business Combination Agreement, the Business Combination Agreement could be terminated and the Business Combination may
not be consummated. See &#8220;<i>The Business Combination Proposal</i>,&#8221; &#8220;<i>The Domestication Merger Proposal</i>,&#8221;
&#8220;<i>The Organizational Documents Proposal</i>,&#8221; &#8220;<i>The Directors Proposal</i>,&#8221; &#8220;<i>The Equity Incentive
Plan Proposal</i>,&#8221; and &#8220;<i>The Nasdaq Proposal</i>,&#8221; of this proxy statement/prospectus, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">BCAR will hold the Extraordinary General
Meeting to consider and vote upon these proposals. This proxy statement/prospectus contains important information about the Business Combination
and the other matters to be acted upon at the Extraordinary General Meeting. Shareholders of BCAR should read it carefully.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">After careful consideration, the BCAR Board
has determined that each of (i) the Business Combination Proposal, (ii) the Domestication Merger Proposal, (iii) the Organizational Documents
Proposal, (iv) the Advisory Organizational Documents Proposals, (v) the Directors Proposal, (vi) the Equity Incentive Plan Proposal, (vii)
the Nasdaq Proposal, and (viii) the Adjournment Proposal, if presented, are in the best interests of BCAR and its shareholders and unanimously
recommends that you vote or give instruction to vote &#8220;FOR&#8221; each of those proposals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">If
BCAR&#8217;s shareholders do not approve each of the Condition Precedent Proposals, then unless certain conditions in the Business Combination
Agreement are waived by the applicable parties to the Business Combination Agreement, the Business Combination Agreement could terminate
and the Business Combination may not be consummated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">The existence of financial and personal
interests of one or more of BCAR&#8217;s directors may result in a conflict of interest on the part of such director(s) between what he,
she or they may believe is in the best interests of BCAR and its shareholders and what he, she or they may believe is best for himself,
herself or themselves in determining to recommend that shareholders vote for the proposals. In addition, BCAR&#8217;s officers have interests
in the Business Combination that may conflict with your interests as a shareholder. See &#8220;<i>The Business Combination Proposal &#8212;
Certain Interests of BCAR&#8217;s Directors and Officers and Others in the Business Combination</i>&#8221; for a further discussion of
these considerations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt"><b><i>Q.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Are the proposals conditioned on one another?</i></b></span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Yes. The Business Combination
        is conditioned on the approval of each of the Condition Precedent Proposals at the Extraordinary General Meeting. Each of the Condition
        Precedent Proposals is cross-conditioned on the approval of each other. The Advisory Organizational Documents Proposals and the Adjournment
        Proposal are not conditioned upon the approval of any other proposal. It is important for you to note that in the event that the Business
        Combination Proposal is not approved, BCAR will not consummate the Business Combination. If BCAR does not consummate the Business Combination
        and fails to complete an initial business combination by February&#160;1, 2027 (or May&#160;1, 2027 if the Sponsor exercises its three-month
        extension option) BCAR will be required to dissolve and liquidate.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt"><b><i>Q.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Why is BCAR proposing the Business Combination?</i></b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt; width: 0.25in"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">BCAR was incorporated to effect a merger, share exchange, asset
        acquisition, share purchase, reorganization or similar business combination, with one or more businesses or entities.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Exascale is a next-generation AI infrastructure
provider operating an asset-light, software-defined GPU compute platform and related AI infrastructure solutions. Exascale&#8217;s core
business includes GaaS, through which it provides reserved and on-demand access to high-performance GPU compute capacity sourced from
third-party data centers globally, as well as GPU cluster management and optimization services for AIDC operators. In addition, Exascale
has developed certain modular data center, high-density liquid cooling, HVDC power and energy storage solutions that are designed to address
deployment bottlenecks in AI infrastructure and that Exascale believes are ready for commercial engagement, although these capabilities
have not yet generated revenue as of the date of this proxy statement/prospectus. The platform is purpose-built for large-scale AI workloads,
including LLM training, fine-tuning, and high-concurrency inference. Additional information about Exascale is set forth in the section
titled &#8220;<i>Information about Exascale</i>&#8221; in this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Based on BCAR&#8217;s due diligence investigations
of Exascale and the industry in which it operates, including the financial and other information provided by Exascale in the course of
BCAR&#8217;s due diligence investigations, the BCAR Board believes that the Business Combination with Exascale is in the best interests
of BCAR and its shareholders, and presents an opportunity to increase shareholder value. However, there is no assurance that the Business
Combination with Exascale will increase shareholder value. See &#8220;<i>The Business Combination Proposal &#8212; BCAR Board of Directors&#8217;
Reasons for the Approval of the Business Combination</i>&#8221; for additional information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Although
the BCAR Board believes that the Business Combination with Exascale presents an attractive business combination opportunity and is in
the best interests of BCAR and its shareholders, the BCAR Board did consider certain potentially material negative factors in arriving
at that conclusion. These factors are discussed in greater detail in &#8220;<i>The Business Combination Proposal &#8212; BCAR Board of
Directors&#8217; Reasons for the Approval of the Business Combination</i>,&#8221; as well as in &#8220;<i>Risk Factors &#8212; Risks Related
to Exascale.&#8221;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Did the BCAR Board obtain a third-party valuation or fairness
        opinion in determining whether or not to proceed with the Business Combination?</b></span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">A.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">No. See <i>&#8220;Risk Factors &#8211; Risks Relating to our
        Search for, and Consummation of or Inability to Consummate, a Business Combination &#8211; Neither the BCAR Board nor any committee thereof
        obtained a fairness opinion (or any similar report or appraisal) in determining whether or not to pursue the Business Combination. Consequently,
        you have no assurance from an independent source that the price BCAR is paying for Exascale is fair to BCAR - and, by extension, its securityholders
        - from a financial point of view&#8221; and &#8220;&#8211;The BCAR Board did not obtain a fairness opinion (or any similar report or appraisal)
        in connection with its determination to approve the Business Combination (including the consideration to be delivered to Exascale stockholders
        under the terms of the Business Combination Agreement).&#8221;</i></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr>
    <td style="vertical-align: top; text-align: justify; width: 0in"/>
    <td style="text-align: justify; vertical-align: top; width: 0.25in"><b><i>Q.</i></b></td>
    <td style="vertical-align: top; text-align: justify"><b><i>What will Exascale Securityholders receive in connection with the Business Combination?</i></b></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><b>A.</b></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
        the Business Combination Agreement, Exascale Securityholders immediately prior to the Closing will collectively receive 50,000,000 shares
        of PubCo Common Stock (the &#8220;<b>Merger Consideration</b>&#8221;) in exchange for their then outstanding interests in Exascale. Holders
        of Exascale Class A common stock and Exascale securities convertible or exchangeable for shares of Exascale Class A common stock (being
        the Exascale Safeholders, the Base Camp Investor and Exascale Equity Incentive Recipients) will receive shares of PubCo Class A Ordinary
        Common Stock in exchange for such interests in Exascale, with each such PubCo Class A Ordinary Common Stock having one (1) vote per share,
        and holders of Exascale Class B common stock will receive shares of PubCo Class B Super Common Stock for their Exascale Class B common
        stock, with each share of such PubCo Class B Super Common Stock having twenty (20) votes per share.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
allocation of the 50,000,000 shares of PubCo Common Stock among Exascale Securityholders will be determined in accordance with (i) the
conversion provisions applicable in the event of a &#8220;liquidity event&#8221; under the SAFEs, (ii) the terms of the Base Camp Investment
Agreement, and (iii) the allocation percentages applicable to the Exascale Equity Incentive Recipients and Exascale stockholders. As a
result, the allocation of the Merger Consideration among Exascale Securityholders is not determined using a single uniform exchange ratio
applicable to all Exascale securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">At
the closing of the Acquisition Merger, each issued and outstanding SAFE will be cancelled and converted into the right to receive a number
of shares of PubCo Class A Ordinary Common Stock based on the SAFE&#8217;s &#8220;implied ownership percentage,&#8221; as determined
under the terms of the applicable SAFE in connection with the Business Combination, which constitutes a &#8220;liquidity event&#8221;
under the SAFEs. In general, a SAFE&#8217;s implied ownership percentage is the product of (i) the quotient obtained by dividing (x)
the SAFE&#8217;s purchase amount by (y) the SAFE&#8217;s post-money valuation cap, multiplied by (ii) 100; subject to the capitalization
adjustments, rounding provisions, and other terms contained in the applicable SAFE and the final closing calculations. The resulting
implied ownership percentage determines the number of shares of the 50,000,000 Merger Consideration issuable for each SAFE. Based on
the foregoing, the aggregate implied ownership percentage of all SAFEs outstanding on the filing date of this proxy statement/prospectus
was 17.533%, entitling all the SAFEs to collectively receive an aggregate of 8,766,500 shares of PubCo Class A Ordinary Common Stock
as their portion of the Merger Consideration in connection with the consummation of the Business Combination. The right of an Exascale
Safeholder to receive PubCo Class A Ordinary Common Stock for their SAFE will be contingent on the execution by such Exascale Safeholder
of an acknowledgement and such other agreements and other documents as Exascale deems necessary, appropriate or expedient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">At the closing of the Acquisition Merger,
the Base Camp Investment Agreement will be cancelled and converted into the right to receive a number of shares of PubCo Class A Ordinary
Common Stock based on the &#8220;implied ownership percentage&#8221; attributable to the Base Camp Investment Agreement. The implied ownership
percentage applicable to the Base Camp Investment Agreement is a fixed percentage determined in accordance with the terms of the Base
Camp Investment Agreement and will equal 0.625%, entitling the Base Camp Investor to receive an aggregate of 312,500 PubCo Class A Ordinary
Common Stock as their portion of the Merger Consideration in connection with the consummation of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">At
the closing of the Acquisition Merger, each then outstanding Exascale Equity Incentive award will be cancelled and converted into the
right to receive a number of shares of PubCo Class A Ordinary Common Stock based on the &#8220;implied ownership percentage&#8221; attributable
to the award. The implied ownership percentage of the Exascale Equity Incentive awards is determined based on Exascale&#8217;s fully diluted
capitalization, and, based on Exascale&#8217;s capitalization as of the filing date of this proxy statement/prospectus, will be 0.154%,
entitling the Exascale Equity Incentive Recipients to receive an aggregate of 77,000 PubCo Class A Ordinary Common Stock as their portion
of the Merger Consideration in connection with the consummation of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">At
the closing of the Acquisition Merger, each issued and outstanding Exascale Class A common stock will be cancelled and converted into
the right to receive a number of shares of PubCo Class A Ordinary Common Stock based on the &#8220;implied ownership percentage&#8221;
attributable to Exascale&#8217;s Class A common stock. The implied ownership percentage of the Exascale Class A common stock is determined
based on Exascale&#8217;s fully diluted capitalization, and, based on Exascale&#8217;s capitalization as of the filing date of this proxy
statement/prospectus, will be 20.200%, entitling the holders of Exascale Class A common stock to receive an aggregate of 10,100,000 PubCo
Class A Ordinary Common Stock as their portion of the Merger Consideration in connection with the consummation of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">At
the closing of the Acquisition Merger, each issued and outstanding Exascale Class B common stock will be cancelled and converted into
the right to receive a number of shares of PubCo Class B Super Common Stock based on the &#8220;implied ownership percentage&#8221; attributable
to Exascale&#8217;s Class B common stock. The implied ownership percentage of the Exascale Class B common stock is determined based on
Exascale&#8217;s fully diluted capitalization, and, based on Exascale&#8217;s capitalization as of the filing date of this proxy statement/prospectus,
will be 61.488%, entitling the holders of Exascale Class B common stock to receive an aggregate of 30,744,000 PubCo Class B Ordinary Common
Stock as their portion of the Merger Consideration in connection with the consummation of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the Effective Time, the holders of Exascale Common Stock, the Exascale Safeholders, the Base Camp Investor, and the Exascale Equity Incentive
Recipients will cease to have any rights with respect to Exascale securities, except the right to receive their portion of the Merger
Consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
allocation of the 50,000,000 shares of PubCo Class A Common Stock is set forth below (based on Exascale&#8217;s capitalization as of the
filing date of this proxy statement/prospectus):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 20%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exascale
        securityholder group</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 31%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Calculation
        basis</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership<br/>
        percentage</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PubCo
        shares&#160;to<br/> be received</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 21%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PubCo<br/>
        share class</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale Safeholders</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sum of each
        Safeholder&#8217;s purchase amount divided by the applicable post-money valuation cap, subject to capitalization, rounding and final closing
        allocation mechanics</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.533%</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,766,500</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo Class A
        Ordinary Common Stock</span></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Base Camp Investment
        Agreement Investor</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.625% of Exascale&#8217;s
        total equity, calculated on a fully diluted basis</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.625%</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">312,500</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo Class A
        Ordinary Common Stock</span></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale Equity
        Incentive Recipients</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">Fixed allocation percentages based on Exascale&#8217;s fully-diluted capitalization</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.154%</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77,000</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo Class A
        Ordinary Common Stock</span></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale Class
        A common stockholders </span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed allocation
        percentages based on Exascale&#8217;s fully-diluted capitalization </span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.200%</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,100,000</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo Class A
        Ordinary Common Stock</span></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale Class
        B common stockholders</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed allocation
        percentages based on Exascale&#8217;s fully-diluted capitalization</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61.488%</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,744,000</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo Class B
        Super Common Stock</span></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>100.000%</b></span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>50,000,000</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing discussion and figures are provided
to illustrate the allocation mechanics, and remain subject to final rounding and closing adjustments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Will PubCo obtain new financing in connection with the Business
        Combination?</b></span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">A.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Pursuant to the Business Combination Agreement, BCAR agreed
        to cause PubCo to receive an amount of at least $5,000,000 in any combination of cash, cash in the trust account, a PIPE, an equity line
        of credit, or third-party financing, net of any outstanding checks, wire transfers, or similar items not yet cleared, and net of any cash
        distributions or transfers made in connection with or as a result of the Business Combination (the &#8220;<b>Minimum Cash Financing</b>&#8221;).
        It is a condition precedent to Closing that PubCo receive the Minimum Cash Financing on or prior to Closing. If the Minimum Cash Financing
        is not met, and such condition is not waived by Exascale under the terms of the Business Combination Agreement, the proposed Business
        Combination will not be consummated. In the event that the Business Combination will not be consummated, all Public Shares submitted for
        redemption will be returned to the holders thereof, and we may instead search for an alternate business combination or liquidate BCAR.
        As of the date hereof, neither BCAR nor PubCo has secured financing for the Minimum Cash Financing. The management teams of BCAR and Exascale
        are continuing to analyze the available financing options based on cost, amount available under the facility and future effects that any
        financing would have on the capitalization of PubCo. BCAR, BCAR&#8217;s Sponsor, Exascale and their affiliates have no prior relationships
        with any of the potential financing sources being considered in connection with the Business Combination. Upon entry into a financing
        arrangement for the Business Combination, including any Minimum Cash Financing, BCAR will disclose such arrangement (including the potential
        dilution) in accordance with the rules of the SEC.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">At any time at or prior to the Extraordinary
General Meeting, during a period when they are not then aware of any material nonpublic information regarding BCAR or its securities,
our Sponsor, officers, directors and/or their affiliates, in compliance with the tender offer rules and other Exchange Act limitations,
including Rule 14e-5 thereunder, may purchase Public Shares from institutional and other investors, execute agreements to purchase shares
from such investors in the future, or they may enter into transactions, including non-redemption agreements, with such investors and others
to provide them with incentives to acquire shares of BCAR and/or not to redeem (or to validly rescind any redemption requests). Our Sponsor,
officers, directors and/or their affiliates anticipate that they may identify such unaffiliated third-party shareholders with whom our
Sponsor, officers, directors or their affiliates may pursue privately negotiated transactions by either the shareholders contacting us
directly or by our receipt of redemption requests submitted by shareholders following our mailing of proxy materials in connection with
the Business Combination. To the extent that our Sponsor, officers, directors, advisors or their affiliates enter into a private transaction
with an unaffiliated third party, they would identify and contact only potential selling or redeeming shareholders who have expressed
their election to redeem their shares for a pro rata share of the trust account, whether or not such shareholder has already submitted
a proxy with respect to the Business Combination but only if such shares have not already been voted at the Extraordinary General Meeting.
Our Sponsor, executive officers, directors, advisors or their affiliates will select which shareholders to purchase shares from based
on the negotiated price and number of shares and any other factors that they may deem relevant, and will be restricted from purchasing
shares if such purchases do not comply with Regulation M under the Exchange Act and the other federal securities laws. Any such privately
negotiated transactions may be effected at purchase prices that are no greater than the per share pro rata portion of the trust account.
Such privately negotiated transactions may include a contractual acknowledgement that such unaffiliated third-party shareholder, although
still the record or beneficial holder of our shares, is no longer the beneficial owner thereof and therefore agrees not to exercise its
redemption rights. In the event that our Sponsor, officers, directors and/or their affiliates purchase shares in privately negotiated
transactions from unaffiliated third-party shareholders who have already elected to exercise their redemption rights, such selling shareholders
would be required to revoke their prior elections to redeem their Public Shares. The purpose of such share purchases and other transactions
would be to limit the number of Public Shares electing to be redeemed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">In accordance with the SEC&#8217;s Compliance
and Disclosure Interpretation 166.01, any Public Shares purchased by our Sponsor, officers, directors and/or their affiliates would not
be voted in favor of approving the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Except as disclosed in this proxy statement/prospectus,
we have not entered into any privately negotiated transactions with respect to our shares as of the date hereof. If they engage in such
privately negotiated transactions, our Sponsor, officers, directors and/or their affiliates will be restricted from making any such purchases
when they are in possession of any material non-public information not disclosed to the seller or if such purchases are prohibited by
Regulation M under the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Our Sponsor, officers, directors and/or
their affiliates will be restricted from making purchases of shares if the purchases would violate Section 9(a)(2) or Rule 10b-5 of the
Exchange Act. We expect any such purchases would be reported by such person pursuant to Section 13 and Section 16 of the Exchange Act
to the extent such purchasers are subject to such reporting requirements. Additionally, in the event our Sponsor, directors, executive
officers, advisors, or their affiliates were to purchase shares or warrants from Public Shareholders, or if any third party investors
are incentivized to acquire Public Shares by our Sponsor, directors, executive officers, or their affiliates, such purchases would be
structured in compliance with the requirements of Rule 14e-5 under the Exchange Act including, in pertinent part, through adherence to
the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">our registration statement/proxy statement filed for our business
        combination transaction would disclose the possibility that our Sponsor, directors, executive officers, advisors or any of their affiliates
        may purchase shares or warrants from Public Shareholders outside the redemption process, along with the purpose of such purchases;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">if our Sponsor, directors, executive officers, advisors or any of their affiliates
        were to purchase shares or warrants from Public Shareholders, they would do so at a price no higher than the price offered through our
        redemption process;</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any of our securities purchased by our Sponsor, directors, executive officers,
        advisors or any of their affiliates would not be voted in favor of approving the business combination transaction;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our Sponsor, directors, executive officers, advisors or any of their affiliates
        would not possess any redemption rights with respect to our securities or, if they do acquire and possess redemption rights, they would
        waive such rights; and</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we would disclose in a Current Report on Form 8-K, before our security holder
        meeting to approve the business combination transaction, the following material items:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the amount of our securities purchased outside of the redemption offer by our
        Sponsor, directors, executive officers, advisors or any of their affiliates, along with the purchase price;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the purpose of the purchases by our Sponsor, directors, executive officers,
        advisors or any of their affiliates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the impact, if any, of the purchases by our Sponsor, directors, executive officers,
        advisors or any of their affiliates on the likelihood that the business combination transaction will be approved;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the identities of our security holders who sold to our Sponsor, directors, executive
        officers, advisors or any of their affiliates (if not purchased on the open market) or the nature of our security holders (e.g., 5% security
        holders) who sold to our Sponsor, directors, executive officers, advisors or any of their affiliates; and</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the number of our securities for which we have received redemption requests
        pursuant to our redemption offer.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">None of the funds in the trust account
will be used to purchase Public Shares in such transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0in"/>
    <td style="vertical-align: top; width: 0.25in"><b><i>Q.</i></b></td>
    <td style="vertical-align: top; text-align: justify"><b><i>What equity stake will current BCAR shareholders and Exascale Securityholders hold
        in PubCo immediately after the consummation of the Business Combination?</i></b></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt;"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify">It is anticipated that, following the Business
    Combination, an aggregate of 91,200,000 shares of PubCo Common Stock will be outstanding, and based on Exascale&#8217;s balance of
    capital stock as of the date of this proxy statement/prospectus, comprised of: (i) 19,256,000 shares of PubCo Class A Ordinary Common
    Stock and 30,744,000 shares of PubCo Class B Super Common Stock, issued to Exascale Securityholders in the Business Combination,
    constituting approximately 54.8% of the outstanding PubCo Common Stock from an economic perspective and 94.0% of the outstanding
    PubCo Common Stock from a voting perspective; (ii) 13,200,000 shares of PubCo Class A Ordinary Common Stock issued to the Sponsor,
    constituting approximately 14.5% of the outstanding shares of PubCo Common Stock from an economic perspective and 2.0% of the outstanding
    PubCo Common Stock from a voting perspective; and (iii) 28,000,000 shares of PubCo Class A Ordinary Common Stock held by Public Shareholders,
    or 30.7% of the outstanding PubCo Common Stock from an economic perspective and 4.2% of the outstanding PubCo Common Stock from a
    voting perspective. These percentages assume that there are no redemptions, no BCAR Warrants will be exercised and there are no other
    issuances of equity securities of PubCo prior to or in connection with the Closing, including any equity awards that may be issued
    under the Equity Incentive Plan following the Business Combination. If the actual facts are different from these assumptions, the
    percentage ownership retained by BCAR&#8217;s existing shareholders in PubCo will be different.</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The
following summarizes the pro forma ownership of PubCo Class A Ordinary Common Stock and PubCo Class B Super Common Stock immediately following
the Business Combination across a range of varying redemption scenarios.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        No<br/> Redemption</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        50% of<br/> Maximum Redemption</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        100% of<br/> Maximum Redemption</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ownership<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Voting<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ownership<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Voting<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ownership<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Voting<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">PubCo
        Class A Ordinary Common Stock held by former Exascale Securityholders (including Exascale Class A common stockholders, the Exascale Safeholders,
        the Exascale Base Camp Investor, and the Exascale Equity Incentive Recipients)<sup>(1)</sup></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">19,256,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">21.1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">19,256,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">24.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">19,256,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30.5</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">PubCo
        Class B Super Common Stock held by former Exascale stockholders<sup>(2)</sup></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,744,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">33.7</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">91.1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,744,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">39.8</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">93.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,744,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">48.6</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">95.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt;">PubCo
    Class A Ordinary Common Stock held by Insiders<sup>(3)</sup></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">14.5</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">17.1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">20.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">PubCo
        Class A Ordinary Common Stock held by Non-Affiliated Public</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">28,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30.7</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">4.2</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">14,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">18.2</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
        pro forma PubCo Class A Ordinary Common Stock and PubCo Class B Super Common Stock</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">91,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">77,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">63,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Consists
        of (i) 10,100,000 PubCo Class A Ordinary Common Stock to be issued to current holders of Exascale Class A common stock, (ii) 8,766,500
        PubCo Class A Ordinary Common Stock to be issued to the Exascale Safeholders, (iii) 312,500 PubCo Class A Ordinary Common Stock to be
        issued to the Exascale Base Camp Investor, and (iv) 77,000 PubCo Class A Ordinary Common Stock to be issued to the Exascale Equity Incentive
        Recipients. For additional details, see &#8220;<i>Questions and Answers for Shareholders of BCAR&#8212;What will Exascale Securityholders
        receive in connection with the Business Combination?&#8221; Proposal No. 1&#8212;The Business Combination Proposal&#8212;The Business
        Combination Agreement&#8212;Consideration&#8221; and &#8220;Unaudited Pro Forma Condensed Combined Financial Information&#8212;Description
        of the Transactions.</i>&#8221;</span></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">2.</td>
    <td style="text-align: justify">Consists of 30,744,000 PubCo Class B Super Common Stock to be issued to
        current holders of Exascale Class B common stock. For additional details, see &#8220;<i>Questions and Answers for Shareholders of BCAR&#8212;What
        will Exascale Securityholders receive in connection with the Business Combination?&#8221; Proposal No. 1&#8212;The Business Combination
        Proposal&#8212;The Business Combination Agreement&#8212;Consideration&#8221; and &#8220;Unaudited Pro Forma Condensed Combined Financial
        Information&#8212;Description of the Transactions.</i>&#8221;</td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">3.</td>
    <td style="text-align: justify">Consists of 13,200,000 PubCo Class A Ordinary Common Stock to
    be issued in exchange for (i) 12,000,000 BCAR Class B Ordinary Shares held by the Sponsor, (ii) 200,000 BCAR Class A Ordinary Shares
    underlying the Private Units held by the Sponsor and (iii) 1,000,000 BCAR Class A Ordinary Shares (being the Representative Shares)
    held by BCAR&#8217;s Chairman and Chief Executive Officer.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Stockholders
will experience additional dilution to the extent PubCo issues additional shares of PubCo Common Stock in connection with any Minimum
Cash Financing and/or after the closing of the Business Combination. The table above excludes any shares that will be issuable upon the
exercise or settlement of: (i) the 100,000 Private Placement Warrants, and (ii) the 14,000,000 Public Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The
following table illustrates varying ownership levels in PubCo immediately following the consummation of the Business Combination based
on the varying levels of redemptions by the Public Shareholders, on a fully diluted basis, showing full exercise and conversion of all
securities, including the Public Warrants and Private Placement Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        No<br/> Redemption</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        50% of<br/> Maximum Redemption</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        100% of<br/> Maximum Redemption</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ownership<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Voting<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ownership<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Voting<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ownership<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Voting<br/>
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">PubCo
        Class A Ordinary Common Stock held by former Exascale Securityholders (including Exascale Class A common stockholders, the Exascale Safeholders,
        the Exascale Base Camp Investor, and the Exascale Equity Incentive Recipients)<sup>(1)</sup></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">19,256,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">18.3</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.8</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">19,256,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">22.8</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">19,256,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30.4</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">PubCo
        Class B Super Common Stock held by former Exascale stockholders<sup>(2)</sup></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,744,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">29.2</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">89.2</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,744,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">36.5</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">92.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,744,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">48.6</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">95.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt;">PubCo
    Class A Ordinary Common Stock held by Insiders<sup>(3)</sup></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,300,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">12.6</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,300,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">15.8</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,300,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">21.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">PubCo
        Class A Ordinary Common Stock held by Non-Affiliated Public</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">42,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">39.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">6.1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">21,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">24.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3.1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
        pro forma PubCo Class A Ordinary Common Stock and PubCo Class B Super Common Stock</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">105,300,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">84,300,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">63,300,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">1.</span></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consists of
        (i) 10,100,000 PubCo Class A Ordinary Common Stock to be issued to current holders of Exascale Class A common stock, (ii) 8,766,500 PubCo
        Class A Ordinary Common Stock to be issued to the Exascale Safeholders, (iii) 312,500 PubCo Class A Ordinary Common Stock to be issued
        to the Exascale Base Camp Investor, and (iv) 77,000 PubCo Class A Ordinary Common Stock to be issued to the Exascale Equity Incentive
        Recipients. For additional details, see &#8220;<i>Questions and Answers for Shareholders of BCAR&#8212;What will Exascale Securityholders
        receive in connection with the Business Combination?&#8221; Proposal No. 1&#8212;The Business Combination Proposal&#8212;The Business
        Combination Agreement&#8212;Consideration&#8221; and &#8220;Unaudited Pro Forma Condensed Combined Financial Information&#8212;Description
        of the Transactions.</i>&#8221;</p></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">2.</td>
    <td style="text-align: justify">Consists of 30,744,000 PubCo Class B Super Common Stock to be issued to
        current holders of Exascale Class B common stock. For additional details, see &#8220;<i>Questions and Answers for Shareholders of BCAR&#8212;What
        will Exascale Securityholders receive in connection with the Business Combination?&#8221; Proposal No. 1&#8212;The Business Combination
        Proposal&#8212;The Business Combination Agreement&#8212;Consideration&#8221; and &#8220;Unaudited Pro Forma Condensed Combined Financial
        Information&#8212;Description of the Transactions.</i>&#8221;</td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">3.</td>
    <td style="text-align: justify">Consists of 13,300,000 PubCo Class A Ordinary Common Stock to
    be issued in exchange for (i) 12,000,000 BCAR Class B Ordinary Shares held by the Sponsor, (ii) 200,000 BCAR Class A Ordinary Shares
    underlying the Private Units held by the Sponsor, (iii) 100,000 BCAR Class A Ordinary Shares underlying Private Placement Warrants
    held by the Sponsor and (iv) 1,000,000 BCAR Class A Ordinary Shares (being the Representative Shares) held by BCAR&#8217;s Chairman
    and Chief Executive Officer.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Although
shares of PubCo Class A Ordinary Common Stock and PubCo Class B Super Common Stock have identical economic rights, each holder of shares
of PubCo Class A Ordinary Common Stock shall be entitled to one (1) vote for each share of PubCo Class A Ordinary Common Stock held and
each holder of shares of PubCo Class B Super Common Stock shall be entitled to twenty (20) votes for each share of Class B Super Common
Stock held.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">For
more information, please see the sections entitled &#8220;<i>Unaudited Pro Forma Condensed Combined Financial Information</i>,&#8221;
<i>&#8220;Proposal No. 1&#8212;The Business Combination Proposal&#8212; The Business Combination Agreement&#8212;Consideration.&#8221;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">All
of the relative percentages above are for illustrative purposes only and are based upon certain assumptions as described in the section
entitled &#8220;<i>Unaudited Condensed Combined Pro Forma Financial Information</i>&#8221;. For more information, including the ownership
percentages reflecting the effect of certain dilutive securities, see the section entitled &#8220;<i>The Business Combination Proposal
&#8212; Ownership of PubCo after the Closing.</i>&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><b><i>Q.</i></b></td>
    <td style="text-align: justify"><b><i>Do any conflicts of interest exist relating to the Business Combination?</i></b></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: justify; width: 0in"/>
    <td style="width: 0.25in; text-align: justify"><b>A.</b></td>
    <td style="text-align: justify">Yes. Certain of BCAR&#8217;s directors and executive officers may be deemed to have interests in the transactions
        contemplated by the Business Combination Agreement that are different from, or in addition to, those of BCAR&#8217;s shareholders generally.
        These interests may present these individuals with certain potential conflicts of interest. Our independent directors reviewed and considered
        these interests during their evaluation and negotiation of the Business Combination and in unanimously approving, as members of the BCAR
        Board, the Business Combination Agreement and the transactions contemplated therein, including the Business Combination. The BCAR Board
        concluded that the potential benefits that it expected BCAR and its shareholders to achieve as a result of the Business Combination outweighed
        the potentially negative factors associated with the Business Combination. When you consider the recommendation of the BCAR Board in favor
        of approval of the Business Combination, you should keep in mind that BCAR&#8217;s directors and officers have interests in the Business
        Combination that are different from, or in addition to, your interests as a shareholder, including:</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If the proposed Business Combination is
        not consummated by February 1, 2027 (or May 1, 2027 if the Sponsor exercises its three-month extension option), then we will be required
        to liquidate. In such event, the 12,000,000 BCAR Class B Ordinary Shares, which were acquired by the BCAR&#8217;s sponsor, MFH 1, LLC
        (the &#8220;<b>Sponsor</b>&#8221;), prior to the IPO for an aggregate purchase price of $25,000, will be worthless. Such BCAR Class B
        Ordinary Shares had an aggregate market value of approximately $[_] based on the closing price of BCAR&#8217;s Public Shares of $[_] on
        Nasdaq as of [_], 2026. As a result of the nominal price of $0.002 per Class B Ordinary Share paid by the Sponsor compared to the recent
        market price of BCAR Class A Ordinary Shares, the Sponsor is likely to earn a positive rate of return on their investments in the Class
        B Ordinary Shares even if the holders of BCAR&#8217;s Class A Ordinary Shares experience a negative rate of return on their investments
        in the Class A Ordinary Shares.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If the proposed Business Combination is
        not consummated by February 1, 2027 (or May 1, 2027 if the Sponsor exercises its three-month extension option), then 200,000 private placement
        units (the &#8220;<b>Private Units</b>&#8221;) purchased by the Sponsor for a total purchase price of $2,000,000, will be worthless. Such
        Private Units had an aggregate market value of approximately $[_] closing price of BCAR Units of $[_] on Nasdaq as of [_], 2026.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Sponsor invested an aggregate of $2,025,000 in BCAR, comprised of the $25,000
        purchase price for the Founder Shares and $2,000,000 purchase price for the Private Units. The amount held in BCAR&#8217;s trust account
        was approximately $[_] on the Record Date, implying a value of $[_] per public share. Based on these assumptions, each PubCo Class A Common
        Stock would have an implied value of $[_] per share upon consummation of the Business Combination, representing a [_]% decrease from the
        initial implied value of $[_] per public share. While the implied value of $[_] per share upon consummation of the Business Combination
        would represent a dilution to our Public Shareholders, this would represent a significant increase in value for the Sponsor relative to
        the price it paid for each Founder Share. At approximately $[_] per share, the 12,200,000 PubCo Class A Common Stock that the Sponsor
        would own upon consummation of the Business Combination would have an aggregate implied value of $[_]. As a result, even if the trading
        price of PubCo Class A Common Stock significantly declines, the value of the PubCo Class A Common Stock held by the Sponsor will be significantly
        greater than the amount the Sponsor paid to purchase such shares. For more information, please see &#8220;<i>Risk Factors &#8211; The
        nominal purchase price paid by the Sponsor and directors and officers of BCAR for the Founder Shares may significantly dilute the implied
        value of the Public Shares in the event the parties complete an initial business combination. In addition, the value of the Founder Shares
        will be significantly greater than the amount the Sponsor and directors and officers of BCAR paid to purchase such shares in the event
        the parties complete an initial business combination, even if the Business Combination causes the trading price of the PubCo Class A Common
        Stock to materially decline.</i>&#8221;</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If the proposed Business Combination is not consummated, then 1,000,000 BCAR
        Class A Ordinary Shares (the &#8220;<b>Representative Shares</b>&#8221;) granted to D. Boral Capital LLC, the underwriter in the IPO,
        as compensation, which are held by David Boral, the CEO of D. Boral Capital LLC and our Chairman and Chief Executive Officer, will be
        worthless. Such Representative Shares had an aggregate market value of approximately $[_] closing price of BCAR Class A Ordinary Shares
        of $[_] on Nasdaq as of [_], 2026;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">As of [_], 2026, BCAR has unsecured promissory
        notes in the aggregate principal amount of $[_] outstanding and BCAR has drawn down an aggregate of $[_] under the notes. The promissory
        notes were issued for working capital purposes. In the absence of shareholder approval for a further extension, if the proposed Business
        Combination is not consummated by February 1, 2027 (or May 1, 2027 if the Sponsor exercises its three-month extension option), then such
        loans may not be repaid.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Unless BCAR consummates the Business Combination,
        its officers, directors and the Sponsor will not receive reimbursement for any out-of-pocket expenses incurred by them to the extent that
        such expenses exceeded the amount of its working capital. As of [_], 2026, $[_] of advances was paid by the Sponsor for expenses incurred
        on BCAR&#8217;s behalf and if the proposed Business Combination is not consummated by February 1, 2027 (or May 1, 2027 if the Sponsor
        exercises its three-month extension option), that amount would not be repaid. As a result, the financial interest of BCAR&#8217;s officers,
        directors and Initial Shareholders or their affiliates could influence its officers&#8217; and directors&#8217; motivation in selecting
        Exascale as a target and therefore there may be a conflict of interest when it determined that the Business Combination is in the shareholders&#8217;
        best interest.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The exercise of BCAR&#8217;s directors&#8217;
        and officers&#8217; discretion in agreeing to changes or waivers in the terms of the transaction may result in a conflict of interest
        when determining whether such changes or waivers are appropriate and in our shareholders&#8217; best interest.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The continued indemnification of current directors and officers and the continuation
        of directors&#8217; and officers&#8217; liability insurance.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">BCAR&#8217;s Current Charter provides that BCAR renounces any interest or expectancy
        in, or in being offered an opportunity to participate in, any potential transaction or matter that may be a corporate opportunity for
        any member of BCAR&#8217;s management, on the one hand, and BCAR, on the other hand, or the participation in which would breach any existing
        legal obligation, under applicable law or otherwise, of a member of BCAR&#8217;s management to any other entity. BCAR is not aware of
        any such corporate opportunities not being offered to BCAR and does not believe that waiver of the corporate opportunities doctrine has
        materially affected BCAR&#8217;s search for an acquisition target or will materially affect BCAR&#8217;s ability to complete an initial
        business combination.</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The foregoing interests may influence
the officers and directors of BCAR to support or approve the Business Combination. As such, the Sponsor and BCAR&#8217;s officers and
directors may be incentivized to complete an acquisition of a less favorable target company or on terms less favorable to BCAR&#8217;s
shareholders rather than liquidate. In considering the recommendations of the BCAR Board to vote for the proposals, BCAR&#8217;s shareholders
should consider these interests. For more information, please see &#8220;<i>Risk Factors &#8212; Some of the BCAR officers and directors
may be argued to have conflicts of interest that may influence them to support or approve the Business Combination without regard to your
interests.<b>&#8221;</b></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt; width: 0.25in"><span style="font-size: 10pt"><b><i>Q.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>How has the announcement of the Business Combination
        affected the trading price of the securities of BCAR?</i></b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt; width: 0.25in"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">On January 12, 2026, the last trading date prior to the public
        announcement of the Business Combination, BCAR Class A Ordinary Shares, Public Warrants, and BCAR Units had closing prices, as reported
        on Nasdaq, of $10.03, $10.35 and $10.28, respectively. As of [_], 2026, the last trading day immediately prior to the filing date of this
        proxy statement/prospectus, the closing prices for each BCAR Class A Ordinary Share, Public Warrants and BCAR Units, as reported on Nasdaq,
        were $[_], $[_] and $[_], respectively.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>How will PubCo be managed following the Business Combination?</b></span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">A.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Immediately following the Closing, PubCo&#8217;s board of directors
        will consist of five directors, all of whom shall be designated by Exascale, and PubCo will be managed by Exascale&#8217;s current management
        team. </span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt; width: 0.25in"><span style="font-size: 10pt"><b><i>Q.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Why is BCAR proposing the Domestication Merger?</i></b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt; width: 0.25in"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The BCAR Board believes that there are significant advantages
        to PubCo that will arise as a result of a change of BCAR&#8217;s domicile to the State of Delaware. Further, the BCAR Board believes that
        any direct benefit that the DGCL provides to a corporation also indirectly benefits its stockholders, who are the owners of the corporation.
        The BCAR Board believes that there are several reasons why a reincorporation in the State of Delaware is in the best interests of BCAR
        and its shareholders, including (i) the prominence, predictability and flexibility of the DGCL, (ii) Delaware&#8217;s well-established
        principles of corporate governance, and (iii) the increased ability for Delaware corporations to attract and retain qualified directors.
        Each of the foregoing are discussed in greater detail in &#8220;<i>The Domestication Merger Proposal &#8212; Reasons for the Domestication</i>.&#8221;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">To
effect the Domestication Merger, BCAR will merge with and into D. Boral ARC Merger Corporation, a Delaware corporation and wholly owned
subsidiary of BCAR, upon which the separate existence of BCAR will cease and D. Boral ARC Merger Corporation will be the surviving corporation
(such surviving company &#8220;<b>PubCo</b>&#8221;) in accordance with the DGCL, the Business Companies Act, (Revised Edition 2020) as
amended, of the British Virgin Islands (As Revised) (the &#8220;<b>Companies Act</b>&#8221;), the Certificate of Merger, which is filed
as Exhibit 3.5 to this proxy statement/prospectus (the &#8220;<b>Certificate of Merger</b>&#8221;), and the amended and restated memorandum
and articles of association of BCAR (as may be amended from time to time, the &#8220;<b>Current Charter</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The approval of the Domestication Merger
Proposal is a condition to the Closing under the Business Combination Agreement. The approval of the Domestication Merger Proposal requires
an ordinary resolution under British Virgin Islands law of holders of BCAR Ordinary Shares, voting as a single class, represented in person
or by proxy and entitled to vote thereon and who do so at the Extraordinary General Meeting. Abstentions and broker non-votes, while considered
present for the purposes of establishing a quorum, will not count as votes cast at the Extraordinary General Meeting and otherwise will
have no effect on a particular proposal under British Virgin Islands law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0in"/>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Q.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>What amendments will be made to the Current Charter?</i></b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The consummation of the Business Combination is conditioned,
        among other things, on the Domestication Merger.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Accordingly, in addition to voting
on the Business Combination, BCAR&#8217;s shareholders are also being asked to consider and vote upon a proposal to approve the Domestication
Merger and replace the Current Charter, in each case, under the Companies Act, with the Proposed Charter and the Proposed Bylaws, in each
case, under the DGCL, which differ materially from the Current Charter. These differences are discussed in greater detail in &#8220;<i>The
Domestication Merger Proposal</i>&#8221; of this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0in"/>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>Q.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>How will the Domestication Merger affect my BCAR Class
        A Ordinary Shares, BCAR Warrants and BCAR Units?</i></b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">In connection with the Domestication Merger, at the effective
        time of the Domestication Merger, (i) each then issued and outstanding BCAR Class A Ordinary Share will convert automatically, on a one-for-one
        basis, into one share of PubCo Class A Ordinary Common Stock; (ii) each whole then issued and outstanding BCAR Warrant (including each
        whole Private Placement Warrant) will become exercisable for one share of PubCo Class A Ordinary Common Stock having the same terms and
        subject to the same conditions of such BCAR Warrant; and (iii) each then issued and outstanding BCAR Unit will separate and convert automatically
        into one share of PubCo Class A Ordinary Common Stock and one-half of one PubCo Warrant.&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0in"/>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>Q.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Will holders of Public Shares or Public Warrants be subject
        to U.S. federal income tax on the PubCo Common Stock or PubCo Warrants received in the Domestication Merger?</i></b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">As discussed more fully under &#8220;<i>Certain Material U.S.
        Federal Income Tax Considerations &#8212; U.S. Holders &#8212; U.S. Federal Income Tax Consequences of the Domestication Merger to U.S.
        Holders of BCAR Securities</i>,&#8221; the Domestication Merger should qualify as a &#8220;reorganization&#8221; within the meaning of
        Section 368 of the Code. However, the provisions of the Code that govern reorganizations are complex, and due to the absence of direct
        guidance on the application of Section 368 to a domestication of a corporation holding only investment-type assets such as BCAR, the qualification
        of the Domestication Merger as a &#8220;reorganization&#8221; within the meaning of Section 368 of the Code is not entirely clear. If
        the Domestication Merger so qualifies, then a U.S. Holder (as defined in &#8220;<i>Certain Material U.S. Federal Income Tax Considerations&#8221;</i>)
        generally will be subject to Section 367(b) of the Code and, as a result:</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a U.S. Holder whose Public Shares have a fair market value
        of less than $50,000 on the date of the Domestication Merger and who on the date of the Domestication Merger owns (directly, indirectly,
        and constructively) less than 10% of the total combined voting power of all classes of BCAR shares entitled to vote and less than 10%
        of the total value of all classes of BCAR shares will generally not recognize any gain or loss and will generally not be required to include
        in income any part of BCAR&#8217;s earnings and profits pursuant to the Domestication Merger;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a U.S. Holder whose Public Shares have a fair market value
        of $50,000 or more on the date of the Domestication Merger, but who on the date of the Domestication Merger owns (directly, indirectly,
        and constructively) less than 10% of the total combined voting power of all classes of BCAR shares entitled to vote and less than 10%
        of the total value of all classes of BCAR shares will generally recognize gain (but not loss) on the exchange of Public Shares for PubCo
        Common Stock pursuant to the Domestication Merger. As an alternative to recognizing gain, such U.S. Holders may file an election to include
        in income as a dividend the &#8220;all earnings and profits amounts,&#8221; (as defined in Treasury Regulation Section&#160;1.367(b)-2(d))
        attributable to their Public Shares, provided certain other requirements are satisfied. BCAR does not expect to have significant cumulative
        earnings and profits on the date of the Domestication Merger; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a U.S. Holder who on the date of the Domestication Merger owns
        (directly, indirectly, and constructively) 10% or more of the total combined voting power of all classes of BCAR shares entitled to vote
        or 10% or more of the total value of all classes of BCAR shares will generally be required to include in income as a dividend the &#8220;all
        earnings and profits amount,&#8221; (as defined in Treasury Regulation Section&#160;1.367(b)-2(d)) attributable to its Public Shares,
        provided certain other requirements are satisfied. Any U.S. Holder that is a corporation may, under certain circumstances, effectively
        be exempt from taxation due to a deduction in the amount of a portion or all of the deemed dividend pursuant to Section&#160;245A of the
        Code. BCAR does not expect to have significant cumulative earnings and profits on the date of the Domestication Merger.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Furthermore, even if the Domestication
Merger qualifies as a &#8220;reorganization&#8221; within the meaning of Section 368 of the Code, a U.S. Holder of BCAR securities may,
in certain circumstances, still recognize gain (but not loss) upon the exchange of its BCAR securities for PubCo Securities pursuant to
the Domestication Merger under the PFIC rules of the Code equal to the excess, if any, of the fair market value of PubCo Securities received
in the Domestication Merger and the U.S. Holder&#8217;s adjusted tax basis in the corresponding BCAR securities surrendered in exchange
therefor. The tax on any such gain so recognized would generally be imposed at the rate applicable to ordinary income and an interest
charge would apply, absent certain elections. For a more complete discussion of the potential application of the PFIC rules to U.S. Holders
as a result of the Domestication Merger, see the discussion in the section titled &#8220;<i>Certain Material U.S. Federal Income Tax Considerations
&#8212; U.S. Holders &#8212; U.S. Federal Income Tax Consequences of the Domestication Merger to U.S. Holders of BCAR Securities &#8212;
Passive Foreign Investment Company Status</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">If the Domestication Merger does not qualify
as a reorganization, then a U.S. Holder that exchanges its BCAR securities for PubCo Securities generally will recognize gain or loss
equal to the difference between (i) the sum of the fair market value of the PubCo Common Stock and PubCo Warrants received and (ii) the
U.S. Holder&#8217;s adjusted tax basis in the Public Shares and Public Warrants exchanged.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Additionally, the Domestication Merger
may cause Non-U.S. Holders (as defined in &#8220;<i>Certain Material U.S. Federal Income Tax Considerations</i>&#8221;) to become subject
to U.S. federal income withholding taxes on any dividends paid in respect of such Non-U.S. Holder&#8217;s shares of Public Shares after
the Domestication Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">For a more detailed discussion of certain
U.S. federal income tax consequences of the Domestication Merger, see &#8220;<i>Certain Material U.S. Federal Income Tax Considerations
&#8212; U.S. Holders &#8212; U.S. Federal Income Tax Consequences of the Domestication Merger to U.S. Holders of BCAR Securities</i>&#8221;
in this proxy statement/consent solicitation statement/prospectus. Holders should consult their own tax advisors to determine the tax
consequences to them (including the application and effect of any state, local or other income and other tax laws) of the Domestication
Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><b><i>Q.</i></b></td>
    <td style="text-align: justify"><b><i>What are the U.S. federal income tax consequences of exercising my Redemption Rights?</i></b></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><b><i>A.</i></b></td>
    <td style="text-align: justify">The U.S. federal income tax consequences of exercising your redemption rights depend on your particular facts
        and circumstances. See the section entitled &#8220;<i>Certain Material U.S. Federal Income Tax Considerations &#8212; U.S. Holders &#8212;
        Certain U.S. Federal Income Tax Consequences to U.S. Holders of Exercising Redemption Rights</i>,&#8221; for additional information. All
        holders considering the exercise of their redemption rights should consult with their tax advisors with respect to the U.S. federal income
        tax consequences of exercising such redemption rights.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><b><i>Q.</i></b></td>
    <td style="text-align: justify"><b><i>How do the Public Warrants differ from the Private Placement Warrants and what are the related risks
        for any Public Warrant Holders post-Business Combination?</i></b></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0pt"/>
    <td style="width: 0.25in; text-align: left"><b><i>A.</i></b></td>
    <td style="text-align: justify">The Public Warrants are identical to the Private Placement Warrants in their respective material terms and
        provisions. The Sponsor has agreed not to transfer, assign or sell any of the Private Placement Warrants until 30 days after the consummation
        of the Business Combination. The aforementioned terms of the Private Placement Warrants are detailed in the Warrant Agreement and are
        not modified as a result of the Business Combination.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">The
Private Placement Warrants are redeemable by BCAR and exercisable by the holders on the same basis as the Public Warrants. Following the
consummation of the Business Combination, PubCo has the ability to redeem the outstanding Public Warrants and Private Placement Warrants
for cash at any time after they become exercisable and prior to their expiration, in whole and not in part, at a price of $0.01 per warrant,
upon a minimum of 30 days&#8217; prior written notice of redemption to each warrant holder, if, among other things, the closing price
of PubCo Class A Ordinary Common Stock is equal to or exceeds $18.00 per share (as adjusted for sub share sub divisions, share capitalizations,
reorganizations, recapitalization and the like) for any 20 trading days within a 30-trading day period commencing at least 30 days after
completion of the Business Combination and ending on the third trading day prior to the date on which PubCo sends the notice of redemption
to warrant holders. The value received upon redemption of the warrants (i) may be less than the value the holders would have received
if they had exercised their warrants at a later time when the underlying share price is higher and (ii) may not compensate the holders
for the value of the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">In the event that PubCo determines to redeem
the Public Warrants and Private Placement Warrants, PubCo will fix a date for the redemption. Notice of redemption will be mailed by first
class mail, postage prepaid, by PubCo not less than thirty (30) days prior to the redemption date to the registered holders of the Public
Warrants to be redeemed at their last addresses as they appear on the registration books. Any notice mailed in the manner herein provided
will be conclusively presumed to have been duly given whether or not the registered holder received such notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><b><i>Q.</i></b></td>
    <td style="padding-left: 0.125in; text-align: justify"><b><i>What conditions must be satisfied to complete the Business Combination?</i></b></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The Business Combination is subject to the satisfaction or
        waiver of customary closing conditions, including, among others: (i) the absence of any order or provisions of any applicable law prohibiting
        the transactions or preventing the transactions; (ii) BCAR receiving approval of the Business Combination from its shareholders in accordance
        with BCAR&#8217;s existing memorandum and articles of association; (iii) the initial stock exchange listing application with respect to
        the PubCo Class A Ordinary Common Stock having been approved by Nasdaq or another nationally recognized securities exchange in the United
        States as may be agreed by BCAR and Exascale; and (iv) the SEC having approved the proxy statement/prospectus filed in connection with
        the Business Combination.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">For more information about conditions to
the consummation of the Business Combination, see &#8220;<i>The Business Combination Proposal &#8212; Business Combination Agreement</i>&#8221;
beginning on page&#160;137 of this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b><i>Q.</i></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>When is the Business Combination expected to be completed?</i></b></span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0in"/>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">It is currently expected that the Business Combination will
        be consummated in the second quarter of 2026. This date depends, among other things, on the approval of the proposals to be put to BCAR
        shareholders at the Extraordinary General Meeting. However, such meeting could be adjourned if the Adjournment Proposal is adopted by
        BCAR&#8217;s shareholders at the Extraordinary General Meeting and BCAR elects to adjourn the Extraordinary General Meeting to a later
        date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for the
        approval of one or more proposals at the Extraordinary General Meeting. For a description of the conditions for the completion of the
        Business Combination, see &#8220;<i>The Business Combination Proposal &#8212; Business Combination Agreement</i>&#8221;.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b><i>Q.</i></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>What happens if the Business Combination is not consummated?</i></b></span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0in"/>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">BCAR will not complete the Domestication Merger to the State
        of Delaware and the Acquisition Merger unless all other conditions to the consummation of the Business Combination have been satisfied
        or waived by the parties in accordance with the terms of the Business Combination Agreement.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b><i>Q.</i></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>What interests do the Sponsor and BCAR&#8217;s current officers and directors
        have in the Business Combination?</i></b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Sponsor and BCAR&#8217;s directors and
        officers have interests in the Business Combination that are different from or in addition to (and which may conflict with) your interests.
        You should take these interests into account in deciding whether to approve the Business Combination. See &#8220;<i>The Business Combination
        Proposal &#8212; Certain Interests of BCAR&#8217;s Directors and Officers and Others in the Business Combination</i>.&#8221;</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0in"/>
    <td style="vertical-align: top; width: 0.25in"><b><i>Q.</i></b></td>
    <td style="vertical-align: top; text-align: justify"><b><i>Do I have appraisal rights or dissenters&#8217; rights in connection with the Business
        Combination?</i></b></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0in"/>
    <td style="vertical-align: top; width: 0.25in"><b><i>A.</i></b></td>
    <td style="vertical-align: top; text-align: justify">No appraisal or dissenters&#8217; rights are available to BCAR&#8217;s shareholders in
        connection with the ordinary resolution to approve the Business Combination Proposal. However, in respect of the resolution to approve
        the Domestication Merger Proposal, under section&#160;179 of the Companies Act, shareholders of a British Virgin Islands company ordinarily
        have dissenters&#8217; rights with respect to a statutory merger. The Companies Act prescribes when shareholder dissenters&#8217; rights
        will be available and sets the limitations on such rights. Where such rights are available, shareholders are entitled to receive fair
        value for their shares. However, regardless of whether such rights are or are not available, BCAR&#8217;s shareholders are still entitled
        to exercise the rights of redemption as detailed in this proxy statement/prospectus and the BCAR Board has determined that the redemption
        proceeds payable to BCAR&#8217;s shareholders who exercise such redemption rights represents the fair value of those shares. Please see
        the section entitled &#8220;<i>Appraisal or Dissenters&#8217; Rights.</i>&#8221;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0in"/>
    <td style="vertical-align: top; width: 0.25in"><b><i>Q.</i></b></td>
    <td style="vertical-align: top; text-align: justify"><b><i>What do I need to do now?</i></b></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">BCAR urges you to read this proxy statement/prospectus, including the Annexes
        and the documents referred to herein, carefully and in their entirety and to consider how the Business Combination will affect you as
        a shareholder or warrant holder. BCAR&#8217;s shareholders should then vote as soon as possible in accordance with the instructions provided
        in this proxy statement/prospectus and on the enclosed proxy card.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0in"/>
    <td style="vertical-align: top; width: 0.25in"><b><i>Q.</i></b></td>
    <td style="vertical-align: top; text-align: justify"><b><i>How do I vote?</i></b></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0in"/>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">If you are a holder of record of BCAR Ordinary Shares on the
        Record Date for the Extraordinary General Meeting, you may vote in person at the Extraordinary General Meeting or by submitting a proxy
        for the Extraordinary General Meeting. You may submit your proxy by completing, signing, dating and returning the enclosed proxy card
        in the accompanying pre-addressed postage-paid envelope. If you hold your shares in &#8220;street name,&#8221; which means your shares
        are held of record by a broker, bank or nominee, you should contact your broker, bank or nominee to ensure that votes related to the shares
        you beneficially own are properly counted. In this regard, you must provide the broker, bank or nominee with instructions on how to vote
        your shares or, if you wish to attend the Extraordinary General Meeting and vote in person, obtain a valid proxy from your broker, bank
        or nominee.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0in"/>
    <td style="vertical-align: top; width: 0.25in"><b><i>Q.</i></b></td>
    <td style="vertical-align: top; text-align: justify"><b><i>If my shares are held in &#8220;street name,&#8221; will my broker, bank or nominee
        automatically vote my shares for me?</i></b></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0in"/>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">No. If your shares are held in a stock brokerage account or
        by a bank or other nominee, you are considered the &#8220;beneficial holder&#8221; of the shares held for you in what is known as &#8220;street
        name.&#8221; If this is the case, this proxy statement/prospectus may have been forwarded to you by your brokerage firm, bank or other
        nominee, or its agent, and you may need to obtain a proxy form from the institution that holds your shares and follow the instructions
        included on that form regarding how to instruct your broker, bank or nominee as to how to vote your shares. Under the rules of various
        national and regional securities exchanges, your broker, bank, or nominee cannot vote your shares with respect to non-discretionary matters
        unless you provide instructions on how to vote in accordance with the information and procedures provided to you by your broker, bank,
        or nominee. We believe all the proposals presented to the shareholders at the Extraordinary General Meeting will be considered non-discretionary
        and therefore your broker, bank, or nominee cannot vote your shares without your instruction. Your bank, broker, or other nominee can
        vote your shares only if you provide instructions on how to vote. As the beneficial holder, you have the right to direct your broker,
        bank or other nominee as to how to vote your shares and you should instruct your broker to vote your shares in accordance with directions
        you provide. If you do not provide voting instructions to your broker on a particular proposal on which your broker does not have discretionary
        authority to vote, your shares will not be voted on that proposal. This is called a &#8220;broker non-vote.&#8221; Abstentions and broker
        non-votes, while considered present for the purposes of establishing a quorum, will not count as votes cast at the Extraordinary General
        Meeting, and otherwise will have no effect on a particular proposal under British Virgin Islands law.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0in"/>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>Q.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>When and where will the Extraordinary General Meeting
        be held?</i></b></span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0in"/>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The Extraordinary General Meeting will be held at 10:00 A.M.,
        Eastern Time, on [_], 2026 at the offices of Loeb &amp; Loeb LLP, 345 Park Avenue, New York, NY 10154. Shareholders may attend the Extraordinary
        General Meeting in person or virtually via telephone at: Telephone number: __________________ Participant Passcode: __________________.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0in"/>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>Q.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Who is entitled to vote at the Extraordinary General
        Meeting?</i></b></span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0in"/>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">BCAR has fixed [_], 2026 as the Record Date for the Extraordinary
        General Meeting. If you were a shareholder of BCAR at the close of business on the Record Date, you are entitled to vote on matters that
        come before the Extraordinary General Meeting. However, a shareholder may only vote his, her or its shares if he, she or it is present
        in person or is represented by proxy at the Extraordinary General Meeting.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr>
    <td style="vertical-align: top; text-align: justify; width: 0in"/>
    <td style="text-align: justify; vertical-align: top; width: 0.25in"><b><i>Q.</i></b></td>
    <td style="vertical-align: top; text-align: justify"><b><i>How many votes do I have?</i></b></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0in"/>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">BCAR shareholders are entitled to one vote at the Extraordinary
        General Meeting for each BCAR Ordinary Share held of record as of the Record Date. As of the close of business on the Record Date for
        the Extraordinary General Meeting, there were 41,200,000 BCAR Ordinary Shares issued and outstanding, of which 28,000,000 were Public
        Shares held by persons other than the Insiders.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr>
    <td style="vertical-align: top; text-align: justify; width: 0in"/>
    <td style="text-align: justify; vertical-align: top; width: 0.25in"><b><i>Q.</i></b></td>
    <td style="vertical-align: top; text-align: justify"><b><i>What constitutes a quorum?</i></b></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0in"/>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">A quorum of BCAR shareholders is necessary to hold a valid
        meeting. A quorum will be present at the Extraordinary General Meeting if the holders of at least thirty percent (30%) of the issued and
        outstanding BCAR Ordinary Shares entitled to vote at the Extraordinary General Meeting are represented in person or by proxy.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0in"/>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>Q.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>What vote is required to approve each proposal at the
        Extraordinary General Meeting?</i></b></span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0in"/>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The following votes are required to approve each proposal being
        presented at the Extraordinary General Meeting:</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><i>Business Combination Proposal </i>&#8212;
The approval of the Business Combination Proposal requires an ordinary resolution under the Current Charter, being the affirmative vote
of a majority of the votes cast by the holders of BCAR Ordinary Shares, voting as a single class, represented in person or by proxy and
entitled to vote thereon at the Extraordinary General Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Domestication Merger Proposal </i>&#8212;
The approval of the Domestication Merger Proposal requires an ordinary resolution under British Virgin Islands law, being the affirmative
vote of a majority of the votes cast by the holders of BCAR Ordinary Shares, voting as a single class, represented in person or by proxy
and entitled to vote thereon at the Extraordinary General Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Organizational Documents Proposal
</i>&#8212; The approval of the Organizational Documents Proposal requires an ordinary resolution under British Virgin Islands law, being
the affirmative vote of a majority of the votes cast by the holders of BCAR Ordinary Shares, voting as a single class, represented in
person or by proxy and entitled to vote thereon at the Extraordinary General Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Advisory Organizational Documents
Proposals </i>&#8212; The separate approval of each of the Advisory Organizational Documents Proposals, each of which is a non-binding
vote, requires an ordinary resolution, being the affirmative vote of a majority of the votes cast by the holders of BCAR Ordinary Shares,
voting as a single class, represented in person or by proxy and entitled to vote thereon at the Extraordinary General Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Directors Proposal</i> &#8212; The
approval of the Directors Proposal requires an ordinary resolution under the Current Charter, being the affirmative vote of a majority
of the votes cast by the holders of BCAR Ordinary Shares, voting as a single class, represented in person or by proxy and entitled to
vote thereon at the Extraordinary General Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Equity Incentive Plan Proposal </i>&#8212;
The approval of the Equity Incentive Plan Proposal requires an ordinary resolution under the Current Charter, being the affirmative vote
of a majority of the votes cast by the holders of BCAR Ordinary Shares, voting as a single class, represented in person or by proxy and
entitled to vote thereon at the Extraordinary General Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Nasdaq Proposal</i> &#8212; The
approval of the Nasdaq Proposal requires an ordinary resolution under the Current Charter, being the affirmative vote of a majority of
the votes cast by the holders of BCAR Ordinary Shares, voting as a single class, represented in person or by proxy and entitled to vote
thereon at the Extraordinary General Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Adjournment
Proposal </i>&#8212; The approval of the Adjournment Proposal requires an ordinary resolution, being the affirmative vote of a simple
majority of the BCAR Ordinary Shares, represented in person or by proxy and entitled to vote thereon at the Extraordinary General Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of the date of this proxy statement/prospectus,
the Insiders, all of whom have agreed to vote in favor of all the proposals being presented at the Extraordinary General Meeting, collectively
own an aggregate of 13,200,000 BCAR Ordinary Shares, collectively representing approximately 32.0% of the issued and outstanding BCAR
Ordinary Shares entitled to vote on the proposals at the Extraordinary General Meeting. As a result, in addition to the shares held by
the Insiders, BCAR would need 7,400,001 Public Shares, or approximately 26.4% of the 28,000,000 Public Shares sold in the BCAR IPO, to
be voted in favor of the Business Combination Proposal, the Domestication Merger Proposal, the Organizational Documents Proposal, the
Advisory Organizational Documents Proposals, the Directors Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal, and, if
presented, the Adjournment Proposal, in order for such proposals to be approved, assuming all outstanding shares are voted and the Insiders
do not acquire any Public Shares. Assuming that only the holders of thirty percent (30%) of the issued and outstanding BCAR ordinary shares,
representing a quorum under BCAR&#8217;s amended and restated memorandum and articles of association, vote their shares at the Extraordinary
General Meeting, BCAR will not need any Public Shares in addition to the shares held by the Insiders to be voted in favor of the Business
Combination Proposal, the Domestication Merger Proposal, the Organizational Documents Proposal, the Advisory Organizational Documents
Proposals, the Directors Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal, and, if presented, the Adjournment Proposal,
in order for such proposals to be approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0in"/>
    <td style="vertical-align: top; width: 0.25in"><b><i>Q.</i></b></td>
    <td style="vertical-align: top; text-align: justify"><b><i>What are the recommendations of the BCAR Board?</i></b></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0in"/>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The BCAR Board believes that the Business Combination Proposal
        and the other proposals to be presented at the Extraordinary General Meeting are in the best interests of Exascale and BCAR&#8217;s shareholders
        and unanimously recommends that BCAR shareholders vote &#8220;FOR&#8221; the approval of the Business Combination Proposal, &#8220;FOR&#8221;
        the approval of the Domestication Merger Proposal, &#8220;FOR&#8221; the approval of the Organizational Documents Proposal, &#8220;FOR&#8221;
        the approval, on an advisory basis, of each of the separate Advisory Organizational Documents Proposals, &#8220;FOR&#8221; the approval
        of the Directors Proposal, &#8220;FOR&#8221; the approval of the Equity Incentive Plan Proposal, &#8220;FOR&#8221; the approval of the
        Nasdaq Proposal, and &#8220;FOR&#8221; the approval of the Adjournment Proposal, if presented, at the Extraordinary General Meeting.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">The existence of financial and personal
interests of one or more of BCAR&#8217;s directors may result in a conflict of interest on the part of such director(s) between what he,
she or they may believe is in the best interests of BCAR and its shareholders and what he, she or they may believe is best for himself,
herself or themselves in determining to recommend that shareholders vote for the proposals. In addition, BCAR&#8217;s officers have interests
in the Business Combination that may conflict with your interests as a shareholder. See &#8220;<i>The Business Combination Proposal &#8212;
Certain Interests of BCAR&#8217;s Directors and Officers and Others in the Business Combination</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0in"/>
    <td style="vertical-align: top; width: 0.25in"><b><i>Q.</i></b></td>
    <td style="vertical-align: top; text-align: justify"><b><i>How do the Insiders intend to vote their BCAR Ordinary Shares?</i></b></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0in"/>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt;"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify">The Sponsor and the officers and directors of
    BCAR, who we collectively refer to as the Insiders, have agreed to vote in favor of all the proposals being presented at the Extraordinary
    General Meeting. The Sponsor, which includes among its members each of the directors and officers of BCAR, owns 200,000 Private Units
    and 12,000,000 Class B Ordinary Shares. The securities held by the Sponsor represent approximately 29.6% of the issued and outstanding
    voting shares of BCAR. In addition to the securities held by the Sponsor, David Boral, BCAR&#8217;s Chairman and Chief Executive
    Officer, holds 1,000,000 Representative Shares which were granted to D. Boral Capital LLC, the underwriter in BCAR&#8217;s IPO, as
    compensation.</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">The existence of financial and personal
interests of one or more of BCAR&#8217;s directors may result in a conflict of interest on the part of such director(s) between what he,
she or they may believe is in the best interests of BCAR and its shareholders and what he, she or they may believe is best for himself,
herself or themselves in determining to recommend that shareholders vote for the proposals. In addition, BCAR&#8217;s officers have interests
in the Business Combination that may conflict with your interests as a shareholder. See &#8220;<i>The Business Combination Proposal &#8212;
Certain Interests of BCAR&#8217;s Directors and Officers and Others in the Business Combination</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0in"/>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>Q.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>What happens if I sell my BCAR Ordinary Shares before
        the Extraordinary General Meeting?</i></b></span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0in"/>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The Record Date for the Extraordinary General Meeting is earlier
        than the date of the Extraordinary General Meeting and earlier than the date that the Business Combination is expected to be completed.
        If you transfer your Public Shares after the applicable Record Date, but before the Extraordinary General Meeting, unless you grant a
        proxy to the transferee, you will retain your right to vote at the Extraordinary General Meeting but the transferee, and not you, will
        have the ability to redeem such shares, so long as such transferee takes the required steps to elect to redeem such shares at least two
        business days prior to the initially scheduled vote on the Business Combination Proposal.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0in"/>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Q.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>How can I vote my shares without attending the Extraordinary
        General Meeting?</i></b></span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0in"/>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">If you are a shareholder of record of BCAR Ordinary Shares
        as of the close of business on the Record Date, you can vote by proxy by e-mail or by mail by following the instructions provided in the
        attached or enclosed proxy card, as the case may be, or at the Extraordinary General Meeting. Please note that if you are a beneficial
        owner of BCAR Ordinary Shares, you may vote by submitting voting instructions to your broker, bank or nominee, or otherwise by following
        instructions provided by your broker, bank or nominee. Telephone and internet voting will be available to beneficial owners. Please refer
        to the vote instruction form provided by your broker, bank or nominee.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: justify; width: 0in"/>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b><i>Q.</i></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>May I revoke my proxy or change my vote after I have mailed my signed
        proxy card?</i></b></span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0in"/>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Yes. Shareholders may send a later-dated, signed proxy card
        to BCAR&#8217;s address set forth below so that it is received by BCAR&#8217;s Chairman prior to the vote at the Extraordinary General
        Meeting (which is scheduled to take place on [_], 2026 or attend the Extraordinary General Meeting in person and vote. Shareholders also
        may revoke their proxy by sending a notice of revocation to BCAR&#8217;s address set forth below, which must be received by the last business
        day prior to the date of the Extraordinary General Meeting. However, if your shares are held in &#8220;street name&#8221; by your broker,
        bank or another nominee, you must contact your broker, bank or other nominee to change your vote.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0in"/>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Q.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>What happens if I fail to take any action with respect
        to the Extraordinary General Meeting?</i></b></span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0in"/>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">If you fail to take any action with respect to the Extraordinary
        General Meeting and the Business Combination is approved by shareholders and the Business Combination is consummated, you will become
        a stockholder or warrant holder of PubCo unless you redeem your shares. If you fail to take any action with respect to the Extraordinary
        General Meeting and the Business Combination is not approved, you will remain a shareholder or warrant holder of BCAR. However, if you
        fail to vote with respect to the Extraordinary General Meeting, you will nonetheless be able to elect to redeem your Public Shares in
        connection with the Business Combination, so long as you take the required steps to elect to redeem your shares at least two business
        days prior to the initially scheduled vote on the Business Combination Proposal.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Do I have redemption rights?</b></span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">A.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">If you are a holder of Public Shares, you have the right to
        request that we redeem all or a portion of your Public Shares for cash provided that you follow the procedures and deadlines described
        elsewhere in this proxy statement/prospectus. Public Shareholders may elect to redeem all or a portion of the Public Shares held by them
        regardless of if or how they vote in respect of the Business Combination Proposal. If you wish to exercise your redemption rights, please
        see the answer to the question: &#8220;<i>How do I exercise my redemption rights?</i>&#8221; below.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Pursuant to the letter agreement,
dated July 30, 2025, entered into by and among BCAR and the Insiders, the Insiders, for no additional consideration, agreed to waive their
redemption rights with respect to all of their Class A Ordinary Shares in connection with the consummation of the Business Combination.
Such shares will be excluded from the pro rata calculation used to determine the per-share redemption price.</p>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Am I required to vote in order to have my Public Shares
        redeemed and how do I exercise my redemption rights?</b></span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">A:</span></td>
    <td style="text-align: justify">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No. You are not required to vote in order to have
        the right to demand that BCAR redeem your Public Shares for cash equal to your pro rata share of the aggregate amount then on deposit
        in the trust account (including interest earned on their pro rata portion of the trust account, net of taxes payable). These rights to
        demand redemption of Public Shares for cash are sometimes referred to herein as redemption rights.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Public Shareholders who seek to have their shares
        redeemed must (i) demand, no later than 5:00 p.m., Eastern time on [_], 2026 (two business days before the Extraordinary General Meeting),
        that BCAR redeem your shares into cash; and (ii) submit your request in writing to BCAR&#8217;s Transfer Agent, at the address listed
        at the end of this section and delivering your shares to BCAR&#8217;s Transfer Agent physically or electronically using the depository
        trust company&#8217;s deposit/withdrawal at custodian (&#8220;DWAC&#8221;) system two business days prior to the vote at the Extraordinary
        General Meeting.</p></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Any corrected or changed written
demand of redemption rights must be received by BCAR&#8217;s Transfer Agent two business days prior to the Extraordinary General Meeting.
No demand for redemption will be honored unless the holder&#8217;s shares have been delivered (either physically or electronically) to
the Transfer Agent two business days prior to the vote at the Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Public Shareholders seeking to exercise
their redemption rights and opting to deliver physical certificates should allot sufficient time to obtain physical certificates from
BCAR&#8217;s Transfer Agent and to effect delivery. It is BCAR&#8217;s understanding that shareholders should generally allot at least
two weeks to obtain physical certificates from the Transfer Agent. However, because we do not have any control over this process or over
the brokers or DTC, it may take significantly longer than two weeks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Public
Shareholders may seek to have their shares redeemed regardless of whether they vote for or against the Business Combination. Public Shareholders
who hold Public Shares on or before [_], 2026 (two business days before the Extraordinary General Meeting) will have the right to demand
that his, her or its shares be redeemed for a pro rata share of the aggregate amount then on deposit in the trust account, less any taxes
then due but not yet paid, at the consummation of the Business Combination. Public Shareholders are eligible to redeem their shares at
any time prior to [_], 2026, regardless of whether such shareholder became a shareholder before or after the Record Date. However, Public
Shareholders will not be able to seek redemption after [_], 2026 (two business days before the Extraordinary General Meeting) and therefore
Public Shareholders will not be able to decide whether to redeem based on whether the Business Combination is approved or not at the Extraordinary
General Meeting as the redemption decision must be made two days prior to such meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Any request for redemption, once
made by a holder of Public Shares, may be withdrawn at any time up to the time the vote is taken with respect to the Business Combination
Proposal at the Extraordinary General Meeting. If you deliver your shares for redemption to BCAR&#8217;s transfer agent and later decide
prior to the Extraordinary General Meeting not to elect redemption, you may request that BCAR&#8217;s transfer agent return the shares
(physically or electronically). You may make such request by contacting BCAR&#8217;s transfer agent at the address listed at the end of
this section.</p>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>If I am a holder of units, can I exercise redemption rights
        with respect to my units?</b></span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">A:</span></td>
    <td style="font-size: 10pt; text-align: justify">
        <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">No. Holders of issued and outstanding units must elect to separate
        the units into the underlying Public Shares and Public Warrants prior to exercising redemption rights with respect to the Public Shares.
        If you hold your units in an account at a brokerage firm or bank, you must notify your broker or bank that you elect to separate the units
        into the underlying Public Shares and Public Warrants or if you hold units registered in your own name, you must contact our Transfer
        Agent, directly and instruct them to do so. The redemption rights include the requirement that a holder must identify itself in writing
        as a beneficial holder and provide its legal name, phone number and address to our Transfer Agent in order to validly redeem its shares.
        You are requested to cause your Public Shares to be separated and your share certificates (if any) and other redemption forms (as applicable)
        be delivered to our Transfer Agent, by 5:00 p.m., Eastern Time, on [_], 2026 (two business days before the Extraordinary General Meeting)
        in order to exercise your redemption rights with respect to your Public Shares.</span></p>
        <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should you elect to separate your BCAR Units into
        the underlying Public Shares and Public Warrants, and decide to exercise your redemption rights in connection with your BCAR Class A Ordinary
        Shares, you will still own your Public Warrants. Upon consummation of the Business Combination, each Public Warrant issued and outstanding
        will convert into a PubCo Warrant to purchase one PubCo Class A Ordinary Common Stock. The PubCo Warrants will have substantially the
        same terms and conditions as set forth in the Public Warrants.</p> </td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>What happens if a substantial number of the Public Shareholders
        vote in favor of the Business Combination Proposal and exercise their redemption rights?</b></span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">A.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Our Public Shareholders are not required to vote in respect
        of the Business Combination in order to exercise their redemption rights. Accordingly, the Business Combination may be consummated even
        though the funds available from the trust account and the number of Public Shareholders is reduced as a result of redemptions by Public
        Shareholders.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>May I seek statutory appraisal rights or dissenter rights
        with respect to my shares?</b></span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">A:</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The Companies Act prescribes when shareholder appraisal rights
        will be available and sets the limitations on such rights. For additional information, see the section entitled &#8220;<i>Extraordinary
        General Meeting of BCAR Shareholders &#8211; Appraisal Rights.</i>&#8221;</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>What happens if the Business Combination is not consummated?</b></span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">A:</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">If BCAR does not
    consummate the Business Combination by February 1, 2027 (or May 1, 2027 if the Sponsor exercises its three-month extension option),
    then pursuant to Article 25.10 of BCAR&#8217;s Current Charter, BCAR&#8217;s directors must take all actions necessary in accordance
    with the Companies Act to dissolve and liquidate BCAR as soon as reasonably practicable. Following dissolution, BCAR will no longer
    exist as a company. In any liquidation, the funds held in the trust account, plus any interest earned thereon (net of taxes payable
    and up to $100,000 of interest to pay dissolution expenses), together with any remaining out-of-trust net assets will be distributed pro-rata to holders of Public Shares who acquired such
    Class A Ordinary Shares in BCAR&#8217;s IPO or in the aftermarket. If the Business Combination is not effected by February 1, 2027
    (or May 1, 2027 if the Sponsor exercises its three-month extension option), then the BCAR Warrants will expire worthless. The
    estimated consideration that each Public Share would be paid at liquidation would be approximately $[_] per share for shareholders
    based on amounts on deposit in the trust account as of [_], 2026. The closing price of Public Shares on the Nasdaq as of [_], 2026
    was $[_]. BCAR&#8217;s Insiders waived the right to any liquidation distribution with respect to any Founder Shares held by
    them.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>What happens to the funds deposited in the trust account
        following the Business Combination?</b></span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">A:</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Following the Closing, funds in the trust account will be released
        to PubCo. Holders of Public Shares exercising redemption rights will receive their per share redemption price. The balance of the funds
        will be utilized to fund the Business Combination. As of the date of this proxy statement/prospectus, there was approximately $[_] million
        in BCAR&#8217;s trust account. Approximately $[_] per outstanding share issued in BCAR&#8217;s IPO will be paid to redeeming public investors.
        Any funds remaining in the trust account after such uses will be used for future working capital and other corporate purposes of PubCo.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b><i>Q.</i></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>What should I do with my share certificates, warrant certificates or unit
        certificates?</i></b></span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b><i>A.</i></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Upon the Domestication Merger, holders of BCAR Units, BCAR Class A Ordinary
        Shares and BCAR Warrants will receive PubCo Class A Ordinary Common Stock and PubCo Warrants, as the case may be, without needing to take
        any action and, accordingly, such holders should not submit any certificates relating to their BCAR Units, BCAR Class A Ordinary Shares,
        or BCAR Warrants.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0in"/>
    <td style="vertical-align: top; width: 0.25in"><b><i>Q.</i></b></td>
    <td style="vertical-align: top; text-align: justify"><b><i>What should I do if I receive more than one set of voting materials?</i></b></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0in"/>
    <td style="vertical-align: top; width: 0.25in"><b><i>A.</i></b></td>
    <td style="vertical-align: top; text-align: justify">Shareholders may receive more than one set of voting materials, including multiple copies
        of this proxy statement/prospectus and multiple proxy cards or voting instruction cards. For example, if you hold your shares in more
        than one brokerage account, you will receive a separate voting instruction card for each brokerage account in which you hold shares. If
        you are a holder of record and your shares are registered in more than one name, you will receive more than one proxy card. Please complete,
        sign, date and return each proxy card and voting instruction card that you receive in order to cast a vote with respect to all of your
        BCAR Ordinary Shares.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0in"/>
    <td style="vertical-align: top; width: 0.25in"><b><i>Q.</i></b></td>
    <td style="vertical-align: top; text-align: justify"><b><i>Who will solicit and pay the cost of soliciting proxies for the Extraordinary General
        Meeting?</i></b></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0in"/>
    <td style="vertical-align: top; width: 0.25in"><b><i>A.</i></b></td>
    <td style="vertical-align: top; text-align: justify">BCAR will pay the cost of soliciting proxies for the Extraordinary General Meeting. BCAR
        has engaged Advantage Proxy to assist in the solicitation of proxies for the Extraordinary General Meeting. BCAR has agreed to pay Advantage
        Proxy a fee of $8,500, plus disbursements. BCAR will also reimburse banks, brokers and other custodians, nominees and fiduciaries representing
        beneficial owners of BCAR Class A Ordinary Shares for their expenses in forwarding soliciting materials to beneficial owners of BCAR Class
        A Ordinary Shares and in obtaining voting instructions from those owners. BCAR&#8217;s directors and officers may also solicit proxies
        by telephone, by facsimile, by mail, on the Internet or in person. They will not be paid any additional amounts for soliciting proxies.</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0in"/>
    <td style="vertical-align: top; width: 0.25in"><b><i>Q.</i></b></td>
    <td style="vertical-align: top; text-align: justify"><b><i>Where can I find the voting results of the Extraordinary General Meeting?</i></b></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0in"/>
    <td style="vertical-align: top; width: 0.25in"><b><i>A.</i></b></td>
    <td style="vertical-align: top; text-align: justify">The preliminary voting results are expected to be announced at the Extraordinary General
        Meeting.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">BCAR will publish final voting results
of the Extraordinary General Meeting in a Current Report on Form 8-K within four business days after the Extraordinary General Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0in"/>
    <td style="vertical-align: top; width: 0.25in"><b><i>Q.</i></b></td>
    <td style="vertical-align: top; text-align: justify"><b><i>Who can help answer my questions?</i></b></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0in"/>
    <td style="vertical-align: top; width: 0.25in"><b><i>A.</i></b></td>
    <td style="vertical-align: top; text-align: justify">If you have questions about the Business Combination or if you need additional copies
        of the proxy statement/prospectus or the enclosed proxy card, you should contact:</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Advantage Proxy, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Tel: 877-870-8565 (toll-free) or 206-870-8565<br/>(banks
and brokers can call collect) Email: karen@advantageproxy.com</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">You also may obtain additional information
about BCAR from documents filed with the SEC by following the instructions in &#8220;<i>Where You Can Find More Information.</i>&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --> <!-- Field: Split-Segment -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_006"></span>SUMMARY OF THE PROXY STATEMENT/PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>This summary highlights selected information
from this proxy statement/prospectus, but does not contain all of the information that may be important to you. To better understand the
proposals to be considered at the Extraordinary General Meeting, including the Business Combination Proposal, whether or not you plan
to attend such meeting, we urge you to read this proxy statement/prospectus (including the Annexes) carefully and in its entirety, including
&#8220;Risk Factors&#8221; section. See also &#8220;Where You Can Find More Information.&#8221;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Parties to the Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>D. Boral ARC Acquisition I Corp. (&#8220;BCAR&#8221;)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR is a blank check company incorporated on March&#160;20,
2025 as a British Virgin Islands business company formed for the purpose of effecting a merger, share exchange, asset acquisition, share
purchase, reorganization or similar business combination with one or more businesses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR&#8217;s Units, Class A Ordinary Shares and
Public Warrants are currently traded on the Nasdaq Global Market under the symbols &#8220;BCARU,&#8221; &#8220;BCAR&#8221; and &#8220;BCARW,&#8221;
respectively</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR&#8217;s principal executive office is located
at 10 East 53rd Street, Suite 3001, New York, NY 10022. Its telephone number is (332) 266-7344. BCAR&#8217;s website and the information
contained on, or that can be accessed through, the website is not deemed to be incorporated by reference in, and is not considered part
of, this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>D. Boral ARC Merger Corporation (&#8220;PubCo&#8221;)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">D. Boral ARC Merger Corporation is a wholly-owned
subsidiary of BCAR formed solely for the purpose of effecting the Domestication Merger and the Business Combination. Pursuant to the Domestication
Merger, BCAR will merge with and into D. Boral ARC Merger Corporation with D. Boral ARC Merger Corporation being the surviving entity.
D. Boral ARC Merger Corporation was incorporated in Delaware on December 19, 2025. D. Boral ARC Merger Corporation (post-Merger, &#8220;<b>PubCo</b>&#8221;)
owns no material assets and does not operate any business. D. Boral ARC Merger Corporation&#8217;s principal executive office is located
at 10 East 53rd Street, Suite 3001, New York, NY 10022. Its telephone number is (332) 266-7344.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon consummation of the Business Combination,
PubCo&#8217;s principal executive office will be located at 820 Gessner Road, Suite 332 and its telephone number at such address will
be (650) 537-7553.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Merger Sub</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Merger Sub is a wholly-owned subsidiary of BCAR formed
solely for the purpose of effecting the Business Combination. Pursuant to the Business Combination, Merger Sub will merge with and into
Exascale with Exascale being the surviving entity and becoming a wholly-owned subsidiary of PubCo. Merger Sub was incorporated in Delaware
on December&#160;19, 2025. Merger Sub owns no material assets and does not operate any business. Merger Sub&#8217;s principal executive
office is located at 10 East 53rd Street, Suite 3001, New York, NY 10022. Its telephone number is (332) 266-7344.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Exascale</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale is a next-generation AI infrastructure
provider operating an asset-light, software-defined GPU compute platform and related AI infrastructure solutions. Exascale&#8217;s core
business includes GaaS, through which it provides reserved and on-demand access to high-performance GPU compute capacity sourced from
third-party data centers globally, as well as GPU cluster management and optimization services for AIDC operators. In addition, Exascale
has developed certain modular data center, high-density liquid cooling, HVDC power and energy storage solutions that are designed to address
deployment bottlenecks in AI infrastructure and that Exascale believes are ready for commercial engagement, although these capabilities
have not yet generated revenue as of the date of this proxy statement/prospectus. The platform is purpose-built for large-scale AI workloads,
including LLM training, fine-tuning, and high-concurrency inference. Additional information about Exascale is set forth in the section
titled &#8220;<i>Information about Exascale</i>&#8221; in this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale&#8217;s principal executive office is
located at 820 Gessner Road, Suite 332 and its telephone number is (650) 537-7553. Exascale&#8217;s corporate website address is www.exascalelabs.ai.
Exascale&#8217;s website and the information contained on, or that can be accessed through, Exascale&#8217;s website is not deemed to
be incorporated by reference in, and is not considered part of, this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>BCAR Board
of Directors&#8217; Reasons for the Approval of the Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The officers
and directors of BCAR have substantial experience in evaluating the operating and financial merits of companies from a wide range of industries
and concluded that their experience and background enabled such officers and directors of BCAR to make the necessary analyses and determinations
regarding the Business Combination. After careful consideration of the terms and conditions of the Business Combination Agreement, the
Board has determined that the Business Combination and the transactions contemplated thereby are fair to and in the best interests of
BCAR and its shareholders because the Board believes that Exascale is a company with strong revenue growth potential. In reaching its
decision with respect to the Business Combination and the transactions contemplated thereby, the BCAR Board also reviewed various industry
and financial data and the due diligence and evaluation materials provided by Exascale, demonstrating that Exascale has a business plan
dedicated to both near term cash flow as well as long term growth. The BCAR Board also carefully considered certain potentially material
negative factors in arriving at its conclusion, which are discussed elsewhere in this proxy statement/prospectus. For additional information
regarding the positive and negative factors the BCAR Board considered in evaluating the Business Combination, see the section entitled
&#8220;<i>The Business Combination Proposal &#8212; BCAR Board of Directors&#8217; Reasons for the Approval of the Business Combination&#8221;
</i><span style="font-weight: normal">on page&#160;130.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exascale&#8217;s Reasons for the Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale evaluated a range of strategic alternatives,
including remaining private, raising additional private capital, pursuing a traditional initial public offering or entering into a merger,
and determined that the Business Combination represents a favorable opportunity to support its long-term growth strategy and competitive
position. Exascale operates in a rapidly evolving AI infrastructure market characterized by strong demand for GPU compute, persistent
supply constraints and increasing power, cooling and deployment challenges, and believes that scaling its asset-light, software-defined
platform and related Infrastructure Solutions offerings requires access to capital, execution certainty and commercial flexibility. Exascale
expects that the Business Combination will provide access to the public capital markets to support capacity sourcing, platform expansion,
working capital needs and operational execution, accelerate its go-to-market strategy and customer growth, enhance credibility with customers,
suppliers and facility partners, and support the commercialization of certain Infrastructure Solutions offerings. These offerings include
modular data center, advanced liquid cooling, HVDC power and energy storage solutions that management believes are ready to support customer
deployments as of the date of this proxy statement/prospectus, although such offerings have not generated revenue to date. In reaching
this determination, Exascale also considered transaction-specific factors, including timing and execution certainty relative to alternative
financing paths, as well as risks and uncertainties associated with the Business Combination, including redemption risk, market volatility,
public company costs and structural considerations, and concluded that the Business Combination offers a favorable balance of strategic
benefits and execution certainty. For additional information regarding the positive and negative factors Exascale considered in evaluating
the Business Combination, see the section entitled &#8220;<i>The Business Combination Proposal &#8212; Exascale&#8217;s Reasons for the
Business Combination&#8221; </i>on page&#160;133.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>The Proposals to be Submitted at the Extraordinary
General Meeting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(1) Proposal No. 1 &#8212; The Business Combination
Proposal </b>&#8212; To consider and vote upon a proposal to approve by way of ordinary resolution and adopt the Agreement and Plan of
Merger, dated as of January 11, 2026 (the &#8220;<b>Business Combination Agreement</b>&#8221;), by and among BCAR, D. Boral ARC Merger
Corporation, a Delaware corporation and a direct, wholly owned subsidiary of the Parent (&#8220;<b>PubCo</b>&#8221;), D. Boral Arc Merger
Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary of the Parent (&#8220;<b>Merger Sub</b>&#8221;), and Exascale Labs
Inc., a Delaware corporation (the &#8220;<b>Company</b>&#8221; or &#8220;<b>Exascale</b>&#8221;), pursuant to which, among other things,
following the closing of the Domestication Merger (as defined below), Merger Sub shall be merged with and into the Company, with the Company
surviving the merger as a wholly-owned subsidiary of PubCo (the &#8220;<b>Acquisition Merger</b>&#8221;), and approve the Acquisition
Merger and the other transactions contemplated by the Business Combination Agreement. The Acquisition Merger, together with the Domestication
Merger and the other agreements and transactions contemplated by the Business Combination Agreement, are referred to herein as the &#8220;<b>Business
Combination</b>.&#8221; We refer to this proposal as the &#8220;<b>Business Combination Proposal</b>.&#8221; A copy of the Business Combination
Agreement is attached to the accompanying proxy statement/prospectus as <i>Annex A</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For additional information, see &#8220;<i>The Business
Combination Proposal</i>,&#8221; below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(2) Proposal No. 2 &#8212; The Domestication Merger
Proposal</b> &#8212; To consider and vote upon a proposal to approve by way of an ordinary resolution and adopt the domestication of D.
Boral ARC Acquisition I Corp., a British Virgin Islands business company (&#8220;<b>BCAR</b>&#8221; or the &#8220;<b>Parent</b>&#8221;)
pursuant to the Business Combination Agreement, and subject to the conditions of the Business Combination Agreement, pursuant to which
the Parent shall continue out of the British Virgin Islands and into the State of Delaware so as to re-domicile as and become a Delaware
corporation by means of a merger (the &#8220;<b>Domestication Merger</b>&#8221;) of the Parent with and into the PubCo, with PubCo as
the surviving company pursuant to the Business Companies Act, (Revised Edition 2020) as amended, of the British Virgin Islands and Section
388 and other applicable provisions of the DGCL. Upon the Domestication Merger, PubCo shall change its name to &#8220;Exascale Labs Holdings
Inc.&#8221; We refer to this proposal as the &#8220;<b>Domestication Merger Proposal</b>.&#8221; A copy of the Business Combination Agreement
is attached to the accompanying proxy statement/prospectus as <i>Annex A.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(3) Proposal No. 3 &#8212; Organizational Documents
Proposal </b>&#8212; To consider and vote upon a proposal to approve by way of ordinary resolution the proposed amended and restated certificate
of incorporation (the &#8220;<b>Proposed Charter</b>&#8221;) and the proposed amended and restated bylaws (&#8220;<b>Proposed Bylaws</b>&#8221;
and, together with the Proposed Charter, the &#8220;<b>Proposed Organizational Documents</b>&#8221;) of PubCo (a corporation incorporated
in the State of Delaware), (the &#8220;<b>Organizational Documents Proposal</b>&#8221;). The forms of each of the Proposed Charter and
the Proposed Bylaws are attached to the accompanying proxy statement/prospectus as <i>Annex B-1 </i>and <i>Annex B-2</i>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For additional information, see &#8220;<i>The Organizational
Documents Proposal,</i>&#8221; below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(4) Proposal No. 4 &#8212; The Advisory Organizational
Documents Proposals </b>&#8212; To consider and vote upon the following six (6) separate proposals (collectively, the &#8220;<b>Advisory
Organizational Documents Proposals</b>&#8221;) to approve on an advisory non-binding basis by way of ordinary resolution the following
material differences between the Current Charter and the Proposed Organizational Documents:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><b>(A) <i>Advisory Organizational Documents
Proposal 4A (Authorized Shares) </i></b>&#8212; authorize the amendment and redesignation of the authorized shares of BCAR from (a) 500,000,000
BCAR Class A Ordinary Shares, 50,000,000 BCAR Class B Ordinary Shares and 5,000,000 BCAR preference shares, in each case par value $0.0001
per share, to (b) 260,000,000 shares of PubCo Class A Ordinary Common Stock, 35,000,000 shares of PubCo Class B Super Common Stock and
5,000,000 shares of PubCo Preferred Stock, in each case par value $0.0001 per share (&#8220;<b>Advisory Organizational Documents Proposal
4A</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><b>(B) <i>Advisory Organizational Documents
Proposal 4B (Change in Voting Rights) </i></b>&#8212; to change the voting rights of PubCo&#8217;s Common Stock such that, each PubCo
Class A Ordinary Common Stock will be entitled to one (1) vote per PubCo Class A Ordinary Common Stock on all matters submitted to a vote
of the stockholders of PubCo, and each PubCo Class B Super Common Stock will be entitled to twenty (20) votes per PubCo Class B Super
Common Stock on all matters submitted to a vote of the stockholders of PubCo, and that the PubCo Class A Ordinary Common Stock and PubCo
Class B Super Common Stock shall vote together on all matters except as explicitly required by the DGCL or as explicitly set forth in
the Proposed Charter (&#8220;<b>Advisory Organizational Documents Proposal 4B</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><b>(C) <i>Advisory Organizational Documents
Proposal 4C (Exclusive Forum Provision) </i></b>&#8212; to authorize adopting Delaware as the exclusive forum for certain stockholder
litigation and adopting the federal district courts of the United States as the exclusive forum for resolving complaints asserting a cause
of action under the Securities Act of 1933, as amended (the &#8220;<b>Securities Act</b>&#8221;) (&#8220;<b>Advisory Organizational Documents
Proposal 4C</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><b>(D)
<i>Advisory Organizational Documents Proposal 4D (Required Vote to Amend Charter) </i></b>&#8212; to approve provisions providing that
the affirmative vote of at least 66&#8532;% of the voting power of all the then outstanding shares of capital stock of PubCo entitled
to vote thereon, voting together as a single class, will be required to amend, alter, repeal or rescind any provision of Article FIFTH,
Article SIXTH, Article SEVENTH, Article EIGHTH, Article NINTH, Article TENTH and Article ELEVENTH of the Proposed Charter (&#8220;<b>Advisory
Organizational Documents Proposal 4D</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><b>(E) <i>Advisory Organizational Documents
Proposal 4E (Removal of Directors) </i></b>&#8212; to approve provisions permitting the removal of a director, but only for cause, and
then by the affirmative vote of at least 66&#8532;% of the voting power of all the then outstanding shares entitled to vote generally
in the election of directors, voting together as a single class (&#8220;<b>Advisory Organizational Documents Proposal 4E</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><b>(F) <i>Advisory Organizational Documents
Proposal 4F (Name Change) </i></b>&#8212; to approve the change of the name of PubCo to &#8220;Exascale Labs Holdings Inc.&#8221; (&#8220;<b>Advisory
Organizational Documents Proposal 4F</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For additional information, see &#8220;<i>The Advisory
Organizational Documents Proposal,</i>&#8221; below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(5) Proposal
No. 5 &#8212; Directors Proposal </b>&#8212; A proposal to elect Hoansoo Lee, Wenying Jia, David Card, Shachar Kariv and Jaeyoung Shin
as the directors of PubCo, with Hoansoo Lee to serve until the 2029 annual meeting and until his successor has been duly elected and qualified
or until his earlier resignation, removal or death, with each of Wenying Jia and David Card to serve until the 2028 annual meeting and
until their respective successors have been duly elected and qualified or until their earlier resignation, removal or death, and with
each of Shachar Kariv and Jaeyoung Shin to serve until the 2027 annual meeting and until their respective successors have been duly elected
and qualified or until their earlier resignation, removal or death (the &#8220;<b>Directors Proposal</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For additional information, see &#8220;<i>The
Directors Proposal,</i>&#8221; below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(6) Proposal No. 6 &#8212; The Equity Incentive
Plan Proposal </b>&#8212; To consider and vote upon a proposal to approve by ordinary resolution the Equity Incentive Plan (the &#8220;<b>Equity
Incentive Plan Proposal</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For additional information, see &#8220;<i>The
Equity Incentive Plan Proposal,</i>&#8221; below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(7) Proposal No. 7 &#8212; The Nasdaq Proposal
</b>&#8212; To consider and vote upon a proposal to approve by ordinary resolution, for purposes of complying with the applicable provisions
of Nasdaq Stock Exchange Listing Rule 5635, the issuance of PubCo Common Stock and PubCo Warrants in connection with the Business Combination
(the &#8220;<b>Nasdaq proposal</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For additional information, see &#8220;<i>The
Nasdaq Proposal,</i>&#8221; below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(8) Proposal No. 8 &#8212; The Adjournment
Proposal </b>&#8212; To consider and vote upon a proposal to approve by way of ordinary resolution the adjournment of the Extraordinary
General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are
insufficient votes for the approval of one or more proposals at the Extraordinary General Meeting (the &#8220;<b>Adjournment Proposal</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For additional information, see &#8220;<i>The Adjournment
Proposal,</i>&#8221; below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Date, Time and Place of the Extraordinary General
Meeting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Extraordinary General Meeting will be held at
10:00 A.M., Eastern Time, on [_], 2026 at the offices of Loeb &amp; Loeb LLP, 345 Park Avenue, New York, New York 10154. Shareholders
may attend the Extraordinary General Meeting in person or virtually via telephone at: Telephone number: __________________ Participant
Passcode: __________________.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Voting Power; Record Date</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR shareholders will be entitled to vote or direct
votes to be cast at the Extraordinary General Meeting if they owned BCAR Ordinary Shares at the close of business on [_], 2026, which
is the Record Date for the Extraordinary General Meeting. Shareholders will have one vote for each BCAR Ordinary Share owned at the close
of business on the Record Date. If your shares are held in &#8220;street name&#8221; or are in a margin or similar account, you should
contact your broker to ensure that votes related to the shares you beneficially own are properly counted. BCAR Warrants do not have voting
rights. As of the close of business on the Record Date, there were 41,200,000 BCAR Ordinary Shares outstanding, of which 28,000,000 were
Public Shares held by persons other than held by the Insiders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Quorum and Vote of BCAR Shareholders</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A quorum of BCAR shareholders is necessary to hold
a valid meeting. A quorum will be present at the BCAR Extraordinary General Meeting if the holders of at least thirty percent (30%) of
the issued and outstanding shares entitled to vote at the Extraordinary General Meeting are represented in person or by proxy (which would
include presence at the Extraordinary General Meeting). Abstentions and broker non-votes, while considered present for the purposes of
establishing a quorum, will not count as a vote cast at the Extraordinary General Meeting and otherwise will have no effect on a particular
proposal under British Virgin Islands law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of the Record Date for the Extraordinary General
Meeting, 12,360,000 BCAR Ordinary Shares would be required to achieve a quorum. Because the Insiders have the right to vote 13,200,000
BCAR Ordinary Shares and have agreed to be present at the Extraordinary General Meeting, the presence at the Extraordinary General Meeting
no additional holders of Ordinary Shares will be needed to establish a quorum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The proposals presented at the Extraordinary General
Meeting require the following votes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Business Combination Proposal</i></b> &#8212; The approval
        of the Business Combination Proposal requires an ordinary resolution under the Current Charter, being the affirmative vote of a majority
        of the votes cast by the holders of BCAR Ordinary Shares, voting as a single class, represented in person or by proxy and entitled to
        vote thereon at the Extraordinary General Meeting.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify"><b><i>Domestication Merger Proposal</i></b> &#8212; The approval of the
        Domestication Merger Proposal requires an ordinary resolution under British Virgin Islands law, being the affirmative vote of a majority
        of the votes cast by the holders of BCAR Ordinary Shares, voting as a single class, represented in person or by proxy and entitled to
        vote thereon at the Extraordinary General Meeting.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify"><b><i>Organizational Documents Proposal</i></b> &#8212; The approval of
        the Organizational Documents Proposal requires an ordinary resolution under British Virgin Islands law, being the affirmative vote of
        a majority of the votes cast by the holders of BCAR Ordinary Shares, represented in person or by proxy and entitled to vote thereon at
        the Extraordinary General Meeting.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Advisory Organizational Documents Proposals </i></b>&#8212;
        The separate approval of each of the Advisory Organizational Documents Proposals, each of which is a non-binding vote, requires an ordinary
        resolution under the Current Charter, being the affirmative vote of a majority of the votes cast by the holders of BCAR Ordinary Shares,
        voting as a single class, represented in person or by proxy and entitled to vote thereon at the Extraordinary General Meeting.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify"><b><i>Directors Proposal</i></b> &#8212; The approval of the Directors Proposal requires an ordinary resolution
        under the Current Charter, being the affirmative vote of a majority of the votes cast by the holders of BCAR Ordinary Shares, voting as
        a single class, represented in person or by proxy and entitled to vote thereon at the Extraordinary General Meeting.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Equity Incentive Plan Proposal</i></b> &#8212; The approval
        of the Equity Incentive Plan Proposal requires an ordinary resolution under the Current Charter, being the affirmative vote of a majority
        of the votes cast by the holders of BCAR Ordinary Shares, voting as a single class, represented in person or by proxy and entitled to
        vote thereon at the Extraordinary General Meeting.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Nasdaq Proposal</i></b> &#8212; The approval of the Nasdaq
        Proposal requires an ordinary resolution under the Current Charter, being the affirmative vote of a majority of the votes cast by the
        holders of BCAR Ordinary Shares, voting as a single class, represented in person or by proxy and entitled to vote thereon at the Extraordinary
        General Meeting.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Adjournment Proposal</i></b> &#8212; The approval of
        the Adjournment Proposal requires an ordinary resolution under the Current Charter, being the affirmative vote of a majority of the votes
        cast by the holders of BCAR Ordinary Shares, voting as a single class, represented in person or by proxy and entitled to vote thereon
        at the Extraordinary General Meeting.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Abstentions and broker non-votes, while considered
present for the purposes of establishing a quorum, will not count as a vote cast at the Extraordinary General Meeting and otherwise will
have no effect on a particular proposal under British Virgin Islands law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Insiders have agreed to vote all of their
BCAR Ordinary Shares in favor of the proposals being presented at the Extraordinary General Meeting. The Sponsor, which includes among
its members each of the directors and officers of BCAR, owns 200,000 Private Units and 12,000,000 Class B Ordinary Shares, and David Boral
owns 1,000,000 Representative Shares. As a result, as of the date of this proxy statement/prospectus, the Insiders own approximately 32.0%
of the issued and outstanding BCAR Ordinary Shares. As a result, in addition to the shares held by the Insiders, BCAR would need 7,400,001
Public Shares, or approximately 26.4% of the 28,000,000 Public Shares sold in the BCAR IPO, to be voted in favor of the Business Combination
Proposal, the Domestication Merger Proposal, the Organizational Documents Proposal, the Advisory Organizational Documents Proposals, the
Directors Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal, and, if presented, the Adjournment Proposal, in order for
such proposals to be approved, assuming all outstanding shares are voted and the Insiders do not acquire any Public Shares. Assuming that
only the holders of thirty percent (30%) of the issued and outstanding BCAR ordinary shares, representing a quorum under BCAR&#8217;s
amended and restated memorandum and articles of association, vote their shares at the Extraordinary General Meeting, BCAR will not need
any Public Shares in addition to the shares held by the Insiders to be voted in favor of the Business Combination Proposal, the Domestication
Merger Proposal, the Organizational Documents Proposal, the Advisory Organizational Documents Proposals, the Directors Proposal, the Equity
Incentive Plan Proposal, the Nasdaq Proposal, and, if presented, the Adjournment Proposal, in order for such proposals to be approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Ownership of PubCo after the Closing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table illustrates varying ownership
levels in PubCo immediately following the consummation of the Business Combination based on the varying levels of redemptions by the Public
Shareholders, excluding the dilutive effect of Public Warrants, and Private Placement Warrants, that will be assumed by PubCo in the Business
Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        No<br/> Redemption</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        50% of<br/> Maximum Redemption</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        100% of<br/> Maximum Redemption</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ownership
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Voting
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ownership
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Voting
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ownership
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Voting
        %</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">PubCo
        Class A Ordinary Common Stock held by former Exascale Securityholders (including Exascale Class A common stockholders, the Exascale Safeholders,
        the Exascale Base Camp Investor, and the Exascale Equity Incentive Recipients)<sup>(1)</sup></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">19,256,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">21.1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">19,256,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">24.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">19,256,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30.5</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">PubCo
        Class B Super Common Stock held by former Exascale stockholders<sup>(2)</sup></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,744,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">33.7</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">91.1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,744,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">39.8</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">93.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,744,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">48.6</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">95.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt;">PubCo
    Class A Ordinary Common Stock held by Insiders<sup>(3)</sup></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">14.5</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">17.1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">20.9</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">PubCo
        Class A Ordinary Common Stock held by Non-Affiliated Public</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">28,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30.7</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">4.2</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">14,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">18.2</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
        pro forma PubCo Class A Ordinary Common Stock and PubCo Class B Super Common Stock</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">91,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">77,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">63,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Consists
        of (i) 10,100,000 PubCo Class A Ordinary Common Stock to be issued to current holders of Exascale Class A common stock, (ii) 8,766,500
        PubCo Class A Ordinary Common Stock to be issued to the Exascale Safeholders, (iii) 312,500 PubCo Class A Ordinary Common Stock to be
        issued to the Exascale Base Camp Investor, and (iv) 77,000 PubCo Class A Ordinary Common Stock to be issued to the Exascale Equity Incentive
        Recipients. For additional details, see &#8220;<i>Questions and Answers for Shareholders of BCAR&#8212;What will Exascale Securityholders
        receive in connection with the Business Combination?&#8221; Proposal No. 1&#8212;The Business Combination Proposal&#8212;The Business
        Combination Agreement&#8212;Consideration&#8221; and &#8220;Unaudited Pro Forma Condensed Combined Financial Information&#8212;Description
        of the Transactions.</i>&#8221;</span></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">2.</td>
    <td style="text-align: justify">Consists of 30,744,000 PubCo Class B Super Common Stock to be issued to
        current holders of Exascale Class B common stock. For additional details, see &#8220;<i>Questions and Answers for Shareholders of BCAR&#8212;What
        will Exascale Securityholders receive in connection with the Business Combination?&#8221; Proposal No. 1&#8212;The Business Combination
        Proposal&#8212;The Business Combination Agreement&#8212;Consideration&#8221; and &#8220;Unaudited Pro Forma Condensed Combined Financial
        Information&#8212;Description of the Transactions.</i>&#8221;</td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">3.</td>
    <td style="text-align: justify">Consists of 13,200,000 PubCo Class A Ordinary Common Stock to
    be issued in exchange for (i) 12,000,000 BCAR Class B Ordinary Shares held by the Sponsor, (ii) 200,000 BCAR Class A Ordinary Shares
    underlying the Private Units held by the Sponsor and (iii) 1,000,000 BCAR Class A Ordinary Shares (being the Representative Shares)
    held by BCAR&#8217;s Chairman and Chief Executive Officer.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stockholders will experience additional dilution
to the extent PubCo issues additional shares of PubCo Common Stock in connection with any Minimum Cash Financing and/or after the closing
of the Business Combination. The table above excludes any shares that will be issuable upon the exercise or settlement of: (i) the 100,000
Private Placement Warrants, and (ii) the 14,000,000 Public Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table illustrates varying ownership
levels in PubCo immediately following the consummation of the Business Combination based on the varying levels of redemptions by the Public
Shareholders, on a fully diluted basis, showing full exercise and conversion of all securities, including the Public Warrants and Private
Placement Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        No<br/> Redemption</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        50% of<br/> Maximum Redemption</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        100% of<br/> Maximum Redemption</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ownership
        %</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Voting
        %</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ownership
        %</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Voting
        %</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ownership
        %</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Voting
        %</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">PubCo
        Class A Ordinary Common Stock held by former Exascale Securityholders (including Exascale Class A common stockholders, the Exascale Safeholders,
        the Exascale Base Camp Investor, and the Exascale Equity Incentive Recipients)<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">19,256,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">18.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">19,256,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">22.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">19,256,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">PubCo
        Class B Super Common Stock held by former Exascale stockholders<sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,744,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">29.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">89.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,744,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">36.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">92.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,744,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">48.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">95.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt;">PubCo
    Class A Ordinary Common Stock held by Insiders<sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,300,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">12.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,300,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">15.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,300,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">21.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">PubCo
        Class A Ordinary Common Stock held by Non-Affiliated Public</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">42,000,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">39.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">6.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">21,000,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">24.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
        pro forma PubCo Class A Ordinary Common Stock and PubCo Class B Super Common Stock</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">105,300,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">84,300,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">63,300,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt;">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt;">Consists
    of (i) 10,100,000 PubCo Class A Ordinary Common Stock to be issued to current holders of Exascale Class A common stock, (ii) 8,766,500
    PubCo Class A Ordinary Common Stock to be issued to the Exascale Safeholders, (iii) 312,500 PubCo Class A Ordinary Common Stock to
    be issued to the Exascale Base Camp Investor, and (iv) 77,000 PubCo Class A Ordinary Common Stock to be issued to the Exascale Equity
    Incentive Recipients. For additional details, see &#8220;<i>Questions and Answers for Shareholders of BCAR&#8212;What will Exascale
    Securityholders receive in connection with the Business Combination?&#8221; Proposal No. 1&#8212;The Business Combination Proposal&#8212;The
    Business Combination Agreement&#8212;Consideration&#8221; and &#8220;Unaudited Pro Forma Condensed Combined Financial Information&#8212;Description
    of the Transactions.</i>&#8221;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt;">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt;">Consists
    of 30,744,000 PubCo Class B Super Common Stock to be issued to current holders of Exascale Class B common stock. For additional details,
    see &#8220;<i>Questions and Answers for Shareholders of BCAR&#8212;What will Exascale Securityholders receive in connection with
    the Business Combination?&#8221; Proposal No. 1&#8212;The Business Combination Proposal&#8212;The Business Combination Agreement&#8212;Consideration&#8221;
    and &#8220;Unaudited Pro Forma Condensed Combined Financial Information&#8212;Description of the Transactions.</i>&#8221;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt;">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt;">Consists
    of 13,300,000 PubCo Class A Ordinary Common Stock to be issued in exchange for (i) 12,000,000 BCAR Class B Ordinary Shares held by
    the Sponsor, (ii) 200,000 BCAR Class A Ordinary Shares underlying the Private Units held by the Sponsor, (iii) 100,000 BCAR Class
    A Ordinary Shares underlying Private Placement Warrants held by the Sponsor and (iv) 1,000,000 BCAR Class A Ordinary Shares (being
    the Representative Shares) held by BCAR&#8217;s Chairman and Chief Executive Officer.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although shares of PubCo Class A Ordinary Common
Stock and PubCo Class B Super Common Stock have identical economic rights, each holder of shares of PubCo Class A Ordinary Common Stock
shall be entitled to one (1) vote for each share of PubCo Class A Ordinary Common Stock held, and each holder of shares of PubCo Class
B Super Common Stock shall be entitled to twenty (20) votes for each share of PubCo Class B Super Common Stock held.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The entirety of the PubCo Class B Super Common
Stock will be held by five shareholders, namely, (i) Zerowave Ltd, (ii) Jisu Paul Lee Non-Grantor Directed Trust, (iii) Sophia Jisun Lee
Non-Grantor Directed Trust, (iv) Gabriel Jihwan Lee Non-Grantor Directed Trust and (v) HSL Capital Management LLC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Zerowave Ltd is affiliated with Wenying Jia, and
the Jisu Paul Lee Non-Grantor Directed Trust, the Sophia Jisun Lee Non-Grantor Directed Trust, the Gabriel Jihwan Lee Non-Grantor Directed
Trust and HSL Capital Management LLC are each affiliated with Hoansoo Lee, as more particularly explained below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Wenying Jia, who is a founder of Exascale, the
current Chairperson and a member of the board of directors of Exascale, and will be the Chairperson and a member of the PubCo Board upon
consummation of the Business Combination, is the sole member and manager of Zerowave Ltd and will have sole voting and dispositive power
with respect to the PubCo Class B Super Common Stock directly held by Zerowave Ltd.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hoansoo Lee, who is a founder of Exascale, the
current Chief Executive Officer, Chief Financial Officer and a member of the board of directors of Exascale, and who will be the Chief
Executive Officer and Interim Chief Financial Officer of PubCo and a member of the PubCo Board upon consummation of the Business Combination,
is the sole member and manager of HSL Capital Management LLC and will have sole voting and dispositive power with respect to the PubCo
Class B Super Common Stock directly held by HSL Capital Management LLC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hoansoo Lee is also the settlor of, and serves
as investment advisor to, each of the Jisu Paul Lee Non-Grantor Directed Trust, the Sophia Jisun Lee Non-Grantor Directed Trust, and the
Gabriel Jihwan Lee Non-Grantor Directed Trust, and the beneficiaries of each of those trusts are the children of Hoansoo Lee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Dilution</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents the net tangible book
value per share, as adjusted, at various redemption levels assuming various sources of material probable dilution (but excluding the effects
of the Business Combination transaction itself):</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Assuming</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No
        Redemption</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Assuming
        50% of</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum
        Redemption</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Assuming
        100% of</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum
        Redemption</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 64%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IPO
        offering price per share</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR
        net tangible book value as of March 31, 2026<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,122</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,122</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,122</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjusted
        for<sup>(2)</sup>: Changes to trust account balance</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">287,319,687</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">143,659,843</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
        transaction expenses</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,066,722</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,066,722</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,066,722</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR
        net tangible book value as of March 31, 2026, as adjusted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">286,307,087</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">142,593,121</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,012,600</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR
        non-redeemable Ordinary Shares as of March 31, 2026<sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,200,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,200,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,200,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR
        Ordinary Shares subject to Possible redemption<sup>(4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,000,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,000,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
        BCAR Ordinary Shares outstanding as of March 31, 2026, as adjusted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,200,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,200,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,200,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR
        net tangible book value per share as of March 31, 2026<sup>(5)</sup></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR
        net tangible book value per share as of March 31, 2026, as adjusted</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.95</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.24</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.08</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Difference
        between IPO offering price per share and adjusted net tangible book value per share</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.05</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.76</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.08</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt"><sup>(1)</sup>&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">BCAR&#8217;s net tangible book value was calculated by total assets minus total
        liabilities minus ordinary shares subject to possible redemptions.</span></td> </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(2)</sup>&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">BCAR&#8217;s trust account balance was adjusted for (i) subsequent actual and
        possible redemptions as a result of different levels of assumption.</span></td> </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(3)</sup>&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Consisted of BCAR&#8217;s Founder Shares
        of 12,000,000, Private Shares of 200,000 issued to the Sponsor and representative shares of 1,000,000 to the underwriter.</span></td>
        </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt;"><sup>(4)</sup>&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt;">Consisted of 28,000,000 BCAR&#8217;s Ordinary
    Shares subject to redemption as of March 31, 2026, adjusted for possible redemptions as a result of different levels of assumption.</span></td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><sup>(5)</sup>&#160;</td>
    <td style="text-align: justify">Respective amounts are less than 0.01.</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Assuming
    <br/> No Redemption</td>
    <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Assuming
    50% of<br/>
    Maximum Redemption</td>
    <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Assuming
    100% of<br/>
    Maximum Redemption</td>
    <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 64%; vertical-align: top">Total
    BCAR Ordinary Shares outstanding as of March 31, 2026, as adjusted</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">41,200,000</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">27,200,000</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">13,200,000</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Post-Combination
    Company common stock issued in the Business Combination to Exascale stockholders</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">50,000,000</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">50,000,000</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">50,000,000</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Number
    of shares after giving effect to the Business Combination</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">91,200,000</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">77,200,000</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">63,200,000</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">The
    company valuation at or above which the non-redeeming shareholders&#8217; interest per share being at least the IPO price per share</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">912,000,000</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">772,000,000</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">632,000,000</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shareholders will experience additional dilution to
the extent PubCo issues additional PubCo Common Stock in connection with or after the closing of the Business Combination. The table above
excludes the following potential sources of dilution that are not probable or not automatically convertible upon the consummation of the
Business Combination: (i) 14,000,000 and 100,000 PubCo Class A Ordinary Common Stock that will be issuable upon the exercise of the 28,000,000
BCAR Public Warrants and 200,000 BCAR Private Placement Warrants, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For each of the three redemption scenarios, potential
dilution results in the amount of non-redeeming&#160;shareholders&#8217; interest per share being at least the IPO price per share:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Appraisal Rights</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No appraisal or dissenters&#8217; rights are available
to BCAR&#8217;s shareholders in connection with the ordinary resolution to approve the Business Combination Proposal. However, in respect
of the resolution to approve the Domestication Merger Proposal, under section&#160;179 of the Companies Act, shareholders of a British
Virgin Islands company ordinarily have dissenters&#8217; rights with respect to a statutory merger. The Companies Act prescribes when
shareholder dissenters&#8217; rights will be available and sets the limitations on such rights. Where such rights are available, shareholders
are entitled to receive fair value for their shares. However, regardless of whether such rights are or are not available, BCAR&#8217;s
shareholders are still entitled to exercise the rights of redemption as detailed in this proxy statement/prospectus and the BCAR Board
has determined that the redemption proceeds payable to BCAR&#8217;s shareholders who exercise such redemption rights represents the fair
value of those shares. Please see the section entitled &#8220;<i>Appraisal or Dissenters&#8217; Rights</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Proxy Solicitation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Proxies may be solicited by mail, telephone or in
person. BCAR has engaged Advantage Proxy to assist in the solicitation of proxies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a shareholder grants a proxy, it may still vote
its shares in person if it revokes its proxy before the Extraordinary General Meeting. A shareholder also may change its vote by submitting
a later-dated proxy as described in &#8220;<i>Extraordinary General Meeting of BCAR &#8212; Revoking Your Proxy.</i>&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sponsor Information </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our sponsor is MFH 1, LLC, a Delaware limited
liability company, which was formed on March&#160;13, 2025 to invest in BCAR. Although our Sponsor is permitted to undertake any activities
permitted under the Delaware Limited Liability Company Act and other applicable law, our sponsor&#8217;s business is focused on investing
in BCAR. MilunaC Technology Limited owns a majority of the membership interests in our sponsor. John Darwin is the manager of our Sponsor,
and Mr. Darwin has sole voting and investment discretion with respect to the securities held by the Sponsor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Prior SPAC Experience</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below are the SPAC business combinations in which
members of our management team have participated, along with certain other information:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>EF Hutton Acquisition Corporation I.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Boral previously served as Co-President and
a Director of EF Hutton Acquisition Corporation I since March 3, 2021. EF Hutton Acquisition Corporation I completed its initial public
offering on September 13, 2022, in which it raised aggregate proceeds of approximately $115 million. On March 6, 2023, EF Hutton Acquisition
Corporation I announced that it had entered into a definitive agreement for a business combination with Humble Imports Inc., d/b/a ECD
Auto Design (&#8220;ECD&#8221;). On December 7, 2023, EF Hutton Acquisition Corporation I held a special meeting of stockholders to approve
the business combination and between the initial public offering and the special meeting to approve the business combination, approximately
11,477,545 public shares were redeemed, representing approximately 98% of the public shares issued in EF Hutton Acquisition Corporation
I&#8217;s initial public offering. Following the closing of the business combination with ECD on December 12, 2023, the common stock and
warrants of ECD began trading on Nasdaq on December 13, 2023, under the ticker symbols &#8220;ECDA&#8221; and &#8220;ECDAW,&#8221; respectively.
On [_], 2026, the closing sale price of ECDA and ECDAW were $[_] and $[_], respectively. As of [_], 2026, the aggregate market capitalization
of ECD reflects a market value of approximately $[_].</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Northern Lights Acquisition Corp.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Darwin previously served as Co-Chief Executive
Officer of Northern Lights Acquisition Corp. since March 19, 2021. Northern Lights Acquisition Corp. completed its initial public offering
on June 24, 2021, in which it raised aggregate proceeds of approximately $115 million. On February 14, 2022, Northern Lights Acquisition
Corp. announced that it had entered into a definitive agreement for a business combination with SHF Holdings, LLC. (&#8220;SHF&#8221;).
On June 28, 2022, Northern Lights Acquisition Corp. held a special meeting of stockholders to approve the business combination and in
connection therewith, approximately 7,573,402 shares were redeemed and an additional 3,804,872 redeemed shares were purchased as part
of a forward purchase agreement for a total of 11,378,274 shares, or 98.9% of the public shares issued in Northern Lights Acquisition
Corp.&#8217;s initial public offering. Following the closing of the business combination with SHF on June 30, 2022, the common stock and
warrants of SHF began trading on Nasdaq on July 1, 2022 under the ticker symbols &#8220;SHFS&#8221; and &#8220;SHFSW,&#8221; respectively.
On [_], 2026, the closing sale price of SHFS and SHFSW were $[_] and $[_], respectively. As of [_], 2026, the aggregate market capitalization
of SHF reflects a market value of approximately $[_].</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Edoc Acquisition Corp.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Chen previously served as Chief Executive
Officer and Director of Edoc Acquisition Corp. since September 2020. Edoc Acquisition Corp. completed its initial public offering on November
12, 2020, in which it raised aggregate proceeds of approximately $90 million. On December 5, 2022, Edoc Acquisition Corp. announced that
it had entered into a definitive agreement for a business combination with Australian Oilseeds Investments Pty Ltd., an Australian proprietary
company (&#8220;AOI&#8221;). On March 5, 2024, Edoc Acquisition Corp. held a special meeting of stockholders to approve the business combination
and between the initial public offering and the special meeting to approve the business combination, approximately 8,833,832 public shares
were redeemed, representing approximately 98% of the public shares issued in Edoc Acquisition Corp.&#8217;s initial public offering. Following
the closing of the business combination with AOI on March 21, 2024, the common stock and warrants of AOI began trading on Nasdaq on March
22, 2024, under the ticker symbols &#8220;COOT&#8221; and &#8220;COOTW,&#8221; respectively. On [_], 2026, the closing sale price of COOT
and COOTW were $[_] and $[_], respectively. As of June 5, 2025, the aggregate market capitalization of AOI reflects a market value of
approximately $[_].</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>InFinT Acquisition Corporation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Chen previously served board member of InFinT
Acquisition Corporation from November 2021 to August 2024. INFINT Acquisition Corporation completed its initial public offering on November
23, 2021, in which it raised aggregate proceeds of approximately $199,998,800. On August 3, 2022, InFinT Acquisition Corporation announced
that it had entered into a definitive agreement for a business combination with Seamless Group Inc., a Cayman Islands exempted company
(&#8220;Seamless&#8221;). On August 6, 2023, InFinT Acquisition Corporation held a special meeting of stockholders to approve the business
combination and between the initial public offering and the special meeting to approve the business combination, approximately 15,252,859
public shares were redeemed, representing approximately 76% of the public shares issued in InFinT Acquisition Corporation&#8217;s initial
public offering. Following the closing of the business combination with Seamless on August 30, 2024, the common stock of Seamless began
trading on Nasdaq on August 31, 2024, under the ticker symbols &#8220;CURR&#8221;. On [_], 2026, the closing sale price of CURR was $[_].
As of [_], 2026, the aggregate market capitalization of Seamless reflects a market value of approximately $[_].</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Conflicts of Interest</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our directors and officers presently have, and
any of them in the future may have, additional, fiduciary or contractual obligations to other entities pursuant to which such officer
or director is or will be required to present a business combination opportunity to such entity. Accordingly, if any of our directors
or officers becomes aware of a business combination opportunity that is suitable for an entity to which he or she has then-current fiduciary
or contractual obligations, he or she may need to honor these fiduciary or contractual obligations to present such business combination
opportunity to such entity, or in the case of a non-compete restriction, may not present such opportunity to us at all. Our amended and
restated memorandum and articles of association provide that, to the fullest extent permitted by applicable law: (i) no individual serving
as a director or an officer shall have any duty, except and to the extent expressly assumed by contract, to refrain from engaging directly
or indirectly in the same or similar business activities or lines of business as us; and (ii) we renounce any interest or expectancy in,
or in being offered an opportunity to participate in, any potential transaction or matter which may be a corporate opportunity for any
director or officer, on the one hand, and us, on the other. In addition our amended and restated articles of association will contain
provisions to exculpate and indemnify, to the maximum extent permitted by law, such persons in respect of any liability, obligation or
duty to the company that may arise as a consequence of such persons becoming aware of any business opportunity or failing to present such
business opportunity. Our directors and officers are also not required to commit any specified amount of time to our affairs, and, accordingly,
will have conflicts of interest in allocating management time among various business activities, including identifying potential business
combinations and monitoring the related due diligence. See &#8220;<i>Risk Factors &#8212; Risks Related to our Team and Their Respective
Affiliates and to the Post-Business Combination Company &#8212; Certain of our directors and officers are now, and all of them may in
the future become, affiliated with entities engaged in business activities similar to those intended to be conducted by us and, accordingly,
may have conflicts of interest in determining to which entity a particular business opportunity should be presented</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the payments to
be received by BCAR&#8217;s promoters and the Sponsor and its affiliates from BCAR prior to or in connection with the completion of BCAR&#8217;s
initial business combination and the securities issued and to be issued by BCAR to the Sponsor or its affiliates:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left; width: 30%">Entity/Individual</td>
    <td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center; width: 33%">
        <p style="text-align: center; margin-top: 0; margin-bottom: 0">Amount of Compensation to be<br/> Received or Securities Issued or to
        be Issued</p></td>
    <td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center; width: 33%">Consideration Paid or
        to be Paid</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">MFH 1, LLC</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">12,000,000 Class B Ordinary Shares</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">$25,000</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">200,000 Private Units purchased simultaneously with the closing of the IPO</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">$2,000,000</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">$20,000 per month, commencing on July 30, 2025</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Office space, utilities and secretarial and administrative services</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Up to $2,500,000 in working capital loans, which loans may be converted into Private
        Units of the post-business combination entity at the price of $10.00 per Private Unit</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Working capital loans to finance transaction costs in connection with an initial
        business combination</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">MFH 1, LLC, our officers, directors,
        advisor or our or their affiliates</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Reimbursement for any out-of-pocket expenses related to identifying, investigating
        and completing an initial business combination</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Services in connection with identifying, investigating and completing an initial
        business combination</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">David Boral</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">1,000,000 Representative Shares </span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Underwriter compensation in connection with the IPO</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, our sponsor, its members, our officers
or our directors or their respective affiliates may be investors, or have other direct or indirect interests, in a business with which
we may enter into a business combination agreement and/or in certain funds or other persons that may purchase shares in this offering
or that may otherwise purchase our BCAR Class A Ordinary Shares in the public market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not believe, however, that the fiduciary
duties or contractual obligations of our directors or officers will materially affect our ability to identify and pursue business combination
opportunities or complete our initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a table summarizing the entities to which
the executive officers and directors of BCAR currently have fiduciary duties or contractual obligations:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: left; width: 14%"><span style="font-size: 10pt"><b>Individual</b></span></td>
    <td style="text-align: left; white-space: nowrap; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 28%; text-align: center"><span style="font-size: 10pt"><b>Entity</b></span></td>
    <td style="text-align: left; white-space: nowrap; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 26%; text-align: center"><span style="font-size: 10pt"><b>Entity&#8217;s Business</b></span></td>
    <td style="text-align: left; white-space: nowrap; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 26%; text-align: center"><span style="font-size: 10pt"><b>Affiliation</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">David Boral</p></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">D. Boral Capital</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Broker-dealer</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">D. Boral Acquisition I Corp.</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">SPAC</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">Chief Executive Officer</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left"><span style="font-size: 10pt">John Darwin</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">D. Boral Capital</p></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Broker-dealer</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Chief Investment Officer</p></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">D. Boral Acquisition I Corp.</p></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">SPAC</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Luminous Capital USA Inc.</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Investment firm</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Managing Partner</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left"><span style="font-size: 10pt">Luisa Ingargiola</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Dragonfly Energy Holdings Corp.</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Energy storage and battery technology</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Avalon GloboCare Corp.</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Biotechnology</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">BioCorRx Inc.</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">Healthcare</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">Director and Audit Committee Chair</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Vision Marine Marine Technologies, Inc.</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">Electric outboard powertrain systems</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Director and Audit Committee Chair</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Fusion Fuel Green PLC</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">Energy fuel technology</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Director and Audit Committee Chair</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">Core AI Holdings, Inc.</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">Mobile games developer and publisher</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">Director and Audit Committee Chair</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">D. Boral Acquisition I Corp.</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">SPAC</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">Director</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">New America Acquisition I Corp.</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">SPAC</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">Director</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left"><span style="font-size: 10pt">Kevin Chen</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Horizon Financial</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Investment advisor</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Chief Investment Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">ACM Macro LLC</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Investment advisor</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Manager</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Australian Oilseeds Investment</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Manufacture and sale of sustainable oilseeds</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">CurrenC Group</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Financial services</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Capitan Investment Ltd.</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Real estate</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Scage International Limited</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Energy heavy-duty commercial vehicles and e-fuel solutions</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left"><span style="font-size: 10pt">Matt Laker</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">N/A</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">N/A</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">N/A</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Interests of BCAR&#8217;s Directors and Officers
in the Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain of BCAR&#8217;s directors and executive
officers may be deemed to have interests in the transactions contemplated by the Business Combination Agreement that are different from,
or in addition to, those of BCAR&#8217;s shareholders generally. These interests may present these individuals with certain potential
conflicts of interest. Our independent directors reviewed and considered these interests during their evaluation and negotiation of the
Business Combination and in unanimously approving, as members of the BCAR Board, the Business Combination Agreement and the transactions
contemplated therein, including the Business Combination. The BCAR Board concluded that the potential benefits that it expected BCAR and
its shareholders to achieve as a result of the Business Combination outweighed the potentially negative factors associated with the Business
Combination. When you consider the recommendation of the BCAR Board in favor of approval of the Business Combination, you should keep
in mind that BCAR&#8217;s directors and officers have interests in the Business Combination that are different from, or in addition to,
your interests as a shareholder, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If the proposed Business Combination is
        not consummated by February 1, 2027 (or May 1, 2027 if the Sponsor exercises its three-month extension option), then we will be required
        to liquidate. In such event, the 12,000,000 BCAR Class B Ordinary Shares, which were acquired by BCAR&#8217;s sponsor, MFH 1, LLC (the
        &#8220;<b>Sponsor</b>&#8221;), prior to the IPO for an aggregate purchase price of $25,000, will be worthless. Such BCAR Class B Ordinary
        Shares had an aggregate market value of approximately $[_] based on the closing price of BCAR&#8217;s Public Shares of $[_] on Nasdaq
        as of [_], 2026. As a result of the nominal price of $0.002 per Class B Ordinary Share paid by the Sponsor compared to the recent market
        price of BCAR&#8217;s Class A Ordinary Shares, the Sponsor is likely to earn a positive rate of return on their investments in the Class
        B Ordinary Shares even if the holders of BCAR&#8217;s Class A Ordinary Shares experience a negative rate of return on their investments
        in the Class A Ordinary Shares.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If the proposed Business Combination is
        not consummated by February 1, 2027 (or May 1, 2027 if the sponsor exercises its three-month extension option), then 200,000 private placement
        units (the &#8220;<b>Private Units</b>&#8221;) purchased by the Sponsor for a total purchase price of $2,000,000, will be worthless. Such
        Private Units had an aggregate market value of approximately $[_] closing price of BCAR Units of $[_] on Nasdaq as of [_], 2026.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Sponsor invested an aggregate of $2,025,000 in BCAR, comprised of the $25,000
        purchase price for the Founder Shares and $2,000,000 purchase price for the Private Units. The amount held in BCAR&#8217;s trust account
        was approximately $[_] on the Record Date, implying a value of $[_] per public share. Based on these assumptions, each PubCo Class A Common
        Stock would have an implied value of $[_] per share upon consummation of the Business Combination, representing a [_]% decrease from the
        initial implied value of $[_] per public share. While the implied value of $[_] per share upon consummation of the Business Combination
        would represent a dilution to our Public Shareholders, this would represent a significant increase in value for the Sponsor relative to
        the price it paid for each Founder Share. At approximately $[_] per share, the 12,200,000 PubCo Class A Common Stock that the Sponsor
        would own upon consummation of the Business Combination would have an aggregate implied value of $[_]. As a result, even if the trading
        price of PubCo Class A Common Stock significantly declines, the value of the PubCo Class A Common Stock held by the Sponsor will be significantly
        greater than the amount the Sponsor paid to purchase such shares. For more information, please see &#8220;<i>Risk Factors &#8211; The
        nominal purchase price paid by the Sponsor and directors and officers of BCAR for the Founder Shares may significantly dilute the implied
        value of the Public Shares in the event the parties complete an initial business combination. In addition, the value of the Founder Shares
        will be significantly greater than the amount the Sponsor and directors and officers of BCAR paid to purchase such shares in the event
        the parties complete an initial business combination, even if the Business Combination causes the trading price of the PubCo Class A Common
        Stock to materially decline.</i>&#8221;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If the proposed Business Combination is not consummated, then 1,000,000 BCAR
        Class A Ordinary Shares (the &#8220;<b>Representative Shares</b>&#8221;) granted to D. Boral Capital LLC, the underwriter in the IPO,
        as compensation, which are held by David Boral, the CEO of D. Boral Capital LLC and our Chairman and Chief Executive Officer, will be
        worthless. Such Representative Shares had an aggregate market value of approximately $[_] closing price of BCAR Class A Ordinary Shares
        of $[_] on Nasdaq as of [_], 2026;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">As of [_], 2026, BCAR has unsecured promissory
        notes in the aggregate principal amount of $[_] outstanding and BCAR has drawn down an aggregate of $[_] under the notes. The promissory
        notes were issued for working capital purposes. In the absence of shareholder approval for a further extension, if the proposed Business
        Combination is not consummated by February 1, 2027 (or May 1, 2027 if the sponsor exercises its three-month extension option), then such
        loans may not be repaid.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Unless BCAR consummates the Business Combination,
        its officers, directors and the sponsor will not receive reimbursement for any out-of-pocket expenses incurred by them to the extent that
        such expenses exceeded the amount of its working capital. As of [_], 2026, $[_] of advances was paid by the Sponsor for expenses incurred
        on BCAR&#8217;s behalf and if the proposed Business Combination is not consummated by February 1, 2027 (or May 1, 2027 if the sponsor
        exercises its three-month extension option), that amount would not be repaid. As a result, the financial interest of BCAR&#8217;s officers,
        directors and Initial Shareholders or their affiliates could influence its officers&#8217; and directors&#8217; motivation in selecting
        Exascale as a target and therefore there may be a conflict of interest when it determined that the Business Combination is in the shareholders&#8217;
        best interest.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The exercise of BCAR&#8217;s directors&#8217;
        and officers&#8217; discretion in agreeing to changes or waivers in the terms of the transaction may result in a conflict of interest
        when determining whether such changes or waivers are appropriate and in our shareholders&#8217; best interest.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The continued indemnification of current directors and officers and the continuation
        of directors&#8217; and officers&#8217; liability insurance.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">BCAR&#8217;s Current Charter provides that BCAR renounces any interest or expectancy
        in, or in being offered an opportunity to participate in, any potential transaction or matter that may be a corporate opportunity for
        any member of BCAR&#8217;s management, on the one hand, and BCAR, on the other hand, or the participation in which would breach any existing
        legal obligation, under applicable law or otherwise, of a member of BCAR&#8217;s management to any other entity. BCAR is not aware of
        any such corporate opportunities not being offered to BCAR and does not believe that waiver of the corporate opportunities doctrine has
        materially affected BCAR&#8217;s search for an acquisition target or will materially affect BCAR&#8217;s ability to complete an initial
        business combination.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing interests may influence the officers
and directors of BCAR to support or approve the Business Combination. As such, the Sponsor and BCAR&#8217;s officers and directors may
be incentivized to complete an acquisition of a less favorable target company or on terms less favorable to BCAR&#8217;s shareholders
rather than liquidate. In considering the recommendations of the BCAR Board to vote for the proposals, BCAR&#8217;s shareholders should
consider these interests. For more information, please see &#8220;<i>Risk Factors &#8212; Some of the BCAR officers and directors may
be argued to have conflicts of interest that may influence them to support or approve the Business Combination without regard to your
interests.<b>&#8221;</b></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Interests of Exascale&#8217;s Directors and
Officers in the Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In considering the Business Combination, Exascale&#8217;s
sole executive officer and Exascale&#8217;s directors have interests that are different from, or in addition to, the interests of Exascale&#8217;s
other stockholders. Following the completion of the Business Combination, Exascale&#8217;s executive officer and directors and their affiliates
will receive or hold shares of PubCo Class B Super Common Voting Stock, which will carry twenty (20) votes per share, while other Exascale
Securityholders participating in the Business Combination will receive PubCo Class A Ordinary Common Voting Stock, which will carry one
(1) vote per share. As a result, Exascale&#8217;s executive officer and directors will hold equity interests with enhanced voting power,
which will enable them to exercise significant influence over matters submitted to PubCo&#8217;s stockholders, including the election
of directors and approval of significant corporate transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, Exascale&#8217;s executive officer
and directors have interests in the Business Combination related to the continuation of their positions with PubCo, anticipated future
equity-based compensation, severance or change-in-control protections, and the opportunity to participate in the future growth of PubCo
as a publicly traded company. Exascale&#8217;s executive officer and directors will also benefit from increased liquidity for their equity
holdings following the Business Combination, subject to applicable lock-up periods, and from the potential appreciation in the value of
PubCo&#8217;s securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These interests may create conflicts of interest
in connection with the approval of the Business Combination and related transactions. Exascale&#8217;s board of directors considered these
interests, among other factors, in evaluating and approving the Business Combination. For a more complete description of the interests
of Exascale&#8217;s executive officer and directors in the Business Combination, see the section of this proxy statement/prospectus entitled
&#8220;<i>The Business Combination Proposal&#8212;Certain Interests of Exascale&#8217;s Directors and Officers in the Business Combination</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Regulatory Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Neither BCAR nor Exascale is aware of any material
regulatory approvals or actions that are required for completion of the Business Combination, other than the regulatory notices and approvals
discussed in &#8220;<i>The Business Combination Proposal &#8212; Business Combination Agreement &#8212; Closing Conditions &#8212; Conditions
to the Obligations of Each Party.</i>&#8221; It is presently contemplated that if any such additional regulatory approvals or actions
are required, those approvals or actions will be sought. There can be no assurance, however, that any additional approvals or actions
will be obtained.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock Exchange Listing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The BCAR Units, BCAR Class A Ordinary Shares and
Public Warrants are currently traded on the Nasdaq Global Market under the symbols &#8220;BCARU&#8221;, &#8220;BCAR&#8221;, and &#8220;BCARW&#8221;,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recommendation to Shareholders of BCAR</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The BCAR Board
believes that the Business Combination Proposal and the other proposals to be presented at the Extraordinary General Meeting are in the
best interests of BCAR and BCAR&#8217;s shareholders and unanimously recommends that its shareholders vote &#8220;FOR&#8221; the approval
of the Business Combination Proposal, &#8220;FOR&#8221; the approval of the Domestication Merger Proposal, &#8220;FOR&#8221; the approval
of the Organizational Documents Proposal, &#8220;FOR&#8221; the approval, on an advisory basis, of each of the separate Advisory Organizational
Documents Proposals, &#8220;FOR&#8221; the approval of the Directors Proposal, &#8220;FOR&#8221; the approval of the Equity Incentive
Plan Proposal, &#8220;FOR&#8221; the approval of the Nasdaq Proposal, and &#8220;FOR&#8221; the approval of the Adjournment Proposal,
if presented to the Extraordinary General Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The existence of financial and personal interests
of one or more of BCAR&#8217;s directors may result in a conflict of interest on the part of such director(s) between what he, she or
they may believe is in the best interests of BCAR and its shareholders and what he, she or they may believe is best for himself, herself
or themselves in determining to recommend that shareholders vote for the proposals. In addition, BCAR&#8217;s officers have interests
in the Business Combination that may conflict with your interests as a shareholder. See &#8220;<i>The Business Combination Proposal &#8212;
Certain Interests of BCAR&#8217;s Directors and Officers and Others in the Business Combination</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>U.S. Federal Income Tax Considerations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a discussion summarizing certain U.S. federal
income tax considerations of the Domestication Merger in connection with the Business Combination, please see &#8220;<i>Certain Material
U.S. Federal Income Tax Considerations</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Accounting Considerations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Business Combination will be accounted for as
a reverse recapitalization, in accordance with U.S. Generally Accepted Accounting Principles (&#8220;<b>GAAP</b>&#8221;). Under this method
of accounting, BCAR will be treated as the &#8220;acquired&#8221; company for financial reporting purposes. Accordingly, the Business
Combination will be treated as the equivalent of Exascale issuing stock for the net assets of BCAR, accompanied by a recapitalization.
The net assets of BCAR will be stated at historical cost, with no goodwill or other intangible assets recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Summary Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR believes
it is important to communicate its expectations to its securityholders. However, there may be events in the future that neither BCAR nor
Exascale is able to predict accurately or over which they have control. The section in this proxy statement/prospectus entitled &#8220;<i>Risk
Factors</i>&#8221; and the other cautionary language discussed in this proxy statement/prospectus provide examples of certain risks, uncertainties
and events that may cause actual results to differ materially from the expectations described by BCAR or Exascale in such forward-looking
statements. Set forth below is only a summary of certain principal risks associated with an investment in our and PubCo&#8217;s securities.
You should carefully consider the following discussion of risks, as well as the discussion of risks included elsewhere in this proxy statement/prospectus,
including those described under &#8220;<i>Risk Factors.</i>&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires, references to Exascale in the summary risk factors below also includes PubCo subsequent to the Business
Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale has a limited operating
        history, has incurred net losses since inception, and may not achieve or sustain growth or profitability.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in">&#9679;</td>
    <td style="text-align: justify">Exascale depends on a limited and constrained supply of advanced GPU chips, and any disruption or increase
        in cost could adversely affect Exascale&#8217;s business and results of operations.</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in">&#9679;</td>
    <td style="text-align: justify">Exascale has incurred operating losses and may not be able to achieve or sustain profitability due to Exascale&#8217;s
        cost structure and ongoing operating expenses.</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s financial statements
        include a going concern qualification, and Exascale may not have sufficient liquidity to fund its operations without additional financing.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Demand for AI compute services and
        accelerated infrastructure may not grow as expected, and customer spending may be volatile.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale operates in a highly competitive
        market, and Exascale may be unable to compete effectively against larger and better-capitalized competitors.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Exascale depends on third-party GPU capacity suppliers, and
        disruptions, non-renewals, pricing increases or capacity limitations could adversely affect its business, results of operations and margins.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GPU capacity used to deliver Exascale&#8217;s
        services is deployed in third-party data centers and partner facilities, and constraints or disruptions in those facilities could materially
        adversely affect Exascale&#8217;s business.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If Exascale fails to deliver expected
        performance, efficiency, or reliability for customer workloads, Exascale&#8217;s reputation, customer relationships, and results of operations
        could be harmed.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s performance optimization
        and utilization practices may not achieve intended results, and Exascale&#8217;s methods may not scale as customer requirements and infrastructure
        complexity increase.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale may experience service
        interruptions, security incidents, or other operational failures, which could expose Exascale to liability and harm its business.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s AI-assisted operational
        tools and automation may not perform as intended and could introduce errors or risks.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s costs may increase,
        and Exascale may be unable to pass increased costs through to customers, which could adversely affect Exascale&#8217;s margins and results
        of operations.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s revenues may be
        concentrated in a limited number of customers or engagements, and Exascale&#8217;s results may be volatile due to usage variability and
        contract dynamics.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s AIDC GPU cluster
        management services may expose Exascale to additional operational, contractual, and liability risks.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Exascale&#8217;s infrastructure solution capabilities, including
        modular data centers, liquid cooling, HVDC power and energy storage solutions have not yet generated revenue and may not achieve commercial
        success.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rapid technological change in GPUs,
        networking, and AI software could require Exascale to adapt quickly, and Exascale may be unable to keep pace.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third parties may claim that Exascale&#8217;s
        platform infringes, misappropriates, or otherwise violates their intellectual property rights, and such claims could be time-consuming
        or costly to defend or settle, result in the loss of significant rights, or harm Exascale&#8217;s relationships with its customers or
        Exascale&#8217;s reputation in the industry.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some of Exascale&#8217;s technology
        incorporates &#8220;open-source&#8221; software, and failure to comply with the terms of the underlying open-source software licenses
        could adversely affect Exascale&#8217;s business, results of operations, financial condition, and future prospects.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale may be unable to protect
        its intellectual property, and third-party claims of infringement could be costly and disruptive.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale is subject to laws and
        regulations, including governmental export and import controls, sanctions, and anti-corruption laws, that could impair Exascale&#8217;s
        ability to compete in Exascale&#8217;s markets and subject Exascale to liability if Exascale is not in full compliance with applicable
        laws.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale is subject to laws, regulations,
        and industry requirements related to data privacy, data protection and information security, and user protection across different markets
        where it conducts its business and such laws, regulations, and industry requirements are constantly evolving and changing. Any actual
        or perceived failure to comply with such laws, regulations, and industry requirements, or Exascale&#8217;s privacy policies, could harm
        Exascale&#8217;s business.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Export controls, trade restrictions,
        and sanctions could limit Exascale&#8217;s ability to procure GPU hardware or serve certain customers and could increase compliance costs.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If Exascale is unable to attract
        and retain qualified personnel, our ability to execute our strategy and maintain service quality could be adversely affected.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s prior evaluation
        of blockchain or digital asset-related concepts could create reputational or regulatory scrutiny, and any future evaluation of such initiatives
        may be subject to heightened regulation.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The price of PubCo Common Stock may be volatile.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo
        will have a dual-class share structure with different voting rights, which may adversely affect the value and liquidity of PubCo&#8217;s
        securities.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo&#8217;s dual-class share structure
        with different voting rights will limit your ability to influence corporate matters and could discourage others from pursuing any change
        of control transactions that stockholders of PubCo may view as beneficial.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The holders of shares of PubCo Class
        B Super Common Stock will be able to control most stockholder votes.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An investment in the PubCo Securities
        may result in uncertain or adverse U.S. federal income tax consequences.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The requirements of being a public
        company may strain PubCo&#8217;s resources and distract management and PubCo will incur substantial costs as a result of being a public
        company.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales of a substantial amount of
        PubCo Common Stock in the public market, particularly sales by PubCo&#8217;s executive officers, directors and significant stockholders,
        or the perception that these sales could occur, could cause the market price of PubCo&#8217;s securities to decline.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A decline in the price of PubCo&#8217;s
        securities could affect PubCo&#8217;s ability to raise working capital and adversely impact PubCo&#8217;s ability to continue operations.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in international trade policies,
        tariffs and treaties affecting imports and exports may have a material adverse effect on PubCo&#8217;s business.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflationary pressures and persistently
        high prices and uncertain availability of inputs used by PubCo and PubCo&#8217;s suppliers, or instability in logistics and related costs,
        could negatively impact PubCo&#8217;s profitability. Pending tariffs proposed by the Trump Administration, may also negatively impact
        the cost structure of PubCo&#8217;s supply chain, and PubCo may not be able to pass these price increases on to its customers.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes to United States tariff
        and import/export regulations may have a material adverse effect on PubCo&#8217;s business, financial condition and results of operations.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the price of PubCo Common Stock
        fluctuates after the Business Combination, you could lose a significant part of your investment.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR Public Shareholders will experience
        immediate dilution as a consequence of the issuance of PubCo Common Stock as consideration in the Business Combination.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo Warrants will become exercisable
        for PubCo Class A Ordinary Common Stock, which would increase the number of shares eligible for future resale in the public market and
        result in dilution to our shareholders. Such dilution will increase if more Public Shares are redeemed.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if the Business Combination
        is consummated, the Public Warrants may never be in the money, and they may expire worthless and the terms of the warrants may be amended
        in a manner adverse to a holder if holders of at least 50% of the then outstanding Public Warrants approve of such amendment.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo may redeem your unexpired
        PubCo Warrants prior to their exercise at a time that is disadvantageous to you, thereby making your PubCo Warrants worthless.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Insiders have agreed to vote
        in favor of the Business Combination, regardless of how BCAR&#8217;s Public Shareholders vote.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since the Sponsor and BCAR&#8217;s
        directors and officers have interests that are different, or in addition to (and which may conflict with), the interests of our shareholders,
        a conflict of interest may have existed in determining whether the Business Combination with Exascale is appropriate as BCAR&#8217;s initial
        business combination.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; text-align: justify; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The exercise of BCAR&#8217;s directors&#8217;
        and officers&#8217; discretion in agreeing to changes or waivers in the terms of the Business Combination may result in a conflict of
        interest when determining whether such changes to the terms of the Business Combination or waivers of conditions are appropriate and in
        BCAR&#8217;s shareholders&#8217; best interest.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon consummation of the Business
        Combination, the rights of holders of PubCo Common Stock arising under the DGCL as well as Proposed Organizational Documents will differ
        from and may be less favorable to the rights of holders of BCAR Class A Ordinary Shares arising under the Companies Act as well as the
        Current Charter.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders of BCAR Class A Ordinary
        Shares are not entitled to vote on any appointment of directors prior to BCAR&#8217;s initial business combination.&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because of BCAR&#8217;s history
        as a special purpose acquisition company, the Business Combination may be subject to increased regulatory scrutiny, which could delay
        or prevent the completion of the Business Combination.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because of BCAR&#8217;s history
        as a special purpose acquisition company, the SEC may treat the Business Combination as an IPO of Exascale, subjecting BCAR to heightened
        disclosure and liability standards.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR may be a controlled foreign
        corporation which could result in adverse U.S. federal income tax consequences to U.S. investors.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR, and subsequent to the Business
        Combination, PubCo may be or become a passive foreign investment company, which could result in adverse U.S. federal income tax consequences
        to U.S. investors.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Domestication Merger may result
        in taxes imposed on holders of BCAR securities and Exascale securities.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The future exercise of registration
        rights granted to our Insiders and holders of our Private Placement Warrants may adversely affect the market price of PubCo&#8217;s securities.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR&#8217;s ability to complete
        the Business Combination with Exascale may be impacted if the Business Combination is subject to U.S. foreign investment regulations and
        review by a U.S. government entity, such as the Committee on Foreign Investment in the United States, and ultimately prohibited.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR and Exascale will incur significant
        transaction and transition costs in connection with the Business Combination.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to the consummation of
        the Business Combination, PubCo may be exposed to unknown or contingent liabilities and may be required to subsequently take write-downs
        or write-offs, restructuring and impairment or other charges that could have a significant negative effect on its financial condition,
        results of operations and its share price, which could cause you to lose some or all of your investment.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR may be subject to the Excise
        Tax included in the Inflation Reduction Act of 2022 in connection with redemptions of Public Shares.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Domestication Merger does
        not qualify as a reorganization under Section 368(a) of the Code, U.S. Holders of Exascale securities may be required to pay substantial
        U.S. federal income taxes.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; text-align: justify; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are risks to BCAR shareholders
        who are not affiliates of the Sponsor of becoming stockholders of PubCo through the Business Combination rather than acquiring securities
        of PubCo directly in an underwritten public offering, including no independent due diligence review by an underwriter and conflicts of
        interest of the Sponsor.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If BCAR&#8217;s due diligence investigation
        of Exascale was inadequate, then BCAR shareholders following the consummation of the Business Combination could lose some or all of their
        investment.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even though BCAR and its legal advisors
        conducted a due diligence investigation of Exascale, BCAR cannot be sure that this due diligence uncovered all material issues that may
        be present in Exascale and its business and operations, or that it would be possible to uncover all material issues through a customary
        amount of due diligence, or that factors outside of Exascale and its business and operations and outside of its control will not later
        arise.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The parties to the Business Combination,
        or any of them, may be targeted by securities class action and derivative lawsuits that could result in substantial costs and may delay
        or prevent the Business Combination from being completed.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware law and PubCo&#8217;s Proposed
        Organizational Documents contain certain provisions, including anti-takeover provisions that limit the ability of stockholders to take
        certain actions and could delay or discourage takeover attempts that stockholders may consider favorable.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provisions of the Proposed Charter
        requiring exclusive forum in the Court of Chancery of the State of Delaware and the federal district courts of the United States for certain
        types of lawsuits may have the effect of discouraging lawsuits against our directors and officers.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="border: Black 1pt solid; padding: 5pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="a_007"></span>MARKET
PRICE AND DIVIDENDS OF SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Market Price of BCAR Ordinary Shares and Public
Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Market Price and Ticker Symbol</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR Units, BCAR Class A Ordinary Shares and the
Public Warrants are currently traded on the Nasdaq Global Market under the symbols &#8220;BCARU&#8221;, &#8220;BCAR&#8221; and &#8220;BCARW&#8221;,
respectively. The BCAR Units commenced public trading on July 31, 2025, and the BCAR Class A Ordinary Shares and Public Warrants commenced
separate public trading on August 20, 2025 on the Nasdaq Global Market. On [_], 2026, the last traded price of BCAR&#8217;s Units, Class
A Ordinary Shares and warrants was $[_], $[_] and $[_], respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Holders</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On [_], 2026, there were [_] holders of record
of BCAR Class A Ordinary Shares, [_] holders of record of BCAR Class B Ordinary Shares and [_] holders of record of BCAR Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Dividends</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR has not paid or declared any cash dividends
on its ordinary shares to date and does not intend to pay cash dividends prior to the completion of its initial business combination.
The payment of cash dividends in the future will be dependent upon BCAR&#8217;s or the combined company&#8217;s, as the case may be, revenues
and earnings, if any, capital requirements and general financial condition subsequent to completion of BCAR&#8217;s initial business combination.
The payment of any cash dividends subsequent to BCAR&#8217;s initial business combination will be within the discretion of the board of
directors of the applicable company at such time. The BCAR Board is not currently contemplating and does not anticipate declaring any
stock dividends in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Market Price of Exascale Securities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Historical market price information regarding
Exascale is not provided because there is no public market for Exascale&#8217;s securities. For information regarding Exascale&#8217;s
liquidity and capital resources, see &#8220;<i>Exascale&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and
Results of Operations &#8212; Liquidity and Capital Resources</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividend Policy of PubCo Following the Business
Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PubCo does not intend to pay cash dividends after
the completion of the Business Combination. The payment of cash dividends in the future will be dependent upon PubCo&#8217;s revenues
and earnings, if any, capital requirements and general financial condition subsequent to completion of the Business Combination. The payment
of any cash dividends subsequent to the Business Combination will be within the discretion of the PubCo Board at such time. If PubCo incurs
any indebtedness, PubCo&#8217;s ability to declare dividends may be limited by restrictive covenants PubCo may agree to in connection
therewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> </div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="a_008"></span>RISK
FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Exascale</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>In this subsection the &#8220;Company&#8221;
refers to Exascale, and subsequent to the Business Combination, PubCo. Investing in PubCo&#8217;s securities involves a high degree of
risk. You should consider and read carefully all of the risks and uncertainties described below, as well as other information included
in this proxy statement/prospectus, including Exascale&#8217;s financial statements and related notes appearing elsewhere in this proxy
statement/prospectus, before making an investment decision. The occurrence of any of the following risks or additional risks and uncertainties
not presently known to Exascale or that Exascale currently believes to be immaterial could materially adversely affect Exascale&#8217;s
business, financial condition, and results of operations. In such case, the trading price of PubCo&#8217;s securities could decline, and
you may lose some or all of your investment. The risks discussed below are not the only risks Exascale faces. Additional risks or uncertainties
not currently known to Exascale, or that Exascale currently deems immaterial, may also have a material adverse effect on Exascale&#8217;s
business, financial condition, prospects, results of operations, or cash flows. Neither Exascale nor BCAR can assure you that any of the
events discussed in the risk factors below will not occur.</i>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale has a limited
operating history, has incurred net losses since inception, and may not achieve or sustain growth or profitability.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale
was formed in June 2022 and has a limited operating history upon which investors can evaluate its business, operating performance and
prospects. As a result, Exascale&#8217;s historical financial information may not be indicative of its future performance, and investors
have limited information on which to base an investment decision. Exascale has incurred net losses since inception. For the fiscal years
ended June 30, 2025 and 2024, and the nine months ended March 31, 2026, Exascale incurred net losses of $7.7 million, $5.0 million, and
$8.0 million, respectively. As at March 31, 2026, Exascale had an accumulated deficit of $21.1 million. Exascale expects to continue to
incur operating losses for the foreseeable future as it invests in product development, platform enhancements, sales and marketing activities,
personnel and infrastructure to support growth. There can be no assurance that Exascale will achieve or sustain profitability in the future.
In addition, Exascale is an AI compute infrastructure platform that delivers GPU-based compute services and related infrastructure management
services. The markets in which Exascale operates are evolving rapidly, and Exascale&#8217;s ability to grow its business depends on a
number of factors, including Exascale&#8217;s ability to maintain access to GPU capacity and suitable data center facilities, deliver
reliable service at scale, and compete effectively against significantly larger competitors. Exascale may encounter unexpected operational,
technical, regulatory, or commercial challenges. If Exascale is unable to successfully execute its business strategy, expand its customer
base, or manage costs as it scales, Exascale&#8217;s business, financial condition and results of operations could be materially adversely
affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale depends on
a limited and constrained supply of advanced GPU chips, and any disruption or increase in cost could adversely affect Exascale&#8217;s
business and results of operations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale&#8217;s business depends on its ability
to obtain a reliable and cost-competitive supply of advanced GPU chips, which are subject to global supply constraints, limited sources
of manufacture, and significant demand volatility. The supply of advanced GPUs is concentrated among a small number of manufacturers and
distributors, and disruptions caused by geopolitical events, trade restrictions, manufacturing delays, or changes in allocation policies
could limit Exascale&#8217;s access to required hardware or increase procurement costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If Exascale is unable to
secure sufficient GPU supply on acceptable terms, its ability to plan capacity, meet customer demand, and expand its services could be
adversely affected. Prolonged or recurring supply limitations could reduce service availability, impair operating efficiency, delay customer
deployments, or negatively impact customer satisfaction and retention, which could materially harm Exascale&#8217;s business, financial
condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale has incurred
operating losses and may not be able to achieve or sustain profitability due to Exascale&#8217;s cost structure and ongoing operating
expenses.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale has incurred and
expects to continue to incur significant operating expenses under its asset-light model, including costs related to the sourcing of GPU
resources and the development of software on top of those resources, data center hosting, power, and network services. These costs are
largely recurring and may not scale proportionately with revenue. As a result, Exascale&#8217;s ability to achieve profitability depends
on its ability to manage operating expenses relative to revenue growth.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Increases in procurement
costs, power prices, or hosting expenses, as well as pricing pressure from customers or competitors, could adversely affect margins. In
addition, efforts to optimize resource utilization or pricing may not be successful or may negatively impact service quality or customer
demand. There can be no assurance that Exascale will be able to achieve or sustain profitability, and continued operating losses could
materially adversely affect its financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale&#8217;s financial
statements include a going concern qualification, and Exascale may not have sufficient liquidity to fund its operations without additional
financing that may or may not be on favorable terms to Exascale.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale&#8217;s
financial statements included elsewhere in this proxy statement/prospectus include qualifications that raise substantial doubt about Exascale&#8217;s
ability to continue as a going concern. As of March 31, 2026, Exascale had $5.1 million of cash and cash equivalents and U.S. Dollar Coin,
and $29.2 million of current liabilities, and has incurred recurring net losses and negative cash flows from operating activities since
inception. For the fiscal year ended June 30, 2025 and the nine months ended March 31, 2026, Exascale used approximately $1.0 million
and $3.8 million, respectively, for operating activities and incurred net losses of approximately $7.7 million and $7.9 million, respectively.
As of March 31, 2026, Exascale had an accumulated deficit of approximately $21.1 million. These conditions indicate that Exascale&#8217;s
existing cash resources are not sufficient to fund its anticipated operating requirements, capital expenditures and obligations for the
next twelve months. Exascale&#8217;s ability to continue as a going concern is dependent upon its ability to obtain additional financing,
increase revenues, manage operating expenses and successfully execute its business plan. Exascale&#8217;s management intends to mitigate
these conditions primarily through the completion of the Business Combination, as well as through additional equity financings and continued
fundraising from investors that may or may not be on the most favorable terms to Exascale. In addition, Exascale is focused on expanding
its market presence, developing client relationships to drive revenue growth and managing operating expenses, with the goal of generating
positive cash flow from operating activities over time. Exascale&#8217;s majority shareholder has also entered into a binding support
agreement to provide funding necessary to cover anticipated operating cash flow shortfalls prior to the completion of a qualifying initial
public offering or the Business Combination. However, these plans have not been fully implemented as of the date of this proxy statement/prospectus,
and there can be no assurance that the Business Combination will be completed, or that additional capital will be available on acceptable
terms, or at all. Exascale may not be able to secure necessary financing in a timely manner or on favorable terms, or successfully execute
its operating plans. As a result, Exascale&#8217;s management&#8217;s plans, although actively pursued, cannot be considered probable
of mitigating the substantial doubt regarding Exascale&#8217;s ability to continue as a going concern. Exascale&#8217;s financial statements
have been prepared assuming that Exascale will continue as a going concern and do not include any adjustments that might result from the
outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Demand for AI compute
services and accelerated infrastructure may not grow as expected, and customer spending may be volatile.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> Exascale&#8217;s business
depends on customer demand for GPU-based compute capacity and related services. Demand may be affected by factors outside Exascale&#8217;s
control, including macroeconomic conditions, changes in corporate IT spending, customer budget constraints, the pace of AI adoption across
industries, and shifts in the economics of AI model development and deployment. In addition, improvements in model efficiency, changes
in customer architecture decisions (including increased in-house deployments), or changes in the availability or pricing of competing
offerings could reduce demand for Exascale&#8217;s products and services. If demand for AI compute services grows more slowly than anticipated
or declines, or if customers reduce or delay spending on AI workloads, Exascale&#8217;s revenues and growth prospects could be materially
adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale operates
in a highly competitive market, and Exascale may be unable to compete effectively against larger and better-capitalized competitors.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The market for GPU-based
compute services and AI infrastructure is highly competitive, and Exascale faces competition from a number of companies and other entities
with varying business models, operating scales and strategic priorities, including (i) large, diversified cloud service providers, (ii)
specialized AI infrastructure providers, (iii) GPU aggregators and marketplaces, and (iv) data center operators and AIDC service providers.
Many of Exascale&#8217;s competitors have substantially greater financial, technical, operational, and marketing resources, broader customer
relationships, longer operating histories, and greater brand recognition than Exascale does. As a result, these competitors may be able
to respond more quickly to new or emerging technologies, devote greater resources to the development, promotion and sale of their offerings,
withstand pricing pressures more effectively, or offer more favorable commercial terms than Exascale. Competitive pressures may require
Exascale to reduce prices, increase spending on technology and operations, expand support commitments, or accept less favorable commercial
terms. If Exascale is unable to compete effectively or maintain differentiation in performance, reliability, ease of use, and service
quality, Exascale&#8217;s business and results of operations could be materially adversely affected. See &#8220;<i>Information about Exascale&#8212;Competition</i>&#8221;
for additional information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale depends on
third-party GPU capacity suppliers, and disruptions, non-renewals, pricing increases or capacity limitations could adversely affect its
business, results of operations and margins.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale&#8217;s asset-light
business model depends on its ability to obtain access to GPU capacity from third-party suppliers. Exascale&#8217;s GPU capacity supplier
arrangements generally provide access to specified GPU servers or GPU capacity, together with bundled hosting, power, rack space, data
center resources, network connectivity and related infrastructure services. Supplier costs are a principal component of Exascale&#8217;s
cost of revenue, and pricing under these arrangements is generally subject to market conditions for GPU compute capacity, although pricing
may be fixed for short periods or for specific usage periods, orders or capacity configurations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale uses a multi-supplier
sourcing model designed to support supply continuity, procurement flexibility and access to alternative sources of GPU capacity. Exascale
has identified and continues to evaluate alternative sources of GPU capacity; however, alternative capacity may differ in pricing, GPU
type, configuration, location, performance, network connectivity, deployment timing or bundled infrastructure services. Exascale&#8217;s
supplier arrangements do not include take-or-pay obligations, minimum purchase commitments or exclusivity provisions. Certain suppliers
may provide non-exclusive priority allocation or preferred access to GPU capacity, but there can be no assurance that such arrangements
or alternative sources will be sufficient to meet Exascale&#8217;s customer demand or growth plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If any significant supplier
reduces available GPU capacity, fails to perform, increases pricing, declines to renew or terminates an arrangement, experiences power,
facility, network or operational issues, or is unable to provide additional capacity when needed, Exascale may not be able to obtain replacement
capacity on a timely basis or on commercially acceptable terms. Any such event could reduce available GPU capacity, impair Exascale&#8217;s
ability to meet customer demand, increase cost of revenue, reduce gross margins, lower utilization, delay customer deployments or adversely
affect customer relationships.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>GPU capacity used
to deliver Exascale&#8217;s services is deployed in third-party data centers and partner facilities, and constraints or disruptions in
those facilities could materially adversely affect Exascale&#8217;s business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">GPU deployments for Exascale&#8217;s
compute services depend on third-party data centers and partner facilities that provide space, power, cooling, and network connectivity.
Exascale&#8217;s ability to deploy and operate GPU capacity is subject to facility availability, build-out timelines, grid interconnection
constraints, power and cooling limitations, and other facility-related requirements. Third-party facilities may experience outages, service
interruptions, cyber incidents, equipment failures, natural disasters, or other events that disrupt operations. If Exascale is unable
to secure sufficient facility capacity, if facility costs increase, or if Exascale&#8217;s deployed capacity experiences material disruptions,
Exascale&#8217;s ability to deliver services and generate revenue could be materially adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b><i>If Exascale fails
to deliver expected performance, efficiency, or reliability for customer workloads, Exascale&#8217;s reputation, customer relationships,
and results of operations could be harmed.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Customers running AI training
and inference workloads may be sensitive to performance, stability, and predictability, particularly for large-scale or time-sensitive
workloads. Exascale&#8217;s value proposition includes applying Exascale&#8217;s technology and operational practices to optimize cluster
performance and utilization, maintain stability and uptime, and reduce operational complexity for customers. Actual performance and reliability
outcomes may vary based on workload characteristics, network and storage conditions, hardware configurations, and other factors. If Exascale&#8217;s
services experience performance degradation, instability, or downtime, or if customers perceive that Exascale&#8217;s services do not
meet their requirements, Exascale may face customer dissatisfaction, reduced usage, non-renewals, contractual disputes, service credits,
or reputational harm, any of which could materially adversely affect Exascale&#8217;s business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale&#8217;s performance
optimization and utilization practices may not achieve intended results, and Exascale&#8217;s methods may not scale as customer requirements
and infrastructure complexity increase.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale seeks to maximize
the compute potential of infrastructure components through configuration, tuning, orchestration, and operational practices across compute,
networking, and related systems. Achieving and sustaining high effective utilization is technically and operationally complex, and outcomes
can be affected by software stack efficiency, data movement bottlenecks, workload-specific behaviors, and operational factors that interrupt
or degrade workload execution. As customer workloads and cluster sizes increase, optimization complexity may increase and may require
additional engineering and operational resources. If Exascale&#8217;s performance optimization methods are ineffective in certain environments,
do not scale as expected, or require greater resources than anticipated, Exascale&#8217;s service quality, margins, and competitiveness
could be materially adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale may experience
service interruptions, security incidents, or other operational failures, which could expose Exascale to liability and harm its business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Operating GPU compute services
and infrastructure management services involves risks of outages, system failures, human errors, misconfigurations, and cyber incidents.
Service interruptions may result from failures of third-party facilities or suppliers, software defects, network disruptions, power events,
or other causes, including causes beyond Exascale&#8217;s control, such as natural disasters that are not in our control. Security incidents
could result in unauthorized access, data exposure, malware, ransomware, or disruption of operations. Any such incident could lead to
loss of customers, reputational harm, regulatory inquiries, litigation, remediation costs, and potential contractual liabilities. If Exascale
is unable to prevent or rapidly remediate operational failures or security incidents, Exascale&#8217;s business and results of operations
could be materially adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale&#8217;s AI-assisted
operational tools and automation may not perform as intended and could introduce errors or risks.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale uses AI-assisted
tools to support certain operational workflows, such as issue detection, analysis, prioritization, and support processes. These tools
may produce inaccurate outputs, fail to identify certain issues, or generate recommendations that are ineffective or inappropriate for
particular operational circumstances. AI-assisted tools may require ongoing training, validation, monitoring, and human oversight, and
their performance may degrade over time as infrastructure configurations, workloads, or external conditions change. If Exascale&#8217;s
AI-assisted tools do not perform as intended, or if reliance on such tools contributes to operational errors, service disruptions, or
customer dissatisfaction, Exascale&#8217;s business could be materially adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale&#8217;s costs
may increase, and Exascale may be unable to pass increased costs through to customers, which could adversely affect Exascale&#8217;s margins
and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">A significant portion of
Exascale&#8217;s cost structure relates to fees paid under GPU capacity sourcing arrangements and costs associated with third-party facilities,
including colocation, power, cooling, and network connectivity. Exascale&#8217;s costs may increase due to changes in supplier pricing,
power price volatility, facility pricing, regulatory or tax changes, insurance costs, or other factors. Competitive pressures or contractual
terms may limit Exascale&#8217;s ability to increase prices or adjust commercial terms to offset cost increases. If Exascale&#8217;s costs
increase materially and Exascale is unable to manage or pass through such increases, Exascale&#8217;s margins and financial performance
could be materially adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale&#8217;s revenues
may be concentrated in a limited number of customers or engagements, and Exascale&#8217;s results may be volatile due to usage variability
and contract dynamics.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Customer demand for compute
services can vary based on project cycles, workload characteristics, and budget constraints. In addition, certain customer arrangements
may be of limited duration or may permit termination under specified conditions. Revenues from GPU cluster management services may be
project-based or dependent on ongoing engagements that can fluctuate in timing and scope. If a significant customer reduces usage, terminates
or does not renew an arrangement, delays implementation, or experiences financial difficulties, Exascale&#8217;s revenues and cash flows
could be materially adversely affected. Exascale may also face increased credit risk, disputes, or collection delays depending on customer
terms and payment practices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale operates
in a highly competitive market, and its failure to acquire, retain, or expand its customer base could adversely affect Exascale&#8217;s
revenue and growth.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale&#8217;s results
of operations depend on sustained customer demand and its ability to attract, retain, and expand relationships with AI developers and
enterprise customers in a competitive market. Customers may evaluate Exascale&#8217;s services against alternative providers based on
performance, reliability, pricing, and available features, and may reduce or discontinue usage for a variety of reasons, including changes
in budget priorities, internal capabilities, or technological preferences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">While Exascale has experienced
customer growth and high renewal rates in recent periods, there can be no assurance that these trends will continue. Increased competition,
service performance issues, pricing pressure, or an inability to address evolving customer requirements could result in lower customer
acquisition, reduced renewals, or decreased usage levels. Any decline in customer demand or retention could materially and adversely affect
Exascale&#8217;s revenue and operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale&#8217;s AIDC
GPU cluster management services may expose Exascale to additional operational, contractual, and liability risks.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale provides GPU cluster
management services to certain AIDC operators, which may involve planning, deployment support, operational monitoring, performance tuning,
and ongoing assistance. These engagements may require coordination with customer environments and third-party facilities, and may depend
on customer-provided information, customer operational practices, and infrastructure conditions outside Exascale&#8217;s control. If Exascale&#8217;s
services do not meet customer expectations, if clusters experience operational issues, or if customers allege that Exascale&#8217;s actions
contributed to performance degradation or outages, Exascale could face contractual disputes, claims, reputational harm, and potential
liabilities. In addition, scaling these services may require specialized personnel and operational capacity, and Exascale may be unable
to expand or deliver such services consistently as demand increases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exascale&#8217;s infrastructure solution
capabilities, including modular data centers, liquid cooling, HVDC power and energy storage solutions have not yet generated revenue and
may not achieve commercial success.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale has
developed certain Infrastructure Solutions offerings intended to support large-scale AI deployments, including modular data center, advanced
liquid cooling, HVDC power and energy storage solutions. While Exascale has made progress in the development and validation of these capabilities
and Exascale&#8217;s management believes these offerings are ready to support customer deployments as of the date of this proxy statement/prospectus,
these offerings have not generated revenue to date. Exascale expects to pursue these offerings on an asset-light basis, primarily through
partnerships, systems integration, contract manufacturing and other collaborative structures. Because these offerings have limited commercial
operating history, Exascale may face challenges in customer adoption, partner execution, technical integration, supply chain availability,
regulatory or permitting requirements, pricing, warranty or performance obligations, and the efficient scaling of deployment and support
capabilities. These offerings may require significant investment to commercialize and scale and may not achieve market acceptance, revenue
generation, margins or profitability on Exascale&#8217;s expected timeline, or at all. If Exascale is unable to successfully commercialize
these offerings, secure customers or partners, or perform customer deployments as expected, Exascale&#8217;s business, financial condition
and results of operations could be materially adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Rapid technological
change in GPUs, networking, and AI software could require Exascale to adapt quickly, and Exascale may be unable to keep pace.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The AI infrastructure market
is characterized by rapid changes in GPU architectures, interconnect technologies, software frameworks, and customer requirements. Exascale&#8217;s
competitiveness may depend on Exascale&#8217;s ability to integrate new GPU generations and adapt Exascale&#8217;s software and operational
systems to evolving infrastructure configurations. If Exascale is unable to access current-generation GPUs on acceptable terms, if Exascale&#8217;s
platform is not compatible with emerging architectures, or if Exascale&#8217;s operational tooling and methods do not evolve with technology
changes, Exascale may lose customers or face increased costs and operational complexity. In addition, customer preferences may shift toward
alternative architectures or deployment models, which could reduce demand for Exascale&#8217;s services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Third parties may
claim that Exascale&#8217;s platform infringes, misappropriates, or otherwise violates their intellectual property rights, and such claims
could be time-consuming or costly to defend or settle, result in the loss of significant rights, or harm Exascale&#8217;s relationships
with its customers or Exascale&#8217;s reputation in the industry.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Third parties may claim
that Exascale&#8217;s current or future offerings infringe their intellectual property rights, and such claims may result in legal claims
against Exascale, Exascale&#8217;s third-party partners, and Exascale&#8217;s customers. These claims may be time consuming, costly to
defend or settle, damage Exascale&#8217;s brand and reputation, harm Exascale&#8217;s customer relationships, and create liability for
Exascale. Contractually, Exascale is expected to indemnify its partners and customers for these types of claims. Exascale expects the
number of such claims (whether warranted or not) to increase once PubCo becomes a public company through the Business Combination with
an increased profile and visibility, as the level of competition in Exascale&#8217;s market grows, as the functionality of Exascale&#8217;s
offerings overlap with that of other cloud infrastructure companies, and as the volume of issued hardware and software patents and patent
applications continues to increase. Exascale generally agrees in its customer and partner contracts to indemnify customers for certain
expenses or liabilities they incur as a result of third-party intellectual property infringement claims associated with Exascale&#8217;s
platform. To the extent that any claim arises as a result of third-party technology Exascale has licensed for use in Exascale&#8217;s
platform, Exascale may be unable to recover from the appropriate third party any expenses or other liabilities that Exascale incurs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Companies in the cloud infrastructure
and technology industries, including some of Exascale&#8217;s current and potential competitors, may own large numbers of patents, copyrights,
trademarks, and trade secrets and frequently enter into litigation based on allegations of infringement or other violations of intellectual
property rights. In addition, many of these companies have the capability to dedicate substantially greater resources to enforce their
intellectual property rights and to defend claims that may be brought against them. Furthermore, patent holding companies, non-practicing
entities, and other adverse patent owners that are not deterred by Exascale&#8217;s existing intellectual property protections may seek
to assert patent claims against Exascale. From time to time, third parties, including certain of these leading companies, may invite Exascale
to license their patents and may assert patent, copyright, trademark, or other intellectual property rights against Exascale, Exascale&#8217;s
third-party partners, or Exascale&#8217;s customers. Exascale may also receive notices that claim Exascale has misappropriated, misused,
or infringed other parties&#8217; intellectual property rights, and, to the extent Exascale gains greater market visibility, Exascale
will face a higher risk of being the subject of intellectual property infringement claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">There may be third-party
intellectual property rights that cover significant aspects of Exascale&#8217;s technologies or business methods and assets. In the event
that Exascale engages software engineers or other personnel who were previously engaged by competitors or other third parties, Exascale
may be subject to claims that those personnel inadvertently or deliberately incorporate proprietary technology of third parties into Exascale&#8217;s
platform or have improperly used or disclosed trade secrets or other proprietary information. Exascale may also in the future be subject
to claims by Exascale&#8217;s third-party manufacturing partners, employees, or contractors asserting an ownership right in Exascale&#8217;s
intellectual property as a result of the work they performed on Exascale&#8217;s behalf. In addition, Exascale may lose valuable intellectual
property rights or personnel. A loss of key personnel or their work product could hamper or prevent Exascale&#8217;s ability to develop,
market, and support potential offerings and platform enhancements, which could severely harm Exascale&#8217;s business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Any intellectual property
claims, with or without merit, could be very time-consuming, could be expensive to settle or litigate, and could divert Exascale&#8217;s
management&#8217;s attention and other resources. These claims could also subject Exascale to significant liability for damages, potentially
including treble damages if Exascale is found to have willfully infringed patents or copyrights, and may require Exascale to indemnify
Exascale&#8217;s customers for liabilities they incur as a result of such claims. These claims could also result in Exascale having to
stop using technology found to be in violation of a third party&#8217;s rights. Exascale might be required to seek a license for the intellectual
property, which may not be available on reasonable terms or at all. Even if a license were available, Exascale could be required to pay
significant royalties, which would increase Exascale&#8217;s operating expenses. Alternatively, Exascale could be required to develop
alternative non-infringing technology, which could require significant time, effort, and expense, and may affect the performance or features
of Exascale&#8217;s platform. If Exascale cannot license or develop alternative non-infringing substitutes for any infringing technology
used in any aspect of Exascale&#8217;s business, Exascale would be forced to limit or stop sales of Exascale&#8217;s platform and may
be unable to compete effectively. Moreover, there could be public announcements of the results of hearings, motions or other interim proceedings
or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect
on the price of Exascale or PubCo&#8217;s securities. Any of these results would adversely affect Exascale&#8217;s business, operating
results, financial condition, and future prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Some of Exascale&#8217;s
technology incorporates &#8220;open-source&#8221; software, and failure to comply with the terms of the underlying open-source software
licenses could adversely affect Exascale&#8217;s business, results of operations, financial condition, and future prospects.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale uses open-source
software in Exascale&#8217;s solutions and services and may continue to use open-source software in the future. Certain open-source licenses
contain requirements that Exascale make available source code for modifications or derivative works Exascale creates. If Exascale combines
its proprietary software with open-source software in a certain manner, Exascale could, under certain open-source licenses, be required
to release the source code of Exascale&#8217;s proprietary software to the public on unfavorable terms or at no cost. Any actual or claimed
requirement to disclose Exascale&#8217;s proprietary source code or pay damages for breach of contract may allow Exascale&#8217;s competitors
to create similar products with lower development effort and time and, ultimately, could result in a loss of sales for Exascale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The use and distribution
of open-source software may entail greater risks than the use of third-party commercial software, as open-source licensors generally do
not provide support, warranties, indemnification or other contractual protections regarding infringement claims or the quality of the
code, which they are not typically required to maintain and update, and they can change the license terms on which they offer the open-source
software. Although Exascale believes that it has complied with its obligations under the applicable licenses for open-source software,
it is possible that Exascale may not be aware of all instances where open-source software has been incorporated into Exascale&#8217;s
proprietary software or used in connection with Exascale&#8217;s solutions or Exascale&#8217;s corresponding obligations under open-source.
Exascale takes steps to monitor its use of open-source software in an effort both to comply with the terms of the applicable open-source
licenses and to avoid subjecting Exascale&#8217;s platform to conditions Exascale does not intend, but there are risks associated with
use of open-source software that cannot be eliminated and could negatively affect Exascale&#8217;s business. Exascale relies on multiple
software programmers to design its proprietary software and, while Exascale takes steps to vet software before it is incorporated into
Exascale&#8217;s proprietary software and monitor the software incorporated into Exascale&#8217;s proprietary software, Exascale cannot
be certain that its programmers have not incorporated open-source software into Exascale&#8217;s proprietary software that Exascale intends
to maintain as confidential or that they will not do so in the future. In addition, the wide availability of source code used in Exascale&#8217;s
offerings could expose Exascale to security vulnerabilities. Such use, under certain circumstances, could materially adversely affect
Exascale&#8217;s business, operating results, financial condition, and future prospects, as well as Exascale&#8217;s reputation, including
if Exascale is required to take remedial action that may divert resources away from Exascale&#8217;s development efforts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On
occasion, companies that use open-source software have faced claims challenging their use of open-source software or compliance with open-source
license terms. There is evolving legal precedent for interpreting the terms of certain open-source licenses, including the determination
of which works are subject to the terms of such licenses. The terms of many open-source licenses have not been interpreted by U.S. courts,
and there is a risk that these licenses could be construed in ways that could impose unanticipated conditions or restrictions on Exascale&#8217;s
ability to commercialize any offerings incorporating such software. Moreover, Exascale cannot provide assurance that its processes for
controlling Exascale&#8217;s use of open-source software in Exascale&#8217;s platform will be effective. From time to time, Exascale may
face claims from third parties asserting ownership of, or demanding release of, the open-source software or derivative works that Exascale
developed using such software (which could include Exascale&#8217;s proprietary source code), or otherwise seeking to enforce the terms
of the applicable open-source license. These claims, regardless of validity, could result in time consuming and costly litigation, divert
management&#8217;s time and attention away from developing Exascale&#8217;s business, expose Exascale to customer indemnity claims, or
force Exascale to disclose source code. Litigation could be costly for Exascale to defend, result in paying damages, entering into unfavorable
licenses, have a negative effect on Exascale&#8217;s business, operating results, financial condition, and future prospects, or cause
delays by requiring Exascale to devote additional research and development resources to change Exascale&#8217;s solution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale may be unable
to protect its intellectual property, and third-party claims of infringement could be costly and disruptive.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale relies on proprietary
software, operational methods, and know-how to differentiate Exascale&#8217;s services. Exascale may be unable to prevent unauthorized
use or disclosure of Exascale&#8217;s proprietary information, and trade secret protections may be difficult to enforce. In addition,
third parties may claim that Exascale&#8217;s technology infringes or misappropriates their intellectual property, whether or not such
claims have merit. Any such claims could result in litigation, require Exascale to obtain licenses, modify Exascale&#8217;s systems, incur
significant costs, or face injunctions, and could materially adversely affect Exascale&#8217;s business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale customarily enters
into confidentiality or license agreements with its employees, consultants, vendors, and customers, and makes significant efforts to limit
access to and distribution of Exascale&#8217;s proprietary information. However, such agreements may not be enforceable in whole or in
part in all jurisdictions and any breach could negatively affect Exascale&#8217;s business and Exascale&#8217;s remedy for such breach
may be limited. The contractual provisions that Exascale enters into may not prevent unauthorized use or disclosure of Exascale&#8217;s
proprietary technology or intellectual property rights and may not provide an adequate remedy in the event of unauthorized use or disclosure
of Exascale&#8217;s proprietary technology or intellectual property rights. Lastly, the measures Exascale employs to limit the access
and distribution of Exascale&#8217;s proprietary information may not prevent unauthorized use or disclosure of Exascale&#8217;s proprietary
technology or intellectual property. As such, Exascale cannot guarantee that the steps taken by Exascale will prevent infringement, violation,
or misappropriation of Exascale&#8217;s technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale pursues the registration
of its trademarks, service marks, patents, and domain names in the United States and in certain foreign jurisdictions. These processes
are expensive and may not be successful in all jurisdictions or for every such application, and Exascale may not pursue such protections
in all jurisdictions that may be relevant, for all Exascale&#8217;s goods or services or in every class of goods and services in which
Exascale operates. As such, policing unauthorized use of Exascale&#8217;s technology or platform is difficult. Additionally, Exascale
may not be able to obtain, maintain, protect, exploit, defend, or enforce Exascale&#8217;s intellectual property rights in every foreign
jurisdiction in which Exascale operates. For example, effective trade secret protection may not be available in every country in which
Exascale&#8217;s platform is available or where Exascale has employees or independent contractors. The loss of trade secret protection
could make it easier for third parties to compete with Exascale&#8217;s platform by copying functionality. Any changes in, or unexpected
interpretations of, the trade secret and employment laws in any country in which Exascale operates may compromise Exascale&#8217;s ability
to enforce Exascale&#8217;s trade secret and intellectual property rights. In addition, Exascale believes that the protection of its trademark
rights is an important factor in product recognition, protecting Exascale&#8217;s brand and maintaining goodwill and if Exascale does
not adequately protect its rights in trademarks from infringement, any goodwill that Exascale has developed in those trademarks could
be lost or impaired, which could harm Exascale&#8217;s brand and business. The legal systems of certain countries do not favor the enforcement
of trademarks, trade names, service marks, trade secrets, and other intellectual property and proprietary protection, which could make
it difficult for Exascale to stop the infringement, misappropriation, dilution, or other violation of Exascale&#8217;s intellectual property
or marketing of competing platforms, solutions, or services in violation of Exascale&#8217;s intellectual property rights generally. Any
changes in, or unexpected interpretations of, intellectual property laws may compromise Exascale&#8217;s ability to enforce Exascale&#8217;s
intellectual property rights. If Exascale fails to maintain, protect and enhance Exascale&#8217;s intellectual property rights, Exascale&#8217;s
business, operating results, financial condition, and future prospects may be harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In addition, defending Exascale&#8217;s
intellectual property rights through litigation might entail significant expense. Such litigation could result in substantial costs and
diversion of resources and could negatively affect Exascale&#8217;s business, operating results, financial condition, and future prospects.
If Exascale is unable to protect its proprietary rights, Exascale could find itself at a competitive disadvantage to others who need not
incur the additional expense, time, and effort required to create Exascale&#8217;s platform and Exascale&#8217;s other offerings. Moreover,
Exascale may need to expend additional resources to defend its intellectual property rights in foreign countries, and Exascale&#8217;s
inability to do so could impair its business or adversely affect Exascale&#8217;s international expansion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale is subject
to laws and regulations, including governmental export and import controls, sanctions, and anti-corruption laws, that could impair Exascale&#8217;s
ability to compete in Exascale&#8217;s markets and subject Exascale to liability if Exascale is not in full compliance with applicable
laws.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale is subject to
laws and regulations, including governmental export and import controls, that could subject Exascale to liability or impair Exascale&#8217;s
ability to compete in its markets. Exascale&#8217;s platform and related technology are subject to U.S. export controls, including the
U.S. Department of Commerce&#8217;s Export Administration Regulations (also known as &#8220;<b>EAR</b>&#8221;), and Exascale and Exascale&#8217;s
employees, representatives, contractors, agents, intermediaries, and other third parties are also subject to various economic and trade
sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control and other U.S. government
agencies. Changes to sanctions and export or import restrictions in the jurisdictions in which Exascale operates could further impact
Exascale&#8217;s ability to do business in certain parts of the world and to do business with certain persons and entities, which could
adversely affect Exascale&#8217;s business, operating results, financial condition, and future prospects. In particular, Exascale is
continuing to monitor recent and forthcoming developments in export controls with respect to the semiconductor industry and their impact
on Exascale&#8217;s sourcing of equipment for Exascale&#8217;s computing infrastructure. In addition, Exascale is also monitoring the
January 29, 2024 proposed rule from the U.S. Department of Commerce, Bureau of Industry and Security (&#8220;BIS&#8221;), which if implemented
as proposed, would impose requirements on Infrastructure-as-a-Service providers (&#8220;IaaS&#8221;) and their foreign resellers to verify
the identity and beneficial ownership of foreign person customers and to perform related reporting to BIS, as well as provide BIS authority
to restrict certain IaaS transactions with foreign persons. While Exascale has implemented certain procedures to facilitate compliance
with applicable laws and regulations, Exascale cannot provide assurance that these procedures are fully effective or that Exascale, or
third parties who Exascale does not control, have complied with all laws or regulations in this regard. Failure by Exascale&#8217;s employees,
representatives, contractors, partners, agents, intermediaries, or other third parties to comply with applicable laws and regulations
also could have negative consequences to Exascale, including reputational harm, government investigations, loss of export privileges
and penalties. Changes in Exascale&#8217;s platform, and changes in or promulgation of new export and import regulations, may create
delays in the introduction of Exascale&#8217;s platform into international markets, prevent Exascale&#8217;s customers with international
operations from deploying Exascale&#8217;s platform globally or, in some cases, prevent the export or import of Exascale&#8217;s platform
to certain countries, governments, or persons altogether. Any change in export or import regulations, economic sanctions, or related
legislation, shift in the enforcement or scope of existing regulations, or change in the countries, governments, persons, or technologies
targeted by such regulations, could result in decreased sales of Exascale&#8217;s platform, solutions, and services, or in Exascale&#8217;s
decreased ability to export or sell Exascale&#8217;s platform, to existing or potential customers with international operations. Any
decreased sales of Exascale&#8217;s platform, solutions, and services or limitation on Exascale&#8217;s ability to export or sell its
platform would adversely affect Exascale&#8217;s business, operating results, financial condition, and future prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale is also subject
to the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#8220;<b>FCPA</b>&#8221;), the United Kingdom Bribery Act 2010 (the
&#8220;<b>Bribery Act</b>&#8221;), and other anti-corruption, sanctions, anti-bribery, anti-money laundering, and similar laws in the
United States and other countries in which Exascale conducts activities. Anti-corruption and anti-bribery laws, which have been enforced
aggressively and are interpreted broadly, prohibit companies and their employees, agents, intermediaries, and other third parties from
promising, authorizing, making, or offering improper payments or other benefits to government officials and others in the public, and
in certain cases, private sector. Exascale leverages third parties, including intermediaries and agents, to conduct Exascale&#8217;s business
in the United States and abroad, to sell Exascale&#8217;s platform. Exascale and such third parties may have direct or indirect interactions
with officials and employees of government agencies or state-owned or affiliated entities and Exascale may be held liable for the corrupt
or other illegal activities of these third-party business partners and intermediaries, Exascale&#8217;s employees, representatives, contractors,
partners, agents, intermediaries, and other third parties, even if Exascale does not explicitly authorize such activities. Exascale cannot
provide assurance that its policies and procedures to address compliance with the FCPA, the Bribery Act, and other anti-corruption, sanctions,
anti-bribery, anti-money laundering, and similar laws, will be effective, or that all of Exascale&#8217;s employees, representatives,
contractors, partners, agents, intermediaries, or other third parties have not taken, or will not take actions, in violation of Exascale&#8217;s
policies and applicable law, for which Exascale may be ultimately held responsible. As Exascale increases its international sales and
business, Exascale&#8217;s risks under these laws will increase. Noncompliance with these laws could subject Exascale to investigations,
severe criminal or civil sanctions, settlements, prosecution, loss of export privileges, suspension or debarment from U.S. government
contracts, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions,
whistleblower complaints, adverse media coverage, and other consequences. Any investigations, actions, or sanctions could harm Exascale&#8217;s
reputation, business, operating results, financial condition, and future prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale is subject
to laws, regulations, and industry requirements related to data privacy, data protection and information security, and user protection
across different markets where it conducts its business and such laws, regulations, and industry requirements are constantly evolving
and changing. Any actual or perceived failure to comply with such laws, regulations, and industry requirements, or Exascale&#8217;s privacy
policies, could harm Exascale&#8217;s business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Various local, state, federal,
and international laws, directives, and regulations apply to Exascale&#8217;s collection, use, retention, protection, disclosure, transfer,
and processing of personal information. These data protection and privacy laws and regulations are subject to uncertainty and continue
to evolve in ways that could adversely impact Exascale&#8217;s business. These laws have a substantial impact on Exascale&#8217;s operations
both in the United States and internationally and compliance with new and existing laws may result in significant costs due to implementation
of new processes, which could ultimately hinder Exascale&#8217;s ability to grow its business by extracting value from Exascale&#8217;s
data assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In the United States, state
and federal lawmakers and regulatory authorities have increased their attention on the collection and use of user data. For example, in
California, the California Consumer Privacy Act of 2018 (as amended, the &#8220;<b>CCPA</b>&#8221;) requires companies that hit certain
broad revenue or data processing related thresholds to, among other things, provide new disclosures to California users, and affords such
users new privacy rights such as the ability to opt-out of certain processing of personal information and expanded rights to access and
require deletion of their personal information, opt out of certain personal information sharing, and receive detailed information about
how their personal information is collected, used, and shared. The CCPA provides for civil penalties for violations, as well as a private
right of action for security breaches that may increase security breach litigation. In addition, other states have enacted laws that contain
obligations similar to the CCPA that have taken effect or will take effect in coming years and many others continue to propose similar
laws, or are considering proposing similar laws. Exascale cannot fully predict the impact of recently proposed or enacted laws or regulations
on Exascale&#8217;s business or operations, but compliance may require Exascale to modify its data processing practices and policies incurring
costs and expense. Further, to the extent multiple state-level laws are introduced with inconsistent or conflicting standards, it may
require costly and difficult efforts to achieve compliance with such laws. Exascale&#8217;s failure or perceived failure to comply with
state or federal privacy laws or regulations passed in the future could have a material adverse effect on Exascale&#8217;s business, including
how Exascale uses personal information, Exascale&#8217;s business, operating results, financial condition, and future prospects and could
expose Exascale to regulatory investigations or possible fines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Additionally, many foreign
countries and governmental bodies, including the European Union, the United Kingdom, Canada, and other jurisdictions in which Exascale
operates or conducts business, have laws and regulations concerning the collection, use, processing, storage, and deletion of personal
data obtained from their residents or by businesses operating within their jurisdiction. These laws and regulations often are more restrictive
than those in the United States. Such laws and regulations may require companies to implement new privacy and security policies, permit
individuals to access, correct, and delete personal information stored or maintained by such companies, inform individuals of security
breaches that affect their personal information, require that certain types of data be retained on local servers within these jurisdictions,
and, in some cases, obtain individuals&#8217; affirmative opt-in consent to collect and use personal information for certain purposes.
The increased focus on data sovereignty and data localization requirements around the world could also impact Exascale&#8217;s business
model with respect to the storage, management, and transfer of data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale is subject to the
European Union&#8217;s General Data Protection Regulation and the United Kingdom&#8217;s General Data Protection Regulation (collectively,
the &#8220;<b>GDPR</b>&#8221;), which comprehensively regulate Exascale&#8217;s use of personal data, including cross-border transfers
of personal data out of the European Economic Area (&#8220;<b>EEA</b>&#8221;) and the United Kingdom. The GDPR imposes stringent privacy
and data protection requirements, and could increase the risk of non-compliance and the costs of providing Exascale&#8217;s services in
a compliant manner. A breach of the GDPR could result in regulatory investigations, reputational damage, fines and sanctions, orders to
cease or change Exascale&#8217;s processing of Exascale&#8217;s data, enforcement notices, or assessment notices (for a compulsory audit).
For example, if regulators assert that Exascale has failed to comply with the GDPR, Exascale may be subject to fines. Since Exascale is
subject to the supervision of relevant data protection authorities under multiple legal regimes (including separately in both the EU and
the United Kingdom), Exascale could be fined under those regimes independently in respect of the same breach. Exascale may also face civil
claims including representative actions and other class action type litigation (where individuals have suffered harm), potentially amounting
to significant compensation or damages liabilities, as well as associated costs, diversion of internal resources, and reputational harm.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The GDPR prohibits transfers
of personal data from the EEA or the United Kingdom to countries not formally deemed adequate by the European Commission or the U.K. Information
Commission Office, respectively, including the United States, unless a particular compliance mechanism (and, if necessary, certain safeguards)
is implemented. The mechanisms that Exascale and many other companies, including Exascale&#8217;s customers, rely upon for European and
U.K. data transfers (for example, Standard Contractual Clauses or the EU-US Data Privacy Framework) are the subject of legal challenge,
regulatory interpretation, and judicial decisions by the Court of Justice of the European Union. The suitability of Standard Contractual
Clauses for data transfer in some scenarios has recently been the subject of legal challenge, and while the United States and the European
Union reached an agreement on the EU-US Data Privacy Framework (and similar agreements were reached with respect to the United Kingdom),
there are legal challenges to that data transfer mechanism as well. Exascale expects the legal complexity and uncertainty regarding international
personal data transfers to continue, and as the regulatory guidance and enforcement landscape in relation to data transfers continues
to develop, Exascale could suffer additional costs, complaints, and/or regulatory investigations or fines; Exascale may have to stop using
certain tools and vendors and make other operational changes; Exascale may have to implement alternative data transfer mechanisms under
the GDPR and/or take additional compliance and operational measures; and/or it could otherwise affect the manner in which Exascale provides
its services, and could adversely affect Exascale&#8217;s business, operating results, financial condition, and future prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale is also subject
to evolving U.S., E.U., and U.K. privacy laws governing cookies, tracking technologies, and e-marketing. In the United States, plaintiffs
are increasingly making use of existing laws such as the California Invasion of Privacy Act to litigate use of tracking technologies.
In the European Union, regulators are increasingly focusing on compliance with requirements in the online behavioral advertising ecosystem.
Also in the European Union, informed consent, including a prohibition on pre-checked consents and a requirement to ensure separate consents
for each cookie, is required for the placement of a non-essential cookie or similar technologies on a user&#8217;s device and for direct
electronic marketing. As regulators start to enforce the strict approach in recent guidance, this could lead to substantial costs, require
significant systems changes, limit the effectiveness of Exascale&#8217;s marketing activities, divert the attention of Exascale&#8217;s
technology personnel, negatively impact Exascale&#8217;s efforts to understand users, adversely affect Exascale&#8217;s margins, increase
costs, and subject Exascale to additional liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">There is also a risk that
as Exascale expands, Exascale may assume liabilities for breaches experienced by the companies Exascale acquires. Additionally, there
are potentially inconsistent world-wide government regulations pertaining to data protection and privacy. Despite Exascale&#8217;s efforts
to comply with applicable laws, regulations and other obligations relating to privacy, data protection, and information security, it is
possible that Exascale&#8217;s practices, offerings, or platform could fail, or be alleged to fail to meet applicable requirements. For
instance, there are changes in the regulatory landscape relating to new and evolving technologies, such as generative AI. Changes to existing
regulations, their interpretation or implementation, or new regulations could impede any potential use or development of AI technologies,
which could impair Exascale&#8217;s competitive position and result in an adverse effect on Exascale&#8217;s business, operating results,
financial condition, and future prospects. Exascale&#8217;s failure, or the failure by Exascale&#8217;s third-party providers or partners,
to comply with applicable laws or regulations and to prevent unauthorized access to, or use or release of personal information, or the
perception that any of the foregoing types of failure has occurred, even if unfounded, could subject Exascale to audits, inquiries, whistleblower
complaints, adverse media coverage, investigations, severe criminal, or civil sanctions, damage Exascale&#8217;s reputation, or result
in fines or proceedings by governmental agencies and private claims and litigation, any of which could adversely affect Exascale&#8217;s
business, operating results, financial condition, and future prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Export controls, trade
restrictions, and sanctions could limit Exascale&#8217;s ability to procure GPU hardware or serve certain customers and could increase
compliance costs.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">GPU hardware and related
technologies may be subject to export controls and trade restrictions, including restrictions on the export, reexport, or transfer of
certain advanced computing items to specific jurisdictions or end users. Compliance obligations may limit Exascale&#8217;s procurement
options, delay deployments, restrict customer eligibility, or require enhanced due diligence and monitoring. Changes in export control
regimes or sanctions programs could increase compliance costs, limit access to critical hardware, or constrain Exascale&#8217;s ability
to conduct business in certain markets, any of which could materially adversely affect Exascale&#8217;s operations, financial condition
and future prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale&#8217;s business
is subject to a wide range of laws and regulations, and failure to comply with those laws and regulations could harm Exascale&#8217;s
business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale&#8217;s business
is subject to regulation by various federal, state, local, and foreign governmental agencies, including agencies responsible for monitoring
and enforcing employment and labor laws, workplace safety and environmental laws, including those related to energy usage and energy efficiency
requirements, privacy and data protection laws, AI, financial services laws, anti-bribery laws, sanctions, national security, import and
export controls, anti-boycott, federal securities laws, and tax laws and regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For example, governmental
authorities have in the past sought to restrict data center development based on environmental considerations and have imposed moratoria
on data center development, citing concerns about energy usage, requiring new data centers to meet energy efficiency requirements. Exascale
may face higher costs from any laws requiring enhanced energy efficiency measures, changes to cooling systems, caps on energy usage, land
use restrictions, limitations on back-up power sources, or other environmental requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In certain foreign jurisdictions,
these regulatory requirements may be more stringent than those in the United States. These laws and regulations are subject to change
over time and thus Exascale must continue to monitor and dedicate resources to ensure continued compliance. In particular, the global
AI regulatory environment continues to evolve as regulators and lawmakers have started proposing and adopting, or are currently considering,
regulations and guidance specifically on the use of AI. Non-compliance with applicable regulations or requirements could subject Exascale
to investigations, sanctions, mandatory product recalls, enforcement actions, disgorgement of profits, fines, damages, civil and criminal
penalties, or injunctions and jail time for responsible employees and managers. If any governmental sanctions are imposed, or if Exascale
does not prevail in any possible civil or criminal litigation, Exascale&#8217;s business, operating results, financial condition, and
future prospects could be materially adversely affected. In addition, responding to any action will likely result in a significant diversion
of management&#8217;s attention and resources and an increase in professional fees. Enforcement actions and sanctions could harm Exascale&#8217;s
business, operating results, financial condition, and future prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale has identified
material weaknesses in its internal control over financial reporting, and following the completion of the Business Combination, PubCo
will be subject to increased regulatory scrutiny and reporting obligations; if PubCo is unable to remediate these material weaknesses
or maintain effective internal controls, PubCo&#8217;s ability to accurately report its financial results and the market price of PubCo&#8217;s
securities could be adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale
is currently a private company with limited accounting and financial reporting personnel and other resources dedicated to internal control
over financial reporting. In connection with the preparation of Exascale&#8217;s audited financial statements as of and for the years
ended June&#160;30, 2025 and 2024, and Exascale&#8217;s unaudited interim condensed financial statements as of and for the three and nine
months ended March&#160;31, 2026 and 2025, Exascale identified material weaknesses in its internal control over financial reporting. A &#8220;material
weakness&#8221; is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable
possibility that a material misstatement of a company&#8217;s annual or interim financial statements will not be prevented or detected
on a timely basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The material weaknesses
identified relate to (i) a lack of sufficient accounting personnel with appropriate knowledge and experience in GAAP and SEC financial
reporting requirements to support financial information processing and reporting, and (ii) the absence of a formal risk assessment process
over financial reporting. Exascale&#8217;s management has concluded that these material weaknesses represent deficiencies in Exascale&#8217;s
overall internal control environment and could adversely affect Exascale&#8217;s ability to accurately and timely report Exascale&#8217;s
financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Upon consummation of the
Business Combination, PubCo will become subject to significantly greater reporting, compliance, and internal control requirements applicable
to U.S. public companies, including expanded disclosure obligations, increased scrutiny by regulators and investors, and, following the
applicable transition period, the requirement to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley
Act. These requirements will place substantial demands on PubCo&#8217;s management, accounting, and finance personnel and systems.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale
has implemented and plans to continue to implement measures designed to remediate the identified material weaknesses, including hiring
additional qualified accounting and reporting personnel with appropriate GAAP and SEC reporting expertise, developing and formalizing
accounting policies and procedures applicable to Exascale&#8217;s business, and providing internal training programs for Exascale&#8217;s
accounting and finance personnel. Exascale, and subsequent to the Business Combination, PubCo, intends to complete the remediation plan
by the end of 2027. The remediation process will require significant time, management attention, and financial resources, and the associated
costs, including personnel-related expenses and potential consulting fees, are expected to increase Exascale&#8217;s and PubCo&#8217;s
general and administrative expenses in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The process of designing,
implementing, and maintaining an effective system of internal control over financial reporting for Exascale is ongoing and inherently
complex. Neither Exascale nor PubCo can assure you that the measures Exascale has implemented or Exascale and PubCo plan to implement
will be sufficient to remediate the identified material weaknesses in a timely manner, or at all, or that additional material weaknesses
will not be identified in the future. If PubCo is unable to maintain effective internal control over financial reporting, PubCo may be
unable to accurately report its financial results, prevent or detect fraud, or comply with applicable reporting requirements, which could
result in regulatory actions, restatements of PubCo&#8217;s financial statements, loss of investor confidence, and a decline in the market
price of PubCo&#8217;s securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale may be unable
to utilize its net operating loss carryforwards to offset future taxable income, which could increase Exascale&#8217;s future tax liabilities.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June
30, 2025 and 2024, Exascale had net operating loss carryforwards (&#8220;<b>NOLs</b>&#8221;) of approximately $5.6 million and $2.5 million,
respectively, for U.S. federal income tax purposes and approximately $5.6 million and $2.5 million, respectively, for state income tax
purposes. Exascale&#8217;s federal NOLs do not expire; however, their use is subject to an annual limitation. The utilization of state
NOLs, including for Delaware corporate income tax purposes, is also subject to certain limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The realization of Exascale&#8217;s
deferred tax assets related to these NOLs depends on Exascale&#8217;s ability to generate sufficient taxable income in future periods,
the timing of such income, and the jurisdictions in which such income is earned, all of which are uncertain. If Exascale does not generate
sufficient taxable income, or if changes in tax laws or interpretations further limit the use of NOLs, Exascale has been required to record
or increase a valuation allowance against its deferred tax assets, which could negatively affect Exascale&#8217;s results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, future ownership changes, including
in connection with the Business Combination or other equity issuances, could further limit Exascale&#8217;s ability to utilize its NOLs
under applicable provisions of the Code and comparable state tax laws. As a result, even if Exascale becomes profitable, Exascale may
be unable to fully realize the expected benefits of its NOLs, which could result in higher cash tax liabilities than anticipated and adversely
affect Exascale&#8217;s financial condition and results of operations. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>If Exascale is unable
to attract or retain qualified personnel or key personnel, our ability to execute our strategy and maintain service quality could be adversely
affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale&#8217;s business
depends on highly skilled personnel, including but not limited to engineers and operations professionals with experience in AI infrastructure,
distributed systems, and data center operations. Competition for such talent is intense. If Exascale is unable to hire, develop, and retain
qualified personnel, or if Exascale experiences turnover among key employees, Exascale&#8217;s ability to operate reliably, improve Exascale&#8217;s
platform, support customers, and expand Exascale&#8217;s services could be materially adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale&#8217;s management&#8217;s
discussion and analysis of Exascale&#8217;s financial condition and results of operations uses non-GAAP financial measures, which have
inherent limitations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale&#8217;s management&#8217;s
discussion and analysis of Exascale&#8217;s financial condition and results of operations elsewhere in this proxy statement/prospectus
uses non-GAAP financial measures, which may not be comparable to similarly titled measures used by other companies and may present Exascale&#8217;s
results of operations differently than GAAP measures. Exascale uses adjusted operating loss and adjusted net loss, which are non-GAAP
financial measures, to evaluate its operating performance and to assist in financial and operational decision-making. Adjusted operating
loss excludes share-based compensation expense, and adjusted net loss excludes share-based compensation expense and changes in the fair
value of SAFEs. These adjustments remove certain expenses that are required to be included in Exascale&#8217;s loss from operations and
net loss under GAAP. Non-GAAP financial measures have inherent limitations and should not be considered in isolation or as a substitute
for loss from operations, net loss, or other measures of financial performance prepared in accordance with GAAP. In addition, adjusted
operating loss and adjusted net loss, as used by Exascale, may not be comparable to similarly titled measures used by other companies,
as other companies may calculate these measures differently or may not exclude the same items. Investors should review the reconciliation
of these non-GAAP financial measures to the most directly comparable GAAP measures and consider Exascale&#8217;s financial results as
a whole. Reliance on non-GAAP financial measures could cause investors to misinterpret Exascale&#8217;s financial performance or trends,
which could adversely affect investment decisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale&#8217;s prior
evaluation of blockchain or digital asset-related concepts could create reputational or regulatory scrutiny, and any future evaluation
of such initiatives may be subject to heightened regulation.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale
has, in the past, evaluated and explored certain blockchain- or digital-asset-related concepts. These activities were exploratory in
nature, did not generate material revenue, and are not part of Exascale&#8217;s current core business operations. As of the date of this
proxy statement/prospectus, Exascale is not engaged in cryptocurrency-related activities, other than the receipt, holding and/or settlement
of Tether USD and U.S. Dollar Coins as part of payment collection, settlement and repayment arrangements. Notwithstanding the foregoing,
third-party perceptions or historical public statements could result in inquiries or reputational considerations. In addition, if Exascale
evaluates any infrastructure-linked financial structures in the future, such initiatives could be subject to evolving laws and regulatory
requirements and could expose Exascale to additional compliance obligations and risks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Exascale may become
involved in litigation that may adversely affect Exascale.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">From
time to time, Exascale may be subject to claims, suits, and other proceedings. Regardless of the outcome, legal proceedings can have an
adverse impact on Exascale because of legal costs and diversion of management&#8217;s attention and resources, and could cause Exascale
to incur significant expenses or liability, adversely affect Exascale&#8217;s brand recognition, or require Exascale to change its business
practices. The expense of litigation and the timing of this expense from period to period are difficult to estimate, subject to change,
and could adversely affect Exascale&#8217;s business, operating results, financial condition, and future prospects. It is possible that
a resolution of one or more such proceedings could result in substantial damages, settlement costs, fines, and penalties that would adversely
affect Exascale&#8217;s business, consolidated financial condition, operating results, or cash flows in a particular period. These proceedings
could also result in reputational harm, sanctions, consent decrees, or orders requiring a change in Exascale&#8217;s business practices.
Because of the potential risks, expenses, and uncertainties of litigation, Exascale may, from time to time, settle disputes, even where
Exascale has meritorious claims or defenses, by agreeing to settlement agreements. Because litigation is inherently unpredictable, Exascale
cannot assure you that the results of any of these actions will not have a material adverse effect on Exascale&#8217;s business, operating
results, financial condition, and prospects. Any of these consequences could adversely affect Exascale&#8217;s business, operating results,
financial condition, and future prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Global events and
other general economic factors may impact our results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Global
events and other general economic factors that are beyond our control, including local, state, and international politics, may impact
our results of operations. These factors can include interest rates; recession; inflation; unemployment trends; the threat or possibility
of war, terrorism or other global or national unrest; political or financial instability; and other matters that influence our customers&#8217;
spending. Potential increasing volatility in financial markets and changes in the economic climate could adversely affect our results
of operations. The impact these potential global events can have on general economic conditions is continuously evolving and the ultimate
impact that they will have on our results of operations continues to remain uncertain. There are no assurances that we will be able to
continue to experience the same growth or not be materially adversely affected should such scenarios occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to PubCo</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PubCo
will have a dual-class share structure with different voting rights, which may adversely affect the value and liquidity of PubCo&#8217;s
securities.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PubCo will
have a dual-class structure with different voting rights, and such dual-class share structure may result in a lower or more volatile market
price of PubCo&#8217;s securities. Each PubCo Class A Ordinary Common Stock will have one (1) vote on all matters submitted to a vote
of PubCo&#8217;s stockholders and each PubCo Class B Super Common Stock will have twenty (20) votes on all matters submitted to a vote
of PubCo&#8217;s stockholders. Holders of PubCo Class A Ordinary Common Stock and PubCo Class B Super Common Stock will vote together
as a single class except where required otherwise by applicable law. The PubCo Class B Super Common Stock may be converted into PubCo
Class A Ordinary Common Stock on a one-for-one basis voluntarily at the option of the holder or automatically upon transfer to certain
persons and entities. The PubCo Class A Ordinary Common Stock will not be convertible into PubCo Class B Super Common Stock under any
circumstances. Certain index providers have announced restrictions on including companies with multiple class share structures in certain
of their indices. Because of PubCo&#8217;s dual class structure, PubCo will likely be excluded from these indices and other stock indices
that take similar actions. Given the sustained flow of investment funds into passive strategies that seek to track certain indices, exclusion
from certain stock indices would likely preclude investment by many of these funds and could make PubCo&#8217;s securities less attractive
to investors. In addition, several shareholder advisory firms have announced their opposition to the use of a multiple class structure
and PubCo&#8217;s dual class structure may cause shareholder advisory firms to publish negative commentary about PubCo&#8217;s corporate
governance or otherwise seek to cause PubCo to change its capital structure. Any such exclusion from indices could result in a less active
trading market for PubCo&#8217;s securities. Any actions or publications by shareholder advisory firms critical of PubCo&#8217;s corporate
governance practices or capital structure could also adversely affect the value of PubCo&#8217;s securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PubCo&#8217;s dual-class share structure
with different voting rights will limit your ability to influence corporate matters and could discourage others from pursuing any change
of control transactions that PubCo&#8217;s stockholders may view as beneficial.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of PubCo&#8217;s dual-class share
structure and the concentration of ownership, Hoansoo Lee, who will be PubCo&#8217;s Chief Executive Officer and a member of the PubCo
Board, Wenying Jia, who will be Chairperson and a member of PubCo&#8217;s Board, and entities affiliated with Hoansoo Lee and Wenying
Jia, will collectively own all of PubCo&#8217;s Class B Super Common Stock, and thus, a significant amount of the total voting power of
PubCo&#8217;s outstanding common stock. As such, Hoansoo Lee and Wenying Jia, and their affiliates, will have substantial influence over
PubCo&#8217;s business, including decisions regarding mergers, consolidations and the sale of all or substantially all of PubCo&#8217;s
assets, election of directors and other significant corporate actions. Hoansoo Lee and Wenying Jia, and their affiliates, may take actions
that are not in the best interest of PubCo&#8217;s other stockholders. Such dual-class arrangement may discourage, delay or prevent a
change in control of PubCo, which could deprive PubCo&#8217;s other stockholders of an opportunity to receive a premium for their PubCo
Common Stock as part of a sale of PubCo and may reduce the price of PubCo&#8217;s securities. This concentrated control will limit your
ability to influence corporate matters and could discourage others from pursuing any potential merger, takeover or other change of control
transactions that PubCo&#8217;s other stockholders may view as beneficial. Further information is available in the &#8220;<i>Beneficial
Ownership of Securities&#8212; Beneficial Ownership of PubCo&#8217;s Common Stock after the closing of the Business Combination</i>&#8221;
section of this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The holders of shares of Class B Super Common
Stock will own a significant voting percentage of the PubCo stock and will be able to exert significant control over matters subject to
stockholder approval.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon consummation of the Business Combination,
the entirety of the PubCo Class B Super Common Stock will be held by five shareholders, namely, (i) Zerowave Ltd, (ii) Jisu Paul Lee Non-Grantor
Directed Trust, (iii) Sophia Jisun Lee Non-Grantor Directed Trust, (iv) Gabriel Jihwan Lee Non-Grantor Directed Trust and (v) HSL Capital
Management LLC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Zerowave Ltd is affiliated with Wenying Jia, and
the Jisu Paul Lee Non-Grantor Directed Trust, the Sophia Jisun Lee Non-Grantor Directed Trust, the Gabriel Jihwan Lee Non-Grantor Directed
Trust and HSL Capital Management LLC are each affiliated with Hoansoo Lee, as more particularly explained below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Wenying Jia, who is a founder of Exascale, the
current Chairperson and a member of the board of directors of Exascale, and will be the Chairperson and a member of the PubCo Board upon
consummation of the Business Combination, is the sole member and manager of Zerowave Ltd and will have sole voting and dispositive power
with respect to the PubCo Class B Super Common Stock directly held by Zerowave Ltd.<br/> <br/> Hoansoo Lee, who is a founder of Exascale,
the current Chief Executive Officer, Chief Financial Officer and a member of the board of directors of Exascale, and who will be the Chief
Executive Officer and Interim Chief Financial Officer of PubCo and a member of the PubCo Board upon consummation of the Business Combination,
is the sole member and manager of HSL Capital Management LLC and will have sole voting and dispositive power with respect to the PubCo
Class B Super Common Stock directly held by HSL Capital Management LLC.<br/> <br/> Hoansoo Lee is also the settlor of, and serves as
investment advisor to, each of the Jisu Paul Lee Non-Grantor Directed Trust, the Sophia Jisun Lee Non-Grantor Directed Trust, and the
Gabriel Jihwan Lee Non-Grantor Directed Trust, and the beneficiaries of each of those trusts are the children of Hoansoo Lee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each share of Class B Super Common Stock will
have twenty (20) votes on any matter brought before the stockholders for a vote, which means that the five stockholders who own all of
the Class B Super Common Stock will have, collectively, 680,880,000 votes on any matter subject to stockholder approval. In contrast,
each share of PubCo Class A Ordinary Common Stock outstanding after the consummation of the Business Combination will have one (1) vote
on any matter brought before the stockholders for a vote. Thus, the five holders of shares of PubCo Class B Super Common Stock may together
be able to determine or significantly influence all matters requiring stockholder approval. For example, these five stockholders may be
able to control elections of directors, amendments of PubCo&#8217;s organizational documents, or approval of any merger, sale of assets,
or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for PubCo&#8217;s stock
that you may feel are in your best interest as one of PubCo&#8217;s stockholders. PubCo&#8217;s Proposed Charter only authorizes 260,000,000
shares of Class A Ordinary Common Stock, which means that even if every authorized share of authorized Class A Ordinary Common Stock was
issued and outstanding, the five holders of shares of Class B Super Common Stock would have more votes than all of the holders of Class
A Ordinary Common Stock together. Further information is available in the sections of this proxy statement/prospectus titled &#8220;<i>Beneficial
Ownership of Securities&#8212; Beneficial Ownership of PubCo&#8217;s Common Stock after the closing of the Business Combination,</i>&#8221;
&#8220;<i>Questions and Answers for Shareholders of BCAR&#8212; What equity stake will current BCAR shareholders and Exascale Securityholders
hold in PubCo immediately after the consummation of the Business Combination?</i>&#8221; and &#8220;<i>Summary of the Proxy Statement/Prospectus&#8212;Ownership
of PubCo after the Closing</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>PubCo will be a &#8220;controlled company&#8221;
within the meaning of Nasdaq listing rules, and as a result, PubCo will be entitled to rely on exemptions from certain corporate governance
requirements that could adversely affect the rights of holders of PubCo Class A Ordinary Common Stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the consummation of the Business Combination,
the holders of PubCo Class B Super Common Stock will own a significant voting percentage of the outstanding voting power of PubCo. Each
share of PubCo Class B Super Common Stock will be entitled to twenty (20) votes per share, while each share of PubCo Class A Ordinary
Common Stock will be entitled to one (1) vote per share. As a result, the five stockholders who collectively own all of the outstanding
shares of Class B Super Common Stock, four of whom are affiliated with PubCo&#8217;s Chief Executive Officer and director and one of whom
is affiliated with a member of the PubCo Board, will be able to exercise voting control over matters submitted to PubCo stockholders for
approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because more than 50% of the voting power of PubCo&#8217;s
outstanding capital stock will be held by these stockholders, PubCo will qualify as a &#8220;controlled company&#8221; under the Nasdaq
Stock Market rules. As a controlled company, PubCo may elect to rely on exemptions from certain corporate governance requirements, including
requirements that a majority of its board of directors be independent and that its compensation and nominating and corporate governance
committees be composed entirely of independent directors. Although PubCo does not currently intend to rely on any of the exemptions afforded
to a &#8220;controlled company&#8221; under Nasdaq Stock Market rules, PubCo may do so in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If PubCo relies on one or more of these exemptions,
holders of PubCo Class A Ordinary Common Stock may not have the same protections afforded to stockholders of companies that are subject
to all Nasdaq corporate governance requirements. In addition, the voting control exercised by the holders of PubCo Class B Super Common
Stock will enable them to determine the outcome of matters requiring stockholder approval, including the election of directors, certain
amendments to PubCo&#8217;s organizational documents, and approval of mergers, asset sales, or other significant corporate transactions.
This concentration of control could discourage or prevent transactions that other stockholders may consider favorable and could limit
the ability of holders of PubCo Class A Ordinary Common Stock to influence corporate matters, which could adversely affect the market
price of PubCo&#8217;s securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
price of PubCo&#8217;s securities may be volatile, and you could lose all or part of your investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
consummation of the Business Combination, the prices of PubCo&#8217;s securities may be highly volatile and could be subject to wide fluctuations
in response to various factors, some of which are beyond PubCo&#8217;s control. In addition to the factors discussed in this &#8220;<i>Risk
Factors</i>&#8221; section and elsewhere in this proxy statement/prospectus, these factors include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of new products or
        services offered by PubCo or PubCo&#8217;s competitors;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of significant acquisitions,
        strategic partnerships, joint ventures or capital commitments by PubCo or PubCo&#8217;s competitors;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo&#8217;s ability to effectively
        manage PubCo&#8217;s growth;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated variations
        in quarterly operating results;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo&#8217;s cash position;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures of key personnel;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss of a strategic relationship;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo&#8217;s failure to meet the
        estimates and projections of the investment community or that PubCo may otherwise provide to the public;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication of research reports
        about PubCo or PubCo&#8217;s industry;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the market valuations
        of similar companies;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overall performance of the equity
        markets;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our PubCo&#8217;s securities
        by PubCo or its stockholders in the future;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading volume of PubCo&#8217;s
        securities;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investor perception of PubCo&#8217;s
        industry or prospects;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insider selling or buying;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ineffectiveness of PubCo&#8217;s
        internal controls; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general political and economic conditions
        and other events or factors, many of which are beyond our control.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of these
factors are beyond PubCo&#8217;s control and may decrease the market price of PubCo&#8217;s securities, regardless of PubCo&#8217;s operating
performance. Neither BCAR nor Exascale can make any predictions or projections as to what the prevailing market price for PubCo&#8217;s
securities will be at any time, including as to whether PubCo&#8217;s securities will sustain current market prices, or as to what effect
that the sale of shares or the availability of PubCo&#8217;s securities for sale at any time will have on the prevailing market price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition,
the securities markets have from time-to-time experienced significant price and volume fluctuations that are unrelated to the operating
performance of particular companies. These market fluctuations may also materially and adversely affect the market price of PubCo&#8217;s
securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
liquid trading market for PubCo&#8217;s securities may not develop or, if developed, may not be sustained.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
active and liquid public trading market for PubCo Class A Ordinary Common Stock and other securities may not develop or be sustained following
the completion of the Business Combination. PubCo&#8217;s securities may experience limited trading volume, and the market price may be
subject to significant volatility due to a number of factors, including limited analyst coverage, the concentration of share ownership
among a small number of stockholders, the resale of shares by legacy Exascale Securityholders following the expiration of applicable lock-up
periods, general market conditions affecting companies operating in the AI and technology sectors, and other factors discussed elsewhere
in this &#8220;Risk Factors&#8221; section.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if a public trading market develops, there can be no assurance that it will be maintained on a consistent or liquid basis. Low trading
volume or volatility could make it difficult for investors to sell their PubCo Securities at or above the price they paid, or at all.
In addition, if PubCo fails to meet the continued listing standards of Nasdaq, its securities could be delisted, which would further reduce
liquidity and market visibility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, investors may experience difficulty in buying or selling PubCo&#8217;s securities, may be unable to sell their securities at
a favorable time or price, and may be required to hold their investment for an extended period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>PubCo will be required to meet the initial listing
requirements to be listed on Nasdaq, and it may not be able to meet those initial listing requirements. Even if PubCo&#8217;s securities
are so listed, it may be unable to maintain the listing of its securities in the future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If PubCo fails to meet the initial listing requirements
and Nasdaq removes its securities from its exchange, PubCo could face significant material adverse consequences, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a limited availability of market quotations for its securities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a limited amount of news and analyst coverage for the company; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a decreased ability to issue additional securities or obtain additional financing
        in the future.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The requirements of being a public company may
strain PubCo&#8217;s resources and distract management and PubCo will incur substantial costs as a result of being a public company.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the consummation of the Business Combination,
PubCo will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, and the Securities Act. These rules,
regulations and requirements are extensive. PubCo will incur significant costs associated with PubCo&#8217;s public company corporate
governance and reporting requirements. The Exchange Act requires, among other things, that PubCo file annual, quarterly and current reports
with respect to its business and operating results. The Sarbanes-Oxley Act requires, among other things, that PubCo maintain effective
disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure
controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight
may be required. As a result, PubCo&#8217;s management&#8217;s attention may be diverted from other business concerns, which could adversely
affect PubCo&#8217;s business and operating results. PubCo may need to hire more corporate employees to comply with these requirements
or engage outside consultants, which would increase PubCo&#8217;s costs and expenses. This may divert management&#8217;s attention from
other business concerns, which could have a material adverse effect on PubCo&#8217;s business, financial condition and results of operations.
These applicable rules and regulations may make it more difficult and more expensive for PubCo to obtain director and officer liability
insurance and PubCo may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same
or similar coverage. As a result, it may be more difficult for PubCo to attract and retain qualified individuals to serve on the PubCo
Board or as executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, changing laws, regulations and standards
relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance
costs and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in
many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided
by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated
by ongoing revisions to disclosure and governance practices. PubCo intends to invest resources to comply with evolving laws, regulations
and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time
and attention from revenue-generating activities to compliance activities. If PubCo&#8217;s efforts to comply with new laws, regulations
and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and
practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of disclosure of information in this
proxy statement/prospectus and in the filings that PubCo will be required to make as a public company, PubCo&#8217;s business, operating
results and financial condition will become more visible, which may result in threatened or actual litigation, including by competitors
and other third parties. If any such claims are successful, PubCo&#8217;s business, operating results and financial condition could be
adversely affected, and even if the claims do not result in litigation or are resolved in PubCo&#8217;s favor, these claims, and the time
and resources necessary to resolve them, could divert the resources of PubCo&#8217;s management and adversely affect PubCo&#8217;s business,
operating results and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A decline
in the price of PubCo Common Stock could affect PubCo&#8217;s ability to raise working capital and adversely impact PubCo&#8217;s ability
to continue operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A prolonged decline in the price of PubCo Class
A Ordinary Common Stock could result in a reduction in the liquidity of the common stock and a reduction in PubCo&#8217;s ability to raise
capital. A decline in the price of PubCo Class A Ordinary Common Stock could be especially detrimental to PubCo&#8217;s liquidity, operations
and strategic plans. Such reductions may force PubCo to reallocate funds from other planned uses and may have a significant negative effect
on PubCo&#8217;s business plan and operations, including PubCo&#8217;s ability to develop new products and services and continue current
operations. If PubCo Class A Ordinary Common Stock&#8217;s price declines, PubCo can offer no assurance that it will be able to raise
additional capital or generate funds from operations sufficient to meet PubCo&#8217;s obligations or raise capital that is on favorable
terms to the PubCo. If PubCo is unable to raise sufficient capital in the future, PubCo may not be able to have the resources to continue
its normal operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in international trade policies,
tariffs and treaties affecting imports and exports may have a material adverse effect on PubCo&#8217;s business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have recently been significant changes to
international trade policies and tariffs affecting imports and exports. Any significant increases in tariffs on goods or materials or
other changes in trade policy could negatively affect PubCo&#8217;s business operations. Recently, the U.S. has implemented a range of
new tariffs and increases to existing tariffs. In response to the tariffs announced by the United States, other countries have imposed,
are considering imposing, and may in the future impose new or increased tariffs on certain exports from the United States. There is currently
significant uncertainty about the future relationship between the United States and other countries with respect to trade policies, taxes,
government regulations and tariffs, and neither BCAR nor Exascale can predict whether, and to what extent, current tariffs will continue
or trade policies will change in the future. Tariffs, or the threat of tariffs or increased tariffs, could have a significant negative
impact on PubCo&#8217;s businesses (either due to our reliance on imported goods or dependence on access to foreign markets).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Among other things, historical financial performance
of companies affected by trade policies and/or tariffs may not provide useful guidance as to the future performance of such companies,
because future financial performance of those companies may be materially affected by new U.S. tariffs or foreign retaliatory tariffs,
or other changes to trade policies. PubCo may not be able to adequately address the risks presented by these tariffs or other potential
trade policy changes. As a result, PubCo&#8217;s business may be negatively impacted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Inflationary
pressures and persistently high prices and uncertain availability of inputs used by PubCo and PubCo&#8217;s suppliers, or instability
in logistics and related costs, could negatively impact PubCo&#8217;s profitability. Pending tariffs proposed by the Trump Administration,
may also negatively impact the cost structure of PubCo&#8217;s supply chain, and PubCo may not be able to pass these price increases on
to its customers.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Increases in prices, including because of inflation
and rising interest rates, for inputs that PubCo and PubCo&#8217;s suppliers use in manufacturing products, systems, components and parts,
or increases in logistics and related costs, have led in the past and may lead in the future to higher production costs for parts, components
and vehicles. Geopolitical risks, fluctuations in supply and demand, fluctuations in interest rates, any weakening of the U.S. dollar
in comparison with other currencies, and other economic and political factors have created and may continue to create pricing pressure
for PubCo&#8217;s inputs. These inflationary pressures could, in turn, negatively impact PubCo&#8217;s profitability because we may not
be able to pass all of those costs on to our customers or require our suppliers to absorb such costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes to United States tariff and import/export
regulations may have a material adverse effect on our business, financial condition and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The United States has recently enacted and proposed
to enact significant new tariffs. Additionally, President Trump has directed various federal agencies to further evaluate key aspects
of U.S. trade policy and there has been ongoing discussion and commentary regarding potential significant changes to U.S. trade policies,
treaties and tariffs. There continues to exist significant uncertainty about the future relationship between the U.S. and other countries
with respect to such trade policies, treaties and tariffs. These developments, or the perception that any of them could occur, may have
a material adverse effect on global economic conditions and the stability of global financial markets, and may significantly reduce global
trade and, in particular, trade between the impacted nations and the U.S. Any of these factors could depress economic activity and restrict
our access to suppliers or customers and have a material adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If the price of PubCo Common Stock fluctuates
after the Business Combination, you could lose a significant part of your investment.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The market price of PubCo Common Stock could be subject
to wide fluctuations in response to, among other things, the risk factors described in this proxy statement/prospectus, and other factors
beyond our control, such as fluctuations in the valuation of companies perceived by investors to be comparable to us. Furthermore, the
stock markets have experienced price and volume fluctuations that have affected and continue to affect the market prices of equity securities
of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These
broad market and industry fluctuations, as well as general economic, political, and market conditions, the occurrence of natural disasters,
pandemics, geopolitical tensions, military conflicts, recessions, inflation, interest rate changes or international currency fluctuations,
may negatively affect the market price of our common stock. In the past, many companies that have experienced volatility in the market
price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future.
Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns,
which could seriously harm our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The
public stockholders will experience immediate dilution as a consequence of the issuance of PubCo Common Stock as consideration in the
Business Combination and due to future issuances pursuant to the Exascale Equity Incentive Plan. Having a minority share position may
reduce the influence that Exascale&#8217;s current stockholders have on the management of PubCo.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is anticipated
that, following the Business Combination, an aggregate of 91,200,000 shares of PubCo Common Stock will be outstanding, based on Exascale&#8217;s
balance of capital stock as of March 31, 2026, comprised of: (i) 50,000,000 shares of PubCo Common Stock issued to Exascale Securityholders
in the Business Combination; and (ii) 13,200,000 shares of PubCo Common Stock issued to the Insiders. These amounts assume that there
are no redemptions, no equity securities are issued in connection with the Minimum Cash Financing, no BCAR Warrants will be exercised
and there are no other issuances of equity securities of PubCo prior to or in connection with the Closing, including any equity awards
that may be issued under the Exascale Equity Incentive Plan following the Business Combination. If the actual facts are different from
these assumptions, the percentage ownership retained by BCAR&#8217;s existing shareholders in the combined company will be different.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>To the extent that PubCo securities are
issued in connection with satisfying the Minimum Cash Financing condition, investors will experience additional dilution.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Business Combination Agreement,
BCAR has agreed to cause PubCo to receive at least $5.0 million in any combination of cash, cash held in the trust account, a PIPE, an
equity line of credit, or other third-party financing, net of certain specified items (the &#8220;<b>Minimum Cash Financing</b>&#8221;).
The receipt of the Minimum Cash Financing is a condition precedent to the consummation of the Business Combination. As of the date of
this proxy statement/prospectus, neither BCAR nor PubCo has secured financing to satisfy the Minimum Cash Financing. If the Minimum Cash
Financing is not met, and such condition is not waived by Exascale under the terms of the Business Combination Agreement, the proposed
Business Combination will not be consummated. In the event that the Business Combination will not be consummated, all Public Shares submitted
for redemption will be returned to the holders thereof, and we may instead search for an alternate business combination or liquidate BCAR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Minimum Cash Financing is satisfied through
the issuance of PubCo&#8217;s equity securities or securities convertible into, exercisable for, or exchangeable for PubCo&#8217;s equity
securities, including in connection with a PIPE investment or other equity-linked financing, investors will experience further dilution
in their ownership interests. Any such securities may be issued at a price per share that is lower than the price paid by existing stockholders
or may include terms, such as conversion features, exercise rights, price adjustments, or other investor protections, that result in additional
dilution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount of dilution experienced by stockholders
will depend on a number of factors, including the structure, timing, pricing, and size of any financing transaction, market conditions
at the time such financing is obtained, and the extent to which the Minimum Cash Financing is satisfied through equity or equity-linked
securities rather than cash. In addition, the issuance of a significant number of PubCo securities in connection with the Minimum Cash
Financing could adversely affect the market price of PubCo&#8217;s securities following the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future sales and issuances of PubCo Securities
could result in additional dilution of the percentage ownership of existing stockholders and could cause PubCo&#8217;s stock price to
fall.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR and Exascale expect that significant additional
capital may be needed in the future to continue PubCo&#8217;s planned operations. To raise capital, PubCo may sell common stock, convertible
securities or other equity securities in one or more transactions at prices and in a manner PubCo determines from time to time. If PubCo
sells common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales
may also result in material dilution to PubCo&#8217;s existing stockholders, and new investors could gain rights, preferences and privileges
senior to the holders of PubCo Class A Ordinary Common Stock common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, PubCo&#8217;s employees are expected
to be granted equity awards under equity incentive plans. You will experience additional dilution when those equity awards and purchase
rights become vested and settled or exercisable, as applicable, for shares of PubCo Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The issuance of additional common stock will significantly
dilute the equity interests of existing holders of BCAR securities and may adversely affect prevailing market prices for BCAR Public Shares
or Public Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PubCo Warrants will become exercisable for
PubCo Common Stock, which would increase the number of shares eligible for future resale in the public market and result in dilution to
our shareholders. Such dilution will increase if more Public Shares are redeemed.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Outstanding PubCo Warrants to purchase an aggregate
of up to 14,100,000 shares of PubCo Class A Ordinary Common Stock, including 14,000,000 Public Warrants and 100,000 Private Placement
Warrants, will become exercisable in accordance with the terms of the Warrant Agreement governing those securities. These warrants will
become exercisable at any time commencing 30 days after the completion of the Business Combination. The exercise price of these warrants
will be $11.50 per share. However, there is no guarantee that the PubCo Warrants will ever be &#8220;in the money&#8221; prior to their
expiration, and, as such, the PubCo Warrants may expire worthless. See &#8220;- <i>Even if the Business Combination is consummated, the
Public Warrants may never be in the money, and they may expire worthless and the terms of the warrants may be amended in a manner adverse
to a holder if holders of at least 50% of the then outstanding Public Warrants approve of such amendment</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent the PubCo Warrants are exercised,
additional shares of PubCo Class A Common Stock will be issued, which will result in dilution to the holders of PubCo Common Stock and
increase the number of shares eligible for resale in the public market. The dilution, as a percentage of outstanding shares, caused by
the exercise of the PubCo Warrants will increase if a large number of BCAR shareholders elect to redeem their shares in connection with
the Business Combination. We cannot predict the ultimate value of the Public Warrants following consummation of the Business Combination.
Sales of substantial numbers of shares issued upon the exercise of PubCo Warrants in the public market or the potential that such warrants
may be exercised could also adversely affect the market price of PubCo Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Even if the Business Combination is consummated,
the Public Warrants may never be in the money, and they may expire worthless and the terms of the warrants may be amended in a manner
adverse to a holder if holders of at least 50% of the then outstanding Public Warrants approve of such amendment.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The exercise price for the outstanding BCAR Warrants
is $11.50 per share. There can be no assurance that the Public Warrants will be in the money following the time they become exercisable
and prior to their expiration and as such, the Public Warrants may expire worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The BCAR Warrants were issued in registered form under
a Warrant Agreement between Odyssey Transfer and Trust Company, as warrant agent, and BCAR. The Warrant Agreement provides that the terms
of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires
the approval by the holders of at least 50% of the then outstanding Public Warrants to make any change that increases the exercise price
or shortens the exercise period of the Public Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accordingly, we may amend the terms of the Public
Warrants in a manner adverse to a holder if holders of at least 50% of the then outstanding Public Warrants approve of such amendment.
Although our ability to amend the terms of the Public Warrants with the consent of at least 50% of the then outstanding Public Warrants
is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the warrants, shorten
the exercise period or decrease the number of shares of PubCo Common Stock purchasable upon exercise of a warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>PubCo may redeem your unexpired PubCo Warrants
prior to their exercise at a time that is disadvantageous to you, thereby making your PubCo Warrants worthless.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have the ability
to redeem outstanding Public Warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per
warrant, provided that the closing price of the shares of PubCo Common Stock equals or exceeds $18.00 per share (as adjusted for share
sub-divisions, share capitalizations, reorganizations, recapitalizations and the like) for any twenty (20) trading days within a thirty
(30) trading-day period ending on the third trading day prior to the date on which we give proper notice of such redemption to the warrant
holders and provided certain other conditions are met. We will not redeem the Public Warrants unless an effective registration statement
under the Securities Act covering the shares issuable upon exercise of the warrants is effective and a current prospectus relating to
those shares is available throughout the thirty (30)-day redemption period, except if we elect to require the warrants to be exercised
on a cashless basis and such cashless exercise is exempt from registration under the Securities Act. If and when the Public Warrants become
redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale
under all applicable state securities laws. Redemption of the outstanding warrants could force you to accept the nominal redemption price
which, at the time the outstanding warrants are called for redemption, is likely to be substantially less than the market value of your
warrants, if you do not otherwise exercise you warrants, as permitted under the Warrant Agreement, before the redemption date. None of
the Private Placement Warrants will be redeemable by us so long as they are held by the Sponsor or any of its permitted transferees. As
of the date of this proxy statement/prospectus, BCAR Class A Ordinary Shares have never traded above $17.00 per share, therefore neither
current nor recent share prices meet or exceed the threshold that would allow PubCo to redeem Public Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we have the ability to redeem the
outstanding Public Warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per warrant upon
a minimum of 30 days&#8217; prior written notice of redemption if the closing price of the PubCo Common Stock equals or exceeds $18.00
per share (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like) for any twenty
(20) trading days within a thirty (30) day trading-day period ending on the third day prior to proper notice of such redemption and provided
that certain other conditions are met, including that holders will be able to exercise their warrants on a cashless basis prior to redemption
for a number of shares of PubCo Common Stock determined based on the redemption date and fair market value of the PubCo Common Stock.
The value received upon exercise of the warrants may be less than the value the holders would have received if they had been able to exercise
their warrants at a later time at which the underlying share price is higher and (2) may not compensate the holders for the value of the
warrants, including because the number of ordinary shares received is capped at 0.361 shares per warrant (subject to adjustment) irrespective
of the remaining life of the warrants. In addition, such redemptions may occur at a time when the PubCo Warrants are &#8220;out-of-the-money,&#8221;
in which case holders thereof would lose any potential embedded value from a subsequent increase in the value of the PubCo Common Stock
had such PubCo Warrants remained outstanding. If the price of the PubCo Common Stock is less than $18.00 and we seek redemption of the
Public Warrants, we must call the Private Placement Warrants for redemption on the same terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that PubCo determines to redeem the
Public Warrants when the closing price of the shares of PubCo Common Stock equals or exceeds $18.00 per share, pursuant to Section 6.2
of the Warrant Agreement, respectively, PubCo will fix a date for the redemption. Notice of redemption will be mailed by first class mail,
postage prepaid, by PubCo not less than thirty (30) days prior to the redemption date to the registered holders of the Public Warrants
to be redeemed at their last addresses as they appear on the registration books. Any notice mailed in the manner herein provided will
be conclusively presumed to have been duly given whether or not the registered holder received such notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Public Warrant Holders will only be able
to exercise their Public Warrants on a &#8220;cashless basis&#8221; under certain circumstances, and if they do so, they will receive
fewer shares of PubCo Common Stock from such exercise than if such warrants were exercised for cash.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Public Warrants generally may not be exercised
on a &#8220;cashless basis&#8221;, except as described below. In contrast, the Private Placement Warrants, for so long as they are held
by the Sponsor and certain permitted transferees, may be exercised on a &#8220;cashless basis&#8221;. The reason that BCAR agreed that
the Private Placement Warrants will be exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees
is because it was not known at the time of BCAR&#8217;s IPO whether the Sponsor would be affiliated with us following a business combination.
If the Sponsor remains affiliated with PubCo, its ability to sell PubCo Securities in the open market will be significantly limited. We
expect PubCo to have policies in place that prohibit insiders from selling securities except during specific periods of time. Even during
such periods of time when insiders will be permitted to sell PubCo Securities, an insider cannot trade in PubCo Securities if he or she
is in possession of material non-public information. Accordingly, unlike Public Shareholders who could exercise their PubCo Warrants and
sell the shares received upon such exercise freely in the open market in order to recoup the cost of such exercise, the Insiders could
be significantly restricted from selling such securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant
Agreement provides that in the following circumstances holders of Public Warrants who seek to exercise their Public Warrants will not
be permitted to do so for cash and will, instead, be required to do so on a cashless basis in accordance with Section 3(a)(9) of the Securities
Act: (i) if the PubCo Common Stock issuable upon exercise of the warrants are not registered under the Securities Act in accordance with
the terms of the Warrant Agreement; (ii) if we have so elected and the PubCo Common Stock is at the time of any exercise of a warrant
not listed on a national securities exchange such that they satisfy the definition of &#8220;covered securities&#8221; under Section 18(b)(1)
of the Securities Act; and (iii) if we have so elected and we call the Public Warrants for redemption. If you exercise your Public Warrants
on a cashless basis, you would pay the warrant exercise price by surrendering the warrants for that number of shares of PubCo Common Stock
equal to the quotient obtained by dividing (x) the product of the number of shares of PubCo Common Stock underlying the Public Warrants,
multiplied by the excess of the &#8220;fair market value&#8221; of the shares of PubCo Common Stock (as defined in the next sentence)
over the exercise price of the warrants by (y) the fair market value. The &#8220;fair market value&#8221; is the average reported closing
price of the shares of PubCo Common Stock for the ten (10) trading days ending on the third trading day prior to the date on which the
notice of exercise is received by the warrant agent or on which the notice of redemption is sent to the holders of warrants, as applicable.
As a result, a holder of Public Warrants would receive fewer shares of PubCo Common Stock from such exercise than if such warrants were
exercised for cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The PubCo Warrants may have an adverse effect
on the market price of the PubCo Common Stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the Business Combination, the BCAR Warrants
will be assumed and converted into PubCo Warrants and will entitle the holders to purchase shares of PubCo Common Stock. Such PubCo Warrants,
when exercised, will increase the number of issued and outstanding shares of PubCo Common Stock and reduce the value of the PubCo Common
Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The Warrant Agreement designates the courts
of the State of New York or the United States District Court for the Southern District of New York as the sole and exclusive forum for
certain types of actions and proceedings that may be initiated by holders of the warrants, which could limit the ability of warrant holders
to obtain a favorable judicial forum for disputes.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Warrant Agreement provides that, subject to applicable
law, (i) any action, proceeding or claim against us arising out of or relating in any way to the Warrant Agreement, including under the
Securities Act, will be brought and enforced in the courts of the State of New York or the United States District Court for the Southern
District of New York, and (ii) that we irrevocably submit to such jurisdiction, which jurisdiction shall be the exclusive forum for any
such action, proceeding or claim. We will waive any objection to such exclusive jurisdiction and that such courts represent an inconvenient
forum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notwithstanding
the foregoing, these provisions of the Warrant Agreement will not apply to suits brought to enforce any liability or duty created by the
Exchange Act or any other claim for which the federal district courts of the United States of America are the sole and exclusive forum.
Any person or entity purchasing or otherwise acquiring any interest in any of our warrants shall be deemed to have notice of and to have
consented to the forum provisions in our Warrant Agreement. If any action, the subject matter of which is within the scope of the forum
provisions of the Warrant Agreement, is filed in a court other than a court of the State of New York or the United States District Court
for the Southern District of New York (a &#8220;foreign action&#8221;) in the name of any holder of our warrants, such holder shall be
deemed to have consented to: (x) the personal jurisdiction of the state and federal courts located in the State of New York in connection
with any action brought in any such court to enforce the forum provisions (an &#8220;enforcement action&#8221;), and (y) having service
of process made upon such warrant holder in any such enforcement action by service upon such warrant holder&#8217;s counsel in the foreign
action as agent for such warrant holder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This choice-of-forum provision may limit a warrant
holder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes, which may discourage such lawsuits and
result in increased costs to warrant holders to bring a lawsuit. Alternatively, if a court were to find this provision of our Warrant
Agreement inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings, we may incur additional
costs associated with resolving such matters in other jurisdictions, which could materially and adversely affect our business, financial
condition and results of operations and result in a diversion of the time and resources of our management and board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PubCo does not intend to pay any cash dividends
in the foreseeable future and, therefore, any return on your investment in PubCo&#8217;s securities must come from increases in the fair
market value and trading price of PubCo&#8217;s securities.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR and Exascale currently anticipate that PubCo
will retain future earnings, if any, for the development, operation and expansion of PubCo&#8217;s business and do not anticipate PubCo
declaring or paying any cash dividends for the foreseeable future. In addition, credit agreements, which PubCo may enter into, may restrict
PubCo&#8217;s ability to pay dividends. Whether PubCo pays cash dividends in the future will be at the discretion of the PubCo Board and
will be dependent upon PubCo&#8217;s financial condition, results of operations, capital requirements and any other factors that the PubCo
Board decides is relevant. Any return to stockholders will therefore be limited to the appreciation of their PubCo Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>PubCo will be a &#8220;smaller reporting company&#8221;
and &#8220;emerging growth company&#8221; under the U.S. federal securities laws, and the reduced reporting requirements applicable to
smaller reporting companies and emerging growth companies could make our common stock less attractive to investors.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PubCo will be a &#8220;smaller reporting company&#8221;
and an &#8220;emerging growth company&#8221; under U.S. federal securities laws. For as long as PubCo continues to be a smaller reporting
company, it may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are
not smaller reporting companies, including reduced disclosure obligations regarding executive compensation in its periodic reports and
proxy statements. Furthermore, as an emerging growth company, PubCo intends to take advantage of exemptions from certain reporting requirements
including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and exemptions
from the requirements of holding a non-binding advisory vote on executive compensation. Investors may not find PubCo&#8217;s common stock
attractive because PubCo may rely on these exemptions and reduced disclosures. If some investors find PubCo&#8217;s common stock less
attractive as a result, there may be a less active trading market for PubCo&#8217;s common stock and PubCo&#8217;s stock price may be
more volatile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PubCo will remain a smaller reporting company
until the last day of the fiscal year in which (i) the market value of PubCo&#8217;s common stock held by non-affiliates exceeds $250
million as of the prior June&#160;30, or (ii) PubCo&#8217;s annual revenues exceeded $100 million during such completed fiscal year and
the market value of PubCo&#8217;s common stock held by non-affiliates exceeds $700 million as of the last business day of the most recently
completed second fiscal quarter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PubCo will remain an emerging growth company until
the earlier of: (i) the last day of the fiscal year (a) following the fifth anniversary of the closing of BCAR&#8217;s IPO, (b) in which
PubCo has total annual gross revenue of at least $1.23 billion, or (c) in which PubCo is deemed to be a large accelerated filer, which
means the market value of PubCo&#8217;s common equity that is held by non-affiliates exceeds $700 million as of the end of the prior fiscal
year&#8217;s second fiscal quarter; and (2) the date on which PubCo has issued more than $1.00 billion in non-convertible debt securities
during the prior three-year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Subsequent to our completion of the Business
Combination or any alternate business combination, we may be required to take write-downs or write-offs, restructuring and impairment
or other charges that could have a significant negative effect on our financial condition, results of operations and the price of our
securities, which could cause you to lose some or all of your investment.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we conduct extensive due diligence on
a target business with which we combine such as Exascale, we cannot assure you that this diligence will identify all material issues that
may be present with the target business, that it would be possible to uncover all material issues through a customary amount of due diligence,
or that factors outside such other target business&#8217;s control and outside of our control will not later arise. As a result of these
factors, we may be forced to later write-down or write-off assets, restructure our operations, or incur impairment or other charges that
could result in our reporting losses. Even if our due diligence successfully identifies certain risks, unexpected risks may arise and
previously known risks may materialize in a manner not consistent with our preliminary risk analysis. Even though these charges may be
non-cash items and not have an immediate impact on our liquidity, the fact that we report charges of this nature could contribute to negative
market perceptions about us or our securities. In addition, charges of this nature may cause us to violate net worth or other covenants
to which we may be subject as a result of assuming pre-existing debt held by a target business or by virtue of our obtaining debt financing
to partially finance the initial business combination or thereafter. Accordingly, any shareholders or warrant holders who choose to remain
shareholders or warrant holders following the Business Combination or any alternate business combination could suffer a reduction in the
value of their securities. Such shareholders or warrant holders are unlikely to have a remedy for such reduction in value unless they
are able to successfully claim that the reduction was due to the breach by our officers or directors of a duty of care or other fiduciary
duty owed to them, or if they are able to successfully bring a private claim under securities laws that the proxy materials or tender
offer documents, as applicable, relating to the business combination contained an actionable material misstatement or material omission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Resources could be wasted in researching business
combinations that are not completed, which could materially adversely affect subsequent attempts to locate and acquire or merge with another
business. If we are unable to complete the Business Combination or an alternate business combination, our warrants will expire worthless.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The investigation of each specific target business
and the negotiation, drafting and execution of relevant agreements, disclosure documents and other instruments requires substantial management
time, attention and substantial costs for accountants, attorneys and others. If we are unable to complete the Business Combination or
an alternate business combination, the costs incurred up to that point for the proposed transaction likely would not be recoverable. Furthermore,
we may fail to complete an initial business combination for any number of reasons including those beyond our control. Any such event will
result in a loss to us of the related costs incurred which could materially adversely affect subsequent attempts to locate and acquire
or merge with another business. If we are unable to complete a business combination, our warrants will expire worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our ability to successfully effect the Business
Combination and to be successful thereafter will be dependent upon the efforts of our key personnel, some of whom may join us following
our initial business combination. The loss of key personnel could negatively impact the operations and profitability of our post-combination
business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our ability to successfully effect our Business Combination
is dependent upon the efforts of our key personnel. However the role of our key personnel, should we pursue an alternate target business
cannot presently be ascertained. While we intend to closely scrutinize any individuals we engage after our initial business combination,
we cannot assure you that our assessment of these individuals will prove to be correct. These individuals may be unfamiliar with the requirements
of operating a company regulated by the SEC, which could cause us to have to expend time and resources helping them become familiar with
such requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our key personnel may negotiate employment
or consulting agreements with a target business in connection with a particular business combination, and a particular business combination
may be conditioned on the retention or resignation of such key personnel. These agreements may provide for them to receive compensation
following our initial business combination and as a result, may cause them to have conflicts of interest in determining whether a particular
business combination is the most advantageous.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our key personnel may be able to remain with our
company after the completion of our initial business combination only if they are able to negotiate employment or consulting agreements
in connection with the business combination. Such negotiations would take place simultaneously with the negotiation of the business combination
and could provide for such individuals to receive compensation in the form of cash payments and/or our securities for services they would
render to us after the completion of the business combination. Such negotiations also could make such key personnel&#8217;s retention
or resignation a condition to any such agreement. The personal and financial interests of such individuals may influence their motivation
in identifying and selecting a target business, subject to their fiduciary duties under British Virgin Islands law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may have a limited ability to assess the
management of an alternate target business and, as a result, may complete our initial business combination with a target business whose
management may not have the skills, qualifications or abilities to manage a public company.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When evaluating the desirability of effecting our
initial business combination with a prospective target business including Exascale, our ability to assess the target business&#8217;s
management may be limited due to a lack of time, resources or information. Our assessment of the capabilities of the target business&#8217;s
management, therefore, may prove to be incorrect and such management may lack the skills, qualifications or abilities we suspected. Should
the target business&#8217;s management not possess the skills, qualifications or abilities necessary to manage a public company, the operations
and profitability of the post-combination business may be negatively impacted. Accordingly, any shareholders or warrant holders who choose
to remain shareholders or warrant holders following the business combination could suffer a reduction in the value of their securities.
Such shareholders or warrant holders are unlikely to have a remedy for such reduction in value unless they are able to successfully claim
that the reduction was due to the breach by our officers or directors of a duty of care or other fiduciary duty owed to them, or if they
are able to successfully bring a private claim under securities laws that the proxy solicitation or tender offer materials, as applicable,
relating to the business combination contained an actionable material misstatement or material omission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The officers and directors of an acquisition
candidate may resign upon completion of our initial business combination. The loss of a business combination target&#8217;s key personnel
could negatively impact the operations and profitability of our post-combination business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The role of an acquisition candidate&#8217;s key personnel
upon the completion of our initial business combination cannot be ascertained at this time. Although we contemplate that certain members
of an acquisition candidate&#8217;s management team will remain associated with the acquisition candidate following our initial business
combination, it is possible that members of the management of an acquisition candidate will not wish to remain in place.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our management may not be able to maintain control
of a target business after our initial business combination. We cannot provide assurance that, upon loss of control of a target business,
new management will possess the skills, qualifications, or abilities necessary to profitably operate such business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We will only complete such business combination if
the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling
interest in the target sufficient for us not to be required to register as an investment company under the Investment Company Act. We
will not consider any transaction that does not meet such criteria. Even if the post-transaction company owns 50% or more of the voting
securities of the target, our shareholders prior to the business combination may collectively own a minority interest in the post-business
combination company, depending on valuations ascribed to the target and us in the business combination. For example, we could pursue a
transaction in which we issue a substantial number of new Class A Ordinary Shares in exchange for all of the outstanding capital stock,
shares or other equity interests of a target. In this case, we would acquire a 100% interest in the target. However, as a result of the
issuance of a substantial number of new Class A Ordinary Shares, our shareholders immediately prior to such transaction could own less
than a majority of our outstanding Class A Ordinary Shares subsequent to such transaction. In addition, other minority shareholders may
subsequently combine their holdings resulting in a single person or group obtaining a larger share of the company&#8217;s shares than
we initially acquired. Accordingly, this may make it more likely that our management will not be able to maintain control of the target
business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Because of our history as a special purpose
acquisition company, the Business Combination may be subject to increased regulatory scrutiny, which could delay or prevent the completion
of the Business Combination.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The SEC has increased oversight over transaction involving
a special purpose acquisition company, and although we are no longer a special purpose acquisition company, our history as one may lead
to increased review and comments from the SEC, which could delay or prevent the completion of the Business Combination. Recent SEC enforcement
trends and proposed rule changes could also delay or prevent the completion of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Because of our history as a special purpose
acquisition company, the SEC may treat the Business Combination as an IPO of Exascale, subjecting us to heightened disclosure and liability
standards.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have an increased risk for liability and scrutiny,
including the type usually associated with an IPO and under Section 11 of the Securities Act for misstatements and omissions tied to financial
projections and forward-looking statements due to our history as a special purpose acquisition company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to BCAR and the Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Unless the context otherwise requires, all references
in this subsection to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to BCAR prior to the consummation
of the Business Combination.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Relating to our Search for, and Consummation
of or Inability to Consummate, a Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>BCAR
will be forced to liquidate the trust account if it cannot consummate a business combination by February 1, 2027 (or May 1, 2027 if the
sponsor exercises its three-month extension option). In the event of a liquidation, BCAR&#8217;s Public Shareholders will receive $[_]
per share and the BCAR Warrants will expire worthless.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If BCAR is
unable to consummate a business combination by February 1, 2027 (or May 1, 2027 if the sponsor exercises its three-month extension option)
and is forced to liquidate, then the per-share liquidation distribution for the outstanding Public Shares will be approximately $[_].
Furthermore, there will be no distribution with respect to the BCAR Warrants, which will expire worthless as a result of BCAR&#8217;s
failure to consummate a business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will
depend on loans from our Sponsor or management team or other equity investments or debt to complete our initial Business Combination.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March
31, 2026, we had cash of $243,576 to fund our working capital requirements. We believe that the funds available to us are not sufficient
to allow us to operate until we complete our Business Combination. We expect to incur significant costs in pursuit of our acquisition
plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">If we were required to seek
additional capital, we would need to borrow funds from our Sponsor, management team or other third parties to operate or may be forced
to liquidate. Neither our Sponsor, members of our management team nor any of their affiliates is under any obligation to advance funds
to us in such circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>The nominal purchase
price paid by the Sponsor and directors and officers of BCAR for the Founder Shares may significantly dilute the implied value of the
Public Shares in the event the parties complete an initial business combination. In addition, the value of the Founder Shares will be
significantly greater than the amount the Sponsor and directors and officers of BCAR paid to purchase such shares in the event the parties
complete an initial business combination, even if the Business Combination causes the trading price of the PubCo Class A Ordinary Common
Stock to materially decline.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The nominal purchase price
paid by the Sponsor and directors and officers of BCAR for the Founder Shares may significantly dilute the implied value of the Public
Shares in the event BCAR completes an initial business combination. The dilution would increase to the extent that Public Shareholders
seek redemptions from the trust account for their Public Shares. In addition, the value of the Founder Shares will be significantly greater
than the amount the Sponsor and directors and officers of BCAR paid to purchase such shares in the event we complete an initial business
combination, even if the Business Combination causes the trading price of the PubCo Class A Ordinary Common Stock to materially decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Sponsor invested an
aggregate of $2,025,000 in BCAR, comprised of the $25,000 purchase price for the Founder Shares and $2,000,000 purchase price for the
Private Units. The amount held in BCAR&#8217;s trust account was approximately $[_] on the Record Date, implying a value of $[_] per public
share. Based on these assumptions, each PubCo Class A Ordinary Common Stock would have an implied value of $[_] per share upon consummation
of the Business Combination, representing a [_]% decrease from the initial implied value of $[_] per public share. While the implied value
of $[_] per share upon consummation of the Business Combination would represent a dilution to our Public Shareholders, this would represent
a significant increase in value for the Sponsor relative to the price it paid for each Insider Share. At approximately $[_] per share,
the 2,875,000 shares of PubCo Class A Ordinary Common Stock that the Sponsor would own upon consummation of the Business Combination would
have an aggregate implied value of $[_]. As a result, even if the trading price of the PubCo Class A Ordinary Common Stock significantly
declines, the value of the PubCo Class A Ordinary Common Stock held by the Sponsor will be significantly greater than the amount the Sponsor
paid to purchase such shares. In addition, the Sponsor and directors and officers of BCAR could potentially recoup their entire investment,
inclusive of their investment in the Private Units, even if the trading price of the PubCo Class A Ordinary Common Stock after the initial
business combination is as low as $[_] per share. As a result, the Sponsor is likely to earn a substantial profit on its investment upon
disposition of the PubCo Class A Ordinary Common Stock even if the trading price of the PubCo Class A Ordinary Common Stock declines after
the consummation of the Business Combination. The Sponsor and directors and officers of BCAR may therefore be economically incentivized
to complete an initial business combination with a riskier, weaker-performing or less-established target business, or on terms less favorable
to the Public Shareholders, rather than liquidating BCAR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>If third parties bring
claims against BCAR, the proceeds held in trust could be reduced and the per-share liquidation price received by BCAR&#8217;s shareholders
may be less than $10.00.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">BCAR&#8217;s placing of
funds in trust may not protect those funds from third party claims against BCAR. Although BCAR has received from many of BCAR&#8217;s
vendors, service providers (other than its independent accountants) and the companies BCAR considered acquiring and with which it entered
into non-disclosure agreements, including Holdings and the other potential business combination candidates disclosed under the section
entitled &#8220;<i>Proposal No. 1 &#8211; The Business Combination Proposal &#8211;Background of the Business Combination</i>,&#8221;
executed agreements waiving any right, title, interest or claim of any kind in or to any monies held in the trust account for the benefit
of BCAR&#8217;s Public Shareholders, they may still seek recourse against the trust account. Additionally, a court may not uphold the
validity of such agreements. Accordingly, the proceeds held in trust could be subject to claims which could take priority over those of
BCAR&#8217;s Public Shareholders. If BCAR liquidates the trust account before the completion of a business combination and distributes
the proceeds held therein to its Public Shareholders, the Sponsor has contractually agreed that it will be liable to ensure that the proceeds
in the trust account are not reduced by the claims of target businesses or claims of vendors or other entities that are owed money by
us for services rendered or contracted for or products sold to us, but only if such a vendor or prospective target business does not execute
such a waiver. However, BCAR cannot assure you that the Sponsor will be able to meet such obligation. Therefore, the per-share distribution
from the trust account for our shareholders may be less than $10.00 due to such claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Additionally, if BCAR is
forced to file a bankruptcy case or an involuntary bankruptcy case is filed against it which is not dismissed, the proceeds held in the
trust account could be subject to applicable bankruptcy law, and may be included in BCAR&#8217;s bankruptcy estate and subject to the
claims of third parties with priority over the claims of its shareholders. To the extent any bankruptcy claims deplete the trust account,
BCAR may not be able to return $10.00 per-share to our Public Shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Any
distributions received by BCAR shareholders could be viewed as an unlawful payment if it was proved that immediately following the date
on which the distribution was made, the value of BCAR&#8217;s liabilities exceeds its assets and/or BCAR was unable to pay its debts as
they fell due.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">BCAR&#8217;s
Current Charter provides that it will continue in existence only until February 1, 2027 (or May 1, 2027 if the sponsor exercises its three-month
extension option). If BCAR is unable to consummate a transaction within the required time periods, upon notice from BCAR, the trustee
of the trust account will distribute the amount in its trust account to its Public Shareholders. Concurrently, BCAR shall pay, or reserve
for payment, from funds not held in trust, its liabilities and obligations, although BCAR cannot assure you that there will be sufficient
funds for such purpose. If there are insufficient funds held outside the trust account for such purpose, the Sponsor has contractually
agreed that, if it liquidates prior to the consummation of a business combination, the Sponsor will be liable to ensure that the proceeds
in the trust account are not reduced by the claims of target businesses or claims of vendors or other entities that are owed money by
BCAR for services rendered or contracted for or products sold to it, but only if such a vendor or prospective target business does not
execute such a waiver.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Thereafter,
BCAR&#8217;s sole business purpose will be to dissolve through the voluntary liquidation procedure under the Cayman Companies Act. In
such a situation under the Cayman Companies Act, a liquidator would be appointed and within 28 days of the commencement of a voluntary
winding up, the liquidator shall file a notice of winding up with the Registrar of Companies; file the liquidator&#8217;s consent to act
with the Registrar of Companies, file the declaration of solvency made by the directors with the Registrar of Companies, and publish notice
of the winding up in the Gazette. As soon as the affairs of BCAR are fully wound-up, the liquidator must make a report and an account
of the winding up showing how it has been conducted and how the Company&#8217;s property has been disposed of and thereupon shall call
an Extraordinary General Meeting of BCAR for the purpose of laying before it the account and giving an explanation for it. At least 21
days before the meeting the liquidator shall send a notice specifying the time, place and object of the meeting to each contributory in
any manner authorized by BCAR&#8217;s Current Charter and published in the Gazette. The liquidator shall no later than 7 days after the
meeting, make a return to the Registrar of Companies in the prescribed form specifying the date on which the meeting was held; and if
a quorum was present, particulars of the resolutions, if any, passed at the meeting. The Registrar of Companies shall, within three days
of receiving a liquidator&#8217;s return, register such return and upon the expiration of three months from the registration of the return
BCAR is deemed to be dissolved. It is BCAR&#8217;s intention to liquidate the trust account to its Public Shareholders as soon as reasonably
possible and BCAR&#8217;s Insiders have agreed to take any such action necessary to liquidate the trust account and to dissolve BCAR as
soon as reasonably practicable if BCAR does not consummate a business combination within the required time period. Pursuant to BCAR&#8217;s
Current Charter, failure to consummate a business combination by February 1, 2027 (or May 1, 2027 if the sponsor exercises its three-month
extension option) will trigger an automatic winding up of BCAR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If BCAR is forced to enter
into an insolvent liquidation, then any distributions received by BCAR shareholders could be viewed as an unlawful payment if it was proved
that immediately following the date on which the distribution was made the value of BCAR&#8217;s liabilities exceeds its assets and/or
BCAR was unable to pay its debts as they fell due. As a result, a liquidator could seek to recover all amounts received by BCAR&#8217;s
shareholders. Furthermore, BCAR&#8217;s board may be viewed as having breached their fiduciary duties to its creditors and/or may have
acted in bad faith, and thereby exposing itself and BCAR to claims of damages, by paying Public Shareholders from the trust account prior
to addressing the claims of creditors. BCAR cannot assure you that claims will not be brought against it for these reasons.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes in laws or regulations, or a failure
to comply with any laws and regulations, may adversely affect our business, including our ability to negotiate and complete our initial
business combination, and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are subject to laws and regulations enacted by
national, regional and local governments. In particular, we are required to comply with certain SEC and other legal requirements. Compliance
with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly. Those laws and regulations, and
their interpretation and application, may also change from time to time and those changes could have a material adverse effect on our
business, investments and results of operations. In addition, a failure to comply with applicable laws or regulations, as interpreted
and applied, could have a material adverse effect on our business, including our Business Combination or another business combination,
and our results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If BCAR&#8217;s due diligence investigation
of Exascale was inadequate, then shareholders of BCAR following the Business Combination could lose some or all of their investment.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even though BCAR conducted a due diligence investigation
of Exascale, it cannot be sure that this diligence uncovered all material issues that may be present inside Exascale, or that it would
be possible to uncover all material issues through a customary amount of due diligence, or that factors outside of Exascale&#8217;s and
outside of its control will not later arise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Our use of valuation
benchmarking as the sole methodology in the determination of Exascale&#8217;s enterprise value, and our reliance on a peer group of comparable
companies comprised of companies with significantly larger market capitalization, longer operating histories, and greater revenues than
Exascale, may result in an inaccurate assessment of Exascale&#8217;s fair value.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In determining the valuation
of Exascale, we relied exclusively on a valuation benchmarking analysis that compared Exascale to a group of publicly traded companies.
Many of the companies included in this peer group have substantially greater market capitalizations, longer operating histories, and significantly
higher revenues than Exascale. As a result, these comparables may not accurately reflect Exascale&#8217;s current stage of development,
risk profile, or market position. The absence of alternative valuation methodologies in our financial analysis of Exascale increases the
risk that our valuation of Exascale may not accurately reflect Exascale&#8217;s intrinsic value or the price at which similar companies
might transact in the market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the valuation benchmarking analysis did not
appropriately capture the unique characteristics or risks associated with Exascale, investors&#8217; assessment of the potential benefits
of the Business Combination may be inaccurate. In addition, should the actual value of Exascale ultimately prove to be significantly lower
than the value determined by our valuation benchmarking analysis, such an outcome could negatively impact our financial results and the
market price of our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>You will be unable to ascertain the merits or
risks of any particular target business&#8217;s operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon completion of the Business Combination, we
will be affected by the risks inherent in the business and operations of our target entity. Although our officers and directors will endeavor
to evaluate the risks inherent in a particular target business, we cannot assure you that we will properly ascertain or assess all of
the significant risk factors or that we will have adequate time to complete due diligence. Furthermore, some of these risks may be outside
of our control and leave us with no ability to control or reduce the chances that those risks will adversely impact a target business.
We also cannot assure you that an investment in our BCAR Class A Ordinary Shares will ultimately prove to be more favorable to investors
than a direct investment, if such opportunity were available a business combination target. Accordingly, any shareholders or warrant holders
who choose to remain shareholders or warrant holders following the business combination could suffer a reduction in the value of their
securities. Such shareholders or warrant holders are unlikely to have a remedy for such reduction in value unless they are able to successfully
claim that the reduction was due to the breach by our officers or directors of a duty of care or other fiduciary duty owed to them, or
if they are able to successfully bring a private claim under securities laws that the proxy materials or tender offer documents, as applicable,
relating to the business combination contained an actionable material misstatement or material omission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may issue notes or other debt securities,
or otherwise incur substantial debt, to complete a business combination, which may adversely affect our leverage and financial condition
and thus negatively impact the value of our shareholders&#8217; investment in us.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may choose to incur additional debt to complete
an initial business combination. The incurrence of debt could have a variety of negative effects, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">default and foreclosure on our assets if our
        operating revenues after an initial business combination are insufficient to repay our debt obligations;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">acceleration of our obligations to repay the
        indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance
        of certain financial ratios or reserves with-out a waiver or renegotiation of that covenant;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">our immediate payment of all principal and
        accrued interest, if any, if the debt is payable on demand;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">our inability to obtain necessary additional
        financing if the debt contains covenants restricting our ability to obtain such financing while the debt is outstanding;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">our inability to pay dividends on our Class
        A Ordinary Shares;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">using a substantial portion of our cash flow
        to pay principal and interest on our debt, which will reduce the funds available for dividends on our Class A Ordinary Shares if declared,
        expenses, capital expenditures, acquisitions and other general corporate purposes;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">limitations on our flexibility in planning
        for and reacting to changes in our business and in the industry in which we operate;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">increased vulnerability to adverse changes
        in general economic, industry and competitive conditions and adverse changes in government regulation; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">limitations on our ability to borrow additional
        amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and
        other disadvantages compared to our competitors who have less debt.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we do not complete the Business Combination
with Exascale, we may seek acquisition opportunities with an early-stage company, a financially unstable business or an entity lacking
an established record of revenue or earnings.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While we intend on completing our Business Combination
with Exascale, if we do not and we complete our initial business combination with an early-stage company, a financially unstable business
or an entity lacking an established record of sales or earnings, we may be affected by numerous risks inherent in the operations of the
business with which we combine. These risks include investing in a business without a proven business model and with limited historical
financial data, volatile revenues or earnings, intense competition and difficulties in obtaining and retaining key personnel. Although
our officers and directors will endeavor to evaluate the risks inherent in a particular target business, we may not be able to properly
ascertain or assess all of the significant risk factors and we may not have adequate time to complete due diligence. Furthermore, some
of these risks may be outside of our control and leave us with no ability to control or reduce the chances that those risks will adversely
impact a target business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have entered into a Business Combination
Agreement with a private company about which little information is available, which may result in a business combination with a company
that is not as profitable as we suspected, if at all.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into a Business Combination Agreement
with a privately held company, about which limited public information is available. As a result, we may have made, and may continue to
rely on, decisions regarding the Business Combination based on incomplete information, which could result in the consummation of a transaction
with a company that will be less profitable than anticipated (if at all) or that fails to achieve the projections or assumptions on which
our valuation was based.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale is a privately held company. Because
there is generally limited publicly available information regarding private companies, our evaluation of the Business Combination was,
and continues to be, based on limited information and assumptions. Accordingly, the Business Combination may not result in a combined
company that does not perform in line with expectations at the time of signing the Business Combination Agreement or that does not achieve
the financial or operational projections used in connection with our assessment of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we do not complete our Business Combination
with Exascale, we may seek business combination opportunities with a high degree of complexity that require significant operational improvements,
which could delay or prevent us from achieving our desired results.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may seek business combination opportunities with
large, highly complex companies that we believe would benefit from operational improvements. To the extent we were unable to implement
such improvements or our efforts are delayed or we are unable to achieve the desired improvements, the business combination may not be
as successful as we anticipate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent we complete an initial business
combination with a large complex business or entity with a complex operating structure, we may also be affected by numerous risks inherent
in the operations of the business with which we combine, which could delay or prevent us from implementing our strategy. Although our
management team will endeavor to evaluate the risks inherent in a particular target business and its operations, we may not be able to
properly ascertain or assess all of the significant risk factors until we complete our business combination. If we are not able to achieve
our desired operational improvements, or the improvements take longer to implement than anticipated, we may not achieve the gains that
we anticipate. Furthermore, some of these risks and complexities may be outside of our control and leave us with no ability to control
or reduce the chances that those risks and complexities will adversely impact a target business. Such combination may not be as successful
as a combination with a smaller, less complex organization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Certain agreements related to our IPO may
be amended without shareholder approval.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the
agreements related to our IPO to which we are a party, other than the Warrant Agreement and the investment management trust agreement,
may be amended without shareholder approval. Such agreements are: (i) the underwriting agreement; (ii) the letter agreement among us and
our Sponsor, officers and directors; and (iii) the registration rights agreement among us and our Insiders; (iv) the private placement
warrants purchase agreement between us and our sponsor. These agreements contain various provisions that our Public Shareholders might
deem to be material. For example, our letter agreement and the contains certain lock-up provisions with respect to the Founder Shares,
Private Placement Warrants and other securities held by our Insiders. Amendments to such agreements would require the consent of the applicable
parties thereto and would need to be approved by our board of directors, which may do so for a variety of reasons, including facilitating
our initial business combination. It may be possible that our board of directors, in exercising its business judgment and subject to its
fiduciary duties, chooses to approve one or more amendments to any such agreement. Any amendment entered into in connection with the consummation
of our Business Combination will be disclosed in our proxy materials or tender offer documents, as applicable, related to such initial
business combination, and any other material amendment to any of our material agreements will be disclosed in a filing with the SEC. Any
such amendments would not require approval from our shareholders, may result in the completion of the Business Combination that may not
otherwise have been possible, and may have an adverse effect on the value of an investment in our securities. Such agreements may have
an adverse effect on the price of our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may be unable to obtain additional financing
to complete the Business Combination or any alternate business combination or to fund the operations and growth of a target business,
which could compel us to restructure or abandon a particular business combination.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the Business
Combination Agreement, we have agreed to obtain an investment of equity or debt securities of an amount of at least $5.0 million unless
such requirement is waived by Exascale. If the Minimum Cash Financing is not met, and such condition is not waived by Exascale under the
terms of the Business Combination Agreement, the proposed Business Combination will not be consummated. In the event that the Business
Combination will not be consummated, all Public Shares submitted for redemption will be returned to the holders thereof, and we may instead
search for an alternate business combination or liquidate BCAR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additional financing
above the Minimum Cash Financing may be required to fund the operations and growth of the post-closing business. The failure to secure
such additional financing could have a material adverse effect on the continued development or growth of the target business in the future.
None of our officers, directors or shareholders is required to provide any financing to us in connection with or after our Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Activities taken by existing BCAR shareholders
to increase the likelihood of approval of the Business Combination Proposal and the other proposals described in this proxy statement/prospectus
could have a depressive effect on BCAR&#8217;s shares.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time prior to the Extraordinary General
Meeting, during a period when they are not then aware of any material nonpublic information regarding BCAR or its securities, the Sponsor,
directors, officers, advisors or any of their respective affiliates and/or their respective affiliates may purchase shares from institutional
and other investors who vote, or indicate an intention to vote, against the Business Combination Proposal, or execute agreements to purchase
such shares from such investors in the future, or they may enter into transactions with such investors and others to provide them with
incentives to acquire shares of BCAR Class A Ordinary Shares or vote their shares in favor of the Business Combination Proposal. The purpose
of such share purchases and other transactions would be to increase the likelihood of satisfaction of the requirements to consummate the
Transactions where it appears that such requirements would otherwise not be met in connection with the consummation of the Business Combination.
Entering into any such arrangements may have a depressive effect on BCAR Class A Ordinary Shares. For example, as a result of these arrangements,
an investor or holder may have the ability to effectively purchase shares at a price lower than market and may therefore be more likely
to sell the shares they own, either prior to or immediately after the Extraordinary General Meeting. As of the date of this proxy statement,
no such transactions have occurred nor are they planned to occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>All of BCAR&#8217;s officers and directors
own BCAR Shares and BCAR Warrants which will not participate in liquidation distributions and, therefore, they may have a conflict of
interest in determining whether the business combination is appropriate.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of BCAR&#8217;s Insiders, including its officers
and directors directly or indirectly own an aggregate of 12,000,000 Founder Shares, 200,000 Private Units and 1,000,000 Class A Ordinary
Shares. Pursuant to the letter agreement, dated July 30, 2025, by and among BCAR and our Insiders, our Insiders agreed, for no additional
consideration, to waive their right to redeem these shares, or to receive distributions with respect to these shares upon the liquidation
of the trust account if BCAR is unable to consummate a business combination. Accordingly, the BCAR Shares, as well as the BCAR Units purchased
by our officers or directors, will be worthless if BCAR does not consummate a business combination. Based on a market price of $[_] per
one Public Share on [_], 2026, and $[_] per one BCAR Warrant on [_], 2026, the value of these shares and units was approximately $[_].
The BCAR Shares acquired prior to the IPO, as well as the BCAR Units will be worthless if BCAR does not consummate a business combination.
Consequently, our directors&#8217; and officers&#8217; discretion in identifying and selecting Exascale as a suitable target business
may result in a conflict of interest when determining whether the terms, conditions and timing of the Business Combination are appropriate
and in BCAR&#8217;s shareholders&#8217; best interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>BCAR is requiring shareholders who wish
to redeem their Class A Ordinary Shares in connection with a proposed business combination to comply with specific requirements for redemption
that may make it more difficult for them to exercise their redemption rights prior to the deadline for exercising their rights.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR is requiring Public Shareholders who wish
to redeem their Class A Ordinary Shares to either tender their certificates to our Transfer Agent at any time at or prior to the Extraordinary
General Meeting or to deliver their shares to the Transfer Agent electronically using the Depository Trust Company&#8217;s, or DTC, DWAC
(deposit/withdrawal at custodian) system. In order to obtain a physical certificate, a shareholder&#8217;s broker and/or clearing broker,
DTC and BCAR&#8217;s Transfer Agent will need to act to facilitate this request. It is BCAR&#8217;s understanding that shareholders should
generally allot at least two weeks to obtain physical certificates from the Transfer Agent. However, because we do not have any control
over this process or over the brokers or DTC, it may take significantly longer than two weeks to obtain a physical stock certificate.
While we have been advised that it takes a short time to deliver shares through the DWAC system, we cannot assure you of this fact. Accordingly,
if it takes longer than BCAR anticipates for shareholders to deliver their Class A Ordinary Shares, shareholders who wish to redeem may
be unable to meet the deadline for exercising their redemption rights and thus may be unable to redeem their Class A Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>BCAR will require its Public Shareholders
who wish to redeem their Class A Ordinary Shares in connection with the Business Combination to comply with specific requirements for
redemption described above, such redeeming shareholders may be unable to sell their securities when they wish to in the event that the
Business Combination is not consummated.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If BCAR requires
Public Shareholders who wish to redeem their Class A Ordinary Shares in connection with the proposed Business Combination to comply with
specific requirements for redemption as described above and the Business Combination is not consummated, BCAR will promptly return such
certificates to its Public Shareholders. Accordingly, investors who attempted to redeem their Class A Ordinary Shares in such a circumstance
will be unable to sell their securities after the failed acquisition until BCAR has returned their securities to them. The market price
for Public Shares may decline during this time, and holders of such shares may not be able to sell their securities when they wish to,
even while other shareholders that did not seek redemption may be able to sell their securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sponsor and the officers and directors of BCAR
control a substantial interest in us and thus may exert a substantial influence on actions requiring a shareholder vote, potentially in
a manner that you do not support.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sponsor and the officers and directors of BCAR own
approximately 32.0% of our issued and outstanding ordinary shares. Accordingly, they may exert a substantial influence on actions requiring
a shareholder vote, potentially in a manner that you do not support, including amendments to our Current Charter. If our Insiders purchase
any additional Class A Ordinary Shares in the aftermarket or in privately negotiated transactions, this would increase their control.
Neither our Sponsor, nor, to our knowledge, any of our officers or directors, have any current intention to purchase additional securities.
Factors that would be considered in making such additional purchases would include consideration of the current trading price of our Class
A Ordinary Shares. In addition, our board of directors, whose members were elected by our Sponsor, is divided into three classes, each
of which will generally serve for a term of three years with only one class of directors being elected in each year. We may not hold an
annual general meeting to elect new directors prior to the completion of our initial business combination, in which case all of the current
directors will continue in office until at least the completion of our initial business combination. If there is an annual general meeting,
as a consequence of our &#8220;staggered&#8221; board of directors, only a minority of the board of directors will be considered for election
and our Insiders, because of their ownership position, will have considerable influence regarding the outcome. In addition, prior to the
completion of an initial business combination, holders of a majority of our Founder Shares may remove a member of the board of directors
for any reason. Accordingly, our Insiders will continue to exert control at least until the completion of our initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Compliance obligations under the Sarbanes-Oxley
Act may make it more difficult for us to effectuate our initial business combination, require substantial financial and management resources,
and increase the time and costs of completing an initial business combination.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Section&#160;404 of the Sarbanes-Oxley Act requires
that we evaluate and report on our system of internal controls beginning with our Annual Report on Form 10-K for the year ending December&#160;31,
2026. Only in the event we are deemed to be a large accelerated filer or an accelerated filer, and no longer qualify as an emerging growth
company, will we be required to comply with the independent registered public accounting firm attestation requirement on our internal
control over financial reporting. Further, for as long as we remain an emerging growth company, we will not be required to comply with
the independent registered public accounting firm attestation requirement on our internal control over financial reporting. The fact that
we are a blank check company makes compliance with the requirements of the Sarbanes-Oxley Act particularly burdensome on us as compared
to other public companies because a target business with which we seek to complete our initial business combination may not be in compliance
with the provisions of the Sarbanes-Oxley Act regarding adequacy of its internal controls. The development of the internal control of
any such entity to achieve compliance with the Sarbanes-Oxley Act may increase the time and costs necessary to complete any such business
combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes in the market for directors&#8217; and
officers&#8217; liability insurance could make it more difficult and more expensive for us to negotiate and complete an initial business
combination.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Over the past year, the market for directors&#8217;
and officers&#8217; liability insurance for special purpose acquisition companies has changed. Fewer insurance companies are offering
quotes for directors and officers liability coverage, the premiums charged for such policies have generally increased and the terms of
such policies have generally become less favorable. There can be no assurance that these trends will not continue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The increased cost and decreased availability of directors&#8217;
and officers&#8217; liability insurance could make it more difficult and more expensive for us to negotiate an initial business combination.
In order to obtain directors and officers liability insurance or modify its coverage as a result of becoming a public company, the post-business
combination entity might need to incur greater expense, accept less favorable terms or both. However, any failure to obtain adequate directors&#8217;
and officers&#8217; liability insurance could have an adverse impact on the post-business combination&#8217;s ability to attract and retain
qualified officers and directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, even after we were to complete an initial
business combination, our directors and officers could still be subject to potential liability from claims arising from conduct alleged
to have occurred prior to the initial business combination. As a result, in order to protect our directors and officers, the post-business
combination entity may need to purchase additional insurance with respect to any such claims, or run-off insurance. The need for run-off
insurance would be an added expense for the post-business combination entity and could interfere with or frustrate our ability to consummate
an initial business combination on terms favorable to our investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Becoming a public company through a merger
rather than an underwritten offering presents risks to unaffiliated investors. Subsequent to the completion of the Business Combination,
PubCo may be required to subsequently take write-downs or write-offs, restructuring and impairment or other charges that could have a
significant negative effect on its financial condition, results of operations and the price of PubCo&#8217;s securities, which could cause
PubCo&#8217;s shareholders to lose some or all of their investment.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Becoming a public company through a merger rather
than an underwritten offering, as Exascale is seeking to do, presents risks to unaffiliated investors. Such risks include the absence
of a due diligence investigation conducted by an underwriter that would be subject to liability for any material misstatements or omissions
in a registration statement. As a result, PubCo may be forced to later write down or write off assets, restructure its operations, or
incur impairment or other charges that could result in it reporting losses. Additionally, unexpected risks may arise and previously known
risks may materialize. Even though these charges may be non-cash items and not have an immediate impact on PubCo&#8217;s liquidity, the
fact that PubCo reports charges of this nature could contribute to negative market perceptions about the post-combination company or its
securities. In addition, charges of this nature may cause PubCo to be unable to obtain future financing on favorable terms or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The BCAR Board did not obtain a fairness
opinion (or any similar report or appraisal) in connection with its determination to approve the Business Combination (including the consideration
to be delivered to Exascale securityholders under the terms of the Business Combination Agreement).</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In part because fairness opinions or any similar
reports or appraisals ordinarily rely in part on financial projections (which were neither prepared by Exascale nor used by the BCAR Board
in connection with its evaluation of the proposed Business Combination), the BCAR Board also did not obtain a fairness opinion (or any
similar report or appraisal) in connection with its determination to approve the Business Combination (including the consideration to
be paid to the Exascale securityholders under the terms of the Business Combination Agreement). Accordingly, investors in BCAR will be
relying solely on the judgment of the BCAR Board in valuing Exascale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR&#8217;s management and the members of the BCAR
Board have substantial experience evaluating the financial merits of companies across a variety of industries, including eCommerce and
other consumer-oriented businesses, which the BCAR Board concluded enabled them to make the necessary analyses and determinations regarding
the Business Combination. See &#8220;<i>Background of the Business Combination</i>&#8221; section of this proxy statement/prospectus,
including the subsection &#8220;&#8220;<i>BCAR Board of Directors&#8221; Reasons for the Approval of the Business Combination</i>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR&#8217;s financial analyses included, among other
materials, (i) certain Exascale historical unaudited financial and operating history information; (ii) analysis of market opportunities,
adoption rates, and overall opportunity relative to other dynamic growth opportunities in the greater AI sector; and (iii) prospective
partnerships and U.S. expansion opportunities, particularly with the sustainable data center site project in the Permian Basin.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investors are also encouraged to read carefully the
descriptions about various risks and uncertainties concerning Exascale&#8217;s business described herein, including under the headings
&#8220;<i>Risk Factors</i>,&#8221; &#8220;<i>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations
of Exascale</i>&#8221; and &#8220;<i>Cautionary Note Regarding Forward-Looking Statements</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because, as described
above, BCAR did not obtain an opinion from an independent third-party valuation firm as to the fairness of the proposed Business Combination
to BCAR from a financial point of view, the BCAR Board may not have properly valued Exascale. As a result, the terms of the proposed Business
Combination may not be fair from a financial point of view to the Public Shareholders of BCAR. Uncertainty about BCAR Board&#8217;s valuation
of Exascale or the consideration being offered to the Exascale stockholders in the Business Combination, may lead to an increased number
of BCAR shareholders to vote against the Business Combination, which could potentially impact BCAR&#8217;s ability to consummate the Business
Combination. Further, investors are encouraged to read carefully the descriptions about various risks and uncertainties concerning Exascale&#8217;s
business described in this proxy statement/prospectus, including under the headings &#8220;<i>Risk Factors</i>,&#8221; &#8220;<i>Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations of Exascale</i>&#8221; and &#8220;<i>Cautionary Note Regarding
Forward-Looking Statements</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The 1% U.S. federal excise tax may be imposed
on us in connection with redemptions of our Public Shares.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to certain exceptions, Section 4501 of
the Code imposes a 1% excise tax on any publicly traded domestic corporation that repurchases its stock (the &#8220;<b>Excise Tax</b>&#8221;).
Because we will be a Delaware corporation as a result of the Domestication Merger, and because our securities may trade on Nasdaq, we
expect to be a &#8220;covered corporation&#8221; within the meaning of Section 4501 of the Code. Thus, it is possible that we will be
subject to the Excise Tax with respect to any subsequent redemptions, including redemptions in connection with the Business Combination
that are treated as repurchases for this purpose. However, subject to certain exceptions, the Excise Tax should not apply in the event
of our complete liquidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Excise Tax is generally imposed on the fair
market value of the repurchased stock. Further, issuances of shares by a repurchasing corporation in a year in which such corporation
repurchases shares may reduce the amount of Excise Tax imposed with respect to such repurchase. The Excise Tax is imposed on the repurchasing
corporation itself, not the shareholders from which shares are repurchased. The imposition of the Excise Tax as a result of redemptions
in connection with the Business Combination, if any, could reduce the amount of cash available to pay redemptions, which could cause the
shareholders of the combined company to economically bear the impact of such Excise Tax. The extent of the Excise Tax that may be incurred
will depend on a number of factors, including the fair market value of our shares redeemed, the extent to which such redemptions could
be treated as dividends and not repurchases, and the interpretation of the final Treasury Regulations and other additional guidance from
the U.S. Treasury that may be issued and applicable to the redemptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although the final Treasury Regulations clarify
certain aspects of the Excise Tax, the interpretation and operation of certain other aspects of the Excise Tax remain unclear. Moreover,
because these regulations are subject to varying interpretations, their application in practice may evolve over time as new guidance becomes
available. The application of the Excise Tax to our particular circumstances is complex and may be subject to uncertainty, and there cannot
be any assurance that the Excise Tax will not apply to redemptions of our Public Shares in connection with the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><b>Risks Relating to our Management
Team</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may not have sufficient funds to satisfy
indemnification claims of our directors and executive officers.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have agreed to indemnify our officers, directors
and advisors to the fullest extent permitted by law. However, any indemnification provided will be able to be satisfied by us only if
we have sufficient funds. Our obligation to indemnify our officers and directors may discourage shareholders from bringing a lawsuit against
our officers or directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of
derivative litigation against our officers and directors, even though such an action, if successful, might otherwise benefit us and our
shareholders. Furthermore, a shareholder&#8217;s investment may be adversely affected to the extent we pay the costs of settlement and
damage awards against our officers and directors pursuant to these indemnification provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Past performance by our management team and
their affiliates may not be indicative of future performance of an investment in us.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Information regarding
performance by, or businesses associated with, our management team or businesses associated with them is presented for informational purposes
only. Past performance by our management team is not a guarantee either (i) of success with respect to any business combination we may
consummate or (ii) that we will be able to locate a suitable candidate for our initial business combination. You should not rely on the
historical record of the performance of our management team&#8217;s or businesses associated with them as indicative of our future performance
of an investment in us or the returns we will, or are likely to, generate going forward.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we do not complete the Business Combination,
we may seek business combination opportunities in industries or sectors that may be outside of our management&#8217;s areas of expertise.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we do not complete the Business Combination, we
may consider a business combination outside of our management&#8217;s areas of expertise if a business combination candidate is presented
to us and we determine that such candidate offers an attractive business combination opportunity for our company. Although our management
will endeavor to evaluate the risks inherent in any particular business combination candidate, we cannot assure you that we will adequately
ascertain or assess all of the significant risk factors. We also cannot assure you that an investment in our securities will not ultimately
prove to be less favorable than a direct investment, if an opportunity were available, in a business combination candidate. In the event
we elect to pursue a business combination outside of the areas of our management&#8217;s expertise, our management&#8217;s expertise may
not be directly applicable to its evaluation or operation, and the information contained in this proxy statement/prospectus regarding
the areas of our management&#8217;s expertise would not be relevant to an understanding of the business that we elect to acquire. As a
result, our management may not be able to ascertain or assess adequately all of the relevant risk factors. Accordingly, any shareholders
who choose to remain shareholders following our initial business combination could suffer a reduction in the value of their shares. Such
shareholders are unlikely to have a remedy for such reduction in value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are dependent upon our executive officers
and directors and their loss could adversely affect our ability to operate.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operations are dependent upon a relatively small
group of individuals and, in particular, our executive officers and directors. We believe that our success depends on the continued service
of our officers and directors, at least until we have completed our initial business combination. In addition, our executive officers
and directors are not required to commit any specified amount of time to our affairs and, accordingly, will have conflicts of interest
in allocating their time among various business activities, including identifying potential business combinations and monitoring the related
due diligence. We do not have an employment agreement with, or key-man insurance on the life of, any of our directors or executive officers.
The unexpected loss of the services of one or more of our directors or executive officers could have a detrimental effect on us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our executive officers and directors will allocate
their time to other businesses thereby causing conflicts of interest in their determination as to how much time to devote to our affairs.
This conflict of interest could have a negative impact on our ability to complete our initial business combination.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our executive officers and directors are not required
to, and will not, commit their full time to our affairs, which may result in a conflict of interest in allocating their time between our
search for an initial business combination target and their other businesses. We do not intend to have any full-time employees prior to
the completion of our initial business combination. Each of our executive officers is engaged in several other business endeavors for
which he or she may be entitled to substantial compensation, and our executive officers are not obligated to contribute any specific number
of hours per week to our affairs. Our independent directors also serve as officers and board members for other entities. If our executive
officers&#8217; and directors&#8217; other business affairs require them to devote substantial amounts of time to such affairs in excess
of their current commitment levels, it could limit their ability to devote time to our affairs which may have a negative impact on our
ability to complete our initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our officers and directors presently have, and
any of them in the future may have additional, fiduciary or contractual obligations to other entities and, accordingly, may have conflicts
of interest in determining to which entity a particular business opportunity should be presented.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each of our officers and directors presently has,
and any of them in the future may have, additional fiduciary or contractual obligations to other entities pursuant to which such officer
or director is or will be required to present a business combination opportunity to such entity. Accordingly, they may have conflicts
of interest in determining to which entity a particular business opportunity should be presented. These conflicts may not be resolved
in our favor and a potential target business may be presented to another entity prior to its presentation to us. Our Current Charter provides
that, to the fullest extent permitted by applicable law: (i) no individual serving as a director or an officer shall have any duty, except
and to the extent expressly assumed by contract, to refrain from engaging directly or indirectly in the same or similar business activities
or lines of business as us; and (ii) we renounce any interest or expectancy in, or in being offered an opportunity to participate in,
any potential transaction or matter which may be a corporate opportunity for any director or officer, on the one hand, and us, on the
other. Any such companies, businesses or ventures may present additional conflicts of interest in pursuing an initial business combination.
However, we do not believe that any such potential conflicts of interest would materially affect our ability to complete an initial business
combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Sponsor or officers may form other blank
check companies including special purpose acquisition corporations in the future, which may occur prior to our completing our Business
Combination and could cause conflicts of interest.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Sponsor or our officers may sponsor or form other
blank check companies including special purpose acquisition companies in the future, which may occur prior to completion of our Business
Combination. Any such companies may pursue similar targets and compete with us for business combination opportunities. Any such companies
may present additional conflicts of interest in pursuing an acquisition target, particularly in the event there is overlap among investment
mandates. Consequently, we may be precluded from procuring such opportunities and such opportunities may be presented to such other companies
instead of us. However, we do not currently expect any other blank check company would materially affect our ability to complete the Business
Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our executive officers, directors, security
holders and their respective affiliates may have competitive pecuniary interests that conflict with our interests.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have not adopted a policy that expressly prohibits
our directors, executive officers, security holders or affiliates from having a direct or indirect pecuniary or financial interest in
any investment to be acquired or disposed of by us or in any transaction to which we are a party or have an interest. In fact, if we do
not complete the Business Combination, we may enter into a business combination with a target business that is affiliated with our sponsor,
our directors or executive officers, although we do not intend to do so. Nor do we have a policy that expressly prohibits any such persons
from engaging for their own account in business activities of the types conducted by us. Accordingly, such persons or entities may have
a conflict between their interests and ours.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The personal and financial interests of our directors
and officers may influence their motivation in timely identifying and selecting a target business and completing a business combination.
Consequently, our directors&#8217; and officers&#8217; discretion in identifying and selecting a suitable target business may result in
a conflict of interest when determining whether the terms, conditions and timing of a particular business combination are appropriate
and in our shareholders&#8217; best interest. If this were the case, it would be a breach of their fiduciary duties to us as a matter
of British Virgin Islands law and we or our shareholders might have a claim against such individuals for infringing on our shareholders&#8217;
rights. However, we might not ultimately be successful in any claim we may make against them for such reason.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we do not complete the Business Combination,
we may engage in a business combination with one or more target businesses that have relationships with entities that may be affiliated
with our sponsor, executive officers, directors or existing holders which may raise potential conflicts of interest.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In light of the involvement of our Sponsor, executive
officers and directors with other entities, if we do not complete the Business Combination, we may decide to acquire one or more businesses
affiliated with our sponsor, executive officers, directors or existing holders. Our directors also serve as officers and board members
for other entities. Such entities may compete with us for business combination opportunities. Our Sponsor, officers and directors are
not currently aware of any specific opportunities for us to complete our initial business combination with any entities with which they
are affiliated, and there have been no substantive discussions concerning a business combination with any such entity or entities. Although
we will not be specifically focusing on, or targeting, any transaction with any affiliated entities, we would pursue such a transaction
if we determined that such affiliated entity met our criteria for a business combination and such transaction was approved by a majority
of our independent and disinterested directors. Potential conflicts of interest still may exist and, as a result, the terms of the business
combination may not be as advantageous to our Public Shareholders as they would be absent any conflicts of interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><b>Risks Relating to BCAR Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Holders of our Class A Ordinary Shares are not
entitled to vote on any appointment of directors prior to our initial business combination.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to our initial business combination, only holders
of our Class B Shares will have the right to vote on the appointment of directors. Holders of our Class A Ordinary Shares will not be
entitled to vote on the appointment of directors during such time. In addition, prior to the completion of an initial business combination,
holders of a majority of our Class B Shares may remove a member of the board of directors for any reason. Accordingly, you may not have
any say in the management of our company prior to the completion of an initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>An investment in our securities may result in
uncertain or adverse U.S. federal income tax consequences.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An investment in our securities may result in uncertain
U.S. federal income tax consequences. For instance, because there are no authorities that directly address instruments similar to the
units we issued in our IPO, the allocation an investor makes with respect to the purchase price of a unit between the Class A Share and
the one-half of a warrant to purchase one Class A Share included in each unit could be challenged by the Internal Revenue Service (the
&#8220;IRS&#8221;) or courts. Furthermore, the U.S. federal income tax consequences of a cashless exercise of warrants included in the
units we issued in our IPO is unclear under current law. Prospective investors are urged to consult their tax advisors with respect to
these and other tax consequences when purchasing, holding or disposing of our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>In the event that a significant number of
Public Shares are redeemed, the stock of PubCo may become less liquid following the Business Combination.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a significant
number of Public Shares are redeemed, PubCo may be left with a significantly smaller number of shareholders. As a result, trading in the
shares of PubCo following the Business Combination may be limited and your ability to sell your shares in the market could be adversely
affected. Nasdaq may not list PubCo Class A Ordinary Common Stock on its exchange, which could limit investors&#8217; ability to make
transactions in PubCo&#8217;s securities and subject BCAR to additional trading restrictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may be a controlled foreign corporation (CFC)
which could result in adverse U.S. federal income tax consequences to U.S. investors.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a U.S. shareholder owns 10% or more of our ordinary
shares, it may be subject to increased U.S. federal income taxation under the CFC rules. A non-U.S. corporation will be classified as
a CFC for any particular taxable year, if U.S. persons (including individuals and entities) who own (directly, indirectly, or constructively)
10% or more of the voting power or value of shares, or 10% U.S. Shareholders, own, in the aggregate, more than 50% of the total combined
voting power or value of the shares. In determining whether a shareholder is treated as a 10% U.S. Shareholder, the voting power of the
shares and any special voting rights, such as to appoint directors, may also be taken into account. In addition, certain constructive
ownership rules apply, which attribute share ownership among certain family members and certain entities and their owners. Such constructive
ownership rules may also attribute share ownership to persons that are entitled to acquire shares pursuant to an option. Shareholders
who own, or contemplate owning, 10% or more of our shares (taking into account the impact of any share repurchases we may undertake and
the constructive ownership rules) are urged to consult their tax advisors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Registration of the Class A Ordinary Shares
issuable upon exercise of the warrants under the Securities Act or any state securities laws may not be in place when an investor desires
to exercise warrants, thus precluding such investor from being able to exercise its warrants except on a cashless basis and potentially
causing such warrants to expire worthless.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the terms of the Warrant Agreement, we have
agreed that, as soon as practicable, but in no event later than 20 business days, after the closing of our initial business combination,
we will use commercially reasonable efforts to file with the SEC a post-effective amendment to the registration statement filed in connection
with our IPO or a new registration statement covering the registration under the Securities Act of the Class A Ordinary Shares issuable
upon exercise of the warrants and thereafter will use commercially reasonable efforts to cause the same to become effective within 60
business days following our initial business combination and to maintain a current prospectus relating to the Class A Ordinary Shares
issuable upon exercise of the warrants until the expiration of the warrants in accordance with the provisions of the Warrant Agreement.
We cannot assure you that we will be able to do so if, for example, any facts or events arise which represent a fundamental change in
the information set forth in the registration statement or prospectus, the financial statements contained or incorporated by reference
therein are not current or correct or the SEC issues a stop order.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If the Class A Ordinary Shares issuable upon
exercise of the warrants are not registered under the Securities Act, we will be required to permit holders to exercise their warrants
on a cashless basis, in which case the number of Class A Ordinary Shares that warrant holders will receive upon cashless exercise will
be based on a formula.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In no event will warrants be exercisable for cash
or on a cashless basis, and we will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance
of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption
from registration or qualification is available. If the issuance of the shares upon exercise of the warrants is not so registered or qualified
or exempt from registration or qualification, the holder of such warrant will not be entitled to exercise such warrant and such warrant
may have no value and expire worthless. In such event, holders who acquired their warrants as part of a purchase of units will have paid
the full unit purchase price solely for the Class A Ordinary Shares included in the units. There may be a circumstance where an exemption
from registration exists for holders of our Private Placement Warrants to exercise their warrants while a corresponding exemption does
not exist for holders of the warrants included as part of units sold in our IPO. In such an instance, our sponsor and its transferees
(which may include our directors and executive officers) would be able to sell the ordinary shares underlying their warrants while holders
of our Public Warrants would not be able to exercise their warrants and sell the underlying ordinary shares. If and when the warrants
become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for
sale under all applicable state securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If our Class A Ordinary Shares are at the time of
any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of &#8220;covered securities&#8221;
under Section&#160;18(b)(1) of the Securities Act, we may, at our option, not permit holders of warrants who seek to exercise their warrants
to do so for cash and, instead, require them to do so on a cashless basis in accordance with Section&#160;3(a)(9) of the Securities Act;
in the event we so elect, we will not be required to file or maintain in effect a registration statement or register or qualify the shares
underlying the warrants under applicable state securities laws, and in the event we do not so elect, we will use commercially reasonable
efforts to register or qualify the shares underlying the warrants under applicable state securities laws to the extent an exemption is
not available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In no event will we be required to net cash settle
any warrant, or issue securities (other than upon a cashless exercise as described above) or other compensation in exchange for the warrants
in the event that we are unable to register or qualify the shares underlying the warrants under the Securities Act or applicable state
securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Warrant holders may only be able to exercise
their Public Warrants on a &#8220;cashless basis&#8221; under certain circumstances, and if a warrant holder does so, it will receive
fewer Class A Ordinary Shares from such exercise than if it were to exercise such warrants for cash.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Warrant Agreement
provides that in the following circumstances holders of warrants who seek to exercise their warrants will not be permitted to do so for
cash and will, instead, be required to do so on a cashless basis in accordance with Section&#160;3(a)(9) of the Securities Act: (i) if
the Class A Ordinary Shares issuable upon exercise of the warrants are not registered under the Securities Act in accordance with the
terms of the Warrant Agreement; (ii) if we have so elected and the Class A Ordinary Shares are at the time of any exercise of a warrant
not listed on a national securities exchange such that they satisfy the definition of &#8220;covered securities&#8221; under Section&#160;18(b)(1)
of the Securities Act; and (iii) if we have so elected and we call the Public Warrants for redemption. If you exercise your Public Warrants
on a cashless basis, you would pay the warrant exercise price by surrendering the warrants for that number of Class A Ordinary Shares
equal to the quotient obtained by dividing (x) the product of the number of Class A Ordinary Shares underlying the warrants, multiplied
by the excess of the &#8220;fair market value&#8221; (defined below) of our Class A Ordinary Shares (as defined in the next sentence)
over the exercise price of the warrants by (y) the fair market value. The &#8220;fair market value&#8221; for purposes of this calculation
(other than in connection with a redemption) is the average last reported sale price of the Class A Ordinary Shares for the 10 trading
days ending on the third trading day prior to the date on which the notice of exercise is received by the warrant agent or on which the
notice of redemption is sent to the holders of warrants, as applicable. If we have elected to call the Public Warrants for redemption
when the price per Class A Share equals or exceeds $18.00 per share, the &#8220;fair market value&#8221; for purposes of this calculation
is the volume weighted average price of our Class A Ordinary Shares for the 10 trading days immediately following the date on which the
notice of redemption is sent to the holders of warrants. As a result, you would receive fewer Class A Ordinary Shares from such exercise
than if you were to exercise such warrants for cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The registration rights granted to our Insiders
and holders of our Private Placement Warrants may make it more difficult to complete our initial business combination, and the future
exercise of such rights may adversely affect the market price of our Class A Ordinary Shares.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to a registration rights agreement entered
into concurrently with our IPO, our Insiders and their permitted transferees can demand that we register the Class A Ordinary Shares that
they hold (including Class A Ordinary Shares into which their Class B Shares are convertible), holders of our Private Placement Warrants
and their permitted transferees can demand that we register the Private Placement Warrants and the Class A Ordinary Shares issuable upon
exercise of the Private Placement Warrants, holders of warrants that may be issued upon conversion of working capital loans may demand
that we register such warrants or the Class A Ordinary Shares issuable upon conversion of such warrants and forward purchasers can demand
that we register the forward purchase securities. We will bear the cost of registering these securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The registration and availability of such a significant
number of securities for trading in the public market may have an adverse effect on the market price of our Class A Ordinary Shares. In
addition, the existence of the registration rights may make our initial business combination more costly or difficult to conclude. This
is because the shareholders of the target business may increase the equity stake they seek in the combined entity or ask for more cash
consideration to offset the negative impact on the market price of our Class A Ordinary Shares that is expected when the ordinary shares
owned by our Insiders, holders of our Private Placement Warrants or holders of our working capital loans or their respective permitted
transferees are registered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The Business Combination Agreement requires
that we issue a significant amount of additional shares to complete such initial business combination and any alternative business combination
agreement would require the same. In addition, we may issue such shares under an employee incentive plan after completion of our initial
business combination. We may also issue Class A Ordinary Shares upon the conversion of the Class B Shares at a ratio greater than one-to-one
at the time of such initial business combination as a result of the anti-dilution provisions contained in our Current Charter. Any such
issuances would dilute the interest of our shareholders and likely present other risks.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Current Charter
authorizes the issuance of up to 500,000,000 Class A Ordinary Shares, par value $0.0001 per share, 50,000,000 Class B Shares, par value
$0.0001 per share, and 5,000,000 preference shares, par value $0.0001 per share. As of March 31, 2026, there are 29,200,000 and 12,000,000
issued and outstanding Class A Ordinary Shares and Class B Shares, respectively. The Class B Shares are automatically convertible into
Class A Ordinary Shares concurrently with or immediately following the consummation of our initial business combination, initially at
a one-for-one ratio but subject to adjustment as set forth herein and in our memorandum and articles of association, including in certain
circumstances in which we issue Class A Ordinary Shares or equity-linked securities related to our initial business combination. As of
the date of this proxy statement/prospectus, there are no preference shares issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Business Combination Agreement calls for us to
issue 50,000,000 shares of PubCo Common Stock. It also provides for the adoption of an equity incentive plan post-closing. We may also
issue Class A Ordinary Shares to redeem the warrants or upon conversion of the Class B Shares at a ratio greater than one-to-one at the
time of our initial business combination as a result of the anti-dilution provisions as set forth therein in connection with such alternate
initial business combination. The issuance of additional shares:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">will significantly dilute the equity interest
        of investors;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">may subordinate the rights of holders of Class
        A Ordinary Shares if preference shares are issued with rights senior to those afforded our Class A Ordinary Shares;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">could cause a change in control if a substantial
        number of Class A Ordinary Shares is issued, which may affect, among other things, our ability to use our net operating loss carry forwards,
        if any, and could result in the resignation or removal of our present officers and directors; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">may adversely affect prevailing market prices
        for our Class A Ordinary Shares and/or warrants.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may amend
the terms of the warrants in a manner that may be adverse to holders of Public Warrants with the approval of the holders of at least 50%
of the then-outstanding Public Warrants and forward purchase warrants. As a result, the exercise price of your warrants could be increased,
the exercise period could be shortened and the number of Class A Ordinary Shares purchasable upon exercise of a warrant could be decreased,
all without your approval.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our warrants were issued in registered form under
a Warrant Agreement between Odyssey Transfer and Trust Company, as warrant agent, and us. The Warrant Agreement provides that the terms
of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision but requires
the approval by the holders of at least 50% of the then-outstanding Public Warrants to make any change that adversely affects the interests
of the registered holders of Public Warrants and forward purchase warrants. Accordingly, we may amend the terms of the Public Warrants
in a manner adverse to a holder if holders of at least 50% of the then-outstanding Public Warrants and forward purchase warrants approve
of such amendment and, solely with respect to any amendment to the terms of the Private Placement Warrants or any provision of the Warrant
Agreement with respect to the Private Placement Warrants, 50% of the number of the then-outstanding Private Placement Warrants. Although
our ability to amend the terms of the Public Warrants with the consent of at least 50% of the then-outstanding Public Warrants and forward
purchase warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of
the warrants, convert the warrants into cash or shares (at a ratio different than initially provided), shorten the exercise period or
decrease the number of Class A Ordinary Shares purchasable upon exercise of a warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may redeem your unexpired warrants prior
to their exercise at a time that is disadvantageous to you, thereby making your warrants worthless.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have the ability to redeem the outstanding Public
Warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per warrant, provided that the last
reported sale price of our Class A Ordinary Shares equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares
issuable upon exercise or the exercise price of a warrant) for any 20 trading days within a 30 trading-day period ending on the third
trading day prior to proper notice of such redemption and provided that certain other conditions are met. None of the Private Placement
Warrants will be redeemable by us in these circumstances for so long as they are held by our sponsor or its permitted transferees. If
and when the warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying
securities for sale under all applicable state securities laws. As a result, we may redeem the warrants as set forth above even if the
holders are otherwise unable to exercise the warrants. Redemption of the outstanding warrants could force you to (i) exercise your warrants
and pay the exercise price therefor at a time when it may be disadvantageous for you to do so, (ii) sell your warrants at the then-current
market price when you might otherwise wish to hold your warrants or (iii) accept the nominal redemption price which, at the time the outstanding
warrants are called for redemption, we expect would be substantially less than the market value of your warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Warrants and Founder Shares may have an
adverse effect on the market price of our Class A Ordinary Shares and make it more difficult to effectuate our initial business combination.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We issued warrants to purchase 14,000,000 Class A
Ordinary Shares as part of the units offered in our IPO and, simultaneously with the closing of our IPO, we issued in a private placement
an aggregate of 100,000 Private Placement Warrants, each exercisable to purchase one Class A Share at $11.50 per share. Our Insiders currently
own an aggregate of 12,000,000 Founder Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the extent we issue Class A Ordinary Shares for
any reason, the potential for the issuance of a substantial number of additional Class A Ordinary Shares upon exercise of these warrants
and conversion rights could make us a less attractive acquisition vehicle to a target business. Such warrants, when exercised, will increase
the number of issued and outstanding Class A Ordinary Shares and reduce the value of the Class A Ordinary Shares issued to complete the
business combination. Therefore, our Warrants and Founder Shares may make it more difficult to effectuate a business transaction or increase
the cost of acquiring the target business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>A provision of our Warrant Agreement may make
it more difficult for us to consummate an initial business combination.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If (i) we issue additional Class A Ordinary Shares
or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at a Newly
Issued Price (as defined in the Warrant Agreement) of less than $9.20 per Class A Share, (ii) the aggregate gross proceeds from such issuances
represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination
on the date of the consummation of our initial business combination (net of redemptions), and (iii) the Market Value (as defined in the
Warrant Agreement) of our Class A Ordinary Shares is below $9.20 per share, then the exercise price of the warrants will be adjusted (to
the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger
price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the
$10.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the
Newly Issued Price. This may make it more difficult for us to consummate an initial business combination with a target business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><b>General Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are a blank check company with no operating
history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a blank check company incorporated under the
laws of the British Virgin Islands with no operating results. Because we lack an operating history, you have no basis upon which to evaluate
our ability to achieve our business objective of completing our initial business combination. If we fail to complete our initial business
combination, we will never generate any operating revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are an emerging growth company and a smaller
reporting company within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements
available to emerging growth companies or smaller reporting companies, this could make our securities less attractive to investors and
may make it more difficult to compare our performance with other public companies.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are an &#8220;emerging growth company&#8221; within
the meaning of the Securities Act, as modified by the JOBS Act, and we may take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being
required to comply with the auditor internal controls attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced
disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements
of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously
approved. As a result, our shareholders may not have access to certain information they may deem important. We could be an emerging growth
company for up to five years, although circumstances could cause us to lose that status earlier, including if the market value of our
Class A Ordinary Shares held by non-affiliates equals or exceeds $700 million as of any June&#160;30 before that time, in which case,
we would no longer be an emerging growth company as of the following December&#160;31. We cannot predict whether investors will find our
securities less attractive because we will rely on these exemptions. If some investors find our securities less attractive as a result
of our reliance on these exemptions, the trading prices of our securities may be lower than they otherwise would be, there may be a less
active trading market for our securities and the trading prices of our securities may be more volatile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, Section&#160;102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when
a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company,
can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our
financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted
out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, we are a &#8220;smaller reporting company&#8221;
as defined in Rule&#160;10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations,
including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until
the last day of the fiscal year in which (1) the market value of our ordinary shares held by non-affiliates equaled or exceeded $250 million
as of the prior June&#160;30<sup>th</sup>, or (2) our annual revenues equaled or exceeded $100 million during such completed fiscal year
and the market value of our ordinary shares held by non-affiliates equaled or exceeded $700 million as of the prior June&#160;30<sup>th</sup>.
To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other
public companies difficult or impossible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Provisions in our Current Charter and British
Virgin Islands law may inhibit a takeover of us, which could limit the price investors might be willing to pay in the future for our Class
A Ordinary Shares and could entrench management.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our memorandum and articles of association contains
provisions that may discourage unsolicited takeover proposals that shareholders may consider to be in their best interests. These provisions
include a staggered board of directors and the ability of the board of directors to designate the terms of and issue new series of preference
shares, which may make the removal of management more difficult and may discourage transactions that otherwise could involve payment of
a premium over prevailing market prices for our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Provisions in our memorandum and articles of
association and British Virgin Islands law may have the effect of discouraging lawsuits against our directors and officers.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">British Virgin Islands law does not limit the extent
to which a company&#8217;s memorandum and articles of association may provide for indemnification of officers and directors, except to
the extent any such provision may be held by the British Virgin Islands courts to be contrary to public policy, such as to provide indemnification
against willful default, fraud or the consequences of committing a crime. Our memorandum and articles of association provide for indemnification
of our officers and directors to the maximum extent permitted by law, including for any liability incurred in their capacities as such,
except through their own actual fraud, willful default or willful neglect. We purchased a policy of directors&#8217; and officers&#8217;
liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances
and insures us against our obligations to indemnify our officers and directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our indemnification obligations may discourage shareholders
from bringing a lawsuit against our officers or directors for breach of their fiduciary duty. These provisions also may have the effect
of reducing the likelihood of derivative litigation against our officers and directors, even though such an action, if successful, might
otherwise benefit us and our shareholders. Furthermore, a shareholder&#8217;s investment may be adversely affected to the extent we pay
the costs of settlement and damage awards against our officers and directors pursuant to these indemnification provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe that these provisions, the insurance and
the indemnity agreements are necessary to attract and retain talented and experienced officers and directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cyber incidents or attacks directed at us could
result in information theft, data corruption, operational disruption and/or financial loss.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We depend on digital technologies, including information
systems, infrastructure and cloud applications and services, including those of third parties with which we may deal. Sophisticated and
deliberate attacks on, or security breaches in, our systems or infrastructure, or the systems or infrastructure of third parties or the
cloud, could lead to corruption or misappropriation of our assets, proprietary information and sensitive or confidential data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As an early-stage company without significant investments
in data security protection, we may not be sufficiently protected against such occurrences. We may not have sufficient resources to adequately
protect against, or to investigate and remediate any vulnerability to, cyber incidents. It is possible that any of these occurrences,
or a combination of them, could have adverse consequences on our business and lead to financial loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Because we are incorporated under the laws of
the British Virgin Islands, your ability to protect your rights through the U.S. Federal courts may be limited.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a business
company incorporated under the laws of the British Virgin Islands. As a result, it may be difficult for investors to effect service of
process within the United States upon our directors or officers, or enforce judgments obtained in the United States courts against our
directors or officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our corporate affairs will be governed by our memorandum
and articles of association, the Companies Act (as the same may be supplemented or amended from time to time) and the common law of the
British Virgin Islands. We will also be subject to the federal securities laws of the United States. The rights of shareholders to take
action against the directors, actions by minority shareholders and the fiduciary responsibilities of our directors to us under British
Virgin Islands law are to a large extent governed by the common law of the British Virgin Islands. The common law of the British Virgin
Islands is derived in part from comparatively limited judicial precedent in the British Virgin Islands as well as from English common
law, the decisions of whose courts are of persuasive authority, but are not binding on a court in the British Virgin Islands. The rights
of our shareholders and the fiduciary responsibilities of our directors under British Virgin Islands law are different from what they
would be under statutes or judicial precedent in some jurisdictions in the United States. In particular, the British Virgin Islands has
a different body of securities laws as compared to the United States, and certain states, such as Delaware, may have more fully developed
and judicially interpreted bodies of corporate law. In addition, British Virgin Islands companies may not have standing to initiate a
shareholders&#8217; derivative action in a Federal court of the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have been advised
by our British Virgin Islands legal counsel that the courts of the British Virgin Islands are unlikely: (i) to recognize or enforce against
us judgments of courts of the United States predicated upon the civil liability provisions of the federal securities laws of the United
States or any state; and (ii) in original actions brought in the British Virgin Islands, to impose liabilities against us predicated upon
the civil liability provisions of the federal securities laws of the United States or any state, so far as the liabilities imposed by
those provisions are penal in nature. In those circumstances, although there is no statutory enforcement in the British Virgin Islands
of judgments obtained in the United States, the courts of the British Virgin Islands will recognize and enforce a foreign money judgment
of a foreign court of competent jurisdiction without retrial on the merits based on the principle that a judgment of a competent foreign
court imposes upon the judgment debtor an obligation to pay the sum for which judgment has been given, provided certain conditions are
met. For a foreign judgment to be enforced in the British Virgin Islands, such judgment must be final and conclusive and for a liquidated
sum, and must not be in respect of taxes or a fine or penalty, inconsistent with a British Virgin Islands judgment in respect of the same
matter, impeachable on the grounds of fraud or obtained in a manner, or be of a kind the enforcement of which is, contrary to natural
justice or the public policy or the British Virgin Islands (awards of punitive or multiple damages may well be held to be contrary to
public policy). A British Virgin Islands court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of all of the above, Public Shareholders
may have more difficulty in protecting their interests in the face of actions taken by management, members of the board of directors or
controlling shareholders than they would as Public Shareholders of a United States company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The Sponsor has agreed to vote in favor of the
Business Combination, regardless of how BCAR&#8217;s Public Shareholders vote.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sponsor and each director and officer of BCAR
have agreed to, among other things, vote in favor of the Business Combination Agreement and the transactions contemplated thereby, in
the case of the Sponsor, subject also to the terms and conditions contemplated by the Sponsor Support Agreement. The Sponsor, which includes
among its members each of the directors and officers of BCAR, owns 200,000 Private Units and 12,000,000 BCAR Class B Ordinary Shares.
As a result and including the Representative Shares held by our Insider, as of the date of this proxy statement/prospectus, the Insiders
own approximately 32.0% of the issued and outstanding BCAR Ordinary Shares. As a result, in addition to the shares held by the Insiders,
BCAR would need 7,400,001 Public Shares, or approximately 26.4% of the 28,000,000 Public Shares sold in the BCAR IPO, to be voted in favor
of the Business Combination Proposal, the Domestication Merger Proposal, the Organizational Documents Proposal, the Advisory Organizational
Documents Proposals, the Directors Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal, and, if presented, the Adjournment
Proposal, in order for such proposals to be approved, assuming all outstanding shares are voted and the Insiders do not acquire any Public
Shares. Assuming that only the holders of thirty percent (30%) of the issued and outstanding BCAR ordinary shares, representing a quorum
under BCAR&#8217;s amended and restated memorandum and articles of association, vote their shares at the Extraordinary General Meeting,
BCAR will not need any Public Shares in addition to the shares held by the Insiders to be voted in favor of the Business Combination Proposal,
the Domestication Merger Proposal, the Organizational Documents Proposal, the Advisory Organizational Documents Proposals, the Directors
Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal, and, if presented, the Adjournment Proposal, in order for such proposals
to be approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>BCAR&#8217;s ability to complete an initial
business combination with Exascale may be impacted if such initial business combination is subject to U.S. foreign investment regulations
and review by a U.S. government entity, such as the Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;), and ultimately
prohibited.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Sponsor is a British Virgin Islands exempted limited
liability company and is likely to be considered a &#8220;foreign person&#8221; under the regulations administered by CFIUS. As such,
an initial business combination with Exascale may be subject to CFIUS jurisdiction, the scope of which includes controlling investments
(within the meaning of &#8220;control&#8221; under the CFIUS regulations) as well as certain non-passive, non-controlling investments
in sensitive U.S. businesses meeting certain criteria. The parties have determined that Exascale is not a TID U.S. business, as that term
is defined in 31 C.F.R. &#167; 800.248, and as a result, it is not mandatory to submit a CFIUS filing with respect to the Business Combination.
The parties may determine to submit a voluntary filing to CFIUS, or to proceed with the initial business combination without notifying
CFIUS and risk CFIUS intervention, before or after closing the initial business combination. CFIUS may decide to delay the Business Combination,
impose conditions to mitigate national security concerns with respect to the Business Combination or recommend that the U.S. president
block the initial business combination or order BCAR to divest all or a portion of Exascale following the Closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are deemed to be an investment company
under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities may be restricted,
which may make it difficult for us to complete our initial business combination or force us to abandon our efforts to complete an initial
business combination.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If we are deemed to be an
investment company under the Investment Company Act, our activities may be restricted, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">restrictions on the nature of our investments; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">restrictions on the issuance of securities, each of which may make it difficult for us to complete our initial
        business combination. In addition, we may have imposed upon us burdensome requirements, including:</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">registration as an investment company;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">adoption of a specific form of corporate structure; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">reporting, record keeping, voting, proxy and disclosure requirements and other rules&#8239;and regulations.</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order not to be regulated as an investment company
under the Investment Company Act, unless it can qualify for an exclusion, a company must ensure that it is engaged primarily in a business
other than investing, reinvesting or trading of securities and that its activities do not include investing, reinvesting, owning, holding
or trading &#8220;investment securities&#8221; constituting more than 40% of our assets (exclusive of U.S. government securities and cash
items) on an unconsolidated basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The SEC recently provided guidance that the determination
of whether a special purpose acquisition company, like us, is an &#8220;investment company&#8221; under the Investment Company Act is
a facts and circumstances determination requiring individualized analysis and depends on a variety of factors, including a SPAC&#8217;s
duration, asset composition, business purpose and activities, and &#8220;is a question of facts and circumstances&#8221; requiring individualized
analysis. When applying these factors to us we do not believe that our principal activities will subject us to the Investment Company
Act. To this end, the Company was formed for the purpose of completing an initial business combination with one or more businesses. Our
business will be focused on identifying and completing an initial business combination, and thereafter, operating the post-transaction
business or assets for the long term. Further, we do not plan to buy businesses or assets with a view to resale or profit from their resale
and we do not plan to buy unrelated businesses or assets or to be a passive investor. In addition, the proceeds held in the trust account
will only be held as cash or in an interest bearing demand deposit account at a bank, or invested in United States &#8220;government securities&#8221;
within the meaning of Section&#8239;2(a)(16) of the Investment Company Act having a maturity of 185&#8239;days or less or in money market
funds meeting certain conditions under Rule&#8239;2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government
treasury obligations; the holding of these assets in this form is intended to be temporary and for the sole purpose of facilitating the
intended business combination. To mitigate</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">the risk that we might be deemed to be an investment
company for purposes of the Investment Company Act, which risk increases the longer that we hold investments in the trust account, we
may, at any time (based on our management team&#8217;s ongoing assessment of all factors related to our potential status under the Investment
Company Act), instruct the trustee to liquidate the investments held in the trust account and instead to hold the funds in the trust account
in cash or in an interest bearing demand deposit account at a bank. Pursuant to the investment management trust agreement, the trustee
will not be permitted to invest in other securities or assets. By restricting the investment of the proceeds in this manner, and by focusing
our directors&#8217; and officers&#8217; time toward, and operating our business for the purpose of, acquiring and growing businesses
for the long term (rather than buying and selling businesses in the manner of a merchant bank or private equity fund or investing in assets
for the purpose of achieving investment returns on such assets), we intend to avoid being deemed an &#8220;investment company&#8221; within
the meaning of the Investment Company Act. Further, investing in our securities is not intended for persons who are seeking a return on
investments in government securities or investment securities. Instead, the trust account will be intended as a holding place for funds
pending the earliest to occur of either: (i)&#8239;the completion of our initial business combination; (ii)&#8239;the redemption of any
Public Shares properly submitted in connection with a shareholder vote to amend our amended and restated memorandum and articles of association
(A)&#8239;to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination
or to redeem 100% of our Public Shares if we do not complete our initial business combination within the completion window or (B)&#8239;with
respect to any other material provisions relating to shareholders&#8217; rights or pre-initial business combination activity; or (iii)&#8239;absent
an initial business combination within the completion window, our return of the funds held in the trust account to our Public Shareholders
as part of our redemption of the Public Shares. If we do not invest the proceeds as described above, we may be deemed to be subject to
the Investment Company Act. Notwithstanding that we have limited our activities as described above, we could nevertheless be considered
to be operating as an unregistered investment company. If our facts and circumstances change over time, we will update our disclosure
in future filings with the SEC to reflect how those changes impact the risk that we may be considered to be operating as an unregistered
investment company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we were deemed to be an investment company for
purposes of the Investment Company Act, we would need to register as such under the Investment Company Act and compliance with these additional
regulatory burdens would require additional expenses for which we have not allotted funds and may hinder our ability to complete a business
combination. We may also be forced to abandon our efforts to complete an initial business combination, and instead be required to liquidate
the trust account and may be required to change our operations or wind down our operations. In which case, our investors would not be
able to realize the benefits of owning shares in a successor operating business, including the potential appreciation in the value of
our securities following such a transaction, and our warrants would expire worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we were deemed to be an investment company
for purposes of the Investment Company Act, compliance with these additional regulatory burdens would require additional expenses for
which we have not allotted funds and may hinder our ability to complete a business combination. We may also be forced to abandon our efforts
to complete an initial business combination and instead be required to liquidate the trust account. If we are required to liquidate the
trust account, our investors would not be able to realize the benefits of owning shares in a successor operating business, including the
potential appreciation in the value of our securities following such a transaction, and our warrants would expire worthless. On the liquidation
of our trust account, our Public Shareholders may receive only approximately $10.00, or less in certain circumstances, and our warrants
will expire worthless. Changes in laws or regulations or in how such laws or regulations are interpreted or applied, or a failure to comply
with any laws and regulations, may adversely affect our business, including our ability to negotiate and complete our initial business
combination, and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are subject to rules&#8239;and regulations enacted
by various national, regional and local governing bodies, including for example, the SEC, and to new and evolving regulatory measures
under applicable law. Compliance with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly
and our efforts to comply with such new and evolving laws and regulations have resulted in and are likely to continue to result in, increased
general and administrative expenses and a diversion of management time and attention,&#8239;In addition, these changes could have a material
adverse effect on our business, investments and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 24, 2024, the SEC adopted a series of new
rules, effective as of July 1, 2024, relating to SPACs (the &#8220;SPAC Rules&#8221;) requiring, among other items, (i) additional disclosures
relating to SPAC business combination transactions; (ii) additional disclosures relating to dilution and to conflicts of interest involving
sponsors and their affiliates in both SPAC initial public offerings and de-SPAC transactions; (iii) the use of projections by SPACs in
SEC filings in connection with proposed business combination transactions; (iv) amendments to the financial statement requirements applicable
to business combination transactions involving SPACs; and (v) both the SPAC and the target company&#8217;s status as co-registrants on
de-SPAC registration statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the SEC&#8217;s adopting release provided
guidance describing circumstances in which a SPAC could become subject to regulation under the Investment Company Act, including its duration,
asset composition, business purpose, and the activities of the SPAC and its management team in furtherance of such goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compliance with the SPAC Rules and related guidance
may increase the costs of and the time needed to negotiate and complete an initial business combination and may constrain the circumstances
under which we could complete an initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This evolution may result in continuing uncertainty
regarding compliance matters and additional costs necessitated by ongoing revisions to our disclosure and governance practices. A failure
to comply with applicable laws or regulations and any subsequent changes, as interpreted and applied, could have a material adverse effect
on our business, including our ability to negotiate and complete our initial business combination, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Some of the BCAR officers
and directors may be argued to have conflicts of interest that may influence them to support or approve the Business Combination without
regard to your interests.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain officers and directors of BCAR participate
in arrangements that provide them with interests in the Business Combination that may be different from that of other investors, including,
among others, the continued service as an officer or director of PubCo, severance benefits, equity grants, continued indemnification and
the potential ability to sell an increased number of shares of common stock of PubCo, as well as potential direct or indirect interests
arising from other business ventures they may be involved with. For more information concerning the interests of BCAR and Exascale executive
officers and directors, see the section entitled &#8220;<i>Proposal No. 1 &#8212; The Business Combination Proposal &#8212; Certain Interests
of BCAR&#8217;s Directors and Officers and Others in the Business Combination</i>&#8221; in this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These interests, among others, may influence the officers
and directors of BCAR to support or approve the Business Combination. As such, the Sponsor and our officers and directors may be incentivized
to complete an acquisition of a less favorable target company or on terms less favorable to shareholders rather than liquidate. In considering
the recommendations of the BCAR Board to vote for the proposals, its shareholders should consider these interests.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The exercise of BCAR&#8217;s directors&#8217;
and officers&#8217; discretion in agreeing to changes or waivers in the terms of the Business Combination may result in a conflict of
interest when determining whether such changes to the terms of the Business Combination or waivers of conditions are appropriate and in
BCAR&#8217;s shareholders&#8217; best interest.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the period leading up to the Closing, events may
occur that, pursuant to the Business Combination Agreement, would require BCAR to agree to amend the Business Combination Agreement, to
consent to certain actions taken by Exascale or to waive rights that BCAR is entitled to under the Business Combination Agreement. Such
events could arise because of changes in the course of Exascale&#8217;s business or a request by Exascale to undertake actions that would
otherwise be prohibited by the terms of the Business Combination Agreement. In any of such circumstances, it would be at BCAR&#8217;s
discretion, acting through the BCAR Board, to grant its consent or waive those rights. The existence of financial and personal interests
of one or more of the directors described in the preceding risk factors (and described elsewhere in this proxy statement/prospectus) may
result in a conflict of interest on the part of such director(s) between what he, she or they may believe is best for BCAR and its shareholders
and what he, she or they may believe is best for himself, herself or themselves in determining whether or not to take the requested action.
As of the date of this proxy statement/prospectus, BCAR does not believe there will be any changes or waivers that BCAR&#8217;s directors
and executive officers would be likely to make after shareholder approval of the Business Combination Proposal has been obtained. While
certain changes could be made without further shareholder approval, BCAR will circulate a new or amended proxy statement/prospectus and
resolicit BCAR&#8217;s shareholders if changes to the terms of the transaction that would have a material impact on its shareholders are
required prior to the vote on the Business Combination Proposal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>BCAR and Exascale will incur significant transaction
and transition costs in connection with the Business Combination.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR and Exascale have both incurred and expect to
incur significant, non-recurring costs in connection with consummating the Business Combination and operating as a public company following
the consummation of the Business Combination. BCAR and Exascale may also incur additional costs to retain key employees. Certain transaction
costs incurred in connection with the Business Combination Agreement (including the Business Combination), including all legal, accounting,
consulting, investment banking and other fees, expenses and costs, will be paid by PubCo following the closing of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Subsequent to the consummation of the Business
Combination, PubCo may be exposed to unknown or contingent liabilities and may be required to subsequently take write-downs or write-offs,
restructuring and impairment or other charges that could have a significant negative effect on its financial condition, results of operations
and its share price, which could cause you to lose some or all of your investment.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot assure you that the due diligence conducted
in relation to Exascale has identified all material issues or risks associated with Exascale, its business or the industry in which it
competes. Furthermore, we cannot assure you that factors outside of Exascale&#8217;s and our control will not later arise. As a result
of these factors, we may be exposed to liabilities and incur additional costs and expenses and we may be forced to later write-down or
write-off assets, restructure our operations, or incur impairment or other charges that could result in our reporting losses. Even if
our due diligence has identified certain risks, unexpected risks may arise and previously known risks may materialize in a manner not
consistent with our preliminary risk analysis. If any of these risks materialize, this could have a material adverse effect on our financial
condition and results of operations and could contribute to negative market perceptions about our securities or PubCo. Additionally, we
have no indemnification rights against the Exascale Securityholders under the Business Combination Agreement and all of the purchase price
consideration will be delivered at the Closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accordingly, any shareholders or warrant holders
of BCAR who choose to remain PubCo stockholders or warrant holders following the Business Combination could suffer a reduction in the
value of their shares or warrants. Such shareholders or warrant holders are unlikely to have a remedy for such reduction in value unless
they are able to successfully claim that the reduction was due to the breach by our directors or officers of a duty of care or other fiduciary
duty owed to them, or if they are able to successfully bring a private claim under securities laws that the registration statement or
proxy statement/prospectus relating to the Business Combination contained an actionable material misstatement or material omission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The historical financial results of Exascale
and unaudited condensed combined pro forma financial information included elsewhere in this proxy statement/prospectus may not be indicative
of what PubCo&#8217;s actual financial position or results of operations would have been.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The historical financial results of Exascale included
in this proxy statement/prospectus do not reflect the financial condition, results of operations or cash flows they would have achieved
as a standalone public company during the periods presented or those PubCo will achieve in the future. This is primarily the result of
the following factors: (i) PubCo will incur additional ongoing costs as a result of the Business Combination, including costs related
to public company reporting, investor relations and compliance with the Sarbanes-Oxley Act; and (ii) PubCo&#8217;s capital structure will
be different from that reflected in Exascale&#8217;s historical financial statements. PubCo&#8217;s financial condition and future results
of operations could be materially different from amounts reflected in its historical financial statements included elsewhere in this proxy
statement/prospectus, so it may be difficult for investors to compare PubCo&#8217;s future results to historical results or to evaluate
its relative performance or trends in its business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Similarly, the unaudited condensed combined pro
forma financial information in this proxy statement/prospectus is presented for illustrative purposes only and has been prepared based
on a number of assumptions including, but not limited to, BCAR being treated as the &#8220;acquired&#8221; company for financial reporting
purposes in the Business Combination, the total debt obligations and the cash and cash equivalents of Exascale on the Closing Date and
the number of BCAR Class A Ordinary Shares that are redeemed in connection with the Business Combination. Accordingly, such unaudited
condensed combined pro forma financial information may not be indicative of PubCo&#8217;s future operating or financial performance and
PubCo&#8217;s actual financial condition and results of operations may vary materially from PubCo&#8217;s pro forma results of operations
and balance sheet contained elsewhere in this proxy statement/prospectus, including as a result of such assumptions not being accurate.
See <i>&#8220;Unaudited Pro Forma Condensed Combined Financial Information.&#8221;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Following the consummation of the Business
Combination, our only significant asset will be our ownership interest in Exascale and such ownership may not be sufficient to pay dividends
or make distributions or loans to enable us to pay any dividends on PubCo Common Stock or satisfy our other financial obligations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the consummation of the Business Combination,
we will have no direct operations and no significant assets other than our ownership of Exascale. We will depend on Exascale for distributions,
loans and other payments to generate the funds necessary to meet our financial obligations, including our expenses as a publicly traded
company and to pay any dividends with respect to PubCo Common Stock. The financial condition and operating requirements of Exascale may
limit our ability to obtain cash from Exascale. The earnings from, or other available assets of, Exascale may not be sufficient to pay
dividends or make distributions or loans to enable us to pay any dividends on PubCo Common Stock or satisfy our other financial obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This lack of diversification may subject us to
numerous economic, competitive and regulatory risks, any or all of which may have a substantial adverse impact upon the particular industry
in which we may operate subsequent to our Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>BCAR may be or may have been a PFIC during a
U.S. Holder&#8217;s holding period.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A non-U.S. corporation generally will be treated
as a PFIC, as defined below, for U.S. federal income tax purposes in any taxable year if either (1) at least 75% of its gross income for
such year is passive income or (2) at least 50% of the value of its assets (generally based on an average of the quarterly values of the
assets) during such year is attributable to assets that produce or are held for the production of passive income. Based upon the composition
of its income and assets, BCAR may be considered a PFIC for its current taxable year that will end as a result of the Business Combination.
The determination of whether the BCAR will be treated as a PFIC for the taxable year that includes the Business Combination will depend
on a number of factors, including the timing of the Business Combination and the amount of cash held by BCAR and its subsidiaries at the
time of the Business Combination, among others.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If BCAR is a passive foreign investment company
(&#8220;<b>PFIC</b>&#8221;) or has been a PFIC during a U.S. Holder&#8217;s holding period, such U.S. Holder may be subject to certain
adverse U.S. federal income tax consequences as a result of the Domestication Merger. There is no assurance that BCAR is not currently
or has not been a PFIC during a U.S. Holder&#8217;s holding period. If (a) BCAR has been a PFIC for any taxable year during the holding
period of a U.S. Holder (and a U.S. Holder of Public Shares has not made certain elections with respect to its Public Shares), and (b)
PubCo is not a PFIC in the taxable year of the Domestication Merger, such U.S. Holder may recognize gain (but not loss if the Domestication
Merger qualifies as a &#8220;reorganization&#8221; within the meaning of Section 368 of the Code) upon the exchange of Public Shares and
Public Warrants as applicable, for PubCo Common Stock or PubCo Warrants pursuant to the Domestication Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whether BCAR
is treated as a PFIC for U.S. federal income tax purposes is a factual determination that must be made annually at the close of each taxable
year and, thus, is subject to significant uncertainty. Accordingly, there can be no assurances in this regard or any assurances that the
BCAR will not be treated as a PFIC in the taxable year that includes the Business Combination or any other taxable year. Moreover, the
application of the PFIC rules is subject to uncertainty in several respects, and there can be no assurance that the IRS will not take
a contrary position or that a court will not sustain such a challenge by the IRS. Please see &#8220;<i>Certain Material U.S. Federal Income
Tax Considerations &#8212; U.S. Holders &#8212; U.S. Federal Income Tax Consequences of the Domestication Merger to U.S. Holders of BCAR
Securities &#8212; Passive Foreign Investment Company Status</i>&#8221; for a more detailed discussion with respect to BCAR&#8217;s potential
PFIC status and certain tax implications thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If the Business Combination does not qualify
as a reorganization under Section&#160;368(a) of the Code, U.S. Holders of Exascale securities may be required to pay substantial U.S.
federal income taxes.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the Business Combination does not qualify as a
&#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, then a U.S. Holder that exchanges its Exascale securities
for BCAR securities may recognize gain in connection with the Business Combination and may be subject to substantial U.S. federal income
taxes. For more information on certain material U.S. federal income tax consequences of the Business Combination to U.S. Holders of Exascale
securities, see <i>&#8220;Certain Material U.S. Federal Income Tax Considerations &#8212; U.S. Holders &#8212; U.S. Federal Income Tax
Consequences of the Business Combination to U.S. Holders of Exascale Securities.&#8221;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There are risks to BCAR shareholders who
are not affiliates of the Sponsor of becoming stockholders of PubCo through the Business Combination rather than acquiring securities
of PubCo directly in an underwritten public offering, including no independent due diligence review by an underwriter and conflicts of
interest of the Sponsor.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because there is no independent third-party underwriter
involved in the Business Combination or the issuance of securities in connection therewith, investors will not receive the benefit of
an outside independent review of PubCo&#8217;s, Exascale&#8217;s and BCAR&#8217;s respective finances and operations typically performed
in an initial public securities offering. Underwritten public offerings of securities conducted by a licensed broker-dealer are subjected
to a due diligence review by the underwriter or dealer manager to satisfy statutory duties under the Securities Act, the rules of Financial
Industry Regulatory Authority, Inc. (FINRA) and the national securities exchange where such securities are listed. Additionally, underwriters
or dealer-managers conducting such public offerings are subject to liability for material misstatements or omissions in a registration
statement filed with the SEC in connection with the public offering. As no such review has been or will be conducted in connection with
the Business Combination, BCAR shareholders must rely on the information in this proxy statement/prospectus and will not have the benefit
of an independent review and investigation of the type normally performed by an underwriter in a public securities offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the Insiders have interests in the Business
Combination that may be different from, or in addition to, the interests of BCAR shareholders generally. Such interests may have influenced
BCAR&#8217;s directors in making their recommendation that you vote in favor of the Business Combination Proposal and the other proposals
described in this proxy statement/prospectus. See &#8220;<i>Risk Factors &#8211; Since the Sponsor and BCAR&#8217;s directors and officers
have interests that are different, or in addition to (and which may conflict with), the interests of our shareholders, a conflict of interest
may have existed in determining whether the Business Combination with Exascale is appropriate as our initial business combination. Such
interests include that the Sponsor will lose its entire investment in us if our business combination is not completed</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The process of taking a company public by means
of a business combination with a publicly traded shell company is different from taking a company public through an underwritten public
offering and may create risks for unaffiliated investors.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An underwritten offering involves a company engaging
underwriters to purchase its shares and resell them to the public. An underwritten offering imposes statutory liability on the underwriters
for material misstatements or omissions contained in the registration statement unless they are able to sustain the burden of providing
that they did not know and could not reasonably have discovered such material misstatements or omissions. This is referred to as a &#8220;due
diligence&#8221; defense and results in the underwriters undertaking a detailed review of the company&#8217;s business, financial condition
and results of operations. Going public via a business combination with a SPAC does not involve any underwriters and does not generally
necessitate the level of review required to establish a &#8220;due diligence&#8221; defense as would be customary in an underwritten offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, going public via a business combination
with a publicly traded shell company (a &#8220;<b>Reverse PubCo Merger</b>&#8221;) does not involve a book-building process as is the
case in an underwritten public offering. In any underwritten public offering, the initial value of a company is set by investors who indicate
the price at which they are prepared to purchase shares from the underwriters. In the case of a Reverse PubCo Merger transaction, the
value of the company is established by means of negotiations between the target company, the publicly traded company and, in some cases,
other investors who agree to purchase shares at the time of the business combination. The process of establishing the value of a company
in a Reverse PubCo Merger business combination may be less effective than the book-building process in an underwritten public offering
and also does not reflect events that may have occurred between the date of the Business Combination Agreement and the closing of the
transaction. In addition, underwritten public offerings are frequently oversubscribed resulting in additional potential demand for shares
in the aftermarket following the underwritten public offering. There is no such book of demand built up in connection with a Reverse PubCo
Merger transaction and no underwriters with the responsibility of stabilizing the share price which may result in the share price being
harder to sustain after the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If BCAR&#8217;s due diligence investigation
of Exascale was inadequate, then BCAR shareholders following the consummation of the Business Combination could lose some or all of their
investment.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Even though BCAR and its legal advisors conducted
a due diligence investigation of Exascale, it cannot be sure that this due diligence uncovered all material issues that may be present
in Exascale and its business and operations, or that it would be possible to uncover all material issues through a customary amount of
due diligence, or that factors outside of Exascale and its business and operations and outside of its control will not later arise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>BCAR may be targeted by securities class action
and derivative lawsuits that could result in substantial costs and may delay or prevent the Business Combination from being completed.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities class
action lawsuits and derivative lawsuits are often brought against public companies that have entered into Business Combination Agreements.
Even if the lawsuits are without merit, defending against these claims can result in substantial costs and divert management time and
resources. An adverse judgment could result in monetary damages, which could have a negative impact on BCAR&#8217;s liquidity and financial
condition. Additionally, if a plaintiff is successful in obtaining an injunction prohibiting completion of the Business Combination, then
that injunction may delay or prevent the Business Combination from being completed, or from being completed within the expected timeframe,
which may adversely affect BCAR&#8217;s and Exascale&#8217;s respective businesses, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to the Consummation of the Domestication
Merger</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The Domestication Merger may be a taxable event
for U.S. Holders of Public Shares and Public Warrants.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the limitations and qualifications
described in &#8220;<i>Certain Material U.S. Federal Income Tax Considerations</i>,&#8221; including the application of the PFIC rules
and Section 367(b) of the Code, the Domestication Merger is intended to qualify as a &#8220;reorganization&#8221; within the meaning of
Section 368 of the Code and, if so treated, a U.S. Holder (as defined below) would not recognize gain or loss on the exchange of Public
Shares or the Public Warrants for PubCo Common Stock or PubCo Warrants, as applicable, pursuant to the Domestication Merger. If the Domestication
Merger qualifies as a &#8220;reorganization&#8221; within the meaning of Section 368 of the Code, a U.S. Holder of BCAR securities may
still recognize gain (but not loss) or be required to include the &#8220;all earnings and profits amount&#8221; upon the exchange of its
BCAR securities for PubCo Securities pursuant to the Domestication Merger under Section 367(b) of the Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alternatively, if the Domestication Merger does
not qualify as a &#8220;reorganization&#8221; within the meaning of Section 368 of the Code, then a U.S. Holder that exchanges its Public
Shares or Public Warrants for the consideration under the Domestication Merger will recognize gain or loss equal to the difference between
(i) the sum of the fair market value of the PubCo Common Stock and PubCo Warrants received and (ii) the U.S. Holder&#8217;s adjusted tax
basis in the Public Shares and Public Warrants exchanged therefor, as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, U.S. Holders of Public Shares and
Public Warrants may be subject to adverse U.S. federal income tax consequences under the PFIC rules. Please see &#8220;<i>Certain Material
U.S. Federal Income Tax Considerations &#8212; U.S. Holders &#8212; U.S. Federal Income Tax Consequences of the Domestication Merger to
U.S. Holders of BCAR Securities &#8212; Passive Foreign Investment Company Status</i>&#8221; for a more detailed discussion with respect
to BCAR&#8217;s potential PFIC status and certain tax implications thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Upon consummation of the Business Combination,
the rights of holders of PubCo Common Stock arising under the DGCL as well as Proposed Organizational Documents will differ from and may
be less favorable to the rights of holders of BCAR Class A Ordinary Shares arising under the Companies Act as well as our Current Charter.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon consummation of the Business Combination,
the rights of holders of PubCo Common Stock will arise under the Proposed Organizational Documents as well as the DGCL. Those new organizational
documents and the DGCL contain provisions that differ in some respects from those in our Current Charter and the Companies Act and, therefore,
some rights of holders of PubCo Common Stock could differ from the rights that holders of BCAR Class A Ordinary Shares currently possess.
For instance, while class actions are generally not available to shareholders under Companies Act, such actions are generally available
under the DGCL. This change could increase the likelihood that PubCo becomes involved in costly litigation, which could have a material
adverse effect on PubCo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, there are differences between the
new organizational documents of PubCo and the current constitutional documents of BCAR. For a more detailed description of the rights
of holders of PubCo Common Stock and how they may differ from the rights of holders of BCAR Class A Ordinary Shares, please see &#8220;<i>Comparison
of Corporate Governance and Shareholder Rights</i>.&#8221; The forms of the Proposed Charter and the Proposed Bylaws of PubCo are attached
as <i>Annex B-1 </i>and <i>Annex B-2</i>, respectively, to this proxy statement/prospectus and we urge you to read them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Delaware law and PubCo&#8217;s Proposed
Organizational Documents contain certain provisions, including anti-takeover provisions that limit the ability of stockholders to take
certain actions and could delay or discourage takeover attempts that stockholders may consider favorable.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Proposed Organizational Documents that will
be in effect upon consummation of the Business Combination, and the DGCL, contain provisions that could have the effect of rendering more
difficult, delaying, or preventing an acquisition that stockholders may consider favorable, including transactions in which stockholders
might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay
in the future for shares of our common stock, and therefore depress the trading price of PubCo&#8217;s common stock. These provisions
could also make it difficult for stockholders to take certain actions, including electing directors who are not nominated by the current
members of the PubCo Board or taking other corporate actions, including effecting changes in our management. Among other things, the Proposed
Organizational Documents include provisions regarding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 125; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the ability of the PubCo Board to issue shares of preferred stock, including
        &#8220;blank check&#8221; preferred stock and to determine the price and other terms of those shares, including preferences and voting
        rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the PubCo Proposed Charter will prohibit cumulative voting in the election of
        directors, which limits the ability of minority stockholders to elect director candidates;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a staggered board of directors;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the limitation of the liability of, and the indemnification of, PubCo&#8217;s
        directors and officers;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the ability of the PubCo Board to amend the Proposed Bylaws, which may allow
        the PubCo Board to take additional actions to prevent an unsolicited takeover and inhibit the ability of an acquirer to amend the Proposed
        Bylaws to facilitate an unsolicited takeover attempt; and</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">advance notice procedures with which stockholders must comply to nominate candidates
        to the PubCo Board or to propose matters to be acted upon at a stockholders&#8217; meeting, which could preclude stockholders from bringing
        matters before annual or special meetings of stockholders and delay changes in the PubCo Board and also may discourage or deter a potential
        acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain
        control of PubCo.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These provisions, alone or together, could delay
or prevent hostile takeovers and changes in control or changes in the PubCo Board or management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The provisions of the Proposed Charter requiring
exclusive forum in the Court of Chancery of the State of Delaware and the federal district courts of the United States for certain types
of lawsuits may have the effect of discouraging lawsuits against our directors and officers.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PubCo&#8217;s Proposed Charter provides that,
to the fullest extent permitted by law, and unless PubCo consents in writing to the selection of an alternative forum, the Court of Chancery
of the State of Delaware (or, in the event that the Chancery Court does not have jurisdiction, the federal district court for the District
of Delaware or other state courts of the State of Delaware) will be the sole and exclusive forum for (i) any derivative action, suit or
proceeding brought on PubCo&#8217;s behalf, (ii) any action, suit or proceeding asserting a claim of breach of a fiduciary duty owed by
any director, officer or stockholder of PubCo to PubCo or PubCo&#8217;s stockholders, (iii) any action, suit or proceeding arising pursuant
to any provision of the DGCL or PubCo&#8217;s Proposed Bylaws or PubCo&#8217;s Proposed Charter (as each may be amended from time to time),
(iv) any action, suit or proceeding as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (v)
any action, suit or proceeding asserting a claim against PubCo or any current or former director, officer or stockholder governed by the
internal affairs doctrine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Section&#160;22 of the Securities Act creates concurrent
jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the
rules and regulations thereunder. Accordingly, both state and federal courts have jurisdiction to entertain such Securities Act claims.
To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts,
among other considerations, the Proposed Charter will also provide that, unless PubCo consents in writing to the selection of an alternative
forum, to the fullest extent permitted by law, the federal district courts of the United States of America will be the exclusive forum
for the resolution of any complaint asserting a cause of action arising under the Securities Act; however, there is uncertainty as to
whether a court would enforce such provision, and investors cannot waive compliance with federal securities laws and the rules and regulations
thereunder. Notwithstanding the foregoing, the Proposed Charter will provide that the exclusive forum provision will not apply to suits
brought to enforce any cause of action arising under the Securities Act, any duty or liability created by the Exchange Act or any other
claim for which the federal courts have exclusive jurisdiction. Section&#160;27 of the Exchange Act creates exclusive federal jurisdiction
over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These provisions may have the effect of discouraging
lawsuits against PubCo&#8217;s directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217;
certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action
brought against PubCo, a court could find the choice of forum provisions contained in the Proposed Charter to be inapplicable or unenforceable
in such action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks if the Domestication Merger and the Business
Combination are not Consummated</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>BCAR&#8217;s independent registered public
accounting firm&#8217;s report for the period from March 20, 2025 (Inception) through December 31, 2025 contains an explanatory paragraph
that expresses substantial doubt about its ability to continue as a &#8220;going concern.&#8221;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December, 2025, BCAR had $420,340 of cash in
its operating bank account, and may not have sufficient liquidity to fund its working capital needs. Further, BCAR has incurred and expects
to continue to incur significant costs in pursuit of its financing and acquisition plans, including the Business Combination. BCAR cannot
assure you that its plans to raise capital or to consummate an initial business combination, including the Business Combination, will
be successful. These factors, among others, raise substantial doubt about its ability to continue as a going concern. BCAR&#8217;s financial
statements contained elsewhere in this proxy statement/prospectus do not include any adjustments that might result from its inability
to consummate the Business Combination or its inability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --> <!-- Field: Split-Segment -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>EXTRAORDINARY GENERAL MEETING OF BCAR</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>General</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR is furnishing this proxy statement/prospectus
to its shareholders as part of the solicitation of proxies by the BCAR Board for use at the Extraordinary General Meeting to be held at
10:00 A.M., Eastern Time, on [_], 2026 at the offices of Loeb &amp; Loeb LLP, 345 Park Avenue, New York, NY 10154, and at any adjournment
or postponement thereof. This proxy statement/prospectus provides BCAR shareholders with information they need to know to be able to vote
or direct their vote to be cast at the Extraordinary General Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Date, Time and Place of the Extraordinary General
Meeting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Extraordinary General Meeting will be held at
10:00 A.M., Eastern Time, on [_], 2026 at the offices of Loeb &amp; Loeb LLP, 345 Park Avenue, New York, NY 10154 on [_], 2026, at 10:00
A.M. Eastern Time. Shareholders may attend the Extraordinary General Meeting in person or virtually via telephone at: Telephone number:
__________________ Participant Passcode: __________________.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Purpose of the Extraordinary General Meeting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At the Extraordinary General Meeting, BCAR is asking
holders of BCAR Ordinary Shares to consider and vote upon:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Business Combination Proposal. A copy of the Business Combination Agreement
        is attached to this proxy statement/prospectus as <i>Annex A</i>;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Domestication Merger Proposal. A copy of the Business Combination Agreement
        is attached to this proxy statement/prospectus as <i>Annex A</i>;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Organizational Documents Proposal. The Proposed Charter and the Proposed
        Bylaws are attached to this proxy statement/prospectus as <i>Annex B-1 </i>and <i>Annex B-2</i>, respectively;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Advisory Organizational Documents Proposals;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Directors Proposal;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Equity Incentive Plan Proposal. A copy of the Equity Incentive Plan is attached
        to this proxy statement/prospectus as <i>Annex C</i>;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Nasdaq Proposal;</span></td> </tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">8.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Adjournment Proposal.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Each of Proposal Nos. 1, 2, 3, 5, 6 and 7 is cross-conditioned
on the approval of each other (the &#8220;<b>Condition Precedent Proposals</b>&#8221;). The Advisory Organizational Documents Proposal
4A-F and the Adjournment Proposal are not cross-conditioned upon the approval of any other proposal set forth in this proxy statement/prospectus.
Notwithstanding the order of the resolutions on the notice to the Extraordinary General Meeting, the Adjournment Proposal may be presented
first to the shareholders if, based on the tabulated vote collected at the time of the Extraordinary General Meeting, there are insufficient
votes for, or otherwise in connection with, the approval of the Condition Precedent Proposals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Recommendation of the BCAR Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The BCAR Board believes that the Business Combination
Proposal and the other proposals to be presented at the Extraordinary General Meeting are in the best interests of BCAR&#8217;s shareholders
and unanimously recommends that its shareholders vote &#8220;FOR&#8221; the approval of the Business Combination Proposal, &#8220;FOR&#8221;
the approval of the Domestication Merger Proposal, &#8220;FOR&#8221; the approval of the Organizational Documents Proposal, &#8220;FOR&#8221;
the approval, on an advisory basis, of each of the separate Advisory Organizational Documents Proposals, &#8220;FOR&#8221; the approval
of the Directors Proposal, &#8220;FOR&#8221; the approval of the Equity Incentive Plan Proposal, &#8220;FOR&#8221; the approval of the
Nasdaq Proposal, and &#8220;FOR&#8221; the approval of the Adjournment Proposal, if presented to the Extraordinary General Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The existence of financial and personal interests
of one or more of BCAR&#8217;s directors may result in a conflict of interest on the part of such director(s) between what he, she or
they may believe is in the best interests of BCAR and its shareholders and what he, she or they may believe is best for himself, herself
or themselves in determining to recommend that shareholders vote for the proposals. In addition, BCAR&#8217;s officers have interests
in the Business Combination that may conflict with your interests as a shareholder. See &#8220;The Business Combination Proposal &#8212;Certain
Interests of BCAR&#8217;s Directors and Officers and Others in the Business Combination&#8221; for a further discussion of these considerations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Record Date; Who is Entitled to Vote</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR shareholders will be entitled to vote or direct
votes to be cast at the Extraordinary General Meeting if they owned BCAR Ordinary Shares at the close of business on [_], 2026, which
is the &#8220;Record Date&#8221; for the Extraordinary General Meeting. Shareholders will have one vote for each BCAR Ordinary Share owned
at the close of business on the Record Date. If your shares are held in &#8220;street name&#8221; or are in a margin or similar account,
you should contact your broker to ensure that votes related to the shares you beneficially own are properly counted. BCAR Warrants do
not have voting rights. As of the close of business on the Record Date, there were 41,200,000 BCAR Ordinary Shares issued and outstanding,
of which 28,000,000 were Public Shares held by persons other than the Insiders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Insiders have agreed to, among other things, vote
in favor of the Business Combination. The Sponsor together with each of the directors and officers of BCAR, owns 13,200,000 BCAR Ordinary
Shares, including both Class A Ordinary Shares and Class B Ordinary Shares. As a result, as of the date of this proxy statement/prospectus,
the Insiders own approximately 32.0% of the issued and outstanding BCAR Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Quorum</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A quorum of BCAR shareholders is necessary to hold
a valid meeting. A quorum will be present at the Extraordinary General Meeting if the holders of at least thirty percent (30%) of the
issued and outstanding BCAR Ordinary Shares entitled to vote at the Extraordinary General Meeting are represented in person or by proxy.
As of the Record Date for the Extraordinary General Meeting, 12,360,000 BCAR Ordinary Shares would be required to achieve a quorum. Because
the Insiders have the right to vote 13,200,000 BCAR Ordinary Shares, the presence at the Extraordinary General Meeting no other holders
of BCAR Ordinary Shares will be needed to establish a quorum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Abstentions and Broker Non-Votes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Proxies that are marked &#8220;abstain&#8221; and
proxies relating to &#8220;street name&#8221; shares that are returned to BCAR but marked by brokers as &#8220;not voted&#8221; will be
treated as shares present for purposes of determining the presence of a quorum on all matters, but they will not be treated as shares
voted on the matter. Under the rules of various national and regional securities exchanges, your broker, bank, or nominee cannot vote
your shares with respect to non-discretionary matters unless you provide instructions on how to vote in accordance with the information
and procedures provided to you by your broker, bank, or nominee. BCAR believes all the proposals presented to the shareholders will be
considered non-discretionary and therefore your broker, bank, or nominee cannot vote your shares without your instruction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Vote Required for Approval</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of the Business Combination Proposal
may be achieved by an ordinary resolution under the Current Charter, being the affirmative vote of a majority of the votes cast by the
holders of BCAR Ordinary Shares, voting as a single class, represented in person or by proxy and entitled to vote thereon at the Extraordinary
General Meeting. The Business Combination Proposal is conditioned on the approval of the other Condition Precedent Proposals. Therefore,
if the other Condition Precedent Proposals are not approved, the Business Combination Proposal will have no effect, even if approved by
holders of BCAR Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of the Domestication Merger Proposal
may be achieved by an ordinary resolution under British Virgin Islands law, being the affirmative vote of a majority of the votes cast
by the BCAR Ordinary Shares, voting as a single class, represented in person or by proxy and entitled to vote thereon at the Extraordinary
General Meeting. The Domestication Merger Proposal is conditioned on the approval of the other Condition Precedent Proposals. Therefore,
if the other Condition Precedent Proposals are not approved, the Domestication Merger Proposal will have no effect, even if approved by
the holders of the BCAR Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of the Organizational Documents Proposal
requires an ordinary resolution under British Virgin Islands law, being the affirmative vote of a majority of the votes cast by the BCAR
Ordinary Shares, represented in person or by proxy and entitled to vote thereon at the Extraordinary General Meeting. The Organizational
Documents Proposal is conditioned on the approval of the other Condition Precedent Proposals. Therefore, if the other Condition Precedent
Proposals are not approved, the Organizational Documents Proposal will have no effect, even if approved by holders of BCAR Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of each of the Advisory Organizational
Documents Proposals, each of which is a non-binding vote, requires an ordinary resolution under the Current Charter, being the affirmative
vote of a majority of the votes cast by the holders of BCAR Ordinary Shares, voting as a single class, represented in person or by proxy
and entitled to vote thereon at the Extraordinary General Meeting. The Advisory Organizational Documents Proposals are not conditioned
upon any other proposal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of the Directors Proposal requires an
ordinary resolution under the Current Charter, being the affirmative vote of a majority of the votes cast by the holders of BCAR Ordinary
Shares, voting as a single class, represented in person or by proxy and entitled to vote thereon at the Extraordinary General Meeting.
The Directors Proposal is conditioned on the approval of the other Condition Precedent Proposals. Therefore, if the other Condition Precedent
Proposals are not approved, the Directors Proposal will have no effect, even if approved by holders of BCAR Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of the Equity Incentive Plan Proposal
requires an ordinary resolution under the Current Charter, being the affirmative vote of a majority of the votes cast by the holders of
BCAR Ordinary Shares, voting as a single class, represented in person or by proxy and entitled to vote thereon at the Extraordinary General
Meeting. The Equity Incentive Plan Proposal is conditioned on the approval of the other Condition Precedent Proposals. Therefore, if the
other Condition Precedent Proposals are not approved, the Equity Incentive Plan Proposal will have no effect, even if approved by holders
of BCAR Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of the Nasdaq Proposal requires an ordinary
resolution under the Current Charter, being the affirmative vote of a majority of the votes cast by the holders of BCAR Ordinary Shares,
voting as a single class, represented in person or by proxy and entitled to vote thereon at the Extraordinary General Meeting. The Nasdaq
Proposal is conditioned on the approval of the other Condition Precedent Proposals. Therefore, if the other Condition Precedent Proposals
are not approved, the Nasdaq Proposal will have no effect, even if approved by holders of BCAR Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of the Adjournment Proposal requires
an ordinary resolution under the Current Charter, being the affirmative vote of a majority of the votes cast by the holders of BCAR Ordinary
Shares, voting as a single class, represented in person or by proxy and entitled to vote thereon at the Extraordinary General Meeting.
The Adjournment Proposal is not conditioned upon any other proposal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 130; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Insiders own 200,000 Private Units, 12,000,000
BCAR Class B Ordinary Shares and 1,000,000 Representative Shares as of the date of this proxy statement/prospectus. As a result, in addition
to the shares held by the Insiders, BCAR would need 7,400,001 Public Shares, or approximately 26.4% of the 28,000,000 Public Shares sold
in the BCAR IPO, to be voted in favor of the Business Combination Proposal, the Domestication Merger Proposal, the Organizational Documents
Proposal, the Advisory Organizational Documents Proposals, the Directors Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal,
and, if presented, the Adjournment Proposal, in order for such proposals to be approved, assuming all outstanding shares are voted and
the Insiders do not acquire any Public Shares. Assuming that only the holders of thirty percent (30%) of the issued and outstanding BCAR
ordinary shares, representing a quorum under BCAR&#8217;s amended and restated memorandum and articles of association, vote their shares
at the Extraordinary General Meeting, BCAR will not need any Public Shares in addition to the shares held by the Insiders to be voted
in favor of the Business Combination Proposal, the Domestication Merger Proposal, the Organizational Documents Proposal, the Advisory
Organizational Documents Proposals, the Directors Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal, and, if presented,
the Adjournment Proposal, in order for such proposals to be approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Voting Restrictions in Connection with Shareholder
Meeting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with any vote for a proposed business
combination, including the vote with respect to the Business Combination Proposal, the Sponsor and the Insiders have agreed to vote the
Founder Shares as well as any BCAR Class A Ordinary Shares acquired in the market in favor of such proposed business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Business Combination Agreement,
BCAR agreed to cause PubCo to receive an amount of at least $5,000,000 in any combination of cash, cash in the trust account, a PIPE,
an equity line of credit, or third-party financing, net of any outstanding checks, wire transfers, or similar items not yet cleared, and
net of any cash distributions or transfers made in connection with or as a result of the Business Combination (the &#8220;<b>Minimum Cash
Financing</b>&#8221;). It is a condition precedent to Closing that PubCo receive the Minimum Cash Financing on or prior to Closing. If
the Minimum Cash Financing is not met, and such condition is not waived by Exascale under the terms of the Business Combination Agreement,
the proposed Business Combination will not be consummated. In the event that the Business Combination will not be consummated, all Public
Shares submitted for redemption will be returned to the holders thereof, and we may instead search for an alternate business combination
or liquidate BCAR. The management teams of BCAR and Exascale are continuing to analyze the available financing options based on cost,
amount available under the facility and future effects that any financing would have on the capitalization of PubCo. BCAR, BCAR&#8217;s
Sponsor, Exascale and their affiliates have no prior relationships with any of the potential financing sources being considered in connection
with the Business Combination. Upon entry into a financing arrangement for the Business Combination, including any Minimum Cash Financing,
BCAR will disclose such arrangement (including the potential dilution) in accordance with the rules of the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At any time at
or prior to the Extraordinary General Meeting, during a period when they are not then aware of any material nonpublic information regarding
BCAR or its securities, our sponsor, officers, directors and/or their affiliates, in compliance with the tender offer rules and other
Exchange Act limitations, including Rule 14e-5 thereunder, may purchase Public Shares from institutional and other investors, execute
agreements to purchase shares from such investors in the future, or they may enter into transactions, including non-redemption agreements,
with such investors and others to provide them with incentives to acquire shares of BCAR and/or not to redeem (or to validly rescind any
redemption requests). Our sponsor, officers, directors and/or their affiliates anticipate that they may identify such unaffiliated third-party
shareholders with whom our sponsor, officers, directors or their affiliates may pursue privately negotiated transactions by either the
shareholders contacting us directly or by our receipt of redemption requests submitted by shareholders following our mailing of tender
offer or proxy materials in connection with the Business Combination. To the extent that our sponsor, officers, directors, advisors or
their affiliates enter into a private transaction with an unaffiliated third party, they would identify and contact only potential selling
or redeeming shareholders who have expressed their election to redeem their shares for a pro rata share of the trust account, whether
or not such shareholder has already submitted a proxy with respect to the Business Combination but only if such shares have not already
been voted at the Extraordinary General Meeting. Our sponsor, executive officers, directors, advisors or their affiliates will select
which shareholders to purchase shares from based on the negotiated price and number of shares and any other factors that they may deem
relevant, and will be restricted from purchasing shares if such purchases do not comply with Regulation M under the Exchange Act and the
other federal securities laws. Any such privately negotiated transactions may be effected at purchase prices that are no greater than
the per share pro rata portion of the trust account. Such privately negotiated transactions may include a contractual acknowledgement
that such unaffiliated third-party shareholder, although still the record or beneficial holder of our shares, is no longer the beneficial
owner thereof and therefore agrees not to exercise its redemption rights. In the event that the Sponsor, officers, directors and/or their
affiliates purchase shares in privately negotiated transactions from unaffiliated third-party shareholders who have already elected to
exercise their redemption rights, such selling shareholders would be required to revoke their prior elections to redeem their Public Shares.
The purpose of such share purchases and other transactions would be to limit the number of Public Shares electing to be redeemed. Entering
into any such arrangements may have a depressive effect on the price of BCAR Ordinary Shares (e.g., by giving an investor or holder the
ability to effectively purchase shares at a price lower than market, such investor or holder may therefore become more likely to sell
the shares he, she or it owns, either at or prior to the Business Combination). If such transactions are effected, the consequence could
be to cause the Business Combination to be consummated in circumstances where such consummation could not otherwise occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 131; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with the SEC&#8217;s Compliance and
Disclosure Interpretation 166.01, any Public Shares purchased by our Sponsor, officers, directors and/or their affiliates would not be
voted in favor of approving the Business Combination.</p>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except as disclosed in this proxy statement/prospectus,
we have not entered into any privately negotiated transactions with respect to our shares as of the date hereof. If they engage in such
privately negotiated transactions, our sponsor, officers, directors and/or their affiliates will be restricted from making any such purchases
when they are in possession of any material non-public information not disclosed to the seller or if such purchases are prohibited by
Regulation M under the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our sponsor, officers, directors and/or their affiliates
will be restricted from making purchases of shares if the purchases would violate Section 9(a)(2) or Rule 10b-5 of the Exchange Act. We
expect any such purchases would be reported by such person pursuant to Section 13 and Section 16 of the Exchange Act to the extent such
purchasers are subject to such reporting requirements. Additionally, in the event our sponsor, directors, executive officers, advisors,
or their affiliates were to purchase shares or warrants from Public Shareholders, or if any third party investors are incentivized to
acquire Public Shares by our sponsor, directors, executive officers, or their affiliates, such purchases would be structured in compliance
with the requirements of Rule 14e-5 under the Exchange Act including, in pertinent part, through adherence to the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our registration statement/proxy statement filed for our business combination
        transaction would disclose the possibility that our sponsor, directors, executive officers, advisors or any of their affiliates may purchase
        shares or warrants from Public Shareholders outside the redemption process, along with the purpose of such purchases;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">if our Sponsor, directors, executive officers, advisors or any of their affiliates
        were to purchase shares or warrants from Public Shareholders, they would do so at a price no higher than the price offered through our
        redemption process;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any of our securities purchased by our Sponsor, directors, executive officers,
        advisors or any of their affiliates would not be voted in favor of approving the business combination transaction;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our Sponsor, directors, executive officers, advisors or any of their affiliates
        would not possess any redemption rights with respect to our securities or, if they do acquire and possess redemption rights, they would
        waive such rights; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we would disclose in a Current Report on Form 8-K, before our security holder
        meeting to approve the business combination transaction, the following material items:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the amount of our securities purchased outside of the redemption offer by our
        Sponsor, directors, executive officers, advisors or any of their affiliates, along with the purchase price;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the purpose of the purchases by our Sponsor, directors, executive officers,
        advisors or any of their affiliates;</span></td></tr>
  </table>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the impact, if any, of the purchases by our Sponsor, directors, executive officers,
        advisors or any of their affiliates on the likelihood that the business combination transaction will be approved;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the identities of our security holders who sold to our Sponsor, directors, executive
        officers, advisors or any of their affiliates (if not purchased on the open market) or the nature of our security holders (e.g., 5% security
        holders) who sold to our sponsor, directors, executive officers, advisors or any of their affiliates; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the number of our securities for which we have received redemption requests
        pursuant to our redemption offer.</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 132; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of the funds in the trust account will be
used to purchase Public Shares in such transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Please see &#8220;<i>Risk Factors &#8212; Activities
taken by existing BCAR shareholders to increase the likelihood of approval of the Business Combination Proposal and the other proposals
described in this proxy statement could have a depressive effect on BCAR&#8217;s shares.</i>&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Voting Your Shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each BCAR Class A Ordinary Share and each BCAR Class
B Ordinary Share that you own in your name entitles you to one vote. Your proxy card shows the number of BCAR Ordinary Shares that you
own.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If you are a record owner of your shares, there are
two ways to vote your BCAR Ordinary Shares at the Extraordinary General Meeting:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>You
Can Vote By Signing and Returning the Enclosed Proxy Card.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you vote by proxy card, your &#8220;proxy,&#8221; whose name is listed on the proxy card, will vote your shares as you instruct on the
proxy card. If you sign and return the proxy card but do not give instructions on how to vote your shares, your shares will be voted as
recommended by the BCAR Board &#8220;FOR&#8221; the approval of the Business Combination Proposal, &#8220;FOR&#8221; the approval of the
Domestication Merger Proposal, &#8220;FOR&#8221; the approval of the Organizational Documents Proposal, &#8220;FOR&#8221; the approval,
on an advisory basis, of each of the separate Advisory Organizational Documents Proposals, &#8220;FOR&#8221; the approval of the Directors
Proposal, &#8220;FOR&#8221; the approval of the Equity Incentive Plan Proposal, &#8220;FOR&#8221; the approval of the Nasdaq Proposal,
and, if presented, &#8220;FOR&#8221; the approval of the Adjournment Proposal. Votes received after a matter has been voted upon at the
Extraordinary General Meeting will not be counted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>You
Can Attend the Extraordinary General Meeting and Vote in Person.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
can attend the Extraordinary General Meeting and vote in person at 10:00 A.M., Eastern Time, on [_], 2026 at the offices of Loeb &amp;
Loeb LLP, 345 Park Avenue, New York, NY 10154. Shareholders may also attend the Extraordinary General Meeting virtually via telephone
at: Telephone number: __________________ Participant Passcode: __________________.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
your shares are held in &#8220;street name&#8221; or are in a margin or similar account, you should contact your broker to ensure that
votes related to the shares you beneficially own are properly counted. If you wish to attend the meeting and vote in person or online
and your shares are held in &#8220;street name,&#8221; you must obtain a legal proxy from your broker, bank or nominee. That is the only
way BCAR can be sure that the broker, bank or nominee has not already voted your shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
note that if you are a beneficial owner of BCAR Ordinary Shares, you may vote by submitting voting instructions to your broker, bank or
nominee, or otherwise by following instructions provided by your broker, bank or nominee. Telephone and internet voting will be available
to beneficial owners. Please refer to the vote instruction form provided by your broker, bank or nominee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>IF YOU RETURN YOUR PROXY CARD WITHOUT AN INDICATION
OF HOW YOU WISH TO VOTE, YOUR SHARES WILL BE VOTED IN FAVOR OF THE BUSINESS COMBINATION PROPOSAL (AS WELL AS THE OTHER PROPOSALS). IN
ORDER TO REDEEM YOUR SHARES, YOU MUST TENDER YOUR SHARES TO OUR TRANSFER AGENT AT LEAST TWO BUSINESS DAYS PRIOR TO THE EXTRAORDINARY GENERAL
MEETING. YOU MAY TENDER YOUR SHARES FOR REDEMPTION BY EITHER DELIVERING YOUR SHARE CERTIFICATE TO THE TRANSFER AGENT OR BY DELIVERING
YOUR SHARES ELECTRONICALLY USING THE DEPOSITORY TRUST COMPANY&#8217;S DEPOSIT/WITHDRAWAL AT CUSTODIAN (&#8220;DWAC&#8221;) SYSTEM. IF
THE BUSINESS COMBINATION IS NOT CONSUMMATED, THEN THESE TENDERED SHARES WILL NOT BE REDEEMED FOR CASH AND WILL BE RETURNED TO THE APPLICABLE
SHAREHOLDER. IF YOU HOLD THE SHARES IN STREET NAME, YOU WILL NEED TO INSTRUCT THE ACCOUNT EXECUTIVE AT YOUR BROKER OR BANK TO WITHDRAW
THE SHARES FROM YOUR ACCOUNT IN ORDER TO EXERCISE YOUR REDEMPTION RIGHTS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 133; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Revoking Your Proxy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If you are a BCAR shareholder and you give a proxy,
you may revoke it at any time before it is exercised by doing any one of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">you may send another proxy card with a later date;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="width: 0.25in; text-align: justify">&#9679;</td>
    <td style="text-align: justify">you may notify David Boral, Chairman and Chief Executive Officer of BCAR, in writing before the Extraordinary
        General Meeting that you have revoked your proxy; or</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="width: 0.25in; text-align: justify">&#9679;</td>
    <td style="text-align: justify">you may attend the Extraordinary General Meeting, revoke your proxy, and vote, as indicated above.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If your shares are held in &#8220;street name&#8221;
or are in a margin or similar account, you should contact your broker for information on how to change or revoke your voting instructions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Who Can Answer Your Questions About Voting Your
Shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If you are a shareholder and have any questions about
how to vote or direct a vote in respect of your BCAR Ordinary Shares, you may call Advantage Proxy, our proxy solicitor, by email at karen@advantageproxy.com.
Individuals may also call Advantage Proxy toll free at 877-870-8565; banks and brokers can call 206-870-8565.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Redemption Rights</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to BCAR&#8217;s Current Charter, a holder
of Public Shares may demand that BCAR redeem such Class A Ordinary Shares for cash at the applicable redemption price per share equal
to the quotient obtained by dividing the (i) the aggregate amount on deposit in the trust account as of two business days prior to the
consummation of the Business Combination, including interest (net of taxes payable), by (ii) the total number of the then outstanding
Public Shares. As of [_], 2026, this would have amounted to approximately $[_] per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">You will be entitled to receive cash for any Public
Shares to be redeemed only if you:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">hold Public Shares; and</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">prior to 5:00 pm Eastern Time, on [_], 2026 (two business days
        prior to BCAR&#8217;s Extraordinary General Meeting), (a) submit a written request to Continental that BCAR redeem your Public Shares
        for cash; and (b) deliver your Public Shares to Continental, physically or electronically through DTC.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR shareholders will be entitled to redeem their
Public Shares for a full pro rata share of the trust account (currently anticipated to be approximately $[_]) net of taxes payable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with tendering your shares for redemption,
you must elect either to physically tender your share certificates to BCAR&#8217;s Transfer Agent or deliver your shares to the Transfer
Agent electronically using The Depository Trust Company&#8217;s DWAC (deposit/withdrawal at custodian) system, in each case, by two business
days prior to the Extraordinary General Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 134; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Through the DWAC system, this electronic delivery
process can be accomplished by contacting your broker and requesting delivery of your shares through the DWAC system. Delivering shares
physically may take significantly longer. In order to obtain a physical stock certificate, a shareholder&#8217;s broker and/or clearing
broker, Deposit Trust Company, and BCAR&#8217;s Transfer Agent will need to act together to facilitate this request. There is a nominal
cost associated with the above-referenced tendering process and the act of certificating the shares or delivering them through the DWAC
system. The Transfer Agent will typically charge the tendering broker $45 and the broker would determine whether or not to pass this cost
on to the redeeming holder. It is BCAR&#8217;s understanding that shareholders should generally allot at least two weeks to obtain physical
certificates from the Transfer Agent. BCAR does not have any control over this process or over the brokers or DTC, and it may take longer
than two weeks to obtain a physical share certificate. Shareholders who request physical share certificates and wish to redeem may be
unable to meet the deadline for tendering their Class A Ordinary Shares before exercising their redemption rights and thus will be unable
to redeem their Class A Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the event that a shareholder tenders its Class
A Ordinary Shares and decides prior to the consummation of the Business Combination that it does not want to redeem its Class A Ordinary
Shares, the shareholder may withdraw the tender. In the event that a shareholder tenders Class A Ordinary Shares and the Business Combination
is not consummated, these Class A Ordinary Shares will not be redeemed for cash and the physical certificates representing these Class
A Ordinary Shares will be returned to the shareholder promptly following the determination that the Business Combination will not be consummated.
BCAR anticipates that a shareholder who tenders Class A Ordinary Shares for redemption in connection with the vote to approve the Business
Combination would receive payment of the redemption price for such Class A Ordinary Shares soon after the completion of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If properly demanded
by BCAR&#8217;s Public Shareholders, BCAR will redeem each share into a pro rata portion of the funds available in the trust account,
calculated as of two business days prior to the anticipated consummation of the Business Combination. As of the Record Date, this would
amount to approximately $[_]. If you exercise your redemption rights, you will be exchanging your Public Shares for cash and will no longer
own the Class A Ordinary Shares. If BCAR is unable to consummate the Business Combination by February 1, 2027 (or May 1, 2027 if the sponsor
exercises its three-month extension option), then it will liquidate and dissolve and Public Shareholders would be entitled to receive
approximately $[_] per share upon such liquidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Tendering Ordinary Share Certificates in connection
with Redemption Rights</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR is requiring the BCAR Public Shareholders seeking
to exercise their redemption rights, whether they are record holders or hold their shares in &#8220;street name,&#8221; to either tender
their certificates to BCAR&#8217;s Transfer Agent, or to deliver their shares to the Transfer Agent electronically using Depository Trust
Company&#8217;s DWAC (deposit/withdrawal at custodian) system, at the holder&#8217;s option prior to two business days immediately preceding
the Extraordinary General Meeting. There is a nominal cost associated with the above-referenced tendering process and the act of certificating
the shares or delivering them through the DWAC system. The Transfer Agent will typically charge the tendering broker $45.00 and it would
be up to the broker whether to pass this cost on to the redeeming holder. However, this fee would be incurred regardless of whether BCAR
requires holders seeking to exercise redemption rights to tender their Class A Ordinary Shares. The need to deliver Class A Ordinary Shares
is a requirement of exercising redemption rights regardless of the timing of when such delivery must be effected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any request for redemption, once made, may be withdrawn
at any time up to two business days immediately preceding the Extraordinary General Meeting. Furthermore, if a shareholder delivered his
certificate for redemption and subsequently decided prior to the date immediately preceding the Extraordinary General Meeting not to elect
redemption, he may simply request that the Transfer Agent return the certificate (physically or electronically).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A redemption payment will only be made in the event
that the proposed Business Combination is consummated. If the proposed Business Combination is not consummated for any reason, then Public
Shareholders who exercised their redemption rights would not be entitled to receive the redemption payment. In such case, BCAR will promptly
return the share certificates to the public shareholder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 135; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Appraisal Rights and Dissenters&#8217; Rights</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No appraisal or dissenters&#8217; rights are available
to BCAR&#8217;s shareholders in connection with the ordinary resolution to approve the Business Combination Proposal. However, in respect
of the resolution to approve the Domestication Merger Proposal, under section&#160;179 of the Companies Act, shareholders of a British
Virgin Islands company ordinarily have dissenters&#8217; rights with respect to a statutory merger. The Companies Act prescribes when
shareholder dissenters&#8217; rights will be available and sets the limitations on such rights. Where such rights are available, shareholders
are entitled to receive fair value for their shares. However, regardless of whether such rights are or are not available, BCAR&#8217;s
shareholders are still entitled to exercise the rights of redemption as detailed in this proxy statement/prospectus and the BCAR Board
has determined that the redemption proceeds payable to BCAR&#8217;s shareholders who exercise such redemption rights represents the fair
value of those shares. Please see the section entitled &#8220;<i>Appraisal or Dissenters&#8217; Rights</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Regardless of whether dissenters&#8217; rights are
or are not available, Public Shareholders can exercise their Redemption Rights as described herein. The BCAR Board has determined that
the redemption proceeds payable to Public Shareholders who exercise their Redemption Rights represent the fair value of the Public Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Proxy Solicitation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR is soliciting proxies on behalf of the BCAR Board.
This solicitation is being made by mail but also may be made by telephone or in person. BCAR and its directors, officers and employees
may also solicit proxies in person, by telephone or by other electronic means. BCAR will file with the SEC all scripts and other electronic
communications as proxy soliciting materials. BCAR will bear the cost of the solicitation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR has engaged Advantage Proxy to assist in the
solicitation process and will pay Advantage Proxy a fee of $8,500, plus disbursements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR will ask banks, brokers and other institutions,
nominees and fiduciaries to forward the proxy materials to their principals and to obtain their authority to execute proxies and voting
instructions. BCAR will reimburse them for their reasonable expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>BCAR Shareholders</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this proxy statement/prospectus,
there are 41,200,000 BCAR Ordinary Shares issued and outstanding, which includes 200,000 Private Units and 12,000,000 BCAR Class B Ordinary
Shares held by the Sponsor. As of the date of this proxy statement/prospectus, there is outstanding an aggregate of 14,100,000 BCAR Warrants,
which consist of the 100,000 Private Placement Warrants and the 14,000,000 Public Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_009"></span>PROPOSAL No. 1</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_010"></span>THE BUSINESS COMBINATION
PROPOSAL</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(1) Proposal No. 1 &#8212; The Business Combination
Proposal </b>&#8212; To consider and vote upon a proposal to approve by way of ordinary resolution and adopt the Agreement and Plan of
Merger, dated as of January&#160;11, 2026 (the &#8220;<b>Business Combination Agreement</b>&#8221;), by and among BCAR, D. Boral ARC Merger
Corporation, a Delaware corporation and a direct, wholly owned subsidiary of the Parent (&#8220;<b>PubCo</b>&#8221;), D. Boral Arc Merger
Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary of the Parent (&#8220;<b>Merger Sub</b>&#8221;), and Exascale Labs
Inc., a Delaware corporation (the &#8220;<b>Company</b>&#8221; or &#8220;<b>Exascale</b>&#8221;). Pursuant to the Business Combination
Agreement: (1) subject to the conditions of the Business Combination Agreement, the Parent shall continue out of the British Virgin Islands
and into the State of Delaware so as to re-domicile as and become a Delaware corporation by means of a merger (the &#8220;<b>Domestication
Merger</b>&#8221;) of the Parent with and into PubCo, with PubCo as the surviving company pursuant to the BVI Business Companies Act,
(Revised Edition 2020) as amended, of the British Virgin Islands and the applicable provisions of the Delaware General Corporation Law,
as amended. Upon the Domestication Merger, PubCo shall change its name to &#8220;Exascale Labs Holdings Inc.&#8221;, and, thereafter (2)
(a) the Merger Sub shall be merged with and into the Company, (b) the separate corporate existence of Merger Sub shall thereupon cease,
and the Company shall be the surviving corporation, and (c) the surviving corporation shall become a wholly-owned subsidiary of PubCo
(the &#8220;<b>Acquisition Merger</b>&#8221; and collectively with the Domestication Merger and the other agreements and transactions
contemplated by the Business Combination Agreement, the &#8220;<b>Business Combination</b>&#8221;). We refer to this proposal as the &#8220;<b>Business
Combination Proposal</b>.&#8221; A copy of the Business Combination Agreement is attached to the accompanying proxy statement/prospectus
as <i>Annex&#160;A</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Background of the Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of the Business Combination Agreement and related ancillary documents are the result of extensive negotiations between BCAR, Exascale
and their respective representatives. The following is a brief description of BCAR&#8217;s formation, the background of BCAR&#8217;s previous
attempts at a business combination, its negotiations with and evaluation of Exascale, the Business Combination Agreement, the Business
Combination, and the related transactions. The following is not intended to be a list of all opportunities initially evaluated or explored
or discussions held by BCAR, but rather summarizes the key meetings and events that led to the signing of the Business Combination Agreement
with Exascale and includes all information that BCAR and Exascale consider material regarding the negotiation of the Business Combination.
All dates and times referred to in the following chronology are Eastern Standard Time in the United&#160;States unless otherwise indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Corporate
History</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2025, BCAR consummated its IPO of 25,000,000 BCAR Units at $10.00 per Unit, generating gross proceeds of $250,000,000. On August
11, 2025, the underwriters of the IPO notified BCAR of their partial exercise of the over-allotment option and purchased 3,000,000 additional
BCAR Units at $10.00 per unit upon the closing of the over-allotment option, generating gross proceeds of $30,000,000. The over-allotment
option closed on August 13, 2025. Each BCAR Unit consists of one Class A Ordinary Share, par value $0.0001 per share, and one-half of
one warrant to purchase a Class A Ordinary Share. Simultaneously with the closing of the IPO, BCAR consummated the sale of 200,000 Private
Units at a price of $10.00 per Private Unit in a private placement to the Sponsor generating proceeds of $2,000,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of $280,000,000 of the proceeds from the IPO and the sale of the Private Units was placed in a U.S.-based trust account maintained
by Odyssey Transfer and Trust Company, acting as trustee (the &#8220;<b>Trust Account</b>&#8221;). The BCAR Units commenced public trading
on July 31, 2025 on the Nasdaq Global Market, and the Class A Ordinary Shares and Public Warrants commenced separate public trading on
August 20, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
BCAR IPO was conducted pursuant to a registration statement on Form&#160;S-1&#160;that became effective on July 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the consummation of the IPO, neither BCAR, nor anyone on its behalf, engaged in any substantive discussions, directly or indirectly,
with any business combination target regarding a business combination with BCAR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promptly
following its IPO, BCAR commenced consideration and evaluation of potential target businesses with the objective of consummating a business
combination. BCAR focused its search for potential target businesses by utilizing internal research and the networks of relationships
of its management, board of directors and with professional service providers (including lawyers, accountants, consultants, and investment
bankers). BCAR educated these parties on its structure as a special purpose acquisition company (&#8220;SPAC&#8221;) and its criteria
for an acquisition. BCAR also responded to inquiries from investment bankers or other similar professionals who represented companies
engaged in either a sale or financing process. On a regular basis, BCAR&#8217;s directors were updated with respect to the status of the
search for a potential target for the business combination. Input received from BCAR&#8217;s directors was material to its management&#8217;s
evaluation of a potential business combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
the closing of the IPO through the signing of the Business Combination Agreement with Exascale on January 11, 2025, representatives of
BCAR contacted and were contacted by numerous individuals and entities with respect to business combination opportunities and engaged
in discussions with several possible targets with respect to a potential business combination. The BCAR management team routinely updated
the BCAR Board on new potential business combination candidates added to the management&#8217;s target search, candidates no longer considered,
the progress of Exascale merger negotiations, and the expected date of the completion of the Business Combination Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
all, prior to the execution of the Business Combination Agreement, representatives of BCAR evaluated over 10 potential initial business
combinations. BCAR executed more than 4 non-disclosure&#160;agreements on standard terms during the course, in addition to its non-disclosure&#160;and
confidentiality agreement with Exascale dated as of August 11, 2025 (the &#8220;<b>NDA</b>&#8221;). Other than the letter of intent entered
into with Exascale, BCAR did not entered into letters of intent with any other potential target companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the potential targets which BCAR considered, Company A, was a regulated and centrally-cleared trading venue dedicated to digital asset
futures and options. BCAR was introduced to Company A by the Sponsor on September 3, 2025, after which BCAR determined to execute a non-disclosure&#160;agreement
with Company A to continue discussions. BCAR conducted due diligence on Company A, including review of the overall business plan and licenses
held, management team and capitalization structure, and historic and budgeted projected statements. Representatives of BCAR met with representatives
of Company A on over five occasions via conference call. BCAR ultimately determined not to pursue Company A due to industry considerations,
stage of the business, and capital needs to execute on growth objectives. The last correspondence between BCAR and Company A was on September
29, 2025, and there was no further communication, negotiation, or diligence conducted after that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Another
potential target, Company B, was a data protection and infrastructure management company. Representatives of BCAR were contacted by management
of Company B with regard to a potential business combination with Company B on August 11, 2025, after which BCAR determined to execute
a non-disclosure&#160;agreement with Company B to continue discussions on August 11, 2025. BCAR conducted conference calls and virtual
meetings with representatives of Company B on more than three occasions and engaged in due diligence on Company B.&#160;As a result of
the discussions with Company B and BCAR&#8217;s due diligence, BCAR determined to end its pursuit of Company B as a potential target due
to concerns over the capital requirements to execute the business plan, industry considerations, and proposed valuation. The last correspondence
between BCAR and Company B was on August&#160;20, 2025, and there was no further communication, negotiation, or diligence conducted after
that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR&#8217;s
third potential target, Company C, was a mining company for critical metals. Representatives of BCAR were contacted by an investor that
BCAR&#8217;s management had previous relationships with in regard to a potential business combination with Company C on September 23,
2025, after which BCAR determined to execute a non-disclosure&#160;agreement on September 24, 2025 with Company C to continue discussions.
BCAR conducted conference calls and virtual meetings with representatives of Company C on more than ten occasions and engaged in due diligence
on Company C.&#160;BCAR ultimately ceased discussions with Company C because the early stage of the company&#8217;s operations and capital
intensive nature of the business, which BCAR determined was not advantageous to the SPAC at the time. The last correspondence between
BCAR and Company C was on October 11, 2025, and there was no further communication, negotiation, or diligence conducted after that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">BCAR&#8217;s fourth potential
target, Company D, was a regional commuter airline company. BCAR was introduced to Company D by the management of Company D through BCAR&#8217;s
underwriter on August 19, 2025, after which BCAR determined to execute a non-disclosure&#160;agreement on August 28, 2025 with Company
D to continue discussions. BCAR conducted due diligence on Company D, including review of business plan, capital investments and projected
capital needs, and historic and budgeted projected statements. Representatives of BCAR met with representatives of Company D on over three&#160;occasions
via conference call. BCAR ultimately determined not to pursue Company D due to business plan considerations and differences around the
minimum cash condition needed for the business. The last correspondence between BCAR and Company D was on August 28, 2025, and there was
no further communication, negotiation, or diligence conducted after that date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 138; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Background of BCAR&#8217;s Interaction with Exascale&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Negotiations
with Exascale</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 5, 2025, John Darwin, the CFO of BCAR, was introduced to Hoansoo Lee, the CEO of Exascale, through ARC Group via email. Mr. Darwin
and Mr. Lee arranged for a call on August 8th, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 8, 2025, Mr. Darwin and Mr. Lee discussed the business plan of Exascale, the company&#8217;s growth plans and ambitions to be a
publicly traded company, and capitalization necessary to achieve its business goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 11, 2025, Exascale and BCAR entered into the NDA to facilitate further discussions and diligence related to a potential business
combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 14, 2025, John Darwin and Hoansoo Lee met in person in New York City to discuss the potential business combination. During this
meeting, Mr. Darwin and Mr. Lee had preliminary discussions regarding Exascale&#8217;s valuation range, transaction structure of the Business
Combination, and proposed timeline for completion of the Business Combination. In this discussion, Mr. Darwin and Mr. Lee discussed recurring
revenue multiples, growth trajectory, and industry comparable considerations for valuations in a SPAC transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 25, 2025, Exascale granted BCAR&#8217;s management and representatives access to Exascale&#8217;s online data room for purposes
of BCAR&#8217;s preliminary due diligence, and BCAR commenced its preliminary due diligence of Exascale. The preliminary due diligence
included a review of publicly available key competitor data and a review of the preliminary materials provided in the online data room
and requests for follow-up data and information from Exascale, including Exascale&#8217;s management&#8217;s responses to due diligence
questions;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 10, 2025, Mr. Lee emailed Mr. Darwin Exascale&#8217;s financial projections (the &#8220;<b>Projections</b>&#8221;) through fiscal
year 2028. The projections were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; color: Black; font-weight: bold; text-align: left">Metric</td>
    <td style="padding-bottom: 1pt; text-align: center; color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: center">2026E</td>
    <td style="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center; color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: center">2027E</td>
    <td style="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center; color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; font-weight: bold; text-align: center">2028E</td>
    <td style="padding-bottom: 1pt; color: Black; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt; width: 64%">Total
        Revenue</td>
    <td style="color: Black; width: 1%">&#160;</td>
    <td style="color: Black; text-align: left; width: 1%">$</td>
    <td style="color: Black; text-align: right; width: 9%">20.0</td>
    <td style="padding-bottom: 1pt; color: Black; text-align: left; width: 1%">M</td>
    <td style="color: Black; width: 1%">&#160;</td>
    <td style="color: Black; text-align: left; width: 1%">$</td>
    <td style="color: Black; text-align: right; width: 9%">40.0</td>
    <td style="padding-bottom: 1pt; color: Black; text-align: left; width: 1%">M</td>
    <td style="color: Black; width: 1%">&#160;</td>
    <td style="color: Black; text-align: left; width: 1%">$</td>
    <td style="color: Black; text-align: right; width: 9%">80.0</td>
    <td style="padding-bottom: 1pt; color: Black; text-align: left; width: 1%">M</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">YoY
        Growth</td>
    <td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: right">-</td>
    <td style="padding-bottom: 1pt; color: Black; text-align: left">&#160;</td>
    <td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: right">100</td>
    <td style="padding-bottom: 1pt; color: Black; text-align: left">%</td>
    <td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: right">100</td>
    <td style="padding-bottom: 1pt; color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">Gross
        Profit</td>
    <td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td>
    <td style="color: Black; text-align: right">4.4</td>
    <td style="padding-bottom: 1pt; color: Black; text-align: left">M</td>
    <td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td>
    <td style="color: Black; text-align: right">10.8</td>
    <td style="padding-bottom: 1pt; color: Black; text-align: left">M</td>
    <td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td>
    <td style="color: Black; text-align: right">28.0</td>
    <td style="padding-bottom: 1pt; color: Black; text-align: left">M</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">Gross
        Margin</td>
    <td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: right">22</td>
    <td style="padding-bottom: 1pt; color: Black; text-align: left">%</td>
    <td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: right">27</td>
    <td style="padding-bottom: 1pt; color: Black; text-align: left">%</td>
    <td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: right">65</td>
    <td style="padding-bottom: 1pt; color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">Operating
        Income</td>
    <td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td>
    <td style="color: Black; text-align: right">(1.5</td>
    <td style="padding-bottom: 1pt; color: Black; text-align: left">M)</td>
    <td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td>
    <td style="color: Black; text-align: right">2.0</td>
    <td style="padding-bottom: 1pt; color: Black; text-align: left">M</td>
    <td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td>
    <td style="color: Black; text-align: right">14.7</td>
    <td style="padding-bottom: 1pt; color: Black; text-align: left">M</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; color: Black; font-weight: bold; text-align: left; padding-bottom: 1pt">Net
        Income</td>
    <td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td>
    <td style="color: Black; text-align: right">(2.3</td>
    <td style="padding-bottom: 1pt; color: Black; text-align: left">M)</td>
    <td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td>
    <td style="color: Black; text-align: right">1.2</td>
    <td style="padding-bottom: 1pt; color: Black; text-align: left">M</td>
    <td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td>
    <td style="color: Black; text-align: right">11.3</td>
    <td style="padding-bottom: 1pt; color: Black; text-align: left">M</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
see the section entitled &#8220;&#8212;<i>Exascale&#8217;s Financial Projections</i>&#8221; for additional details regarding the Projections.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 17, 2025, BCAR sent an initial draft of the letter of intent (the &#8220;<b>LOI</b>&#8221;) to Exascale, which reflected a proposed
pre-Business Combination&#160;consolidated enterprise value of Exascale of $450&#160;million. The initial valuation was determined by
BCAR with an emphasis on the high revenue growth, overall market size of the industry, potential large scale contracts, and revenue projections
of Exascale. For a discussion of BCAR&#8217;s valuation analysis, see the section entitled &#8220;&#8212;<i>Summary of BCAR&#8217;s Financial
and Valuation Analysis.</i>&#8221; The LOI outlined the proposed terms for the Business Combination for discussion purposes, including,
among other things, structuring considerations, and sources and uses of capital. The draft LOI contained a one-way&#160;exclusivity provision
restricting Exascale from exploring an acquisition transaction for a period of 45 calendar days. The draft did not include any condition
relating to minimum cash at closing or minimum cash in trust. The LOI also provided for key terms regarding lock-up&#160;arrangements
with respect to securities of PubCo to be held by the Sponsor and the shareholders of Exascale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2025, Exascale sent a markup of the LOI, which, among other things, (i) proposed a pre-Business Combination value of $500
million instead of $450 million, (ii) changed the exclusivity period from 45 days to 60 days, (iii) introduced a supervoting class of
PubCo shares, the Class B Super Common Share, which will be held by Mr. Lee and other Exascale founders and have 20 votes per share, and
(iv) included a minimum cash condition of $5.0 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2025, Mr. Darwin and Mr. Lee held a telephonic meeting during which they discussed the Exascale&#8217;s counter valuation
of $500 million and Exascale&#8217;s other changes to the LOI, including the Class B Super Common Share. Mr. Lee also requested that BCAR
include a provision in the LOI allowing Exascale to raise capital during the LOI exclusivity period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
September 22, 2025 and September 30, 2025, BCAR&#8217;s management team revisited its research and financial assumptions in connection
with the Business Combination and discussed the proposed valuation with D. Boral Capital and ARC Group. While BCAR initially offered $450
million in consideration for Exascale, the ultimate valuation of $500 million was still within the valuation range set forth BCAR&#8217;s
valuation analysis. See the section entitled &#8220;&#8212;<i>Summary of BCAR&#8217;s Financial and Valuation Analysis</i>.&#8221; BCAR&#8217;s
initial offer was intended to anchor the starting point for the valuation discussion within the acceptable range for BCAR. Following negotiations,
BCAR determined that $500 million was a fair valuation based on the existing revenue and contracts, Projections and the comparable company
analysis performed by BCAR&#8217;s management. In addition, given that the success of Exascale, in BCAR&#8217;s management view, largely
depends on the skill and investment of the founders, BCAR determined that it would be in the interest of BCAR&#8217;s shareholders for
the Exascale founders to retain voting control of PubCo through the Class B Super Common Share following the closing of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2025. BCAR sent a markup of the LOI to Exascale. The markup included a provision allowing Exascale to engage in non-routine
transactions (each such transaction, a &#8220;<b>Non-Routine Transaction</b>&#8221;), including (i) negotiating, entering into and consummating
commercial agreements with customers, suppliers, and strategic collaborators (including research, development, licensing and distribution
arrangements), and (ii) evaluating and, if appropriate, consummating equity or equity-linked financings that do not (A) constitute a Competing
Transaction (as defined in the LOI) or (B) result in any third party obtaining, at or prior to Closing, control of Exascale or a contractual
right to block the Acquisition. The LOI provided BCAR the right to terminate the LOI if the Non-Routine Transaction had a materially adverse
effect on the economic or other benefits of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR
and Exascale executed the LOI on October 1, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR,
Exascale, Loeb &amp; Loeb LLP (&#8220;<b>Loeb &amp; Loeb</b>&#8221;) and Kesse PLC (&#8220;<b>Kesse</b>&#8221;) held a kick off call on
October 7, 2025 to align on overall process, including due diligence and preparation of the business combination agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 8, 2025, Mr. Darwin advised the BCAR Board via email of the progress on the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
granted the Loeb &amp; Loeb team access to the data room on October 8, 2025. Loeb &amp; Loeb and BCAR sent an expanded due diligence request
list to Exascale on October 13, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Chief Executive Officer of Exascale and management from BCAR discussed transaction timing and the due diligence process on a phone call
on October 22, 2025. Exascale began populating responses to requested information in the data room in the weeks that followed. Exascale
and its counsel corresponded regarding status of legal due diligence and structure of the business combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2025, Loeb &amp; Loeb sent an initial draft of the business combination agreement to Exascale and its counsel. Subsequently
and until the execution of the Business Combination Agreement on January 11, 2026, representatives of Loeb &amp; Loeb and Kesse exchanged
multiple drafts of the Business Combination Agreement and related ancillary documents and also engaged in multiple conversations and communications.
The principal terms of the Business Combination Agreement and related ancillary documents negotiated during such time related to, among
other things, (i) the structure and terms of the Merger, (ii) the scope of representations, warranties and covenants made by each of Exascale
and BCAR, (iii) the closing conditions and approvals required to consummate the Business Combination, (iv) certain provisions related
to the transaction financing, (v) certain reorganization steps to be undertaken by BCAR prior to the closing of the Business Combination,
(vi) the conversion mechanics of Exascale&#8217;s SAFEs, and (vii) the scope of the terms of the Parent Support Agreement, Company Shareholder
Support Agreement, and Company Shareholder Lock-up Agreement and other ancillary documents relating to the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 25, 2025, the parties agreed to extend exclusivity for an additional thirty days pursuant to the LOI.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 2, 2025, Kesse sent preliminary comments on the business combination agreement to BCAR and Loeb &amp; Loeb. In the weeks that
followed, Kesse and Loeb &amp; Loeb traded drafts of the business combination agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 140; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR
and Exascale had a call with their respective outside counsel on December 24, 2025 with the goal of resolving all open points in the business
combination agreement. These points included the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Which party would bear tax liability
        for a pre-closing reorganization where BCAR would be domiciled in Delaware;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timing for delivery of audited financials
        of Exascale;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR&#8217;s right to terminate
        the business combination agreement if audited financials were not delivered by a certain date; and</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The scope of the definition of an
        &#8220;Alternative Transaction&#8221;, which impacts the scope of the no-shop provisions in the business combination agreement.</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties exchanged drafts of the business combination agreement to resolve these and other issues. Numerous conversations between the Chief
Executive Officer and management of BCAR occurred during the days following the all hands call. Drafts of ancillary agreements, such as
the support agreements, lock-up agreements and disclosure schedules were exchanged from December 30<sup>th</sup>, 2025 through January
10, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10, 2026, the BCAR Board met via video conference. In attendance were all members of the BCAR Board. Following a presentation
by the BCAR management team, and deliberations by members of the BCAR Board, the BCAR Board unanimously approved BCAR&#8217;s entry into
the Business Combination Agreement and ancillary documents, as well as other corporate matters in connection with the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
[_], 2026, the sole director and sole shareholder of Merger Sub adopted the respective written resolutions approving the Business Combination
Agreement and the transactions contemplated therein, as well as other corporate matters in connection with the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 11, 2026, BCAR, Exascale, PubCo and Merger Sub executed the Business Combination Agreement and other related transaction agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 13, 2026, prior to market open, BCAR and Exascale issued a joint press release announcing the Business Combination. On January&#160;13,
2026, BCAR filed a Current Report on Form&#160;8-K&#160;that included the Business Combination Agreement, other agreements entered into
in connection with the Business Combination, and a joint press release as exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exascale&#8217;s
Financial Projections</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR
and Exascale do not, as a matter of general practice, publicly disclose long-term&#160;forecasts or internal projections as to future
revenues, earnings or other results due to, among other reasons, the uncertainty, unpredictability and subjectivity of the underlying
assumptions and estimates. However, prior to approval by the BCAR Board on January 10, 2026, and the execution of the Business Combination
Agreement and related agreements, Exascale provided BCAR with recently prepared, internal financial projections for each of the years
in the three-year&#160;period ending December&#160;31, 2028. The financial projections presented in this proxy statement/prospectus constitute
the entirety of the financial forecasts presented to the BCAR Board in approving the Business Combination. The decision to prepare projections
until 2028 was based on Exascale management&#8217;s assessment that such three year revenue forecast was a reasonable time period for
the projections. As further discussed below, the financial statements are based solely on assumptions regarding growth rates. Exascale
is an early-stage&#160;company with limited operations. Exascale has historically generated revenue since the third quarter of 2023 and
has grown revenue in each subsequent quarter with an average of 70%+ revenue growth quarter over quarter. Revenue projections for each
business line and corresponding margins were benchmarked against estimated U.S. market size gathered from primary and secondary industry
research. A summary of the financial projections is set forth below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 141; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
projected financial information was not prepared with a view toward complying with the guidelines established by the American Institute
of Certified Public Accountants, but, in the view of BCAR&#8217;s management, reflects currently available estimates and assumptions,
was prepared on a reasonable basis and presents, to the best of management&#8217;s knowledge and belief, the expected implementation of
Exascale&#8217;s business plan and the expected future financial performance, in each case at the time such information was provided to
the BCAR Board, which may be different from the information currently available at the time of filing this proxy statement/prospectus.
Further, Exascale affirmed to BCAR that the financial projections reflect the view of Exascale&#8217;s management about its future performance
as of April 20, 2026. However, the financial projections are not a statement of fact and should not be relied upon as being necessarily
indicative of future results, and readers of this proxy statement/prospectus are cautioned not to place undue reliance on the prospective
financial information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
inclusion of the financial projections should not be deemed an admission or representation by BCAR, or Exascale or any of their respective
officers, directors, affiliates, advisors, or other representatives with respect to such financial projections. The financial projections
are not included to influence your views on the Business Combination and are summarized in this proxy statement/prospectus solely to provide
shareholders access to certain non-public&#160;information considered by the Exascale Board in connection with its evaluation of the Business
Combination and provided to the BCAR Board in connection with its consideration of the Business Combination. The information from the
financial projections should be evaluated, if at all, in conjunction with the historical financial statements and other information regarding
Exascale in this proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
projected financials were prepared by Exascale&#8217;s management. BCAR&#8217;s management was not involved in the development of any
of the below Exascale projections and assumptions, and independently discussed, reviewed, confirmed or verified a limited number of such
assumptions, or the reasonableness thereof. No&#160;independent auditors have audited, reviewed, examined, compiled nor applied agreed-upon&#160;procedures
with respect to the financial projections and, accordingly, neither BCAR&#8217;s nor Exascale&#8217;s independent auditors express an
opinion or any other form of assurance with respect thereto or its achievability, and each assumes no responsibility for, and disclaims
any association with, the financial projections. The audit reports included in this proxy statement/prospectus relate to historical financial
information. They do not extend to the prospective financial information and should not be read to do so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key elements of the Exascale&#8217;s projections provided to BCAR and relied upon by BCAR in its valuation analysis are set forth in the
table below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Metric</td>
    <td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026E</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2027E</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2028E</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt; width: 64%">Total
        Revenue</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td>
    <td style="text-align: right; width: 9%">20.0</td>
    <td style="padding-bottom: 1pt; text-align: left; width: 1%">M</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td>
    <td style="text-align: right; width: 9%">40.0</td>
    <td style="padding-bottom: 1pt; text-align: left; width: 1%">M</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td>
    <td style="text-align: right; width: 9%">80.0</td>
    <td style="padding-bottom: 1pt; text-align: left; width: 1%">M</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">YoY
        Growth</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">100</td>
    <td style="padding-bottom: 1pt; text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">100</td>
    <td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Gross
        Profit</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">4.4</td>
    <td style="padding-bottom: 1pt; text-align: left">M</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">10.8</td>
    <td style="padding-bottom: 1pt; text-align: left">M</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">28.0</td>
    <td style="padding-bottom: 1pt; text-align: left">M</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Gross
        Margin</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">22</td>
    <td style="padding-bottom: 1pt; text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">27</td>
    <td style="padding-bottom: 1pt; text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">65</td>
    <td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Operating
        Income</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(1.5</td>
    <td style="padding-bottom: 1pt; text-align: left">M)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">2.0</td>
    <td style="padding-bottom: 1pt; text-align: left">M</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">14.7</td>
    <td style="padding-bottom: 1pt; text-align: left">M</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Net
        Income</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(2.3</td>
    <td style="padding-bottom: 1pt; text-align: left">M)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">1.2</td>
    <td style="padding-bottom: 1pt; text-align: left">M</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">11.3</td>
    <td style="padding-bottom: 1pt; text-align: left">M</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All amounts are estimates as of
        the date such projections were prepared.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
projections assume moderate growth in 2026 relative to Exascale&#8217;s 2025 unaudited annual recurring revenue run rate of $15m and then
overall compounded average growth of 58.7% from 2026-2028.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial projections were prepared using a number of assumptions, including the following assumptions that Exascale&#8217;s management
believes to be material:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion within existing customer
        accounts;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new customer acquisitions, particularly
        enterprise accounts;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential large contract wins currently
        in advanced discussions;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market share gains in the high-growth
        AI compute sector; and</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 142; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Additional hires of technical and management team members to
        support growth. </span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
financial projections are contingent upon many assumptions, as outlined above, some of which may prove incorrect, and may cause Exascale
to incur substantial costs, or require Exascale to change its business practices that materially change results under the scenarios covered
by the financials projections. In general, these contingencies include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">meeting milestones and successful
        development of Exascale&#8217;s products;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiating and securing planned
        joint ventures;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ability to achieve anticipated reductions
        in capital expenditures from production process innovations;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new laws, regulations and government
        policies both domestically and internationally;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AI adoption in line with internal
        expectations of forecasted market size; and</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ability to offer products that can
        compete in the highly competitive AI industry.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition
to the foregoing, the BCAR Board considered the recent volatility within the AI industry and the AI infrastructure industry (including
power and supply constraints and related price impacts) but determined that the impact would be mitigated on an &#8220;asset-light&#8221;
model such as Exascale that does not rely on heavy capital investment into data centers or AI training. Further, the BCAR Board also discussed
Exascale&#8217;s ability to scale it operations up with its limited executive management team and employees. The BCAR management team
and Exascale management team had multiple discussions throughout the business combination negotiation period about Exascale hiring additional
support to accelerate growth.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial projections also reflect continued investment in research and development to address market opportunities. While research and
development, sales and marketing and general, and administrative expenses are expected to increase in absolute dollars as Exascale grows,
such expenses are expected to represent a smaller percentage of revenue as Exascale scales, contributing to improvements in EBITDA margin
over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although the assumptions and estimates on which
the financial projections for revenues and costs are based are believed by Exascale&#8217;s management to be reasonable and based on the
best then available information, the financial projections are forward-looking&#160;statements that are based on assumptions that are
inherently subject to significant uncertainties and contingencies, many of which are beyond Exascale&#8217;s and BCAR&#8217;s control.
In addition, the financial projections relate to a business model with a limited track record. There will be differences between actual
and projected results, and actual results may be materially less than those contained in the projections. Since the projections cover
multiple years, such information by its nature becomes less predictive with each successive year. There are many risks associated with
such long term forecasts including uncertainties related to the timing of completion of product development, future market growth, market
penetration, and the timing and impact of future competition. These financial projections are subjective in many respects and thus are
susceptible to multiple interpretations and periodic revisions based on actual experience and business developments. As such, these financial
projections constitute forward-looking&#160;information and are subject to risks and uncertainties, including the various risks set forth
in the section entitled &#8220;<i>Risk Factors</i>&#8221; in this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of BCAR&#8217; Financial and Valuation Analysis</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the material financial
and valuation analyses presented to and reviewed by the BCAR Board in connection with the valuation of Exascale in the Business Combination.
BCAR&#8217;s management team led by John Darwin, the CFO, prepared the valuation analysis of Exascale set forth in this section between
August 15, 2025 and September 17, 2025. The summary set forth below does not purport to be a complete description of the financial and
valuation analyses reviewed or factors considered by BCAR&#8217;s management, nor does the order of the financial analyses described represent
the relative importance or weight given to those financial analyses by the BCAR Board. BCAR may have deemed various assumptions more or
less probable than other assumptions. Some of the summaries of the financial analyses set forth below include information presented in
tabular format. Considering the data in the tables specified below without considering all financial analyses or factors or the full narrative
description of such analyses or factors, including the methodologies and assumptions underlying such analyses or factors, could create
a misleading or incomplete view of the processes underlying BCAR&#8217;s financial analyses and the recommendation of the BCAR Board.
BCAR&#8217;s management, its advisors, or the BCAR Board did not performed any other valuation analysis of Exascale beyond the comparable
company analysis and valuation benchmarking of the comparable companies described on this section.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 143; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation analyses reviewed by the BCAR Board
were conducted based upon numerous material assumptions with respect to, among other things, the market size, commercial efforts, industry
performance, general business and economic conditions and numerous other matters, many of which are beyond the control of BCAR, Exascale
or any other parties to the Business Combination. None of BCAR, Exascale or any other person assumes responsibility if future results
are materially different from those discussed. Any estimates contained in these analyses are not necessarily indicative of actual values
or predictive of future results or values, which may be significantly more or less favorable than as set forth below. In addition, analyses
relating to the value of Exascale do not purport to be appraisals or reflect the prices at which Exascale or PubCo shares may actually
be valued or trade in the open market after the consummation of the Business Combination. Accordingly, the assumptions and estimates used
in, and the results derived from, the financial analysis are inherently subject to substantial uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While valuation benchmarking for an earlier stage,
high-growth company is more difficult than a larger publicly traded company, the valuation analysis performed by BCAR utilized the comparable
companies analysis. Exascale&#8217;s valuation has increased in line with its revenue growth and trajectory with support from other notable
venture capital firms. After receiving the initial projections, the BCAR management team considered whether to use discounted cash flow
(&#8220;DCF&#8221;) analysis for valuation purposes. BCAR determined that using DCF analysis was not advisable for the following reasons:
(i) estimating a sustainable long-term growth rate is problematic given the AI infrastructure industry&#8217;s nascency and the potential
for market paradigm shifts, (ii) selecting an appropriate discount rate is difficult due to the industry&#8217;s inherent risks, such
as regulatory uncertainty and cyber threats, which make risk-adjusted discount rates highly subjective, and (iii) projecting future cash
flows is difficult due to unpredictable revenue streams and the fast evolution of the industry, which makes long term forecasting speculative.
As a result, BCAR did not perform DCF analysis in connection with the evaluation of the Business Combination. In discussions with the
BCAR Board, the BCAR management team highlighted that DCF analysis was not used in the financial analysis on account of the methodology&#8217;s
heavy reliance on long-term forecasts, subjective inputs, and uncertain assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR also considered Exascale&#8217;s last two
most recent private funding rounds (which had implied an enterprise value in the range of $150,000,000 and $300,000,000 respectfully)
as a reference point for valuation purposes. In its review, the BCAR board and financial advisors noted that the previous private financing,
completed in the fourth quarter of 2024, had involved a sophisticated group of institutional investors. The following round, which was
launched in second quarter of 2025 (&#8220;Q2 2025&#8221;) and completed in fourth quarter of 2025 (&#8220;Q4 2025&#8221;), was also led
by a sophisticated institutional investor. The terms and implied valuation from that round provided a relevant market-based benchmark
for assessing Exascale&#8217;s enterprise value in the proposed Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the completion of that previous financing
round, Exascale had achieved several notable milestones. Specifically, Exascale secured additional strategic partnerships with key industry
participants, which broadened its commercial relationships and market reach. In addition, Exascale demonstrated recurring revenue growth,
including an approximately 58% increase in annualized recurring revenue (&#8220;ARR&#8221;) over the period from Q2 2025 to Q4 2025. The
BCAR management team viewed these developments as indicative of positive business momentum and fundamental value creation, which supported
the ultimate valuation ascribed to Exascale in the context of the business combination negotiations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In light of the inadequacy of alternative valuation
methodologies, the BCAR management team determined that valuation benchmarking was more appropriate for an early stage, high growth company
with contract backlog. For more information, please see &#8220;<i>Risk Factors &#8211; Our use of valuation benchmarking as the sole methodology
in the determination of Exascale&#8217;s enterprise value, and our reliance on a peer group of comparable companies comprised of companies
with significantly larger market capitalization, longer operating histories, and greater revenues than Exascale, may result in an inaccurate
assessment of Exascale&#8217;s fair value.</i>&#8221; The enterprise multiples vary for the public companies and the BCAR management team
determined that for a company at Exascale&#8217;s stage of development, taking into account both the implied valuation from Exascale&#8217;s
last private round and the subsequent operational and financial achievements, a larger enterprise multiple reflected an appropriate premium
to the prior financing in light of Exascale&#8217;s strengthened business prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following quantitative information, to the
extent that it is based on market data, is not necessarily indicative of current market conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 144; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparable
Company Analysis</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of this valuation assessment, the management and board of directors of BCAR took into account two comparable company sets
weighted as follows: (a) primary comparable companies (high growth private market and public AI infrastructure)and (b) secondary comparable
companies (cloud infrastructure and later stage AI-adjacent companies).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth the comparable companies selected as part of the financial analyses of Exascale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparable
        Company</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Primary
        Comparable Companies (High-Growth AI Infrastructure)</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CoreWeave,
        Inc. (&#8220;CoreWeave&#8221;)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CoreWeave
        is a specialized cloud infrastructure provider offering GPU-accelerated computing services for artificial intelligence, machine learning,
        visual effects rendering, and high-performance computing applications.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lambda
        Labs, Inc. (&#8220;Lambda&#8221;)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lambda
        Labs is a cloud computing company providing GPU infrastructure and workstations optimized for deep learning, artificial intelligence research,
        and machine learning model training and deployment</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Together
        AI, Inc. (&#8220;Together AI&#8221;)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Together
        AI is a cloud platform company providing infrastructure and tools for building, training, and deploying generative artificial intelligence
        models, offering access to open-source large language models and customizable AI solutions.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modal
        Labs, Inc. (&#8220;Modal&#8221;) </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modal
        is a cloud computing platform providing serverless infrastructure for running and deploying machine learning workloads, enabling developers
        to execute AI and data processing tasks without managing underlying infrastructure.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Secondary
        Comparable Companies (Cloud Infrastructure and AI-Adjacent)</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cloudflare,
        Inc. (&#8220;Cloudflare&#8221;)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cloudflare
        is a global network services company providing content delivery network (CDN), internet security, DDoS mitigation, and distributed cloud
        computing services, with significant AI inference and edge computing capabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Snowflake,
        Inc. (&#8220;Snowflake&#8221;)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Snowflake
        is a cloud-based data platform company providing data warehousing, data lake, and data sharing services with integrated AI and machine
        learning capabilities for large-scale data processing and analytics.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key selection criteria used to determine the comparable companies included, among others, the following factors: (i) the products and
services offered, (ii) business model similarity in revenue recurrence, (iii) revenue growth profile, and/or (iv) gross margin. Companies
were selected because they demonstrate (a) similar product and service offerings as Exascale&#8217;s, and/or (b) leading technology applied
in their respective product and service offerings. The comparable companies were broken down into two distinct sets of public companies,
which can be summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Primary
Comparable Companies (High-Growth AI Infrastructure)</b>: These selected companies develop and provide services in the AI infrastructure
industry similar to Exascale. These companies face similar macro trends driven by business innovation and digital transformation and are
generally expected to have comparable estimated or actual revenue growth in 2026 as Exascale or experienced similar growth trajectories
with benchmarked valuation through investment or acquisition at a similar stage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 145; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Secondary
Comparable Companies (Cloud Infrastructure and AI-Adjacent)</b>: These selected companies provide products and services that are either
similar to Exascale&#8217;s but different company stage and revenue growth or different products and services but share similar characteristics
in terms of recurring revenue streams and industry size or addressable markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation
Benchmarking</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The BCAR Board reviewed an analysis of the estimated
total enterprise value/annual recurring revenue and estimated total enterprise value of each of the comparable companies in the primary
comparable company set and the secondary comparable company set. Exascale does not currently generate EBITDA and is a hyper growth company
based on the revenue growth quarter-over-quarter. The Board and management did not rely on EBITDA multiples or analysis in the valuation
of Exascale and instead focused on revenue and ARR multiples. These were estimates based on publicly available information as of August&#160;30,
2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated revenue multiples of enterprise value are summarized in the table below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Exascale</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Modal</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Cloudflare</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Snowflake</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>CoreWeave</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Lambda</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>Together
        AI</b></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 44%; text-align: left">Enterprise
        Value / 2025E Annual Recurring Revenue (or last ARR)<sup>(1)</sup></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 5%; text-align: right">33.3</td>
    <td style="width: 1%; text-align: left">x</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 5%; text-align: right">64.0</td>
    <td style="width: 1%; text-align: left">x</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 5%; text-align: right">34.1</td>
    <td style="width: 1%; text-align: left">x</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 5%; text-align: right">16.9</td>
    <td style="width: 1%; text-align: left">x</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 5%; text-align: right">12.9</td>
    <td style="width: 1%; text-align: left">x</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 5%; text-align: right">6.0</td>
    <td style="width: 1%; text-align: left">x</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 5%">54.2</td>
    <td style="width: 1%">x</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(1)</td>
    <td style="text-align: justify">The enterprise values set forth in this table are estimates based on publicly available information, including
        estimates for 2025E recurring revenue for both public and private companies.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Th<span style="font-family: Times New Roman, Times, Serif">e
following table sets forth the average estimated total enterprise value/2025E Annual Recurring Revenue (EV/ARR) for the benchmarking group:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; font-style: italic"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; font-style: italic; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EV/2025E<br/>
        Revenue</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; font-style: italic"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 88%; font-style: italic; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale</span></td>
    <td style="width: 1%; font-style: italic"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 9%; font-style: italic; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33.3</span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-style: italic; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modal</span></td>
    <td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-style: italic; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64.0</span></td>
    <td style="padding-bottom: 1pt; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-style: italic; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cloudflare</span></td>
    <td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-style: italic; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.1</span></td>
    <td style="padding-bottom: 1pt; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-style: italic; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Snowflake</span></td>
    <td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-style: italic; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.9</span></td>
    <td style="padding-bottom: 1pt; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-style: italic; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CoreWeave</span></td>
    <td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-style: italic; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.9</span></td>
    <td style="padding-bottom: 1pt; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-style: italic; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lambda</span></td>
    <td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-style: italic; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.0</span></td>
    <td style="padding-bottom: 1pt; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-style: italic; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Together
        AI</span></td>
    <td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-style: italic; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54.2</span></td>
    <td style="padding-bottom: 1pt; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a comparison of Exascale&#8217;s actual December 31, 2025 ARR with the estimated 2025E amount:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; width: 72%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="padding-bottom: 1pt; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025A</b></span></td>
    <td style="padding-bottom: 1pt; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025E</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARR</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.2M</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.0M</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
difference between the actual ARR for the year ended December 31, 2025 and the estimated amount was due to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contracts closing in the end of
        the quarter vs. beginning so not capturing the full revenue in the audited revenue numbers for the quarter</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional customer agreements being
        delayed into the next year</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 146; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Considering</span>
that Exascale&#8217;s substantial revenue growth rate relative to comparable later-stage adjacent businesses, the BCAR Board concluded
that Exascale&#8217;s enterprise value as multiples of 2025E annual recurring revenue represented an attractive valuation relative to
the enterprise value as multiples of estimated or actual 2025 recurring revenue of primary comparable companies (High-growth AI infrastructure)
and secondary comparable companies (Cloud infrastructure and AI-Adjacent). While noting the high variance in enterprise value as multiples
of estimated or actual 2025 EBITDA of comparable companies, the BCAR management team determined that the stage of Exascale&#8217;s growth
was most similar to high-growth companies such as Together AI and Modal so determined that the higher revenue multiple was appropriate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The results of the above-referenced analyses supported
the BCAR Board&#8217;s determination that, based on a number of factors, it was fair to and in the best interests of BCAR and its shareholders,
and that it was advisable, to enter into the Business Combination Agreement and the ancillary documents to which BCAR is, or will be,
a party and to consummate the transactions contemplated thereby (including the Business Combination). For additional information, see
the section of this proxy statement/prospectus titled &#8220;<i>BCAR&#8217;s Board of Directors&#8217; Reasons for the Approval of the
Business Combination</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>BCAR Board of Directors&#8217; Reasons for
the Approval of the Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As described under &#8220;<i>&#8212; Background of
the Business Combination</i>&#8221; above, in evaluating the Business Combination, the BCAR Board consulted with BCAR&#8217;s management
and financial and legal advisors. In reaching its unanimous decision to approve the Business Combination Agreement and the transactions
contemplated by the Business Combination Agreement, the BCAR Board considered a range of factors, including but not limited to, the factors
discussed below. In light of the complexity of those factors, the BCAR Board, as a whole, did not consider it practicable to, nor did
it attempt to, quantify or otherwise assign relative weights to the specific factors it took into account in reaching its decision. Individual
members of the BCAR Board may have given different weight to different factors. Certain information presented in this section, is forward-looking
in nature and, therefore, should be read in light of the factors discussed under &#8220;<i>Cautionary Note Regarding Forward-Looking Statements</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
reaching its decision, the BCAR Board discussed and reviewed the results of the due diligence conducted by its management and advisors,
which included:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">extensive
        meetings and calls with the management team and advisors of Exascale;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">detailed
        analysis on the AI-compute and AI-infrastructure industry and market size;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s
        current capitalization, prior funding rounds and valuation, and notable VC investors throughout their history;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">management
        team analysis and background on third parties engaged for legal and audit work;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">revenue
        scalability and financial forecast relative to other comparable companies;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">capital
        expenditure to achieve financial forecast and ability to sustain the revenue growth rate;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">valuation
        metrics and considerations for comparable companies;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
        of material contracts, partnerships and other material matters; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 147; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial,
        tax, legal, insurance, accounting, operational, business and other due diligence.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The officers and
directors of BCAR have substantial experience in evaluating the operating and financial merits of companies from a wide range of industries
and concluded that their experience and background enabled such officers and directors of BCAR to make the necessary analyses and determinations
regarding the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The BCAR Board considered a number of factors pertaining
to the Business Combination as generally supporting its decision to enter into the Business Combination Agreement and the transactions
contemplated thereby, including, but not limited to, the following factors:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Positive Factors</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Proven Existing Management Team</i></b><i>.</i> Exascale
        has an experienced management team with a proven track record of operational excellence. BCAR is confident in the management team&#8217;s
        deep industry knowledge and strategic vision and believe that the BCAR and Exascale teams will form a collaborative and effective long-term
        partnership that is positioned to create and enhance stockholder value going forward.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Defensible Revenue Model</i></b><i>. </i>Exascale has demonstrated significant
        revenue growth each quarter and secured large scale, multi-year contracts. BCAR is confident in Exascale&#8217;s ability to continue growing
        its revenue base and also maintaining the recurring revenue from existing contracts.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Strong Market Dynamics</i></b><i>.</i> The AI compute infrastructure market
        is large and growing with increasing enterprise AI adoption. BCAR believes Exascale is uniquely positioned to capture this market growth.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Capital Needs at Closing</i></b>. The BCAR Board reviewed the capital
        needs in the merger consideration and minimum cash at closing condition requirement as a positive for potential to close the transaction
        and minimize dilution through additional equity raise at closing.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Terms of the Business Combination Agreement</i></b><i>.</i>&#160;The BCAR
        Board reviewed the financial and other terms and conditions of the Business Combination Agreement, including the consideration to be issued
        to the Exascale Securityholders in connection with the Business Combination, and determined that they were reasonable and were the product
        of arm&#8217;s-length negotiations among the parties.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Shareholder Approval</i></b><i>.</i>&#160;The BCAR Board considered the
        fact that in connection with the Business Combination BCAR&#8217;s shareholders have the option to (i) remain shareholders of BCAR, (ii)
        sell their shares on the open market or (iii) redeem their shares.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Independent
        Director Role</i></b><i>.</i>&#160;The BCAR Board is comprised of a majority of independent directors who are not affiliated with the
        Sponsor and its affiliates. In connection with the Business Combination, BCAR&#8217;s independent directors took an active role in evaluating
        the proposed terms of the Business Combination, including the Business Combination Agreement and the related agreements. BCAR&#8217;s
        independent directors evaluated and approved, as members of the BCAR Board, the Business Combination Agreement and the related agreements
        and the transactions contemplated thereby.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other Alternatives</i></b><i>.</i>&#160;The
        BCAR Board&#8217;s belief is that the Business Combination Agreement represents the best potential business combination for BCAR based
        upon the process utilized to evaluate and assess other potential acquisition targets, and BCAR&#8217;s board of directors&#8217; and management&#8217;s
        belief that such processes had not presented a better alternative.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 148; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Negative
Factors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
BCAR Board also identified and considered the following factors and risks weighing negatively against pursuing the Business Combination,
although not weighted or in any order of significance:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Benefits
        Not Achieved</i></b>. The risk that the potential benefits of the Business Combination may not be fully achieved, or may not be achieved
        within the expected timeframe.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Liquidation of BCAR</i></b>.
        The risks and costs to BCAR if the Business Combination is not completed, including the risk of diverting management focus and resources
        from other business combination opportunities, which could result in BCAR being unable to effect an initial business combination by February
        1, 2027 (or May 1, 2027 if the Sponsor exercises its three-month extension option), and force BCAR to liquidate.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exclusivity</i></b>.
        The fact that the Business Combination Agreement includes an exclusivity provision that prohibits BCAR from soliciting other business
        combination proposals, which restricts BCAR&#8217;s ability, so long as the Business Combination Agreement is in effect, to consider other
        potential business combinations.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shareholder&#160;vote</i></b>.
        The risk that BCAR&#8217;s shareholders may fail to provide the votes necessary to effect the Business Combination.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Limitations
        of review.&#160;</i></b>The BCAR Board considered that they were not obtaining an opinion from any independent investment banking or accounting
        firm that the consideration to be received by the Exascale Securityholders is fair to BCAR or its shareholders from a financial point
        of view. Accordingly, the BCAR Board considered that BCAR may not have properly valued Exascale.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Closing
        conditions.&#160;</i></b>The fact that completion of the Business Combination is conditioned on the satisfaction of certain closing conditions
        that are not within BCAR&#8217;s control, including approval by BCAR&#8217;s shareholders and approval by Nasdaq of the initial listing
        application in connection with the Business Combination.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fees
        and expenses.&#160;</i></b>The fees and expenses associated with completing the Business Combination.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation.&#160;</i></b>The
        possibility of litigation challenging the Business Combination or that an adverse judgment granting permanent injunctive relief could
        indefinitely enjoin consummation of the Business Combination.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
        risks.&#160;</i></b>Various other risks associated with the Business Combination, the business of BCAR and the business of Exascale described
        under the section entitled &#8220;<i>Risk Factors</i>.&#8221;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to considering the factors described above, the BCAR Board also considered that the Insiders may have interests in the Business
Combination as individuals that are in addition to, and that may be different from, the interests of BCAR&#8217;s shareholders. BCAR&#8217;s
independent directors reviewed and considered these interests during the negotiation of the Business Combination Agreement and in evaluating
and approving, as members of the BCAR Board, the Business Combination Agreement and the transactions contemplated therein, including the
Business Combination. The BCAR Board concluded that the potential benefits that it expected BCAR and its shareholders to achieve as a
result of the Business Combination outweighed the potentially negative factors associated with the Business Combination. Accordingly,
the BCAR Board determined that the Business Combination Agreement, the Business Combination and the other transactions contemplated under
the Business Combination Agreement, were advisable, fair to, and in the best interests of, BCAR and its shareholders. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although BCAR did not obtain a fairness opinion in
connection with the Business Combination Agreement, BCAR received certain financial statements and projections from Exascale and had multiple
discussions with the management of Exascale regarding Exascale&#8217;s projected performance. This information gave the comfort around
Exascale&#8217;s business and prospective performance on a go-forward basis. Additionally management of BCAR reviewed contracts and purchase
orders that Exascale has in place with various parties. The BCAR Board was comfortable that Exascale was positioned to generate revenue
and profitability at good margins. One of the key factors the BCAR Board focused on was Exascale&#8217;s strong margin profile, with minimal
capital expenditure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The BCAR Board believed the Business Combination
was in the best interests of the shareholders of BCAR. The BCAR Board was interested in maximizing value for BCAR&#8217;s shareholders
and desired to consummate the Business Combination because it believed that Exascale is well positioned to capitalize on the macroeconomic
factors of AI data center growth and infrastructure surrounding the sector. The BCAR Board also believed that Exascale&#8217;s strategic
relationships are compelling and provide upside value to BCAR&#8217;s shareholders and potential new investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 149; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the foregoing the BCAR Board recommended
BCAR&#8217;s entry into the Business Combination Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exascale&#8217;s
Reasons for the Business Combination</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
evaluated a range of strategic alternatives with the objective of positioning Exascale to execute its long-term growth strategy, strengthen
its competitive position and enhance its ability to deliver scalable, reliable AI compute infrastructure and related services in a rapidly
evolving market. These alternatives included remaining a private company and continuing to raise capital through private financings, pursuing
a traditional initial public offering, pursuing a traditional merger, and entering into a business combination with a SPAC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
evaluating these alternatives, Exascale considered, among other factors, prevailing market conditions, the capital requirements of its
business model, execution certainty, timing considerations and the strategic benefits associated with becoming a publicly traded company.
After considering these factors, Exascale determined that entering into the proposed Business Combination represented a compelling opportunity
to advance its business objectives. The following is a non-exhaustive list of Exascale&#8217;s reasons for the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Market
Opportunity and Business Model Considerations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale operates in a market characterized by
strong and growing demand for AI compute infrastructure, persistent supply constraints for advanced GPUs, and increasing physical constraints
related to power availability, cooling capacity and deployment timelines. Exascale&#8217;s asset-light, software-defined platform aggregates
and manages GPU capacity sourced from third-party data centers and differentiates through its proprietary orchestration software, operational
tooling and service offerings, including GaaS and related Infrastructure Solutions offerings, designed to optimize performance, utilization
and reliability for AI workloads.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
believes that successfully scaling this model requires access to capital to support working capital needs, secure GPU capacity under commercial
arrangements, integrate deployments across multiple facilities and continue investing in Exascale&#8217;s platform and operational capabilities.
Exascale also believes that the competitive dynamics of the AI infrastructure market favor participants that can demonstrate scale, reliability
and long-term operating stability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Access
to Capital and Capital-Efficient Growth </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
principal reason for entering into the Business Combination is to obtain access to the public capital markets in a manner that Exascale
believes provides greater execution certainty and flexibility than alternative financing options. The proceeds from any offerings PubCo
conducts as a public company are expected to be used to support PubCo&#8217;s plans to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">scale
        GPU capacity sourcing and deployments in a supply-constrained environment;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand PubCo&#8217;s platform and
        related enterprise offerings;</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fund working capital needs associated
        with customer onboarding, capacity commitments and service delivery; and</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">support continued investment in
        operational execution and infrastructure.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
believes that its business can be scaled in a capital-efficient manner if supported by sufficient liquidity and access to public capital
over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Acceleration
of Go-to-Market and Customer Growth </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale also believes that the Business Combination
will accelerate its go-to-market strategy and customer growth across multiple customer segments, including foundation model developers,
AI-native enterprises, academic and research institutions, AIDC operators and other infrastructure participants. In addition to providing
GPU compute services, Exascale offers revenue-generating GPU cluster management services to AIDC operators, and Exascale&#8217;s management
believes that additional resources and visibility will support broader adoption of these offerings and facilitate customer engagement
for Exascale&#8217;s Infrastructure Solutions offerings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 150; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
expects that public-company status may enhance its credibility with enterprise customers, suppliers and facility partners, particularly
in infrastructure markets where counterparties often evaluate scale, governance and perceived long-term viability when entering into commercial
relationships.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Capital-Efficient
Scaling of an Asset-Light Model</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Exascale&#8217;s business model relies on third-party data center facilities, GPU hardware resources, and the associated baseline infrastructure
and hardware operations services, rather than owning and operating data center real estate. While this asset-light approach is intended
to reduce upfront capital intensity, scaling Exascale&#8217;s platform requires working capital and commercial flexibility to secure GPU
capacity, integrate deployments across multiple facilities and manage deployment timelines in coordination with customers and facility
partners. Exascale believes that the Business Combination will provide improved access to capital and liquidity to support these activities
and enable it to scale its platform in a capital-efficient manner while maintaining operational flexibility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Support for Commercialization of Infrastructure
Solutions Offerings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale has developed certain Infrastructure
Solutions offerings related to next-generation AI infrastructure, including modular data center, advanced liquid cooling, HVDC power and
energy storage solutions. Exascale&#8217;s management believes these offerings are ready to support customer deployments as of the date
of this proxy statement/prospectus, although they have not generated revenue to date. Exascale believes that the Business Combination
will provide a platform to support the commercialization of these offerings in a disciplined and capital-efficient manner, primarily through
partnerships, joint ventures, systems integration, contract manufacturing and other collaborative structures, supported by access to public
capital markets following the completion of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Transaction-Specific
Considerations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the strategic considerations described above, Exascale considered transaction-specific factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing and execution certainty
        of the Business Combination relative to alternative financing paths, including a traditional initial public offering or additional private
        financings; and</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the experience, sector focus and
        relationships of the Sponsor and its affiliates, which Exascale believes may facilitate access to suppliers, customers and strategic partners.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
evaluating the Business Combination, Exascale also considered a number of potential risks and uncertainties associated with the Business
Combination, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Redemption
Risk and Capital Uncertainty</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale considered the risk that a significant
portion of BCAR&#8217;s Public Shareholders could elect to redeem their BCAR Ordinary Shares in connection with the Business Combination,
which could reduce the amount of cash available at the Closing and limit the capital resources available to support Exascale&#8217;s business
plan. Exascale also considered the uncertainty associated with the ultimate level of redemptions and the extent to which additional financing
arrangements would be required to offset any such redemptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Market
Volatility and Post-Closing Trading Risks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
considered the risk that PubCo&#8217;s securities may experience significant price volatility following the completion of the Business
Combination and that a liquid trading market may not develop or be sustained. Exascale also considered broader market conditions affecting
technology and AI-related companies, which could negatively impact investor sentiment, valuation and access to follow-on capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 151; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Public
Company Readiness and Ongoing Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
considered the additional costs, management time and operational complexity associated with becoming and remaining a public company, including
compliance with SEC reporting requirements, internal controls, corporate governance obligations and investor relations activities. Exascale
also considered the risk that these requirements could divert management attention from executing Exascale&#8217;s business strategy,
particularly during the early post-Closing period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sponsor
and Structural Considerations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
considered the economic interests of the Sponsor and its affiliates, which may differ from those of Exascale&#8217;s stockholders, including
incentives that could encourage completion of the Business Combination even if alternative outcomes might be more favorable to Exascale
under certain circumstances. Exascale also considered the structural features of BCAR, including promote economics and warrant overhang,
and their potential impact on post-Closing capitalization and market perception.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Timing
and Execution Risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
considered the risk that delays in completing the Business Combination, regulatory review, or failure to satisfy Closing conditions could
adversely affect Exascale&#8217;s operations, financing plans or strategic initiatives. Exascale also considered the risk that transaction
execution could be affected by market conditions outside the control of the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Alternatives
Foregone</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
considered that entering into the Business Combination could limit its ability to pursue alternative financing or strategic transactions
in the near term, including additional private financings or a traditional initial public offering, and that such alternatives could become
more attractive if market conditions improved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on these considerations, Exascale concluded that the Business Combination offered a favorable balance of access to capital, strategic
flexibility and execution certainty, and represented an attractive path to support Exascale&#8217;s long-term growth strategy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Certain Interests of BCAR&#8217;s Directors and
Officers and Others in the Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of BCAR&#8217;s directors and executive officers may be deemed to have interests in the transactions contemplated by the Business Combination
Agreement that are different from, or in addition to, those of BCAR&#8217;s shareholders generally. These interests may present these
individuals with certain potential conflicts of interest. BCAR&#8217;s independent directors reviewed and considered these interests during
their evaluation and negotiation of the Business Combination and in unanimously approving, as members of the BCAR Board, the Business
Combination Agreement and the transactions contemplated therein, including the Business Combination. The BCAR Board concluded that the
potential benefits that it expected BCAR and its shareholders to achieve as a result of the Business Combination outweighed the potentially
negative factors associated with the Business Combination. When you consider the recommendation of the BCAR Board in favor of approval
of the Business Combination, you should keep in mind that BCAR&#8217;s directors and officers have interests in the Business Combination
that are different from, or in addition to, your interests as a shareholder, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">If the proposed Business
        Combination is not consummated by February 1, 2027 (or May 1, 2027 if the sponsor exercises its three-month extension option), then we
        will be required to liquidate. In such event, the 12,000,000 BCAR Class B Ordinary Shares, which were acquired by BCAR&#8217;s sponsor,
        MFH 1, LLC (the &#8220;<b>Sponsor</b>&#8221;), prior to the IPO for an aggregate purchase price of $25,000, will be worthless. Such BCAR
        Class B Ordinary Shares had an aggregate market value of approximately $[_] based on the closing price of BCAR&#8217;s Public Shares of
        $[_] on Nasdaq as of [_], 2026. As a result of the nominal price of $0.002 per Class B Ordinary Share paid by the Sponsor compared to
        the recent market price of BCAR Class A Ordinary Shares, the Sponsor is likely to earn a positive rate of return on their investments
        in the Class B Ordinary Shares even if the holders of BCAR&#8217;s Class A Ordinary Shares experience a negative rate of return on their
        investments in the Class A Ordinary Shares.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If the proposed Business Combination is
        not consummated by February 1, 2027 (or May 1, 2027 if the sponsor exercises its three-month extension option), then 200,000 private placement
        units (the &#8220;<b>Private Units</b>&#8221;) purchased by the Sponsor for a total purchase price of $2,000,000, will be worthless. Such
        Private Units had an aggregate market value of approximately $[_] closing price of BCAR Units of $[_] on Nasdaq as of [_], 2026.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 152; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Sponsor invested an aggregate of $2,025,000 in BCAR, comprised of the $25,000
        purchase price for the Founder Shares and $2,000,000 purchase price for the Private Units. The amount held in BCAR&#8217;s trust account
        was approximately $[_] on the Record Date, implying a value of $[_] per public share. Based on these assumptions, each PubCo Class A Common
        Stock would have an implied value of $[_] per share upon consummation of the Business Combination, representing a [_]% decrease from the
        initial implied value of $[_] per public share. While the implied value of $[_] per share upon consummation of the Business Combination
        would represent a dilution to our Public Shareholders, this would represent a significant increase in value for the Sponsor relative to
        the price it paid for each Founder Share. At approximately $[_] per share, the 12,200,000 PubCo Class A Common Stock that the Sponsor
        would own upon consummation of the Business Combination would have an aggregate implied value of $[_]. As a result, even if the trading
        price of PubCo Class A Common Stock significantly declines, the value of the PubCo Class A Common Stock held by the Sponsor will be significantly
        greater than the amount the Sponsor paid to purchase such shares. For more information, please see &#8220;<i>Risk Factors &#8211; The
        nominal purchase price paid by the Sponsor and directors and officers of BCAR for the Founder Shares may significantly dilute the implied
        value of the Public Shares in the event the parties complete an initial business combination. In addition, the value of the Founder Shares
        will be significantly greater than the amount the Sponsor and directors and officers of BCAR paid to purchase such shares in the event
        the parties complete an initial business combination, even if the Business Combination causes the trading price of the PubCo Class A Common
        Stock to materially decline.</i>&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
        the proposed Business Combination is not consummated, then 1,000,000 BCAR Class A Ordinary Shares (the &#8220;Representative Shares&#8221;)
        granted to D. Boral Capital LLC, the underwriter in the IPO, as compensation, which are held by David Boral, the CEO of D. Boral Capital
        LLC and our Chairman and Chief Executive Officer, will be worthless. Such Representative Shares had an aggregate market value of approximately
        $[_] closing price of BCAR Class A Ordinary Shares of $[_] on Nasdaq as of [_], 2026;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
        of [_], 2026, BCAR has unsecured promissory notes in the aggregate principal amount of $[_] outstanding and BCAR has drawn down an aggregate
        of $[_] under the notes. The promissory notes were issued for working capital purposes. In the absence of shareholder approval for a further
        extension, if the proposed Business Combination is not consummated by February 1, 2027 (or May 1, 2027 if the sponsor exercises its three-month
        extension option), then such loans may not be repaid.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
        BCAR consummates the Business Combination, its officers, directors and the sponsor will not receive reimbursement for any out-of-pocket
        expenses incurred by them to the extent that such expenses exceeded the amount of its working capital. As of [_], 2026, $[_] of advances
        was paid by the Sponsor for expenses incurred on BCAR&#8217;s behalf and if the proposed Business Combination is not consummated by February
        1, 2027 (or May 1, 2027 if the sponsor exercises its three-month extension option), that amount would not be repaid. As a result, the
        financial interest of BCAR&#8217;s officers, directors and Initial Shareholders or their affiliates could influence its officers&#8217;
        and directors&#8217; motivation in selecting Exascale as a target and therefore there may be a conflict of interest when it determined
        that the Business Combination is in the shareholders&#8217; best interest.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
        exercise of BCAR&#8217;s directors&#8217; and officers&#8217; discretion in agreeing to changes or waivers in the terms of the transaction
        may result in a conflict of interest when determining whether such changes or waivers are appropriate and in our shareholders&#8217; best
        interest.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
        continued indemnification of current directors and officers and the continuation of directors&#8217; and officers&#8217; liability insurance.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR&#8217;s
        Current Charter provides that BCAR renounces any interest or expectancy in, or in being offered an opportunity to participate in, any
        potential transaction or matter that may be a corporate opportunity for any member of BCAR&#8217;s management, on the one hand, and BCAR,
        on the other hand, or the participation in which would breach any existing legal obligation, under applicable law or otherwise, of a member
        of BCAR&#8217;s management to any other entity. BCAR is not aware of any such corporate opportunities not being offered to BCAR and does
        not believe that waiver of the corporate opportunities doctrine has materially affected BCAR&#8217;s search for an acquisition target
        or will materially affect BCAR&#8217;s ability to complete an initial business combination.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing interests may influence the officers and directors of BCAR to support or approve the Business Combination. As such, the Sponsor
and BCAR&#8217;s officers and directors may be incentivized to complete an acquisition of a less favorable target company or on terms
less favorable to BCAR&#8217;s shareholders rather than liquidate. In considering the recommendations of the BCAR Board to vote for the
proposals, BCAR&#8217;s shareholders should consider these interests. For more information, please see &#8220;<i>Risk Factors &#8212;
Some of the BCAR officers and directors may be argued to have conflicts of interest that may influence them to support or approve the
Business Combination without regard to your interests.<b>&#8221;</b></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 153; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Certain Interests of Exascale&#8217;s Directors
and Officers in the Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In considering the Business Combination, Exascale&#8217;s
sole executive officer and Exascale&#8217;s directors have interests that are different from, or in addition to, the interests of Exascale&#8217;s
other stockholders. Following the completion of the Business Combination, Exascale&#8217;s executive officer and directors and their affiliates
will receive or hold shares of PubCo Class B Super Common Voting Stock, which will carry twenty (20) votes per share, while other Exascale
Securityholders participating in the Business Combination will receive PubCo Class A Ordinary Common Voting Stock, which will carry one
(1) vote per share. As a result, Exascale&#8217;s executive officer and directors will hold equity interests with enhanced voting power,
which will enable them to exercise significant influence over matters submitted to PubCo&#8217;s stockholders, including the election
of directors and approval of significant corporate transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, Exascale&#8217;s executive officer
and directors have interests in the Business Combination related to the continuation of their positions with PubCo, anticipated future
equity-based compensation, severance or change-in-control protections, and the opportunity to participate in the future growth of PubCo
as a publicly traded company. Exascale&#8217;s executive officer and directors will also benefit from increased liquidity for their equity
holdings following the Business Combination, subject to applicable lock-up periods, and from the potential appreciation in the value of
PubCo&#8217;s securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These interests may create conflicts of interest
in connection with the approval of the Business Combination and related transactions. Exascale&#8217;s board of directors considered these
interests, among other factors, in evaluating and approving the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>The Business Combination Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>This subsection of the proxy statement/prospectus
describes the material provisions of the Business Combination Agreement, but does not purport to describe all of the terms of the Business
Combination Agreement. The following summary is qualified in its entirety by reference to the complete text of the Business Combination
Agreement, a copy of which is attached as Annex A to this proxy statement/prospectus. You are urged to read the Business Combination Agreement
in its entirety because it is the primary legal document that governs the Business Combination.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The Business Combination Agreement contains representations,
warranties and covenants that the respective parties made to each other as of the date of the Business Combination Agreement or other
specific dates set forth therein. The assertions embodied in those representations, warranties and covenants were made for purposes of
the contract among the respective parties and are subject to important qualifications and limitations agreed to by the parties in connection
with negotiating the Business Combination Agreement. The representations, warranties and covenants in the Business Combination Agreement
are also modified in part by the underlying disclosure letters (the &#8220;disclosure letters&#8221;), which are not filed publicly and
which are subject to a contractual standard of materiality different from that generally applicable to shareholders and were used for
the purpose of allocating risk among the parties rather than establishing matters as facts. We do not believe that the disclosure letters
contain information that is material to an investment decision. Additionally, the representations and warranties of the parties to the
Business Combination Agreement may or may not have been accurate as of any specific date and do not purport to be accurate as of the date
of this proxy statement/prospectus. Accordingly, no person should rely on the representations and warranties in the Business Combination
Agreement or the summaries thereof in this proxy statement/prospectus as characterizations of the actual state of facts about BCAR, Exascale
or any other matter.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January&#160;11, 2026, D. Boral ARC Acquisition
I Corp., a British Virgin Islands business company (the &#8220;<b>Parent</b>&#8221;), entered into that certain Agreement and Plan of
Merger (as it may be amended, supplemented or otherwise modified from time to time, the &#8220;<b>Business Combination Agreement</b>&#8221;),
by and among the Parent, D. Boral ARC Merger Corporation, a Delaware corporation and a direct, wholly owned subsidiary of the Parent (&#8220;<b>PubCo</b>&#8221;),
D. Boral Arc Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary of the Parent (&#8220;<b>Merger Sub</b>&#8221;),
and Exascale Labs Inc., a Delaware corporation (the &#8220;<b>Company</b>&#8221;). Capitalized terms used but not defined herein shall
have the meaning given to them in the Business Combination Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 154; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale is a next-generation artificial intelligence
(&#8220;<b>AI</b>&#8221;) infrastructure provider operating an asset-light, software-defined graphics processing unit (&#8220;<b>GPU</b>&#8221;)
compute platform and related AI infrastructure solutions. Exascale&#8217;s core business includes GPU as a Service (&#8220;<b>GaaS</b>&#8221;),
through which it provides reserved and on-demand access to high-performance GPU compute capacity sourced from third-party data centers
globally, as well as GPU cluster management and optimization services for artificial intelligence data center (&#8220;<b>AIDC</b>&#8221;)
operators. In addition, Exascale has developed certain modular data center, high-density liquid cooling, high-voltage direct current (&#8220;<b>HVDC</b>&#8221;)
power and energy storage solutions that are designed to address deployment bottlenecks in AI infrastructure and that Exascale believes
are ready for commercial engagement, although these capabilities have not yet generated revenue as of the date of this proxy statement/prospectus.
The platform is purpose-built for large-scale AI workloads, including large language model (&#8220;<b>LLM</b>&#8221;) training, fine-tuning,
and high-concurrency inference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional information about Exascale is set forth
in the section titled &#8220;<i>Information about Exascale</i>&#8221; in this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Consideration</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the Business Combination Agreement, Exascale
Securityholders immediately prior to the Closing will collectively receive 50,000,000 shares of PubCo Common Stock (the &#8220;<b>Merger
Consideration</b>&#8221;) in exchange for their then outstanding interests in Exascale. Holders of Exascale Class A common stock and Exascale
securities convertible or exchangeable for shares of Exascale Class A common stock (being the Exascale Safeholders, the Base Camp Investor
and Exascale Equity Incentive Recipients) will receive shares of PubCo Class A Ordinary Common Stock in exchange for such interests in
Exascale, with each such PubCo Class A Ordinary Common Stock having one (1) vote per share, and holders of Exascale Class B common stock
will receive shares of PubCo Class B Super Common Stock for their Exascale Class B common stock, with each share of such PubCo Class B
Super Common Stock having twenty (20) votes per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The allocation
of the 50,000,000 shares of PubCo Common Stock among Exascale Securityholders will be determined in accordance with (i) the conversion
provisions applicable in the event of a &#8220;liquidity event&#8221; under the SAFEs, (ii) the terms of the Base Camp Investment Agreement,
and (iii) the allocation percentages applicable to the Exascale Equity Incentive Recipients and Exascale stockholders. As a result, the
allocation of the Merger Consideration among Exascale Securityholders is not determined using a single uniform exchange ratio applicable
to all Exascale securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At the closing
of the Acquisition Merger, each issued and outstanding SAFE will be cancelled and converted into the right to receive a number of shares
of PubCo Class A Ordinary Common Stock based on the SAFE&#8217;s &#8220;implied ownership percentage,&#8221; as determined under the
terms of the applicable SAFE in connection with the Business Combination, which constitutes a &#8220;liquidity event&#8221; under the
SAFEs. In general, a SAFE&#8217;s implied ownership percentage is the product of (i) the quotient obtained by dividing (x) the SAFE&#8217;s
purchase amount by (y) the SAFE&#8217;s post-money valuation cap, multiplied by (ii) 100; subject to the capitalization adjustments,
rounding provisions, and other terms contained in the applicable SAFE and the final closing calculations. The resulting implied ownership
percentage determines the number of shares of the 50,000,000 Merger Consideration issuable for each SAFE. Based on the foregoing, the
aggregate implied ownership percentage of all SAFEs outstanding on the filing date of this proxy statement/prospectus was 17.533%, entitling
all the SAFEs to collectively receive an aggregate of 8,766,500 shares of PubCo Class A Ordinary Common Stock as their portion of the
Merger Consideration in connection with the consummation of the Business Combination. The right of an Exascale Safeholder to receive
PubCo Class A Ordinary Common Stock for their SAFE will be contingent on the execution by such Exascale Safeholder of an acknowledgement
and such other agreements and other documents as Exascale deems necessary, appropriate or expedient.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the closing of the Acquisition Merger, the
Base Camp Investment Agreement will be cancelled and converted into the right to receive a number of shares of PubCo Class A Ordinary
Common Stock based on the &#8220;implied ownership percentage&#8221; attributable to the Base Camp Investment Agreement. The implied ownership
percentage applicable to the Base Camp Investment Agreement is a fixed percentage determined in accordance with the terms of the Base
Camp Investment Agreement and will equal 0.625%, entitling the Base Camp Investor to receive an aggregate of 312,500 PubCo Class A Ordinary
Common Stock as their portion of the Merger Consideration in connection with the consummation of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 155; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the closing
of the Acquisition Merger, each then outstanding Exascale Equity Incentive award will be cancelled and converted into the right to receive
a number of shares of PubCo Class A Ordinary Common Stock based on the &#8220;implied ownership percentage&#8221; attributable to the
award. The implied ownership percentage of the Exascale Equity Incentive awards is determined based on Exascale&#8217;s fully diluted
capitalization, and, based on Exascale&#8217;s capitalization as of the filing date of this proxy statement/prospectus, will be 0.154%,
entitling the Exascale Equity Incentive Recipients to receive an aggregate of 77,000 PubCo Class A Ordinary Common Stock as their portion
of the Merger Consideration in connection with the consummation of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the closing
of the Acquisition Merger, each issued and outstanding Exascale Class A common stock will be cancelled and converted into the right to
receive a number of shares of PubCo Class A Ordinary Common Stock based on the &#8220;implied ownership percentage&#8221; attributable
to Exascale&#8217;s Class A common stock. The implied ownership percentage of the Exascale Class A common stock is determined based on
Exascale&#8217;s fully diluted capitalization, and, based on Exascale&#8217;s capitalization as of the filing date of this proxy statement/prospectus,
will be 20.200%, entitling the holders of Exascale Class A common stock to receive an aggregate of 10,100,000 PubCo Class A Ordinary Common
Stock as their portion of the Merger Consideration in connection with the consummation of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the closing
of the Acquisition Merger, each issued and outstanding Exascale Class B common stock will be cancelled and converted into the right to
receive a number of shares of PubCo Class B Super Common Stock based on the &#8220;implied ownership percentage&#8221; attributable to
Exascale&#8217;s Class B common stock. The implied ownership percentage of the Exascale Class B common stock is determined based on Exascale&#8217;s
fully diluted capitalization, and, based on Exascale&#8217;s capitalization as of the filing date of this proxy statement/prospectus,
will be 61.488%, entitling the holders of Exascale Class B common stock to receive an aggregate of 30,744,000 PubCo Class B Ordinary Common
Stock as their portion of the Merger Consideration in connection with the consummation of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At the Effective Time, the holders of Exascale Common
Stock, the Exascale Safeholders, the Base Camp Investor, and the Exascale Equity Incentive Recipients will cease to have any rights with
respect to Exascale securities, except the right to receive their portion of the Merger Consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The allocation of the 50,000,000 shares of PubCo Class
A Common Stock is set forth below (based on Exascale&#8217;s capitalization as of the filing date of this proxy statement/prospectus):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 20%"><span style="font-size: 10pt"><b>Exascale securityholder group</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 31%; text-align: center"><span style="font-size: 10pt"><b>Calculation
        basis</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 12%; text-align: center"><span style="font-size: 10pt"><b>Ownership<br/>
        percentage</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 12%; text-align: center"><span style="font-size: 10pt"><b>PubCo
        shares to<br/> be received</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 21%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PubCo</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>share class</b></p></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Exascale Safeholders</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Sum of each Safeholder&#8217;s purchase amount divided by the applicable post-money
        valuation cap, subject to capitalization, rounding and final closing allocation mechanics</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">17.533%</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8,766,500</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">PubCo Class A Ordinary Common Stock</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Base Camp Investment Agreement Investor</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">0.625% of Exascale&#8217;s total equity, calculated on a fully diluted basis</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">0.625%</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">312,500</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">PubCo Class A Ordinary Common Stock</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Exascale Equity Incentive Recipients</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Fixed allocation percentages based on Exascale&#8217;s fully-diluted capitalization</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">0.154%</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">77,000</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">PubCo Class A Ordinary Common Stock</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Exascale Class A common stockholders </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Fixed allocation percentages based on Exascale&#8217;s fully-diluted capitalization
        </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">20.200%</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10,100,000</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">PubCo Class A Ordinary Common Stock</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Exascale Class B common stockholders</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Fixed allocation percentages based on Exascale&#8217;s fully-diluted capitalization</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">61.488%</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">30,744,000</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">PubCo Class B Super Common Stock</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><b>Total</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>100.000%</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>50,000,000</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing discussion and figures are provided
to illustrate the allocation mechanics, and remain subject to final rounding and closing adjustments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 156; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>PubCo Board of Directors and Executive Officers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Immediately following the Closing, PubCo&#8217;s board
of directors will consist of five directors, all of whom shall be designated by Exascale. PubCo may, in its sole discretion, elect to
classify the post-closing board of directors into two or more classes, effective immediately after the Closing or such other time after
the Closing as PubCo may determine in its discretion, with directors in each class serving staggered terms, with the term of office of
at least one class expiring each year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Representations and Warranties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the Business Combination Agreement, Exascale makes
certain representations and warranties (with certain exceptions set forth in the disclosure schedules to the Business Combination Agreement)
relating to, among other things: (a) proper corporate organization and similar corporate matters; (b) authorization, execution, delivery
and enforceability of the Business Combination Agreement and other transaction documents; (c) required consents and approvals; (d) non-contravention;
(e) capital structure; (f) absence of bankruptcy proceedings, (g) financial statements, (h) liabilities, (i) absence of certain developments,
(j) accounts receivable and accounts payable, (k) compliance with laws, (l) title to property, (m) international trade and anti-bribery
compliance, (n) tax matters, (o) intellectual property, (p) insurance, (q) absence of litigation, (r) bank accounts and powers of attorney,
(s) labor matters, (t) employee benefits, (u) environmental and safety, (v) related party transactions, (w) material contacts, (x) SEC
matters, (y) brokers and other advisors, and (z) other customary representations and warranties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the Business Combination Agreement, BCAR, PubCo
and Merger Sub make certain representations and warranties relating to, among other things: (a) proper corporate organization and similar
corporate matters; (b) authorization, execution, delivery and enforceability of the Business Combination Agreement and other transaction
documents; (c) non-contravention, (d) brokers and other advisors, (e) capitalization, (f) issuance of the Merger Consideration, (g) consents
and required approvals, (h) the trust account, (i) employees, (j) tax matters, (k) stock exchange listing, (l) reporting company status,
(m) undisclosed liabilities, (n) SEC filings and financial statements, (o) business activities, (p) BCAR contracts, (q) absence of litigation,
(r) investment company status; and (s) other customary representations and warranties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Covenants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Business Combination Agreement also contains,
among other things, covenants providing for:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">Exascale operating its business in the ordinary
        course prior to the Closing and not taking certain specified actions without the prior written consent of BCAR;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">Exascale providing access to its books and
        records and providing information relating to its business to BCAR;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">Exascale delivering the financial statements
        required by BCAR to make applicable filings with the SEC;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">BCAR maintaining its existing listing on
        Nasdaq until the Closing and obtaining approval of the listing of PubCo on Nasdaq (or on another nationally recognized securities exchange
        in the United States as may be agreed by BCAR and Exascale) and the continued listing of BCAR securities issued in connection with the
        IPO; and</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">BCAR keeping current, and timely filing,
        all reports required to be filed or furnished with the SEC and otherwise comply in all material respects with its reporting obligations
        under applicable laws.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 157; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Conduct Prior to Closing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From the date of the Business Combination Agreement
until the earlier of the Closing or the date of termination of the Business Combination Agreement, the parties agreed, among other things,
to the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">The parties will not solicit, initiate,
        encourage or continue discussions with any third party with respect to any transaction other than the transactions contemplated or permitted
        by the Business Combination Agreement; and</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">BCAR, with the assistance of Exascale, will
        file and cause to become effective a proxy statement/prospectus of BCAR for the purpose of soliciting proxies from BCAR&#8217;s shareholders
        for approval of certain matters related to the transactions contemplated by the Business Combination Agreement.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Conditions to Closing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>General Conditions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Consummation of the transactions contemplated by the
Business Combination Agreement is conditioned on, among other things, (i) the absence of any order or provisions of any applicable law
prohibiting the transactions or preventing the transactions; (ii) BCAR receiving approval of the Business Combination from its shareholders
in accordance with BCAR&#8217;s existing memorandum and articles of association; (iii) the Nasdaq initial listing application with respect
to the Business Combination having been approved by Nasdaq (or the stock exchange initial listing application with respect to the Business
Combination having been approved by another nationally recognized securities exchange in the United States as may be agreed by BCAR and
Exascale), (iv) the SEC having approved the proxy statement/prospectus filed in connection with the Business Combination, (v) and BCAR
causing PubCo to receive, as of the Closing Date, an aggregate amount not less than $5,000,000 in any combination of cash, cash in the
trust account, a PIPE, an equity line of credit, or third-party financing, net of any outstanding checks, wire transfers, or similar items
not yet cleared, and net of any cash distributions or transfers made in connection with or as a result of the transactions contemplated
by the Business Combination Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Exascale&#8217;s Conditions to Closing</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The obligations of Exascale to consummate the transactions
contemplated by the Business Combination Agreement, in addition to the conditions described above, are conditioned upon each of the following,
among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">BCAR complying with all of its obligations
        under the Business Combination Agreement in all material respects;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">the representations and warranties of BCAR
        being true on and as of the Closing in all material respects; and</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">there having been no Material Adverse Effect
        (as defined in the Business Combination Agreement) to BCAR.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>BCAR&#8217;s Conditions to Closing</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The obligations of BCAR, PubCo and Merger Sub to consummate
the transactions contemplated by the Business Combination Agreement, in addition to the conditions described above, are conditioned upon
each of the following, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">the representations and warranties of Exascale
        being true on and as of the Closing, other than as would not reasonably be expected to have a Material Adverse Effect (as defined in the
        Business Combination Agreement); and</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">Exascale complying with all of the obligations
        under the Business Combination Agreement in all material respects.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 158; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Termination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Business Combination Agreement may be terminated
and/or abandoned at any time prior to the Closing upon mutual agreement of the parties or by:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">BCAR, if Exascale has breached any representation,
        warranty, agreement or covenant contained in the Business Combination Agreement, such that the conditions to BCAR&#8217;s obligations
        to close would not be met, and such breach has not been cured within the earlier of (A) September&#160;1, 2026 (the &#8220;Outside Date&#8221;)
        and (B) thirty (30) days following the receipt by Exascale of a notice describing such breach;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">Exascale, if BCAR, PubCo or Merger Sub has
        breached any representation, warranty, agreement or covenant contained in the Business Combination Agreement, such that the conditions
        to Exascale&#8217;s obligations to close would not be met, and such breach has not been cured within the earlier of (A) the Outside Date
        and (B) thirty (30) days following the receipt by BCAR a notice describing such breach;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: middle">either BCAR or Exascale, if the Closing
        has not occurred by the Outside Date, provided that the failure of the Business Combination to have been consummated on or before the
        Outside Date was not due to such party&#8217;s breach of or failure to perform any of its representations, warranties, covenants or agreements
        set forth in the Business Combination Agreement;</td> </tr>
  </table>

<p style="margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">either BCAR or Exascale, if an Order (as defined in the Business Combination
        Agreement) permanently restraining, enjoining or otherwise prohibiting the transactions contemplated by the Business Combination Agreement
        shall be in effect and shall have become final and non-appealable; provided that this right shall not be available to a party if such
        Order was due to such party&#8217;s breach of or failure to perform any of its representations, warranties, covenants or agreements set
        forth in the Business Combination Agreement;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">either Exascale or BCAR, if the Business Combination Agreement or the transactions
        contemplated thereby fail to be authorized or approved by BCAR shareholders;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Exascale, if the BCAR Board shall have withdrawn, amended, qualified or modified
        its recommendation to the shareholders of BCAR that they vote in favor of Parent Proposals (as defined in the Business Combination Agreement);</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">BCAR, if the shareholders of Exascale do not approve the Business Combination
        Agreement and the transactions contemplated thereunder; and</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">BCAR, if the requisite audited financial statements of Exascale or the requisite
        interim financial statements of Exascale have not been delivered by January&#160;31, 2026 or such other date that may be mutually agreed
        between the parties.</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Business Combination Agreement and other agreements
described below have been included to provide investors with information regarding their respective terms. They are not intended to provide
any other factual information about BCAR, Exascale or the other parties thereto. In particular, the assertions embodied in the representations
and warranties in the Business Combination Agreement were made as of a specified date, are modified or qualified by information in one
or more disclosure letters prepared in connection with the execution and delivery of the Business Combination Agreement, may be subject
to a contractual standard of materiality different from what might be viewed as material to investors, or may have been used for the purpose
of allocating risk between the parties. Accordingly, the representations and warranties in the Business Combination Agreement are not
necessarily characterizations of the actual state of facts about BCAR, Exascale or the other parties thereto at the time they were made
or otherwise and should only be read in conjunction with the other information that BCAR makes publicly available in reports, statements
and other documents filed with the SEC. BCAR and Exascale investors and securityholders are not third-party beneficiaries under the Business
Combination Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing summary of the Business Combination
Agreement does not purport to be complete and is qualified in its entirety by reference to the actual Business Combination Agreement,
a copy of which is attached to this proxy statement/prospectus as <i>Annex A.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 159; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Certain Related Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sponsor Support Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the execution of the Business Combination
Agreement, the Sponsor, has entered into a Sponsor Support Agreement (the &#8220;<b>Sponsor Support Agreement</b>&#8221;) with Exascale
and BCAR, pursuant to which the Sponsor has agreed to appear at the shareholder meeting or cause its shares to be counted as present for
the purpose of establishing a quorum, vote all shares of BCAR it beneficially owns in favor of each of the proposals to be presented at
the Extraordinary General Meeting, to take all actions reasonably necessary to consummate the Business Combination and to vote against
any proposal that would prevent the satisfaction of the conditions to the Business Combination set forth in the Business Combination Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Company Support Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Business Combination Agreement,
the majority shareholder of Exascale entered into a Shareholder Support Agreement (the &#8220;<b>Company Support Agreement</b>&#8221;)
with BCAR and Exascale, pursuant to which such shareholder has agreed to appear at the shareholder meeting of Exascale to approve the
Business Combination or cause its shares to be counted as present at such meeting for the purpose of establishing a quorum, vote the shares
of Exascale it beneficially owns in favor of each of the proposals to be included in the applicable written consent of Exascale&#8217;s
shareholders, to take all actions reasonably necessary to consummate the Business Combination and to vote against any proposal that would
prevent the satisfaction of the conditions to the Business Combination set forth in the Business Combination Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Lock-Up Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Closing, the majority shareholder
of Exascale will enter into a Lock-Up Agreement (the &#8220;<b>Lock-up Agreement</b>&#8221;) with BCAR, pursuant to which it will agree,
subject to certain customary exceptions, not to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">offer, sell, contract to sell, pledge, or otherwise dispose of, directly or
        indirectly, any PubCo Common Stock or securities convertible into or exercisable or exchangeable for PubCo Common Stock held by them immediately
        after the Closing, or enter into a transaction that would have the same effect;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">enter into any swap, hedge or other arrangement that transfers, in whole or
        in part, any of the economic consequences of ownership of any of such shares, whether any of these transactions are to be settled by delivery
        of such shares, in cash or otherwise; or</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">(iii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">publicly disclose the intention to make any offer, sale, pledge or disposition,
        or to enter into any transaction, swap, hedge or other arrangement, or engage in any &#8220;Short Sales&#8221; (as defined in the Lock-up
        Agreement) with respect to any security of PubCo;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">until the date that is six months after the Closing;
<i>provided</i>, <i>however</i>, that the restrictions set forth in the Lock-up Agreement shall not apply to the exceptions as set forth
in the Lock-up Agreement. Without limitation to the foregoing, if after the Closing, there is a &#8220;Change of Control&#8221; of PubCo
(as defined in the Lock-up Agreement), all of the shares shall be released from the restrictions set forth therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing descriptions of agreements and the transactions
and documents contemplated thereby are not complete and are subject to and qualified in their entirety by reference to the form of Sponsor
Support Agreement, the form of Company Support Agreement, and the form of Lock-Up Agreement, copies of which are attached to this proxy
statement/prospectus as <i>Annex D, Annex E, and Annex F</i>, respectively, and the terms of which are incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 160; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><b>Redemption Rights</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">Pursuant to BCAR&#8217;s Current
Charter, a holder of Public Shares may demand that BCAR redeem such Public Shares for cash at the applicable redemption price per share
equal to the quotient obtained by dividing the (i) the aggregate amount on deposit in the trust account as of two business days prior
to the consummation of the Business Combination, including interest (net of taxes payable), by (ii) the total number of the then outstanding
Public Shares. As of [_], 2026, this would have amounted to approximately $[_] per Public Share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">You will be entitled to receive
cash for any Public Share to be redeemed only if you:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">hold Public Shares; and</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">prior to 5:00 pm Eastern Time, on [_], 2026 (two business days
        prior to BCAR&#8217;s Extraordinary General Meeting), (a) submit a written request to Continental that BCAR redeem your Public Shares
        for cash; and (b) deliver your Public Shares to Continental, physically or electronically through DTC.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">If a holder exercises its redemption
rights, then such holder will be exchanging its Public Shares for cash and will no longer own shares of PubCo. Such a holder will be entitled
to receive cash for its Public Shares only if it properly demands redemption and delivers its shares (either physically or electronically)
to BCAR&#8217;s Transfer Agent in accordance with the procedures described herein. Please see the section entitled &#8220;<i>Extraordinary
General Meeting of BCAR Shareholders &#8211; Redemption Rights</i>&#8221; for the procedures to be followed if you wish to redeem your
shares for cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Expected Accounting Treatment of the Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The Business Combination</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Business Combination will be accounted for as
a reverse recapitalization, in accordance with GAAP. Under this method of accounting, BCAR will be treated as the &#8220;acquired&#8221;
company for financial reporting purposes. Accordingly, the Business Combination will be treated as the equivalent of Exascale issuing
stock for the net assets of BCAR, accompanied by a recapitalization. The net assets of BCAR will be stated at historical cost, with no
goodwill or other intangible assets recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Regulatory Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Neither BCAR nor
Exascale is aware of any material regulatory approvals or actions that are required for completion of the Business Combination, other
than the regulatory notices and approvals discussed in &#8220;<i>The Business Combination Proposal &#8212; Business Combination Agreement
&#8212; Closing Conditions &#8212; Conditions to the Obligations of Each Party</i>&#8221;. It is presently contemplated that if any such
additional regulatory approvals or actions are required, those approvals or actions will be sought. There can be no assurance, however,
that any additional approvals or actions will be obtained.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Vote Required for Approval</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of the Business Combination Proposal
requires an ordinary resolution under the Current Charter, being the affirmative vote of a majority of the votes cast by the holders of
BCAR Ordinary Shares issued and outstanding, represented in person or by proxy and entitled to vote thereon at the Extraordinary General
Meeting. Abstentions and broker non-votes, while considered present for the purposes of establishing a quorum, will not count as votes
cast at the Extraordinary General Meeting and otherwise will have no effect on a particular proposal under British Virgin Islands law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 161; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Business Combination Proposal is conditioned
on the approval of each of the other Condition Precedent Proposals. Therefore, if each of the Condition Precedent Proposals is not approved,
the Business Combination Proposal will have no effect, even if approved by holders of BCAR Ordinary Shares. The Sponsor, which includes
among its members each of the directors and officers of BCAR, owns 12,200,000 BCAR Ordinary Shares, including both Class A Ordinary Shares
and Class B Ordinary Shares and David Boral owns 1,000,000 Representative Shares. As a result, as of the date of this proxy statement/prospectus,
the Insiders own approximately 32.0% of the issued and outstanding BCAR Ordinary Shares. As a result, in addition to the shares held by
the Insiders, BCAR would need 7,400,001 Public Shares, or approximately 26.4% of the 28,000,000 Public Shares sold in the BCAR IPO, to
be voted in favor of the Business Combination Proposal, the Domestication Merger Proposal, the Organizational Documents Proposal, the
Advisory Organizational Documents Proposals, the Directors Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal, and, if
presented, the Adjournment Proposal, in order for such proposals to be approved, assuming all outstanding shares are voted and the Insiders
do not acquire any Public Shares. Assuming that only the holders of thirty percent (30%) of the issued and outstanding BCAR ordinary shares,
representing a quorum under BCAR&#8217;s amended and restated memorandum and articles of association, vote their shares at the Extraordinary
General Meeting, BCAR will not need any Public Shares in addition to the shares held by the Insiders to be voted in favor of the Business
Combination Proposal, the Domestication Merger Proposal, the Organizational Documents Proposal, the Advisory Organizational Documents
Proposals, the Directors Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal, and, if presented, the Adjournment Proposal,
in order for such proposals to be approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Resolution to be Voted Upon</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The full text of the resolution to be passed is as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>RESOLVED</b>, as an ordinary resolution,
that BCAR&#8217;s entry into the Business Combination Agreement, dated as of January&#160;11, 2026, by and among BCAR, Merger Sub, Inc.,
Exascale Labs Inc., and D. Boral ARC Merger Corporation (as may be further amended and/or restated from time to time, the &#8220;<b>Business
Combination Agreement</b>&#8221;), pursuant to which, among other things, following the Domestication Merger of BCAR to the State of Delaware
as described below, the merger of Merger Sub with and into Exascale (the &#8220;<b>Acquisition Merger</b>&#8221;), with Exascale surviving
the merger, in accordance with the terms and subject to the conditions of the Business Combination Agreement, and in accordance with the
laws of the State of Delaware, to be approved, ratified and confirmed in all respects.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recommendation of the BCAR Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>THE BCAR BOARD UNANIMOUSLY RECOMMENDS THAT BCAR
SHAREHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE BUSINESS COMBINATION PROPOSAL.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The BCAR Board believes that the Business Combination
Proposal to be presented at the Extraordinary General Meeting is in the best interests of BCAR&#8217;s shareholders and unanimously recommends
that its shareholders vote &#8220;FOR&#8221; the approval of the Business Combination Proposal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The existence of financial and personal interests
of one or more of BCAR&#8217;s directors may result in a conflict of interest on the part of such director(s) between what he, she or
they may believe is in the best interests of BCAR and its shareholders and what he, she or they may believe is best for himself, herself
or themselves in determining to recommend that shareholders vote for the proposals. In addition, BCAR&#8217;s officers have interests
in the Business Combination that may conflict with your interests as a shareholder. See &#8220;<i>The Business Combination Proposal &#8212;
Certain Interests of BCAR&#8217;s Directors and Officers and Others in the Business Combination</i>&#8221; for a further discussion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 162; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_011"></span>PROPOSAL No. 2</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_012"></span>THE DOMESTICATION MERGER
PROPOSAL</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(2) Proposal No. 2 &#8212; The Domestication Merger
Proposal</b> &#8212; To consider and vote upon a proposal to approve by way of ordinary resolution and adopt the domestication of D. Boral
ARC Acquisition I Corp., a British Virgin Islands business company (&#8220;<b>BCAR</b>&#8221; or the &#8220;<b>Parent</b>&#8221;) pursuant
to the business combination agreement, dated as of January&#160;11, 2026 (the &#8220;<b>Business Combination Agreement</b>&#8221;), by
and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and a direct, wholly owned subsidiary of the Parent (&#8220;<b>PubCo</b>&#8221;),
D. Boral Arc Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary of the Parent (&#8220;<b>Merger Sub</b>&#8221;),
and Exascale Labs Inc., a Delaware corporation (the &#8220;<b>Company</b>&#8221;). Pursuant to the Business Combination Agreement, subject
to the conditions of the Business Combination Agreement, the Parent shall continue out of the British Virgin Islands and into the State
of Delaware so as to re-domicile as and become a Delaware corporation by means of a merger (the &#8220;<b>Domestication Merger</b>&#8221;)
of the Parent with and into PubCo, with PubCo as the surviving company pursuant to the BVI Business Companies Act, (Revised Edition 2020)
as amended, of the British Virgin Islands and the applicable provisions of the Delaware General Corporation Law, as amended. Upon the
Domestication Merger, PubCo shall change its name to &#8220;Exascale Labs Holdings Inc.&#8221; We refer to this proposal as the &#8220;<b>Domestication
Merger Proposal</b>.&#8221; A copy of the Business Combination Agreement is attached to the accompanying proxy statement/prospectus as
<i>Annex A.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As discussed in this proxy statement/prospectus, if
the Business Combination Proposal is approved, then BCAR is asking its shareholders to approve the Domestication Merger Proposal. Under
the Business Combination Agreement, the approval of the Domestication Merger Proposal is also a condition to the consummation of the Acquisition
Merger. If, however, the Domestication Merger Proposal is approved, but the Business Combination Proposal is not approved, then neither
the Domestication Merger nor the Acquisition Merger will be consummated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a condition to Closing the Business Combination,
the BCAR Board has unanimously approved a change of BCAR&#8217;s jurisdiction of incorporation through its merger with PubCo, a Delaware
entity and wholly owned subsidiary of BCAR and shall adopt the Certificate of Merger in the form attached as Exhibit 3.5 to this proxy
statement/prospectus. To effect the Domestication Merger, BCAR will merge with and into PubCo so that PubCo will be the surviving company
and all assets and liabilities of BCAR will vest in PubCo by virtue of the Business Companies Act, (Revised Edition 2020) as amended,
of the British Virgin Islands. In connection with the Domestication Merger and simultaneously with the Domestication Merger, the corporate
name of PubCo will change to &#8220;Exascale Labs Holdings Inc.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with applicable law, the Certificate
of Merger will provide that at the effective time of the Domestication Merger, by virtue of the Domestication Merger, and without any
action on the part of any shareholder, (i) each then issued and outstanding BCAR Class A Ordinary Share will convert automatically, on
a one-for-one basis, into one share of the PubCo Class A Ordinary Common Stock; (ii) each then issued and outstanding BCAR Class B Ordinary
Share shall automatically be converted into one PubCo Class A Ordinary Common Stock, and (iii) each whole then issued and outstanding
BCAR Warrant will become exercisable for one share of PubCo Class A Ordinary Common Stock having the same terms and subject to the same
conditions of such BCAR Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Domestication Merger Proposal, if approved, will
approve a merger of BCAR into PubCo which is being effected to change BCAR&#8217;s jurisdiction of incorporation from the British Virgin
Islands to the State of Delaware. Accordingly, while BCAR is currently governed by the Companies Act, upon the closing of the Domestication
Merger, PubCo will be governed by the DGCL. BCAR encourages shareholders to carefully consult the information in &#8220;<i>Comparison
of Corporate Governance and Shareholder Rights</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 163; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Reasons for the Domestication Merger</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The BCAR Board believes that it would be in the best
interests of BCAR, simultaneously with the completion of the Business Combination, to effect the Domestication Merger. Further, the BCAR
Board believes that any direct benefit that the DGCL provides to a corporation also indirectly benefits its stockholders, who are the
owners of the corporation. In addition, because PubCo will operate within the United States following the Business Combination, it was
the view of the BCAR Board that PubCo should be structured as a corporation organized in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The BCAR Board believes that there are several reasons
why a reincorporation in Delaware is in the best interests of BCAR and its shareholders. These additional reasons can be summarized as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Prominence,
Predictability and Flexibility of Delaware Law</span>. For many years, Delaware has followed a policy of encouraging incorporation in
its state and, in furtherance of that policy, has been a leader in adopting, construing, and implementing comprehensive, flexible corporate
laws responsive to the legal and business needs of corporations organized under its laws. Many corporations have chosen Delaware initially
as a state of incorporation or have subsequently changed corporate domicile to Delaware. Because of Delaware&#8217;s prominence as the
state of incorporation for many major corporations, both the legislature and courts in Delaware have demonstrated the ability and a willingness
to act quickly and effectively to meet changing business needs. The DGCL is frequently revised and updated to accommodate changing legal
and business needs and is more comprehensive, widely used and interpreted than other state corporate laws. This favorable corporate and
regulatory environment is attractive to businesses such as PubCo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Well-Established
Principles of Corporate Governance</span>. There is substantial judicial precedent in the Delaware courts as to the legal principles applicable
to measures that may be taken by a corporation and to the conduct of a company&#8217;s board of directors, such as under the business
judgment rule and other standards. Because the judicial system is based largely on legal precedents, the abundance of Delaware case law
provides clarity and predictability to many areas of corporate law. BCAR believes such clarity would be advantageous to PubCo, the PubCo
Board and management to make corporate decisions and take corporate actions with greater assurance as to the validity and consequences
of those decisions and actions. Further, investors and securities professionals are generally more familiar with Delaware corporations,
and the laws governing such corporations, increasing their level of comfort with Delaware corporations relative to other jurisdictions.
The Delaware courts have developed considerable expertise in dealing with corporate issues, and a substantial body of case law has developed
construing Delaware law and establishing public policies with respect to corporate legal affairs. Moreover, Delaware&#8217;s vast body
of law on the fiduciary duties of directors provides appropriate protection for PubCo&#8217;s stockholders from possible abuses by directors
and officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Increased
Ability to Attract and Retain Qualified Directors</span>. Reincorporation from the British Virgin Islands to Delaware is attractive to
directors, officers, and stockholders alike. PubCo&#8217;s incorporation in Delaware may make PubCo more attractive to future candidates
for the PubCo Board, because many such candidates are already familiar with Delaware corporate law from their past business experiences.
To date, BCAR has not experienced difficulty in retaining directors or officers, but directors of public companies are exposed to significant
potential liability. Thus, candidates&#8217; familiarity and comfort with Delaware laws &#8212; especially those relating to director
indemnification (as discussed below) &#8212; draw such qualified candidates to Delaware corporations. The BCAR Board therefore believes
that providing the benefits afforded directors by Delaware law will enable PubCo to compete more effectively with other public companies
in the recruitment of talented and experienced directors and officers. Moreover, Delaware&#8217;s vast body of law on the fiduciary duties
of directors provides appropriate protection for BCAR&#8217;s shareholders from possible abuses by directors and officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The frequency of claims and litigation pursued against
directors and officers has greatly expanded the risks facing directors and officers of corporations in carrying out their respective duties.
The amount of time and money required to respond to such claims and to defend such litigation can be substantial. While both British Virgin
Islands and Delaware law permit a corporation to include a provision in its governing documents to reduce or eliminate the monetary liability
of directors for breaches of fiduciary duty in certain circumstances, BCAR believes that, in general, Delaware law is more developed and
provides more guidance than British Virgin Islands law on matters regarding a company&#8217;s ability to limit director liability. As
a result, BCAR believes that the corporate environment afforded by Delaware will enable PubCo to compete more effectively with other public
companies in attracting and retaining new directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 164; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Reasons for the Name Change</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The BCAR Board believes that it would be in the best
interests of BCAR to, in connection with the Business Combination, change the corporate name to &#8220;Exascale Labs Holdings Inc.&#8221;
in order to more accurately reflect the business purpose and activities of PubCo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Regulatory Approvals; Third-Party Consents</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR is not required to make any filings or to obtain
any approvals or clearances from any antitrust regulatory authorities in the United States or other countries in order to complete the
Domestication Merger. However, because the Domestication Merger must occur at least one day prior to the Acquisition Merger, it will not
occur unless the Acquisition Merger can be completed, which will require the approvals as described under &#8220;<i>The Business Combination
Proposal</i>&#8221;. BCAR must comply with applicable United States federal and state securities laws in connection with the Domestication
Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Domestication Merger will not breach any covenants
or agreements binding upon BCAR and will not be subject to any additional federal or state regulatory requirements, except compliance
with the laws of the British Virgin Islands and Delaware necessary to effect the Domestication Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Proposed Charter and Proposed Bylaws</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Commencing with the effective time of the Domestication
Merger, the Proposed Charter and the Proposed Bylaws will govern the rights of stockholders in PubCo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A chart comparing your rights as a holder of BCAR
Ordinary Shares as a British Virgin Islands business company with your rights as a holder of the shares of PubCo Common Stock can be found
in &#8220;<i>Comparison of Corporate Governance and Shareholder Rights</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Accounting Treatment of the Domestication Merger</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Domestication Merger is being proposed solely
for the purpose of changing the legal domicile of BCAR. There will be no accounting effect or change in the carrying amount of the assets
and liabilities of BCAR as a result of the Domestication Merger. The business, capitalization, assets and liabilities and financial statements
of BCAR immediately following the Domestication Merger will be the same as those immediately prior to the Domestication Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Vote Required for Approval</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of the Domestication Merger Proposal
requires an ordinary resolution under British Virgin Islands law, being the affirmative vote of a majority of the votes cast by holders
of BCAR Ordinary Shares, represented in person or by proxy and entitled to vote thereon at the Extraordinary General Meeting. Abstentions
and broker non-votes, while considered present for the purposes of establishing a quorum, will not count as votes cast at the Extraordinary
General Meeting and otherwise will have no effect on a particular proposal under British Virgin Islands law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Domestication Merger Proposal is conditioned
on the approval of each of the other Condition Precedent Proposals. Therefore, if each of the other Condition Precedent Proposals is not
approved, the Domestication Merger Proposal will have no effect. The Sponsor, which includes among its members each of the directors and
officers of BCAR, owns 12,200,000 BCAR Ordinary Shares, including both BCAR Class A Ordinary Shares and BCAR Class B Ordinary Shares,
and David Boral owns 1,000,000 Representative Shares. As a result, as of the date of this proxy statement/prospectus, the Insiders own
approximately 32.0% of the issued and outstanding BCAR Ordinary Shares. As a result, in addition to the shares held by the Insiders, BCAR
would need 7,400,001 Public Shares, or approximately 26.4% of the 28,000,000 Public Shares sold in the BCAR IPO, to be voted in favor
of the Business Combination Proposal, the Domestication Merger Proposal, the Organizational Documents Proposal, the Advisory Organizational
Documents Proposals, the Directors Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal, and, if presented, the Adjournment
Proposal, in order for such proposals to be approved, assuming all outstanding shares are voted and the Insiders do not acquire any Public
Shares. Assuming that only the holders of thirty percent (30%) of the issued and outstanding BCAR ordinary shares, representing a quorum
under BCAR&#8217;s amended and restated memorandum and articles of association, vote their shares at the Extraordinary General Meeting,
BCAR will not need any Public Shares in addition to the shares held by the Insiders to be voted in favor of the Business Combination Proposal,
the Domestication Merger Proposal, the Organizational Documents Proposal, the Advisory Organizational Documents Proposals, the Directors
Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal, and, if presented, the Adjournment Proposal, in order for such proposals
to be approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 165; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Resolution to be Voted Upon</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The full text of the resolution to be passed is as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>RESOLVED</b>, as an ordinary resolution
of the holders of Ordinary Shares that: (a) BCAR be and is hereby authorized to merge with and into D. Boral ARC Merger Corporation with
D. Boral ARC Merger Corporation being the surviving company and all the undertaking, property and liability of BCAR vest in D. Boral ARC
Merger Corporation by virtue of such merger pursuant to the Business Companies Act, (Revised Edition 2020) as amended, of the British
Virgin Islands and the DGCL; (b) the Certificate of Merger, the form of which is attached to the proxy statement/consent solicitation
statement/prospectus as Exhibit 3.5 (the &#8220;<b>Certificate of Merger</b>&#8221;), be authorized, approved and confirmed in all respects
and BCAR be authorized to enter into the Certificate of Merger; and (c) the Certificate of Merger be executed by any one director of BCAR
(a &#8220;Director&#8221;) on behalf of BCAR and any Director or, with their authorization, BCAR&#8217;s officers on behalf of BCAR, be
authorized to submit the Certificate of Merger, together with any supporting documentation, for registration to the Registrar of Companies
of the British Virgin Islands and with the Secretary of State of the State of Delaware.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recommendation of the BCAR Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>THE BCAR BOARD UNANIMOUSLY RECOMMENDS THAT BCAR
SHAREHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE DOMESTICATION MERGER PROPOSAL.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The existence of financial and personal interests
of one or more of BCAR&#8217;s directors may result in a conflict of interest on the part of such director(s) between what he, she or
they may believe is in the best interests of BCAR and its shareholders and what he, she or they may believe is best for himself, herself
or themselves in determining to recommend that shareholders vote for the proposals. In addition, BCAR&#8217;s officers have interests
in the Business Combination that may conflict with your interests as a shareholder. See &#8220;<i>The Business Combination Proposal &#8212;
Certain Interests of BCAR&#8217;s Directors and Officers and Others in the Business Combination</i>&#8221; for a further discussion of
these considerations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 166; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span id="a_013"></span><b>PROPOSAL
No. 3</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="a_014"></span>THE
ORGANIZATIONAL DOCUMENTS PROPOSAL</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the Domestication Merger Proposal is approved and
the Business Combination is consummated, BCAR will replace the Current Charter, under the Companies Act, with the Proposed Charter and
the Proposed Bylaws of PubCo and change the name of PubCo to &#8220;Exascale Labs Holdings Inc.,&#8221; in each case, pursuant to the
DGCL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR&#8217;s shareholders are asked to consider and
vote upon and to adopt the Proposed Organizational Documents in connection with the replacement of the Current Charter with the Proposed
Organizational Documents. The Organizational Documents Proposal is conditioned on the approval of the Condition Precedent Proposals. Therefore,
if any of the Condition Precedent Proposals is not approved, the Organizational Documents Proposal will have no effect, even if approved
by holders of BCAR Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(3) Proposal No. 3 &#8212; Organizational Documents
Proposal </b>&#8212; To consider and vote upon a proposal to approve by way of ordinary resolution the proposed amended and restated certificate
of incorporation (the &#8220;<b>Proposed Charter</b>&#8221;) and the proposed amended and restated bylaws (&#8220;<b>Proposed Bylaws</b>&#8221;
and, together with the Proposed Charter, the &#8220;<b>Proposed Organizational Documents</b>&#8221;) of PubCo (a corporation incorporated
in the State of Delaware), (the &#8220;<b>Organizational Documents Proposal</b>&#8221;). The forms of each of the Proposed Charter and
the Proposed Bylaws are attached to the accompanying proxy statement/prospectus as <i>Annex B-1 </i>and <i>Annex B-2</i>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Reasons for the Amendments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The BCAR Board&#8217;s reasons for proposing the Proposed
Organizational Documents are set forth below. The following is a summary of the key changes effected by the Proposed Organizational Documents,
but this summary is qualified in its entirety by reference to the full text of the Proposed Charter, a copy of which is included as <i>Annex
B-1</i>, and by reference to the full text of the Proposed Bylaws, a copy of which is included as <i>Annex B-2</i>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">To change the corporate name from &#8220;D. Boral ARC Acquisition I Corp.&#8221; to &#8220;Exascale Labs Holdings
        Inc.&#8221;;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">To amend and redesignate the authorized share capital of the
        Company from (a) 500,000,000 BCAR Class A Ordinary Shares, 50,000,000 BCAR Class B Ordinary Shares and 5,000,000 BCAR preference shares,
        in each case par value $0.0001 per share, to (b) 260,000,000 shares of PubCo Class A Ordinary Common Stock, 35,000,000 shares of PubCo
        Class B Super Common Stock and 5,000,000 shares of PubCo Preferred Stock, in each case par value $0.0001 per share, with each share of
        PubCo Class A Ordinary Common Stock having one (1) vote on all matters submitted to vote of the stockholders of PubCo and each share of
        PubCo Class B Super Common Stock having twenty (20) votes on all matters submitted to vote of the stockholders of PubCo; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="width: 0.25in; text-align: justify">&#9679;</td>
    <td style="text-align: justify">To authorize all other changes in connection with the replacement of the Current Charter with the Proposed
        Charter and the Proposed Bylaws in connection with the consummation of the Business Combination (copies of which are attached to this
        proxy statement/prospectus as <i>Annex B-1 </i>and <i>Annex B-2</i>, respectively).</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Resolution to be Voted Upon</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The full text of the resolutions to be passed is as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>RESOLVED</b>, as an ordinary resolution,
that the Current Charter currently in effect be amended and restated by the deletion in their entirety and the substitution in their place
of the Proposed Charter and Proposed Bylaws (copies of which are attached to the proxy statement/prospectus as <i>Annex B-1 </i>and <i>Annex
B-2</i>, respectively), with such principal changes as described in the Advisory Organizational Documents Proposals 4A through 4F.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 167; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Vote Required for Approval</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of the Organizational Documents Proposal
requires an ordinary resolution under British Virgin Islands law, being the affirmative vote of the holders of a majority of the votes
cast by the holders of BCAR Ordinary Shares, represented in person or by proxy and entitled to vote thereon at the Extraordinary General
Meeting. Abstentions and broker non-votes, while considered present for the purposes of establishing a quorum, will not count as a vote
cast at the Extraordinary General Meeting and otherwise will have no effect on a particular proposal under British Virgin Islands law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Organizational Documents Proposal is conditioned
on the approval of each of the Condition Precedent Proposals. Therefore, if each of the Condition Precedent Proposals is not approved,
the Organizational Documents Proposal will have no effect, even if approved by holders of BCAR Ordinary Shares. The Sponsor, which includes
among its members each of the directors and officers of BCAR, owns 12,200,000 BCAR Ordinary Shares, including both Class A Ordinary Shares
and Class B Ordinary Shares, and David Boral owns 1,000,000 Representative Shares. As a result, as of the date of this proxy statement/prospectus,
the Insiders own approximately 32.0% of the issued and outstanding BCAR Ordinary Shares. As a result, in addition to the shares held by
the Insiders, BCAR would need 7,400,001 Public Shares, or approximately 26.4% of the 28,000,000 Public Shares sold in the BCAR IPO, to
be voted in favor of the Business Combination Proposal, the Domestication Merger Proposal, the Organizational Documents Proposal, the
Advisory Organizational Documents Proposals, the Directors Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal, and, if
presented, the Adjournment Proposal, in order for such proposals to be approved, assuming all outstanding shares are voted and the Insiders
do not acquire any Public Shares. Assuming that only the holders of thirty percent (30%) of the issued and outstanding BCAR ordinary shares,
representing a quorum under BCAR&#8217;s amended and restated memorandum and articles of association, vote their shares at the Extraordinary
General Meeting, BCAR will not need any Public Shares in addition to the shares held by the Insiders to be voted in favor of the Business
Combination Proposal, the Domestication Merger Proposal, the Organizational Documents Proposal, the Advisory Organizational Documents
Proposals, the Directors Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal, and, if presented, the Adjournment Proposal,
in order for such proposals to be approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recommendation of the BCAR Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>THE BCAR BOARD UNANIMOUSLY RECOMMENDS THAT BCAR
SHAREHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE ORGANIZATIONAL DOCUMENTS PROPOSAL.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The existence of financial and personal interests
of one or more of BCAR&#8217;s directors may result in a conflict of interest on the part of such director(s) between what he, she or
they may believe is in the best interests of BCAR and its shareholders and what he, she or they may believe is best for himself, herself
or themselves in determining to recommend that shareholders vote for the proposals. In addition, BCAR&#8217;s officers have interests
in the Business Combination that may conflict with your interests as a shareholder. See &#8220;<i>The Business Combination Proposal &#8212;
Certain Interests of BCAR&#8217;s Directors and Officers and Others in the Business Combination</i>&#8221; for a further discussion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 168; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_015"></span>PROPOSAL No. 4</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_016"></span>THE ADVISORY ORGANIZATIONAL
DOCUMENTS PROPOSALS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR&#8217;s shareholders are also being asked to
vote on a separate proposal with respect to certain governance provisions in the Proposed Organizational Documents, which are separately
being presented in accordance with SEC guidance to give shareholders the opportunity to present their separate views on important corporate
governance provisions and which will be voted upon on a non-binding advisory basis. This separate vote is not otherwise required by the
Companies Act or the DGCL separate and apart from the Organizational Documents Proposal, but pursuant to SEC guidance, BCAR is required
to submit these provisions to its shareholders separately for approval. However, the shareholder votes regarding these proposals are advisory
in nature, and are not binding on BCAR or the BCAR Board (separate and apart from the approval of the Organizational Documents Proposal).
Furthermore, the Business Combination is not conditioned on the separate approval of the Advisory Organizational Documents Proposals (separate
and apart from approval of the Organizational Documents Proposal). Accordingly, regardless of the outcome of the non-binding advisory
vote on this proposal, BCAR intends that the Proposed Organizational Documents will take effect at the Closing (assuming approval of the
Organizational Documents Proposal).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Proposed Organizational Documents differ materially
from the Current Charter. The following table sets forth a summary of the principal changes proposed between the Current Charter and the
Proposed Organizational Documents. This summary is qualified by reference to the complete text of the Current Charter of BCAR, the complete
text of the Proposed Charter, a copy of which is attached to this proxy statement/prospectus as <i>Annex B-1</i>, and the complete text
of the Proposed Bylaws, a copy of which is attached to this proxy statement/prospectus as <i>Annex B-2</i>. All shareholders are encouraged
to read the Proposed Organizational Documents in their entirety for a more complete description of their terms. Additionally, as the Current
Charter are governed by the Companies Act and the Proposed Organizational Documents will be governed by the DGCL, BCAR encourages shareholders
to carefully consult the information set out under the section entitled &#8220;<i>Comparison of Corporate Governance and Shareholder Rights</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(4) Proposal No. 4 &#8212; The Advisory Organizational
Documents Proposals </b>&#8212; To consider and vote upon the following six (6) separate proposals (collectively, the &#8220;<b>Advisory
Organizational Documents Proposals</b>&#8221;) to approve on an advisory non-binding basis by way of ordinary resolution the following
material differences between the Current Charter and the Proposed Organizational Documents:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><b>(A) <i>Advisory Organizational Documents
Proposal 4A (Authorized Shares) </i></b>&#8212; authorize the amendment and redesignation of the authorized shares of BCAR from (a) 500,000,000
BCAR Class A Ordinary Shares, 50,000,000 BCAR Class B Ordinary Shares and 5,000,000 BCAR preference shares, in each case par value $0.0001
per share, to (b) 260,000,000 shares of PubCo Class A Ordinary Common Stock, 35,000,000 shares of PubCo Class B Super Common Stock and
5,000,000 shares of PubCo Preferred Stock, in each case par value $0.0001 per share (&#8220;<b>Advisory Organizational Documents Proposal
4A</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><b>(B) <i>Advisory Organizational Documents
Proposal 4B (Change in Voting Rights) &#8212; </i></b>to change the voting rights of PubCo&#8217;s Common Stock such that, each PubCo
Class A Ordinary Common Stock will be entitled to one (1) vote per PubCo Class A Ordinary Common Stock on all matters submitted to a vote
of the stockholders of PubCo, and each PubCo Class B Super Common Stock will be entitled to twenty (20) votes per PubCo Class B Super
Common Stock on all matters submitted to a vote of the stockholders of PubCo, and that the PubCo Class A Ordinary Common Stock and PubCo
Class B Super Common Stock shall vote together on all matters except as explicitly required by the DGCL or as explicitly set forth in
the Proposed Charter (&#8220;<b>Advisory Organizational Documents Proposal 4B</b>&#8221;)<i>.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><b>(C) <i>Advisory Organizational Documents
Proposal 4C (Exclusive Forum Provision) </i></b>&#8212; to authorize adopting Delaware as the exclusive forum for certain stockholder
litigation and adopting the federal district courts of the United States as the exclusive forum for resolving complaints asserting a cause
of action under the Securities Act of 1933, as amended (the &#8220;<b>Securities Act</b>&#8221;) (&#8220;<b>Advisory Organizational Documents
Proposal 4C</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><b>(D)
<i>Advisory Organizational Documents Proposal 4D (Required Vote to Amend Charter) </i></b>&#8212; to approve provisions providing that
the affirmative vote of at least 66&#8532;% of the voting power of all the then outstanding shares of capital stock of PubCo entitled
to vote thereon, voting together as a single class, will be required to amend, alter, repeal or rescind any provision of Article FIFTH,
Article SIXTH, Article SEVENTH, Article EIGHTH, Article NINTH, Article TENTH or Article ELEVENTH of the Proposed Charter (&#8220;<b>Advisory
Organizational Documents Proposal 4D</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><b>(E) <i>Advisory Organizational Documents
Proposal 4E (Removal of Directors) </i></b>&#8212; to approve provisions permitting the removal of a director, but only for cause, and
then by the affirmative vote of at least 66&#8532;% of the voting power of all the then outstanding shares entitled to vote generally
in the election of directors, voting together as a single class (&#8220;<b>Advisory Organizational Documents Proposal 4E</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><b>(F) <i>Advisory Organizational Documents
Proposal 4F (Name Change) </i></b>&#8212; to approve the change of the name of PubCo to &#8220;Exascale Labs Holdings Inc.&#8221; (&#8220;<b>Advisory
Organizational Documents Proposal 4F</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 169; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 27%; vertical-align: bottom">
        <p style="margin-top: 0; margin-bottom: 0"><b>Advisory Organizational</b></p>
        <p style="margin-top: 0; margin-bottom: 0"><b>Documents Proposal</b></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: center; vertical-align: bottom"><b>Description
        of Change</b></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><b>Authorized
        Shares</b> <i>(Advisory Organizational Documents Proposal 4A)</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Current Charter has an authorized shares of 500,000,000
        BCAR Class A Ordinary Shares, 50,000,000 BCAR Class B Ordinary Shares and 5,000,000 BCAR preference shares, in each case par value $0.0001
        per share.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Proposed Charter authorizes 260,000,000 shares
        PubCo Class A Ordinary Common Stock, 35,000,000 shares of PubCo Class B Super Common Stock and 5,000,000 shares of PubCo Preferred Stock,
        in each case par value $0.0001 per share. <i>See Article Fourth of the Proposed Charter.</i></p> </td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><b>Change
        in Voting Rights</b> <i>(Advisory Organizational Documents Proposal 4A)</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">
        <p style="margin-top: 0; margin-bottom: 0">Under the Current Charter each BCAR Class A Ordinary Share and each BCAR Class B Ordinary Share
        is entitled to one (1) vote per share on all matters submitted to a vote of shareholders.</p>
        <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
        <p style="margin-top: 0; margin-bottom: 0">Under the Proposed Organizational Documents, each share of PubCo Class A Ordinary Common Stock
        will be entitled to one (1) vote per share on all matters submitted to a vote of stockholders, and each share of PubCo Class B Super Common
        Stock will be entitled to twenty (20) votes per share on all matters submitted to a vote of stockholders. <i>See Paragraph A of Article
        Fifth of the Proposed Charter</i>.</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><b>Exclusive
        Forum Provision</b> <i>(Advisory Organizational Documents Proposal 4C)</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Current Charter does not contain a provision adopting
        an exclusive forum for certain shareholder litigation.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Proposed Organizational Documents adopt (a) Delaware
        as the exclusive forum for certain stockholder litigation and (b) the federal district courts of the United States as the exclusive forum
        for the resolution of any complaint asserting a cause of action arising under the Securities Act. <i>See Article Tenth of the Proposed
        Charter.</i></p> </td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><b>Required
        Vote to Amend Charter</b> <i>(Advisory Organizational Documents Proposal 4D)</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Current Charter
        provides that amendments may be made by an ordinary resolution under British Virgin Islands law, being the affirmative vote of holders
        of a majority of the votes cast by the holders of BCAR Ordinary Shares represented in person or by proxy and entitled to vote at a general
        meeting and who vote at a general meeting. <i>See Clause 30 of the Current Charter</i></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Proposed Charter
        adopts provisions requiring the affirmative vote of at least 66&#8532;% of the voting power of all the then outstanding shares in the
        capital of PubCo entitled to vote thereon, to amend, alter, repeal or rescind all or any portion of Article Fifth, Article Sixth, Article
        Seventh, Article Eighth, Article Ninth, Article Tenth or Article Eleventh of the Proposed Charter. <i>See Article Eleventh of the Proposed
        Charter.</i></p> </td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><b>Removal
        of Directors</b> <i>(Advisory Organizational Documents Proposal 4E)</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Current Charter provides that prior to the closing
        of an initial business combination, only holders of BCAR Class B Ordinary Shares may remove any director by an ordinary resolution, being
        the affirmative vote of holders of a majority of the votes cast by the holders of BCAR Class B Ordinary Shares represented in person or
        by proxy and entitled to vote at a general meeting and who vote at a general meeting, and that after the closing of an initial business
        combination, the holders of BCAR Ordinary Shares may by ordinary resolution remove any director.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Proposed Organizational Documents adopt provisions
        permitting the removal of a director, but only for cause, and then by the affirmative vote of at least 66&#8532;% of the voting power
        of all the then outstanding shares in the capital of PubCo entitled to vote generally in the election of directors. <i>See Paragraph C
        of Article Sixth of the Proposed Charter.</i></p> </td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><b>Name
        Change</b> <i>(Advisory Organizational Documents Proposal 4F)</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Current Charter names the company D. Boral ARC
        Acquisition I Corp. <i>See Clause 1 of the Current Charter.</i></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Proposed Organizational Documents rename the company
        Exascale Labs Holdings Inc. <i>See Article First of the Proposed Charter.</i></p> </td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 170; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Advisory Organizational Documents Proposal 4A &#8212;
Authorized Shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR&#8217;s shareholders are being asked to approve
and adopt an amendment to the Current Charter to authorize the amendment and redesignation of the authorized shares of BCAR from (a) 500,000,000
BCAR Class A Ordinary Shares, 50,000,000 BCAR Class B Ordinary Shares and 5,000,000 BCAR preference shares, in each case par value $0.0001
per share, to (b) 260,000,000 shares of PubCo Class A Ordinary Common Stock, 35,000,000 shares PubCo Class B Super Common Stock and 5,000,000
shares of PubCo Preferred Stock, in each case par value $0.0001 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of the date of this proxy statement/prospectus,
there are (a) 29,200,000 BCAR Class A Ordinary Shares issued and outstanding, (b) 12,000,000 BCAR Class B Ordinary Share issued and outstanding
and (c) no BCAR preference shares issued and outstanding. In addition, as of the date of this proxy statement/prospectus, there is an
aggregate of (i) 14,000,000 Public Warrants and (ii) 100,000 Private Placement Warrants, in each case, issued and outstanding. Subject
to the terms and conditions of the Warrant Agreement, each whole BCAR Warrant will be exercisable after giving effect to the Business
Combination for one share of PubCo Class A Ordinary Common Stock at an exercise price of $11.50 per share. BCAR Warrants will become exercisable
30 days after the Closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the
Business Combination Agreement, the Exascale Securityholders will receive aggregate consideration of 50,000,000 shares of PubCo Common
Stock in exchange for their outstanding equity interests.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to ensure that PubCo has sufficient authorized
capital for future issuances, the BCAR Board has approved, subject to shareholder approval, that the Proposed Organizational Documents
of PubCo amend and redesignate the authorized share capital of BCAR from (a) 500,000,000 BCAR Class A Ordinary Shares, 50,000,000 BCAR
Class B Ordinary Shares and 5,000,000 BCAR preference shares, in each case par value $0.0001 per share, to (b) 260,000,000 shares of PubCo
Class A Ordinary Common Stock, 35,000,000 shares of PubCo Class B Super Common Stock and 5,000,000 shares of PubCo Preferred Stock, in
each case par value $0.0001 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This summary is qualified by reference to the complete
text of the Proposed Organizational Documents of PubCo, copies of which are attached to this proxy statement/prospectus as <i>Annex B-1
</i>and <i>Annex B-2</i>. All shareholders are encouraged to read the Proposed Organizational Documents in their entirety for a more complete
description of their terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reasons for Amendment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The principal purpose of this proposal is to provide
for an authorized capital structure of PubCo that will enable it to continue as an operating company governed by the DGCL. The BCAR Board
believes that it is important for BCAR to have available for issuance a number of authorized shares of PubCo Common Stock and preferred
stock sufficient to support its growth and to provide flexibility for future corporate needs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Resolution to be Voted Upon</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The full text of the resolution to be considered and
if thought fit, passed and approved is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>RESOLVED</b>, as an ordinary resolution,
on an advisory non-binding basis, that the authorized shares of BCAR be amended and redesignated from 500,000,000 BCAR Class A Ordinary
Shares, par value $0.0001 per share, 50,000,000 BCAR Class B Ordinary Shares, par value $0.0001 per share, and 5,000,000 BCAR preference
shares, par value $0.0001 per share, to 260,000,000 shares of PubCo Class A Ordinary Common Stock, par value $0.0001 per share, 35,000,000
shares of PubCo Class B Super Common Stock, par value $0.0001 per share and 5,000,000 shares of PubCo Preferred Stock, par value $0.0001
per share, as described in Advisory Organizational Documents Proposal 4A.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 171; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Advisory Organizational Documents Proposal 4B &#8212;
Change in Voting Rights</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR&#8217;s shareholders are being asked to approve
and adopt an amendment to the Current Charter to effect a change in the voting rights of PubCo Common Stock in connection with the Domestication
Merger and the adoption of the Proposed Organizational Documents of PubCo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Current Charter, each BCAR Class A Ordinary
Share and each BCAR Class B Ordinary Share is entitled to one (1) vote per share on all matters submitted to a vote of shareholders of
BCAR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Proposed Organizational Documents, each
share of PubCo Class A Ordinary Common Stock will be entitled to one (1) vote per share on all matters submitted to a vote of PubCo stockholders,
and each share of PubCo Class B Super Common Stock will be entitled to twenty (20) votes per share on all matters submitted to a vote
of PubCo stockholders. As a result, holders of PubCo Class B Super Common Stock will be able to exercise significantly greater voting
power relative to their economic ownership of PubCo than holders of PubCo Class A Ordinary Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary is qualified by reference to the
complete text of the Proposed Organizational Documents of PubCo, copies of which are attached to this proxy statement/prospectus as <i>Annex
B-1</i> and <i>Annex B-2</i>. Shareholders are encouraged to read the Proposed Organizational Documents in their entirety for a more complete
description of the voting rights associated with each class of PubCo capital stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reasons for Amendment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The principal purposes of this proposal is to
align voting power with the continued operational involvement and long-term commitments of certain founders of Exascale, which the BCAR
Board believes will support long-term strategic decision-making and stability of control following the completion of the Business Combination.
The BCAR Board believes that providing enhanced voting rights to holders of PubCo Class B Super Common Stock will help ensure continuity
of leadership and alignment of voting control with the long-term vision and growth strategy of PubCo as a public company governed by the
DGCL, while still allowing public investors to participate economically through ownership of PubCo Class A Ordinary Common Stock. The
BCAR Board believes that granting enhanced voting rights to holders of PubCo Class B Super Common Stock appropriately reflects the role
such holders are expected to play in shaping PubCo&#8217;s strategic direction, overseeing execution of PubCo&#8217;s business plan, and
contributing industry expertise, relationships and intellectual capital that may not be proportionally reflected in their economic ownership.
The BCAR Board further believes that this voting structure may help protect PubCo from short-term market pressures and opportunistic actions
that could disrupt the execution of PubCo&#8217;s long-term growth strategy, while preserving economic participation for holders of PubCo
Class A Ordinary Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Resolution to be Voted Upon</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The full text of the resolution to be considered
and, if thought fit, passed and approved is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>RESOLVED</b>, as an ordinary resolution,
on an advisory non-binding basis, that the voting rights of BCAR&#8217;s Ordinary Shares be amended such that, following the Domestication
Merger and adoption of the Proposed Organizational Documents of PubCo, each share of PubCo Class A Ordinary Common Stock, par value $0.0001
per share, shall be entitled to one (1) vote per share on all matters submitted to a vote of PubCo&#8217;s stockholders, and each share
of PubCo Class B Super Common Stock, par value $0.0001 per share, shall be entitled to twenty (20) votes per share on all matters submitted
to a vote of PubCo&#8217;s stockholders, as described in Advisory Organizational Documents Proposal 4B.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Advisory Organizational Documents Proposal 4C &#8212;
Exclusive Forum Provision</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR&#8217;s shareholders are being asked to approve
and adopt an amendment to the Current Charter to authorize adopting Delaware as the exclusive forum for certain stockholder litigation
and adopting the federal district courts of the United States as the exclusive forum for resolving complaints asserting a cause of action
under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 172; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Proposed Organizational Documents stipulate that,
unless PubCo consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (the &#8220;<b>Court
of Chancery</b>&#8221;) (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware)
shall, to the fullest extent permitted by law, be the sole and exclusive forum for (1) any derivative action or proceeding brought on
behalf of PubCo, (2) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of PubCo
to PubCo or PubCo&#8217;s stockholders, (3) any action arising pursuant to any provision of the DGCL or the Proposed Charter or the Proposed
Bylaws (as either may be amended from time to time), or (4) any action asserting a claim governed by the internal affairs doctrine. Unless
PubCo consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall
be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This summary is qualified by reference to the complete
text of the Proposed Organizational Documents of PubCo, copies of which are attached to this proxy statement/prospectus as <i>Annex B-1
</i>and <i>Annex B-2</i>. All shareholders are encouraged to read the Proposed Organizational Documents in their entirety for a more complete
description of their terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reasons for Amendment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Adopting Delaware as the exclusive forum for certain
stockholder litigation is intended to assist PubCo in avoiding multiple lawsuits in multiple jurisdictions regarding the same matter.
The ability to require such claims to be brought in a single forum will help to assure consistent consideration of the issues, the application
of a relatively known body of case law and level of expertise and should promote efficiency and cost-savings in the resolutions of such
claims. The BCAR Board believes that the Delaware courts are best suited to address disputes involving such matters given that after the
Domestication Merger, PubCo will be incorporated in Delaware. Delaware law generally applies to such matters and the Delaware courts have
a reputation for expertise in corporate law matters. Delaware offers a specialized Court of Chancery to address corporate law matters,
with streamlined procedures and processes, which help provide relatively quick decisions. This accelerated schedule can minimize the time,
cost and uncertainty of litigation for all parties. The Court of Chancery has developed considerable expertise with respect to corporate
law issues, as well as a substantial and influential body of case law construing Delaware&#8217;s corporate law and long-standing precedent
regarding corporate governance. This provides stockholders and the post-combination company with more predictability regarding the outcome
of intra-corporate disputes. In the event the Court of Chancery does not have jurisdiction, the other state courts located in Delaware
would be the most appropriate forums because these courts have more expertise on matters of Delaware law compared to other jurisdictions.
The BCAR Board further believes that providing that, unless we consent in writing to an alternative forum, the federal district courts
of the United States of America will be the exclusive forum for resolving actions arising under the Securities Act, provides the flexibility
to file such suits in any federal district court while providing the benefits of eliminating duplicative litigation and having such cases
heard by courts that are well-versed in the applicable law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, this amendment would promote judicial
fairness and avoid conflicting results, as well as make PubCo&#8217;s defense of applicable claims less disruptive and more economically
feasible, principally by avoiding duplicative discovery.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Resolution to be Voted Upon</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The full text of the resolution to be considered and
if thought fit, passed and approved is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>RESOLVED</b>, as an ordinary resolution,
on an advisory non-binding basis, that (a) Delaware be adopted as the exclusive forum for certain stockholder litigation and (b) the federal
district courts of the United States be adopted as the exclusive forum for asserting a cause under the Securities Act of 1933, as amended,
as described in Advisory Organizational Documents Proposal 4C.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Advisory Organizational Documents Proposal 4D &#8212;
Required Vote to Amend Charter</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR&#8217;s shareholders
are being asked to approve provisions providing that the affirmative vote of at least 66&#8532;% of the voting power of all the then outstanding
shares of capital stock of PubCo entitled to vote thereon, voting together as a single class, will be required to amend, alter, repeal
or rescind any provision of Article Fifth, Article Sixth, Article Seventh, Article Eighth, Article Ninth, Article Tenth and Article Eleventh
of the Proposed Charter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 173; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reasons for Amendment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Current Charter
provides that amendments may be made by an ordinary resolution under British Virgin Islands law, being the affirmative vote of holders
of a majority of the votes cast by the holders of BCAR Ordinary Shares who, being present in person or by proxy and entitled to vote at
a general meeting, vote at a general meeting. The Proposed Organizational Documents require the affirmative vote of at least 66&#8532;%
of the voting power of all the then outstanding shares of capital stock of PubCo entitled to vote thereon, voting together as a single
class, to amend, alter, repeal or rescind any provision of Article Fifth, Article Sixth, Article Seventh, Article Eighth, Article Ninth,
Article Tenth or Article Eleventh of the Proposed Charter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The amendments are intended to protect certain key
provisions of the Proposed Charter from arbitrary amendment and to prevent a simple majority of stockholders from taking actions that
may be harmful to other stockholders or making changes to provisions that are intended to protect all stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Resolution to be Voted Upon</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The full text of the resolution to be considered and
if thought fit, passed and approved is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>RESOLVED</b>,
as an ordinary resolution, on an advisory non-binding basis, that the provisions providing that the affirmative vote of at least 66&#8532;%
of the voting power of all the then outstanding shares of capital stock of PubCo entitled to vote thereon, voting together as a single
class, will be required to amend, alter, repeal or rescind any provision of Article Fifth, Article Sixth, Article Seventh, Article Eighth,
Article Ninth, Article Tenth or Article Eleventh of the Proposed Charter, as described in Advisory Organizational Documents Proposal 4D,
be approved.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Advisory Organizational Documents Proposal 4E &#8212;
Removal of Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR&#8217;s shareholders are being asked to approve
provisions permitting the removal of a director, but only for cause, and then by the affirmative vote of at least 66&#8532;% of the voting
power of all the then outstanding shares entitled to vote generally in the election of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This summary is qualified by reference to the complete
text of the Proposed Organizational Documents of PubCo, copies of which are attached to this proxy statement/prospectus as <i>Annex B-1
</i>and <i>Annex B-2</i>. All stockholders are encouraged to read the Proposed Organizational Documents in their entirety for a more complete
description of their terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reasons for Amendment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Current Charter
provides that prior to the closing of an initial business combination, only holders of BCAR Class B Ordinary Shares may remove any director
by an ordinary resolution, being the affirmative vote of holders of a majority of the votes cast by the holders of BCAR Class B Ordinary
Shares represented in person or by proxy and entitled to vote at a general meeting and who vote at a general meeting, and that after the
closing of an initial business combination, the holders of BCAR Ordinary Shares may remove any director by ordinary resolution, being
the affirmative vote of holders of a majority of the votes cast by the holders of BCAR Class B Ordinary Shares represented in person or
by proxy and entitled to vote at a general meeting and who vote at a general meeting. Upon consummation of the Domestication Merger, the
BCAR Class B Ordinary Shares shall automatically convert into PubCo Class A Ordinary Common Stock along with the BCAR Class A Ordinary
Shares. The Proposed Organizational Documents permit the removal of a director, but only for cause, and then by the affirmative vote of
at least 66&#8532;% of the voting power of all the then outstanding PubCo Common Stock entitled to vote generally in the election of directors,
voting together as a single class. The BCAR Board believes that such a standard will (a) increase board continuity and the likelihood
that experienced board members with familiarity of PubCo&#8217;s business operations would serve on the board at any given time and (ii)
make it more difficult for a potential acquiror or other person, group or entity to gain control of the PubCo Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Resolution to be Voted Upon</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The full text of the resolution to be considered and
if thought fit, passed and approved is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>RESOLVED</b>, as an ordinary resolution,
on an advisory non-binding basis, that the provisions permitting the removal of a director, but only for cause, and then by the affirmative
vote of at least 66&#8532;% of the voting power of all the then outstanding shares entitled to vote generally in the election of directors,
voting together as a single class, as described in Advisory Organizational Documents Proposal 4E, be approved.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 174; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Advisory Organizational Documents Proposal 4F
&#8212; Name Change</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">BCAR&#8217;s shareholders are being asked to approve
provisions that change the name of the company to &#8220;Exascale Labs Holdings Inc.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">This summary is qualified by reference to the complete
text of the Proposed Organizational Documents of PubCo, copies of which are attached to this proxy statement/prospectus as <i>Annex B-1
</i>and <i>Annex B-2</i>. All stockholders are encouraged to read the Proposed Organizational Documents in their entirety for a more complete
description of their terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Reasons for Amendment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The BCAR Board believes that changing the name of
PubCo is desirable because it reflects the effective name of the combined company following consummation of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Resolution to be Voted Upon</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The full text of the resolution to be considered
and if thought fit, passed and approved is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#8220;<b>RESOLVED</b>, as an ordinary resolution,
on an advisory non-binding basis, that the provisions that change the name of the company to &#8220;Exascale Labs Holdings Inc.,&#8221;
as described in Advisory Organizational Documents Proposal 4F, be approved.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Vote Required for Approval</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The approval of the Advisory Organizational Documents
Proposals requires an ordinary resolution under the Current Charter, being the affirmative vote of a majority of the votes cast by the
holders of BCAR Ordinary Shares, voting as a single class, represented in person or by proxy and entitled to vote thereon at the Extraordinary
General Meeting. Abstentions and broker non-votes, while considered present for the purposes of establishing a quorum, will not count
as votes cast at the Extraordinary General Meeting and otherwise will have no effect on a particular proposal under British Virgin Islands
law. The Advisory Organizational Documents Proposals are not conditioned upon any other proposal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sponsor, which includes among its members
each of the directors and officers of BCAR, owns 12,200,000 BCAR Ordinary Shares, including both Class A Ordinary Shares and Class B Ordinary
Shares, and David Boral owns 1,000,000 Representative Shares. As a result, as of the date of this proxy statement/prospectus, the Insiders
own approximately 32.0% of the issued and outstanding BCAR Ordinary Shares. As a result, in addition to the shares held by the Insiders,
BCAR would need 7,400,001 Public Shares, or approximately 26.4% of the 28,000,000 Public Shares sold in the BCAR IPO, to be voted in favor
of the Business Combination Proposal, the Domestication Merger Proposal, the Organizational Documents Proposal, the Advisory Organizational
Documents Proposals, the Directors Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal, and, if presented, the Adjournment
Proposal, in order for such proposals to be approved, assuming all outstanding shares are voted and the Insiders do not acquire any Public
Shares. Assuming that only the holders of thirty percent (30%) of the issued and outstanding BCAR ordinary shares, representing a quorum
under BCAR&#8217;s amended and restated memorandum and articles of association, vote their shares at the Extraordinary General Meeting,
BCAR will not need any Public Shares in addition to the shares held by the Insiders to be voted in favor of the Business Combination Proposal,
the Domestication Merger Proposal, the Organizational Documents Proposal, the Advisory Organizational Documents Proposals, the Directors
Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal, and, if presented, the Adjournment Proposal, in order for such proposals
to be approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Recommendation of the BCAR Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>THE BCAR BOARD UNANIMOUSLY RECOMMENDS THAT BCAR
SHAREHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF EACH OF THE ADVISORY ORGANIZATIONAL DOCUMENTS PROPOSALS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The existence of financial and personal interests
of one or more of BCAR&#8217;s directors may result in a conflict of interest on the part of such director(s) between what he, she or
they may believe is in the best interests of BCAR and its shareholders and what he, she or they may believe is best for himself, herself
or themselves in determining to recommend that shareholders vote for the proposals. In addition, BCAR&#8217;s officers have interests
in the Business Combination that may conflict with your interests as a shareholder. See &#8220;<i>The Business Combination Proposal &#8212;&#160;Certain
Interests of BCAR&#8217;s Directors and Officers and Others in the Business Combination</i>&#8221; for a further discussion of these considerations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 175; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_017"></span>PROPOSAL No. 5</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_018"></span>THE DIRECTORS PROPOSAL</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this Extraordinary
General Meeting, five directors will be elected to be the directors of PubCo upon the closing of the Business Combination. If the nominees
are elected, the members of PubCo&#8217;s board of directors will consist of the following members: Hoansoo Lee, Wenying Jia (Chairperson),
David Card, Shachar Kariv and Jaeyoung Shin, with Hoansoo Lee to serve until the 2029 annual meeting and until his successor has been
duly elected and qualified or until his earlier resignation, removal or death, with each of Wenying Jia and David Card to serve until
the 2028 annual meeting and until their respective successors have been duly elected and qualified or until their earlier resignation,
removal or death, and with each of Shachar Kariv and Jaeyoung Shin to serve until the 2027 annual meeting and until their respective successors
have been duly elected and qualified or until their earlier resignation, removal or death. At each annual meeting of stockholders, the
successors to the class of directors whose terms expire at such meeting will be elected to hold office for a term expiring at the annual
meeting of stockholders held in the third year following their year of election. After this election, the terms of Class I, II and III
directors will expire at the annual meeting of stockholders to be held in 2027, 2028 and 2029 respectively. Each director will hold office
for the term to which he or she is elected or until his or her successor is duly elected and qualified.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shachar Kariv
and Jaeyoung Shin are the proposed Class I directors whose term will expire at the 2027 annual meeting of stockholders. Wenying Jia and
David Card are the proposed Class II directors whose term will expire at the 2028 annual meeting of stockholders. Hoansoo Lee is the proposed
Class III director whose term will expire at the 2029 annual meeting of stockholders. Biographical information about the nominees can
be found in &#8220;<i>Executive Officers and Directors of Exascale</i>&#8221; below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each of the nominees has agreed to be named in this
proxy statement/prospectus and to serve as a director if elected. Unless authority is withheld or the shares are subject to a broker non-vote,
the proxies solicited by the BCAR Board will be voted &#8220;<b>FOR</b>&#8221; the election of all of these nominees. In case any of the
nominees becomes unavailable for election to the PubCo Board, an event that is not anticipated, the persons named as proxies, or their
substitutes, will have full discretion and authority to vote or refrain from voting for any other candidate in accordance with their judgment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Resolution to be Voted Upon</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The full text of the resolution to be passed is as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>RESOLVED</b>,
that effective as of the effective time of the Business Combination, and conditioned upon the consummation of the Business Combination,
that Hoansoo Lee, Wenying Jia, David Card, Shachar Kariv and Jaeyoung Shin be elected the directors of PubCo, with Hoansoo Lee to serve
as a Class III director until the 2029 annual meeting and until his successor has been duly elected and qualified or until his earlier
resignation, removal or death, with each of Wenying Jia and David Card to serve as a Class II director until the 2028 annual meeting and
until their respective successors have been duly elected and qualified or until their earlier resignation, removal or death, and with
each of Shachar Kariv and Jaeyoung Shin to serve as a Class I director until the 2027 annual meeting and until their respective successors
have been duly elected and qualified or until their earlier resignation, removal or death.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Vote Required for Approval</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each of the nominees will be elected if he or she
receives the affirmative vote of a majority of BCAR Ordinary Shares cast by the holders of BCAR Ordinary Shares, represented in person
or by proxy at the Extraordinary General Meeting. Abstentions and broker non-votes with respect to this proposal will have no effect on
the vote. There is no cumulative voting in the election of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Directors Proposal is conditioned upon the approval
of the Business Combination Proposal and Closing of the Business Combination. If the Business Combination Proposal is not approved, the
Directors Proposal will have no effect even if approved by BCAR shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the Directors Proposal is not approved, the Business
Combination will not occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recommendation of the Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>THE BCAR BOARD UNANIMOUSLY RECOMMENDS THAT BCAR
SHAREHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE DIRECTORS PROPOSAL.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 176; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->159<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_019"></span>PROPOSAL No. 6</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_020"></span>THE EQUITY INCENTIVE PLAN
PROPOSAL</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of 10,000,000 shares of PubCo Class A Ordinary Common Stock will be reserved for issuance under the Exascale Labs Holdings Inc.
2026 Omnibus Equity Incentive Plan (the &#8220;<b>Equity Incentive Plan</b>&#8221;), subject to annual increases as described below. The
Equity Incentive Plan, a copy of which is attached to this proxy statement/prospectus as <i>Annex </i>C, will become effective upon the
Closing. The BCAR Board has approved the Equity Incentive Plan, subject to approval by BCAR&#8217;s shareholders. If the Equity Incentive
Plan is approved by BCAR shareholders, then the Equity Incentive Plan will be effective upon the closing of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the material features of the Equity Incentive Plan. This summary is qualified in its entirety by the full text
of the Equity Incentive Plan, a copy of which is attached as <i>Annex C</i> to this proxy statement/prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of the Exascale Labs Holdings Inc. 2026 Omnibus Equity Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Equity Incentive Plan was adopted by the BCAR Board prior to the Closing, subject to BCAR shareholder approval, and will become effective
upon the Closing. The Equity Incentive Plan allows PubCo to make equity and equity-based incentive awards to PubCo&#8217;s officers, employees,
directors and consultants. The BCAR Board anticipates that providing such persons with a direct stake in PubCo will promote long-term
value creation, enhance retention and motivation, and align the interests of such individuals with those of PubCo and PubCo&#8217;s stockholders,
thereby stimulating their efforts on PubCo&#8217;s behalf and strengthening their desire to remain with PubCo, particularly in light of
competitive labor market conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo
will initially reserve 10,000,000 shares of PubCo Class A Ordinary Common Stock for the issuance of awards under the Equity Incentive
Plan (the &#8220;<b>Initial Limit</b>&#8221;). The Equity Incentive Plan provides that the number of shares reserved and available for
issuance under the Equity Incentive Plan will automatically increase each January 1, beginning on January 1, 2026, by five percent (5.0%)
of the outstanding number of shares of PubCo Class A Ordinary Common Stock on the immediately preceding December 31, or such lesser amount
as determined by the PubCo Board in its discretion (the &#8220;<b>Annual Increase</b>&#8221;). This limit is subject to adjustment in
the event of a reorganization, recapitalization, reclassification, stock split, stock dividend, reverse stock split or other similar change
in PubCo&#8217;s capitalization. The maximum aggregate number of shares of PubCo Class A Ordinary Common Stock that may be issued upon
exercise of incentive stock options under the Equity Incentive Plan shall not exceed the Initial Limit cumulatively increased on January
1, 2026 and on each January 1 thereafter by the lesser of the Annual Increase or 3,200,000 shares of PubCo Class A Ordinary Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Equity Incentive Plan contains a limitation whereby the value of all awards under the Equity Incentive Plan and all other cash compensation
paid by PubCo to any non-employee director may not exceed $750,000 in any calendar year; <i><span style="text-decoration: underline">provided</span></i>,
<i><span style="text-decoration: underline">however</span></i>, that such amount will be $1,000,000 for the first calendar year a non-employee
director is initially appointed to the PubCo Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 177; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->160<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Equity Incentive Plan
will be administered by the compensation committee of the PubCo Board, the PubCo Board or such other similar committee pursuant to the
terms of the Equity Incentive Plan. The administrator, which initially will be the compensation committee of the PubCo Board, will have
broad discretionary authority to select, from among the individuals eligible for awards, the individuals to whom awards will be granted,
to make any combination of awards to participants, and to determine the specific terms and conditions of each award, subject to the provisions
of the Equity Incentive Plan. The administrator may delegate to a committee consisting of one or more officers the authority to grant
stock options and other awards to employees who are not subject to the reporting and other provisions of Section 16 of the Exchange Act
and not members of the delegated committee, to the maximum extent permitted by applicable law, subject to certain limitations and guidelines.
Persons eligible to participate in the Equity Incentive Plan will be those full or part-time officers, employees, non-employee directors
and consultants as selected from time to time by the administrator in its discretion. As of the date of this proxy statement/prospectus,
approximately [_] individuals will be eligible to participate in the Equity Incentive Plan, which includes approximately [_] officers,
approximately [_] employees who are not officers and three non-employee directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Incentive Equity Plan
permits the granting of both options to purchase PubCo Class A Ordinary Common Stock intended to qualify as incentive stock options under
Section 422 of the Code and options that do not so qualify. Options granted under the Equity Incentive Plan will be non-qualified options
if they fail to qualify as incentive stock options or exceed the annual limit on Equity Incentive Plan. Incentive stock options may only
be granted to employees of PubCo and its subsidiaries. Non-qualified options may be granted to any persons eligible to receive awards
under the Equity Incentive Plan. The option exercise price of each option will be determined by the administrator but may not be less
than 100% of the fair market value of the PubCo Class A Ordinary Common Stock on the date of grant or, in the case of an incentive stock
option granted to a ten percent stockholder, 110% of such share&#8217;s fair market value. The term of each option will be fixed by the
administrator and may not exceed ten years from the date of grant. The administrator will determine at what time or times each option
may be exercised, including the ability to accelerate the vesting of such options. Subject to the terms of the applicable award certificate,
the consideration received or to be received for the grant or extension of an option may include cash, stock or other property, as determined
by the administrator.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Upon exercise of options,
the option exercise price must be paid in full either in cash, by certified or bank check or other instrument acceptable to the administrator
or by delivery (or attestation to the ownership) of shares of PubCo Class A Ordinary Common Stock that are beneficially owned by the optionee
free of restrictions or were purchased in the open market. Subject to applicable law, the exercise price may also be delivered by a broker
pursuant to irrevocable instructions to the broker from the optionee. In addition, to the extent permitted by applicable law, the administrator
may permit non-qualified options to be exercised using a &#8220;net exercise&#8221; arrangement that reduces the number of shares issued
to the optionee by the largest whole number of shares with fair market value that does not exceed the aggregate exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The administrator may award
stock appreciation rights subject to such conditions and restrictions as it may determine. Stock appreciation rights entitle the recipient
to shares of PubCo Class A Ordinary Common Stock, or cash, equal to the value of the appreciation in the price of PubCo Class A Ordinary
Common Stock over the exercise price. The exercise price may not be less than 100% of the fair market value of PubCo Class A Ordinary
Common Stock on the date of grant. The term of each stock appreciation right will be fixed by the administrator and may not exceed ten
years from the date of grant. The administrator will determine at what time or times each stock appreciation right may be exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The administrator may award
restricted shares of PubCo Class A Ordinary Common Stock and restricted stock units to participants subject to such conditions and restrictions
as it may determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment
with PubCo through a specified vesting period. The administrator may also grant shares of PubCo Class A Ordinary Common Stock that are
free from any restrictions under the Equity Incentive Plan. Unrestricted stock may be granted to participants in recognition of past services
or for other valid consideration and may be issued in lieu of cash compensation due to such participant. The administrator may grant dividend
equivalent rights to participants that entitle the recipient to receive credits for dividends that would be paid if the recipient had
held a specified number of shares of PubCo Class A Ordinary Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The administrator may grant
cash bonuses under the Equity Incentive Plan to participants, subject to the achievement of certain performance goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 178; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->161<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Equity Incentive Plan
provides that upon the effectiveness of a &#8220;sale event,&#8221; as defined in the Equity Incentive Plan, an acquirer or successor
entity may assume, continue or substitute outstanding awards under the Equity Incentive Plan. To the extent that awards granted under
the Equity Incentive Plan are not assumed or continued or substituted by the successor entity, upon the effective time of the sale event,
such awards under the Equity Incentive Plan shall terminate. In such case, except as may be otherwise provided in the relevant award agreement,
all options and stock appreciation rights with time-based vesting, conditions of restrictions that are not exercisable immediately prior
to the effective time of the sale event will become fully exercisable as of the effective time of the sale event, all other awards with
time-based vesting conditions or restrictions will become fully vested and nonforfeitable as of the effective time of the sale event and
all awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in the
discretion of the administrator or as specified in the relevant award certificate. In the event of such termination, individuals holding
options and stock appreciation rights will, for each such award, either (i) receive a payment in cash or in kind in an amount equal to
the per share cash consideration payable to stockholders in the sale event less the applicable exercise price or (ii) be permitted to
exercise such options and stock appreciation rights (to the extent exercisable) within a specified period of time prior to the sale event.
Participants in the Equity Incentive Plan are responsible for the payment of any federal, state or local taxes that PubCo is required
by law to withhold upon the exercise of options or stock appreciation rights or vesting of other awards. Subject to approval by the administrator,
participants may elect to have the minimum tax withholding obligations satisfied by authorizing PubCo to withhold shares of PubCo Class
A Ordinary Common Stock to be issued pursuant to the exercise or vesting of such award.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The administrator may amend
or discontinue the Equity Incentive Plan and the administrator may amend or cancel outstanding awards for purposes of satisfying changes
in law or any other lawful purpose, but no such action may materially and adversely affect rights under an award without the holder&#8217;s
consent. Certain amendments to the Equity Incentive Plan require the approval of PubCo&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">No awards may be granted
under the Equity Incentive Plan after the date that is ten years from the date immediately preceding the Closing. No awards under the
Equity Incentive Plan have been made prior to the date hereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Form S-8</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Following the consummation
of the Business Combination, when permitted by SEC rules, PubCo intends to file with the SEC a registration statement on Form S-8 covering
the PubCo Class A Ordinary Common Stock issuable under the Equity Incentive Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Certain U.S. Federal
Income Tax Aspects</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following is a summary
of certain material U.S. federal income tax consequences of certain transactions under the Equity Incentive Plan. This summary reflects
U.S. federal income tax law in effect as of the date of this proxy statement/prospectus and does not address all possible tax consequences,
nor does it describe state or local tax consequences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Equity Incentive Plan</i>.
No taxable income is generally realized by the optionee upon the grant or exercise of an incentive stock option. However, the exercise
of an incentive stock option may give rise to alternative minimum tax liability. If shares of PubCo Common Stock issued to an optionee
pursuant to the exercise of an incentive stock option are sold or transferred after two years from the date of grant and after one year
from the date of exercise, then generally (i) upon sale of such shares, any amount realized in excess of the option exercise price (the
amount paid for the shares) will be taxed to the optionee as a long-term capital gain, and any loss sustained will be a long-term capital
loss, and (ii) PubCo will not be entitled to any deduction for U.S. federal income tax purposes; provided that such incentive stock option
otherwise meets all of the technical requirements of an incentive stock option. The exercise of an incentive stock option will give rise
to an item of tax preference that may result in alternative minimum tax liability for the optionee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If shares of PubCo Common
Stock acquired upon the exercise of an incentive stock option are disposed of prior to the expiration of the two-year and one-year holding
periods described above (a &#8220;<b>disqualifying disposition</b>&#8221;), generally (i) the optionee will realize ordinary income in
the year of disposition in an amount equal to the excess (if any) of the fair market value of the shares of PubCo Common Stock at exercise
(or, if less, the amount realized on a sale of such shares of PubCo Common Stock) over the option price thereof, and (ii) PubCo will be
entitled to deduct such amount. Special rules will apply where all or a portion of the exercise price of the incentive stock option is
paid by tendering shares of PubCo Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 179; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->162<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If an incentive stock option
is exercised at a time when it no longer qualifies for the tax treatment described above, the option is treated as a non-qualified option.
Generally, an incentive stock option will not be eligible for the tax treatment described above if it is exercised more than three months
following termination of employment (or one year in the case of termination of employment by reason of disability). In the case of termination
of employment by reason of death, the three-month rule does not apply.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Non-Qualified Options</i>.
No income is generally realized by the optionee at the time a non-qualified option is granted. Generally (i) at exercise, ordinary income
is realized by the optionee in an amount equal to the difference between the option exercise price and the fair market value of the shares
of PubCo Common Stock on the date of exercise, and PubCo receives a tax deduction for the same amount, subject to Section 162(m), and
(ii) at disposition, appreciation or depreciation after the date of exercise is treated as either short-term or long-term capital gain
or loss depending on how long the shares of PubCo Common Stock have been held. Special rules will apply where all or a portion of the
exercise price of the non-qualified option is paid by tendering shares of PubCo Common Stock. Upon exercise, the optionee will also be
subject to Social Security taxes on the excess of the fair market value over the exercise price of the option.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Other Awards</i>. PubCo
generally will be entitled to a tax deduction in connection with other awards under the Equity Incentive Plan in an amount equal to the
ordinary income realized by the participant at the time the participant recognizes such income. Participants typically are subject to
income tax and recognize such tax at the time that an award is exercised, vests or becomes non-forfeitable, unless the award provides
for deferred settlement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Section 162(m)</i>. Under
current law, Section 162(m) applies to a broader group of covered employees and no longer includes an exception for performance-based
compensation. As a result, certain compensation may be non-deductible. The Equity Incentive Plan is intended to provide flexibility to
mitigate adverse tax consequences where possible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Parachute Payments</i>.
The vesting of any portion of an award that is accelerated due to the occurrence of a change in control (such as a sale event) may cause
all or a portion of the payments with respect to such accelerated awards to be treated as &#8220;parachute payments&#8221; as defined
in the Code. Any such parachute payments may be non-deductible to PubCo, in whole or in part, and may subject the recipient to a non-deductible
20% federal excise tax on all or a portion of such payment (in addition to other taxes ordinarily payable).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>New Equity Incentive
Plan Benefits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">No awards have been previously
granted under the Equity Incentive Plan and no awards have been granted that are contingent on stockholder approval of the Equity Incentive
Plan. The awards that are to be granted to any participant or group of participants are indeterminable at the date of this proxy statement/prospectus
because participation and the types of awards that may be granted under the Equity Incentive Plan are subject to the discretion of the
administrator. Consequently, no new plan benefits table is included in this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Vote Required for Approval</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The approval of the Equity
Incentive Plan Proposal requires an ordinary resolution under British Virgin Islands law, being the affirmative vote of at least a majority
of the votes cast by the holders of BCAR Ordinary Shares present in person or represented by proxy at the Extraordinary General Meeting
and entitled to vote on such matter. Abstentions and broker non-votes, while considered present for the purposes of establishing a quorum,
will not count as votes cast at the Extraordinary General Meeting, and otherwise will have no effect on a particular proposal under British
Virgin Islands law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Equity Incentive Plan
Proposal is conditioned on the approval of each of the other Condition Precedent Proposals. Therefore, if each of the other Condition
Precedent Proposals is not approved, the Equity Incentive Plan Proposal will have no effect. The Sponsor, which includes among its members
each of the directors and officers of BCAR, and together with each of the directors and officers of BCAR, owns 13,200,000 BCAR Ordinary
Shares, including both BCAR Class A Ordinary Shares and BCAR Class B Ordinary Shares. As a result, as of the date of this proxy statement/prospectus,
the Insiders own approximately 32.0% of the issued and outstanding BCAR Ordinary Shares. Accordingly, no additional votes of holders of
Public Shares will be required to approve the Equity Incentive Plan Proposal assuming only a quorum of BCAR Ordinary Shares are present
at the Extraordinary General Meeting. However, should all issued and outstanding BCAR Ordinary Shares entitled to vote at the Extraordinary
General Meeting be present, an additional 7,400,001 votes would be necessary to approve the Equity Incentive Plan Proposal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 180; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->163<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Resolution to be Voted
Upon</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The full text of the resolution
to be passed is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#8220;<b>RESOLVED</b>,
as an ordinary resolution, that the Exascale Labs Holdings Inc. 2026 Omnibus Equity Incentive Plan, a copy of which is attached to the
proxy statement/prospectus as <i>Annex C</i>, be adopted and approved.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Recommendation of the
BCAR Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>THE BCAR BOARD UNANIMOUSLY
RECOMMENDS THAT BCAR SHAREHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE EQUITY INCENTIVE PLAN PROPOSAL.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The existence of financial
and personal interests of one or more of BCAR&#8217;s directors may result in a conflict of interest on the part of such director(s) between
what he, she or they may believe is in the best interests of BCAR and its shareholders and what he, she or they may believe is best for
himself, herself or themselves in determining to recommend that shareholders vote for the proposals. In addition, BCAR&#8217;s officers
have interests in the Business Combination that may conflict with your interests as a shareholder. See &#8220;<i>The Business Combination
Proposal &#8212; Certain Interests of BCAR&#8217;s Directors and Officers and Others in the Business Combination</i>&#8221; for a further
discussion of these considerations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 181; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->164<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="a_020a"></span><b>PROPOSAL
No. 7</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="a_020b"></span><b>THE
NASDAQ PROPOSAL</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Under Nasdaq Listing Rule
5635(a)(1), shareholder approval is required prior to the issuance of common stock, or of securities convertible into or exercisable for
common stock, in connection with the acquisition of another company if such securities are not issued in a public offering for cash and
(i)&#160;the common stock has, or will have upon issuance, voting power equal to or in excess of 20% of the voting power outstanding before
the issuance of such securities (or securities convertible into or exercisable for common stock; or (ii)&#160;the number of shares of
common stock to be issued is or will be equal to or in excess of 20% of the number of shares of common stock outstanding before the issuance
of the stock or securities. If the Business Combination is completed pursuant to the Business Combination Agreement, BCAR currently expects
to issue up to 91,200,000 shares of PubCo Common Stock (assuming that none of BCAR&#8217;s outstanding Public Shares are redeemed) in
connection with the Business Combination. Additionally, under Nasdaq Listing Rule 5635(b), shareholder approval is required prior to the
issuance of securities when the issuance or potential issuance will result in a change of control of the registrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Under Nasdaq Listing Rule
5635(d), shareholder approval is required for a transaction other than a public offering, involving the sale, issuance or potential issuance
by an issuer of common stock (or securities convertible into or exercisable for common stock) at a price that is less than the lesser
of the official Nasdaq closing price immediately before signing of the binding agreement and the average official Nasdaq closing price
for the five trading days immediately preceding the signing of the binding agreement of the stock if the number of shares of common stock
to be issued is or may be equal to 20% or more of the common stock, or 20% or more of the voting power, outstanding before the issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In the event that this proposal
is not approved by BCAR shareholders, the Business Combination cannot be consummated. In the event that this proposal is approved by BCAR
shareholders, but the Business Combination Agreement is terminated (without the Business Combination being consummated) prior to the issuance
of shares of PubCo Common Stock pursuant to the Business Combination Agreement, PubCo will not issue such shares of PubCo Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Vote Required for Approval</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The approval of the Nasdaq
Proposal requires an ordinary resolution under British Virgin Islands law, being the affirmative vote of at least a majority of the votes
cast by the holders of BCAR Ordinary Shares present in person or represented by proxy at the Extraordinary General Meeting and entitled
to vote on such matter. Abstentions and broker&#160;non-votes,&#160;while considered present for the purposes of establishing a quorum,
will not count as votes cast at the Extraordinary General Meeting, and otherwise will have no effect on a particular proposal under British
Virgin Islands law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Nasdaq Proposal is conditioned on the approval
and adoption of each of the other Condition Precedent Proposals. The Sponsor, which includes among its members each of the directors and
officers of BCAR, owns 200,000 Private Units and 12,000,000 BCAR Class B Ordinary Shares, and David Boral owns 1,000,000 Representative
Shares. As a result, as of the date of this proxy statement/prospectus, the Insiders own approximately 32.0% of the issued and outstanding
BCAR Ordinary Shares. As a result, in addition to the shares held by the Insiders, BCAR would need 7,400,001 Public Shares, or approximately
26.4% of the 28,000,000 Public Shares sold in the BCAR IPO, to be voted in favor of the Business Combination Proposal, the Domestication
Merger Proposal, the Organizational Documents Proposal, the Advisory Organizational Documents Proposals, the Directors Proposal, the Equity
Incentive Plan Proposal, the Nasdaq Proposal, and, if presented, the Adjournment Proposal, in order for such proposals to be approved,
assuming all outstanding shares are voted and the Insiders do not acquire any Public Shares. Assuming that only the holders of thirty
percent (30%) of the issued and outstanding BCAR ordinary shares, representing a quorum under BCAR&#8217;s amended and restated memorandum
and articles of association, vote their shares at the Extraordinary General Meeting, BCAR will not need any Public Shares in addition
to the shares held by the Insiders to be voted in favor of the Business Combination Proposal, the Domestication Merger Proposal, the Organizational
Documents Proposal, the Advisory Organizational Documents Proposals, the Directors Proposal, the Equity Incentive Plan Proposal, the Nasdaq
Proposal, and, if presented, the Adjournment Proposal, in order for such proposals to be approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 182; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->165<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Resolution to be Voted
Upon</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The full text of the resolution
to be passed is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#8220;<b>RESOLVED</b>,
as an ordinary resolution, that for the purposes of complying with the applicable provisions of Nasdaq Stock Exchange Listing Rule 5635,
the issuance of shares of PubCo Common Stock be approved.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Recommendation of the
BCAR Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>THE BCAR BOARD UNANIMOUSLY
RECOMMENDS THAT BCAR SHAREHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE NASDAQ PROPOSAL.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The existence of financial
and personal interests of one or more of BCAR&#8217;s directors may result in a conflict of interest on the part of such director(s) between
what he, she or they may believe is in the best interests of BCAR and its shareholders and what he, she or they may believe is best for
himself, herself or themselves in determining to recommend that shareholders vote for the proposals. In addition, BCAR&#8217;s officers
have interests in the Business Combination that may conflict with your interests as a shareholder. See &#8220;<i>The Business Combination
Proposal &#8212; Certain Interests of BCAR&#8217;s Directors and Officers and Others in the Business Combination</i>&#8221; for a further
discussion of these considerations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 183; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->166<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_021"></span>PROPOSAL No. 8</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_022"></span>THE ADJOURNMENT PROPOSAL</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Adjournment Proposal allows the BCAR Board to
submit a proposal to approve, by ordinary resolution, the adjournment of the Extraordinary General Meeting to a later date or dates, if
necessary, to permit further solicitation and vote of proxies in the event that, based on the tabulated votes, there are not sufficient
votes at the time of the Extraordinary General Meeting to approve the Condition Precedent Proposals. The purpose of the Adjournment Proposal
is to permit further solicitation of proxies and votes and to provide additional time for the Sponsor, BCAR and their members and shareholders,
respectively, to make purchases of BCAR Ordinary Shares or other arrangements that would increase the likelihood of obtaining a favorable
vote on the proposals to be put to the Extraordinary General Meeting. See &#8220;<i>The Business Combination Proposal &#8212; Certain
Interests of BCAR&#8217;s Directors and Officers and Others in the Business Combination</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Vote Required for Approval</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of the Adjournment Proposal requires
an ordinary resolution, being the affirmative vote of a majority of the votes cast by the holders of BCAR Ordinary Shares, represented
in person or by proxy and entitled to vote thereon at the Extraordinary General Meeting. Abstentions and broker non-votes, while considered
present for the purposes of establishing a quorum, will not count as votes cast at the Extraordinary General Meeting and otherwise will
have no effect on a particular proposal under British Virgin Islands law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Adjournment Proposal is not conditioned upon
any other proposal. The Sponsor, which includes among its members each of the directors and officers of BCAR, owns 200,000 Private Units
and 12,000,000 BCAR Class B Ordinary Shares, and David Boral owns 1,000,000 Representative Shares. As a result, as of the date of this
proxy statement/prospectus, the Insiders own approximately 32.0% of the issued and outstanding BCAR Ordinary Shares. As a result, in addition
to the shares held by the Insiders, BCAR would need 7,400,001 Public Shares, or approximately 26.4% of the 28,000,000 Public Shares sold
in the BCAR IPO, to be voted in favor of the Business Combination Proposal, the Domestication Merger Proposal, the Organizational Documents
Proposal, the Advisory Organizational Documents Proposals, the Directors Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal,
and, if presented, the Adjournment Proposal, in order for such proposals to be approved, assuming all outstanding shares are voted and
the Insiders do not acquire any Public Shares. Assuming that only the holders of thirty percent (30%) of the issued and outstanding BCAR
ordinary shares, representing a quorum under BCAR&#8217;s amended and restated memorandum and articles of association, vote their shares
at the Extraordinary General Meeting, BCAR will not need any Public Shares in addition to the shares held by the Insiders to be voted
in favor of the Business Combination Proposal, the Domestication Merger Proposal, the Organizational Documents Proposal, the Advisory
Organizational Documents Proposals, the Directors Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal, and, if presented,
the Adjournment Proposal, in order for such proposals to be approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Resolution to be Voted Upon</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The full text of the resolution to be passed is as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>RESOLVED</b>, as an ordinary resolution,
that the adjournment of the Extraordinary General Meeting to a later date or dates, if necessary, to permit further solicitation and vote
of proxies in the event that there are insufficient votes for the approval of one or more proposals at the Extraordinary General Meeting
be approved.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recommendation of the BCAR Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>THE BCAR BOARD UNANIMOUSLY RECOMMENDS THAT SHAREHOLDERS
VOTE &#8220;FOR&#8221; THE APPROVAL OF THE ADJOURNMENT PROPOSAL.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The existence of financial and personal interests
of BCAR&#8217;s directors may result in a conflict of interest on the part of one or more of the directors between what he, she or they
may believe is in the best interests of BCAR and its shareholders and what he, she or they may believe is best for himself, herself or
themselves in determining to recommend that shareholders vote for the proposals. See &#8220;<i>The Business Combination Proposal &#8212;
Certain Interests of BCAR&#8217;s Directors and Officers and Others in the Business Combination</i>&#8221; for a further discussion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 184; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->167<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_023"></span>CERTAIN MATERIAL U.S. FEDERAL
INCOME TAX CONSIDERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following is a discussion
of certain material U.S. federal income tax consequences of (i) the Domestication Merger to U.S. Holders (defined below) of Public Shares
and Public Warrants (collectively, the &#8220;<b>BCAR securities</b>&#8221;), (ii) the Business Combination to U.S. Holders and Non-U.S.
Holders of Exascale Common Stock and securities convertible into Exascale Common Stock (the &#8220;<b>Company securities</b>&#8221;),
and (iii) the ownership and disposition of PubCo Common Stock and PubCo Warrants (collectively, the &#8220;<b>PubCo securities</b>&#8221;)
received in the Business Combination to U.S. Holders and Non-U.S. Holders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This discussion is based on provisions of the
Code, the Treasury regulations promulgated thereunder (whether final, temporary, or proposed) (&#8220;<b>Treasury Regulations</b>&#8221;),
administrative rulings of the IRS, and judicial decisions, all as in effect on the date hereof, and all of which are subject to differing
interpretations or change, possibly with retroactive effect. This discussion does not purport to be a complete analysis or listing of
all potential U.S. federal income tax considerations that may apply to a holder as a result of the Business Combination or as a result
of the ownership and disposition of PubCo securities. In addition, this discussion does not address all aspects of U.S. federal income
taxation that may be relevant to particular holders nor does it take into account the individual facts and circumstances of any particular
holder that may affect the U.S. federal income tax consequences to such holder, and accordingly, is not intended to be, and should not
be construed as, tax advice. This discussion does not address the U.S. federal 3.8% Medicare tax imposed on certain net investment income
or any aspects of U.S. federal taxation other than those pertaining to the income tax, nor does it address any tax consequences arising
under any tax laws other than the U.S. federal income tax law, such as gift or estate tax laws, U.S. state and local, or non-U.S. tax
laws or, except as discussed herein, any tax reporting obligations of a holder of BCAR securities, Company securities or PubCo securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders
should consult their own tax advisors regarding such tax consequences in light of their particular circumstances.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
ruling has been requested or will be obtained from the IRS regarding the U.S. federal income tax consequences of the Business Combination
or any other related matter; thus, there can be no assurance that the IRS will not challenge the U.S. federal income tax treatment described
below or that, if challenged, such treatment will be sustained by a court.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary is limited to considerations relevant to holders that hold BCAR securities or Company securities and, after the completion of
the Business Combination, PubCo securities, as &#8220;capital assets&#8221; within the meaning of Section 1221 of the Code (generally,
property held for investment). This discussion does not address all aspects of U.S. federal income taxation that may be important to holders
in light of their individual circumstances, including holders subject to special treatment under the U.S. tax laws, such as, for example:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks or other financial institutions,
        underwriters, or insurance companies;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">taxpayers who elect to apply a mark-to-market
        method of accounting;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">real estate investment trusts and
        regulated investment companies;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt organizations, qualified
        retirement plans, individual retirement accounts, pension plans, or other tax-deferred accounts;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or former citizens or former long-term
        residents of the United States;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subchapter S corporations and any
        beneficial owners of such entities;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dealers or traders in securities,
        commodities or currencies;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons subject to the alternative
        minimum tax;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">partnerships (including entities
        and arrangements classified as partnerships) for U.S. federal income tax purposes and any beneficial owners of such partnerships;</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 185; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->168<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">grantor trusts;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">cooperatives;</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurance companies;</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">broker-dealers;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. persons whose &#8220;functional
        currency&#8221; is not the U.S. dollar;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">persons who received Public Shares or Company securities through
        the issuance of restricted stock under an incentive plan or through a tax-qualified retirement plan or otherwise as compensation;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that acquired BCAR securities,
        Company securities or PubCo securities pursuant to an exercise of employee share options, in connection with employee share incentive
        plans or otherwise as compensation;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons who own (directly, indirectly,
        or through attribution) 5% or more (by vote or value) all classes of the outstanding Public Shares or Company securities, or, after the
        Business Combination, all classes of the issued PubCo Common Stock;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">holders holding BCAR securities
        or Company securities, or, after the Business Combination, PubCo securities, as a position in a &#8220;straddle,&#8221; as part of a &#8220;synthetic
        security&#8221; or &#8220;hedge,&#8221; as part of a &#8220;conversion transaction,&#8221; or other integrated investment or risk reduction
        transaction;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">controlled foreign corporations,
        passive foreign investment companies, or foreign corporations with respect to which there are one or more United States shareholders within
        the meaning of Treasury Regulation Section 1.367(b)-3(b)(1)(ii); or</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insiders or their affiliates.</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this proxy statement/consent solicitation statement/prospectus, the term &#8220;U.S. Holder&#8221; means a beneficial owner of
BCAR securities or Company securities, and, after the Business Combination, PubCo securities received in the Business Combination, that
is, for U.S. federal income tax purposes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual who is a citizen or
        resident of the United States;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a corporation (or other entity that
        is classified as a corporation for U.S. federal income tax purposes) that is created or organized in or under the laws of the United States
        or any state thereof or the District of Columbia;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate the income of which is
        subject to U.S. federal income tax regardless of its source; or</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust (i) if a court within the
        United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have the authority
        to control all substantial decisions of the trust, or (ii) that has a valid election in effect under applicable Treasury Regulations to
        be treated as a U.S. person for U.S. federal income tax purposes.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a partnership (including any entity or arrangement that is treated as a partnership) for U.S. federal income tax purposes holds BCAR securities
or Company securities, and, after the completion of the Business Combination, PubCo securities received in the Business Combination, the
U.S. federal income tax treatment of a partner in such partnership will generally depend on the status of the partner and the activities
of the partner and the partnership. A holder that is a partnership and the partners in such partnership should consult their own tax advisors
with regard to the U.S. federal income tax consequences of the Business Combination and the subsequent ownership and disposition of PubCo
securities received in the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 186; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->169<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
BCAR Units will be separated into their component parts immediately prior to the consummation of the Business Combination, a beneficial
owner of a BCAR Unit should generally be treated as the owner of the underlying component BCAR securities for U.S. federal income tax
purposes. Accordingly, the discussion below with respect to BCAR securities should also apply to holders of BCAR Units (as the deemed
owner of the underlying component BCAR securities).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THIS
SUMMARY DOES NOT PURPORT TO BE A COMPREHENSIVE ANALYSIS OR DESCRIPTION OF ALL POTENTIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS OF THE
DOMESTICATION, MERGER, OWNERSHIP AND DISPOSITION OF BCAR SECURITIES, COMPANY SECURITIES, AND PUBCO SECURITIES. IN ADDITION, THE U.S. FEDERAL
INCOME TAX TREATMENT OF THE BENEFICIAL OWNERS OF BCAR SECURITIES, COMPANY SECURITIES OR PUBCO SECURITIES MAY BE AFFECTED BY MATTERS NOT
DISCUSSED HEREIN AND DEPENDS IN SOME INSTANCES ON DETERMINATIONS OF FACT AND INTERPRETATIONS OF COMPLEX PROVISIONS OF U.S. FEDERAL INCOME
TAX LAW FOR WHICH NO CLEAR PRECEDENT OR AUTHORITY MAY BE AVAILABLE. HOLDERS OF BCAR SECURITIES, COMPANY SECURITIES SHOULD CONSULT WITH
THEIR TAX ADVISORS REGARDING THE PARTICULAR TAX CONSEQUENCES TO THEM OF THE BUSINESS COMBINATION AND OF THE OWNERSHIP AND DISPOSITION
OF PUBCO SECURITIES AFTER THE BUSINESS COMBINATION, INCLUDING THE APPLICABILITY AND EFFECTS OF U.S. FEDERAL, STATE, LOCAL, AND OTHER TAX
LAWS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>U.S. Federal Income
Tax Consequences of the Domestication Merger to U.S. Holders of BCAR Securities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>If the Domestication
Merger Qualifies as a Reorganization</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
U.S. Federal Income Tax Consequences</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The
U.S. federal income tax consequences of the Domestication Merger to U.S. Holders will depend primarily on whether the Domestication Merger
qualifies as a reorganization within the meaning of Section 368 of the Code (a &#8220;Reorganization&#8221;). The Domestication Merger
is intended to qualify as a Reorganization pursuant to Section 368(a)(1)(F) of the Code. Under Section 368(a)(1)(F) of the Code, a &#8220;mere
change in identity, form or place of organization of one corporation, however effected&#8221; qualifies as a Reorganization. Pursuant
to the Domestication Merger, BCAR, a British Virgin Islands business company, will merge with and into PubCo, with PubCo surviving as
a corporation incorporated under the laws of the State of Delaware.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon customary assumptions, as well as certain
representations made by, and covenants and undertakings of, BCAR, it is the opinion of Loeb &amp; Loeb LLP, legal counsel to BCAR, that
the Domestication Merger should qualify as a Reorganization pursuant to Section 368(a)(1)(F) of the Code. However, the provisions of the
Code that govern Reorganizations are complex, and due to the absence of direct guidance on the application of Section 368 to a reincorporation
merger of a corporation holding only investment-type assets such as BCAR, the qualification of the Domestication Merger as a Reorganization
is not entirely clear. If any of the facts, assumptions, representations, covenants or undertakings by BCAR are incorrect, incomplete
or inaccurate or are violated, the accuracy of the opinion may be affected and the U.S. federal income tax consequences of the Domestication
Merger could differ from those described in this proxy statement/prospectus. However, the completion of the Domestication Merger is not
conditioned upon the receipt of an opinion of BCAR&#8217;s legal counsel regarding the U.S. federal income tax consequences of the Domestication
Merger. U.S. Holders should be aware that BCAR has not requested and, following the Domestication Merger, PubCo does not intend to request
a ruling from the IRS with respect to the U.S. federal income tax treatment of the Domestication Merger. There can be no assurance that
the IRS will not take a contrary position to views expressed herein or that a court will not agree with a contrary position of the IRS.
The remainder of this discussion assumes the Domestication Merger qualifies as a Reorganization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If
the Domestication Merger qualifies as a Reorganization, the Domestication Merger will be treated for U.S. federal income tax purposes
as if BCAR (1) transferred all of its assets and liabilities to PubCo in exchange for all of the outstanding common stock and warrants
of PubCo and (2) then distributed the shares of PubCo Common Stock and PubCo Warrants to the holders of BCAR Ordinary Shares or BCAR
Warrants in liquidation of BCAR, and the taxable year of BCAR will end on the date of the Domestication Merger. Assuming the Domestication
Merger qualifies as a Reorganization (and subject to the PFIC rules discussed below under the heading &#8220;&#8212; <i>Passive Foreign
Investment Company Status</i>,&#8221; and the discussion below regarding the effect of Section 367 of the Code), a U.S. Holder that exchanges
its BCAR securities pursuant to the Domestication Merger should not recognize gain or loss on the exchange of BCAR securities for PubCo
securities. The aggregate adjusted tax basis of a U.S. Holder in the PubCo Common Stock received as a result of the Domestication Merger
should equal the aggregate adjusted tax basis of the Public Shares surrendered in the exchange, and the aggregate adjusted tax basis
in the PubCo Warrants received as a result of such exchange should equal the aggregate adjusted tax basis of the Public Warrants surrendered
in the exchange, in each case increased by any amount included in the income of such U.S. Holder under Section 367(b) of the Code, if
any (as discussed below). A U.S. Holder&#8217;s holding period for the PubCo securities received in the exchange should include the holding
period for the BCAR securities surrendered in the exchange.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 187; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->170<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Effect
of Section 367 of the Code to U.S. Holders of Public Shares</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Section 367 of the Code
applies to certain non-recognition transactions involving foreign corporations, including a domestication of a foreign corporation in
a transaction that qualifies as a Reorganization. When it applies, Section 367 generally gives rise to gain recognition or other income
inclusions with respect to certain United States persons in connection with transactions that would otherwise be non-recognition transactions
for U.S. federal income tax purposes. Section 367(b) generally will apply to U.S. Holders that exchange Public Shares (but not the Public
Warrants) for PubCo Common Stock as part of the Domestication Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">A.
U.S. Holders Who Own 10 Percent or More of the Voting Power or Value of BCAR</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">A U.S. Holder that on the
day of the Domestication Merger beneficially owns (directly, indirectly, or constructively) (i) ten percent (10%) or more of the total
combined voting power of all classes of BCAR stock entitled to vote or (ii) ten percent (10%) or more of the total value of shares of
all classes of BCAR stock (a &#8220;U.S. Shareholder&#8221;) must include in income as a dividend the &#8220;all earnings and profits
amount&#8221; attributable to the Public Shares it directly owns, within the meaning of Treasury Regulation Section 1.367(b)-2(d). Complex
attribution rules apply in determining whether a U.S. Holder owns 10% or more of the total combined voting power of all classes of BCAR
securities entitled to vote or 10% or more of the total value of shares of all classes of BCAR securities for U.S. federal income tax
purposes, and all U.S. Holders are urged to consult their tax advisors with respect to these attribution rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
U.S. Shareholder&#8217;s earnings and profits amount with respect to its Public Shares is the net positive earnings and profits of the
corporation (as determined under Treasury Regulation Section 1.367(b)-2(d)(2)) attributable to the Public Shares (as determined under
Treasury Regulation Section 1.367(b)-2(d)(3)) but without regard to any gain that would be realized on a sale or exchange of such Public
Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Accordingly, under Treasury
Regulation Section 1.367(b)-3(b)(3), a U.S. Shareholder will be required to include in income as a deemed dividend the earnings and profits
amount (as defined in Treasury Regulation Section 1.367(b)-2(d)) with respect to its Public Shares as a result of the Domestication Merger.
Any such U.S. Shareholder that is a corporation may, under certain circumstances, effectively be exempt from taxation due to a deduction
in the amount of a portion or all of the deemed dividend pursuant to Section 245A of the Code. See &#8220;&#8212; <i>Passive Foreign Investment
Company Status</i>&#8221; for a discussion of whether the amount of inclusion under Section 367(b) of the Code should be reduced by amounts
required to be taken into account by a Non-Electing Shareholder (as defined below) under the proposed Treasury Regulations under Section
1291(f) of the Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">B.
U.S. Holders Who Own Less Than 10 Percent of the Voting Power and Value of BCAR</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">A U.S. Holder that on the
day of the Domestication Merger beneficially owns (directly, indirectly, or constructively) Public Shares with a fair market value of
$50,000 or more but less than (i) ten percent (10%) of the total combined voting power of all classes of BCAR stock entitled to vote and
(ii) ten percent (10%) of the total value of shares of all classes of BCAR stock must either recognize gain with respect to the Domestication
Merger or, in the alternative, elect to recognize the &#8220;all earnings and profits&#8221; amount, in each case as described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Unless a U.S. Holder makes
the &#8220;all earnings and profits election&#8221; as described below, such holder generally must recognize gain (but not loss) with
respect to PubCo Common Stock received in exchange for its Public Shares pursuant to the Domestication Merger. Any such gain would be
equal to the excess of the fair market value of such PubCo Common Stock received over the U.S. Holder&#8217;s adjusted tax basis in the
Public Shares surrendered in exchange therefor. Subject to the PFIC rules discussed below, such gain would be capital gain, and should
be long-term capital gain if the U.S. Holder held the Public Shares for longer than one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
lieu of recognizing any gain as described in the preceding paragraph, a U.S. Holder may elect to include in income the earnings and profits
amount attributable to its Public Shares under Section 367(b). There are, however, strict conditions for making this election, as enumerated
in the Treasury Regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 188; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->171<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders are strongly urged to consult with their own tax advisors regarding whether to make this election and if the election is determined
to be advisable, the appropriate filing requirements with respect to this election. See &#8220;&#8212; <i>Passive Foreign Investment Company
Status</i>&#8221; for a discussion of whether the amount of inclusion under Section 367(b) of the Code should be reduced by amounts required
to be taken into account by a Non-Electing Shareholder (as defined below) under the proposed Treasury Regulations under Section 1291(f)
of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder (who is not a U.S. Shareholder)
that beneficially owns (directly, indirectly, or constructively) Public Shares with a fair market value of less than $50,000 would not
be required to recognize any gain or loss or include any part of the earnings and profits amount in income under Section 367(b) of the
Code in connection with the Domestication Merger, for federal income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If the Domestication Merger Does Not Qualify
as a Reorganization</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Domestication Merger fails to qualify as
a Reorganization, and subject to the PFIC rules discussed below under the heading &#8220;&#8212; <i>Passive Foreign Investment Company
Status</i>,&#8221; a U.S. Holder that exchanges its BCAR securities for PubCo securities in the Domestication Merger will recognize gain
or loss equal to the difference between (i) the fair market value of the PubCo securities received and (ii) the U.S. Holder&#8217;s adjusted
tax basis in the BCAR securities exchanged therefor. A U.S. Holder&#8217;s aggregate tax basis in the PubCo securities received will be
the fair market value of the PubCo securities on the date of the Domestication Merger. The U.S. Holder&#8217;s holding period for the
PubCo securities received pursuant to the Domestication Merger will begin on the day after the date of the Domestication Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Such gain or loss will be a capital gain or loss
and will be a long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the BCAR securities exceeds one year at the
time of the Domestication Merger. Long-term capital gains recognized by non-corporate U.S. Holders, including individuals, currently are
subject to preferential rates of U.S. federal income taxation. The deductibility of capital losses is subject to limitations under the
Code. Any such capital gain or loss recognized by a U.S. Holder will generally be treated as U.S. source gain or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">U.S. Holders should consult their own tax advisors
as to the particular consequences to them of the exchange of BCAR securities for PubCo securities pursuant to the Domestication Merger,
the qualification of the Domestication Merger as a Reorganization, and the application of Section 367(b) to the Domestication Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Passive
Foreign Investment Company Status</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Even if the Domestication
Merger qualifies as a Reorganization, the Domestication Merger may be a taxable event to U.S. Holders of BCAR securities under the PFIC
provisions of the Code, to the extent that Section 1291(f) of the Code applies. Because BCAR is a blank check company with no current
active operating business, based upon the composition of its income and assets, BCAR believes that it may be classified as a PFIC for
its most recent taxable year ended on December 31, 2025, and may be classified as a PFIC for its current taxable year which will end as
a result of the Domestication Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Definition
and General Taxation of a PFIC</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-U.S. corporation will be classified as a PFIC for any taxable year (a) if at least 75% of its gross income consists of passive income,
such as dividends, interest, rents and royalties (except for rents and royalties earned in the active conduct of a trade or business),
and gains on the disposition of property that produces such income, or (b) if at least 50% of the fair market value of its assets (determined
on the basis of a quarterly average) is attributable to assets that produce, or are held for the production of, passive income (including
for these purposes its pro rata share of the gross income and assets of any corporation and partnership in which it is considered to own
at least 25% of the interest, by value). The determination of whether a foreign corporation is a PFIC is made annually. BCAR&#8217;s U.S.
counsel expresses no opinion with respect to BCAR&#8217;s PFIC status for any taxable year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
BCAR is determined to be a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S. Holder of BCAR
securities and, in the case of Public Shares, the U.S. Holder did not make either (a) a timely qualified electing fund (&#8220;<b>QEF</b>&#8221;)
election under Section 1295 of the Code for BCAR&#8217;s first taxable year as a PFIC in which the U.S. Holder held (or was deemed to
hold) Public Shares or (b) a QEF election along with a &#8220;purging election,&#8221; both of which are discussed further below, such
holder generally will be subject to special rules with respect to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any gain recognized by the U.S.
        Holder on the sale or other disposition of BCAR securities; and</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 189; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->172<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any &#8220;excess distribution&#8221;
        made to the U.S. Holder (generally, any distributions to such U.S. Holder during a taxable year of the U.S. Holder that are greater than
        125% of the average annual distributions received by such U.S. Holder in respect of the Public Shares during the three preceding taxable
        years of such U.S. Holder or, if shorter, such U.S. Holder&#8217;s holding period for the Public Shares).</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
these rules,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the U.S. Holder&#8217;s gain or
        excess distribution will be allocated ratably over the U.S. Holder&#8217;s holding period for the BCAR securities;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated to the U.S.
        Holder&#8217;s taxable year in which the U.S. Holder recognized the gain or received the excess distribution, or to the period in the
        U.S. Holder&#8217;s holding period before the first day of BCAR&#8217;s first taxable year in which it qualified as a PFIC, will be taxed
        as ordinary income;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated to other taxable
        years (or portions thereof) of the U.S. Holder and included in its holding period will be taxed at the highest tax rate in effect for
        that year and applicable to the U.S. Holder; and</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the interest charge generally applicable
        to underpayments of tax will be imposed in respect of the tax attributable to each such other taxable year of the U.S. Holder.</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, if BCAR is determined to be a PFIC, a U.S. Holder may avoid the PFIC tax consequences described above with respect to its Public
Shares by making a timely QEF election (or a QEF election along with a purging election), as described below. Pursuant to the QEF election,
a U.S. Holder will be required to include in income its pro rata share of BCAR&#8217;s net capital gain (as long-term capital gain) and
other earnings and profits (as ordinary income), on a current basis, whether or not distributed, in the taxable year of the U.S. Holder
in which or with which BCAR&#8217;s taxable year ends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impact
of PFIC Rules on Certain U.S. Holders</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The impact of the PFIC rules
on a U.S. Holder of BCAR securities will depend on whether the U.S. Holder has made a timely and effective election to treat BCAR as a
QEF, for BCAR&#8217;s first taxable year as a PFIC in which the U.S. Holder held (or was deemed to hold) Public Shares, or if the U.S.
Holder made an effective QEF election along with a &#8220;purging election,&#8221; as discussed below. A U.S. Holder&#8217;s ability to
make an effective QEF election with respect &#8220;BCAR is contingent upon, among other things, the provision by BCAR of certain information
that would enable the U.S. Holder to make and maintain a QEF election. BCAR will endeavor to provide to a U.S. Holder upon request such
information as the IRS may require, including a PFIC annual information statement, in order to enable the U.S. Holder to make and maintain
a QEF election. A U.S. Holder of a PFIC that made a timely and effective QEF election for BCAR&#8217;s first taxable year as a PFIC in
which the U.S. Holder held (or was deemed to hold) Public Shares, or that made a QEF election along with a purging election, as discussed
below, is hereinafter referred to as an &#8220;<b>Electing Shareholder</b>.&#8221; A U.S. Holder of a PFIC that did not make a timely
and effective QEF election for BCAR&#8217;s first taxable year as a PFIC in which the U.S. Holder held (or was deemed to hold) Public
Shares, or that did not make a QEF election along with a purging election, is hereinafter referred to as a &#8220;<b>Non-Electing Shareholder</b>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
indicated above, if a U.S. Holder of Public Shares has not made a timely and effective QEF election with respect to BCAR&#8217;s first
taxable year as a PFIC in which the U.S. Holder held (or was deemed to hold) Public Shares, such U.S. Holder generally may nonetheless
qualify as an Electing Shareholder by filing on a timely filed U.S. income tax return (including extensions) a QEF election and a purging
election to recognize under the rules of Section 1291 of the Code any gain that it would otherwise recognize if the U.S. Holder sold its
Public Shares for their fair market value on the &#8220;<b>qualification date</b>.&#8221; The qualification date is the first day of BCAR&#8217;s
tax year in which BCAR qualifies as a QEF with respect to such U.S. Holder. The purging election can only be made if such U.S. Holder
held Public Shares on the qualification date. The gain recognized by the purging election will be subject to the special tax and interest
charge rules treating the gain as an excess distribution, as described above. As a result of the purging election, the U.S. Holder will
increase the adjusted tax basis in its Public Shares by the amount of the gain recognized and will also have a new holding period in the
Public Shares for purposes of the PFIC rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">A U.S. Holder may not make
a QEF election with respect to its Public Warrants. As a result, if a U.S. Holder of Public Warrants sells or otherwise disposes of such
rights (including for this purpose exchanging the Public Warrants for PubCo Warrants in the Domestication Merger), any gain recognized
will be subject to the special tax and interest charge rules treating the gain as an excess distribution, as described above, if BCAR
were a PFIC at any time during the period the U.S. Holder held the Public Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 190; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->173<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --> <!-- Field: Split-Segment -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders that hold (or are deemed to hold) stock of a foreign corporation that qualifies as a PFIC may instead elect to annually mark such
stock to its market value if such stock is regularly traded on a national securities exchange that is registered with the SEC or certain
foreign exchanges or markets of which the IRS has approved (a &#8220;<b>mark-to-market election</b>&#8221;). Nasdaq currently is considered
to be an exchange that would allow a U.S. Holder to make a mark-to-market election. U.S. Holders are urged to consult their own tax advisors
regarding the availability and tax consequences of a mark-to-market election with respect to their Public Shares under their particular
circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Effect of PFIC Rules
on the Domestication Merger</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Even if the Domestication
Merger qualifies as a Reorganization, Section 1291(f) of the Code requires that, to the extent provided in regulations, a U.S. person
that disposes of stock of a PFIC (including rights to acquire stock of a PFIC) must recognize gain notwithstanding any other provision
of the Code. No final Treasury Regulations are in effect under Section 1291(f). Proposed Treasury Regulations under Section 1291(f), (the
&#8220;<b>Proposed Regulations</b>&#8221;) were promulgated in 1992, with a retroactive effective date once they become finalized. If
finalized in their present form, or if gain recognition under Section 1291(f) of the Code is effective even in the absence of final Treasury
Regulations, the Proposed Regulations would require taxable gain recognition by a Non-Electing Shareholder with respect to its exchange
of BCAR securities for PubCo securities in the Domestication Merger if BCAR were classified as a PFIC at any time during such U.S. Holder&#8217;s
holding period in BCAR securities. Any such gain would be treated as an &#8220;excess distribution&#8221; made in the year of the Domestication
Merger and subject to the special tax and interest charge rules discussed above under &#8220;&#8212; <i>Definition and General Taxation
of a PFIC</i>.&#8221; In addition, the Proposed Regulations include coordinating rules with Section 367(b) of the Code, whereby, if the
gain recognition rule of the Proposed Regulations applied to a disposition of PFIC stock that results from a transfer with respect to
which Section 367(b) requires the shareholder to recognize gain or include an amount in income as a distribution under Section 301 of
the Code, the gain realized on the transfer is taxable as an excess distribution under Section 1291 of the Code, and the excess, if any,
of the amount to be included in income under Section 367(b) over the gain realized under Section 1291 is taxable as provided under Section
367(b). See &#8220;&#8212; <i>U.S. Federal Income Tax Consequences of the Domestication Merger to U.S. Holders of BCAR Securities &#8212;
Effect of Section 367 of the Code to U.S. Holders of Public Shares.&#8221;</i> The Proposed Regulations should not apply to an Electing
Shareholder with respect to its Public Shares for which a timely QEF election, a QEF election along with a purging election, or mark-to-market
election is made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">An Electing Shareholder
may, however, be subject to the rules discussed below under the section entitled &#8220;&#8212; <i>U.S. Federal Income Tax Consequences
of the Domestication Merger to U.S. Holders of BCAR Securities &#8212; Effect of Section 367 of the Code to U.S. Holders of Public Shares.</i>&#8221;
In addition, as discussed above, since a QEF election cannot be made with respect to Public Warrants, the Proposed Regulations may apply
to cause gain recognition under the PFIC rules on the exchange of Public Warrants for PubCo Warrants pursuant to the Domestication Merger.
It is not possible to determine at this time whether, in what form, and with what effective date, final Treasury Regulations under Section
1291(f) of the Code will be adopted if at all, and, further, whether the IRS would take the position that Section 1291(f) of the Code
is effective in the absence of final Treasury Regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The rules dealing with PFICs
and with the QEF election and purging election (or a mark-to-market election) are very complex and are affected by various factors in
addition to those described above. Accordingly, a U.S. Holder of BCAR securities should consult its own tax advisor concerning the application
of the PFIC rules to such securities under such holder&#8217;s particular circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Certain U.S. Federal Income Tax Consequences
to U.S. Holders of Exercising Redemption Rights</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Prior to a redemption of
a U.S. Holder&#8217;s Public Shares, if a U.S. Holder so elects, such Public Shares will first be exchanged for shares of PubCo Common
Stock in the Domestication Merger. Accordingly, the following discussion is with regard to a U.S. Holder&#8217;s potential redemption
of PubCo Common Stock. In the event that a U.S. Holder elects to redeem its PubCo Common Stock received in the Domestication Merger for
cash, the treatment of the transaction for U.S. federal income tax purposes will depend on whether the redemption qualifies as sale or
exchange of the PubCo Common Stock under Section 302 of the Code or is treated as a distribution under Section 301 of the Code with respect
to the U.S. Holder. If the redemption qualifies as a sale or exchange of the PubCo Common Stock, the U.S. Holder will be treated as recognizing
capital gain or loss equal to the difference between the amount realized on the redemption and such U.S. Holder&#8217;s adjusted tax basis
in the PubCo Common Stock surrendered in such redemption transaction. Any such capital gain or loss generally will be long-term capital
gain or loss if the U.S. Holder&#8217;s holding period for the PubCo Common Stock redeemed exceeds one year. Long-term capital gains recognized
by non-corporate U.S. Holders will be eligible to be taxed at preferential rates. However, it is unclear whether the redemption rights
with respect to the PubCo Common Stock may prevent a U.S. Holder from satisfying the applicable holding period requirement. The deductibility
of capital losses is subject to limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 191; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->174<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If the redemption does not
qualify as a sale or exchange of PubCo Common Stock, the U.S. Holder will be treated as receiving a corporate distribution. Such distributions
generally will constitute dividends for U.S. federal income tax purposes to the extent paid from PubCo&#8217;s current or accumulated
earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of current and accumulated earnings
and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#8217;s adjusted
tax basis in the PubCo Common Stock. Any remaining excess will be treated as gain realized on the sale or other disposition of the PubCo
Common Stock. Dividends paid to a U.S. Holder that is a taxable corporation generally will qualify for the dividends received deduction
if the requisite holding period is satisfied. With certain exceptions (including, but not limited to, dividends treated as <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investment
income for purposes of investment interest deduction limitations) and provided certain holding period requirements are met, dividends
paid to a non-corporate U.S. Holder generally will constitute &#8220;qualified dividends&#8221; that will be subject to tax at the preferential
tax rate accorded to long-term capital gains. However, it is unclear whether the redemption rights with respect to the PubCo Common Stock
may prevent a U.S. Holder from satisfying the applicable holding period requirements with respect to the dividends received deduction
or the preferential tax rate on qualified dividend income, as the case may be.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
a redemption qualifies for sale or exchange treatment will generally depend on the total number of PubCo Common Stock treated as held
by the U.S. Holder (including any PubCo Common Stock constructively owned by the U.S. Holder as a result of owning PubCo Warrants) relative
to all of the PubCo Common Stock outstanding both before and after the redemption. The redemption of Public Shares generally will be treated
as a sale or exchange of the PubCo Common Stock (rather than as a corporate distribution) if the redemption (i) is &#8220;substantially
disproportionate&#8221; with respect to the U.S. Holder, (ii) results in a &#8220;complete termination&#8221; of the U.S. Holder&#8217;s
interest in PubCo or (iii) is &#8220;not essentially equivalent to a dividend&#8221; with respect to the U.S. Holder. These tests are
explained more fully below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining whether any of the foregoing tests are satisfied, a U.S. Holder takes into account not only PubCo Common Stock actually owned
by the U.S. Holder, but also PubCo Common Stock that are constructively owned by it. A U.S. Holder may constructively own, in addition
to stock owned directly, stock owned by certain related individuals and entities, including those in which the U.S. Holder has an interest
or that have an interest in such U.S. Holder, as well as any stock the U.S. Holder has a right to acquire by exercise of an option, which
would generally include PubCo Common Stock which could be acquired pursuant to the exercise of the PubCo Warrants. In order to meet the
substantially disproportionate test, the percentage of PubCo&#8217;s outstanding voting stock actually and constructively owned by the
U.S. Holder immediately following the redemption of the PubCo Common Stock must be less than 80% of the percentage of PubCo&#8217;s outstanding
voting stock actually and constructively owned by the U.S. Holder immediately before the redemption, (ii) the U.S. Holder&#8217;s percentage
ownership (including constructive ownership) of the outstanding PubCo Common Stock (both voting and nonvoting) immediately after the redemption
must be less than 80% of such percentage ownership (including constructive ownership) immediately before the redemption; and (iii) the
U.S. Holder must own (including through constructive ownership), immediately after the redemption, less than 50% of the total combined
voting power of all classes of stock of PubCo entitled to vote. There will be a complete termination of a U.S. Holder&#8217;s interest
if either (i) all of the shares of the PubCo Common Stock directly, indirectly, and constructively owned by the U.S. Holder are redeemed
or (ii) all of the shares of the PubCo Common Stock directly owned by the U.S. Holder are redeemed and the U.S. Holder is eligible to
waive, and effectively waives in accordance with specific rules, the attribution of stock owned by certain family members and the U.S.
Holder does not constructively own any other PubCo Common Stock. The redemption of the PubCo Common Stock will not be essentially equivalent
to a dividend if a U.S. Holder&#8217;s conversion results in a &#8220;meaningful reduction&#8221; of the U.S. Holder&#8217;s proportionate
interest in PubCo. Whether the redemption will result in a meaningful reduction in a U.S. Holder&#8217;s proportionate interest in PubCo
will depend on the particular facts and circumstances. However, the IRS has indicated in a published ruling that even a small reduction
in the proportionate interest of a small minority shareholder in a publicly held corporation who exercises no control over corporate affairs
may constitute such a &#8220;meaningful reduction.&#8221; A U.S. Holder should consult with its own tax advisors as to the tax consequences
of a redemption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
none of the foregoing tests is satisfied, then the redemption will be treated as a corporate distribution. After the application of those
rules regarding corporate distributions, any remaining tax basis of the U.S. Holder in the redeemed ordinary shares will be added to the
U.S. Holder&#8217;s adjusted tax basis in its remaining PubCo Common Stock, or, if it has none, to the U.S. Holder&#8217;s adjusted tax
basis in its PubCo Warrants or possibly in other PubCo Common Stock constructively owned by it. Shareholders who hold different blocks
of PubCo Common Stock (generally, shares of BCAR purchased or acquired on different dates or at different prices) should consult their
tax advisors to determine how the above rules apply to them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 192; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->175<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the Domestication Merger will occur prior to the redemption of U.S. Holders that exercise redemption rights with respect to Public Shares,
U.S. Holders exercising such redemption rights will be deemed to have exchanged their Public Shares for shares of PubCo Common Stock and
be subject to the potential tax consequences of Section 367(b) of the Code and the tax rules relating to PFICs as a result of the Domestication
Merger (as discussed further above).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
U.S. Holders are urged to consult their tax a</span>dvisors as to the tax consequences to them of a redemption of all or a portion of
their PubCo Common Stock pursuant to an exercise of redemption rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>U.S. Federal Incom<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e
Tax Consequences of the Acquisition Merger to U.S. Holders of Company Securities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
Exascale, BCAR, nor Merger Sub has requested or intends to request a ruling from the IRS as to the U.S. federal income tax consequences
of the Acquisition. Consequently, no assurance can be given that the IRS will not assert, or that a court would not sustain, a position
that the Acquisition Merger does not constitute a reorganization within the meaning of Section 368 of the Code (i.e., a Reorganization).
Accordingly, each U.S. Holder is urged to consult its tax advisor with respect to the particular tax consequence of the Acquisition Merger
to such holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the qualifications and limitations set forth herein, Exascale, BCAR and Merger Sub intend for the Acquisition Merger to qualify as
a Reorganization. Based upon customary assumptions, as well as certain representations made by, and covenants and undertakings of, Exascale
and BCAR, it is the opinion of tax counsel to Exascale that the Acquisition Merger should qualify as a Reorganization pursuant to Section
368(a) of the Code. However, the provisions of the Code that govern Reorganizations are complex. If any of the facts, assumptions, representations,
covenants or undertakings by Exascale or BCAR are incorrect, incomplete or inaccurate or are violated, the accuracy of the opinion may
be affected and the U.S. federal income tax consequences of the Acquisition Merger could differ from those described in this proxy statement/prospectus.
However, the completion of the Acquisition Merger is not conditioned upon the receipt of an opinion of Exascale&#8217;s legal or tax counsel
regarding the U.S. federal income tax consequences of the Acquisition Merger. U.S. Holders should be aware that Exascale has not requested
and, following the Acquisition, PubCo does not intend to request a ruling from the IRS with respect to the U.S. federal income tax treatment
of the Acquisition Merger. There can be no assurance that the IRS will not take a contrary position to views expressed herein or that
a court will not agree with a contrary position of the IRS. The remainder of this discussion assumes the Acquisition Merger qualifies
as a Reorganization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If so treated, U.S. Holders of Company securities
should generally not recognize any gain or loss as a result of the Acquisition Merger. Pursuant to the Acquisition Merger, U.S. Holders
of Company securities will receive PubCo Common Stock in exchange for their Company securities. Each U.S. Holder&#8217;s tax basis in
the PubCo Common Stock received in the Acquisition Merger will be the same as his, her or its tax basis in Company securities surrendered
in the Acquisition Merger in exchange therefor. The holding period of the PubCo Common Stock received in the Acquisition Merger by the
U.S. Holder will include the holding period of Company securities surrendered in the Acquisition Merger in exchange therefor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Acquisition Merger fails to qualify as
a Reorganization, a U.S. Holder of Company securities would recognize gain or loss in an amount equal to the difference between (i) the
fair market value of the PubCo securities received in exchange for such surrendered Company securities upon completion of the Acquisition
Merger and (ii) the holder&#8217;s basis in Company securities surrendered. Gain or loss on each block of Company securities (generally
shares acquired at the same cost in a single transaction) will be calculated separately. Gain or loss on surrendered Company securities
generally will be capital gain or loss, and will be long-term capital gain or loss if such Company securities have been held for more
than one year at the time of the Acquisition Merger. Long-term capital gain of non-corporate U.S. Holders (including individuals) generally
is taxed at preferential U.S. federal income tax rates. The deductibility of capital losses is subject to limitations. A U.S. Holder&#8217;s
tax basis in the PubCo securities received in the Acquisition Merger would be equal to the fair market value of the PubCo securities received,
and the U.S. Holder&#8217;s holding period in such PubCo securities would begin on the day following the Acquisition Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All U.S. Holders
are urged to consult their tax advisors as to the tax consequences to them of the Acquisition Merger under such holder&#8217;s particular
circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 193; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->176<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
Federal Income Tax Consequences of Ownership and Disposition of PubCo Common Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Taxation
of Distributions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, distributions of cash or other property to U.S. Holders of PubCo Common Stock (other than certain distributions of PubCo stock
or rights to acquire PubCo stock) generally will constitute dividends for U.S. federal income tax purposes to the extent paid from PubCo&#8217;s
current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of current
and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero)
the U.S. Holder&#8217;s adjusted tax basis in its PubCo Common Stock. Any remaining excess will be treated as gain realized on the sale
or other disposition of the PubCo Common Stock and will be treated as described below under the section entitled &#8220;<i>&#8212; Gain
or Loss on Sale, Exchange or Other Taxable Disposition of PubCo securities</i>&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
paid to a U.S. Holder that is treated as a taxable corporation for U.S. federal income tax purposes generally will qualify for the dividends
received deduction if the requisite holding period is satisfied. With certain exceptions (including, but not limited to, dividends treated
as investment income for purposes of investment interest deduction limitations), and provided certain holding period requirements are
met, dividends paid to a non-corporate U.S. Holder may constitute &#8220;qualified dividend income&#8221; that will be subject to tax
at preferential rates accorded to long-term capital gains.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gain
or Loss on Sale, Exchange or Other Taxable Disposition of PubCo Securities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
a sale or other taxable disposition of PubCo securities (which, in general, would include a redemption of PubCo Warrants that is treated
as a sale of such warrants as described below), a U.S. Holder generally will recognize capital gain or loss in an amount equal to the
difference between the amount realized and the U.S. Holder&#8217;s adjusted tax basis in the PubCo securities. Any such capital gain or
loss generally will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the PubCo securities so disposed of
exceeds one year. Long-term capital gains recognized by non-corporate U.S. Holders may be eligible to be taxed at preferent</span>ial
rates. The deductibility of capital losses is subject to limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Generally, the amount of
gain or loss recognized by a U.S. Holder is an amount equal to the difference between (i) the sum of the amount of cash and the fair market
value of any property received in such disposition and (ii) the U.S. Holder&#8217;s adjusted tax basis in its PubCo securities so disposed
of. See the section entitled &#8220;<i>Tax E<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ffects of the Domestication
Merger to U.S. Holders</span></i><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8221; above for discussion
of a U.S. Holder&#8217;s adjusted tax basis in its PubCo securities following the Domestication <i>Merger</i>. See the section entitled
&#8220;<i>&#8212; Exercise, Lapse or Redemption of PubCo Warrants</i>&#8221; below for a discussion regarding a U.S. Holder&#8217;s tax
basis in PubCo Common Stock acquired pursuant to the exercise of a PubCo Warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercise,
Lapse or Redemption of PubCo Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
U.S. Holder generally will not recognize taxable gain or loss on the acquisition of PubCo Common Stock upon exercise of PubCo Warrants
for cash. The U.S. Holder&#8217;s tax basis in the PubCo Common Stock received upon exercise of the PubCo Warrants generally will be an
amount equal to the sum of the U.S. Holder&#8217;s tax basis in the PubCo Warrants and the exercise price. It is unclear whether the U.S.
Holder&#8217;s holding period for the PubCo Common Stock received upon exercise of the PubCo Warrants will begin on the date following
the date of exercise or on the date of exercise of the PubCo Warrants; in either case, the holding period will not include the period
during which the U.S. Holder held the PubCo Warrants. If any PubCo Warrants are allowed to lapse unexercised, a U.S. Holder generally
will recognize a capital loss equal to such holder&#8217;s tax basis in the lapsed PubCo Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax consequences of a cashless exercise of PubCo Warrants are not clear under current tax law. A cashless exercise may not be taxable,
either because the exercise is not a realization event or because the exercise is treated as a recapitalization for U.S. federal income
tax purposes. In either situation, a U.S. Holder&#8217;s basis in the PubCo Common Stock received would equal the U.S. Holder&#8217;s
basis in the PubCo Warrants exercised therefor. If the cashless exercise were treated as not being a realization event, it is unclear
whether a U.S. Holder&#8217;s holding period in the PubCo Common Stock would be treated as commencing on the date following the date of
exercise or on the date of exercise of the PubCo Warrants; in either case, the holding period would not include the period during which
the U.S. Holder held the PubCo Warrants. If the cashless exercise were treated as a recapitalization, the holding period of the PubCo
Common Stock would include the holding period of the PubCo Warrants exercised therefor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 194; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->177<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is also possible that a cashless exercise could be treated in part as a taxable exchange in which gain or loss would be recognized. In
such event, a U.S. Holder could be deemed to have surrendered a number of PubCo Warrants equal to the number of shares of PubCo Common
Stock having a value equal to the exercise price for the total number of PubCo Warrants to be exercised. In such case, the U.S. Holder
would recognize capital gain or loss with respect to the PubCo Warrants deemed surrendered in an amount equal to the difference between
the fair market value of the PubCo Common Stock that would have been received in a regular exercise of the PubCo Warrants deemed surrendered
and the U.S. Holder&#8217;s tax basis in the PubCo Warrants deemed surrendered. In this case, a U.S. Holder&#8217;s aggregate tax basis
in the PubCo Common Stock received would equal the sum of the U.S. Holder&#8217;s tax basis in the PubCo Warrants deemed exercised and
the aggregate exercise price of such PubCo Warrants. It is unclear whether a U.S. Holder&#8217;s holding period for the PubCo Common Stock
would commence on the date following the date of exercise or on the date of exercise of the PubCo Warrants; in either case, the holding
period would not include the period during which the U.S. Holder held the PubCo Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the absence of authority on the U.S. federal income tax treatment of a cashless exercise, including when a U.S. Holder&#8217;s holding
period would commence with respect to the PubCo Common Stock received, there can be no assurance regarding which, if any, of the alternative
tax consequences and holding periods described above would be adopted by the IRS or a court of law. Accordingly, U.S. Holders should consult
their tax advisors regarding the tax consequences of a cashless exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
PubCo redeems PubC</span>o Warrants for cash or if it purchases PubCo Warrants in an open market transaction, such redemption or purchase
generally will be treated as a taxable disposition to the U.S. Holder, taxed as described above under the section entitled &#8220;<i>&#8212;
Gain or Loss on Sale, Exchange or Other Taxable Disposition of PubCo securities</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Possible
Constructive Distributions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The terms of each PubCo
Warrant provide for an adjustment to the number of shares of PubCo Common Stock for which the PubCo Warrant may be exercised or to the
exercise price of the PubCo Warrant in certain events. An adjustment which has the effect of preventing dilution generally is not taxable.
A U.S. Holder of the PubCo Warrants could, however, be treated as receiving a constructive distribution from PubCo if, for example, the
adjustment increases the U.S. Holder&#8217;s proportionate interest in PubCo&#8217;s assets or earnings and profits (for example, through
an increase in the number of shares of PubCo Common Stock that would be obtained upon exercise or through a decrease in the exercise price
of the PubCo Warrant), which adjustment may be made as a result of a distribution of cash or other property, such as other securities,
to the holders of PubCo securities, or as a result of the issuance of a stock dividend to holders of PubCo Common Stock, in each case,
which is taxable to the holders of such shares as a distribution. Such constructive distribution would be subject to tax as described
above under the section entitled &#8220;<i>&#8212; Taxation of Distributions</i>&#8221; in the same manner as if the U.S. Holders of the
PubCo Warrants received a cash distribution from PubCo equal to the fair market value of such increased interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Information Reporting
and Backup Withholding</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Payments of distributions
on and the proceeds from a sale or other disposition of PubCo securities will be subject to information reporting to the IRS and U.S.
backup withholding on such payments may be possible. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct
taxpayer identification number on an IRS Form W-9 and makes other required certifications, or who is otherwise exempt from backup withholding
and establishes such exempt status.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Backup withholding is not
an additional tax. Any amounts withheld as backup withholding may be credited against a U.S. Holder&#8217;s U.S. federal income tax liability,
if any, and the U.S. Holder generally may obtain a refund of any excess amounts withheld under the backup withholding rules by timely
filing the appropriate claim for refund with the IRS and furnishing any required information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 195; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->178<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Non-U.S. Holders</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As used herein, a &#8220;Non-U.S.
Holder&#8221; means a beneficial owner of a BCAR securities, Company securities or, after the Business Combination, PubCo securities,
other than a partnership (or any entity or arrangement classified as a partnership) for U.S. federal income tax purposes, who or that
is not a U.S. Holder and, for U.S. federal income tax purposes is:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a non-resident alien individual, other than certain former
        citizens and residents of the United States subject to U.S. tax as expatriates;</span></td></tr>
  </table>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a foreign corporation; or</span></td></tr>
  </table>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">an estate or trust.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>U.S. Federal Income
Tax Consequences of the Acquisition Merger to Non-U.S. Holders of Company Securities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If the Acquisition Merger
qualifies as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code, Non-U.S. Holders of Company securities should
generally not recognize any gain or loss as a result of the Acquisition Merger. Pursuant to the Acquisition Merger, Non-U.S. Holders of
Company securities will receive PubCo Common Stock in exchange for their shares of Company securities. Each Non-U.S. Holder&#8217;s tax
basis in the PubCo Common Stock received in the Acquisition Merger will be the same as his, her or its tax basis in Company securities
surrendered in the Acquisition Merger in exchange therefor. The holding period of the PubCo Common Stock received in the Acquisition Merger
by the Non-U.S. Holder will include the holding period of Company securities surrendered in the Acquisition Merger in exchange therefor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If the Acquisition Merger
fails to qualify as a &#8220;reorganization&#8221; under Section 368(a) of the Code, a Non-U.S. Holder of Company securities would be
subject to the rules described in the section entitled &#8220;&#8212;<i>Sale, Exchange or Other Taxable Disposition of PubCo securities&#8221;
</i>below for Non-U.S. Holders of PubCo securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Tax Consequenc<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">es
for Non-U.S. Holders of Owning and Disposing of PubCo Common Stock</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Taxation
of Distributions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, any distributions (including constructive distributions, but not including certain distributions of PubCo stock or rights to
acquire PubCo stock) made to a Non-U.S. Holder of shares of PubCo Common Stock, to the extent paid out of PubCo&#8217;s current or accumulated
earnings and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes
and, provided such dividends are not effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the
United States, PubCo will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such Non-U.S. Holder
is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility
for such reduced rate (usually on an IRS Form W-8BEN or W-8BEN-E). In the case of any constructive dividend, it is possible that this
tax would be withheld from any amount owed to a Non-U.S. Holder by the applicable withholding agent, including cash distributions on other
property or sale proceeds from warrants or other property subsequently paid or credited to such Non-U.S. Holder. Any distribution not
constituting a dividend will be treated first as reducing (but not below zero) the Non-U.S. Holder&#8217;s adjusted tax basis in its shares
of PubCo Common Stock and, to the extent such distribution exceeds the Non-U.S. Holder&#8217;s adjusted tax basis, as gain realized from
the sale or other disposition of the PubCo Common Stock, which will be treated as described under &#8220;<i>&#8212; Sale, Exchange or
Other Taxable Disposition of PubCo securities</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
withholding tax generally does not apply to dividends paid to a Non-U.S. Holder who provides a Form W-8ECI, certifying that the dividends
are effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States. Instead, the effectively
connected dividends will be subject to regular U.S. federal income tax as if the Non-U.S. Holder were a U.S. resident, subject to an applicable
income tax treaty providing otherwise. A corporate Non-U.S. Holder receiving effectively connected dividends may also be subject to an
additional &#8220;branch profits tax&#8221; imposed at a rate of 30% (or a lower applicable treaty rate).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sale,
Exchange or Other Taxable Disposition of PubCo securities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Non-U.S. Holder generally will not be subject to U.S. federal income or withholding tax in respect of gain recognized on a sale, taxable
exchange or other taxable disposition of its PubCo Common Stock or PubCo Warrants (including an expiration or redemption of the PubCo
Warrants as described under &#8220;<i>&#8212; Exercise, Lapse or Redemption of a PubCo Warrant</i>&#8221;, or a redemption of PubCo Common
Stock that is treated as a sale or exchange as described under &#8220;<i>&#8212; Effects to Non-U.S. Holders of Exercising Redemption
Rights</i>&#8221;), unless:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the gain is effectively
        connected with the conduct by the Non-U.S. Holder of a trade or business within the United States (and, under certain income tax treaties,
        is attributable to a United States permanent establishment or fixed base maintained by the Non-U.S. Holder);</span></td></tr>
  </table>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 196; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->179<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such Non-U.S. Holder
        is an individual who was present in the United States for 183 days or more in the taxable year of such disposition (as such days are calculated
        pursuant to Section 7701(b)(3) of the Code) and certain other requirements are met; or</span></td></tr>
  </table>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo is or has
        been a &#8220;United States real property holding corporation&#8221; for U.S. federal income tax purposes at any time during the shorter
        of the five-year period ending on the date of disposition or the Non-U.S. Holder&#8217;s holding period for the applicable PubCo security
        being disposed of, except, in the case where shares of PubCo Common Stock are &#8220;regularly traded&#8221; on an &#8220;established
        securities market&#8221; (as such terms are defined under applicable Treasury Regulations), (x) the Non-U.S. Holder is disposing of PubCo
        Common Stock and has owned, whether directly, indirectly, or based on the application of constructive ownership rules, five percent (5%)
        or less of PubCo Common Stock at all times within the shorter of the five-year period preceding such disposition of PubCo Common Stock
        or such Non-U.S. Holder&#8217;s holding period for such PubCo Common Stock or (y) the Non-U.S. Holder is disposing of PubCo Warrants and
        has owned, whether directly, indirectly, or based on the application of constructive ownership rules, five percent (5%) or less of the
        total fair market value of PubCo Warrants (provided the PubCo Warrants are considered to be &#8220;regularly traded&#8221;) at all times
        within the shorter of the five-year period preceding such disposition of PubCo Warrants or such Non-U.S. Holder&#8217;s holding period
        for such PubCo Warrants. There can be no assurance that PubCo Common Stock or PubCo Warrants are or will be treated as regularly traded
        on an established securities market for this purpose. It is unclear how the rules for determining the five percent (5%) threshold for
        this purpose would be applied with respect to PubCo Common Stock or PubCo Warrants, including how a Non-U.S. Holder&#8217;s ownership
        of PubCo Warrants impacts the five percent (5%) threshold determination with respect to PubCo Common Stock and whether the five percent
        (5%) threshold determination with respect to PubCo Warrants must be made with or without reference to the Private Placement Warrants.
        In addition, special rules may apply in the case of a disposition of PubCo Warrants if PubCo Common Stock is considered to be &#8220;regularly
        traded&#8221;, but PubCo Warrants are not considered to be &#8220;regularly traded&#8221;. Non-U.S. Holders should consult their own tax
        advisors regarding the application of the foregoing rules in light of their particular facts and circumstances.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
an applicable treaty provides otherwise, gain described in the first bullet point above will be subject to tax at generally applicable
U.S. federal income tax rates as if the Non-U.S. Holder were a U.S. resident. Any gains described in the first bullet point above of a
corporate Non-U.S. Holder may also be subject to an additional &#8220;branch profits tax&#8221; at a thirty percent (30%) rate (or a lower
applicable income tax treaty rate).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the second bullet point applies to a Non-U.S. Holder, such Non-U.S. Holder will be subject to U.S. tax on such Non-U.S. Holder&#8217;s
net capital gain for such year at a tax rate of thirty percent (30%).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If the third bullet point
above applies to a Non-U.S. Holder, gain recognized by such holder will be subject to tax at generally applicable U.S. federal income
tax rates. In addition, PubCo may be required to withhold U.S. federal income tax at a rate of fifteen percent (15%) of the amount realized
upon such disposition or redempt<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ion. Based on the nature of
the business and activities of Exascale, it generally is not expected that PubCo would be a United States real property holding corporation
after the Domestication Merger or immediately after the Business Combination is completed. However, neither Exascale nor BCAR has undertaken
a formal analysis of PubCo&#8217;s possible status as a United States real property holding corporation. In addition, such determination
is factual in nature and subject to change. Accordingly, no assurance can be provided as to whether PubCo would be treated as a United
States real property holding corporation in any taxable year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-U.S.
Holders should consult their tax advisors regarding the U.S. federal income tax consequences to them in respect of any loss recognized
on a sale, taxable exchange or other taxable disposition of its PubCo securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercise,
Lapse or Redemption of PubCo Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Non-U.S. Holder generally will not recognize taxable gain or loss on the acquisition of PubCo Common Stock upon exercise of PubCo Warrants
for cash. The Non-U.S. Holder&#8217;s tax basis in the share of PubCo Common Stock received upon exercise of PubCo Warrants generally
will be an amount equal to the sum of the Non-U.S. Holder&#8217;s tax basis in such PubCo Warrants and the exercise price. It is unclear
whether the Non-U.S. Holder&#8217;s holding period for the PubCo Common Stock received upon exercise of the PubCo Warrants will begin
on the date following the date of exercise or on the date of exercise of the PubCo Warrants; in either case, the holding period will not
include the period during which the Non-U.S. Holder held the PubCo Warrants. If any PubCo Warrants are allowed to lapse unexercised, a
Non-U.S. Holder generally will recognize a capital loss equal to such holder&#8217;s tax basis in such lapsed PubCo Warrants and generally
will be taxed as described above under &#8220;&#8212; <i>Sale, Exchange or Other Taxable Disposition of PubCo securities</i>&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 197; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->180<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo
Warrants may be exercised on a cashless basis in certain circumstances. The U.S. federal income tax characterization of a cashless exercise
of PubCo Warrants is not clear under current tax law. A cashless exercise may not be a taxable exchange, either because the exercise is
not a realization event or because the exercise is treated as a recapitalization for U.S. federal income tax purposes. In either situation,
a Non-U.S. Holder&#8217;s tax basis in the PubCo Common Stock received would equal the Non-U.S. Holder&#8217;s tax basis in the PubCo
Warrants exercised therefor. If the cashless exercise were treated as not being a realization event, it is unclear whether a Non-U.S.
Holder&#8217;s holding period in the PubCo Common Stock would be treated as commencing on the date following the date of exercise or on
the date of exercise of the PubCo Warrants; in either case, the holding period would not include the Non-U.S. Holder&#8217;s holding period
for the PubCo Warrants exercised therefor. If the cashless exercise were treated as a recapitalization, the holding period of the PubCo
Common Stock would include the holding period of the PubCo Warrants exercised therefor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is also possible that a cashless exercise could be treated in part as a taxable exchange in which gain or loss would be recognized. In
such event, a Non-U.S. Holder could be deemed to have surrendered a number of PubCo Warrants equal to the number of shares of PubCo Common
Stock having a value equal to the exercise price for the total number of PubCo Warrants to be exercised. In such case, the Non-U.S. Holder
would recognize capital gain or loss with respect to the PubCo Warrants deemed surrendered in an amount equal to the difference between
the fair market value of the PubCo Common Stock that would have been rece</span>ived in a regular exercise of the PubCo Warrants deemed
surrendered and the Non-U.S. Holder&#8217;s tax basis in the PubCo Warrants deemed surrendered. Any gain or loss recognized by a Non-U.S.
Holder generally will be taxed as described above in &#8220;&#8212; <i>Sale, Exchange or Other Taxable Disposition of PubCo securities</i>&#8221;.
It is unclear whether a Non-U.S. Holder&#8217;s holding period for the PubCo Common Stock would commence on the date following the date
of exercise or on the date of exercise of the PubCo Warrants; in either case, the holding period would not include the Non-U.S. Holder&#8217;s
holding period for the PubCo Warrants exercised therefor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Due to the absence of authority
on the U.S. federal income tax treatment of a cashless exercise, including when a Non-U.S. Holder&#8217;s holding period would commence
with respect to the PubCo Common Stock received, there can be no assurance regarding which, if any, of the alternative tax consequences
and holding periods described <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">above would be adopted by the
IRS or a court of law. Accordingly, Non-U.S. Holders should consult their tax advisors regarding the tax consequences of a cashless exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
PubCo redeems PubCo Warrants for cash or if PubCo purchases PubCo Warrants in an open market transaction, such redemption or purchase
generally will be treated as a taxable disposition to the Non-U.S. Holder, taxed as described above under &#8220;&#8212; <i>Sale, Exchange
or Other Taxable Disposition of PubCo securities</i>&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-U.S.
Holders should consult their tax advisors regarding the tax consequences of the exercise, lapse, or redemption of PubCo Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Possible
Constructive Distributions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of each PubCo Warrant provide for an adjustment to the number of shares of PubCo Common Stock for which the PubCo Warrant may be
exercised or to the exercise price of the PubCo Warrant in certain events. An adjustment which has the effect of preventing dilution generally
is not a taxable event. A Non-U.S. Holder of the PubCo Warrants could, however, be treated as receiving a constructive distribution from
PubCo if, for example, the adjustment increases the Non-U.S. Holder&#8217;s proportionate interest in PubCo&#8217;s assets or earnings
and profits (for example, through an increase in the number of shares of PubCo Common Stock that would be obtained upon exercise or through
a decrease in the exercise price of the PubCo Warrant), which adjustment may be made as a result of a distribution of cash or other property,
such as other securities, to the holders of shares of PubCo stock, or as a result of the issuance of a stock dividend to holders of shares
of PubCo stock, in each case, which is taxable to the holders of such stock as a distribution. Any constructive distribution received
by a Non-U.S. Holder would be subject to U.S. federal income tax (including any applicable withholding) in the same manner as if such
Non-U.S. Holder received a corporate distribution from PubCo equal to the fair market value of such increased interest without any corresponding
receipt of cash, the U.S. federal income tax consequences of which are described above under &#8220;<i>&#8212; Tax Consequences of Ownership
and Disposition of PubCo securities &#8212; Taxation of Distributions</i>&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 198; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->181<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Information
Reporting and Backup Withholding</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
returns will be filed with the IRS in connection with payments of distributions and the proceeds from a sale or other disposition of PubCo
Securities. A Non-U.S. Holder may have to comply with certification procedures to establish that it is not a U.S. person in order to avoid
information reporting and backup withholding requirement</span>s. The certification procedures required to claim a reduced rate of withholding
under a treaty generally will satisfy the certification requirements necessary to avoid the backup withholding as well.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup
withholding is not an additional tax. The amount of any backup withholding from a payment to a Non-U.S. Holder generally will be allowed
as a credit against such Non-U.S. Holder&#8217;s U.S. federal income tax liability, if any, and may entitle such Non-U.S. Holder to a
refund, provided that the required information is timely furnished to the IRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Account Tax Compliance Act</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Provisions commonly referred
to as &#8220;FATCA&#8221; impose withholding of thirty percent (30%) on payments of dividends (including constructive dividends) on PubCo
securities to &#8220;foreign financial institutions&#8221; (which is broadly defined for this purpose and in general includes investment
vehicles) and certain other non-U.S. entities unless various U.S. information reporting and due diligence requirements (generally relating
to ownership by U.S. persons of interests in or accounts with those entities) have been satisfied by, or an exemption applies to, the
payee (typically certified as to by the delivery of a properly completed IRS Form W-8BEN-E). Foreign financial institutions located in
jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. Under
certain circumstances, a Non-U.S. Holder might be eligible for refunds or credits of such withholding taxes, and a Non-U.S. Holder might
be required to file a U.S. federal income tax return to claim such refunds or credits. Thirty percent (30%) withholding under FATCA was
scheduled to apply to payments of gross proceeds from the sale or other disposition of property that produces U.S.-source interest or
dividends beginning on January 1, 2019, but on December 13, 2018, the IRS released proposed regulations that, if finalized in their proposed
form, would eliminate the obligation to withhold on gross proceeds. Such proposed regulations also delayed withholding on certain other
payments received from other foreign financial institutions that are allocable, as provided for under final Treasury Regulations, to payments
of U.S.-source dividends, and other fixed or determinable annual or periodic income. Although these proposed</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Although these proposed
Treasury Regulations are not final, taxpayers generally may rely on them until final Treasury Regulations are issued. However, there can
be no assurance that final Treasury Regulations will provide the same exceptions from FATCA withholding as the proposed Treasury Regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Non-U.S. Holders should
consult their tax advisors regarding the effects of FATCA on their ownership and disposition of PubCo securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 199; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->182<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_024"></span>UNAUDITED
PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Introduction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited
pro forma condensed combined financial information presents the combination of the historical financial statements of BCAR and Exascale,
adjusted to give effect to the Business Combination and certain transactions contemplated in connection with the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR is a
blank check company incorporated in the British Virgin Islands on March&#160;20, 2025. BCAR was formed for the purpose of effecting a
merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more
businesses. BCAR has neither engaged in any operations nor generated any revenue to date. Additional information about BCAR is set forth
in the section titled &#8220;<i>Information about BCAR</i>&#8221; in this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale Labs
Inc. is a next-generation AI infrastructure provider operating an asset-light, software-defined GPU compute platform and related AI infrastructure
solutions. Exascale&#8217;s core business includes GPU as a Service (&#8220;<b>GaaS</b>&#8221;), through which it provides reserved and
on-demand access to high-performance GPU compute capacity sourced from third-party data centers globally, as well as GPU cluster management
and optimization services for AIDC operators. In addition, Exascale has developed certain modular data center, high-density liquid cooling,
HVDC power and energy storage solutions that are designed to address deployment bottlenecks in AI infrastructure and that Exascale believes
are ready for commercial engagement, although these capabilities have not yet generated revenue as of the date of this proxy statement/prospectus.
The platform is purpose-built for large-scale AI workloads, including LLM training, fine-tuning, and high-concurrency inference. Additional
information about Exascale is set forth in the section titled &#8220;<i>Information about Exascale</i>&#8221; in this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited
pro forma condensed combined balance sheet as of March 31, 2026 combines the historical balance sheet of BCAR as of March&#160;31, 2026
with the historical balance sheet of Exascale as of March 31, 2026 on a pro forma basis as if the Business Combination had been consummated
on March 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited
pro forma condensed combined statement of operations for the nine months ended March 31, 2026 combines the historical statement of operations
of BCAR for the nine months ended March 31, 2026 and the historical statement of operations of Exascale for the nine months ended March
31, 2026 on a pro forma basis as if the Business Combination had been consummated on July&#160;1, 2024. The unaudited pro forma condensed
combined statement of operations for the year ended June&#160;30, 2025 combines the historical statement of operations of BCAR for the
period from March 20, 2025 (inception) through June 30, 2025 and the historical statement of operations of Exascale for the year ended
June&#160;30, 2025 on a pro forma basis as if the Business Combination had been consummated on July&#160;1, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information was derived from and should be read in conjunction with the following historical
financial statements and the accompanying notes, which are included elsewhere in this proxy statement/prospectus:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the historical unaudited
        financial statements of BCAR as of and for the period from March 20, 2025 (inception) through June 30, 2025, the historical audited financial
        statements of BCAR as of and for the period from March 20, 2025 (inception) through December 31, 2025 and the historical unaudited financial
        statements of BCAR as of and for the three months ended March 31, 2026;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the historical audited financial statements
        of Exascale as of and for the year ended June 30, 2025 and the historical unaudited financial statements of Exascale as of and for the
        three and nine months ended March 31, 2026; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
        information relating to Exascale and BCAR included in this proxy statement/prospectus, including the description of the Business Combination
        Agreement and the transactions contemplated in connection therewith under the section titled &#8220;<i>The Business Combination Proposal.</i>&#8221;</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited
pro forma condensed combined financial information should also be read together with &#8220;<i>Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations of BCAR</i>&#8221; and &#8220;<i>Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations of Exascale</i>&#8221; included elsewhere in this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 200; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->183<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited
pro forma condensed combined financial statements have been presented for illustrative purposes only and do not necessarily reflect what
Exascale&#8217;s financial condition or results of operations would have been had the Business Combination been consummated on the dates
indicated. The unaudited pro forma condensed combined financial information also may not be useful in predicting the future financial
condition and results of operations of the post-combination company. The unaudited pro forma condensed combined financial statements include
certain assumptions, which may ultimately not come to fruition. The actual financial position and results of operations may differ significantly
from the pro forma amounts reflected herein due to a variety of factors. The unaudited pro forma adjustments and the assumptions included
in these unaudited pro forma condensed combined financial statements represent management&#8217;s estimates based on information available
as of the date of these unaudited pro forma condensed combined financial statements and are subject to change as additional information
becomes available and analyses are performed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
of the Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January
11, 2026, BCAR, Exascale, PubCo and Merger Sub entered into the Business Combination Agreement. Pursuant to the Business Combination Agreement,
the Business Combination will be effected in two steps: (i) BCAR will continue out of the British Virgin Islands and into the State of
Delaware so as to re-domicile as, and become, a Delaware corporation by merging with and into PubCo, with PubCo continuing as the surviving
publicly traded entity and changing its name to &#8220;Exascale Labs Holdings Inc.&#8221; (the &#8220;<b>Domestication Merger</b>&#8221;);
and (ii) after the Domestication Merger, Merger Sub will be merged with and into Exascale, resulting in Exascale being a wholly owned
subsidiary of PubCo (the &#8220;<b>Acquisition&#160;Merger</b>&#8221; and together with the Domestication Merger, the &#8220;<b>Business
Combination</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate
consideration for the&#160;Acquisition&#160;Merger is $500,000,000 (the &#8220;<b>Merger Consideration</b>&#8221;), payable in the form
of 50,000,000 newly issued shares of common stock of PubCo valued at $10.00 per share to Exascale and its securityholders. Holders of
Exascale Class A common stock and Exascale securities convertible or exchangeable for shares of Exascale Class A common stock (being the
Exascale Safeholders, the Base Camp Investor and Exascale Equity Incentive Recipients) will receive shares of PubCo Class A Ordinary Common
Stock in exchange for such interests in Exascale, with each such PubCo Class A Ordinary Common Stock having one (1) vote per share, and
holders of Exascale Class B common stock will receive shares of PubCo Class B Super Common Stock for their Exascale Class B common stock,
with each share of such PubCo Class B Super Common Stock having twenty (20) votes per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The allocation
of the 50,000,000 shares of PubCo Common Stock among Exascale Securityholders will be determined in accordance with (i) the conversion
provisions applicable in the event of &#8220;liquidity event&#8221; under the SAFEs, (ii) the terms of the Base Camp Investment Agreement,
and (iii) the allocation percentages applicable to the Exascale Equity Incentive Recipients and Exascale stockholders. As a result, the
allocation of the Merger Consideration among Exascale Securityholders is not determined using a single uniform exchange ratio applicable
to all Exascale securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the closing
of the Acquisition Merger, each issued and outstanding SAFE will be cancelled and converted into the right to receive a number of shares
of PubCo Class A Ordinary Common Stock based on the SAFE&#8217;s &#8220;implied ownership percentage,&#8221; as determined under the terms
of the applicable SAFE in connection with the Business Combination, which constitutes a &#8220;liquidity event&#8221; under the SAFEs.
In general, a SAFE&#8217;s implied ownership percentage is the product of (i) the quotient obtained by dividing (x) the SAFE&#8217;s purchase
amount by (y) the SAFE&#8217;s post-money valuation cap, multiplied by (ii) 100; subject to the capitalization adjustments, rounding provisions,
and other terms contained in the applicable SAFE and the final closing calculations. The resulting implied ownership percentage determines
the number of shares of the 50,000,000 Merger Consideration issuable for each SAFE. Based on the foregoing, the aggregate implied ownership
percentage of all SAFEs outstanding on the filing date of this proxy statement/prospectus was 17.533%, entitling all the SAFEs to collectively
receive an aggregate of 8,766,500 shares of PubCo Class A Ordinary Common Stock as their portion of the Merger Consideration in connection
with the consummation of the Business Combination. The right of an Exascale Safeholder to receive PubCo Class A Ordinary Common Stock
for their SAFE will be contingent on the execution by such Exascale Safeholder of an acknowledgement and such other agreements and other
documents as Exascale deems necessary, appropriate or expedient.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 201; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->184<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the closing
of the Acquisition Merger, the Base Camp Investment Agreement will be cancelled and converted into the right to receive a number of shares
of PubCo Class A Ordinary Common Stock based on the &#8220;implied ownership percentage&#8221; attributable to the Base Camp Investment
Agreement. The implied ownership percentage applicable to the Base Camp Investment Agreement is a fixed percentage determined in accordance
with the terms of the Base Camp Investment Agreement and will equal 0.625%, entitling the Base Camp Investor to receive an aggregate of
312,500 PubCo Class A Ordinary Common Stock as their portion of the Merger Consideration in connection with the consummation of the Business
Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the closing
of the Acquisition Merger, each then outstanding Exascale Equity Incentive award will be cancelled and converted into the right to receive
a number of shares of PubCo Class A Ordinary Common Stock based on the &#8220;implied ownership percentage&#8221; attributable to the
award. The implied ownership percentage of the Exascale Equity Incentive awards is determined based on Exascale&#8217;s fully diluted
capitalization, and, based on Exascale&#8217;s capitalization as of the filing date of this proxy statement prospectus, will be 0.154%,
entitling the Exascale Equity Incentive Recipients to receive an aggregate of 77,000 PubCo Class A Ordinary Common Stock as their portion
of the Merger Consideration in connection with the consummation of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the closing
of the Acquisition Merger, each issued and outstanding Exascale Class A common stock will be cancelled and converted into the right to
receive a number of shares of PubCo Class A Ordinary Common Stock based on the &#8220;implied ownership percentage&#8221; attributable
to Exascale&#8217;s Class A common stock. The implied ownership percentage of the Exascale Class A common stock is determined based on
Exascale&#8217;s fully diluted capitalization, and, based on Exascale&#8217;s capitalization as of the filing date of this proxy statement
prospectus, will be 20.200%, entitling the holders of Exascale Class A common stock to receive an aggregate of 10,100,000 PubCo Class
A Ordinary Common Stock as their portion of the Merger Consideration in connection with the consummation of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the closing
of the Acquisition Merger, each issued and outstanding Exascale Class B common stock will be cancelled and converted into the right to
receive a number of shares of PubCo Class B Super Common Stock based on the &#8220;implied ownership percentage&#8221; attributable to
Exascale&#8217;s Class B common stock. The implied ownership percentage of the Exascale Class B common stock is determined based on Exascale&#8217;s
fully diluted capitalization, and, based on Exascale&#8217;s capitalization as of the filing date of this proxy statement prospectus,
will be 61.488%, entitling the holders of Exascale Class B common stock to receive an aggregate of 30,744,000 PubCo Class B Ordinary Common
Stock as their portion of the Merger Consideration in connection with the consummation of the Business Combination.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Effective
Time, the holders of Exascale Common Stock, the Exascale Safeholders, the Base Camp Investor, and the Exascale Equity Incentive Recipients
will cease to have any rights with respect to Exascale securities, except the right to receive their portion of the Merger Consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The allocation
of the 50,000,000 shares of PubCo Class A Common Stock is set forth below (based on Exascale&#8217;s capitalization as of the filing date
of this proxy statement/prospectus):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 20%"><span style="font-size: 10pt"><b>Exascale
        securityholder group</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 31%; text-align: center"><span style="font-size: 10pt"><b>Calculation
        basis</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 12%; text-align: center"><span style="font-size: 10pt"><b>Ownership<br/>
        percentage</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 12%; text-align: center"><span style="font-size: 10pt"><b>PubCo
        shares&#160;to<br/> be received</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 21%; text-align: center"><span style="font-size: 10pt"><b>PubCo<br/>
        share class</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Exascale Safeholders</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Sum of each Safeholder&#8217;s purchase
        amount divided by the applicable post-money valuation cap, subject to capitalization, rounding and final closing allocation mechanics</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">17.533%</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8,766,500</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">PubCo Class A Ordinary Common Stock</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Base Camp Investment Agreement Investor</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">0.625% of Exascale&#8217;s total equity,
        calculated on a fully diluted basis</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">0.625%</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">312,500</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">PubCo Class A Ordinary Common Stock</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Exascale Equity Incentive Recipients</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Fixed allocation percentages based on Exascale&#8217;s
        fully-diluted capitalization</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">0.154%</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">77,000</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">PubCo Class A Ordinary Common Stock</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Exascale Class A common stockholders </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Fixed allocation percentages based on Exascale&#8217;s
        fully-diluted capitalization </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">20.200%</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10,100,000</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">PubCo Class A Ordinary Common Stock</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Exascale Class B common stockholders</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Fixed allocation percentages based on Exascale&#8217;s
        fully-diluted capitalization</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">61.488%</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">30,744,000</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">PubCo Class B Super Common Stock</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><b>Total</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>100.000%</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>50,000,000</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing
discussion and figures are provided to illustrate the allocation mechanics, and remain subject to final rounding and closing adjustments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 202; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->185<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to
the Business Combination Agreement, BCAR has agreed to cause PubCo to receive an amount of at least $5,000,000 in any combination of cash,
cash in the trust account, a PIPE, an equity line of credit, or third-party financing, net of any outstanding checks, wire transfers,
or similar items not yet cleared, and net of any cash distributions or transfers made in connection with or as a result of the Business
Combination (the &#8220;<b>Minimum Cash Financing</b>&#8221;). It is a condition precedent to Closing that PubCo obtain this Minimum Cash
Financing. If the Minimum Cash Financing is not met, and such condition is not waived by Exascale under the terms of the Business Combination
Agreement, the proposed Business Combination will not be consummated. In the event that the Business Combination is not consummated, all
Public Shares submitted for redemption will be returned to the holders thereof, and BCAR may instead search for an alternate business
combination or liquidate BCAR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the
filing date of this proxy statement/prospectus, neither BCAR nor Exascale has entered into any agreements or commitments with respect
to any financing or other alternative sources of funding to satisfy the Minimum Cash Financing condition. The management teams of BCAR
and Exascale are continuing to analyze the available financing options based on cost, amount available under any such facility and future
effects that any financing would have on the capitalization of PubCo. BCAR, the Sponsor, Exascale and their affiliates will have no prior
relationships with any of the potential financing sources that will be considered in connection with the Business Combination. Upon entry
into a financing arrangement for the Business Combination, including any Minimum Cash Financing, BCAR will disclose such arrangement (including
the potential dilution) in accordance with the rules of the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For more information
about the Business Combination, please see the section entitled &#8220;<i>Proposal 1 &#8212; The Business Combination Proposal</i>.&#8221;
A copy of the Business Combination Agreement is attached to this proxy statement/prospectus as Annex A.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expected
Accounting Treatment of the Business Combination</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
all three scenarios, the Business Combination will be accounted for as a reverse recapitalization in accordance with GAAP. Under this
method of accounting, while BCAR is the legal acquirer, it is expected to be treated as the acquired company for financial reporting purposes.
Accordingly, the financial statements of Exascale will represent a continuation of the financial statements of Exascale, with the Business
Combination treated as the equivalent of Exascale issuing stock for the net assets of BCAR, accompanied by a recapitalization. The net
assets of BCAR and Exascale will be stated at historical cost, with no goodwill or other intangible assets recorded. Transaction costs
will be recorded within equity in the unaudited pro forma condensed combined financial statements. Operations prior to the Business Combination
will be those of Exascale in future reports of the post-combination company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
has been determined to be the accounting acquirer based on the evaluation of the following facts and circumstances:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
        stockholders will have a significant majority of the voting power of the post-combination company;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
        post-combination company&#8217;s board of directors will consist of five members, all of whom will be designated by Exascale;</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s
        senior management will comprise the senior management of the post-combination company and will be responsible for the day-to-day operations
        of the post-combination company;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
        is the larger entity based on historical operating activity and employee base; and</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Exascale&#8217;s operations will comprise the ongoing operations of the
        post-combination company.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale has
been designated as the accounting acquirer and has a fiscal year end of June 30. Upon the Closing, the surviving public entity will continue
to have June 30 as its fiscal year end.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
of Pro Forma Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
historical financial information has been adjusted to give pro forma effect to events that are related and/or directly attributable to
the Business Combination, are factually supportable, and as it relates to the unaudited pro forma combined statement of operations, are
expected to have a continuing impact on the results of the post-combination company. The adjustments presented on the unaudited pro forma
combined financial statements have been identified and presented to provide relevant information necessary for an accurate understanding
of the post-combination company upon consummation of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 203; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->186<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma combined financial information is for illustrative purposes only. The financial results may have been different had
the companies always been combined. You should not rely on the unaudited pro forma combined financial information as being indicative
of the historical financial position and results that would have been achieved had the companies always been combined or the future financial
position and results that the post-combination company will experience. Exascale and BCAR have not had any historical relationship prior
to the Business Combination. Accordingly, no pro forma adjustments were required to eliminate activities between the companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited
pro forma combined financial information illustrates three alternative redemption levels. The &#8220;Maximum Redemption Scenario&#8221;
reflects an assumption that 28,000,000 BCAR ordinary shares (i.e., 100% of the Public Shares) are redeemed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scenario
        1 &#8212; <b>Assuming No Redemptions:</b> This presentation assumes that no additional BCAR shareholders exercise their redemption rights.
        Accordingly, all BCAR Ordinary Shares previously classified as subject to possible redemption, totaling 28,000,000, would be reclassified
        to permanent equity.</span></td></tr>
  </table>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scenario
        2 &#8212; <b>Assuming 50% of Maximum Redemptions:&#160;</b>This presentation assumes that BCAR shareholders exercise their redemption
        rights with respect to&#160;50% of the maximum number of BCAR Ordinary Shares that can be redeemed. Accordingly, 14,000,000 of BCAR ordinary
        shares are assumed to be redeemed.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scenario
        3 &#8212; <b>Assuming 100% of Maximum Redemptions: </b>This presentation assumes that BCAR shareholders exercise their redemption rights
        with respect to&#160;100% of the maximum number of BCAR ordinary shares. Accordingly, 28,000,000 of BCAR ordinary shares are assumed to
        be redeemed.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under three scenarios,
the Business Combination will be accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting,
while BCAR is the legal acquirer, it is expected to be treated as the &#8220;acquired&#8221; company for financial reporting purposes.
Accordingly, for accounting purposes, the financial statements of Exascale will represent a continuation of the financial statements of
Exascale with the Business Combination treated as the equivalent of Exascale issuing stock for the net assets of BCAR, accompanied by
a recapitalization. The net assets of BCAR and Exascale will be stated at historical cost, with no goodwill or other intangible assets
recorded. Transaction costs will be recorded within equity in the unaudited pro forma condensed combined financial statements. Operations
prior to the Business Combination will be those of Exascale in future reports of the post<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-combination
company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
has been determined to be the accounting acquirer based on evaluation of the following facts and circumstances:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
        stockholders will have a significant majority of the voting power of the post-combination company;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
        post-combination company&#8217;s board of directors will consist of five members, all of whom will be designated by Exascale;</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s
        senior management will comprise the senior management of the post-combination company and will be responsible for the day-to-day operations
        of the post-combination company;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
        is the larger entity based on historical operating activity and employee base; and</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s
        operations will comprise the ongoing operations of the post-combination company.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-Transaction
Reporting Consideration</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the Business Combination is consummated, Exascale&#8217;s historical financial statements will replace those of BCAR beginning with the
filing of the financial statements that first include the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 204; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->187<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED
PRO FORMA CONDENSED COMBINED BALANCE SHEET</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
of March&#160;31, 2026</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 0.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Exascale</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>BCAR</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Transaction
        Accounting<br/>Adjustments<br/>(Assuming No Redemption)</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Pro
        Forma<br/>Combined (Assuming No Redemption)</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Transaction
        Accounting<br/>Adjustments<br/>(Assuming 50% of Maximum Redemption)</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Pro
        Forma<br/>Combined (Assuming 50% of Maximum Redemption)</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Transaction
        Accounting<br/>Adjustments<br/>(Assuming 100% of Maximum Redemption)</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Pro
        Forma<br/>Combined (Assuming 100% of Maximum Redemption)</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
        </tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 0.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>$</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>$</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>$</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>$</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>$</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>$</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>$</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
        </tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">ASSETS</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Current
        assets:</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 21%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Cash
        and cash equivalents</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">984,830</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">243,576</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">287,319,687</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; width: 3%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>A</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">287,611,341</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">287,319,687</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; width: 3%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>A</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">143,951,497</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">287,319,687</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; width: 3%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>A</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">291,654</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(270,030</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B1</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(270,030</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B1</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(270,030</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B1</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(666,722</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B2</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(666,722</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B2</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(666,722</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B2</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>C</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(143,659,844</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>C</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(287,319,687</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>C</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">U.S.
        Dollar Coin</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,074,415</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,074,415</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,074,415</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,074,415</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accounts
        receivable, net</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,830,105</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,830,105</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,830,105</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,830,105</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Prepaid
        research and development expenses</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">625,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">625,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">625,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">625,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Advance
        to suppliers</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">106,801</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">106,801</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">106,801</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">106,801</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Refundable
        deposits receivable</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">510,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">510,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">510,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">510,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Prepayment
        and other receivable</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">156,259</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">156,259</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">156,259</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">156,259</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
        current assets</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,131,151</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">399,835</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">286,382,935</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">294,913,921</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">142,723,091</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">151,254,077</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(936,752</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,594,234</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Non-current
        assets:</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Cash
        and securities held in Trust Account</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">287,319,687</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(287,319,687</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>A</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(287,319,687</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>A</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(287,319,687</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>A</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equipment,
        net</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">14,406</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">14,406</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">14,406</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">14,406</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Deferred
        offering cost</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">95,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(95,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B1</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(95,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B1</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(95,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B1</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
        non-current assets</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">109,406</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">287,319,687</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(287,414,687</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">14,406</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(287,414,687</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">14,406</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(287,414,687</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">14,406</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">TOTAL
        ASSETS</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,240,557</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">287,719,522</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,031,752</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">294,928,327</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(144,691,596</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">151,268,483</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(288,351,439</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,608,640</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">LIABILITIES,
        TEMPORARY EQUITY AND SHAREHOLDERS&#8217; EQUITY(DEFICIT)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accounts
        payable</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">743,742</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">743,742</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">743,742</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">743,742</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Simple
        agreements for future equity</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">26,842,205</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(26,842,205</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>E</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(26,842,205</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>E</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(26,842,205</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>E</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Contract
        liabilities</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">109,657</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">109,657</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">109,657</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">109,657</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Refundable
        deposits payable</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,174,702</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,174,702</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,174,702</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,174,702</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accrued
        expense and other current liabilities</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">283,612</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">345,713</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">400,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B2</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">979,325</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">400,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B2</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">979,325</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">400,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B2</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">979,325</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(50,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>D</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(50,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>D</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(50,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>D</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
        current liabilities</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">29,153,918</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">345,713</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(26,492,205</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,007,426</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(26,492,205</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,007,426</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(26,492,205</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,007,426</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
        liabilities</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">29,153,918</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">345,713</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(26,492,205</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,007,426</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(26,492,205</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,007,426</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(26,492,205</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,007,426</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">COMMITMENTS
        AND CONTINGENCIES</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Temporary
        equity:</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Common
        stock subject to possible redemption</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">287,319,687</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(287,319,687</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>C</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(287,319,687</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>C</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(287,319,687</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>C</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stockholders&#8217;
        equity (deficit):</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Class
        A common shares</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">120</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,800</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>C</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">6,046</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,400</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>C</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,646</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>C</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,246</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">31</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>D</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">31</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>D</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">31</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>D</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">877</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>E</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">877</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>E</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">877</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>E</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,200</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>F</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,200</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>F</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,200</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>F</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,018</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>G</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,018</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>G</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,018</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>G</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>G</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>G</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>G</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Class
        B common shares</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">12</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,200</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,200</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>F</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,074</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,200</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>F</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,074</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,200</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>F</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,074</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,074</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>G</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,074</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>G</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,074</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>G</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(12</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>G</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(12</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>G</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(12</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>G</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Additional
        paid-in capital</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">220,636</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(233,600</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B1</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">314,112,515</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(233,600</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B1</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">170,454,071</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(233,600</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B1</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">26,795,628</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">287,316,887</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>C</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">143,658,443</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>C</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>C</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">49,969</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>D</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">49,969</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>D</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">49,969</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>D</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">26,841,328</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>E</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">26,841,328</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>E</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">26,841,328</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>E</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(82,705</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>G</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(82,705</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>G</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(82,705</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>G</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(Accumulated
        deficit) retained earning</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(21,134,012</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">52,802</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(131,430</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B1</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(22,200,734</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(131,430</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B1</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(22,200,734</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(131,430</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B1</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(22,200,734</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,066,722</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B2</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,066,722</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B2</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,066,722</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B2</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">78,628</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>G</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">78,628</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>G</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">78,628</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>G</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
        stockholders&#8217; equity (deficit)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(20,913,361</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">54,122</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">312,780,140</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">291,920,901</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">169,120,296</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">148,261,057</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">25,460,453</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,601,214</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">TOTAL
        LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,240,557</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">287,719,522</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,031,752</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">294,928,327</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(144,691,596</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">151,268,483</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(288,351,439</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,608,640</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the unaudited pro forma condensed combined financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 205; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->188<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unaudited
Pro Forma Condensed Combined Statement of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the nine months ended March&#160;31, 2026</b></span></p>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="9" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Scenario
        1</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="9" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Scenario
        2</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="9" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Scenario
        3</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>For
        the<br/> nine months ended </b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="9" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        <br/> No Redemption</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="9" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        50%<br/> of Maximum<br/> Redemption</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="9" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
        100%<br/> of Maximum<br/> Redemption</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">March&#160;31,</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Pro</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Pro</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Pro</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Pro</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Pro</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Pro</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2026</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Forma</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Forma</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Forma</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Forma</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Forma</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Forma</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Exascale</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">BCAR</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Adjustments</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Combined</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Adjustments</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Combined</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Adjustments</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Combined</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 21%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Revenue</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">10,561,331</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 3%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">10,561,331</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 3%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">10,561,331</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 3%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">10,561,331</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Cost
        of revenues</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(8,902,966</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(8,902,966</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(8,902,966</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(8,902,966</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Operating
        costs and expenses:</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Selling
        and marketing expenses</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(310,582</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(310,582</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(310,582</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(310,582</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">General
        and administrative expenses</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(928,255</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(928,255</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(928,255</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(928,255</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Research
        and development expenses</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,238,185</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,238,185</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,238,185</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,238,185</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Formation
        and operational costs</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(810,979</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">160,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>I</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(650,979</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">160,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>I</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(650,979</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">160,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>I</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(650,979</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
        operating expenses</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,477,022</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(810,979</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">160,000</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5,128,001</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">160,000</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5,128,001</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">160,000</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5,128,001</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Income
        (loss) from operations</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,818,657</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(810,979</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">160,000</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,469,636</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">160,000</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,469,636</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">160,000</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,469,636</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Other
        income (expense):</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Change
        in fair value of simple agreements for future equity</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5,098,320</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">5,098,320</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>K</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">5,098,320</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>K</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">5,098,320</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>K</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Unrealized
        loss on marketable securities held in Trust Account</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,319,687</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(7,319,687</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>J</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(7,319,687</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>J</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(7,319,687</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>J</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
        other income (expense)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5,098,320</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,319,687</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,221,367</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,221,367</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,221,367</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Loss
        before income tax expense</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(7,916,977</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">6,508,708</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,061,367</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,469,636</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,061,367</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,469,636</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,061,367</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,469,636</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Income
        tax expense</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
        (loss) income</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(7,916,977</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">6,508,708</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,061,367</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,469,636</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,061,367</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,469,636</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,061,367</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,469,636</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Basic
        and Diluted</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Loss
        per share</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(0.038</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(0.045</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(0.055</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  </table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 206; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->189<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unaudited
Pro Forma Condensed Combined Statement of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Year ended June&#160;30, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 0.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="9" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Scenario
        1</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="9" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Scenario
        2</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="9" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Scenario
        3</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
        </tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 0.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>For
        the <br/>year ended</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="9" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Assuming
        <br/>No Redemption</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="9" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Assuming
        50%<br/>of Maximum<br/>Redemption</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="9" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Assuming
        100%<br/>of Maximum<br/>Redemption</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
        </tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>June&#160;30,</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Pro</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Pro</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Pro</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Pro</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Pro</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Pro</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
        </tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 0.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>2025</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Forma</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Forma</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Forma</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Forma</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Forma</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Forma</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
        </tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 0.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Exascale</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>BCAR</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Adjustments</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Combined</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Adjustments</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Combined</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Adjustments</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Combined</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
        </tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 0.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>$</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>$</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>$</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>$</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>$</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>$</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>$</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>$</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
        </tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 21%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Revenue</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,015,512</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 3%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,015,512</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 3%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,015,512</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 3%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,015,512</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Cost
        of revenues</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5,910,315</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5,910,315</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5,910,315</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5,910,315</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Operating
        costs and expenses:</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Selling
        and marketing expenses</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(989,155</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(989,155</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(989,155</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(989,155</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">General
        and administrative expenses</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(362,982</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,066,722</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B2</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,429,704</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,066,722</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B2</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,429,704</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,066,722</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>B2</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,429,704</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Research
        and development expenses</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,797,906</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,797,906</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,797,906</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,797,906</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Formation
        and operational costs</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(41,420</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(41,420</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(41,420</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(41,420</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
        operating expenses</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,150,043</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(41,420</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,066,722</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5,258,185</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,066,722</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5,258,185</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,066,722</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5,258,185</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Loss
        from operations</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,044,846</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(41,420</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,066,722</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,152,988</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,066,722</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,152,988</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,066,722</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,152,988</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Other
        income (expense):</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Change
        in fair value of simple agreements for future equity</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,614,821</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,614,821</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>K</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,614,821</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>K</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,614,821</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>K</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
        other income (expense)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,614,821</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,614,821</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,614,821</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,614,821</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Loss
        before income tax expense</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>(7,659,667</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>)</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>(41,420</b></span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>)</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>3,548,099</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>(4,152,988</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>)</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>3,548,099</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>(4,152,988</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>)</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>3,548,099</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>(4,152,988</b></span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>)</b></span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Income
        tax expense</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
        (loss) income</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(7,659,667</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(41,420</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,548,099</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,152,988</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,548,099</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,152,988</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,548,099</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,152,988</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Basic
        and Diluted</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Loss
        per share</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(0.046</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(0.054</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(0.066</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the unaudited pro forma condensed combined financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 207; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->190<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1&#8212;Description of the Business Combination</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January
11, 2026, BCAR, Exascale, PubCo and Merger Sub entered into the Business Combination Agreement. Pursuant to the Business Combination Agreement,
the transactions contemplated thereby will be effected in two steps. First, BCAR will continue out of the British Virgin Islands and into
the State of Delaware so as to re-domicile as, and become, a Delaware corporation by merging with and into PubCo, with PubCo continuing
as the surviving, publicly traded entity (the &#8220;<b>Domestication Merger</b>&#8221;). Following the Domestication Merger, at the Closing,
among other things, Merger Sub, a wholly owned subsidiary of PubCo, will merge with and into Exascale, with Exascale being the surviving
corporation as a wholly owned subsidiary of PubCo (the &#8220;<b>Acquisition Merger</b>,&#8221; and together with the Domestication Merger,
the &#8220;<b>Business Combination</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2&#8212;Basis of the Pro Forma Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited
pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X. The unaudited pro
forma condensed combined balance sheet as of March 31, 2026 assumes that the Business Combination had been consummated on March 31, 2026.
The unaudited pro forma condensed combined statements of operations for the nine months ended March&#160;31, 2026 and the year ended June&#160;30,
2025 present the pro forma effect to the Business Combination as if it had been completed on July&#160;1, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information was derived from and should be read in conjunction with the following historical
financial statements and the accompanying notes, which are included elsewhere in this proxy statement/prospectus:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify">the historical unaudited financial statements of BCAR
        as of and for the period from March 20, 2025 (inception) through June 30, 2025, the historical audited financial statements of BCAR as
        of and for the period from March 20, 2025 (inception) through December 31, 2025 and the historical unaudited financial statements of BCAR
        as of and for the three months ended March&#160;31, 2026;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr>
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify">the historical audited financial statements of Exascale
        as of and for the year ended June 30, 2025 and the historical unaudited financial statements of Exascale as of and for the three and nine
        months ended March 31, 2026; and</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
        information relating to Exascale and BCAR included in this proxy statement/prospectus, including the description of the Business Combination
        Agreement and the transactions contemplated in connection therewith under the section titled &#8220;<i>The Business Combination Proposal.</i>&#8221;</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited
pro forma condensed combined financial information should also be read together with &#8220;<i>Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations of BCAR</i>&#8221; and &#8220;<i>Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations of Exascale</i>&#8221; included elsewhere in this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has made significant estimates and assumptions in its determination of the pro forma adjustments. As the unaudited pro forma condensed
combined financial information has been prepared based on these preliminary estimates, the final amounts recorded may differ materially
from the information presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 208; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->191<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information does not give effect to any anticipated synergies, operating efficiencies,
tax savings or cost savings that may be associated with the Business Combination. The pro forma adjustments reflecting the consummation
of the Business Combination are based on certain currently available information and certain assumptions and methodologies that management
believes are reasonable under the circumstances. The unaudited pro forma adjustments, which are described in the accompanying notes, may
be revised as additional information becomes available and is evaluated. Therefore, it is likely that the actual adjustments will differ
from the pro forma adjustments and it is possible the difference may be material. Management believes that its assumptions and methodologies
provide a reasonable basis for presenting all the significant effects of the Business Combination based on information available to management
at this time and that the pro forma adjustments give appropriate effect to those assumptions and are properly applied in the unaudited
pro forma condensed combined financial information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information does not include income tax effects as the parties to the Business Combination
are evaluating the post-Closing tax implications of Exascale. Accordingly, the unaudited pro forma condensed combined provision for income
taxes does not necessarily reflect the amounts that would have resulted had the parties to the Business Combination filed consolidated
income tax returns during the periods presented, nor does it reflect the amounts of pro forma deferred tax assets or liabilities as of
the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information is not necessarily indicative of what the actual results of operations and
financial position would have been had the Business Combination been consummated on the dates indicated, nor are they indicative of the
future consolidated results of operations or financial position of the post-combination company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3&#8212;Pro Forma Adjustments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information has been prepared to illustrate the effect of the Business Combination and
has been prepared for informational purposes only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X. Article
11 provides guidance to depict the accounting for the transaction (&#8220;<b>Transaction Accounting Adjustments</b>&#8221;) and present
the reasonably estimable synergies and other transaction effects that have occurred or are reasonably expected to occur (&#8220;<b>Management
Adjustments</b>&#8221;). Given such Management Adjustments, if any, would not enhance an understanding of the pro forma effects of the
Transaction, BCAR has elected not to present any Management Adjustments and will only be presenting Transaction Accounting Adjustments
in the following unaudited pro forma condensed combined financial information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCAR
and Exascale have not had any historical relationship prior to the Business Combination. Accordingly, no pro forma adjustments were required
to eliminate activities between the companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pro
Forma Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
adjustments included in the unaudited pro forma condensed combined balance sheet as of March&#160;31, 2026 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.5in; text-align: left; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
        the reclassification of cash and cash equivalents from the trust account that become available for use post-Closing.</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
        the settlement of total estimated professional fees incurred by Exascale not yet recognized in its historical financial statements. These
        costs are accounted for as equity issuance costs.</span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left; vertical-align: middle">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
        the settlements and accruals of total estimated professional fees incurred by BCAR not yet recognized in its historical financial statements.
        These costs are accounted for as expenses.</span></td> </tr>
  </table>

<p style="margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 209; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->192<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
        the reclassification of common stock subject to possible redemption to permanent equity.</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(D)</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
        pro forma adjustments to record (i) $50,000 of cash proceeds received under the investor provider arrangement as other current liabilities,
        and (ii) share-based compensation expense for services that were fully provided, the total equity conversion to 312,500 common shares,
        with the related liability reclassified to common shares and additional paid-in capital.</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(E)</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
        the conversion of Exascale SAFEs into an aggregate of 8,766,500 shares of Class A common stock.</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(F)</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
        the share exchanges for the recapitalization of BCAR.</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(G)</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
        the share exchanges for the recapitalization of Exascale including share-based compensation.</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Transaction
Accounting Adjustments to Unaudited Pro Forma Condensed Combined Statements of Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pro forma
adjustments included in the unaudited pro forma condensed combined statements of operations for the nine months ended March&#160;31, 2026
and for the year ended June&#160;30, 2025 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 0.5in">&#160;</td>
    <td style="vertical-align: top; width: 0.5in"><span style="font-size: 10pt">(B2)</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Reflects the settlement
        of total estimated professional fees incurred by BCAR not yet recognized in its historical financial statements. These costs are accounted
        for as expenses.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">(I)</span></td>
    <td style="text-align: justify; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reflects the
        elimination of monthly administration fee of $20,000 paid to the Sponsor after giving effect to the Business Combination as if it had
        occurred on July 1, 2024.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(BCAR entered
        into an administrative services agreement, commencing on August 1, 2025, through the earlier of BCAR&#8217;s consummation of an initial
        business combination or its liquidation, to pay to the Sponsor a total of $20,000 per month for office space, secretarial and administrative
        services provided to members of BCAR&#8217;s management team.)</p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 0.5in; font-size: 10pt; text-align: left">&#160;</td>
    <td style="vertical-align: top; width: 0.5in; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(J)
        </span></td>
    <td style="text-align: justify; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
        the elimination of interest income generated from the investments held in the trust account after giving effect to the Business Combination
        as if it had occurred on July 1, 2024.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.5in; text-align: justify; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(K)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
        the elimination of remeasurement gains and losses on SAFEs.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 210; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->193<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4&#8212;Loss per Share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Business Combination is being reflected as if it had been consummated on July&#160;1, 2024, the calculation of weighted average shares
outstanding for pro forma basic and diluted net loss per share assumes the following events occurred as of July&#160;1, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-size: 8pt; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Scenario
        1</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Scenario
        2</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Scenario
        3</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Combined<br/>
        Assuming No<br/> Redemption</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Combined<br/>
        Assuming 50%<br/> of Maximum<br/> Redemption</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Combined<br/>
        Assuming 100%<br/> of Maximum<br/> Redemption</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Year
        Ended<br/> June&#160;30,<br/> 2025</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Nine
        months Ended<br/> March&#160;31,<br/> 2026</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Year
        Ended<br/> June&#160;30,<br/> 2025</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Nine
        months Ended<br/> March&#160;31,<br/> 2026</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Year
        Ended<br/> June&#160;30,<br/> 2025</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Nine
        months Ended<br/> March&#160;31,</b></span></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>2026</b></span></p></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Pro
        forma net loss</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,152,988</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,469,636</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,152,988</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,469,636</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,152,988</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,469,636</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Weighted
        average shares outstanding &#8211; basic</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">91,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">91,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">77,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">77,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">63,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">63,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Weighted
        average shares outstanding &#8211; diluted</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">91,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">91,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">77,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">77,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">63,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">63,200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
        loss per share &#8211; basic</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(0.046</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(0.038</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(0.054</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(0.045</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(0.066</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(0.055</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
        loss per share &#8211; diluted</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(0.046</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(0.038</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(0.054</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(0.045</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(0.066</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(0.055</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Weighted
        average shares calculation, basic and diluted</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">BCAR
        Public Shares</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">28,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">28,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">14,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">14,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">BCAR
        private placement shares held by Sponsor</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">200,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">BCAR
        Founder Shares held by Sponsor</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">12,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">12,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">12,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">12,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">12,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">12,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Underwriter
        Representative shares</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Post-Combination
        Company ordinary shares issued in the Business Combination to Exascale Securityholders</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">50,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">50,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">50,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">50,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">50,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">50,000,000</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Weighted
        average shares outstanding, basic and diluted</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">91,200,000</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">91,200,000</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">77,200,000</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">77,200,000</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">63,200,000</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">63,200,000</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Scenario
        1</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Scenario
        2</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Scenario
        3</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Combined<br/>
        Assuming No<br/> Redemptions</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Combined<br/>
        Assuming 50%<br/> of Maximum<br/> Redemptions</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Combined<br/>
        Assuming 100%<br/> of Maximum<br/> Redemptions</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Year
        Ended<br/> June&#160;30,<br/> 2025</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Nine
        months Ended<br/> March&#160;31,<br/> 2026</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Year
        Ended<br/> June&#160;30,<br/> 2025</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Nine
        months Ended<br/> March&#160;31,<br/> 2026</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Year
        Ended<br/> June&#160;30,<br/> 2025</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Nine
        months Ended<br/> March&#160;31,<br/> 2026</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 40%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">BCAR
        public shares</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30.70</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30.70</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">18.13</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">18.13</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">BCAR
        shares private placement shares held by Sponsor</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">0.22</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">0.22</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">0.26</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">0.26</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">0.32</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">0.32</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">BCAR
        founder&#8217;s shares held by Sponsor</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13.16</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">13.16</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">15.54</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">15.54</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">18.98</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">18.98</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Underwriter
        Represent shares</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1.10</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1.10</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1.30</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1.30</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1.58</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1.58</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Post-Combination
        Company ordinary shares issued in the Business Combination to Exascale Securityholders</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">54.82</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">54.82</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">64.77</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">64.77</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">79.12</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">79.12</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">100</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 211; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->194<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_025"></span>INFORMATION ABOUT PUBCO
BEFORE THE BUSINESS COMBINATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">D. Boral ARC Merger Corporation (&#8220;PubCo&#8221;)
was incorporated in Delaware on December&#160;19, 2025 for the purpose of merging with D. Boral ARC Acquisition I Corp., a British Virgin
Islands business company (&#8220;BCAR&#8221;) prior to the transactions contemplated in the Business Combination Agreement, to facilitate
the consummation of a business combination. PubCo is a party to the Business Combination Agreement, as amended, and will become the ultimate
parent company following the transactions contemplated in the Business Combination Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 212; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->195<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>INFORMATION ABOUT BCAR</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR is a blank check company incorporated on March&#160;20,
2025 as a BVI business company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share
purchase, reorganization or similar business combination with one or more businesses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recent Developments &#8211; Business Combination
Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 11, 2026, BCAR entered into an Agreement
and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the &#8220;<b>Business Combination Agreement</b>&#8221;),
by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and a direct, wholly owned subsidiary of BCAR (&#8220;<b>PubCo</b>&#8221;),
D. Boral Arc Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary of BCAR (&#8220;<b>Merger Sub</b>&#8221;),
and Exascale Labs Inc., a Delaware corporation (&#8220;<b>Exascale</b>&#8221;). The Business Combination Agreement is attached to this
proxy statement/prospectus as part of <i>Annex A</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale is a next-generation AI infrastructure
provider operating an asset-light, software-defined GPU compute platform and related AI infrastructure solutions. Exascale&#8217;s core
business includes GaaS, through which it provides reserved and on-demand access to high-performance GPU compute capacity sourced from
third-party data centers globally, as well as GPU cluster management and optimization services for AIDC operators. In addition, Exascale
has developed certain modular data center, high-density liquid cooling, HVDC power and energy storage solutions that are designed to address
deployment bottlenecks in AI infrastructure and that Exascale believes are ready for commercial engagement, although these capabilities
have not yet generated revenue as of the date of this proxy statement/prospectus. The platform is purpose-built for large-scale AI workloads,
including LLM training, fine-tuning, and high-concurrency inference. Additional information about Exascale is set forth in the section
titled &#8220;<i>Information about Exascale</i>&#8221; in this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Business Combination Agreement provides that,
among other things and upon the terms and subject to the conditions thereof, the following transactions will occur (together with the
other agreements and transactions contemplated by the Business Combination Agreement, the &#8220;<b>Business Combination</b>&#8221;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Subject to the conditions of the Business Combination Agreement,
        BCAR shall continue out of the British Virgin Islands and into the State of Delaware so as to re-domicile as and become a Delaware corporation
        by means of a merger (the &#8220;<b>Domestication Merger</b>&#8221;) of BCAR with and into PubCo, with PubCo as the surviving company
        pursuant to the Business Companies Act, (Revised Edition 2020) as amended, of the British Virgin Islands and the applicable provisions
        of the Delaware General Corporation Law, as amended. Upon the Domestication Merger, PubCo shall change its name to &#8220;Exascale Labs
        Holdings Inc.&#8221;; and, thereafter</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">(2)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">(a) the Merger Sub shall be merged with and into Exascale,
        (b) the separate corporate existence of Merger Sub shall thereupon cease, and Exascale shall be the surviving corporation, and (c) the
        surviving corporation shall become a wholly-owned subsidiary of PubCo (the &#8220;<b>Acquisition Merger</b>&#8221;).</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Merger Consideration
is 50,000,000 shares of PubCo Common Stock to be issued at the closing of the Business Combination. Completion of the Business Combination
is subject to the satisfaction or waiver, where permissible, of various conditions to closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Corporate History</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Formation and IPO.
</i></b>On August 1, 2025, BCAR consummated its IPO of 25,000,000 BCAR Units at $10.00 per Unit, generating gross proceeds of $250,000,000.
On August 11, 2025, the underwriters of the IPO notified BCAR of their partial exercise of the over-allotment option and purchased 3,000,000
additional BCAR Units at $10.00 per unit upon the closing of the over-allotment option, generating gross proceeds of $30,000,000. The
over-allotment option closed on August 13, 2025. Each BCAR Unit consists of one BCAR Class A Ordinary Share, par value $0.0001 per share,
and one-half of one redeemable warrant, each whole warrant to purchase one BCAR Class A Ordinary Share (the &#8220;<b>Public Warrants</b>&#8221;).
Simultaneously with the closing of the IPO, BCAR consummated the sale of 200,000 Private Units at a price of $10.00 per Private Unit in
a private placement to the Sponsor generating proceeds of $2,000,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 213; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->196<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">A total of $280,000,000
of the proceeds from the IPO and the sale of the Private Units was placed in a U.S.-based trust account maintained by Odyssey Transfer
and Trust Company, acting as trustee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The BCAR Units commenced public trading on July
31, 2025 on the Nasdaq Global Market, and the BCAR Class A Ordinary Shares and Public Warrants commenced separate public trading on August
20, 2025. The BCAR Units, BCAR Class A Ordinary Shares and Public Warrants are currently traded on the Nasdaq Global Market under the
symbols &#8220;BCARU,&#8221; &#8220;BCAR&#8221; and &#8220;BCARW,&#8221; respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Redemption Rights</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to BCAR&#8217;s Current Charter, BCAR
shareholders (except the Insiders and the officers and directors of BCAR) will be entitled to redeem their Public Shares for a pro rata
share of the trust account (currently anticipated to be approximately $[_] per Class A Ordinary Share for shareholders) net of taxes payable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR&#8217;s Insiders do not have redemption rights
with respect to any BCAR Shares owned by them, directly or indirectly (nor will they seek appraisal rights with respect to such Class
A Ordinary Shares if appraisal rights would be available to them).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Automatic Dissolution and Subsequent Liquidation
of trust account if No Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we do not
consummate an initial business combination by February 1, 2027 (or May 1, 2027 if the sponsor exercises its three-month extension option),
it will trigger our automatic winding up, dissolution and liquidation pursuant to the terms of BCAR&#8217;s Current Charter. As a result,
this has the same effect as if we had formally gone through a voluntary liquidation procedure under the Business Companies Act. Accordingly,
no vote would be required from our shareholders to commence such a voluntary winding up, dissolution and liquidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to consummate our business combination
within such time period permitted under BCAR&#8217;s Current Charter, we will, as promptly as possible but not more than ten business
days thereafter, redeem 100% of our outstanding Public Shares for a pro rata portion of the funds held in the trust account, including
a pro rata portion of any interest earned on the funds held in the trust account and not necessary to pay our taxes, and then seek to
liquidate and dissolve. However, we may not be able to distribute such amounts as a result of claims of creditors which may take priority
over the claims of our Public Shareholders. In the event of our dissolution and liquidation, the public warrants will expire and will
be worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount in the trust account under the Business
Companies Act will be treated as share premium which is distributable under the Business Companies Act provided that immediately following
the date on which the proposed distribution is proposed to be made, we are able to pay our debts as they fall due in the ordinary course
of business. If we are forced to liquidate the trust account, we anticipate that we would distribute to our Public Shareholders the amount
in the trust account calculated as of the date that is two days prior to the distribution date (including any accrued interest). Prior
to such distribution, we would be required to assess all claims that may be potentially brought against us by our creditors for amounts
they are actually owed and make provision for such amounts, as creditors take priority over our Public Shareholders with respect to amounts
that are owed to them. We cannot assure you that we will properly assess all claims that may be potentially brought against us. As such,
our shareholders could potentially be liable for any claims of creditors to the extent of distributions received by them as an unlawful
payment in the event we enter an insolvent liquidation. Furthermore, while we will seek to have all vendors and service providers (which
would include any third parties we engaged to assist us in any way in connection with our search for a target business) and prospective
target businesses execute agreements with us waiving any right, title, interest or claim of any kind they may have in or to any monies
held in the trust account, there is no guarantee that they will execute such agreements. Nor is there any guarantee that, even if such
entities execute such agreements with us, they will not seek recourse against the trust account or that a court would conclude that such
agreements are legally enforceable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the letter agreement, dated July 30,
2025, entered into by and among BCAR and the Insiders, the Insiders agreed, for no additional consideration, to waive their rights to
participate in any liquidation of our trust account or other assets with respect to the Founder Shares and Private Units and to vote their
Founder Shares and Private Shares in favor of any dissolution and plan of distribution which we submit to a vote of shareholders. There
will be no distribution from the trust account with respect to our warrants or rights, which will expire worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 214; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->197<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to consummate a business combination
and expend all of the net proceeds of the IPO, other than the proceeds deposited in the trust account, and without taking into account
interest, if any, earned on the trust account, the per-share distribution from the trust account would be approximately $[_].</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proceeds deposited in the trust account could,
however, become subject to the claims of our creditors which would be prior to the claims of our Public Shareholders. Although we will
seek to have all vendors, including lenders for money borrowed, prospective target businesses or other entities we engage execute agreements
with us waiving any right, title, interest or claim of any kind in or to any monies held in the trust account for the benefit of our Public
Shareholders, there is no guarantee that they will execute such agreements or even if they execute such agreements that they would be
prevented from bringing claims against the trust account, including but not limited to, fraudulent inducement, breach of fiduciary responsibility
or other similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain an advantage with
a claim against our assets, including the funds held in the trust account. If any third party refused to execute an agreement waiving
such claims to the monies held in the trust account, we would perform an analysis of the alternatives available to us if we chose not
to engage such third party and evaluate if such engagement would be in the best interest of our shareholders if such third party refused
to waive such claims. Examples of possible instances where we may engage a third party that refused to execute a waiver include the engagement
of a third-party consultant whose particular expertise or skills are believed by management to be significantly superior to those of other
consultants that would agree to execute a waiver or in cases where management is unable to find a provider of required services willing
to provide the waiver. In any event, our management would perform an analysis of the alternatives available to it and would only enter
into an agreement with a third party that did not execute a waiver if management believed that such third party&#8217;s engagement would
be significantly more beneficial to us than any alternative. In addition, there is no guarantee that such entities will agree to waive
any claims they may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with us and will not
seek recourse against the trust account for any reason.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Out Sponsor has agreed that if we liquidate the
trust account prior to the consummation of a business combination, it will be liable to pay debts and obligations to target businesses
or vendors or other entities that are owed money by us for services rendered or contracted for or products sold to us in excess of the
net proceeds of the IPO not held in the trust account, but only to the extent necessary to ensure that such debts or obligations do not
reduce the amounts in the trust account and only if such parties have not executed a waiver agreement. However, we cannot assure you that
the Sponsor will be able to satisfy those obligations if it is required to do so. Accordingly, the actual per-share distribution could
be less than $10.00 due to claims of creditors. Additionally, if we are forced to file a bankruptcy case or an involuntary bankruptcy
case is filed against us which is not dismissed, the proceeds held in the trust account could be subject to applicable bankruptcy law
and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our shareholders.
To the extent any bankruptcy claims deplete the trust account, we cannot assure you we will be able to return to our Public Shareholders
at least $10.00 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Initial Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the IPO, BCAR has evaluated over 10 potential
target businesses including Exascale. When evaluating each prospective target business, BCAR conducted a thorough due diligence review
that encompassed, among other things, meetings with incumbent management and employees, document reviews and a review of financial and
other information that was made available to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Our Business Combination
Process</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">BCAR is not prohibited from
pursuing an initial business combination with a company that is affiliated with BCAR&#8217;s Sponsor, officers or directors although Exascale
is not affiliated. In the event BCAR does not complete the proposed Business Combination, and instead seek to complete an initial business
combination with a company that is affiliated with BCAR&#8217;s Sponsor, officers or directors, BCAR, or a committee of independent directors,
will obtain an opinion from an independent investment banking firm or another independent entity that commonly renders valuation opinions
that BCAR&#8217;s initial business combination is fair to the company from a financial point of view.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 215; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->198<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Certain of BCAR&#8217;s
officers and directors presently have fiduciary or contractual obligations to other entities pursuant to which such officer or director
is or will be required to present a business combination opportunity to such other entity. Accordingly, if any of BCAR&#8217;s officers
or directors becomes aware of a business combination opportunity that is suitable for an entity to which he or she has then-current fiduciary
or contractual obligations to present the opportunity to such entity, he or she will honor his or her fiduciary or contractual obligations
to present such opportunity to such entity. BCAR believes, however, that the fiduciary duties or contractual obligations of BCAR&#8217;s
officers or directors will not materially affect BCAR&#8217;s ability to complete an initial business combination. The Current Charter
provides that, to the fullest extent permitted by applicable law: (i) no individual serving as a director or an officer shall have any
duty, except and to the extent expressly assumed by contract, to refrain from engaging directly or indirectly in the same or similar business
activities or lines of business as BCAR; and (ii) BCAR renounces any interest or expectancy in, or in being offered an opportunity to
participate in, any potential transaction or matter which may be a corporate opportunity for any director or officer, on the one hand,
and BCAR, on the other. BCAR&#8217;s Sponsor, directors and officers are, or may become, affiliated with entities that are engaged in
a business similar to BCAR. BCAR&#8217;s Sponsor, directors and officers are not prohibited from sponsoring, investing in or otherwise
becoming involved with, any other blank check companies (including SPACs similar to BCAR), including in connection with their initial
business combinations, prior to BCAR completing an initial business combination. However, BCAR does not believe that any such potential
conflicts of interest would materially affect BCAR&#8217;s ability to complete the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Competition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If BCAR is unable to complete
the Business Combination with Exascale, BCAR expects to encounter competition in identifying, evaluating and selecting a target business
for BCAR&#8217;s alternate business combination, from other entities having a business objective similar to BCAR, including from SPACs,
private equity groups and leveraged buyout funds, public companies and operating businesses seeking strategic acquisitions. Many of these
entities are well established and have extensive experience identifying and effecting business combinations directly or through affiliates.
Moreover, many of these competitors possess greater financial, technical, human and other resources than BCAR. BCAR&#8217;s ability to
acquire larger target businesses will be limited by BCAR&#8217;s available financial resources. This inherent limitation gives others
an advantage in pursuing the acquisition of a target business. Furthermore, BCAR&#8217;s outstanding warrants, and the future dilution
they potentially represent, may not be viewed favorably by certain target businesses. Either of these factors may place BCAR at a competitive
disadvantage in successfully negotiating an alternate business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Employees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">BCAR currently has two executive
officers. These individuals are not obligated to devote any specific number of hours to BCAR&#8217;s matters, but they have devoted and
will continue to devote as much of their time as they deem necessary to BCAR&#8217;s affairs until BCAR has completed its initial business
combination. The amount of time they will devote in any time period will vary based on whether a target business has been selected for
BCAR&#8217;s initial business combination and the stage of the business combination process BCAR is in. BCAR does not intend to have any
full-time employees prior to the completion of its initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">BCAR is an &#8220;emerging
growth company,&#8221; as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012
(the &#8220;<b>JOBS Act</b>&#8221;). As such, BCAR is eligible to take advantage of certain exemptions from various reporting requirements
that are applicable to other public companies that are not &#8220;emerging growth companies&#8221; including, but not limited to, not
being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure
obligations regarding executive compensation in BCAR&#8217;s periodic reports and proxy statements, and exemptions from the requirements
of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously
approved. If some investors find BCAR&#8217;s securities less attractive as a result, there may be a less active trading market for BCAR&#8217;s
securities and the prices of BCAR&#8217;s securities may be more volatile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In addition, Section 107
of the JOBS Act also provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided
in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an &#8220;emerging
growth company&#8221; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.
BCAR intends to take advantage of the benefits of this extended transition period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 216; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->199<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">BCAR will remain an emerging
growth company until the earlier of: (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of the
IPO, (b) in which BCAR has total annual gross revenue of at least $1.235 billion, or (c) in which BCAR is deemed to be a large accelerated
filer, which means the market value of BCAR&#8217;s ordinary shares that is held by non-affiliates equals or exceeds $700 million as of
the end of that year&#8217;s second fiscal quarter; and (2) the date on which BCAR has issued more than $1.00 billion in non-convertible
debt during the prior three-year period. References herein to &#8220;emerging growth company&#8221; shall have the meaning associated
with it in the JOBS Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Additionally, BCAR is a
&#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage
of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. BCAR
will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of its ordinary shares held
by non-affiliates equaled or exceeded $250 million as of the end of that fiscal year&#8217;s second fiscal quarter, or (2) BCAR&#8217;s
annual revenues equaled or exceeded $100 million during such completed fiscal year and the market value of BCAR&#8217;s ordinary shares
held by non-affiliates equaled or exceeded $700 million as of the end of that fiscal year&#8217;s second fiscal quarter. To the extent
BCAR takes advantage of such reduced disclosure obligations, it may also make comparison of BCAR&#8217;s financial statements with other
public companies difficult or impossible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">BCAR&#8217;s executive offices
are located at 10 East 53rd Street, Suite 3001, New York, NY 10022 and its phone number is (332) 266-7344. BCAR&#8217;s website and the
information contained on, or that can be accessed through, the website is not deemed to be incorporated by reference in, and is not considered
part of, this Proxy Statement/Prospectus. You should not rely on any such information in making your decision whether to invest in BCAR&#8217;s
or PubCo&#8217;s Securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 217; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->200<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_026"></span>DIRECTORS, OFFICERS, EXECUTIVE
COMPENSATION AND<br/> CORPORATE GOVERNANCE OF BCAR PRIOR TO THE BUSINESS COMBINATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Directors, Executive Officers and Corporate Governance.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Officers and Directors</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Name</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Age</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Position</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 30%; text-align: left">David Boral</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">42</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 59%; text-align: left">Chairman of the Board and Chief Executive Officer</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">John Darwin</td>
    <td>&#160;</td>
    <td style="text-align: center">37</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Chief Financial Officer and Director</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Kevin Chen</td>
    <td>&#160;</td>
    <td style="text-align: center">47</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Director</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Luisa Ingargiola</td>
    <td>&#160;</td>
    <td style="text-align: center">58</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Director</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Matt Laker</td>
    <td>&#160;</td>
    <td style="text-align: center">49</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Director</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>David Boral</b> has served as our Chairman and
Chief Executive Officer since March&#160;2025. Mr. Boral has also served as the chief executive officer and a chairman of D. Boral Acquisition
I Corp., a special purpose acquisition company in the process of completing its initial business combination, since October 2025, and
as the chief executive officer and a chairman of D. Boral ARC Acquisition II Corp., a special purpose acquisition company in the process
of completing its initial public offering, from May 2025 until October 2025. Mr. Boral is also the chief executive officer and founder
of D. Boral Capital, a global investment bank which he established in May 2020. In his role as chief executive officer, Mr. Boral ensures
that the company&#8217;s vision and strategy are executed daily through the efforts of the D. Boral Capital team. Before founding D. Boral
Capital, Mr. Boral held several leadership roles in Investment Banking and Capital Markets. With approximately 20 years of experience,
Mr. Boral has led and participated in a wide range of transactions, including traditional IPOs, SPAC IPOs &amp; de-SPAC transactions,
follow on and secondary offerings, private placement/PIPEs, reverse mergers, bankruptcies and restructurings, dual and cross-listings,
and other private and public offerings both in the U.S. and internationally. Mr. Boral served as Co-President and a Director of EF Hutton
Acquisition Corporation I, a special purpose acquisition company from March 3, 2021 until it completed its initial business combination
on December 12, 2023. Mr. Boral received a BBA in Finance from the Lubin School of Business at Pace University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe Mr.&#160;Boral is qualified to serve on
our board of directors due to his extensive and varied deal experience throughout his career, including his prior special purpose acquisition
company experience.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>John Darwin</b> has served as our Chief Financial
Officer and a member of our board of directors since March&#160;2025. Mr. Darwin has also served as the chief financial officer and a
member of the board of directors of D. Boral Acquisition I Corp., a special purpose acquisition company in the process of completing its
initial business combination, since October 2025, and as the chief financial officer and a member of the board of directors of D. Boral
ARC Acquisition II Corp., a special purpose acquisition company in the process of completing its initial public offering, from May 2025
until October 2025. Mr. Darwin is also the chief investment officer of D. Boral Capital, since November 2025. From 2022 until October
2025, Mr. Darwin was a managing director at ARC Group Limited, a global investment bank and management consultancy firm. Mr. Darwin has
deep experience as a SPAC executive, board member, and private equity investor in emerging industries across a wide range of geographies.
Before joining ARC Group, Mr. Darwin was Managing Partner of Luminous Capital USA, Inc., a U.S. based private investment firm focused
on emerging industries and technologies since December 2020. While at Luminous USA, Inc., Mr. Darwin was Co-Chief Executive Officer of
Northern Lights Acquisition Corp. from June 2021 until its business combination in September 2022. Previously, from March 2018 to March
2021, Mr. Darwin was President of OCG, Inc., a U.S. based retail franchisor. Prior to OCG, Mr. Darwin held various roles in private equity
and corporate finance and has over a decade of transaction experience in public and private entities. Mr. Darwin received his BBA in Finance
from the Cox School of Business at Southern Methodist University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe Mr.&#160;Darwin is qualified to serve on
our board of directors due to his extensive and varied deal experience throughout his career, including his prior special purpose acquisition
company experience.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Kevin Chen</b> has served as a member of our board
of directors since July 2025. Mr.&#160;Chen has been serving as Chief Investment Officer and Chief Economist of Horizon Financial, a New
York based investment management company that offers cross-border investment solutions to global financial institutions and individuals,
since May&#160;2018, where he is responsible for advising clients in investing in healthcare facilities in the United States, among other
investment activities. Mr.&#160;Chen served as chairman of the board of directors and Chief Executive Officer of EDOC Acquisition Corp.
from September&#160;2020 to March&#160;2024. From November&#160;2021 to August&#160;2024, Mr.&#160;Chen was a board member of InFinT Acquisition
Corporation (NYSE: IFIN.U), a special purpose acquisition company that completed its initial public offering in November&#160;23, 2021.
Mr.&#160;Chen served as a board member of Horizon Global Access Fund (Cayman), a segregate portfolio of Flagship Healthcare Properties
Fund, a leading U.S. Healthcare REIT, from February&#160;2019 to October&#160;2024. He is a Member of the Economic Club of New York, a
Member of the Miami Economic Club, a Member of the Council for Foreign Relations, Fellow of the Foreign Policy Association. Mr.&#160;Chen
obtained his PhD in Finance from the Financial Asset Management Engineering Center at University of Lausanne, Switzerland in 2005.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 218; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->201<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Luisa Ingargiola</b> has served as a member of
our board of directors since July 2025. Since February 2017, Ms. Ingargiola has served as Chief Financial Officer of Avalon GloboCare
Corp. (NASDAQ: ALBT), a publicly listed bio-tech health care company. Prior to joining Avalon GloboCare Corp., Ms. Ingargiola served as
the Chief Financial Officer and Co-Founder of MagneGas Corporation, an alternative energy company, from 2007 to 2018. Ms. Ingargiola has
also served as a director and audit committee chair for various over-the-counter, Nasdaq and NYSE traded companies. Ms. Ingargiola has
served as a member of the board of directors and the audit committee chair of Core AI Holdings, Inc. (NASDAQ: CHAI) since October 2025,
on the board of directors of New America Acquisition I Corp. (NYSE: NWAX) since December 2025, on the board of directors of D. Boral Acquisition
I Corp. (NASDAQ: DBCAU), a special purpose acquisition company, and its audit committee since February 2026, as a member of the board
of directors and the audit committee chair of Vision Marine Technologies, Inc. (NASDAQ: VMAR) since December 2020, as a member of the
board of directors and the audit committee chair of Fusion Fuel Green PLC (Nasdaq: HTOO) since February 2025, and as a member of the board
of directors and audit committee chair of BioCorRx Inc. (OTC: BICX) since April 2018. Ms. Ingargiola has served on the board of directors
of Dragonfly Energy Holdings Corp. (NASDAQ: DFLI) since October 2022 and served on the board of directors of Dragonfly Energy Corp. from
August 2021 to October 2022. Ms. Ingargiola also served as a member of the board of directors and as the audit committee chair for Progress
Acquisition Corporation (NASDAQ: PGRWU) from November 2020 to February 2023, as a member of the board of directors and the audit committee
chair for AgEagle Aerial Systems Inc. (NYSE American: UAVS) from May 2018 to November 2022, as the audit committee chair of Siyata Mobile
(NASDAQ: SYTA) from December 2020 to December 2021, as a member of the board of directors for Xos, Inc. (NASDAQ: XOS) from March 2024
to June 2025, and as a member of the board of directors, the compensation committee chair and the audit committee chair for Electra Meccanica
Vehicles Corp. (Nasdaq: SOLO) from March 2018 to March 2024. Ms. Ingargiola holds a Master of Health Administration from the University
of South Florida and a B.S. in Finance from Boston University. Ms. Ingargiola is qualified to serve on our board of directors based on
her previous roles serving as chief financial officer for multiple companies and extensive experience serving on multiple boards of directors
for Nasdaq and NYSE traded companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Matt Laker</b> has served as a member of our board
of directors since July 2025. Mr.&#160;Laker has over 22 years of international strategic and operational experience in the financial
services industry, with extensive expertise within the automotive finance, payments and e-commerce, and insurance and retirement sectors.
Since April&#160;2024, Mr.&#160;Laker has served as Chief of Staff for Wolfe LLC, an e-commerce and online business services company.
From March&#160;2020 to January&#160;2024, Mr.&#160;Laker served as the Head of Enterprise Communications, Marketing &amp; Philanthropy
for Jackson National Life, a financial services company, after having served as the company&#8217;s Chief of Staff from September&#160;2012
through March&#160;2020. Mr.&#160;Laker began his career at Mercedes Benz Financial Services and has since held senior cross functional
leadership roles in consulting, credit, program management, mergers and acquisitions, communications, philanthropy and board level engagement
support. Mr.&#160;Laker holds an M.B.A. from Thunderbird School of Global Management and a B.A. in Marketing from Weber State University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Number and Terms of Office of Officers and Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors consists of five (5) members
and is divided into three classes with only one class of directors being appointed in each year, and with each class (except for those
directors appointed prior to our first annual general meeting) serving a three-year term. Prior to the closing of our initial business
combination, only holders of BCAR Class B Ordinary Shares will be entitled to vote on the appointment and removal of directors or continuing
the company in a jurisdiction outside the British Virgin Islands (including any ordinary resolution required to amend our constitutional
documents or to adopt new constitutional documents, in each case, as a result of our approving a transfer by way of continuation in a
jurisdiction outside the British Virgin Islands). Holders of our Public Shares will not be entitled to vote on such matters during such
time. These provisions of our amended and restated memorandum and articles of association relating to these rights of holders of BCAR
Class B Ordinary Share may be amended by an ordinary resolution passed by the affirmative vote of the holders representing at least 90%
of the issued BCAR Class B Ordinary Share. In accordance with Nasdaq corporate governance requirements, we are not required to hold an
annual general meeting until one year after our first fiscal year end following our listing on Nasdaq. The term of office of the first
class of directors, which consists of Kevin Chen and Matt Laker will expire at our first annual general meeting. The term of office of
the second class of directors, which consists of John Darwin and Luisa Ingargiola, will expire at the second annual general meeting. The
term of office of the third class of directors, which consists of David Boral, will expire at the third annual general meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our officers are appointed by the board of directors
and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized
to appoint officers as it deems appropriate pursuant to our amended and restated memorandum and articles of association.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 219; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->202<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nasdaq rules require that a majority of our board
of directors be independent within one year of our initial public offering. An &#8220;independent director&#8221; is defined generally
as a person who, in the opinion of the company&#8217;s board of directors, has no material relationship with the listed company (either
directly or as a partner, shareholder or officer of an organization that has a relationship with the company). We have three &#8220;independent
directors&#8221; as defined in Nasdaq rules and applicable SEC rules prior to completion of this offering. Our board of directors determined
that Luisa Ingargiola, Kevin Chen and Matt Laker are &#8220;independent directors&#8221; as defined in Nasdaq listing standards and applicable
SEC rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Executive Officer and Director Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus, none of our
officers has received any cash compensation for services rendered to us. Commencing on the date that our securities are first listed on
Nasdaq through the earlier of consummation of our initial business combination and our liquidation, we will pay an affiliate of our sponsor
$20,000 per month for office space, utilities and secretarial and administrative and support services provided to us and members of our
management team. As more fully discussed in the section of this prospectus entitled &#8220;<i>The Offering &#8212; Limited payments to
insiders</i>&#8221;, our Sponsor, officers and directors, or any affiliate of theirs, will be entitled to certain payments including,
but not limited to, reimbursement for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying
potential target businesses and performing due diligence on suitable business combinations. We may pay cash compensation to our independent
directors for services rendered to us. Additionally, we may pay consulting, success, advisory, or finder&#8217;s fees to our Sponsor,
our officers or directors, our advisors, or affiliates thereof in connection with the consummation of our initial business combination.
Our audit committee will review on a quarterly basis all payments that were made to our Sponsor, officers or directors, or our or their
affiliates. Any such payments prior to an initial business combination will be made from funds held outside the trust account. Other than
quarterly audit committee review of such payments, we do not expect to have any additional controls in place governing our reimbursement
payments to our directors and officers for their out-of-pocket expenses incurred in connection with identifying and consummating an initial
business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After the completion of our initial business combination,
directors or members of our management team who remain with us may be paid consulting or management fees from the combined company. All
of these fees will be fully disclosed to shareholders, to the extent then known, in the tender offer materials or proxy solicitation materials
furnished to our shareholders in connection with a proposed initial business combination. We have not established any limit on the amount
of such fees that may be paid by the combined company to our directors or members of management. It is unlikely the amount of such compensation
will be known at the time of the proposed initial business combination, because the directors of the post-combination business will be
responsible for determining officer and director compensation. Any compensation to be paid to our officers will be determined, or recommended
to the board of directors for determination, either by a compensation committee constituted solely by independent directors or by a majority
of the independent directors on our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not intend to take any action to ensure that
members of our management team maintain their positions with us after the consummation of our initial business combination, although it
is possible that some or all of our officers and directors may negotiate employment or consulting arrangements to remain with us after
our initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with
us may influence our management&#8217;s motivation in identifying or selecting a target business but we do not believe that the ability
of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision
to proceed with any potential business combination. We are not party to any agreements with our officers and directors that provide for
benefits upon termination of employment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Committees of the Board of Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have two standing committees: an audit committee
and a compensation committee. Subject to phase-in rules, the rules of Nasdaq and Rule&#160;10A-3 of the Exchange Act require that the
audit committee of a listed company be comprised solely of independent directors. Each committee operates under a charter that was approved
by our board and has the composition and responsibilities described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 220; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->203<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Audit Committee</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Luisa Ingargiola, Kevin Chen and Matt Laker serve
as the members of our audit committee. Under the Nasdaq listing standards and applicable SEC rules, we are required to have three members
of the audit committee, all of whom must be independent. Luisa Ingargiola, Kevin Chen and Matt Laker are each independent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Luisa Ingargiola serves as the chairman of the audit
committee. Each member of the audit committee is financially literate and our board of directors has determined that Luisa Ingargiola
qualifies as an &#8220;audit committee financial expert&#8221; as defined in applicable SEC rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have adopted an audit committee charter, which
details the principal functions of the audit committee, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">assisting board oversight of (1) the integrity of our financial statements, (2) our compliance with legal
        and regulatory requirements, (3) our independent registered public accounting firm&#8217;s qualifications and independence, and (4) the
        performance of our internal audit function and independent registered public accounting firm; the appointment, compensation, retention,
        replacement, and oversight of the work of the independent auditors and any other independent registered public accounting firm engaged
        by us;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">pre-approving all audit and non-audit services
        to be provided by the independent registered public accounting firm or any other registered public accounting firm engaged by us, and
        establishing pre-approval policies and procedures; reviewing and discussing with the independent registered public accounting firm all
        relationships the independent registered public accounting firm have with us in order to evaluate their continued independence;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">setting clear policies for audit partner rotation
        in compliance with applicable laws and regulations; obtaining and reviewing a report, at least annually, from the independent registered
        public accounting firm describing (1) the independent registered public accounting firm&#8217;s internal quality-control procedures and
        (2) any material issues raised by the most recent internal quality-control review, or peer review, of the independent registered public
        accounting firm, or by any inquiry or investigation by governmental or professional authorities, within the preceding five years respecting
        one or more independent audits carried out by the firm and any steps taken to deal with such issues;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">meeting to review and discuss our annual audited
        financial statements and quarterly financial statements with management and the independent registered public accounting firm, including
        reviewing our specific disclosures under <i>&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;</i>;
        reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the
        SEC prior to us entering into such transaction; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">reviewing with management, the independent
        registered public accounting firm, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any
        correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding
        our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial
        Accounting Standards Board, the SEC or other regulatory authorities.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Compensation Committee</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The members of our compensation committee will be
Luisa Ingargiola, Kevin Chen, and Matt Laker. Kevin Chen serves as chair of the compensation committee. Under the Nasdaq listing standards
and applicable SEC rules, we are required to have a compensation committee of at least two members, all of whom must be independent. Luisa
Ingargiola, Kevin Chen, and Matt Laker are each independent. We have adopted a compensation committee charter, which details the principal
functions of the compensation committee, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">reviewing and approving on an annual basis
        the corporate goals and objectives relevant to our chief executive officer&#8217;s compensation, evaluating our chief executive officer&#8217;s
        performance in light of such goals and objectives and determining and approving the remuneration (if any) of our chief executive officer
        based on such evaluation;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 221; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->204<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">reviewing and making recommendations to our
        board of directors with respect to the compensation, and any incentive compensation and equity based plans that are subject to board approval
        of all of our other officers;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">reviewing our executive compensation policies
        and plans;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">implementing and administering our incentive
        compensation equity-based remuneration plans;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">assisting management in complying with our
        proxy statement and annual report disclosure requirements;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">approving all special perquisites, special
        cash payments and other special compensation and benefit arrangements for our executive officers and employees;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">producing a report on executive compensation
        to be included in our annual proxy statement; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">reviewing, evaluating and recommending changes,
        if appropriate, to the remuneration for directors.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The charter also provides that the compensation committee
may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other adviser and will be directly
responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice
from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider the independence
of each such adviser, including the factors required by Nasdaq and the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Director Nominations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not have a standing nominating committee though
we intend to form a corporate governance and nominating committee as and when required to do so by law or Nasdaq rules. In accordance
with Rule&#160;5605I(2) of the Nasdaq rules, a majority of the independent directors may recommend a director nominee for selection by
our board of directors. Our board of directors believes that the independent directors can satisfactorily carry out the responsibility
of properly selecting or approving director nominees without the formation of a standing nominating committee. The directors who participate
in the consideration and recommendation of director nominees are Luisa Ingargiola, Kevin Chen and Matt Laker. In accordance with Rule&#160;5605(e)(1)(A)
of the Nasdaq rules, all such directors are independent. As there is no standing nominating committee, we do not have a nominating committee
charter in place.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board of directors will also consider director
candidates recommended for nomination by our shareholders during such times as they are seeking proposed nominees to stand for appointment
at the next annual general meeting (or, if applicable, an Extraordinary General Meeting). Our shareholders that wish to nominate a director
for appointment to our board of directors should follow the procedures set forth in our amended and restated memorandum and articles of
association.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not formally established any specific,
minimum qualifications that must be met or skills that are necessary for directors to possess. In general, in identifying and evaluating
nominees for director, our board of directors considers educational background, diversity of professional experience, knowledge of our
business, integrity, professional reputation, independence, wisdom, and the ability to represent the best interests of our shareholders.
Prior to our initial business combination, holders of our Public Shares will not have the right to recommend director candidates for nomination
to our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Compensation Committee Interlocks and Insider Participation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None of our executive officers currently serves, in
the past year has served, as a member of the compensation committee of any entity that has one or more executive officers serving on our
board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Clawback Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have adopted a compensation recovery policy that
is compliant with Nasdaq listing rules as required by the Dodd-Frank Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 222; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->205<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Code of Ethics</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have adopted a Code of Ethics applicable to our
directors, officers and employees. We filed a copy of our Code of Ethics as an exhibit to the registration statement of which this prospectus
is a part. You will be able to review this document by accessing our public filings at the SEC&#8217;s website at <i>www.sec.gov</i>.
In addition, a copy of the Code of Ethics and the charters of the committees of our board of directors will be provided without charge
upon request from us. If we make any amendments to our Code of Ethics other than technical, administrative or other non-substantive amendments,
or grant any waiver, including any implicit waiver, from a provision of the Code of Ethics applicable to our principal executive officer,
principal financial officer, principal accounting officer or controller or persons performing similar functions requiring disclosure under
applicable SEC or Nasdaq rules, we will disclose the nature of such amendment or waiver on our website. The information included on our
website is not incorporated by reference into this Form S-4 or in any other report or document we file with the SEC, and any references
to our website are intended to be inactive textual references only.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Executive Compensation.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Executive Officer and Director Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None of our executive officers or directors has received
any cash compensation for services rendered to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Commencing on the date that our securities were first
listed on Nasdaq, we paid an affiliate of our Sponsor $20,000 per month for office space, secretarial and administrative services provided
to members of our management team. In addition, our Sponsor, executive officers and directors, or any of their respective affiliates will
be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target
businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments
that were made to our sponsor, executive officers or directors, or our or their affiliates. Other than quarterly audit committee review
of such reimbursements, we do not expect to have any additional controls in place governing our reimbursement payments to our directors
and executive officers for their out-of-pocket expenses incurred in connection with our activities on our behalf in connection with identifying
and consummating an initial business combination. Other than these payments and reimbursements, no cash compensation of any kind, including
finder&#8217;s and consulting fees, will be paid by BCAR to our Sponsor, executive officers and directors, or any of their respective
affiliates, prior to completion of our initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After the completion of our initial business combination,
directors or members of our management team who remain with us may be paid consulting or management fees from the combined company. All
of these fees will be fully disclosed to shareholders, to the extent then known, in the proxy solicitation materials or tender offer materials
furnished to our shareholders in connection with a proposed business combination. We have not established any limit on the amount of such
fees that may be paid by the combined company to our directors or members of management. It is unlikely the amount of such compensation
will be known at the time of the proposed business combination, because the directors of the post-combination business will be responsible
for determining executive officer and director compensation. Any compensation to be paid to our executive officers will be determined,
or recommended to the board of directors for determination, either by a compensation committee constituted solely by independent directors
or by a majority of the independent directors on our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not intend to take any action to ensure that
members of our management team maintain their positions with us after the consummation of our initial business combination, although it
is possible that some or all of our executive officers and directors may negotiate employment or consulting arrangements to remain with
us after our initial business combination. We are not party to any agreements with our executive officers and directors that provide for
benefits upon termination of employment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Compensation Committee Interlocks and Insider
Participation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None of our executive officers currently serves, and
in the past year has not served, as a member of the compensation committee of any entity that has one or more executive officers serving
on our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 223; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->206<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Securities Authorized for Issuance under Equity
Compensation Plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Changes in Control</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sponsor
Information </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Sponsor is MFH 1, LLC, a Delaware limited
liability company, which was formed on March&#160;13, 2025 to invest in BCAR. Although our Sponsor is permitted to undertake any activities
permitted under the Delaware Limited Liability Company Act and other applicable law, our Sponsor&#8217;s business is focused on investing
in BCAR. John Darwin is the manager of our Sponsor, and Mr. Darwin has sole voting and investment discretion with respect to the securities
held by the sponsor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prior
SPAC Experience</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
are the SPAC business combinations in which members of our management team have participated, along with certain other information:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>EF
Hutton Acquisition Corporation I.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Boral previously served as Co-President and a Director of EF Hutton Acquisition Corporation I since March 3, 2021. EF Hutton Acquisition
Corporation I completed its initial public offering on September 13, 2022, in which it raised aggregate proceeds of approximately $115
million. On March 6, 2023, EF Hutton Acquisition Corporation I announced that it had entered into a definitive agreement for a business
combination with Humble Imports Inc., d/b/a ECD Auto Design (&#8220;ECD&#8221;). On December 7, 2023, EF Hutton Acquisition Corporation
I held a special meeting of stockholders to approve the business combination and between the initial public offering and the special meeting
to approve the business combination, approximately 11,477,545 public shares were redeemed, representing approximately 98% of the public
shares issued in EF Hutton Acquisition Corporation I&#8217;s initial public offering. Following the closing of the business combination
with ECD on December 12, 2023, the common stock and warrants of ECD began trading on Nasdaq on December 13, 2023, under the ticker symbols
&#8220;ECDA&#8221; and &#8220;ECDAW,&#8221; respectively. On [_], 2026, the closing sale price of ECDA and ECDAW were $[_] and $[_], respectively.
As of [_], 2026, the aggregate market capitalization of ECD reflects a market value of approximately $[_].</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Northern
Lights Acquisition Corp.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Darwin previously served as Co-Chief Executive Officer of Northern Lights Acquisition Corp. since March 19, 2021. Northern Lights Acquisition
Corp. completed its initial public offering on June 24, 2021, in which it raised aggregate proceeds of approximately $115 million. On
February 14, 2022, Northern Lights Acquisition Corp. announced that it had entered into a definitive agreement for a business combination
with SHF Holdings, LLC. (&#8220;SHF&#8221;). On June 28, 2022, Northern Lights Acquisition Corp. held a special meeting of stockholders
to approve the business combination and in connection therewith, approximately 7,573,402 shares were redeemed and an additional 3,804,872
redeemed shares were purchased as part of a forward purchase agreement for a total of 11,378,274 shares, or 98.9% of the public shares
issued in Northern Lights Acquisition Corp.&#8217;s initial public offering. Following the closing of the business combination with SHF
on June 30, 2022, the common stock and warrants of SHF began trading on Nasdaq on July 1, 2022 under the ticker symbols &#8220;SHFS&#8221;
and &#8220;SHFSW,&#8221; respectively. On [_], 2026, the closing sale price of SHFS and SHFSW were $[_] and $[_], respectively. As of
[_], 2026, the aggregate market capitalization of SHF reflects a market value of approximately $[_].</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 224; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->207<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Edoc
Acquisition Corp.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Chen previously served as Chief Executive Officer and Director of Edoc Acquisition Corp. since September 2020. Edoc Acquisition Corp.
completed its initial public offering on November 12, 2020, in which it raised aggregate proceeds of approximately $90 million. On December
5, 2022, Edoc Acquisition Corp. announced that it had entered into a definitive agreement for a business combination with Australian Oilseeds
Investments Pty Ltd., an Australian proprietary company (&#8220;AOI&#8221;). On March 5, 2024, Edoc Acquisition Corp. held a special meeting
of stockholders to approve the business combination and between the initial public offering and the special meeting to approve the business
combination, approximately 8,833,832 public shares were redeemed, representing approximately 98% of the public shares issued in Edoc Acquisition
Corp.&#8217;s initial public offering. Following the closing of the business combination with AOI on March 21, 2024, the common stock
and warrants of AOI began trading on Nasdaq on March 22, 2024, under the ticker symbols &#8220;COOT&#8221; and &#8220;COOTW,&#8221; respectively.
On [_], 2026, the closing sale price of COOT and COOTW were $[_] and $[_], respectively. As of [_], the aggregate market capitalization
of AOI reflects a market value of approximately $[_].</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>InFinT
Acquisition Corporation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Chen previously served board member of InFinT Acquisition Corporation from November 2021 to August 2024. INFINT Acquisition Corporation
completed its initial public offering on November 23, 2021, in which it raised aggregate proceeds of approximately $199,998,800. On August
3, 2022, InFinT Acquisition Corporation announced that it had entered into a definitive agreement for a business combination with Seamless
Group Inc., a Cayman Islands exempted company (&#8220;Seamless&#8221;). On August 6, 2023, InFinT Acquisition Corporation held a special
meeting of stockholders to approve the business combination and between the initial public offering and the special meeting to approve
the business combination, approximately 15,252,859 public shares were redeemed, representing approximately 76% of the public shares issued
in InFinT Acquisition Corporation&#8217;s initial public offering. Following the closing of the business combination with Seamless on
August 30, 2024, the common stock of Seamless began trading on Nasdaq on August 31, 2024, under the ticker symbols &#8220;CURR&#8221;.
On [_], 2026, the closing sale price of CURR was $[_]. As of [_], 2026, the aggregate market capitalization of Seamless reflects a market
value of approximately $[_].</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Conflicts of Interest</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our directors and officers presently have, and any
of them in the future may have, additional, fiduciary or contractual obligations to other entities pursuant to which such officer or director
is or will be required to present a business combination opportunity to such entity. Accordingly, if any of our directors or officers
becomes aware of a business combination opportunity that is suitable for an entity to which he or she has then-current fiduciary or contractual
obligations, he or she may need to honor these fiduciary or contractual obligations to present such business combination opportunity to
such entity, or in the case of a non-compete restriction, may not present such opportunity to us at all. Our amended and restated memorandum
and articles of association provide that, to the fullest extent permitted by applicable law: (i) no individual serving as a director or
an officer shall have any duty, except and to the extent expressly assumed by contract, to refrain from engaging directly or indirectly
in the same or similar business activities or lines of business as us; and (ii) we renounce any interest or expectancy in, or in being
offered an opportunity to participate in, any potential transaction or matter which may be a corporate opportunity for any director or
officer, on the one hand, and us, on the other. In addition our amended and restated articles of association will contain provisions to
exculpate and indemnify, to the maximum extent permitted by law, such persons in respect of any liability, obligation or duty to the company
that may arise as a consequence of such persons becoming aware of any business opportunity or failing to present such business opportunity.
Our directors and officers are also not required to commit any specified amount of time to our affairs, and, accordingly, will have conflicts
of interest in allocating management time among various business activities, including identifying potential business combinations and
monitoring the related due diligence. See &#8220;Risk Factors &#8212; Risks Related to our Team and Their Respective Affiliates and to
the Post-Business Combination Company &#8212; Certain of our directors and officers are now, and all of them may in the future become,
affiliated with entities engaged in business activities similar to those intended to be conducted by us and, accordingly, may have conflicts
of interest in determining to which entity a particular business opportunity should be presented.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 225; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->208<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the payments to
be received by BCAR&#8217;s promoters and the Sponsor and its affiliates from BCAR prior to or in connection with the completion of BCAR&#8217;s
initial business combination and the securities issued and to be issued by BCAR to the Sponsor or its affiliates:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left; width: 30%">Entity/Individual</td>
    <td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center; width: 33%">
        <p style="text-align: center; margin-top: 0; margin-bottom: 0">Amount of Compensation to be<br/> Received or Securities Issued or to
        be Issued</p></td>
    <td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center; width: 33%">Consideration Paid or
        to be Paid</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MFH
        1, LLC</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,000,000
        Class B Ordinary Shares</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$25,000</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000
        Private Units purchased simultaneously with the closing of the IPO</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,000,000</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$20,000
        per month, commencing on July 30, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
        space, utilities and secretarial and administrative services</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
        to $2,500,000 in working capital loans, which loans may be converted into Private Units of the post-business combination entity at the
        price of $10.00 per Private Unit</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Working
        capital loans to finance transaction costs in connection with an initial business combination</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MFH
        1, LLC, our officers, directors, advisor or our or their affiliates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reimbursement
        for any out-of-pocket expenses related to identifying, investigating and completing an initial business combination</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Services
        in connection with identifying, investigating and completing an initial business combination</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
        Boral</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000,000
        Representative Shares </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriter
        compensation in connection with the IPO</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of BCAR&#8217;s directors and executive officers may be deemed to have interests in the transactions contemplated by the Business Combination
Agreement that are different from, or in addition to, those of BCAR&#8217;s shareholders generally. These interests may present these
individuals with certain potential conflicts of interest. Our independent directors reviewed and considered these interests during their
evaluation and negotiation of the Business Combination and in unanimously approving, as members of the BCAR Board, the Business Combination
Agreement and the transactions contemplated therein, including the Business Combination. The BCAR Board concluded that the potential benefits
that it expected BCAR and its shareholders to achieve as a result of the Business Combination outweighed the potentially negative factors
associated with the Business Combination. When you consider the recommendation of the BCAR Board in favor of approval of the Business
Combination, you should keep in mind that BCAR&#8217;s directors and officers have interests in the Business Combination that are different
from, or in addition to, your interests as a shareholder, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
        the proposed Business Combination is not consummated by February 1, 2027 (or May 1, 2027 if the sponsor exercises its three- month -extension
        option), then we will be required to liquidate. In such event, the 12,000,000 BCAR Class B Ordinary Shares, which were acquired by the
        BCAR&#8217;s sponsor, MFH 1, LLC (the &#8220;<b>Sponsor</b>&#8221;), prior to the IPO for an aggregate purchase price of $25,000, will
        be worthless. Such BCAR Class B Ordinary Shares had an aggregate market value of approximately $[_] based on the closing price of BCAR&#8217;s
        Public Shares of $[_] on Nasdaq as of [_], 2026. As a result of the nominal price of $0.002 per Class B Ordinary Share paid by the Sponsor
        compared to the recent market price of BCAR Class A Ordinary Shares, the Sponsor is likely to earn a positive rate of return on their
        investments in the Class B Ordinary Shares even if the holders of BCAR&#8217;s Class A Ordinary Shares experience a negative rate of return
        on their investments in the Class A Ordinary Shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
        the proposed Business Combination is not consummated by February 1, 2027 (or May 1, 2027 if the sponsor exercises its three- month -extension
        option), then 200,000 private placement units (the &#8220;<b>Private Units</b>&#8221;) purchased by the Sponsor for a total purchase price
        of $2,000,000, will be worthless. Such Private Units had an aggregate market value of approximately $[_] closing price of BCAR Units of
        $[_] on Nasdaq as of [_], 2026.</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 226; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->209<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Sponsor invested an aggregate of $2,025,000 in BCAR, comprised of the $25,000
        purchase price for the Founder Shares and $2,000,000 purchase price for the Private Units. The amount held in BCAR&#8217;s trust account
        was approximately $[_] on the Record Date, implying a value of $[_] per public share. Based on these assumptions, each PubCo Class A Common
        Stock would have an implied value of $[_] per share upon consummation of the Business Combination, representing a [_]% decrease from the
        initial implied value of $[_] per public share. While the implied value of $[_] per share upon consummation of the Business Combination
        would represent a dilution to our Public Shareholders, this would represent a significant increase in value for the Sponsor relative to
        the price it paid for each Founder Share. At approximately $[_] per share, the 12,200,000 PubCo Class A Common Stock that the Sponsor
        would own upon consummation of the Business Combination would have an aggregate implied value of $[_]. As a result, even if the trading
        price of PubCo Class A Common Stock significantly declines, the value of the PubCo Class A Common Stock held by the Sponsor will be significantly
        greater than the amount the Sponsor paid to purchase such shares. For more information, please see &#8220;<i>Risk Factors &#8211; The
        nominal purchase price paid by the Sponsor and directors and officers of BCAR for the Founder Shares may significantly dilute the implied
        value of the Public Shares in the event the parties complete an initial business combination. In addition, the value of the Founder Shares
        will be significantly greater than the amount the Sponsor and directors and officers of BCAR paid to purchase such shares in the event
        the parties complete an initial business combination, even if the Business Combination causes the trading price of the PubCo Class A Common
        Stock to materially decline.</i>&#8221;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If the proposed Business Combination is not consummated, then 1,000,000 BCAR
        Class A Ordinary Shares (the &#8220;<b>Representative Shares</b>&#8221;) granted to D. Boral Capital LLC, the underwriter in the IPO,
        as compensation, which are held by David Boral, the CEO of D. Boral Capital LLC and our Chairman and Chief Executive Officer, will be
        worthless. Such Representative Shares had an aggregate market value of approximately $[_] closing price of BCAR Class A Ordinary Shares
        of $[_] on Nasdaq as of [_], 2026;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">As of [_], 2026, BCAR has unsecured promissory
        notes in the aggregate principal amount of $[_] outstanding and BCAR has drawn down an aggregate of $[_] under the notes. The promissory
        notes were issued for working capital purposes. In the absence of shareholder approval for a further extension, if the proposed Business
        Combination is not consummated by February 1, 2027 (or May 1, 2027 if the sponsor exercises its three-month extension option), then such
        loans may not be repaid.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">Unless BCAR consummates the Business Combination, its officers, directors
        and the sponsor will not receive reimbursement for any out-of-pocket expenses incurred by them to the extent that such expenses exceeded
        the amount of its working capital. As of [_], 2026, $[_] of advances was paid by the Sponsor for expenses incurred on BCAR&#8217;s behalf
        and if the proposed Business Combination is not consummated by February 1, 2027 (or May 1, 2027 if the sponsor exercises its three-month
        extension option), that amount would not be repaid. As a result, the financial interest of BCAR&#8217;s officers, directors and Initial
        Shareholders or their affiliates could influence its officers&#8217; and directors&#8217; motivation in selecting Exascale as a target
        and therefore there may be a conflict of interest when it determined that the Business Combination is in the shareholders&#8217; best
        interest.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The exercise of BCAR&#8217;s directors&#8217;
        and officers&#8217; discretion in agreeing to changes or waivers in the terms of the transaction may result in a conflict of interest
        when determining whether such changes or waivers are appropriate and in our shareholders&#8217; best interest.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The continued indemnification of current directors and officers and the continuation
        of directors&#8217; and officers&#8217; liability insurance.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">BCAR&#8217;s Current Charter provides that BCAR renounces any interest or expectancy in, or in being offered
        an opportunity to participate in, any potential transaction or matter that may be a corporate opportunity for any member of BCAR&#8217;s
        management, on the one hand, and BCAR, on the other hand, or the participation in which would breach any existing legal obligation, under
        applicable law or otherwise, of a member of BCAR&#8217;s management to any other entity. BCAR is not aware of any such corporate opportunities
        not being offered to BCAR and does not believe that waiver of the corporate opportunities doctrine has materially affected BCAR&#8217;s
        search for an acquisition target or will materially affect BCAR&#8217;s ability to complete an initial business combination.</td></tr>
  </table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 227; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->210<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing interests may influence the officers
and directors of BCAR to support or approve the Business Combination. As such, the Sponsor and BCAR&#8217;s officers and directors may
be incentivized to complete an acquisition of a less favorable target company or on terms less favorable to BCAR&#8217;s shareholders
rather than liquidate. In considering the recommendations of the BCAR Board to vote for the proposals, BCAR&#8217;s shareholders should
consider these interests. For more information, please see &#8220;<i>Risk Factors &#8212; Some of the BCAR officers and directors may
be argued to have conflicts of interest that may influence them to support or approve the Business Combination without regard to your
interests.<b>&#8221;</b></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, our Sponsor, its members, our officers
or our directors or their respective affiliates may be investors, or have other direct or indirect interests, in a business with which
we may enter into a business combination agreement and/or in certain funds or other persons that may purchase shares in this offering
or that may otherwise purchase our BCAR Class A Ordinary Shares in the public market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not believe, however, that the fiduciary duties
or contractual obligations of our directors or officers will materially affect our ability to identify and pursue business combination
opportunities or complete our initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The conflicts described above may not be resolved
in our favor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accordingly, as a result of multiple business affiliations,
our directors, officers and director nominees have similar legal obligations relating to presenting business opportunities meeting the
above-listed criteria to multiple entities. Below is a table summarizing the entities to which our directors, officers and director nominees
currently have fiduciary duties or contractual obligations:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Below is a table summarizing the entities to which
the executive officers and directors of BCAR currently have fiduciary duties or contractual obligations:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 14%; vertical-align: bottom"><b>Individual</b></td>
    <td style="text-align: left; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 28%; text-align: center; vertical-align: bottom"><b>Entity</b></td>
    <td style="text-align: center; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 26%; text-align: center; vertical-align: bottom"><b>Entity&#8217;s Business</b></td>
    <td style="text-align: center; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 26%; text-align: center; vertical-align: bottom"><b>Affiliation</b></td> </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">David Boral</p> </td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">D. Boral Capital</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">Broker-dealer</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">Chief Executive Officer</td> </tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">John Darwin</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">ARC Group Limited</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">Advisory firm</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">Managing Director</td> </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">JD ARC Consulting LLC</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">Provides services to ARC Group Limited</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">Managing Member</td> </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">Luminous Capital USA Inc.</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">Investment firm</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">Managing Partner</td> </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">ARC Luminous GP, LLC</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">Investment Firm</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">Owned by ARC Group Limited and Luminous Capital USA, Inc.</td> </tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Luisa Ingargiola</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Dragonfly Energy Holdings Corp.</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Energy storage and battery technology</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Avalon GloboCare Corp.</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Biotechnology</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Electrameccanica Vehicles Corp.</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Electric vehicle industry</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">BioCorRx Inc.</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Healthcare</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Marine Technologies, Inc.</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Fusion Fuel Green PLC</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Kevin Chen</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Horizon Financial</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Investment advisor</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Chief Investment Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">ACM Macro LLC</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Investment advisor</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Manager</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Australian Oilseeds Investment</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Manufacture and sale of sustainable oilseeds</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">CurrenC Group</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Financial services</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Capitan Investment Ltd.</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Real estate</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Scage International Limited</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Energy heavy-duty commercial vehicles and e-fuel solutions</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Matt Laker</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">N/A</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">N/A</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">N/A</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 228; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->211<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_027"></span>MANAGEMENT&#8217;S DISCUSSION
AND ANALYSIS OF</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF
BCAR</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">References to &#8220;BCAR,&#8221;
&#8220;our,&#8221; &#8220;us&#8221; or &#8220;we&#8221; refer to D. Boral ARC Acquisition I Corp. The following discussion and analysis
of BCAR&#8217;s financial condition and results of operations should be read in conjunction with BCAR&#8217;s financial statements and
the notes thereto contained elsewhere in this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Cautionary Note Regarding
Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>This Section includes
forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. We have based
these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are
subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance
or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied
by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221;
&#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;estimate,&#8221; and &#8220;continue,&#8221; or the negative of such terms or other similar expressions. Such statements include,
but are not limited to, possible business combinations and the financing thereof, and related matters, as well as all other statements
other than statements of historical fact included in this Section. Factors that might cause or contribute to such a discrepancy include,
but are not limited to, those described in the &#8220;Risk Factors&#8221; section and elsewhere in this proxy statement/prospectus. Except
as expressly required by applicable securities law, we disclaim any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">BCAR is a blank check company
formed under the laws of the British Virgin Islands on March 20, 2025 for the purpose of effecting a merger, share exchange, asset acquisition,
share purchase, reorganization or similar business combination with one or more businesses. BCAR intends to effectuate its initial business
combination using cash from the proceeds of its IPO and the Private Units, the proceeds of the sale of our securities in connection with
our initial business combination, our shares, debt or a combination of cash, stock and debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We expect to continue to
incur significant costs in the pursuit of our initial business combination plans. We cannot assure you that our plans to raise capital
or to complete our initial business combination will be successful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have neither
engaged in any operations nor generated any revenues to date. Our only activities from inception to March&#160;31, 2026 related to our
formation and the IPO. Since the IPO, our activity has been limited to the costs in pursuit of the consummation of an initial business
combination. We do not expect to generate any operating revenues until after the completion of our initial business combination. We expect
to continue to generate non-operating income in the form of interest income on cash and marketable securities held after the IPO. We
expect that we will incur increased expenses as a result of being a public company (for legal, financial reporting, accounting and auditing
compliance), as well as for due diligence expenses in connection with completing a business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three
months ended March&#160;31, 2026, we had a net income of $2,011,318, which comprised of operating costs of $531,741 and interest income
on the trust account of $2,543,059.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the period
from March&#160;20, 2025 (inception) through March 31, 2025, we had a net loss of $5,420, which was formation cost.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the period from March 20, 2025 (inception) through
December 31, 2025, we had a net income of $4,455,970, which consists of formation and operating costs of $320,658, and interest earned
on cash held of $4,776,628.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 229; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->212<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As
of March&#160;31, 2026, we had available to us $243,576 of cash on our balance sheet and a working capital of $54,122. As of December&#160;31,
2025, we had available to us $420,340 of cash on our balance sheet and a working capital of $585,863.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On August 1, 2025, BCAR
consummated its IPO, which consisted of 25,000,000 units (the &#8220;<b>BCAR Units</b>&#8221;). The BCAR Units were sold at a price of
$10.00 per Unit, generating gross proceeds to BCAR of $250,000,000. Each BCAR Unit consists of one BCAR Class A Ordinary Share, par value
$0.0001 per share, and one-half of one redeemable warrant (each whole such warrant, a &#8220;<b>Public Warrant</b>&#8221;), with each
whole Public Warrant entitling the holder thereof to purchase one BCAR Class A Ordinary Share for $11.50 per share. BCAR granted the underwriters
a 45-day option to purchase up to 3,750,000 additional units at the IPO price to cover over-allotments, if any.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Simultaneously with the
closing of the IPO, pursuant to a Private Placement Units Purchase Agreement, BCAR completed the private placement of an aggregate of
200,000 units (the &#8220;<b>Private Units</b>&#8221;) to the Sponsor at $10.00 per Private Unit, each Private Unit consisting of one
BCAR Class A Ordinary Share and one-half of one redeemable warrant (each whole such warrant, a &#8220;<b>Private Placement Warrant</b>&#8221;),
each whole Private Placement Warrant exercisable to purchase one BCAR Class A Ordinary Share for $11.50 per share. The Private Placement
Warrants are identical to the Public Warrants, except as otherwise disclosed elsewhere in this proxy statement/prospectus. No underwriting
discounts or commissions were paid with respect to such sale. The issuance of the Private Units was made pursuant to the exemption from
registration contained in Section 4(a)(2) of the&#160;Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On August 11, 2025, the
underwriters of the IPO notified BCAR of their partial exercise of the over-allotment option and purchased 3,000,000 additional units
at $10.00 per unit upon the closing of the over-allotment option, generating gross proceeds of $30,000,000. The over-allotment option
closed on August 13, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">BCAR intends to use the
funds held outside of the trust account established in connection with the IPO for identifying and evaluating prospective acquisition
candidates, performing business due diligence on prospective target businesses, traveling to and from the offices, plants or similar locations
of prospective target businesses, reviewing corporate documents and material agreements of prospective target businesses, selecting the
target business to acquire and structuring, negotiating and consummating the Business Combination. The interest income earned on the investments
in the trust account are unavailable to fund operating expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In order to finance transaction
costs in connection with a business combination, the Sponsor or an affiliate of the Sponsor, or BCAR&#8217;s officers and directors may,
but are not obligated to, loan BCAR funds as may be required (&#8220;<b>Working Capital Loans</b>&#8221;). Such Working Capital Loans
would be evidenced by promissory notes. The notes would either be repaid upon consummation of a business combination, without interest,
or, at the lender&#8217;s discretion, up to $2,500,000 of notes may be converted upon consummation of a business combination into additional
Private Units at a price of $10.00 per Private Unit. In the event that a business combination does not close, BCAR may use a portion of
proceeds held outside the trust account to repay the Working Capital Loans, but no proceeds held in the trust account would be used to
repay the Working Capital Loans. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR will
have until the date that is 18 months from the closing of the IPO, with one (1) three-month extension at the option of the Sponsor (as
may be extended further by shareholder approval to amend BCAR&#8217;s amended and restated memorandum and articles of association to extend
the date by which BCAR must consummate its initial business combination) or until such earlier liquidation date as the BCAR Board may
approve, to consummate BCAR&#8217;s initial business combination. If BCAR anticipates that it may be unable to consummate an initial business
combination within such 18-month period (or 21-month period if the Sponsor exercises its three-month extension option), BCAR may seek
shareholder approval to amend its amended and restated memorandum and articles of association to extend the date by which BCAR must consummate
its initial business combination. There are no limitations on the number of times BCAR may seek shareholder approval for an extension
or the length of time of any such extension. However, if BCAR seeks shareholder approval for an extension, holders of Public Shares will
be offered an opportunity to redeem their shares at a per share price, payable in cash, equal to the aggregate amount then on deposit
in the trust account, including interest earned thereon (less taxes payable), divided by the number of then issued and outstanding Public
Shares, subject to applicable law. If BCAR is unable to complete its initial business combination within 18 months from the closing of
the IPO, with one (1) three-month extension at the option of the Sponsor, or by such earlier liquidation date as the BCAR Board may approve,
BCAR will redeem 100% of the Public Shares at a per share price, payable in cash, equal to the aggregate amount then on deposit in the
trust account, including interest earned thereon (less taxes payable and up to $100,000 of interest income to pay dissolution expenses),
divided by the number of then issued and outstanding Public Shares, subject to applicable law as further described in this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 230; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->213<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-style: normal"><b>Off-Balance
Sheet Financing Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR has no obligations, assets or liabilities
which would be considered off-balance sheet arrangements. BCAR does not participate in transactions that create relationships with unconsolidated
entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose
of facilitating off-balance sheet arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR has not entered any off-balance sheet financing
arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or entered any non-financial
assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contractual Obligations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March&#160;31,
2026 and December 31, 2025, we did not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities,
other than an agreement to pay our Sponsor an aggregate of $20,000 per month for office space, secretarial and administrative support.
We began incurring these fees on July 31, 2025, and will continue to incur these fees monthly until completion of our initial business
combination or liquidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation
of financial statements and related disclosures in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements,
and income and expenses during the periods reported. Actual results could materially differ from those estimates. As of March&#160;31,
2026 and December 31, 2025, we did not have any critical accounting estimates to be made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Policies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation
of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent
assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could
materially differ from those estimates. As of December 31, 2025 and March 31, 2026, BCAR has identified the following critical accounting
policies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Net Income per Ordinary
Share</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR complies with accounting and disclosure requirements
of FASB&#160;ASC Topic 260, &#8220;Earnings Per Share.&#8221; Net income per share of ordinary shares is computed by dividing net income
applicable to ordinary shareholders by the weighted average number of shares of ordinary shares outstanding during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR has not considered the effect of the warrants
sold in the IPO and Private Placement to purchase an aggregate of 14,100,000 Class A ordinary shares in the calculation of diluted income
per share, since their inclusion would be anti-dilutive under the treasury stock method and are contingent on future events. As a result,
diluted income per share of Class A ordinary shares is the same as basic income per share of ordinary shares for the period presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR has two classes of ordinary shares, which
are referred to as Class A ordinary shares and Class B ordinary shares. Income are shared pro rata among the two classes of ordinary shares.
Net income per share of ordinary shares is calculated by dividing the net income by the weighted average number of shares of ordinary
shares outstanding during the respective period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 231; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->214<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Class A Ordinary Shares
Subject to Possible Redemption</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The public
shares contain a redemption feature which allows for the redemption of such public shares in connection with BCAR&#8217;s liquidation,
or if there is a shareholder vote or tender offer in connection with BCAR&#8217;s initial business combination. In accordance with&#160;ASC
480-10-S99, BCAR classifies public shares subject to redemption outside of permanent equity as the redemption provisions are not solely
within the control of BCAR. BCAR recognizes changes in redemption value immediately as they occur and will adjust the carrying value
of redeemable shares to equal the redemption value at the end of each reporting period. Immediately upon the closing of the IPO, BCAR
recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable shares will
result in charges against additional paid-in capital (to the extent available) and Retained earnings. Accordingly, Class A ordinary shares
subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders&#8217; equity section
of BCAR&#8217;s balance sheet. As of December 31, 2025 and March 31, 2026, there were 28,000,000 Class A ordinary shares subject to redemption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Warrant Instruments</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We account for warrants as either equity-classified
or liability-classified instruments based on an assessment of the instruments&#8217; specific terms and applicable authoritative guidance
in&#160;ASC 480&#160;and FASB&#160;ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;). The assessment considers
whether the instruments are freestanding financial instruments pursuant to&#160;ASC 480, meet the definition of a liability pursuant to&#160;ASC
480, and whether the instruments meet all of the requirements for equity classification under&#160;ASC 815, including whether the instruments
are indexed to a company&#8217;s common shares and whether the instrument holders could potentially require &#8220;net cash settlement&#8221;
in a circumstance outside of a company&#8217;s control, among other conditions for equity classification. This assessment, which requires
the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while
the instruments are outstanding. Upon review of the warrant agreement, Management concluded that the public warrants and private warrants
issued pursuant to such warrant agreement qualify for equity accounting treatment. Following the closing of the IPO on August 1, 2025
and underwriter&#8217;s exercise of over-allotment option on August 13, 2025, BCAR accounted for the 14,000,000 public warrants and 100,000
private warrants issued under equity treatment at their assigned values.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Offering Costs Associated
with the Initial Public Offering</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCAR complies
with the requirements of the&#160;ASC 340-10-S99&#160;and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A - &#8220;Expenses
of Offering.&#8221; Deferred offering costs consist principally of professional and registration fees that are related to the IPO. Financial
Accounting Standards Board (&#8220;FASB&#8221;)&#160;ASC 470-20, &#8220;Debt with Conversion and Other Options,&#8221; addresses the
allocation of proceeds from the issuance of convertible debt into its equity and debt components. BCAR applies this guidance to allocate
IPO proceeds from the Public Units between Class A ordinary shares and warrants based on their relative fair values. Offering costs allocated
to the Class A ordinary shares subject to possible redemption were charged to temporary equity, and offering costs allocated to the warrants
included in the Public Units and Private Units were charged to shareholder&#8217;s equity as the warrants, after management&#8217;s evaluation,
were accounted for under equity treatment. As of December 31, 2025 and March 31, 2026, BCAR had offering costs of $3,582,634.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 232; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->215<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_028"></span>INFORMATION ABOUT EXASCALE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Unless
otherwise indicated or the context otherwise requires, references in this Section to &#8220;Exascale&#8221; &#8220;we,&#8221; &#8220;us,&#8221;
&#8220;our&#8221; and other similar terms refer to Exascale Labs Inc. and its subsidiaries.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale is a Delaware corporation incorporated
in June 2022, and is a next-generation AI infrastructure provider operating an asset-light, software-defined GPU compute platform and
related AI infrastructure solutions. Exascale&#8217;s core business includes GaaS, through which it provides reserved and on-demand access
to high-performance GPU compute capacity sourced from third-party data centers globally, as well as GPU cluster management and optimization
services for AIDC operators. In addition, Exascale has developed certain modular data center, high-density liquid cooling, HVDC power
and energy storage solutions that are designed to address deployment bottlenecks in AI infrastructure and that Exascale believes are ready
for commercial engagement, although these capabilities have not yet generated revenue as of the date of this proxy statement/prospectus.
The platform is purpose-built for large-scale AI workloads, including LLM training, fine-tuning, and high-concurrency inference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale&#8217;s business consists of two primary
product and service categories. First, Exascale provides GPU-based compute services through its GaaS offering, which delivers scalable
access to high-performance GPU capacity via bare-metal and VM configurations. These services are offered through both on-demand and reserved
usage models and are designed to support a range of AI workloads, including large-scale model training, fine-tuning, and high-concurrency
inference. Second, Exascale provides Infrastructure Solutions for AI deployments, which include (i) GPU cluster management and operational
services provided to AIDC operators, including planning and configuration support, monitoring, performance tuning, and ongoing operational
assistance for large-scale GPU deployments, which are revenue-generating and delivered pursuant to commercial service arrangements, and
(ii) certain modular data center, advanced liquid cooling, HVDC power, and energy storage solutions that management believes are ready
to support customer deployments as of the date of this proxy statement/prospectus, although such offerings have not generated revenue
to date. Exascale expects to pursue these offerings on an asset-light basis, primarily through partnerships, systems integration, contract
manufacturing and other collaborative structures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Industry
and Market Background</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The AI industry is undergoing
a generational paradigm shift, driven by the rapid adoption of Generative AI and LLMs. This shift has created an unprecedented demand
for specialized, high-performance accelerated computing infrastructure that far exceeds the capabilities of traditional general-purpose
cloud architectures. Exascale believes the market is currently in the early stages of a secular transition from legacy central processing
unit (&#8220;<b>CPU</b>&#8221;)-centric data centers to accelerated computing environments purpose-built for AI.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proliferation of foundational models and AI-native applications has triggered a massive capital investment cycle. According to a September
2025 report by Gartner, Inc., a business and technology insights company, global spending on AI infrastructure is projected to reach nearly
$1.5 trillion in 2025 and grow to exceed $2.0 trillion by 2026. This growth is driven not only by the training of increasingly larger
models which now regularly exceed trillions of parameters, but also by the exponential rise in inference workloads as enterprises integrate
AI into production environments. The demand for compute capacity is outstripping supply by a significant margin. As of early 2026, despite
increases in manufacturing capacity, the demand for cutting-edge GPUs, such as NVIDIA&#8217;s Blackwell architecture and subsequent generations,
remains robust. Market indicators suggest that supply constraints for high-end AI processors could extend through 2027 and into 2028.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Limitations
of Legacy Cloud Infrastructure</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Traditional
hyperscale cloud providers have historically architected their infrastructure to primarily support general-purpose web applications, such
as web-hosting, e-commerce, databases, and search, and have historically relied on CPU-based, web-scale computing architectures. While
hyperscale cloud providers have added GPU offerings and continue to invest in AI-related infrastructure, the operational and architectural
assumptions that underlie general-purpose cloud platforms, such as multi-tenant abstractions designed for a wide set of workloads, may
not be optimized for certain AI workloads that require dense GPU clusters, high-performance interconnects, and operational practices focused
on maximizing effective utilization and minimizing job disruption. Industry participants have stated that certain large, diversified cloud
providers are not purpose-built for the AI and accelerated compute use cases served by specialized AI infrastructure providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 233; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->216<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
AI adoption accelerates, the market increasingly demands infrastructure that is purpose-built to address the unique characteristics of
AI workloads. This shift is driving specific requirements for platforms and service providers that combine GPU capacity with specialized
software, operational tooling, and infrastructure management practices intended to (i) optimize performance, (ii) maintain stability and
uptime, and (iii) reduce the complexity of operating high-performance AI infrastructure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, AI adoption has driven demand for infrastructure that can address several interrelated requirements, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
        at scale through balanced system design</i>. Large AI training workloads can require high-throughput data pipelines and coordinated operation
        across many GPUs. In these settings, performance is often influenced not only by the GPUs themselves but also by the design and operation
        of supporting infrastructure components (including networking, storage, and systems software).</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Maximizing effective
        utilization of expensive GPU resources</i>. Because GPU compute capacity is a significant input cost for many AI workloads, effective
        utilization can meaningfully affect the economics and throughput of AI development and deployment. Industry users place strong emphasis
        on the degree to which real-world performance approaches hardware potential, and on how that performance can be affected by software stack
        efficiency, data movement and bottlenecks, as well as operational factors that interrupt or degrade workload execution.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reliability,
        stability, and operational consistency</i>. Large-scale training runs and production inference environments can be sensitive to interruptions,
        failures, and performance variability. As clusters scale, operational stability and uptime become increasingly important for avoiding
        disruptions and managing overall compute costs and time-to-completion. Exascale has observed an increasing demand for lifecycle management,
        monitoring, validation, and proactive health-checking capabilities intended to prevent failures and rapidly remediate issues in complex
        AI infrastructure environments.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reducing operational
        complexity for customers and improving usability</i>. Deploying and operating GPU clusters at scale often involves significant complexity,
        including provisioning, configuration management, observability, incident response workflows, and ongoing tuning of infrastructure and
        software environments. The industry requires monitoring and observability solutions, as well as operational services designed to support
        the deployment, ongoing operation, and remediation of infrastructure components throughout their full lifecycle. These capabilities are
        needed to shift a meaningful portion of the infrastructure management burden from customers to the platform.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Speed of deployment
        and access to current-generation GPU capability</i>. AI demand has increased the importance of time-to-capacity, including the ability
        to deploy and operate GPU clusters in a timely manner and, in some cases, to adopt new GPU generations as they become commercially available.
        Industry participants have cited speed to market and the scale of GPU clusters as factors relevant to competitive positioning in accelerated
        computing markets.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Evolution of Purpose-built AI Clouds (NeoClouds)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to the demand for accelerated compute capacity and the constraints associated with obtaining and deploying advanced GPU resources,
a category of purpose-built AI infrastructure providers, often referred to in industry discussions as &#8220;neoclouds,&#8221; has emerged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neocloud
providers generally offer GPU-centric infrastructure and services designed specifically for AI workloads. By combining compute capacity
with managed configuration, monitoring, incident response workflows, and workload tuning practices, these platforms are intended to improve
effective utilization and deliver more predictable performance for model training and large-scale inference, while supporting service
stability and uptime. Neocloud offerings are also commonly structured to reduce the operational complexity associated with deploying and
operating high-performance GPU clusters and to provide customers with more rapid access to scalable GPU capacity as demand changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
models among neocloud providers vary. Some specialized providers have adopted capital-intensive approaches that involve significant investments
in GPU fleets and data center capacity, and certain market participants have described their operations as capital-intensive and related
capital market risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 234; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->217<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Capital
Investment and Industry Trajectory</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
AI infrastructure sector continues to attract unprecedented levels of capital investment, driven by what Exascale believes is a secular
transition in global computing architecture. However, this rapid expansion is inherently capital-intensive, often requiring substantial
upfront expenditures that can translate into significant balance sheet leverage, while simultaneously exposing operators to risks associated
with hardware obsolescence, accelerated depreciation, and rapid technology refresh cycles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
November 2025 report by CreditSights projects combined capital expenditures for the top five hyperscalers increasing from approximately
$256.0 billion in 2024 to approximately $443.0 billion in 2025 and approximately $602.0 billion in 2026. Specifically, estimates for 2025
capital expenditures by individual industry leaders range from approximately $70.0 billion to over $100.0 billion per entity, reflecting
a strategic prioritization of AI infrastructure capabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
management believes that this investment cycle is in its early stages. According to an April 2025 article by McKinsey &amp; Company, global
data centers will require a cumulative investment of approximately $6.7 trillion by 2030, of which approximately $5.2 trillion is specifically
attributed to AI-related infrastructure. This forecast implies a sustained, multi-year expansion in the addressable market for data center
delivery, specialized compute services, and hardware optimization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
believes these capital inflows underscore the strategic importance of computing power as a fundamental resource for future economic growth.
At the same time, the scale and structure of these investments highlight the importance of capital-efficient models that can mitigate
leverage, manage asset lifecycle risk, and optimize returns amid ongoing hardware evolution. The magnitude of the projected investment
suggests durable market demand for infrastructure providers capable of delivering high-performance resources with speed and capital efficiency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Physical
Constraints: Data Center, Power, and Deployment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
scaling of AI infrastructure is increasingly constrained by physical limitations related to power availability, thermal management, and
data center construction timelines. As the thermal design power (&#8220;<b>TDP</b>&#8221;) of next-generation AI accelerators approaches
and, in some cases, exceeds 1,000 watts per GPU, legacy data centers designed for lower-density workloads, typically supporting approximately
10 to 15 kilowatts per rack, are becoming insufficient for modern AI deployments. As a result, the industry is undergoing a structural
transition toward high-density computing environments capable of supporting rack densities ranging from approximately 40 kilowatts to
over 100 kilowatts per rack. Exascale believes this transition requires the adoption of advanced infrastructure technologies, including
next-generation liquid cooling solutions and modular data center (&#8220;<b>MDC</b>&#8221;) architectures, to overcome the thermal and
power-efficiency limitations of traditional air-cooled facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to thermal constraints, limitations on utility power availability and transmission capacity are increasingly influencing the
design and deployment of AI infrastructure. These constraints have driven growing interest in HVDC power architectures, which are designed
to improve power transmission efficiency and reduce energy losses within high-density AI computing environments. Collectively, these physical
constraints are becoming a critical factor in determining the pace at which AI infrastructure can be deployed and scaled and are increasingly
viewed as a prerequisite to sustaining continued performance improvements in next-generation AI models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
GPU TDP continues to rise, software optimization has emerged as a critical economic lever for AI infrastructure providers and their customers.
Given the high capital cost and ongoing scarcity of advanced AI hardware, the ability to improve effective compute throughput and increase
GPU utilization rates through software-defined efficiency is becoming increasingly important to the economic viability of AI workloads.
At the same time, the industry is mandating a shift toward liquid cooling technologies to support next-generation rack densities that
exceed 100 kilowatts, which Exascale believes requires AI infrastructure to be architected from the ground up to operate reliably and
efficiently in high-density environments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
believes that the convergence of supply constraints, increasing technical complexity, and the need for rapid deployment has created a
significant and durable market opportunity for asset-light, execution-focused AI infrastructure providers, such as Exascale, that can
deliver high-performance compute capacity while addressing these evolving physical and operational challenges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 235; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->218<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exascale&#8217;s
Solution </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale has developed an
asset-light, software-defined AI infrastructure platform designed to provide customers with access to high-performance GPU compute and
related infrastructure services for large-scale AI workloads. The platform supports reserved and on-demand compute services and is intended
to enable customers and infrastructure operators to provision, manage, monitor, and optimize GPU environments used for large-scale model
training, fine-tuning, and high-concurrency inference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale&#8217;s business
is organized around two primary product and service categories:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in">(i)</td>
    <td style="text-align: justify"><i>GaaS</i>: Exascale provides GPU-based compute services through its GaaS offering, which delivers scalable
        access to high-performance GPU capacity via bare-metal and VM configurations. These services are offered through both on-demand and reserved
        usage models and are designed to support a range of AI workloads, including large-scale model training, fine-tuning, and high-concurrency
        inference.</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="text-align: justify; width: 0.25in">(ii)</td>
    <td style="text-align: justify"><i>Infrastructure Solutions</i>. Exascale provides Infrastructure Solutions for AI deployments, which include
        (a) GPU cluster management and operational services provided to AIDC operators, including planning and configuration support, monitoring,
        performance tuning, and ongoing operational assistance for large-scale GPU deployments, which are revenue-generating and delivered pursuant
        to commercial service arrangements, and (b) certain modular data center, advanced liquid cooling, HVDC power, and energy storage solutions
        that management believes are ready to support customer deployments as of the date of this proxy statement/prospectus, although such offerings
        have not generated revenue to date.</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Supporting these offerings,
Exascale utilizes infrastructure-level interfaces, APIs, and operational tooling to facilitate provisioning, resource management, monitoring,
incident response, performance management, and service delivery across its compute and infrastructure services. Exascale expects to pursue
its broader infrastructure offerings on an asset-light basis, primarily through partnerships, systems integration, contract manufacturing,
and other collaborative structures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale believes that its
combination of GPU compute services, operational capabilities, and infrastructure solutions is designed to address the performance, reliability,
deployment, and operational requirements of modern AI infrastructure and to position Exascale for long-term growth in the accelerated
computing market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competitive Strengths</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The
following subsections describe certain competitive strengths that Exascale&#8217;s management believes differentiate Exascale in the rapidly
evolving AI infrastructure market and may support Exascale&#8217;s ability to compete as the market continues to evolve. The following
competitive strengths should be balanced with, and considered in the context of, the risks Exascale faces, as discussed in the &#8220;<i>Risk
Factors</i>&#8221; section of this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Purpose-Built for Large-Scale AI Workloads</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale&#8217;s platform
and service model are designed for large-scale AI workloads, including model training, fine-tuning and high-concurrency inference. Exascale&#8217;s
management believes this focus allows Exascale to align its compute services, tooling and operational processes with the performance,
stability and usability requirements of GPU-intensive environments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Proprietary Software-Defined Efficiency</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In an industry constrained
by the high cost and scarcity of compute resources, Exascale views software optimization as its primary lever for value creation. Exascale
has developed a proprietary Intelligent Scheduling System designed to decouple workload performance from raw hardware availability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Key elements of this approach include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Process-Level
        Orchestration</i></b>. Unlike conventional schedulers that typically manage resources at the server level, Exascale&#8217;s system is
        engineered to provide deep, process-level observability and control. It dynamically schedules computing tasks and optimizes memory allocation
        to address bottlenecks inherent in large-scale cluster training and parallel computing workloads.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Focus on
        Cost-Performance Efficiency</i></b>. By optimizing kernel execution and mitigating network latency, Exascale&#8217;s platform is designed
        to achieve utilization rates that significantly exceed standard industry benchmarks for generalized clouds. This efficiency objective
        allows Exascale to potentially lower the effective total cost of ownership for Exascale&#8217;s customers while maximizing the revenue
        yield of Exascale&#8217;s deployed capacity.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 236; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->219<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Asset-Light and Scalable Delivery Model</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
prioritizes leveraging the underlying hardware resources and operational services of third-party data centers, and integrates those resources
through its proprietary software systems and service capabilities to deliver GPU-as-a-Service and related software offerings to end customers,
rather than incurring heavy capital expenditures on real estate and direct hardware ownership. This model is intended to provide several
operational benefits, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Agility and
        Risk Mitigation</i></b>: Exascale&#8217;s model enables Exascale to scale capacity in response to customer demand without the long lead
        times and significant balance-sheet burdens associated with building greenfield data centers or owning depreciating hardware assets. It
        also provides the flexibility to adapt to new hardware generations, aiming to reduce the risk of technology obsolescence.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Focus on
        Core Competencies</i></b>: By partnering with top-tier data center operators for physical facilities, Exascale focuses its resources on
        what Exascale believes are its core differentiators, namely: software orchestration, supply chain integration, and customer service delivery.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rapid
Deployment and Global Operational Reach</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time-to-market
is a critical differentiator for Exascale&#8217;s customers in the AI sector. Exascale leverages the extensive experience of its technical
leadership team to navigate complex supply chains and accelerate infrastructure delivery across a truly global footprint. This approach
entails the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Global Execution
        Network</i></b>: Unlike providers constrained to a single geography, Exascale has established a diversified operational footprint. Exascale&#8217;s
        customers currently span 12 key innovation hubs, including the United States, Canada, the United Kingdom, Australia, South Korea, Singapore,
        India, Malaysia, Hong Kong, Hungary, Poland, and Italy. To support this footprint, Exascale has engaged with data center partners and
        suppliers across the United States, Canada, Japan, Singapore, Australia, the United Kingdom, France, Malaysia and Norway. This global
        mesh enables Exascale to service international demand and mitigates risks associated with regional capacity constraints.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Proven Delivery
        Capabilities</i></b>: Drawing on Exascale&#8217;s leadership&#8217;s prior experience deploying large-scale, high-performance computing
        clusters, Exascale applies specialized execution methodologies to significantly compress deployment timelines compared to industry standards.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Diversified
Customer Base</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
has strategically cultivated a diversified customer base to enhance commercial resilience and revenue stability. As of June 30, 2025,
Exascale served 55 distinct customers, with Exascale&#8217;s largest single customer contributing approximately 14.0% of Exascale&#8217;s
total revenue. Exascale believes this level of diversification differentiates Exascale in the specialized AI cloud market, where high
revenue concentration from a small number of anchor tenants is often a prevalent structural characteristic. Exascale believes its broad
customer distribution reduces Exascale&#8217;s dependency on any single entity and validates the widespread applicability of Exascale&#8217;s
service offerings. Exascale&#8217;s diversified portfolio helps Exascale mitigate counterparty risks and maintain more predictable revenue
streams amid fluctuating market cycles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accessible
Service Model </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
has architected its product and service framework to democratize access to high-performance AI infrastructure, addressing a significant
gap in the market for underserved segments. While many specialized infrastructure providers prioritize massive-scale engagements with
high minimum spend thresholds, effectively excluding a large portion of the market, Exascale maintains a flexible engagement model. Exascale
offers product configurations, technical support structures, and commercial terms specifically designed to be accessible to small-and-medium-sized
enterprises (SMEs) and emerging AI startups. Exascale&#8217;s service delivery model includes dedicated technical support suited for organizations
that may lack the massive internal engineering resources of large technology giants. By providing this level of accessibility, Exascale
is able to capture high-growth opportunities within the broader AI ecosystem that are often overlooked by other providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 237; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->220<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Infrastructure
Expertise and Future-Readiness</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In addition to its compute
services and revenue-generating GPU cluster management offerings, Exascale has developed certain modular data center, advanced liquid
cooling, HVDC power and energy storage solutions that Exascale&#8217;s management believes are ready to support customer deployments as
of the date of this proxy statement/prospectus, although such offerings have not generated revenue to date. Exascale expects to pursue
these offerings primarily through partnerships, systems integration, contract manufacturing and other collaborative structures. Exascale&#8217;s
management believes this approach may allow Exascale to participate in broader AI infrastructure deployments over time while maintaining
an asset-light operating model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exascale&#8217;s
Principal Products and Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale&#8217;s products and services are organized
into two primary categories: (i) GPU-as-a-Service (&#8220;<b>GaaS</b>&#8221;), which includes software-defined AI compute services, infrastructure-level
interfaces, and operational tools that enable customers and operators to provision and manage GPU resources at scale; and (ii) AI Infrastructure
Solutions, which includes revenue-generating GPU cluster management and operational services for AI data center operators, as well as
complementary infrastructure solution capabilities, including modular data center solutions, high-density liquid cooling systems, HVDC
power architectures, and energy storage capabilities, that management believes are ready for commercial engagement but that have not yet
generated revenue as of the date of this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AI
Compute Services (GPU-as-a-Service)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s
flagship offering is GPU-as-a-Service (&#8220;<b>GaaS</b>&#8221;), which provides customers with reserved or on-demand, scalable access
to high-performance computing resources. Delivered through Exascale&#8217;s unified control plane, these services are designed to meet
the performance requirements of modern AI workloads.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
offers GPU compute configurations through both bare metal instances and virtual machines (&#8220;<b>VMs</b>&#8221;). Exascale provides
single-tenant, bare-metal servers that offer customers direct access to hardware resources without virtualization overhead. This configuration
is optimized for large-scale cluster training and performance-critical workloads that require maximum throughput and low latency. Exascale
also offers flexible, isolated VM instances suitable for development, testing, and scalable inference workloads. These instances allow
for rapid provisioning and efficient resource scaling.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
offers its compute services through multiple commercial models, including on-demand offerings that allow customers to provision capacity
on a pay-as-you-go basis for short-term or burst workloads, as well as reserved instance offerings that provide guaranteed capacity and
pricing stability for customers with predictable, long-term production requirements. Reserved arrangements typically range from one to
three years and are intended to provide customers with supply certainty while providing Exascale with improved revenue visibility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s
platform supports a range of AI workloads, including large-scale multi-node training, enterprise fine-tuning of pre-trained models and
production inference workloads requiring optimized latency and throughput. In connection with these services, Exascale may also provide
ancillary services that support compute usage, including networking and storage configuration, operating environment setup, and support
services, as required by the customer and within the scope of the service arrangement. The availability of specific configurations and
services may depend on supplier arrangements, data center capacity, and operational considerations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Infrastructure-Level
Interfaces and APIs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
provides infrastructure-level interfaces designed for developers and enterprise customers that support automated creation, management,
and monitoring of compute resources through APIs. These interfaces are intended to enable customers to programmatically provision and
manage resources without accessing a separate management console, including within the customer&#8217;s own systems and workflows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s
API capabilities are intended to support, among other things, (i) programmatic provisioning and lifecycle management of compute resources,
including GPU and CPU nodes, (ii) Command Line Interfaces (CLIs) that allow developers to provision, manage, and monitor compute resources
via code, which enables direct integration with customers&#8217; internal machine learning operations pipelines and CI/CD workflows, (iii)
programmatic management and monitoring of customer environments, and (iv) integration of compute resources with networking and storage
configurations as supported under the applicable service offering. The scope of API functionality available to any customer depends on
the customer&#8217;s service configuration, access permissions, and the terms of the applicable arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 238; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->221<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operational
and Management Tools Supporting Service Delivery</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
operates internal operational and management tools used by its personnel to manage the compute infrastructure and support service delivery.
These tools are used to manage server resources and underlying services and to support ongoing operations. Core functions supported by
these internal tools include (i) server management and operations, including onboarding, configuration, operational control, monitoring,
and inspection workflows, (ii) environment management and operations, including monitoring and management of network conditions, thermal
conditions, and power-related parameters, and (iii) supporting functions, including access management, logging, analytics and reporting,
and integrations with third-party tools used to support operations. These internal tools are intended to support consistent operational
procedures across infrastructure deployed in third-party facilities and to enable Exascale to provision and manage customer compute environments
through its platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AI Infrastructure Solutions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale&#8217;s Infrastructure Solutions category
includes GPU cluster management and operational services for AIDC operators, as well as certain infrastructure solutions designed to support
large-scale AI deployments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>GPU Cluster Management and Operational Services</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale provides GPU cluster management services
to AIDC operators. These services are intended to assist AIDC operators in deploying, operating, and optimizing large-scale GPU clusters
and may be delivered in connection with customer deployments or ongoing operations, depending on the terms of the engagement. These services
have generated revenue for the Company. The scope of Exascale&#8217;s GPU cluster management services may include, as applicable, (i)
planning and configuration support for GPU cluster deployments, (ii) operational monitoring and incident response support, (iii) performance
tuning and optimization activities, and (iv) operational process support and ongoing assistance. Engagement terms, service scope, and
duration may vary depending on the customer&#8217;s requirements and the nature of the deployment or operating environment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Complementary Infrastructure Solution Capabilities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, Exascale has developed complementary
infrastructure solution capabilities intended to support large-scale AI deployments, including modular data center solutions, high-density
liquid cooling systems, HVDC power architectures, and energy storage capabilities. Exascale has made progress in the development and validation
of these capabilities, and management believes that certain of these solutions are ready for commercial engagement with prospective customers.
However, as of the date of this proxy statement/prospectus, these capabilities have not been deployed at scale under binding commercial
contracts and have not generated revenue. Exascale expects to pursue these offerings primarily on an asset-light basis through partnerships,
systems integration, contract manufacturing, and other collaborative structures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales
and Marketing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s
go-to-market approach is designed to support the delivery of GPU-based compute services and related infrastructure management services
to developers, enterprise customers, academic and research institutions, and certain AIDC operators. Exascale&#8217;s strategy includes
a mix of direct sales to enterprise clients and collaborations with cloud service providers and value-added resellers to broaden market
reach. Exascale engages customers through a combination of (i) platform-led provisioning of compute services and (ii) direct, service-oriented
engagements for certain infrastructure management services. Exascale&#8217;s go-to-market approach is implemented in conjunction with
the Exascale&#8217;s sourcing and facility relationships, including third-party GPU capacity suppliers and data center partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 239; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->222<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Customer
Acquisition Channels</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s
customer acquisition and engagement channels generally include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Platform-led
        onboarding and ordering</i>. For compute services, customers can access Exascale&#8217;s platform to provision and manage compute resources
        via self-service workflows and interfaces, including API-based provisioning and management.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Direct sales
        and account-driven engagements</i>. For certain enterprise customers and service engagements, Exascale may pursue direct customer relationships
        that involve structured onboarding, customized configurations, support requirements, or other service terms.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Service-driven
        engagements with AIDC operators</i>. For GPU cluster management services, Exascale typically engages customers through direct service
        arrangements, which may be structured as project-based engagements or ongoing support arrangements, depending on customer requirements.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
mix of channels utilized for a given customer may depend on the customer segment, workload characteristics, service configuration requirements,
and the scope of support requested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Partnerships
and Ecosystem Relationships</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale&#8217;s go-to-market activities are supported
by relationships with third parties, which include (i) GPU capacity suppliers as described further below under &#8220;&#8212;GPU Capacity
Supplier Arrangements,&#8221; from which Exascale sources GPU hardware resources and underlying hardware operations services and integrates
them through its proprietary software systems and customer-facing service capabilities to provide GPU-as-a-Service, (ii) data center and
facility partners, which provide physical infrastructure inputs such as space, power, cooling, and network connectivity, (iii) technology
and service providers, including vendors and tools used to support monitoring, management, security, and operations within Exascale&#8217;s
infrastructure environment, and (iv) systems integration, engineering, manufacturing and component partners that may support Exascale&#8217;s
Infrastructure Solutions offerings, including modular data center, advanced liquid cooling, HVDC power and energy storage solutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These relationships are intended to support Exascale&#8217;s
ability to deliver its GaaS and Infrastructure Solutions offerings at scale. Exascale&#8217;s ability to expand customer engagements may
be affected by supplier availability, data center capacity constraints, component availability, partner execution, permitting requirements,
and operational integration and deployment timelines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>GPU Capacity Supplier Arrangements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale&#8217;s GPU capacity supplier arrangements
are primarily integrated GPU capacity and related infrastructure service arrangements. Under these arrangements, third-party suppliers
provide Exascale with access to specified GPU servers or GPU capacity, together with bundled hosting, power, rack space, data center resources,
network connectivity and related infrastructure services necessary to operate and make such GPU capacity available. The primary commercial
purpose of these arrangements is to obtain access to GPU compute capacity. The hosting, power, rack space, data center resources, network
connectivity and similar services provided by these suppliers are bundled infrastructure components that support the operation and delivery
of such GPU capacity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale pays GPU capacity suppliers primarily
through usage-based fee arrangements. Depending on the supplier and the applicable order or service arrangement, Exascale may be required
to pay deposits or prepayments, or may be invoiced periodically in arrears based on actual usage. Certain supplier arrangements involve
rolling monthly usage-based payments, which may be structured as prepaid amounts or invoiced after usage. Exascale does not enter into
revenue-sharing arrangements with its GPU capacity suppliers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 240; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->223<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale relies on multiple GPU capacity supplier
relationships as part of its overall supply model. This multi-supplier approach is designed to support supply continuity, procurement
flexibility and access to alternative sources of GPU capacity. Exascale actively evaluates capacity availability across existing and prospective
third-party GPU capacity suppliers and seeks to diversify its sourcing relationships so that it is not operationally dependent on any
single supplier arrangement. Exascale believes that maintaining multiple supplier relationships provides flexibility to source additional
or replacement GPU capacity from existing suppliers or alternative third-party providers, subject to market availability, pricing, technical
configuration, location, deployment timing and other commercial and operational considerations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale&#8217;s GPU capacity supplier arrangements
vary in duration. Certain arrangements have longer-term contract periods, typically ranging from one to three years, while other arrangements
may be shorter-term, order-based or subject to rolling monthly usage-based terms. Exascale&#8217;s GPU capacity supplier arrangements
do not include take-or-pay obligations, minimum purchase commitments or exclusivity obligations. Certain suppliers provide non-exclusive
priority allocation or preferred access to GPU capacity, which is intended to support supply availability for Exascale; however, such
arrangements do not require Exascale to purchase a minimum amount of capacity and do not provide Exascale with exclusive rights to a supplier&#8217;s
GPU capacity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Supplier costs under these arrangements are a
principal component of Exascale&#8217;s cost of revenue. Pricing under Exascale&#8217;s GPU capacity supplier arrangements is generally
subject to market conditions for GPU compute capacity, although pricing may be fixed for short periods or for specific usage periods,
orders or capacity configurations. Under certain usage-based arrangements, Exascale&#8217;s unit cost may decrease as usage volume increases.
However, Exascale may not be able to maintain or reduce unit costs if GPU supply becomes constrained, supplier pricing increases, utilization
levels decline or Exascale is unable to obtain favorable terms</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale&#8217;s GPU capacity supplier arrangements
do not involve revenue sharing, the purchase or lease of GPU equipment or data center equipment from such suppliers, or a long-term lease
of data center facilities. Although Exascale relies on multiple supplier relationships as part of its overall supply model, Exascale&#8217;s
purchases have been concentrated among a limited number of suppliers during the periods presented. Based on Exascale&#8217;s review of
its current supplier arrangements, Exascale does not believe that any individual GPU capacity supplier arrangement or the limited hosting
arrangement described above represents the major part of its requirements for GPU capacity or related infrastructure services or otherwise
constitutes a material contract required to be filed pursuant to Item 601(b)(10) of Regulation S-K. Exascale will continue to evaluate
its supplier arrangements and will update its disclosure and exhibit index if any such arrangement is determined to be material.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Segment-Specific
Engagement Considerations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale&#8217;s engagement approach may vary
by customer segment. Developers and AI-native companies may primarily engage through platform-led ordering and provisioning workflows
and may provision compute capacity as needed based on project cycles and workload requirements. Enterprise customers may require structured
onboarding, defined service parameters, access controls, and support arrangements consistent with internal operational requirements. Academic
and research institutions may have procurement and budgeting processes that differ from commercial enterprises and may require scheduling,
data handling, or operational considerations tailored to research workflows and institutional requirements. AIDC operators engaging Exascale
for GPU cluster management services typically require operational support for deployment, ongoing operations, and the optimization of
large-scale GPU clusters. In addition, certain enterprise customers, infrastructure operators or AIDC operators may engage Exascale in
connection with Infrastructure Solutions offerings, including modular data center, advanced liquid cooling, HVDC power and energy storage
solutions, which may require coordination with facility infrastructure, third-party partners, and project-specific operational constraints.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 241; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->224<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Implementation,
Onboarding, and Account Management</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For compute services, customer onboarding generally
includes account setup, access provisioning, configuration of compute environments within Exascale&#8217;s managed platform, and operational
coordination based on the customer&#8217;s selected service configuration. Customers may expand or modify service configurations over
time, subject to the Exascale&#8217;s available capacity, operational constraints, and the terms of the applicable arrangement. For GPU
cluster management services, implementation typically includes scoping of the engagement, aligning with deployment or operational objectives,
and delivering services consistent with the agreed scope and duration. For Infrastructure Solutions offerings, implementation may include
solution scoping, design and deployment planning, coordination with facility, engineering, manufacturing or other third-party partners,
integration activities, and commissioning or operational support, depending on the scope of the customer arrangement. Exascale&#8217;s
account management activities may include operational coordination, support, and escalation processes, as well as periodic service reviews
depending on the engagement structure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The industry and markets in which Exascale operates
are highly competitive, rapidly evolving and characterized by technological change, capacity constraints and significant capital requirements.
Exascale competes in the provision of GPU-based compute services and related Infrastructure Solutions for AI deployments. Exascale&#8217;s
current revenue-generating offerings include GaaS and GPU cluster management and operational services for AIDC. In addition, as Exascale
commercializes its modular data center, advanced liquid cooling, HVDC power and energy storage offerings, Exascale expects to compete
more directly in additional segments of the AI infrastructure market. Competitive dynamics are influenced by, among other factors, the
availability and configuration of GPU capacity, performance and reliability requirements, deployment constraints, including power availability
and cooling capacity, service quality, customer support, pricing and commercial terms, security and compliance capabilities, systems integration
and deployment capabilities, and the pace of innovation in AI hardware and software.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
faces competition from a range of entities with differing business models, operating scales and strategic priorities, including the following
categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General-Purpose
Cloud Computing Providers</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
competes with large, diversified cloud service providers that offer GPU-based compute as part of broader cloud platforms. These providers
include Amazon Web Services (&#8220;AWS&#8221;), Microsoft Azure, Google Cloud Platform, Oracle Cloud Infrastructure and IBM Cloud. These
platforms typically benefit from significant financial resources, global infrastructure footprints, established customer relationships
and extensive product ecosystems. However, their platforms were generally developed to support a wide range of general-purpose workloads
and may not be purpose-built for certain AI workloads that require specialized GPU-centric configurations, high-performance interconnects
and optimized utilization of underlying infrastructure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Specialized
AI Infrastructure and GPU Compute Providers (&#8220;NeoClouds&#8221;)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
also competes with specialized providers focused on delivering GPU compute and AI-optimized infrastructure services. These providers include
CoreWeave, Nebius, Lambda, Crusoe, Voltage Park, WhiteFiber and Hyperstack, among others. Certain of these competitors operate capital-intensive
business models that involve owning and operating substantial GPU fleets and, in some cases, developing or controlling data center facilities.
These providers may offer deep specialization for AI workloads but may face higher capital requirements and balance-sheet exposure associated
with hardware ownership and facility development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>GPU
Aggregators and Compute Marketplaces</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
also competes with GPU aggregators and marketplaces that aggregate third-party GPU capacity and provide access to compute resources through
software platforms. Examples of such providers include Vast.ai, Aethir Cloud, Hyperbolic and similar marketplace-based offerings. These
platforms may offer flexible access to distributed capacity but may have more limited involvement in underlying infrastructure deployment,
operational management and deep performance optimization, and may have varying levels of control over service quality, reliability and
customer experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 242; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->225<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Data
Center Operators and AIDC Service Providers</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
data center operators and AIDC participants offer AI infrastructure services directly or through affiliated service offerings. In addition,
some AIDC operators may provide managed cluster services or otherwise compete for customer workloads requiring large-scale GPU deployments.
To the extent such operators internalize capabilities that overlap with Exascale&#8217;s services, including GPU cluster management and
operational support, they may compete with Exascale for certain customer engagements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>AI Data Center Infrastructure and Solutions
Providers</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent Exascale pursues commercial engagements
for its infrastructure solution capabilities, including modular data center solutions, liquid cooling systems, and HVDC power architectures,
Exascale may also face competition from established infrastructure equipment manufacturers and solutions providers. These may include
providers of data center power distribution, cooling, and modular infrastructure products. These companies generally have significantly
greater manufacturing scale, established supply chains, broader product portfolios, and longer track records of commercial deployment
than Exascale. Exascale&#8217;s infrastructure solution capabilities have not yet generated revenue, and there can be no assurance that
Exascale will be able to compete effectively in such market segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Factors
Affecting Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
believes that competition in the markets in which it operates is generally based on a combination of factors, including, without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability of
        GPU capacity and configuration options, including access to relevant GPU types and deployment timelines;</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance and
        efficiency, including the ability to optimize workload performance and utilization within given infrastructure constraints;</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reliability and
        stability, including uptime, operational consistency, and network interconnect performance for cluster-based workloads;</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operational capabilities
        and support, including deployment planning, monitoring, incident response, and customer support processes;</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ease of use and
        integration, including tooling, automation features and API-based controls that reduce operational complexity for customers;</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">infrastructure constraints and deployment considerations, including access to
        suitable facilities, power, cooling, component availability and partner execution;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">speed and efficiency of infrastructure deployment, including the ability to
        design, configure, and commission AI-ready compute environments within compressed timelines;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">pricing and commercial terms, including flexibility and alignment with customer
        needs and requirements; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">security, data protection and regulatory compliance considerations.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 243; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->226<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The industry and markets in which Exascale operates
are highly competitive, and Exascale faces competition from a number of companies and other entities with varying business models, operating
scales and strategic priorities. Many of Exascale&#8217;s current and potential competitors have substantially greater financial, technical,
marketing and other resources, broader customer relationships, longer operating histories, greater brand recognition, and more established
infrastructure than Exascale. As a result, these competitors may be able to respond more quickly to new or emerging technologies, devote
greater resources to the development, promotion and sale of their offerings, withstand pricing pressures more effectively, or offer more
favorable commercial terms than Exascale. Increased competition could result in pricing pressure, reduced margins, increased customer
acquisition costs or loss of market share. For additional discussion of risks related to the competition Exascale faces, see the section
of this proxy statement/prospectus captioned &#8220;<i>Risk Factors</i>.&#8221; Notwithstanding the foregoing, Exascale believes its business
model differs from certain capital-intensive providers by sourcing GPU capacity through third-party arrangements and delivering GaaS and
Infrastructure Solutions through Exascale&#8217;s managed platform, technology systems and operational processes on an asset-light basis.
Exascale intends to compete by applying its technology and operations capabilities to support performance optimization, operational stability,
and usability for customers operating GPU-based workloads, including through GPU cluster management services for AIDC operators and, over
time, through its complementary infrastructure solution capabilities as those offerings are commercially deployed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Seasonality</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale&#8217;s business is not inherently seasonal.
Demand for GaaS (including its APIs and supporting tools) is driven by ongoing AI training, inference, and production workloads, which
are generally non-seasonal in nature. At present, revenue within Exascale&#8217;s Infrastructure Solutions category is derived from GPU
cluster management and operational services. Revenues from these services, and from other Infrastructure Solutions offerings if and when
they begin to generate revenue, may exhibit period-to-period variability due to the timing of customer capital expenditure decisions,
project milestones, deployment schedules, facility readiness, partner execution and delivery timelines. Such fluctuations are primarily
project-based rather than seasonal, and Exascale&#8217;s management does not believe seasonality has a material impact on Exascale&#8217;s
business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
concerning Exascale&#8217;s patents and copyright, as of the date of this proxy statement/prospectus, is set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pa</i></b></span><b><i>tents</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<table cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; vertical-align: bottom; width: 40%; text-align: left"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Number</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Registration
        Date</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Jurisdiction</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Status</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; text-align: left"><span style="font-size: 10pt">COMPUTING
        POWER NETWORK SYSTEM</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">12,058,179</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">August
        6, 2024</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">United
        States</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">Granted
        and in force</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; text-align: left">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">AIOPS SCHEDULING METHOD AND
        SYSTEM BASED ON MULTI-AGENT COLLABORATIVE AUTONOMY</p></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">19/440,612</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">January
        5, 2026</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">United
        States</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">Pending</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; text-align: left"><span style="font-size: 10pt">AN
        ADAPTIVE EXTERNAL SUPPLY-AND-RETURN WATER TEMPERATURE REGULATION SYSTEM AND METHOD FOR A MODULAR DATA CENTER</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">19/440,577</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">January
        5, 2026</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">United
        States</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">Pending</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; text-align: left"><span style="font-size: 10pt">A
        METHOD AND SYSTEM FOR MAXIMIZING THROUGHPUT OF A GPU CLUSTER</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">19/444,167
        </span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">January
        8, 2026</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">United
        States</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">Pending</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Software Copyright</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; vertical-align: bottom; width: 40%; text-align: left"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Case
        Number</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Application
        Date</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Jurisdiction</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Status</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; text-align: left"><span style="font-size: 10pt;">EXASCALE
    ARTIFICIAL INTELLIGENCE COMPUTING POWER MANAGEMENT PLATFORM</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt;">1-15021399291</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt;">October
    15, 2025</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt;">United
    States</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt;">Pending</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 244; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->227<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Exascale
is subject to the laws and regulations of various jurisdictions and governmental agencies affecting Exascale&#8217;s operations, products
and services including, but not limited, laws relating to AI, intellectual property, tax, import and export requirements, anti-corruption,
economic and trade sanctions, national security and foreign investment, data privacy and security requirements, competition, advertising,
employment, product regulations, environment, health and safety requirements, and consumer laws. A discussion of the risks related to
Exascale with respect to such laws is set forth in the &#8220;</span><span style="font: normal 10pt Times New Roman, Times, Serif"><i>Risk
Factors &#8212; Risks Related to Exascale</i><span style="font-style: normal">&#8221; subsection of this proxy statement/prospectus, as
supplemented by the discussion below. To date, costs and accruals incurred to comply with regulations have not been material to Exascale&#8217;s
capital expenditures and results of operations. Although there is no assurance that existing or future governmental laws and regulations
applicable to Exascale&#8217;s operations, products and services will not have a material adverse effect on Exascale&#8217;s capital expenditures,
operating results, and competitive position, Exascale does not currently anticipate material expenditures for compliance with regulations.
Nonetheless, Exascale believes that global trade regulations could potentially have a material impact on its business.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">As
a global company, the import and export of Exascale&#8217;s products and services are subject to laws and regulations including international
treaties, U.S. export controls and sanctions laws, customs regulations, and local trade rules around the world. The scope, nature, and
severity of such controls varies widely across different countries and may change frequently over time. Such laws, rules, and regulations
may delay the introduction of products and services or impact Exascale&#8217;s competitiveness through restricting Exascale&#8217;s ability
to conduct business in certain jurisdictions or with certain entities and individuals. For example, the U.S. Department of Commerce continues
to tighten export controls and add firms to the &#8220;Entity List.&#8221; These export restrictions, which would require that Exascale
obtain licenses from the U.S. Department of Commerce to allow Exascale to export infrastructure services to such listed firms, could limit
or prevent Exascale from doing business with certain potential customers or potential suppliers. These restrictive governmental actions
and any similar measures that may be imposed on U.S. companies by other governments could limit Exascale&#8217;s ability to conduct business
globally.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Exascale&#8217;s
operations, and the third-party data center and partner-operated facilities in which Exascale&#8217;s GPU capacity is deployed, are subject
to laws and regulations of various jurisdictions and governmental agencies, including local, state, and federal environment laws, health
and safety requirements. These requirements may relate to, among other things, the siting, build-out and operation of data center facilities,
power and cooling infrastructure, and the handling and disposal of certain equipment and materials. In addition, because a significant
portion of Exascale&#8217;s cost structure is driven by third-party facility inputs (including colocation, power, cooling and network
connectivity), changes in environmental laws at the local, state, and federal level, regulations or permitting requirements applicable
to such facilities or related utilities could increase Exascale&#8217;s operating costs, delay deployments, or otherwise affect Exascale&#8217;s
ability to scale capacity on expected timelines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">To
date, costs and accruals incurred to comply with governmental regulations (including the environment, health and safety requirements described
above) have not been material to Exascale&#8217;s capital expenditures and results of operations, and Exascale does not currently anticipate
material expenditures for compliance with regulations; however, there can be no assurance that existing or future governmental laws and
regulations applicable to Exascale or its products and services will not have a material adverse effect on Exascale&#8217;s capital expenditures,
operating results, and competitive position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale has developed infrastructure solution
capabilities, including high-density liquid cooling systems designed to lower power usage effectiveness and HVDC power architectures intended
to improve overall energy efficiency and facilitate better integration with renewable energy sources and grid-scale storage. To the extent
Exascale commercially deploys these infrastructure solution capabilities, such deployments may be subject to additional regulatory, permitting
and compliance requirements, including those related to electrical systems, building codes, environmental standards, and equipment safety
certifications, which could vary by jurisdiction and may affect deployment timelines and costs. As of the date of this proxy statement/prospectus,
these capabilities have not been commercially deployed and Exascale has not incurred material regulatory compliance costs in connection
with these capabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 245; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->228<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale is a Delaware corporation incorporated
in the State of Delaware in June 2022. Exascale&#8217;s principal executive office is located at 820 Gessner Road, Suite 332 and its telephone
number is (650) 537-7553. Exascale&#8217;s corporate website address is www.exascalelabs.ai. Exascale&#8217;s website and the information
contained on, or that can be accessed through, Exascale&#8217;s website is not deemed to be incorporated by reference in, and is not considered
part of, this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
foregoing principal executive offices address, telephone number and website will be the principal executive offices address, telephone
number and website, respectively, of PubCo immediately following consummation of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this proxy statement/prospectus,
Exascale had 10 full-time employees on a consolidated basis. Of these employees, four were directly employed by Exascale in the United
States, and six were employed by Exascale&#8217;s wholly owned Singapore subsidiary. The subsidiary employees work remotely in support
of Exascale&#8217;s business operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale&#8217;s workforce currently consists
of (i) one Chief Executive Officer, who also serves as Exascale&#8217;s Chief Financial Officer; (ii) one data center partnerships lead;
(iii) one research and development lead; (iv) one marketing lead; (v) one business development lead; (vi) three senior research and development
engineers; and (vii) two operations personnel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale&#8217;s core research and development
activities are led and performed by internal personnel, including Exascale&#8217;s research and development lead and senior research and
development engineers. Customer service and support are also handled internally by Exascale personnel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale also utilizes certain third-party service
providers to support specific functions. For example, Exascale engages project-based outsourced development teams to assist with specific
development tasks, certain third-party personnel to provide on-site data center operations support, and third-party service providers
to assist with certain finance-related execution functions. These arrangements supplement Exascale&#8217;s internal workforce and do not
replace internal responsibility for management, core research and development, customer support, or overall business oversight.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Facilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale does not have any
principal physical properties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Legal
Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">From
time to time, Exascale may be subject to legal proceedings. Exascale is not currently a party to or aware of any proceedings that Exascale
believes will have, individually or in the aggregate, a material adverse effect on Exascale&#8217;s business, financial condition or results
of operations. Regardless of outcome, litigation can have an adverse impact on Exascale because of defense and settlement costs, diversion
of management resources and other factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 246; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->229<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Recent Sales of Unregistered
Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On June 1, 2022, Exascale
issued an aggregate of 1,500 common shares to Wenying Jia, as nominee for the founders of Exascale, in connection with the formation of
Exascale. No cash consideration was paid in respect of such issuance. Part of the aggregate of 1,500 common shares were subsequently transferred
to the various founders. The foregoing transaction was exempt from the registration requirements of the Securities Act pursuant to Section
4(a)(2) thereof, as transactions by an issuer not involving a public offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On January 8, 2026, Exascale
amended and restated its certificate of incorporation to (i) create two classes of common stock with differing voting rights (being Class
A common stock with one (1) vote per share and Class B common stock with twenty (20) votes per share), and (ii) effect the automatic reclassification
of Exascale&#8217;s then outstanding common shares into Class A common stock and Class B common stock, Pursuant to the reclassification,
1,197 then outstanding Exascale common shares were converted into Exascale Class B common stock and the remaining 303 then outstanding
Exascale common shares were converted into Exascale Class A common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>SAFEs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From inception to the date of this proxy statement/prospectus,
Exascale has sold and issued an aggregate of 26 SAFEs for an aggregate amount of $14,092,500. The foregoing transactions were exempt from
the registration requirements of the Securities Act pursuant to Section 4(a)(2) thereof, as transactions by an issuer not involving a
public offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SAFEs are governed by substantially similar
forms of SAFE agreements. In general, each SAFE provides that, upon the occurrence of a liquidity event, the SAFE holder becomes entitled
to the consideration specified in the SAFE based on the form and amount of proceeds payable in such liquidity event, including, where
applicable, shares determined by reference to the applicable liquidity price. The Business Combination will constitute a liquidity event
pursuant to the terms of the SAFEs and the outstanding SAFEs will be automatically settled in connection with the consummation of the
Business Combination without any separate holder election, consent or approval, although, for administrative expediency, the Business
Combination Agreement requires an Exascale Safeholder to execute an acknowledge (and such other agreements or documents as Exascale may
determine) as a condition to receiving the merger consideration. The requirement to execute an acknowledge and such other agreements and
forms as Exascale may determine is procedural only and does not create any separate holder approval or election right with respect to
conversion of the SAFEs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of the date of this proxy statement/prospectus, based on the outstanding
SAFEs, Exascale expects that 8,766,500 shares of PubCo Class A Ordinary Common Stock will be issued to SAFE holders at the closing of
the Business Combination as a result of such automatic conversion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 247; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->230<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: center; margin-top: 0; margin-bottom: 0"><b><span id="a_029"></span>EXASCALE&#8217;S
MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF <br/>FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><i>Unless
the context otherwise requires, all references in this section to &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to Exascale.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><i>You
should read the following discussion and analysis of Exascale&#8217;s financial condition and results of operations together with Exascale&#8217;s
audited financial statements and notes thereto and unaudited condensed financial statements and notes thereto included elsewhere in this
proxy statement/prospectus. Certain of the information contained in this discussion and analysis or set forth elsewhere in this proxy
statement/prospectus, including information with respect to plans and strategy for Exascale&#8217;s or PubCo&#8217;s business, includes
forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the
section entitled &#8220;Risk Factors,&#8221; Exascale&#8217;s actual results could differ materially from the results described in or
implied by the forward-looking statements contained in the following discussion and analysis. You should carefully read the section entitled
&#8220;Risk Factors&#8221; to gain an understanding of the important factors that could cause actual results to differ materially from
Exascale&#8217;s forward-looking statements. Please also see the section entitled &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><i>All
interim financial data included for the three and nine months ended March&#160;31, 2025 and 2026 is derived from Exascale&#8217;s unaudited
interim condensed financial statements included elsewhere in this proxy statement/prospectus. All annual financial data included for the
fiscal years ended June&#160;30, 2024 and 2025 is derived from Exascale&#8217;s audited financial statements included elsewhere in this
proxy statement/prospectus. The financial statements were prepared in accordance with GAAP.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>OVERVIEW</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Exascale
was incorporated in the State of Delaware in June&#160;2022. Exascale is a next-generation AI infrastructure provider operating an asset-light,
software-defined GPU compute platform and related AI infrastructure solutions. Exascale&#8217;s core business includes GaaS, through which
it provides reserved and on-demand access to high-performance GPU compute capacity sourced from third-party data centers globally, as
well as GPU cluster management and optimization services for AIDC operators. In addition, Exascale has developed certain modular data
center, high-density liquid cooling, HVDC power and energy storage solutions that are designed to address deployment bottlenecks in AI
infrastructure and that Exascale believes are ready for commercial engagement, although these capabilities have not yet generated revenue
as of the date of this proxy statement/prospectus. The platform is purpose-built for large-scale AI workloads, including LLM training,
fine-tuning, and high-concurrency inference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Exascale&#8217;s
business consists of two primary product and service categories. First, Exascale provides GPU-based compute services through its GaaS
offering, which delivers scalable access to high-performance GPU capacity via bare-metal and VM configurations. These services are offered
through both on-demand and reserved usage models and are designed to support a range of AI workloads, including large-scale model training,
fine-tuning, and high-concurrency inference. Second, Exascale provides Infrastructure Solutions for AI deployments, which include (i)
GPU cluster management and operational services provided to AIDC operators, including planning and configuration support, monitoring,
performance tuning, and ongoing operational assistance for large-scale GPU deployments, which are revenue-generating and delivered pursuant
to commercial service arrangements, and (ii) certain modular data center, advanced liquid cooling, HVDC power, and energy storage solutions
that management believes are ready to support customer deployments as of the date of this proxy statement/prospectus, although such offerings
have not generated revenue to date. Exascale expects to pursue these offerings on an asset-light basis, primarily through partnerships,
systems integration, contract manufacturing and other collaborative structures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 248; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->231<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Non-GAAP
Measures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Exascale
uses adjusted operating loss and adjusted net loss, with are non-GAAP financial measures, to evaluate Exascale&#8217;s operating results
and for financial and operational decision-making purposes. Adjusted operating loss represents loss from operations excluding share-based
compensation expenses. Adjusted net loss represents net loss excluding share-based compensation and change in fair value of simple agreements
for future equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Exascale
believes that both adjusted operating loss and adjusted net loss helps identify underlying trends in Exascale&#8217;s business that could
otherwise be distorted by the effect of certain expenses that Exascale includes in loss from operations and net loss. Exascale believes
that adjusted operating loss and adjusted net loss provide useful information about Exascale&#8217;s operating results, enhances the overall
understanding of Exascale&#8217;s past performance and future prospects and allows for greater visibility with respect to key metrics
used by Exascale&#8217;s management in its financial and operational decision-making.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Non-GAAP
financial measures have inherent limitations, and adjusted operating loss and adjusted net loss should not be considered in isolation
or construed as an alternative to loss from operations, net loss, or any other measures of financial performance prepared in accordance
with GAAP or as an indicator of Exascale&#8217;s operating performance. For example, share-based compensation, which is excluded in the
determination of adjusted net loss, may continue to be significant as we grow. Investors are encouraged to review the historical non-GAAP
financial measures to the most directly comparable GAAP measures. Adjusted operating loss and adjusted net loss presented here may not
be comparable to similarly titled measures used by other companies. Other companies may calculate similarly titled measures differently,
limiting their usefulness as comparative measures to Exascale&#8217;s data. Exascale encourages investors and others to review its financial
information in its entirety and not rely on a single financial measure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The table
below sets forth a reconciliation of our loss from operations to adjusted operating loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the <br/>Nine Months Ended <br/>March&#160;31,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the <br/>Years Ended <br/>June&#160;30,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2026</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2024</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Loss
        from operations</b></td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">(2,462,485</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">(2,818,657</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">(1,845,829</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">(3,044,846</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">)</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Add:</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Share-based
        compensation</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">153,266</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">-</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">21,104</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">153,266</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Adjusted
        operating loss</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>(2,309,219</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>(2,818,657</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>(1,824,725</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>(2,891,580</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The table
below sets forth a reconciliation of our net loss to adjusted net loss for the periods indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the <br/>Nine Months Ended <br/>March&#160;31,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the<br/> Years Ended <br/> June&#160;30,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2026</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2024</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Net
        loss</b></td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">(6,178,537</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">(7,916,977</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">(4,956,347</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">(7,659,667</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">)</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Add:</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Share-based
        compensation</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">153,266</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">21,104</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">153,266</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Change
        in fair value of simple agreements for future equity</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">3,716,052</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">5,098,320</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">3,110,518</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">4,614,821</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Adjusted
        net loss</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>(2,309,219</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>(2,818,657</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>(1,824,725</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>(2,891,580</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 249; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->232<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Key
Financial Metrics</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the<br/> Nine Months Ended<br/> March&#160;31,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the<br/>Years Ended<br/>June 30,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2026</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2024</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Total
        revenues</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">4,475,885</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">10,561,331</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">1,319,115</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">7,015,512</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Loss
        from operations</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(2,462,485</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(2,818,657</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(1,845,829</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(3,044,846</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Net
        loss</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(6,178,537</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(7,916,977</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(4,956,347</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(7,659,667</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Adjusted
        operating loss (non-GAAP)<sup>(1)</sup></td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(2,309,219</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(2,818,657</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(1,824,725</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(2,891,580</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Adjusted
        net loss (non-GAAP)<sup>(2)</sup></td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(2,309,219</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(2,818,657</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(1,824,725</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(2,891,580</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><i>Note:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman; width: 0.25in; text-align: justify">(1)</td>
    <td style="font: 10pt Times New Roman; text-align: justify">Adjusted operating loss, a non-GAAP financial
        measure, represents loss from operations excluding share-based compensation expenses. See &#8220;<i>&#8212;Non-GAAP Financial Measures</i>.&#8221;</td>
        </tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman; text-align: justify">(2)</td>
    <td style="font: 10pt Times New Roman; text-align: justify">Adjusted net loss, a non-GAAP financial measure,
        represents net loss excluding share-based compensation and change in fair value of simple agreements for future equity. See &#8220;<i>&#8212;Non-GAAP
        Financial Measures</i>.&#8221;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Key
Performance and Operating Metrics</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Exascale
uses certain key performance and operating metrics to evaluate the performance of its business, monitor customer demand and utilization,
assess capacity sourcing and deployment, evaluate supplier procurement and pricing, and support resource allocation decisions. Management
reviews these metrics together with Exascale&#8217;s financial results, including revenue, cost of revenue, gross margin, operating expenses
and cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The following
table presents Exascale&#8217;s key performance and operating metrics for the fiscal years ended June&#160;30, 2024 and 2025 and for the
nine months ended March&#160;31, 2025 and 2026. Exascale calculates GPU-hours using a standard 730-hour month for each month presented,
rather than the actual number of calendar days in each month. The Company uses 730 hours because it approximates the average number of
hours in a month and is applied consistently across all periods presented to enhance period-to-period comparability and avoid fluctuations
caused solely by differences in the number of calendar days in individual months. Accordingly, available GPU-hours are calculated as deployed
GPU capacity multiplied by 730 hours for each month, and billable GPU-hours are calculated as customer-contracted GPU capacity multiplied
by 730 hours for each month. Exascale&#8217;s current KPI framework does not separately track or present on-demand GPU-hours as a key
operating metric. On-demand usage, to the extent generated during the periods presented, is discussed through revenue and MD&amp;A rather
than through this KPI.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">For capacity-based
metrics, Exascale presents monthly average amounts for the applicable period because management believes period-average capacity metrics
are more directly comparable to period revenue, cost of revenue, available GPU-hours, billable GPU-hours and utilization. Monthly average
amounts are calculated as the simple average of the monthly capacity amounts compiled by management for each month in the applicable period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 250; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->233<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt"><b>&#160;</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the<br/>years ended<br/>June&#160;30,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt"><b>&#160;</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt"><b>&#160;</b></td>
    <td colspan="2" style="font: 10pt Times New Roman; text-align: center"><b>For the<br/>Nine Months ended
        <br/>March&#160;31,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt"><b>&#160;</b></td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt"><b>&#160;</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2024</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt"><b>&#160;</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt"><b>&#160;</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2026</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt"><b>&#160;</b></td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Average
        contracted GPU supply</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 12%; text-align: right">190.7 GPUs</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 12%; text-align: right">935.3 GPUs</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 12%; text-align: right">1281.78GPUs</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Average
        theoretical GPU compute power related to contracted GPU supply</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">112,265 Tflops</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">733,231 Tflops</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,980,365 Tflops</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Average
        deployed GPU capacity</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">170.0 GPUs</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">816.7 GPUs</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,153.8 GPUs</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Average
        theoretical GPU compute power related to deployed GPU capacity</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">99,283 Tflops</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">595,289 Tflops</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,646,381 Tflops</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Average
        customer-contracted GPU capacity</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">146.7 GPUs</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">754.7 GPUs</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,082.0 GPUs</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Average
        theoretical GPU compute power related to customer-contracted GPU capacity</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">85,973 Tflops</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">532,238 Tflops</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,513,805Tflops</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Available
        GPU-hours</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,489,200</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">7,154,000</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">7,580,320</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Billable
        GPU-hours</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,284,800</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">6,610,880</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">7,108,448</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Utilization
        of deployed GPU capacity</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">86.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">92.4</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">93.8</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Weighted-average
        remaining customer contract term, as of period end</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">8.7 months</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">4.2 months</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">7.8 months</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Average
contracted GPU supply.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The monthly
average GPU capacity secured under binding supplier arrangements during the applicable period. This metric includes GPU capacity available
to Exascale under binding supplier arrangements during the period and excludes non-binding forecasts, options, allocation indications,
MOUs and similar non-binding arrangements. Monthly average amounts are calculated as the simple average of the monthly capacity amounts
compiled by management for each month in the applicable period. Provides visibility into Exascale&#8217;s access to GPU supply and capacity
sourcing over the applicable period. Management uses this metric for supplier procurement planning, deployment planning, capacity expansion
decisions and alignment of supplier capacity with expected customer demand.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Average
theoretical GPU compute power related to contracted GPU supply.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The monthly
average theoretical compute power associated with average contracted GPU supply during the applicable period, calculated based on the
GPU types and theoretical performance characteristics used by management. Theoretical GPU compute power does not represent actual realized
throughput, which may vary based on workload type, configuration, utilization, software optimization, networking, memory, customer usage
patterns and other factors. Helps investors understand the compute capacity associated with Exascale&#8217;s contracted GPU supply. Management
uses this metric to assess the scale and performance profile of contracted GPU resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Average
deployed GPU capacity.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The monthly
average GPU capacity that was installed, configured and made available for customer workloads on Exascale&#8217;s platform during the
applicable period. Monthly average amounts are calculated as the simple average of the monthly capacity amounts compiled by management
for each month in the applicable period. Helps investors understand the average amount of capacity available for revenue-generating customer
workloads during the period. Management uses this metric to assess deployment progress, available service capacity and operational readiness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 251; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->234<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Average
theoretical GPU compute power related to deployed GPU capacity.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The monthly
average theoretical compute power associated with average deployed GPU capacity during the applicable period, calculated based on the
GPU types and theoretical performance characteristics used by management. Theoretical GPU compute power does not represent actual realized
throughput, which may vary based on workload type, configuration, utilization, software optimization, networking, memory, customer usage
patterns and other factors. Helps investors understand the compute capacity associated with Exascale&#8217;s deployed GPU capacity. Management
uses this metric to assess deployed platform scale and capacity available to support customer workloads.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Average
customer-contracted GPU capacity.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The monthly
average customer demand committed under binding customer arrangements during the applicable period, measured by reference to GPUs committed
to customers or equivalent committed GPU-hours, as applicable, and excluding non-binding MOUs, letters of intent, cancellable trial arrangements,
pipeline opportunities and similar non-binding discussions. Monthly average amounts are calculated as the simple average of the monthly
capacity amounts compiled by management for each month in the applicable period. Provides visibility into committed demand and forward
utilization. Management uses this metric to assess demand visibility, customer commitments, capacity allocation and alignment between
supplier capacity and customer demand.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Average
theoretical GPU compute power related to customer-contracted GPU capacity.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The monthly
average theoretical compute power associated with average customer-contracted GPU capacity during the applicable period, calculated based
on the GPU types and theoretical performance characteristics used by management. Theoretical GPU compute power does not represent actual
realized throughput, which may vary based on workload type, configuration, utilization, software optimization, networking, memory, customer
usage patterns and other factors. Helps investors understand the compute power associated with customer-contracted demand. Management
uses this metric to assess customer demand, capacity allocation and utilization planning.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Available
GPU-hours.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The aggregate
standardized GPU-hours during the applicable period attributable to deployed GPU capacity available to support customer workloads, calculated
as the sum, for each month in the applicable period, of deployed GPU capacity multiplied by 730 hours. Exascale uses a standard 730-hour
month for this calculation and does not adjust the calculation based on differences in the actual number of calendar days in each month.
Available GPU-hours is a standardized capacity metric based on deployed GPU capacity made available for customer workloads and does not
reflect actual customer usage. Serves as the denominator for utilization and helps investors understand the amount of deployed capacity
available to generate revenue. Management uses this metric to monitor platform availability, operating capacity and potential idle capacity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Billable
GPU-hours.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The aggregate
standardized GPU-hours during the applicable period attributable to customer-contracted GPU capacity under reserved or other binding customer
arrangements, calculated as the sum, for each month in the applicable period, of customer-contracted GPU capacity multiplied by 730 hours.
Exascale uses a standard 730-hour month for this calculation and does not adjust the calculation based on differences in the actual number
of calendar days in each month. Exascale&#8217;s current KPI framework does not separately track or present on-demand GPU-hours as a key
operating metric. On-demand usage, to the extent generated during the periods presented, is discussed through revenue and MD&amp;A rather
than through this KPI. Serves as the numerator for utilization and helps investors understand the portion of available deployed capacity
covered by customer-contracted arrangements. Management uses this metric to evaluate customer commitments, revenue generation and capacity
monetization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 252; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->235<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Utilization
of deployed GPU capacity.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Billable
GPU-hours divided by available GPU-hours for the applicable period. Helps investors evaluate the efficiency with which Exascale monetizes
deployed capacity. Management uses this metric to identify idle capacity, evaluate demand, plan procurement, assess pricing and support
expansion decisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Weighted-average
remaining customer contract term.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Weighted-average
remaining term of binding fixed-term customer contracts as of the end of the applicable period, weighted by monthly committed revenue.
Helps investors assess revenue visibility, renewal timing and customer contract duration. Management uses this metric to manage renewals,
assess revenue visibility and align customer commitments with supplier arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Exascale
reviews supplier pricing and procurement cost information in connection with procurement planning, customer pricing, margin management
and supplier negotiations. However, Exascale does not use a single standardized average procurement cost per GPU-hour or per billable
GPU-hour as a key operating metric. Exascale&#8217;s supplier arrangements are primarily usage-based and bundled with related infrastructure
services, and pricing may vary based on GPU type, capacity configuration, usage volume, supplier terms, deposits, prepayments, service
period, hosting, power, network connectivity and prevailing market conditions. Exascale therefore discusses supplier cost trends through
cost of revenue, gross margin and qualitative period-over-period MD&amp;A discussion, rather than presenting a separate unit-cost KPI.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>SPECIFIC
FACTORS AFFECTING OUR RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">As AI
infrastructure provider, Exascale&#8217;s operational performance is shaped by key factors tied to the rapid evolution of the AI industry.
While influenced by these broader industry trends, Exascale believes its results of operations are more directly affected by company-specific
factors, including the following major factors:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Our
ability to secure a stable and competitive supply of advanced GPU chips</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our business
depends on its ability to obtain a reliable and cost-competitive supply of advanced GPU chips. Given the current global environment, in
which supply chains are concentrated and subject to periodic constraints, access to GPUs is an important input to our capacity planning,
ability to meet customer requirements, and anticipated growth. GPUs represent a foundational component of our technology platform, and
limitations in supply could adversely affect operating efficiency and service delivery. We believe that its current chip technology compares
favorably with available alternatives and supports customer acquisition and retention.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Our
ability to manage computing power supply under an asset-light model</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We operates
under an asset-light model and does not own core hardware. As a result, our service offerings depend on the availability of GPU servers
and related computing capacity sourced and integrated from third-party providers. Supplier concentration, access to advanced GPU hardware,
procurement terms, and delivery timelines may affect our available capacity, cost structure, and deployment flexibility. Disruptions in
the supply chain, changes in technology, or modifications to relationships with key suppliers could adversely impact the business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We seek
to mitigate these risks through supplier relationship management, capacity planning, and the use of contractual arrangements designed
to provide flexibility where feasible. We have expanded its available computing capacity over time, which supports anticipated business
growth and may contribute to improved procurement efficiency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 253; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->236<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Our
ability to develop and scale our technical and operational platform</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our service
offerings depend on the performance and reliability of its software platform and operational systems, which enable the delivery and management
of computing services. While GPU hardware is sourced from third parties, our software and operational capabilities are required to allocate
resources, manage performance, support automation, and provide customer support at scale. The effectiveness of this technical and operational
layer influences service reliability, operating costs, and the customer experience.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We continue
to develop and enhance its internal software platform and operational processes, including the addition of new functionality intended
to address evolving customer requirements and support the scaling of its services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Our
ability to manage third-party data center dependencies</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We rely
on third-party providers for data center facilities, including space, power, cooling, and network connectivity. These infrastructure components
are not directly controlled by Exascale, and their availability, cos and performance may affect service delivery. Under its asset-light
model, we seek to manage these dependencies through capacity planning, system architecture design, service-level management, and the use
of multiple facilities where feasible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our approach
is intended to support operational continuity and provide flexibility as service demand evolves; however, disruptions or changes in third-party
data center relationships could adversely impact operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Our
ability to acquire, retain, and expand our customer base</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our results
depend on continued customer demand for its services and its ability to attract and retain customers in a competitive market. Serving
both AI developers and enterprise customers requires offerings that meet customer performance, reliability, and cost expectations, as
well as the ability to respond to evolving use cases and requirements. Competition, changes in customer preferences, or the availability
of alternative solutions could affect customer acquisition and retention.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We seek
to support customer retention by maintaining service quality and reliability and by demonstrating the value of its services over time.
For the fiscal year ended June&#160;30, 2025, our customer renewal rate exceeded 90%. During the same period, our customer base increased
from 12 customers as of June&#160;30, 2024 to over 50 customers as of June&#160;30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Our
ability to achieve profitability through cost management</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Under
its asset-light model, we incur operating expenses in place of significant capital expenditures. Our primary cost components include GPU
hardware resources, data center hosting, power, and network services. As a result, operating results are influenced by the company&#8217;s
ability to manage these ongoing costs in relation to revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We seek
to improve financial performance by managing resource utilization, negotiating procurement arrangements, and applying pricing practices
intended to reflect cost structures and market conditions, while maintaining service quality. There can be no assurance that these efforts
will result in sustained profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>KEY
COMPONENTS OF RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">During
the year ended June&#160;30, 2024, we operated for 10 months since initiating revenue generation in September&#160;2023, achieving total
revenue of $1.3 million. During the year ended June&#160;30, 2025, Exascale had total revenues of $7.0 million, reflecting an 431.8% increase
compared to the previous fiscal year. During the nine months ended March&#160;31, 2025 and 2026, total revenue of $4.5 million and $10.6
million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 254; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->237<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our business
is primarily comprised of the following two revenue streams: (i) providing intelligent computing power service to commercial enterprise
clients with substantial GPU computing requirements, and (ii) providing comprehensive data center service to data center asset owners.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><i>(i)
Revenue from intelligent computing power service</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We leverage
our expertise in high-performance computing and cloud-native architectures to build and operate stable, efficient, and scalable GPU computing
platforms through modular data center design and liquid cooling technology. We use these platforms to provide computing resources for
large-scale AI training, model inference, and high-performance scientific computing to commercial enterprise clients with substantial
GPU computing requirements. Supporting services include GPU server environment deployment, cluster scheduling and performance optimization,
high-speed network interconnection, real-time monitoring and intelligent alerting systems, as well as industry-compliant security and
regulatory assurance. Under ASC 606, all related services are accounted for as a single performance obligation, and revenue is recognized
on a straight-line basis over the contractual service period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><i>(ii)
Revenue from comprehensive data center service</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We leverage
our project experience in infrastructure management, cluster optimization, and system monitoring to provide full-cycle operational support
to data center asset owners. Services encompass facility environment deployment, network architecture implementation, security and compliance
system development, daily operational monitoring, and emergency fault response. Under ASC 606, revenue from each distinct service, which
constitutes a separate performance obligation, is recognized on a straight-line basis over the contractual service period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Cost
of Revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our cost
of revenues primarily include computing power service, professional service fees and staff costs and employee benefits. All the cost of
revenues are recognized in the period in which the related services occur or the benefits are received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Operating
expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our selling
and marketing expenses primarily includes: (i) advertising and promotion expenses, (ii) staff costs, employee benefits and share-based
compensation, and (iii) travel and other routine office expenses. All expenses are recognized in the period in which the related services
occur or the benefits are received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our research
and development expenses mainly consist of software development outsourcing service fees, staff costs and employee benefits, and testing
expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our general
and administrative expenses mainly consist of staff costs and employee benefits, professional service fees, depreciation expenses and
other operating expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 255; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->238<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>RESULTS
OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Fiscal
year ended June&#160;30, 2024 compared to fiscal year ended June&#160;30, 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The following
table summarizes the results of our operations for the years ended June&#160;30, 2024 and 2025 and provides information regarding the
dollar and percentage increase or (decrease) during such periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the Years Ended<br/>June&#160;30,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="font: 10pt Times New Roman; text-align: center; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2024</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>Fluctuation</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; width: 28%"><b>Revenues</b></td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenue
        from intelligent computing power service</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,193,982</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">90.5</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">6,546,249</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">93.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">5,352,267</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">448.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Revenue
        from comprehensive data center service</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">125,133</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">9.5</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">469,263</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">6.7</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">344,130</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">275.0</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Total
        revenues</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>1,319,115</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>100.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>7,015,512</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>100.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>5,696,397</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>431.8</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Cost
        of revenues</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(1,263,548</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-95.8</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(5,910,315</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-84.2</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(4,646,767</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">367.8</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Gross
        profit</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>55,567</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>4.2</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>1,105,197</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>15.8</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>1,049,630</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>1888.9</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Operating
        expenses</b></td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Selling
        and marketing expenses</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(262,614</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-19.9</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(989,155</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-14.1</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(726,541</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">276.7</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">General
        and administrative expenses</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(273,349</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-20.7</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(362,982</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-5.2</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(89,633</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">32.8</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Research
        and development expenses</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(1,365,433</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-103.5</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(2,797,906</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-39.9</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(1,432,473</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">104.9</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Total
        operating expenses</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(1,901,396</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-144.1</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(4,150,043</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-59.2</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(2,248,647</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>118.3</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Loss
        from operations</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(1,845,829</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-139.9</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(3,044,846</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-43.4</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(1,199,017</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>65.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Change
        in fair value of simple agreements for future equity</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(3,110,518</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-235.8</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(4,614,821</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-65.8</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(1,504,303</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">48.4</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Loss
        before income tax expenses</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(4,956,347</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-375.7</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(7,659,667</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-109.2</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(2,703,320</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>54.5</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Income
        tax expenses</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">-</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">-</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">-</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Net
        loss</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(4,956,347</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-375.7</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(7,659,667</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-109.2</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(2,703,320</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>54.5</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Loss
        per ordinary share</b></td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Basic
        and diluted</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">$</td>
    <td style="font: 10pt Times New Roman; text-align: right">(3,304.23</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">$</td>
    <td style="font: 10pt Times New Roman; text-align: right">(5,106.44</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Weighted
        average number of ordinary shares</b></td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Basic
        and diluted</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,500</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,500</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Pro
        forma loss per share:</b></td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Class
        A and Class B ordinary shares&#8212;basic and diluted (unaudited)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">$</td>
    <td style="font: 10pt Times New Roman; text-align: right">(3,304.23</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">$</td>
    <td style="font: 10pt Times New Roman; text-align: right">(5,106.44</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Weighted
        average number of ordinary shares used in pro forma loss per share computation:</b></td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Class
        A and Class B ordinary shares&#8212;basic and diluted (unaudited)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,500</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,500</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 256; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->239<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Exascale&#8217;s
revenues consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the Years Ended <br/> June 30,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman; text-align: center; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman; text-align: center; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2024</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>Fluctuation</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; width: 28%"><b>Revenues</b></td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenue
        from intelligent computing power service</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,193,982</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">90.5</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">6,546,249</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">93.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">5,352,267</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">448.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Revenue
        from comprehensive data center service</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">125,133</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">9.5</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">469,263</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">6.7</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">344,130</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">275.0</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total
        revenues</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>1,319,115</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 1.25pt"><b>100.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>7,015,512</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 1.25pt"><b>100.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>5,696,397</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 1.25pt"><b>431.8</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>%</b></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our
total revenue increased by $5.7 million, or 431.8%, from $1.3 million for the year ended June&#160;30, 2024 to $7.0 million for the
year ended June&#160;30, 2025. This exceptional growth was primarily driven by revenue from our intelligent computing power service,
which increased by approximately $5.4 million, or 448.3%, from $1.2 million for the year ended June&#160;30, 2024 to $6.5 million
for the year ended June&#160;30, 2025. This segment constituted 93.3% of our total revenue for fiscal year 2025, up from 90.5% in
the prior fiscal year, solidifying its position as the core driver of our expansion. Revenue from our comprehensive data center
service also contributed to this growth, increasing by $0.4 million, or 275.0%, from $0.1 million for the year ended June&#160;30,
2024 to $0.5 million for the year ended June&#160;30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We quantified
the increase in revenue attributable to expansion within our existing customer base and new customer additions as follows: (i) Expansion
within existing customer base: $2.2 million (approximately 37.8% of total revenue growth), representing increased spending by customers
that generated revenue for the year ended June&#160;30, 2024. The increase in average revenue per existing customer was primarily associated
with higher service utilization, as average service usage increased from 4.7 months for the year ended June&#160;30, 2024 to 8.2 months
for the year ended June&#160;30, 2025, and with a 51% increase in average monthly service fees, which we believe reflects increased customer
demand for compute services and higher workload and performance requirements. (ii) New customers: $3.5 million (approximately 62.2% of
total revenue growth), representing revenue from customers that first generated revenue for the year ended June&#160;30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The revenue
growth analysis for our two revenue stream is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">(1) Revenue
from intelligent computing power service</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our revenue
from intelligent computing power service increased by approximately $5.4 million, or 448.3%, from $1.2 million for the year ended June&#160;30,
2024 to $6.5 million for the year ended June&#160;30, 2025. the increase was mainly due to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><i>Expansion
and Efficiency Enhancement of Our Core Resource Pool</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our intelligent
computing power resource pool has seen significant improvements in both scale and performance. Through strategic investments, we have
not only expanded our total computing power supply but also optimized our resource scheduling efficiency and stability, particularly with
the latest GPU computing cards. This enables us to meet the stringent demands of high-end customers for low-latency, highly reliable computing
power while supporting more high-load clients, laying a solid physical foundation for revenue scaling.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 257; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->240<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><i>Deepening
Product Value and Enhancing Solution Added Value</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We continuously
enhance the value delivered to customers through rapid iteration of product features and strengthening of our technical service systems.
Specific manifestations include: (i) Rapid evolution of product functionality: Keeping pace with cutting-edge demands, we have consistently
enhanced core features such as model training optimization, inference acceleration, and dedicated resource scheduling, enabling customers
to utilize computing power more efficiently. (ii) Professionalization of technical services: We provide in-depth support for technology-driven
clients, including architecture consulting, performance tuning, and rapid troubleshooting, transforming from a &#8220;resource provider&#8221;
to a &#8220;technology partner.&#8221; (iii) Enhancement of solution added value: By offering integrated solutions that include software
tool chains, industry optimization practices, and ongoing technical support, we help customers reduce total cost of ownership and accelerate
innovation, thereby achieving higher average revenue per customer and deeper customer engagement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><i>High
Customer Renewal Rate and Strengthening of Long-Term Partnerships</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our customer
agreements generally fall into two categories, namely, (i) agreements for compute services and (ii) agreements for GPU cluster management
services and related infrastructure support services. With respect to compute services, we offer both reserved arrangements and on-demand
arrangements. Reserved arrangements generally provide committed intelligent computing power services for a defined service term. Historically,
most reserved arrangements have had initial terms of approximately one year, although actual contract durations have generally ranged
from approximately three months to three years. On-demand arrangements are generally provided under our platform terms and conditions
and allow customers to obtain services on a pay-as-you-go basis without a fixed committed service term. With respect to GPU cluster management
services and related infrastructure support services, we generally enter into customer agreements that provide for services to be delivered
either over a defined service period on a fixed-term basis or on a project basis to complete specified scope, deliverables, or implementation
work within an agreed timeframe.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">During
the fiscal year ended June&#160;30, 2024, we had 12 customers across our current revenue-generating offerings, of which 11 continued to
generate revenue during the fiscal year ended June&#160;30, 2025. Accordingly, our customer renewal rate was approximately 92% (11 out
of 12). The average revenue per enterprise customer increased from $110,000 to $250,000, directly contributing to stable revenue growth.
The high renewal rate stems from:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 0.25in; text-align: justify">(i)</td>
    <td style="font: 10pt Times New Roman; text-align: justify"><i>Industry-leading hardware and software
        in our computing services</i>: The reliability and performance of our products consistently meet standards.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 0.25in; text-align: justify">(ii)</td>
    <td style="font: 10pt Times New Roman; text-align: justify"><i>Establishment of long-term partnerships</i>:
        Transitioning from transactional relationships to strategic collaborations, we have signed long-term framework agreements with several
        leading customers, ensuring sustainable and predictable revenue.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><i>Expanded
our market presence.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">During
the initial operational phase of year ended June&#160;30, 2024, our revenue primarily originated from early-established regional markets,
such as Canada and Hong Kong. Entering year ended June&#160;30, 2025, we successfully extended our reach to strategic markets including
Singapore and the United States, resulting in a more balanced and diversified revenue structure. Specifically, the combined contribution
from the Singapore and U.S. markets amounted to $4.6 million, accounting for 65.1% of total revenue, marking a substantial breakthrough
in our global expansion strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Overall,
our growth model has established a virtuous cycle encompassing &#8220;supply capacity, product value, customer relationships, and market
presence&#8221;: resource expansion supports scale growth, product evolution enhances monetization capabilities, customer relationships
provide a stable foundation, and market optimization strengthens development resilience. This comprehensive growth system has laid a solid
groundwork for our future sustainable development, while also validating the effectiveness of our strategic execution and the sustainability
of our business model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 258; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->241<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">(2) Revenue
from comprehensive data center service</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our revenue
from our comprehensive data center service increased by $0.4 million, or 275.0%, from $0.1 million for the year ended June&#160;30, 2024
to $0.5 million for the year ended June&#160;30, 2025. The increase was mainly due to our client base has grown from 1 for the year ended
June&#160;30, 2024 to 2 for the year ended June&#160;30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Cost
of revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our cost
of revenues increased by $4.6 million, from $1.3 million for the year ended June&#160;30, 2024 to $5.9 million for the year ended June&#160;30,
2025, representing a growth rate of 367.8%. This increase primarily reflects the scaling of our business operations in line with revenue
expansion, while demonstrating improved cost efficiency as evidenced by the reduction in the cost-to-revenue ratio from 95.8% to 84.2%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Gross
profit and gross margin</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The following
table sets forth our gross profit and gross margin by revenue types for the years indicated:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the<br/>Years Ended<br/>June&#160;30,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman; text-align: center; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman; text-align: center; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2024</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>Fluctuation</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; width: 52%">Revenues</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">1,319,115</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">7,015,512</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">5,696,397</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">431.8</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">%</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Cost
        of revenues</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(1,263,548</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(5,910,315</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(4,646,767</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">367.8</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Gross
        profit</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>55,567</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>1,105,197</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>1,049,630</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>1,888.9</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Gross
        margin</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right">4.2</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right">15.8</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our gross
profit increased by $1.0 million, from $0.1 million for the year ended June&#160;30, 2024 to $1.1 million for the year ended June&#160;30,
2025, representing a growth rate of 1,888.9%. This substantial improvement was accompanied by a significant expansion in gross margin,
which rose from 4.2% to 15.8%, reflecting an increase of 11.6 percentage points.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The simultaneous
improvement in both gross profit and gross margin reflects our ability to maintain scalable operational efficiency alongside rapid revenue
expansion. This margin enhancement was achieved primarily through continuous optimization of our technology infrastructure management,
energy efficiency initiatives, and dynamic resource scheduling systems. These measures effectively contained the growth rate of cost of
revenues to 367.8%, which remained significantly below our revenue growth rate of 431.8%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Operating
expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our operating
expenses consist of selling and marketing expenses, general and administrative expenses, and research and development expenses. Operating
expenses increased by $2.2 million, or 118.3%, from $1.9 million for the year ended June&#160;30, 2024 to $4.2 million for the year ended
June&#160;30, 2025. The increase was primarily due to: (i) research and development expenses increased by $1.4 million; and (ii) selling
and marketing expenses increased by $0.7 million, partially offset by (iii) a moderate increase in general and administrative expenses
of $0.1 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The following
table sets forth our operating expenses, both in absolute amount and as a percentage of the total revenues, for the years indicated:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 259; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->242<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the Years Ended <br/> June 30,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman; text-align: center; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman; text-align: center; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2024</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>Fluctuation</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; width: 28%"><b>Operating
        expenses</b></td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Selling
        and marketing expenses</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(262,614</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-19.9</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(989,155</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-14.1</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(726,541</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">276.7</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">General
        and administrative expenses</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(273,349</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-20.7</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(362,982</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-5.2</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(89,633</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">32.8</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Research
        and development expenses</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(1,365,433</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">-103.5</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(2,797,906</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">-39.9</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(1,432,473</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">104.9</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total
        operating expenses</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>(1,901,396</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>-144.1</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>(4,150,043</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>-59.2</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>(2,248,647</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>118.3</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>%</b></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our selling
and marketing expenses increased by $0.7 million, or 276.7%, from $0.3 million for the year ended June&#160;30, 2024 to $1.0 million for
the year ended June&#160;30, 2025. This increase was primarily driven by: (i) outsourcing services and share-based compensation expenses
totaling $0.4 million related to the hiring of sales personnel, particularly senior sales staff; (ii) advertising and promotion expenses
of $0.2 million to support brand promotion and market expansion initiatives. Overall, the increase reflects our enhanced marketing efforts
to support business growth and investments in new regional markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">General
and administrative expenses increased by $0.1 million, or 32.8%, from $0.3 million for the year ended June&#160;30, 2024 to $0.4 million
for the year ended June&#160;30, 2025. In the context of rapid business expansion, this moderate increase reflects effective control
over administrative expenditures and operational efficiency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Research
and development expenses increased by $1.4 million, or 104.9%, from $1.4 million for the year ended June&#160;30, 2024 to $2.8 million
for the year ended June&#160;30, 2025. This increase demonstrates our continued commitment to technological innovation and product development
to strengthen the core competitiveness of our intelligent computing power services and comprehensive for data center.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Loss
from operations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our loss
from operations amounted to $3.0 million for the year ended June&#160;30, 2025, compared to $1.8 million for the year ended June&#160;30,
2024, representing an increase in operating loss of $1.2 million. This change was primarily attributable to the significant growth in
operating expenses as we scaled the business and invested in market expansion and research and development activities, which was partially
offset by the substantial revenue growth we achieved during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Change
in fair value of simple agreements for future equity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The change
in fair value of simple agreements for future equity resulted in a loss of $4.6 million for the year ended June&#160;30, 2025, compared
to a loss of $3.1 million for the year ended June&#160;30, 2024. The reduction in loss of $1.5 million reflects the relative stabilization
in the valuation of these instruments during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Net
loss</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our net
loss increased by $2.7 million, from $5.0 million for the year ended June&#160;30, 2024 to $7.7 million for the year ended June&#160;30,
2025. The increase in net loss was primarily driven by the growth in operating loss and the fair value adjustment on simple agreements
for future equity, as we continued to invest in scaling our infrastructure, expanding our market presence, and advancing our technology
platform.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 260; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->243<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Loss
per share and pro forma loss per share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Basic
loss per share and diluted loss per share have been calculated in accordance with ASC 260, &#8220;Earnings Per Share&#8221;. Loss per
share for the years ended June&#160;30, 2024 and 2025 were $3,304.23 and $5,106.44, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Pursuant
to the resolution of the board of directors on January&#160;8, 2026, the authorized share capital of 1,500 ordinary shares was re-designated
into 303 Class A ordinary shares and 1,197 Class B ordinary shares. Holders of Class A ordinary shares and Class B ordinary shares have
the same rights, except for voting and conversion rights. Each Class A ordinary share is entitled to one vote, and each Class B ordinary
share is entitled to twenty votes and is convertible into one Class A ordinary share at any time by the holder thereof. Class A ordinary
shares are not convertible into Class B ordinary shares under any circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The unaudited
pro forma loss per share is computed using the weighted-average number of ordinary shares outstanding as of June&#160;30, 2024 and 2025,
and assumes the completion of re-designation on July&#160;1, 2023. Pro forma loss per share for the years ended June&#160;30, 2024 and
2025 were $3,304.23 and $5,106.44, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Three
and Nine months ended March&#160;31, 2025 compared to Three and Nine months ended March&#160;31, 2026</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The following
table summarizes the results of our operations for the three months ended March&#160;31, 2025 and 2026 and provides information regarding
the dollar and percentage increase or (decrease) during such periods:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the Three Months Ended<br/> March&#160;31,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="font: 10pt Times New Roman; text-align: center; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2026</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>Fluctuation</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; width: 28%"><b>Revenues</b></td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenue
        from intelligent computing power service</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,764,357</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">94.7</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">3,726,656</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">99.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,962,299</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">111.2</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Revenue
        from comprehensive data center service</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">97,801</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">5.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">27,930</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">0.7</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(69,871</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-71.4</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Total
        revenues</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>1,862,158</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>100.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>3,754,586</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>100.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>1,892,428</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>101.6</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Cost
        of revenues</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(1,649,077</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-88.6</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(3,167,659</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-84.4</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(1,518,582</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">92.1</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Gross
        profit</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>213,081</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>11.4</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>586,927</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>15.6</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>373,846</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>175.4</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Operating
        expenses</b></td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Selling
        and marketing expenses</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(378,511</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-20.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(104,729</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-2.8</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">273,782</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-72.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">General
        and administrative expenses</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(103,107</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-5.5</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(468,696</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-12.5</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(365,589</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">354.6</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Research
        and development expenses</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(377,999</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-20.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(1,235,476</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-32.9</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(857,477</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">226.8</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Total
        operating expenses</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(859,617</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-46.1</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(1,808,901</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-48.2</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(949,284</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>110.4</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Loss
        from operations</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(646,536</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-34.7</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(1,221,974</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-32.6</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(575,438</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>89.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Change
        in fair value of simple agreements for future equity</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(890,523</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-47.8</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(1,410,457</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-37.6</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(519,934</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">58.4</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Loss
        before income tax expenses</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(1,537,059</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-82.5</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(2,632,431</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-70.2</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(1,095,372</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>71.3</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Income
        tax expenses</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">-</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">-</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>-</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Net
        loss</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(1,537,059</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-82.5</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(2,632,431</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-70.2</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(1,095,372</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>71.3</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Loss
        per ordinary share<sup>(1)</sup></b></td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Basic
        and diluted</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">$</td>
    <td style="font: 10pt Times New Roman; text-align: right">(1,024.70</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">$</td>
    <td style="font: 10pt Times New Roman; text-align: right">(1,754.95</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Weighted
        average number of ordinary shares</b></td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Basic
        and diluted</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,500</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,500</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(1):</td><td style="text-align: justify">On January&#160;8, 2026,
the Company re-designated its authorized share capital of 1,500 ordinary shares to 303 Class A ordinary shares and 1,197 Class B ordinary
shares.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 261; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->244<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The following
table summarizes the results of our operations for the nine months ended March&#160;31, 2025 and 2026 and provides information regarding
the dollar and percentage increase or (decrease) during such periods:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the Nine Months Ended<br/>March&#160;31,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="font: 10pt Times New Roman; text-align: center; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2026</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>Fluctuation</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; width: 28%"><b>Revenues</b></td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenue
        from intelligent computing power service</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">4,168,467</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">93.1</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">10,441,509</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">98.9</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">6,273,042</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">150.5</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Revenue
        from comprehensive data center service</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">307,418</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">6.9</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">119,822</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">1.1</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(187,596</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-61.0</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Total
        revenues</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>4,475,885</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>100.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>10,561,331</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>100.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>6,085,446</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>136.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Cost
        of revenues</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(3,827,444</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-85.5</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(8,902,966</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-84.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(5,075,522</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">132.6</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Gross
        profit</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>648,441</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>14.5</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>1,658,365</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>15.7</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>1,009,924</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>155.7</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Operating
        expenses</b></td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Selling
        and marketing expenses</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(726,914</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-16.2</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(310,582</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-2.9</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">416,332</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-57.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">General
        and administrative expenses</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(268,159</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-6.0</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(928,255</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-8.8</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(660,096</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">246.2</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Research
        and development expenses</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(2,115,853</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-47.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(3,238,185</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-30.7</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(1,122,332</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">53.0</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Total
        operating expenses</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(3,110,926</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-69.5</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(4,477,022</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-42.4</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(1,366,096</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>43.9</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Loss
        from operations</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(2,462,485</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-55.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(2,818,657</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-26.7</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(356,172</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>14.5</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Change
        in fair value of simple agreements for future equity</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(3,716,052</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-83.0</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(5,098,320</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-48.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(1,382,268</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">37.2</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Loss
        before income tax expenses</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(6,178,537</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-138.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(7,916,977</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-75.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(1,738,440</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>28.1</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Income
        tax expenses</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>-</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>-</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>-</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Net
        loss</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(6,178,537</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-138.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(7,916,977</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>-75.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>(1,738,440</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt"><b>28.1</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Loss
        per ordinary share<sup>(1)</sup></b></td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Basic
        and diluted</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">$</td>
    <td style="font: 10pt Times New Roman; text-align: right">(4,119.02</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">$</td>
    <td style="font: 10pt Times New Roman; text-align: right">(5,277.98</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Weighted
        average number of ordinary shares</b></td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Basic
        and diluted</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,500</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,500</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(1):</td><td style="text-align: justify">On January&#160;8, 2026,
the Company re-designated its authorized share capital of 1,500 ordinary shares to 303 Class A ordinary shares and 1,197 Class B ordinary
shares.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 262; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->245<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Exascale&#8217;s
revenues consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the Three Months Ended<br/>March&#160;31,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="font: 10pt Times New Roman; text-align: center; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2026</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>Fluctuation</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; width: 28%"><b>Revenues</b></td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenue
        from intelligent computing power service</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,764,357</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">94.7</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">3,726,656</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">99.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">1,962,299</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">111.2</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Revenue
        from comprehensive data center service</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">97,801</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">5.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">27,930</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">0.7</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(69,871</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-71.4</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total
        revenues</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>1,862,158</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 1.25pt"><b>100.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>3,754,586</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 1.25pt"><b>100.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>1,892,428</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 1.25pt"><b>101.6</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>%</b></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the Nine Months Ended<br/>March&#160;31,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="font: 10pt Times New Roman; text-align: center; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2026</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>Fluctuation</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; width: 28%"><b>Revenues</b></td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenue
        from intelligent computing power service</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">4,168,467</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">93.1</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">10,441,509</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">98.9</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">6,273,042</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">150.5</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Revenue
        from comprehensive data center service</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">307,418</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">6.9</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">119,822</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">1.1</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(187,596</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 0.5pt">-61.0</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total
        revenues</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>4,475,885</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 1.25pt"><b>100.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>10,561,331</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 1.25pt"><b>100.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>6,085,446</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 1.25pt"><b>136.0</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>%</b></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our total
revenue increased by $1.9 million, or 101.6%, from $1.9 million for the three months ended March&#160;31, 2025 to $3.8 million for the
three months ended March&#160;31, 2026. This increase was primarily attributable to the increase of $2.0 million, or 111.2%, from intelligent
computing power service revenue. Similarly, our total revenue increased by $6.1 million, or 136.0%, from $4.5 million for the nine months
ended March&#160;31, 2025 to $10.6 million for the nine months ended March&#160;31, 2026. This increase was primarily attributable to
the increase of $6.3 million, or 150.5%, from intelligent computing power service revenue, partially offset by a decrease of $0.2 million,
or 61.0%, from comprehensive data center service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We quantified
the increase in revenue attributable to expansion within our existing customer base and new customer additions as follows: (i) Expansion
within existing customer base: $4.6 million (approximately 75.7% of total revenue growth), representing increased spending by customers
that generated revenue for nine months ended March&#160;31, 2025. The increase in average revenue per existing customer was primarily
associated with higher service utilization, as average service usage increased from 7.9 months for the nine months ended March&#160;31,
2025 to 8.8 months for the nine months ended March&#160;31, 2026, and with a 112.5% increase in average monthly service fees, which we
believe reflects increased customer demand for compute services and higher workload and performance requirements.(ii) New customers: $1.5
million (approximately 24.3% of total revenue growth), representing revenue from customers that first generated revenue for the nine months
ended March&#160;31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The year-over-year
increase in revenues for each three-month and nine-month period ended March&#160;31 was primarily driven by the expansion and efficiency
enhancement of our core resource pool, efforts to deepen product value and enhance the value-added nature of our solutions, a high customer
renewal rate, and strengthened long-term partnerships.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 263; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->246<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The revenue
growth analysis for our two revenue streams is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">(1) Revenue
from intelligent computing power service</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The year-over-year
increase in intelligent computing power service revenue for each three-month and nine-month period ended March&#160;31 was primarily driven
by accelerated expansion in the United States and Canada and higher customer value contribution from deeper technical partnerships and
higher-value integrated solutions, as reflected by an increase in average revenue per enterprise customer from approximately $180,000
to $420,000. For the three months ended March&#160;31, 2026, revenue from the United States and Canada increased to $1.6 million and $1.1
million, respectively, compared to $0.6 million and $0.4 million for the three months ended March&#160;31, 2025. For the nine months ended
March&#160;31, 2026, revenue from the United States and Canada increased to $4.6 million and $3.2 million, respectively, compared to $1.3
million and $1.1 million for the nine months ended March&#160;31, 2025. This reflects our successful shift toward deeper technical partnerships
and high-value integrated solutions, which have strengthened customer loyalty and laid a solid foundation for sustained growth.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">(2) Revenue
from comprehensive data center service</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Revenue
from comprehensive data center service decreased year-over-year for each three-month and nine-month period ended March&#160;31, and remained
relatively small in absolute dollars. As a percentage of total revenue, it decreased from 5.3% to 0.7% and from 6.9% to 1.1%. These decreases
reflect the segment&#8217;s early-stage nature and limited scale, including a relatively small and still-evolving customer base, and may
not be indicative of future results. We believe this performance is not indicative of its long-term potential. With continued investment
and market development efforts, we expect this segment to expand as we broaden our customer base and scale our service offerings, although
the timing and extent of such growth remain subject to execution and market conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Cost
of revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our cost
of revenues increased by $1.5 million, or 92.1%, from $1.7 million for the three months ended March&#160;31, 2025 to $3.2 million for
the three months ended March&#160;31, 2026. Similarly, our cost of revenues increased by $5.1 million, or 132.6%, from $3.8 million for
the nine months ended March&#160;31, 2025 to $8.9 million for the nine months ended March&#160;31, 2026. The change followed the same
trend with our increased revenues in the same period, reflecting the expansion of the customer base. Cost of revenues as a percentage
of revenues remained relatively stable, reflecting generally consistent unit economics over the periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Gross
profit and gross profit margin</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the<br/>Three Months Ended<br/>March&#160;31,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="font: 10pt Times New Roman; text-align: center; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2026</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>Fluctuation</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenues</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">1,862,158</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">3,754,586</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">1,892,428</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">101.6</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">%</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Cost
        of revenues</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(1,649,077</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(3,167,659</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(1,518,582</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">92.1</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Gross
        profit</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>213,081</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>586,927</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>373,846</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>175.4</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Gross
        margin</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right">11.4</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right">15.6</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 264; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->247<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the<br/>Nine Months Ended<br/>March&#160;31,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="font: 10pt Times New Roman; text-align: center; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2026</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>Fluctuation</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenues</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">4,475,885</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">10,561,331</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">6,085,446</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">136.0</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">%</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Cost
        of revenues</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(3,827,444</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(8,902,966</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(5,075,522</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">132.6</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Gross
        profit</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>648,441</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>1,658,365</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>1,009,924</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right"><b>155.7</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>%</b></td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Gross
        margin</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right">14.5</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right">15.7</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our gross
profit increased by $0.4 million or 175.4%, from $0.2 million for the three months ended March&#160;31, 2025 to $0.6 million for the three
months ended March&#160;31, 2026. Similarly, our gross profit increased by $1.0 million or 155.7%, from $0.7 million for the nine months
ended March&#160;31, 2025 to $1.7 million for the nine months ended March&#160;31, 2026. It was primarily attributable to the increase
in revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our gross
profit margin increased by 4.2% from 11.4% for the three months ended March&#160;31, 2025 to 15.6% for the three months ended March&#160;31,
2026. Similarly, our gross profit margin increased by 1.2% from 14.5% for the nine months ended March&#160;31, 2025 to 15.7% for the nine
months ended March&#160;31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Operating
expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the Three Months Ended<br/>March&#160;31,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="font: 10pt Times New Roman; text-align: center; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2026</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>Fluctuation</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Operating
        expenses</b></td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Selling
        and marketing expenses</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(378,511</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-20.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(104,729</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-2.8</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">273,782</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-72.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">General
        and administrative expenses</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(103,107</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-5.5</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(468,696</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-12.5</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(365,589</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">354.6</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Research
        and development expenses</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(377,999</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">-20.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(1,235,476</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">-32.9</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(857,477</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">226.8</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total
        operating expenses</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>(859,617</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>-46.1</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>(1,808,901</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>-48.2</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>(949,284</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>110.4</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>%</b></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the Nine Months Ended<br/>March&#160;31,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="font: 10pt Times New Roman; text-align: center; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2026</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>Fluctuation</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Operating
        expenses</b></td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Selling
        and marketing expenses</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(726,914</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-16.2</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(310,582</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-2.9</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">416,332</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-57.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">General
        and administrative expenses</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(268,159</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-6.0</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(928,255</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">-8.8</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(660,096</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">246.2</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Research
        and development expenses</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(2,115,853</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">-47.3</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(3,238,185</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">-30.7</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(1,122,332</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">53.0</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">%</td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total
        operating expenses</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>(3,110,926</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>-69.5</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>(4,477,022</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>-42.4</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>%</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>(1,366,096</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>43.9</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>%</b></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 265; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->248<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our operating
expenses consist of selling and marketing expenses, general and administrative expenses, and research and development expenses. Operating
expenses increased by $0.9 million, or 110.4% from $0.9 million for the three months ended March&#160;31, 2025 to $1.8 million for the
three months ended March&#160;31, 2026. The increase was mainly due to our investment in research and development expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Similarly,
operating expenses increased by $1.4 million, or 43.9% from $3.1 million for the nine months ended March&#160;31, 2025 to $4.5 million
for the nine months ended March&#160;31, 2026. The increase was primarily attributable to: (i) research and development expenses increased
by $1.1 million, from $2.1 million to $3.2 million, (ii) general and administrative expenses increased by $0.6 million, from $0.3 million
to $0.9 million, reflecting our continued strategic focus on enhancing our intelligent computing platform and service capabilities, and
partly offset by selling and marketing expenses decreased by $0.4 million, from $0.7 million to $0.3 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Selling
and marketing expenses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our Selling
and marketing expenses declined for the three and the nine months ended March&#160;31, 2026; given their small scale, these changes were
immaterial to our results of operations. The decrease was primarily driven by lower share-based compensation expense and reduced marketing
and promotional spending. We expect our selling expenses to remain relatively stable as a percentage to total revenue in the foreseeable
future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>General
and administrative expenses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our general
and administrative expenses increased significantly by $0.4 million or 354.6%, from $0.1 million for the three months ended March&#160;31,
2025 to $0.5 million for the three months ended March&#160;31, 2026. Similarly, our general and administrative expenses increased significantly
by $0.6 million or 246.2%, from $0.3 million for the nine months ended March&#160;31, 2025 to $0.9 million for the nine months ended March&#160;31,
2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The increase
was primarily attributable to salaries and compensations paid to operational support staff and professional fees related to consulting
and audit. Despite the increase, we believe our general and administrative spending remained disciplined and aligned with our ongoing
focus on administrative cost control and operating efficiency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Research
and development expenses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our research
and development expenses increased by $0.8 million or 226.8%, from $0.4 million for the three months ended March&#160;31, 2025 to $1.2
million for the three months ended March&#160;31, 2026. Similarly, our research and development expenses increased by $1.1 million or
53.0%, from $2.1 million for the nine months ended March&#160;31, 2025 to $3.2 million for the nine months ended March&#160;31, 2026.
We expect to continue increasing our investment in research and development to enhance our product capabilities and maintain our competitiveness
in the market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Loss
from operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">As a result
of the foregoing, we incurred an loss from operations of $0.6 million and $1.2 million for the three months ended March&#160;31, 2025
and 2026, respectively, and $2.5 million and $2.8 million for the nine months ended March&#160;31, 2025 and 2026, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Change
in fair value of simple agreements for future equity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We recorded
change in fair value of simple agreements for future equity of $0.9 million and $1.4 million for the three months ended March&#160;31,
2025 and 2026, respectively, and $3.7 million and $5.1 million for the nine months ended March&#160;31, 2025 and 2026, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 266; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->249<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Net
loss</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">As a result
of the foregoing, we incurred net loss of $1.5 million and $2.6 million for the three months ended March&#160;31, 2025 and 2026, respectively,
and $6.2 million and $7.9 million for the nine months ended March&#160;31, 2025 and 2026, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>LIQUIDITY
AND CAPITAL RESOURCES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Going
Concern Considerations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our primary
sources of liquidity have historically been cash generated from the operation of our business and financing activities, which have supported
our working capital needs, operating activities and capital expenditure requirements in prior periods. As of March&#160;31, 2026 and June&#160;30,
2025, we had cash and cash equivalents and U.S. Dollar Coin(&#8220;USDC&#8221;) of $5.1 million and $4.2 million, respectively. As of
and for the nine months ended March&#160;31, 2026, we had an accumulated deficit of approximately $21.1 million, a working capital deficit
of $21.0 million, net cash used in operating activities of $3.8 million, and a net loss of $7.9 million. These factors raise substantial
doubt regarding our ability to continue as a going concern within one year of the date these financial statements are issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We have
formulated and are actively pursuing plans to mitigate these conditions and secure the Company&#8217;s continued operations. In connection
with the Company&#8217;s contemplated business combination with a SPAC and related financing activities, the Company expects to access
additional capital through external funding sources. In addition, the Company continues to focus on expanding its market presence and
developing client relationships to drive revenue growth, while managing operating expenses, with the objective of improving cash flows
from operations over time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">For purposes
of this disclosure, &#8220;SPAC&#8221; refers to a special purpose acquisition company formed to effect a merger, share exchange, asset
acquisition, share purchase, reorganization or similar business combination with one or more operating businesses. &#8220;De-SPAC&#8221;
refers to the business combination transaction pursuant to which an operating company combines with a SPAC, following which the combined
company becomes publicly listed (or otherwise succeeds to the SPAC&#8217;s public company status).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our negative
working capital position is primarily attributable to the classification of SAFEs. Excluding the accounting impact of the SAFEs, we believes
our available cash resources are sufficient for near-term operating needs. If additional liquidity is required, our majority shareholder
has entered into a binding support agreement to provide funding to cover anticipated operating cash flow shortfalls through the completion
of the contemplated de-SPAC transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">However,
the aforementioned plans, particularly the de-SPAC transaction (including the SAFEs conversion) and the raising of additional capital,
have not been fully implemented as of the date these financial statements are issued. There can be no assurance that these plans will
be successfully completed within the required time frame, on acceptable terms, or at all. If the primary plans are not successful, our
alternative courses of action would further intensify efforts in market expansion and client development to increase revenue, while diligently
controlling costs to ensure sufficient cash flow from operating activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We may
not be able to secure necessary financing in a timely manner or on favorable terms, or successfully execute its operational turnaround.
Consequently, our plans, although actively pursued, cannot be deemed probable of mitigating the substantial doubt at this stage. As a
result, our plans cannot be considered probable and thus do not alleviate substantial doubt about our ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Notwithstanding
the substantial doubt described above, the accompanying audited financial statements and unaudited condensed consolidated financial statements
have been prepared assuming that we will continue as a going concern and do not include any adjustments that might result from the outcome
of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 267; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->250<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>Cash
Flows</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Fiscal
year ended June&#160;30, 2024 compared to fiscal year ended June&#160;30, 2025</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The following
table sets forth a summary of our cash flows for the years ended June&#160;30, 2024 and 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the<br/>Years Ended<br/>June&#160;30,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2024</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; width: 76%">Net
        cash used in operating activities</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">(560,909</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">(1,010,799</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">)</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Net
        cash used in investing activities</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(27,806</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(2,138</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Net
        cash provided by financing activities</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">1,285,000</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">4,275,000</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Net
        change in cash and cash equivalents</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">696,285</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">3,262,063</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Cash
        and cash equivalents at the beginning of year</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">273,341</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">969,626</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Cash
        and cash equivalents at the end of year</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">969,626</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">4,231,689</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Operating
Activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">For the
year ended June&#160;30, 2024, net cash used in operating activities was $0.6 million. This outflow was primarily attributable to: (i)
a net loss of $5.0 million; (ii) an increase in accounts receivable of $0.1 million; and (iii) an increase in advance to suppliers of
$0.3 million. This outflow was partly offset by: (i) a non-cash change in the fair value of the simple agreements for future equity of
$3.1 million; (ii) a decrease in other receivables of $1.5 million, mainly due to the offset of investment funds held by an employee against
supplier payments made on the Company&#8217;s behalf; (iii) an increase in accounts payable of $0.1 million resulting from business expansion;
and (iv) an increase in contract liabilities of $0.1 million resulting from business expansion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">For the
year ended June&#160;30, 2025, net cash used in operating activities was $1.0 million. This outflow was primarily attributable to: (i)
a net loss of $7.7 million; (ii) an increase in advance to suppliers of $0.8 million, mainly due to strategic advances to secure priority
access to key resources; and (iii) an increase in refundable deposits receivable, mainly due to business expansion. This outflow was significantly
offset by non-cash adjustments and favorable changes in working capital, including: (i) a change in the fair value of the simple agreements
for future equity of $4.6 million; (ii) a decrease in other receivables of $1.7 million due to the offset of investment funds held by
an employee against supplier payments made on the Company&#8217;s behalf; (iii) an increase in refundable deposits payable of $1.2 million,
primarily due to higher customer deposits resulting from business expansion; and (iv) an increase in contract liabilities of $0.3 million,
mainly driven by an increase in both the customer base and the average revenue per customer resulting from business expansion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Investing
Activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Net cash
used in investing activities was $27.8 thousand and $2.1 thousand for the years ended June30, 2024 and 2025, respectively, solely attributable
to the purchase of equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Financing
Activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Net cash
provided by financing activities was $1.3 million and $4.3 million for the years ended June&#160;30, 2024 and 2025, respectively, solely
attributable to proceeds from the simple agreements for future equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 268; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->251<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Nine
months ended March&#160;31, 2025 compared to nine months ended March&#160;31, 2026</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The following
table sets forth a summary of our cash flows for nine months ended March&#160;31, 2025 and 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the<br/>Nine Months Ended<br/>March&#160;31,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2026</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; width: 76%">Net
        cash used in operating activities</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">(757,960</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">(3,758,611</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">)</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Net
        cash (used in) provided by investing activities</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">(2,138</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">)</td>
    <td style="font: 10pt Times New Roman">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; text-align: right">606,752</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Net
        cash provided by (used in) financing activities</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">4,275,000</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(95,000</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Net
        change in cash and cash equivalents</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">3,514,902</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">(3,246,859</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Cash
        and cash equivalents at the beginning of period</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">969,626</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">4,231,689</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Cash
        and cash equivalents at the end of period</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">4,484,528</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">984,830</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Operating
Activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">For the
nine months ended March&#160;31, 2025, net cash used in operating activities was $0.8 million. These cash outflows primarily driven by:
(i) a net loss of $6.2 million; and (ii) an increase in advance to suppliers of $0.3 million. This outflow was partially offset by: (i)
a loss from the change in the fair value of simple agreements for future equity of $3.7 million; (ii) a decrease in other receivables
of $1.8 million, due to the offset of investment funds held by an employee against supplier payments made on the Company&#8217;s behalf,
and (iii) an increase in refundable deposits payable of $0.2 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">For the
nine months ended March&#160;31, 2026, net cash used in operating activities was $3.8 million. This out flow was primarily driven by (i)
a net loss of $7.9 million, (ii) an increase in accounts receivable of $1.7 million, mainly due to the extension of credit terms granted
to customers who maintain security deposits, and (iii) we settled certain operating activities using digital assets and USDC totaling
$1.7 million. This outflow was partially offset by (i) a $5.1 million loss from the change in the fair value of simple agreements for
future equity, which did not involve cash, (ii) a decrease in other receivables of $1.7 million, mainly due to the offset of investment
funds held by an employee against supplier payments made on the our behalf, and (iii) a decrease in advance to suppliers of $0.9 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Investing
Activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Net cash
used in investing activities for the nine months ended March&#160;31, 2025 was $2.1 thousand, which was primarily attributable to the
purchases of equipment of $2.1 thousand.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Net cash
provided by investing activities for the nine months ended March&#160;31, 2026 was 0.6 million, which was proceeds from sale USDT and
USDC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Financing
Activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Net cash
provided by financing activities was $4.3 million for the nine months ended March&#160;31, 2025, solely attributable to proceeds from
the simple agreements for future equity. Net cash used in financing activities was $0.1 million for the nine months ended March&#160;31,
2026, solely attributable to payment for deferred offering costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">During
the nine months ended March&#160;31, 2026, the Company received $3.5 million of SAFEs proceeds through non-cash channels, consisting of
$3.0 million received in USDC and $0.5 million received by an employee on behalf of the Company. These amounts were disclosed as supplemental
non-cash financing information and therefore were not included in net cash provided by financing activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 269; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->252<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>CAPITAL
EXPENDITURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Our capital
expenditures were minimal for the periods presented. We spent $2.1 thousand and nil on equipment purchases for the nine months ended March&#160;31,
2025 and 2026. Going forward, we expect to make necessary capital expenditures to meet the expected growth of our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>COMMITMENTS
AND CONTRACTUAL OBLIGATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We had
no commitments and contractual obligations during any of the periods presented other than those disclosed in Note &#8220;COMMITMENTS and
CONTINGENCIES&#8221; of our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>OFF
BALANCE SHEET ARRANGEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We had
no off-balance sheet arrangements during any of the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>CRITICAL
ACCOUNTING POLICIES AND ESTIMATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We prepare
our financial statements in accordance with GAAP, which requires our management to make estimates that affect the reported amounts of
assets and liabilities at the dates of the balance sheets, as well as the reported amounts of revenues and expenses during the reporting
periods. To the extent that there are material differences between these estimates and actual results, our financial condition or results
of operations would be affected. We base our estimates on our own historical experience and other assumptions that we believe are reasonable
after taking account of our circumstances and expectations for the future based on available information. We evaluate these estimates
on an ongoing basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We consider
an accounting estimate to be critical if: (i) the accounting estimate requires us to make assumptions about matters that were highly uncertain
at the time the accounting estimate was made, and (ii) changes in the estimate that are reasonably likely to occur from period to period
or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial
condition or results of operations. There are other items within our financial statements that require estimation but are not deemed critical,
as defined above. Changes in estimates used in these and other items could have a material impact on our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Revenue
Recognition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We applied
ASC Topic 606 &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;) for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The five-step
model defined by ASC606 requires us to (i) identify our contracts with clients, (ii) identify our performance obligations under those
contracts, (iii) determine the transaction prices of those contracts, (iv) allocate the transaction prices to our performance obligations
in those contracts, and (v) recognize revenue when each performance obligation under those contracts is satisfied. Revenue is recognized
when promised goods or services are transferred to the client in an amount that reflects the consideration expected in exchange for those
goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We report
all of our revenues on a gross basis. This determination is based on our assessment that we are the principal in our revenue arrangements.
We control the service delivery platform and infrastructure before the service is provided to the customer. It is primarily responsible
for fulfilling the service promise, has discretion in setting prices, and assumes the credit risk associated with the customer receivable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">As a practical
expedient, we elected to expense the incremental costs of obtaining a contract when incurred if the amortization period of the asset that
we otherwise would have recognized is one year or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 270; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->253<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Pursuant
to ASC 606, we recognize revenue based on the transaction price, which is the amount of consideration it expects to be entitled to in
exchange for transferring services to customers. For intelligent computing power services, contract consideration is generally fixed and
is typically stated as a fixed monthly fee determined by (i) the contractually specified number of GPUs (capacity) and (ii) the service
period. Accordingly, the transaction price is generally the fixed contractual amount. We recognize revenue over time as the services are
provided throughout the contract term. We offer payment terms ranging from 0 to 6 months, depending on customers&#8217; credit profiles
and service requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We don&#8217;t
provide warranties for our services or offer service-type warranty arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The following
is a description of our principal activities from which we generate our revenue under ASC 606.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">(i) Revenue
for intelligent computing power service</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We leverage
our expertise in high-performance computing and cloud-native architectures to build and operate stable, efficient, and scalable GPU computing
platforms through modular data center design and liquid cooling technology. We use these platforms to provide computing resources for
large-scale AI training, model inference, and high-performance scientific computing to commercial enterprise clients with substantial
GPU computing requirements. Supporting services include GPU server environment deployment, cluster scheduling and performance optimization,
high-speed network interconnection, real-time monitoring and intelligent alerting systems, as well as industry-compliant security and
regulatory assurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0; color: #0F1115">We
account for the above promises as a single performance obligation because they are highly integrated and not separately identifiable in
the context of the contract. We provide an integrated, managed GPU computing platform in which computing capacity, deployment/configuration,
scheduling, networking, monitoring, and security/compliance are interdependent and together deliver a single combined service&#8212;continuous
access to a functioning and secured platform over the contractual term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0; color: #0F1115">We
provide intelligent computing power services under two pricing models: (i) reserved capacity arrangements and (ii) on-demand (pay-as-you-go)
arrangements. The following table presents revenue recognized during the period by arrangement type:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the <br/>Nine Months Ended <br/>March&#160;31,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the <br/>Years Ended <br/>June&#160;30,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2026</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2024</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; color: #0F1115; width: 52%">Reserved
        capacity arrangements</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">4,161,985</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">10,428,983</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">1,193,982</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">6,501,569</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; color: #0F1115; padding-bottom: 0.5pt">On-demand
        arrangements</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">6,482</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">12,526</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">-</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">44,680</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; color: #0F1115; padding-bottom: 1.25pt"><b>Total</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>4,168,467</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>10,441,509</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>1,193,982</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right"><b>6,546,249</b></td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0; color: #0F1115">Reserved
capacity arrangements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We enter
into reserved capacity arrangements, which generally provide committed intelligent computing power services for a defined service term
ranging from 3 months to 3 years, with the majority of such arrangements having a one-year term. These contracts typically are non-cancelable,
or may be canceled only under limited conditions with early notifications required. Payment terms generally range from 0-6 months upon
the completion of services, and certain arrangements require prepayments. Any prepayments are recorded as contract liabilities and recognized
over the service term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">The performance
obligation is satisfied over time because the customer simultaneously receives and consumes the benefits. Revenue is recognized using
a time-elapsed output method over the contractual service period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 271; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->254<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0; color: #0F1115">On-demand
(pay-as-you-go) arrangements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We provide
customers with on-demand access to intelligent computing power and GPU resources under a pay-as-you-go model, which requires advance payment.
Customer advances are recorded as contract liabilities and recognized as revenue over time during the provision of the related services
underlying the contract term. We recognize revenue over time because the customer simultaneously receives and consumes the benefits during
the service period. These arrangements generally do not include a fixed contractual term or minimum usage commitments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">(ii) Revenue
from comprehensive data center service</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We leverage
our project experience in infrastructure management, cluster optimization, and system monitoring to provide full-cycle operational support
to data center asset owners. Services encompass facility environment deployment, network architecture implementation, security and compliance
system development, daily operational monitoring, and emergency fault response. Under ASC 606, revenue from each distinct service, which
constitutes a separate performance obligation, is recognized on a straight-line basis over the contractual service period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">For the
nine months ended March&#160;31, 2025 and 2026, $4.5 million and $10.6 million of our revenue was recognized over time, respectively.
For the years ended June&#160;30, 2024 and 2025, $1.3 million and $7.0 million of our revenue was recognized over time, respectively.
Revenue is recognized over time because our services are performed throughout the contract term and the customer benefits as the services
are provided.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Revenue
disaggregated by service lines for the nine months ended March&#160;31, 2025 and 2026 and for the years ended June&#160;30, 2024 and 2025
is disclosed in the table below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the<br/>Nine Months Ended<br/>March&#160;31,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>For
        the<br/>Years Ended<br/>June&#160;30,</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2026</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2024</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>2025</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: center"><b>$</b></td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; width: 52%">Revenue
        from intelligent computing power service</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">4,168,467</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">10,441,509</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">1,193,982</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman; width: 9%; text-align: right">6,546,249</td>
    <td style="font: 10pt Times New Roman; width: 1%; text-align: left; white-space: nowrap">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Revenue
        from comprehensive data center service</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">307,418</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">119,822</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">125,133</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; text-align: right">469,263</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="font: 10pt Times New Roman; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right">4,475,885</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right">10,561,331</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right">1,319,115</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman; text-align: right">7,015,512</td>
    <td style="font: 10pt Times New Roman; text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Contract
Liabilities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We receive
advance payments from our customers for services to be provided in the future. These payments are recorded as contract liabilities on
the balance sheet within &#8220;Contract liabilities&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Contract
liabilities are recognized when consideration is received from a customer prior to us satisfying our related performance
obligations. For these service contracts, we recognize revenue, and reduce the contract liabilities over time as the services are
rendered and the performance obligations are satisfied. Revenue recognized during the years ended June&#160;30, 2024 and 2025 that
was included in the contract liability balance at the beginning of the period was nil and $95,326, respectively. Revenue recognized
during the nine months ended March&#160;31, 2025 and 2026 that was included in the contract liability balance at the beginning of
the period was $95,326 and $366,075, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Income
taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Current
income taxes are provided on the basis of income before income taxes for financial reporting purposes, and adjusted for income and expense
items which are not assessable or deductible for income tax purposes, in accordance with the regulations of the relevant tax jurisdictions.
Deferred income taxes are provided using the liability method. Under this method, deferred income tax assets and liabilities are recognized
for the tax effects of temporary differences and are determined by applying enacted tax rates expected to apply to taxable income in the
periods in which those temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities
of a change in tax rates or tax laws is recognized in the statements of comprehensive income in the period the change in tax rates or
tax laws is enacted. A valuation allowance is provided to reduce the amount of deferred income tax assets if based on the weight of available
evidence, it is more-likely-than-not that some portion, or all, of the deferred income tax assets will not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 272; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->255<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We apply
a &#8220;more likely than not&#8221; recognition threshold in the evaluation of uncertain tax positions. We recognize the benefit of a
tax position in the financial statements if the tax position is &#8220;more likely than not&#8221; to prevail based on the facts and technical
merits of the position. Tax positions that meet the &#8220;more likely than not&#8221; recognition threshold are measured at the largest
amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. Unrecognized tax benefits may
be affected by changes in interpretation of laws, rulings of tax authorities, tax audits, and expiry of statutory limitations. In addition,
changes in facts, circumstances and new information may require us to adjust the recognition and measurement estimates with regard to
individual tax positions. Accordingly, unrecognized tax benefits are periodically reviewed and re-assessed. Adjustments, if required,
are recorded in our financial statements in the period in which the change that necessities the adjustments occur. The ultimate outcome
for a particular tax position may not be determined with certainty prior to the conclusion of a tax audit and, in certain circumstances,
a tax appeal or litigation process. We record interest and penalties related to unrecognized tax benefits (if any) in interest expenses
and general and administrative expenses, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Share-based
compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We grant
our share options to eligible employees and non-employees. We account for share-based awards issued to employees and non-employees in
accordance with ASC Topic 718 <i>Compensation&#8211;Stock Compensation</i>. We recognize forfeitures as they occur. The share-based compensation
expenses have been categorized as either general and administrative expenses or selling and marketing expenses, depending on the job functions
of the grantees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Exascale&#8217;s
share-based compensation awards are expected to be settled through transfers of existing ordinary shares held by the controlling shareholder,
rather than through the issuance of new shares by us. The underlying ordinary shares are included in issued and outstanding shares as
of the balance sheet date; accordingly, such settlement is not expected to increase the Company&#8217;s total issued and outstanding shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Employees&#8217;
share-based awards and non-employees&#8217; share-based awards are measured at the grant date fair value of the awards and recognized
as expenses a) immediately at grant date if no vesting conditions are required; or b) using graded vesting method, net of estimated forfeitures,
over the requisite service period, which is the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">We employ
discounted cash flow method to determine the fair value of our share-based compensation arrangements, where the key valuation variables
include risk free rate, discount rate and perpetual rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0"><b>RECENT
ACCOUNTING PRONOUNCEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman; text-align: justify; margin-top: 0; margin-bottom: 0">Please
refer to Note 2 to our financial statements included elsewhere in this prospectus. We have reviewed all the recently issued, but not yet
effective, accounting pronouncements and we do not believe any of these pronouncements will have a material impact on we financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 273; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->256<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXECUTIVE OFFICERS AND DIRECTORS OF EXASCALE
AND<br/> EXECUTIVE OFFICERS AND DIRECTORS OF PUBCO</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Unless the context otherwise requires, all
references in this section to &#8220;Exascale,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to Exascale, Inc.
prior to the consummation of the Business Combination, and all references in this section to &#8220;PubCo,&#8221; &#8220;we,&#8221; &#8220;us&#8221;
or &#8220;our&#8221; refer to D. Boral ARC Merger Corporation after the consummation of the Business Combination.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Executive Officers and Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Set forth below are the names, ages and positions
as of the date of this proxy statement/prospectus of Exascale&#8217;s current executive officers and directors as well as the names, ages
and positions as of the date hereof of the executive officers and director nominees of PubCo after the Business Combination:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: left; width: 30%"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 9%"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 29%; text-align: center"><span style="font-size: 10pt"><b>Exascale
        Position(s)</b></span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 29%; text-align: center"><span style="font-size: 10pt"><b>PubCo
        Position(s)</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">Hoansoo Lee</span></td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">42</span></td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Chief Executive Officer, Chief Financial Officer, and Director</span></td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Chief Executive Officer, Interim Chief Financial Officer and
        Class III Director</span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">Wenying Jia</span></td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">57</span></td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Chairperson and Director</span></td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Chairperson and Class II Director</span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">David Card</span></td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">70</span></td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Class II Director</span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">Shachar Kariv</span></td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">55</span></td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Class I Director</span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">Jaeyoung Shin</span></td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">48</span></td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Class I Director</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Executive Officers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Hoansoo Lee</i></b> is the co-founder of
Exascale and has served as Exascale&#8217;s Chief Executive Officer since June 2022, Exascale&#8217;s Chief Financial Officer since October
2025, and a member of the board of directors of Exascale since June, 2022. Dr. Lee will serve as the Chief Executive Officer and Interim
Chief Financial Officer of PubCo, and Chairman and a member of the PubCo Board, in each case, upon consummation of the Business Combination.
Previously, from June 2020 to December 2025, Dr. Lee was the founder and Chief Executive Officer of HSL Capital Management LLC, a multi-strategy
hedge fund. From June 2002 to May 2020, he served in roles of increasing responsibilities, including as a Staff Economist, for the Council
of Economic Advisers, Executive Office of the President in the Obama Administration; Assistant Professor of Finance in the School of Economics
and Management at Tsinghua University; Portfolio Manager and Head of Quantitative Equities, for China Merchants Bank International Asset
Management; Managing Director for TusPark Ventures, a subsidiary of Tsinghua Holdings, the endowment fund of Tsinghua University, where
he lead cross-border early-stage technology investments and University spin-outs. Dr. Lee earned a B.A. in Mathematics (Valedictorian
and Highest Honors), and Economics (Highest Honors) from the University of California at Berkeley; an A.M. and Ph.D. in Business Economics
from Harvard University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Lee is qualified to serve on the PubCo Board
due to being the founder and Chief Executive Officer of Exascale, as a consequence of which he brings deep operational leadership and
expertise to PubCo that are directly relevant to PubCo&#8217;s future strategic growth and long-term value creation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Directors</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Biographical information with respect to Exascale&#8217;s
current non-employee director and the executive officers and director nominees of PubCo after the Business Combination is set forth below.
Hoansoo Lee&#8217;s biographical information is set forth above under &#8220;<i>&#8212; Executive Officer</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Wenying Jia</i></b> has served as a member
of the board of directors of Exascale since inception. Ms. Jia is an angel investor with experience in digital assets, cloud computing,
and emerging technology infrastructure, and has been involved in the digital asset sector since 2014. In 2017, Ms. Jia expanded her activities
to include GPU-based mining operations as Ethereum&#8217;s proof-of-work network gained adoption, recognizing the potential of smart contract
functionality alongside bitcoin&#8217;s role as a store of value. From 2017 through 2022, Ms. Jia invested in and supported multiple GPU-
and data-storage-related infrastructure projects. During this period, she developed relationships with several individuals who later became
core members of Exascale. Ms. Jia played a significant role in facilitating the formal establishment of Exascale in 2022 and was among
Exascale&#8217;s earliest investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 274; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->257<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ms. Jia is qualified to serve on the PubCo Board
because she brings early-stage investor experience and deep, long-standing expertise in GPU-based infrastructure, along with institutional
knowledge as a founding-era director who helped establish Exascale and its core team.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>David Card</i></b> is a renowned labor economist
and Nobel Laureate (2021). Dr. Card is the Class of 1950 Emeritus Professor of Economics at the University of California, Berkeley. Dr.
Card has been a member of the University of California, Berkeley faculty since 1997. Prior to joining Berkeley, Dr. Card held academic
appointments at Princeton University and the University of Chicago. Dr. Card is widely recognized for his contributions to empirical labor
economics and applied econometrics, particularly in the analysis of labor markets, education, immigration and wage dynamics. Dr. Card
was awarded half of the 2021 Nobel Memorial Prize in Economic Sciences for his empirical contributions to labor economics. Dr. Card previously
served as President of the American Economic Association and has held editorial roles at several leading academic journals. He is a Fellow
of the American Academy of Arts and Sciences and the Econometric Society. Dr. Card received his B.A. from Queen&#8217;s University and
his M.A. and Ph.D. in Economics from Princeton University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Card is qualified to serve on the PubCo Board
due to his internationally recognized expertise in Economics and his distinguished academic leadership and service in prominent economic
institutions, which we believe will provide strong governance insight and an independent perspective that will contribute meaningfully
to the PubCo Board&#8217;s decision-making processes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Shachar Kariv</i></b> is an economist and
the Benjamin N. Ward Professor of Economics at the University of California, Berkeley, a position he has held since 2014. Dr. Kariv has
a rich academic career spanning over two decades. Prior to his current position, Dr. Kariv was a Professor in the Department of Economics
at the University of California, Berkeley (2010 to 2014), an Associate Professor (with tenure) in the Department of Economics at the University
of California, Berkeley (2008 to 2010), and an Assistant Professor in the Department of Economics at the University of California, Berkeley
(2003 to 2008). Dr. Kariv also previously served as the Department Chair of the Department of Economics at the University of California,
Berkeley, from 2014 to 2017 and from 2021 to 2022. Dr. Kariv&#8217;s research primarily focuses on Economic Theory, Experimental Economics,
and Behavioral Economics. Dr. Kariv has held several visiting positions, including at the Institute for Advanced Studies, the European
University Institute, Stanford University, the University of Cambridge and the Norwegian School of Economics. He has received numerous
awards for his teaching excellence, including the Earl F. Cheit Award for Excellence in Teaching from the University of California, Berkeley,
Haas School of Business, and the Dean&#8217;s Outstanding Teaching Award at New York University. Dr. Kariv earned his B.A. in Economics
from Tel Aviv University, and an M.A. and Ph.D. in Economics from New York University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Kariv is qualified to serve as a member of
the PubCo Board due to his extensive expertise in Economics, as well as his experience leading a major academic department and collaborating
across global research institutions, which we believe equips him with strong governance, analytical and strategic capabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Jaeyoung
Shin</i></b> is Vice President and Head of Asia at Samsung Ventures Investment Corporation, where he oversees the firm&#8217;s investment
activities across Greater China, Japan, India, and Southeast Asia. In this role, he is responsible for sourcing, evaluating, and managing
venture capital investments in technology and growth-stage companies, as well as overseeing portfolio strategy and regional investment
execution. Mr. Shin has extensive experience in venture capital, corporate venture investing, and cross-border technology investments,
with a focus on semiconductors, digital transformation, and emerging technologies. Since joining Samsung Ventures in 2010, Mr. Shin has
led and supported investments across semiconductors, AI chips, image sensors, display technologies, and other advanced technology sectors,
with notable IPO and M&amp;A exits, including Montage Technology, VeriSilicon, Silergy, Amlogic, GalaxyCore, SmartSens, Deep Glint, DeePhi,
and PlayNitride. Prior to Samsung Ventures, Mr. Shin worked as a fuel cell researcher at the Samsung Advanced Institute of Technology
in Korea and as a Research and Development staff member at the Fuel Cell Lab of Forschungszentrum J&#252;lich in Germany. Mr. Shin holds
a Bachelor&#8217;s degree in Mechanical Engineering from Aachen University of Applied Science in Germany.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Shin
is qualified to serve as a member of the PubCo Board due to his extensive experience in investing in technology companies and his leadership
in evaluating and scaling businesses across technology ecosystems. Mr. Shin brings a combination of strategic investment expertise, technology
sector knowledge, and market insight that we believe will be highly relevant to PubCo&#8217;s long-term growth objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 275; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->258<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Composition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PubCo&#8217;s business and affairs will be managed
under the direction of the PubCo Board. Following the Business Combination, the PubCo Board will consist of five (5) directors. Subject
to the rights of holders of any series of PubCo Preferred Stock to elect directors, the PubCo Board shall be divided into three classes,
designated Class I, Class II and Class III. Each class shall consist, as nearly as may be possible, of one third of the total number of
directors constituting the entire PubCo Board. The PubCo Board is authorized to assign members of the Board already in office to Class
I, Class II or Class III at the time such classification becomes effective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to
the Directors Proposal, BCAR has put forward that the Class I directors consist of Shachar Kariv and Jaeyoung Shin; the Class II directors
consist of Wenying Jia and David Card and that the Class III director be Hoansoo Lee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Role of the Board in Risk Oversight</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The PubCo Board will have extensive involvement
in the oversight of risk management related to PubCo and its business and will accomplish this oversight through the regular reporting
to the PubCo Board by the audit committee. The audit committee will represent the PubCo Board by periodically reviewing PubCo&#8217;s
accounting, reporting and financial practices, including the integrity of its financial statements, the surveillance of administrative
and financial controls and its compliance with legal and regulatory requirements. Through its regular meetings with management, including
the finance, legal, internal audit and information technology functions, the audit committee will review and discuss all significant areas
of PubCo business and summarize for the PubCo Board all areas of risk and the appropriate mitigating factors. In addition, the PubCo Board
will receive periodic detailed operating performance reviews from management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our securities are not listed on a national securities
exchange or in an inter-dealer quotation system which has requirements that directors be independent. However, we have adopted the independence
standards of the NASDAQ Capital Market to determine the independence of our directors and those directors serving on any committee. These
standards provide that a person will be considered an independent director if he or she is not an officer of the company and is, in the
view of the company&#8217;s board of directors, free of any relationship that would interfere with the exercise of independent judgment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">David Card,
Shachar Kariv and Jaeyoung Shin are anticipated to be PubCo&#8217;s independent directors, as defined under the rules promulgated by Nasdaq.
PubCo&#8217;s independent directors will have regularly scheduled meetings at which only independent directors are present. Any affiliated
transactions will be on terms that the PubCo Board will believe are no less favorable to PubCo than could be obtained from independent
parties. None of the independent directors has any relationship with Exascale or PubCo besides their future service on the PubCo Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We have determined that each of the directors is
qualified to serve as a director of PubCo based on a review of the experience, qualifications, attributes and skills of each director.
In reaching this determination, we have considered a variety of criteria, including, among other things: character and integrity; ability
to review critically, evaluate, question and discuss information provided, to exercise effective business judgment and to interact effectively
with the other directors; and willingness and ability to commit the time necessary to perform the duties of a director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Board Committees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">After the completion of the Business Combination,
the standing committees of the PubCo Board will consist of an audit committee, a compensation committee and a nominating and corporate
governance committee. The PubCo Board may from time to time establish other committees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">PubCo&#8217;s chief executive officer and other
executive officers will regularly report to the non-executive directors and the audit, the compensation and the nominating and corporate
governance committees to ensure effective and efficient oversight of PubCo&#8217;s activities and to assist in proper risk management
and the ongoing evaluation of management controls. PubCo believes that the leadership structure of the PubCo Board will provide appropriate
risk oversight of PubCo&#8217;s activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 276; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->259<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Audit Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PubCo intends
to establish an audit committee of the PubCo Board, which is anticipated to consist of David Card, Shachar Kariv and Jaeyoung Shin, who
are independent directors under Nasdaq&#8217;s listing standards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jaeyoung Shin
will be the chairperson of the audit committee. The audit committee&#8217;s duties, which are specified in PubCo&#8217;s Audit Committee
Charter, include, but are not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">assisting board oversight of (1) the integrity of our financial statements,
        (2) our compliance with legal and regulatory requirements, (3) our independent registered public accounting firm&#8217;s qualifications
        and independence, and (4) the performance of our internal audit function and independent registered public accounting firm; the appointment,
        compensation, retention, replacement and oversight of the work of the independent auditors and any other independent registered public
        accounting firm engaged by us;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">pre-approving all audit and non-audit services to be provided by the independent
        auditors or any other registered public accounting firm engaged by us, and establishing pre-approval policies and procedures; reviewing
        and discussing with the independent registered public accounting firm all relationships the auditors have with us in order to evaluate
        their continued independence;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">setting clear policies for audit partner rotation in compliance with applicable
        laws and regulations; obtaining and reviewing a report, at least annually, from the independent registered public accounting firm describing
        (1) the independent registered public accounting firm&#8217;s internal quality-control procedures and (2) any material issues raised by
        the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry or investigation by governmental
        or professional authorities, within the preceding five years respecting one or more independent audits carried out by the firm and any
        steps taken to deal with such issues;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">meeting to review and discuss our annual audited financial statements and quarterly financial
        statements with management and the independent auditor, including reviewing our specific disclosures under &#8220;Management&#8217;s Discussion
        and Analysis of Financial Condition and Results of Operations&#8221;&#894; reviewing and approving any related party transaction required
        to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">reviewing with management, the independent and our legal advisors, as appropriate, any
        legal, regulatory or compliance matters, including any correspondence with regulators or government agencies and any employee complaints
        or published reports that raise material issues regarding our financial statements or accounting policies and any significant changes
        in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities.</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Financial Experts on Audit Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to Nasdaq rules, the audit committee will
at all times be composed exclusively of independent directors who are able to read and understand fundamental financial statements, including
a company&#8217;s balance sheet, income statement and cash flow statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, PubCo
intends to have at least one member who has past employment experience in finance or accounting, requisite professional certification
in accounting, or other comparable experience or background results in the individual&#8217;s financial sophistication. The PubCo Board
believes that Jaeyoung Shin qualifies as an &#8220;audit committee financial expert,&#8221; as defined under the rules and regulations
of Nasdaq and the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Corporate Governance and Nominating Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PubCo intends
to establish a corporate governance and nominating committee of the board of directors, which is anticipated to consist of David Card,
Shachar Kariv and Jaeyoung Shin. David Card is anticipated to be the chairperson of the corporate governance and nominating committee.
The corporate governance and nominating committee is responsible for overseeing the selection of persons to be nominated to serve on the
PubCo Board. The corporate governance and nominating committee considers persons identified by its members, management, stockholders,
investment bankers and others.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 277; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->260<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Guidelines for Selecting Director Nominees</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The guidelines for selecting nominees, which are specified
in the Corporate Governance and Nominating Committee Charter, generally provide that persons to be nominated:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">should have demonstrated notable or significant achievements
        in business, education or public service;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">should possess the requisite intelligence, education and experience to make
        a significant contribution to the board of directors and bring a range of skills, diverse perspectives and backgrounds to its deliberations;
        and</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">should have the highest ethical standards, a strong sense of professionalism
        and intense dedication to serving the interests of the stockholders.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The corporate governance and nominating committee
will consider a number of qualifications relating to management and leadership experience, background and integrity and professionalism
in evaluating a person&#8217;s candidacy for membership on the board of directors. The corporate governance and nominating committee may
require certain skills or attributes, such as financial or accounting experience, to meet specific board needs that arise from time to
time and will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of board members. The corporate
governance and nominating committee does not distinguish among nominees recommended by stockholders and other persons.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Compensation Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PubCo intends
to establish a compensation committee of its board of directors, which is anticipated to consist of David Card, Shachar Kariv and Jaeyoung
Shin. Shachar Kariv is anticipated to be the chairperson of the compensation committee. The compensation committee&#8217;s duties, which
are specified in our Compensation Committee Charter, include, but are not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0.25in"/>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">reviewing and approving on an annual basis the corporate goals and objectives relevant
        to our Chief Executive Officer&#8217;s compensation evaluating our Chief Executive Officer&#8217;s performance in light of such goals
        and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0.25in"/>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">reviewing and making recommendations to our board of directors with respect to compensation
        and any incentive compensation and equity-based plans that are subject to board approval of all of our other officers;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0.25in"/>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">reviewing our executive compensation policies and plans;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0.25in"/>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">implementing and administering our incentive compensation equity-based remuneration plans;</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0.25in"/>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">assisting management in complying with our proxy statement and annual report disclosure
        requirements;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0.25in"/>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">all special perquisites, special cash payments and other special compensation and benefit
        arrangements for our officers and employees;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0.25in"/>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">producing a report on executive compensation to be included in our annual proxy statement;
        and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: right; width: 0.25in"/>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">reviewing, evaluating and recommending changes, if appropriate, to the remuneration for
        directors.&#8203;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The charter also provides that the compensation committee
may, in its sole discretion, retain or obtain the advice of a compensation consultant, independent legal counsel or other adviser and
will be directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging
or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider
the independence of each such adviser, including the factors required by Nasdaq and the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 278; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->261<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Code of Business Conduct</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PubCo will adopt a code of business conduct that applies
to all of its directors, officers and employees, including its principal executive officer, principal financial officer and principal
accounting officer, which will be available on PubCo&#8217;s website upon the completion of the Business Combination. PubCo&#8217;s code
of business conduct is a &#8220;code of ethics,&#8221; as defined in Item 406(b) of Regulation S-K. Please note that PubCo&#8217;s Internet
website address is provided as an inactive textual reference only. PubCo will make any legally required disclosures regarding amendments
to, or waivers of, provisions of its code of ethics on its Internet website.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Management Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Employment agreement
with Hoansoo Lee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From April 1, 2023 through September 30, 2025,
Hoansoo Lee provided services to Exascale pursuant to an independent contractor arrangement. During such period, Dr. Lee was compensated
as a non-employee consultant and received monthly consulting fees pursuant to such arrangement. No employee benefits were provided in
connection with such consulting services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2025, Exascale entered into an employment
agreement with Dr. Lee pursuant to which he transitioned from independent contractor status to full-time employee status. Pursuant to
the agreement, Dr. Lee&#8217;s employment is for a fixed term ending on September 30, 2027, unless earlier terminated in accordance with
its terms. Under the agreement, Dr. Lee is entitled to an initial monthly base salary of $9,000, payable monthly. Dr. Lee is also eligible
to accrue paid time off in accordance with Exascale&#8217;s policies and applicable law and may participate in employee benefit plans
required by law and offered by Exascale. As of the date of this proxy statement/prospectus, Exascale has not paid, and does not currently
maintain, any cash bonus, equity incentive, or other incentive compensation arrangements for Mr. Lee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale and PubCo have not yet entered into an
employment agreement with Dr. Lee in connection with his future position as the Chief Executive Officer of PubCo, but expect to do so
in connection with the consummation of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Director Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale has not entered into any separate director
service or compensation agreements with its directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Director and Officer
Indemnification Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the consummation of the Business Combination,
PubCo intends to enter into agreements with each of its executive officers and Directors, whereby PubCo will agree to indemnify each of
them to the fullest extent permitted by law, for all amounts (including, without limitation, judgments, fines, settlement payments, expenses
and reasonable out of pocket attorneys&#8217; fees) incurred or paid by any of them in connection with any action, suit, investigation
or proceeding, or threatened action, suit, investigation or proceeding, arising out of or relating to their performance of services for
PubCo or any subsidiary of PubCo. Any fees or other necessary expenses incurred by any of them in defending any such action, suit, investigation
or proceeding shall be paid by PubCo in advance, subject to PubCo&#8217;s right to seek repayment from them a determination is made that
the applicable officer or Director was not entitled to indemnification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 279; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->262<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>COMPENSATION OF NAMED EXECUTIVE OFFICERS AND DIRECTORS
OF EXASCALE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale currently has one named executive officer,
Hoansoo Lee, who serves as the Company&#8217;s Chief Executive Officer and Chief Financial Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary Compensation Table</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information concerning
the compensation of our named executive officer for the fiscal years ended June 30, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Name and Principal Position</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Fiscal Year</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Salary<br/>
        ($)<sup>(1)</sup></b></span></td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Stock
        Awards<sup>(1)</sup><br/> ($)</b></span></td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">All Other<br/> Compensation<br/>
        ($)</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Total<br/> ($)</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 40%; text-align: left">Hoansoo Lee<i></i></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center">2025</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">100,150</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">-</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">-</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">100,150</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; vertical-align: top"><i>Chief Executive Officer and Chief Financial
        Officer</i></td>
    <td>&#160;</td>
    <td style="text-align: center">2024</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">75,245</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">75,245</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(1)</td>
    <td style="text-align: justify">Represents consulting fees paid to Hoansoo Lee pursuant to Exascale&#8217;s consulting arrangement with Hoansoo
        Lee. See &#8220;<i>&#8212;Executive Compensation Arrangements&#8221; </i>below.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Narrative to Summary Compensation Table</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the fiscal years ended June 30, 2025 and 2024,
Hoansoo Lee provided services to Exascale pursuant to an independent contractor arrangement. During this period, Dr. Lee was compensated
as a non-employee consultant and received monthly consulting fees pursuant to such arrangement. No employee benefits were provided in
connection with such consulting services. For the years ended June 30, 2024 and 2025, Exascale paid consulting fees totaling $75,245 and
$100,150, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Executive Compensation Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From April 1, 2023 through September 30, 2025,
Dr. Lee provided services to Exascale pursuant to an independent contractor arrangement. During this period, Dr. Lee was compensated as
a non-employee consultant and received monthly consulting fees pursuant to such arrangement. No employee benefits were provided in connection
with such consulting services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective October 1, 2025, Exascale entered into
an employment agreement with Dr. Lee, pursuant to which he transitioned from independent contractor status to full-time employee status.
Under the employment agreement, Dr. Lee serves as Chief Executive Officer and Chief Financial Officer and receives a base salary of $9,000
per month, paid monthly. Dr. Lee is eligible to participate in employee benefit plans required by applicable law and offered by Exascale.
As of the date of this proxy statement/prospectus, Exascale has not paid, and does not currently maintain, any cash bonus, equity incentive,
or other incentive compensation arrangements for Dr. Lee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale has not entered into any change-in-control,
severance, retention, or transaction-related compensation arrangements with its named executive officer in connection with the Business
Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale&#8217;s board of directors consists of
two directors, Hoansoo Lee and Wenying Jia, each of whom is a significant stockholder of Exascale. Neither director receives any cash
compensation, equity compensation, or other remuneration for their service on the board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exascale has not entered into any change-in-control,
severance, retention, or transaction-related compensation arrangements with its named executive officer or directors in connection with
the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Director and Officer Indemnification Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the consummation of the Business Combination,
PubCo will enter into agreements with each of its executive officers and directors, pursuant to which the PubCo will agree to indemnify
each of them to the fullest extent permitted by law, for all amounts (including, without limitation, judgments, fines, settlement payments,
expenses and reasonable out of pocket attorneys&#8217; fees) incurred or paid by any of them in connection with any action, suit, investigation
or proceeding, or threatened action, suit, investigation or proceeding, arising out of or relating to their performance of services for
PubCo or any subsidiary of PubCo. Any fees or other necessary expenses incurred by any of them in defending any such action, suit, investigation
or proceeding will be paid by PubCo in advance, subject to PubCo&#8217;s right to seek repayment from them if a determination is made
that the applicable officer or director was not entitled to indemnification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 280; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->263<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_030"></span>BENEFICIAL OWNERSHIP OF
SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth information regarding
(i) the beneficial ownership of BCAR Ordinary Shares as of [_], 2026, which is prior to the consummation of the Business Combination and
(ii) the expected beneficial ownership of shares of PubCo Common Stock immediately following consummation of the Business Combination
by:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">each person who is known to be the beneficial owner of more
        than 5% of BCAR Ordinary Shares and is expected to be the beneficial owner of more than 5% of shares of PubCo Common Stock post-Business
        Combination;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: justify; width: 0.25in"/>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">each of BCAR&#8217;s current executive officers and directors;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">each person who will become an executive officer or director
        of PubCo post-Business Combination; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">all executive officers and directors of BCAR as a group pre-Business
        Combination, and all executive officers and directors of PubCo as a group post-Business Combination.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beneficial ownership is determined according to
the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or
shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within
60 days. In computing the number of shares beneficially owned by a person or entity and the percentage ownership of that person or entity
in the table below, all shares subject to options, warrants or other convertible securities held by such person or entity were deemed
outstanding prior to the Business Combination if such securities are currently exercisable, or exercisable within 60 days of [_], 2026
and were deemed outstanding post-Business Combination if such securities are exercisable within 60 days of the closing of the Business
Combination. These shares were not deemed outstanding, however, for the purpose of computing the percentage ownership of any other person
or entity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The beneficial ownership of BCAR Ordinary Shares pre-Business
Combination is based on 41,200,000 BCAR Ordinary Shares issued and outstanding as of [_], 2026, which includes 200,000 BCAR Class A Ordinary
Shares underlying the Private Units and 12,000,000 BCAR Class B Ordinary Share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the foregoing assumptions and Exascale&#8217;s
balance of capital stock as of [_], 2026, we estimate that there would be 91,200,000 shares of PubCo Common Stock issued and outstanding
immediately following the consummation of the Business Combination. If the actual facts are different from the foregoing assumptions,
ownership figures in the combined company and the columns under Post-Business Combination in the table that follows will be different.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise indicated, BCAR believes that all
persons named in the table below have sole voting and investment power with respect to the voting securities beneficially owned by them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 281; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->264<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Beneficial Ownership of BCAR Ordinary Shares before
the closing of the Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><b>Name and Address of Beneficial
        Owner<sup>(1)</sup></b></td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/>Shares Beneficially<br/>Owned</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% of<br/>Class</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold; text-align: left">Directors and
        Executive Officers</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">David Boral<sup>(2)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">John Darwin<sup>(3)(4)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Kevin Chen</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Luisa Ingargiola</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Matt Laker</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">All officers and directors
        as a group (5 individuals)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">5% Stockholders other than
        Directors and Officers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">MFH 1, LLC<sup>(3)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: justify"><sup>(1)</sup>&#160;</td>
    <td style="vertical-align: top; text-align: justify">Unless otherwise noted, the business address of each of the following is c/o D. Boral
        ARC Acquisition I Corp., 10 E. 53rd St. Suite 3001, New York, NY 10022.</td> </tr>
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><sup>(2)</sup>&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Interests shown consist solely of Representative Shares, classified as BCAR
        Class A Ordinary Shares.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><sup>(3)</sup>&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Interests shown consist solely of 12,000,000 BCAR Class B Ordinary Shares and
        200,000 Private Placement Shares. The Founder Shares will automatically convert into BCAR Class A Ordinary Shares concurrently with or
        immediately following the consummation of our initial business combination or earlier at the option of the holder on a one-for-one basis,
        subject to adjustment, as described in the section entitled &#8220;<i>Description of Securities.</i>&#8221;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><sup>(4)</sup>&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">MFH 1, LLC is the record holder of the 12,000,000 BCAR Class B Ordinary Shares
        and 200,000 Private Placement Shares. John Darwin is the manager of MFH 1, LLC and accordingly, Mr. Darwin has sole voting and investment
        discretion with respect to the ordinary shares held of record by MFH 1, LLC. However, Mr. Darwin disclaims any economic interest in the
        shares held by MFH 1, LLC, except to the extent of his pecuniary interest therein.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 282; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->265<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Beneficial Ownership of Exascale Securities Prior to the Business
Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Name
        and Address of Beneficial Owner<sup>(1)</sup></b></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exascale Class A Common Stock Beneficially Owned</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exascale Class B Common Stock Beneficially Owned</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Percentage of Outstanding Exascale Securities<sup>(2)</sup></b></td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Voting Percentage of Outstanding Exascale
        Securities<sup>(3)</sup></b></td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 52%; vertical-align: top">Hoansoo Lee<sup>(4)</sup></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#8212;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">150.0</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">10.0</td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">12.4</td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Wenying Jia<sup>(5)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,047.0</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">69.8</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">86.4</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">All directors and executive officers as a
        group (2 persons)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,197.0</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">79.8</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">98.8</td>
    <td style="text-align: left">%</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">(1)</td>
    <td style="text-align: justify">Unless otherwise noted, the business address of each of the following is c/o Exascale Labs Inc., 820 Gessner
        Road, Suite 332, Houston, Texas 77024.</td></tr>
  <tr style="vertical-align: top">
    <td>(2)</td>
    <td style="text-align: justify">Percentage ownership is based on 1,500 Exascale Common Stock outstanding, consisting of (i) 303 shares of
        Exascale Class A Common Stock and (ii) 1,197 shares of Exascale Class B Common Stock.</td></tr>
  <tr style="vertical-align: top">
    <td>(3)</td>
    <td style="text-align: justify">Each share of Exascale Class A Common Stock is entitled to one vote per share on all matters submitted to
        a vote of the stockholders of Exascale and each share of Exascale Class B Common Stock is entitled to 20 votes per share on all matters
        submitted to a vote of the stockholders of Exascale. The voting percentage is calculated based on such voting rights.</td></tr>
  <tr style="vertical-align: top">
    <td>(4)</td>
    <td style="text-align: justify">Consists (i) 60 shares of Exascale Class B Common Stock directly held by HSL Capital Management LLC, (ii)
        30 shares of Exascale Class B Common Stock directly held by Jisu Paul Lee Non-Grantor Directed Trust, (iii) 30 shares of Exascale Class
        B Common Stock directly held by Sophia Jisun Lee Non-Grantor Directed Trust and (iv) shares of Exascale Class B Common Stock directly
        held by Gabriel Jihwan Lee Non-Grantor Directed Trust. Mr. Lee is the sole member and manager of HSL Capital Management LLC and has sole
        voting and dispositive power over the shares directly held by HSL Capital Management LLC. Mr. Lee is the settlor of, and serves as investment
        advisor to, each of the Jisu Paul Lee Non-Grantor Directed Trust, the Sophia Jisun Lee Non-Grantor Directed Trust, and the Gabriel Jihwan
        Lee Non-Grantor Directed Trust, and the beneficiaries of each of those trusts are the children of Hoansoo Lee. As such, Mr. Lee may be
        deemed to beneficially own the shares directly held by such trusts. Mr. Lee disclaims beneficial ownership of such shares directly held
        by such trusts except to the extent of his pecuniary interest therein, if any, and the inclusion of such shares in this table shall not
        be deemed an admission of beneficial ownership for any purpose.</td></tr>
  <tr style="vertical-align: top">
    <td>(5)</td>
    <td style="text-align: justify">Consists of shares of Exascale Class B Common Stock directly held by Zerowave Ltd. Ms. Jia is the sole member
        and manager of Zerowave Ltd and has sole voting and dispositive power with respect to the shares directly held by Zerowave Ltd.</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Beneficial Ownership of PubCo&#8217;s Common Stock
after the closing of the Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><b>Name</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>PubCo<br/> Class A<br/>
        Ordinary Common Stock<br/> Beneficially Owned</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Percent of<br/> PubCo<br/>
        Class A<br/> Ordinary Common Stock</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>PubCo<br/>
        Class B<br/> Super Common Stock. Beneficially Owned</b></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td>
    <td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Percent
        of<br/> PubCo<br/> Class B<br/> Super Common Stock</b></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td>
    <td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Percent
        of <br/>Voting Control<sup>(7)</sup></b></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%; font-weight: bold; text-align: left">Directors,
        New Director Nominee and Other Named Executive Officers</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Hoansoo Lee</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Wenying Jia</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">David Card</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shachar Kariv</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Jaeyoung Shin</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">5% Stockholders
        other than Directors and Officers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">[_]</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">[_]</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: justify; width: 0.25in"><sup>(1)</sup>&#160;</td>
    <td style="vertical-align: top; text-align: justify">Unless otherwise noted, the business address of each of the following is c/o Exascale
        Labs Holdings Inc., 820 Gessner Road, Suite 332, Houston, Texas 77024</td> </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><sup>(2)</sup>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><sup>(3)</sup>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 283; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->266<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_031"></span>CERTAIN RELATIONSHIPS AND
RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Certain Relationships and Related Transactions&#8212;BCAR</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March&#160;25, 2025, the Sponsor purchased,
and BCAR issued to the Sponsor, 12,321,429 BCAR Class B Ordinary Shares for an aggregate purchase price of $25,000 (up to 1,607,143 of
which were subject to forfeiture by the holders thereof depending on the extent to which the underwriter&#8217;s over-allotment option
is exercised). Following the partial exercise of the over-allotment option, the Sponsor forfeited 321,429 BCAR Class B Ordinary Shares
for no consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sponsor purchased an aggregate of 200,000
Private Units at a price of $10.00 per unit, or $2,000,000 in the aggregate, in a private placement that closed simultaneously with the
closing of the IPO. The Private Units are identical to the BCAR Units sold in the IPO except that the Private Units (including the component
securities as well as any securities underlying those component securities) (i) are locked-up until the completion of our initial business
combination, (ii) are entitled to registration rights and (iii) the BCAR Class A Ordinary Shares included as a component of the Private
Units are not entitled to redemption rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are no redemption rights or liquidating distributions
from the trust account with respect to the Founder Shares and the Private Units (or the underlying securities), which will expire worthless
if we do not consummate a business combination within the allotted 18-month period (or 21 months, if extended).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to or in connection with the completion of our
initial business combination, there may be payment by the company to the Sponsor, officers or directors, advisor, or our or their affiliates,
of a finder&#8217;s fee, advisory fee, consulting fee or success fee for any services they render in order to effectuate the completion
of our initial business, which, if made prior to the completion of our initial business combination, will be paid from funds held outside
the trust account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We will reimburse an affiliate of the Sponsor in an
amount equal to $20,000 per month for office space, utilities and secretarial, and administrative support services made available to us.
Upon completion of our initial business combination or our liquidation, we will cease paying these monthly fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to the closing of the IPO, the Sponsor loaned
us funds in an aggregate amount of up to $350,000 to be used for a portion of the expenses of the IPO. This loan was non-interest bearing
and was repaid upon the consummation of the IPO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in order to finance transaction costs
in connection with an intended initial business combination, the Sponsor or an affiliate of the Sponsor or certain of our officers and
directors may, but are not obligated to, loan us funds as may be required on a non-interest basis. If we complete an initial business
combination, we would repay such loaned amounts. In the event that the initial business combination does not close, we may use amounts
held outside the trust account to repay such loaned amounts but no proceeds from our trust account would be used for such repayment. Up
to $2,500,000 of such loans may be convertible into Private Unites of the post business combination entity at a price of $10.00 per unit
at the option of the applicable lender. Such units would be identical to the Private Units. Except as set forth above, the terms of such
loans, if any, have not been determined and no written agreements exist with respect to such loans. Prior to the completion of our initial
business combination, we do not expect to seek loans from parties other than the Sponsor or an affiliate of the Sponsor as we do not believe
third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our trust
account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have until the date that is 18 months from
the closing of the IPO, with one (1) three-month extension at the option of the Sponsor (as may be extended by shareholder approval to
amend our amended and restated memorandum and articles of association to extend the date by which we must consummate our initial business
combination) or until such earlier liquidation date as our board of directors may approve, to consummate our initial business combination.
If we anticipate that we may be unable to consummate our initial business combination within such 21-month period, we may seek shareholder
approval to amend our amended and restated memorandum and articles of association to extend the date by which we must consummate our initial
business combination. There are no limitations on the number of times we may seek shareholder approval for an extension or the length
of time of any such extension. However, if we seek shareholder approval for an extension, holders of Public Shares will be offered an
opportunity to redeem their shares at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account,
including interest earned thereon (less taxes payable), divided by the number of then issued and outstanding Public Shares, subject to
applicable law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 284; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->267<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any of the foregoing payments to the Sponsor, repayments
of loans from the Sponsor or repayments of working capital loans prior to our initial business combination will be made using funds held
outside the trust account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After our initial business combination, members of
our management team who remain with us may be paid consulting, management or other fees from the combined company with any and all amounts
being fully disclosed to our shareholders, to the extent then known, in the proxy solicitation or tender offer materials, as applicable,
furnished to our shareholders. It is unlikely the amount of such compensation will be known at the time of distribution of such tender
offer materials or at the time of a general meeting held to consider our initial business combination, as applicable, as it will be up
to the directors of the post-combination business to determine executive and director compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As described herein, each of our officers and directors
presently has, and any of them in the future may have additional, fiduciary, contractual or other obligations or duties to one or more
other entities, pursuant to which such officer or director is or will be required to present a business combination opportunity to such
entities. Accordingly, if any of our officers or directors becomes aware of a business combination opportunity which is suitable for an
entity to which he or she has then current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual
obligations to present such business combination opportunity to such other entity, subject to their fiduciary duties under British Virgin
Islands law. Our amended and restated memorandum and articles of association provide that, to the fullest extent permitted by law: (i)
no individual serving as a director or an officer, among other persons, shall have any duty, except and to the extent expressly assumed
by contract, to refrain from engaging directly or indirectly in the same or similar business activities or lines of business as us, and
(ii) we renounce any interest or expectancy in, or in being offered an opportunity to participate in, any potential transaction or matter
which (a) may be a corporate opportunity for any director or officer, on the one hand, and us, on the other or (b) the presentation of
which would breach an existing legal obligation of a director or officer to any other entity. As a result, the fiduciary duties or contractual
obligations of our officers or directors could materially affect our ability to complete our initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Policy for Approval of Related Party Transactions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The audit committee of our board of directors have
adopted a policy setting forth the policies and procedures for its review and approval or ratification of &#8220;related party transactions.&#8221;
A &#8220;related party transaction&#8221; is any consummated or proposed transaction or series of transactions: (i) in which the company
was or is to be a participant; (ii) the amount of which exceeds (or is reasonably expected to exceed) the lesser of $120,000 or 1% of
the average of the company&#8217;s total assets at year-end for the prior two completed fiscal years in the aggregate over the duration
of the transaction (without regard to profit or loss); and (iii) in which a &#8220;related party&#8221; had, has or will have a direct
or indirect material interest. &#8220;Related parties&#8221; under this policy include: (i) our directors, nominees for director or officers
or any person who has served in such roles since the beginning of the most recent fiscal year, even if he or she does not currently serve
in that role; (ii) any record or beneficial owner of more than 5% of any class of our voting securities; (iii) any immediate family member
of any of the foregoing if the foregoing person is a natural person; and (iv) any other person who maybe a &#8220;related person&#8221;
pursuant to Item 404 of Regulation S-K under the Exchange Act. Pursuant to the policy, the audit committee will consider (i) the relevant
facts and circumstances of each related party transaction, including if the transaction is on terms comparable to those that could be
obtained in arm&#8217;s-length dealings with an unrelated third party, (ii) the extent of the related party&#8217;s interest in the transaction,
(iii) whether the transaction contravenes our code of ethics or other policies, (iv) whether the audit committee believes the relationship
underlying the transaction to be in the best interests of the company and its shareholders and (v) if the related party is a director
or an immediate family member of a director, the effect that the transaction may have on a director&#8217;s status as an independent member
of the board and on his or her eligibility to serve on the board&#8217;s committees. Management will present to the audit committee each
proposed related party transaction, including all relevant facts and circumstances relating thereto. Under the policy, we may consummate
related party transactions only if our audit committee approves or ratifies the transaction in accordance with the guidelines set forth
in the policy. The policy will not permit any director or officer to participate in the discussion of, or decision concerning, a related
person transaction in which he or she is the related party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 285; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->268<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are not prohibited from paying any fees (including
advisory fees), reimbursements or cash payments to the Sponsor, our officers or directors, or our or their affiliates, for services rendered
to us prior to or in connection with the completion of our initial business combination, including the following payments, all of which,
if made prior to the completion of our initial business combination, will be paid from funds held outside the trust account:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">reimbursement for office space, utilities and secretarial, and administrative support
        services made available to us by an affiliate of the Sponsor, in an amount equal to $20,000 per month;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">Payment of consulting, success or finder fees to our independent directors, advisor,
        or their respective affiliates in connection with the consummation of our initial business combination;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">We may engage the Sponsor or an affiliate of the Sponsor as an advisor or otherwise in
        connection with our initial business combination and certain other transactions and pay such person or entity a salary or fee in an amount
        that constitutes a market standard for comparable transactions;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">Reimbursement for any out-of-pocket expenses related to identifying, investigating, negotiating
        and completing an initial business combination; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">Repayment of loans which may be made by the Sponsor or an affiliate of the Sponsor or
        certain of our officers and directors to finance transaction costs in connection with an intended initial business combination. Up to
        $2,500,000 of such loans may be convertible into Private Units of the post-business combination entity at a price of $10.00 per unit at
        the option of the applicable lender. Such units would be identical to the Private Units. Except for the foregoing, the terms of such loans,
        if any, have not been determined and no written agreements exist with respect to such loans.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Certain Relationships and Related Person Transactions&#8201;&#8212;&#8201;Exascale</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended June 30, 2023, 2024 and 2025,
for the three months ended September 30, 2025, and for the period since October 1, 2025 up to the date of the document, Exascale incurred
and paid consulting fees totaling $58,310, $75,245, $100,150, $27,000 and nil, respectively, to Hoansoo Lee, Exascale&#8217;s Chief Executive
Officer and Chief Financial Officer, pursuant to Exascale&#8217;s consulting arrangement with Hoansoo Lee. See &#8220;<i>Compensation
of Named Executive Officers and Directors of Exascale</i>&#8221; for additional information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended June 30, 2023, Exascale incurred
and paid consulting fees totaling $45,947 to LP Real Estate Holdings LLC, for consulting services provided by LP Real Estate Holdings
LLC to Exascale. LP Real Estate Holdings LLC is 100% owned by Hoansoo Lee, Exascale&#8217;s Chief Executive Officer and Chief Financial
Officer. There were no consulting fees incurred with such entity for the years ended June 30, 2024, and 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 286; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->269<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_032"></span>COMPARISON OF CORPORATE
GOVERNANCE AND SHAREHOLDER RIGHTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR is a business company incorporated under the
Companies Act. The Companies Act and the Current Charter govern the rights of its shareholders. The Companies Act differs in some material
respects from laws generally applicable to United States corporations and their stockholders. In addition, the Current Charter will differ
in certain material respects from the Proposed Organizational Documents. As a result, when you become a stockholder of PubCo, your rights
will differ in some regards as compared to when you were a shareholder of BCAR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Below is a summary chart outlining important similarities
and differences in the corporate governance and stockholder/shareholder rights associated with each of BCAR and PubCo according to applicable
law or the organizational documents of BCAR and PubCo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This summary is qualified by reference to the complete
text of the Current Charter of BCAR, attached to this proxy statement/prospectus as Exhibit 3.1, the complete text of the Proposed Charter,
a copy of which is attached to this proxy statement/prospectus as <i>Annex B-1</i>, and the complete text of the Proposed Bylaws, a copy
of which is attached to this proxy statement/prospectus as <i>Annex B-2</i>. You should review each of the Proposed Organizational Documents,
as well as the Delaware corporate law and corporate laws of the British Virgin Islands, including the Companies Act, to understand how
these laws apply to PubCo and BCAR, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>British
        Virgin Islands</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-bottom: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Shareholder
        Meetings</span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Held
        at a time and place as designated in the articles of association. Our articles of association provide that our board may designate such
        time and place.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
        be held within or without the British Virgin Islands</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice:</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="margin-left: 0.25in; text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever
        shareholders are required to take action at a meeting, written notice shall state the place, date and hour of the meeting and indicate
        that it is being issued by or at the direction of the person calling the meeting.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="margin-left: 0.25in; text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
        copy of the notice of any meeting shall be given personally or sent by mail or electronic form as designated in the Articles of Association.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="margin-left: 0.25in; text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
        of not less than 7&#160;days&#8217; before the meeting</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Held
        at such time or place as designated in the certificate of incorporation or the by-laws, or if not so designated, as determined by the
        board of directors</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
        be held within or without Delaware</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice:</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="margin-left: 0.25in; text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever
        shareholders are required to take any action at a meeting, a written notice of the meeting shall be given which shall state the place,
        if any, date and hour of the meeting, and the means of remote communication, if any.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="margin-left: 0.25in; text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
        notice shall be given not less than 10 nor more than 60&#160;days before the meeting.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-bottom: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Shareholders&#8217;
        Voting Rights</span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-bottom: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
        action required to be taken by meeting of shareholders may be taken without meeting if consent is in writing and is signed by a majority
        of the shareholders entitled to vote if permitted by the articles of association. Our articles of association provide for such consent
        in writing.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
        person authorized to vote may authorize another person or persons to act for him by proxy if permitted by the articles of association.
        Our articles of association permit such proxies.</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
        action required to be taken by meeting of shareholders may be taken without meeting if consent is in writing and is signed by all the
        shareholders entitled to vote</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
        person authorized to vote may authorize another person or persons to act for him by proxy.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
        stock corporations, certificate of incorporation or by-laws may specify the number to constitute a quorum but in no event shall a quorum
        consist of less than one-third of shares entitled to vote at a meeting. In the absence of such specifications, a majority of shares entitled
        to vote shall constitute a quorum.</span></p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 287; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->270<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>British
        Virgin Islands</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quorum
        is as designated in the articles of Association. Quorum in our articles of association is shareholders representing not less than one-half
        of the votes of the shares entitled to vote on resolutions of members to be considered at the meeting.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
        amended and restated memorandum and articles of association may provide for cumulative voting in the election of directors. Our articles
        of association do not provide for cumulative voting.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
        in the rights of shareholders as set forth in the amended and restated memorandum and articles of association require approval of at least
        50% of the shareholders.</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
        certificate of incorporation may provide for cumulative voting.</span></p> </td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-bottom: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Directors</span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-bottom: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
        must consist of at least one director. Our articles of association provide that there shall be no less than two directors.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum
        number of directors can be changed by an amendment to the articles of association. Our articles of association do not provide for a maximum
        number.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
        the board is authorized to change the number of directors actually appointed, provided that the number still falls within the maximum
        and the minimum number of directors as set out in the articles of association, it can do so provided that it complies with the procedure
        set out in the articles of association. Our articles of association permit our board to appoint additional directors.</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
        must consist of at least one member.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
        of board members shall be fixed by the by-laws, unless the certificate of incorporation fixes the number of directors, in which case a
        change in the number shall be made only by amendment of the certificate.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-bottom: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Fiduciary
        Duties</span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-bottom: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
        summary, directors and officers owe the following fiduciary duties:</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="margin-left: 0.25in; text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duty
        to act in good faith in what the directors believe to be in the best interests of the company as a whole;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="margin-left: 0.25in; text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duty
        to exercise powers for the purposes for which those powers were conferred and not for a collateral purpose;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="margin-left: 0.25in; text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
        should not improperly fetter the exercise of future discretion;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
        and officers must act in good faith, with the care of a prudent person, and in the best interest of the corporation as a whole.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
        and officers must refrain from self-dealing, usurping corporate opportunities and receiving improper personal benefits.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decisions
        made by directors and officers on an informed basis, in good faith and in the honest belief that the action was taken in the best interest
        of the corporation will be protected by the &#8220;business judgment rule.&#8221;</span></p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 288; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->271<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>British
        Virgin Islands</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <div style="margin-left: 0.25in; text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duty
        to exercise powers fairly as between different groups of shareholders;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="margin-left: 0.25in; text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duty
        not to put himself in a position of conflict between their duty to the company and their personal interests; and</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="margin-left: 0.25in; text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duty
        to exercise independent judgment.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
        addition to the above, directors also owe a duty of care which is not fiduciary in nature. This duty has been defined as a requirement
        to act as &#8220;a reasonably diligent person having both:</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="margin-left: 0.25in; text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
        general knowledge, skill and experience that may reasonably be expected of a person carrying out the same functions as are carried out
        by that director in relation to the company, and</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="margin-left: 0.25in; text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
        nature of the company, the nature of the decision and the position of the director and the responsibilities undertaken.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
        set out above, directors have a duty not to put themselves in a position of conflict and this includes a duty not to engage in self-dealing,
        or to otherwise benefit as a result of his position. However, in some instances a breach of this duty can be forgiven and/or authorized
        in advance by the shareholders provided that there is full disclosure by the directors. This can be done by way of permission granted
        in the articles of association or alternatively by shareholder approval at general meetings.&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Shareholders&#8217;
        Derivative Actions</span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally
        speaking, the company is the proper plaintiff in any action. Derivative actions brought by one or more of the registered shareholders
        may only be brought with the leave of the Supreme Court where the following circumstances apply:</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="margin-left: 0.25in; text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Those
        who control the company have refused a request by the shareholders to move the company to bring the action;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="margin-left: 0.25in; text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Those
        who control the company have refused to do so for improper reasons such that they are perpetrating a &#8220;fraud on the minority&#8221;
        (this is a legal concept and is different to &#8220;fraud&#8221; in the sense of dishonesty);</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
        any derivative suit instituted by a shareholder of a corporation, it shall be averred in the complaint that the plaintiff was a shareholder
        of the corporation at the time of the transaction of which he complains or that such shareholder&#8217;s stock thereafter devolved upon
        such shareholder by operation of law.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complaint
        shall set forth with particularity the efforts of the plaintiff to obtain the action by the board or the reasons for not making such effort.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
        action shall not be dismissed or compromised without the approval of the Chancery Court.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 289; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->272<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>British
        Virgin Islands</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <div style="margin-left: 0.25in; text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
        company is acting or proposing to act illegally or beyond the scope of its authority;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="margin-left: 0.25in; text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
        act complained of, although not beyond the scope of the authority, could only be effected if duly authorized by more than the number of
        votes which have actually been obtained; or</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="margin-left: 0.25in; text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
        individual rights of the plaintiff shareholder have been infringed or are about to be infringed.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
        a shareholder has relinquished his, her or its shares (whether by redemption or otherwise), it is generally the case that they could no
        longer bring a derivative action as they would no longer be a registered shareholder.</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <div style="text-align: justify; float: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></div>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
        of a Delaware corporation that redeemed their shares, or whose shares were canceled in connection with dissolution, would not be able
        to bring a derivative action against the corporation after the shares have been redeemed or canceled.</span></p></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Material Differences in British Virgin Islands
and Delaware Law</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We believe that the material
differences between British Virgin Islands and Delaware corporate law are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify"><i>Shareholder Notice. </i>Delaware law requires written notice of shareholders meetings of between 10 and
        60&#160;days. British Virgin Islands law permits a company&#8217;s articles to have 7&#160;days&#8217; notice. Our amended and restated
        memorandum and articles of Association provide that we must give shareholders 7&#160;days&#8217; (exclusive of the date that notice is
        given and the date on which event for which notice is given is to take effect) notice of shareholders meetings.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify"><i>Quorum. </i>Delaware law requires a minimum quorum of one-third of the issued and outstanding shares for
        a shareholders meeting, whereas British Virgin Islands law enables a company&#8217;s articles of association to designate the minimum
        quorum requirements. Our amended and restated memorandum and articles of association provide that a quorum consists of shareholders representing
        at least 30% of the votes of the shares entitled to vote on resolutions of members to be considered at the meeting.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify"><i>Shareholder Derivative Suits. </i>Delaware generally allows shareholders to commence derivative actions
        in their own name. Under British Virgin Islands law, derivative actions are normally instituted by a shareholder in the name of the company
        and require leave of the Court. Accordingly, British Virgin Islands law is more restrictive than Delaware law and shareholders may be
        restricted from initiating shareholder derivative suits in their own name.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Certain Differences in Corporate Law</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our corporate affairs are
governed by our amended and restated memorandum and articles of association and the provisions of applicable British Virgin Islands law,
including the Companies Law. The Companies Law differs from laws applicable to United&#160;States corporations and their shareholders.
Set forth below is a summary of the material differences between the provisions of the Companies Law applicable to us and the laws applicable
to companies incorporated in the United&#160;States and their shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 290; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->273<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Mergers and Similar Arrangements.
</i>The Companies Law provides for mergers as that expression is understood under United&#160;States corporate law. Under the Companies
Law, two or more companies may either merge into one of such existing companies (the &#8220;surviving company&#8221;) or consolidate with
both existing companies ceasing to exist and forming a new company (the &#8220;consolidated company&#8221;). The procedure for a merger
or consolidation between the company and another company (which need not be a BVI business company, and which may be the company&#8217;s
parent or subsidiary, but need not be) is set out in the Companies Law. The directors of the BVI business company or BVI business companies
which are to merge or consolidate must approve a written plan of merger or consolidation which., with the exception of a merger between
a parent company and its subsidiary, must also be approved by a resolution of a majority of the shareholders who are entitled to vote
and actually vote at a quorate meeting of shareholders or by written resolution of the shareholders of the BVI business company or BVI
business companies which are to merge. A foreign company which is able under the laws of its foreign jurisdiction to participate in the
merger or consolidation is required by the Companies Law to comply with the laws of that foreign jurisdiction in relation to the merger
or consolidation. The company must then execute articles of merger or consolidation, containing certain prescribed details. The plan and
articles of merger or consolidation are then filed with the Registrar of Corporate Affairs in the British Virgin Islands. The Registrar
then registers the articles of merger or consolidation and any amendment to the memorandum and articles of the surviving company in a
merger or the memorandum and articles of association of the new consolidated company in a consolidation and issue a certificate of merger
or consolidation (which is conclusive evidence of compliance with all requirements of the Companies Law in respect of the merger or consolidation).
The merger is effective on the date that the articles of merger are registered with the Registrar or on such subsequent date, not exceeding
thirty&#160;days, as is stated in the articles of merger or consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As soon as a merger becomes
effective: (a)&#160;the surviving company or consolidated company (so far as is consistent with its memorandum and articles of association,
as amended or established by the articles of merger or consolidation) has all rights, privileges, immunities, powers, objects and purposes
of each of the constituent companies; (b)&#160;in the case of a merger, the memorandum and articles of association of any surviving company
are automatically amended to the extent, if any, that changes to its amended memorandum and articles of association are contained in the
articles of merger or, in the case of a consolidation, the memorandum and articles of association filed with the articles of consolidation
are the memorandum and articles of the consolidated company; (c)&#160;assets of every description, including choses-in-action and the
business of each of the constituent companies, immediately vest in the surviving company or consolidated company; (d)&#160;the surviving
company or consolidated company is liable for all claims, debts, liabilities and obligations of each of the constituent companies; (e)&#160;no
conviction, judgment, ruling, order, claim, debt, liability or obligation due or to become due, and no cause existing, against a constituent
company or against any member, director, officer or agent thereof, is released or impaired by the merger or consolidation; and (f)&#160;no
proceedings, whether civil or criminal, pending at the time of a merger by or against a constituent company, or against any member, director,
officer or agent thereof, are abated or discontinued by the merger or consolidation; but: (i)&#160;the proceedings may be enforced, prosecuted,
settled or compromised by or against the surviving company or consolidated company or against the member, director, officer or agent thereof;
as the case may be; or (ii)&#160;the surviving company or consolidated company may be substituted in the proceedings for a constituent
company. The Registrar shall strike off the register of companies each constituent company that is not the surviving company in the case
of a merger and all constituent companies in the case of a consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If the directors determine
it to be in the best interests of the company, it is also possible for a merger to be approved as a Court approved plan of arrangement
or scheme of arrangement in accordance with the Companies Law. However, we do not anticipate the use of such statutory provisions because
we expect the required terms of the initial business combination will be capable of being achieved through other means, such as a merger
or consolidation (as described above), a share exchange, asset acquisition or control, through contractual arrangements, of an operating
business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Poison Pill Defenses.
</i>Under the Companies Law there are no provisions, which specifically prevent the issuance of preferred shares or any such other &#8216;poison
pill&#8217; measures. The amended and restated memorandum and articles of association of the Company also do not contain any express prohibitions
on the issuance of any preferred shares. Therefore, the directors without the approval of the holders of ordinary shares may issue preferred
shares (if such shares have been created and authorized for issue by the Company) that have characteristics that may be deemed to be anti-takeover.
Additionally, such a designation of shares may be used in connection with plans that are poison pill plans. However, as noted above under
the Companies Law, a director in the exercise of his powers and performance of his duties is required to act honestly and in good faith
in what the director believes to be the best interests of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 291; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->274<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Directors. </i>Our directors are appointed
by our Class&#160;B ordinary shareholders prior to the closing of a business combination and by our shareholders or directors after closing
of a business combination. After the closing of a business combination, each director holds office for the term, if any, fixed by a resolution
of our shareholders or a resolution of our directors, and if no such term is fixed on the appointment of a director, the director shall
serve indefinitely until his earlier death, resignation or removal. After closing of a business combination, the directors may by resolution
appoint a replacement director to fill a casual vacancy arising on the resignation, disqualification or death of a director. The replacement
director will then hold office until the next annual general meeting at which the director he replaces would have been subject to retirement
by rotation. Under our amended and restated memorandum and articles of association, a director may not be appointed or removed from office
by a resolution of our BCAR Class A Ordinary Shareholders or our directors prior to the consummation of our business combination. There
is nothing under the laws of the British Virgin Islands, which specifically prohibits or restricts the creation of cumulative voting rights
for the election of our directors. Our amended and restated memorandum and articles of association do not provide for cumulative voting
for such elections. There are no share ownership qualifications for directors. Meetings of our board of directors may be convened at any
time by any of our directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">A meeting of our board of
directors will be quorate if at least two directors are present unless the total number of directors of the Company is one, in which case
the quorum shall be one. At any meeting of our directors, each director, by his or her presence, is entitled to one vote. Questions arising
at a meeting of our board of directors are required to be decided by simple majority votes of the directors present or represented at
the meeting. In the case of an equality of votes, the chairman of the meeting shall not have a second or deciding vote. Our board of directors
also may pass resolutions in writing without a meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Agents. </i>Our board
of directors has the power to appoint any person (whether or not a director or other officer of the company) to be an agent of the company
except that, as stated in our amended and restated memorandum and articles of association and the Companies Law, no agent shall be given
any power or authority to amend the memorandum or the articles of association in place of the directors or members; to change the registered
office or registered agent; to designate committees of directors; to delegate powers to a committee of directors; to appoint or remove
directors; to appoint or remove an agent; to approve a plan of merger, consolidation or arrangement; to make a declaration of solvency
or to approve a liquidation plan; or to authorize the Company to continue as a company incorporated under the laws of a jurisdiction outside
the British Virgin Islands. The resolution of directors appointing the agent may authorize the agent to appoint one or more substitutes
or delegates to exercise some or all of the powers conferred on the agent. Our directors may remove an agent and may revoke or vary a
power conferred on the agent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Indemnification of Directors.
</i>Our amended and restated memorandum and articles of association provide that, subject to certain limitations, the company shall indemnify
its directors and officers against all expenses, including legal fees, and against all judgments, fines and amounts paid in settlement
and reasonably incurred in connection with legal, administrative or investigative proceedings. Such indemnity only applies if the person
acted honestly and in good faith with a view to what the person believed were in the best interests of the company and, in the case of
criminal proceedings, the person had no reasonable cause to believe that their conduct was unlawful. The decision of the directors as
to whether the person acted honestly and in good faith and with a view to the best interests of the company and as to whether the person
had no reasonable cause to believe that his conduct was unlawful is, in the absence of fraud, sufficient for the purposes of the memorandum
and articles of association, unless a question of law is involved. The termination of any proceedings by any judgment, order, settlement,
conviction or the entering of a nolle prosequi does not, by itself, create a presumption that the person did not act honestly and in good
faith and with a view to the best interests of the company or that the person had reasonable cause to believe that his conduct was unlawful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Directors and Conflicts
of Interest. </i>As noted in the table above, pursuant to the Companies Law and the company&#8217;s amended and restated memorandum and
articles of association, a director of a company who has an interest in a transaction and who has declared such interest to the other
directors, may:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">(a)</td>
    <td style="text-align: justify">vote on a matter relating to the transaction;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">(b)</td>
    <td style="text-align: justify">attend a meeting of directors at which a matter relating to the transaction arises and be included among the
        directors present at the meeting for the purposes of a quorum; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">(c)</td>
    <td style="text-align: justify">sign a document on behalf of the Company, or do any other thing in his capacity as a director, that relates
        to the transaction.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<!-- Field: Page; Sequence: 292; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->275<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Shareholders&#8217; Suits.
</i>Our British Virgin Islands counsel is not aware of any reported class action having been brought in a British Virgin Islands court.
The enforcement of the company&#8217;s rights will ordinarily be a matter for its directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In certain limited circumstances,
a shareholder has the right to seek various remedies against the company in the event the directors are in breach of their duties under
the Companies Law. Pursuant to Section&#160;184B of the Companies Law, if a company or director of a company engages in, or proposes to
engage in or has engaged in, conduct that contravenes the provisions of the Companies Law or the memorandum or articles of association
of the company, the British Virgin Islands Court may, on application of a shareholder or director of the company, make an order directing
the company or director to comply with, or restraining the company or director from engaging in conduct that contravenes the Companies
Law or the memorandum or articles. Furthermore, pursuant to section 184I(1)&#160;of the Companies Law a shareholder of a company who considers
that the affairs of the company have been, are being or likely to be, conducted in a manner that is, or any acts of the company have been,
or are likely to be oppressive, unfairly discriminatory, or unfairly prejudicial to him in that capacity, may apply to the British Virgin
Islands Court for an order which, inter alia, can require the company or any other person to pay compensation to the shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Companies Law provides
for a series of remedies available to shareholders. Where a company incorporated under the Companies Law conducts some activity, which
breaches the Act or the company&#8217;s memorandum and articles of association, the court can issue a restraining or compliance order.
Under the Companies Law, a shareholder of a company may bring an action against the company for breach of a duty owed by the company to
him as a member. A shareholder also may, with the permission of the British Virgin Islands Court, bring an action or intervene in a matter
in the name of the company, in certain circumstances. Such actions are known as derivative actions. As noted above, the British Virgin
Islands Court may only grant permission to bring a derivative action where the following circumstances apply:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">the company does not intend to bring, diligently continue or defend or discontinue proceedings; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">it is in the interests of the company that the conduct of the proceedings not be left to the directors or
        to the determination of the shareholders as a whole.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">When considering whether to grant leave, the British Virgin Islands Court is also required to have regard
        to the following matters:</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">whether the shareholder is acting in good faith;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">whether a derivative action is in the company&#8217;s best interests, taking into account the directors&#8217;
        views on commercial matters;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">whether the action is likely to proceed;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">the costs of the proceedings; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">whether an alternative remedy is available.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Any member of a company
may apply to the British Virgin Islands Court under the Insolvency Act for the appointment of a liquidator to liquidate the company and
the court may appoint a liquidator for the company if it is of the opinion that it is just and equitable to do so.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Companies Law provides
that any shareholder of a company is entitled to payment of the fair value of his shares upon dissenting from any of the following: (a)&#160;a
merger if the company is a constituent company, unless the company is the surviving company and the member continues to hold the same
or similar shares; (b)&#160;a consolidation if the company is a constituent company; (c)&#160;any sale, transfer, lease, exchange or other
disposition of more than 50 per cent in value of the assets or business of the company if not made in the usual or regular course of the
business carried on by the company but not including: (i)&#160;a disposition pursuant to an order of the court having jurisdiction in
the matter, (ii)&#160;a disposition for money on terms requiring all or substantially all net proceeds to be distributed to the members
in accordance with their respective interest within one year after the date of disposition, or (iii)&#160;a transfer pursuant to the power
of the directors to transfer assets for the protection thereof; (d)&#160;a compulsory redemption of 10 per cent, or fewer of the issued
shares of the company required by the holders of 90 percent, or more of the shares of the company pursuant to the terms of the Act; and
(e)&#160;a plan of arrangement, if permitted by the British Virgin Islands Court.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 293; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->276<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Generally any other claims
against a company by its shareholders must be based on the general laws of contract or tort applicable in the British Virgin Islands or
their individual rights as shareholders as established by a company&#8217;s memorandum and articles of association. There are common law
rights for the protection of shareholders that may be invoked, largely derived from English common law. Under the general English company
law known as the rule in <i>Foss v. Harbottle</i>, a court will generally refuse to interfere with the management of a company at the
insistence of a minority of its shareholders who express dissatisfaction with the conduct of the company&#8217;s affairs by the majority
or the board of directors. However, every shareholder is entitled to seek to have the affairs of the company conducted properly according
to law and the constituent documents of the corporation. As such, if those who control the company have persistently disregarded the requirements
of company law or the provisions of a company&#8217;s memorandum and articles of association, then the courts may grant relief. Generally,
the areas in which the courts will intervene are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">a company is acting or proposing to act illegally or beyond the scope of its authority;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">the act complained of, although not beyond the scope of the authority, could only be effected if duly authorized
        by more than the number of votes which have actually been obtained;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">the individual rights of the plaintiff shareholder have been infringed or are about to be infringed; or</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679; </td>
    <td style="text-align: justify">those who control the company are perpetrating a &#8220;fraud on the minority.&#8221;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Under the law of Delaware,
the rights of minority shareholders are similar to that which will be applicable to the shareholders of the company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Compulsory Acquisition.</i>
Under the Companies Law, subject to any limitations in a company&#8217;s memorandum or articles, members holding 90% of the votes of the
outstanding shares entitled to vote, and members holding 90% of the votes of the outstanding shares of each class of shares entitled to
vote, may give a written instruction to the company directing the company to redeem the shares held by the remaining members. Upon receipt
of such written instruction, the company shall redeem the shares specified in the written instruction, irrespective of whether or not
the shares are by their terms redeemable. The company shall give written notice to each member whose shares are to be redeemed stating
the redemption price and the manner in which the redemption is to be effected. A member whose shares are to be so redeemed is entitled
to dissent from such redemption, and to be paid the fair value of his shares, as described under &#8220;Shareholders&#8217; Suits&#8221;
above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Share Repurchases and
Redemptions. </i>As permitted by the Companies Law and our amended and restated memorandum and articles of association, shares may be
repurchased, redeemed or otherwise acquired by us. Depending on the circumstances of the redemption or repurchase, our directors may need
to determine that immediately following the redemption or repurchase we will be able to satisfy our debts as they fall due and the value
of our assets exceeds our liabilities. Our directors may only exercise this power on our behalf, subject to the Companies Law, our amended
and restated memorandum and articles of association and to any applicable requirements imposed from time to time by the SEC, the Nasdaq
Global Market or any other stock exchange on which our securities are listed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Dividends. </i>Subject
to the Companies Law and our amended and restated memorandum and articles of association, our directors may declare dividends at a time
and amount they think fit if they are satisfied, on reasonable grounds, that, immediately after distribution of the dividend, the value
of our assets will exceed our liabilities and we will be able to pay our debts as they fall due. No dividend shall carry interest against
us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Rights of Non-resident
or Foreign Shareholders and Disclosure of Substantial Shareholdings. </i>There are no limitations imposed by our amended and restated
memorandum and articles of association on the rights of non-resident or foreign shareholders to hold or exercise voting rights on our
shares. In addition, there are no provisions in our amended and restated memorandum and articles of association governing the ownership
threshold above which shareholder ownership must be disclosed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Transfer of Shares. </i>Subject
to any applicable restrictions set forth in our amended and restated memorandum and articles of association or contractually agreed, any
of our shareholders may transfer all or any of his or her shares by an instrument of transfer in the usual or common form or in any other
form which our directors may approve.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 294; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->277<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Inspection of Books and
Records. </i>Under the Companies Law, members of the general public, on payment of a nominal fee, can obtain copies of the public records
of a company available at the office of the Registrar which will include the company&#8217;s certificate of incorporation, its memorandum
and articles of association (with any amendments) and records of license fees paid to date and will also disclose any articles of dissolution,
articles of merger and a register of charges if the company has elected to file such a register. A member of a company is entitled, on
giving written notice to the company, to inspect: (a)&#160;the memorandum and articles; (b)&#160;the register of members; (c)&#160;the
register of directors; and (d)&#160;the minutes of meetings and resolutions of members and of those classes of members of which he is
a member; and to make copies of or take extracts from the documents and records referred to in (a)&#160;to (d)&#160;above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Subject to the amended and
restated memorandum and articles of association, the directors may, if they are satisfied that it would be contrary to the company&#8217;s
interests to allow a member to inspect any document, or part of a document, specified in (b), (c)&#160;or (d)&#160;above, refuse to permit
the member to inspect the document or limit the inspection of the document, including limiting the making of copies or the taking of extracts
from the records.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Where a company fails or
refuses to permit a member to inspect a document or permits a member to inspect a document subject to limitations, that member may apply
to the British Virgin Islands Court for an order that he should be permitted to inspect the document or to inspect the document without
limitation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Dissolution; Winding
Up. </i>As permitted by the Companies Law and our amended and restated memorandum and articles of association, we may be voluntarily liquidated
under Part&#160;XII of the Companies Law by resolution of directors and resolution of shareholders if we have no liabilities or we are
able to pay our debts as they fall due.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We also may be wound up
in circumstances where we are insolvent in accordance with the terms of the Insolvency Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 295; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->278<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --> <!-- Field: Split-Segment -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>DESCRIPTION OF SECURITIES OF BCAR</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>As of
the date of this proxy statement/prospectus, BCAR has the following three classes of securities registered under Section 12 of the Exchange
Act: (i) its units, each consisting of one BCAR Class A ordinary share and one-half of one redeemable warrant, (ii) BCAR Class A ordinary
shares, par value $0.0001 per share (the &#8220;<b>BCAR Class A Ordinary Shares</b>&#8221;), and (iii) redeemable warrants, each whole
warrant exercisable for one Class A ordinary share at an exercise price of $11.50. In addition, this Description of Securities also references
BCAR&#8217;s Class B ordinary shares, par value $0.0001 per share (the &#8220;<b>BCAR Class B Ordinary Shares</b>&#8221;), which are
not registered pursuant to Section 12 of the Exchange Act but are convertible into BCAR Class A Ordinary Shares. BCAR Class A Ordinary
Shares. As of March 31, 2026, there were 29,200,000 BCAR Class A Ordinary Shares and 12,000,000 BCAR Class B Ordinary Shares issued and
outstanding. The description of the BCAR Class B Ordinary Shares is included to assist in the description of the BCAR Class A Ordinary
Shares. Unless the context otherwise requires, references to &#8220;Initial Shareholders&#8221; are to the holders of our Founder Shares
prior to our IPO.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a
BVI business company and our affairs are governed by the Current Charter, the Companies Act and the common law of the British Virgin
Islands. Pursuant to the Current Charter, we are authorized to issue 500,000,000 BCAR Class A Ordinary Shares, $0.0001 par value each,
50,000,000 BCAR Class B Ordinary Shares, $0.0001 par value each as well as 5,000,000 BCAR preference shares, $0.0001 par value each.
The following description summarizes certain terms of our securities as set out more particularly in the Current Charter. Because it
is only a summary, it may not contain all the information that is important to you. We encourage you to read the Current Charter for
additional information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Units</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Public Units</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each BCAR
Unit consists of one BCAR Class A Ordinary Share and one-half of one redeemable warrant. Each warrant entitles the holder thereof to
purchase one BCAR Class A Ordinary Share at a price of $11.50 per share, subject to certain adjustment. Pursuant to the Warrant Agreement,
a warrant holder may exercise its warrants only for a whole number of BCAR Class A Ordinary Shares. This means only a whole warrant may
be exercised at any given time by a warrant holder. For example, if a warrant holder holds one-half of one warrant to purchase a BCAR
Class A Ordinary Share, such warrant will not be exercisable. If a warrant holder holds two halves of one warrant, such whole warrant
will be exercisable for one BCAR Class A Ordinary Share at a price of $11.50 per share. The BCAR Units commenced public trading on July
31, 2025, and the BCAR Class A Ordinary Shares and warrants comprising the BCAR Units commenced separate public trading on August 20,
2025 on the Nasdaq Global Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Private Units</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Private Units
(including the component securities of such Private Units as well as any securities underlying such component securities) have terms
and provisions that are identical the BCAR Units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we do not consummate an initial business combination
within the completion window, the proceeds from the sale of the Private Units held in the trust account will be used to fund the redemption
of our Public Shares (subject to the requirements of applicable law) and the Private Units (and the component securities) will expire
worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 296; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->279<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to fund
working capital deficiencies or finance transaction costs in connection with an intended initial business combination, our Sponsor or
an affiliate of our Sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required.
Up to $2,500,000 of such loans may be convertible into private units at a price of $10.00 per unit at the option of the lender at the
time of the business combination. Such units would be identical to the Private Units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following the
expiration of applicable lock-ups with respect to the Private Units, units issuable upon conversion of working capital loans and extension
loans and their respective component securities, such securities will be transferable, assignable or saleable, subject to an effective
registration statement covering such securities or an applicable exemption from registration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Ordinary Shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ordinary shareholders
of record are entitled to one vote for each share held on all matters to be voted on by shareholders. However, only holders of BCAR Class
B Ordinary Shares will have the right to (i) appoint and remove directors in any election held prior to the completion of our initial
business combination, meaning that holders of BCAR Class A Ordinary Shares will not have the right to appoint any directors until after
the completion of our initial business combination and (ii) continue the company in a jurisdiction outside the British Virgin Islands
(including any ordinary resolution required to amend our constitutional documents or to adopt new constitutional documents, in each case,
as a result of our approving a transfer by way of continuation in a jurisdiction outside the British Virgin Islands). The provisions
of the Current Charter governing these matters prior to our initial business combination may only be amended by an ordinary resolution
passed by the affirmative vote of the holders representing at least 90% of the issued BCAR Class B Ordinary Shares. On any other matter
submitted to a vote of our shareholders prior to or in connection with the completion of our initial business combination, holders of
BCAR Class A Ordinary Shares and holders of BCAR Class B Ordinary Shares will vote together as a single class on all matters submitted
to a vote of our shareholders except as required by law. Unless otherwise specified in the Current Charter, or as required by applicable
provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of BCAR Ordinary Shares that are
represented in person or by proxy and are voted is required to approve any such matter voted on by our shareholders. Approval of certain
actions will require an ordinary resolution under British Virgin Islands law, which (except as outlined above) requires the affirmative
vote of in excess of 50 percent of the votes of the holders of BCAR Ordinary Shares as, being entitled to do so, vote in person or, where
proxies are allowed, by proxy at the applicable general meeting, (noting that the Current Charter requires that resolutions put to the
vote of a meeting may be decided on a poll, and regard shall be had to the number of votes to which each member is entitled to cast when
computing whether the requisite approval threshold has been obtained to pass an ordinary resolution); such actions include amending the
Current Charter (other than the provisions referred to above) and approving a statutory merger or consolidation with another company.
The BCAR Board is divided into three classes, each of which will generally serve for a term of three years with only one class of directors
being appointed in each year. There is no cumulative voting with respect to the appointment of directors, with the result that the holders
of more than 50% of the shares entitled to vote and voted for the appointment of directors can appoint all of the directors. Our shareholders
are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally available therefor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because the Current
Charter authorizes the issuance of up to 500,000,000 BCAR Class A Ordinary Shares, if we were to enter into a business combination, we
may (depending on the terms of such a business combination) be required to increase the number of BCAR Class A Ordinary Shares which
we are authorized to issue at the same time as our shareholders vote on the business combination to the extent we seek shareholder approval
in connection with our initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with Nasdaq corporate governance requirements,
we are not required to hold an annual general meeting until one year after our first fiscal year end following our listing on Nasdaq.
There is no requirement under the Companies Act for us to hold annual or general meetings or appoint directors other than to ensure that
the company has at least one director at all times. We may not hold an annual general meeting to appoint new directors prior to the consummation
of our initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 297; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->280<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will provide
our Public Shareholders with the opportunity to redeem all or a portion of their Public Shares, regardless of whether they abstain, vote
for, or vote against, our initial business combination, upon the completion of our initial business combination at a per-share price,
payable in cash, equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation
of our initial business combination, including interest earned on the funds held in the trust account (less taxes payable), divided by
the number of then outstanding Public Shares, subject to the limitations and on the conditions described herein. Our Sponsor, officers
and directors pursuant to a letter agreement with us, they have agreed to waive their redemption rights with respect to their Founder
Shares, Private Shares and any Public Shares they acquired during the IPO or after the IPO, and the representative of the underwriters
pursuant to the underwriting agreement has agreed to waive its redemption rights with respect to its Representative Shares in connection
with the completion of our initial business combination or otherwise, although they will be entitled to liquidating distributions from
the trust account with respect to any Public Shares they hold if we fail to consummate our initial business combination within the completion
window. Unlike many special purpose acquisition companies that hold shareholder votes and conduct proxy solicitations in conjunction
with their initial business combinations and provide for related redemptions of Public Shares for cash upon completion of such initial
business combinations even when a vote is not required by law, if a shareholder vote is not required by law and we do not decide to hold
a shareholder vote for business or other legal reasons, we will, pursuant to the Current Charter, conduct the redemptions pursuant to
the tender offer rules of the SEC, and file tender offer documents with the SEC prior to completing our initial business combination.
The Current Charter requires these tender offer documents to contain substantially the same financial and other information about our
initial business combination and the redemption rights as is required under the SEC&#8217;s proxy rules. If, however, a shareholder approval
of the transaction is required by law, or we decide to obtain shareholder approval for business or other reasons, we, like many special
purpose acquisition companies, would offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and
not pursuant to the tender offer rules. If we seek shareholder approval, we will complete our initial business combination only if we
receive an ordinary resolution under British Virgin Islands law and the Current Charter, which requires the affirmative vote of at least
a majority of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy
at the applicable general meeting of the company. However, if our initial business combination is structured as a statutory merger or
consolidation of the company with another company under British Virgin Islands law, the approval of our initial business combination
will require an ordinary resolution, which requires the affirmative vote of in excess of 50 percent of the votes of the holders of the
ordinary shares as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting,
(noting that the Current Charter requires that resolutions put to the vote of a meeting may be decided on a poll, and regard shall be
had to the number of votes to which each member is entitled to cast when computing whether the requisite approval threshold has been
obtained to pass an ordinary resolution). However, the participation of our Sponsor, officers, directors, the representative of the underwriters
or our or their affiliates in privately-negotiated transactions (as described elsewhere in this proxy statement/prospectus), if any,
could result in the approval of our initial business combination even if a majority of our Public Shareholders vote, or indicate their
intention to vote, against such initial business combination. For purposes of seeking approval of an ordinary resolution, non-votes will
have no effect on the approval of our initial business combination once a quorum is obtained. The Current Charter requires that at least
seven days&#8217; notice will be given of any general meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we seek
shareholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination
pursuant to the tender offer rules, the Current Charter provides that a Public Shareholder, together with any affiliate of such shareholder
or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of
the Exchange Act), will be restricted from redeeming its shares with respect to excess shares without our prior consent. However, we
would not be restricting our shareholders&#8217; ability to vote all of their shares (including excess shares) for or against our initial
business combination. Our shareholders&#8217; inability to redeem the excess shares will reduce their influence over our ability to complete
our initial business combination, and such shareholders could suffer a material loss in their investment if they sell such excess shares
on the open market. Additionally, such shareholders will not receive redemption distributions with respect to the excess shares if we
complete our initial business combination. And, as a result, such shareholders will continue to hold that number of shares exceeding
15% and, in order to dispose such shares, would be required to sell their shares in open market transactions, potentially at a loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 298; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->281<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we seek
shareholder approval in connection with our initial business combination, our Insiders have agreed to vote their Founder Shares, Private
Shares, Representative Shares and any Public Shares purchased during the IPO or after the IPO (including in open market and privately-negotiated
transactions) in favor of our initial business combination (except that any Public Shares such parties may purchase in compliance with
the requirements of Rule&#160;14e-5 under the Exchange Act would not be voted in favor of approving the business combination transaction).
As a result, in addition to the shares held by the Insiders, BCAR would need 7,400,001 Public Shares, or approximately 26.4% of the 28,000,000
Public Shares sold in the BCAR IPO, to be voted in favor of the Business Combination Proposal, the Domestication Merger Proposal, the
Organizational Documents Proposal, the Advisory Organizational Documents Proposals, the Directors Proposal, the Equity Incentive Plan
Proposal, the Nasdaq Proposal, and, if presented, the Adjournment Proposal, in order for such proposals to be approved, assuming all
outstanding shares are voted and the Insiders do not acquire any Public Shares. Assuming that only the holders of thirty percent (30%)
of the issued and outstanding BCAR ordinary shares, representing a quorum under the Current Charter, vote their shares at the Extraordinary
General Meeting, BCAR will not need any Public Shares in addition to the shares held by the Insiders to be voted in favor of the Business
Combination Proposal, the Domestication Merger Proposal, the Organizational Documents Proposal, the Advisory Organizational Documents
Proposals, the Directors Proposal, the Equity Incentive Plan Proposal, the Nasdaq Proposal, and, if presented, the Adjournment Proposal,
in order for such proposals to be approved. Additionally, Public Shareholders may elect to redeem their Public Shares irrespective of
whether they vote for or against the proposed transaction, or whether they do not vote or abstain from voting on the proposed transaction,
or whether they were Public Shareholders on the record date for the general meeting held to approve the proposed transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant
to the Current Charter, if we have not completed our initial business combination within the completion window, we will (i) cease all
operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter
(and subject to lawfully available funds therefor), redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate
amount then on deposit in the trust account, including interest earned on the funds held in the trust account (which interest shall be
net of taxes and less up to $100,000 of interest to pay dissolution expenses), divided by the number of then-outstanding Public Shares,
which redemption will completely extinguish Public Shareholders&#8217; rights as shareholders (including the right to receive further
liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption,
subject to the approval of our remaining shareholders and our board of directors, liquidate and dissolve, subject in each case to our
obligations under British Virgin Islands law to provide for claims of creditors and the requirements of other applicable law. Our Sponsor,
officers and directors pursuant to a letter agreement with us, and the representative of the underwriters in the IPO pursuant to the
underwriting agreement in the IPO and solely with respect to the Representative Shares, have agreed to waive their rights to liquidating
distributions from the trust account with respect to their Founder Shares, Representative Shares and Private Shares if we fail to complete
our initial business combination within the completion window. However, if our Sponsor or management team or the representative of the
underwriters in the IPO acquired Public Shares in the IPO or after the IPO, they will be entitled to liquidating distributions from the
trust account with respect to such Public Shares if we fail to complete our initial business combination within the prescribed time period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the event of a liquidation, dissolution or winding
up of the company after a business combination, our shareholders are entitled to share ratably in all assets remaining available for distribution
to them after payment of liabilities and after provision is made for each class of shares, if any, having preference over the ordinary
shares. Our shareholders have no preemptive or other subscription rights. There are no sinking fund provisions applicable to the ordinary
shares, except that we will provide our Public Shareholders with the opportunity to redeem their Public Shares for cash at a per share
price equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account
(less taxes payable), divided by the number of then outstanding Public Shares, upon the completion of our initial business combination,
subject to the limitations and on the conditions described herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Founder Shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Founder Shares
are designated as BCAR Class B Ordinary Shares and, except as described below, are identical to the BCAR Class A Ordinary Shares, and
holders of Founder Shares have the same shareholder rights as Public Shareholders, except that (i) the Founder Shares are subject to
certain transfer restrictions, as described in more detail below, (ii) the Founder Shares are entitled to registration rights; (iii)
our Sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed to (A) waive their
redemption rights with respect to their Founder Shares, Private Shares and Public Shares in connection with the completion of our initial
business combination, (B) waive their redemption rights with respect to their Founder Shares, Private Shares and Public Shares in connection
with a shareholder vote to approve an amendment to</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 299; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->282<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the Current
Charter (a) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination
or to redeem 100% of our Public Shares if we have not consummated an initial business combination within the completion window or (b)
with respect to any other material provisions relating to shareholders&#8217; rights or pre-initial business combination activity, (C)
waive their rights to liquidating distributions from the trust account with respect to their Founder Shares and Private Shares if we
fail to complete our initial business combination within the completion window, although they will be entitled to liquidating distributions
from the trust account with respect to any Public Shares they hold if we fail to complete our initial business combination within such
time period and to liquidating distributions from assets outside the trust account and (D) vote any Founder Shares held by them and any
Public Shares purchased during or after this offering (including in open market and privately-negotiated transactions) in favor of our
initial business combination (except that any Public Shares such parties may purchase in compliance with the requirements of Rule&#160;14e-5
under the Exchange Act would not be voted in favor of approving the business combination transaction), (iv) the Founder Shares are automatically
convertible into BCAR Class A Ordinary Shares concurrently with or immediately following the consummation of our initial business combination
or earlier at the option of the holder on a one-for-one basis, subject to adjustment as described herein and in the Current Charter,
and (v) prior to the closing of our initial business combination, only holders of BCAR Class B Ordinary Shares will be entitled to vote
on the appointment and removal of directors or continuing the company in a jurisdiction outside the British Virgin Islands (including
any ordinary resolution required to amend our constitutional documents or to adopt new constitutional documents, in each case, as a result
of our approving a transfer by way of continuation in a jurisdiction outside the British Virgin Islands).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Founder
Shares will automatically convert into BCAR Class A Ordinary Shares concurrently with or immediately following the consummation of our
initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions,
share capitalizations, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein. In the
case that additional BCAR Class A Ordinary Shares, or any other equity-linked securities, are issued or deemed issued in excess of the
amounts sold in the IPO and related to or in connection with the closing of the initial business combination, the ratio at which BCAR
Class B Ordinary Shares convert into BCAR Class A Ordinary Shares will be adjusted (unless the holders of a majority of the outstanding
BCAR Class B Ordinary Shares agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number
of BCAR Class A Ordinary Shares issuable upon conversion of all BCAR Class B Ordinary Shares will equal, in the aggregate, 30% of the
sum of (i) the total number of all BCAR Class A Ordinary Shares outstanding upon the completion of the IPO (including any BCAR Class
A Ordinary Shares issued pursuant to the IPO underwriters&#8217; over-allotment option and excluding the BCAR Class A Ordinary Shares
that are included within the Private Units), plus (ii) all BCAR Class A Ordinary Shares and equity-linked securities issued or deemed
issued, in connection with the closing of the initial business combination (excluding any shares or equity-linked securities issued,
or to be issued, to any seller in the initial business combination and any Private Unites issued to our Sponsor or any of its affiliates
or to our officers or directors upon conversion of working capital loans) minus (iii) any redemptions of BCAR Class A Ordinary Shares
by Public Shareholders in connection with an initial business combination; provided that such conversion of Founder Shares will never
occur on a less than one-for-one basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With certain
limited exceptions, the Founder Shares are not transferable, assignable or saleable (except to our officers and directors and other persons
or entities affiliated with our sponsor, each of whom will be subject to the same transfer restrictions) until the completion of our
initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except in certain limited circumstances, no member
of the sponsor may transfer all or any portion of its membership interests in the sponsor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Register of Members</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under British Virgin Islands law, we must keep a register
of members and there will be entered therein:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">the names and addresses of the members, a statement of the shares held by each member,
        and of the amount paid or agreed to be considered as paid, on the shares of each member and the voting rights of the shares of each member;</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">whether voting rights attach to the shares in issue;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 300; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->283<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">the date on which the name of any person was entered on the register as a member; and</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">the date on which any person ceased to be a member.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Under British Virgin Islands law, the register
of members of our company is prima facie evidence of the matters set out therein (i.e. the register of members will raise a presumption
of fact on the matters referred to above unless rebutted) and a member registered in the register of members will be deemed as a matter
of British Virgin Islands law to have legal title to the shares as set against its name in the register of members. The shareholders recorded
in the register of members are deemed to have legal title to the shares set against their names. However, there are certain limited circumstances
where an application may be made to a British Virgin Islands court for a determination on whether the register of members reflects the
correct legal position. Further, the British Virgin Islands court has the power to order that the register of members maintained by a
company should be rectified where it considers that the register of members does not reflect the correct legal position. If an application
for an order for rectification of the register of members were made in respect of our ordinary shares, then the validity of such shares
may be subject to re-examination by a British Virgin Islands court.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Preference Shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Current Charter authorizes 5,000,000 preference shares and provide
that preference shares may be issued from time to time in one or more series. The BCAR Board is authorized to fix the voting rights, if
any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations
and restrictions thereof, applicable to the shares of each series. The BCAR Board will be able to, without shareholder approval, issue
preference shares with voting and other rights that could adversely affect the voting power and other rights of the holders of the ordinary
shares and could have anti-takeover effects. The ability of the BCAR Board to issue preference shares without shareholder approval could
have the effect of delaying, deferring or preventing a change of control of us or the removal of existing management. We have no preference
shares outstanding at the date of this proxy statement/prospectus. Although we do not currently intend to issue any preference shares,
we cannot assure you that we will not do so in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Public Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each whole warrant entitles the registered holder
to purchase one BCAR Class A Ordinary Share at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing
30 days after the completion of our initial business combination, provided that we have an effective registration statement under the
Securities Act covering the BCAR Class A Ordinary Share issuable upon exercise of the warrants and a current prospectus relating to them
is available (or we permit holders to exercise their warrants on a cashless basis under the circumstances specified in the Warrant Agreement)
and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence
of the holder. We may, in our sole discretion, lower the warrant exercise price at any time prior to the warrant expiration date for a
period of not less than 20 business days and any such reduction will be applied consistently to all of the warrants, provided that we
will provide at least 3 days&#8217; prior written notice to registered holders of the warrants. Pursuant to the Warrant Agreement, a warrant
holder may exercise its warrants only for a whole number of BCAR Class A Ordinary Share. This means only a whole warrant may be exercised
at a given time by a warrant holder. No fractional warrants will be issued upon separation of the units and only whole warrants will trade.
Accordingly, unless you purchase at least two units, you will not be able to receive or trade a whole warrant. The warrants will expire
five years after the completion of our initial business combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 301; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->284<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We will not be obligated to deliver any BCAR Class
A Ordinary Share pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration
statement under the Securities Act with respect to the BCAR Class A Ordinary Share underlying the warrants is then effective and a prospectus
relating thereto is current, subject to our satisfying our obligations described below with respect to registration. No warrant will be
exercisable and we will not be obligated to issue a BCAR Class A Ordinary Share upon exercise of a warrant unless the BCAR Class A Ordinary
Share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state
of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are
not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may
have no value and expire worthless. In no event will we be required to net cash settle any warrant. In the event that a registration statement
is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for
the unit solely for the BCAR Class A Ordinary Share underlying such unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif;">We
registered the BCAR Class A Ordinary Shares issuable upon exercise of the warrants in the registration statement relating to the IPO
because the warrants will become exercisable 30 days after the completion of our initial business combination, which may be within one
year of the IPO. However, because the warrants will be exercisable until their expiration date of up to five years after the completion
of our initial business combination, in order to comply with the requirements of Section&#160;10(a)(3) of the Securities Act following
the consummation of our initial business combination, under the terms of the Warrant Agreement, we have agreed that, as soon as practicable,
but in no event later than 20 business days, after the closing of our initial business combination, we will use our commercially reasonable
efforts to file with the SEC a post-effective amendment to the registration statement relating to the IPO or a new registration statement
covering the registration under the Securities Act of the BCAR Class A Ordinary Shares issuable upon exercise of the warrants and thereafter
will use our commercially reasonable efforts to cause the same to become effective within 60 business days following our initial business
combination and to maintain a current prospectus relating to the BCAR Class A Ordinary Shares issuable upon exercise of the warrants
until the expiration of the warrants in accordance with the provisions of the Warrant Agreement. If a registration statement covering
the BCAR Class A Ordinary Shares issuable upon exercise of the warrants is not effective by the sixtieth (60<sup>th</sup>) business day
after the closing of our initial business combination, warrant holders may, until such time as there is an effective registration statement
and during any period when we will have failed to maintain an effective registration statement, exercise warrants on a &#8220;cashless
basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if our BCAR
Class A Ordinary Shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy
the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1) of the Securities Act, we may, at our option, require
holders of Public Warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9)
of the Securities Act and, in the event we so elect, we will not be required to file or maintain in effect a registration statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Redemption of warrants when the price per </i>BCAR
Class A Ordinary Share <i>equals or exceeds $18.00.</i> Once the warrants become exercisable, we may redeem the outstanding warrants:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">in whole and not in part;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">at a price of $0.01 per warrant; upon a minimum of 30 days&#8217; prior written notice
        of redemption (the &#8220;30-day redemption period&#8221;); and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">if, and only if, the closing price of the BCAR Class
    A Ordinary Shares equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise
    or the exercise price of a warrant as described under the heading &#8220;&#8212; Redemption Procedures &#8212; Anti-dilution Adjustments&#8221;)
    for any 20 trading days within a 30-trading day period commencing at least 30 days after completion of our initial business combination
    and ending three business days before we send the notice of redemption to the warrant holders.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We will not redeem the warrants as described above
unless a registration statement under the Securities Act covering the issuance of the BCAR Class A Ordinary Shares issuable upon exercise
of the warrants is then effective and a current prospectus relating to those BCAR Class A Ordinary Share is available throughout the measurement
period. If and when the warrants become redeemable by us, we may not exercise our redemption right if the issuance of ordinary shares
upon exercise of the warrants is not exempt from registration or qualification under applicable state blue sky laws or we are unable to
effect such registration or qualification. We will use our best efforts to register or qualify such BCAR Ordinary</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 302; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->285<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shares under
the blue sky laws of the state of residence in those states in which the warrants were offered by us in the IPO. We established the last
of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium
to the warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption of the warrants, each warrant
holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the BCAR Class
A Ordinary Shares may fall below the $18.00 redemption trigger price (as adjusted for share sub-divisions, share capitalizations, reorganizations,
recapitalizations and the like) as well as the $11.50 warrant exercise price after the redemption notice is issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Redemption procedures</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A holder of a warrant may notify us in writing in
the event it elects to be subject to a requirement that such holder will not have the right to exercise such warrant, to the extent that
after giving effect to such exercise, such person (together with such person&#8217;s affiliates), to the warrant agent&#8217;s actual
knowledge, would beneficially own in excess of 4.9% or 9.8% (as specified by the holder) of the BCAR Class A Ordinary Shares outstanding
immediately after giving effect to such exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Anti-dilution Adjustments.</i> If the number of
outstanding BCAR Class A Ordinary Shares is increased by a share capitalization payable in Class A ordinary shares, or by a sub-division
of ordinary shares or other similar event, then, on the effective date of such share capitalization, sub-division or similar event, the
number of BCAR Class A Ordinary Shares issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding
ordinary shares. A rights offering made to all or substantially all holders of ordinary shares entitling holders to purchase BCAR Class
A Ordinary Shares at a price less than the fair market value will be deemed a share capitalization of a number of BCAR Class A Ordinary
Shares equal to the product of (i) the number of BCAR Class A Ordinary Shares actually sold in such rights offering (or issuable under
any other equity securities sold in such rights offering that are convertible into or exercisable for BCAR Class A Ordinary Shares) and
(ii) the quotient of (x) the price per BCAR Class A Ordinary Share paid in such rights offering and (y) the fair market value. For these
purposes (i) if the rights offering is for securities convertible into or exercisable for BCAR Class A Ordinary Shares, in determining
the price payable for BCAR Class A Ordinary Shares, there will be taken into account any consideration received for such rights, as well
as any additional amount payable upon exercise or conversion and (ii) fair market value means the volume weighted average price of BCAR
Class A Ordinary Shares as reported during the ten (10) trading day period ending on the trading day prior to the first date on which
the BCAR Class A Ordinary Shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive
such rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, if we, at any time while the warrants
are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to all or substantially all the
holders of BCAR Class A Ordinary Shares on account of such BCAR Class A Ordinary Shares (or other securities into which the warrants are
convertible), other than (a) as described above, (b) certain ordinary cash dividends, (c) to satisfy the redemption rights of the holders
of BCAR Class A Ordinary Shares in connection with a proposed initial business combination, or (d) in connection with the redemption of
our Public Shares upon our failure to complete our initial business combination, then the warrant exercise price will be decreased, effective
immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets
paid on each BCAR Class A Ordinary Share in respect of such event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the number of outstanding BCAR Class A Ordinary
Shares is decreased by a consolidation, combination, reverse share sub-division or reclassification of BCAR Class A Ordinary Shares or
other similar event, then, on the effective date of such consolidation, combination, reverse share sub-division, reclassification or similar
event, the number of BCAR Class A Ordinary Shares issuable on exercise of each warrant will be decreased in proportion to such decrease
in outstanding BCAR Class A Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Whenever the number of BCAR Class A Ordinary Shares
purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying
the warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of BCAR Class
A Ordinary Shares purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y) the denominator of which
will be the number of BCAR Class A Ordinary Shares so purchasable immediately thereafter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 303; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->286<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, if (x) we issue additional BCAR Class
A Ordinary Shares or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination
at a Newly Issued Price of less than $9.20 per BCAR Class A Ordinary Share, (y) the aggregate gross proceeds from such issuances represent
more than 60% of the total equity proceeds (including from such issuances and this offering), and interest thereon, available for the
funding of our initial business combination on the date of the consummation of our initial business combination (net of redemptions),
and (z) the Market Value of our BCAR Class A Ordinary Shares is below $9.20 per share, then the exercise price of the warrants will be
adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share
redemption trigger prices described above under &#8220;<i>Description of Securities &#8212; Warrants &#8212; Public Warrants &#8212; Redemption
of warrants when the price per BCAR Class A Ordinary Share equals or exceeds $18.00</i>&#8221; will be adjusted (to the nearest cent)
to be equal to 180% of the higher of the Market Value and the Newly Issued Price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In case of any reclassification or reorganization
of the outstanding BCAR Class A Ordinary Shares (other than those described above or that solely affects the par value of such BCAR Class
A Ordinary Shares), or in the case of any merger or consolidation of us with or into another corporation (other than a consolidation or
merger in which we are the continuing corporation and that does not result in any reclassification or reorganization of our issued and
outstanding BCAR Class A Ordinary Shares), or in the case of any sale or conveyance to another corporation or entity of the assets or
other property of us as an entirety or substantially as an entirety in connection with which we are dissolved, the holders of the warrants
will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants and
in lieu of the BCAR Class A Ordinary Shares immediately theretofore purchasable and receivable upon the exercise of the rights represented
thereby, the kind and amount of BCAR Class A Ordinary Shares or other securities or property (including cash) receivable upon such reclassification,
reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the warrants would
have received if such holder had exercised their warrants immediately prior to such event (the &#8220;Alternative Issuance&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The warrants
were issued in registered form under a Warrant Agreement between Odyssey Transfer and Trust Company, as warrant agent, and us. The Warrant
Agreement may be amended without the consent of any holder for the purpose of (i) curing any ambiguity or to correct any defective provision
or mistake, including to conform the provisions of the Warrant Agreement to the description of the terms of the warrants and the Warrant
Agreement set forth in this prospectus, (ii) adjusting the provisions relating to cash dividends on ordinary shares as contemplated by
and in accordance with the Warrant Agreement, (iii) adding or changing any provisions with respect to matters or questions arising under
the Warrant Agreement as the parties to the Warrant Agreement may deem necessary or desirable and that the parties deem to not adversely
affect the rights of the registered holders of the warrants or (iv) to provide for the delivery of the Alternative Issuance. All other
modifications or amendments of the Warrant Agreement will require the vote or written consent of at least 50% of the Public Warrants,
and solely with respect to any amendment of the terms of the Private Placement Warrants or working capital warrants or any provision
of the Warrant Agreement with respect to the Private Placement Warrants or working capital warrants (including, for the avoidance of
doubt, the forfeiture or cancellation of any Private Placement Warrants or working capital warrants), 50% of the then outstanding Private
Placement Warrants and working capital warrants (including the vote or written consent of D. Boral Capital).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">You should review a copy of the Warrant Agreement,
which was filed as an exhibit to the registration statement of which this prospectus is a part, for a complete description of the terms
and conditions applicable to the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The warrants may be exercised upon surrender of the
warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side
of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis,
if applicable), by certified or official bank check payable to us, for the number of warrants being exercised. The warrant holders do
not have the rights or privileges of holders of ordinary shares and any voting rights until they exercise their warrants and receive BCAR
Class A Ordinary Shares. After the issuance of BCAR Class A Ordinary Shares upon exercise of the warrants, each holder will be entitled
to one vote for each share held of record on all matters to be voted on by shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have agreed that, subject to applicable law, any
action, proceeding or claim against us arising out of or relating in any way to the Warrant Agreement will be brought and enforced in
the courts of the State of New York located in the County of New York or the United States District Court for the Southern District of
New York, and we irrevocably submit to such jurisdiction, which jurisdiction will be the exclusive forum for any such action, proceeding
or claim. See <i>&#8220;Risk Factors &#8212; Our Warrant Agreement designates the courts of the State of New York or the United States
District Court for the Southern District of New York as the sole and exclusive forum for certain types of actions and proceedings that
may be initiated by holders of our warrants, which could limit the ability of warrant holders to obtain a favorable judicial forum for
disputes with our company.&#8221;</i> This provision applies to claims under the Securities Act but does not apply to claims under the
Exchange Act or any claim for which the federal district courts of the United States of America are the sole and exclusive forum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 304; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->287<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Private Placement Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Private Placement
Warrants are, and any working capital warrants will be, identical to the Public Warrants except that, so long as they are held by our
Sponsor or its permitted transferees, the Private Placement Warrants and working capital warrants (i) are locked-up until the completion
of our initial business combination and (ii) will be entitled to registration rights. The Warrant Agreement may be amended without the
consent of any holder for the purpose of (i) curing any ambiguity or to correct any defective provision or mistake, including to conform
the provisions of the Warrant Agreement to the description of the terms of the warrants and the Warrant Agreement set forth in this prospectus,
(ii) adjusting the provisions relating to cash dividends on ordinary shares as contemplated by and in accordance with the Warrant Agreement,
(iii) adding or changing any provisions with respect to matters or questions arising under the Warrant Agreement as the parties to the
Warrant Agreement may deem necessary or desirable and that the parties deem to not adversely affect the rights of the registered holders
of the warrants or (iv) to provide for the delivery of the Alternative Issuance. All other modifications or amendments of the Warrant
Agreement will require the vote or written consent of holders of at least 50% of the Public Warrants and, solely with respect to any
amendment to the terms of the Private Placement Warrants or working capital warrants or any provision of the Warrant Agreement with respect
to the Private Placement Warrants or working capital warrants (including, for the avoidance of doubt, the forfeiture or cancellation
of any Private Placement Warrants or working capital warrants), 50% of the then outstanding Private Placement Warrants and working capital
warrants (including the vote or written consent of D. Boral Capital). The Private Placement Warrants may be redeemed by the PubCo after
the consummation of the Business Combination as governed by the Warrant Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Dividends</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have not paid any cash dividends on our ordinary
shares to date and do not intend to pay cash dividends prior to the completion of our initial business combination. A BVI business company
may pay a dividend on its shares, provided that it satisfies the solvency test in section&#160;56 of the Companies Act that the company&#8217;s
assets exceed its liabilities and it would be able to pay its debts as they fall due. The payment of cash dividends following completion
of our initial business combination will be within the discretion of our board of directors at such time and will be dependent upon our
revenues and earnings, if any, capital requirements and general financial condition at such time. There is no certainty we will be in
a position to, or decide to, pay cash dividends after completing any business combination. If we incur any indebtedness in connection
with our initial business combination, our ability to declare dividends following completion of our initial business combination may be
limited by restrictive covenants we may agree to in connection therewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Our Transfer Agent and Warrant Agent</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The transfer agent for our BCAR Class A Ordinary Shares
and warrant agent for our warrants is Odyssey Transfer and Trust Company. We have agreed to indemnify Odyssey Transfer and Trust Company
in its roles as transfer agent and warrant agent, its agents and each of its shareholders, directors, officers and employees against all
claims and losses that may arise out of acts performed or omitted for its activities in that capacity, except for any liability due to
any gross negligence or intentional misconduct of the indemnified person or entity. Odyssey Transfer and Trust Company has agreed that
it has no right of set-off or any right, title, interest or claim of any kind to, or to any monies in, the trust account, and has irrevocably
waived any right, title, interest or claim of any kind to, or to any monies in, the trust account that it may have now or in the future.
Accordingly, any indemnification provided will only be able to be satisfied, or a claim will only be able to be pursued, solely against
us and our assets outside the trust account and not against the any monies in the trust account or interest earned thereon.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 305; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->288<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Certain Differences in Corporate Law</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">British Virgin Islands companies are governed by the
Companies Law. The Companies Law is modeled on English law but does not follow recent English law statutory enactments, and differs from
laws applicable to United States corporations and their shareholders. Set forth below is a summary of the material differences between
the provisions of the Companies Law applicable to us and the laws applicable to companies incorporated in the United States and their
shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Mergers and Similar Arrangements.</i> In certain
circumstances, the Companies Law allows for mergers or consolidations between two British Virgin Islands companies, or between a BVI business
company and a company incorporated in another jurisdiction (provided that is facilitated by the laws of that other jurisdiction).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the Companies Law, two or more companies may
either merge into one of such existing companies (the &#8220;surviving company&#8221;) or consolidate with both existing companies ceasing
to exist and forming a new company (the &#8220;consolidated company&#8221;). The procedure for a merger or consolidation between the company
and another company (which need not be a British Virgin Islands company, and which may be the company&#8217;s parent or subsidiary, but
need not be) is set out in the Companies Law. The directors of the British Virgin Islands company or British Virgin Islands companies
which are to merge or consolidate must approve a written plan of merger or consolidation which., with the exception of a merger between
a parent company and its subsidiary, must also be approved by a resolution of a majority of the shareholders who are entitled to vote
and actually vote at a quorate meeting of shareholders or by written resolution of the shareholders of the British Virgin Islands company
or British Virgin Islands companies which are to merge. A foreign company which is able under the laws of its foreign jurisdiction to
participate in the merger or consolidation is required by the Companies Law to comply with the laws of that foreign jurisdiction in relation
to the merger or consolidation. The company must then execute articles of merger or consolidation, containing certain prescribed details.
The plan and articles of merger or consolidation are then filed with the Registrar of Corporate Affairs in the British Virgin Islands.
The Registrar then registers the articles of merger or consolidation and any amendment to the memorandum and articles of the surviving
company in a merger or the memorandum and articles of association of the new consolidated company in a consolidation and issue a certificate
of merger or consolidation (which is conclusive evidence of compliance with all requirements of the Companies Law in respect of the merger
or consolidation). The merger is effective on the date that the articles of merger are registered with the Registrar or on such subsequent
date, not exceeding thirty days, as is stated in the articles of merger or consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As soon as a merger becomes effective: (a) the surviving
company or consolidated company (so far as is consistent with its memorandum and articles of association, as amended or established by
the articles of merger or consolidation) has all rights, privileges, immunities, powers, objects and purposes of each of the constituent
companies; (b) in the case of a merger, the memorandum and articles of association of any surviving company are automatically amended
to the extent, if any, that changes to its amended memorandum and articles of association are contained in the articles of merger or,
in the case of a consolidation, the memorandum and articles of association filed with the articles of consolidation are the memorandum
and articles of the consolidated company; (c) assets of every description, including choses-in-action and the business of each of the
constituent companies, immediately vest in the surviving company or consolidated company; (d) the surviving company or consolidated company
is liable for all claims, debts, liabilities and obligations of each of the constituent companies; (e) no conviction, judgment, ruling,
order, claim, debt, liability or obligation due or to become due, and no cause existing, against a constituent company or against any
member, director, officer or agent thereof, is released or impaired by the merger or consolidation; and (f) no proceedings, whether civil
or criminal, pending at the time of a merger by or against a constituent company, or against any member, director, officer or agent thereof,
are abated or discontinued by the merger or consolidation; but: (i) the proceedings may be enforced, prosecuted, settled or compromised
by or against the surviving company or consolidated company or against the member, director, officer or agent thereof; as the case may
be; or (ii) the surviving company or consolidated company may be substituted in the proceedings for a constituent company. The Registrar
shall strike off the register of companies each constituent company that is not the surviving company in the case of a merger and all
constituent companies in the case of a consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the directors determine it to be in the best interests
of the company, it is also possible for a merger to be approved as a Court approved plan of arrangement or scheme of arrangement in accordance
with the Companies Law. However, we do not anticipate the use of such statutory provisions because we expect the required terms of the
initial business combination will be capable of being achieved through other means, such as a merger or consolidation (as described above),
a share exchange, asset acquisition or control, through contractual arrangements, of an operating business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 306; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->289<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Companies Law provides for a right of dissenting
shareholders to be paid the fair value of their shares upon their dissenting to the merger or consolidation in certain circumstances if
they follow a prescribed procedure. In essence, where such rights apply, that procedure is as follows: (i) the shareholder must give his
written objection to the merger or consolidation to the constituent company before the vote on the merger or consolidation, including
a statement that the shareholder proposes to demand payment for their shares if the merger or consolidation is authorized by the vote;
(ii) within 20 days following the date on which the merger or consolidation is authorized by the shareholders, the constituent company
must give written notice to each shareholder who made a written objection; (iii) a shareholder must within 20 days following receipt of
such notice from the constituent company, give the constituent company a written notice of his intention to dissent including, among other
details, a demand for payment of the fair value of their shares; (iv) within seven days following the date of the expiration of the period
set out in paragraph (ii) above or seven days following the date on which the plan of merger or consolidation is filed, whichever is later,
the constituent company, the surviving company or the consolidated company must make a written offer to each dissenting shareholder to
purchase their shares at a price that the company determines is the fair value and if the company and the shareholder agree the price
within 30 days following the date on which the offer was made, the company must pay the shareholder such amount; and (v) if the company
and the shareholder fail to agree on a price within such 30 day period, within 20 days following the date on which such 30 day period
expires, the company and any dissenting shareholder shall each designate an appraiser. The designated appraisers shall designate another
appraiser and the appraisers shall fix the fair value of all dissenting shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, British Virgin Islands law has separate
statutory provisions that facilitate the reconstruction or amalgamation of companies in certain circumstances, commonly referred to in
the British Virgin Islands as a &#8220;scheme of arrangement,&#8221; which may be tantamount to a merger. Schemes of arrangement will
generally be more suited for complex mergers or other transactions involving widely held companies. In the event that a merger was sought
pursuant to a scheme of arrangement (the procedures for which are more rigorous and take longer to complete than the procedures typically
required to consummate a merger in the United States), the arrangement in question must be approved (i) in relation to a compromise or
arrangement between a company and its creditors or any class of them, a majority in number of such creditors or class of creditors with
whom the arrangement is to be made and who must in addition represent 75% in value of such creditors or class of creditors, as the case
may be, that are present and voting either in person or by proxy at a meeting summoned for that purpose; and (ii) in relation to a compromise
or arrangement between a company and its shareholders or any class of them, shareholders who represent 75% in value of the company&#8217;s
shareholders or class of shareholders, as the case may be, that are present and voting either in person or by proxy at a meeting summoned
for that purpose. The convening of the meetings and subsequently the terms of the arrangement must be sanctioned by the High Court of
the British Virgin Islands. While a dissenting shareholder would have the right to express to the court the view that the transaction
should not be approved, the court can be expected to approve the arrangement if it satisfies itself that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">we are not proposing to act illegally or beyond the scope of our corporate authority
        and the statutory provisions as to majority vote have been complied with;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">the shareholders have been fairly represented at the meeting in question;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">the arrangement is such as a businessman would reasonably approve; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">the arrangement is not one that would more properly be sanctioned under some other provision
        of the Companies Law or that would be oppressive, unfairly discriminatory or unfairly prejudicial to the dissenting shareholders (being
        a minority).</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a scheme of arrangement or takeover offer (as described
below) is approved, any dissenting shareholder would have no rights comparable to dissenters&#8217; rights or appraisal rights (providing
rights to receive payment in cash for the judicially determined value of the shares), which would otherwise ordinarily be available to
dissenting shareholders of United States corporations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, transactions similar to a merger, reconstruction
and/or an amalgamation may in some circumstances be achieved through means other than these statutory provisions, such as a share capital
exchange, asset acquisition or control, or through contractual arrangements of an operating business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 307; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->290<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Shareholders&#8217; Suits.</i> Our British Virgin
Islands counsel is not aware of any reported class action having been brought in a British Virgin Islands court. The enforcement of the
company&#8217;s rights will ordinarily be a matter for its directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In certain limited circumstances, a shareholder has
the right to seek various remedies against the company in the event the directors are in breach of their duties under the Companies Law.
Pursuant to Section&#160;184B of the Companies Law, if a company or director of a company engages in, or proposes to engage in or has
engaged in, conduct that contravenes the provisions of the Companies Law or the memorandum or articles of association of the company,
the British Virgin Islands Court may, on application of a shareholder or director of the company, make an order directing the company
or director to comply with, or restraining the company or director from engaging in conduct that contravenes the Companies Law or the
memorandum or articles. Furthermore, pursuant to section&#160;184I(1) of the Companies Law a shareholder of a company who considers that
the affairs of the company have been, are being or likely to be, conducted in a manner that is, or any acts of the company have been,
or are likely to be oppressive, unfairly discriminatory, or unfairly prejudicial to him in that capacity, may apply to the British Virgin
Islands Court for an order which, inter alia, can require the company or any other person to pay compensation to the shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Companies Law provides for a series of remedies
available to shareholders. Where a company incorporated under the Companies Law conducts some activity, which breaches the Act or the
company&#8217;s memorandum and articles of association, the court can issue a restraining or compliance order. Under the Companies Law,
a shareholder of a company may bring an action against the company for breach of a duty owed by the company to him as a member. A shareholder
also may, with the permission of the British Virgin Islands Court, bring an action or intervene in a matter in the name of the company,
in certain circumstances. Such actions are known as derivative actions. As noted above, the British Virgin Islands Court may only grant
permission to bring a derivative action where the following circumstances apply:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">the company does not intend to bring, diligently continue or defend or discontinue proceedings;
        and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">it is in the interests of the company that the conduct of the proceedings not be left
        to the directors or to the determination of the shareholders as a whole.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">When considering whether to grant leave, the British Virgin Islands Court is also required
        to have regard to the following matters:</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">whether the shareholder is acting in good faith;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">whether a derivative action is in the company&#8217;s best interests, taking into account
        the directors&#8217; views on commercial matters;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">whether the action is likely to proceed;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">the costs of the proceedings; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">whether an alternative remedy is available.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any member of a company may apply to the British Virgin
Islands Court under the Insolvency Act for the appointment of a liquidator to liquidate the company and the court may appoint a liquidator
for the company if it is of the opinion that it is just and equitable to do so.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Companies Law provides that any shareholder of
a company is entitled to payment of the fair value of his shares upon dissenting from any of the following: (a) a merger if the company
is a constituent company, unless the company is the surviving company and the member continues to hold the same or similar shares; (b)
a consolidation if the company is a constituent company; (c) any sale, transfer, lease, exchange or other disposition of more than 50
percent in value of the assets or business of the company if not made in the usual or regular course of the business carried on by the
company but not including: (i) a disposition pursuant to an order of the court having jurisdiction in the matter, (ii) a disposition for
money on terms requiring all or substantially all net proceeds to be distributed to the members in accordance with their respective interest
within one year after the date of disposition, or (iii) a transfer pursuant to the power of the directors to transfer assets for the protection
thereof; (d) a compulsory redemption of 10 percent, or fewer of the issued shares of the company required by the holders of 90 percent,
or more of the shares of the company pursuant to the terms of the Act; and (e) a plan of arrangement, if permitted by the British Virgin
Islands Court.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 308; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->291<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Generally any other claims against a company by its
shareholders must be based on the general laws of contract or tort applicable in the British Virgin Islands or their individual rights
as shareholders as established by a company&#8217;s memorandum and articles of association. There are common law rights for the protection
of shareholders that may be invoked, largely derived from English common law. Under the general English company law known as the rule
in Foss v. Harbottle, a court will generally refuse to interfere with the management of a company at the insistence of a minority of its
shareholders who express dissatisfaction with the conduct of the company&#8217;s affairs by the majority or the board of directors. However,
every shareholder is entitled to seek to have the affairs of the company conducted properly according to law and the constituent documents
of the corporation. As such, if those who control the company have persistently disregarded the requirements of company law or the provisions
of a company&#8217;s memorandum and articles of association, then the courts may grant relief. Generally, the areas in which the courts
will intervene are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">a company is acting or proposing to act illegally or beyond the scope of its authority;</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">the act complained of, although not beyond the scope of the authority, could only be
        effected if duly authorized by more than the number of votes which have actually been obtained;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">the individual rights of the plaintiff shareholder have been infringed or are about to
        be infringed; or</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">those who control the company are perpetrating a &#8220;fraud on the minority.&#8221;</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the law of Delaware, the rights of minority
shareholders are similar to that which will be applicable to the shareholders of the company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compulsory Acquisition. Under the Companies Law, subject
to any limitations in a company&#8217;s memorandum or articles, members holding 90% of the votes of the outstanding shares entitled to
vote, and members holding 90% of the votes of the outstanding shares of each class of shares entitled to vote, may give a written instruction
to the company directing the company to redeem the shares held by the remaining members. Upon receipt of such written instruction, the
company shall redeem the shares specified in the written instruction, irrespective of whether or not the shares are by their terms redeemable.
The company shall give written notice to each member whose shares are to be redeemed stating the redemption price and the manner in which
the redemption is to be effected. A member whose shares are to be so redeemed is entitled to dissent from such redemption, and to be paid
the fair value of his shares, as described under &#8220;Shareholders&#8217; Suits&#8221; above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Enforcement of Civil Liabilities.</i> The British
Virgin Islands has a different body of securities laws as compared to the United States and provides less protection to investors. Additionally,
British Virgin Islands companies may not have standing to sue before the Federal courts of the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have been advised
by Forbes Hare, our British Virgin Islands legal counsel, that the courts of the British Virgin Islands are unlikely (i) to recognize
or enforce against us judgments of courts of the United States predicated upon the civil liability provisions of the federal securities
laws of the United States or any state; and (ii) in original actions brought in the British Virgin Islands, to impose liabilities against
us predicated upon the civil liability provisions of the federal securities laws of the United States or any state, so far as the liabilities
imposed by those provisions are penal in nature. In those circumstances, although there is no statutory enforcement in the British Virgin
Islands of judgments obtained in the United States, the courts of the British Virgin Islands will recognize and enforce a foreign money
judgment of a foreign court of competent jurisdiction without retrial on the merits based on the principle that a judgment of a competent
foreign court imposes upon the judgment debtor an obligation to pay the sum for which judgment has been given provided certain conditions
are met. For a foreign judgment to be enforced in the British Virgin Islands, such judgment must be final and conclusive and for a liquidated
sum, and must not be in respect of taxes or a fine or penalty, inconsistent with a British Virgin Islands judgment in respect of the same
matter, impeachable on the grounds of fraud or obtained in a manner, or be of a kind the enforcement of which is, contrary to natural
justice or the public policy of the British Virgin Islands (awards of punitive or multiple damages may well be held to be contrary to
public policy). A British Virgin Islands Court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 309; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->292<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Special Considerations for BVI Business Companies.
</i>We are a BVI business company with limited liability under the Companies Act. Requirements for BVI business companies are minimal
for example:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">a BVI business company does not have to hold an annual general meeting;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">a BVI business company may issue an unlimited number of shares with no nominal or par
        value;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">a BVI business company may obtain a tax exemption certificate to evidence the exemption
        provided by section&#160;242 of the Companies Law; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">a BVI business company may register by way of continuation in another jurisdiction and
        be deregistered in the British Virgin Islands;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;Limited liability&#8221; means that the liability
of each shareholder is limited to the amount unpaid by the shareholder on the shares of the company (except in exceptional circumstances,
such as involving fraud, the establishment of an agency relationship or an illegal or improper purpose or other circumstance in which
a court may be prepared to pierce or lift the corporate veil).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Our Amended and Restated Memorandum and Articles
of Association</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our amended and restated memorandum and articles of
association contains certain requirements and restrictions relating to this offering that will apply to us until the completion of our
initial business combination. These provisions cannot be amended without an ordinary resolution. As a matter of British Virgin Islands
law, an ordinary resolution is a resolution that (i) has been passed by a majority of in excess of 50 percent of the votes (or any higher
threshold specified in a company&#8217;s articles of association) of such of a company&#8217;s shareholders as, being entitled to do so,
vote in person or, where proxies are allowed, by proxy at a general meeting for which notice has been given; or (ii) if so authorized
by a company&#8217;s articles of association, has been approved by a written resolution of in excess of 50 percent of the votes of the
company&#8217;s shareholders who are entitled to vote on such matter (or such lower threshold as may be allowed under the Companies Law
from time to time), but if any such resolution is adopted otherwise than by the unanimous written consent of all shareholders, a copy
of such resolution shall as soon as reasonably practicable be sent to all shareholders not consenting to such resolution. The amended
and restated memorandum and articles of association of the Company will require that resolutions put to the vote of a meeting may be decided
on a poll, and regard shall be had to the number of votes to which each member is entitled to cast when computing whether the requisite
approval threshold has been obtained to pass an ordinary resolution). The provisions regulating the appointment and removal of directors
and continuing the company in a jurisdiction outside the British Virgin Islands may only be amended by an ordinary resolution passed by
the affirmative vote of the holders representing at least 90% of the issued BCAR Class B Ordinary Shares. Other than as described above,
our amended and restated memorandum and articles of association provide that ordinary resolutions must be approved either by in excess
of 50 percent of the votes of the holders of the ordinary shares as, being entitled to do so, vote in person or, where proxies are allowed,
by proxy at the applicable general meeting, (noting that the amended and restated memorandum and articles of association of the Company
will require that resolutions put to the vote of a meeting may be decided on a poll and regard shall be had to the number of votes to
which each member is entitled to cast when computing whether the requisite approval threshold has been obtained to pass an ordinary resolution)
(i.e., the lowest threshold permissible under British Virgin Islands law), or by a written resolution passed in accordance with the amended
and restated memorandum and articles of association.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Our Initial Shareholders, who will (assuming they
do not purchase any units in this offering) collectively own 30% of our ordinary shares upon the closing of this offering (not including
the BCAR Class A Ordinary Shares that are included within the Private Units), will participate in any vote to amend our amended and restated
memorandum and articles of association and will have the discretion to vote in any manner they choose. Specifically, our amended and restated
memorandum and articles of association provides, among other things, that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">If we have not completed our initial business combination within the completion window,
        we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business
        days thereafter (and subject to lawfully available funds therefor), redeem the Public Shares, at a per-share price, payable in cash, equal
        to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (which
        interest shall be net of taxes and less up to $100,000 of interest to pay dissolution expenses), divided by the number of then-outstanding
        Public Shares, which redemption will completely extinguish Public Shareholders&#8217; rights as shareholders (including the right to receive
        further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption,
        subject to the approval of our remaining shareholders and our board of directors, liquidate and dissolve, subject in each case to our
        obligations under British Virgin Islands law to provide for claims of creditors and the requirements of other applicable law;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 310; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->293<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Prior to our initial business combination, we may not, except
        in connection with the conversion of BCAR Class B Ordinary Shares into BCAR Class A Ordinary Shares where the holders of such shares have
        waived any rights to receive funds from the trust account, issue additional shares that would entitle the holders thereof to (i) receive
        funds from the trust account or (ii) vote as a class with Public Shares on any initial business combination;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If a shareholder vote on our initial business combination is not required by
        law and we do not decide to hold a shareholder vote for business or other reasons, we would offer to redeem our Public Shares pursuant
        to Rule&#160;13e-4 and Regulation 14E of the Exchange Act, and will file tender offer documents with the SEC prior to completing our initial
        business combination which contain substantially the same financial and other information about our initial business combination and the
        redemption rights as is required under Regulation 14A of the Exchange Act;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">Nasdaq rules require that we must complete one or more business combinations having an
        aggregate fair market value of at least 80% of the value of the assets held in the trust account (excluding taxes payable on the interest
        earned on the trust account).</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">If our shareholders approve an amendment to our amended and
        restated memorandum and articles of association not for the purposes of approving, or in conjunction with the consummation of, an initial
        business combination (i) to modify the substance or timing of our obligation to allow redemption in connection with an initial business
        combination or to redeem 100% of our Public Shares if we do not complete an initial business combination within the completion window
        or (ii) with respect to any other provision relating to the rights of holders of our BCAR Class A Ordinary Shares or pre-initial business
        combination activity, we will provide our Public Shareholders with the opportunity to redeem all or a portion of their BCAR Class A Ordinary
        Shares upon such approval at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including
        interest earned on the funds held in the trust account (which interest shall be net of taxes payable), divided by the number of then-outstanding
        Public Shares;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">We will not effectuate our initial business combination solely with another blank check
        company or a similar company with nominal operations; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Only holders of BCAR Class B Ordinary Shares have the right
        to vote on appointing or removing directors or continuing our company in a jurisdiction outside the British Virgin Islands (as further
        described herein), prior to the consummation of our initial business combination.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our amended and restated memorandum and articles of
association provide that unless we consent in writing to the selection of an alternative forum, the courts of the British Virgin Islands
shall have exclusive jurisdiction over any claim or dispute arising out of or in connection with our amended and restated memorandum and
articles of association or otherwise related in any way to each shareholder&#8217;s shareholding in us, including but not limited to (i)
any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of any fiduciary or other duty
owed by any of our current or former directors, officers or other employees to us or our shareholders, (iii) any action asserting a claim
arising pursuant to any provision of the Companies Act or our amended and restated memorandum and articles of association, or (iv) any
action asserting a claim against us governed by the internal affairs doctrine (as such concept is recognized under the laws of the United
States of America) and that each shareholder irrevocably submits to the exclusive jurisdiction of the courts of the British Virgin Islands
over all such claims or disputes. Our amended and restated memorandum and articles of association also provide that, without prejudice
to any other rights or remedies that we may have, each of our shareholders acknowledges that damages alone would not be an adequate remedy
for any breach of the selection of the courts of the British Virgin Islands as exclusive forum and that accordingly we shall be entitled,
without proof of special damages, to the remedies of injunction, specific performance or other equitable relief for any threatened or
actual breach of the selection of the courts of the British Virgin Islands as exclusive forum. The forum selection provision in our amended
and restated memorandum and articles of association will not apply to actions or suits brought to enforce any liability or duty created
by the Securities Act, Exchange Act or any claim for which the federal district courts of the United States of America are, as a matter
of the laws of the United States of America, the sole and exclusive forum for determination of such a claim.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 311; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->294<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Anti-Money Laundering, Counter Terrorist Financing,
Prevention of Proliferation Financing and Financial Sanctions Compliance &#8212; British Virgin Islands</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If any person resident in the British Virgin Islands
knows or suspects, or has reasonable grounds for knowing or suspecting, that another person is engaged in criminal conduct, is involved
with terrorism or terrorist property or proliferation financing or is the business combination partner of a financial sanction and the
information for that knowledge or suspicion came to their attention in the course of business in the regulated sector or other trade,
profession, business or employment, the person will be required to report such knowledge or suspicion to the Financial Investigation Agency
of the British Virgin Islands, pursuant to the Proceeds of Crime Criminal Conduct Act (Revised Edition 2020) of the British Virgin Islands
if the disclosure relates to criminal conduct, money laundering or proliferation financing or is the business combination partner of a
financial sanction. Such a report will not be treated as a breach of confidence or of any restriction upon the disclosure of information
imposed by any enactment or otherwise. We reserve the right to refuse to make any payment to a shareholder if our directors or officers
suspect or are advised that the payment to such shareholder might result in a breach of applicable anti-money laundering, counter-terrorist
financing, prevention of proliferation financing and financial sanctions or other laws or regulations by any person in any relevant jurisdiction,
or if such refusal is considered necessary or appropriate to ensure our compliance with any such laws or regulations in any applicable
jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Should a shareholder or its duly authorized delegates
or agents be, or become (or is believed by the company or its affiliates (&#8220;Agents&#8221;) to be or become) at any time while it
owns or holds an interest in the company, (a) an individual or entity named on any sanctions list maintained by the United Kingdom (including
as extended to the British Virgin Islands by Orders in Council) or the British Virgin Islands or any similar list maintained under applicable
law or is otherwise subject to applicable sanctions in the British Virgin Islands (a &#8220;Sanctions Subject&#8221;) or (b) an entity
owned or controlled directly or indirectly by a Sanctions Subject, as determined by the company in its sole discretion, then (i) the company
or its Agents may immediately and without notice to the shareholder cease any further dealings with the shareholder or freeze any dealings
with the interests or accounts of the shareholder (e.g., by prohibiting payments by or to the shareholder or restricting or suspending
dealings with the interests or accounts) or freeze the assets of the company (including interests or accounts of other shareholders who
are not Sanctions Subjects), until the relevant person ceases to be a Sanctions Subject or a license is obtained under applicable law
to continue such dealings (a &#8220;Sanctioned Persons Event&#8221;), (ii) the company and its Agents may be required to report such action
or failure to comply with information requests and to disclose the shareholder&#8217;s identity (and/or the identity of the shareholder&#8217;s
beneficial owners and control persons) to the Office of the Governor of the British Virgin Islands or other applicable governmental or
regulatory authorities (without notifying the Subscriber that such information has been so provided) and (iii) the company and its Agents
have no liability whatsoever for any liabilities, costs, expenses, damages and/or losses (including but not limited to any direct, indirect
or consequential losses, loss of profit, loss of revenue, loss of reputation and all interest, penalties and legal costs and all other
professional costs and expenses) incurred by the shareholder as a result of a Sanctioned Persons Event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Data Protection &#8212; British Virgin Islands</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have certain duties under the Data Protection Act,
2021 of the British Virgin Islands, as amended from time to time and any regulations, codes of practice, or orders promulgated pursuant
thereto (the &#8220;DPL&#8221;) based on internationally accepted principles of data privacy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Privacy Notice</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Introduction</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This privacy notice puts our shareholders on notice
that through your investment in the company you will provide us with certain personal information which constitutes personal data within
the meaning of the DPL (&#8220;personal data&#8221;). In the following discussion, the &#8220;company&#8221; refers to us and our affiliates
and/or delegates, except where the context requires otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are committed to processing personal data in accordance
with the DPL. In our use of personal data, we will be characterized under the DPL as a &#8220;data controller,&#8221; whilst certain of
our service providers, affiliates, and delegates may act as &#8220;data processors&#8221; under the DPL. These service providers may process
personal data for their own lawful purposes in connection with services provided to us. For the purposes of this Privacy Notice, &#8220;you&#8221;
or &#8220;your&#8221; shall mean the subscriber and shall also include any individual connected to the subscriber.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 312; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->295<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">By virtue of your investment in the company, we and
certain of our service providers may collect, record, store, transfer, and otherwise process personal data by which individuals may be
directly or indirectly identified. We may combine personal data that you provide to use with personal data that we collect from, or about
you. This may include personal data collected in an online or offline context including from credit reference agencies and other available
public databases or data sources, such as news outlines, websites and other media sources and international sanctions lists.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Your personal data will be processed fairly and for
lawful purposes, including (a) carrying out investor on boarding checks; (b) issuing, redeeming, managing and administering our public
securities; (c) updating investor&#8217;s with circulars, supplements and revised prospectuses; (d) complying with our obligations under
the prospectus and the subscription agreement; (e) marketing the company and public securities; (f) complying with legal or regulatory
requirements applicable to the company or an investor; (g) protecting the investor&#8217;s vital interests; (h) disclosing or transferring
whether in the British Virgin Islands or to jurisdictions, countries or territories outside of the British Virgin Islands (including without
limitation the U.S.), which may not have the equivalent data protection laws to the British Virgin Islands, to third parties, regulatory
bodies, auditors, technology providers or to the company and its delegates and its or their duly appointed agents and any of their respective
related, associated or affiliated companies for the purposes specified above; and (i) for other legitimate business interests of the company.
As a data controller, we will only use your personal data for the purposes for which we collected it. If we need to use your personal
data for an unrelated purpose, we will contact you.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We anticipate that we will share your personal data
with our service providers for the purposes set out in this privacy notice. We may also share relevant personal data where it is lawful
to do so and necessary to comply with our contractual obligations or your instructions or where it is necessary or desirable to do so
in connection with any regulatory reporting obligations. In exceptional circumstances, we will share your personal data with regulatory,
prosecuting, and other governmental agencies or departments, and parties to litigation (whether pending or threatened), in any country
or territory including to any other person where we have a public or legal duty to do so (e.g. to assist with detecting and preventing
fraud, tax evasion, and financial crime or compliance with a court order).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Your personal data shall not be held by the company
for longer than necessary with regard to the purposes of the data processing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We will not sell your personal data. Any transfer
of personal data outside of the British Virgin Islands shall be in accordance with the requirements of the DPL. Where necessary, we will
ensure that separate and appropriate legal agreements are put in place with the recipient of that data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We will only transfer personal data in accordance
with the requirements of the DPL, and will apply appropriate technical and organizational information security measures designed to protect
against unauthorized or unlawful processing of the personal data and against the accidental loss, destruction, or damage to the personal
data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Investor Data</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We will collect,
use, disclose, retain and secure personal data to the extent reasonably required only and within the parameters that could be reasonably
expected during the normal course of business. We will only process, disclose, transfer or retain personal data to the extent legitimately
required to conduct our activities on an ongoing basis or to comply with legal and regulatory obligations to which we are subject. We
will only transfer personal data in accordance with the requirements of the DPL, and will apply appropriate technical and organizational
information security measures designed to protect against unauthorized or unlawful processing of the personal data and against the accidental
loss, destruction or damage to the personal data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In our use of this personal data, we will be characterized
as a &#8220;data controller&#8221; for the purposes of the DPL, while our affiliates and service providers who may receive this personal
data from us in the conduct of our activities may either act as our &#8220;data processors&#8221; for the purposes of the DPL or may process
personal information for their own lawful purposes in connection with services provided to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may also obtain personal data from other public
sources. Personal data includes, without limitation, the following information relating to a shareholder and/or any individuals connected
with a shareholder as an investor: name, residential address, email address, contact details, corporate contact information, signature,
nationality, place of birth, date of birth, tax identification, credit history, correspondence records, passport number, bank account
details, source of funds details and details relating to the shareholder&#8217;s investment activity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 313; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->296<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Who this Affects</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If you are a natural person, this will affect you
directly. If you are a corporate investor (including, for these purposes, legal arrangements such as trusts or exempted limited partnerships)
that provides us with personal data on individuals connected to you for any reason in relation to your investment in the company, this
will be relevant for those individuals and you should transmit the content of this Privacy Notice to such individuals or otherwise advise
them of its content.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>How the Company May Use a Shareholder&#8217;s
Personal Data</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The company, as the data controller, may collect,
store and use personal data for lawful purposes, including, in particular:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify">1.</td>
    <td style="vertical-align: top; text-align: justify">carrying out investor on boarding checks;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify">2.</td>
    <td style="vertical-align: top; text-align: justify">issuing, redeeming, managing and administering our public securities;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify">3.</td>
    <td style="vertical-align: top; text-align: justify">updating investor&#8217;s with circulars, supplements and revised prospectuses;</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify">4.</td>
    <td style="vertical-align: top; text-align: justify">complying with our obligations under the prospectus and the subscription agreement;</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify">5.</td>
    <td style="vertical-align: top; text-align: justify">marketing the company and public securities;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify">6.</td>
    <td style="vertical-align: top; text-align: justify">complying with legal or regulatory requirements applicable to the company or investor;</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify">7.</td>
    <td style="vertical-align: top; text-align: justify">protecting the investor&#8217;s vital interests;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify">8.</td>
    <td style="vertical-align: top; text-align: justify">disclosing or transferring whether in the British Virgin Islands or to jurisdictions,
        countries or territories outside of the British Virgin Islands (including without limitation the U.S.), which may not have the equivalent
        data protection laws to the British Virgin Islands, to third parties, regulatory bodies, auditors, technology providers or to the company
        and its delegates and its or their duly appointed agents and any of their respective related, associated or affiliated companies for the
        purposes specified above; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify">9.</td>
    <td style="vertical-align: top; text-align: justify">for other legitimate business interests of the company.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Should we wish to use personal data for other specific
purposes (including, if applicable, any purpose that requires your consent), we will contact you.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Why We May Transfer Your Personal Data</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In certain circumstances we may be legally obliged
to share personal data and other information with respect to your shareholding with the relevant regulatory authorities such as the British
Virgin Islands Financial Services Commission or the International Tax Authority or the Financial Investigation Agency. They, in turn,
may exchange this information with foreign authorities, including tax authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We anticipate disclosing personal data to persons
who provide services to us and their respective affiliates (which may include certain entities located outside the United States, the
British Virgin Islands or the European Economic Area), who will process your personal data on our behalf.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The Data Protection Measures We Take</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any transfer of personal data by us or our duly authorized
affiliates and/or delegates outside of the British Virgin Islands shall be in accordance with the requirements of the DPL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 314; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->297<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We and our duly authorized affiliates and/or delegates
shall apply appropriate technical and organizational information security measures designed to protect against unauthorized or unlawful
processing of personal data, and against accidental loss or destruction of, or damage to, personal data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We shall notify you of any personal data breach that
is reasonably likely to result in a risk to your interests, fundamental rights or freedoms or those data subjects to whom the relevant
personal data relates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Rights of Individual Data Subjects</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Individual data subjects have certain data protection
rights, including the right to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">be informed whether your personal data is being processed;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">know within 30 days of a request to access your personal data whether or not access will
        be given to all or part of your data;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">if your personal data is being processed, be informed about the purposes for which your
        personal data are processed;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">have incomplete or inaccurate personal data corrected;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">complain to the Information Commissioner.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If you consider that your personal data has not been
handled correctly, or you are not satisfied with our responses to any requests you have made regarding the use of your personal data,
you have the right to complain to the British Virgin Islands&#8217; Information Commissioner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Certain Anti-Takeover Provisions of our Amended
and Restated Memorandum and Articles of Association</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our amended and restated memorandum and articles of
association provide that our board of directors will be classified into three classes of directors. In addition, prior to the closing
of our initial business combination, only holders of BCAR Class B Ordinary Shares will have the right to appoint and remove directors
prior to the completion of our initial business combination. As a result, in most circumstances, a person can gain control of our board
only by successfully engaging in a proxy contest at two or more annual general meetings and obtaining the support of our sponsor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our authorized but unissued ordinary shares and preference
shares are available for future issuances without shareholder approval and could be utilized for a variety of corporate purposes, including
future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved
ordinary shares and preference shares could render more difficult or discourage an attempt to obtain control of us by means of a proxy
contest, tender offer, merger or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Extraordinary General Meetings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our amended and restated memorandum and articles of
association provide that Extraordinary General Meetings may be called only by a majority vote of our board of directors, by our Chief
Executive Officer or by our Chairman or if requested in writing by members entitled to exercise at least 30% of the voting rights in respect
of the matter for which the meeting is requested.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 315; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->298<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Advance Notice Requirements for Shareholder Proposals
and Director Nominations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our amended and restated memorandum and articles of
association provide that shareholders seeking to bring business before our annual general meeting, or to nominate candidates for appointment
as directors at our annual general meeting must provide timely notice of their intent in writing. To be timely, a shareholder&#8217;s
notice will need to be received by the company secretary at our principal executive offices not later than the close of business on the
90<sup>th</sup> day nor earlier than the close of business on the 150<sup>th</sup> day prior to the anniversary date of the immediately
preceding annual general meeting. Pursuant to Rule&#160;14a-8 under the Exchange Act, proposals seeking inclusion in our annual proxy
statement must comply with the notice periods contained therein. Our amended and restated memorandum and articles of association will
also specify certain requirements as to the form and content of a shareholders&#8217; meeting. These provisions may preclude our shareholders
from bringing matters before our annual general meeting or from making nominations for directors at our annual general meeting. Our amended
and restated memorandum and articles of association will allow the chairman of the meeting at a meeting of the shareholders to adopt rules
and regulations for the conduct of meetings which may have the effect of precluding the conduct of certain business at a meeting if the
rules and regulations are not followed. These provisions may also defer, delay or discourage a potential acquirer from conducting a solicitation
of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to influence or obtain control of us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Written Resolutions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to the consummation of the offering, any
action required or permitted to be taken by our shareholders may be effected by a duly called annual general meeting or Extraordinary
General Meeting or by written resolution passed in accordance with the Companies Law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Classified Board of Directors</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our board of directors will initially be divided into
three classes, Class I, Class II and Class III, with members of each class serving staggered three year terms. Our amended and restated
memorandum and articles of association provide that the authorized number of directors may be changed only by resolution of the board
of directors. Subject to the terms of any preference shares, any or all of the directors may be removed from office at any time by an
ordinary resolution, which requires the affirmative vote of at least a majority of the votes cast by such shareholders as, being entitled
to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the company. Prior to the consummation
of an initial business combination, only holders of BCAR Class B Ordinary Shares will have the right to vote on the appointment and removal
of directors. Our board of directors may, by a vote of a majority of our directors then in office, appoint any person to be a director,
either to fill a vacancy or as an additional director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Rule&#160;144</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to Rule&#160;144, a person who has beneficially
owned restricted shares or warrants for at least six months would be entitled to sell their securities provided that (i) such person is
not deemed to have been one of our affiliates at the time of, or at any time during the three months preceding, a sale and (ii) we are
subject to the Exchange Act periodic reporting requirements for at least three months before the sale and have filed all required reports
under Section&#160;13 or 15(d) of the Exchange Act during the 12 months (or such shorter period as we were required to file reports) preceding
the sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Persons who have beneficially owned restricted shares
or warrants for at least six months but who are our affiliates at the time of, or at any time during the three months preceding, a sale,
would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number
of securities that does not exceed the greater of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">1% of the total number of BCAR Class A Ordinary Shares then
        outstanding, which will equal 357,142 shares immediately after this offering (or 410,714 shares if the underwriters exercise in full their
        over-allotment option); or</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 316; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->299<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the average weekly reported trading volume of the BCAR Class
        A Ordinary Shares during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales by our affiliates under Rule&#160;144 are also
limited by manner of sale provisions and notice requirements and to the availability of current public information about us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Restrictions on the Use of Rule&#160;144 by Shell
Companies or Former Shell Companies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rule&#160;144 is not available for the resale of securities
initially issued by shell companies (other than business combination related shell companies) or issuers that have been at any time previously
a shell company. However, Rule&#160;144 also includes an important exception to this prohibition if the following conditions are met:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">the issuer of the securities that was formerly a shell company has ceased to be a shell
        company;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">the issuer of the securities is subject to the reporting requirements of Section&#160;13
        or 15(d) of the Exchange Act;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">the issuer of the securities has filed all Exchange Act reports and material required
        to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and
        materials), other than Current Reports on Form 8-K; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">at least one year has elapsed from the time that the issuer filed current Form 10 type
        information with the SEC reflecting its status as an entity that is not a shell company.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;">As a result, our Initial Shareholders will be
able to sell their Founder Shares and Private Units, as applicable, pursuant to Rule&#160;144 without registration one year after we have
completed our initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Listing of Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Units, Class A Ordinary Shares and Public Warrants
are currently traded on the Nasdaq Global Market under the symbols &#8220;BCARU,&#8221; &#8220;BCAR&#8221; and &#8220;BCARW,&#8221; respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 317; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->300<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>DESCRIPTION OF EXASCALE&#8217;S SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The following descriptions of the capital stock
of Exascale, and provisions of Exascale&#8217;s amended and restated certificate of incorporation as in effect on the date of this proxy
statement/prospectus, Exascale&#8217;s bylaws as in effect on the date of this proxy statement/prospectus, and applicable provisions of
the DGCL, are summaries, do not purport to be complete, and are qualified in their entirety by reference to Exascale&#8217;s amended and
restated certificate of incorporation and bylaws, in each case as in effect on the date of this proxy statement/prospectus, and the text
of the DGCL.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Authorized Capital Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale&#8217;s amended
and restated <span style="font-weight: normal">certificate of incorporation</span> authorizes the issuance of up to 1,500 shares of common
stock, par value $0.01 per share, divided into (i) 303 shares of Class A common stock, and (ii) 1,197 shares of Class B common stock.
As of the date of <span style="font-weight: normal">this proxy statement/prospectus</span>, 303 shares of Exascale Class A common stock
and 1,197 shares of Exascale&#8217;s Class B common stock were outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><i>Voting Rights </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Each holder of shares of
Exascale&#8217;s common stock is entitled to one (1) vote for each share of Exascale Class A common stock held and twenty (20) votes for
each share of Exascale Class B common stock held. Except with respect to the foregoing voting rights, and except as otherwise required
by law, Exascale&#8217;s Class A common stock and Exascale&#8217;s Class B common stock have the same rights, powers, privileges, preferences
and restrictions, and rank equally, share ratably and are identical in all respects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Holders of Exascale&#8217;s
common stock have no cumulative voting rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Dividend Rights</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Holders of shares of Exascale
common stock are entitled to receive dividends and other distributions, if any, in cash, stock or property, when, as and if declared by
Exascale&#8217;s board of directors out of legally available funds, subject to applicable law and any rights of holders of any outstanding
securities having preferences over Exascale&#8217;s common stock with respect to dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale has not declared
or paid any cash dividends on its common stock to date and does not intend to declare any dividends in the near future. The declaration
of any future dividends will be at the discretion of Exascale&#8217;s board of directors and will depend on, among other things, Exascale&#8217;s
results of operations, financial condition, capital requirements and other factors deemed relevant by the board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Liquidation Rights</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Upon Exascale&#8217;s liquidation,
dissolution or winding up, whether voluntary or involuntary, holders of Exascale common stock are entitled to share ratably in all assets
of Exascale remaining after the payment of all liabilities and the satisfaction of any liquidation preferences applicable to any outstanding
securities senior to Exascale&#8217;s common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Preemptive, Subscription
and Conversion Rights</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Holders of Exascale common
stock do not have any preemptive rights, conversion rights, subscription rights or other rights to purchase or receive additional shares
of Exascale capital stock, except as may be expressly provided by law or in future agreements approved by Exascale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Equal Treatment of Exascale&#8217;s
Class A Common Stock and Exascale&#8217;s Class B Common Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Except with respect to the
above-described voting rights, and except as otherwise required by law, Exascale&#8217;s Class A common stock and Exascale&#8217;s Class
B common stock are treated equally in all respects, including with respect to dividend rights, liquidation rights, and other economic
interests.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 318; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->301<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Quorum and Stockholder
Action</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">At all meetings of Exascale&#8217;s
stockholders, unless otherwise required by law, Exascale&#8217;s amended and restated certificate of incorporation or Exascale&#8217;s
bylaws, a majority of the outstanding shares of Exascale capital stock entitled to vote, present in person or represented by proxy, constitutes
a quorum for the transaction of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale&#8217;s
stockholders are permitted to act by written consent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Market </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Market information regarding
Exascale&#8217;s securities is not provided because there is no public market for Exascale&#8217;s securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Holders</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this proxy statement/prospectus,
there are six holders of Exascale Class A common stock and five holders of Exascale Class B common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Number
of Holders Exascale Class A Common Stock and Class B Common Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the date
of this proxy statement/prospectus, there are six holders of Exascale Class A common stock and five holders of Exascale Class B common
stock</span></p>

<p style="margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Anti-Takeover Effects
of Exascale&#8217;s Capital Structure</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Exascale&#8217;s capital
structure, including the concentration of voting power in holders of its Class B common stock, may discourage, delay or prevent a change
in control of Exascale, even if such a transaction would be considered beneficial by holders of Exascale&#8217;s Class A common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Holders of Exascale&#8217;s
Class B common stock are entitled to significantly greater voting power per share than holders of Exascale&#8217;s Class A common stock.
As a result, holders of Exascale&#8217;s Class B common stock are able to exercise substantial control over matters requiring stockholder
approval, including the election and removal of directors, amendments to Exascale&#8217;s organizational documents, approval of mergers,
consolidations or other business combinations, and approval of the sale of all or substantially all of Exascale&#8217;s assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">This concentration of voting
control may have the effect of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in; text-indent: 0in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; text-indent: 0in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discouraging
        or preventing unsolicited takeover proposals, tender offers or proxy contests that are not supported by the holders of Exascale&#8217;s
        Class B common stock;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; text-indent: 0in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; text-indent: 0in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; text-indent: 0in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; text-indent: 0in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delaying
        or preventing a change in control of Exascale, even if a change in control would be favored by holders of Exascale&#8217;s Class A common
        stock or would otherwise be perceived as enhancing stockholder value;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; text-indent: 0in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; text-indent: 0in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; text-indent: 0in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; text-indent: 0in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
        the ability of Exascale&#8217;s Class A common stockholders to influence corporate governance matters, including strategic decisions,
        management succession and board composition; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; text-indent: 0in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; text-indent: 0in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; text-indent: 0in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; text-indent: 0in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing
        the likelihood that third parties will pursue a transaction involving Exascale, due to the difficulty of obtaining the approval of the
        holders of Exascale&#8217;s Class B common stock.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Because voting control is
concentrated, potential acquirers may be unwilling to pursue a transaction with Exascale unless it is supported by the holders of Exascale&#8217;s
Class B common stock, which could result in fewer acquisition proposals and may limit the potential for stockholders to receive a premium
for their shares in connection with a change-of-control transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt">In addition, the existence of super-voting stock may make Exascale
less attractive to certain investors, strategic partners or potential acquirers that prefer companies with a single-class voting structure
or more dispersed voting power.</p>

<p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>2</sup></span></td>
    <td style="text-align: justify">Exascale Team: please provide.</td> </tr>
  </table>

<p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 319; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->302<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>DESCRIPTION OF PUBCO&#8217;S SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>If the Business Combination is consummated, BCAR
will replace its Current Charter with the Proposed Charter in the form attached to this proxy statement/prospectus as Annex B-1 and the
Proposed Bylaws in the form attached to this proxy statement/prospectus as Annex B-2. The following is a description of the capital stock
of PubCo (&#8220;<b>PubCo</b>,&#8221; &#8220;<b>we</b>,&#8221; &#8220;<b>us</b>,&#8221; or &#8220;<b>our</b>&#8221;) if the Business Combination
is consummated. The provisions of the Proposed Charter, Proposed Bylaws and the Delaware General Corporate Law (&#8220;DGCL&#8221;) are
summaries and are qualified in their entirety by reference to the Proposed Charter in the form attached to this proxy statement/prospectus
as Annex B-1, the Proposed Bylaws in the form attached to this proxy statement/prospectus as Annex B-2 and the text of the DGCL.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>General</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Proposed Charter authorizes the issuance of
up to 295,000,000 shares of common stock, par value $0.0001 per share (&#8220;<b>PubCo Common Stock</b>&#8221;), and 5,000,000 shares
of preferred stock, par value $0.0001 per share (&#8220;<b>Preferred Stock</b>&#8221;). 260,000,000 shares of the PubCo Common Stock have
been designated as Class A Ordinary Common Stock (&#8220;<b>PubCo Class A Ordinary Common Stock</b>&#8221;) and 35,000,000 shares of the
PubCo Common Stock have been designated as PubCo Class B Super Common Stock (&#8220;<b>PubCo Class B Super Common Stock</b>&#8221;). It
is anticipated that if the Business Combination is consummated, immediately after the time of consummation, 60,456,000 shares of PubCo
Class A Ordinary Common Stock will be issued and outstanding (assuming no redemptions of Public Shares), 30,744,000 shares of PubCo Class
B Super Common Stock will be issued and outstanding, and no shares of the PubCo Preferred Stock will be issued and outstanding. The following
description summarizes all of the material terms of our securities. Because it is only a summary, it may not contain all the information
that is important to you. For a complete description you should refer to the Proposed Charter in the form attached to this proxy statement/prospectus
as <i>Annex B-1</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>PubCo Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The voting, dividend and liquidation rights of the
holders of the PubCo Common Stock are subject to and qualified by the rights of the holders of the PubCo Preferred Stock of any series
as may be designated by the PubCo Board upon any issuance of the PubCo Preferred Stock of any series. Each holder of shares of PubCo Common
Stock shall be entitled to one vote for each share of PubCo Class A Ordinary Common Stock held and twenty (20) votes for each share of
PubCo Class B Super Common Stock held. Holders of our PubCo Common Stock have no cumulative voting rights. Further, holders of our PubCo
Common Stock have no preemptive or conversion rights or other subscription rights. Upon our liquidation, dissolution or winding-up, holders
of our PubCo Common Stock are entitled to share in all assets remaining after payment of all liabilities and the liquidation preferences
of any of our outstanding shares of PubCo Preferred Stock. Subject to the rights of the holders of PubCo Preferred Stock, holders of shares
of PubCo Common Stock are entitled to receive such dividends and distributions and other distributions in cash, stock or property of the
corporation when, as and if declared thereon by the PubCo Board from time to time out of assets or funds of the corporation legally available
therefor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At all meetings of stockholders, unless otherwise
required by law, the Proposed Charter, or the Proposed Bylaws, a majority in voting power of the shares of the corporation entitled to
vote at the meeting, present in person or represented by proxy, shall constitute a quorum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each share of PubCo Class B Super Common Stock
may be convertible into one share of PubCo Class A Common Stock at the option of the holder thereof at any time upon written notice to
the transfer agent of PubCo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 320; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->303<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, each share of PubCo Class B Super
Common Stock shall automatically, without any further action, convert into one share of PubCo Class A Ordinary Common Stock upon a transfer,
other than a transfer to a &#8220;qualified stockholder,&#8221; of such share. For purposes of the foregoing, a &#8220;qualified stockholder&#8221;
means (i) Hoansoo Lee, (ii) Wenying Jia, (iii) any other registered holder of a share of PubCo Class B Super Common Stock immediately
after the effective time of the Proposed Charter, (iv) the initial registered holder of any shares of PubCo Class B Super Common Stock
that are originally issued by PubCo pursuant to the exercise, conversion or settlement of a right (provided that such right was issued
to and at all times held by a holder who would have been a &#8220;qualified stockholder&#8221; if such right had been a share and without
reference to this clause (iv)), (v) each natural person who transfers shares of, or rights for, PubCo Class B Super Common Stock to a
permitted trust, permitted IRA, permitted entity or Permitted foundation that is or becomes a &#8220;qualified stockholder&#8221; in connection
with such transfer, or (vi) a transferee of shares of PubCo Class B Super Common Stock received in a transfer that constitutes a &#8220;permitted
transfer&#8221; (as such term is defined in the Proposed Charter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PubCo may, from time to time, establish such policies
and procedures relating to the conversion of the PubCo Class B Super Common Stock into PubCo Class A Ordinary Common Stock and the general
administration of PubCo&#8217;s multi<b>-</b>class stock structure, as it may deem reasonably necessary or advisable, and may from time
to time request that holders of shares of PubCo Class B Super Common Stock furnish certifications, affidavits or other proof to PubCo
as PubCo deems necessary to verify the ownership of PubCo Class B Super Common Stock and to confirm that a conversion into PubCo Class
A Ordinary Common Stock has not occurred. A determination in good faith by PubCo that a transfer results or has resulted in a conversion
into PubCo Class A Ordinary Common Stock shall be conclusive and binding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon any conversion of PubCo Class B Super Common
Stock into PubCo Class A Ordinary Common Stock, all rights of the holder of such shares of PubCo Class B Super Common Stock shall cease
and the person or persons in whose names or names the certificate or certificates (or book-entry position(s)) representing the shares
of PubCo Class A Ordinary Common Stock are to be issued shall be treated for all purposes as having become the record holder or holders
of such shares of PubCo Class A Ordinary Common Stock. Shares of PubCo Class B Super Common Stock that are converted into shares of PubCo
Class A Ordinary Common Stock shall be retired and may not be reissued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except for certain types of dividends specified
in the Proposed Charter that become payable in accordance with the applicable provision of the Proposed Charter or certain stock adjustments
specified in the Proposed Charter that are effected pursuant to the applicable provision of the Proposed Charter, PubCo cannot, at any
time after the effective date of the Proposed Charter, issue any additional shares of PubCo Class B Super Common Stock, unless such issuance
is approved by the affirmative vote of the holders of a majority of the outstanding shares of PubCo Class A Ordinary Common Stock, voting
as a separate class.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, in addition to any other vote required
by law or the Proposed Charter, any amendment to the Proposed Charter that (i) increases the voting power of the PubCo Class B Super Common
Stock or (ii) alters or changes the provisions relating to the conversion of the PubCo Class B Super Common Stock, as set forth in the
Proposed Charter, in a manner that adversely affects the holders of PubCo Class A Ordinary Common Stock shall not be approved, in each
case, without the affirmative vote of the holders of at least a majority of the total voting power of all then-outstanding shares of PubCo
Class A Ordinary Common Stock entitled to vote thereon, voting as a separate class.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>PubCo Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The PubCo Preferred Stock may be issued without stockholder
approval, from time to time in one or more series, each series to be appropriately designated by a distinguishing letter or title prior
to the issuance of any shares thereof, as determined by the PubCo Board. The PubCo Board may authorize the issuance of PubCo Preferred
Stock with voting or conversion rights that could harm the voting power or other rights of the holders of the Common Stock. The issuance
of PubCo Preferred Stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among
other things, have the effect of delaying, deferring or preventing a change in control of us and might harm the market price of our PubCo
Common Stock and the voting and other rights of the holders of PubCo Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PubCo Preferred stock may be issued from time to time,
in one or more series, as authorized by the PubCo Board, without stockholder approval. As of the date of this proxy statement/prospectus,
we have no PubCo Preferred Stock designated or issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 321; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->304<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Certain Anti-Takeover Provisions of Delaware Law,
our Certificate of Incorporation and Bylaws</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The provisions of Delaware law, the Proposed Charter
and the Proposed Bylaws of PubCo could discourage or make it more difficult to accomplish a proxy contest or other change in our management
or the acquisition of control by a holder of a substantial amount of our voting stock. It is possible that these provisions could make
it more difficult to accomplish, or could deter, transactions that stockholders may otherwise consider to be in their best interests or
in our best interests. These provisions are intended to enhance the likelihood of continuity and stability in the composition of the PubCo
Board and in the policies formulated by the PubCo Board and to discourage certain types of transactions that may involve an actual or
threatened change of our control. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and
to discourage certain tactics that may be used in proxy fights. Such provisions also may have the effect of preventing changes in our
management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Proposed Charter provides that subject to the
rights of holders of any series of Preferred Stock to elect directors, the PubCo Board is divided into three classes, designated Class
I, Class II and Class III, with each class being nearly as possible to one third of the total number of directors constituting the entire
PubCo Board. Terms for directors are generally three years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PubCo is expected to be subject to the provisions
of Section&#160;203 of the DGCL regulating corporate takeovers. This statute prevents certain Delaware corporations, under certain circumstances,
from engaging in a &#8220;business combination&#8221; with:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: left; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">a stockholder who owns 10% or more of our outstanding voting stock (otherwise known as
        an &#8220;interested stockholder&#8221;);</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: left; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">an affiliate of an interested stockholder; or</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: left; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">an associate of an interested stockholder, for three years following the date that the
        stockholder became an interested stockholder.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8203;A &#8220;business combination&#8221; includes
a merger or sale of more than 10% of our assets. However, the above provisions of Section&#160;203 do not apply if:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the PubCo Board approves the transaction that made the stockholder
        an &#8220;interested stockholder,&#8221; prior to the date of the transaction;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: left; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">after the completion of the transaction that resulted in the stockholder becoming an
        interested stockholder, that stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, other
        than statutorily excluded shares of common stock; or</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: left; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">on or subsequent to the date of the transaction, the business combination is approved
        by the PubCo Board and authorized at a meeting of our stockholders, and not by written consent, by an affirmative vote of at least two-thirds
        of the outstanding voting stock not owned by the interested stockholder.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Exclusive Forum for Certain Lawsuits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Proposed Charter provides that unless the corporation
consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent
permitted by law, be the sole and exclusive forum for (1) any derivative action or proceeding brought on behalf of the corporation, (2)
any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the corporation to the corporation
or the corporation&#8217;s stockholders, (3) any action arising pursuant to any provision of the DGCL or the Certificate of Incorporation
or the Bylaws, or (4) any action asserting a claim governed by the internal affairs doctrine. Unless the corporation consents in writing
to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for
the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 322; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->305<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Special meeting of stockholders</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Special meetings of the stockholders of the corporation
may be called, for any purpose or purposes, by (i) the Chair of the PubCo Board, (ii) the Chief Executive Officer, (iii) the PubCo Board
or (iv) by the Secretary following receipt of written demand from stockholders holding, at least 25% of the voting power of the outstanding
shares of the corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stockholder Action by Written Consent</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Proposed Bylaws permit our stockholders to act
by written consent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Advance notice requirements for stockholder proposals
and director nominations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Proposed Bylaws provide that stockholders seeking
to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting
of stockholders must provide timely notice of their intent in writing, as well as additional information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These provisions may preclude our stockholders from
bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Authorized but unissued shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our authorized but unissued Common Stock and Preferred
Stock is available for future issuances without stockholder approval, and could be utilized for a variety of corporate purposes, including
future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved
Common Stock and Preferred Stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest,
tender offer, merger or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 323; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->306<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_033"></span>SECURITIES ACT RESTRICTIONS
ON RESALE OF PUBCO SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to Rule 144 under the Securities Act (&#8220;<b>Rule
144</b>&#8221;), a person who has beneficially owned restricted PubCo Common Stock or PubCo Warrants for at least six months would be
entitled to sell their securities provided that (i) such person is not deemed to have been an affiliate of PubCo at the time of, or at
any time during the three months preceding, a sale and (ii) PubCo is subject to the Exchange Act periodic reporting requirements for at
least three months before the sale, has filed all required reports under Section 13 or 15(d) of the Exchange Act during the 12 months
(or such shorter period as PubCo was required to file reports) preceding the sale, and has submitted electronically every interactive
data file required to be submitted pursuant to Rule 405 of the Securities Act during the 12 months (or such shorter period as PubCo was
required to file reports) preceding the sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Persons who have beneficially owned restricted shares
of PubCo Common Stock or PubCo Warrants for at least six months but who are affiliates of PubCo at the time of, or at any time during
the three months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within
any three-month period only a number of securities that does not exceed the greater of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">1% of the total number of shares of PubCo Common Stock then outstanding; or</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">the average weekly reported trading volume of PubCo Common Stock during the four calendar
        weeks preceding the filing of a notice on Form 144 with respect to the sale.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales by affiliates of PubCo under Rule&#160;144 are
also limited by manner of sale provisions and notice requirements and to the availability of current public information about PubCo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Restrictions on the Use of Rule&#160;144 by Shell
Companies or Former Shell Companies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rule&#160;144 is not available for the resale of securities
initially issued by shell companies (other than business combination related shell companies) or issuers that have been at any time previously
a shell company. However, Rule&#160;144 also includes an important exception to this prohibition if the following conditions are met:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">the issuer of the securities that was formerly a shell company has ceased to be a shell
        company;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">the issuer of the securities is subject to the reporting requirements of Section&#160;13
        or 15(d) of the Exchange Act;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">the issuer of the securities has filed all Exchange Act reports and material required
        to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and
        materials), other than Form 8-K reports; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">at least one year has elapsed from the time that the issuer filed current Form 10 type
        information with the SEC reflecting its status as an entity that is not a shell company.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result, the Sponsor will be able to sell their
Founder Shares and Private Placement Warrants, as applicable, pursuant to Rule&#160;144 without registration once Rule&#160;144 becomes
available for resale of PubCo, subject to the provisions of the Sponsor Support Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR anticipates that following the consummation of
the Business Combination, PubCo will no longer be a shell company, and so, once the conditions set forth in the exceptions listed above
are satisfied, Rule&#160;144 will become available for the resale of the above noted restricted securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 324; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->307<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_034"></span>STOCKHOLDER PROPOSALS AND
DIRECTOR NOMINATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stockholder Proposals</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Proposed Bylaws
establish an advance notice procedure for stockholders who wish to present a proposal before an annual meeting of stockholders. The Proposed
Bylaws provide that the only business that may be conducted at an annual meeting of stockholders is business that is (a) specified in
the notice of such meeting (or any supplement or amendment thereto) given by or at the direction of the PubCo Board or any committee thereof,
(b) otherwise properly brought before such meeting by or at the direction of the PubCo Board or any committee thereof, or (c) otherwise
properly brought before such meeting by a stockholder who (A) (1) was a record owner of shares of PubCo both at the time of giving the
notice and at the time of the meeting, (2) is entitled to vote at such meeting, and (3) has complied with notice procedures specified
in the Proposed Bylaws in all applicable respects or (B) properly made such proposal in accordance with Rule 14a-8 under the Exchange
Act. To be timely for PubCo&#8217;s annual meeting of stockholders, a stockholder&#8217;s notice must be delivered to PubCo&#8217;s secretary
at PubCo&#8217;s principal executive offices not less than 90 days nor more than 120 days prior to the one-year anniversary of the preceding
year&#8217;s annual meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the event that no annual meeting was held in the
previous year or PubCo holds its annual meeting of stockholders more than 30 days before or more than 60 days after the one-year anniversary
of a preceding year&#8217;s annual meeting, to be timely, notice of a stockholder proposal must be delivered not later than the 90th day
prior to such annual meeting or, if later, the 10th day following the day on which public disclosure of the date of such annual meeting
was first made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notice of a nomination or proposal must be delivered
to PubCo no later than the 10th day following the earlier of the day on which such notice of the date of such meeting was mailed and the
day the public disclosure of the date of the annual meeting is made. Nominations and proposals also must satisfy other requirements set
forth in the Proposed Bylaws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under Rule 14a-8 of the Exchange Act, a stockholder
proposal (other than nominations) to be included in the proxy statement and proxy card for the annual general meeting pursuant to Rule
14a-8 must be received at PubCo&#8217;s principal office at a reasonable time before PubCo begins to print and send its proxy materials
and must comply with Rule 14a-8.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A stockholder will update and supplement its notice
to PubCo&#8217;s secretary, if necessary, so that the information provided or required to be provided in such notice as described above
will be true and correct as of the record date for notice of the annual meeting and as of the date that is 10 business days prior to the
annual meeting or any adjournment or postponement thereof, and such update and supplement will be delivered to, or mailed and received
by, PubCo&#8217;s secretary not later than five business days after the record date for stockholders entitled to vote at the meeting &#8216;(in
the case of the update and supplement required to be made as of such record date), and not later than eight business days prior to the
date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date
prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made
as of 10 business days prior to the meeting or any adjournment or postponement thereof).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stockholder Director Nominees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Proposed Bylaws permit stockholders to nominate
directors for election at an annual meeting or at a special meeting (but only if the election of directors is a matter specified in the
notice of meeting given by or at the direction of the person calling such special meeting) of stockholders, subject to the provisions
of the Proposed Charter. To nominate a director, the stockholder must provide the information required by the Proposed Bylaws. In addition,
the stockholder must give timely notice to PubCo&#8217;s secretary in accordance with the Proposed Bylaws, which, in general, require
that the notice be received by PubCo&#8217;s secretary within the time periods described above under the section &#8220;<i>&#8212; Stockholder
Proposals</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 325; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->308<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_035"></span>SHAREHOLDER COMMUNICATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shareholders and interested parties may communicate
with the BCAR Board, any committee chairperson or the non-management directors as a group by writing to the BCAR Board or committee chairperson
in care of D. Boral ARC Acquisition I Corp., 10 East 53rd Street, Suite 3001, New York, NY 10022. Following the Closing, such communications
should be sent to Exascale Labs Inc., at 500 Seventh Avenue, 14th Floor, New York, NY 10018. Each communication will be forwarded, depending
on the subject matter, to the PubCo Board, the appropriate committee chairperson or all non-management directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_036"></span>LEGAL MATTERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Loeb &amp; Loeb LLP will pass upon the validity of
the securities of PubCo to be issued in connection with the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_037"></span>OTHER MATTERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of the date of this proxy statement/prospectus,
the BCAR Board does not know of any matters that will be presented for consideration at the Extraordinary General Meeting other than as
described in this proxy statement/prospectus. If any other matters properly come before the Extraordinary General Meeting, or any adjournment
or postponement thereof, and are voted upon, the enclosed proxy will be deemed to confer discretionary authority on the individuals that
it names as proxies to vote the shares represented by the proxy as to any of these matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_038"></span>EXPERTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements of D. Boral ARC Merger
Corporation as of December 31, 2025 and for the period from December 19, 2025 (inception) through December 31, 2025 included in this proxy
statement/prospectus have been so included in reliance on the reports of Guangdong Prouden CPAs GP, an independent registered public accounting
firm, given on the authority of said firm as experts in auditing and accounting. The report on the financial statements contains an explanatory
paragraph regarding D. Boral ARC Merger Corporation&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements of D. Boral ARC Acquisition
I Corp. as of December 31, 2025 and for the period from March 20, 2025 (inception) through December 31, 2025 included in this proxy statement/prospectus
have been so included in reliance on the reports of Guangdong Prouden CPAs GP, an independent registered public accounting firm, given
on the authority of said firm as experts in auditing and accounting. The report on the financial statements contains an explanatory paragraph
regarding D. Boral ARC Acquisition I Corp.&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements of Exascale Labs Inc.
as of June 30, 2024 and 2025, and for each of the years in the two-year period ended June 30, 2025, included in this proxy statement/prospectus,
have been included in reliance on the report of HTL International, LLC, an independent registered public accounting firm, given on the
authority of said firm as experts in auditing and accounting. The report on the financial statements contains an explanatory paragraph
regarding Exascale Labs Inc.&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 326; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->309<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_039"></span>DELIVERY OF DOCUMENTS TO
SHAREHOLDERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the rules of the SEC, BCAR and services
that it employs to deliver communications to its shareholders are permitted to deliver to two or more shareholders sharing the same address
a single copy of each of BCAR&#8217;s annual report to shareholders and BCAR&#8217;s proxy statement. Upon written or oral request, BCAR
will deliver a separate copy of the annual report to shareholders and/or proxy statement to any shareholder at a shared address to which
a single copy of each document was delivered and who wishes to receive separate copies of such documents. Shareholders receiving multiple
copies of such documents may likewise request that BCAR deliver single copies of such documents in the future. Shareholders receiving
multiple copies of such documents may request that BCAR deliver single copies of such documents in the future. Shareholders may notify
BCAR of their requests by calling or writing BCAR at its principal executive offices at</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_040"></span>ENFORCEABILITY OF CIVIL
LIABILITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR is a British Virgin Islands business company.
If BCAR does not change its jurisdiction of incorporation from the British Virgin Islands to Delaware by effecting the Domestication Merger,
you may have difficulty serving legal process within the United States upon BCAR. You may also have difficulty enforcing, both in and
outside the United States, judgments you may obtain in U.S. courts against BCAR in any action, including actions based upon the civil
liability provisions of U.S. federal or state securities laws. Furthermore, there is doubt that the courts of the British Virgin Islands
would enter judgments in original actions brought in those courts predicated on U.S. federal or state securities laws. However, BCAR may
be served with process in the United States with respect to actions against BCAR arising out of or in connection with violation of U.S.
federal securities laws relating to offers and sales of BCAR&#8217;s securities by serving BCAR&#8217;s U.S. agent irrevocably appointed
for that purpose.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 327; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->310<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_041"></span>WHERE YOU CAN FIND MORE
INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BCAR has filed a registration statement on Form S-4
to register the issuance and resale of securities described elsewhere in this proxy statement/prospectus. This proxy statement/prospectus
is a part of that registration statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Information and statements contained in this proxy
statement/prospectus or any Annex to this proxy statement/prospectus are qualified in all respects by reference to the copy of the relevant
contract or other Annex filed as an exhibit to the registration statement of which this proxy statement/prospectus forms a part.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All information contained in this proxy statement/prospectus
relating to BCAR has been supplied by BCAR, and all such information relating to Exascale has been supplied by Exascale, respectively.
Information provided by one another does not constitute any representation, estimate or projection of the other.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This document is a (i) prospectus of PubCo with respect
to the PubCo Common Stock and PubCo Warrants to be issued to BCAR shareholders and warrant holders and Exascale Securityholders if the
Business Combination described herein is consummated and (ii) proxy statement of BCAR for the Extraordinary General Meeting. BCAR and
Exascale have not authorized anyone to give any information or make any representation about the Business Combination, BCAR or Exascale
that is different from, or in addition to, that contained in this proxy statement/prospectus. Therefore, if anyone does give you information
of this sort, you should not rely on it. The information contained in this proxy statement/prospectus speaks only as of the date of this
proxy statement/prospectus unless the information specifically indicates that another date applies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If you would like additional copies of this proxy
statement/prospectus, or if you have questions about the business combination, you should contact via phone or in writing:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">D. Boral ARC Acquisition I Corp.<br/>10 East 53rd
Street, Suite 3001</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">New York, NY 10022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Tel. No. (332) 266-7344</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Attention: David Boral, Chief Executive Officer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">E-mail: dboral@dboralcapital.com</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">You may also obtain these documents by requesting
them in writing or by telephone from BCAR&#8217;s proxy solicitation agent at the following address and telephone number:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Advantage Proxy Inc.<br/>PO Box 10904, Yakima, WA
98909<br/>Toll-Free 877-870-8565, or collect at 206-870-8565<br/>Email: KSmith@advantageproxy.com</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If you are a shareholder of BCAR and would like to
request documents, please do so no later than five business days before the Extraordinary General Meeting in order to receive them before
the Extraordinary General Meeting. If you request any documents from BCAR, BCAR will mail them to you by first class mail, or another
equally prompt means. Information and statements contained in this proxy statement/prospectus or any Annex to this proxy statement/prospectus
are qualified in all respects by reference to the copy of the relevant contract or other Annex filed as an exhibit to the registration
statement of which this proxy statement/prospectus forms a part, which includes exhibits incorporated by reference from other documents
that are not included with this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 328; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->311<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_042"></span><b>INDEX TO FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Financial
Statements of D. Boral ARC Merger Corporation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 90%; text-align: justify">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: center"><span style="font-size: 10pt"><b>Page(s)</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-size: 10pt"><b>Audited Financial
        Statements of D. Boral ARC Merger Corporation as of December&#160;31, 2025 and For the Period from December 19, 2025 (inception) through
        December 31, 2025</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#fin2_001"><span style="font-size: 10pt">Report
        of Independent Registered Public Accounting Firm (PCAOB ID No: 7254)</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">F-3</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-size: 10pt">Audited Financial
        Statements:</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#fin2_002"><span style="font-size: 10pt">Balance
        Sheet as of December&#160;31, 2025</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">F-4</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#fin2_003"><span style="font-size: 10pt">Statement
        of Operations for the period from December&#160;19, 2025 (inception) through December&#160;31, 2025</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">F-5</td></tr>
  <tr style="background-color: white">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#fin2_004"><span style="font-size: 10pt">Statement
        of Changes in Stockholders&#8217; Deficit for the period from December&#160;19, 2025 (inception) through December&#160;31, 2025</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">F-6</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#fin2_005"><span style="font-size: 10pt">Statement
        of Cash Flows for the period from December&#160;19, 2025 (inception) through December&#160;31, 2025</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">F-7</td></tr>
  <tr style="background-color: white">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><a href="#fin2_006"><span style="font-size: 10pt">Notes
        to the Financial Statements</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">F-8&#160;&#8211;&#160;F-11</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 90%"><span style="font-size: 10pt"><b>Unaudited Financial
    Statements of D. Boral ARC Merger Corporation as of March 31, 2026 and For the Three Months Ended March 31, 2026</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; width: 9%">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-size: 10pt">Unaudited Financial
    Statements:</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#b_001"><span style="font-size: 10pt">Balance
    Sheets as of March 31, 2026 and December&#160;31, 2025</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-12</span></td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#b_002"><span style="font-size: 10pt">Statement
    of Operations for the three months ended March 31, 2026</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-13</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#b_003"><span style="font-size: 10pt">Statement
    of Changes in Stockholders&#8217; Deficit for the three months ended March 31, 2026</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-14</span></td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#b_004"><span style="font-size: 10pt">Statement
    of Cash Flows for the three months ended March 31, 2026</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-15</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#b_005"><span style="font-size: 10pt">Notes
    to the Unaudited Condensed Interim Financial Statements</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-16 &#8211; F-19</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Financial
Statements of D. Boral ARC Acquisition I Corp.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><b>Audited
        Consolidated Financial Statements of D. Boral ARC Acquisition I Corp. as of December 31, 2025 and For the Period from March 20, 2025 (inception)
        through December 31, 2025</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_001">Report
        of Independent Registered Public Accounting Firm (PCAOB ID #7254)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-20</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
        Statements:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_002">Consolidated
        Balance Sheet as of December&#160;31, 2025</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-21</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_003">Consolidated
        Statements of Operations for the period from March&#160;20, 2025 (inception) through December&#160;31, 2025</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-22</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_004">Consolidated
        Statements of Changes in Stockholders&#8217; Deficit for the period from March&#160;20, 2025 (inception) through December&#160;31, 2025</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-23</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_005">Consolidated
        Statements of Cash Flows for the period from March&#160;20, 2025 (inception) through December&#160;31, 2025</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-24</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_006">Notes
        to the Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-25&#160;&#8211;&#160;F-41</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif;width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; width: 90%"><span style="font-size: 10pt;"><b>Unaudited
    Consolidated Financial Statements of D. Boral ARC Acquisition I Corp. as of March 31, 2026 and For the Period ended March 31, 2026</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; width: 9%"><span style="font-size: 10pt;">&#160;</span></td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span><a href="#fin3_001"><span style="font-size: 10pt">Consolidated
    Condensed Balance Sheets as of March&#160;31, 2026 (unaudited) and December&#160;31, 2025</span></a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt;">F-42</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><a href="#fin3_002"><span style="font-size: 10pt">Consolidated
    Condensed Statements of Operations for the three months ended March 31, 2026 and for the period from March&#160;20, 2025 (inception)
    through March&#160;31, 2025</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt;">F-43</span></td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><a href="#fin3_003"><span style="font-size: 10pt">Consolidated
    Condensed Statements of Changes in Shareholders&#8217; Equity (Deficit) for the three months ended March&#160;31, 2026 and for the
    period from March 20, 2025 (inception) through March&#160;31, 2025</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt;">F-44</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><a href="#fin3_004"><span style="font-size: 10pt">Consolidated
    Condensed Statements of Cash Flows for the three months ended March&#160;31, 2026 and for the period from March&#160;20, 2025 (inception)
    through March&#160;31, 2025</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt;">F-45</span></td></tr>
  <tr style="background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><a href="#fin3_005"><span style="font-size: 10pt">Notes
    to Financial Statements (Unaudited)</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt;">F-46&#160;&#8211;&#160;</span>F-60</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<!-- Field: Page; Sequence: 329; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Financial
Statements of Exascale Labs Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Page(s)</b></span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif"><b>Audited
        Financial Statements of Exascale Labs Inc.:</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin1_001">Report
        of Independent Registered Public Accounting Firm (PCAOB ID: 7000)</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-61</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; width: 90%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin1_002">Balance
        Sheets as of June&#160;30, 2024 and 2025</a></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-62</span><span style="font-family: Times New Roman, Times, Serif"></span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin1_003">Statements
        of Operations and Comprehensive Loss for the years ended June&#160;30, 2024 and 2025</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-63</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin1_004">Statements
        of Change in Shareholders&#8217; Deficit for the years ended June&#160;30, 2024 and 2025</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-64</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin1_005">Statements
        of Cash Flows for the years ended June&#160;30, 2024 and 2025</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-65</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin1_006">Notes
        to the Financial Statements</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-66&#160;&#8211;&#160;F-86</span></td>
        </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 91%; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>Unaudited
        Condensed Consolidated Financial Statements of Exascale Labs Inc.:</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 8%; text-align: center">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top; padding-left: 0.25in; text-indent: -9pt"><a href="#fin4_001">Condensed
        Consolidated Balance Sheets as of June 30, 2025 and <span style="font-size: 10pt">March 31, 2026</span> (unaudited)</a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-87</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.25in; text-indent: -9pt"><a href="#fin4_002">Unaudited
        Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and <span style="font-size: 10pt">Nine</span> Months
        ended <span style="font-size: 10pt">March 31, 2025</span> and 202<span style="font-size: 10pt">6</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-88</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top; padding-left: 0.25in; text-indent: -9pt"><a href="#fin4_003">Unaudited
        Condensed Consolidated Statements of Change in Shareholders&#8217; Deficit for the Three and <span style="font-size: 10pt">Nine</span>
        Months ended <span style="font-size: 10pt">March 31, 2025</span> and 202<span style="font-size: 10pt">6</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-89</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.25in; text-indent: -9pt"><a href="#fin4_004">Unaudited
        Condensed Consolidated Statements of Cash Flows for the <span style="font-size: 10pt">Nine</span> Months ended <span style="font-size: 10pt">March
        31, 2025</span> and 202<span style="font-size: 10pt">6</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-90</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top; padding-left: 0.25in; text-indent: -9pt"><a href="#fin4_005">Notes to
        Unaudited Condensed Consolidated Financial Statements</a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-91 &#8211; F-113</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 330; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="fin2_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">To the Shareholders and Board of Directors of<br/>
D. Boral ARC Merger Corporation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion on the Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying balance sheet
of D. Boral ARC Merger Corporation (the &#8220;Company&#8221;) as of December 31, 2025, the related statements of operations, change in
shareholders&#8217; equity and cash flows for the period from December 19, 2025 (inception) through December 31, 2025, and the related
notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in
all material respects, the financial position of the Company as of December 31, 2025 and the results of its operations and its cash flows
for the period from December 19, 2025 (inception) through December 31, 2025, in conformity with accounting principles generally accepted
in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Explanatory Paragraph &#8212; Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. As more fully described in Note 1 to the financial statements, the
Company is the surviving company in connection with a contemplated business combination between the Parent and a target company, which
has no principal operations or revenue producing activities. The Company lacks the capital resources it needs to fund its operations for
a reasonable period of time, which is generally considered to be one year from the issuance of the financial statements. These matters
raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans with regard to these
matters are also described in Note 1 to the financial statements. The financial statements do not include any adjustments that might result
from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Basis for Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audit in accordance with the
standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require
that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement,
whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over
financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but
not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly,
we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Guangdong Prouden CPAs GP</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Guangdong Prouden CPAs GP</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Guangzhou, China</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">February 11, 2026</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCAOB ID NO. 7254</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 331; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase"><b><span id="fin2_002"></span>D.
BORAL ARC MERGER CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-transform: uppercase">BALANCE
SHEET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_303_111_zdMgQQ2z62y3" summary="xdx: Statement - BALANCE SHEET" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_498_20251231_zcxgOMQLCMJh" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">December&#160;31,<br/>
        2025</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zajdnlKRzvag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">LIABILITIES
        AND STOCKHOLDERS&#8217; DEFICIT</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesCurrentAbstract_i01B_z6cv7susdUfl" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Current
        liabilities</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzsob_zM2OFKKyojIg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 88%; text-align: left">Accrued
        expenses</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000031" format="ixt:numdotdecimal" decimals="0" unitRef="USD">590</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrent_i01TI_mtCzsob_maCz9dm_zZyJba59us8f" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Total
        current liabilities</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000033" format="ixt:numdotdecimal" decimals="0" unitRef="USD">590</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Liabilities_iTI_mtCz9dm_maCzsVD_zis2MEUh3903" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Total
        liabilities</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-12-31" id="Fact000035" format="ixt:numdotdecimal" decimals="0" unitRef="USD">590</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquityAbstract_iB_zW18kdW0KLu2" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stockholders&#8217;
        Deficit</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CommonStockValue_iI_maCzIXz_zX3k3utTNJv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Common
        stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231_pd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000041" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value; <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_c20251231_pd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000043" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></span> shares authorized; <span id="xdx_905_eus-gaap--CommonStockSharesIssued_c20251231_pd" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_c20251231_pd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact000045" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000047" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0039">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdditionalPaidInCapital_iI_maCzIXz_zy3O1qxk2eb6" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Additional
        paid-in capital</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-12-31" id="Fact000049" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maCzIXz_zffOAp13kMoc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accumulated
        deficit</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-12-31" id="Fact000051" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">590</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquityNoteSubscriptionsReceivable_iNI_di_msCzIXz_z3eyRfibKJYe" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Subscription
        fee receivable</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" contextRef="AsOf2025-12-31" id="Fact000053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquity_iTI_pp0d_mtCzIXz_maCzsVD_zmm4cPdJ7AA2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Total
        Stockholders&#8217; Deficit</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000055" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">590</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_pp0d_mtCzsVD_zbzLonNCTfKi" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total
        Liabilities and Stockholders&#8217; Deficit</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0057">-</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
audited financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 332; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="fin2_003"></span>D. BORAL ARC MERGER CORPORATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENT OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_113_z03X4ZvQ498e" summary="xdx: Statement - STATEMENT OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_49D_20251219__20251231_z7kteMfyXrNb" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">For
        the<br/> Period from<br/> December&#160;19,<br/> 2025 (Inception)<br/> Through<br/> December&#160;31,<br/> 2025</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingExpenses_iNT_di_msCzeia_zbn28KmOPvA4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Formation
        costs</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-12-192025-12-31" id="Fact000059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">590</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingIncomeLoss_iT_mtCzeia_maCzvaM_zVWw5HE70Hq" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Loss
        from operations</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-12-192025-12-31" id="Fact000061" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">590</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzvaM_maCzLKX_zsTU2DlEn065" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Loss
        before provision for income taxes:</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-12-192025-12-31" id="Fact000063" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">590</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_msCzLKX_zcjeg0flBePa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Provision
        for income taxes</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0065">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_iT_mtCzLKX_zjPjgt7bqM17" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net
        Loss</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-12-192025-12-31" id="Fact000067" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">590</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted
        average shares outstanding of common stock</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20251219__20251231_pd" title="Weighted average shares outstanding of common stock, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20251219__20251231_pd" title="Weighted average shares outstanding of common stock, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-12-192025-12-31" id="Fact000069" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-12-192025-12-31" id="Fact000071" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Basic
        and diluted net loss per share</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20251219__20251231_pd" title="Basic loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20251219__20251231_pd" title="Diluted loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-12-192025-12-31" id="Fact000073" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-12-192025-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">5.90</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
audited financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 333; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="fin2_004"></span>D. BORAL ARC MERGER CORPORATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENT OF CHANGES IN STOCKHOLDERS&#8217; DEFICIT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_zTRHfYzTdxw" summary="xdx: Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_za3pbjf5MKad" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zQOmf1bS11l5" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zLdlC4fdjNN6" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_custom--SubscriptionReceivableMember_z4TPOWcnHKK4" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_4BC_z2tlYowDqoF2" style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="text-align: center; font-size: 10pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="text-align: center; font-size: 10pt; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-size: 10pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">Additional</td>
    <td style="text-align: center; font-size: 10pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-size: 10pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="text-align: center; font-size: 10pt; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-size: 10pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="text-align: center; font-size: 10pt; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-size: 10pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">Total</td>
    <td style="text-align: center; font-size: 10pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">Common
        Stock</td>
    <td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">Paid in</td>
    <td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">Accumulated</td>
    <td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">Subscription</td>
    <td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">Stockholders&#8217;</td>
    <td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">Shares</td>
    <td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">Amount</td>
    <td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">Capital</td>
    <td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">Deficit</td>
    <td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">Receivable</td>
    <td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">Deficit</td>
    <td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_436_c20251219__20251231_eus-gaap--StockholdersEquity_iS_zhqbE5VWTIXb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 28%; font-size: 10pt; font-weight: bold; vertical-align: top">Balance
        &#8211; December&#160;19, 2025</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20251219__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--DBoralArcMergerCorporationMember_zBiGBzj55cO5" title="Beginning balance, shares" style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0083">-</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0077">-</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0078">-</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0079">-</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0080">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td>
    <td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0081">-</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--CommonStockIssuedToInitialShareholderForSubscriptionFee_zfGHqPM8Io0a" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left">Common stock issued to initial
        shareholder for subscription fee</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--CommonStockIssuedToInitialShareholderForSubscriptionFeeShares_c20251219__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--DBoralArcMergerCorporationMember_zSIjFOvV0yq3" title="Common stock issued to initial shareholder for subscription fee, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFeeShares" contextRef="From2025-12-192025-12-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember" id="Fact000091" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0085">-</span></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee" contextRef="From2025-12-192025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0087">-</span></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee" contextRef="From2025-12-192025-12-31_custom_SubscriptionReceivableMember" id="Fact000088" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">100</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0089">-</span></td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProfitLoss_zyRywrJRGPuk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">Net
        loss</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0093">-</span></td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0094">-</span></td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-12-192025-12-31_us-gaap_RetainedEarningsMember" id="Fact000095" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">590</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0096">-</span></td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-12-192025-12-31" id="Fact000097" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">590</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_432_c20251219__20251231_eus-gaap--StockholdersEquity_iE_z6QWxWoWM9v6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; vertical-align: top">Balance
        &#8211; December&#160;31, 2025</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20251219__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--DBoralArcMergerCorporationMember_zI8EjIxLUvSl" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember" id="Fact000105" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0099">-</span></td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000100" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember" id="Fact000101" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">590</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_custom_SubscriptionReceivableMember" id="Fact000102" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">100</ix:nonFraction></b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><b>)</b></td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">590</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
audited financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 334; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="fin2_005"></span>D. BORAL ARC MERGER CORPORATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENT OF CASH FLOWS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_112_zqysNtFucJJ1" summary="xdx: Statement - STATEMENT OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_495_20251219__20251231_zgwhmktTSS96" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
        <p style="text-align: center; margin-top: 0; margin-bottom: 0">For the<br/> Period from<br/>December&#160;19,<br/> 2025 (inception)<br/>
        through<br/>December&#160;31,</p>
        <p style="text-align: center; margin-top: 0; margin-bottom: 0">2025</p></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zQ5SvLR2qtaj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash
        flow from operating activities:</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_i01_di_maCz7uv_zBtbzXbFJqsg" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Net
        loss</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-12-192025-12-31" id="Fact000109" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">590</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zFLHj0IWcIc9" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Adjustments
        to reconcile net loss to net cash used in operating activities:</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_iB_zwpq29fQ79V" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Changes
        in operating assets and liabilities:</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i01_maCz7uv_zVULfnOZANNj" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Accrued
        expenses</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2025-12-192025-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">590</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCz7uv_maCzsMO_z1OGAGTUREBb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Net
        cash used in operating activities</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0117">-</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zEadw52X9ubd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash
        flows from investing activities:</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_maCzsMO_zbJkLv1sA9Ic" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Net
        cash used in investing activities</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0121">-</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zH4VScWlwzf8" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash
        flow from financing activities:</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_maCzsMO_z6gVkSaduTvi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Net
        cash provided by financing activities</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0125">-</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzsMO_zCf76O4bqn55" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net
        change in cash</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0127">-</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zmEon7EOtyE6" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Cash
        at the beginning of the period</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0129">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zcs39NC58ov8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Cash
        at the end of the period</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0131">-</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zXU7h2EZe783" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplemental
        disclosure of non-cash financing activities:</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssued1_i01_zJVshjQOAQHd" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Common
        stock issued to initial shareholder for subscription fee</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2025-12-192025-12-31" id="Fact000135" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
audited financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 335; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p id="xdx_047_c20251219__20251231_zZp8XJLRdQRc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="fin2_006"></span>D. BORAL ARC MERGER CORPORATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-12-192025-12-31" escape="true" id="Fact000137" name="us-gaap:NatureOfOperations"><p id="xdx_80B_eus-gaap--NatureOfOperations_zJC9E8GNL4Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1 &#8212; <span id="xdx_821_zu9lUW4uEBC">Description of Organization and
Business Operations</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Business Operations</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">D. Boral ARC Merger Corporation
(the &#8220;Company&#8221; or &#8220;PubCo&#8221;) is a Delaware company formed by D. Boral ARC Acquisition I Corp. (the &#8220;Parent&#8221;
or &#8220;BCAR&#8221;) on December&#160;19, 2025 (inception). The Company has adopted a fiscal year-end of December&#160;31. The Company
is authorized to issue <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_zZtAwYCwpUPa" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></span> shares of Common Stock of par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zHBaoiIxdGw7" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000141" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> each share. The Company was formed to be the surviving company
in connection with a contemplated business combination between the Parent and a target company. The Company has no principal operations
or revenue producing activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Going Concern</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company was formed by the
Parent. The Parent has until February&#160;1, 2027 to complete its initial business combination (unless further extended). If the Parent
is unable to complete the initial business combination by February&#160;1, 2027, the Parent must cease all operations and dissolve and
liquidate (unless further extended).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The accompanying financial statements
have been prepared assuming that the Company will continue as a going concern. If the Parent is unable to raise additional funds to alleviate
liquidity needs as well as complete a business combination by close of February&#160;1, 2027 (unless further extended), then the Company
will cease all operations except for the purpose of liquidating. The liquidity condition and date for liquidation and subsequent dissolution
raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any
adjustments that might result from the outcome of these uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-12-192025-12-31" escape="true" id="Fact000143" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_z3Y09X9ArJqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 &#8212; <span id="xdx_827_z1QOLi23x5K2">Significant Accounting Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-12-192025-12-31" escape="true" id="Fact000145" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zIQgZvNM5Ow6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zJc7JPdBlxC3">Basis of Presentation</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and
pursuant to the rules and regulations of the SEC. The financial statements as of December&#160;31, 2025 and for the period from December&#160;19,
2025 (inception) through December&#160;31, 2025 respectively, are audited. In the opinion of management, the financial statements include
all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating
results and cash flows for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-12-192025-12-31" escape="true" id="Fact000147" name="cik0002065779:EmergingGrowthCompanyPolicyTextBlock"><p id="xdx_844_ecustom--EmergingGrowthCompanyPolicyTextBlock_zIflyZXwhT3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zieh9LOsfqE3">Emerging Growth Company</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is an &#8220;emerging
growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of
2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.</p>

<ix:exclude><p id="xdx_238_zMoG63ziq1Rl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 336; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period
which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company,
as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-12-192025-12-31" escape="true" id="Fact000150" name="us-gaap:UseOfEstimates"><p id="xdx_84C_eus-gaap--UseOfEstimates_zfT5mqcHOWl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zE9hBnagYMVa">Use of Estimates</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-12-192025-12-31" escape="true" id="Fact000152" name="cik0002065779:RisksAndUncertaintiesPolicyTextBlock"><p id="xdx_841_ecustom--RisksAndUncertaintiesPolicyTextBlock_zOgwh60tmOf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_863_zT2IwjyYxMwg">Risks and Uncertainties</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-12-192025-12-31" escape="true" id="Fact000154" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zkhtSX54qy75" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86C_ziSLvQsMEBHb">Income Taxes</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company complies with the
accounting and reporting requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach to
financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the
financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 740 prescribes a recognition
threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be
taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#8217;s management determined the United States is the Company&#8217;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The provision for income taxes
was deemed to be immaterial for the period from December&#160;19, 2025 (inception) through December&#160;31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-12-192025-12-31" escape="true" id="Fact000156" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z9GnwSb4VdD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Loss Per Share</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company computes basic loss
per share (&#8220;EPS&#8221;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of December&#160;31, 2025 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.</p>

<ix:exclude><p id="xdx_233_zMtLSbgyowBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 337; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-12-192025-12-31" escape="true" id="Fact000159" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrqiA2cU5R4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zTUwRw7Nlatj">Fair Value of Financial Instruments</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Fair value is defined as the
price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants
at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active
        markets;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly
        observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets
        that are not active; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity
        to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant
        value drivers are unobservable.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In some circumstances, the inputs
used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value
measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair
value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-12-192025-12-31" escape="true" id="Fact000161" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSNNhvz3V6Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zM7M5EBTVgG3">Recently adopted accounting pronouncements</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November&#160;2023, the FASB
issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose
information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public
entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment
disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since inception.
Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material
effect on the Company&#8217;s financial statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2025-12-192025-12-31" escape="true" id="Fact000163" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_80F_eus-gaap--SegmentReportingDisclosureTextBlock_zWj9pExp7IJj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3&#8201;&#8212;&#8201;<span>Segment Information</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span>&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_823_zBCYtPTrZJgj" style="display: none">Segment information</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 280, &#8220;Segment
Reporting,&#8221; establishes standards for companies to report in their financial statement information about operating segments, products,
services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial
information is available that is regularly evaluated by the Company&#8217;s chief operating decision maker, or group, in deciding how
to allocate resources and assess performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s chief operating
decision maker has been identified as directors (&#8220;CODM&#8221;), who review the operating results for the Company as a whole to make
decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only
has one operating segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">When evaluating the Company&#8217;s
performance and making key decisions regarding resource allocation, the CODM reviews several key metrics, formation and operational costs
which includes the accompanying statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The key measures of segment profit
or loss reviewed by our CODM is formation and operational costs. Formation and operational costs are reviewed and monitored by the CODM
to manage and forecast cash to ensure enough capital is available to complete a business combination within the business combination period.
The CODM also reviews formation and operational costs to manage, maintain and enforce all contractual agreements to ensure costs are aligned
with all agreements and budget.</p>

<ix:exclude><p id="xdx_233_z30nBomqpWVe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 338; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-12-192025-12-31" escape="true" id="Fact000166" name="us-gaap:BusinessCombinationDisclosureTextBlock"><p id="xdx_80F_eus-gaap--BusinessCombinationDisclosureTextBlock_zJxmo93c5NE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4 &#8212; <span id="xdx_825_zpHDqrU5OLkc">Business Combination</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January&#160;11, 2026, D. Boral
ARC Acquisition I Corp. (&#8220;BCAR&#8221; or the &#8220;Company&#8221;) entered into the Agreement and Plan of Merger (the &#8220;Merger
Agreement&#8221;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly owned subsidiary of BCAR (&#8220;PubCo&#8221;),
D. Boral Arc Merger Sub Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and a wholly-owned subsidiary of BCAR, and Exascale Labs
Inc.., a Delaware corporation (&#8220;Exascale&#8221;). Pursuant to the Merger Agreement, the Business Combination will be effected in
two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into PubCo, with PubCo remaining as the surviving
publicly traded entity (the &#8220;Reincorporation Merger&#8221;); (ii) after the Reincorporation Merger, Merger Sub will be merged with
and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#8220;Acquisition Merger&#8221; and together with
the Reincorporation Merger, the &#8220;Business Combination&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The aggregate consideration for
the Acquisition Merger is $<span id="xdx_906_ecustom--AggregateConsideration_c20260101__20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_pp0p" title="Aggregate consideration"><ix:nonFraction name="cik0002065779:AggregateConsideration" contextRef="From2026-01-012026-01-11_custom_DBoralARCAcquisitionICorp.Member" id="Fact000168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000,000</ix:nonFraction></span> (the &#8220;Merger Consideration&#8221;), payable in the form of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_pd" title="New shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2026-01-012026-01-11_custom_DBoralARCAcquisitionICorp.Member" id="Fact000170" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></span> newly issued shares
of common stock of PubCo valued at $<span id="xdx_902_eus-gaap--SharePrice_c20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_pd" title="Share Price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2026-01-11_custom_DBoralARCAcquisitionICorp.Member" id="Fact000172" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per share to Exascale and its shareholders. At the closing of the Acquisition Merger (the &#8220;Closing&#8221;),
the issued and outstanding shares in Exascale held by the former Exascale shareholders will be cancelled and cease to exist as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #FFFFFF; text-align: justify">Each issued and
        outstanding share of Exascale Class B common stock shall be cancelled and converted into the right to receive a number of shares of PubCo
        Class B common stock (the &#8220;PubCo Class B Shares&#8221;) equal to the quotient obtained by dividing (a) the quotient equal to the
        Merger Consideration divided by the fully diluted Exascale capitalization (the &#8220;Per Share Merger Consideration&#8221;) by (b) Ten
        Dollars ($10.00), with each such PubCo Class B Share having twenty (20) votes per share; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #FFFFFF; text-align: justify">Each issued and
        outstanding share of Exascale Class A common stock shall be cancelled and converted into the right to receive a number of shares of PubCo
        Class A common stock (the &#8220;PubCo Class A Shares&#8221;) equal to the quotient obtained by dividing (a) the Per Share Merger Consideration
        by (b) Ten Dollars ($10.00), with each such PubCo Class A Share having one (1) vote per share.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-12-192025-12-31" escape="true" id="Fact000174" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zhxdEDXzYVGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 5 &#8212; <span id="xdx_826_z8QPFSfZW7Qi">Share Capital</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company is authorized to issue
<span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_z5fNqfWf2Exk" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000176" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></span> shares of Common Stock of par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zUx4YfEZD1lg" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000178" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> each share. Holders of the Company&#8217;s common stock are entitled to one vote for each
share. On December&#160;19, 2025, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zATkjkJr6MK4" title="Common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-12-192025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000180" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></span> shares of common stock to its Parent D. Boral ARC Acquisition I Corp., at a purchase
price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_z76UKaf0Ad1g" title="Purchase price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember62742453" id="Fact000182" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share, or an aggregate purchase price of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0d_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zeyJujuSXK4h" title="Aggregate purchase price"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-12-192025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></span>. The subscription fee was not received yet as of December&#160;31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-12-192025-12-31" escape="true" id="Fact000186" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zdsxE17ClwOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 6 &#8212; <span id="xdx_827_zf6PwHW1lV13">Subsequent Events</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In preparing the financial statements,
the Company considered disclosures of events occurring after December&#160;31, 2025, until the issuance of the financial statements. Based
on this review, the Company identified the following subsequent event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January&#160;11, 2026, D. Boral
ARC Acquisition I Corp. (&#8220;BCAR&#8221; or the &#8220;Company&#8221;) entered into the Agreement and Plan of Merger (the &#8220;Merger
Agreement&#8221;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly owned subsidiary of BCAR (&#8220;PubCo&#8221;),
D. Boral Arc Merger Sub Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and a wholly-owned subsidiary of BCAR, and Exascale Labs
Inc.., a Delaware corporation (&#8220;Exascale&#8221;).</p>

</ix:nonNumeric><p id="xdx_81E_zO6w44CGTHcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 339; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0; text-transform: uppercase"><span id="b_001"></span><b>D.
BORAL ARC MERGER CORPORATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0; text-transform: uppercase"><b>BALANCE
SHEETs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_111_zmrbm4DUi6G4" summary="xdx: Statement - BALANCE SHEET" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_490_20251231_zCG04xeYUSad" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_498_20260331_zTTXGQQktd95" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December&#160;31,<br/>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March&#160;31,<br/> 2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 0.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>(Audited)</b></td>
    <td style="padding-bottom: 0.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 0.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>(Unaudited)</b></td>
    <td style="padding-bottom: 0.5pt"><b>&#160;</b></td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zIvQuYqiHpS" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>LIABILITIES AND STOCKHOLDERS&#8217;
    DEFICIT</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesCurrentAbstract_i01B_zhsCdHRqLGu3" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Current liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_404_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCz6LT_zc6K5rh7Tja7" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Accrued expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000194" format="ixt:numdotdecimal" decimals="0" unitRef="USD">590</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2026-03-31" id="Fact000195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">590</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_408_ecustom--AmountDueToRelatedParty_iIP3us-gaap--AccruedLiabilitiesCurrent_maCz6LT_maCzsob_zlpEQeArTTV7" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 0.5pt">Amount due
    to related party</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0197">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="cik0002065779:AmountDueToRelatedParty" contextRef="AsOf2026-03-31" id="Fact000198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesCurrent_i01TI_mtCz6LT_maCz76D_zTKqC6zaIFY4" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 0.5pt">Total current
    liabilities</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="0" unitRef="USD">590</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2026-03-31" id="Fact000201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,590</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_401_eus-gaap--Liabilities_iTI_mtCz76D_maCzQu4_zjRRhTPmdlE9" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Total
    liabilities</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">590</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2026-03-31" id="Fact000204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,590</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquityAbstract_iB_zHgJJ16svZy4" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Stockholders&#8217; Deficit</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_408_eus-gaap--CommonStockValue_iI_maCzGoC_zoASKb1Vl1ne" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Common stock, $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_z1qwkK1NPvK4" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value;
    <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_zHrjnaXJxhWi" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></span> shares authorized; <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20251231_zRgnbfzRPVXc" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_zAKDXjBdn7Kc" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0209">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0210">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_409_eus-gaap--AdditionalPaidInCapital_iI_maCzGoC_zI4Z6sg6Rnr" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Additional paid-in capital</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-12-31" id="Fact000220" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2026-03-31" id="Fact000221" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40B_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maCzGoC_zuwOjMXN8eH2" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Accumulated deficit</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-12-31" id="Fact000223" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">590</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2026-03-31" id="Fact000224" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,590</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquityNoteSubscriptionsReceivable_iNI_di_msCzGoC_zrPy3XMPeSld" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 0.5pt">Subscription receivable</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" contextRef="AsOf2025-12-31" id="Fact000226" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" contextRef="AsOf2026-03-31" id="Fact000227" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquity_iTI_pp0d_mtCzGoC_maCzQu4_zJdffxA5oVI3" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Total
    Stockholders&#8217; Deficit</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000229" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">590</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31" id="Fact000230" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,590</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td> </tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_pp0d_mtCzQu4_zbEUFPJmAD01" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 2.5pt"><b>Total
    Liabilities and Stockholders&#8217; Deficit</b></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span style="-sec-ix-hidden: xdx2ixbrl0232">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span style="-sec-ix-hidden: xdx2ixbrl0233">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 2.5pt">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">The accompanying notes are
an integral part of these unaudited financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 340; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b><span id="b_002"></span>D.
BORAL ARC MERGER CORPORATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>STATEMENT OF OPERATIONS<br/>
(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_113_zmQ1FYxzKkjl" summary="xdx: Statement - STATEMENT OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_492_20260101__20260331_zjk1zd7fjnw1" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months Ended<br/>
    March&#160;31,<br/> 2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_407_eus-gaap--OperatingExpenses_iNT_di_msCzVT1_zcbXknzVU8Zc" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Formation and operating costs</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2026-01-01to2026-03-31" id="Fact000235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_407_eus-gaap--OperatingIncomeLoss_iT_mtCzVT1_maCzbz7_zbaxwjAuRkje" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Loss
    from operations</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2026-01-01to2026-03-31" id="Fact000237" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,000</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzbz7_maCzUz7_z8x3V0v3etde" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Loss before provision for income
    taxes:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2026-01-01to2026-03-31" id="Fact000239" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,000</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_msCzUz7_zUGvrCNsqRS1" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Provision
    for income taxes</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0241">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iT_mtCzUz7_zuow2gaU3rBb" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Net
    Loss</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2026-01-01to2026-03-31" id="Fact000243" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,000</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Weighted average shares outstanding
    of common stock</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331_pd" title="Weighted average shares outstanding of common stock, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331_pd" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2026-01-01to2026-03-31" id="Fact000245" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2026-01-01to2026-03-31" id="Fact000246" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Basic and diluted net loss
    per share</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><b><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20260101__20260331_pd" title="Basic loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20260101__20260331_pd" title="Diluted loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2026-01-01to2026-03-31" id="Fact000248" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2026-01-01to2026-03-31" id="Fact000250" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">100.00</ix:nonFraction></ix:nonFraction></span></span></b></td>
    <td style="text-align: left; white-space: nowrap"><b>)</b></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">The accompanying notes are
an integral part of these unaudited financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 341; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b><span id="b_003"></span>D.
BORAL ARC MERGER CORPORATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>STATEMENT OF CHANGES IN
STOCKHOLDERS&#8217; DEFICIT<br/>
(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_304_114_zeIHrOZRWhT4" summary="xdx: Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zdz1rdGVZRJg" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z5EhPsQ5VrG2" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z5huPODVJx9k" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_custom--SubscriptionReceivableMember_zhKnqnVLZzSk" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4BB_zva4Y24eFAKb" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Additional</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Total</b></td>
    <td>&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Common Stock</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; padding-bottom: 0.5pt"><b>Paid in</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; padding-bottom: 0.5pt"><b>Accumulated</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; padding-bottom: 0.5pt"><b>Subscription</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; padding-bottom: 0.5pt"><b>Stockholders&#8217;</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Shares</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Amount</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Capital</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Deficit</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Receivable</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Deficit</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_436_c20260101__20260331_eus-gaap--StockholdersEquity_iS_zFLdw2J9PBje" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Balance &#8211; December&#160;31,
    2025</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--DBoralArcMergerCorporationMember_zI53lGboOsv2" title="Beginning balance, shares" style="width: 9%; text-align: right"><b><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember" id="Fact000258" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0252">-</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000253" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left"><b>$</b></td>
    <td style="width: 9%; text-align: right"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember" id="Fact000254" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">590</ix:nonFraction></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap"><b>)</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_custom_SubscriptionReceivableMember" id="Fact000255" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">100</ix:nonFraction></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap"><b>)</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000256" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">590</ix:nonFraction></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_40E_eus-gaap--ProfitLoss_zi836dMDph11" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Net loss</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0260">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember" id="Fact000262" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,000</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0263">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2026-01-01to2026-03-31" id="Fact000264" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,000</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr id="xdx_435_c20260101__20260331_eus-gaap--StockholdersEquity_iE_zrzfZE4BXJs3" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Balance
    &#8211; December&#160;31, 2025</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--SharesOutstanding_iE_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--DBoralArcMergerCorporationMember_zSFaAh0kXdEi" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2026-03-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember" id="Fact000272" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember" id="Fact000268" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,590</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_custom_SubscriptionReceivableMember" id="Fact000269" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">100</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31" id="Fact000270" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,590</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">)</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">The accompanying notes are
an integral part of these unaudited financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 342; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b><span id="b_004"></span>D.
BORAL ARC MERGER CORPORATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>STATEMENT OF CASH FLOWS<br/>
(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_300_112_zKkQ2XMtsNte" summary="xdx: Statement - STATEMENT OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_498_20260101__20260331_zO4Jdp22Jgc9" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months Ended<br/>
    March&#160;31,<br/> 2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zcHOQIoa10C8" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Cash flow from operating activities:</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_i01_maCztsM_zN1fu1rlClxd" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Net loss</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2026-01-01to2026-03-31" id="Fact000276" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,000</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zkILc0plXP3d" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Adjustments to reconcile net loss
    to net cash used in operating activities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_iB_zBgx7Qk4xtU" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Changes in operating assets
    and liabilities:</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40F_ecustom--PaymentOfExpensesThroughRelatedParty_iP3us-gaap--IncreaseDecreaseInAccruedLiabilities_maCztsM_maCz7uv_zMtORyrmXmda" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 0.5pt">Payment
    of expenses through related party</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="cik0002065779:PaymentOfExpensesThroughRelatedParty" contextRef="From2026-01-01to2026-03-31" id="Fact000282" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCztsM_maCzADn_zYpcsZNHwdja" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.375in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Net
    cash used in operating activities</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><span style="-sec-ix-hidden: xdx2ixbrl0284">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zXEECpYZ8GUc" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Cash flows from investing activities:</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_maCzADn_zEFOVkj9oMod" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.375in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Net
    cash used in investing activities</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><span style="-sec-ix-hidden: xdx2ixbrl0288">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zb2DGcSYAI3i" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Cash flow from financing activities:</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_maCzADn_zB2lSewE3Tyh" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.375in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Net
    cash provided by financing activities</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><span style="-sec-ix-hidden: xdx2ixbrl0292">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzADn_z0FePT0pkBl8" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Net change in cash</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><b><span style="-sec-ix-hidden: xdx2ixbrl0294">-</span></b></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zYJ7OpyPSBNb" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Cash at
    the beginning of the period</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zZu3wSXjGT3f" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Cash
    at the end of the period</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span style="-sec-ix-hidden: xdx2ixbrl0298">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">The accompanying notes are
an integral part of these unaudited financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 343; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->



<p id="xdx_041_c20260101__20260331_z8RzCBCRdDV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="b_005"></span>D. BORAL ARC MERGER CORPORATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000300" name="us-gaap:NatureOfOperations"><p id="xdx_80C_eus-gaap--NatureOfOperations_zf7kYOkK4Imf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1 &#8212; <span><span id="xdx_824_zEQebogyAwxh">Description of Organization
and Business Operations</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Business Operations</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">D. Boral ARC Merger Corporation
(the &#8220;Company&#8221; or &#8220;PubCo&#8221;) is a Delaware company formed by D. Boral ARC Acquisition I Corp. (the &#8220;Parent&#8221;
or &#8220;BCAR&#8221;) on December&#160;19, 2025 (inception). The Company has adopted a fiscal year-end of December&#160;31. The Company
is authorized to issue <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_zAlPgdaBLNye" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000302" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></span> shares of Common Stock of par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zyXoKWlrnUJg" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000304" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> each share. The Company was formed to be the surviving company
in connection with a contemplated business combination between the Parent and a target company. The Company has no principal operations
or revenue producing activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Going Concern</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company was formed by
the Parent. The Parent has until February&#160;1, 2027 to complete its initial business combination (unless further extended). If the
Parent is unable to complete the initial business combination by February&#160;1, 2027, the Parent must cease all operations and dissolve
and liquidate (unless further extended).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The accompanying financial
statements have been prepared assuming that the Company will continue as a going concern. If the Parent is unable to raise additional
funds to alleviate liquidity needs as well as complete a business combination by close of February&#160;1, 2027 (unless further extended),
then the Company will cease all operations except for the purpose of liquidating. The liquidity condition and date for liquidation and
subsequent dissolution raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements
do not include any adjustments that might result from the outcome of these uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000306" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zhfiwIBnxW47" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 &#8212; <span><span id="xdx_82F_z8WT7pqmunKd">Significant Accounting Policies</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000308" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoCc0oxIXVye" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86A_zRelC9ayrXw9">Basis of Presentation</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. The financial statements as of March
31, 2026 and for the three months ended March 31, 2026 respectively, are un audited. In the opinion of management, the financial
statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the
financial position, operating results and cash flows for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000310" name="cik0002065779:EmergingGrowthCompanyPolicyTextBlock"><p id="xdx_84E_ecustom--EmergingGrowthCompanyPolicyTextBlock_zxCuTvrFDI99" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_864_zu39EgO8Buwg">Emerging Growth Company</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is an &#8220;emerging
growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act
of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.</p>

<ix:exclude><p id="xdx_235_zmhv8zSfDTcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 344; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition
period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging
growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because
of the potential differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000313" name="us-gaap:UseOfEstimates"><p id="xdx_84A_eus-gaap--UseOfEstimates_zBvkspy1qQI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86E_zvzbCsC8L8Ff">Use of Estimates</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000315" name="cik0002065779:RisksAndUncertaintiesPolicyTextBlock"><p id="xdx_845_ecustom--RisksAndUncertaintiesPolicyTextBlock_zSX4tZHeTxo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86D_zOSz8DGNyjqf">Risk and Uncertainties</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000317" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zAGgh3xYfpt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_865_zOgsMgqR3B78">Income Taxes</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company complies with
the accounting and reporting requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach
to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between
the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 740 prescribes a
recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected
to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#8217;s management determined the United States is the Company&#8217;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provision for income
taxes was deemed to be immaterial for the three months ended March 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000319" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z6IKhtn0tFHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_866_z5LJmpNKovA1">Loss Per Share</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company computes basic
loss per share (&#8220;EPS&#8221;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of March 31, 2026 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.</p>

<ix:exclude><p id="xdx_231_zFaayNtH95cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 345; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000322" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zPwok5ETZsz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86E_zAu283mu3nxe">Fair Value of Financial Instruments</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Fair value is defined
as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market
participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring
fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments
    in active markets;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly
    or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar
    instruments in markets that are not active; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring
    an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs
    or significant value drivers are unobservable.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In some circumstances, the
inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair
value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the
fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000324" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhxo4ncWR2Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zIe1QxnsUF6c">Recently adopted accounting pronouncements</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November&#160;2023, the
FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to
disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis.
Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing
segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since
inception. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would
have a material effect on the Company&#8217;s financial statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000326" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_800_eus-gaap--SegmentReportingDisclosureTextBlock_ziZWg2OvQdfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3&#8201;&#8212;&#8201;<span><span>Segment Information</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_82C_z7uy5yMbcEtj" style="display: none">Segment information</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 280, &#8220;Segment
Reporting,&#8221; establishes standards for companies to report in their financial statement information about operating segments, products,
services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial
information is available that is regularly evaluated by the Company&#8217;s chief operating decision maker, or group, in deciding how
to allocate resources and assess performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s chief
operating decision maker has been identified as directors (&#8220;CODM&#8221;), who review the operating results for the Company as a
whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the
Company only has one operating segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">When evaluating the Company&#8217;s
performance and making key decisions regarding resource allocation, the CODM reviews several key metrics, formation and operational costs
which includes the accompanying statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The key measures of segment
profit or loss reviewed by our CODM is formation and operational costs. Formation and operational costs are reviewed and monitored by
the CODM to manage and forecast cash to ensure enough capital is available to complete a business combination within the business combination
period. The CODM also reviews formation and operational costs to manage, maintain and enforce all contractual agreements to ensure costs
are aligned with all agreements and budget.</p>

<ix:exclude><p id="xdx_23A_zwxuEsC0tFM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 346; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000329" name="us-gaap:BusinessCombinationDisclosureTextBlock"><p id="xdx_809_eus-gaap--BusinessCombinationDisclosureTextBlock_zz0pi87aYuh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4 &#8212; <span><span id="xdx_82A_zmgpl2ui5l4b">Business Combination</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January&#160;11, 2026,
D. Boral ARC Acquisition I Corp. (&#8220;BCAR&#8221; or the &#8220;Company&#8221;) entered into the Agreement and Plan of Merger (the
&#8220;Merger Agreement&#8221;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly owned subsidiary
of BCAR (&#8220;PubCo&#8221;), D. Boral Arc Merger Sub Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and a wholly-owned subsidiary
of BCAR, and Exascale Labs Inc.., a Delaware corporation (&#8220;Exascale&#8221;). Pursuant to the Merger Agreement, the Business Combination
will be effected in two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into PubCo, with PubCo remaining
as the surviving publicly traded entity (the &#8220;Reincorporation Merger&#8221;); (ii) after the Reincorporation Merger, Merger Sub
will be merged with and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#8220;Acquisition Merger&#8221;
and together with the Reincorporation Merger, the &#8220;Business Combination&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The aggregate consideration
for the Acquisition Merger is $<span id="xdx_900_ecustom--AggregateConsideration_pp0d_c20260101__20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_zXXqwXv1BXGd" title="Aggregate consideration"><ix:nonFraction name="cik0002065779:AggregateConsideration" contextRef="From2026-01-012026-01-11_custom_DBoralARCAcquisitionICorp.Member" id="Fact000331" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000,000</ix:nonFraction></span> (the &#8220;Merger Consideration&#8221;), payable in the form of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_zocbYDaoU3K4" title="New shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2026-01-012026-01-11_custom_DBoralARCAcquisitionICorp.Member" id="Fact000333" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></span> newly issued shares
of common stock of PubCo valued at $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_zRXflzuZMDy4" title="Share Price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2026-01-11_custom_DBoralARCAcquisitionICorp.Member" id="Fact000335" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per share to Exascale and its shareholders. At the closing of the Acquisition Merger (the &#8220;Closing&#8221;),
the issued and outstanding shares in Exascale held by the former Exascale shareholders will be cancelled and cease to exist as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #FFFFFF; text-align: justify">Each
    issued and outstanding share of Exascale Class B common stock shall be cancelled and converted into the right to receive a number
    of shares of PubCo Class B common stock (the &#8220;PubCo Class B Shares&#8221;) equal to the quotient obtained by dividing (a) the
    quotient equal to the Merger Consideration divided by the fully diluted Exascale capitalization (the &#8220;Per Share Merger Consideration&#8221;)
    by (b) Ten Dollars ($10.00), with each such PubCo Class B Share having twenty (20) votes per share; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #FFFFFF; text-align: justify">Each
    issued and outstanding share of Exascale Class A common stock shall be cancelled and converted into the right to receive a number
    of shares of PubCo Class A common stock (the &#8220;PubCo Class A Shares&#8221;) equal to the quotient obtained by dividing (a) the
    Per Share Merger Consideration by (b) Ten Dollars ($10.00), with each such PubCo Class A Share having one (1) vote per share.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000337" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z85SDJ4YhdWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 5 &#8212; <span><span id="xdx_822_zaJ0zlFDAKm2">Share Capital</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company is authorized
to issue 100 shares of Common Stock of par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zGw25nXRyHs8" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000339" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> each share. Holders of the Company&#8217;s common stock are entitled to one
vote for each share. On December&#160;19, 2025, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zTgHwRfLctwa" title="Common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-12-192025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000341" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></span> shares of common stock to its Parent D. Boral ARC Acquisition
I Corp., at a purchase price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zFcXUa3HlvSa" title="Purchase price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember62742453" id="Fact000343" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share, or an aggregate purchase price of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0d_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zAz0GKFnQxRf" title="Aggregate purchase price"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-12-192025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000345" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></span>. The subscription fee was not received yet as
of March 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000347" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zjwom0VPgJzj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 6 &#8212; <span><span id="xdx_828_z3M5gtjk58V7">Subsequent Events</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In preparing the financial
statements, the Company considered disclosures of events occurring after March 31, 2026, until the issuance of the financial statements.
Based on this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial
statements.</p>

</ix:nonNumeric><p id="xdx_81D_zqd2l5McoHKl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 347; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #231F20">To the Shareholders
and Board of Directors of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #231F20">D. Boral
ARC Acquisition I Corp.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #231F20">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Opinion on the Consolidated
Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We have audited the accompanying
consolidated balance sheets of <span style="color: #231F20">D. Boral ARC Acquisition I Corp.</span> (the &#8220;Company&#8221;) as of
December 31, 2025, the related consolidated statements of operations, changes in shareholders&#8217; deficit and cash flows for the period
from March 20, 2025 (Inception) through December 31, 2025, and the related notes (collectively referred to as the &#8220;consolidated
financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2025, and the results of its operations and its cash flows for the period from March 20, 2025
(Inception) through December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Explanatory Paragraph
&#8211; Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The accompanying consolidated
financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note 1 to the consolidated
financial statements, the Company is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset
acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company has incurred
and expects to continue to incur significant costs in pursuit of its acquisition plans and the Company&#8217;s business plan is dependent
on the completion of a business combination within the Combination period and if not completed will cease all operations except for the
purpose of liquidating. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s
plans in regard to these matters are also described in Note 1. The consolidated financial statement does not include any adjustments that
might result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Basis for Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">These consolidated financial
statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We conducted our audit in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are
required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the
effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our audit included performing
procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates
made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit
provides a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">/s/ Guangdong Prouden CPAs
GP</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Guangdong Prouden CPAs GP</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We have served as the Company&#8217;s
auditor since 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Guangzhou, China</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">March 13, 2026</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">PCAOB ID NO. 7254</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 348; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="fin_002"></span>D.
Boral ARC Acquisition I Corp.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Consolidated
BALANCE SHEETs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_111_zVIm3ATW1RU7" summary="xdx: Statement - BALANCE SHEET" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_492_20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zh1Cvys76uXg" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December&#160;31,<br/> 2025</b></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsAbstract_iBP2us-gaap--LiabilitiesAndStockholdersEquityAbstract_zlDimuZ0efnk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">ASSETS</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrentAbstract_iBP3us-gaap--AssetsAbstract_zYR896XvwTh9" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Current Assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iIP3us-gaap--AssetsCurrentAbstract_maCze5E_zrCSkNbW1kAj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Cash</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,340</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidExpenseCurrent_iIP3us-gaap--CashAndCashEquivalentsAtCarryingValue_maCze5E_z2nNMxBXdI7c" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Prepaid expenses</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000355" format="ixt:numdotdecimal" decimals="0" unitRef="USD">203,134</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsCurrent_iTIP3us-gaap--PrepaidExpenseCurrent_mtCze5E_maCz4fI_z8TpbNFNUvk5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Total Current Assets</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000357" format="ixt:numdotdecimal" decimals="0" unitRef="USD">623,474</ix:nonFraction></td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--CashHeldInTrustAccount_iIP3us-gaap--AssetsCurrent_maCz4fI_zhoVmInoug2f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Cash held in trust account</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="cik0002065779:CashHeldInTrustAccount" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000359" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,776,628</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Assets_iTIP3custom--CashHeldInTrustAccount_mtCz4fI_zGWwxqJcJjVb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total
        Assets</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">285,400,102</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zOZ6HYZnZyra" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">LIABILITIES AND SHAREHOLDERS&#8217;
        DEFICIT</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesCurrentAbstract_i01B_zc7dFiX4a4z6" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzNr7_zXe5pjRhadKi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued expenses</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000367" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,611</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesCurrent_i01TI_mtCzNr7_maCzlLC_z60eCtWY3xI4" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Total Current Liabilities</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000369" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,611</ix:nonFraction></td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Liabilities_iTI_mtCzlLC_maCzNiI_ze3AjeEze596" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Total
        Liabilities</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,611</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CommitmentsAndContingencies_iIP3us-gaap--Liabilities_zUNOD4hZZCwi" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Commitments and Contingencies</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iIP3us-gaap--CommitmentsAndContingencies_maCzNiI_maCzsVD_zZR9Sv8pyIE4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Class A ordinary shares subject to possible
        redemption, $<span id="xdx_906_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zEga9fVpdrAc" title="Shares subject to possible redemption issued"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000377" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value; <span id="xdx_902_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zOl5GHZxPPQ1" title="Shares subject to possible redemption issued"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000379" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000,000</ix:nonFraction></span> shares authorized; <span id="xdx_905_eus-gaap--TemporaryEquitySharesIssued_iI_c20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_z0yrKjophqDl" title="Shares subject to possible redemption issued"><span id="xdx_907_eus-gaap--TemporaryEquitySharesOutstanding_c20251231_pd" title="Shares subject to possible redemption outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000381" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000383" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,000,000</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding, at redemption value of $<span id="xdx_907_eus-gaap--TemporaryEquityRedemptionPricePerShare_iI_c20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zvyfmfppn9f8" title="Shares subject to possible redemption , redemption price per share"><ix:nonFraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000385" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.17</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000375" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,776,628</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockholdersEquityAbstract_iB_zhsWJ1tkrzn1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Shareholders&#8217; Equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockValue_iIP3us-gaap--StockholdersEquityAbstract_maCzi8c_maCzIXz_zYKWvOpIhvI3" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Preferred shares, $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zgtg75EnGcMc" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000391" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value; <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zMDVXkA86O4j" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000393" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span>
        shares authorized; <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_dn_c20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zl7Heqdv8Y2i" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zaqirHWHKJma" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000395" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000397" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Class A ordinary shares, $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zNztOY7F5rdi" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000399" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value;
        <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_ziSdC7hpCg0c" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000401" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000,000</ix:nonFraction></span> shares authorized; <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zGnsTQdOGzWk" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zLae5s9CQKm2" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000403" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000405" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,200,000</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding (excluding <span id="xdx_90B_ecustom--SharesSubjectToRedemption_iI_c20251231__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zTsxs1WgG7B7" title="Shares subject to redemption"><ix:nonFraction name="cik0002065779:SharesSubjectToRedemption" contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000407" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,000,000</ix:nonFraction></span> shares subject to redemption)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--CommonStockValue_iI_maCzi8c_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zmqKIUk6OGha" title="Common stock, value" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000409" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Class B ordinary Shares, $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_znYv0T06IvR6" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000411" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value;
        <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zVGyoze6JpWc" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000413" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></span> shares authorized; <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zu4PTaxfGFS2" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_ziB8KkmUZ8k1" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000415" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000417" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,000,000</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--CommonStockValue_iI_maCzi8c_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zhTySpAV2Dpd" title="Common stock, value" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000419" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,200</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdditionalPaidInCapital_iI_maCzi8c_zjLaDn6Jb0a7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Additional paid-in capital</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maCzi8c_zTNmbSgoPv46" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Retained earnings</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">584,543</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockholdersEquity_iTI_mtCzi8c_maCzNiI_zOy9FFjk6Hqe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Total
        Shareholders&#8217; Equity</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000425" format="ixt:numdotdecimal" decimals="0" unitRef="USD">585,863</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzNiI_zwWHKNWKFxP7" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total
        Liabilities and Shareholders&#8217; Equity</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000427" format="ixt:numdotdecimal" decimals="0" unitRef="USD">285,400,102</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 349; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="fin_003"></span>D.
Boral ARC Acquisition I Corp.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_113_zyswD1nIGpH3" summary="xdx: Statement - STATEMENT OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49B_20250320__20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zXReGLrkcQ" style="font-weight: bold; text-align: right">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/>Period from<br/>March&#160;20,
        2025<br/>(Inception) through<br/> December&#160;31,<br/> 2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpenses_iNT_di_msCzBTb_zfKb0HP3Jwm8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 1pt">Formation
        and operating costs</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000429" format="ixt:numdotdecimal" decimals="0" unitRef="USD">320,658</ix:nonFraction></td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_iT_mtCzBTb_maCzLXD_zDohqBw4MoRg" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Loss from Operations</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000431" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">320,658</ix:nonFraction></td>
    <td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherIncomeAbstract_iBP3us-gaap--OperatingIncomeLoss_zps3SaWJ1rJ1" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Other Income</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestIncomeOther_iP3us-gaap--OtherIncomeAbstract_maCzLXD_maCzLKX_zIhPzMkfUdu6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Interest income on trust
        account</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000435" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,776,628</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_iT_mtCzLXD_zSNYeq383rj3" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net
        Income</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000437" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,455,970</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Weighted average shares
        outstanding of Class A ordinary shares</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zfc2hw3StcUk" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zKjJYeFWsIw8" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember" id="Fact000438" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember" id="Fact000439" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,393,007</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic
        and diluted net income per ordinary share</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_c20250320__20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z3PRw6s7WGPf" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z5GDPYbUqzlb" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember" id="Fact000440" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember" id="Fact000441" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.16</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Weighted average shares
        outstanding of Class B ordinary share</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zrzBD70Hzofi" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z8YaRJo636W3" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember" id="Fact000442" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember" id="Fact000443" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,935,190</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic
        and diluted net income per ordinary share</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20250320__20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z489WHNuxTl9" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zPeOATYJHrXc" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember" id="Fact000444" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember" id="Fact000445" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.16</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 350; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="fin_004"></span>D.
Boral ARC Acquisition I Corp.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; DEFICIT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE PERIOD FROM MARCH 20, 2025 (INCEPTION) THROUGH December&#160;31, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_zxsxoOJAkQv4" summary="xdx: Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_custom--OrdinarySharesClassAMember_dei--LegalEntityAxis_custom--DBoralARCAcquisitionICorpMember_znhtGGIvWf9e" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_custom--OrdinarySharesClassBMember_dei--LegalEntityAxis_custom--DBoralARCAcquisitionICorpMember_zueffFrmfDki" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_dei--LegalEntityAxis_custom--DBoralARCAcquisitionICorpMember_z0qV4jQqDcR" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_dei--LegalEntityAxis_custom--DBoralARCAcquisitionICorpMember_zFeMrFX1ygL8" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_custom--SubscriptionReceivableMember_dei--LegalEntityAxis_custom--DBoralARCAcquisitionICorpMember_z7ibUQdWXA37" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4BD_dei--LegalEntityAxis_custom--DBoralARCAcquisitionICorpMember_zDMWH9cSdhAi" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Class A<br/>Ordinary shares</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Class B<br/>Ordinary shares</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional<br/>Paid-In</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Retained</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Subscription</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total<br/>Shareholder&#8217;s</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Earnings</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Receivable</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43F_c20250320__20251231_eus-gaap--StockholdersEquity_iS_zrPSyZv2JNoj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Balance &#8211; March&#160;20, 2025 (inception)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--SharesOutstanding_iS_c20250320__20251231__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassAMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zL5v2EKpdOui" title="Beginning balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98E_eus-gaap--SharesOutstanding_iS_c20250320__20251231__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zSwAbub20Irj" title="Beginning balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0456">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0449">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ClassBOrdinarySharesIssuedToSponsor_zQXWr8UFmlXh" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 28%; text-align: left">Class B ordinary shares issued
        to Sponsor</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 6%; text-align: right">-</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">-</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--ClassBOrdinarySharesIssuedToSponsorShares_c20250320__20251231__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zsKkBdE3D8gk" title="Class B ordinary shares issued to Sponsor, shares" style="width: 6%; text-align: right"><ix:nonFraction name="cik0002065779:ClassBOrdinarySharesIssuedToSponsorShares" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000465" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,321,429</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 6%; text-align: right"><ix:nonFraction name="cik0002065779:ClassBOrdinarySharesIssuedToSponsor" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000459" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,232</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 6%; text-align: right"><ix:nonFraction name="cik0002065779:ClassBOrdinarySharesIssuedToSponsor" contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000460" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,768</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0461">-</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="color: White; width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">-</span>&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 6%; text-align: right"><ix:nonFraction name="cik0002065779:ClassBOrdinarySharesIssuedToSponsor" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000463" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--SaleOfPrivateUnitsNetOfIssuanceCosts_zgvQGuME3xY6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Sale of Private Units, net of issuance costs</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--SaleOfPrivateUnitsNetOfIssuanceCostsShares_c20250320__20251231__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassAMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zolDWocLXQEb" title="Sale of Private Units, net of issuance costs, shares" style="text-align: right"><ix:nonFraction name="cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCostsShares" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000474" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000467" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts" contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,971,400</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000472" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,971,420</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--IssuanceOfPublicWarrantsNetOfIssuanceCosts_z4t814K7cy9l" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Issuance of Public Warrants, net of issuance
        costs</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0476">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0477">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts" contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000478" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,913,405</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0479">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0480">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000481" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,913,405</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--IssuanceOfRepresentativeShares_zOS9aRsTcFUj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Issuance of Representative Shares</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_988_ecustom--IssuanceOfRepresentativeSharesShares_c20250320__20251231__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassAMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_z29EzGDoCEN4" title="Issuance of Representative Shares, shares" style="text-align: right"><ix:nonFraction name="cik0002065779:IssuanceOfRepresentativeSharesShares" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000490" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:IssuanceOfRepresentativeShares" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000483" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:IssuanceOfRepresentativeShares" contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000485" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,419,300</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0487">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:IssuanceOfRepresentativeShares" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000488" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,419,400</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AccretionInValueOfClassOrdinaryShares_iN_di_zozOXhGekDxc" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accretion in value of Class A ordinary shares</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0492">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:AccretionInValueOfClassOrdinaryShares" contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000494" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,233,074</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:AccretionInValueOfClassOrdinaryShares" contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000495" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,301,388</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:AccretionInValueOfClassOrdinaryShares" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000497" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,534,462</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--ReverseOverallotmentOptionLiability_zRFrSS7BKDsd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">reverse over-allotment option liability</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0499">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0500">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:ReverseOverallotmentOptionLiability" contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">860,414</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:ReverseOverallotmentOptionLiability" contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000502" format="ixt:numdotdecimal" decimals="0" unitRef="USD">429,961</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0503">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:ReverseOverallotmentOptionLiability" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000504" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,290,375</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ForfeitureOfFounderShares_iN_di_zmhfGQ4T9Ij7" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Forfeiture of founder shares</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0506">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--ForfeitureOfFounderSharesShares_c20250320__20251231__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zBRs4sL8ACwf" title="Forfeiture of founder shares, shares" style="text-align: right">(<ix:nonFraction name="cik0002065779:ForfeitureOfFounderSharesShares" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000513" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">321,429</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:ForfeitureOfFounderShares" contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000507" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:ForfeitureOfFounderShares" contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000508" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0509">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0510">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0511">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--AdjustmentOfAccruedOfferingCosts_zMtnhjgwPTZf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Adjustment of accrued offering costs</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0516">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:AdjustmentOfAccruedOfferingCosts" contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000517" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,755</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0518">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0519">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:AdjustmentOfAccruedOfferingCosts" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000520" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,755</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProfitLoss_zN27Q5xdEPwk" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Net income</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0522">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0524">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000525" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,455,970</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0526">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000527" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,455,970</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20250320__20251231_eus-gaap--StockholdersEquity_iE_znSXlFnwe5kb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Balance &#8211; December&#160;31,
        2025</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--SharesOutstanding_iE_c20250320__20251231__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassAMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zo2V90NbKO87" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember" id="Fact000536" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,200,000</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember" id="Fact000529" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--SharesOutstanding_iE_c20250320__20251231__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zOurfUt91Dtl" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000538" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,000,000</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000530" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,200</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0531">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000532" format="ixt:numdotdecimal" decimals="0" unitRef="USD">584,543</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0533">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000534" format="ixt:numdotdecimal" decimals="0" unitRef="USD">585,863</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 351; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="fin_005"></span>D.
Boral ARC Acquisition I Corp.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_112_zflNa4JuI1n" summary="xdx: Statement - STATEMENT OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_495_20250320__20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zVWyoeVJNKXi" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/> period from<br/> March&#160;20,
        2025<br/> (inception) through<br/> December&#160;31,<br/> 2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zvazlrIdlvqb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash flows from operating
        activities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_i01_maCzy2N_zjJUxB46qkJc" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Net income</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000542" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,455,970</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zvxAwDlvnGP2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Adjustments to reconcile
        net income to net cash used in operating activities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InterestIncomeOther_iNP3custom--PaymentOfExpensesThroughRelatedParty_di_msCzy2N_msCz7uv_zjU3I5QaYI0j" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Interest income on trust account</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,776,628</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--PaymentOfExpensesThroughPromissoryNoteRelatedParty_iP3us-gaap--InterestIncomeOther_maCzy2N_maCz7uv_zrchNeARk8k2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Payment of expenses through promissory note
        &#8211; related party</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:PaymentOfExpensesThroughPromissoryNoteRelatedParty" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000548" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,420</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_iB_zBF29vJEAGs6" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Changes in operating assets
        and liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInPrepaidExpense_iNP3custom--PaymentOfExpensesThroughPromissoryNoteRelatedParty_di_msCzy2N_msCz7uv_z5QQA8Q2oK47" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Prepaid expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000552" format="ixt:numdotdecimal" decimals="0" unitRef="USD">203,134</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i01_maCzy2N_zX7ECzD3wgk8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued expenses</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000554" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,611</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzy2N_maCzb8O_zcG904gvTNaf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Net
        cash used in operating activities</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000556" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">444,761</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zkysvg8h96J3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash flows from investing
        activities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PaymentsToAcquireRestrictedInvestments_iNP2us-gaap--NetCashProvidedByUsedInInvestingActivities_di_msCzB7O_zhuxyJ7Df1y3" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Investment of cash in
        Trust Account</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireRestrictedInvestments" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000560" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,000,000</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_mtCzB7O_maCzb8O_zVkuoEEYO76a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Net
        cash provided by investing activities</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000562" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">280,000,000</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zeblkuqFk4v3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash flows from financing
        activities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromIssuanceOfCommonStock_iP2us-gaap--NetCashProvidedByUsedInFinancingActivities_maCzg4P_zRNTyVU9FHy9" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Proceeds from issuance of Class B ordinary
        shares to Sponsor</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000566" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid_iP3us-gaap--ProceedsFromIssuanceOfCommonStock_maCzg4P_zMwGZJdtWWwb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Proceeds from sale of Units, net of underwriting
        discount paid</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000568" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,000,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_iP3custom--ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid_maCzg4P_zeFOfjnxgH16" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Proceeds from sale of private placement units</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000570" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RepaymentsOfDebt_iNP3us-gaap--ProceedsFromIssuanceOfPrivatePlacement_di_msCzg4P_z3EcnpIzfQac" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Repayment of promissory note</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000572" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,461</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsForRepurchaseOfInitialPublicOffering_iNP3us-gaap--RepaymentsOfDebt_di_msCzg4P_zz8aAwx4IOEf" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Payment of offering costs</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000574" format="ixt:numdotdecimal" decimals="0" unitRef="USD">934,438</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCzg4P_maCzb8O_z6N0Bovl4Ry2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Net
        cash used in financing activities</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000576" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,865,101</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzb8O_zlRz3soQHYdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Net
        change in cash</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000578" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,340</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zpEbxhid2bYi" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash at the beginning of the period</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0580">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zNNmPeRPwx5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash
        at the end of the period</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000582" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,340</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zNHfCikfDQIl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Supplemental disclosure
        of non-cash investing and financing activities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NotesIssued1_iP3us-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_zdqtWr3IOzqh" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Forfeiture of founder
        shares</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NotesIssued1" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000586" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NoncashOrPartNoncashAcquisitionDebtAssumed1_iP3us-gaap--NotesIssued1_zr8BV1JHb6ke" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Re-measurement of ordinary
        shares subject to redemption</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,776,628</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NoncashOrPartNoncashAcquisitionDescription_iP3us-gaap--NoncashOrPartNoncashAcquisitionDebtAssumed1_z63FnEdD8Z1c" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Issuance of representative
        shares</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000590" name="us-gaap:NoncashOrPartNoncashAcquisitionDescription">2,419,400</ix:nonNumeric></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 352; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p id="xdx_044_c20250320__20251231_zmZVF1aeGbSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_006"></span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
BORAL ARC ACQUISITION I CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
2025 and 2024</b></span></p>

<p id="xdx_119_hdei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zHJAtRTG3ne4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000592" name="us-gaap:NatureOfOperations"><p id="xdx_803_eus-gaap--NatureOfOperations_zLLaTa8ZGhCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. <span id="xdx_82D_zfE85CfSiSl">DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
BORAL ARC ACQUISITION I CORP. (the &#8220;Company&#8221;) is a blank check company incorporated in the British Virgin Islands on March&#160;20,
2025. The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more businesses (&#8220;Business Combination&#8221;). While the Company may pursue an acquisition
opportunity in any business, industry, sector or geographical location, the Company intends to focus on industries that complement our
management team&#8217;s background, and to capitalize on the ability of our management team to identify and acquire a business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December&#160;31, 2025, the Company had not yet commenced any operations. All activity through December&#160;31, 2025 related to the Company&#8217;s
formation and the Initial Public Offering (as defined below). The Company will not generate any operating revenues until after the completion
of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on
cash and cash equivalents from the proceeds derived from the Initial Public Offering. The Company has selected December&#160;31 as its
fiscal year end. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated
with early stage and emerging growth companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s sponsor is MFH 1, LLC (the &#8220;Sponsor&#8221;). The registration statement for the Company&#8217;s Initial Public Offering
was declared effective on July&#160;30, 2025. On August&#160;1, 2025, the Company consummated its Initial Public Offering of <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zymewYmUk4Hc" title="Sale of units in initial public offering"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000594" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000,000</ix:nonFraction></span>
units (the &#8220;Units&#8221; and, with respect to the Class A Ordinary Shares included in the Units being offered, the &#8220;Public
Shares&#8221;), at $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zLpBFIdH2am2" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000596" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per Unit, generating gross proceeds of $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zeMvai1aOgU5" title="Sale of units in initial public offering aggragate amount"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000598" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000,000</ix:nonFraction></span> (the &#8220;Initial Public Offering&#8221;). The Company
granted the underwriter a 45-day option to purchase up to an additional <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zvvgsX2GXdI2" title="Sale of units in initial public offering"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000600" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750,000</ix:nonFraction></span> Units at the Initial Public Offering price to cover
over-allotments, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously
with the consummation of the closing of the Offering, the Company consummated the private placement of an aggregate of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z1oRfYkYwYg7" title="Sale of units in initial public offering"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000602" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> units (the
&#8220;Placement Units&#8221;) to the Sponsor at a price of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ztuGwqkmsSn4" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000604" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per Unit, generating gross proceeds of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z6JLWVjCNLD2" title="Sale of units in initial public offering aggragate amount"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000606" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></span> (the &#8220;Private
Placement&#8221;). (see Note 4).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction
costs amounted to $<span id="xdx_90D_ecustom--TransactionCosts_pp0p0_c20250320__20251231_zWv4AjHSzFBk" title="Transaction costs"><ix:nonFraction name="cik0002065779:TransactionCosts" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000608" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,582,634</ix:nonFraction></span>, consisting of $<span id="xdx_900_ecustom--RepresentativeShares_pp0p0_c20250320__20251231_zfnVet6jBnE8" title="Representative shares"><ix:nonFraction name="cik0002065779:RepresentativeShares" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000610" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,419,400</ix:nonFraction></span> of the Representative Shares (discussed in the below) and $<span id="xdx_900_ecustom--OtherOfferingCosts_pp0p0_c20250320__20251231_zzbsFZ9QoI29" title="Other offering costs"><ix:nonFraction name="cik0002065779:OtherOfferingCosts" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000612" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,163,234</ix:nonFraction></span> of other offering
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with the IPO, the Company issued to the underwriter <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_z9JyvNUCifek" title="Number of share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000614" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> Class A ordinary shares for no consideration (the &#8220;Representative
Shares&#8221;). The fair value of the Representative Shares accounted for as compensation under Accounting Standards Codification (&#8220;ASC&#8221;)
718, &#8220;Compensation &#8211; Stock Compensation&#8221; (&#8220;ASC 718&#8221;) is included in the offering costs. The estimated fair
value of the Representative Shares as of the IPO date totaled $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zkjrdeMbCkic" title="Number of share issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000616" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,419,400</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the closing of the Initial Public Offering on August&#160;1, 2025, an amount of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zAYQK4eRIMDe" title="proceeds from sale of initial public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000618" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000,000</ix:nonFraction></span> ($10.00 per Unit) from the net proceeds of
the sale of the Units in the Initial Public Offering and a portion of the proceeds from the sale of the Placement Units was placed in
a trust account (the &#8220;Trust Account&#8221;), located in the United States and held as cash items and will be invested only in U.S.
government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule&#160;2a-7 under
the Investment Company Act, that invest only in direct U.S. government treasury obligations; the holding of these assets in this form
is intended to be temporary and for the sole purpose of facilitating the intended business combination. To mitigate the risk that the
Company might be deemed to be an investment company for purposes of the Investment Company Act, which risk increases the longer that the
Company hold investments in the trust account, the Company may, at any time (based on our management team&#8217;s ongoing assessment of
all factors related to our potential status under the Investment Company Act), instruct the trustee to liquidate the investments held
in the trust account and instead to hold the funds in the trust account in cash or in an interest bearing demand deposit account at a
bank.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 353; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zpweLSd6aeA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zdzc8zZ0VQJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
BORAL ARC ACQUISITION I CORP.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zZNbPn4q5G87" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zjKzPYMaABB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
2025 and 2024</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zohSNjxrCe4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zRfJqv5cGm8a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS (Continued)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zgSkciqSXgr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August&#160;11, 2025, the underwriters of the IPO notified the Company of their partial exercise of the over-allotment option and purchased
<span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zDA2VnME7U0b" title="Sale of units in initial public offering"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000627" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction></span> additional units (the &#8220;Option Units&#8221;) at $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zR9U3nh9D7Y8" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000629" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per unit upon the closing of the over-allotment option, generating
gross proceeds of $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zlDHmMAY5wM4" title="Sale of units in initial public offering aggragate amount"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000631" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,000,000</ix:nonFraction></span>. The over-allotment option closed on August&#160;13, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September&#160;9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and
thereby forfeit the option. As a result,&#160;on September&#160;9, 2025,&#160;the Company cancelled a total of <span id="xdx_905_ecustom--CancelledFounderShares_c20250905__20250909_zuJm4Jjl1XIk" title="Cancelled founder shares"><ix:nonFraction name="cik0002065779:CancelledFounderShares" contextRef="From2025-09-052025-09-09_custom_DBoralARCAcquisitionICorpMember" id="Fact000633" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">321,429</ix:nonFraction></span> of the Company&#8217;s
founder shares, issued to MFH 1, LLC thereby reducing the sponsor&#8217;s total shares to <span id="xdx_909_ecustom--CancelledFounderShares_c20250729__20250801_z24hspa4c7wl" title="Cancelled founder shares"><ix:nonFraction name="cik0002065779:CancelledFounderShares" contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember" id="Fact000635" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,000,000</ix:nonFraction></span>, which was effective from August&#160;1,
2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion
of our initial business combination either (i) in connection with a shareholder meeting called to approve the initial business combination
or (ii) by means of a tender offer. In connection with a proposed Business Combination, the Company may seek shareholder approval of a
Business Combination at a meeting called for such purpose at which shareholders may seek to redeem their shares, regardless of how they
vote for the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially
$<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zi26VOwh3vcj" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000637" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company
to pay its tax obligations). The per-share amount to be distributed to shareholders who redeem their Public Shares will not be reduced
by the deferred underwriting commissions the Company will pay to the underwriter. These ordinary shares was recorded at a redemption value
and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification
(&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other reasons, the Company
will, pursuant to its amended and restated memorandum and articles of association conduct the redemptions pursuant to Rule&#160;13e-4
and Regulation 14E of the Exchange Act, which regulate issuer tender offers, and file tender offer documents with the SEC prior to completing
our initial business combination which contain substantially the same financial and other information about the initial business combination
and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sponsor, officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed to (i) waive
their redemption rights with respect to their founder shares, private shares and public shares in connection with the completion of our
initial business combination; (ii) waive their redemption rights with respect to their founder shares, private shares and public shares
in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and articles of association; (iii)
waive their rights to liquidating distributions from the trust account with respect to their founder shares and private shares if the
Company fail to complete our initial business combination within the completion window, although they will be entitled to liquidating
distributions from the trust account with respect to any public shares they hold if the Company fail to complete our initial business
combination within the prescribed time frame and to liquidating distributions from assets outside the trust account; and (iv) vote any
founder shares and private shares held by them and any public shares they may purchase (including in open market and privately-negotiated
transactions) in favor of our initial business combination (except that any public shares such parties may purchase in compliance with
the requirements of Rule&#160;14e-5 under the Exchange Act would not be voted in favor of approving the business combination transaction).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 354; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zuEFgT6ZGnrh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zIrwE1dB9sak" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
BORAL ARC ACQUISITION I CORP.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_z3DqgSFgZTe1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zjNtQAnyf8ra" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
2025 and 2024</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zwnUYUFz8O85" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zWZm2nLer5L" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS (Continued)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zDxMGRaZQd4g" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will have until 18 months from the closing of the Initial Public Offering, with one (1) three-month extension at the option of
the sponsor (as may be extended by shareholder approval to amend our amended and restated memorandum and articles of association to extend
the date by which the Company must consummate our initial business combination) or until such earlier liquidation date as our board of
directors may approve, to consummate a Business Combination (the &#8220;Combination Period&#8221;). If the Company is unable to complete
a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up,
(ii) as promptly as reasonably possible but not more than ten business days thereafter (and subject to lawfully available funds therefor),
redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including
interest earned on the funds held in the trust account (which interest shall be net of taxes and less up to $<span id="xdx_900_eus-gaap--LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_iI_c20251231_zMMxKKn8j5Nc" title="Dissolution expenses"><ix:nonFraction name="us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000646" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> of interest to pay
dissolution expenses), divided by the number of then-outstanding public shares, which redemption will completely extinguish public shareholders&#8217;
rights as shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii)
as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors,
liquidate and dissolve, subject in each case to our obligations under British Virgin Islands law to provide for claims of creditors and
the requirements of other applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriter has agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event the Company
does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds
held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is
possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price
per Unit ($10.00).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sponsor has agreed that it will be liable to us if and to the extent any claims by a third party for services rendered or products sold
to us (except for the Company&#8217;s independent auditors), or a prospective target business with which the Company has entered into
a written letter of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in
the trust account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account
as of the date of the liquidation of the trust account, if less than $10.00 per public share due to reductions in the value of the trust
assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business
who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will
it apply to any claims under our indemnity of the underwriters of our IPO against certain liabilities, including liabilities under the
Securities Act. However, the Company has not asked our sponsor to reserve for such indemnification obligations, nor has the Company independently
verified whether our sponsor has sufficient funds to satisfy its indemnity obligations and the Company believe that our sponsor&#8217;s
only assets are securities of our company. Therefore, the Company cannot assure you that our sponsor would be able to satisfy those obligations.
As a result, if any such claims were successfully made against the trust account, the funds available for our initial business combination
and redemptions could be reduced to less than $10.00 per public share. In such event, the Company may not be able to complete our initial
business combination, and you would receive such lesser amount per share in connection with any redemption of your public shares. None
of our officers or directors will indemnify us for claims by third parties including, without limitation, claims by vendors and prospective
target businesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January&#160;11, 2026, D. Boral ARC Acquisition I Corp. (&#8220;BCAR&#8221; or the &#8220;Company&#8221;) entered into the Agreement and
Plan of Merger (the &#8220;Merger Agreement&#8221;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly
owned subsidiary of BCAR (&#8220;PubCo&#8221;), D. Boral Arc Merger Sub Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and a
wholly-owned subsidiary of BCAR, and Exascale Labs Inc., a Delaware corporation (&#8220;Exascale&#8221;). Pursuant to the Merger Agreement,
the Business Combination will be effected in two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into
PubCo, with PubCo remaining as the surviving publicly traded entity (the &#8220;Reincorporation Merger&#8221;); (ii) after the Reincorporation
Merger, Merger Sub will be merged with and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#8220;Acquisition
Merger&#8221; and together with the Reincorporation Merger, the &#8220;Business Combination&#8221;).&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 355; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zFxyQGr00tx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zVeYjNwJyw4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
BORAL ARC ACQUISITION I CORP.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_238_zXgzZDQsHQ2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zdrFXyL7lQvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
2025 and 2024</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_236_zJuh4gl4oEh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zTWGyMb5kpxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS (Continued)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_z1gR33X5lLl9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate consideration for the Acquisition Merger is $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250320__20251231_zLQu92JYDcL4" title="Share newly issued of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000655" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000,000</ix:nonFraction></span> (the &#8220;Merger Consideration&#8221;), payable in the form of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250320__20251231_zrpwY2DyvnT9" title="Share newly issued of common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000657" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></span>
newly issued shares of common stock of PubCo valued at $10.00 per share to Exascale and its shareholders. At the closing of the Acquisition
Merger (the &#8220;Closing&#8221;), the issued and outstanding shares in Exascale held by the former Exascale shareholders will be cancelled
and cease to exist as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each issued and outstanding share
        of Exascale Class B common stock shall be cancelled and converted into the right to receive a number of shares of PubCo Class B common
        stock (the &#8220;PubCo Class B Shares&#8221;) equal to the quotient obtained by dividing (a) the quotient equal to the Merger Consideration
        divided by the fully diluted Exascale capitalization (the &#8220;Per Share Merger Consideration&#8221;) by (b) Ten Dollars ($10.00), with
        each such PubCo Class B Share having twenty (20) votes per share; and</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each issued and outstanding share
        of Exascale Class A common stock shall be cancelled and converted into the right to receive a number of shares of PubCo Class A common
        stock (the &#8220;PubCo Class A Shares&#8221;) equal to the quotient obtained by dividing (a) the Per Share Merger Consideration by (b)
        Ten Dollars ($10.00), with each such PubCo Class A Share having one (1) vote per share.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity,
Capital Resources and Going Concern Consideration</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December&#160;31, 2025, the Company had $<span id="xdx_901_eus-gaap--Cash_iI_pp0p0_c20251231_zBQBHTAL4Sk4" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000659" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">420,340</ix:nonFraction></span> of cash in its operating bank account and working capital of $<span id="xdx_904_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20251231_zaoDT1sVQ0Cb" title="Working capital deficit"><ix:nonFraction name="cik0002065779:WorkingCapitalDeficit" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000661" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">585,863</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through the payment of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--FounderSharesMember_zd9iA0x85lrl"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-03-202025-12-31_custom_FounderSharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000662" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span>
from the Sponsor to cover for certain offering costs on the Company&#8217;s behalf in exchange for issuance of Founder Shares (as defined
in Note 4), and loan from the Sponsor of $<span id="xdx_900_eus-gaap--LoansPayable_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z97qhlWYqK2h"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2025-12-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000663" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,461</ix:nonFraction></span> under the Note (as defined in Note 4). On August&#160;1, 2025, the Company has repaid
$<span id="xdx_903_eus-gaap--RepaymentOfNotesReceivableFromRelatedParties_c20250729__20250801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zb9jcZE28Ibk"><ix:nonFraction name="us-gaap:RepaymentOfNotesReceivableFromRelatedParties" contextRef="From2025-07-292025-08-01_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000664" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,461</ix:nonFraction></span> under the promissory note. Subsequent to the consummation of the Initial Public Offering, the Company&#8217;s liquidity has been
satisfied through the net proceeds from the consummation of the Initial Public Offering and the Private Placement held outside of the
Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate
of the Sponsor, or certain of the Company&#8217;s officers and directors may, but are not obligated to, provide the Company Working Capital
Loans (as defined in Note 4). As of December&#160;31, 2025, there were no amounts outstanding under any Working Capital Loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to incur significant costs in pursuit of its acquisition plans and will not generate any operating revenues until after
the completion of its initial business combination. In addition, the Company expects to have negative cash flows from operations as it
pursues an initial business combination target. In connection with the Company&#8217;s assessment of going concern considerations in accordance
with Accounting Standards Update (&#8220;ASU&#8221;) 2014-15, &#8220;Disclosures of Uncertainties about an Entity&#8217;s Ability to Continue
as a Going Concern&#8221; the Company does not currently have adequate liquidity to sustain operations, which consist solely of pursuing
a Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 356; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zKukruEGHJY7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zatHNnVlLTo7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
BORAL ARC ACQUISITION I CORP.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zDbndVpC0D2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_z1mTV6DvNTUl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
2025 and 2024</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_238_z2XHWJ4mTtvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zSHSSe1oBpo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS (Continued)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zFCwx8HcXRUf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may raise additional capital through loans or additional investments from the Sponsor or its shareholders, officers, directors,
or third parties. The Company&#8217;s officers and directors and the Sponsor may, but are not obligated to (except as described above),
loan the Company funds, from time to time, in whatever amount they deem reasonable in their sole discretion, to meet the Company&#8217;s
working capital needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is customary for a special purpose acquisition company, if the Company is not able to consummate a Business Combination during the Combination
Period, it will cease all operations and redeem the Public Shares. Management plans to continue its efforts to consummate a Business Combination
during the Combination Period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company expects to have access to additional sources of capital if necessary, there is no current commitment on the part of any financing
source to provide additional capital and no assurances can be provided that such additional capital will ultimately be available. The
liquidity condition and mandatory liquidation raise substantial doubt about the Company&#8217;s ability to continue as a going concern
until the earlier of the consummation of the Business Combination or the date the Company is required to liquidate. There is no assurance
that the Company&#8217;s plans to raise additional capital (to the extent ultimately necessary) or to consummate a Business Combination
will be successful or successful within the Combination Period. The consolidated financial statements do not include any adjustments that
might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000673" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zy7FcDCgeNii" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. <span id="xdx_82E_z6Po6lfWFJF7">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000675" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zTqQLi3oj3F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zknhPtMT4xkj">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
information and note disclosures normally included in the annual consolidated financial statements prepared in accordance with generally
accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although the Company believes that
the disclosures made are adequate to make the information not misleading. The consolidated financial statements as of December&#160;31,
2025 and for period from March&#160;20, 2025 (inception) through December&#160;31, 2025 are audited. In the opinion of management, the
consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary to provide a fair
statement of the results for the periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000677" name="cik0002065779:EmergingGrowthCompanyPolicyTextBlock"><p id="xdx_84E_ecustom--EmergingGrowthCompanyPolicyTextBlock_zjHTebZGYcF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z9adgwwH5gz6">Emerging
Growth Company</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart
Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being
required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 357; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_z9kIs0ySRiH1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zofFMiAc1SIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
BORAL ARC ACQUISITION I CORP.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zFGYOgHJSUDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zZ6xKIHFaKYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
2025 and 2024</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zzuvrBiPFaB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zsRwgsExtchj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zZZzzF0lQul4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not
have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply
to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended
transition period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#8217;s consolidated financial statements with another public company which is neither
an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible
because of the potential differences in accounting standards used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000686" name="us-gaap:UseOfEstimates"><p id="xdx_849_eus-gaap--UseOfEstimates_zCSpiRUyiDb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z9wBQjRDfAXk">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making
estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of
a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered
in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results
could differ significantly from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000688" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zxisgP8Xl37k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zAhdNNso56Nb">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash
equivalents are carried at cost, which approximates fair value. The Company had $<span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20251231_zmXdChwNJcJ4" title="Cash"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000690" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,340</ix:nonFraction></span> in cash as of December&#160;31, 2025 The Company
had <span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20251231_zyjNNzvKrPke" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000692" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> cash equivalents as of December&#160;31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000694" name="cik0002065779:CashHeldInTrustAccountPolicyTextBlock"><p id="xdx_843_ecustom--CashHeldInTrustAccountPolicyTextBlock_z4HvK1JPIUmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zTYNKhDkXdT7">Cash
Held in Trust Account</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had $<span id="xdx_90E_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20251231_z8h7Eqz2G7o8" title="Cash held in trust"><ix:nonFraction name="cik0002065779:CashHeldInTrustAccount" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000696" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">284,776,628</ix:nonFraction></span> of cash in the trust account held in an interest bearing demand deposit account as of December&#160;31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000698" name="cik0002065779:OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock"><p id="xdx_843_ecustom--OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock_zjYwZgXnflQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zHG5bezvliwj">Offering
Costs Associated with the Initial Public Offering</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212; &#8220;Expenses
of Offering.&#8221; Deferred offering costs consist principally of professional and registration fees that are related to the Initial
Public Offering. Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 470-20, &#8220;Debt with Conversion and Other Options,&#8221;
addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this
guidance to allocate Initial Public Offering proceeds from the Public Units between Class A ordinary shares and warrants based on their
relative fair values. Offering costs allocated to the Class A ordinary shares subject to possible redemption were charged to temporary
equity, and offering costs allocated to the warrants included in the Public Units and Private Units were charged to shareholder&#8217;s
equity as the warrants, after management&#8217;s evaluation, were accounted for under equity treatment. As of August&#160;1, 2025, the
Company had offering costs of $<span id="xdx_90C_ecustom--OfferingCost_iI_pp0p0_c20250801_zTEBye9LC6Sa" title="Offering costs"><ix:nonFraction name="cik0002065779:OfferingCost" contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember" id="Fact000700" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,582,634</ix:nonFraction></span>, consisting of $<span id="xdx_901_ecustom--RepresentativeShares_c20250729__20250801_zO3HwvtfCCL3" title="Representative shares"><ix:nonFraction name="cik0002065779:RepresentativeShares" contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember" id="Fact000702" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,419,400</ix:nonFraction></span> of the Representative Shares (as discussed in Note 1) and $<span id="xdx_903_ecustom--OtherOfferingCost_pp0p0_c20250729__20250801_zGB9Qx0HWUBg" title="Other offering costs"><ix:nonFraction name="cik0002065779:OtherOfferingCost" contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember" id="Fact000704" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,163,234</ix:nonFraction></span>
of other offering costs. Approximately $<span id="xdx_90C_eus-gaap--OtherExpenses_pp0p0_c20250729__20250801_z3GNIDiBSqvd" title="other costs"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember" id="Fact000706" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">143,775</ix:nonFraction></span> of such costs were allocated to the Public Warrants and the Private Placement Units and
the remainder, approximately $<span id="xdx_90D_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_c20250801_zBavxm1BynCj" title="Ordinary shares subject to redemption"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember" id="Fact000708" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,438,859</ix:nonFraction></span> was allocated to Class A ordinary shares subject to redemption. As of December&#160;31, 2025,
the Company had offering costs of $<span id="xdx_900_ecustom--OfferingCost_iI_pp0p0_c20251231_ziNhZdkvYfdf" title="Offering costs"><ix:nonFraction name="cik0002065779:OfferingCost" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000710" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,582,634</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 358; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_z6QaiEAG2cg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zXK6UOSa20hc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
BORAL ARC ACQUISITION I CORP.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_231_zJe4JpCaPhJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zVFoSACHtNpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
2025 and 2024</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_230_z81DUV2QrXaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zzqZxjDNEQN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zDoFAXlrG67i" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000719" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z5OSpTZZj5k8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zcqL0aCgOVV7">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the accounting and reporting requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset
and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed
for differences between the consolidated financial statement and tax bases of assets and liabilities that will result in future taxable
or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable
income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 740 prescribes a recognition threshold and a measurement attribute for the consolidated financial statement recognition and measurement
of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not
to be sustained upon examination by taxing authorities. The Company&#8217;s management determined the British Virgin Islands is the Company&#8217;s
only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income
tax expense. There were no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The
Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from
its position. The Company is considered to be an exempted British Virgin Islands company with no connection to any other taxable jurisdiction
and is presently not subject to income taxes or income tax filing requirements in the British Virgin Islands or the United States. As
such, the provision for income taxes was deemed to be <i>de minimis</i> for the period from March&#160;20, 2025 (inception) to December&#160;31,
2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000721" name="us-gaap:DerivativesReportingOfDerivativeActivity"><p id="xdx_849_eus-gaap--DerivativesReportingOfDerivativeActivity_zfMMEAmeHDb5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zun6kxhx1xka">Derivative
Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#8220;Derivatives and Hedging.&#8221; For derivative financial instruments that are accounted
for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each
reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative
liabilities are classified in the balance sheet as current or non-current based on whether or not net cash settlement or conversion of
the instrument could be required within 12 months of the balance sheet date. The underwriters&#8217; over-allotment option is deemed to
be a freestanding financial instrument indexed to the contingently redeemable shares and was accounted for as a liability pursuant to
ASC 480 if not fully exercised at the time of the Initial Public Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000723" name="us-gaap:ExtendedProductWarrantyPolicy"><p id="xdx_845_eus-gaap--ExtendedProductWarrantyPolicy_z0FLSxdwRnzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zDBCwQoAzPGl">Warrant
Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for Warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#8217;
specific terms and applicable authoritative guidance in ASC 480 and FASB ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC
815&#8221;). The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815,
including whether the instruments are indexed to a company&#8217;s common shares and whether the instrument holders could potentially
require &#8220;net cash settlement&#8221; in a circumstance outside of a company&#8217;s control, among other conditions for equity classification.
This assessment, which requires the use of professional judgment, is conducted at the time of Warrant issuance and as of each subsequent
quarterly period end date while the instruments are outstanding. Upon review of the Warrant Agreement, Management concluded that the&#160;public
warrants and private warrants issued pursuant to such warrant agreement qualify for equity accounting treatment.&#160;Following the closing
of the Initial Public Offering on August&#160;1, 2025 and underwriter&#8217;s exercise of over-allotment option on August&#160;13, 2025,
the Company accounted for the&#160;<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20251231_zdWSGahahNSi" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightUnissued" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000725" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,000,000</ix:nonFraction></span> public warrants and&#160;<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zi4ctrzVvrZc" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightUnissued" contextRef="AsOf2025-12-31_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000727" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> private warrants issued under equity treatment at their
assigned values. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 359; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zlMAhnzI2QNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_z54pd7KI7HHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
BORAL ARC ACQUISITION I CORP.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zjzd7MzzvFzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zasGi0Tt2ODi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
2025 and 2024</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zf6g3WfGdLke" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zcEnWiRYjco2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_z1Ja5AegLikf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000736" name="cik0002065779:ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock"><p id="xdx_846_ecustom--ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_z39K6VkBlVx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zMsjsksIRMVh">Class
A Ordinary Shares Subject to Possible Redemption</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public shares contain a redemption feature which allows for the redemption of such public shares in connection with the Company&#8217;s
liquidation, or if there is a shareholder vote or tender offer in connection with the Company&#8217;s initial Business Combination. In
accordance with ASC 480-10-S99, the Company classifies public shares subject to redemption outside of permanent equity as the redemption
provisions are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as they occur
and will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately
upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value.
The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the extent available)
and Retained earnings. Accordingly, Class A ordinary shares subject to possible redemption are presented at redemption value as temporary
equity, outside of the shareholders&#8217; equity section of the Company&#8217;s balance sheet. As of December&#160;31, 2025, the 28,000,000
Class A ordinary shares subject to redemption reflected in the balance sheet are reconciled in the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000738" name="us-gaap:TemporaryEquityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--TemporaryEquityTableTextBlock_zPcXeTqfm8lb" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BD_zLSvphjsOLC3" style="display: none">Schedule of ordinary shares subject to redemption</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Gross proceeds from IPO, August&#160;1,
        2025</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_904_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_pp0d_c20250802__20251231_z2o34efAYZBg" title="Ordinary shares subject to possible redemption, beginning"><ix:nonFraction name="us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital" contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember" id="Fact000740" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,000,000</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Less:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Proceeds allocated to Public Warrants</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_ecustom--ProceedsAllocatedToPublicWarrants_pp0d_c20250802__20251231_znh5ksE756X8" title="Proceeds allocated to Public Warrants">(<ix:nonFraction name="cik0002065779:ProceedsAllocatedToPublicWarrants" contextRef="From2025-08-022025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000742" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,028,600</ix:nonFraction></span></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Proceeds allocated to Over-allotment Option</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_ecustom--ProceedsAllocatedToOverallotmentOption_pp0d_c20250802__20251231_zF18AYVY4Fwe" title="Proceeds allocated to Over-allotment Option">(<ix:nonFraction name="cik0002065779:ProceedsAllocatedToOverallotmentOption" contextRef="From2025-08-022025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000744" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,290,375</ix:nonFraction></span></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Class A ordinary shares issuance costs</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_ecustom--ClassOrdinarySharesIssuanceCosts_pp0d_c20250802__20251231_zFN36aIn6kRf" title="Class A ordinary shares issuance costs">(<ix:nonFraction name="cik0002065779:ClassOrdinarySharesIssuanceCosts" contextRef="From2025-08-022025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000746" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,438,859</ix:nonFraction></span></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Plus:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Accretion of carrying
        value to redemption value</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--TemporaryEquityAccretionToRedemptionValue_pp0d_c20250802__20251231_z1giMb4Fdhpj" title="Ordinary shares subject to possible redemption"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="From2025-08-022025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000748" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,534,462</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Class A ordinary shares
        subject to possible redemption, December&#160;31, 2025</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_pp0d_c20250802__20251231_z92pFQBkwJ85" title="Ordinary shares subject to possible redemption, ending"><ix:nonFraction name="us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000750" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,776,628</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zCe7sjt49b28" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000752" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zhFehGf6YTR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zQunJD1xUwzi">Net
Income per Ordinary Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company complies with accounting and disclosure
requirements of FASB ASC Topic 260, &#8220;Earnings Per Share.&#8221; Net income per share of ordinary shares is computed by dividing
net income applicable to ordinary shareholders by the weighted average number of shares of ordinary shares outstanding during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not considered the effect of the Warrants sold in the Offering and Private Placement to purchase an aggregate of&#160;<span id="xdx_903_eus-gaap--WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_c20250320__20251231_zIYauijVJJe6" title="Weighted average aggregate shares"><ix:nonFraction name="us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000754" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,100,000</ix:nonFraction></span>&#160;Class
A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock
method and are contingent on future events. As a result, diluted income per share of Class A ordinary shares is the same as basic income
per share of ordinary shares for the period presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two classes of ordinary shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income are shared
pro rata among the two classes of ordinary shares. Net income per share of ordinary shares is calculated by dividing the net income by
the weighted average number of shares of ordinary shares outstanding during the respective period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 360; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zQXWjkm4hQL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zXj5X9pNeDS3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
BORAL ARC ACQUISITION I CORP.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_z1RhBwreKdCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_z7WrrKoRipge" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
2025 and 2024</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_z6M2rFksgNT9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zTAoybHYTCwb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zBsLQL9y38Ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables reflect the net income per share after allocating income between the shares based on outstanding shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000763" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zK6g7uklULf4" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"><i><span id="xdx_8BF_zaGSXzmsgspk" style="display: none">Schedule
    of earning per share basic and diluted</span></i></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/>Period from <br/>March&#160;20,
        2025<br/>(Inception) through <br/>December&#160;31, <br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Class A</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Class B</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left">Numerator:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Basic and diluted net income
        per share:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold; text-align: left">Allocation
        of income &#8211; basic and diluted</td>
    <td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z3sCrZfmImf8" title="Allocation of income - basic"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zOP8f6mC3Gdc" title="Allocation of income - diluted"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember" id="Fact000765" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember" id="Fact000767" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,509,890</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z2qJnxTMSxqk"><span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_ziM4aHJWJMT8" title="Allocation of income - diluted"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember" id="Fact000768" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember" id="Fact000770" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,946,080</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Basic and diluted weighted
        average share of ordinary shares:</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zLS14Lz9LzJi" title="Basic weighted average share of ordinary shares"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z7DNrJH4OfBj" title="Diluted weighted average share of ordinary shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember" id="Fact000772" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember" id="Fact000774" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,393,007</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zZ1AoE0JuY4c" title="Basic weighted average share of ordinary shares"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z5EwpZeeFiAi" title="Diluted weighted average share of ordinary shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember" id="Fact000776" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember" id="Fact000778" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,935,190</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Basic and diluted net income
        per share</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td>
    <td style="font-weight: bold; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zWEL5OqBJofa" title="Basic net income per share"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zT2ajwWAS9G6" title="Diluted net income per share"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember" id="Fact000780" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember" id="Fact000782" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.16</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td>
    <td style="font-weight: bold; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zjBGNV05rIv" title="Basic net income per share"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zAOQ6qINRSph" title="Diluted net income per share"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember" id="Fact000784" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember" id="Fact000786" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.16</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zQW6yz6aHTG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000788" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zIcrYsjdOnUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zU8Q18WJlnoi">Concentration
of credit risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution
which, at times may exceed the Federal depository insurance coverage of $<span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_c20251231_zTBZxivW96d5" title="FDIC Insured Amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000790" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>. At December&#160;31, 2025, the Company had not experienced
losses on this account and management believes the Company is not exposed to significant risks on such account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000792" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zD59y9ZVJcWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zbcnfxYlFdrl">Fair
value of financial instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value
Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to
their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000794" name="cik0002065779:RisksAndUncertaintiesPolicyTextBlock"><p id="xdx_842_ecustom--RisksAndUncertaintiesPolicyTextBlock_zxL0KasiCzxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zjcWV21IYFn1">Risks
and Uncertainties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the
ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict,
the North Atlantic Treaty Organization (&#8220;NATO&#8221;) deployed additional military forces to eastern Europe, and the United States,
the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus
and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank
Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide
military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of
Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken
in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries
have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact
of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity
prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally,
any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity
in capital markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 361; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zPTi4yISu1Xh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_z244NOCNuxfe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
BORAL ARC ACQUISITION I CORP.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_236_z8ZytPlL3uBe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zSuWFnupLZh9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
2025 and 2024</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zrevkKRbMj65" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zReuMSarxIub" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zSRAV3zUa6N5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the above-mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting
from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely
affect the Company&#8217;s search for an initial Business Combination and any target business with which the Company may ultimately consummate
an initial Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000803" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8qxlOQm7eDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zJUe6H2lTeAa">Recent
Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which
requires the disclosure of additional segment information. ASU No. 2023-07 is effective for fiscal years beginning after December&#160;15,
2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted ASU 2023-07 as of the inception
of the Company. Adoption of the ASU did not impact the Company&#8217;s financial position, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December&#160;2023, the FASB issued ASU 2023-09, <i>Income taxes</i> (Topic 740): Improvements to Income Tax Disclosure (&#8220;ASU 2023-09&#8221;),
which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 will be effective for fiscal years beginning after
December&#160;15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for
issuance. The Company adopted ASU 2023-09 as of the inception of the Company. Adoption of the ASU did not impact the Company&#8217;s financial
position, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000805" name="cik0002065779:InitialPublicOfferingDisclosureTextBlock"><p id="xdx_80D_ecustom--InitialPublicOfferingDisclosureTextBlock_zSLJnITYDvT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3. <span id="xdx_82B_z1KbCnrudoXf">INITIAL PUBLIC OFFERING</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August&#160;1, 2025, the Company consummated its Initial Public Offering of <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z68SWSkXouvl" title="Sale of units in initial public offering"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000807" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000,000</ix:nonFraction></span> Units, at $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zuYTl7DjGW56" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000809" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per Unit, generating gross proceeds
of $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNsLNzuqxtP2" title="Sale of units in initial public offering aggragate amount"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000811" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000,000</ix:nonFraction></span>. The Company granted the underwriter a 45-day option to purchase up to an additional <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zLyPTOsY05De" title="Sale of units in initial public offering"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000813" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750,000</ix:nonFraction></span> Units at the Initial Public
Offering price to cover over-allotments, if any. On August&#160;11, 2025, the underwriters of the IPO notified the Company of their partial
exercise of the over-allotment option and purchased <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z2DvOPHYNdv4" title="Sale of units in initial public offering"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000815" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction></span> additional units (the &#8220;Option Units&#8221;) at $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z5FkLaLYZBbb" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000817" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per unit upon
the closing of the over-allotment option, generating gross proceeds of $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zF2cRkgObqV" title="Sale of units in initial public offering aggragate amount"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000819" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,000,000</ix:nonFraction></span>. On September&#160;9, 2025, the Underwriters advised
the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option. Each Unit consists
of one Ordinary Share and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary
share at a price of $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z5vX2ACUCNo7" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000821" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.50</ix:nonFraction></span> per share, subject to adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000823" name="cik0002065779:PrivatePlacementDisclosureTextBlock"><p id="xdx_801_ecustom--PrivatePlacementDisclosureTextBlock_zpb49dy82Zdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4. <span id="xdx_82F_zsyzzDUiuM6e">PRIVATE PLACEMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously
with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zock4izgOfti" title="Sale of units in initial public offering"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000825" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> Private Units at a price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zwMvmX5ifFuc" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000827" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per
Placement Unit raising $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIzdEwofmxtc" title="Sale of units in initial public offering aggragate amount"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000829" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></span> in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proceeds from the sale of the Private Units were added to the net proceeds from the Offering held in the Trust Account. The Placement
Units are identical to the Units sold in the Initial Public Offering, as described in Note 7. If the Company does not complete a Business
Combination within the Combination Period, the proceeds from the sale of the Private Units will be used to fund the redemption of the
Public Shares (subject to the requirements of applicable law) and the Private Warrants will expire worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 362; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zgWjjqvWpqbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zTvD5cHNDBok" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
BORAL ARC ACQUISITION I CORP.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_z84DuvYP2ro6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zU5PGhdKVwGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
2025 and 2024</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_236_ze4lqQKQqju2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000836" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrYpFvvjFz9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5. <span id="xdx_825_zCNNFCMF78fe">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Founder
Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March&#160;25, 2025, the Company issued an aggregate of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250301__20250325__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zKIH67EkvYIj" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-03-012025-03-25_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000838" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,321,429</ix:nonFraction></span> founder shares to the Sponsor for an aggregate purchase price of $<span id="xdx_90F_eus-gaap--Cash_iI_c20250325__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zGVXdJ6E6tx1" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2025-03-25_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000840" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span>
in cash. The funds were received on May&#160;27, 2025. Following the partial exercise of the over-allotment option on August&#160;11,
2025, on September&#160;9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment
option and thereby forfeit the option. As a result, on September&#160;9, 2025, the Company cancelled a total of <span id="xdx_905_ecustom--CancelledFounderShares_c20250905__20250909_zl4zcqqhZ3uf" title="Cancelled founder shares"><ix:nonFraction name="cik0002065779:CancelledFounderShares" contextRef="From2025-09-052025-09-09_custom_DBoralARCAcquisitionICorpMember" id="Fact000842" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">321,429</ix:nonFraction></span> founder shares.
As of December&#160;31, 2025, sponsor held a total of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20250320__20251231__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zrz4M0un8z1i" title="Forfeiture shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2025-03-202025-12-31_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000844" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,000,000</ix:nonFraction></span> founder shares and none was subject to forfeiture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
founder shares are designated as Class B ordinary shares and, except as described below, are identical to the Class A ordinary shares
included in the units being sold in the IPO, and holders of founder shares have the same shareholder rights as public shareholders, except
that (i) the founder shares are subject to certain transfer restrictions, as described in more detail below, (ii) the founder shares are
entitled to registration rights; (iii) our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which
they have agreed to (A) waive their redemption rights with respect to their founder shares, private shares and public shares in connection
with the completion of our initial business combination, (B) waive their redemption rights with respect to their founder shares, private
shares and public shares in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and articles
of association (a) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination
or to redeem <span id="xdx_908_ecustom--PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination_dp_c20250320__20251231_zW3TNlBemkUl" title="Percentage of redemption of public shares"><ix:nonFraction name="cik0002065779:PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000846" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">100</ix:nonFraction>%</span> of our public shares if we have not consummated an initial business combination within the completion window or (b)
with respect to any other material provisions relating to shareholders&#8217; rights or pre-initial business combination activity, (C)
waive their rights to liquidating distributions from the trust account with respect to their founder shares and private shares if we fail
to complete our initial business combination within the completion window, although they will be entitled to liquidating distributions
from the trust account with respect to any public shares they hold if we fail to complete our initial business combination within such
time period and to liquidating distributions from assets outside the trust account and (D) vote any founder shares held by them and any
public shares they may purchase (including in open market and privately-negotiated transactions) in favor of our initial business combination
(except that any public shares such parties may purchase in compliance with the requirements of Rule&#160;14e-5 under the Exchange Act
would not be voted in favor of approving the business combination transaction), (iv) the founder shares are automatically convertible
into Class A ordinary shares concurrently with or immediately following the consummation of our initial business combination or earlier
at the option of the holder on a one-for-one basis, subject to adjustment as described herein and in our amended and restated memorandum
and articles of association, and (v) prior to the closing of our initial business combination, only holders of our Class B ordinary shares
will be entitled to vote on the appointment and removal of directors or continuing the company in a jurisdiction outside the British Virgin
Islands (including any ordinary resolution required to amend our constitutional documents or to adopt new constitutional documents, in
each case, as a result of our approving a transfer by way of continuation in a jurisdiction outside the British Virgin Islands).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
certain limited exceptions, the founder shares are not transferable, assignable or saleable (except to our officers and directors and
other persons or entities affiliated with our sponsor, each of whom will be subject to the same transfer restrictions) until the completion
of our initial business combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Promissory
Note &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March&#160;20, 2025, the Sponsor issued an unsecured promissory note to the Company, pursuant to which the Company may borrow up to an
aggregate principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20251231__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredPromissoryNoteMember_zilx2XNUQ3Jd" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-12-31_custom_UnsecuredPromissoryNoteMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000848" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">350,000</ix:nonFraction></span>, to be used for payment of costs related to the Proposed Offering. The note is non-interest bearing
and payable on the earlier of (i) December&#160;31, 2025 or (ii) the consummation of the Initial Public Offering. On August&#160;1, 2025,
the Company has repaid $<span id="xdx_901_eus-gaap--RepaymentOfNotesReceivableFromRelatedParties_c20250729__20250801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zNBRf0ZD3Bcg" title="Repayment of promissory note"><ix:nonFraction name="us-gaap:RepaymentOfNotesReceivableFromRelatedParties" contextRef="From2025-07-292025-08-01_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000850" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,461</ix:nonFraction></span> under the promissory note with the Sponsor out of the $<span id="xdx_90B_eus-gaap--PaymentsForRepurchaseOfInitialPublicOffering_c20250729__20250801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zcDb7GEDXP32" title="Payment of offering expenses"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" contextRef="From2025-07-292025-08-01_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000852" format="ixt:numdotdecimal" decimals="0" unitRef="USD">700,000</ix:nonFraction></span> of offering proceeds that has been allocated
for the payment of offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 363; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zwYonh9hHZuk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zCqAeE7aszq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
BORAL ARC ACQUISITION I CORP.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_z5q7pXrTsKxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zl3H1j1bVi4g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
2025 and 2024</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zmvHNqWZRrn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zO53PiFNJOD7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5. RELATED PARTY TRANSACTIONS (Continued)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zafIpqSbejF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Administrative
Services Arrangement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
affiliate of our Sponsor has agreed, commencing from the date that the Company&#8217;s securities are first listed on Nasdaq, through
the earlier of the Company&#8217;s consummation of a Business Combination and its liquidation, to make available to the Company our Sponsor
certain office space, utilities and secretarial and administrative support as may be reasonably required by the Company. The Company has
agreed to pay to the affiliate of our Sponsor, $<span id="xdx_900_eus-gaap--PaymentsOfDistributionsToAffiliates_c20250320__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zlnaPZbdyeKh" title="Payment to affiliate"><ix:nonFraction name="us-gaap:PaymentsOfDistributionsToAffiliates" contextRef="From2025-03-202025-12-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000861" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></span> per month, for up to 18 months, subject to extension to up to 21 months, for such
administrative services. For the period from March&#160;20, 2025 (inception) to December&#160;31, 2025, $<span id="xdx_909_eus-gaap--AdministrativeFeesExpense_c20250320__20251231_zx13woO4Tfnc" title="Administrative services"><ix:nonFraction name="us-gaap:AdministrativeFeesExpense" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000863" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> was charged to operations
and no amounts were outstanding at December&#160;31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Party Loans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to finance transaction costs in connection with a Business Combination, the Company&#8217;s Sponsor or an affiliate of the Sponsor,
or the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working
Capital Loans&#8221;). Up to $<span id="xdx_90D_eus-gaap--DebtConversionOriginalDebtAmount1_c20250320__20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zoSGVPE4L9ll" title="Conversion of debt"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2025-03-202025-12-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000865" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction></span> of such loans may be convertible into private units, at a price of $<span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_c20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zoryQ0v2dVwg" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-12-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000867" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per unit, at the option
of the applicable lender. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside
the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital
Loans. As of December&#160;31, 2025, no amounts under such loans have been drawn.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Representative
Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August&#160;1, 2025, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zEnpb1MH6gf7" title="Number of share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000869" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> representative shares to D. Boral Capital, LLC and/or its designees (whether or not
the over-allotment is exercised) as part of representative compensation (the &#8220;Representative Shares&#8221;). The Representative
Shares have been deemed compensation by FINRA and are therefore subject to a lock-up for a period of 180 days immediately following the
commencement of sales of the IPO pursuant to FINRA Rule&#160;5110(e)(1). Pursuant to this FINRA lock-up, these securities cannot be sold,
transferred, assigned, pledged or hypothecated or the subject of any hedging, short sale, derivative, put or call transaction that would
result in the economic disposition of the securities by any person for a period of 180 days from the commencement of sales of the Initial
Public Offering except as permitted under FINRA Rule&#160;5110(e)(2), including to any underwriter and selected dealer participating in
the Initial Public Offering and their officers or partners, registered persons or affiliates. The Representative Shares have resale registration
rights including two demand (one at the Company&#8217;s expense and one at D. Boral Capital, LLC&#8217;s expense) and unlimited &#8220;piggy-back&#8221;
rights for periods of five and seven years, respectively, from the commencement of sales of the Initial Public Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000871" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zOodEbadoGl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. <span id="xdx_827_zvnDuwuTDke4">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of the (i) founder shares, which were issued in a private placement prior to the closing of the initial public offering, (ii)
Private Units (including the component securities as well as any securities underlying those component securities), which was issued in
a private placement simultaneously with the closing of the initial public offering and (iii) private units (including the component securities
as well as any securities underlying those component securities) that may be issued upon conversion of working capital loans will have
registration rights to require the Company to register a sale of any of our securities held by them and any other securities of the company
acquired by them prior to the consummation of a Business Combination pursuant to a registration rights agreement to be signed prior to
or on the effective date of the initial public offering. The holders of these securities are entitled to make up to three demands, excluding
short form demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration
rights with respect to registration statements filed subsequent to the completion of the Business Combination. The registration rights
granted to the underwriter are limited to two demand (one at the Company&#8217;s expense and one at D. Boral Capital, LLC&#8217;s expense)
and unlimited &#8220;piggy-back&#8221; rights for periods of five and seven years, respectively, from the commencement of sales of the
Initial Public Offering. The Company will bear the expenses incurred in connection with the filing of any such registration statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 364; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zJoXFazftv5l" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_z3d5nLGvx051" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
BORAL ARC ACQUISITION I CORP.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zIRBa2wQcryh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zHKSPeS9eJr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
2025 and 2024</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zLJQtCoEQ1aj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zDgttOQYBHY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. COMMITMENTS AND CONTINGENCIES (Continued)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zbOjphgaIhAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underwriting
Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has granted the underwriters a 45-day option to purchase up to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250320__20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zFjNTzXClord" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-03-202025-12-31_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000880" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750,000</ix:nonFraction></span> additional Units to cover over-allotments at the Initial
Public Offering price, less the underwriting discounts and commissions. On August&#160;11, 2025, the underwriters of the IPO notified
the Company of their partial exercise of the over-allotment option and purchased <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zsDsQ7BIzSY4" title="Sale of units in initial public offering"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000882" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction></span> additional units (the &#8220;Option Units&#8221;)
at $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z00hlruxNby8" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000884" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per unit upon the closing of the over-allotment option, generating gross proceeds of $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zTKQ26a264L8" title="Sale of units in initial public offering aggragate amount"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000886" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,000,000</ix:nonFraction></span>. On September&#160;9, 2025,
the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters were not entitled to any cash underwriting fee at closing of the Initial Public Offering. The underwriters were entitled
to <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250320__20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_z7WKxjLfpBE3" title="Number of share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-03-202025-12-31_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000888" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> Representative Shares (whether or not the over-allotment is exercised) at closing of the Initial Public Offering. The underwriters
will not be entitled to any deferred underwriting fee upon closing of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000890" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zLymJvSLjwni" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. <span id="xdx_829_zo6eGMSSg8H3">STOCKHOLDER&#8217;S EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preference
shares</i> &#8212; The Company is authorized to issue <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_c20251231_zVKs3Ud7A2J1" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000892" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> preference shares with a par value of $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_c20251231_zGdq3Sz7TMP2" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000894" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share. Holders of the
Company&#8217;s ordinary shares are entitled to one vote for each share. On December&#160;31, 2025, there were <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_do_c20251231_zes6MDUpNOee" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20251231_zggQcNldTD8j" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000896" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000898" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> preferred shares issued
or outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Class
A Ordinary shares</i> &#8212; The Company is authorized to issue <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zUIiqFEC1YKa" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000900" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000,000</ix:nonFraction></span> ordinary shares with a par value of $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zpG2arjDcUM5" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000902" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share. Holders
of the Company&#8217;s ordinary shares are entitled to one vote for each share. As a result of closing of the IPO and the partial exercise
of the over-allotment option partial exercise of the over-allotment option, there were <span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zX4U9Oph6c9b" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000904" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,200,000</ix:nonFraction></span> Class A ordinary shares issued or outstanding,
excluding <span id="xdx_90D_ecustom--OrdinarySharesSubjectToPossibleRedemption_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zM1hbLvnyh4d" title="Ordinary shares subject to possible redemption"><ix:nonFraction name="cik0002065779:OrdinarySharesSubjectToPossibleRedemption" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000906" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,000,000</ix:nonFraction></span> Class A ordinary shares subject to possible redemption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Class
B Ordinary shares</i> &#8212; The Company is authorized to issue <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zaDu9F4i7evd"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000907" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></span> ordinary shares with a par value of $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zaOL9jf9dkb3"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000908" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share. Holders
of the Company&#8217;s ordinary shares are entitled to one vote for each share. On March&#160;25, 2025, the Company issued an aggregate
of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250301__20250325__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zfTMSHKHds0l"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-03-012025-03-25_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000909" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,321,429</ix:nonFraction></span> ordinary shares to the Sponsor for an aggregate purchase price of $<span id="xdx_90D_ecustom--AggregatePurchasePrice_iI_pp0p0_c20250325_ztIeXeeDmxNc" title="Aggregate purchase price"><ix:nonFraction name="cik0002065779:AggregatePurchasePrice" contextRef="AsOf2025-03-25_custom_DBoralARCAcquisitionICorpMember" id="Fact000911" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction></span> in cash, of which <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20250301__20250325__us-gaap--StatementEquityComponentsAxis__custom--ClassAOrdinarySharesMember_zxJWaCgaTD7h"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2025-03-012025-03-25_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000912" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,607,143</ix:nonFraction></span> shares held by the
Sponsor are subject to forfeiture to the extent that the underwriter&#8217;s over-allotment option is not exercised in full. Following
the partial exercise of the over-allotment option on August&#160;11, 2025 and cancellation <span id="xdx_901_ecustom--CancellationOfOrdinaryShares_iI_c20250811_zQ94bGRQlFb7" title="Cancellation of ordinary shares"><ix:nonFraction name="cik0002065779:CancellationOfOrdinaryShares" contextRef="AsOf2025-08-11_custom_DBoralARCAcquisitionICorpMember" id="Fact000914" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">321,429</ix:nonFraction></span> ordinary shares on September&#160;9,
2025, on December&#160;31, 2025, there were <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zigcy70u45ba" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zX4NnnaGuwf" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000916" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000918" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,000,000</ix:nonFraction></ix:nonFraction></span></span> ordinary shares issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation
of our initial business combination, or at any time prior thereto at the option of the holder thereof, on a one-for-one basis, subject
to adjustment as provided herein. Because our sponsor acquired the Class B ordinary shares at a nominal price, our public shareholders
will incur an immediate and substantial dilution upon the closing of the IPO, assuming no value is ascribed to the warrants included in
the units. In the case that additional Class A ordinary shares, or equity-linked securities (as described herein), are issued or deemed
issued in excess of the amounts issued in the IPO and related to the closing of our initial business combination, the ratio at which the
Class B ordinary shares will convert into Class A ordinary shares will be adjusted (unless the holders of a majority of the issued and
outstanding Class B ordinary shares agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance)
so that the number of Class A ordinary shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, 30%
of the sum of (i) the total number of all Class A ordinary shares outstanding upon the completion of the IPO (including any Class A ordinary
shares issued pursuant to the underwriters&#8217; over-allotment option and excluding the Class A ordinary shares that are included within
the private units), plus (ii) all Class A ordinary shares and equity-linked securities issued or deemed issued, in connection with the
closing of the initial business combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in
the initial business combination and any units issued to our sponsor or any of its affiliates or to our officers or directors upon conversion
of working capital loans) minus (iii) any redemptions of Class A ordinary shares by public shareholders in connection with an initial
business combination; provided that such conversion of founder shares will never occur on a less than <span id="xdx_904_eus-gaap--CommonStockConversionBasis_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--CommonStockClassBMember_zwHvTm6YpHfl" title="Conversion basis"><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_CommonStockClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000920" name="us-gaap:CommonStockConversionBasis">one-for-one basis</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 365; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zPgExyGlmltf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zXU0W3K9ToJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
BORAL ARC ACQUISITION I CORP.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_232_z2WbdVm92wK" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zlOX9JDodVS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
2025 and 2024</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_234_z9TBWg7gfE7c" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zB8k9FFOznZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. STOCKHOLDER&#8217;S EQUITY (Continued)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_234_z1a2JSp5EzJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of record of the Company&#8217;s Class A ordinary shares and Class B ordinary shares are entitled to one vote for each share held on all
matters to be voted on by shareholders. Unless specified in the amended and restated memorandum and articles of association or as required
by the Companies Act or stock exchange rules, an ordinary resolution under British Virgin Islands law and the amended and restated memorandum
and articles of association, which requires the affirmative vote of at least a majority of the votes cast by such shareholders as, being
entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the company is generally
required to approve any matter voted on by the Company&#8217;s shareholders. Approval of certain actions require an ordinary resolution
under British Virgin Islands law, which (except as specified below) requires the affirmative vote of in excess of 50 percent of the votes
cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general
meeting, and pursuant to the Company&#8217;s amended and restated memorandum and articles of association, such actions include amending
the amended and restated memorandum and articles of association and approving a statutory merger or consolidation with another company.
There is no cumulative voting with respect to the appointment of directors, meaning, following the Company&#8217;s initial Business Combination,
the holders of more than 50% of the ordinary shares voted for the appointment of directors can elect all of the directors. Prior to the
consummation of the initial Business Combination, only holders of the Class B ordinary shares will (i) have the right to vote on the appointment
and removal of directors and (ii) be entitled to vote on continuing the Company in a jurisdiction outside the British Virgin Islands (including
any ordinary resolution required to amend the constitutional documents or to adopt new constitutional documents, in each case, as a result
of approving a transfer by way of continuation in a jurisdiction outside the British Virgin Islands). Holders of the Class A ordinary
shares will not be entitled to vote on these matters during such time. These provisions of our amended and restated memorandum and articles
of association may only be amended if approved by an ordinary resolution passed by the affirmative vote of the holders representing at
least 90% of the issued Class B ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants
&#8212; </i>Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Warrants.
The Warrants will become exercisable <span id="xdx_900_ecustom--PeriodAfterWhichTheWarrantsAreExercisable_dtD_c20250320__20251231_zqmaOpl3oGMf" title="Period of warrants exercisable"><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" format="ixt-sec:durday" id="Fact000929" name="cik0002065779:PeriodAfterWhichTheWarrantsAreExercisable">30</ix:nonNumeric></span> days after the completion of our initial business combination, provided that the Company has an
effective registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the warrants
and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the
securities, or blue sky, laws of the state of residence of the holder (or we permit holders to exercise their warrants on a cashless basis
under the circumstances specified in the warrant agreement). If a registration statement covering the Class A ordinary shares issuable
upon exercise of the warrants is not effective by the 60th business day after the closing of our initial business combination, warrant
holders may, until such time as there is an effective registration statement and during any period when we will have failed to maintain
an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the
Securities Act or another exemption. Notwithstanding the above, if our Class A ordinary shares are at the time of any exercise of a warrant
not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1)
of the Securities Act, we may, at our option, require holders of public warrants who exercise their warrants to do so on a &#8220;cashless
basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event we so elect, we will not be required to file
or maintain in effect a registration statement. The Warrants will expire five years from the consummation of a Business Combination or
earlier upon redemption or liquidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may call the Warrants for redemption:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
        whole and not in part;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
        a price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z0R8vEvtgNEk" title="Warrant price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantsMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000931" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per warrant; upon a minimum of <span id="xdx_908_ecustom--MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants_dtD_c20250320__20251231_zrGTHCbEFza3" title="Holders of warrants"><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" format="ixt-sec:durday" id="Fact000933" name="cik0002065779:MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants">30</ix:nonNumeric></span> days&#8217; prior written notice of redemption (the &#8220;30-day redemption period&#8221;);
        and</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
        and only if, the closing price of the Class A ordinary shares equals or exceeds $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zm2Uo06WbIbb" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000935" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.00</ix:nonFraction></span> per share (as adjusted for adjustments to the number
        of shares issuable upon exercise or the exercise price of a warrant) for any <span id="xdx_904_ecustom--NumberOfTradingDaysForDeterminingTheSharePrice_dtD_c20250320__20251231_z9LF9cWDtqp1" title="Number of trading days"><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" format="ixt-sec:durday" id="Fact000937" name="cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice">20</ix:nonNumeric></span> trading days within a <span id="xdx_901_ecustom--NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_dtD_c20250320__20251231_zO5hmy55kbj4" title="Number of consecutive trading days"><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" format="ixt-sec:durday" id="Fact000939" name="cik0002065779:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice">30</ix:nonNumeric></span>-trading day period commencing
        at least 30 days after completion of our initial business combination and ending three business days before we send the notice of redemption
        to the warrant holders.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 366; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zt9AiLMmkCVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zAKBPQ2kUZWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
BORAL ARC ACQUISITION I CORP.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_231_zoPQvKhgtevl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_234_z35cwz5IQdl9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
2025 and 2024</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zkQeOU2u3Ua7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zqNMVYIkdHbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. STOCKHOLDER&#8217;S EQUITY (Continued)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zZBC6UEV32Mg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
private warrants are identical to the warrants sold in the IPO except that, so long as they are held by our sponsor or its permitted transferees,
the private warrants (i) are locked-up until the completion of our initial business combination and (ii) will be entitled to registration
rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted for share sub-divisions, share capitalizations,
reorganizations, recapitalizations and the like. Additionally, in no event will the Company be required to net cash settle the warrants.
If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in
the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution
from the Company&#8217;s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire
worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price is $11.50 per share, subject to adjustment as described herein. In addition, if (x) we issue additional Class A ordinary
shares or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at
an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price
to be determined in good faith by our board of directors and, in the case of any such issuance to our initial shareholders or their affiliates,
without taking into account any founder shares held by our initial shareholders or such affiliates, as applicable, prior to such issuance)
(the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity
proceeds, and interest thereon, available for the funding of our initial business combination on the date of the consummation of our initial
business combination (net of redemptions), and (z) the volume weighted average trading price of our Class A ordinary shares during the
<span id="xdx_90F_ecustom--NumberOfTradingDaysForDeterminingTheSharePrice_dtD_c20250320__20251231_zwi57d75Gbnf" title="Number of trading days"><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" format="ixt-sec:durday" id="Fact000948" name="cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice">20</ix:nonNumeric></span> trading day period starting on the trading day prior to the day on which we consummate our initial business combination (such price,
the &#8220;Market Value&#8221;) is below $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231_z9oNRy7TT9cb" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000950" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.20</ix:nonFraction></span> per share, then the exercise price of the warrants will be adjusted (to the nearest cent)
to be equal to <span id="xdx_90C_eus-gaap--AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate_iI_dp_c20251231_zqUGRVZptye" title="Market value"><ix:nonFraction name="us-gaap:AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000952" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">115</ix:nonFraction>%</span> of the higher of the Market Value and the Newly Issued Price, and the $<span id="xdx_90C_eus-gaap--PreferredStockRedemptionPricePerShare_iI_c20251231_zMU6AAn42sQf" title="Redemption price"><ix:nonFraction name="us-gaap:PreferredStockRedemptionPricePerShare" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000954" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.00</ix:nonFraction></span> per share redemption trigger prices will
be adjusted (to the nearest cent) to be equal to <span id="xdx_900_ecustom--ShareRedemptionTriggerPrices_iI_dp_c20251231_zSYWzSorZM4l" title="Share redemption trigger prices"><ix:nonFraction name="cik0002065779:ShareRedemptionTriggerPrices" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact000956" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">180</ix:nonFraction>%</span> of the higher of the Market Value and the Newly Issued Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000958" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_zhQ9pqoDD5x" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8. <span id="xdx_821_zmhkA80TXS8d">FAIR VALUE MEASUREMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would
have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction
between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company
seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable
inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is
used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which
transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets
or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 367; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_za5r3xikFDr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zc2FJ6KvZJx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
BORAL ARC ACQUISITION I CORP.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zyOiJEbM4jl3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zrwfI41uWkfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
2025 and 2024</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_z5IVmjMNzrI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zjAnFOj34Gkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8. FAIR VALUE MEASUREMENTS (Continued)</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zl4x3fRd3d1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s assets that are measured at fair value as of August&#160;1, 2025 and
December&#160;31, 2025, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair
value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000967" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zl5uLowJiXVi" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8B6_zXfmlkhV9ysd" style="display: none">Schedule of fair value assets and liabilities</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">August&#160;1, <br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Liability:</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">Fair value of over-allotment liability</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center">3</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20250801__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAcSNoM2bO7g" title="Liability" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-08-01_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember" id="Fact000969" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,290,375</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Equity:</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Fair value of Public Warrants for Class A
        ordinary shares subject to possible redemption allocation</td>
    <td>&#160;</td>
    <td style="text-align: center">3</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_986_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20250801__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSFisT03zLO" title="Equity" style="text-align: right"><ix:nonFraction name="us-gaap:EquityFairValueDisclosure" contextRef="AsOf2025-08-01_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember" id="Fact000971" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,061,250</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
        <br/>2025</b></span></p></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Asset:</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Cash held in trust</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center">1</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zfsfJbWiQ3Yl" title="Assets" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_custom_DBoralARCAcquisitionICorpMember" id="Fact000973" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">284,776,628</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zKnLC9z1gto9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
over-allotment option was accounted for as a liability in accordance with ASC 815-40 and was presented within liabilities on the balance
sheet. The over-allotment option liability is measured at fair value at August&#160;1, 2025 and on a recurring basis, with changes in
fair value presented within change in fair value of over-allotment option liability in the statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used a Black-Scholes model to value the over-allotment option. The over-allotment option liability was classified within Level
3 of the fair value hierarchy at the measurement dates due to the use of unobservable inputs inherent in pricing models and assumptions
related to expected share-price volatility, expected life and risk-free interest rate. The Company estimates the volatility of its ordinary
share based on historical volatility that matches the expected remaining life of the over-allotment option. The risk-free interest rate
is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the over-allotment
option. The expected life of the over-allotment option is assumed to be equivalent to its remaining contractual term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs into the Black-Scholes model were as follows at initial measurement of the over-allotment option:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000975" name="cik0002065779:OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zGeBHNQlGzMa" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B7_zoaVPMUgkntk" style="display: none">Schedule of initial measurement</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">August&#160;1, <br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Risk-free interest rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250729__20250801_zykgUgOp2FO7" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember" id="Fact000977" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.31</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expected term (years)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250729__20250801_zNNkudmOAsxi" title="Expected terms (years)"><ix:nonNumeric contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember" format="ixt-sec:duryear" id="Fact000979" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">0.12</ix:nonNumeric></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expected volatility</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250729__20250801_zYdfJmo8Jv1" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember" id="Fact000981" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">22.7</ix:nonFraction></span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Exercise price</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20250801_zsPlpHwwdwY4" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember" id="Fact000983" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Fair value of over-allotment option</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90F_ecustom--FairValueOfOverallotmentOption_iI_c20250801_zvdduBXteOCb" title="Fair value of over-allotment option"><ix:nonFraction name="cik0002065779:FairValueOfOverallotmentOption" contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember" id="Fact000985" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.3441</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zhBNM0cZxCt8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of Public Warrants was determined using Monte Carlo Simulation Model. The Public Warrants have been classified within shareholders&#8217;
equity and will not require remeasurement after issuance. The following table presents the quantitative information regarding market assumptions
used in the valuation of the Public Warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact000987" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_znIXiw709dNi" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BE_zsvTOTvZXEk3" style="display: none">Schedule of market assumptions</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">August&#160;1, <br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Estimated share price</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--SharePrice_c20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_pd" title="Estimated share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000989" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.68</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Exercise price</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_pd" title="Exercise Price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000991" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.50</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Term (years)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zdgGz9zVX1q2" title="Term (years)"><ix:nonNumeric contextRef="From2025-07-292025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember" format="ixt-sec:duryear" id="Fact000993" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">2.75</ix:nonNumeric></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Annual risk-free rate (term-matched)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zDaikQy4IZnb" title="Annual risk-free rate (term-matched)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-07-292025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000995" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">3.75</ix:nonFraction></span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expected warrant implied volatility based
        on warrants from comparable SPAC securities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zDGNenuK2YQ2" title="Expected warrant implied volatility based on warrants from comparable SPAC securities"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-07-292025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember" id="Fact000997" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">14.44</ix:nonFraction></span></td>
    <td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zvYcYlSuTAmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 368; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zFo4cicGt7Yc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zVrTmKfzGU7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
BORAL ARC ACQUISITION I CORP.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_238_zXHSko4tw9D7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zLw6tIgzBbN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
2025 and 2024</b></span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001003" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_809_eus-gaap--SegmentReportingDisclosureTextBlock_zlDYq8wDTeqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. <span>SEGMENT INFORMATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_82A_ziXv0oR4ze67" style="display: none">Segment information</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 280, &#8220;Segment Reporting,&#8221; establishes standards for companies to report in their financial statement information about
operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise
for which separate financial information is available that is regularly evaluated by the Company&#8217;s chief operating decision maker,
or group, in deciding how to allocate resources and assess performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s chief operating decision maker has been identified as the Chief Financial Officer (&#8220;CODM&#8221;), who reviews the
operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly,
management has determined that the Company only has one operating segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
evaluating the Company&#8217;s performance and making key decisions regarding resource allocation the CODM reviews several key metrics,
which include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001005" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zV8K2gwOpH16" summary="xdx: Disclosure - Segment information (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span id="xdx_8BC_zWWW3w6SRnKb" style="display: none">Schedule of segment information</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/> Period from <br/>March&#160;20,
        2025<br/>(inception) through<br/>December&#160;31,<br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 2.5pt">Formation
        and operating costs</td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"><span id="xdx_902_eus-gaap--OperatingExpenses_iNT_pp0d_di_c20250320__20251231_zktdSzpr5NMa" title="Formation and operating costs">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001007" format="ixt:numdotdecimal" decimals="0" unitRef="USD">320,658</ix:nonFraction></span></td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Interest income on
        cash held in trust account</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--InterestIncomeOther_c20250320__20251231_pp0p" title="Interest income on cash held in trust account"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001009" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,776,628</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Cash held in Trust
        Account</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--CashHeldInTrustAccounts_c20250320__20251231_pp0p" title="Cash held in Trust Account"><ix:nonFraction name="cik0002065779:CashHeldInTrustAccounts" contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001011" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,776,628</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key measures of segment profit or loss reviewed by the CODM are formation and operating costs, interest income on cash held in trust account,
and cash held in trust account. The CODM reviews interest earned on cash or investments held in Trust Account to measure and monitor shareholder
value and determine the most effective strategy of investment with the Trust Account funds while maintaining compliance with the trust
agreement. Within the operating expenses, the CODM specifically reviews professional service fees, which are a significant segment expense,
and include legal fees and advisory fees. These expenses are monitored to manage and forecast cash available to complete a Business Combination
within the required period. Other general and administrative expenses, including accounting expenses, printing expenses, and regulatory
filing fees, are reviewed in the aggregate to ensure alignment with budget and contractual obligations. Funds invested in the Trust Account
represent the predominant portion of the Company&#8217;s total assets and are monitored by the CODM to determine the most effective strategy
of investment with the Trust Account funds, while maintaining compliance with the trust agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001013" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zAojbVU1a7zi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. <span>SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_826_zmvFa0ix0mr6" style="display: none">Subsequent Events</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC Topic 855, &#8220;Subsequent Events&#8221;, which establishes general standards of accounting for and disclosure of
events that occur after the balance sheet date but before consolidated financial statements are issued, the Company has evaluated all
events or transactions that occurred up to the date the consolidated financial statements were available to issue. Based upon this review,
the Company identified the following subsequent events:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January&#160;11, 2026, D. Boral ARC Acquisition I Corp. (&#8220;BCAR&#8221; or the &#8220;Company&#8221;) entered into the Agreement and
Plan of Merger (the &#8220;Merger Agreement&#8221;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly
owned subsidiary of BCAR (&#8220;PubCo&#8221;), D. Boral Arc Merger Sub Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and a
wholly-owned subsidiary of BCAR, and Exascale Labs Inc., a Delaware corporation (&#8220;Exascale&#8221;). Pursuant to the Merger Agreement,
the Business Combination will be effected in two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into
PubCo, with PubCo remaining as the surviving publicly traded entity (the &#8220;Reincorporation Merger&#8221;); (ii) after the Reincorporation
Merger, Merger Sub will be merged with and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#8220;Acquisition
Merger&#8221; and together with the Reincorporation Merger, the &#8220;Business Combination&#8221;).&#160;</span></p>

</ix:nonNumeric><p id="xdx_817_zmDHgvvOU731" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 369; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: center"><span id="fin3_001"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D. BORAL ARC ACQUISITION I CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED CONDENSED BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" summary="xdx: Statement - BALANCE SHEET" id="xdx_308_111_zhYLIr9G4kgd" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_492_20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zke2BrUXmrhf" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_495_20260331__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_z131aXCb5G5" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2025</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March&#160;31,<br/>
    2026</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><b>&#160;</b></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><b>(Audited)</b></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>(Unaudited)</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr id="xdx_403_eus-gaap--AssetsAbstract_iB_zRlpERbFEQB5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">ASSETS</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsAbstract_iB_zGD90s4rMKRf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Current Assets</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_maAzi8u_zwfLtzKan2ja" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,340</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="text-align: right; width: 9%"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001022" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,576</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidExpenseCurrent_i01I_maAzi8u_zJ0PW1M3OPMl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left">Prepaid expenses</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001024" format="ixt:numdotdecimal" decimals="0" unitRef="USD">203,134</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001025" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,259</ix:nonFraction></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrent_iTI_mtAzi8u_maAzPhI_zLyDba9X5JQ5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b>Total Current
    Assets</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><b>&#160;</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><b><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001027" format="ixt:numdotdecimal" decimals="0" unitRef="USD">623,474</ix:nonFraction></b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td style="text-align: right"><b><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001028" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399,835</ix:nonFraction></b></td>
    <td><b>&#160;</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_ecustom--CashHeldInTrustAccount_iI_maAzPhI_zUSP6Mbcjuw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left">Cash held in trust account</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cik0002065779:CashHeldInTrustAccount" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001030" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,776,628</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="cik0002065779:CashHeldInTrustAccount" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001031" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,319,687</ix:nonFraction></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_iTI_mtAzPhI_zCfDL5bTrcI3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total
    Assets</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001033" format="ixt:numdotdecimal" decimals="0" unitRef="USD">285,400,102</ix:nonFraction></b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001034" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,719,522</ix:nonFraction></b></td>
    <td style="padding-bottom: 2.5pt"><b>&#160;</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zdmMHJahsqRd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIABILITIES AND SHAREHOLDERS&#8217; DEFICIT</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesCurrentAbstract_i01B_zwgmHnDARoAh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current liabilities</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCzBsC_zSfkfcwmsSi9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left">Accrued expenses</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,611</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">$</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001043" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,713</ix:nonFraction></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesCurrent_i01TI_mtLCzBsC_maLzR4R_z41XgWWSz3T6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Total
    Current Liabilities</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001045" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,611</ix:nonFraction></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,713</ix:nonFraction></b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Liabilities_i01TI_mtLzR4R_maLASEzOJn_zSAt83Z3ThRc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><b>Total
    Liabilities</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><b><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,611</ix:nonFraction></b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001049" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,713</ix:nonFraction></b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzOJn_z3iJEhvjgxsb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments and Contingencies</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_i01I_maLASEzOJn_zVE1MzP4Lg79" style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Class
    A ordinary shares subject to possible redemption, $<span id="xdx_908_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20260331__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zZURx8lHBCFd"><span id="xdx_90D_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zYbQaJJNd3b9"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001056" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001057" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">par value; <span id="xdx_90A_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20260331__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_z3CvvpNiUmI8"><span id="xdx_908_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zMDFS5IPR1xg"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001058" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001059" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000,000</ix:nonFraction></ix:nonFraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">shares authorized;
    <span id="xdx_90B_eus-gaap--TemporaryEquitySharesIssued_iI_c20260331__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zxQtqheg7We3"><span id="xdx_908_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20260331__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zdvxsDor93Gl"><span id="xdx_90D_eus-gaap--TemporaryEquitySharesIssued_iI_c20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zKZh8H2ZAhRh"><span id="xdx_90B_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zVdOypf9ilS2"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001060" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001061" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001062" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001063" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,000,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">shares issued and
    outstanding, at redemption value of $<span id="xdx_905_eus-gaap--TemporaryEquityRedemptionPricePerShare_iI_c20260331__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zRNIRJAim4zc"><ix:nonFraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001064" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.26</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">on March&#160;31, 2026
    and $<span id="xdx_906_eus-gaap--TemporaryEquityRedemptionPricePerShare_iI_c20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zIZ9jBW2L9Mh"><ix:nonFraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001065" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.17</ix:nonFraction> </span>on December&#160;31, 2025, respectively</span></td>
    <td style="font: normal 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,776,628</ix:nonFraction></span></td>
    <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right; font-style: normal; font-weight: normal"><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,319,687</ix:nonFraction></span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--StockholdersEquityAbstract_i01B_zpvo8ip93s09" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders&#8217; Equity</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PreferredStockValue_iI_maSEzHxV_z78KiuiULmul" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred shares, $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260331__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_z3aCRvjToLZf" title="Preferred stock, par value"><span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zEkEB4AjhGz4" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001073" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001075" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zKGJIHtsNNVg" title="Preferred stock, shares authorized"><span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zd44HVeYsHjd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001077" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001079" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_dn_c20260331__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zcrS6hUTrTdk" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20260331__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zzG2Gx8CZqe3" title="Preferred stock, shares outstanding"><span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_dn_c20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_z4GOTMGECPre" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zl5wXEDk2Pc7" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001081" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001083" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001085" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001087" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1071">-</span></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Class A ordinary shares, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zNTa7SdY3J7c" title="Common stock, par value"><span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_z7b3E3qs8pgc" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001089" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001091" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_z77biDblNwhk" title="Common stock, shares authorized"><span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zv1yLXM5Kra" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001093" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001095" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zoTst7Ugmc1c" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zo4uGXm2dGih" title="Common stock, shares outstanding"><span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zicjPajHvb6g" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_z1KQZ71B5wD" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001097" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001099" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001101" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001103" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,200,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding (excluding <span id="xdx_901_ecustom--SharesSubjectToRedemption_iI_c20260331__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassAMember_zdgq1YI3UZ27" title="Shares subject to redemption"><span id="xdx_905_ecustom--SharesSubjectToRedemption_iI_c20251231__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassAMember_zLcrs0zKRirf" title="Shares subject to redemption"><ix:nonFraction name="cik0002065779:SharesSubjectToRedemption" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember" id="Fact001105" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="cik0002065779:SharesSubjectToRedemption" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember" id="Fact001107" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,000,000</ix:nonFraction></ix:nonFraction></span></span> shares subject to redemption)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--CommonStockValue_iI_maSEzHxV_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zJRkhjhjFSpi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--CommonStockValue_iI_maSEzHxV_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_z1uvVQ8vMX4f" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Class B ordinary
Shares, $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zZvDVp0nu90k"><span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_z6SiyKNWc7Qd"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001110" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001111" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span>
</span>par value; <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zTXlglCVKcjd"><span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zUabVAxqHJe1"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001112" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001113" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></ix:nonFraction></span>
</span>shares authorized; <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_z9WOtqruquQg"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zTJANae4Gy21"><span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zYVr8Vw9Ikfd"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zEK5mwHdetB9"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001114" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001115" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001116" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001117" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,000,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>
</span>issued and outstanding<sup></sup></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--CommonStockValue_iI_maSEzHxV_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_fKDEp_ztnUrl6tkME3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,200</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--CommonStockValue_iI_maSEzHxV_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_fKDEp_zvRpn1zWODK3" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001119" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,200</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdditionalPaidInCapital_iI_maSEzHxV_zuq6izOAcp3f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional paid-in capital</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1121">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1122">-</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maSEzHxV_zDnnOPML0GH6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left">Retained earnings</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">584,543</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,802</ix:nonFraction></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockholdersEquity_iTI_mtSEzHxV_maLASEzOJn_zl6JoW8qm6Wg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total
    Shareholders&#8217; Equity (Deficit)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001127" format="ixt:numdotdecimal" decimals="0" unitRef="USD">585,863</ix:nonFraction></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001128" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,122</ix:nonFraction></b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtLASEzOJn_zToWAX6D2if3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total
    Liabilities and Shareholders&#8217; Equity (Deficit)</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">285,400,102</ix:nonFraction></b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,719,522</ix:nonFraction></b></td>
    <td style="padding-bottom: 2.5pt"><b>&#160;</b></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these unaudited condensed financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 370; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: center"><span id="fin3_002"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D. BORAL ARC ACQUISITION I CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_113_zgQKXffJejV2" summary="xdx: Statement - STATEMENT OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_49D_20250320__20250331__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zK5hpDCQnlSc" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_491_20260101__20260331__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_ztwWe6O4tG5e" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the<br/>
Period from<br/>
March&#160;20, 2025<br/>
(Inception) through<br/>
March&#160;31,<br/>
2025</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the<br/>
three months ended<br/>
March&#160;31,<br/>
2026</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpenses_iNT_di_msNILzZhD_ziWwMoRC6apk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formation and operating costs</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001133" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,420</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">531,741</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherIncomeAbstract_iB_z4peDZWvOJZc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other income:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InterestIncomeOther_maOIzzAL_zBirgxabeTUc" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt">Interest income on cash held in trust account</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1139">-</span></td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,543,059</ix:nonFraction></td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherIncome_iTP3us-gaap--InterestIncomeOther_mtOIzzAL_maNILzZhD_maCzLKX_zfMGBGSuGPZ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Total other income</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1142">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,543,059</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_iTP3us-gaap--OtherIncome_mtNILzZhD_zp8ww1s1gM2h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt; width: 76%"><span style="font: normal 10pt Times New Roman, Times, Serif">Net
    (loss)/income</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right; width: 9%"><span style="font-style: normal">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001145" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,420</ix:nonFraction></span></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left; width: 1%"><span style="font: normal 10pt Times New Roman, Times, Serif">)</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right; width: 9%"><span style="font: normal 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,011,318</ix:nonFraction></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left; width: 1%"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Weighted average shares of Class A ordinary shares outstanding, basic and diluted</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zz7dTC8inzbf" title="Weighted average shares of Class A ordinary shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zlhUlbwEahnj" title="Weighted average shares of Class A ordinary shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span style="-sec-ix-hidden: xdx2ixbrl1148"><span style="-sec-ix-hidden: xdx2ixbrl1150">-</span></span></span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zxGfU3l67Z3e" title="Weighted average shares of Class A ordinary shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zbgHHAu1N2m4" title="Weighted average shares of Class A ordinary shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001152" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001154" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,200,000</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Class A ordinary shares - basic and diluted net income per share</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zJk3wjh8i9E9" title="Class A ordinary shares - basic net income per share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zdStQcL0CeQ5" title="Class A ordinary shares - diluted net income per share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001156" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001158" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zc1a2yWl1VP9" title="Class A ordinary shares - basic net income per share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zS3iVItC13M9" title="Class A ordinary shares - diluted net income per share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001160" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001162" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.07</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average shares of Class B ordinary shares outstanding, basic and diluted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_z3bVSXyESuBb" title="Weighted average shares of Class B ordinary shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zJm0vlf9MGd8" title="Weighted average shares of Class B ordinary shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001164" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,714,286</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zYForXFiyoc1" title="Weighted average shares of Class B ordinary shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zwlCMgamHJs4" title="Weighted average shares of Class B ordinary shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001170" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,000,000</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Class B ordinary shares - basic and diluted net income per share</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_z0TWdjhrKiU3" title="Class B ordinary shares - basic net income per share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zOteSrD7seYg" title="Class B ordinary shares - diluted net income per share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001172" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001174" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zYUc608v71l" title="Class B ordinary shares - basic net income per share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zsY6A4ZP6zH2" title="Class B ordinary shares - diluted net income per share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001176" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001178" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.17</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying notes are an integral part of these unaudited financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 371; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: center"><span id="fin3_003"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D. BORAL ARC ACQUISITION I CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: center"><b>CONSOLIDATED CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217;
EQUITY (DEFICIT)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: center"><b>FOR THE THREE MONTHS ENDED MARCH 31, 2026</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: center"><b>(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" summary="xdx: Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT" id="xdx_30F_114_z86cI00rtyak" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_custom--OrdinarySharesClassAMember_dei--LegalEntityAxis_custom--DBoralARCAcquisitionICorpMember_zo1sjsEIZVWk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_custom--OrdinarySharesClassBMember_dei--LegalEntityAxis_custom--DBoralARCAcquisitionICorpMember_zaENMFgHkT54" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_dei--LegalEntityAxis_custom--DBoralARCAcquisitionICorpMember_zdpspaqJqCI1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_dei--LegalEntityAxis_custom--DBoralARCAcquisitionICorpMember_zk4htDDC5R67" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_custom--SubscriptionReceivableMember_dei--LegalEntityAxis_custom--DBoralARCAcquisitionICorpMember_z22ylMguhXVk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B7_dei--LegalEntityAxis_custom--DBoralARCAcquisitionICorpMember_zitffICn5BBa" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Class A<br/>
Ordinary shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Class B<br/>
Ordinary shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional<br/>
Paid-In</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Subscription</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total<br/>
Shareholder&#8217;s<br/>
Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Deficit)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43F_c20260101__20260331_eus-gaap--StockholdersEquity_iS_ztJM75fEuJy1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 28%; vertical-align: top">Balance &#150; January 1, 2026</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassAMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_z3V2LKpF10Yi" title="Beginning balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember" id="Fact001187" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,200,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember" id="Fact001180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zBPomjSe9Y9c" title="Beginning balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001189" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,200</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1182">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">584,543</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1184">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001185" format="ixt:numdotdecimal" decimals="0" unitRef="USD">585,863</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AccretionInValueOfClassOrdinaryShares_zWk1KviqBV1e" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accretion in value of Class A ordinary shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1191">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1192">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1193">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="cik0002065779:AccretionInValueOfClassOrdinaryShares" contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001194" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,543,059</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1195">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="cik0002065779:AccretionInValueOfClassOrdinaryShares" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001196" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,543,059</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--ProfitLoss_zDG5NkmxW3w6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Net income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1198">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1199">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1200">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,011,318</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,011,318</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_430_c20260101__20260331_eus-gaap--StockholdersEquity_iE_z78oCqWrL9K5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top">Balance &#150; March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassAMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_z8Awva8NHnU4" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember" id="Fact001212" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,200,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember" id="Fact001205" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zj8ZFhXJWJY4" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001214" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001206" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,200</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1207">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001208" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,802</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1209">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001210" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,122</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: center"><b>CONSOLIDATED CONDENSED STATEMENTS OF CHANGES SHAREHOLDER&#8217;S
EQUITY (DEFICIT)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: center"><b>FOR THE PERIOD FROM MARCH 20, 2025 (INCEPTION)
THROUGH MARCH&#160;31, 2025<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Class A<br/> Ordinary shares</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class B<br/> Ordinary shares</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional<br/>Paid-In</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total<br/>Shareholder&#8217;s<br/>
Equity</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></td>
    <td>&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></td>
    <td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deficit</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Receivable</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Deficit)</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr id="xdx_43E_c20250320__20250331_eus-gaap--StockholdersEquity_iS_zs4T0OH1UeZb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance &#8211; March&#160;20, 2025 (inception)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20250320__20250331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassAMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zr4WoqytP6T5" title="Beginning balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1223">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1216">-</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20250320__20250331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_z4vXyaKh5kPa" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1225">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1217">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1218">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1219">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1220">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1221">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--ClassBOrdinarySharesIssuedToSponsor_iP3us-gaap--SharesOutstanding_zO6hCSh9AsKd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class B ordinary shares issued to Sponsor<sup id="xdx_F44_zvLAKY5w4kr9">(1)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 6%">-</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 6%"><span style="-sec-ix-hidden: xdx2ixbrl1227">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_985_ecustom--ClassBOrdinarySharesIssuedToSponsorShares_iP3custom--ClassBOrdinarySharesIssuedToSponsor_c20250320__20250331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zY8MonlmcWqk" title="Class B ordinary shares issued to Sponsor, shares" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cik0002065779:ClassBOrdinarySharesIssuedToSponsorShares" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738984" id="Fact001234" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,321,429</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cik0002065779:ClassBOrdinarySharesIssuedToSponsor" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738984" id="Fact001228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,232</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cik0002065779:ClassBOrdinarySharesIssuedToSponsor" contextRef="From2025-03-202025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001229" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,768</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1230">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="cik0002065779:ClassBOrdinarySharesIssuedToSponsor" contextRef="From2025-03-202025-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001231" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,000</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1232">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--ProfitLoss_zmua8gDSFMYk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1236">-</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1237">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1238">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-03-202025-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001239" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,420</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1240">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001241" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,420</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_43F_c20250320__20250331_eus-gaap--StockholdersEquity_iE_zLsJIJMhBaHl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance &#8211; March&#160;31, 2025</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20250320__20250331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassAMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zgYSN1ncfiXf" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1250">-</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1243">-</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98A_eus-gaap--SharesOutstanding_iE_c20250320__20250331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zTJQVEFKcC9b" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001252" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,321,429</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001244" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,232</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001245" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,768</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001246" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,420</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001247" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,000</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001248" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,420</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
</table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->





<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span id="xdx_F0A_zqrU8UjmxeRk" style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span id="xdx_F14_zi1hBKHavmUe" style="font-size: 10pt"><ix:footnote id="Footnote001253" xml:lang="en-US">Includes an aggregate of 321,429
Ordinary Shares cancelled on September&#160;9, 2025 to the extent that the underwriters&#8217; over-allotment was not exercised.</ix:footnote></span></td>
</tr></table>
<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying notes are an integral part of these unaudited financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 372; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: center"><span id="fin3_004"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D. BORAL ARC ACQUISITION I CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_112_z2OsUOX35817" summary="xdx: Statement - STATEMENT OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_496_20250320__20250331__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zunGr0uNzvp2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_49C_20260101__20260331__dei--LegalEntityAxis__custom--DBoralARCAcquisitionICorpMember_zO9pvrQa1uo5" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="font: normal bold 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: normal bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: normal bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: normal bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: normal bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
                                            the<br/>
                                            period from<br/>
                                            March&#160;20, 2025<br/>
                                            (inception) through<br/>
                                            March&#160;31,<br/>
                                            2025</b></span></p></td>
    <td style="font: normal bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0; font-weight: bold"><b>For
                                            the</b></p>
                    <p style="text-align: center; margin-top: 0; margin-bottom: 0; font-weight: bold"><b>three months
                    ended<br/>
                    March&#160;31,<br/>
                    2026</b></p></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zucLvafd9av9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash flows from Operating Activities:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_i01_maNCPBUzSwd_zClkkDgvSXzh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    (loss)/income</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001258" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,420</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="text-align: right; width: 9%"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001259" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,011,318</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zp2vHKgK92b5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments to reconcile net (loss)/income to net cash used in operating activities:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_ecustom--PaymentOfExpensesThroughPromissoryNoteRelatedParty_maNCPBUzSwd_zaXec4gAT32l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of expenses through promissory note &#8211; related party</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cik0002065779:PaymentOfExpensesThroughPromissoryNoteRelatedParty" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,420</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1265">-</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestIncomeOther_i02N_di_msNCPBUzSwd_zlkyWCkMSy9b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Investment income in trust account</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1267">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001268" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,543,059</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_iB_zpg5mLSo3MO5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Changes in operating assets and liabilities:</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInPrepaidExpense_i01N_di_msNCPBUzSwd_zxTdokA6RbHi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Prepaid expenses</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1273">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001274" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">46,875</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i01_maNCPBUzSwd_zJc4Idbw3R58" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accrued Expenses</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1276">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001277" format="ixt:numdotdecimal" decimals="0" unitRef="USD">308,102</ix:nonFraction></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtNCPBUzSwd_maCzVoY_zEwnHbwoNfFb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash used in operating activities</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1279">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001280" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">176,764</ix:nonFraction></td>
    <td style="padding-bottom: 1pt">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zSUVofYxktg2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash flows from investing activities:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsToAcquireRestrictedInvestments_iN_di_msNCPBUz0DJ_zFsvv0Kh9J7a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-style: normal; font-weight: normal">Investment of cash in Trust Account</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1285">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1286">-</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_mtNCPBUz0DJ_maCzVoY_zn5mJNYg2krd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Net cash used in investing activities</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromIssuanceOfCommonStock_maNCPBUzi2r_zgXCwoQjnyZj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from issuance of Class B ordinary shares to Sponsor</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1291">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1292">-</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid_maNCPBUzi2r_zPzQr3dttkOe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from sale of Units, net of underwriting discount paid</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1294">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1295">-</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_maNCPBUzi2r_z7qgXjBQHAle" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from sale of private placement units</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1297">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1298">-</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RepaymentsOfDebt_iN_di_msNCPBUzi2r_zFAQ1fTts8Hi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Repayment of promissory note</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1300">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1301">-</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PaymentsForRepurchaseOfInitialPublicOffering_iN_di_msNCPBUzi2r_znmWlHipCIif" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Payment of offering costs</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtNCPBUzi2r_maCzVoY_zGgMpLccGAPc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash provided by financing activities</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1306">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1307">-</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzVoY_zjz88JQE1FBc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net change in cash</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1309">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001310" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">176,764</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zqI62S9Px4F6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash at the beginning of the period</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1312">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,340</ix:nonFraction></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zeLFQLeSJsa1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash at the end of the period</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1315">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,576</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zzfKDhX8Ot1k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental disclosure of non-cash financing activities:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_iP3us-gaap--NoncashOrPartNoncashAcquisitionDescription_zdgFCJrLK8v5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred offering costs included in promissory note</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,420</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1322">-</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NoncashOrPartNoncashAcquisitionInventoryAcquired1_iP3us-gaap--NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_z1WHOrGqRqpb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accretion of carrying value of redeemable shares to redemption value</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1324">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionInventoryAcquired1" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001325" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,543,059</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying notes are an integral part of these unaudited financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 373; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p id="xdx_042_c20260101__20260331_zFzEw43q5cU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: center"><span id="fin3_005"></span><b>D. BORAL ARC ACQUISITION I CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: center"><b>NOTES TO THE CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001327" name="us-gaap:NatureOfOperations"><p id="xdx_80C_eus-gaap--NatureOfOperations_zygend9e1RRc" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 1. <span id="xdx_82D_zrYalJ697s07">DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">D. BORAL ARC
ACQUISITION I CORP. (the &#8220;Company&#8221;) is a blank check company incorporated in the British Virgin Islands on March&#160;20,
2025. The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase,
reorganization or similar business combination with one or more businesses (&#8220;Business Combination&#8221;). While the Company may
pursue an acquisition opportunity in any business, industry, sector or geographical location, the Company intends to focus on industries
that complement our management team&#8217;s background, and to capitalize on the ability of our management team to identify and acquire
a business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31,
2026, the Company had not yet commenced any operations. All activity through March 31, 2026 related to the Company&#8217;s formation
and the Initial Public Offering (as defined below). Since the IPO, the Company&#8217;s activity has been limited to the costs in pursuit
of the consummation of an initial business combination. The Company will not generate any operating revenues until after the completion
of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on
cash and cash equivalents from the proceeds derived from the Initial Public Offering. The Company has selected December&#160;31 as its
fiscal year end. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated
with early stage and emerging growth companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company&#8217;s sponsor is MFH 1, LLC (the &#8220;Sponsor&#8221;). The registration statement for the Company&#8217;s Initial Public Offering was declared effective on July&#160;30, 2025. On August&#160;1, 2025, the Company consummated its Initial Public Offering of <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zZC60ip9O139" title="Sale of units in initial public offering"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001329" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000,000</ix:nonFraction></span> units (the &#8220;Units&#8221; and, with respect to the Class A Ordinary Shares included in the Units being offered, the &#8220;Public Shares&#8221;), at $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z3ISudk5ZSw6" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001331" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per Unit, generating gross proceeds of $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zjX8VKK92qjd" title="Sale of units in initial public offering aggragate amount"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001333" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000,000</ix:nonFraction></span> (the &#8220;Initial Public Offering&#8221;). The Company granted the underwriter a 45-day option to purchase up to an additional <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z9eUpL924fa5" title="Sale of units in initial public offering"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001335" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750,000</ix:nonFraction></span> Units at the Initial Public Offering price to cover over-allotments, if any. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Simultaneously with the consummation of the closing of the Offering, the Company consummated the private placement of an aggregate of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGrtbDdoicDg" title="Sale of units in initial public offering"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001337" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> units (the &#8220;Placement Units&#8221;) to the Sponsor at a price of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zABeT3cNd0K6" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001339" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per Unit, generating gross proceeds of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zm3i9GAh1wZ" title="Sale of units in initial public offering aggragate amount"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001341" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></span> (the &#8220;Private Placement&#8221;). (see Note 4).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Transaction costs amounted to $<span id="xdx_90C_ecustom--TransactionCosts_pp0p0_c20260101__20260331_zlNHw2cetME1" title="Transaction costs"><ix:nonFraction name="cik0002065779:TransactionCosts" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001343" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,582,634</ix:nonFraction></span>, consisting of $<span id="xdx_905_ecustom--RepresentativeShares_pp0p0_c20260101__20260331_zpYwsp2Au2o7" title="Representative shares"><ix:nonFraction name="cik0002065779:RepresentativeShares" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001345" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,419,400</ix:nonFraction></span> of the Representative Shares (discussed in the below) and $<span id="xdx_90B_ecustom--OtherOfferingCosts_pp0p0_c20260101__20260331_z1IYHYmkc8Vf" title="Other offering costs"><ix:nonFraction name="cik0002065779:OtherOfferingCosts" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001347" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,163,234</ix:nonFraction></span> of other offering costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">In conjunction with the IPO, the Company issued to the underwriter <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zC8C67MdLPre" title="Number of share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001349" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> Class A ordinary shares for no consideration (the &#8220;Representative Shares&#8221;). The fair value of the Representative Shares accounted for as compensation under Accounting Standards Codification (&#8220;ASC&#8221;) 718, &#8220;Compensation &#8211; Stock Compensation&#8221; (&#8220;ASC 718&#8221;) is included in the offering costs. The estimated fair value of the Representative Shares as of the IPO date totaled $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zHyEfQAcbCTg" title="Number of share issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001351" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,419,400</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Following the closing of the Initial Public Offering on August&#160;1, 2025, an amount of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_ziUw4vAAKbAd" title="proceeds from sale of initial public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000,000</ix:nonFraction></span> ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and a portion of the proceeds from the sale of the Placement Units was placed in a trust account (the &#8220;Trust Account&#8221;), located in the United States and held as cash items and will be invested only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule&#160;2a-7 under the Investment Company Act, that invest only in direct U.S. government treasury obligations; the holding of these assets in this form is intended to be temporary and for the sole purpose of facilitating the intended business combination. To mitigate the risk that the Company might be deemed to be an investment company for purposes of the Investment Company Act, which risk increases the longer that the Company hold investments in the trust account, the Company may, at any time (based on our management team&#8217;s ongoing assessment of all factors related to our potential status under the Investment Company Act), instruct the trustee to liquidate the investments held in the trust account and instead to hold the funds in the trust account in cash or in an interest bearing demand deposit account at a bank.</p>

<ix:exclude><p id="xdx_238_zIjkUm8DDeF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 374; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zy6aRwsRJkvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zqp1ilSKeaIg" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>D. BORAL ARC ACQUISITION I CORP.</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zcYUV1hidE07" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>NOTES TO THE CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zVK2f4Ryzrqf" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zFybGYp2M8Zh" style="font: 10pt Times New Roman, Times, Serif;text-align: justify; margin-top: 0; margin-bottom: 0"><b>NOTE 1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zvH75StAsinf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">On August&#160;11, 2025, the underwriters of the IPO notified the Company of their partial exercise of the over-allotment option and purchased <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zJQr08Hr1169" title="Sale of units in initial public offering"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001362" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction></span> additional units (the &#8220;Option Units&#8221;) at $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zGc1BiSVx6Wi" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001364" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per unit upon the closing of the over-allotment option, generating gross proceeds of $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zwO1mOZUQPp7" title="Sale of units in initial public offering aggragate amount"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001366" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,000,000</ix:nonFraction></span>. The over-allotment option closed on August&#160;13, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">On September 9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option. As a result,&#160;on September 9, 2025,&#160;the Company cancelled a total of <span id="xdx_90C_ecustom--CancelledFounderShares_c20250905__20250909_zMn2lTaGsGg9" title="Cancelled founder shares"><ix:nonFraction name="cik0002065779:CancelledFounderShares" contextRef="From2025-09-052025-09-09_custom_DBoralARCAcquisitionICorpMember" id="Fact001368" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">321,429</ix:nonFraction></span> of the Company&#8217;s founder shares, issued to MFH 1, LLC thereby reducing the sponsor&#8217;s total shares to <span id="xdx_90F_ecustom--CancelledFounderShares_c20250729__20250801_zE8aHeKIinuh" title="Cancelled founder shares"><ix:nonFraction name="cik0002065779:CancelledFounderShares" contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember" id="Fact001370" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,000,000</ix:nonFraction></span>, which was effective from August 1, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of our initial business combination either (i) in connection with a shareholder meeting called to approve the initial business combination or (ii) by means of a tender offer. In connection with a proposed Business Combination, the Company may seek shareholder approval of a Business Combination at a meeting called for such purpose at which shareholders may seek to redeem their shares, regardless of how they vote for the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zvYo0cYwbk22" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001372" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter. These ordinary shares was recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its amended and restated memorandum and articles of association conduct the redemptions pursuant to Rule&#160;13e-4 and Regulation 14E of the Exchange Act, which regulate issuer tender offers, and file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The sponsor, officers and directors have entered
into a letter agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to
their founder shares, private shares and public shares in connection with the completion of our initial business combination; (ii)
waive their redemption rights with respect to their founder shares, private shares and public shares in connection with a
shareholder vote to approve an amendment to our amended and restated memorandum and articles of association; (iii) waive their
rights to liquidating distributions from the trust account with respect to their founder shares and private shares if the Company
fail to complete our initial business combination within the completion window, although they will be entitled to liquidating
distributions from the trust account with respect to any public shares they hold if the Company fail to complete our initial
business combination within the prescribed time frame and to liquidating distributions from assets outside the trust account; and
(iv) vote any founder shares and private shares held by them and any public shares they may purchase (including in open market and privately-negotiated transactions) in favor of our initial business combination (except that
any public shares such parties may purchase in compliance with the requirements of Rule&#160;14e-5 under the Exchange Act would not
be voted in favor of approving the business combination transaction).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company will have until 18 months from the closing of the Initial Public Offering, with one (1) three-month extension at the option of the sponsor (as may be extended by shareholder approval to amend our amended and restated memorandum and articles of association to extend the date by which the Company must consummate our initial business combination) or until such earlier liquidation date as our board of directors may approve, to consummate a Business Combination (the &#8220;Combination Period&#8221;). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter (and subject to lawfully available funds therefor), redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (which interest shall be net of taxes and less up to $<span id="xdx_901_eus-gaap--LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_iI_c20251231_zW7hO2wBkNSk" title="Dissolution expenses"><ix:nonFraction name="us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001374" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> of interest to pay dissolution expenses), divided by the number of then-outstanding public shares, which redemption will completely extinguish public shareholders&#8217; rights as shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors, liquidate and dissolve, subject in each case to our obligations under British Virgin Islands law to provide for claims of creditors and the requirements of other applicable law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 375; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zp5imo4ZqC2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>


<ix:exclude><p id="xdx_23B_zmLL1B1J0aF2" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>D. BORAL ARC ACQUISITION I CORP.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_z0VAMMgeyzzb" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>NOTES TO THE CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zThNMB0MMPJc" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_232_zufeOWYFNuIc" style="font: 10pt Times New Roman, Times, Serif;text-align: justify; margin-top: 0; margin-bottom: 0"><b>NOTE 1. DESCRIPTION OF ORGANIZATION,
BUSINESS OPERATIONS (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zksWFl2n9vha" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The underwriter
has agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event the Company does not complete
a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust
Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the
per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Sponsor has
agreed that it will be liable to us if and to the extent any claims by a third party for services rendered or products sold to us (except
for the Company&#8217;s independent auditors), or a prospective target business with which the Company has entered into a written letter
of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in the trust account
to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account as of the date
of the liquidation of the trust account, if less than $10.00 per public share due to reductions in the value of the trust assets, less
taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed
a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply
to any claims under our indemnity of the underwriters of our IPO against certain liabilities, including liabilities under the Securities
Act. However, the Company has not asked our sponsor to reserve for such indemnification obligations, nor has the Company independently
verified whether our sponsor has sufficient funds to satisfy its indemnity obligations and the Company believe that our sponsor&#8217;s
only assets are securities of our company. Therefore, the Company cannot assure you that our sponsor would be able to satisfy those obligations.
As a result, if any such claims were successfully made against the trust account, the funds available for our initial business combination
and redemptions could be reduced to less than $10.00 per public share. In such event, the Company may not be able to complete our initial
business combination, and you would receive such lesser amount per share in connection with any redemption of your public shares. None
of our officers or directors will indemnify us for claims by third parties including, without limitation, claims by vendors and prospective
target businesses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January&#160;11,
2026, D. Boral ARC Acquisition I Corp. (&#8220;BCAR&#8221; or the &#8220;Company&#8221;) entered into the Agreement and Plan of Merger
(the &#8220;Merger Agreement&#8221;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly owned subsidiary
of BCAR (&#8220;PubCo&#8221;), D. Boral Arc Merger Sub Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and a wholly-owned subsidiary
of BCAR, and Exascale Labs Inc., a Delaware corporation (&#8220;Exascale&#8221;). Pursuant to the Merger Agreement, the Business Combination
will be effected in two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into PubCo, with PubCo remaining
as the surviving publicly traded entity (the &#8220;Reincorporation Merger&#8221;); (ii) after the Reincorporation Merger, Merger Sub
will be merged with and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#8220;Acquisition Merger&#8221;
and together with the Reincorporation Merger, the &#8220;Business Combination&#8221;).&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate
consideration for the Acquisition Merger is $500,000,000 (the &#8220;Merger Consideration&#8221;), payable in the form of 50,000,000
newly issued shares of common stock of PubCo valued at $10.00 per share to Exascale and its shareholders. At the closing of the Acquisition
Merger (the &#8220;Closing&#8221;), the issued and outstanding shares in Exascale held by the former Exascale shareholders will be cancelled
and cease to exist as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt;">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt;">Each issued and outstanding
    share of Exascale Class B common stock shall be cancelled and converted into the right to receive a number of shares of PubCo Class
    B common stock (the &#8220;PubCo Class B Shares&#8221;) equal to the quotient obtained by dividing (a) the quotient equal to the
    Merger Consideration divided by the fully diluted Exascale capitalization (the &#8220;Per Share Merger Consideration&#8221;) by (b)
    Ten Dollars ($10.00), with each such PubCo Class B Share having twenty (20) votes per share; and</span></td></tr>
  </table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt;">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt;">Each issued and outstanding
    share of Exascale Class A common stock shall be cancelled and converted into the right to receive a number of shares of PubCo Class
    A common stock (the &#8220;PubCo Class A Shares&#8221;) equal to the quotient obtained by dividing (a) the Per Share Merger Consideration
    by (b) Ten Dollars ($10.00), with each such PubCo Class A Share having one (1) vote per share.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 376; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zyXm1UzUgYmc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>


<ix:exclude><p id="xdx_236_zZbJ4qAvxGsd" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>D. BORAL ARC ACQUISITION I CORP.</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zvwtBtxOr3C3" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>NOTES TO THE CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_z8eDoZkYmMlj" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zJUrehCa11g5" style="font: 10pt Times New Roman, Times, Serif;text-align: justify; margin-top: 0; margin-bottom: 0"><b>NOTE 1. DESCRIPTION OF ORGANIZATION,
BUSINESS OPERATIONS (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zQnYuC6YV3lf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>Liquidity, Capital Resources and Going Concern
Consideration</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">As of March 31, 2026, the Company had $<span id="xdx_90D_eus-gaap--Cash_iI_pp0p0_c20260331_zcgybPa75Rrh" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001388" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">243,576</ix:nonFraction></span> of cash in its operating bank account and working capital of $<span id="xdx_90E_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20260331_z6EhFQhvkWk2" title="Working capital deficit"><ix:nonFraction name="cik0002065779:WorkingCapitalDeficit" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001390" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,122</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company&#8217;s liquidity needs prior to the
consummation of the Initial Public Offering were satisfied through the payment of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--FounderSharesMember_zDESmG0pruoc" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2026-01-012026-03-31_custom_FounderSharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001392" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span>
from the Sponsor to cover for certain offering costs on the Company&#8217;s behalf in exchange for issuance of Founder Shares (as
defined in Note 4), and loan from the Sponsor of $<span id="xdx_90F_eus-gaap--LoansPayable_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zcxmPKgrvA99" title="Loan payable"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2026-03-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,461</ix:nonFraction></span>
under the Note (as defined in Note 4). On August&#160;1, 2025, the Company has repaid $<span id="xdx_903_eus-gaap--RepaymentOfNotesReceivableFromRelatedParties_c20250729__20250801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zL71zekeZW5i" title="Repayment of promissory note"><ix:nonFraction name="us-gaap:RepaymentOfNotesReceivableFromRelatedParties" contextRef="From2025-07-292025-08-01_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001396" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,461</ix:nonFraction></span>
under the promissory note. Subsequent to the consummation of the Initial Public Offering, the Company&#8217;s liquidity has been
satisfied through the net proceeds from the consummation of the Initial Public Offering and the Private Placement held outside of
the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an
affiliate of the Sponsor, or certain of the Company&#8217;s officers and directors may, but are not obligated to, provide the
Company Working Capital Loans (as defined in Note 4). As of December&#160;31, 2025 and March&#160;31, 2026, there were no amounts
outstanding under any Working Capital Loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expects
to incur significant costs in pursuit of its acquisition plans and will not generate any operating revenues until after the completion
of its initial business combination. In addition, the Company expects to have negative cash flows from operations as it pursues an initial
business combination target. In connection with the Company&#8217;s assessment of going concern considerations in accordance with Accounting
Standards Update (&#8220;ASU&#8221;) 2014-15, &#8220;Disclosures of Uncertainties about an Entity&#8217;s Ability to Continue as a Going
Concern&#8221; the Company does not currently have adequate liquidity to sustain operations, which consist solely of pursuing a Business
Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company may
raise additional capital through loans or additional investments from the Sponsor or its shareholders, officers, directors, or third
parties. The Company&#8217;s officers and directors and the Sponsor may, but are not obligated to (except as described above), loan the
Company funds, from time to time, in whatever amount they deem reasonable in their sole discretion, to meet the Company&#8217;s working
capital needs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As is customary
for a special purpose acquisition company, if the Company is not able to consummate a Business Combination during the Combination Period,
it will cease all operations and redeem the Public Shares. Management plans to continue its efforts to consummate a Business Combination
during the Combination Period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">While the Company expects to have access to
additional sources of capital if necessary, there is no current commitment on the part of any financing source to provide additional
capital and no assurances can be provided that such additional capital will ultimately be available. The liquidity condition and
mandatory liquidation raise substantial doubt about the Company&#8217;s ability to continue as a going concern until the earlier of
the consummation of the Business Combination or the date the Company is required to liquidate. There is no assurance that the
Company&#8217;s plans to raise additional capital (to the extent ultimately necessary) or to consummate a Business Combination will
be successful or successful within the Combination Period. The consolidated condensed financial statements do not include any
adjustments that might result from the outcome of this uncertainty.</p>





<ix:exclude><p id="xdx_23D_zAFKACxUUU7c" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 377; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zCn8Xvw0Yrtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_23D_z1dygwr9DV4e" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>D. BORAL ARC ACQUISITION I CORP.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zgxc4Kw3yoWe" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>NOTES
            TO THE CONSOLIDATED CONDENSED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zQv0eQQG9OCf" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>&#160;</b></p></ix:exclude>


</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001403" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zwMIFdJLnGU" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 2. <span id="xdx_820_zHeBz4zKHT1d">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001405" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z0IWy53sD0Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_865_z1Rf2RuPJR21">Basis of Presentation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The accompanying consolidated condensed financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
and pursuant to the rules and regulations of the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Certain information and note disclosures normally
included in the annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been
condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to
make the information not misleading. The interim financial statements as of March 31, 2026 and for the three months ended March 31, 2026
are unaudited. In the opinion of management, the consolidated condensed financial statements include all adjustments, consisting only of normal
recurring adjustments, necessary to provide a fair statement of the results for the periods. The accompanying balance sheet as of December
31, 2025, is derived from the audited financial statements presented in the Company&#8217;s Annual Report on Form 10-K for the year ended
December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001407" name="cik0002065779:EmergingGrowthCompanyPolicyTextBlock"><p id="xdx_845_ecustom--EmergingGrowthCompanyPolicyTextBlock_zmhW1kdqSIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_86C_zt6czdzfWEih">Emerging Growth Company</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Further, Section&#160;102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make
comparison of the Company&#8217;s consolidated financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001409" name="us-gaap:UseOfEstimates"><p id="xdx_84F_eus-gaap--UseOfEstimates_zQYZj3djUeb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_864_zRzz8424e6p3">Use of Estimates</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The preparation of consolidated condensed financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the consolidated condensed financial statements and the
reported amounts of revenues and expenses during the reporting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Making estimates requires management to exercise
significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances
that existed at the date of the consolidated condensed financial statements, which management considered in formulating its estimate,
could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly
from those estimates.</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 378; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_23C_zkTXDJImvgY8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p></ix:exclude>


<ix:exclude><p id="xdx_234_zoiUt2d4c1b3" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>D. BORAL ARC ACQUISITION I CORP.</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_z7pq0o0hQfl" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>NOTES TO THE CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zRSnHYqGDRka" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zHRCz4ROy5w2" style="font: 10pt Times New Roman, Times, Serif;text-align: justify; margin-top: 0; margin-bottom: 0"><b>NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_z1XYBJb4H2V3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001417" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPzrLcIyQfel" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_860_zu37CGZfznfc">Cash and Cash Equivalents</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company considers all highly liquid
investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents are carried at
cost, which approximates fair value. The Company had $<span id="xdx_90E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20251231_zKSiK1lJFQo5"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001418" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,340</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20260331_zBLVCNltQyz5"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001419" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,576</ix:nonFraction></span>
in cash as of December&#160;31, 2025 and March&#160;31, 2026, respectively. The Company had <span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20251231_zHKchSeuPLR4" title="Cash equivalents"><span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20260331_zbssSpEVMX26" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001421" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001423" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>
cash equivalents as of December&#160;31, 2025 and March&#160;31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001425" name="cik0002065779:CashHeldInTrustAccountPolicyTextBlock"><p id="xdx_844_ecustom--CashHeldInTrustAccountPolicyTextBlock_zf23zmDeFAC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"><b><span id="xdx_863_zgMHfmHrvZ42">Cash Held in Trust Account</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company had $<span id="xdx_90F_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20251231_z5sY6BBpp9d4"><ix:nonFraction name="cik0002065779:CashHeldInTrustAccount" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001426" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">284,776,628</ix:nonFraction></span> and $<span id="xdx_905_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20260331_zKMPpHYYWvXd"><ix:nonFraction name="cik0002065779:CashHeldInTrustAccount" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001427" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">287,319,687</ix:nonFraction></span>
a of cash in the trust account held in an interest bearing demand deposit account as of December 31, 2025 and March&#160;31,
2026, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001429" name="cik0002065779:OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock"><p id="xdx_84F_ecustom--OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock_z7CN7IDO18Rg" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_860_zF0eseXwdsYe">Offering Costs Associated with the Initial Public Offering</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212;
&#8220;Expenses of Offering.&#8221; Deferred offering costs consist principally of professional and registration fees that are related
to the Initial Public Offering. Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 470-20, &#8220;Debt with Conversion and
Other Options,&#8221; addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components.
The Company applies this guidance to allocate Initial Public Offering proceeds from the Public Units between Class A ordinary shares and
warrants based on their relative fair values. Offering costs allocated to the Class A ordinary shares subject to possible redemption were
charged to temporary equity, and offering costs allocated to the warrants included in the Public Units and Private Units were charged
to shareholder&#8217;s equity as the warrants, after management&#8217;s evaluation, were accounted for under equity treatment. As of August&#160;1,
2025, the Company had offering costs of $<span id="xdx_903_ecustom--OfferingCost_iI_pp0p0_c20250801_z4hgPDFmpaOa" title="Offering costs"><ix:nonFraction name="cik0002065779:OfferingCost" contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember" id="Fact001431" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,582,634</ix:nonFraction></span>,
consisting of $<span id="xdx_901_ecustom--RepresentativeShares_c20250729__20250801_z17XWIvrJ0Ql" title="Representative shares"><ix:nonFraction name="cik0002065779:RepresentativeShares" contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember" id="Fact001433" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,419,400</ix:nonFraction></span>
of the Representative Shares (as discussed in Note 1) and $<span id="xdx_903_ecustom--OtherOfferingCost_pp0p0_c20250729__20250801_z3stLaw1Yk4h" title="Other offering costs"><ix:nonFraction name="cik0002065779:OtherOfferingCost" contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember" id="Fact001435" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,163,234</ix:nonFraction></span>
of other offering costs. Approximately $<span id="xdx_90C_eus-gaap--OtherExpenses_pp0p0_c20250729__20250801_zacUbSCdNTya" title="other costs"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember" id="Fact001437" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">143,775</ix:nonFraction></span>
of such costs were allocated to the Public Warrants and the Private Placement Units and the remainder, approximately $<span id="xdx_90D_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_c20250801_z05aQ6gzdoVi" title="Ordinary shares subject to redemption"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember" id="Fact001439" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,438,859</ix:nonFraction></span>
was allocated to Class A ordinary shares subject to redemption. As of December&#160;31, 2025, the Company had offering costs of $<span id="xdx_900_ecustom--OfferingCost_iI_pp0p0_c20251231_zXALNb75mMuc" title="Offering costs"><ix:nonFraction name="cik0002065779:OfferingCost" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001441" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,582,634</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001443" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_z77b7DWKM4ee" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_86A_zVc6ABTVy162">Income Taxes</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company complies with the accounting and reporting
requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach to financial accounting and
reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the consolidated financial
statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws
and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established,
when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">ASC Topic 740 prescribes a recognition threshold and a measurement
attribute for the consolidated financial statement recognition and measurement of tax positions taken or expected to be taken in a tax
return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.
The Company&#8217;s management determined the British Virgin Islands is the Company&#8217;s only major tax jurisdiction. The Company recognizes
accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were no unrecognized tax benefits
as of March 31, 2026 and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review
that could result in significant payments, accruals or material deviation from its position. The Company is considered to be an exempted
British Virgin Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income
tax filing requirements in the British Virgin Islands or the United States. As such, the provision for income taxes was deemed to be <i>de
minimis</i> for the three months ended March 31, 2026.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 379; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_237_zslmFbDxgMcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zdx4Xy96jV6a" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>D. BORAL ARC ACQUISITION I CORP.</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zjnvuqolOQ5a" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>NOTES TO THE CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zw0sDh6s5HR2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zpNktEeOfzQh" style="font: 10pt Times New Roman, Times, Serif;text-align: justify; margin-top: 0; margin-bottom: 0"><b>NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_z6FWBkyK0wee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>


</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001451" name="us-gaap:ExtendedProductWarrantyPolicy"><p id="xdx_840_eus-gaap--ExtendedProductWarrantyPolicy_zIfpp4pkn1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_863_zpXKgEMQKf8">Warrant Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">We account for Warrants as either equity-classified
or liability-classified instruments based on an assessment of the instruments&#8217; specific terms and applicable authoritative guidance
in ASC 480 and FASB ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;). The assessment considers whether the
instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to
a company&#8217;s common shares and whether the instrument holders could potentially require &#8220;net cash settlement&#8221; in a circumstance
outside of a company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional
judgment, is conducted at the time of Warrant issuance and as of each subsequent quarterly period end date while the instruments are outstanding.
Upon review of the Warrant Agreement, Management concluded that the&#160;public warrants and private warrants issued pursuant to such
warrant agreement qualify for equity accounting treatment.&#160;Following the closing of the Initial Public Offering on August&#160;1,
2025 and underwriter&#8217;s exercise of over-allotment option on August&#160;13, 2025, the Company accounted for the&#160;<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331_zZXCPtdZIUn7" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightUnissued" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001453" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,000,000</ix:nonFraction></span>
public warrants and&#160;<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zV9MLoZewlLk" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightUnissued" contextRef="AsOf2026-03-31_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001455" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> private warrants issued under equity treatment at their assigned values.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001457" name="cik0002065779:ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock"><p id="xdx_84F_ecustom--ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_zd7Gejgazmwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_86B_zNHDcMFMuEE">Class A Ordinary Shares Subject to Possible Redemption</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The public shares contain
a redemption feature which allows for the redemption of such public shares in connection with the Company&#8217;s liquidation, or if
there is a shareholder vote or tender offer in connection with the Company&#8217;s initial Business Combination. In accordance with
ASC 480-10-S99, the Company classifies public shares subject to redemption outside of permanent equity as the redemption provisions
are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as they occur and
will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately
upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount
value. The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the
extent available) and Retained earnings. Accordingly, Class A ordinary shares subject to possible redemption are presented at
redemption value as temporary equity, outside of the shareholders&#8217; equity section of the Company&#8217;s balance sheet. As of
March 31, 2026 and December 31, 2025, the 28,000,000 Class A ordinary shares subject to redemption reflected in the balance sheet
are reconciled in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001459" name="us-gaap:TemporaryEquityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--TemporaryEquityTableTextBlock_zI3yMm7Bm2me" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B8_zvz98VUo83yh" style="display: none">Schedule of ordinary shares subject to redemption</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Class A ordinary shares subject to possible redemption, December 31, 2025</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_c20260101__20260331_zuYUa9ZjRBt2" style="text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001460" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,776,628</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Plus:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top">Accretion of carrying value to redemption value</td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td>
    <td id="xdx_98D_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20260101__20260331_zjT475ucOqx7" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001461" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,543,059</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Class A ordinary shares subject to possible redemption, March 31, 2026</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_c20260101__20260331_zXneNCCbjKKh" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001462" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,319,687</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 380; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><p id="xdx_232_z9jHxNfGyeMk" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>D. BORAL ARC ACQUISITION I CORP.</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zGrOztKwaYVc" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>NOTES TO THE CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zxqf3GJk9628" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zfpGVqnU9RX7" style="font: 10pt Times New Roman, Times, Serif;text-align: justify; margin-top: 0; margin-bottom: 0"><b>NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zZPunnU2SYCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>
</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001469" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zWhlay9HXAC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_866_zIRLAGvnsr1d">Net (Loss)/Income per Ordinary Share</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share.&#8221; Net income per share of ordinary shares is computed by dividing net income applicable to ordinary shareholders by the weighted average number of shares of ordinary shares outstanding during the period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The Company has not considered the effect of the Warrants sold in the Offering and Private Placement to purchase an aggregate of&#160;<span id="xdx_906_eus-gaap--WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_c20260101__20260331_zLwsCzFCHW3" title="Weighted average aggregate shares"><ix:nonFraction name="us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001471" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,100,000</ix:nonFraction></span>&#160;Class A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method and are contingent on future events. As a result, diluted income per share of Class A ordinary shares is the same as basic income per share of ordinary shares for the period presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The Company has two classes of ordinary shares,
which are referred to as Class A ordinary shares and Class B ordinary shares. Net income per share of ordinary shares is calculated by
dividing the net income by the weighted average number of shares of ordinary shares outstanding during the respective period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The following tables reflect the net (loss)/income
per share after allocating income between the shares based on outstanding shares:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001473" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z9nBryRVgBB1" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"><b><i><span id="xdx_8BC_zW0SKWND27gd" style="display: none">&#160;Schedule
    of earning per share basic and diluted</span></i></b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <br/>
Period from <br/>
March&#160;20, 2025
<br/>
(Inception) through <br/>
March&#160;31,<br/>
2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the<br/>
three months ended <br/>
March&#160;31, <br/>
2026</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class A</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class B</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class A</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class B</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerator:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net income per share:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation of (loss)/income &#150; basic and diluted</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zy8q1CRpivSl" title="Allocation of (loss)/income - basic"><span id="xdx_900_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z2LX5LzP7HYe" title="Allocation of (loss)/income - diluted"><span style="-sec-ix-hidden: xdx2ixbrl1475"><span style="-sec-ix-hidden: xdx2ixbrl1477">-</span></span></span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zaYIpma7fKI5" title="Allocation of (loss)/income - basic"><span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zUhkVNCQNGB4" title="Allocation of (loss)/income - diluted">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001479" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001481" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,420</ix:nonFraction></ix:nonFraction></span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0iSNiakF4xg" title="Allocation of (loss)/income - basic"><span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zFRQnvemDvP9" title="Allocation of (loss)/income - diluted"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001483" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001485" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,011,318</ix:nonFraction></ix:nonFraction></span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zTfMrVC9Nq08" title="Allocation of (loss)/income - basic"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwCyQpQUqFfg" title="Allocation of (loss)/income - diluted"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001487" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001489" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,011,318</ix:nonFraction></ix:nonFraction></span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominator:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted weighted average share of ordinary shares:</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zaCBbKkxOUll" title="Weighted average shares of Class A ordinary shares outstanding, basic"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zBiG6LXmLI06" title="Weighted average shares of Class A ordinary shares outstanding, diluted"><span style="-sec-ix-hidden: xdx2ixbrl1491"><span style="-sec-ix-hidden: xdx2ixbrl1493">-</span></span></span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwozb4274lpk" title="Weighted average shares of Class B ordinary shares outstanding, basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z4aO9n9RdMz2" title="Weighted average shares of Class B ordinary shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001495" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001497" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,714,286</ix:nonFraction></ix:nonFraction></span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zngzHuVdEMLb" title="Weighted average shares of Class A ordinary shares outstanding, basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z4D9HtOcAKq" title="Weighted average shares of Class A ordinary shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001499" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001501" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,200,000</ix:nonFraction></ix:nonFraction></span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMgqLWjjG1Ug" title="Weighted average shares of Class B ordinary shares outstanding, basic"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMDCWHjrReMl" title="Weighted average shares of Class B ordinary shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001503" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001505" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,000,000</ix:nonFraction></ix:nonFraction></span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net income per share</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z38VIFVXOnne" title="Class A ordinary shares - basic net income per share"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zzqpPBahwyhi" title="Class A ordinary shares - diluted net income per share"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001507" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001509" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></ix:nonFraction></span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0i8nL2oW9si" title="Class B ordinary shares - basic net income per share"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z3ekJQDEjG8d" title="Class B ordinary shares - diluted net income per share"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001511" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001513" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></ix:nonFraction></span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zEF9ZlGITAD2" title="Class A ordinary shares - basic net income per share"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zA6RCCMfP971" title="Class A ordinary shares - diluted net income per share"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001515" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001517" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.07</ix:nonFraction></ix:nonFraction></span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zIcku8QW2zV5" title="Class B ordinary shares - basic net income per share"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zBzYlBzAMw96" title="Class B ordinary shares - diluted net income per share"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001519" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001521" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.17</ix:nonFraction></ix:nonFraction></span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric></ix:nonNumeric><p id="xdx_8AC_zNWMKWxINBke" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001523" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zKmI21KJxxNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_864_zHGfCbGDFHJ">Concentration of credit risk</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Financial instruments that potentially subject
the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the
Federal depository insurance coverage of $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20260331_zpCvUwnIYIca" title="FDIC Insured Amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001525" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>.
At December&#160;31, 2025 and March&#160;31, 2026, the Company had not experienced losses on this account and management believes the
Company is not exposed to significant risks on such account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001527" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zCslz5Xo6Ob6" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_867_zDDHritlLFyi">Fair value of financial instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 381; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zBjSZwaXgwDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zUABnA6Gu3aa" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>D. BORAL ARC ACQUISITION I CORP.</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zipOQLWp9ZYd" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>NOTES TO THE CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zvId5buM8yZ" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_232_zxiC6ZpiJRue" style="font: 10pt Times New Roman, Times, Serif;text-align: justify; margin-top: 0; margin-bottom: 0"><b>NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_z4cnhm988G57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>
</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001535" name="cik0002065779:RisksAndUncertaintiesPolicyTextBlock"><p id="xdx_84D_ecustom--RisksAndUncertaintiesPolicyTextBlock_zrNJxHwjrMDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_869_zOCJzQXdOYs6">Risks and Uncertainties</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (&#8220;NATO&#8221;) deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Any of the above-mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely affect the Company&#8217;s search for an initial Business Combination and any target business with which the Company may ultimately consummate an initial Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001537" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z2mXSzfQOpif" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_861_zJiXM6UsbELc">Recent Accounting Pronouncements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">In November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires the disclosure of additional segment information. ASU No. 2023-07 is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted ASU 2023-07 as of the inception of the Company. Adoption of the ASU did not impact the Company&#8217;s financial position, results of operations or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">In December&#160;2023, the FASB issued ASU 2023-09, <i>Income taxes</i> (Topic 740): Improvements to Income Tax Disclosure (&#8220;ASU 2023-09&#8221;), which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 will be effective for fiscal years beginning after December&#160;15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company adopted ASU 2023-09 as of the inception of the Company. Adoption of the ASU did not impact the Company&#8217;s financial position, results of operations or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001539" name="cik0002065779:InitialPublicOfferingDisclosureTextBlock"><p id="xdx_800_ecustom--InitialPublicOfferingDisclosureTextBlock_zxUzX7SDLfn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 3. <span id="xdx_82D_zIv3avamgFu2">INITIAL PUBLIC OFFERING</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">On August&#160;1, 2025, the Company consummated its Initial Public Offering of <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_ziiKEuBh8qWg" title="Sale of units in initial public offering"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001541" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000,000</ix:nonFraction></span> Units, at $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z7BSNxGdjR2d" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001543" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per Unit, generating gross proceeds of $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z7xJdTWIQs8j" title="Sale of units in initial public offering aggragate amount"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001545" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000,000</ix:nonFraction></span>. The Company granted the underwriter a 45-day option to purchase up to an additional <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zi3AGJrNogke" title="Sale of units in initial public offering"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001547" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750,000</ix:nonFraction></span> Units at the Initial Public Offering price to cover over-allotments, if any. On August&#160;11, 2025, the underwriters of the IPO notified the Company of their partial exercise of the over-allotment option and purchased <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zaK7CJ35Z6P" title="Sale of units in initial public offering"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001549" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction></span> additional units (the &#8220;Option Units&#8221;) at $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zdx2OOuJjDy3" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001551" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per unit upon the closing of the over-allotment option, generating gross proceeds of $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zzL7qvdcW5v5" title="Sale of units in initial public offering aggragate amount"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001553" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,000,000</ix:nonFraction></span>. On September 9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option. Each Unit consists of one Ordinary Share and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zywvxCggRqMi" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001555" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.50</ix:nonFraction></span> per share, subject to adjustment.</p>

<ix:exclude><p id="xdx_234_zjshf9muwyt6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 382; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zYFrpIcqtomc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_z670A8tCWle" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>D. BORAL ARC ACQUISITION I CORP.</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zp20Y5UtrjEl" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>NOTES
            TO THE CONSOLIDATED CONDENSED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zunOJHR9AVAd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p></ix:exclude>
</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001562" name="cik0002065779:PrivatePlacementDisclosureTextBlock"><p id="xdx_801_ecustom--PrivatePlacementDisclosureTextBlock_zNIFkS0LzBs2" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 4. <span id="xdx_828_zdpqfBsTh2A9">PRIVATE PLACEMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zWpVriUo9y18" title="Sale of units in initial public offering"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001564" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> Private Units at a price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zF0n5WVwkcP5" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001566" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per Placement Unit raising $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zld7xUyBfm51" title="Sale of units in initial public offering aggragate amount"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001568" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></span> in the aggregate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The proceeds from the sale of the Private Units were added to the net proceeds from the Offering held in the Trust Account. The Placement Units are identical to the Units sold in the Initial Public Offering, as described in Note 7. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Warrants will expire worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001570" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_803_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zpNHGTe8sIDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 5. <span id="xdx_82C_z82mcy6I8tZ8">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>Founder Shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">On March&#160;25, 2025, the Company issued an aggregate
of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250301__20250325__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zMVgGcUrVxOe"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-03-012025-03-25_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001571" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,321,429</ix:nonFraction>
</span>founder shares to the Sponsor for an aggregate purchase price of $<span id="xdx_90F_eus-gaap--Cash_iI_c20250325__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_z6RLEudCp3Uj"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2025-03-25_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001572" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction>
</span>in cash. The funds were received on May&#160;27, 2025. Following the partial exercise of the over-allotment option on August 11,
2025, on September 9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option
and thereby forfeit the option. As a result, on September 9, 2025, the Company cancelled a total of <span id="xdx_909_ecustom--CancelledFounderShares_c20250905__20250909_zTcSZxGrsg3e" title="Cancelled founder shares"><ix:nonFraction name="cik0002065779:CancelledFounderShares" contextRef="From2025-09-052025-09-09_custom_DBoralARCAcquisitionICorpMember" id="Fact001574" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">321,429</ix:nonFraction>
</span>founder shares. As of March&#160;31, 2026, sponsor held a total of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zF5BsS2pB1Sd"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2026-01-012026-03-31_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001575" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,000,000</ix:nonFraction>
</span>founder shares and none was subject to forfeiture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The founder shares are designated as Class B
ordinary shares and, except as described below, are identical to the Class A ordinary shares included in the units being sold in the
IPO, and holders of founder shares have the same shareholder rights as public shareholders, except that (i) the founder shares are
subject to certain transfer restrictions, as described in more detail below, (ii) the founder shares are entitled to registration
rights; (iii) our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed
to (A) waive their redemption rights with respect to their founder shares, private shares and public shares in connection with the
completion of our initial business combination, (B) waive their redemption rights with respect to their founder shares, private
shares and public shares in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and
articles of association (a) to modify the substance or timing of our obligation to allow redemption in connection with our initial
business combination or to redeem <span id="xdx_90D_ecustom--PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination_dp_c20260101__20260331_zXCLnhDFZiBd" title="Percentage of redemption of public shares"><ix:nonFraction name="cik0002065779:PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001577" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">100</ix:nonFraction></span>%
of our public shares if we have not consummated an initial business combination within the completion window or (b) with respect to
any other material provisions relating to shareholders&#8217; rights or pre-initial business combination activity, (C) waive their
rights to liquidating distributions from the trust account with respect to their founder shares and private shares if we fail to
complete our initial business combination within the completion window, although they will be entitled to liquidating distributions
from the trust account with respect to any public shares they hold if we fail to complete our initial business combination within
such time period and to liquidating distributions from assets outside the trust account and (D) vote any founder shares held by them
and any public shares they may purchase (including in open market and privately-negotiated transactions) in favor of our initial
business combination (except that any public shares such parties may purchase in compliance with the requirements of Rule&#160;14e-5
under the Exchange Act would not be voted in favor of approving the business combination transaction), (iv) the founder shares are
automatically convertible into Class A ordinary shares concurrently with or immediately following the consummation of our initial
business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment as described herein and in
our amended and restated memorandum and articles of association, and (v) prior to the closing of our initial business combination,
only holders of our Class B ordinary shares will be entitled to vote on the appointment and removal of directors or continuing the
company in a jurisdiction outside the British Virgin Islands (including any ordinary resolution required to amend our constitutional
documents or to adopt new constitutional documents, in each case, as a result of our approving a transfer by way of continuation in
a jurisdiction outside the British Virgin Islands).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">With certain limited exceptions, the founder shares are not transferable, assignable or saleable (except to our officers and directors and other persons or entities affiliated with our sponsor, each of whom will be subject to the same transfer restrictions) until the completion of our initial business combination.</p>

<ix:exclude><p id="xdx_238_zs6ruwroUcZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 383; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23D_zoa76pjOFkOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p></ix:exclude>


<ix:exclude><p id="xdx_23E_zPXd7d5AWye6" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>D. BORAL ARC ACQUISITION I CORP.</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zuQO9UitCPo2" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>NOTES TO THE CONSOLIDATED CONDENSED
FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zfEVQqbitKGj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zjxzpdCXZWP4" style="font: 10pt Times New Roman, Times, Serif;text-align: justify; margin-top: 0; margin-bottom: 0"><b>NOTE 5. RELATED PARTY TRANSACTIONS
(Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zNybo09C4Oq5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>Administrative Services Arrangement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">An affiliate of our Sponsor has agreed, commencing
from the date that the Company&#8217;s securities are first listed on Nasdaq, through the earlier of the Company&#8217;s consummation
of a Business Combination and its liquidation, to make available to the Company our Sponsor certain office space, utilities and secretarial
and administrative support as may be reasonably required by the Company. The Company has agreed to pay to the affiliate of our Sponsor,
$<span id="xdx_90C_eus-gaap--PaymentsOfDistributionsToAffiliates_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zQldRVTZCDxg"><ix:nonFraction name="us-gaap:PaymentsOfDistributionsToAffiliates" contextRef="From2026-01-012026-03-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001585" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction>
</span>per month, for up to 18 months, subject to extension to up to 21 months, for such administrative services. For the three months ended March&#160;31, 2026, $<span id="xdx_908_eus-gaap--AdministrativeFeesExpense_c20260101__20260331_zjj5mvpwbgkc"><ix:nonFraction name="us-gaap:AdministrativeFeesExpense" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001586" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000</ix:nonFraction>
</span> was charged to operations and no amounts were outstanding at March 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>Related Party Loans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">In order to finance transaction costs in connection with a Business Combination, the Company&#8217;s Sponsor or an affiliate of the Sponsor, or the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). Up to $<span id="xdx_904_eus-gaap--DebtConversionOriginalDebtAmount1_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z58fA98SjFOl" title="Conversion of debt"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2026-01-012026-03-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction></span> of such loans may be convertible into private units, at a price of $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zuLJDC7MopX3" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2026-03-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001590" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per unit, at the option of the applicable lender. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of March&#160;31, 2026, no amounts under such loans have been drawn.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>Representative Shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">On August&#160;1, 2025, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z6QXz08pyPJ3" title="Number of share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001592" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span>
representative shares to D. Boral Capital, LLC and/or its designees (whether or not the over-allotment is exercised) as part of
representative compensation (the &#8220;Representative Shares&#8221;). The Representative Shares have been deemed compensation by
FINRA and are therefore subject to a lock-up for a period of 180 days immediately following the commencement of sales of the IPO
pursuant to FINRA Rule&#160;5110(e)(1). Pursuant to this FINRA lock-up, these securities cannot be sold, transferred, assigned,
pledged or hypothecated or the subject of any hedging, short sale, derivative, put or call transaction that would result in the
economic disposition of the securities by any person for a period of 180 days from the commencement of sales of the Initial Public
Offering except as permitted under FINRA Rule&#160;5110(e)(2), including to any underwriter and selected dealer participating in the
Initial Public Offering and their officers or partners, registered persons or affiliates. The Representative Shares have resale
registration rights including two demand (one at the Company&#8217;s expense and one at D. Boral Capital, LLC&#8217;s expense) and
unlimited &#8220;piggy-back&#8221; rights for periods of five and seven years, respectively, from the commencement of sales of the
Initial Public Offering.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001594" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z3K0SX2d4Sw9" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 6. <span id="xdx_82F_zdVOlujD2uBh">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>Registration Rights</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The holders of the (i) founder shares, which were issued in a private placement prior to the closing of the initial public offering, (ii) Private Units (including the component securities as well as any securities underlying those component securities), which was issued in a private placement simultaneously with the closing of the initial public offering and (iii) private units (including the component securities as well as any securities underlying those component securities) that may be issued upon conversion of working capital loans will have registration rights to require the Company to register a sale of any of our securities held by them and any other securities of the company acquired by them prior to the consummation of a Business Combination pursuant to a registration rights agreement to be signed prior to or on the effective date of the initial public offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of the Business Combination. The registration rights granted to the underwriter are limited to two demand (one at the Company&#8217;s expense and one at D. Boral Capital, LLC&#8217;s expense) and unlimited &#8220;piggy-back&#8221; rights for periods of five and seven years, respectively, from the commencement of sales of the Initial Public Offering. The Company will bear the expenses incurred in connection with the filing of any such registration statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 384; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23C_zWJOloIlWX67" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zujHrjWrPbp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p></ix:exclude>


<ix:exclude><p id="xdx_23F_z4FLJ5fCIAtj" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>D. BORAL ARC ACQUISITION I CORP.</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zLJ1g6LyYB3e" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>NOTES TO THE CONSOLIDATED CONDENSED
FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zZNxMHzEzUQh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zCXccR4X84f5" style="font: 10pt Times New Roman, Times, Serif;text-align: justify; margin-top: 0; margin-bottom: 0"><b>NOTE 6. COMMITMENTS AND CONTINGENCIES (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_232_zL9C66rSgCd8" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p></ix:exclude>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>Underwriting Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company has granted the underwriters a 45-day option to purchase up to <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zjtEhPvhMXQe" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2026-01-012026-03-31_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001603" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750,000</ix:nonFraction></span> additional Units to cover over-allotments at the Initial Public Offering price, less the underwriting discounts and commissions. On August 11, 2025, the underwriters of the IPO notified the Company of their partial exercise of the over-allotment option and purchased <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zR7wbwMpc9wh" title="Sale of units in initial public offering"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001605" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction></span> additional units (the &#8220;Option Units&#8221;) at $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zGqMeTvcqykf" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001607" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per unit upon the closing of the over-allotment option, generating gross proceeds of $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zbSfvKxgSk01" title="Sale of units in initial public offering aggragate amount"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001609" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,000,000</ix:nonFraction></span>. On September 9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The underwriters were not entitled to any cash underwriting fee at closing of the Initial Public Offering. The underwriters were entitled to <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zFQcKs3SbWef" title="Number of share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2026-01-012026-03-31_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001611" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> Representative Shares (whether or not the over-allotment is exercised) at closing of the Initial Public Offering. The underwriters will not be entitled to any deferred underwriting fee upon closing of the Business Combination.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001613" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwhUP6jv9mqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 7. <span id="xdx_823_zaILIlDlzmsc">STOCKHOLDER&#8217;S EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><i>Preference shares</i> &#8212; The Company is
authorized to issue <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331_zFMVgjM8NmY9" title="Preferred stock, shares authorized"><span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_c20251231_z0Jl6MArvzB9" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001615" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001617" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span>
preference shares with a par value of $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260331_zAytd7i2p886" title="Preferred stock, par value"><span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_c20251231_zfL19UEBgrDa" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001619" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001621" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>
per share. Holders of the Company&#8217;s ordinary shares are entitled to one vote for each share. On December&#160;31, 2025 and
March&#160;31, 2026, there were <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_do_c20260331_zroPfs1eRoNk" title="Preferred stock, shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20260331_z9d8GSit2B5" title="Preferred stock, shares outstanding"><span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_do_c20251231_zMEOzupxxnI8" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20251231_zyzADJxkUXd2" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001623" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001625" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001627" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001629" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span>
preferred shares issued or outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><i>Class A Ordinary shares</i> &#8212; The
Company is authorized to issue <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zKveQpajq4V5"><span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zskfIMqX190e"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001630" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001631" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000,000</ix:nonFraction></ix:nonFraction></span> </span>ordinary
shares with a par value of $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zdRFWPvGhFOd"><span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zjY855rQwcpd"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001632" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001633" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span> </span>per
share. Holders of the Company&#8217;s ordinary shares are entitled to one vote for each share. As a result of closing of the IPO and
the partial exercise of the over-allotment option partial exercise of the over-allotment option, on December&#160;31, 2025 and March&#160;31,
2026, there were <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zxB3PXFsHCU5"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zsLdgforxL9e"><span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zxt2nAqbsMr9"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_z4vLyiaVVyR6"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001634" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001635" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001636" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001637" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,200,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span> </span>Class
A ordinary shares issued or outstanding, excluding <span id="xdx_904_ecustom--OrdinarySharesSubjectToPossibleRedemption_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinaryShareMember_zMl1aYF2ihsk"><span id="xdx_90C_ecustom--OrdinarySharesSubjectToPossibleRedemption_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zVJMl0G8IzV"><ix:nonFraction name="cik0002065779:OrdinarySharesSubjectToPossibleRedemption" contextRef="AsOf2025-12-31_custom_ClassAOrdinaryShareMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001638" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="cik0002065779:OrdinarySharesSubjectToPossibleRedemption" contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001639" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,000,000</ix:nonFraction></ix:nonFraction></span> </span>Class
A ordinary shares subject to possible redemption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><i>Class B Ordinary shares</i> &#8212; The
Company is authorized to issue <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zXVGRwMjVDql"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zMMZnne8IkL6"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001640" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001641" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></ix:nonFraction></span> </span>ordinary
shares with a par value of $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_ztG2sNw8sNFl"><span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zED6jktrmjAl"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001642" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001643" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span> </span>per
share. Holders of the Company&#8217;s ordinary shares are entitled to one vote for each share. On March&#160;25, 2025, the Company
issued an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250301__20250325__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zRVwJpN6yZVk"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-03-012025-03-25_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001644" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,321,429</ix:nonFraction> </span>ordinary
shares to the Sponsor for an aggregate purchase price of $<span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20250325_zAFxq56sMRg6"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-03-25_custom_DBoralARCAcquisitionICorpMember" id="Fact001645" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction> </span>in
cash, of which <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20250301__20250325__us-gaap--StatementEquityComponentsAxis__custom--ClassAOrdinarySharesMember_znPFdJkwaY27"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2025-03-012025-03-25_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001646" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,607,143</ix:nonFraction> </span>shares
held by the Sponsor are subject to forfeiture to the extent that the underwriter&#8217;s over-allotment option is not exercised in
full. Following the partial exercise of the over-allotment option on August 11, 2025 and cancellation <span id="xdx_901_ecustom--CancellationOfOrdinaryShares_iI_c20250811_zKYsRghvexAh" title="Cancellation of ordinary shares"><ix:nonFraction name="cik0002065779:CancellationOfOrdinaryShares" contextRef="AsOf2025-08-11_custom_DBoralARCAcquisitionICorpMember" id="Fact001648" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">321,429</ix:nonFraction></span>
ordinary shares on September 9, 2025, on December&#160;31, 2025 and March&#160;31, 2026, there were <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zKBpaz3TRFH" title="Common stock, shares issued"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zIOANVibuum3" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001650" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001652" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,000,000</ix:nonFraction></ix:nonFraction></span></span>
ordinary <span style="display: none">12,300,000</span>shares issued and outstanding.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of our initial business combination, or at any time prior thereto at the option of the holder thereof, on a one-for-one basis, subject to adjustment as provided herein. Because our sponsor acquired the Class B ordinary shares at a nominal price, our public shareholders will incur an immediate and substantial dilution upon the closing of the IPO, assuming no value is ascribed to the warrants included in the units. In the case that additional Class A ordinary shares, or equity-linked securities (as described herein), are issued or deemed issued in excess of the amounts issued in the IPO and related to the closing of our initial business combination, the ratio at which the Class B ordinary shares will convert into Class A ordinary shares will be adjusted (unless the holders of a majority of the issued and outstanding Class B ordinary shares agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance) so that the number of Class A ordinary shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, <span id="xdx_909_ecustom--PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion_iI_dp_c20260331__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--ConversionOfClassBToClassACommonStockMember_zszikt6CRcY8" title="Percentage of total number of ordinary shares"><ix:nonFraction name="cik0002065779:PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion" contextRef="AsOf2026-03-31_custom_ConversionOfClassBToClassACommonStockMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001654" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">30</ix:nonFraction></span>% of the sum of (i) the total number of all Class A ordinary shares outstanding upon the completion of the IPO (including any Class A ordinary shares issued pursuant to the underwriters&#8217; over-allotment option and excluding the Class A ordinary shares that are included within the private units), plus (ii) all Class A ordinary shares and equity-linked securities issued or deemed issued, in connection with the closing of the initial business combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the initial business combination and any units issued to our sponsor or any of its affiliates or to our officers or directors upon conversion of working capital loans) minus (iii) any redemptions of Class A ordinary shares by public shareholders in connection with an initial business combination; provided that such conversion of founder shares will never occur on a less than <span id="xdx_903_eus-gaap--CommonStockConversionBasis_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--CommonStockClassBMember_zkHKuUlOOCQg" title="Conversion basis"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_CommonStockClassBMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001656" name="us-gaap:CommonStockConversionBasis">one-for-one basis</ix:nonNumeric></span>.</p>
<ix:exclude><p id="xdx_23F_z8NRPeiuS9rc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 385; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_238_z8q9GugUzrl9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_235_zLixRLHoZMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p></ix:exclude>


<ix:exclude><p id="xdx_23A_zodaMMaZfPx2" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>D. BORAL ARC ACQUISITION I CORP.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_z4NfIXA6VXO5" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>NOTES TO THE CONSOLIDATED CONDENSED
FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zleItG6LFRpb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zaGNRHn0ov23" style="font: 10pt Times New Roman, Times, Serif;text-align: justify; margin-top: 0; margin-bottom: 0"><b>NOTE 7. STOCKHOLDER&#8217;S EQUITY (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Holders of record of the Company&#8217;s Class A ordinary shares and Class B ordinary shares are entitled to one vote for each share held on all matters to be voted on by shareholders. Unless specified in the amended and restated memorandum and articles of association or as required by the Companies Act or stock exchange rules, an ordinary resolution under British Virgin Islands law and the amended and restated memorandum and articles of association, which requires the affirmative vote of at least a majority of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the company is generally required to approve any matter voted on by the Company&#8217;s shareholders. Approval of certain actions require an ordinary resolution under British Virgin Islands law, which (except as specified below) requires the affirmative vote of in excess of 50 percent of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting, and pursuant to the Company&#8217;s amended and restated memorandum and articles of association, such actions include amending the amended and restated memorandum and articles of association and approving a statutory merger or consolidation with another company. There is no cumulative voting with respect to the appointment of directors, meaning, following the Company&#8217;s initial Business Combination, the holders of more than 50% of the ordinary shares voted for the appointment of directors can elect all of the directors. Prior to the consummation of the initial Business Combination, only holders of the Class B ordinary shares will (i) have the right to vote on the appointment and removal of directors and (ii) be entitled to vote on continuing the Company in a jurisdiction outside the British Virgin Islands (including any ordinary resolution required to amend the constitutional documents or to adopt new constitutional documents, in each case, as a result of approving a transfer by way of continuation in a jurisdiction outside the British Virgin Islands). Holders of the Class A ordinary shares will not be entitled to vote on these matters during such time. These provisions of our amended and restated memorandum and articles of association may only be amended if approved by an ordinary resolution passed by the affirmative vote of the holders representing at least 90% of the issued Class B ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><i>Warrants &#8212; </i>Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Warrants. The Warrants will become exercisable <span id="xdx_90C_ecustom--PeriodAfterWhichTheWarrantsAreExercisable_dtD_c20260101__20260331_zWeApScMc3eb" title="Period of warrants exercisable"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" format="ixt-sec:durday" id="Fact001665" name="cik0002065779:PeriodAfterWhichTheWarrantsAreExercisable">30</ix:nonNumeric></span> days after the completion of our initial business combination, provided that the Company has an effective registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or we permit holders to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement). If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th business day after the closing of our initial business combination, warrant holders may, until such time as there is an effective registration statement and during any period when we will have failed to maintain an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if our Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1) of the Securities Act, we may, at our option, require holders of public warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event we so elect, we will not be required to file or maintain in effect a registration statement. The Warrants will expire five years from the consummation of a Business Combination or earlier upon redemption or liquidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company may call the Warrants for redemption:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif;width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">in whole and not in part;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif;width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">at a price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zoNP9mOnjT3c" title="Warrant price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_WarrantsMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001667" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per warrant; upon a minimum of <span id="xdx_90D_ecustom--MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants_dtD_c20260101__20260331_zOnTLMGfRTZ7" title="Holders of warrants"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" format="ixt-sec:durday" id="Fact001669" name="cik0002065779:MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants">30</ix:nonNumeric></span> days&#8217; prior written notice of redemption (the &#8220;30-day redemption period&#8221;); and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif;width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">if, and only if, the closing price of the Class A ordinary shares equals or exceeds $<span id="xdx_909_eus-gaap--SharePrice_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zJ9mqOJX3QCl" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember" id="Fact001671" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.00</ix:nonFraction></span> per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant) for any <span id="xdx_900_ecustom--NumberOfTradingDaysForDeterminingTheSharePrice_dtD_c20260101__20260331_zvrNRerpdBn3" title="Number of trading days"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" format="ixt-sec:durday" id="Fact001673" name="cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice">20</ix:nonNumeric></span> trading days within a <span id="xdx_906_ecustom--NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_dtD_c20260101__20260331_zwbDb1yUTWP9" title="Number of consecutive trading days"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" format="ixt-sec:durday" id="Fact001675" name="cik0002065779:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice">30</ix:nonNumeric></span>-trading day period commencing at least 30 days after completion of our initial business combination and ending three business days before we send the notice of redemption to the warrant holders.</td> </tr>
  </table>
<ix:exclude><p id="xdx_23E_z0SQIN9JOGle" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 386; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>


<ix:exclude><p id="xdx_233_z6WHXj8QLdKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>








<ix:exclude><p id="xdx_239_zNuCgab2tFek" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>D. BORAL ARC ACQUISITION I CORP.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zFydLyYW8uPh" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>NOTES TO THE CONSOLIDATED CONDENSED
FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zqVVGGDE8qXd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zlk8f0t0R9j5" style="font: 10pt Times New Roman, Times, Serif;text-align: justify; margin-top: 0; margin-bottom: 0"><b>NOTE 7. STOCKHOLDER&#8217;S EQUITY (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The private warrants are identical to the warrants sold in the IPO except that, so long as they are held by our sponsor or its permitted transferees, the private warrants (i) are locked-up until the completion of our initial business combination and (ii) will be entitled to registration rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The exercise price is $11.50 per share, subject to adjustment as described herein. In addition, if (x) we issue additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price to be determined in good faith by our board of directors and, in the case of any such issuance to our initial shareholders or their affiliates, without taking into account any founder shares held by our initial shareholders or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination on the date of the consummation of our initial business combination (net of redemptions), and (z) the volume weighted average trading price of our Class A ordinary shares during the <span id="xdx_905_ecustom--NumberOfTradingDaysForDeterminingTheSharePrice_dtD_c20260101__20260331_zc5q1DDThXIl" title="Number of trading days"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" format="ixt-sec:durday" id="Fact001683" name="cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice">20</ix:nonNumeric></span> trading day period starting on the trading day prior to the day on which we consummate our initial business combination (such price, the &#8220;Market Value&#8221;) is below $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331_zs54CHaUkD4i" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001685" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.20</ix:nonFraction></span> per share, then the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to <span id="xdx_904_eus-gaap--AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate_iI_dp_c20260331_zv6Vv7qifSKb" title="Market value"><ix:nonFraction name="us-gaap:AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001687" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">115</ix:nonFraction></span>% of the higher of the Market Value and the Newly Issued Price, and the $<span id="xdx_90C_eus-gaap--PreferredStockRedemptionPricePerShare_iI_c20260331_zBQoRodwKOZj" title="Redemption price"><ix:nonFraction name="us-gaap:PreferredStockRedemptionPricePerShare" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001689" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.00</ix:nonFraction></span> per share redemption trigger prices will be adjusted (to the nearest cent) to be equal to <span id="xdx_900_ecustom--ShareRedemptionTriggerPrices_iI_dp_c20260331_zxXMTxXeNMw5" title="Share redemption trigger prices"><ix:nonFraction name="cik0002065779:ShareRedemptionTriggerPrices" contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001691" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">180</ix:nonFraction></span>% of the higher of the Market Value and the Newly Issued Price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001693" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_805_eus-gaap--FairValueDisclosuresTextBlock_zgzIFlKymks6" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 8. <span id="xdx_822_zoFua9dYO0U2">FAIR VALUE MEASUREMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in;text-align: justify">Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in;text-align: justify">Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in;text-align: justify">Level 3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</p>



<ix:exclude><p id="xdx_235_zXJIMEYlk8S7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The following table presents information about
the Company&#8217;s assets that are measured at fair value as of March 31, 2026 and December&#160;31, 2025, and indicates the fair
value hierarchy of the valuation inputs the Company utilized to determine such fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001696" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zn8oEnihuBh3" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B4_zvKnFHZJudo8" style="display: none">Schedule of fair value assets and liabilities</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March&#160;31,<br/>
    2026</b></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Asset:</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Cash held in trust</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center">1</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zC6ecbqmxuZ2" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember" id="Fact001697" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">284,776,628</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2BhS1HcIrvl" style="text-align: right; width: 9%"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember" id="Fact001698" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">287,319,687</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zgzxRXAizoPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 387; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zPIpdbWLBg63" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>








<ix:exclude><p id="xdx_230_zcRwZCPN4cWa" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>D. BORAL ARC ACQUISITION I CORP.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zvMseIF58Oik" style="font: 10pt Times New Roman, Times, Serif;text-align: center; margin-top: 0; margin-bottom: 0"><b>NOTES TO THE CONSOLIDATED CONDENSED
FINANCIAL STATEMENTS</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001703" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_803_eus-gaap--SegmentReportingDisclosureTextBlock_zwZU5ZaBhVlh" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 9. <span>SEGMENT INFORMATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_822_zUpXgs0k561c" style="display: none">Segment information</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">ASC Topic 280, &#8220;Segment Reporting,&#8221; establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated by the Company&#8217;s chief operating decision maker, or group, in deciding how to allocate resources and assess performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company&#8217;s chief operating decision maker has been identified as the Chief Financial Officer (&#8220;CODM&#8221;), who reviews the operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one operating segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">When evaluating the Company&#8217;s performance and making key decisions regarding resource allocation the CODM reviews several key metrics, which include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001705" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z8FE3uJgARte" summary="xdx: Disclosure - Segment information (Details)" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8BC_zLnzHUlq4rs8" style="display: none">Schedule of segment information</span></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_499_20260101__20260331_zAqMewnjj797" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>For the<br/>
Three Months Ended<br/> March&#160;31,<br/>
2026</b></p></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpenses_iNT_di_zLbGcDlF4Xxk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left">Formation and operating costs</td>
    <td style="padding-bottom: 2.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001707" format="ixt:numdotdecimal" decimals="0" unitRef="USD">531,741</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--InterestIncomeOther_zZ0f6IcMo791" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 2.5pt">Interest income on cash held in trust account</td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001709" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,543,059</ix:nonFraction></td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--CashHeldInTrustAccounts_zt3sLmGGM7pf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Cash held in Trust Account</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="cik0002065779:CashHeldInTrustAccounts" contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" id="Fact001711" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,319,687</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zWjH3W0mD6S6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The key measures of segment profit or loss reviewed
by the CODM are formation and operating costs, interest income on cash held in trust account, and cash held in trust account. The CODM
reviews interest earned on cash or investments held in Trust Account to measure and monitor shareholder value and determine the most effective
strategy of investment with the Trust Account funds while maintaining compliance with the trust agreement. Within the operating expenses,
the CODM specifically reviews professional service fees, which are a significant segment expense, and include legal fees and advisory
fees. These expenses are monitored to manage and forecast cash available to complete a Business Combination within the required period.
Other general and administrative expenses, including accounting expenses, printing expenses, and regulatory filing fees, are reviewed
in the aggregate to ensure alignment with budget and contractual obligations. Funds invested in the Trust Account represent the predominant
portion of the Company&#8217;s total assets and are monitored by the CODM to determine the most effective strategy of investment with
the Trust Account funds, while maintaining compliance with the trust agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember" escape="true" id="Fact001713" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zi2Xqda1MaI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 10. <span>SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_829_zMAhencS9Vr8" style="display: none">Subsequent Events</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">In accordance with ASC Topic 855, &#8220;Subsequent Events&#8221;, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued, the Company has evaluated all events or transactions that occurred through the date the consolidated condensed financial statements were available to issue. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.</p>

</ix:nonNumeric><p id="xdx_810_zY8Lv7j4Evq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 388; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->
<p id="xdx_810_z8zGqzxoFRh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="fin1_001"></span>REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">To the Board of Directors and Stockholders of<br/>Exascale
Labs Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Opinion on the Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying balance sheets of
Exascale Labs Inc. (the &#8220;Company&#8221;) as of June&#160;30, 2024 and 2025, and the related statements of operations and comprehensive
loss, changes in shareholders&#8217; deficit, and cash flows for each of the years in the two-year period ended June&#160;30, 2025, and
the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in
all material respects, the financial position of the Company as of June 30, 2024 and 2025, and the results of its operations and its cash
flows for each of the years in the two-year period ended June&#160;30, 2025, in accordance with accounting principles generally accepted
in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements have been prepared
assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered
recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going
concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The financial statements do not include any
adjustments that might result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis for Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal
control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal
control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ HTL International, LLC</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have served as the Company&#8217;s auditor since
2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Houston, Texas</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">February&#160;11, 2026</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 389; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p id="xdx_110_hdei--LegalEntityAxis__custom--ExascaleLabsIncMember_zx6558tz4yAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="fin1_002"></span>EXASCALE LABS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BALANCE SHEETS AS OF JUNE 30, 2024 AND 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(All amounts in US$, except for number of shares)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_309_111_zI44PvXRuEqe" summary="xdx: Statement - BALANCE SHEET" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_49D_20240630_zOiE2oBGh5cl" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_495_20250630_z83j6pDvbook" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As of<br/> June&#160;30,</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsAbstract_iB_zKbpgkXuXXs3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">ASSETS</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsCurrentAbstract_i01B_zVjCDdzn475e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current
        Assets</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCztLZ_zsGQfBIcY8a8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Cash
        and cash equivalents</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001721" format="ixt:numdotdecimal" decimals="0" unitRef="USD">969,626</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001722" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,231,689</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsAndOtherReceivablesNetCurrent_iIP3us-gaap--CashAndCashEquivalentsAtCarryingValue_maCztLZ_maCze5E_z0fgqxMzzm4l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accounts
        receivable, net</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001724" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,332</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001725" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,536</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AdvanceToSuppliers_iIP3us-gaap--AccountsAndOtherReceivablesNetCurrent_maCztLZ_maCze5E_zar38DaTzr7a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Advance
        to suppliers</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cik0002065779:AdvanceToSuppliers" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001727" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,497</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cik0002065779:AdvanceToSuppliers" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001728" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,030,761</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--RefundableDepositsReceivable_iIP3custom--AdvanceToSuppliers_maCztLZ_maCze5E_zh359zjH7sii" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Refundable
        deposits receivable</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cik0002065779:RefundableDepositsReceivable" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001730" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,000</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cik0002065779:RefundableDepositsReceivable" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001731" format="ixt:numdotdecimal" decimals="0" unitRef="USD">681,125</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherReceivablesNetCurrent_iIP3custom--RefundableDepositsReceivable_maCztLZ_maCze5E_zDSTxImc3mmg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Other
        receivables</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001733" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,884,694</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001734" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,207,626</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrent_i01TI_mtCztLZ_maCzqyV_zctBDPhx1Se2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Total
        Current Assets</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001736" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,368,149</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001737" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,303,737</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsNoncurrentAbstract_iBP3us-gaap--AssetsCurrent_zBn6jw9LeR9g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-Current
        Assets</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_iIP3us-gaap--AssetsNoncurrentAbstract_maCzORO_zc9rGmzhkZJl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Equipment,
        net</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001742" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,696</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001743" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,600</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsNoncurrent_iTIP3us-gaap--PropertyPlantAndEquipmentNet_mtCzORO_maCzqyV_maCz4fI_zAA042axlUD6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Total
        Non-Current Assets</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001745" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,696</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001746" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,600</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Assets_iTI_mtCzqyV_zqvuHxlgFyHf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total
        Assets</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001748" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,391,845</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001749" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,323,337</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z7WXlwlK2iZi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">LIABILITIES
        AND SHAREHOLDERS&#8217; DEFICIT</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrentAbstract_i01B_z4rhNg2zw1yi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current
        Liabilities</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_iIP3us-gaap--AccruedLiabilitiesCurrent_maCzXIS_maCzsob_zFkMm5tchR09" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accounts
        payable</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001757" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,040</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001758" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,015</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--SimpleAgreementsForFutureEquity_iIP3us-gaap--AccountsPayableCurrent_maCzXIS_maCzsob_z2O1LeSlvGli" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Simple
        agreements for future equity</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cik0002065779:SimpleAgreementsForFutureEquity" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001760" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,321,564</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cik0002065779:SimpleAgreementsForFutureEquity" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001761" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,243,885</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DepositContractsLiabilities_iIP3custom--SimpleAgreementsForFutureEquity_maCzXIS_maCzsob_zUwp7z8Cml18" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Contract
        liabilities</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepositContractsLiabilities" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001763" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,326</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepositContractsLiabilities" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001764" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,760</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--RefundableDepositsPayable_iIP3us-gaap--DepositContractsLiabilities_maCzXIS_maCzsob_zfehsPxIBOkj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Refundable
        deposits payable</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cik0002065779:RefundableDepositsPayable" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001766" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,205</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cik0002065779:RefundableDepositsPayable" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001767" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,445,580</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--OtherCurrentLiabilities_iIP3custom--RefundableDepositsPayable_maCzXIS_maCzsob_znbGuGCGQc65" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Other
        current liabilities</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cik0002065779:OtherCurrentLiabilities" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001769" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113,693</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cik0002065779:OtherCurrentLiabilities" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001770" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,481</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrent_i01TI_mtCzXIS_maCzIBD_zg53s8EFofI3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Total
        Current Liabilities</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001772" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,881,828</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001773" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,319,721</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Liabilities_iTI_mtCzIBD_maLASEzaeS_zE7F59SRMbT3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Total
        Liabilities</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001775" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,881,828</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001776" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,319,721</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CommitmentsAndContingencies_iI_zPqVZnzMVCvf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Commitments
        and contingencies (Note 15)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquityAbstract_iB_zCYC7qkrf2Tc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shareholders&#8217;
        Deficit</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_iI_maCz6KD_zJdDBGuVhDpd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Ordinary
        shares (US$<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240630_znoknIIyBbyg" title="Common stock, par value"><span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250630_zEysH2fLxS3b" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001787" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001789" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value per share; <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20240630_z5Gu8B36eagf" title="Common stock, shares authorized"><span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20250630_zsdTFCoAqKBh" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001791" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001793" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20240630_zetrXnAvhGC9" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20240630_zV9MmbfD6yHb" title="Common stock, shares outstanding"><span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20250630_zo975oGMprSd" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20250630_zTaHzR8OxkO" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001795" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001797" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001799" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001801" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of June&#160;30, 2024 and 2025)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001784" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001785" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AdditionalPaidInCapital_iI_maCz6KD_zWw6rtSB4NO6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Additional
        paid-in capital</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001803" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,370</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001804" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,636</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maCz6KD_zKIDe0RKR1Cd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Accumulated
        deficit</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001806" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,557,368</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001807" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,217,035</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--StockholdersEquity_iTI_pp0d_mtCz6KD_maLASEzaeS_z4F561MFOQMf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Total
        Shareholders&#8217; Deficit</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001809" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,489,983</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001810" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,996,384</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_pp0d_mtLASEzaeS_z9fUR9zQ8Lyc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total
        Liabilities and Shareholders&#8217; Deficit</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001812" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,391,845</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001813" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,323,337</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 390; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="fin1_003"></span>EXASCALE LABS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FOR THE YEARS ENDED JUNE 30, 2024 AND 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(All amounts in US$, except for number of shares
and per share data)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_307_113_ze9uUmgJEiP9" summary="xdx: Statement - STATEMENT OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_49D_20230701__20240630_zgTq2I6fIBXh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_491_20240701__20250630_zTAYUCFl3Tm9" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the<br/>years
        ended<br/>June&#160;30,</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Revenues_iP2us-gaap--OperatingExpenses_maCzkIy_zZX48WUInzxl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Revenues</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001815" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,319,115</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001816" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,015,512</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CostOfRevenue_iP3us-gaap--RevenuesAbstract_msCzkIy_ziNz1rsmpI2f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Cost
        of revenues</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001818" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,263,548</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001819" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,910,315</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--GrossProfit_iTP3us-gaap--CostOfRevenue_mtCzkIy_maCzd9U_zZLVkfydXqb3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Gross
        profit</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001821" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,567</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001822" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,105,197</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingExpensesAbstract_iBP3us-gaap--GrossProfit_z1hqqYxB1wT7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Operating
        expenses</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--SellingAndMarketingExpense_iNP3us-gaap--OperatingExpensesAbstract_di_maCzwMx_zZmQ5rpypDQ1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Selling
        and marketing expenses</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001827" format="ixt:numdotdecimal" decimals="0" unitRef="USD">262,614</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001828" format="ixt:numdotdecimal" decimals="0" unitRef="USD">989,155</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_iNP3us-gaap--SellingAndMarketingExpense_di_maCzwMx_zYhNISSZPuta" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">General
        and administrative expenses</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001830" format="ixt:numdotdecimal" decimals="0" unitRef="USD">273,349</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">362,982</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_iNP3us-gaap--GeneralAndAdministrativeExpense_di_maCzwMx_zspABovx9EDa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Research
        and development expenses</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001833" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,365,433</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001834" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,797,906</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpenses_i02NT_di_mtCzwMx_msCzd9U_zwy7686LD2Ci" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Total
        operating expenses</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001836" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,901,396</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001837" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,150,043</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingIncomeLoss_iT_mtCzd9U_maCzcCH_z1ZGvuwIvDU" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Loss
        from operations</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001839" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,845,829</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001840" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,044,846</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--ChangeInFairValueOfSimpleAgreementsForFutureEquity_iNP3us-gaap--OperatingIncomeLoss_di_msCzcCH_msCzvaM_zTIWIsKWVral" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Change
        in fair value of simple agreements for future equity</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001842" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,110,518</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001843" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,614,821</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzcCH_maCz6iE_zXA55mQQ7nM4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Loss
        before income tax expenses</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001845" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,956,347</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001846" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,659,667</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_msCz6iE_zxR3MHcpAp29" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Income
        tax expenses</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1848">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1849">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_iT_mtCz6iE_zVupl3ANpNWe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net
        loss and total comprehensive loss</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001851" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,956,347</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001852" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,659,667</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--LossPerOrdinaryShareAbstarct_iP2us-gaap--EarningsPerShareBasic_zqRTibzp9ta" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Loss
        per ordinary share</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Basic
        and diluted</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230701__20240630_pd" title="Basic Loss per ordinary share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20230701__20240630_pd" title="Diluted Loss per ordinary share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001857" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001859" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">3,304.23</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_c20240701__20250630_pd" title="Basic Loss per ordinary share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20240701__20250630_pd" title="Diluted Loss per ordinary share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001861" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001863" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">5,106.44</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iBP2us-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zyFEpbkpy9Nk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted
        average number of per ordinary shares</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Basic
        and diluted</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230701__20240630_pd" title="Weighted average number of per ordinary shares Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230701__20240630_zeo3lVdkawH9" title="Weighted average number of per ordinary shares Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001868" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001870" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20250630_pd" title="Weighted average number of per ordinary shares Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20250630_zoNPELgqmLO2" title="Weighted average number of per ordinary shares Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001872" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001874" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 391; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="fin1_004"></span>EXASCALE LABS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; DEFICIT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FOR THE YEARS ENDED JUNE 30, 2024 AND 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(All amounts in US$, except for number of shares)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_113_zuOB0OToEWN4" summary="xdx: Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_custom--OrdinarySharesMember_z9TwlvcqrEEc" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zXcqVAI5f3cf" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zYrVHZNP3Cc9" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_4BC_zeuQdfEKxh5b" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Ordinary shares</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Additional<br/>paid-in</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Accumulated</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total<br/>shareholders&#8217;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">capital</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">deficit</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">deficit</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_43A_c20230701__20240630_eus-gaap--StockholdersEquity_iS_zOSTkoHZleOe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 40%; text-align: left; padding-bottom: 1pt">Balance
        as of June&#160;30, 2023</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpQKo7azDZv8" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact001881" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact001876" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="Fact001877" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,266</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="Fact001878" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">601,021</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_custom_ExascaleLabsIncMember" id="Fact001879" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">554,740</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProfitLoss_i_pp0p" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net
        loss</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1883">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1884">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="Fact001885" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,956,347</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001886" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,956,347</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensation_i_pp0p" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Share-based
        compensation</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1888">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="Fact001889" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,104</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1890">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001891" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,104</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20240701__20250630_eus-gaap--StockholdersEquity_iS_zGZqCx9iFv2k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Balance
        as of June&#160;30, 2024</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLpMXicZbar" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact001898" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact001893" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="Fact001894" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,370</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="Fact001895" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,557,368</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001896" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,489,983</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProfitLoss_zthuetvOglrh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net
        loss</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1900">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1901">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="Fact001902" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,659,667</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001903" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,659,667</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_zRFOFKcyRgkb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Share-based
        compensation</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1905">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="Fact001906" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,266</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1907">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001908" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,266</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20240701__20250630_eus-gaap--StockholdersEquity_iE_zWlPmJyQ029d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Balance
        as of June&#160;30, 2025</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--SharesOutstanding_iE_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcAoyYsMuiCd" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact001915" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact001910" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="Fact001911" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,636</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="Fact001912" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,217,035</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001913" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,996,384</ix:nonFraction></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 392; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="fin1_005"></span>EXASCALE LABS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENTS OF CASH FLOWS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FOR THE YEARS ENDED JUNE 30, 2024 AND 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(All amounts in US$)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_112_zMQBQGDp7d45" summary="xdx: Statement - STATEMENT OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_49B_20230701__20240630_zZuj1To3WVO4" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_495_20240701__20250630_zhRbG2FuSjCb" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/>years ended<br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zuB4PwpXU39g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash flows from operating
        activities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_i01_maCzIwo_zWOCwf820Hya" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold; text-align: left">Net loss</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001920" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,956,347</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001921" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,659,667</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_z7mXoSBAcMki" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Adjustments to reconcile
        net loss to net cash used in operating activities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Depreciation_iP2us-gaap--IncreaseDecreaseInOperatingCapitalAbstract_maCzIwo_maCz7uv_zO81XGDLEUIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Depreciation of equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001926" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,110</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001927" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,234</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_iP3us-gaap--Depreciation_maCzIwo_maCz7uv_zduCJIBzecqk" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share-based compensation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001929" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,104</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001930" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,266</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--ChangeInFairValueOfSimpleAgreementsForFutureEquities_iP3us-gaap--EmployeeBenefitsAndShareBasedCompensation_maCzIwo_maCz7uv_zA8U7QDchvZk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Change in fair value of simple agreements
        for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001932" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,110,518</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001933" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,614,821</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_iB_zJlmlsFvIfEj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Changes in operating assets
        and liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInAccountsReceivable_iNP3us-gaap--IncreaseDecreaseInPrepaidExpense_di_msCzIwo_msCz7uv_zKXBbOx9ouR3" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accounts receivable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001938" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,332</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001939" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,204</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--IncreaseDecreaseInAdvanceToSuppliers_iNP3us-gaap--IncreaseDecreaseInAccountsReceivable_di_msCz7uv_zyuo6IaKnsH7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Advance to suppliers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:IncreaseDecreaseInAdvanceToSuppliers" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001941" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,497</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:IncreaseDecreaseInAdvanceToSuppliers" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001942" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,264</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--IncreaseDecreaseInRefundableDepositsReceivable_iNP3custom--IncreaseDecreaseInAdvanceToSuppliers_di_msCz7uv_z8gl1VGxLHA1" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Refundable deposits receivable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001944" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001945" format="ixt:numdotdecimal" decimals="0" unitRef="USD">571,125</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccountsAndOtherReceivables_iNP3custom--IncreaseDecreaseInRefundableDepositsReceivable_di_msCzIwo_msCz7uv_zuhtWX8jznji" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other receivables</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001947" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,515,306</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001948" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,709,568</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInAccountsPayable_iP3us-gaap--IncreaseDecreaseInAccountsAndOtherReceivables_maCzIwo_maCz7uv_zlUdtAR535Si" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accounts payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001950" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,040</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001951" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38,025</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_iP3us-gaap--IncreaseDecreaseInAccountsPayable_maCzIwo_maCz7uv_zbtgJAnEniB9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Contract liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001953" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,326</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001954" format="ixt:numdotdecimal" decimals="0" unitRef="USD">337,434</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--IncreaseDecreaseInRefundableDepositsPayable_iP3us-gaap--IncreaseDecreaseInContractWithCustomerLiability_maCz7uv_zd1y7HeGxUi1" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Refundable deposits payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:IncreaseDecreaseInRefundableDepositsPayable" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001956" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,205</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:IncreaseDecreaseInRefundableDepositsPayable" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001957" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,222,375</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_iP3custom--IncreaseDecreaseInRefundableDepositsPayable_maCzIwo_maCz7uv_z3TbGYI6in5a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Other current liabilities</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001959" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">198,342</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001960" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,212</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzIwo_maCznW9_zJUH1CUguJC1" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Net
        cash used in operating activities</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001962" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">560,909</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001963" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,010,799</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zaCMWhCv3oGk" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash flows from investing
        activities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_iNP3us-gaap--PaymentsToAcquireRestrictedInvestments_di_msCzDBG_msCzB7O_zEVf7Lb5wCUh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Purchase of equipment</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001968" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,806</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001969" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,138</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzDBG_maCznW9_zI68xug3Cu72" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Net
        cash used in investing activities</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001971" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27,806</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001972" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,138</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zuEnW6IOIQNk" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash flows from financing
        activities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ProceedsFromSimpleAgreementsForFutureEquity_iP3us-gaap--PaymentsForRepurchaseOfInitialPublicOffering_maNCPBUzcW5_maCzg4P_z3qm7ZJiQla5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Proceeds from Simple
        agreements for future equity</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="cik0002065779:ProceedsFromSimpleAgreementsForFutureEquity" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001977" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,285,000</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="cik0002065779:ProceedsFromSimpleAgreementsForFutureEquity" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001978" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,275,000</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_maCznW9_mtNCPBUzcW5_zxOsVPYKaNad" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Net
        cash provided by financing activities</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001980" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,285,000</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001981" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,275,000</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCznW9_zmXDNracg5k2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Net
        increase in cash and cash equivalents</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact001983" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696,285</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact001984" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,262,063</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_z65PVus3SuGa" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Cash
        and cash equivalents at the beginning of year</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-06-30_custom_ExascaleLabsIncMember" id="Fact001986" format="ixt:numdotdecimal" decimals="0" unitRef="USD">273,341</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001987" format="ixt:numdotdecimal" decimals="0" unitRef="USD">969,626</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zc1wBzsBUUFb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Cash
        and cash equivalents at the end of year</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact001989" format="ixt:numdotdecimal" decimals="0" unitRef="USD">969,626</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact001990" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,231,689</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zx3PyNShkqOa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Supplementary Information:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxesPaid_zjNsIXPQHX02" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Income tax paid</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1995">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="text-align: left">$</td>
    <td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1996">-</span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InterestPaid_zLHrZjzrtjl5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Interest expense paid</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1998">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1999">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zDmJAPidUXka" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Supplemental schedule of
        non-cash financing activities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NotesAssumed1_iP3us-gaap--NoncashOrPartNoncashAcquisitionInventoryAcquired1_zpX8XtLpi2C8" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Investment proceeds received by an employee
        on behalf of the Company from SAFEs investors</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:NotesAssumed1" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002004" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,400,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:NotesAssumed1" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002005" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,500</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 393; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p id="xdx_041_c20240701__20250630_zCR4BcItZM7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="fin1_006"></span>EXASCALE LABS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(All amounts in US$, except for number of shares
and per share data)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002007" name="us-gaap:NatureOfOperations"><p id="xdx_80E_eus-gaap--NatureOfOperations_zPEtwaHe5HV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>1. <span id="xdx_821_zp6MNea2BKv9">Organization and principal activities</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June&#160;1, 2022, Exascale Labs Inc. (the &#8220;Company&#8221;)
was formally incorporated in the State of Delaware. In accordance with the Company&#8217;s Certificate of Incorporation, the Company is
authorized to issue <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20220601_zokPjcfKfLZ4" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-06-01_custom_ExascaleLabsIncMember" id="Fact002009" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></span> shares of ordinary shares, with a par value of $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220701_zXzvDlrClWQ5" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-07-01_custom_ExascaleLabsIncMember" id="Fact002011" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share, all in a single class. The governance structure
of the Company stipulates that the business and affairs of the Company shall be managed by or under the direction of its board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is a next-generation AI infrastructure
provider operating an asset-light, software-defined GPU compute platform and related AI infrastructure solutions. Exascale&#8217;s core
business includes GaaS, through which it provides reserved and on-demand access to high-performance GPU compute capacity sourced from
third-party data centers globally, as well as GPU cluster management and optimization services for AIDC operators. In addition, Exascale
has developed certain modular data center, high-density liquid cooling, HVDC power and energy storage solutions that are designed to address
deployment bottlenecks in AI infrastructure and that Exascale believes are ready for commercial engagement, although these capabilities
have not yet generated revenue as of the date of this proxy statement/prospectus. The platform is purpose-built for large-scale AI workloads,
including LLM training, fine-tuning, and high-concurrency inference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January&#160;2026, the Company adopted an Amended
and Restated Certificate of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#8217;s
equity is divided into 303 Class A ordinary shares and 1,197 Class B ordinary shares, which are entitled to one (1) vote and twenty (20)
votes per share, respectively. Despite the differential in voting power, Class A and Class B ordinary shares rank pari passu in all other
respects, sharing ratably in dividends and any distributions upon liquidation. Furthermore, all outstanding Simple Agreements for Future
Equity (&#8220;SAFEs&#8221;) are designated to convert or settle exclusively into Class A ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January&#160;2026, the Company entered into an
Agreement and Plan of Merger (&#8220;BCA&#8221;) with D. Boral ARC Acquisition I Corp.(&#8220;BCAR&#8221;), a publicly traded special
purpose acquisition company (&#8220;SPAC&#8221;), D. Boral ARC Merger Corporation, a Delaware corporation and a direct, wholly owned subsidiary
of BCAR and D. Boral Arc Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary of BCAR. Upon closing of the transaction,
the combined company will be named Exascale Labs Holdings Inc.(such surviving company, &#8220;PubCo&#8221;) and is expected to be traded
on a national securities exchange.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002013" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zly3FShCFXe3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2. <span id="xdx_826_znoSd0puRsll">Summary of significant accounting policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002015" name="cik0002065779:GoingConcernPolicyTextBlock"><p id="xdx_845_ecustom--GoingConcernPolicyTextBlock_zorhFCi8emlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>a. <span id="xdx_864_z1YlhGMWNLQ3">Going concern</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June&#160;30, 2025, the Company had cash
and cash equivalents of $4.2 million <span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20250630_zP8AepDgmXQ1" title="Cash and cash equivalents" style="display: none"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002017" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,231,689</ix:nonFraction></span>
and current liabilities of $20.3 <span id="xdx_902_eus-gaap--LiabilitiesCurrent_iI_c20250630_z4jwfecaN8A1" title="Current liabilities" style="display: none"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002019" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,319,721</ix:nonFraction></span>
million. For the years ended June&#160;30, 2024 and 2025, the Company used $0.6 <span title="Net losses"><span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20230701__20240630_zimEv9wUsnDk" title="Cash for operating activities" style="display: none">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002021" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">560,909</ix:nonFraction>)</span>
million and $1.0 <span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20240701__20250630_zVTfCY856dug" title="Cash for operating activities" style="display: none">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002023" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,010,799</ix:nonFraction>)</span>
million in cash for operating activities, and incurred net losses of $5.0 <span id="xdx_901_eus-gaap--NetIncomeLoss_c20230701__20240630_zVEtJqHinOV8" title="Net losses" style="display: none">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002025" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,956,347</ix:nonFraction>)</span>
million and $7.7 <span id="xdx_903_eus-gaap--NetIncomeLoss_c20240701__20250630_zUawJwOLj0Yh" title="Net losses" style="display: none">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002027" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,659,667</ix:nonFraction>)</span>
million, respectively. The Company has incurred recurring net losses from operations and negative cash flows from operating
activities since inception. As of June&#160;30, 2025, the Company had an accumulated deficit of $13.2
<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20250630_zuIwST4zPt2k" title="Accumulated deficit" style="display: none">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002029" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,217,035</ix:nonFraction>)</span> million. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern
within one year of the date these financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has formulated and is actively pursuing
plans to mitigate these conditions and secure the Company&#8217;s continued operations. In connection with the Company&#8217;s contemplated
business combination with a SPAC and related financing activities, the Company expects to access additional capital through external funding
sources. In addition, the Company continues to focus on expanding its market presence and developing client relationships to drive revenue
growth, while managing operating expenses, with the objective of improving cash flows from operations over time.</p>

<ix:exclude><p id="xdx_23B_zIwiqrA11sY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 394; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zZS3W0QuMGvf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_ze1IgCLQaWkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2. Summary of significant accounting policies (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zEYN2mEL8wo8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zHG7WwOOKMlk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>a. Going concern (Continued)</i></b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of this disclosure, &#8220;SPAC&#8221;
refers to a special purpose acquisition company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more operating businesses. &#8220;De-SPAC&#8221; refers to the business combination transaction
pursuant to which an operating company combines with a SPAC, following which the combined company becomes publicly listed (or otherwise
succeeds to the SPAC&#8217;s public company status).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s negative working capital position
is primarily attributable to the classification of SAFEs. Excluding the accounting impact of the SAFEs, which will only be paid in cash
upon Liquidity Events and Dissolution Event (as defined in Note 9) and the SAFE holders choose to claim the invested proceeds back, management
believes the Company&#8217;s available cash resources are sufficient for near-term operating needs. If additional liquidity is required,
the Company&#8217;s majority shareholder has entered into a binding support agreement to provide funding to cover anticipated operating
cash flow shortfalls through the completion of the contemplated de-SPAC transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">However, the aforementioned plans, particularly the
de-SPAC transaction (including the SAFEs conversion) and the raising of additional capital, have not been fully implemented as of the
date these financial statements are issued. There can be no assurance that these plans will be successfully completed within the required
time frame, on acceptable terms, or at all. If the primary plans are not successful, the Company&#8217;s alternative courses of action
would further intensify efforts in market expansion and client development to increase revenue, while diligently controlling costs to
ensure sufficient cash flow from operating activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company may not be able to secure necessary financing
in a timely manner or on favorable terms, or successfully execute its operational turnaround. These circumstances give rise to substantial
doubt that the Company will continue as a going concern and these financial statements do not include any adjustments that might result
from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002036" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoHPeRGXD8V6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>b. <span id="xdx_863_zpBEwXbVSFgl">Basis of presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The financial statements have been prepared in accordance
with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the applicable
rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002038" name="us-gaap:UseOfEstimates"><p id="xdx_849_eus-gaap--UseOfEstimates_zm9vWs4Czw0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>c. <span id="xdx_86E_zKFaeK3WfP28">Use of estimates and assumptions</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and
accompanying notes. Management believes that the estimates used in preparing the financial statements are reasonable and prudent; however,
actual results could differ from these estimates under different assumptions or conditions.&#160;Significant accounting estimates include
revenue recognition, recognition and measurement of SAFEs notes, the allowance for expected credit losses, recognition and measurement
of share-based compensation, deferred tax assets and valuation allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002040" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zdsq5TZx08Bg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>d. <span id="xdx_86B_zgmcgXMRrdyd">Fair value measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #212529; color: #212529">In accordance
with FASB ASC 820&#160;</span><i><span style="color: #212529; color: #212529">Fair Value Measurements and Disclosures</span></i><span style="color: #212529; color: #212529">,
</span>fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. <span style="color: #212529; color: #212529">The Company uses a three-level hierarchy
for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant
assumptions developed from market data obtained from outside sources (observable inputs) and the Company&#8217;s own assumptions about
market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). </span></p>

<ix:exclude><p id="xdx_23B_zmLEtHVzXqa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 395; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zkMrl2yc4VMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zow3rPUYNMp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2. Summary of significant accounting policies (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_z0kTI4nEGUJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zzNuHKAuLa9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>d. Fair value measurements (Continued)</i></b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The hierarchy requires entities to maximize the use
of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #212529; color: #212529">Level
1: Quoted prices in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #212529; color: #212529">Level
2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #212529; color: #212529">Level
3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash
flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment
or estimation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #212529; color: #212529">The fair
value measurements discussed herein are based upon certain market assumptions and pertinent information available to management during
the years ended June&#160;30, 2024 and 2025. The carrying amount of cash and </span>cash equivalents<span style="color: #212529; color: #212529">,
accounts receivable, r</span>efundable deposits receivable, other receivables, <span style="color: #212529; color: #212529">accounts payable,
r</span>efundable deposits payable <span style="color: #212529; color: #212529">and other current liabilities approximated their fair
values as of June&#160;30, 2024 and 2025. For the years ended June&#160;30, 2024 and 2025, the Company carried SAFEs at their fair value
(see&#160;Note 4-Fair Value Measurements&#160;for fair value information).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002047" name="cik0002065779:FunctionalCurrencyPolicyTextBlock"><p id="xdx_84F_ecustom--FunctionalCurrencyPolicyTextBlock_zlxnMooXoEU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>e. <span id="xdx_865_zAyE0XfHmhD6">Functional currency</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements are presented
in the United States dollar (&#8220;US$&#8221;). The functional currency of the Company is the US$.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All transactions are measured and recorded in the
Company&#8217;s functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002049" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zbK7C7pPqW23" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>f. <span id="xdx_863_zISAmbUCaane">Cash and cash equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid debt instruments
purchased with a maturity period of three months or less to be cash or cash equivalents. The carrying amounts reported in the accompanying
balance sheets for cash and cash equivalents approximate their fair value. As of June&#160;30, 2024 and 2025, the Company does <span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20240630_zJxii2H5kkT6" title="Cash equivalents"><span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zqb5W6PdbHal" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002051" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002053" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t have
any cash equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002055" name="cik0002065779:ExpectedCreditLossAndAccountsReceivablePolicyTextBlock"><p id="xdx_84E_ecustom--ExpectedCreditLossAndAccountsReceivablePolicyTextBlock_zSEmIHvv90sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>g. <span id="xdx_867_zsUZxth16ncb">Expected credit loss and accounts receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company adopted Financial Standards Accounting
Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 326 &#8220;<i>Financial Instruments&#160;&#8212;&#160;Credit
Losses</i>&#8221; (&#8220;ASC&#160;326&#8221;) on January&#160;1, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s accounts receivable is within
the scope of ASC&#160;326. ASC&#160;326 introduces an approach based on expected credit losses on financial assets at amortized cost.
Upon adoption of ASC&#160;326, the Company estimates the expected credit losses for accounts receivable using the roll-rate method on
a collective basis when similar risk characteristics exist. Expected credit losses are included in general and administrative expenses
in the statements of operations and comprehensive loss. After all attempts to collect a receivable have failed, the receivable is written
off against the allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable represents those receivables derived
in the ordinary course of business, net of an allowance for any potentially uncollectible amounts. The Company makes estimates of expected
credit and collectability trends for the allowance for credit losses based upon its assessment of various factors, including historical
experience, the age of the accounts receivable balances, credit quality of its customers, current economic conditions, reasonable and
supportable forecasts of future economic conditions that may vary by geography, customer-type, or industry sub-vertical, and other factors
that may affect its ability to collect from customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although the Company has historically not experienced
significant credit losses, they may experience increasing credit loss risks from accounts receivable in future periods if its customers
are adversely affected by economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific
factors, and actual experience in the future may differ from their past experiences or current assessment.</p>

<ix:exclude><p id="xdx_23D_zV2MjRbILF3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 396; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zJfY3g6Iuruj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zSvtFWIbsCp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2. Summary of significant accounting policies (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002060" name="cik0002065779:AdvanceToSuppliersPolicyTextBlock"><p id="xdx_848_ecustom--AdvanceToSuppliersPolicyTextBlock_ziKHq9XEjP3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>h. <span id="xdx_86C_zgfztbsMVxIj">Advance to suppliers</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advance to suppliers represent prepayments made to
vendors in connection with the purchase of services. Advance are recorded at the amount paid and are classified as current assets when
the related services are expected to be received within one year or the normal operating cycle.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002062" name="cik0002065779:RefundableDepositsReceivablePolicyTextBlock"><p id="xdx_844_ecustom--RefundableDepositsReceivablePolicyTextBlock_zHSdExpu5L9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>i. <span id="xdx_86D_z7CffKljqsfj">Refundable deposits receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Refundable deposits receivable mainly represent security
deposits and refundable cooperation deposits paid to suppliers and business partners that are contractually recoverable upon the completion
of services. These amounts are recorded as assets when paid, generally at the amount paid. Deposits expected to be recovered within one
year are classified as current; otherwise, they are classified as non-current. The Company evaluates the credit risk of refundable deposits
receivable and recognizes an allowance for credit losses based on the current expected credit losses (&#8220;CECL&#8221;) model. Specific
balances are written off when they are deemed uncollectible and all collection efforts have been exhausted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June&#160;30, 2024 and 2025, the balances were
$<span id="xdx_90E_ecustom--RefundableDepositsReceivable_iI_c20240630_za7GUMIQ0fl5" title="Refundable deposits receivable"><ix:nonFraction name="cik0002065779:RefundableDepositsReceivable" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,000</ix:nonFraction></span> and $<span id="xdx_90E_ecustom--RefundableDepositsReceivable_iI_c20250630_z0ReoE3c16C9" title="Refundable deposits receivable"><ix:nonFraction name="cik0002065779:RefundableDepositsReceivable" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">681,125</ix:nonFraction></span>, respectively. The increase was primarily driven by revenue growth and business expansion. As of June&#160;30, 2024
and 2025, there was <span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20240630_zLZRW1Dk6Ukj" title="Allowance for expected credit losses"><span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_z3aW6vPWJeid" title="Allowance for expected credit losses"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002068" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002070" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> allowance for expected credit losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002072" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z0zrIdAY4IM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>j. <span id="xdx_86F_zf8ptRHzRO28">Equipment, net</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equipment, net is stated at cost less accumulated
depreciation and impairment, if any. Depreciation is computed using the straight-line method over the estimated useful lives of three
or five years, depending on the asset category.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002074" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z4iWfcQYqTqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>k. <span id="xdx_86E_zLIGi7CATnu7">Impairment of long-lived assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews its long-lived assets, equipment,
for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability
of assets held and used is measured by comparison of the carrying amount of an asset to the future undiscounted cash flows expected to
be generated from the use of the asset and its eventual disposition. If such assets are considered to be impaired, the impairment to be
recognized is measured by the amount by which the carrying amount exceeds the fair value of the impaired assets. Assets to be disposed
of are reported at the lower of their carrying amount or fair value less cost to sell. There was <span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20230701__20240630_zgA1bYYr7Yec" title="Impairment of long-lived assets"><span id="xdx_907_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20240701__20250630_zZHdVotNKmAc" title="Impairment of long-lived assets"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002076" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002078" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> impairment of long-lived assets as
of and for the years ended June&#160;30, 2024 and 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002080" name="cik0002065779:SimpleAgreementsForFutureEquityPolicyTextBlock"><p id="xdx_844_ecustom--SimpleAgreementsForFutureEquityPolicyTextBlock_zFgYzNF7u2n6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>l. </i><i><span style="color: #212529; color: #212529"><span id="xdx_867_z4BrJrohRAA9">Simple
agreements for future equity</span></span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">SAFEs issued by the Company are freestanding financial
instruments. As they contain certain redemption or liquidation features that&#160;may&#160;require the Company to settle the obligation
in cash upon the occurrence of defined events (e.g., a change of control or dissolution), the instruments&#160;create an obligation that
meets the definition of a liability. Accordingly, the SAFEs are classified in their entirety as liabilities on the balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These liabilities are measured at fair value upon
initial recognition and are subsequently remeasured at fair value at each reporting date. All changes in their fair value are recognized
in&#160;the statement of operations and comprehensive loss in the period in which they occur.</p>

<ix:exclude><p id="xdx_23B_z7tnCJUCUY3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 397; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zu9Gt7TG2qah" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zs7yu4FfYMGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2. Summary of significant accounting policies (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002085" name="us-gaap:RevenueRecognitionDeferredRevenue"><p id="xdx_840_eus-gaap--RevenueRecognitionDeferredRevenue_zJ2s2gZGnL58" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>m. <span id="xdx_86E_zA2yNWLqfBFd">Revenue recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company applied ASC Topic&#160;606 &#8220;<i>Revenue
from Contracts with Customers</i>&#8221; (&#8220;ASC&#160;606&#8221;) for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The five-step model defined by ASC&#160;606 requires
the Company to (i)&#160;identify its contracts with clients, (ii)&#160;identify its performance obligations under those contracts, (iii)&#160;determine
the transaction prices of those contracts, (iv)&#160;allocate the transaction prices to its performance obligations in those contracts,
and (v)&#160;recognize revenue when each performance obligation under those contracts is satisfied. Revenue is recognized when promised
goods or services are transferred to the client in an amount that reflects the consideration expected in exchange for those goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reports all of its revenues on a gross
basis.&#160;This determination is based on the Company&#8217;s assessment that it is the principal in its revenue arrangements. The Company
controls the service delivery platform and infrastructure before the service is provided to the customer. It is primarily responsible
for fulfilling the service promise, has discretion in setting prices, and assumes the credit risk associated with the customer receivable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a practical expedient, the Company elected to expense
the incremental costs of obtaining a contract when incurred if the amortization period of the asset that the Company otherwise would have
recognized is one year or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to ASC 606, the Company recognizes revenue
based on the transaction price, which is the amount of consideration it expects to be entitled to exchange for transferring services to
customers. For Intelligent Computing Power Services, contract consideration is generally fixed and is typically stated as a fixed monthly
fee determined by (i) the contractually specified number of GPUs (capacity) and (ii) the service period. Accordingly, the transaction
price is generally the fixed contractual amount. The Company recognizes revenue over time as the services are provided throughout the
contract term. The Company offers payment terms ranging from 0 to 6 months, depending on customers&#8217; credit profiles and service
requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company does not provide warranties for its services
and does not offer service-type warranty arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a description of the principal activities
of the Company from which the Company generates its revenue under ASC 606.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(i) Revenue for intelligent computing power service</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #0F1115; color: #0F1115">The Company
leverages its expertise in high-performance computing and cloud-native architectures to build and operate stable, efficient, and scalable
GPU computing platforms through modular data center design and liquid cooling technology. The Company uses these platforms to provide
computing resources for large-scale AI training, model inference, and high-performance scientific computing to commercial enterprise clients
with substantial GPU computing requirements. Supporting services include GPU server environment deployment, cluster scheduling and performance
optimization, high-speed network interconnection, real-time monitoring and intelligent alerting systems, as well as industry-compliant
security and regulatory assurance. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for the above promises as a single
performance obligation because they are highly integrated and not separately identifiable in the context of the contract. The Company
provides an integrated, managed GPU computing platform in which computing capacity, deployment/configuration, scheduling, networking,
monitoring, and security/compliance are interdependent and together deliver a single combined service&#8212;continuous access to a functioning
and secured platform over the contractual term.</p>

<ix:exclude><p id="xdx_237_z2KP5cPDzWZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 398; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zjeO1z6H3KUg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zqgR9P7r56Lb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2. Summary of significant accounting policies (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zQWHntskXs45" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zxLpHtoKlC03" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>m. Revenue recognition (Continued)</i></b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company provides intelligent computing power services
under two pricing models: (i) reserved capacity arrangements and (ii) on-demand (pay-as-you-go) arrangements. The following table presents
revenue recognized during the period by arrangement type:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002092" name="cik0002065779:ScheduleOfRevenueRecognitionTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zRG8fPT8BVR9" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BF_zPudrh40sc0l" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Schedule of Revenue recognition</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/> years ended<br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Reserved capacity arrangements</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember" id="Fact002094" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,193,982</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember" id="Fact002096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,501,569</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">On-demand arrangements</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl2098">-</span></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember" id="Fact002100" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,680</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_900_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember" id="Fact002102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,193,982</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90E_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember" id="Fact002104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,546,249</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8A0_zqlXSFBPlAkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reserved capacity arrangements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company enters into reserved capacity arrangements,
which generally provide committed intelligent computing power services for a defined service term ranging from 3 months to 3 years, with
the majority of such arrangements having a one-year term. These contracts typically are non-cancelable, or may be canceled only under
limited conditions with early notifications required. Payment terms generally range from 0-6 months upon the completion of services, and
certain arrangements require prepayments. Any prepayments are recorded as contract liabilities and recognized over the service term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The performance obligation is satisfied over time
because the customer simultaneously receives and consumes the benefits. Revenue is recognized using a time-elapsed output method over
the contractual service period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On-demand (pay-as-you-go) arrangements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company provides customers with on-demand access
to intelligent computing power and GPU resources under pay-as-you-go model which requires advance payment. Customer advances are recorded
as contract liabilities and recognized as revenue over the time during the provision of related services underlying the contract term.
The revenue is recognized over time because the customer can simultaneously receives and consumes the benefits during the service period.
These arrangements generally do not include a fixed contractual term or minimum usage commitments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(ii) Revenue from comprehensive data center service</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leverages its project experience in infrastructure
management, cluster optimization, and system monitoring to provide full-cycle operational support to data center asset owners. Services
encompass facility environment deployment, network architecture implementation, security and compliance system development, daily operational
monitoring, and emergency fault response. Revenue is recognized over time because the Company&#8217;s services are performed throughout
the contract term and the customer benefits as the services are provided.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the&#160;years ended June&#160;30, 2024 and 2025,
$<span id="xdx_905_eus-gaap--Revenues_c20230701__20240630_pp0p" title="Revenue"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,319,115</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--Revenues_c20240701__20250630_pp0p" title="Revenue"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,015,512</ix:nonFraction></span> of the revenue of the Company&#8217;s was recognized over time, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue disaggregated by service lines for the&#160;years
ended June&#160;30, 2024 and 2025 is disclosed in the table below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002110" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zC7KRbYjMXPd" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BF_zOrqnCzeKVC3" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Schedule of Revenue disaggregated</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/>years ended<br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Revenue from intelligent computing
        power service</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zLe37nj4DRT9" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember" id="Fact002112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,193,982</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_907_eus-gaap--Revenues_pp0d_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z5LhznXQI8B2" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember" id="Fact002114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,546,249</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Revenue from comprehensive
        data center services</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012024-06-30_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember" id="Fact002116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,133</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-06-30_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember" id="Fact002118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">469,263</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630_zw4xoiRMPQs7" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,319,115</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90A_eus-gaap--Revenues_pp0d_c20240701__20250630_zxIqgXFsjdA6" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,015,512</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zFyS7keq5WFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 399; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zmnO1OLuUupi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zGP6v8uJbKP9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2. Summary of significant accounting policies (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zhqilFbJ31b3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002127" name="cik0002065779:ContractLiabilitiesPolicyTextBlock"><p id="xdx_845_ecustom--ContractLiabilitiesPolicyTextBlock_zZWQnliQBId8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>n. <span id="xdx_864_zhAHETYm7uU4">Contract liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company receives advance payments from its customers
for services to be provided in the future. These payments are recorded as&#160;contract liabilities&#160;on the balance sheet within &#8220;Contract
liabilities&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Contract liabilities are recognized when
consideration is received from a customer prior to the Company satisfying its related performance obligations. For these service
contracts, the Company recognizes revenue, and reduces the contract liabilities,&#160;over time&#160;as the services are rendered
and the performance obligations are satisfied. Revenue recognized that was included in the contract liability balance at the
beginning of the year was nil <span id="xdx_90A_ecustom--RevenueRecognized_c20230701__20240630_pp0p" title="Revenue recognized" style="display: none"><ix:nonFraction name="cik0002065779:RevenueRecognized" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002129" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_904_ecustom--RevenueRecognized_c20240701__20250630_pp0p" title="Revenue recognized"><ix:nonFraction name="cik0002065779:RevenueRecognized" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,326</ix:nonFraction></span> for the years ended June&#160;30, 2024 and 2025, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002133" name="us-gaap:CostOfSalesPolicyTextBlock"><p id="xdx_847_eus-gaap--CostOfSalesPolicyTextBlock_zd6uOxmwVUC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>o. <span id="xdx_868_zt2YqZ7h4862">Cost of revenues</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s cost of revenues primarily includes
computing power service and professional service fees. All the cost of revenues are recognized in the period in which the related services
occur or the benefits are received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002135" name="cik0002065779:SellingAndMarketingExpensesPolicyTextBlock"><p id="xdx_84E_ecustom--SellingAndMarketingExpensesPolicyTextBlock_zNtKHlQglhzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>p. <span id="xdx_861_z8U06Sm8eK8b">Selling and marketing expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s selling and marketing expenses
primarily include: (i) advertising and promotion expenses, (ii) compensation and benefits for sales personnel and related share based
compensation, and (iii) travel and other routine office expense. All expenses are recognized in the period in which the related services
occur or the benefits are received. The Company expenses advertising costs as incurred, and for the years ended June&#160;30, 2024 and
2025, the Company incurred advertising and promotion expenses of $<span id="xdx_908_eus-gaap--MarketingAndAdvertisingExpense_c20230701__20240630_pp0p" title="Advertising and promotion expenses"><ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002137" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,340</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20240701__20250630_pp0p" title="Advertising and promotion expenses"><ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002139" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,388</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002141" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zTShSXVP9mc7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>q. <span id="xdx_864_zLpo4DODnKa5">Research and development expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s research and development expenses
mainly consist of <span style="color: #0F1115; color: #0F1115">software development outsourcing service fees and testing expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002143" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock"><p id="xdx_844_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zdyBpybY30kg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>r. <span id="xdx_866_z1OzlN0cGTed">General and administrative expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s general and administrative expenses
mainly consist of <span style="color: #0F1115; color: #0F1115">software subscription fees, legal and professional service fees, certification
service fees, depreciation expenses and handling charges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002145" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zH16tov7HOHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>s. <span id="xdx_86A_zfzDgxosnhkd">Income tax</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Income taxes are determined in accordance with the
provisions of ASC Topic 740, <i>Income Taxes</i> (&#8220;ASC Topic 740&#8221;). Under this method, deferred tax assets and liabilities
are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing
assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates
expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. Any effect
on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 740 prescribes a comprehensive model for how companies
should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on
a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the
position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as
the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority
assuming full knowledge of the position and relevant facts.</p>

<ix:exclude><p id="xdx_235_zMjKgBTZbJBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 400; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zP3LVuxJMn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zAvkl1p7UTc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2. Summary of significant accounting policies (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002150" name="cik0002065779:CapitalStructurePolicyTextBlock"><p id="xdx_842_ecustom--CapitalStructurePolicyTextBlock_zrhorRvRLTn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>t. <span id="xdx_86F_zOYxMEHi9sP1">Capital structure</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized to issue <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20240630_pd" title="Common stock, shares authorized"><span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_c20250630_pd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002152" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002154" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></ix:nonFraction></span></span> ordinary
shares of $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20240630_pd" title="Common stock, par value"><span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_c20250630_pd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002156" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002158" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value each. As of June&#160;30, 2024 and 2025, there were <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_c20240630_pd" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_c20240630_pd" title="Common stock, shares outstanding"><span id="xdx_90A_eus-gaap--CommonStockSharesIssued_c20250630_pd" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_c20250630_pd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002160" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002162" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002164" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the resolution of the board of directors
on January&#160;8, 2026, the authorized share capital of <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_c20260108_pd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-01-08_custom_ExascaleLabsIncMember" id="Fact002168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></span> ordinary shares was re-designated to <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-01-08_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact002170" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">303</ix:nonFraction></span> Class A ordinary shares and <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-01-08_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact002172" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,197</ix:nonFraction></span>
Class B ordinary shares. Holders of Class A ordinary shares and Class B ordinary shares have the same rights, except for voting and conversion
rights. Each Class A ordinary share is entitled to one vote; and each Class B ordinary share is entitled to twenty votes and is convertible
into one Class A ordinary share at any time by the holder thereof. Class A ordinary shares are not convertible into Class B ordinary shares
under any circumstances. Furthermore, all outstanding warrants, options, and SAFEs are designated to convert or settle exclusively into
Class A ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002174" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_848_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zyjuGtgiN2l4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>u. <span id="xdx_860_zz7zMNdlRtT9">Share-based compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company grants Share awards of the Company to
eligible employees and&#160;non-employees. The Company accounts for share-based awards issued to employees and&#160;non-employees in accordance
with ASC Topic 718 <i>Compensation &#8211; Stock Compensation. </i>The Company recognizes forfeitures as they occur. The share-based compensation
expenses have been categorized as either general and administrative expenses or selling and marketing expenses, depending on the job functions
of the grantees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s share-based compensation awards
are expected to be settled through transfers of existing ordinary shares held by the controlling shareholder, rather than through the
issuance of new shares by the Company. The underlying ordinary shares are included in issued and outstanding shares as of the balance
sheet date; accordingly, such settlement is not expected to increase the Company&#8217;s total issued and outstanding shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Employees&#8217; share-based awards and non-employees&#8217;
share-based awards are measured at the grant date fair value of the awards and recognized as expenses a) immediately at grant date if
no vesting conditions are required; or b) using graded vesting method, net of estimated forfeitures, over the requisite service period,
which is the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company employs discounted cash flow method to
determine the fair value of our share-based compensation arrangements, where the key valuation variables include risk free rate, discount
rate and perpetual rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002176" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zj5A0O1qUZwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>v. <span id="xdx_867_zetDcyDJZsD4">Segment reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 280, &#8220;Segment Reporting&#8221;, establishes
standards for reporting information about operating segments on a basis consistent with the Company&#8217;s internal organizational structure
as well as information about geographical areas, business segments and major customers in financial statements for details on the Company&#8217;s
business segments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the &#8220;management approach&#8221;
in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#8217;s
chief operating decision maker (&#8220;CODM&#8221;) for making operating decisions and assessing performance as the source for determining
the Company&#8217;s reportable segments. The Company&#8217;s CODM is the chief executive director. The CODM regularly reviews entity-wide
operating results and reviews revenues and net loss when making decisions about allocating resources and assessing performance of the
segment, and hence, the Company has only&#160;one&#160;reportable segment. Therefore, as the Company has determined it operates as a single
reportable segment, the CODM assesses the Company&#8217;s performance and results of operations on an entity-wide basis.</p>

<ix:exclude><p id="xdx_23F_zhnLZ0y3E3Q" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 401; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zDsvDFWDAvXg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_z0QSGhIA59Wa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2. Summary of significant accounting policies (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002181" name="cik0002065779:RelatedPartiesPolicyTextBlock"><p id="xdx_84D_ecustom--RelatedPartiesPolicyTextBlock_zmOqA55enEsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>w. <span id="xdx_862_zI2bQw1nSKC">Related parties</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parties are considered to be related if one party
has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial
and operating decisions. Parties are also considered to be related if they are subject to common control or significant influence, such
as a family member or relative, shareholder, or a related corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002183" name="cik0002065779:ComprehensiveLossPolicyTextBlock"><p id="xdx_849_ecustom--ComprehensiveLossPolicyTextBlock_z3GLuD1HtmQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>x. <span id="xdx_866_zJfxnr89HArh">Comprehensive loss</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Comprehensive loss is defined as a change in equity
during a period from transactions and other events and circumstances&#160;from&#160;non-owner&#160;sources.&#160;The Company&#8217;s comprehensive
loss was the same as its reported net loss for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002185" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zRr2tTiRL483" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>y.<span id="xdx_864_zWpJBAyOYapg"> Loss&#160;per share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per share of ordinary shares attributable
to ordinary shareholders is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average shares of ordinary
shares outstanding for the period. Potentially dilutive shares, which are based on the weighted-average shares of ordinary shares underlying
outstanding share-based awards or options using the treasury stock method or the if-converted method, as applicable, are included when
calculating diluted net income per share of ordinary shares attributable to ordinary shareholders when their effect is dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Diluted net loss per share attributable to ordinary
shareholders is computed by adjusting the weighted-average number of ordinary shares outstanding for the dilutive effect of all potential
ordinary share equivalents. For the Company, potential ordinary share equivalents consisted of share-based compensation, which are assessed
using the&#160;treasury stock method. These potential shares are included in the diluted earnings per share calculation only when their
effect is&#160;dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In periods where the Company reports a&#160;net loss,
diluted net loss per share is calculated in the same manner as basic net loss per share because the inclusion of any potential ordinary
shares would have an&#160;anti-dilutive&#160;effect. Consequently, all potential ordinary share equivalents were excluded from the calculation
for the years in which a net loss was incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002187" name="us-gaap:RevenueRecognitionDividends"><p id="xdx_844_eus-gaap--RevenueRecognitionDividends_z5kiNZU4iFJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>z. <span id="xdx_86E_z1wQVhVX3E9i">Dividends</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dividends are recognized when declared. <span id="xdx_908_eus-gaap--Dividends_pp0d_do_c20230701__20240630_z4eZ64ybMTmi" title="Dividends"><span id="xdx_903_eus-gaap--Dividends_pp0d_do_c20240701__20250630_zSkJu776q1A8" title="Dividends"><ix:nonFraction name="us-gaap:Dividends" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002189" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:Dividends" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002191" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></ix:nonFraction></span></span> dividends
were declared for the years ended June&#160;30, 2024 and 2025, respectively. The Company does not have any present plan to pay any dividends
on ordinary shares in the foreseeable future. The Company currently intends to retain the available funds and any future earnings to operate
and expand its business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002193" name="cik0002065779:RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock"><p id="xdx_840_ecustom--RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock_z7z0wstCtqqk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>aa. <span id="xdx_86F_zUUr7JvI51i1">Recently adopted accounting standard updates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June&#160;2016, the FASB issued ASU&#160;2016-13,
<i>Financial Instruments&#160;&#8212;&#160;Credit Losses</i> (Topic&#160;326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU&#160;2016-13&#8221;).
The new accounting standard introduced the current expected credit losses methodology (&#8220;CECL&#8221;) for estimating allowances for
credit losses. The measurement of expected credit losses under the CECL methodology is applicable to financial assets measured at amortized
costs, including loans and trade receivables. ASU&#160;2016-13 is effective for the Company, as an emerging growth company, for annual
and interim reporting periods beginning after December&#160;15, 2022. The Company adopted the standard on July&#160;1, 2023 using the
modified retrospective method for all financial assets in scope. The adoption of the standard did not have a material impact on the Company&#8217;s
statements of income, or statements of cash flows.</p>

<ix:exclude><p id="xdx_237_zxLBTgJAuIAh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 402; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zxmV3mj7FHY7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zJ0zzZPoD6c2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2. Summary of significant accounting policies (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zdEd0krtQVue" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zZoigfnaPFAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>aa. Recently adopted accounting standard updates
(Continued)</i></b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November&#160;2023, the FASB issued ASU&#160;2023-07,
&#8220;Segment Reporting (Topic&#160;280): <i>Improvements to Reportable Segment Disclosures</i>.&#8221; The amendments in this ASU are
intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating decision mark (&#8220;CODM&#8221;),
an amount for other segment items by reportable segment and a description of its composition, all annual disclosures required by FASB
ASU Topic&#160;280 in interim periods as well, and the title and position of the CODM and how the CODM uses the reported measures. Additionally,
this ASU requires that at least one of the reported segment profit and loss measures should be the measure that is most consistent with
the measurement principles used in an entity&#8217;s financial statements. Lastly, this ASU requires public business entities with a single
reportable segment to provide all disclosures required by these amendments in this ASU and all existing segment disclosures in Topic&#160;280.
This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning
after December&#160;15, 2024. The Company has early adopted ASU 2023-07 on July&#160;1, 2023. As a result of adoption, the required disclosures
have been included in Note 2 and Note 14.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002200" name="cik0002065779:EmergingGrowthCompanyPolicyTextBlock"><p id="xdx_84B_ecustom--EmergingGrowthCompanyPolicyTextBlock_zXbI2MERplLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>bb. <span id="xdx_860_zodYVIxzme09">Emerging growth company</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company intends to operate as an &#8220;emerging
growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). The JOBS Act permits
companies with emerging growth company status to take advantage of an extended transition period to comply with new or revised accounting
standards, delaying the adoption of these accounting standards until such time as those standards would apply to private companies. The
Company elected to use this extended transition period to enable it to comply with new or revised accounting standards that have different
effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company
or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company&#8217;s
financial statements may not be comparable to companies that comply with the new or revised accounting standards as of public company
effective dates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002202" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztzNempdfu57" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>cc. <span id="xdx_86D_z61KGdSvMHp3">Recently accounting pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December&#160;2023, the FASB issued ASU&#160;No.&#160;2023-09,&#160;<i>Improvements
to Income Tax Disclosures</i>&#160;(&#8220;ASU&#160;2023-09&#8221;),&#160;which requires entities to make incremental income tax disclosures
on an annual basis. The amendments require that public business entities disclose specific categories in the rate reconciliation and provide
additional information for reconciling items meeting a quantitative threshold. The amendments also require disclosure of income taxes
paid to be disaggregated by jurisdiction, and the disclosure of income tax expense disaggregated by federal, state, and foreign. ASU&#160;2023-09&#160;is
effective for the Company&#8217;s annual reporting periods ending December&#160;31, 2025 and thereafter, with early adoption permitted.
The Company is evaluating adoption timing and the impact ASU&#160;2023-09&#160;will have on its financial statements and related disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March&#160;2024, the FASB issued ASU No. 2024-02,
<i>Codification Improvements-Amendments to Remove References to the Concepts Statements</i> (&#8220;ASU 2024-02&#8221;). The amendments
in this Update affect a variety of Topics in the Codification. The amendments apply to all reporting entities within the scope of the
affected accounting guidance. This update contains amendments to the Codification that remove references to various Concepts Statements.
In most instances, the references are extraneous and not required to understand or apply the guidance. In other instances, references
were used in prior statements to provide guidance in certain topical areas. ASU 2024-02 is effective for public business entities for
fiscal years beginning after December&#160;15, 2024. For all other entities, the amendments are effective for fiscal years beginning after
December&#160;15, 2025. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or
made available for issuance. The adoption did not have a material impact on the Company&#8217;s financial statement.</p>

<ix:exclude><p id="xdx_230_z8fYkytYq8lc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 403; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zSyZuOUbNOl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zi8bGXEBZ6j9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2. Summary of significant accounting policies (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zRNtLiV8DMqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zYUSxQqlwJ4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>cc. Recently accounting pronouncements (Continued)</i></b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November&#160;2024, the FASB issued ASU 2024-03
&#8220;<i>Income Statement&#8212;Reporting comprehensive (loss) income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation
of Income Statement Expenses</i>&#8221; (&#8220;ASU 2024-03&#8221;). The amendments in this update intend to improve the disclosures about
a public business entity&#8217;s expenses and address requests from investors for more detailed information about the types of expenses
(including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions
(such as cost of sales, selling, general and administrative expenses, and research and development). ASU 2024-03 is effective for fiscal
years beginning after December&#160;15, 2026, and interim periods beginning after December&#160;15, 2027. The Company is currently evaluating
the impact from the adoption of this ASU on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January&#160;2025, the FASB issued Accounting Standards
Update (ASU) No. 2025-01, <i>Income Statement &#8212; Reporting comprehensive (loss) income &#8212; Expense Disaggregation Disclosures</i>
(Subtopic 220-40): Clarifying the Effective Date. The amendment clarifies the effective date of ASU No. 2024-03 that all public business
entities are required to adopt the guidance in annual reporting periods beginning after December&#160;15, 2026, and interim periods within
annual reporting periods beginning after December&#160;15, 2027. Early adoption of Update 2024-03 is permitted. The Company is currently
evaluating the impact of the above new accounting pronouncements or guidance on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July&#160;2025, the FASB issued Accounting Standards
Update (ASU) No. 2025-05, <i>Financial Instruments &#8212; Credit Losses</i> (Topic 326): Measurement of Credit Losses for Accounts Receivable
and Contract Assets. The amendment provides (1) all entities with a practical expedient to assume that current conditions as of the balance
sheet date do not change for the remaining life of the assets and (2) entities other than public business entities with an accounting
policy election to consider collection activity after the balance sheet date when estimating expected credit losses for current accounts
receivable and current contract assets arising from transactions accounted for under Topic 606. This guidance is effective for annual
reporting periods beginning after December&#160;15, 2025 and interim reporting periods within those annual reporting periods. Early adoption
is permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or guidance on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except as mentioned above, the Company does not believe
other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the balance sheets,
statements of income and comprehensive loss and cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002209" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p id="xdx_80E_eus-gaap--ConcentrationRiskDisclosureTextBlock_zCNDhVCVmNLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>3. <span id="xdx_82C_zFBbZ0r7Zud1">Concentration and risk</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Concentration of credit risk</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject us
to concentrations of credit risk consisted primarily of cash and cash equivalents, and accounts receivable. We perform ongoing credit
evaluations of our customers&#8217; financial condition and maintain an allowance for potential credit losses. This allowance consisted
of an amount identified for specific customers and an amount based on overall estimated exposure. Our overall estimated exposure excludes
amounts covered by credit insurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Concentration of customers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s revenue was concentrated among
a limited number of customers during the periods presented. The following table summarized customers with greater than 10% of the total
revenue:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002211" name="cik0002065779:ScheduleOfConcentrationOfCustomersTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfConcentrationOfCustomersTableTextBlock_zed2bAfuUphh" summary="xdx: Disclosure - Concentration and risk (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B4_z48bm01L1Eva" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Schedule of Concentration of customers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/> years ended<br/> June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Customer A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zI3jDRHvmOHb" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember" id="Fact002213" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">12.0</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zCJR511w04rj" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember" id="Fact002215" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">14.0</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zJeeMwjQDM02" title="Concentration of credit risk" style="color: White"><span style="-sec-ix-hidden: xdx2ixbrl2217">-</span></span>*</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_z2sWdo9WBpLi" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember" id="Fact002219" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">12.5</ix:nonFraction></span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer C</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zvX47L5fSCGl" title="Concentration of credit risk" style="color: rgb(204,238,255)"><span style="-sec-ix-hidden: xdx2ixbrl2221">-</span></span>*</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_z7lIZvAGakw4" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember" id="Fact002223" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">10.2</ix:nonFraction></span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer D</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_ziuVreXhY8Jc" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember" id="Fact002225" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">31.6</ix:nonFraction></span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zsJSn6PWGOta" title="Concentration of credit risk" style="color: White"><span style="-sec-ix-hidden: xdx2ixbrl2227">-</span></span>**</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer E</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zdcO0AkLU83b" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember" id="Fact002229" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">11.9</ix:nonFraction></span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zapiuLRQgfx9" title="Concentration of credit risk" style="color: rgb(204,238,255)"><span style="-sec-ix-hidden: xdx2ixbrl2231">-</span></span>**</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer F</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zXQQtM1R6mP3" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember" id="Fact002233" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">11.0</ix:nonFraction></span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zkn4huYfaA16" title="Concentration of credit risk" style="color: White"><span style="-sec-ix-hidden: xdx2ixbrl2235">-</span></span>**</td>
    <td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">*:</td>
    <td style="text-align: justify">nil, new customer for the year ended June&#160;30, 2025</td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

<p id="xdx_8A3_zXQpMtPkMqqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 404; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zppTuoRtGLka" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zWyDP3gtxK2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>3. Concentration and risk (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zwrxsxF5TrXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zNnDPEBxDzm1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Concentration of customers (Continued)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zFNvpPIpBoT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s account receivable was concentrated
among a limited number of customers during the periods presented. The following table summarized customers with greater than 10% of the
total account receivable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002242" name="cik0002065779:ScheduleOfAccountsReceivableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfAccountsReceivableTextBlock_zul5l5RzGYv6" summary="xdx: Disclosure - Concentration and risk (Details 1)" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BD_zHRJbQ5m4O88" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Schedule of account receivable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of<br/> June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Customer G</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_ztRPBtEWTJi8" title="Concentration of credit risk" style="color: rgb(204,238,255)"><span style="-sec-ix-hidden: xdx2ixbrl2244">-</span></span>*</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zfLH42HKXt76" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember" id="Fact002246" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">42.7</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer H</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zNKBHqTWkrn4" title="Concentration of credit risk" style="color: White"><span style="-sec-ix-hidden: xdx2ixbrl2248">-</span></span>*</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zEKpxvmQvgCh" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember" id="Fact002250" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">38.3</ix:nonFraction></span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer F</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zGqVCvs69Qf1" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember" id="Fact002252" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">23.4</ix:nonFraction></span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zC5KwJCVT3zf" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember" id="Fact002254" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">19.0</ix:nonFraction></span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer D</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_znrResZohiG9" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember" id="Fact002256" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">43.5</ix:nonFraction></span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_z6V3t8cHkLUj" title="Concentration of credit risk" style="color: White"><span style="-sec-ix-hidden: xdx2ixbrl2258">-</span></span>**</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer I</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zYzaLovelHqg" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerIMember_custom_ExascaleLabsIncMember" id="Fact002260" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">15.3</ix:nonFraction></span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span></span>**</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">*:</td>
    <td style="text-align: justify">nil, new customer for as of June&#160;30, 2025</td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zazzTEdf3qC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Concentration of suppliers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s purchases was concentrated among
a limited number of suppliers during the periods presented. The following table summarized suppliers with greater than 10% of the total
purchase:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002262" name="cik0002065779:ScheduleOfConcentrationOfSuppliersTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfConcentrationOfSuppliersTableTextBlock_zdj4W8YCipk8" summary="xdx: Disclosure - Concentration and risk (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B7_zFinAf9oIFQc" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Schedule of Concentration of suppliers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/> years ended<br/> June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Supplier A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__srt--MajorCustomersAxis__custom--SupplierAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGIyJJPBbOil" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012024-06-30_custom_PurchaseMember_custom_SupplierAMember_us-gaap_CustomerConcentrationRiskMember_custom_ExascaleLabsIncMember" id="Fact002264" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">56.6</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zXZaKxf02Dlh" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember" id="Fact002266" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">41.4</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplier B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zgOzrD5jGv2g" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012024-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember" id="Fact002268" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">14.6</ix:nonFraction></span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_z26lViCdPaY" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember" id="Fact002270" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">31.7</ix:nonFraction></span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplier C</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zo7uj5B50TF2" title="Concentration of credit risk" style="color: rgb(204,238,255)"><span style="-sec-ix-hidden: xdx2ixbrl2272">-</span></span>**</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_z9dWnq9LW8u3" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember" id="Fact002274" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">18.4</ix:nonFraction></span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplier D</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zG0uIze1Y1Ua" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012024-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember" id="Fact002276" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">12.8</ix:nonFraction></span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zPqI0xfZVU09" title="Concentration of credit risk" style="color: White"><span style="-sec-ix-hidden: xdx2ixbrl2278">-</span></span>**</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zNVjriFteaE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s account payable was concentrated
among a limited number of suppliers during the periods presented. The following table summarized suppliers with greater than 10% of the
total account payable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002280" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zUoSMF44CI8f" summary="xdx: Disclosure - Concentration and risk (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BC_zrFgXmZyLEDl" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Schedule of account payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of<br/> June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Supplier E</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90E_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zD1SOuo8O6Gl" title="Concentration of credit risk" style="color: rgb(204,238,255)"><span style="-sec-ix-hidden: xdx2ixbrl2282">-</span></span>*</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_909_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_znsgNbuG5cH8" title="Concentration of credit risk"><ix:nonFraction name="cik0002065779:ConcentrationRiskPercentage" contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember" id="Fact002284" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">54.9</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplier F</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_zdOC7T9Z4elg" title="Concentration of credit risk" style="color: White"><span style="-sec-ix-hidden: xdx2ixbrl2286">-</span></span>*</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_zoDYy0fMwpSi" title="Concentration of credit risk"><ix:nonFraction name="cik0002065779:ConcentrationRiskPercentage" contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember" id="Fact002288" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">32.3</ix:nonFraction></span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplier C</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_z0VhqD2tSjGa" title="Concentration of credit risk"><ix:nonFraction name="cik0002065779:ConcentrationRiskPercentage" contextRef="From2023-07-012024-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember" id="Fact002290" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">99.4</ix:nonFraction></span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zwMhyEreZMRe" title="Concentration of credit risk"><ix:nonFraction name="cik0002065779:ConcentrationRiskPercentage" contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember" id="Fact002292" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">12.1</ix:nonFraction></span></td>
    <td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">*:</td>
    <td style="text-align: justify">nil, new supplier for the year ended June&#160;30, 2025</td> </tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zUoOBb8uOtB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 405; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zBH9OP6O2mf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002295" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_809_eus-gaap--FairValueDisclosuresTextBlock_zZLKhN6jsn7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>4. <span id="xdx_820_zfA52tDeRbgk">Fair value measurements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June&#160;30, 2024 and 2025, information about
inputs into the fair value measurement of the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis
in periods subsequent to their initial recognition is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002297" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zaDKp93MBRA3" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BC_zDd0pvvQ169b" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Schedule of fair value assets and liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measurement at reporting date using</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Description</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value <br/>as of<br/>June&#160;30,<br/>2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted Prices in<br/>Active Markets for<br/>Identical
        Assets <br/>(Level 1)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other<br/>Observable Inputs <br/>(Level
        2)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant <br/>Unobservable Inputs <br/>(Level
        3)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left">Simple agreements for future equity<sup>(1)</sup></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zZ4Gbth8BH69" title="Liability"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember" id="Fact002299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,321,564</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zjkwY6IR5PDj" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2301">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zZGm8phKzm75" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2303">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zwGllHMiXKtd" title="Liability"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember" id="Fact002305" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,321,564</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other payable related to the equity option<sup>(2)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zAoKTZ3VLxo3" title="Liability"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember" id="Fact002307" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,333</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zoB0jQpIEfc6" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2309">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_z30wtD4xs1Jf" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2311">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zwMRf4C7bDM6" title="Liability"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember" id="Fact002313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,333</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measurement at reporting date using</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Description</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Fair value <br/>as of<br/>June&#160;30,</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2025</b></p></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted Prices in<br/>Active Markets for<br/>Identical
        Assets <br/>(Level 1)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other<br/>Observable Inputs <br/>(Level
        2)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant <br/>Unobservable Inputs <br/>(Level
        3)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left">Simple agreements for future equity<sup>(1)</sup></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zLQGMKOLzu9g" title="Liability"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember" id="Fact002315" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,243,885</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zrVTS8w1XDWd" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2317">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zaXQfj4FsIb" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2319">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zchHueBxrDm8" title="Liability"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember" id="Fact002321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,243,885</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other payable related to the equity option<sup>(2)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zqgBO7cAGUw8" title="Liability"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember" id="Fact002323" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,333</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zy2IwQHN8iz8" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2325">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zzWPmd3ZrEEg" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2327">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zaU0cwEh6R2h" title="Liability"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember" id="Fact002329" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,333</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td id="xdx_F02_zz6sJxvOrWkk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left">(1)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
        <p id="xdx_F12_z2I6TVTCss33" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><ix:footnote id="Footnote002330" xml:lang="en-US">The Company classifies its SAFEs as financial liabilities
        measured at fair value. The value of the agreements depends significantly on future financing activities, liquidity events, or other material
        milestones, and their valuation relies on significant inputs that are not observable in the public market. Accordingly, they are classified
        within Level 3 of the fair value hierarchy.</ix:footnote></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value measurement is based on an integrated
        framework combining&#160;scenario analysis and financial instrument decomposition (i.e. Bond Plus Call Method). The proceeds from the
        SAFEs on the date of issuance was $10,592,500, Refer to Note 9-Simple Agreements for Future Equity for further details.</p> </td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span id="xdx_F06_zXSVw5NzMGUg" style="color: #0F1115; color: #0F1115">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span id="xdx_F1A_z1nxpK5jT4mb" style="color: #0F1115; color: #0F1115"><ix:footnote id="Footnote002331" xml:lang="en-US">Equity
        option. On May&#160;9, 2023, the Company entered into an agreement with a third-party service provider (the &#8220;Service Provider&#8221;).
        The Service Provider received a freestanding equity-linked right exercisable, at the Service Provider&#8217;s option, upon the closing
        of the Company&#8217;s next qualified equity financing. The right provides the ability to subscribe for up to the value of $200,000 at
        a 25% discount price per share on the grant date. The equity option is remeasured at fair value at each reporting date, with changes in
        fair value recognized in earnings. As of June&#160;30, 2024 and June&#160;30, 2025, the fair value of the equity option was $53,333, and
        no gain or loss from changes in fair value was recognized for the periods presented. The fair value measurement of the equity option is
        categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based analysis, which incorporates significant
        unobservable inputs and management judgment regarding the probability and timing of potential future financing outcomes.</ix:footnote></span></td> </tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zHmdNJR8ytF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 406; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zY78sBvghYWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002334" name="us-gaap:AccountsAndNontradeReceivableTextBlock"><p id="xdx_806_eus-gaap--AccountsAndNontradeReceivableTextBlock_zdje7HeU8Tqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>5. <span id="xdx_826_z2cS9GvZHBdg">Accounts receivable </span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002336" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zOSA2JgZjj2j" summary="xdx: Disclosure - Accounts receivable (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B0_zVKrFI6QAXc2" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Schedule of Accounts receivable</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of<br/> June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Accounts receivable</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_903_eus-gaap--AccountsReceivableNetCurrent_c20240630_pp0p" title="Accounts receivable"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,332</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--AccountsReceivableNetCurrent_c20250630_pp0p" title="Accounts receivable"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002340" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,536</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less: allowance for credit
        losses</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_c20240630_zTKCr1aFiAHe" title="Less: allowance for credit losses"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002342" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">-</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_c20250630_zo59ljd2r8vk" title="Less: allowance for credit losses"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002344" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">-</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Accounts
        receivable, net</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_901_eus-gaap--AccountsReceivableNet_c20240630_pp0p" title="Accounts receivable, net"><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,332</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_902_eus-gaap--AccountsReceivableNet_c20250630_pp0p" title="Accounts receivable, net"><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002348" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,536</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts Receivable are recorded at the invoiced amount
and do not bear interest. The Company maintains an allowance for credit losses for expected losses over the life of the accounts receivable
using the current expected credit loss methodology. The Company determines the allowance based on historical loss experience, current
conditions, and reasonable and supportable forecasts. As of June&#160;30, 2024 and 2025, there was <span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20240630_zNwMZQsRvRJ9" title="Allowance for credit losses"><span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_z7pQLRmnRnl8" title="Allowance for credit losses"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002350" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002352" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> allowance for expected credit losses.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002354" name="cik0002065779:OtherReceivablesTextBlock"><p id="xdx_80A_ecustom--OtherReceivablesTextBlock_zA37jU1ZOfV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<br/><b>6. <span id="xdx_821_zYjS7DyznEb5">Other receivables</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other receivables represent funds temporarily held
in trust by an employee acting as the Company&#8217;s behalf. As of June&#160;30, 2024 and 2025, the balance were $<span id="xdx_90D_eus-gaap--OtherReceivables_c20240630_pp0p" title="Other receivables"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,884,694</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--OtherReceivables_c20250630_pp0p" title="Other receivables"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002358" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,207,626</ix:nonFraction></span>,
respectively, primary comprising proceeds from SAFEs agreements received via the employee <span style="color: #0F1115; color: #0F1115">and
net of payments made to designated suppliers at the Company&#8217;s direction. The outstanding balance was fully settled in January&#160;2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002360" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zLYDRpyLKNhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>7. <span id="xdx_820_z8sx4dTJBxsg">Equipment, net</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equipment, net consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002362" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--PropertyPlantAndEquipmentTextBlock_zWlZAMPXOKe1" summary="xdx: Disclosure - Equipment, net (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B5_z96otHUhXDyg" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Schedule of Equipment</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_497_20240630_zIHWu3xL186" style="font-weight: bold; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_492_20250630_zYNqMLOHwIRg" style="font-weight: bold; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of<br/> June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt">Equipment</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002364" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,806</ix:nonFraction></td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002365" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,944</ix:nonFraction></td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherNet" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002367" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,806</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherNet" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,944</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_pp0d_di_zx2ts7Yln7tf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002370" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,110</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,344</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net
        carrying amount</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002373" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,696</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002374" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,600</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expenses for the&#160;years ended June&#160;30,
2024 and 2025 were $<span id="xdx_900_eus-gaap--Depreciation_c20230701__20240630_zomGNXN2kYl4" title="Depreciation expenses"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002376" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,110</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--Depreciation_c20240701__20250630_zueTAB6r85N5" title="Depreciation expenses"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,234</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002380" name="cik0002065779:RefundableDepositsPayableTextBlock"><p id="xdx_80D_ecustom--RefundableDepositsPayableTextBlock_zdT8v1NNaUXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>8. <span id="xdx_82D_zslWpkq71Jm9">Refundable deposits payable </span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Refundable deposits payable represent security payments
received from a third party and customers, which are required for certain intelligent computing power service arrangements. As of June&#160;30,
2024 and 2025, the balance were $<span id="xdx_908_ecustom--RefundableDepositsPayable_c20240630_pp0p" title="Refundable deposits payable"><ix:nonFraction name="cik0002065779:RefundableDepositsPayable" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002382" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,205</ix:nonFraction></span> and $<span id="xdx_909_ecustom--RefundableDepositsPayable_c20250630_pp0p" title="Refundable deposits payable"><ix:nonFraction name="cik0002065779:RefundableDepositsPayable" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002384" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,445,580</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002386" name="cik0002065779:SimpleAgreementsForFutureEquityTextBlock"><p id="xdx_803_ecustom--SimpleAgreementsForFutureEquityTextBlock_zOlXnvXLN6Ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>9. <span id="xdx_821_zGErECRHaUFh">Simple agreements for future equity</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has entered into SAFEs with various investors
that were classified as liabilities on the Company&#8217;s balance sheets and accounted for at fair value, subject to remeasurement each
reporting period. Each SAFEs has no maturity date, does not bear any interest and provides the investor with the right to convert into
a variable number of shares of future equity in the Company at the stated conversion amount, if certain events or conditions are triggered.</p>

<ix:exclude><p id="xdx_238_zQhu2zaI3lD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 407; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zYzpAZxJ4D5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zOrdPvS7NGB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>9. Simple agreements for future equity (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period from October&#160;2022 through June&#160;2025,
the Company entered into Simple Agreements for Future Equity with third-party investors, receiving aggregate gross proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromOtherEquity_c20221001__20250630_pp0p" title="Aggregate gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2022-10-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002391" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,592,500</ix:nonFraction></span>.
Of this amount, $<span id="xdx_900_eus-gaap--ProceedsFromOtherEquity_c20230701__20240630_pp0p" title="Aggregate gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002393" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,685,000</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--ProceedsFromOtherEquity_c20240701__20250630_pp0p" title="Aggregate gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002395" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,307,500</ix:nonFraction></span> were recorded in the fiscal years ended June&#160;30, 2024 and 2025, respectively. Subsequent
to June&#160;30, 2025, the Company received additional SAFEs proceeds of $<span id="xdx_905_ecustom--AdditionalSafesProceeds_pp0d_c20240701__20250606__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkdoR94mROG6" title="Additional SAFEs proceeds"><ix:nonFraction name="cik0002065779:AdditionalSafesProceeds" contextRef="From2024-07-012025-06-06_us-gaap_SubsequentEventMember_custom_ExascaleLabsIncMember" id="Fact002397" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span>, resulting in cumulative proceeds of $<span id="xdx_908_ecustom--CumulativeProceeds_pp0d_c20240701__20250606__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVj7nuUFaL8k" title="Cumulative proceeds"><ix:nonFraction name="cik0002065779:CumulativeProceeds" contextRef="From2024-07-012025-06-06_us-gaap_SubsequentEventMember_custom_ExascaleLabsIncMember" id="Fact002399" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,092,500</ix:nonFraction></span> as
of the date of this report. No issuance costs were incurred in connection with these arrangements. As of the date these financial statements
are issued, none of the SAFEs have been settled or converted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The SAFEs agreements grant investors the right to
participate in the Company&#8217;s future equity financing events. The agreements contain various conversion and redemption provisions,
including conversion upon an equity financing event, as well as settlement in the event of a liquidity event or dissolution of the Company.
Key terms of the SAFEs are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Equity Financing</i></b>&#160;&#8211; Upon the
occurrence of an equity financing event, each SAFEs automatically converts into a greater of (i)&#160;the number of shares of preferred
stock equal to SAFEs purchase amount divided by <span style="color: #0F1115; color: #0F1115">the lowest price per share paid for the standard
preferred stock</span> or (ii)&#160;the number of shares of preferred stock equal to the SAFEs purchase amount divided by the SAFEs price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#8220;SAFEs price&#8221; means <span style="color: #0F1115; color: #0F1115">is
        calculated by dividing a fixed post-money valuation cap by the Company capitalization, a defined term that includes all outstanding equity
        and convertible instruments.</span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#8220;Equity Financing&#8221; means a bona
        fide transaction or series of transactions with the principal purpose of raising capital, pursuant to which the Company issues and sells
        preferred share at a fixed valuation, including but not limited to, a pre-money or post-money valuation.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not all SAFEs agreements contain the equity financing
conversion provision described above. Certain SAFEs are structured without an Equity Financing conversion feature and are generally settled
only upon a Liquidity Event or a Dissolution Event (as defined in the respective SAFEs agreements). The Company considered the contractual
terms of the SAFEs, including whether an Equity Financing conversion feature is present and the settlement provisions upon a Liquidity
Event or a Dissolution Event, in the valuation and measurement of these instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June&#160;30, 2025, <span id="xdx_90D_ecustom--EquityFinancingDescription_pp0d_c20240701__20250630_zpoJJ0lxxOh" title="Equity Financing description"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002401" name="cik0002065779:EquityFinancingDescription">SAFEs with an aggregate
purchase amount of $10,132,500 include an Equity Financing conversion feature, while SAFEs with an aggregate purchase amount of $460,000
do not include this feature and are generally settled only upon a Liquidity Event or a Dissolution Event, in accordance with their terms.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #0F1115; color: #0F1115">The Company
does not have any preferred stock outstanding as of February&#160;11, 2026; therefore, an equity financing event has not been triggered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Liquidity Event</i></b>&#160;&#8211; If there
is a liquidity event before the conversion of each SAFE, the holder of each SAFEs will automatically be entitled to the greater of (i)
SAFEs purchase amount, or (ii)&#160;the amount payable on the number of shares of ordinary shares equal to the purchase amount divided
by the Liquidity Price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#8220;Liquidity Price&#8221; is calculated
        by dividing the post-money valuation cap by the separately defined capital base, referred to as &#8220;liquidity capitalization&#8221;
        in the SAFEs agreements.</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#8220;Liquidity Event&#8221; means a change
        of control, a direct Listing or an initial public offering.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Dissolution Event</i></b>&#160;&#8211; If there
is a dissolution event before the conversion of each SAFE, the holder of each SAFEs will automatically be entitled to receive a portion
of proceeds equal to SAFEs purchase amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company classifies its SAFEs as financial liabilities
measured at fair value. Since the value of these instruments depends on significant unobservable inputs, including future financing activities
and liquidity events, they are classified as Level 3 within the fair value hierarchy.</p>

<ix:exclude><p id="xdx_23B_zQ2st8kZNvs2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 408; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zK3o78AK2Raf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zHi8brNfrnjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>9. Simple agreements for future equity (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value measurement utilizes a combined scenario
analysis and financial instrument decomposition approach. Based on management&#8217;s assessment of the Company&#8217;s prospects, probability
distributions are assigned to potential settlement-triggering events. Valuation is performed using a &#8220;debt plus option&#8221; model:
the debt component is valued using a discounted cash flow method with key assumptions including expected settlement timing, risk-free
interest rate, and credit spread; the embedded conversion right is treated as a call option and valued using the Black-Scholes model,
with key inputs including the fair value of ordinary shares, expected term, and volatility. The overall fair value represents the probability-weighted
sum across all scenarios, supported by an independent third-party valuation specialist.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June&#160;30, 2024 and 2025, the SAFEs liabilities
were measured at fair value using the above Level 3 methodology. Significant unobservable inputs&#8212;including timing of events, volatility,
and credit spreads&#8212;are based on management&#8217;s reasonable estimates as of each valuation date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following tables set forth a summary of the activity
of the SAFEs liabilities, respectively, which represents a recurring fair value measurement at the end of each reporting period:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002406" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zfdZKaMA3CCa" summary="xdx: Disclosure - Simple agreements for future equity (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BD_z692NbrbQ79l" style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Schedule of fair value measurement</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left; padding-bottom: 1pt">Balance at
        June&#160;30, 2023</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b><span id="xdx_90A_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20230701__20240630_z3t0Cul6FTGe" title="Balance at beginning"><ix:nonFraction name="cik0002065779:SimpleAgreementsForFutureEquity" contextRef="AsOf2023-06-30_custom_ExascaleLabsIncMember" id="Fact002408" format="ixt:numdotdecimal" decimals="0" unitRef="USD">526,046</ix:nonFraction></span></b></td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Issuance of simple agreements for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20230701__20240630_z8DBIBOQ2pC6" title="Issuance of simple agreements for future equity"><ix:nonFraction name="cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002410" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,685,000</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Change in fair value</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--ChangeInFairValue_c20230701__20240630_pp0p" title="Change in fair value"><ix:nonFraction name="cik0002065779:ChangeInFairValue" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002412" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,110,518</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Balance at June&#160;30,
        2024</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span id="xdx_90F_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20240701__20250630_zmXBtU0sSxXj" title="Balance at beginning"><ix:nonFraction name="cik0002065779:SimpleAgreementsForFutureEquity" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,321,564</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Issuance of simple agreements for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20240701__20250630_zpOe9NCtkcUa" title="Issuance of simple agreements for future equity"><ix:nonFraction name="cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002416" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,307,500</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Change in fair value</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--ChangeInFairValue_pp0d_c20240701__20250630_zSYkDe6txhu7" title="Change in fair value"><ix:nonFraction name="cik0002065779:ChangeInFairValue" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002418" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,614,821</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Balance at June&#160;30,
        2025</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span id="xdx_901_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20240701__20250630_zgTzyRzot0oc" title="Balance at ending"><ix:nonFraction name="cik0002065779:SimpleAgreementsForFutureEquity" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002420" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,243,885</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #0F1115; color: #0F1115">If and
when the SAFEs are converted into equity, management currently expects that such conversion would be settled through transfers of existing
ordinary shares held by the controlling shareholder, rather than through the issuance of new shares by the Company, subject to the final
conversion terms and the relevant agreements. To the extent settled in this manner, the underlying ordinary shares are already included
in the Company&#8217;s issued and outstanding shares as of the balance sheet date; therefore, such settlement would not be expected to
increase the Company&#8217;s total issued and outstanding shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to June&#160;30, 2025 (see Note 1), in
connection with the proposed business combination, the outstanding SAFEs are expected to be settled upon the closing of the transaction
(the &#8220;Closing&#8221;). Pursuant to their terms, if a SPAC transaction occurs prior to the termination of the SAFEs, each SAFE will
automatically convert at the Closing into the right to receive Class A ordinary shares of PubCo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At the Closing of BCA transaction, each of SAFEs is
expected to convert into the Class A shares of the PubCo without any action required by the SAFE holders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002422" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zcy1yoqRg3A8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>10. <span id="xdx_829_zqCnxgL6N714">Income taxes</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company was incorporated in the State of Delaware
and is subject to income taxes in its primary jurisdictions: U.S. federal income tax and Delaware state corporate income tax. The statutory
tax rates applicable to the Company are <span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c20230701__20240630_pd" title="Federal income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002424" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">21</ix:nonFraction>%</span> at the federal level and <span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c20230701__20240630_pd" title="State income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002426" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">8.7</ix:nonFraction>%</span> at the Delaware state level.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The current and deferred components of income tax
expense reflected in the statements of operations and comprehensive loss were nil for the years ended June&#160;30, 2024 and 2025.</p>

<ix:exclude><p id="xdx_23F_zAxqcY9B1Qnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 409; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zwJ23BMqWyU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_ze7QkGDV3QUl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>10. Income taxes (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table reconciles the statutory rate
to the Company&#8217;s effective tax rate. The effective tax rate reconciliation is based on the U.S. federal statutory rate of <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c20240701__20250630_pd" title="Federal income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002431" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">21</ix:nonFraction>%</span> and
State income tax rate of <span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c20240701__20250630_pd" title="State income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002433" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">8.7</ix:nonFraction>%</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002435" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zsAoZZYShxpj" summary="xdx: Disclosure - Income taxes (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B0_zDFQbJEySiid" style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Schedule
    of effective tax rate reconciliation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_493_20230701__20240630_zzRi4Ul5zEh4" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_494_20240701__20250630_z4awAYIlbT9i" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/>years ended <br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zobXWve4AQQ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">US Statutory income tax rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002437" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">21.0</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002438" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">21.0</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zXJf7zZEBnT9" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">State income tax rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002440" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">8.7</ix:nonFraction></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002441" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">8.7</ix:nonFraction></td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_z7RcGEC6ZYGk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Change in fair value of simple agreements
        for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002443" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Ratio">18.6</ix:nonFraction></td>
    <td style="text-align: left">)%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002444" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Ratio">17.9</ix:nonFraction></td>
    <td style="text-align: left">)%</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zr3zjXhd2iGj" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Changes in valuation
        allowance</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002446" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Ratio">11.1</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)%</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002447" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Ratio">11.8</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_zoxSlARfz4f7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Effective income tax
        rate</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002449" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Ratio">-</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002450" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Ratio">-</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zEYZ96HGd4s6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s effective income tax rate was&#160;<span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20230701__20240630_pd" title="Effective income tax rate"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20240701__20250630_pd" title="Effective income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002452" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002454" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0</ix:nonFraction></ix:nonFraction>%</span></span>&#160;for
both years ended June&#160;30, 2024 and 2025. This is primarily attributable to the&#160;recognition of a full valuation allowance against
the net deferred tax assets, as the Company has concluded that it is not more likely than not that these assets will be realized in the
foreseeable future. Accordingly, no tax benefit has been recognized for the losses incurred during these periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The principal components of deferred tax assets and
deferred tax liabilities were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002456" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z7D3h5I8b915" summary="xdx: Disclosure - Income taxes (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B9_zttoKTamREFa" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Schedule of deferred tax assets liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_494_20240630_za1CYiN8uNR8" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_497_20250630_zzAPMP8qH497" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of <br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zBsuAX9Qs0ka" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Deferred tax assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0d_maDTAGzLH3_zHcERxaR5LOi" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net operating loss carry forward</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002461" format="ixt:numdotdecimal" decimals="0" unitRef="USD">748,679</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002462" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,652,998</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0d_mtDTAGzLH3_maDTANzse2_zpw9mkr8b4Dl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Total deferred tax assets</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002464" format="ixt:numdotdecimal" decimals="0" unitRef="USD">748,679</ix:nonFraction></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,652,998</ix:nonFraction></td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0d_di_msDTANzse2_zkDKYZabHnVh" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less: valuation allowance</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002467" format="ixt:numdotdecimal" decimals="0" unitRef="USD">748,679</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002468" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,652,998</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_pp0d_mtDTANzse2_zy5BDhrvNfsk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total
        deferred tax assets, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2470">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2471">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zuxWXyBw7azl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The changes in valuation allowance for the years ended
June&#160;30, 2024 and 2025 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002473" name="us-gaap:SummaryOfValuationAllowanceTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--SummaryOfValuationAllowanceTextBlock_zEsllNSptTmj" summary="xdx: Disclosure - Income taxes (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B0_zZZDDEY0OvS5" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Schedule of valuation allowance</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/>years ended<br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Balance at the beginning of the
        year</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pp0d_di_c20230701__20240630_zJGpG8QdG3kj" title="Balance at the beginning of the year">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-06-30_custom_ExascaleLabsIncMember" id="Fact002475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,468</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pp0d_di_c20240701__20250630_zQtXy1pEoPm8" title="Balance at the beginning of the year">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002477" format="ixt:numdotdecimal" decimals="0" unitRef="USD">748,679</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Additions</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230701__20240630_pp0p" title="Additions">(<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002479" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">548,211</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20240701__20250630_pp0p" title="Additions">(<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002481" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">904,319</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance
        at the end of the year</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_908_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pp0d_di_c20230701__20240630_zoH4it63AAy2" title="Balance at the end of the year">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002483" format="ixt:numdotdecimal" decimals="0" unitRef="USD">748,679</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_907_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pp0d_di_c20240701__20250630_zU4aB0tVNds8" title="Balance at the end of the year">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002485" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,652,998</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z8CNIKlnZrV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June&#160;30, 2024 and 2025, the Company had
net operating loss carryforwards (&#8220;NOLs&#8221;) of $<span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20240630__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_zpz7739yT5vi" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-06-30_us-gaap_DomesticCountryMember_custom_ExascaleLabsIncMember" id="Fact002487" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.5</ix:nonFraction> </span>million and $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20250630__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_zc5tGTGft7Zk" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-06-30_us-gaap_DomesticCountryMember_custom_ExascaleLabsIncMember" id="Fact002489" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">5.6</ix:nonFraction></span> million for U.S. federal income tax purposes and $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20240630__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--StateAndLocalJurisdictionMember_zrcfQglwNFDb" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-06-30_us-gaap_StateAndLocalJurisdictionMember_custom_ExascaleLabsIncMember" id="Fact002491" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million
and $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20250630__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--StateAndLocalJurisdictionMember_zrvFbn738Xcg" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-06-30_us-gaap_StateAndLocalJurisdictionMember_custom_ExascaleLabsIncMember" id="Fact002493" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">5.6</ix:nonFraction></span> million for state income tax purposes.&#160;The federal NOLs&#160;do not expire but are subject to an annual deduction limit
of 80% of taxable income.&#160;The Company&#8217;s NOLs can be carried forward to offset current year profit for Delaware corporate income
tax purposes, subject to certain limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes deferred tax assets if it is
more likely than not that those deferred tax assets will be realized. Management reviews deferred tax assets periodically for recoverability
and makes estimates and judgments regarding the expected geographic sources of taxable income in assessing the need for a valuation allowance
to reduce deferred tax assets to their estimated realizable value. Realization of the Company&#8217;s deferred tax assets is dependent
upon future earnings, if any, the timing and amount of which are uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company had <span id="xdx_909_eus-gaap--UnrecognizedTaxBenefits_iI_pp0d_do_c20250630_zIwngjxvmio1" title="Unrecognized tax benefits"><span id="xdx_903_eus-gaap--UnrecognizedTaxBenefits_iI_pp0d_do_c20240630_zXcxlUP6ogpf" title="Unrecognized tax benefits"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002495" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002497" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> unrecognized tax benefits as of
June&#160;30, 2024 and 2025. The Company currently files income tax returns in the U.S., as well as Delaware. All tax years are open for
examination. The Company currently has no federal or state tax examinations in progress.</p>

<ix:exclude><p id="xdx_23E_zjtelajDfENj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 410; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002500" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock"><p id="xdx_80A_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zEMl0kz98Cb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>11. <span id="xdx_82F_zojw0uTLGhUa">Share-based compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended June&#160;30, 2024 and 2025, total
share-based compensation expenses recognized were $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230701__20240630_pp0p" title="Share-based compensation expenses"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002502" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,104</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630_pp0p" title="Share-based compensation expenses"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002504" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,266</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the share-based compensation
expenses for the years ended June&#160;30, 2024 and 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002506" name="us-gaap:ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock_zYgAKTu1lo7k" summary="xdx: Disclosure - Share-based compensation (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BB_zwzJiikWfcV4" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Schedule of share-based compensation expenses</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <br/>years ended <br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Selling and marketing expenses</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensation_c20230701__20240630__custom--IncomeStatementLocationsAxis__custom--SellingAndMarketingExpensesMember_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2508">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20240701__20250630__custom--IncomeStatementLocationsAxis__custom--SellingAndMarketingExpensesMember_pp0p" title="Total"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-06-30_custom_SellingAndMarketingExpensesMember_custom_ExascaleLabsIncMember" id="Fact002510" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,266</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">General and administrative
        expenses</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230701__20240630__custom--IncomeStatementLocationsAxis__custom--GeneralAndAdministrativeExpensesMember_pp0p" title="Total"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_custom_GeneralAndAdministrativeExpensesMember_custom_ExascaleLabsIncMember" id="Fact002512" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,104</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630__custom--IncomeStatementLocationsAxis__custom--GeneralAndAdministrativeExpensesMember_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2514">-</span></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0d_c20230701__20240630_zG6MuWsZDbL5" title="Total"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002516" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,104</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0d_c20240701__20250630_zgdo4PX2S2yh" title="Total"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002518" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,266</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Employee</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January&#160;6, 2025, with the approval from the
Board of the Company, an employee was granted equity award from inception of the employment agreement, which represented 0.1% of the Company&#8217;s
total shares outstanding at issuance date (the &#8220;0.1% Award&#8221;, i.e., 1.5 shares). The equity award had a vesting period of 24
months after grant, but with no requisite service period. Alongside with the employee&#8217;s separation in September&#160;2025, the equity
award remained its vesting pace under the 24-month vesting schedule. As of June&#160;30, 2025, <span id="xdx_907_ecustom--SharesDescription_pp0d_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_ziZsFKTjvi5i" title="Shares description"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember" id="Fact002520" name="cik0002065779:SharesDescription">0.375 shares of the Company were vested,
with remaining 1.125 shares unvested.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determined January&#160;6, 2025 to be
the grant date of the 0.1% Award and recognized total share-based compensation expense amounted to $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_pp0p" title="Share-based compensation expenses"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember" id="Fact002522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,000</ix:nonFraction></span> at the grant date for the
award since the explicit service vesting condition is not the employee&#8217;s requisite service period, and the vesting condition is
not a service condition but is merely a delayed exercisability provision. The share-based compensation expense was calculated based on
the fair value of the 0.1% Award as of the grant date. The fair value of the 0.1% Award was determined with assistance of an independent
third-party valuation specialist using discounted cash flow method with key assumptions of risk free rate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Risk free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember" id="Fact002524" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.24</ix:nonFraction>%</span>, discount rate of <span id="xdx_900_ecustom--DiscountRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Discount rate"><ix:nonFraction name="cik0002065779:DiscountRate" contextRef="From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember" id="Fact002526" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">13.6</ix:nonFraction>%</span>
and perpetual rate of <span id="xdx_901_ecustom--PerpetualRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Perpetual rate"><ix:nonFraction name="cik0002065779:PerpetualRate" contextRef="From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember" id="Fact002528" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">3.0</ix:nonFraction>%</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) Non-employee</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December&#160;2, 2024, with the approval from the
Board of the Company, a contractor was granted equity award from inception of the contractor agreement representing 0.053333% of the Company&#8217;s
total shares outstanding at issuance date (&#8220;0.05% Award&#8221;, i.e., 0.8 shares). The equity award had a vesting period of 24 months
after grant, with half vested as of April&#160;1, 2025 and remaining as of November&#160;1, 2026, but with no requisite service period.
As of June&#160;30, 2025, the first half of the equity award had been vested, the remaining half had been outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determined December&#160;2, 2024 to be
the grant date of the 0.05% Award and recognized total share-based compensation expense amounted to $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pp0p" title="Share-based compensation expenses"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-06-30_custom_NonEmployeeMember_custom_ExascaleLabsIncMember" id="Fact002530" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,266</ix:nonFraction></span> at the grant date for the
award since the explicit service vesting condition is not the nonemployee&#8217;s vesting period, and the vesting condition is not a service
condition but is merely a delayed exercisability provision. The share-based compensation expense was calculated based on the fair value
of the 0.1% Award as of the grant date. The fair value of the 0.05% Award was determined with assistance of an independent third-party
valuation specialist using discounted cash flow method with key assumptions of risk free rate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pd" title="Risk free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-07-012025-06-30_custom_NonEmployeeMember_custom_ExascaleLabsIncMember" id="Fact002532" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.36</ix:nonFraction>%</span>, discount rate of <span id="xdx_90C_ecustom--DiscountRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pd" title="Discount rate"><ix:nonFraction name="cik0002065779:DiscountRate" contextRef="From2024-07-012025-06-30_custom_NonEmployeeMember_custom_ExascaleLabsIncMember" id="Fact002534" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">14.9</ix:nonFraction>%</span> and perpetual
rate of <span id="xdx_90E_ecustom--PerpetualRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pd" title="Perpetual rate"><ix:nonFraction name="cik0002065779:PerpetualRate" contextRef="From2024-07-012025-06-30_custom_NonEmployeeMember_custom_ExascaleLabsIncMember" id="Fact002536" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">3.0</ix:nonFraction>%</span>.</p>

<ix:exclude><p id="xdx_23B_zRRGv2smc239" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 411; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zshaAFthb1dd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zJejHVpb1v6l" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>11. Share-based compensation (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May&#160;9, 2023, the Company entered into an agreement
with a third-party Service Provider to receive accelerator training services. In consideration for these services, the Company agreed
to grant the Service Provider equity equal to 0.425% of shares outstanding at issuance. The Company accounts for the award as consideration
for services in accordance with ASC 718, <i>Compensation&#8212;Stock Compensation.</i> The Company measures equity instruments granted
to a non-employee in exchange for services at their fair value on the grant date and engaged an independent third-party valuation specialist
to determine the grant-date fair value using discounted cash flow method with key assumptions of risk free rate of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--ThirdPartyServiceProviderMember_pd" title="Risk free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-07-012025-06-30_custom_ThirdPartyServiceProviderMember_custom_ExascaleLabsIncMember" id="Fact002541" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">3.81</ix:nonFraction>%</span>, discount rate
of <span id="xdx_906_ecustom--DiscountRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--ThirdPartyServiceProviderMember_pd" title="Discount rate"><ix:nonFraction name="cik0002065779:DiscountRate" contextRef="From2024-07-012025-06-30_custom_ThirdPartyServiceProviderMember_custom_ExascaleLabsIncMember" id="Fact002543" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">15.5</ix:nonFraction>%</span> and perpetual rate of <span id="xdx_904_ecustom--PerpetualRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--ThirdPartyServiceProviderMember_pd" title="Perpetual rate"><ix:nonFraction name="cik0002065779:PerpetualRate" contextRef="From2024-07-012025-06-30_custom_ThirdPartyServiceProviderMember_custom_ExascaleLabsIncMember" id="Fact002545" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">3.0</ix:nonFraction>%</span>. The related compensation cost is recognized as expense, with a corresponding increase to additional
paid-in capital, on a straight-line basis over the requisite service period during which the counterparty provides services, which was
from May&#160;2023 through July&#160;2023. For the year ended June&#160;30, 2024, the Company recognized $<span id="xdx_908_eus-gaap--GeneralAndAdministrativeExpense_c20230701__20240630__srt--CounterpartyNameAxis__custom--ThirdPartyServiceProviderMember_pp0p" title="General and administrative expense"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-07-012024-06-30_custom_ThirdPartyServiceProviderMember_custom_ExascaleLabsIncMember" id="Fact002547" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,104</ix:nonFraction></span>, which was recorded within
general and administrative expense in the statements of operations and comprehensive loss. The award was fully vested as of June&#160;30,
2024 and 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s share-based compensation awards
are expected to be settled through transfers of existing ordinary shares held by the controlling shareholder, rather than through the
issuance of new shares by the Company. The underlying ordinary shares are included in the issued and outstanding shares as of the balance
sheet date; accordingly, such settlement is not expected to increase the Company&#8217;s total issued and outstanding shares. The vested
shares are not recorded in the individual names of the holders on the Company&#8217;s stock ledger, but held by the controlling shareholder
on their behalf, mainly due to the plan to a direct register of shares under the listed company during de-SPAC transaction. The Company,
as well as the controlling shareholder deemed the grant as the time when the employee and non-employees are entitled to economic benefits
and risks of the subsequent changes in fair value of the granted shares accordingly to the agreed vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002549" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zZF2x5NNJfbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>12. <span id="xdx_82E_zervGI5CRFMj">Related party transactions</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Hoansoo Lee serves as the Company&#8217;s Chief Executive
Officer and Chief Financial Officer. The Company has entered into a consulting services agreement with Hoansoo Lee, pursuant to which
Hoansoo Lee provides strategic consulting and advisory services to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended June&#160;30, 2024 and 2025, the
Company incurred and paid consulting fees totaling $<span id="xdx_902_ecustom--ConsultingFees_c20230701__20240630_pp0p" title="Consulting fees"><ix:nonFraction name="cik0002065779:ConsultingFees" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002551" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,245</ix:nonFraction></span> and $<span id="xdx_904_ecustom--ConsultingFees_c20240701__20250630_pp0p" title="Consulting fees"><ix:nonFraction name="cik0002065779:ConsultingFees" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002553" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,150</ix:nonFraction></span>, respectively. As of June&#160;30, 2024 and 2025, there were <span id="xdx_90B_ecustom--OutstandingBalancesPayable_iI_pp0d_do_c20250630_zv4U4ppRoKV9" title="Outstanding balances payable"><span id="xdx_906_ecustom--OutstandingBalancesPayable_iI_pp0d_do_c20240630_zJHMH77lauR4" title="Outstanding balances payable"><ix:nonFraction name="cik0002065779:OutstandingBalancesPayable" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002555" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="cik0002065779:OutstandingBalancesPayable" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002557" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>
outstanding balances payable to Hoansoo Lee as all amounts had been fully settled during the respective periods.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002559" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_80E_eus-gaap--EarningsPerShareTextBlock_zcKacb4NfAse" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>13. <span id="xdx_828_zmptkHzMOqij">Basic and diluted net loss per share</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic loss per share and diluted loss per share have
been calculated in accordance with ASC 260, &#8220;<i>Earnings Per Share</i>&#8221; on computation of loss per share for the years ended
June&#160;30, 2024 and 2025 as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002561" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zt9m69C0XZ2d" summary="xdx: Disclosure - Basic and diluted net loss per share (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B3_z4fVOy9hZcC8" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Schedule of basic share and diluted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_490_20230701__20240630_zNS6ebSpnWrd" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_49D_20240701__20250630_z1q8DgL1dZak" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <br/>years ended <br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Numerator:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net loss attributable to ordinary
        shareholders</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002563" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,956,347</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002564" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,659,667</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DenominatorForBasicAndDilutedLossPerShareAbstract_iB_zvdjC7dKX30c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Denominator for basic and diluted loss per
        share</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted-average ordinary shares outstanding,
        Basic and diluted*</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230701__20240630_fKg_____zQHyzKNbmYni" title="Weighted-average ordinary shares outstanding, Basic"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230701__20240630_fKg_____znyMMFNDxhuf" title="Weighted-average ordinary shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002569" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002571" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20250630_fKg_____zSHuzJLV0GTl" title="Weighted-average ordinary shares outstanding, Basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20250630_fKg_____zTkjibsim5P6" title="Weighted-average ordinary shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002573" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002575" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Basic and diluted loss per share</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230701__20240630_zmSb1V03Vrje" title="Basic loss per share"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20230701__20240630_zyJQB2bVMLV5" title="Diluted loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002577" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002579" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">3,304.23</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20240701__20250630_zD02im0uKoQi" title="Basic loss per share"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20240701__20250630_zN38w6qibdk8" title="Diluted loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002581" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002583" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">5,106.44</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td id="xdx_F08_zym9vF1L9h5a" style="width: 0.25in; text-align: left">*</td>
    <td id="xdx_F1F_zWe9J1egNUee" style="text-align: justify"><ix:footnote id="Footnote002584" xml:lang="en-US">The Company&#8217;s share-based compensation awards are expected to be settled through transfers of existing
        ordinary shares held by the controlling shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary
        shares are included in issued and outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase
        the Company&#8217;s total issued and outstanding shares. During the years ended June&#160;30, 2024 and 2025, diluted net loss per share
        is calculated in the same manner as basic net loss per share.</ix:footnote></td> </tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zykAwSGmR6Q2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 412; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_znNf5JQHvKtj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002587" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_zw6BQqHEgLZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>14. <span id="xdx_821_z4EX1JG2ykx6">Segment information</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company manages its business in a centralized
manner and operates as a single segment and accordingly has only one operating and reportable segment, the provision of GPU computing
platform services. The Company&#8217;s Chief Executive Officer serves as the Chief Operating Decision Maker (&#8220;CODM&#8221;). The
CODM regularly reviews entity-level operating results, including revenue and net loss as presented in the statement of operations and
comprehensive loss, when making decisions about resource allocation and assessing segment performance. Therefore, the Company has one
reportable segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary measures of segment revenue and profitability
for the Company&#8217;s operating segment&#160;are considered to be&#160;revenue and net loss. The CODM uses revenue to assess market
performance and growth, and net loss to evaluate profitability and cost management. Both measures are used together to allocate resources,
including personnel and capital resources. Significant expense categories regularly provided to and reviewed by the CODM include those
presented in the statements of operations and comprehensive loss as well as disaggregated expenses of staff costs and employee benefits,
professional service expenses, share-based compensation, and other general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents the segment information
of the Company for the measurement of segment profitability for the years ended June&#160;30, 2024 and 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002589" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zaZ6gYRQMRih" summary="xdx: Disclosure - Segment information (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B7_z0szaN7zwBSj" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b>Schedule
    of segment information</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_490_20230701__20240630_zry6rmEzVCB1" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_49D_20240701__20250630_zCZ2bAgyHGX5" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the<br/> years ended</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Revenues_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Revenues</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002591" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,319,115</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002592" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,015,512</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CostOfRevenue_zNi1liCsOXci" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cost of revenues</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002594" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,263,548</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002595" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,910,315</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_iN_di_zkj1o72qnmk8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Research and development expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,365,433</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002598" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,797,906</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--SellingAndMarketingExpenseAbstract_i01B_pp0d_zxMJN07A1pXg" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Selling and marketing expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--StaffCostsEmployeeBenefitsAndOfficeExpenses_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#8211; Staff costs, employee benefits and
        office expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002603" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">262,614</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002604" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">835,889</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--ShareBasedCompensations_i01_pp0d_z9QrXvmlrCpc" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#8211; Share-based compensation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2606">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:ShareBasedCompensations" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002607" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">153,266</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--SellingGeneralAndAdministrativeExpenseAbstract_i01B_pp0d_zDwHZaCWa85" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">General and administrative expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StaffCostsEmployeeBenefitsAndOthers_i01_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#8211; Staff costs, employee benefits and
        Others</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:StaffCostsEmployeeBenefitsAndOthers" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002612" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">244,651</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:StaffCostsEmployeeBenefitsAndOthers" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002613" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">328,662</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--ProfessionalAndContractServicesExpense_i01N_di_zh2ZOZkpFGtk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#8211; Professional service expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002615" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,594</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002616" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,320</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--ShareBasedCompensation1_i01N_pp0d_di_zzVfAlQURxe7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#8211; Share-based compensation</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="cik0002065779:ShareBasedCompensation1" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002618" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,104</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2619">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_i01_pp0d_z65lbRpLFMOh" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Loss
        from operations</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002621" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,845,829</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002622" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,044,846</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--ChangeInFairValueOfSimpleAgreementsForFutureEquity_i01N_di_zLicrVyEo7og" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Change in fair value
        of simple agreements for future equity</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002624" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,110,518</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002625" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,614,821</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeLossBeforeReclassificationsTax_i01_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Loss
        before income tax expenses</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002627" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,956,347</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002628" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,659,667</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Income tax expense</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2630">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2631">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProfitLoss_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Net
        loss</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002633" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,956,347</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002634" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,659,667</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zMAAq6XghBbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Geographic Information</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As substantially all of the Company&#8217;s long-lived
assets are located in the United States, no geographical segments of assets are presented. The following table presents the Company&#8217;s
revenue from major geographical areas for the periods indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002636" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zxaRjvXJPaOg" summary="xdx: Disclosure - Segment information (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BE_zWpnQqztGuFi" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Schedule of geographic information</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <br/>years ended <br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Singapore</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012024-06-30_country_SG_custom_ExascaleLabsIncMember" id="Fact002638" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,941</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-06-30_country_SG_custom_ExascaleLabsIncMember" id="Fact002640" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,484,905</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">United States of America</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012024-06-30_country_US_custom_ExascaleLabsIncMember" id="Fact002642" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,600</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-06-30_country_US_custom_ExascaleLabsIncMember" id="Fact002644" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,085,579</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Canada</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012024-06-30_country_CA_custom_ExascaleLabsIncMember" id="Fact002646" format="ixt:numdotdecimal" decimals="0" unitRef="USD">574,664</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-06-30_country_CA_custom_ExascaleLabsIncMember" id="Fact002648" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,443,306</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Hong Kong</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012024-06-30_country_HK_custom_ExascaleLabsIncMember" id="Fact002650" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,500</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-06-30_country_HK_custom_ExascaleLabsIncMember" id="Fact002652" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">United Kingdom</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012024-06-30_country_GB_custom_ExascaleLabsIncMember" id="Fact002654" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,410</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-06-30_country_GB_custom_ExascaleLabsIncMember" id="Fact002656" format="ixt:numdotdecimal" decimals="0" unitRef="USD">391,722</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Others</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012024-06-30_custom_OthersMember_custom_ExascaleLabsIncMember" id="Fact002658" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,000</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-06-30_custom_OthersMember_custom_ExascaleLabsIncMember" id="Fact002660" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90E_eus-gaap--Revenues_pp0d_c20230701__20240630_zoK7sngi7uI1" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember" id="Fact002662" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,319,115</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90F_eus-gaap--Revenues_pp0d_c20240701__20250630_zJvmNbPZ8VZg" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" id="Fact002664" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,015,512</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zSK0DbrUr1O8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 413; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zlFJNtWbhP41" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002667" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zV94gEMyYrl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>15. <span id="xdx_822_zL1TK7zRpema">Commitments and contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From inception to date, the Company has not been a
party to any legal proceedings, claims, or disputes arising in the ordinary course of business. As of June&#160;30, 2025, the Company
had no outstanding litigation, and there were no commitments or contingencies that management believes would have a material effect on
the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember" escape="true" id="Fact002669" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zFgRhy6z3nKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>16. <span>Subsequent events</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span><span id="xdx_829_zHJhA3sZiti7" style="display: none">Subsequent Events</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluated all events and transactions
that occurred after June&#160;30, 2025, up through February&#160;11, 2026, which is the date that these financial statements are issued,
unless as disclosed elsewhere and below, there was no other material subsequent events occurred that would require recognition or disclosure
in the Company&#8217;s financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Incorporation of a Subsidiary</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December&#160;16, 2025, subsequent to the reporting
period but prior to the authorization of these financial statements for issue, the Company incorporated its wholly-owned subsidiary, Evana
Alpha Pte. Ltd., in Singapore. The Company subscribed for all <span id="xdx_90A_ecustom--OrdinarySharesIssued_c20251201__20251216__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_pd" title="Ordinary shares issued"><ix:nonFraction name="cik0002065779:OrdinarySharesIssued" contextRef="From2025-12-012025-12-16_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember" id="Fact002671" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></span> ordinary shares of the subsidiary, with a issued share capital of
Singapore Dollars <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251201__20251216__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_pd" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-12-012025-12-16_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember" id="Fact002673" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></span>. The subsidiary&#8217;s principal business activity is information technology consultancy (excluding cybersecurity).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>SAFEs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From October&#160;1, 2025 to <span style="color: #0F1115; color: #0F1115">February&#160;11,</span>
2026, certain institutional and accredited investors provided $<span id="xdx_903_eus-gaap--ProceedsFromSaleOfNotesReceivable_pn3n3_dm_c20251001__20260211__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_zobhxoREKnUk" title="Proceeds from safes"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfNotesReceivable" contextRef="From2025-10-012026-02-11_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember" id="Fact002675" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.5</ix:nonFraction></span>&#160;million to the Company in the form of SAFEs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Capital Structure and Dual-Class Share Reclassification</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January&#160;2026, the Company adopted an Amended
and Restated Certificate of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#8217;s
equity is divided into Class A Ordinary Shares and Class B Ordinary Shares, which are entitled to one (1) vote and twenty (20) votes per
share, respectively. Despite the differential in voting power, Class A and Class B Ordinary Shares rank pari passu in all other respects,
sharing ratably in dividends and any distributions upon liquidation. Furthermore, all outstanding warrants, options, and SAFEs are designated
to convert or settle exclusively into Class A Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Business combination agreement and related events</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January&#160;2026, the Company entered into an
BCA with BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and a direct, wholly owned subsidiary of BCAR and D. Boral Arc
Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary of BCAR. Upon closing of the transaction, the combined company
will be named Exascale Labs Holdings Inc. and is expected to be traded on a national securities exchange. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate consideration for the Business Combination
is $<span id="xdx_902_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_dm_c20260101__20260131_z970NdDaFbca" title="Business combination payable"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2026-01-012026-01-31_custom_ExascaleLabsIncMember" id="Fact002677" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">500.0</ix:nonFraction></span> million, payable by the surviving publicly traded entity in the form of <span id="xdx_90F_ecustom--OrdinarySharesIssued_c20260101__20260131_pd" title="Ordinary shares issued"><ix:nonFraction name="cik0002065779:OrdinarySharesIssued" contextRef="From2026-01-012026-01-31_custom_ExascaleLabsIncMember" id="Fact002679" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></span> newly issued ordinary shares valued at $<span id="xdx_90D_ecustom--OrdinarySharesPerShare_c20260101__20260131_pd" title="ordinary shares per share"><ix:nonFraction name="cik0002065779:OrdinarySharesPerShare" contextRef="From2026-01-012026-01-31_custom_ExascaleLabsIncMember" id="Fact002681" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction>
</span>per share. At the effective time of the merger of the Company into the surviving publicly traded entity pursuant to the BCA, the Company&#8217;s
outstanding ordinary shares and outstanding SAFEs are expected to be cancelled and converted into the right to receive shares of the surviving
publicly traded entity in accordance with the terms of the BCA and the applicable SAFE instruments. Class A ordinary shares are expected
to have one vote per share, and Class B ordinary shares are expected to have 20 votes per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of February&#160;11, 2026, the transactions contemplated
by the BCA had not been consummated. Accordingly, the Company has not recorded any amounts in these financial statements related to the
BCA, as it represents a non-recognized subsequent event.</p>

</ix:nonNumeric><p id="xdx_812_zbIASJzJebR" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 414; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span id="fin4_001"></span><b>EXASCALE
LABS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>UNAUDITED
CONDENSED CONSOLIDATED</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>BALANCE
SHEETS AS OF JUNE 30, 2025 AND MARCH 31, 2026</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>(All
amounts in US$, except for number of shares)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_302_111_zM9wXZtxX73l" summary="xdx: Statement - BALANCE SHEET" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_491_20250630_zjwxKSkBs4ic" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_49B_20260331_zXxIL6Xnb7f5" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>As of<br/>June&#160;30,<br/>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>As of March&#160;31, 2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>(Unaudited)</b></td>
    <td>&#160;</td> </tr>
  <tr id="xdx_401_eus-gaap--AssetsAbstract_iB_zKUheLbaqqP4" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>ASSETS</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_403_eus-gaap--AssetsCurrentAbstract_i01B_z1g66WPQbIl" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Current
        Assets</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzNM3_zDdXjCd4pirh" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Cash and
        cash equivalents</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002689" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,231,689</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002690" format="ixt:numdotdecimal" decimals="0" unitRef="USD">984,830</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_409_ecustom--U.s.DollarCoin_iIP3us-gaap--CashAndCashEquivalentsAtCarryingValue_maCzNM3_maCze5E_ztG06dlrBu4j" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">U.S. Dollar
        Coin</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2692">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:U.s.DollarCoin" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002693" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,074,415</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_404_eus-gaap--AccountsAndOtherReceivablesNetCurrent_i02I_maCzNM3_zsXxTHtj7Cah" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Accounts
        receivable, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002695" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,536</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002696" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,830,105</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_408_ecustom--PrepaidResearchAndDevelopmentExpenses_iIP3us-gaap--AccountsAndOtherReceivablesNetCurrent_maCzNM3_maCze5E_zOS0YPjubU0e" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Prepaid
        research and development expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2698">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:PrepaidResearchAndDevelopmentExpenses" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002699" format="ixt:numdotdecimal" decimals="0" unitRef="USD">625,000</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_402_ecustom--AdvanceToSuppliers_i02I_maCzNM3_z3D1aNGbMh9l" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Advance
        to suppliers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:AdvanceToSuppliers" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002701" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,030,761</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:AdvanceToSuppliers" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002702" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,801</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_408_ecustom--RefundableDepositsReceivable_i02I_maCzNM3_zv0drYJjdeKg" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Refundable
        deposits receivable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:RefundableDepositsReceivable" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002704" format="ixt:numdotdecimal" decimals="0" unitRef="USD">681,125</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:RefundableDepositsReceivable" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002705" format="ixt:numdotdecimal" decimals="0" unitRef="USD">510,000</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_402_eus-gaap--OtherReceivablesNetCurrent_i02I_maCzNM3_zdKjEM3XJUii" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Other
        receivables</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002707" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,207,626</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2708">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrent_i01TI_mtCzNM3_maCzAhD_z1YsGLO53dK" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Total
        Current Assets</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002710" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,303,737</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002711" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,131,151</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40B_eus-gaap--AssetsNoncurrentAbstract_i01B_zOMwwizdCim1" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Non-Current
        Assets</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_407_eus-gaap--DeferredOfferingCosts_iIP2us-gaap--PropertyPlantAndEquipmentNet_d0_maCzcH5_maCzORO_zVnO8UtUYdEi" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Deferred
        offering costs</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002716" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">-</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002717" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,000</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maCzcH5_zr4vaM2Brxol" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Equipment,
        net</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002719" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,600</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002720" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,406</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_40E_eus-gaap--AssetsNoncurrent_i02TI_mtCzcH5_maCzAhD_zWToRTKl8PX" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Total
        Non-Current Assets</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002722" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,600</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002723" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,406</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_40D_eus-gaap--Assets_iTI_mtCzAhD_zb5ztTpMtNrf" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total
        Assets</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002725" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,323,337</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002726" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,240,557</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zS1RnTZ7FOp5" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>LIABILITIES
        AND SHAREHOLDERS&#8217; DEFICIT</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesCurrentAbstract_i01B_zl6cieUJpSo8" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Current
        Liabilities</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_i02I_maCzYrw_ziQNP3VahD2i" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Accounts
        payable</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002734" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,015</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002735" format="ixt:numdotdecimal" decimals="0" unitRef="USD">743,742</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_402_ecustom--SimpleAgreementsForFutureEquity_i02I_maCzYrw_z8Z60T5ZDt9" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Simple
        agreements for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:SimpleAgreementsForFutureEquity" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002737" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,243,885</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:SimpleAgreementsForFutureEquity" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002738" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,842,205</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40F_eus-gaap--DepositContractsLiabilities_i02I_maCzYrw_zLLKSl3Yvc84" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Contract
        liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DepositContractsLiabilities" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002740" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,760</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DepositContractsLiabilities" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002741" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,657</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40A_ecustom--RefundableDepositsPayable_i02I_maCzYrw_zS4xy5QCkpad" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Refundable
        deposits payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:RefundableDepositsPayable" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002743" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,445,580</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:RefundableDepositsPayable" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002744" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,174,702</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_403_ecustom--OtherCurrentLiabilities_i02I_maCzYrw_zASTRMXRl2Ei" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Other
        current liabilities</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="cik0002065779:OtherCurrentLiabilities" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002746" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,481</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="cik0002065779:OtherCurrentLiabilities" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002747" format="ixt:numdotdecimal" decimals="0" unitRef="USD">283,612</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesCurrent_i01TI_mtCzYrw_maCz9gn_zudxZ3ELxD19" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Total
        Current Liabilities</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002749" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,319,721</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002750" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,153,918</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_400_eus-gaap--Liabilities_iTI_mtCz9gn_maLASEzkC5_zKRTpvl4P1r2" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Total
        Liabilities</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002752" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,319,721</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002753" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,153,918</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_405_eus-gaap--CommitmentsAndContingencies_iI_zAbMVJ0LrYd6" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Commitments
        and contingencies (Note 14)</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_400_eus-gaap--StockholdersEquityAbstract_iB_zCa0x1NypILg" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Shareholders&#8217;
        Deficit</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_iI_maCzYs0_zOiLrB8O29p2" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Ordinary
        shares (US$<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250630_zob33jA59jDg" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002764" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> par value per share; <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20250630_zqPwOch4osJj" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002766" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></span> shares authorized; <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20250630_zllB42BL1fMa" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20250630_zmk5HKWH6yIj" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002768" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002770" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of June&#160;30, 2025)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002761" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2762">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Class
        A ordinary shares (US$<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_z8tPppwxP0id" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact002772" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> par value per share; <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zc0FWIBFpH96" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact002774" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">303</ix:nonFraction></span> shares authorized; <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zoo8eZGgocL8" title="Common stock, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zdPBmTTPhmq" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact002776" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact002778" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">303</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of March&#160;31, 2026)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--CommonStockValue_iI_maCzYs0_c20250630__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_znmLfWmQNFMe" title="Ordinary shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2780">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_987_eus-gaap--CommonStockValue_iI_maCzYs0_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zD2wQap80yg3" title="Ordinary shares" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact002782" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Class
        B ordinary shares (US$<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zOGHgrdc8CY5" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact002784" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> par value per share; <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_z0TPl7nWU3l" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact002786" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,197</ix:nonFraction></span> shares authorized; <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zaqTOf6ttlk1" title="Common stock, shares issued"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zuchtHifuZzf" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact002788" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact002790" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,197</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of March&#160;31, 2026)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_987_eus-gaap--CommonStockValue_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zSjrhydIOPga" title="Ordinary shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2792">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--CommonStockValue_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zJmeIKlwDDF7" title="Ordinary shares" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact002794" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40E_eus-gaap--AdditionalPaidInCapital_iI_maCzYs0_z4I7N2ysJ3re" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Additional
        paid-in capital</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002796" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,636</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002797" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,636</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40E_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maCzYs0_zokm45wP48ck" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Accumulated
        deficit</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002799" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,217,035</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002800" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,134,012</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr id="xdx_403_eus-gaap--StockholdersEquity_iTI_pp0d_mtCzYs0_maLASEzkC5_zir2Fpwt1Dgl" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Total
        Shareholders&#8217; Deficit</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002802" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,996,384</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002803" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,913,361</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td> </tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_pp0d_mtLASEzkC5_z7F6hJ3TZja2" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total
        Liabilities and Shareholders&#8217; Deficit</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact002805" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,323,337</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002806" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,240,557</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 415; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span id="fin4_002"></span><b>EXASCALE
LABS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>UNAUDITED
CONDENSED CONSOLIDATED</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>STATEMENTS
OF OPERATIONS AND COMPREHENSIVE LOSS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>FOR
THE THREE AND NINE MONTHS ENDED MARCH 31, 2025 AND 2026</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>(All
amounts in US$, except for number of shares, and per share data)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_305_113_zmnWMmd0kUte" summary="xdx: Statement - STATEMENT OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_49B_20250101__20250331_zhw3ytHIK6Kl" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_499_20260101__20260331_zRGUWha49wJj" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_494_20240701__20250331_zYYCr2PgFS6i" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_490_20250701__20260331_z20Gvwlfl4F4" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_40E_eus-gaap--Revenues_zSEV7cEds2mi" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Revenues</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002808" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,862,158</ix:nonFraction></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002809" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,754,586</ix:nonFraction></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002810" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,475,885</ix:nonFraction></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002811" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,561,331</ix:nonFraction></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40C_eus-gaap--CostOfRevenue_i01_msCzrzC_z0n3VFIlqkdf" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Cost
        of revenues</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002813" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,649,077</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002814" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,167,659</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002815" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,827,444</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002816" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,902,966</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr id="xdx_404_eus-gaap--GrossProfit_i01T_mtCzrzC_maCzjN5_zz0PiilLtN4j" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Gross
        profit</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002818" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,081</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002819" format="ixt:numdotdecimal" decimals="0" unitRef="USD">586,927</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002820" format="ixt:numdotdecimal" decimals="0" unitRef="USD">648,441</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002821" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,658,365</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpensesAbstract_i01B_z21VkM1oCFZ3" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Operating
        expenses</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_405_eus-gaap--SellingAndMarketingExpense_i02N_di_maCzTCt_zKIuy4S13qm" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Selling
        and marketing expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002828" format="ixt:numdotdecimal" decimals="0" unitRef="USD">378,511</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002829" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,729</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002830" format="ixt:numdotdecimal" decimals="0" unitRef="USD">726,914</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">310,582</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_408_eus-gaap--GeneralAndAdministrativeExpense_i02N_di_maCzTCt_zhKNyPNWItL3" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">General
        and administrative expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002833" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,107</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002834" format="ixt:numdotdecimal" decimals="0" unitRef="USD">468,696</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002835" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,159</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002836" format="ixt:numdotdecimal" decimals="0" unitRef="USD">928,255</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i02N_di_maCzTCt_zx76j5zm25A" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Research
        and development expenses</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002838" format="ixt:numdotdecimal" decimals="0" unitRef="USD">377,999</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002839" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,235,476</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002840" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,115,853</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002841" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,238,185</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr id="xdx_403_eus-gaap--OperatingExpenses_i02NT_di_mtCzTCt_msCzjN5_zCpXrnZdMZLe" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Total
        operating expenses</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002843" format="ixt:numdotdecimal" decimals="0" unitRef="USD">859,617</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002844" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,808,901</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002845" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,110,926</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002846" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,477,022</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_iT_mtCzjN5_maCzIwH_zjbkLGZNgYA7" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Loss
        from operations</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002848" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">646,536</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002849" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,221,974</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002850" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,462,485</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002851" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,818,657</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td> </tr>
  <tr id="xdx_404_ecustom--ChangeInFairValueOfSimpleAgreementsForFutureEquity_iN_di_msCzIwH_zPGSpW8gUqv8" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Change
        in fair value of simple agreements for future equity</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002853" format="ixt:numdotdecimal" decimals="0" unitRef="USD">890,523</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002854" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,410,457</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002855" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,716,052</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002856" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,098,320</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzIwH_maCzxqK_zOC4Y26EPeCf" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Loss
        before income tax expenses</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002858" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,537,059</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002859" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,632,431</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002860" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,178,537</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002861" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,916,977</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td> </tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_msCzxqK_ztX3cDEXWXkg" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Income
        tax expenses</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><span style="-sec-ix-hidden: xdx2ixbrl2863">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><span style="-sec-ix-hidden: xdx2ixbrl2864">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><span style="-sec-ix-hidden: xdx2ixbrl2865">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><span style="-sec-ix-hidden: xdx2ixbrl2866">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_pp0d_mtCzxqK_zdvDs1eHNlDj" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Net
        loss and comprehensive loss</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002868" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,537,059</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002869" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,632,431</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002870" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,178,537</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002871" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,916,977</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_409_ecustom--LossPerOrdinaryShareAbstarct_zNywEgMhm7B" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Loss
        per ordinary share</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Basic and diluted</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20250101__20250331_zi8zMArmPHC4" title="Basic Loss per ordinary share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250101__20250331_zC7zNVtFnOtc" title="Diluted Loss per ordinary share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002878" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002880" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1,024.70</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20260101__20260331_zMpGNUoEA4S7" title="Basic Loss per ordinary share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20260101__20260331_zPrMZeS9ixfc" title="Diluted Loss per ordinary share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002882" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002884" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1,754.95</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20240701__20250331_zhk1MOCIoVpl" title="Basic Loss per ordinary share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_c20240701__20250331_z3fSGJINbUef" title="Diluted Loss per ordinary share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002886" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002888" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">4,119.02</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20250701__20260331_zzhGXbxCxVuh" title="Basic Loss per ordinary share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250701__20260331_zJlPfJuQaqL6" title="Diluted Loss per ordinary share" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002890" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002892" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">5,277.98</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Weighted
        average number of ordinary shares</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Basic and diluted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250331_z7K0FPzqgG8k" title="Weighted average number of per ordinary shares Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250331_ztpwvzKarpq3" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA" title="Weighted average number of per ordinary shares Diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002894" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002896" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331_zKcRYiwgKRlj" title="Weighted average number of per ordinary shares Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331_znGttELiuNV6" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002898" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002899" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20250331_z4z1Vbl2e4ze" title="Weighted average number of per ordinary shares Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20250331_zFrv4Hk4gc5k" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002901" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002902" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250701__20260331_zu1lCuZqjWP4" title="Weighted average number of per ordinary shares Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250701__20260331_zu1toJYtRyic" class="xdx_phnt_U3RhdGVtZW50IC0gU1RBVEVNRU5UIE9GIE9QRVJBVElPTlMA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002904" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002905" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 416; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b><span id="fin4_003"></span>EXASCALE
LABS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>UNAUDITED
CONDENSED CONSOLIDATED</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>STATEMENTS
OF CHANGES IN SHAREHOLDERS&#8217; DEFICIT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>FOR
THE THREE AND NINE MONTHS ENDED MARCH 31, 2025 AND 2026</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>(All
amounts in US$, except for number of shares)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>For
the Three Months Ended March&#160;31, 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_114_zc8OnJ26yQc7" summary="xdx: Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z8BQ7QQ74Wo2" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zIVYxTFuAcm8" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zSsoQHrX0ybh" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4BC_zqOqh85T8c2d" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Ordinary shares</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; padding-bottom: 0.5pt"><b>Additional<br/>paid-in</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; padding-bottom: 0.5pt"><b>Accumulated</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; padding-bottom: 0.5pt"><b>Total<br/>shareholders&#8217;</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Shares</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Amount</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>capital</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>deficit</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>deficit</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_43A_c20250101__20250331_eus-gaap--StockholdersEquity_iS_zB2eUYJySwdf" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Balance
        as of December&#160;31, 2024 (unaudited)</b></td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zt7UD0HLTOAh" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact002912" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact002907" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="Fact002908" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,636</ix:nonFraction></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="Fact002909" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,198,846</ix:nonFraction></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_custom_ExascaleLabsIncMember" id="Fact002910" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,079,195</ix:nonFraction></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
        </tr>
  <tr id="xdx_407_eus-gaap--ProfitLoss_zHNkDBgIhx86" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Net loss</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2914">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2915">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="Fact002916" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,537,059</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002917" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,537,059</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_zIKDzijCrZ3b" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Share-based
        compensation</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2919">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="Fact002920" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,000</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2921">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002922" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,000</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_43D_c20250101__20250331_eus-gaap--StockholdersEquity_iE_zumhxDEApKYg" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Balance
        as of March&#160;31, 2025 (unaudited)</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZJFIAeGCs42" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact002929" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact002924" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="Fact002925" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,636</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="Fact002926" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,735,905</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_custom_ExascaleLabsIncMember" id="Fact002927" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,515,254</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>For
the Nine Months Ended March&#160;31, 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Ordinary shares</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; padding-bottom: 0.5pt"><b>Additional<br/>paid-in</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; padding-bottom: 0.5pt"><b>Accumulated</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; padding-bottom: 0.5pt"><b>Total<br/>shareholders&#8217;</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Shares</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Amount</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>capital</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>deficit</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>deficit</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_438_c20240701__20250331_eus-gaap--StockholdersEquity_iS_zwiz1BWLmKZ3" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Balance
        as of June&#160;30, 2024</b></td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwKneodlrtL7" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact002936" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact002931" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="Fact002932" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,370</ix:nonFraction></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="Fact002933" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,557,368</ix:nonFraction></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact002934" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,489,983</ix:nonFraction></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
        </tr>
  <tr id="xdx_40D_eus-gaap--ProfitLoss_zkcO5PY9y2F5" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Net loss</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2938">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2939">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-07-012025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="Fact002940" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,178,537</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002941" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,178,537</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_z49lZRctmVTl" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Share-based
        compensation</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2943">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="Fact002944" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,266</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2945">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact002946" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,266</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_43B_c20240701__20250331_eus-gaap--StockholdersEquity_iE_zRlNSvwuhFP8" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Balance
        as of March&#160;31, 2025 (unaudited)</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfYbMDz5SDba" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact002953" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact002948" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="Fact002949" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,636</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="Fact002950" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,735,905</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_custom_ExascaleLabsIncMember" id="Fact002951" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,515,254</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>For
the Three Months Ended March&#160;31, 2026</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td style="text-align: right; font-size: 8pt">&#160;</td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z39tsZZcWnz4" style="text-align: right; font-size: 8pt">&#160;</td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td style="text-align: right; font-size: 8pt">&#160;</td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_custom--OrdinarySharesClassAMember_zNCitf4iu5gi" style="text-align: right; font-size: 8pt">&#160;</td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td style="text-align: right; font-size: 8pt">&#160;</td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_custom--OrdinarySharesClassBMember_zjKNrWotQoij" style="text-align: right; font-size: 8pt">&#160;</td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z0VlJsJoOM2l" style="text-align: right; font-size: 8pt">&#160;</td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zP9WisNylfVb" style="text-align: right; font-size: 8pt">&#160;</td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_4B1_zRemdfqjY6V2" style="text-align: right; font-size: 8pt">&#160;</td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th colspan="6" style="border-bottom: #000000 1pt solid; text-align: center; font-size: 8pt"><b>Ordinary
        shares</b></th>
    <th style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt">
        <p style="margin-top: 0; margin-bottom: 0"><b>Class A<br/>ordinary shares</b></p></th>
    <th style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt">
        <p style="margin-top: 0; margin-bottom: 0"><b>Class B<br/>ordinary shares</b></p></th>
    <th style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th colspan="2" style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt"><b>Additional<br/>paid-in</b></th>
    <th style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th colspan="2" style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt"><b>Accumulated</b></th>
    <th style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th colspan="2" style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt"><b>Total<br/> shareholders&#8217;</b></th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>Shares</b></th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>Amount</b></th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>Shares</b></th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>Amount</b></th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>Shares</b></th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>Amount</b></th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>capital</b></th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>deficit</b></th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>deficit</b></th>
    <th style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</th> </tr>
  <tr id="xdx_43B_c20260101__20260331_eus-gaap--StockholdersEquity_iS_z7YmUxXn1YD9" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; font-size: 8pt; padding-bottom: 0.5pt"><b>Balance
        as of December&#160;31, 2025 (unaudited)</b></td>
    <td style="width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%; font-size: 8pt">&#160;</td>
    <td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy7IGGf5Zh75" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; text-align: right; width: 5%; font-size: 8pt"><b><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact002962" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; width: 5%; font-size: 8pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact002955" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%; font-size: 8pt">&#160;</td>
    <td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassAMember_zuFIN6ttTwid" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; text-align: right; width: 5%; font-size: 8pt"><b><span style="-sec-ix-hidden: xdx2ixbrl2964">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; width: 5%; font-size: 8pt"><b><span style="-sec-ix-hidden: xdx2ixbrl2956">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%; font-size: 8pt">&#160;</td>
    <td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassBMember_zA8MhvDSeFXa" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; text-align: right; width: 5%; font-size: 8pt"><b><span style="-sec-ix-hidden: xdx2ixbrl2966">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; width: 5%; font-size: 8pt"><b><span style="-sec-ix-hidden: xdx2ixbrl2957">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; width: 5%; font-size: 8pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="Fact002958" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,636</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; width: 5%; font-size: 8pt"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="Fact002959" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,501,581</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; width: 1%; font-size: 8pt; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; width: 5%; font-size: 8pt"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_custom_ExascaleLabsIncMember" id="Fact002960" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,280,930</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; width: 1%; font-size: 8pt; padding-bottom: 0.5pt"><b>)</b></td>
        </tr>
  <tr id="xdx_408_ecustom--RedesignationOfAuthorizedOrdinaryShares_zztNsGo6KJ06" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; font-size: 8pt">Re-designation
        of authorized ordinary shares</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_982_ecustom--RedesignationOfAuthorizedOrdinarySharesShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGCgoPVA9YQf" title="Re-designation of authorized ordinary shares, shares" style="text-align: right; font-size: 8pt">(<ix:nonFraction name="cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares" contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact002975" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,500</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">)</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td style="text-align: right; font-size: 8pt">(<ix:nonFraction name="cik0002065779:RedesignationOfAuthorizedOrdinaryShares" contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact002968" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">)</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_987_ecustom--RedesignationOfAuthorizedOrdinarySharesShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassAMember_zM333nhsE0v" title="Re-designation of authorized ordinary shares, shares" style="text-align: right; font-size: 8pt"><ix:nonFraction name="cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember" id="Fact002977" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">303</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td style="text-align: right; font-size: 8pt"><ix:nonFraction name="cik0002065779:RedesignationOfAuthorizedOrdinaryShares" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember" id="Fact002969" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_989_ecustom--RedesignationOfAuthorizedOrdinarySharesShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassBMember_zqX1OXrhqhU7" title="Re-designation of authorized ordinary shares, shares" style="text-align: right; font-size: 8pt"><ix:nonFraction name="cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember" id="Fact002979" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,197</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td style="text-align: right; font-size: 8pt"><ix:nonFraction name="cik0002065779:RedesignationOfAuthorizedOrdinaryShares" contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember" id="Fact002970" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td style="text-align: right; font-size: 8pt"><b><span style="-sec-ix-hidden: xdx2ixbrl2971">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td style="text-align: right; font-size: 8pt"><b><span style="-sec-ix-hidden: xdx2ixbrl2972">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td style="text-align: right; font-size: 8pt"><b><span style="-sec-ix-hidden: xdx2ixbrl2973">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td> </tr>
  <tr id="xdx_405_eus-gaap--ProfitLoss_ztmcM64sZ04j" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; font-size: 8pt; padding-bottom: 0.5pt">Net
        loss</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">-</td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl2981">-</span></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">-</td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl2982">-</span></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">-</td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl2983">-</span></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl2984">-</span></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="Fact002985" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,632,431</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">)</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact002986" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,632,431</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">)</td>
        </tr>
  <tr id="xdx_434_c20260101__20260331_eus-gaap--StockholdersEquity_iE_z7Jd1NVBoqm9" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; font-size: 8pt; padding-bottom: 1.25pt"><b>Balance
        as of March&#160;31, 2026 (unaudited)</b></td>
    <td style="font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkg28XPLz4di" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><b><span style="-sec-ix-hidden: xdx2ixbrl2995">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><b><span style="-sec-ix-hidden: xdx2ixbrl2988">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassAMember_z0DgoniZOzUk" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><b><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember" id="Fact002997" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">303</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember" id="Fact002989" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_989_eus-gaap--SharesOutstanding_iE_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassBMember_zkf1d7bv2S44" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><b><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember" id="Fact002999" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,197</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember" id="Fact002990" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="Fact002991" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,636</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="Fact002992" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,134,012</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact002993" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,913,361</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 1.25pt"><b>)</b></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>For
the Nine Months Ended March&#160;31, 2026</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: #000000 1pt solid; text-align: center; font-size: 8pt"><b>Ordinary
        shares</b></td>
    <td style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>Class A<br/>ordinary
        shares</b></td>
    <td style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt">
        <p style="margin-top: 0; margin-bottom: 0"><b>Class B</b></p>
        <p style="margin-top: 0; margin-bottom: 0"><b>ordinary shares</b></p></td>
    <td style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt"><b>Additional<br/>paid-in</b></td>
    <td style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt"><b>Accumulated</b></td>
    <td style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt"><b>Total<br/> shareholders&#8217;</b></td>
    <td style="text-align: center; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>Shares</b></td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>Amount</b></td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>Shares</b></td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>Amount</b></td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>Shares</b></td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>Amount</b></td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>capital</b></td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>deficit</b></td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt"><b>deficit</b></td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_435_c20250701__20260331_eus-gaap--StockholdersEquity_iS_z2stnzh5BIp6" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; font-size: 8pt; padding-bottom: 0.5pt"><b>Balance
        as of June&#160;30, 2025</b></td>
    <td style="width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_987_eus-gaap--SharesOutstanding_iS_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMJHZV9tKKX6" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; width: 5%; text-align: right; font-size: 8pt"><b><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact003008" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 5%; text-align: right; font-size: 8pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact003001" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_98E_eus-gaap--SharesOutstanding_iS_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassAMember__dei--LegalEntityAxis__custom--ExascaleLabsIncMember_zR0n5KnDnHh2" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; width: 5%; text-align: right; font-size: 8pt"><b><span style="-sec-ix-hidden: xdx2ixbrl3010">-</span></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 5%; text-align: right; font-size: 8pt"><b><span style="-sec-ix-hidden: xdx2ixbrl3002">-</span></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--ExascaleLabsIncMember_z8qmQGdutTi1" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; width: 5%; text-align: right; font-size: 8pt"><b><span style="-sec-ix-hidden: xdx2ixbrl3012">-</span></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 5%; text-align: right; font-size: 8pt"><b><span style="-sec-ix-hidden: xdx2ixbrl3003">-</span></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 5%; text-align: right; font-size: 8pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="Fact003004" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,636</ix:nonFraction></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 5%; text-align: right; font-size: 8pt"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="Fact003005" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,217,035</ix:nonFraction></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="width: 1%; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 5%; text-align: right; font-size: 8pt"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003006" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,996,384</ix:nonFraction></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt"><b>)</b></td>
        </tr>
  <tr id="xdx_408_ecustom--RedesignationOfAuthorizedOrdinaryShares_z8gyQcmjEsS1" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; font-size: 8pt">Re-designation
        of authorized ordinary shares</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_98A_ecustom--RedesignationOfAuthorizedOrdinarySharesShares_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTcXgb4amiki" title="Re-designation of authorized ordinary shares, shares" style="text-align: right; font-size: 8pt">(<ix:nonFraction name="cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares" contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact003021" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,500</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">)</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td style="text-align: right; font-size: 8pt">(<ix:nonFraction name="cik0002065779:RedesignationOfAuthorizedOrdinaryShares" contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember" id="Fact003014" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">)</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_982_ecustom--RedesignationOfAuthorizedOrdinarySharesShares_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassAMember__dei--LegalEntityAxis__custom--ExascaleLabsIncMember_ziGBDFBkuPSb" title="Re-designation of authorized ordinary shares, shares" style="text-align: right; font-size: 8pt"><ix:nonFraction name="cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares" contextRef="From2025-07-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember" id="Fact003023" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">303</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td style="text-align: right; font-size: 8pt"><ix:nonFraction name="cik0002065779:RedesignationOfAuthorizedOrdinaryShares" contextRef="From2025-07-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember" id="Fact003015" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_987_ecustom--RedesignationOfAuthorizedOrdinarySharesShares_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassBMember__dei--LegalEntityAxis__custom--ExascaleLabsIncMember_zQMH8nbzowei" title="Re-designation of authorized ordinary shares, shares" style="text-align: right; font-size: 8pt"><ix:nonFraction name="cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares" contextRef="From2025-07-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember" id="Fact003025" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,197</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td style="text-align: right; font-size: 8pt"><ix:nonFraction name="cik0002065779:RedesignationOfAuthorizedOrdinaryShares" contextRef="From2025-07-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember" id="Fact003016" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td style="text-align: right; font-size: 8pt"><b><span style="-sec-ix-hidden: xdx2ixbrl3017">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td style="text-align: right; font-size: 8pt"><b><span style="-sec-ix-hidden: xdx2ixbrl3018">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt">&#160;</td>
    <td style="text-align: left; font-size: 8pt">&#160;</td>
    <td style="text-align: right; font-size: 8pt"><b><span style="-sec-ix-hidden: xdx2ixbrl3019">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt">&#160;</td> </tr>
  <tr id="xdx_40D_eus-gaap--ProfitLoss_zOtobFEmTeH7" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; font-size: 8pt; padding-bottom: 0.5pt">Net
        loss</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">-</td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl3027">-</span></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">-</td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl3028">-</span></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">-</td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl3029">-</span></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl3030">-</span></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-07-012026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="Fact003031" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,916,977</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">)</td>
    <td style="font-size: 8pt; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003032" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,916,977</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 0.5pt">)</td>
        </tr>
  <tr id="xdx_43D_c20250701__20260331_eus-gaap--StockholdersEquity_iE_zhXDzVEH1842" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; font-size: 8pt; padding-bottom: 1.25pt"><b>Balance
        as of March&#160;31, 2026 (unaudited)</b></td>
    <td style="font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_989_eus-gaap--SharesOutstanding_iE_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zE2olu7vqnR5" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><b><span style="-sec-ix-hidden: xdx2ixbrl3041">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><b><span style="-sec-ix-hidden: xdx2ixbrl3034">-</span></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassAMember_zKbLMV6N2fF" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><b><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember" id="Fact003043" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">303</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember" id="Fact003035" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">&#160;</td>
    <td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesClassBMember_zTObAkfzZtol" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><b><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember" id="Fact003045" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,197</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember" id="Fact003036" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember" id="Fact003037" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,636</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember" id="Fact003038" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,134,012</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="font-size: 8pt; padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003039" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,913,361</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; font-size: 8pt; padding-bottom: 1.25pt"><b>)</b></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 417; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span id="fin4_004"></span><b>EXASCALE
LABS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>CASH
FLOWS FOR THE NINE MONTHS ENDED MARCH 31, 2025 AND 2026</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>(All
amounts in US$)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_112_zwvd24ctzNE9" summary="xdx: Statement - STATEMENT OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_499_20240701__20250331_zqAruVxMTb6e" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_498_20250701__20260331_ztjRqYHLM5Bl" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zwmaUYGqU7tl" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Cash
        flows from operating activities:</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_i01_maCzomT_zLv8ZcdSgIZi" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Net
        loss</b></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003050" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,178,537</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003051" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,916,977</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zm1pRYyrT0lj" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Adjustments
        to reconcile net loss to net cash used in operating activities:</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40E_eus-gaap--Depreciation_i02_maCzomT_zaYcfiZr0Ud3" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Depreciation
        of equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,633</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,194</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_i02_maCzomT_zNXnCmqJ6KB" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Share-based
        compensation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,266</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3060">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_401_ecustom--ChangeInFairValueOfSimpleAgreementsForFutureEquities_i02_maCzomT_zWx8rZi4Bz98" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Change
        in fair value of simple agreements for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,716,052</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,098,320</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_408_ecustom--OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin_iNP3custom--ChangeInFairValueOfSimpleAgreementsForFutureEquities_di_msCz7uv_z17iUaKMy5ce" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Other operating
        activities settled in digital assets and U.S. Dollar Coin</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3065">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,681,167</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_iB_zAVH9GVca8i1" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Changes
        in operating assets and liabilities:</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccountsReceivable_i01N_di_msCzomT_zfFt2xrwuSYj" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Accounts
        receivable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,483</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,677,569</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_401_ecustom--IncreaseDecreaseInAdvanceToSuppliers_i01NI_di_zWJGSp7ugXRi" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Advance
        to suppliers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:IncreaseDecreaseInAdvanceToSuppliers" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">278,612</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:IncreaseDecreaseInAdvanceToSuppliers" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003075" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">923,960</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInPrepaidExpensesOther_iNP3custom--IncreaseDecreaseInAdvanceToSuppliers_di_msCzomT_msCz7uv_zzjB2VyObiik" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Prepaid
        research and development expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3077">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">625,000</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInAccountsPayable_i01_maCzomT_zpfAyEZTFTi9" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Accounts
        payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003080" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">104,717</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">653,727</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i01_maCzomT_zL4qD1dVmadc" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Other current
        liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003083" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">113,693</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,131</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_i01_maCzomT_zIV9eYthDZOi" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Contract
        liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,082</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003087" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">323,103</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_403_ecustom--IncreaseDecreaseInRefundableDepositsReceivable_i01NI_di_zz36DSzIlgVe" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Refundable
        deposits receivable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003090" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">171,125</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40C_ecustom--IncreaseDecreaseInRefundableDepositsPayable_i01_zNyVaxe2mCEc" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Refundable
        deposits payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:IncreaseDecreaseInRefundableDepositsPayable" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">224,279</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:IncreaseDecreaseInRefundableDepositsPayable" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003093" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">270,878</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccountsAndOtherReceivables_i01N_di_msCzomT_z0CFwwHdAKI" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 0.5pt">Other
        receivables</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003095" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,835,770</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003096" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,707,626</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzomT_maCzZ5t_zX8H3cRpNiq6" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Net
        cash used in operating activities</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003098" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">757,960</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003099" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,758,611</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zEUoFOuCXlrg" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Cash
        flows from investing activities:</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_406_ecustom--ProceedsFromSaleOfDigitalAssetsAndUsdc_iP2us-gaap--PaymentsToAcquirePropertyPlantAndEquipment_maCz9cs_maCzB7O_zgRjwHmSUPJh" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Disposal of digital assets and U.S. Dollar Coin</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3104">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="cik0002065779:ProceedsFromSaleOfDigitalAssetsAndUsdc" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003105" format="ixt:numdotdecimal" decimals="0" unitRef="USD">606,752</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCz9cs_z9yHxibsxHTc" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 0.5pt">Purchase
        of equipment</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,138</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3108">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCz9cs_maCzZ5t_zXbkVur4Cw4f" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Net
        cash (used in) provided by investing activities</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003110" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,138</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003111" format="ixt:numdotdecimal" decimals="0" unitRef="USD">606,752</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_ziNsov92UmCj" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Cash
        flows from financing activities:</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_405_ecustom--PaymentForDeferredOfferingCosts_iNP2custom--ProceedsFromSimpleAgreementsForFutureEquity_di_msCzBiW_msCzg4P_zZsNSDAXZNwe" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Payment
        for deferred offering costs</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3116">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:PaymentForDeferredOfferingCosts" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,000</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_40E_ecustom--ProceedsFromSimpleAgreementsForFutureEquity_i01_maCzBiW_zqT1mnsZOAVc" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 0.5pt">Proceeds
        from Simple agreements for future equity</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="cik0002065779:ProceedsFromSimpleAgreementsForFutureEquity" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003119" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,275,000</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3120">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzBiW_maCzZ5t_zq0nHJZX7Ctc" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Net
        cash provided by (used in) financing activities</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,275,000</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003123" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">95,000</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td> </tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzZ5t_z3TlprxOlMYe" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Net
        change in cash and cash equivalents</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,514,902</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003126" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,246,859</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zPLaodxa6xee" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Cash
        and cash equivalents at the beginning of the period</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact003128" format="ixt:numdotdecimal" decimals="0" unitRef="USD">969,626</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003129" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,231,689</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zMAEoei8Hyvh" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Cash
        and cash equivalents at the end of period</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-03-31_custom_ExascaleLabsIncMember" id="Fact003131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,484,528</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">984,830</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_401_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zlPzCxDgL4s8" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Supplementary
        Information:</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxesPaid_i01_zYfxPeDkr0qe" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Income
        tax paid</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3137">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3138">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_403_eus-gaap--InterestPaid_i01_zrQTuZUJeHy8" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Interest
        expense paid</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3140">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3141">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_407_eus-gaap--NotesAssumed1_i01_zl83rZufeXcc" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Investment
        proceeds received by an employee on behalf of the Company from SAFEs investors</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3143">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:NotesAssumed1" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_404_eus-gaap--LoansAssumed1_ze7QXeSatWy8" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Investment
        proceeds received through USDC from SAFEs investors</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3146">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:LoansAssumed1" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003147" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 418; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p id="xdx_046_c20250701__20260331_zbsYvwms87Z6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span id="fin4_005"></span><b>EXASCALE
LABS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>(All
amounts in US$, except for number of shares and per share data)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003149" name="us-gaap:NatureOfOperations"><p id="xdx_803_eus-gaap--NatureOfOperations_zZfsaWCqvzt2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>1.
<span id="xdx_827_zX0y8kzKCG">Organization and principal activities</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">On
June&#160;1, 2022, Exascale Labs Inc. (the &#8220;Company&#8221;) was formally incorporated in the State of Delaware. In accordance with
the Company&#8217;s Certificate of Incorporation, the total authorized share capital of the Company consists of <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20260331_pd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003151" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></span> shares of ordinary
shares, with a par value of $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20260331_pd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003153" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share, all of which are of one class. The governance structure of the Company stipulates that the
business and affairs of the Company shall be managed by or under the direction of its board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">On
December&#160;16, 2025, the Company incorporated its wholly-owned subsidiary, Evana Alpha Pte. Ltd., in Singapore. The Company subscribed
for all <span id="xdx_907_ecustom--OrdinarySharesIssued_c20251201__20251216__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_zM1cMUnQc5T6" title="Ordinary shares issued"><ix:nonFraction name="cik0002065779:OrdinarySharesIssued" contextRef="From2025-12-012025-12-16_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember" id="Fact003155" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></span> ordinary shares of the subsidiary, with a total issued share capital of Singapore Dollars <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251201__20251216__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_zTUt0Dx8cvJd" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-12-012025-12-16_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember" id="Fact003157" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></span>. The subsidiary&#8217;s
principal business activity is information technology consultancy (excluding cybersecurity).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company is a next-generation artificial intelligence (&#8220;AI&#8221;) infrastructure provider operating an asset-light, software-defined
graphics processing unit (&#8220;GPU&#8221;) compute platform and related AI infrastructure solutions. Exascale&#8217;s core business
includes GPU as a Service (&#8220;GaaS&#8221;), through which it provides reserved and on-demand access to high-performance GPU compute
capacity sourced from third-party data centers globally, as well as GPU cluster management and optimization services for artificial intelligence
data center (&#8220;AIDC&#8221;) operators. In addition, Exascale has developed certain modular data center, high-density liquid cooling,
high-voltage direct current (&#8220;HVDC&#8221;) power and energy storage solutions that are designed to address deployment bottlenecks
in AI infrastructure and that Exascale believes are ready for commercial engagement, although these capabilities have not yet generated
revenue as of the date of this proxy statement/prospectus. The platform is purpose-built for large-scale AI workloads, including large
language model (&#8220;LLM&#8221;) training, fine-tuning, and high-concurrency inference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
January&#160;2026, the Company adopted an Amended and Restated Certificate of Incorporation, which established a dual-class ordinary share
structure. Under this new structure, the Company&#8217;s equity is divided into 303 Class A ordinary shares and 1,197 Class B ordinary
shares, which are entitled to one (1) vote and twenty (20) votes per share, respectively. Despite the differential in voting power, Class
A and Class B ordinary shares rank pari passu in all other respects, sharing ratably in dividends and any distributions upon liquidation.
Furthermore, all outstanding Simple Agreements for Future Equity (&#8220;SAFEs&#8221;) are designated to convert or settle exclusively
into Class A ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
January&#160;2026, the Company entered into an Agreement and Plan of Merger (&#8220;BCA&#8221;) with D. Boral ARC Acquisition I Corp.(&#8220;BCAR&#8221;),
a publicly traded special purpose acquisition company (&#8220;SPAC&#8221;), D. Boral ARC Merger Corporation, a Delaware corporation and
a direct, wholly owned subsidiary of BCAR and D. Boral Arc Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary
of BCAR. Upon closing of the transaction, the combined company will be named Exascale Labs Holdings Inc.(such surviving company, &#8220;PubCo&#8221;)
and is expected to be traded on a national securities exchange.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003159" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_z3uJvVhT76yk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>2.
<span id="xdx_823_zJDfylZ6eVGa">Summary of significant accounting policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003161" name="cik0002065779:GoingConcernPolicyTextBlock"><p id="xdx_84E_ecustom--GoingConcernPolicyTextBlock_zjTeaYmk2USj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>a.
<span id="xdx_867_zT6r15wrPfT">Going concern</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">As
of March&#160;31, 2026, the Company had cash and cash equivalents and U.S. Dollar Coin (&#8220;USDC&#8221;) of $<span id="xdx_90B_ecustom--CashAndCashEquivalentsAndU.s.DollarCoin_iI_pn3n3_dm_c20260331_zOweLGQ0nMmd" title="Cash and cash equivalents and U.S. Dollar Coin"><ix:nonFraction name="cik0002065779:CashAndCashEquivalentsAndU.s.DollarCoin" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003163" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">5.1</ix:nonFraction> </span>million
and current liabilities of $29.2 <span id="xdx_90B_eus-gaap--LiabilitiesCurrent_iI_c20260331_zx0VQfPseO64" title="Current liabilities" style="display: none"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003165" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,153,918</ix:nonFraction></span>
million. For the nine months ended March&#160;31, 2025, the Company used $0.8 <span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20240701__20250331_zXrnaRJA6DE6" title="Cash for operating activities" style="display: none">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003167" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">757,960</ix:nonFraction>)</span>
million in operating activities, while for the nine months ended March&#160;31, 2026, it used $3.8 <span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20250701__20260331_z0FbPDcDfL21" title="Cash for operating activities" style="display: none">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003169" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,758,611</ix:nonFraction>)</span>
million. The Company incurred net losses of $6.2 <span id="xdx_90B_eus-gaap--NetIncomeLoss_c20240701__20250331_zVBAnoAbYj2e" title="Net losses" style="display: none">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003171" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,178,537</ix:nonFraction>)</span>
million and $7.9 <span id="xdx_906_eus-gaap--NetIncomeLoss_c20250701__20260331_zwLqC0GO7Qj2" title="Net losses" style="display: none">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003173" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,916,977</ix:nonFraction>)</span>
million for these respective periods. Since inception, the Company has incurred recurring net losses from operations and negative
cash flows from operating activities. As of March&#160;31, 2026, the Company had an accumulated deficit of $21.1 <span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20260331_zxZwKyas1Wfb" title="Accumulated deficit" style="display: none">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003175" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,134,012</ix:nonFraction>)</span>
million. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern within one year
of the date these unaudited condensed consolidated financial statements are issued.</p>

<ix:exclude><p id="xdx_23D_zDSnGD49Utl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 419; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_z8BbXEoYGVGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zuSSTZwtEO7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>2. Summary of significant accounting
policies (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zkNZ8NXSzHqe" style="font: 10pt Times New Roman, Times, serif; margin: 0px">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zLMXmpyRMHuh" style="font: 10pt Times New Roman, Times, serif; text-align: justify; margin-top: 0px; margin-bottom: 0px"><b><i>a.
Going concern (Continued)</i></b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Management
has formulated and is actively pursuing plans to mitigate these conditions and secure the Company&#8217;s continued operations. In connection
with the Company&#8217;s contemplated business combination with a SPAC and related financing activities, the Company expects to access
additional capital through external funding sources. In addition, the Company continues to focus on expanding its market presence and
developing client relationships to drive revenue growth, while managing operating expenses, with the objective of improving cash flows
from operations over time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
purposes of this disclosure, &#8220;SPAC&#8221; refers to a special purpose acquisition company formed to effect a merger, share exchange,
asset acquisition, share purchase, reorganization or similar business combination with one or more operating businesses. &#8220;De-SPAC&#8221;
refers to the business combination transaction pursuant to which an operating company combines with a SPAC, following which the combined
company becomes publicly listed (or otherwise succeeds to the SPAC&#8217;s public company status).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s
negative working capital position is primarily attributable to the classification of SAFEs. Excluding the accounting impact of the SAFEs,
which will only be paid in cash upon Liquidity Events and Dissolution Event (as defined in Note 8), management believes the Company&#8217;s
available cash resources are sufficient for near-term operating needs. If additional liquidity is required, the Company&#8217;s majority
shareholder has entered into a binding support agreement to provide funding to cover anticipated operating cash flow shortfalls through
the completion of the contemplated de-SPAC transaction. The support agreement is effective for a period of eighteen months from June&#160;10,
2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However,
the de-SPAC transaction (including the SAFEs conversion) have not been fully implemented as of the date these unaudited condensed consolidated
financial statements are issued. There can be no assurance that these plans will be successfully completed within the required time frame,
on acceptable terms, or at all. If the primary plans are not successful, the Company&#8217;s alternative courses of action would further
intensify efforts in market expansion and client development to increase revenue, while diligently controlling costs to ensure sufficient
cash flow from operating activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company may not be able to secure necessary financing in a timely manner or on favorable terms, or successfully execute its operational
turnaround. These circumstances give rise to substantial doubt that the Company will continue as a going concern and these unaudited condensed
consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003182" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zrDsuQdfyKG2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>b.
<span id="xdx_860_z2ZzsSnntEpd">Basis of presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally
accepted accounting principles (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange
Commission (&#8220;SEC&#8221;) regarding interim financial reporting. Certain information and note disclosures normally included in
the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP have been condensed consolidated or
omitted pursuant to such rules and regulations. As such, the information included in this interim financial report should be read in
conjunction with the audited financial statements and accompanying notes for the two years ended June&#160;30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
accompanying unaudited condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly
the financial position, operating results and cash flows of the Company for each of the periods presented. The results of operations for
the three and nine months ended March&#160;31, 2026 are not necessarily indicative of results to be expected for any other interim period
or for the year ending June&#160;30, 2026. The condensed consolidated balance sheet as of June&#160;30, 2025 was derived from the audited
financial statements at that date but does not include all of the disclosures required by U.S. GAAP for annual financial statements.</p>

<ix:exclude><p id="xdx_231_zDGtXrujgqEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 420; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zAjM2YR3eQcb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zBJTWh0RBzM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>2. Summary of significant accounting
policies (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003187" name="us-gaap:UseOfEstimates"><p id="xdx_841_eus-gaap--UseOfEstimates_zcUBkLyQ302a" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>c.
<span id="xdx_869_zJzlNRZuupR8">Use of estimates and assumptions</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation
of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported
in the unaudited condensed consolidated financial statements and accompanying notes. Management believes that the estimates used in preparing
the unaudited condensed consolidated financial statements are reasonable and prudent; however, actual results could differ from these
estimates under different assumptions or conditions.&#160;Significant accounting estimates include recognition and measurement of SAFEs
notes, recognition and measurement of share-based compensation, the allowance for expected credit losses, deferred tax assets and valuation
allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003189" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z3MfqTrj1Ctg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>d.
<span id="xdx_861_zefs2YE20oYg">Fair value measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
accordance with FASB ASC 820&#160;<i>Fair Value Measurements and Disclosures</i>, fair value is defined as the price that would be received
to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company
uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes
between market participant assumptions developed from market data obtained from outside sources (observable inputs) and the Company&#8217;s
own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable
inputs).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of
inputs used to measure fair value are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Level
1: Quoted prices in active markets for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Level
2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Level
3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash
flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment
or estimation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management during
the nine months ended March&#160;31, 2025 and 2026. The carrying amount of cash and cash equivalents, accounts receivable, refundable
deposits receivable, other receivables, accounts payable, refundable deposits payable and other current liabilities approximated their
fair values as of June&#160;30, 2025 and March&#160;31, 2026. For the nine months ended March&#160;31, 2025 and 2026, the Company carried
SAFEs and digital assets at their fair value (see&#160;Note 4-Fair Value Measurements for fair value information).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003191" name="cik0002065779:FunctionalCurrencyPolicyTextBlock"><p id="xdx_844_ecustom--FunctionalCurrencyPolicyTextBlock_z2nCVmTUVaCh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>e.
<span id="xdx_86D_zpLd8Tfyfj3f">Functional currency</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
accompanying unaudited condensed consolidated financial statements are presented in the United States dollar (&#8220;US$&#8221;).
The functional currency of the Company and its subsidiary is the US$.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">All
transactions are measured and recorded in the Company&#8217;s functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003193" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z91JQokNSbAl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>f.
<span id="xdx_867_zTk17b0iUrZg">Cash and cash equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company considers all highly liquid investments instruments purchased with a maturity period of three months or less to be cash or cash
equivalents. The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents approximate their fair value.
As of June&#160;30, 2025 and March&#160;31, 2026, the Company does <span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zmHRDKKWlBMg" title="Cash equivalents"><span id="xdx_908_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20260331_zVbuobGqAgp7" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003195" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003197" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t have any cash equivalents.</p>

<ix:exclude><p id="xdx_23C_zz53lsBsOlg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 421; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zwB7QDbaBmV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zjXvcYJvtwM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>2. Summary of significant accounting
policies (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003202" name="cik0002065779:CryptoAssets"><p id="xdx_84A_ecustom--CryptoAssets_zZhlCmsQAIQk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>g.
<span id="xdx_862_zW5hKqqXdcS6">Crypto assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s
crypto assets classified in current assets are held primarily for use in the ordinary course of business which is expected to be actively
utilized or converted within the normal operating cycle and such crypto assets can be sold in a highly liquid marketplace. During the
nine months ended March&#160;31, 2026, the Company only held crypto assets of Tether USD (&#8220;USDT&#8221;) and USDC, which are principally
funded by SAFE investors and as a form of payment for transaction revenue. The Company&#8217;s crypto assets are held with qualified
third-party custodians who provide secure storage and safeguarding of the Company&#8217;s crypto assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><i><span style="text-decoration: underline">USDC</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">USDC
is a stablecoin redeemable on a one-to-one basis for U.S. dollars and is accounted for as a financial instrument in the unaudited condensed
consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><i><span style="text-decoration: underline">Crypto
assets other than USDC</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">On
December&#160;13, 2023, the FASB issued ASU 2023-08, which addresses the accounting and disclosure requirements for certain cryptocurrencies.
The new guidance requires entities to subsequently measure certain cryptocurrencies at fair value, with changes in fair value recorded
in net income in each reporting period. The Company applied the ASU since its holding of crypto assets in December&#160;2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Digital
assets that are received as noncash consideration in our revenue arrangements and paid in purchases of professional service and others
are presented as cash flows from operating activities in other operating activities settled in digital assets and USDC. Digital assets
that are received in our revenue arrangements and sold for cash within seven days are presented as cash flows from operating activities,
while other digital asset activity held longer than seven days is reflected as cash flows from investing activities under disposal of
digital assets and USDC held in the consolidated statements of cash flows. The Company presents crypto assets other than USDC separately
from other intangible assets and USDC, recorded as digital assets on the unaudited condensed consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
the three months ended March&#160;31, 2026, the Company recorded receipt and disbursement of digital assets amounted to $<span id="xdx_90E_ecustom--ReceiptOfDigitalAssets_c20260101__20260331_pp0p" title="Receipt of digital assets"><ix:nonFraction name="cik0002065779:ReceiptOfDigitalAssets" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">644,616</ix:nonFraction></span> and $<span id="xdx_901_ecustom--DisbursementOfDigitalAssets_c20260101__20260331_pp0p" title="Disbursement of digital assets"><ix:nonFraction name="cik0002065779:DisbursementOfDigitalAssets" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003206" format="ixt:numdotdecimal" decimals="0" unitRef="USD">796,781</ix:nonFraction></span>.&#160;For
the nine months ended March&#160;31, 2026, the Company recorded receipt and disbursement of digital assets amounted to $<span id="xdx_909_ecustom--ReceiptOfDigitalAssets_c20250701__20260331_pp0p" title="Receipt of digital assets"><ix:nonFraction name="cik0002065779:ReceiptOfDigitalAssets" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003208" format="ixt:numdotdecimal" decimals="0" unitRef="USD">939,397</ix:nonFraction></span> and $<span id="xdx_904_ecustom--DisbursementOfDigitalAssets_c20250701__20260331_pp0p" title="Disbursement of digital assets"><ix:nonFraction name="cik0002065779:DisbursementOfDigitalAssets" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003210" format="ixt:numdotdecimal" decimals="0" unitRef="USD">939,397</ix:nonFraction></span>,
respectively, which resulted in an ending balance of nil. The Company&#8217;s balances related to digital assets and stablecoins during
the period included USDT and USDC, both of which are USD-pegged stablecoins. <span id="xdx_901_ecustom--FairValueGainOrLossOnDigitalAssets_pp0d_do_c20260101__20260331_zi458qVUCNt1" title="Fair value gain or loss on digital assets"><span id="xdx_905_ecustom--FairValueGainOrLossOnDigitalAssets_pp0d_do_c20250701__20260331_zVXF30cgUVQc" title="Fair value gain or loss on digital assets"><ix:nonFraction name="cik0002065779:FairValueGainOrLossOnDigitalAssets" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003212" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="cik0002065779:FairValueGainOrLossOnDigitalAssets" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003214" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></ix:nonFraction></span></span> fair value gain or loss on digital assets was recognized
for the three and nine months ended March&#160;31, 2026 considering the low volatility in the fair value of USDT during the three and
nine months ended March&#160;31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003216" name="cik0002065779:ExpectedCreditLossAndAccountsReceivablePolicyTextBlock"><p id="xdx_843_ecustom--ExpectedCreditLossAndAccountsReceivablePolicyTextBlock_zyxTRes82yL6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>h.
<span id="xdx_863_z4jvYtW2zBHk">Expected credit loss and accounts receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company adopted Financial Standards Accounting Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 326 &#8220;<i>Financial
Instruments&#160;&#8212;&#160;Credit Losses</i>&#8221; (&#8220;ASC&#160;326&#8221;) on January&#160;1, 2023.</p>

<ix:exclude><p id="xdx_232_z1Vrh7HOS4X1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 422; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zkXObIKdJYIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zLEHEPIIWlce" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>2. Summary of significant accounting
policies (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zKc5WBwZgKfi" style="font: 10pt Times New Roman, Times, serif; margin: 0px">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_z0P2DjOgvbW4" style="font: 10pt Times New Roman, Times, serif; text-align: justify; margin-top: 0px; margin-bottom: 0px"><b><i>h.
Expected credit loss and accounts receivable (Continued)</i></b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s accounts receivable are within the scope of ASC&#160;326. ASC&#160;326 introduces an approach based on expected credit
losses on financial assets at amortized cost. Upon adoption of ASC&#160;326, the Company estimates the expected credit losses for accounts
receivable using the roll-rate method on a collective basis when similar risk characteristics exist. Expected credit losses are included
in general and administrative expenses in the statements of operations and comprehensive loss. After all attempts to collect a receivable
have failed, the receivable is written off against the allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Accounts
receivable represents those receivables derived in the ordinary course of business, net of an allowance for any potentially uncollectible
amounts. The Company makes estimates of expected credit and collectability trends for the allowance for credit losses based upon its assessment
of various factors, including historical experience, the age of the accounts receivable balances, credit quality of its customers, current
economic conditions, reasonable and supportable forecasts of future economic conditions that may vary by geography, customer-type, or
industry sub-vertical, and other factors that may affect its ability to collect from customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Although
the Company has historically not experienced significant credit losses, they may experience increasing credit loss risks from accounts
receivable in future periods if its customers are adversely affected by economic pressures or uncertainty associated with local or global
economic recessions, or other customer-specific factors, and actual experience in the future may differ from their past experiences or
current assessment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003223" name="cik0002065779:DeferredOfferingCostsPolicyTextBlock"><p id="xdx_849_ecustom--DeferredOfferingCostsPolicyTextBlock_zampFPTaHJw6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>i.
<span id="xdx_866_zIRNVy8x1Vb6">Deferred offering costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company follows the requirements of FASB ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212; &#8220;Expenses
of Offering&#8221;. Deferred offering costs consist of underwriting, legal, and other professional expenses incurred through the balance
sheet date that are directly related to the intended de-SPAC Transaction. These costs will be charged to shareholders&#8217; equity, netted
against the proceeds, upon the completion of the Business Combination. Should the transaction prove to be unsuccessful, these deferred
costs, as well as additional expenses to be incurred, will be charged to the statements of operations and comprehensive loss. As of June&#160;30,
2025 and March&#160;31, 2026, the Company deferred nil <span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20250630_z5VXiUJdObX8" title="Deferred offering costs" style="display: none"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003225" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--DeferredOfferingCosts_iI_c20260331_zPoYFoMfe149" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003227" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,000</ix:nonFraction></span> of transaction costs, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003229" name="cik0002065779:AdvanceToSuppliersPolicyTextBlock"><p id="xdx_846_ecustom--AdvanceToSuppliersPolicyTextBlock_zZ6KgRaaPBG2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>j.
<span id="xdx_866_zzQ6PbxNF5wb">Advance to suppliers</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Advance
to suppliers represent prepayments made to vendors in connection with the purchase of services. Advance is recorded at the amount paid
and are classified as current assets when the related services are expected to be received within one year or the normal operating cycle.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003231" name="cik0002065779:RefundableDepositsReceivablePolicyTextBlock"><p id="xdx_848_ecustom--RefundableDepositsReceivablePolicyTextBlock_zk0hhYTHhzHb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>k.
<span id="xdx_869_zdl6xUSc9d8g">Refundable deposits receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Refundable
deposits receivable mainly represents security deposits and refundable cooperation deposits paid to suppliers and business partners that
are contractually recoverable upon the completion of services. These amounts are recorded as assets when paid, generally at the amount
paid. Deposits expected to be recovered within one year are classified as current; otherwise, they are classified as non-current. Allowance
should be assessed under CECL, and write off when not recoverable. The Company evaluates the credit risk of refundable deposits receivable
and recognizes an allowance for credit losses based on the current expected credit losses (&#8220;CECL&#8221;) model. Specific balances
are written off when they are deemed uncollectible and all collection efforts have been exhausted. As of June&#160;30, 2025 and March&#160;31,
2026, <span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_zDO4z5wPjGpf" title="Allowance for expected credit losses"><span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20260331_zQu1ABES8Qma" title="Allowance for expected credit losses"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003233" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003235" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> allowance for credit losses was recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003237" name="cik0002065779:PrepaidResearchAndDevelopmentExpensesPolicyTextBlock"><p id="xdx_845_ecustom--PrepaidResearchAndDevelopmentExpensesPolicyTextBlock_zj47oP2LEO03" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>l.
<span id="xdx_866_zznJ5p0oZj1b">Prepaid research and development expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Prepaid
research and development expenses represent advance payments to third-party service providers for technical, design, and development services.
These amounts are initially recorded as prepaid assets and are subsequently recognized as research and development expenses in the period
the services are rendered, in accordance with the terms of the respective agreements. The Company periodically reviews the status of these
agreements to ensure the prepaid balance properly reflects the value of services not yet received. For the three and nine months ended
March&#160;31, 2026, the Company recognized&#160;$<span id="xdx_907_ecustom--AmortizationOfPrepaidResearchAndDevelopmentCosts_c20260101__20260331_zCXNiflih5bg" title="Amortization of prepaid research and development costs"><ix:nonFraction name="cik0002065779:AmortizationOfPrepaidResearchAndDevelopmentCosts" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003239" format="ixt:numdotdecimal" decimals="0" unitRef="USD">625,000</ix:nonFraction></span> and $<span id="xdx_90C_ecustom--AmortizationOfPrepaidResearchAndDevelopmentCosts_c20250701__20260331_zBFunA6k8NXc" title="Amortization of prepaid research and development costs"><ix:nonFraction name="cik0002065779:AmortizationOfPrepaidResearchAndDevelopmentCosts" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003241" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,875,000</ix:nonFraction></span>, respectively, of expense related to the amortization of prepaid
research and development costs, which was included in research and development expense.</p>

<ix:exclude><p id="xdx_232_zipGBDNNMgVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 423; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zQuGFQ0ffTP3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zdlrnCY8Avi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>2. Summary of significant accounting
policies (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003246" name="cik0002065779:OtherReceivablesPolicyRextBlock"><p id="xdx_84D_ecustom--OtherReceivablesPolicyRextBlock_zhEjVv3wuafj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>m.
<span id="xdx_86D_zATAJPzQnQpl">Other receivables</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Other
receivables represent funds temporarily held in trust by an employee acting on the Company&#8217;s behalf. As of June&#160;30, 2025
and March&#160;31, 2026, the balance were $<span id="xdx_90D_eus-gaap--OtherReceivables_iI_pp0d_c20250630_za2VXMC6Mpee" title="Other receivables"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003248" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,207,626</ix:nonFraction></span>
and <span id="xdx_908_eus-gaap--OtherReceivables_iI_pp0d_c20260331_zA3XBehG7pA7" title="Other receivables" style="display: none"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003250" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> nil, respectively, with the nil balance as of March 31, 2026 resulting from the employee having repaid all outstanding amounts to the Company. The balance
as of June 30, 2025 was primarily comprising proceeds from SAFEs agreements received via the employee and net of payments made to
designated suppliers at the Company&#8217;s direction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003252" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zCXIK2Zay5zh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>n.
<span id="xdx_865_zZTnYmCZy9f7">Equipment, net</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Equipment,
net is stated at cost less accumulated depreciation and impairment, if any. Depreciation is computed using the straight-line method over
the estimated useful lives of three or five years, depending on the asset category.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003254" name="cik0002065779:RefundableDepositsPayablePolicyTextBlock"><p id="xdx_847_ecustom--RefundableDepositsPayablePolicyTextBlock_zPSaUzzvIgEa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>o.
<span id="xdx_86F_zFO7q56sC1Ja">Refundable deposits payable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Refundable
deposits payable represent security payments received from a third party and customers, which are required for certain intelligent computing
power service arrangements. As of June&#160;30, 2025 and March&#160;31, 2026, the balance were $<span id="xdx_906_ecustom--RefundableDepositsPayable_iI_pp0d_c20250630_zT5OwPspNGaa" title="Refundable deposits payable"><ix:nonFraction name="cik0002065779:RefundableDepositsPayable" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,445,580</ix:nonFraction></span> and $<span id="xdx_907_ecustom--RefundableDepositsPayable_iI_pp0d_c20260331_zlF8FJ2gxvTd" title="Refundable deposits payable"><ix:nonFraction name="cik0002065779:RefundableDepositsPayable" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003258" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,174,702</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003260" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zVTnprYtqQTc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>p.
<span id="xdx_862_zigYXt8xtSLl">Impairment of long-lived assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company reviews its long-lived assets, equipment, for impairment whenever events or changes in circumstances indicate the carrying amount
of an asset may not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset
to the future undiscounted cash flows expected to be generated from the use of the asset and its eventual disposition. If such assets
are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair
value of the impaired assets. Assets to be disposed of are reported at the lower of their carrying amount or fair value less cost to sell.
There was <span id="xdx_905_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20240701__20250331_zrLs0b2fiOF6" title="Impairment of long-lived assets"><span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20250701__20260331_z8ukRmzY0PX3" title="Impairment of long-lived assets"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003262" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003264" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> impairment of long-lived assets for the nine months ended March&#160;31, 2025 and 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003266" name="cik0002065779:SimpleAgreementsForFutureEquityPolicyTextBlock"><p id="xdx_849_ecustom--SimpleAgreementsForFutureEquityPolicyTextBlock_zdOdrfeIirK4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>q.
<span id="xdx_86C_zSfMxlp0w9ih">Simple agreements for future equity</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">SAFEs
issued by the Company are freestanding financial instruments. As they contain certain redemption or liquidation features that&#160;may&#160;require
the Company to settle the obligation in cash upon the occurrence of defined events (e.g., a change of control or dissolution), the instruments&#160;create
an obligation that meets the definition of a liability. Accordingly, the SAFEs are classified in their entirety as liabilities on the
balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">These
liabilities are measured at fair value upon initial recognition and are subsequently remeasured at fair value at each reporting date.
All changes in their fair value are recognized in&#160;the condensed consolidated statement of operations and comprehensive loss in the
period in which they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003268" name="us-gaap:RevenueRecognitionDeferredRevenue"><p id="xdx_84A_eus-gaap--RevenueRecognitionDeferredRevenue_z7voQ64y5MR7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>r.
<span id="xdx_86B_zHHFuv3eFudi">Revenue recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company applied ASC Topic&#160;606 &#8220;<i>Revenue from Contracts with Customers</i>&#8221; (&#8220;ASC&#160;606&#8221;) for all periods
presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
five-step model defined by ASC&#160;606 requires the Company to (i)&#160;identify its contracts with clients, (ii)&#160;identify its performance
obligations under those contracts, (iii)&#160;determine the transaction prices of those contracts, (iv)&#160;allocate the transaction
prices to its performance obligations in those contracts, and (v)&#160;recognize revenue when each performance obligation under those
contracts is satisfied. Revenue is recognized when promised goods or services are transferred to the client in an amount that reflects
the consideration expected in exchange for those goods or services.</p>

<ix:exclude><p id="xdx_235_zjWFuy6qGzA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 424; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zfe4YAQuRp3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zRHnQFNsMaug" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>2. Summary of significant accounting
policies (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zxUfOcI6qeX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zX3O0rik5G3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>r. Revenue recognition (Continued)</i></b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company reports all of its revenues on a gross basis.&#160;This determination is based on the Company&#8217;s assessment that it is the
principal in its revenue arrangements. The Company controls the service delivery platform and infrastructure before the service is provided
to the customer. It is primarily responsible for fulfilling the service promise, has discretion in setting prices, and assumes the credit
risk associated with the customer receivable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">As
a practical expedient, the Company elected to expense the incremental costs of obtaining a contract when incurred if the amortization
period of the asset that the Company otherwise would have recognized is one year or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Pursuant
to ASC 606, the Company recognizes revenue based on the transaction price, which is the amount of consideration it expects to be entitled
to exchange for transferring services to customers. For Intelligent Computing Power Services, contract consideration is generally fixed
and is typically stated as a fixed monthly fee determined by (i) the contractually specified number of GPUs (capacity) and (ii) the service
period. Accordingly, the transaction price is generally the fixed contractual amount. The Company recognizes revenue over time as the
services are provided throughout the contract term. The Company offers payment terms ranging from 0 to 6 months, depending on customers&#8217;
credit profiles and service requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company does not provide warranties for its services and does not offer service-type warranty arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
following is a description of the principal activities of the Company from which the Company generates its revenue under ASC 606.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">(i)
Revenue for intelligent computing power service</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company leverages its expertise in high-performance computing and cloud-native architectures to build and operate stable, efficient, and
scalable GPU computing platforms through modular data center design and liquid cooling technology. The Company uses these platforms to
provide computing resources for large-scale AI training, model inference, and high-performance scientific computing to commercial enterprise
clients with substantial GPU computing requirements. Supporting services include GPU server environment deployment, cluster scheduling
and performance optimization, high-speed network interconnection, real-time monitoring and intelligent alerting systems, as well as industry-compliant
security and regulatory assurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company accounts for the above promises as a single performance obligation because they are highly integrated and not separately identifiable
in the context of the contract. The Company provides an integrated, managed GPU computing platform in which computing capacity, deployment/configuration,
scheduling, networking, monitoring, and security/compliance are interdependent and together deliver a single combined service&#8212;continuous
access to a functioning and secured platform over the contractual term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company provides intelligent computing power services under two pricing models: (i) reserved capacity arrangements and (ii) on-demand
(pay-as-you-go) arrangements. The following table presents revenue recognized during the period by arrangement type:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003275" name="cik0002065779:ScheduleOfRevenueRecognitionTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zd2TxFvdYVol" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8BE_zsDAbjhGLAp7" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of Revenue recognition</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Reserved
        capacity arrangements</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90A_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember" id="Fact003277" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,758,921</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_908_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember" id="Fact003279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,725,315</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember" id="Fact003281" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,161,985</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember" id="Fact003283" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,428,983</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">On-demand
        arrangements</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember" id="Fact003285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,436</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember" id="Fact003287" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,341</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember" id="Fact003289" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,482</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember" id="Fact003291" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,526</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_905_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember" id="Fact003293" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,764,357</ix:nonFraction></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_903_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember" id="Fact003295" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,726,656</ix:nonFraction></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_900_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember" id="Fact003297" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,168,467</ix:nonFraction></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_90E_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember" id="Fact003299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,441,509</ix:nonFraction></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zk9Xg0gC6OZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 425; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><p id="xdx_230_zgGKoQKrKl5c" style="font: 10pt Times New Roman, Times, serif; margin: 0px"><b>2. Summary of significant accounting
policies (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_ziFVA2tC4QLi" style="font: 10pt Times New Roman, Times, serif; margin: 0px">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zV9bjoQeIGXk" style="font: 10pt Times New Roman, Times, serif; margin: 0px"><b><i>r. Revenue recognition (Continued)</i></b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, serif; margin: 0px"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Reserved
capacity arrangements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company enters into reserved capacity arrangements, which generally provide committed intelligent computing power services for a defined
service term ranging from 3 months to 3 years, with the majority of such arrangements having a one-year term. These contracts typically
are non-cancelable, or may be canceled only under limited conditions with early notifications required. Payment terms generally range
from 0-6 months upon the completion of services, and certain arrangements require prepayments. Any prepayments are recorded as contract
liabilities and recognized over the service term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
performance obligation is satisfied over time because the customer simultaneously receives and consumes the benefits. Revenue is recognized
using a time-elapsed output method over the contractual service period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">On-demand
(pay-as-you-go) arrangements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif;text-align: justify; margin-top: 0; margin-bottom: 0">The Company provides customers with on-demand
access to intelligent computing power and GPU resources under pay-as-you-go model which requires advance payment. Customer advances are
recorded as contract liabilities and recognized as revenue over the time during the provision of related services underlying the contract
term. The revenue is recognized over time because the customer can simultaneously receive and consume the benefits during the service
period. These arrangements generally do not include a fixed contractual term or minimum usage commitments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">(ii)
Revenue from comprehensive data center service</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company leverages its project experience in infrastructure management, cluster optimization, and system monitoring to provide full-cycle
operational support to data center asset owners. Services encompass facility environment deployment, network architecture implementation,
security and compliance system development, daily operational monitoring, and emergency fault response. Revenue is recognized over time
because the Company&#8217;s services are performed throughout the contract term and the customer benefits as the services are provided.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
the three months ended March&#160;31, 2025 and 2026, $<span id="xdx_909_eus-gaap--Revenues_c20250101__20250331_pp0p" title="Revenue"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,862,158</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--Revenues_c20260101__20260331_pp0p" title="Revenue"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003306" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,754,586</ix:nonFraction></span> of the revenue of the Company&#8217;s was recognized over
time, respectively. For the nine months ended March&#160;31, 2025 and 2026, $<span id="xdx_905_eus-gaap--Revenues_c20240701__20250331_pp0p" title="Revenue"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003308" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,475,885</ix:nonFraction> </span>and $<span id="xdx_903_eus-gaap--Revenues_c20250701__20260331_pp0p" title="Revenue"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003310" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,561,331</ix:nonFraction></span> of the revenue of the Company&#8217;s
was recognized over time, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Revenue
disaggregated by service lines for the three months and the nine months ended March&#160;31, 2025 and 2026 is disclosed in the table below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003312" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_z4whYoH0Yw36" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B8_z323FGsdNtth" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of Revenue disaggregated</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenue
        from intelligent computing power service</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z29WimMIRYO5" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember" id="Fact003314" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,764,357</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--Revenues_pp0d_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z0wPR3mOXwde" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember" id="Fact003316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,726,656</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_904_eus-gaap--Revenues_pp0d_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zzqz7UuAay4i" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember" id="Fact003318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,168,467</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zh7mCphOG5Ja" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember" id="Fact003320" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,441,509</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Revenue
        from comprehensive data center service</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember" id="Fact003322" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,801</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2026-01-012026-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember" id="Fact003324" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,930</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember" id="Fact003326" format="ixt:numdotdecimal" decimals="0" unitRef="USD">307,418</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-07-012026-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember" id="Fact003328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,822</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_90B_eus-gaap--Revenues_pp0d_c20250101__20250331_zwjWXHIVxdh" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003330" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,862,158</ix:nonFraction></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_90D_eus-gaap--Revenues_pp0d_c20260101__20260331_zNTOV4dIJ4Sh" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003332" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,754,586</ix:nonFraction></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_903_eus-gaap--Revenues_pp0d_c20240701__20250331_zNWqBnz3BD5a" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003334" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,475,885</ix:nonFraction></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_906_eus-gaap--Revenues_pp0d_c20250701__20260331_zdRfOMzRsXv6" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003336" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,561,331</ix:nonFraction></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zatc3Yp3kc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003338" name="cik0002065779:ContractLiabilitiesPolicyTextBlock"><p id="xdx_84C_ecustom--ContractLiabilitiesPolicyTextBlock_z2PT6xnTNlO" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>s.
<span id="xdx_869_z3dd7lxTNbH4">Contract liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company receives advance payments from its customers for services to be provided in the future. These payments are recorded as&#160;contract
liabilities&#160;on the balance sheet within &#8220;Contract liabilities&#8221;.</p>

<ix:exclude><p id="xdx_233_zqiJLED0OqI7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 426; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_z4iN80Khyioc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zFfraNufBdSl" style="font: 10pt Times New Roman, Times, serif; text-align: justify; margin-top: 0px; margin-bottom: 0px"><b>2.
Summary of significant accounting policies (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zFUZ0fslEXE5" style="font: 10pt Times New Roman, Times, serif; margin: 0px">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zsNvVSERAY83" style="font: 10pt Times New Roman, Times, serif; text-align: justify; margin-top: 0px; margin-bottom: 0px"><b><i>s.
Contract liabilities (Continued)</i></b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Contract
liabilities are recognized when consideration is received from a customer prior to the Company satisfying its related performance obligations.
For these service contracts, the Company recognizes revenue, and reduces the contract liabilities,&#160;over time&#160;as the services
are rendered and the performance obligations are satisfied. Revenue recognized during the nine months ended March&#160;31, 2025 and 2026
that was included in the contract liability balance at the beginning of the period was $<span id="xdx_90A_ecustom--RevenueRecognized_c20240701__20250331_pp0p" title="Revenue recognized"><ix:nonFraction name="cik0002065779:RevenueRecognized" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003345" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,326</ix:nonFraction></span> and $<span id="xdx_90D_ecustom--RevenueRecognized_pp0d_c20250701__20260331_z9oT97FjUGcd" title="Revenue recognized"><ix:nonFraction name="cik0002065779:RevenueRecognized" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003347" format="ixt:numdotdecimal" decimals="0" unitRef="USD">366,075</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003349" name="us-gaap:CostOfSalesPolicyTextBlock"><p id="xdx_84F_eus-gaap--CostOfSalesPolicyTextBlock_zaoHhLB8Cxzj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>t.
<span id="xdx_863_z6GbgvPwOLFd">Cost of revenues</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s cost of revenues primarily includes computing power service, professional service fees and staff costs and employee benefits.
All the cost of revenues are recognized in the period in which the related services occur or the benefits are received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003351" name="cik0002065779:SellingAndMarketingExpensesPolicyTextBlock"><p id="xdx_844_ecustom--SellingAndMarketingExpensesPolicyTextBlock_zw8zqwj9sNL3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>u.
<span id="xdx_864_ziTHMzLNeaI4">Selling and marketing expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s selling and marketing expenses primarily include: (i) advertising and promotion expenses, (ii) staff costs, employee benefits
and share-based compensation, and (iii) travel and other routine office expenses. All expenses are recognized in the period in which the
related services occur or the benefits are received. The Company expenses advertising costs as incurred, and for the nine months ended
March&#160;31, 2025 and 2026, the Company incurred advertising and promotion expenses of $<span id="xdx_908_eus-gaap--MarketingAndAdvertisingExpense_c20240701__20250331_pp0p" title="Advertising and promotion expenses"><ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,090</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20250701__20260331_pp0p" title="Advertising and promotion expenses"><ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003355" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,113</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003357" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zPGLlXD14Ag2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>v.
<span id="xdx_86B_zfPkq0yTYPQi">Research and development expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s research and development expenses mainly consist of software development outsourcing service fees, staff costs and employee
benefits, and testing expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003359" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock"><p id="xdx_841_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zXxvFOjeOFW2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>w.
<span id="xdx_866_zkb75BAicCy2">General and administrative expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s general and administrative expenses mainly consist of staff costs and employee benefits, professional service fees, depreciation
expenses and other operating expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003361" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zM8egXJLQ5Fa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>x.
<span id="xdx_863_znTdepZ9jHh1">Income tax</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Income
taxes are determined in accordance with the provisions of ASC Topic 740, &#8220;Income Taxes&#8221; (&#8220;ASC Topic 740&#8221;). Under
this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities
are measured using enacted income tax rates expected to apply to taxable income in the periods in which those temporary differences are
expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income
in the period that includes the enactment date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">ASC
740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial
statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be
recognized in the unaudited condensed consolidated financial statements when it is more likely than not the position will be
sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest
amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority
assuming full knowledge of the position and relevant facts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003363" name="cik0002065779:CapitalStructurePolicyTextBlock"><p id="xdx_847_ecustom--CapitalStructurePolicyTextBlock_zj8IHwVClyZk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>y.
<span id="xdx_865_zxrlWlb60CN6">Capital structure</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company is authorized to issue <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20250630_zxhDDryref03" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003365" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></span> ordinary shares of $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250630_z9V4hGvU5My3" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003367" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> par value each. As of June&#160;30, 2025, there were <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20250630_zDM1htk1G69f" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20250630_zYzvDTOvJVAi" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003369" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003371" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></ix:nonFraction></span></span> shares issued
and outstanding.</p>

<ix:exclude><p id="xdx_236_zrdJF0pNIVFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 427; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zfWPfyUSlZza" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zEBmBoNHUJ12" style="font: 10pt Times New Roman, Times, serif; text-align: justify; margin-top: 0px; margin-bottom: 0px"><b>2.
Summary of significant accounting policies (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zHypv7bbBUH8" style="font: 10pt Times New Roman, Times, serif; margin: 0px">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_z5MG6hQX0mNf" style="font: 10pt Times New Roman, Times, serif; text-align: justify; margin-top: 0px; margin-bottom: 0px"><b><i>y.
Capital structure (Continued)</i></b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Pursuant
to the resolution of the board of directors on January&#160;8, 2026, the authorized share capital of <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20260108_z7MXAFFZzI8i" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-01-08_custom_ExascaleLabsIncMember" id="Fact003378" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></span> ordinary shares was re-designated
to <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zYWtA0wxDxN4" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-01-08_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact003380" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">303</ix:nonFraction></span> Class A ordinary shares and <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_z1Wg9UO1Hwh6" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-01-08_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact003382" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,197</ix:nonFraction></span> Class B ordinary shares. Holders of Class A ordinary shares and Class B ordinary shares have
the same rights, except for voting and conversion rights. Each Class A ordinary share is entitled to one vote; and each Class B ordinary
share is entitled to twenty votes and is convertible into one Class A ordinary share at any time by the holder thereof. Class A ordinary
shares are not convertible into Class B ordinary shares under any circumstances. Furthermore, all outstanding warrants, options, and SAFEs
are designated to convert or settle exclusively into Class A ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">As
of March&#160;31, 2026, there were <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact003384" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">303</ix:nonFraction></span> Class A ordinary shares and <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember" id="Fact003386" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,197</ix:nonFraction></span> Class B ordinary shares outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003388" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z72hDOJ3JON1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>z.
<span id="xdx_86B_z63uLSARL1W8">Share-based compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company grants share options of the Company to eligible employees and&#160;non-employees. The Company accounts for share-based awards
issued to employees and&#160;non-employees in accordance with ASC Topic 718 <i>Compensation &#8211; Stock Compensation. </i>The Company
recognizes forfeitures as they occur. The share-based compensation expenses have been categorized as either general and administrative
expenses or selling and marketing expenses, depending on the job functions of the grantees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s share-based compensation awards are expected to be settled through transfers of existing ordinary shares held by the controlling
shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary shares are included in issued and
outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase the Company&#8217;s total issued
and outstanding shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Employees&#8217;
share-based awards and non-employees&#8217; share-based awards are measured at the grant date fair value of the awards and recognized
as expenses a) immediately at grant date if no vesting conditions are required; or b) using graded vesting method, net of estimated forfeitures,
over the requisite service period, which is the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company employs discounted cash flow method to determine the fair value of our share-based compensation arrangements, where the key valuation
variables include risk free rate, discount rate, and perpetual rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003390" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zh2bCTq9oe5d" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>aa.
<span id="xdx_864_zR4H5vg2NKs8">Segment reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">ASC
280, &#8220;Segment Reporting&#8221;, establishes standards for reporting information about operating segments on a basis consistent with
the Company&#8217;s internal organizational structure as well as information about geographical areas, business segments and major customers
in financial statements for details on the Company&#8217;s business segments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company uses the &#8220;management approach&#8221; in determining reportable operating segments. The management approach considers the
internal organization and reporting used by the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) for making operating
decisions and assessing performance as the source for determining the Company&#8217;s reportable segments. The Company&#8217;s CODM is
the chief executive officer. The CODM regularly reviews consolidated operating results and reviews consolidated revenues and net loss
when making decisions about allocating resources and assessing performance of the segment, and hence, the Group has only&#160;one&#160;reportable
segment. Therefore, as the Group has determined it operates as a single reportable segment, the CODM assesses the Group&#8217;s performance
and results of operations on a consolidated basis.</p>

<ix:exclude><p id="xdx_230_zZIiYyBI5o66" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 428; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zCccwHoEMR3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zXV2m6ZU0xKi" style="font: 10pt Times New Roman, Times, serif; text-align: justify; margin-top: 0px; margin-bottom: 0px"><b>2.
Summary of significant accounting policies (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003395" name="cik0002065779:RelatedPartiesPolicyTextBlock"><p id="xdx_848_ecustom--RelatedPartiesPolicyTextBlock_zrZgPAsibWna" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>bb.
<span id="xdx_86A_zzhxddzLg2h3">Related parties</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Parties
are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant
influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject
to common control or significant influence, such as a family member or relative, shareholder, or a related corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003397" name="cik0002065779:ComprehensiveLossPolicyTextBlock"><p id="xdx_84F_ecustom--ComprehensiveLossPolicyTextBlock_zbTFOSz89y33" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>cc.
<span id="xdx_86C_znQfJNLN3lgc">Comprehensive loss</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Comprehensive
loss is defined as a change in equity during a period from transactions and other events and circumstances&#160;from&#160;non-owner&#160;sources.&#160;The
Company&#8217;s comprehensive loss was the same as its reported net loss for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003399" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_846_eus-gaap--EarningsPerSharePolicyTextBlock_z0CKE94bvxGf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>dd.
<span id="xdx_869_zTML0LCjGgK">Loss per share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Basic
net loss per share of ordinary shares attributable to common shareholders is calculated by dividing net loss attributable to common shareholders
by the weighted-average shares of common shares outstanding for the period. Potentially dilutive shares, which are based on the weighted-average
shares of common stock underlying outstanding share-based awards or options using the treasury stock method or the if-converted method,
as applicable, are included when calculating diluted net income per share of common stock attributable to common shareholders when their
effect is dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Diluted
net loss per share attributable to ordinary shareholders is computed by adjusting the weighted-average number of ordinary shares outstanding
for the dilutive effect of all potential ordinary share equivalents. For the Company, potential ordinary share equivalents consist of
share-based compensation, which are assessed using the&#160;treasury stock method. These potential shares are included in the diluted
earnings per share calculation only when their effect is&#160;dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
periods where the Company reports a&#160;net loss, diluted net loss per share is calculated in the same manner as basic net loss per share
because the inclusion of any potential ordinary shares would have an&#160;anti-dilutive&#160;effect. Consequently, all potential ordinary
share equivalents were excluded from the calculation for the years in which a net loss was incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003401" name="us-gaap:RevenueRecognitionDividends"><p id="xdx_84E_eus-gaap--RevenueRecognitionDividends_zJ8w8TuqR9s" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>ee.
<span id="xdx_860_zcInrRKO5aA2">Dividends</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Dividends
are recognized when declared. <span id="xdx_907_eus-gaap--Dividends_pp0d_do_c20240701__20250331_zbPIn012EOig" title="Dividends"><span id="xdx_90C_eus-gaap--Dividends_pp0d_do_c20250701__20260331_zuV7f8fIUas1" title="Dividends"><ix:nonFraction name="us-gaap:Dividends" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003403" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:Dividends" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003405" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></ix:nonFraction></span></span> dividends were declared for the nine months ended March&#160;31, 2025 and 2026, respectively. The Company
does not have any present plan to pay any dividends on ordinary shares in the foreseeable future. The Company currently intends to retain
the available funds and any future earnings to operate and expand its business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003407" name="cik0002065779:EmergingGrowthCompanyPolicyTextBlock"><p id="xdx_841_ecustom--EmergingGrowthCompanyPolicyTextBlock_zX6M59dr8xPl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>ff</i></b>.
<b><i><span id="xdx_86A_zwrHCIubN67h">Emerging growth company</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company intends to operate as an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012
(the &#8220;JOBS Act&#8221;). The JOBS Act permits companies with emerging growth company status to take advantage of an extended transition
period to comply with new or revised accounting standards, delaying the adoption of these accounting standards until such time as those
standards would apply to private companies. The Company elected to use this extended transition period to enable it to comply with new
or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that
it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period
provided in the JOBS Act. As a result, the Company&#8217;s financial statements may not be comparable to companies that comply with the
new or revised accounting standards as of public company effective dates.</p>

<ix:exclude><p id="xdx_232_zZkiKL4xBVah" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 429; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zuseYAVgy8Nd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zpE4s8eSWjBa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>2.
Summary of significant accounting policies (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003412" name="cik0002065779:RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock"><p id="xdx_842_ecustom--RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock_zt2bjFLbuL9h" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>gg.
<span id="xdx_86D_zcwKuWVskW29">Recently adopted accounting standard updates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
June&#160;2016, the FASB issued ASU&#160;2016-13, <i>Financial Instruments&#160;&#8212;&#160;Credit Losses </i>(Topic&#160;326): Measurement
of Credit Losses on Financial Instruments (&#8220;ASU&#160;2016-13&#8221;). The new accounting standard introduced the current expected
credit losses methodology (&#8220;CECL&#8221;) for estimating allowances for credit losses. The measurement of expected credit losses
under the CECL methodology is applicable to financial assets measured at amortized costs, including loans and trade receivables. ASU&#160;2016-13
is effective for the Company, as an emerging growth company, for annual and interim reporting periods beginning after December&#160;15,
2022. The Company adopted the standard on July&#160;1, 2023 using the modified retrospective method for all financial assets in scope.
The adoption of the standard did not have a material impact on the Company&#8217;s statements of income, or statements of cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
November&#160;2023, the FASB issued ASU&#160;2023-07, &#8220;Segment Reporting (Topic&#160;280): Improvements to Reportable Segment Disclosures.&#8221;
The amendments in this ASU are intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about
significant segment expenses. This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating
decision mark (&#8220;CODM&#8221;), an amount for other segment items by reportable segment and a description of its composition, all
annual disclosures required by FASB ASU Topic&#160;280 in interim periods as well, and the title and position of the CODM and how the
CODM uses the reported measures. Additionally, this ASU requires that at least one of the reported segment profit and loss measures should
be the measure that is most consistent with the measurement principles used in an entity&#8217;s financial statements. Lastly, this ASU
requires public business entities with a single reportable segment to provide all disclosures required by these amendments in this ASU
and all existing segment disclosures in Topic&#160;280. This ASU is effective for fiscal&#160;years beginning after December&#160;15,
2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. The Company has early adopted ASU&#160;2023-07
on July&#160;1, 2023. As a result of adoption, the required disclosures have been included in Note 2 and Note 13.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003414" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOp72ws5iCAh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>hh.
<span id="xdx_86A_z38IxEch0007">Recently accounting pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
December&#160;2023, the FASB issued ASU&#160;No.&#160;2023-09,&#160;<i>Improvements to Income Tax Disclosures</i>&#160;(&#8220;ASU&#160;2023-09&#8221;),&#160;which
requires entities to make incremental income tax disclosures on an annual basis. The amendments require that public business entities
disclose specific categories in the rate reconciliation and provide additional information for reconciling items meeting a quantitative
threshold. The amendments also require disclosure of income taxes paid to be disaggregated by jurisdiction, and the disclosure of income
tax expense disaggregated by federal, state, and foreign. Amendments are effective for annual periods beginning after December&#160;15,
2025 and thereafter, with early adoption permitted. The Company is evaluating adoption timing and the impact ASU&#160;2023-09&#160;will
have on its financial statements and related disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
March&#160;2024, the FASB issued ASU No. 2024-02, <i>Codification Improvements-Amendments to Remove References to the Concepts Statements</i>
(&#8220;ASU 2024-02&#8221;). The amendments in this Update affect a variety of Topics in the Codification. The amendments apply to all
reporting entities within the scope of the affected accounting guidance. This update contains amendments to the Codification that remove
references to various Concepts Statements. In most instances, the references are extraneous and not required to understand or apply the
guidance. In other instances, references were used in prior statements to provide guidance in certain topical areas. ASU 2024-02 is effective
for public business entities for fiscal years beginning after December&#160;15, 2024. Early adoption is permitted for both interim and
annual financial statements that have not yet been issued or made available for issuance. The adoption did not have a material impact
on the Company&#8217;s financial statement.</p>

<ix:exclude><p id="xdx_23C_zEIYcFwwcF1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 430; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zUoUGWxGXac4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zPPJMXY4vQ55" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>2.
Summary of significant accounting policies (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zHyuNdQnFrU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zyFtig6QJkMj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>hh.
Recently accounting pronouncements (Continued)</i></b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
November&#160;2024, the FASB issued ASU 2024-03 &#8220;<i>Income Statement&#8212;Reporting comprehensive (loss) income&#8212;Expense Disaggregation
Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i>&#8221; (&#8220;ASU 2024-03&#8221;). The amendments in this
update intend to improve the disclosures about a public business entity&#8217;s expenses and address requests from investors for more
detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization,
and depletion) in commonly presented expense captions (such as cost of sales, selling, general and administrative expenses, and research
and development). ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods beginning after
December&#160;15, 2027. The Company is currently evaluating the impact from the adoption of this ASU on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
January&#160;2025, the FASB issued Accounting Standards Update (ASU) No. 2025-01, <i>Income Statement &#8212; Reporting comprehensive
(loss) income &#8212; Expense Disaggregation Disclosures</i> (Subtopic 220-40): Clarifying the Effective Date. The amendment clarifies
the effective date of ASU No. 2024-03 that all public business entities are required to adopt the guidance in annual reporting periods
beginning after December&#160;15, 2026, and interim periods within annual reporting periods beginning after December&#160;15, 2027. Early
adoption of Update 2024-03 is permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or
guidance on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
July&#160;2025, the FASB issued Accounting Standards Update (ASU) No. 2025-05, <i>Financial Instruments &#8212; Credit Losses</i> (Topic
326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The amendment provides (1) all entities with a practical
expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the assets and (2) entities
other than public business entities with an accounting policy election to consider collection activity after the balance sheet date when
estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for
under Topic 606. This guidance is effective for annual reporting periods beginning after December&#160;15, 2025 and interim reporting
periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of the above
new accounting pronouncements or guidance on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
September&#160;2025, the FASB issued&#160;<i>ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40):
Accounting for and Disclosure of Software Costs&#160;</i>(&#8220;ASU 2025-06&#8221;), which amends certain aspects of the accounting for
and disclosure of internal-use software costs. ASU 2025-06 is effective for annual reporting periods beginning with the year ending December&#160;31,
2028, with early adoption permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or guidance
on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December&#160;2025,
the FASB issued <i>ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements</i>, which clarifies interim disclosure
requirements resulting in a comprehensive list of interim disclosures that are required by GAAP, and includes a disclosure principle
that requires the disclosure of events since the end of the last annual reporting period that have a material impact on the Company.
ASU 2025-11 is effective for the Company&#8217;s interim reporting periods within fiscal years beginning after December 15, 2028, with
early adoption permitted. ASU 2025-11 may be applied either prospectively or retrospectively. The Company is currently evaluating the
impact of the above new accounting pronouncements or guidance on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Except
as mentioned above, the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted,
would have a material effect on the balance sheets, statements of income and comprehensive loss and cash flows.</p>

<ix:exclude><p id="xdx_23A_zyY1uWCBuRxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 431; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003422" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p id="xdx_803_eus-gaap--ConcentrationRiskDisclosureTextBlock_zS5TxZ8a2Pfc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>3.
<span id="xdx_829_zr7ePs3Ws0Bk">Concentration and risk</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Concentration
of credit risk</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Financial
instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.
The Company performs ongoing credit evaluations of the customers&#8217; financial condition and maintains an allowance for potential credit
losses. This allowance consists of an amount identified for specific customers and an amount based on overall estimated exposure. Our
overall estimated exposure excludes amounts covered by credit insurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Concentration
of customers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s revenue was concentrated among a limited number of customers during the periods presented. The following table summarized
customers with greater than 10% of the total revenue:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003424" name="cik0002065779:ScheduleOfConcentrationOfCustomersTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfConcentrationOfCustomersTableTextBlock_zdrUY4cApChh" summary="xdx: Disclosure - Concentration and risk (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8BB_zF0IjA1n3Cgf" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of Concentration of customers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zxlgA7Wnag01" title="Concentration of credit risk" style="color: rgb(204,238,255)"><span style="-sec-ix-hidden: xdx2ixbrl3426">-</span></span>**</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zqH7DAOCXZV8" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember" id="Fact003428" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">24.9</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_z4iANF7QCG72" title="Concentration of credit risk" style="color: rgb(204,238,255)"><span style="-sec-ix-hidden: xdx2ixbrl3430">-</span></span>**</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_z5ok8h33NPNk" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember" id="Fact003432" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">24.6</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zl0hTdibTWy2" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember" id="Fact003434" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">11.7</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zr78XgBdGFo5" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember" id="Fact003436" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">11.8</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zEivBBjP6d54" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember" id="Fact003438" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">10.0</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zJU8ZQcVPnQ2" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember" id="Fact003440" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">22.3</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        C</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zFn7N05enlt1" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember" id="Fact003442" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">13.7</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zh9iXLwhZpMf" title="Concentration of credit risk" style="color: rgb(204,238,255)"><span style="-sec-ix-hidden: xdx2ixbrl3444">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_ziHKyapdTwK3" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember" id="Fact003446" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">17.0</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zjeLxYJlsrI1" title="Concentration of credit risk" style="color: rgb(204,238,255)"><span style="-sec-ix-hidden: xdx2ixbrl3448">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        D</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_z796I4O4Ft1f" title="Concentration of credit risk" style="color: White"><span style="-sec-ix-hidden: xdx2ixbrl3450">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zRbhCM2LF7S5" title="Concentration of credit risk" style="color: White"><span style="-sec-ix-hidden: xdx2ixbrl3452">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zgDdNqfgOq26" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember" id="Fact003454" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">10.2</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zwowQSBgSD2k" title="Concentration of credit risk" style="color: White"><span style="-sec-ix-hidden: xdx2ixbrl3456">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        E</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zN6m8I45z7m6" title="Concentration of credit risk" style="color: rgb(204,238,255)"><span style="-sec-ix-hidden: xdx2ixbrl3458">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z7iN0ziOqvYg" title="Concentration of credit risk" style="color: rgb(204,238,255)"><span style="-sec-ix-hidden: xdx2ixbrl3460">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zyjXbig4uFfc" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember" id="Fact003462" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">10.1</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z34E1WctisKk" title="Concentration of credit risk" style="color: rgb(204,238,255)"><span style="-sec-ix-hidden: xdx2ixbrl3464">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        F</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zKgQ6gkcige5" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember" id="Fact003466" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">15.6</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zWsV8sKzzwa8" title="Concentration of credit risk" style="color: White"><span style="-sec-ix-hidden: xdx2ixbrl3468">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zB7onhtTK1u9" title="Concentration of credit risk" style="color: White"><span style="-sec-ix-hidden: xdx2ixbrl3470">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zxDehDpeHJYc" title="Concentration of credit risk" style="color: White"><span style="-sec-ix-hidden: xdx2ixbrl3472">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zpwvFHT7lvqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s account receivable was concentrated among a limited number of customers during the periods presented. The following table
summarized customers with greater than 10% of the total account receivable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003474" name="cik0002065779:ScheduleOfAccountsReceivableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfAccountsReceivableTextBlock_zssuHJd4Ga7j" summary="xdx: Disclosure - Concentration and risk (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B7_zUHNVQLGGhr4" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of account receivable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>As of<br/>June&#160;30,</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>As of<br/>March&#160;31,</b></td>
    <td>&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zZDJYmdTS6e7" title="Concentration of credit risk" style="color: rgb(204,238,255)"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember" id="Fact003476" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Ratio">-</ix:nonFraction></span>**</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zA8eCEY2tIWj" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember" id="Fact003478" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">29.7</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zBKTwHAkynJb" title="Concentration of credit risk" style="color: White"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember" id="Fact003480" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Ratio">-</ix:nonFraction></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zK6G4BVNOl4d" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember" id="Fact003482" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">19.5</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        E</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_ztBmu7lekrwl" title="Concentration of credit risk" style="color: rgb(204,238,255)"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember" id="Fact003484" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Ratio">-</ix:nonFraction></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z4Qc91H8QUS6" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember" id="Fact003486" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">10.5</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        G</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zL35tipxfmbl" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember" id="Fact003488" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">42.7</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zqXdvkL42fyj" title="Concentration of credit risk" style="color: White"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember" id="Fact003490" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Ratio">-</ix:nonFraction></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        H</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_z8f6t0ucYWmb" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember" id="Fact003492" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">38.3</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zMd1APLqZ6f8" title="Concentration of credit risk" style="color: rgb(204,238,255)"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember" id="Fact003494" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Ratio">-</ix:nonFraction></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        I</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zVQSNFcXuZY3" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerIMember_custom_ExascaleLabsIncMember" id="Fact003496" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">19.0</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zHUH7nofxl86" title="Concentration of credit risk" style="color: White"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerIMember_custom_ExascaleLabsIncMember" id="Fact003498" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Ratio">-</ix:nonFraction></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zdxUw16dlq13" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 432; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zb1TrUmXMSn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_z52JL3ektjE3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>3.
Concentration and risk (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Concentration
of suppliers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s purchases was concentrated among a limited number of suppliers during the periods presented. The following table summarized
suppliers with greater than 10% of the total purchase:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003502" name="cik0002065779:ScheduleOfConcentrationOfSuppliersTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfConcentrationOfSuppliersTableTextBlock_z3CdJRz1h27f" summary="xdx: Disclosure - Concentration and risk (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8BE_zyVdblECd42c" style="display: none; padding-bottom: 0.5pt">Schedule of Concentration of suppliers</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td></tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zZfZ870bnb8a" title="Concentration of credit risk" style="color: rgb(204,238,255)"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember" id="Fact003504" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Ratio">-</ix:nonFraction></span>*</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zfZK2HfIukSg" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember" id="Fact003506" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">13.0</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_fKg_____zoMyxzTZqNtf" title="Concentration of credit risk" style="color: rgb(204,238,255)"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember" id="Fact003508" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Ratio">-</ix:nonFraction></span>*</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zuAu6Jniu74e" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember" id="Fact003510" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">26.4</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_z1RvSNaoV0gg" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember" id="Fact003512" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">14.4</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zmAjaL9pPKIb" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember" id="Fact003514" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">30.2</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zu3OB7u7IVK3" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember" id="Fact003516" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">21.1</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zubilSVoZOol" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember" id="Fact003518" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">24.9</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        C</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zlOyPiZv8SE3" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember" id="Fact003520" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">32.9</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zmj4eUM2HHn1" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember" id="Fact003522" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">33.7</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zqiSFV5na4Ac" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember" id="Fact003524" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">24.0</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zougKUG4D7eh" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember" id="Fact003526" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">24.2</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        D</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_z39sRFJ0NCt8" title="Concentration of credit risk" style="color: White"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember" id="Fact003528" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Ratio">-</ix:nonFraction></span>*</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zMuGucfinjtf" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember" id="Fact003530" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">13.8</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zGlfi03BgXDb" title="Concentration of credit risk" style="color: White"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember" id="Fact003532" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Ratio">-</ix:nonFraction></span>*</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zZ6OSrj6FVIa" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember" id="Fact003534" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">11.5</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        E</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zJ08L3iZ3sFe" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember" id="Fact003536" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">45.5</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zrqGEIvYjMWe" title="Concentration of credit risk" style="color: rgb(204,238,255)"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember" id="Fact003538" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Ratio">-</ix:nonFraction></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zHbQGldke1jg" title="Concentration of credit risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember" id="Fact003540" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">47.6</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zd2hl76uQNH" title="Concentration of credit risk" style="color: rgb(204,238,255)"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember" id="Fact003542" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Ratio">-</ix:nonFraction></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">*:</td>
    <td style="text-align: justify">nil, new supplier for the nine months ended March&#160;31, 2026</td>
        </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zBBE52ciJOOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s account payable was concentrated among a limited number of suppliers during the periods presented. The following table
summarized suppliers with greater than 10% of the total account payable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003544" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zRgvFNJVonif" summary="xdx: Disclosure - Concentration and risk (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B1_z1KfkhgkdJa9" style="display: none">Schedule of account payable</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>As of<br/>June&#160;30,</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>As of<br/>March&#160;31,</b></td>
    <td>&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        B</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90D_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zoy1O16r6pC2" title="Concentration of credit risk"><ix:nonFraction name="cik0002065779:ConcentrationRiskPercentage" contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember" id="Fact003546" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">12.1</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90E_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zT52WewH3gKf" title="Concentration of credit risk"><ix:nonFraction name="cik0002065779:ConcentrationRiskPercentage" contextRef="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember" id="Fact003548" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">74.0</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        D</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_ecustom--ConcentrationRiskPercentage_dp0_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_z49d3JRTVlqf" title="Concentration of credit risk" style="color: White"><ix:nonFraction name="cik0002065779:ConcentrationRiskPercentage" contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember" id="Fact003550" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Ratio">-</ix:nonFraction></span>*</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zH861vcBqWw8" title="Concentration of credit risk"><ix:nonFraction name="cik0002065779:ConcentrationRiskPercentage" contextRef="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember" id="Fact003552" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">12.6</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        E</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_ecustom--ConcentrationRiskPercentage_dp0_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zbDTqTB9gdUl" title="Concentration of credit risk" style="color: rgb(204,238,255)"><ix:nonFraction name="cik0002065779:ConcentrationRiskPercentage" contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember62755093" id="Fact003554" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Ratio">-</ix:nonFraction></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zowygHhsFI98" title="Concentration of credit risk"><ix:nonFraction name="cik0002065779:ConcentrationRiskPercentage" contextRef="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember" id="Fact003556" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">13.4</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        F</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_z9tjQJ8njxna" title="Concentration of credit risk"><ix:nonFraction name="cik0002065779:ConcentrationRiskPercentage" contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember62755109" id="Fact003558" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">54.9</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_ecustom--ConcentrationRiskPercentage_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_z0EDwEhAYvj3" title="Concentration of credit risk" style="color: White"><ix:nonFraction name="cik0002065779:ConcentrationRiskPercentage" contextRef="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember" id="Fact003560" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Ratio">-</ix:nonFraction></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        G</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--SupplierGMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbgS1YdQk6w3" title="Concentration of credit risk"><ix:nonFraction name="cik0002065779:ConcentrationRiskPercentage" contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_custom_SupplierGMember_us-gaap_CustomerConcentrationRiskMember_custom_ExascaleLabsIncMember" id="Fact003562" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">32.3</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_ecustom--ConcentrationRiskPercentage_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierGMember_zx8Qj3Ar38J3" title="Concentration of credit risk" style="color: rgb(204,238,255)"><ix:nonFraction name="cik0002065779:ConcentrationRiskPercentage" contextRef="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierGMember_custom_ExascaleLabsIncMember" id="Fact003564" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Ratio">-</ix:nonFraction></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">*:</td>
    <td style="text-align: justify">nil, new supplier for the nine months ended March&#160;31, 2026</td>
        </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003566" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_80D_eus-gaap--FairValueDisclosuresTextBlock_zhBirMcj7P27" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>4.
<span id="xdx_827_ze9UXnp1dT7e">Fair value measurements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">As
of June&#160;30, 2025 and March&#160;31, 2026, information about inputs into the fair value measurement of the Company&#8217;s assets
and liabilities that are measured at fair value on a recurring basis in periods subsequent to their initial recognition is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003568" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_znXIjy2B1Unc" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B3_zmXrZbsyeyG7" style="display: none; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Schedule of fair value assets and liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>Fair value measurement
        at reporting date using</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid"><b>Description</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Fair value <br/>as of<br/>June&#160;30,<br/>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Quoted Prices in<br/>Active
        Markets for<br/>Identical Assets <br/>(Level 1)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Significant Other<br/>Observable
        Inputs <br/>(Level 2)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Significant <br/>Unobservable
        Inputs <br/>(Level 3)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Liabilities:</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Simple
        agreements for future equity<sup>(1)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zdI2HsL9LKmf" title="Liability"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember" id="Fact003570" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,243,885</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_z1nxmlaF6O8" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3572">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zmfS5uxBUmhg" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3574">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zHPcFlOlK9Vi" title="Liability"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember" id="Fact003576" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,243,885</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Other payable
        related to the equity option<sup>(2)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zShE7VowVnA1" title="Liability"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember" id="Fact003578" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,333</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_z5tNnS5uRuuj" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3580">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zzBB0KU0oEw4" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3582">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zkq0aEofGkY2" title="Liability"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember" id="Fact003584" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,333</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<ix:exclude><p id="xdx_230_z1rTDV8frEZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 433; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zXVRbORZ9Fl3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zi9pQcNi73kh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>4. Fair value measurements (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>Fair value measurement
        at reporting date using</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid"><b>Description</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Fair value <br/>as of<br/>March&#160;31,
        <br/>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Quoted Prices in<br/>Active
        Markets for<br/>Identical Assets <br/>(Level 1)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Significant Other<br/>Observable
        Inputs <br/>(Level 2)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Significant <br/>Unobservable
        Inputs <br/>(Level 3)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Liabilities:</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%">&#160;</td>
    <td style="text-align: left; white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%">&#160;</td>
    <td style="text-align: left; white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%">&#160;</td>
    <td style="text-align: left; white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%">&#160;</td>
    <td style="text-align: left; white-space: nowrap; width: 1%">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Simple
        agreements for future equity<sup>(1)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zuhbr7cQGsg7" title="Liability"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember" id="Fact003589" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,842,205</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zkBbNkVaZqr1" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3591">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_z9y0FcYieMIb" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3593">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zc1rFDya6DW8" title="Liability"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember" id="Fact003595" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,842,205</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Other payable
        related to the equity option<sup>(2)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zvtu6XUHzxw3" title="Liability"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember" id="Fact003597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,333</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zmtSvpn5Ftt7" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3599">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zQh5SQC30bZf" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3601">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zbm43rdQGMmd" title="Liability"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember" id="Fact003603" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,333</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span id="xdx_F0A_zChGi8tau4Y2">(1)</span></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span id="xdx_F10_zFPLD0zjBMIf"><ix:footnote id="Footnote003604" xml:lang="en-US">The
        Company classifies its SAFEs as financial liabilities measured at fair value. The value of these agreements depends significantly on future
        financing activities, liquidity events, or other material milestones, and their valuation relies on significant inputs that are not observable
        in the public market. Accordingly, they are classified within Level 3 of the fair value hierarchy.</ix:footnote></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
        fair value measurement is based on an integrated framework combining&#160;scenario analysis and financial instrument decomposition (i.e.
        Bond Plus Call Method). The proceeds of the SAFEs on the date of issuance were $14,092,500, Refer to Note 8-Simple Agreements for Future
        Equity for further details.</p> </td> </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; color: #0F1115"><span id="xdx_F00_zI5V4PyahiJg">(2)</span></td>
    <td style="text-align: justify"><span id="xdx_F13_z2JSmT6vIOn7"><ix:footnote id="Footnote003605" xml:lang="en-US">Equity options. On May&#160;9, 2023, the Company entered into an agreement
        with a third-party service provider (the &#8220;Service Provider&#8221;). The Service Provider received a freestanding equity-linked right
        exercisable, at the Service Provider&#8217;s option, upon the closing of the Company&#8217;s next qualified equity financing. The right
        provides the ability to subscribe for up to the value of $200,000 at a 25% discount price per share on the grant date. The equity option
        is remeasured at fair value at each reporting date, with changes in fair value recognized in earnings. As of June&#160;30, 2025 and March&#160;31,
        2026, the fair value of the equity option was $53,333, and no gain or loss from changes in fair value was recognized for the periods presented.
        The fair value measurement of the equity option is categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based
        analysis, which incorporates significant unobservable inputs and management judgment regarding the probability and timing of potential
        future financing outcomes.</ix:footnote></span></td> </tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zAeVWeK19ZUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003607" name="us-gaap:CryptoAssetTextBlock"><p id="xdx_803_eus-gaap--CryptoAssetTextBlock_zi6RMK8i16tg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>5.
<span id="xdx_829_zy7JjRUSo6a6">Crypto assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company uses crypto assets like USDT and USDC as medium of exchange for collecting and settling business-related payments and for receiving
investment proceeds. As of June&#160;30, 2025 and March&#160;31, 2026, the Company held nil and 4,074,415 units of USDT and USDC, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
the nine months ended March&#160;31, 2026, the movement for digital assets and USDC were as below&#65306;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003609" name="us-gaap:CryptoAssetActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--CryptoAssetActivityTableTextBlock_z6IoVbbXa5M" summary="xdx: Disclosure - Crypto assets (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8BB_z5ypZmSGKPI6" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of digital assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Digital assets</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>USDC</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Balance
        at June&#160;30, 2025</b></td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b><span id="xdx_90B_eus-gaap--CryptoAssetFairValue_iS_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zVU8fnykwyVd" title="Beginning balance, January 1"><span style="-sec-ix-hidden: xdx2ixbrl3611">-</span></span></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b><span id="xdx_907_eus-gaap--CryptoAssetFairValue_iS_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_zucsqhJMum0h" title="Beginning balance, January 1"><span style="-sec-ix-hidden: xdx2ixbrl3613">-</span></span></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Additions<sup>(i)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--CryptoAssetPurchase_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_fKGkp_zCVR14RVanL4" title="Additions"><ix:nonFraction name="us-gaap:CryptoAssetPurchase" contextRef="From2025-07-012026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember" id="Fact003615" format="ixt:numdotdecimal" decimals="0" unitRef="USD">939,397</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--CryptoAssetPurchase_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_fKGkp_z7IluYPLL2H6" title="Additions"><ix:nonFraction name="us-gaap:CryptoAssetPurchase" contextRef="From2025-07-012026-03-31_custom_USDCMember_custom_ExascaleLabsIncMember" id="Fact003617" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,711,169</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Disposals
        - sold for US dollars</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--CryptoAssetSale_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zFhrH4pyNUOi" title="Disposals - sold for US dollars">(<ix:nonFraction name="us-gaap:CryptoAssetSale" contextRef="From2025-07-012026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember" id="Fact003619" format="ixt:numdotdecimal" decimals="0" unitRef="USD">596,852</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--CryptoAssetSale_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_zZ3TE6pXpuRg" title="Disposals - sold for US dollars">(<ix:nonFraction name="us-gaap:CryptoAssetSale" contextRef="From2025-07-012026-03-31_custom_USDCMember_custom_ExascaleLabsIncMember" id="Fact003621" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,900</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Disposals - others<sup>(ii)</sup></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--CryptoAssetDisposition_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_fKGlpKQ_____z0eXchozqDD5" title="Disposals">(<ix:nonFraction name="us-gaap:CryptoAssetDisposition" contextRef="From2025-07-012026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember" id="Fact003623" format="ixt:numdotdecimal" decimals="0" unitRef="USD">342,545</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--CryptoAssetDisposition_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_fKGlpKQ_____zih1kjx1tNMl" title="Disposals">(<ix:nonFraction name="us-gaap:CryptoAssetDisposition" contextRef="From2025-07-012026-03-31_custom_USDCMember_custom_ExascaleLabsIncMember" id="Fact003625" format="ixt:numdotdecimal" decimals="0" unitRef="USD">626,854</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Balance
        at March&#160;31, 2026</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_905_eus-gaap--CryptoAssetFairValue_iE_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zwakqvuSDr0k" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl3627">-</span></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_901_eus-gaap--CryptoAssetFairValue_iE_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_z5rCPa9Emov5" title="Ending balance"><ix:nonFraction name="us-gaap:CryptoAssetFairValue" contextRef="AsOf2026-03-31_custom_USDCMember_custom_ExascaleLabsIncMember" id="Fact003629" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,074,415</ix:nonFraction></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: left"><span id="xdx_F05_z0wsheXoxiZe">(i)</span></td>
    <td style="text-align: justify"><span id="xdx_F13_zlhgBGZ4Kxka"><ix:footnote id="Footnote003630" xml:lang="en-US">The Company acquired a total of 939,397 USDT at a cost of $939,397, funded by revenues and collections of other receivables. The Company acquired a total of 4,711,169 USDC at a cost of $4,711,169, funded by revenues, interest income,
        collections of other receivables and investment proceeds from SAFEs.</ix:footnote></span></td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><span id="xdx_F05_zMHGNT0qLCIg">(ii)</span></td>
    <td style="text-align: justify"><span id="xdx_F1F_z3QKCOoBgzb2"><ix:footnote id="Footnote003631" xml:lang="en-US">The Company used digital assets and USDC to settle professional service
        fees and other expenditures.</ix:footnote></span></td> </tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zlzUyMcRzUte" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 434; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_z4vVVgXYwom6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zbH5n2nP2ATi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>5. Crypto assets (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zEW704EYCcF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s balances related to digital assets are USD-pegged stablecoins. No fair value gain or loss on digital assets was recognized
for the three and nine months ended March&#160;31, 2026 considering the low volatility in the fair value of USDT during the three and
nine months ended March&#160;31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
following table summarizes other operating activities settled in digital assets and USDC:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003636" name="us-gaap:CashFlowOperatingCapitalTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--CashFlowOperatingCapitalTableTextBlock_zvjZLHvPjup5" summary="xdx: Disclosure - Crypto assets (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span id="xdx_8B8_zB2Vyc1Bo39h">Schedule of operating activities</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        ended March&#160;31,<br/>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenue</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--Revenues_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Revenue">(<ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember" id="Fact003638" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,197,326</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">)</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Other
        receivables</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_ecustom--OtherCurrentAssets_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_zgPbcYEBBUwe" title="Other current assets">(<ix:nonFraction name="cik0002065779:OtherCurrentAssets" contextRef="From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember" id="Fact003640" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,452,102</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Cost and
        expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--CostsAndExpenses_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Cost and expenses"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember" id="Fact003642" format="ixt:numdotdecimal" decimals="0" unitRef="USD">969,399</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Interest
        income</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--InterestIncomeOther_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_zDM56zONgaVd" title="Interest income">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember" id="Fact003644" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,138</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total
        operating activities settled in digital assets and USDC</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_903_ecustom--TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Total operating activities settled in digital assets and USDC">(<ix:nonFraction name="cik0002065779:TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc" contextRef="From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember" id="Fact003646" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,681,167</ix:nonFraction></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td> </tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zJhdLNbXqBJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">During
the three and nine months ended March&#160;31, 2026, the Company received $<span id="xdx_90D_eus-gaap--PaymentsForProceedsFromInvestments_pn3n3_dm_c20250701__20260331_zf0QgnFTWzBf" title="Investment proceeds"><span id="xdx_907_eus-gaap--PaymentsForProceedsFromInvestments_pn3n3_dm_c20260101__20260331_z5QJhWbmUOj2" title="Investment proceeds"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromInvestments" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003648" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromInvestments" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003650" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">3.0</ix:nonFraction></ix:nonFraction></span></span> million of investment proceeds from SAFEs in USDC. These
amounts were disclosed as supplemental non-cash financing information and therefore were not included in net cash provided by financing
activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003652" name="us-gaap:AccountsAndNontradeReceivableTextBlock"><p id="xdx_801_eus-gaap--AccountsAndNontradeReceivableTextBlock_zt83sqIk2p94" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>6.
<span id="xdx_821_zw6NyDc9ffw7">Accounts receivable</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Accounts
receivable consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003654" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zWg6RZJgXvzh" summary="xdx: Disclosure - Accounts receivable (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B9_zVJkzX5GW98" style="display: none; padding-bottom: 0.5pt">Schedule of Accounts receivable</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250630_zm7wuCB6PhW8" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20260331_zS3fEQLzuX3k" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td></tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>As of<br/>June&#160;30,<br/>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>As of<br/>March&#160;31,<br/>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableNetCurrent_iI_pp0p" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Accounts
        receivable</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003656" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,536</ix:nonFraction></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003657" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,830,105</ix:nonFraction></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_403_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_zpFjs0QPDHU9" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Less:
        allowance for credit losses</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003659" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">-</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003660" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">-</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_407_eus-gaap--AccountsReceivableNet_iI_pp0p" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Accounts
        receivable, net</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003662" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,536</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003663" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,830,105</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Accounts
receivable are recorded at the invoiced amount and do not bear interest. The Company maintains an allowance for credit losses for expected
losses over the life of the accounts receivable using the current expected credit loss methodology. The Company determines the allowance
based on historical loss experience, current conditions, and reasonable and supportable forecasts. As of June&#160;30, 2025 and March&#160;31,
2026, there was <span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_zYCAUmcH4Uyf" title="Allowance for credit losses"><span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20260331_zI2AqCult1gj" title="Allowance for credit losses"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003665" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003667" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> allowance for expected credit losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003669" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zdX7g6UQPBw2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>7.
<span id="xdx_822_zmlf6pOH23ii">Equipment, net</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Equipment,
net consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003671" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6SXjtYgd1Rl" summary="xdx: Disclosure - Equipment, net (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8BE_zhFe2H6s0JL3" style="display: none; padding-bottom: 0.5pt">Schedule of Equipment</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250630_zjhFyVyhBbpc" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20260331_zJzRw9osXoxa" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td></tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>As of<br/>June&#160;30,
        <br/>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>As of<br/>March&#160;31,<br/>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_zDy4QedUaU9k" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Equipment</td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003673" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,944</ix:nonFraction></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003674" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,198</ix:nonFraction></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_pp0d_zz24YPuTInVl" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Total</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherNet" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003676" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,944</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherNet" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003677" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,198</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_pp0d_di_ztschh1CeBb2" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Less:
        accumulated depreciation</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003679" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,344</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003680" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,792</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0d_zJcMcc2HfH0g" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Net
        carrying amount</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003682" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,600</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003683" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,406</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 435; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><p id="xdx_236_zGNvH0CTOX27" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>7. Equipment, net (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_z5mMxJV7rjd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Depreciation
expenses for the three months ended March&#160;31, 2025 and 2026 were $<span id="xdx_909_eus-gaap--Depreciation_c20250101__20250331_pp0p" title="Depreciation expenses"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003687" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,601</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--Depreciation_c20260101__20260331_pp0p" title="Depreciation expenses"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003689" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,565</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Depreciation
expenses for the nine months ended March&#160;31, 2025 and 2026 were $<span id="xdx_902_eus-gaap--Depreciation_c20240701__20250331_pp0p" title="Depreciation expenses"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003691" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,633</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--Depreciation_c20250701__20260331_pp0p" title="Depreciation expenses"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003693" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,194</ix:nonFraction></span> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003695" name="cik0002065779:SimpleAgreementsForFutureEquityTextBlock"><p id="xdx_800_ecustom--SimpleAgreementsForFutureEquityTextBlock_zvL0mGPqikAj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>8.
<span id="xdx_826_zuUPRpykS4s9">Simple agreements for future equity</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company has entered into SAFEs with various investors that were classified as liabilities on the Company&#8217;s balance sheets and accounted
for at fair value, subject to remeasurement each reporting period. Each SAFEs has no maturity date, does not bear any interest and provides
the investor with the right to convert into a variable number of shares of future equity in the Company at the stated conversion amount,
if certain events or conditions are triggered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">During
the period from October&#160;2022 through March&#160;31, 2026, the Company entered into Simple Agreements for Future Equity with third-party
investors, receiving aggregate gross proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromOtherEquity_c20221001__20260331_pp0p" title="Aggregate gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2022-10-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003697" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,092,500</ix:nonFraction></span>. For the nine months ended March&#160;31, 2025 and 2026, the Company received
SAFEs proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromOtherEquity_pp0d_c20240701__20250331_zUakL51Li8jh" title="Aggregate gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003699" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,275,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ProceedsFromOtherEquity_pp0d_c20250701__20260331_z2WDlnQfzWRe" title="Aggregate gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003701" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></span>, respectively, with nil and $3,000,000 received in USDC, respectively. No issuance costs were incurred in connection with these arrangements. As of
the date these unaudited condensed consolidated financial statements are issued, none of the SAFEs have been settled or converted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
SAFEs agreements grant investors the right to participate in the Company&#8217;s future equity financing events. The agreements contain
various conversion and redemption provisions, including conversion upon an equity financing event, as well as settlement in the event
of a liquidity event or dissolution of the Company. Key terms of the SAFEs are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Equity
Financing</i></b>&#160;&#8211; Upon the occurrence of an equity financing event, each SAFEs automatically converts into a greater of (i)&#160;the
number of shares of preferred stock equal to SAFEs purchase amount divided by the lowest price per share paid for the standard preferred
stock or (ii)&#160;the number of shares of preferred stock equal to the SAFEs purchase amount divided by the SAFEs price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">&#8220;SAFEs price&#8221; means is calculated by dividing a fixed post-money
        valuation cap by the Company capitalization, a defined term that includes all outstanding equity and convertible instruments.</td>
        </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#9679;</td>
    <td style="text-align: justify">&#8220;Equity Financing&#8221; means a bona fide transaction or series
        of transactions with the principal purpose of raising capital, pursuant to which the Company issues and sells preferred share at a fixed
        valuation, including but not limited to, a pre-money or post-money valuation.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Not
all SAFEs agreements contain the equity financing conversion provision described above. Certain SAFEs are structured without an Equity
Financing conversion feature and are generally settled only upon a Liquidity Event or a Dissolution Event (as defined in the respective
SAFEs agreements). The Company considered the contractual terms of the SAFEs, including whether an Equity Financing conversion feature
is present and the settlement provisions upon a Liquidity Event or a Dissolution Event, in the valuation and measurement of these instruments.
As of March&#160;31, 2026, <span id="xdx_90F_ecustom--EquityFinancingDescription_c20240701__20250331_z5HMRpZeny35" title="Equity Financing description"><ix:nonNumeric contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003703" name="cik0002065779:EquityFinancingDescription">SAFEs with an aggregate purchase amount of $13,632,500 include an Equity Financing conversion feature, while
SAFEs with an aggregate purchase amount of $460,000 do not include this feature and are generally settled only upon a Liquidity Event
or a Dissolution Event, in accordance with their terms.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company does not have any preferred stock outstanding as of the date these unaudited condensed consolidated financial statements are issued;
therefore, an equity financing event has not been triggered.</p>

<ix:exclude><p id="xdx_239_zOQelgjC0xci" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 436; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zINAKYclnAIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_ztpt759HR2w1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>8. Simple agreements for future
equity (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, serif; text-align: justify; margin-top: 0px; margin-bottom: 0px"><b><i>Liquidity
Event</i></b>&#160;&#8211; If there is a liquidity event before the conversion of each SAFE, the holder of each SAFEs will automatically
be entitled to the greater of (i) SAFEs purchase amount, or (ii)&#160;the amount payable on the number of shares of ordinary shares equal
to the purchase amount divided by the Liquidity Price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">&#8220;Liquidity Price&#8221; is calculated by dividing the post-money
        valuation cap by the separately defined capital base, referred to as &#8220;liquidity capitalization&#8221; in the SAFEs agreements.</td>
        </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#9679;</td>
    <td style="text-align: justify">&#8220;Liquidity Event&#8221; means a change of control, a direct Listing
        or an initial public offering.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Dissolution
Event</i></b>&#160;&#8211; If there is a dissolution event before the conversion of each SAFE, the holder of each SAFEs will automatically
be entitled to receive a portion of proceeds equal to SAFEs purchase amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company classifies its SAFEs as financial liabilities measured at fair value. Since the value of these instruments depends on significant
unobservable inputs, including future financing activities and liquidity events, they are classified as Level 3 within the fair value
hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
fair value measurement utilizes a combined scenario analysis and financial instrument decomposition approach. Based on management&#8217;s
assessment of the Company&#8217;s prospects, probability distributions are assigned to potential settlement-triggering events. Valuation
is performed using a &#8220;debt plus option&#8221; model: the debt component is valued using a discounted cash flow method with key assumptions
including expected settlement timing, risk-free interest rate, and credit spread; the embedded conversion right is treated as a call option
and valued using the Black-Scholes model, with key inputs including the fair value of ordinary shares, expected term, and volatility.
The overall fair value represents the probability-weighted sum across all scenarios, supported by an independent third-party valuation
specialist.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">As
of June&#160;30, 2025 and March&#160;31, 2026, the SAFE liabilities were measured at fair value using the above Level 3 methodology. Significant
unobservable inputs&#8212;including timing of events, volatility, and credit spreads&#8212;are based on management&#8217;s reasonable
estimates as of each valuation date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
following tables set forth a summary of the activity of the SAFE liabilities, respectively, which represents a recurring fair value measurement
at the end of each reporting period:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003708" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zJ7zAKCvB5s" summary="xdx: Disclosure - Simple agreements for future equity (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B0_zlyvnZCHN8oh" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of fair value measurement</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Amount</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Balance
        at June&#160;30, 2024</b></td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b><span id="xdx_90A_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20240701__20250331_zsdjo0SWVk52" title="Balance at beginning"><ix:nonFraction name="cik0002065779:SimpleAgreementsForFutureEquity" contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember" id="Fact003710" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,321,564</ix:nonFraction></span></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Issuance
        of simple agreements for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20240701__20250331_zNBYySXf6A5j" title="Issuance of simple agreements for future equity"><ix:nonFraction name="cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003712" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,275,000</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Change
        in fair value</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--ChangeInFairValue_c20240701__20250331_pp0p" title="Change in fair value"><ix:nonFraction name="cik0002065779:ChangeInFairValue" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003714" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,716,052</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Balance
        at March&#160;31, 2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><span id="xdx_90C_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20240701__20250331_zHo7SoRKeCab" title="Balance at ending"><ix:nonFraction name="cik0002065779:SimpleAgreementsForFutureEquity" contextRef="AsOf2025-03-31_custom_ExascaleLabsIncMember" id="Fact003716" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,312,616</ix:nonFraction></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Balance
        at June&#160;30, 2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><span id="xdx_903_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20250701__20260331_zv833aNiJuE" title="Balance at beginning"><ix:nonFraction name="cik0002065779:SimpleAgreementsForFutureEquity" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003718" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,243,885</ix:nonFraction></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Issuance
        of simple agreements for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20250701__20260331_zSP3vbHmvvpg" title="Issuance of simple agreements for future equity"><ix:nonFraction name="cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003720" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Change
        in fair value</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--ChangeInFairValue_c20250701__20260331_pp0p" title="Change in fair value"><ix:nonFraction name="cik0002065779:ChangeInFairValue" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003722" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,098,320</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Balance
        at March&#160;31, 2026</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_908_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20250701__20260331_zmoiw9Md1KUg" title="Balance at ending"><ix:nonFraction name="cik0002065779:SimpleAgreementsForFutureEquity" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003724" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,842,205</ix:nonFraction></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Subsequent
to March&#160;31, 2026 (see Note 1), in connection with the proposed business combination, the outstanding SAFEs are expected to be settled
upon the closing of the transaction (the &#8220;Closing&#8221;). Pursuant to their terms, if a SPAC transaction occurs prior to the termination
of the SAFEs, each SAFE will automatically convert at the Closing into the right to receive Class A ordinary shares of PubCo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">At
the Closing of the BCA transaction, each SAFE is expected to convert into Class A shares of PubCo, if the amount payable of $26,842,205
is greater than the purchase amount.</p>

<ix:exclude><p id="xdx_23F_zFwd6naUsXth" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 437; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003727" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zyFahVjLxWI4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>9.
<span id="xdx_82B_ziKKVuFGi2S9">Income taxes</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Exascale
Labs Inc. is incorporated in the State of Delaware and is subject to income taxes in its primary jurisdictions: U.S. federal income
tax, California state corporate income tax and Delaware state corporate income tax. The statutory tax rates applicable to the
Company are <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c20250701__20260331_pd" title="Federal income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003729" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">21</ix:nonFraction>%</span>
at the federal level, 8.84% at the California state level and <span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c20250701__20260331_pd" title="State income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003731" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">8.7</ix:nonFraction>%</span>
at the Delaware state level.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Evana
Alpha Pte. Ltd. is incorporated in Singapore and is subject to the statutory corporate income tax rate of <span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20250701__20260331__us-gaap--IncomeTaxAuthorityNameAxis__custom--EvanaAlphaPteLtdMember_pd" title="Effective income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2025-07-012026-03-31_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember" id="Fact003733" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">17</ix:nonFraction>%</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
current and deferred components of income tax expense reflected in the statements of operations and comprehensive loss were nil <span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20250701__20260331_zQiioohpuxS4" title="Effective income tax rate"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20240701__20250331_zur6gJAGXbi2" title="Effective income tax rate" style="display: none"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003735" format="ixt:numdotdecimal" decimals="INF" unitRef="Ratio"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003737" format="ixt:numdotdecimal" decimals="INF" unitRef="Ratio">0</ix:nonFraction></ix:nonFraction></span></span>
for the nine months ended March&#160;31, 2025 and 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s effective income tax rate was&#160;nil&#160;for the nine months ended March&#160;31, 2025 and 2026. This was primarily
attributable to the&#160;recognition of a full valuation allowance against the net deferred tax assets, as the Company has concluded that
it is not more likely than not that these assets will be realized in the foreseeable future. Accordingly, no tax benefit has been recognized
for the losses incurred during these periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company
had no unrecognized tax benefits as of March 31, 2026. The Company currently files income tax returns in the United States, as well as
Delaware and California. All tax years are open for examination. The Company currently has no federal or state tax examinations in progress.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003739" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock"><p id="xdx_809_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zmD9QmjKORy7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>10.
<span id="xdx_820_zFODMdXSgusi">Share-based compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
the three and nine months ended March&#160;31, 2025, total share-based compensation expenses recognized were $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20250101__20250331_pp0p" title="Share-based compensation expenses"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003741" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,000</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20240701__20250331_pp0p" title="Share-based compensation expenses"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003743" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,266</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
the three and nine months ended March&#160;31, 2026, total share-based compensation expenses recognized were nil<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20260101__20260331_pp0p" title="Share-based compensation expenses"><span id="xdx_900_eus-gaap--ShareBasedCompensation_c20250701__20260331_pp0p" title="Share-based compensation expenses" style="display: none"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003745" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003747" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">(1)
Employee</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">On
January&#160;6, 2025, with the approval from the Board of the Company, an employee was granted equity award from inception of the employment
agreement, which represented <span id="xdx_901_ecustom--GrantedEquityAward_c20250106__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Granted equity award"><ix:nonFraction name="cik0002065779:GrantedEquityAward" contextRef="AsOf2025-01-06_custom_EmployeeMember_custom_ExascaleLabsIncMember" id="Fact003749" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0.1</ix:nonFraction>%</span> of the Company&#8217;s total shares outstanding at issuance date (the &#8220;0.1% Award&#8221;, i.e.,
1.5 shares). The equity award had a vesting period of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20250701__20260331__srt--CounterpartyNameAxis__custom--EmployeeMember_z1Z0diGK94pe" title="Vesting period"><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_EmployeeMember_custom_ExascaleLabsIncMember" format="ixt-sec:durmonth" id="Fact003751" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">24</ix:nonNumeric></span> months after grant, but with no requisite service period. Alongside the employee&#8217;s
separation in September&#160;2025, the equity award remained its vesting pace under the 24-month vesting schedule. As of March&#160;31,
2026, <span id="xdx_906_ecustom--SharesDescription_c20250701__20260331__srt--CounterpartyNameAxis__custom--EmployeeMember_zlx0SpyKOQ08" title="Shares description"><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_EmployeeMember_custom_ExascaleLabsIncMember" id="Fact003753" name="cik0002065779:SharesDescription">0.9375 shares of the Company were vested, with remaining 0.5625 shares unvested.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">(2)
Non-employee</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">On
December&#160;2, 2024, with the approval from the Board of the Company, a contractor was granted equity award from inception of the contractor
agreement representing <span id="xdx_908_ecustom--GrantedEquityAward_c20241202__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pd" title="Granted equity award"><ix:nonFraction name="cik0002065779:GrantedEquityAward" contextRef="AsOf2024-12-02_custom_NonEmployeeMember_custom_ExascaleLabsIncMember" id="Fact003755" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0.053333</ix:nonFraction>%</span> of the Company&#8217;s total shares outstanding at issuance date (&#8220;0.05% Award&#8221;, i.e., 0.8
shares). The equity award had a vesting period of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20250701__20260331__srt--CounterpartyNameAxis__custom--NonEmployeeMember_zQkNCDGTocwl" title="Vesting period"><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_NonEmployeeMember_custom_ExascaleLabsIncMember" format="ixt-sec:durmonth" id="Fact003757" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">24</ix:nonNumeric></span> months after grant, with half vested as of April&#160;1, 2025 and remaining as of
November&#160;1, 2026, but with no requisite service period. As of March&#160;31, 2026, <span id="xdx_904_ecustom--SharesDescription_c20250701__20260331__srt--CounterpartyNameAxis__custom--NonEmployeeMember_z3nHrh1RAC13" title="Shares description"><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_NonEmployeeMember_custom_ExascaleLabsIncMember" id="Fact003759" name="cik0002065779:SharesDescription">the first half of the equity award had been vested</ix:nonNumeric></span>,
the remaining half had been outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s share-based compensation awards are expected to be settled through transfers of existing ordinary shares held by the controlling
shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary shares are included in the issued
and outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase the Company&#8217;s total
issued and outstanding shares. The vested shares are not recorded in the individual names of the holders on the Company&#8217;s stock
ledger, but held by the controlling shareholder on their behalf, mainly due to the plan to a direct register of shares under the listed
company during de-SPAC transaction. The Company, as well as the controlling shareholder deemed the grant as the time when the employee
and non-employees are entitled to economic benefits and risks of the subsequent changes in fair value of the granted shares accordingly
to the agreed vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 438; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003761" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zW0BXdSt3Dza" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>11.
<span id="xdx_826_zRqJaIvukVIi">Related party transactions</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Hoansoo
Lee serves as the Company&#8217;s Chief Executive Officer and Chief Financial Officer. The Company has entered into a consulting services
agreement with Hoansoo Lee, pursuant to which Hoansoo Lee provides strategic consulting and advisory services to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
the three and nine months ended March&#160;31, 2025, the Company incurred consulting service fees of $<span id="xdx_90F_ecustom--ConsultingFees_c20250101__20250331_pp0p" title="Consulting fees"><ix:nonFraction name="cik0002065779:ConsultingFees" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003763" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,000</ix:nonFraction></span> and $<span id="xdx_902_ecustom--ConsultingFees_c20240701__20250331_pp0p" title="Consulting fees"><ix:nonFraction name="cik0002065779:ConsultingFees" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003765" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,150</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
the three and nine months ended March&#160;31, 2026, the Company incurred consulting service fees of nil <span id="xdx_901_ecustom--ConsultingFees_c20260101__20260331_pp0p" title="Consulting fees" style="display: none"><ix:nonFraction name="cik0002065779:ConsultingFees" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003767" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_904_ecustom--ConsultingFees_c20250701__20260331_pp0p" title="Consulting fees"><ix:nonFraction name="cik0002065779:ConsultingFees" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003769" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,000</ix:nonFraction></span>,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">As
of June&#160;30, 2025 and March&#160;31, 2026, there were <span id="xdx_90A_ecustom--OutstandingBalancesPayable_iI_pp0d_do_c20250630_zypmsCbXcuw1" title="Outstanding balances payable"><span id="xdx_90D_ecustom--OutstandingBalancesPayable_iI_pp0d_do_c20260331_zGm0xhqAZNP4" title="Outstanding balances payable"><ix:nonFraction name="cik0002065779:OutstandingBalancesPayable" contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember" id="Fact003771" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="cik0002065779:OutstandingBalancesPayable" contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember" id="Fact003773" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> outstanding balances payable to Hoansoo Lee as all amounts had been fully
settled during the respective periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003775" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_z4GoZXwnHKv4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>12.
<span id="xdx_829_zB59rzSX6LQb">Basic and diluted net loss per share</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Basic
loss per share and diluted loss per share have been calculated in accordance with ASC 260, &#8220;<i>Earnings Per Share</i>&#8221; on
computation of earnings per share for the three and nine months ended March&#160;31, 2025 and 2026 as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003777" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z2sxwJ1VHpU" summary="xdx: Disclosure - Basic and diluted net loss per share (Details)" style="font: 10pt Times New Roman; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B0_z8caDlAsTD0j" style="display: none; padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Schedule of basic share and diluted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_497_20250101__20250331_zC16hdQy39z7" style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_490_20260101__20260331_zlPyFMn73iHk" style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_491_20240701__20250331_zCkUO6zYutQ4" style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_496_20250701__20260331_zOuUJ3ksGux6" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <th style="text-align: left; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th> </tr>
  <tr style="vertical-align: bottom">
    <th style="text-align: left; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th> </tr>
  <tr id="xdx_406_ecustom--NumeratorAbstract_iB_zNkHTVkijEU3" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Numerator:</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td> </tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_z6giu4JTNcaj" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Net loss
        attributable to ordinary shareholders</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003784" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,537,059</ix:nonFraction></td>
    <td style="white-space: nowrap; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003785" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,632,431</ix:nonFraction></td>
    <td style="white-space: nowrap; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003786" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,178,537</ix:nonFraction></td>
    <td style="white-space: nowrap; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003787" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,916,977</ix:nonFraction></td>
    <td style="text-align: left">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td> </tr>
  <tr id="xdx_40E_ecustom--DenominatorAbstract_iB_zgkk1b9Igsvl" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"><b>Denominator:</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td> </tr>
  <tr id="xdx_406_ecustom--DenominatorForBasicAndDilutedLossPerShareAbstract_iB_zy2lnWnhwA39" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Denominator
        for basic and diluted loss per share</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Weighted-average
        ordinary shares outstanding<sup>(i)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250331_fKGkp_zDQw4h37Wwsb" title="Weighted-average ordinary shares outstanding, Basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250331_fKGkp_z1Ku37KqqS1c" title="Weighted-average ordinary shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003799" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003801" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331_fKGkp_zx8fH2VBa76l" title="Weighted-average ordinary shares outstanding, Basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331_fKGkp_ztHfVbfGRHOe" title="Weighted-average ordinary shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003803" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003805" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20250331_fKGkp_zdZsZI7uuxig" title="Weighted-average ordinary shares outstanding, Basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20250331_fKGkp_zxdrS9L5B374" title="Weighted-average ordinary shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003807" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003809" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250701__20260331_fKGkp_zxPaAudjLjnd" title="Weighted-average ordinary shares outstanding, Basic"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250701__20260331_fKGkp_znBJ1PFMXWY8" title="Weighted-average ordinary shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003811" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003813" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="text-align: left">&#160;</td> </tr>
  <tr id="xdx_404_ecustom--LossPerOrdinaryShareAbstarct_zCAzhDqWJjpb" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Basic
        and diluted<sup>(ii)</sup></td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Basic
        and diluted loss per share</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250101__20250331_fKGlpKQ_____zRg0YrtZsJH6" title="Basic loss per share"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20250101__20250331_fKGlpKQ_____zLTKtVSBtLic" title="Diluted loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003820" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003822" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1,024.70</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="white-space: nowrap; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20260101__20260331_fKGlpKQ_____zMOHv6Iu2y06" title="Basic loss per share"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20260101__20260331_fKGlpKQ_____zOAlpfAhDrW7" title="Diluted loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003824" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003826" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1,754.95</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="white-space: nowrap; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20240701__20250331_fKGlpKQ_____zOMDMotp0PLj" title="Basic loss per share"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240701__20250331_fKGlpKQ_____zcmGyzLnWIBj" title="Diluted loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003828" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003830" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">4,119.02</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="white-space: nowrap; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20250701__20260331_fKGlpKQ_____zvq1iE1ENBpf" title="Basic loss per share"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20250701__20260331_fKGlpKQ_____zANr2fj6apLe" title="Diluted loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003832" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003834" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">5,277.98</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="text-align: left">)</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span id="xdx_F08_zYCld0TSLmlc">(i)</span></td>
    <td style="text-align: justify"><span id="xdx_F1E_zckvTnJmQEhg"><ix:footnote id="Footnote003835" xml:lang="en-US">In January&#160;2026, the Company adopted an Amended and Restated Certificate
        of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#8217;s equity is divided
        into 303 Class A ordinary shares and 1,197 Class B ordinary shares, which are entitled to one (1) vote and twenty (20) votes per share,
        respectively. Despite the differential in voting power, Class A and Class B ordinary shares rank pari passu in all other respects, sharing
        ratably in dividends and any distributions upon liquidation.</ix:footnote></span></td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span id="xdx_F07_zMNm9OVFQe92">(ii)</span></td>
    <td style="text-align: justify"><span id="xdx_F1B_zgBQGgyBG4z3"><ix:footnote id="Footnote003836" xml:lang="en-US">During the three and nine months ended March&#160;31, 2025 and 2026, diluted
        net loss per share is calculated in the same manner as basic net loss per share, as the Company was in a net loss position and all potential ordinary shares were anti-dilutive.</ix:footnote></span></td> </tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zRrW0FzXJpr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003838" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_805_eus-gaap--SegmentReportingDisclosureTextBlock_zEoFgwHUEmak" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>13.
<span id="xdx_82A_zGToUPHTxt3k">Segment information</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company manages its business in a centralized manner and operates as a single segment and accordingly has only one operating and reportable
segment, the provision of GPU computing platform services. The Company&#8217;s Chief Executive Officer serves as the CODM. The CODM regularly
reviews entity-wide operating results and reviews consolidated revenues and net loss as reported in the statement of operations and comprehensive
loss when making decisions about allocating resources and assessing performance of the segment, and hence, the Group has only&#160;one&#160;reportable
segment.</p>

<ix:exclude><p id="xdx_234_zr1JtpLVHa9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 439; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zfD4uTxRwB66" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zsBVdyNHEInh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>13. Segment information (Continued)</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
primary measures of segment revenue and profitability for the Group&#8217;s operating segment&#160;are considered to be&#160;consolidated&#160;revenue
and net loss.&#160;The CODM uses consolidated revenue to assess market performance and growth, and net loss to evaluate segment profitability
and cost management. Both measures are used together to allocate resources, including employee or capital resources. Significant expense
categories regularly provided to and reviewed by the CODM include those presented in the statements of operations and comprehensive loss
as well as disaggregated expenses of staff costs and employee benefits, professional service expenses, share-based compensation, and other
general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
following table presents the segment information of the Company for the measurement of segment profitability for the three and nine months
ended March&#160;31, 2025 and 2026:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003843" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zdn75OK0oi0h" summary="xdx: Disclosure - Segment information (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B8_zPb6QMuV4209" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of segment information</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_495_20250101__20250331_zb2RdiMZ4mJg" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_496_20260101__20260331_zSm0FoNHA26" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_495_20240701__20250331_zyMTxSXq4PM5" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_491_20250701__20260331_zadqFxbEPU4i" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td> </tr>
  <tr id="xdx_401_eus-gaap--Revenues_zI3a3deH3fwf" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenues</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003845" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,862,158</ix:nonFraction></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003846" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,754,586</ix:nonFraction></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003847" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,475,885</ix:nonFraction></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003848" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,561,331</ix:nonFraction></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_407_eus-gaap--CostOfRevenue_pp0d_zMTLZ9zSLNl4" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Cost
        of revenues</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003850" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,649,077</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003851" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,167,659</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003852" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,827,444</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003853" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,902,966</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr id="xdx_40C_eus-gaap--GrossProfit_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Gross
        profit</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003855" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,081</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003856" format="ixt:numdotdecimal" decimals="0" unitRef="USD">586,927</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003857" format="ixt:numdotdecimal" decimals="0" unitRef="USD">648,441</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003858" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,658,365</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_iN_pp0d_di_zn8IOfQoWaoe" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Research
        and development expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003860" format="ixt:numdotdecimal" decimals="0" unitRef="USD">377,999</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003861" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,235,476</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003862" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,115,853</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003863" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,238,185</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_408_eus-gaap--SellingAndMarketingExpenseAbstract_iB_zVd2FY3RkMFc" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Selling
        and marketing expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_407_ecustom--StaffCostsEmployeeBenefitsAndOfficeExpenses_i_pp0p" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#8211;
        Staff costs, employee benefits and office expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003870" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">277,511</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003871" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">104,729</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003872" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">573,648</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003873" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">310,582</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_407_ecustom--ShareBasedCompensations_zJ7xD2oOp4Ui" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#8211;
        Share-based compensation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:ShareBasedCompensations" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003875" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">101,000</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3876">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:ShareBasedCompensations" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003877" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">153,266</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3878">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">General
        and administrative expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40A_ecustom--StaffCostsEmployeeBenefitsAndOthers_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#8211;
        Staff costs, employee benefits and Others</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:StaffCostsEmployeeBenefitsAndOthers" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003885" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,890</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:StaffCostsEmployeeBenefitsAndOthers" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003886" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">360,657</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:StaffCostsEmployeeBenefitsAndOthers" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003887" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,785</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:StaffCostsEmployeeBenefitsAndOthers" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003888" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">563,641</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_40B_eus-gaap--ProfessionalAndContractServicesExpense_iN_di_z78VitJx7Eo3" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">&#8211;
        Professional service expenses</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003890" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,217</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003891" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,039</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003892" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,374</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003893" format="ixt:numdotdecimal" decimals="0" unitRef="USD">364,614</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Loss
        from operations</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003895" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">646,536</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003896" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,221,974</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003897" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,462,485</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003898" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,818,657</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td> </tr>
  <tr id="xdx_40D_ecustom--ChangeInFairValueOfSimpleAgreementsForFutureEquity_iN_di_z4jz79hEVis9" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Change
        in fair value of simple agreements for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003900" format="ixt:numdotdecimal" decimals="0" unitRef="USD">890,523</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003901" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,410,457</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003902" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,716,052</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003903" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,098,320</ix:nonFraction></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Income
        tax expenses</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3905">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3906">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3907">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3908">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_400_eus-gaap--ProfitLoss_zq0n3eRYdw7k" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Net
        loss</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003910" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,537,059</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003911" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,632,431</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003912" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,178,537</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003913" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,916,977</ix:nonFraction></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td> </tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zZ3FKbItpbC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Substantially
all of the Company&#8217;s long-lived assets are located in the United States. The following table presents the Company&#8217;s revenue
from major geographical areas for the periods indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003915" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zIPxDBsoGFvj" summary="xdx: Disclosure - Segment information (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B4_z6QXFE6MCFp1" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of geographic information</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">United
        States of America</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90A_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_country_US_custom_ExascaleLabsIncMember" id="Fact003917" format="ixt:numdotdecimal" decimals="0" unitRef="USD">581,009</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2026-01-012026-03-31_country_US_custom_ExascaleLabsIncMember" id="Fact003919" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,564,836</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-03-31_country_US_custom_ExascaleLabsIncMember" id="Fact003921" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,273,279</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_901_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-07-012026-03-31_country_US_custom_ExascaleLabsIncMember" id="Fact003923" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,560,992</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Canada</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_country_CA_custom_ExascaleLabsIncMember" id="Fact003925" format="ixt:numdotdecimal" decimals="0" unitRef="USD">367,107</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2026-01-012026-03-31_country_CA_custom_ExascaleLabsIncMember" id="Fact003927" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,139,055</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-03-31_country_CA_custom_ExascaleLabsIncMember" id="Fact003929" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,089,559</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-07-012026-03-31_country_CA_custom_ExascaleLabsIncMember" id="Fact003931" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,232,326</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Singapore</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_country_SG_custom_ExascaleLabsIncMember" id="Fact003933" format="ixt:numdotdecimal" decimals="0" unitRef="USD">662,559</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2026-01-012026-03-31_country_SG_custom_ExascaleLabsIncMember" id="Fact003935" format="ixt:numdotdecimal" decimals="0" unitRef="USD">425,009</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-03-31_country_SG_custom_ExascaleLabsIncMember" id="Fact003937" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,361,844</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-07-012026-03-31_country_SG_custom_ExascaleLabsIncMember" id="Fact003939" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,237,464</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Hong Kong</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_country_HK_custom_ExascaleLabsIncMember" id="Fact003941" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2026-01-012026-03-31_country_HK_custom_ExascaleLabsIncMember" id="Fact003943" format="ixt:numdotdecimal" decimals="0" unitRef="USD">417,992</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-03-31_country_HK_custom_ExascaleLabsIncMember" id="Fact003945" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450,000</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-07-012026-03-31_country_HK_custom_ExascaleLabsIncMember" id="Fact003947" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,118,534</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">United
        Kingdom</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_country_GB_custom_ExascaleLabsIncMember" id="Fact003949" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,483</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2026-01-012026-03-31_country_GB_custom_ExascaleLabsIncMember" id="Fact003951" format="ixt:numdotdecimal" decimals="0" unitRef="USD">207,694</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-03-31_country_GB_custom_ExascaleLabsIncMember" id="Fact003953" format="ixt:numdotdecimal" decimals="0" unitRef="USD">291,203</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-07-012026-03-31_country_GB_custom_ExascaleLabsIncMember" id="Fact003955" format="ixt:numdotdecimal" decimals="0" unitRef="USD">412,015</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Others</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_custom_OthersMember_custom_ExascaleLabsIncMember" id="Fact003957" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl3959">-</span></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-03-31_custom_OthersMember_custom_ExascaleLabsIncMember" id="Fact003961" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl3963">-</span></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_908_eus-gaap--Revenues_pp0d_c20250101__20250331_zUms2zS7QOY6" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003965" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,862,158</ix:nonFraction></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_907_eus-gaap--Revenues_pp0d_c20260101__20260331_z3I7DIpNDZGg" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003967" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,754,586</ix:nonFraction></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_908_eus-gaap--Revenues_pp0d_c20240701__20250331_zsHyuymBBcp8" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember" id="Fact003969" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,475,885</ix:nonFraction></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_906_eus-gaap--Revenues_pp0d_c20250701__20260331_zWKBKmLtNdw2" title="Total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" id="Fact003971" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,561,331</ix:nonFraction></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_z1dwOhMrHlX7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 440; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zQqF25MQMl6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003974" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zLihNGvAxZLg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>14.
<span id="xdx_827_zx6q22XsxzOc">Commitments and contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">From
inception to date, the Company has not been a party to any legal proceedings, claims, or disputes arising in the ordinary course of business.
As of March&#160;31, 2026, the Company had no outstanding litigation, and there were no commitments or contingencies that management believes
would have a material effect on the unaudited condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember" escape="true" id="Fact003976" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zRLEv2ZbvEdd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>15.
Subsequent events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_82A_zSew4Do77Ac5" style="display: none">Subsequent Events</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company
evaluated all events and transactions that occurred after March&#160;31, 2026, up through June&#160;11, 2026, which is the date that
these unaudited condensed consolidated financial statements are issued, unless as disclosed elsewhere, no other material subsequent events
occurred that would require recognition or disclosure in the Company&#8217;s unaudited condensed consolidated financial statements.</p>

</ix:nonNumeric><p id="xdx_816_ztkgMPZio9sd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 441; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><b><span id="annex_a"></span>ANNEX A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Execution
Version</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">AGREEMENT
AND PLAN OF MERGER</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">by
and among</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
BORAL ARC ACQUISITION I CORP.<br/>as Parent,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
BORAL ARC MERGER CORPORATION<br/>as Purchaser</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
BORAL ARC MERGER SUB INC.,<br/>as Merger Sub, and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXASCALE
LABS INC.,<br/>as the Company</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Dated
as of January 11, 2026</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 442 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
        I DEFINITIONS</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; width: 0.5in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defined
        Terms</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
        II REINCORPORATION</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reincorporation</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reincorporation
        Effective Time</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
        of Reincorporation</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charter
        Documents</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
        and Officers of Purchaser Surviving Corporation</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
        on Issued Securities of Parent</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surrender
        of Parent Shares</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lost,
        Stolen or Destroyed Certificates</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reincorporation
        Intended Tax Treatment</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taking
        of Necessary Action&#894; Further Action</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dissenter&#8217;s
        Rights</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="3" style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
        III THE MERGER</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
        Merger</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
        Time</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effects
        of the Merger</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
        of Incorporation of Company Surviving Corporation</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-Closing
        Board of Directors and Officers of Purchaser Surviving Corporation</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
        and Officers of Company Surviving Corporation</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
        Further Ownership Rights in Company Shares</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taking
        of Necessary Action; Further Action</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.11</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Withholding</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.12</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dissenter&#8217;s
        Rights</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.13</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualification
        as a Reorganization</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
        IV MERGER CONSIDERATION</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger
        Consideration</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
        of Company Shares and SAFEs</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
        on Share Capital of the Company</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
        Capital of Merger Sub</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
        of the Merger Consideration</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
        Liability</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
        V REPRESENTATIONS AND WARRANTIES OF THE COMPANY</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organization,
        Qualification and Standing</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority;
        Enforceability</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 443; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>TABLE OF CONTENTS CONTINUED</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consents;
        Required Approvals</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Contravention</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bankruptcy</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
        Statements</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal
        Accounting Controls</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absence
        of Certain Developments</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
        Receivable; Accounts Payable</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
        with Law</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
        to Properties</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
        Trade Matters; Anti-Bribery Compliance</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
        Matters</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
        Property</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank
        Accounts; Powers of Attorney</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
        Partners</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Labor
        Matters</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.22</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
        Benefits</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.23</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental
        and Safety</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.24</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
        Party Transactions</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.25</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
        Contracts</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.26</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC
        Matters</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.27</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers
        and Other Advisors</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.28</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclaimer
        of Other Representations and Warranties</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="3" style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
        VI REPRESENTATIONS AND WARRANTIES OF PARENT, PURCHASER AND MERGER SUB</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organization,
        Qualification and Standing</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority;
        Enforceability</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Contravention</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers
        and Other Advisors</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
        of Shares</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consents;
        Required Approvals</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trust
        Account</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.10</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
        Matters</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.11</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Listing</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.12</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reporting
        Company</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.13</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undisclosed
        Liabilities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.14</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
        SEC Documents and Parent Financial Statements</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.15</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
        Activities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.16</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
        Contracts</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.17</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.18</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
        Investigation</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 444 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>TABLE OF CONTENTS CONTINUED</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.19</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
        Supplied</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.20</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment
        Company</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.21</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lockup</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.22</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
        and Shareholder Approval</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.23</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclaimer
        of Other Representations and Warranties</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.24</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advice
        of U.S.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.25</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
        Trade Matters; Anti-Bribery Compliance</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
        VII COVENANTS AND AGREEMENTS OF THE COMPANY</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
        of Business of the Company</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access
        to Information</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
        Financial Information</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lock-Up</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
        of Changes</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="3" style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
        VIII COVENANTS OF PARENT, PURCHASER AND MERGER SUB</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Listing</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trust
        Account</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
        Public Filings</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
        16 Matters</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
        of Changes</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.6</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D&amp;O
        Insurance; Indemnification of Officers and Directors</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="3" style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
        IX TAX COVENANTS</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
        Matters</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="3" style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
        X ACTIONS PRIOR TO THE CLOSING</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
        Shop</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
        to Consummate the Transactions</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cooperation
        with Proxy Statement; Other Filings</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder
        Vote; Recommendation of Parent&#8217;s Board of Directors</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
        Shareholders&#8217; Meeting</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
        8-K; Press Releases</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees
        and Expenses</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder
        Litigation</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="3" style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
        XI CONDITIONS PRECEDENT</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions
        to Each Party&#8217;s Obligation to Effect the Merger</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions
        to Obligations of Parent, Purchaser and Merger Sub</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions
        to Obligation of the Company</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
        XII TERMINATION</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
        of Termination</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 445 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>TABLE OF CONTENTS CONTINUED</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
        XIII MISCELLANEOUS</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
        or Supplement</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extension
        of Time, Waiver, Etc.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.3</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.4</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterparts;
        Facsimile; Electronic Transmission</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.5</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entire
        Agreement; No Third-Party Beneficiaries</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.6</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing
        Law; Jurisdiction</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.7</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WAIVER
        OF JURY TRIAL</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.8</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specific
        Enforcement</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.9</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.10</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.11</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remedies</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.12</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waiver</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.13</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publicity</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.14</span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Recourse</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: justify; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBITS.</b></span></td>
    <td style="text-align: justify">&#160;</td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; text-align: justify; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit A</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Company Shareholder Support
        Agreement</span></td> </tr>
  <tr style="vertical-align: top; text-align: justify; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit B</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Sponsor Support Agreement</span></td>
        </tr>
  <tr style="vertical-align: top; text-align: justify; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit C</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Lock-Up Agreement</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 446 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGREEMENT
AND PLAN OF MERGER dated as of January __, 2026 (this &#8220;<span style="text-decoration: underline">Agreement</span>&#8221;), by and
among D. Boral ARC Acquisition I Corp., a company organized under the laws of the British Virgin Islands (&#8220;<span style="text-decoration: underline">Parent</span>&#8221;),
D. Boral ARC Merger Corporation, a Delaware corporation and a wholly-owned subsidiary of Parent (&#8220;<span style="text-decoration: underline">Purchaser</span>&#8221;),
D. Boral Arc Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (&#8220;<span style="text-decoration: underline">Merger
Sub</span>&#8221;), and Exascale Labs Inc., a Delaware corporation (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;).
Parent, Purchaser, Merger Sub and Company are sometimes referred to herein individually as a &#8220;<span style="text-decoration: underline">Party</span>&#8221;
and, collectively, as the &#8220;<span style="text-decoration: underline">Parties</span>&#8221;. All capitalized terms used but not otherwise
defined in this Agreement shall have the meanings set forth or referenced in <span style="text-decoration: underline">Section&#160;1.1</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">RECITALS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Parent is a blank check company formed for the sole purpose of entering into a merger, amalgamation, share exchange, asset acquisition,
share purchase, reorganization or similar business combination with one or more businesses;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Purchaser is a wholly owned subsidiary of Parent and was formed for the sole purpose of effecting the merger of Parent with and into Purchaser
(the &#8220;<span style="text-decoration: underline">Reincorporation</span>&#8221;), in which Purchaser will be the surviving company,
in accordance with this Agreement and the BVI BCA&#894;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Parent and Purchaser represent that they have taken all corporate and governmental actions necessary to consummate the Reincorporation,
are in good standing under applicable Law, and have no knowledge of any impediments or conditions that would reasonably be expected to
prevent or delay the Reincorporation;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
promptly (but no earlier than the subsequent day and no later than the third (3<sup>rd</sup>) Business Day) after the Reincorporation,
the Parties hereto intend to effect a merger of Merger Sub with and into the Company (the &#8220;<span style="text-decoration: underline">Merger</span>&#8221;),
in which the Company will be the surviving entity, in accordance with this Agreement and the applicable Laws of Delaware;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Parties acknowledge that consummation of the Merger is conditioned upon, and shall occur immediately following, the consummation of
the Reincorporation, and nothing herein shall obligate the Company to close the Merger absent the prior completion of the Reincorporation;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
for U.S. federal income Tax purposes, the parties intend, and each of Parent, Purchaser and the Company acknowledges, that each of the
Reincorporation and the Merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code and
the Treasury Regulations promulgated thereunder, and the Boards of Directors of Parent and Purchaser have approved this Agreement and
intend that it constitute a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulation Sections&#160;1.368-2(g) and
1.368-3 with respect to each of the Reincorporation and the Merger;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
upon consummation of the Merger, Merger Sub will cease to exist, the Company Surviving Corporation will become a wholly owned subsidiary
of Purchaser Surviving Corporation and the outstanding Company Shares and SAFEs will be converted into the right to receive the consideration
described in this Agreement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 447; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
each of the Boards of Directors of Purchaser and the Company has (a) determined that this Agreement, the Merger and the Transactions are
fair and advisable to, and in the best interests of, their respective shareholders, (b) approved the Merger, (c) adopted this Agreement
and (d) determined to recommend that its shareholders adopt, authorize and approve this Agreement, the Merger and the Transactions;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Board of Directors of Parent has (a) determined that this Agreement, the Reincorporation, the Merger and the Transactions are fair
and advisable to, and in the best interests of Parent and its shareholders, (b) approved the Merger and adopted this Agreement and (d)
determined to recommend that the shareholders of Parent adopt, authorize and approve this Agreement, the Reincorporation, the Merger and
the Transactions;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
contemporaneously with the execution and delivery of this Agreement and in connection with the Transactions, Parent, the Company and the
Company Shareholder which owns a majority voting interest in the Company (the &#8220;<span style="text-decoration: underline">Majority
Shareholder</span>&#8221;) have entered into the Company Shareholder Support Agreement dated as of the date hereof, substantially in the
form attached hereto as <span style="text-decoration: underline">Exhibit A</span> (the &#8220;<span style="text-decoration: underline">Company
Shareholder Support Agreement</span>&#8221;), providing that, among other things, the Majority Shareholder will vote its Company Shares
in favor of this Agreement, the Merger and the other Transactions; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
contemporaneously with the execution and delivery of this Agreement and in connection with the Transactions, the Company, Parent and Sponsor
have entered into the Sponsor Support Agreement dated as of the date hereof, substantially in the form attached hereto as <span style="text-decoration: underline">Exhibit
B</span> (the &#8220;<span style="text-decoration: underline">Sponsor Support Agreement</span>&#8221;), providing that, among other things,
the Sponsor shall and each of the signatories thereto will direct the Sponsor, with respect to their allocation of Parent Shares to vote
in favor of this Agreement, the Reincorporation, the Merger and the other Transactions and Sponsor shall agree to waive any anti-dilution
or similar adjustment rights with respect to its Class B Parent Ordinary Shares (including any securities issued upon conversion of such
Class B Parent Ordinary Shares).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the premises, covenants, agreements, representations and warranties set forth herein, and for other good
and valuable consideration, the Parties to this Agreement, intending to be legally bound, agree as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DEFINITIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<span style="text-decoration: underline">Defined Terms</span>. All capitalized terms used but not otherwise defined in this Agreement
have the meanings set forth or referenced below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Additional
Parent SEC Documents</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;6.14(a)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 448 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Affiliate</span>&#8221;
means, as to any Person, another Person that directly or indirectly controls, is controlled by, or is under common control with such Person.
For this purpose, &#8220;control&#8221; (including, with its correlative meanings, &#8220;controlled by&#8221; and &#8220;under common
control with&#8221;) means the possession, directly or indirectly, of the power to direct or cause the direction of management or policies
of a Person, whether through the ownership of voting securities, by contract or otherwise. For purposes of this definition, &#8220;Affiliate&#8221;
shall not include any individual family member of any officer, director or employee unless such individual otherwise has control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Affiliate
Transaction</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.24(a)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Agreement</span>&#8221;
has the meaning provided in the Preamble to this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Alternative
Proposal</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;10.1(b)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Alternative
Transaction</span>&#8221; means any of the following transactions involving the Company (other than the transactions contemplated by this
Agreement, <span style="text-decoration: underline">including Schedule&#160;7.1(a)</span>): (a) any merger, acquisition, consolidation,
recapitalization, share exchange, business combination or other similar transaction, public investment or public offering or (b) any sale,
lease, exchange, transfer or other disposition of a material portion of the assets of such Person (other than sales of inventory or other
transaction in the Ordinary Course) or any class or series of the capital stock, membership interests or other equity interests of the
Company in a single transaction or series of transactions. For the avoidance of doubt, &#8220;Alternative Transaction&#8221; shall exclude
any equity or debt financing, joint venture, strategic partnership, commercial agreement, or other transaction entered into for working
capital or operational purposes in the Ordinary Course that does not otherwise constitute an Alternative Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Anti-Corruption
Laws</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.14(a)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Assets</span>&#8221;
means, with respect to any Person, all of the assets, rights, interests and other properties, real, personal and mixed, tangible and intangible,
owned, leased, subleased or licensed by such Person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Authorization
Notice</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;2.11(b)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Balance
Sheet Date</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.7(a)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Benefit
Arrangements</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.22(a)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Bonds</span>&#8221;
has the meaning provided in <span style="text-decoration: underline">Section&#160;5.17(a)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Business
Day</span>&#8221; means a day except a Saturday, a Sunday or any other day on which the SEC or banks in the City of New York or the British
Virgin Islands are authorized or required by Law to be closed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">BVI
BCA</span>&#8221; means the Business Companies Act, (Revised Edition 2020) as amended, of the British Virgin Islands.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">BVI
Registrar</span>&#8221; means the Registrar of Corporate Affairs of the British Virgin Islands appointed under section&#160;229 of the
BVI BCA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 449 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Class
A Parent Ordinary Shares</span>&#8221; means the Class A ordinary shares, par value $0.0001 per share, of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Class
B Parent Ordinary Shares</span>&#8221; means the Class B ordinary shares, par value $0.0001 per share, of Parent initially issued to Sponsor
in a private placement prior to the IPO, which will (a) automatically convert into Class A Parent Ordinary Shares upon consummation of
Parent&#8217;s Reincorporation or (b) convert into Class A Parent Ordinary Shares at any time prior to the closing of Merger at the election
of Sponsor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Closing
Date</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;3.2</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Closing
Press Release</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;10.6(b)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Code</span>&#8221;
means the Internal Revenue Code of 1986.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company</span>&#8221;
has the meaning provided in the Preamble to this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Class A Common Stock</span>&#8221; means the Class A common stock of the Company, par value $0.01 per share, with each such share having
one (1) vote per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Class B Common Stock</span>&#8221; means the Class B common stock of the Company, par value $0.01 per share, with each such share having
twenty (20) votes per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Disclosure Schedules</span>&#8221; means the Disclosure Schedules delivered to Parent by the Company on the date hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Dissenting Shares</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;3.12</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Equityholders</span>&#8221; means the Company Shareholders and Company Safeholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Financial Statements</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.7(a)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Safeholder</span>&#8221; means the holders of the SAFEs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Securities</span>&#8221; means the Company Shares and SAFEs of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Shareholder Approval</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.2(c)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Shareholders</span>&#8221; means the holders of the Company Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Shares</span>&#8221; means the Company Class A Common Stock and the Company Class B Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Surviving Corporation</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;3.1</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Company
Transaction Expenses</span>&#8221; means (a)&#160;the fees and disbursements of outside counsel to the Company incurred in connection
with the Transactions and (b)&#160;the fees and expenses of any other agents, advisors, consultants, experts, financial advisors, accountants
and other service providers engaged by the Company in connection with the Transactions. For the avoidance of doubt, &#8220;Company Transaction
Expenses&#8221; shall not include any fees or expenses incurred by Parent, Purchaser or the Sponsor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 450 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Computer
Systems</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.16(h)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Contracts</span>&#8221;
means any and all written and oral agreements, contracts, deeds, arrangements, purchase orders, binding commitments and understandings,
and other instruments and interests therein, and all amendments thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">D&amp;O
Indemnitees</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;8.6(a)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">DGCL</span>&#8221;
means the General Corporation Law of the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Effective
Time</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;3.3</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Environmental
and Safety Requirements</span>&#8221; means all Laws and Orders concerning public health and safety, worker health and safety, and pollution
or protection of the environment, including all those relating to the presence, use, production, generation, handling, transportation,
treatment, storage, disposal, distribution, labeling, testing, processing, discharge, release, threatened release, control or cleanup
of any hazardous materials, substances or wastes, chemical substances or mixtures, pesticides, pollutants, contaminants, toxic chemicals,
petroleum products or byproducts, asbestos, polychlorinated biphenyls, noise or radiation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Equityholder
Allocation Schedule</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;4.2(c)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">ERISA</span>&#8221;
has the meaning provided in <span style="text-decoration: underline">Section&#160;5.22(a)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Exchange
Act</span>&#8221; means the Securities Exchange Act of 1934.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Exchange
Fund</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;4.5(b)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Excluded
Matter</span>&#8221; means any one or more of the following: (a) general economic or political conditions; (b) conditions generally affecting
the industries in which such Person or its Subsidiaries operates; (c) any changes in financial, banking or securities markets in general,
including any disruption thereof and any decline in the price of any security or any market index or any change in prevailing interest
rates; (d) acts of war (whether or not declared), armed hostilities or terrorism, or the escalation or worsening thereof; (e) any action
required or permitted by this Agreement or any action or omission taken by the Company with the written consent or at the request of Parent
or any action or omission taken by Parent or Merger Sub with the written consent or at the request of the Company; (f) any changes in
applicable Laws or accounting rules (including GAAP) or the enforcement, implementation or interpretation thereof; (g) the announcement,
pendency or completion of the transactions contemplated by this Agreement; or (h) any natural or man-made disaster, acts of God or pandemics;
<span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>, that the exclusions
provided in the foregoing clauses (a) through (d), clause (f) and clause (h) shall not apply to the extent that Parent and Merger Sub,
taken as a whole, on the one hand, or the Company, on the other hand, is disproportionately affected by any such exclusions or any change,
event or development to the extent resulting from any such exclusions relative to all other similarly situated companies that participate
in the industry in which they operate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 451 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Export
Control Laws</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.14(a)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Fully
Diluted Company Capitalization</span>&#8221; means, without duplication, the aggregate number of Company Shares (a) outstanding immediately
prior to the Effective Time and (b) issuable upon the exercise of the SAFEs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">GAAP</span>&#8221;
means generally accepted accounting principles in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Governmental
Authority</span>&#8221; means any United States, non-United States or multi-national government entity, body or authority, including any
(a) United States federal, state or local government (including any town, village, municipality, district or other similar governmental
or administrative jurisdiction or subdivision thereof, whether incorporated or unincorporated), (b) non-United States or multi-national
government or governmental authority or any political subdivision thereof, (c) United States, non-United States or multi-national regulatory
or administrative entity, authority, instrumentality, jurisdiction, agency, body or commission, exercising, or entitled or purporting
to exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power, including any court,
tribunal, commission or arbitrator, (d) self-regulatory organization or (e) official of any of the foregoing acting in such capacity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Indebtedness</span>&#8221;
means, without duplication, the following obligations of a Person, whether or not contingent: (a)&#160;all obligations of such Person
for borrowed money or with respect to deposits or advances of any kind (including amounts by reason of overdrafts and amounts owed by
reason of letter of credit reimbursement agreements), including with respect thereto, all interests, fees and costs and prepayment and
other penalties; (b)&#160;all obligations evidenced by bonds, debentures, notes, or other similar instruments; (c)&#160;all reimbursement
obligations with respect to mortgages, letters of credit (including standby letters of credit to the extent drawn upon), bankers&#8217;
acceptances or similar facilities issued for the account of the Company or its Subsidiaries (inclusive of any current portion thereof);
(d) all obligations of such Person under capitalized leases to the extent required to be capitalized under GAAP; (e) all obligations of
such Person issued or assumed as the deferred purchase price of property or services (other than accounts payable, accrued expenses, deferred
revenue and other trade payables incurred in the Ordinary Course and (i) not past due by more than 60 days or (ii) being contested in
good faith); (f) all recourse Indebtedness of others secured by (or for which the holder of such Indebtedness has an existing right, contingent
or otherwise, to be secured by) any lien or security interest on property owned or acquired by such Person, whether or not the obligations
secured thereby have been assumed; (g) all guarantees by such Person; (h) all obligations of the type referred to in clauses (a) through
(g) of another Person the payment of which the Company or any of its Subsidiaries has guaranteed or for which the Company or any of its
Subsidiaries is responsible or liable, directly or indirectly, jointly or severally, as obligor or guarantor; and (i) any agreement to
incur or provided any of the foregoing. For the avoidance of doubt, &#8220;Indebtedness&#8221; shall not include: (w) bonuses, severance,
change-in-control amounts or other compensation obligations; (x) Taxes; (y) any amounts included in Company Transaction Expenses; or (z)
any obligations or amounts outstanding pursuant to SAFEs, including any amounts classified as liabilities under GAAP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 452 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Intellectual
Property</span>&#8221; means all of the worldwide intellectual property and proprietary rights associated with any of the following, whether
registered, unregistered or registrable, to the extent recognized in a particular jurisdiction: (a)&#160;trademarks and service marks,
trade dress, product configurations, trade names and other indications of origin, applications or registrations in any jurisdiction pertaining
to the foregoing and all goodwill associated therewith; (b) discoveries, ideas, Know-How, systems, technology, whether patentable or not,
and all issued patents, industrial designs, and utility models, and all applications pertaining to the foregoing, in any jurisdiction,
including re-issues, continuations, divisionals, continuations-in-part, re-examinations, renewals, extensions, and other extension of
legal protestation pertaining thereto; (c)&#160;trade secrets and other rights in confidential and other nonpublic information that derive
economic value from not being generally known and not being readily ascertainable by proper means, including the right in any jurisdiction
to limit the use or disclosure thereof; (d)&#160;software; (e)&#160;copyrights in writings, designs, software, mask works, content and
any other original works of authorship in any medium, including applications or registrations in any jurisdiction for the foregoing; (f)&#160;data
and databases; and (g)&#160;internet websites, domain names and applications and registrations pertaining thereto as well as social media
accounts and respective social media identifiers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Interim
Financial Statements</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.7(a)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">International
Trade Control Laws</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.14(a)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">IPO</span>&#8221;
means the initial public offering of Parent pursuant to a prospectus dated July&#160;30, 2025 and filed with the SEC on August&#160;1,
2025 (the &#8220;<span style="text-decoration: underline">Prospectus</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Key
Employee</span>&#8221; means each of the individuals identified on <span style="text-decoration: underline">Schedule A</span> of the Company
Disclosure Schedules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Know-How</span>&#8221;
means all information, unpatented inventions (whether or not patentable), improvements, practices, algorithms, formulae, trade secrets,
techniques, methods, procedures, knowledge, results, protocols, processes, models, designs, drawings, specifications, materials and any
other information related to the development, marketing, pricing, distribution, cost, sales and manufacturing of products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Knowledge
of Parent</span>&#8221; or &#8220;<span style="text-decoration: underline">to Parent&#8217;s Knowledge</span>&#8221; means the actual
knowledge, after due inquiry, of David Boral, John Darwin, Kevin Chen, Luisa Ingargiola, and Matt Laker.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Knowledge
of the Company</span>&#8221; or &#8220;<span style="text-decoration: underline">to the Company&#8217;s Knowledge</span>&#8221; means the
actual knowledge, after due inquiry, of Hoansoo Lee, Wenying Jia, and Zachary Bright.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Law</span>&#8221;
means any federal, state, local, municipal, foreign or other law, statute, constitution, ordinance, code, rule or regulation, issued,
enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any applicable Governmental Authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Leased
Real Property(ies)</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.13(b)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Letter
of Transmittal</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;4.5(c)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 453 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Liability</span>&#8221;
means any known liability, obligation or commitment of any nature whatsoever, asserted or unasserted, absolute or contingent, accrued
or unaccrued, matured or unmatured or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Lien</span>&#8221;
means any security interest, pledge, bailment (in the nature of a pledge or for purposes of security), mortgage, deed of trust, the grant
of a power to confess judgment, conditional sale or title retention agreement (including any lease in the nature thereof), charge, encumbrance,
easement, reservation, restriction, cloud, right of first refusal or first offer, third-party-claim, encroachment, encumbrance, right-of-way,
option, or other similar arrangement or interest in real or personal property, but excluding Intellectual Property licenses and covenants
not to sue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Lock-Up
Agreement</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;7.4</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Majority
Shareholder</span>&#8221; has the meaning provide in the Recitals to this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Material
Adverse Effect</span>&#8221; means any fact, effect, event, development, change, state of facts, condition, circumstance, violation or
occurrence (an &#8220;<span style="text-decoration: underline">Effect</span>&#8221;) that, individually or together with one or more other
contemporaneous Effects, (a) has or would reasonably be expected to have a materially adverse effect on the financial condition, assets,
liabilities, business or results of operations of the Company and the Company&#8217;s Subsidiaries, on the one hand, or on Parent and
Merger Sub, on the other hand, in either case taken as a whole; or (b) prevents or materially impairs or would reasonably be expected
to prevent or materially impair the ability of the Company Equityholders and the Company, on the one hand, or on Parent and Merger Sub,
on the other hand, to consummate the Merger and the other transactions contemplated by this Agreement in accordance with the terms and
conditions of this Agreement; <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>,
that (i) a Material Adverse Effect shall not be deemed to include Effects (and solely to the extent of such Effects) resulting from an
Excluded Matter, and (ii) a Parent Material Adverse Effect (as defined below) shall not include (u) redemptions or anticipated redemptions,
(v) loss of financing, PIPE or trust proceeds, (w) Nasdaq delisting risk or notices, (x) restatements of financials or SEC comments, (y)
Sponsor resignations, or (z) any change in Parent&#8217;s share price, trading volume or redemption rate. A Material Adverse Effect with
respect to the Company is sometimes referred to herein as a &#8220;<span style="text-decoration: underline">Company Material Adverse Effect</span>&#8221;;
and a Material Adverse Effect with respect to Parent and Merger Sub is sometimes referred to herein as a &#8220;<span style="text-decoration: underline">Parent
Material Adverse Effect</span>&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Material
Contract</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.25(a)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Material
Customer</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.20</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Material
Partners</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.20</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Material
Supplier</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.20</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Merger</span>&#8221;
has the meaning provided in the Recitals to this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Merger
Consideration</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;4.1</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Merger
Sub</span>&#8221; has the meaning provided in the Preamble to this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 454 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Merger
Sub Shares</span>&#8221; means the shares of common stock, no par value each of Merger Sub.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Modification
in Recommendation</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;10.4</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Nasdaq</span>&#8221;
means The Nasdaq Stock Market LLC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Nasdaq
Listing Application</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;8.1</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Non-Disclosure
Agreement</span>&#8221; means that certain Non-Disclosure and Confidentiality Agreement, dated as of August&#160;11, 2025, by and between
Parent and the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Non-U.S.
Subsidiaries</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;9.1(e)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Odyssey</span>&#8221;
has the meaning provided in <span style="text-decoration: underline">Section&#160;4.5(b)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Offer
Documents</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;10.3(a)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Order</span>&#8221;
means any order, decision, ruling, charge, writ, judgment, injunction, decree, stipulation, award or binding determination issued, promulgated
or entered by or with any Governmental Authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Ordinary
Course</span>&#8221; means in the ordinary course of business of the Person, consistent with past practice before the date hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Organizational
Documents</span>&#8221; means the memorandum and articles of association or certificate or articles of incorporation and bylaws or certificate
of formation and limited liability company operating agreement of a Person, as in effect from time to time including any amendments thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Outside
Date</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;12.1(d)(i)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Owned
Intellectual Property</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.16(a)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Owned
Real Property</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.13(a)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent</span>&#8221;
has the meaning provided in the Preamble to this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Certifications</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;6.14(c)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Disclosure Schedules</span>&#8221; means the Disclosure Schedules delivered to Company by Parent, Purchaser and/or Merger Sub on the date
hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Dissenting Shareholder</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;2.11</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Excluded Shares</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;2.6(d)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 455 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Financial Statements</span>&#8221; means, collectively, the financial statements and notes contained or incorporated by reference in Parent
SEC Documents and the Additional Parent SEC Documents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Ordinary Shares</span>&#8221; means the Class A Parent Ordinary Shares and the Class B Parent Ordinary Shares, collectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Preferred Shares</span>&#8221; means the preference shares of Parent, par value $0.0001.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Proposals</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;10.3(e)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Public Shareholders</span>&#8221; the shareholders of Parent who purchased Parent Units in the IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Required Vote</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;6.22(b)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
SEC Documents</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;6.14(a)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Shareholders</span>&#8221; means the holders of Parent Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Shareholders&#8217; Meeting</span>&#8221; the meeting of holders of Parent Shares to be called for the purpose of soliciting proxies from
the holders of Parent Shares to, among other things, vote in favor of the adoption of this Agreement, the approval of the Reincorporation,
the Merger and the other Parent Proposals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Shares</span>&#8221; means Parent Ordinary Shares and Parent Preferred Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Transaction Expenses</span>&#8221; means all fees, expenses and disbursements incurred by or on behalf of Merger Sub or Parent for outside
counsel, agents, advisors, consultants, experts, financial advisors and other service providers engaged by or on behalf of Parent or Merger
Sub in connection with the Transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Unit</span>&#8221; means a unit of Parent comprised of (a) one Class A Parent Ordinary Share and (b) one-half of one Parent Warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Parent
Warrant</span>&#8221; means the redeemable warrants included as a component of Parent Units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">PCAOB</span>&#8221;
means the Public Company Accounting Overview Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Per
Share Merger Consideration</span>&#8221; means the quotient equal to the Merger Consideration divided by the Fully Diluted Company Capitalization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Permit</span>&#8221;
means any permit, license, authorization, registration, franchise, approval, consent, certificate, variance and similar right obtained,
or required to be obtained for the conduct of the Company&#8217;s business as currently conducted, from any Governmental Authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 456 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Permitted
Liens</span>&#8221; means only (a) Liens for Taxes not yet due and delinquent or being contested in good faith by appropriate proceedings
and for which appropriate and adequate reserves have been created in the applicable financial statements; (b) Liens arising under equipment
leases, purchase-money financing, software licenses, IP licenses, or other Ordinary Course commercial agreements; (c) workers or unemployment
compensation Liens arising in the Ordinary Course; (d) mechanic&#8217;s, materialman&#8217;s, supplier&#8217;s, vendor&#8217;s or similar
Liens arising in the Ordinary Course securing amounts that are past due and being contested in good faith, and for which appropriate and
adequate reserves have been created in the applicable financial statements, or not delinquent; (e) zoning ordinances, easements and other
restrictions of legal record affecting real property which would be revealed by a survey or a search of public records and would not,
individually or in the aggregate, materially interfere with the value or usefulness of such real property to the respective businesses
of the Company or any of its Subsidiaries as presently conducted; (f) title of a lessor under a capital or operating lease; (g) Liens
arising under Indebtedness to be paid at Closing; (h) Liens imposed by applicable securities Laws; (i) such imperfections of title, easements,
encumbrances, Liens or restrictions that do not materially impair or interfere with the current use of the Company&#8217;s or its Subsidiary&#8217;s
Assets that are subject thereto; and (j) rights of first refusal, rights of first offer, proxy, voting trusts, voting agreements or similar
arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Person</span>&#8221;
means an individual, a corporation, a limited liability company, a partnership, an association, joint stock company, joint venture, a
trust or any other entity, including a Governmental Authority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">PFIC</span>&#8221;
has the meaning provided in <span style="text-decoration: underline">Section&#160;9.1(e)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Plan
of Merger</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;2.2</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Policies</span>&#8221;
has the meaning provided in <span style="text-decoration: underline">Section&#160;5.17(a)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Post-Closing
Board of Directors</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;3.6(a)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Privacy
Policy</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.16(i)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Proceeding</span>&#8221;
means any action, suit, proceeding, complaint, claim, charge, hearing, labor dispute, inquiry or investigation before or by a Governmental
Authority or an arbitrator.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Prohibited
Party</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.14(b)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Prospectus</span>&#8221;
has the meaning set forth in the definition of IPO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Proxy
Statement</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;10.3(a)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Purchaser</span>&#8221;
has the meaning provided in the Preamble to this Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Purchaser
Class A Shares</span>&#8221; means the Class A shares of common stock, par value $0.0001 per share, of Purchaser Surviving Corporation,
with each such share having one (1) vote per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 457 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Purchaser
Class B Shares</span>&#8221; means the Class B shares of common stock, par value $0.0001 per share, of Purchaser Surviving Corporation,
with each such share having twenty (20) votes per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Purchaser
Shares</span>&#8221; or &#8220;<span style="text-decoration: underline">Purchaser Surviving Corporation Shares</span>&#8221; means, collectively,
the Purchaser Class A Shares and Purchaser Class B Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Purchaser
Surviving Corporation</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;2.1</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Real
Property Lease(s)</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.13(b)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Reincorporation</span>&#8221;
has the meaning provided in the Recitals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Reincorporation
Effective Time</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;2.2</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Reincorporation
Intended Tax Treatment</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;2.9</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Representative</span>&#8221;
means, with respect to any Person, shall mean persons authorized by such Party to act on its behalf in connection with the Transactions;
contractors and distributors shall be Representatives only to the extent performing such authorized duties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Requisite
Vote</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.2(c)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">SAFEs</span>&#8221;
means those certain Simple Agreements for Future Equity, by and between the Company and each Company Safeholder. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Sanctions
Laws</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.14(a)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Scheduled
Intellectual Property</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;5.16(a)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">SEC</span>&#8221;
means the Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Securities
Act</span>&#8221; means the Securities Act of 1933.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Sensitive
Data</span>&#8221; means all confidential information, classified information, proprietary information, trade secrets and any other information,
the security or confidentiality of which is protected by Law or Contract, that is collected, maintained, stored, transmitted, used, disclosed
or otherwise processed by the Company. Sensitive Data also includes &#8220;personal data&#8221;, which is information held, stored, collected,
transmitted, transferred (including cross-border transfers), disclosed, sold or used by the Company or its Subsidiaries that is defined
as &#8220;personal data&#8221;, &#8220;personally identifiable information&#8221;, &#8220;personal information&#8221; or similar term
under any applicable Laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Specified
Courts</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;13.6</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Sponsor</span>&#8221;
means MFH 1, LLC, a Delaware limited liability company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 458 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Subsidiary</span>&#8221;,
when used with respect to any Person, shall mean any corporation, limited liability company, partnership, association, trust or other
entity the accounts of which would be consolidated with those of such Party in such Party&#8217;s consolidated financial statements if
such financial statements were prepared in accordance with GAAP, as applicable, as well as any other corporation, limited liability company,
partnership, association, trust or other entity of which securities or other ownership interests representing more than fifty percent
(50%) of the equity or more than fifty percent (50%) of the ordinary voting power (or, in the case of a partnership, more than fifty percent
(50%) of the general partnership interests) are, as of such date, owned by such Party or one or more Subsidiaries of such Party or by
such Party and one or more Subsidiaries of such Party. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Tax</span>&#8221;
or &#8220;<span style="text-decoration: underline">Taxes</span>&#8221; means any and all federal, state, local, non-U.S. and other taxes,
levies, fees, imposts, duties and charges of whatever kind in the nature of a tax (including any interest, penalties or additions to the
tax imposed in connection therewith or with respect thereto), including taxes imposed on, or measured by, income, franchise, profits or
gross receipts, and also <i>ad valorem</i>, value added, sales, use, service, real or personal property, capital stock, license, payroll,
withholding, employment, social security, workers&#8217; compensation, utility, unemployment compensation, severance, production, excise,
stamp, occupation, premium, windfall profits, transfer and gains taxes and customs duties, whether disputed or not.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Tax
Return</span>&#8221; means all returns, reports, information statements and other documentation (including any additional or supporting
material) filed or maintained, or required to be filed or maintained, in connection with the calculation, determination, assessment, claim
for refund or collection of any Tax, including any amendment or attachment thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Transaction
Documents</span>&#8221; means, collectively, to this Agreement, the Lock-Up Agreement and each other agreement, document, instrument or
certificate contemplated by this Agreement to be executed in connection with the transactions contemplated hereby.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Transactions</span>&#8221;
means, collectively, the transactions contemplated by this Agreement and the other Transaction Documents, including the Reincorporation
and the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Trust
Account</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;6.8(a)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#8220;<span style="text-decoration: underline">Trust
Agreement</span>&#8221; has the meaning provided in <span style="text-decoration: underline">Section&#160;6.8(a)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.2 <span style="text-decoration: underline">
Construction</span>. The following rules of construction shall apply to this Agreement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) When a reference is made in
this Agreement to an Article, a Section, Exhibit or Schedule, such reference shall be to an Article of, a Section of, or an Exhibit or
Schedule to, this Agreement unless otherwise indicated. The table of contents and headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of this Agreement. The words &#8220;hereof&#8221;, &#8220;herein&#8221;
and &#8220;hereunder&#8221; and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to
any particular provision of this Agreement. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) All terms defined in this
Agreement shall have the defined meanings when used in any certificate or other document made or delivered pursuant hereto unless otherwise
defined therein. The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms
and to the masculine as well as to the feminine and neuter genders of such term. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 459 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) Whenever the words &#8220;include&#8221;,
&#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without
limitation&#8221;. The word &#8220;or&#8221; shall not be exclusive. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) Any agreement, instrument
or statute defined or referred to herein means such agreement, instrument or statute as from time to time amended, modified or supplemented,
including, in the case of agreements or instruments, by waiver or consent and, in the case of statutes, by succession of comparable successor
statutes and including, in the case of agreements or instruments, all attachments thereto and instruments incorporated therein, and, in
the case of statutes, all rules and regulations promulgated thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e) References to a Person are
also to its permitted successors and assigns. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f) Any reference in this Agreement
to a &#8220;day&#8221; or a number of &#8220;days&#8221; (without explicit reference to &#8220;Business Days&#8221;) shall be interpreted
as a reference to a calendar day or number of calendar days. If any action is to be taken or given on or by a particular calendar day,
and such calendar day is not a Business Day, then such action may be deferred until the next Business Day. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(g) All references to &#8220;$&#8221;
or &#8220;dollars&#8221; shall mean United States Dollars.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(h) The Parties have participated
jointly in the negotiation and drafting of this Agreement and, in the event an ambiguity or question of intent or interpretation arises,
this Agreement shall be construed as jointly drafted by the Parties and no presumption or burden of proof shall arise favoring or disfavoring
any Party by virtue of the authorship of any provision of this Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ARTICLE II </b><br/><b>REINCORPORATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.1 <span style="text-decoration: underline">Reincorporation</span>.
At the Reincorporation Effective Time, subject to and upon the terms and conditions of this Agreement and in accordance with the applicable
provisions of the BVI BCA and the DGCL, Parent shall be merged with and into Purchaser, the separate corporate existence of Parent shall
cease and Purchaser shall continue as the surviving company. Purchaser as the surviving company after the Reincorporation is hereinafter
sometimes referred to as &#8220;<span style="text-decoration: underline">Purchaser Surviving Corporation</span>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.2 <span style="text-decoration: underline">Reincorporation
Effective Time</span>. On a date no later than three (3) Business Days after the satisfaction or waiver of all the conditions set forth
in <span style="text-decoration: underline">ARTICLE XI</span> that are required to be satisfied prior to the Closing Date, Parent and
Purchaser shall cause the Reincorporation to be consummated by filing the plan of merger (and any other documents required by the BVI
BCA and DGCL) (collectively, the &#8220;<span style="text-decoration: underline">Plan of Merger</span>&#8221;) with the BVI Registrar
and the Delaware Secretary of State (the &#8220;<span style="text-decoration: underline">DE SOS</span>&#8221;) in accordance with the
relevant provisions of the BVI BCA and DGCL. The effective time of Reincorporation shall be the date that the Plan of Merger is filed
with, and the certificate of merger is issued by, the DE SOS, or such later time as specified in or in accordance with the Plan of Merger
being the &#8220;<span style="text-decoration: underline">Reincorporation Effective Time</span>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 460 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.3 <span style="text-decoration: underline">Effect
of Reincorporation</span>. At the Reincorporation Effective Time, the effect of Reincorporation shall be as provided in this Agreement,
the Plan of Merger and the applicable provisions of the BVI BCA and DGCL. At the Reincorporation Effective Time, all the property, rights,
privileges, agreements, powers and franchises, debts, liabilities, duties and obligations of Parent and Purchaser prior to the Reincorporation
Effective Time shall become the property, rights, privileges, agreements, powers and franchises, debts, liabilities, duties and obligations
of Purchaser Surviving Corporation, which shall include the assumption by Purchaser Surviving Corporation of any and all agreements, covenants,
duties and obligations of Parent set forth in this Agreement or any other outstanding agreement to which Parent is a party to be performed
after the Closing. All securities of Purchaser Surviving Corporation issued and outstanding as a result of the conversion under <span style="text-decoration: underline">Section&#160;2.6</span>
shall be listed on Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.4 <span style="text-decoration: underline">Charter
Documents</span>. At the Reincorporation Effective Time, the certificate of incorporation of Purchaser shall be amended and restated to
a form acceptable to the Company and Parent which shall become the certificate of incorporation of Purchaser Surviving Corporation (&#8220;<span style="text-decoration: underline">Amended
and Restated COI of Purchaser Surviving Corporation</span>&#8221;). The new name of Purchaser Surviving Corporation will be such name
as provided by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.5 <span style="text-decoration: underline">Directors
and Officers of Purchaser Surviving Corporation</span>. As of the Reincorporation Effective Time, the Persons constituting the officers
and directors of Parent prior to the Reincorporation Effective Time shall continue to be the officers and directors of Purchaser Surviving
Corporation (holding the same title as held at Parent) until the Effective Time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.6 <span style="text-decoration: underline">Effect
on Issued Securities of Parent</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) With respect to Parent Shares,
at the Reincorporation Effective Time, (A) each issued and outstanding Class A Parent Ordinary Share (other than the Parent Excluded Shares,
the Parent Dissenting Shares and Parent Ordinary Shares redeemed pursuant to the Offer) shall automatically be converted into one Purchaser
Class A Share and (B) each issued and outstanding Class B Parent Ordinary Share (other than the Parent Excluded Shares, the Parent Dissenting
Shares and Parent Ordinary Shares redeemed pursuant to the Offer) shall automatically be converted into one Purchaser Class A Share. At
the Reincorporation Effective Time, all Parent Ordinary Shares shall cease to be outstanding, shall be canceled and shall cease to exist.
The holders of issued Parent Ordinary Shares immediately prior to the Reincorporation Effective Time, as evidenced by the register of
members of Parent, shall cease to have any rights with respect to such Parent Ordinary Shares, except the right to receive the same number
of Purchaser Surviving Corporation Shares or as otherwise required by Law. Each certificate (if any) previously evidencing Parent Ordinary
Shares (other than the Parent Excluded Shares, the Parent Dissenting Shares and Parent Ordinary Shares redeemed pursuant to the Offer)
shall be exchanged for a certificate representing the same number of Purchaser Shares upon the surrender of such certificate in accordance
with <span style="text-decoration: underline">Section&#160;2.7</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 461 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) Each Parent Dissenting Share
issued and outstanding immediately prior to the Reincorporation Effective Time shall no longer be outstanding and shall automatically
be cancelled by virtue of the Reincorporation, and each former holder of Parent Dissenting Shares shall thereafter cease to have any rights
with respect to such securities, except the right to be paid the fair value of such Parent Dissenting Shares and such other rights as
are granted by the BVI BCA. Notwithstanding the foregoing, if any such holder shall have failed to perfect or prosecute or shall have
otherwise waived, effectively withdrawn or lost its rights under the BVI BCA or a court of competent jurisdiction shall determine that
such holder is not entitled to the relief provided by the BVI BCA, then the right of such holder to be paid the fair value of such holder&#8217;s
Parent Dissenting Shares under the BVI BCA shall cease and such former Parent Ordinary Shares shall no longer be considered Parent Dissenting
Shares for purposes hereof and shall thereupon be deemed to have been converted as of the Reincorporation Effective Time into the right
to receive the applicable Purchaser Surviving Corporation Shares pursuant to <span style="text-decoration: underline">Section&#160;2.6(a)</span>,
without any interest thereon.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) At the Reincorporation Effective
Time, (i) all Parent Units will separate into their individual components of Class A Parent Ordinary Shares and Parent Warrants, and will
cease separate existence and trading and (ii) each issued and outstanding Parent Warrant shall cease to be a warrant with respect to Parent
Ordinary Shares, shall be assumed by Purchaser Surviving Corporation and be converted into one Purchaser Surviving Corporation Warrant
(exercisable for Purchaser Class A Shares) and shall cease separate existence and trading. Each Purchaser Surviving Corporation Warrant
shall have, and be subject to, the same terms and conditions set forth in the applicable agreements governing the Parent Warrants that
are outstanding immediately prior to the Reincorporation Effective Time (it being understood and agreed that such Parent Warrants shall
be exercisable for Purchaser Class A Shares). At or prior to the Reincorporation Effective Time, Purchaser shall take all corporate action
necessary to reserve for future issuance, and shall maintain such reservation for so long as any of Purchaser Surviving Corporation Warrants
remain outstanding, a sufficient number of Purchaser Class A Shares for delivery upon the exercise of Purchaser Surviving Corporation
Warrants after the Reincorporation Effective Time. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) At the Reincorporation Effective
Time, any Parent Ordinary Shares owned by Parent as treasury shares or owned by any direct or indirect wholly owned subsidiary of Parent
immediately prior to the Reincorporation Effective Time (the &#8220;<span style="text-decoration: underline">Parent Excluded Shares</span>&#8221;),
shall be canceled and extinguished without any conversion thereof or payment therefor. In addition, as of the Reincorporation Effective
Time, the one (1) share of Purchaser owned by Parent immediately prior to the Reincorporation Effective Time shall be automatically cancelled
and extinguished without any conversion or consideration delivered in exchange therefor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e) Notwithstanding anything to
the contrary in this <span style="text-decoration: underline">Section&#160;2.6</span>, none of Purchaser Surviving Corporation, Parent,
the Company or any other Party hereto shall be liable to any person for any amount properly paid to a public official pursuant to any
applicable abandoned property, escheat or similar law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.7 <span style="text-decoration: underline">Surrender
of Parent Shares</span>. All securities issued upon the surrender of the Parent Shares in accordance with the terms hereof, shall be deemed
to have been issued in full satisfaction of all rights pertaining to such securities, <span style="text-decoration: underline">provided</span>
that any restrictions on the sale and transfer of the Parent Shares shall also apply to Purchaser Surviving Corporation Shares so issued
in conversion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 462 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.8 <span style="text-decoration: underline">Lost,
Stolen or Destroyed Certificates</span>. In the event any certificates representing securities shall have been lost, stolen or destroyed,
Purchaser shall, upon the affidavit of that fact by the holder thereof, issue in exchange for such lost, stolen or destroyed certificates
such securities as would be issuable under <span style="text-decoration: underline">Section&#160;2.6</span>&#894; <span style="text-decoration: underline">provided</span>,
<span style="text-decoration: underline">however</span><i>, </i>that Purchaser Surviving Corporation may, in its discretion and as a condition
precedent to the issuance thereof, require the owner of such lost, stolen or destroyed certificates to execute and deliver a deed of indemnity
with respect thereto in the form required by Purchaser Surviving Corporation as indemnity against any claim that may be made against it
with respect to the certificates alleged to have been lost, stolen or destroyed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.9 <span style="text-decoration: underline">Reincorporation
Intended Tax Treatment</span>. Parent and Purchaser intend that the Reincorporation qualify as a &#8220;reorganization&#8221; within the
meaning of Section&#160;368(a) of the Code and the Treasury Regulations promulgated thereunder to which each of Parent and the Purchaser
is a party under Section&#160;368(b) of the Code (the &#8220;<span style="text-decoration: underline">Reincorporation Intended Tax Treatment</span>&#8221;).
Each of Parent and Purchaser hereby (a) adopts this Agreement as a &#8220;plan of reorganization&#8221; within the meaning of Treasury
Regulation Section&#160;1.368-2(g), (b) agrees to file and retain such information as shall be required under Treasury Regulation Section&#160;1.368-3
and (c) agrees to file all Tax and other informational returns on a basis consistent with the Reincorporation Intended Tax Treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.10 <span style="text-decoration: underline">Taking
of Necessary Action&#894; Further Action</span>. If, at any time after the Reincorporation Effective Time, any further action is necessary
or desirable to carry out the purposes of this Agreement and to vest Purchaser Surviving Corporation with full right, title and possession
to all assets, property, rights, privileges, powers and franchises of Parent and Purchaser, the officers and directors of Parent and Purchaser
are fully authorized in the name of their respective corporations or otherwise to take, and will take, all such lawful and necessary action,
so long as such action is not inconsistent with this Agreement and does not create any additional obligations for the Company inconsistent
with this Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.11 <span style="text-decoration: underline">Dissenter&#8217;s
Rights</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) No Person who has validly
exercised their dissenters&#8217; rights in respect of the Reincorporation pursuant to section&#160;179 of the BVI BCA (each, a &#8220;<span style="text-decoration: underline">Parent
Dissenting Shareholder</span>&#8221;) shall be entitled to receive the securities of Purchaser Surviving Corporation in accordance with
this <span style="text-decoration: underline">Section&#160;2.11</span>, with respect to the shares of Parent owned by such Person (&#8220;<span style="text-decoration: underline">Parent
Dissenting Shares</span>&#8221;) unless and until such Person shall have effectively withdrawn or lost such Person&#8217;s dissenters&#8217;
rights under the BVI BCA. Each Parent Dissenting Shareholder shall be entitled to receive only the payment resulting from the procedure
in the BVI BCA with respect to the Parent Dissenting Shares owned by such Parent Dissenting Shareholder. If any Parent Shareholder gives
to Parent, before the vote on the Reincorporation, written objection to the Reincorporation (each, an &#8220;<span style="text-decoration: underline">RC
Written Objection</span>&#8221;) in accordance with the BVI BCA:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) Parent shall, in accordance
with the BVI BCA, within twenty (20) days after the date on which the vote of members giving authorization of the Reincorporation is made,
give a written notice of the authorization (the &#8220;<span style="text-decoration: underline">Authorization Notice</span>&#8221;) to
each such Parent Shareholder who has made an RC Written Objection, and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 463 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) No party shall be obligated
to commence the Reincorporation, and the Plan of Merger shall not be filed with the BVI Registrar, until at least twenty (20) days shall
have elapsed since the date on which the Authorization Notice is given (being the period allowed for written notice of an election to
dissent under the BVI BCA, as referred to in the BVI BCA), but in any event subject to the satisfaction or waiver of all of the conditions
set forth in <span style="text-decoration: underline">ARTICLE XI</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ARTICLE III </b><br/><b>THE MERGER</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.1 <span style="text-decoration: underline">The
Merger</span>. Upon the terms and subject to the conditions set forth in this Agreement and the Organizational Documents of Merger Sub
and in accordance with the DGCL, at the Effective Time, (a) Merger Sub shall be merged with and into the Company, (b) the separate corporate
existence of Merger Sub shall thereupon cease, (c) the Company shall be the surviving company in the Merger (&#8220;<span style="text-decoration: underline">Company
Surviving Corporation</span>&#8221;) and (d) the Company shall become a wholly-owned Subsidiary of Purchaser Surviving Corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.2 <span style="text-decoration: underline">Closing</span>.
The closing of the Transactions (the &#8220;<span style="text-decoration: underline">Closing</span>&#8221;) shall take place by means
of telecommunication on the third (3rd) Business Day following the satisfaction or waiver (to the extent permitted by applicable Law and
the Organizational Documents of Parent) of the conditions set forth in <span style="text-decoration: underline">ARTICLE XI</span> (other
than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of such conditions
at such time), unless another time or date, or both, are agreed in writing by the Company and Parent but in no case earlier than the day
after the completion of the Reincorporation; <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>,
that the Closing shall occur no earlier than the first (1<sup>st</sup>) Business Day following the Reincorporation. The Company and the
Parent shall have the right to confirm that all conditions precedent are satisfied prior to Closing. The date on which the Closing is
held is herein referred to as the &#8220;<span style="text-decoration: underline">Closing Date</span>&#8221;. The Closing will take place
remotely via exchange of documents and signature pages via electronic transmission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.3 <span style="text-decoration: underline">Effective
Time</span>. Subject to the provisions of this Agreement, at the Closing, after the Reincorporation, Merger Sub or the Company shall file
a certificate of merger with the DE SOS. The effective time of the Merger shall be the date that the certificate of merger has been filed
with the DE SOS (the time at which the Merger becomes effective is herein referred to as the &#8220;<span style="text-decoration: underline">Effective
Time</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.4 <span style="text-decoration: underline">Effects
of the Merger</span>. The Merger shall have the effects set forth herein and in the DGCL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.5 <span style="text-decoration: underline">Certificate
of Incorporation of Company Surviving Corporation</span>. From and after the Effective Time and until further amended in accordance with
applicable Law, the Certificate of Incorporation of Merger Sub as in effect immediately prior to the Effective Time shall be the Certificate
of Incorporation of Company Surviving Corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.6 <span style="text-decoration: underline">Post-Closing
Board of Directors and Officers of Purchaser Surviving Corporation</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) Immediately after the Closing,
the initial slate of Purchaser Surviving Corporation&#8217;s board of directors (the &#8220;<span style="text-decoration: underline">Post-Closing
Board of Directors</span>&#8221;) will consist of five (5) directors, at least a majority of whom shall qualify as independent directors
under the Securities Act and the Nasdaq rules (subject to any phase-in periods under the Nasdaq rules). All five (5) directors shall be
designated by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 464 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) The Company may, in its sole
discretion, elect to classify the Post-Closing Board of Directors into two or more classes, effective immediately after the Closing or
such other time after the Closing as the Company may determine in its discretion, with directors in each class serving staggered terms,
with the term of office of at least one class expiring each year. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) Purchaser Surviving Corporation
shall take all action necessary (if needed), including causing the executive officer(s) of Purchaser Surviving Corporation prior to the
Closing to resign, so that the individuals serving as executive officers of Purchaser Surviving Corporation immediately after the Closing
will be the individuals set forth on <span style="text-decoration: underline">Schedule&#160;3.6(c)</span> (or such other Persons as designated
by the Company prior to the Closing).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.7 <span style="text-decoration: underline">Directors
and Officers of Company Surviving Corporation</span>. From and after the Effective Time, the director(s) and officer(s) of Company Surviving
Corporation shall be the person(s) set forth on <span style="text-decoration: underline">Schedule&#160;3.7</span> (or such other Persons
as designated by the Company prior to the Closing). The director(s) and officer(s) of Company Surviving Corporation shall hold office
for the term specified in, and subject to the provisions contained in, Company Surviving Corporation&#8217;s Organizational Documents
and applicable Law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.8 <span style="text-decoration: underline">No
Further Ownership Rights in Company Shares</span>. At the Effective Time, the share transfer books of the Company shall be closed and
thereafter there shall be no further registration of transfers of Company Shares on the records of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration: none">3.9
</span><span style="text-decoration: none">[Reserved]</span> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.10 <span style="text-decoration: underline">Taking
of Necessary Action; Further Action</span>. Purchaser Surviving Corporation, Merger Sub, and the Company, respectively, shall each use
its respective best efforts to take all such action as may be necessary or appropriate to effectuate the Merger under DGCL in accordance
with <span style="text-decoration: underline">Section&#160;3.3</span>. If, at any time after the Effective Time, any further action is
necessary or desirable to carry out the purposes of this Agreement and to vest Company Surviving Corporation with full right, title and
possession to all properties, rights, privileges, immunities, powers and franchises of either of the constituent corporations, the officers
of Purchaser Surviving Corporation and Company Surviving Corporation are fully authorized in the name of each constituent corporation
or otherwise to take, and shall take, all such lawful and necessary action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.11 <span style="text-decoration: underline">Withholding</span>.
Purchaser Surviving Corporation and Company Surviving Corporation shall each be entitled to deduct and withhold from the consideration
otherwise payable to any Person pursuant to this Agreement such amounts as are required to be deducted or withheld with respect to the
making of such payment under the Code or under any provision of state, local or non-U.S. Tax Law. Purchaser Surviving Corporation and
Company Surviving Corporation shall provide prompt notice to the Company and the affected Company Equityholder of any required withholding.
To the extent that amounts are so deducted and withheld and paid over to the appropriate taxing authorities in accordance with applicable
Law, such amounts shall be treated for all purposes under this Agreement as having been paid to the Person in respect of which such deduction
and withholding was made. Notwithstanding the foregoing, Purchaser Surviving Corporation and Company Surviving Corporation shall use commercially
reasonable efforts to reduce or eliminate any such withholding, including requesting and providing recipients of consideration a reasonable
opportunity to provide documentation establishing exemptions from or reductions of such withholdings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 465 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.12 <span style="text-decoration: underline">Dissenter&#8217;s
Rights</span>. Notwithstanding anything in this Agreement to the contrary, Company Shares issued and outstanding immediately prior to
the Closing held by a Company Shareholder who has not voted in favor of the Merger or consented thereto in writing or executed an enforceable
waiver of appraisal rights to the extent permitted by applicable Law, and who has properly exercised its appraisal rights with respect
to such shares (the &#8220;<span style="text-decoration: underline">Company Dissenting Shares</span>&#8221;) in accordance with Section&#160;262
of the DGCL (the &#8220;<span style="text-decoration: underline">Dissenters&#8217; Rights Statute</span>&#8221;) shall not be converted
into a right to receive the applicable portion of the Merger Consideration, but shall instead have the rights set forth in the Dissenters&#8217;
Rights Statute unless such Company Shareholder subsequently withdraws its demand for appraisal or waives, fails to perfect or otherwise
loses such Company Shareholder&#8217;s appraisal rights, if any (in which case such Company Shares shall thereupon be deemed to have been
converted into, and to have become exchangeable for, as of the Effective Time, the right to receive the applicable portion of the Merger
Consideration). At the Closing, Company Shareholders holding Company Dissenting Shares shall cease to have any rights with respect thereto,
except the rights provided under applicable Law and as provided in this <span style="text-decoration: underline">Section&#160;3.12</span>.
If, after the Effective Time, such Company Shareholder fails to perfect or loses any such right to appraisal, each such Company Dissenting
Share of such Company Shareholder shall be treated as a Company Share that had been converted as of the Closing into the right to receive
the applicable portion of the Merger Consideration, without interest, in accordance with <span style="text-decoration: underline">Section&#160;4.2</span>.
The Company shall give Parent (i) prompt written notice of any demands for the Company to purchase the Company Shareholders&#8217; Company
Shares for cash received by the Company and withdrawals or attempted withdrawals of any such demands, and (ii) after the Closing, the
right to direct and control all negotiations and proceedings with respect to any such demands. Prior to the Closing, the Company shall
not, without the prior written consent of Parent, make any payment with respect to, or settle, offer to settle or otherwise negotiate,
any such demands.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.13 <span style="text-decoration: underline">Qualification
as a Reorganization</span>. The Parties intend that the Merger qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)
of the Code and the Treasury Regulations promulgated thereunder to which each of Purchaser, Merger Sub, and Company is a party under Section&#160;368(b)
of the Code (the &#8220;<span style="text-decoration: underline">Merger Intended Tax Treatment</span>&#8221;). Each of Purchaser, Merger
Sub, and Company hereby (a) adopts this Agreement as a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulation
Section&#160;1.368-2(g), (b) agrees to file and retain such information as shall be required under Treasury Regulation Section&#160;1.368-3
and (c) agrees to file all Tax and other informational returns on a basis consistent with the Merger Intended Tax Treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ARTICLE IV </b><br/><b>MERGER CONSIDERATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.1 <span style="text-decoration: underline">Merger
Consideration</span>. As consideration for the Merger, the Company Equityholders collectively shall be entitled to receive from Purchaser
Surviving Corporation, in the aggregate, a number of Purchaser Surviving Corporation Shares, each valued at $10.00 per share, with an
aggregate value equal to Five Hundred Million U.S. Dollars ($500,000,000) (&#8220;<span style="text-decoration: underline">Merger Consideration</span>&#8221;).
Notwithstanding anything to the contrary, the type of Purchaser Surviving Corporation Shares to be received by the Company Equityholders
shall be as set forth in <span style="text-decoration: underline">Section&#160;4.2</span> below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 466 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.2 <span style="text-decoration: underline">Conversion
of Company Shares and SAFEs</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) At the Effective Time, by
virtue of the Merger and without any action on the part of any holder of Company Shares, each Company Share issued and outstanding immediately
prior to the Effective Time (other than (i) any Company Shares held in the treasury of the Company, which treasury shares shall be canceled
as part of the Merger and shall not constitute &#8220;Company Shares&#8221; hereunder, and (ii) any Company Dissenting Shares) shall be
canceled and converted as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(i) Each issued and outstanding
share of Company Class B Common Stock held by a Company Shareholder shall be cancelled and converted into the right to receive a number
of Purchaser Class B Shares equal to the quotient obtained by <i>dividing</i> (a) the Per Share Merger Consideration by (b) Ten Dollars
($10.00), with each such Purchaser Class B Share having twenty (20) votes per share; and each such Company Shareholder will cease to have
any rights with respect to such Company Shares, except the right to receive the Per Share Merger Consideration as provided herein or by
Law; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(ii) Each issued and outstanding
share of Company Class A Common Stock held by a Company Shareholder shall be cancelled and converted into the right to receive a number
of Purchaser Class A Shares equal to the quotient obtained by <i>dividing</i> (a) the Per Share Merger Consideration by (b) Ten Dollars
($10.00), with each such Purchaser Class A Share having one (1) vote per share; and each such Company Shareholder will cease to have any
rights with respect to the Company Shares, except the right to receive the Per Share Merger Consideration as provided herein or by Law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) At the Effective Time, by
virtue of the Merger, each SAFE issued and outstanding immediately prior to the Effective Time shall be cancelled and converted into the
right to receive a number of Purchaser Class A Shares calculated in accordance with the terms of the SAFE in the event of a Liquidity
Event (as such term is defined in the SAFE), and each Company Safeholder will cease to have any rights with respect to the Company Securities,
except the right to receive the Per Share Merger Consideration as provided herein or by Law. Notwithstanding anything to the contrary
in this Agreement, the right of a Company Safeholder to receive Purchaser Class A Shares as contemplated herein shall be contingent on
the execution by such Company Safeholder of an acknowledgement and such other agreements and other documents as the Company deems necessary,
appropriate or expedient. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) Two (2) Business Days prior
to the anticipated Closing Date (by 8:00 p.m. Eastern Time), the Company shall deliver to Purchaser Surviving Corporation a schedule setting
forth the name of each Company Equityholder as of the Closing and its pro rata share of the Merger Consideration (the &#8220;<span style="text-decoration: underline">Equityholder
Allocation Schedule</span>&#8221;). If there is any change to the Equityholder Allocation Schedule between the time of such delivery and
the Closing, the Company shall promptly deliver an updated Equityholder Allocation Schedule to Purchaser Surviving Corporation. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 467 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.3 <span style="text-decoration: underline">Effect
on Share Capital of the Company</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) Upon the terms and subject
to the conditions of this Agreement, at the Effective Time, by virtue of the Merger and without any further action on the part of Purchaser
Surviving Corporation, Merger Sub, or the Company, any Company Shares then held by the Company (or held in the Company&#8217;s treasury)
shall be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) Each Company Dissenting Share
issued and outstanding as of immediately prior to the Effective Time shall no longer be outstanding and shall automatically be cancelled
by virtue of the Merger and each former holder of Company Dissenting Shares shall cease to have any rights with respect to such securities,
except as set forth in <span style="text-decoration: underline">Section&#160;3.12</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.4 <span style="text-decoration: underline">Share
Capital of Merger Sub</span><i>.</i> Each share in Merger Sub that is issued immediately prior to the Effective Time will, by virtue of
the Merger and without further action on the part of Purchaser Surviving Corporation, continue to be part of the issued shares of Company
Surviving Corporation (and such shares shall be the only issued shares of Company Surviving Corporation immediately after the Effective
Time). Each certificate evidencing ownership of shares of Merger Sub will, as of the Effective Time, evidence ownership of such shares
of Company Surviving Corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.5 <span style="text-decoration: underline">Issuance
of the Merger Consideration</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) No certificates representing
fractional Purchaser Surviving Corporation Shares will be issued pursuant to the Merger, and instead any such fractional share that would
otherwise be issued will be rounded to the nearest whole share, with a Company Equityholder&#8217;s portion of the Merger Consideration
that would result in a fractional share of 0.50 or greater rounding up and a Company Equityholder&#8217;s portion of the Merger Consideration
that would result in a fractional share of less than 0.50 rounding down.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) On the Closing Date, Purchaser
Surviving Corporation shall deposit, or shall cause to be deposited, with Odyssey Transfer and Trust Company (&#8220;<span style="text-decoration: underline">Odyssey</span>&#8221;)
for the benefit of the Company Equityholders, for exchange in accordance with this <span style="text-decoration: underline">ARTICLE IV</span>,
the number of Purchaser Surviving Corporation Shares sufficient to deliver the aggregate Merger Consideration payable pursuant to this
Agreement (such Purchaser Surviving Corporation Shares, the &#8220;<span style="text-decoration: underline">Exchange Fund</span>&#8221;).
Purchaser Surviving Corporation shall cause Odyssey, pursuant to irrevocable instructions, to pay the Merger Consideration out of the
Exchange Fund in accordance with the Equityholder Allocation Schedule and the other applicable provisions contained in this Agreement.
The Exchange Fund shall not be used for any other purpose other than as contemplated by this Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) As soon as practicable following
the Effective Time, and in any event within two (2) Business Days following the Effective Time (but in no event prior to the Effective
Time), Purchaser Surviving Corporation shall cause Odyssey to deliver to each Company Equityholder as of immediately prior to the Effective
Time a letter of transmittal and instructions for use in exchanging such Company Equityholder&#8217;s Company Shares or canceling such
Company Equityholder&#8217;s SAFEs, as applicable, for such party&#8217;s applicable portion of the Merger Consideration from the Exchange
Fund (a &#8220;<span style="text-decoration: underline">Letter of Transmittal</span>&#8221;), and, promptly following receipt of a Company
Equityholder&#8217;s properly executed Letter of Transmittal, deliver to such Company Equityholder its applicable portion of the Merger
Consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 468 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) The Merger Consideration shall
be adjusted to reflect appropriately the effect of any share split, reverse share split, share dividend, recapitalization, reclassification,
combination, exchange of shares or other like change with respect to Purchaser Surviving Corporation Shares occurring prior to the date
the Merger Consideration is issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e) Any portion of the Exchange
Fund relating to the Merger Consideration that remains undistributed to the Company Equityholders for one (1) year after the Effective
Time shall be delivered to Purchaser Surviving Corporation, upon demand, and any Company Equityholders who have not theretofore complied
with this <span style="text-decoration: underline">Section&#160;4.5</span> shall thereafter look only to Purchaser Surviving Corporation
for their portion of the Merger Consideration. Any portion of the Exchange Fund remaining unclaimed by Company Equityholders as of a date
which is immediately prior to such time as such amounts would otherwise escheat to or become property of any Governmental Authority shall,
to the extent permitted by applicable Law, become the property of Purchaser Surviving Corporation free and clear of any claims or interest
of any person previously entitled thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.6 <span style="text-decoration: underline">No
Liability</span>. The Parties agree that Purchaser Surviving Corporation shall be entitled to rely conclusively on information set forth
in the Equityholder Allocation Schedule and any amounts delivered by Purchaser Surviving Corporation to an applicable Company Equityholder
in accordance with the Equityholder Allocation Schedule shall be deemed for all purposes to have been delivered to the applicable Company
Equityholder in full satisfaction of the obligations of Purchaser Surviving Corporation under this Agreement and Purchaser Surviving Corporation
shall not be responsible or liable for the calculations or the determinations regarding such calculations set forth therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ARTICLE V </b><br/><b>REPRESENTATIONS AND WARRANTIES
OF THE COMPANY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purposes of this <span style="text-decoration: underline">ARTICLE
V</span>, unless the context otherwise requires, references to the Company shall include, as appropriate, references to all direct and
indirect Subsidiaries of the Company. Except as set forth in the Company Disclosure Schedules (which qualify (a) the correspondingly numbered
representation, warranty or covenant specified therein and (b) such other representations, warranties or covenants where its relevance
as an exception to (or disclosure for purposes of) such other representation, warranty or covenant is reasonably apparent on its face
or cross-referenced), the Company represents and warrants to Parent and Purchaser as hereafter set forth in this <span style="text-decoration: underline">ARTICLE
V,</span> that each of the following representations and warranties are true, correct and complete as of the date of this Agreement and
as of the Closing Date (except for representations and warranties that are made as of a specific date, which are made only as of such
date):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 469 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.1 <span style="text-decoration: underline">Organization,
Qualification and Standing</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) The Company is duly incorporated,
validly existing and in good standing under the jurisdiction of its incorporation, has all requisite power and authority to own, lease
and operate its Assets and to conduct its business as presently conducted, and is duly registered, qualified and authorized to transact
business and in good standing in every jurisdiction in which the conduct of its business or the nature of its properties requires such
registration qualification or authorization. The Organizational Documents of the Company, true, complete and correct copies of which have
been made available to Parent, are in full force and effect. The Company is not in violation of its Organizational Documents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) <span style="text-decoration: underline">Schedule&#160;5.1</span>
sets forth a true, complete and correct list of each Subsidiary of the Company, and, except as set forth on <span style="text-decoration: underline">Schedule&#160;5.1</span>,
the Company does not directly or indirectly own, or hold any rights to acquire, any capital stock or any other securities or interests
in any other Person. Each Subsidiary of the Company has been duly incorporated or formed and is validly existing as a corporation or limited
liability company in good standing (or equivalent status) (to the extent such concept exists) under the laws of the jurisdiction of its
incorporation or formation and the jurisdictions in which the conduct of its business or the nature of its properties requires such registration,
qualification or authorization, and has the corporate power and authority to own, lease and operate its Assets and to conduct its business
as presently conducted. All of the issued and outstanding capital stock of each Subsidiary has been duly authorized and validly issued,
is fully paid and non-assessable and is owned (either directly or indirectly) by the Company free and clear of any Lien (except for Permitted
Liens). No Subsidiary is in violation of its Organizational Documents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.2 <span style="text-decoration: underline">Authority;
Enforceability</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) The Company&#8217;s board
of directors has authorized and approved the Merger, this Agreement and the Transactions contemplated herein. The Company has the requisite
corporate power and authority to execute and deliver this Agreement and each other Transaction Document to which it is or will be a party
and to consummate the Transactions, subject only to obtaining the Company Shareholder Approval. The execution and delivery of this Agreement,
the other Transaction Documents to which the Company is or will be a party and the consummation of the Transactions have been duly authorized
by all necessary corporate action on the part of the Company, subject to obtaining the Company Shareholder Approval. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) This Agreement has been, and
the other Transaction Documents to which the Company is a party will be, duly executed and delivered by the Company and, assuming due
authorization, execution and delivery hereof by Parent, Purchaser and Merger Sub, constitute legal, valid and binding obligations of the
Company, enforceable against each in accordance with their terms, subject to the effect of any applicable bankruptcy, reorganization,
insolvency, moratorium or similar Law affecting creditors&#8217; rights generally and, as to enforceability, subject to the effect of
general principles of equity (regardless of whether such enforceability is considered in a Proceeding in equity or at Law). </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 470 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) The (i) affirmative vote of
the holders of a majority of aggregate voting power of the Company Shares (the &#8220;<span style="text-decoration: underline">Requisite
Vote</span>&#8221;) having voting power present in person or represented by proxy at a meeting of Company Shareholders at which a quorum
is present or (ii) written consent of the Requisite Vote, is the only vote or consent of the holders of any class or series of share capital
or other securities of the Company necessary to adopt this Agreement and approve the Transactions (the &#8220;<span style="text-decoration: underline">Company
Shareholder Approval</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.3 <span style="text-decoration: underline">Consents;
Required Approvals</span>. Assuming the truth and accuracy of the representations and warranties of Parent, Purchaser and Merger Sub set
forth in &#8206;this Agreement, no notices to, filings with, or authorizations, consents, waivers or approvals from any Governmental
Authority are necessary for the execution, delivery or performance by the Company of this Agreement or any other Transaction Document
or the consummation by the Company of the Transactions, except (a) for the filing of the certificate of merger with the DE SOS and (b)
where the failure to obtain such consents, approvals, authorizations or permits, or to make such filings or notifications, would not have
or would not reasonably be expected to have a Company Material Adverse Effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.4 <span style="text-decoration: underline">Non-Contravention</span>.
Except as set forth on <span style="text-decoration: underline">Schedule&#160;5.4</span>, the execution, delivery and performance of this
Agreement and the other Transaction Documents to which the Company is or will be a party by the Company, as applicable, and the consummation
of the Merger and the other Transactions and compliance with the provisions hereof and thereof do not and will not with or without notice
or lapse of time or both (a) violate any Law or Order to which the Company or any of the Company&#8217;s Subsidiaries or any of the Company&#8217;s
or the Company&#8217;s Subsidiaries&#8217; Assets are subject, (b) violate any provision of the Organizational Documents of the Company
or any Subsidiary (subject to obtaining the Company Shareholder Approval), (c) violate, conflict with, result in a breach of, constitute
(or with due notice or lapse of time or both would become) a default under, result in the acceleration of, create in any Person the right
to accelerate, terminate, modify or cancel, require any notice under, or otherwise give rise to any Liability under, any Material Contract,
or (d) result in the creation or imposition of any Lien (other than Permitted Liens) upon any of the properties or Assets of the Company
or the Company&#8217;s Subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.5 <span style="text-decoration: underline">Capitalization</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) As of the date of this Agreement,
the Company is authorized to issue 1,500 Company Shares with par value $0.01 each, consisting of 303 Company Class A Common Stock and
1197 Company Class B Common Stock, of which all shares are issued and outstanding as of the date of this Agreement, and no other authorized
equity interests of the Company are issued and outstanding. As of the date of this Agreement, all outstanding Company Shares are owned
of record by the Persons set forth on <span style="text-decoration: underline">Schedule&#160;5.5(a)</span> in the amounts set forth opposite
their respective names. All of the outstanding Company Shares are validly issued and outstanding, fully paid and non-assessable with no
personal Liability attaching to the ownership thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 471 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) Except for the SAFEs set forth
on <span style="text-decoration: underline">Schedule&#160;5.5(a)</span>, as of the date hereof, there are and, immediately after consummation
of the Closing, there will be, no (i)&#160;outstanding warrants, options, agreements, convertible securities, performance units or other
commitments or instruments pursuant to which the Company is or may become obligated to issue or sell any of its shares or other securities,
(ii) outstanding obligations of the Company to repurchase, redeem or otherwise acquire outstanding capital stock of the Company or any
securities convertible into or exchangeable for any shares of the Company, as applicable, (iii)&#160;treasury shares of the Company, (iv)
bonds, debentures, notes or other Indebtedness of the Company having the right to vote (or convertible into, or exchangeable for, securities
having the right to vote) on any matters on which shareholders of the Company may vote, are issued or outstanding, (v) preemptive or similar
rights to purchase or otherwise acquire shares or other securities of the Company pursuant to any provision of Law, the Company&#8217;s
Organizational Documents or any Contract to which the Company is a party, or (vi) Liens (other than Permitted Liens) with respect to the
sale or voting of shares or securities of the Company (whether outstanding or issuable).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) Upon the consummation of the
Merger, Purchaser Surviving Corporation will own all of the issued and outstanding shares and equity securities of the Company free and
clear of all Liens (other than Permitted Liens).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.6 <span style="text-decoration: underline">Bankruptcy</span>.
Neither the Company nor any of the Company&#8217;s Subsidiaries is involved in any Proceeding by or against it as a debtor before any
Governmental Authority under the United States Bankruptcy Code or any other insolvency or debtors&#8217; relief act or Law or for the
appointment of a trustee, receiver, liquidator, assignee, sequestrator or other similar official for any part of the Assets of the Company
or any of the Company&#8217;s Subsidiaries. Neither the Company nor or any of the Company&#8217;s Subsidiaries is, and after giving effect
to the consummation of the Transactions, will be &#8220;insolvent&#8221; within the meaning of Section&#160;101(32) of title 11 of the
United States Code or any applicable fraudulent conveyance or transfer Law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.7 <span style="text-decoration: underline">Financial
Statements</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) Set forth on <span style="text-decoration: underline">Schedule&#160;5.7(a)</span>
are true, complete and correct copies of the (i) unaudited financial statements of the Company as of June&#160;30, 2025 and June&#160;30,
2024 and the related statements of income, cash flows and profit and loss statements for the fiscal year then ended (the &#8220;<span style="text-decoration: underline">Annual
Financial Statements</span>&#8221;) and (ii) unaudited balance sheet as of September&#160;30, 2025 (such date, the &#8220;<span style="text-decoration: underline">Balance
Sheet Date</span>&#8221;) and the related statements of income, cash flows and profit and loss statements for the fiscal quarter then
ended (the &#8220;<span style="text-decoration: underline">Interim Financial Statements</span>,&#8221; and together with the Annual Financial
Statements, the &#8220;<span style="text-decoration: underline">Company Financial Statements</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) The Company Financial Statements
(i) accurately reflect the books and records of the Company as of the times and for the periods referred to therein in all material respects,
(ii) were prepared in accordance with GAAP, consistently applied throughout and among the periods involved (except that the unaudited
statements exclude the footnote disclosures and other presentation items required for GAAP and exclude year-end adjustments which will
not be material in amount), (iii) comply with all applicable accounting requirements under the Securities Act and the rules and regulations
of the SEC thereunder (except with respect to any requirements for annual financial statements to be audited), (iv) fairly present in
all material respects the consolidated financial position of the Company as of the respective dates thereof and the consolidated results
of the operations and cash flows of the Company for the periods indicated and (v) when delivered by the Company for inclusion in the Proxy
Statement for filing with the SEC following the date of this Agreement in accordance with <span style="text-decoration: underline">Section&#160;7.3</span>,
will comply in all material respects with the applicable accounting requirements and with the rules and regulations of the SEC, the Exchange
Act and the Securities Act applicable to a registrant, in effect as of the respective dates thereof. None of the Company or any of its
Subsidiaries has ever been subject to the reporting requirements of Sections&#160;13(a) and 15(d) of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 472 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Company maintains accurate books and records reflecting its assets and Liabilities (excluding for the purpose of this section, unknown
Liabilities) and maintains commercially reasonable internal accounting controls that provide reasonable assurance that (i) the Company
does not maintain any off-the-book accounts and are designed to ensure that the Company&#8217;s assets are used only in accordance with
management&#8217;s directives, (ii) transactions are executed with management&#8217;s authorization, (iii) transactions are recorded as
necessary to permit preparation of the financial statements of the Company and to maintain accountability for the Company, (iv) access
to the Company&#8217;s assets is permitted only in accordance with management&#8217;s authorization, (v) the reporting of the Company&#8217;s
assets is compared with existing assets at regular intervals and verified for actual amounts, and (vi) accounts, notes and other receivables
and inventory are recorded accurately, and commercially reasonable procedures are implemented to effect the collection of accounts, notes
and other receivables on a current and timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
All of the financial books and records of the Company are complete and accurate in all material respects and have been maintained in the
Ordinary Course and in accordance with applicable Laws. Since its inception, the Company has not been subject to or involved in any fraud
that involves management or other employees who have a role in the internal controls over financial reporting of the Company. Since its
inception, the Company has not received any written, or the Knowledge of the Company, oral, complaint, allegation, assertion or claim
regarding the accounting or auditing practices, procedures, methodologies or methods of the Company or its internal accounting controls,
including any complaint, allegation, assertion or claim that the Company has engaged in questionable accounting or auditing practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
All financial projections with respect to the Company that were delivered by or on behalf of the Company to Parent or its Representatives
were prepared in good faith using assumptions that the Company believes to be reasonable at the time made, it being understood that projections
are forward-looking in nature and subject to uncertainties and no representation or warranty is made regarding actual future performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8
<span style="text-decoration: underline">Liabilities</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Except (i) as set forth in the Company Financial Statements, (ii) for Liabilities incurred since the Balance Sheet Date in the Ordinary
Course that are not material, or (iii) for Liabilities incurred in connection with the Transactions, the Company has no Liabilities (excluding
for the purpose of this section, unknown Liabilities) of a nature required to be reflected on a balance sheet of the Company prepared
in accordance with GAAP, except as would not reasonably be expected to be material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Set forth in <span style="text-decoration: underline">Schedule&#160;5.8(b)</span> is a list of all Indebtedness of the Company and its
Subsidiaries. Neither the Company nor any of the Company&#8217;s Subsidiaries has guaranteed any other Person&#8217;s Indebtedness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9
<span style="text-decoration: underline">Internal Accounting Controls</span>. The Company has established a system of internal accounting
controls sufficient to provide reasonable assurance that (a) transactions are executed in accordance with management&#8217;s general or
specific authorizations in all material respects, (b) transactions are recorded as necessary to permit preparation of financial statements
in conformity with the Company&#8217;s historical practices and to maintain asset accountability in all material respects, (c) access
to material assets is permitted only in accordance with management&#8217;s general or specific authorization and (d) the recorded accountability
for material assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 473 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10
<span style="text-decoration: underline">Absence of Certain Developments</span>. Except as set forth in <span style="text-decoration: underline">Schedule&#160;5.10</span>,
between the Balance Sheet Date and the date hereof, none of the Company or any of the Company&#8217;s Subsidiaries has taken any action
that, if such action were taken after the date hereof, would have required Parent consent pursuant to <span style="text-decoration: underline">Section&#160;7.1</span>.
As of the date hereof, none of the Company or any of the Company&#8217;s Subsidiaries has received any grant or other financial support,
financial benefits or relief from any Governmental Authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11
<span style="text-decoration: underline">Accounts Receivable; Accounts Payable</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All notes and accounts receivable of the Company reflected in the Company Financial Statements are current and collectible in amounts
not less than the aggregate amount thereof (net of reserves that are established in accordance with GAAP applied consistently with prior
practice) carried (or to be carried) on the books of the Company and represent bona fide transactions that arose in the Ordinary Course
and are properly reflected on the Company&#8217;s books and records. As of the date of this Agreement, none of such notes or accounts
receivable that relate to a Material Customer are (i) past due more than ninety (90) days and, to the Knowledge of the Company, there
is no material contest, claim, defense or right of setoff with any account debtor of an accounts receivable relating to the amount or
validity of such accounts receivable and (ii) to the Knowledge of the Company, (A) all such notes or accounts receivable that relate to
a Material Customer (net of reserves that are established in accordance with GAAP applied consistently with prior practice) are reasonably
expected to be collectable in the Ordinary Course and (B) no request for or an agreement for a material deduction or discount has been
made with respect to such accounts receivable that relate to a Material Customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The&#160;accounts payable of the&#160;Company reflected in the Company Financial Statements and all accounts payable&#160;arising subsequent
to the date thereof arose from bona fide transactions in the Ordinary Course consistent with past practice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12
<span style="text-decoration: underline">Compliance with Law</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
None of the Company or any of the Company&#8217;s Subsidiaries has been since inception, is in or has any Liability in respect of any
violation of, and no event has occurred or circumstance exists that (with or without notice or due to lapse of time) would constitute
or result in (i) a material violation by the Company or any of the Company&#8217;s Subsidiaries of, (ii) the material failure on the part
of the Company or any of the Company&#8217;s Subsidiaries to comply with or (iii) any material Liability suffered or incurred by the Company
or any of the Company&#8217;s Subsidiaries in respect of any violation of or material noncompliance with any Laws, Orders or policies
of any Governmental Authority that are or were applicable to the Company or any such Subsidiary or the conduct or operation of its business
or the ownership or use of any of its Assets, and no Proceeding is pending, or to the Knowledge of the Company, threatened in writing,
alleging any such violation or noncompliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 474 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Company and its Subsidiaries have all Permits necessary for the conduct of their businesses as presently conducted; and (i) each of
the Permits is in full force and effect; (ii) the Company and its Subsidiaries are in compliance in all material respects with the terms,
provisions and conditions thereof; (iii) there are no outstanding violations, notices of noncompliance, Orders or Proceedings adversely
affecting any of the Permits; and (iv) no condition (including the execution of this Agreement and the other Transaction Documents to
which the Company is a party and the consummation of the Transactions) exists and no event has occurred which (whether with or without
notice, lapse of time or the occurrence of any other event) would reasonably be expected to result in the suspension or revocation of
any of the Permits other than by expiration of the term set forth therein, except in each case as would not reasonably be expected to
have, individually or in the aggregate, a Company Material Adverse Effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13
<span style="text-decoration: underline">Title to Properties</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<span style="text-decoration: underline">Section&#160;5.13(a)</span> of the Company Disclosure Schedules sets forth as of the date hereof
the address of each real property owned by the Company or any Subsidiary thereof (the &#8220;<span style="text-decoration: underline">Owned
Real Property</span>&#8221;). The Company or the applicable Subsidiary has good and marketable title to all Owned Real Property and valid
leasehold interests in all Leased Real Property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<span style="text-decoration: underline">Schedule&#160;5.13(b)</span> hereto includes a true, complete and correct list, as of the date
hereof, of (i) all Contracts under which the Company or any of the Company&#8217;s Subsidiaries leases, subleases, licenses or otherwise
uses or occupies any real property as a lessee, sublessee, licensee or occupant thereof, whether in the Company&#8217;s or any Subsidiary&#8217;s
capacity as lessee, sublessee, licensee, lessor, sublessor, or licensor, as the case may be (such Contracts are hereby referred to individually
as a &#8220;<span style="text-decoration: underline">Real Property Lease</span>&#8221; and collectively, as the &#8220;<span style="text-decoration: underline">Real
Property Leases</span>&#8221;) and (ii)&#160;the street address of the real property that is leased, subleased, licensed or otherwise
used or occupied pursuant to each Real Property Lease (each, a &#8220;<span style="text-decoration: underline">Leased Real Property</span>&#8221;
and collectively, the &#8220;<span style="text-decoration: underline">Leased Real Properties</span>&#8221;). The Company has made available
to Parent true, complete and correct copies of all Real Property Leases. To the Knowledge of the Company, no Person other than the Company
or a Subsidiary thereof has any option or right to terminate any of the Real Property Leases other than as expressly set forth in Schedule&#160;5.13(b).
There are no parties physically occupying or using any portion of any of the Leased Real Properties nor, to the Knowledge of the Company,
do any other parties have the right to physically occupy or use any portion of the Leased Real Properties, in each case, other than the
Company or its Subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
As of the date hereof, (i) all required deposits and additional rents due to date pursuant to each Real Property Lease have been paid
in full, (ii) neither the Company nor any Subsidiary has prepaid rent or any other amounts due under any Real Property Lease more than
thirty (30) days in advance and (iii) no party has any rights of offset against any rents, required security deposits or additional rents
payable under any Real Property Lease except for rights that would not reasonably be expected to have a Company Material Adverse Effect.
None of the Owned Real Property or Leased Real Property is subject to any Lien, except Permitted Liens.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Company and each of the Company&#8217;s Subsidiaries owns good, valid and marketable title, free and clear of all Liens (other than
Permitted Liens), to all of their respective material tangible Assets. The Company and each of the Company&#8217;s Subsidiaries owns,
leases under valid leases or has use of or valid access under valid agreements to all material facilities, machinery, equipment and other
tangible Assets necessary for the conduct of their respective businesses as presently conducted, and all such facilities, machinery and
equipment are in good working order in all material respects, Ordinary Course wear and tear excepted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 475 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14
<span style="text-decoration: underline">International Trade Matters; Anti-Bribery Compliance</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company and the Company&#8217;s Subsidiaries currently are, and each has since its inception been, in compliance with applicable Laws
related to (i) anti-corruption or anti-bribery, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, 15 U.S.C. &#167;&#167;
78dd-1, et seq., and any other equivalent or comparable applicable Laws of other countries (collectively, &#8220;<span style="text-decoration: underline">Anti-Corruption
Laws</span>&#8221;), (ii) economic sanctions administered, enacted or enforced by any applicable Governmental Authority (collectively,
&#8220;<span style="text-decoration: underline">Sanctions Laws</span>&#8221;), (iii) export controls, including the U.S. Export Administration
Regulations, 15 C.F.R. &#167;&#167; 730, et seq., and any other equivalent or comparable applicable Laws of other countries (collectively,
&#8220;<span style="text-decoration: underline">Export Control Laws</span>&#8221;), (iv) anti-money laundering, including the Money Laundering
Control Act of 1986, 18 U.S.C. &#167;&#167; 1956, 1957, and any other equivalent or comparable Laws of other countries; (v) anti-boycott
regulations, as administered by the U.S. Department of Commerce; and (vi) importation of goods, including applicable Laws administered
by the U.S. Customs and Border Protection, Title 19 of the U.S.C. and C.F.R., and any other equivalent or comparable applicable Laws of
other countries (collectively, &#8220;<span style="text-decoration: underline">International Trade Control Laws</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
None of the Company or the Company&#8217;s Subsidiaries, or to the Knowledge of the Company, any director, officer, employee or agent
of the Company or the Company&#8217;s Subsidiaries (acting on behalf of the Company or the Company&#8217;s Subsidiaries), is or is acting
under the direction, on behalf or for the benefit of a Person that is (i) the target of Sanctions Laws or identified on any sanctions
or prohibited party lists administered by a an applicable Governmental Authority, including the U.S. Department of the Treasury&#8217;s
Specially Designated Nationals List, the U.S. Department of Commerce&#8217;s Denied Persons List and Entity List, the U.S. Department
of State&#8217;s Debarred List, HM Treasury&#8217;s Consolidated List of Financial Sanctions Targets and the Investment Bank List, or
any similar list enforced by any other relevant Governmental Authority, or any Person that is fifty percent (50%) or more owned or otherwise
controlled by any of the foregoing (collectively, &#8220;<span style="text-decoration: underline">Prohibited Party</span>&#8221;); or
(ii) located, organized or resident in a country or territory that is, or whose government is, the target of comprehensive trade sanctions
under Sanctions Laws, including, as of the date of this Agreement, Crimea, Cuba, Iran, North Korea and Syria. None of the Company or the
Company&#8217;s Subsidiaries, or, to the Knowledge of the Company, any director or officer or any employee or agent of the Company or
the Company&#8217;s Subsidiaries (acting on behalf of the Company or the Company&#8217;s Subsidiaries), (A) has participated in any transaction
involving a Prohibited Party or a Person who is the target of any Sanctions Laws, or any country or territory that was during such period
or is, or whose government was during such period or is, the target of comprehensive trade sanctions under Sanctions Laws, (B) has exported
(including deemed exportation) or re-exported, directly or indirectly, any commodity, software, technology, or services in violation of
any applicable Export Control Laws or (C) has participated in any transaction in violation of or connected with any purpose prohibited
by Anti-Corruption Laws or any applicable International Trade Control Laws, including support for international terrorism and nuclear,
chemical, or biological weapons proliferation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 476 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
None of the Company or the Company&#8217;s Subsidiaries has received written notice of, and, to the Knowledge of the Company, none of
their respective officers, employees, agents or Representatives is or has been the subject of, any investigation, inquiry or enforcement
proceedings by any Governmental Authority regarding any offense or alleged offense under Anti-Corruption Laws, Sanctions Laws, Export
Control Laws or International Trade Control Laws (including by virtue of having made any disclosure relating to any offense or alleged
offense) and, to the Knowledge of the Company, there are no circumstances likely to give rise to any such investigation, inquiry or proceeding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15
<span style="text-decoration: underline">Tax Matters</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company and its Subsidiaries have filed all Tax Returns required by applicable Law to be filed by the Company; all such Tax Returns
were true, complete and correct in all respects; and all Taxes (whether or not shown on any Tax Returns) due and owing by the Company
and its Subsidiaries have been paid, other than Taxes being contested in good faith and for which adequate reserves have been established
in accordance with GAAP or that are not material in amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
There is no Proceeding, audit or claim now in progress against the Company or any of its Subsidiaries in respect of any Tax, nor has any
Proceeding for additional Tax been asserted in writing by any Tax authority that has not been resolved or settled in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
No written claim has been made by any Tax authority in a jurisdiction where the Company or any of its Subsidiaries has not filed a Tax
Return that it is or may be subject to Tax by such jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Neither the Company nor any of its Subsidiaries is a party to any Tax sharing agreement, Tax indemnification agreement, Tax allocation
agreement or similar agreement (other than Contracts entered into in the Ordinary Course and not relating primarily to Taxes).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Each of the Company and each of its Subsidiaries has withheld and paid all Taxes required to be withheld in connection with any amounts
paid or owing to any employee, creditor, independent contractor or other third party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Neither the Company nor any of its Subsidiaries has an outstanding request for any extension of time within which to pay any Taxes or
file any Tax Returns, and there has been no waiver or extension of any applicable statute of limitations for the assessment or collection
of any Taxes of the Company or any of its Subsidiaries that will remain outstanding as of the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Neither the Company nor any of its Subsidiaries has distributed the stock of another Person, or had its stock distributed by another Person,
in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 or Section&#160;361 of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
There are no Liens for Taxes upon any Assets of the Company or its Subsidiaries other than Permitted Liens.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 477 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Neither the Company nor any of its Subsidiaries has been a party to or bound by any closing agreement, private letter rulings, technical
advice memoranda, offer in compromise or similar agreement with any Tax authority in respect of which the Company or any of its Subsidiaries
could have any Tax Liability after the Closing. Neither the Company nor any of its Subsidiaries has any request for a ruling in respect
of Taxes pending between the Company or its Subsidiaries and any Tax authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
Neither the Company nor any of its Subsidiaries (i) has been a member of an affiliated group filing a consolidated U.S. federal income
Tax Return (other than a group the common parent of which was the Company) or other comparable group for state, local or foreign Tax purposes
or (ii) has Liability for the Taxes of any Person (other than the Company or its Subsidiaries) under Treasury Regulations Section&#160;1.1502-6
(or any similar provision of state, local, or foreign Law), as a transferee or successor, by Contract (other than Contracts entered into
in the Ordinary Course and not relating primarily to Taxes), or otherwise by Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
Neither the Company nor any of its Subsidiaries has participated in a &#8220;listed transaction&#8221; or has failed to disclose a &#8220;reportable
transaction&#8221; in each case required to be disclosed pursuant to Treasury Regulations Section&#160;1.6011-4(b).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
Neither the Company nor any of its Subsidiaries will be required to include any material item of income in, or exclude any material item
of deduction from, taxable income for any Tax period (or portion thereof) ending after the Closing as a result of (i) any use of an improper
or change in method of accounting for any Tax period on or before the Closing, (ii)&#160;any &#8220;closing agreement&#8221; as described
in Section&#160;7121 of the Code (or any comparable or similar provisions of applicable Law) executed on or before the Closing, (iii)
any installment sale or open transaction disposition made on or before the Closing, (iv) any deferred intercompany gain or any excess
loss account described in Treasury Regulations under Section&#160;1502 of the Code (or any predecessor provision or any similar provision
of state, local or foreign Law) arising on or before the Closing; (v) prepaid amount received or deferred revenue accrued prior to the
Closing outside the Ordinary Course, (vi) an election under Section&#160;108(i) of the Code made on or before the Closing, (vii) the Company
or any of its Subsidiaries that is a &#8220;controlled foreign corporation&#8221; (within the meaning of Section&#160;957(a) of the Code)
having &#8220;subpart F income&#8221; (within the meaning of Section&#160;952(a) of the Code) accrued on or before the Closing, (viii)
&#8220;global intangible low-taxed income&#8221; of the Company or any of its Subsidiaries within the meaning of Section&#160;951A of
the Code (or any similar provision of state, local or non-U.S. Law) attributable to any taxable period (or portion thereof) on or before
the Closing or (ix) election made pursuant to Section&#160;965(h) of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
The unpaid Taxes of the Company or any of its Subsidiaries for the current fiscal year (i) did not, as of the most recent fiscal month
end, exceed the reserve for Tax liability (other than any reserve for deferred Taxes established to reflect timing differences between
book and Tax income) set forth on the financial statements and (ii) will not exceed that reserve as adjusted for the passage of time through
the Closing in accordance with the past custom and practice of the Company and its Subsidiaries in filing Tax Returns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
The Company is not aware of the existence of any fact, nor has the Company or any of its Subsidiaries taken or agreed to take any action,
that would reasonably be expected to prevent or impede the Merger from qualifying for the Merger Intended Tax Treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 478 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16
<span style="text-decoration: underline">Intellectual Property</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<span style="text-decoration: underline">Schedule&#160;5.16(a)</span> sets forth a true, accurate and complete list of all (i) issued
patents and pending patent applications (including provisional applications) including any application, registration, patent or serial
numbers, application or registration date, the applicable jurisdiction and status, (ii) trademark registrations and pending trademark
applications, including any application, registration, or serial numbers, application or registration date, the applicable jurisdiction
and status, (iii) registered copyrights and pending copyright applications, including any application or registration numbers, application
or registration date, the applicable jurisdiction and status, and (iv) internet domain name/weblinks, and (v) social media accounts, in
each case that are owned by the Company or any of its Subsidiaries (&#8220;<span style="text-decoration: underline">Scheduled Intellectual
Property</span>&#8221; and collectively, and together with other Intellectual Property owned by or purported to be owned by the Company
or any of its Subsidiaries, the &#8220;<span style="text-decoration: underline">Owned Intellectual Property</span>&#8221;). All of the
accounts, registrations, applications, and issuance within the Scheduled Intellectual Property are subsisting, in full force and effect,
and are, to the Knowledge of the Company, valid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Except for any licenses granted to Owned Intellectual Property, the Company exclusively owns or otherwise possesses sufficient and valid
rights to all right, title and interest in and to the Owned Intellectual Property free and clear of all Liens, other than Permitted Liens.
The Owned Intellectual Property that is licensed to a customer pursuant to a Contract is, to the Company&#8217;s Knowledge, valid, subsisting
and enforceable. (i) No Owned Intellectual Property is the subject of any current opposition, cancellation, or similar Proceeding before
any Governmental Authority other than Proceedings involving the examination of applications for registration of Intellectual Property
(e.g., patent prosecution Proceedings, trademark prosecution Proceedings, copyright prosecution Proceedings, and Uniform Domain-Name Dispute-Resolution
Policy Proceedings), (ii) neither the Company nor any of its Subsidiaries is subject to any injunction or other specific judicial, administrative
or other Order that restricts or impairs its ownership, registrability, enforceability, use or distribution of any Owned Intellectual
Property and (iii) neither the Company nor any of its Subsidiaries is subject to any current Proceeding that the Company reasonably expects
would materially and adversely affect the validity, use or enforceability of any Owned Intellectual Property. To the Knowledge of the
Company no Proceedings described in this <span style="text-decoration: underline">Section&#160;5.16(b)</span> have been threatened in
writing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
To the Knowledge of the Company, the Company or its Subsidiary, as applicable, owns all right, title and interest in and to, or has valid,
sufficient, subsisting and enforceable rights to use all Owned Intellectual Property material to its business as currently conducted.
The Company and each of its Subsidiaries is in compliance with all material contractual obligations in a Contract set forth on <span style="text-decoration: underline">Schedule&#160;5.25(a)(viii)
</span>and to the Knowledge of the Company is in compliance with all material contractual obligations in all applicable Contracts involving
open source software. The consummation of the Transactions will not, by itself, directly and immediately materially impair any rights
of the Company or any of its Subsidiaries to any Owned Intellectual Property or any licensed Intellectual Property. Following the Closing,
the Purchaser will have the right to exercise all of its rights under all Intellectual Property Contracts, to the same extent the Company
would have been able to had the Transactions not occurred and without being required to pay any additional amounts or consideration other
than fees, royalties or payments that the Company would otherwise be required to pay had the Transactions not occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 479 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
To the Knowledge of the Company, the conduct of the business of the Company, including its Subsidiaries, as is currently conducted or
conducted since inception, including any use of the Owned Intellectual Property as currently used by the Company or any of its Subsidiaries,
does not infringe, misappropriate, or violate any Intellectual Property or other proprietary right of any Person. There are no Proceedings
that are pending in which it is alleged that the Company or any of its Subsidiaries is infringing, misappropriating, or violating the
Intellectual Property of any Person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
As of the date of this Agreement, there are no pending Proceedings in which it is alleged that any Person is infringing, misappropriating
or violating rights of the Company or any of its Subsidiaries to Owned Intellectual Property. Except as would not have a Company Material
Adverse Effect, to the Knowledge of the Company, no Person is infringing, violating or misappropriating the rights of the Company or any
of its Subsidiaries in or to any Owned Intellectual Property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Each current and former officer, employee or contractor of the Company or any of its Subsidiaries who, in the regular course of such Person&#8217;s
employment or engagement with the Company or such Subsidiary, has created or contributed to the Owned Intellectual Property has executed
an assignment or similar agreement with the Company or such Subsidiary assigning to the Company or such Subsidiary all right, title, and
interest in and to such Owned Intellectual Property, except where failure to obtain such assignment would not reasonably be expected to
have a Company Material Adverse Effect. No Governmental Authority or academic institution has any right to, ownership of, or right or
royalties for, any Owned Intellectual Property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Each of the Company and each of its Subsidiaries has taken commercially reasonable steps to safeguard and maintain the secrecy and confidentiality
of, and their proprietary rights in and to, all non-public Owned Intellectual Property. To the Knowledge of the Company, no present or
former officer, director, employee, agent or independent contractor of or consultant to the Company or any of its Subsidiaries has misappropriated
any trade secrets or other confidential information of any other Person in the course of the performance of responsibilities to the Company
or Subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
The Company and its Subsidiaries have established and implemented, and, to the Knowledge of the Company, are operating in material compliance
with, policies, programs and procedures that are commercially reasonable and include administrative, technical and physical safeguards,
designed to protect the confidentiality and security of Sensitive Data in their possession, custody or control against unauthorized access,
use, modification, disclosure or other misuse. The Company and its Subsidiaries maintain security controls for all material information
technology systems owned by the Company or one of its Subsidiaries, including computer hardware, software, networks, information technology
systems, electronic data processing systems, telecommunications networks, network equipment, interfaces, platforms and peripherals, and
data or information contained therein or transmitted thereby, including any outsourced systems and processes (collectively, the &#8220;<span style="text-decoration: underline">Computer
Systems</span>&#8221;), that are designed to protect the Computer Systems against attacks (including virus, worm and denial-of-service
attacks), unauthorized activities or access of any employee, hackers or any other person, and to otherwise maintain and protect the integrity,
operation and security of such Computer Systems and all information (including Sensitive Data) stored thereon or transmitted thereby.
For the past twelve (12) months, the Computer Systems have not suffered any material failures, breakdowns, continued substandard performance,
unauthorized intrusions, or other adverse events affecting any such Computer Systems that, in each case, have caused any substantial disruption
of or interruption in or to the use of such Computer Systems, except as would not, individually or in the aggregate, have a Company Material
Adverse Effect. Except as would not have a Company Material Adverse Effect, the Company has remedied in all material respects any material
privacy or data security issues identified in any privacy or data security audits of its businesses (including third-party audits of the
Computer Systems). To the Knowledge of the Company, the Computer Systems are sufficient in all material respects for the current operations
of the Company and its Subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 480 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Company and its Subsidiaries have in place policies (including a privacy policy), rules and procedures (collectively, the &#8220;<span style="text-decoration: underline">Privacy
Policy</span>&#8221;) regarding the Company&#8217;s and its Subsidiaries&#8217; collection, use, processing, disclosure, disposal, dissemination,
storage and protection of customers&#8217; personal data. To the Knowledge of the Company, the Company has materially complied with the
Privacy Policy and applicable Laws regarding the collection, use, storage and transfer of personal data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
Except as would not, individually or in the aggregate, have a Company Material Adverse Effect, no Proceedings are pending or, to the Knowledge
of the Company, threatened in writing against the Company or its Subsidiaries relating to the collection, use, dissemination, storage
and protection of personal data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
None of the Software within the Owned Intellectual Property is currently or was in the past distributed or used by the Company or any
Subsidiary thereof with any open source software in a manner that requires any such Software within the Owned Intellectual Property to
be dedicated to the public domain, disclosed, distributed in source code form, made available at no charge or reverse engineered. The
Company is not and has never been a member of, a contributor to, or affiliated with, any industry standards or open source organization,
body, working group, project, or similar organization (a &#8220;<span style="text-decoration: underline">Standards Organization</span>&#8221;),
and neither the Company, nor any Owned Intellectual Property, is subject to any licensing, assignment, contribution, disclosure, or other
requirements or restrictions of any Standards Organization. None of the Software with the Owned Intellectual Property is currently or
was in the past distributed or used by the Company or any Subsidiary thereof in a manner that requires any such Software within the Owned
Intellectual Property to be dedicated to a Standard Organization or offered to members of the Standard Organization at a reduced licensing
rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17
<span style="text-decoration: underline">Insurance</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<span style="text-decoration: underline">Schedule&#160;5.17</span> sets forth, as of the date hereof, a true, complete and correct list
of all fidelity bonds, letters of credit, cash collateral, performance bonds and bid bonds issued to or in respect of the Company and
its Subsidiaries (collectively, the &#8220;<span style="text-decoration: underline">Bonds</span>&#8221;) and all policies of title insurance,
liability and casualty insurance, property insurance, auto insurance, business interruption insurance, tenant&#8217;s insurance, workers&#8217;
compensation, life insurance, disability insurance, excess or umbrella insurance and any other type of insurance insuring the properties,
Assets, employees or operations of the Company and its Subsidiaries (collectively, the &#8220;<span style="text-decoration: underline">Policies</span>&#8221;),
including in each case the applicable coverage limits, deductibles (if applicable) and the policy expiration dates. All Policies and Bonds
are in amounts and types that the Company reasonably believes to be customary for businesses of similar size and risk profile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 481 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
All Policies and Bonds are in full force and effect and, to the Knowledge of the Company, will not be terminated, cancelled or materially
adversely affected by reason of the consummation of the Transactions. None of the Company or any of its Subsidiaries is in default under
any provisions of the Policies or Bonds; there is no claim by the Company or any of its Subsidiaries or any other Person pending under
any of the Policies or Bonds as to which coverage has been materially disputed in writing by the underwriters or issuers of such Policies
or Bonds; and none of the Company or any of its Subsidiaries has received any written notice from or on behalf of any insurance carrier
or other issuer issuing such Policies or Bonds that (i) insurance rates or other annual premium or fee in effect as of the date hereof
will hereafter be substantially increased (except to the extent that insurance rates or other fees may be increased for all similarly
situated risks) or (ii) there will be a non-renewal, cancellation or increase in a deductible (or an increase in premiums in order to
maintain an existing deductible) of any of the Policies or Bonds in effect as of the date hereof, except, in each case, as would not reasonably
be expected to have a Company Material Adverse Effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18
<span style="text-decoration: underline">Litigation</span>. As of the date hereof, there is no Proceeding pending or, to the Knowledge
of the Company, threatened in writing by or against the Company or the Company&#8217;s Subsidiaries or against any officer, director,
shareholder, employee or agent of the Company or any of the Company&#8217;s Subsidiaries in their capacity as such or relating to their
employment services or relationship with the Company or any of the Company&#8217;s Subsidiaries, and neither the Company nor any of its
Subsidiaries is bound by any Order. As of the date hereof, the Company does not have any Proceedings pending against any Governmental
Authority or other Person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19
<span style="text-decoration: underline">Bank Accounts; Powers of Attorney</span>. <span style="text-decoration: underline">Schedule&#160;5.19</span>
sets forth, as of the date hereof, a true, complete and correct list of each bank, trust company, savings institution, brokerage firm,
mutual fund or other financial institution with which the Company and each of the Company&#8217;s Subsidiaries has an account or safe
deposit box, including the names and identification of all Persons authorized to draw thereon or have access thereto; <span style="text-decoration: underline">provided</span>,
<span style="text-decoration: underline">however</span>, that the Company makes no representation regarding the continued authority or
status of any such Persons following the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20
<span style="text-decoration: underline">Material Partners</span>. <span style="text-decoration: underline">Schedule&#160;5.20</span>
sets forth the ten (10) largest customers of the Company and its Subsidiaries by revenue (each a &#8220;<span style="text-decoration: underline">Material
Customer</span>&#8221;) and the three (3) largest vendors (including suppliers and manufacturers) of the Company and its Subsidiaries
by expense (each a &#8220;<span style="text-decoration: underline">Material Supplier</span>&#8221;, and together with the Materials Customers,
the &#8220;<span style="text-decoration: underline">Material Partners</span>&#8221;), in each case for the 12-month period ended December&#160;31,
2024. No such Material Partner has terminated or materially adversely changed its relationship with the Company nor has the Company received
written notification that any such Material Partner intends to terminate or materially and adversely change such relationship or that
such Material Partner is not solvent. There are no currently pending or, to the Knowledge of the Company, written threatened disputes
between the Company and any of its Material Partners that (a) could reasonably be expected to materially and adversely affect the relationship
between the Company and any Material Partner or (b) could reasonably be expected to materially and adversely affect the Company. For purposes
of clarity, routine contract negotiations, Ordinary Course service issues and immaterial disputes shall not be deemed to constitute &#8220;disputes&#8221;
under this Section&#160;5.20. To the Knowledge of the Company, there is no basis for any Material Partner to assert a claim against the
Company or any of its Subsidiaries based upon the Company entering into of this Agreement or the other Transaction Documents to which
it is a party or the consummation of the Transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 482 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21
<span style="text-decoration: underline">Labor Matters</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Since inception, the Company and each of its Subsidiaries has, in all material respects, complied with all applicable Laws relating to
the hiring of employees and the employment of labor. Since inception, the Company and each of its Subsidiaries has met all material requirements
required by Law or regulation relating to the employment of foreign citizens (if any), and neither the Company nor any of its Subsidiaries
currently employs, nor has it ever employed, any Person who was not permitted to work in the jurisdiction in which such Person was employed.
Since inception, the Company and each of its Subsidiaries have complied with all applicable Laws in all material respects that could require
overtime to be paid to any current or former employee of the Company and its Subsidiaries, and no employee has ever brought or, to the
Knowledge of the Company, threatened in writing to bring a claim for unpaid compensation or employee benefits, including overtime amounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Neither the Company nor any of its Subsidiaries is delinquent in any material respects in payments to any of its current or former employees
for any wages, salaries, commissions, bonuses or other direct compensation for any services performed by them or amounts required to be
reimbursed to such employees or in payments owed upon any termination of the employment of any such employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
There is no unfair labor practice complaint pending or, to the Knowledge of the Company, threatened in writing against or involving the
Company or any of its Subsidiaries pending before the National Labor Relations Board or any other Governmental Authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
There is no labor strike, material dispute, slowdown or stoppage pending or, to the Knowledge of the Company, threatened in writing against
or involving the Company or any of its Subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
No labor union represents any employees of the Company or any of its Subsidiaries with regard to their employment with the Company or
any of its Subsidiaries. Since inception, to the Knowledge of the Company, no labor union has taken any action with respect to organizing
the employees of the Company or any of its Subsidiaries regarding their employment with the Company or any of its Subsidiaries. Neither
the Company nor any of its Subsidiaries is a party to or bound by any collective bargaining or similar agreement or union contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
To the Knowledge of the Company, (i) no Key Employee or officer of the Company or any of its Subsidiaries is a party to or is bound by
any confidentiality agreement, non-competition agreement or other contract (with any Person) that would materially and adversely interfere
with (A) the performance by such officer or Key Employee of any of his or her duties or responsibilities as an officer or employee of
the Company or any of its Subsidiaries or (B) the Company&#8217;s business or operations; and (ii) no Key Employee or officer of the Company
or any of its Subsidiaries, or any group of officers of the Company, has given written notice of their interest to terminate their employment
with the Company, nor does the Company have any intention to terminate the employment of any of the foregoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 483 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Except as set forth on <span style="text-decoration: underline">Schedule&#160;5.21(g)</span>, the employment of each of the Key Employees
is terminable at will without any penalty or severance obligation of any kind on the part of the employer. All material sums due for employee
compensation and benefits and all vacation time owing to any employees of the Company or any of its Subsidiaries have been duly and adequately
accrued on the accounting records of the Company and its Subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Since inception, with regard to any individual who performs or performed services for the Company and who is not treated as an employee
for Tax purposes by the Company and each of its Subsidiaries, to the Knowledge of the Company, (i) the Company and its Subsidiaries have
complied in all material respects with applicable Laws concerning independent contractors, including for Tax withholding purposes or Benefit
Arrangement purposes and (ii) neither the Company nor any Subsidiary has any Liability by reason of any individual who performs or performed
services for the Company or any Subsidiary, in any capacity, being improperly excluded from participating in any Benefit Arrangement.
Since inception, to the Knowledge of the Company, each of the employees of the Company and the Subsidiaries has been properly classified
by the Company and the Subsidiaries as &#8220;exempt&#8221; or &#8220;non-exempt&#8221; under applicable Law except as would not be material
and adverse to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Since inception, neither the Company nor any of its Subsidiaries has entered into any settlement agreement related to allegations of sexual
harassment or sexual misconduct by any director, officer or employee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
Neither the execution, delivery and performance of this Agreement or the other Transaction Documents to which the Company is or will be
a party nor the consummation of the Transactions will (either alone or in combination with another event) result in any payment (whether
in cash or property or the vesting of property) to any &#8220;disqualified individual&#8221; (as such term is defined in Treasury Regulations
Section&#160;1.280G-1) that could reasonably be construed, individually or in combination with any other such payment, to constitute an
&#8220;excess parachute payment&#8221; (as defined in Section&#160;280G(b)(1) of the Code) on account of the Transactions. No person is
entitled to receive any additional payment (including any tax gross-up or other payment) from the Company any of its Subsidiaries as a
result of the imposition of the excise taxes required by Section&#160;4999 of the Code or any taxes required by Section&#160;409A of the
Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.22
<span style="text-decoration: underline">Employee Benefits</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<span style="text-decoration: underline">Schedule&#160;5.22(a)</span> sets forth an accurate and complete list of all &#8220;<span style="text-decoration: underline">Benefit
Arrangements</span>&#8221;. For purposes of this Agreement, &#8220;<span style="text-decoration: underline">Benefit Arrangements</span>&#8221;
means all &#8220;employee benefit plans&#8221; (as defined in Section&#160;3(3) of the Employee Retirement Income Security Act of 1974
(&#8220;<span style="text-decoration: underline">ERISA</span>&#8221;)), whether or not subject to ERISA, and any other bonus, profit sharing,
compensation, pension, severance, savings, deferred compensation, fringe benefit, insurance, welfare, post-retirement health or welfare
benefit, health, life, stock option, stock purchase, restricted stock, company car, scholarship, relocation, disability, accident, sick
pay, sick leave, accrued leave, vacation, holiday, termination, unemployment, individual employment, consulting, executive compensation,
incentive, commission, payroll practices, retention, change in control, non-competition, or other plan, agreement, policy, trust fund,
or arrangement (whether written or unwritten, insured or self-insured) maintained, sponsored, or contributed to (or with respect to which
any obligation to contribute has been undertaken) by the Company or any of its Subsidiaries on behalf of any employee, officer, director,
consultant or other service provider of the Company or any Subsidiary or under which the Company or any of its subsidiaries which has
any material Liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 484 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
With respect to each Benefit Arrangement, the Company has provided to Parent a true and complete copy, to the extent applicable, of (i)
each writing constituting a part of such Benefit Arrangement and all amendments thereto, (ii) the most recent annual report and accompanying
schedule, (iii) the current summary plan description and any material modifications thereto, (iv) the most recent annual financial and
actuarial reports, (v) the most recent determination or opinion letter received by the Company or any Subsidiary from the IRS (if applicable)
regarding the tax-qualified status of such Benefit Arrangement and (vi)&#160;the most recent written results of all required compliance
testing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
With respect to each Benefit Arrangement, (i) it has been established, maintained and administered in all material respects in accordance
with its express terms and with the requirements of applicable Law; (ii) there are no pending or, to the Knowledge of the Company, written
threatened actions, claims or lawsuits against or relating to the Benefit Arrangement or, to the Knowledge of the Company, against any
fiduciary of the Benefit Arrangement with respect to the operation of such arrangements (other than routine benefits claims); (iii) no
such Benefit Arrangement is under audit or investigation by any Governmental Authority or regulatory authority; and (iv) all payments
required to be made by the Company or any of its subsidiaries under any Benefit Arrangement, any contract, or by Law (including all contributions
(including all employer contributions and employee salary reduction contributions), insurance premiums or intercompany charges) since
inception have been timely made or properly accrued and reflected in the most recent consolidated balance sheet prior to the date hereof,
in accordance with the provisions of each of the Benefit Arrangement, applicable Law and GAAP, in each case, in all material respects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Neither the execution, delivery and performance of this Agreement or the other Transaction Documents to which the Company is or will be
a party nor the consummation of the Transactions will (i) result in any severance or other payment becoming due, or increase the amount
of any compensation or benefits due, to any current or former employee, officer, director, consultant or other service provider of the
Company and its Subsidiaries; (ii) limit or restrict the right of the Company or any Subsidiary to merge, amend or terminate any Benefit
Arrangement; or (iii) result in the acceleration of the time of payment or vesting, or result in any payment or funding (through a grantor
trust or otherwise) of any such compensation or benefits under, or increase the amount of compensation or benefits due under, any Benefit
Arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.23
<span style="text-decoration: underline">Environmental and Safety</span>. Since inception, the Company and its Subsidiaries have complied
in all material respects and are in compliance in all material respects with all, and have not received any written notice alleging or
otherwise relating to any violation of any, Environmental and Safety Requirements, and there are no Proceedings pending or, to the Knowledge
of the Company, threatened in writing against the Company or any of its Subsidiaries alleging any failure to so comply. Since inception,
neither the Company nor any of its Subsidiaries has received any written notice or report with respect to it or its facilities regarding
any (a) actual or alleged violation of Environmental and Safety Requirements, or (b) actual or potential Liability arising under Environmental
and Safety Requirements, including any investigatory, remedial or corrective obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 485 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.24
<span style="text-decoration: underline">Related Party Transactions</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<span style="text-decoration: underline">Schedule&#160;5.24(a)</span> sets forth a true, complete and correct list of the following (each
such arrangement of the type required to be set forth thereon, whether or not actually set forth thereon, an &#8220;<span style="text-decoration: underline">Affiliate
Transaction</span>&#8221;): (i) each Contract entered into between the Company or any of its Subsidiaries, on the one hand, and any current
or former Affiliate of the Company or any of its Subsidiaries on the other hand; and (ii) all Indebtedness (for monies actually borrowed
or lent) owed by any current or former Affiliate to the Company or any of its Subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
None of the Company Equityholders own or have any rights in or to any of the material Assets, properties or rights used by the Company
or any of its Subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.25
<span style="text-decoration: underline">Material Contracts</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<span style="text-decoration: underline">Schedule&#160;5.25</span> sets forth a true, complete and correct list, as of the date hereof,
of each of the following Contracts (other than Benefit Arrangements) to which the Company or any of its Subsidiaries is a party (each
such Contract of the type required to be set forth thereon, whether or not actually set forth thereof, a &#8220;<span style="text-decoration: underline">Material
Contract</span>&#8221;):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Contracts that require annual payments or expenses by, or annual payments or income to, the Company of $100,000 or more individually (other
than standard purchase and sale orders entered into in the Ordinary Course);</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Sales, advertising, agency, lobbying, broker, sales promotion, market research, marketing or similar contracts and agreements, in each
case requiring the payment of any commissions by the Company in excess of $100,000 individually on an annual basis;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
Collective bargaining agreement or other Contract with any labor organization, union or association or Contract with a professional employer
organization, or other Contract providing for co-employment of employees of the Company or any of its Subsidiaries, or Contract with a
professional employer organization or co-employer organization or other Contract provision for co-employment of employees of the Company
or its Subsidiaries;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Contracts that provide for a payment or benefit, accelerated vesting, upon the execution of this Agreement, the other Transaction Documents
to which the Company is a party or the Closing in connection with any of the Transactions;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
Contract relating to Indebtedness, including the mortgaging, pledging or otherwise placing a Lien (other than Permitted Liens) on any
Asset or group of Assets of the Company or any of its Subsidiaries and issuance of any Indebtedness by the Company or its Subsidiaries
in excess of $100,000 individually;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 486 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
Real Property Leases and Contracts under which the Company or any of its Subsidiaries is the lessee of or the holder or operator of any
material personal property owned by any other Person;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
Contracts under which the Company or any of its Subsidiaries is the lessor of or permits any third Person to hold or operate any Owned
Real Property, Leased Real Property or material personal property owned or controlled by the Company or any of its Subsidiaries;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
Contracts (i) under which the Company or any of its Subsidiaries is currently: (A) licensing or otherwise providing the right to use to
any third party of any Owned Intellectual Property or (B) licensing or otherwise receiving the right to use from any third party any material
Intellectual Property, with the exception of (1) non-exclusive licenses and subscriptions to commercially available software or technology
used for internal use by the Company, with a dollar value individually not in excess of $100,000 individually, (2) any Contract related
to open source software and (3) any Contract under which the Company licenses any of its Intellectual Property in the Ordinary Course;
and (ii) under which the Company or any of its Subsidiaries has entered into an agreement not to assert or sue with respect to any Intellectual
Property;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)
Contracts with respect to Affiliate Transactions;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
Contracts involving any Governmental Authority other than Contracts for the sale of the Company&#8217;s products in the Ordinary Course;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)
Contracts relating to secrecy, confidentiality and nondisclosure agreements substantially limiting the freedom of the Company to compete
in any line of business or with any Person or in any geographic area;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)
Contracts relating to patents, trademarks, service marks, trade names, brands, copyrights, trade secrets and other material Intellectual
Property Rights of the Company;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)
Contracts providing for guarantees, indemnification arrangements and other hold harmless arrangements made or provided by the Company,
including all ongoing agreements for repair, warranty, maintenance, service, indemnification or similar obligations;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)
Contracts relating to the voting or control of the equity interests of the Company or the election of directors of the Company (other
than the Organizational Documents of the Company);</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)
Contracts that can be terminated, or the provisions of which are altered, as a result of the consummation of the transactions contemplated
by this Agreement or any of the Transaction Documents;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)
Contracts relating to material property or assets (whether real or personal, tangible or intangible) in which the Company holds a leasehold
interest; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 487 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvii)
Contracts related to joint ventures, partnerships, relationships for joint marketing (other than co-marketed items) or joint development
with another Person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Each Material Contract (i) is valid, binding and enforceable against the Company or its Subsidiary, as the case may be, except that such
enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws now or hereafter in effect relating
to creditors&#8217; rights and general principles of equity, and (ii) is in full force and effect on the date hereof. The Company or its
Subsidiary, as the case may be, has performed all obligations, including the making of all payments, required to be performed by it under,
and is not in default or breach of in respect of, any Material Contract, and no event has occurred which, with due notice or lapse of
time or both, would constitute such a default. There has been made available to Parent a true, complete and correct copy of each of the
Material Contracts listed on <span style="text-decoration: underline">Schedule&#160;5.25(a)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.26
<span style="text-decoration: underline">SEC Matters</span>. The information relating to the Company and the Company&#8217;s Subsidiaries
supplied by the Company expressly for inclusion in the Proxy Statement will not as of the date on which the Proxy Statement (or any amendment
or supplement thereto) is first distributed to Parent Shareholders or at the time of Parent Shareholders&#8217; Meeting contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they are made, not misleading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.27
<span style="text-decoration: underline">Brokers and Other Advisors</span>. No broker, investment banker, financial advisor or other Person
is entitled to any broker&#8217;s, finder&#8217;s or other similar fee or commission in connection with the Transactions based upon arrangements
made by or on behalf of Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.28
<span style="text-decoration: underline">Disclaimer of Other Representations and Warranties</span>. Notwithstanding the delivery or disclosure
to Parent, Purchaser and/or Merger Sub or any of their respective Representatives of any documentation or other information (including
any financial projections or other supplemental data), except for the representations and warranties contained in this <span style="text-decoration: underline">ARTICLE
V</span>, none of the Company, the Company&#8217;s Subsidiaries or any other Person makes any express or implied representation or warranty,
either written or oral, with respect to the Company or the Company&#8217;s Subsidiaries, and the Company and the Company&#8217;s Subsidiaries
expressly disclaim any other representations or warranties, whether made by the Company, any Subsidiary of the Company or any other Person
(including their respective Affiliates, officers, directors, managers, employees, agents, Representatives or advisors).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
VI </b><br/><b>REPRESENTATIONS AND WARRANTIES OF PARENT, PURCHASER AND MERGER SUB</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth in the Parent Disclosure Schedules (which qualify (a) the correspondingly numbered representation, warranty or covenant specified
therein and (b) such other representations, warranties or covenants where its relevance as an exception to (or disclosure for purposes
of) such other representation, warranty or covenant is reasonably apparent on its face or cross-referenced), Parent, Purchaser and Merger
Sub, jointly and severally, represent and warrant to the Company that each of the following representations and warranties are true, correct
and complete as of the date of this Agreement and as of the Closing Date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 488 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
<span style="text-decoration: underline">Organization, Qualification and Standing</span>. Each of Parent, Purchaser and Merger Sub is
duly incorporated, validly existing and in good standing under the laws of the jurisdiction of its incorporation, has all requisite power
and authority to own, lease and operate its Assets and to conduct its business as presently conducted, and is duly registered, qualified
and authorized to transact business and in good standing in every jurisdiction in which the conduct of its business or the nature of its
properties requires such registration qualification or authorization. The Organizational Documents of each of Parent, Purchaser and Merger
Sub, true, complete and correct copies of which have been made available to the Company, are in full force and effect. Neither Parent,
Purchaser nor Merger Sub is in violation of its Organizational Documents and neither Parent, Purchaser nor Merger Sub has taken any action
in violation with any such Organizational Documents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
<span style="text-decoration: underline">Authority; Enforceability</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Each of Parent, Purchaser and Merger Sub has all necessary corporate power and authority to execute and deliver this Agreement and the
other Transaction Documents to which it is or will be a party and to perform their respective obligations hereunder and to consummate
the Transactions. The execution, delivery and performance by Parent, Purchaser and Merger Sub of this Agreement and the other Transaction
Documents to which it is or will be a party and the consummation by Parent, Purchaser and Merger Sub of the Transactions have been duly
authorized and approved by their respective boards of directors and, subject to obtaining the Parent Required Vote, the approval of the
shareholders of Purchaser and the approval of the shareholders of Merger Sub, no other corporate action on the part of Parent, Purchaser
or Merger Sub is necessary to authorize the execution, delivery and performance by Parent, Purchaser or Merger Sub of this Agreement,
the other Transaction Documents to which either is a party, and the consummation by them of the Transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
This Agreement and the other Transaction Documents to which it is or will be a party have been duly executed and delivered by Parent,
Purchaser or Merger Sub and, assuming due authorization, execution and delivery hereof by the Company, constitute legal, valid and binding
obligations of Parent, Purchaser or Merger Sub, enforceable against each in accordance with their terms, subject to the effect of any
applicable bankruptcy, reorganization, insolvency, moratorium, or similar Law affecting creditors&#8217; rights generally and subject,
as to enforceability, to the effect of general principles of equity (regardless of whether such enforceability is considered in a proceeding
in equity or at Law).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
<span style="text-decoration: underline">Non-Contravention</span>. Except as set forth on <span style="text-decoration: underline">Schedule&#160;6.3</span>,
the execution, delivery and performance of this Agreement and the other Transaction Documents to which it is or will be a party by Parent,
Purchaser or Merger Sub, the consummation by Parent, Purchaser or Merger Sub of the Transactions, or compliance by Parent, Purchaser or
Merger Sub with any of the terms or provisions hereof and thereof, do not and will not with or without notice or lapse of time or both
(a) conflict with or violate any provision of the Organizational Documents of Parent, Purchaser or Merger Sub, (b) violate any Law or
Order applicable to Parent, Purchaser or Merger Sub or any of their respective properties or Assets, or (c) violate, conflict with, result
in the loss of any benefit under, constitute a default (or an event which, with notice or lapse of time, or both, would constitute a default)
under, result in the termination of or a right of termination or cancellation under, accelerate the performance required by, or result
in the creation of any Lien upon any of the respective properties or assets of, Parent, Purchaser or Merger Sub under, any of the terms,
conditions or provisions of any Contract to which Parent, Purchaser or Merger Sub is a party or by which they or any of their respective
properties or Assets may be bound or affected, except, in the case of clause (c), for such violations, conflicts, defaults, terminations,
cancellations, accelerations or Liens as, individually or in the aggregate, would not reasonably be expected to have a Material Adverse
Effect or prevent or materially impair the ability of the Parties to consummate the Transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 489 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4
<span style="text-decoration: underline">Brokers and Other Advisors</span>. There is no investment banker, broker, finder or other intermediary
which has been retained by or is authorized to act on behalf of Parent or its Affiliates who might be entitled to any fee or commission
from Parent or any of its Affiliates upon consummation of the Transactions contemplated by this Agreement or any of the Transaction Documents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5
<span style="text-decoration: underline">Capitalization</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The authorized share capital of Parent consists of (i) 500,000,000 Class A Parent Ordinary Shares, of which 29,200,000 Class A Parent
Ordinary Shares are issued and outstanding as of the date hereof, (ii) 50,000,000 Class B Parent Ordinary Shares, of which 12,000,000
Class B Parent Ordinary Shares are issued and outstanding as of the date hereof, and (iii) 5,000,000 Parent Preferred Shares, none of
which are issued and outstanding as of the date hereof. As of the date hereof, there are 14,100,000 Parent Warrants issued and outstanding,
and 14,100,000 Parent Ordinary Shares are reserved for issuance upon the exercise of Parent Warrants. All outstanding Parent Ordinary
Shares are duly authorized, validly issued, fully paid and nonassessable and not subject to or issued in violation of any purchase option,
right of first refusal, preemptive right, subscription right or any similar right under any provision of the BVI BCA, Parent&#8217;s Organizational
Documents or any contract to which Parent is a party or by which Parent is bound. Other than as set forth in Parent&#8217;s Organizational
Documents, there are no outstanding contractual obligations of Parent to repurchase, redeem or otherwise acquire any Parent Shares or
any capital equity of Parent. Other than as set forth in the Parent&#8217;s Organizational Documents, there are no outstanding or authorized
options, warrants, convertible securities or other rights, agreements, arrangements or commitments of any character relating to the share
capital of Parent or obligating Parent to issue or sell any shares of, or any other interest in, Parent. Parent does not have outstanding
or authorized any share appreciation, phantom shares, profit participation or similar rights. Except as set forth in <span style="text-decoration: underline">Schedule&#160;6.5</span>,
there are no voting trusts, shareholder agreements, proxies or other agreements or understandings in effect with respect to the voting
or transfer of any of Parent Shares. There are no outstanding contractual obligations of Parent to provide funds to, or make any investment
(in the form of a loan, capital contribution or otherwise) in, any other Person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The authorized share capital of Purchaser consists of 555,000,000 Purchaser Class A Shares and 50,000,000 Purchaser Class B Shares, par
value $0.0001 per share, of which one (1) Purchaser Class A Share is issued and outstanding as of the date hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Merger Sub is authorized to issue 100 Merger Sub Shares, with no par value each share, of which one (1) Merger Sub Share is issued and
outstanding as of the date hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 490 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Other than Purchaser and Merger Sub, Parent does not directly or indirectly own, or hold any rights to acquire, any capital stock or any
other securities or interests in any other Person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6
<span style="text-decoration: underline">Issuance of Shares</span>. The Merger Consideration, when issued in accordance with this Agreement,
will be duly authorized and validly issued, fully paid and non-assessable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7
<span style="text-decoration: underline">Consents; Required Approvals</span>. Except as set forth on Schedule&#160;6.7, no notices to,
designations, declarations or filings with, or authorizations, consents or approvals of any Governmental Authority are necessary for the
execution, delivery or performance of this Agreement, the other Transaction Documents to which either is a party or the consummation by
Parent, Purchaser, or Merger Sub of the Transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8
<span style="text-decoration: underline">Trust Account</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
As of the date hereof, Parent has approximately $281,963,221 in the trust account established by Parent for the benefit of Parent Public
Shareholders (the &#8220;<span style="text-decoration: underline">Trust Account</span>&#8221;), and such monies are invested in &#8220;government
securities&#8221; (as such term is defined in the Investment Company Act of 1940) and held in trust by Odyssey pursuant to the Investment
Management Trust Agreement, dated as of July&#160;30, 2025, between Parent and the Odyssey, as amended from time to time (as so amended,
the &#8220;<span style="text-decoration: underline">Trust Agreement</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Trust Agreement is valid and in full force and effect and enforceable in accordance with its terms. Parent has complied in all respects
with the terms of the Trust Agreement and is not in breach thereof or default thereunder and there does not exist under the Trust Agreement
any event which, with the giving of notice or the lapse of time, would constitute such a breach or default by Parent or, to the Knowledge
of Parent, by Odyssey.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
There are no separate agreements, side letters or other agreements or understandings (whether written or unwritten, express or implied)
that would cause the description of the Trust Agreement in Parent SEC Documents to be inaccurate in any material respect or that would
entitle any Person to any portion of the proceeds in the Trust Account. Prior to the Closing, none of the funds held in the Trust Account
may be released except (i)&#160;to pay income and other Tax obligations from any interest income earned in the Trust Account or (ii)&#160;to
redeem Class A Parent Ordinary Shares in accordance with the provisions of Parent&#8217;s Organizational Documents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
There are no claims or proceedings pending or, to the Knowledge of Parent, threatened with respect to the Trust Account. As of the date
hereof, assuming the accuracy of the representations and warranties of the Company contained herein and the compliance by the Company
with its obligations which are relevant hereunder, neither Parent, Purchaser nor Merger Sub have any reason to believe that any of the
conditions to the use of funds in the Trust Account will not be satisfied or funds available in the Trust Account will not be available
to Parent and Merger Sub on the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9
<span style="text-decoration: underline">Employees</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Other than the individuals set forth on Schedule&#160;6.9(a), Parent and Merger Sub have never employed any employees or retained any
contractors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 491 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Neither Parent nor Merger Sub has any unsatisfied Liability with respect to any officer or director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Parent, Purchaser and Merger Sub have never, and do not currently, maintain, sponsor, or contribute to or have any Liability pursuant
to any plan, program or arrangement that would fall under the definition of &#8220;Benefit Arrangement&#8221; determined as if such definition
referenced Parent instead of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.10
<span style="text-decoration: underline">Tax Matters</span>. For purposes of this <span style="text-decoration: underline">Section&#160;6.10</span>,
any reference to &#8220;Parent&#8221; shall also include Purchaser and Merger Sub.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Parent has filed all Tax Returns, if required by applicable Law to be filed by Parent, all such Tax Returns were true, complete and correct
in all respects, and all Taxes (whether or not shown on any Tax Returns) due and owing by Parent have been paid other than Taxes being
contested in good faith and for which adequate reserves have been established.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
There is no Proceeding, audit or claim now in progress or, to the Parent&#8217;s Knowledge, threatened against Parent in respect of any
Tax, nor has any Proceeding for additional Tax been asserted in writing by any Tax authority that has not been resolved or settled in
full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
No written claim has been made by any Tax authority in a jurisdiction where Parent has not filed a Tax Return that it is or may be subject
to Tax by such jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Parent is not a party to any Tax sharing agreement, Tax indemnification agreement, Tax allocation agreement or similar agreement (other
than Contracts entered into in the Ordinary Course and not relating primarily to Taxes).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Parent has withheld and paid all Taxes required to be withheld in connection with any amounts paid or owing to any employee, creditor,
independent contractor or other third party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
There is no outstanding request for any extension of time within which to pay any Taxes or file any Tax Returns, and there has been no
waiver or extension of any applicable statute of limitations for the assessment or collection of any Taxes of Parent that will remain
outstanding as of the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Parent has not distributed the stock of another Person, or had its shares distributed by another Person, in a transaction that was purported
or intended to be governed in whole or in part by Section&#160;355 or Section&#160;361 of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
There are no Liens for Taxes upon any Assets of Parent, except for Liens for Taxes not yet due and delinquent or being contested in good
faith by appropriate proceedings and for which appropriate and adequate reserves have been created in the applicable financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Parent has not been a party to or bound by any closing agreement, private letter rulings, technical advice memoranda, offer in compromise,
or any similar agreement with any Tax authority in respect of which Parent could have any Tax Liability after the Closing. Parent does
not have any request for a ruling in respect of Taxes pending between Parent and any Tax authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 492 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
Parent (i) has not been a member of an affiliated group filing a consolidated U.S. federal income Tax Return or other comparable group
for state, local or foreign Tax purposes and (ii) has no Liability for the Taxes of any Person (other than Parent) under Treasury Regulations
Section&#160;1.1502-6 (or any similar provision of state, local, or foreign Law), as a transferee or successor, by Contract (other than
Contracts entered into in the Ordinary Course and not relating primarily to Taxes), or otherwise by Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
Parent has not participated in a &#8220;listed transaction&#8221; required to be disclosed pursuant to Treasury Regulations Section&#160;1.6011-4(b).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
Parent will not be required to include any item of income in, or exclude any item of deduction from, taxable income for any Tax period
(or portion thereof) ending after the Closing as a result of (i) any use of an improper or change in method of accounting for any Tax
period that occurred on or before Closing, (ii) any &#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or
any comparable or similar provisions of applicable Law) executed on or before Closing, (iii) any installment sale or open transaction
disposition made on or before the Closing, (iv) any deferred intercompany gain or any excess loss account described in Treasury Regulations
under Section&#160;1502 of the Code (or any predecessor provision or any similar provision of state, local or foreign Law), (v) prepaid
amount received or deferred revenue accrued on or before the Closing outside the Ordinary Course, or (vi) an election under Section&#160;108(i)
of the Code made on or before the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
The unpaid Taxes of the Parent for the current fiscal year (i) did not, as of the most recent fiscal month end, exceed the reserve for
Tax liability (other than any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth
on the financial statements and (ii) will not exceed that reserve as adjusted for the passage of time through the Closing in accordance
with the past custom and practice of the Parent in filing Tax Returns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
Parent is not aware of the existence of any fact, nor has taken or agreed to take any action, that would reasonably be expected to prevent
or impede the Reincorporation from qualifying for the Reincorporation Intended Tax Treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.11
<span style="text-decoration: underline">Listing</span>. Parent Units, Class A Parent Ordinary Shares and Parent Warrants are listed on
the Nasdaq Global Market, with trading tickers BCARU, BCAR, and BCARW, respectively. There is no Proceeding pending or, to the Knowledge
of Parent, threatened against Parent by Nasdaq or the SEC with respect to any intention by such entity to prohibit, suspend or terminate
the listing of Parent Units, Class A Parent Ordinary Shares and Parent Warrants on the Nasdaq Global Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.12
<span style="text-decoration: underline">Reporting Company</span>. Parent is a publicly held company subject to reporting obligations
pursuant to Section 13 of the Exchange Act, and the Class A Parent Ordinary Shares, Parent Units and Parent Warrants are registered pursuant
to Section&#160;12(b) of the Exchange Act. There is no Proceeding pending or, to Parent&#8217;s Knowledge, threatened in writing against
Parent by the SEC or any securities exchange with respect to the deregistration of the Parent Units, Class A Parent Ordinary Shares or
Parent Warrants under the Exchange Act. Parent has taken no action in an attempt to terminate the registration of Parent Units, Class
A Parent Ordinary Shares and Parent Warrants under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 493 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.13
<span style="text-decoration: underline">Undisclosed Liabilities</span>. Parent has no Liabilities (absolute, accrued, contingent or otherwise)
of a nature required to be disclosed on a balance sheet or in the related notes to Parent Financial Statements that are, individually
or in the aggregate, material to the business, results of operations or financial condition of Parent, except (a) Liabilities provided
for or otherwise disclosed in the balance sheet included in the most recent Parent Financial Statements or in the notes to the most recent
Parent Financial Statements, (b) Liabilities arising in the ordinary course of Parent&#8217;s business since the date of the most recent
Parent Financial Statement including all promissory notes issued by Parent to Sponsor and (c) Liabilities incurred in the connection with
the Transactions, none of which, individually or in the aggregate, would have a Parent Material Adverse Effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.14
<span style="text-decoration: underline">Parent SEC Documents and Parent Financial Statements</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Since Parent&#8217;s formation, Parent has timely filed all forms, reports, schedules, statements and other documents, including all exhibits
thereto, required to be filed or furnished by Parent with the SEC under the Exchange Act or the Securities Act, together with any amendments,
restatements or supplements thereto (the &#8220;<span style="text-decoration: underline">Parent SEC Documents</span>&#8221;); and Parent
will file all such forms, reports, schedules, statements and other documents required to be filed subsequent to the date of this Agreement
(the &#8220;<span style="text-decoration: underline">Additional Parent SEC Documents</span>&#8221;). Parent has furnished to the Company
true and correct copies of all documents and other instruments that previously had been filed by Parent with the SEC and are currently
in effect. The Parent SEC Documents were, and the Additional Parent SEC Documents will be, prepared in all material respects in accordance
with the requirements of the Securities Act, the Exchange Act and the Sarbanes-Oxley Act, as applicable. The Parent SEC Documents did
not, and the Additional Parent SEC Documents will not, at the time they were or are filed with the SEC (or, if any information contained
in any Parent SEC Document has been or is revised or superseded by a later filed Parent SEC Document or Additional Parent SEC Document,
then on the date of such filing) contain any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading.
As used in this <span style="text-decoration: underline">Section&#160;6.14</span>, the term &#8220;file&#8221; shall be broadly construed
to include any manner in which a document or information is furnished, supplied or otherwise made available to the SEC. Each director
and executive officer of Parent has timely filed with the SEC all documents required to be filed with respect to Parent by Section&#160;16(a)
of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Each of the financial statements (including, in each case, any notes thereto) contained or incorporated by reference in any Parent SEC
Document and/or Additional Parent SEC Document is or, when filed, will be in conformity with GAAP (applied on a consistent basis), Regulation
S-X and Regulation S-K, as applicable, throughout the periods indicated, and each is or, when filed, will be complete and each fairly
presents or, when filed, will fairly present, in all material respects, the financial position, results of operations and cash flows of
Parent as at the respective dates thereof and for the respective periods indicated therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Parent has timely filed all certifications and statements required by (i)&#160;Rule&#160;13a-14 or Rule&#160;15d-14 under the Exchange
Act or (ii)&#160;18 U.S.C. Section&#160;1350 (Section&#160;906 of the Sarbanes-Oxley Act) with respect to any Parent SEC Document (the
&#8220;<span style="text-decoration: underline">Parent Certifications</span>&#8221;). Each of the Parent Certifications is true and correct.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 494 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Since its initial public offering, Parent has maintained, and currently maintains, disclosure controls and procedures required by Rule&#160;13a-15
or Rule&#160;15d-15 under the Exchange Act, which controls and procedures are reasonably designed to ensure that all material information
concerning Parent and other material information required to be disclosed by Parent in the reports and other documents that it files or
furnishes under the Exchange Act is made known on a timely basis to the individuals responsible for the preparation of Parent&#8217;s
SEC filings and other public disclosure documents. Such disclosure controls and procedures are effective in timely alerting Parent&#8217;s
principal executive officer and principal financial officer to material information required to be included in Parent&#8217;s periodic
reports required under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Parent maintains a standard system of accounting established and administered in accordance with GAAP. Parent has designed and maintains
a system of internal controls over financial reporting, as defined in Rules&#160;13a-15(f) and 15d-15(f) of the Exchange Act, sufficient
to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP. Since its initial public offering, Parent has maintained and currently maintains a system of internal
accounting controls sufficient to provide reasonable assurance that (i)&#160;transactions are executed in accordance with management&#8217;s
general or specific authorizations, (ii)&#160;transactions are recorded as necessary to permit preparation of financial statements in
conformity with GAAP and to maintain asset accountability, (iii)&#160;access to assets is permitted only in accordance with management&#8217;s
general or specific authorization and (iv)&#160;the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. Parent has delivered to the Company, to the extent applicable,
a true and complete copy of any disclosure (or, if unwritten, a summary thereof) by any representative of Parent to Parent&#8217;s independent
auditors relating to any material weaknesses in internal controls and any significant deficiencies in the design or operation of internal
controls that would adversely affect the ability of Parent to record, process, summarize and report financial data. Since its incorporation,
Parent has not received any written complaint, allegation, assertion or claim that there is (i) a &#8220;significant deficiency&#8221;
in the internal controls over financial reporting of Parent, (ii) a &#8220;material weakness&#8221; in the internal controls over financial
reporting of Parent or (iii) fraud, whether or not material, that involves management or other employees of Parent who have a significant
role in the internal controls over financial reporting of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Parent has no off-balance sheet arrangements. No financial statements other than those of Parent are required by GAAP to be included in
the consolidated financial statements of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Neither Parent nor, to the Knowledge of Parent, any manager, director, officer, employee, auditor, accountant or representative of Parent
has received or otherwise had or obtained knowledge of any complaint, allegation, assertion or claim, whether written or oral, regarding
the accounting or auditing practices, procedures, methodologies or methods of Parent or their respective internal accounting controls,
including any complaint, allegation, assertion or claim that Parent has engaged in questionable accounting or auditing practices or fraud.
No attorney representing Parent, whether or not employed by Parent, has reported evidence of a material violation of securities laws,
breach of fiduciary duty or similar violation by Parent or any of its officers, directors, employees or agents to Parent&#8217;s board
of directors (or any committee thereof) or to any director or officer of Parent. Since Parent&#8217;s inception, there have been no internal
investigations regarding accounting or revenue recognition discussed with, reviewed by or initiated at the direction of the chief executive
officer, chief financial officer or Parent&#8217;s board of directors or any committee thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 495 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Parent is in compliance in all material respects with the applicable listing and corporate governance rules and regulations of Nasdaq
and all rules and regulations promulgated by the SEC that are applicable to Parent, Purchaser and Merger Sub.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
There are no outstanding loans or other extensions of credit made by Parent to any executive officer (as defined in Rule&#160;3b-7 under
the Exchange Act) or director of Parent and Parent has not taken any action prohibited by Section&#160;402 of the Sarbanes-Oxley Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
Except as and to the extent set forth in Parent SEC Documents, Parent does not have any Liability or obligation of a nature (whether accrued,
absolute, contingent or otherwise) required to be reflected on a balance sheet prepared in accordance with GAAP, except for Liabilities
and obligations arising in the Ordinary Course of Parent&#8217;s and Merger Sub&#8217;s business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
As of the date hereof, there are no outstanding comments from the SEC with respect to Parent SEC Documents. To the Knowledge of Parent,
none of the Parent SEC Documents filed on or prior to the date hereof is subject to ongoing SEC review or investigation as of the date
hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
Except with respect to information about the Company and its Subsidiaries supplied by the Company expressly for inclusion in the Proxy
Statement, the Proxy Statement will not, as of the date on which the Proxy Statement (or any amendment or supplement thereto) is first
distributed to Company Shareholders or at the time of the meeting of the Company Shareholders, contain any statement which, at such time
and in light of the circumstances under which they were made, are false or misleading with respect to any material fact or omit to state
any material fact required to be stated therein or necessary in order to make the statement therein not false or misleading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.15
<span style="text-decoration: underline">Business Activities</span>. Since its formation, Parent has not conducted any business activities
other than activities directed toward completing a business combination (as defined in Parent&#8217;s Organizational Documents). Each
of Purchaser and Merger Sub was formed solely for the purpose of engaging in the Transactions, and neither Purchaser nor Merger Sub has
engaged in any business activities or conducted any operations or incurred any obligation or Liability, other than as contemplated by
this Agreement. Except as set forth in Parent&#8217;s Organizational Documents, there is no agreement, commitment or Order binding on
Parent or to which Parent is a party that has or would reasonably be expected to have the effect of prohibiting or impairing any business
practice of Parent, any acquisition of property by Parent or the conduct of business by Parent as currently conducted or as contemplated
to be conducted as of the Closing. Other than Purchaser and Merger Sub, Parent does not directly or indirectly own any interest or investment
(whether equity or debt) in any corporation, partnership, joint venture, business, trust or other entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.16
<span style="text-decoration: underline">Parent Contracts</span>. Except as disclosed in Parent SEC Documents, as of the date hereof,
Parent is not party to any Contract (other than engagement agreements and nondisclosure agreements containing customary terms that were
entered into in the Ordinary Course).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 496 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.17
<span style="text-decoration: underline">Litigation</span>. There is no Proceeding pending or, to the Knowledge of Parent, threatened
against Parent, Purchaser or Merger Sub or any of their respective properties or rights; and none of Parent, Purchaser nor Merger Sub
is subject to any outstanding Order. As of the date hereof, there are no Proceedings (at Law or in equity) or investigations pending or,
to the Knowledge of Parent, threatened that seek or would reasonably be expected to prevent, hinder, modify, delay or challenge the Transactions
or would reasonably be expected to have a Parent Material Adverse Effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.18
<span style="text-decoration: underline">Independent Investigation</span>. Parent acknowledges that it has conducted its own independent
review and analysis of the business, operations, assets, liabilities, results of operations, financial condition and prospects of the
Company and that the Company has provided Parent with adequate access to the personnel, properties, premises and books and records of
the Company for this purpose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.19
<span style="text-decoration: underline">Information Supplied</span>. None of the information supplied or to be supplied by Parent expressly
for inclusion or incorporation by reference in the filings with the SEC and mailings to Parent Shareholders with respect to the solicitation
of proxies to approve the Transactions will, at the date of filing or mailing, as the case may be, contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of
the circumstances under which they are made, not misleading (subject to the qualifications and limitations set forth in the materials
provided by Parent or that is included in Parent SEC Documents).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.20
<span style="text-decoration: underline">Investment Company</span>. As of the date of this Agreement, Parent is not, and, upon the Closing,
Parent will not be, an &#8220;investment company,&#8221; a company controlled by an &#8220;investment company,&#8221; or an &#8220;affiliated
person&#8221; of, or &#8220;promoter&#8221; or &#8220;principal underwriter&#8221; for, an &#8220;investment company,&#8221; as such terms
are defined in the Investment Company Act of 1940.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.21
<span style="text-decoration: underline">Lockup</span>. All existing lock up agreements between Parent and any of its shareholders or
holders of any other securities of Parent entered into in connection with the IPO provide for a lock up period that is in full force and
effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.22
<span style="text-decoration: underline">Board and Shareholder Approval</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Parent&#8217;s board of directors (including any required committee or subgroup of such board but excluding any interested directors)
has, as of the date of this Agreement, unanimously (i) declared the advisability of the Reincorporation, the Merger and the other Transactions,
(ii) determined that the Reincorporation, the Merger and the other Transactions are in the best interests of the shareholders of Parent,
(iii) determined that the Transactions constitute a &#8220;business combination&#8221; as such term is defined in Parent&#8217;s Organizational
Documents and (iv) resolved to recommend that the shareholders of Parent approve each of the matters requiring Parent Required Vote and
directed that this Agreement, the Reincorporation and the Merger be submitted for consideration by the shareholders of Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 497 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The affirmative vote of a majority of the directors of the Parent as, being entitled to vote at a meeting of the board of directors of
the Parent called for such purpose or the execution of a resolution of directors in writing by all the directors of the Parent and the
affirmative vote of a majority of in excess of fifty percent (50%) of the votes of the holders of Class A Parent Ordinary Shares and the
holders of Class B Parent Ordinary Shares of the Parent (voting as a single class) as, being entitled to do so, vote in person or by proxy
at the Parent Shareholders&#8217; Meeting or a written resolution of members consented to in writing by the holders of Class A Parent
Ordinary Shares and the holders of Class B Parent Ordinary Shares of the Parent holding in excess of fifty percent (50%) of the votes
entitled to vote is required to approve the Reincorporation and the entry into the Plan of Merger, and the affirmative vote of the holders
of a majority of in excess of fifty percent (50%) of the votes of the holders of Class A Parent Ordinary Shares and the holders of Class
B Parent Ordinary Shares of the Parent (voting as a single class) entitled to vote thereon and present in person or by proxy at the Parent
Shareholders&#8217; Meeting or a written resolution of members consented to in writing by the holders of Class A Parent Ordinary Shares
and the holders of Class B Parent Ordinary Shares of the Parent holding in excess of fifty percent (50%) of the votes entitled to vote
is required to approve the entry into this Agreement and the consummation of the Transactions (the &#8220;<span style="text-decoration: underline">Parent
Required Vote</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.23
<span style="text-decoration: underline">Disclaimer of Other Representations and Warranties</span>. Except for the representations and
warranties contained in this <span style="text-decoration: underline">ARTICLE VI</span>, none of Parent, Parent&#8217;s Affiliates or
any other Person makes any express or implied representation or warranty with respect to Parent, and Parent expressly disclaims any other
representations or warranties, whether made by Parent or any other Person (including its Affiliates, officers, directors, employees, agents,
representatives or advisors).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.24
<span style="text-decoration: underline">Advice of U.S. Tax Counsel</span>. Parent has, with advice of U.S. tax counsel, considered the
qualification of the Reincorporation for the Reincorporation Intended Tax Treatment and, after such consideration, Parent is not aware
of the existence of any fact, nor has taken or agreed to take any action, that would reasonably be expected to prevent or impede the Reincorporation
from qualifying for the Reincorporation Intended Tax Treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.25
<span style="text-decoration: underline">International Trade Matters; Anti-Bribery Compliance</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Parent currently is, and has since its inception been, in compliance with all (i) Anti-Corruption Laws, (ii) Sanctions Laws, (iii)
Export Control Laws, (iv) anti-money laundering, including the Money Laundering Control Act of 1986, 18 U.S.C. &#167;&#167; 1956, 1957,
and any other equivalent or comparable Laws of other countries, (v) anti-boycott regulations, as administered by the U.S. Department of
Commerce, and (vi) International Trade Control Laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Neither the Parent, nor to the Knowledge of the Parent, any director, officer, employee or agent of the Parent, is or is acting under
the direction, on behalf or for the benefit of a Person that is (i) the target of Sanctions Laws or a Prohibited Party; or (ii) located,
organized or resident in a country or territory that is, or whose government is, the target of comprehensive trade sanctions under Sanctions
Laws, including, as of the date of this Agreement, Crimea, Cuba, Iran, North Korea and Syria. Neither the Parent nor, to the Knowledge
of the Parent, any director or officer or any employee or agent of the Parent, (A) has participated in any transaction involving a Prohibited
Party or a Person who is the target of any Sanctions Laws, or any country or territory that was during such period or is, or whose government
was during such period or is, the target of comprehensive trade sanctions under Sanctions Laws, (B) has exported (including deemed exportation)
or re-exported, directly or indirectly, any commodity, software, technology, or services in violation of any applicable Export Control
Laws or (C) has participated in any transaction in violation of or connected with any purpose prohibited by Anti-Corruption Laws or any
applicable International Trade Control Laws, including support for international terrorism and nuclear, chemical, or biological weapons
proliferation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 498 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Parent has not received written notice of, and, to the Knowledge of the Parent, none of its officers, employees, agents or Representatives
is or has been the subject of, any investigation, inquiry or enforcement proceedings by any Governmental Authority regarding any offense
or alleged offense under Anti-Corruption Laws, Sanctions Laws, Export Control Laws or International Trade Control Laws (including by virtue
of having made any disclosure relating to any offense or alleged offense) and, to the Knowledge of the Parent, there are no circumstances
likely to give rise to any such investigation, inquiry or proceeding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
VII </b><br/><b>COVENANTS AND AGREEMENTS OF THE COMPANY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<span style="text-decoration: underline">Conduct of Business of the Company</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Except as contemplated by this Agreement, as set forth on <span style="text-decoration: underline">Schedule&#160;7.1(a)</span> or as required
by applicable Law, from the date of this Agreement until the earlier of the Effective Time or valid termination of this Agreement pursuant
to <span style="text-decoration: underline">ARTICLE XII</span>, without the prior written consent of Parent (which consent shall not be
unreasonably withheld, conditioned or delayed and may be given as set forth below), the Company and each of the Company&#8217;s Subsidiaries
shall use commercially reasonable efforts to conduct its business in the Ordinary Course, preserve its goodwill, keep available the services
of its officers and employees and maintain satisfactory relationships with customers and vendors; and none of the Company or any Subsidiary
shall:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Amend its Organizational Documents;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Adopt a plan or agreement of liquidation, dissolution, restructuring, merger, consolidation, recapitalization or other reorganization
or otherwise merge or consolidate with or into any other Person;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
Other than as set forth on Schedule&#160;7.1(a), (A) issue, sell, pledge or grant, or authorize the issuance, sale, pledge or grant of,
any equity interests of the Company or any of the Company&#8217;s Subsidiaries, or any convertible securities or other commitments or
instruments pursuant to which the Company or any of the Company&#8217;s Subsidiaries may become obligated to issue or sell any of its
shares of capital stock or other securities, or the holders may have the right to vote (or convertible into, or exchangeable for, securities
having the right to vote) on any matters on which shareholders of the Company or the Company&#8217;s Subsidiaries may vote, other than
the issuance of Company Shares, upon the exercise, exchange or conversion of convertible securities or other commitments or instruments;
(B) split, combine, subdivide or reclassify any of its shares of capital stock, (C) declare, set aside or pay any dividend or other distribution
with respect to shares of its capital stock other than dividends from a Subsidiary of the Company, or (D)&#160;redeem, purchase or otherwise
acquire any of its shares of capital stock, other than in connection with the forfeiture or cancellation of such interests;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 499 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
(A) Make, cancel or compromise any loans, advances, guarantees or capital contributions to any Person other than to a Subsidiary of the
Company or for amounts not in excess of $100,000 in the aggregate or (B) incur, assume, accelerate, guarantee or otherwise become liable
for any Indebtedness;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
Make or commit to make any capital expenditures except (A) as contemplated by the Company&#8217;s current budget, (B) in the Ordinary
Course, or (C) for amounts not in excess of $100,000 in the aggregate;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
Acquire, transfer, mortgage, assign, sell, lease, create a Lien (other than Permitted Liens) upon or otherwise dispose of or pledge any
Asset of the Company or any of its Subsidiaries other than in the Ordinary Course;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
Acquire, directly or indirectly (including by merger, consolidation, purchase of equity interests or assets, or any other form of business
combination), any corporation, partnership, limited liability company, business organization, division, or any material assets of any
of the foregoing;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
Commence any Proceeding or release, assign, compromise, settle, waive or abandon any pending or threatened Proceeding, other than any
such Proceeding that would not reasonably be expected to result in damages or otherwise have a value, individually, in excess of $100,000
or are non-monetary in nature;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)
Except as required by applicable Law, under the terms of any Benefit Arrangement disclosed in <span style="text-decoration: underline">Schedule&#160;5.22(a)</span>
or in the Ordinary Course (A) grant or announce any increase in salaries, bonuses, severance, termination, retention or change-in-control
pay, equity based or other compensation and benefits payable or to become payable by the Company or any of its Subsidiaries to any current
or former employee in excess of $100,000 in the aggregate, (B) terminate, adopt, enter into or materially amend any Benefit Arrangement,
or (C) adopt, establish or enter into any plan, policy or arrangement that would constitute a Benefit Arrangement if it were in existence
on the date hereof, other than in the case of the renewal of group health or welfare plans;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
Enter into, amend, terminate or extend any collective bargaining agreement or any other agreement with a labor or trade union, employee
association or works council or recognize or certify any labor union, labor organization, or group of employees of as the bargaining representative
for any employees;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)
Change its fiscal year or any material method of accounting or material accounting practice, except for any such change required by GAAP;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)
Terminate, assign, waiver (other than expiration in accordance with its terms) or amend any material term of any Material Contract or
enter into any Contract that would be a Material Contract if entered into prior to the date hereof;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)
Assign, transfer, abandon, modify, waive, terminate, fail to renew, let lapse or otherwise fail to maintain or otherwise change any material
Permit or insurance policy, except in the Ordinary Course;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 500 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)
Make, revoke or change any Tax election, adopt or change any Tax accounting method or period, file an amended Tax Return, enter into any
Tax allocation, Tax sharing, Tax indemnity or other closing agreement or settlement related to Taxes, settle any material Tax claim or
assessment, or consent to any extension or waiver of the statute of limitations period applicable to any Tax claim or assessment;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)
Grant, modify, abandon, dispose of or terminate any rights relating to any Intellectual Property of the Company or the Company&#8217;s
Subsidiaries, other than in the Ordinary Course, or otherwise permit any of its rights relating to any Intellectual Property to lapse
(other than in the Ordinary Course or registrations for trademarks that are no longer in use by, are not planned to be used in the future
by and are no longer being maintained by Company and its Subsidiaries);</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)
Take any action, or knowingly fail to take any action that would reasonably be expected to prevent or impede the Reincorporation Intended
Tax Treatment;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvii)
Enter into any new line of business; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xviii)
Agree or commit to do, or resolve, authorize or approve any action to do, any of the foregoing, or take any action or omission that would
result in any of the foregoing;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">provided</span>,
<span style="text-decoration: underline">however</span>, that nothing in the <span style="text-decoration: underline">Section&#160;7.1(a)</span>
shall require the Company to do or not do anything that would be reasonably expected to violate applicable antitrust, competition Law
or any Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Company shall be permitted to request consent from Parent in writing (including by electronic mail) by delivering written notice (including
by electronic mail) to Parent in accordance with <span style="text-decoration: underline">Section&#160;13.9</span>. For purposes of this
&#8206;<span style="text-decoration: underline">Section&#160;7.1</span>, Parent shall respond (including by return email) to such request
as promptly as practicable, and if Parent does not respond (including by return email) to any request within three Business Days after
the Company delivers such written request for consent to Parent (including at the email addresses set forth in <span style="text-decoration: underline">Section&#160;13.9</span>),
Parent shall be deemed to have provided its prior written consent to the taking of such action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
<span style="text-decoration: underline">Access to Information</span>. Subject to confidentiality obligations that may be applicable to
information furnished to the Company by third parties from time to time and applicable attorney-client privilege and, in all cases, solely
to the extent permitted by applicable Law, from and after the date hereof until the earlier of the Closing or the termination of this
Agreement in accordance with its terms, upon reasonable advance written notice, the Company shall provide to Parent and its authorized
Representatives reasonable access (which access will be under the supervision of the Company&#8217;s personnel) to the personnel, books,
records, properties, financial statements, internal and external audit reports, regulatory reports, Contracts, Permits, commitments and
any other reasonably requested documents and other information of the Company and its Subsidiaries during normal business hours (in a
manner so as to not interfere with the normal business operations of the Company or any of its Subsidiaries) and use commercially reasonable
efforts to cause the employees, legal counsel, accountants and representatives of the Company to reasonably cooperate with Parent in its
investigation of the Company; <span style="text-decoration: underline">provided</span> that no investigation pursuant to this <span style="text-decoration: underline">Section&#160;7.2</span>
shall affect any representation or warranty given by the Company. All of such information shall be treated as confidential information
pursuant to the terms of the Non-Disclosure Agreement. Notwithstanding anything herein to the contrary, Parent and Merger Sub shall not,
without the prior written consent of the Company, make inquiries of Persons having business relationships with the Company (including
suppliers, customers and vendors) regarding the Company or such business relationships. From and after the Closing, the Non-Disclosure
Agreement shall terminate and be of no force and effect with respect to any information relating to the Company and its Subsidiaries,
unless terminated earlier by either party thereto in accordance with the terms thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 501 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
<span style="text-decoration: underline">Additional Financial Information</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
No later than January&#160;31, 2026 or such other date that may be mutually agreed between the parties, the Company shall deliver to Parent
(i) the Interim Financial Statements and (ii) the audited consolidated financial statements (the &#8220;Audited Financial Statements&#8221;)
of the Company and its Subsidiaries (including, in each case, any related notes thereto), consisting of the balance sheets of the Company
as of June&#160;30, 2025 and June&#160;30, 2024, and the related audited income statements, changes in stockholder equity and statements
of cash flows for the fiscal years then ended, and as applicable, audited by a PCAOB qualified auditor in accordance with GAAP and the
requirements of the PCAOB for public companies, and the related audited income statements, changes in stockholder equity and statements
of cash flows for the twelve months then ended. If the Company does not deliver the Interim Financial Statements and the Audited Financial
Statements on or before January&#160;31, 2026, or such other agreed date, Parent shall have the right to terminate this Agreement in accordance
with <span style="text-decoration: underline">ARTICLE XI</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Subsequent to the delivery of the Interim Financial Statements pursuant to <span style="text-decoration: underline">Section&#160;7.3(a)</span>,
the Company shall deliver to Parent copies of the Company&#8217;s and its Subsidiaries&#8217; unaudited consolidated interim financial
information for each fiscal quarterly period thereafter no later than forty five (45) calendar days following the end of each such fiscal
quarterly period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
All of the financial statements to be delivered pursuant to this <span style="text-decoration: underline">Section&#160;7.3</span>, shall
be prepared under GAAP in accordance with requirements of the PCAOB for public companies and shall fairly present the financial position
and results of operations of the Company and its Subsidiaries as of the date or for the periods indicated, in accordance with GAAP, except
as otherwise indicated in such statements and subject to year-end audit adjustments. The Company will promptly provide additional Company
financial information reasonably requested by Parent for inclusion in the Proxy Statement and any other filings to be made by Parent with
the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4
<span style="text-decoration: underline">Lock-Up</span>. Prior to the Closing, the Company shall cause the Company Shareholders to enter
into an agreement with Parent, substantially the form attached hereto as <span style="text-decoration: underline">Exhibit C</span> (the
&#8220;<span style="text-decoration: underline">Lock-Up Agreement</span>&#8221;), to be effective as of the Closing, pursuant to which
the each Company Shareholder&#8217;s pro rata share of the Merger Consideration shall be subject to a lock-up on the terms and conditions
set forth therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 502 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5
<span style="text-decoration: underline">Notice of Changes</span>. The Company shall give prompt written notice to Parent of (a) any representation
or warranty made by the Company contained in this Agreement becoming untrue or inaccurate such that the condition set forth in <span style="text-decoration: underline">Section&#160;11.2(a)</span>
would not be satisfied, (b) any breach of any covenant or agreement of the Company contained in this Agreement such that the condition
set forth in <span style="text-decoration: underline">Section&#160;11.2(b)</span> would not be satisfied, (c) any event, circumstance
or development that would reasonably be expected to have a Company Material Adverse Effect and (d) any Proceeding initiated by or against
the Company or any of the Company&#8217;s Subsidiaries or any of their predecessors or against any officer or director of the Company
or any of the Company&#8217;s Subsidiaries in their capacity as such in an amount in controversy equal to or greater than $100,000 individually
as set out in the filings related to such Proceeding; <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>,
that in each case (i) no such notification shall affect the representations, warranties, covenants, agreements or conditions to the obligations
of the Parties under this Agreement and (ii) no such notification shall be deemed to amend or supplement the Company Disclosure Schedules
or to cure any breach of any covenant or agreement or inaccuracy of any representation or warranty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
VIII </b><br/><b>COVENANTS OF PARENT, PURCHASER AND MERGER SUB</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1
<span style="text-decoration: underline">Listing</span>. Parent shall use its commercially reasonable efforts (a)(i) to maintain its existing
listing on Nasdaq until the Closing Date, and (ii) to obtain approval of the listing of Purchaser Surviving Corporation and the listing
of Purchaser Surviving Corporation Shares and Purchaser Surviving Corporation Warrants on Nasdaq; (b) without derogating from the generality
of the requirements of clause (a) and to the extent required by the rules and regulations of Nasdaq, to (i) prepare and submit to Nasdaq
a notification form for the listing of Purchaser Surviving Corporation Shares to be issued in the Merger and (ii) to cause such shares
to be approved for listing (subject to notice of issuance) on Nasdaq (unless otherwise determined); and (c) to the extent required by
Nasdaq Marketplace Rule&#160;5110, to file an initial listing application for Purchaser Surviving Corporation Shares on Nasdaq (the &#8220;<span style="text-decoration: underline">Nasdaq
Listing Application</span>&#8221;) and to cause such Nasdaq Listing Application to be conditionally approved prior to the Effective Time.
The Company will cooperate with Parent as reasonably requested by Parent with respect to the Nasdaq Listing Application and promptly furnish
to Parent all information concerning the Company and its shareholders that may be required or reasonably requested in connection with
any action contemplated by this <span style="text-decoration: underline">Section&#160;8.1</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2
<span style="text-decoration: underline">Trust Account</span>. Parent has established the Trust Account from the proceeds of the IPO and
from certain private placements occurring simultaneously with the IPO for the benefit of Parent Public Shareholders and certain parties
(including the underwriters of the IPO). Prior to the Closing, Parent shall disburse monies from the Trust Account only (a)&#160;to pay
income and other Tax obligations from any interest income earned in the Trust Account or (b)&#160;to redeem Class A Parent Ordinary Shares
in accordance with the provisions of Parent&#8217;s Organizational Documents. The Trust Agreement will not be amended or modified prior
to the Effective Time unless deemed necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3
<span style="text-decoration: underline">Parent Public Filings</span>. From the date hereof through the Closing, Parent will use commercially
reasonable efforts to keep current and timely file all reports required to be filed or furnished with the SEC and otherwise comply in
all material respects with its reporting obligations under applicable Laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 503 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4
<span style="text-decoration: underline">Section&#160;16 Matters</span>. Prior to the Closing, the board of directors of Parent, or an
appropriate committee of &#8220;non-employee directors&#8221; (as defined in Rule&#160;16b-3 of the Exchange Act) thereof, shall adopt
a resolution consistent with the interpretive guidance of the SEC so that the acquisition of Merger Consideration pursuant to this Agreement
and the other agreements contemplated hereby by any Person owning securities of the Company who is expected to become a director or officer
(as defined under Rule&#160;16a-1(f) under the Exchange Act) of Purchaser following the Closing shall be an exempt transaction for purposes
of Section&#160;16(b) of the Exchange Act pursuant to Rule&#160;16b-3 thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5
<span style="text-decoration: underline">Notice of Changes</span>. Parent shall give prompt written notice to the Company of (a) any representation
or warranty made by Parent, Purchaser or Merger Sub contained in this Agreement becoming untrue or inaccurate such that the condition
set forth in <span style="text-decoration: underline">Section&#160;11.3(a)</span> would not be satisfied, (b) any breach of any covenant
or agreement of Parent, Purchaser or Merger Sub contained in this Agreement such that the condition set forth in <span style="text-decoration: underline">Section&#160;11.3(b)</span>
would not be satisfied, (c) any event, circumstance or development that would reasonably be expected to have a Parent Material Adverse
Effect and (d) any Proceeding initiated by or against Parent or its Subsidiaries or any of their predecessors or against any officer or
director of Parent or any of its Subsidiaries in their capacity; <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>,
that in each case (i) no such notification shall affect the representations, warranties, covenants, agreements or conditions to the obligations
of the Parties under this Agreement and (ii) no such notification shall be deemed to cure any breach of any covenant or agreement or inaccuracy
of any representation or warranty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.6
<span style="text-decoration: underline">D&amp;O Insurance; Indemnification of Officers and Directors</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
From and after the Closing Date through the sixth (6th) anniversary of the Closing Date, Purchaser shall cause (i) its Organizational
Documents to contain provisions no less favorable to the current or former directors, managers, officers or employees of the Company or
Parent (collectively, &#8220;<span style="text-decoration: underline">D&amp;O Indemnitees</span>&#8221;) with respect to limitation of
certain liabilities, advancement of expenses and indemnification than are set forth as of the date of this Agreement in the Organizational
Documents of the Company or Parent, as applicable, which provisions in each case shall not be amended, repealed or otherwise modified
in a manner that would adversely affect the rights thereunder of the D&amp;O Indemnitees with respect to any acts or omissions occurring
at or prior to the Closing, except as required by Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Prior to the Closing Date, Parent shall purchase, at the expense of Purchaser Surviving Corporation, a directors&#8217; and officers&#8217;
liability tail insurance policy on terms and conditions reasonably satisfactory to Parent for all of the officers and directors of Parent
as of immediately prior to the Merger, with respect to claims arising from facts and events that occurred prior to the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The provisions of this <span style="text-decoration: underline">Section&#160;8.6</span> are intended to be for the benefit of, and shall
be enforceable by, each D&amp;O Indemnitee for all periods ending on or before the Closing Date and may not be changed with respect to
any officer or director without his or her written consent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
On the Closing Date, Purchaser shall enter into customary indemnification agreements reasonably satisfactory to each of the Company and
Purchaser with the post-Closing directors and officers of Purchaser, which indemnification agreements shall continue to be effective following
the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 504 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
IX </b><br/><b>TAX COVENANTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1
<span style="text-decoration: underline">Tax Matters</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Each of the Parties shall use their reasonable best efforts to cause each of the Reincorporation and the Merger to qualify for the Reincorporation
Intended Tax Treatment and the Merger Intended Tax Treatment, respectively, and no Party or their respective Affiliates has taken or will
take any action (or fail to take any action), if such action (or failure to act), whether before or after the Effective Time, would reasonably
be expected to prevent or impede the Reincorporation or the Merger from qualifying for such intended Tax treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Each of Parent, Purchaser, the Company, and their respective Affiliates shall file all Tax Returns consistent with the Reincorporation
Intended Tax Treatment (including attaching the statement described in Treasury Regulations Section&#160;1.368-(a) on or with its Tax
Return for the taxable year of the Reincorporation), and shall take no position inconsistent with the Reincorporation Intended Tax Treatment
(whether in audits, Tax Returns or otherwise), unless otherwise required by a Taxing Authority as a result of a &#8220;determination&#8221;
within the meaning of Section&#160;1313(a) of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Each of Purchaser, Merger Sub, and Company, and their respective Affiliates shall file all Tax Returns consistent with the Merger Intended
Tax Treatment (including attaching the statement described in Treasury Regulations Section&#160;1.368-(a) on or with its Tax Return for
the taxable year of the Merger), and shall take no position inconsistent with the Merger Intended Tax Treatment (whether in audits, Tax
Returns or otherwise), unless otherwise required by a Taxing Authority as a result of a &#8220;determination&#8221; within the meaning
of Section&#160;1313(a) of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Any and all Transfer Taxes shall be paid by Purchaser, unless the Transfer Taxes are imposed in connection with the Merger and are an
obligation of the Company&#8217;s shareholders under applicable Law, in which case such Transfer Taxes shall be borne by the applicable
Company&#8217;s shareholders. The party required by Law to do so shall file all necessary Tax Returns and other documentation with respect
to all such Transfer Taxes, and, if required by applicable Law, the parties shall, and shall cause their respective Affiliates to, join
in the execution of any such Tax Returns and other document. Notwithstanding any other provision of this Agreement, the parties shall
(and shall cause their respective Affiliates to) cooperate in good faith to minimize, to the extent permissible under applicable Law,
the amount of any such Transfer Taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Within sixty (60) days after the end of Purchaser&#8217;s current taxable year and each subsequent taxable year of Purchaser for which
Purchaser reasonably believes that it may be a &#8220;passive foreign investment company&#8221; within the meaning of Section&#160;1297
of the Code (&#8220;<span style="text-decoration: underline">PFIC</span>&#8221;), Purchaser shall (i) determine its status as a PFIC,
(ii) determine the PFIC status of each of its Subsidiaries that at any time during such taxable year was a foreign corporation within
the meaning of Section&#160;7701(a) of the Code (the &#8220;<span style="text-decoration: underline">Non-U.S. Subsidiaries</span>&#8221;)
and (iii) make such PFIC status determinations available to the shareholders of Purchaser as of immediately prior to the Effective Time.
If Purchaser determines that it was, or could reasonably be deemed to have been, a PFIC in such taxable year, Purchaser shall use commercially
reasonable efforts to provide the statements and information (including a PFIC Annual Information Statement meeting the requirements of
Treasury Regulation Section&#160;1.1295-1(g))</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 505 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">necessary
to enable Purchaser shareholders as of immediately prior to the Effective Time and their direct or indirect owners that are United States
persons (within the meaning of Section&#160;7701(a)(30) of the Code) to comply with all provisions of the Code with respect to PFICs,
including making and complying with the requirements of a &#8220;Qualified Electing Fund&#8221; election pursuant to Section&#160;1295
of the Code or filing a &#8220;protective statement&#8221; pursuant to Treasury Regulation Section&#160;1.1295-3 with respect to Purchaser
or any of the Non-U.S. Subsidiaries, as applicable. The covenants contained in this <span style="text-decoration: underline">Section&#160;9.1(e)</span>,
notwithstanding any provision elsewhere in this Agreement, shall survive in full force and effect until the later of (A) two (2) years
after the end of Purchaser&#8217;s current taxable year or (B) such time as Purchaser has reasonably determined that it is not a PFIC
for three (3) consecutive taxable years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2
<span style="text-decoration: underline">Opinion</span>. In the event the SEC requires a tax opinion regarding the Reincorporation Intended
Tax Treatment or its consequences to Parent security holders, Parent shall make commercially reasonable efforts to cause its U.S. tax
counsel to deliver such tax opinion to Parent. In the event the SEC requires a tax opinion regarding the Merger Intended Tax Treatment
or its consequences to Company security holders, the Company shall make commercially reasonable efforts to cause its U.S. tax counsel
to deliver such tax opinion to the Company. Each party shall use commercially reasonable efforts to execute and deliver customary representation
letters to the applicable tax counsel in form and substance reasonably satisfactory to such counsel. Notwithstanding anything to the contrary
in this Agreement, Loeb&#8239;&amp; Loeb LLP shall not be required to provide any opinion to any party regarding the tax consequences
or characterization of the Merger and Kesse PLLC shall not be required to provide any opinion to any party regarding the tax consequences
or characterization of the Reincorporation and/or Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
X </b><br/><b>ACTIONS PRIOR TO THE CLOSING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1
<span style="text-decoration: underline">No Shop</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
From the date hereof through the earlier of the Closing Date and the date on which this Agreement is properly terminated in accordance
with <span style="text-decoration: underline">ARTICLE XI</span>, the Company shall not, and the Company shall use commercially reasonable
efforts to cause its members, officers, directors, Affiliates, managers, consultants, employees, representatives and agents not to, directly
or indirectly, (i) encourage, solicit, initiate, engage, participate, enter into discussions or negotiations with, or make any proposal
to, any Person concerning any Alternative Transaction, (ii) take any other action intended or designed to facilitate the efforts of any
Person relating to a possible Alternative Transaction (including providing any due diligence materials), (iii) grant any waiver, amendment
or release under any confidentiality agreement or the anti-takeover laws of any state or (iv) approve, recommend or enter into any Alternative
Transaction or any Contract related to any Alternative Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In the event that there is an unsolicited proposal for, or an indication of an interest in entering into, an Alternative Transaction,
communicated orally or in writing to the Company or any of their representatives or agents (each, an &#8220;<span style="text-decoration: underline">Alternative
Proposal</span>&#8221;), such party shall as promptly as practicable (and in any event within one Business Day after receipt) advise Parent
orally and in writing of such Alternative Proposal and the material terms and conditions of such Alternative Proposal (including any changes
thereto). The Company shall keep Parent informed on a reasonably current basis of material developments with respect to any such Alternative
Proposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 506 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
From and after the date hereof, the Company shall instruct its officers and directors to, and such parties shall instruct and cause the
Company&#8217;s representatives to, immediately cease and terminate all discussions and negotiations with any Persons that may be ongoing
with respect to an Alternative Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2
<span style="text-decoration: underline">Efforts to Consummate the Transactions</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Subject to the terms and conditions herein provided, each of Parent, Purchaser, Merger Sub, and the Company shall use reasonable best
efforts to take, or cause to be taken, all action and to do, or cause to be done, all things reasonably necessary, proper or advisable
to consummate and make effective as promptly as practicable the Reincorporation and the Merger (including the satisfaction, but not waiver,
of the closing conditions set forth in <span style="text-decoration: underline">&#8206;ARTICLE XI</span>). Each of Parent, Purchaser,
Merger Sub, and the Company shall use reasonable best efforts to obtain consents of any Governmental Authority necessary to consummate
the Transactions as promptly as practicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Without limiting the foregoing, the Parties agree to use reasonable best efforts to (i) promptly notify the other of, and if in writing,
furnish the other with copies of (or, in the case of oral communications, advise the other of) any communications from or with any Governmental
Authority with respect to the this Agreement or the Transactions contemplated hereby; (ii) permit the other to review and discuss in advance,
and consider in good faith the view of the other in connection with, any proposed written or oral communication with any Governmental
Authority; (iii) not participate in any substantive meeting or have any substantive communication with any Governmental Authority unless
it has given the other Parties a reasonable opportunity to consult with it in advance and, to the extent permitted by such Governmental
Authority, gives the other the opportunity to attend and participate therein; (iv) furnish the other Parties&#8217; outside legal counsel
with copies of all filings and communications between it and any such Governmental Authority with respect to this Agreement and the Transactions;
<span style="text-decoration: underline">provided</span> that such material may (A) be redacted as necessary (1) to comply with contractual
arrangements, (2) to address legal privilege concerns or (3) to remove references concerning the valuation of the Parties or (B) be designated
as &#8220;outside counsel only&#8221;, in which event such materials and the information contained therein shall be given only to outside
counsel and previously-agreed outside economic consultants of the recipient and will not be disclosed by such outside counsel or outside
economic consultants to employees, officers, or directors of the recipient without the advance written consent of the party providing
such materials; and (v) furnish the other parties&#8217; outside legal counsel with such necessary information and reasonable assistance
as the other parties&#8217; outside legal counsel may reasonably request in connection with its preparation of necessary submissions of
information to any such Governmental Authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
In the event any Proceeding by any Governmental Authority or other Person is commenced which questions the validity or legality of the
Merger or seeks damages in connection therewith, Parent, Purchaser, Merger Sub, and the Company agree to cooperate and use their reasonable
best efforts to defend against such Proceeding and, if an injunction or other Order is issued in any such Proceeding, to use reasonable
best efforts to have such injunction or other Order lifted, and to cooperate reasonably regarding any other impediment to the consummation
of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 507 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Notwithstanding the foregoing, nothing in this <span style="text-decoration: underline">Section&#160;10.2</span> shall require, or be
construed to require, Parent, Purchaser, Merger Sub, or the Company or any of their respective Affiliates to agree to (i) sell, hold,
divest, discontinue or limit, before or after the Closing Date, any assets, businesses or interests of Parent, Purchaser, Merger Sub,
or the Company or any of their respective Affiliates, (ii) any conditions relating to, or changes or restrictions in, the operations of
any such assets, businesses or interests or (iii) any modification or waiver of the terms and conditions of this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Company shall use its commercially reasonable efforts to obtain or provide, as applicable, at the earliest practicable date, all consents,
approvals and notices listed in <span style="text-decoration: underline">Schedule&#160;10.2(e)</span>. The Company shall keep Parent apprised
of its efforts undertaken by reason of this <span style="text-decoration: underline">Section&#160;10.2(e)</span> and the results of such
efforts including by giving Parent copies of consents obtained and notices provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3
<span style="text-decoration: underline">Cooperation with Proxy Statement; Other Filings</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company shall promptly provide to Parent such information concerning the Company and the Company Shareholders as is either required
by the federal securities Laws or reasonably requested by Parent for inclusion in the Offer Documents. Promptly after the receipt by Parent
from the Company of all such information, Parent shall prepare and file with the SEC, and with all other applicable regulatory bodies,
proxy materials for the purpose of soliciting proxies from holders of Parent Shares sufficient to obtain the necessary approval of such
holders at the Parent Shareholders&#8217; Meeting. Such proxy materials shall be in the form of a proxy/information statement/prospectus
(the &#8220;<span style="text-decoration: underline">Proxy Statement</span>&#8221;), which shall be included in a Registration Statement
on Form S-4 (the &#8220;<span style="text-decoration: underline">Form S-4</span>&#8221;) filed by Parent with the SEC, pursuant to which
the offer and issuance of the Purchaser Shares in the Merger shall be registered. Parent shall promptly respond to any SEC comments on
the Form S-4. The Proxy Statement, the Form S-4 and the documents included or referred to therein, together with any supplements, amendments
or exhibits thereto, are referred to herein as the &#8220;<span style="text-decoration: underline">Offer Documents</span>&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Parent: (i) shall permit the Company and its counsel to review and comment on the Proxy Statement and the Form S-4 and any exhibits, amendments
or supplements thereto (or other related documents) at a reasonable time prior to the filing; (ii) shall consider any such comments reasonably
and in good faith; and (iii) shall not file the Proxy Statement and the Form S-4 or any exhibit, amendment or supplement thereto without
giving reasonable and good faith consideration to the comments of the Company. As promptly as practicable after receipt thereof, Parent
shall provide to the Company and its counsel notice and a copy of all correspondence (or, to the extent such correspondence is oral, a
summary thereof), including any comments from the SEC or its staff, between Parent or any of its Representatives, on the one hand, and
the SEC or its staff or other government officials, on the other hand, with respect to the Proxy Statement and the Form S-4 and, in each
case, shall consult reasonably and in good faith with the Company and its counsel concerning any such correspondence. Parent shall not
file any response letters to any comments from the SEC without consulting reasonably and in good faith with the Company except to the
extent not practicable or legally permissible. Parent will advise the Company, promptly after it receives notice thereof, of the time
when the Proxy Statement or the Form S-4 or any amendment or supplement thereto has been filed with the SEC and the time when the Form
S-4 declared effective or any stop order relating to the Form S-4 is issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 508 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
As soon as practicable following the date on which the Form S-4 is declared effective by the SEC (the &#8220;<span style="text-decoration: underline">S-4
Effective Date</span>&#8221;), Parent shall distribute the Proxy Statement to the holders of Parent Shares and, pursuant thereto, shall
call the Parent Shareholders&#8217; Meeting to be held on a date no later than 45 days after the S-4 Effective Date in accordance with
its organizational documents and the laws of the British Virgin Islands and, subject to the other provisions of this Agreement, solicit
proxies from such holders to vote in favor of the adoption of this Agreement and the approval of the transactions contemplated hereby
and the other matters presented to the Parent Shareholders for approval or adoption at the Parent Shareholders&#8217; Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Parent and the Company shall comply with all applicable provisions of and rules under the Securities Act, the Exchange Act, and all applicable
Laws of the State of Delaware and the British Virgin Islands, and Nasdaq rules, in the preparation, filing and distribution of the Form
S-4 and the Proxy Statement (or any amendment or supplement thereto), as applicable, the solicitation of proxies pursuant to the Proxy
Statement and the calling and holding of the Parent Shareholders&#8217; Meeting. Without limiting the foregoing, Parent shall use its
reasonable best efforts to ensure that the Form S-4, at the time it is initially filed with the SEC, at each time at which it is amended,
and on the S-4 Effective Date, and the Proxy Statement, on the date it is first distributed to Parent Shareholders and on the date of
the Parent Shareholders&#8217; Meeting, does not contain any untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements made, in light of the circumstances under which they were made, not misleading (provided, that Parent
shall not be responsible for the accuracy or completeness of any information relating to the Company (or any other information) that is
furnished by the Company expressly for inclusion in the Proxy Statement). The Company shall use its reasonable best efforts to ensure
that the information relating to the Company that has been supplied by the Company expressly for inclusion in the Proxy Statement or the
Form S-4, as applicable, (i) complies in all material respects with the applicable provisions of the Securities Act, the Exchange Act,
and the rules and regulations thereunder and (ii) does not, with respect to the Form S-4, at the time it is initially filed with the SEC,
at each time at which it is amended, or on the S-4 Effective Date and, with respect to the Proxy Statement, on the date that the Proxy
Statement (or any amendment or supplement thereto) is first distributed to Parent Shareholders or on the date of the Parent Shareholders&#8217;
Meeting, does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
made, in light of the circumstances under which they were made, not misleading. If at any time prior to the Effective Time, a change in
the information relating to the Company or any other information furnished by Parent, Merger Sub or the Company for inclusion in the Proxy
Statement that would make the preceding sentence incorrect should be discovered by Parent, Merger Sub or the Company, as applicable, such
party shall promptly notify the other parties of such change or discovery and an appropriate amendment or supplement describing such information
shall be promptly filed with the SEC and, to the extent required by Law, disseminated to Parent&#8217;s and the Company&#8217;s stockholders.
In connection therewith, Parent, Merger Sub and the Company shall instruct their respective employees, counsel, financial advisors, auditors
and other authorized Representatives to reasonably cooperate with Parent as relevant if required to achieve the foregoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 509 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
In accordance with the Parent Certificate of Incorporation and applicable securities Laws and the BVI BCA, in the Proxy Statement, Parent
shall seek from the holders of Parent Shares the approval of the following proposals: (i) the approval and adoption of the Business Combination
(as defined in Parent&#8217;s Organizational Documents), this Agreement and the other Transaction Documents, the Merger and the other
Transactions; (ii) the approval and adoption of the Reincorporation and the entry into the PM; (iii) adoption and approval of the Amended
and Restated COI of Parent, with effect from the Closing, (iv) approval of the appointment of the director nominees to the Post-Closing
Board of Directors as contemplated by <span style="text-decoration: underline">Section&#160;3.6</span>; (v) approval to adjourn Parent
Shareholders&#8217; Meeting, if necessary, to permit further solicitation of proxies because there are not sufficient votes to approve
and adopt any of the foregoing; and (vi) approval to obtain any and all other mutually agreed upon approvals necessary or advisable to
effect the consummation of the Merger (the proposals set forth in the forgoing clauses (i) through (vi) are referred to as the &#8220;<span style="text-decoration: underline">Parent
Proposals</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Parent, with the assistance of the Company, shall use its reasonable best efforts to promptly respond to any comments from the SEC or
its staff with respect to the Form S-4 and have the Form S-4 declared effective under the Securities Act as promptly as reasonably practicable
after it is filed with the SEC, and to keep the Form S-4 effective as long as is necessary to consummate the transactions contemplated
hereby. As soon as practicable after the S-4 Effective Date, Parent shall cause the Proxy Statement, together will all other Offer Documents,
to be disseminated to holders of Parent Shares. The Offer Documents shall provide the public stockholders of Parent with the opportunity
to redeem all or a portion of their Public Shares of Class A Parent Ordinary Shares, all in accordance with and as required by Parent&#8217;s
Organizational Documents, the Trust Agreement, applicable Law and any applicable rules and regulations of the SEC. Within 45 days following
the S-4 Effective Date, Parent shall call and hold the Parent Shareholders&#8217; Meeting for the purpose of seeking the approval of each
of the Parent Proposals, and Parent shall consult in good faith with the Company with respect to the date on which such meeting is to
be held. Parent shall use reasonable best efforts to solicit from its stockholders proxies in favor of the approval of the Parent Proposals.
If on the date for which the Parent Shareholders&#8217; Meeting is scheduled (including any postponed or adjourned date), Parent has not
received proxies representing a sufficient number of shares to obtain the approval of the Parent Shareholders, whether or not a quorum
is present, Parent shall make one or more successive postponements or adjournments of the Parent Shareholders&#8217; Meeting, each such
postponement or adjournment to be no more than 10 Business Days, and shall continue to use its reasonable best efforts to solicit from
its stockholders proxies in favor of the Parent Proposal; provided that, without the consent of the Company, Parent shall not postpone
or adjourn the Parent Shareholders&#8217; Meeting to a date later than the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
The Company acknowledges that a substantial portion of the Proxy Statement/Form S-4 shall include disclosure regarding the Company and
its management, operations and financial condition. Accordingly, the Company agrees to as promptly as reasonably practical provide Parent
with such information as shall be requested by Parent for inclusion in or attachment to the Proxy Statement/Form S-4, and shall use its
reasonable best efforts to ensure that such information is accurate in all material respects and complies as to form in all material respects
with the requirements of the Exchange Act and the rules and regulations promulgated thereunder. The Company understands that such information
shall be included in the Proxy Statement/Form S-4 or responses to comments from the SEC or its staff in connection therewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 510 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Notwithstanding anything else to the contrary in this Agreement or any Transaction Documents, each of Parent and the Company may make
any public filing with respect to the Merger, this Agreement, or the Transaction Documents to the extent required by applicable Law, provided
that (i) prior to making any filing that includes information regarding the Company, Parent shall provide a copy of the filing to the
Company and permit the Company to make revisions to protect confidential or proprietary information of the Company, and (ii) prior to
making any filing that includes information regarding the Parent, Purchaser or Merger Sub, the Company shall provide a copy of the filing
to Parent and permit Parent to make revisions to protect confidential or proprietary information of the Parent, Purchaser or Merger Sub.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Prior to the S-4 Effective Date, each of Parent and the Company shall use its commercially reasonable efforts to take all or any action
required under any applicable federal or state securities Laws in connection with the issuance of the Purchase Surviving Corporation Shares
pursuant to this Agreement. Each of Parent and the Company also agrees to use its commercially reasonable efforts to obtain all necessary
state securities law or &#8220;Blue Sky&#8221; permits and approvals required to carry out the transactions contemplated hereby, and the
Company shall furnish all information concerning the Company or the Company Shareholders as may be reasonably requested by Parent in connection
with any such action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
In connection with the preparation and filing of the Form S-4 and any amendments thereto, the Company shall reasonably cooperate with
Parent and shall make its directors, officers and appropriate senior employees reasonably available to Parent and its counsel in connection
with the drafting of the Form S-4, including the Proxy Statement, and responding in a timely manner to comments from the SEC or its staff
thereon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
Parent and the Company shall mutually agree upon and issue a press release announcing the effectiveness of this Agreement. Parent and
the Company shall cooperate in good faith with respect to the prompt preparation of such press release, and, as promptly as practicable
after the effective date of this Agreement (but in any event within four (4) Business Days thereafter), Parent shall file with the SEC,
with cooperation and following consultation from the Company, a Form 8-K pursuant to the Exchange Act to report the execution of this
Agreement as of its effective date. Prior to the Closing, Parent and the Company shall mutually agree upon and prepare the press release
announcing the consummation of the transactions contemplated by this Agreement. Concurrently with or promptly after the Closing, Parent
shall issue such press release. Parent and the Company shall cooperate in good faith with respect to the preparation of such press release,
and, at least five (5) days prior to the Closing, Parent shall prepare, with cooperation and consultation from the Company, a draft Form
8-K announcing the Closing, together with, or incorporating by reference, the required pro forma financial statements and the historical
financial statements prepared by the Company and its accountant. Concurrently with the Closing, or as soon as practicable (but in any
event within four (4) Business Days) thereafter, Parent shall file such Form 8-K with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4
<span style="text-decoration: underline">Shareholder Vote; Recommendation of Parent&#8217;s Board of Directors</span>. Parent, through
Parent&#8217;s board of directors, shall recommend that Parent Shareholders vote in favor of adopting and approving all Parent Proposals,
and Parent shall include such recommendation in the Proxy Statement. Parent&#8217;s board of directors shall not withdraw, amend, qualify
or modify its recommendation to the shareholders of Parent that they vote in favor of Parent Proposals (together with any withdrawal,
amendment, qualification or modification of its recommendation to the shareholders of Parent, a &#8220;<span style="text-decoration: underline">Modification
in Recommendation</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 511 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5
<span style="text-decoration: underline">Parent Shareholders&#8217; Meeting</span>. Parent shall take all action necessary under applicable
Law, in consultation with the Company, to establish a record date for, call, give notice of and hold a meeting of the holders of Parent
Shares to consider and vote on Parent Proposals at Parent Shareholders&#8217; Meeting. Parent Shareholders&#8217; Meeting shall be held
as promptly as practicable, in accordance with applicable Law and Parent&#8217;s Organizational Documents, after the Proxy Statement is
&#8220;cleared&#8221; by the SEC, but in no event later than 30 days following the date the Proxy Statement is &#8220;cleared&#8221; by
the SEC. Parent shall take reasonable measures to ensure that all proxies solicited in connection with Parent Shareholders&#8217; Meeting
are solicited in compliance with all applicable Law. Notwithstanding anything to the contrary contained herein, if on the date of Parent
Shareholders&#8217; Meeting, or a date preceding the date on which Parent Shareholders&#8217; Meeting is scheduled, Parent (after consultation
with the Company) reasonably believes that (i) it will not receive proxies sufficient to obtain Parent Required Vote for each Parent Proposal,
whether or not a quorum would be present or (ii) it will not have sufficient Parent Shares represented (whether in person or by proxy)
to constitute a quorum necessary to conduct the business of Parent Shareholders&#8217; Meeting, Parent may adjourn, or make one or more
successive adjournments of, Parent Shareholders&#8217; Meeting in compliance with the Laws of the British Virgin Islands and Parent&#8217;s
Organizational Documents, as long as the date of Parent Shareholders&#8217; Meeting is not adjourned more than an aggregate of twenty
(20) clear days in connection with any adjournments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6
<span style="text-decoration: underline">Form 8-K; Press Releases</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
As promptly as practicable after execution of this Agreement, but no later than four (4) Business Days thereafter, Parent will file a
Current Report on Form 8-K pursuant to the Exchange Act to report the execution of this Agreement, a copy of which will be provided to
the Company at least two Business Days before its filing deadline and which the Company may review and comment upon prior to filing. Promptly
after the execution of this Agreement, Parent and the Company shall also issue a joint press release announcing the execution of this
Agreement, in form and substance mutually acceptable to Parent and the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Prior to the Closing, Parent and the Company shall prepare a mutually agreeable press release announcing the consummation of the Merger
(the &#8220;<span style="text-decoration: underline">Closing Press Release</span>&#8221;). Concurrently with the Closing, Parent shall
distribute the Closing Press Release and, as soon as practicable thereafter, file a Current Report on Form 8-K with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7
<span style="text-decoration: underline">Fees and Expenses</span>. Except as otherwise set forth in this Agreement, including in <span style="text-decoration: underline">Section&#160;9.1(c)</span>,
each party hereto shall be responsible for and pay its own expenses incurred in connection with this Agreement and the transactions contemplated
hereby, including all fees of its legal counsel, financial advisers and accountants; <span style="text-decoration: underline">provided</span>
that, if the Closing shall occur, Purchaser shall pay or cause to be paid the Company Transaction Expenses and Parent Transaction Expenses
related to the Merger and the Transactions. Any payments to be made (or to cause to be made) by Purchaser pursuant to this <span style="text-decoration: underline">Section&#160;10.7</span>
shall be paid upon consummation of the Merger and release of proceeds from the Trust Account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 512 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8
<span style="text-decoration: underline">Shareholder Litigation</span>. In the event that any litigation related to this Agreement, any
Transaction Documents or the Transactions is brought or, to the Knowledge of Parent, threatened in writing, against Parent or the Board
of Directors of Parent by any Parent Shareholder prior to the Closing, Parent shall promptly notify the Company of any such litigation
and keep the Company reasonably informed with respect to the status thereof. Parent shall give due consideration to the Company&#8217;s
advice with respect to such litigation and shall not settle any such litigation without prior written consent of the Company, such consent
not to be unreasonably withheld, conditioned or delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
XI </b><br/><b>CONDITIONS PRECEDENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1
<span style="text-decoration: underline">Conditions to Each Party&#8217;s Obligation to Effect the Merger</span>. The respective obligations
of each Party to effect the Merger shall be subject to the satisfaction (or waiver, if permissible under applicable Law) on or prior to
the Closing Date of the following conditions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
There shall not be any Order or Law in effect that restrains, enjoins, prevents, prohibits or make illegal the consummation of the Merger;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Reincorporation, the Merger and each of the Parent Proposals (other than Parent Proposals described in <span style="text-decoration: underline">Section&#160;10.3(e)(vi)
&#8211; (vii)</span>) have been approved by Parent Required Vote in accordance with the provisions of Parent&#8217;s Organizational Documents
and the Laws of the British Virgin Islands;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Purchaser Surviving Corporation&#8217;s initial listing application in connection with the Transactions shall have been approved by
Nasdaq so that immediately following the Merger, Purchaser Surviving Corporation&#8217;s satisfies any applicable initial and continuing
listing requirements of Nasdaq;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
All consents, approvals and actions of, filings with and notices to any Governmental Authority required to consummate the Transactions
shall have been made or obtained;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Offer shall have been completed in accordance with the terms hereof and the Proxy Statement; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The Purchaser shall have, as of the Closing Date, an aggregate amount not less than $5,000,000 in any combination of cash, cash in the
Trust Account, a private investment in public equity, an equity line of credit, or third-party financing, net of any outstanding checks,
wire transfers, or similar items not yet cleared, and net of any cash distributions or transfers made in connection with or as a result
of the Transactions contemplated by this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2
<span style="text-decoration: underline">Conditions to Obligations of Parent, Purchaser and Merger Sub</span>. The obligations of Parent,
Purchaser and Merger Sub to effect the Reincorporation and the Merger are further subject to the satisfaction (or waiver, if permissible
under applicable Law) on or prior to the Closing Date of the following conditions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 513 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The representations and warranties of the Company set forth in <span style="text-decoration: underline">Article V</span> shall be true
and correct as of the date hereof and as of the Closing, except (i)&#160;for representations and warranties that speak as of a specific
date or time (which need be true and correct only as of such date or time) and (ii) for breaches of the representations and warranties
of the Company set forth in <span style="text-decoration: underline">ARTICLE V</span> that would not, individually or in the aggregate,
have a Company Material Adverse Effect;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Company shall have performed in all material respects all obligations required to be performed by it under this Agreement at or prior
to the Closing Date;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Since the date of this Agreement, there shall not be any event that is continuing that would individually, or in the aggregate, reasonably
be expected to have a Company Material Adverse Effect;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Parent shall have received a certificate or letter, signed by the CEO of the Company, certifying or confirming as to the matters set forth
in <span style="text-decoration: underline">Section&#160;11.2(a)</span>, <span style="text-decoration: underline">Section&#160;11.2(b)</span>
and <span style="text-decoration: underline">Section&#160;11.2(c)</span>;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Company shall have executed and delivered to Parent a copy of each Transaction Document to which it is a party;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The Company Shareholders shall have executed and delivered to Parent the Lock-Up Agreement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Parent shall have received a certificate or confirmation letter, signed by a director or officer of the Company and each of the Company&#8217;s
Subsidiaries certifying or confirming that true, latest and correct copies of the Organizational Documents of the Company and each of
the Company&#8217;s Subsidiaries, as in effect on the Closing Date, are attached to such certificate or confirmation letter;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Parent shall have received copies of third party consents (if applicable) set forth on <span style="text-decoration: underline">Schedule&#160;11.2(h)</span>
in form and substance reasonably satisfactory to Parent, and no such consents have been revoked;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Parent shall have received a certificate or letter, signed by a director or officer of the Company, certifying or confirming that true,
complete and correct copies of (i) the resolutions of the directors of the Company and (ii) by the directors of the Company authorizing
the execution and delivery of this Agreement and the other Transaction Documents to which it is a party and performance by the Company,
as applicable, of the Transactions, including the Merger, having been duly and validly adopted and being in full force and effect as of
the Closing Date, are attached to such certificate or letter; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
The Company shall have delivered to Parent good standing certificates (or similar documents applicable for such jurisdictions) for the
Company certified as of a date no earlier than five (5) days prior to the Closing Date from the Delaware Secretary of State and from each
other jurisdiction in which the Company is qualified to do business as a foreign corporation or other entity as of the Closing, in each
case provided that good standing certificates or similar documents for the Company are generally available in such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 514 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
Parent shall have received an acknowledgement duly executed by each Company Safeholder that such Company Safeholder is receiving Purchaser
Class A Shares, in a form reasonably acceptable to Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3
<span style="text-decoration: underline">Conditions to Obligation of the Company</span>. The obligation of the Company and the Company
Equityholders to effect the Merger is further subject to the satisfaction (or waiver, if permissible under applicable Law) on or prior
to the Closing Date of the following conditions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The representations and warranties of Parent, Purchaser and Merger Sub set forth in <span style="text-decoration: underline">ARTICLE VI</span>
shall be true and correct in all material respects, on and as of the Closing Date, as though made on and as of the Closing Date, except
(i) to the extent of changes or developments contemplated by the terms of this Agreement and (ii) for such representations and warranties
that speak as of a specific date or time (which need be true and correct only as of such date or time);</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Parent, Purchaser and Merger Sub shall have performed in all material respects all obligations required to be performed by them under
this Agreement at or prior to the Closing Date;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Since the date of this Agreement, there shall not be any event that is continuing that would individually, or in the aggregate, reasonably
be expected to have a Parent Material Adverse Effect;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Company shall have received a certificate or letter, signed by the CEO or CFO of Parent, certifying as to the matters set forth in
<span style="text-decoration: underline">Section&#160;11.3(a)</span>, <span style="text-decoration: underline">Section&#160;11.3(b)</span>
and <span style="text-decoration: underline">Section&#160;11.3(c)</span> above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Parent shall have executed and delivered to the Company copy of each Transaction Document to which it is a party;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Parent shall have delivered to the Company a certificate, signed by an officer of Parent, certifying true, complete and correct copies
of (i) the resolutions duly passed by Parent Required Vote at Parent Shareholders&#8217; Meeting and by Purchaser, as the sole shareholder
of Merger Sub, approving the Merger and the consummation of the Transactions contemplated by this Agreement and the other Transaction
Documents; (ii) certified copies of the resolutions duly passed by Parent&#8217;s board of directors, Purchaser and Merger Sub authorizing
the execution, delivery and performance of this Agreement and the other Transaction Documents to which each is a party and the performance
by Parent, Purchaser and Merger Sub of the Transactions, including the Merger, each having been duly and validly passed and being in full
force and effect as of the Closing Date; and (iii) written resignations, in forms satisfactory to the Company, dated as of the Closing
Date and effective as of the Closing, executed by such officer(s) and such person(s) serving as director(s) of Parent immediately prior
to the Closing;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Parent shall have delivered to the Company a certificate or letter, signed by an officer of Parent, certifying that true, complete and
correct copies of the Organizational Documents of Parent, Purchaser and Merger Sub, as in effect on the Closing Date, are attached to
such certificate or letter;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 515 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Parent shall have delivered to the Company certificates of good standing with respect to Parent, Purchaser and Merger Sub from their respective
applicable jurisdictions of incorporation; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Except for Parent Shares to be issued pursuant to this Agreement, from the date of this Agreement through the Closing, no Parent Shares
shall have been issued to any Person in an amount or on terms other than those approved with the prior written consent of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Closing occurs, all Closing conditions set forth in <span style="text-decoration: underline">Section&#160;11.1</span> and <span style="text-decoration: underline">Section&#160;11.3</span>
that have not been fully satisfied as of the Closing will be deemed to have been waived by Company, and all closing conditions set forth
in <span style="text-decoration: underline">Section&#160;11.1 </span>and Section <span style="text-decoration: underline">11.2</span>
that have not been fully satisfied as of the Closing will be deemed to have been waived by Parent, Purchaser and Merger Sub.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
XII </b><br/><b>TERMINATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1
<span style="text-decoration: underline">Termination</span>. This Agreement may be terminated and the Transactions abandoned at any time
prior to the Effective Time:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
By the mutual written consent of the Company and Parent duly authorized by each of their respective boards of directors;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
By Parent, if any of the representations or warranties of the Company set forth in <span style="text-decoration: underline">ARTICLE V</span>
shall not be true and correct, or if the Company has failed to perform any covenant or agreement on the part of the Company set forth
in this Agreement (including an obligation to consummate the Closing), in each case such that the conditions to Closing set forth in either
<span style="text-decoration: underline">&#8206;Section&#160;11.2(a)</span>, <span style="text-decoration: underline">Section&#160;11.2(b)</span>
or <span style="text-decoration: underline">&#8206;Section&#160;11.2(c)</span> would not be satisfied and the breach or breaches causing
such representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, are
not cured (or waived by Parent) by the earlier of (i) the Outside Date or (ii) thirty (30) days after written notice thereof is delivered
to the Company; <span style="text-decoration: underline">provided</span> that Parent shall not have the right to terminate this Agreement
pursuant to this <span style="text-decoration: underline">Section&#160;12.1(b)</span> if Parent or Merger Sub is then in material breach
of any representation, warranty, covenant or obligation hereunder, which breach has not been cured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
By the Company, if any of the representations or warranties of Parent, Purchaser or Merger Sub set forth in <span style="text-decoration: underline">&#8206;ARTICLE
VI</span> shall not be true and correct, or if either Parent, Purchaser or Merger Sub has failed to perform any covenant or agreement
on the part of Parent, Purchaser or Merger Sub set forth in this Agreement (including an obligation to consummate the Closing), in each
case such that the conditions to Closing set forth in either <span style="text-decoration: underline">&#8206;Section&#160;11.3(a)</span>
or <span style="text-decoration: underline">&#8206;Section&#160;11.3(b)</span> would not be satisfied and the breach or breaches causing
such representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, are
not cured (or waived by the Company) by the earlier of (i) the Outside Date or (ii) thirty (30) days after written notice thereof is delivered
to Parent; <span style="text-decoration: underline">provided</span> that the Company shall not have the right to terminate this Agreement
pursuant to this <span style="text-decoration: underline">Section&#160;12.1(c)</span> if the Company is then in material breach of any
representation, warranty, covenant or obligation hereunder, which breach has not been cured;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 516 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
By either the Company or Parent:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
On or after September&#160;1, 2026 (the &#8220;<span style="text-decoration: underline">Outside Date</span>&#8221;), if the Merger shall
not have been consummated prior to the Outside Date; <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>,
that the right to terminate this Agreement under this <span style="text-decoration: underline">Section&#160;12.1(d)(i)</span> shall not
be available to a Party if the failure of the Merger to have been consummated on or before the Outside Date was due to such Party&#8217;s
breach of or failure to perform any of its representations, warranties, covenants or agreements set forth in this Agreement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
If any Order having the effect set forth in <span style="text-decoration: underline">&#8206;Section&#160;11.1</span> shall be in effect
and shall have become final and non-appealable; <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>,
that the right to terminate this Agreement under this <span style="text-decoration: underline">&#8206;Section&#160;12.1(d)(ii)</span>
shall not be available to a Party if such Order was due to such Party&#8217;s breach of or failure to perform any of its representations,
warranties, covenants or agreements set forth in this Agreement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
If any of Parent Proposals (other than Parent Proposals described in <span style="text-decoration: underline">Section&#160;10.3(e)(vi</span>)
or <span style="text-decoration: underline">10.3(e)(vii))</span> shall fail to receive Parent Required Vote for approval at Parent Shareholders&#8217;
Meeting (unless such Parent Shareholders&#8217; Meeting has been adjourned, in which case at the final adjournment thereof);</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
By the Company if there has been a Modification in Recommendation;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
By Parent if the Company Shareholder Approval shall not have been obtained within seven (7) Business Days of the delivery to the Company
Shareholders of the Proxy Statement; <span style="text-decoration: underline">provided</span> that the termination right under this <span style="text-decoration: underline">Section&#160;12.1(f)</span>
shall be of no further force or effect if such Company Shareholder Approval is delivered to Parent prior to the termination of the Agreement
(even if after the seven (7) Business Day period provided above); or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
By Parent if the Audited Financial Statements or the Interim Financial Statements have not been delivered by January&#160;31, 2026 or
such other date that may be mutually agreed between the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2
<span style="text-decoration: underline">Effect of Termination</span>. In the event of the termination of this Agreement as provided in
&#8206;<span style="text-decoration: underline">Section&#160;12.1</span> (other than termination pursuant to <span style="text-decoration: underline">Section&#160;12.1(a)</span>)),
written notice thereof shall be given by the Party desiring to terminate to the other Party or Parties, specifying the provision hereof
pursuant to which such termination is made, and, following such delivery, this Agreement shall become null and void (other than the provisions
of <span style="text-decoration: underline">ARTICLE XIII</span> and this <span style="text-decoration: underline">Section&#160;12.2</span>).
The termination of this Agreement shall not affect the obligations of Parent or its Affiliates under the Non-Disclosure Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
XIII </b><br/><b>MISCELLANEOUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1
<span style="text-decoration: underline">Amendment or Supplement</span>. This Agreement may only be amended, modified or supplemented
by a duly authorized written agreement signed by each of the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 517 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2
<span style="text-decoration: underline">Extension of Time, Waiver, Etc</span>. At any time prior to the Effective Time, any party may,
subject to applicable Law, (a) waive any inaccuracies in the representations and warranties of any other Parties hereto, (b) extend the
time for the performance of any of the obligations or acts of any other Parties hereto or (c) waive compliance by the other Parties with
any of the agreements contained herein or any of such Party&#8217;s conditions. Notwithstanding the foregoing, no failure or delay by
the Company, Parent or Merger Sub in exercising any right hereunder shall operate as a waiver thereof nor shall any single or partial
exercise thereof preclude any other or further exercise thereof or the exercise of any other right hereunder. Any agreement on the part
of a Party hereto to any such extension or waiver shall be valid only if set forth in an instrument in writing signed on behalf of such
Party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.3
<span style="text-decoration: underline">Assignment</span>. Neither this Agreement nor any of the rights, interests or obligations hereunder
shall be assigned, in whole or in part, by operation of Law or otherwise, by any of the parties without the prior written consent of the
other parties. This Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the parties and their respective
successors and permitted assigns. Any purported assignment not permitted under this &#8206;<span style="text-decoration: underline">Section&#160;13.3</span>
shall be null and void.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.4
<span style="text-decoration: underline">Counterparts; Facsimile; Electronic Transmission</span>. This Agreement may be executed in counterparts
(each of which shall be deemed to be an original but all of which taken together shall constitute one and the same agreement) and shall
become effective when one or more counterparts have been signed by each of the Parties and delivered to the other parties. The exchange
of copies of this Agreement and of signature pages by facsimile or electronic transmission shall constitute effective execution and delivery
of this Agreement as to the parties and may be used in lieu of the original Agreement for all purposes. Signatures of the parties transmitted
by facsimile or electronic transmission shall be deemed to be their original signatures for all purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.5
<span style="text-decoration: underline">Entire Agreement; No Third-Party Beneficiaries</span>. This Agreement, the Non-Disclosure Agreement,
and the Transaction Documents (a) constitute the entire agreement, and supersede all other prior agreements and understandings, both written
and oral, among the parties, or any of them, with respect to the subject matter hereof and thereof and (b) are not intended to and shall
not confer any rights upon any Person other than the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.6
<span style="text-decoration: underline">Governing Law; Jurisdiction</span>. This Agreement shall be governed by, construed and enforced
in accordance with the Laws of the State of Delaware without regard to the conflict of laws principles thereof; <span style="text-decoration: underline">provided</span>
that matters that as a matter of the Laws of the British Virgin Islands are required to be governed by the law of the British Virgin Islands
(including the effects of the Reincorporation) shall be governed by, and construed in accordance with, the Laws of the British Virgin
Islands, without regard to Laws that may be applicable under conflicts of laws principles that would cause the application of the Laws
of any jurisdiction other than the British Virgin Islands. Subject to the previous sentence, all Proceedings arising out of or relating
to this Agreement shall be heard and determined exclusively in any state or federal court located in the State of Delaware (or in any
appellate court thereof) (the &#8220;<span style="text-decoration: underline">Specified Courts</span>&#8221;). Each Party hereto hereby
(a) submits to the exclusive jurisdiction of any Specified Court for the purpose of any Proceeding arising out of or relating to this
Agreement brought by any Party hereto and (b) irrevocably waives, and agrees not to assert by way of motion, defense or otherwise, in
any such Proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt
or immune from attachment or execution, that the Proceeding is brought in an inconvenient forum, that the venue of the Proceeding is improper,
or that this Agreement or the transactions contemplated hereby may not be enforced in or by any Specified Court. Each party agrees that
a final judgment in any Proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other
manner provided by Law. Each party irrevocably consents to the service of the summons and complaint and any other process in any other
Proceeding relating to the transactions contemplated by this Agreement, on behalf of itself, or its property, by personal delivery of
copies of such process to such party at the applicable address set forth in <span style="text-decoration: underline">Section&#160;13.10</span>.
Nothing in this <span style="text-decoration: underline">Section&#160;13.6</span> shall affect the right of any party to serve legal process
in any other manner permitted by Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 518 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.7
<span style="text-decoration: underline">WAIVER OF JURY TRIAL</span>. EACH PARTY HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED
BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER
OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE OF
ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION, SEEK TO ENFORCE
THAT FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG
OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <span style="text-decoration: underline">SECTION 13.7</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.8
<span style="text-decoration: underline">Specific Enforcement</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The parties hereby agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would
occur in the event that any provision of this Agreement (including failing to take such actions as are required of it hereunder to consummate
the Reincorporation, the Merger or the other Transactions) is not performed in accordance with its specific terms or is otherwise breached.
Accordingly, the parties agree that each party shall be entitled to an injunction or injunctions, or any other appropriate form of specific
performance or equitable relief, to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in
any court of competent jurisdiction in accordance with <span style="text-decoration: underline">Section&#160;13.6</span>, this being in
addition to any other remedy to which they are entitled under the terms of this Agreement at Law or in equity (and each party hereby waives
any requirement for the securing or posting of any bond in connection with such remedy).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Each of the parties agrees that it will not oppose the granting of an injunction, specific performance and other equitable relief when
expressly available pursuant to the terms of this Agreement on the basis that the other parties have an adequate remedy at Law or an award
of specific performance is not an appropriate remedy for any reason at Law or equity. Any party seeking an injunction or injunctions to
prevent breaches or threatened breaches of, or to enforce compliance with this Agreement when expressly available pursuant to the terms
of this Agreement shall not be required to provide any bond or other security in connection with any such Order or injunction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 519 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.9
<span style="text-decoration: underline">Notices</span>. All notices and other communications under this Agreement shall be in writing
and shall be deemed given (a) when delivered personally by hand (with written confirmation of receipt), by 5:00 p.m. on a Business Day,
addressee&#8217;s day and time, on the date of delivery, and otherwise on the first Business Day after such delivery, (b) when sent by
email (with written confirmation of transmission) if by 5:00 p.m. on a Business Day, addressee&#8217;s day and time, and otherwise on
the first Business Day after the date of such written confirmation; (c) when delivered after posting in the United States mail having
been sent registered or certified mail return receipt requested, postage prepared; or (d) one Business Day following the day sent by overnight
courier (with written confirmation of receipt), in each case at the following addresses (or to such other address as a party may have
specified by notice given to the other parties pursuant to this <span style="text-decoration: underline">Section&#160;13.9</span>):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to Parent, Purchaser or Merger Sub:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
Boral ARC Acquisition I Corp. <br/>590 Madison Ave<br/>New York, NY 10022<br/>Attn: John Darwin, Chief Financial Officer<br/>Email:
jdarwin@dboralcapital.com</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to (which shall not constitute notice):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loeb
&amp; Loeb<br/>345 Park Avenue, 19th Floor<br/>New York, NY 10154<br/> Attention: David Levine<br/> E-mail: dlevine@loeb.com</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Company:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
Labs Inc.<br/> 820 Gessner Road, Suite 332<br/>Houston, TX 77024<br/>Attention: Hoansoo Lee<br/> E-mail: hoansoo@exabits.xyz</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to (which shall not constitute notice):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kesse
PLLC<br/>845 Texas Avenue, Suite 200<br/>Houston, TX 77002<br/> Attention: Kelvin Kesse<br/> E-mail: kelvinkesse@kessepllc.com</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.10
<span style="text-decoration: underline">Severability</span>. If any term or other provision of this Agreement is determined by a court
of competent jurisdiction to be invalid, illegal or incapable of being enforced by any rule of Law or public policy, all other terms,
provisions and conditions of this Agreement shall nevertheless remain in full force and effect. Upon such determination that any term
or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement
so as to effect the original intent of the Parties as closely as possible to the fullest extent permitted by applicable Law in an acceptable
manner to the end that the Transactions are fulfilled to the extent possible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 520 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.11
<span style="text-decoration: underline">Remedies</span>. Except as otherwise provided in this Agreement, any and all remedies expressly
conferred upon a Party to this Agreement will be cumulative with, and not exclusive of, any other remedy contained in this Agreement,
at Law or in equity. The exercise by a Party to this Agreement of any one remedy will not preclude the exercise by it of any other remedy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.12
<span style="text-decoration: underline">Waiver</span>. The Company understands that Parent has established the Trust Account for the
benefit of the Parent Shareholders and the underwriters of the IPO pursuant to the Trust Agreement and that Parent may disburse monies
from the Trust Account only for the purposes set forth in the Trust Agreement and Parent Organizational Documents. For and in consideration
of Parent agreeing to enter into this Agreement, the Company and the Company Equityholders hereby agree that they do not have any right,
title, interest or claim of any kind in or to any monies in the Trust Account and hereby agree that they will not seek recourse against
the Trust Account for any claim they may have in the future as a result of, or arising out of, any negotiations, contracts or agreements
with Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.13
<span style="text-decoration: underline">Publicity</span>. Except as required by any Governmental Authority or Law including any applicable
securities Law or stock exchange rule, in which case the party making the announcement shall use commercially reasonable efforts to consult
with the other party in advance as to its form, content and timing, or as contemplated by this Agreement, the Parties agree that neither
they nor their agents shall issue any press release or make any other public disclosure concerning the Transactions without the prior
approval of the other Parties hereto, which approval shall not be unreasonably withheld. If a Party is required to make such a disclosure
as required by Law, the Parties will use their commercially reasonable efforts to cause a mutually agreeable release or public disclosure
to be issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.14
<span style="text-decoration: underline">Non-Recourse</span>. Except in the case of claims against a Person in respect of such Person&#8217;s
actual fraud:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Solely with respect to the Company, Parent and Merger Sub, this Agreement may only be enforced against, and any claim or cause of action
based upon, arising out of, or related to this Agreement or the transactions contemplated hereby may only be brought against, the Company,
Parent and Merger Sub as named Parties hereto; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Except to the extent a party hereto (and then only to the extent of the specific obligations undertaken by such party hereto), (i)&#160;no
past, present or future director, officer, employee, incorporator, member, partner, shareholder, Affiliate, agent, attorney, advisor or
representative or Affiliate of the Company, Parent or Merger Sub and (ii)&#160;no past, present or future director, officer, employee,
incorporator, member, partner, shareholder, Affiliate, agent, attorney, advisor or representative or Affiliate of any of the foregoing
shall have any liability (whether in Contract, tort, equity or otherwise) for any one or more of the representations, warranties, covenants,
agreements or other obligations or liabilities of any one or more of the Company, Parent or Merger Sub under this Agreement for any claim
based on, arising out of, or related to this Agreement or the transactions contemplated hereby.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>[signature
pages follow]</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 521 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed and delivered as of the date first above written.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="3" style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt"><span style="text-decoration: underline">Parent</span>:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="3" style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="3" style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">D. BORAL ARC ACQUISITION I CORP.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">/s/ John Darwin</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; width: 50%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 4%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 5%; text-indent: 0pt"><span style="font-size: 10pt">Name:&#160;</span></td>
    <td style="padding: 0pt; width: 41%; text-indent: 0pt"><span style="font-size: 10pt">John Darwin</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Title:</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="3" style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt"><span style="text-decoration: underline">Purchaser</span>:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="3" style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="3" style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">D. BORAL ARC MERGER CORPORATION</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">/s/ David Boral</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; width: 50%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 4%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 5%; text-indent: 0pt"><span style="font-size: 10pt">Name:&#160;</span></td>
    <td style="padding: 0pt; width: 41%; text-indent: 0pt"><span style="font-size: 10pt">David Boral</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Title:</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="3" style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt"><span style="text-decoration: underline">Merger Sub</span>:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="3" style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="3" style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">D. BORAL ARC MERGER SUB INC.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">/s/ David Boral</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; width: 50%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 4%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 5%; text-indent: 0pt"><span style="font-size: 10pt">Name:&#160;</span></td>
    <td style="padding: 0pt; width: 41%; text-indent: 0pt"><span style="font-size: 10pt">David Boral</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Title:</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="3" style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt"><span style="text-decoration: underline">The Company</span>:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="3" style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="3" style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">EXASCALE LABS INC.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">/s/ Hoansoo Lee</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; width: 50%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 4%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 5%; text-indent: 0pt"><span style="font-size: 10pt">Name:&#160;</span></td>
    <td style="padding: 0pt; width: 41%; text-indent: 0pt"><span style="font-size: 10pt">Hoansoo Lee</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Title:</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page to Agreement and Plan of Merger]</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 522 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><b><span id="annex_b1"></span>ANNEX B-1</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AMENDED
AND RESTATED </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTIFICATE
OF INCORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
BORAL ARC MERGER CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
Boral Arc Merger Corporation, a corporation organized and existing under the laws of the state of Delaware (the &#8220;<span style="text-decoration: underline">Corporation</span>&#8221;),
does hereby certify as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
        name of the Corporation is &#8220;D. Boral Arc Merger Corporation&#8221;. The original certificate of incorporation of the Corporation
        was filed with the Secretary of State of the State of Delaware on December&#160;19, 2025 (the &#8220;<span style="text-decoration: underline">Original
        Certificate</span>&#8221;). The name under which the Original Certificate was filed is &#8220;D. Boral Arc Merger Corporation&#8221;</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
        Amended and Restated Certificate of Incorporation (this &#8220;<span style="text-decoration: underline">Amended and Restated Certificate</span>&#8221;),
        which both restates and amends the provisions of the Original Certificate, was duly adopted in accordance with Sections&#160;242 and 245
        of the General Corporation Law of the State of Delaware.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Amended
        and Restated Certificate shall become effective upon filing with the Secretary of State of the State of Delaware.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
        Amended and Restated Certificate has been adopted in connection with the transactions contemplated by that certain Agreement and Plan
        of Merger, dated as of January&#160;11, 2026, by and among the Corporation, D. Boral ARC Acquisition I Corp., D. Boral Arc Merger Sub
        Inc., and Exascale Labs Inc. (as amended, supplemented or otherwise modified from time to time, the &#8220;<span style="text-decoration: underline">Merger
        Agreement</span>&#8221;).</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
        Amended and Restated Certificate hereby amends and restates the provisions of the Original Certificate to read in its entirety as follows:</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
I </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
name of the corporation is Exascale Labs Holdings Inc. (the &#8220;<span style="text-decoration: underline">Corporation</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
II </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
address of the Corporation&#8217;s registered office in the State of Delaware is 1521 Concord Pike, Suite 201, in the City of Wilmington,
County of New Castle, State of Delaware, 19803, and the name of the Corporation&#8217;s registered agent at such address is Corporate
Creations Network Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
III </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation
Law of the State of Delaware (the &#8220;<span style="text-decoration: underline">DGCL</span>&#8221;) as it now exists or may hereafter
be amended and supplemented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
IV </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total number of shares of capital stock that the Corporation shall have authority to issue is 300,000,000, consisting of: (i) 260,000,000
shares of Class A common stock, having a par value of $0.0001 per share (the &#8220;<span style="text-decoration: underline">Class A Common
Stock</span>&#8221;); (ii) 35,000,000 shares of Class B common stock, having a par value of $0.0001 per share (the &#8220;<span style="text-decoration: underline">Class
B Common Stock</span>&#8221; and together with the Class A Common Stock, the &#8220;<span style="text-decoration: underline">Common Stock</span>&#8221;);
and (iv) 5,000,000 shares of preferred stock, having a par value of $0.0001 per share (the &#8220;<span style="text-decoration: underline">Preferred
Stock</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 523; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
V </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
designations and the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each class
of capital stock of the Corporation are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&#160;COMMON
STOCK</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General</span>.
        The voting, dividend, liquidation and other rights and powers of the Common Stock are subject to and qualified by the rights, powers and
        preferences of any series of Preferred Stock as may be designated by the board of directors of the Corporation (the &#8220;<span style="text-decoration: underline">Board
        of Directors</span>&#8221;) and outstanding from time to time.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Voting</span>.
        Except as otherwise provided herein or expressly required by law, each holder of Common Stock, as such, shall be entitled to vote on each
        matter submitted to a vote of stockholders generally and shall be entitled to (i) one (1) vote for each share of Class A Common Stock
        and (ii) twenty (20) votes for each share of Class B Common Stock, in each case, held of record by such holder as of the record date for
        determining stockholders entitled to vote on such matter. Except as otherwise required by law, holders of Common Stock, as such, shall
        not be entitled to vote on any amendment to this Amended and Restated Certificate, as may be amended and/or restated from time to time
        (including any Certificate of Designation (as defined below)) that relates solely to the rights, powers, preferences (or the qualifications,
        limitations or restrictions thereof) or other terms of one or more outstanding series of Preferred Stock or other classes of Common Stock
        if the holders of such affected series of Preferred Stock or Common Stock, as applicable, are entitled exclusively, either separately
        or together with the holders of one or more other such series, to vote thereon pursuant to this Amended and Restated Certificate (including
        any Certificate of Designation) or pursuant to the DGCL.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise required pursuant to this Amended and Restated Certificate and subject to the rights of any holders of any outstanding series
of Preferred Stock, the number of authorized shares of each class of Common Stock or Preferred Stock may be increased or decreased (but
not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of the Corporation
entitled to vote, irrespective of the provisions of Section&#160;242(b)(2) of the DGCL (or any successor provision thereto).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise required in this Amended and Restated Certificate or by the DGCL, the holders of Common Stock will vote together as a single
class on all matters (or, if any holders of Preferred Stock are entitled to vote together with such holders of Common Stock, as a single
class with the holders of Preferred Stock).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Dividends</span>.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
        to applicable law and the rights and preferences of any holders of any outstanding series of Preferred Stock, the holders of Common Stock,
        as such, shall be entitled to the payment of dividends on the Common Stock when, as and if declared by the Board of Directors in accordance
        with applicable law.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
        of cash or property may not be declared or paid on any class of Common Stock unless a dividend of the same amount per share and same type
        of cash or property (or combination thereof) per share is concurrently declared or paid on the other classes of outstanding Common Stock.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
        no event will any stock dividend, stock split, reverse stock split, combination of stock, subdivision, exchange, reclassification or recapitalization
        be declared or made on any class of Common Stock (each, a &#8220;<span style="text-decoration: underline">Stock Adjustment</span>&#8221;)
        unless a corresponding Stock Adjustment for all other classes of Common Stock at the time outstanding is made in the same proportion and
        the same manner (unless such requirement is waived in advance by the written consent or affirmative vote of the holders of shares representing
        a majority of the voting power of any such other class of Common Stock (voting separately as a single class), in which event, no such
        Stock Adjustment need be made for such other class of Common Stock). Stock dividends with respect to each class of Common Stock may only
        be paid with shares of stock of the same class of Common Stock.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Liquidation</span>.
        Subject to the rights and preferences of any holders of any shares of any outstanding series of Preferred Stock, in the event of any liquidation,
        dissolution or winding up of the Corporation, whether voluntary or involuntary, the funds and assets of the Corporation that may be legally
        distributed to the Corporation&#8217;s stockholders shall be distributed among the holders of the then outstanding Common Stock <i>pro
        rata</i> in accordance with the number of shares of Common Stock held by each such holder.</span></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 524 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Merger,
        Consolidation, Tender or Exchange Offer</span>. Except as expressly provided in this Article V, all shares of Common Stock shall, as among
        each other, have the same rights, preferences and privileges and rank equally, share ratably and be identical in all respects as to all
        matters (unless holders of shares representing a majority of the voting power of any outstanding class of Common Stock (voting separately
        as a single class) waive such requirement in advance and in writing as to different treatment of such class of Common Stock, in which
        event different treatment may be permitted for such class of Common Stock). Without limiting the generality of the foregoing, unless such
        requirement as to different treatment of such class of Common Stock is waived in advance by the affirmative vote or written consent of
        holders of shares representing a majority of the voting power of any outstanding class of Common Stock (voting separately as a single
        class), in which event, different treatment may be permitted for such class of Common Stock, (i) in the event of a merger, consolidation
        or other business combination requiring the approval of the holders of the Corporation&#8217;s capital stock entitled to vote thereon
        (whether or not the Corporation is the surviving entity), the holders of any class of Common Stock shall have the right to receive, or
        the right to elect to receive, the same form of consideration, if any, as the holders of any other class of Common Stock, and the holders
        of any class of Common Stock shall have the right to receive, or the right to elect to receive, at least the same amount of consideration,
        if any, on a per share basis as the holders of any other class of Common Stock, and (ii) in the event of (a) any tender or exchange offer
        to acquire any shares of Common Stock by any third party pursuant to an agreement to which the Corporation is a party or (b) any tender
        or exchange offer by the Corporation to acquire any shares of Common Stock, pursuant to the terms of the applicable tender or exchange
        offer, the holders of any class of Common Stock shall have the right to receive, or the right to elect to receive, the same form of consideration,
        if any, as the holders of any other class of Common Stock, and the holders of any class of Common Stock shall have the right to receive,
        or the right to elect to receive, at least the same amount of consideration, if any, on a per share basis as the holders of any other
        class of Common Stock; provided that, for the purposes of the foregoing clauses (i) and (ii) and notwithstanding the first sentence of
        this Article V, Section A.5, in the event any such consideration includes securities, the consideration payable to holders of Class B
        Common Stock shall be deemed the same form of consideration and at least the same amount of consideration on a per share basis as the
        holders of Class A Common Stock on a per share basis if the only difference in the per share distribution to the holders of Class B Common
        Stock is that each share of the securities distributed to such holders has twenty (20) times the voting power of each share of the securities
        distributed to the holder of a share of Class A Common Stock.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Transfer
        Rights</span>. Subject to applicable law and the transfer restrictions set forth in the Bylaws and Article V, Section A.7 of this Amended
        and Restated Certificate, shares of Common Stock and the rights and obligations associated therewith shall be fully transferable to any
        transferee.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Conversion
        of Class B Common Stock</span>.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Voluntary
        Conversion</span>. Each share of Class B Common Stock shall be convertible into one share of Class A Common Stock at the option of the
        holder thereof at any time upon written notice to the transfer agent of the Corporation.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Automatic
        Conversion</span>. Each share of Class B Common Stock shall automatically, without any further action, convert into one share of Class
        A Common Stock upon a Transfer, other than to a Qualified Stockholder, of such share.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Procedures</span>.
        The Corporation may, from time to time, establish such policies and procedures relating to the conversion of Class B Common Stock into
        Class A Common Stock and the general administration of this multi<b>-</b>class stock structure, including the issuance of stock certificates
        (or the establishment of book-entry positions) with respect thereto, as it may deem reasonably necessary or advisable, and may from time
        to time request that holders of shares of Class B Common Stock furnish certifications, affidavits or other proof to the Corporation as
        it deems necessary to verify the ownership of Class B Common Stock and to confirm that a conversion into Class A Common Stock has not
        occurred. A determination in good faith by the Secretary of the Corporation that a Transfer results or has resulted in a conversion into
        Class A Common Stock shall be conclusive and binding.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 525 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Immediate
        Effect of Conversion</span>. In the event of a conversion of shares of Class B Common Stock into shares of Class A Common Stock pursuant
        to this Article V, Section A.7, such conversion(s) shall be deemed to have been made at the time that the Transfer of shares occurred.
        Upon any conversion of Class B Common Stock into Class A Common Stock, all rights of the holder of shares of Class B Common Stock shall
        cease and the person or persons in whose names or names the certificate or certificates (or book-entry position(s)) representing the shares
        of Class A Common Stock are to be issued shall be treated for all purposes as having become the record holder or holders of such shares
        of Class A Common Stock. Shares of Class B Common Stock that are converted into shares of Class A Common Stock as provided in this Article
        V, Section A.7 shall be retired and may not be reissued.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Reservation
        of Stock</span>. The Corporation shall at all times reserve and keep available out of its authorized but unissued shares of Class A Common
        Stock, solely for the purpose of effecting the conversion of the shares of Class B Common Stock, such number of shares of Class A Common
        Stock as shall from time to time be sufficient to effect the conversion of all outstanding shares of Class B Common Stock into shares
        of Class A Common Stock.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">No
        Further Issuances</span>. Except for a dividend payable in accordance with Article V, Section A.3 or a Stock Adjustment effectuated in
        accordance with Article V, Section A.3, the Corporation shall not at any time after the effective date of this Amended and Restated Certificate
        issue any additional shares of Class B Common Stock, unless such issuance is approved by the affirmative vote of the holders of a majority
        of the outstanding shares of Class A Common Stock, voting as a separate class.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
        purposes of this Article V, Section A, references to:</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Change
        of Control Issuance</span>&#8221; means the issuance by the Corporation, in a transaction or series of related transactions, of voting
        securities to any person or persons acting as a group as contemplated in Rule&#160;13d-5(b) under the Securities Exchange Act of 1934,
        as amended (the &#8220;<span style="text-decoration: underline">Exchange Act</span>&#8221;) (or any successor provision) that immediately
        prior to such transaction or series of related transactions held fifty percent (50%) or less of the total voting power of the outstanding
        voting securities of the Corporation, such that, immediately following such transaction or series of related transactions, such person
        or group of persons would hold more than fifty percent (50%) of the total voting power of the outstanding voting securities of the Corporation.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Change
        of Control Transaction</span>&#8221; means (a) the sale, lease, exclusive license, exchange, or other disposition (other than liens and
        encumbrances created in the ordinary course of business, including liens or encumbrances to secure indebtedness for borrowed money that
        are approved by the Board of Directors, so long as no foreclosure occurs in respect of any such lien or encumbrance) of all or substantially
        all of the Corporation&#8217;s property and assets (which shall for such purpose include the property and assets of any direct or indirect
        subsidiary of the Corporation), provided that any sale, lease, exclusive license, exchange or other disposition of property or assets
        exclusively between or among the Corporation and any direct or indirect subsidiary or subsidiaries of the Corporation shall not be deemed
        a &#8220;Change of Control Transaction&#8221;; (b) the merger, consolidation, business combination, or other similar transaction of the
        Corporation with any other entity, other than a merger, consolidation, business combination, or other similar transaction that would result
        in the voting securities of the Corporation outstanding immediately prior thereto continuing to represent (either by remaining outstanding
        or by being converted into voting securities of the surviving entity or its parent) more than fifty percent (50%) of the total voting
        power represented by the outstanding voting securities of the Corporation (or such surviving or parent entity) or more than fifty percent
        (50%) of the total number of outstanding shares of the Corporation&#8217;s (or such surviving or parent entity&#8217;s) capital stock,
        in each case as outstanding immediately after such merger, consolidation, business combination, or other similar transaction, and the
        stockholders of the Corporation immediately prior to the merger, consolidation, business combination, or other similar transaction continuing
        to own voting securities of the Corporation, the surviving entity or its parent immediately following the merger, consolidation, business
        combination, or other similar transaction in substantially the same proportions (vis-&#224;-vis each other) as such stockholders owned
        of the voting securities of the Corporation immediately prior to the transaction; (c) a recapitalization, liquidation, dissolution, or
        other similar transaction involving the Corporation, other than a recapitalization, liquidation, dissolution, or other similar transaction
        that would result in the voting securities of the Corporation outstanding immediately prior thereto continuing to represent (either by
        remaining outstanding or being converted into voting securities of the surviving entity or its parent) more than fifty percent (50%) of
        the total voting power represented by the voting securities of the Corporation (or such surviving or parent entity) or more than fifty
        percent (50%) of the total number of outstanding shares of the Corporation&#8217;s (or such surviving or parent entity&#8217;s) capital
        stock, in each case as outstanding immediately after such recapitalization, liquidation, dissolution or other similar transaction, and
        the stockholders of the Corporation immediately prior to the recapitalization, liquidation, dissolution or other similar transaction continuing
        to own voting securities of the Corporation, the surviving entity or its parent immediately following the recapitalization, liquidation,
        dissolution or other similar transaction in substantially the same proportions (vis-&#224;-vis each other) as such stockholders owned
        of the voting securities of the Corporation immediately prior to the transaction; and (d) any Change of Control Issuance.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 526 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Dispositive
        Power</span>&#8221; means the power to directly or indirectly cause a Transfer of the owner&#8217;s shares (including, without limitation,
        the power to direct a trustee of a Permitted Trust to Transfer such Permitted Trust&#8217;s shares).</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Family
        Member</span>&#8221; means an individual&#8217;s spouse, ex-spouse, domestic partner, lineal (including by adoption) descendant or antecedent,
        brother or sister, or the spouse or domestic partner of any child, adopted child or grandchild (including by adoption) of such individual.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Founders</span>&#8221;
        means Hoansoo Lee and Wenying Jia.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Permitted
        Entity</span>&#8221; means, with respect to a Qualified Stockholder, (i) a corporation in which such Qualified Stockholder directly, or
        indirectly through one or more Permitted Entities, owns shares with sufficient Voting Control in the corporation, or otherwise has legally
        enforceable rights, such that the Qualified Stockholder retains Dispositive Power and Voting Control with respect to the shares of Class
        B Common Stock held by such corporation; (ii) a partnership in which such Qualified Stockholder directly, or indirectly through one or
        more Permitted Entities, owns partnership interests with sufficient Voting Control in the partnership, or otherwise has legally enforceable
        rights, such that the Qualified Stockholder retains Dispositive Power and Voting Control with respect to the shares of Class B Common
        Stock held by such partnership; or (iii) a limited liability company in which such Qualified Stockholder directly, or indirectly through
        one or more Permitted Entities, owns membership interests with sufficient Voting Control in the limited liability company, or otherwise
        has legally enforceable rights, such that the Qualified Stockholder retains Dispositive Power and Voting Control with respect to the shares
        of Class B Common Stock held by such limited liability company.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Permitted
        Foundation</span>&#8221; means with respect to a Qualified Stockholder: (i) a trust or private non-operating organization that is tax-exempt
        under Section&#160;501(c)(3) of the Internal Revenue Code (the &#8220;<span style="text-decoration: underline">Code</span>&#8221;) so
        long as such Qualified Stockholder has Dispositive Power and Voting Control with respect to the shares of Class B Common Stock held by
        such trust or organization and the Transfer to such trust does not involve any payment of cash, securities, property or other consideration
        (other than an interest in such trust or organization) to such Qualified Stockholder.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Permitted
        IRA</span>&#8221; means an Individual Retirement Account, as defined in Section&#160;408(a) of the Code, or a pension, profit sharing,
        stock bonus or other type of plan or trust of which a Qualified Stockholder is a participant or beneficiary and which satisfies the requirements
        for qualification under Section&#160;401 of the Code; provided that in each case such Qualified Stockholder has Dispositive Power and
        Voting Control with respect to the shares of Class B Common Stock held in such account, plan or trust.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Permitted
        Transfer</span>&#8221; means, and is restricted to, any Transfer of a share of Class B Common Stock: (i) by a Qualified Stockholder to
        (a) any Permitted Trust of such Qualified Stockholder, (b) any Permitted IRA of such Qualified Stockholder, (c) any Permitted Entity of
        such Qualified Stockholder, and (d) any Permitted Foundation of such Qualified Stockholder; or (ii) by a Permitted Trust, Permitted IRA,
        Permitted Entity or Permitted Foundation of a Qualified Stockholder to (a) such Qualified Stockholder, or (b) any other Permitted Entity
        of such Qualified Stockholder.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Permitted
        Trust</span>&#8221; means with respect to a Qualified Stockholder a trust which (i) is held for the benefit of such Qualified Stockholder
        and/or one or more Family Members of the Qualified Stockholder in which no person other than such Qualified Stockholder and/or one or
        more Family Members of the Qualified Stockholder is then a beneficiary entitled to distributions of income or principal from such trust,
        and (ii) confers upon the Qualified Stockholder a Dispositive Power and Voting Control with respect to the shares of Class B Common Stock
        held by such trust.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 527 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Qualified
        Stockholder</span>&#8221; means (a) a Founder; (b) any other registered holder of a share of Class B Common Stock immediately after the
        effective time of this Amended and Restated Certificate; (c) the initial registered holder of any shares of Class B Common Stock that
        are originally issued by this Corporation pursuant to the exercise, conversion or settlement of a Right (provided that such Right was
        issued to and at all times held by a holder who would have been a Qualified Stockholder if such Right had been a share and without reference
        to this clause (c)); d) each natural person who Transfers shares of, or Rights for, Class B Common Stock to a Permitted Trust, Permitted
        IRA, Permitted Entity or Permitted Foundation that is or becomes a Qualified Stockholder in connection with such Transfer; or (e) a transferee
        of shares of Class B Common Stock received in a Transfer that constitutes a Permitted Transfer.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Rights</span>&#8221;
        means any option, restricted stock unit, warrant, conversion right or contractual right of any kind to acquire (through purchase, conversion
        or otherwise) shares of the Corporation&#8217;s authorized but unissued capital stock (or issued but not outstanding capital stock).</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)</span></td>
    <td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Transfer</span>&#8221;
        means, with respect to a share of Class B Common Stock, any sale, assignment, transfer, conveyance, hypothecation or other transfer or
        disposition of such share or any legal or beneficial interest in such share, whether or not for value and whether voluntary or involuntary
        or by operation of law, including, without limitation, a transfer to a broker or other nominee (regardless of whether there is a corresponding
        change in beneficial ownership), or the transfer of, or entering into a binding agreement with respect to, Voting Control over such share
        by proxy or otherwise; provided that the following shall not be considered a &#8220;<span style="text-decoration: underline">Transfer</span>&#8221;:
        (a) the granting of a revocable proxy to officers or directors or agents of the Corporation with the approval and at the request of the
        Board of Directors in connection with actions to be taken at an annual or special meeting of stockholders; (b) entering into a voting
        trust, agreement or arrangement (with or without granting a proxy) (1) solely with stockholders who are holders of Class B Common Stock
        that (A) is disclosed either in a Schedule&#160;13D or 13G filed with the Securities and Exchange Commission or in writing to the Secretary
        of this Corporation, (B) either has a term not exceeding one year or is terminable by the holder of the shares subject thereto at any
        time and (C) does not involve any payment of cash, securities, property or other consideration to the holder of the shares subject thereto
        other than the mutual promise to vote shares in a designated manner, or (2) pursuant to a written agreement to which the Corporation is
        a party; (c) in connection with a Change of Control Transaction that has been approved by the Board of Directors, the entering into a
        support, voting, tender or similar agreement or arrangement (in each case, with or without the grant of a proxy) that has also been approved
        by the Board of Directors; (d) the pledge of shares of Class B Common Stock by a stockholder that creates a mere security interest in
        such shares pursuant to a bona fide loan or indebtedness transaction for so long as such stockholder (or the Founder) continues to exercise
        Voting Control over such pledged shares and no such Voting Control is exercised by the Person to whom the shares are pledged (other than
        the Founder if the Founder is the Person to whom the shares are pledged), provided that a foreclosure on such shares or other similar
        action by the pledgee shall constitute a &#8220;Transfer&#8221; unless such foreclosure or similar action qualifies as a &#8220;Permitted
        Transfer&#8221; or (e) the fact that, as of the effective time of this Amended and Restated Certificate or at any time thereafter, the
        spouse of any holder of Class B Common Stock possesses or obtains an interest in such holder&#8217;s shares of Class B Common Stock arising
        solely by reason of the application of the community property laws of any jurisdiction, so long as no other event or circumstance shall
        exist or have occurred that constitutes a Transfer of such shares of Class B Common Stock (including a Transfer by operation of law pursuant
        to a qualified domestic order or in connection with a divorce settlement or any other court order).</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
A Transfer shall also be deemed to have occurred with respect to a share of Class B Common Stock beneficially held by (i) an entity that
is a Permitted Trust, Permitted IRA, Permitted Entity or Permitted Foundation, if there occurs any act or circumstance that causes such
entity to no longer be a Permitted Trust, Permitted IRA, Permitted Entity or Permitted Foundation or if there occurs a Transfer on a cumulative
basis, from and after the effective date of this Amended and Restated Certificate, of a majority of the voting power of the voting securities
of such entity or any direct or indirect parent of such entity, other than a Transfer to parties that are, as of the effective date of
this Amended and Restated Certificate, holders of voting securities of any such entity or parent of such entity, or (ii) an entity that
is a Qualified Stockholder, if there occurs a Transfer on a cumulative basis, from and after the effective date of this Amended and Restated
Certificate, of a majority of the voting power of the voting securities of such entity or any direct or indirect parent of such entity,
other than a Transfer to parties that are, as of the effective date of this Amended and Restated Certificate, holders of voting securities
of any such entity or parent of such entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 528 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"/>
    <td style="width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<span style="text-decoration: underline">Voting
        Control</span>&#8221; means, with the respect to a share of Class B Common Stock, the power (whether directly or indirectly) to vote or
        direct the voting of an equity interest, interest in a trust or other interest or security by proxy, voting agreement, or otherwise. For
        this purpose, the Voting Control with respect to shares transferred to and held in a Permitted Trust shall be deemed to be held exclusively
        by the trustee of such Permitted Trust; provided, however, if there is any individual powerholder who possesses the power to remove and
        replace the trustee of such Permitted Trust (i) without cause and (ii) for any reason, then the Voting Control of such Permitted Trust&#8217;s
        shares shall be deemed to be held exclusively by such individual powerholder (and not the trustee of such Permitted Trust).</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.&#160;PREFERRED
STOCK<br/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of Preferred Stock may be issued from time to time in one or more series, each of such series to have such terms as stated or expressed
herein and in the resolution or resolutions providing for the creation and issuance of such series adopted by the Board of Directors as
hereinafter provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority
is hereby expressly granted to the Board of Directors from time to time to issue the Preferred Stock in one or more series, and in connection
with the creation of any such series, by adopting a resolution or resolutions providing for the issuance of the shares thereof and by
filing a certificate of designation relating thereto in accordance with the DGCL (a &#8220;<span style="text-decoration: underline">Certificate
of Designation</span>&#8221;), to determine and fix the number of shares of such series and such voting powers, full or limited, or no
voting powers, and such designations, preferences and relative participating, optional or other special rights, and qualifications, limitations
or restrictions thereof, including without limitation thereof, dividend rights, conversion rights, redemption privileges and liquidation
preferences, and to increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of
any series as shall be stated and expressed in such resolutions, all to the fullest extent now or hereafter permitted by the DGCL. Without
limiting the generality of the foregoing, the resolution or resolutions providing for the creation and issuance of any series of Preferred
Stock may provide that such series shall be superior or rank equally or be junior to any other series of Preferred Stock to the extent
permitted by law and this Amended and Restated Certificate (including any Certificate of Designation). Except as otherwise required by
law, holders of any series of Preferred Stock shall be entitled only to such voting rights, if any, as shall expressly be granted thereto
by this Amended and Restated Certificate (including any Certificate of Designation).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
VI </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the management of the business and for the conduct of the affairs of the Corporation it is further provided that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
The directors of the Corporation shall be classified with respect to the time for which they severally hold office into three classes,
designated as Class I, Class II and Class III. Each class shall consist, as nearly as may be possible, of one third of the total number
of directors constituting the whole Board of Directors. The initial Class I directors shall serve for a term expiring at the 2027 annual
meeting of the stockholders of the Corporation; the initial Class II directors shall serve for a term expiring at the 2028 annual meeting
of the stockholders of the Corporation; and the initial Class III directors shall serve for a term expiring at the 2029 annual meeting
of stockholders of stockholders at the Corporation. At each annual meeting of stockholders of the Corporation beginning with the 2027
annual meeting of stockholders, the successors of the class of directors whose term expires at that meeting shall be elected to hold office
for a term expiring at the annual meeting of stockholders held in the third year following the year of their election. If the number of
such directors is changed, any increase or decrease shall be apportioned among the classes so as to maintain the number of directors in
each class as nearly equal as possible, and any such additional director of any class elected to fill a newly created directorship resulting
from an increase in such class shall hold office for a term that shall coincide with the remaining term of that class, but in no case
shall a decrease in the number of directors remove or shorten the term of any incumbent director. Any such director shall hold office
until the annual meeting at which his or her term expires and until his or her successor shall be elected and qualified, or his or her
death, resignation, retirement, disqualification or removal from office. The Board of Directors is authorized to assign members of the
Board of Directors already in office to their respective class. Each director shall hold office until his or her successor is duly elected
and qualified or until his or her earlier death, resignation, disqualification or removal in accordance with this Amended and Restate
Certificate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 529 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Except as otherwise expressly provided by the DGCL or this Amended and Restate Certificate, the business and affairs of the Corporation
shall be managed by or under the direction of the Board of Directors. The number of directors that shall constitute the whole Board of
Directors shall be fixed exclusively by one or more resolutions adopted from time to time by the Board of Directors in accordance with
the Bylaws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
Subject to the special rights of the holders of one or more outstanding series of Preferred Stock to elect directors, the Board of Directors
or any individual director may be removed from office at any time only for cause and then only by the affirmative vote of the holders
of at least 66&#8532;% of the voting power of all the then outstanding shares of voting stock of the Corporation entitled to vote generally
in the election of directors, voting together as a single class.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
Subject to the special rights of the holders of one or more outstanding series of Preferred Stock to elect directors, except as otherwise
provided by law, any vacancies on the Board of Directors resulting from death, resignation, disqualification, retirement, removal or other
causes and any newly created directorships resulting from any increase in the number of directors shall be filled (i) after no shares
of Class B Common Stock are outstanding, by the affirmative vote of a majority of the directors then in office, even though less than
a quorum, or by a sole remaining director and, (ii) when any shares of Class B Common Stock are outstanding, only by the affirmative vote
of the holders of at least a majority of the voting power of all of the then outstanding shares of voting stock of the Corporation entitled
to vote at an election of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.
Whenever the holders of any one or more series of Preferred Stock issued by the Corporation shall have the right, voting separately as
a series or separately as a class with one or more such other series, to elect directors at an annual or special meeting of stockholders,
the election, term of office, removal and other features of such directorships shall be governed by the terms of this Amended and Restated
Certificate (including any Certificate of Designation). Notwithstanding anything to the contrary in this Article VI, the number of directors
that may be elected by the holders of any such series of Preferred Stock shall be in addition to the number fixed pursuant to paragraph
B of this Article VI, and the total number of directors constituting the whole Board of Directors shall be automatically adjusted accordingly.
Except as otherwise provided in the Certificate of Designation(s) in respect of one or more series of Preferred Stock, whenever the holders
of any series of Preferred Stock having such right to elect additional directors are divested of such right pursuant to the provisions
of such Certificate of Designation(s), the terms of office of all such additional directors elected by the holders of such series of Preferred
Stock, or elected to fill any vacancies resulting from the death, resignation, disqualification or removal of such additional directors,
shall forthwith terminate (in which case each such director thereupon shall cease to be qualified as, and shall cease to be, a director)
and the total authorized number of directors of the Corporation shall automatically be reduced accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.
In furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to adopt, amend
or repeal the Bylaws, without the assent or vote of the stockholders of the Corporation entitled to vote with respect thereto in any manner
not inconsistent with the laws of the State of Delaware or this Amended and Restated Certificate. Notwithstanding anything to the contrary
contained in this Amended and Restated Certificate or any provision of law that might otherwise permit a lesser vote of the stockholders,
in addition to any vote of the holders of any class or series of stock of the Corporation required by applicable law or by this Amended
and Restated Certificate (including any Certificate of Designation(s) in respect of one or more series of Preferred Stock) or the Bylaws
of the Corporation, the adoption, amendment or repeal of the Bylaws of the Corporation by the stockholders of the Corporation shall require
the affirmative vote of the holders of at least 66&#8532;% of the voting power of all of the then outstanding shares of voting stock of
the Corporation entitled to vote generally in an election of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.
The directors of the Corporation need not be elected by written ballot unless the Bylaws so provide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 530 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
VII </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
Any action required or permitted to be taken by the stockholders of the Corporation may be effected at a duly called annual or special
meeting of stockholders or may, except as otherwise required by applicable law or this Amended and Restated Certificate, be taken without
a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, shall be signed by the
holders of outstanding shares of stock having not less than the minimum number of votes that would be necessary to authorize or take such
action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation in accordance
with the applicable provisions of the DGCL.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Subject to the special rights of the holders of one or more series of Preferred Stock, and to the requirements of applicable law, special
meetings of the stockholders of the Corporation may be called for any purpose or purposes, at any time only (i) by or at the direction
of the Board of Directors, the Chairperson of the Board of Directors or the Chief Executive Officer, in each case, in accordance with
the Bylaws, or (ii) by the Secretary of the Corporation upon the request, in writing, of any holder of record of at least 25% of the voting
power of the issued and outstanding shares of stock of the Corporation. Any such special meeting so called may be postponed, rescheduled
or cancelled by the Board of Directors or other person calling the meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
Advance notice of stockholder nominations for the election of directors and of other business proposed to be brought by stockholders before
any meeting of the stockholders of the Corporation shall be given in the manner provided in the Bylaws. Any business transacted at any
special meeting of stockholders shall be limited to matters relating to the purpose or purposes identified in the notice of meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
VIII </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
director of the Corporation shall have any personal liability to the Corporation or its stockholders for monetary damages for any breach
of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL
as the same exists or hereafter may be amended. Any amendment, repeal or modification of this Article VIII, or the adoption of any provision
of this Amended and Restated Certificate inconsistent with this Article VIII, shall not adversely affect any right or protection of a
director of the Corporation with respect to any act or omission occurring prior to such amendment, repeal, modification or adoption. If
the DGCL is amended after approval by the stockholders of this Article VIII to authorize corporate action further eliminating or limiting
the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest
extent permitted by the DGCL as so amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
IX </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
Subject to Article IX, Section C, the Corporation shall indemnify any person who was or is a party or is threatened to be made a party
to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than
an action by or in the right of the Corporation), by reason of the fact that such person is or was a director or officer of the Corporation,
or while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees),
judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or
proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests
of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person&#8217;s conduct
was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere
or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which such person
reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding,
had reasonable cause to believe that such person&#8217;s conduct was unlawful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 531 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Subject to Article IX(C), the Corporation shall indemnify any person who was or is a party or is threatened to be made a party to any
threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment in its favor by reason of
the fact that such person is or was a director or officer of the Corporation, or while a director or officer of the Corporation, is or
was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture,
trust or other enterprise, against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection
with the defense or settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed
to be in or not opposed to the best interests of the Corporation; except that no indemnification shall be made in respect of any claim,
issue or matter as to which such person shall have been adjudged to be liable to the Corporation unless and only to the extent that the
Court of Chancery of the State of Delaware or the court in which such action or suit was brought shall determine upon application that,
despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled
to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
Any indemnification under this Article IX (unless ordered by a court) shall be made by the Corporation only as authorized in the specific
case upon a determination that indemnification of the present or former director or officer is proper in the circumstances because such
person has met the applicable standard of conduct set forth in Article IX(A) or Article IX(B), as the case may be. Such determination
shall be made, with respect to a person who is a director or officer at the time of such determination, (i) by a majority vote of the
directors who are not parties to such action, suit or proceeding, even though less than a quorum, or (ii) by a committee of such directors
designated by a majority vote of such directors, even though less than a quorum, or (iii) if there are no such directors, or if such directors
so direct, by independent legal counsel in a written opinion or (iv) by the stockholders. Such determination shall be made, with respect
to former directors and officers, by any person or persons having the authority to act on the matter on behalf of the Corporation. To
the extent, however, that a present or former director or officer of the Corporation has been successful on the merits or otherwise in
defense of any action, suit or proceeding described above, or in defense of any claim, issue or matter therein, such person shall be indemnified
against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection therewith, without the
necessity of authorization in the specific case.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
For purposes of any determination under Article IX(C), a person shall be deemed to have acted in good faith and in a manner such person
reasonably believed to be in or not opposed to the best interests of the Corporation, or, with respect to any criminal action or proceeding,
to have had no reasonable cause to believe such person&#8217;s conduct was unlawful, if such person&#8217;s action is based on the records
or books of account of the Corporation or another enterprise, or on information supplied to such person by the officers of the Corporation
or another enterprise in the course of their duties, or on the advice of legal counsel for the Corporation or another enterprise or on
information or records given or reports made to the Corporation or another enterprise by an independent certified public accountant or
by an appraiser or other expert selected with reasonable care by the Corporation or another enterprise. The provisions of this Article
IX(D) shall not be deemed to be exclusive or to limit in any way the circumstances in which a person may be deemed to have met the applicable
standard of conduct set forth in Article IX(A) or Article IX(B), as the case may be.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.
Notwithstanding any contrary determination in the specific case under Article IX(C), and notwithstanding the absence of any determination
thereunder, any director or officer may apply to the Court of Chancery of the State of Delaware or any other court of competent jurisdiction
in the State of Delaware for indemnification to the extent otherwise permissible under Article IX(A) or Article IX(B). The basis of such
indemnification by the Corporation shall be a determination by such court that indemnification of the director or officer is proper in
the circumstances because such person has met the applicable standard of conduct set forth in Article IX(A) or Article IX(B), as the case
may be. Neither a contrary determination in the specific case under Article IX(C) nor the absence of any determination thereunder shall
be a defense to such application or create a presumption that the director or officer seeking indemnification has not met any applicable
standard of conduct. Notice of any application for indemnification pursuant to this Article IX shall be given to the Corporation promptly
upon the filing of such application. If successful, in whole or in part, the director or officer seeking indemnification shall also be
entitled to be paid the expense of prosecuting such application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 532 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.
Expenses (including attorneys&#8217; fees) incurred by a present or former director or officer in appearing at, participating in or defending
any civil, criminal, administrative or investigative action, suit or proceeding in advance of its final disposition or in connection with
a proceeding brought to establish or enforce a right to indemnification or advancement of expenses under this Article IX shall be paid
by the Corporation upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately
be determined that such person is not entitled to be indemnified by the Corporation as authorized in this Article IX. Such expenses (including
attorneys&#8217; fees) incurred by employees and agents of the Corporation or by persons acting at the request of the Corporation as directors,
officers, employees or agents of another corporation, partnership, joint venture, trust or other enterprise may be so paid upon such terms
and conditions, if any, as the Corporation deems appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.
The indemnification and advancement of expenses provided by, or granted pursuant to, this Article IX shall not be deemed exclusive of
any other rights to which those seeking indemnification or advancement of expenses may be entitled under this Amended and Restated Certificate,
the Bylaws, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person&#8217;s official
capacity and as to action in another capacity while holding such office, it being the policy of the Corporation that indemnification of
the persons specified in Article IX(A) or Article IX(B) shall be made to the fullest extent permitted by law. The provisions of this Article
IX shall not be deemed to preclude the indemnification of any person who is not specified in Article IX(A) or Article IX(B) but whom the
Corporation has the power or obligation to indemnify under the provisions of the DGCL, or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.
The Corporation may purchase and maintain insurance on behalf of any person who is or was a director or officer of the Corporation, or
is or was a director or officer of the Corporation serving at the request of the Corporation as a director, officer, employee or agent
of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred
by such person in any such capacity, or arising out of such person&#8217;s status as such, whether or not the Corporation would have the
power or the obligation to indemnify such person against such liability under the provisions of this Article IX.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.
For purposes of this Article IX, references to &#8220;the Corporation&#8221; shall include, in addition to the resulting corporation,
any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate
existence had continued, would have had power and authority to indemnify its directors or officers, so that any person who is or was a
director or officer of such constituent corporation, or is or was a director or officer of such constituent corporation serving at the
request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture,
trust or other enterprise, shall stand in the same position under the provisions of this Article IX with respect to the resulting or surviving
corporation as such person would have with respect to such constituent corporation if its separate existence had continued. The term &#8220;another
enterprise&#8221; as used in this Article IX shall mean any other corporation or any partnership, joint venture, trust, employee benefit
plan or other enterprise of which such person is or was serving at the request of the Corporation as a director, officer, employee or
agent. For purposes of this Article IX, references to &#8220;fines&#8221; shall include any excise taxes assessed on a person with respect
to an employee benefit plan; and references to &#8220;serving at the request of the Corporation&#8221; shall include any service as a
director, officer, employee or agent of the Corporation which imposes duties on, or involves services by, such director or officer with
respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person
reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted
in a manner &#8220;not opposed to the best interests of the Corporation&#8221; as referred to in this Article IX.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>J.
The indemnification and advancement of expenses provided by, or granted pursuant to, this Article IX shall, unless otherwise provided
when authorized or ratified as provided in this Article IX, continue as to a person who has ceased to be a director or officer and shall
inure to the benefit of the heirs, executors and administrators of such a person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">K.
Notwithstanding anything contained in this Article IX to the contrary, except for proceedings to enforce rights to indemnification (which
shall be governed by Article IX, Section E), the Corporation shall not be obligated to indemnify any present or former director or officer
(or his or her heirs, executors or personal or legal representatives) or advance expenses in connection with a proceeding (or part thereof)
initiated by such person unless such proceeding (or part thereof) was authorized or consented to by the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">L.
The Corporation may, to the extent authorized from time to time by the Board of Directors, provide rights to indemnification and to the
advancement of expenses to employees and agents of the Corporation and to persons serving at the request of the Corporation as directors,
officers, employees and agents of another corporation, partnership, joint venture, trust or other enterprise similar to those conferred
in this Article IX to directors and officers of the Corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 533 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M.
Notwithstanding that a director, officer, employee or agent of the Corporation (collectively, the &#8220;<span style="text-decoration: underline">Covered
Persons</span>&#8221;) may have certain rights to indemnification, advancement of expenses and/or insurance provided by other persons
(collectively, the &#8220;<span style="text-decoration: underline">Other Indemnitors</span>&#8221;), with respect to the rights to indemnification,
advancement of expenses and/or insurance set forth herein, the Corporation: (i) shall be the indemnitor of first resort (i.e., its obligations
to Covered Persons are primary and any obligation of the Other Indemnitors to advance expenses or to provide indemnification for the same
expenses or liabilities incurred by Covered Persons are secondary); and (ii) shall be required to advance the full amount of expenses
incurred by Covered Persons and shall be liable for the full amount of all liabilities, without regard to any rights Covered Persons may
have against any of the Other Indemnitors. No advancement or payment by the Other Indemnitors on behalf of Covered Persons with respect
to any claim for which Covered Persons have sought indemnification from the Corporation shall affect the immediately preceding sentence,
and the Other Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all
of the rights of recovery of Covered Persons against the Corporation. Notwithstanding anything to the contrary herein, the obligations
of the Corporation under this Article IX(M) shall only apply to Covered Persons in their capacity as Covered Persons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N.
Any repeal or amendment of this Article IX by the Board of Directors or the stockholders of the Corporation or by changes in applicable
law, or the adoption of any other provision of this Amended and Restated Certificate inconsistent with this Article IX, will, to the extent
permitted by applicable law, be prospective only (except to the extent such amendment or change in applicable law permits the Corporation
to provide broader indemnification rights to Indemnitees on a retroactive basis than permitted prior thereto), and will not in any way
diminish or adversely affect any right or protection existing hereunder in respect of any act or omission occurring prior to such repeal
or amendment or adoption of such inconsistent provision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><br/>ARTICLE
X </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery (the &#8220;<span style="text-decoration: underline">Chancery
Court</span>&#8221;) of the State of Delaware (or, in the event that the Chancery Court does not have jurisdiction, the federal district
court for the District of Delaware or other state courts of the State of Delaware) and any appellate court thereof shall, to the fullest
extent permitted by law, be the sole and exclusive forum for (i) any derivative action, suit or proceeding brought on behalf of the Corporation,
(ii) any action, suit or proceeding asserting a claim of breach of a fiduciary duty owed by any current or former director, officer, stockholder
or employee of the Corporation to the Corporation or to the Corporation&#8217;s stockholders, (iii) any action, suit or proceeding arising
pursuant to any provision of the DGCL or the Bylaws or this Amended and Restated Certificate (as either may be amended from time to time),
(iv) any action, suit or proceeding as to which the DGCL confers jurisdiction on the Chancery Court, or (v) any action, suit or proceeding
asserting a claim against the Corporation or any current or former director, officer or stockholder governed by the internal affairs doctrine.
If any action the subject matter of which is within the scope of the immediately preceding sentence is filed in a court other than the
courts in the State of Delaware (a &#8220;<span style="text-decoration: underline">Foreign Action</span>&#8221;) in the name of any stockholder,
such stockholder shall be deemed to have consented to (i) the personal jurisdiction of the state and federal courts in the State of Delaware
in connection with any action brought in any such court to enforce the provisions of the immediately preceding sentence and (ii) having
service of process made upon such stockholder in any such action by service upon such stockholder&#8217;s counsel in the Foreign Action
as agent for such stockholder. Notwithstanding the foregoing, the provisions of this Article X(A) shall not apply to suits brought to
enforce any liability or duty created by the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities
Act</span>&#8221;), the Exchange Act or any other claim for which the federal courts of the United States have exclusive jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Unless the Corporation consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal
district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of
action arising under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
Any person or entity purchasing or otherwise acquiring any interest in any security of the Corporation shall be deemed to have notice
of and consented to this Article X.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 534 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
XI </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
Notwithstanding anything contained in this Certificate of Incorporation to the contrary, in addition to any vote required by applicable
law, the following provisions in this Amended and Restated Certificate may not be amended, altered, repealed or rescinded, in whole or
in part, and no provision inconsistent therewith or herewith may be adopted, without the affirmative vote of the holders of at least 66&#8532;%
of the total voting power of all the then outstanding shares of stock of the Corporation entitled to vote thereon, voting together as
a single class: Article V, Article VI, Article VII, Article VIII, Article IX, Article X, and this Article XI; provided, however, that,
in addition to any other vote required by law or this Certificate of Incorporation, any amendment to this Amended and Restated Certificate
that (i) increases the voting power of the Class B Common Stock pursuant to Article V, Section A.2 or (ii) alters or changes Article V,
Section A.7 in a manner that adversely affects the holders of Class A Common Stock shall not be approved, in each case, without the affirmative
vote of the holders of at least a majority of the total voting power of all then-outstanding shares of Class A Common Stock of the Corporation
entitled to vote thereon, voting as a separate class.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
If any provision or provisions of this Amended and Restated Certificate shall be held to be invalid, illegal or unenforceable as applied
to any circumstance for any reason whatsoever: (i) the validity, legality and enforceability of such provisions in any other circumstance
and of the remaining provisions of this Amended and Restated Certificate (including, without limitation, each portion of any paragraph
of this Amended and Restated Certificate containing any such provision held to be invalid, illegal or unenforceable that is not itself
held to be invalid, illegal or unenforceable) shall not, to the fullest extent permitted by applicable law, in any way be affected or
impaired thereby and (ii) to the fullest extent permitted by applicable law, the provisions of this Amended and Restated Certificate (including,
without limitation, each such portion of any paragraph of this Amended and Restated Certificate containing any such provision held to
be invalid, illegal or unenforceable) shall be construed so as to permit the Corporation to protect its directors, officers, employees
and agents from personal liability in respect of their good faith service to or for the benefit of the Corporation to the fullest extent
permitted by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<i>Remainder
of page intentionally left blank.</i>]</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 535 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Corporation has caused this Amended and Restated Certificate to be executed by its duly authorized officer as this
[_] day of [_], 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
        Boral Arc Merger Corporation</b></span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; width: 50%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 536 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><b><span id="annex_b2"></span>ANNEX B-2</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bylaws
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exascale
Labs Holdings Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a
Delaware corporation) </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 537 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="3" style="text-align: justify; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Page</b></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
        I - Corporate Offices</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">1</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered Office</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center; width: 9%">1</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
        Offices</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">1</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="3" style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
        II - Meetings of Stockholders</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">1</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Place
        of Meetings</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">1</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
        Meeting</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">1</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special Meeting</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">1</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of Business to be Brought before a Meeting</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">1</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of Nominations for Election to the Board of Directors</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">4</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
        Requirements for Valid Nomination of Candidates to Serve as Director and, if Elected, to be Seated as Directors</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">5</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of Stockholders&#8217; Meetings</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">6</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quorum</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">7</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjourned Meeting; Notice</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">7</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct of Business</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">7</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">8</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Record
        Date for Stockholder Meetings and Other Purposes</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">8</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proxies</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">9</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Stockholders Entitled to Vote</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">9</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inspectors of Election</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">9</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery to the Corporation</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
        III - Directors</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">10</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Powers</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">10</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
        of Directors</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">10</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Election,
        Qualification and Term of Office of Directors</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">10</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resignation
        and Vacancies</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">10</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Place
        of Meetings; Meetings by Telephone</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">10</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regular
        Meetings</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">10</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
        Meetings; Notice</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">10</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quorum</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">11</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
        Action without a Meeting</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">11</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees
        and Compensation of Directors</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">11</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="3" style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
        IV - Committees</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">11</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Committees
        of Directors</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">11</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Meetings
        and Actions of Committees</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">12</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subcommittees</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">12</td> </tr>
  </table>

<p style="margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 538; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
        V - Officers</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">12</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officers</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center; width: 9%">12</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
        of Officers</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">12</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subordinate Officers</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">12</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Removal and Resignation of Officers</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">12</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vacancies
        in Offices</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">13</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representation
        of Shares of Other Corporations</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">13</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority
        and Duties of Officers</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">13</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">13</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="3" style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
        VI - Records</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">13</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="3" style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
        VII - General Matters</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">13</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Execution
        of Corporate Contracts and Instruments</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">13</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Certificates</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">14</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
        Designation of Certificates</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">14</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lost
        Certificates</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">14</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
        Without Certificates</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">14</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction;
        Definitions</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">14</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">14</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fiscal
        Year</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">15</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.9
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seal</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">15</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.10
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer
        of Stock</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">15</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.11
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
        Transfer Agreements</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">15</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.12
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered
        Stockholders</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">15</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.13
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waiver
        of Notice</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">15</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="3" style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
        VIII - Notice</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">16</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery
        of Notice; Notice by Electronic Transmission</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">16</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="3" style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
        IX - Indemnification</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">16</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power to Indemnify in Actions, Suits or Proceedings other than
        Those by or in the Right of the Corporation</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">16</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
        to Indemnify in Actions, Suits or Proceedings by or in the Right of the Corporation</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">17</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorization
        of Indemnification</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">17</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Good
        Faith Defined</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">17</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification
        by a Court</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">17</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses Payable in Advance</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">18</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonexclusivity
        of Indemnification and Advancement of Expenses</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">18</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.8
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">18</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Definitions</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">18</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.10
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Survival
        of Indemnification and Advancement of Expenses</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">19</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.11
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitation
        on Indemnification</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">19</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.12
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification
        of Employees and Agents</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">19</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.13
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primacy
        of Indemnification</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">19</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.14
        </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center">19</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
        X - Amendments</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">19</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
        XI - Definitions</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">20</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 539 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Bylaws</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>of </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exascale Labs Holdings Inc.</b><br/><br/><b>Article
I - Corporate Offices </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1.1 <span style="text-decoration: underline">Registered
Office</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The address of the registered office of Exascale Labs
Holdings Inc. (the &#8220;<span style="text-decoration: underline">Corporation</span>&#8221;) in the State of Delaware, and the name of
its registered agent at such address, shall be as set forth in the Corporation&#8217;s certificate of incorporation, as the same may be
amended and/or restated from time to time (the &#8220;<span style="text-decoration: underline">Certificate of Incorporation</span>&#8221;).
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1.2 <span style="text-decoration: underline">Other
Offices</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Corporation may have additional offices at any
place or places, within or outside the State of Delaware, as the Corporation&#8217;s board of directors (the &#8220;<span style="text-decoration: underline">Board</span>&#8221;)
may from time to time establish or as the business of the Corporation may require. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Article II - Meetings of Stockholders </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.1 <span style="text-decoration: underline">Place
of Meetings</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Meetings of stockholders shall be held at any place
within or outside the State of Delaware, designated by the Board. The Board may, in its sole discretion, determine that a meeting of stockholders
shall not be held at any place, but may instead be held solely by means of remote communication as authorized by the General Corporation
Law of the State of Delaware (the &#8220;<span style="text-decoration: underline">DGCL</span>&#8221;). In the absence of any such designation
or determination, stockholders&#8217; meetings shall be held at the Corporation&#8217;s principal executive office. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.2 <span style="text-decoration: underline">Annual
Meeting</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board shall designate the date and time of the
annual meeting. At the annual meeting, directors shall be elected and other proper business properly brought before the meeting in accordance
with Section&#160;2.4 of these bylaws may be transacted. The Board may postpone, reschedule or cancel any previously scheduled annual
meeting of stockholders. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.3 <span style="text-decoration: underline">Special
Meeting</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Special meetings of the stockholders may be called,
postponed, rescheduled or cancelled only by such persons and only in such manner as set forth in the Certificate of Incorporation. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No business may be transacted at any special meeting
of stockholders other than the business specified in the notice of such meeting. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.4 <span style="text-decoration: underline">Notice
of Business to be Brought before a Meeting</span>. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(i) At an annual meeting of the
stockholders, only such business shall be conducted as shall have been properly brought before the meeting. To be properly brought before
an annual meeting, business must be (i) specified in a notice of meeting (or any supplement thereto) given by or at the direction of the
Board, (ii) if not specified in a notice of meeting, otherwise brought before the meeting by the Board or the Chairperson of the Board
or (iii) otherwise properly brought before the meeting by a stockholder present in person who (A) (1) was a record owner of shares of
the Corporation both at the time of giving the notice provided for in this Section&#160;2.4 and at the time of the meeting, (2) is entitled
to vote at the meeting, and (3) has complied with this Section&#160;2.4 in all applicable respects or (B) properly made such proposal
in accordance with Rule&#160;14a-8 under the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (as
so amended and inclusive of such rules and regulations, the &#8220;<span style="text-decoration: underline">Exchange Act</span>&#8221;).
The foregoing clause (iii) shall be the exclusive means for a stockholder to propose business to be brought </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 540; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">before an annual meeting of the stockholders. For
purposes of this Section&#160;2.4, &#8220;present in person&#8221; shall mean that the stockholder proposing that the business be brought
before the annual meeting of the Corporation, or a qualified representative of such proposing stockholder, appear at such annual meeting.
A &#8220;qualified representative&#8221; of such proposing stockholder shall be a duly authorized officer, manager or partner of such
stockholder or any other person authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder
to act for such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission,
or a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders. Stockholders seeking to nominate
persons for election to the Board must comply with Section&#160;2.5 and Section&#160;2.6 and this Section 2.4 shall not be applicable
to nominations except as expressly provided in Section 2.5 and Section&#160;2.6. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(ii) Without qualification, for
business to be properly brought before an annual meeting by a stockholder pursuant to Section&#160;2.4(i)(iii), the stockholder must (i)
provide Timely Notice (as defined below) thereof in writing and in proper form to the Secretary of the Corporation and (ii) provide any
updates or supplements to such notice at the times and in the forms required by this Section&#160;2.4. To be timely, a stockholder&#8217;s
notice must be delivered to, or mailed and received at, the principal executive offices of the Corporation not less than 90 days nor more
than 120 days prior to the one-year anniversary of the preceding year&#8217;s annual meeting; <span style="text-decoration: underline">provided</span>,
<span style="text-decoration: underline">however</span>, that if the date of the annual meeting is more than 30 days before or more than
60 days after such anniversary date, notice by the stockholder to be timely must be so delivered, or mailed and received, not later than
the 90th day prior to such annual meeting or, if later, the 10th day following the day on which public disclosure of the date of such
annual meeting was first made by the Corporation (such notice within such time periods, &#8220;<span style="text-decoration: underline">Timely
Notice</span>&#8221;). In no event shall any adjournment or postponement of an annual meeting or the announcement thereof commence a new
time period (or extend any time period) for the giving of Timely Notice as described above. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(iii) To be in proper form for
purposes of this Section&#160;2.4, a stockholder&#8217;s notice to the Secretary shall set forth: </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) As to each Proposing Person (as defined below),
(1) the name and address of such Proposing Person (including, if applicable, the name and address that appear on the Corporation&#8217;s
books and records); and (2) the class or series and number of shares of the Corporation that are, directly or indirectly, owned of record
or beneficially owned (within the meaning of Rule&#160;13d-3 under the Exchange Act) by such Proposing Person (the disclosures to be made
pursuant to the foregoing clauses (1) and (2) are referred to as &#8220;<span style="text-decoration: underline">Stockholder Information</span>&#8221;);
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) As to each Proposing Person, (1) any material
pending or threatened legal proceeding in which such Proposing Person is a party or material participant involving the Corporation or
any of its officers or directors, or any affiliate of the Corporation, (2) any other material relationship between such Proposing Person,
on the one hand, and the Corporation, any affiliate of the Corporation, on the other hand, (3) any direct or indirect material interest
in any material contract or agreement of such Proposing Person with the Corporation or any affiliate of the Corporation (including, in
any such case, any employment agreement, collective bargaining agreement or consulting agreement), (4) a representation that such Proposing
Person intends or is part of a group which intends to deliver a proxy statement or form of proxy to holders of at least the percentage
of the Corporation&#8217;s outstanding capital stock required to approve or adopt the proposal or otherwise solicit proxies from stockholders
in support of such proposal, (5) a description of any agreement, arrangement or understanding with respect to the nomination or proposal
and/or the voting of shares of any class or series of stock of the Corporation between or among the Proposing Persons, and (6) any other
information relating to such Proposing Person that would be required to be disclosed in a proxy statement or other filing required to
be made in connection with solicitations of proxies or consents by such Proposing Person in support of the business proposed to be brought
before the meeting pursuant to Section&#160;14(a) of the Exchange Act (the disclosures to be made pursuant to the foregoing clauses (1)
through (6) are referred to as &#8220;<span style="text-decoration: underline">Disclosable Interests</span>&#8221;); <span style="text-decoration: underline">provided</span>,
<span style="text-decoration: underline">however</span>, that Disclosable Interests shall not include any such disclosures with respect
to the ordinary course business activities of any broker, dealer, commercial bank, trust company or other nominee who is a Proposing Person
solely as a result of being the stockholder directed to prepare and submit the notice required by these bylaws on behalf of a beneficial
owner; and </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) As to each item of business that the stockholder
proposes to bring before the annual meeting, (1) a brief description of the business desired to be brought before the annual meeting,
the reasons for conducting such business at the annual meeting and any material interest in such business of each Proposing Person, (2)
the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event that such business
includes a proposal to amend the bylaws of the Corporation, the language of the proposed amendment), and (3) any other information relating
to such item of business that would be required to be disclosed in a proxy statement or other filing required to be made in connection
with solicitations of proxies in support of the business proposed to be brought before the meeting pursuant to Section&#160;14(a) of the
Exchange Act; <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>, that
the disclosures required by this paragraph (c) shall not include any disclosures with respect to any broker, dealer, commercial bank,
trust company or other nominee who is a Proposing Person solely as a result of being the stockholder directed to prepare and submit the
notice required by these bylaws on behalf of a beneficial owner. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 541 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of this Section&#160;2.4, the term &#8220;<span style="text-decoration: underline">Proposing
Person</span>&#8221; shall mean (i) the stockholder providing the notice of business proposed to be brought before an annual meeting,
(ii) the beneficial owner or beneficial owners, if different, on whose behalf the notice of the business proposed to be brought before
the annual meeting is made, and (iii) any participant (as defined in paragraphs (a)(ii)-(vi) of Instruction 3 to Item 4 of Schedule&#160;14A)
with such stockholder in such solicitation. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(iv) A Proposing Person shall
update and supplement its notice to the Corporation of its intent to propose business at an annual meeting, if necessary, so that the
information provided or required to be provided in such notice pursuant to this Section 2.4 shall be true and correct as of the record
date for stockholders entitled to vote at the meeting and as of the date that is 10 business days prior to the meeting or any adjournment
or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary of the Corporation
at the principal executive offices of the Corporation not later than five business days after the record date for stockholders entitled
to vote at the meeting (in the case of the update and supplement required to be made as of such record date), and not later than eight
business days prior to the date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable,
on the first practicable date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement
required to be made as of 10 business days prior to the meeting or any adjournment or postponement thereof). For the avoidance of doubt,
the obligation to update and supplement as set forth in this paragraph or any other Section of these bylaws shall not limit the Corporation&#8217;s
rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder or enable or
be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any proposal or to submit any new proposal,
including by changing or adding matters, business or resolutions proposed to be brought before a meeting of the stockholders. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(v) Notwithstanding anything in
these bylaws to the contrary, no business shall be conducted at an annual meeting that is not properly brought before the meeting in accordance
with this Section&#160;2.4. The Board or chairperson of the meeting shall, if the facts warrant, determine that the business was not properly
brought before the meeting in accordance with this Section&#160;2.4, and if he or she should so determine, he or she shall so declare
to the meeting and any such business not properly brought before the meeting shall not be transacted. Notwithstanding the foregoing provisions
of this Section&#160;2.4, if the Proposing Person (or a qualified representative of the Proposing Person) does not appear at the annual
meeting to present the proposed business, such proposed business shall not be transacted, notwithstanding that proxies in respect of such
matter may have been received by the Corporation. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(vi) This Section&#160;2.4 is
expressly intended to apply to any business proposed to be brought before an annual meeting of stockholders other than any proposal made
in accordance with Rule&#160;14a-8 under the Exchange Act and included in the Corporation&#8217;s proxy statement. In addition to the
requirements of this Section&#160;2.4 with respect to any business proposed to be brought before an annual meeting, each Proposing Person
shall comply with all applicable requirements of the Exchange Act with respect to any such business. Nothing in this Section&#160;2.4
shall be deemed to affect the rights of stockholders to request inclusion of proposals in the Corporation&#8217;s proxy statement pursuant
to Rule&#160;14a-8 under the Exchange Act. Notwithstanding anything to the contrary contained in this Section&#160;2.4, until no shares
of Class B Common Stock are outstanding, any holder of record of at least 25% in voting power of the outstanding capital stock of the
Corporation entitled to vote in an election of directors generally shall not be subject to the notice procedures set forth in the foregoing
provisions of this Section&#160;2.4 and may bring any business before an annual meeting of stockholders in person at the annual meeting,
without prior notice. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(vii) For purposes of these bylaws,
&#8220;public disclosure&#8221; shall mean disclosure in a press release reported by a national news service, in a document publicly filed
by the Corporation with the Securities and Exchange Commission pursuant to Sections&#160;13, 14 or 15(d) of the Exchange Act or by such
other means as is reasonably designed to inform the public or securityholders of the Corporation in general of such information including,
without limitation, posting on the Corporation&#8217;s investor relations website. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 542 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.5 <span style="text-decoration: underline">Notice
of Nominations for Election to the Board of Directors</span>. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(i) Subject in all respects to
the provisions of the Corporation&#8217;s Certificate of Incorporation, nominations of any person for election to the Board at an annual
meeting or at a special meeting (but only if the election of directors is a matter specified in the notice of meeting given by or at the
direction of the person calling such special meeting) may be made at such meeting only (x) by or at the direction of the Board, including
by any committee or persons authorized to do so by the Board or these bylaws, or (y) by a stockholder present in person (A) who was a
record owner of shares of the Corporation both at the time of giving the notice provided for in this Section&#160;2.5 and at the time
of the meeting, (B) is entitled to vote at the meeting, and (C) has complied with this Section&#160;2.5 and Section&#160;2.6 as to such
notice and nomination. For purposes of this Section&#160;2.5, &#8220;present in person&#8221; shall mean that the stockholder proposing
that the business be brought before the meeting of the Corporation, or a qualified representative of such stockholder, appear at such
meeting. A &#8220;qualified representative&#8221; of such proposing stockholder shall be a duly authorized officer, manager or partner
of such stockholder or any other person authorized by a writing executed by such stockholder or an electronic transmission delivered by
such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic
transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders. Except as may be otherwise
provided by the terms of one or more series of Preferred Stock with respect to the rights of holders of one or more series of Preferred
Stock to elect directors, the foregoing clause (y) shall be the exclusive means for a stockholder to make any nomination of a person or
persons for election to the Board at an annual meeting or special meeting. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(ii) Without qualification, for
a stockholder to make any nomination of a person or persons for election to the Board at an annual meeting, the stockholder must (1) provide
Timely Notice (as defined in Section&#160;2.4) thereof in writing and in proper form to the Secretary of the Corporation, (2) provide
the information, agreements and questionnaires with respect to such stockholder and its candidate for nomination as required to be set
forth by this Section&#160;2.5 and Section&#160;2.6 and (3) provide any updates or supplements to such notice at the times and in the
forms required by this Section&#160;2.5 and Section 2.6. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(iii) Without qualification, if
the election of directors is a matter specified in the notice of meeting given by or at the direction of the person calling a special
meeting in accordance with the Certificate of Incorporation, then for a stockholder to make any nomination of a person or persons for
election to the Board at a special meeting, the stockholder must (1) provide timely notice thereof in writing and in proper form to the
Secretary of the Corporation at the principal executive offices of the Corporation, (2) provide the information with respect to such stockholder
and its candidate for nomination as required by this Section&#160;2.5 and Section&#160;2.6 and (3) provide any updates or supplements
to such notice at the times and in the forms required by this Section&#160;2.5. To be timely, a stockholder&#8217;s notice for nominations
to be made at a special meeting must be delivered to, or mailed and received at, the principal executive offices of the Corporation not
earlier than the 120th day prior to such special meeting and not later than the 90th day prior to such special meeting or, if later, the
10th day following the day on which public disclosure (as defined in Section&#160;2.4) of the date of such special meeting was first made.
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(iv) In no event shall any adjournment
or postponement of an annual meeting or special meeting or the announcement thereof commence a new time period (or extend any time period)
for the giving of a stockholder&#8217;s notice as described above. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(v) In no event may a Nominating
Person provide notice with respect to a greater number of director candidates than are subject to election by stockholders at the applicable
meeting. If the Corporation shall, subsequent to such notice, increase the number of directors subject to election at the meeting, such
notice as to any additional nominees shall be due on the later of (i) (x) in the case of an annual meeting, the conclusion of the time
period for Timely Notice or (y) in the case of a special meeting, the conclusion of the time period for Timely Notice as set forth in
Section&#160;2.5(iii), or (iii) the tenth day following the date of public disclosure (as defined in Section 2.4) of such increase. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(vi) To be in proper form for
purposes of this Section&#160;2.5, a stockholder&#8217;s notice to the Secretary shall set forth: </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) As to each Nominating Person (as defined below),
the Stockholder Information (as defined in Section&#160;2.4(iii)(a), except that for purposes of this Section&#160;2.5 the term &#8220;Nominating
Person&#8221; shall be substituted for the term &#8220;Proposing Person&#8221; in all places it appears in Section&#160;2.4(iii)(a));
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) As to each Nominating Person, any Disclosable
Interests (as defined in Section 2.4(iii)(b), except that for purposes of this Section&#160;2.5 the term &#8220;Nominating Person&#8221;
shall be substituted for the term &#8220;Proposing Person&#8221; in all places it appears in Section&#160;2.4(iii)(b) and the disclosure
with respect to the business to be brought before the meeting in Section&#160;2.4(iii)(b) shall be made with respect to the election of
directors at the meeting); and </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 543 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) As to each candidate whom a Nominating Person
proposes to nominate for election as a director, (A) all information with respect to such candidate for nomination that would be required
to be set forth in a stockholder&#8217;s notice pursuant to this Section 2.5 and Section&#160;2.6 if such candidate for nomination were
a Nominating Person, (B) all information relating to such candidate for nomination that is required to be disclosed in a proxy statement
or other filings required to be made in connection with solicitations of proxies for election of directors in a contested election pursuant
to Section&#160;14(a) under the Exchange Act (including such candidate&#8217;s written consent to being named in the Corporation&#8217;s
proxy statement as a nominee and to serving as a director if elected), (C) a description of any direct or indirect material interest in
any material contract or agreement between or among any Nominating Person, on the one hand, and each candidate for nomination or his or
her respective associates or any other participants in such solicitation, on the other hand, including, without limitation, all information
that would be required to be disclosed pursuant to Item 404 under Regulation S-K if such Nominating Person were the &#8220;registrant&#8221;
for purposes of such rule and the candidate for nomination were a director or executive officer of such registrant (the disclosures to
be made pursuant to the foregoing clauses (A) through (C) are referred to as &#8220;<span style="text-decoration: underline">Nominee Information</span>&#8221;),
and (D) a completed and signed questionnaire, representation and agreement as provided in Section&#160;2.6(i). </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of this Section&#160;2.5, the term &#8220;<span style="text-decoration: underline">Nominating
Person</span>&#8221; shall mean (i) the stockholder providing the notice of the nomination proposed to be made at the meeting, (ii) the
beneficial owner or beneficial owners, if different, on whose behalf the notice of the nomination proposed to be made at the meeting is
made, and (iii) any other participant in such solicitation. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(vii) A stockholder providing
notice of any nomination proposed to be made at a meeting shall further update and supplement such notice, if necessary, so that the information
provided or required to be provided in such notice pursuant to this Section&#160;2.5 shall be true and correct as of the record date for
stockholders entitled to vote at the meeting and as of the date that is 10 business days prior to the meeting or any adjournment or postponement
thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary at the principal executive offices
of the Corporation not later than five business days after the record date for stockholders entitled to vote at the meeting (in the case
of the update and supplement required to be made as of such record date), and not later than eight business days prior to the date for
the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior
to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of
10 business days prior to the meeting or any adjournment or postponement thereof). For the avoidance of doubt, the obligation to update
and supplement as set forth in this paragraph or any other Section of these bylaws shall not limit the Corporation&#8217;s rights with
respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder or enable or be deemed
to permit a stockholder who has previously submitted notice hereunder to amend or update any nomination or to submit any new nomination.
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(viii) In addition to the requirements
of this Section&#160;2.5 with respect to any nomination proposed to be made at a meeting, each Nominating Person shall comply with all
applicable requirements of the Exchange Act with respect to any such nominations. Notwithstanding anything to the contrary contained in
this Section&#160;2.5, until no shares of Class B Common Stock are outstanding, any holder of record of at least 25% in voting power of
the outstanding capital stock of the Corporation entitled to vote in an election of directors generally shall not be subject to the notice
procedures set forth in the foregoing notice and nomination provisions of this Section&#160;2.5 and Section&#160;2.6 and may nominate
any person for election at an annual meeting or at a special meeting in person at the annual or special meeting, without prior notice.
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.6 <span style="text-decoration: underline">Additional
Requirements for Valid Nomination of Candidates to Serve as Director and, if Elected, to be Seated as Directors</span>. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(i) To be eligible to be a candidate
for election as a director of the Corporation at an annual or special meeting, a candidate must be nominated in the manner prescribed
in Section&#160;2.5 and the candidate for nomination, whether nominated by the Board or by a stockholder of record, must have previously
delivered (in accordance with the time period prescribed for delivery in a notice to such candidate given by or on behalf of the Board),
to the Secretary at the principal executive offices of the Corporation, (i) a completed written questionnaire (in a form provided by the
Corporation) with respect to the background, qualifications, stock ownership and independence of such proposed nominee, and such additional
information with respect to such proposed nominee as would be required to be provided by the Corporation pursuant to Schedule&#160;14A
if such proposed nominee were a participant in the solicitation of proxies by the Corporation in connection with such annual or special
meeting and (ii) a written representation and agreement (in form provided by the Corporation) that such candidate for nomination (A) if
elected as a director of the Corporation, will comply with all applicable corporate governance, conflict of interest, confidentiality,
stock ownership and trading and other policies and guidelines of the Corporation applicable to directors and in effect during such person&#8217;s
term in office as a director (and, if requested by any candidate for nomination, the Secretary of the Corporation shall provide to such
candidate for nomination all such policies and guidelines then in effect), and (B) consents to being named as a nominee in the Corporation&#8217;s
proxy statement pursuant to Rule&#160;14a-4(d) under the Exchange Act and any associated proxy card of the Corporation and agrees to serve
if elected as a director. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 544 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(ii) The Board may also require
any proposed candidate for nomination as a Director to furnish such other information as may be requested by the Board in writing prior
to the meeting of stockholders at which such candidate&#8217;s nomination is to be acted upon in order for the Board to determine the
eligibility of such candidate for nomination to be an independent director of the Corporation in accordance with the Corporation&#8217;s
Corporate Governance Guidelines, the Exchange Act and applicable stock exchange rules. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(iii) A candidate for nomination
as a director shall further update and supplement the materials delivered pursuant to this Section&#160;2.6, if necessary, so that the
information provided or required to be provided pursuant to this Section&#160;2.6 shall be true and correct as of the record date for
stockholders entitled to vote at the meeting and as of the date that is 10 business days prior to the meeting or any adjournment or postponement
thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary at the principal executive offices
of the Corporation (or any other office specified by the Corporation in any public announcement) not later than five business days after
the record date for stockholders entitled to vote at the meeting (in the case of the update and supplement required to be made as of such
record date), and not later than eight business days prior to the date for the meeting or, if practicable, any adjournment or postponement
thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been adjourned or postponed)
(in the case of the update and supplement required to be made as of 10 business days prior to the meeting or any adjournment or postponement
thereof). For the avoidance of doubt, the obligation to update and supplement as set forth in this paragraph or any other Section of these
bylaws shall not limit the Corporation&#8217;s rights with respect to any deficiencies in any notice provided by a stockholder, extend
any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend
or update any proposal or to submit any new proposal, including by changing or adding nominees, matters, business or resolutions proposed
to be brought before a meeting of the stockholders. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(iv) No candidate shall be eligible
for nomination as a director of the Corporation unless such candidate for nomination and the Nominating Person seeking to place such candidate&#8217;s
name in nomination has complied with Section&#160;2.5 and this Section&#160;2.6, as applicable. The Board or chairperson of the meeting
shall, if the facts warrant, determine that a nomination was not properly made in accordance with Section&#160;2.5 and this Section&#160;2.6,
and if he or she should so determine, he or she shall so declare such determination to the meeting, the defective nomination shall be
disregarded and any ballots cast for the candidate in question (but in the case of any form of ballot listing other qualified nominees,
only the ballots cast for the nominee in question) shall be void and of no force or effect. Notwithstanding the foregoing provisions of
Section&#160;2.5, if the stockholder (or a qualified representative of the stockholder) does not appear at the meeting of stockholders
of the Corporation to present the nomination, such nomination shall be disregarded, notwithstanding that proxies in respect of such nomination
may have been received by the Corporation. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(v) Notwithstanding anything in
these bylaws to the contrary, no candidate for nomination shall be eligible to be seated as a director of the Corporation unless nominated
and elected in accordance with Section&#160;2.5 and this Section&#160;2.6. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.7 <span style="text-decoration: underline">Notice
of Stockholders&#8217; Meetings</span>. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise provided by law, the Certificate
of Incorporation or these bylaws, the notice of any meeting of stockholders shall be sent or otherwise given in accordance with Section&#160;8.1
of these bylaws not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting.
The notice shall specify the place, if any, date and time of the meeting, the means of remote communication, if any, by which stockholders
and proxy holders may be deemed to be present in person and vote at such meeting, the record date for determining the stockholders entitled
to vote at the meeting (if such date is different from the record date for stockholders entitled to notice of the meeting) and, in the
case of a special meeting, the purpose or purposes for which the meeting is called. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 545 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.8 <span style="text-decoration: underline">Quorum</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise provided by law, the Certificate
of Incorporation or these bylaws, the holders of a majority in voting power of the stock issued and outstanding and entitled to vote,
present in person, or by remote communication, if applicable, or represented by proxy, shall constitute a quorum for the transaction of
business at all meetings of the stockholders, except that when specified business is to be voted on by a class or series of stock voting
as a class, the holders of shares representing a majority of the voting power of the outstanding shares of such class or series shall
constitute a quorum of such class or series for the transaction of such business. A quorum, once established at a meeting, shall not be
broken by the withdrawal of enough votes to leave less than a quorum. If, however, a quorum is not present or represented at any meeting
of the stockholders, then either (i) the person presiding over the meeting or (ii) a majority in voting power of the stockholders entitled
to vote at the meeting, present in person, or by remote communication, if applicable, or represented by proxy, shall have power to recess
the meeting or adjourn the meeting from time to time in the manner provided in Section&#160;2.9 of these bylaws until a quorum is present
or represented. At any recessed or adjourned meeting at which a quorum is present or represented, any business may be transacted that
might have been transacted at the meeting as originally noticed. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.9 <span style="text-decoration: underline">Adjourned
Meeting; Notice</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When a meeting is adjourned to another time or place,
unless these bylaws otherwise require, notice need not be given of the adjourned meeting if the time, place, if any, thereof, and the
means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such
adjourned meeting are announced at the meeting at which the adjournment is taken. At any adjourned meeting, the Corporation may transact
any business which might have been transacted at the original meeting. If the adjournment is for more than 30 days, a notice of the adjourned
meeting shall be given to each stockholder of record entitled to vote at the meeting. If after the adjournment a new record date for determination
of stockholders entitled to vote is fixed for the adjourned meeting, the Board shall fix as the record date for determining stockholders
entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote
at the adjourned meeting, and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such meeting
as of the record date so fixed for notice of such adjourned meeting. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.10 <span style="text-decoration: underline">Conduct
of Business</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The chairperson of each annual and special meeting
shall be the Chairperson of the Board or, in the absence (or inability or refusal to act) of the Chairperson of the Board, the Chief Executive
Officer (if he or she shall be a director) or, in the absence (or inability or refusal to act) of the Chief Executive Officer or if the
Chief Executive Officer is not a director, the President (if he or she shall be a director) or, in the absence (or inability or refusal
to act) of the President or if the President is not a director, such other person as shall be appointed by the Board. The date and time
of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced at the
meeting by the chairperson of the meeting. The Board may adopt by resolution such rules and regulations for the conduct of the meeting
of stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted by the Board,
the chairperson of the meeting of stockholders shall have the right and authority to convene and (for any or no reason) to recess and/or
adjourn the meeting, to prescribe such rules, regulations and procedures (which need not be in writing) and to do all such acts as, in
the judgment of the chairperson of the meeting, are appropriate for the proper conduct of the meeting. Such rules, regulations or procedures,
whether adopted by the Board or prescribed by the chairperson of the meeting, may include, without limitation, the following: (i) the
establishment of an agenda or order of business for the meeting; (ii) rules and procedures for maintaining order at the meeting and the
safety of those present (including, without limitation, rules and procedures for removal of disruptive persons from the meeting); (iii)
limitations on attendance at or participation in the meeting to stockholders entitled to vote at the meeting, their duly authorized and
constituted proxies or such other persons as the chairperson of the meeting shall determine; (iv) restrictions on entry to the meeting
after the time fixed for the commencement thereof; and (v) limitations on the time allotted to questions or comments by participants.
The chairperson of the meeting, in addition to making any other determinations that may be appropriate to the conduct of the meeting (including,
without limitation, determinations with respect to the administration and/or interpretation of any of the rules, regulations or procedures
of the meeting, whether adopted by the Board or prescribed by the chairperson of the meeting), shall, if the facts warrant, determine
and declare to the meeting that a matter of business was not properly brought before the meeting and if such chairperson should so determine,
such chairperson shall so declare to the meeting and any such matter or business not properly brought before the meeting shall not be
transacted or considered. Unless and to the extent determined by the Board or the chairperson of the meeting, meetings of stockholders
shall not be required to be held in accordance with the rules of parliamentary procedure. The secretary of each annual and special meeting
of stockholders shall be the Secretary or, in the absence (or inability or refusal to act) of the Secretary, an Assistant Secretary so
appointed to act by the chairperson of the meeting. In the absence (or inability or refusal to act) of the Secretary and all Assistant
Secretaries, the chairperson of the meeting may appoint any person to act as secretary of the meeting. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 546 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.11 <span style="text-decoration: underline">Voting</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except as may be otherwise provided in the Certificate
of Incorporation, these bylaws or the DGCL, each stockholder shall be entitled to (i) one (1) vote for each share of Class A Common Stock
held by such stockholder, and (ii) twenty (20) votes for each shares of Class B Common Stock held by such stockholder. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except as otherwise provided by the Certificate of
Incorporation and subject to the rights of the holders of one or more series of Preferred Stock, voting separately by class or series,
to elect directors pursuant to the terms of one or more series of Preferred Stock, at all duly called or convened meetings of stockholders
at which a quorum is present, for the election of directors, a plurality of the votes cast shall be sufficient to elect a director. Except
as otherwise provided by the Certificate of Incorporation, these bylaws, the rules or regulations of any stock exchange applicable to
the Corporation, or applicable law or pursuant to any regulation applicable to the Corporation or its securities, each other matter presented
to the stockholders at a duly called or convened meeting at which a quorum is present shall be decided by a majority of the votes cast
(excluding abstentions and broker non-votes) on such matter. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.12 <span style="text-decoration: underline">Record
Date for Stockholder Meetings and Other Purposes</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order that the Corporation may determine the stockholders
entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board may fix a record date, which record
date shall not precede the date upon which the resolution fixing the record date is adopted by the Board, and which record date shall,
unless otherwise required by law, not be more than 60 days nor less than 10 days before the date of such meeting. If the Board so fixes
a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board determines,
at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination.
If no record date is fixed by the Board, the record date for determining stockholders entitled to notice of or to vote at a meeting of
stockholders shall be the close of business on the next day preceding the day on which notice is first given, or, if notice is waived,
at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled
to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <span style="text-decoration: underline">provided</span>,
<span style="text-decoration: underline">however</span>, that the Board may fix a new record date for determination of stockholders entitled
to vote at the adjourned meeting; and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned
meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance herewith at the adjourned
meeting. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise restricted by the Certificate of
Incorporation, in order that the Corporation may determine the stockholders entitled to express consent to corporate action without a
meeting, the Board may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date
is adopted by the Board, and which record date shall not be more than ten (10) days after the date upon which the resolution fixing the
record date is adopted by the Board. If no record date for determining stockholders entitled to express consent to corporate action without
a meeting is fixed by the Board, (i) when no prior action of the Board is required by the DGCL, the record date for such purpose shall
be the first date on which a signed consent setting forth the action taken or proposed to be taken is delivered to the Corporation in
accordance with applicable law, and (ii) if prior action by the Board is required by the DGCL, the record date for such purpose shall
be at the close of business on the day on which the Board adopts the resolution taking such prior action. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order that the Corporation may determine the stockholders
entitled to receive payment of any dividend or other distribution or allotment or any rights or the stockholders entitled to exercise
any rights in respect of any change, conversion or exchange of capital stock, or for the purposes of any other lawful action, the Board
may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which
record date shall be not more than 60 days prior to such action. If no record date is fixed, the record date for determining stockholders
for any such purpose shall be at the close of business on the day on which the Board adopts the resolution relating thereto. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 547 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.13 <span style="text-decoration: underline">Proxies</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each stockholder entitled to vote at a meeting of
stockholders or to express consent or dissent to corporate action in writing without a meeting may authorize another person or persons
to act for such stockholder by proxy authorized by an instrument in writing or by a transmission permitted by law in any manner provided
under the DGCL or as otherwise provided under applicable law and filed in accordance with the procedure established for the meeting, but
no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. The revocability
of a proxy that states on its face that it is irrevocable shall be governed by the provisions of the DGCL. A proxy may be in the form
of an electronic transmission that sets forth or is submitted with information from which it can be determined that the transmission was
authorized by the stockholder. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.14 <span style="text-decoration: underline">List
of Stockholders Entitled to Vote</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Corporation shall prepare, at least 10 days before
every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and
showing the address of each stockholder and the number of shares registered in the name of each stockholder. The Corporation shall not
be required to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the
examination of any stockholder, for any purpose germane to the meeting for a period of at least 10 days prior to the meeting: (i) on a
reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice
of the meeting, or (ii) during ordinary business hours, at the Corporation&#8217;s principal executive office. In the event that the Corporation
determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information
is available only to stockholders of the Corporation. If the meeting is to be held at a place, then the list shall be produced and kept
at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present. If the meeting
is to be held solely by means of remote communication, then the list shall also be open to the examination of any stockholder during the
whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided
with the notice of the meeting. Such list shall presumptively determine the identity of the stockholders entitled to vote at the meeting
and the number of shares held by each of them. Except as otherwise provided by law, the stock ledger shall be the only evidence as to
who are the stockholders entitled to examine the list of stockholders required by this Section&#160;2.14 or to vote in person or by proxy
at any meeting of stockholders. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.15 <span style="text-decoration: underline">Inspectors
of Election</span>. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Before any meeting of stockholders, the Corporation
shall appoint an inspector or inspectors of election to act at the meeting or its adjournment and make a written report thereof. The Corporation
may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If any person appointed as inspector
or any alternate fails to appear or fails or refuses to act, then the person presiding over the meeting shall appoint a person to fill
that vacancy. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Such inspectors shall: </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(i) determine the number of shares
outstanding and the voting power of each, the number of shares represented at the meeting and the validity of any proxies and ballots;
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(ii) count all votes or ballots;
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(iii) count and tabulate all votes;
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(iv) determine and retain for
a reasonable period a record of the disposition of any challenges made to any determination by the inspector(s); and </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(v) certify its or their determination
of the number of shares represented at the meeting and its or their count of all votes and ballots. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any report or certificate made by the inspectors of
election is prima facie evidence of the facts stated therein. The inspectors of election may appoint such persons to assist them in performing
their duties as they determine. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 548 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Article III - Directors </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.1 <span style="text-decoration: underline">Powers</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except as otherwise provided by the Certificate of
Incorporation or the DGCL, the business and affairs of the Corporation shall be managed by or under the direction of the Board. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.2 <span style="text-decoration: underline">Number
of Directors</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subject to the Certificate of Incorporation or any
certificate of designation with respect to any series of Preferred Stock, the total number of directors constituting the Board shall be
determined from time to time by resolution of the Board. Except as otherwise provided in the Certificate of Incorporation, no reduction
of the authorized number of directors shall have the effect of removing any director before that director&#8217;s term of office expires.
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.3 <span style="text-decoration: underline">Election,
Qualification and Term of Office of Directors</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Directors shall be elected by stockholders at their
annual meeting, and the term of each director shall be as set forth in the Certificate of Incorporation. Directors need not be stockholders.
The Certificate of Incorporation or these bylaws may prescribe qualifications for directors. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.4 <span style="text-decoration: underline">Resignation
and Vacancies</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any director may resign at any time upon notice given
in writing or by electronic transmission to the Corporation. The resignation shall take effect at the time specified therein or upon the
happening of an event specified therein, and if no time or event is specified, at the time of its receipt. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subject to the special rights of the holders of one
or more series of Preferred Stock to elect directors, except as otherwise provided by applicable law, vacancies resulting from the death,
resignation, disqualification or removal of any director, and newly created directorships resulting from any increase in the authorized
number of directors shall be filled as set forth in the Certificate of Incorporation. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.5 <span style="text-decoration: underline">Place
of Meetings; Meetings by Telephone</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board may hold meetings, both regular and special,
either within or outside the State of Delaware. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise restricted by the Certificate of
Incorporation or these bylaws, members of the Board, or any committee designated by the Board, may participate in a meeting of the Board,
or any committee, by means of conference telephone or other communications equipment by means of which all persons participating in the
meeting can hear each other, and such participation in a meeting pursuant to this bylaw shall constitute presence in person at the meeting.
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.6 <span style="text-decoration: underline">Regular
Meetings</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Regular meetings of the Board may be held within or
outside the State of Delaware and at such time and at such place as which has been designated by the Board and publicized among all directors,
either orally or in writing, by telephone, including a voice-messaging system or other system designed to record and communicate messages,
facsimile, telegraph or telex, or by electronic mail or other means of electronic transmission. No further notice shall be required for
regular meetings of the Board. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.7 <span style="text-decoration: underline">Special
Meetings; Notice</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Special meetings of the Board for any purpose or purposes
may be held within or outside the State of Delaware and called at any time by the Chairperson of the Board, the Chief Executive Officer,
the President, the Secretary or a majority of the total number of directors constituting the Board. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notice of the time and place of special meetings shall
be: </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(i)&#160;delivered personally
by hand, by courier or by telephone; </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 549 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(ii)&#160;sent by United States
first-class mail, postage prepaid; </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(iii)&#160;sent by facsimile or
electronic mail; or </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(iv)&#160;sent by other means
of electronic transmission,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">directed to each director at that director&#8217;s
address, telephone number, facsimile number or electronic mail address, or other address for electronic transmission, as the case may
be, as shown on the Corporation&#8217;s records.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the notice is (i) delivered personally by hand,
by courier or by telephone, (ii) sent by facsimile or electronic mail, or (iii) sent by other means of electronic transmission, it shall
be delivered or sent at least 24 hours before the time of the holding of the meeting. If the notice is sent by U.S. mail, it shall be
deposited in the U.S. mail at least four days before the time of the holding of the meeting. The notice need not specify the place of
the meeting (if the meeting is to be held at the Corporation&#8217;s principal executive office) nor the purpose of the meeting. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.8 <span style="text-decoration: underline">Quorum</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At all meetings of the Board, unless otherwise provided
by the Certificate of Incorporation, a majority of the total number of directors shall constitute a quorum for the transaction of business.
The vote of a majority of the directors present at any meeting at which a quorum is present shall be the act of the Board, except as may
be otherwise specifically provided by statute, the Certificate of Incorporation or these bylaws. If a quorum is not present at any meeting
of the Board, then the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at
the meeting, until a quorum is present. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.9 <span style="text-decoration: underline">Board
Action without a Meeting</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise restricted by the Certificate of
Incorporation or these bylaws, any action required or permitted to be taken at any meeting of the Board, or of any committee thereof,
may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing or by electronic
transmission. After an action is taken, the consent or consents relating thereto shall be filed with the minutes of the proceedings of
the Board, or the committee thereof, in the same paper or electronic form as the minutes are maintained. Such action by written consent
or consent by electronic transmission shall have the same force and effect as a unanimous vote of the Board. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.10 <span style="text-decoration: underline">Fees
and Compensation of Directors</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise restricted by the Certificate of
Incorporation or these bylaws, the Board shall have the authority to fix the compensation, including fees and reimbursement of expenses,
of directors for services to the Corporation in any capacity. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Article IV - Committees </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4.1 <span style="text-decoration: underline">Committees
of Directors</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board may designate one or more committees, each
committee to consist of one or more of the directors of the Corporation. The Board may designate one or more directors as alternate members
of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification
of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not such
member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such
absent or disqualified member. Each committee of the Board may fix its own rules of procedure and shall hold its meetings as provided
by such rules, except as may otherwise be provided by a resolution of the Board designating such committee. Unless otherwise provided
in such a resolution, the presence of at least a majority of the members of the committee shall be necessary to constitute a quorum unless
the committee shall consist of one or two members, in which event one member shall constitute a quorum; and all matters shall be determined
by a majority vote of the members present at a meeting of the committee at which a quorum is present. Any such committee, to the extent
provided in the resolution of the Board or in these bylaws, shall have and may exercise all the powers and authority of the Board in the
management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers that
may require it; but no such committee shall have the power or authority to (i) approve or adopt, or recommend to the stockholders, any
action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for
approval, or (ii) adopt, amend or repeal any bylaw of the Corporation. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 550 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4.2 <span style="text-decoration: underline">Meetings
and Actions of Committees</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Meetings and actions of committees shall be governed
by, and held and taken in accordance with, the provisions of: </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(i)&#160;Section&#160;3.5 (place
of meetings; meetings by telephone); </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(ii)&#160;Section&#160;3.6 (regular
meetings); </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(iii)&#160;Section&#160;3.7 (special
meetings; notice); </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(iv)&#160;Section&#160;3.9 (board
action without a meeting); and </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(v)&#160;Section&#160;7.13 (waiver
of notice),</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">with such changes in the context of those bylaws as
are necessary to substitute the committee and its members for the Board and its members. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4.3 <span style="text-decoration: underline">Subcommittees</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise provided in the Certificate of Incorporation,
these bylaws, the resolutions of the Board designating the committee or the charter of such committee adopted by the Board, a committee
may create one or more subcommittees, each subcommittee to consist of one or more members of the committee, and delegate to a subcommittee
any or all of the powers and authority of the committee. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Article V - Officers </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5.1 <span style="text-decoration: underline">Officers</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The officers of the Corporation shall include a Chief
Executive Officer, a President and a Secretary. The Corporation may also have, at the discretion of the Board, a Chairperson of the Board,
a Vice Chairperson of the Board, a Chief Financial Officer, a Treasurer, one or more Vice Presidents, one or more Assistant Vice Presidents,
one or more Assistant Treasurers, one or more Assistant Secretaries, and any such other officers as may be appointed in accordance with
the provisions of these bylaws. Any number of offices may be held by the same person. No officer need be a stockholder or director of
the Corporation. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5.2 <span style="text-decoration: underline">Appointment
of Officers</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board shall appoint the officers of the Corporation,
except such officers as may be appointed in accordance with the provisions of Section&#160;5.3 of these bylaws. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5.3 <span style="text-decoration: underline">Subordinate
Officers</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board may appoint, or empower the Chief Executive
Officer or, in the absence of a Chief Executive Officer, the President, to appoint, such other officers and agents as the business of
the Corporation may require. Each of such officers and agents shall hold office for such period, have such authority, and perform such
duties as are provided in these bylaws or as the Board may from time to time determine. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5.4 <span style="text-decoration: underline">Removal
and Resignation of Officers</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subject to the rights, if any, of an officer under
any contract of employment, any officer may be removed, either with or without cause, by the Board or, except in the case of an officer
chosen by the Board, by any officer upon whom such power of removal may be conferred by the Board. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 551 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any officer may resign at any time by giving written
notice to the Corporation. Any resignation shall take effect at the date of the receipt of that notice or at any later time specified
in that notice. Unless otherwise specified in the notice of resignation, the acceptance of the resignation shall not be necessary to make
it effective. Any resignation is without prejudice to the rights, if any, of the Corporation under any contract to which the officer is
a party. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5.5 <span style="text-decoration: underline">Vacancies
in Offices</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any vacancy occurring in any office of the Corporation
shall be filled as provided in Section&#160;5.2 or Section&#160;5.3, as applicable. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5.6 <span style="text-decoration: underline">Representation
of Shares of Other Corporations</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Chairperson of the Board, the Chief Executive
Officer or the President of the Corporation, or any other person authorized by the Board, the Chief Executive Officer or the President,
is authorized to vote, represent and exercise on behalf of this Corporation all rights incident to any and all shares or voting securities
of any other corporation or other person standing in the name of the Corporation. The authority granted herein may be exercised either
by such person directly or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the
authority. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5.7 <span style="text-decoration: underline">Authority
and Duties of Officers</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All officers of the Corporation shall respectively
have such authority and perform such duties in the management of the business of the Corporation as may be provided herein or designated
from time to time by the Board and, to the extent not so provided, as generally pertain to their respective offices, subject to the control
of the Board. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5.8 <span style="text-decoration: underline">Compensation</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The compensation of the officers of the Corporation
for their services as such shall be fixed from time to time by or at the direction of the Board. An officer of the Corporation shall not
be prevented from receiving compensation by reason of the fact that he or she is also a director of the Corporation. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Article VI - Records </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A stock ledger consisting of one or more records in
which the names of all of the Corporation&#8217;s stockholders of record, the address and number of shares registered in the name of each
such stockholder, and all issuances and transfers of stock of the corporation are recorded in accordance with the DGCL shall be administered
by or on behalf of the Corporation. Any records administered by or on behalf of the Corporation in the regular course of its business,
including its stock ledger, books of account, and minute books, may be kept on, or by means of, or be in the form of, any information
storage device, or method, or one or more electronic networks or databases (including one or more distributed electronic networks or databases),
provided that the records so kept can be converted into clearly legible paper form within a reasonable time and, with respect to the stock
ledger, that the records so kept (i) can be used to prepare the list of stockholders specified in the DGCL, (ii) record the information
specified in the DGCL, and (iii) record transfers of stock as governed by Article 8 of the Uniform Commercial Code as adopted in the State
of Delaware. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Article VII - General Matters </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.1 <span style="text-decoration: underline">Execution
of Corporate Contracts and Instruments</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board, except as otherwise provided in these bylaws,
may authorize any officer or officers, or agent or agents, to enter into any contract or execute any instrument in the name of and on
behalf of the Corporation; such authority may be general or confined to specific instances. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 552 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.2 <span style="text-decoration: underline">Stock
Certificates</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The shares of the Corporation shall be uncertificated,
provided that the Board by resolution may provide that some or all of the shares of any class or series of stock of the Corporation shall
be certificated. Certificates for the shares of stock, if any, shall be in such form as is consistent with the Certificate of Incorporation
and applicable law. Every holder of stock represented by a certificate shall be entitled to have a certificate signed by, or in the name
of the Corporation by, any two officers authorized to sign stock certificates representing the number of shares registered in certificate
form. The Chairperson or Vice Chairperson of the Board, Chief Executive Officer, the President, the Treasurer, any Assistant Treasurer,
the Secretary or any Assistant Secretary of the Corporation shall be specifically authorized to sign stock certificates. Any or all of
the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile
signature has been placed upon a certificate has ceased to be such officer, transfer agent or registrar before such certificate is issued,
it may be issued by the Corporation with the same effect as if he or she were such officer, transfer agent or registrar at the date of
issue. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.3 <span style="text-decoration: underline">Special
Designation of Certificates</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the Corporation is authorized to issue more than
one class of stock or more than one series of any class, then the powers, the designations, the preferences and the relative, participating,
optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such
preferences and/or rights shall be set forth in full or summarized on the face or on the back of the certificate that the Corporation
shall issue to represent such class or series of stock (or, in the case of uncertificated shares, set forth in a notice provided pursuant
to the DGCL); <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>, that
except as otherwise provided in Section&#160;202 of the DGCL, in lieu of the foregoing requirements, there may be set forth on the face
of back of the certificate that the Corporation shall issue to represent such class or series of stock (or, in the case of any uncertificated
shares, included in the aforementioned notice) a statement that the Corporation will furnish without charge to each stockholder who so
requests the powers, the designations, the preferences and the relative, participating, optional or other special rights of each class
of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.4 <span style="text-decoration: underline">Lost
Certificates</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except as provided in this Section&#160;7.4, no new
certificates for shares shall be issued to replace a previously issued certificate unless the latter is surrendered to the Corporation
and cancelled at the same time. The Corporation may issue a new certificate of stock or uncertificated shares in the place of any certificate
theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may, in addition to any other requirements
as may be imposed by the Corporation, require the owner of the lost, stolen or destroyed certificate, or such owner&#8217;s legal representative,
to give the Corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss,
theft or destruction of any such certificate or the issuance of such new certificate or uncertificated shares. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.5 <span style="text-decoration: underline">Shares
Without Certificates</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Corporation may adopt a system of issuance, recordation
and transfer of its shares of stock by electronic or other means not involving the issuance of certificates, provided the use of such
system by the Corporation is permitted in accordance with applicable law. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.6 <span style="text-decoration: underline">Construction;
Definitions</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless the context requires otherwise, the general
provisions, rules of construction and definitions in the DGCL shall govern the construction of these bylaws. Without limiting the generality
of this provision, the singular number includes the plural and the plural number includes the singular. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.7 <span style="text-decoration: underline">Dividends</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board, subject to any restrictions contained in
either (i) the DGCL or (ii) the Certificate of Incorporation, may declare and pay dividends upon the shares of its capital stock. Dividends
may be paid in cash, in property or in shares of the Corporation&#8217;s capital stock. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 553 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board may set apart out of any of the funds of
the Corporation available for dividends a reserve or reserves for any proper purpose and may abolish any such reserve. Such purposes shall
include but not be limited to equalizing dividends, repairing or maintaining any property of the Corporation, and meeting contingencies.
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.8 <span style="text-decoration: underline">Fiscal
Year</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fiscal year of the Corporation shall be fixed
by resolution of the Board and may be changed by the Board. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.9 <span style="text-decoration: underline">Seal</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Corporation may adopt a corporate seal, which
shall be adopted and which may be altered by the Board. The Corporation may use the corporate seal by causing it or a facsimile thereof
to be impressed or affixed or in any other manner reproduced. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.10 <span style="text-decoration: underline">Transfer
of Stock</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shares of stock of the Corporation shall be transferred
on the books of the Corporation only by the holder of record thereof or by such holder&#8217;s attorney duly authorized in writing, upon
surrender to the Corporation of the certificate or certificates representing such shares endorsed by the appropriate person or persons
(or by delivery of duly executed instructions with respect to uncertificated shares), with such evidence of the authenticity of such endorsement
or execution, transfer, authorization and other matters as the Corporation may reasonably require, and accompanied by all necessary stock
transfer stamps. No transfer of stock shall be valid as against the Corporation for any purpose until it shall have been entered in the
stock records of the Corporation by an entry showing the names of the persons from and to whom it was transferred. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.11 <span style="text-decoration: underline">Stock
Transfer Agreements</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Corporation shall have power to enter into and
perform any agreement with any number of stockholders of any one or more classes or series of stock of the Corporation to restrict the
transfer of shares of stock of the Corporation of any one or more classes owned by such stockholders in any manner not prohibited by the
DGCL or other applicable law. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.12 <span style="text-decoration: underline">Registered
Stockholders</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Corporation: </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(i) shall be entitled to recognize
the exclusive right of a person registered on its books as the owner of shares to receive dividends and to vote as such owner; and </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(ii) shall not be bound to recognize
any equitable or other claim to or interest in such share or shares on the part of another person, whether or not it shall have express
or other notice thereof, except as otherwise provided by the laws of the State of Delaware. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.13 <span style="text-decoration: underline">Waiver
of Notice</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Whenever notice is required to be given under any
provision of the DGCL, the Certificate of Incorporation or these bylaws, a written waiver, signed by the person entitled to notice, or
a waiver by electronic transmission by the person entitled to notice, whether before or after the time of the event for which notice is
to be given, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting,
except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting, to the transaction of any
business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular
or special meeting of the stockholders need be specified in any written waiver of notice or any waiver by electronic transmission unless
so required by the Certificate of Incorporation or these bylaws. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 554 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Article VIII - Notice </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">8.1 <span style="text-decoration: underline">Delivery
of Notice; Notice by Electronic Transmission</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Without limiting the manner by which notice otherwise
may be given effectively to stockholders, any notice to stockholders given by the Corporation under any provisions of the DGCL, the Certificate
of Incorporation, or these bylaws may be given in writing directed to the stockholder&#8217;s mailing address (or by electronic transmission
directed to the stockholder&#8217;s electronic mail address, as applicable) as it appears on the records of the Corporation and shall
be given (1) if mailed, when the notice is deposited in the U.S. mail, postage prepaid, (2) if delivered by courier service, the earlier
of when the notice is received or left at such stockholder&#8217;s address or (3) if given by electronic mail, when directed to such stockholder&#8217;s
electronic mail address unless the stockholder has notified the Corporation in writing or by electronic transmission of an objection to
receiving notice by electronic mail. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Without limiting the manner by which notice otherwise
may be given effectively to stockholders, any notice to stockholders given by the Corporation under any provision of the DGCL, the Certificate
of Incorporation or these bylaws shall be effective if given by a form of electronic transmission consented to by the stockholder to whom
the notice is given. Any such consent shall be revocable by the stockholder by written notice or electronic transmission to the Corporation.
Notwithstanding the provisions of this paragraph, the Corporation may give a notice by electronic mail in accordance with the first paragraph
of this section without obtaining the consent required by this paragraph. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any notice given pursuant to the preceding paragraph
shall be deemed given: </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(i)&#160;if by facsimile telecommunication,
when directed to a number at which the stockholder has consented to receive notice; </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(ii)&#160;if by a posting on an
electronic network together with separate notice to the stockholder of such specific posting, upon the later of (A) such posting and (B)
the giving of such separate notice; and </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">(iii)&#160;if by any other form
of electronic transmission, when directed to the stockholder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notwithstanding the foregoing, a notice may not be
given by an electronic transmission from and after the time that (1) the Corporation is unable to deliver by such electronic transmission
two consecutive notices given by the Corporation and (2) such inability becomes known to the Secretary or an Assistant Secretary of the
Corporation or to the transfer agent, or other person responsible for the giving of notice, <span style="text-decoration: underline">provided</span>,
<span style="text-decoration: underline">however</span>, the inadvertent failure to discover such inability shall not invalidate any meeting
or other action. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An affidavit of the Secretary or an Assistant Secretary
or of the transfer agent or other agent of the Corporation that the notice has been given shall, in the absence of fraud, be prima facie
evidence of the facts stated therein. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Article IX - Indemnification </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.1 <span style="text-decoration: underline">Power
to Indemnify in Actions, Suits or Proceedings other than Those by or in the Right of the Corporation</span>. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subject to Section&#160;9.3, the Corporation shall
indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or
proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation), by
reason of the fact that such person is or was a director or officer of the Corporation, or while a director or officer of the Corporation,
is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement
actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith
and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to
any criminal action or proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful. The termination of any
action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not,
of itself, create a presumption that the person did not act in good faith and in a manner which such person reasonably believed to be
in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had reasonable cause
to believe that such person&#8217;s conduct was unlawful. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 555 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.2 <span style="text-decoration: underline">Power
to Indemnify in Actions, Suits or Proceedings by or in the Right of the Corporation</span>. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subject to Section&#160;9.3, the Corporation shall
indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit
by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that such person is or was a director or
officer of the Corporation, or while a director or officer of the Corporation, is or was serving at the request of the Corporation as
a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses
(including attorneys&#8217; fees) actually and reasonably incurred by such person in connection with the defense or settlement of such
action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best
interests of the Corporation; except that no indemnification shall be made in respect of any claim, issue or matter as to which such person
shall have been adjudged to be liable to the Corporation unless and only to the extent that the Court of Chancery of the State of Delaware
or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but
in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court
of Chancery or such other court shall deem proper. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.3 <span style="text-decoration: underline">Authorization
of Indemnification</span>. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any indemnification under this Article IX (unless
ordered by a court) shall be made by the Corporation only as authorized in the specific case upon a determination that indemnification
of the present or former director or officer is proper in the circumstances because such person has met the applicable standard of conduct
set forth in Section 9.1 or Section&#160;9.2, as the case may be. Such determination shall be made, with respect to a person who is a
director or officer at the time of such determination, (i) by a majority vote of the directors who are not parties to such action, suit
or proceeding, even though less than a quorum, or (ii) by a committee of such directors designated by a majority vote of such directors,
even though less than a quorum, or (iii) if there are no such directors, or if such directors so direct, by independent legal counsel
in a written opinion or (iv) by the stockholders. Such determination shall be made, with respect to former directors and officers, by
any person or persons having the authority to act on the matter on behalf of the Corporation. To the extent, however, that a present or
former director or officer of the Corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding
described above, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#8217;
fees) actually and reasonably incurred by such person in connection therewith, without the necessity of authorization in the specific
case. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.4 <span style="text-decoration: underline">Good
Faith Defined</span>. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of any determination under Section&#160;9.3,
a person shall be deemed to have acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best
interests of the Corporation, or, with respect to any criminal action or proceeding, to have had no reasonable cause to believe such person&#8217;s
conduct was unlawful, if such person&#8217;s action is based on the records or books of account of the Corporation or another enterprise,
or on information supplied to such person by the officers of the Corporation or another enterprise in the course of their duties, or on
the advice of legal counsel for the Corporation or another enterprise or on information or records given or reports made to the Corporation
or another enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by
the Corporation or another enterprise. The provisions of this Section&#160;9.4 shall not be deemed to be exclusive or to limit in any
way the circumstances in which a person may be deemed to have met the applicable standard of conduct set forth in Section&#160;9.1 or
9.2, as the case may be. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.5 <span style="text-decoration: underline">Indemnification
by a Court</span>. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notwithstanding any contrary determination in the
specific case under Section&#160;9.3, and notwithstanding the absence of any determination thereunder, any director or officer may apply
to the Court of Chancery of the State of Delaware or any other court of competent jurisdiction in the State of Delaware for indemnification
to the extent otherwise permissible under Section&#160;9.1 or 9.2. The basis of such indemnification by the Corporation shall be a determination
by such court that indemnification of the director or officer is proper in the circumstances because such person has met the applicable
standard of conduct set forth in Section&#160;9.1 or Section&#160;9.2, as the case may be. Neither a contrary determination in the specific
case under Section&#160;9.3 nor the absence of any determination thereunder shall be a defense to such application or create a presumption
that the director or officer seeking indemnification has not met any applicable standard of conduct. Notice of any application for indemnification
pursuant to this Article IX shall be given to the Corporation promptly upon the filing of such application. If successful, in whole or
in part, the director or officer seeking indemnification shall also be entitled to be paid the expense of prosecuting such application.
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 556 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.6 <span style="text-decoration: underline">Expenses
Payable in Advance</span>. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Expenses (including attorneys&#8217; fees) incurred
by a present or former director or officer in appearing at, participating in or defending any civil, criminal, administrative or investigative
action, suit or proceeding in advance of its final disposition or in connection with a proceeding brought to establish or enforce a right
to indemnification or advancement of expenses under this Article IX shall be paid by the Corporation upon receipt of an undertaking by
or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to
be indemnified by the Corporation as authorized in this Article IX. Such expenses (including attorneys&#8217; fees) incurred by employees
and agents of the Corporation or by persons acting at the request of the Corporation as directors, officers, employees or agents of another
corporation, partnership, joint venture, trust or other enterprise may be so paid upon such terms and conditions, if any, as the Corporation
deems appropriate. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.7 <span style="text-decoration: underline">Nonexclusivity
of Indemnification and Advancement of Expenses</span>. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The indemnification and advancement of expenses provided
by, or granted pursuant to, this Article IX shall not be deemed exclusive of any other rights to which those seeking indemnification or
advancement of expenses may be entitled under the Certificate of Incorporation, these bylaws, agreement, vote of stockholders or disinterested
directors or otherwise, both as to action in such person&#8217;s official capacity and as to action in another capacity while holding
such office, it being the policy of the Corporation that indemnification of the persons specified in Section&#160;9.1 or 9.2 shall be
made to the fullest extent permitted by law. The provisions of this Article IX shall not be deemed to preclude the indemnification of
any person who is not specified in Section 9.1 or Section&#160;9.2 but whom the Corporation has the power or obligation to indemnify under
the provisions of the DGCL, or otherwise. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.8 <span style="text-decoration: underline">Insurance</span>.
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Corporation may purchase and maintain insurance
on behalf of any person who is or was a director or officer of the Corporation, or is or was a director or officer of the Corporation
serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture,
trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising
out of such person&#8217;s status as such, whether or not the Corporation would have the power or the obligation to indemnify such person
against such liability under the provisions of this Article IX. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.9 <span style="text-decoration: underline">Certain
Definitions</span>. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of this Article IX, references to &#8220;the
Corporation&#8221; shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of
a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority
to indemnify its directors or officers, so that any person who is or was a director or officer of such constituent corporation, or is
or was a director or officer of such constituent corporation serving at the request of such constituent corporation as a director, officer,
employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under
the provisions of this Article IX with respect to the resulting or surviving corporation as such person would have with respect to such
constituent corporation if its separate existence had continued. The term &#8220;another enterprise&#8221; as used in this Article IX
shall mean any other corporation or any partnership, joint venture, trust, employee benefit plan or other enterprise of which such person
is or was serving at the request of the Corporation as a director, officer, employee or agent. For purposes of this Article IX, references
to &#8220;fines&#8221; shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to
&#8220;serving at the request of the Corporation&#8221; shall include any service as a director, officer, employee or agent of the Corporation
which imposes duties on, or involves services by, such director or officer with respect to an employee benefit plan, its participants
or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants
and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#8220;not opposed to the best interests of the
Corporation&#8221; as referred to in this Article IX. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 557 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.10 <span style="text-decoration: underline">Survival
of Indemnification and Advancement of Expenses</span>. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The indemnification and advancement of expenses provided
by, or granted pursuant to, this Article IX shall, unless otherwise provided when authorized or ratified as provided in this Article IX,
continue as to a person who has ceased to be a director or officer and shall inure to the benefit of the heirs, executors and administrators
of such a person. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.11 <span style="text-decoration: underline">Limitation
on Indemnification</span>. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notwithstanding anything contained in this Article
IX to the contrary, except for proceedings to enforce rights to indemnification (which shall be governed by Section 9.5), the Corporation
shall not be obligated to indemnify any present or former director or officer (or his or her heirs, executors or personal or legal representatives)
or advance expenses in connection with a proceeding (or part thereof) initiated by such person unless such proceeding (or part thereof)
was authorized or consented to by the Board of the Corporation. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.12 <span style="text-decoration: underline">Indemnification
of Employees and Agents</span>. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Corporation may, to the extent authorized from
time to time by the Board, provide rights to indemnification and to the advancement of expenses to employees and agents of the Corporation
and to persons serving at the request of the Corporation as directors, officers, employees and agents of another corporation, partnership,
joint venture, trust or other enterprise similar to those conferred in this Article IX to directors and officers of the Corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">9.13 <span style="text-decoration: underline">Primacy of Indemnification</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notwithstanding that a director, officer, employee
or agent of the Corporation (collectively, the &#8220;<span style="text-decoration: underline">Covered Persons</span>&#8221;) may have
certain rights to indemnification, advancement of expenses and/or insurance provided by other persons (collectively, the &#8220;<span style="text-decoration: underline">Other
Indemnitors</span>&#8221;), with respect to the rights to indemnification, advancement of expenses and/or insurance set forth herein,
the Corporation: (i) shall be the indemnitor of first resort (i.e., its obligations to Covered Persons are primary and any obligation
of the Other Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Covered Persons
are secondary); and (ii) shall be required to advance the full amount of expenses incurred by Covered Persons and shall be liable for
the full amount of all liabilities, without regard to any rights Covered Persons may have against any of the Other Indemnitors. No advancement
or payment by the Other Indemnitors on behalf of Covered Persons with respect to any claim for which Covered Persons have sought indemnification
from the Corporation shall affect the immediately preceding sentence, and the Other Indemnitors shall have a right of contribution and/or
be subrogated to the extent of such advancement or payment to all of the rights of recovery of Covered Persons against the Corporation.
Notwithstanding anything to the contrary herein, the obligations of the Corporation under this Section 9.13 shall only apply to Covered
Persons in their capacity as Covered Persons. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.14 <span style="text-decoration: underline">Amendments</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any repeal or amendment of this Article IX by the
Board or the stockholders of the Corporation or by changes in applicable law, or the adoption of any other provision of these bylaws inconsistent
with this Article IX, will, to the extent permitted by applicable law, be prospective only (except to the extent such amendment or change
in applicable law permits the Corporation to provide broader indemnification rights to Indemnitees on a retroactive basis than permitted
prior thereto), and will not in any way diminish or adversely affect any right or protection existing hereunder in respect of any act
or omission occurring prior to such repeal or amendment or adoption of such inconsistent provision. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Article X - Amendments </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board is expressly empowered to adopt, amend or
repeal the bylaws of the Corporation. The stockholders also shall have power to adopt, amend or repeal the bylaws of the Corporation;
<span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>, that such action by
stockholders shall require, in addition to any other vote required by the Certificate of Incorporation or applicable law, the affirmative
vote of the holders of at least 66&#8532;%) of the voting power of all the then-outstanding shares of voting stock of the Corporation
with the power to vote generally in an election of directors, voting together as a single class.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 558 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Article XI - Definitions </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As used in these bylaws, unless the context otherwise
requires, the following terms shall have the following meanings: </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An &#8220;<span style="text-decoration: underline">electronic
transmission</span>&#8221; means any form of communication, not directly involving the physical transmission of paper, including the use
of, or participation in, one or more electronic networks or databases (including one or more distributed electronic networks or databases),
that creates a record that may be retained, retrieved and reviewed by a recipient thereof, and that may be directly reproduced in paper
form by such a recipient through an automated process. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An &#8220;<span style="text-decoration: underline">electronic
mail</span>&#8221; means an electronic transmission directed to a unique electronic mail address (which electronic mail shall be deemed
to include any files attached thereto and any information hyperlinked to a website if such electronic mail includes the contact information
of an officer or agent of the Corporation who is available to assist with accessing such files and information). </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An &#8220;<span style="text-decoration: underline">electronic
mail address</span>&#8221; means a destination, commonly expressed as a string of characters, consisting of a unique user name or mailbox
(commonly referred to as the &#8220;local part&#8221; of the address) and a reference to an internet domain (commonly referred to as the
&#8220;domain part&#8221; of the address), whether or not displayed, to which electronic mail can be sent or delivered. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The term &#8220;<span style="text-decoration: underline">person</span>&#8221;
means any individual, general partnership, limited partnership, limited liability company, corporation, trust, business trust, joint stock
company, joint venture, unincorporated association, cooperative or association or any other legal entity or organization of whatever nature,
and shall include any successor (by merger or otherwise) of such entity. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 559 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><b><span id="annex_c"></span>ANNEX C</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXASCALE
LABS HOLDINGS INC. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2026
OMNIBUS EQUITY INCENTIVE PLAN</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
1. <span style="text-decoration: underline">GENERAL PURPOSE OF THE PLAN; DEFINITIONS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
name of the plan is the Exascale Labs Holdings Inc. 2026 Omnibus Equity Incentive Plan (the &#8220;<span style="text-decoration: underline">Plan</span>&#8221;).
The purpose of the Plan is to encourage and enable the officers, employees, non-employee directors and consultants of Exascale Labs Holdings
Inc. (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;) and its Affiliates upon whose judgment, initiative and
efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is
anticipated that providing such persons with a direct stake in the Company&#8217;s welfare will assure a closer identification of their
interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company&#8217;s behalf and strengthening
their desire to remain with the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following terms shall be defined as set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Act</span>&#8221;
</i>means the Securities Act of 1933, as amended, and the rules and regulations thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Administrator</span>&#8221;
</i>means either the Board, or the Compensation Committee of the Board or a similar committee performing the functions of that committee
and which is comprised of not less than two Non-Employee Directors who are independent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i><span style="text-decoration: underline">Affiliate</span></i>&#8221;
means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in
Rule 405 of the Act. The Board will have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221;
status is determined within the foregoing definition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Award</span>&#8221;
</i>or <i>&#8220;<span style="text-decoration: underline">Awards</span>,&#8221;</i> except where referring to a particular category of
grant under the Plan, shall include Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock
Units, Restricted Stock Awards, Unrestricted Stock Awards, Cash-Based Awards, and Dividend Equivalent Rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Award
Certificate</span>&#8221;</i> means a written or electronic document setting forth the terms and provisions applicable to an Award granted
under the Plan. Each Award Certificate is subject to the terms and conditions of the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Board</span>&#8221;
</i>means the Board of Directors of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Cash-Based
Award</span>&#8221;</i> means an Award entitling the recipient to receive a cash-denominated payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Closing
Date</span>&#8221; </i>means the date of the closing of the transactions contemplated by that certain Agreement and Plan of Merger, dated
as of January 11, 2026, by and among the Company and the other parties thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Code</span>&#8221;
</i>means the Internal Revenue Code of 1986, as amended, and any successor Code, and related rules, regulations and interpretations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Consultant</span>&#8221;
</i>means a consultant or adviser who provides <i>bona fide</i> services to the Company or an Affiliate as an independent contractor and
who qualifies as a consultant or advisor under Instruction A.1.(a)(1) of Form S-8 under the Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Dividend
Equivalent Right</span>&#8221;</i> means an Award entitling the grantee to receive credits based on cash dividends that would have been
paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued
to and held by the grantee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Effective
Date</span>&#8221;</i> means the date on which the Plan becomes effective as set forth in Section 20.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Exchange
Act</span>&#8221;</i> means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 560; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Fair
Market Value</span>&#8221;</i> of the Stock on any given date means the fair market value of the Stock determined in good faith by the
Administrator; provided, however, that if the Stock is listed on the Nasdaq Stock Market, The New York Stock Exchange or another national
securities exchange or traded on any established market, the determination shall be made by reference to the closing price on such date.
If there is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which
there is a closing price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Incentive
Stock Option</span>&#8221;</i> means any Stock Option intended to qualify as an &#8220;incentive stock option&#8221; as defined in Section
422 of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Non-Employee
Director</span>&#8221;</i> means a member of the Board who is not also an employee of the Company or any Subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Non-Qualified
Stock Option</span>&#8221;</i> means any Stock Option that is not an Incentive Stock Option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Option</span>&#8221;
</i>or <i>&#8220;<span style="text-decoration: underline">Stock Option</span>&#8221;</i> means any option to purchase shares of Stock
granted pursuant to Section 5.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Restricted
Shares</span>&#8221;</i> means the shares of Stock underlying a Restricted Stock Award that remain subject to a risk of forfeiture or
the Company&#8217;s right of repurchase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Restricted
Stock Award</span>&#8221;</i> means an Award of Restricted Shares subject to such restrictions and conditions as the Administrator may
determine at the time of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Restricted
Stock Units</span>&#8221;</i> means a right to receive, in cash and/or shares of Stock, as determined by the Administrator, the Fair Market
Value of a share of Stock, subject to such restrictions on transfer, vesting conditions and other restrictions or limitations as may be
set forth in this Plan and the applicable Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Sale
Event</span>&#8221;</i> shall mean (i) the sale of all or substantially all of the assets of the Company on a consolidated basis to an
unrelated person or entity, (ii) a merger, reorganization or consolidation pursuant to which the holders of the Company&#8217;s outstanding
voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding
stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion
of such transaction, (iii) the sale of all of the Stock of the Company to an unrelated person, entity or group thereof acting in concert,
or (iv) any other transaction in which, immediately upon completion of the transaction, an unrelated person, entity or group thereof acting
in concert will own at least a majority of the outstanding voting power of the Company or any successor entity other than (A) as a result
of the acquisition of securities directly from the Company and (B) any acquisition by any employee benefit plan (or related trust) sponsored
or maintained by the Company or any entity controlled by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i><span style="text-decoration: underline">Sale
Price</span></i>&#8221; means the value as determined by the Administrator of the consideration payable, or otherwise to be received by
stockholders, per share of Stock pursuant to a Sale Event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Section
409A</span>&#8221;</i> means Section 409A of the Code and the regulations and other guidance promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Service
Relationship</span>&#8221; </i>means any relationship as an employee, director or Consultant of the Company or any Affiliate (e.g., a
Service Relationship shall be deemed to continue without interruption in the event an individual&#8217;s status changes from full-time
employee to part-time employee or Consultant).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Stock</span>&#8221;
</i>means the Class A Ordinary Common Stock, par value $0.0001 per share, of the Company, subject to adjustments pursuant to Section 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Stock
Appreciation Right</span>&#8221;</i> means an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly
provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of the Stock on the date
of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which
the Stock Appreciation Right shall have been exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 561; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Subsidiary</span>&#8221;
</i>means any corporation or other entity (other than the Company) in which the Company has at least a fifty percent (50%) interest, either
directly or indirectly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Ten
Percent Owner</span>&#8221;</i> means an employee who owns or is deemed to own (by reason of the attribution rules of Section 424(d) of
the Code) more than ten percent (10%) of the combined voting power of all classes of stock of the Company or any parent or subsidiary
corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<span style="text-decoration: underline">Unrestricted
Stock Award</span>&#8221;</i> means an Award of shares of Stock free of any restrictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
2. <span style="text-decoration: underline">ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="color: Black">(a)</span></td>
    <td style="text-align: justify"><span style="color: Black"><span style="text-decoration: underline">Administration of Plan</span>. The Plan
        shall be administered by the Administrator.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="color: Black">(b)</span></td>
    <td style="text-align: justify"><span style="color: Black"><span style="text-decoration: underline">Powers of Administrator</span>. The Administrator
        shall have the power and authority to grant Awards consistent with the terms of the Plan, including the power and authority to:</span></td>
        </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="color: Black">&#160;</span></td>
    <td style="width: 0.35in; text-align: justify; font-size: 10pt; color: #346094"><span style="color: Black">(i)</span></td>
    <td style="text-align: justify; font-size: 10pt; color: #346094"><span style="color: Black">select the individuals to whom Awards may from
        time to time be granted;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="color: Black">&#160;</span></td>
    <td style="width: 0.35in; text-align: justify; font-size: 10pt; color: #346094"><span style="color: Black">(ii)</span></td>
    <td style="text-align: justify; font-size: 10pt; color: #346094"><span style="color: Black">determine the time or times of grant, and the
        extent, if any, of Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted
        Stock Units, Unrestricted Stock Awards, Cash-Based Awards, and Dividend Equivalent Rights, or any combination of the foregoing, granted
        to any one or more grantees;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="color: Black">&#160;</span></td>
    <td style="width: 0.35in; text-align: justify; font-size: 10pt; color: #346094"><span style="color: Black">(iii)</span></td>
    <td style="text-align: justify; font-size: 10pt; color: #346094"><span style="color: Black">determine the number of shares of Stock to be
        covered by any Award;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="color: Black">&#160;</span></td>
    <td style="width: 0.35in; text-align: justify; font-size: 10pt; color: #346094"><span style="color: Black">(iv)</span></td>
    <td style="text-align: justify; font-size: 10pt; color: #346094"><span style="color: Black">correct any defect, supply any omission or reconcile
        any inconsistency in the Plan, in any Award, or in any Award Certificate;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="color: Black">&#160;</span></td>
    <td style="width: 0.35in; text-align: justify; font-size: 10pt; color: #346094"><span style="color: Black">(v)</span></td>
    <td style="text-align: justify; font-size: 10pt; color: #346094"><span style="color: Black">determine and modify from time to time the terms
        and conditions, including restrictions, not inconsistent with the terms of the Plan, of any Award, which terms and conditions may differ
        among individual Awards and grantees, and to approve the forms of Award Certificates;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="color: Black">&#160;</span></td>
    <td style="width: 0.35in; text-align: justify; font-size: 10pt; color: #346094"><span style="color: Black">(vi)</span></td>
    <td style="text-align: justify; font-size: 10pt; color: #346094"><span style="color: Black">accelerate at any time the exercisability or vesting
        of all or any portion of any Award or waive any forfeiture provision with respect to an Award;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="color: Black">&#160;</span></td>
    <td style="width: 0.35in; text-align: justify; font-size: 10pt; color: #346094"><span style="color: Black">(vii)</span></td>
    <td style="text-align: justify; font-size: 10pt; color: #346094"><span style="color: Black">subject to the provisions of Section 5(c) or Section
        6(d), extend at any time of the period in which Stock Options or Stock Appreciation Right, respectively, may be exercised; and</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="color: Black">&#160;</span></td>
    <td style="width: 0.35in; text-align: justify; font-size: 10pt; color: #346094"><span style="color: Black">(viii)</span></td>
    <td style="text-align: justify; font-size: 10pt; color: #346094"><span style="color: Black">at any time to adopt, alter and repeal such rules,
        guidelines and practices for administration of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret
        the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable
        for the administration of the Plan; to decide all disputes arising in connection with the Plan; and to otherwise supervise the administration
        of the Plan.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Plan grantees.<br/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="color: Black">(c)</span></td>
    <td style="text-align: justify"><span style="color: Black"><span style="text-decoration: underline">Delegation of Authority to Grant Awards</span>.
        Subject to applicable law, the Administrator, in its discretion, may delegate to a committee consisting of one or more officers of the
        Company, including the Chief Executive Officer of the Company, all or part of the Administrator&#8217;s authority and duties with respect
        to the granting of Awards to individuals who are (i) not subject to the reporting and other provisions of Section 16 of the Exchange Act
        and (ii) not members of the delegated committee. Any such delegation by the Administrator shall include a limitation as to the amount
        of Stock underlying Awards that may be granted during the period of the delegation and shall contain guidelines as to the determination
        of the exercise price and the vesting criteria. The Administrator may revoke or amend the terms of a delegation at any time but such action
        shall not invalidate any prior actions of the Administrator&#8217;s delegate or delegates that were consistent with the terms of the Plan.</span></td>
        </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="color: Black">&#160;</span></p>

<!-- Field: Page; Sequence: 562; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="color: Black">(d)</span></td>
    <td style="text-align: justify"><span style="color: Black"><span style="text-decoration: underline">Award Certificate</span>. Awards under
        the Plan shall be evidenced by Award Certificates that set forth the terms, conditions and limitations for each Award which may include,
        without limitation, the term of an Award and the provisions applicable in the event employment or service terminates.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="color: Black">(e)</span></td>
    <td style="text-align: justify"><span style="color: Black"><span style="text-decoration: underline">Indemnification</span>. Neither the Board
        nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any act, omission, interpretation, construction
        or determination made in good faith in connection with the administration of the Plan, and the members of the Board and the Administrator
        (and any delegate thereof) shall be entitled in all cases to indemnification and reimbursement by the Company in respect of any claim,
        loss, damage or expense (including, without limitation, reasonable attorneys&#8217; fees) arising or resulting therefrom to the fullest
        extent permitted by law and/or under the Company&#8217;s certificate of incorporation or bylaws or any directors&#8217; and officers&#8217;
        liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and
        the Company.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"><span style="color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="color: Black">(f)</span></td>
    <td style="text-align: justify"><span style="color: Black"><span style="text-decoration: underline">Foreign Award Recipients</span>. Notwithstanding
        any provision of the Plan to the contrary, in order to comply with the laws in other countries in which the Company and its Subsidiaries
        operate or have employees or other individuals eligible for Awards, the Administrator, in its sole discretion, shall have the power and
        authority to: (i) determine which Subsidiaries shall be covered by the Plan; (ii) determine which individuals outside the United States
        are eligible to participate in the Plan; (iii) modify the terms and conditions of any Award granted to individuals outside the United
        States to comply with applicable foreign laws; (iv) establish subplans and modify exercise procedures and other terms and procedures,
        to the extent the Administrator determines such actions to be necessary or advisable (and such subplans and/or modifications shall be
        attached to this Plan as appendices); <i><span style="text-decoration: underline">provided</span></i>, <i><span style="text-decoration: underline">however</span></i>,
        that no such subplans and/or modifications shall increase the share limitations contained in Section 3(a) hereof; and (v) take any action,
        before or after an Award is made, that the Administrator determines to be necessary or advisable to obtain approval or comply with any
        local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the Administrator may not take any actions hereunder,
        and no Awards shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or
        any other applicable United States governing statute or law.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
3. <span style="text-decoration: underline">STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="color: Black">(a)</span></td>
    <td style="text-align: justify"><span style="color: Black"><span style="text-decoration: underline">Stock Issuable</span>. The maximum number
        of shares of Stock reserved and available for issuance under the Plan shall be 10,000,000 shares (the &#8220;<span style="text-decoration: underline">Initial
        Limit</span>&#8221;), subject to adjustment as provided in this Section 3, plus on January 1, 2027 and each January 1 thereafter, the
        number of shares of Stock reserved and available for issuance under the Plan shall be cumulatively increased by five percent (5%) of the
        number of shares of Stock issued and outstanding on the immediately preceding December 31 or such lesser amount as determined by the Board
        (the &#8220;<span style="text-decoration: underline">Annual Increase</span>&#8221;). Subject to such overall limitation, the maximum aggregate
        number of shares of Stock that may be issued in the form of Incentive Stock Options shall not exceed the Initial Limit cumulatively increased
        on January 1, 2027 and on each January 1 thereafter by the lesser of the Annual Increase for such year or 3,200,000 shares of Stock, subject
        in all cases to adjustment as provided in this Section 3. For purposes of this limitation, the shares of Stock underlying any awards under
        the Plan that are forfeited, canceled, held back upon exercise of an Option or settlement of an Award to cover the exercise price or tax
        withholding, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by
        exercise) shall be added back to the shares of Stock available for issuance under the Plan and, to the extent permitted under Section
        422 of the Code and the regulations promulgated thereunder, the shares of Stock that may be issued as Incentive Stock Options. The shares
        available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company. Awards
        that may be settled solely in cash shall not be counted against the share reserve, nor shall they reduce the shares of Stock authorized
        for grant to any grantee in any calendar year.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 563; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="color: Black">(b)</span></td>
    <td style="text-align: justify"><span style="color: Black"><span style="text-decoration: underline">Changes in Stock</span>. Subject to Section
        3(c) hereof, if, as a result of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split
        or other similar change in the Company&#8217;s capital stock, the outstanding shares of Stock are increased or decreased or are exchanged
        for a different number or kind of shares or other securities of the Company, or additional shares or new or different shares or other
        securities of the Company or other non-cash assets are distributed with respect to such shares of Stock or other securities, or, if, as
        a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock
        are converted into or exchanged for securities of the Company or any successor entity (or a parent or subsidiary thereof), the Administrator,
        in its sole discretion, shall make an appropriate or proportionate adjustment in (i) the maximum number of shares reserved for issuance
        under the Plan, including the maximum number of shares that may be issued in the form of Incentive Stock Options, (ii) the number and
        kind of shares or other securities subject to any then outstanding Awards under the Plan, (iii) the repurchase price, if any, per share
        subject to each outstanding Restricted Stock Award, and (iv) the exercise price for each share subject to any then outstanding Stock Options
        and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the
        number of shares subject to Stock Options and Stock Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights
        remain exercisable. The Administrator may also make equitable or proportionate adjustments in the number of shares subject to outstanding
        Awards and the exercise price and the terms of outstanding Awards to take into consideration cash dividends paid other than in the ordinary
        course or any other extraordinary corporate event. The adjustment by the Administrator shall be final, binding and conclusive. No fractional
        shares of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a
        cash payment in lieu of fractional shares.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="color: Black">(c)</span></td>
    <td style="text-align: justify"><span style="color: Black"><span style="text-decoration: underline">Mergers and Other Transactions</span>.
        In the case of and subject to the consummation of a Sale Event, the parties thereto may cause the assumption or continuation of Awards
        theretofore granted by the successor entity, or the substitution of such Awards with new Awards of the successor entity or parent thereof,
        with appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties shall
        agree. To the extent the parties to such Sale Event do not provide for the assumption, continuation or substitution of Awards, upon the
        effective time of the Sale Event, the Plan and all outstanding Awards granted hereunder shall terminate. In such case, except as may be
        otherwise provided in the relevant Award Certificate, all Options and Stock Appreciation Rights with time-based vesting conditions or
        restrictions that are not vested and/or exercisable immediately prior to the effective time of the Sale Event shall become fully vested
        and exercisable as of the effective time of the Sale Event, all other Awards with time-based vesting, conditions or restrictions shall
        become fully vested and nonforfeitable as of the effective time of the Sale Event, and all Awards with conditions and restrictions relating
        to the attainment of performance goals may become vested and nonforfeitable in connection with a Sale Event in the Administrator&#8217;s
        discretion or to the extent specified in the relevant Award Certificate. In the event of such termination, the Administrator shall have
        the option (in its sole discretion) to effect either of the following alternatives, which may vary among individual holders and which
        may vary among Awards held by any individual holder: (i) make or provide for a payment, in cash or in kind, to the grantees holding Options
        and Stock Appreciation Rights, in exchange for the cancellation thereof, in an amount equal to the difference between (A) the Sale Price
        multiplied by the number of shares of Stock subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable
        at prices not in excess of the Sale Price) and (B) the aggregate exercise price of all such outstanding Options and Stock Appreciation
        Rights (provided that, in the case of an Option or Stock Appreciation Right with an exercise price equal to or greater than the Sale Price,
        such Option or Stock Appreciation Right shall be cancelled for no consideration); or (ii) permit a grantee to exercise all or any portion
        of such grantee&#8217;s outstanding Options and Stock Appreciation Rights (to the extent then exercisable), for a limited period of time
        on or before a date prior to the consummation of the Sale Event as specified by the Administrator, after which specified date all unexercised
        Awards and all rights of holders thereunder shall terminate. The Administrator shall also have the option (in its sole discretion) to
        make or provide for a payment, in cash or in kind, to the grantees holding Awards other than Options and Stock Appreciation Rights, in
        an amount equal to the Sale Price multiplied by the number of vested shares of Stock under such Awards.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="color: Black">(d)</span></td>
    <td style="text-align: justify"><span style="color: Black"><span style="text-decoration: underline">Maximum Awards to Non-Employee Directors</span>.
        The aggregate amount of compensation, including both Awards granted under this Plan and cash compensation, paid to any Non-Employee Director
        in a calendar year period shall not exceed $750,000; <i><span style="text-decoration: underline">provided</span></i>, <i><span style="text-decoration: underline">however</span></i>,
        that such amount shall be $1,000,000 for the calendar year in which the applicable Non-Employee Director is initially appointed to the
        Board. For the purpose of this limitation, the amount of any Award paid in a calendar year shall be its grant date fair value, as determined
        in accordance with ASC 718 or successor provision but excluding the impact of estimated forfeitures related to service-based vesting provisions.</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<!-- Field: Page; Sequence: 564; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
4. <span style="text-decoration: underline">ELIGIBILITY</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grantees
under the Plan will be such employees, Non-Employee Directors or Consultants of the Company and its Affiliates as are selected from time
to time by the Administrator in its sole discretion; provided that Awards may not be granted to employees, Directors or Consultants who
are providing services only to any &#8220;parent&#8221; of the Company, as such term is defined in Rule 405 of the Act, unless (i) the
stock underlying the Awards is treated as &#8220;service recipient stock&#8221; under Section 409A or (ii) the Company has determined
that such Awards are exempt from or otherwise comply with Section 409A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
5. <span style="text-decoration: underline">STOCK OPTIONS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Award
        of Stock Options</span>. The Administrator may grant Stock Options under the Plan. Any Stock Option granted under the Plan shall be in
        such form as the Administrator may from time to time approve.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Stock Options granted under the Plan may be either Incentive Stock Options or Non-Qualified Stock Options. Incentive Stock Options may
be granted only to employees of the Company or any Subsidiary that is a &#8220;subsidiary corporation&#8221; within the meaning of Section
424(f) of the Code. To the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a Non-Qualified Stock
Option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
Options granted pursuant to this Section 5 shall be subject to the following terms and conditions and shall contain such additional terms
and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable. If the Administrator so determines,
Stock Options may be granted in lieu of cash compensation at the optionee&#8217;s election, subject to such terms and conditions as the
Administrator may establish.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Exercise
        Price</span>. The exercise price per share for the Stock covered by a Stock Option granted pursuant to this Section 5 shall be determined
        by the Administrator at the time of grant but shall not be less than 100 percent of the Fair Market Value on the date of grant. In the
        case of an Incentive Stock Option that is granted to a Ten Percent Owner, the exercise price of such Incentive Stock Option shall be not
        less than 110 percent of the Fair Market Value on the grant date.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(c)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Option Term</span>. The term of each Stock Option shall be fixed
        by the Administrator, but no Stock Option shall be exercisable more than ten years after the date the Stock Option is granted. In the
        case of an Incentive Stock Option that is granted to a Ten Percent Owner, the term of such Stock Option shall be no more than five years
        from the date of grant.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(d)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Exercisability; Rights of a Stockholder</span>. Stock Options shall
        become exercisable at such time or times, whether or not in installments, as shall be determined by the Administrator at or after the
        grant date. The Administrator may at any time accelerate the exercisability of all or any portion of any Stock Option. An optionee shall
        have the rights of a stockholder only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options.</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Method
        of Exercise</span>. Stock Options may be exercised in whole or in part, by giving written or electronic notice of exercise to the Company,
        specifying the number of shares to be purchased. Payment of the purchase price may be made by one or more of the following methods except
        to the extent otherwise provided in the Award Certificate:</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.35in; text-align: left">(i)</td>
    <td style="text-align: justify">In cash, by certified or bank check or other instrument acceptable to the Administrator;</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.35in; text-align: left">(ii)</td>
    <td style="text-align: justify">Through the delivery (or attestation to the ownership following such procedures as the Company may prescribe)
        of shares of Stock that are not then subject to restrictions under any Company plan, with such surrendered shares to be valued at Fair
        Market Value on the exercise date;</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.35in; text-align: left">(iii)</td>
    <td style="text-align: justify">By the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions
        to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided
        that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with such procedures
        and enter into such agreements of indemnity and other agreements as the Company shall prescribe as a condition of such payment procedure;
        or</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 565; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.35in; text-align: left">(iv)</td>
    <td style="text-align: justify">To the extent permitted by the Administrator and set forth in an Award Certificate, with respect to Stock
        Options that are not Incentive Stock Options, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the
        number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the
        aggregate exercise price.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
instruments will be received subject to collection. The transfer to the optionee on the records of the Company or of the transfer agent
of the shares of Stock to be purchased pursuant to the exercise of a Stock Option will be contingent upon receipt from the optionee (or
a purchaser acting in his or her stead in accordance with the provisions of the Stock Option) by the Company of the full purchase price
for such shares and the fulfillment of any other requirements contained in the Award Certificate or applicable provisions of laws (including
the satisfaction of any withholding taxes that the Company is obligated to withhold with respect to the optionee). In the event an optionee
chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred
to the optionee upon the exercise of the Stock Option shall be net of the number of attested shares. In the event that the Company establishes,
for itself or using the services of a third party, an automated system for the exercise of Stock Options, such as a system using an internet
website or interactive voice response, then the paperless exercise of Stock Options may be permitted through the use of such an automated
system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Annual
        Limit on Incentive Stock Options</span>. To the extent required for &#8220;incentive stock option&#8221; treatment under Section 422 of
        the Code, the aggregate Fair Market Value (determined as of the time of grant) of the shares of Stock with respect to which Incentive
        Stock Options granted under this Plan and any other plan of the Company or its parent and subsidiary corporations become exercisable for
        the first time by an optionee during any calendar year shall not exceed $100,000. To the extent that any Stock Option exceeds this limit,
        it shall constitute a Non-Qualified Stock Option.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
6. <span style="text-decoration: underline">STOCK APPRECIATION RIGHTS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(a)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Award of Stock Appreciation Rights</span>. The Administrator may
        grant Stock Appreciation Rights under the Plan. A Stock Appreciation Right is an Award entitling the recipient to receive shares of Stock
        (or cash, to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market
        Value of a share of Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of
        shares of Stock with respect to which the Stock Appreciation Right shall have been exercised.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(b)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Exercise Price of Stock Appreciation Rights</span>. The exercise
        price of a Stock Appreciation Right shall not be less than 100 percent of the Fair Market Value of the Stock on the date of grant.</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Grant
        and Exercise of Stock Appreciation Rights</span>. Stock Appreciation Rights may be granted by the Administrator independently of any Stock
        Option granted pursuant to Section 5 of the Plan.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Terms
        and Conditions of Stock Appreciation Rights</span>. Stock Appreciation Rights shall be subject to such terms and conditions as shall be
        determined on the date of grant by the Administrator. The term of a Stock Appreciation Right may not exceed ten years. The terms and conditions
        of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees.</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
7. <span style="text-decoration: underline">RESTRICTED STOCK AWARDS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(a)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Nature of Restricted Stock Awards</span>. The Administrator may grant
        Restricted Stock Awards under the Plan. A Restricted Stock Award is any Award of Restricted Shares subject to such restrictions and conditions
        as the Administrator may determine at the time of grant. Conditions may be based on continuing employment (or other Service Relationship)
        and/or achievement of pre-established performance goals and objectives.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 566; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(b)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Rights as a Stockholder</span>. Upon the grant of the Restricted
        Stock Award and payment of any applicable purchase price, a grantee shall have the rights of a stockholder with respect to the voting
        of the Restricted Shares and receipt of dividends; provided that any dividends paid by the Company shall accrue and shall not be paid
        to the grantee until the lapse of restrictions on such Restricted Shares, and such dividends shall expire or be forfeited or annulled
        under the same conditions as the Restricted Shares. Unless the Administrator shall otherwise determine, (i) uncertificated Restricted
        Shares shall be accompanied by a notation on the records of the Company or the transfer agent to the effect that they are subject to forfeiture
        until such Restricted Shares are vested as provided in Section 7(d) below, and (ii) certificated Restricted Shares shall remain in the
        possession of the Company until such Restricted Shares are vested as provided in Section 7(d) below, and the grantee shall be required,
        as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(c)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Restrictions</span>. Restricted Shares may not be sold, assigned,
        transferred, pledged or otherwise encumbered or disposed of except as specifically provided herein or in the Restricted Stock Award Certificate.
        Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 16 below, in writing after
        the Award is issued, if a grantee&#8217;s employment (or other Service Relationship) with the Company and its Subsidiaries terminates
        for any reason, any Restricted Shares that have not vested at the time of termination shall automatically and without any requirement
        of notice to such grantee from or other action by or on behalf of, the Company be deemed to have been reacquired by the Company at its
        original purchase price (if any) from such grantee or such grantee&#8217;s legal representative simultaneously with such termination of
        employment (or other Service Relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights
        of the grantee as a stockholder. Following such deemed reacquisition of Restricted Shares that are represented by physical certificates,
        a grantee shall surrender such certificates to the Company upon request without consideration.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(d)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Vesting of Restricted Shares</span>. The Administrator at the time
        of grant shall specify the date or dates and/or the attainment of pre-established performance goals, objectives and other conditions on
        which the non-transferability of the Restricted Shares and the Company&#8217;s right of repurchase or forfeiture shall lapse. Subsequent
        to such date or dates and/or the attainment of such pre-established performance goals, objectives and other conditions, the shares on
        which all restrictions have lapsed shall no longer be Restricted Shares and shall be deemed &#8220;vested.&#8221;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
8. <span style="text-decoration: underline">RESTRICTED STOCK UNITS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(a)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Nature of Restricted Stock Units</span>. The Administrator may grant
        Restricted Stock Units under the Plan. The vesting conditions or other restrictions associated with the Restricted Stock Unit may be based
        on continuing employment (or other Service Relationship) and/or achievement of pre-established performance goals and objectives. The terms
        and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual
        Awards and grantees. Except in the case of Restricted Stock Units with a deferred settlement date that complies with Section 409A, at
        the end of the vesting period, the Restricted Stock Units, to the extent vested, shall be settled in the form of shares of Stock (or cash,
        to the extent explicitly provided for in the Award Certificate). Restricted Stock Units with deferred settlement dates may be subject
        to Section 409A and shall contain such additional terms and conditions as the Administrator shall determine in its sole discretion in
        order to comply with the requirements of Section 409A.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(b)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Election to Receive Restricted Stock Units in Lieu of Compensation</span>.
        The Administrator may, in its sole discretion, permit a grantee to elect to receive a portion of future cash compensation otherwise due
        to such grantee in the form of an award of Restricted Stock Units. Any such election shall be made in writing and shall be delivered to
        the Company no later than the date specified by the Administrator and in accordance with Section 409A and such other rules and procedures
        established by the Administrator. Any such future cash compensation that the grantee elects to defer shall be converted to a fixed number
        of Restricted Stock Units based on the Fair Market Value of Stock on the date the compensation would otherwise have been paid to the grantee
        if such payment had not been deferred as provided herein. The Administrator shall have the sole right to determine whether and under what
        circumstances to permit such elections and to impose such limitations and other terms and conditions thereon as the Administrator deems
        appropriate. Any Restricted Stock Units that are elected to be received in lieu of cash compensation shall be fully vested, unless otherwise
        provided in the Award Certificate.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(c)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Rights as a Stockholder</span>. A grantee shall have the rights as
        a stockholder only as to shares of Stock acquired by the grantee upon settlement of Restricted Stock Units; <i><span style="text-decoration: underline">provided</span></i>,
        <i><span style="text-decoration: underline">however</span></i>, that the grantee may be credited with Dividend Equivalent Rights with
        respect to the stock units underlying his Restricted Stock Units, subject to the provisions of Section 11 and such terms and conditions
        as the Administrator may determine.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 567; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(d)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Termination</span>. Except as may otherwise be provided by the Administrator
        either in the Award Certificate or, subject to Section 16 below, in writing after the Award is issued, a grantee&#8217;s right in all
        Restricted Stock Units that have not vested shall automatically terminate upon the grantee&#8217;s termination of employment (or cessation
        of Service Relationship) with the Company and its Subsidiaries for any reason.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
9. <span style="text-decoration: underline">UNRESTRICTED STOCK AWARDS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Grant
or Sale of Unrestricted Stock</span>. The Administrator may grant (or sell at par value or such higher purchase price determined by the
Administrator) an Unrestricted Stock Award under the Plan. An Unrestricted Stock Award is an Award pursuant to which the grantee may receive
shares of Stock free of any restrictions under the Plan. Unrestricted Stock Awards may be granted in respect of past services or other
valid consideration, or in lieu of cash compensation due to such grantee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
10. <span style="text-decoration: underline">CASH-BASED AWARDS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Grant
of Cash-Based Awards</span>. The Administrator may grant Cash-Based Awards under the Plan. A Cash-Based Award is an Award that entitles
the grantee to a payment in cash upon the attainment of specified performance goals. The Administrator shall determine the maximum duration
of the Cash-Based Award, the amount of cash to which the Cash-Based Award pertains, the conditions upon which the Cash-Based Award shall
become vested or payable, and such other provisions as the Administrator shall determine. Each Cash-Based Award shall specify a cash-denominated
payment amount, formula or payment ranges as determined by the Administrator. Payment, if any, with respect to a Cash-Based Award shall
be made in accordance with the terms of the Award and may be made in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
11. <span style="text-decoration: underline">DIVIDEND EQUIVALENT RIGHTS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(a)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Dividend Equivalent Rights</span>. The Administrator may grant Dividend
        Equivalent Rights under the Plan. A Dividend Equivalent Right is an Award entitling the grantee to receive credits based on cash dividends
        that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other Award to which it relates) if such
        shares had been issued to the grantee. A Dividend Equivalent Right may be granted hereunder to any grantee as a component of an award
        of Restricted Stock Units or as a freestanding award. In no event shall any Dividend Equivalent Right be granted to an optionee as a component
        of a Stock Option. The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Certificate. Dividend equivalents
        credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional shares of
        Stock, which may thereafter accrue additional equivalents. Any such reinvestment shall be at Fair Market Value on the date of reinvestment
        or such other price as may then apply under a dividend reinvestment plan sponsored by the Company, if any. Dividend Equivalent Rights
        may be settled in cash or shares of Stock or a combination thereof, in a single installment or installments. A Dividend Equivalent Right
        granted as a component of an Award of Restricted Stock Units shall provide that such Dividend Equivalent Right shall be settled only upon
        settlement or payment of, or lapse of restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be forfeited
        or annulled under the same conditions as such other Award.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(b)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Termination</span>. Except as may otherwise be provided by the Administrator
        either in the Award Certificate or, subject to Section 16 below, in writing after the Award is issued, a grantee&#8217;s rights in all
        Dividend Equivalent Rights shall automatically terminate upon the grantee&#8217;s termination of employment (or cessation of Service Relationship)
        with the Company and its Subsidiaries for any reason.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
12. <span style="text-decoration: underline">TRANSFERABILITY OF AWARDS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(a)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Transferability</span>. Except as provided in Section 12(b) below,
        during a grantee&#8217;s lifetime, his or her Awards shall be exercisable only by the grantee, or by the grantee&#8217;s legal representative
        or guardian in the event of the grantee&#8217;s incapacity. No Awards shall be sold, assigned, transferred or otherwise encumbered or
        disposed of by a grantee other than by will or by the laws of descent and distribution or pursuant to a domestic relations order. No Awards
        shall be subject, in whole or in part, to attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall
        be null and void.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 568; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(b)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Administrator Action</span>. Notwithstanding Section 12(a), the Administrator,
        in its discretion, may provide either in the Award Certificate regarding a given Award or by subsequent written approval that the grantee
        (who is an employee or director) may transfer his or her Non-Qualified Stock Options to his or her immediate family members, to trusts
        for the benefit of such family members, or to partnerships in which such family members are the only partners, provided that the transferee
        agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award. In no event may
        an Award be transferred by a grantee for value.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(c)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Family Member</span>. For purposes of Section 12(b), &#8220;family
        member&#8221; shall mean a grantee&#8217;s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling,
        niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships,
        any person sharing the grantee&#8217;s household (other than a tenant of the grantee), a trust in which these persons (or the grantee)
        have more than fifty percent (50%) of the beneficial interest, a foundation in which these persons (or the grantee) control the management
        of assets, and any other entity in which these persons (or the grantee) own more than fifty percent (50%) of the voting interests.</td>
        </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(d)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Designation of Beneficiary</span>. To the extent permitted by the
        Company, each grantee to whom an Award has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award
        or receive any payment under any Award payable on or after the grantee&#8217;s death. Any such designation shall be on a form provided
        for that purpose by the Administrator and shall not be effective until received by the Administrator. If no beneficiary has been designated
        by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee&#8217;s estate.</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
13. <span style="text-decoration: underline">TAX WITHHOLDING</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(a)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Payment by Grantee</span>. Each grantee shall, no later than the
        date as of which the value of an Award or of any Stock or other amounts received thereunder first becomes includable in the gross income
        of the grantee for Federal or non-U.S. income tax purposes, pay to the Company, or make arrangements satisfactory to the Administrator
        regarding payment of, any federal, state, or local taxes of any kind required by law to be withheld by the Company with respect to such
        income. The Company and its Subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes from any payment
        of any kind otherwise due to the grantee. The Company&#8217;s obligation to deliver evidence of book entry (or stock certificates) to
        any grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(b)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Payment in Stock</span>. The Administrator may require the Company&#8217;s
        tax withholding obligation to be satisfied, in whole or in part, by the Company withholding from shares of Stock to be issued pursuant
        to any Award a number of shares with an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the
        withholding amount due; <i><span style="text-decoration: underline">provided</span></i>, <i><span style="text-decoration: underline">however</span></i>,
        that the amount withheld does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid liability accounting
        treatment. For purposes of share withholding, the Fair Market Value of withheld shares shall be determined in the same manner as the value
        of Stock includible in income of the grantees. The Administrator may also require the Company&#8217;s tax withholding obligation to be
        satisfied, in whole or in part, by an arrangement whereby a certain number of shares of Stock issued pursuant to any Award are immediately
        sold and proceeds from such sale are remitted to the Company in an amount that would satisfy the withholding amount due.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
14. <span style="text-decoration: underline">SECTION 409A AWARDS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
are intended to be exempt from Section 409A to the greatest extent possible and to otherwise comply with Section 409A. The Plan and all
Awards shall be interpreted in accordance with such intent. To the extent that any Award is determined to constitute &#8220;nonqualified
deferred compensation&#8221; within the meaning of Section 409A (a &#8220;<span style="text-decoration: underline">409A Award</span>&#8221;),
the Award shall be subject to such additional rules and requirements as specified by the Administrator from time to time in order to comply
with Section 409A. In this regard, if any amount under a 409A Award is payable upon a &#8220;separation from service&#8221; (within the
meaning of Section 409A) to a grantee who is then considered a &#8220;specified employee&#8221; (within the meaning of Section 409A),
then no such payment shall be made prior to the date that is the earlier of (i) six months and one day after the grantee&#8217;s separation
from service, or (ii) the grantee&#8217;s death, but only to the extent such delay is necessary to prevent such payment from being subject
to interest, penalties and/or additional tax imposed pursuant to Section 409A. Further, the settlement of any 409A Award may not be accelerated
except to the extent permitted by Section 409A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 569; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
15. <span style="text-decoration: underline">TERMINATION OF SERVICE RELATIONSHIP, TRANSFER, LEAVE OF ABSENCE, ETC</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(a)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Termination of Service Relationship</span>. If the grantee&#8217;s
        Service Relationship is with an Affiliate and such Affiliate ceases to be an Affiliate, the grantee shall be deemed to have terminated
        his or her Service Relationship for purposes of the Plan.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(b)</td>
    <td style="text-align: justify">For purposes of the Plan, the following events shall not be deemed a termination of a Service Relationship:</td>
        </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.35in; text-align: left">(i)</td>
    <td style="text-align: justify">a transfer to the employment of the Company from an Affiliate or from the Company to an Affiliate, or from
        one Affiliate to another;</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.35in; text-align: left">(ii)</td>
    <td style="text-align: justify">an approved leave of absence for military service or sickness, or for any other purpose approved by the Company,
        if the employee&#8217;s right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which
        the leave of absence was granted or if the Administrator otherwise so provides in writing;</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.35in; text-align: left">(iii)</td>
    <td style="text-align: justify">an employee becoming a Consultant or a Non-Employee Director upon the termination of such employee&#8217;s
        employment, unless otherwise determined by the Administrator, in its sole discretion; or</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.35in; text-align: left">(iv)</td>
    <td style="text-align: justify">a Consultant or a Non-Employee Director becoming an employee.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
16. <span style="text-decoration: underline">AMENDMENTS AND TERMINATION</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for
the purpose of satisfying changes in law or for any other lawful purpose, but no such action shall materially and adversely affect rights
under any outstanding Award without the holder&#8217;s consent. The Administrator is specifically authorized to exercise its discretion
to reduce the exercise price of outstanding Stock Options or Stock Appreciation Rights or effect the repricing of such Awards through
cancellation and re-grants. To the extent required under the rules of any securities exchange or market system on which the Stock is listed,
to the extent determined by the Administrator to be required by the Code to ensure that Incentive Stock Options granted under the Plan
are qualified under Section 422 of the Code, Plan amendments shall be subject to approval by Company stockholders. Nothing in this Section
16 shall limit the Administrator&#8217;s authority to take any action permitted pursuant to Section 3(b) or 3(c).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
17. <span style="text-decoration: underline">STATUS OF PLAN</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by
a grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Administrator shall otherwise
expressly determine in connection with any Award or Awards. In its sole discretion, the Administrator may authorize the creation of trusts
or other arrangements to meet the Company&#8217;s obligations to deliver Stock or make payments with respect to Awards hereunder, provided
that the existence of such trusts or other arrangements is consistent with the foregoing sentence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
18. <span style="text-decoration: underline">GENERAL PROVISIONS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(a)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">No Distribution</span>. The Administrator may require each person
        acquiring Stock pursuant to an Award to represent to and agree with the Company in writing that such person is acquiring the shares without
        a view to distribution thereof.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(b)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Issuance of Stock</span>. To the extent certificated, stock certificates
        to grantees under this Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall
        have mailed such certificates in the United States mail, addressed to the grantee, at the grantee&#8217;s last known address on file with
        the Company. Uncertificated Stock shall be deemed delivered for all purposes when the Company or a Stock transfer agent of the Company
        shall have given to the grantee by electronic mail (with proof of receipt) or by United States mail, addressed to the grantee, at the
        grantee&#8217;s last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include
        electronic &#8220;book entry&#8221; records). Notwithstanding anything herein to the contrary, the Company shall not be required to issue
        or deliver any evidence of book entry or certificates evidencing shares of Stock pursuant to the </td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 570; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="text-align: justify; margin-left: 0.25in; margin-top: 0; margin-bottom: 0">exercise or settlement of any Award, unless and until
the Administrator has determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that
the issuance and delivery is in compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements
of any exchange on which the shares of Stock are listed, quoted or traded. Any Stock issued pursuant to the Plan shall be subject to any
stop-transfer orders and other restrictions as the Administrator deems necessary or advisable to comply with federal, state or foreign
jurisdiction, securities or other laws, rules and quotation system on which the Stock is listed, quoted or traded. The Administrator may
place legends on any Stock certificate or notations on any book entry to reference restrictions applicable to the Stock. In addition to
the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements,
and representations as the Administrator, in its discretion, deems necessary or advisable in order to comply with any such laws, regulations,
or requirements. The Administrator shall have the right to require any individual to comply with any timing or other restrictions with
respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Administrator.</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(c)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Stockholder Rights</span>. Until Stock is deemed delivered in accordance
        with Section 18(b), no right to vote or receive dividends or any other rights of a stockholder will exist with respect to shares of Stock
        to be issued in connection with an Award, notwithstanding the exercise of a Stock Option or any other action by the grantee with respect
        to an Award.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(d)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Other Compensation Arrangements; No Employment Rights</span>. Nothing
        contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, including trusts, and such
        arrangements may be either generally applicable or applicable only in specific cases. The adoption of this Plan and the grant of Awards
        do not confer upon any employee any right to continued employment with the Company or any Subsidiary.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(e)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Trading Policy Restrictions</span>. Option exercises and other Awards
        under the Plan shall be subject to the Company&#8217;s insider trading policies and procedures, as in effect from time to time.</td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left">(f)</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Clawback Policy</span>. Awards under the Plan shall be subject to
        the Company&#8217;s clawback policy, as in effect from time to time.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
19. <span style="text-decoration: underline">STATUS UNDER ERISA</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Plan shall not constitute an &#8220;employee benefit plan&#8221; for purposes of Section 3(3) of the Employee Retirement Income Security
Act of 1974, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
20. <span style="text-decoration: underline">EFFECTIVE DATE OF PLAN</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Plan shall become effective upon the date immediately preceding the Closing Date subject to prior stockholder approval in accordance with
applicable state law, the Company&#8217;s bylaws and certificate of incorporation, and applicable securities exchange rules. No grants
of Stock Options and other Awards may be made hereunder after the tenth anniversary of the Effective Date and no grants of Incentive Stock
Options may be made hereunder after the tenth anniversary of the date the Plan is approved by the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
21. <span style="text-decoration: underline">GOVERNING LAW</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with, the laws of the State of Delaware,
applied without regard to conflict of law principles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DATE
APPROVED BY BOARD OF DIRECTORS:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DATE
APPROVED BY STOCKHOLDERS:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 571; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><b><span id="annex_d"></span>ANNEX D</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><i>Execution Version</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COMPANY
SHAREHOLDER SUPPORT AGREEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
COMPANY SHAREHOLDER SUPPORT AGREEMENT is dated as of January 11, 2026 (this &#8220;<span style="text-decoration: underline">Support Agreement</span>&#8221;),
by the shareholder which has a majority interest in the Company as listed on <span style="text-decoration: underline">Exhibit A</span>
hereto (&#8220;<span style="text-decoration: underline">Shareholder</span>&#8221;), Exascale Labs Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline">Company</span>&#8221;),
and D. Boral ARC Acquisition I Corp., a company organized under the laws of the British Virgin Islands (&#8220;<span style="text-decoration: underline">Parent</span>&#8221;).
Capitalized terms used but not defined in this Support Agreement shall have the meanings ascribed to them in the Merger Agreement (as
defined below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Parent and Company, together with Purchaser and Merger Sub have entered into an Agreement and Plan of Merger (as the same may be amended,
restated or supplemented, the &#8220;<span style="text-decoration: underline">Merger Agreement</span>&#8221;), pursuant to which, among
other things, (a) Parent will merge with and into Purchaser, in which Purchaser will be the surviving entity (the &#8220;<span style="text-decoration: underline">Reincorporation
Merger</span>&#8221;); and (b) promptly following the Reincorporation Merger, Merger Sub will merge with and into Company, in which Company
will be the surviving corporation and a wholly-owned subsidiary of Purchaser (the &#8220;<span style="text-decoration: underline">Merger</span>&#8221;
and, together with Reincorporation Merger and the other transactions contemplated by the Merger Agreement, the &#8220;<span style="text-decoration: underline">Transactions</span>&#8221;);</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
as of the date hereof, the Shareholder owns the number of shares of Company set forth opposite its name on <span style="text-decoration: underline">Exhibit
A</span> (all such shares, or any additional shares of Company or any successor entity of which ownership of record or the power to vote,
directly or indirectly, is hereafter acquired by the Shareholder prior to the termination of this Support Agreement being referred to
herein as the &#8220;<span style="text-decoration: underline">Shareholder Shares</span>&#8221;); and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
in order to induce Parent, Purchaser and Merger Sub to enter into the Merger Agreement, the Shareholder is executing and delivering this
Support Agreement to Parent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements contained herein, and intending to be legally
bound hereby, the parties hereby agree as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<span style="text-decoration: underline"> Voting Agreements</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period commencing on the date hereof and ending on the earlier to occur of (i) the Closing Date, and (ii) such date and time as the
Merger Agreement shall be terminated in accordance with Section 12.1 thereof (whichever is earlier, the &#8220;<span style="text-decoration: underline">Expiration
Time</span>&#8221;), the Shareholder, in its capacity as a shareholder of Company, agrees that, at any meeting of Company&#8217; shareholders
related to the Transactions (whether annual or special and whether or not an adjourned or postponed meeting, however called and including
any adjournment or postponement thereof) and/or in connection with any written consent of Company&#8217; shareholders related to the Transactions
(all meetings or consents related to the Merger Agreement, collectively, the &#8220;<span style="text-decoration: underline">Meeting</span>&#8221;),
such Shareholder shall:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
when the Meeting is held, appear at the Meeting or otherwise cause its Shareholder Shares to be counted as present thereat for the purpose
of establishing a quorum;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 572; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
vote (or execute and return an action by written consent), or cause to be voted at the Meeting (or validly execute and return and cause
such consent to be granted with respect to), all of its Shareholder Shares in favor of the Merger Agreement and the Transactions;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
authorize and approve any amendment to Company&#8217;s Organizational Documents that is deemed necessary or advisable by Company for purposes
of effecting the Transactions; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
vote (or execute and return an action by written consent), or cause to be voted at the Meeting (or validly execute and return and cause
such consent to be granted with respect to), all of its Shareholder Shares against any other action that would reasonably be expected
to (i) materially impede, interfere with, delay, postpone or adversely affect the Merger or any of the Transactions, (ii) result in a
breach of any covenant, representation or warranty or other obligation or agreement of Company under the Merger Agreement or (iii) result
in a breach of any covenant, representation or warranty or other obligation or agreement of the Shareholder contained in this Support
Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<span style="text-decoration: underline">Restrictions on Transfer</span>. Until the Expiration Time, the Shareholder agrees that, it shall
not sell, assign or otherwise transfer any of its Shareholder Shares unless the buyer, assignee or transferee thereof executes a joinder
agreement to this Support Agreement in substantially the form set forth on <span style="text-decoration: underline">Exhibit B</span>.
Company shall not register any sale, assignment or transfer of the Shareholder Shares on its stock ledger (book entry or otherwise) that
is not in compliance with this <span style="text-decoration: underline">Section 2</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<span style="text-decoration: underline">New Securities</span>. During the period commencing on the date hereof and ending at the Expiration
Time, in the event that, (a) any Company Shares or other equity securities of Company are issued to the Shareholder after the date of
this Support Agreement pursuant to any stock dividend, stock split, recapitalization, reclassification, combination or other securities
of any other entity in exchange for Company&#8217; securities owned by the Shareholder, (b) the Shareholder purchases or otherwise acquires
beneficial ownership of any Company Shares or other equity securities of Company or securities of any other entity in exchange for Company
securities owned by the Shareholder, after the date of this Support Agreement, or (c) the Shareholder acquires the right to vote or share
in the voting of any Company Shares (apart from Company&#8217; securities owned by the Shareholder) or other equity securities of Company
after the date of this Support Agreement (such Company Shares or other equity securities of Company, collectively the &#8220;<span style="text-decoration: underline">New
Securities</span>&#8221;), then such New Securities acquired or purchased by the relevant Shareholder shall be subject to the terms of
this Support Agreement to the same extent as if they constituted the Shareholder Shares as of the date hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<span style="text-decoration: underline">No Challenge</span>. The Shareholder agrees, in its capacity as a shareholder only, not to commence,
join in, facilitate, assist or encourage, and agrees to take all actions necessary to opt out of any class in any class action with respect
to, any claim, derivative or otherwise, against Parent, Purchaser, Merger Sub or Company or any of their respective successors or directors
(a) challenging the validity of, or seeking to enjoin the operation of, any provision of this Support Agreement or the Merger Agreement
or (b) alleging a breach of any fiduciary duty of any person in connection with the evaluation, negotiation or entry into the Merger Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 573 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<span style="text-decoration: underline">Consent to Disclosure</span>. The Shareholder hereby consents to the publication and disclosure
in the Proxy Statement, if necessary (and, as and to the extent otherwise required by applicable securities Laws or the SEC or any other
securities authorities, any other documents or communications provided by Parent, Purchaser, Merger Sub or Company to any Governmental
Authority or to securityholders of Parent or Company) of such Shareholder&#8217;s identity and beneficial ownership of Shareholder Shares
and the nature of such Shareholder&#8217;s commitments, arrangements and understandings under and relating to this Support Agreement and,
if deemed appropriate by Parent, Purchaser, Merger Sub or Company, a copy of this Support Agreement. Each Shareholder will promptly provide
any information reasonably requested by Parent, Purchaser, Merger Sub or Company for any regulatory application or filing made or approval
sought in connection with the Transactions (including filings with the SEC).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&#160;<span style="text-decoration: underline">Termination
of Company Financing Agreements, Related Agreements</span>. The Shareholder, by this Support Agreement with respect to its Shareholder
Shares, severally and not jointly, hereby agrees to terminate, subject to the Closing and effective as of the Effective Time, (a) all
agreements with respect to Affiliate Transactions to which such Shareholder is party that are set forth on Schedule 5.24(a) of the Company
Disclosure Schedules, if applicable to the Shareholder (the &#8220;<span style="text-decoration: underline">Company Financing Agreements</span>&#8221;);
(b) any management rights or side letters between the Company and the Shareholder; and (c) any rights under any letter or agreement providing
for redemption rights, put rights, purchase rights or other similar rights not generally available to shareholders of the Company (clauses
(a) through (c), collectively, the &#8220;<span style="text-decoration: underline">Terminating Rights</span>&#8221;) between Shareholder
and the Company, but excluding, (i) for the avoidance of doubt, any rights Shareholder may have that relate to any commercial or employment
agreements or arrangements between the Shareholder and the Company or any Subsidiary thereof, which shall survive the Closing in accordance
with their terms, and (ii) any indemnification, advancement of expenses and exculpation rights of the Shareholder or any of its Affiliates
set forth in the foregoing documents, which shall survive the Closing in accordance with their terms; provided that all Terminating Rights
between the Company and any other holder of Company Shares shall also terminate at such time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<span style="text-decoration: underline">Waiver</span>. The Shareholder irrevocably and unconditionally (a) waives any rights of appraisal,
dissenter&#8217;s rights and any similar rights relating to the Merger Agreement and the consummation by the parties of the Transactions,
including the Merger, that such Shareholder may have under applicable law and (b) waives its or its successor entity&#8217;s right to
certain payments upon liquidation of Company or other entity of which the Shareholder Shares represents ownership interests pursuant to
Company&#8217; or such other entity&#8217;s Organizational Documents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<span style="text-decoration: underline">Shareholder Representations</span>. The Shareholder represents and warrants to Parent and Company,
as of the date hereof, that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.&#160;such
Shareholder has full right and power, without violating any agreement to which it is bound (including, without limitation, any non-competition
or non-solicitation agreement with any employer or former employer), to enter into this Support Agreement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 574 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.&#160;(i)
if such Shareholder is an entity, such Shareholder is duly organized, validly existing and in good standing under the Laws of the jurisdiction
in which it is organized, and the execution, delivery and performance of this Support Agreement and the consummation of the transactions
contemplated hereby are within such Shareholder&#8217;s powers and have been duly authorized by all necessary actions on the part of the
Shareholder, or (ii) if such Shareholder is an individual, the signature on this Support Agreement is genuine and such Shareholder has
legal competence and capacity to execute the same;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.&#160;this
Support Agreement has been duly executed and delivered by such Shareholder and, this Support Agreement constitutes a legally valid and
binding obligation of such Shareholder, enforceable against such Shareholder in accordance with the terms hereof (except as enforceability
may be limited by bankruptcy Laws, other similar Laws affecting creditors&#8217; rights and general principles of equity affecting the
availability of specific performance and other equitable remedies);</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.&#160;the
execution and delivery of this Support Agreement by such Shareholder do not, and the performance by such Shareholder of its obligations
hereunder will not, (i) if such Shareholder is an entity, conflict with or result in a violation of the organizational documents of such
Shareholder, or (ii) whether such Shareholder is any entity or an individual, require any consent or approval from any third party that
has not been given or other action that has not been taken by any third party, in each case, to the extent such consent, approval or other
action would prevent, enjoin or materially delay the performance by such Shareholder of its obligations under this Support Agreement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.&#160;there
are no Proceedings pending or, to the knowledge of such Shareholder, threatened against such Shareholder before (or, in the case of threatened
Proceedings, that would be before) any arbitrator or any Governmental Authority, which in any manner challenges or seeks to prevent, enjoin
or materially delay the performance by such Shareholder of such Shareholder&#8217;s obligations under this Support Agreement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.&#160;no
broker, finder, investment banker or other Person is entitled to any brokerage fee, finders&#8217; fee or other commission in connection
with this Support Agreement or any of the respective transactions contemplated hereby, based upon arrangements made by the Shareholder
or, to the knowledge of such Shareholder, by Company;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.&#160;such
Shareholder has had the opportunity to read the Merger Agreement and this Support Agreement and has had the opportunity to consult with
such Shareholder&#8217;s tax, financial and legal advisors;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.&#160;such
Shareholder has not entered into, and shall not enter into, any agreement that would prevent such Shareholder from performing any of such
Shareholder&#8217;s obligations hereunder;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 575 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.&#160;such
Shareholder has good title to the Shareholder Shares set forth opposite such Shareholder&#8217;s name on <span style="text-decoration: underline">Exhibit
A</span>, free and clear of any Liens other than Liens pursuant to this Agreement, the other Transaction Documents, the Organizational
Documents of Company and Permitted Liens, and such Shareholder has the sole power to vote or cause to be voted such Shareholder Shares;
and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.&#160;the
Shareholder Shares listed opposite such Shareholder&#8217;s name on <span style="text-decoration: underline">Exhibit A</span> are the
only shares of Company&#8217; capital stock owned of record or beneficially owned by the Shareholder as of the date hereof, and none of
such Shareholder Shares are subject to any proxy, voting trust or other agreement or arrangement with respect to the voting of such Shareholder
Shares that is inconsistent with such Shareholder&#8217;s obligations pursuant to this Support Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&#160;<span style="text-decoration: underline">Damages;
Remedies</span>. The Shareholder hereby agrees and acknowledges that (a) Parent and Company would be irreparably injured in the event
of a breach by the Shareholder of its obligations under this Support Agreement, (b) monetary damages may not be an adequate remedy for
such breach and (c) the non-breaching party shall be entitled to injunctive relief, in addition to any other remedy that such party may
have in law or in equity, in the event of such breach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&#160;<span style="text-decoration: underline">Binding
Effect of Merger Agreement</span>. The Shareholder shall be bound by and comply with Sections 10.1 (<i>No Shop</i>) and 13.13 (<i>Publicity</i>)
of the Merger Agreement (and any relevant definitions contained in any such Sections) as if (x) the Shareholder was an original signatory
to the Merger Agreement with respect to such provisions, and (y) each reference to the &#8220;Company&#8221; contained in such provisions
also referred to such Shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&#160;<span style="text-decoration: underline">Entire
Agreement; Amendment</span>. This Support Agreement and the other agreements referenced herein constitute the entire agreement and understanding
of the parties hereto in respect of the subject matter hereof and supersede all prior understandings, agreements or representations by
or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated
hereby. This Support Agreement may not be changed, amended, modified or waived (other than to correct a typographical error) as to any
particular provision, except by a written instrument executed by all parties hereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<span style="text-decoration: underline">Assignment</span>. No party hereto may, except as set forth herein, assign either this Support
Agreement or any of its rights, interests, or obligations hereunder without the prior written consent of the other parties. Any purported
assignment in violation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title
to the purported assignee. This Support Agreement shall be binding on each Shareholder, Parent and Company and each of their respective
successors, heirs, personal representatives and assigns and permitted transferees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<span style="text-decoration: underline">Counterparts</span>. This Support Agreement may be executed in any number of original, electronic
or facsimile counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts
shall together constitute but one and the same instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 576 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<span style="text-decoration: underline">Severability</span>. This Support Agreement shall be deemed severable, and the invalidity or
unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Support Agreement or of any other
term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that
there shall be added as a part of this Support Agreement a provision as similar in terms to such invalid or unenforceable provision as
may be possible and be valid and enforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<span style="text-decoration: underline">Governing Law; Jurisdiction; Jury Trial Waiver</span>. Section 13.6 and Section 13.7 of the Merger
Agreement are incorporated by reference herein and shall apply <i>mutatis mutandis</i> with full force to any disputes arising under this
Support Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<span style="text-decoration: underline">Notice</span>. Any notice, consent or request to be given in connection with any of the terms
or provisions of this Support Agreement shall be in writing and shall be sent or given in accordance with the terms of Section 13.9 of
the Merger Agreement to the applicable party, with respect to Parent or Company at the address set forth in Section 13.9 of the Merger
Agreement, and, with respect to each Shareholder, at its address set forth on <span style="text-decoration: underline">Exhibit A</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<span style="text-decoration: underline">Termination</span>. This Support Agreement shall terminate on the earlier of the Closing or the
termination of the Merger Agreement. No such termination shall relieve the Shareholder, Parent or Company from any liability resulting
from a breach of this Support Agreement occurring prior to such termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.&#160;<span style="text-decoration: underline">Adjustment
for Stock Split</span>. If, and as often as, there are any changes in the Shareholder Shares by way of stock split, stock dividend, combination
or reclassification, or through merger, consolidation, reorganization, recapitalization or business combination, or by any other means,
equitable adjustment shall be made to the provisions of this Support Agreement as may be required so that the rights, privileges, duties
and obligations hereunder shall continue with respect to each Shareholder, Parent, Company and the Shareholder Shares as so changed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<span style="text-decoration: underline">Further Actions</span>. Each of the parties hereto agrees to execute and deliver hereafter any
further document, agreement or instrument of assignment, transfer or conveyance as may be necessary or desirable to effectuate the purposes
hereof and as may be reasonably requested in writing by another party hereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>[remainder
of page intentionally left blank]</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 577 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have executed this Support Agreement as of the date first written above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="3" style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt"><b>D. BORAL ARC ACQUISITION I CORP.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; width: 50%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 4%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 5%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 41%; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">/s/ John Darwin</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Name:&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">John Darwin</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Title:</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="3" style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt"><b>EXASCALE LABS INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; width: 50%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 4%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 5%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 41%; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">/s/ Hoansoo Lee</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Name:&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Hoansoo Lee</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Title:</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i>[Signature Page to Company
Shareholder Support Agreement]</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 578 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have executed this Support Agreement as of the date first written above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: left">&#160;</td>
    <td colspan="2" style="text-align: left"><b>SHAREHOLDER</b></td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: left; width: 50%">&#160;</td>
    <td style="text-align: left; width: 5%">&#160;</td>
    <td style="text-align: left; width: 45%">&#160;</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: left">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: left">/s/ Wenying Jia</td></tr>
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Name:</td>
    <td style="text-align: left">Wenying Jia</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>[Signature
Page to Company Shareholder Support Agreement]</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 579 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHAREHOLDER</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 25%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shareholder</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 25%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
        of Shares</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 25%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Email
        for Notices</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 25%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Address
        for Notices</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 580 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
B</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
OF JOINDER AGREEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Joinder Agreement (this &#8220;<span style="text-decoration: underline">Joinder Agreement</span>&#8221;) is made as of the date written
below by the undersigned (the &#8220;<span style="text-decoration: underline">Joining Party</span>&#8221;) in accordance with Company
Shareholder Support Agreement dated as of [&#160;&#160;&#160;], 2026 (as the same may be amended from time to time, the &#8220;<span style="text-decoration: underline">Support
Agreement</span>&#8221;), by and among Exascale Labs Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline">Company</span>&#8221;),
D. Boral ARC Acquisition I Corp., a company organized under the laws of the British Virgin Islands (&#8220;<span style="text-decoration: underline">Parent</span>&#8221;),
and the shareholders party thereto. Capitalized terms used but not otherwise defined herein shall have the meaning ascribed to such terms
in the Support Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
executing and delivering this Joinder Agreement to Company and Parent, the undersigned hereby agrees to become a party to, to be bound
by and to comply with the Support Agreement as a Shareholder in the same manner as if the undersigned were an original signatory to the
Support Agreement; <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>,
that (a) the expressions of &#8220;the date hereof&#8221; and &#8220;the date of this Support Agreement&#8221; or similar expressions
the Support Agreement shall be deemed to be the date of this Joinder Agreement, and (b) for purposes of the Support Agreement and this
Joinder Agreement, the Shareholder Shares owned by the Joining Party as of the date of this Joinder Agreement are __________ ___, 20__.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IN
WITNESS WHEREOF</b>, the undersigned has executed this&#160;Joinder&#160;Agreement as of the date written below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
__________ ___, 20__</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left"><b>[NAME OF JOINING PARTY]</b></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left; width: 50%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices
Information:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 581 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><b><span id="annex_e"></span>ANNEX E</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><i>Execution Version</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">SPONSOR</span><span style="text-decoration: underline">
SUPPORT AGREEMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This SPONSOR SUPPORT AGREEMENT
dated as of January&#160;11, 2026 (this &#8220;<span style="text-decoration: underline">Support Agreement</span>&#8221;), is entered into
by and among MFH 1, LLC, a Delaware limited liability company (&#8220;<span style="text-decoration: underline">Sponsor</span>&#8221;),
Exascale Labs Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline">Company</span>&#8221;), and D. Boral ARC Acquisition
I Corp., a company organized under the laws of the British Virgin Islands (&#8220;<span style="text-decoration: underline">Parent</span>&#8221;).
Capitalized terms used but not defined in this Support Agreement shall have the meanings ascribed to them in the Merger Agreement (as
defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, Parent and Company, together
with Purchaser and Merger Sub have entered into an Agreement and Plan of Merger (as the same may be amended, restated or supplemented,
the &#8220;<span style="text-decoration: underline">Merger Agreement</span>&#8221;), pursuant to which, among other things, (a) Parent
will merge with and into Purchaser, with Purchaser as the surviving entity (the &#8220;<span style="text-decoration: underline">Reincorporation
Merger</span>&#8221;); and (b) promptly following the Reincorporation Merger, Merger Sub will merge with and into Company, with Company
as the surviving corporation and a wholly-owned subsidiary of Purchaser (the &#8220;<span style="text-decoration: underline">Merger</span>&#8221;
and, together with Reincorporation Merger and the other transactions contemplated by the Merger Agreement, the &#8220;<span style="text-decoration: underline">Transactions</span>&#8221;);
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, as of the date hereof,
the Sponsor is the holder of record of 12,000,000 Class B ordinary shares of a par value of US$0.0001 each (&#8220;<span style="text-decoration: underline">Class
B Shares</span>&#8221;) and 200,000 Class A ordinary shares of a par value of US$0.0001 each (&#8220;<span style="text-decoration: underline">Class
A Shares</span>&#8221;) (all such shares, or any successor, replacement or additional shares of Parent of which ownership of record or
the power to vote is hereafter acquired by the Sponsor prior to the termination of this Support Agreement being referred to herein as
the &#8220;<span style="text-decoration: underline">Sponsor Shares</span>&#8221;); and </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, in order to induce Company
to enter into the Merger Agreement, the Sponsor is executing and delivering this Support Agreement to Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing and of the mutual covenants and agreements contained herein, and intending to be legally bound hereby, the parties hereby
agree as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1. <span style="text-decoration: underline">Voting
Agreements</span>. During the period commencing on the date hereof and ending on the earlier to occur of (a) the Closing Date and (b)
such date and time as the Merger Agreement shall be terminated in accordance with Section&#160;12.1 thereof (whichever is earlier, the
&#8220;<span style="text-decoration: underline">Expiration Time</span>&#8221;), the Sponsor agrees that, at the Parent Shareholders&#8217;
Meeting, at any other meeting of Parent Shareholders related to the Transactions (whether annual or extraordinary and whether or not an
adjourned meeting, however called and including any adjournment thereof) and/or in connection with any written resolution of Parent Shareholders
related to the Transactions (the Parent Shareholders&#8217; Meeting and all other meetings or resolutions related to the Merger Agreement,
collectively, the &#8220;<span style="text-decoration: underline">Meeting</span>&#8221;), the Sponsor shall:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">a. when the Meeting
is held, appear at the Meeting or otherwise cause the Sponsor Shares to be counted as present thereat for the purpose of establishing
a quorum;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">b. vote (or execute
and return an action by written resolution), or cause to be voted at the Meeting (or validly execute and return and cause such resolution
to be passed with respect to), all of the Sponsor Shares in favor of each of the Parent Proposals; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 582; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">c. vote (or execute
and return an action by written resolution), or cause to be voted at the Meeting (or validly execute and return and cause such resolution
to be passed with respect to), all of the Sponsor Shares against any action that would reasonably be expected to (i) materially impede,
interfere with, delay, postpone or adversely affect the Merger or any of the Transactions, (ii) result in a breach of any covenant, representation
or warranty or other obligation or agreement of Parent, Purchaser or Merger Sub under the Merger Agreement or (iii) result in a breach
of any covenant, representation or warranty or other obligation or agreement contained in this Support Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The obligations of the Sponsor specified in this <span style="text-decoration: underline">Section&#160;1</span>
shall apply whether or not the Merger or any action described above is recommended by the board of directors of Parent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2. <span style="text-decoration: underline">Restrictions
on Transfer</span>. Until the Expiration Time, the Sponsor agrees that it shall not, directly or indirectly, sell, assign or otherwise
transfer any of the Sponsor Shares unless the buyer, assignee or transferee thereof executes a joinder agreement to this Support Agreement
in a form reasonably acceptable to Parent and Company. Parent shall not register any sale, assignment or transfer of the Sponsor Shares
on Parent&#8217;s transfer books or register (book entry or otherwise) that is not in compliance with this <span style="text-decoration: underline">Section&#160;2</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3. <span style="text-decoration: underline">No
Redemption</span>. The Sponsor hereby agrees that it shall not redeem, or submit a request to Parent&#8217;s transfer agent or otherwise
exercise any right to redeem, any Sponsor Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4. <span style="text-decoration: underline">Waiver
of Anti-dilution Rights</span>. The Sponsor hereby waives any anti-dilution rights that the Sponsor may have under any Law or arising
under the Organizational Documents of Parent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5. <span style="text-decoration: underline">New
Securities</span>. During the period commencing on the date hereof and ending at the Expiration Time, in the event that (a) any Parent
Ordinary Shares or other equity securities of Parent are issued to the Sponsor after the date of this Support Agreement pursuant to any
share dividend, share split, recapitalization, reclassification, combination, or other securities of any other entity are issued in exchange
for Parent Ordinary Shares owned or held of record by the Sponsor, (b) the Sponsor purchases or otherwise acquires beneficial or record
ownership of any Parent Ordinary Shares or other equity securities of Parent or securities of any other entity in exchange for Parent
Shares after the date of this Support Agreement, or (c) the Sponsor acquires the right to vote or share in the voting of any Parent Ordinary
Shares or other equity securities of Parent after the date of this Support Agreement (such Parent Ordinary Shares or other equity securities
of Parent, collectively the &#8220;<span style="text-decoration: underline">New Securities</span>&#8221;), then such New Securities acquired
or purchased by the Sponsor shall be subject to the terms of this Support Agreement to the same extent as if they constituted the Sponsor
Shares as of the date hereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 583 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6. <span style="text-decoration: underline">Consent
to Disclosure</span>. The Sponsor hereby consents to the publication and disclosure in the Proxy Statement, if necessary (and, as and
to the extent otherwise required by applicable securities Laws or the SEC or any other securities authorities, any other documents or
communications provided by Parent, Purchaser, Merger Sub or Company to any Governmental Authority or to security holders of Parent or
Company) of the Sponsor&#8217;s identity and ownership (legal or beneficial) of Sponsor Shares and the nature of the Sponsor&#8217;s commitments,
arrangements and understandings under and relating to this Support Agreement and, if deemed appropriate by Parent, Purchaser, Merger Sub
or Company, a copy of this Support Agreement. The Sponsor will promptly provide any information reasonably requested by Parent, Purchaser,
Merger Sub or Company for any regulatory application or filing made or approval sought in connection with the Transactions (including
filings with the SEC).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7. <span style="text-decoration: underline">No
Challenge</span>. The Sponsor, in its capacity as a shareholder of Parent, agrees not to commence, join in, facilitate, assist or encourage,
and agrees to take all actions necessary to opt out of any class in any class action with respect to, any claim, derivative or otherwise,
against Parent, Purchaser, Merger Sub or Company or any of their respective successors or directors (a) challenging the validity of, or
seeking to enjoin the operation of, any provision of this Support Agreement or the Merger Agreement or (b) alleging a breach of any fiduciary
duty of any Person in connection with the evaluation, negotiation or entry into the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8. <span style="text-decoration: underline">Waiver</span>.
The Sponsor irrevocably and unconditionally waives any rights of appraisal, dissenter&#8217;s rights and any similar rights relating to
the Merger Agreement and the consummation by the parties of the Transactions, including the Merger, that the Sponsor may have under applicable
law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9. <span style="text-decoration: underline">Sponsor
Representations</span>. The Sponsor represents and warrants to Parent and Company, as of the date hereof, that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">a. the Sponsor has never
been suspended or expelled from membership in any securities or commodities exchange or association or had a securities or commodities
license or registration denied, suspended or revoked;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">b. the Sponsor has full
right and power, without violating any agreement to which it is bound, to enter into this Support Agreement;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">c. the Sponsor is duly
incorporated, organized, validly existing and in good standing under the Laws of the jurisdiction in which it is organized, formed or
incorporated and the execution, delivery and performance of this Support Agreement and the consummation of the transactions contemplated
hereby are within the Sponsor&#8217;s powers and have been duly authorized by all necessary actions on the part of the Sponsor;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">d. this Support Agreement
has been duly executed and delivered by the Sponsor, this Support Agreement constitutes a legally valid and binding obligation of the
Sponsor, enforceable against the Sponsor in accordance with the terms hereof (except as enforceability may be limited by bankruptcy Laws,
other similar Laws affecting creditors&#8217; rights and general principles of equity affecting the availability of specific performance
and other equitable remedies);</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 584 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">e. the execution and delivery
of this Support Agreement by the Sponsor do not, and the performance by the Sponsor of its obligations hereunder will not, (i) conflict
with or result in a violation of the organizational documents of the Sponsor or (ii) require any consent or approval from any third party
that has not been given or other action that has not been taken by any third party, in each case, to the extent such consent, approval
or other action would prevent, enjoin or materially delay the performance by the Sponsor of its obligations under this Support Agreement;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">f. there are no Proceedings
pending or, to the knowledge of the Sponsor, threatened against the Sponsor before (or, in the case of threatened Proceedings, that would
be before) any arbitrator or any Governmental Authority, which in any manner challenges or seeks to prevent, enjoin or materially delay
the performance by the Sponsor of its obligations under this Support Agreement;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">g. no broker, finder,
investment banker or other Person is entitled to any brokerage fee, finders&#8217; fee or other commission in connection with this Support
Agreement or any of the respective transactions contemplated hereby, based upon arrangements made by the Sponsor or, to the knowledge
of the Sponsor, by Parent;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">h. the Sponsor has had
the opportunity to read the Merger Agreement and this Support Agreement and has had the opportunity to consult with its tax and legal
advisors; </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">i. the Sponsor has not
entered into, and shall not enter into, any agreement that would prevent the Sponsor from performing any of its obligations hereunder;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">j. the Sponsor has good
title to the Sponsor Shares set forth opposite the Sponsor&#8217;s name on Exhibit A, free and clear of any Liens, and the Sponsor has
the sole power to vote or cause to be voted such Sponsor Shares; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">k. the Sponsor Shares
set forth opposite the Sponsor&#8217;s name on Exhibit A are the only Parent Ordinary Shares owned of record or beneficially owned by
the Sponsor as of the date hereof, and none of such Sponsor Shares are subject to any proxy, voting trust or other agreement or arrangement
with respect to the voting of such Sponsor Shares that is inconsistent with the Sponsor&#8217;s obligations pursuant to this Support Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10. <span style="text-decoration: underline">Damages;
Remedies</span>. The Sponsor hereby agrees and acknowledges that (a) Parent and Company would be irreparably injured in the event of a
breach by the Sponsor of its obligations under this Support Agreement, (b) monetary damages may not be an adequate remedy for such breach
and (c) the non-breaching party shall be entitled to injunctive relief, in addition to any other remedy that such party may have in law
or in equity, in the event of such breach. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">11. <span style="text-decoration: underline">Binding
Effect of Merger Agreement</span>. The Sponsor shall be bound by and comply with Section&#160;13.13 (<i>Publicity</i>) of the Merger Agreement
(and any relevant definitions contained in any such Section) as if (a) the Sponsor was an original signatory to the Merger Agreement with
respect to such provision, and (b) each reference to the &#8220;Parent&#8221; or a &#8220;party&#8221; contained in such provision also
referred to the Sponsor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 585 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">12. <span style="text-decoration: underline">Entire
Agreement; Amendment</span>. This Support Agreement and the other agreements referenced herein constitute the entire agreement and understanding
of the parties hereto in respect of the subject matter hereof and supersede all prior understandings, agreements or representations by
or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated
hereby. This Support Agreement may not be changed, amended, modified or waived (other than to correct a typographical error) as to any
particular provision, except by a written instrument executed by all parties hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">13. <span style="text-decoration: underline">Assignment</span>.
No party hereto may, except as set forth herein, assign either this Support Agreement or any of its rights, interests or obligations hereunder
without the prior written consent of the other parties. Any purported assignment in violation of this paragraph shall be void and ineffectual
and shall not operate to transfer or assign any interest or title to the purported assignee. This Support Agreement shall be binding on
the Sponsor, Parent and Company and each of their respective successors, heirs, personal representatives and assigns and permitted transferees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">14. <span style="text-decoration: underline">Counterparts</span>.
This Support Agreement may be executed in any number of original, electronic or facsimile counterparts and each of such counterparts shall
for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">15. <span style="text-decoration: underline">Severability</span>.
This Support Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect
the validity or enforceability of this Support Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid
or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Support Agreement a provision
as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">16. <span style="text-decoration: underline">Governing
Law; Jurisdiction; Jury Trial Waiver</span>. Section&#160;13.6 and Section&#160;13.7 of the Merger Agreement are incorporated by reference
herein and shall apply <i>mutatis mutandis</i> with full force to any disputes arising under this Support Agreement. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">17. <span style="text-decoration: underline">Notice</span>.
Any notice, consent or request to be given in connection with any of the terms or provisions of this Support Agreement shall be in writing
and shall be sent or given in accordance with the terms of Section&#160;13.9 of the Merger Agreement to the applicable party, with respect
to Company and Parent, at the address set forth in Section&#160;13.9 of the Merger Agreement, and with respect to the Sponsor, at its
address set forth on Exhibit A.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18. <span style="text-decoration: underline">Termination</span>.
This Support Agreement shall terminate on the earlier of the Closing or the termination of the Merger Agreement. No such termination shall
relieve the Sponsor, Parent or Company from any liability resulting from a breach of this Support Agreement occurring prior to such termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">19. <span style="text-decoration: underline">Adjustment
for Share Split</span>. If, and as often as, there are any changes in the Parent Shares or the Sponsor Shares by way of share split, share
dividend, combination or reclassification, or through merger, consolidation, reorganization, recapitalization or business combination,
or by any other means, equitable adjustment shall be made to the provisions of this Support Agreement as may be required so that the rights,
privileges, duties and obligations hereunder shall continue with respect to the Sponsor, Parent, Company and the Sponsor Shares as so
changed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">20. <span style="text-decoration: underline">Further
Actions</span>. Each of the parties hereto agrees to execute and deliver hereafter any further document, agreement or instrument of assignment,
transfer or conveyance as may be necessary or desirable to effectuate the purposes hereof and as may be reasonably requested in writing
by another party hereto. </p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>[remainder of page intentionally left blank]</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 586 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
have executed this Support Agreement as of the date first written above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: left"/>
    <td colspan="2" style="text-align: left"><b>D. BORAL ARC ACQUISITION I CORP.</b></td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: left">&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: left; width: 50%"/>
    <td style="text-align: left; width: 5%">By:</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 45%">/s/ John Darwin</td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: left"/>
    <td style="text-align: left">Name:&#160;</td>
    <td style="text-align: left">John Darwin</td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: left"/>
    <td style="text-align: left">Title:</td>
    <td style="text-align: left"> Chief Financial Officer</td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: left"/>
    <td colspan="2" style="text-align: left"><b>EXASCALE LABS INC.</b></td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: left">&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">By:</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">/s/ Hoansoo Lee</td></tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Name:</td>
    <td style="text-align: left">Hoansoo Lee</td></tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Title:</td>
    <td style="text-align: left">Chief Executive Officer</td></tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: left"/>
    <td colspan="2" style="text-align: left"><b>MFH 1, LLC</b></td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: left">&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">By:</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">/s/ John Darwin</td></tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Name:</td>
    <td style="text-align: left">John Darwin</td></tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Title:</td>
    <td style="text-align: left">Manager</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">[Signature page to Sponsor Support
Agreement]</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 587 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">Exhibit
A</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">Sponsor</span>
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 33%; text-align: left"><b>Name</b></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 34%; text-align: left">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Number of Sponsor Shares</b></p> </td>
    <td style="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 33%; text-align: left"><b>Address
        for Notices</b></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 588 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><b><span id="annex_f"></span>ANNEX F</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
OF LOCK-UP AGREEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
LOCK-UP AGREEMENT (this &#8220;<span style="text-decoration: underline">Agreement</span>&#8221;) is dated as of [&#160;&#160;&#160;],
2026, by and between the undersigned (the &#8220;<span style="text-decoration: underline">Holders</span>&#8221;) and D. Boral ARC Merger
Corporation, a Delaware corporation and a wholly-owned subsidiary of Parent (as defined below) (&#8220;<span style="text-decoration: underline">Purchaser</span>&#8221;).
Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Merger Agreement (as defined below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">BACKGROUND</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
        Boral ARC Acquisition I Corp., a company organized under the laws of the British Virgin Islands (&#8220;<span style="text-decoration: underline">Parent</span>&#8221;),
        Purchaser, D. Boral Arc Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (&#8220;<span style="text-decoration: underline">Merger
        Sub</span>&#8221;), and Exascale Labs Inc., a Delaware corporation (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;),
        entered into an Agreement and Plan of Merger dated as of [&#160;&#160;&#160;], 2026 (the &#8220;<span style="text-decoration: underline">Merger
        Agreement</span>&#8221;).</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
        Holders are the record and/or beneficial owners of a certain number of common shares of Company, or securities exchangeable or convertible
        into shares of Company Shares.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
        a condition of, and as a material inducement for Parent to enter into and consummate the transactions contemplated by the Merger Agreement,
        the Holders have agreed to execute and deliver this Agreement.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, for and in consideration of the mutual covenants and agreements set forth herein, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound, agree as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">AGREEMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<span style="text-decoration: underline">Lock-up</span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Except as permitted by this <span style="text-decoration: underline">Section&#160;1</span>, during the Lock-up Period (as defined below),
each Holder irrevocably agrees, it, he or she will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly,
any of the Lock-up Shares (as defined below), enter into a transaction that would have the same effect, or enter into any swap, hedge
or other arrangement that transfers, in whole or in part, any of the economic consequences of ownership of such Lock-up Shares, whether
any of these transactions are to be settled by delivery of any such Lock-up Shares, in cash or otherwise, publicly disclose the intention
to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement, or engage in any Short
Sales (as defined below) with respect to any security of Purchaser Surviving Corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In furtherance of the foregoing, Purchaser or Purchaser Surviving Corporation, as the case may be, will (i) place a stop order on all
Lock-up Shares, including those which may be covered by a registration statement, and (ii) notify Purchaser Surviving Corporation&#8217;s
transfer agent in writing of the stop order and the restrictions on such Lock-up Shares under this Agreement and direct Purchaser Surviving
Corporation&#8217;s transfer agent not to process any attempts by any Holder to resell or transfer any Lock-up Shares, except in compliance
with this Agreement. Such stop order will expire, be revoked or be rescinded upon the expiration of the Lock-up Period or any waiver,
amendment or rescission of this <span style="text-decoration: underline">Section&#160;1</span> pursuant to the terms of this Agreement
or the termination of this Agreement pursuant to <span style="text-decoration: underline">Section&#160;5</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 589; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
For purposes hereof, &#8220;<span style="text-decoration: underline">Short Sales</span>&#8221; include, without limitation, all &#8220;short
sales&#8221; as defined in Rule&#160;200 promulgated under Regulation SHO under the Securities Exchange Act of 1934, as amended (the &#8220;<span style="text-decoration: underline">Exchange
Act</span>&#8221;), and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, swaps and similar
arrangements (including on a total return basis), and sales and other transactions through non-US broker dealers or foreign regulated
brokers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
For purpose of this Agreement, the &#8220;<span style="text-decoration: underline">Lock-up Period</span>&#8221; means with respect to
the Lock-up Shares, the period commencing on the Closing Date and ending on the earlier of (1) the date that is six (6) months after the
Closing Date or (2) the date on which Purchaser Surviving Corporation completes a liquidation, merger, share exchange, reorganization
or other similar transaction that results in all of the stockholders of Purchaser Surviving Corporation having the right to exchange their
Purchaser Surviving Corporation Shares for cash, securities or other property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, and subject to the conditions below, the restrictions set forth herein shall not apply to: (1) transfers or distributions
of Lock-up Shares (or equity of the respective Holder or the respective Holder&#8217;s partners, members or stockholders) to the respective
Holder&#8217;s current or former general or limited partners, subsidiaries, managers or members, stockholders, other equityholders or
direct or indirect affiliates (within the meaning of Rule&#160;405 under the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;)) or to the estates of any of the foregoing; (2) transfers by bona fide gift, including to charitable organizations, or to
a member of the respective Holder&#8217;s immediate family or to a trust, the beneficiary of which is the respective Holder or a member
of the respective Holder&#8217;s immediate family for estate planning purposes; (3) by virtue of the laws of descent and distribution
upon death of the respective Holder; (4) transfers pursuant to a qualified domestic relations order; (5) transfers to Purchaser Surviving
Corporation&#8217;s officers, directors or their affiliates; (6) private sales or transfers made in connection with any forward purchase
agreement or similar arrangement or in connection with the consummation of the Merger at prices no greater than the price at which the
securities were originally purchased; (7) transfers pursuant to a bona fide tender offer, merger, consolidation, capital stock exchange,
or other similar transaction (including negotiating and entering into an agreement providing for any such transaction) which results in
all of the respective Holder&#8217;s stockholders having the right to exchange their shares of Common Stock for cash, securities or other
property subsequent to the respective Holder&#8217;s completion of the Merger, provided that in the event that such tender offer, merger,
capital stock exchange, consolidation or other such transaction is not completed, the respective Holder&#8217;s Lock-up Shares shall remain
subject to the provisions of this <span style="text-decoration: underline">Section&#160;1</span>; (8) by virtue of the laws of the State
of Delaware or the State or other jurisdiction of the respective Holder&#8217;s incorporation or organization, the respective Holder&#8217;s
limited liability company agreement, bylaws or other comparable document upon its dissolution, if applicable; or (9) the Purchaser&#8217;s
liquidation prior to the completion of the Merger; provided, however, that, in the case of any transfer pursuant to the foregoing (1)
through (5) clauses, it shall be a condition to any such transfer that the transferee/donee agrees in writing (a copy of which shall be
provided by the respective Holder to the Purchaser Surviving Corporation), to be bound by the terms of this Agreement (including, without
limitation, the restrictions set forth in the preceding sentence) to the same extent as if the transferee/donee were a party hereto; and
(ii) each party (donor, donee, transferor or transferee) shall not be required by law (including without limitation the disclosure requirements
of the Securities Act and the Exchange Act) to make, and shall agree to not voluntarily make, any filing or public announcement of the
transfer or disposition prior to the expiration of the Lock-up Period. For the avoidance of doubt, the restrictions set forth herein shall
also not apply to transactions relating to Purchaser Surviving Corporation Shares or other securities convertible into or exercisable
or exchangeable for shares acquired in open market transactions after the effective time of the Merger. Each Holder shall be permitted
to enter into a trading plan established in accordance with Rule&#160;10b5-1 under the Exchange Act during the applicable Lock-up Period
so long as no transfers or other dispositions of the respective Holder&#8217;s Lock-up Shares in contravention of&#160;this <span style="text-decoration: underline">Section&#160;1</span>
are effected prior to the expiration of the applicable Lock-up Period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 590 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that any Holder is granted a discretionary release, waiver or termination of the restrictions set forth herein or in any other
agreement containing restrictions similar to those contained in this Agreement, such discretionary release or waiver shall automatically
apply pro rata to all Holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<span style="text-decoration: underline">Representations and Warranties</span>. Each of the parties hereto, by their respective execution
and delivery of this Agreement, hereby represents and warrants to the others and to all third party beneficiaries of this Agreement that
(a) such party has the full right, capacity and authority to enter into, deliver and perform its respective obligations under this Agreement,
(b) this Agreement has been duly executed and delivered by such party and is the binding and enforceable obligation of such party, enforceable
against such party in accordance with the terms of this Agreement (except as such enforceability may be limited or otherwise affected
by bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors
generally and principles of equity, whether considered at law or equity), and (c) the execution, delivery and performance of such party&#8217;s
obligations under this Agreement will not conflict with or breach the terms of any other agreement, contract, commitment or understanding
to which such party is a party or to which the assets or securities of such party are bound. Each Holder has independently evaluated the
merits of his/her/its decision to enter into and deliver this Agreement, and such Holder confirms that he/she/it has not relied on the
advice of the Company, Parent, Purchaser, their respective legal counsels, or any other person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<span style="text-decoration: underline">Beneficial Ownership</span><span style="text-decoration: none">. Each Holder hereby represents
and warrants that, as of the date of this Agreement, it does not beneficially own, directly or through its nominees (as determined in
accordance with Section&#160;13(d) of the Exchange Act, and the rules and regulations promulgated thereunder), any shares of capital stock
of Parent or Company, or any economic interest in or derivative of such stock, other than those securities specified on the signature
page hereto. For purposes of this Agreement, the &#8220;</span><span style="text-decoration: underline">Lock-up Shares</span><span style="text-decoration: none">&#8221;
shall mean the Purchaser Shares held by such Holder immediately following the Closing.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<span style="text-decoration: underline">No Additional Fees/Payment</span><span style="text-decoration: none">. Other than the consideration
specifically referenced herein, the parties hereto agree that no fee, payment or additional consideration in any form has been or will
be paid to the Holders in connection with this Agreement.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<span style="text-decoration: underline">Termination</span><span style="text-decoration: none">. This Agreement and all of its provisions
shall terminate and be of no further force or effect upon the earlier to occur of (a) termination of the Merger Agreement in accordance
with its terms or (b) the expiration of the Lock-up Period.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<span style="text-decoration: underline">Notices</span><span style="text-decoration: none">. Any notices required or permitted to be sent
hereunder shall be sent in writing, addressed as specified below, and shall be deemed given: (a) if by hand or recognized courier service,
by 4:00 PM on a business day, addressee&#8217;s day and time, on the date of delivery, and otherwise on the first business day after such
delivery; (b) if by fax or email, on the date that transmission is confirmed electronically, if by 4:00 PM on a business day, addressee&#8217;s
day and time, and otherwise on the first business day after the date of such confirmation; or (c) five (5) days after mailing by certified
or registered mail, return receipt requested. Notices shall be addressed to the respective parties as follows (excluding telephone numbers,
which are for convenience only), or to such other address as a party shall specify to the others in accordance with these notice provisions:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to Purchaser Surviving Corporation, to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exascale
Labs Inc. <br/>820 Gessner Road, Suite 332<br/>Houston, TX 77024<br/>Attention: Hoansoo Lee<br/>E-mail: hoansoo@exabits.xyz</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 591 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to (which shall not constitute notice):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kesse
PLLC<br/>845 Texas Avenue, Suite 200<br/>Houston, TX 77002<br/>Attention: Kelvin Kesse<br/>E-mail: kelvinkesse@kessepllc.com</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;If
to any Holder, to the address set forth on the respective Holder&#8217;s signature page hereto, or to such other address as any party
may have furnished to the others in writing in accordance herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<span style="text-decoration: underline">Enumeration and Headings</span>;<span style="text-decoration: underline"> Interpretation</span><span style="text-decoration: none">.
The enumeration and headings contained in this Agreement are for convenience of reference only and shall not control or affect the meaning
or construction of any of the provisions of this Agreement. The titles and subtitles used in this Agreement are for convenience only and
are not to be considered in construing or interpreting this Agreement. In this Agreement, unless the context otherwise requires: (i) any
pronoun used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns, pronouns
and verbs shall include the plural and vice versa; (ii) &#8220;including&#8221; (and with correlative meaning &#8220;include&#8221;) means
including without limiting the generality of any description preceding or succeeding such term and shall be deemed in each case to be
followed by the words &#8220;without limitation&#8221;; and (iii) the words &#8220;herein,&#8221; &#8220;hereto,&#8221; and &#8220;hereby&#8221;
and other words of similar import shall be deemed in each case to refer to this Agreement as a whole and not to any particular section
or other subdivision of this Agreement.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<span style="text-decoration: underline">Counterparts</span><span style="text-decoration: none">. This Agreement may be executed in facsimile
and in any number of counterparts, each of which when so executed and delivered shall be deemed an original, but all of which shall together
constitute one and the same agreement. The delivery of an electronic signature to, or a copy/scan of a manual signature on a counterpart
to, this Agreement by facsimile, email or other electronic transmission shall be deemed an original signature for all purposes hereunder.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<span style="text-decoration: underline">Successors and Assigns</span><span style="text-decoration: none">. This Agreement and the terms,
covenants, provisions and conditions hereof shall be binding upon, and shall inure to the benefit of, the respective heirs, successors
and assigns of the parties hereto. Each Holder hereby acknowledges and agrees that this Agreement is entered into for the benefit of and
is enforceable by Purchaser and its successors and assigns.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<span style="text-decoration: underline">No Third Parties</span><span style="text-decoration: none">. Nothing contained in this Agreement
or in any instrument or document executed by any party in connection with the transactions contemplated hereby shall create any rights
in, or be deemed to have been executed for the benefit of, any person or entity that is not a party hereto or thereto or a successor or
permitted assign of such a party.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<span style="text-decoration: underline">Severability</span><span style="text-decoration: none">. If any provision of this Agreement is
held to be invalid or unenforceable for any reason, such provision will be conformed to prevailing law rather than voided, if possible,
in order to achieve the intent of the parties and, in any event, the remaining provisions of this Agreement shall remain in full force
and effect and shall be binding upon the parties hereto.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 592 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<span style="text-decoration: underline">Amendments and Waivers</span><span style="text-decoration: none">. This Agreement may be amended
or modified by written agreement executed by each of the parties hereto. No failure or delay by a party in exercising any right hereunder
shall operate as a waiver thereof. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more
instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<span style="text-decoration: underline">Further Assurances</span><span style="text-decoration: none">. Each party shall do and perform,
or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates,
instruments and documents, as any other party may reasonably request in order to carry out the intent and accomplish the purposes of this
Agreement and the consummation of the transactions contemplated hereby.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<span style="text-decoration: underline">No Strict Construction</span><span style="text-decoration: none">. The language used in this
Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction
will be applied against any party.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<span style="text-decoration: underline">Governing Law</span><span style="text-decoration: none">. The terms and provisions of this Agreement
shall be construed in accordance with the laws of the State of Delaware. </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<span style="text-decoration: underline">Controlling Agreement</span><span style="text-decoration: none">. To the extent the terms of
this Agreement (as amended, supplemented, restated or otherwise modified from time to time) directly conflicts with a provision in the
Merger Agreement, the terms of this Agreement shall control.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<i>Signature
Page Follows</i>]</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 593 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Lock-up Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td colspan="3" style="font-weight: bold; vertical-align: middle; text-align: left">D. <span style="text-transform: uppercase">Boral ARC Merger
        Corporation</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td colspan="3" style="text-align: left; vertical-align: middle">&#160;</td></tr>
  <tr>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: middle; text-align: left">By:</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-align: left; vertical-align: bottom; width: 50%">&#160;</td>
    <td style="vertical-align: middle; text-align: left; width: 4%">&#160;</td>
    <td style="vertical-align: middle; text-align: left; width: 5%">Name:</td>
    <td style="vertical-align: middle; text-align: left; width: 41%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Title:</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>[Signature
Page to Company Shareholders Lock-up Agreement]</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<!-- Field: Page; Sequence: 594 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Lock-up Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font-weight: bold; vertical-align: middle; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">HOLDERS</span>:</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: left; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: left; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#160;&#160;&#160;]</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: left; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: bottom; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: left; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: left; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="vertical-align: middle; text-align: left; width: 41%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>NUMBER
        AND TYPE OF Lock-up Shares:</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>[Signature
Page to Company Shareholders Lock-up Agreement]</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 595 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INFORMATION
NOT REQUIRED IN PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
20. Indemnification of Directors and Officers.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo
and Exascale is each a Delaware corporation. Section&#160;145 of the DGCL provides, in general, that a corporation may indemnify any person
who was or is a party (or is threatened to be made a party) to any threatened, pending or completed action, suit or proceeding, whether
civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), because he or she is or
was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer,
employee or agent of another corporation, partnership, joint venture or other enterprise, against expenses (including attorneys&#8217;
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action,
suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best
interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct
was unlawful. A Delaware corporation may also indemnify directors, officers, employees and other agents of such corporation in an action
by or in the right of the corporation under the same conditions, except that no indemnification is permitted without judicial approval
if the person to be indemnified has been adjudged to be liable to the corporation. The DGCL provides that Section&#160;145 of the DGCL
is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders
or disinterested directors or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo&#8217;s
and Exascale&#8217;s Bylaws each contain provisions that require it to indemnify any person who was or is made or is threatened to be
made a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative, by
reason of the fact that such person, or a person for whom such person is the legal representative, is or was a director or officer of
such entity or, while a director or officer of such entity, is or was serving at the request of such as a director, officer, employee
or agent of another corporation or of a partnership, joint venture, limited liability company, trust, enterprise or nonprofit entity,
including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys&#8217;
fees) reasonably incurred by such person, to the fullest extent permitted by the DGCL, as it may be amended from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the current Exascale Certificate of Incorporation and the PubCo Certificate of Incorporation (as will be in effect upon the
consummation of the Business Combination) contains provisions requiring such entity to indemnify and advance expenses to any director
incurred in defending or otherwise participating in any proceeding in advance of its final disposition, provided that such director presents
to such entity a written undertaking to repay such amount if it shall ultimately be determined that such director is not entitled to be
indemnified by such entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
permitted by Section&#160;102(b)(7) of the DGCL, the current Certificate of Incorporation of Exascale and PubCo&#8217;s Certificate of
Incorporation (as will be in effect upon completion of the Business Combination) each contains provisions eliminating the personal liability
of directors to such entity or its stockholders for monetary damages for breach of fiduciary duty as a director to the fullest extent
permitted under the DGCL.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PubCo
expects to maintain standard policies of insurance under which coverage is provided (a) to its directors and officers against losses arising
from claims made by reason of breach of duty or other wrongful act by such persons in their respective capacities as officers and directors
of PubCo, and (b) to PubCo with respect to payments which may be made by the registrant to such officers and directors pursuant to the
above indemnification provision or otherwise as a matter of law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 596; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
21. Exhibits and Financial Statement Schedules.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following exhibits are filed
        as part of this registration statement:</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: left; width: 9%"><b>Exhibit No.</b></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 90%"><b>Description</b></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">2.1*&#8224;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="#annex_a">Business Combination Agreement, dated January&#160;11, 2026, by and among D. Boral ARC
        Acquisition I Corp., D. Boral ARC Merger Corporation, D. Boral Arc Merger Sub Inc. and Exascale Labs Inc. (included as Annex A to the
        proxy statement/prospectus, which is a part of this Registration Statement)</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: left">3.1*</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="dboralarcacq_ex3-1.htm">Amended and Restated Memorandum
    and Articles of Association</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">3.2*</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="#annex_b1">Form of Amended and Restated Certificate of Incorporation of PubCo (included as Annex
        B-1 to the proxy statement/prospectus, which is a part of this Registration Statement).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: left">3.5*</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="#annex_b2">Form of Bylaws of PubCo (included as Annex B-2 to the proxy statement/prospectus, which
        is a part of this Registration Statement).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">4.1(1)</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/2065779/000182912625004386/dboralarcacq1_ex4-2.htm">Specimen Ordinary Share Certificate</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: left">4.3*</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="dboralarcacq_ex4-4.htm" style="-sec-extract: exhibit">Specimen Warrant Certificate (included as an exhibit to Exhibit 4.4).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">4.4*</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="dboralarcacq_ex4-4.htm"><span>Warrant Agreement between Odyssey Transfer and Trust Company and the Registrant</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: left">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5.1*</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="dboralarcacq_ex5-1.htm">Opinion of Loeb &amp; Loeb LLP as to the validity of the securities of the registrant.</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">8.1**</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/2065779/000182912626005168/dboralarcacqmer_ex8-1.htm">Tax
        Opinion of Altro LLP.</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: left">8.2**</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/2065779/000182912626005168/dboralarcacqmer_ex8-2.htm">Tax
        Opinion of Loeb &amp; Loeb LLP.</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">10.1*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="dboralarcacq_ex10-1.htm">Letter Agreement among the
    Registrant, MFH 1, LLC and each of the executive officers and directors of the Registrant</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left; vertical-align: top">10.2*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="dboralarcacq_ex10-2.htm">Investment Management Trust Agreement between Odyssey Transfer and Trust Company and the Registrant</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">10.3*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="dboralarcacq_ex10-3.htm">Registration Rights Agreement among the Registrant, MFH 1, LLC and the Holders signatory thereto</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left; vertical-align: top">10.4*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="dboralarcacq_ex10-4.htm">Private Placement Warrants Purchase Agreement between the Registrant and MFH 1, LLC</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">10.5*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="dboralarcacq_ex10-5.htm">Form of Indemnity Agreement</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left; vertical-align: top">10.6*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="dboralarcacq_ex10-6.htm">Securities Subscription Agreement between the Registrant and MFH 1, LLC</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">10.7*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="#annex_e">Sponsor Support Agreement dated January&#160;11,
    2026 (included as Annex E to the proxy statement/prospectus, which is a part of this Registration Statement)</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left; vertical-align: top">10.8*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="#annex_d">Company Support Agreement, dated as of January
    2025 (included as Annex D to the proxy statement/prospectus, which is a part of this Registration Statement)</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">10.9*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="#annex_f">Form of Lock-up Agreement (included as Annex
    F to the proxy statement/prospectus, which is a part of this Registration Statement)</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left; vertical-align: top">10.10*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="dboralarcacq_ex10-10.htm">Administrative Services Agreement by and between the Registrant and the Sponsor</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">10.13+</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="#annex_c">Form of 2026 Equity Incentive Plan (included as Annex C to the proxy statement/prospectus,
        which is a part of this Registration Statement)</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left; vertical-align: top">23.1*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="dboralarcacq_ex23-1.htm">Consent of Guangdong Prouden CPAs GP (D. Boral ARC Merger Corporation)</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">23.2*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="dboralarcacq_ex23-2.htm">Consent of Guangdong Prouden CPAs GP (D. Boral ARC Acquisition I Corp.)</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left; vertical-align: top">23.3*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="dboralarcacq_ex23-3.htm">Consent of HTL International, LLC (Exascale)</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">23.4*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="dboralarcacq_ex5-1.htm">Consent of Loeb &amp; Loeb LLP
    (included as part of the opinion filed as Exhibit 5.1 hereto and incorporated herein by reference)</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left; vertical-align: top">23.5**</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/2065779/000182912626005168/dboralarcacqmer_ex8-1.htm">Consent
        of Altro LLP (included as part of Exhibit 8.1 hereto)</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">23.6**</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/2065779/000182912626005168/dboralarcacqmer_ex8-2.htm">Consent
        of Loeb &amp; Loeb, LLP (included as part of Exhibit 8.2 hereto)</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left; vertical-align: top">97.1 (2)</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/2065779/000182912626002312/dboralarcacq1_ex97-1.htm">Clawback Policy</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">99.1*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="dboralarcacq_ex99-1.htm">Form of Preliminary Proxy Card.</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left; vertical-align: top">99.2**</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/2065779/000182912626005168/dboralarcacqmer_ex99-2.htm">Consent
        of Hoansoo Lee to be named as a Director of PubCo.</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">99.3**</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/2065779/000182912626005168/dboralarcacqmer_ex99-3.htm">Consent
        of Wenying Jia to be named as a director of PubCo.</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left; vertical-align: top">99.4**</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/2065779/000182912626005168/dboralarcacqmer_ex99-4.htm">Consent
        of David Card to be named as a director of PubCo.</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">99.5**</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/2065779/000182912626005168/dboralarcacqmer_ex99-5.htm">Consent
        of Shachar Kariv to be named as a Director of PubCo.</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left; vertical-align: top">99.6*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="dboralarcacq_ex99-6.htm">Consent of Jaeyoung Shin to be named as a Director of PubCo.</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">107*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="dboralarcacq_ex107.htm">Calculation of Registration Fee Table</a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
        herewith.</span></td> </tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">**</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Previously filed.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify">(1)</td>
    <td style="font-size: 10pt; text-align: justify">Incorporated by reference exhibit 4.2 to the Form S-1 filed by D. Boral ARC Acquisition I Corp. with the SEC on June 11, 2025.&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify">(2)</td>
    <td style="font-size: 10pt; text-align: justify">Incorporated by reference to exhibit 97.1 to the Annual Report on Form 10-K filed by D. Boral ARC Acquisition I Corp. with the SEC on
March 16, 2026.&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
        a management or compensatory plan.</span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
        schedules and similar attachments to this Exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K. Registrant agrees
        to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 597 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
22. Undertakings.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrants each hereby undertake as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To file, during any period in which
        offers or sales are being made, a post-effective amendment to this registration statement:</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.75in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To include any prospectus required
        by Section&#160;10(a)(3) of the Securities Act;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.75in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To reflect in the prospectus any
        facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which,
        individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding
        the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed
        that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the
        form of prospectus filed with the SEC pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no
        more than 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table
        in the effective registration statement;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.75in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To include any material information
        with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information
        in the registration statement.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining
        any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating
        to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
        thereof.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To remove from registration by means
        of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining
        liability under the Securities Act to any purchaser, if the registrant is subject to Rule&#160;430C, each prospectus filed pursuant to
        Rule&#160;424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule&#160;430B
        or other than prospectuses filed in reliance on Rule&#160;430A, shall be deemed to be part of and included in the registration statement
        as of the date it is first used after effectiveness; provided, however, that no statement made in a registration statement or prospectus
        that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
        statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such
        first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
        statement or made in any such document immediately prior to such date of first use.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining
        any liability under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes
        that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting
        method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following
        communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to
        such purchaser:</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.75in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any preliminary prospectus or prospectus
        of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#160;424;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.75in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any free writing prospectus relating
        to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.75in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The portion of any other free writing
        prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or
        on behalf of the undersigned registrant; and</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.75in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any other communication that is
        an offer in the offering made by the undersigned registrant to the purchaser.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 598 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That prior to any public reoffering
        of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party
        who is deemed to be an underwriter within the meaning of Rule&#160;145(c), the issuer undertakes that such reoffering prospectus will
        contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters,
        in addition to the information called for by the other items of the applicable form.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That every prospectus: (i) that
        is filed pursuant to the immediately preceding paragraph, or (ii) that purports to meet the requirements of Section&#160;10(a)(3) of the
        Securities Act and is used in connection with an offering of securities subject to Rule&#160;415, will be filed as a part of an amendment
        to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability
        under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities
        offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
        as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
        each registrant pursuant to the foregoing provisions, or otherwise, each registrant has been advised that in the opinion of the SEC such
        indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim
        for indemnification against such liabilities (other than the payment by each registrant of expenses incurred or paid by a director, officer
        or controlling person of the undersigned in the successful defense of any action, suit or proceeding) is asserted by such director, officer
        or controlling person in connection with the securities being registered, each registrant will, unless in the opinion of its counsel the
        matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
        by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each registrant hereby undertakes
        to supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved therein,
        that was not the subject of and included in the registration statement when it became effective.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 599 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Pursuant
to the requirements of the&#160;Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing this Registration Statement on Form S-4 and has duly caused this Registration Statement
to be signed on its behalf by the undersigned, thereunto duly authorized, in New York on June&#160;11, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
        Boral ARC Merger Corporation</b></span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
        David Boral</span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
        Boral</span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sole
        Director</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Pursuant
to the requirements of the&#160;Securities Act of 1933, as amended, this Registration Statement has been signed by the following person
on June&#160;11, 2026 in the capacities indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 48%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
        David Boral</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sole
        Director of Registrant</span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
        Boral</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
        </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, the co-registrant has duly caused this registration statement to be signed
on its behalf by the undersigned, thereunto duly authorized, in Houston, on June&#160;11, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXASCALE
        LABS INC</b></span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
        Hoansoo Lee</span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hoansoo
        Lee</span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
        Executive Officer</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following person on
June&#160;11, 2026 in the capacities indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 48%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
        Hoansoo Lee</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
        </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">Hoansoo Lee</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">/s/ Wenying
        Jia</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">Chairperson and Director</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">Wenying Jia</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 600 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><a href="#toc">Table of contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURE
OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Pursuant
to the&#160;Securities Act of 1933, as amended, the undersigned, the duly authorized representative of the Registrant in the United States
of America, has signed this Registration Statement on Form S-4 thereto in Newark, Delaware on June&#160;11, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
        David Boral</span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
        Boral</span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sole
        Director</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 601 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>

    <!-- Field: /Page -->




</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>dboralarcacq_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><B>Exhibit 3.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="color: rgb(0,66,80)">FH Corporate Services Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="color: rgb(0,66,80)">Clarence Thomas Building</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="color: rgb(0,66,80)">P.O. Box 4649, Road Town</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="color: rgb(0,66,80)">Tortola VG1110</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="color: rgb(0,66,80)">British Virgin Islands</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="vertical-align: bottom; width: 80%; text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Company Number: 2172570</FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: Black"><B>&nbsp;</B></FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: Black"><B>TERRITORY OF THE BRITISH VIRGIN ISLANDS</B></FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: Black"><B>&nbsp;</B></FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: Black"><B>THE BVI BUSINESS COMPANIES ACT, 2004</B></FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: Black"><B>&nbsp;</B></FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: Black"><B>(the &ldquo;Act&rdquo;)</B></FONT></P></TD>
    <TD STYLE="text-align: right; width: 20%"><IMG SRC="ex3-1_001.jpg" ALT="" STYLE="height: 144px; width: 150px"></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex3-1_002.jpg" ALT="" STYLE="height: 158px; width: 150px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>MEMORANDUM AND ARTICLES OF ASSOCIATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>D. Boral ARC Acquisition I Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Incorporated on 20 March 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Amended and Restated on 30 July 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TERRITORY OF THE BRITISH VIRGIN ISLANDS<BR></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE BVI BUSINESS COMPANIES ACT, 2004</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(the &ldquo;Act&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>MEMORANDUM OF ASSOCIATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>D. Boral ARC Acquisition I Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(the &ldquo;Company&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top"><B>1.</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>NAME</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The name of the Company is <B>D. Boral ARC Acquisition I Corp</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top"><B>2.</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>COMPANY LIMITED BY SHARES</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The Company is a company limited by shares. The liability of each member is limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; width: 0.5in; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; width: 0.5in; vertical-align: bottom">(i)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; vertical-align: bottom">the amount from time to time unpaid on such member&rsquo;s shares;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">(ii)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">any liability expressly provided for in the Memorandum or the Articles; and</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">(iii)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">any liability to repay a distribution pursuant to section 58(1) of the Act.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; width: 0in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify; vertical-align: bottom; width: 0.5in"><B>3.</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; vertical-align: bottom"><B>REGISTERED OFFICE</B></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> The first registered office of the Company will be situated at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands. Thereafter, the registered office may be situated at such other place as the directors or members may from time to time determine.</P>

<P STYLE="text-align: justify; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; width: 0in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; width: 0.5in"><B>4.</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><B>REGISTERED AGENT</B></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The first registered agent of the Company will be FH Corporate Services Ltd, of Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands. Thereafter, the directors or members may from time to time change the Registered Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top"><B>5.</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>GENERAL OBJECTS AND POWERS</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Subject to Regulation 6 below, the Company shall have full power and authority to carry out any object not prohibited by the Act as amended from time to time, or any other law of the British Virgin Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; width: 0in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top"><B>6.</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>AUTHORISED SHARES</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">6.1.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The Company is authorised to issue 555,000,000 million shares divided into the following three classes of shares:</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(i)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">500,000,000 Class A ordinary shares with US$0.0001 par value each (the &ldquo;<B>Class A Shares</B>&rdquo;);</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(ii)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">50,000,000 Class B ordinary shares with US$0.0001 par value each (the &ldquo;<B>Class B Shares</B>&rdquo;); and</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(iii)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; text-indent: 0in">5,000,000 preferred shares of US$0.0001 par value (the &ldquo;<B>Preference Shares</B>&rdquo;).</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">6.2.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The directors or members may from time to time set a maximum limit to the number of shares the Company is authorised to issue, by amendment to this Memorandum in accordance with the provisions below.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: justify"><B>7.</B></TD>
    <TD STYLE="text-align: justify"><B>SHARE RIGHTS</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">7.1.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>Class A Shares</B>. Each Class A Share in the Company confers on the holder:</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(i)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">the right to one vote at a meeting of the Members or on any Resolution of the Members;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(ii)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">the right to an equal share in any distribution made by the Company in accordance with the Act; and</TD> </TR>
  </TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(iii)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">unless otherwise agreed by the Member, the right to an equal share in the distribution of the surplus assets of the Company on a winding up.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">7.2.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>Class B Shares</B>. Each Class B Share in the Company confers on the holder:</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(i)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">the right to one vote at a meeting of the Members or on any Resolution of the Members;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in; vertical-align: top">(ii)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">the right to an equal share in any distribution made by the Company in accordance with the Act;</TD></TR>
  </TABLE>





<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(iii)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">the option to convert into a Class A Share at any time up to the closing of the initial Business Combination; and</TD> </TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; vertical-align: top; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in; vertical-align: top; width: 0.5in">(iv)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">unless otherwise agreed by the Member, the right to an equal share in the distribution of the surplus assets of the Company on a winding up.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; width: 0in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify">7.3.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; vertical-align: bottom"><B>Preference Shares</B>. The Board may, by amendment to this Memorandum in accordance with clause 11 below, from time to time create and constitute (or re-designate, as the case may be), such further class or classes of Preference Shares (and designate series within such Preference Shares) with such name or names and with such preferred, deferred or other rights or such restrictions, whether in regard to voting, dividends, distributions, liquidations or otherwise as the Board may, by resolution of Directors determine (a &ldquo;<B>Preference Share Designation</B>&rdquo;) and as may be permitted by the Act.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top"><B>8.</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>VARIATION OF RIGHTS</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">If at any time the shares are divided into different classes, the rights attached to any class may only be varied, whether or not the Company is in liquidation, with the consent in writing of the holders of not less than 50% of the issued shares of that class and the holders of not less than 50% of the issued shares of any other class of shares which may be affected by such variation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top"><B>9.</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>RIGHTS NOT VARIED BY THE ISSUE OF SHARES PARI PASSU</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The rights conferred upon the holders of the shares of any class shall not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation or issue of further shares ranking pari passu therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>



<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top"><B>10.</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>REGISTERED SHARES ONLY</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Shares in the Company may only be issued as registered shares and the Company is not authorised to issue bearer shares. Registered shares may not be exchanged for bearer shares or converted to bearer shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top"><B>11.</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>AMENDMENTS TO MEMORANDUM AND ARTICLES</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The Company may, by Resolution of Directors or Resolution of Members, amend the Memorandum and Articles, save that no amendment may be made by a Resolution of Directors (other than any such amendments required to increase the number of Ordinary Shares and create and constitute the Preference Shares and the rights, restrictions and preferences attached thereto pursuant to the provisions of this Memorandum):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(i)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">to restrict the rights or powers of the voting members to amend the Memorandum or Articles;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(ii)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">to change the percentage of voting members required to pass a resolution to amend the Memorandum or Articles; or</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(iii)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">in circumstances where the Memorandum or Articles may only be amended by the voting members.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top"><B>12.</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>INTERPRETATION</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">In the Memorandum and Articles the following defined terms will have the meanings ascribed to them, if not inconsistent with the subject or context:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left; width: 2in"><B>&ldquo;Act&rdquo; </B></TD>
    <TD STYLE="text-align: justify">means the BVI Business Companies Act, 2004;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;Affiliate&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means a person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with that person;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;Articles&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means the Company&rsquo;s articles of association as attached to this Memorandum, as amended and/or restated from time to time;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;Auditor&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means the person for the time being performing the duties of auditor of the Company (if any);</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;Board&rdquo; or &ldquo;Directors&rdquo;</B></TD>
    <TD STYLE="text-align: justify">the board of directors of the Company;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;Business Combination&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganisation or similar business combination, with one or more businesses (the &ldquo;target business&rdquo;), which Business Combination in accordance with NASDAQ rules must occur with one or more target businesses that together have an aggregate fair market value of at least 80% of the assets held in the Company&rsquo;s trust account (excluding taxes payable on the income earned on the trust account) at the time of the agreement to enter into the Business Combination [unless the Company is not then listed on the Designated Stock Exchange at the time of such Business Combination in which case the Company will not be required to comply with the 80% fair market value requirement;</TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left; width: 2in"><B>&ldquo;Class A Shares&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means the Class A Shares of the Company as defined and set out in the Memorandum;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;Class B Shares&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means the Class B Shares of the Company as defined and set out in the Memorandum;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;completion window&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means (i) the period ending on the date that is 18 months from the closing of the Offering, with one (1) three-month extension at the option of the sponsor of the Company, or such earlier liquidation date as the board of directors may approve, in which the Company must complete an initial business combination or (ii) such other time period in which the Company must complete an initial business combination pursuant to the Memorandum and Articles;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;Designated Stock Exchange&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means any national securities exchange in the United States of America on which Public Shares of the Company may be listed for trading, including the NASDAQ Stock Market LLC, the NYSE MKT LLC or The New York Stock Exchange LLC;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;Exchange Act&rdquo;</B></TD>
    <TD STYLE="text-align: justify">the Securities Exchange Act of 1934 of the United States of America as amended;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;FINRA&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means the Financial Industry Regulatory Authority of the United States of America;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;founder shares&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means the Class B Shares;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;IPO&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means the Company&rsquo;s initial public offering of Securities;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;Member&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means a Shareholder;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;Memorandum&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means this, the Company&rsquo;s memorandum of association, as amended and/or restated from time to time;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;Offering&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means the offering under the Registration Statement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;Ordinary Shares&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means the Class A Shares and the Class B Shares of the Company as defined and set out in the Memorandum;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&ldquo;<B>Preference Shares</B>&rdquo;</TD>
    <TD STYLE="text-align: justify">means the Preference Shares of the Company as defined and set out in the Memorandum;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;Person&rdquo;</B></TD>
    <TD STYLE="text-align: justify">includes individuals, corporations, trusts, the estates of deceased individuals, partnerships and unincorporated associations of persons;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;Prospectus&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means the prospectus set out in the Registration Statement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;public shares&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means the Class A Shares;</TD></TR>
  </TABLE>



<P STYLE="margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left; width: 2in"><B>&ldquo;public shareholder&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means the holder of a Class A Share whose name is entered in the register of members as the holder of one or more Class A Shares or fractional Class A Shares;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;Register of Directors&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means the register of directors of the Company required to be kept pursuant to the Act;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;Register of Members&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means the register of members of the Company required to be kept pursuant to the Act;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><B>&ldquo;Registered Agent&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means the Company&rsquo;s registered agent, from time to time;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 2in"><B>&ldquo;Registrar&rdquo;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">means the Registrar of Corporate Affairs appointed under section 229 of the Act;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>&ldquo;Registration Statement&rdquo;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">means the Company&rsquo;s registration statement on Form S-1 filed with the SEC in connection with the IPO;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>&ldquo;Relevant System&rdquo;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">means a system utilised for the purposes of holding and transferring shares of the Company;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>&ldquo;Resolution of Directors&rdquo;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">means a resolution of the directors passed either at a meeting of directors, or by way of a written resolution, in either case in accordance with the provisions of the Articles;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>&ldquo;Resolution of Members&rdquo;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">means a resolution of the members passed either at a meeting of members, or by way of a written resolution, in either case in accordance with the provisions of the Articles;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>&ldquo;SEC&rdquo;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">means the United States Securities and Exchange Commission;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>&ldquo;Securities&rdquo;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">means Shares and debt obligations of every kind of the Company, and including without limitation options, warrants and rights to acquire Shares or debt obligations;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>&ldquo;Shareholder&rdquo;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">means a Person whose name is entered in the register of members as the holder of one or more Shares or fractional Shares;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>&ldquo;Shares&rdquo;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">means collectively, the Ordinary Shares and the Preference Shares;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>&ldquo;Treasury Share&rdquo;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">means a Share that was previously issued but was repurchased, redeemed or otherwise acquired by the Company and not cancelled;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>&ldquo;trust account&rdquo;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">means the trust account referred to in the Prospectus.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">12.1.</TD>
    <TD STYLE="text-align: justify">In the Memorandum and Articles:</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.5in">(1)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; vertical-align: bottom">reference to a provision of law is a reference to that provision as extended, applied, amended or re-enacted and includes any subordinate legislation;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">(2)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">the headings are for convenience only and shall not affect the construction of the Memorandum or Articles;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">(3)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">
        <P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">words and expressions defined in the Act shall have the same meaning and, unless otherwise required by the context, the singular shall include the plural and vice versa, the masculine shall include the feminine and the neuter and references to persons shall include corporations and all entities capable of having a legal existence;</P></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in">(4)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">reference to a thing being &ldquo;written&rdquo; or &ldquo;in writing&rdquo; includes all forms of writing, including all electronic records which satisfy the requirements of the Electronic Transactions Act, 2001;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in">(5)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">reference to a thing being &ldquo;signed&rdquo; or to a person&rsquo;s &ldquo;signature&rdquo; shall include reference to an electronic signature which satisfies the requirements of the Electronic Transactions Act, 2001, and reference to the Company&rsquo;s &ldquo;seal&rdquo; shall include reference to an electronic seal which satisfies the Electronic Transactions Act, 2001.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: justify; width: 100%"><DIV STYLE="text-align: justify; font-size: 1pt; border-top: Black 3pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NAME, ADDRESS AND DESCRIPTION OF INCORPORATOR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: justify; width: 100%"><DIV STYLE="text-align: justify; font-size: 1pt; border-top: Black 3pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">We, <B>FH Corporate Services Ltd</B>, of Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, registered agent of the Company, hereby sign this Memorandum of Association for the purposes of incorporating a company limited by shares under the BVI Business Companies Act, 2004.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">FH Corporate Services Ltd</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">Clarence Thomas Building</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">P.O. Box 4649, Road Town, Tortola</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">British Virgin Islands</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left; width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 50%"><B>Incorporator</B></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Jos&eacute; Santos</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">For and on behalf of</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">FH Corporate Services Ltd</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">20 March&nbsp;2025</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TERRITORY OF THE BRITISH VIRGIN ISLANDS<BR></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE BVI BUSINESS COMPANIES ACT, 2004</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(the &ldquo;Act&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLES OF ASSOCIATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>D. Boral ARC Acquisition I Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(the &ldquo;Company&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">1.<B></B></TD>
    <TD STYLE="text-align: justify"><B>SHARE CERTIFICATES</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">1.1.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>Form of Share Certificate</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Each share certificate issued by the Company shall be signed by a director of the Company or under the common seal of the Company (which the Registered Agent is authorised to affix to such certificate) with or without the signature of a director or officer of the Company or by such other person who has been duly authorised by a Resolution of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; width: 0in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: justify; vertical-align: bottom">1.2.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; vertical-align: bottom"><B>Member Entitled to Certificate</B></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The directors shall determine whether and in what circumstances share certificates and certificates in respect of any other security issued by the Company shall be issued. Each member is entitled, without charge, to one share certificate representing the shares of each class or series of shares registered in the member&rsquo;s name, provided that in respect of a share held jointly by several persons, the Company is not bound to issue more than one share certificate and delivery of a share certificate to one of several joint members or to one of the members&rsquo; duly authorised agents will be sufficient delivery to all.</P>

<P STYLE="text-align: justify; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">1.3.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>Replacement of Worn Out or Defaced Certificate</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">If the directors are satisfied that a share certificate is worn out or defaced, they shall, on production to them of the share certificate and on such other terms, if any, as they think fit:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(1)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">order the share certificate to be cancelled; and</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(2)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">issue a replacement share certificate.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">1.4.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>Replacement of Lost, Stolen or Destroyed Certificate</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">If the directors receive proof satisfactory to them that a share certificate is lost, stolen or destroyed, a replacement share certificate shall be issued to the person entitled to that share certificate upon request and the receipt by the directors of such indemnity as they may reasonably require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>





<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">1.5.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>Recognition of Trusts</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Except as required by law, and notwithstanding that a share certificate may refer to a member holding shares &ldquo;as trustee&rdquo; or similar expression, no person shall be recognised by the Company as holding any share upon any trust, and the Company shall not be bound by or compelled in any way to recognise (even when having notice thereof) any equitable, contingent, future or partial interest in any share or any interest in any fractional part of a share or (except as required by law or these Articles) any other rights in respect of any share except an absolute right to the entirety thereof in the member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>



<!-- Field: Page; Sequence: 9; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">2.<B></B></TD>
    <TD STYLE="text-align: justify"><B>ISSUE OF SHARES</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">2.1.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>Directors Authorised</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(i)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">Subject to the Act, the Memorandum and these Articles and without prejudice to any special rights or restrictions for the time being attached to any shares or any class of shares, the unissued shares of the Company (whether forming part of the original or any increased authorised shares) shall be at the disposal of the Board, which may offer, allot, grant options over or otherwise dispose of them to such persons, at such times and for such consideration and upon such terms and conditions as the Board may in its absolute discretion determine but so that no shares shall be issued at a discount. In particular and without prejudice to the generality of the foregoing, subject to amending Clause 6 of the Memorandum the Board is hereby empowered to authorize by Resolution of Directors from time to time the issuance of one or more classes or series of Preference Shares and to fix the designations, powers, preferences and relative, participating, optional and other rights, if any, and the qualifications, limitations and restrictions thereof, if any, including, without limitation, the number of shares constituting each such class or series, dividend rights, conversion rights, redemption privileges, voting powers, full or limited or no voting powers, and liquidation preferences, and to increase or decrease the size of any such class or series (but not below the number of shares of any class or series of Preference Shares then outstanding) to the extent permitted by the Act. The issue price for a share with par value must be equal to or greater than the par value of the share.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.5in">(ii)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; vertical-align: bottom">Except as otherwise expressly provided in the resolution or resolutions providing for the establishment of any class or series of Preference Shares, no vote of the holders of Preference Shares of or Ordinary shares shall be a prerequisite to the issuance of any shares of any class or series of the Preference Shares authorized by and complying with the conditions of the Memorandum and Articles of Association.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">2.2.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>Non Cash Consideration</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The consideration for the issue of shares of the Company may take any form acceptable to the directors, including money, a promissory note, or other written obligation to contribute money or property, real property, personal property (including goodwill and know-how), services rendered or a contract for future services. Before issuing shares for a consideration other than money, the directors shall pass a Resolution of Directors stating:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(1)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">the amount to be credited for the issue of the shares;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(2)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">that, in their opinion, the present cash value of the non-money consideration and the money consideration, if any for the issue is not less than the amount to be credited for the issue of shares.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">2.3.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>Brokerage</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The Company may pay such brokerage fee or other consideration as may be lawful for or in connection with the sale or placement of its securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">2.4.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>Share Purchase Warrants and Rights</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Subject to the Act, the Company may issue share purchase warrants, options and rights upon such terms and conditions as the directors determine, which share purchase warrants, options and rights may be issued alone or in conjunction with debentures, debenture stock, bonds, shares or any other securities issued or created by the Company from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">3.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>REGISTER OF MEMBERS</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The Directors shall keep, or cause to be kept, the original Register of Members at such place as the Directors may from time to time determine and, in the absence of any such determination, the original Register of Members shall be kept either at the office of the Registered Agent or the office of the Company&rsquo;s transfer agent. The entry in the Register of Members of a person as the holder of shares shall be prima facie evidence of the title of the member to those shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">4.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>SHARE TRANSFERS</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; width: 0in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: justify; vertical-align: bottom">4.1.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; vertical-align: bottom"><B>Registering Transfers</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Shares in the Company shall be transferred by a written instrument of transfer sent to the Company, signed by the transferor and containing the name and address of the transferee. The instrument of transfer shall also be signed by the transferee if registration as a holder of the shares imposes a liability to the Company on the transferee. The transfer of a registered share is effective when the name of the transferee is entered in the Register of Members. Notwithstanding any other provisions of the Memorandum and Articles, shares in the Company may be transferred by means of a Relevant System and the operator of the Relevant System (and any other person necessary to ensure the Relevant System is effective to transfer shares) shall act as agent of the members for the purposes of the transfer of any shares transferred by means of the Relevant System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">4.2.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>Refusal to Recognise a Transfer</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Subject to the Memorandum, these Articles and the Act, the Company shall, on receipt of an instrument of transfer, enter the name of the transferee of the share in the Register of Members unless the directors resolve to refuse or delay the registration of the transfer in which case the directors&rsquo; reasons to refuse or delay registration shall be specified by resolution. Where the directors pass such a resolution, the Company shall send to the transferor and the transferee a notice of the refusal or delay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">5.<B></B></TD>
    <TD STYLE="text-align: justify"><B>TRANSMISSION OF SHARES</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">5.1.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><B>Executors, Administrators, Guardians and Trustees</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Subject to the Act, the executor or administrator of a deceased member, the guardian of an incompetent member or the trustee of a bankrupt member shall be the only person recognised by the Company as having any title to his share but they shall not be entitled to exercise any rights as a member of the Company until the Company has received the notice required hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">5.2.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Evidence of Entitlement</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">The production to the Company of any document which is evidence of a grant of probate of the will, or grant of letters of administration of the estate, or confirmation of the appointment of an executor (or analogous position in the relevant jurisdiction) of a deceased member, or of the appointment of a guardian (or analogous position in the relevant jurisdiction) of an incompetent member, or the appointment of a trustee (or analogous position in the relevant jurisdiction) of a bankrupt member, or any other reasonable evidence of the applicant&rsquo;s legal and/or beneficial ownership of shares, shall be accepted by the Company even if the deceased, incompetent or bankrupt member is domiciled outside the British Virgin Islands if the document is issued by a foreign court which had competent jurisdiction in the matter. For the purposes of establishing whether or not a foreign court had competent jurisdiction in such a matter the directors may obtain appropriate legal advice. The directors may also require an indemnity to be given by the executor, administrator, guardian or trustee in bankruptcy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">5.3.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Sole Member</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Subject to the Act in the event of the death, incompetence or bankruptcy of any member or members of the Company as a consequence of which the Company no longer has any directors or members, then upon production of the documentation required in these Articles for transmission of shares and such other documentation which is reasonable evidence of the applicant being entitled to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(1)</TD>
    <TD STYLE="text-align: justify">a grant of probate of the deceased&rsquo;s will, or grant of letters of administration of the deceased&rsquo;s estate, or confirmation of the appointment as executor or administrator (as the case may be, or analogous position in the relevant jurisdiction), of a deceased member&rsquo;s estate;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(2)</TD>
    <TD STYLE="text-align: justify">the appointment of a guardian (or analogous position in the relevant jurisdiction) of an incompetent member;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(3)</TD>
    <TD STYLE="text-align: justify">the appointment as trustee (or analogous position in the relevant jurisdiction) of a bankrupt member; or</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(4)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">upon production of any other reasonable evidence of the applicant&rsquo;s beneficial ownership of, or entitlement to the shares,</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">to the Registered Agent together with (if requested by the Registered Agent) a notarised copy of the share certificate(s) of the deceased, incompetent or bankrupt member, an indemnity in favour of the Registered Agent and/or appropriate legal advice in respect of any document issued by a foreign court, then the administrator, executor, guardian or trustee in bankruptcy (as the case may be) notwithstanding that their name has not been entered into the Register of Members, may upon receipt of a written resolution of the applicant, endorsed with written approval of the Registered Agent, be appointed as a director and/or entered in the Register of Members as the legal and/or beneficial owner of the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">5.4.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Application Deemed to be Transfer</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">Any person becoming entitled by operation of law or otherwise to a share or shares in consequence of the death, incompetence or bankruptcy of any member may be registered as a member upon such evidence being produced as may reasonably be required by the directors. An application by any such person to be registered as a member shall for all purposes be deemed to be a transfer of shares of the deceased, incompetent or bankrupt member and the directors shall treat it as such.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">5.5.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Alternate Holder</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">Any person who has become entitled to a share or shares in consequence of the death, incompetence or bankruptcy of any member may, instead of being registered himself, request in writing that some person to be named by him be registered as the transferee of such share or shares and such request shall likewise be treated as if it were a transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">5.6.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Competence</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">What amounts to incompetence on the part of a person is a matter to be determined by the court having regard to all the relevant evidence and the circumstances of the case.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">6.</TD>
    <TD STYLE="text-align: justify"><B>ACQUISITION OF OWN SHARES</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">6.1.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">Subject to (i) the provisions of the Act, (ii) where applicable, the rules of the Designated Stock Exchange and (iii) Article 6.7 the directors may, on behalf of the Company, subject to the written consent of all the members whose shares are to be purchased, redeemed or otherwise acquired, purchase, redeem or otherwise acquire any of the Company&rsquo;s own shares for such consideration as the directors consider fit, and either cancel or hold such shares as treasury shares. Shares may be purchased or otherwise acquired in exchange for newly issued shares in the Company.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">6.2.</TD>
    <TD STYLE="text-align: justify">The Company may acquire its own fully paid share or shares for no consideration by way of surrender of the share or shares to the Company by the Shareholder holding the share or shares. Any surrender of a share or shares under this Article shall be in writing and signed by the Shareholder.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">6.3.</TD>
    <TD STYLE="text-align: justify">On any redemption, acquisition, buyback or conversion of shares in accordance with these Articles the directors shall have the power to divide in specie the whole or any part of the assets of the Company and appropriate such assets in satisfaction or part satisfaction of the redemption, purchase or conversion price.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">6.4.</TD>
    <TD STYLE="text-align: justify">Sections 60 and 61 of the Act shall not apply to the Company.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Restrictions on Redemptions </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An Ordinary Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &ldquo;group&rdquo; (as defined under Section 13 of the Exchange Act), will be restricted from redeeming its Ordinary Shares with respect to more than an aggregate of 15% of the Ordinary Shares sold in the offering set out in the Registration Statement, without the directors prior consent.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In no event will the Company redeem Ordinary Shares in an amount that would cause the Company&rsquo;s net tangible assets, after payment of the deferred underwriting commissions, to be less than $5,000,001.</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Automatic Conversion of Class B Shares to Class A Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.05pt"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to applicable law and to the Company being able to pass the solvency test in section 56 of the Act, on the closing of the initial
    Business Combination the Company shall convert all the issued Class B Shares into Class A Shares on a one for one basis subject to
    adjustment in accordance with the terms set out in the Registration Statement.</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.05pt"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All conversions of Class B Shares to Class A Shares may be effected at the director's discretion either:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by way of compulsory redemption of the Class B Share and the issue of a new Class A Share; or</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by conversion of Class B Shares to Class A Shares.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">7.</TD>
    <TD STYLE="text-align: justify"><B>TREASURY SHARES</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">7.1.</TD>
    <TD STYLE="text-align: justify">Shares may only be held as treasury shares by the Company to the extent that the number of treasury shares does not exceed 50% of the shares of that class previously issued by the Company, excluding shares that have been cancelled.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; vertical-align: top">7.2.</TD>
    <TD STYLE="vertical-align: top; text-align: justify">The directors may dispose of any shares held as treasury shares on such terms and conditions as they may from time to time determine.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; vertical-align: top">7.3.</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Where and for so long as shares are held by the Company as treasury shares, all rights and obligations attaching to such shares are suspended and shall not be exercised by or against the Company.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">8.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>FORFEITURE OF SHARES</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">The Company may, at any time after the due date for payment, serve on a member who has not paid in full for shares registered in the name of that member, a written notice of call (&ldquo;Notice of Call&rdquo;) specifying a date for payment to be made. The Notice of Call shall name a further date not earlier than the expiration of 14 days from the date of service of the Notice of Call on or before which the payment required by the Notice of Call is to be made and shall contain a statement that in the event of non-payment at or before the time named in the Notice of Call the shares, or any of them, in respect of which payment is not made will be liable to be forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Where a written Notice of Call has been issued and the requirements of the Notice of Call have not been complied with, the directors may, at any time before tender of payment, forfeit and cancel the shares to which the Notice of Call relates. The Company is under no obligation to refund any monies to the member whose shares have been cancelled pursuant to this Article and that member shall be discharged from any further obligation to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">9.</TD>
    <TD STYLE="text-align: justify"><B>MEETINGS OF MEMBERS</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">9.1.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Calling of Meetings of Members</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The directors may call a meeting of members at such times and in such manner and location as the directors consider necessary or desirable and they shall call such a meeting upon the written request of members entitled to exercise at least thirty (30) percent of the voting rights in respect of the matter for which the meeting is requested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">9.2.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Notice for Meetings</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">The Company shall provide a minimum of seven (7) days&rsquo; notice specifying at least the date, time, location and general nature of the business of any meeting of members to each member entitled to attend the meeting and to each director of the Company. Shareholders seeking to bring business before the annual general meeting, or to nominate candidates for appointment as directors at the annual general meeting must provide timely notice of their intent in writing. To be timely, a shareholder&rsquo;s notice will need to be received by the Company secretary at the principal executive offices not later than the close of business on the 90th day nor earlier than the close of business on the 150th day prior to the anniversary date of the immediately preceding annual general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 34pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">9.3.</TD>
    <TD STYLE="text-align: justify"><B>Record Date for Notice</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The record date for the purpose of determining members entitled to notice of any meeting of members shall be 5 p.m. on the day on which the notice is sent or, if no notice is sent, the beginning of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">9.4.</TD>
    <TD STYLE="text-align: justify"><B>Record Date for Voting</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The directors may set a date as the record date for the purpose of determining members entitled to vote at any meeting of members. The record date must not precede the date on which the meeting is to be held by more than one month. If no record date is set, the record date is 5 p.m. on the date on which the notice is sent or, if no notice is sent, the beginning of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">9.5.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Waiver of Notice</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Notwithstanding Article 9.2, a meeting of members held in contravention of the requirement to give notice is valid if members holding a ninety (90) percent majority of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(1)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">the total voting rights on all the matters to be considered at the meeting; or</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(2)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">the votes of each class or series of shares where members are entitled to vote thereon as a class or series,</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">have waived notice of the meeting and, for this purpose, the presence of a member at the meeting shall be deemed to constitute waiver on his part (unless such member objects in writing before or at the meeting).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">9.6.</TD>
    <TD STYLE="text-align: justify"><B>Failure to Give Notice</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The inadvertent failure to give notice of a meeting to a member or the fact that a member has not received a notice that has been properly given, shall not invalidate the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">10.</TD>
    <TD STYLE="text-align: justify"><B>PROCEEDINGS AT MEETINGS OF MEMBERS</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">10.1.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Requirement of Quorum</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">No business, other than the election of a chair of the meeting and the adjournment of the meeting, may be transacted at any meeting of members unless a quorum of members entitled to vote is present at the commencement of the meeting, but such quorum need not be present throughout the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">10.2.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Quorum</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">The quorum for the transaction of business at a meeting of members shall consist of the holder or holders present in person or by proxy entitled to exercise at least thirty (30) percent of the voting rights of shares of each class or series of shares entitled to vote as a class or series thereon and the same proportion of the votes of the remaining shares entitled to vote thereon. A member shall be deemed to be present at a meeting of members if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(1)</TD>
    <TD STYLE="text-align: justify">he or his proxy participates by telephone or other electronic means; and</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(2)</TD>
    <TD STYLE="text-align: justify">all members and proxies participating in the meeting are able to hear each other.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">10.3.</TD>
    <TD STYLE="text-align: justify"><B>Lack of Quorum</B></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">If, within half an hour from the time set for the holding of a meeting of members, a quorum is not present, the meeting shall be dissolved.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">10.4.</TD>
    <TD STYLE="text-align: justify"><B>Other Persons May Attend</B></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">The directors, the president (if any), the secretary (if any), any lawyer for the Company, and any other persons invited by the directors are entitled to attend any meeting of members, but if any of those persons does attend a meeting of members, that person is not to be counted in the quorum and is not entitled to vote at the meeting unless that person is a member or proxy holder entitled to vote at the meeting.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">10.5.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Chairman</B></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following individual is entitled to preside as chairman at a meeting of members (the &ldquo;<B>Chairman</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(1)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">the chair of the board, if any; or</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(2)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">if the chair of the board is absent or unwilling to act as chair of the meeting, the president, if any.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">10.6.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Selection of Alternate Chairman</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">If, at any meeting of members, there is no chair of the board or president present within 15 minutes after the time set for holding the meeting, or if the chair of the board and the president are unwilling to act as Chairman, or if the chair of the board and the president have advised the secretary, if any, or any director present at the meeting, that they will not be present at the meeting, the directors present may choose one of their number to be Chairman or if all of the directors present decline to take the chair or fail to so choose or if no director is present, the members entitled to vote at the meeting who are present in person or by proxy may choose any person present at the meeting to chair the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">10.7.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Adjournments</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Chairman may, and if so directed by the meeting by Resolution of Members shall, adjourn the meeting from time to time and from place to place, but no business may be transacted at any adjourned meeting other than the business left unfinished at the meeting from which the adjournment took place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">10.8.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Notice of Adjourned Meeting</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">It is not necessary to give any notice of an adjourned meeting or of the business to be transacted at an adjourned meeting of members except that, when a meeting is adjourned for 30 days or more, notice of the adjourned meeting must be given as in the case of the original meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">10.9.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Decisions by Show of Hands or Poll</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">Subject to the Act, a resolution put to the vote of the meeting shall be decided on a show of hands unless a poll is (before or on the declaration of the result of the show of hands) demanded:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(1)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">by the Chairman; or</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(2)</TD>
    <TD STYLE="text-align: justify">by any member or members present in person or by proxy and holding in aggregate not less than one tenth of the total voting shares issued and entitled to vote on the resolution.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">
        <P>10.10.</P> </TD>
    <TD STYLE="text-align: justify"><B>Declaration of Result</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Unless a poll is demanded, a declaration by the Chairman that a resolution has, on a show of hands, been carried, or carried unanimously, or by a particular majority, or lost, and an entry to that effect made in the book of the proceedings of the Company, shall be conclusive evidence of the fact, without proof of the number or proportion of the votes recorded in favour of, or against, that resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">10.11.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Casting Vote</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In the case of an equality of votes, whether on a show of hands or on a poll, the Chairman of the meeting at which the show of hands takes place, or at which a poll is demanded, shall not be entitled to a second or casting vote. The Chairman may adopt such rules and regulations for the conduct of meetings of members as the Chairman reasonably deems fit and proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">10.12.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Manner of Taking Poll</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">If a poll is duly demanded at a meeting of members:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(1)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">the poll must be taken, subject to Article 10.13, in the manner, at the time and at the place that the Chairman directs;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(2)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">the result of the poll shall be deemed to be the resolution of the meeting at which the poll was demanded; and</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(3)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">the demand for the poll may be withdrawn by the person who demanded it.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>





<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">10.13.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Demand for Poll on Adjournment</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">A poll demanded at a meeting of members on a question of adjournment must be taken immediately at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">10.14.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Chairman Must Resolve Dispute</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">In the case of any dispute as to the admission or rejection of a vote given on a poll, the Chairman must determine the dispute, and his or her determination made in good faith is final and conclusive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">10.15.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Demand for Poll Not to Prevent Continuance of Meeting</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">The demand for a poll at a meeting of members does not, unless the Chairman so rules, prevent the continuation of a meeting for the transaction of any business other than the question on which a poll has been demanded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">10.16.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Retention of Ballots and Proxies</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Company must, for at least three months after a meeting of members, keep each ballot cast on a poll and each proxy voted at the meeting, and, during that period, make them available for inspection during normal business hours by any member or proxy holder entitled to vote at the meeting. At the end of such three month period, the Company may destroy such ballots and proxies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">11.</TD>
    <TD STYLE="text-align: justify"><B>VOTES OF MEMBERS</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">11.1.</TD>
    <TD STYLE="text-align: justify"><B>Number of Votes by Member or by Shares</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Subject to any special rights or restrictions attached to any shares, on a show of hands every member present in person and every person representing a member by proxy shall, at a member&rsquo;s meeting, each have one vote and on a poll every member and every person representing a member by proxy shall have one vote for each share of which he or the person represented by proxy is the holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">11.2.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Votes by Joint Holders</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">Where shares are registered in the names of joint owners:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(1)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">each registered owner may be present in person or by a proxy at a meeting of members and may speak as a member;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(2)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">if only one of them is present in person or by proxy, he may vote on behalf of all of them; and</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(3)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">if two or more are present in person or by proxy, they must vote as one. If more than one joint owner votes in person or by proxy at any meeting of members of by written resolution, the vote of the joint owner whose name appears first among such voting joint holders on the Register of Members shall alone be counted.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">11.3.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Representative of a Corporate Member</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">Any corporation or other form of corporate legal entity which is a member may appoint a person to act as its representative at any meeting of members of the Company, and:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>





<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(1)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">for that purpose, the instrument appointing a representative must:</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 1in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(a)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">be received at the registered office of the Company or at any other place specified in the notice calling the meeting, for the receipt of proxies, within the number of business days specified in the notice for the receipt of proxies, or if no number of days is specified, two business days before the day set for the holding of the meeting; or</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 1in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(b)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">be provided, at the meeting, to the Chairman or to a person designated by the Chairman;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(2)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">if a representative is appointed under this Article 11.3:</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 1in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(a)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">the representative is entitled to exercise in respect of and at that meeting the same rights on behalf of the corporation that the representative represents as that corporation could exercise if it were a member who is an individual, including, without limitation, the right to appoint a proxy holder; and</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 1in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(b)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">the representative, if present at the meeting, is to be counted for the purpose of forming a quorum and is deemed to be a member present in person at the meeting.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Evidence of the appointment of any such representative may be sent to the Company by written instrument, fax or any other method of transmitting legibly recorded messages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">11.4.</TD>
    <TD STYLE="text-align: justify"><B>Votes of Persons in Representative Capacity</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">A person who is not a member may vote at a meeting of members, whether on a show of hands or on a poll, and may appoint a proxy holder to act at the meeting, if, before doing so, the person satisfies the Chairman, or the directors, that the person is a legal personal representative or a trustee in bankruptcy for a member who is entitled to vote at the meeting. Two or more legal personal representatives of a member in whose sole name any share is registered are, for the purposes of Article 11.2, deemed to be joint members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">11.5.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Appointment of Proxy Holders</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">Every member of the Company, including a corporation that is a member entitled to vote at a meeting of members of the Company may, by proxy, appoint a proxy holder to attend and act at the meeting in the manner, to the extent and with the powers conferred by the proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">11.6.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>Deposit of Proxy</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">A proxy for a meeting of members must:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(1)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">be received at the registered office of the Company or at any other place specified in the notice calling the meeting, for the receipt of proxies, within the number of business days specified in the notice, or if no number of days is specified, two business days before the day set for the holding of the meeting; or</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(2)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">unless the notice provides otherwise, be provided, at the meeting, to the Chairman or to a person designated by the Chairman of the meeting.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in">A proxy may be sent to the Company by written instrument, fax or any other method of transmitting legibly recorded messages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.7.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Validity of Proxy Vote</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A vote given in accordance with the terms of a proxy is valid notwithstanding the death or incapacity of the member giving the proxy and despite the revocation of the proxy or the revocation of the authority under which the proxy is given, unless notice in writing of that death, incapacity or revocation is received:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">at the registered office of the Company, at any time up to and including the last business day before the day set for the holding of the meeting at which the proxy is to be used; or</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">by the Chairman, before the vote is taken.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.8.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Form of Proxy</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A proxy, whether for a specified meeting or otherwise, must be either in the following form or in any other form approved by the directors or the Chairman:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">INSERT NAME OF COMPANY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(the &ldquo;Company&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The undersigned, being a member of the Company, hereby appoints <I>[name]</I> or, failing that person, <I>[name]</I>, as proxy holder for the undersigned to attend, act and vote for and on behalf of the undersigned at the meeting of members of the Company to be held on <I>[month, day, year]</I> and at any adjournment of that meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number of shares in respect of which this proxy is given (if no number is specified, then this proxy is given in respect of all shares registered in the name of the member):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 10%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Signed <I>[month, day, year]</I></FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>[Signature of member]</I></FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>[Name of member&mdash;printed]</I></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.9.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Revocation of Proxy</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject to Article 11.10, every proxy may be revoked by an instrument in writing that is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">received at the registered office of the Company at any time up to and including the last business day before the day set for the holding of the meeting at which the proxy is to be used; or</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">provided, at the meeting, to the Chairman.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.10.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Revocation of Proxy Must Be Signed</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">An instrument referred to in Article 11.9 must be signed as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">if the member for whom the proxy holder is appointed is an individual, the instrument must be signed by the member or his or her legal personal representative or trustee in bankruptcy; or</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">if the member for whom the proxy holder is appointed is a corporation, the instrument must be signed by the corporation or by a representative appointed for the corporation under Article 11.3.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.11.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Production of Evidence of Authority to Vote</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Chairman may, but need not, inquire into the authority of any person to vote at the meeting and may, but need not, demand from that person production of evidence as to the existence of the authority to vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.12.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Written Resolution</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">An action that may be taken by the members at a meeting may also be taken by a Resolution of Members consented to in writing or by telex, telegram, cable, facsimile or other written electronic communication, without the need for any notice, by the holders of in excess of 50 percent of the votes entitled to vote, but if any such resolution is adopted otherwise than by the unanimous written consent of all members, a copy of such Resolution of Members shall as soon as reasonably practicable be sent to all members not consenting to such Resolution of Members. The consent may be in the form of counterparts in like form each counterpart being signed by one or more members.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><B>APPOINTMENT AND REMOVAL OF DIRECTORS</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.1.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>First Directors</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The first directors shall be appointed by the Registered Agent. If, before the Company has any members, a sole director, or all the directors appointed by the Registered Agent die, or cease to exist (as the case may be), the Registered Agent may appoint one or more persons as directors of the Company.</FONT></P>

<P STYLE="font-family: Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.2.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Subsequent Directors</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject to Article 12.1, directors of the Company shall prior to the initial Business Combination only be appointed and removed by Resolution of Members passed by members holding 90% of the issued Class B Shares and thereafter by Resolution of Members or Resolution of Directors on such terms as the members or directors may determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Save that the directors may only appoint a person as a director by Resolution of Directors to replace a director to fill a casual vacancy arising on the resignation, disqualification or death of a director. The replacement director will then hold office until the next annual general meeting at which the director he replaces would have been subject to retirement by rotation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sections&nbsp;114(2) and 114(3) of the Act shall not apply to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.3.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Number of Directors</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unless and until the Company shall otherwise determine by Resolution of Directors, the number of directors shall be not less than two.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.4.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Term of Directorship</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each director continues to hold office until:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">his death;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">his resignation;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">



<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">his disqualification to act as a director under section&nbsp;111 of the Act; </FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">his retirement by rotation; or</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">the effective date of his removal by Resolution of Directors or Resolution of Members.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.5.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Retirement by Rotation</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The directors shall be divided into Class I, Class II and Class III directors for the purposes of retirement by rotation to ensure that all the directors do not face re-election at the same annual general meeting. On the adoption of these Articles the existing directors shall pass a Resolution of Directors classify the directors as Class I, Class II or Class III.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Class I directors shall retire from office at the first annual general meeting after he or she was appointed. Thereafter if re-elected each Class I director shall retire from office at the third annual general meeting after the general meeting at which he or she was re-elected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each Class II director shall retire from office at the second annual general meeting after the annual general meeting or general meeting (as the case may be) at which he was previously appointed. Thereafter if re-elected each Class II director shall retire from office at the third annual general meeting after the general meeting at which he or she was re-elected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each Class III director shall retire from office at the third annual general meeting after the annual general meeting or general meeting (as the case may be) at which he was previously appointed. Thereafter if re-elected each Class III director shall retire from office at the third annual general meeting after the general meeting at which he or she was re-elected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.6.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Position of Retiring Director</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A director who retires at an annual general meeting (whether by rotation or otherwise) may, if willing to act, be re-appointed. If he is not re-appointed or deemed to have been re-appointed, he shall retain office until the meeting appoints someone in his place or, if it does not do so, until the end of the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">12.7.</TD>
    <TD STYLE="text-align: justify"><B>Deemed Re-Appointment of Directors</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(a)</TD>
    <TD STYLE="text-align: justify">at the annual general meeting in any year any resolution or resolutions for the appointment or re-appointment of the persons eligible for appointment or re-appointment as directors are put to the meeting and lost; and</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(b)</TD>
    <TD STYLE="text-align: justify">at the end of that meeting the number of directors is fewer than any minimum number of Directors required under Article 0.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">All retiring directors who stood for re-appointment at that meeting (<B>&ldquo;Retiring Directors&rdquo;</B>) shall be deemed to have been re-appointed as directors and shall remain in office but the Retiring Directors may only act for the purpose of convening general meetings of the Company and perform such duties as are essential to maintain the Company as a going concern, and not for any other purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Retiring Directors shall convene a general meeting as soon as reasonably practicable following the meeting referred to in Article
12.7 above and they shall retire from office at that meeting. If at the end of any meeting convened under this Article the number of directors
is fewer than any minimum number of directors required under Article 0, the provisions of this Article shall also apply to that meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.8.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Qualification of Directors</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The following are disqualified for appointment as a director:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">an individual who is under 18 years of age;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">a person who is a disqualified person within the meaning of section&nbsp;260(4) of the Insolvency Act, 2003;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">a person who is a restricted person within the meaning of section&nbsp;409 of the Insolvency Act, 2003.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A director shall not require a share qualification, but nevertheless shall be entitled to attend and speak at any meeting of the directors and meeting of the members and at any separate meeting of the holders of any class of shares in the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.9.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Consent to be a Director</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A person shall not be appointed as a director or alternate director or nominated as a reserve director unless he has consented in writing to be a director or alternate director or to be nominated as a reserve director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.10.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Remuneration of Directors</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The remuneration of directors (whether by way of salary, commission, participation in profits or otherwise) in respect of services rendered or to be rendered in any capacity to the Company (including to any company in which the Company may be interested) shall be fixed by Resolution of Directors or Resolution of Members. The directors may also be paid such travelling, hotel and other expenses properly incurred by them in attending and returning from meetings of the directors, or any committee of the directors, or meetings of the members, or in connection with the business of the Company as shall be approved by Resolution of Directors or Resolution of Members.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ALTERNATE AND RESERVE DIRECTORS</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.1.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Appointment of Alternate Director</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any director (an &ldquo;appointer&rdquo;) may appoint any person who is not disqualified to act as a director to be his or her alternate to exercise the appointer&rsquo;s powers and to carry out the appointer&rsquo;s responsibilities, in relation to the taking of decisions by the directors in the absence of the appointer. The appointment and the termination of the appointment of an alternate director shall be in writing and written notice of the appointment or termination shall be given by the appointer to the Company as soon as reasonably practicable. The termination of the appointment of an alternate director does not take effect until written notice of the termination has been given to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">



<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.2.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Rights and Powers of Alternate Director</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">An alternate director has the same rights as the appointer in relation to any directors&rsquo; meeting and any written resolution circulated for written consent. An alternate director has no power to appoint an alternate, whether of the appointer or of the alternate director and does not act as an agent of or for the appointer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.3.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Termination of Appointment of Alternate Director</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">An appointer may at any time, terminate the appointment of an alternate director appointed by him.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The appointment of an alternate director ceases when:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">his or her appointer ceases to be a director and is not promptly re-elected or re-appointed;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">the alternate director dies;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">the alternate director resigns as an alternate director by notice in writing provided to the Company or a lawyer for the Company;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">the alternate director ceases to be qualified to act as a director pursuant to the Act; or</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">his or her appointer revokes the appointment of the alternate director.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.4.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Appointment of Reserve Director</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Where the Company only has one member who is an individual and that member is also the sole director of the Company, that sole member/director may, by instrument in writing, nominate a person who is not disqualified from being a director of the Company under section 111(1) of the Act as a reserve director of the Company to act in the place of the sole director in the event of his death. The nomination of a person as a reserve director of the Company ceases to have effect if:</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">before the death of the sole member/director who nominated him:</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">he resigns as a reserve director, or</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the sole member/director revokes the nomination in writing; or</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the sole member/director who nominated him ceases to be the sole member/director of the Company for any reason other than his death.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><B>POWERS AND DUTIES OF DIRECTORS</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.1.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Powers of Management</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The business of the Company shall be managed by, or be under the direction or supervision of, the directors who may pay all expenses incurred preliminary to and in connection with the formation and registration of the Company and may exercise all such powers of the Company necessary for managing and for directing and supervising the business and affairs of the Company as are not by the Act or by the Memorandum and Articles required to be exercised by the members, subject to any delegation of such powers as may be authorised by the Memorandum and Articles and permitted by the Act and to such requirements as may be prescribed by Resolution of Members.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.2.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Remaining director&rsquo;s power to act</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If the number of directors shall have been fixed at two or more persons and by reason of vacancies having occurred in the board there shall be only one continuing director, he shall be authorised to act alone only for the purpose of appointing another director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.3.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Delegation to committees, directors and officers</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The board of directors may entrust to and confer upon any director or officer any of the powers exercisable by it upon such terms and conditions and with such restrictions as it thinks fit, and either collaterally with, or to the exclusion of, its own powers, and may from time to time revoke, withdraw, alter or vary all or any of such powers. Subject to the provisions of Section&nbsp;110 of the Act, the directors may delegate any of their powers to committees consisting of such member or members of their body as they think fit. Any committee so formed shall in the exercise of powers so delegated conform to any regulations that may be imposed on it by the directors or the provisions of the Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.4.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Limits on powers of delegation to committees</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The directors have no power to delegate the following powers to a committee of directors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">to amend the Memorandum or Articles;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">to designate committees of directors;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">to delegate powers to committees of directors;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">to appoint or remove directors;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">to appoint or remove an agent;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">to approve a plan or merger, consolidation or arrangement;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">to make a declaration of solvency for the purposes of section 198(1) of the Act or approve a liquidation plan; or</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">to make a determination under section 57(1) of the Act that the Company will, immediately after a proposed distribution, satisfy the solvency test.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.5.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Agents</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The directors may appoint any person, including a person who is a director, to be an agent of the Company. Subject to Article 14.6, an agent of the Company has such powers and authority of the directors, including the power and authority to affix the common seal of the Company, as are set out in the Resolution of Directors appointing the agent. The directors may at any time remove an agent and may revoke or vary a power conferred on him.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.6.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Limits on powers of delegation to agents</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The directors have no power to delegate the following powers to an agent of the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">to amend the Memorandum or Articles;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">to change the registered office or Registered Agent;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">to designate committees of directors;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">to delegate powers to committees of directors;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">to appoint or remove directors;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">to appoint or remove an agent;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">to fix emoluments of directors;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">to approve a plan or merger, consolidation or arrangement;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">to make a declaration of solvency for the purposes of section&nbsp;198(1) of the Act or approve a liquidation plan; or</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(10)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">to make a determination under section&nbsp;57(1) of the Act that the Company will, immediately after a proposed distribution, satisfy the solvency test; or</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(11)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">to authorise the Company to continue as a company incorporated under the laws of a jurisdiction outside the British Virgin Islands.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.7.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Appointment of Attorney of Company</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The directors may from time to time, by power of attorney appoint any person, company, firm or body of persons to be the attorney of the Company for such purposes, and with such powers, authorities and discretions (not exceeding those vested in or exercisable by the directors under these Articles or the Act) and for such period, and with such remuneration and subject to such conditions as the directors think fit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.8.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Execution of Documents</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All cheques, promissory notes, drafts, bills of exchange and other negotiable instruments and all receipts for monies paid to the Company, shall be signed, drawn, accepted, endorsed or otherwise executed as the case may be, in such manner as the directors shall from time to time by Resolution of Directors determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.9.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Disposition of Assets</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For the purposes of section 175 of the Act (Disposition of assets), the directors may by Resolution of Directors determine that any sale, transfer, lease, exchange or other disposition is in the usual or regular course of the business carried on by the Company and such determination is, in the absence of fraud, conclusive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.10.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Duty to act in the best interests of the Company</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A director, in exercising his powers or performing his duties, shall act honestly and in good faith and in what the director believes to be in the best interest of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.11.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Duty to act in the best interests of the Company&rsquo;s parent</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding the foregoing Article, if the Company is a wholly-owned subsidiary, a director may, when exercising powers or performing duties as a director, act in a manner which he believes is in the best interests of the Company&rsquo;s parent (as defined in the Act) even though it may not be in the best interests of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.12.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Duty to exercise powers for a proper purpose</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A director shall exercise his powers as a director for a proper purpose and shall not act, or agree to the Company acting, in a manner that contravenes the Act or the Memorandum or Articles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.13.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Standard of Care</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A director, when exercising powers or performing duties as a director, shall exercise the care, diligence and skill that a reasonable director would exercise in the same circumstances taking into account, but without limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">the nature of the Company;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">the nature of the decision; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">the position of the director and the nature of the responsibilities undertaken by him.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.14.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Reliance</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A director, when exercising his powers or performing his duties as a director, is entitled to rely upon the Register of Members and upon books, records, financial statements and other information prepared or supplied, and on professional or expert advice given, by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">an employee of the Company whom the director believes on reasonable grounds to be reliable and competent in relation to the matters concerned;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">a professional adviser or expert in relation to matters which the director believes on reasonable grounds to be within the person&rsquo;s professional or expert competence; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">any other director, or committee of directors upon which the director did not serve, in relation to matters within the director&rsquo;s or committee&rsquo;s designated authority,</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">provided that the director (a) acts in good faith; (b) makes proper inquiry where the need for the inquiry is indicated by the circumstances; and (c) has no knowledge that his reliance on the Register of Members or the books, records, financial statements and other information or expert advice is not warranted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DISCLOSURE OF INTEREST OF DIRECTORS</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.1.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Self Interested Transactions</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">No director shall be disqualified from his office for contracting with the Company either as a vendor, purchaser or otherwise, nor shall any such contract or arrangement entered into by or on behalf of the Company in which any director shall be in any way interested be voided, nor shall any director so contracting or being so interested be liable to account to the Company for any profit realised by any such contract or arrangement, by reason of such director holding that office or by reason of the fiduciary relationship thereby established, provided the procedure in Article 15.2 below is followed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.2.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Disclosure of Self Interest</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A director of the Company shall, immediately after becoming aware of the fact that he is interested in a transaction entered into or to be entered into by the Company, disclose such interest to the board of directors. Any such disclosure shall not be effective unless brought to the attention of every director on the board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.3.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exemption for Ordinary Course of Business</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A director of the Company is not required to comply with Article 15.2 above if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">the transaction or proposed transaction is between the director and the Company; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">the transaction or proposed transaction is in the ordinary course of the</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Company&rsquo;s business and on usual terms and conditions.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.4.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Nature of Disclosure</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For the purposes of Article 15.2 above, a disclosure to the board to the effect that a director is a member, director, officer or trustee of another named company or other person and is to be regarded as interested in any transaction which may, after the date of the entry or disclosure, be entered into with that company or person, is a sufficient disclosure of interest in relation to that transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.5.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Failure to Disclose does not Invalidate Transaction</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject to Section&nbsp;125(1) of the Act, the failure by a director to comply with Article 15.2 does not affect the validity of a transaction entered into by the director or the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.6.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Interested Director Counted in Quorum</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A director who is interested in a transaction entered into or to be entered into by the Company may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">vote on a matter relating to the transaction;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">attend a meeting of directors at which a matter relating to the transaction arises and be included among the directors present at the meeting for the purposes of a quorum; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">sign a document on behalf of the Company, or do any other thing in his capacity as a director, that relates to the transaction.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.7.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Director Holding Other Office in the Company</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A director may hold any office or place of profit with the Company, other than the office of auditor of the Company, in conjunction with his or her office of director for the period and on the terms (as to remuneration or otherwise) that the directors may determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.8.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Professional Services by Director or Officer</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject to the Act, a director or officer, or any person in which a director or officer has an interest, may act in a professional capacity for the Company, except as auditor of the Company, and the director or officer or such person is entitled to remuneration for professional services as if that director or officer were not a director or officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.9.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Director or Officer in Other Corporations</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A director or officer may be or become a director, officer or employee of, or otherwise be interested in, any person in which the Company may be interested as a member or otherwise, and, subject to the Act, the director or officer is not accountable to the Company for any remuneration or other benefits received by him as director, officer or employee of, or from his or her interest in, such other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.10.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Directors may compete</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">To the fullest extent permitted by BVI law: (i) no individual serving as a director or an officer shall have any duty, except and to the extent expressly assumed by contract, to refrain from engaging directly or indirectly in the same or similar business activities or lines of business as the Company; and (ii) the Company renounces any interest or expectancy in, or in being offered an opportunity to participate in, any potential transaction or matter which may be a corporate opportunity for any director or officer not related to the initial Business Combination or any Business Combination of the Company.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PROCEEDINGS OF DIRECTORS</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.1.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Meetings of Directors</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The directors may meet together (either within or outside the British Virgin Islands) for the conduct of business, adjourn and otherwise regulate their meetings as they think fit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">



<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.2.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Voting at Meetings</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Questions arising at any meeting of directors are to be decided by a majority of votes and, in the case of an equality of votes, the chair of the meeting does not have a second or casting vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.3.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Chair of Meetings</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The following individual is entitled to preside as chair at a meeting of directors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">the chair of the board, if any;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">in the absence of the chair of the board, the president, if any, if the president is a director; or</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">any other director chosen by the directors if:</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 1in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">neither the chair of the board nor the president, if a director, is present at the meeting within 15 minutes after the time set for holding the meeting;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 1in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">neither the chair of the board nor the president, if a director, is willing to chair the meeting; or</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 1in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">the chair of the board and the president, if a director, have advised the secretary, if any, or any other director, that they will not be present at the meeting</FONT>.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.4.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Meetings by Telephone or Other Communications Medium</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A director shall be deemed to be present at a meeting of directors if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">he participates by telephone or other electronic means; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify">
        <P STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">all directors participating in the meeting are able to hear each other.</FONT></P> </TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.5.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Calling of Meetings</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A director may, and the secretary of the Company, if any, on the request of a director shall, call a meeting of the directors at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.6.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Notice of Meetings</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A minimum of three (3) days notice of each meeting of the directors shall be given to each of the directors and the alternate directors by any method set out in Article 21.1 or orally or by telephone. Such notice shall specify the place, date, time and general nature of the business of the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.7.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Waiver of Notice of Meetings</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding Article 16.6, a meeting of directors held in contravention of Article 16.6 is valid if a majority of directors entitled to vote at the meeting have waived the notice of the meeting and, for this purpose, the presence of a director at the meeting shall be deemed to constitute waiver on his part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">



<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.8.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Meeting Valid Despite Failure to Give Notice</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The inadvertent failure to give notice of any meeting of directors to, or the non-receipt of any notice by, any director or alternate director, does not invalidate any proceedings at that meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">



<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.9.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Quorum</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">The quorum necessary for the transaction of the business of the directors may be set by the directors and, if not so set, is deemed to be set at two directors unless the total number of directors of the Company is one, in which case the quorum shall be one.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.10.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consent Resolutions in Writing </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any action that may be taken by the directors or a committee of directors at a meeting may also be taken by a Resolution of Directors or a committee of directors consented to in writing or by telex, telegram, cable, facsimile or other electronic communication by all of the directors or by all of the members of the committee, as the case maybe, without the need for notice. Such resolution may be in two or more counterparts which together are deemed to constitute one resolution in writing. A resolution passed in that manner is effective on the date stated in the resolution or on the latest date stated on any counterpart.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OFFICERS</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors May Appoint Officers </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The directors may, by Resolution of Directors, from time to time, appoint such officers, if any, as the directors determine and the directors may, at any time, terminate any such appointment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><B>Functions, Duties and Powers of Officers</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The directors may, for each officer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">determine the functions and duties of the officer;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">entrust to and confer on the officer any of the powers exercisable by the directors on such terms and conditions and with such restrictions as the directors think fit; and</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">revoke, withdraw, alter or vary all or any of the functions, duties and powers of the officer.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Qualifications </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One person may hold more than one position as an officer of the Company. Any person appointed as the chair of the board or as the managing director must be a director. Any other officer need not be a director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Remuneration and Terms of Appointment </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All appointments of officers are to be made on the terms and conditions and at the remuneration (whether by way of salary, fee, commission, participation in profits or otherwise) that the directors think fit. The officers shall remain in office until removed from office by the directors, whether or not a successor is appointed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate Officer </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any officer (including any director) who is a body corporate may appoint any person as its duly authorised representative for the purpose of representing it and of transacting any of the business of the officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEMNIFICATION </B></FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the provisions of the Act, the Company may indemnify against all expenses, including legal fees, and against all judgments, fines and amounts paid in settlement and reasonably incurred in connection with legal, administrative or investigative proceedings any person who:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is or was a party or is threatened to be made a party to any threatened, pending or completed proceedings, whether civil, criminal, administrative or investigative, by reason of the fact that the person is or was a director of the Company; </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is or was, at the request of the Company, serving as a director of, or in any other capacity is or was acting for, another company or a partnership, joint venture, trust or other enterprise, </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided that the person acted honestly and in good faith and in what he believed to be in the best interests of the Company and, in the case of criminal proceedings, the person had no reasonable cause to believe that his conduct was unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DISTRIBUTIONS</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font-family: Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><B>Distributions Subject to Special Rights</B></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font-family: Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 0.5in; font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The provisions of this Article 19 are subject to the rights, if any, of members holding shares with special rights as to distributions.</FONT></P>

<P STYLE="font-family: Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><B>Declaration of Distributions</B></TD> </TR>
  </TABLE>

<P STYLE="font-family: Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font-family: Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject to the Act, the directors may, by Resolution of Directors, authorise a distribution by the Company to members at such times and of such an amounts, as they think fit if they are satisfied, on reasonable grounds, that immediately after the distribution the value of the Company&rsquo;s assets will exceed the Company&rsquo;s liabilities, and the Company is able to pay its debts as they fall due.</FONT></P>

<P STYLE="font-family: Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0pt 0pt 0; font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice of Distribution </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of any distribution that may have been declared shall be given to each member pursuant to Article 21 and all distributions unclaimed for three years after having been declared may be forfeited by the directors for the benefit of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Record Date </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The directors may set a date as the record date for the purpose of determining those members entitled to receive payment of a distribution. The record date must not precede the date on which the distribution is to be paid by more than one month. If no record date is set, the record date is 5 p.m. on the date on which the directors pass the resolution declaring the distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manner of Paying Distribution </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A resolution declaring a distribution may direct payment of the distribution wholly or partly by the distribution of specific assets or of fully paid shares or of bonds, debentures or other securities of the Company, or in any one or more of those ways.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Setting Aside Profits </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The directors may, before recommending any distribution, set aside out of the profits of the company such sums as they think proper as a reserve or reserves which shall, at their discretion, either be employed in the business of the Company or be invested in such investments as the directors may from time to time think fit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>When Distribution Payable </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any distribution may be made payable on such date as is fixed by the directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Distribution to be Paid in Accordance with Number of Shares </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All distributions of shares of any class or series of shares must be declared and paid according to the number of such shares held.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.9.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Receipt by Joint Members </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If several persons are joint members of any share, any one of them may give an effective receipt for any distribution, bonus or other money payable in respect of the share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.10.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Distribution Bears No Interest </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No distribution bears interest against the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.11.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fractional Distribution </B></FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If a distribution to which a member is entitled includes a fraction of the smallest monetary unit of the currency of the distribution, that fraction may be disregarded in making payment of the distribution and that payment represents full payment of the distribution</FONT>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.12.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payment of Distribution</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font-family: Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font-family: Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any dividend or other distribution payable in cash in respect of shares may be paid by cheque, made payable to the order of the person to whom it is sent, and mailed to the address of the member, or in the case of joint members, to the address of the joint member who is first named on the Register of Members, or to the person and to the address the member or joint members may direct in writing. The mailing of such cheque will, to the extent of the sum represented by the cheque, discharge all liability for the distribution unless such cheque is not paid on presentation.</FONT></P>

<P STYLE="text-align: justify; font-family: Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DOCUMENTS, RECORDS AND REPORTS</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company Records and Underlying Documentation </B></FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall keep (at the office of the Registered Agent or at such other places within or outside of the British Virgin Islands as the directors may determine) records and underlying documentation that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are sufficient to show and explain the Company&rsquo;s transactions; and </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will at any time, enable the financial position of the Company to be determined with reasonable accuracy. </FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such records and underlying documentation must be retained for a period of at least five years from the date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of completion of the transaction to which the records and underlying documentation relate, or </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that the Company terminates the business relationship to which the records and underlying documentation relate. </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Resolutions of Members and Directors </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall keep (at the office of the Registered Agent or at such other place or places, within or outside the British Virgin Islands, as the directors may determine) the following records:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">minutes of meetings and resolutions of members and of classes of members; and </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">minutes of meetings and resolutions of directors and committees of directors. </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Location of Company Records </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where the resolutions referred to in Article 20.2 and the records and underlying documentation referred to in Article 20.1 are kept at a place other than the office of the Registered Agent, the Company must provide the Registered Agent with a written record of the physical address of the place or places at which such resolutions, records and underlying documentation are kept and a written record of the name of the person who maintains and controls the Company&rsquo;s records and underlying documentation and, where such place and/or the name of such person is changed, the Company shall provide the Registered Agent with the physical address of the new location of the resolutions, records and underlying documentation and/or the name of the new person who maintains and controls the Company&rsquo;s records and underlying documentation within fourteen days of the change of location.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: left">20.4.</TD>
    <TD STYLE="text-align: justify"><B>Register of Directors</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The Company shall keep a register to be known as a Register of Directors containing the particulars stated in section 118A of the Act, and such other information as may be prescribed by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Register of Members </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall maintain an accurate and complete Register of Members showing the full names and addresses of all persons holding registered shares in the Company, the number of each class and series of registered shares held by such person, the date on which the name of each member was entered in the Register of Members and where applicable, the date such person ceased to hold any registered shares in the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Documents to be Kept at Registered Office </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall keep the following documents at the office of the Registered Agent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Memorandum and Articles of the Company; </FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Register of Members maintained in accordance with Article 20.5 or a copy of the Register of Members; </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Register of Directors maintained in accordance with Article 20.4 or a copy of the Register of Directors; </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">copies of all notices and other documents filed by the Company in the previous ten years; </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a copy of the register of charges kept by the Company pursuant to Section 162(1) of the Act; and </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an imprint of the common seal. </FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Copies of Registers </B></FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Where the Company keeps a copy of the Register of Members or the Register of Directors at a place other than the office of the Registered Agent, it shall:</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif; width: 1in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">within fifteen (15) days of any change in the Register of Members or Register of Directors, notify the Registered Agent, in writing, of the change; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif; width: 1in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide the Registered Agent with a written record of the physical address of the place or places at which the original Register of Members or the original Register of Directors is kept.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where the place at which the original Register of Members or the original Register of Directors is kept is changed, the Company shall provide the Registered Agent with the physical address of the new location of the records within fourteen (14) days of the change of location.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where a change occurs in the relevant charges or in the details of the charges required to be recorded in the Company&rsquo;s register of charges which is kept at the office of the Registered Agent, the Company shall within fourteen (14) days of the change occurring, transmit details of the change to the Registered Agent.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><B>Inspection of Records by Directors</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The records, documents and registers required by this Article 20 to be kept by the Company shall be open to the inspection of the directors at all times.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.9.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inspection of Records by Members </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The directors shall from time to time determine whether and to what extent and at what times and places and under what conditions the records, documents and registers of the Company or any of them shall be open to the inspection of members not being directors, and no member (not being a director) shall have any right to inspect any records, documents or registers of the Company except as conferred by the Act or authorised by a Resolution of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICES</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Method of Giving Notice </B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless the Act or these Articles provide otherwise, a notice, statement, report or other record required or permitted by the Act or these Articles to be sent by or to a person may be sent by any one of the following methods:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mail addressed to the person at the applicable address for that person as follows: </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for a record mailed to a member, the member&rsquo;s address as shown in the Register of Members; </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for a record mailed to a director or officer, the prescribed address for mailing shown for the director or officer in the records kept by the Company or the mailing address provided by the recipient for the sending of that record or records of that class; </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in any other case, the mailing address of the intended recipient. </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delivery at the applicable address for that person as follows, addressed to the person: </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for a record delivered to a member, the member&rsquo;s address as shown in the Register of Members; </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for a record delivered to a director or officer, the prescribed address for delivery shown for the director or officer in the records kept by the Company or the delivery address provided by the recipient for the sending of that record or records of that class; </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 1in"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">(c)</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;in any other case, the delivery address of the intended recipient.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">sending the record by fax to the fax number provided by the intended recipient for the sending of that record or records of that class;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">sending the record by email to the email address provided by the intended recipient for the sending of that record or records of that class;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">(5)</TD>
    <TD STYLE="text-align: justify">through a Relevant System, where the notice or document relates to uncertificated shares;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->





<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">(6)</TD>
    <TD STYLE="text-align: justify">where appropriate, by making it available on a website and notifying the member of its availability in accordance with this Article;</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">(7)</TD>
    <TD STYLE="text-align: justify">in accordance with the rules of a Designated Stock Exchange; and</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">(8)</TD>
    <TD STYLE="text-align: justify">by any other means authorised in writing by the member.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><B>Deemed Receipt of Mailing</B></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A record that is mailed to a person by ordinary mail to the applicable address for that person referred to in Article 21.1 is deemed to be received by the person to whom it was mailed on the seventh day, Saturdays, Sundays and holidays excepted, following the date of mailing.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certificate of Sending </B></FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A certificate signed by the secretary, if any, or other officer of the Company or of any other corporation acting in that behalf for the Company stating that a notice, statement, report or other record was addressed as required by Article 21.1, prepaid and mailed or otherwise sent as permitted by Article 21.1 is conclusive evidence of that fact.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice to Joint Members </B></FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A notice, statement, report or other record may be provided by the Company to the joint members of a share by providing the notice to the joint member first named in the Register of Members in respect of the share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SEAL </B></FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The common seal when affixed to any instrument, shall be witnessed by a director or officer of the Company or any other person so authorised from time to time by the directors. The directors may provide for a facsimile of the common seal and approve the signature of any director or authorised person which may be reproduced by printing or other means on any instrument and it shall have the same force and validity as if the seal has been affixed to such instrument and the same had been signed as hereinbefore described.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AUDIT</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audit </B></FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The directors may by Resolution of Directors call for the accounts of the Company to be examined by an auditor or auditors to be appointed by them at such remuneration as may from time to time be agreed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Eligible Auditor </B></FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The auditor may be a member of the Company but no director or officer shall be eligible to serve as auditor during his continuance in office.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Access </B></FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every auditor of the Company shall have a right of access at all times to the books of accounts of the Company, and shall be entitled to require from the officers of the Company such information and explanations as he thinks necessary for the performance of his duties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Auditors Report </B></FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in">The report of the auditor shall be annexed to the accounts upon which he reports, and the auditor shall be entitled to receive notice of, and to attend, any meeting at which the Company&rsquo;s audited financial statements are to be presented.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">24.</TD>
    <TD STYLE="text-align: justify"><B>WINDING UP</B></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may be voluntarily liquidated under Part XII of the Act if (1) it has no liabilities or (2) it is able to pay its debts as they fall due and the value of its assets equals or exceeds its liabilities. If the Company shall be wound up, the liquidator may divide amongst the members in specie or in kind the whole or any part of the assets of the Company (whether they shall consist of property of the same kind or not) and may for such purpose set such value as he deems fair upon any such property to be divided as aforesaid and may determine how such division shall be carried out as between the members or different classes of members. The liquidator may vest the whole or any part of such assets in trustees upon such trust for the benefit of the contributors as the liquidator shall think fit, but so that no member shall be compelled to accept any shares or other securities whereon there is any liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">25.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BUSINESS COMBINATION</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">25.1.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding any other provision of these Articles, this Regulation 25 shall apply during the period commencing upon the adoption of these Articles and terminating upon the first to occur of the consummation of any Business Combination and the complete liquidation of the trust account. In the event of a conflict between this Regulation 25 and any other Regulation of these Articles, the provisions of this Regulation 25 shall prevail.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">25.2.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &ldquo;group&rdquo; (as defined under Section 13 of the Exchange Act), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the shares sold in this offering without the prior consent of the Company.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">25.3.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall provide its public shareholders with the opportunity to redeem all or a portion of their public shares, regardless of whether they abstain, vote for, or vote against, the Company&rsquo;s initial business combination, upon the completion of the initial business combination either (i) in connection with a general meeting called to approve the initial business combination or (ii) without a shareholder vote by means of a tender offer.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">25.4.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company seeks shareholder approval of its initial business combination, such initial business combination will be approved by an ordinary resolution requiring the affirmative vote of at least a majority of the votes cast by the holders of ordinary shares as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the Company.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">25.5.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall not effectuate its initial Business Combination solely with another blank check company or similar company with nominal operations.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">25.6.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the initial Business Combination, except in connection with the conversion of Class B ordinary shares into Class A ordinary shares where the holders of such shares have waived any rights to receive funds from the trust account, the Company may not issue additional shares that would entitle the holders thereof to (i) receive funds from the trust account or (ii) vote as a class with public shares on any initial Business Combination.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">25.7.</TD>
    <TD STYLE="text-align: justify">If the Company seeks shareholder approval of its initial business combination and the Company does not conduct redemptions in connection with its initial business combination pursuant to the tender offer rules, a public shareholder, together with any affiliate of such public shareholder or any other person with whom such shareholder is acting in concert or as a &ldquo;group&rdquo; (as defined under Section 13 of the Exchange Act), will be restricted from seeking redemption rights with respect to Excess Shares without our prior consent.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">25.8.</TD>
    <TD STYLE="text-align: justify">If a shareholder vote on our initial Business Combination is not required by law and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will offer to redeem its public shares pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, and will file tender offer documents with the SEC prior to completing its initial Business Combination which contain substantially the same financial and other information about its initial Business Combination and the redemption rights as is required under Regulation 14A of the Exchange Act.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">25.9.</TD>
    <TD STYLE="text-align: justify">Nasdaq rules require that the Company must complete one or more Business Combinations having an aggregate fair market value of at least 80% of the value of the assets held in the trust account (excluding the deferred underwriting commissions and taxes payable on the interest earned on the trust account).</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">25.10.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will have only the completion window to complete its initial business combination. If the Company has not completed its initial business combination within the completion window, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter (and subject to lawfully available funds therefor), redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (which interest shall be net of taxes and less up to $100,000 of interest to pay dissolution expenses), divided by the number of then-outstanding public shares, which redemption will completely extinguish public shareholders&rsquo; rights as shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company&rsquo;s remaining shareholders and the board of directors, liquidate and dissolve, subject in each case to the Company&rsquo;s obligations under British Virgin Islands law to provide for claims of creditors and the requirements of other applicable law.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">25.11.</TD>
    <TD STYLE="text-align: justify">If shareholders approve an amendment to the Memorandum and Articles not for the purposes of approving, or in conjunction with the consummation of, an initial Business Combination (i) to modify the substance or timing of our obligation to allow redemption in connection with an initial Business Combination or to redeem 100% of our public shares if the Company does not complete an initial Business Combination within the completion window or (ii) with respect to any other provision relating to the rights of holders of Class A Shares or pre-initial Business Combination activity, the Company will provide its public shareholders with the opportunity to redeem all or a portion of their Class A Shares upon such approval at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (which interest shall be net of taxes payable), divided by the number of then-outstanding public shares.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35pt 0pt 36.2pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35pt 0pt 36.2pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">25.12.</TD>
    <TD STYLE="text-align: justify">If shareholders vote at any time to amend these memorandum and articles of association to modify the amount of time the Company will have to complete an initial Business Combination, the public shareholders will be offered an opportunity to redeem their public shares.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">26.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>REMOVAL OF DIRECTORS</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">26.1.</TD>
    <TD STYLE="text-align: justify">Prior to the Company&rsquo;s initial Business Combination, only holders of the Company&rsquo;s founder shares will have the right to vote on the appointment of directors and that only holders of a majority of the Company&rsquo;s founder shares may remove a member of the board of directors for any reason.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">26.2.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Article 26 may only be amended by a resolution of members passed by at least 90% of holders of the Company&rsquo;s ordinary shares who, being eligible, attend (in person or by proxy) and vote at a general meeting of the Company.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With respect to any other matter submitted to a vote of the shareholders of the Company, including any vote in connection with the initial Business Combination, except as required by law, holders of the Company&rsquo;s founder shares and holders of the Company&rsquo;s public shares will vote together as a single class, with each share entitling the holder to one vote.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">27.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONTINUATION OUT</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">27.1.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the Company&rsquo;s initial Business Combination only holders of the Company&rsquo;s founder shares will have the right to vote on a resolutions to transfer the Company by way of continuation out of the British Virgin Islands to another jurisdiction (including, but not limited to, the approval of the organizational documents of the Company in such other jurisdiction).</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">27.2.</TD>
    <TD STYLE="text-align: justify">After the Company&rsquo;s initial Business Combination, only the holders of the Company&rsquo;s ordinary shares will have the right to vote on a resolutions to transfer the Company by way of continuation out of the British Virgin Islands to another jurisdiction (including, but not limited to, the approval of the organizational documents of the Company in such other jurisdiction).</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">27.3.</TD>
    <TD STYLE="text-align: justify">This Article 27 may only be amended by a resolution of members passed by at least 90% of holders of the Company&rsquo;s ordinary shares who, being eligible, attend (in person or by proxy) and vote at a general meeting of the Company.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">28.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>BUSINESS OPPORTUNITIES</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">28.1.</TD>
    <TD STYLE="text-align: justify">To the fullest extent permitted by Applicable Law, no individual serving as a director or an officer of the Company (&ldquo;Management&rdquo;) shall have any duty, except and to the extent expressly assumed by contract, to refrain from engaging directly or indirectly in the same or similar business activities or lines of business as the Company. To the fullest extent permitted by Applicable Law, the Company renounces any interest or expectancy of the Company in, or in being offered an opportunity to participate in, any potential transaction or matter which may be a corporate opportunity for Management, on the one hand, and the Company, on the other. Except to the extent expressly assumed by contract, to the fullest extent permitted by Applicable Law, Management shall have no duty to communicate or offer any such corporate opportunity to the Company and shall not be liable to the Company or its Members for breach of any fiduciary duty as a Member, director and/or Officer solely by reason of the fact that such party pursues or acquires such corporate opportunity for itself, directs such corporate opportunity to another person, or does not communicate information regarding such corporate opportunity to the Company.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">28.2.</TD>
    <TD STYLE="text-align: justify">Except as provided elsewhere in these Articles, the Company hereby renounces any interest or expectancy of the Company in, or in being offered an opportunity to participate in, any potential transaction or matter which may be a corporate opportunity for both the Company and Management, about which a director and/or Officer who is also a member of Management acquires knowledge.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">28.3.</TD>
    <TD STYLE="text-align: justify">To the extent a court might hold that the conduct of any activity related to a corporate opportunity that is renounced in this Article to be a breach of duty to the Company or its Members, the Company hereby waives, to the fullest extent permitted by Applicable Law, any and all claims and causes of action that the Company may have for such activities. To the fullest extent permitted by Applicable Law, the provisions of this Article apply equally to activities conducted in the future and that have been conducted in the past.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">29.</TD>
    <TD STYLE="text-align: justify"><B>FORUM SELECTION</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">29.1.</TD>
    <TD STYLE="text-align: justify">Subject to Article 29.2, unless the directors consent in writing to the selection of an alternative forum, the courts of the British Virgin Islands shall have exclusive jurisdiction over any claim or dispute arising out of or in connection with these Memorandum and Articles of association or otherwise related in any way to each Member&rsquo;s shareholding in the Company, including but not limited to:</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">(i)</TD>
    <TD STYLE="text-align: justify">any derivative action or proceeding brought on behalf of the Company,</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">(ii)</TD>
    <TD STYLE="text-align: justify">any action asserting a claim of breach of any fiduciary or other duty owed by any of the current or former director, officer or other employee to the Company or the shareholders,</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">(iii)</TD>
    <TD STYLE="text-align: justify">any action asserting a claim arising pursuant to any provision of the Act or the Memorandum and Articles of association, or</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(iv)</TD>
    <TD STYLE="text-align: justify">any action asserting a claim against the Company governed by the internal affairs doctrine (as such concept is recognized under the laws of the United States of America) and that each shareholder irrevocably submits to the exclusive jurisdiction of the courts of the British Virgin Islands over all such claims or disputes.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">29.2.</TD>
    <TD STYLE="text-align: justify">Save that Article 29.1 will not apply to actions or suits brought to enforce any liability or duty created by the Securities Act of the United States of America, Exchange Act of the United States of America or any claim for which the federal district courts of the United States of America are, as a matter of the laws of the United States of America, the sole and exclusive forum for determination of such a claim.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">29.3.</TD>
    <TD STYLE="text-align: justify">Without prejudice to any other rights or remedies that the Company may have, each of the Members acknowledges that damages alone would not be an adequate remedy for any breach of the selection of the courts of the British Virgin Islands as exclusive forum and that accordingly the Company shall be entitled, without proof of special damages, to the remedies of injunction, specific performance or other equitable relief for any threatened or actual breach of the selection of the courts of the British Virgin Islands as exclusive forum.</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENT TO ARTICLES </B></FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to these Articles and the Act, the Company may alter or modify the conditions contained in these Articles as originally drafted or as amended from time to time by a Resolution of Directors or a Resolution of Members.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: justify; width: 100%"><DIV STYLE="text-align: justify; font-size: 1pt; border-top: Black 3pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NAME, ADDRESS AND DESCRIPTION OF INCORPORATOR</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: justify; width: 100%"><DIV STYLE="text-align: justify; font-size: 1pt; border-top: Black 3pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We, <B>FH Corporate Services Ltd</B>, of Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, registered agent of the Company, hereby sign these Articles of Association for the purposes of incorporating a company limited by shares under the BVI Business Companies Act, 2004</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FH Corporate Services Ltd</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clarence Thomas Building</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">P.O. Box 4649, Road Town, Tortola</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">British Virgin Islands</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Incorporator</B></FONT></TD> </TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jos&eacute; Santos</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">For and on behalf of</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">FH Corporate Services Ltd</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20&nbsp;March 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>3
<FILENAME>dboralarcacq_ex4-4.htm
<DESCRIPTION>EXHIBIT 4.4
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 4.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WARRANT AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS WARRANT AGREEMENT</B> (this &ldquo;<B><I>Agreement</I></B>&rdquo;), dated as of July&nbsp;30, 2025, is by and between D. Boral ARC Acquisition I Corp., a BVI business company (the &ldquo;<B><I>Company</I></B>&rdquo;), and Odyssey Transfer and Trust Company, a corporation organized under the laws of Minnesota, as warrant agent (in such capacity, the &ldquo;<B><I>Warrant Agent</I></B>,&rdquo; and also referred to herein as the &ldquo;<B><I>Transfer Agent</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>, the Company is engaged in an initial public offering (the &ldquo;<B><I>Offering</I></B>&rdquo;) of units of the Company&rsquo;s equity securities, each such unit comprised of one Class A ordinary share of the Company, par value $0.0001 per share (&ldquo;<B><I>Class A Shares</I></B>&rdquo;) and one-half of one redeemable Public Warrant (as defined below) (the &ldquo;<B><I>Units</I></B>&rdquo;) and, in connection therewith, has determined to issue and deliver up to 12,500,000 warrants (or up to 14,375,000 warrants if the Over-allotment Option (as defined below) is exercised in full) to public investors in the Offering (the &ldquo;<B><I>Public Warrants</I></B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>, the Company entered into that certain Private Placement Units Purchase Agreement with MFH 1, LLC, a Delaware limited liability company (the &ldquo;<B><I>Sponsor</I></B>&rdquo;), pursuant to which the Sponsor agreed to purchase an aggregate of 200,000 private placement units (whether or not the Over-allotment Option is exercised) simultaneously with the closing of the Offering (the &ldquo;<B><I>Sponsor Private Placement Units</I></B>&rdquo;) at a purchase price of $10.00 per Private Placement Unit, and in connection therewith, the issuance of up to 100,000 warrants (whether or not the Over-allotment Option is exercised) underlying the Private Placement Units (the &ldquo;<B><I>Private Placement Warrants</I></B>&rdquo;), each bearing the legend set forth in Exhibit A hereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>, the Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (a &ldquo;<B><I>Business Combination</I></B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>, in order to finance the Company&rsquo;s transaction costs in connection with an intended initial Business Combination, the Sponsor or an affiliate of the Sponsor or the Company&rsquo;s officers and directors (collectively, the &ldquo;<B><I>Initial Purchasers</I></B>&rdquo;) may, but are not obligated to, loan to the Company funds as the Company may require, of which up to $2,500,000 of such loans may be convertible into up to an additional 250,000 units at a price of $10.00 per unit (the &ldquo;<B><I>Working Capital Units</I></B>&rdquo;), which will be identical to the Private Placement Units, and in connection with the issuance of Working Capital Units, the issuance of up to 125,000 warrants (the &ldquo;<B><I>Working Capital Warrants</I></B>&rdquo; and, together with the Public Warrants and the Private Placement Warrants, the &ldquo;<B><I>Warrants</I></B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>, each Warrant entitles the holder thereof to purchase one Class A Share at a price of $11.50 per share, subject to adjustment as described herein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>, the Company has filed with the U.S. Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) a registration statement on Form S-1, File No. 333-286810 (the &ldquo;<B><I>Registration Statement</I></B>&rdquo;), and a prospectus (the &ldquo;<B><I>Prospectus</I></B>&rdquo;), for the registration, under the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities Act</I></B>&rdquo;), of the Units, the Public Warrants and the Class A Shares included in the Units;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>, the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, registration, transfer, exchange, redemption and exercise of the Warrants;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>, the Company desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective rights, limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>, all acts and things have been done and performed which are necessary to make the Warrants, when executed on behalf of the Company and countersigned by or on behalf of the Warrant Agent, as provided herein, the valid, binding and legal obligations of the Company, and to authorize the execution and delivery of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW, THEREFORE</B>, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Appointment of Warrant Agent</U>. The Company hereby appoints the Warrant Agent to act as agent for the Company for the Warrants, and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth in this Agreement.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Warrants</U>.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Form of Warrant</U>. Each Warrant shall be issued in registered form only, and, if a physical certificate is issued, shall be in substantially the form of <U>Exhibit B</U> hereto, the provisions of which are incorporated herein and shall be signed by, or bear the facsimile signature of, the Chairperson of the Company&rsquo;s board of directors (the &ldquo;<B><I>Board</I></B>&rdquo;), President, Chief Executive Officer, Chief Financial Officer, Secretary or other principal officer of the Company. In the event the person whose facsimile signature has been placed upon any Warrant shall have ceased to serve in the capacity in which such person signed the Warrant before such Warrant is issued, it may be issued with the same effect as if he or she had not ceased to be such at the date of issuance. All of the Public Warrants shall initially be represented by one or more book-entry certificates (each, a &ldquo;<B><I>Book-Entry Warrant Certificate</I></B>&rdquo;).</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Effect of Countersignature</U>. If a physical certificate is issued, unless and until countersigned by the Warrant Agent pursuant to this Agreement, a Warrant certificate shall be invalid and of no effect and may not be exercised by the holder thereof.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration</U>.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.1.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Warrant Register</U>. The Warrant Agent shall maintain books (the &ldquo;<B><I>Warrant Register</I></B>&rdquo;) for the registration of original issuance and the registration of transfer of the Warrants. Upon the initial issuance of the Warrants, the Warrant Agent shall issue and register the Warrants in the names of the respective holders thereof in such denominations and otherwise in accordance with instructions delivered to the Warrant Agent by the Company. All of the Public Warrants shall initially be represented by one or more Book-Entry Warrant Certificates deposited with The Depository Trust Company (the &ldquo;<B><I>Depositary</I></B>&rdquo;) and registered in the name of Cede &amp; Co., a nominee of the Depositary. Ownership of beneficial interests in the Public Warrants shall be shown on, and the transfer of such ownership shall be effected through, records maintained by (i) the Depositary or its nominee for each Book-Entry Warrant Certificate, or (ii) institutions that have accounts with the Depositary (each such institution, with respect to a Warrant in its account, a &ldquo;<B><I>Participant</I></B>&rdquo;).</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Depositary subsequently ceases to make its book-entry settlement system available for the Public Warrants, the Company may instruct the Warrant Agent regarding making other arrangements for book-entry settlement. In the event that the Public Warrants are not eligible for, or it is no longer necessary to have the Public Warrants available in, book-entry form, the Warrant Agent shall provide written instructions to the Depositary to deliver to the Warrant Agent for cancellation each Book-Entry Warrant Certificate, and the Company shall instruct the Warrant Agent to deliver to the Depositary definitive certificates in physical form evidencing such Warrants (&ldquo;<B><I>Definitive Warrant Certificate</I></B>&rdquo;). Such Definitive Warrant Certificate shall be in the form annexed hereto as <U>Exhibit B,</U> with appropriate insertions, modifications and omissions, as provided above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.2.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registered Holder</U>. Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and treat the person in whose name such Warrant is registered in the Warrant Register (the &ldquo;<B><I>Registered Holder</I></B>&rdquo;) as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation of ownership or other writing on a Definitive Warrant Certificate made by anyone other than the Company or the Warrant Agent), for the purpose of any exercise thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Detachability of Warrants</U>. The Class A Shares and Public Warrants comprising the Units shall begin separate trading on the 52nd day following the date of the Prospectus or, if such 52nd day is not on a day, other than a Saturday, Sunday or federal holiday, on which banks in New York City are generally open for normal business (a &ldquo;<B><I>Business Day</I></B>&rdquo;), then on the immediately succeeding Business Day following such date, or earlier (the &ldquo;<B><I>Detachment Date</I></B>&rdquo;) with the consent of D. Boral Capital LLC, as representative of the several underwriters, but in no event shall the Class A Shares and the Public Warrants comprising the Units be separately traded until the Company issues a press release and files with the Commission a Current Report on Form 8-K announcing when such separate trading shall begin. The Private Placement Units shall be eligible to be separated into their component Class A Shares and Warrants on the Detachment Date. Holders of Warrants shall contact the Transfer Agent in order to effect such separation.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Fractional Warrants Other Than as Part of Units</U>. The Company shall not issue fractional Warrants other than as part of the Units, each of which is comprised of one Class A Share and one-half of one Public Warrant. If, upon the detachment of Public Warrants from the Units or otherwise, a holder of Warrants would be entitled to receive a fractional Warrant, the Company shall round down to the nearest whole number the number of Warrants to be issued to such holder.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Private Placement Warrants and Working Capital Warrants</U>. The Private Placement Warrants and Working Capital Warrants shall be identical to the Public Warrants, except that until the date that is thirty (30) days after the completion by the Company of an initial Business Combination the Private Placement Warrants and the Working Capital Warrants may not be transferred, assigned or sold by the holders thereof, other than:</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.1.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to the Company&rsquo;s officers or directors, any affiliate or family member of any of the Company&rsquo;s officers or directors, any members or partners of the Sponsor or their affiliates, any affiliates of the Sponsor, or any employees of such affiliates;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.2.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the case of an individual, by gift to a member of such individual&rsquo;s immediate family or to a trust, the beneficiary of which is a member of such individual&rsquo;s immediate family, an affiliate of such individual or to a charitable organization;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.3.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the case of an individual, by virtue of the laws of descent and distribution upon death of such person;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.4.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the case of an individual, pursuant to a qualified domestic relations order;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.5.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by private sales or transfers made in connection with any forward purchase agreement or similar arrangement, in connection with an extension of the timeframe for the Company to consummate a Business Combination or in connection with the consummation of an initial Business Combination at prices no greater than the price at which the Warrants were originally purchased;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.6.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by pro rata distributions from the Sponsor to its members, partners or stockholders pursuant to the Sponsor&rsquo;s limited liability company agreement or other charter documents;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.7.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by virtue of the laws of the British Virgin Islands or the limited liability company agreement of the Sponsor upon dissolution of the Sponsor;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.8.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the event of the Company&rsquo;s liquidation prior to the consummation of a Business Combination;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.9.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under <U>clauses 2.6.1</U> through <U>2.6.7</U> above;</FONT></TD> </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.10.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to the Company for no value for cancellation in connection with the consummation of an initial Business Combination; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.11.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the event that, subsequent to the consummation of an initial Business Combination, the Company completes a liquidation, merger, share exchange or other similar transaction which results in all of its shareholders having the right to exchange their Class A Shares for cash, securities or other property; <U>provided, however,</U> that, in the case of <U>clauses 2.6.1</U> through <U>2.6.7</U>, and <U>2.6.9</U> these transferees (the &ldquo;<B><I>Permitted Transferees</I></B>&rdquo;) enter into a written agreement with the Company agreeing to be bound by the transfer restrictions in this Agreement and the other restrictions contained in the letter agreement, dated as of the date hereof, by and among the Company, the Sponsor, and the Company&rsquo;s officers and directors.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Working Capital Warrants</U>. Each of the Working Capital Warrants shall be identical to the Private Placement Warrants.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Terms and Exercise of Warrants</U>.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Warrant Price</U>. Each Warrant shall entitle the Registered Holder thereof, subject to the provisions of such Warrant and of this Agreement, including without limitation, <U>subsection&nbsp;3.3.5</U>, to purchase from the Company the number of Class A Shares stated therein, at the price of $11.50 per share, subject to the adjustments provided in <U>Section&nbsp;4</U> hereof and in the last sentence of this <U>Section&nbsp;3.1</U>. The term &ldquo;Warrant Price&rdquo; as used in this Agreement shall mean the price per share (including in cash or by payment of Warrants pursuant to a &ldquo;cashless exercise,&rdquo; to the extent permitted hereunder) described in the prior sentence at which the Class A Shares may be purchased at the time a Warrant is exercised. The Company in its sole discretion may lower the Warrant Price at any time prior to the Expiration Date (as defined below) for a period of not less than twenty (20) Business Days (unless otherwise required by the Commission, any national securities exchange on which the Warrants are listed or applicable law), provided, that the Company shall provide at least three (3) days&rsquo; prior written notice of such reduction to Registered Holders of the Warrants and, provided further that any such reduction shall be identical among all of the Warrants.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Duration of Warrants</U>. A Warrant may be exercised only during the period (the &ldquo;<B><I>Exercise Period</I></B>&rdquo;) (A) commencing on the date that is thirty (30) days after the first date on which the Company completes a Business Combination, and terminating on the earliest to occur of: (x) 5:00 p.m., New York City time on the date that is five (5) years after the date on which the Company completes its initial Business Combination, (y) the liquidation of the Company, and (z) with respect to a redemption pursuant to <U>Section&nbsp;6.1</U> hereof, 5:00 p.m., New York City time on the Redemption Date (as defined below) as provided in <U>Section&nbsp;6.2</U> hereof (the &ldquo;<B><I>Expiration Date</I></B>&rdquo;); provided, however, that the exercise of any Warrant shall be subject to the satisfaction of any applicable conditions, as set forth in <U>subsection&nbsp;3.3.2</U> below, with respect to an effective registration statement or a valid exemption therefrom being available. Each outstanding Warrant not exercised on or before the Expiration Date shall become void, and all rights thereunder and all rights in respect thereof under this Agreement shall cease at 5:00 p.m. New York City time on the Expiration Date. The Company in its sole discretion may extend the duration of the Warrants by delaying the Expiration Date; provided, that the Company shall provide at least twenty (20) days prior written notice of any such extension to Registered Holders of the Warrants and, provided further that any such extension shall be identical in duration among all the Warrants.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exercise of Warrants</U>.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.1.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Payment</U>. Subject to the provisions of the Warrant and this Agreement, including without limitation, <U>subsection&nbsp;3.3.5</U>, a Warrant may be exercised by the Registered Holder thereof by delivering to the Warrant Agent at its corporate trust department (i) the Definitive Warrant Certificate evidencing the Warrants to be exercised, or, in the case of a Book-Entry Warrant Certificate, the Warrants to be exercised (the &ldquo;<B><I>Book-Entry Warrants</I></B>&rdquo;) on the records of the Depositary to an account of the Warrant Agent at the Depositary designated for such purposes in writing by the Warrant Agent to the Depositary from time to time, (ii) an election to purchase (&ldquo;<B><I>Election to Purchase</I></B>&rdquo;) Class A Shares pursuant to the exercise of a Warrant, properly completed and executed by the Registered Holder on the reverse of the Definitive Warrant Certificate or, in the case of a Book-Entry Warrant Certificate, properly delivered by the Participant in accordance with the Depositary&rsquo;s procedures, and (iii) payment in full of the Warrant Price for each Class A Share as to which the Warrant is exercised and any and all applicable taxes due in connection with the exercise of the Warrant, the exchange of the Warrant for the Class A Shares and the issuance of such Class A Shares, as follows:</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in lawful money of the United States, in good bank draft or good certified check payable to the order of the Warrant Agent or by wire transfer of immediately available funds;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the event of a redemption pursuant to <U>Section&nbsp;6</U> hereof in which the Company&rsquo;s board of directors (the &ldquo;<B><I>Board</I></B>&rdquo;) has elected to require all holders of the Warrants to exercise such Warrants on a &ldquo;cashless basis,&rdquo; by surrendering the Warrants for that number of Class A Shares equal to the quotient obtained by dividing (x) the product of the number of Class A Shares underlying the Warrants, multiplied by the excess of the &ldquo;Fair Market Value&rdquo;, as defined in this <U>subsection&nbsp;3.3.1(b)</U>, over the Warrant Price by (y) the Fair Market Value. Solely for purposes of this <U>subsection&nbsp;3.3.1(b)</U> and <U>Section&nbsp;6.3</U>, the &ldquo;Fair Market Value&rdquo; shall mean the average reported closing price of the Class A Shares for the ten (10) trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of the Warrants, pursuant to <U>Section&nbsp;6</U> hereof; or</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on a cashless basis as provided in <U>Section&nbsp;7.4</U> hereof.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.2.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Issuance of Class A Shares on Exercise</U>. As soon as practicable after the exercise of any Warrant and the clearance of the funds in payment of the Warrant Price (if payment is pursuant to <U>subsection&nbsp;3.3.1(a))</U>, the Company shall issue to the Registered Holder of such Warrant a book-entry position or certificate, as applicable, for the number of Class A Shares to which he, she or it is entitled, registered in such name or names as may be directed by him, her or it, and if such Warrant shall not have been exercised in full, a new book-entry position or countersigned Warrant, as applicable, for the number of Class A Shares as to which such Warrant shall not have been exercised. If fewer than all the Warrants evidenced by a Book-Entry Warrant Certificate are exercised, a notation shall be made to the records maintained by the Depositary, its nominee for each Book-Entry Warrant Certificate, or a Participant, as appropriate, evidencing the balance of the Warrants remaining after such exercise. Notwithstanding the foregoing, the Company shall not be obligated to deliver any Class A Shares pursuant to the exercise of a Warrant and shall have no obligation to settle such Warrant exercise unless a registration statement under the Securities Act with respect to the Class A Shares underlying the Public Warrants is then effective and a prospectus relating thereto is current, subject to the Company&rsquo;s satisfying its obligations under <U>Section&nbsp;7.4 or a valid exemption from registration is available</U>. No Warrant shall be exercisable and the Company shall not be obligated to issue Class A Shares upon exercise of a Warrant unless the Class A Shares issuable upon such Warrant exercise have been registered, qualified or deemed to be exempt from registration or qualification under the securities laws of the state of residence of the Registered Holder of the Warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a Warrant, the holder of such Warrant shall not be entitled to exercise such Warrant. In no event will the Company be required to net cash settle the Warrant exercise. The Company may require holders of Public Warrants to settle the Warrant on a &ldquo;cashless basis&rdquo; pursuant to <U>Section&nbsp;7.4</U>. If, by reason of any exercise of Warrants on a &ldquo;cashless basis,&rdquo; the holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a Class A Share, the Company shall round down to the nearest whole number, the number of Class A Shares to be issued to such holder.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.3.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Valid Issuance</U>. All Class A Shares issued upon the proper exercise of a Warrant in conformity with this Agreement shall be validly issued, fully paid and non-assessable.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.4.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Date of Issuance</U>. Each person in whose name any book-entry position or certificate, as applicable, for Class A Shares is issued shall for all purposes be deemed to have become the holder of record of such Class A Shares on the date on which the Warrant, or book-entry position representing such Warrant, was surrendered and payment of the Warrant Price was made, irrespective of the date of delivery of such certificate in the case of a certificated Warrant, except that, if the date of such surrender and payment is a date when the share transfer books of the Company or book-entry system of the Warrant Agent are closed, such person shall be deemed to have become the holder of such Class A Shares at the close of business on the next succeeding date on which the share transfer books or book-entry system are open.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.5.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Maximum Percentage</U>. A holder of a Warrant may notify the Company in writing in the event it elects to be subject to the provisions contained in this <U>subsection&nbsp;3.3.5</U>; <U>however,</U> no holder of a Warrant shall be subject to this <U>subsection&nbsp;3.3.5</U> unless he, she or it makes such election. If the election is made by a holder, the Warrant Agent shall not effect the exercise of the holder&rsquo;s Warrant, and such holder shall not have the right to exercise such Warrant, to the extent that after giving effect to such exercise, such person (together with such person&rsquo;s affiliates) or any &ldquo;group&rdquo; of which the holder or its affiliate is a member, would beneficially own in excess of 4.9% or 9.8% (or such other amount as a holder may specify)(the &ldquo;<B><I>Maximum Percentage</I></B>&rdquo;) of the Class A Shares outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of Class A Shares beneficially owned by such person and its affiliates, or any group of which such person and its affiliates is a member, shall include the number of Class A Shares issuable upon exercise of the Warrant with respect to which the determination of such sentence is being made, but shall exclude Class A Shares that would be issuable upon (x) exercise of the remaining, unexercised portion of the Warrant beneficially owned by such person and its affiliates, or any group of which any such person or its affiliates is a member, and (y) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such person and its affiliates, or any group of which such person or its affiliates is a member (including, without limitation, any convertible notes or convertible preferred shares or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended (the &ldquo;<B><I>Exchange </I>Act</B>&rdquo;), and the applicable regulations of the Commission. For purposes hereof, &ldquo;group&rdquo; has the meaning set forth in Section&nbsp;13(d) of the Exchange Act and applicable regulations of the Commission, and the percentage held by the holder shall be determined in a manner consistent with the provisions of Section&nbsp;13(d) of the Exchange Act. To the extent that a holder makes the election described in this <U>subsection&nbsp;3.3.5</U>, the Warrant Agent shall not effect the exercise of the holder&rsquo;s Warrant, and such holder shall not have the right to exercise such Warrant unless it provides to the Warrant Agent in its Election to Purchase, a certification that, upon after giving effect to such exercise, such person (together with such person&rsquo;s affiliates) or any &ldquo;group&rdquo; of which such holder or its affiliates is a member, would not beneficially own in excess of the Maximum Percentage of the Class A Shares outstanding immediately after giving effect to such exercise as determined in accordance with this <U>subsection&nbsp;3.3.5</U>. For purposes of the Warrant, in determining the number of outstanding Class A Shares, the holder may rely on the number of outstanding Class A Shares as reflected in (1) the Company&rsquo;s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other public filing with the Commission as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or the Transfer Agent setting forth the number of Class A Shares outstanding. For any reason at any time, upon the written request of the holder of the Warrant, the Company shall, within two (2) Business Days, confirm orally and in writing to such holder the number of Class A Shares then outstanding. In any case, the number of outstanding Class A Shares shall be determined after giving effect to the conversion or exercise of equity securities of the Company by the holder and its affiliates since the date as of which such number of outstanding Class A Shares was reported. By written notice to the Company, the holder of a Warrant may from time to time increase or decrease the Maximum Percentage applicable to such holder to any other percentage specified in such notice; <U>provided, however,</U> that any such increase shall not be effective until the sixty-first (61st) day after such notice is delivered to the Company.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="text-align: justify; vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Adjustments</U>.</FONT></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top; width: 0in"></TD>
    <TD STYLE="text-align: justify; vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Share Capitalizations</U>.</FONT></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Sub-division</U>. If after the date hereof, and subject to the provisions of <U>Section&nbsp;4.6</U> below, the number of outstanding Class A Shares is increased by a share capitalization payable in Class A Shares, or by a sub-division of Class A Shares or other similar event, then, on the effective date of such share capitalization, sub-division or similar event, the number of Class A Shares issuable on exercise of each Warrant shall be increased in proportion to such increase in the outstanding Class A Shares. A rights offering made to all or substantially all holders of the Class A Shares entitling holders to purchase Class A Shares at a price less than the &ldquo;Historical Fair Market Value&rdquo; (as defined below) shall be deemed a share capitalization of a number of Class A Shares equal to the product of (i) the number of Class A Shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Class A Shares) and (ii) one (1) minus the quotient of (x) the price per Class A Share paid in such rights offering divided by (y) the Historical Fair Market Value. For purposes of this <U>subsection&nbsp;4.1.1</U>, (i) if the rights offering is for securities convertible into or exercisable for Class A Shares, in determining the price payable for Class A Shares, there shall be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) &ldquo;<B><I>Historical Fair Market Value</I></B>&rdquo; means the volume weighted average price of the Class A Shares as reported during the ten (10) trading day period ending on the trading day prior to the first date on which the Class A Shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. No Class A Shares shall be issued at less than their par value.</FONT></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Extraordinary Dividends</U>. If the Company, at any time while the Warrants are outstanding and unexpired, shall pay a dividend or make a distribution in cash, securities or other assets to all or substantially all of the holders of Class A Shares on account of such Class A Shares (or other shares of the Company&rsquo;s share capital into which the Warrants are convertible), other than (a) as described in <U>subsection&nbsp;4.1.1</U> above, (b) Ordinary Cash Dividends (as defined below), (c) to satisfy the redemption rights of the holders of Class A Shares in connection with a proposed initial Business Combination, (d) to satisfy the redemption rights of the holders of Class A Shares in connection with a shareholder vote to amend the Company&rsquo;s amended and restated memorandum and articles of association (as amended from time to time, the &ldquo;<B><I>Charter</I></B>&rdquo;) (A) to modify the substance or timing of the Company&rsquo;s obligation to allow redemption in connection with the Company&rsquo;s initial business combination or to redeem 100% of the Class A Shares included in the Units sold in the Offering (the &ldquo;<B><I>Public Shares</I></B>&rdquo;) if the Company does not complete the Business Combination within the period set forth in the Charter or (B) with respect to any other material provisions relating to shareholders&rsquo; rights or pre-initial Business Combination activity or (e) in connection with the redemption of Public Shares upon the failure of the Company to complete its initial Business Combination and any subsequent distribution of its assets upon its liquidation (any such non-excluded event being referred to herein as an &ldquo;<B><I>Extraordinary Dividend</I></B>&rdquo;), then the Warrant Price shall be decreased, effective immediately after the effective date of such Extraordinary Dividend, by the amount of cash and/or the fair market value (as determined by the Board, in good faith) of any securities or other assets paid on each Class A Share in respect of such Extraordinary Dividend. For purposes of this <U>subsection&nbsp;4.1.2</U>, &ldquo;<B><I>Ordinary Cash Dividends</I></B>&rdquo; means any cash dividend or cash distribution which, when combined on a per share basis, with the per share amounts of all other cash dividends and cash distributions paid on the Class A Shares during the 365-day period ending on the date of declaration of such dividend or distribution (as adjusted to appropriately reflect any of the events referred to in other subsections of this <U>Section&nbsp;4</U> and excluding cash dividends or cash distributions that resulted in an adjustment to the Warrant Price or to the number of Class A Shares issuable on exercise of each Warrant) does not exceed $0.50 (being 5% of the offering price of the Units in the Offering) but only with respect to the amount of the aggregate cash dividends or cash distributions equal to or less than $0.50. Solely for purposes of illustration, if the Company, at a time while the Warrants are outstanding and unexpired, pays a cash dividend of $0.35 and previously paid an aggregate of $0.40 of cash dividends and cash distributions on the Class A Shares during the 365-day period ending on the date of declaration of such $0.35 dividend, then the Warrant Price will be decreased, effectively immediately after the effective date of such $0.35 dividend, by $0.25 (the absolute value of the difference between $0.75 (the aggregate amount of all cash dividends and cash distributions paid or made in such 365-day period, including such $0.35 dividend) and $0.50 (the greater of (x) $0.50 and (y) the aggregate amount of all cash dividends and cash distributions paid or made in such 365-day period prior to such $0.35 dividend)).</FONT></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Aggregation of Shares</U>. If after the date hereof, and subject to the provisions of <U>Section&nbsp;4.6</U> hereof, the number of outstanding Class A Shares is decreased by a consolidation, combination, reverse share sub-division or reclassification of Class A Shares or other similar event, then, on the effective date of such consolidation, combination, reverse share sub-division, reclassification or similar event, the number of Class A Shares issuable on exercise of each Warrant shall be decreased in proportion to such decrease in outstanding Class A Shares.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Adjustments in Warrant Price</U>.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.1.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever the number of Class A Shares purchasable upon the exercise of the Warrants is adjusted, as provided in <U>subsection&nbsp;4.1.1</U> or <U>Section&nbsp;4.2</U> above, the Warrant Price shall be adjusted (to the nearest cent) by multiplying such Warrant Price immediately prior to such adjustment by a fraction (x) the numerator of which shall be the number of Class A Shares purchasable upon the exercise of the Warrants immediately prior to such adjustment, and (y) the denominator of which shall be the number of Class A Shares so purchasable immediately thereafter.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If (x) the Company issues additional Class A Shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per Class A Share (with such issue price or effective issue price to be determined in good faith by the Board and, in the case of any such issuance to the initial shareholders (as defined in the Prospectus) or their affiliates, without taking into account any Class B Ordinary Shares (as defined below) held by such shareholders or their affiliates, as applicable, prior to such issuance (the &ldquo;<B><I>Newly Issued Price</I></B>&rdquo;)), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for funding the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Class A Shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the Business Combination (such price, the &ldquo;<B><I>Market Value</I></B>&rdquo;) is below $9.20 per share, the Warrant Price shall be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described in <U>Section&nbsp;6.1</U> below shall be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Replacement of Securities
upon Reorganization, etc</U>. In case of any reclassification or reorganization of the outstanding Class A Shares (other than a change
covered by <U>subsections&nbsp;4.1.1</U>, <U>4.1.2</U> or <U>Section&nbsp;4.2</U> hereof or that solely affects the par value of such
Class A Shares), or in the case of any merger or consolidation of the Company with or into another entity or conversion of the Company
as another entity (other than a consolidation or merger in which the Company is the continuing corporation and is not a subsidiary of
another entity whose shareholders did not own all or substantially all of the Class A Shares of the Company in substantially the same
proportions immediately before such transaction and that does not result in any reclassification or reorganization of the outstanding
Class A Shares), or in the case of any sale or conveyance to another entity of the assets or other property of the Company as an entirety
or substantially as an entirety in connection with which the Company is dissolved, the holders of the Warrants shall thereafter have
the right to purchase and receive, upon the basis and upon the terms and conditions specified in the Warrants and in lieu of the Class
A Shares of the Company immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind
and amount of shares or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or
consolidation, or upon a dissolution following any such sale or transfer, that the holder of the Warrants would have received if such
holder had exercised his, her or its Warrant(s) immediately prior to such event (the &ldquo;<B><I>Alternative Issuance</I></B>&rdquo;);
<U>provided</U>, <U>however</U>, that (i) if the holders of the Class A Shares were entitled to exercise a right of election as to the
kind or amount of securities, cash or other assets receivable upon such consolidation or merger, then the kind and amount of securities,
cash or other assets constituting the Alternative Issuance for which each Warrant shall become exercisable shall be deemed to be the
weighted average of the kind and amount received per share by the holders of the Class A Shares in such consolidation or merger that
affirmatively make such election, and (ii) if a tender, exchange or redemption offer shall have been made to and accepted by the holders
of the Class A Shares (other than a tender, exchange or redemption offer made by the Company in connection with redemption rights held
by shareholders of the Company as provided for in the Charter or as a result of the redemption of Class A Shares by the Company if a
proposed initial Business Combination is presented to the shareholders of the Company for approval) under circumstances in which, upon
completion of such tender or exchange offer, the maker thereof, together with members of any group (within the meaning of Rule&nbsp;13d-5(b)(1)
under the Exchange Act (or any successor rule)) of which such maker is a part, and together with any affiliate or associate of such maker
(within the meaning of Rule&nbsp;12b-2 under the Exchange Act (or any successor rule)) and any members of any such group of which any
such affiliate or associate is a part, own beneficially (within the meaning of Rule&nbsp;13d-3 under the Exchange Act (or any successor
rule)) more than 65% of the voting power of the Company&rsquo;s outstanding equity securities (including with respect to the election
of directors), the holder of a Warrant shall be entitled to receive as the Alternative Issuance, the weighted average of the amount of
cash, securities or other property to which such holder would actually have been entitled as a shareholder if such Warrant holder had
exercised the Warrant prior to the expiration of such tender or exchange offer, accepted such offer and participated in such tender or
exchange offer on a pro rata basis with all other holders of Class A Shares, subject to adjustments (from and after the consummation
of such tender or exchange offer) as nearly equivalent as possible to the adjustments provided for in this <U>Section&nbsp;4</U>.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provisions of this <U>Section&nbsp;4.4</U> shall similarly apply to successive
reclassifications, reorganizations, mergers or consolidations, sales or other transfers. In no event will the Warrant Price be
reduced to less than the par value per share issuable upon exercise of the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices of Changes in Warrant</U>. Upon every adjustment of the Warrant Price or the number of Class A Shares issuable upon exercise of a Warrant, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Warrant Price resulting from such adjustment and the increase or decrease, if any, in the number of Class A Shares purchasable at such price upon the exercise of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon the occurrence of any event specified in <U>Sections&nbsp;4.1</U>, <U>4.2</U>, <U>4.3</U> or <U>4.4</U>, the Company shall give written notice of the occurrence of such event to each holder of a Warrant, at the last address set forth for such holder in the Warrant Register, of the record date or the effective date of the event. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such event.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Fractional Shares</U>. Notwithstanding any provision contained in this Agreement to the contrary, the Company shall not issue fractional Class A Shares upon the exercise of Warrants. If, by reason of any adjustment made pursuant to this <U>Section&nbsp;4,</U> the holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share, the Company shall, upon such exercise, round down to the nearest whole number the number of Class A Shares to be issued to such holder.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Form of Warrant</U>. The form of Warrant need not be changed because of any adjustment pursuant to this <U>Section&nbsp;4,</U> and Warrants issued after such adjustment may state the same Warrant Price and the same number of Class A Shares as is stated in the Warrants initially issued pursuant to this Agreement; <U>provided, however,</U> that the Company may at any time in its sole discretion make any change in the form of Warrant that the Company may deem appropriate and that does not affect the substance thereof, and any Warrant thereafter issued or countersigned, whether in exchange or substitution for an outstanding Warrant or otherwise, may be in the form as so changed.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other Events</U>. In case any event shall occur affecting the Company as to which none of the provisions of the preceding subsections of this <U>Section&nbsp;4</U> are strictly applicable, but which would require an adjustment to the terms of the Warrants in order to (i) avoid an adverse impact on the Warrants and (ii) effectuate the intent and purpose of this <U>Section&nbsp;4</U>, then, in each such case, the Company shall appoint a firm of independent public accountants, investment banking or other appraisal firm of recognized national standing, which shall give its opinion as to whether or not any adjustment to the rights represented by the Warrants is necessary to effectuate the intent and purpose of this <U>Section&nbsp;4</U> and, if they determine that an adjustment is necessary, the terms of such adjustment. The Company shall adjust the terms of the Warrants in a manner that is consistent with any adjustment recommended in such opinion. For the avoidance of doubt, all adjustments made pursuant to this <U>Section&nbsp;4.8</U> shall be made equally to all outstanding Warrants.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Adjustment</U>. For the avoidance of doubt, no adjustment shall be made to the terms of the Warrants solely as a result of an adjustment to the conversion ratio of the Company&rsquo;s Class B ordinary shares (the &ldquo;<B><I>Class B Ordinary Shares</I></B>&rdquo;) into Class A Shares or the conversion of the Class B Ordinary Shares into Class A Shares, in each case, pursuant to the Charter.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transfer and Exchange of Warrants</U>.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration of Transfer</U>. The Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant upon the Warrant Register, upon surrender of such Warrant for transfer, in the case of a certificated Warrant, properly endorsed with signatures properly guaranteed and accompanied by appropriate instructions for transfer. Upon any such transfer, a new Warrant representing an equal aggregate number of Warrants shall be issued and the old Warrant shall be cancelled by the Warrant Agent. In the case of certificated Warrants, the Warrants so cancelled shall be delivered by the Warrant Agent to the Company from time to time upon request.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Procedure for Surrender of Warrants</U>. Warrants may be surrendered to the Warrant Agent, together with a written request for exchange or transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the Registered Holder of the Warrants so surrendered, representing an equal aggregate number of Warrants; <U>provided, however,</U> that except as otherwise provided herein or in any Book-Entry Warrant Certificate or Definitive Warrant Certificate, each Book-Entry Warrant Certificate and Definitive Warrant Certificate may be transferred only in whole and only to the Depositary, to another nominee of the Depositary, to a successor depository, or to a nominee of a successor depository; <U>provided further, however,</U> that in the event that a Warrant surrendered for transfer bears a restrictive legend (as in the case of the Private Placement Warrants and the Working Capital Warrants), the Warrant Agent shall not cancel such Warrant and issue new Warrants in exchange thereof until the Warrant Agent has received an opinion of counsel for the Company stating that such transfer may be made and indicating whether the new Warrants must also bear a restrictive legend.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Fractional Warrants</U>. The Warrant Agent shall not be required to effect any registration of transfer or exchange which shall result in the issuance of a warrant certificate or book-entry position for a fraction of a warrant, except as part of the Units.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Service Charges</U>. No service charge shall be made for any exchange or registration of transfer of Warrants.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Warrant Execution and Countersignature</U>. The Warrant Agent is hereby authorized to countersign and to deliver, in accordance with the terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this <U>Section&nbsp;5,</U> and the Company, whenever required by the Warrant Agent, shall supply the Warrant Agent with Warrants duly executed on behalf of the Company for such purpose.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transfer of Warrants</U>. Prior to the Detachment Date, the Public Warrants may be transferred or exchanged only together with the Unit in which such Warrant is included, and only for the purpose of effecting, or in conjunction with, a transfer or exchange of such Unit. Furthermore, each transfer of a Unit on the register relating to such Units shall operate also to transfer the Warrants included in such Unit. Notwithstanding the foregoing, the provisions of this <U>Section&nbsp;5.6</U> shall have no effect on any transfer of Warrants on and after the Detachment Date.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Redemption</U>.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Redemption of Warrants for Cash</U>. All, but not less than all, of the outstanding Warrants may be redeemed (in whole and not in part), at the option of the Company, at any time during the Exercise Period, at the office of the Warrant Agent, upon notice to the Registered Holders of the Warrants, as described in <U>Section&nbsp;6.2</U> below, at a Redemption Price (as defined below) of $0.01 per Warrant; <U>provided</U> that (a) the Reference Value equals or exceeds $18.00 per share (subject to adjustment in compliance with <U>Section&nbsp;4</U> hereof) and (b) there is an effective registration statement covering the Class A Shares issuable upon exercise of the Warrants, and a current prospectus relating thereto, available throughout the Measurement Period and the 30-day Redemption Period (each as defined in <U>Section&nbsp;6.2</U> below).</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Date Fixed for, and Notice of, Redemption; Redemption Price; Reference Value</U>. In the event that the Company elects to redeem the Warrants pursuant to <U>Section&nbsp;6.1</U>, the Company shall fix a date for the redemption (the &ldquo;<B><I>Redemption Date</I></B>&rdquo;). Notice of redemption shall be mailed by first class mail, postage prepaid, by the Company not less than thirty (30) days prior to the Redemption Date (such period, the &ldquo;<B><I>Redemption Period</I></B>&rdquo;) to the Registered Holders of the Warrants to be redeemed at their last addresses as they shall appear on the registration books. Any notice mailed in the manner herein provided shall be conclusively presumed to have been duly given whether or not the Registered Holder received such notice. As used in this Agreement, (a) &ldquo;<B><I>Redemption Price</I></B>&rdquo; shall mean the price per Warrant at which any Warrants are redeemed pursuant to <U>Sections&nbsp;6.1</U> and (b) &ldquo;<B><I>Reference Value</I></B>&rdquo; shall mean the last reported sales price of the Class A Shares for any twenty (20) trading days within the thirty (30) trading-day period commencing at least 30 days after the completion of the initial Business Combination and ending on the third trading day prior to the date on which notice of the redemption is given (the &ldquo;<B><I>Measurement Period</I></B>&rdquo;).</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exercise After Notice of Redemption</U>. The Warrants may be exercised, for cash (or on a &ldquo;cashless basis&rdquo; in accordance with <U>Section&nbsp;3</U> of this Agreement) at any time after notice of redemption shall have been given by the Company pursuant to <U>Section&nbsp;6.2</U> hereof and prior to the Redemption Date. In the event the Company determines to require all holders of Warrants to exercise their Warrants on a &ldquo;cashless basis&rdquo; pursuant to <U>subsection&nbsp;3.3.1(b)</U>, the notice of redemption will contain the information necessary to calculate the number of Class A Shares to be received upon exercise of the Warrants, including the &ldquo;Fair Market Value&rdquo; (as such term is defined in subsection&nbsp;3.3.1(b) hereof) in such case. On and after the Redemption Date, the record holder of the Warrants shall have no further rights except to receive, upon surrender of the Warrants, the Redemption Price.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other Provisions Relating to Rights of Holders of Warrants</U>.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Rights as Shareholder</U>. A Warrant does not entitle the Registered Holder thereof to any of the rights of a shareholder of the Company, including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights to vote or to consent or to receive notice as shareholders in respect of the meetings of shareholders or the election of directors of the Company or any other matter.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Lost, Stolen, Mutilated, or Destroyed Warrants</U>. If any Warrant is lost, stolen, mutilated, or destroyed, the Company and the Warrant Agent may on such terms as to indemnity or otherwise as they may in their discretion impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor, and date as the Warrant so lost, stolen, mutilated, or destroyed. Any such new Warrant shall constitute a substitute contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated, or destroyed Warrant shall be at any time enforceable by anyone.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Reservation of Class A Shares</U>. The Company shall at all times reserve and keep available a number of its authorized but unissued Class A Shares that shall be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration of Class A Shares; Cashless Exercise at Company&rsquo;s Option</U>.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4.1.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration of the Class A Shares</U>. The Company agrees that as soon as practicable, but in no event later than twenty (20) Business Days after the closing of its initial Business Combination, it shall use its commercially reasonable efforts to file with the Commission a post-effective amendment to the Registration Statement, or a new registration statement registering, under the Securities Act, the issuance of the Class A Shares issuable upon exercise of the Warrants. The Company shall use its commercially reasonable efforts to cause the same to become effective and to maintain the effectiveness of such post-effective amendment or registration statement, and a current prospectus relating thereto, until the expiration or redemption of the Warrants in accordance with the provisions of this Agreement. If any such post-effective or registration statement has not been declared effective by the sixtieth (60th) Business Day following the closing of the initial Business Combination, holders of the Warrants shall have the right, during the period beginning on the sixty-first (61st) Business Day after the closing of the initial Business Combination and ending upon such post-effective amendment or registration statement being declared effective by the Commission, and during any other period when the Company shall fail to have maintained an effective registration statement covering the Class A Shares issuable upon exercise of the Warrants, to exercise such Warrants on a &ldquo;cashless basis,&rdquo; by exchanging the Warrants (in accordance with Section&nbsp;3(a)(9) of the Securities Act (or any successor rule) or another exemption) for that number of Class A Shares equal to the quotient obtained by dividing (x) the product of the number of Class A Shares underlying the Warrants, multiplied by the excess of the &ldquo;Fair Market Value&rdquo; (as defined below) over the Warrant Price by (y) the Fair Market Value. Solely for purposes of this <U>subsection&nbsp;7.4.1</U>, &ldquo;Fair Market Value&rdquo; shall mean the average reported closing price of the Class A Shares as reported during the ten (10) trading day period ending on the third (3<SUP>rd</SUP>) trading day prior to the date that notice of exercise is received by the Warrant Agent from the holder of such Warrants or its securities broker or intermediary. The date that notice of &ldquo;cashless exercise&rdquo; is received by the Warrant Agent shall be conclusively determined by the Warrant Agent. In connection with the &ldquo;cashless exercise&rdquo; of a Public Warrant, the Company shall, upon request, provide the Warrant Agent with an opinion of counsel for the Company (which shall be an outside law firm with securities law experience) stating that (i) the exercise of the Warrants on a &ldquo;cashless basis&rdquo; in accordance with this <U>subsection&nbsp;7.4.1</U> is not required to be registered under the Securities Act and (ii) the Class A Shares issued upon such exercise shall be freely tradable under United States federal securities laws by anyone who is not an affiliate (as such term is defined in Rule&nbsp;144 under the Securities Act (or any successor rule)) of the Company and, accordingly, shall not be required to bear a restrictive legend. Except as provided in <U>subsection&nbsp;7.4.2</U>, for the avoidance of any doubt, unless and until all of the Warrants have been exercised or have expired, the Company shall continue to be obligated to comply with its registration obligations under the first three sentences of this <U>subsection&nbsp;7.4.1</U>.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4.2.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Cashless Exercise at Company&rsquo;s Option</U>. If the Class A Shares are at the time of any exercise of a Warrant not listed on a national securities exchange such that they satisfy the definition of &ldquo;covered securities&rdquo; under Section&nbsp;18(b)(1) of the Securities Act (or any successor rule), the Company may, at its option, require holders of Warrants who exercise their Warrants to exercise such Public Warrants on a &ldquo;cashless basis&rdquo; in accordance with Section&nbsp;3(a)(9) of the Securities Act (or any successor rule) as described in <U>subsection&nbsp;7.4.1</U> and (i) in the event the Company so elects, the Company shall not be required to file or maintain in effect a registration statement for the registration, under the Securities Act, of the Class A Shares issuable upon exercise of the Warrants, notwithstanding anything in this Agreement to the contrary or (ii) if the Company does not so file or maintain such registration statement, the Company agrees to use its commercially reasonable efforts to register or qualify for sale the Class A Shares issuable upon exercise of the Public Warrants under the applicable blue sky laws of the state of residence of the exercising Public Warrant holder to the extent an exemption is not available.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Concerning the Warrant Agent and Other Matters</U>.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Payment of Taxes</U>. The Company shall from time to time promptly pay all taxes and charges that may be imposed upon the Company or the Warrant Agent in respect of the issuance or delivery of Class A Shares upon the exercise of the Warrants, but the Company shall not be obligated to pay any transfer taxes in respect of the Warrants or such Class A Shares.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Resignation, Consolidation, or Merger of Warrant Agent</U>.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.1.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Appointment of Successor Warrant Agent</U>. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged from all further duties and liabilities hereunder after giving sixty (60) days&rsquo; notice in writing to the Company. If the office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of thirty (30) days after it has been notified in writing of such resignation or incapacity by the Warrant Agent or by the holder of a Warrant (who shall, with such notice, submit his, her or its Warrant for inspection by the Company), then the holder of any Warrant may apply to the Supreme Court of the State of New York for the County of New York for the appointment of a successor Warrant Agent at the Company&rsquo;s cost. Any successor Warrant Agent, whether appointed by the Company or by such court, shall be a corporation or other entity organized and existing under the laws of the State of New York, in good standing and having its principal office in the Borough of Manhattan, City and State of New York, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination by federal or state authority. After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without any further act or deed; but if for any reason it becomes necessary or appropriate, the predecessor Warrant Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all the authority, powers, and rights of such predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.2.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notice of Successor Warrant Agent</U>. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof to the predecessor Warrant Agent and the Transfer Agent for the Class A Shares not later than the effective date of any such appointment.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.3.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Merger or Consolidation of Warrant Agent</U>. Any entity into which the Warrant Agent may be merged or with which it may be consolidated or any entity resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor Warrant Agent under this Agreement without any further act.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Fees and Expenses of Warrant Agent</U>.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3.1.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Remuneration</U>. The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such Warrant Agent hereunder and shall, pursuant to its obligations under this Agreement, reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably incur in the execution of its duties hereunder.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3.2.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Further Assurances</U>. The Company agrees to perform, execute, acknowledge, and deliver or cause to be performed, executed, acknowledged, and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the Warrant Agent for the carrying out or performing of the provisions of this Agreement.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Liability of Warrant Agent</U>.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4.1.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Reliance on Company Statement</U>. Whenever in the performance of its duties under this Agreement, the Warrant Agent shall deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a statement signed by the Chief Executive Officer, Chief Financial Officer, President, Executive Vice President, Vice President, Secretary or Chairman of the Board of the Company and delivered to the Warrant Agent. The Warrant Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant to the provisions of this Agreement.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4.2.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Indemnity</U>. The Warrant Agent shall be liable hereunder only for its own gross negligence, willful misconduct, fraud or bad faith. The Company agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, out of pocket costs and reasonable outside counsel fees, for anything done or omitted by the Warrant Agent in the execution of this Agreement, except as a result of the Warrant Agent&rsquo;s gross negligence, willful misconduct, fraud or bad faith.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4.3.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exclusions</U>. The Warrant Agent shall have no responsibility with respect to the validity of this Agreement or with respect to the validity or execution of any Warrant (except its countersignature thereof). The Warrant Agent shall not be responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant. The Warrant Agent shall not be responsible to make any adjustments required under the provisions of <U>Section&nbsp;4</U> hereof or responsible for the manner, method, or amount of any such adjustment or the ascertaining of the existence of facts that would require any such adjustment; nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any Class A Shares to be issued pursuant to this Agreement or any Warrant or as to whether any Class A Shares shall, when issued, be valid and fully paid and non-assessable.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Acceptance of Agency</U>. The Warrant Agent hereby accepts the agency established by this Agreement and agrees to perform the same upon the terms and conditions herein set forth and among other things, shall account promptly to the Company with respect to Warrants exercised and concurrently account for, and pay to the Company, all monies received by the Warrant Agent for the purchase of Class A Shares through the exercise of the Warrants.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.6.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Waiver</U>. The Warrant Agent has no right of set-off or any other right, title, interest or claim of any kind (&ldquo;<B><I>Claim</I></B>&rdquo;) in, or to any distribution of, the Trust Account (as defined in that certain Investment Management Trust Agreement, dated as of the date hereof, by and between the Company and the Warrant Agent as trustee thereunder) and hereby agrees not to seek re0.5incourse, reimbursement, payment or satisfaction for any Claim against the Trust Account for any reason whatsoever. The Warrant Agent hereby irrevocably waives any and all Claims against the Trust Account, including any monies therein or any distribution therefrom, and any and all rights to seek access to the Trust Account.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous Provisions</U>.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Successors</U>. All the covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure to the benefit of their respective successors and assigns.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices</U>. Any notice, statement or demand authorized by this Agreement to be given or made by the Warrant Agent or by the holder of any Warrant to or on the Company shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier service within five (5) days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the Company with the Warrant Agent), as follows:</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D. Boral ARC Acquisition I Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10 E. 53rd Street, Suite 3001</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, New York 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: David Boral, Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any notice, statement or demand authorized by this Agreement to be given or made by the holder of any Warrant or by the Company to or on the Warrant Agent shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier service within five (5) days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the Warrant Agent with the Company), as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Odyssey Transfer and Trust Company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATTN: Operations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2155 Woodlane Drive Suite 100</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Woodbury, MN 55125</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: BPaulson@OdysseyTrust.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in each case, with copies to:</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Hastings LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200 Park Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, NY 10166</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: Gil Savir, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
gilsavir@paulhastings.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D. Boral Capital LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">590 Madison Avenue, 39th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, New York 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: Mr.&nbsp;Gaurav Verma, Co-Head of Investment Banking</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: gverma@dboralcapital.com</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loeb&amp; Loeb LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">345 Park Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, New York 10154</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel: (212) 407-4000</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: David Levine, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: dlevine@loeb.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Applicable Law and Exclusive Forum</U>. The validity, interpretation, and performance of this Agreement and of the Warrants shall be governed in all respects by the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. The Company hereby agrees that any action, proceeding or claim against it arising out of or relating in any way to this Agreement, including under the Securities Act, shall be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be the exclusive forum for any such action, proceeding or claim. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Notwithstanding the foregoing, the provisions of this paragraph will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal district courts of the United States of America are the sole and exclusive forum. Any person or entity purchasing or otherwise acquiring any interest in the Warrants shall be deemed to have notice of and to have consented to the forum provisions in this <U>Section&nbsp;9.3</U>. If any action, the subject matter of which is within the scope the forum provisions above, is filed in a court other than a court located within the State of New York or the United States District Court for the Southern District of New York (a &ldquo;<B><I>foreign action</I></B>&rdquo;) in the name of any warrant holder, such warrant holder shall be deemed to have consented to: (x) the personal jurisdiction of the state and federal courts located within the State of New York or the United States District Court for the Southern District of New York in connection with any action brought in any such court to enforce the forum provisions (an &ldquo;<B><I>enforcement action</I></B>&rdquo;), and (y) having service of process made upon such warrant holder in any such enforcement action by service upon such warrant holder&rsquo;s counsel in the foreign action as agent for such warrant holder.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Persons Having Rights under this Agreement</U>. Nothing in this Agreement shall be construed to confer upon, or give to, any person, corporation or other entity other than the parties hereto and the Registered Holders of the Warrants any right, remedy, or claim under or by reason of this Agreement or of any covenant, condition, stipulation, promise, or agreement hereof. All covenants, conditions, stipulations, promises, and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors and assigns and of the Registered Holders of the Warrants.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Examination of the Warrant Agreement</U>. A copy of this Agreement shall be available at all reasonable times at the office of the Warrant Agent in the Borough of Manhattan, City and State of New York, for inspection by the Registered Holder of any Warrant. The Warrant Agent may require any such holder to submit such holder&rsquo;s Warrant for inspection by the Warrant Agent.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Counterparts</U>. This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Effect of Headings</U>. The section headings herein are for convenience only and are not part of this Agreement and shall not affect the interpretation thereof.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.8.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amendments</U>. This Agreement may be amended by the parties hereto without the consent of any Registered Holder (i) for the purpose of (x) curing any ambiguity or to correct any defective provision contained herein, including to conform the provisions hereof to the description of the terms of the Warrants and this Agreement set forth in the Prospectus, (y) adjusting the definition of &ldquo;Ordinary Cash Dividend&rdquo; as contemplated by and in accordance with the second sentence of <U>subsection&nbsp;4.1.2</U> or (z) adding or changing any other provisions with respect to matters or questions arising under this Agreement as the parties may deem necessary or desirable and that the parties deem shall not adversely affect the interest of the Registered Holders, and (ii) to provide for the delivery of an Alternative Issuance pursuant to <U>Section&nbsp;4.4</U>. All other modifications or amendments, including any modification or amendment to increase the Warrant Price or shorten the Exercise Period shall require the vote or written consent of the Registered Holders of 50% of the number of the then outstanding Public Warrants and, solely with respect to any amendment to the terms of the Private Placement Warrants or Working Capital Warrants or any provision of this Agreement with respect to the Private Placement Warrants, or Working Capital Warrants (including, for the avoidance of doubt, the forfeiture or cancellation of any Private Placement Warrants or Working Capital Warrants), 50% of the number of then outstanding Private Placement Warrants and Working Capital Warrants. Notwithstanding the foregoing, the Company may lower the Warrant Price or extend the duration of the Exercise Period pursuant to <U>Sections&nbsp;3.1</U> and <U>3.2,</U> respectively, without the consent of the Registered Holders.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.9.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Severability</U>. This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature Page Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>D. BORAL ARC ACQUISITION I CORP.</B></FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Boral</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ODYSSEY TRANSFER AND TRUST COMPANY</B>, as Warrant Agent</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature Page to Warrant Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRIVATE PLACEMENT WARRANTS LEGEND</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE. IN ADDITION, SUBJECT TO ANY ADDITIONAL LIMITATIONS ON TRANSFER DESCRIBED IN THE AGREEMENTS BY AND AMONG D. BORAL ARC ACQUISITION I CORP. (THE &ldquo;COMPANY&rdquo;), MFH 1, LLC AND THE OTHER SIGNATORIES THERETO, THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD OR TRANSFERRED PRIOR TO THE DATE UPON WHICH THE COMPANY COMPLETES ITS INITIAL BUSINESS COMBINATION (AS DEFINED IN SECTION 3 OF THE WARRANT AGREEMENT REFERRED TO HEREIN) EXCEPT TO A PERMITTED TRANSFEREE WHO AGREES IN WRITING WITH THE COMPANY TO BE SUBJECT TO SUCH TRANSFER PROVISIONS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES
EVIDENCED BY THIS CERTIFICATE AND ORDINARY SHARES OF THE COMPANY ISSUED UPON EXERCISE OF SUCH SECURITIES SHALL BE ENTITLED TO REGISTRATION
RIGHTS UNDER A REGISTRATION RIGHTS AGREEMENT TO BE EXECUTED BY THE COMPANY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 18; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Form
of Warrant Certificate]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[FACE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS WARRANT SHALL BE VOID IF NOT EXERCISED PRIOR TO<BR>THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR IN THE<BR>WARRANT AGREEMENT DESCRIBED BELOW</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>D.
BORAL ARC ACQUISITION I CORP.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Incorporated Under the Laws of the British Virgin Islands</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CUSIP [_]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrant Certificate</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>This Warrant Certificate certifies that,</B> or registered assigns, is the registered holder of warrants evidenced hereby (the <B>&ldquo;Warrants&rdquo; </B>and each, a <B>&ldquo;Warrant&rdquo;</B>) to purchase Class A Ordinary Shares, $0.0001 par value per share (the <B>&ldquo;Ordinary Shares&rdquo;</B>), of D. Boral ARC Acquisition I Corp., a BVI business company (the <B>&ldquo;Company&rdquo;</B>). Each whole Warrant entitles the holder, upon exercise during the period set forth in the Warrant Agreement referred to below, to receive from the Company that number of fully paid and non-assessable Ordinary Shares as set forth below, at the exercise price (the <B>&ldquo;Warrant Price&rdquo;</B>) as determined pursuant to the Warrant Agreement, payable in lawful money (or through &ldquo;cashless exercise&rdquo; as provided for in the Warrant Agreement) of the United States of America upon surrender of this Warrant Certificate and payment of the Warrant Price at the office or agency of the Warrant Agent referred to below, subject to the conditions set forth herein and in the Warrant Agreement. Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each whole Warrant is initially exercisable for one fully paid and non-assessable Ordinary Share. No fractional shares will be issued upon exercise of any Warrant. If, upon the exercise of Warrants, a holder would be entitled to receive a fractional interest in an Ordinary Share, the Company will, upon exercise, round down to the nearest whole number the number of Ordinary Shares to be issued to the Warrant holder. The number of Ordinary Shares issuable upon exercise of the Warrants is subject to adjustment upon the occurrence of certain events set forth in the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The initial Warrant Price per Ordinary Share for any Warrant is equal to $11.50 per share. The Warrant Price is subject to adjustment upon the occurrence of certain events set forth in the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the conditions set forth in the Warrant Agreement, the Warrants may be exercised only during the Exercise Period and to the extent not exercised by the end of such Exercise Period, such Warrants shall become void. The Warrants may be redeemed, subject to certain conditions, as set forth in the Warrant Agreement. In addition, and notwithstanding anything else in this Warrant Certificate or the Warrant Agreement, to the extent that the holder of a Warrant has delivered a notice contemplated by <U>subsection&nbsp;3.5.5</U> of the Warrant Agreement, neither the Company nor the Warrant Agent shall issue to Holder, and Holder may not acquire, any right it might have to acquire, a number of Ordinary Shares upon exercise of any Warrant to the extent that, upon such exercise, the number of Ordinary Shares then beneficially owned by Holder would exceed the Maximum Percentage of Ordinary Shares outstanding immediately after giving effect to such exercise as determined in accordance with <U>subsection&nbsp;3.3.5</U>. of the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 19; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference is hereby made to the further provisions of this Warrant Certificate set forth on the reverse hereof and such further provisions shall for all purposes have the same effect as though fully set forth at this place.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Warrant Certificate shall not be valid unless countersigned by the Warrant Agent, as such term is used in the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Warrant Certificate shall be governed by and construed in accordance with the internal laws of the State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D. BORAL ARC ACQUISITION I CORP.</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left; vertical-align: top; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David Boral</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> David Boral</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ODYSSEY TRANSFER AND TRUST COMPANY as Warrant Agent</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left; vertical-align: top; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Rebecca Paulson</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rebecca Paulson</FONT></TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Form of Warrant Certificate]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reverse]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Warrants evidenced by this Warrant Certificate are part of a duly authorized issue of Warrants entitling the holder on exercise to receive Ordinary Shares and are issued or to be issued pursuant to a Warrant Agreement dated as of [_], 2025 (the <B>&ldquo;Warrant Agreement&rdquo;</B>), duly executed and delivered by the Company to Odyssey Transfer and Trust Company, a corporation organized under the laws of Minnesota, as warrant agent (the <B>&ldquo;Warrant Agent&rdquo;</B>), which Warrant Agreement is hereby incorporated by reference in and made a part of this instrument and is hereby referred to for a description of the rights, limitation of rights, obligations, duties and immunities thereunder of the Warrant Agent, the Company and the holders (the words <B>&ldquo;holders&rdquo; </B>or <B>&ldquo;holder&rdquo;</B> meaning the Registered Holders or Registered Holder, respectively) of the Warrants. A copy of the Warrant Agreement may be obtained by the holder hereof upon written request to the Company. Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants may be exercised at any time during the Exercise Period set forth in the Warrant Agreement. The holder of Warrants evidenced by this Warrant Certificate may exercise them by surrendering this Warrant Certificate, with the form of election to purchase set forth hereon properly completed and executed, together with payment of the Warrant Price as specified in the Warrant Agreement (or through &ldquo;cashless exercise&rdquo; as provided for in the Warrant Agreement) at the principal corporate trust office of the Warrant Agent. In the event that upon any exercise of Warrants evidenced hereby the number of Warrants exercised shall be less than the total number of Warrants evidenced hereby, there shall be issued to the holder hereof or his, her or its assignee, a new Warrant Certificate evidencing the number of Warrants not exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding anything else in this Warrant Certificate or the Warrant Agreement, no Warrant may be exercised unless at the time of exercise (i) a registration statement covering the Ordinary Shares to be issued upon exercise is effective under the Securities Act of 1933, as amended, and (ii) a prospectus thereunder relating to the Ordinary Shares is current, except through &ldquo;cashless exercise&rdquo; as provided for in the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Warrant Agreement provides that upon the occurrence of certain events the number of Ordinary Shares issuable upon the exercise of the Warrants set forth on the face hereof may, subject to certain conditions, be adjusted. If, upon exercise of a Warrant, the holder thereof would be entitled to receive a fractional interest in an Ordinary Share, the Company shall, upon exercise, round down to the nearest whole number of Ordinary Shares to be issued to the holder of the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Certificates, when surrendered at the principal corporate trust office of the Warrant Agent by the Registered Holder thereof in person or by legal representative or attorney duly authorized in writing, may be exchanged, in the manner and subject to the limitations provided in the Warrant Agreement, but without payment of any service charge, for another Warrant Certificate or Warrant Certificates of like tenor evidencing in the aggregate a like number of Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon due presentation for registration of transfer of this Warrant Certificate at the office of the Warrant Agent, a new Warrant Certificate or Warrant Certificates of like tenor and evidencing in the aggregate a like number of Warrants shall be issued to the transferee(s) in exchange for this Warrant Certificate, subject to the limitations provided in the Warrant Agreement, without charge except for any tax or other governmental charge imposed in connection therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and the Warrant Agent may deem and treat the Registered Holder(s) hereof as the absolute owner(s) of this Warrant Certificate (notwithstanding any notation of ownership or other writing hereon made by anyone), for the purpose of any exercise hereof, of any distribution to the holder(s) hereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary. Neither the Warrants nor this Warrant Certificate entitles any holder hereof to any rights of a shareholder of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Election to Purchase</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(To Be Executed Upon Exercise of Warrant)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Certificate, to receive Ordinary Shares and
herewith tenders payment for such Ordinary Shares to the order of D. Boral ARC Acquisition I Corp. (the <B>&ldquo;Company&rdquo;</B>)
in the amount of $_____ in accordance with the terms hereof. The undersigned requests that a certificate for such Ordinary Shares be
registered in the name of, whose address is, and that such Ordinary Shares be delivered to, whose address is. If said number of
Ordinary Shares is less than all of the Ordinary Shares purchasable hereunder, the undersigned requests that a new Warrant
Certificate representing the remaining balance of such Ordinary Shares be registered in the name of, ______ whose address is _______
and that such Warrant Certificate be delivered to ______, whose address is ________.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event that the Warrant has been called for redemption by the Company pursuant to <U>Section&nbsp;6.1</U> of the Warrant Agreement and the Company has required &ldquo;cashless&rdquo; exercise pursuant to <U>Section&nbsp;6.3</U> and <U>Section&nbsp;3.3.1(b)</U> of the Warrant Agreement, the number of Ordinary Shares that this Warrant is exercisable for shall be determined in accordance with <U>Section&nbsp;6.3</U> and <U>Section&nbsp;3.3.1(b)</U> of the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event that the Warrant is to be exercised on a &ldquo;cashless&rdquo; basis pursuant to <U>Section&nbsp;7.4</U> of the Warrant Agreement, the number of Ordinary Shares that this Warrant is exercisable for shall be determined in accordance with <U>Section&nbsp;7.4</U> of the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event that the Warrant may be exercised, to the extent allowed by the Warrant Agreement, through cashless exercise (i) the number of Ordinary Shares that this Warrant is exercisable for would be determined in accordance with the relevant section of the Warrant Agreement which allows for such cashless exercise and (ii) the holder hereof shall complete the following: The undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Certificate, through the cashless exercise provisions of the Warrant Agreement, to receive Ordinary Shares. If said number of Ordinary Shares is less than all of the Ordinary Shares purchasable hereunder (after giving effect to the cashless exercise), the undersigned requests that a new Warrant Certificate representing the remaining balance of such Ordinary Shares be registered in the name of, whose address is and that such Warrant Certificate be delivered to, whose address is.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be included in any Election to Purchase of a holder who has provided the notice set forth in <U>subsection&nbsp;3.3.5</U> of the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By signing this Election to Purchase, the undersigned hereby certifies that upon after giving effect to such exercise, the undersigned (together with such person&rsquo;s affiliates) or any &ldquo;group&rdquo; of which holder or its affiliates is a member, would not beneficially own in excess of the Maximum Percentage of the Ordinary Shares outstanding immediately after giving effect to such exercise as determined in accordance with <U>subsection&nbsp;3.3.5</U>. of the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature Page Follows]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature) </FONT></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address)</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Tax Identification Number)</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature Guaranteed:</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%"></TD>
    <TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO SEC RULE 17Ad-15 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (OR ANY SUCCESSOR RULE)).</FONT></P> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>dboralarcacq_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="vertical-align: middle; width: 33%; text-align: left"><IMG SRC="ex5-1_001.jpg" ALT="" STYLE="height: 100px; width: 100px">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 34%; vertical-align: middle">
        <P STYLE="margin-top: 0; margin-bottom: 0"><B><FONT STYLE="font-variant: small-caps">Loeb</FONT> &amp; <FONT STYLE="font-variant: small-caps">Loeb</FONT> LLP</B></P>
        <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">345 Park Avenue<BR> New York, NY 10154</P></TD>
    <TD STYLE="vertical-align: middle; text-align: left; width: 33%">
        <P STYLE="margin-top: 0; margin-bottom: 0">Main&nbsp;&nbsp;&nbsp;212.407.4000</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">Fax&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;212.656.1307</P></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">June 10, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">D. Boral ARC Merger Corporation</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">10 East 53rd Street, Suite 3001</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: justify">Re:</TD>
    <TD STYLE="text-align: justify">D. Boral ARC Merger Corporation</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">We have acted as United States securities counsel to D. Boral ARC Merger Corporation, a Delaware Corporation (the &ldquo;<B>Company</B>&rdquo;), in connection with the Registration Statement on Form S-4 (File No. 333-295869) initially filed by the Company with the Securities and Exchange Commission (the &ldquo;<B>Commission&rdquo;</B>) on May&nbsp;14, 2026 under the Securities Act of 1933, as amended (the &ldquo;<B>Act</B>&rdquo;). Such Registration Statement as amended, or supplemented, is hereinafter referred to as the &ldquo;<B>Registration Statement</B>&rdquo;. The Company has entered into a Business Combination Agreement, dated as of January&nbsp;11, 2026 (the &ldquo;<B>Business Combination Agreement</B>&rdquo;) by and among the Company, D. Boral ARC Acquisition I Corp., a British Virgin Islands business company and the parent of the Company (&ldquo;<B>Parent</B>&rdquo;), D. Boral Arc Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of Parent (&ldquo;<B>Merger Sub</B>&rdquo;), and Exascale Labs Inc., a Delaware corporation <B>(&ldquo;Exascale&rdquo;</B>). Pursuant to the Business Combination Agreement, Merger Sub will merge with and into Exascale, with Exascale continuing as the surviving entity and as a wholly-owned subsidiary of the Company (the &ldquo;<B>Merger</B>&rdquo;). Prior to the effective time of the Merger (the &ldquo;<B>Effective Time</B>&rdquo;), the Company will merge with and into Parent with the Company continuing as the surviving entity in order to change from an exempted company in the Cayman Islands to a corporation incorporated under the laws of the State of Delaware (the <B>&ldquo;Domestication Merger&rdquo;</B>). The Domestication Merger is subject to the approval of the shareholders of the Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">On the effective date of the Domestication Merger, among other things, (i) all of the currently issued and outstanding ordinary shares, par value $0.0001 per share, of Parent (the <B>&ldquo;Ordinary Shares</B>&rdquo;) will convert automatically by operation of law, on a one-for-one basis, into shares of Class A Ordinary Common Stock, par value $0.0001 per share, of the Company (the &ldquo;<B>Class A Ordinary Common Stock</B>&rdquo;), and (ii) each of Parent&rsquo;s currently issued and outstanding warrants (the &ldquo;<B>Warrants</B>&rdquo;), issued pursuant to that certain Warrant Agreement, dated as of July&nbsp;30, 2025, by and between Parent and Odyssey Transfer and Trust Company (the <B>&ldquo;Warrant Agreement&rdquo;</B>), will automatically become, pursuant to Section&nbsp;4.5 of the Warrant Agreement, warrants to acquire shares of Class A Ordinary Common Stock (the <B>&ldquo;Company Warrants&rdquo;</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 50%; text-align: left"><IMG SRC="ex5-1_001.jpg" ALT="" STYLE="height: 90px; width: 90px"></TD><TD STYLE="vertical-align: bottom; text-align: right; width: 50%"><P STYLE="margin-top: 0; margin-bottom: 0">D. Boral ARC Merger Corporation</P><P STYLE="margin-top: 0; margin-bottom: 0">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></TD></TR><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This opinion is being rendered in connection with
the registration under the above-referenced Registration Statement of (i) 41,200,000 shares of Class A Ordinary Common Stock issuable
upon conversion of the outstanding Class A Ordinary Shares and Class B Ordinary Shares of Parent into shares of Class A Ordinary Common
Stock (the &ldquo;<B>Conversion Shares</B>&rdquo;), (ii) 19,256,000 shares of Class A Ordinary Common Stock issued as consideration to
certain holders of issued and outstanding shares of common stock of Exascale pursuant to the Business Combination Agreement the <B>&ldquo;Exascale
Class A Shares</B>&rdquo;), (iii) 30,744,000 shares of Class B Super Common Stock, par value $0.0001 per share, issuable as consideration
to certain holders of the issued and outstanding shares of common stock of Exascale pursuant to the Business Combination Agreement (the
&ldquo;<B>Exascale Class B Shares</B>&rdquo;), and (iv) 14,100,000 Company Warrants to purchase 14,100,000 shares of Class A Ordinary
Common Stock (the &ldquo;<B>Company Warrants</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">We have examined such documents and considered such legal matters as we have deemed necessary and relevant as the basis for the opinions set forth below. With respect to such examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as reproduced or certified copies, and the authenticity of the originals of those latter documents. As to questions of fact material to this opinion, we have, to the extent deemed appropriate, relied upon representations of certain officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">Based upon the foregoing, we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left">1.</TD>
    <TD STYLE="text-align: justify">Upon the effectiveness and closing of the Domestication Merger, the Conversion Shares will be validly issued, fully paid and non-assessable.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left">2.</TD>
    <TD STYLE="text-align: justify">Upon the effectiveness and closing of the Domestication Merger, each issued and outstanding Company Warrant will be a valid and binding agreement of the Company, enforceable against the Company in accordance with its terms.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Upon issuance in accordance with the Business Combination Agreement,
the Exascale Class A Shares and Exascale Class B Shares will be validly issued, fully paid and non-assessable.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">The opinions we express above are based upon a review only of those laws, statutes, rules, ordinances and regulations which, in our experience, a securities lawyer who is a member of the bar of the State of New York and practicing before the Commission exercising customary professional diligence would reasonably recognize as being applicable to the foregoing transactions. In addition, we have assumed that the effectiveness of the Domestication Merger will result in the Company assuming all rights, duties and obligations of Parent under the Warrant Agreement by operation of the Business Companies Act (Revised Edition 2020), as amended, of the British Virgin Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 50%; text-align: left"><IMG SRC="ex5-1_001.jpg" ALT="" STYLE="height: 90px; width: 90px"></TD><TD STYLE="vertical-align: bottom; text-align: right; width: 50%"><P STYLE="margin-top: 0; margin-bottom: 0">D. Boral ARC Merger Corporation</P><P STYLE="margin-top: 0; margin-bottom: 0">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></TD></TR><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">The opinion set forth in paragraphs 2 above is subject to (i) the effect of any applicable bankruptcy, insolvency, reorganization, moratorium or similar law relating to or affecting creditors&rsquo; rights generally (including, without limitation, fraudulent conveyance laws) and (ii) the effect of general principles of equity, including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance or injunctive relief, regardless whether considered in a proceeding in equity or at law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">We express no opinion as to the enforceability of (i) provisions that relate to choice of law, forum selection or submission to jurisdiction (including, without limitation, any express or implied waiver of any objection to venue in any court or of any objection that a court is an inconvenient forum) to the extent that the validity, binding effector enforceability of any such provision is to be determined by any court other than a state court of the State of New York or (ii) waivers by the Company of any statutory or constitutional rights or remedies. We draw your attention to the fact that, under certain circumstances, the enforceability of terms to the effect that provisions may not be waived or modified except in writing may be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">The opinions we express herein are limited to matters involving the internal laws of the State of New York and the applicable provisions of the General Corporation Law of the State of Delaware. We express no opinion with respect to any other laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference made to us under the caption, &ldquo;Legal Matters,&rdquo; in the Registration Statement and in the prospectus constituting a part of the Registration Statement. In giving this consent, we do not hereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act, or the rules and regulations promulgated thereunder or Item 509 of Regulation S-K promulgated under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 50%">/s/ Loeb &amp; Loeb LLP</TD>
    <TD STYLE="width: 50%; text-align: left; padding-bottom: 0.5pt">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Loeb &amp; Loeb LLP</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>dboralarcacq_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">July&nbsp;30, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">D. Boral ARC Acquisition I Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">10 E. 53rd Street, Suite 3001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">Re:</TD>
    <TD STYLE="text-align: justify"><U>Initial Public Offering</U></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">This letter (this &ldquo;<B><U>Letter Agreement</U></B>&rdquo;) is being delivered to you in accordance with the Underwriting Agreement (the &ldquo;<B><U>Underwriting Agreement</U></B>&rdquo;) entered into by and among D. Boral ARC Acquisition I Corp., a BVI business company (the &ldquo;<B><U>Company</U></B>&rdquo;) and D. Boral Capital LLC, as representative (the &ldquo;<B><U>Representative</U></B>&rdquo;) of the underwriters (the &ldquo;<B><U>Underwriters</U></B>&rdquo;), relating to an underwritten initial public offering (the &ldquo;<B><U>Public Offering</U></B>&rdquo;), of up to 28,750,000 of the Company&rsquo;s units (including up to 3,750,000 units which may be purchased to cover over-allotments, if any) (the &ldquo;<B><U>Units</U></B>&rdquo;), each comprised of one Class A ordinary share, par value $0.0001 per share, of the Company (the &ldquo;<B><U>Class A Ordinary Shares</U></B>&rdquo;) and one-half of one redeemable warrant (each whole warrant, a &ldquo;<B><U>Warrant</U></B>&rdquo;). Each Warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $11.50 per share, subject to adjustment. The Units shall be sold in the Public Offering pursuant to the registration statement on Form S-1 (File No. 333-286810) and prospectus (the &ldquo;<B><U>Prospectus</U></B>&rdquo;) filed by the Company with the U.S. Securities and Exchange Commission (the &ldquo;<B><U>Commission</U></B>&rdquo;) and the Company shall apply to have the Units listed on the Nasdaq Global Market. Certain capitalized terms used herein are defined in paragraph 11 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">In order to induce the Company and the Underwriters to enter into the Underwriting Agreement and to proceed with the Public Offering and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, MFH 1, LLC, a Delaware limited liability company (the &ldquo;<B><U>Sponsor</U></B>&rdquo;) and each of the undersigned individuals, each of whom is, or will be, a member of the Company&rsquo;s board of directors and/or management team (each an &ldquo;<B><U>Insider</U></B>&rdquo; and, collectively, the &ldquo;<B><U>Insiders</U></B>&rdquo;), hereby agree with the Company as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">1. The Sponsor and each
Insider agree that if the Company seeks shareholder approval of a proposed Business Combination, then in connection with such
proposed Business Combination, it, he or she shall (i) vote all Founder Shares and any shares acquired by it, him or her in the
Public Offering or the secondary public market in favor of such proposed Business Combination, except that it, he or she shall not
vote any Class A Ordinary Shares that it, he or she purchased after the Company publicly announces its intention to engage in such
proposed Business Combination for or against such proposed Business Combination and (ii) not redeem any Class A Ordinary Shares
owned by it, him or her in connection with such shareholder approval. If the Company seeks to consummate a proposed Business
Combination by engaging in a tender offer, the Sponsor and each Insider agrees that it, he or she will not sell or tender any
Ordinary Shares (as defined below) owned by it, him or her in connection herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2. The Sponsor and each Insider agree that in the event that the Company fails to consummate a Business Combination by the date that is 18 months after the closing of the Public Offering (or 21 months if the time to complete a Business Combination is extended for 3 months by the Sponsor in accordance with the terms of the Company&rsquo;s amended and restated memorandum and articles of association (as amended from time to time, the &ldquo;<B><U>Memorandum and Articles</U></B>&rdquo;)), or such earlier date as Company&rsquo;s board of directors may approve, or such later date as the Company&rsquo;s shareholders may approve, in each case in accordance with the Memorandum and Articles (the &ldquo;<B><U>Completion Window</U></B>&rdquo;), the Sponsor and each Insider shall take all reasonable steps to cause the Company to (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten (10) business days thereafter, subject to lawfully available funds therefor, redeem 100% of the Class A Ordinary Shares sold as part of the Units in the Public Offering (the &ldquo;<B><U>Offering Shares</U></B>&rdquo;), at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account (which interest shall be net of taxes payable and less up to $100,000 of interest to pay dissolution expenses), divided by the number of Offering Shares then in issue, which redemption will completely extinguish the Public Shareholders&rsquo; rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company&rsquo;s remaining shareholders and the Company&rsquo;s board of directors, dissolve and liquidate, subject in each case to the Company&rsquo;s obligations under British Virgin Islands law to provide for claims of creditors and other requirements of applicable law. The Sponsor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: justify">and the Insiders agree to not propose any amendment to the Memorandum and Articles not for the purposes of approving, or in conjunction with the consummation of, a Business Combination (A) to modify the substance or timing of the Company&rsquo;s obligation to allow redemption in connection with a Business Combination or to redeem one hundred per cent (100%) of the Offering Shares if the Company has not consummated a Business Combination within the Completion Window or (B) with respect to any other material provisions relating to the rights of holders of Class A Ordinary Shares or pre-initial Business Combination activity, unless the Company provides its Public Shareholders with the opportunity to redeem their Offering Shares upon effectiveness of any such amendment at a per share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the Trust Account and not previously released to the Company to pay its taxes, divided by the number of Offering Shares then in issue, subject to applicable law. The Sponsor and each Insider acknowledges that it, he or she will not be entitled to rights to liquidating distributions from the Trust Account with respect to any Founder Shares held by it, him or her if the Company fails to complete a Business Combination within the Completion Window; although it, he or she will be entitled to liquidating distributions from the Trust Account with respect to any Offering Shares it, he or she holds if the Company fails to complete a Business Combination within the prescribed time frame. The Sponsor and each Insider hereby further acknowledge that it, he or she will not be entitled to (a) redemption rights with respect to any Founder Shares and Offering Shares held by it, him or her, in connection with the consummation of a Business Combination, or (b) redemption rights with respect to Founder Shares and Offering Shares held by it, him or her in connection with a shareholder vote to amend the Memorandum and Articles in the manner described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">3. To the fullest extent permitted by applicable law and the Memorandum and Articles, the Company hereby agrees to defend, indemnify, hold harmless and exonerate (including the advancement of expenses to the fullest extent permitted by applicable law) the Sponsor and its members (present and former), managers and affiliates and their respective present and former officers and directors (each, a &ldquo;<B><U>Sponsor Indemnitee</U></B>&rdquo;) from any and all costs, fees, expenses, judgments, liabilities, fines, penalties, reasonable attorneys&rsquo; fees and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such costs, fees, expenses, judgments, liabilities, fines, penalties and amounts paid in settlement) actually, and reasonably, incurred by a Sponsor Indemnitee or on a Sponsor Indemnitee&rsquo;s behalf in connection with any threatened, pending or completed action, suit, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, hearing or any other actual, threatened or completed proceeding instituted by the Company or any third party, whether civil, criminal, administrative or investigative in nature, in respect of any investment opportunities sourced by a Sponsor Indemnitee for the Company or any liability arising with respect to a Sponsor Indemnitee&rsquo;s activities in connection with the affairs of the Company (in each case to the extent that such indemnification, hold harmless and exoneration obligations with respect to such matters are not expressly covered by a separate written agreement between the Company and the applicable Sponsor Indemnitee); <I>provided</I>, that in no event shall a Sponsor Indemnitee be entitled to be indemnified or held harmless hereunder in respect of any costs, fees, expenses, judgments, liabilities, fines, penalties and amounts paid in settlement (if any) that a Sponsor Indemnitee may incur by reason of such person&rsquo;s own actual fraud or intentional misconduct; <I>provided</I>, <I>further</I>, that, for the avoidance of doubt, under no circumstance shall a Sponsor Indemnitee have a claim to any monies or assets held in the Trust Account, and the Company shall not be permitted to procure monies or assets held in the Trust Account for the satisfaction of its obligations to any Sponsor Indemnitee in respect of the indemnification provided hereunder. The Sponsor Indemnitees shall be third party beneficiaries of this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">4. [Reserved]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5. In the event of the liquidation of the Trust Account, the Sponsor (which for purposes of clarification shall not extend to any officer, member or manager of the Sponsor) agrees to indemnify and hold harmless the Company against any and all loss, liability, claim, damage and expense whatsoever (including, but not limited to, any and all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, whether pending or threatened, or any claim whatsoever) to which the Company may become subject as a result of any claim by (i) any third party (other than the Company&rsquo;s independent public accountants) for services rendered or products sold to the Company or (ii) a prospective target business with which the Company has entered into a letter of intent, confidentiality or other similar agreement or business combination agreement (a &ldquo;<B><U>Target</U></B>&rdquo;); <I>provided</I>, <I>however</I>, that such indemnification of the Company by the Sponsor shall apply only to the extent necessary to ensure that such claims by a third party for services rendered (other than the Company&rsquo;s independent public accountants) or products sold to the Company or a Target do not reduce the amount of funds in the Trust Account to below (A) $10.00 per share of the Offering Shares or (B) such lesser amount per share of the Offering Shares held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case including interest earned on the funds held in the Trust Account and net of taxes payable, except as to any claims by a third party or Target that executed an agreement waiving claims against and all rights to seek access to the Trust Account whether or not such agreement is enforceable. In the event that any such executed waiver is deemed to be unenforceable against such third party, the Sponsor shall not be responsible for any liability as a result of any such third-party claims. Notwithstanding any of the foregoing, such indemnification of the Company by the Sponsor shall not apply as to any claims under the Company&rsquo;s obligation to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &ldquo;<B><U>Securities Act</U></B>&rdquo;). The Sponsor shall have the right to defend against any such claim with counsel of its choice reasonably satisfactory to the Company if, within fifteen (15) days following written receipt of notice of the claim to the Sponsor, the Sponsor notifies the Company in writing that it shall undertake such defense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">6. To the extent that the Underwriters do not exercise their over-allotment option to purchase an additional 3,750,000 Units (as described in the Prospectus), the Sponsor agrees, upon the expiration or waiver of such option, to forfeit and surrender for no consideration for cancellation, a number of Founder Shares equal to the product of 1,607,143 multiplied by a fraction, (i) the numerator of which is 3,750,000 minus the number of Units purchased by the Underwriters upon the exercise of their over-allotment option, and (ii) the denominator of which is 3,750,000. The forfeiture and surrender will be adjusted to the extent that the over-allotment option is not exercised in full by the Underwriters so that the Founder Shares will represent approximately 30% of the Company&rsquo;s issued and outstanding Ordinary Shares after the Public Offering. The Sponsor further agrees that to the extent that the size of the Public Offering is increased or decreased and the Sponsor has either purchased or sold Ordinary Shares or an adjustment to the number of Founder Shares has been effected by way of a share dividend or share capitalization, or a surrender for no consideration or share contribution back to capital, or otherwise, in each case in connection with such increase or decrease in the size of the Public Offering, then (A) the references to 3,750,000 in the numerator and denominator of the formula in the first sentence of this paragraph 6 shall be changed to a number equal to 15% of the number of Class A Ordinary Shares included in the Units issued in the Public Offering and (B) the reference to 1,607,143 in the formula set forth in the first sentence of this paragraph 6 shall be adjusted to such number of Founder Shares that the Sponsor would have to collectively return to the Company in order for all holders of Founder Shares to hold an aggregate of approximately 30% of the Company&rsquo;s issued and outstanding Ordinary Shares after the Public Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">7. The Sponsor and each Insider hereby agrees and acknowledges that: (i) each of the Underwriters and the Company would be irreparably injured in the event of a breach by the Sponsor of its obligations (as applicable) under paragraphs 1, 2, 4, 5, 6, 8(a) and 8(b) or by each Insider of its obligations under paragraphs 1, 2, 4, 8(a) and 8(b), (ii) monetary damages may not be an adequate remedy for such breach and (iii) the non-breaching party shall be entitled to injunctive relief, in addition to any other remedy that such party may have in law or in equity, in the event of such breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">8. <U>Transfer Restrictions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">(a) Subject to the exceptions set forth herein, the Sponsor and each Insider agree not to Transfer any Founder Shares or the Class A Ordinary Shares issuable upon conversion of the Founder Shares held by it, him or her until the completion of a Business Combination (the &ldquo;<B><U>Lock-up</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">(b) Subject to the exceptions set forth herein, the Sponsor and each Insider agree not to Transfer any Private Placement Units (including the Private Placement Warrants, the Private Placement Shares and the Class A Ordinary Shares issuable upon exercise of the Private Placement Warrants) held by it, he or she until the completion of a Business Combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">(c) Notwithstanding the provisions set forth in paragraphs 8(a) and 8(b), transfers of the Founder Shares (including the Class A Ordinary Shares issued or issuable upon the conversion of the Founder Shares) and Private Placement Units (including the Private Placement Warrants, the Private Placement Shares and the Class A Ordinary Shares issuable upon exercise of the Private Placement Warrants) that are held by the Sponsor, any Insider or any of their permitted transferees, as applicable (that have complied with any applicable requirements of this paragraph 8(c)), are permitted (i) to the Company&rsquo;s officers, directors, advisors or consultants, any affiliate or family member of any of the Company&rsquo;s officers, directors, advisors or consultants, any members or partners of the Sponsor or their affiliates and funds and accounts advised by such members or partners, any affiliates of the Sponsor, or any employees of such affiliates, (ii) in the case of an individual, as a gift to such person&rsquo;s immediate family or to a trust, the beneficiary of which is a member of such person&rsquo;s immediate family, an affiliate of such person or to a charitable organization; (iii) in the case of an individual, by virtue of laws of descent and distribution upon death of such person; (iv) in the case of an individual, pursuant to a qualified domestic relations order; (v) by private sales or transfers made in connection with any forward purchase agreement or similar arrangement, in connection with an extension of the Completion Window or in connection with the consummation of a Business Combination at prices no greater than the price at which the shares or warrants were originally purchased; (vi) pro rata distributions from the Sponsor to its members, partners or shareholders pursuant to the Sponsor&rsquo;s limited liability company agreement or other charter documents; (vii) by virtue of the laws of the British Virgin Islands or the Sponsor&rsquo;s limited liability company agreement upon dissolution of the Sponsor, (viii) in the event of the Company&rsquo;s liquidation prior to consummation of a Business Combination; (ix) in the event that, subsequent to the consummation of a Business Combination, the Company completes a liquidation, merger, share exchange or other similar transaction which results in all of its shareholders having the right to exchange their Class A ordinary shares for cash, securities or other property or (x) to a nominee or custodian of a person or entity to whom a transfer would be permissible under clauses (i) through (vii); <I>provided</I>, <I>however</I>, that, in the case of clauses (i) through (vii), these permitted transferees must enter into a written agreement agreeing to be bound by these transfer restrictions herein and the other restrictions contained in this Agreement (including provisions relating to voting, the Trust Account and liquidating distributions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">9. Each Insider&rsquo;s biographical information furnished to the Company and the Representative that is included in the Prospectus is true and accurate in all respects and does not omit any material information with respect to such Insider&rsquo;s background and contains all of the information required to be disclosed pursuant to Item 401 of Regulation S-K, promulgated under the Securities Act. Each Insider&rsquo;s questionnaire furnished to the Company and the Representative including any such information that is included in the Prospectus is true and accurate in all respects. Each Insider represents and warrants that: (i) such Insider is not subject to or a respondent in any legal action for, any injunction, cease-and-desist order or order or stipulation to desist or refrain from any act or practice relating to the offering of securities in any jurisdiction; (ii) such Insider has never been convicted of, or pleaded guilty to, any crime (A) involving fraud, (B) relating to any financial transaction or handling of funds of another person or (C) pertaining to any dealings in any securities and such Insider is not currently a defendant in any such criminal proceeding; and (iii) none of the Sponsor or any such Insider has ever been suspended or expelled from membership in any securities or commodities exchange or association or had a securities or commodities license or registration denied, suspended or revoked.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">10. The Sponsor and each Insider has full right and power, without violating any agreement to which it, he or she is bound (including, without limitation, any non-competition or non-solicitation agreement with any employer or former employer), to enter into this Letter Agreement and, as applicable, to serve as an officer of the Company or as a director on the board of directors of the Company and each Insider hereby consents to being named in the Prospectus as an officer and/or director of the Company, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">11. As used herein, (i)
&ldquo;<B><U>Business Combination</U></B>&rdquo; shall mean a merger, amalgamation, share exchange, asset acquisition, share
purchase, reorganization or similar business combination, involving the Company and one or more businesses or entities; (ii)
&ldquo;<B><U>Founder Shares</U></B>&rdquo; shall mean the Company&rsquo;s Class B ordinary shares, par value $0.0001 per share (the
&ldquo;<B>Class B Ordinary Shares</B>&rdquo; and, together with the <B>Class A Ordinary Shares</B>, the &ldquo;<B>Ordinary
Shares</B>&rdquo;), held by the Sponsor prior to the consummation of the Public Offering; (iii) &ldquo;<B><U>Private Placement
Shares</U></B>&rdquo; shall mean the 200,000 Class A Ordinary Shares (whether or not the underwriters&rsquo; over-allotment option
is exercised) comprising part of the Private Placement Units; (v) &ldquo;<B><U>Private Placement Warrants</U></B>&rdquo; shall mean
the 100,000 warrants (whether or not the underwriters&rsquo; over-allotment option is exercised) comprising part of the Private
Placement Units; (iv) &ldquo;<B><U>Private Placement Units</U></B>&rdquo; shall mean an aggregate of 200,000 private placement units
(whether or not the underwriters&rsquo; over-allotment option is exercised) that the Representative and Sponsor have agreed to
purchase for an aggregate purchase price of $2,000,000 (whether or not the underwriters&rsquo; over-allotment option is exercised in
full), or $10.00 per unit, in a private placement that shall occur simultaneously with the consummation of the Public Offering; (v)
&ldquo;<B><U>Public Shareholders</U></B>&rdquo; shall mean the holders of Offering Shares other than the Sponsor and the Insiders;
(vi) &ldquo;<B><U>Trust Account</U></B>&rdquo; shall mean the trust fund into which a portion of the net proceeds of the Public
Offering and the sale of the Private Placement Units shall be deposited; and (vii) &ldquo;<B><U>Transfer</U></B>&rdquo; shall mean
the (a) sale of, offer to sell, contract or agreement to sell, hypothecate, pledge, grant of any option to purchase or otherwise
dispose of or agreement to dispose of, directly or indirectly, or establishment or increase of a put equivalent position or
liquidation with respect to or decrease of a call equivalent position within the meaning of Section&nbsp;16 of the Exchange Act, and
the rules and regulations of the Commission promulgated thereunder with any respect to, any security, (b) entry into any swap or
other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any security,
whether any such transaction is to be settled by delivery of such securities, in cash or otherwise, or (c) public announcement of
any intention to effect any transaction specified in clause (a) or (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">12. This Letter Agreement constitutes the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and supersedes all prior understandings, agreements or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated hereby. This Letter Agreement may not be changed, amended, modified or waived (other than to correct a typographical error) as to any particular provision, except by a written instrument executed by all parties hereto. Each of the parties hereto hereby acknowledges and agrees that each Representative is a third-party beneficiary of this Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">13. No party hereto may assign either this Letter Agreement or any of its rights, interests or obligations hereunder without the prior written consent of the other parties. Any purported assignment in violation of this paragraph 13 shall be void and ineffectual and shall not operate to transfer or assign any interest or title to the purported assignee. This Letter Agreement shall be binding on the Sponsor, each Insider and each of their respective successors, heirs and assigns and permitted transferees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">14. This Letter Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. The parties hereto (i) all agree that any action, proceeding, claim or dispute arising out of, or relating in any way to, this Letter Agreement shall be brought and enforced in the courts of the State of New York located in the City and County of New York, Borough of Manhattan, and irrevocably submit to such jurisdiction and venue, which jurisdiction and venue shall be exclusive and (ii) waive any objection to such exclusive jurisdiction and venue or that such courts represent an inconvenient forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">15. Any notice, consent or request to be given in connection with any of the terms or provisions of this Letter Agreement shall be in writing and shall be sent by express mail or similar private courier service, by certified mail (return receipt requested), by hand delivery or facsimile transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">16. This Letter Agreement shall terminate on the earlier of (i) the expiration of the Lock-up or (ii) the liquidation of the Company; <I>provided</I>, <I>however</I>, that this Letter Agreement shall earlier terminate in the event that the Public Offering is not consummated and closed by December&nbsp;31, 2025; <I>provided</I>, <I>further</I>, that paragraph 5 of this Letter Agreement shall survive such liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD COLSPAN="2" STYLE="text-align: left; vertical-align: top">Sincerely,</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-align: left; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-align: left; vertical-align: top"><B>MFH 1, LLC</B></TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  <TR>
    <TD STYLE="text-align: left; width: 5%; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 45%; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 50%; vertical-align: middle">&nbsp;</TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; vertical-align: top">/s/ John Darwin</TD>
    <TD STYLE="text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top">Name:</TD>
    <TD STYLE="text-align: left; vertical-align: top">John Darwin</TD>
    <TD STYLE="text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top">Title:</TD>
    <TD STYLE="text-align: left; vertical-align: top">Manager</TD>
    <TD STYLE="text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><I>[SIGNATURE PAGE TO LETTER AGREEMENT]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><B>INSIDERS:</B></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 45%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: left">/s/ John Darwin</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Name: </TD>
    <TD STYLE="text-align: left">John Darwin</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: left">/s/ Kevin Chen</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Name: </TD>
    <TD STYLE="text-align: left">Kevin Chen</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: left">/s/ Luisa Ingargiola</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Name:</TD>
    <TD STYLE="text-align: left">Luisa Ingargiola</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: left">/s/ Matt Laker</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Name:</TD>
    <TD STYLE="text-align: left">Matt Laker</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: left">/s/ David Boral</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Name:</TD>
    <TD STYLE="text-align: left">David Boral</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><I>[SIGNATURE PAGE TO LETTER AGREEMENT]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>6
<FILENAME>dboralarcacq_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INVESTMENT MANAGEMENT TRUST AGREEMENT</B></P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">This Investment Management Trust Agreement (this &ldquo;<B><U>Agreement</U></B>&rdquo;) is made effective as of July&nbsp;30, 2025 by and between D. Boral ARC Acquisition I Corp., a BVI business company (the &ldquo;<B><U>Company</U></B>&rdquo;), and Odyssey Transfer and Trust Company, a corporation organized under the laws of Minnesota (the &ldquo;<B><U>Trustee</U></B>&rdquo;).</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">WHEREAS, the Company&rsquo;s registration statement on Form S-1, (File No. 333-286810) (the &ldquo;<B><U>Registration Statement</U></B>&rdquo;) and prospectus (the &ldquo;<B><U>Prospectus</U></B>&rdquo;) for the initial public offering of the Company&rsquo;s units (the &ldquo;<B><U>Units</U></B>&rdquo;), each of which consists of one of the Company&rsquo;s Class A ordinary shares, par value $0.0001 per share (the &ldquo;<B><U>Ordinary Shares</U></B>&rdquo;), and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one Ordinary Share (such initial public offering hereinafter referred to as the &ldquo;<B><U>Offering</U></B>&rdquo;), has been declared effective as of the date hereof by the U.S. Securities and Exchange Commission;</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">WHEREAS, the Company has entered into an Underwriting Agreement (the &ldquo;<B><U>Underwriting Agreement</U></B>&rdquo;) with D. Boral Capital LLC as representative (the &ldquo;<B><U>Representative</U></B>&rdquo;) of the underwriters (the &ldquo;<B><U>Underwriters</U></B>&rdquo;) named therein;</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">WHEREAS, as described in the Registration Statement, $250,000,000 of the gross proceeds of the Offering and sale of the Private Placement Units (as defined in the Underwriting Agreement) (or $287,500,000 if the Underwriters&rsquo; over-allotment option is exercised in full) will be delivered to the Trustee to be deposited and held in a segregated trust account located at all times in the United States (the &ldquo;<B><U>Trust Account</U></B>&rdquo;) for the benefit of the Company and the holders of the Ordinary Shares included in the Units issued in the Offering as hereinafter provided (the amount to be delivered to the Trustee (and any interest subsequently earned thereon) is referred to herein as the &ldquo;<B><U>Property</U></B>,&rdquo; the shareholders for whose benefit the Trustee shall hold the Property will be referred to as the &ldquo;<B><U>Public Shareholders</U></B>,&rdquo; and the Public Shareholders and the Company will be referred to together as the &ldquo;<B><U>Beneficiaries</U></B>&rdquo;); and</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">WHEREAS, the Company and the Trustee desire to enter into this Agreement to set forth the terms and conditions pursuant to which the Trustee shall hold the Property.</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">NOW THEREFORE, IT IS AGREED:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">1. <B><U>Agreements and Covenants of Trustee</U></B>. The Trustee hereby agrees and covenants to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(a) Hold the Property in
trust for the Beneficiaries in accordance with the terms of this Agreement in the Trust Account established by the Trustee in the
United States at Citibank, NA (or at another U.S. chartered commercial bank with consolidated assets of $100 billion
or more) and at a brokerage institution selected by the Trustee that is reasonably satisfactory to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(b) Manage, supervise and administer the Trust Account subject to the terms and conditions set forth herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(c) Promptly upon receipt of written instruction of the Company, (i) invest and reinvest the Property, initially solely in United States government securities within the meaning of Section&nbsp;2(a)(16) of the Investment Company Act of 1940, as amended, having a maturity of 185 days or less, or in money market funds meeting the conditions of paragraphs (d)(1), (d)(2), (d)(3) and (d)(4) of Rule&nbsp;2a-7 promulgated under the Investment Company Act of 1940, as amended (or any successor rule), which invest only in direct U.S. government treasury obligations, (ii) hold the Property as uninvested cash or (iii) hold the Property in an interest or non-interest bearing demand deposit account at a U.S. chartered commercial bank with consolidated assets of $100 billion or more selected by the Trustee that is reasonably satisfactory to the Company; the Trustee may not invest in any other securities or assets, it being understood that the Trust Account will earn no interest while account funds are uninvested awaiting the Company&rsquo;s instructions hereunder and, while invested or uninvested, the Trustee may earn bank credits or other consideration;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(d) Collect and receive, when due, all interest or other income arising from the Property, which shall become part of the &ldquo;<B><U>Property</U></B>,&rdquo; as such term is used herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(e) Promptly notify the Company and the Representative of all communications received by the Trustee with respect to any Property requiring action by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(f) Supply any necessary information or documents as may be requested by the Company (or its authorized agents) in connection with the Company&rsquo;s preparation of the tax returns relating to assets held in the Trust Account or in connection with the preparation of the Company&rsquo;s financial statements or completion of the audit of the Company&rsquo;s financial statements by the Company&rsquo;s auditors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(g) Participate in any plan or proceeding for protecting or enforcing any right or interest arising from the Property if, as and when instructed by the Company to do so;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(h) Render to the Company monthly written statements of the activities of, and amounts in, the Trust Account reflecting all receipts and disbursements of the Trust Account;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(i) Commence liquidation of the Trust Account only after and promptly after (x) receipt of, and only in accordance with, the terms of a letter from the Company (&ldquo;<B><U>Termination Letter</U></B>&rdquo;) in a form substantially similar to that attached hereto as either <U>Exhibit A</U> or <U>Exhibit B</U>, as applicable, signed on behalf of the Company by its Chief Executive Officer, President, Chief Financial Officer, Secretary or Chairperson of the board of directors of the Company (the &ldquo;<B><U>Board</U></B>&rdquo;) or other director or authorized officer of the Company, and, in the case of Exhibit A, acknowledged and agreed to by the Representative, and complete the liquidation of the Trust Account and distribute the Property in the Trust Account, including interest earned on the funds held in the Trust Account (which interest shall be net of taxes payable (other than any excise or similar tax) or owed and, in the case of <U>Exhibit B</U>, less up to $100,000 of interest to pay dissolution expenses), only as directed in the Termination Letter and the other documents referred to therein, or (y) upon the date which is the later of (1) 18 months after the closing of the Offering (or 21 months if the time to complete a Business Combination is extended for 3 months by the Sponsor in accordance with the terms of the Company&rsquo;s amended and restated memorandum and articles of association (as amended from time to time, the &ldquo;<B><U>Memorandum and Articles</U></B>&rdquo;)) (or such earlier date as the Company&rsquo;s board of directors may approve); and (2) such later date as may be approved by the Company&rsquo;s shareholders in accordance with the Memorandum and Articles (such period, the &ldquo;<B>Completion Window</B>&rdquo;), if a Termination Letter has not been received by the Trustee prior to such date, in which case the Trust Account shall be liquidated by the Trustee in accordance with the procedures set forth in the Termination Letter attached as <U>Exhibit B</U> and the Property in the Trust Account, including interest earned on the funds held in the Trust Account (which interest shall be net of taxes payable (other than any excise or similar tax) or owed and up to $100,000 of interest to pay dissolution expenses), shall be distributed to the Public Shareholders of record as of such date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(j) Upon written request from the Company, which may be given from time to time in a form substantially similar to that attached hereto as <U>Exhibit C</U> (a &ldquo;<B><U>Tax Payment Withdrawal Instruction</U></B>&rdquo;), withdraw from the Trust Account and distribute to the Company the amount of interest earned on the Property requested by the Company to cover any income tax obligation (not including any excise or similar tax) owed by the Company, which amount shall be delivered directly to the Company by electronic funds transfer or other method of prompt payment, and the Company shall forward such payment to the relevant taxing authority, so long as there is no reduction in the principal amount per share initially deposited in the Trust Account; <I>provided</I>, <I>however</I>, that to the extent there is not sufficient cash in the Trust Account to pay such tax obligation, the Trustee shall liquidate such assets held in the Trust Account as shall be designated by the Company in writing to make such distribution (it being acknowledged and agreed that any such amount in excess of interest income earned on the Property shall not be payable from the Trust Account). The written request of the Company referenced above shall constitute presumptive evidence that the Company is entitled to said funds, and the Trustee shall have no responsibility to look beyond said request;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(k) Upon written request from the Company, which may be given from time to time in a form substantially similar to that attached hereto as <U>Exhibit D</U> (a &ldquo;<B><U>Shareholder Redemption Withdrawal Instruction</U></B>&rdquo;), the Trustee shall distribute on behalf of the Company the amount requested by the Company to be used to redeem Ordinary Shares from Public Shareholders properly submitted in connection with a shareholder vote to approve an amendment to the Memorandum and Articles not for the purposes of approving, or in conjunction with the consummation of, a Business Combination (as defined below) (A) to modify the substance or timing of the Company&rsquo;s obligation to allow redemption in connection with a Business Combination or to redeem one hundred per cent (100%) of the Public Shares if the Company has not consummated a Business Combination within the Completion Window or (B) with respect to any other material provisions relating to the rights of holders of Ordinary Shares or pre-initial Business Combination activity. The written request of the Company referenced above shall constitute presumptive evidence that the Company is entitled to distribute said funds, and the Trustee shall have no responsibility to look beyond said request; and</P>

<P STYLE="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(l) Not make any withdrawals or distributions from the Trust Account other than pursuant to <U>Sections&nbsp;1(i)</U>, <U>1(j),</U> and <U>1(k)</U> above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">2. <B><U>Agreements and Covenants of the Company</U></B>. The Company hereby agrees and covenants to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(a) Give all instructions to the Trustee hereunder in writing, signed by the Company&rsquo;s Chairperson of the Board, President, Chief Executive Officer, Chief Financial Officer, Secretary or other director or authorized officer of the Company. In addition, except with respect to its duties under <U>Sections&nbsp;1(i), 1(j) and 1(k)</U> hereof, the Trustee shall be entitled to rely on, and shall be protected in relying on, any verbal or telephonic advice or instruction which it, in good faith and with reasonable care, believes to be given by any one of the persons authorized above to give written instructions, <I>provided </I>that the Company shall promptly confirm such instructions in writing;</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(b) Subject to <U>Section&nbsp;4</U> hereof, hold the Trustee harmless and indemnify the Trustee from and against any and all expenses, including reasonable counsel fees and disbursements, or losses suffered by the Trustee in connection with any action taken by it hereunder and in connection with any action, suit or other proceeding brought against the Trustee involving any claim, or in connection with any claim or demand, which in any way arises out of or relates to this Agreement, the services of the Trustee hereunder, or the Property or any interest earned on the Property, except for expenses and losses resulting from the Trustee&rsquo;s gross negligence, fraud or willful misconduct. Promptly after the receipt by the Trustee of notice of demand or claim or the commencement of any action, suit or proceeding, pursuant to which the Trustee intends to seek indemnification under this <U>Section&nbsp;2(b)</U>, it shall notify the Company in writing of such claim (hereinafter referred to as the &ldquo;<B><U>Indemnified Claim</U></B>&rdquo;). The Trustee shall have the right to conduct and manage the defense against such Indemnified Claim; <I>provided </I>that the Trustee shall obtain the consent of the Company with respect to the selection of counsel, which consent shall not be unreasonably withheld. The Trustee may not agree to settle any Indemnified Claim without the prior written consent of the Company, which such consent shall not be unreasonably withheld, conditioned, or delayed; provided, further that the Company may conduct and manage the defense against any Indemnified Claim if the Trustee does not promptly take reasonable steps to mount such a defense. The Company may participate in such action with its own counsel;</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(c) Pay the Trustee the fees set forth on <U>Schedule A</U> hereto, including an initial acceptance fee, annual administration fee and transaction processing fee which fees shall be subject to modification by the parties from time to time. It is expressly understood that the Property shall not be used to pay such fees unless and until it is distributed to the Company pursuant to <U>Sections&nbsp;1(i)</U> through <U>1(k)</U> hereof. The Company shall pay the Trustee the initial acceptance fee and the first annual administration fee at the consummation of the Offering. The Company shall not be responsible for any other fees or charges of the Trustee except as set forth in this <U>Section&nbsp;2(c)</U>, <U>Schedule A</U> and as may be provided in <U>Section&nbsp;2(b)</U> hereof;</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(d) In connection with any vote of the Company&rsquo;s shareholders regarding a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination involving the Company and one or more businesses or entities (the &ldquo;<B><U>Business Combination</U></B>&rdquo;), provide to the Trustee an affidavit or certificate of the inspector of elections for the general meeting verifying the vote of such shareholders regarding such Business Combination;</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(e) Provide the Representative with a copy of any Termination Letter(s) and/or any other correspondence that is sent to the Trustee with respect to any proposed withdrawal from the Trust Account promptly after it issues the same;</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(f) Instruct the Trustee to make only those distributions that are permitted under this Agreement, and refrain from instructing the Trustee to make any distributions that are not permitted under this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">3. <B><U>Limitations of Liability</U></B>. The Trustee shall have no responsibility or liability to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(a) Imply obligations, perform duties, inquire or otherwise be subject to the provisions of any agreement or document other than this Agreement and that which is expressly set forth herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(b) Take any action with respect to the Property, other than as directed in <U>Section&nbsp;1</U> hereof, and the Trustee shall have no liability to any third party except for liability arising out of the Trustee&rsquo;s gross negligence, fraud or willful misconduct;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(c) Institute any proceeding for the collection of any principal and income arising from, or institute, appear in or defend any proceeding of any kind with respect to, any of the Property unless and until it shall have received instructions from the Company given as provided herein to do so and the Company shall have advanced or guaranteed to it funds sufficient to pay any expenses incident thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(d) Refund any depreciation in principal of any Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(e) Assume that the authority of any person designated by the Company to give instructions hereunder shall not be continuing unless provided otherwise in such designation, or unless the Company shall have delivered a written revocation of such authority to the Trustee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(f) The other parties hereto or to anyone else for any action taken or omitted by it, or any action suffered by it to be taken or omitted, in good faith and in the Trustee&rsquo;s best judgment, except for the Trustee&rsquo;s gross negligence, fraud or willful misconduct. The Trustee may rely conclusively and shall be protected in acting upon any order, notice, demand, certificate, opinion or advice of counsel (including counsel chosen by the Trustee, which counsel may be the Company&rsquo;s counsel), statement, instrument, report or other paper or document (not only as to its due execution and the validity and effectiveness of its provisions, but also as to the truth and acceptability of any information therein contained) which the Trustee believes, in good faith and with reasonable care, to be genuine and to be signed or presented by the proper person or persons. The Trustee shall not be bound by any notice or demand, or any waiver, modification, termination or rescission of this Agreement or any of the terms hereof, unless evidenced by a written instrument delivered to the Trustee, signed by the proper party or parties and, if the duties or rights of the Trustee are affected, unless it shall give its prior written consent thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(g) Verify the accuracy of the information contained in the Registration Statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(h) Provide any assurance that any Business Combination entered into by the Company or any other action taken by the Company is as contemplated by the Registration Statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(i) File information returns with respect to the Trust Account with any local, state or federal taxing authority or provide periodic written statements to the Company documenting the taxes payable by the Company, if any, relating to any interest income earned on the Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(j) Prepare, execute and file tax reports, income or other tax returns and pay any taxes with respect to any income generated by, and activities relating to, the Trust Account, regardless of whether such tax is payable by the Trust Account or the Company, including, but not limited to, tax obligations, except pursuant to <U>Section&nbsp;1(j)</U> hereof; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(k) Verify calculations, qualify or otherwise approve the Company&rsquo;s written requests for distributions pursuant to <U>Sections&nbsp;1(i)</U>, <U>1(j) and1(k)</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">4. <B><U>Trust Account Waiver</U></B>. The Trustee has no right of set-off or any right, title, interest or claim of any kind (&ldquo;<B><U>Claim</U></B>&rdquo;) to, or to any monies in, the Trust Account, and hereby irrevocably waives any Claim to, or to any monies in, the Trust Account that it may have now or in the future. In the event the Trustee has any Claim against the Company under this Agreement, including, without limitation, under <U>Section&nbsp;2(b)</U> or <U>Section&nbsp;2(c)</U> hereof, the Trustee shall pursue such Claim solely against the Company and its assets outside the Trust Account and not against the Property or any monies in the Trust Account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">5. <B><U>Termination</U></B>. This Agreement shall terminate as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(a) If the Trustee gives written notice to the Company that it desires to resign under this Agreement, the Company shall use its reasonable efforts to locate a successor trustee, pending which the Trustee shall continue to act in accordance with this Agreement. At such time that the Company notifies the Trustee that a successor trustee has been appointed and has agreed to become subject to the terms of this Agreement, the Trustee shall transfer the management of the Trust Account to the successor trustee, including but not limited to the transfer of copies of the reports and statements relating to the Trust Account, whereupon this Agreement shall terminate; <I>provided</I>, <I>however</I>, that in the event that the Company does not locate a successor trustee within ninety (90) days of receipt of the resignation notice from the Trustee, the Trustee may submit an application to have the Property deposited with any court in the State of New York or with the United States District Court for the Southern District of New York and upon such deposit, the Trustee shall be immune from any liability whatsoever; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(b) At such time that the Trustee has completed the liquidation of the Trust Account and its obligations in accordance with the provisions of <U>Section&nbsp;1(i)</U> hereof and distributed the Property in accordance with the provisions of the Termination Letter, this Agreement shall terminate except with respect to <U>Section&nbsp;2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(c) If the Offering is not consummated within ten (10) business days of the date of this Agreement, any funds received by the Trustee from the Company or Sponsor for purposes of funding the Trust Account shall be promptly returned to the Company or Sponsor, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">6. <B><U>Miscellaneous</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(a) The Company and the Trustee each acknowledge that the Trustee will follow the security procedures set forth below with respect to funds transferred from the Trust Account. The Company and the Trustee will each restrict access to confidential information relating to such security procedures to authorized persons. Each party must notify the other party immediately if it has reason to believe unauthorized persons may have obtained access to such confidential information, or of any change in its authorized personnel. In executing funds transfers, the Trustee shall rely upon all information supplied to it by the Company, including, account names, account numbers and all other identifying information relating to a Beneficiary, Beneficiary&rsquo;s bank or intermediary bank. Except for any liability arising out of the Trustee&rsquo;s gross negligence, fraud or willful misconduct, the Trustee shall not be liable for any loss, liability or expense resulting from any error in the information or transmission of the funds.</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(b) This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. This Agreement may be executed in several original or facsimile counterparts, each one of which shall constitute an original, and together shall constitute but one instrument.</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(c) This Agreement contains the entire agreement and understanding of the parties hereto with respect to the subject matter hereof. Except for <U>Sections&nbsp;1(i)</U>, <U>1(j), 1(k) and 1(l)</U> hereof (which sections may not be modified, amended or deleted unless such modification, amendment or deletion is approved by the affirmative vote of two- thirds of the then outstanding Ordinary Shares and Class B ordinary shares, par value $0.0001 per share, of the Company which are represented in person or by proxy and are voted at a general meeting of the Company, voting together as a single class; <I>provided </I>that no such amendment will affect any Public Shareholder who has properly elected to redeem his, her or its Ordinary Shares in connection with a shareholder vote to approve an amendment to this Agreement (A) to modify the substance or timing of the Company&rsquo;s obligation to allow redemption in connection with a Business Combination or to redeem one hundred per cent (100%) of the Public Shares if the Company has not consummated a Business Combination within the Completion Window or (B) with respect to any other material provisions relating to the rights of holders of Ordinary Shares or pre-initial Business Combination activity) this Agreement or any provision hereof may only be changed, amended or modified (other than to correct a typographical error) by a writing signed by each of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(d) The parties hereto consent to the jurisdiction and venue of any state or federal court located in the City of New York, State of New York, for purposes of resolving any disputes hereunder. AS TO ANY CLAIM, CROSS-CLAIM OR COUNTERCLAIM IN ANY WAY RELATING TO THIS AGREEMENT, EACH PARTY WAIVES THE RIGHT TO TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(e) Any notice, consent or request to be given in connection with any of the terms or provisions of this Agreement shall be in writing and shall be sent by express mail or similar private courier service, by certified mail (return receipt requested), by hand delivery or by facsimile or email transmission:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left">if to the Trustee, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Odyssey Transfer and Trust Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">ATTN: Operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">2155 Woodlane Drive Suite 100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Woodbury, MN 55125</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Email: BPaulson@OdysseyTrust.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left">if to the Company, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">D. Boral ARC Acquisition I Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">10 E. 53rd Street, Suite 3001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Telephone: (332) 266-7344</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Attn: David Boral</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Email: david@dboralcapital.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left">in each case, with copies to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Loeb &amp; Loeb LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">345 Park Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">New York, New York 10154</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Tel: (212) 407-4000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Attn: David Levine, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">D. Boral Capital LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">590 Madison Avenue, 39th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">New York, New York 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Attn: Mr.&nbsp;Gaurav Verma, Co-Head of Investment Banking</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Email: gverma@dboralcapital.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(f) Each of the Company and the Trustee hereby represents that it has the full right and power and has been duly authorized to enter into this Agreement and to perform its respective obligations as contemplated hereunder. The Trustee acknowledges and agrees that it shall not make any claims or proceed against the Trust Account, including by way of set-off, and shall not be entitled to any funds in the Trust Account under any circumstance.</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(g) This Agreement is the joint product of the Trustee and the Company and each provision hereof has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(h) Each of the Company and the Trustee hereby acknowledges and agrees that the Representative, on behalf of the Underwriters, is a third-party beneficiary of this Agreement.</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(i) Except as specified herein, no party to this Agreement may assign its rights or delegate its obligations hereunder to any other person or entity without the prior written consent of the other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the parties have duly executed this Investment Management Trust Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>Odyssey Transfer and Trust Company, as Trustee</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">/s/ Rebecca Paulson</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Rebecca Paulson</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">President</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>D. Boral ARC Acquisition I Corp.</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">/s/ John Darwin</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">John Darwin</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Chief Financial Officer</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature page to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-variant: small-caps">investment management trust agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SCHEDULE A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>[Letterhead of Company]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>[Insert date]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Odyssey Transfer and Trust Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ATTN: Operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2155 Woodlane Drive Suite 100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Woodbury, MN 55125</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">Re:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">Trust Account&mdash;Termination Letter</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dear [_]:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Pursuant to <U>Section&nbsp;1(i)</U> of the Investment Management Trust Agreement between D. Boral ARC Acquisition I Corp. (the &ldquo;<B><U>Company</U></B>&rdquo;) and Odyssey Transfer and Trust Company (the &ldquo;<B><U>Trustee</U></B>&rdquo;), dated as of _____, 2025 (the &ldquo;<B><U>Trust Agreement</U></B>&rdquo;), this is to advise you that the Company has entered into an agreement with [&#9679;] (the &ldquo;<B><U>Target Business</U></B>&rdquo;) to consummate a business combination with Target Business (the &ldquo;<B><U>Business Combination</U></B>&rdquo;) on or about [insert date]. The Company shall notify you at least seventy-two (72) hours in advance of the actual date of the consummation of the Business Combination (the &ldquo;<B><U>Consummation Date</U></B>&rdquo;). Capitalized terms used but not defined herein shall have the meanings set forth in the Trust Agreement.</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In accordance with the terms of the Trust Agreement, we hereby authorize you to commence to liquidate all of the assets of the Trust Account and to transfer the proceeds into the trust operating account in the United States at JP Morgan Chase, NA to the effect that, on the Consummation Date, all of the funds held in the Trust Account will be immediately available for transfer to the account or accounts that the Company shall direct on the Consummation Date. It is acknowledged and agreed that while the funds are on deposit in the trust operating account at JP Morgan Chase, NA awaiting distribution, the Company will not earn any interest or dividends.</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">On the Consummation Date (i) counsel for the Company shall deliver to you written notification that the Business Combination has been consummated, or will be consummated concurrently with your transfer of funds to the accounts as directed by the Company (the &ldquo;<B><U>Notification</U></B>&rdquo;), (ii) the Company shall deliver to you (a) a certificate of the Chief Executive Officer or Chief Financial Officer of the Company, which verifies that the Business Combination has been approved by a vote of the Company&rsquo;s shareholders, if a vote is held and (b) a joint written instruction signed by the Company and the Representative with respect to the transfer of the funds held in the Trust Account, including payment of amounts owed to Public Shareholders who have properly exercised their redemption rights (the &ldquo;<B><U>Instruction Letter</U></B>&rdquo;). You are hereby directed and authorized to transfer the funds held in the Trust Account immediately upon your receipt of the Notification and the Instruction Letter, in accordance with the terms of the Instruction Letter. In the event that certain deposits held in the Trust Account may not be liquidated by the Consummation Date without penalty, you will notify the Company in writing of the same and the Company shall direct you as to whether such funds should remain in the Trust Account and be distributed after the Consummation Date to the Company. Upon the distribution of all the funds, net of any payments necessary for reasonable unreimbursed expenses related to liquidating the Trust Account, your obligations under the Trust Agreement shall be terminated.</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In the event that the Business Combination is not consummated on the Consummation Date described in the notice thereof and we have not notified you on or before the original Consummation Date of a new Consummation Date, then upon receipt by the Trustee of written instructions from the Company, the funds held in the Trust Account shall be reinvested as provided in <U>Section&nbsp;1(c)</U> of the Trust Agreement on the business day immediately following the Consummation Date as set forth in such written instructions as soon thereafter as possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Very truly yours,</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">D. Boral ARC Acquisition I Corp.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Agreed and acknowledged by:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">D. BORAL CAPITAL LLC</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 45%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 50%">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exhibit B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>[Letterhead of Company]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>[Insert date]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Odyssey Transfer and Trust Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ATTN: Operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2155 Woodlane Drive Suite 100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Woodbury, MN 55125</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">Re:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">Trust Account&mdash;Termination Letter</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dear [_]:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Pursuant to <U>Section&nbsp;1(i)</U> of the Investment Management Trust Agreement between D. Boral ARC Acquisition I Corp. (the &ldquo;<B><U>Company</U></B>&rdquo;) and Odyssey Transfer and Trust Company (the &ldquo;<B><U>Trustee</U></B>&rdquo;), dated as of _____, 2025 (the &ldquo;<B><U>Trust Agreement</U></B>&rdquo;), this is to advise you that [the Company has been unable to effect a business combination with a Target Business within the time frame specified in the Company&rsquo;s amended and restated memorandum and articles of association, as may be amended from time to time (the &ldquo;<B><U>Memorandum and Articles</U></B>&rdquo;)] OR [the Company&rsquo;s board of directors has determined to terminate the period in which the Company must consummate a Business Combination on ____, 20___ pursuant to the Company&rsquo;s amended and restated memorandum and articles of association, as may be amended from time to time (the &ldquo;<B><U>Memorandum and Articles</U></B>&rdquo;)] as described in the Company&rsquo;s Prospectus relating to the Offering. Capitalized terms used but not defined herein shall have the meanings set forth in the Trust Agreement.</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In accordance with the terms of the Trust Agreement, we hereby authorize you to liquidate all of the assets in the Trust Account and to transfer the total proceeds into the trust operating account in the United States at JP Morgan Chase to await distribution to the Public Shareholders, less taxes payable and up to $100,000 to cover dissolution expenses of the Company. In accordance with the terms of the Trust Agreement, you are hereby directed and authorized to transfer (via wire transfer) such $_____ promptly upon your receipt of this letter to the Company&rsquo;s operating account at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[WIRE INSTRUCTION INFORMATION].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The Company has selected [&#9679;], 20[ ]<SUP>1</SUP> as the effective date for the purpose of determining when the Public Shareholders will be entitled to receive their share of the liquidation proceeds. You agree to be the Paying Agent of record and, in your separate capacity as Paying Agent, agree to distribute said funds directly to the Company&rsquo;s Public Shareholders in accordance with the terms of the Trust Agreement and the Amended and Restated Memorandum and Articles of Association. Upon the distribution of all the funds, net of any payments necessary for reasonable unreimbursed expenses related to liquidating the Trust Account, your obligations under the Trust Agreement shall be terminated, except to the extent otherwise provided in <U>Section&nbsp;1(j)</U> of the Trust Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Very truly yours,</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">D. Boral ARC Acquisition I Corp.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">By:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">cc:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">D. Boral Capital LLC</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->





<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><SUP>1</SUP></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">18 months after the closing of the Offering (or 21 months if the time to complete a Business Combination is extended for 3 months by the Sponsor in accordance with the terms of the Company&rsquo;s amended and restated memorandum and articles of association), such earlier date as the Company&rsquo;s board of directors may approve, or such later date as the Company&rsquo;s shareholders may approve.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exhibit C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>[Letterhead of Company]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>[Insert date]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Odyssey Transfer and Trust Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ATTN: Operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2155 Woodlane Drive Suite 100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Woodbury, MN 55125</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">Re:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">Trust Account&mdash;Tax Payment Withdrawal Instruction</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dear [_]:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt; text-align: justify">Pursuant to <U>Section&nbsp;1(j)</U> of the Investment Management Trust Agreement between D. Boral ARC Acquisition I Corp. (the &ldquo;<B><U>Company</U></B>&rdquo;) and Odyssey Transfer and Trust Company (the &ldquo;<B><U>Trustee</U></B>&rdquo;), dated as of _____, 2025 (the &ldquo;<B><U>Trust Agreement</U></B>&rdquo;), the Company hereby requests that you deliver to the Company $[&#9679;] of the interest income earned on the Property as of the date hereof. Capitalized terms used but not defined herein shall have the meanings set forth in the Trust Agreement.</P>

<P STYLE="text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt; text-align: justify">The Company needs such funds to pay for the tax obligations, as permitted under the Trust Agreement, as set forth on the attached tax return or tax statement. In accordance with the terms of the Trust Agreement, you are hereby directed and authorized to transfer (via wire transfer) such funds promptly upon your receipt of this letter to the Company&rsquo;s operating account at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>[WIRE INSTRUCTION INFORMATION]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Very truly yours,</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">D. Boral ARC Acquisition I Corp.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">cc:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">D. Boral Capital LLC</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exhibit D</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>[Letterhead of Company]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>[Insert date]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Odyssey Transfer and Trust Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ATTN: Operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2155 Woodlane Drive Suite 100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Woodbury, MN 55125</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">Re:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">Trust Account&mdash;Shareholder Redemption Withdrawal Instruction</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dear [_]:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Pursuant to <U>Section&nbsp;1(k)</U> of the Investment Management Trust Agreement between D. Boral ARC Acquisition I Corp. (the &ldquo;<B><U>Company</U></B>&rdquo;) and Odyssey Transfer and Trust Company (the &ldquo;<B><U>Trustee</U></B>&rdquo;), dated as of _____, 2025 (the &ldquo;<B><U>Trust Agreement</U></B>&rdquo;), the Company hereby requests that you deliver to the redeeming Public Shareholders of the Company $[&#9679;] of the principal and interest income earned on the Property as of the date hereof to a segregated account held by you on behalf of the Beneficiaries for distribution to the Public Shareholders who have requested redemption of their Ordinary Shares. Capitalized terms used but not defined herein shall have the meanings set forth in the Trust Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The Company needs such funds to pay its Public Shareholders who have properly elected to have their Ordinary Shares redeemed by the Company in connection with a shareholder vote to approve an amendment to the Company&rsquo;s amended and restated memorandum and articles of association, as may be amended from time to time (the &ldquo;<B><U>Memorandum and Articles</U></B>&rdquo;) not for the purposes of approving, or in conjunction with the consummation of, a Business Combination (A) to modify the substance or timing of the Company&rsquo;s obligation to allow redemption in connection with a Business Combination or to redeem one hundred per cent (100%) of the Public Shares if the Company has not consummated a Business Combination within the Completion Window or (B) with respect to any other material provisions relating to the rights of holders of Ordinary Shares or pre-initial Business Combination activity. As such, you are hereby directed and authorized to transfer (via wire transfer) such funds promptly upon your receipt of this letter to the redeeming Public Shareholders in accordance with your customary procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Very truly yours,</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">D. Boral ARC Acquisition I Corp.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">By:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">cc:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">D. Boral Capital LLC</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>7
<FILENAME>dboralarcacq_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 10.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION RIGHTS AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS REGISTRATION RIGHTS AGREEMENT (this &ldquo;<B><U>Agreement</U></B>&rdquo;), dated as of July&nbsp;30, 2025 is made and entered into by and among D. Boral ARC Acquisition I Corp., a BVI business company (the &ldquo;<B><U>Company</U></B>&rdquo;), MFH 1, LLC, a Delaware limited liability company (the &ldquo;<B><U>Sponsor</U></B>&rdquo;), D. Boral Capital LLC (the &ldquo;<B><U>Representative</U></B>&rdquo;) and the undersigned parties listed under Holder on the signature pages hereto (each such party, and any person or entity who hereafter becomes a party to this Agreement pursuant to <U>Section&nbsp;5.2</U> of this Agreement, a &ldquo;<B><U>Holder</U></B>&rdquo; and collectively the &ldquo;<B><U>Holders</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RECITALS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>, the Company intends to consummate an initial public offering of the Company&rsquo;s units (the &ldquo;<B><U>IPO</U></B>&rdquo;), each unit consisting of Class A Ordinary Share, par value $0.0001 per share (the &ldquo;<B>Ordinary Shares</B>&rdquo;), of the Company, and one-half of one redeemable warrant (a &ldquo;<B><U>Warrant</U></B>&rdquo;) to be governed by the Warrant Agreement to be entered into between the Company and Odyssey Transfer and Trust Company, as warrant agent (the &ldquo;<B><U>Warrant Agreement</U></B>&rdquo;). Each whole Warrant entitles the holder to purchase one Class A Ordinary Share at an exercise price of $11.50 per Ordinary Share;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>, the Sponsor owns an aggregate of 12,321,429 of the Company&rsquo;s Class B ordinary shares, par value $0.0001 per share (the &ldquo;<B><U>Founder Shares</U></B>&rdquo;) up to 1,607,143 of which will be surrendered to the Company for no consideration depending on the extent to which the underwriters of the IPO exercise their over-allotment option;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>, the Founder Shares are convertible into Ordinary Shares, on the terms and conditions provided in the Company&rsquo;s amended and restated memorandum and articles of association, as may be further amended from time to time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS,
</B>on the date hereof, the Company and the Sponsor have entered into certain Private Placement Units Purchase Agreement with the Company
(the &ldquo;<B><U>Private Placement Units Purchase Agreement</U></B>&rdquo;), pursuant to which the Sponsor agreed to purchase an aggregate
of 200,000 units (whether or not the over-allotment option in connection with the IPO is exercised) (the &ldquo;<B><U>Private Placement
Units</U></B>&rdquo;), each Private Placement Unit consisting of one Ordinary Share (the &ldquo;<B><U>Private Placement Shares</U></B>&rdquo;)
and one-half of one redeemable Warrant (the &ldquo;<B><U>Private Placement Warrants</U></B>&rdquo;) in a private placement transaction
occurring simultaneously with the closing of the IPO. Each whole Sponsor Private Placement Warrant entitles the holder thereof to purchase
one Ordinary Share (a &ldquo;<B><U>Warrant Share</U></B>&rdquo;) at an exercise price of $11.50 per Ordinary Share;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS, </B>the Company issued an aggregate of 1,000,000 of Ordinary Shares to the Representative and/or its designees (the &ldquo;<B><U>Representative Shares</U></B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>, in order to finance the Company&rsquo;s transaction costs in connection with its search for and consummation of an initial Business Combination (as defined below), the Sponsor, its affiliates or any of the Company&rsquo;s officers and directors may loan to the Company funds as the Company may require, of which up to $2,500,000 of such loans may be convertible into additional units (the &ldquo;<B><U>Working Capital Units</U></B>&rdquo;) at a price of $10.00 per Working Capital Unit at the option of the lender. Each Working Capital Unit consists of one Ordinary Share (the &ldquo;<B><U>Working Capital Shares</U></B>&rdquo;) and one-half of one redeemable Warrant (the &ldquo;<B><U>Working Capital Warrants</U></B>&rdquo;), with each whole Working Capital Warrant entitling the holder thereof to purchase one Ordinary Share (a &ldquo;<B><U>Working Capital Warrant Share</U></B>&rdquo;) at an exercise price of $11.50 per Ordinary Share;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>, the Company and the Holders desire to enter into this Agreement, pursuant to which the Company shall grant the Holders certain registration rights with respect to certain securities of the Company, as set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW, THEREFORE</B>, in consideration of the representations, covenants and agreements contained herein, and certain other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE 1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>DEFINITIONS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.1 <U>Definitions</U></B>. The terms defined in this <U>Article 1</U> shall, for all purposes of this Agreement, have the respective meanings set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Agreement</U></B>&rdquo; shall have the meaning given in the Preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Block Trade</U></B>&rdquo; shall have the meaning given to it in <U>subsection&nbsp;2.3.1</U> of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Board</U></B>&rdquo; shall mean the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Business Combination</U></B>&rdquo; shall mean any merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses or entities, involving the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Commission</U></B>&rdquo; shall mean the U.S. Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Company</U></B>&rdquo; shall have the meaning given in the Preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Demanding Holder</U></B>&rdquo; shall mean any Holder or group of Holders, that together elects to dispose of Registrable Securities having an aggregate value of at least $25 million, at the time of the Underwritten Demand, under a Registration Statement pursuant to an Underwritten Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Effectiveness Period</U></B>&rdquo; shall have the meaning given in <U>subsection&nbsp;3.1.1</U> of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Exchange Act</U></B>&rdquo; shall mean the Securities Exchange Act of 1934, as it may be amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Financial Counterparty</U></B>&rdquo; shall have the meaning given in <U>subsection&nbsp;2.3.1</U> of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Founder Shares</U></B>&rdquo; shall have the meaning given in the Recitals hereto and shall be deemed to include the Ordinary Shares issuable upon conversion thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Holder Indemnified Persons</U></B>&rdquo; shall have the meaning given in <U>subsection&nbsp;4.1.1</U> of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><U>Founder Shares Lock-up Period</U></B>&rdquo; shall mean
the period ending upon the completion of the Company&rsquo;s initial Business Combination.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Holders</U></B>&rdquo; shall have the meaning given in the Preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Insider Letter</U></B>&rdquo; shall mean that certain letter agreement, dated as of the date hereof, by and among the Company, the Sponsor and each of the Company&rsquo;s officers and directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;<U>IPO</U>&rdquo; </B>shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Maximum Number of Securities</U></B>&rdquo; shall have the meaning given in <U>subsection&nbsp;2.1.4</U> of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Misstatement</U></B>&rdquo; shall mean, in the case of a Registration Statement, an untrue statement of a material fact or an omission to state a material fact required to be stated therein, or necessary to make the statements therein not misleading, and in the case of a Prospectus, an untrue statement of a material fact or an omission to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Ordinary Shares</U></B>&rdquo; shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Other Coordinated Offering</U></B>&rdquo; shall have the meaning given to it in <U>subsection&nbsp;2.3.1</U> of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Piggyback Registration</U></B>&rdquo; shall have the meaning given in <U>subsection&nbsp;2.2.1</U> of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Permitted Transferees</U></B>&rdquo; shall mean any person or entity to whom a Holder of Registrable Securities is permitted to transfer such Registrable Securities prior to the expiration of the Founder Shares Lock-up Period, Private Placement Lock-up Period or any other lock-up period, as the case may be, under the Insider Letter, the Private Placement Units Purchase Agreement, this Agreement and any other applicable agreement between such Holder and the Company, and to any transferee thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Private Placement Lock-up Period</U></B>&rdquo; shall mean the period ending upon the completion of the Company&rsquo;s initial Business Combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Private Placement Shares</U></B>&rdquo; shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Private Placement Units</U></B>&rdquo; shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Private Placement Units Purchase Agreement</U></B>&rdquo; shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Private Placement Warrants</U></B>&rdquo; shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Pro Rata</U></B>&rdquo; shall have the meaning given in <U>subsection&nbsp;2.1.4</U> of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Prospectus</U></B>&rdquo; shall mean the prospectus included in any Registration Statement, as supplemented by any and all prospectus supplements and as amended by any and all post-effective amendments and including all material incorporated by reference in such prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Registrable Security</U></B>&rdquo; shall mean (a) the Founder Shares and the Ordinary Shares issued or issuable upon the conversion of any Founder Shares, (b) the Private Placement Units, Private Placement Shares, Private Placement Warrants and Warrant Shares, (c) the Representative Shares, (d) any outstanding Ordinary Shares or any other equity security (including the Ordinary Shares issued or issuable upon the exercise of any other equity security) of the Company held by a Holder as of the date of this Agreement or acquired prior to or in connection with the Business Combination, which, for the avoidance of doubt, shall include any Ordinary Shares received by a Holder on or after the date hereof as a distribution from the Sponsor in connection with its liquidation and dissolution, (e) any Working Capital Units, Working Capital Shares, Working Capital Warrants and Working Capital Warrant Shares, and (f) any other equity security of the Company issued or issuable with respect to any such Ordinary Share by way of a share capitalization or share split or in connection with a combination of shares, recapitalization, merger, consolidation or reorganization; <U>provided</U>, <U>however</U>, that, as to any particular Registrable Security, such securities shall cease to be Registrable Securities when: (A) a Registration Statement with respect to the sale of such securities shall have become effective under the Securities Act and such securities shall have been sold, transferred, disposed of or exchanged in accordance with such Registration Statement; (B) such securities shall have been otherwise transferred, new certificates for such securities not bearing a legend restricting further transfer shall have been delivered by the Company and subsequent public distribution of such securities shall not require registration under the Securities Act; (C) such securities shall have ceased to be outstanding; (D) such securities may be sold without registration pursuant to Rule&nbsp;144 promulgated under the Securities Act (or any successor rule promulgated thereafter by the Commission) (but with no volume or other restrictions or limitations); or (E) such securities have been sold to, or through, a broker, dealer or underwriter in a public distribution or other public securities transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Registration</U></B>&rdquo; shall mean a registration effected by preparing and filing a registration statement or similar document in compliance with the requirements of the Securities Act, and the applicable rules and regulations promulgated thereunder, and any such registration statement having become effective by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Registration Expenses</U></B>&rdquo; shall mean the out-of-pocket expenses of a Registration, including, without limitation, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) all registration and filing fees (including fees with respect to filings required to be made with the Financial Industry Regulatory Authority) and any securities exchange on which the Ordinary Shares are then listed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) fees and expenses of compliance with securities or blue sky laws (including reasonable fees and disbursements of counsel for the Underwriters in connection with blue sky qualifications of Registrable Securities);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) printing, messenger, telephone and delivery expenses;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) reasonable fees and disbursements of counsel for the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) reasonable fees and disbursements of all independent registered public accountants of the Company incurred specifically in connection with such Registration or Underwritten Offering;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) the fees and expenses incurred in connection with the listing of any Registrable Securities on each securities exchange or automated quotation system on which similar securities issued by the Company are then listed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) the fees and expenses incurred by the Company in connection with any road show for any Underwritten Offerings; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h) reasonable fees and expenses of one (1) legal counsel selected jointly by the Demanding Holders initiating an Underwritten Demand, the Requesting Holders participating in an Underwritten Offering and the Holders participating in a Piggyback Registration, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Registration Statement</U></B>&rdquo; shall mean any registration statement under the Securities Act that covers the Registrable Securities pursuant to the provisions of this Agreement, including the Prospectus included in such registration statement, amendments (including post-effective amendments) and supplements to such registration statement and all exhibits to and all material incorporated by reference in such registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Representative</U></B>&rdquo; shall have the meaning given in the Preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Representative Shares</U></B>&rdquo; shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Requesting Holder</U></B>&rdquo; shall have the meaning given in <U>subsection&nbsp;2.1.3</U> of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Securities Act</U></B>&rdquo; shall mean the Securities Act of 1933, as amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Shelf Registration</U></B>&rdquo; shall have the meaning given in <U>subsection&nbsp;2.1.1</U> of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Sponsor</U></B>&rdquo; shall have the meaning given in the Preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Suspension Event</U></B>&rdquo; shall have the meaning given in <U>Section&nbsp;3.4</U> of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Underwriter</U></B>&rdquo; shall mean a securities dealer who purchases any Registrable Securities as principal in an Underwritten Offering and not as part of such dealer&rsquo;s market-making activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Underwritten Demand</U></B>&rdquo; shall have the meaning given in <U>subsection&nbsp;2.1.3</U> of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Underwritten Offering</U></B>&rdquo; shall mean a Registration in which securities of the Company are sold to an Underwriter in a firm commitment underwriting for distribution to the public.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;<U>Warrant</U>&rdquo; </B>shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;<U>Warrant Share</U>&rdquo; </B>shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;<U>Warrant Agreement</U>&rdquo; </B>shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Working Capital Shares</U></B>&rdquo; shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Working Capital Units</U></B>&rdquo; shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Working Capital Warrants</U></B>&rdquo; shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><U>Working Capital Warrant Shares</U></B>&rdquo; shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE 2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>REGISTRATIONS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.1 <U>Registration</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.1 <U>Shelf Registration</U>. The Company agrees that, within twenty (20) business days after the consummation of the Business Combination, the Company will use commercially reasonable efforts to file with the Commission (at the Company&rsquo;s sole cost and expense) a Registration Statement registering the resale or other disposition of the Registrable Securities (a &ldquo;<B><U>Shelf Registration</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.2 <U>Effective Registration</U>. The Company shall use commercially reasonable efforts to cause such Registration Statement to become effective by the Commission as soon as reasonably practicable after the initial filing of the Registration Statement. Subject to the limitations contained in this Agreement, the Company shall effect any Shelf Registration on such appropriate registration form of the Commission (a) as shall be selected by the Company and (b) as shall permit the resale or other disposition of the Registrable Securities by the Holders. If at any time a Registration Statement filed with the Commission pursuant to <U>Section&nbsp;2.1.1</U> is effective and a Holder provides written notice to the Company that it intends to effect an offering of all or part of the Registrable Securities included on such Registration Statement, the Company will use commercially reasonable efforts to amend or supplement such Registration Statement as may be necessary in order to enable such offering to take place in accordance with the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.3 <U>Underwritten Offering</U>. Subject to the provisions of <U>subsection&nbsp;2.1.4</U> and <U>Sections&nbsp;2.4</U> and <U>3.4</U> hereof, any Demanding Holder may make a written demand for an Underwritten Offering pursuant to a Registration Statement filed with the Commission in accordance with <U>Section&nbsp;2.1.1</U> (an &ldquo;<B><U>Underwritten Demand</U></B>&rdquo;). The Company shall, within ten (10) days of the Company&rsquo;s receipt of the Underwritten Demand, notify, in writing, all other Holders of such demand, and each Holder who thereafter requests to include all or a portion of such Holder&rsquo;s Registrable Securities in such Underwritten Offering pursuant to such Underwritten Demand (each such Holder that requests to include all or a portion of such Holder&rsquo;s Registrable Securities in such Underwritten Offering, a &ldquo;<B><U>Requesting Holder</U></B>&rdquo;) shall so notify the Company, in writing, within two (2) days (one (1) day if such offering is an overnight or bought Underwritten Offering) after the receipt by the Holder of the notice from the Company. Upon receipt by the Company of any such written notification from a Requesting Holder(s), such Requesting Holder(s) shall be entitled to have their Registrable Securities included in such Underwritten Offering pursuant to such Underwritten Demand. All such Holders proposing to distribute their Registrable Securities through such Underwritten Offering under this <U>subsection&nbsp;2.1.3</U> shall enter into an underwriting agreement in customary form with the Underwriter(s) selected for such Underwritten Offering by the Demanding Holders initiating such Underwritten Offering. Notwithstanding the foregoing, the Company is not obligated to effect more than an aggregate of three (3) Underwritten Offerings pursuant to this <U>subsection&nbsp;2.1.3</U> and is not obligated to effect an Underwritten Offering pursuant to this <U>subsection&nbsp;2.1.3</U> within ninety (90) days after the closing of an Underwritten Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.4 <U>Reduction of Underwritten Offering</U>. If the managing Underwriter or Underwriters in an Underwritten Offering pursuant to an Underwritten Demand, in good faith, advises the Company, the Demanding Holders, the Requesting Holders and other persons or entities holding Ordinary Shares or other equity securities of the Company that the Company is obligated to include pursuant to separate written contractual arrangements with such persons or entities (if any) in writing that the dollar amount or number of Registrable Securities or other equity securities of the Company requested to be included in such Underwritten Offering exceeds the maximum dollar amount or maximum number of equity securities of the Company that can be sold in the Underwritten Offering without adversely affecting the proposed offering price, the timing, the distribution method or the probability of success of such offering (such maximum dollar amount or maximum number of such securities, as applicable, the &ldquo;<B><U>Maximum Number of Securities</U></B>&rdquo;), then the Company shall include in such Underwritten Offering, as follows: (a) first, the Registrable Securities of the Demanding Holders (pro rata based on the respective number of Registrable Securities that each Demanding Holder has requested be included in such Underwritten Offering and the aggregate number of Registrable Securities that the Demanding Holders have requested be included in such Underwritten Offering (such proportion is referred to herein as &ldquo;<B><U>Pro Rata</U></B>&rdquo;)) that can be sold without exceeding the Maximum Number of Securities; (b) second, to the extent that the Maximum Number of Securities has not been reached under the foregoing <U>clause (a)</U>, the Registrable Securities of the Requesting Holders, Pro Rata, which can be sold without exceeding the Maximum Number of Securities; (c) third, to the extent that the Maximum Number of Securities has not been reached under the foregoing <U>clauses (a)</U> and <U>(b)</U>, Ordinary Shares or other equity securities of the Company that the Company desires to sell and that can be sold without exceeding the Maximum Number of Securities; and (d) fourth, to the extent that the Maximum Number of Securities has not been reached under the foregoing <U>clauses (a)</U>, <U>(b)</U> and <U>(c)</U>, Ordinary Shares or other equity securities of the Company held by other persons or entities that the Company is obligated to include pursuant to separate written contractual arrangements with such persons or entities and that can be sold without exceeding the Maximum Number of Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.2 <U>Piggyback Registration</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1 <U>Piggyback Rights</U>. Subject to the provisions of <U>subsection&nbsp;2.2.2</U> and <U>Sections&nbsp;2.4</U> and <U>3.4</U> hereof, if, at any time on or after the date the Company consummates a Business Combination, the Company proposes to consummate an Underwritten Offering for its own account or for the account of shareholders of the Company, then the Company shall give written notice of such proposed action to all of the Holders as soon as practicable, which notice shall (a) describe the amount and type of securities to be included, the intended method(s) of distribution and the name of the proposed managing Underwriter or Underwriters, if any, and (b) offer to all of the Holders the opportunity to include of such number of Registrable Securities as such Holders may request in writing within two (2) days (unless such offering is an overnight or bought Underwritten Offering, then one (1) day), in each case after receipt of such written notice (such Registration a &ldquo;<B><U>Piggyback Registration</U></B>&rdquo;). The Company shall, in good faith, cause such Registrable Securities to be included in such Piggyback Registration and shall use its reasonable best efforts to cause the managing Underwriter or Underwriters of a proposed Underwritten Offering to permit the Registrable Securities requested by the Holders pursuant to this <U>subsection&nbsp;2.2.1</U> to be included in a Piggyback Registration on the same terms and conditions as any similar securities of the Company included in such Piggyback Registration and to permit the resale or other disposition of such Registrable Securities in accordance with the intended method(s) of distribution thereof. All such Holders proposing to include Registrable Securities in an Underwritten Offering under this <U>subsection&nbsp;2.2.1</U> shall enter into an underwriting agreement in customary form with the Underwriter(s) selected for such Underwritten Offering by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.2 <U>Reduction of Piggyback Registration</U>. If the managing Underwriter or Underwriters in an Underwritten Offering that is to be a Piggyback Registration, in good faith, advises the Company and the Holders of Registrable Securities participating in the Piggyback Registration in writing that the dollar amount or number of shares or equity securities of the Company that the Company desires to sell, taken together with (a) the shares or equity securities of the Company, if any, as to which the Underwritten Offering has been demanded pursuant to separate written contractual arrangements with persons or entities other than the Holders of Registrable Securities hereunder, (b) the Registrable Securities as to which a Piggyback Registration has been requested pursuant to this <U>Section&nbsp;2.2</U> and (c) the shares or equity securities of the Company, if any, as to which inclusion in the Underwritten Offering has been requested pursuant to separate written contractual piggyback registration rights of other shareholders of the Company, exceeds the Maximum Number of Securities, then:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) If the Underwritten Offering is undertaken for the Company&rsquo;s account, the Company shall include in any such Underwritten Offering (A) first, the Ordinary Shares or other equity securities of the Company that the Company desires to sell, which can be sold without exceeding the Maximum Number of Securities; (B) second, to the extent that the Maximum Number of Securities has not been reached under the foregoing <U>clause (A)</U>, the Registrable Securities of Holders requesting a Piggyback Registration pursuant to <U>subsection&nbsp;2.2.1</U>, Pro Rata, which can be sold without exceeding the Maximum Number of Securities; and (C) third, to the extent that the Maximum Number of Securities has not been reached under the foregoing <U>clauses (A)</U> and <U>(B)</U>, Ordinary Shares or other equity securities of the Company, if any, as to which inclusion in the Underwritten Offering has been requested pursuant to written contractual piggyback registration rights of other shareholders of the Company, which can be sold without exceeding the Maximum Number of Securities; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) If the Underwritten Offering is pursuant to a request by persons or entities other than the Holders of Registrable Securities, then the Company shall include in any such Underwritten Offering (A) first, Ordinary Shares or other equity securities of the Company, if any, of such requesting persons or entities, other than the Holders, which can be sold without exceeding the Maximum Number of Securities; (B) second, to the extent that the Maximum Number of Securities has not been reached under the foregoing <U>clause (A)</U>, the Registrable Securities of Holders requesting a Piggyback Registration pursuant to <U>subsection&nbsp;2.2.1</U>, Pro Rata, which can be sold without exceeding the Maximum Number of Securities; (C) third, to the extent that the Maximum Number of Securities has not been reached under the foregoing <U>clauses (A)</U> and <U>(B)</U>, Ordinary Shares or other equity securities of the Company that the Company desires to sell, which can be sold without exceeding the Maximum Number of Securities; and (D) fourth, to the extent that the Maximum Number of Securities has not been reached under the foregoing <U>clauses (A)</U>, <U>(B)</U> and <U>(C)</U>, Ordinary Shares or other equity securities of the Company for the account of other persons or entities that the Company is obligated to register pursuant to separate written contractual arrangements with such persons or entities, which can be sold without exceeding the Maximum Number of Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.3 <U>Piggyback Registration Withdrawal</U>. Any Holder shall have the right to withdraw from a Piggyback Registration for any or no reason whatsoever upon written notification to the Company and the Underwriter or Underwriters (if any) of his, her or its intention to withdraw from such Piggyback Registration prior to the commencement of the Underwritten Offering. Notwithstanding anything to the contrary in this Agreement, the Company shall be responsible for the Registration Expenses incurred in connection with the Piggyback Registration prior to its withdrawal under this <U>subsection&nbsp;2.2.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.4 <U>Unlimited Piggyback Registration Rights</U>. For purposes of clarity, any Registration or Underwritten Offering effected pursuant to this <U>Section&nbsp;2.2</U> shall not be counted as an Underwritten Offering pursuant to an Underwritten Demand effected under <U>Section&nbsp;2.1</U> hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.3 <U>Block Trades Other Coordinated Offerings</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.1 Notwithstanding any other provision of this <U>Article 2</U>, but subject to <U>Sections&nbsp;2.4</U> and <U>3.4</U>, at any time and from time to time when an effective Registration Statement is on file with the Commission, if a Demanding Holder wishes to engage in (a) an underwritten registered offering not involving a &ldquo;roadshow,&rdquo; an offer commonly known as a &ldquo;block trade&rdquo; (a &ldquo;<B><U>Block Trade</U></B>&rdquo;) or (b) an &ldquo;at the market&rdquo; or similar registered offering through a broker, sales agent or distribution agent, whether as agent or principal, (an &ldquo;<B><U>Other Coordinated Offering</U></B>&rdquo;), in each case, with a total offering price reasonably expected to exceed, in the aggregate, $25 million, then if such Demanding Holder requires any assistance from the Company pursuant to this <U>Section&nbsp;2.3</U>, such Holder shall notify the Company promptly of the Block Trade or Other Coordinated Offering at least five (5) business days prior to the day such offering is to commence and the Company shall use its commercially reasonable efforts to facilitate such Block Trade or Other Coordinated Offering; provided that the Demanding Holders representing a majority of the Registrable Securities wishing to engage in the Block Trade or Other Coordinated Offering shall use commercially reasonable efforts to work with the Company and any Underwriters or brokers, sales agents or placement agents (each, a &ldquo;<B><U>Financial Counterparty</U></B>&rdquo;) prior to making such request in order to facilitate preparation of the registration statement, prospectus and other offering documentation related to the Block Trade or Other Coordinated Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.2 Prior to the filing of the applicable &ldquo;red herring&rdquo; prospectus or prospectus supplement used in connection with a Block Trade or Other Coordinated Offering, a majority-in interest of the Demanding Holders initiating such Block Trade or Other Coordinated Offering shall have the right to withdraw from such Block Trade or Other Coordinated Offering for any or no reason whatsoever upon written notification to the Company, the Underwriter or Underwriters (if any) and Financial Counterparty (if any) of their intention to withdraw from such Block Trade or Other Coordinated Offering. Notwithstanding anything to the contrary in this Agreement, the Company shall be responsible for the Registration Expenses incurred in connection with a Block Trade or Other Coordinated Offering prior to its withdrawal under this <U>subsection&nbsp;2.3.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.3 Notwithstanding anything to the contrary in this Agreement, <U>Section&nbsp;2.2</U> shall not apply to a Block Trade or Other Coordinated Offering initiated by a Demanding Holder pursuant to <U>Section&nbsp;2.3</U> of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.4 The Demanding Holder in a Block Trade or Other Coordinated Offering shall have the right to select the Underwriters and Financial Counterparty (if any) for such Block Trade or Other Coordinated Offering (in each case, which shall consist of one or more reputable nationally recognized investment banks).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.5 A Demanding Holder in the aggregate may demand no more than four (4) Block Trades or Other Coordinated Offerings pursuant to this <U>Section&nbsp;2.3</U> in any twelve (12) month period. For the avoidance of doubt, any Block Trade or Other Coordinated Offering effected pursuant to this <U>Section&nbsp;2.3</U> shall not be counted as a demand for an Underwritten Offering pursuant to <U>subsection&nbsp;2.1.3</U> hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.4 <U>Restrictions on Registration Rights</U></B>. If (a) the Holders have requested an Underwritten Offering pursuant to an Underwritten Demand and the Company and the Holders are unable to obtain the commitment of underwriters to firmly underwrite the offer; or (b) the Holders have requested an Underwritten Offering pursuant to an Underwritten Demand and in the good faith judgment of the Board such Underwritten Offering would be seriously detrimental to the Company and the Board concludes as a result that it is essential to defer the undertaking of such Underwritten Offering at such time, then in each case the Company shall furnish to such Holders a certificate signed by the Chairman of the Board stating that in the good faith judgment of the Board it would be seriously detrimental to the Company to undertake such Underwritten Offering in the near future and that it is therefore essential to defer the undertaking of such Underwritten Offering. In such event, the Company shall have the right to defer such offering for a period of not more than thirty (30) days; provided, however, that the Company shall not defer its obligation in this manner more than once in any twelve (12)-month period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE 3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>COMPANY PROCEDURES</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.1 <U>General Procedures</U>.</B> The Company shall use its reasonable best efforts to effect such Registration or Underwritten Offering to permit the resale or other disposition of such Registrable Securities in accordance with the intended plan of distribution thereof, and pursuant thereto the Company shall, as expeditiously as possible and to the extent applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.1 prepare and file with the Commission after the consummation of the Business Combination a Registration Statement with respect to such Registrable Securities and use commercially reasonable efforts to cause such Registration Statement to become effective in accordance with <U>Section&nbsp;2.1</U> hereof and remain effective, including filing a replacement Registration Statement, if necessary, until all Registrable Securities covered by such Registration Statement have been sold or are no longer outstanding (such period, the &ldquo;<B><U>Effectiveness Period</U></B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.2 prepare and file with the Commission such amendments and post-effective amendments to the Registration Statement, and such supplements to the Prospectus, as may be reasonably requested by the Holders or any Underwriter or as may be required by the rules, regulations or instructions applicable to the registration form used by the Company or by the Securities Act or rules and regulations thereunder to keep the Registration Statement effective until all Registrable Securities covered by such Registration Statement are sold in accordance with the intended plan of distribution set forth in such Registration Statement or supplement to the Prospectus or are no longer outstanding;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.3 prior to filing a Registration Statement or Prospectus, or any amendment or supplement thereto, furnish without charge to the Underwriters or Financial Counterparty, if any, and the Holders of Registrable Securities included in such Registration or Underwritten Offering or Block Trade, and such Holders&rsquo; legal counsel, copies of such Registration Statement as proposed to be filed, each amendment and supplement to such Registration Statement (in each case including all exhibits thereto and documents incorporated by reference therein), the Prospectus (including each preliminary Prospectus) and such other documents as the Underwriters and the Holders of Registrable Securities included in such Registration or Underwritten Offering or the legal counsel for any such Holders may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Holders; provided, that the Company will not have any obligation to provide any document pursuant to this clause that is available on the Commission&rsquo;s EDGAR system;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.4 prior to any Underwritten Offering of Registrable Securities, use commercially reasonable efforts to (a) register or qualify the Registrable Securities covered by the Registration Statement under such securities or &ldquo;<B><U>blue sky</U></B>&rdquo; laws of such jurisdictions in the United States as the Holders of Registrable Securities included in such Registration Statement (in light of their intended plan of distribution) may request and (b) take such action necessary to cause such Registrable Securities covered by the Registration Statement to be registered with or approved by such other governmental authorities as may be necessary by virtue of the business and operations of the Company and do any and all other acts and things that may be necessary or advisable to enable the Holders of Registrable Securities included in such Registration Statement to consummate the disposition of such Registrable Securities in such jurisdictions; provided, however, that the Company shall not be required to qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify or take any action to which it would be subject to general service of process or taxation in any such jurisdiction where it is not then otherwise so subject;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.5 cause all such Registrable Securities to be listed on each securities exchange or automated quotation system on which similar securities issued by the Company are then listed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.6 provide a transfer agent or warrant agent, as applicable, and registrar for all such Registrable Securities no later than the effective date of such Registration Statement or Underwritten Offering;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.7 advise each seller of such Registrable Securities, promptly after it shall receive notice or obtain knowledge thereof, of the issuance of any stop order by the Commission suspending the effectiveness of such Registration Statement or the initiation or threatening of any proceeding for such purpose and promptly use its reasonable best efforts to prevent the issuance of any stop order or to obtain its withdrawal if such stop order should be issued;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.8 during the Effectiveness Period, furnish a conformed copy of each filing of any Registration Statement or Prospectus or any amendment or supplement to such Registration Statement or Prospectus or any document that is to be incorporated by reference into such Registration Statement or Prospectus, promptly after such filing of such documents with the Commission to each seller of such Registrable Securities or its counsel; provided, that the Company will not have any obligation to provide any document pursuant to this clause that is available on the Commission&rsquo;s EDGAR system;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.9 notify the Holders at any time when a Prospectus relating to such Registration Statement is required to be delivered under the Securities Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.10 subject to the provisions of this Agreement, notify the Holders of the happening of any event as a result of which a Misstatement exists, and then to correct such Misstatement as set forth in <U>Section&nbsp;3.4</U> hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.11 in the event of an Underwritten Offering, a Block Trade, an Other Coordinated Offering, or sale by a Financial Counterparty pursuant to such Registration, permit a representative of the Holders, the Underwriters or other Financial Counterparty facilitating such Underwritten Offering, Block Trade, Other Coordinated Offering or other sale pursuant to such Registration, if any, and any attorney or accountant retained by such Holders or Underwriter to participate, at each such person&rsquo;s own expense, in the preparation of the Registration Statement or the Prospectus, and cause the Company&rsquo;s officers, directors and employees to supply all information reasonably requested by any such representative, Underwriter, Financial Counterparty, attorney or accountant in connection with the Registration; provided, however, that such representatives or Underwriters or Financial Counterparty enter into confidentiality agreements, in form and substance reasonably satisfactory to the Company, prior to the release or disclosure of any such information;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.12 obtain a comfort letter from the Company&rsquo;s independent registered public accountants in the event of an Underwritten Offering, a Block Trade, an Other Coordinated Offering, or sale by a Financial Counterparty pursuant to such Registration (subject to such Financial Counterparty providing such certification or representation reasonably requested by the Company&rsquo;s independent registered public accountants and the Company&rsquo;s counsel), in customary form and covering such matters of the type customarily covered by comfort letters as the managing Underwriter may reasonably request, and reasonably satisfactory to a majority-in-interest of the participating Holders;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.13 in the event of an Underwritten Offering, a Block Trade, an Other Coordinated Offering, or sale by a Financial Counterparty pursuant to such Registration, on the date the Registrable Securities are delivered for sale pursuant to such Registration, obtain an opinion, dated such date, of counsel representing the Company for the purposes of such Registration, addressed to the participating Holders or the Financial Counterparty, if any, and the Underwriters, if any, covering such legal matters with respect to the Registration in respect of which such opinion is being given as the participating Holders, Financial Counterparty or Underwriter may reasonably request and as are customarily included in such opinions and negative assurance letters, and reasonably satisfactory to such participating Holders, Financial Counterparty or Underwriter;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.14 in the event of an Underwritten Offering or a Block Trade, or an Other Coordinated Offering or sale by a Financial Counterparty pursuant to such Registration to which the Company has consented, to the extent reasonably requested by such Financial Counterparty in order to engage in such offering, allow the Underwriters or Financial Counterparty to conduct customary &ldquo;underwriter&rsquo;s due diligence&rdquo; with respect to the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.15 in the event of any Underwritten Offering, a Block Trade, an Other Coordinated Offering or sale by a Financial Counterparty pursuant to such Registration, enter into and perform its obligations under an underwriting agreement or other purchase or sales agreement, in usual and customary form, with the managing Underwriter or the Financial Counterparty of such offering or sale;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.16 make available to its security holders, as soon as reasonably practicable, an earnings statement covering the period of at least twelve (12) months beginning with the first (1st) day of the Company&rsquo;s first full calendar quarter after the effective date of the Registration Statement which satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule&nbsp;158 thereunder (or any successor rule promulgated thereafter by the Commission);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.17 use its reasonable efforts to make available senior executives of the Company to participate in customary &ldquo;<B><U>road show</U></B>&rdquo; presentations that may be reasonably requested by the Underwriter in any Underwritten Offering; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.18 otherwise, in good faith, cooperate reasonably with, and take such customary actions as may reasonably be requested by the Holders, in connection with such Registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding the foregoing, the Company shall not be required to provide any documents or information to an Underwriter or Financial Counterparty if such Underwriter of Financial Counterparty has not then been named with respect to the applicable Underwritten Offering or other offering involving a registration as an Underwriter or Financial Counterparty, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.2 <U>Registration Expenses</U></B>. The Registration Expenses in respect of all Registrations shall be borne by the Company. It is acknowledged by the Holders that the Holders shall bear all incremental selling expenses relating to the sale of Registrable Securities, such as Underwriters&rsquo; commissions and discounts, brokerage fees, Underwriter marketing costs and, other than as set forth in the definition of &ldquo;<B>Registration Expenses</B>,&rdquo; all reasonable fees and expenses of any legal counsel representing the Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3 <U>Requirements for Participation in Underwritten Offerings</U></B>. No person or entity may participate in any Underwritten Offering for equity securities of the Company pursuant to a Registration initiated by the Company hereunder unless such person or entity (a) agrees to sell such person&rsquo;s or entity&rsquo;s securities on the basis provided in any underwriting arrangements approved by the Company and (b) completes and executes all customary questionnaires, powers of attorney, indemnities, lock-up agreements, underwriting agreements and other customary documents as may be reasonably required under the terms of such underwriting arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.4 <U>Suspension of Sales</U></B>. Notwithstanding anything to the contrary in this Agreement, the Company shall be entitled to (A) delay or postpone the (i) initial effectiveness of any Registration Statement or (ii) launch of any Underwritten Offering, in each case, filed or requested pursuant to this Agreement, and (B) from time to time to require the Holders not to sell under any Registration Statement or Prospectus or to suspend the effectiveness thereof, if the negotiation or consummation of a transaction by the Company or its subsidiaries is pending or an event has occurred, which negotiation, consummation or event, the Board reasonably believes, upon the advice of legal counsel, would require additional disclosure by the Company in the applicable Registration Statement or Prospectus of material information that the Company has a bona fide business purpose for keeping confidential and the non-disclosure of which in the Registration Statement or Prospectus would be expected, in the reasonable determination of the Board, upon the advice of legal counsel, to cause the Registration Statement or Prospectus to fail to comply with applicable disclosure requirements (each such circumstance, a &ldquo;<B><U>Suspension Event</U></B>&rdquo;); provided, however, that the Company may not delay or suspend a Registration Statement, Prospectus or Underwritten Offering on more than two occasions, for more than sixty (60) consecutive calendar days, or more than ninety (90) total calendar days, in each case during any twelve (12)-month period. Upon receipt of any written notice from the Company of a Suspension Event while a Registration Statement filed pursuant to this Agreement is effective or if as a result of a Suspension Event a Misstatement exists, each Holder agrees that (i) it will immediately discontinue offers and sales of Registered Securities under each Registration Statement filed pursuant to this Agreement until the Holder receives copies of a supplemental or amended Prospectus (which the Company agrees to promptly prepare) that corrects the relevant misstatements or omissions and receives notice that any post-effective amendment has become effective or unless otherwise notified by the Company that it may resume such offers and sales and (ii) it will maintain the confidentiality of information included in such written notice delivered by the Company unless otherwise required by law or subpoena. If so directed by the Company, the Holders will deliver to the Company or, in Holders&rsquo; sole discretion destroy, all copies of each Prospectus covering Registrable Securities in Holders&rsquo; possession; provided, however, that this obligation to deliver or destroy shall not apply (A) to the extent the Holders are required to retain a copy of such Prospectus (x) to comply with applicable legal, regulatory, self-regulatory or professional requirements or (y) in accordance with a bona fide pre-existing document retention policy or (B) to copies stored electronically on archival servers as a result of automatic data back-up.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.5 <U>Reporting Obligations</U></B>. As long as any Holder shall own Registrable Securities, the Company, at all times while it shall be a reporting company under the Exchange Act, covenants to file timely (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act. The Company further covenants that it shall take such further action as any Holder may reasonably request, all to the extent required from time to time to enable such Holder to resell or otherwise dispose of Registrable Securities held by such Holder without registration under the Securities Act within the limitation of the exemptions provided by Rule&nbsp;144 promulgated under the Securities Act (or any successor rule promulgated thereafter by the Commission), including providing any legal opinions. Upon the request of any Holder, the Company shall deliver to such Holder a written certification of a duly authorized officer as to whether it has complied with such requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.6 <U>Limitation on Registration Rights</U></B>. Notwithstanding anything herein to the contrary, (i) the Representative may not exercise its rights under Sections 2.1 and 2.2 hereunder after five (5)
and seven (7) years, respectively, from the effective date of the Company&rsquo;s registration statement on Form S-1, and (ii) the Representative
may not exercise its rights under Section 2.1 more than two times, and only one time shall the Representative have Registration Expenses
borne by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE 4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>INDEMNIFICATION AND CONTRIBUTION</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.1 <U>Indemnification</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.1 The Company agrees to indemnify, to the extent permitted by law, each Holder of Registrable Securities, its officers, directors, employees, advisors, agents, representatives, members and each person who controls such Holder (within the meaning of the Securities Act) (collectively, the &ldquo;<B><U>Holder Indemnified Persons</U></B>&rdquo;) against all losses, claims, damages, liabilities and expenses (including reasonable attorneys&rsquo; fees and inclusive of all reasonable attorneys&rsquo; fees arising out of the enforcement of each such persons&rsquo; rights under this <U>Section&nbsp;4.1</U>) resulting from any Misstatement, except insofar as the same are caused by or contained or included in any information furnished in writing to the Company by or on behalf of such Holder Indemnified Person specifically for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.2 In connection with any Registration Statement in which a Holder of Registrable Securities is participating, such Holder shall furnish to the Company in writing such information and affidavits as the Company reasonably requests for use in connection with any such Registration Statement or Prospectus and, to the extent permitted by law, shall, severally and not jointly, indemnify the Company, its officers, directors, employees, advisors, agents, representatives and each person who controls the Company (within the meaning of the Securities Act) against any losses, claims, damages, liabilities and expenses (including reasonable attorneys&rsquo; fees and inclusive of all reasonable attorneys&rsquo; fees arising out of the enforcement of each such persons&rsquo; rights under this <U>Section&nbsp;4.1</U>) resulting from any Misstatement, but only to the extent that the same are made in reliance on and in conformity with information relating to the Holder so furnished in writing to the Company by or on behalf of such Holder specifically for use therein. In no event shall the liability of any selling Holder hereunder be greater in amount than the net proceeds received by such Holder from the sale of Registrable Securities pursuant to such Registration Statement giving rise to such indemnification obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.3 Any person entitled to indemnification herein shall (a) give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification (provided that the failure to give prompt notice shall not impair any person&rsquo;s right to indemnification hereunder to the extent such failure has not materially prejudiced the indemnifying party) and (b) unless in such indemnified party&rsquo;s reasonable judgment a conflict of interest between such indemnified and indemnifying parties may exist with respect to such claim or there may be reasonable defenses available to the indemnified party that are different from or additional to those available to the indemnifying party, permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party. If such defense is assumed, the indemnifying party shall not be subject to any liability for any settlement made by the indemnified party without its consent (but such consent shall not be unreasonably withheld). An indemnifying party who is not entitled to, or elects not to, assume the defense of a claim shall not be obligated to pay the fees and expenses of more than one counsel for all parties indemnified by such indemnifying party with respect to such claim, unless in the reasonable judgment of any indemnified party a conflict of interest may exist between such indemnified party and any other of such indemnified parties with respect to such claim. No indemnifying party shall, without the consent of the indemnified party, consent to the entry of any judgment or enter into any settlement which cannot be settled in all respects by the payment of money (and such money is so paid by the indemnifying party pursuant to the terms of such settlement) or which settlement does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.4 The indemnification provided for under this Agreement shall remain in full force and effect regardless of any investigation made by or on behalf of the indemnified party or any officer, director, employee, advisor, agent, representative, member or controlling person of such indemnified party and shall survive the transfer of securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.5 If the indemnification provided under this <U>Section&nbsp;4.1</U> is held by a court of competent jurisdiction to be unavailable to an indemnified party in respect of any losses, claims, damages, liabilities and expenses referred to herein, then the indemnifying party, in lieu of indemnifying the indemnified party, shall to the extent permitted by law contribute to the amount paid or payable by the indemnified party as a result of such losses, claims, damages, liabilities and expenses in such proportion as is appropriate to reflect the relative fault of the indemnifying party and the indemnified party, as well as any other relevant equitable considerations. The relative fault of the indemnifying party and indemnified party shall be determined by a court of law by reference to, among other things, whether the Misstatement relates to information supplied by such indemnifying party or such indemnified party and the indemnifying party&rsquo;s and indemnified party&rsquo;s relative intent, knowledge, access to information and opportunity to correct or prevent such action; provided, however, that the liability of any Holder under this <U>subsection&nbsp;4.1.5</U> shall be limited to the amount of the net proceeds received by such Holder in such offering giving rise to such liability. The amount paid or payable by a party as a result of the losses or other liabilities referred to above shall be deemed to include, subject to the limitations set forth in <U>subsections&nbsp;4.1.1</U>, <U>4.1.2</U> and <U>4.1.3</U> above, any legal or other fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. The parties hereto agree that it would not be just and equitable if contribution pursuant to this <U>subsection&nbsp;4.1.5</U> were determined by pro rata allocation or by any other method of allocation, which does not take account of the equitable considerations referred to in this <U>subsection&nbsp;4.1.5</U>. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution pursuant to this <U>subsection&nbsp;4.1.5</U> from any person who was not guilty of such fraudulent misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE 5</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>MISCELLANEOUS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1 <U>Notices</U></B>. Any notice or communication under this Agreement must be in writing and given by (a) deposit in the United States mail, addressed to the party to be notified, postage prepaid and registered or certified with return receipt requested, (b) delivery in person or by courier service or sent by overnight mail via a reputable overnight carrier, in each case providing evidence of delivery or (c) transmission by facsimile or email. Each notice or communication that is mailed, delivered or transmitted in the manner described above shall be deemed sufficiently given, served, sent, and received, in the case of mailed notices, on the third (3rd) business day following the date on which it is mailed, in the case of notices delivered by courier service, hand delivery or overnight mail, at such time as it is delivered to the addressee (with the delivery receipt or the affidavit of messenger) or at such time as delivery is refused by the addressee upon presentation, and in the case of notices delivered by facsimile or email, at such time as it is successfully transmitted to the addressee. Any notice or communication under this Agreement must be addressed, if to the Company, to: 10 E. 53rd Street, Suite 3001, New York, New York 10022, and, if to any other Holder, to the address of such Holder as it appears in the applicable register for the Registrable Securities or such other address as may be designated in writing by such Holder (including on the signature pages hereto). Any party may change its address for notice at any time and from time to time by written notice to the other parties hereto, and such change of address shall become effective thirty (30) days after delivery of such notice as provided in this <U>Section&nbsp;5.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2 <U>Assignment; No Third Party Beneficiaries</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.1 This Agreement and the rights, duties and obligations of the Company hereunder may not be assigned or delegated by the Company in whole or in part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.2. Prior to the expiration of the Founder Shares Lock-up Period or the Private Placement Lock-up Period, as the case may be, no Holder may assign or delegate such Holder&rsquo;s rights, duties or obligations under this Agreement, in whole or in part, except in connection with a transfer of Registrable Securities by such Holder to a Permitted Transferee but only if such Permitted Transferee agrees to become bound by the transfer restrictions set forth in this Agreement. After the expiration of the Founder Shares Lock-up Period or the Private Placement Lock-up Period, as the case may be, the Holder may assign or delegate such Holder&rsquo;s rights, duties or obligations under this Agreement, in while or in part, to any transferee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.3 This Agreement and the provisions hereof shall be binding upon and shall inure to the benefit of each of the parties and its successors and the permitted assigns of the Holders, which shall include Permitted Transferees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.4 This Agreement shall not confer any rights or benefits on any persons that are not parties hereto, other than as expressly set forth in this Agreement and this <U>Section&nbsp;5.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.5 No assignment by any party hereto of such party&rsquo;s rights, duties and obligations hereunder shall be binding upon or obligate the Company unless and until the Company shall have received (a) written notice of such assignment as provided in <U>Section&nbsp;5.1</U> hereof and (b) the written agreement of the assignee, in a form reasonably satisfactory to the Company, to be bound by the terms and provisions of this Agreement (which may be accomplished by an addendum or certificate of joinder to this Agreement). Any transfer or assignment made other than as provided in this <U>Section&nbsp;5.2</U> shall be null and void.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.3 <U>Counterparts</U></B>. This Agreement may be executed in multiple counterparts (including facsimile or PDF counterparts), each of which shall be deemed an original, and all of which together shall constitute the same instrument, but only one of which need be produced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.4 <U>Governing Law; Venue</U></B>. NOTWITHSTANDING THE PLACE WHERE THIS AGREEMENT MAY BE EXECUTED BY ANY OF THE PARTIES HERETO, THE PARTIES EXPRESSLY AGREE THAT THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED UNDER THE LAWS OF THE STATE OF NEW YORK AS APPLIED TO AGREEMENTS AMONG NEW YORK RESIDENTS ENTERED INTO AND TO BE PERFORMED ENTIRELY WITHIN NEW YORK, WITHOUT REGARD TO THE CONFLICT OF LAW PROVISIONS OF SUCH JURISDICTION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.5 <U>Amendments and Modifications</U></B>. Upon the written consent of the Company and the Holders of at least a majority in interest of the Registrable Securities at the time in question (which majority must include the Representative if such amendment or modification is material and adverse to the Representative), compliance with any of the provisions, covenants and conditions set forth in this Agreement may be waived, or any of such provisions, covenants or conditions may be amended or modified; provided, however, that notwithstanding the foregoing, any amendment hereto or waiver hereof that adversely affects any Holder, solely in his, her or its capacity as a holder of the shares of the Company, in a manner that is materially different from the other Holders (in such capacity) shall require the consent of each such Holder so affected. No course of dealing between any Holder or the Company and any other party hereto or any failure or delay on the part of a Holder or the Company in exercising any rights or remedies under this Agreement shall operate as a waiver of any rights or remedies of any Holder or the Company. No single or partial exercise of any rights or remedies under this Agreement by a party shall operate as a waiver or preclude the exercise of any other rights or remedies hereunder or thereunder by such party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.6 <U>Other Registration Rights</U></B>. The Company represents and warrants that no person, other than (a) a Holder of Registrable Securities, (b) the holders of the Company&rsquo;s warrants pursuant to that certain Public Warrant Agreement dated as of July&nbsp;30, 2025, each by and between the Company and Odyssey Transfer and Trust Company and (c) holders of Private Placement Units, Private Placement Shares and Private Placement Warrants pursuant to that certain Private Placement Units Purchase Agreement dated as of July&nbsp;30, 2025, has any right to require the Company to register any securities of the Company for sale or to include such securities of the Company in any Registration filed by the Company for the sale of securities for its own account or for the account of any other person. Further, the Company represents and warrants that this Agreement supersedes any other registration rights agreement or agreement with similar terms and conditions and in the event of a conflict between any such agreement or agreements and this Agreement, the terms of this Agreement shall prevail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.7 <U>Term</U></B>. This Agreement shall terminate upon the earlier of (a) the tenth (10th) anniversary of the date of this Agreement and (b) the date as of which the Holders cease to hold any Registrable Securities. The provisions of <U>Article 4</U> shall survive any termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature Page Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN WITNESS WHEREOF</B>, the undersigned have caused this Agreement to be executed as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY:</B></FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D. BORAL ARC ACQUISITION I CORP.,</FONT></P>
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a BVI business company</FONT></P> </TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Boral</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Boral</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HOLDERS:</B></FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MFH 1, LLC,</FONT></P>
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a Delaware limited liability company</FONT></P> </TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John Darwin</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">John Darwin</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manager</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D. BORAL CAPITAL LLC</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: Black 1pt solid">/s/ Gaurav Verma</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gaurav
Verma</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Head of Investment Banking</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Signature page to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">registration rights agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>8
<FILENAME>dboralarcacq_ex10-4.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 10.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRIVATE PLACEMENT UNITS PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS PRIVATE PLACEMENT UNITS PURCHASE AGREEMENT, dated as of July&nbsp;30, 2025 (as it may from time to time be amended, this &ldquo;<B><I>Agreement</I></B>&rdquo;), is entered into by and between D. Boral ARC Acquisition I Corp., a BVI business company (the &ldquo;<B><I>Company</I></B>&rdquo;), and MFH 1, LLC, a Delaware limited liability company (the &ldquo;<B><I>Purchaser</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS, the Company intends to consummate an initial public offering of the Company&rsquo;s units (the &ldquo;<B><I>Public Offering</I></B>&rdquo;), each unit consisting of one Class A Ordinary Share, par value $0.0001 per share, of the Company (an &ldquo;<B><I>Ordinary Share</I></B>&rdquo;), and one-half of one redeemable warrant (a &ldquo;<B><I>Warrant</I></B>&rdquo;) to purchase Ordinary Share (a &ldquo;<B><I>Warrant Share</I></B>&rdquo;) to be governed by the Warrant Agreement to be entered into between the Company and Odyssey Transfer and Trust Company, as warrant agent (the &ldquo;<B><I>Warrant Agreement</I></B>&rdquo;). Each whole Warrant entitles the holder to purchase one Ordinary Share at an exercise price of $11.50 per Ordinary Share. The Purchaser has agreed to purchase an aggregate of 200,000 private placement units (whether or not the underwriters&rsquo; over-allotment option is exercised) (the &ldquo;<B><I>Private Placement Units</I></B>&rdquo;), each Private Placement Unit comprised of one Ordinary Share (the &ldquo;<B><I>Private Placement Shares</I></B>&rdquo;) and one-half of one redeemable Warrant (the &ldquo;<B><I>Private Placement Warrants</I></B>&rdquo;) to purchase one Ordinary Shares (the &ldquo;<B><I>Private Placement Warrant Shares</I></B>&rdquo;), as provided in the registration statement in connection with the Public Offering, for a purchase price of $2,000,000 (whether or not the underwriters&rsquo; over-allotment option is exercised), or $10.00 per unit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW THEREFORE, in consideration of the mutual promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties to this Agreement hereby, intending legally to be bound, agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>AGREEMENT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;1. Authorization, Purchase and Sale; Terms of the Private Placement Units.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A. <U>Authorization of the Private Placement Units</U>. The Company has duly authorized the issuance and sale of the Private Placement Units to the Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B. <U>Purchase and Sale of the Private Placement Units</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) On the date of the consummation of the Public Offering or on such earlier time and date as may be mutually agreed by the Purchaser and the Company (the &ldquo;<B><I>Closing Date</I></B>&rdquo;), the Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the Company, an aggregate of 200,000 Placement Units (whether or not the underwriters&rsquo; over-allotment option is exercised) at a price of $10.00 per unit for an aggregate purchase price of $2,000,000 (whether or not the underwriters&rsquo; over-allotment option is exercised) (the &ldquo;<B><I>Purchase Price</I></B>&rdquo;), which shall be paid by wire transfer of immediately available funds to the Company at least one business day prior to the Closing Date in accordance with the Company&rsquo;s wiring instructions. On the Closing Date, upon the payment by the Purchaser of the Purchase Price, the Company, at its option, shall deliver a certificate evidencing the Private Placement Units purchased by the Purchaser on such date duly registered in the Purchaser&rsquo;s name to the Purchaser, or effect such delivery in book-entry form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C. <U>Terms of the Private Placement Units and Private Placement Warrants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) Each Private Placement Unit shall have the terms set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) Each Private Placement Warrant shall have the terms set forth in the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) At the time of the closing of the Public Offering, the Company and the Purchaser shall enter into a registration rights agreement (the &ldquo;<B><I>Registration Rights Agreement</I></B>&rdquo;) pursuant to which the Company will grant certain registration rights to the Purchaser relating to the Private Placement Units, the Private Placement Shares, the Private Placement Warrants and the Private Placement Warrant Shares (together, the &ldquo;<B><I>Securities</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;2. Representations and Warranties of the Company.</B> As a material inducement to the Purchaser to enter into this Agreement and purchase the Private Placement Units, the Company hereby represents and warrants to the Purchaser (which representations and warranties shall survive the Closing Date) that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A. <U>Incorporation and Corporate Power</U>. The Company is an exempted company duly incorporated, validly existing and in good standing under the laws of the British Virgin Islands and is qualified to do business in every jurisdiction in which the failure to so qualify would reasonably be expected to have a material adverse effect on the financial condition, operating results or assets of the Company. The Company possesses all requisite corporate power and authority necessary to carry out the transactions contemplated by this Agreement and the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B. <U>Authorization; No Breach</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) The execution, delivery and performance of this Agreement and the Private Placement Units have been duly authorized by the Company as of the Closing Date. This Agreement constitutes the valid and binding obligation of the Company, enforceable in accordance with its terms, subject to bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other laws of general applicability relating to or affecting creditors&rsquo; rights and to general equitable principles (whether considered in a proceeding in equity or law). Upon issuance in accordance with, and payment pursuant to, the terms of the Warrant Agreement and this Agreement, the Private Placement Units, the Private Placement Shares and Private Placement Warrants comprising such units, and Private Placement Warrant Shares will constitute valid and binding obligations of the Company, enforceable in accordance with their terms as of the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) The execution and delivery by the Company of this Agreement and the Private Placement Units, the issuance and sale of the Private Placement Units, the issuance of the Private Placement Shares and Private Placement Warrant comprising the Private Placement Units, the issuance of the Private Placement Warrant Shares and the fulfillment of, and compliance with, the respective terms hereof and thereof by the Company, do not and will not as of the Closing Date (a) conflict with or result in a breach of the terms, conditions or provisions of, (b) constitute a default under, (c) result in the creation of any lien, security interest, charge or encumbrance upon the Company&rsquo;s equity or assets under, (d) result in a violation of, or (e) require any authorization, consent, approval, exemption or other action by or notice or declaration to, or filing with, any court or administrative or governmental body or agency pursuant to the Amended and Restated Memorandum and Articles of Association of the Company in effect on the date hereof or as may be amended at or prior to completion of the contemplated Public Offering, or any material law, statute, rule or regulation to which the Company is subject, or any agreement, order, judgment or decree to which the Company is subject, except for any filings required after the date hereof under federal or state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C. <U>Title to Securities</U>. Upon issuance in accordance with, and payment pursuant to, the terms hereof, the Warrant Agreement and the Amended and Restated Memorandum and Articles of Association of the Company, as the case may be, each of the Securities will be duly and validly issued, fully paid and non-assessable. On the date of issuance of the Private Placement Units, the Private Placement Shares, the Private Placement Warrants and the Warrant Shares shall have been reserved for issuance. Upon issuance in accordance with the terms hereof and the Warrant Agreement, the Purchaser will have or receive good title to the Private Placement Units, the Private Placement Shares, the Private Placement Warrants and the Warrant Shares, free and clear of all liens, claims and encumbrances of any kind other than (i) transfer restrictions hereunder and pursuant to the insider letter to be entered into on or prior to the closing of the Public Offering and (ii) transfer restrictions under federal and state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D. <U>Governmental Consents</U>. No permit, consent, approval or authorization of, or declaration to or filing with, any governmental authority is required in connection with the execution, delivery and performance by the Company of this Agreement or the consummation by the Company of any other transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E. <U>Regulation D Qualification</U>. Neither the Company nor, to its knowledge, any of its affiliates, members, officers, directors or beneficial shareholders of 20% or more of its outstanding securities, has experienced a disqualifying event as enumerated pursuant to Rule&nbsp;506(d) of Regulation D under the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities Act</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;3. Representations and Warranties of the Purchaser.</B> As a material inducement to the Company to enter into this Agreement and issue and sell the Private Placement Units to the Purchaser, the Purchaser hereby represents and warrants to the Company (which representations and warranties shall survive each Closing Date) that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A. <U>Organization and Requisite Authority</U>. The Purchaser possesses all requisite power and authority necessary to carry out the transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B. <U>Authorization; No Breach</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) This Agreement constitutes a valid and binding obligation of the Purchaser, enforceable in accordance with its terms, subject to bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other laws of general applicability relating to or affecting creditors&rsquo; rights and to general equitable principles (whether considered in a proceeding in equity or law).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) The execution and delivery by the Purchaser of this Agreement and the fulfillment of and compliance with the terms hereof by the Purchaser does not and shall not as of each Closing Date conflict with or result in a breach by the Purchaser of the terms, conditions or provisions of any agreement, instrument, order, judgment or decree to which the Purchaser is subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C. <U>Investment Representations</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) The Purchaser is acquiring the Securities, for the Purchaser&rsquo;s own account, for investment purposes only and not with a view towards, or for resale in connection with, any public sale or distribution thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) The Purchaser is an &ldquo;accredited investor&rdquo; as such term is defined in Rule&nbsp;501(a)(3) of Regulation D, and the Purchaser has not experienced a disqualifying event as enumerated pursuant to Rule&nbsp;506(d) of Regulation D under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) The Purchaser understands that the Securities are being offered and will be sold to it in reliance on specific exemptions from the registration requirements of the United States federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the Purchaser&rsquo;s compliance with, the representations and warranties of the Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of the Purchaser to acquire such Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) The Purchaser did not decide to enter into this Agreement as a result of any general solicitation or general advertising within the meaning of Rule&nbsp;502(c) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) The Purchaser has been furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Securities which have been requested by the Purchaser. The Purchaser has been afforded the opportunity to ask questions of the executive officers and directors of the Company. The Purchaser understands that its investment in the Securities involves a high degree of risk and it has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to the acquisition of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi) The Purchaser understands that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities by the Purchaser nor have such authorities passed upon or endorsed the merits of the offering of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii) The Purchaser understands that: (a) the Securities have not been and are not being registered under the Securities Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (1) subsequently registered thereunder or (2) sold in reliance on an exemption therefrom; and (b) except as specifically set forth in the Registration Rights Agreement, neither the Company nor any other person is under any obligation to register the Securities under the Securities Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder. While the Purchaser understands that Rule&nbsp;144 under the Securities Act is not available for the resale of securities initially issued by shell companies (other than business combination related shell companies) or issuers that have been at any time previously a shell company, the Purchaser understands that Rule&nbsp;144 includes an exception to this prohibition if the following conditions are met: (i) the issuer of the securities that was formerly a shell company has ceased to be a shell company; (ii) the issuer of the securities is subject to the reporting requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, as amended (the &ldquo;<B><I>Exchange Act</I></B>&rdquo;); (iii) the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and (iv) at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii) The Purchaser has such knowledge and experience in financial and business matters, knows of the high degree of risk associated with investments in the securities of companies in the development stage such as the Company, is capable of evaluating the merits and risks of an investment in the Securities and is able to bear the economic risk of an investment in the Securities in the amount contemplated hereunder for an indefinite period of time. The Purchaser has adequate means of providing for its current financial needs and contingencies and will have no current or anticipated future needs for liquidity which would be jeopardized by the investment in the Securities. The Purchaser can afford a complete loss of its investment in the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;4. Conditions of the Purchaser&rsquo;s Obligations.</B> The obligation of the Purchaser to purchase and pay for the Private Placement Units is subject to the fulfillment, on or before each Closing Date, of each of the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A. <U>Representations and Warranties</U>. The representations and warranties of the Company contained in <U>Section&nbsp;2</U> shall be true and correct at and as of such Closing Date as though then made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B. <U>Performance</U>. The Company shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before such Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C. <U>No Injunction</U>. No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this Agreement or the Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D. <U>Warrant Agreement</U>. The Company shall have entered into the Warrant Agreement on terms satisfactory to the Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;5. Conditions of the Company&rsquo;s Obligations.</B> The obligations of the Company to the Purchaser under this Agreement are subject to the fulfillment, on or before each Closing Date, of each of the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A. <U>Representations and Warranties</U>. The representations and warranties of the Purchaser contained in <U>Section&nbsp;3</U> shall be true and correct at and as of such Closing Date as though then made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B. <U>Performance</U>. The Purchaser shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by the Purchaser on or before such Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C. <U>Corporate Consents</U>. The Company shall have obtained the consent of its Board of Directors authorizing the execution, delivery and performance of this Agreement and the Warrant Agreement and the issuance and sale of the Private Placement Units hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D. <U>No Injunction</U>. No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E. <U>Warrant Agreement</U>. The Company shall have entered into the Warrant Agreement on terms satisfactory to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;6. Termination.</B> This Agreement may be terminated at any time after December&nbsp;31, 2025 upon the election by either the Company or the Purchaser upon written notice to the other party if the closing of the Public Offering does not occur prior to such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;7. Survival of Representations and Warranties.</B> All of the representations and warranties contained herein shall survive each Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;8. Definitions.</B> Terms used but not otherwise defined in this Agreement shall have the meaning assigned to such terms in the registration statement on Form S-1 the Company has filed with the U.S. Securities and Exchange Commission, under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;9. Miscellaneous.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A. <U>Successors and Assigns</U>. Except as otherwise expressly provided herein, all covenants and agreements contained in this Agreement by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors of the parties hereto whether so expressed or not. Notwithstanding the foregoing or anything to the contrary herein, the parties may not assign this Agreement, other than assignments by the Purchaser to affiliates thereof (including, without limitation one or more of its members).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B. <U>Severability</U>. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C. <U>Counterparts</U>. This Agreement may be executed simultaneously in two or more counterparts, none of which need contain the signatures of more than one party, but all such counterparts taken together shall constitute one and the same agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D. <U>Descriptive Headings; Interpretation</U>. The descriptive headings of this Agreement are inserted for convenience only and do not constitute a substantive part of this Agreement. The use of the word &ldquo;including&rdquo; in this Agreement shall be by way of example rather than by limitation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E. <U>Governing Law</U>. This Agreement shall be deemed to be a contract made under the laws of the State of New York and for all purposes shall be construed in accordance with the internal laws of the State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F. <U>Amendments</U>. This Agreement may not be amended, modified or waived as to any particular provision, except by a written instrument executed by all parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature Page Follows]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN WITNESS WHEREOF</B>, the parties hereto have executed this Agreement to be effective as of the date first set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY</B>:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>D. BORAL ARC ACQUISITION I CORP.</B></FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Boral</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Boral</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASER</B>:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MFH 1, LLC</B>,</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a Delaware limited liability company</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John Darwin</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
Darwin</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manager</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature Page to Private Placement Units Purchase Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>9
<FILENAME>dboralarcacq_ex10-5.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> INDEMNITY AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>THIS INDEMNITY AGREEMENT</B> (this
&ldquo;<B><I>Agreement</I></B>&rdquo;) is made as of July&nbsp;30, 2025, by and between D. Boral ARC Acquisition I Corp., a BVI business
company (the &ldquo;<B><I>Company</I></B>&rdquo;), and the undersigned (&ldquo;<B><I>Indemnitee</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>WHEREAS, </B>highly competent persons have become more reluctant to serve publicly-held companies as directors, officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of such companies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>WHEREAS</B>, the Board of Directors of the Company (the &ldquo;<B><I>Board</I></B>&rdquo;) has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its Subsidiaries (as defined below) from certain liabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>WHEREAS</B>, while the Amended and Restated Memorandum and Articles of Association of the Company provide for the indemnification of the officers and directors of the Company, Indemnitee may also be entitled to indemnification pursuant to applicable British Virgin Islands law, and the Amended and Restated Memorandum and Articles of Association (as may be amended from time to time, the &ldquo;<B><I>Amended and Restated Memorandum and Articles of Association</I></B>&rdquo;) provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the Board, officers and other persons with respect to indemnification, hold harmless, exoneration, advancement and reimbursement rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>WHEREAS</B>, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>WHEREAS</B>, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company&rsquo;s shareholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>WHEREAS</B>, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, hold harmless, exonerate and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company so that they will serve or continue to serve the Company free from undue concern that they will not be so protected against liabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>WHEREAS</B>, this Agreement is a supplement to and in furtherance of the Amended and Restated Memorandum and Articles of Association of the Company and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>WHEREAS</B>, Indemnitee may not be willing to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve in such capacity, and Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he or she be so indemnified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOW, THEREFORE</B>, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 27 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TERMS AND CONDITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>1. SERVICES TO THE COMPANY.</B> In consideration of the Company&rsquo;s covenants and obligations hereunder, Indemnitee will serve or continue to serve as an officer, director, advisor, key employee or any other capacity of the Company, as applicable, for so long as Indemnitee is duly elected or appointed or retained or until Indemnitee tenders his or her resignation or until Indemnitee is removed. The foregoing notwithstanding, this Agreement shall continue in full force and effect after Indemnitee has ceased to serve as a director, officer, advisor, key employee or in any other capacity of the Company, as provided in Section&nbsp;17. This Agreement, however, shall not impose any obligation on Indemnitee or the Company to continue Indemnitee&rsquo;s service to the Company beyond any period otherwise required by law or by other agreements or commitments of the parties, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>2. DEFINITIONS. </B>As used in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) References to &ldquo;<B><I>agent</I></B>&rdquo; shall mean any person who is or was a director, officer or employee of the Company or a Subsidiary (as defined below) of the Company or other person authorized by the Company to act for the Company, to include such person serving in such capacity as a director, officer, employee, fiduciary or other official of another company, corporation, partnership, limited liability company, joint venture, trust or other enterprise at the request of, for the convenience of, or to represent the interests of the Company or a Subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) The terms &ldquo;<B><I>Beneficial Owner</I></B>&rdquo; and &ldquo;<B><I>Beneficial Ownership</I></B>&rdquo; shall have the meanings set forth in Rule&nbsp;13d-3 promulgated under the Exchange Act (as defined below) as in effect on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) &ldquo;<B><I>BVI Court</I></B>&rdquo; shall mean the courts of the British Virgin Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(d) A &ldquo;<B><I>Change in Control</I></B>&rdquo; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(i) <U>Acquisition of Shares by Third Party</U>. Other than an affiliate of MFH 1, LLC, a Delaware limited liability company (the &ldquo;<B><I>Sponsor</I></B>&rdquo;), any Person (as defined below) is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing fifteen percent (15%) or more of the combined voting power of the Company&rsquo;s then outstanding securities entitled to vote generally in the election of directors, unless (1) the change in the relative Beneficial Ownership of the Company&rsquo;s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors, or (2) such acquisition was approved in advance by the Continuing Directors (as defined below) and such acquisition would not constitute a Change in Control under part (iii) of this definition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(ii) <U>Change in Board of Directors</U>. Individuals who, as of the date hereof, constitute the Board, and any new director whose election by the Board or nomination for election by the Company&rsquo;s shareholders was approved by a vote of at least two-thirds of the directors then still in office who were directors on the date hereof or whose election for nomination for election was previously so approved (collectively, the &ldquo;<B><I>Continuing Directors</I></B>&rdquo;), cease for any reason to constitute at least a majority of the members of the Board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(iii) <U>Corporate Transactions</U>. The effective date of a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination, involving the Company and one or more businesses (a &ldquo;<B><I>Business Combination</I></B>&rdquo;), in each case, unless, following such Business Combination: (1) all or substantially all of the individuals and entities who were the Beneficial Owners of securities entitled to vote generally in the election of directors immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the combined voting power of the then outstanding securities of the Company entitled to vote generally in the election of directors resulting from such Business Combination (including, without limitation, a company which as a result of such transaction owns the Company or all or substantially all of the Company&rsquo;s assets either directly or through one or more Subsidiaries) in substantially the same proportions as their ownership immediately prior to such Business Combination, of the securities entitled to vote generally in the election of directors; (2) other than an affiliate of the Sponsor, no Person (excluding any company resulting from such Business Combination) is the Beneficial Owner, directly or indirectly, of 15% or more of the combined voting power of the then outstanding securities entitled to vote generally in the election of directors of the surviving company except to the extent that such ownership existed prior to the Business Combination; and (3) at least a majority of the Board of Directors of the company resulting from such Business Combination were Continuing Directors at the time of the execution of the initial agreement, or of the action of the Board of Directors, providing for such Business Combination;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(iv) <U>Liquidation</U>. The approval by the shareholders of the Company of a complete liquidation of the Company or an agreement or series of agreements for the sale or disposition by the Company of all or substantially all of the Company&rsquo;s assets, other than factoring the Company&rsquo;s current receivables or escrows due (or, if such approval is not required, the decision by the Board to proceed with such a liquidation, sale, or disposition in one transaction or a series of related transactions); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(v) <U>Other Events</U>. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule&nbsp;14A of Regulation 14A (or any successor rule) (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act, whether or not the Company is then subject to such reporting requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(e) &ldquo;<B><I>Companies Law</I></B>&rdquo; shall mean the BVI Business Companies Act 2004, as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(f) &ldquo;<B><I>Corporate Status</I></B>&rdquo; describes the status of a person who is or was a director, officer, trustee, general partner, manager, managing member, fiduciary, employee or agent of the Company or of any other Enterprise (as defined below) which such person is or was serving at the request of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(g) &ldquo;<B><I>Disinterested Director</I></B>&rdquo; shall mean a director of the Company who is not and was not a party to the Proceeding (as defined below) in respect of which indemnification is sought by Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(h) &ldquo;<B><I>Enterprise</I></B>&rdquo; shall mean the Company and any other company, corporation, constituent company or corporation (including any constituent of a constituent) absorbed in a consolidation or merger to which the Company (or any of its wholly owned Subsidiaries) is a party, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, trustee, general partner, managing member, fiduciary, employee or agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(i) &ldquo;<B><I>Exchange Act</I></B>&rdquo; shall mean the United States Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(j) &ldquo;<B><I>Expenses</I></B>&rdquo; shall include all direct and indirect costs, fees and expenses of any type or nature whatsoever, including, without limitation, all reasonable attorneys&rsquo; fees and costs, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, fees of private investigators and professional advisors, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, fax transmission charges, secretarial services and all other disbursements, obligations or expenses in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, settlement or appeal of, or otherwise participating in, a Proceeding, including reasonable compensation for time spent by the Indemnitee for which he or she is not otherwise compensated by the Company or any third party. Expenses also shall include Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the principal, premium, security for, and other costs relating to any cost bond, supersedes bond, or other appeal bond or its equivalent. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(k) References to &ldquo;<B><I>fines</I></B>&rdquo; shall include any excise tax assessed on Indemnitee with respect to any employee benefit plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(l) References to &ldquo;<B><I>serving at the request of the Company</I></B>&rdquo; shall include any service as a director, officer, employee, agent or fiduciary of the Company or a Subsidiary of the Company which imposes duties on, or involves services by, such director, officer, employee, agent or fiduciary with respect to an employee benefit plan, its participants or beneficiaries; and if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan, Indemnitee shall be deemed to have acted in a manner &ldquo;<B><I>not opposed to the best interests of the Company</I></B>&rdquo; as referred to in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(m) &ldquo;<B><I>Independent Counsel</I></B>&rdquo; shall mean a law firm or a member of a law firm with significant experience in matters of corporation law and that neither presently is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements); or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term &ldquo;Independent Counsel&rdquo; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&rsquo;s rights under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(n) The term &ldquo;<B><I>Person</I></B>&rdquo; shall have the meaning as set forth in Sections&nbsp;13(d) and 14(d) of the Exchange Act as in effect on the date hereof; provided, however, that &ldquo;Person&rdquo; shall exclude: (i) the Company; (ii) any Subsidiaries of the Company; (iii) any employment benefit plan of the Company or of a Subsidiary of the Company or of any corporation owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of shares of the Company; and (iv) any trustee or other fiduciary holding securities under an employee benefit plan of the Company or of a Subsidiary of the Company or of a corporation owned directly or indirectly by the shareholders of the Company in substantially the same proportions as their ownership of shares of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(o) The term &ldquo;<B><I>Proceeding</I></B>&rdquo; shall include any threatened, pending or completed action, suit, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil (including intentional or unintentional tort claims), criminal, administrative or investigative or related nature, in which Indemnitee was, is, will or might be involved as a party or otherwise by reason of the fact that Indemnitee is or was a director or officer of the Company, by reason of any action (or failure to act) taken by him or her or of any action (or failure to act) on his or her part while acting as a director or officer of the Company, or by reason of the fact that he or she is or was serving at the request of the Company as a director, officer, trustee, general partner, managing member, fiduciary, employee or agent of any other Enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement, or advancement of expenses can be provided under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(p) The term &ldquo;<B><I>Subsidiary,</I></B>&rdquo; with respect to any Person, shall mean any corporation, limited liability company, partnership, joint venture, trust or other entity of which a majority of the voting power of the voting equity securities or equity interest is owned, directly or indirectly, by that Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>3. INDEMNITY IN THIRD-PARTY PROCEEDINGS.</B> To the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, the Company shall indemnify, hold harmless and exonerate Indemnitee in accordance with the provisions of this Section&nbsp;3 if Indemnitee was, is, or is threatened to be made, a party to or a participant (as a witness, deponent or otherwise) in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor by reason of Indemnitee&rsquo;s Corporate Status. Pursuant to this Section&nbsp;3, Indemnitee shall be indemnified, held harmless and exonerated against all Expenses, judgments, liabilities, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) actually, and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding, had no reasonable cause to believe that his or her conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>4. INDEMNITY IN PROCEEDINGS BY OR IN THE RIGHT OF THE COMPANY. </B>To the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, the Company shall indemnify, hold harmless and exonerate Indemnitee in accordance with the provisions of this Section&nbsp;4 if Indemnitee was, is, or is threatened to be made, a party to or a participant (as a witness, deponent or otherwise) in any Proceeding by or in the right of the Company to procure a judgment in its favor by reason of Indemnitee&rsquo;s Corporate Status. Pursuant to this Section&nbsp;4, Indemnitee shall be indemnified, held harmless and exonerated against all Expenses actually and reasonably incurred by him or her on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. No indemnification, hold harmless or exoneration for Expenses shall be made under this Section&nbsp;4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that any court in which the Proceeding was brought or the BVI Court shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification, to be held harmless or to exoneration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>5. INDEMNIFICATION FOR EXPENSES OF A PARTY WHO IS WHOLLY OR PARTLY SUCCESSFUL.</B> Notwithstanding any other provisions of this Agreement except for Section&nbsp;27, to the extent that Indemnitee was or is, by reason of Indemnitee&rsquo;s Corporate Status, a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall, to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, indemnify, hold harmless and exonerate Indemnitee against all Expenses actually and reasonably incurred by him or her in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall, to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, indemnify, hold harmless and exonerate Indemnitee against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection with each successfully resolved claim, issue or matter. If Indemnitee is not wholly successful in such Proceeding, the Company also shall, to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, indemnify, hold harmless and exonerate Indemnitee against all Expenses reasonably incurred in connection with a claim, issue or matter related to any claim, issue, or matter on which Indemnitee was successful. For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>6. INDEMNIFICATION FOR EXPENSES OF A WITNESS</B>. Notwithstanding any other provision of this Agreement except for Section&nbsp;27, to the extent that Indemnitee is, by reason of his or her Corporate Status, a witness or deponent in any Proceeding to which Indemnitee was or is not a party or threatened to be made a party, he or she shall, to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, be indemnified, held harmless and exonerated against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>7. ADDITIONAL INDEMNIFICATION, HOLD HARMLESS AND EXONERATION RIGHTS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) Notwithstanding any limitation in Sections&nbsp;3, 4, or 5, except for Section&nbsp;27, the Company shall, to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, indemnify, hold harmless and exonerate Indemnitee if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) actually and reasonably incurred by Indemnitee in connection with the Proceeding. No indemnification, hold harmless or exoneration rights shall be available under this Section&nbsp;7(a) on account of Indemnitee&rsquo;s conduct which constitutes a breach of Indemnitee&rsquo;s duty of loyalty to the Company or its shareholders or is an act or omission not in good faith or which involves intentional misconduct or a knowing violation of the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) Notwithstanding any limitation in Sections&nbsp;3, 4, 5 or 7(a), except for Section&nbsp;27, the Company shall, to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, indemnify, hold harmless and exonerate Indemnitee if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) actually and reasonably incurred by Indemnitee in connection with the Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>8. CONTRIBUTION IN THE EVENT OF JOINT LIABILITY.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) To the fullest extent permissible under applicable law, if the indemnification, hold harmless and/or exoneration rights provided for in this Agreement are unavailable to Indemnitee in whole or in part for any reason whatsoever, the Company, in lieu of indemnifying, holding harmless or exonerating Indemnitee, shall pay, in the first instance, the entire amount incurred by Indemnitee, whether for judgments, liabilities, fines, penalties, amounts paid or to be paid in settlement and/or for Expenses, in connection with any Proceeding without requiring Indemnitee to contribute to such payment, and the Company hereby waives and relinquishes any right of contribution it may have at any time against Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) The Company shall not enter into any settlement of any Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding) unless such settlement provides for a full and final release of all claims asserted against Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) The Company hereby agrees to fully indemnify, hold harmless and exonerate Indemnitee from any claims for contribution which may be brought by officers, directors or employees of the Company other than Indemnitee who may be jointly liable with Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>9. EXCLUSIONS. </B>Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnification, advance expenses, hold harmless or exoneration payment in connection with any claim made against Indemnitee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) for which payment has actually been received by or on behalf of Indemnitee under any insurance policy or other indemnity or advancement provision and which payment has not subsequently been returned, except with respect to any excess beyond the amount actually received under any insurance policy, contract, agreement, other indemnity or advancement provision or otherwise;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section&nbsp;16(b) of the Exchange Act (or any successor rule) or similar provisions of state statutory law or common law; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) except as otherwise provided in Sections&nbsp;14(f)-(g) hereof, prior to a Change in Control, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii) the Company provides the indemnification, hold harmless or exoneration payment, in its sole discretion, pursuant to the powers vested in the Company under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>10. ADVANCES OF EXPENSES; DEFENSE OF CLAIM.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) Notwithstanding any provision of this Agreement to the contrary except for Section&nbsp;27, and to the fullest extent not prohibited by applicable law, the Company shall pay the Expenses incurred by Indemnitee (or reasonably expected by Indemnitee to be incurred by Indemnitee within three months) in connection with any Proceeding within ten (10) days after the receipt by the Company of a statement or statements requesting such advances from time to time, prior to the final disposition of any Proceeding. Advances shall, to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, be unsecured and interest free. Advances shall, to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, be made without regard to Indemnitee&rsquo;s ability to repay the Expenses and without regard to Indemnitee&rsquo;s ultimate entitlement to be indemnified, held harmless or exonerated under the other provisions of this Agreement. Advances shall include any and all reasonable Expenses incurred pursuing a Proceeding to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company to support the advances claimed. To the fullest extent required by applicable law, such payments of Expenses in advance of the final disposition of the Proceeding shall be made only upon the Company&rsquo;s receipt of an undertaking, by or on behalf of Indemnitee, to repay the advanced amounts to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company under the provisions of this Agreement, the Amended and Restated Memorandum and Articles of Association, applicable law or otherwise. This Section&nbsp;10(a) shall not apply to any claim made by Indemnitee for which an indemnification, hold harmless or exoneration payment is excluded pursuant to Section&nbsp;9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) The Company will be entitled to participate in the Proceeding at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) The Company shall not settle any action, claim or Proceeding (in whole or in part) which would impose any Expense, judgment, fine, penalty or limitation on Indemnitee without Indemnitee&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>11. PROCEDURE FOR NOTIFICATION AND APPLICATION FOR INDEMNIFICATION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) Indemnitee agrees to notify promptly the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding, claim, issue or matter therein which may be subject to indemnification, hold harmless or exoneration rights, or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) Indemnitee may deliver to the Company a written application to indemnify, hold harmless or exonerate Indemnitee in accordance with this Agreement. Such application(s) may be delivered from time to time and at such time(s) as Indemnitee deems appropriate in his or her sole discretion. Following such a written application for indemnification by Indemnitee, Indemnitee&rsquo;s entitlement to indemnification shall be determined according to Section&nbsp;12(a) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>12. PROCEDURE UPON APPLICATION FOR INDEMNIFICATION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) A determination, if required by applicable law, with respect to Indemnitee&rsquo;s entitlement to indemnification shall be made in the specific case by one of the following methods, which shall be at the election of Indemnitee: (i) by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (ii) by a committee of such directors designated by majority vote of such directors, (iii) if there are no Disinterested Directors or if such directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee, or (iv) by vote of the shareholders. The Company promptly will advise Indemnitee in writing with respect to any determination that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been denied. If it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such determination. Indemnitee shall reasonably cooperate with the person, persons or entity making such determination with respect to Indemnitee&rsquo;s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or Expenses (including reasonable attorneys&rsquo; fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee&rsquo;s entitlement to indemnification) and the Company hereby agrees to indemnify and to hold Indemnitee harmless therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section&nbsp;12(a) hereof, the Independent Counsel shall be selected as provided in this Section&nbsp;12(b). The Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected and certifying that the Independent Counsel so selected meets the requirements of &ldquo;Independent Counsel&rdquo; as defined in Section&nbsp;2 of this Agreement. If the Independent Counsel is selected by the Board, the Company shall give written notice to Indemnitee advising him or her of the identity of the Independent Counsel so selected and certifying that the Independent Counsel so selected meets the requirements of &ldquo;Independent Counsel&rdquo; as defined in Section&nbsp;2 of this Agreement. In either event, Indemnitee or the Company, as the case may be, may, within ten (10) days after such written notice of selection shall have been received, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &ldquo;Independent Counsel&rdquo; as defined in Section&nbsp;2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court of competent jurisdiction has determined that such objection is without merit. If, within twenty (20) days after submission by Indemnitee of a written request for indemnification pursuant to Section&nbsp;11(b) hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the BVI Court for resolution of any objection which shall have been made by the Company or Indemnitee to the other&rsquo;s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the BVI Court, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section (a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section&nbsp;14(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) The Company agrees to pay the reasonable fees and expenses of Independent Counsel and to fully indemnify and hold harmless such Independent Counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>13. PRESUMPTIONS AND EFFECT OF CERTAIN PROCEEDINGS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) In making a determination with respect to entitlement to indemnification hereunder, the person, persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section&nbsp;11(b) of this Agreement, and the Company shall have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption. Neither the failure of the Company (including by the Disinterested Directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by the Disinterested Directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) If the person, persons or entity empowered or selected under Section&nbsp;12 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within thirty (30) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall, to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, be deemed to have been made and Indemnitee 12 shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&rsquo;s statement not materially misleading, in connection with the request for indemnification, or (ii) a final judicial determination that any or all such indemnification is expressly prohibited under applicable law or the Amended and Restated Memorandum and Articles of Association of the Company; provided, however, that such 30-day period may be extended for a reasonable time, not to exceed an additional fifteen (15) days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(d) For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee&rsquo;s action is based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the directors, manager, or officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise, its Board, any committee of the Board or any director, trustee, general partner, manager or managing member, or on information or records given or reports made to the Enterprise, its Board, any committee of the Board or any director, trustee, general partner, manager or managing member, by an independent certified public accountant or by an appraiser or other expert selected by the Enterprise, its Board, any committee of the Board or any director, trustee, general partner, manager or managing member. The provisions of this Section&nbsp;13(d) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed or found to have met the applicable standard of conduct set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(e) The knowledge and/or actions, or failure to act, of any other director, officer, trustee, partner, manager, managing member, fiduciary, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>14. REMEDIES OF INDEMNITEE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) In the event that (i) a determination is made pursuant to Section&nbsp;12 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses, to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, is not timely made pursuant to Section&nbsp;10 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section&nbsp;12(a) of this Agreement within thirty (30) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Section&nbsp;5, 6, 7 or the last sentence of Section&nbsp;12(a) of this Agreement within ten (10) days after receipt by the Company of a written request therefor, (v) a contribution payment is not made in a timely manner pursuant to Section&nbsp;8 of this Agreement, (vi) payment of indemnification pursuant to Section&nbsp;3 or 4 of this Agreement is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification, or (vii) payment to Indemnitee pursuant to any hold harmless or exoneration rights under this Agreement or otherwise is not made in accordance with this Agreement, Indemnitee shall be entitled to an adjudication by the BVI Court to such indemnification, hold harmless, exoneration, contribution or advancement rights. Alternatively, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Except as set forth herein, the provisions of British Virgin Islands law (without regard to its conflict of laws rules) shall apply to any such arbitration. The Company shall not oppose Indemnitee&rsquo;s right to seek any such adjudication or award in arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) In the event that a determination shall have been made pursuant to Section&nbsp;12(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;14 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) In any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;14, Indemnitee shall be presumed to be entitled to be indemnified, held harmless, exonerated to receive advancement of Expenses under this Agreement and the Company shall have the burden of proving Indemnitee is not entitled to be indemnified, held harmless, exonerated and to receive advancement of Expenses, as the case may be, and the Company may not refer to or introduce into evidence any determination pursuant to Section&nbsp;12(a) of this Agreement adverse to Indemnitee for any purpose. If Indemnitee commences a judicial proceeding or arbitration pursuant to this Section&nbsp;14, Indemnitee shall not be required to reimburse the Company for any advances pursuant to Section&nbsp;10 until a final determination is made with respect to Indemnitee&rsquo;s entitlement to indemnification (as to which all rights of appeal have been exhausted or lapsed).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(d) If a determination shall have been made pursuant to Section&nbsp;12(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;14, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&rsquo;s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(e) The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;14 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(f) The Company shall indemnify and hold harmless Indemnitee to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company against all Expenses and, if requested by Indemnitee, shall (within ten (10) days after the Company&rsquo;s receipt of such written request) pay to Indemnitee, to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, such Expenses which are incurred by Indemnitee in connection with any judicial proceeding or arbitration brought by Indemnitee: (i) to enforce his or her rights under, or to recover damages for breach of, this Agreement or any other indemnification, hold harmless, exoneration, advancement or contribution agreement or provision of the Amended and Restated Memorandum and Articles of Association now or hereafter in effect; or (ii) for recovery or advances under any insurance policy maintained by any person for the benefit of Indemnitee, regardless of the outcome and whether Indemnitee ultimately is determined to be entitled to such indemnification, hold harmless or exoneration right, advancement, contribution or insurance recovery, as the case may be (unless such judicial proceeding or arbitration was not brought by Indemnitee in good faith).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(g) Interest shall be paid by the Company to Indemnitee at the legal rate under New York law for amounts which the Company indemnifies, holds harmless or exonerates, or advances, or is obliged to indemnify, hold harmless or exonerate or advance for the period commencing with the date on which Indemnitee requests indemnification, to be held harmless, exonerated, contribution, reimbursement or advancement of any Expenses and ending with the date on which such payment is made to Indemnitee by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>15. SECURITY</B>. Notwithstanding anything herein to the contrary, except for Section&nbsp;27, to the extent requested by Indemnitee and approved by the Board, the Company may at any time and from time to time provide security to Indemnitee for the Company&rsquo;s obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral. Any such security, once provided to Indemnitee, may not be revoked or released without the prior written consent of Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>16. NON-EXCLUSIVITY; SURVIVAL OF RIGHTS; INSURANCE; SUBROGATION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) The rights of Indemnitee as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Amended and Restated Memorandum and Articles of Association, any agreement, a vote of shareholders or a resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any Proceeding (regardless of when such Proceeding is first threatened, commenced or completed) or claim, issue or matter therein arising out of, or related to, any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in applicable law, whether by statute or judicial decision, permits greater indemnification, hold harmless or exoneration rights or advancement of Expenses than would be afforded currently under the Amended and Restated Memorandum and Articles of Association or this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) The Companies Law and the Amended and Restated Memorandum and Articles of Association permit the Company to purchase and maintain insurance or furnish similar protection or make other arrangements including, but not limited to, providing a trust fund, letter of credit, or surety bond (&ldquo;<B><I>Indemnification Arrangements</I></B>&rdquo;) on behalf of Indemnitee against any liability asserted against him or her or incurred by or on behalf of him or her or in such capacity as a director, officer, employee or agent of the Company, or arising out of his or her status as such, whether or not the Company would have the power to indemnify him or her against such liability under the provisions of this Agreement or under the Companies Law, as it may then be in effect. The purchase, establishment, and maintenance of any such Indemnification Arrangement shall not in any way limit or affect the rights and obligations of the Company or of Indemnitee under this Agreement except as expressly provided herein, and the execution and delivery of this Agreement by the Company and Indemnitee shall not in any way limit or affect the rights and obligations of the Company or the other party or parties thereto under any such Indemnification Arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, trustees, partners, managers, managing members, fiduciaries, employees, or agents of the Company or of any other Enterprise which such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, trustee, partner, managers, managing member, fiduciary, employee or agent under such policy or policies. If, at the time the Company receives notice from any source of a Proceeding as to which Indemnitee is a party or a participant (as a witness, deponent or otherwise), the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such Proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(d) In the event of any payment under this Agreement, the Company, to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, including with respect to any insurance. The Indemnitee shall execute all papers required and take all action necessary to secure such 16 rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights. No such payment by the Company shall be deemed to relieve any insurer of its obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(e) The Company&rsquo;s obligation to indemnify, hold harmless, exonerate or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, trustee, partner, manager, managing member, fiduciary, employee or agent of any other Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification, hold harmless or exoneration payments or advancement of expenses from such Enterprise. Notwithstanding any other provision of this Agreement to the contrary except for Section&nbsp;27, (i) Indemnitee shall have no obligation to reduce, offset, allocate, pursue or apportion any indemnification, hold harmless, exoneration, advancement, contribution or insurance coverage among multiple parties possessing such duties to Indemnitee prior to the Company&rsquo;s satisfaction and performance of all its obligations under this Agreement, and (ii) the Company shall perform fully its obligations under this Agreement without regard to whether Indemnitee holds, may pursue or has pursued any indemnification, advancement, hold harmless, exoneration, contribution or insurance coverage rights against any person or entity other than the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(f) Notwithstanding anything contained herein, the Company is the primary indemnitor, and any indemnification or advancement obligation of the Sponsor or its affiliates is secondary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>17. DURATION OF AGREEMENT</B>. All agreements and obligations of the Company contained herein shall continue during the period Indemnitee serves as a director or officer of the Company or as a director, officer, trustee, partner, manager, managing member, fiduciary, employee or agent of any other corporation, partnership, joint venture, trust, employee benefit plan or other Enterprise which Indemnitee serves at the request of the Company and shall continue thereafter so long as Indemnitee shall be subject to any possible Proceeding (including any rights of appeal thereto and any Proceeding commenced by Indemnitee pursuant to Section&nbsp;14 of this Agreement) by reason of his or her Corporate Status, whether or not he or she is acting in any such capacity at the time any liability or expense is incurred for which indemnification or advancement can be provided under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>18. SEVERABILITY. </B>If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any Section, paragraph or sentence of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section, paragraph or sentence of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>19. ENFORCEMENT AND BINDING EFFECT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director, officer or key employee of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director, officer or key employee of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) Without limiting any of the rights of Indemnitee under the Amended and Restated Memorandum and Articles of Association of the Company as they may be amended from time to time, this Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) The indemnification, hold harmless, exoneration and advancement of expenses rights provided by or granted pursuant to this Agreement shall be binding upon and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business and/or assets of the Company), shall continue as to an Indemnitee who has ceased to be a director, officer, employee or agent of the Company or a director, officer, trustee, general partner, manager, managing member, fiduciary, employee or agent of any other Enterprise at the Company&rsquo;s request, and shall inure to the benefit of Indemnitee and his or her spouse, assigns, heirs, devisees, executors and administrators and other legal representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(d) The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(e) The Company and Indemnitee agree herein that a monetary remedy for breach of this Agreement, at some later date, may be inadequate, impracticable and difficult of proof, and further agree that such breach may cause Indemnitee irreparable harm. Accordingly, the parties hereto agree that Indemnitee may, to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, enforce this Agreement by seeking, among other things, injunctive relief and/or specific performance hereof, without any necessity of showing actual damage or irreparable harm and that by seeking injunctive relief and/or specific performance, Indemnitee shall not be precluded from seeking or obtaining any other relief to which he or she may be entitled. The Company and Indemnitee further agree that Indemnitee shall, to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, be entitled to such specific performance and injunctive relief, including temporary restraining orders, preliminary injunctions and permanent injunctions, without the necessity of posting bonds or other undertaking in connection therewith. The Company acknowledges that in the absence of a waiver, a bond or undertaking may be required of Indemnitee by a court of competent jurisdiction, Company hereby waives any such requirement of such a bond or undertaking to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>20. MODIFICATION AND WAIVER.</B> No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by the Company and Indemnitee. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>21. NOTICES. </B>All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given (i) if delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, or (ii) mailed by certified or registered mail with postage prepaid, on the third (3rd) business day after the date on which it is so mailed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee shall provide in writing to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) If to the Company, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">D. Boral ARC Acquisition I Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">10 E. 53rd Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Suite 3001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">New York, NY 10022&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Attn: David Boral</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">With a copy, which shall not constitute notice, to</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Loeb &amp; Loeb LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">345 Park Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">New York, New York 10154</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Attn: David Levine, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">or to any other address as may have been furnished to Indemnitee in writing by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>22. APPLICABLE LAW AND CONSENT TO JURISDICTION.</B> This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section&nbsp;14(a) of this Agreement, to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, the Company and Indemnitee hereby irrevocably and unconditionally: (a) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the BVI Court and not in any other state or federal court in the United States of America or any court in any other country; (b) consent to submit to the exclusive jurisdiction of the BVI Court for purposes of any action or proceeding arising out of or in connection with this Agreement; (c) waive any objection to the laying of venue of any such action or proceeding in the BVI Court; and (d) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the BVI Court has been brought in an improper or inconvenient forum, or is subject (in whole or in part) to a jury trial. To the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, the parties hereby agree that the mailing of process and other papers in connection with any such action or proceeding in the manner provided by Section&nbsp;21 or in such other manner as may be permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, shall be valid and sufficient service thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>23. IDENTICAL COUNTERPARTS.</B> This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>24. MISCELLANEOUS. </B>Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>25. PERIOD OF LIMITATIONS.</B> No legal action shall be brought and no cause of action shall be asserted by or in the right of the Company against Indemnitee, Indemnitee&rsquo;s spouse, heirs, executors or personal or legal representatives after the expiration of two years from the date of accrual of such cause of action, and any claim or cause of action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such two-year period; provided, however, that if any shorter period of limitations is otherwise applicable to any such cause of action such shorter period shall govern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>26. ADDITIONAL ACTS.</B> If for the validation of any of the provisions in this Agreement any act, resolution, approval or other procedure is required to the fullest extent permitted by applicable law and the Amended and Restated Memorandum and Articles of Association of the Company, the Company undertakes to cause such act, resolution, approval or other procedure to be affected or adopted in a manner that will enable the Company to fulfill its obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>27. WAIVER OF CLAIMS TO TRUST ACCOUNT.</B> Indemnitee hereby agrees that he or she does not have any right, title, interest or claim of any kind (each, a &ldquo;<B><I>Claim</I></B>&rdquo;) in or to any monies in the trust account established in connection with the Company&rsquo;s initial public offering for the benefit of the Company and holders of shares issued in such offering, and hereby waives any Claim he or she may have in the future as a result of, or arising out of, any services provided to the Company and will not seek recourse against such trust account for any reason whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>28. MAINTENANCE OF INSURANCE.</B> The Company shall use commercially reasonable efforts to obtain and maintain in effect during the entire period for which the Company is obligated to indemnify the Indemnitee under this Agreement, one or more policies of insurance with reputable insurance companies to provide the officers/directors of the Company with coverage for losses from wrongful acts and omissions and to ensure the Company&rsquo;s performance of its indemnification obligations under this Agreement. The Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director or officer under such policy or policies. In all such insurance policies, the Indemnitee shall be named as an insured in such a manner as to provide the Indemnitee with the same rights and benefits as are accorded to the most favorably insured of the Company&rsquo;s directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>29. INTERPRETATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">(a)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">words importing the singular number include the plural number and vice versa; words importing the masculine gender include the feminine gender; words importing persons include corporations as well as any other legal or natural person;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">(b)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&ldquo;written&rdquo; and &ldquo;in writing&rdquo; include all modes of representing or reproducing words in visible form, including in the form of an electronic record;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">(e)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&ldquo;shall&rdquo; shall be construed as imperative and &ldquo;may&rdquo; shall be construed as permissive;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">(f)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">references to provisions of any law or regulation shall be construed as references to those provisions as amended, modified, re-enacted or replaced;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">(g)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">any phrase introduced by the terms &ldquo;including&rdquo;, &ldquo;include&rdquo;, &ldquo;in particular&rdquo; or any similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">(h)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">the term &ldquo;and/or&rdquo; is used herein to mean both &ldquo;and&rdquo; as well as &ldquo;or.&rdquo; The use of &ldquo;and/or&rdquo; in certain contexts in no respects qualifies or modifies the use of the terms &ldquo;and&rdquo; or &ldquo;or&rdquo; in others. The term &ldquo;or&rdquo; shall not be interpreted to be exclusive and the term &ldquo;and&rdquo; shall not be interpreted to require the conjunctive (in each case, unless the context otherwise requires);</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">(i)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">headings are inserted for reference only and shall be ignored in construing this Agreement;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">(j)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">any requirements as to delivery under this Agreement include delivery in the form of an electronic record (as defined in the Electronic Transactions Act (Revised));</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">(k)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">any requirements as to execution or signature under this Agreement including the execution of this Agreement itself can be satisfied in the form of an electronic signature (as defined in the Electronic Transactions Act (Revised));</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">(l)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">sections&nbsp;8 and 19(3) of the Electronic Transactions Act (Revised) shall not apply.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[Signature Page Follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Indemnity Agreement to be signed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: left"><B>D. BORAL ARC ACQUISITION I CORP.</B></TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 5%; text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; vertical-align: top; width: 45%">/s/ David Boral</TD>
    <TD STYLE="text-align: left; width: 50%; vertical-align: middle">&nbsp;</TD> </TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left">Name:</TD>
    <TD STYLE="vertical-align: top; text-align: left">David Boral</TD>
    <TD STYLE="text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left">Title:</TD>
    <TD STYLE="vertical-align: top; text-align: left">Chief Executive Officer</TD>
    <TD STYLE="text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><B>INDEMNITEE</B></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: left">/s/ David Boral</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top">Name:</TD>
    <TD STYLE="text-align: left; vertical-align: top">David Boral</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: left; width: 5%">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: left; width: 45%">/s/ John Darwin</TD>
    <TD STYLE="text-align: left; width: 50%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top">Name:</TD>
    <TD STYLE="text-align: left; vertical-align: top">John Darwin</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: left">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: left">/s/ Kevin Chen</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top">Name:</TD>
    <TD STYLE="text-align: left; vertical-align: top">Kevin Chen</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: left">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: left">/s/ Luisa Ingargiola</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top">Name:</TD>
    <TD STYLE="text-align: left; vertical-align: top">Luisa Ingargiola</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: left">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: left">/s/ Matt Laker</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top">Name:</TD>
    <TD STYLE="text-align: left; vertical-align: top">Matt Laker</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[<I>Signature page - Indemnity Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>10
<FILENAME>dboralarcacq_ex10-6.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 10.6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SUBSCRIPTION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">TO:</TD><TD STYLE="text-align: justify">The Directors of D. Boral ARC Acquisition I Corp. (the &ldquo;Company&rdquo;).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">We hereby subscribe for 12,321,429 Class B ordinary shares of the Company (the &ldquo;Shares&rdquo;). In consideration for the issue of the Shares, we hereby agree and undertake to pay $25,000 to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">We agree to accept the Shares subject to the Memorandum and Articles of Association of the Company and we authorize you to enter the following name and address in the register of members of the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="text-align: justify; width: 1in">Name:</TD>
    <TD STYLE="text-align: justify">MFH 1, LLC</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="text-align: justify; width: 1in">Address:</TD>
    <TD STYLE="text-align: justify">10 E. 53<SUP>rd</SUP> St. Suite 3001<BR> New York, NY 10022</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">MFH 1, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left; width: 5%">Signed:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">/s/ John Darwin</TD>
    <TD STYLE="text-align: left; width: 50%">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">Name:&nbsp;</TD>
    <TD STYLE="text-align: left"> John Darwin</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">Dated:&nbsp;</TD>
    <TD STYLE="text-align: left"> March&nbsp;25, 2025</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD COLSPAN="2" STYLE="text-align: left">Accepted:</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD COLSPAN="2" STYLE="text-align: left">D. BORAL ARC ACQUISITION I CORP.</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left; width: 5%">Signed:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">/s/ David Boral</TD>
    <TD STYLE="text-align: left; width: 50%">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">Name:&nbsp;</TD>
    <TD STYLE="text-align: left"> David Boral</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">Title:&nbsp;</TD>
    <TD STYLE="text-align: left">Chief Executive Officer</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">Dated:&nbsp;</TD>
    <TD STYLE="text-align: left"> March&nbsp;25, 2025</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>11
<FILENAME>dboralarcacq_ex10-10.htm
<DESCRIPTION>EXHIBIT 10.10
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit 10.10</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>D. BORAL ARC ACQUISITION I CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">10 E. 53rd Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Suite 3001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">July&nbsp;30, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">Re:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">Administrative Services Agreement</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Ladies and Gentlemen:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">This letter of agreement by and between D. Boral ARC Acquisition I Corp. (the &ldquo;<B><I>Company</I></B>&rdquo;) and the Company&rsquo;s sponsor, MFH 1, LLC (&ldquo;<B><I>Sponsor</I></B>&rdquo;), dated as of the date hereof, will confirm our agreement that, commencing on the date the securities of the Company are first listed on the Nasdaq Global Market (the &ldquo;<B><I>Listing Date</I></B>&rdquo;), pursuant to a Registration Statement on Form S-1 and prospectus filed with the U.S. Securities and Exchange Commission (the &ldquo;<B><I>Registration Statement</I></B>&rdquo;) and continuing until the earlier of the consummation by the Company of an initial business combination and the Company&rsquo;s liquidation (in each case as described in the Registration Statement) (such earlier date hereinafter referred to as the &ldquo;<B><I>Termination Date</I></B>&rdquo;):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(i) The Sponsor shall make available (or cause other persons to make available) to the Company, at 10 E. 53rd Street, Suite 3001, New York, NY 10022 (or any successor location of the Sponsor), certain office space and administrative services as may be reasonably required by the Company. As reimbursement therefor, the Company shall pay the Sponsor (and the Sponsor will receive on behalf of itself or, to the extent it causes another person to make support available to the Company, as nominee on behalf of such other person) the sum of $20,000 per month beginning on the Listing Date and continuing monthly thereafter until the Termination Date.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(ii) The Sponsor hereby irrevocably waives any and all right, title, interest, causes of action and claims of any kind as a result of, or arising out of, this letter agreement (each, a &ldquo;<B><I>Claim</I></B>&rdquo;) in or to, and any and all right to seek payment of any amounts due to it out of, the trust account established for the benefit of the public shareholders of the Company and into which substantially all of the proceeds of the Company&rsquo;s initial public offering will be deposited (the &ldquo;<B><I>Trust Account</I></B>&rdquo;), and hereby irrevocably waives any Claim it may have in the future, which Claim would reduce, encumber or otherwise adversely affect the Trust Account or any monies or other assets in the Trust Account, and further agrees not to seek recourse, reimbursement, payment or satisfaction of any Claim against the Trust Account or any monies or other assets in the Trust Account for any reason whatsoever.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">This letter agreement constitutes the entire agreement and understanding of the parties hereto in respect of its subject matter and supersedes all prior understandings, agreements or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated hereby.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">This letter agreement may not be amended, modified or waived as to any particular provision, except by a written instrument executed by the parties hereto.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">No party hereto may assign either this letter agreement or any of its rights, interests or obligations hereunder without the prior written approval of the other party; provided, however, that the Sponsor may assign this letter agreement, in whole or in part, to Sponsor or any other person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, Sponsor without the prior written approval of the Company. Any purported assignment in violation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title to the purported assignee.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">This letter agreement constitutes the entire relationship of the parties hereto, and any litigation between the parties (whether grounded in contract, tort, statute, law or equity) shall be governed by, construed in accordance with and interpreted pursuant to the laws of the State of New York, without giving effect to its choice of laws principles.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Very truly yours,</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>D. BORAL ARC ACQUISITION I CORP.</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"> /s/ David Boral</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Name: </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">David Boral</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Chief Executive Officer</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">AGREED TO AND ACCEPTED BY:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>MFH 1, LLC</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"> /s/ John Darwin</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Name: </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">John Darwin</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Manager</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD> </TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>[SIGNATURE PAGE TO ADMINISTRATIVE SERVICES AGREEMENT]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>12
<FILENAME>dboralarcacq_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: right"><IMG SRC="ex23-1_001.jpg" ALT="" STYLE="height: 36px; width: 200px"></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: right"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="color: rgb(127,127,127)">&nbsp;</FONT></P>
                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="color: rgb(127,127,127)">Guangdong Prouden CPAs
                              GP</FONT></P>
                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="color: rgb(127,127,127)">&nbsp;</FONT></P>
                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt; color: rgb(127,127,127)">Ste.2201,
                              Yuehai Financial Center,21 Zhujiang</FONT></P>
                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt; color: rgb(127,127,127)">West Rd.,
                              Guangzhou, Guangdong</FONT></P></TD></TR>
     </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the inclusion in this
Registration Statement of D. Boral ARC Merger Corporation on the Amendment No.1 to Form S-4 of our report dated February 11, 2026,
which includes an explanatory paragraph relating to D. Boral ARC Merger Corporation&rsquo;s ability to continue as a going concern,
with respect to our audit of the financial statements of D. Boral ARC Merger Corporation. as of December 31, 2025 and for the period
from December 19, 2025 (inception) through December 31, 2025 appearing in the Prospectus, which is part of this Registration
Statement. We also consent to the reference to our firm under the heading &ldquo;Experts&rdquo; in such Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Guangdong Prouden CPAs GP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guangdong
Prouden CPAs GP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guangzhou,
China</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&nbsp;10, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>13
<FILENAME>dboralarcacq_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: right"><IMG SRC="ex23-1_001.jpg" ALT="" STYLE="height: 36px; width: 200px"></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: right"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="color: rgb(127,127,127)">&nbsp;</FONT></P>
                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="color: rgb(127,127,127)">Guangdong Prouden CPAs
                              GP</FONT></P>
                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="color: rgb(127,127,127)">&nbsp;</FONT></P>
                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt; color: rgb(127,127,127)">Ste.2201,
                              Yuehai Financial Center,21 Zhujiang</FONT></P>
                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt; color: rgb(127,127,127)">West Rd.,
                              Guangzhou, Guangdong</FONT></P></TD></TR>
     </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the inclusion in this Registration Statement of D. Boral ARC Acquisition I Corp. on the Amendment No.1 to Form S-4 of our
report dated March 13, 2025, which includes an explanatory paragraph relating to D. Boral ARC Acquisition I Corp.&rsquo;s ability to
continue as a going concern, with respect to our audit of the financial statements of D. Boral ARC Acquisition I Corp. as of
December 31, 2025 and for the period from March 20, 2025 (inception) through December 31, 2025 appearing in the Prospectus, which is
part of this Registration Statement. We also consent to the reference to our firm under the heading &ldquo;Experts&rdquo; in such
Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Guangdong Prouden CPAs GP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guangdong
Prouden CPAs GP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guangzhou,
China</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&nbsp;10, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>14
<FILENAME>dboralarcacq_ex23-3.htm
<DESCRIPTION>EXHIBIT 23.3
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 23.3</B></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We hereby consent to the inclusion in Amendment No. 1 to the Registration Statement on Form S-4 of D. Boral ARC Merger Corporation (the &ldquo;Registration Statement&rdquo;), of our report dated February 11, 2026, which includes an explanatory paragraph regarding Exascale Labs Inc.&rsquo;s ability to continue as a going concern, relating to our audits of the financial statements of Exascale Labs Inc. as of June 30, 2025 and 2024, and for each of the years then ended, appearing in the proxy statement/prospectus included in the Registration Statement and related prospectus of D. Boral ARC Merger Corporation for registration of shares of common stock and warrants to purchase shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We also consent to the reference to our firm under the heading &ldquo;Experts&rdquo; in the Registration Statement.</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR></FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ HTL International, LLC<BR></FONT></P>

<P STYLE="margin: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Houston, Texas</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">June&nbsp;11, 2026</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>15
<FILENAME>dboralarcacq_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>D. BORAL ARC ACQUISITION I CORP.</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>10 East 53rd Street,&nbsp;Suite 3001</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>New York,&nbsp;NY&nbsp;10022</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>+ (332) 266-7344</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF<BR>D. BORAL ARC ACQUISITION I CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0; margin-bottom: 0">The undersigned hereby appoints David Boral and John Darwin as proxies (the &ldquo;Proxies&rdquo;),with full power to act to appoint a substitute, and hereby authorizes the Proxy to represent and to vote, as designated on the reverse side, all ordinary shares of D. Boral ARC Acquisition I Corp. (&ldquo;BCAR&rdquo;) held of record by the undersigned on ____, 2026 at the Extraordinary General Meeting of shareholders to be held on ______________, 2026, or any postponement or adjournment thereof (the &ldquo;Extraordinary General Meeting&rdquo;). BCAR has determined that the Extraordinary General Meeting will be a virtual meeting conducted via live webcast at ____________________. For the purposes of British Virgin Islands law and the amended and restated memorandum and articles of association of BCAR, the physical location of the Extraordinary General Meeting will be at the offices of Loeb &amp; Loeb LLP, 345 Park Avenue, New York, NY 10154 on [_], 2026, at 10:00 A.M. Eastern Time and virtually using the following dial-in information: Telephone number: __________________ Participant Passcode: __________________. To register and receive access to the virtual meeting, shareholders of record and beneficial owners (those holding shares through a bank, broker or other nominee) will need to follow the instructions applicable to them provided in the proxy statement. Such shares shall be voted as indicated with respect to the proposals listed on the reverse side hereof and in the Proxy&rsquo;s discretion on such other matters as may properly come before the Extraordinary General Meeting, or any postponement or adjournment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0; margin-bottom: 0"><B>The undersigned acknowledges receipt of the accompanying proxy statement and revokes all prior proxies for the Extraordinary General Meeting.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0; margin-bottom: 0">THE SHARES REPRESENTED BY THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED SHAREHOLDER. IF NO SPECIFIC DIRECTION IS GIVEN AS TO THE PROPOSALS ON THE REVERSE SIDE, THIS PROXY WILL BE VOTED &ldquo;FOR&rdquo; EACH OF THE PROPOSALS PRESENTED TO THE SHAREHOLDERS. PLEASE MARK, SIGN, DATE AND RETURN THE PROXY CARD PROMPTLY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>PLEASE DETACH ALONG PERFORATED LINE AND MAIL IN THE ENVELOPE PROVIDED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>THIS PROXY REVOKES ALL PRIOR PROXIES GIVEN BY THE UNDERSIGNED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>(Continued and to be marked, dated and signed on reverse side)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>PRELIMINARY COPY &ndash; NOT FOR USE</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>PROXY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>THIS PROXY WILL BE VOTED AS DIRECTED. IF NO DIRECTIONS ARE GIVEN, THIS PROXY WILL BE VOTED &ldquo;FOR&rdquo; PROPOSALS 1 THROUGH 8 BELOW. BCAR&rsquo;S BOARD OF DIRECTORS RECOMMENDS A VOTE &ldquo;FOR&rdquo; EACH PROPOSAL.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>(1) Proposal No. 1 &mdash; The Business Combination Proposal </B>&mdash; To consider and vote upon a proposal to approve by way of ordinary resolution and adopt the Agreement and Plan of Merger, dated as of January&nbsp;11, 2026 (the &ldquo;<B>Business Combination Agreement</B>&rdquo;), by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and a direct, wholly owned subsidiary of BCAR (&ldquo;<B>PubCo</B>&rdquo;), D. Boral Arc Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary of BCAR (&ldquo;<B>Merger Sub</B>&rdquo;), and Exascale Labs Inc., a Delaware corporation (&ldquo;<B>Exascale</B>&rdquo;), pursuant to which, among other things, BCAR shall continue out of the British Virgin Islands and into the State of Delaware so as to re-domicile as and become a Delaware corporation by means of a merger (the &ldquo;<B>Domestication Merger</B>&rdquo;) of BCAR with and into PubCo, with PubCo as the surviving company pursuant to the BVI Business Companies Act, (Revised Edition 2020) as amended, of the British Virgin Islands and the applicable provisions of the Delaware General Corporation Law, as amended. Following the closing of the Domestication Merger, Merger Sub shall be merged with and into Exascale, with Exascale surviving the merger as a wholly-owned subsidiary of PubCo (the &ldquo;<B>Acquisition Merger</B>&rdquo; and collectively with the Domestication Merger and the other agreements and transactions contemplated by the Business Combination Agreement, the &ldquo;<B>Business Combination</B>&rdquo;). We refer to this proposal as the &ldquo;<B>Business Combination Proposal</B>.&rdquo; A copy of the Business Combination Agreement is attached to the accompanying proxy statement/prospectus as&nbsp;<I>Annex&nbsp;A</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#9744;&nbsp;FOR&nbsp;&nbsp;&nbsp;&#9744;&nbsp;AGAINST&nbsp;&nbsp;&nbsp;&#9744;&nbsp;ABSTAIN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>(2) Proposal No. 2 &mdash; The Domestication Merger Proposal</B> &mdash; To consider and vote upon a proposal to approve by way of ordinary resolution and adopt the domestication of BCAR pursuant to the Business Combination Agreement. Subject to the conditions of the Business Combination Agreement, BCAR shall continue out of the British Virgin Islands and into the State of Delaware so as to re-domicile as and become a Delaware corporation by means of a merger of BCAR with and into PubCo, with PubCo as the surviving company pursuant to the BVI Business Companies Act, (Revised Edition 2020) as amended, of the British Virgin Islands and the applicable provisions of the Delaware General Corporation Law, as amended. Upon the Domestication Merger, PubCo shall change its name to &ldquo;Exascale Labs Holdings Inc.&rdquo; We refer to this proposal as the &ldquo;<B>Domestication Merger Proposal</B>.&rdquo; A copy of the Business Combination Agreement is attached to the accompanying proxy statement/prospectus as&nbsp;<I>Annex A.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#9744;&nbsp;FOR&nbsp;&nbsp;&nbsp;&#9744;&nbsp;AGAINST&nbsp;&nbsp;&nbsp;&#9744;&nbsp;ABSTAIN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>(3) Proposal No. 3 &mdash; Organizational Documents Proposal </B>&mdash; To consider and vote upon a proposal to approve by way of ordinary resolution the proposed amended and restated certificate of incorporation (the &ldquo;<B>Proposed Charter</B>&rdquo;) and the proposed amended and restated bylaws (&ldquo;<B>Proposed Bylaws</B>&rdquo; and, together with the Proposed Charter, the &ldquo;<B>Proposed Organizational Documents</B>&rdquo;) of PubCo. The forms of each of the Proposed Charter and the Proposed Bylaws are attached to the accompanying proxy statement/prospectus as&nbsp;<I>Annex B-1&nbsp;</I>and&nbsp;<I>Annex B-2</I>, respectively.&nbsp;We refer to this proposal as the &ldquo;<B>Organizational Documents Proposal.</B>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#9744;&nbsp;FOR&nbsp;&nbsp;&nbsp;&#9744;&nbsp;AGAINST&nbsp;&nbsp;&nbsp;&#9744;&nbsp;ABSTAIN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>(4) Proposal No. 4 &mdash; The Advisory Organizational Documents Proposals </B>&mdash; To consider and vote upon the following six (6) separate proposals (collectively, the &ldquo;<B>Advisory Organizational Documents Proposals</B>&rdquo;) to approve on an advisory non-binding basis by way of ordinary resolution the following material differences between the Current Charter and the Proposed Organizational Documents:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin-left: 1in; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>(A) <I>Advisory Organizational Documents Proposal 4A (Authorized Shares) </I></B>&mdash; authorize the amendment and redesignation of the authorized shares of BCAR from (a) 500,000,000 BCAR Class A Ordinary Shares, 50,000,000 BCAR Class B Ordinary Shares and 5,000,000 BCAR preference shares, in each case par value $0.0001 per share, to (b) 260,000,000 shares of PubCo Class A Ordinary Common Stock, 35,000,000 shares of PubCo Class B Super Common Stock and 5,000,000 shares of PubCo Preferred Stock, in each case par value $0.0001 per share (&ldquo;<B>Advisory Organizational Documents Proposal 4A</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#9744;&nbsp;FOR&nbsp;&nbsp;&nbsp;&#9744;&nbsp;AGAINST&nbsp;&nbsp;&nbsp;&#9744;&nbsp;ABSTAIN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin-left: 1in; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>(B) <I>Advisory Organizational Documents Proposal 4B (Change in Voting Rights) </I></B>&mdash; to change the voting rights of PubCo&rsquo;s Common Stock such that, each PubCo Class A Ordinary Common Stock will be entitled to one (1) vote per PubCo Class A Ordinary Common Stock on all matters submitted to a vote of the stockholders of PubCo, and each PubCo Class B Super Common Stock will be entitled to twenty (20) votes per PubCo Class B Super Common Stock on all matters submitted to a vote of the stockholders of PubCo, and that the PubCo Class A Ordinary Common Stock and PubCo Class B Super Common Stock shall vote together on all matters except as explicitly required by the DGCL or as explicitly set forth in the Proposed Charter (&ldquo;<B>Advisory Organizational Documents Proposal 4B</B>&rdquo;)<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#9744;&nbsp;FOR&nbsp;&nbsp;&nbsp;&#9744;&nbsp;AGAINST&nbsp;&nbsp;&nbsp;&#9744;&nbsp;ABSTAIN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin-left: 1in; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>(C) <I>Advisory Organizational Documents Proposal 4C (Exclusive Forum Provision) </I></B>&mdash; to authorize adopting Delaware as the exclusive forum for certain stockholder litigation and adopting the federal district courts of the United States as the exclusive forum for resolving complaints asserting a cause of action under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;) (&ldquo;<B>Advisory Organizational Documents Proposal 4C</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#9744;&nbsp;FOR&nbsp;&nbsp;&nbsp;&#9744;&nbsp;AGAINST&nbsp;&nbsp;&nbsp;&#9744;&nbsp;ABSTAIN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin-left: 1in; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>(D) <I>Advisory Organizational Documents Proposal 4D (Required Vote to Amend Charter) </I></B>&mdash; &nbsp;to approve provisions providing that the affirmative vote of at least 66&#8532;% of the voting power of all the then outstanding shares of capital stock of PubCo entitled to vote thereon, voting together as a single class, will be required to amend, alter, repeal or rescind any provision of Article FIFTH, Article SIXTH, Article SEVENTH, Article EIGHTH, Article NINTH, Article TENTH or Article ELEVENTH of the Proposed Charter (&ldquo;<B>Advisory Organizational Documents Proposal 4D</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#9744;&nbsp;FOR&nbsp;&nbsp;&nbsp;&#9744;&nbsp;AGAINST&nbsp;&nbsp;&nbsp;&#9744;&nbsp;ABSTAIN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin-left: 1in; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>(E) <I>Advisory Organizational Documents Proposal 4E (Removal of Directors) </I></B>&mdash; to approve provisions permitting the removal of a director, but only for cause, and then by the affirmative vote of at least 66&#8532;% of the voting power of all the then outstanding shares entitled to vote generally in the election of directors, voting together as a single class (&ldquo;<B>Advisory Organizational Documents Proposal 4E</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#9744;&nbsp;FOR&nbsp;&nbsp;&nbsp;&#9744;&nbsp;AGAINST&nbsp;&nbsp;&nbsp;&#9744;&nbsp;ABSTAIN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin-left: 1in; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>(F) <I>Advisory Organizational Documents Proposal 4F (Name Change)&nbsp;</I></B>&mdash; to approve the change of the name of PubCo to &ldquo;Exascale Labs Holdings Inc.&rdquo; (&ldquo;<B>Advisory Organizational Documents Proposal 4F</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#9744;&nbsp;FOR&nbsp;&nbsp;&nbsp;&#9744;&nbsp;AGAINST&nbsp;&nbsp;&nbsp;&#9744;&nbsp;ABSTAIN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>(5) Proposal No. 5 &mdash; Directors Proposal</B> &mdash; A proposal to elect Hoansoo Lee, Wenying Jia, David Card, Shachar Kariv and Jaeyoung Shin as the directors of PubCo, with Hoansoo Lee to serve until the 2029 annual meeting and until his successor has been duly elected and qualified or until his earlier resignation, removal or death, with each of Wenying Jia and David Card to serve until the 2028 annual meeting and until their respective successors have been duly elected and qualified or until their earlier resignation, removal or death, and with each of Shachar Kariv and Jaeyoung Shin to serve until the 2027 annual meeting and until their respective successors have been duly elected and qualified or until their earlier resignation, removal or death (the &ldquo;<B>Directors Proposal</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#9744;&nbsp;FOR&nbsp;&nbsp;&nbsp;&#9744;&nbsp;AGAINST&nbsp;&nbsp;&nbsp;&#9744;&nbsp;ABSTAIN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>(6) Proposal No. 6 &mdash; The Equity Incentive Plan Proposal </B>&mdash; To consider and vote upon a proposal to approve by an ordinary resolution the Equity Incentive Plan (the &ldquo;<B>Equity Incentive Plan Proposal</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#9744;&nbsp;FOR&nbsp;&nbsp;&nbsp;&#9744;&nbsp;AGAINST&nbsp;&nbsp;&nbsp;&#9744;&nbsp;ABSTAIN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>(7) Proposal No. 7 &mdash; The Nasdaq Proposal </B>&mdash; To consider and vote upon a proposal to approve by an ordinary resolution, for purposes of complying with the applicable provisions of Nasdaq Stock Exchange Listing Rule&nbsp;5635, the issuance of PubCo Common Stock and PubCo Warrants in connection with the Business Combination (the &ldquo;<B>Nasdaq Proposal</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#9744;&nbsp;FOR&nbsp;&nbsp;&nbsp;&#9744;&nbsp;AGAINST&nbsp;&nbsp;&nbsp;&#9744;&nbsp;ABSTAIN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>(8) Proposal No. 8 &mdash; The Adjournment Proposal </B>&mdash; To consider and vote upon a proposal to approve by way of ordinary resolution the adjournment of the Extraordinary General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for the approval of the Business Combination Proposal, the Domestication Merger Proposal, the Organizational Documents Proposal, the Advisory Organizational Documents Proposals, the Directors Proposal, the Equity Incentive Plan Proposal, or the Nasdaq Proposal at the Extraordinary General Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#9744;&nbsp;FOR&nbsp;&nbsp;&nbsp;&#9744;&nbsp;AGAINST&nbsp;&nbsp;&nbsp;&#9744;&nbsp;ABSTAIN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0; margin-bottom: 0">THIS PROXY WILL BE VOTED IN ACCORDANCE WITH THE SPECIFIC INDICATION ABOVE. IN THE ABSENCE OF SUCH INDICATION, THIS PROXY WILL BE VOTED &ldquo;FOR&rdquo; ALL DIRECTOR NOMINEES AND &ldquo;FOR&rdquo; EACH OF THE OTHER PROPOSALS AND, AT THE DISCRETION OF THE PROXY HOLDER, ON ANY OTHER MATTERS THAT MAY PROPERLY COME BEFORE THE ANNUAL MEETING OR ANY POSTPONEMENT OR ADJOURNMENT THEREOF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; width: 5%; padding-bottom: 0.5pt">Dated:</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; width: 15%">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: left; padding-bottom: 0.5pt"></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; width: 50%">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Signature of Stockholder</TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; padding-bottom: 0.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">PLEASE PRINT NAME</TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; padding-bottom: 0.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Certificate Number(s)</TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; padding-bottom: 0.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Total Number of Shares Owned</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>IN THEIR DISCRETION THE PROXY IS AUTHORIZED AND EMPOWERED TO VOTE UPON OTHER MATTERS THAT MAY PROPERLY COME BEFORE THE MEETING OF SHAREHOLDERS AND ALL CONTINUATIONS, ADJOURNMENTS OR POSTPONEMENTS THEREOF.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>Sign exactly as name appears on this proxy card. If shares are held jointly, each holder should sign. Executors, administrators, trustees, guardians, attorneys and agents should give their full titles. If shareholder is a corporation, sign in corporate name by an authorized officer, giving full title as such. If shareholder is a partnership, sign in partnership name by an authorized person, giving full title as such.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>IMPORTANT: PLEASE MARK, SIGN, DATE AND MAIL THIS PROXY CARD PROMPTLY!</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></DIV>

    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>16
<FILENAME>dboralarcacq_ex99-6.htm
<DESCRIPTION>EXHIBIT 99.6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.6</B></FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF JAEYOUNG SHIN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the filing by D. Boral ARC Merger Corporation of the Registration Statement on Form S-4 with the Securities and Exchange
Commission under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), I hereby consent, pursuant to Rule 438 of
the Securities Act, to being named as a nominee to the board of directors of D. Boral ARC Merger Corporation in the Registration Statement
and any and all amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to such Registration Statement
and any amendments thereto.</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
Dated: June 1, 2026</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>/s/
Jaeyoung Shin</U></I></FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jaeyoung
Shin</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>17
<FILENAME>dboralarcacq_ex107.htm
<DESCRIPTION>EXHIBIT 107
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ffd="http://xbrl.sec.gov/ffd/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:CIK0002065779="http://CIK0002065779/20260610">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_027_FFD%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_CIK0002065779_CIK0002065779_20260610 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20260610_20260610 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0002065779 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Ratio_4_xbrli%2D%2Dpure -->
<body>
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-06-10" id="Fact000003" name="dei:EntityCentralIndexKey">0002065779</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-06-10" id="xdx2ixbrl0010" name="ffd:FeeExhibitTp">EX-FILING FEES</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-06-10" id="xdx2ixbrl0013" name="ffd:SubmissnTp">S-4/A</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-06-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-06-10</xbrli:startDate>
        <xbrli:endDate>2026-06-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-06-102026-06-10_1">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ffd:OfferingAxis">
            <dei:lineNo>1</dei:lineNo>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-06-10</xbrli:startDate>
        <xbrli:endDate>2026-06-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-06-102026-06-10_2">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ffd:OfferingAxis">
            <dei:lineNo>2</dei:lineNo>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-06-10</xbrli:startDate>
        <xbrli:endDate>2026-06-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-06-102026-06-10_3">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ffd:OfferingAxis">
            <dei:lineNo>3</dei:lineNo>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-06-10</xbrli:startDate>
        <xbrli:endDate>2026-06-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-06-102026-06-10_4">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ffd:OfferingAxis">
            <dei:lineNo>4</dei:lineNo>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-06-10</xbrli:startDate>
        <xbrli:endDate>2026-06-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-06-102026-06-10_5">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ffd:OfferingAxis">
            <dei:lineNo>5</dei:lineNo>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-06-10</xbrli:startDate>
        <xbrli:endDate>2026-06-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-06-102026-06-10_24993218">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ffd:OffsetAxis">
            <dei:lineNo>2</dei:lineNo>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-06-10</xbrli:startDate>
        <xbrli:endDate>2026-06-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-06-102026-06-10_14993234">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002065779</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ffd:OffsetAxis">
            <dei:lineNo>1</dei:lineNo>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-06-10</xbrli:startDate>
        <xbrli:endDate>2026-06-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Ratio">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90F_effd--CombinedProspectusTableNa_c20260610__20260610_zkKYLbJQZzP7"><span style="display: none"><ix:nonNumeric contextRef="AsOf2026-06-10" id="Fact000009" name="ffd:CombinedProspectusTableNa">N/A</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><b><span id="xdx_906_effd--FeeExhibitTp_dxL_c20260610__20260610_zKrbJzfrzBqk" title="::XDX::EX-FILING FEES"><span style="-sec-ix-hidden: xdx2ixbrl0010">Exhibit 107</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span><span id="xdx_902_effd--RegnFileNb_c20260610__20260610_zVQJJ0JHOMW7" style="display: none"><ix:nonNumeric contextRef="AsOf2026-06-10" id="Fact000011" name="ffd:RegnFileNb">333-295869</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Calculation of Filing Fee Tables</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b><span id="xdx_907_effd--FormTp_c20260610__20260610_z5CN6rRlWpc1"><span id="xdx_909_effd--SubmissnTp_dxL_c20260610__20260610_zNpDauTN3wGi" title="::XDX::S-4%2FA"><ix:nonNumeric contextRef="AsOf2026-06-10" id="Fact000012" name="ffd:FormTp"><span style="-sec-ix-hidden: xdx2ixbrl0013">S-4</span></ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b><span><span>&#160;</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90D_edei--EntityRegistrantName_c20260610__20260610_zI00H9Eal235" style="display: none"><ix:nonNumeric contextRef="AsOf2026-06-10" id="Fact000014" name="dei:EntityRegistrantName">D. Boral ARC Acquisition I Corp</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 14pt"><b>D. Boral ARC Merger Corporation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 50%"><b>Table 1: Newly Registered and Carry Forward Securities</b></td>
    <td style="text-align: right; width: 50%"><b>&#9744;&#160;Not Applicable</b></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="3" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Security Type</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Security Class Title</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Fee Calculation<br/> or&#160;Carry Forward<br/> Rule</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount <br/> Registered</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Proposed Maximum<br/> Offering Price<br/> Per Unit</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Maximum Aggregate<br/> Offering Price</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Fee Rate</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount of<br/> Registration Fee</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Carry Forward<br/> Form Type</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Carry Forward<br/> File Number</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Carry Forward<br/> Initial<br/> Effective Date</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Filing Fee<br/> Previously <br/> Paid in<br/> Connection with<br/> Unsold Securities<br/> to be Carried<br/> Forward</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="14" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Newly Registered Securities</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; width: 12%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_907_effd--PrevslyPdFlg_dbT_c20260610__20260610__ffd--OfferingAxis__1_zVO9dZR7xlah"><ix:nonNumeric contextRef="From2026-06-102026-06-10_1" format="ixt:booleantrue" id="Fact000015" name="ffd:PrevslyPdFlg">Fees Previously Paid</ix:nonNumeric></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1</span></td>
    <td id="xdx_98D_effd--OfferingSctyTp_c20260610__20260610__ffd--OfferingAxis__1_zlvYTLYham6" style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; width: 6%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonNumeric contextRef="From2026-06-102026-06-10_1" id="Fact000016" name="ffd:OfferingSctyTp">Equity</ix:nonNumeric></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; width: 20%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_906_effd--OfferingSctyTitl_c20260610__20260610__ffd--OfferingAxis__1_zDS6Q4lJRb0j"><ix:nonNumeric contextRef="From2026-06-102026-06-10_1" id="Fact000017" name="ffd:OfferingSctyTitl">Class A Common Stock, par value $0.0001 per share, to be issued to shareholders</ix:nonNumeric></span> of D. Boral ARC Acquisition I Corp. (&#8220;BCAR&#8221;)</span></td>
    <td id="xdx_980_effd--FeesOthrRuleFlg_dbT_c20260610__20260610__ffd--OfferingAxis__1_zgkvdyAkW3Pd" style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonNumeric contextRef="From2026-06-102026-06-10_1" format="ixt:booleantrue" id="Fact000018" name="ffd:FeesOthrRuleFlg">Other</ix:nonNumeric></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90B_effd--AmtSctiesRegd_c20260610__20260610__ffd--OfferingAxis__1_zvVhu5OawBZ6"><ix:nonFraction name="ffd:AmtSctiesRegd" contextRef="From2026-06-102026-06-10_1" id="Fact000019" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,200,000</ix:nonFraction></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$<span id="xdx_90C_effd--MaxOfferingPricPerScty_pin2_dp_c20260610__20260610__ffd--OfferingAxis__1_znuf3tm96Ksj"><ix:nonFraction name="ffd:MaxOfferingPricPerScty" contextRef="From2026-06-102026-06-10_1" id="Fact000020" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">10.67</ix:nonFraction></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$<span id="xdx_90E_effd--MaxAggtOfferingPric_pp2p0_c20260610__20260610__ffd--OfferingAxis__1_z3Nd3DgjzH8"><ix:nonFraction name="ffd:MaxAggtOfferingPric" contextRef="From2026-06-102026-06-10_1" id="Fact000021" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">439,604,000</ix:nonFraction></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">0.00013810</span></td>
    <td id="xdx_985_effd--FeeAmt_pp2p0_uUSD_c20260610__20260610__ffd--OfferingAxis__1_znmQqEAp3xqg" style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$<ix:nonFraction name="ffd:FeeAmt" contextRef="From2026-06-102026-06-10_1" id="Fact000022" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">60,709.32</ix:nonFraction></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90F_effd--PrevslyPdFlg_dbT_c20260610__20260610__ffd--OfferingAxis__2_z1jtcA0N6TBj"><ix:nonNumeric contextRef="From2026-06-102026-06-10_2" format="ixt:booleantrue" id="Fact000023" name="ffd:PrevslyPdFlg">Fees Previously Paid</ix:nonNumeric></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2</span></td>
    <td id="xdx_98A_effd--OfferingSctyTp_c20260610__20260610__ffd--OfferingAxis__2_zGKZ9XJBLchi" style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonNumeric contextRef="From2026-06-102026-06-10_2" id="Fact000024" name="ffd:OfferingSctyTp">Other</ix:nonNumeric></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_906_effd--OfferingSctyTitl_c20260610__20260610__ffd--OfferingAxis__2_zCVdaJtcn4Y9"><ix:nonNumeric contextRef="From2026-06-102026-06-10_2" id="Fact000025" name="ffd:OfferingSctyTitl">Warrants of BCAR</ix:nonNumeric></span></span></td>
    <td id="xdx_981_effd--FeesOthrRuleFlg_dbT_c20260610__20260610__ffd--OfferingAxis__2_zU7L3zDasEc8" style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonNumeric contextRef="From2026-06-102026-06-10_2" format="ixt:booleantrue" id="Fact000026" name="ffd:FeesOthrRuleFlg">Other</ix:nonNumeric></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_907_effd--AmtSctiesRegd_c20260610__20260610__ffd--OfferingAxis__2_z7pnr90SdZd9"><ix:nonFraction name="ffd:AmtSctiesRegd" contextRef="From2026-06-102026-06-10_2" id="Fact000027" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,100,000</ix:nonFraction></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$<span id="xdx_90B_effd--MaxOfferingPricPerScty_pin2_dp_c20260610__20260610__ffd--OfferingAxis__2_ztUiMTuQZvV3"><ix:nonFraction name="ffd:MaxOfferingPricPerScty" contextRef="From2026-06-102026-06-10_2" id="Fact000028" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.00</ix:nonFraction></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$<span id="xdx_90B_effd--MaxAggtOfferingPric_pp2p0_c20260610__20260610__ffd--OfferingAxis__2_zSQWmUzHe8yk"><ix:nonFraction name="ffd:MaxAggtOfferingPric" contextRef="From2026-06-102026-06-10_2" id="Fact000029" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">0.00</ix:nonFraction></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td id="xdx_982_effd--FeeAmt_pp2p0_uUSD_c20260610__20260610__ffd--OfferingAxis__2_zhSho7g8EExg" style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$<ix:nonFraction name="ffd:FeeAmt" contextRef="From2026-06-102026-06-10_2" id="Fact000030" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">0.00</ix:nonFraction></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_900_effd--PrevslyPdFlg_dbT_c20260610__20260610__ffd--OfferingAxis__3_zVFgQHZFPxtf"><ix:nonNumeric contextRef="From2026-06-102026-06-10_3" format="ixt:booleantrue" id="Fact000031" name="ffd:PrevslyPdFlg">Fees Previously Paid</ix:nonNumeric></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3</span></td>
    <td id="xdx_989_effd--OfferingSctyTp_c20260610__20260610__ffd--OfferingAxis__3_zdHoy25VzWZb" style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonNumeric contextRef="From2026-06-102026-06-10_3" id="Fact000032" name="ffd:OfferingSctyTp">Equity</ix:nonNumeric></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_902_effd--OfferingSctyTitl_c20260610__20260610__ffd--OfferingAxis__3_zNgf60Oe4bg9"><ix:nonNumeric contextRef="From2026-06-102026-06-10_3" id="Fact000033" name="ffd:OfferingSctyTitl">Class A Common Stock issuable upon exercise of Warrants of BCAR</ix:nonNumeric></span></span></td>
    <td id="xdx_988_effd--Rule457aFlg_dbT_c20260610__20260610__ffd--OfferingAxis__3_zOpS5ZDu7KJ3" style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonNumeric contextRef="From2026-06-102026-06-10_3" format="ixt:booleantrue" id="Fact000034" name="ffd:Rule457aFlg">457(a)</ix:nonNumeric></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_902_effd--AmtSctiesRegd_c20260610__20260610__ffd--OfferingAxis__3_zcpwXqkL4kp7"><ix:nonFraction name="ffd:AmtSctiesRegd" contextRef="From2026-06-102026-06-10_3" id="Fact000035" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,100,000</ix:nonFraction></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$<span id="xdx_90E_effd--MaxOfferingPricPerScty_pin2_dp_c20260610__20260610__ffd--OfferingAxis__3_zZNluNopozsk"><ix:nonFraction name="ffd:MaxOfferingPricPerScty" contextRef="From2026-06-102026-06-10_3" id="Fact000036" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.59</ix:nonFraction></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$<span id="xdx_901_effd--MaxAggtOfferingPric_pp2p0_c20260610__20260610__ffd--OfferingAxis__3_zZr2UjYz0ID4"><ix:nonFraction name="ffd:MaxAggtOfferingPric" contextRef="From2026-06-102026-06-10_3" id="Fact000037" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">22,419,000</ix:nonFraction></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">0.00013810</span></td>
    <td id="xdx_982_effd--FeeAmt_pp2p0_uUSD_c20260610__20260610__ffd--OfferingAxis__3_zft1k9Ln1dYj" style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$<ix:nonFraction name="ffd:FeeAmt" contextRef="From2026-06-102026-06-10_3" id="Fact000038" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">3,096.06</ix:nonFraction></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_900_effd--PrevslyPdFlg_dbT_c20260610__20260610__ffd--OfferingAxis__4_zYY5zkBzQuja"><ix:nonNumeric contextRef="From2026-06-102026-06-10_4" format="ixt:booleantrue" id="Fact000039" name="ffd:PrevslyPdFlg">Fees Previously Paid</ix:nonNumeric></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">4</span></td>
    <td id="xdx_98E_effd--OfferingSctyTp_c20260610__20260610__ffd--OfferingAxis__4_zwoB9Nsadtl3" style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonNumeric contextRef="From2026-06-102026-06-10_4" id="Fact000040" name="ffd:OfferingSctyTp">Equity</ix:nonNumeric></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90E_effd--OfferingSctyTitl_c20260610__20260610__ffd--OfferingAxis__4_zt4EoIzb5nSd"><ix:nonNumeric contextRef="From2026-06-102026-06-10_4" id="Fact000041" name="ffd:OfferingSctyTitl">Class A Common Stock, par value $0.0001 per share, to be issued to shareholders of Exascale Labs</ix:nonNumeric></span> Holdings Inc.(&#8220;Exascale&#8221;)</span></td>
    <td id="xdx_988_effd--FeesOthrRuleFlg_dbT_c20260610__20260610__ffd--OfferingAxis__4_zfn1djEwpCG6" style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonNumeric contextRef="From2026-06-102026-06-10_4" format="ixt:booleantrue" id="Fact000042" name="ffd:FeesOthrRuleFlg">Other</ix:nonNumeric></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90B_effd--AmtSctiesRegd_c20260610__20260610__ffd--OfferingAxis__4_ziEAJGPZgWKl"><ix:nonFraction name="ffd:AmtSctiesRegd" contextRef="From2026-06-102026-06-10_4" id="Fact000043" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,256,000</ix:nonFraction></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$<span id="xdx_904_effd--MaxAggtOfferingPric_pp2p0_c20260610__20260610__ffd--OfferingAxis__4_zF9R4HpmZxAf"><ix:nonFraction name="ffd:MaxAggtOfferingPric" contextRef="From2026-06-102026-06-10_4" id="Fact000044" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">57,768</ix:nonFraction></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">0.00013810</span></td>
    <td id="xdx_981_effd--FeeAmt_pp2p0_uUSD_c20260610__20260610__ffd--OfferingAxis__4_z5arrS07I2T1" style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$<ix:nonFraction name="ffd:FeeAmt" contextRef="From2026-06-102026-06-10_4" id="Fact000045" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">7.98</ix:nonFraction></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-size: 8pt"><span id="xdx_906_effd--PrevslyPdFlg_dbF_c20260610__20260610__ffd--OfferingAxis__5_zdGUu6DtLdRi"><ix:nonNumeric contextRef="From2026-06-102026-06-10_5" format="ixt:booleanfalse" id="Fact000046" name="ffd:PrevslyPdFlg">Fees to be Paid</ix:nonNumeric></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 8pt">5</span></td>
    <td id="xdx_987_effd--OfferingSctyTp_c20260610__20260610__ffd--OfferingAxis__5_zpBaRFeVL18h" style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-size: 8pt"><ix:nonNumeric contextRef="From2026-06-102026-06-10_5" id="Fact000047" name="ffd:OfferingSctyTp">Equity</ix:nonNumeric></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-size: 8pt"><span id="xdx_906_effd--OfferingSctyTitl_c20260610__20260610__ffd--OfferingAxis__5_zMiiopoxmEo2"><ix:nonNumeric contextRef="From2026-06-102026-06-10_5" id="Fact000048" name="ffd:OfferingSctyTitl">Class B Common Stock, par value $0.0001 per share, to be issued to certain shareholders</ix:nonNumeric></span> of Exascale</span></td>
    <td id="xdx_987_effd--FeesOthrRuleFlg_dbT_c20260610__20260610__ffd--OfferingAxis__5_zOUpRKggSAud" style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 8pt"><ix:nonNumeric contextRef="From2026-06-102026-06-10_5" format="ixt:booleantrue" id="Fact000049" name="ffd:FeesOthrRuleFlg">Other</ix:nonNumeric></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 8pt"><span id="xdx_902_effd--AmtSctiesRegd_c20260610__20260610__ffd--OfferingAxis__5_zLkaCxx0q4zb"><ix:nonFraction name="ffd:AmtSctiesRegd" contextRef="From2026-06-102026-06-10_5" id="Fact000050" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,744,000</ix:nonFraction></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 8pt">$<span id="xdx_902_effd--MaxAggtOfferingPric_pp2p0_c20260610__20260610__ffd--OfferingAxis__5_z6Qg3LubKt46"><ix:nonFraction name="ffd:MaxAggtOfferingPric" contextRef="From2026-06-102026-06-10_5" id="Fact000051" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">92,232</ix:nonFraction></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td id="xdx_987_effd--FeeAmt_pp2p0_uUSD_c20260610__20260610__ffd--OfferingAxis__5_zua9VCAWjd7h" style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 8pt">$<ix:nonFraction name="ffd:FeeAmt" contextRef="From2026-06-102026-06-10_5" id="Fact000052" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">12.74</ix:nonFraction></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="14" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carry Forward Securities</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carry Forward Securities</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: middle; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: middle; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: middle; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: middle; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: middle; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="6" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: right; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total Offering Amounts:</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td id="xdx_985_effd--TtlOfferingAmt_pp2p0_c20260610__20260610_zT81mknUevE1" style="border-top: Black 1pt solid; border-right: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$<ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="AsOf2026-06-10" id="Fact000053" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">462,173,000</ix:nonFraction></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td id="xdx_987_effd--TtlFeeAmt_pp2p0_uUSD_c20260610__20260610_zeilMBW3hQSd" style="border-top: Black 1pt solid; border-right: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$<ix:nonFraction name="ffd:TtlFeeAmt" contextRef="AsOf2026-06-10" id="Fact000054" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">63,826.10</ix:nonFraction></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"/><td style="border-top: Black 1pt solid; border-right: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: right; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total Fees Previously Paid:</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td id="xdx_984_effd--TtlPrevslyPdAmt_pp2p0_uUSD_c20260610__20260610_z4Nc13qvqwC8" style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$<ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="AsOf2026-06-10" id="Fact000055" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">0.00</ix:nonFraction> </span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: right; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total Fee Offsets:</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td id="xdx_98A_effd--TtlOffsetAmt_pp2p0_uUSD_c20260610__20260610_zP09RBaha1Sd" style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$<ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="AsOf2026-06-10" id="Fact000056" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">63,826.10</ix:nonFraction></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border: Black 1pt solid; vertical-align: top; text-align: right; padding-bottom: 1pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net Fee Due:</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td id="xdx_985_effd--NetFeeAmt_pp2p0_uUSD_c20260610__20260610_zVuThA9IClxa" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$<ix:nonFraction name="ffd:NetFeeAmt" contextRef="AsOf2026-06-10" id="Fact000057" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">0.00</ix:nonFraction></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div id="xdx_98F_effd--OfferingNote_c20260610__20260610__ffd--OfferingAxis__1_zAfyaOeKRiei">

<div id="xdx_981_effd--OfferingNote_c20260610__20260610__ffd--OfferingAxis__2_z2BIUNBVhTE8">

<div id="xdx_98F_effd--OfferingNote_c20260610__20260610__ffd--OfferingAxis__3_z2bOj28d9Cx5">

<div id="xdx_982_effd--OfferingNote_c20260610__20260610__ffd--OfferingAxis__4_ze1VnkS8YECd">

<div id="xdx_981_effd--OfferingNote_c20260610__20260610__ffd--OfferingAxis__5_zfxvfQAQF8Vi"><ix:nonNumeric contextRef="From2026-06-102026-06-10_1" escape="true" id="Fact000058" name="ffd:OfferingNote"><ix:nonNumeric contextRef="From2026-06-102026-06-10_2" escape="true" id="Fact000059" name="ffd:OfferingNote"><ix:nonNumeric contextRef="From2026-06-102026-06-10_3" escape="true" id="Fact000060" name="ffd:OfferingNote"><ix:nonNumeric contextRef="From2026-06-102026-06-10_4" escape="true" id="Fact000061" name="ffd:OfferingNote"><ix:nonNumeric contextRef="From2026-06-102026-06-10_5" escape="true" id="Fact000062" name="ffd:OfferingNote">

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Offering Note</b></p>



















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">1</td>
    <td style="text-align: justify">Represents Common Stock issuable, pursuant to the Business Combination described in the proxy statement/prospectus forming part of this registration statement, to holders of (i) 29,000,000 Class A ordinary shares of BCAR, (ii) 12,000,000 Class B ordinary shares of BCAR, and (iii) 200,000 Class A ordinary shares of BCAR underlying the private units, each consisting of one Class A ordinary share and one -half of one warrant (the &#8220;Private Units&#8221;), issued in a private placement that closed concurrently with BCAR&#8217;s initial public offering. The per unit price is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum aggregate is based on the average of the high and low prices of BCAR Class A Ordinary Shares, as quoted on the Nasdaq Global Market on May&#160;8, 2026, which was approximately $10.67 per share&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">2</td>
    <td style="text-align: justify">Represents the warrants issuable to holders of 14,000,000 public warrants of BCAR and 100,000 private warrants of BCAR. Consistent with the response to Question 240.06 of the Securities Act Rules Compliance and Disclosure Interpretations and pursuant to Rule&#160;457(g) of the Securities Act, the registration fee with respect to the warrants has been allocated to the Common Stock underlying BCAR&#8217;s public warrants, and those shares of Class A Common Stock are included in the total registration fee.&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">3</td>
    <td style="text-align: justify">Represents 14,000,000 shares of Common Stock underlying BCAR&#8217;s public warrants and 100,000 shares of Common Stock underlying BCAR&#8217;s private warrants, with the per unit price estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum offering price per share is based on the average of the high and low prices of BCAR&#8217;s public warrants as quoted on Nasdaq Global Market on May&#160;8, 2026, which was $1.59 per warrant.&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">4</td>
    <td style="text-align: justify">Rule&#160;457(f) Fee Calculation Details <br/><br/>The amount to be registered represents the maximum amount of Class A Common Stock issuable to the stockholders of Exascale in connection with the Business Combination described in the proxy statement/prospectus forming part of this registration statement. The value per share of the securities to be received by Exascale upon the issuance of such securities and the proposed maximum offering price per share is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(f)(2) under the Securities Act. Exascale is a private company, no market exists for its securities, and Exascale has an accumulated deficit. Therefore, the proposed maximum offering price per share is one-third of the aggregate par value of the securities expected to be exchanged in the Business Combination. No cash is to be received or paid by BCAR in connection with the securities to be exchanged in the Business Combination.&#160;</td> </tr>
  </table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount of<br/> Securities<br/> to be Received <br/> or Cancelled</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Value per <br/> Share of Securities<br/> to be Received<br/> or Cancelled</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Total Value <br/> of Securities <br/> to be Received <br/> or Cancelled</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cash Consideration<br/> Received by<br/> the registrant</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cash Consideration<br/> (Paid) by the<br/> registrant</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maximum Aggregate <br/> Offering Price</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: middle; width: 15%; text-align: center">19,256,000</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">$0.003</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">$57,768</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">$57,768</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></div>

</div>

</div>

</div>

</div>

<table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">4</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Rule 457(f) Fee Calculation Details <br/> <br/> The amount to be registered represents the maximum amount of Class B Common Stock issuable to the certain stockholders of Exascale in connection with the Business Combination described in the proxy statement/prospectus forming part of this registration statement. The value per share of the securities to be received by Exascale upon the issuance of such securities and the proposed maximum offering price per share is estimated solely for purposes of calculating the registration fee in accordance with Rule 457(f)(2) under the Securities Act. Exascale is a private company, no market exists for its securities, and Exascale has an accumulated deficit. Therefore, the proposed maximum offering price per share is one-third of the aggregate par value of the securities expected to be exchanged in the Business Combination. No cash is to be received or paid by BCAR in connection with the securities to be exchanged in the Business Combination.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 15%"><span style="font-size: 10pt"><b>Amount of<br/> Securities<br/> to be Received <br/> or Cancelled</b></span></td>
    <td style="text-align: center; padding-bottom: 1pt; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 15%"><span style="font-size: 10pt"><b>Value per <br/> Share of Securities<br/> to be Received<br/> or Cancelled</b></span></td>
    <td style="text-align: center; padding-bottom: 1pt; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 15%"><span style="font-size: 10pt"><b>Total Value <br/> of Securities <br/> to be Received <br/> or Cancelled</b></span></td>
    <td style="text-align: center; padding-bottom: 1pt; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 15%"><span style="font-size: 10pt"><b>Cash Consideration<br/> Received by<br/> the registrant</b></span></td>
    <td style="text-align: center; padding-bottom: 1pt; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 15%"><span style="font-size: 10pt"><b>Cash Consideration<br/> (Paid) by the<br/> registrant</b></span></td>
    <td style="text-align: center; padding-bottom: 1pt; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 15%"><span style="font-size: 10pt"><b>Maximum Aggregate <br/> Offering Price</b></span></td></tr>
  <tr>
    <td style="text-align: center"><span style="font-size: 10pt">30,744,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">$0.003</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">$57,768</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">$92,232</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>











<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif"><b>Table 2: Fee <span id="xdx_909_effd--OffsetExpltnForClmdAmt_c20260610__20260610__ffd--OffsetAxis__2_zcMNWZjM0u8f"><ix:nonNumeric contextRef="From2026-06-102026-06-10_24993218" escape="true" id="Fact000063" name="ffd:OffsetExpltnForClmdAmt">Offset Claims </ix:nonNumeric></span>and Sources&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 50%"><span style="font-family: Times New Roman, Times, Serif"><b>&#9744; Not Applicable&#160;</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="3" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Registrant or<br/> Filer Name</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Form or<br/> Filing Type</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">File Number</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Initial Filing Date</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Filing Date</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Fee Offset Claimed</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Security Type Associated with Fee Offset Claimed</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Security Title Associated with Fee Offset Claimed</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Unsold Securities Associated with Fee Offset Claimed</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Unsold Aggregate Offering Amount Associated with Fee Offset Claimed</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Fee Paid with Fee Offset Source</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="12" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Rules 457(b) and 0-11(a)(2)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 23%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Fee Offset Claims</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 7%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 7%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 7%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 7%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 7%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 7%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 7%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 7%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 7%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 7%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; width: 7%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Fee Offset Sources</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="12" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Rule 457(p)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90C_effd--Rule457bOffsetFlg_dbT_c20260610__20260610__ffd--OffsetAxis__1_zrtfRVtJuwW7"><span id="xdx_90F_effd--OffsetClmdInd_dbF_c20260610__20260610__ffd--OffsetAxis__1_zjGgsVcenA03"><ix:nonNumeric contextRef="From2026-06-102026-06-10_14993234" format="ixt:booleantrue" id="Fact000064" name="ffd:Rule457bOffsetFlg"><ix:nonNumeric contextRef="From2026-06-102026-06-10_14993234" format="ixt:booleanfalse" id="Fact000065" name="ffd:OffsetClmdInd">Fee Offset Claims</ix:nonNumeric></ix:nonNumeric></span></span></span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_909_effd--OffsetPrrFilerNm_c20260610__20260610__ffd--OffsetAxis__1_zsdnJ5jEG1ob"><ix:nonNumeric contextRef="From2026-06-102026-06-10_14993234" id="Fact000066" name="ffd:OffsetPrrFilerNm">D. Boral ARC Acquisition I Corp.</ix:nonNumeric></span></span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90E_effd--OffsetPrrFormTp_c20260610__20260610__ffd--OffsetAxis__1_z9MK39Wy0Snd"><ix:nonNumeric contextRef="From2026-06-102026-06-10_14993234" id="Fact000067" name="ffd:OffsetPrrFormTp">S-4</ix:nonNumeric></span></span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_903_effd--OffsetPrrFileNb_c20260610__20260610__ffd--OffsetAxis__1_zVOlGbZA6cSg"><ix:nonNumeric contextRef="From2026-06-102026-06-10_14993234" id="Fact000068" name="ffd:OffsetPrrFileNb">333-295869</ix:nonNumeric></span></span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90F_effd--OffsetSrcFilgDt_c20260610__20260610__ffd--OffsetAxis__1_zoWH0PP72MGc"><ix:nonNumeric contextRef="From2026-06-102026-06-10_14993234" format="ixt:dateyearmonthday" id="Fact000069" name="ffd:OffsetSrcFilgDt">2026-05-14</ix:nonNumeric></span></span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$<span id="xdx_901_effd--OffsetPrrFeeAmt_pp2p0_c20260610__20260610__ffd--OffsetAxis__1_zwDluIUfGFl"><ix:nonFraction name="ffd:OffsetPrrFeeAmt" contextRef="From2026-06-102026-06-10_14993234" id="Fact000070" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">63,826.10</ix:nonFraction></span></span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_909_effd--OffsetClmdInd_dbT_c20260610__20260610__ffd--OffsetAxis__2_z2ZQzfLpxMx4"><span id="xdx_90A_effd--Rule457bOffsetFlg_dbT_c20260610__20260610__ffd--OffsetAxis__2_zeQU08St9vpf"><ix:nonNumeric contextRef="From2026-06-102026-06-10_24993218" format="ixt:booleantrue" id="Fact000071" name="ffd:OffsetClmdInd"><ix:nonNumeric contextRef="From2026-06-102026-06-10_24993218" format="ixt:booleantrue" id="Fact000072" name="ffd:Rule457bOffsetFlg">Fee Offset Sources</ix:nonNumeric></ix:nonNumeric></span></span></span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">D. Boral ARC Acquisition I Corp.</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90C_effd--OffsetPrrFormTp_c20260610__20260610__ffd--OffsetAxis__2_zGSUOj9C7FA2"><ix:nonNumeric contextRef="From2026-06-102026-06-10_24993218" id="Fact000073" name="ffd:OffsetPrrFormTp">S-4</ix:nonNumeric></span></span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90F_effd--OffsetPrrFileNb_c20260610__20260610__ffd--OffsetAxis__2_zacBQxHrlnq"><ix:nonNumeric contextRef="From2026-06-102026-06-10_24993218" id="Fact000074" name="ffd:OffsetPrrFileNb">333-295869</ix:nonNumeric></span></span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_901_effd--OffsetClmInitlFilgDt_c20260610__20260610__ffd--OffsetAxis__2_zLSTjlAmDiH"><ix:nonNumeric contextRef="From2026-06-102026-06-10_24993218" format="ixt:dateyearmonthday" id="Fact000075" name="ffd:OffsetClmInitlFilgDt">2026-05-14</ix:nonNumeric></span></span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$<span id="xdx_902_effd--OffsetClmdAmt_pp2p0_c20260610__20260610__ffd--OffsetAxis__2_zbjgQS8kvxNk"><ix:nonFraction name="ffd:OffsetClmdAmt" contextRef="From2026-06-102026-06-10_24993218" id="Fact000076" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USD">63,826.10</ix:nonFraction></span></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif"><b>Table 3: Combined Prospectuses&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 50%"><span style="font-family: Times New Roman, Times, Serif"><b>&#9745; Not Applicable&#160;</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="3" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Security Type</b></span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Security Class Title</b></span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount of Securities<br/> Previously Registered</b></span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Maximum Aggregate<br/> Offering Price of<br/> Securities Previously Registered</b></span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Form Type</b></span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>File Number</b></span></p></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Initial Effective Date</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border: Black 1pt solid; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>

    <!-- Field: /Page --> <!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2Wkolg7wrMYksQiK63XKMJd2R2e3vkXrLNiUaBoaZc745Qvgip6VqkOG4KAvYY9s10iKUWCOjPqNzpKt1Am6WeFHGstS2X39gSo5Bx0xHk5O79867MlglEMTjYDaOphCGSTyD+UZ4Xz0lXasKtVWyAakr2DF1rNBKfg0f9vJJmtpXn3RANop0AuEoGOQ3REEYwZbu8kF8NVAUqfD8vjyRM90658qeFvWXhKzB1sWZgf639wHLbUpb -->

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex23-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W 30# 2(  A$! Q$!_\0
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M)_UH>TDX&37B'B&Y74/$E[-#\RO,0FWG<!P#^.*ZV\N/&FMPO;K8_98),@X
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MK4Y)63(<(MW:-)$2- B*JJ.@48 IU%%06-=$D4JZJRGL1D5!_9]E_P ^=O\
M]^E_PHHIIM;":3W#^S[+_GSM_P#OTO\ A4L4$4(Q%$D8]%4"BBB[862)****
M0QKHDB[756'H1FH/[/LO^?.W_P"_2_X444TVMA-)[A_9]E_SYV__ 'Z7_"E6
MQM$8,MK I'0B,"BBCF?<.5=BQTJ&6UMYFW2P12-ZN@)HHI7L.UQT5O!!GRH8
8X\_W% J2BB@ I" >H!^M%% "T444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex3-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #B .L# 2(  A$! Q$!_\0
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M6M6:QJPD[)FY1114F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^:J^E?A!_P DYL?^NDO_ *&:ZJWPGG83^(SNJ***Y#U HHHH **** "BBB@
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MKD/4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /E;XB?\
M)0]<_P"OC_V45WGP);:^NL<\+$>/^!5P?Q$_Y*'KG_7Q_P"RBN^^ H_?ZY](
MO_9JZY_PSRJ7\<)O'GQ)%Q+Y'AP^3O;9FS<G;GC//I3#X\^)P_YEP?\ @$__
M ,57MN*SM<OUTK0;^_8X%O \@/N <?K6"DMK'8Z<EKS'RMX@U>^US6[C4=1V
MBZD(5U48"[1C 'X5T_@S6/&/A_396T'1&N;>Z?>9C;,X8@8X((XKA69Y6+$D
MNYS^)KZU\+Z6-&\+Z9I^,&"W16'^UC)_4FMZDN56L<5"#G-RN>5?\)Y\3_\
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M?A!_R3FQ_P"NDO\ Z&:ZZWPGF83^(SNJ***Y#U HHHH **** "BBB@ HHHH
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MO$\*:G]LCM5;9\OV<$ C(ZY[T6%=FF/$>CDX_M*VY_VZO)=PR3F!9%,JJ'*
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C>#G:Z\1PQW#&9$8E5D.X*1T(!HHJ5U#JCUL=*6BBL3<__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex3-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-1_002.jpg
M_]C_X2KM17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    @    ?@$R  (    4
M    G@$[  (    >    LH=I  0    !    T    /P +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P($-3-B H36%C:6YT;W-H*0 R,#(U.C T.C(S
M(# S.C(P.C W $9I;F%N8VEA;"!397)V:6-E<R!#;VUM:7-S:6]N   #H $
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M6ZAGC]J8XPFTL;7M82\.E_VG&=[-_P!*JRE_]=1YN(XY")(E(<((^8<76/\
M6_<2-[TTHZ^:+JG3;[V/S\6EN-=E6,Q<7"8=Q=56UP-]QE_NW8]?\VYG_"KI
M/\7'U:^UY65U#JN-!QK&-J(EM=E[#9Z[K*W[G.LQG>G]#]7?ZOYZROJ+A]0Z
MIF.JQW-/V=KM]MKG;JV6.#G[ X.=Z[W?S?\ @_3_ )RSU5ZWA8E6%B58M4EE
M+&L#G:N=M&W?8[\^Q_Y[U7Y:&4RD<L019X9'>?;T_NPX?TY?.NE*!&D:E?CM
M_C>KB_Z"8  0! ' "\S_ ,9O_+^.#NUP'$$/<W:1:3O;L<UN[^LO35YE_C,_
M\46+Q_03SQ_.GE3<P2,4B&')\KQ=-EEYIHQ6VY.0^ X!]D:#][>UF]W^8CM8
M7,WM]7;KKOLC3GW;MJ-@]8R.G#U,<L8TAPLK%59@L.QV0VUS?5;6SZ.S\_U/
MYM-9?9:XV%VKM_T/8PBP!KF^@S;5^;^XLV4\O$>D.AXY&7%^EQ)RQP\-\,H3
MXI<4:TA+_-HVU@N W/$F/YRSO_;65D]6MJN>:ZW&II],->^XDD'W/W-L:W?[
M7;?Y"UN-?!7'X'[1Z)E8'V-M&1C-9;CY))!L?8^O:P#^75>I,66C<^*428PO
MBEZ.,\*.6QPR2G&6_ 3 5Q:C_HN9BY&/F5FRAU@ ,%KK'RV?H[O>I,>UPL(<
M\[0Y[0++ XL:-W\VY_J>I_94,3I>7TMV1CYC17DES192/S"S>-KO\[\SV*SC
MG&Q[[,J[%;=[PYYLL<S1IW&ZIU#MWN_T?^$_PB&67!.<8F<@/E%^KR]1BMA'
M'Q2$@>'2I],>L>+BX?\ PM&YE3RY@>Y^V"YOJ6 CAXEN_<N\_P 54[^LMDD"
MW'B7%W-4GZ9<N+ZED5YMQR<:BK%)>UY=7)]5K0UNVZ?YOVM_P:[C_%<0?VP0
MW;-U)GL9KX']12\E.1F.*]8&XR/%PR]*>&,,AC&7%O'8QJO[SW:\\_QE?5QW
MV6K)Z9C.;79:]^?9606M<X5UTWV5N]_IL<W<_P!'V,_/7H:A;57=4^FUH?78
MTL>T\%KAM<TJ]*(D*(!ZBQ>K-&7";W[A\2Z9TVS'S;SEQ=G5UP*+"T-NJV-N
MJMH>W9758RW9_.OV?X+^=7I'U*ZTW+H^Q/L!MKJ9:&%I#A(;]I%CMK:OT=]F
MSV+D_KMAV=$RF67;'8UI-=%H:-YJC?Z#MH:]MU5OT/\ !?9:_P"<^U?HED_5
M[JW4\+J/VSHM8R'.V8MSK'.+#Z@]6II;9^E8W91^ENKK]7>J.,\P,X.2/!&-
MZ1'ZH<?#&52_S?HA[?Z:^4L0B(0O6O5+T_)_W7K?:DD$95!Q/MF[]!L]7?\
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M2:]YJ8]K'S^CM?ZI;^YLM+6?]0A=*Z?CY&0*.I6&H-K<ZFO>UK"9;NLMN?\
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M-C?^X]=FYMGKOV_X+]_^<03C/Z717]D<Y]L;;,:U[WU6U?X1EM-F^E]UCO\
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MJ[&V;_3]7WJ'+S G*> ^FQ492^2?[]R_YO\ K%0AQ0)QD')8/]:'\OYR<O\
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M7]+@\C_W;"1$:1NJK4_-KOP_H?W?6I)))2H4DDDDI__0]522224I))))2DQ
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M;VX .$))300E       0$8S&$,PZ;0;@<Q #H4]D9#A"24T$.@      Y0
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M;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
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M;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M   08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N
M9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H
M=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0
M 2P    !  $!+     $  3A"24T$)@      #@             _@   .$))
M300-       $    >#A"24T$&0      !    !XX0DE- _,       D
M      $ .$))32<0       *  $          3A"24T#]0      2  O9F8
M 0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M     0 U     0 M    !@       3A"24T#^       <   ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H   X0DE-! @      !     !   "0    D      .$))300>
M       $     #A"24T$&@     #MP    8              64   %2
M00 R #  ,@ U "T ,  S "T ,@ P "  1  N "  0@!O '( 80!L "  00!2
M $, ( !! &, <0!U &D <P!I '0 :0!O &X ( !) "  0P!O '( <  N "
M+0 @ $T )@!! "  * !) &X 8P!O '( < !O '( 80!T &D ;P!N "D    !
M                          $              5(   %E
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   %E     %)G:'1L
M;VYG   !4@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   !90    !29VAT;&]N9P   5(    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!0       0    ".$))300,     "FG     0   )<
M  "@   !R  !'0   "F+ !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" "@ )<# 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
M @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1
M Q$ /P#U5))))2DDDDE*4+;JJ*S;<]M5;?I/>0UHD[=7.7+?6GZX.P<:]G37
M,;=6W3*M_F]X_G*JA]*RVMFVS^;]'WKS_)^O7UBZA4RK-L-E&(-V0&L8U[RX
MGTK7MV,J_P +776QGL]/])_/J*>8",I0]?">'3Y?<_<X_P!Y=P$ $D"ZH'YI
M1EQ>O^[Z>%](Z[]=<3IF*;L2E^<]MPH>&AS6,)#W![K2QS-GZ+V_OK(N_P 9
M>-DNHJP6^F+F,+W%CKG-<_VOJVT1Z#J?]+=^CM_,_FUQ.1D.ZA2*/7R,W.R
MVQN)^CKJK+1MQ[+GU>E_,TV.K>U[T'H>'U'-M)Q,9CJJ!4S(MEVM;BX,L_0.
M^E[;/^$5<YL\\-Q$HS-CT1_](\?JR?W_ &U\X  &,?38,I69<,9\/#[GZ$?Z
MKZ1]5.JXECOVAG9US\OJ)]/%Q\ANPMK83^BK;LK]6SU/6M<]G^"77K@_JVSJ
M/2\H'-Q'=0;D/!&7M ?3,5"MM3O2J92S^<<ZIGJ^]=V3I($^2LX.+VX\0,95
MKQ<=_P#CL826Y !+0@@Z^DQ(_P":\A]:^JX6\9.#E6LZGTS<VRJECBXU6;76
MT6NV/KQO5=16ZN^_V?HU1Q/\8]&!E,Q.J;K<:PQ3F@&8'TGW@#_R"M?6?$ZM
MU6^^G"Z7:T5&*L^E]+'/<)%@MKR+FMMI_=WUK@/K%T3J_2Z:W=2QG8QR YC'
M%U3P15[YL%3[6L=^D_P?\XJ\Y9AS%@'VQ42/5PR_E_47<-P@(CBE(]-91K^[
M_P!V^A?5[Z^V9V7DXO5<;[+Z+AZ=K6N;(>6^DQ^._?=_-O\ 7?D_S'I+KJKJ
M;ZQ;2]MM;IA["'-,':8<W^4O$\6MV,RO,I.7B9F/5L#G^G;7>PF=FY_K;+_T
MG^%V?H=B=_UKZY50_&IR75XV88+2T-V;?YUNZMFZJQMC?^T_\XG0YHG-+'5P
M&@E^GQ_NU\DN+]"?&J<87'40E,C0<7MQC+]+_.1X?THOMR2Y3ZH_6JK(Z1BL
MZC:WU6M;4W)!EEFT!K7V&7.JN=]*[U&UUKJU8C.,KX2#PDQE7Z,H_HL9!&_F
MI))).0I))))3_]#U5))))3&RQE;"]Y#6M$DG@+SOZX?7;K&#;2[&+*NG9POQ
MZMA)N)JV,OR)V-]*ROU6_965V?I/\)Z:E]>_KET_)Q:^G]->[*N;DEM^.T';
M8VL6UOJL_P!)C^K[_P#K=:Y=O4K>H4OM996[,N<7LONM#3B^MJ]M5SO;317M
M_FO\(JV?.82X:N)%7<8U.4OTIR^2$62$031TE6TA^C./IX?WI2_0:V-D/SLD
MNS15EV%[F851<327%K9K9CEGI>G[O?;M13]7^I]3SZ6X1??>_:S/%3 VNN+!
MM]NYK/3HJ;6UK_S_ $UT7U)^HWJ=2OSNHTMMP8(&YL5W.</\'4XNWX]7ML9?
M_-V6+TC%Q,;#QV8V+4VBBN0RI@#6B3N]K1_**;AY40D38X2.$1X>G]7]V,OF
M5Q^D1E4Q'4&Y?I1_3^64N#B>>P/\7_1,5H]8.NLW;G/9-)>3JXWBAS?7_P"N
MK;Z;TCIO2J/0Z=C5XU9U<*V@%Q\7N'T_[2N)*S&$8_*!&]Z66: O0;#LI)))
M.0I R\'"S6!F9CU9+&F6MN8UX!\0+ Y'224X>7]3.@Y;RZRNUC'$%U%5]M51
M(^B?L]-C*?\ H+S+K7U>ZITSJ^8'L<VFI[K,.ZZ7XI83^A;[]WKV-HL].W?5
M_.KVE)1RQ1(-"()TNN_IU71G1LCB.GJ/SQH\7HG^C)\+S,MU3G4XK::\BYP+
M\2EK15+NWV;:VC)I_P".9^D72?4[ZV_63(L<7.%_3.F@,R,<F;W,=+*BRY[2
M^Z^M_OLWO9^C1_KE]1LF_K(ZACX[+.FO =;16-NRP?2L>P;M_K;OTMW^>N=>
MW]EL+W6,8S2_$S<:P%_HD[6X+7MW;J&V56.;7_AGW65JGZ>5!B#Q3EL-C+]R
M7^LX?\U\\&2(,I&>G 1ZC\WM_P!7^K+]R? ^S8N53EX[,BAP?58):X>1VN']
MER*O+OJG]?L/IM^3C]3NL?3;%M;@PO\ =#&NVO;[?3;6/?\ \(O3,7)HR\>O
M)QWBRFYH>Q[=001(5['/C@)51(!,?W26(C8B^$WPR(X>+A2I)))R'__1]4(!
M!!X.A7.?73JM>'@LQ7:59)#<EX=M<RK\W;^]Z]S68WL_TJWLO*HPL2[,R';*
M,:MUMKX)AC ;+';6^[Z+5XS]=NM]6ZAGC]J8XPFTL;7M82\.E_VG&=[-_P!*
MJRE_]=1YN(XY")(E(<((^8<76/\ 6_<2-[TTHZ^:+JG3;[V/S\6EN-=E6,Q<
M7"8=Q=56UP-]QE_NW8]?\VYG_"KI/\7'U:^UY65U#JN-!QK&-J(EM=E[#9Z[
MK*W[G.LQG>G]#]7?ZOYZROJ+A]0ZIF.JQW-/V=KM]MKG;JV6.#G[ X.=Z[W?
MS?\ @_3_ )RSU5ZWA8E6%B58M4EE+&L#G:N=M&W?8[\^Q_Y[U7Y:&4RD<L01
M9X9'>?;T_NPX?TY?.NE*!&D:E?CM_C>KB_Z"8  0! ' "\S_ ,9O_+^.#NUP
M'$$/<W:1:3O;L<UN[^LO35YE_C,_\46+Q_03SQ_.GE3<P2,4B&')\KQ=-EEY
MIHQ6VY.0^ X!]D:#][>UF]W^8CM87,WM]7;KKOLC3GW;MJ-@]8R.G#U,<L8T
MAPLK%59@L.QV0VUS?5;6SZ.S\_U/YM-9?9:XV%VKM_T/8PBP!KF^@S;5^;^X
MLV4\O$>D.AXY&7%^EQ)RQP\-\,H3XI<4:TA+_-HVU@N W/$F/YRSO_;65D]6
MMJN>:ZW&II],->^XDD'W/W-L:W?[7;?Y"UN-?!7'X'[1Z)E8'V-M&1C-9;CY
M))!L?8^O:P#^75>I,66C<^*428POBEZ.,\*.6QPR2G&6_ 3 5Q:C_HN9BY&/
MF5FRAU@ ,%KK'RV?H[O>I,>UPL(<\[0Y[0++ XL:-W\VY_J>I_94,3I>7TMV
M1CYC17DES192/S"S>-KO\[\SV*SCG&Q[[,J[%;=[PYYLL<S1IW&ZIU#MWN_T
M?^$_PB&67!.<8F<@/E%^KR]1BMA''Q2$@>'2I],>L>+BX?\ PM&YE3RY@>Y^
MV"YOJ6 CAXEN_<N\_P 54[^LMDD"W'B7%W-4GZ9<N+ZED5YMQR<:BK%)>UY=
M7)]5K0UNVZ?YOVM_P:[C_%<0?VP0W;-U)GL9KX']12\E.1F.*]8&XR/%PR]*
M>&,,AC&7%O'8QJO[SW:\\_QE?5QWV6K)Z9C.;79:]^?9606M<X5UTWV5N]_I
ML<W<_P!'V,_/7H:A;57=4^FUH?78TL>T\%KAM<TJ]*(D*(!ZBQ>K-&7";W[A
M\2Z9TVS'S;SEQ=G5UP*+"T-NJV-NJMH>W9758RW9_.OV?X+^=7I'U*ZTW+H^
MQ/L!MKJ9:&%I#A(;]I%CMK:OT=]FSV+D_KMAV=$RF67;'8UI-=%H:-YJC?Z#
MMH:]MU5OT/\ !?9:_P"<^U?HED_5[JW4\+J/VSHM8R'.V8MSK'.+#Z@]6II;
M9^E8W91^ENKK]7>J.,\P,X.2/!&-Z1'ZH<?#&52_S?HA[?Z:^4L0B(0O6O5+
MT_)_W7K?:DD$95!Q/MF[]!L]7?\ R(W[O\U):#$__]+O?K9U.OI?0LC+L$L&
MUA]VT0\BN2Z'?O+S,W.?CY=5-MC,SJ#J?LEGJ%A:QEE5K\=EH^A[:[+_ %?Y
M?\VMS_&3UCJ>2S)Z;BLI?TIC65Y+[ 6VMRBY_I,]UE?Z"S]!Z61Z7H;_ %?T
MOZ-<,#F-ZE4QN-<QU3V>M4_4-ML8S':0P-;8W?6ZOT'_ .D5/F<.266$H$@Q
M'%_5/L3AFAQ1_=]W@982H<!@)QEXQ'#*?HC'CE_-\7J?5_J7T#&P[<OJ[2;+
M,L^DQSWFQ[!6?3RF&TAN[ULJGU;7_P"%?[UU2J],H&/T_&IVEA94P.:Z"X.@
M;]Y;MW/W?35I6H1,8QB3Q$  RVXCUE_A,<C9)^S6Z'Z,?\%2\S_QG#_+^([F
M<)S2!S'J%>F+S3_&=_R[B#QPWC[WN4?,_P U)9D'I+RW2+>E]/>Z_+Q_M%-C
M0&&U_M8[3:UV.YC]V1_P^_\ 1*+O2:]YJ8]K'S^CM?ZI;^YLM+6?]0A=*Z?C
MY&0*.I6&H-K<ZFO>UK"9;NLMN?\ HV4M_/K<[>]Z+4RCTGSD-O>!N8ZH$-@C
MV,]%V^W:[_2_065(1$Y&Y2D:XOF,.']#A_09<HF<8D)XS"Y\,C[?'*/];^[_
M +-&[86[;'-8QY%;GO\ H@//IR[_ #EZ53T[#IL;EM9=:&5U%K#5OFQE+,6K
M,QF[_P VG]'Z?\O^<7GSW# KN>YGJ9HKLV,(,52SV?\ &9&N]FW_ (-=_P!&
MJZVSHK<K-%.1F8WHY%0K!87!V-Z'ZR;'N:Y]=-_YOIJYR=2C(D#A$HF,B?TO
MY?I,<(^V".+]8=)QC_DQ^[,_YS]_'^A_?>/^L#['VXEUKA9D.^TUY%KA%KS0
M^JNKU/I._0;GMV;OT:P\;$P1<YN5E_9\(/AQ],6.U_[3/>;*O2]+_ 6_X-]O
MT%J]2:]M6(;G>H_U,RQI(<"*[K*K*17N^E4Y@6=@X.?DY?V4W- ):7/L>QK"
MUY+7O>Q^UUFQK?TF/6[UE7D:]RYU1G<SO_.3]4>/C7R!^\2X0-L9]K7AGZ(^
MGTI,G&P<7)V=-R/MF(0(AH#9/TG?:P^SU]G_ !?_ '77=?XK(V]7C4>K3!XT
M]-<._I]N':_%MNH+*R64BM[7N.GJS9Z=CO1^E[*[?TB[C_%7]#JW_&T_^>U+
MR1!R#U<?I^?K/^L>%CR"7O>J AK+0"OH]XDDDM)<\A]?OJY1GUT=6+GLLPR&
M/])NY[FN+FT;6@MW>CE6UW+AZ*_LM#SEV.=UJC(=<S):)M>&E[/1OOGU-EOJ
M>H]G_!KV'+-8Q+C:SU*Q6[>S]YL'<S^TO#F>OEW6##I->/DW;<'"$U6L: _3
M'MO]ES:(]/(]K_>J?.XLDX^F9C >J<>GZOBN7'_LY?K/WV;'D,8DB(E/2,+E
MZO5ZHQA#]+U0XGT_HW4</J'U/RX#AB8M5^+Q#O3JKV3M_?\ 327$?5G]L8_1
M,W#ORF-P<KI^>_'QC!K>YM0%E@N^C535O9^G?;Z5_J?HDE/1]GAO7AX.+_F<
M3%IO8JN+:7!MQ</#\W^K?__3-]:+L1O4LJG)?LR6Y@RL9CPZ+&8PKO=4?3&U
M]3O^&3_5]V/U#KE]KB/M6;95<6:EI%0J_1U?G[Z_L_JK*^N.;F]5^M=UU>/L
M;TS=A.:PESGAI<[(=4"VOU+;*;OYO\S]] ^I63U ?6/%S*:-] M<+&G45;V.
MQ-MUCF[\>S:?4:ROZ?\ ;6?+EC][&3CD/7&1L]\L,GLQ'[D^#$RC+*CCJ!'
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MLN+G01X;W.6FG240  H"@.@9%)))(J4DDDDI22222G__V0 X0DE-!"$
M %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"
M24T$!@      !P $ 0$  0$ _^$056AT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR
M95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM
M971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U
M-C8Q+" R,#$R+S R+S V+3$T.C4V.C(W(" @(" @(" B/B \<F1F.E)$1B!X
M;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y
M;G1A>"UN<R,B/B \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN
M<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM;&YS
M.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UL;G,Z<&1F
M/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(B!X;6QN<SIP9&9X/2)H
M='1P.B\O;G,N861O8F4N8V]M+W!D9G@O,2XS+R(@>&UL;G,Z>&UP34T](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T179T/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N
M=",B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N
M<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B(&1C.F9O<FUA=#TB:6UA9V4O
M:G!E9R(@>&UP.D-R96%T941A=&4](C(P,C4M,#,M,C!4,30Z-#<Z,3,M,#0Z
M,# B('AM<#I#<F5A=&]R5&]O;#TB36EC<F]S;V9TPJX@5V]R9"!F;W(@36EC
M<F]S;V9T(#,V-2(@>&UP.DUO9&EF>41A=&4](C(P,C4M,#0M,C-4,#,Z,C Z
M,#<K,#4Z,S B('AM<#I-971A9&%T841A=&4](C(P,C4M,#0M,C-4,#,Z,C Z
M,#<K,#4Z,S B('!D9CI0<F]D=6-E<CTB36EC<F]S;V9TPJX@5V]R9"!F;W(@
M36EC<F]S;V9T(#,V-3L@;6]D:69I960@=7-I;F<@:51E>'3"KB U+C,N,2#"
MJ3(P,# M,C Q,B Q5#-85"!"5D)!("A!1U!,+79E<G-I;VXI(B!P9&9X.FES
M4W1A;7!E9#TB665S(B!X;7!-33I$;V-U;65N=$E$/2)U=6ED.C(W.&8X-F%C
M+39D.&$M-&4T9BUA9F%F+3<V9F5B-3<R.35A,R(@>&UP34TZ26YS=&%N8V5)
M1#TB>&UP+FEI9#I$,3@V1C<Y-S,Q,C V.#$Q.# X,T5&.#,P-D5#1C$P.2(@
M>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/2)U=6ED.C(W.&8X-F%C+39D.&$M
M-&4T9BUA9F%F+3<V9F5B-3<R.35A,R(@<&AO=&]S:&]P.D-O;&]R36]D93TB
M,R(@<&AO=&]S:&]P.DE#0U!R;V9I;&4](G-21T(@245#-C$Y-C8M,BXQ(CX@
M/&1C.F-R96%T;W(^(#QR9&8Z4V5Q/B \<F1F.FQI/D9I;F%N8VEA;"!397)V
M:6-E<R!#;VUM:7-S:6]N/"]R9&8Z;&D^(#PO<F1F.E-E<3X@/"]D8SIC<F5A
M=&]R/B \>&UP34TZ2&ES=&]R>3X@/')D9CI397$^(#QR9&8Z;&D@<W1%=G0Z
M86-T:6]N/2)C;VYV97)T960B('-T179T.G!A<F%M971E<G,](F9R;VT@87!P
M;&EC871I;VXO<&1F('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H
M;W B+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](F1E<FEV960B('-T179T.G!A
M<F%M971E<G,](F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B
M92YP:&]T;W-H;W @=&\@:6UA9V4O:G!E9R(O/B \<F1F.FQI('-T179T.F%C
M=&EO;CTB<V%V960B('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z1#$X-D8W
M.3<S,3(P-C@Q,3@P.#-%1C@S,#9%0T8Q,#DB('-T179T.G=H96X](C(P,C4M
M,#0M,C-4,#,Z,C Z,#<K,#4Z,S B('-T179T.G-O9G1W87)E06=E;G0](D%D
M;V)E(%!H;W1O<VAO<"!#4S8@*$UA8VEN=&]S:"DB('-T179T.F-H86YG960]
M(B\B+SX@/"]R9&8Z4V5Q/B \+WAM<$U-.DAI<W1O<GD^(#QX;7!-33I$97)I
M=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)U=6ED.C4V-CEB-3(R+30Y,3 M
M9#8T-RUA-3 X+3DY,F4P-V$Q8S(X9"(@<W12968Z9&]C=6UE;G1)1#TB=75I
M9#HR-SAF.#9A8RTV9#AA+31E-&8M869A9BTW-F9E8C4W,CDU83,B('-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#TB=75I9#HR-SAF.#9A8RTV9#AA+31E-&8M
M869A9BTW-F9E8C4W,CDU83,B+SX@/"]R9&8Z1&5S8W)I<'1I;VX^(#PO<F1F
M.E)$1CX@/"]X.GAM<&UE=&$^(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @/#]X
M<&%C:V5T(&5N9#TB=R(_/O_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M               !  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
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M9IIO+.),^NG65E)E.$B-;8.W9\XT^J,PI$RI[:-6,3=PM&NG4G;W36>XR]
M$+U[.+8G0:G3S&/(S[SG>3'SW7>^<;QKG6TE!HY4JR<K/K&WJ,UZ /DBF_#1
M:<N6.=KOB%NWT"\T4[G/3S'$V[LWI+>X)D7)QV>66&B-72:(+3Z-O#O'L733
M:^U>DV]-R)'J?H !2M'>5I:\]H>?EX%Y9=<2Z>5'F\HC1NK"GN?#GYWIC7=(
M_0*.>>^@?'KG6KL]+\_Z:2SZ*Q/HM-54*#4%3H^H.)[\>^XNW?L8\/3S)7MA
MYB;VSB:O;#SSV8RNUV7A9RU-9UAQ_5ZSMZ3JZWHLWST#Q]<^_.;V*^S-=-US
M>VKN@^BJLGST1[QR?QUSJL*[23?+FZ2+TCMRRO/10D?= ^!["Y.<BZF/:1SM
M85Y=YQ^I\TT-#TUK30_N+Z>@ \^<O-S:+UM)UK[]]8PK&.?)^NVD++23O-)]
M0Y?I&TIL_P ]$+VX\N\5,^X,N0U]W=754-D=)6@"EHWO,U-JQO-6KN;[LZ73
M6CYLK['9QUSW1_6.5_\ #Z]C Z.,VU<O8%S]?S$SE>0SS5S_ %L2OJG3Z:,C
MWY]QV4[VY+F;>4G?^^^51S4RO.3ZF7T5GZXQZ<["CA%UE;=U1=72H^.<-1^@
MTU+S7SAA,]DGL*]QV>ST :_WSB758ZROA9F&=FP)_3O356@]\HGY?W<"M='O
MU7*V+\_Z^&SHVOST6#32-OV=/:]W5;&5KA>.OGJ#'C$+7=5GNNV5)R,,X?"W
MU=R]G%X\N,V>N;T-AJ;VMK2PUW?P?:;GLN+Z!ZBCJ.ME\]^PXSM\C>$SM>=&
MM/WP #S><\82(;I\<#T4?G4M^]9!N":B>*-:L[)D:XWIVTGP_12+D;S1V<.#
MW\.44^WUNZF>9O2YC8[S]T9XM%8PN/N\-.ZNKZLOS@.IJOK>>M^^J+<Z.#53
M=^T^VR+>-@>.=. Z'22(NSOX/W*GW_*K9OMT  #3^>\[<K>5]$K8O9Q-=>;;
M/\L^R)--Z>>@:\K/F+*HHDJP>(Z"H^TH)-33)94V55==0R/7+W-!,SM&SG;Z
M)S71/SOI(I<>S.5"LGK.8G-EK^P?)1NNPIF)JT%%7RBLLI;JM+:[6CLF?J_0
M  "+/.8ZC"J<=>-:^3FKEWQG.O"VKOOST :*+[ :*VJZ/IUU1:SR@MJ^Z35N
MHFB'6T2S>5G::TPD=Y2S:\CV%;0,K'T 0FMV\QUUK ;JGV7/P]/82>NFRW+G
M     4EKF4'%LMGHI_GF)WTA6#VRS]N-C>Z@ /@U.>,/K,M;IM]M$U:^3YOK
M6LE^S+W\?H ,5Y&?<.?.!M8UEMTMM(@W1P.O,HMW-7Z    #X*JJM]1\U=PW
M;31RQA:BQGRV1+ZRQB6#-B  #\/@]    :C6Y0BV,!BZ\6-66!S\K]W76PZB
M-T]9U>_>      5%4>T)#T5W8;]SIE3FBL\#+RY>KIHE[:=#2*G=L17V7O/D
MZ-^;:[=1_-!C92S+;TU"S] 5Y[EE:5-<#=P6W\@%Q38'L.8TN/0]Q.NFVU^O
MGH      &I]\XQA]-,]O.Z3BKG5;*.,VVCWN9UD\GT%BV%!9?31>.M]?JK>G
M]]TG109^YSK=K)U=4\OU<>BHSR]A1?02/#1633G-N^@W=7?1^9U&CH.NY//6
M[M       ?!]@CFO&!\U;T[$B5S/@8DV/,HMYM*&XUV^BC?14\6Z?#)QW=@:
M=GAYNHBUA:>SHL;@^IV?-I! G0+K-&MP;2#%LJAOK"N]TIZ7G+1SS^GH
M  'X?H -?CY36,RA=%GOM%!D\=?1RPYJ"7_FP[.L^->N4V]%I*ZTT^JQ\(\G
MSYO9*ZBRG]#+K[L8.DW7_1?O.WC(\D.Y]^           /DB&6$7K)NGH<(I
M8P-1:;=%*]H[?A+9>G2R->FI["1W-;D5FNUZ"?+(MI,-&S3]'$O/='SO/0
M           *;WZ.:[_GHY76$Z@67:VG=XE+8^57T?,Z:5#D,2UZSH.@V?F(
M              &,< =-42/913BKN.B:JWDGFT#\>P?-R7>U5_4EG=^KT
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M"1L[2FJ1L?0%".V@JN_OS$<G"&.VT$EO=TMA+;T+Y.SP;4)+9K.K4<%45/\
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MV\BI7( ZM7 [*9MA5G 'W'NA:1UE6':QXEK3;47GQ:U(G@Z.^WLFFE<*SK/
M+'C$X_D%8P,/%NB^[@O:L.<+FGHK;:$2DK456]1ZMHXX%NG7MOIZ&K<=@'I"
M.14$?,\)*2KT.DI$U7..-(VN[D1T 0$UX]>/7CUV;Z?@D J&R]FE#;1M**]J
M:[$TVJCJ,FQ^JIOIQYV0<F%(9&.T?<ZV8%*C^*-UA\^]9 -26V$7>4[>2(I=
M)?55O"W 8C[N2D^V;FQ"CDB_#TA"*:F;*/C!5>:5M4:4]7U6VPU7MMBBQ_(R
MBZ8^OH8?5HY4IR<W%<\#DEKSHVZ+S9;=W2I(FB+REOMIF2A$%B" 2[KT+]8O
MD PIC3QV*-.H%BX(S[!'F=+K'F8I-SH8DWOJ3\W!W1V=]TY I&N^17."2UL7
M3XHRX*[IT0GT;(; ' 62T*R7Q-V,R&Z+TU3K2/.]GW#CG:@2D%2557I5?Y-5
M?D@-H:$_'D(R!$B(GHNHSA@;/D5B2VK&GGD<4EVU(8-@XETXUJ;<.N*U()-*
M*FHIL/2#B@1$NS N&=3+9:!_9#]?^<Z*K6H,%PACDOEGE#(>HOJB3D2M;:W<
ME _ )N ^8N,&":7YQ(X=\J4J-O.>0YD96"::1PLG?8?>CJ +))93IHH&XFZ!
M]/3'1I3MU@H$5L7#9K?$]/B>!_U;%559#9MH0]D.L4T(=BZGV.Q8DE6"A6[3
MCMG)B"TMAWE+G>?T5=E;V4G"-5H6T*3?D"*BJFH2@:U,1D7+AMKO*0)I);0%
M#Z>E4WU6-"XE?7*W)E;)J<ZCS'J,SP:;D(VY'?0"D3T1M555ZI_R@1F"A-QT
M<-*E'-)\%]*^&LER=#&.ZA"FJQPVWKYH34BV2SB> JJP-G5B^X9.R'' -/@'
MT]4:0312K+R:?LR;23*,11=TTVWWE*A(T#JGY4$W4*$ZQ["?\HLHOM$B=Q3<
M8-&Y4;S.3X'@&JJ5F:D/QH8/ODX2$NA0C.V1OQQU%%M'&3><CDZ:L$XI,&BF
MOP#Z>K;?007O#*[U(7!(;PH[BZ:0U<E/N*H-(D8)) <^><ASKG?(73%*J6Z)
M2;1U&F);ABZ^[)6V>.O5=R,B32)W:@-JDC)U G#3X#.C=]2<>1JW)B,X\:M)
M(4%4/IZM]M.7AMQ(Y[N7,9%-:PP#4)%^XL&2+4L!< *]MEEOY=<WY:(=4M<+
MI_;"1U$G[4IY*3L=E#7N7;R+JI?\;<DC)RO B=MZ[[1R*I[2P=0^W3GR;^GK
MJ51&WJX6';2O VYB[M=R:CH2O./NH<&S0FSL/X@FR=9F2EI?E7ODT,=K<YK#
MB:D5)F_X#!T4THZA=J,R'^\X)D+EJXLIZ/'(]-(Z^"HJ$:_ /IZVGG!63/<,
MH]LF[TX##MTZ:B+;CW8@ILU%DHVB[^PFK\.PNW?3,PVTJ;Q65.YC.$[;J01W
M%[]_@B[*ZXKCDLEW!T@5F^=5QB3&=2\N4;?=E"A;#H=NWKBP7GU;%QA8TI'-
M,0RUY$U4$RH2G45\F5;&+=#]N'RZYI(J5T)'([,?<W8XFBCMH?AK;;45%[D9
MV)47=ME2.8"B42+YSNJQ8SL-MQO4ALT)$33"(I[^PJ;,HIN/=[IQD!FML60B
M>4-1H8NM.13;<G5Y"W!B(C#?RZY;(CJ*^Y]M#K7GUD4#O;+KW$=DQE;5=,^1
M$)_?0S#TLPUU-474ACN;LLS&L@R9!L0R-IZHD-ZAJO>J>PKE3QA' Y5Q&06B
MIS;8U D>-^:T,A7W5>T<_P 8M_+K??[U2.XK-?:JVCMSY$B22[''%-=0U52:
MV)QUI.W;X.#L(KLD.4K3X7+))/FC]Q(MB)%0M@W[>N-/1D3?;19#PJU.E"37
M9IOM0WI?\&;!0"0XVJC[ OJA@7XYMGO)&(OC0DTB^D)?Y,K_ "=^A41&WFU4
M8S:*=[#;C.@T I(BH.DT1$.A7<>MY%-%DIM]XZ.G"W]%T<)5U#)L4AM->2W
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MB:%M-KZF4&^"NR5$/9$M@-,L-PM7FBZB_,*<,)U!W<VJ8[:A.GQ+VI:93KU
MV+FEB%6U;\O%OBL=EDM42G2J,C%U&)O%HJ.EUUWW3&511:FV7UX_^>ONGIE3
M U-S!OLRT7^[-IV= @<D8YMA^N54388!Y:P%3,8=C[,#(672MQ)LS8ORPBXV
MF;<W@-8,.'#[\L4XHMVV\2CHS-_U]:$]-')6(K;%M9L7J/RPK4?+NMS3;2_E
MA/U]4G4)5:8+>+[T*OA6L^6+K2?-[,LU!:_+*U,[/3<)2@Z+:"E+9: )6@A8
M].T8943=@YH%JU*0NE679R]9A]0G?'?2WLQ4&75JOVH *YOY]2LO9:L.*$E;
MN].'L^-W030L/N]2MUL3*S 2@!"RM<TK4*W-"I\AIZTVP6X90^ Y9M%QZ#ML
M"4.(?J2@ @J*W2K##RRY67FP]2L%#;LE&Q'TQ*Z=QYN2%1EV?=ZOU12-R2B;
MIJ:;FAUDL7">5E_%-G11=\-0>\X<4JN>GS(*9( )= R&Y])?5QMZWJRC[^C;
M,.Z4._J=F5'34_I\4"+DTZ?9Z*MPRQ<L8D&[AVP@]+'6+#6OX<MF#L^M&4_I
MUMTO4F#?&5J>;KE[Z8;K:>[FEH%I\](CFK*#=DX<,#(@7;P#X>C"2OJPABNH
MU>)L4!#67_7,)O'9@W5M7BA8><8845-KKG7AV>B :@6[G=<7EYHSIJ#4*_TU
M&;WYM5A^SIWPC=25)NFS9-FV;595Y[3AE21JU^K_ ,IWFG6U1^B@S_9^#AFR
MJ%<R?@:7-\I>T</X9137-E:5U-J6G/D\G-!;;[-(:$9OP]!KA'-26JW>\5B_
M#B@9EMNVK43 COZBL_W80P*^MU[0=F67G+%#Y67W9@V:?#/6Z+EWP!O)T52=
MWJ;3-DV^>,6SW895ZUE0#*Z=*'ZYLM_?.']\X?WRKC^,P@W4@1/TGSQE;<LJ
M)J:CTM<EEE%R=%JF;_X2X[ST6#,JR_4&/UI8<NF2NG!J*0$VC<&S0LYKM)^U
MUZS$%4P^G#"Y^S$#FS3KC?DE-)EU!7A]'5V&D(IWEW,<L#%K+CE]V&FV.&\=
MT"#"6E/,L&L2UHJO8BV@\7X8"PHVV-3E,&H+F9L-GCZL\E8 3W5IK?SPV%7]
M!^N5)(_;U2K-W8"W7?N@!/DA""OHFU_F?VZRI*LUO%S2M+1R^!J(:GU9OQ5A
M!.)I35%VSA\5ER;$ Q=:GDA[PEOV+^67:8*ZC9V\;HFH"+5'Q?5VI^^4/- ?
M,&@LV:E<TJ2-WCPQ=34%P9K</M>KRS K*?'M0XL'#L7^76"#B-LPT74RLV;M
M<<JQJT8'R3O*;1X0-0'$K8NS*(%)J&P=F6G<[8KH78VHV5H-&@M?Q_#"-);R
MN^6Z@L;K[YOG=A5I^V VKLFT!?5F^4Z]3&N%&X(W>DZ8MNP^RL8$T-/^8U#E
M6[#*#PMQ&RDN10IM@4G8(-7R)X_BA9"5N@8C9;;B]J5\C$_0M,:JWC59?]Q=
M]Z,FD!IKA^[,!LL@:MS9<,NUQWHKQ<L8?XP[CAP\DJQJ?#G4T\3MFAMRQJD^
M/[)>MUP]$QFTFMLM05FF #=JCB*]F6G,.F[R1@AJR9MC3O"%IN\<4QA55LOJ
M_OF_JU05$M/DS2K.P_?\$6H'=:9P,O\ ::F+$>5>6%5^J4843BA72Q#Q]7Z&
M=-=%:MQBWX9<@91V87%4V_R@#&\^G)+PYBMJ,VIW>6YH-4A;WX=E_E7\,J&#
M='=I=B7A];\L)N*ELV^4OP<LH=MLN!/DFF"Y(U")3H-]-W%+NZ#J.'9\,=U'
M=C4)95Y+OAEFHO?ZGO?BAL%#;P\&&5(9C^V/J'5TQ8/T^)O>AM]WZ'66MNMC
M!<]?^5@9LSXI@RP#%?\ BG>#*V'?X\L-*V\4/=RX9A,7EG=U^9!66Z>:HFF3
M3"1*O+E_27/,$M/1WW"!;"[_ -3&OWOQ38?X0_1J12Y"JK+FR[X6TSIVX<.G
M;^&74=]MVYH :H:Y:^F*H;898%R\4[Q0:*N5?6/Q2NT&V78Z^U&N+>3-7ZYN
M8_LE^W!]4!)Q5R<7EGD"P]VO>5'!^68DU/:5XS'672;32^S9=ZF=9;7O!*$[
M/I= =GH$JV^5.^%CN,M.Z4E%S0'9OZ":X1FV"4(:_B\;I1R"AFSS3$WNK&*G
M]7/]/+^59EF([8#T[8:7;3*6M+&W,V;]DV;O]!HNZV&X5V0]X0SU_E /,.I4
M3;+A2@@_T"J"XP,=X\$%\W^N?__:  @! 0$&/P#\.UJL@-P@U-'V@99_EQ)<
MW,@B@B&J21N '><4VVZ@NY0>9-1R6G'+VX7TK;[/%U=QC#*T3/U1H8N=.=.$
M6-LCO$:.Z6VC6>-_$KA<P?B;5ZBLDEDAV:.2XG521%R,KTDH>&6(9_NJ#H.&
MT2AGH2&([\+ ;J%;N1M,4"DU;*N5<%F-%45)]@Q'9[?ND%S<RUZ<2$ECI4L:
M9=BBO\,SP;^=6FC#JFB+26JWRD8W2XV87-G=06<[12D1G3($)1N+>$C#;C=[
MS<RO*IC8A8M5:BG%0."XMYX+FX39HX*;E8D1:IC6N5*_TEQ<16^WW44L<>IG
M8)0BH'8YPF^W]A/-N5I=2PP7+Z0RQ]!3I%&"_P!8_P"UA4C@E!:@ .C*N78V
M*CX"\T;N 0.2GO9]I&+FRO-ON+B&XB>.1!HH5(H0:.#GB[2VBDA].B(>2V[E
MK$_(6/$\6ZA\?OX7<+6ZDBE@'41HPI8$G3EJ%,2VU^][/<+;G5(PA +$TKD1
MBW@VF_DLMS*L]O=46B55@W%6XH&7PXV6#>S/?;C=0V\4URH2C3%5#N<UR9C7
MPXR8$]U?X0);Z80QM6C$,W 5/A!Q%L]CNZS;E.K-%;B*=20JEF.IHPOA5O>P
M^T[9>0W$VJXM-S1XI]41%(Z*:(M:Z_I^'&O<-QZ%J,C(4D8ZFX#E1OS8]2[5
MM$UO<ONZ/# LD<VIBRNJ:35%75K][!&X0K#-J!=4[#3+WF]W%I-:J\D0 :1G
M*Y'^;A3&@;+FKV"ORXMO37IJ5;]K\LZJZNLAD5"S ,W30 )%JSQ)O%Q+=Q[G
M?!);N!I(3&D@.HJ@5*TJ?IMB@^ V]P[HA8-6,@&H^4-BYO\ T_U[N&59+N\>
M[>-@C(:@*$6$Z<S]+$ANIECO"RF6)%>@HM!2H;LI[V(HF4#;G3^\3^\N9X9_
M)[N%:.4F-9 86-<R,Q7(8N-_N;2%+NVTP)''41E=:YD,[-7[1O>P;7=[Q+6Y
MZ$4?31)3]I0AEJ XR.%W"QN4ENXU*K',DA2CBAKI"'^=B6Y@W.)]VCM#(ML8
M;C1Y@1E@AY1R]3E\?ZV&V2Y:U6Y2W>=XX(YE8!2H',[.M*/_  6ZW)H_.26R
M*ZV<3J)) SA.49]]>&(+ZTO9]NBG+RK:,Y)C5E\!I3AB.:VO98MQ128MRC<J
MR*P*E0WM&I?UL&^GNI;IY).O<N26+DMJ8L<_%GCR,NW@H1KYZ,O+[*8CGM]E
MMO,01:RD?3#N\8!RRKJKB7<8[.6RLY]/3AD!TJ44(<Z 9E6;"6J/-'([:$!U
M$GY!B9;F^D6,1<J2*X%=0[\#>=H86=]:D]&:!"LJEAH8JPX55R,)9;M;7NX.
M_3@$\CF@;50OS ]^*C#-2M 33Y,>?:W>8:PG24T;.N?#V8O8;VQW&\LY)'7H
M/K9.F2>2A6FFF);J#TU/#U&7EZ#$T"@=B^S$][>V-PUO *NLD3@::CM84[<=
M3RP2/5J2,CA[,):7WIV6ZL'+/-"P'38Z>6H*TR95.(=YLMO@@%V&N5M8U77&
M" X0T[16F#Y>ME=,V18\X"G/A0YXM[."9X6KT9I U YJ%U'\N#?6&XM#N+1-
M&]Q"Q60H2,J@UIDN(8I[=[=U$<;RS.O,=.;Y@8#Q.LB-P92"#\X_@4=U?R&*
M*601*P1GYBI;@H/8N([[?9>E>0Q@1")&*],L0"0NK/46Q>Q;0L4UJK,T18:#
MH;($ZB,7#;K%T[H2+14D4C074#A7VXW"T#D2)$(J$$YJ&7C3"WVVJ'W"I4!R
M-&BM#D:?GQ#N'J*+HR!Q/:F)U((KJ8D+J^KBVM=I198UFZBZR%- 7#9L1[S8
ML-XWVS$<5C<+SQ3Q91Z:U*@L3F<%WZ^HFII(/]G&E>M0FN;C^3"O]K5"&'..
M(^;&A:TK7/X.A/714-RFAJ,4CK3+B:\/@W39XE+O>1"-4#!">8-XCD.&'Z6W
M(;%'K QNH-1 [^;'3]1:H++2'F:,ZV"L=*4T:O? Q&FP322@N1<=56%%RTTU
M*OMQY\LPTJ%KF1GEPIBUBVYFDGFF"N&JHUNX"CF [<?>UC9PF!_LD>26(\>/
M+K!XKCI[O((Y50+2-&[!S<-7;A?O)XHO2?3:/;)UB9YFE+ZJ.%):F4W%,+$3
MSN*J*?A];D4J!FP7C\N.CLFWWT%H()$N=TLIYNG;G5D\C11A5-/I2+B+8MQN
M;J5;+[4;C<W<D@E;,4TOVTD_WC>'$$]Y%//H6GDYF=NH.;L8'M/T<+<Q6*6<
MQBU,B@*[$9Z20JG$-[N%S/M5G1HI-ON-;QDHI(<ZS$N;'+D]W&X=.\$8%Q-T
M@J:1-I<T"T;.OLU>+%MOMUN!M3))/&;&6UUD:'TAM32)Q_0PT>X06NZ>$1F>
MUC.@**$#69/%@)%L]E&@X*MM$H%<^ 7!6")(E/$(H4?D_!4(J/;@B]VNTN@0
M 1-!%)4 U YE/;BJ^G-K![Q96_\ L8F:TL_NS8A;6]9XH>E:"0@Y54)%K8^W
M%RUB ]Q"E8YX%!<.%.EU*YAJBJX38]Q\XD,(:7S]P\I1FU5"Z7 %>;Z?NXF+
M1]6BDZCEP^8XEEN)Y)[!EI#M\DC=&)LN95-4KDW!/>P/+;IO NZZ(;>.[NI)
M&H*\H4AOQ#&W[7OR/;;A:VT:37-_.1-++6AU"55?7\K,WX4GNQ=>F;5V%Y;"
M.9E9!HTF-6R;_P!P8]7V=YK\Y>6\C6Y057PTS-1VXCN+?IF"12T>IM)R:F>6
M(+K<6+=)>**/#F. IVG!N9F!VUZ/;  !PM>VGLQ#M_IJ@>=6T"X.@:HU+O4G
M5[HP9O6%JL\D)C>T-O<2+1ZDR$Z-/<E,)MNV1F*TC9G5&9G-7-3FQ)X_P";;
M-T@,\4K1LRB1XOW;:AFA!Q.GI^"*(2 A>K<.WA!Z?B#=^"N\&&J.JMTFU9N"
MR]@[,2K?2*86#4"J*Z/F&(HHED\XIU2D@A=.?#/VKC:OOXUGZC2H8!K'3,;*
M/HYZ@<?>5DK:G;KJSU7VC+/"V>ZR&3<Y9'Z91 J=-4#"NFG<WX3>8EDZ4MQM
MUXL<H;2RMT6 9:=HKA([J>.XO$#"2XGE^U8,VH:F-6R%!QQ/)<7+;BEQ-UA!
M<$LI4^Y0EJK@1[8$@NEF5I;.U.EHTT'BJTH*Z<)?7MF]E;PH%D+(0E*FA)('
M:U,?>5U$9+*ZM(GMGEA5HF!:O(6R.6!);64$$BUTO'$B$5%#FH'\$U-91W;E
MA570/V'/,'AA[+<K>6T-Y<R>7CF4KJ0R$<BMQ&(E"*THJ&!1=7$G/%WM&Z01
M_>EW<%[:2YIY@)H3]WJ&K35&X'Z6+F[COYG%Q_\ 3ZB%C''*AQ:;B',RPK(.
MDTC!3KC9<^/TL;9?2%8VO;:&8+6HK)&K4!/'C^"N)+5IX;^-X:311Q.-,C4(
MI(:</JX\E->W#R7D$T,!:&W509E"\VD5IF,1[E>NDLDK%&92030D#(!5X+B"
MVTR]=B$B8JND'AGS?Q8GO-XL);F>5-+O&S"K56AIU$'A&(KB[6VF],HQ@W&Q
MDDF261@NL:3&M::FC_K4\.+3:ML@%O9V<2PP0AG<*B\!J<LQ^<_P;S[;7&V]
MVZ-]WW<D]PJQR,=52J/I/-])&Q7>;?S!Z@@)M6=N=E+@\YBRTC%M=V=KTKB*
M$&.34YH2S#@6(X' @M&>.>*2ERQ52&'<*ZOS+@7>WS&&R1 &C95+ES45%0W>
M/>Q96IWMO(60ACAA%O:U6)**%KTJGE6G,V(3=--+>N\M972-!I0Y#D/_ )?C
M4QI!)%:U.)Q<S+%+/#*MLK5YW"<!3VD8^_\ =[A[9M/2:/(QY9*<PQKB]N]A
M4[C;PW<DMXYI2)5D++]'(@-^SB2XGT1S,H5H372,A3\@Q91[-,U[>RRA8H%I
MG(V87,#'WMN:SP;A=6[13VLG3*(>H"*4!-:(.W%%  ]F7P^M3<7LT+)NUZ84
M5LB3<RY=O<,&"2>5;8+7JZC6M.&&D:[F$:C46U=@SK@&*]E<',48]F6/\5-^
MUC_%3?M8_P 5-^UC_%3?M8-Q=WTT,"D!I"QH*Y#$XNMU>*-3_=VU-SC//@?J
MX%S:7LTT#$A9 QH2#0XSNIOVL?XJ;]K#/!>RNJFA(8Y''^*F_:Q_BIOVL1,U
M[<*8CJ&EN/#C^+$DZ74Q8.@H6/:V/39U%F.U6)8GO\NGPA)0* ZJT!SI3MQN
MEYMLMQ>QPHLS/<:*!FD5-/*%RIA;Q85+SR5*FM!VY9X,,=D/,R *D4?:$.HG
M,]V$BN9C%?[-;P]2  ?OD6C(^1]Z.F6(MQO%BMX!U$+\VFIR'#$4Z$%)45U(
MX$,*CX^W1[9<FS&U3W!O@Q'VJKHR%*_0;CA[7;+MK1792"Q!4:34\*\<;RTL
M,;W][8L_72H)E$+U<U^L]<><8Q_: ^,-7EY>P>S&U;OMVFRL]HOXQ>0.K:I2
M,ZK0$?C^+ZO_ -8O?\U+AE<EHP@Y1WD8CAME>-""D@XAJT'9B'<Q.%MYB8TB
MH0P.IAW4]S!(1AIR)(QF"!WGX!\N#9!V:R:-&: >$M4FOY,1UC(+*=->S(86
M 3R>56M(5I0$FM<\=1%(* :JTS)%>S E9&D!;31>.8)_BQIB(C1FJR]YIBVG
M4EQ,^FB9FE*YX2&./IZEKG3V_P F.\8E_33^D,>G/]*L?\NGQ-WV.RG2VNKV
M-$BGDJ54K*CYZ03P7%[M&]-'>&T?I1RZ6":P::EJ%Q;22SJ\$<19ECJ!5U=/
M>&)[G8%3:[Q+=I=QF;C<.R$@Y:O>#G];";=N0:ZN1*[M**4(+5 SH<L&.")X
MA81P1-K*FM4(RH3]#XW3GDT.1JII8Y'Y <;_ &P,?2DN[R.,Z7J078=^!:6T
M<;1ABP+@DU)SX,,;-%.$'2Z2'I@K37H!\1/=B.RV6)+B[C>IBE^@Q+$UU1KQ
M([<$6S2%KL)-.)&5J/IS"Z0N7Q?5_P#J][_FI<&:5G#D $*0!E\H.%M]VW*:
MWN[AXULXPCL'89$$I$X',5\17$6W7.X2K:Q2=1'5'UZN;B>F?I'W<70VJ-)T
M%<Y,C7LXE.S%K%=*B7*'5(B T!S'&K#\OPPKH8HR,*HRJ>52?>Q%>013,+:&
MXFD+214&A%;AD3P[,=1ZACQ X98W$#L=?S''S8AMYHBL4K$,59*TH3EF<.DM
MF5VH(!:3B6'6PKVC43W^XN$O($G>QCA59)C+$"&U,*4(#>\ONX7;$84@D\O1
M@2W*=.9&5<26SE@I*-D17C\F/3Z,**FV62H>T@6Z#/XMHP65C9RM<-TW1*47
MMUC/YL7"S3.)6Z:A8^7)9 WO*<"WMV+26\6B)6KFR+1030#LQ5((SNNH?89:
M=%>-=5.'U\;G:[O<+;7=S):I#&L<C:G <,*H' YB.)PL\#:XGKI:A%:&AR-#
MQ'Q'D/! 6/9P%<1[[Z=OKZ#8[>SBAFBLI9&@,W4<$L\7V8?[2/CS>'%U=[G/
M+,UP[2@W!8G4Q+,:MVYYXY"KY\%(/YL6ME;7+S27TT$*3QAG\J9&TJQTDTTZ
MJ^[X,12[Q<1[I-HD1VFB.HEI*J3K+>%1IP%44 % !V ?%]7_ .KWO^:EP;]I
MC)#DGE :9G+5Q_BQ%>R0HUQ&O5MP0-8:@;D/&M>[%)7:(T),;MF*&G TP45R
M%;Q <#C/X3N%F)BT?*.@65N;E-"/EQO@W)Y)&EL/L?,DN8S-#)JIJ_5U8:*/
MJK8A05O5ADZ):@Y0PY:U^MB2)2K&2FLJ-.:BF?P-,(Y+62-J(34-PXC(8GGN
M-ZN9;.4:;>U:9PD9J#RU:GXL17";Q=)MZQZ);+JN4=AJ.HC5I[5[/=Q%.C".
M97ZDLE.9S4&I/?AYV1KA@5&GB3G\^-B9JBNVV9"GLK N7Q2K ,K"A!X$'#^J
M=O"+MEG#%%)L4$-!*[R%.IR\N745OW?]7B^DFN.LE]._3M=5#:#63H()--.K
M3P7P8-VLRW# A:(XKG[<\6D5L]W ^[2*8+F/J+TBS#2]1QTZZY8VW:MSNWO]
MRA6X>>[F8F1P;EV6H8EN5&5>/Q)5<T65'3AWJ<7WI.-F3;[N9;N56!=]1>/@
M_9^Y7+&\7>[B0VMG UQ9M&Q4Z2KL2P SR5<"#:7N6WLL2BOK": >;,BG#$$?
MIQ8VL(]ULEWXS$:E03D?9ZB/=ZOA^/ZO_P!7O?\ -2X: _NZ*?;PQ9V;&NX&
M1(=N4"BF1B%4,>'BT\<?>N\Q+'UG$+-'(K<Q!TY+]5,"*V8LU= !!&?SX#.
M 309U^!@GCH=->_LQ<[C?AAZA2\T1A&^RZ6M!P&5:%L;9:[,JM%>QQQ;OU"
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MM$#- A*.[.%!HI+:D:J=F+?<!=1)?/KBDCZRQRA3(QS:NJE%7$,G'6BM7CQ
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M$UKS,>(/4D]N-HO+%))YFO1)<)50J*%XBM,;EMNVS"XNI^ATXE!!.BXC=LV
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M)BD9L-2-<<X#=-C4T]NG"C98J7>L:NI)R].AKQ]NG#1[BJ .VKD8'EI3LP6
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M._[A"D*6]D8&:+) -$]*J6=JUDQ+')(PDL^J;58\M3D9!M0/:H^CA/3.Y1+
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M0I+7Q'0(?=]N#!91=&)F+E=3-S$ $\Q/=\5MN(F%W?0.;>2-49%(-.;4P/\
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>XOK4_ OUZ=&G/JX4Q-]W]+S5/MNGXJ5[?X#_ /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "\ +P# 2(  A$! Q$!_\0
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M[@KGZZ#QI_R,3?[@KGZ[</\ PT>=B/XC"BBBMS **** "BBB@ HHHH ****
M/&Z***R.L**** "BBB@ HHHH **** &O]QOI7U;\._\ D1-*_P"N(KY2?[C?
M2OJWX=_\B)I7_7$5P8WX4=N$^)G,>-/^1B;_ '!7/UT'C3_D8F_W!7/UVX?^
M&CSL1_$84445N8!1110 4444 %%%% !1110!XW11161UA1110 4444 %%%%
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&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>22
<FILENAME>cik0002065779-20260331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Plus; Version: 6.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /aI5s7xRiXgen8uLbXcsOaqDebPtxZd2mYlBuWV9HalaDysuIwZtQSMQv5imYdsL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:cik0002065779="http://cik0002065779/20260331" elementFormDefault="qualified" targetNamespace="http://cik0002065779/20260331">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://cik0002065779/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/BalanceSheet" id="BalanceSheet">
          <link:definition>00000002 - Statement - BALANCE SHEET</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/BalanceSheetParenthetical" id="BalanceSheetParenthetical">
          <link:definition>00000003 - Statement - BALANCE SHEET (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/StatementOfOperations" id="StatementOfOperations">
          <link:definition>00000004 - Statement - STATEMENT OF OPERATIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/StatementOfChangesInStockholdersDeficit" id="StatementOfChangesInStockholdersDeficit">
          <link:definition>00000005 - Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/StatementOfCashFlows" id="StatementOfCashFlows">
          <link:definition>00000006 - Statement - STATEMENT OF CASH FLOWS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperations" id="DescriptionOfOrganizationAndBusinessOperations">
          <link:definition>999007 - Disclosure - Description of Organization and Business Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
          <link:definition>999008 - Disclosure - Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SegmentInformation" id="SegmentInformation">
          <link:definition>999009 - Disclosure - Segment information</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/BusinessCombination" id="BusinessCombination">
          <link:definition>999010 - Disclosure - Business Combination</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/ShareCapital" id="ShareCapital">
          <link:definition>999011 - Disclosure - Share Capital</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999012 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/DescriptionOfOrganizationBusinessOperations" id="DescriptionOfOrganizationBusinessOperations">
          <link:definition>999013 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/InitialPublicOffering" id="InitialPublicOffering">
          <link:definition>999015 - Disclosure - INITIAL PUBLIC OFFERING</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/PrivatePlacement" id="PrivatePlacement">
          <link:definition>999016 - Disclosure - PRIVATE PLACEMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999017 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999018 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999019 - Disclosure - STOCKHOLDER&#8217;S EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/FairValueMeasurements" id="FairValueMeasurements">
          <link:definition>999020 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/OrganizationAndPrincipalActivities" id="OrganizationAndPrincipalActivities">
          <link:definition>999021 - Disclosure - Organization and principal activities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDisclosure" id="SummaryOfSignificantAccountingPoliciesDisclosure">
          <link:definition>999022 - Disclosure - Summary of significant accounting policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/ConcentrationAndRisk" id="ConcentrationAndRisk">
          <link:definition>999023 - Disclosure - Concentration and risk</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/FairValueMeasurementsDisclosure" id="FairValueMeasurementsDisclosure">
          <link:definition>999024 - Disclosure - Fair value measurements</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/AccountsReceivable" id="AccountsReceivable">
          <link:definition>999025 - Disclosure - Accounts receivable</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/OtherReceivables" id="OtherReceivables">
          <link:definition>999026 - Disclosure - Other receivables</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/EquipmentNet" id="EquipmentNet">
          <link:definition>999027 - Disclosure - Equipment, net</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/RefundableDepositsPayable" id="RefundableDepositsPayable">
          <link:definition>999028 - Disclosure - Refundable deposits payable</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SimpleAgreementsForFutureEquity" id="SimpleAgreementsForFutureEquity">
          <link:definition>999029 - Disclosure - Simple agreements for future equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999030 - Disclosure - Income taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/Share-basedCompensation" id="Share-basedCompensation">
          <link:definition>999031 - Disclosure - Share-based compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/RelatedPartyTransactionsDisclosure" id="RelatedPartyTransactionsDisclosure">
          <link:definition>999032 - Disclosure - Related party transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/BasicAndDilutedNetLossPerShare" id="BasicAndDilutedNetLossPerShare">
          <link:definition>999033 - Disclosure - Basic and diluted net loss per share</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/CommitmentsAndContingenciesDisclosure" id="CommitmentsAndContingenciesDisclosure">
          <link:definition>999034 - Disclosure - Commitments and contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/CryptoAssets" id="CryptoAssets">
          <link:definition>999035 - Disclosure - Crypto assets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
          <link:definition>999036 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999037 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" id="SummaryOfSignificantAccountingPoliciesPoliciesDisclosure">
          <link:definition>999038 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
          <link:definition>999040 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure" id="SummaryOfSignificantAccountingPoliciesTablesDisclosure">
          <link:definition>999041 - Disclosure - Summary of significant accounting policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/ConcentrationAndRiskTables" id="ConcentrationAndRiskTables">
          <link:definition>999042 - Disclosure - Concentration and risk (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/FairValueMeasurementsTablesDisclosure" id="FairValueMeasurementsTablesDisclosure">
          <link:definition>999043 - Disclosure - Fair value measurements (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/AccountsReceivableTables" id="AccountsReceivableTables">
          <link:definition>999044 - Disclosure - Accounts receivable (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/EquipmentNetTables" id="EquipmentNetTables">
          <link:definition>999045 - Disclosure - Equipment, net (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SimpleAgreementsForFutureEquityTables" id="SimpleAgreementsForFutureEquityTables">
          <link:definition>999046 - Disclosure - Simple agreements for future equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999047 - Disclosure - Income taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/Share-basedCompensationTables" id="Share-basedCompensationTables">
          <link:definition>999048 - Disclosure - Share-based compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/BasicAndDilutedNetLossPerShareTables" id="BasicAndDilutedNetLossPerShareTables">
          <link:definition>999049 - Disclosure - Basic and diluted net loss per share (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/CryptoAssetsTables" id="CryptoAssetsTables">
          <link:definition>999050 - Disclosure - Crypto assets (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperationsDetailsNarrative" id="DescriptionOfOrganizationAndBusinessOperationsDetailsNarrative">
          <link:definition>999051 - Disclosure - Description of Organization and Business Operations (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/BusinessCombinationDetailsNarrative" id="BusinessCombinationDetailsNarrative">
          <link:definition>999052 - Disclosure - Business Combination (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/ShareCapitalDetailsNarrative" id="ShareCapitalDetailsNarrative">
          <link:definition>999053 - Disclosure - Share Capital (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative" id="DescriptionOfOrganizationBusinessOperationsDetailsNarrative">
          <link:definition>999054 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
          <link:definition>999055 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1" id="SummaryOfSignificantAccountingPoliciesDetails1">
          <link:definition>999056 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999057 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/InitialPublicOfferingDetailsNarrative" id="InitialPublicOfferingDetailsNarrative">
          <link:definition>999058 - Disclosure - INITIAL PUBLIC OFFERING (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/PrivatePlacementDetailsNarrative" id="PrivatePlacementDetailsNarrative">
          <link:definition>999059 - Disclosure - PRIVATE PLACEMENT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>999060 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999062 - Disclosure - STOCKHOLDER&#8217;S EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
          <link:definition>999063 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/FairValueMeasurementsDetails1" id="FairValueMeasurementsDetails1">
          <link:definition>999064 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/FairValueMeasurementsDetails2" id="FairValueMeasurementsDetails2">
          <link:definition>999065 - Disclosure - FAIR VALUE MEASUREMENTS (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SegmentInformationDetails" id="SegmentInformationDetails">
          <link:definition>999066 - Disclosure - Segment information (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative" id="OrganizationAndPrincipalActivitiesDetailsNarrative">
          <link:definition>999067 - Disclosure - Organization and principal activities (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2" id="SummaryOfSignificantAccountingPoliciesDetails2">
          <link:definition>999068 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3" id="SummaryOfSignificantAccountingPoliciesDetails3">
          <link:definition>999069 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" id="SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure">
          <link:definition>999070 - Disclosure - Summary of significant accounting policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/ConcentrationAndRiskDetails" id="ConcentrationAndRiskDetails">
          <link:definition>999071 - Disclosure - Concentration and risk (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/ConcentrationAndRiskDetails1" id="ConcentrationAndRiskDetails1">
          <link:definition>999072 - Disclosure - Concentration and risk (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/ConcentrationAndRiskDetails2" id="ConcentrationAndRiskDetails2">
          <link:definition>999073 - Disclosure - Concentration and risk (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/ConcentrationAndRiskDetails3" id="ConcentrationAndRiskDetails3">
          <link:definition>999074 - Disclosure - Concentration and risk (Details 3)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/AccountsReceivableDetails" id="AccountsReceivableDetails">
          <link:definition>999075 - Disclosure - Accounts receivable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/AccountsReceivableDetailsNarrative" id="AccountsReceivableDetailsNarrative">
          <link:definition>999076 - Disclosure - Accounts receivable (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/OtherReceivablesDetailsNarrative" id="OtherReceivablesDetailsNarrative">
          <link:definition>999077 - Disclosure - Other receivables (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/EquipmentNetDetails" id="EquipmentNetDetails">
          <link:definition>999078 - Disclosure - Equipment, net (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/EquipmentNetDetailsNarrative" id="EquipmentNetDetailsNarrative">
          <link:definition>999079 - Disclosure - Equipment, net (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/RefundableDepositsPayableDetailsNarrative" id="RefundableDepositsPayableDetailsNarrative">
          <link:definition>999080 - Disclosure - Refundable deposits payable (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SimpleAgreementsForFutureEquityDetails" id="SimpleAgreementsForFutureEquityDetails">
          <link:definition>999081 - Disclosure - Simple agreements for future equity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative" id="SimpleAgreementsForFutureEquityDetailsNarrative">
          <link:definition>999082 - Disclosure - Simple agreements for future equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
          <link:definition>999083 - Disclosure - Income taxes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
          <link:definition>999084 - Disclosure - Income taxes (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
          <link:definition>999085 - Disclosure - Income taxes (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999086 - Disclosure - Income taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/Share-basedCompensationDetails" id="Share-basedCompensationDetails">
          <link:definition>999087 - Disclosure - Share-based compensation (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/Share-basedCompensationDetailsNarrative" id="Share-basedCompensationDetailsNarrative">
          <link:definition>999088 - Disclosure - Share-based compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrativeDisclosure" id="RelatedPartyTransactionsDetailsNarrativeDisclosure">
          <link:definition>999089 - Disclosure - Related party transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails" id="BasicAndDilutedNetLossPerShareDetails">
          <link:definition>999090 - Disclosure - Basic and diluted net loss per share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/SegmentInformationDetails1" id="SegmentInformationDetails1">
          <link:definition>999091 - Disclosure - Segment information (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure" id="CommitmentsAndContingenciesDetailsNarrativeDisclosure">
          <link:definition>999092 - Disclosure - Commitments and contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/CryptoAssetsDetails" id="CryptoAssetsDetails">
          <link:definition>999093 - Disclosure - Crypto assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/CryptoAssetsDetails1" id="CryptoAssetsDetails1">
          <link:definition>999094 - Disclosure - Crypto assets (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cik0002065779/role/CryptoAssetsDetailsNarrative" id="CryptoAssetsDetailsNarrative">
          <link:definition>999095 - Disclosure - Crypto assets (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="cik0002065779-20260331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cik0002065779-20260331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cik0002065779-20260331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cik0002065779-20260331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
    <element id="cik0002065779_DBoralARCAcquisitionICorpMember" name="DBoralARCAcquisitionICorpMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ClassAOrdinarySharesMember" name="ClassAOrdinarySharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ClassBOrdinarySharesMember" name="ClassBOrdinarySharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ExascaleLabsIncMember" name="ExascaleLabsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OrdinarySharesClassBMember" name="OrdinarySharesClassBMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OrdinarySharesClassAMember" name="OrdinarySharesClassAMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SubscriptionReceivableMember" name="SubscriptionReceivableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_DBoralArcMergerCorporationMember" name="DBoralArcMergerCorporationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OrdinarySharesMember" name="OrdinarySharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_DBoralARCAcquisitionICorp.Member" name="DBoralARCAcquisitionICorp.Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_UnderwriterMember" name="UnderwriterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_FounderSharesMember" name="FounderSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SponsorMember" name="SponsorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_FounderMember" name="FounderMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_UnsecuredPromissoryNoteMember" name="UnsecuredPromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CommonStockClassBMember" name="CommonStockClassBMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ClassAOrdinaryShareMember" name="ClassAOrdinaryShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ConversionOfClassBToClassACommonStockMember" name="ConversionOfClassBToClassACommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SimpleAgreementsForFutureEquityMember" name="SimpleAgreementsForFutureEquityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OtherPayableRelatedToTheEquityOptionMember" name="OtherPayableRelatedToTheEquityOptionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_PublicWarrantsMember" name="PublicWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_EvanaAlphaPteLtdMember" name="EvanaAlphaPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_RevenueFromIntelligentComputingPowerServiceMember" name="RevenueFromIntelligentComputingPowerServiceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ReservedCapacityArrangementsMember" name="ReservedCapacityArrangementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OnDemandArrangementsMember" name="OnDemandArrangementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_RevenueFromComprehensiveDataCenterServicesMember" name="RevenueFromComprehensiveDataCenterServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CustomerAMember" name="CustomerAMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CustomerBMember" name="CustomerBMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CustomerCMember" name="CustomerCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CustomerDMember" name="CustomerDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CustomerEMember" name="CustomerEMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CustomerFMember" name="CustomerFMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CustomerGMember" name="CustomerGMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CustomerHMember" name="CustomerHMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CustomerIMember" name="CustomerIMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_PurchaseMember" name="PurchaseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SupplierAMember" name="SupplierAMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SupplierBMember" name="SupplierBMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SupplierCMember" name="SupplierCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SupplierDMember" name="SupplierDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SupplierEMember" name="SupplierEMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SupplierFMember" name="SupplierFMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SupplierGMember" name="SupplierGMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_EmployeeMember" name="EmployeeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_NonEmployeeMember" name="NonEmployeeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ThirdPartyServiceProviderMember" name="ThirdPartyServiceProviderMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SellingAndMarketingExpensesMember" name="SellingAndMarketingExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_GeneralAndAdministrativeExpensesMember" name="GeneralAndAdministrativeExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OthersMember" name="OthersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_DigitalAssetsMember" name="DigitalAssetsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_USDCMember" name="USDCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_DigitalAssetsAndUSDCMember" name="DigitalAssetsAndUSDCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_U.s.DollarCoin" name="U.s.DollarCoin" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_PrepaidResearchAndDevelopmentExpenses" name="PrepaidResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_AdvanceToSuppliers" name="AdvanceToSuppliers" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_RefundableDepositsReceivable" name="RefundableDepositsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CashHeldInTrustAccount" name="CashHeldInTrustAccount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SimpleAgreementsForFutureEquity" name="SimpleAgreementsForFutureEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_RefundableDepositsPayable" name="RefundableDepositsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OtherCurrentLiabilities" name="OtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_AmountDueToRelatedParty" name="AmountDueToRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SharesSubjectToRedemption" name="SharesSubjectToRedemption" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity" name="ChangeInFairValueOfSimpleAgreementsForFutureEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_LossPerOrdinaryShareAbstarct" name="LossPerOrdinaryShareAbstarct" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFee" name="CommonStockIssuedToInitialShareholderForSubscriptionFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFeeShares" name="CommonStockIssuedToInitialShareholderForSubscriptionFeeShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ClassBOrdinarySharesIssuedToSponsor" name="ClassBOrdinarySharesIssuedToSponsor" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_RedesignationOfAuthorizedOrdinaryShares" name="RedesignationOfAuthorizedOrdinaryShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ClassBOrdinarySharesIssuedToSponsorShares" name="ClassBOrdinarySharesIssuedToSponsorShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCosts" name="SaleOfPrivateUnitsNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCostsShares" name="SaleOfPrivateUnitsNetOfIssuanceCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_IssuanceOfPublicWarrantsNetOfIssuanceCosts" name="IssuanceOfPublicWarrantsNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_IssuanceOfRepresentativeShares" name="IssuanceOfRepresentativeShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_IssuanceOfRepresentativeSharesShares" name="IssuanceOfRepresentativeSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_AccretionInValueOfClassOrdinaryShares" name="AccretionInValueOfClassOrdinaryShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ReverseOverallotmentOptionLiability" name="ReverseOverallotmentOptionLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ForfeitureOfFounderShares" name="ForfeitureOfFounderShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ForfeitureOfFounderSharesShares" name="ForfeitureOfFounderSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_AdjustmentOfAccruedOfferingCosts" name="AdjustmentOfAccruedOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_RedesignationOfAuthorizedOrdinarySharesShares" name="RedesignationOfAuthorizedOrdinarySharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquities" name="ChangeInFairValueOfSimpleAgreementsForFutureEquities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin" name="OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_PaymentOfExpensesThroughRelatedParty" name="PaymentOfExpensesThroughRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_PaymentOfExpensesThroughPromissoryNoteRelatedParty" name="PaymentOfExpensesThroughPromissoryNoteRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_IncreaseDecreaseInAdvanceToSuppliers" name="IncreaseDecreaseInAdvanceToSuppliers" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_IncreaseDecreaseInRefundableDepositsReceivable" name="IncreaseDecreaseInRefundableDepositsReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_IncreaseDecreaseInRefundableDepositsPayable" name="IncreaseDecreaseInRefundableDepositsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ProceedsFromSaleOfDigitalAssetsAndUsdc" name="ProceedsFromSaleOfDigitalAssetsAndUsdc" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid" name="ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_PaymentForDeferredOfferingCosts" name="PaymentForDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ProceedsFromSimpleAgreementsForFutureEquity" name="ProceedsFromSimpleAgreementsForFutureEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_DisclosureInitialPublicOfferingAbstract" name="DisclosureInitialPublicOfferingAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_InitialPublicOfferingDisclosureTextBlock" name="InitialPublicOfferingDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_DisclosurePrivatePlacementAbstract" name="DisclosurePrivatePlacementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_PrivatePlacementDisclosureTextBlock" name="PrivatePlacementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_DisclosureOtherReceivablesAbstract" name="DisclosureOtherReceivablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OtherReceivablesTextBlock" name="OtherReceivablesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_DisclosureRefundableDepositsPayableAbstract" name="DisclosureRefundableDepositsPayableAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_RefundableDepositsPayableTextBlock" name="RefundableDepositsPayableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_DisclosureSimpleAgreementsForFutureEquityAbstract" name="DisclosureSimpleAgreementsForFutureEquityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SimpleAgreementsForFutureEquityTextBlock" name="SimpleAgreementsForFutureEquityTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_EmergingGrowthCompanyPolicyTextBlock" name="EmergingGrowthCompanyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CashHeldInTrustAccountPolicyTextBlock" name="CashHeldInTrustAccountPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock" name="OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock" name="ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_GoingConcernPolicyTextBlock" name="GoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_FunctionalCurrencyPolicyTextBlock" name="FunctionalCurrencyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ExpectedCreditLossAndAccountsReceivablePolicyTextBlock" name="ExpectedCreditLossAndAccountsReceivablePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_AdvanceToSuppliersPolicyTextBlock" name="AdvanceToSuppliersPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_RefundableDepositsReceivablePolicyTextBlock" name="RefundableDepositsReceivablePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SimpleAgreementsForFutureEquityPolicyTextBlock" name="SimpleAgreementsForFutureEquityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ContractLiabilitiesPolicyTextBlock" name="ContractLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SellingAndMarketingExpensesPolicyTextBlock" name="SellingAndMarketingExpensesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CapitalStructurePolicyTextBlock" name="CapitalStructurePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_RelatedPartiesPolicyTextBlock" name="RelatedPartiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ComprehensiveLossPolicyTextBlock" name="ComprehensiveLossPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock" name="RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CryptoAssets" name="CryptoAssets" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_PrepaidResearchAndDevelopmentExpensesPolicyTextBlock" name="PrepaidResearchAndDevelopmentExpensesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OtherReceivablesPolicyRextBlock" name="OtherReceivablesPolicyRextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_RefundableDepositsPayablePolicyTextBlock" name="RefundableDepositsPayablePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" name="OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ScheduleOfRevenueRecognitionTableTextBlock" name="ScheduleOfRevenueRecognitionTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ScheduleOfConcentrationOfCustomersTableTextBlock" name="ScheduleOfConcentrationOfCustomersTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ScheduleOfAccountsReceivableTextBlock" name="ScheduleOfAccountsReceivableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ScheduleOfConcentrationOfSuppliersTableTextBlock" name="ScheduleOfConcentrationOfSuppliersTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_AggregateConsideration" name="AggregateConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_TransactionCosts" name="TransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_RepresentativeShares" name="RepresentativeShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OtherOfferingCosts" name="OtherOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CancelledFounderShares" name="CancelledFounderShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_WorkingCapitalDeficit" name="WorkingCapitalDeficit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ProceedsAllocatedToPublicWarrants" name="ProceedsAllocatedToPublicWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ProceedsAllocatedToOverallotmentOption" name="ProceedsAllocatedToOverallotmentOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ClassOrdinarySharesIssuanceCosts" name="ClassOrdinarySharesIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OfferingCost" name="OfferingCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OtherOfferingCost" name="OtherOfferingCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination" name="PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OrdinarySharesSubjectToPossibleRedemption" name="OrdinarySharesSubjectToPossibleRedemption" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_AggregatePurchasePrice" name="AggregatePurchasePrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CancellationOfOrdinaryShares" name="CancellationOfOrdinaryShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_PeriodAfterWhichTheWarrantsAreExercisable" name="PeriodAfterWhichTheWarrantsAreExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" name="MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_NumberOfTradingDaysForDeterminingTheSharePrice" name="NumberOfTradingDaysForDeterminingTheSharePrice" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" name="NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ShareRedemptionTriggerPrices" name="ShareRedemptionTriggerPrices" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion" name="PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_FairValueOfOverallotmentOption" name="FairValueOfOverallotmentOption" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CashHeldInTrustAccounts" name="CashHeldInTrustAccounts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_StaffCostsEmployeeBenefitsAndOfficeExpenses" name="StaffCostsEmployeeBenefitsAndOfficeExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ShareBasedCompensations" name="ShareBasedCompensations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_StaffCostsEmployeeBenefitsAndOthers" name="StaffCostsEmployeeBenefitsAndOthers" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ShareBasedCompensation1" name="ShareBasedCompensation1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OrdinarySharesIssued" name="OrdinarySharesIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_RevenueRecognized" name="RevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CashAndCashEquivalentsAndU.s.DollarCoin" name="CashAndCashEquivalentsAndU.s.DollarCoin" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ReceiptOfDigitalAssets" name="ReceiptOfDigitalAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_DisbursementOfDigitalAssets" name="DisbursementOfDigitalAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_FairValueGainOrLossOnDigitalAssets" name="FairValueGainOrLossOnDigitalAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_AmortizationOfPrepaidResearchAndDevelopmentCosts" name="AmortizationOfPrepaidResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ConcentrationRiskPercentage" name="ConcentrationRiskPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_IssuanceOfSimpleAgreementsForFutureEquity" name="IssuanceOfSimpleAgreementsForFutureEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ChangeInFairValue" name="ChangeInFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_AdditionalSafesProceeds" name="AdditionalSafesProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_CumulativeProceeds" name="CumulativeProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_EquityFinancingDescription" name="EquityFinancingDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_IncomeStatementLocationsAxis" name="IncomeStatementLocationsAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="cik0002065779_IncomeStatementLocationsDomain" name="IncomeStatementLocationsDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_SharesDescription" name="SharesDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_DiscountRate" name="DiscountRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_PerpetualRate" name="PerpetualRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_GrantedEquityAward" name="GrantedEquityAward" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_ConsultingFees" name="ConsultingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OutstandingBalancesPayable" name="OutstandingBalancesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_DenominatorForBasicAndDilutedLossPerShareAbstract" name="DenominatorForBasicAndDilutedLossPerShareAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_NumeratorAbstract" name="NumeratorAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_DenominatorAbstract" name="DenominatorAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OrdinarySharesPerShare" name="OrdinarySharesPerShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_OtherCurrentAssets" name="OtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cik0002065779_TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc" name="TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>23
<FILENAME>cik0002065779-20260331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Plus; Version: 6.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#Cover" roleURI="http://cik0002065779/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BalanceSheet" roleURI="http://cik0002065779/role/BalanceSheet" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BalanceSheetParenthetical" roleURI="http://cik0002065779/role/BalanceSheetParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#StatementOfOperations" roleURI="http://cik0002065779/role/StatementOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#StatementOfChangesInStockholdersDeficit" roleURI="http://cik0002065779/role/StatementOfChangesInStockholdersDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#StatementOfCashFlows" roleURI="http://cik0002065779/role/StatementOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#DescriptionOfOrganizationAndBusinessOperations" roleURI="http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SignificantAccountingPolicies" roleURI="http://cik0002065779/role/SignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SegmentInformation" roleURI="http://cik0002065779/role/SegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BusinessCombination" roleURI="http://cik0002065779/role/BusinessCombination" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ShareCapital" roleURI="http://cik0002065779/role/ShareCapital" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SubsequentEvents" roleURI="http://cik0002065779/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#DescriptionOfOrganizationBusinessOperations" roleURI="http://cik0002065779/role/DescriptionOfOrganizationBusinessOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#InitialPublicOffering" roleURI="http://cik0002065779/role/InitialPublicOffering" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#PrivatePlacement" roleURI="http://cik0002065779/role/PrivatePlacement" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#RelatedPartyTransactions" roleURI="http://cik0002065779/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CommitmentsAndContingencies" roleURI="http://cik0002065779/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#StockholdersEquity" roleURI="http://cik0002065779/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurements" roleURI="http://cik0002065779/role/FairValueMeasurements" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#OrganizationAndPrincipalActivities" roleURI="http://cik0002065779/role/OrganizationAndPrincipalActivities" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDisclosure" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ConcentrationAndRisk" roleURI="http://cik0002065779/role/ConcentrationAndRisk" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurementsDisclosure" roleURI="http://cik0002065779/role/FairValueMeasurementsDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#AccountsReceivable" roleURI="http://cik0002065779/role/AccountsReceivable" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#OtherReceivables" roleURI="http://cik0002065779/role/OtherReceivables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#EquipmentNet" roleURI="http://cik0002065779/role/EquipmentNet" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#RefundableDepositsPayable" roleURI="http://cik0002065779/role/RefundableDepositsPayable" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SimpleAgreementsForFutureEquity" roleURI="http://cik0002065779/role/SimpleAgreementsForFutureEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#IncomeTaxes" roleURI="http://cik0002065779/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#Share-basedCompensation" roleURI="http://cik0002065779/role/Share-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#RelatedPartyTransactionsDisclosure" roleURI="http://cik0002065779/role/RelatedPartyTransactionsDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BasicAndDilutedNetLossPerShare" roleURI="http://cik0002065779/role/BasicAndDilutedNetLossPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CommitmentsAndContingenciesDisclosure" roleURI="http://cik0002065779/role/CommitmentsAndContingenciesDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CryptoAssets" roleURI="http://cik0002065779/role/CryptoAssets" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://cik0002065779/role/SignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurementsTables" roleURI="http://cik0002065779/role/FairValueMeasurementsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesTablesDisclosure" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ConcentrationAndRiskTables" roleURI="http://cik0002065779/role/ConcentrationAndRiskTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurementsTablesDisclosure" roleURI="http://cik0002065779/role/FairValueMeasurementsTablesDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#AccountsReceivableTables" roleURI="http://cik0002065779/role/AccountsReceivableTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#EquipmentNetTables" roleURI="http://cik0002065779/role/EquipmentNetTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SimpleAgreementsForFutureEquityTables" roleURI="http://cik0002065779/role/SimpleAgreementsForFutureEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#IncomeTaxesTables" roleURI="http://cik0002065779/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#Share-basedCompensationTables" roleURI="http://cik0002065779/role/Share-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BasicAndDilutedNetLossPerShareTables" roleURI="http://cik0002065779/role/BasicAndDilutedNetLossPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CryptoAssetsTables" roleURI="http://cik0002065779/role/CryptoAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#DescriptionOfOrganizationAndBusinessOperationsDetailsNarrative" roleURI="http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperationsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BusinessCombinationDetailsNarrative" roleURI="http://cik0002065779/role/BusinessCombinationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ShareCapitalDetailsNarrative" roleURI="http://cik0002065779/role/ShareCapitalDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#DescriptionOfOrganizationBusinessOperationsDetailsNarrative" roleURI="http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#InitialPublicOfferingDetailsNarrative" roleURI="http://cik0002065779/role/InitialPublicOfferingDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#PrivatePlacementDetailsNarrative" roleURI="http://cik0002065779/role/PrivatePlacementDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#StockholdersEquityDetailsNarrative" roleURI="http://cik0002065779/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurementsDetails" roleURI="http://cik0002065779/role/FairValueMeasurementsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurementsDetails1" roleURI="http://cik0002065779/role/FairValueMeasurementsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurementsDetails2" roleURI="http://cik0002065779/role/FairValueMeasurementsDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SegmentInformationDetails" roleURI="http://cik0002065779/role/SegmentInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#OrganizationAndPrincipalActivitiesDetailsNarrative" roleURI="http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetails2" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetails3" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ConcentrationAndRiskDetails" roleURI="http://cik0002065779/role/ConcentrationAndRiskDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ConcentrationAndRiskDetails1" roleURI="http://cik0002065779/role/ConcentrationAndRiskDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ConcentrationAndRiskDetails2" roleURI="http://cik0002065779/role/ConcentrationAndRiskDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ConcentrationAndRiskDetails3" roleURI="http://cik0002065779/role/ConcentrationAndRiskDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#AccountsReceivableDetails" roleURI="http://cik0002065779/role/AccountsReceivableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#AccountsReceivableDetailsNarrative" roleURI="http://cik0002065779/role/AccountsReceivableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#OtherReceivablesDetailsNarrative" roleURI="http://cik0002065779/role/OtherReceivablesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#EquipmentNetDetails" roleURI="http://cik0002065779/role/EquipmentNetDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#EquipmentNetDetailsNarrative" roleURI="http://cik0002065779/role/EquipmentNetDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#RefundableDepositsPayableDetailsNarrative" roleURI="http://cik0002065779/role/RefundableDepositsPayableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SimpleAgreementsForFutureEquityDetails" roleURI="http://cik0002065779/role/SimpleAgreementsForFutureEquityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SimpleAgreementsForFutureEquityDetailsNarrative" roleURI="http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#IncomeTaxesDetails" roleURI="http://cik0002065779/role/IncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#IncomeTaxesDetails1" roleURI="http://cik0002065779/role/IncomeTaxesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#IncomeTaxesDetails2" roleURI="http://cik0002065779/role/IncomeTaxesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#IncomeTaxesDetailsNarrative" roleURI="http://cik0002065779/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#Share-basedCompensationDetails" roleURI="http://cik0002065779/role/Share-basedCompensationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#Share-basedCompensationDetailsNarrative" roleURI="http://cik0002065779/role/Share-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#RelatedPartyTransactionsDetailsNarrativeDisclosure" roleURI="http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrativeDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BasicAndDilutedNetLossPerShareDetails" roleURI="http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SegmentInformationDetails1" roleURI="http://cik0002065779/role/SegmentInformationDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CommitmentsAndContingenciesDetailsNarrativeDisclosure" roleURI="http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CryptoAssetsDetails" roleURI="http://cik0002065779/role/CryptoAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CryptoAssetsDetails1" roleURI="http://cik0002065779/role/CryptoAssetsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CryptoAssetsDetailsNarrative" roleURI="http://cik0002065779/role/CryptoAssetsDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/BalanceSheet" xlink:title="00000002 - Statement - BALANCE SHEET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaapAccountsAndOtherReceivablesNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsAndOtherReceivablesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AdvanceToSuppliers" xlink:label="loc_cik0002065779AdvanceToSuppliers" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_cik0002065779AdvanceToSuppliers" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsReceivable" xlink:label="loc_cik0002065779RefundableDepositsReceivable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_cik0002065779RefundableDepositsReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_U.s.DollarCoin" xlink:label="loc_cik0002065779U.s.DollarCoin" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_cik0002065779U.s.DollarCoin" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PrepaidResearchAndDevelopmentExpenses" xlink:label="loc_cik0002065779PrepaidResearchAndDevelopmentExpenses" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_cik0002065779PrepaidResearchAndDevelopmentExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CashHeldInTrustAccount" xlink:label="loc_cik0002065779CashHeldInTrustAccount" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_cik0002065779CashHeldInTrustAccount" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AmountDueToRelatedParty" xlink:label="loc_cik0002065779AmountDueToRelatedParty" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_cik0002065779AmountDueToRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SimpleAgreementsForFutureEquity" xlink:label="loc_cik0002065779SimpleAgreementsForFutureEquity" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_cik0002065779SimpleAgreementsForFutureEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositContractsLiabilities" xlink:label="loc_us-gaapDepositContractsLiabilities" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDepositContractsLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsPayable" xlink:label="loc_cik0002065779RefundableDepositsPayable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_cik0002065779RefundableDepositsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherCurrentLiabilities" xlink:label="loc_cik0002065779OtherCurrentLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_cik0002065779OtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/BalanceSheetParenthetical" xlink:title="00000003 - Statement - BALANCE SHEET (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/StatementOfOperations" xlink:title="00000004 - Statement - STATEMENT OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherIncome" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity" xlink:label="loc_cik0002065779ChangeInFairValueOfSimpleAgreementsForFutureEquity" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_cik0002065779ChangeInFairValueOfSimpleAgreementsForFutureEquity" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/StatementOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - STATEMENT OF CHANGES IN STOCKHOLDERS&apos; DEFICIT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/StatementOfCashFlows" xlink:title="00000006 - Statement - STATEMENT OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PaymentOfExpensesThroughRelatedParty" xlink:label="loc_cik0002065779PaymentOfExpensesThroughRelatedParty" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cik0002065779PaymentOfExpensesThroughRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PaymentOfExpensesThroughPromissoryNoteRelatedParty" xlink:label="loc_cik0002065779PaymentOfExpensesThroughPromissoryNoteRelatedParty" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cik0002065779PaymentOfExpensesThroughPromissoryNoteRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquities" xlink:label="loc_cik0002065779ChangeInFairValueOfSimpleAgreementsForFutureEquities" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cik0002065779ChangeInFairValueOfSimpleAgreementsForFutureEquities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IncreaseDecreaseInAdvanceToSuppliers" xlink:label="loc_cik0002065779IncreaseDecreaseInAdvanceToSuppliers" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cik0002065779IncreaseDecreaseInAdvanceToSuppliers" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IncreaseDecreaseInRefundableDepositsReceivable" xlink:label="loc_cik0002065779IncreaseDecreaseInRefundableDepositsReceivable" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cik0002065779IncreaseDecreaseInRefundableDepositsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IncreaseDecreaseInRefundableDepositsPayable" xlink:label="loc_cik0002065779IncreaseDecreaseInRefundableDepositsPayable" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cik0002065779IncreaseDecreaseInRefundableDepositsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin" xlink:label="loc_cik0002065779OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cik0002065779OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaapPaymentsToAcquireRestrictedInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireRestrictedInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ProceedsFromSaleOfDigitalAssetsAndUsdc" xlink:label="loc_cik0002065779ProceedsFromSaleOfDigitalAssetsAndUsdc" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_cik0002065779ProceedsFromSaleOfDigitalAssetsAndUsdc" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid" xlink:label="loc_cik0002065779ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_cik0002065779ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="loc_us-gaapPaymentsForRepurchaseOfInitialPublicOffering" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForRepurchaseOfInitialPublicOffering" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ProceedsFromSimpleAgreementsForFutureEquity" xlink:label="loc_cik0002065779ProceedsFromSimpleAgreementsForFutureEquity" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_cik0002065779ProceedsFromSimpleAgreementsForFutureEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PaymentForDeferredOfferingCosts" xlink:label="loc_cik0002065779PaymentForDeferredOfferingCosts" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_cik0002065779PaymentForDeferredOfferingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperations" xlink:title="999007 - Disclosure - Description of Organization and Business Operations" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SignificantAccountingPolicies" xlink:title="999008 - Disclosure - Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SegmentInformation" xlink:title="999009 - Disclosure - Segment information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/BusinessCombination" xlink:title="999010 - Disclosure - Business Combination" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/ShareCapital" xlink:title="999011 - Disclosure - Share Capital" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SubsequentEvents" xlink:title="999012 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/DescriptionOfOrganizationBusinessOperations" xlink:title="999013 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPolicies" xlink:title="999014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/InitialPublicOffering" xlink:title="999015 - Disclosure - INITIAL PUBLIC OFFERING" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/PrivatePlacement" xlink:title="999016 - Disclosure - PRIVATE PLACEMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/RelatedPartyTransactions" xlink:title="999017 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/CommitmentsAndContingencies" xlink:title="999018 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/StockholdersEquity" xlink:title="999019 - Disclosure - STOCKHOLDER&#8217;S EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurements" xlink:title="999020 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/OrganizationAndPrincipalActivities" xlink:title="999021 - Disclosure - Organization and principal activities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDisclosure" xlink:title="999022 - Disclosure - Summary of significant accounting policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/ConcentrationAndRisk" xlink:title="999023 - Disclosure - Concentration and risk" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurementsDisclosure" xlink:title="999024 - Disclosure - Fair value measurements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/AccountsReceivable" xlink:title="999025 - Disclosure - Accounts receivable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/OtherReceivables" xlink:title="999026 - Disclosure - Other receivables" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/EquipmentNet" xlink:title="999027 - Disclosure - Equipment, net" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/RefundableDepositsPayable" xlink:title="999028 - Disclosure - Refundable deposits payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SimpleAgreementsForFutureEquity" xlink:title="999029 - Disclosure - Simple agreements for future equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/IncomeTaxes" xlink:title="999030 - Disclosure - Income taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/Share-basedCompensation" xlink:title="999031 - Disclosure - Share-based compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/RelatedPartyTransactionsDisclosure" xlink:title="999032 - Disclosure - Related party transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/BasicAndDilutedNetLossPerShare" xlink:title="999033 - Disclosure - Basic and diluted net loss per share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/CommitmentsAndContingenciesDisclosure" xlink:title="999034 - Disclosure - Commitments and contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/CryptoAssets" xlink:title="999035 - Disclosure - Crypto assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SignificantAccountingPoliciesPolicies" xlink:title="999036 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999037 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" xlink:title="999038 - Disclosure - Summary of significant accounting policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurementsTables" xlink:title="999040 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure" xlink:title="999041 - Disclosure - Summary of significant accounting policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/ConcentrationAndRiskTables" xlink:title="999042 - Disclosure - Concentration and risk (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurementsTablesDisclosure" xlink:title="999043 - Disclosure - Fair value measurements (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/AccountsReceivableTables" xlink:title="999044 - Disclosure - Accounts receivable (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/EquipmentNetTables" xlink:title="999045 - Disclosure - Equipment, net (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SimpleAgreementsForFutureEquityTables" xlink:title="999046 - Disclosure - Simple agreements for future equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/IncomeTaxesTables" xlink:title="999047 - Disclosure - Income taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/Share-basedCompensationTables" xlink:title="999048 - Disclosure - Share-based compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/BasicAndDilutedNetLossPerShareTables" xlink:title="999049 - Disclosure - Basic and diluted net loss per share (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/CryptoAssetsTables" xlink:title="999050 - Disclosure - Crypto assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperationsDetailsNarrative" xlink:title="999051 - Disclosure - Description of Organization and Business Operations (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/BusinessCombinationDetailsNarrative" xlink:title="999052 - Disclosure - Business Combination (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/ShareCapitalDetailsNarrative" xlink:title="999053 - Disclosure - Share Capital (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative" xlink:title="999054 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="999055 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1" xlink:title="999056 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999057 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/InitialPublicOfferingDetailsNarrative" xlink:title="999058 - Disclosure - INITIAL PUBLIC OFFERING (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/PrivatePlacementDetailsNarrative" xlink:title="999059 - Disclosure - PRIVATE PLACEMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999060 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/StockholdersEquityDetailsNarrative" xlink:title="999062 - Disclosure - STOCKHOLDER&#8217;S EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurementsDetails" xlink:title="999063 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurementsDetails1" xlink:title="999064 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurementsDetails2" xlink:title="999065 - Disclosure - FAIR VALUE MEASUREMENTS (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SegmentInformationDetails" xlink:title="999066 - Disclosure - Segment information (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative" xlink:title="999067 - Disclosure - Organization and principal activities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2" xlink:title="999068 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3" xlink:title="999069 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" xlink:title="999070 - Disclosure - Summary of significant accounting policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/ConcentrationAndRiskDetails" xlink:title="999071 - Disclosure - Concentration and risk (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/ConcentrationAndRiskDetails1" xlink:title="999072 - Disclosure - Concentration and risk (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/ConcentrationAndRiskDetails2" xlink:title="999073 - Disclosure - Concentration and risk (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/ConcentrationAndRiskDetails3" xlink:title="999074 - Disclosure - Concentration and risk (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/AccountsReceivableDetails" xlink:title="999075 - Disclosure - Accounts receivable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/AccountsReceivableDetailsNarrative" xlink:title="999076 - Disclosure - Accounts receivable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/OtherReceivablesDetailsNarrative" xlink:title="999077 - Disclosure - Other receivables (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/EquipmentNetDetails" xlink:title="999078 - Disclosure - Equipment, net (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/EquipmentNetDetailsNarrative" xlink:title="999079 - Disclosure - Equipment, net (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/RefundableDepositsPayableDetailsNarrative" xlink:title="999080 - Disclosure - Refundable deposits payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SimpleAgreementsForFutureEquityDetails" xlink:title="999081 - Disclosure - Simple agreements for future equity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative" xlink:title="999082 - Disclosure - Simple agreements for future equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/IncomeTaxesDetails" xlink:title="999083 - Disclosure - Income taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/IncomeTaxesDetails1" xlink:title="999084 - Disclosure - Income taxes (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/IncomeTaxesDetails2" xlink:title="999085 - Disclosure - Income taxes (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/IncomeTaxesDetailsNarrative" xlink:title="999086 - Disclosure - Income taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/Share-basedCompensationDetails" xlink:title="999087 - Disclosure - Share-based compensation (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/Share-basedCompensationDetailsNarrative" xlink:title="999088 - Disclosure - Share-based compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrativeDisclosure" xlink:title="999089 - Disclosure - Related party transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails" xlink:title="999090 - Disclosure - Basic and diluted net loss per share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SegmentInformationDetails1" xlink:title="999091 - Disclosure - Segment information (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure" xlink:title="999092 - Disclosure - Commitments and contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/CryptoAssetsDetails" xlink:title="999093 - Disclosure - Crypto assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/CryptoAssetsDetails1" xlink:title="999094 - Disclosure - Crypto assets (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cik0002065779/role/CryptoAssetsDetailsNarrative" xlink:title="999095 - Disclosure - Crypto assets (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>24
<FILENAME>cik0002065779-20260331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Plus; Version: 6.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#Cover" roleURI="http://cik0002065779/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BalanceSheet" roleURI="http://cik0002065779/role/BalanceSheet" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BalanceSheetParenthetical" roleURI="http://cik0002065779/role/BalanceSheetParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#StatementOfOperations" roleURI="http://cik0002065779/role/StatementOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#StatementOfChangesInStockholdersDeficit" roleURI="http://cik0002065779/role/StatementOfChangesInStockholdersDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#StatementOfCashFlows" roleURI="http://cik0002065779/role/StatementOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#DescriptionOfOrganizationAndBusinessOperations" roleURI="http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SignificantAccountingPolicies" roleURI="http://cik0002065779/role/SignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SegmentInformation" roleURI="http://cik0002065779/role/SegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BusinessCombination" roleURI="http://cik0002065779/role/BusinessCombination" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ShareCapital" roleURI="http://cik0002065779/role/ShareCapital" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SubsequentEvents" roleURI="http://cik0002065779/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#DescriptionOfOrganizationBusinessOperations" roleURI="http://cik0002065779/role/DescriptionOfOrganizationBusinessOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#InitialPublicOffering" roleURI="http://cik0002065779/role/InitialPublicOffering" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#PrivatePlacement" roleURI="http://cik0002065779/role/PrivatePlacement" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#RelatedPartyTransactions" roleURI="http://cik0002065779/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CommitmentsAndContingencies" roleURI="http://cik0002065779/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#StockholdersEquity" roleURI="http://cik0002065779/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurements" roleURI="http://cik0002065779/role/FairValueMeasurements" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#OrganizationAndPrincipalActivities" roleURI="http://cik0002065779/role/OrganizationAndPrincipalActivities" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDisclosure" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ConcentrationAndRisk" roleURI="http://cik0002065779/role/ConcentrationAndRisk" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurementsDisclosure" roleURI="http://cik0002065779/role/FairValueMeasurementsDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#AccountsReceivable" roleURI="http://cik0002065779/role/AccountsReceivable" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#OtherReceivables" roleURI="http://cik0002065779/role/OtherReceivables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#EquipmentNet" roleURI="http://cik0002065779/role/EquipmentNet" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#RefundableDepositsPayable" roleURI="http://cik0002065779/role/RefundableDepositsPayable" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SimpleAgreementsForFutureEquity" roleURI="http://cik0002065779/role/SimpleAgreementsForFutureEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#IncomeTaxes" roleURI="http://cik0002065779/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#Share-basedCompensation" roleURI="http://cik0002065779/role/Share-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#RelatedPartyTransactionsDisclosure" roleURI="http://cik0002065779/role/RelatedPartyTransactionsDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BasicAndDilutedNetLossPerShare" roleURI="http://cik0002065779/role/BasicAndDilutedNetLossPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CommitmentsAndContingenciesDisclosure" roleURI="http://cik0002065779/role/CommitmentsAndContingenciesDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CryptoAssets" roleURI="http://cik0002065779/role/CryptoAssets" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://cik0002065779/role/SignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurementsTables" roleURI="http://cik0002065779/role/FairValueMeasurementsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesTablesDisclosure" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ConcentrationAndRiskTables" roleURI="http://cik0002065779/role/ConcentrationAndRiskTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurementsTablesDisclosure" roleURI="http://cik0002065779/role/FairValueMeasurementsTablesDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#AccountsReceivableTables" roleURI="http://cik0002065779/role/AccountsReceivableTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#EquipmentNetTables" roleURI="http://cik0002065779/role/EquipmentNetTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SimpleAgreementsForFutureEquityTables" roleURI="http://cik0002065779/role/SimpleAgreementsForFutureEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#IncomeTaxesTables" roleURI="http://cik0002065779/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#Share-basedCompensationTables" roleURI="http://cik0002065779/role/Share-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BasicAndDilutedNetLossPerShareTables" roleURI="http://cik0002065779/role/BasicAndDilutedNetLossPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CryptoAssetsTables" roleURI="http://cik0002065779/role/CryptoAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#DescriptionOfOrganizationAndBusinessOperationsDetailsNarrative" roleURI="http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperationsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BusinessCombinationDetailsNarrative" roleURI="http://cik0002065779/role/BusinessCombinationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ShareCapitalDetailsNarrative" roleURI="http://cik0002065779/role/ShareCapitalDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#DescriptionOfOrganizationBusinessOperationsDetailsNarrative" roleURI="http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#InitialPublicOfferingDetailsNarrative" roleURI="http://cik0002065779/role/InitialPublicOfferingDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#PrivatePlacementDetailsNarrative" roleURI="http://cik0002065779/role/PrivatePlacementDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#StockholdersEquityDetailsNarrative" roleURI="http://cik0002065779/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurementsDetails" roleURI="http://cik0002065779/role/FairValueMeasurementsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurementsDetails1" roleURI="http://cik0002065779/role/FairValueMeasurementsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurementsDetails2" roleURI="http://cik0002065779/role/FairValueMeasurementsDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SegmentInformationDetails" roleURI="http://cik0002065779/role/SegmentInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#OrganizationAndPrincipalActivitiesDetailsNarrative" roleURI="http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetails2" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetails3" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ConcentrationAndRiskDetails" roleURI="http://cik0002065779/role/ConcentrationAndRiskDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ConcentrationAndRiskDetails1" roleURI="http://cik0002065779/role/ConcentrationAndRiskDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ConcentrationAndRiskDetails2" roleURI="http://cik0002065779/role/ConcentrationAndRiskDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ConcentrationAndRiskDetails3" roleURI="http://cik0002065779/role/ConcentrationAndRiskDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#AccountsReceivableDetails" roleURI="http://cik0002065779/role/AccountsReceivableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#AccountsReceivableDetailsNarrative" roleURI="http://cik0002065779/role/AccountsReceivableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#OtherReceivablesDetailsNarrative" roleURI="http://cik0002065779/role/OtherReceivablesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#EquipmentNetDetails" roleURI="http://cik0002065779/role/EquipmentNetDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#EquipmentNetDetailsNarrative" roleURI="http://cik0002065779/role/EquipmentNetDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#RefundableDepositsPayableDetailsNarrative" roleURI="http://cik0002065779/role/RefundableDepositsPayableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SimpleAgreementsForFutureEquityDetails" roleURI="http://cik0002065779/role/SimpleAgreementsForFutureEquityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SimpleAgreementsForFutureEquityDetailsNarrative" roleURI="http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#IncomeTaxesDetails" roleURI="http://cik0002065779/role/IncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#IncomeTaxesDetails1" roleURI="http://cik0002065779/role/IncomeTaxesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#IncomeTaxesDetails2" roleURI="http://cik0002065779/role/IncomeTaxesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#IncomeTaxesDetailsNarrative" roleURI="http://cik0002065779/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#Share-basedCompensationDetails" roleURI="http://cik0002065779/role/Share-basedCompensationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#Share-basedCompensationDetailsNarrative" roleURI="http://cik0002065779/role/Share-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#RelatedPartyTransactionsDetailsNarrativeDisclosure" roleURI="http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrativeDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BasicAndDilutedNetLossPerShareDetails" roleURI="http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SegmentInformationDetails1" roleURI="http://cik0002065779/role/SegmentInformationDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CommitmentsAndContingenciesDetailsNarrativeDisclosure" roleURI="http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CryptoAssetsDetails" roleURI="http://cik0002065779/role/CryptoAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CryptoAssetsDetails1" roleURI="http://cik0002065779/role/CryptoAssetsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CryptoAssetsDetailsNarrative" roleURI="http://cik0002065779/role/CryptoAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/BalanceSheet" xlink:title="00000002 - Statement - BALANCE SHEET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassAOrdinarySharesMember" xlink:label="loc_cik0002065779ClassAOrdinarySharesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779ClassAOrdinarySharesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassBOrdinarySharesMember" xlink:label="loc_cik0002065779ClassBOrdinarySharesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779ClassBOrdinarySharesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrentAbstract_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_U.s.DollarCoin" xlink:label="loc_cik0002065779U.s.DollarCoin_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779U.s.DollarCoin_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaapAccountsAndOtherReceivablesNetCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsAndOtherReceivablesNetCurrent_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PrepaidResearchAndDevelopmentExpenses" xlink:label="loc_cik0002065779PrepaidResearchAndDevelopmentExpenses_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779PrepaidResearchAndDevelopmentExpenses_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AdvanceToSuppliers" xlink:label="loc_cik0002065779AdvanceToSuppliers_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779AdvanceToSuppliers_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsReceivable" xlink:label="loc_cik0002065779RefundableDepositsReceivable_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RefundableDepositsReceivable_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrent_160" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent_160" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsNoncurrentAbstract_160" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_160" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_160" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsNoncurrent_160" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CashHeldInTrustAccount" xlink:label="loc_cik0002065779CashHeldInTrustAccount_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CashHeldInTrustAccount_160" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets_160" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_160" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_160" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_160" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_160" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_160" xlink:to="loc_us-gaapAccountsPayableCurrent_160" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SimpleAgreementsForFutureEquity" xlink:label="loc_cik0002065779SimpleAgreementsForFutureEquity_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_160" xlink:to="loc_cik0002065779SimpleAgreementsForFutureEquity_160" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositContractsLiabilities" xlink:label="loc_us-gaapDepositContractsLiabilities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_160" xlink:to="loc_us-gaapDepositContractsLiabilities_160" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsPayable" xlink:label="loc_cik0002065779RefundableDepositsPayable_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_160" xlink:to="loc_cik0002065779RefundableDepositsPayable_160" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherCurrentLiabilities" xlink:label="loc_cik0002065779OtherCurrentLiabilities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_160" xlink:to="loc_cik0002065779OtherCurrentLiabilities_160" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AmountDueToRelatedParty" xlink:label="loc_cik0002065779AmountDueToRelatedParty_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_160" xlink:to="loc_cik0002065779AmountDueToRelatedParty_160" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaapLiabilitiesCurrent_160" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities_160" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommitmentsAndContingencies_160" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_160" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract_160" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockValue_160" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockValue_160" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital_160" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_160" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable_160" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_160" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_160" xlink:type="arc" order="37" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/BalanceSheetParenthetical" xlink:title="00000003 - Statement - BALANCE SHEET (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassAOrdinarySharesMember" xlink:label="loc_cik0002065779ClassAOrdinarySharesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779ClassAOrdinarySharesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassBOrdinarySharesMember" xlink:label="loc_cik0002065779ClassBOrdinarySharesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779ClassBOrdinarySharesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesClassBMember" xlink:label="loc_cik0002065779OrdinarySharesClassBMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_cik0002065779OrdinarySharesClassBMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesClassAMember" xlink:label="loc_cik0002065779OrdinarySharesClassAMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_cik0002065779OrdinarySharesClassAMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaapTemporaryEquityRedemptionPricePerShare_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityRedemptionPricePerShare_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_150" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_150" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SharesSubjectToRedemption" xlink:label="loc_cik0002065779SharesSubjectToRedemption_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779SharesSubjectToRedemption_150" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/StatementOfOperations" xlink:title="00000004 - Statement - STATEMENT OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesClassAMember" xlink:label="loc_cik0002065779OrdinarySharesClassAMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779OrdinarySharesClassAMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesClassBMember" xlink:label="loc_cik0002065779OrdinarySharesClassBMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779OrdinarySharesClassBMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpenses_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity" xlink:label="loc_cik0002065779ChangeInFairValueOfSimpleAgreementsForFutureEquity_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ChangeInFairValueOfSimpleAgreementsForFutureEquity_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAbstract" xlink:label="loc_us-gaapOtherIncomeAbstract_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherIncomeAbstract_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestIncomeOther_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherIncome_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfRevenue_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSellingAndMarketingExpense_180" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_180" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_180" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_180" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_180" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_180" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract_180" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_180" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_180" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_LossPerOrdinaryShareAbstarct" xlink:label="loc_cik0002065779LossPerOrdinaryShareAbstarct_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779LossPerOrdinaryShareAbstarct_180" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_180" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_180" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/StatementOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - STATEMENT OF CHANGES IN STOCKHOLDERS&apos; DEFICIT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SubscriptionReceivableMember" xlink:label="loc_cik0002065779SubscriptionReceivableMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_cik0002065779SubscriptionReceivableMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesClassAMember" xlink:label="loc_cik0002065779OrdinarySharesClassAMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_cik0002065779OrdinarySharesClassAMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesClassBMember" xlink:label="loc_cik0002065779OrdinarySharesClassBMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_cik0002065779OrdinarySharesClassBMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesMember" xlink:label="loc_cik0002065779OrdinarySharesMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_cik0002065779OrdinarySharesMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralArcMergerCorporationMember" xlink:label="loc_cik0002065779DBoralArcMergerCorporationMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralArcMergerCorporationMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFee" xlink:label="loc_cik0002065779CommonStockIssuedToInitialShareholderForSubscriptionFee_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CommonStockIssuedToInitialShareholderForSubscriptionFee_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFeeShares" xlink:label="loc_cik0002065779CommonStockIssuedToInitialShareholderForSubscriptionFeeShares_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CommonStockIssuedToInitialShareholderForSubscriptionFeeShares_200" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_200" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassBOrdinarySharesIssuedToSponsor" xlink:label="loc_cik0002065779ClassBOrdinarySharesIssuedToSponsor_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ClassBOrdinarySharesIssuedToSponsor_200" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RedesignationOfAuthorizedOrdinaryShares" xlink:label="loc_cik0002065779RedesignationOfAuthorizedOrdinaryShares_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RedesignationOfAuthorizedOrdinaryShares_200" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassBOrdinarySharesIssuedToSponsorShares" xlink:label="loc_cik0002065779ClassBOrdinarySharesIssuedToSponsorShares_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ClassBOrdinarySharesIssuedToSponsorShares_200" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCosts" xlink:label="loc_cik0002065779SaleOfPrivateUnitsNetOfIssuanceCosts_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779SaleOfPrivateUnitsNetOfIssuanceCosts_200" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCostsShares" xlink:label="loc_cik0002065779SaleOfPrivateUnitsNetOfIssuanceCostsShares_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779SaleOfPrivateUnitsNetOfIssuanceCostsShares_200" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IssuanceOfPublicWarrantsNetOfIssuanceCosts" xlink:label="loc_cik0002065779IssuanceOfPublicWarrantsNetOfIssuanceCosts_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779IssuanceOfPublicWarrantsNetOfIssuanceCosts_200" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IssuanceOfRepresentativeShares" xlink:label="loc_cik0002065779IssuanceOfRepresentativeShares_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779IssuanceOfRepresentativeShares_200" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IssuanceOfRepresentativeSharesShares" xlink:label="loc_cik0002065779IssuanceOfRepresentativeSharesShares_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779IssuanceOfRepresentativeSharesShares_200" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AccretionInValueOfClassOrdinaryShares" xlink:label="loc_cik0002065779AccretionInValueOfClassOrdinaryShares_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779AccretionInValueOfClassOrdinaryShares_200" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ReverseOverallotmentOptionLiability" xlink:label="loc_cik0002065779ReverseOverallotmentOptionLiability_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ReverseOverallotmentOptionLiability_200" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ForfeitureOfFounderShares" xlink:label="loc_cik0002065779ForfeitureOfFounderShares_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ForfeitureOfFounderShares_200" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ForfeitureOfFounderSharesShares" xlink:label="loc_cik0002065779ForfeitureOfFounderSharesShares_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ForfeitureOfFounderSharesShares_200" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AdjustmentOfAccruedOfferingCosts" xlink:label="loc_cik0002065779AdjustmentOfAccruedOfferingCosts_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779AdjustmentOfAccruedOfferingCosts_200" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RedesignationOfAuthorizedOrdinarySharesShares" xlink:label="loc_cik0002065779RedesignationOfAuthorizedOrdinarySharesShares_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RedesignationOfAuthorizedOrdinarySharesShares_200" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/StatementOfCashFlows" xlink:title="00000006 - Statement - STATEMENT OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_100" xlink:to="loc_us-gaapNetIncomeLoss_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_100" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquities" xlink:label="loc_cik0002065779ChangeInFairValueOfSimpleAgreementsForFutureEquities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ChangeInFairValueOfSimpleAgreementsForFutureEquities_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin" xlink:label="loc_cik0002065779OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_100" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PaymentOfExpensesThroughRelatedParty" xlink:label="loc_cik0002065779PaymentOfExpensesThroughRelatedParty_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_100" xlink:to="loc_cik0002065779PaymentOfExpensesThroughRelatedParty_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_100" xlink:to="loc_us-gaapInterestIncomeOther_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PaymentOfExpensesThroughPromissoryNoteRelatedParty" xlink:label="loc_cik0002065779PaymentOfExpensesThroughPromissoryNoteRelatedParty_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_100" xlink:to="loc_cik0002065779PaymentOfExpensesThroughPromissoryNoteRelatedParty_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_100" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_100" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IncreaseDecreaseInAdvanceToSuppliers" xlink:label="loc_cik0002065779IncreaseDecreaseInAdvanceToSuppliers_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_100" xlink:to="loc_cik0002065779IncreaseDecreaseInAdvanceToSuppliers_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_100" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IncreaseDecreaseInRefundableDepositsReceivable" xlink:label="loc_cik0002065779IncreaseDecreaseInRefundableDepositsReceivable_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_100" xlink:to="loc_cik0002065779IncreaseDecreaseInRefundableDepositsReceivable_100" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_100" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables_100" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_100" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_100" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_100" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability_100" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IncreaseDecreaseInRefundableDepositsPayable" xlink:label="loc_cik0002065779IncreaseDecreaseInRefundableDepositsPayable_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_100" xlink:to="loc_cik0002065779IncreaseDecreaseInRefundableDepositsPayable_100" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_100" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities_100" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_100" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaapPaymentsToAcquireRestrictedInvestments_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:to="loc_us-gaapPaymentsToAcquireRestrictedInvestments_100" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ProceedsFromSaleOfDigitalAssetsAndUsdc" xlink:label="loc_cik0002065779ProceedsFromSaleOfDigitalAssetsAndUsdc_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:to="loc_cik0002065779ProceedsFromSaleOfDigitalAssetsAndUsdc_100" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_100" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_100" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_100" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_100" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_100" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid" xlink:label="loc_cik0002065779ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_100" xlink:to="loc_cik0002065779ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid_100" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_100" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_100" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_100" xlink:to="loc_us-gaapRepaymentsOfDebt_100" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="loc_us-gaapPaymentsForRepurchaseOfInitialPublicOffering_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_100" xlink:to="loc_us-gaapPaymentsForRepurchaseOfInitialPublicOffering_100" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PaymentForDeferredOfferingCosts" xlink:label="loc_cik0002065779PaymentForDeferredOfferingCosts_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_100" xlink:to="loc_cik0002065779PaymentForDeferredOfferingCosts_100" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ProceedsFromSimpleAgreementsForFutureEquity" xlink:label="loc_cik0002065779ProceedsFromSimpleAgreementsForFutureEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_100" xlink:to="loc_cik0002065779ProceedsFromSimpleAgreementsForFutureEquity_100" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_100" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_100" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_100" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_100" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_100" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_100" xlink:to="loc_us-gaapStockIssued1_100" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaapNotesIssued1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNotesIssued1_100" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionDebtAssumed1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionDebtAssumed1_100" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionDescription" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionDescription_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionDescription_100" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_100" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionInventoryAcquired1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionInventoryAcquired1_100" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAssumed1" xlink:label="loc_us-gaapNotesAssumed1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNotesAssumed1_100" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract_100" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxesPaid_100" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestPaid_100" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansAssumed1" xlink:label="loc_us-gaapLoansAssumed1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLoansAssumed1_100" xlink:type="arc" order="51" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperations" xlink:title="999007 - Disclosure - Description of Organization and Business Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SignificantAccountingPolicies" xlink:title="999008 - Disclosure - Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SegmentInformation" xlink:title="999009 - Disclosure - Segment information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/BusinessCombination" xlink:title="999010 - Disclosure - Business Combination" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/ShareCapital" xlink:title="999011 - Disclosure - Share Capital" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SubsequentEvents" xlink:title="999012 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSubsequentEventsTextBlock_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/DescriptionOfOrganizationBusinessOperations" xlink:title="999013 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNatureOfOperations_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPolicies" xlink:title="999014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/InitialPublicOffering" xlink:title="999015 - Disclosure - INITIAL PUBLIC OFFERING">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_InitialPublicOfferingDisclosureTextBlock" xlink:label="loc_cik0002065779InitialPublicOfferingDisclosureTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779InitialPublicOfferingDisclosureTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/PrivatePlacement" xlink:title="999016 - Disclosure - PRIVATE PLACEMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PrivatePlacementDisclosureTextBlock" xlink:label="loc_cik0002065779PrivatePlacementDisclosureTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779PrivatePlacementDisclosureTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/RelatedPartyTransactions" xlink:title="999017 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/CommitmentsAndContingencies" xlink:title="999018 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/StockholdersEquity" xlink:title="999019 - Disclosure - STOCKHOLDER&#8217;S EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurements" xlink:title="999020 - Disclosure - FAIR VALUE MEASUREMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/OrganizationAndPrincipalActivities" xlink:title="999021 - Disclosure - Organization and principal activities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNatureOfOperations_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDisclosure" xlink:title="999022 - Disclosure - Summary of significant accounting policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/ConcentrationAndRisk" xlink:title="999023 - Disclosure - Concentration and risk">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurementsDisclosure" xlink:title="999024 - Disclosure - Fair value measurements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/AccountsReceivable" xlink:title="999025 - Disclosure - Accounts receivable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:label="loc_us-gaapAccountsAndNontradeReceivableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsAndNontradeReceivableTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/OtherReceivables" xlink:title="999026 - Disclosure - Other receivables">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherReceivablesTextBlock" xlink:label="loc_cik0002065779OtherReceivablesTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779OtherReceivablesTextBlock_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/EquipmentNet" xlink:title="999027 - Disclosure - Equipment, net">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/RefundableDepositsPayable" xlink:title="999028 - Disclosure - Refundable deposits payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsPayableTextBlock" xlink:label="loc_cik0002065779RefundableDepositsPayableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RefundableDepositsPayableTextBlock_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SimpleAgreementsForFutureEquity" xlink:title="999029 - Disclosure - Simple agreements for future equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SimpleAgreementsForFutureEquityTextBlock" xlink:label="loc_cik0002065779SimpleAgreementsForFutureEquityTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779SimpleAgreementsForFutureEquityTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/IncomeTaxes" xlink:title="999030 - Disclosure - Income taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/Share-basedCompensation" xlink:title="999031 - Disclosure - Share-based compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/RelatedPartyTransactionsDisclosure" xlink:title="999032 - Disclosure - Related party transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/BasicAndDilutedNetLossPerShare" xlink:title="999033 - Disclosure - Basic and diluted net loss per share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/CommitmentsAndContingenciesDisclosure" xlink:title="999034 - Disclosure - Commitments and contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/CryptoAssets" xlink:title="999035 - Disclosure - Crypto assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetTextBlock" xlink:label="loc_us-gaapCryptoAssetTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCryptoAssetTextBlock_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SignificantAccountingPoliciesPolicies" xlink:title="999036 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999037 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EmergingGrowthCompanyPolicyTextBlock" xlink:label="loc_cik0002065779EmergingGrowthCompanyPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779EmergingGrowthCompanyPolicyTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUseOfEstimates_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CashHeldInTrustAccountPolicyTextBlock" xlink:label="loc_cik0002065779CashHeldInTrustAccountPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CashHeldInTrustAccountPolicyTextBlock_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock" xlink:label="loc_cik0002065779OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="loc_us-gaapDerivativesReportingOfDerivativeActivity_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativesReportingOfDerivativeActivity_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtendedProductWarrantyPolicy" xlink:label="loc_us-gaapExtendedProductWarrantyPolicy_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapExtendedProductWarrantyPolicy_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock" xlink:label="loc_cik0002065779ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConcentrationRiskCreditRisk_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_cik0002065779RisksAndUncertaintiesPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RisksAndUncertaintiesPolicyTextBlock_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_40" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" xlink:title="999038 - Disclosure - Summary of significant accounting policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_GoingConcernPolicyTextBlock" xlink:label="loc_cik0002065779GoingConcernPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779GoingConcernPolicyTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUseOfEstimates_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_FunctionalCurrencyPolicyTextBlock" xlink:label="loc_cik0002065779FunctionalCurrencyPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779FunctionalCurrencyPolicyTextBlock_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExpectedCreditLossAndAccountsReceivablePolicyTextBlock" xlink:label="loc_cik0002065779ExpectedCreditLossAndAccountsReceivablePolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ExpectedCreditLossAndAccountsReceivablePolicyTextBlock_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AdvanceToSuppliersPolicyTextBlock" xlink:label="loc_cik0002065779AdvanceToSuppliersPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779AdvanceToSuppliersPolicyTextBlock_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsReceivablePolicyTextBlock" xlink:label="loc_cik0002065779RefundableDepositsReceivablePolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RefundableDepositsReceivablePolicyTextBlock_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SimpleAgreementsForFutureEquityPolicyTextBlock" xlink:label="loc_cik0002065779SimpleAgreementsForFutureEquityPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779SimpleAgreementsForFutureEquityPolicyTextBlock_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionDeferredRevenue" xlink:label="loc_us-gaapRevenueRecognitionDeferredRevenue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueRecognitionDeferredRevenue_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ContractLiabilitiesPolicyTextBlock" xlink:label="loc_cik0002065779ContractLiabilitiesPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ContractLiabilitiesPolicyTextBlock_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaapCostOfSalesPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfSalesPolicyTextBlock_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SellingAndMarketingExpensesPolicyTextBlock" xlink:label="loc_cik0002065779SellingAndMarketingExpensesPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779SellingAndMarketingExpensesPolicyTextBlock_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CapitalStructurePolicyTextBlock" xlink:label="loc_cik0002065779CapitalStructurePolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CapitalStructurePolicyTextBlock_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RelatedPartiesPolicyTextBlock" xlink:label="loc_cik0002065779RelatedPartiesPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RelatedPartiesPolicyTextBlock_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ComprehensiveLossPolicyTextBlock" xlink:label="loc_cik0002065779ComprehensiveLossPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ComprehensiveLossPolicyTextBlock_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionDividends" xlink:label="loc_us-gaapRevenueRecognitionDividends_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueRecognitionDividends_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock" xlink:label="loc_cik0002065779RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EmergingGrowthCompanyPolicyTextBlock" xlink:label="loc_cik0002065779EmergingGrowthCompanyPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779EmergingGrowthCompanyPolicyTextBlock_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CryptoAssets" xlink:label="loc_cik0002065779CryptoAssets_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CryptoAssets_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DeferredOfferingCostsPolicyTextBlock" xlink:label="loc_cik0002065779DeferredOfferingCostsPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779DeferredOfferingCostsPolicyTextBlock_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PrepaidResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="loc_cik0002065779PrepaidResearchAndDevelopmentExpensesPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779PrepaidResearchAndDevelopmentExpensesPolicyTextBlock_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherReceivablesPolicyRextBlock" xlink:label="loc_cik0002065779OtherReceivablesPolicyRextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779OtherReceivablesPolicyRextBlock_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsPayablePolicyTextBlock" xlink:label="loc_cik0002065779RefundableDepositsPayablePolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RefundableDepositsPayablePolicyTextBlock_40" xlink:type="arc" order="33" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaapTemporaryEquityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurementsTables" xlink:title="999040 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_cik0002065779OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_60" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure" xlink:title="999041 - Disclosure - Summary of significant accounting policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ScheduleOfRevenueRecognitionTableTextBlock" xlink:label="loc_cik0002065779ScheduleOfRevenueRecognitionTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ScheduleOfRevenueRecognitionTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/ConcentrationAndRiskTables" xlink:title="999042 - Disclosure - Concentration and risk (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ScheduleOfConcentrationOfCustomersTableTextBlock" xlink:label="loc_cik0002065779ScheduleOfConcentrationOfCustomersTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ScheduleOfConcentrationOfCustomersTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ScheduleOfAccountsReceivableTextBlock" xlink:label="loc_cik0002065779ScheduleOfAccountsReceivableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ScheduleOfAccountsReceivableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ScheduleOfConcentrationOfSuppliersTableTextBlock" xlink:label="loc_cik0002065779ScheduleOfConcentrationOfSuppliersTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ScheduleOfConcentrationOfSuppliersTableTextBlock_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurementsTablesDisclosure" xlink:title="999043 - Disclosure - Fair value measurements (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/AccountsReceivableTables" xlink:title="999044 - Disclosure - Accounts receivable (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/EquipmentNetTables" xlink:title="999045 - Disclosure - Equipment, net (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SimpleAgreementsForFutureEquityTables" xlink:title="999046 - Disclosure - Simple agreements for future equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/IncomeTaxesTables" xlink:title="999047 - Disclosure - Income taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaapSummaryOfValuationAllowanceTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSummaryOfValuationAllowanceTextBlock_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/Share-basedCompensationTables" xlink:title="999048 - Disclosure - Share-based compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/BasicAndDilutedNetLossPerShareTables" xlink:title="999049 - Disclosure - Basic and diluted net loss per share (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/CryptoAssetsTables" xlink:title="999050 - Disclosure - Crypto assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetActivityTableTextBlock" xlink:label="loc_us-gaapCryptoAssetActivityTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCryptoAssetActivityTableTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowOperatingCapitalTableTextBlock" xlink:label="loc_us-gaapCashFlowOperatingCapitalTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFlowOperatingCapitalTableTextBlock_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperationsDetailsNarrative" xlink:title="999051 - Disclosure - Description of Organization and Business Operations (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/BusinessCombinationDetailsNarrative" xlink:title="999052 - Disclosure - Business Combination (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorp.Member" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorp.Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorp.Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AggregateConsideration" xlink:label="loc_cik0002065779AggregateConsideration_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_cik0002065779AggregateConsideration_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapSharePrice_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/ShareCapitalDetailsNarrative" xlink:title="999053 - Disclosure - Share Capital (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative" xlink:title="999054 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_UnderwriterMember" xlink:label="loc_cik0002065779UnderwriterMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cik0002065779UnderwriterMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SponsorMember" xlink:label="loc_cik0002065779SponsorMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cik0002065779SponsorMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_FounderSharesMember" xlink:label="loc_cik0002065779FounderSharesMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779FounderSharesMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_TransactionCosts" xlink:label="loc_cik0002065779TransactionCosts_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779TransactionCosts_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RepresentativeShares" xlink:label="loc_cik0002065779RepresentativeShares_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RepresentativeShares_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherOfferingCosts" xlink:label="loc_cik0002065779OtherOfferingCosts_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779OtherOfferingCosts_200" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_200" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_200" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_200" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CancelledFounderShares" xlink:label="loc_cik0002065779CancelledFounderShares_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CancelledFounderShares_200" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" xlink:label="loc_us-gaapLiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_200" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash_200" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_WorkingCapitalDeficit" xlink:label="loc_cik0002065779WorkingCapitalDeficit_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779WorkingCapitalDeficit_200" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_200" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLoansPayable_200" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaapRepaymentOfNotesReceivableFromRelatedParties_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRepaymentOfNotesReceivableFromRelatedParties_200" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="999055 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="loc_us-gaapTemporaryEquityValueExcludingAdditionalPaidInCapital_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityValueExcludingAdditionalPaidInCapital_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ProceedsAllocatedToPublicWarrants" xlink:label="loc_cik0002065779ProceedsAllocatedToPublicWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ProceedsAllocatedToPublicWarrants_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ProceedsAllocatedToOverallotmentOption" xlink:label="loc_cik0002065779ProceedsAllocatedToOverallotmentOption_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ProceedsAllocatedToOverallotmentOption_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassOrdinarySharesIssuanceCosts" xlink:label="loc_cik0002065779ClassOrdinarySharesIssuanceCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ClassOrdinarySharesIssuanceCosts_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaapTemporaryEquityAccretionToRedemptionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityAccretionToRedemptionValue_60" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1" xlink:title="999056 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesClassAMember" xlink:label="loc_cik0002065779OrdinarySharesClassAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779OrdinarySharesClassAMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesClassBMember" xlink:label="loc_cik0002065779OrdinarySharesClassBMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779OrdinarySharesClassBMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999057 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CashHeldInTrustAccount" xlink:label="loc_cik0002065779CashHeldInTrustAccount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CashHeldInTrustAccount_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OfferingCost" xlink:label="loc_cik0002065779OfferingCost_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779OfferingCost_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RepresentativeShares" xlink:label="loc_cik0002065779RepresentativeShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RepresentativeShares_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherOfferingCost" xlink:label="loc_cik0002065779OtherOfferingCost_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779OtherOfferingCost_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherExpenses_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaapClassOfWarrantOrRightUnissued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightUnissued_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" xlink:label="loc_us-gaapWeightedAverageLimitedPartnershipUnitsOutstandingDiluted_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageLimitedPartnershipUnitsOutstandingDiluted_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_90" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/InitialPublicOfferingDetailsNarrative" xlink:title="999058 - Disclosure - INITIAL PUBLIC OFFERING (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/PrivatePlacementDetailsNarrative" xlink:title="999059 - Disclosure - PRIVATE PLACEMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999060 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_FounderMember" xlink:label="loc_cik0002065779FounderMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_cik0002065779FounderMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_UnsecuredPromissoryNoteMember" xlink:label="loc_cik0002065779UnsecuredPromissoryNoteMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_cik0002065779UnsecuredPromissoryNoteMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SponsorMember" xlink:label="loc_cik0002065779SponsorMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cik0002065779SponsorMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCash_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CancelledFounderShares" xlink:label="loc_cik0002065779CancelledFounderShares_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_cik0002065779CancelledFounderShares_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination" xlink:label="loc_cik0002065779PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_cik0002065779PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaapRepaymentOfNotesReceivableFromRelatedParties_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentOfNotesReceivableFromRelatedParties_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="loc_us-gaapPaymentsForRepurchaseOfInitialPublicOffering_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfInitialPublicOffering_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDistributionsToAffiliates" xlink:label="loc_us-gaapPaymentsOfDistributionsToAffiliates_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsOfDistributionsToAffiliates_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdministrativeFeesExpense" xlink:label="loc_us-gaapAdministrativeFeesExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAdministrativeFeesExpense_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1_170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_170" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_UnderwriterMember" xlink:label="loc_cik0002065779UnderwriterMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cik0002065779UnderwriterMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/StockholdersEquityDetailsNarrative" xlink:title="999062 - Disclosure - STOCKHOLDER&#8217;S EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassAOrdinarySharesMember" xlink:label="loc_cik0002065779ClassAOrdinarySharesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779ClassAOrdinarySharesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassBOrdinarySharesMember" xlink:label="loc_cik0002065779ClassBOrdinarySharesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779ClassBOrdinarySharesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CommonStockClassBMember" xlink:label="loc_cik0002065779CommonStockClassBMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779CommonStockClassBMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassAOrdinaryShareMember" xlink:label="loc_cik0002065779ClassAOrdinaryShareMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779ClassAOrdinaryShareMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SponsorMember" xlink:label="loc_cik0002065779SponsorMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cik0002065779SponsorMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassAOrdinarySharesMember" xlink:label="loc_cik0002065779ClassAOrdinarySharesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_cik0002065779ClassAOrdinarySharesMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_WarrantsMember" xlink:label="loc_cik0002065779WarrantsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cik0002065779WarrantsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaapConversionOfStockNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" xlink:to="loc_us-gaapConversionOfStockNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaapConversionOfStockNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" xlink:to="loc_us-gaapConversionOfStockNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ConversionOfClassBToClassACommonStockMember" xlink:label="loc_cik0002065779ConversionOfClassBToClassACommonStockMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConversionOfStockNameDomain" xlink:to="loc_cik0002065779ConversionOfClassBToClassACommonStockMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesSubjectToPossibleRedemption" xlink:label="loc_cik0002065779OrdinarySharesSubjectToPossibleRedemption_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_cik0002065779OrdinarySharesSubjectToPossibleRedemption_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AggregatePurchasePrice" xlink:label="loc_cik0002065779AggregatePurchasePrice_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_cik0002065779AggregatePurchasePrice_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_190" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CancellationOfOrdinaryShares" xlink:label="loc_cik0002065779CancellationOfOrdinaryShares_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_cik0002065779CancellationOfOrdinaryShares_190" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_190" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaapCommonStockConversionBasis_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockConversionBasis_190" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PeriodAfterWhichTheWarrantsAreExercisable" xlink:label="loc_cik0002065779PeriodAfterWhichTheWarrantsAreExercisable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_cik0002065779PeriodAfterWhichTheWarrantsAreExercisable_190" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_190" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" xlink:label="loc_cik0002065779MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_cik0002065779MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants_190" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_190" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:label="loc_cik0002065779NumberOfTradingDaysForDeterminingTheSharePrice_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_cik0002065779NumberOfTradingDaysForDeterminingTheSharePrice_190" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:label="loc_cik0002065779NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_cik0002065779NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_190" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate" xlink:label="loc_us-gaapAdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapAdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate_190" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaapPreferredStockRedemptionPricePerShare_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionPricePerShare_190" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ShareRedemptionTriggerPrices" xlink:label="loc_cik0002065779ShareRedemptionTriggerPrices_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_cik0002065779ShareRedemptionTriggerPrices_190" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_190" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion" xlink:label="loc_cik0002065779PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_cik0002065779PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion_190" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurementsDetails" xlink:title="999063 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SimpleAgreementsForFutureEquityMember" xlink:label="loc_cik0002065779SimpleAgreementsForFutureEquityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_cik0002065779SimpleAgreementsForFutureEquityMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherPayableRelatedToTheEquityOptionMember" xlink:label="loc_cik0002065779OtherPayableRelatedToTheEquityOptionMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_cik0002065779OtherPayableRelatedToTheEquityOptionMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_290" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaapEquityFairValueDisclosure_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapEquityFairValueDisclosure_290" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_290" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurementsDetails1" xlink:title="999064 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_FairValueOfOverallotmentOption" xlink:label="loc_cik0002065779FairValueOfOverallotmentOption_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779FairValueOfOverallotmentOption_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurementsDetails2" xlink:title="999065 - Disclosure - FAIR VALUE MEASUREMENTS (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PublicWarrantsMember" xlink:label="loc_cik0002065779PublicWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cik0002065779PublicWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharePrice_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SegmentInformationDetails" xlink:title="999066 - Disclosure - Segment information (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpenses_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestIncomeOther_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CashHeldInTrustAccounts" xlink:label="loc_cik0002065779CashHeldInTrustAccounts_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CashHeldInTrustAccounts_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfRevenue_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpenseAbstract" xlink:label="loc_us-gaapSellingAndMarketingExpenseAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSellingAndMarketingExpenseAbstract_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_StaffCostsEmployeeBenefitsAndOfficeExpenses" xlink:label="loc_cik0002065779StaffCostsEmployeeBenefitsAndOfficeExpenses_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract_90" xlink:to="loc_cik0002065779StaffCostsEmployeeBenefitsAndOfficeExpenses_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ShareBasedCompensations" xlink:label="loc_cik0002065779ShareBasedCompensations_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract_90" xlink:to="loc_cik0002065779ShareBasedCompensations_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpenseAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract_90" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpenseAbstract_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_StaffCostsEmployeeBenefitsAndOthers" xlink:label="loc_cik0002065779StaffCostsEmployeeBenefitsAndOthers_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract_90" xlink:to="loc_cik0002065779StaffCostsEmployeeBenefitsAndOthers_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract_90" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ShareBasedCompensation1" xlink:label="loc_cik0002065779ShareBasedCompensation1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract_90" xlink:to="loc_cik0002065779ShareBasedCompensation1_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract_90" xlink:to="loc_us-gaapOperatingIncomeLoss_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity" xlink:label="loc_cik0002065779ChangeInFairValueOfSimpleAgreementsForFutureEquity_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract_90" xlink:to="loc_cik0002065779ChangeInFairValueOfSimpleAgreementsForFutureEquity_90" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossBeforeReclassificationsTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract_90" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossBeforeReclassificationsTax_90" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract_90" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_90" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract_90" xlink:to="loc_us-gaapProfitLoss_90" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit_90" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_90" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative" xlink:title="999067 - Disclosure - Organization and principal activities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EvanaAlphaPteLtdMember" xlink:label="loc_cik0002065779EvanaAlphaPteLtdMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_cik0002065779EvanaAlphaPteLtdMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesIssued" xlink:label="loc_cik0002065779OrdinarySharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_cik0002065779OrdinarySharesIssued_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2" xlink:title="999068 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RevenueFromIntelligentComputingPowerServiceMember" xlink:label="loc_cik0002065779RevenueFromIntelligentComputingPowerServiceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_cik0002065779RevenueFromIntelligentComputingPowerServiceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapTransactionTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ReservedCapacityArrangementsMember" xlink:label="loc_cik0002065779ReservedCapacityArrangementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_cik0002065779ReservedCapacityArrangementsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OnDemandArrangementsMember" xlink:label="loc_cik0002065779OnDemandArrangementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_cik0002065779OnDemandArrangementsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenues_190" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3" xlink:title="999069 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RevenueFromIntelligentComputingPowerServiceMember" xlink:label="loc_cik0002065779RevenueFromIntelligentComputingPowerServiceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_cik0002065779RevenueFromIntelligentComputingPowerServiceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RevenueFromComprehensiveDataCenterServicesMember" xlink:label="loc_cik0002065779RevenueFromComprehensiveDataCenterServicesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_cik0002065779RevenueFromComprehensiveDataCenterServicesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenues_190" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" xlink:title="999070 - Disclosure - Summary of significant accounting policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassAOrdinarySharesMember" xlink:label="loc_cik0002065779ClassAOrdinarySharesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779ClassAOrdinarySharesMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassBOrdinarySharesMember" xlink:label="loc_cik0002065779ClassBOrdinarySharesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779ClassBOrdinarySharesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrent_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsReceivable" xlink:label="loc_cik0002065779RefundableDepositsReceivable_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RefundableDepositsReceivable_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RevenueRecognized" xlink:label="loc_cik0002065779RevenueRecognized_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RevenueRecognized_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="loc_us-gaapMarketingAndAdvertisingExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketingAndAdvertisingExpense_150" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_150" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_150" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_150" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_150" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Dividends" xlink:label="loc_us-gaapDividends_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividends_150" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CashAndCashEquivalentsAndU.s.DollarCoin" xlink:label="loc_cik0002065779CashAndCashEquivalentsAndU.s.DollarCoin_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CashAndCashEquivalentsAndU.s.DollarCoin_150" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ReceiptOfDigitalAssets" xlink:label="loc_cik0002065779ReceiptOfDigitalAssets_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ReceiptOfDigitalAssets_150" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DisbursementOfDigitalAssets" xlink:label="loc_cik0002065779DisbursementOfDigitalAssets_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779DisbursementOfDigitalAssets_150" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_FairValueGainOrLossOnDigitalAssets" xlink:label="loc_cik0002065779FairValueGainOrLossOnDigitalAssets_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779FairValueGainOrLossOnDigitalAssets_150" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_150" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AmortizationOfPrepaidResearchAndDevelopmentCosts" xlink:label="loc_cik0002065779AmortizationOfPrepaidResearchAndDevelopmentCosts_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779AmortizationOfPrepaidResearchAndDevelopmentCosts_150" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherReceivables_150" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsPayable" xlink:label="loc_cik0002065779RefundableDepositsPayable_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RefundableDepositsPayable_150" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/ConcentrationAndRiskDetails" xlink:title="999071 - Disclosure - Concentration and risk (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerAMember" xlink:label="loc_cik0002065779CustomerAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerAMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerBMember" xlink:label="loc_cik0002065779CustomerBMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerBMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerCMember" xlink:label="loc_cik0002065779CustomerCMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerCMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerDMember" xlink:label="loc_cik0002065779CustomerDMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerDMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerEMember" xlink:label="loc_cik0002065779CustomerEMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerEMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerFMember" xlink:label="loc_cik0002065779CustomerFMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerFMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_360" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/ConcentrationAndRiskDetails1" xlink:title="999072 - Disclosure - Concentration and risk (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerGMember" xlink:label="loc_cik0002065779CustomerGMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerGMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerHMember" xlink:label="loc_cik0002065779CustomerHMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerHMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerFMember" xlink:label="loc_cik0002065779CustomerFMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerFMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerDMember" xlink:label="loc_cik0002065779CustomerDMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerDMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerIMember" xlink:label="loc_cik0002065779CustomerIMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerIMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerAMember" xlink:label="loc_cik0002065779CustomerAMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerAMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerBMember" xlink:label="loc_cik0002065779CustomerBMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerBMember_110" xlink:type="arc" order="113" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerEMember" xlink:label="loc_cik0002065779CustomerEMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerEMember_130" xlink:type="arc" order="133" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_200" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/ConcentrationAndRiskDetails2" xlink:title="999073 - Disclosure - Concentration and risk (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PurchaseMember" xlink:label="loc_cik0002065779PurchaseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_cik0002065779PurchaseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierAMember" xlink:label="loc_cik0002065779SupplierAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierAMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierBMember" xlink:label="loc_cik0002065779SupplierBMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierBMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierCMember" xlink:label="loc_cik0002065779SupplierCMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierCMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierDMember" xlink:label="loc_cik0002065779SupplierDMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierDMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierEMember" xlink:label="loc_cik0002065779SupplierEMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierEMember_240" xlink:type="arc" order="243" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_290" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/ConcentrationAndRiskDetails3" xlink:title="999074 - Disclosure - Concentration and risk (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaapAccountsPayableMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsPayableMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierEMember" xlink:label="loc_cik0002065779SupplierEMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierEMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierFMember" xlink:label="loc_cik0002065779SupplierFMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierFMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierCMember" xlink:label="loc_cik0002065779SupplierCMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierCMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierBMember" xlink:label="loc_cik0002065779SupplierBMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierBMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierDMember" xlink:label="loc_cik0002065779SupplierDMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierDMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierGMember" xlink:label="loc_cik0002065779SupplierGMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierGMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaapAccountsPayableMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapAccountsPayableMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ConcentrationRiskPercentage" xlink:label="loc_cik0002065779ConcentrationRiskPercentage_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_cik0002065779ConcentrationRiskPercentage_170" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/AccountsReceivableDetails" xlink:title="999075 - Disclosure - Accounts receivable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsReceivableNet_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/AccountsReceivableDetailsNarrative" xlink:title="999076 - Disclosure - Accounts receivable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/OtherReceivablesDetailsNarrative" xlink:title="999077 - Disclosure - Other receivables (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherReceivables_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/EquipmentNetDetails" xlink:title="999078 - Disclosure - Equipment, net (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOtherNet_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOtherNet_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOtherAccumulatedDepreciation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOtherAccumulatedDepreciation_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/EquipmentNetDetailsNarrative" xlink:title="999079 - Disclosure - Equipment, net (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/RefundableDepositsPayableDetailsNarrative" xlink:title="999080 - Disclosure - Refundable deposits payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsPayable" xlink:label="loc_cik0002065779RefundableDepositsPayable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RefundableDepositsPayable_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SimpleAgreementsForFutureEquityDetails" xlink:title="999081 - Disclosure - Simple agreements for future equity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SimpleAgreementsForFutureEquity" xlink:label="loc_cik0002065779SimpleAgreementsForFutureEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779SimpleAgreementsForFutureEquity_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IssuanceOfSimpleAgreementsForFutureEquity" xlink:label="loc_cik0002065779IssuanceOfSimpleAgreementsForFutureEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779IssuanceOfSimpleAgreementsForFutureEquity_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ChangeInFairValue" xlink:label="loc_cik0002065779ChangeInFairValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ChangeInFairValue_100" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative" xlink:title="999082 - Disclosure - Simple agreements for future equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromOtherEquity_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AdditionalSafesProceeds" xlink:label="loc_cik0002065779AdditionalSafesProceeds_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779AdditionalSafesProceeds_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CumulativeProceeds" xlink:label="loc_cik0002065779CumulativeProceeds_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CumulativeProceeds_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EquityFinancingDescription" xlink:label="loc_cik0002065779EquityFinancingDescription_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779EquityFinancingDescription_80" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/IncomeTaxesDetails" xlink:title="999083 - Disclosure - Income taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/IncomeTaxesDetails1" xlink:title="999084 - Disclosure - Income taxes (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsGrossAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGrossAbstract_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract_30" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract_30" xlink:to="loc_us-gaapDeferredTaxAssetsGross_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract_30" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsNet_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/IncomeTaxesDetails2" xlink:title="999085 - Disclosure - Income taxes (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/IncomeTaxesDetailsNarrative" xlink:title="999086 - Disclosure - Income taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapDomesticCountryMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EvanaAlphaPteLtdMember" xlink:label="loc_cik0002065779EvanaAlphaPteLtdMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_cik0002065779EvanaAlphaPteLtdMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_120" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/Share-basedCompensationDetails" xlink:title="999087 - Disclosure - Share-based compensation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IncomeStatementLocationsAxis" xlink:label="loc_cik0002065779IncomeStatementLocationsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_cik0002065779IncomeStatementLocationsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IncomeStatementLocationsDomain" xlink:label="loc_cik0002065779IncomeStatementLocationsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cik0002065779IncomeStatementLocationsAxis" xlink:to="loc_cik0002065779IncomeStatementLocationsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IncomeStatementLocationsDomain" xlink:label="loc_cik0002065779IncomeStatementLocationsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_cik0002065779IncomeStatementLocationsAxis" xlink:to="loc_cik0002065779IncomeStatementLocationsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SellingAndMarketingExpensesMember" xlink:label="loc_cik0002065779SellingAndMarketingExpensesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cik0002065779IncomeStatementLocationsDomain" xlink:to="loc_cik0002065779SellingAndMarketingExpensesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_GeneralAndAdministrativeExpensesMember" xlink:label="loc_cik0002065779GeneralAndAdministrativeExpensesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cik0002065779IncomeStatementLocationsDomain" xlink:to="loc_cik0002065779GeneralAndAdministrativeExpensesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/Share-basedCompensationDetailsNarrative" xlink:title="999088 - Disclosure - Share-based compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EmployeeMember" xlink:label="loc_cik0002065779EmployeeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_cik0002065779EmployeeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_NonEmployeeMember" xlink:label="loc_cik0002065779NonEmployeeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_cik0002065779NonEmployeeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ThirdPartyServiceProviderMember" xlink:label="loc_cik0002065779ThirdPartyServiceProviderMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_cik0002065779ThirdPartyServiceProviderMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SharesDescription" xlink:label="loc_cik0002065779SharesDescription_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779SharesDescription_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DiscountRate" xlink:label="loc_cik0002065779DiscountRate_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779DiscountRate_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PerpetualRate" xlink:label="loc_cik0002065779PerpetualRate_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779PerpetualRate_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_GrantedEquityAward" xlink:label="loc_cik0002065779GrantedEquityAward_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779GrantedEquityAward_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_150" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrativeDisclosure" xlink:title="999089 - Disclosure - Related party transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ConsultingFees" xlink:label="loc_cik0002065779ConsultingFees_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ConsultingFees_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OutstandingBalancesPayable" xlink:label="loc_cik0002065779OutstandingBalancesPayable_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779OutstandingBalancesPayable_100" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails" xlink:title="999090 - Disclosure - Basic and diluted net loss per share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DenominatorForBasicAndDilutedLossPerShareAbstract" xlink:label="loc_cik0002065779DenominatorForBasicAndDilutedLossPerShareAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779DenominatorForBasicAndDilutedLossPerShareAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_NumeratorAbstract" xlink:label="loc_cik0002065779NumeratorAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779NumeratorAbstract_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DenominatorAbstract" xlink:label="loc_cik0002065779DenominatorAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779DenominatorAbstract_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_LossPerOrdinaryShareAbstarct" xlink:label="loc_cik0002065779LossPerOrdinaryShareAbstarct_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779LossPerOrdinaryShareAbstarct_70" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/SegmentInformationDetails1" xlink:title="999091 - Disclosure - Segment information (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_SG" xlink:label="loc_countrySG_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countrySG_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="loc_countryUS_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CA" xlink:label="loc_countryCA_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCA_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_HK" xlink:label="loc_countryHK_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryHK_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB" xlink:label="loc_countryGB_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryGB_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OthersMember" xlink:label="loc_cik0002065779OthersMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_cik0002065779OthersMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_430" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure" xlink:title="999092 - Disclosure - Commitments and contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EvanaAlphaPteLtdMember" xlink:label="loc_cik0002065779EvanaAlphaPteLtdMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_cik0002065779EvanaAlphaPteLtdMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesIssued" xlink:label="loc_cik0002065779OrdinarySharesIssued_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_cik0002065779OrdinarySharesIssued_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:label="loc_us-gaapProceedsFromSaleOfNotesReceivable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromSaleOfNotesReceivable_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesPerShare" xlink:label="loc_cik0002065779OrdinarySharesPerShare_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_cik0002065779OrdinarySharesPerShare_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/CryptoAssetsDetails" xlink:title="999093 - Disclosure - Crypto assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingLineItems" xlink:label="loc_us-gaapCryptoAssetHoldingLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingTable" xlink:label="loc_us-gaapCryptoAssetHoldingTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetHoldingTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetAxis" xlink:label="loc_srtCryptoAssetAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapCryptoAssetHoldingTable" xlink:to="loc_srtCryptoAssetAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetDomain" xlink:label="loc_srtCryptoAssetDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCryptoAssetAxis" xlink:to="loc_srtCryptoAssetDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetDomain" xlink:label="loc_srtCryptoAssetDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCryptoAssetAxis" xlink:to="loc_srtCryptoAssetDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DigitalAssetsMember" xlink:label="loc_cik0002065779DigitalAssetsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtCryptoAssetDomain" xlink:to="loc_cik0002065779DigitalAssetsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_USDCMember" xlink:label="loc_cik0002065779USDCMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtCryptoAssetDomain" xlink:to="loc_cik0002065779USDCMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapCryptoAssetHoldingTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetFairValue" xlink:label="loc_us-gaapCryptoAssetFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetFairValue_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetPurchase" xlink:label="loc_us-gaapCryptoAssetPurchase_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetPurchase_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetSale" xlink:label="loc_us-gaapCryptoAssetSale_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetSale_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetDisposition" xlink:label="loc_us-gaapCryptoAssetDisposition_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetDisposition_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/CryptoAssetsDetails1" xlink:title="999094 - Disclosure - Crypto assets (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingLineItems" xlink:label="loc_us-gaapCryptoAssetHoldingLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingTable" xlink:label="loc_us-gaapCryptoAssetHoldingTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetHoldingTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetAxis" xlink:label="loc_srtCryptoAssetAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapCryptoAssetHoldingTable" xlink:to="loc_srtCryptoAssetAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetDomain" xlink:label="loc_srtCryptoAssetDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCryptoAssetAxis" xlink:to="loc_srtCryptoAssetDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetDomain" xlink:label="loc_srtCryptoAssetDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCryptoAssetAxis" xlink:to="loc_srtCryptoAssetDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DigitalAssetsAndUSDCMember" xlink:label="loc_cik0002065779DigitalAssetsAndUSDCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtCryptoAssetDomain" xlink:to="loc_cik0002065779DigitalAssetsAndUSDCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapCryptoAssetHoldingTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapRevenues_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherCurrentAssets" xlink:label="loc_cik0002065779OtherCurrentAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_cik0002065779OtherCurrentAssets_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCostsAndExpenses_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapInterestIncomeOther_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc" xlink:label="loc_cik0002065779TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_cik0002065779TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc_20" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cik0002065779/role/CryptoAssetsDetailsNarrative" xlink:title="999095 - Disclosure - Crypto assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>25
<FILENAME>cik0002065779-20260331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Plus; Version: 6.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="cik0002065779_DBoralARCAcquisitionICorpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_DBoralARCAcquisitionICorpMember" xlink:to="cik0002065779_DBoralARCAcquisitionICorpMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_DBoralARCAcquisitionICorpMember_lbl" xml:lang="en-US">D. Boral ARC Acquisition I Corp [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassAOrdinarySharesMember" xlink:label="cik0002065779_ClassAOrdinarySharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ClassAOrdinarySharesMember" xlink:to="cik0002065779_ClassAOrdinarySharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ClassAOrdinarySharesMember_lbl" xml:lang="en-US">Class A Ordinary Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassBOrdinarySharesMember" xlink:label="cik0002065779_ClassBOrdinarySharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ClassBOrdinarySharesMember" xlink:to="cik0002065779_ClassBOrdinarySharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ClassBOrdinarySharesMember_lbl" xml:lang="en-US">Class B Ordinary Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="cik0002065779_ExascaleLabsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ExascaleLabsIncMember" xlink:to="cik0002065779_ExascaleLabsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ExascaleLabsIncMember_lbl" xml:lang="en-US">Exascale Labs Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesClassBMember" xlink:label="cik0002065779_OrdinarySharesClassBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OrdinarySharesClassBMember" xlink:to="cik0002065779_OrdinarySharesClassBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OrdinarySharesClassBMember_lbl" xml:lang="en-US">Ordinary Shares Class B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesClassAMember" xlink:label="cik0002065779_OrdinarySharesClassAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OrdinarySharesClassAMember" xlink:to="cik0002065779_OrdinarySharesClassAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OrdinarySharesClassAMember_lbl" xml:lang="en-US">Ordinary Shares Class A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SubscriptionReceivableMember" xlink:label="cik0002065779_SubscriptionReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SubscriptionReceivableMember" xlink:to="cik0002065779_SubscriptionReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SubscriptionReceivableMember_lbl" xml:lang="en-US">Subscription Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralArcMergerCorporationMember" xlink:label="cik0002065779_DBoralArcMergerCorporationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_DBoralArcMergerCorporationMember" xlink:to="cik0002065779_DBoralArcMergerCorporationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_DBoralArcMergerCorporationMember_lbl" xml:lang="en-US">D. Boral Arc Merger Corporation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesMember" xlink:label="cik0002065779_OrdinarySharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OrdinarySharesMember" xlink:to="cik0002065779_OrdinarySharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OrdinarySharesMember_lbl" xml:lang="en-US">Ordinary Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Combination [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorp.Member" xlink:label="cik0002065779_DBoralARCAcquisitionICorp.Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_DBoralARCAcquisitionICorp.Member" xlink:to="cik0002065779_DBoralARCAcquisitionICorp.Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_DBoralARCAcquisitionICorp.Member_lbl" xml:lang="en-US">D. Boral ARC Acquisition I Corp. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_UnderwriterMember" xlink:label="cik0002065779_UnderwriterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_UnderwriterMember" xlink:to="cik0002065779_UnderwriterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_UnderwriterMember_lbl" xml:lang="en-US">Underwriter [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_FounderSharesMember" xlink:label="cik0002065779_FounderSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_FounderSharesMember" xlink:to="cik0002065779_FounderSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_FounderSharesMember_lbl" xml:lang="en-US">Founder Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SponsorMember" xlink:label="cik0002065779_SponsorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SponsorMember" xlink:to="cik0002065779_SponsorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SponsorMember_lbl" xml:lang="en-US">Sponsor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_FounderMember" xlink:label="cik0002065779_FounderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_FounderMember" xlink:to="cik0002065779_FounderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_FounderMember_lbl" xml:lang="en-US">Founder [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_UnsecuredPromissoryNoteMember" xlink:label="cik0002065779_UnsecuredPromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_UnsecuredPromissoryNoteMember" xlink:to="cik0002065779_UnsecuredPromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_UnsecuredPromissoryNoteMember_lbl" xml:lang="en-US">Unsecured promissory note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CommonStockClassBMember" xlink:label="cik0002065779_CommonStockClassBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CommonStockClassBMember" xlink:to="cik0002065779_CommonStockClassBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CommonStockClassBMember_lbl" xml:lang="en-US">Common Stock Class B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_WarrantsMember" xlink:label="cik0002065779_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_WarrantsMember" xlink:to="cik0002065779_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassAOrdinaryShareMember" xlink:label="cik0002065779_ClassAOrdinaryShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ClassAOrdinaryShareMember" xlink:to="cik0002065779_ClassAOrdinaryShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ClassAOrdinaryShareMember_lbl" xml:lang="en-US">Class A Ordinary Share [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ConversionOfClassBToClassACommonStockMember" xlink:label="cik0002065779_ConversionOfClassBToClassACommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ConversionOfClassBToClassACommonStockMember" xlink:to="cik0002065779_ConversionOfClassBToClassACommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ConversionOfClassBToClassACommonStockMember_lbl" xml:lang="en-US">Conversion of class B to class A common stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US">Liability Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SimpleAgreementsForFutureEquityMember" xlink:label="cik0002065779_SimpleAgreementsForFutureEquityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SimpleAgreementsForFutureEquityMember" xlink:to="cik0002065779_SimpleAgreementsForFutureEquityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SimpleAgreementsForFutureEquityMember_lbl" xml:lang="en-US">Simple agreements for future equity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherPayableRelatedToTheEquityOptionMember" xlink:label="cik0002065779_OtherPayableRelatedToTheEquityOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OtherPayableRelatedToTheEquityOptionMember" xlink:to="cik0002065779_OtherPayableRelatedToTheEquityOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OtherPayableRelatedToTheEquityOptionMember_lbl" xml:lang="en-US">Other payable related to the equity option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PublicWarrantsMember" xlink:label="cik0002065779_PublicWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_PublicWarrantsMember" xlink:to="cik0002065779_PublicWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_PublicWarrantsMember_lbl" xml:lang="en-US">Public Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EvanaAlphaPteLtdMember" xlink:label="cik0002065779_EvanaAlphaPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_EvanaAlphaPteLtdMember" xlink:to="cik0002065779_EvanaAlphaPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_EvanaAlphaPteLtdMember_lbl" xml:lang="en-US">Evana Alpha Pte. Ltd. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RevenueFromIntelligentComputingPowerServiceMember" xlink:label="cik0002065779_RevenueFromIntelligentComputingPowerServiceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_RevenueFromIntelligentComputingPowerServiceMember" xlink:to="cik0002065779_RevenueFromIntelligentComputingPowerServiceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_RevenueFromIntelligentComputingPowerServiceMember_lbl" xml:lang="en-US">Revenue from intelligent computing power service [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionTypeAxis_lbl" xml:lang="en-US">Transaction Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ReservedCapacityArrangementsMember" xlink:label="cik0002065779_ReservedCapacityArrangementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ReservedCapacityArrangementsMember" xlink:to="cik0002065779_ReservedCapacityArrangementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ReservedCapacityArrangementsMember_lbl" xml:lang="en-US">Reserved Capacity Arrangements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OnDemandArrangementsMember" xlink:label="cik0002065779_OnDemandArrangementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OnDemandArrangementsMember" xlink:to="cik0002065779_OnDemandArrangementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OnDemandArrangementsMember_lbl" xml:lang="en-US">On demand arrangements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RevenueFromComprehensiveDataCenterServicesMember" xlink:label="cik0002065779_RevenueFromComprehensiveDataCenterServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_RevenueFromComprehensiveDataCenterServicesMember" xlink:to="cik0002065779_RevenueFromComprehensiveDataCenterServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_RevenueFromComprehensiveDataCenterServicesMember_lbl" xml:lang="en-US">Revenue from comprehensive data center services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerAMember" xlink:label="cik0002065779_CustomerAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CustomerAMember" xlink:to="cik0002065779_CustomerAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CustomerAMember_lbl" xml:lang="en-US">Customer A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerBMember" xlink:label="cik0002065779_CustomerBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CustomerBMember" xlink:to="cik0002065779_CustomerBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CustomerBMember_lbl" xml:lang="en-US">Customer B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerCMember" xlink:label="cik0002065779_CustomerCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CustomerCMember" xlink:to="cik0002065779_CustomerCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CustomerCMember_lbl" xml:lang="en-US">Customer C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerDMember" xlink:label="cik0002065779_CustomerDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CustomerDMember" xlink:to="cik0002065779_CustomerDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CustomerDMember_lbl" xml:lang="en-US">Customer D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerEMember" xlink:label="cik0002065779_CustomerEMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CustomerEMember" xlink:to="cik0002065779_CustomerEMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CustomerEMember_lbl" xml:lang="en-US">Customer E [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerFMember" xlink:label="cik0002065779_CustomerFMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CustomerFMember" xlink:to="cik0002065779_CustomerFMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CustomerFMember_lbl" xml:lang="en-US">Customer F [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerGMember" xlink:label="cik0002065779_CustomerGMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CustomerGMember" xlink:to="cik0002065779_CustomerGMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CustomerGMember_lbl" xml:lang="en-US">Customer G [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerHMember" xlink:label="cik0002065779_CustomerHMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CustomerHMember" xlink:to="cik0002065779_CustomerHMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CustomerHMember_lbl" xml:lang="en-US">Customer H [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerIMember" xlink:label="cik0002065779_CustomerIMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CustomerIMember" xlink:to="cik0002065779_CustomerIMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CustomerIMember_lbl" xml:lang="en-US">Customer I [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PurchaseMember" xlink:label="cik0002065779_PurchaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_PurchaseMember" xlink:to="cik0002065779_PurchaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_PurchaseMember_lbl" xml:lang="en-US">Purchase [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierAMember" xlink:label="cik0002065779_SupplierAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SupplierAMember" xlink:to="cik0002065779_SupplierAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SupplierAMember_lbl" xml:lang="en-US">Supplier A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierBMember" xlink:label="cik0002065779_SupplierBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SupplierBMember" xlink:to="cik0002065779_SupplierBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SupplierBMember_lbl" xml:lang="en-US">Supplier B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierCMember" xlink:label="cik0002065779_SupplierCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SupplierCMember" xlink:to="cik0002065779_SupplierCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SupplierCMember_lbl" xml:lang="en-US">Supplier C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierDMember" xlink:label="cik0002065779_SupplierDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SupplierDMember" xlink:to="cik0002065779_SupplierDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SupplierDMember_lbl" xml:lang="en-US">Supplier D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierEMember" xlink:label="cik0002065779_SupplierEMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SupplierEMember" xlink:to="cik0002065779_SupplierEMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SupplierEMember_lbl" xml:lang="en-US">Supplier E [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US">Accounts Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierFMember" xlink:label="cik0002065779_SupplierFMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SupplierFMember" xlink:to="cik0002065779_SupplierFMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SupplierFMember_lbl" xml:lang="en-US">Supplier F [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierGMember" xlink:label="cik0002065779_SupplierGMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SupplierGMember" xlink:to="cik0002065779_SupplierGMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SupplierGMember_lbl" xml:lang="en-US">Supplier G [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EmployeeMember" xlink:label="cik0002065779_EmployeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_EmployeeMember" xlink:to="cik0002065779_EmployeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_EmployeeMember_lbl" xml:lang="en-US">Employee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_NonEmployeeMember" xlink:label="cik0002065779_NonEmployeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_NonEmployeeMember" xlink:to="cik0002065779_NonEmployeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_NonEmployeeMember_lbl" xml:lang="en-US">Non employee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ThirdPartyServiceProviderMember" xlink:label="cik0002065779_ThirdPartyServiceProviderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ThirdPartyServiceProviderMember" xlink:to="cik0002065779_ThirdPartyServiceProviderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ThirdPartyServiceProviderMember_lbl" xml:lang="en-US">Third party service provider [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IncomeStatementLocationsAxis" xlink:label="cik0002065779_IncomeStatementLocationsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_IncomeStatementLocationsAxis" xlink:to="cik0002065779_IncomeStatementLocationsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_IncomeStatementLocationsAxis_lbl" xml:lang="en-US">Income Statement Locations [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SellingAndMarketingExpensesMember" xlink:label="cik0002065779_SellingAndMarketingExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SellingAndMarketingExpensesMember" xlink:to="cik0002065779_SellingAndMarketingExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SellingAndMarketingExpensesMember_lbl" xml:lang="en-US">Selling and marketing expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_GeneralAndAdministrativeExpensesMember" xlink:label="cik0002065779_GeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_GeneralAndAdministrativeExpensesMember" xlink:to="cik0002065779_GeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_GeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">General and administrative expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_SG" xlink:label="country_SG" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_SG" xlink:to="country_SG_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_SG_lbl" xml:lang="en-US">SINGAPORE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CA" xlink:label="country_CA" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CA" xlink:to="country_CA_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CA_lbl" xml:lang="en-US">CANADA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_HK" xlink:label="country_HK" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_HK_lbl" xml:lang="en-US">HONG KONG</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB" xlink:label="country_GB" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_GB_lbl" xml:lang="en-US">UNITED KINGDOM</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OthersMember" xlink:label="cik0002065779_OthersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OthersMember" xlink:to="cik0002065779_OthersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OthersMember_lbl" xml:lang="en-US">Others [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetAxis" xlink:label="srt_CryptoAssetAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CryptoAssetAxis" xlink:to="srt_CryptoAssetAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CryptoAssetAxis_lbl" xml:lang="en-US">Crypto Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DigitalAssetsMember" xlink:label="cik0002065779_DigitalAssetsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_DigitalAssetsMember" xlink:to="cik0002065779_DigitalAssetsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_DigitalAssetsMember_lbl" xml:lang="en-US">Digital Assets [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_USDCMember" xlink:label="cik0002065779_USDCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_USDCMember" xlink:to="cik0002065779_USDCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_USDCMember_lbl" xml:lang="en-US">USDC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DigitalAssetsAndUSDCMember" xlink:label="cik0002065779_DigitalAssetsAndUSDCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_DigitalAssetsAndUSDCMember" xlink:to="cik0002065779_DigitalAssetsAndUSDCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_DigitalAssetsAndUSDCMember_lbl" xml:lang="en-US">Digital assets and USDC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_U.s.DollarCoin" xlink:label="cik0002065779_U.s.DollarCoin" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_U.s.DollarCoin" xlink:to="cik0002065779_U.s.DollarCoin_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_U.s.DollarCoin_lbl" xml:lang="en-US">U.S. Dollar Coin</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PrepaidResearchAndDevelopmentExpenses" xlink:label="cik0002065779_PrepaidResearchAndDevelopmentExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_PrepaidResearchAndDevelopmentExpenses" xlink:to="cik0002065779_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_PrepaidResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Prepaid research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AdvanceToSuppliers" xlink:label="cik0002065779_AdvanceToSuppliers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_AdvanceToSuppliers" xlink:to="cik0002065779_AdvanceToSuppliers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_AdvanceToSuppliers_lbl" xml:lang="en-US">Advance to suppliers</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsReceivable" xlink:label="cik0002065779_RefundableDepositsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_RefundableDepositsReceivable" xlink:to="cik0002065779_RefundableDepositsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_RefundableDepositsReceivable_lbl" xml:lang="en-US">Refundable deposits receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total Non-Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CashHeldInTrustAccount" xlink:label="cik0002065779_CashHeldInTrustAccount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CashHeldInTrustAccount" xlink:to="cik0002065779_CashHeldInTrustAccount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CashHeldInTrustAccount_lbl" xml:lang="en-US">Cash held in trust account</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SimpleAgreementsForFutureEquity" xlink:label="cik0002065779_SimpleAgreementsForFutureEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SimpleAgreementsForFutureEquity" xlink:to="cik0002065779_SimpleAgreementsForFutureEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SimpleAgreementsForFutureEquity_lbl" xml:lang="en-US">Simple agreements for future equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositContractsLiabilities" xlink:label="us-gaap_DepositContractsLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositContractsLiabilities" xlink:to="us-gaap_DepositContractsLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositContractsLiabilities_lbl" xml:lang="en-US">Contract liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsPayable" xlink:label="cik0002065779_RefundableDepositsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_RefundableDepositsPayable" xlink:to="cik0002065779_RefundableDepositsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_RefundableDepositsPayable_lbl" xml:lang="en-US">Refundable deposits payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherCurrentLiabilities" xlink:label="cik0002065779_OtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OtherCurrentLiabilities" xlink:to="cik0002065779_OtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AmountDueToRelatedParty" xlink:label="cik0002065779_AmountDueToRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_AmountDueToRelatedParty" xlink:to="cik0002065779_AmountDueToRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_AmountDueToRelatedParty_lbl" xml:lang="en-US">Amount due to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 14)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Class A ordinary shares subject to possible redemption, $0.0001 par value; 500,000,000 shares authorized; 28,000,000 shares issued and outstanding, at redemption value of $10.26 on March&#160;31, 2026 and $10.17 on December&#160;31, 2025, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred shares, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl" xml:lang="en-US">Subscription receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Shareholders&#8217; Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Shareholders&#8217; Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Shares subject to possible redemption issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Shares subject to possible redemption issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Shares subject to possible redemption issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Shares subject to possible redemption outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl" xml:lang="en-US">Shares subject to possible redemption , redemption price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SharesSubjectToRedemption" xlink:label="cik0002065779_SharesSubjectToRedemption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SharesSubjectToRedemption" xlink:to="cik0002065779_SharesSubjectToRedemption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SharesSubjectToRedemption_lbl" xml:lang="en-US">Shares subject to redemption</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity" xlink:label="cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity" xlink:to="cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity_lbl" xml:lang="en-US">Change in fair value of simple agreements for future equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAbstract" xlink:label="us-gaap_OtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_OtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAbstract_lbl" xml:lang="en-US">Other income:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income on cash held in trust account</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Total other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Selling and marketing expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income tax expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of per ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of per ordinary shares Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of per ordinary shares Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_LossPerOrdinaryShareAbstarct" xlink:label="cik0002065779_LossPerOrdinaryShareAbstarct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_LossPerOrdinaryShareAbstarct" xlink:to="cik0002065779_LossPerOrdinaryShareAbstarct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_LossPerOrdinaryShareAbstarct_lbl" xml:lang="en-US">Loss per ordinary share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic Loss per ordinary share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted Loss per ordinary share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFee" xlink:label="cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFee" xlink:to="cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFee_lbl" xml:lang="en-US">Common stock issued to initial shareholder for subscription fee</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFeeShares" xlink:label="cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFeeShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFeeShares" xlink:to="cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFeeShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFeeShares_lbl" xml:lang="en-US">Common stock issued to initial shareholder for subscription fee, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassBOrdinarySharesIssuedToSponsor" xlink:label="cik0002065779_ClassBOrdinarySharesIssuedToSponsor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ClassBOrdinarySharesIssuedToSponsor" xlink:to="cik0002065779_ClassBOrdinarySharesIssuedToSponsor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ClassBOrdinarySharesIssuedToSponsor_lbl" xml:lang="en-US">Class B ordinary shares issued to Sponsor</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RedesignationOfAuthorizedOrdinaryShares" xlink:label="cik0002065779_RedesignationOfAuthorizedOrdinaryShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_RedesignationOfAuthorizedOrdinaryShares" xlink:to="cik0002065779_RedesignationOfAuthorizedOrdinaryShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_RedesignationOfAuthorizedOrdinaryShares_lbl" xml:lang="en-US">Re-designation of authorized ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassBOrdinarySharesIssuedToSponsorShares" xlink:label="cik0002065779_ClassBOrdinarySharesIssuedToSponsorShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ClassBOrdinarySharesIssuedToSponsorShares" xlink:to="cik0002065779_ClassBOrdinarySharesIssuedToSponsorShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ClassBOrdinarySharesIssuedToSponsorShares_lbl" xml:lang="en-US">Class B ordinary shares issued to Sponsor, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCosts" xlink:label="cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCosts" xlink:to="cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCosts_lbl" xml:lang="en-US">Sale of Private Units, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCostsShares" xlink:label="cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCostsShares" xlink:to="cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCostsShares_lbl" xml:lang="en-US">Sale of Private Units, net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IssuanceOfPublicWarrantsNetOfIssuanceCosts" xlink:label="cik0002065779_IssuanceOfPublicWarrantsNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_IssuanceOfPublicWarrantsNetOfIssuanceCosts" xlink:to="cik0002065779_IssuanceOfPublicWarrantsNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_IssuanceOfPublicWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of Public Warrants, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IssuanceOfRepresentativeShares" xlink:label="cik0002065779_IssuanceOfRepresentativeShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_IssuanceOfRepresentativeShares" xlink:to="cik0002065779_IssuanceOfRepresentativeShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_IssuanceOfRepresentativeShares_lbl" xml:lang="en-US">Issuance of Representative Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IssuanceOfRepresentativeSharesShares" xlink:label="cik0002065779_IssuanceOfRepresentativeSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_IssuanceOfRepresentativeSharesShares" xlink:to="cik0002065779_IssuanceOfRepresentativeSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_IssuanceOfRepresentativeSharesShares_lbl" xml:lang="en-US">Issuance of Representative Shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AccretionInValueOfClassOrdinaryShares" xlink:label="cik0002065779_AccretionInValueOfClassOrdinaryShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_AccretionInValueOfClassOrdinaryShares" xlink:to="cik0002065779_AccretionInValueOfClassOrdinaryShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cik0002065779_AccretionInValueOfClassOrdinaryShares_lbl" xml:lang="en-US">Accretion in value of Class A ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ReverseOverallotmentOptionLiability" xlink:label="cik0002065779_ReverseOverallotmentOptionLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ReverseOverallotmentOptionLiability" xlink:to="cik0002065779_ReverseOverallotmentOptionLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ReverseOverallotmentOptionLiability_lbl" xml:lang="en-US">reverse over-allotment option liability</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ForfeitureOfFounderShares" xlink:label="cik0002065779_ForfeitureOfFounderShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ForfeitureOfFounderShares" xlink:to="cik0002065779_ForfeitureOfFounderShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cik0002065779_ForfeitureOfFounderShares_lbl" xml:lang="en-US">Forfeiture of founder shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ForfeitureOfFounderSharesShares" xlink:label="cik0002065779_ForfeitureOfFounderSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ForfeitureOfFounderSharesShares" xlink:to="cik0002065779_ForfeitureOfFounderSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ForfeitureOfFounderSharesShares_lbl" xml:lang="en-US">Forfeiture of founder shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AdjustmentOfAccruedOfferingCosts" xlink:label="cik0002065779_AdjustmentOfAccruedOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_AdjustmentOfAccruedOfferingCosts" xlink:to="cik0002065779_AdjustmentOfAccruedOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_AdjustmentOfAccruedOfferingCosts_lbl" xml:lang="en-US">Adjustment of accrued offering costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_AccretionInValueOfClassOrdinaryShares" xlink:to="cik0002065779_AccretionInValueOfClassOrdinaryShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_AccretionInValueOfClassOrdinaryShares_2_lbl" xml:lang="en-US">Accretion in value of Class A ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RedesignationOfAuthorizedOrdinarySharesShares" xlink:label="cik0002065779_RedesignationOfAuthorizedOrdinarySharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_RedesignationOfAuthorizedOrdinarySharesShares" xlink:to="cik0002065779_RedesignationOfAuthorizedOrdinarySharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_RedesignationOfAuthorizedOrdinarySharesShares_lbl" xml:lang="en-US">Re-designation of authorized ordinary shares, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquities" xlink:label="cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquities" xlink:to="cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquities_lbl" xml:lang="en-US">Change in fair value of simple agreements for future equity</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin" xlink:label="cik0002065779_OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin" xlink:to="cik0002065779_OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cik0002065779_OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin_lbl" xml:lang="en-US">Other operating activities settled in digital assets and U.S. Dollar Coin</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PaymentOfExpensesThroughRelatedParty" xlink:label="cik0002065779_PaymentOfExpensesThroughRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_PaymentOfExpensesThroughRelatedParty" xlink:to="cik0002065779_PaymentOfExpensesThroughRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_PaymentOfExpensesThroughRelatedParty_lbl" xml:lang="en-US">Payment of expenses through related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeOther_2_lbl" xml:lang="en-US">Investment income in trust account</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PaymentOfExpensesThroughPromissoryNoteRelatedParty" xlink:label="cik0002065779_PaymentOfExpensesThroughPromissoryNoteRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_PaymentOfExpensesThroughPromissoryNoteRelatedParty" xlink:to="cik0002065779_PaymentOfExpensesThroughPromissoryNoteRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_PaymentOfExpensesThroughPromissoryNoteRelatedParty_lbl" xml:lang="en-US">Payment of expenses through promissory note &#8211; related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IncreaseDecreaseInAdvanceToSuppliers" xlink:label="cik0002065779_IncreaseDecreaseInAdvanceToSuppliers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_IncreaseDecreaseInAdvanceToSuppliers" xlink:to="cik0002065779_IncreaseDecreaseInAdvanceToSuppliers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cik0002065779_IncreaseDecreaseInAdvanceToSuppliers_lbl" xml:lang="en-US">Advance to suppliers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Prepaid research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IncreaseDecreaseInRefundableDepositsReceivable" xlink:label="cik0002065779_IncreaseDecreaseInRefundableDepositsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_IncreaseDecreaseInRefundableDepositsReceivable" xlink:to="cik0002065779_IncreaseDecreaseInRefundableDepositsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cik0002065779_IncreaseDecreaseInRefundableDepositsReceivable_lbl" xml:lang="en-US">Refundable deposits receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Contract liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IncreaseDecreaseInRefundableDepositsPayable" xlink:label="cik0002065779_IncreaseDecreaseInRefundableDepositsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_IncreaseDecreaseInRefundableDepositsPayable" xlink:to="cik0002065779_IncreaseDecreaseInRefundableDepositsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_IncreaseDecreaseInRefundableDepositsPayable_lbl" xml:lang="en-US">Refundable deposits payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="us-gaap_PaymentsToAcquireRestrictedInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:to="us-gaap_PaymentsToAcquireRestrictedInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireRestrictedInvestments_lbl" xml:lang="en-US">Investment of cash in Trust Account</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ProceedsFromSaleOfDigitalAssetsAndUsdc" xlink:label="cik0002065779_ProceedsFromSaleOfDigitalAssetsAndUsdc" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ProceedsFromSaleOfDigitalAssetsAndUsdc" xlink:to="cik0002065779_ProceedsFromSaleOfDigitalAssetsAndUsdc_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ProceedsFromSaleOfDigitalAssetsAndUsdc_lbl" xml:lang="en-US">Disposal of digital assets and U.S. Dollar Coin</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of Class B ordinary shares to Sponsor</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid" xlink:label="cik0002065779_ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid" xlink:to="cik0002065779_ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid_lbl" xml:lang="en-US">Proceeds from sale of Units, net of underwriting discount paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from sale of private placement units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayment of promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xml:lang="en-US">Payment of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PaymentForDeferredOfferingCosts" xlink:label="cik0002065779_PaymentForDeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_PaymentForDeferredOfferingCosts" xlink:to="cik0002065779_PaymentForDeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cik0002065779_PaymentForDeferredOfferingCosts_lbl" xml:lang="en-US">Payment for deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ProceedsFromSimpleAgreementsForFutureEquity" xlink:label="cik0002065779_ProceedsFromSimpleAgreementsForFutureEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ProceedsFromSimpleAgreementsForFutureEquity" xlink:to="cik0002065779_ProceedsFromSimpleAgreementsForFutureEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ProceedsFromSimpleAgreementsForFutureEquity_lbl" xml:lang="en-US">Proceeds from Simple agreements for future equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at the beginning of the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents at the end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental schedule of non-cash financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Common stock issued to initial shareholder for subscription fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US">Forfeiture of founder shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_lbl" xml:lang="en-US">Re-measurement of ordinary shares subject to redemption</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionDescription" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionDescription" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionDescription_lbl" xml:lang="en-US">Issuance of representative shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl" xml:lang="en-US">Deferred offering costs included in promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1_lbl" xml:lang="en-US">Accretion of carrying value of redeemable shares to redemption value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAssumed1" xlink:label="us-gaap_NotesAssumed1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAssumed1" xlink:to="us-gaap_NotesAssumed1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAssumed1_lbl" xml:lang="en-US">Investment proceeds received by an employee on behalf of the Company from SAFEs investors</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplementary Information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income tax paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest expense paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansAssumed1" xlink:label="us-gaap_LoansAssumed1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansAssumed1" xlink:to="us-gaap_LoansAssumed1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansAssumed1_lbl" xml:lang="en-US">Investment proceeds received through USDC from SAFEs investors</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Description of Organization and Business Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">Business Combination</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Share Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NatureOfOperations_2_lbl" xml:lang="en-US">DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_2_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_InitialPublicOfferingDisclosureTextBlock" xlink:label="cik0002065779_InitialPublicOfferingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_InitialPublicOfferingDisclosureTextBlock" xlink:to="cik0002065779_InitialPublicOfferingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_InitialPublicOfferingDisclosureTextBlock_lbl" xml:lang="en-US">INITIAL PUBLIC OFFERING</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PrivatePlacementDisclosureTextBlock" xlink:label="cik0002065779_PrivatePlacementDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_PrivatePlacementDisclosureTextBlock" xlink:to="cik0002065779_PrivatePlacementDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_PrivatePlacementDisclosureTextBlock_lbl" xml:lang="en-US">PRIVATE PLACEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">STOCKHOLDER&#8217;S EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_3_lbl" xml:lang="en-US">Organization and principal activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_3_lbl" xml:lang="en-US">Summary of significant accounting policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">Concentration and risk</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_2_lbl" xml:lang="en-US">Fair value measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:label="us-gaap_AccountsAndNontradeReceivableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:to="us-gaap_AccountsAndNontradeReceivableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndNontradeReceivableTextBlock_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherReceivablesTextBlock" xlink:label="cik0002065779_OtherReceivablesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OtherReceivablesTextBlock" xlink:to="cik0002065779_OtherReceivablesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_OtherReceivablesTextBlock_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsPayableTextBlock" xlink:label="cik0002065779_RefundableDepositsPayableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_RefundableDepositsPayableTextBlock" xlink:to="cik0002065779_RefundableDepositsPayableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_RefundableDepositsPayableTextBlock_lbl" xml:lang="en-US">Refundable deposits payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SimpleAgreementsForFutureEquityTextBlock" xlink:label="cik0002065779_SimpleAgreementsForFutureEquityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SimpleAgreementsForFutureEquityTextBlock" xlink:to="cik0002065779_SimpleAgreementsForFutureEquityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_SimpleAgreementsForFutureEquityTextBlock_lbl" xml:lang="en-US">Simple agreements for future equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2_lbl" xml:lang="en-US">Related party transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Basic and diluted net loss per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetTextBlock" xlink:label="us-gaap_CryptoAssetTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetTextBlock" xlink:to="us-gaap_CryptoAssetTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetTextBlock_lbl" xml:lang="en-US">Crypto assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EmergingGrowthCompanyPolicyTextBlock" xlink:label="cik0002065779_EmergingGrowthCompanyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_EmergingGrowthCompanyPolicyTextBlock" xlink:to="cik0002065779_EmergingGrowthCompanyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US">Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RisksAndUncertaintiesPolicyTextBlock" xlink:label="cik0002065779_RisksAndUncertaintiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_RisksAndUncertaintiesPolicyTextBlock" xlink:to="cik0002065779_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_RisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Risk and Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently adopted accounting pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CashHeldInTrustAccountPolicyTextBlock" xlink:label="cik0002065779_CashHeldInTrustAccountPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CashHeldInTrustAccountPolicyTextBlock" xlink:to="cik0002065779_CashHeldInTrustAccountPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CashHeldInTrustAccountPolicyTextBlock_lbl" xml:lang="en-US">Cash Held in Trust Account</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock" xlink:label="cik0002065779_OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock" xlink:to="cik0002065779_OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock_lbl" xml:lang="en-US">Offering Costs Associated with the Initial Public Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="us-gaap_DerivativesReportingOfDerivativeActivity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesReportingOfDerivativeActivity" xlink:to="us-gaap_DerivativesReportingOfDerivativeActivity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesReportingOfDerivativeActivity_lbl" xml:lang="en-US">Derivative Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtendedProductWarrantyPolicy" xlink:label="us-gaap_ExtendedProductWarrantyPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtendedProductWarrantyPolicy" xlink:to="us-gaap_ExtendedProductWarrantyPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtendedProductWarrantyPolicy_lbl" xml:lang="en-US">Warrant Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock" xlink:label="cik0002065779_ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock" xlink:to="cik0002065779_ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_lbl" xml:lang="en-US">Class A Ordinary Shares Subject to Possible Redemption</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_2_lbl" xml:lang="en-US">Net (Loss)/Income per Ordinary Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of credit risk</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_2_lbl" xml:lang="en-US">Fair value of financial instruments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_RisksAndUncertaintiesPolicyTextBlock" xlink:to="cik0002065779_RisksAndUncertaintiesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_RisksAndUncertaintiesPolicyTextBlock_2_lbl" xml:lang="en-US">Risks and Uncertainties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_GoingConcernPolicyTextBlock" xlink:label="cik0002065779_GoingConcernPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_GoingConcernPolicyTextBlock" xlink:to="cik0002065779_GoingConcernPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_GoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Going concern</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Basis of presentation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UseOfEstimates_2_lbl" xml:lang="en-US">Use of estimates and assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair value measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_FunctionalCurrencyPolicyTextBlock" xlink:label="cik0002065779_FunctionalCurrencyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_FunctionalCurrencyPolicyTextBlock" xlink:to="cik0002065779_FunctionalCurrencyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_FunctionalCurrencyPolicyTextBlock_lbl" xml:lang="en-US">Functional currency</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExpectedCreditLossAndAccountsReceivablePolicyTextBlock" xlink:label="cik0002065779_ExpectedCreditLossAndAccountsReceivablePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ExpectedCreditLossAndAccountsReceivablePolicyTextBlock" xlink:to="cik0002065779_ExpectedCreditLossAndAccountsReceivablePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ExpectedCreditLossAndAccountsReceivablePolicyTextBlock_lbl" xml:lang="en-US">Expected credit loss and accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AdvanceToSuppliersPolicyTextBlock" xlink:label="cik0002065779_AdvanceToSuppliersPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_AdvanceToSuppliersPolicyTextBlock" xlink:to="cik0002065779_AdvanceToSuppliersPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_AdvanceToSuppliersPolicyTextBlock_lbl" xml:lang="en-US">Advance to suppliers</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsReceivablePolicyTextBlock" xlink:label="cik0002065779_RefundableDepositsReceivablePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_RefundableDepositsReceivablePolicyTextBlock" xlink:to="cik0002065779_RefundableDepositsReceivablePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_RefundableDepositsReceivablePolicyTextBlock_lbl" xml:lang="en-US">Refundable deposits receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SimpleAgreementsForFutureEquityPolicyTextBlock" xlink:label="cik0002065779_SimpleAgreementsForFutureEquityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SimpleAgreementsForFutureEquityPolicyTextBlock" xlink:to="cik0002065779_SimpleAgreementsForFutureEquityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_SimpleAgreementsForFutureEquityPolicyTextBlock_lbl" xml:lang="en-US">Simple agreements for future equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionDeferredRevenue" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionDeferredRevenue" xlink:to="us-gaap_RevenueRecognitionDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue_lbl" xml:lang="en-US">Revenue recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ContractLiabilitiesPolicyTextBlock" xlink:label="cik0002065779_ContractLiabilitiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ContractLiabilitiesPolicyTextBlock" xlink:to="cik0002065779_ContractLiabilitiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_ContractLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Contract liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SellingAndMarketingExpensesPolicyTextBlock" xlink:label="cik0002065779_SellingAndMarketingExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SellingAndMarketingExpensesPolicyTextBlock" xlink:to="cik0002065779_SellingAndMarketingExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SellingAndMarketingExpensesPolicyTextBlock_lbl" xml:lang="en-US">Selling and marketing expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CapitalStructurePolicyTextBlock" xlink:label="cik0002065779_CapitalStructurePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CapitalStructurePolicyTextBlock" xlink:to="cik0002065779_CapitalStructurePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CapitalStructurePolicyTextBlock_lbl" xml:lang="en-US">Capital structure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RelatedPartiesPolicyTextBlock" xlink:label="cik0002065779_RelatedPartiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_RelatedPartiesPolicyTextBlock" xlink:to="cik0002065779_RelatedPartiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_RelatedPartiesPolicyTextBlock_lbl" xml:lang="en-US">Related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ComprehensiveLossPolicyTextBlock" xlink:label="cik0002065779_ComprehensiveLossPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ComprehensiveLossPolicyTextBlock" xlink:to="cik0002065779_ComprehensiveLossPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ComprehensiveLossPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_3_lbl" xml:lang="en-US">Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionDividends" xlink:label="us-gaap_RevenueRecognitionDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionDividends" xlink:to="us-gaap_RevenueRecognitionDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionDividends_lbl" xml:lang="en-US">Dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock" xlink:label="cik0002065779_RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock" xlink:to="cik0002065779_RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock_lbl" xml:lang="en-US">Recently adopted accounting standard updates</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_EmergingGrowthCompanyPolicyTextBlock" xlink:to="cik0002065779_EmergingGrowthCompanyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_EmergingGrowthCompanyPolicyTextBlock_2_lbl" xml:lang="en-US">Emerging growth company</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3_lbl" xml:lang="en-US">Recently accounting pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CryptoAssets" xlink:label="cik0002065779_CryptoAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CryptoAssets" xlink:to="cik0002065779_CryptoAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_CryptoAssets_lbl" xml:lang="en-US">Crypto assets</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DeferredOfferingCostsPolicyTextBlock" xlink:label="cik0002065779_DeferredOfferingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_DeferredOfferingCostsPolicyTextBlock" xlink:to="cik0002065779_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_DeferredOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PrepaidResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="cik0002065779_PrepaidResearchAndDevelopmentExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_PrepaidResearchAndDevelopmentExpensesPolicyTextBlock" xlink:to="cik0002065779_PrepaidResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_PrepaidResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xml:lang="en-US">Prepaid research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherReceivablesPolicyRextBlock" xlink:label="cik0002065779_OtherReceivablesPolicyRextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OtherReceivablesPolicyRextBlock" xlink:to="cik0002065779_OtherReceivablesPolicyRextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_OtherReceivablesPolicyRextBlock_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsPayablePolicyTextBlock" xlink:label="cik0002065779_RefundableDepositsPayablePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_RefundableDepositsPayablePolicyTextBlock" xlink:to="cik0002065779_RefundableDepositsPayablePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_RefundableDepositsPayablePolicyTextBlock_lbl" xml:lang="en-US">Refundable deposits payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US">Schedule of earning per share basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of earning per share basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="cik0002065779_OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="cik0002065779_OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of initial measurement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of market assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of segment information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of geographic information</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ScheduleOfRevenueRecognitionTableTextBlock" xlink:label="cik0002065779_ScheduleOfRevenueRecognitionTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ScheduleOfRevenueRecognitionTableTextBlock" xlink:to="cik0002065779_ScheduleOfRevenueRecognitionTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ScheduleOfRevenueRecognitionTableTextBlock_lbl" xml:lang="en-US">Schedule of Revenue recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Revenue disaggregated</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ScheduleOfConcentrationOfCustomersTableTextBlock" xlink:label="cik0002065779_ScheduleOfConcentrationOfCustomersTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ScheduleOfConcentrationOfCustomersTableTextBlock" xlink:to="cik0002065779_ScheduleOfConcentrationOfCustomersTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ScheduleOfConcentrationOfCustomersTableTextBlock_lbl" xml:lang="en-US">Schedule of Concentration of customers</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ScheduleOfAccountsReceivableTextBlock" xlink:label="cik0002065779_ScheduleOfAccountsReceivableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ScheduleOfAccountsReceivableTextBlock" xlink:to="cik0002065779_ScheduleOfAccountsReceivableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ScheduleOfAccountsReceivableTextBlock_lbl" xml:lang="en-US">Schedule of account receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ScheduleOfConcentrationOfSuppliersTableTextBlock" xlink:label="cik0002065779_ScheduleOfConcentrationOfSuppliersTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ScheduleOfConcentrationOfSuppliersTableTextBlock" xlink:to="cik0002065779_ScheduleOfConcentrationOfSuppliersTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ScheduleOfConcentrationOfSuppliersTableTextBlock_lbl" xml:lang="en-US">Schedule of Concentration of suppliers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of account payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value measurement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of effective tax rate reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US">Schedule of valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Schedule of share-based compensation expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2_lbl" xml:lang="en-US">Schedule of basic share and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetActivityTableTextBlock" xlink:label="us-gaap_CryptoAssetActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetActivityTableTextBlock" xlink:to="us-gaap_CryptoAssetActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowOperatingCapitalTableTextBlock" xlink:label="us-gaap_CashFlowOperatingCapitalTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingCapitalTableTextBlock" xlink:to="us-gaap_CashFlowOperatingCapitalTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowOperatingCapitalTableTextBlock_lbl" xml:lang="en-US">Schedule of operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Business Combination [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Combination [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AggregateConsideration" xlink:label="cik0002065779_AggregateConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_AggregateConsideration" xlink:to="cik0002065779_AggregateConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_AggregateConsideration_lbl" xml:lang="en-US">Aggregate consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">New shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of units in initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of units per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of units in initial public offering aggragate amount</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_TransactionCosts" xlink:label="cik0002065779_TransactionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_TransactionCosts" xlink:to="cik0002065779_TransactionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_TransactionCosts_lbl" xml:lang="en-US">Transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RepresentativeShares" xlink:label="cik0002065779_RepresentativeShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_RepresentativeShares" xlink:to="cik0002065779_RepresentativeShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_RepresentativeShares_lbl" xml:lang="en-US">Representative shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherOfferingCosts" xlink:label="cik0002065779_OtherOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OtherOfferingCosts" xlink:to="cik0002065779_OtherOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OtherOfferingCosts_lbl" xml:lang="en-US">Other offering costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Number of share issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Number of share issued, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">proceeds from sale of initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CancelledFounderShares" xlink:label="cik0002065779_CancelledFounderShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CancelledFounderShares" xlink:to="cik0002065779_CancelledFounderShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CancelledFounderShares_lbl" xml:lang="en-US">Cancelled founder shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" xlink:label="us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" xlink:to="us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_lbl" xml:lang="en-US">Dissolution expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_WorkingCapitalDeficit" xlink:label="cik0002065779_WorkingCapitalDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_WorkingCapitalDeficit" xlink:to="cik0002065779_WorkingCapitalDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_WorkingCapitalDeficit_lbl" xml:lang="en-US">Working capital deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Loan payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:to="us-gaap_RepaymentOfNotesReceivableFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties_lbl" xml:lang="en-US">Repayment of promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl" xml:lang="en-US">Ordinary shares subject to possible redemption, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ProceedsAllocatedToPublicWarrants" xlink:label="cik0002065779_ProceedsAllocatedToPublicWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ProceedsAllocatedToPublicWarrants" xlink:to="cik0002065779_ProceedsAllocatedToPublicWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ProceedsAllocatedToPublicWarrants_lbl" xml:lang="en-US">Proceeds allocated to Public Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ProceedsAllocatedToOverallotmentOption" xlink:label="cik0002065779_ProceedsAllocatedToOverallotmentOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ProceedsAllocatedToOverallotmentOption" xlink:to="cik0002065779_ProceedsAllocatedToOverallotmentOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ProceedsAllocatedToOverallotmentOption_lbl" xml:lang="en-US">Proceeds allocated to Over-allotment Option</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassOrdinarySharesIssuanceCosts" xlink:label="cik0002065779_ClassOrdinarySharesIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ClassOrdinarySharesIssuanceCosts" xlink:to="cik0002065779_ClassOrdinarySharesIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ClassOrdinarySharesIssuanceCosts_lbl" xml:lang="en-US">Class A ordinary shares issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xml:lang="en-US">Ordinary shares subject to possible redemption</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_2_lbl" xml:lang="en-US">Ordinary shares subject to possible redemption, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Allocation of (loss)/income - basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Allocation of (loss)/income - diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average shares of Class B ordinary shares outstanding, basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted average shares of Class B ordinary shares outstanding, diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Class B ordinary shares - basic net income per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Class B ordinary shares - diluted net income per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CashHeldInTrustAccount" xlink:to="cik0002065779_CashHeldInTrustAccount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_CashHeldInTrustAccount_2_lbl" xml:lang="en-US">Cash held in trust</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OfferingCost" xlink:label="cik0002065779_OfferingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OfferingCost" xlink:to="cik0002065779_OfferingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OfferingCost_lbl" xml:lang="en-US">Offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherOfferingCost" xlink:label="cik0002065779_OtherOfferingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OtherOfferingCost" xlink:to="cik0002065779_OtherOfferingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_OtherOfferingCost_lbl" xml:lang="en-US">Other offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">other costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2_lbl" xml:lang="en-US">Ordinary shares subject to redemption</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" xlink:label="us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" xlink:to="us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_lbl" xml:lang="en-US">Weighted average aggregate shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">FDIC Insured Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Forfeiture shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination" xlink:label="cik0002065779_PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination" xlink:to="cik0002065779_PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination_lbl" xml:lang="en-US">Percentage of redemption of public shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_2_lbl" xml:lang="en-US">Payment of offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDistributionsToAffiliates" xlink:label="us-gaap_PaymentsOfDistributionsToAffiliates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDistributionsToAffiliates" xlink:to="us-gaap_PaymentsOfDistributionsToAffiliates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDistributionsToAffiliates_lbl" xml:lang="en-US">Payment to affiliate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdministrativeFeesExpense" xlink:label="us-gaap_AdministrativeFeesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdministrativeFeesExpense" xlink:to="us-gaap_AdministrativeFeesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdministrativeFeesExpense_lbl" xml:lang="en-US">Administrative services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US">Conversion of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Option granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesSubjectToPossibleRedemption" xlink:label="cik0002065779_OrdinarySharesSubjectToPossibleRedemption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OrdinarySharesSubjectToPossibleRedemption" xlink:to="cik0002065779_OrdinarySharesSubjectToPossibleRedemption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_OrdinarySharesSubjectToPossibleRedemption_lbl" xml:lang="en-US">Ordinary shares subject to possible redemption</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AggregatePurchasePrice" xlink:label="cik0002065779_AggregatePurchasePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_AggregatePurchasePrice" xlink:to="cik0002065779_AggregatePurchasePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_AggregatePurchasePrice_lbl" xml:lang="en-US">Aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CancellationOfOrdinaryShares" xlink:label="cik0002065779_CancellationOfOrdinaryShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CancellationOfOrdinaryShares" xlink:to="cik0002065779_CancellationOfOrdinaryShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CancellationOfOrdinaryShares_lbl" xml:lang="en-US">Cancellation of ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConversionBasis" xlink:to="us-gaap_CommonStockConversionBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConversionBasis_lbl" xml:lang="en-US">Conversion basis</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PeriodAfterWhichTheWarrantsAreExercisable" xlink:label="cik0002065779_PeriodAfterWhichTheWarrantsAreExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_PeriodAfterWhichTheWarrantsAreExercisable" xlink:to="cik0002065779_PeriodAfterWhichTheWarrantsAreExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_PeriodAfterWhichTheWarrantsAreExercisable_lbl" xml:lang="en-US">Period of warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" xlink:label="cik0002065779_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" xlink:to="cik0002065779_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants_lbl" xml:lang="en-US">Holders of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:label="cik0002065779_NumberOfTradingDaysForDeterminingTheSharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:to="cik0002065779_NumberOfTradingDaysForDeterminingTheSharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_NumberOfTradingDaysForDeterminingTheSharePrice_lbl" xml:lang="en-US">Number of trading days</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:label="cik0002065779_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:to="cik0002065779_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_lbl" xml:lang="en-US">Number of consecutive trading days</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate" xlink:label="us-gaap_AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate" xlink:to="us-gaap_AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate_lbl" xml:lang="en-US">Market value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xml:lang="en-US">Redemption price</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ShareRedemptionTriggerPrices" xlink:label="cik0002065779_ShareRedemptionTriggerPrices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ShareRedemptionTriggerPrices" xlink:to="cik0002065779_ShareRedemptionTriggerPrices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ShareRedemptionTriggerPrices_lbl" xml:lang="en-US">Share redemption trigger prices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Cash and Cash Equivalent</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion" xlink:label="cik0002065779_PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion" xlink:to="cik0002065779_PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion_lbl" xml:lang="en-US">Percentage of total number of ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xml:lang="en-US">Fair Value, off-Balance-Sheet Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xml:lang="en-US">Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueDisclosure" xlink:to="us-gaap_EquityFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityFairValueDisclosure_lbl" xml:lang="en-US">Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected terms (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_FairValueOfOverallotmentOption" xlink:label="cik0002065779_FairValueOfOverallotmentOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_FairValueOfOverallotmentOption" xlink:to="cik0002065779_FairValueOfOverallotmentOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_FairValueOfOverallotmentOption_lbl" xml:lang="en-US">Fair value of over-allotment option</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_3_lbl" xml:lang="en-US">Estimated share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Term (years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Annual risk-free rate (term-matched)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Expected warrant implied volatility based on warrants from comparable SPAC securities</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CashHeldInTrustAccounts" xlink:label="cik0002065779_CashHeldInTrustAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CashHeldInTrustAccounts" xlink:to="cik0002065779_CashHeldInTrustAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CashHeldInTrustAccounts_lbl" xml:lang="en-US">Cash held in Trust Account</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpenseAbstract" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_SellingAndMarketingExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract_lbl" xml:lang="en-US">Selling and marketing expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_StaffCostsEmployeeBenefitsAndOfficeExpenses" xlink:label="cik0002065779_StaffCostsEmployeeBenefitsAndOfficeExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_StaffCostsEmployeeBenefitsAndOfficeExpenses" xlink:to="cik0002065779_StaffCostsEmployeeBenefitsAndOfficeExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_StaffCostsEmployeeBenefitsAndOfficeExpenses_lbl" xml:lang="en-US">&#8211; Staff costs, employee benefits and office expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ShareBasedCompensations" xlink:label="cik0002065779_ShareBasedCompensations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ShareBasedCompensations" xlink:to="cik0002065779_ShareBasedCompensations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ShareBasedCompensations_lbl" xml:lang="en-US">&#8211; Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_StaffCostsEmployeeBenefitsAndOthers" xlink:label="cik0002065779_StaffCostsEmployeeBenefitsAndOthers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_StaffCostsEmployeeBenefitsAndOthers" xlink:to="cik0002065779_StaffCostsEmployeeBenefitsAndOthers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_StaffCostsEmployeeBenefitsAndOthers_lbl" xml:lang="en-US">&#8211; Staff costs, employee benefits and Others</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">&#8211; Professional service expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ShareBasedCompensation1" xlink:label="cik0002065779_ShareBasedCompensation1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ShareBasedCompensation1" xlink:to="cik0002065779_ShareBasedCompensation1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cik0002065779_ShareBasedCompensation1_lbl" xml:lang="en-US">&#8211; Share-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_lbl" xml:lang="en-US">Loss before income tax expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesIssued" xlink:label="cik0002065779_OrdinarySharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OrdinarySharesIssued" xlink:to="cik0002065779_OrdinarySharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OrdinarySharesIssued_lbl" xml:lang="en-US">Ordinary shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Nature of Operation, Product Information, Concentration of Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash for operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for expected credit losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US">Impairment of long-lived assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_3_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RevenueRecognized" xlink:label="cik0002065779_RevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_RevenueRecognized" xlink:to="cik0002065779_RevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_RevenueRecognized_lbl" xml:lang="en-US">Revenue recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="us-gaap_MarketingAndAdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingAndAdvertisingExpense" xlink:to="us-gaap_MarketingAndAdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingAndAdvertisingExpense_lbl" xml:lang="en-US">Advertising and promotion expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Dividends_lbl" xml:lang="en-US">Dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CashAndCashEquivalentsAndU.s.DollarCoin" xlink:label="cik0002065779_CashAndCashEquivalentsAndU.s.DollarCoin" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CashAndCashEquivalentsAndU.s.DollarCoin" xlink:to="cik0002065779_CashAndCashEquivalentsAndU.s.DollarCoin_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CashAndCashEquivalentsAndU.s.DollarCoin_lbl" xml:lang="en-US">Cash and cash equivalents and U.S. Dollar Coin</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ReceiptOfDigitalAssets" xlink:label="cik0002065779_ReceiptOfDigitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ReceiptOfDigitalAssets" xlink:to="cik0002065779_ReceiptOfDigitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ReceiptOfDigitalAssets_lbl" xml:lang="en-US">Receipt of digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DisbursementOfDigitalAssets" xlink:label="cik0002065779_DisbursementOfDigitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_DisbursementOfDigitalAssets" xlink:to="cik0002065779_DisbursementOfDigitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_DisbursementOfDigitalAssets_lbl" xml:lang="en-US">Disbursement of digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_FairValueGainOrLossOnDigitalAssets" xlink:label="cik0002065779_FairValueGainOrLossOnDigitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_FairValueGainOrLossOnDigitalAssets" xlink:to="cik0002065779_FairValueGainOrLossOnDigitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_FairValueGainOrLossOnDigitalAssets_lbl" xml:lang="en-US">Fair value gain or loss on digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AmortizationOfPrepaidResearchAndDevelopmentCosts" xlink:label="cik0002065779_AmortizationOfPrepaidResearchAndDevelopmentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_AmortizationOfPrepaidResearchAndDevelopmentCosts" xlink:to="cik0002065779_AmortizationOfPrepaidResearchAndDevelopmentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_AmortizationOfPrepaidResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Amortization of prepaid research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration of credit risk</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ConcentrationRiskPercentage" xlink:label="cik0002065779_ConcentrationRiskPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ConcentrationRiskPercentage" xlink:to="cik0002065779_ConcentrationRiskPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_ConcentrationRiskPercentage_lbl" xml:lang="en-US">Concentration of credit risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_2_lbl" xml:lang="en-US">Less: allowance for credit losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_3_lbl" xml:lang="en-US">Allowance for credit losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Net carrying amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SimpleAgreementsForFutureEquity" xlink:to="cik0002065779_SimpleAgreementsForFutureEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="cik0002065779_SimpleAgreementsForFutureEquity_2_lbl" xml:lang="en-US">Balance at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IssuanceOfSimpleAgreementsForFutureEquity" xlink:label="cik0002065779_IssuanceOfSimpleAgreementsForFutureEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_IssuanceOfSimpleAgreementsForFutureEquity" xlink:to="cik0002065779_IssuanceOfSimpleAgreementsForFutureEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_IssuanceOfSimpleAgreementsForFutureEquity_lbl" xml:lang="en-US">Issuance of simple agreements for future equity</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ChangeInFairValue" xlink:label="cik0002065779_ChangeInFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ChangeInFairValue" xlink:to="cik0002065779_ChangeInFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ChangeInFairValue_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SimpleAgreementsForFutureEquity" xlink:to="cik0002065779_SimpleAgreementsForFutureEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="cik0002065779_SimpleAgreementsForFutureEquity_3_lbl" xml:lang="en-US">Balance at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US">Aggregate gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AdditionalSafesProceeds" xlink:label="cik0002065779_AdditionalSafesProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_AdditionalSafesProceeds" xlink:to="cik0002065779_AdditionalSafesProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_AdditionalSafesProceeds_lbl" xml:lang="en-US">Additional SAFEs proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CumulativeProceeds" xlink:label="cik0002065779_CumulativeProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CumulativeProceeds" xlink:to="cik0002065779_CumulativeProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CumulativeProceeds_lbl" xml:lang="en-US">Cumulative proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EquityFinancingDescription" xlink:label="cik0002065779_EquityFinancingDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_EquityFinancingDescription" xlink:to="cik0002065779_EquityFinancingDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_EquityFinancingDescription_lbl" xml:lang="en-US">Equity Financing description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">US Statutory income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Change in fair value of simple agreements for future equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Changes in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forward</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total deferred tax assets, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Balance at the beginning of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Additions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_3_lbl" xml:lang="en-US">Balance at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Federal income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_IncomeStatementLocationsAxis" xlink:to="cik0002065779_IncomeStatementLocationsAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_IncomeStatementLocationsAxis_2_lbl" xml:lang="en-US">IncomeStatementLocationsAxis [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_3_lbl" xml:lang="en-US">Share-based compensation expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SharesDescription" xlink:label="cik0002065779_SharesDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SharesDescription" xlink:to="cik0002065779_SharesDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SharesDescription_lbl" xml:lang="en-US">Shares description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3_lbl" xml:lang="en-US">Risk free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DiscountRate" xlink:label="cik0002065779_DiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_DiscountRate" xlink:to="cik0002065779_DiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_DiscountRate_lbl" xml:lang="en-US">Discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PerpetualRate" xlink:label="cik0002065779_PerpetualRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_PerpetualRate" xlink:to="cik0002065779_PerpetualRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_PerpetualRate_lbl" xml:lang="en-US">Perpetual rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and administrative expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_GrantedEquityAward" xlink:label="cik0002065779_GrantedEquityAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_GrantedEquityAward" xlink:to="cik0002065779_GrantedEquityAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_GrantedEquityAward_lbl" xml:lang="en-US">Granted equity award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ConsultingFees" xlink:label="cik0002065779_ConsultingFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ConsultingFees" xlink:to="cik0002065779_ConsultingFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ConsultingFees_lbl" xml:lang="en-US">Consulting fees</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OutstandingBalancesPayable" xlink:label="cik0002065779_OutstandingBalancesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OutstandingBalancesPayable" xlink:to="cik0002065779_OutstandingBalancesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OutstandingBalancesPayable_lbl" xml:lang="en-US">Outstanding balances payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net loss attributable to ordinary shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DenominatorForBasicAndDilutedLossPerShareAbstract" xlink:label="cik0002065779_DenominatorForBasicAndDilutedLossPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_DenominatorForBasicAndDilutedLossPerShareAbstract" xlink:to="cik0002065779_DenominatorForBasicAndDilutedLossPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_DenominatorForBasicAndDilutedLossPerShareAbstract_lbl" xml:lang="en-US">Denominator for basic and diluted loss per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3_lbl" xml:lang="en-US">Weighted-average ordinary shares outstanding, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3_lbl" xml:lang="en-US">Weighted-average ordinary shares outstanding, diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_3_lbl" xml:lang="en-US">Basic loss per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_3_lbl" xml:lang="en-US">Diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_NumeratorAbstract" xlink:label="cik0002065779_NumeratorAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_NumeratorAbstract" xlink:to="cik0002065779_NumeratorAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_NumeratorAbstract_lbl" xml:lang="en-US">Numerator:</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DenominatorAbstract" xlink:label="cik0002065779_DenominatorAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_DenominatorAbstract" xlink:to="cik0002065779_DenominatorAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_DenominatorAbstract_lbl" xml:lang="en-US">Denominator:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_LossPerOrdinaryShareAbstarct" xlink:to="cik0002065779_LossPerOrdinaryShareAbstarct_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cik0002065779_LossPerOrdinaryShareAbstarct_2_lbl" xml:lang="en-US">Basic and diluted(ii)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:label="us-gaap_ProceedsFromSaleOfNotesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:to="us-gaap_ProceedsFromSaleOfNotesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfNotesReceivable_lbl" xml:lang="en-US">Proceeds from safes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Business combination payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesPerShare" xlink:label="cik0002065779_OrdinarySharesPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OrdinarySharesPerShare" xlink:to="cik0002065779_OrdinarySharesPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OrdinarySharesPerShare_lbl" xml:lang="en-US">ordinary shares per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingTable" xlink:label="us-gaap_CryptoAssetHoldingTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetHoldingTable" xlink:to="us-gaap_CryptoAssetHoldingTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetHoldingTable_lbl" xml:lang="en-US">Crypto Asset, Holding [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingLineItems" xlink:label="us-gaap_CryptoAssetHoldingLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetHoldingLineItems" xlink:to="us-gaap_CryptoAssetHoldingLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetHoldingLineItems_lbl" xml:lang="en-US">Crypto Asset, Holding [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetFairValue" xlink:label="us-gaap_CryptoAssetFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetFairValue" xlink:to="us-gaap_CryptoAssetFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CryptoAssetFairValue_lbl" xml:lang="en-US">Beginning balance, January 1</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetPurchase" xlink:label="us-gaap_CryptoAssetPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetPurchase" xlink:to="us-gaap_CryptoAssetPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CryptoAssetPurchase_lbl" xml:lang="en-US">Additions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetSale" xlink:label="us-gaap_CryptoAssetSale" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetSale" xlink:to="us-gaap_CryptoAssetSale_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CryptoAssetSale_lbl" xml:lang="en-US">Disposals - sold for US dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetDisposition" xlink:label="us-gaap_CryptoAssetDisposition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetDisposition" xlink:to="us-gaap_CryptoAssetDisposition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CryptoAssetDisposition_lbl" xml:lang="en-US">Disposals</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetFairValue" xlink:to="us-gaap_CryptoAssetFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CryptoAssetFairValue_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherCurrentAssets" xlink:label="cik0002065779_OtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OtherCurrentAssets" xlink:to="cik0002065779_OtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Cost and expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_InterestIncomeOther_3_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc" xlink:label="cik0002065779_TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc" xlink:to="cik0002065779_TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc_lbl" xml:lang="en-US">Total operating activities settled in digital assets and USDC</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl" xml:lang="en-US">Investment proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_2_lbl" xml:lang="en-US">Stockholders' Equity Note, Subscriptions Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_2_lbl" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_2_lbl" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity" xlink:to="cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity_2_lbl" xml:lang="en-US">ChangeInFairValueOfSimpleAgreementsForFutureEquity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_2_lbl" xml:lang="en-US">Other Income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_2_lbl" xml:lang="en-US">Selling and Marketing Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and Development Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ForfeitureOfFounderShares" xlink:to="cik0002065779_ForfeitureOfFounderShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ForfeitureOfFounderShares_2_lbl" xml:lang="en-US">ForfeitureOfFounderShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_2_lbl" xml:lang="en-US">Employee Benefits and Share-Based Compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin" xlink:to="cik0002065779_OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin_2_lbl" xml:lang="en-US">OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_IncreaseDecreaseInAdvanceToSuppliers" xlink:to="cik0002065779_IncreaseDecreaseInAdvanceToSuppliers_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_IncreaseDecreaseInAdvanceToSuppliers_2_lbl" xml:lang="en-US">IncreaseDecreaseInAdvanceToSuppliers</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_IncreaseDecreaseInRefundableDepositsReceivable" xlink:to="cik0002065779_IncreaseDecreaseInRefundableDepositsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_IncreaseDecreaseInRefundableDepositsReceivable_2_lbl" xml:lang="en-US">IncreaseDecreaseInRefundableDepositsReceivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_IncreaseDecreaseInRefundableDepositsPayable" xlink:to="cik0002065779_IncreaseDecreaseInRefundableDepositsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_IncreaseDecreaseInRefundableDepositsPayable_2_lbl" xml:lang="en-US">IncreaseDecreaseInRefundableDepositsPayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:to="us-gaap_PaymentsToAcquireRestrictedInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireRestrictedInvestments_2_lbl" xml:lang="en-US">Payments to Acquire Restricted Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_2_lbl" xml:lang="en-US">Repayments of Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_PaymentForDeferredOfferingCosts" xlink:to="cik0002065779_PaymentForDeferredOfferingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_PaymentForDeferredOfferingCosts_2_lbl" xml:lang="en-US">PaymentForDeferredOfferingCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_2_lbl" xml:lang="en-US">Stock Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OtherReceivablesTextBlock" xlink:to="cik0002065779_OtherReceivablesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OtherReceivablesTextBlock_2_lbl" xml:lang="en-US">OtherReceivablesTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_RefundableDepositsPayableTextBlock" xlink:to="cik0002065779_RefundableDepositsPayableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_RefundableDepositsPayableTextBlock_2_lbl" xml:lang="en-US">RefundableDepositsPayableTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SimpleAgreementsForFutureEquityTextBlock" xlink:to="cik0002065779_SimpleAgreementsForFutureEquityTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SimpleAgreementsForFutureEquityTextBlock_2_lbl" xml:lang="en-US">SimpleAgreementsForFutureEquityTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_2_lbl" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_AdvanceToSuppliersPolicyTextBlock" xlink:to="cik0002065779_AdvanceToSuppliersPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_AdvanceToSuppliersPolicyTextBlock_2_lbl" xml:lang="en-US">AdvanceToSuppliersPolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_RefundableDepositsReceivablePolicyTextBlock" xlink:to="cik0002065779_RefundableDepositsReceivablePolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_RefundableDepositsReceivablePolicyTextBlock_2_lbl" xml:lang="en-US">RefundableDepositsReceivablePolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_SimpleAgreementsForFutureEquityPolicyTextBlock" xlink:to="cik0002065779_SimpleAgreementsForFutureEquityPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_SimpleAgreementsForFutureEquityPolicyTextBlock_2_lbl" xml:lang="en-US">SimpleAgreementsForFutureEquityPolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ContractLiabilitiesPolicyTextBlock" xlink:to="cik0002065779_ContractLiabilitiesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ContractLiabilitiesPolicyTextBlock_2_lbl" xml:lang="en-US">ContractLiabilitiesPolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_2_lbl" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_2_lbl" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_CryptoAssets" xlink:to="cik0002065779_CryptoAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_CryptoAssets_2_lbl" xml:lang="en-US">CryptoAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_DeferredOfferingCostsPolicyTextBlock" xlink:to="cik0002065779_DeferredOfferingCostsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_DeferredOfferingCostsPolicyTextBlock_2_lbl" xml:lang="en-US">DeferredOfferingCostsPolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_PrepaidResearchAndDevelopmentExpensesPolicyTextBlock" xlink:to="cik0002065779_PrepaidResearchAndDevelopmentExpensesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_PrepaidResearchAndDevelopmentExpensesPolicyTextBlock_2_lbl" xml:lang="en-US">PrepaidResearchAndDevelopmentExpensesPolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OtherReceivablesPolicyRextBlock" xlink:to="cik0002065779_OtherReceivablesPolicyRextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OtherReceivablesPolicyRextBlock_2_lbl" xml:lang="en-US">OtherReceivablesPolicyRextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_RefundableDepositsPayablePolicyTextBlock" xlink:to="cik0002065779_RefundableDepositsPayablePolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_RefundableDepositsPayablePolicyTextBlock_2_lbl" xml:lang="en-US">RefundableDepositsPayablePolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_3_lbl" xml:lang="en-US">Temporary Equity, Par Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OtherOfferingCost" xlink:to="cik0002065779_OtherOfferingCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OtherOfferingCost_2_lbl" xml:lang="en-US">OtherOfferingCost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_OrdinarySharesSubjectToPossibleRedemption" xlink:to="cik0002065779_OrdinarySharesSubjectToPossibleRedemption_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_OrdinarySharesSubjectToPossibleRedemption_2_lbl" xml:lang="en-US">OrdinarySharesSubjectToPossibleRedemption</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_AggregatePurchasePrice" xlink:to="cik0002065779_AggregatePurchasePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_AggregatePurchasePrice_2_lbl" xml:lang="en-US">AggregatePurchasePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_2_lbl" xml:lang="en-US">Professional and Contract Services Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ShareBasedCompensation1" xlink:to="cik0002065779_ShareBasedCompensation1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ShareBasedCompensation1_2_lbl" xml:lang="en-US">ShareBasedCompensation1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2_lbl" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Dividends_2_lbl" xml:lang="en-US">Dividends [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_2_lbl" xml:lang="en-US">Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_2_lbl" xml:lang="en-US">Concentration Risk, Percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cik0002065779_ConcentrationRiskPercentage" xlink:to="cik0002065779_ConcentrationRiskPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cik0002065779_ConcentrationRiskPercentage_2_lbl" xml:lang="en-US">ConcentrationRiskPercentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_2_lbl" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_2_lbl" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Other, Accumulated Depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_4_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetFairValue" xlink:to="us-gaap_CryptoAssetFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetFairValue_3_lbl" xml:lang="en-US">Crypto Asset, Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetPurchase" xlink:to="us-gaap_CryptoAssetPurchase_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetPurchase_2_lbl" xml:lang="en-US">Crypto Asset, Purchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetSale" xlink:to="us-gaap_CryptoAssetSale_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetSale_2_lbl" xml:lang="en-US">Crypto Asset, Sale</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetDisposition" xlink:to="us-gaap_CryptoAssetDisposition_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetDisposition_2_lbl" xml:lang="en-US">Crypto Asset, Disposition</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>26
<FILENAME>cik0002065779-20260331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Plus; Version: 6.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#Cover" roleURI="http://cik0002065779/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BalanceSheet" roleURI="http://cik0002065779/role/BalanceSheet" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BalanceSheetParenthetical" roleURI="http://cik0002065779/role/BalanceSheetParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#StatementOfOperations" roleURI="http://cik0002065779/role/StatementOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#StatementOfChangesInStockholdersDeficit" roleURI="http://cik0002065779/role/StatementOfChangesInStockholdersDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#StatementOfCashFlows" roleURI="http://cik0002065779/role/StatementOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#DescriptionOfOrganizationAndBusinessOperations" roleURI="http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SignificantAccountingPolicies" roleURI="http://cik0002065779/role/SignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SegmentInformation" roleURI="http://cik0002065779/role/SegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BusinessCombination" roleURI="http://cik0002065779/role/BusinessCombination" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ShareCapital" roleURI="http://cik0002065779/role/ShareCapital" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SubsequentEvents" roleURI="http://cik0002065779/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#DescriptionOfOrganizationBusinessOperations" roleURI="http://cik0002065779/role/DescriptionOfOrganizationBusinessOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#InitialPublicOffering" roleURI="http://cik0002065779/role/InitialPublicOffering" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#PrivatePlacement" roleURI="http://cik0002065779/role/PrivatePlacement" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#RelatedPartyTransactions" roleURI="http://cik0002065779/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CommitmentsAndContingencies" roleURI="http://cik0002065779/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#StockholdersEquity" roleURI="http://cik0002065779/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurements" roleURI="http://cik0002065779/role/FairValueMeasurements" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#OrganizationAndPrincipalActivities" roleURI="http://cik0002065779/role/OrganizationAndPrincipalActivities" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDisclosure" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ConcentrationAndRisk" roleURI="http://cik0002065779/role/ConcentrationAndRisk" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurementsDisclosure" roleURI="http://cik0002065779/role/FairValueMeasurementsDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#AccountsReceivable" roleURI="http://cik0002065779/role/AccountsReceivable" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#OtherReceivables" roleURI="http://cik0002065779/role/OtherReceivables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#EquipmentNet" roleURI="http://cik0002065779/role/EquipmentNet" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#RefundableDepositsPayable" roleURI="http://cik0002065779/role/RefundableDepositsPayable" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SimpleAgreementsForFutureEquity" roleURI="http://cik0002065779/role/SimpleAgreementsForFutureEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#IncomeTaxes" roleURI="http://cik0002065779/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#Share-basedCompensation" roleURI="http://cik0002065779/role/Share-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#RelatedPartyTransactionsDisclosure" roleURI="http://cik0002065779/role/RelatedPartyTransactionsDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BasicAndDilutedNetLossPerShare" roleURI="http://cik0002065779/role/BasicAndDilutedNetLossPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CommitmentsAndContingenciesDisclosure" roleURI="http://cik0002065779/role/CommitmentsAndContingenciesDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CryptoAssets" roleURI="http://cik0002065779/role/CryptoAssets" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://cik0002065779/role/SignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurementsTables" roleURI="http://cik0002065779/role/FairValueMeasurementsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesTablesDisclosure" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ConcentrationAndRiskTables" roleURI="http://cik0002065779/role/ConcentrationAndRiskTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurementsTablesDisclosure" roleURI="http://cik0002065779/role/FairValueMeasurementsTablesDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#AccountsReceivableTables" roleURI="http://cik0002065779/role/AccountsReceivableTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#EquipmentNetTables" roleURI="http://cik0002065779/role/EquipmentNetTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SimpleAgreementsForFutureEquityTables" roleURI="http://cik0002065779/role/SimpleAgreementsForFutureEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#IncomeTaxesTables" roleURI="http://cik0002065779/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#Share-basedCompensationTables" roleURI="http://cik0002065779/role/Share-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BasicAndDilutedNetLossPerShareTables" roleURI="http://cik0002065779/role/BasicAndDilutedNetLossPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CryptoAssetsTables" roleURI="http://cik0002065779/role/CryptoAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#DescriptionOfOrganizationAndBusinessOperationsDetailsNarrative" roleURI="http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperationsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BusinessCombinationDetailsNarrative" roleURI="http://cik0002065779/role/BusinessCombinationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ShareCapitalDetailsNarrative" roleURI="http://cik0002065779/role/ShareCapitalDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#DescriptionOfOrganizationBusinessOperationsDetailsNarrative" roleURI="http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#InitialPublicOfferingDetailsNarrative" roleURI="http://cik0002065779/role/InitialPublicOfferingDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#PrivatePlacementDetailsNarrative" roleURI="http://cik0002065779/role/PrivatePlacementDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#StockholdersEquityDetailsNarrative" roleURI="http://cik0002065779/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurementsDetails" roleURI="http://cik0002065779/role/FairValueMeasurementsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurementsDetails1" roleURI="http://cik0002065779/role/FairValueMeasurementsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#FairValueMeasurementsDetails2" roleURI="http://cik0002065779/role/FairValueMeasurementsDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SegmentInformationDetails" roleURI="http://cik0002065779/role/SegmentInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#OrganizationAndPrincipalActivitiesDetailsNarrative" roleURI="http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetails2" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetails3" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" roleURI="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ConcentrationAndRiskDetails" roleURI="http://cik0002065779/role/ConcentrationAndRiskDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ConcentrationAndRiskDetails1" roleURI="http://cik0002065779/role/ConcentrationAndRiskDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ConcentrationAndRiskDetails2" roleURI="http://cik0002065779/role/ConcentrationAndRiskDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#ConcentrationAndRiskDetails3" roleURI="http://cik0002065779/role/ConcentrationAndRiskDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#AccountsReceivableDetails" roleURI="http://cik0002065779/role/AccountsReceivableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#AccountsReceivableDetailsNarrative" roleURI="http://cik0002065779/role/AccountsReceivableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#OtherReceivablesDetailsNarrative" roleURI="http://cik0002065779/role/OtherReceivablesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#EquipmentNetDetails" roleURI="http://cik0002065779/role/EquipmentNetDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#EquipmentNetDetailsNarrative" roleURI="http://cik0002065779/role/EquipmentNetDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#RefundableDepositsPayableDetailsNarrative" roleURI="http://cik0002065779/role/RefundableDepositsPayableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SimpleAgreementsForFutureEquityDetails" roleURI="http://cik0002065779/role/SimpleAgreementsForFutureEquityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SimpleAgreementsForFutureEquityDetailsNarrative" roleURI="http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#IncomeTaxesDetails" roleURI="http://cik0002065779/role/IncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#IncomeTaxesDetails1" roleURI="http://cik0002065779/role/IncomeTaxesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#IncomeTaxesDetails2" roleURI="http://cik0002065779/role/IncomeTaxesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#IncomeTaxesDetailsNarrative" roleURI="http://cik0002065779/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#Share-basedCompensationDetails" roleURI="http://cik0002065779/role/Share-basedCompensationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#Share-basedCompensationDetailsNarrative" roleURI="http://cik0002065779/role/Share-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#RelatedPartyTransactionsDetailsNarrativeDisclosure" roleURI="http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrativeDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#BasicAndDilutedNetLossPerShareDetails" roleURI="http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#SegmentInformationDetails1" roleURI="http://cik0002065779/role/SegmentInformationDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CommitmentsAndContingenciesDetailsNarrativeDisclosure" roleURI="http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CryptoAssetsDetails" roleURI="http://cik0002065779/role/CryptoAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CryptoAssetsDetails1" roleURI="http://cik0002065779/role/CryptoAssetsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cik0002065779-20260331.xsd#CryptoAssetsDetailsNarrative" roleURI="http://cik0002065779/role/CryptoAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpPensionBenefitsAdjustments" roleURI="http://xbrl.sec.gov/ecd/role/PvpPensionBenefitsAdjustments" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/BalanceSheet" xlink:title="00000002 - Statement - BALANCE SHEET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassAOrdinarySharesMember" xlink:label="loc_cik0002065779ClassAOrdinarySharesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779ClassAOrdinarySharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassBOrdinarySharesMember" xlink:label="loc_cik0002065779ClassBOrdinarySharesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779ClassBOrdinarySharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_U.s.DollarCoin" xlink:label="loc_cik0002065779U.s.DollarCoin" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779U.s.DollarCoin" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaapAccountsAndOtherReceivablesNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsAndOtherReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PrepaidResearchAndDevelopmentExpenses" xlink:label="loc_cik0002065779PrepaidResearchAndDevelopmentExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779PrepaidResearchAndDevelopmentExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AdvanceToSuppliers" xlink:label="loc_cik0002065779AdvanceToSuppliers" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779AdvanceToSuppliers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsReceivable" xlink:label="loc_cik0002065779RefundableDepositsReceivable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RefundableDepositsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CashHeldInTrustAccount" xlink:label="loc_cik0002065779CashHeldInTrustAccount" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CashHeldInTrustAccount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SimpleAgreementsForFutureEquity" xlink:label="loc_cik0002065779SimpleAgreementsForFutureEquity" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_cik0002065779SimpleAgreementsForFutureEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositContractsLiabilities" xlink:label="loc_us-gaapDepositContractsLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDepositContractsLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsPayable" xlink:label="loc_cik0002065779RefundableDepositsPayable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_cik0002065779RefundableDepositsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherCurrentLiabilities" xlink:label="loc_cik0002065779OtherCurrentLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_cik0002065779OtherCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AmountDueToRelatedParty" xlink:label="loc_cik0002065779AmountDueToRelatedParty" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_cik0002065779AmountDueToRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/BalanceSheetParenthetical" xlink:title="00000003 - Statement - BALANCE SHEET (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassAOrdinarySharesMember" xlink:label="loc_cik0002065779ClassAOrdinarySharesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779ClassAOrdinarySharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassBOrdinarySharesMember" xlink:label="loc_cik0002065779ClassBOrdinarySharesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779ClassBOrdinarySharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesClassBMember" xlink:label="loc_cik0002065779OrdinarySharesClassBMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_cik0002065779OrdinarySharesClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesClassAMember" xlink:label="loc_cik0002065779OrdinarySharesClassAMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_cik0002065779OrdinarySharesClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaapTemporaryEquityRedemptionPricePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityRedemptionPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SharesSubjectToRedemption" xlink:label="loc_cik0002065779SharesSubjectToRedemption" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779SharesSubjectToRedemption" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/StatementOfOperations" xlink:title="00000004 - Statement - STATEMENT OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesClassAMember" xlink:label="loc_cik0002065779OrdinarySharesClassAMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779OrdinarySharesClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesClassBMember" xlink:label="loc_cik0002065779OrdinarySharesClassBMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779OrdinarySharesClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity" xlink:label="loc_cik0002065779ChangeInFairValueOfSimpleAgreementsForFutureEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ChangeInFairValueOfSimpleAgreementsForFutureEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAbstract" xlink:label="loc_us-gaapOtherIncomeAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherIncomeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_LossPerOrdinaryShareAbstarct" xlink:label="loc_cik0002065779LossPerOrdinaryShareAbstarct" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779LossPerOrdinaryShareAbstarct" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/StatementOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - STATEMENT OF CHANGES IN STOCKHOLDERS&apos; DEFICIT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SubscriptionReceivableMember" xlink:label="loc_cik0002065779SubscriptionReceivableMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_cik0002065779SubscriptionReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesClassAMember" xlink:label="loc_cik0002065779OrdinarySharesClassAMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_cik0002065779OrdinarySharesClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesClassBMember" xlink:label="loc_cik0002065779OrdinarySharesClassBMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_cik0002065779OrdinarySharesClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesMember" xlink:label="loc_cik0002065779OrdinarySharesMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_cik0002065779OrdinarySharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralArcMergerCorporationMember" xlink:label="loc_cik0002065779DBoralArcMergerCorporationMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_cik0002065779DBoralArcMergerCorporationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFee" xlink:label="loc_cik0002065779CommonStockIssuedToInitialShareholderForSubscriptionFee" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CommonStockIssuedToInitialShareholderForSubscriptionFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFeeShares" xlink:label="loc_cik0002065779CommonStockIssuedToInitialShareholderForSubscriptionFeeShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CommonStockIssuedToInitialShareholderForSubscriptionFeeShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassBOrdinarySharesIssuedToSponsor" xlink:label="loc_cik0002065779ClassBOrdinarySharesIssuedToSponsor" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ClassBOrdinarySharesIssuedToSponsor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RedesignationOfAuthorizedOrdinaryShares" xlink:label="loc_cik0002065779RedesignationOfAuthorizedOrdinaryShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RedesignationOfAuthorizedOrdinaryShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassBOrdinarySharesIssuedToSponsorShares" xlink:label="loc_cik0002065779ClassBOrdinarySharesIssuedToSponsorShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ClassBOrdinarySharesIssuedToSponsorShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCosts" xlink:label="loc_cik0002065779SaleOfPrivateUnitsNetOfIssuanceCosts" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779SaleOfPrivateUnitsNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCostsShares" xlink:label="loc_cik0002065779SaleOfPrivateUnitsNetOfIssuanceCostsShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779SaleOfPrivateUnitsNetOfIssuanceCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IssuanceOfPublicWarrantsNetOfIssuanceCosts" xlink:label="loc_cik0002065779IssuanceOfPublicWarrantsNetOfIssuanceCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779IssuanceOfPublicWarrantsNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IssuanceOfRepresentativeShares" xlink:label="loc_cik0002065779IssuanceOfRepresentativeShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779IssuanceOfRepresentativeShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IssuanceOfRepresentativeSharesShares" xlink:label="loc_cik0002065779IssuanceOfRepresentativeSharesShares" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779IssuanceOfRepresentativeSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AccretionInValueOfClassOrdinaryShares" xlink:label="loc_cik0002065779AccretionInValueOfClassOrdinaryShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779AccretionInValueOfClassOrdinaryShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ReverseOverallotmentOptionLiability" xlink:label="loc_cik0002065779ReverseOverallotmentOptionLiability" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ReverseOverallotmentOptionLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ForfeitureOfFounderShares" xlink:label="loc_cik0002065779ForfeitureOfFounderShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ForfeitureOfFounderShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ForfeitureOfFounderSharesShares" xlink:label="loc_cik0002065779ForfeitureOfFounderSharesShares" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ForfeitureOfFounderSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AdjustmentOfAccruedOfferingCosts" xlink:label="loc_cik0002065779AdjustmentOfAccruedOfferingCosts" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779AdjustmentOfAccruedOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AccretionInValueOfClassOrdinaryShares" xlink:label="loc_cik0002065779AccretionInValueOfClassOrdinaryShares_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779AccretionInValueOfClassOrdinaryShares_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RedesignationOfAuthorizedOrdinarySharesShares" xlink:label="loc_cik0002065779RedesignationOfAuthorizedOrdinarySharesShares" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RedesignationOfAuthorizedOrdinarySharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/StatementOfCashFlows" xlink:title="00000006 - Statement - STATEMENT OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquities" xlink:label="loc_cik0002065779ChangeInFairValueOfSimpleAgreementsForFutureEquities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ChangeInFairValueOfSimpleAgreementsForFutureEquities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin" xlink:label="loc_cik0002065779OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PaymentOfExpensesThroughRelatedParty" xlink:label="loc_cik0002065779PaymentOfExpensesThroughRelatedParty" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_cik0002065779PaymentOfExpensesThroughRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PaymentOfExpensesThroughPromissoryNoteRelatedParty" xlink:label="loc_cik0002065779PaymentOfExpensesThroughPromissoryNoteRelatedParty" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_cik0002065779PaymentOfExpensesThroughPromissoryNoteRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IncreaseDecreaseInAdvanceToSuppliers" xlink:label="loc_cik0002065779IncreaseDecreaseInAdvanceToSuppliers" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_cik0002065779IncreaseDecreaseInAdvanceToSuppliers" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IncreaseDecreaseInRefundableDepositsReceivable" xlink:label="loc_cik0002065779IncreaseDecreaseInRefundableDepositsReceivable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_cik0002065779IncreaseDecreaseInRefundableDepositsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IncreaseDecreaseInRefundableDepositsPayable" xlink:label="loc_cik0002065779IncreaseDecreaseInRefundableDepositsPayable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_cik0002065779IncreaseDecreaseInRefundableDepositsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaapPaymentsToAcquireRestrictedInvestments" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireRestrictedInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ProceedsFromSaleOfDigitalAssetsAndUsdc" xlink:label="loc_cik0002065779ProceedsFromSaleOfDigitalAssetsAndUsdc" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_cik0002065779ProceedsFromSaleOfDigitalAssetsAndUsdc" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid" xlink:label="loc_cik0002065779ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_cik0002065779ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="loc_us-gaapPaymentsForRepurchaseOfInitialPublicOffering" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForRepurchaseOfInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PaymentForDeferredOfferingCosts" xlink:label="loc_cik0002065779PaymentForDeferredOfferingCosts" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_cik0002065779PaymentForDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ProceedsFromSimpleAgreementsForFutureEquity" xlink:label="loc_cik0002065779ProceedsFromSimpleAgreementsForFutureEquity" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_cik0002065779ProceedsFromSimpleAgreementsForFutureEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaapNotesIssued1" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNotesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionDebtAssumed1" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionDescription" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionDescription" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionInventoryAcquired1" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionInventoryAcquired1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAssumed1" xlink:label="loc_us-gaapNotesAssumed1" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNotesAssumed1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansAssumed1" xlink:label="loc_us-gaapLoansAssumed1" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLoansAssumed1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperations" xlink:title="999007 - Disclosure - Description of Organization and Business Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SignificantAccountingPolicies" xlink:title="999008 - Disclosure - Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SegmentInformation" xlink:title="999009 - Disclosure - Segment information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/BusinessCombination" xlink:title="999010 - Disclosure - Business Combination">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaapBusinessCombinationDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/ShareCapital" xlink:title="999011 - Disclosure - Share Capital">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SubsequentEvents" xlink:title="999012 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/DescriptionOfOrganizationBusinessOperations" xlink:title="999013 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPolicies" xlink:title="999014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/InitialPublicOffering" xlink:title="999015 - Disclosure - INITIAL PUBLIC OFFERING">
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DisclosureInitialPublicOfferingAbstract" xlink:label="loc_cik0002065779DisclosureInitialPublicOfferingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cik0002065779DisclosureInitialPublicOfferingAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_InitialPublicOfferingDisclosureTextBlock" xlink:label="loc_cik0002065779InitialPublicOfferingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779InitialPublicOfferingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/PrivatePlacement" xlink:title="999016 - Disclosure - PRIVATE PLACEMENT">
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DisclosurePrivatePlacementAbstract" xlink:label="loc_cik0002065779DisclosurePrivatePlacementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cik0002065779DisclosurePrivatePlacementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PrivatePlacementDisclosureTextBlock" xlink:label="loc_cik0002065779PrivatePlacementDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779PrivatePlacementDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/RelatedPartyTransactions" xlink:title="999017 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/CommitmentsAndContingencies" xlink:title="999018 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/StockholdersEquity" xlink:title="999019 - Disclosure - STOCKHOLDER&#8217;S EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurements" xlink:title="999020 - Disclosure - FAIR VALUE MEASUREMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/OrganizationAndPrincipalActivities" xlink:title="999021 - Disclosure - Organization and principal activities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDisclosure" xlink:title="999022 - Disclosure - Summary of significant accounting policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/ConcentrationAndRisk" xlink:title="999023 - Disclosure - Concentration and risk">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurementsDisclosure" xlink:title="999024 - Disclosure - Fair value measurements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/AccountsReceivable" xlink:title="999025 - Disclosure - Accounts receivable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditLossAbstract" xlink:label="loc_us-gaapCreditLossAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditLossAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:label="loc_us-gaapAccountsAndNontradeReceivableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsAndNontradeReceivableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/OtherReceivables" xlink:title="999026 - Disclosure - Other receivables">
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DisclosureOtherReceivablesAbstract" xlink:label="loc_cik0002065779DisclosureOtherReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cik0002065779DisclosureOtherReceivablesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherReceivablesTextBlock" xlink:label="loc_cik0002065779OtherReceivablesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779OtherReceivablesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/EquipmentNet" xlink:title="999027 - Disclosure - Equipment, net">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/RefundableDepositsPayable" xlink:title="999028 - Disclosure - Refundable deposits payable">
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DisclosureRefundableDepositsPayableAbstract" xlink:label="loc_cik0002065779DisclosureRefundableDepositsPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cik0002065779DisclosureRefundableDepositsPayableAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsPayableTextBlock" xlink:label="loc_cik0002065779RefundableDepositsPayableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RefundableDepositsPayableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SimpleAgreementsForFutureEquity" xlink:title="999029 - Disclosure - Simple agreements for future equity">
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DisclosureSimpleAgreementsForFutureEquityAbstract" xlink:label="loc_cik0002065779DisclosureSimpleAgreementsForFutureEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cik0002065779DisclosureSimpleAgreementsForFutureEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SimpleAgreementsForFutureEquityTextBlock" xlink:label="loc_cik0002065779SimpleAgreementsForFutureEquityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779SimpleAgreementsForFutureEquityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/IncomeTaxes" xlink:title="999030 - Disclosure - Income taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/Share-basedCompensation" xlink:title="999031 - Disclosure - Share-based compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/RelatedPartyTransactionsDisclosure" xlink:title="999032 - Disclosure - Related party transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/BasicAndDilutedNetLossPerShare" xlink:title="999033 - Disclosure - Basic and diluted net loss per share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/CommitmentsAndContingenciesDisclosure" xlink:title="999034 - Disclosure - Commitments and contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/CryptoAssets" xlink:title="999035 - Disclosure - Crypto assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetTextBlock" xlink:label="loc_us-gaapCryptoAssetTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCryptoAssetTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SignificantAccountingPoliciesPolicies" xlink:title="999036 - Disclosure - Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EmergingGrowthCompanyPolicyTextBlock" xlink:label="loc_cik0002065779EmergingGrowthCompanyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_cik0002065779EmergingGrowthCompanyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_cik0002065779RisksAndUncertaintiesPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_cik0002065779RisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999037 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EmergingGrowthCompanyPolicyTextBlock" xlink:label="loc_cik0002065779EmergingGrowthCompanyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779EmergingGrowthCompanyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CashHeldInTrustAccountPolicyTextBlock" xlink:label="loc_cik0002065779CashHeldInTrustAccountPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CashHeldInTrustAccountPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock" xlink:label="loc_cik0002065779OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="loc_us-gaapDerivativesReportingOfDerivativeActivity" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativesReportingOfDerivativeActivity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtendedProductWarrantyPolicy" xlink:label="loc_us-gaapExtendedProductWarrantyPolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapExtendedProductWarrantyPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock" xlink:label="loc_cik0002065779ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_cik0002065779RisksAndUncertaintiesPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" xlink:title="999038 - Disclosure - Summary of significant accounting policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_GoingConcernPolicyTextBlock" xlink:label="loc_cik0002065779GoingConcernPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779GoingConcernPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_FunctionalCurrencyPolicyTextBlock" xlink:label="loc_cik0002065779FunctionalCurrencyPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779FunctionalCurrencyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExpectedCreditLossAndAccountsReceivablePolicyTextBlock" xlink:label="loc_cik0002065779ExpectedCreditLossAndAccountsReceivablePolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ExpectedCreditLossAndAccountsReceivablePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AdvanceToSuppliersPolicyTextBlock" xlink:label="loc_cik0002065779AdvanceToSuppliersPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779AdvanceToSuppliersPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsReceivablePolicyTextBlock" xlink:label="loc_cik0002065779RefundableDepositsReceivablePolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RefundableDepositsReceivablePolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SimpleAgreementsForFutureEquityPolicyTextBlock" xlink:label="loc_cik0002065779SimpleAgreementsForFutureEquityPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779SimpleAgreementsForFutureEquityPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionDeferredRevenue" xlink:label="loc_us-gaapRevenueRecognitionDeferredRevenue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueRecognitionDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ContractLiabilitiesPolicyTextBlock" xlink:label="loc_cik0002065779ContractLiabilitiesPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ContractLiabilitiesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaapCostOfSalesPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfSalesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SellingAndMarketingExpensesPolicyTextBlock" xlink:label="loc_cik0002065779SellingAndMarketingExpensesPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779SellingAndMarketingExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CapitalStructurePolicyTextBlock" xlink:label="loc_cik0002065779CapitalStructurePolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CapitalStructurePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RelatedPartiesPolicyTextBlock" xlink:label="loc_cik0002065779RelatedPartiesPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RelatedPartiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ComprehensiveLossPolicyTextBlock" xlink:label="loc_cik0002065779ComprehensiveLossPolicyTextBlock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ComprehensiveLossPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionDividends" xlink:label="loc_us-gaapRevenueRecognitionDividends" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueRecognitionDividends" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock" xlink:label="loc_cik0002065779RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EmergingGrowthCompanyPolicyTextBlock" xlink:label="loc_cik0002065779EmergingGrowthCompanyPolicyTextBlock" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779EmergingGrowthCompanyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CryptoAssets" xlink:label="loc_cik0002065779CryptoAssets" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CryptoAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DeferredOfferingCostsPolicyTextBlock" xlink:label="loc_cik0002065779DeferredOfferingCostsPolicyTextBlock" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779DeferredOfferingCostsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PrepaidResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="loc_cik0002065779PrepaidResearchAndDevelopmentExpensesPolicyTextBlock" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779PrepaidResearchAndDevelopmentExpensesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherReceivablesPolicyRextBlock" xlink:label="loc_cik0002065779OtherReceivablesPolicyRextBlock" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779OtherReceivablesPolicyRextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsPayablePolicyTextBlock" xlink:label="loc_cik0002065779RefundableDepositsPayablePolicyTextBlock" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RefundableDepositsPayablePolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaapTemporaryEquityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurementsTables" xlink:title="999040 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_cik0002065779OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure" xlink:title="999041 - Disclosure - Summary of significant accounting policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ScheduleOfRevenueRecognitionTableTextBlock" xlink:label="loc_cik0002065779ScheduleOfRevenueRecognitionTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ScheduleOfRevenueRecognitionTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/ConcentrationAndRiskTables" xlink:title="999042 - Disclosure - Concentration and risk (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ScheduleOfConcentrationOfCustomersTableTextBlock" xlink:label="loc_cik0002065779ScheduleOfConcentrationOfCustomersTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ScheduleOfConcentrationOfCustomersTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ScheduleOfAccountsReceivableTextBlock" xlink:label="loc_cik0002065779ScheduleOfAccountsReceivableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ScheduleOfAccountsReceivableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ScheduleOfConcentrationOfSuppliersTableTextBlock" xlink:label="loc_cik0002065779ScheduleOfConcentrationOfSuppliersTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ScheduleOfConcentrationOfSuppliersTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurementsTablesDisclosure" xlink:title="999043 - Disclosure - Fair value measurements (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/AccountsReceivableTables" xlink:title="999044 - Disclosure - Accounts receivable (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditLossAbstract" xlink:label="loc_us-gaapCreditLossAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditLossAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/EquipmentNetTables" xlink:title="999045 - Disclosure - Equipment, net (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SimpleAgreementsForFutureEquityTables" xlink:title="999046 - Disclosure - Simple agreements for future equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DisclosureSimpleAgreementsForFutureEquityAbstract" xlink:label="loc_cik0002065779DisclosureSimpleAgreementsForFutureEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cik0002065779DisclosureSimpleAgreementsForFutureEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/IncomeTaxesTables" xlink:title="999047 - Disclosure - Income taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaapSummaryOfValuationAllowanceTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSummaryOfValuationAllowanceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/Share-basedCompensationTables" xlink:title="999048 - Disclosure - Share-based compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/BasicAndDilutedNetLossPerShareTables" xlink:title="999049 - Disclosure - Basic and diluted net loss per share (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/CryptoAssetsTables" xlink:title="999050 - Disclosure - Crypto assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetActivityTableTextBlock" xlink:label="loc_us-gaapCryptoAssetActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCryptoAssetActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowOperatingCapitalTableTextBlock" xlink:label="loc_us-gaapCashFlowOperatingCapitalTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFlowOperatingCapitalTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperationsDetailsNarrative" xlink:title="999051 - Disclosure - Description of Organization and Business Operations (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/BusinessCombinationDetailsNarrative" xlink:title="999052 - Disclosure - Business Combination (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorp.Member" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorp.Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorp.Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AggregateConsideration" xlink:label="loc_cik0002065779AggregateConsideration" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_cik0002065779AggregateConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/ShareCapitalDetailsNarrative" xlink:title="999053 - Disclosure - Share Capital (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative" xlink:title="999054 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_UnderwriterMember" xlink:label="loc_cik0002065779UnderwriterMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cik0002065779UnderwriterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SponsorMember" xlink:label="loc_cik0002065779SponsorMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cik0002065779SponsorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_FounderSharesMember" xlink:label="loc_cik0002065779FounderSharesMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779FounderSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_TransactionCosts" xlink:label="loc_cik0002065779TransactionCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779TransactionCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RepresentativeShares" xlink:label="loc_cik0002065779RepresentativeShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RepresentativeShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherOfferingCosts" xlink:label="loc_cik0002065779OtherOfferingCosts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779OtherOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CancelledFounderShares" xlink:label="loc_cik0002065779CancelledFounderShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CancelledFounderShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" xlink:label="loc_us-gaapLiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_WorkingCapitalDeficit" xlink:label="loc_cik0002065779WorkingCapitalDeficit" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779WorkingCapitalDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaapRepaymentOfNotesReceivableFromRelatedParties" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRepaymentOfNotesReceivableFromRelatedParties" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="999055 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="loc_us-gaapTemporaryEquityValueExcludingAdditionalPaidInCapital" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ProceedsAllocatedToPublicWarrants" xlink:label="loc_cik0002065779ProceedsAllocatedToPublicWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ProceedsAllocatedToPublicWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ProceedsAllocatedToOverallotmentOption" xlink:label="loc_cik0002065779ProceedsAllocatedToOverallotmentOption" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ProceedsAllocatedToOverallotmentOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassOrdinarySharesIssuanceCosts" xlink:label="loc_cik0002065779ClassOrdinarySharesIssuanceCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ClassOrdinarySharesIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaapTemporaryEquityAccretionToRedemptionValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityAccretionToRedemptionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="loc_us-gaapTemporaryEquityValueExcludingAdditionalPaidInCapital_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityValueExcludingAdditionalPaidInCapital_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1" xlink:title="999056 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesClassAMember" xlink:label="loc_cik0002065779OrdinarySharesClassAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779OrdinarySharesClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesClassBMember" xlink:label="loc_cik0002065779OrdinarySharesClassBMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779OrdinarySharesClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999057 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CashHeldInTrustAccount" xlink:label="loc_cik0002065779CashHeldInTrustAccount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CashHeldInTrustAccount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OfferingCost" xlink:label="loc_cik0002065779OfferingCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779OfferingCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RepresentativeShares" xlink:label="loc_cik0002065779RepresentativeShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RepresentativeShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherOfferingCost" xlink:label="loc_cik0002065779OtherOfferingCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779OtherOfferingCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaapClassOfWarrantOrRightUnissued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightUnissued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" xlink:label="loc_us-gaapWeightedAverageLimitedPartnershipUnitsOutstandingDiluted" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageLimitedPartnershipUnitsOutstandingDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/InitialPublicOfferingDetailsNarrative" xlink:title="999058 - Disclosure - INITIAL PUBLIC OFFERING (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DisclosureInitialPublicOfferingAbstract" xlink:label="loc_cik0002065779DisclosureInitialPublicOfferingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cik0002065779DisclosureInitialPublicOfferingAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/PrivatePlacementDetailsNarrative" xlink:title="999059 - Disclosure - PRIVATE PLACEMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DisclosurePrivatePlacementAbstract" xlink:label="loc_cik0002065779DisclosurePrivatePlacementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cik0002065779DisclosurePrivatePlacementAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999060 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_FounderMember" xlink:label="loc_cik0002065779FounderMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_cik0002065779FounderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_UnsecuredPromissoryNoteMember" xlink:label="loc_cik0002065779UnsecuredPromissoryNoteMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_cik0002065779UnsecuredPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SponsorMember" xlink:label="loc_cik0002065779SponsorMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cik0002065779SponsorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CancelledFounderShares" xlink:label="loc_cik0002065779CancelledFounderShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_cik0002065779CancelledFounderShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination" xlink:label="loc_cik0002065779PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_cik0002065779PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaapRepaymentOfNotesReceivableFromRelatedParties" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentOfNotesReceivableFromRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="loc_us-gaapPaymentsForRepurchaseOfInitialPublicOffering" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDistributionsToAffiliates" xlink:label="loc_us-gaapPaymentsOfDistributionsToAffiliates" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsOfDistributionsToAffiliates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdministrativeFeesExpense" xlink:label="loc_us-gaapAdministrativeFeesExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAdministrativeFeesExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_UnderwriterMember" xlink:label="loc_cik0002065779UnderwriterMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cik0002065779UnderwriterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/StockholdersEquityDetailsNarrative" xlink:title="999062 - Disclosure - STOCKHOLDER&#8217;S EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassAOrdinarySharesMember" xlink:label="loc_cik0002065779ClassAOrdinarySharesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779ClassAOrdinarySharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassBOrdinarySharesMember" xlink:label="loc_cik0002065779ClassBOrdinarySharesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779ClassBOrdinarySharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CommonStockClassBMember" xlink:label="loc_cik0002065779CommonStockClassBMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779CommonStockClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassAOrdinaryShareMember" xlink:label="loc_cik0002065779ClassAOrdinaryShareMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779ClassAOrdinaryShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SponsorMember" xlink:label="loc_cik0002065779SponsorMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cik0002065779SponsorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassAOrdinarySharesMember" xlink:label="loc_cik0002065779ClassAOrdinarySharesMember_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_cik0002065779ClassAOrdinarySharesMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_WarrantsMember" xlink:label="loc_cik0002065779WarrantsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cik0002065779WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaapConversionOfStockNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockByUniqueDescriptionAxis" xlink:to="loc_us-gaapConversionOfStockNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ConversionOfClassBToClassACommonStockMember" xlink:label="loc_cik0002065779ConversionOfClassBToClassACommonStockMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConversionOfStockNameDomain" xlink:to="loc_cik0002065779ConversionOfClassBToClassACommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesSubjectToPossibleRedemption" xlink:label="loc_cik0002065779OrdinarySharesSubjectToPossibleRedemption" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_cik0002065779OrdinarySharesSubjectToPossibleRedemption" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AggregatePurchasePrice" xlink:label="loc_cik0002065779AggregatePurchasePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_cik0002065779AggregatePurchasePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CancellationOfOrdinaryShares" xlink:label="loc_cik0002065779CancellationOfOrdinaryShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_cik0002065779CancellationOfOrdinaryShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaapCommonStockConversionBasis" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockConversionBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PeriodAfterWhichTheWarrantsAreExercisable" xlink:label="loc_cik0002065779PeriodAfterWhichTheWarrantsAreExercisable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_cik0002065779PeriodAfterWhichTheWarrantsAreExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" xlink:label="loc_cik0002065779MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_cik0002065779MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:label="loc_cik0002065779NumberOfTradingDaysForDeterminingTheSharePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_cik0002065779NumberOfTradingDaysForDeterminingTheSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:label="loc_cik0002065779NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_cik0002065779NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate" xlink:label="loc_us-gaapAdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapAdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaapPreferredStockRedemptionPricePerShare" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ShareRedemptionTriggerPrices" xlink:label="loc_cik0002065779ShareRedemptionTriggerPrices" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_cik0002065779ShareRedemptionTriggerPrices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion" xlink:label="loc_cik0002065779PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_cik0002065779PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurementsDetails" xlink:title="999063 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SimpleAgreementsForFutureEquityMember" xlink:label="loc_cik0002065779SimpleAgreementsForFutureEquityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_cik0002065779SimpleAgreementsForFutureEquityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherPayableRelatedToTheEquityOptionMember" xlink:label="loc_cik0002065779OtherPayableRelatedToTheEquityOptionMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_cik0002065779OtherPayableRelatedToTheEquityOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaapEquityFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapEquityFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurementsDetails1" xlink:title="999064 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_FairValueOfOverallotmentOption" xlink:label="loc_cik0002065779FairValueOfOverallotmentOption" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779FairValueOfOverallotmentOption" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/FairValueMeasurementsDetails2" xlink:title="999065 - Disclosure - FAIR VALUE MEASUREMENTS (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PublicWarrantsMember" xlink:label="loc_cik0002065779PublicWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cik0002065779PublicWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SegmentInformationDetails" xlink:title="999066 - Disclosure - Segment information (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DBoralARCAcquisitionICorpMember" xlink:label="loc_cik0002065779DBoralARCAcquisitionICorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779DBoralARCAcquisitionICorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CashHeldInTrustAccounts" xlink:label="loc_cik0002065779CashHeldInTrustAccounts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CashHeldInTrustAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpenseAbstract" xlink:label="loc_us-gaapSellingAndMarketingExpenseAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSellingAndMarketingExpenseAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_StaffCostsEmployeeBenefitsAndOfficeExpenses" xlink:label="loc_cik0002065779StaffCostsEmployeeBenefitsAndOfficeExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract" xlink:to="loc_cik0002065779StaffCostsEmployeeBenefitsAndOfficeExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ShareBasedCompensations" xlink:label="loc_cik0002065779ShareBasedCompensations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract" xlink:to="loc_cik0002065779ShareBasedCompensations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpenseAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_StaffCostsEmployeeBenefitsAndOthers" xlink:label="loc_cik0002065779StaffCostsEmployeeBenefitsAndOthers" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract" xlink:to="loc_cik0002065779StaffCostsEmployeeBenefitsAndOthers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ShareBasedCompensation1" xlink:label="loc_cik0002065779ShareBasedCompensation1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract" xlink:to="loc_cik0002065779ShareBasedCompensation1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity" xlink:label="loc_cik0002065779ChangeInFairValueOfSimpleAgreementsForFutureEquity" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract" xlink:to="loc_cik0002065779ChangeInFairValueOfSimpleAgreementsForFutureEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossBeforeReclassificationsTax" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSellingAndMarketingExpenseAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative" xlink:title="999067 - Disclosure - Organization and principal activities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EvanaAlphaPteLtdMember" xlink:label="loc_cik0002065779EvanaAlphaPteLtdMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_cik0002065779EvanaAlphaPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesIssued" xlink:label="loc_cik0002065779OrdinarySharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_cik0002065779OrdinarySharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2" xlink:title="999068 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RevenueFromIntelligentComputingPowerServiceMember" xlink:label="loc_cik0002065779RevenueFromIntelligentComputingPowerServiceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_cik0002065779RevenueFromIntelligentComputingPowerServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ReservedCapacityArrangementsMember" xlink:label="loc_cik0002065779ReservedCapacityArrangementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_cik0002065779ReservedCapacityArrangementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OnDemandArrangementsMember" xlink:label="loc_cik0002065779OnDemandArrangementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_cik0002065779OnDemandArrangementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3" xlink:title="999069 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RevenueFromIntelligentComputingPowerServiceMember" xlink:label="loc_cik0002065779RevenueFromIntelligentComputingPowerServiceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_cik0002065779RevenueFromIntelligentComputingPowerServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RevenueFromComprehensiveDataCenterServicesMember" xlink:label="loc_cik0002065779RevenueFromComprehensiveDataCenterServicesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_cik0002065779RevenueFromComprehensiveDataCenterServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" xlink:title="999070 - Disclosure - Summary of significant accounting policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassAOrdinarySharesMember" xlink:label="loc_cik0002065779ClassAOrdinarySharesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779ClassAOrdinarySharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ClassBOrdinarySharesMember" xlink:label="loc_cik0002065779ClassBOrdinarySharesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cik0002065779ClassBOrdinarySharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsReceivable" xlink:label="loc_cik0002065779RefundableDepositsReceivable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RefundableDepositsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RevenueRecognized" xlink:label="loc_cik0002065779RevenueRecognized" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RevenueRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="loc_us-gaapMarketingAndAdvertisingExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketingAndAdvertisingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Dividends" xlink:label="loc_us-gaapDividends" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividends" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CashAndCashEquivalentsAndU.s.DollarCoin" xlink:label="loc_cik0002065779CashAndCashEquivalentsAndU.s.DollarCoin" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CashAndCashEquivalentsAndU.s.DollarCoin" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ReceiptOfDigitalAssets" xlink:label="loc_cik0002065779ReceiptOfDigitalAssets" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ReceiptOfDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DisbursementOfDigitalAssets" xlink:label="loc_cik0002065779DisbursementOfDigitalAssets" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779DisbursementOfDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_FairValueGainOrLossOnDigitalAssets" xlink:label="loc_cik0002065779FairValueGainOrLossOnDigitalAssets" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779FairValueGainOrLossOnDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AmortizationOfPrepaidResearchAndDevelopmentCosts" xlink:label="loc_cik0002065779AmortizationOfPrepaidResearchAndDevelopmentCosts" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779AmortizationOfPrepaidResearchAndDevelopmentCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsPayable" xlink:label="loc_cik0002065779RefundableDepositsPayable" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RefundableDepositsPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/ConcentrationAndRiskDetails" xlink:title="999071 - Disclosure - Concentration and risk (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerAMember" xlink:label="loc_cik0002065779CustomerAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerBMember" xlink:label="loc_cik0002065779CustomerBMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerCMember" xlink:label="loc_cik0002065779CustomerCMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerDMember" xlink:label="loc_cik0002065779CustomerDMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerEMember" xlink:label="loc_cik0002065779CustomerEMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerEMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerFMember" xlink:label="loc_cik0002065779CustomerFMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerFMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/ConcentrationAndRiskDetails1" xlink:title="999072 - Disclosure - Concentration and risk (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerGMember" xlink:label="loc_cik0002065779CustomerGMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerGMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerHMember" xlink:label="loc_cik0002065779CustomerHMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerHMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerFMember" xlink:label="loc_cik0002065779CustomerFMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerFMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerDMember" xlink:label="loc_cik0002065779CustomerDMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerIMember" xlink:label="loc_cik0002065779CustomerIMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerIMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerAMember" xlink:label="loc_cik0002065779CustomerAMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerBMember" xlink:label="loc_cik0002065779CustomerBMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CustomerEMember" xlink:label="loc_cik0002065779CustomerEMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779CustomerEMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/ConcentrationAndRiskDetails2" xlink:title="999073 - Disclosure - Concentration and risk (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PurchaseMember" xlink:label="loc_cik0002065779PurchaseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_cik0002065779PurchaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierAMember" xlink:label="loc_cik0002065779SupplierAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierBMember" xlink:label="loc_cik0002065779SupplierBMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierCMember" xlink:label="loc_cik0002065779SupplierCMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierDMember" xlink:label="loc_cik0002065779SupplierDMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierEMember" xlink:label="loc_cik0002065779SupplierEMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierEMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/ConcentrationAndRiskDetails3" xlink:title="999074 - Disclosure - Concentration and risk (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaapAccountsPayableMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierEMember" xlink:label="loc_cik0002065779SupplierEMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierEMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierFMember" xlink:label="loc_cik0002065779SupplierFMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierFMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierCMember" xlink:label="loc_cik0002065779SupplierCMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierBMember" xlink:label="loc_cik0002065779SupplierBMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierDMember" xlink:label="loc_cik0002065779SupplierDMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SupplierGMember" xlink:label="loc_cik0002065779SupplierGMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_cik0002065779SupplierGMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaapAccountsPayableMember_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapAccountsPayableMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ConcentrationRiskPercentage" xlink:label="loc_cik0002065779ConcentrationRiskPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_cik0002065779ConcentrationRiskPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/AccountsReceivableDetails" xlink:title="999075 - Disclosure - Accounts receivable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditLossAbstract" xlink:label="loc_us-gaapCreditLossAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditLossAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsReceivableNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/AccountsReceivableDetailsNarrative" xlink:title="999076 - Disclosure - Accounts receivable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditLossAbstract" xlink:label="loc_us-gaapCreditLossAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditLossAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/OtherReceivablesDetailsNarrative" xlink:title="999077 - Disclosure - Other receivables (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DisclosureOtherReceivablesAbstract" xlink:label="loc_cik0002065779DisclosureOtherReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cik0002065779DisclosureOtherReceivablesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/EquipmentNetDetails" xlink:title="999078 - Disclosure - Equipment, net (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOtherNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOtherNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOtherAccumulatedDepreciation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/EquipmentNetDetailsNarrative" xlink:title="999079 - Disclosure - Equipment, net (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/RefundableDepositsPayableDetailsNarrative" xlink:title="999080 - Disclosure - Refundable deposits payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DisclosureRefundableDepositsPayableAbstract" xlink:label="loc_cik0002065779DisclosureRefundableDepositsPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cik0002065779DisclosureRefundableDepositsPayableAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_RefundableDepositsPayable" xlink:label="loc_cik0002065779RefundableDepositsPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779RefundableDepositsPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SimpleAgreementsForFutureEquityDetails" xlink:title="999081 - Disclosure - Simple agreements for future equity (Details)">
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DisclosureSimpleAgreementsForFutureEquityAbstract" xlink:label="loc_cik0002065779DisclosureSimpleAgreementsForFutureEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cik0002065779DisclosureSimpleAgreementsForFutureEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SimpleAgreementsForFutureEquity" xlink:label="loc_cik0002065779SimpleAgreementsForFutureEquity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779SimpleAgreementsForFutureEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IssuanceOfSimpleAgreementsForFutureEquity" xlink:label="loc_cik0002065779IssuanceOfSimpleAgreementsForFutureEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779IssuanceOfSimpleAgreementsForFutureEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ChangeInFairValue" xlink:label="loc_cik0002065779ChangeInFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ChangeInFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SimpleAgreementsForFutureEquity" xlink:label="loc_cik0002065779SimpleAgreementsForFutureEquity_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779SimpleAgreementsForFutureEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative" xlink:title="999082 - Disclosure - Simple agreements for future equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DisclosureSimpleAgreementsForFutureEquityAbstract" xlink:label="loc_cik0002065779DisclosureSimpleAgreementsForFutureEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cik0002065779DisclosureSimpleAgreementsForFutureEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromOtherEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_AdditionalSafesProceeds" xlink:label="loc_cik0002065779AdditionalSafesProceeds" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779AdditionalSafesProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_CumulativeProceeds" xlink:label="loc_cik0002065779CumulativeProceeds" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779CumulativeProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EquityFinancingDescription" xlink:label="loc_cik0002065779EquityFinancingDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779EquityFinancingDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/IncomeTaxesDetails" xlink:title="999083 - Disclosure - Income taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/IncomeTaxesDetails1" xlink:title="999084 - Disclosure - Income taxes (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsGrossAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/IncomeTaxesDetails2" xlink:title="999085 - Disclosure - Income taxes (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/IncomeTaxesDetailsNarrative" xlink:title="999086 - Disclosure - Income taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EvanaAlphaPteLtdMember" xlink:label="loc_cik0002065779EvanaAlphaPteLtdMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_cik0002065779EvanaAlphaPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/Share-basedCompensationDetails" xlink:title="999087 - Disclosure - Share-based compensation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IncomeStatementLocationsAxis" xlink:label="loc_cik0002065779IncomeStatementLocationsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_cik0002065779IncomeStatementLocationsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_IncomeStatementLocationsDomain" xlink:label="loc_cik0002065779IncomeStatementLocationsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cik0002065779IncomeStatementLocationsAxis" xlink:to="loc_cik0002065779IncomeStatementLocationsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SellingAndMarketingExpensesMember" xlink:label="loc_cik0002065779SellingAndMarketingExpensesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cik0002065779IncomeStatementLocationsDomain" xlink:to="loc_cik0002065779SellingAndMarketingExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_GeneralAndAdministrativeExpensesMember" xlink:label="loc_cik0002065779GeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cik0002065779IncomeStatementLocationsDomain" xlink:to="loc_cik0002065779GeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/Share-basedCompensationDetailsNarrative" xlink:title="999088 - Disclosure - Share-based compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCounterpartyNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EmployeeMember" xlink:label="loc_cik0002065779EmployeeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_cik0002065779EmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_NonEmployeeMember" xlink:label="loc_cik0002065779NonEmployeeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_cik0002065779NonEmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ThirdPartyServiceProviderMember" xlink:label="loc_cik0002065779ThirdPartyServiceProviderMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_cik0002065779ThirdPartyServiceProviderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_SharesDescription" xlink:label="loc_cik0002065779SharesDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779SharesDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DiscountRate" xlink:label="loc_cik0002065779DiscountRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779DiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_PerpetualRate" xlink:label="loc_cik0002065779PerpetualRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779PerpetualRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_GrantedEquityAward" xlink:label="loc_cik0002065779GrantedEquityAward" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779GrantedEquityAward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrativeDisclosure" xlink:title="999089 - Disclosure - Related party transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ConsultingFees" xlink:label="loc_cik0002065779ConsultingFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779ConsultingFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OutstandingBalancesPayable" xlink:label="loc_cik0002065779OutstandingBalancesPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779OutstandingBalancesPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails" xlink:title="999090 - Disclosure - Basic and diluted net loss per share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DenominatorForBasicAndDilutedLossPerShareAbstract" xlink:label="loc_cik0002065779DenominatorForBasicAndDilutedLossPerShareAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779DenominatorForBasicAndDilutedLossPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_NumeratorAbstract" xlink:label="loc_cik0002065779NumeratorAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779NumeratorAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DenominatorAbstract" xlink:label="loc_cik0002065779DenominatorAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779DenominatorAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_LossPerOrdinaryShareAbstarct" xlink:label="loc_cik0002065779LossPerOrdinaryShareAbstarct" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cik0002065779LossPerOrdinaryShareAbstarct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/SegmentInformationDetails1" xlink:title="999091 - Disclosure - Segment information (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_SG" xlink:label="loc_countrySG" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countrySG" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CA" xlink:label="loc_countryCA" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCA" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_HK" xlink:label="loc_countryHK" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryHK" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB" xlink:label="loc_countryGB" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryGB" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OthersMember" xlink:label="loc_cik0002065779OthersMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_cik0002065779OthersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure" xlink:title="999092 - Disclosure - Commitments and contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_EvanaAlphaPteLtdMember" xlink:label="loc_cik0002065779EvanaAlphaPteLtdMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_cik0002065779EvanaAlphaPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesIssued" xlink:label="loc_cik0002065779OrdinarySharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_cik0002065779OrdinarySharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:label="loc_us-gaapProceedsFromSaleOfNotesReceivable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromSaleOfNotesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OrdinarySharesPerShare" xlink:label="loc_cik0002065779OrdinarySharesPerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_cik0002065779OrdinarySharesPerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/CryptoAssetsDetails" xlink:title="999093 - Disclosure - Crypto assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingTable" xlink:label="loc_us-gaapCryptoAssetHoldingTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapCryptoAssetHoldingTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingLineItems" xlink:label="loc_us-gaapCryptoAssetHoldingLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingTable" xlink:to="loc_us-gaapCryptoAssetHoldingLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetAxis" xlink:label="loc_srtCryptoAssetAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingTable" xlink:to="loc_srtCryptoAssetAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetDomain" xlink:label="loc_srtCryptoAssetDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCryptoAssetAxis" xlink:to="loc_srtCryptoAssetDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DigitalAssetsMember" xlink:label="loc_cik0002065779DigitalAssetsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCryptoAssetDomain" xlink:to="loc_cik0002065779DigitalAssetsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_USDCMember" xlink:label="loc_cik0002065779USDCMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCryptoAssetDomain" xlink:to="loc_cik0002065779USDCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetFairValue" xlink:label="loc_us-gaapCryptoAssetFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetPurchase" xlink:label="loc_us-gaapCryptoAssetPurchase" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetPurchase" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetSale" xlink:label="loc_us-gaapCryptoAssetSale" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetSale" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetDisposition" xlink:label="loc_us-gaapCryptoAssetDisposition" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetDisposition" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetFairValue" xlink:label="loc_us-gaapCryptoAssetFairValue_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCryptoAssetFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/CryptoAssetsDetails1" xlink:title="999094 - Disclosure - Crypto assets (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingTable" xlink:label="loc_us-gaapCryptoAssetHoldingTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapCryptoAssetHoldingTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingLineItems" xlink:label="loc_us-gaapCryptoAssetHoldingLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingTable" xlink:to="loc_us-gaapCryptoAssetHoldingLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetAxis" xlink:label="loc_srtCryptoAssetAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingTable" xlink:to="loc_srtCryptoAssetAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CryptoAssetDomain" xlink:label="loc_srtCryptoAssetDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCryptoAssetAxis" xlink:to="loc_srtCryptoAssetDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_DigitalAssetsAndUSDCMember" xlink:label="loc_cik0002065779DigitalAssetsAndUSDCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCryptoAssetDomain" xlink:to="loc_cik0002065779DigitalAssetsAndUSDCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_OtherCurrentAssets" xlink:label="loc_cik0002065779OtherCurrentAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_cik0002065779OtherCurrentAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc" xlink:label="loc_cik0002065779TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCryptoAssetHoldingLineItems" xlink:to="loc_cik0002065779TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cik0002065779/role/CryptoAssetsDetailsNarrative" xlink:title="999095 - Disclosure - Crypto assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cik0002065779-20260331.xsd#cik0002065779_ExascaleLabsIncMember" xlink:label="loc_cik0002065779ExascaleLabsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cik0002065779ExascaleLabsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>135
<FILENAME>0001829126-26-006917-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001829126-26-006917-xbrl.zip
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MK*+'4Y)!Z,\O<\($'Z\ V&R)EP _L$JSC!(Q1C%/2!*K1,?QRP9B(6F:52H
M'5?,*\DH$;HQJM1<:EZ2?4JS:9D?C\]ZQQ>]O*3C?26=]/SLS>7;M^^WI4NI
MM-2;LPM:!OHP@&%\':%@ )<@\8G4WQ+@>TL/ND=6#- *QK1'XPUP8%-U^;@
M81B1X4.&<)9"TS8;CXR/;0))HOWI XI\N""B6/0'&;^2;]#<TWY$],^1Y9%&
M3'\6:LOK<^'2"SWV[6S ]JQC.CP3*BCYR4I^/*T2\S4E&+J3\&_L]P9!3(HS
MF6Y)0E8^(ZDOZP#?2?Q.17?\U97,TO.6W*N)KX@*(D-VOH8P3ENZE*+4X.>D
ME:GZA%F+7]FW]K@_M.:?A\.%:7F%EI\"1&1>P]@C(O PE+.5,+FHP\3ZH53C
M?QN,)!AM6W"RG&RH"4.^C5-\Q%E*V/Q8P6:^L!?#N^%X84VNK<ET.+,7H\EX
M;E!I1J6_!N$*XE$XCR/GZSKR76)*DIG-<[R8PZF66 FYRSKD^I_M\<UP;HW&
M)'W2_Y_/D]O!<#;_BS487H_Z(Z,)5? $>'WM1T_\(-OE*"'UIA8I>_[9NKZ=
M?#%C3(;) &('>1OZ2:+@T J$WA^,=3MTKQ+LA1#CJDIL6:8>1[)8.3M[2TTY
MLK+R(YP@2/_8?<**EE;Q(Q8(72O_C+7[CH%8-NR\54CL?@>$L>TX41+&9&D_
MC7RB#F$^_FI)% !\5P6P4*.UJ]+*ZS1@R<""*ZK)J,L!!8SG#"$^70&6]QPL
M:366MZO'0"$SW#,=TX^"!R\L8"'*: :C=U8%8ZO$"A49-&0#8TV6,GVP\>)\
MY51*46C_'C<8: 565H-I>%G#)P\8?DN(K,-'\D\^8U13%0 XYP#85F*EM1@0
MVIIIK6VT3@9:[X(ST(;S_FPTI0M8MIJ=W=CCT>]L0?M7Z^I^/AH/YW.SR%49
M7D$ T,MDJ6*FJ=$JX/DC-Q3O[^[LV6\4R_GH9CPB*UF;+*+L?G]R/UZ,QC?6
M=')+5K=#@Z0,R1']'/"GR0/!8;)<0D1 28$39RG@=%G%:30>+4;VK36]OR)P
M$+BNAS."C@%% LH4>8\@AE,?.,Q%D.+!I2I \:8*Q70V^L5>#*WIK=UG+@<#
M@@2$&22<0G<*4/RR0"#$P"E,5=)<!5 XQ\%L>$LP&5A3>[;XS5K,[/'<[IL9
MJ'[W+0B\F X#;(=N/V*3"0QWTTX=@0)&G&^@/[F[&RWHB)E;]GA _F8SS'!L
MII=:[^G.F3W\EGCQ2^X[Y=(50.$] SM7]G_]Y[OSWMN?YM;PY_O1XC>#B 21
M:^ A%@ER!P%MQ6"W/!)G->-RSCD)KNW1S/K%OKT?6G=#>WX_8U.-&28R4"K^
M:#+3$T6U ;Y-)I5'PDFNU!3H%.#B? J<IWJ35VR!;<T&O+T60[L&;[,L*I12
M %;@JV ?H;L1N.#;!CO?]L;XMIL,C= A@J)\S,T\_#6W, 0Y"BAQ;HE216S\
M(5*50:3-#%8=7DU$"CAQ[@9:I_5(*[6"0JT&* E0F3K#,^A LG1]\#-L!.D*
M<'!>A;P:"VWK,5#(#(QX#=&NO7-SHIJJ  /G46"5%# PXT$& EWH;*C*&.?A
MC*44A<;G/ ?;"OYJA3 V+2_UY2R3T*6]<P W$?9B/ 4O.X4DSU; A/,4[&JS
MW*PZ:Y/69P"2AGL$&Q_:*P33.?4Z0M=)3-JSY#1H(%( B_<@L#HML*W46D;(
M6K)J+<CJ-:!)]PZ<*( +\)S/)\6$9C N.+=!6MZ*:06FU>MB"H[IT1>W'P4;
M&.)BQ(TD4P$-<:1!6I?E%"HSR+3<,:BN313H%/#B%OM9M62N(?5:<:%B@YCT
MF /V'+)T'WA^0IJ.6&&W$<93B%C?S\\ZU-(H(,4M^%F5;*'OII52X\TBV<10
M(+8TIA4;S-KO_%0'FAJI H*<*Z!0,\/1*=9MH)-!AUXV<61C#/,MAU** A"<
M$R"MP *L!M/P7:*I6T15MXC6N> <!0W1U=8/^2]SY&N_K88N\5=MD.6\$.IQ
M6 ;D0X/<;5^IT_[2!7]@0GE_R0!_*. 7!0=NJQ(* //ND18C._V,@;?5OE41
MS3J"9O!^5(W",$@=<B!VT[]<605\>0=-"^UK(&^_S5\<FS7Y"M!QOAKQEK^!
M:0\=JA0!T&7<<>X;21R 0:]]0$!QB$ES%3#B'#2"X "#3YL-ZB(R@G0%3#A?
M37FSVL"QYZ9H:2&@1*H FL!KT[A!:I!LL5-:1(U/5D"(\[X4=TT-%!VW3TN#
MJ99$ 2+>3R+92C5P[;=#5T1-B5(!/,X'HK);9X!LL_=36ECQZ<T@77*^CM(^
MD$'CL#<H#6 ,/!^/ :()C[#+C4I<'0HH<QZ/#C<L63]D7[:VGS;=HL7M,6+L
M50@5 .;\(J+;90R";<V;['88,72U% J8<>Z0THTT!JQ#:.&]5?!A]"_G56E[
M@8KI#0??=<@:M-4APJR( N*<SZ;-!F#V'8/P01#N=8"XIX(Q[^)IC['5,R@?
M!.7JY-RMK +J>P7M&"V^WX5*8K#52!6PY?Q-D@N7#) M@*Q>MR3&L)%* 3[.
MX\1=TF2 .\0Q#"& RM3-0+[AO%+RBYT,H@<*^1>"VJ:  JZ<'ZKV,B@#;1MC
MB;L(2F(8-=,I ,E?D"*]0,J@N&]83FFE6DNA@!P?A",+;C2KT#W ZC6CI;+&
M?,/?G=( EUE0=@/LO!FP<Q7 .,=/(V#G!C#U]Q#*7CMIM@)0O/>&?QW!*,$#
MW+@GMD,ZE%, E7/.*-W(9TR4U_+*G7?PQBFI63XRJ(,7SFC>PZ!\T0'E"Q64
M]SI&E:-\85 ^K(>]XPV<\EJ:>\);SB/4YLR.T>Y['=\IV5QU! HX\AX@R0$>
M8WAU1ZK7")7*VO.M\F$KL_3<!ZWS1K14+**WBK?A&NMG/[0N&M%2L6S>"B["
MJ4?+6#$M3L.59BQYM@).*I?EFLFJ.T05KX "G0)HG&NG#C1C%2HX>2KW&TM<
M.DU4"M#Q#ISJK<@&N!; %0^<EI2B*$,!'L[M4CV*:C1A>T0JPZB60@$CSFDB
MP<B,'Y40&,F%UK(8&%7R9AS?\4$P\ONP#:AMO%[U9[S+6TQJM IP\K?.J!P(
M-_KT(&!6@V!:%E* EX^(:0&O&;4J\<#;,_ZE$2I(5X"+\Y:4#_^;8=<:C9X,
M#A5?XSO.'R+$PW@8VR!R+D-$Q9_XCG]\6(B(\2*V0(0[MR G4$"(<W.($3)S
M2]>[3,J68#V- E[\R2'I;29F_MD+,=%);05B!0Q;W$ACQM_!3YHH/P"R3ZS!
M.\Z!(G\0Q*#< N7ZBX5*RE:-M!G+]YP31>T2(J-_NT;F]AI"<U56 ^]Y7TE-
M;*Y9%!SDP%>;-U_V4:_O!6$E-6_ & W;!N["'6#EJ"U!A@)4?$Q)^78PHR;;
M ]*3(J*D&OG $2$D1BFV J5Z[+6.0@&D^M>5_M^K-/H/73'-X-)Z9BDQ(?MT
MA)G+_"A+6R.X_'14PN_X_.S\S=G%1>\?1/Z3Y\#/:>FGMI _/3V=/#\@_R1"
MJ]/SL[.+%/9JDV4<Y%4 Y'"U/%VP.GH$U%-&12J)B)E(#XV<YE+D%<1>3(M/
M"Y^QZ'>("CY]C2;PP4/;)B!%H/^*LM_2^E]5:-)WVPI=Z>ZO)'I_]Y57;0 R
M MLV0'G0OI+\@^U'>/$_GH+-AIKN60KY.PRC=(CD2:0%(A1;(0@@W@"G3B@O
MQ#$('<(!=M8P +>1PZJJ*4+_.L[+'=.DX][Y\47OY!F[.T[;,+%KAG9,Y.4Z
M,,%JP] Y646/!%2/U'I^*?X^EI'3'[0S7:I^= GP Q,AP<<K #8J'Q66.85^
MC/.4SBS0\8+WYX%5TXJ)$IQNC$YI%;32'X_/>@1$.3M-)=G?N%,G@([;IA/D
MY/1'*^%+M;!02O32YL/%(OD?W;H 1G$K]'/Z%'GR5^?/=NAZ_,>E_0[Z,'5P
MN!7-_X_!582 ;\_ZMO,M\3!3L:-^A#9W,'B Z(BQ3?1O(YGG^S14Z--1C!*J
MO0FKW@>BU;W(7;!9R$W2Z/,C*YV52%]-&?[@1@'PPE$, TI)Q$\>,-'[":6^
M05&R^7245N<1$B6I^CZQA>T)<KT0H!?FU<-E@6HI])/EJE$6&856L@R? 28&
M$R26'!Z%3ED,6:96$I1;.6WYLABU%+K+8C?*8NLIRYS4D-^QNPL2+TO30*.5
M/)G"1608H!5$5-5&Z=>%BKF.3BNYZO38]Z#!I!/AB>*$>:*G7/>A"]$3(O2H
M+(@H0RO.KXG!YV9;=Y4.)<[2BOOY)@IQ5&GS:J)6'&>-*FQI/3F^#\E*(4'0
MG:(H\#!IV9=Q%,-J/Z\GTDHBNJ<5A>RR/9$)(L_62HHOU#\=QI5!RZ5JQ;-@
MW="XL-!4DBA\A A[]$V"M)<LHI3Y0O>I]JLV1;22MB$FOZ)_%8FUDI =9<P.
M!&4A18MHL<YXGFQXV[%5":UD3>_B%NL/29Y6_ \?00AL?[,&TQC>QFYE(2S+
MU4J&&7R$80*OR70Y"F/H^]Z*$-((R"2]F.>)6%X0/7I.14-V*:B9Y)BP!]T^
MV "'C!2;=K55JBJJHBI0:B7;)!S  (2N7*9:"JUD*70TVKL07,,0TX B$(,^
M*;+M9AQJK<MI)7<_P7$40%1QYO#)6G)=M66Y9"VY[HNY[NO-]4#,]4!OKH=B
MKH=Z<WTMYOI:;ZYOQ%S?Z,WU9S'7G_7F>B3F>J0GU],$.6N 8=7ZKJ1JQ?,\
MV6Q\CYL9^60MN;X2<ZWIS)BSUQ=SK>G,F+,W$'.MZ<R8LS<4<ZWIS)BS=RWF
M6M.9,6?O1LRUIC/C,-CXT0NL:&LN52N>QU$H9EN4H17GB[6'TG.#V4IQBJ)'
MC]LU:2;32JHY]=6$*SMT[P#Z"JFS9OA,CZ16%] JA%I)=@-#2+=K0]=V R_T
M<)P&SHO%4Z;62D;F[:WZ<LII6O$[\%;TI>KTF$1E<UV8I17W]_-!Q? II6C%
M:ZDY2:_F>:^ET$J6^Q-\,H@(1Z@?>>&V[:NIC3RGT=QQGO4 ?!K;37B'#UZ<
M"Y+F!5$(8X!>#KJX0G #/)?ZCP%94-&SRO 1^A&[:"_7,]LUER*Q[D+;[B/]
MWB+*;:FMA,(<W<7AK^O;!9WM7,VU-+J+V =X_1GZ[BA<H 3GSS)L'1BR7-W%
M:MC_5=PFWD=0!T'WS^FCV7ZPO(/N"+27CIDW_00ADGWK@0?/9P\RE:P?8;;V
MDMD!'4J#A*C$XBTE6WTIS=9>LC18;YX\_!,Z,67?A<$FM1ZR45=#H"Y=40QV
M*P<^J%Y<TZW14;A][X^^7J.D4SJ5;&&!_3D*-;M>I10599-*B;FRG2T::%I;
MF1FV,7VM_95B[T88)S1F)GLAGK&</GY+,"I&FU_#K4+M7KP[RO^JL=M1MG1$
M[]E VTJZ=I3#*P'!L9Q<HBS"MQ0TV$BJ?P>@RIB^E\6XF"SM)%Y'R/L#NF71
M=L:%*KG^HBM 6.GG+0IHTZ?GP"<STA21%4H,[\FPQ&,83Y:4;]K<_0C'6P$5
M:;6?O%3D*$/;JH0VV.;L$<Y+(91RA%N5T![GG30SN+O-X[$R/352?>=RMI%6
MOSYL.T3?T^*C,+.>F9H53S^JQ/I//C1B$6$X>:3[$G[$;CM+X[?S=>W+;LY5
M(=6^$Q,#< D]N@J:+$O'O'8GDN0$^@,JY5Y12 U'IOO/!*>];4D''K%S)LLE
MI*NSTIRB0*=]YU2T:SL9P_HAV]IE47#!=2RK?0]@KL4)X0C0S>_=J_-S&,<^
M=$<AMZ,FW+?:OQK]5=T4O*2C/=^I6JQ)/:NUR*^I2*M]]Y#)43Y[VJ8%:DMJ
MWQZCD/0V@.$ IO\?A?*]0$5:_3L^+XC*CF'K4O\W&J*R+=6NB/;]GXQ>!T(7
MTR-'J?. 4^S8=7;[_8K4WZ'<.V_)]N(),O/1VT[ICM84>*Z\%93*ZM\FJ88G
M9L\ $KL72>SD9C+]!WX)0K7]L79%M =[=XUOML>1.M)R*.G^%P*[/3)E<I#]
MRB779_M,R/A.K@5\CJ_\R/FZT_3*]'L$HL5Y-:\#;N8*GOK 8<1R7.64^D):
MY;D&3352?8&L/D(M!U).J2^059XY^.H(] 5-:AK*T5,HHB^,4N8Y/)4H]06V
MP0"0PZM<4%^0&T3@H&Y!KQO@PP"B%6D^4OHI7M,K&4#X,HV(/<"+J4BKFX@S
M#W]E"S=B?*(8>"'U\DE$5*35341Q-+!$1E5BW80LK<'(<CQR/.J(^^+%Z\5:
M;+1+6N @->G6/*);E[>1G-,(8X]=195'=,HZQ[ZUZ-8L-Q$#FHYGF<SU)+H)
M=)V$[ 5#X*?AU8Y,7:L0ZB8<];P[9"CVF9>$AJW2DX"IABJX7F435-?2NC4#
M[W672*Q"J)MP=3YUV;3<JHAN C>8AQ*96Y?236SZ\""U[PO'/V23C@JE;N+5
M',26(=JFA&[B]L&&;H/,"3L.[852X[*)3#?!"ONY->N"!B+=A"K=K<=.?\A&
M7B.=;J)1S1_&_HOM1AL"23:]D[$TCP&9(Y![OW$)5G(DNQ;7K2&*3QUN\2RG
MZ<:R<#M- I0BK6XB*AT8EXC<L:QN35#U9*<<SYH<WCR9;H))7;K*9JN47C=1
M)_05%[)L3.V5<12B_$_Z##NF\82,G05TUJ'W+8%X(?2"'Z >W9IF[JRAF_@L
M;I]=9DLDC%;I"XKB1FA50E]QF8LDC%$619O?H2A!OD,Y?47GG0@U\M83ZRMD
M!:>M2Z$EOO)RNHENK\CJ>D6L/2(!IG>#91_/?"NR7/V#?Q8(A!@P[U\IL$F0
MKGT83]V!L>_UF%@:>RX*/1/F:"]/GW[-]Z$K/"XDS=7FF,67"'VE[9TZ+^B#
MR(ZWW=J696I_W4<>SV?[/GWNE!Y^+I\EK0;^U1'JK_0$4@A.XM7(+*;67W#!
MR4KAD6(%.OV%+>I&T7[N/@/SS]+^4N7_/>C^*434^@,KMKS)-X;S8^M9-PL=
M@$G^F-H==%LC)<EVVJ\2[(408Y+UX(4E&^RU*M_#$MVD+!VT0ZANMV\[2HL"
MVD]36SL[O]]^BCP'<E9X-5?W49Y9/=FB2'Q*OH%&ERNWINR3]C*&Z,O:<VB0
M3&X9V @.G\F(\'#Q"%&; AV-P#SUD'+>>:$7),$XBNE]T2D+T16\(6N+D+W>
M]IE=D(0GRZH%U:FD1I*/$WKA[&1)%H@N/0, 7C [_4( I+<PARLB NN6I;'9
MNI2&$M/%/702NG[L)GR7"C1J!\;7;L)8(&^U@H@QNKMSIYZFK9IZU;FT:#&0
M9E]$9,V60U56L),DIFQ1Q)BFVKW *;(^]JA+J_8IW 90LSIJI-I+)M9FKQ__
M6IAF9=GZKW?F,5@NV?(L?Y;A"H9PZ;&SJ&2M0,9@]<[J=D6T7V"PWG)%+#^7
MFO>$;<9-63D)L_67K!8H]GZ &J8YJ?X2"\'JU6/9^QXD$UTV*%ZN;?.T<7^6
M=R7_V#$NRM!?95)U3T8%_1^-E7P$/HV?E%X$HTZN^Y*3;3ANXLJ=!<7()V&N
M]F-KX.&'!&&8WLXB%*Z>1'L)M_;6#?#"":*1>)-0**@2I?;RVD&$8N^/S/%1
M&_=4OL&L?3GMVZ*T?4X/H.V6'84 Z1H2O9R9NVLM%:^=:%- ?S"KEZYM(11D
MZ#^5VJ[+HI2 /P=+B/--L]WQ$UFV_J+UDR#Q6=Q 52IACOX"I8/DFEB:H4.]
M4'![A?OV?%0=A3:GKT>A$P60+'AB1G%+MV?IBLY^]HH7E=70_(M/EKOQ!]<+
M: Q]ZIK;2\H!>[:K2<Z<:G])7_510[92$71$488V_2^_U&I&&KU@7A;3])IQ
MB3&P@7$"_"+'U42]6+ZA>R#0S:Z$> )HN^04YFCE0:4._\2G1T:N8?%IC4JJ
M]J9*P6=]E7ZZ>A-@+87V^\H#&$8!W?*/Z),F--S<H2L$ST](_\I>Q-F^A%.Z
MRZ1]07WO,ADG 8U<C5!52D&&OE(4(*E!ZWN0I.P+S'N2V%-8R-U/?1]\PZ7X
MO%O9/R',T5X7LJV]5I=!%^X,[5I8@R7%QU/LK&$ R,__!5!+ P04    "  W
M?MI<?AJ=YZ$5   /&@$ '@   &-I:S P,#(P-C4W-SDM,C R-C S,S%?8V%L
M+GAM;.T]:V_C.)+?#[C_H,L"BSE@W7EU)YV>Z5LXMM,M;&+[;&?VYKX,%)E.
MA)8E#R7EL;_^2,ER)/.AHFV1'. :F)Z.HRK7BZP'BZ5?_OZZ#)UGA),@CKX>
MG7XX.7)0Y,?S('K\>G0_[72G/=<]<I+4B^9>&$?HZU$4'_W]O_[]WQSRYY?_
MZ'2<FP"%\R]./_8[;K2(?W:&WA)]<;ZA"&$OC?'/SJ]>F-%/XIL@1-@9AUE"
M/BR^](MS\>'3@]/I %#^BJ)YC.\G[@;E4YJNDB_'QR\O+Q^B^-E[B?&/Y(,?
M+V$(IZF7YK04V$Y>3]9_"O!?PB#Z\87^]> ER"&BBI(OKTGP]8A^[_IK7\X_
MQ/CQ^.SDY/3X?^YNI_X36GJ=(*(B\]%1"46Q\.!.KZZNCO/?EH\R3[X^X+#\
MCO/CDIP-9O+;0/)\A9(D^)+DY-W&OI?F&F_\&D?X!/VI4S[6H1]U3L\ZYZ<?
M7I/Y42G\7((X#M$$+9R<S2_IVXI841(L5R$E*O_L":/%UR,_^$%D?W9R\>GR
M\HI@/+LX.2_P_:47$R,]<B@FHO\-W36(8_K;X_63QX>FX-H+J1BG3PBE($+J
M *W2,_8PBM(GE :^%RH3MP5]<$KI*D-+\A6CQ6A%]P1B>0F(2@%DFQ3VGKSH
M$25N-$UC_\=3',[)/M5'B\ /8&H'XVJ5"R]YN@GC%V4Q5P /3E\?)3X.5E2)
M1)_XT8N"?^4J[4;SZRP)(I0DB@:BBO+P,@\>HX HU(O2KN_'6902SSF.0Z)B
M!!2^',/A*4:/5-74#>)E+A<8F1RPP^]I:Y7UXN5#$,&)X\(=7G)/9*/L>:L@
M!6ZR=8##TY,]).B/C&AE\$S^ IH; Z1OG1]ZD>M9X=ERZ>&WT>( 2QV(ZN \
MN%&0!EXXSA[(5XP6"X3)]X%(%D >G,(Q#IZ)$QJ'GI][(A!Q+-#!Z9J@D'S#
MG(1(Z=L,>U'B^7##%0,?G$ZR\RV#E HA(:ZO%^<613(YJ&E*X5N(5-[CH<$?
M69"^ >,4%NS@M-UX <[SP3OD)1G.#0LF0P'DP2G<BG/(*B!Z6GEAEUC7,UFN
M0)5#T!C:3?M!XH<QE>$!]]4JTA;6'\FFHA27TIP$R0_@PN,!ZK%J13$WXC@X
MU6LE)A/D([+5/X0P0GE@AU^%)&/&[]\ 7',,T,'IHAOCBJIF"*Q3U %:\*"+
M+)I3;OMH%2=!FHR]-[ J)= MY'+T\>XC1H5IW\3X)DN)9:NXJ"8<+<1V?KQ$
M,^\5:(*UY]O)D3JT(DB"B.4*D9@'GF**8+5%=8H;(@1-"W6_)/")H^@'84:^
MG"S:VSA)Q@CGX@,6_^0H=$:GBB('8CH\!_AME<;=)$' 8+ .H+?N=+CZ4YMU
M*%#0UD)^;0U/K42Y6J)=&"DS>%RDAE!/=*Q OA3>J/1;L3$6M99\2D$A,G"=
MUG.(#$N#M-F$24'68N!6<QL%"GE@NK,'E<T0AJG-3$*!6@Z4KJQ"1:9R#)JC
M= 7"88A:C7=5]ET.F.%SY#Y*O2!,AAZF'SS#-N)]OT+'R>A.C('PM'IRNA/9
M<@0F3S /:UY&; M8/B\(.61!OL1HEJ/3P[-T:IHGQ=6U(VH]Y]0[L03$U/HY
M]D[$-R/15Q'=A7XX,JV5QEU84<*GX9Q\M_4-0*/IQ%'!B<@1:*47YB(:,&BE
M^&QOBL^T]!XJ115B: ,]%CNMQ%W0FHTD8(:DBM(L3^>'Y^G<-$\;@VFG=T;R
M)5IJORK[A!1>)[4PMR%'H)->V%J7(]!)+VP=RQ%HJ*6KV*X$6A^E:CX-@J;U
M[JO=O'$CDE9/,%3L@@NG@SHUB<H1Z.LMVS%M!6/3?7JD%"8#41GB03%U5<79
MYJF8BA9X8!IH@X4<7#@-U,$"#"Z<!NI4*XP2>%TGH$K[0@,*S33O<  $P66L
M,GJHWE&=F9;\<%G%N("8]%64@*<Z$G"3M>D#=L5JS=PKQ_]*&3L/3@=UP R=
M"ZB#/L7#"BF".KV^%_I9F)O\+?FY1C=Z35$T1_.2<HH<,')CC2)(Z=,GQ9]3
MIT.GKF34-LD_N<,Y#DE*?>@&CZ(S0L9FX 'Y]W7WMCOL#9SI]\%@5LXM*4D+
M8[]&3D@'I\2XKM)R"$T^'F7A)0_YC)0LZ3QZWNJ8J/C3,0K3I/R$*OU3KO#U
M![\7&NME&.>76 O<H?> POP;?U\_M_78L1%:Z8 (NL>0_]$0_-D+\UTG[1%#
M>R.[3GZ<(.8!"+[-6\5$NMAW8CQ'^.O1:?D]'O9KAL$.JUD_<9S0<B=%TPF(
M!93P"QPO9:)>BS7>A96J2@@51\X+"AZ?TIQZ,RH<8[3R@OG@E891J-'L!(_#
M5'1F5$523FU225E#(_:T790BH53SS@ #AZGLW*C*E"1Q0!5*_'+M5[]WY\_4
MP\SB:;9:A0'""4<O-1 >!$P5'\VHHI%Z<])G:W352[YR/<AA81KY9(%&(#*P
M:7/;94?;?QN[,+J-V;EWW7](/O3C,/1P+PZBIO6R_31,[I<6K! ^GR8DOHY
M)BA!Y(MIO-A'SRB,\T.2=5S2Z$" 2&#Z^6R!?I2D8M-65K XC",?EJQ5GS05
M[,<KA-.W<4@;.Z)Y?=J#..:70=F1G;%:8*+_9M9M,JX^6B#"S[QL5^[%2<K;
M&];/"QZW(R]K5(Z469NT4E[AER]T6Q:%**OB;LT&_"&MEGQ'X=R-9CA+RDZS
M)@<H@K+#UJ6N3LXP3 5F\G2I*7'6MT5K]C;P'H(P[Z=MS#1XSQHK N$,S56(
MEX"8WH_$;+ 5'SG;1JH\2[I,^QF:Q=63VL92CPC,]$[5K T8'_:M];)@N.[5
M M=*MY\WO>FJK!<)PR862^/0,_FB <],,U4L55P\0''8M(C6A43:.8 ]/TTJ
M',L2$ F0Z7(J>#D!6+>CT+T9?*A:Y68F)IHJG"JNHT81F-!+7MA=4R]?)34X
M(9CIHJJB3AK8MVE/ ^UA.^A"2\@LV*RT!,E[2YXWIUND -E,;\V=+?%R&1>O
M:FEJ8F&>-&TY8HEO-ZT(F+3)?+KS>4!9]L*Q%\S=:/,&#6%(+P(PG76!U=+
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M2UH'OF0B"972O.[(@JW2BW>;2S:2$)3I=6PX$MIYCNH2?,:@QT])R.?M&)?
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MOTEW<TJP=OT&)+"HL^4@,CSIRO2<?\60&IY]&P6.1X) <H#(-EE_GSLKSV&
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M<OS+?')<@1JX DUT!3)A4T# &H^5W/ET21Q>=7>RO/,CSR:"_AHHV!5P2@P
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M$@FDA@3RZF5T2GTV:X:[J<L/RGCVD9!(96S*M*)]'%/:&-U8Z(PL(\_F"]N
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M2L@,D(=HLN#Q/0S">W7ASXC-_L;_'4_QPJL<W(2^0%:R!,)25:$XJ7C.35Y
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MD!W:A7IF9&ON8I:^Y+MB07)"A,>Q[EB'I/K *5H+9%KI&J#RMH'Q6&4!@\2
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M_GZDI&W@CM@[9>OFE#5#*-U?!9'XGD84KGWJ_(L4G&4LEGN\4<MQA#*Y14R
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MY2$G,\W%.^!2 NJ"G5XU*B/\51V*E2ZHR0-] W/'_9(!88L O_[56[&14@C
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M,;<T=)Z)[,0IV$ZGP*UN(83V9[5S+/?FKIQ;XR8ZA6(EXXJV4]1\KU/J+TG
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MG/LY2K:R.2G6HP]SN$<?YBI.[<MVZ5Y+<%I1T*E] ^[4OJ'B9+=LI^ZU!,-
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MYFA@#ADS$@+$%#4R#4,Z822DXQS0%M4CNB"+.3QE"1BS>.#CVD;0HU/;2EE
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M7\]\ETX+0G;1J DNJ46-2G0:^>%T22H*/3SR])-FZ-:[(D>=\&RRP)>YI%$
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MO,T9'<OTTVFM=/B70PM9)K8D"F;B9,8G+^;#X\\-KJT)%".9D%Q1PNLS9"
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M9\'M]9V+A)!7QO+N+CD6B> U+Y"S2V'?A2="$ #EZ63!&DX/9()/P,PA<4\
M$,5D5(8#YYLV>T)42Q1[STF!<'-Y)Z)T><+/2;YLE]'9S9U)\=JD6\RN+JOF
M>%H)H YS?QFK72F;%\N2K/G5H99E4F?MH(M(?DT:K"^YJ8+AKA]>PQ(F'=5[
M>O%7*<7E.H_)5UPI3NIHI0)7^%)!'-7QZHN H8T:E^ST^(U%=?(5QG&6]N(E
M(R'Z(F'9((-376T%C <2*)D$0J2MR Z#"M=E4M@BH9%,2#(HX?79,!  0P<5
M*J](J+T$ZO/#Q3G,<.>6K)(B^R\^RIVS$ZIYEHJALDCONJ6>LKA=-GN#2?Y
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MN!^*,U\X](-2SR@.]2MP7HMC-4V^9ZFGCWH&^*IC_]^B&&K]G!1HJ 1E#G.
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MP[%D=&8YP1M3J"<6^/*Y>[QA=X,5-5\$$6& L45JA1@W'^F!JVXYDJ6!4<4
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MH%1S'2U%7F?KK,FM+C"IGK/-9U;UJ;<8:=YAFFXN)!_W;;1A,=K9%A@6[]D
MZYITTA7^!'):FE\T=S$_GQ?5EOIX,6@8)O\*V> 7 .K@2O?]C07!T,R$;LPA
M)H<:030[2"VY_>LC;I^J+,W8/=E$1!V?</U<IO/B!5<UQKU*>V>OLG K9KS.
MXZ _$?::],,_G.%UZH>S#^:-.$*CI-*-G18J"1)Z2/P*:O5/4%O@D?_4"7JD
MK05S6\>N!;W'<6VY?\.F%.?5,#5 37:5!D#Z&F#J"3FB'8CK*5QOQ0(W'U9@
M4U^0!:3D>G=M4>\LYVO_/I2SU\$W3G=@>=F*<\W5A.:J;[+R, 3'8>R!7C[>
MR^40%T3]\K)0!BY-&VU#EUTM[.ESMT8,3YR;=<#PT1&H!_4<A[#XEZ#>T\B/
MC@0LV8R)S;XD)+W!]>WRJB1+G-5;N2S= >T"N)G%_S$X5VQU,0KF'3A42Z09
M?"<1NGHS;<""58Y>\7&F7<&_78K3Q\T)O6*1L#)F-ZQJ^7J38R'2%)@\:^['
M[EV/;=Q-/-(O1CA+?,Q'ISAZ?(R?B_YFA6NC=+"Y^RTVJ]KM7O$**.+L/9 5
MV O\5,\+ZERV[+#U5;+ QD58O7C(D<0&NC] Z&2CL],1H'QF/BL6V2;)'6[V
M.&(7W(F2/A4=7>YQ>XU8]Z8XU$'VT \\R3=UUB384A?NRB%U"2U@ZG&V+61G
M("JQ>\]O)"YGRV669S3>UH6C3II!"W6[-T5%38,:.#[:L>I(6)<H:66CDV^6
MKK."-83?-G*%<=7D 6F:;Y /230K[#Z]M,)@2&5#*)UR',BC"I.7; ' E;&1
M];PL7C"I6!A'LA6-VG+VJ1AAWQM&9(M>Z&C'J1GCL,>H!(9MKDCE"YE;'3:0
MIE0^.N':LV:L2O>:O3%\CM"[$OSL=2?2.& ^E1<UCJJ//!]I7HB9OVF#X8 _
M$OSFYX,_(&EKZ&"_ .8E.4JSI 1,,4==,5D ^7"[38IFXYTG^;EM0"DTXFPS
M::&K-Y,D<3@,M&*4MCE%#H,XKKG;7 :R*=1DC#HE,6AD(^3MVE,6E()@6&1"
MIS[GZYV5<-@S0H-R<@\B(_VQO&LJ+>W6$8U+CQY6(IPI\FVBXJR1JPDHR1K[
MP3]>4;:#<G?69OO>->M4@WP:Y9/0J81GI1F\3$&U/$R^&;%*D^LN9[M=;H22
M.;1G2-K;N3SRC$?Y2V]IVF-X5(><^RA^!DS@<+RV*;/S3KD=U/\MU/LQ]/2*
M^G+M8BK_Q9.F9'%U@GJ_RLZXB]\-?<=A(C8QAZ.<T4&9%:/==VALB/;60Z56
M=%Y[0]7<@-@5EQM5PXD^//1*Y>U6ZOBE=KJI@4$AZ$S+"GPPW=)*1Z>8,T3#
MRBHK@!4T88CZQ]FRQN3GYVSQ_/B,VT.:,X(OOV*RR"K%^L]D*U$2>_R:J$S6
M<3,1G8'[X58DU5!]YNN^M"=W\4XIOL-3'4%N6B4B_.[+JOFVTNU 3;05_2"Y
M:W.M!\QMAJ)3^Q#HM0?2&UH?:*;G['X_946VWJYORIK^JGC;'LLS_#%[P<5C
M25_7'T7-VUV+C._[%'/A'?+T1LN>V=]6=!X?J %C*C=R?6<=C,9M#=='DO S
M\LDKF_U=8#KNL#R%8D7;(9\O4SX/7U/AZ3NML3)U_>P H^TD\&/*"B.,L;4P
M@U)J)SAK:?!=X<669=(<D, 3K,;C\N1'H*>UMTF@#)_:#CW9%SN+!R7^ 7(!
MVXM1VIOM7Z]+VMXMX6L>O"8%O]MI2UA9J5'ME(NLXL4G[Y-:GSQXN!\(FVUX
MZ <S3$\\E/7HK]#1FC1^FSXEY!=<HQ=6A3;Z>W-'S6#:$'%2;+=YR=U!6V-;
M\Z0<=8,F<?LT9WA#O(,B&([ZH)6/P7;GB\).&#FHW:\_DFRUPH1#-D\-S8KA
M(P^7ALC!A4DK.K&\H:JK5/3.KM5"27 L5MG-(]?3_R%HO]&0[1#5]'_0;A%5
MSR@I4L3_V!F(<@"81J6/99WD;20[W.3JU;3C"\2[+0C;DO(!?B#N\=Y]'XSY
M-.]4Z\#\UP&;9#ZK6S/+J.BF1]"V57=IN%=)1OC[?[M<GB4Y"V ?GC&N[[/J
M%\<L:1<3<=*FW1NGSJ.VZT<G^!Z@I1(/5!%QS1-VHO2T43[EVHBI@TF[-K:1
M3;7RDM6:G!?+DJP3ES(]>UD,R>X#-+U/]CW,@>'^_FWP?Q6J$[2SC'JF814-
M:I<J,EQU3VF'6_,\;4HAZ>[6@#ZCS1I@2.L$<\S+;N4I.K%$Z5%W3AGD0]+)
M"GMP]YU.& R); C'_!'RT<DSJRI<>S@D@WS0)7,;[,$*N$X8#'EL"*4S!%P^
M.GDFYW!W+:4-V8K5J(H-Y5<$T]B 3O)P9=KH"?"[;^(T@>]C/,C9 M<?!?-R
MA6JIM(I/14^75!9EC3 B$&JR\,8^V9_'D\OS8(5$6!7#1TS6NN3'8_Y@\/?T
MJ ].>D&/\FNPWLQC-E$*NAH9Q'(K*O3M*TY(]3L8;^2A/%3;QI]*=I:$S5!"
MC:2Z7WZS8ZGY41YM-%7_+*RW-DA;M:_O2R?]:WMW>WGF81[_X ??\)NJ>'!'
M?$%[O_9K?2_E)LJO8Y13#;TUYEN6T97G9<W:<FNOVV%3#;]Q[-88>4O8K!>=
MDQ/ *A?^>08>W[:E>J>=(BH!WQUJVJHU*40_[*7=AM5+1R>:,T1M,:)&A5WB
MQ97 [*PJFW3M5ME*JQ2=9%(#K$2[!K?+Z033@W#7;^=Z+F#Y= ID4I12U=F:
MWRI3N5W3]?_'O/: $.8M;<=MJS;\O7O;Y9O:*R_;&PNJV_H9D\?GI&C*WO0R
M\$9'*>[Q.N%'E,[+HB;)HMXF.5M_TUYP! OCFYCN'K-[#N(MC@$0S% /\:F,
M'1'[SF4M&R*[86]A_KJ'.6.3I92#HJ T1*3;U&1[F>A;MI%R2L,KEO/ZJR ?
MK#7_7S<!+8W6+O\W%2A0MM[DV6 [ /&M0E06NY)"C"MH0<$FA,WKT</=[!RQ
M$]*$9_P%+-Y7/?^(\W1>/))M5<\6_!"JK6Z?1B=&R3XC?%6U/J5"])'=!Z7R
M -8S%6?%'[D":C3BA_\XS]D1F2(5AY?IW\TE+[.GBD<1NC?:03%HH.S<D($S
MMFJ!\Z2NB*5SG$*1'P1<MZH'NV_,_:QPG2R7YV555Y?4#9>O&)_A B^SNJ)-
MNETNZ9RX:8_EZ+"/G0@GB?V;J3A8[&X$F'_T1SZFZV]_\R\?WK__"^*6Z$!,
M39T@W!A#3XTUSN:2VXM 9650XW#B7:43Z;"['K[FG+NL (UZ1I1:FO$JSB(,
M7/3TH S0'RGA29+3MV=XRYK78.UL),+ [=E Q2#N: 'H@.Z'?DSC1IN[PV1X
M#1^P$9XM9^TSLC?ZT$;T0;-\1W*N#,V-.B/>8^06=J+[V#M2+G%5\=)0K,Q&
MLW[ZT%Q@:;Y[U%4Y;+$DGP8-JR6Y:(;AZI\$5PM^[4EJ\J%>J'5\[1MI+R^%
M$E2.ST@XZD )*M_[!I6!#AO8&>8#]I"QY1&=P^T&L]"@6,T+B@9?EY5R8T\A
M!N@"=A,ZZ<PU_5*LYY9"BTX'HH\Y?.AC+"+XF1*"1FJ[EISA9<G*="U8[D]&
M)[<"\V/R5?<T)AH+.2;MU^ !,R=9@D/=?> KN?W$M5#&S: Z^>HT;!VQKS\2
M"HN-IYERPM;[&I!+4:&2YEE,!FVX4'07LM^: ,C%@#U6 =[H]/_7,^\?UE^;
M5]46CV_R<U&(??/I$+CMDE,A'=V'.4.TW5F:<>'HKFU7#(TZY'2[J'OUF=QJ
MVFGUXA2RLS1#7;U.HQ2=;;Y(I:KS";L*D26UW[8!^0EJ3/0K<9V@<_:,BYIT
MU]N!*F(GM_K:<L["J!%XA<@&?;0LI!,'PT8[1JGDITPY"*<J[O$++K98V1'M
M=_!2O"1D4KXI*ZD:Z9'V:K4UU?U5#U>6 C0],8"3\HW$]RC?J41Z[C>X9LE/
M]$5[R5*<GKU^KG Z+[K5F]F"QJH<H*H_W+4!]=,$T,I\,>J2VO4JEK73:<7K
M2?-ZX4 @\($O2W\H<$DA"::O"Q4 4-IYEN?E%U:LE%WG4VZ?ZN4V;Q,,[_$"
M9R^& -A5.6C5/:\&#4KP.6F"H9H77"E3OE7F;SYNDY87!*<9&&[.UYLD(_P0
M_I+=G7.=O>!4E!5DZ;"TW9^U&Z6.NB&9Z=6</C&=%*%%:#Z@Q^S<Z;)96$ZU
M3W.FCA)K3<G8D3*PL\<2+OD:'RX0;-VN^3WJH,I5D?V79=%.(1U^Q4X+65ZN
MDT2CCQ9N^#2L0*03C#X8= GH?/&:.J ZJW;IZ!KZVY1"NG^W!O2=BEDC.K6\
M8$H!R$Z0[R=LZ+,J^9K(H;82]F;<1<;F5$6J6U[K?1^21Q*L/F6Z+Z&% V-@
M8SYTWP<]ZZ:XYJI(/[^KWEV4>9Z0\S(SU^IRMA'G+)Q'\]1GXQP,1'=#^Z#6
M7EZV8'_@G0'^X>=W#^^0L(&8D8!!$YW.;6@@?9&MLCK)11AM&>G5*C'")Q-X
M50RED@=&,R-(.9KBPFPNDPIQAXG,00ETD55/6SI5$-,Q=Q89]<)3R:$9,I\,
M2L!(94<JCYH[C8CTZL[-?TRRXI:PM<_;PIUE+NH1JUY:&V6H?*G5!48]9\"&
M"I@KJLH*QK'50U;=(!(99^N23BS^BV^PLEP!O$FR]!Y7F#Y@%AI<T+EM7F[8
M*\-/G!B?B[^Q\$2=VF"9MKZ6@)%X(GQI:MHSPYSJ1AA"I+'$8\%T9TN<.HH^
M7>69OKN%?]VL518+GI>M "EE7/=DH$UE-?BD9#<FQE;06KGH#!GD-['<)F,5
M8(UPT.*L1L"#HJQ*R>C^R0F>- D=I*&!RD&3VG%M*_5K4(C*) FXD4W7X/+/
MK!!=6'4-Z.I1J4&[*[)U=S:95:+22P'>2+">/+3AS@&KF6LTA&KR"EAAOG#K
MNWK<YA5$DUZ$=5Q[,Q1KMWHE*/3R!1R28_MG54EY."Q1;Y@+.D[G,:H$S:!R
M #_(FS+(0V&;!U9I.MBH]$+Y2 DH1T]M Y?F[8E;.J^*J^K/*!GDNL%*<5/R
MT8>[ %R#LT\ QRX#2 <O<((*;#R7^Y9= ; \-D_4YG176"[@CK#$^_KUCB*N
M9P4ORL[7%?GQ;\WSL"D%/MWET(#1 2^#!I@YMA-,J0!T*P276'QE4C_...B!
MH->X&4X,:Y7@DVR$U/N &P".40^]76]S5N[H F_HR)DEBNL/][0%AXN6YKKS
M4V,(2IFJ0S1"$ZKO=%#:4XH496D;Z.MUV&L,;G+EA%9U=&V1$/+*$W?7MK+R
M1^P<VRLV(!VXAZ]$)Z7W](1B55D:U:1CUUG@V8I@GG-4T7#\:LOJ*XBKA/0K
MDA;%P!U$>9^5Z4.=D-J^-ND*?=Q[9TG.IQQ)C9[P*BO8;4G!5K]9'1;VZ[=+
MQRY3-MW#2OB5<>\FRJQT-A$]7-P/MW3 KM%GZ^85MX"2S@2?(R^Y$9X"O?\%
M]NY[-L_LBIYYT:6CF3<-9.D(^S,ZR(I=F;$H,%;I\$E;+UR.72^S[++_?IVC
M4MA5,#$J718NM6$=@1O&),RO]8,P@UQ@G%97M%_YO$$Y+%FE \\"39!',P*5
M:/07WPV?M(RZHH1CTT*T:DM3<NUPN;UIFM6\9O9#LL15B][XJFAU(F3JFN$K
M$G+5"M'IXX-2/OG92J.'V=5E!!:=BS6&[ 4[$4@E'B'.T()6!!J2+##&: '*
MQ:5:P? T$:[P*BOHB$E'R@M<+4BV42Q@NJN%IXV]$3)]]#K :&0%JMJ<J5]1
MIX'2G4KT2.ARN<2L\%93H?LQ^<IN&F6U&BC67*P"S>HKG+(BO ]U4F\IAM>!
ML&:4/XCED!'6 1]%/QH[@-GH;\#AVS)^23X_H$Z^7^:=7:;\)EX2AA[/Z#2*
M(L@[.>V)F/U,0GLM;(WW?1]T]M[4BV!IA'1[*1-_D]07.V_I/[95S=<%]GAF
MLBEH5-<UUI?B8SO0]HKV:(/+TEV@1> @_&^7,"_P$A."4RHDCB^S]4PQ)K:I
M8'L\;*]?@?;63'A$OB^4QT^\J6'$OUWJ]Z]B+^!+J[-+4 ;ZBK$;[K)B2^=+
M705]OX%%;2#^BV%JF)WS*FW@=#9 EJ;*K0%P<9#T]O%T3,L%1#:EH!7<G!HP
MS&4Q:8 AG1-,.<E%*'&"':96R.$IUA549Y51SEG^$XV/OB1$7QS0QT)4\MF;
M9F2B7ATN+:V855EON_+XO, -3X)#C1X\PIH.#^B$X_M =]\7]G@*R[4V9_,9
M,"HSMU'Z%MR>\ZP)W$QHXNP&S(S%/0M[^F1$Y%Q#G(=(;=*?5E&+1J6:)CM<
M)0?<C5F.GZB<6,Q3D4=\Z0/E)P]?^SMSFO(4_(:$L/H9[Q*5V:(@^^ 5)R2Z
M.Y#;,VYRNS(SXR<2-,_)WTQ(-S*UD7TF^]H $Z)/!*[++8IU1<@1'5"@5%25
M ])DI$Y!;W$_N$A!.1[]1-%4.L^J%;3BHEL3!@48S2I@G(8;3JDN8S>/Y]?9
M#_3 %-K3-^W:4G'/21,& :6FN)'P&EPQ/G>L?F2\CGX[+.!$+'!'.@_9**G,
MMM "MQ?CO2X.91G<;]7[#2QR'VQ-NU6+SJW/Q>[Z,?I^G.$"+S-M2I-6.B2K
M+)#[E-*(@N&3&9^4,]J3YM[IJ9&/>BY0^%:>S<>2FECV'Y\=SKYFAM,3)BTX
MH\X$S-(I8(,2^AO[WUAAQ\-S0O!94N'TO%RSL@?:*@]J23C=Y(@3TO7U>S]\
M8+7C+"BEY%\F?OK$Y-&BIW"PBPF=#R!Q))7KN2.%=/CC1EK(BK/78]'H0Y\;
M/B5?*M>31,'?VQDA;.&4.?BSUYW(7?+*/IJQ4*\[[S^KJNV:-Z%B-9BO"*9S
M&?I^X:K6S>2._J-OPYL<H\'2-7*L9O^22A]DZN=S=QROLZDX7V82C'([G 14
M>1U<)P7,XRB@*2Y\XR)A*7"'R0;7VR2W<F D&9X$2J@R"P9BP&B@PC;F02=C
M)<(1!YR/=(Y'DIQ?^[S.BJSBU?A?L.%*:XM*X+C=-/]U13KNF4:/7Q*6##3;
M #+8:_N1CDDU3L6A9SX&&7FG$@__ NM!RV^Q+!N=/HX )=8(P>:H%4I ))5.
M#G7X__Q$XYFL6(DM9-T5/H?]B9!+?<=X. <)K!7VH[\51VS4^$UJA) HIA7R
MMJ%JF[-?OL+227.S:)0[A11@E=<(]>2BL\@!G.*6H$8(+7' I9O;;5W5":^P
MUJ2X5)3.BIP1=[7P-+$W0J:,7@<8?:Q I:WZG0)Z:C301JA$"L!O<"W6\-F>
MW^PER7(&YK&DSG7-BAZ4BU^>RSS%I*(.-5NHAAE/$_ 6UJ<V0+4=RC=!D[HF
MV=.V9F907:*2T"Y/R"NJV,C4V JW^H*+DDXBF(6KDO FL)N,LWS+C@50O'0T
MY$.FYOSCWM8BK.-,;;)BL<?7%# G-16_?,:RL\,+.SPQ2^(>:V%+4)_&3(+E
MD?S9SSA;/5,T,_K>)RM\LUT_87*[%"OL X>M\69>!J"M+$\#/^[JULII(LR,
M_%>%RIVE$\1MP>KMAMU2LSWZ6V?BC?2X%?Y^?=Z\\K$R"A/"SI=TGDO[+BL%
MH?6@&:2<[<[<+@A7.P;><,ZE(QI1Z%TQABEOI?B.? <-[.C+SG+O2N(4N"FD
MPP=F6LARX"6) @NL=/BD64$K]^<8$;]O3 \D:O>*RX$21(_0$%L;27+T'FCF
M [?-V-_-"Z@A0U>8M.#,]B=@5@^^O3G/MUGVN^A[+/T"_ ])CF^7-V6-%7>X
MCD8[![U85R(8FZ&['$&I%-TG^"*5MND;/<2>%JI8=?SHC#O;5EF!J^J\7#\Q
MM\7JVI5%E:5-0;!'DA25.-&IV[7S,Q&2AU,:UZ>DCSX8=DX +3G'Q@3+>&UM
MN"QN'W;3I._/NSC>O(JO48FP66($K]@H4<I'YY0'R#&'QHL.!YM3[>WRSLGK
MIB[YX?0?RYRM@IB.;VNE0SHR"^2^S]*(1J>2&SYIQY9+(RY^@AH%,.>RY;9<
M6\YC&S7B,DJ";F;5-;ASUW:,CNRZ=CMH'9IBNFL0S:*12*6\ -$D!^G&5P><
M4LC4E4IJL@%.T+\GQ98-@.\AD>B./JKGI'+@T$XR$H7&4#4,:L6@+$[8(4ZJ
M4Q2:*&QB:V^9D(I$D#Y$#3F8"+02C6IXBK,=F[)*\@J=HHJ.3'RG_O,#2LL\
M3_9/.3DD50343'$FT28<B3@*P!K^]"0!TTA&J653I W&O2*#&+?!6ZJ<&7%*
MQ?,':8+A%E#8)3#G6T)8VC0OQ6:>W2O$(RR<:$$K%DTDV>AS$4> 4C8I$T0+
M(0FE_O-Y6=75K$B;,T[:*:TD%M2K:T .G,I()CI++,#DM/6JYEM5+C4'COBL
MVW/)(L.6<U;UN!5B<>I5/MJ21$Q(Y?(H0K8INA7,B_/:'UTYIQDK*48'>EP]
MX+K.<3HO+K)51D6$?Z%D^ERE"Z-7FF@Q_%BP5]/EX6*2N>B^XG!M4!?MWA7]
M2CIKJ!+FV,54J3#8#$K<#7U^N#B//CHUY\&JJY+T]V/GQ0LVWW;HHAATL]RY
M(8/=<JM6=.9Z0Y5=;BOA=-WW$?M(O$Y-)*?JCH$ H'/K:ES2 E13J[^1B_J0
M;ZB@[3GO9, ]:@4TW=/>B49]X/K'#.[A6AXI^ML%7B;;O$8\Z(M5KNXZ2YZR
MG ^DJF?;^QK0 U:ADFZ(V<G$*FK5.\ GRBBPS*N'[5-7;<N29.9E %#W3,,M
MWV2]L_+?D;"#F*$3-#"%=K; =+1;;_[]?P#NL@Z<M$#(OSY!L]%AT[LDXNC0
M>]OI/,*M0VPZ@-XH9Z@&+\AG0Y?6^["/V$F/>+TI24)>!0J1F37;UL\E8<5W
M57UD40'41:Y(I8EMJX?:%ZNIRKC3A=1=\ZK:>G25$(?>32.4SETD]")U3[>P
M8EI-EH0 =84>F_ZJB<LXB\JC\BW-?4[=9MKM\B%;;W(\6Q&,V^6#JVV])5@>
M?O:U!: '#]8$]1WS/J9BO7QL^5VLQ"M?N]W7 +K+A$J]N3>W;AL<,YS&><[6
MBXOT4T)^P3T/H0RKM=* GKP#2&GZ(U1XU-8IM?XO4L_<XPI3\6=6R ._X+S<
ML%?2T#E&!4#]XX93JFK<:/$^ZNE%[J5=32&V<GU>%I0Y6TJ>9A2E4^8SO"S)
M[JX?7%U^K4G2'H+@R<1LO8]JTM]D+&SW$]4[J$?[.4 ,"=%*]247Z%OVJ[\3
MY_!V/XQVOXR>^$\W7AOQ'Q<KMKL?0^VOQ:SP;JN)$KOJB=&%.Y<T$9(GJ"<;
M-5RE$=,29RQDNEU>E=LB;<Y"&9*5M"H WDA?I-)]9#J-6.5,:'Q;OF+<7E/$
M%GB<KS%Q5@;0<=,Q2TN0C074FN CL+C]A%M!?3-17SX>3WOE0+RKWEWPM.GS
M,C/<0;*G80!\.$Y[E!.:Z7;CQ7 $4R9?8/'?>7%'\";)4D.P;=,!T.7>4!4A
M$5= W[:JOV-Y/XUV_,![U*K9@E]Y8=GG<]$#W7D&N(X=V%J(MYDG74HW;F/Z
MPA+B'\N'[6:39YB8K^&S:@/HT#U Z[K5I SFK1SZFLJ0&^RB": C)P*>YES9
MS(:9 ?9^WN,EC>69X[C _'R1QNGN8P= 5Q\$OOWM-9D!\QZW@P8-VC@C=Q"5
M>V%>!@!T]7ZX?0=>-H,2B_\]:^"Z6E'$WUGI373I&*MO-]Y%K>HOMXLM6+(*
MA#]G]?/YMJK+-29M4HHR*\?3!.A.=4/NV,6M,?2%6D.MN1/4&00_(%MOX/ P
M J#?]\<^91R&]H+WCXU:DHF=E0%T[G3,CJ^S&&L;.RA^MG)[\.6QG"W^N<T(
MOL=53;)%S=;(G$[WF#4!]:DG8*DR9J/.DEX; VAG ?5,0.G*.\(.SM6O=[0=
M-3O"2S_E.]5.W:G5AMRE=M NW=I:.4'<SDF70\M-Q;LZZ3RIGBFVERS%Z=GK
MYXH15_!NL,:MZEYW;4#=.P&TE%I&]5%K #V]HF^9#>J)?X<Z,ZBQ0_N;>NU\
MRRMA\'N+^:X[%>\VW:-EX&P:FMXN+_"3\@4>RP#J1RTT.;6F%43E$C'1J-%M
MXQNN2G*!137:VR7]+Z4'KXJ@CV@MB@"Z9AI>C?/4Z<'RE%=9D12+J9Y2H0V@
M&_< [>$I.S/P/25K!?M_-EJ_)#GFVU-MD,:^H$'!\(.>I+BG=1S[7WYM6DK_
MX(G*[);S2\KSA=(/AT4 B(.1&J[B\0GB;-[9/^F'ZD*"Q72C#P<* A%2S.-.
M4(<+M< 00X8$M%_GRW%PK@/*\CM,.X[%1%7V9\PSK^+\D_H.\-[W@%R3$I;R
MY'&<PUV*G*C>=LPC_EJ?Y12<)2U,I0*@$WR1*E.Y5!JQUEET:PS,U^=EM258
MV6-3] %TWUZP%=?+]%=6A@LK:&<)_8W90MQ8Z!H90[YJE^(=WDJ[+H#^G0Q9
MGKS;5*-VI.5$H4-WNEH UZG>P*6AT=% S%,F@\H(@^3R;I78Y)5];0#HY+VA
M*X^PC&NOC'/LNP5S,"Y:SCF\*_-LX?)*6U4!=/-4Q'()?XLFL'%V%_(Y=Z>'
M$7 =.P6[?0C6VH 6/!OZV%<70-=.ANP5,-,/N1GTM^:_4#RR)5YP?I_][ #H
M]X/ ]XR^('GQ-ENME]CBW-EV77 =[ %9+IAN4XVU2%Q6]>V2W?IBZCJ[-(#.
M\@"IK&=?+M''LDR;<Z:8O&0+#,#7[IJU.^UZCW-63IYONSIUFY,JJ#[T0RQW
MZ$X?-080MP!V%.U=X&+(->A+ >@O!W#J*PYGUAM%CO[ E4D,SN.7BS:X#O("
M+=W8Y* <-X%'G&$SUOEQ[^ IUL!U^%Z-D&<G_L9 ;:T);/?^&VPC17#=[(K7
MMMDVT@.V1-1L,.RQ/J2V *X[O8$[;\[ F'2,ZK/R(I!=DDU[]VB2WU%G,R_.
MDPTKW:&*:Z?8 92'LA=\>_W:NX0@;C.^#^Z'#!:OVQ<%]V+J$:HKTO0DXW9"
M4Z!.U,!ZV#[] R_JQ_*NK*J,>H5[G%+VC,M/330!K].\D4N=Z6HA[L;8:D7X
M-7/MY<YW)%L8#F*JY<%UGP6FM.^E%(^W_['$E"3,C=-PN5T%;!:7*D.=)S=-
M )TU$;!BYZ-3YPMPW4GHUD*DND^C-7YE#;OW^I=,HP"@X_QP*I,'9/E8)Y;7
M=&)*V#3T=GE=%JOK[ 6G8HGI1YRG5R7YK"FGYJ((H+.FX95.*7?:)XAIGW)U
MQ/5/$#-PNBS)Z>=HQ=4N,G8>I4B5Z>?=EX#Z0\8DWW/>2 "Y"\REB [@.CG.
MI7"@E+DY9R)L*.-;&5GURQTF[(-DA94Y]29Y0/W@!%.Q"[I30DR+'[QI]&)O
M9>O:8]S#UBD!Z"I_K,;^&NK$NB!2*D+)SD(:;N<TR /H(B^8TDQ'+J=Y@I)E
M3=W>+,_++RS]#]'Q')T3G&9TV*'3U>@WJJH:ZMQQT'OLH%T%+66/#ZBT(=OU
MEF^G7^ -P8M,6[5\DB% /;P??L_,/F[S!/6LHK[96%7K^0%7.D?H+KQ@YUXI
MAZEJE@MHXFFD_]@:B@=-L0.("7O!E\K:M\9Z-WF(X\1#@PTG4,]F%RS%FITU
M"0 4L9AR?B343RFG:DI)0%UJ :A+?>"=U=Z6S56@= 7;Z.&\Z<83IWZ1U0#=
M5^N#UJG'.OW=J NE_S1AD$H.\FMD"H*474(56.(EG)[II:=U%Q0JY^D*.4![
MRT9XZI2\=AV0R4?9.%9@;S=Q+#W0B@%Z-4SHS,^_%8__]%D.M>7),Q&83WV
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M)>XA(#FX=!6VLK3$T=F!\OAU_/5=% 0.'465<.JL^65K-$L/+'SI\ U9*/N
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M$.K!UH3H5A7VA6H#4W3L"]7VA6K[0G4?<T!:29 "*\#L_(\I2?BQ/Z?1B\]
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MQ*=RLY>C$WH(&+T&.;)^A6(O:4>#)W07P94> O2 (#UQUW$2F!8W]-8NHMM
M%_8^VL#[Z&X57>-:^HOV+[7FS>A [;7]44P6>2+X0RY>(<<9NR^$/D4QR=JB
M^K+BG-?,WZ/>'"0DP+GQOL]S0R4P4S>";->JOP]<D@-5_5V?5:TC2!/\H\*
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M;P?\5"JK\OCQXW#Q]\'L?K"<?)A.[B>CX70U&(Y&L\?I:C+],)C/'B:CR=B
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M]>';0KPE[9A8B%?Z=KW0AA)085X%-%285RH/ZX8Q:+NSKASKRK&NG"L=Z\6
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MTXNX/?(*"H*#32=>#CQ8LN2Z3(!X2)9N\PWJCT#6ES^;86#12F;N% <&I6=
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M[:MXU'EWP?*G#T#EJ/E@#0R!.)88AWBGG$+42-?:.ZBU&6S"1<0 !C5Q72R
M(@[@:[?YPR+<)LX%5-EWC2AQS)NZ ^ !Q%H&7]'9@LZ816?/ ]23+Y1D#3TR
M:F6>-C]BUVR8"4()Z_LITPOO";$3 /QW9[SYB1/N\SLQ.T1#1;XL)9%*Y"Y2
M/B7="$BV=GT.)\Q+N2[%]*N_ >YH>,B-&$2"<T+( *0^YPUB/0I0>!K;2>(X
M#V<B2*L"T>;$/Q<J]-)EGG;8P>)B3&%\C/VZ+0Y(+6FPM4G]-2F)RA'KK:-$
MTO>'=%#I<NDZ,^+J))[F(V,-P10MX LU:5/J0SF';C;AJKQ<C&"59#%),-<
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MU#+3;86!^EX\/M=U,.R& P/4&9UODH8L"\F\J@0@?).K BD'Y!F^# ^.>*]
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MJ'#))^]DQBX*A(#;.U1M!?D&'7 I$Z0@/';^I1&V$E]%0IV\UZ5=>+7+ EL
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M^XPGY5@+EPX%ZY@9*HPMKO'LW 0U%^]%X70MI^ZTP # ^]=I"K=7 "F!H)J
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M2I'ZI5[110HM(^L&;.B]2548"4A&%'DJ;V'X$NLC&HL?*D6RVNW4Y0$S":I
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MC]BW $TKM$9*U=2"]1^.Z1KSC5*\G @5\W7ZUL<NFN$.K>#0Y>.Y@[@FG-I
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M"TY$3X1"XB8<<!P5)8S%Y"$)DVL<1A.3<@#L#8!XW:2\SL18)V@-E"-\3BD
ME5)RU@*KGCZ37$4I5>J3KJKH9TGM4I94%FSO;4Q,NI2[XDVOJ\:TS-AY9W=!
M:5&\F39<K)]4#@+_^%HK;N*X(J7-FAM=) KOT*GP9.E-_A$=VR/EB2$+.X(F
ML%5QM5S4H"][@<"VPGWW/!';M_!L8_E!@K),-&'\N? U)PWM^7,OR:SU,Y^:
MH.8V2[#%83::HDL/E!7'6CQ7+RA+CG>GR3?GJ)7N/@JC]5;*S] ,F918P<H
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M'L#"#=]%OT#/=]OX[@@_G\2+6G!)Y048#CP3$\G>0-@T JM.U,HU BP&#XE
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M?&YQ,&*<FHF<IWE4:$?SNX34! J88F0FBENZ/"R4$:)K:T.JTT4'"=4"1Y/
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MAT[3OD6+2$Z@^G:Q' 17?1^(\4\05=F8I?YX@U!A&SI@SXGIKVP5)1>!E%J
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MXH@Y,')D/ECL5;6QO57<(!I.@I(]%YG1MBW <\V+KYGU1"D&UI'CV"AC0E#
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MJD\C/S;3V$I%/*=C^QF.-9YA%E3=/ZT3F^4PF6).E<ND(IM:Y\-A1.\6EA3
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M8B*+"K@%;6G35+"EM+65:N P(CC7',X3?@YG"WN=PK_KV'O]59;G^*A:+(E
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MX"F&KPUY6W&_\/X G;E^>""YTS97(A6>I ^>H-!8M/D%6?^D0="SHX_3>5*
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MBBUMB%SO2 +D\B<8'M;F#^4W;!5Q"W6+<:*B\RHI:LFO8[I&M9FU2^2I6E>
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M/8D0DH7L(/K93'O6T$Z+B/<WV:2I$Z?W7[@'M&2U3R<6[[L3C4=4-+,U492
M[-HE+R#NAV"K^//S4K9#*I1T 5MVX?*=A'S*R.R[V<0.TWTL/*CPB>(V%1UR
M68@=&E!W!"L %1QN?LSX1&@2^BOJN6,_>_\Z-T,7^N%D:R>\/CA;&^TS:,-:
MK9MJS_V4@'#(>K4$N>[-UV_3%JE]Z-B=7</(U()J?-B8,-:*9QQH5VJX:L1"
MX6L$CLW9G<U\&;Y*IF8CH\[83WRK>+CV0CM>V$V+7OE2N#JY8VI$Y[^IE_M;
M*TSHM*BW=G#'V0QG9VZ+>QYTS_KUTNSRP2AY@F!CMH8EX'@PC<QG5![+',1
MF_5_XH>PJ&@[$+&QKZ2+*0. G0$#YRKA++ !P;)&(,:FH"Z1/'UCR@8"QN)!
M(#]:8*,X@1L92YVOW*JG4%V<-M5OCP"N\6T^>?@@)1<+2*)4^S>)4C5:4.):
M?5QIA)M-G2#0JB=1D*:9H,[-,KAPY !^QC?0@!==JR7U THW5,M\=#QQI]:Z
M<LI,D7*LM*.FG#1@78IK HSVO$UT ;,?X!4'CQODM8;DG1J'=VCJ!W"@?8S^
M#8'Y)RLGQ9SLT=A#22'<C,ML:FX7]T.)EG!+\1U%F3/($=)=I8P=#B<(1T*C
M6B&P$ZI7]JZ8'^HS<HAT6!A7Y51:!'2(_NF$VW,33]"%1[X[L$MGFVH,:<8N
M3^1GZWO[L*]R?G=-S5"HA1)@@FW-^II/ZC*!?_,>9]C,O0NLWC<MX$-[GN%^
M51VQ&^KQE 510Q/C_I\D-8691&*AC4:[/"G+#SPQBUM*-81>,URM>J,,*TA\
MV7*X6&K"7'Z&]7!YULW*TDJ3DV!&[7KQCI>FN7#=GX(Q/DI,$I'OLPI!40E4
MC2<@56<2$,S5!?E2V?.GF;2W+"!NG5]&62Q.VIR)^4922&^;$%_3>YAQMGMM
MB/M[1/Y#/@<,(LL'6$8H2!=R';_:E,E2)I:E;2F./6=4/S8!94,33<*<F1_
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MOW]U<O@'V?N_G;\Y@C_^/U!+ P04    "  W?MI<]YC.5QD$   A&@  %P
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MWANL_++\4>>"=6"LFLQ'PZ.36X.HIC#*\U8WJ>H?3_[3)_\Q]!]02P,$%
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M<%L[B4S'1;CV\."BK4@6*!XK!:_96X@WVCK*VK35$11QJG)^&JH?U^5?N<6
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MP<Q; )<G_P 0=9-YRUPIC/CG-23_O."=]9G%!/!R!W0F>4@G0P(P%"D4*20
MMY0 C%=[?_XD>F^GO;OV*[_8HB\^ZZ(O$Q* 0]:,3PD$BLL1@&#;3_4T4S9X
MT937Q$)L  $8'T9=G X)0._R<V$"$"!EQHOJ>4](*!4Q&/LP:WT7&1.#Q0Y/
MPCKJBA?&OIS\"\I#1PSJ7*D=.F\A.W?.^"9R.H =A*#R.H3QK\5/+7^VPD0#
M&\<ESCJMQ-EP!V& [QP#WJ1B[N+L]J7Q?"D'32=Z!S^W')V8.6 3R;UA$'8P
MSA]AQ>*!L6( Y%+F/OY+:[UT<O75L&)>.,>7)Q82J8-4,KT7>)Z9$6.69L0
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M_TH_*):<O(+_IYP4RZ!MZ(C>M=+9],]0.X#R< /#>FXX'7\#KXCX)MS,;&W
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M(=&Y_5J!;:L";^Z0K79-HGY^-6M:QPS83@AF4W]=XBJHG&&H-8D\="&/(O9
M;,F4]TCN1P4:%H>>XNV9Z ,6S7.(R1HTL?@9,>OV=9B/'=&"M5P)[@Q1=DT'
M[*PUTB0O6>$GY\(/\F";CC+,OSQ^BK[&$T/'*,,AP+GO*UTZ> ?.TD> 3A8G
M]7VH"PRAM[8@;4HH52A5*%4H52A5*%4HU88F+]M\H;\FE%Q/^&@_(%D1<K<
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M\G.@U]Y^+**OH,C2V5PD5\%Q.1M)^/CEW@\OW_Q0EY[%!WN<X;Y<'"[88[,
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MI'M3S_B=KFK__@]GI2O[FB7=D1$N$ZG.#/!&R>[,2-L53%=%XTX@D:7H@+M
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M&35S"[5T"PT0+N'&EG:&OHS3O#" +)333#>;@V%P4VGNC*%=_Q%FE+3,@\;
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MY)IKJK69KJ(L'.*@&!"I?5GXQQ*53W5[6P,#<#/3#+NL\@.V,K=Q>_NG9F6
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MHMV:VHQ^4RM.0I,.&J=$-9F&+B0NA]>23[ ?MAL[A08X5^MF:JA G$:<O/?
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M%[0=3810(K&I_) TKFU.7.,=M-[\I+X;&@;R6R1AEO!22\R) 7FW#8%XE&&
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M9%T[EVS%RV=S9HM$L":%QB8N0_63%TSC7P_]PB!"&UF+\NI[\[JL 7?E?,V
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MQPS-0)>BEB,H$SBGFFE:51Y%MY "?3)RCN#J&&O6KZ]95N$78ZDP!;[4YFU
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M@YM&'8PN FMSC<BH3]X=,,?/I9R4,6=?3UYKU8_][0M3B=-Y5I5&A,.5$-O
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M63@-3EZ<O.[#JK>OJ1WWMZ:VKG+TE_<7'__O5_SC[]>??H<__A]02P,$%
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M11?UG-TM^&;E;U'34CSGD;&1/R<Q%2C)KL'0T()IAG(3SXV^0+%;-4^.Q\*
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M5!.IMK>14@T,ZM<EHX18V O!"4F&"Y(,58#.9;P9 CC1S.+F>X*BA8,Y,\^
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M2VH<-)D3\^[0$"3+3C=70U!'HP+C)R=:C6YMCE3_\E"M+4K=X%Y<)!6%FQ3
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M\,_?X]+4&9^>G?P"IP5'_\@2.#::T1D"??ID_,O1X?CXH(,^D>)/S@Z!=LZ
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M?YG/40(!AJ+W8G>W1:J7$"G%$I?X8%A311W$X&2\22%S,BUAK'!54;"?EO1
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MP!G87)5KA U*S@29ZK"TG@YW(D8ZN*1V42_<E$@-;_"@,9E.=(@"X5@H\$]
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MOP%]SFZEBF)X,DF>.+XWC!T<IUO)F2MO!;L3 P<G+X#\UYR_*CL%FK#/(%9
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M*?:7GS(O@V1M9/[TJ*E/!G',/0CE)4PB'KR/%&<+HD7_[5PO)6E'+C76*\P
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M\,%2F>"GLJW;R2]GGFS3SVW^&U!+ P04    "  W?MI<-7X,VML"  #=#0
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MZ'&ZK3/LN5BRK+Z!V36@"V!_)OSV)\E&%_9_5%QS/2ON:^9:]QM02P,$%
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M]:1G ?F3C/3=&R9(P.WH6O>[:EFJD0GPUV3ZD]1\^:U)8$W53R\7,F,)9$0
MJ3E"FP% %C207LICD@SN&1[E8(:C.MHS\^S)[0(_O2AW!J/.!NRGF;/=^A.=
M"< SXKAVMVLQ_G*#!SYO^QR84:QN>XE+;X]A&X-?4\G3RY?,?/!9 #^]K8KH
M\.\9'@!FM_"_JJZ;#IX=NN4]]U(JQEN'?48+^R:&OA[H6[6,UO/4AYX!Y%NU
MC#3^HVGUF>:X%NCZ1],U>LS*!;^W:AGI^+H#SL2$::67,I?)]&:!Z/32\C(9
M\M+#R2H_M/<G=(AS4A^79Y?U;OM]9@'F\A!J:-4S.A*4^;C77(WJ&?%32N/.
MAJ;J&054TYWL3-AJ\\>I-J;"C4UGI6Y031N;/UF6I(I99#RT&IL_@+9!K6OD
MY9Q:)G.7WI&2%4>7X<RE?VP@BTS(=3) 6ND?J=](TF&]EM[NX+(=GTB/7[KC
MJ2O,QK(EZQD<L5RF\^M)OIZ^B7 #780UWA&G@6Z= 9N?++'6$-*O@\,[+?J?
M;=>/4I?^=Z8]#8 FVQCT>F)?77SO;7\J3>M"M;7N<H-+VSZ%X8>]CK0RTA(D
M<*7I+GPZ)U]M\S*(I("FEI67&V.H7C]-/Y\R)\80C"VC/=G5MVL23ZRMC=SC
MQDGS]*S5G!+"658!LHT(83DW-%D(N=NU7/'0Y:JJD+^=RY4.;ZX\_-2+5JQZ
M-#5#1<_@,%9J8TQ+CS<=#MRLFC;2VVO-\@CURJ/;EJVQF;G;UN&U3<S<M@]X
M967@-]+;3\K7D<-Z(_UR6/DY<@BCR\N!RC1W^F!8.5&T+$BDD9/CE$OW>VLE
M4S/FOL@FW4X=.82QM5(<6_KGS[+P"8XG*[^!%+*JJ9J:"+*AT69&24ZI3_W2
M ]MFSL"&0-M,W21+<8RK.+(8AYP<8^K&V=)CS-0\:VXZ&)$XAUE8,D=;M60R
MW.]H'*5?#&UQ>R#+@:6ZD1-=%.[4L4BADX45[<>!9;I/6.IKJ-FP)(R_F@Y+
MKC(Z+Q2S[%#3OSICTYO&C>,L;B>)E"&[,>XL-@+"DY.6[7A.LJCF.3$>F< 9
MJD*:\9CR5HPPO9&E'V46%&$_FKP+%@LRID35PN%TME3:HTKO$HD41I4:V:5W
M"#5D:'09Z]G8T^ H:J@X9[;3E-Y^[7H#2FV&LMI[#0]+%,@(*F-\P^,G+Y:&
MK'&EV?P:1+1N,YZZC/(-4AMI>G.:Q7YJ#$AER9,[7>TR)).,YR\+IVS54:4W
M5ZF[8O=@. GFO^U?L4ZVL]),?T]TH?ZG)?]F+7U"E[W_:%HP%-?J#L  O.W+
M6XU$A1#O'$_&<Y/^,8]UQY;>O&VJ;O7B=[.D-6N;LMR7+&Z=PISEZY:6M"ZG
M26O>"W$/S#I[=<UZODJ@+Q+K6GJ(J=M>7TVC"_V^M3 X)?\(=\9P *5:1V=M
MVV:.+9V]7CU;74[_[,/<<3[#G)G6>/8 4U/'],\0 @V+$!V&R=O/JJ9CK/O1
M#/EZ,L:<AP,&1R?I(WEA <@#!UL70>H+5I&.F!Q%@AWE/&(2+2J5E@R6N>RI
M6:V=",8^JM:.J\V:-Y+K5]7NPD+V6>W8T&!\_T_3+VV_3.>/_,ZW5NK\IA.*
M$X4=!5844HN-Y31]9VS9L2RUI[S@J%)?);F$@?[ 6C.'"#!^N_3&9RO]!,9U
MQK58'LYB0SO;=!9[(@FL/4UG&\_(GQY+^DIUEGY,:@GP93E;J5N4:XTK1:4Z
M2S^TX2^SS$[<,5C/-CA+?Y]@D4ZO9Q.<I7\CEY<_D9F8,S#!YO1X71FG;G=A
M.4G#30@P)LI7_HKOS\"O=%U[8H:#JN[BCMJ=^<*L!V8]:]V)E+%;XXH-P8%H
M8R'N)[Z-LX):-VKI3]VE:72A-Q8GJGO-_GG'+/P 7*'X@$:R,8";C;84$;C6
M<GS^?95\G,R:>F%4#MYC%RN()WJ(Y1[?L+L"NEQ%0)'#"=L24/+*EZJ KE82
M4!X0M"$!7:\BH&:)$/1Q)0&U<B"@&;YVER=]V%/)S2O*Z-,J,CHZ*I6,?EM)
M1J<YD-$,]S)E&:W$UJT\R"C16KR3^0BK">;!'8UT;<5U_J21 \$D&OWI"&8E
MQ)RDB)B)PU[)XEF1?N[4\>IZY4EII47^-$7X%$)**ZWTD63BE)0LE(__4=4L
M7B4'$S5UTW:M^'*-DX+Q?W=C@%MJ?P9C2*]/B,=_Y@M3L>&A2%3HNA9F2DW(
M2!N.=-9^LACS<JT^NEBY79P\6D%R&22Y922W1L[DEOJ>30[QQ@\,2:V6QZ >
MS<>!%)NX\V,EX:4>1,HAZ+(27GH7)ZPAO$D;M !,EWY9E8SDEC.F2[^R20[Q
MEI6R-E+?1\DAZ#(37NH:>R7+;C^JKR(E\BMS9BX.R_0WQ5N$E^[O"GLYC13O
M_4TS0^,!-W.,I[;1^Z):/YG#\ZW%^>P50-2J;3-=(]'O_L0,O#T-!MGN#35#
ML[E?],S6&6D]HU-L\>-=<K]NH2$<9W6)6?P0EHR5+#:$])?+C:4$-H[3*[^S
M\91 Z'Q&!9._'=@'5Z:NJ]:EJ1FIT>]Q=N=K>7V$>V8SU>KB,8<K7.'-$:[A
M'L&D.(S4"9;;$T$T&Q>]2[ [I@Y<QI?17*C7)^DO"Z%4]84O]%BLK\?IGXU9
MI*\3:! IT^NF>C5.TK\&9N717*P_FO24>!7&;/EG=EHK .OT.(OJ)@MW/O'
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M(A%F<()[M6N?UM6@;+8 YZ[-*0_C+,V;,9:V V<<^%V5"9JUK5TL-G\\*_
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M*[N%2=S??;IS "T".J).($Y#II&D\#P+7_W6ZFF&:HT?!JK%[!VE*L^H?G!
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ME-ENN"9N(&Z8S0W79>:&,ML-Q W$#<0-R=Q09KOA(W$#<<-L;OA89FXHL]U
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M@6%3N F&>U_Q"<SS9%5.P.?+P9H7%B/ $^!+%2S[Q QFJ3I,8KLWU S-YF=
MGAFA/@'UBPFLG- O%M<3] GZI6-]D?SZX^'3SN$:'5$?QY^8^62IHX$&0Y/@
M$2-_]_"IG  M"C<30$L*T((QZ+>'L@+TVT,Y 5HP!B6 E@V@!6/0RW99 7K9
M+B= "\:@!-"R ;1@#/K;[V4%Z&^_EQ.@!6-0 FC9 %HP!OUT45: ?KHH)T +
MQJ $T+(!M"@,*E!YZPR8M:M;I?.0&D%16!+E1&Y1J)602\@M .>*TSX2N2*I
MG$+[)0WM2RPL"]!LT\:/?8 >$T!+#M#C%0"ZV:HS!-!2 W3%)3Y;@,:<&R.
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M?EQ[_^%P=+YF4_!H[;V"@<&JJFM/\%&78=KGWOF'SGG;5OJ:SGJ5%\T9*,Z
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MDB=RX<R]!7ZRU/Q<QZ] 64^\]]I/_*V7XJ7Q &@WCUZN?N__WT^=U=-D%@-
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M'UV P!8K6K R).4<QZ0SZ'B:3(034+=X,H:72NQYX+-VVRM^2$;H(JZN\2$
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MM^O-AM-HMN"W;Z)]6;G,W-"J?;HZJUPV6]]$Y5.M4?TF/E?@,1<7K>:7VHF
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M1.&Y1%Z0*,S.9I[U$R&5#B8X@"*0D2OTKLL@8^G*U"3P#"M2H27#!M3)K)B
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MJA>!^M.^ 7/=B\0?7@32"6V,?WC^)$Q'UT[[QN0OF1X QFRF@(KU%AH)[4>
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MT>S(EQ/_&!C3D+"]/'@3P U7XY0^G]**1PM"0V;H+ J7RYP9Z=R__:*.MNA
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M,:,94W1/FZWS"H+SI-9HUTXTK-FI"!>=UAN51A7/I-Z@BQ'BSP;P=^L093D
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M<I,=["9%*EUI[> ?1M]Q_5I1#HOZ90)LG#Y0[ZC+9='A;=";KJRGVD?A]?O
M__6,"HMOP>\9?5L627)#'AT6I4- YA9V0::ZR&XHT((,@-?@Y^<Q 3>)D[B4
MY3QM:\S#3>C(A([>;$)':Q8Z*D(0RN7\/1YCG]K>_[SR_K6W=PC?_8K??#RO
MM/ZH78I*XT34&R=7[<O6-W%2N:P@)UD+AOC5I\E%F$V.N8YP@HYJ"](+8LQ(
M3"/N'>D%(^6>*A^_(SZ'=_ZM3QP,L[4\R:D6?P2E0(+8P58,N!)V:FE],!CU
M8/D1YHI+*:551O)6)+A_SI[523S\!.I[38EDJF.._P-?Z26J%D->&))"AMF@
M(!OCX#\^J9G747B7W CL<(]OB 7WYH/=V3LE_?/6BX(P11D>1+T==./!5L,T
MZN*=J#+&<3H<\VN'7H^*%?0N]&,Y?8!O(RU37:)%R?=1>#?P>]=:Z/ &8HH9
M4?].+K5D6:-J(."0+O$([&6KYCOHV!YZE)B@Q!V/YH.K;\/!K2]&Z="/8'..
MO0F\G4PAAJ5J5C^U>]-YA(^>HS%\K#.PQ8("Z>H=U&["CKP P>VHAW?\0>#?
MLM),N5EHE0W\72H?*\&;D,:9^U2O$:>=OVB\1 AF'K;($#T?M2^$<#J2[<L2
MMENB(/X.6CV&\X"$TD'"\U$,#/$B"WVM)9C-:C@O0!E(K-8"I:-!(XQ"N[['
M*H5CR""Y"6,@:C_N1D&'7Z:TH>!CU2.\0*=B TV=EG_M173;:1AAM\F=LS D
M?:FM2_[1SE#:$N[-/*T%4!&GO 3Z>O_@@X-?QO!@.>XQ%*8-;O8Y_B#V[Q#E
M%F$VJ\5DI[USLV6(IX7(9:MR4D-)TH8'X]^B43FOM1V4*NU:ZTN]6A/T\Y*D
MRNQ5/H4']G(^[T<"BWEB%&I,,8V#C(!+(B6A08Y_"TR[E&R->1P1&K"V=CCP
M@;T@!Z1PW"C I[B+/T+HQ 5X<08)B]OPH=(.]K_O<9HHF$>RF?/^V]?4VAG0
M^_6[@P\BG@P[X0!>WX%+B*V931)IC\($I[9PRT-Z>8]RK,D:0.Y\YU'C62]Q
M<B6%\%^?C!%*(L#G '<&7N6JZ'\_'0R +V'G./0P<+\Q^P'>G4L2(P*6E]"D
M+EKA E!S). ;?D".$[(\0?\T_)7W),=W8T>2"-6+\< C7XA51Q7XL91M]LOL
ML\-[LZ<E3Z@L>Q]!B069Q*<'+*)N@C$=%]EGL#I@5NQ\P1>PZ4;7J'0">S\=
M-)EU=9=:^:HD\+W>6&'&"GN[L<)>IA7V6@O0:N7JLMYL5,#X:C0O:Z)5^U1I
MG=0;GYS39NLK_+ESUFS^ 9]%^[)R63NO-2Z7)4M73&;VI;8V8&W-B"O2^/W8
MSU]AMW"2!8>N%F)&GW?MZYB#RDELMOV$$K?/85+I-,.@LA^1JHLBV%'3;P6U
MD/*O,6Z$W#?_%"H<D-?Z5D%>)C8@DPF560@J-RZ*[!@9B5&L.]/X.@D=U5BJ
MQ%//T+)VC;6 P.;3A$K4_^*4H)@J__VN%\OVVK/!*]N;2B%_G7H4M0?E!A9I
MP0C4%S)WK!<#SF,5%0Z'#/J!<3^BDJ_-IXGHA?1D.AU<>11T$Y!X<$B /:"*
M@YP?(+!E<2'=#FCQ]0:L*9#)/6>^N@VH :(C9L7 BY7*#QL)NL$8KI=ZO!["
M)NVQ_->PI:FO0FP]F>I+'?U].NCE+U;VU=3WA$?Y;]4)Y;]GI23_+2AS4U^A
M1I1?&"@O4YL8AS'Y4*:_1U8,U##U RB9P?2*)8+EOXY]_WM^&?%-$8#P]*?!
MGF WHJFGHL(X]9WU4-;T@+@&'E%JY,>Q]%M,'(F5DU+$[TB%V.O$:B9@0N3%
MV-0+@<01=65%*)4EZ_O1),<?<R]8,<MO!N,^+>.V\ZC-D3V94='LR2H^J]*2
M&8$V(!;Q'J"AHKE\GQBOAYPPP]Z]#O#^]TL!+PMLZPD[?0_P:/)^WC/H6O2[
M\2O-09&\EVM+2-7I^H/!V.NAL^)_7NV]HL]P55=]OO?Z[X)><H.7[OVRH H&
M2M7O2:3>=(NEL<!K%3+ O:^DWI7TU$7R)7N[!T?!Z-6O<WY?*B!_>_/V-P/)
MI#?U[N*&!DM; 7$"+3$PAVKD]P,=QJ+5X#]%<CFS;OA71+#_E3#AI]!UGI*]
M0>0-(A<BLM0TT1<+,C$=#KV<6JGQ.5/(;ORRJF<_WG,>C()A.A15+[X! TW%
MG;MJ2O@&_3?HOU+H7V;M:<3711?98HT-?]\@^$HC. ?78E5?(<-X?<L/K#.B
M%*J#KMU+NTG&.QYOD'J#U"N#U%,9!.PS\55V@ZMQ64WC,A%L*RL"B:)2QS!V
MY&%?O"[WU,,A*WP+>6W'40!6/ER'#C?TG,GLA U%;"AB92@B;X_:#FO1]?#H
MDHDABS0!C?\_4HWW;KU@(&T B?>@K(=#G"=CS;33Q/;IXDK3PGC@)?BB#3%L
MB&&EB$%+!(RX<TQ#G)V=8PP^P)P\0PN@]_L[*!"H6! NI8E"NH%AE_*<I'OR
M+HR^#T*OEQU#JBG#-J2],5D5%&7@-6QH9$,C*T,C9;CK__"[P-PUA:!?,Q_T
M!$D!)$:S4&%QX="/,DDIL:R.PJ294 =*NW;K8QE,E-FN9LS.8**,E2G=3*^(
M5; -06T(:FT)2N9A&W*"EV 6B_R>+9: 4B+H>ATQ X(;D&CA2D*\?F.+;"AA
M=2@ADP@3Z21L12":"OP?LBTUIDU$GO(XZ1K<Z0((?P@4,.JE0TYCQ\XLLH1O
M0P ; E@9 K -\<3OWHS"07@-@B"B]&$L@5$DT/-!WPG',F=ACDD!*(!I*[((
MPCPM^Q3J[X34DG'CJG8H&TFQ(935(90I;)>A.! :*=@2862YK 8@2 ;&9!@$
M- C)']T&43CBHG(K'NTE"=8F1Z92I^<EGHBYTP=H6V!;R+>0#PSKN8!$TQA4
M,'X)7<]YN[*R"N79![T>N*:0E!8\?8W&%M2+OBL]">OZ);U?8L2B"R 3D!K%
M82:A9#7:P<[5!"^)SSQ"=MW<C&;,MBVJT72DWW;@RSX*5.^J2_?GE.#AB F[
MG+]0^+!)0LM0!2TJ\=96\EPGFS]LE52ZLF*0BRX]++OL\/"WO]+>M=3RL/Z3
M:S?3$?\=49T=?Z.*%0-9K\/E*JHX$-<XT0,Q'.HMFB8X;8O@0:IE.)B1? U7
M!)$UA<KN8Y#I;Z#;(N PK6Z7)G)=#R9NR;DYG-1*:9^RBA..D/HK>LB89 .U
M0+:,,7T5IB.SXC;P[V)YRKA=JRTJ'GA)T9)#6G+B??=Y,E78 ?3S>(18"*OI
M45T6R$S!H\ )N'<8\()-(BSHKA+L-$6NLL"6QBOW!W@K#DJE1G].-XBZZ1"5
M=2H2HXY_&EU-!T$L(L:F'=Q9T#,5J;CQ$5"8A?ZN$A;\%N3^'O:< ''OR_:H
ML@NM-QY[B+-.[KVX8"S<BLRNT:G5]<>)ZF)!!_?O-, RNJEBL]BTC7JDX1)E
M]5%'F_HH4Q_U;E,?]33U48\J7A^O]NA;F J+']/,*B3H5);74T+_2";TSZX_
M0L=TS^\&I&/>A'=B$J81]]623\=ACR '!<W:PU_P2KI*->\=909$8F^#!"76
M(G7B3IM?@FVTX07#D!MIVU)U<5&*.9Y1 (#ZCT_%HW(#4IK.U0TR?1-X5"5E
M]:/, ($"ZP6*8.9-,LT*2"O.JE8PF(#<[5.(+9&-S\C"E64:/LDFK'PU94.E
MIX3%TT-?:0AR+!EMKNMAW6YN<6@;T.M-50'6>J@B)]4:+PF744Y0@J,;"WEC
M(1>&LJF55J2*CJB]R2W9NYS;9U)4U3#/K+9EX7_/QV+U67FK^(!KU((IX4E6
MW .)#O7OLUMTF19P&P?3AGQ6AGRR/6R,E0J8K-.];8].5DSY6'[*MV9B&F0Z
M<J&NY6#2]9&Z&,@EZLE<7T)"&\+9$,[*$ YKC7:1//=?UYVC[,((J=#^Q0E7
MIH["[@]%80GI:;$;)YDB^ W^;_!_9?"?]*XT(?^15+HH (%XWO5]FH>I28 T
M+&G4!*K! @:RL9U%8C5HDPXZ4T+DC48A$A6W["E1KTB$F)ZI['?SAV,I?="5
MU9EL*&A#02M%08"]=FEI0;^2HL)2@6X9U?#+"P;HY$77-#5+%%,]RI&B8FNN
MEAPLHV\M:GT%C\.2514BX,)4= 7H]71YSIA*1=S8/!O"6Q/"(V5*^^[D.!P3
MJY"_F+AZ\.\TZ 6R%RBVJ-ND4VT0>I40&ODOVB.FRVX1-S8Y54$<I6,,3<I0
MM9V:H/,X-@B^0?!50G!+48K\;G@]@M]%KJI/HWBNVTPA/:CA%VK2#)574 "E
M>$ ,UV'(SN*J'9W5@XZ['\#R,.$\D\2835P'[0R6!HBX,4<V-+8Z-,9#1BQW
M[<8-N\':E<?:LG1PMH=-IX,4$]8"5'CPA*D3_D#HN3\\L*&+R4V$"AR9P*$_
M</U )M9F&T%1*TO.PKH.99T&3K384,B&0E:&0LC--!Q[/+=QBEXB?\CUWJ;V
M;M3S.R #B._;0\ VC9TVB+]&B%_<V&EJ*HQQ:!9,%<H'Y;C.5-H!MSA.8=2#
MIXQQ[H2I8_)OY00>:L1LEI&=PT#"Q918;"SN#?&L#O'(IB#V)"1L$&*:/!FU
M2O8_L\DF!CGA1SL)H/Z.7>NG9ZF")#H[.X]=FSITFP350T1EENO^TKUK/^$.
M[=BC!+^CM,R@GUBAQA"3'D%C _T-A1(6543=FR#QJ4%"S(FG.S=A&ONZ28^>
MF+6AP0T-K@P-]@?8U(.% Q*(U9.*I]/9*2;%3:A47RLI\SC)<>1?>[*/"#N]
M@-!N?3!EJ%@(3TU6)4EO,!#T $?]8?[_ACXV]+$J]*$U+IIY00E9MA"RNXQG
MNKTAG>AN;CP\T&KMIBI@"XE*=7/C4<J (/A?RN[R./DX&(W"6R91[IUX ]((
M)\AG',)QV$_H2ROU&*O5_8+2-EV8#D089[3/#3%NB'%EB-&VBJ@JA90M*E:Y
MF0#Y$5+CK$IM;@W"U$SDD],QL:Y409K:7"7^-0_!F&IU193@C0)?"2L*UF!K
M4O,PMM^N(Q\+:52K4UB7'M$:&0X1!=2%O3_P?P3,#UXF?9653+[9E$R:DLG?
M-B63CUXR.6>)F5K?C6!82\&0]3\/O6X4JNZYJC+="M'PQ#'@]*KO2.1WU20J
M'"?JZ\%4S/5!B\+O^[X74; ?/K],MKW!_K7$_IP36H%+>J-S&?(F^];#$6X;
M;]0&DU<'D[-\7*4.ZEF@&I.O0X D]9NR@ANLH<,/,0Y9S%GIXFJWO0LL'%1+
M;&!%=>ITPR!$4O'2Y";DU-P-06P(8J4(PLH'&7CI"+07;,(S%5I4,1*NH%5M
M![FAD$D'5/VBJ2,T/F>XF:.QP?K5QGK9N'GVK*1L%^<@&R=4<V751&=^&GWJ
M_CL-XF 3E-O@_TKCO^PLF^E&KG%?=^PG1V:$Z8:RW9Z6!%V_AXY25W>3HYR0
MH=\+U(1),'AO@S"-T1UJAH.KUD#BSO>^\_QTBH87/<;JWS!1/>'*'[6AN W%
MK13%@684QK+,E4K-3<P.B(AZHUO5']P"-TX&>&&BVCD228Q3[E$"Z-[SANC!
MM%LX3 7?,CUQ-U2QH8J5H@J@B3A0LLAV(+E<C&3R0V1?!57JU$-+W.1_<-<X
M#J IWZRK!]J0H_57DBTFQ"=[QWV8V>5Y0Q8;LG@&LF DGM72,1CU 'BVJ)C?
M5#+KK,*VBS'/AP6KACO>HK0XV/O0P@K<4Z8+^FK_PR(]*W/(]Y)HJ"S4_'83
M:C:AYOV]3:SY:=KS9B+*RVM6SQ@"^^Q(D@IZ__/*^]?>WA%\QS3QSZM:^[+>
M;+1%I7$"_VM_K;7:XK39<MJ?*ZW:Y^;9"7[1/"51_?NOG66TU%_BALL:LP;8
MI%\ TL:F_Y\WBN\P!:<#]O$=C8P<H.]?A*/!Q 'E@_4.NP.:[&P+[+(7=E.*
M(%#8 &X0G2CP^ZBPR!$O,?:= H5D2+]Z\7=XEO7^#C8,SK81!O6^PZE)>%:P
MOL3!"VH_P'J@=O5>-!&?<,P%D,*Y[R=4$SB[%&16#=2N0%B86JEBJ/1"ZITK
M&^HZWF @N!^0 0=I= ",8(CC(KP1O373=MANZK/+&EX:8;0QT^V'"N:]WCWD
M' &F,AKY/Z3+FII]D615)X.%8WT_BKA4F#O;XQQ=^#;%S"WV8\OY >AJB'QV
MF/#/9C15:4<O6HCL$6V<)52)L,#9<<[S73# AI.P1FS>G #2O]_;$Y7=\UU7
MU+P8_3*$\E3_^7__]?^YXF#OX(TK9"<-GG(0.UBQ$/H=\=_></R!_SP[NW#%
MX>LC8.31=U&A%&J7*.E;&'V'O[[!R_:/7N\*[*Z-NC?@(=BO";"\WOP-B-L@
MPC[, *[;P /*&_CCFW $R *D^_NO0'/J&]G>^KWXU]0_N#:NOP#\N?#BN!OV
M_*(+=P50\:D$[#B-@&I\RJ@XQM!;?".^!,@(1#VFFB<L8'+4\55E,+ *:(>)
M=EL>(+C?MX8>;+O\W)M)3.%OC.S9'7/+ :&.,'LD0AZ)\Z CJ?>QZ[A (LFT
M'T]NHC"]OA&>Z'@CN*,3A=_]R+0.1N-HY,-#\6Y:&'Q"(G!PAH1=60RH-2;J
M&ZLC2'R5!S '<PE^<3<*.GYO$1T2L6'YTH)-(%;$"JV?O'7T<]:0U/BZP#F]
M<0Q(JOY2-E"I+<'*B%S-#GZ2ZDB!Q:1?K"V@#LJP?THX=HHME\('%<M#>MS7
M&R#XH:A3"E-PR_9#Z3G^;^;]8IEVP.J?[H,LW/GF;8&I,FWT9'ZEPZM8N##;
MF,W=O'#?>OM]*!L\&NFU();@U!9JTP\<R+@\L<+ EONZJQ\RZ8E\!PKB9, R
MFX8R2(Y:SG[1YSKF"09<2,NCPXP9S#P>%9_ !/ZT#H?!;]0CXO>/9>26:Z=/
MD42Z@!&4H8<'(7W![J8XV?T&I.5NOS>M+.#O60:)>'EJT,B-H[/# 0C7A"X)
M9BF'&BOSN!V.2G'Z4?V;&[3]&Z"M8MIV@S JZ9(?JV3#BG82=K^;5M\:7[]Z
M4>2-> A+<3-7F06-5PGUG=0R3\!(CO& 2-4^]\$VC-B>"R6)R'S3MHQPY>XO
MZT&[NP)4\3/OX/^3^%/XJ@)0XZ!!G])3R.' 78!PE%Y$MA")5!Q@EVT@IWT0
M\+7^8$M5<@Q@:?P"G73Y8DL<%_H@G,OY#Y)54L0QBSO>;07;L_'(UB^V GGE
M4/_&5SGMM,.>$YW89F)4]+W&P3B-;I7^HQ[D4M<,&B=( R?H#C5TA5$_3CM_
M61X9JU=QKO6?4P@%LK5H3A0[)HS9Y0]B_PZEP"(&&*"7K^( TAM6"/T+>?JH
M7,H8 6%.]M9">!?<2K*.%M_S$R\8L.N)3N4XQ"X(0:S$HYZRQ9M0^I\2EH5
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MX=" F/B)D%CM]]1 83P1:0*BBKU !)8M.HW!>"WWHMKII,& K:D!3D?:X9W
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M_!H[ASSA_LH,QCN?!C3CK'K? ZCJ_L]$I0, V0B5B^(Q I$9XT@LP"!0)3N
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M'>P3;RV0ZG9B4K_/@DS<;2!JR\&GVIHY39$G.XS$09V3]05U=O-F[@?_V*R
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M^*7[,8D7<0IS_Q /W&,Y]I>&7^FG:YXS></6\^>7B1!SV"OY R)_F#M]JZ:
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M="S"@.1H831$6N])-L5S"MJ);@,NZ7F19ZHGN:F=5R@'W:DE@JX41&Z.N6Q
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M<?AU;V/W0A;& UKU VH8R3D$:$,'*75N3#2D3GY7=;872,@NT=:#LN^>:);
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M*%Q]NPMLN5F3:8^%J9%L\G$Y,]VU"GZB7J?M25!\\7/2C-0K#M)#X#O9-18
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M@?7F+D)_+(IM0$@6=VSJ:K4KENU=2YOHAZDQ\3@<1/>>D09:^4BE>HW%&X!
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MHZ]O3+[0N9(DSG6&0DJBJ![$4D<#I@]!MQ03&493JH=M]I0TS[(5I!--?:U
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MR$CF)ZPSI%SIPF&J20W<WQ9QU-EO(%L3%U_25G:3=9Z0D%HHW)G)^A+PKUX
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MR]BO+^8LZPSBNO5TZEHX#38BD%9 F#[K$:86PO2X1YANHYY?+Q6WJRS%,D$
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M[.OB25L,J)9?B!42QS,!DDGFV.%-4=!GRE+ZQ4_&,Y[2R=!SL(LC)^6]QNJ
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M>'C1->Q I;Q3651E"L4+D3 T\T;+YJ63V"U.N_]7<K6:L(YF3,O.0&7BR8-
M,_39R1 ,SS0%TQ/FZT_T*9R>\+VIVW.$^:,QJ>I)XWL=>._!D[/A(9SITZ.G
M9V>G^W(0K<)!$OOG?+1&CK_YR9MI5_FWV\B_G:[\NQN+KJ]@;$VMB5$[[[[Y
MZ=@/Y<?ZKV;62S\=B7$\9XNF9;TR_=B>1@M7=BRNS(=F6+/UBN_@K>8M;5?8
MJ;!1=_?9Z+8NJ2*0W;RB+3Q,4S9=T@@?X7Y^Q/3/+] N2'R.$^4)N12QTG\B
M28EH/6):.R*?*!CH\31#PCV:B"D9$7_]^!NY W),IP[]#*^ZS+P(B8XJP[BJ
MF Y0IYJAILTQ)KQHVU[V.$C=O_K^9T\9)3(UA>&".&&$5Z8BN5)5RJ,CV7:3
MS1DJK /3/X)5D1V$UHD][[&/(7VXYFF<)PCIH4:+8)PDDR.T56XPG\27/O+4
MO21#&;,<?32U$"J:\OO"'!-<X&PB_Y*[,:C>D'/EPL!YPDUCJ.'YQ=LW<K,Q
M&9YJ(,E@H*?WQD&$ZT2 U0Q/3BAMTJ<$FDF.CA!K:AXO<X(U=3)5S@56&8?D
MD_W;/V"T17PME6&DA$LTO&)*_=&G(CM()-CJ +-IV-23PMB9B$48W]#:,)03
MPEO&7RG"6#UHW4+;8K%A "M1"4'^A*4!',0<JS(@2R+L\)S; (>F;FO*QS0*
MP@#]EPY!!U27/$G5U+3P2D2YD&5Q5JBBP,4<- 7CLRR>CD9Y$'+#,-CN2W'$
M*X'58H6!$)2:U'.,Y_KGGW]!]PI!93V$1HFC+.<_J+$]'A#H7NR+&:-/3MK+
M _>\-@XL41'V7:[4L9?>;:=2=_&B\3U6A)??LG%+W.9YKHSH;2NN?#;LX\I6
M7/FTCRO?0<K3G4:.[]CFK CZ5EO>^5X3$O7-HK58JVK(,C#:72H-3OCU]?7U
M0,A?A/XH'?C!P*F\HL7/ZJ[H9VU\=]GIZGR'T]7=DM-U*YHY69:O8S^9(-CX
MK<HPD1OH?J)2E2:7B H;7?EAF[-CK[1[U%=4)@V!Z$R2C;*[R\UR",2>!))2
M7 ';D?O:[+:U_@FANB-2R4 U"S@K8JS+AA(,PD<&!7H<AO.X<.8DQZJ!@N>#
M:@ZJ[U()-'E+<@9D5 /_NTRPE"!H?LBF)9! IPC5+PRKGV/A4ZK0KPN>@MH=
MWJ0R9VDBL,JE/-C4X<[%[1Z&<P*52[A!J9*DI)K:UD)MW0[.,36-U5E$;1"]
MNJS1\_RL[:E_@V(NU*Y457DE239?L(E%];^P;RW6I?2#A$LTZL)[(T$9=US4
M%&?K<%E7R3P+;=]5*W::#<U5J^Q%33ZPBK>R'R7%CJR76@.'4[V&3Q<Q2EP@
M([)N$DS$)^1_AJ:$;$_<M2UN]ZWP3 E17H5,YKL*Q#4\=>4G09RGBF!OG"+!
MDTFEQL*.W!.P.BXUS:IK0WTG5(Z=-$6)':M-\K#)>(Q 3'7)[!V<<<\]M4Z"
MT\ + I9\&%V+85LB 38>4@J6'IBYTS"^MLU.+*K+7_-^LQE37KA!T%@"01F2
M^H3"&[T>)\)^YBB3IXRCH52-)&&G&*P""8?O=TK&*IOD9#0&Z3@GV2;"5%P3
MO*:#@=%28;YT=ZFL9"!+%5?F63IW:[U5AE?O06PJ9^\8L^K+TDXZ)(5.7MI3
M69>04N%T<D=5ZE!="W34*"7[T2LL5@C:K'0NG@X+'?[V6J4$%:"B-)7W<X-"
M?D<4:D73J"P;24PL1UP&8_2AB"2B.U+P4Y@JBZ")7\'#GHOM%>AZFULHOU-%
M%#VN8LY.< 21F-L:D'XAZSN"](:58!WLQ"5CEI.]J#>@1 ,YMHQ>*@-U^C2R
M3&IHQ2;= N&26'/OAOO8T]_<J108XY'%&-66W$CA/5^(C-B(P_P$Y;_>4^E*
M9ZX'^[*@;J7B*@Z)_U4]75Q-VQV#* 4^!.O]7Y8$4B9*=R12I>5W]"A'&6OB
M1)F#<Y?\F=Q'F<J\'F/-=3HG]-QYRITG=1SMC(.APU# \<M.E$6QC<N28K?=
MG^O4^G OBJO]K%V%ZJ!3U14JM7RNFFBDA8=&$<N<3)^"<OM-0_$M(.?>C3D'
MAW,NTR7$P<F(LDNM&9Y#3$2/J@8H'U-JTTK1]TM^.KT%,+Q/Y<D]IUQ-%#.0
M9#+[0JJ(QI1%*8+S"#D@@YM^&1]E\9$DDR(I8OD V 9)I[!;T8P\U'#P$[DE
MK"&I)^$>$[4$2C\&V<>/H8V'V?=, FJ)7.5!;;7&TDVU!K#\>$FMH%"=.F_I
MFG=JW="4IX..].]R05MN]!J_L7V&<F,LYW2ZN@?8\C<K$T2N5?N:JWYF;)T
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M$-<2ANB^6SL?CUB"(3\S,0D'8Q)G.B:AV::A#)MFSPNQ4>(S0(1^E,:Q^[,
M7OB[X&#8?P6^Y[[UP8IPWU!#IL\S'Q/KW/_K)R#A4.W]+U_<Q#D\^WD61(ZT
M50M5 FQP@C4*90UAI3 P2K. F>7)\.0YMO/+J=2!T 40^ GN#4%)94 1F+,]
MPKC!),>$0-D? I_^ WX>3 ,P-N+$^JGP$\S30@M!N< ](R 2=R)\S/FB>:K8
MHK41]&JS%PW3?U8S?4<_$216:-"L1:8U+5F-JU?#;^JX'GP'KLE1:UIRA@T+
M>]I\+JLOS/G^A54P-!62WP0GO,,LXY6XH%/=CLUPN[M//,>X:"$T^Z00FGWW
M1X[IF"!:4>.Z$@[EL:P+3-(4\BR/RMDS)9+EAYS20SWY OG6[]^])^6G)5)^
M6B!EV1Q"R_SUTZY'!I&LMJC+#(4D C6@J!:^ASYF.3^.H[R3O47<GX.4@VXY
M_.#LR>D9@Q2"%&&(8TL]KH_5F+X9 17RBJ11U)H-ZY1NFIS9HK]:PBE1T;V]
M2\]*=^E9";'S[SA/(H)@;@E9Z)LA:]N:EW-:.1"*&5>)S)OG_T5<Q-24VB+L
M [L]W&F>D$\ /4SC(#/1)^7 0'1;P,4TR,5PA9-1052,<27"":(TQY)? 7['
M 5U5P\6W:N+8O7T,'*E+O[-*6IVU,?LL_=9DOE8)<S-W].[RO=]2C1O\F<HL
M'HO:*Z%[MZ\WS?N.5OYEZ<50@:Z9"#'OW3D>OA@.W?/!+P./RK^+)*(Q/80D
M_/>__D=F6\M+QX7Z2&S_'(N1^Y_^?/&2__GSSQ\]]_3Q&:80?'7/J6!&H6:\
M_!>L\_CL\8!16A)RX6!#1-E9</G=QBIF\"/N$'85)%E.U<RNP( VI4%]V-$O
MI4*A+]Q_5?[C4HL\K$V*M\%/TW$\$74/[ICCIIGT)0+I([J)L>;8&#;2Q?NP
M>Q4,VOK:%0H5UH&"6. DTA/DL!B1W3'1@=Y)3@3$$E2N/ U<P1%F.L6<6(A.
M;;(OB*R)A[D6^+"UZUJRM4ZD>!]XO>380.JEE>)KR+]2,TDY?7NF3FFFI5D-
M7&[*GJA@ ;Z%>(+I'IU2#PCR,%NI6CY7^//E*=I=^A#EGF/BE&FJ[LBFZCP6
M-_XFCR!H (E@O8!/3E6?DHAY.2U\$Q=P&7/-0E@I30'U 9%0#2T84DRX)YI1
MY2<QU?"A/>1XAL,PNX%[KE$PM6=:VBE/ZBW7^%^/C[T3&U!:IA4K"D/)2UPH
M\>29AF_B6U2[/OD;VG70[9BGI;K. 5BCZBN<T@5KBFNOV+OMVNRG?5#="JH_
MZ8/J#ZTV^U:4@+_GA.!#W?<?TC CAF5+F;W1!\[=/W@Y:A4%W0"+G^NBT%@#
M!#YW?(2]!Q,52@"FK]ZA5 E98E()37IO%UW!M6#".EB/W6,R8N%C*JUS.OP!
M$]D<Y892O6HZ!.D[J2U<]T0N@<N,&95X="-3S Y8_%R3()8E_.2ZQ]T&.H2-
M&U')2H(^4"XRRW#,TB'!39I/L>B9VMI2ZR\J1HUYAR#]TAFC1_E0)/Z.:]CG
M4<:( ]J.[JJ<SOZ]#E)A:5!1+!N.N>Q9(7T?JQCJINH2L]J091SZ>^.O:KH_
M6N'IK)<ZNG'\\8EW^J1%Y2'JJD GQS.LX*@/&+0SJ]2X4F7X? A$@ZJ9O@+'
MITK+<NHU<FRM@S^E<D*J-VWI0K<2BR<S8U>X"DX4VSX6BPM4=D1R&*P:RK/3
M1&\V9+\IZLO,]L@9/M2VD8JD%*&4$A")F6P@QRXCE6,LPE!*]#\_&CZBOU.L
M!2O_ON5PK=J/UAJ.AT-4&T"UR1(UTA4"Z,=^J+867O1(ZC_91#TD?S\<G)P%
MD5E7-JD\2=7 T^!_!<]>#ZU^6BT=;A[&%S]_\O3Y2UTLO,L ]9I'ZS#<8&])
M_2S&/A4\Z<HG3'/"_[35/="N=E.CN+[XB4E4**6$>E9OR%J('ISUO^,$ ZNE
M";$E2R)+6FT6FZAC91IK5P-)7R[?N:BNUA_T;&ST>R?>-K!/'OXK(6+]D:[.
M@[V.#21^^SM:>+)J45G7L.;';3W'V\N&M%PH2;>:<%K?U/%"-6M1#_)>P5&Z
M_8W:LQO5H69(^ZW2))-5JE;486HW?+/T;,P-^XZ;M?+]*=^;PN;T]Z=7$$L*
M8O>,@K2,E=>DA?=1ES*QQ9U=TF>%@3S]0]F.F'HL6Y5*D,:]VHNLY[1>W?/V
M-]B69^N2D;W.^; D9!T6>KFB69<UL$3V:6*]TRMCKHHE2^_BRO3B\,&)PW:@
M\DH.D_97]1Z37GJM^4(NNV;WXX:6\,Z=)"'_1A/@-N]@X]W3L]GF'5Q^]_2T
M;GL'"Z1>)?3^ONW9?:M'<Z_@D:E[P=9OGI[174F_PLTS>NT.2;_UE(19 9SV
MN >G6>"TISTXK0>GK1V,LC*>R&G!$[G;Q!,Y[7@BD[2U#3S1=M+<OE3@.@9S
MPW"U4*FT05*/UH&E4X=.)?P,;H3%9C?TB '*XY0^+X ZL,R.],8RMBWE3G$.
M-FJ8"\SX2 O^7E,S@LZ6<EF,K/406YZZ"M_]43;#QDJ)_(/C$PWC;J@Y[%D5
M'*ASBD.O/-:_^Z1D-&L(_"M"I/NH:N1AYMVFE6T!5$4(^06EX6$Q[/#&/3T9
M#']0!5H;X(AU1U>:&*+^)0"JA-*OPZE[_$J&AR$4RGWJ/:9M."X"X#W**BA,
M^.3)X+$N>V2AYXO >>"%$Y5F2&-=?/S5DV PI,U)A?1:FU[R-K:&P+UN\3QO
M]>A"5E]0H8/7QK/,2>M#:M403,WM\AHU7SI9DC3(81TJ-&PN*>^GS$'%<HA
M/]R;&&]^%="*T%3>?55975.FS,GPQXS_POJ)A1-%>I,OIW*25#^KI!4W(&V7
MDK;F)VDYC&D+#L6YX1>J"K-3VS8#V O<[V@B,=8^5V9D4+#LIQS(TI-"UAQ1
M^],)GLAW1PDQO#Y.9;M6O) KWPRWY68XV[P9-6$#^V8TE;=8]\UP6V_&GB,Z
ML5/*-7:3GP4+4S#!GV;*YN4.J[N7,[!$>;'ZQ))Z#U<JY][@J7L%5X^ZQJJ%
M.Z&X$B%=+%Y_,)^+2<!"J=1Q%A20?"Z[A+==HI&/E5EE7ID:48X#OS.=U%-U
M8?F2.W:JAL>UF74C\DF 3@D@>*6)3A5K4 EPK(HH)8;RGXFTS?>4>Z>PRL35
MN;2X7'E46)+=DV^;E+XA9YRTX[&QB;](P4Y5_UK)!<?&9+T7[H7[;/DTZE]8
M9^;7.<:F_CP(;UXL&\1RHCUC5QWO;[NG#B<#,J3#(NI\$O*PM+E]C&9JT_9M
M8V5POOCIGQ\]>=3JR[%L[-5VX4Z.4JE+VGGW(?YIE/SX"NP,Q54>V#FO>@/W
M8E&:>$\>W2\6<U\.Z/[>IP?"-\^&Z&Y@WOF+_RV8@UW7\]#[=$5['KKC!W1_
M[],#X:%H,?5,]%[?T9Z)[N8!:0B&\55\Y[GT3HW=/>VVZW@/! L'-Q[84=[?
ME=U/(M6Q$JW^_/# SO7^KNQ^4BR7!>W)]=ZM['Z2:Z\%W*N5W4\B[;6 ^[NR
M^TFQO19P3U=V/\FUUP+NU<KN)Y'V6L#]7=G]I-B'J06L/TKRTAW!X5\F<1Y-
M$$P:)R_<Y')T<#)\[)V</O-.SLX.UQA),06"@F@B\"5'P\$Q5_91FXSICYBT
M+3^6:-:39S_4%?]9VV839EC3$V='G9MTHD+?/96;@#VJ1.+J1M6?Q3C')&F5
M['' 65T(>=;/J#>/^84IOE!#I#FM0KW-GVKP=*G@G'SBM9_""_WYPKV(KD1*
M7=M]W8!(/E3)O?DDQL$"^Y:EAS^E^>+5P?$AT%B.2:)K"#(J\/$/NQD#U=/;
M*#&M?\)GI0E3N?$USOCX.5SU)YBB]J"WN2?;_2+;D^/!\1YM< <UI:?5>TNK
M@^=[M+\]J>[PA'MMH-<&]G _-\YA'_<L=D>/OJ?57AOH274_2;77!GJRW4.R
M/1T.SO9H@WL6N\,3WCBM#O:)MQ9(=3LQJ=]G02;N-A"UY>#3:_=SOA!)M\B3
M'4;BH,[)^H(ZNWDS]X-_;%; >4\?/UZ;7K8/&[J+<]J/G=LP*9X.GN[Z5JY#
MP=K]DWV8]/=\77' GOYV:]/VA/YZ4;P3<]J/G=LP*3X?/-OUK>Q9X>[,<NVB
M>%V^C)[^=FO3]H3^>E&\$W/:CYW;+"D^?C9XLNM;V;/"W9GEVD7QV9Z)XH>8
MW[*QO7UIQQ6Z);2H1AL<0CCM0PB[-LNU0SM./=DMZL%LZ"[.:3]V;L.D^'A-
M<(U>6=JM3=L3^CO9,UVI)[][17Z])-Z).>W'SFV8%)_VP=3=.-F'27^])-Z1
M@WV8Y-=+XIV8TW[LW(8YX7!-66(]*]RM3=L7^MLS2?Q@<Q%J2Y3=<76L#W%T
M=#Z=!F% _<:YN^]:R&FS:UU^-[O5S]MU#K.15:R= SU#16QMREAM(;_]X/,]
MT>_L*C:0N;J>;(IMD_MZ<EA[2M_95:P=(34XZ0F])_3=6\7ZH]N]'M,3_8ZO
M8NU$_ZQG[SVE[^(JUN\H6T_$M"?TG2&1GM#KEG&TEV3>JR\]K3\46N]9>D_F
M#XW,=RMOZ+:-DS82!SP9G*WUZGZ),S_4D<!%$KM8B\QW*4*X)#*(O6GLY^I*
MG&V$&->]";>\^30-=Q+GHU#L-0M;PT+67P%HK:BM6@K:5QVU)_^=6\C:76W#
MX9JP.MNG_,UHK#W1[]Q">J+OB;XG^N]<R=.GO:+3D__>+*3G^3W/[XG^^XF^
M)_F>Y'=Y(>LF^2?KS<+KU9R=I)J>_'LUIR?Z?5W(EM6<.Z9D'63\,?-ASUXY
MSD^+(E4?#Y?OW]Q/+@.8*3XZ+$[^WWF:!=,;<Z(+'./_'!VY[P,13EZXG_)0
M''WT+X5[=/3JITEPI8:7;9].SK#ME_6Y//@L7C0$G^5BCVTZ@M^_DO]MC?UC
M87"8%VV".Q9A"%LTAG/Y\Z/A(_I;GA/];1^"'&N(AZ8:50V'/SPJ16YKPJ)-
MD=8N&RY'&@XP8EI'&V9:0(&#Y;RKRZ"UQ]H^])LX2H,T2W5L-9ZZ!\$A?.L=
MLR+4*<::Q>Y(N$&:YF*"?XSS)!%1YLKF4/A6W35*O6G,+Z F4AX,"J,^\YX^
M>>*=#8=Z.K<9/)L),]IG?RKD+&@0&.7T^ 3'Z/YN/9N&,5[[*2S+GR_<B^A*
MP((2CZ+.!\'5H?OTZ:UWL3#(NS_R(,-BF6/8V.#*3.J3& >+ #Y,!^[[.''Q
M'F1!'/FA.Q&9'X2P\%0(]S__X]G)"5RUX-7?<Y@D/)'2+,^C]!K/: J__3SS
M$V$=VNLWYY_P=\<G+W^?^1F0=1A:>RO@G&%2\@=Z1HD8"YBA&T1PR%$DQC@8
M_#:;T9)>YVD0"=@'6/P(M@&__0O-[OBE^S&)%W$*<_\0#]QC.?:7AE_IIVN>
M,WG#UO/GEXD0<]@K^0,B?Y@[?:NF@)LB-^NWR,]A-S&1.(EQ=^<^O ]Q$BE\
MQF^&?[R']T?C &9]$1$PX?]G[\V;V\:2/='_\2GPJJMNN"(@6I(M+^UJOY!E
MNTI]R\NS7%UQW\3$Q"%Q2*(- BPLDMF??G(Y*P@NDBB)E# 1<[M,D<!9<L]?
M9NK'P2O>RG)0)%/\Q&4R/(BOA<A*0:=3@@A(7JL5K)#_5@:Z,J\I$Z^H(UAL
M[R/,0WV@%1]]=CD)ND D-26<%I8@*1\O_&-O4>/:PUZKV&Q]LQ9W> .V9?M*
M>$B3,\U%KI9S;SPY=^,<:E:VE%-OCT.M(%_,J;?*H69!2SEU-8<"Q84=;Z[B
MS2=7Y$W;#6E-Q4EOL"P*="V_#\8B \,1N89,FD-=#$=,8_C3/))8JS2=)/#^
MSZ:P*%3G9)X<SO_\N/ES6D@-]%>D,[AN>LKG(CD7E0S_R)*J]?G*6L!W'+0M
M<NXMX:.^U$__(J?P"7",0+- ?>%G6H=^E1$2SU\!MXU% H2?T4M/QHE$F07R
M@7[]:3A,!K+H+23PVW ^;N@=9\ZX4I:/\CM(>C"=!M*3R4E:D^Q2)A@\"V4\
M$R(16.E^O>0; :I5I.I29HN %=DL_)!DR:2>@-%8CK5L@NN$&WF,U#"L0 'A
MJP=I#C)R%"AQU"8Q>R'*4I8[HI^?XWH':1WC(N%-:G65L=X4D]#W:R _M459
M#!*P8N'MI:RJE$0P[.GOQ#KX%>4.!)J8/X-GQ]_Z4Q0@)JM2&[WZ!Z;X5'5A
M,5_LW>P]6UH*V:.\?9\9/=97\*"_:B2NOX='1Z_"?XFT1K^+/%D2B/,^<R-8
M8MUF5P$\0U>VH0">492JL<L,%5QZ:=<1'0Q9-)1.RSO)@71WK??[*OPZF\)6
MCPO13P:OPH]B(OE,/N:X^R<O/!]?_XSB"X^G*@PP?T2%%-_V^A+D.3QM2B=\
MF\?"2.?U#D6$XT(.__'#WT (_/#Z*S$;\#"( A0EY2^/Q=Q.W1-Q AZW0;AS
M=-@2MU'F#)"R$TAY^0(MC9U6"B@\AWF:YA>D3^FF0$S"G\'DA(>?@]+%O^07
M&:B-<3(-4GDNTQ(EN]((DXF,L=M4.G.?A-(;E'L]81LS7"+"P[Y 8U7)8OU&
M]1[X72%C.9FR/Z ,!Y:H@>L-1/@ $0[K%!9".@R>"4].T+L8\ZKPCU;8H[B&
M-8)Q6*H5"OASR;Y"@@>99*A*C!WCBW%&UK,Z".;5P:U)^9LSNY54'L"MBFD)
M4D?_UZ6,;18-UXDF+JH6N7K9!LOX.T@\4IG*5352:[G/HN.^C:T!/>"G__CA
MV0]+-?E<]=7:Q[#TZF_J,H_!0)R@W:F=Y8_Y+_WB\6OP-;0D>F@W?:U@_-;N
MRM#OX16DXYV0YH.[HGO,4P]%>A[M_P3&%4O0#^([>?Z=)+U?;-I)TJV_HGO,
M4P]%DJ*[U8G2>\ZGG2C=UBM:V/'BZC?3A47NH5QJX>#[H(XXM?K0+O,>;^V>
MTNDGDZO0=M,:X/C[=;/W>&OWE&C_E5>NI=]1[/W9VCVEV,X<N&=;NZ=TVID#
M]WEK]Y1H.W/@WF[MGE)L9P[<LZW=4SKMS('[O+5[2K0/U!RX@83+=7J,7^6M
M5^@OKAL+O/CI1OLL7&6\,-8,RF)Q8>4CBYA>6O!N,-L+B]7-PM8J-5]:*NZ4
MB/_\2UE/7S\Z^!FHK,8"A$VD+#46^J<M3:F:]6U%ZZ5+K/BHL>*-MSYY">S^
M;+UV5_?ZH#O2W3G2?=%[LDM'O(;%TM'K/:;7P]Z+73KACERW>\6=9=!9!CMZ
MHC<N:3M1N\6WW]'KO&7P<I=.N"/7[5YQ9QETEL&.GNA-D^Z3_=[373KB3M1N
M]XIOG%[7:<:^/2>\WG#<S6:N_APGE;SC=-4MIZA:&Y0NRD^YR29._1QN,/6S
MI>RY(U+D9E6=;F[[@(YT*Q>U(V=WPS[NR][AUA_F1LRM';C<!TJ#+SH:W)[+
M?: TV*GE;5G4CIS=#9/CL][1UA]F)Q*W:IF;IL&7AYN*<G0TN&W'MBLTV*GE
M;5G4CIS=S9+CTQ>]9UM_F)U(W*IE;EPM'^V:6GZ8M3(W=KJOW.S#>L4QISRJ
M2R4:GG2)ABU<YL;A($^B)^M.3+\W1[J5B]J1L[MA<CSL3*>MN=R'2H.; G1V
M)+AMQ[8S)-AIY2U9U(Z<W0V3X]&F2C(ZD;AMQ[8K--BE&;;G;A\H"79:>5L6
MM2-G=\,2\: 3B5MSN0^5!GL'6W^675V#'G[=TA;MCOMQ?<RSO>/A,$EQ '.L
M)A1OAJ)N=K.K&72]MGU;+V=N9AL;3[D?HEFV.=.LM8'@CLC[CO"W>!L;ASZ]
MW%2T^K9)?D/5L1VU;_$V-DWMSS9E;G;$OD54TA'[ O^^LVDZPM^!;6R<\)]V
M-DU'[=NZC<UW">ELFH[8MW0;FR;VO=TD]<Z4Z>C](=%[)]H[4G^(I+YE-4A7
MGNET(]G"P][11OGW:UZ)U.0+IT4>8O<S$5(><47^$&?FN-]K:ZIV,_2XZ5.X
M(OO3,L(XK_NIW&U!MHF=;!SIM7^T6:A7*Q7MK,G:\< 6[F3S/+"_*7S9[5/_
M#1FP'>%OX4YN@/ [LN_(?MMWLO'^BD\[DZ=C@9W:26?R=+*_(_S.Y.G(OB/[
M*\$)-US0UYD\6THX'0MT)D]'^#N]DULV>>Z8F$TB\G$EX-!>!\$OT\L3]D04
MHP16BE_=]Q?_[[JLDN',7ND4W_'_[.V%[Q.9QG\/O]2IW/LL1C+<VWO]2YR<
MZ]>K852'1SB/S/E<W7R53Q>DJ-5F#UQ"@M^_5O_7>?=C[^6P+CJ$<"#3%(YH
M /?RCQ_V?Z!_JWNB?[N7H-ZUCY>FQV?M[__T0R.[VY(XO4[5IGK3?@]SJFVT
MX2P+&TUMOG;6W.N*=Y_D69F454EOS8?AH^1G^%-TP.;06CG8*@_[,DS*LI8Q
M_F-0%X7,JE"-J\*GFCE6^DD#?@"-M8K@I?#6%]'S9\^BH_U]6LI57ER-I7W3
MF1A*M0)Z ;SAR<$A/G_-9],R%C__C2AA.V(R#4^S<PD;*2+*1C]*SG\.GS^_
M\NEY+WGW5YU4,UK):3: 0TW.9?A%#I)I O\H>^'[O B1\JLDST0:QK(220H;
M+J4,_^MO+PX/@;F2U_]?#0N$;Y2TPN.LO,![&<)OS\:BD,Y%O3DY_H*_.SA\
M]>=85$#(:6J60^LXDW"_L"C]HT(.)*XJR>!2LTP.\$7PNVI,6WE3ETDF8?^P
MZ3YL'__Z_]+*#EZ%GXM\FI>P[H]Y+SQ0[_VZX%?FV_9[M*#6[QZ/"BDG<$;J
MRT3FL%[ZJWX]'H8ZI#\R4<,I8NEQD>.I3@0\#S$3)7S&3X;_> _/SP8)K/@T
M(Y""?AR\XJTL!T4RQ4\T,^$!?"U$5@HZE1+X/'FMWKX";K)1@;12"AQND02R
M3=Q7(CNN('K>>*)G(0/18FZ$B2[!0+2(&V>BJS,0K>_&F&BG&.C)%C&0;4]T
M>04$1"B_#\8B Y,+29O, 5-33Y1M&,D\CNB_U+T<#-6>36%AJ!9)O1_./^)X
M[A$U$$N1SL"0HR=\+I)S4<GPCRRIS//GGDT62_/AM(JE+] /_PPV*E%Z^*<H
M@-;:WV1U^T';:<R_Z5%?PEO,87R14_@4WB)(A_.7?C9O,B+C^2O@P[%(@"TR
M>N?).)$HQ4!JT"\_#8?)0!:]=;T$MOW9'-_7KH!Q9_8;AO\-.1?':37.Z]$X
M+/EP@$J7DF:P/KHO' L4GHAN1'8/)0C1?)(,V%&$94HQ&"N%@.]=<P7\\ "^
M#;(;^ ,?7Z6L9?),AH\.?@[/\XJYA%Y!#U[SN73O;"^NL[R@=>.M:ZLNX%^S
M\-'A/J^O7+' A5-H>S=+$;=!=:C<\&P*"2>BM,GBO2N:(V4-AVHF\2+3E8Z&
MC\),3&0ZBT@X_O^RR"^0 G^O8B7I_IF4=?A9U&GX.Q@0V-GF5Q0K< UO82D#
MU(]?"UBC%EYG^72<"/I9AC\)EO\$1-"OHE^ APP_&5^(;,5K6'+!KWX[^QT<
MEFE2 9=\$!EXU23U?O_]Y![<M7L/H,Q"89L)D2_RI\Q(ZO\S$<1W 1+#^C=%
MFJ!Q3RM_L.8U!?::%E]1B+Q+;-S<V6\YV$=YCH^'G97A)(=O3@5:/W4J0-F!
M1I^F@DROODSSBWMPV]YM7HQSNG&0=*3>7:N?+B+0;@$I5N#X,F?=*L*)G/3Y
M%WAA_5P4,?XCIJO)?0^"Y;66#_C]5<]C8?.&GEJ#'1& ;BKK"5N\^DMMYG>$
M&\(_ECEX#.JA^(8)$06]P*-XLS+2AO0KD/YX1/B7."G!Z$_(?ICFX+<$1#F@
M:*:P31UU6*D6^%2 H+1L=)=P:U05<ISP]B.A&(=\!0_ZJY;9 ,SOHV>OPG^)
MM$9+G.*39/7/1T(;,7 ;#'5-LV<8H&P89\\H^]#8988>4WII9P*#1[+PW[G?
M\LY]>J>S:[W?5^'7V12V>ER(?C)X%7X$)<AG\C''W3]YZ45N]<\H:OQXJH*[
M\T=42/%MKR_!2(&G3>F$;_-8N,)EO4,1X;B0PW_\\#=@!C N*!0-? @\76$P
M[I?'8FZG[HDX8>S;(-PY.FR)QJN@.9"R$QY_^0*CXSNM'CR5>!GUT.IJ1>H/
M-FZA_G!U'0)+\O4(/#^8>S%]]Q3Y-IDL7(.QY]=10.':"BA8K8"6&2N74T?A
M0G447$8=W6L#UZ%I(N>TY&,J956E.5X(TU8IBW-9!F ()I27H",0\7F"08PJ
M5_ZPNOH;-(!Q+<A<E_)5S,^ ,S()!)X(^#%QD%UV7@+7X+=+,HKQVX-QDL;
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MOTW$L(1O"I#DY3CX5X+G')Z6*0B/TKC):L\)2,BQ@ 4M/%XZ);4GV@%<M:A
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M\.+@&\Z785L@#V2%35@T5D2KON-/IYY'QV8&[_'IPCUN3M\%M^_!A2^B%T]
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M!!>2ET<U"&C9\<M3HA)<(/_+5"# N1&!)),D%86]5PLBQC^G^"$>F_U["3?
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M,CK<&]DP<&2H2<3GB8I^T7=U,SP;!KLS#OHBDTF_+DH'*8AYXKK:RX=[TWR
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M\EP9TE!,DG3V]U4/;RF$8KFEJBYV8]'<"R30B#QXF2WHT5F[$CMO$CH8$Y[
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MCL84<)M,945SRYQ.(0@];5$=?>PIK@TJ_J4,)9G:!"8-Q0CL*C"34D&I?7Q
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MS?*F'X>-Z<=*M77TVM'K=42KAQK .+$D_P)<C7Z:#!Q8+0\/1J+E_J>-R7M
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MO_.\1?3N)!J:289*ZV(L:8;I(N[FJC>W38?3YAD#-1ZK<\6_;2UE6EH-[G?
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MG!==48Y3E'/0%>7<1E'.NH2[9=4ZG3[N]/$5TA^(CL*N14GYK=2(7J\8Q:C
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MJ)FC>S?AW-VP/\Q-:TQO7V(8>0X>"@9!W?*#R'D"_ ?IQ8R3V(%A6!!#W.P
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MFNXN?KRT88AQ,Z_3EA"R,0L<H\O=!#8V%K$Z-(1M&+I 'R6_R/B\FE T>,1
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M!XP6"^9._*XO?DG=!J[;MZHH; I4X13L<F+4M(')76/ M<U7Q]F4C[4XD?!
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M[<:R,A$Z%W</G6%W;RN_E>4P/C>+2@TY6)<E7:VEH\N@DQT:87&(&!O)-4<
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M_)-]S+6*96L7U($5%^^!\"94P@&(5#+MX9L>]9&#V<RP@=]2Q P=_XTX1B_
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M*,A&WXP],%)V8[).0RY+##"!2VB0J!#?&X=+_:UK)R1&?WD^!YY%?(Y9TWV
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M1_ P==#A86";,.JXD'WT_Y%3=BH']"QI[YV7,3W^2C8T>!V+8XK>]GA^C/"
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M3$-EW>#GQ&9.S7Z<VZ4? Y=253O[C=9V &;G=$"Y'!4C="(91.9,1Y_9[D(
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M(N1E U%X55\R#H00LP#6D(L(@8KO"V[R^/E::5V$S!X4NO>-"%&I\[%7Y?7
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MX*]>OOB[+O8?D!SF5QU0T^%2GWBX]*M)HJZP9'OZ\0?Y1T?_EW9;N/^W,IT
M (*[ZO3_UWPFWAH_]37]?1_3CSC&U^$8OPO'*%\9CL%%YS>LYR7O.+WM0E[W
M3O"TO]ZTQ&G00\R:ZZZ+M6B$'4D&2I($DBNN8PB\,A+A_5LYK,M_%4T],!9B
MWVC;8&DI<].WH3;=*%4SSRNO?JBV0D>0@*ZBN8C0EK1G'TIQII,$[7N,S_"+
MO;H3TO*^Y?[O<BDY_IW9KWF/\P[U&^L(9A  ?ADCA-VD=WFT^&"E:^RHTY_A
MF;"LC22O3OBP[N2+$FAR>$=&'#WOV<]!+K*=&GD-T_"+#?DSU$YVY2\2?5B>
MFSL?L:*.(OL'[!'18]U$+O-(DF$Q69];$5Y/#G^N.A?1U*;B9SQY9TIUOXK9
M@9\]E$U,V>2+A[+)O9@=>/P="A;?<KSM_:%/G_ZGJH%)[1YG]UJ 5P"I3A63
M.=ZU]S_Q*YC6^L!^QREO1D#XM#SV8 2%\%=&\,*-$>4]?H8=486H^L?Z,=FT
MJ3@]8>S?E!P]2V,3.$C&^61P2C+SN3)%<:,O.)P,UR7]"W7"MF7(O4[Z682X
M(_U;#4J2B/B6<0$-+\6\,*S$;UWC0]#]I3;7A#DA$G @ T*C!>W61;"\W45O
M94ACKD&]?^[!BELZ/E1[=FMO3;ILHMF'[^N%D6S$NL[Y/<O"$KH1XA8OW-T<
MX\!6R;E0;3SV9GBGD;<>6I9''%@U:I=*@!-*UA%'[*^RG-[)*Y.U01AE$Y)>
MXF6H CG/I;60I$H8]:^J;9K2,\Q)3&UT3@K/HD<AYU.8SD5HRS&Y.76 SLC-
MA7%6DIP+D%1DY)"?L]RLT[A1B^2[<!D845:LNSQ&%4:XYA@1.(,!# 2CF_*F
M8Q;2B%@$VA$QB8(=[QS.G8!'IM#1R4#RO4W?NX<XB'>WZ  Q/'T0VHFHW:E\
M-2@#+%)%=2X!8BMX%[G@6-<S28 /:I<^R*/]_FY8A "DGJA<C(5 QL"$3N6H
M7%(6O5NOA JO)E8[YJ2E*B]*T,2M1+]P4S))E1##++P3L96X6%G4A:<F;]*"
MMDR,EM:TE61&:/%UT*I7NC$;2KP [AO^19LS58 QNC[N0'X?*DCR;B&W^:\/
M3&BF)!WD7MZ*-LTU[71[^?_\Q]/_P'_[WUKI?]_YP[QH[*[H5Y_^YYGAH0_X
M_GO7ZYO0*+PBCEW>#?^W_R$QX6ZMOS3)E2)O%I:4W_Z8/WJG6_[%9Y]_$?=\
MMSYG0>]R!35=I?4^^$ZM_\MK_@EY1E@-_7]A.A!*@^P&LJ\PJA&N9.*2OPK)
ME_G_I\<Y_A92]2/OQ.0!G9=A>+@I#S?EQZ] >[Y#A3_IQXN5=!\%ADLCW?(K
M.$524O.O^&=74T;?/XA'.<2N8LX3\"L>;MC##?NH;E@JY';"(T)'U'3"W6*8
M9'8QF++MX4X\W(G[<B=*BIX05]LIM!0Y24RE]X&GIQ):BG+ .?_LPY5XN!+W
MY4IDOA 1B"O[SH.8/XCY?1%SS6P)>SM%$#KX+9F'_2#S#S)_7V0>DP>9^".$
MSA@=1?? Q\X/LOX@Z_=%UE,W9E/6#?%GT9S&JD*9-+CV.K!FT)$5_TQP^0E7
M(B60F'D''#O*&X/:3:3V$TI,+9HP==[#Y7JX7/?E<ADR2+HD-"&Z[%?4 4O4
M5#%J-LR8XS1KW:[]ROK#P\5XN!CWY6)D@T2$:#7,C8TW P4.Y@T..+.'B_!P
M$>[+1>C ])Q-NQ;,++K[3*4!<W@>A/]!^.^+\ .Y"E;>_3S#=K@ MA!-"/@$
M<9J@OA_NR,,=N2]W1+GH:6;&=HR.-<@HO3 ?D?0?Z]O[_*%O+_;M??[TH6_O
M9^S;^[7>CP?K<,^M@TZ0X8;\,$-IVD1H(HG;>63.[T=D+1YNP[V_#=QQ-O@C
M!9])7RSW1.#Y(.0/0GY_A#S@4-%"=43=8UAVHXU* ^B8'F["PTVX)S=!QX#'
MD>EHF1L/!8]UMC!<1Z:*TXQU;?O;"E_!J.W/C*>_^'BNS\_4*/A7.T+1::_B
MJ2;+,'-G76%@?67+1B?[AA<RSZF9TI<1I>Q,$O["?V4-20&5G@]@(WL>C:+'
MK$?,U>FK=6W&_QE81(DN_UOE@*4.^K)NS&!!7OB(WM),-HXT2SN\;>?WVW(.
MZ"O J#C?,HNGR)#-P!%H%R$,H''!;&-<(+!5$E EK&*N%:%J#!W\LPN@;\0C
MS'<DY*_'=NBA_WZ"%<0093@AR8P-TJ@4\=;RJ%;_?*],GF#;JQ^\G-<5YH;:
MYC&61KIHDFNT3=.1VV/?]G&4.8_NG;@_) UQ.$"LW6(H[Q"N;O(*C ,GDFY"
M&?4R0:T]2MXP<_?= WG#^UDTDS>\<#RFO;C#X-1 .K/VIKCIKKU*61 +KOQG
MM5Z$WUB: <$/_ WO<=$O6L<3<7$-Y8P9TS1[U&=,.Q?"F&.BD)RY?WC3=+>D
M89CSDOBR3]%)Y&3.V>NB$F0NFBH*+VN_R*N?:!HAX[:TZ@D[)L@HR!JN]Q6/
MC&_WRJ$8/,UHO_7=I8_3#@/A)@D/<,ELX&."'J&U#+2XI=_82X(I;PE#$-^4
MDJJ!-+7*+/CR4#3>*5H=9EF!X[8+A==U'5=B!\G[=SW97Y/VK[NU?Y_ZY;)Q
MT0\7_9V.-H]-8E+#??&*M[Y:7;5=TUT>P(C!W.9!>L8$&X$JPV54&\2S40C/
M1L:Q<?&!7<@/4HM\[4,M5Q.:?EIUR*UG0>W9O5[22%+BM]KW\":$]BZXPUNO
M&$0Y$%,*DTT-.^&9%TVU+/W/+HJ_=+?Z2J=5U-Y>53.]O=YA'C1Y+:S3PHAV
M7/7*O]U,#"TBB3@YMN1!+[L;.Q'4_R\?(I3UFOWK';$37;B$Y:Q6MBO"7@\6
M>8W@IVZ)S5WYF$&MZ".9(7(U+Q@,$5<22'#6%?T965(.:9G(?2.LZSR]5"PW
M;0.'6 S$JX>:O?J'&_(^[.S@(JEPE+C,3@7!)*Y%26QC$(5DN^>C7V%,VK=*
MUFL$>; B[)<1V=H0+""D]9*\"!'X,G#V(0( =3P_RN#_,9*#R#.)$]+_(ML&
MV&O_U(]=J.Y Y&ZW.NB%NJTQR5>T0D8OVM'?\<TGY:A:@LZOWEFG6J5!GDOD
M:=F3,W;&KV52Q2Q4"]R/7:%J1UZ7B)YJ;GR(OD8H4(TLYBR>]X6Y_=6\MC^V
M]XY.3V@T_8\ZFE>5[1@"??I9]0.CJY4:E>V!=YBJQ%?5(%O#:]A0P858'_6_
MWN.FQY2]3='G*?R?DK+_4=GX)(=^XCLFTN#G_/E86?T\N?:DM3>&'UD>3]R
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MRC/\ 5QVW1KV1 \)LQ39'; ,K'$A"H97)^!4:&$U?O%WV0,N1GY_\?K"[\U
MG] @9JG@E*%LUVT<67\K>O$C:-36#P*"E-] W<H.;46<%?Z:1^*%H>#?MT X
MO:;PG.)(_F""._6TTS@PVMC!AX? K.JL:MUQRI=&Q'-B)^4/X;QP^EUR6V;?
M)=\7KDO(!"4+0_*T1[Y17)SFX.RQVL0A,T2;9=AY!%[H=K<D=Z-WF(Z9^/UY
M;3-3"/Y+?B"]P!FI+5=%T\RN?"MO47NT45KZH[5'6:)D[3*FLO)N$:JONH=P
MO8*#02"T]*[POW,%. 4@%6]T:0)=XY0&H@0]H(E3TS#\B#_L)+:;56Q^78]D
M*R1W1_DS?TZ<;:0P!)>9\J!Z,=?5->4#Y=]+Y$3H+\G6^C5H*^_C>Q"7OY@H
M?E_5U.D ZH:8C#!=Q ZV6SO%-*6#:SY2GK^E Y<C5B=6!PSXF&>S;V**OPR>
ML]RFK'.9LU6ABN*6U:K<#^&W)]?*@6@W5&;%6D,S_<SF&TB%0$L:R=2#IZ*(
M%QPD<%5&Z2*DRGMT>2_FO7C_:__:^X70(M;K'H)&/GT]O*4 J1I80[,*'2J[
M* D@.V3:R\:E!H/7<K3\GB>1C7GA6_7A9)&/^EROV@VK21^).MK3(: C:% 2
M=ZA)@59'G=,_!DT_0F+7[?7>6Y#]8&<=A^IQ[,'84R4 W9Y0;\,NUIR+IKLD
M:[K2BC<7$5!B6HSM_60*RU^D3:W/]$+FE9:QSO3/L*9J@-_T^^UU\<)4> CK
M%/K[QV_C#,ZPHZP',0+T4WP>](V0M[I=9!7T3-:O2Y;N0=,WT;GH6B=PGI4_
MNV[+E>8/#&WVRCI\2N!A<O.BKKAXP1+)">EZ"'57E/_80>)&1PB:*54<D3*2
M1WJU7_Z>.G'W\)PTE[,HAH.7]"VDRYN\EF%D+5<%6(\E+NM1 85);JI05/%G
MNPNN65.5Z\P_ XH&1=3K.%*<ZZDHD6,)9F'8F)OJJEXUI,7^6'613PC*<9&R
M5/BWB20""5EM483.?R7?8JJ!W/HXNFJEWRFXR.NN:<K>H6;L+X-_)<HVWD43
M70_?B#TSPU^D+$?8UK!@;8O&I@$F@.9RWJR04:/L#?X-LL-'Q[K*C2D;6#"T
MTE\;#5=$#0<MLL!)['LOTG?2)T%>;RN]S"Z_S-3?;@PLG29A2=C'"C<9N3.N
MK.$?HL"2 5P.7;]4V^Z?<"],SLOH"J2>/^MF#JW@=_Z6PQ&70YY.!_*V#GQ7
M\-6O4[?.!_39+E( &V+[JH6KHN!'F#RR)OAY%C3<QM#U14@94VS\G=\G[Y/Z
M7V(K26]@W)A,U.WV7E-5:P9*7/+51TP@C=L5CTFI,'^Q9!97<I39E;2NF10D
MD:,8.#.A$!+A3="SH^H)52AZ"U$)#M],/F/T1DXGA112#!0UU%4-%&/\XAT$
MO+2*B3AWA.'%S1\%NW/+'2HM5 !:&0)*P[3+G$B!SVPKSE2W\CI[$>Z6.WJW
M+IMNZ?]A@K4NU).#,T?OD=^/EU!"Q)BN,#O:' 1%*'\FGCO#?5M#T+20?;'[
MJIYYT9;I>K#A+PR-6S [4LNN8!B,C6( S$'5A#\>*BSM>Q/Q1E7=684.3-3/
MK* ^ ,4DX<7F9"E;_1!JQM[LJGZ^]: X='LYL(:,:IKU(-&@5QQH:R.RZ\-3
MYY,\83-%6X$HDDJ_I;1![M29!.0<F)\#ZDA/4PVKOEZJ]\K0PAGDT 2]C1LS
M4"Y8C7E]GJ^.7AXF:!5)Y@0ZJ[[A "VA-%E*NJ)7;VOOM=\W;&D(+X1O<EQ5
M3WCE+(O<&<QQ?(<U^9'4=\DUF^9UPU7E,4B698 1@8<QJ5SRVLZ+?\OOA>6+
MO'4=6AI@P'O8Y5U(*4>@S/',CKS1+?NN#*PIG,46CG6[%F!4;XESP_]?Q4"J
M=EQ$]UUU>$:;Q'(%J])7LAZ_Z#T]Q7^(CX<H\'=^93X:\5$4,3"9( :=.WC,
MEJP(V7C_[(TW@#O &($QE=J]./>+-'X)-A^!FZUAR)*RSW7<TI"7$*9H^UBR
M(W0#B7X-\Q;9.1M1LN)GJ'R2>7(NO$6H3B#%42(LB9>ASP&BH.2X,6+"+HI_
M*/N7%A\N*\XKT[7>':[Q)@,B2Q/3SC1@F5\RB,L<]3+1.]<&H!CMV\DVC-DF
M%F?;,(8*/B>EI<I^F]C2G\$X'BG6?_'TH5AOBO6?/!3KWT>Q_GW6Y+W1<(+Q
M3::7H9YEJ)YJ'XVM@=%>U\V>%<4@-&<J!SIT>1CV:J0F?)MR",5-JY7<E$O(
M^H4MLA8[Y>G4M=G3_PR]J:'(]S7;YU>@*B3<V'=-Z;7EG\H;[NS=UBVASP]"
M7DC%5>VZ<Q*<,/N--R%5P%_IXV-?FI0(DWVSY,&V1U"VXAY!#5X! 4;68%5?
MHQ^$MFF1<31.._J$TKN\I+A^!S'YXMGB^=.GBZ=/GP8ZYTG940 <M1)2<P.*
MXDN43?WOY"?D?'RI@J@(LT%ET/_LKYA\_,FS1?'\Z?//. /K?65ZV.:_BD?U
MX^)3K.GTNL!:@2+R''6E@GZG]@,D)OY]_H7//CEO(^(+Z:&O^#H%KY.)5-#U
M3+ZO4F;W%: %+:$RO5]V+:Z<_^^11PNPN;R$>X=:YJ<,?9[%7^NVWNZWQ<MR
MN/(:4%@X\#C4W?]1]CWU>(9#JW[P/C]MKXM9(%D/>P7Q:D\YV7$G_"%UZ!:&
M\S>YN)>-("8,,;GWV^2AY2WZW; OXD#)M^[;M42HQ[7)&5(.\*,TV^PE$<[[
MRMTX(*6CSE1.6."LKHUWC0BIW:&I4NE5I:>1HR;:Y=@<I/ 4B$TV@W*%5:&
MP1WN>B1A)1]*XOFT/>,;P3 .6SM*9=O-R_;@3V_8'/1HI\4\QD*6'C$WF@:9
MJU;S'AF [S+[.VG 7W@M#Q.X<- *E/8MZ6=07EQD,6!QY 2(E;2IJ*CVFT\O
MGE*,V(B?(+%7>#H4^W"UP/];7%5-*+WM^CT5Y5;(O7J#4WSWZKNOR? XT0$
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M&+J"AB* =9*L#6T5NB<D$GE-I!(=Q$3(9(B>+BY\)[%:Q2R+&E5)3T%QLJ<
M(>2H&"0U-1A23M6  H;F0Y./_)MGGR>61AP-[)(T*3A5,2T.? 7P$3=Y,J(
M1/?!>HDV\2\E5<QV\59R;DUW:QM3H&9_I:B#YP^H X,Z^/0!=? 1H X2G-KM
MV/M.:Q'NE_3 0^J*'":']G-@L_WO2.U7(';R[-N>E&QK_$BC_\/$J G/_0[^
MNCOEKQ?OQ5]W)_UU>'EPP,_TV1-?_:1';EUO[@<^Y7^G#0Q$_F(9$PQ)9'
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MIKXM8B%8WV4JJ0#7@OS!/&.F$#%@VR<Z8))B=P0,7+AD'%] 44X9$R%283;
M=QWGN<DX[U=1R?WDH9)K*KF?/51R[TLE]Q0'^50#* _H:+/A.JY+8#DG$O6_
MTIZ8(UO^O7:833-GXU^2GIA0=QPXORF33(C5!V926732#FKNXFUW]:Y)RUVV
MO_LH'0IWRZ>/IC$.5?2+UXNLFS#U-Y02L%U/="W.]U+J *FCQ1]W?]K?3.!F
M&EQ\S.9_F>?J(03>][L Q,*H.-H6>O7_Z?JWVG^8CI+[0\W!K]\S_]?!$7GM
M3^.JZMOX[_9)G+<BBU/)#'A)LM/?[[>@>-#T',T@X>:(500#>/^3BBS4!U D
M%-P4))3"'I75&*)/8>>$(/=36-1'=#_T"92L9G?8NQR;\J;CN4+_W*]K#.0*
MB\8$GOVN^@ '!)YH?UK8N3+1(7-->;M O(M>)F%3C*>#IJ:FK+=V)$PI UL)
MBXOJ=H3P"C_S;7E0IW"B*!;+Y2$@=FE,%Y@;BB50OTSA4;7 B@:_G^6]>*?R
M[J;D?1')^1D?6*'V?M/1'AZ$JC?,\ONG_Y"!NI89EP19M3\CY<8?)Q%2?G5H
M"SE[>.1 (@8<),B,T<0)"\I<7&%]>K("S@YH\['L8U_)O&U.-<)^M!1*.JSL
M5];N-7,5_M;M*'VBAL1Q*JNO,%\2IG,P#7E'R#X"O+[$5%UL*&6M52 Q8).Q
MR[3U31W4C]<B>_]_=<XMAU?N:\V24+Y',;7(P?/]HG./X99.VERK-*:RGHJT
M_^&+;44#ZXM2T,)SFMD'8"V@4P,3/,/Z']3:BWQ% '.YHD2;3DX(T[?DEG<\
M*"L$5D&NI>JKV?<8.T+N^*=.>M(B@37+OSF;FD<HCLY&H/-17^&+1;UM:=@4
M7 O>S3K R?!;J^XZ^ IXH3M#&  6WVC5N>3#",ULI?G13U!%[CS3^RC4L$BL
MO?#++BBG?$B*E#&W%Z-L>UZ"_Y%_U,-SV>'98_JOF#^"!'D!3=2*9CIV 68F
M8BS2VWB%N8OZ>[Q-"4L$3TJ-YQRNGHA?U%WV,DY*TB-_1K)K\GNXX^G.B98_
M/*8/Y_I/?X/VV TK8( LUI4I5Z1^1K*P\7N0].-'SCXB#A;J]G[?FYB-QUD[
M>1(&*&!X"-5XQH_Y,'3U&VH16%UU?D,(/I:=&EQ"]N[*K%TJ#I:+)<0EJRG1
MIKBFF7_'U8T=$4&O!^,&6K]/[36]FX81>^DJ-;--O2TP 53+BCPP&MC(:'@P
M2*?NIUV>/.2B>"'D^P(- L<*"S-P"#3LJH:5YC8*V1.YPN,:C@\.8UM.A]9.
M%D#\()\Y;%EF]=*&818CAYV9S]5?7\2A @ *&L9='@<X#-W*5'S]:[OF)M33
M6#^S<H<"M1HD\^T-J2RZQW+^DYD!N^Z, ;L9)US)$PP'H\483<J_Y5\DA,_I
MA$/\^[(K^_6O[,:=R=6W[BI&#9!I9]M,A0N0!U#Y#74#_P]A=!7IH:&2.05,
MO <BKYUVX2SPQSR;@C+(V:3>4*V>8A5G*"0![I'+C90%^O*R[ET"6H8_(8GP
MDZSE]PC(,R;$EJ8GW!2=QE9$"*43U!1B8#FXJ@29'?>O@6)#/1 S87P1[XSX
MD]=EJ]<DW>F "\' /@8<FL7P.M:55]"].)I>UM2W3,4MK&0L;QF$F4?W,$9'
MYC:P!HD=[\A1R_ -[H"74=_I\HTMN2X/<2T^T!*PC$P>HXI,MMR453QDXS@O
M07:D3ZC\^$%?D=Z ,0FCN# UH9(VD6Q[)^:'+Z9UVR),NI-".=,P0(6&J$-G
M0:<4?XX7Y4\)F0.4B9J*^OL9@BD7FZ*AT:3(H . _6=(COKVQ'%1D56(NQ P
M(K\45]6Q(LSO'HHPI@CS^4,1YJ,HPAA\.JDO#9F&+750]U+?9FH]D#)IFP=I
M%@VOMA6]Z;*X[+O;W57VFP8!\_W%ZXL0'V8=Y'$J"Z?YU^;5J4J+/N^N<W/K
M5.+QZ;7QE"9V-]]6H]'?C)GW3FM?,H^!UVAAR,"O-$U\=&#?CS]B$T2?<\K'
M3OBB^(9R8$. P?*Z=!B',C*4Q6AA;J6$8#57#7:@NU(.&D$Y:$,3',F;$J/$
MYX0(%I 29XDTB9D4;&0V[)W(3,B].2)Q-LVM4DR>0-,-Y"-T_K&7$HH0>3*P
MEK3RU1Y2%AK1@+-H%09<=SY2DM=Q()JUV-/.\KRN+7OCS/XQ?5[:D<+>/S;]
M]&YJ76=Z-UW\:L:2FU_@<8]$;'R(U%2E_V6:K45A(7T%&"SL\?@E"!",[\?O
MGOXNY-G*?EEZE_/)MS\TU0&95?91=<6.1Z%<5:-'DN?"$3DA8)<UEQW]A]=#
MUQ^*FXY!--,'0CZHG7]"7XIH/?78K!IQ1H,H:MN2,ODMX9HOTT;HCL=2IY6>
M 1G0@2*E.._DQ *@Q^PJ2HO$@>\6B/!$YXF^D_A* J_Q=+KD+>5H$78T$;_
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M[F%M3,WEJC\0!<3'Y^?W90Q7QOCLOHSQT9 V1X?\?[5; SNEQ+IIU4E=OFO
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MO9P$QI#<-Y?P(YF0Y>L:[#"HFB&CCAER4>Z0L5].K%0217+2#?XN468V&UL
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MK<EM=M=,TY%8I+=#K(6_)=Y78V'=T,$E<C5'NQ$R<=W3DF1\[P6ZK^\+=*Y
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MME<<M*6G[+M,.HNN&25,LFL@Y-+GYQ8B5E^PV.VB(I$JVE1.*RQHDSWN9!?
ME:]I%]RT,6JD[]^MO,;?Q_6S?Y6PW"2S2T56!B4\1@=8-)]]RVP"PM+/C&31
MH-#<KEL)IY90Z,3Q\>3<*3Q6.X)W+C;R#+-E%DL>3A]J_9.;.: 'S8ARSOIA
MYNO% O+N<9X6S;).%/DO?G@&C&B_><2,)X!7QS>=*S:726'<EC$.,5P*X7HB
MWT^(# K?4=,D58*)"T W*3'/N,],[ZB#&[;0#1L.;UBK5_.8WV;\+"?%G7!
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MR)\'#16)YF5O!1?C*^UNE,Q/.*EI83NV3MY8WAP,^1D\Y4$\+C=\6EGQ5O/
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M6I&.;SU);*$@$!)KKZ(17!*?Q2BDYZL8%:_B:2K-\3(C_[E=U\*"?EYP\"&
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MN G*11?_>7OQK"55YM?B%FBBNU08U"7<RM)=>"@P6XD JTML)_O1@P%IG3)
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MBF">5"NK0BE2NN$^@<F!)%;%=8H)$HU4^9*C\Y95NX7,>.1<6V%]?->GGP:
M-R#01%X;:QDLQ5AI428,[N25?&/7J%;:<:!QE%*QB%_%1O.(K7DR2S(RRRF\
MV8"S5G3P9<N^%N= $AXN;24W]S+A,CZ4N2R/Q*I@/:F"@[R@3SFU8)02C;[
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MMS$8E TR22[-D"<7B2'09#(4 OB$)ES%,4KU8R9%PJU;*4<0F-4!OTPNBCX
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MY'L?T-H1XRYE<13;:]1UZE:\E^7%$E7P'M"+WL.]@) ],5M5+,5^<(/>31B
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MV+6V3)1BGWC(<C*YNWD<E7&\4:2&1>,((":/RZI6"]&"-ZIWT&W.&U7-COJ
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MK +^PM?) <#RVN8!P-]YI<$KU/\NV)VE9;U/_GR;LE\\NUX-V:K%8[K754K
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M?(2DB]XMZ+P1O#DP")Q'Z@_A0A<3S^?WZ&<6WVJ1(Q#KH+'I;*Y]%&K[$=U
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M*F:%%XYK>T\GW(A2W0>P[$;X-\+_]84_AT^JF(-X6]9P^ IA&@[F$VQ4MB>
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MOBAE3P\/P[8>K1\7?W.')>_[_LE7?6;V#1_+2UL\W#Z'GEF6-TQ@G_6XJ\[
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M3)]P+!C'<1W9-ME8/ =\CP#&1V'*3O@L3NEF&4M.^B7ATFE4"_R#%D<OI$_
MSP2I>5YD"<+1!^SAPYW*\^+D(B54S(AFP^%3K+7V0J-*GQ2+B5[LL3;V3+0
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MX"/8,EM)K</? _$AN,+--)BDI;N"5H!?Y7CO"7>NN!L+NQNK"SB>CTK:3:=
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M@7&'%,81+U)PS_!#7U!1Y0-EZ1L"5NMAO6W8R3#!]8>O7/>.0+<@P79TB+'
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MIB_HOM+'5X$PDJA#HAB-+%-%G3$,IV(G-?KE4 8BI? '(&K0K1BLI8S:@_1
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M>Z9Z<A$YMER"_J:UF@4..SM^_0K.9"^55_DYRQ:#DAUG!2MQ*WQ3OFH/"VD
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M$D'J8*MP>((42[/9HJ!$B'K&K=4RD[4O)TCXUB2UIO/+W?O3%7(S O_74+C
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M(@R;GW<;9?!7?@W*5U]6#G<U]/C#O4O8P"6/B([67_'5(U77>MYGT]%-O,8
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M&_\:^(X@I3G<I3V"+-*&0C"GZI?[(@)M[<5.E0(;B59QF#E5W(["G,SNA,C
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M'HB:Q[NY6/)*=P7.O3"CTSK87_YZC2OWN 7\'O&3#&UFH"=DWOC5"M%5"O[
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M:YN_4Y>(G@YH'<!*(V@(T,8(?!V25\$;C;[QP#MPR][8T#B--_Z:%^=E.KO
MNAGDX2U*@;2DI\5B'NAGY!O&VFCJLXKWP[F&^]SK$.1AX,6]\2T$3=/[CAOX
MU\5::$+O,0ZU[V6O[%*A!D_/R\P:3 AA$"F85Z8+/3?U]"^YY':[\S,5 -I:
M0CM"S0D7B*J09)>('2^,7RU._RG\S&D]8<LQ84K:<"HF'^9SU]_"@URIBN#
MLX.#O#T\\EJQ-,#ME%Y03UR7B&(<1/),&5#ZL['K=XHQ$_CO8II>IOF8/"@B
M]];'BJKS2F#0'+"\R7 %<B9)1III[@\K1B6;>)7L2%KIS >R;'EIB)\ZGR\X
MF6T3QP00PNA"F5EJ2+<!FDPGAH2SDCH2(R6+9.M)?]I<[Q 3&I041.DV'((Y
MCNS.M@ M1Y+DT3D>CD=^/2@6W8$>>V@.U!<!Q 0!1J O\S +>%;OI"F%=18@
MZ;+:[G=4 -?A[ VDS4$-_," KGY 2AE'FP,W2%9PV0([-^K*=CAU1".31-3Q
MESE[O;P(S]DSZW;V@FFUS"KF YJ[\P$CTU0?T*SL _KS;9GN@_,,GTJ?T#L
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MF]D5T$<VH=1&7 RD%H'C#(NAE4"UK\8/LJ7C)J8(KO)ET"(*Z($M1K+RMEX
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MF@EXC.)V1C/ &/BEL:=EB:ZEM*-$6X43-OETB)3<O'CC_!,88Q<%=\$M3M'
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MWX%D,2  ![<+.D@BH -R4[W*&&-U"P&*O+'?')30[+#26@4F92?SPA#DHWT
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M[@O9!Y2[&GA#\)9O?>(IMUUQC)S@.FS<?<+E&NTB^*;,MMX83M#H7-M-)X8
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M4.MTO4P@VVTOI !2L' MCVI< TFP'3Z0A,6'=BX*1^TCNT5AC>.[!0)0WQF
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MK^-0";037D7=:&>+\%JMEI5@7U>_KSLG=]NP?S:U&S[SON]_N'S_IO_A!=<
MCP Z<NLZ<J_7A4< M!-=!3P"> 3P". 10$?"(X!' +3#(X!' (\ '@%T)#P"
MNK'Y=8M>U]42%L;JK^/,Z"JK8O2/&LIHB]%:3X+778T%RN@I2ZE=(QUY1\?'
M7JNS1L=JJK9XC:,*9  R4$,L'Q)@,6P@ <\_NU,5@ 8=Q^KS_RFGLU,%"-0D
MU.1B1Z'KM3LG3%.V[=64<!4@ W 5X"K 58"K #4)5P&N F0 K@)<!;@*<!6@
M)N$J6),;L+1NO\$) 9?C03P*=$; 7A2GZ6OW)HE'104_L@*@DIZEDCK>2?O$
MZW6/&Z*2( .0@<?* +("( %6+07G=YS?<7['^1UJ\F4=A4/OJ'?J]0Y[]FI*
MN J0 ;@*<!7@*L!5@)J$JP!7 3( 5P&N EP%N I0DW 5K,D*J'%,]GQ@_W&)
M 16Y!13U(T6:2*CG+2N '6,F19KLX!Q@"!B2HQ(P;#@,*1_XL,--YAP4#6!(
MCDK L.$PA+UK^@Y3Y1P4#6!(CDK L.$PA+UK^@Y3Y1P43165NUU46R-KOV9W
M0:++9T-13>ONJ7;:K]]"],E0"=$'# E0"1@"A@2H! P;#D.<N)J^PU0Y!T4#
M&)*C$C!L. QA[YJ^PU0Y!T4#&)*C$C!L. QA[YJ^PU0Y!T6SO8A:C05IM.-J
MYW?^^+;H2QN.W1L_3-Q[/YH&;GSCIN%H$@6N?YL$P8A1F[(G).[--)LF@1O\
M.0VS!R@),E1NH,EUZ_3$.^RL4?B_78:NT=\"*+04A?L[PT>*--G!N<TBT!HU
M6&\3"[*$;?B(]K[_X;_?O^E_V RY5$6((DUV< [F#PBD1"7,'\P?S!^43R.4
M#\P?G;VERCF8/Y@_F#\H'P)4POQ1*'K;3EQNTTU??Q\G 7O=_P9#';#C<R3=
M>.R._.2/(//[4>"FP6":A%G(GGP7, 45CMWK9)IF[ME@P!B8U0(H.[K;4I.,
M%UD%30U$M9TSL&[S*NK&^K%WV#[U>B=K3% %YJU#"S!?F>1A-^@;--GDV=1N
M_F3\SWI/QM"0M'0+-"0\8&#=IE7 &X W &\ &A(:$MX L ZLPQN -P!O !H2
M&A+> +V@_;IUM5ML6KMIZ;V.,S_2\?N8][6=ZV?;'+.%*;3;\-H>D;%(U1I#
M!B #+Q3)IRH"+W H: AX( >+;4''ZW3:WF'/8D&HH[G#]N%?WV& <D\J*$FJ
MF@5*\CF'>*JZ$?@'_N$DP$F DP E"24))P'X!_[A),!)@), )0DE"2>!?DX
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MCWD0.PV&[%^C?CAF_[C*_"P8,0+X#GV=!(F?A?&8[5'_@U7+90MTLKO _9_
M3]R +7/H_G,Z#N3&';8\IH8ZW7I75<!"/$IH7[:X*%*) 7][U7HE?F8O'.0_
M/_IU2CD.XBCR)RE;<OZO=^Z/<)C=\:>T?GDUDUPQGQOQE\_BOT7I%,^8)?[<
MA(G9 O"6+ #?;![%!GLZM%ZN(P+;6_[;O[WJO*K!C]_J4BSBND6D B @=3V
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M*@@?5*'="?"8\CD7 *&E2Z 18?X!=JM6 ?/?1.T.\P^ 0"/2T(@P_P [V57
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M\R,=O8]YY>Q<Q6QS;!7Z7!,/UU,UP9 !R,"&C3%5Z#?MO +\TSZRVRX'%HA
M?=X_Y8QWJ@"!HH2BA*, _#=B*7 4X"C 48"BA**$HP#\ _]P%*B8,&L(A:,
M10E%"4>!3C+ NA7]#<X+>-__\&N<ICHSH!_<Q$F0IP9D_D]790=L/+6JWD7E
MD%I.M#6*BL"*ZM97;$E[QUZO>^KU>L=V)^ZQI;R&?$ ^:I>/H[9WU&GMBG T
M32X:)1+;EX9#KWMTXK5.3S>))AI;8IL\$+X6V,(:@!IH4;):=._(:W<[WNG)
MB<T" 8\"L@"/HL&V 1X%4$-$\4"+PJ. +$ 6X%%8+0_P*( :(HH'6G0G/0H"
M'0Z:F<1P*;(5= Y#*6N!O"I",Q5"RJ<IS52 =6 =6 ?6;5T%L-XPK!,^?>]
MX8 % ($RA#($UH%U8+U96(?A!T"@#*$,@75@'5C?(:S#\ ,@4(90AG4R'VT!
M%D;4.P?=6N7W2Y#I@/I>%*?I:]448'.5J'4OX8G"*\APA_&T'P6$2IRWO)K:
MIP48M?\;!92M\P(@#8174__L#%7I#U& *-BUFKI%P4BAMU<8-GA,>WEA>!ZI
M]I[EZ< $BA.*<PT?HLB:MU=SPHV -,"-@!L!-P)N!!0GW BX$9 &N!&TC9M%
MI,*-@!L!Q0DWXBEN!('Z_2VF'-3(U8]^&@YT=H$_'KJ?PFB:!<,:%"=-94Y
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M\2OPYB2G["J(T> QR4Z5+,N)LFU+KV4G9]>M6Z= <I'$-@AP8Y#,_/K;TQH
M A1E41(IX]8]M1V*!'JMU:OG?MJEWHE&MU#<\W\#%0=,4(([[;B1AZZS'6'6
M&0Q85KNHUU4RH6T%]B$_'IUWRKXM!*RK'J+G[*?4F./)JYC7@(^&=>BR/@S
M---$.T<^-=YB=(8=1_7J,_/$X;,%93=AWDZ(K(=@JN3!@S6Y8&)^9 HT\) ;
MG,()3AZ#N36)9G!H$=[C=D>FYHHE:4L\X5+1]?I/&<%U\^"!DOPHR%"-+M@#
MZ:OB$H45Q]W0?(-/.S98FP'W2_0KF&W>@MF&)_S)W%1KV1V9FWJD;^HKJ9$^
MQQII;E_]5DR^UN+#]>I[]]I4:S56#G.T%K+7J\$SJGYB<;W."MR[*;;EI%]C
ML5.]&.K:2W'JFGZ6%R% =!S.<J!,_ZM>\K3J\]LPI5>AK%Y6-8V&0QSC:^J?
M&B>QMOWN%D^J%8+A:U99K7"\Q6&SO)1'AWLK /]\]4)N68Q\X&B@K2AFFWD0
MAWE.*08=.!F$.;>ZT3]0/5^ ?8"2QR13B@SHTY8]V\Z<S'%R#6CLEWDU@MM;
M7FBU&7=F]5NRI!AWC;S ;'PW[VJJ,][:X]DB(7:K8NO5@Q-;N2J*F!U5]'73
M GP472]%9M!(48$>?#Q2%'@6G[X_MPX/^CIS55 MU3B!5PYU79CC^30BM&!6
M.K<EX%AYP"EWD8@2"T-G&Z1G,?>C''O+!XJ_6I&"G?3KI%\G_6Y3^NT_7.DG
M91:#05:&<7Y]64A!P:^7@X8JDH=+Y>"7&;JC;:*OH<*^#2ML:47HRZXBU*T(
MW>\J0J]=$=K&=YL676AO=;J;3J>K5,(U??5;H/'1T5+!OS'BO-$'3Z=3;),!
MOOZ,&#'_ECH[4Z4( EQQJ1U]K."J)6@.L\%9$;..!7/7[6A?R28=5=W!-=[H
MUYM_HYM3783#A3DQ_U'TV/_^Z6ZPN[MK@FWPFX%20VKK483680NVH^1"H16F
M\^R8E,["1-*T&,:GG+;4E+NU>X'MFD[PO?!BFN.WPT7"F$L#FXQ%CMAG9*[E
M*KN(!KJJF9)THQ(1JX2"(5=7BJ7)#BYH7-C]7,31P=Y^\!36IZ48OM4AQU3A
M4UH12-%$SQU9R%GVRA/8V+6UY+,P&NY@/7TXBPIJZ.SNSM93U1U<7>@=;[[0
MDYX8+0)<((7SPS?'.:/FP=O#\3A38\$J?!$\?_:,!(7<;_CL"*^_?U@Q@+J+
M_1"HZ@ZN?K'?;,?%ILL)%L)@@F:'!9<#7<V*-_K;^"T84.JNZT.@JCNX^G7]
M[>%=5Z.E+:1+FXO0?*NO$;C=@CHXIYC5:RYFO491W'D%6,K"?GQK]7%+062,
MM[R."K?UP*%Z2]#%#"2J0(S52^7N#+=TJZ+1-T"M:YG;<IT$WTT$<Y.PK:7@
M7(#&.TV^M2?=#$G+DF]-^OV:YW3]<[U&LOWKB;J"74Z6<DLCREP[7BK]^I8N
MO,MPYF6Z1%X4. DS;*X?PJ<1-7%1)[$B!_O[?8XS8J!,%^R?S["G$OAB5*@,
M6_H%6.,Z*,Z6YTVO#.,X^Q4(Y]O>($<BWO:K'M%EE:$2#KZ>1#6<W;]0-H :
MFG$1%,] X!)LVTG\PW*,!91[%AN685JI_2[,X@B.1KPI SOF8HXP-B6\/RH0
M;$S3T]<'Y[:\8E->@;@9_\'^+&X&PI11.%]@"1%@+N<@KA3R&,F2%/%78'V@
M9U2 T'N9*D)$Q9#(K+L+ABBS&SI\3"@4A$:;+RS2HE/ .833WF-.W]X9A.:W
M5:%^10ZYMJ9KUF6MD !>X05K]-_^>.Q4'-]< ZR$:[U6SZXF^R.21GFA03?&
M*D&+5V.]V^01F\03%1N#NEJ_?4U5X(+Q6F#_):I@-;^QN\0/L<VD]09M89GB
MW5:O_/.AE2W6Q%<&:C[,RXRU_3B,!#0J3G-&#.#4T>H5@QL8.5E6K+BWVQ4K
MNL6*!UVQ8@=?>4=X-4\$K^8MR!KR<<XQZOTM165O?:L/<Z\UEA#E,BE/$,H8
M)7)A2%0%16IA3!17(8%B&VAD$D2ZHNG8^#Q0>WAAN++ 2\O"P&8PU**.(R/\
MXH 4SS"*2P+&4 4I(6(,SJ;8"5\NCH6ZX%BSMGRYIWJ!T*UKH;[6T(@5IJ:W
MFK!+)T4X!+^8-?2YL'!MLV97'>:N9X3O[/;V>$:$K'P'13L:>_+Q'3:NW/KH
M>JW-]5*UGMI;ML]WL3)@#/ST']\]^VZI%;1GK:#K[4+SXFYO*#,M^!R>&&91
M:JSAO6_L6!_NRKX1AMW_QH[UX:[L&V'8@V_C6%N;D[_ZH#I[Z@&PQ0._[;K$
MZI=^]J--_1ZBCX9NV?N4_N!_,"URW]BI/]R5?9/\_'3W!V9H FS[$DW+:<?@
M#W1EWR2#8_2GX_#.GNO$P\KB8?\AB8=_J=#.K#W&8FN^_96*:_X(R^6^L3-_
MN"M[F-S\OF$ZN,/4U8X#P]7/OK&S?[@K>YA<W<GHCIL?#C=W,KKCZH?'U9V,
M7IF;'\JBOIJ1U\S#K0U8*[QG2?_5VJ\(%@!>2_;72@*W9YFLKRK4/]S[L/ZX
MV<]^'^[-.$O+9(B5:VGVDY^-^X_V=Y\$^P<O@OVG3Q_?(+;6'BU;.> FI7-/
ML$GD%N-L.!M(<SU73.KZR+5(65T ^,-F*@%#WJWN\??KI/5YC=8,*V+72.RC
M)\'>T_W@Y8L76[3#*_32=,QZ7P3?.L<>!$^>O0R>':S@P&W,-G<<N\$$=S*V
MX]B.8SL9VW'L%G-L)V,[CMTNCMUZ&7LW<9J_)E&A;EKX5&GPOG$IU!HW]"]I
M<;4P+)565]]M=:4VY[V?N<EU#4RSF==O.X3$;4J&EWO!_BXA=GTS&[J)-&W'
MSG6LV+'B1E*Y;E9\_KQCQ0V@:3MVKF/%CA4WDLIUL^*S@XX5-X"F[=BYCA4?
M3,G)3:,:*]7ZW'^H0U"\UL)0#4N^TTNZME*^>Q4UM[**#7=;&R_+=@C\CNDW
M=A4=TW=,WS']9KGB'=-O%KMT3-\Q?<?T6[F*#0\O=$R_6>S2,?TWP?3?1LW0
M/437WBL[O+*&=[_NNJ%. JVRBJ5M8%LA?![M]G:?K*<Z\:X%SWHJ:SLVW]A5
MW :O'ZRG=KSC]8WADH[7VWC]Z9..USM>W[Q5W(H-LP(X3L?KV\0E':^W\?JS
MSE[O>'T#5W$K-LP#D.O??.'9?N_I1@3';K/2C-9X_W>8R/"':=G'*=^;((RN
M'R-;PQJV*$PFEV/K%&_'\!NWD"T*F'5<?]_,TG']W8?..JZ_;V;IN/[N@V@=
MU]\WLW1<?_?AM([K[YM9.JZ_^\#:'7/]MU%J=KN!LZYI>\.H7/=U_\8V<Q-I
MVHZ=Z]BP8\.-H[)CPXX--X#*C@T[-MP *CLV[-AP ZCLV' 32WN^9OKCYL4C
MKL*0@A</RC@LHA0>1?UN?I@,UUC<T_%U)R0V@,I-I&D[=JYCPXX--X[*C@T[
M-MP *CLV[-AP ZCLV+!CPPV@LF/#KHYB7;OZZNCP@XE9G)7].!KXYQ2RZ"[\
MQE"Y[@N__P*!N[83$+]CQ8X5MWM#-Y&F[=BYVV7%O2<=*VX 3=NQ<QTK=JRX
MD52NFQ5WOIE]W$2:MF/G.@[<Z J+KWAID<ZN&Z>XQ0VN!"EF6701%LJ?Q>%
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MZ33B60Z_IUGT=YI8VPME *S9PPH?D0..H*WH)0?7D31U+KX9)X+<G^EA:M1
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MHP2'=!A*4N85.HQU'^E5FA?P&"< 6:>D+:#7EC;36&,>)\\YEBS!6R>DU)9
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M*BK!P3\AN"14&U1';-&74G<<3WTMG/[0SZ-4NL82NH(1&(W*2:-,4JK#C;#
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M,H\//.S,S$(J%<'!T-%%-4Q,!;>H!0=18?XL(6XSF;EM'^M\Z6 %+AA4@><
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M#'PNDUX>TWI>JP%OU?.5E^2=^&22A 971W?M83ZI2 >?3?==*MVO+,F;A+C
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MF5[/)-JN6/3M&0;G*IS&J/1^R])R)LFPT#\*YW"L_DD>@XC,L=1[2G@J=1M
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M:ZYX0*@@9SJ888PDQ[B#&N3*1#- J4_30B-B4%>+],:16D=?W$I1,M<((\M
M6;&%5(<B6H2!<E_J+4/VL'$CVU$M:1NQ-!'=DS]P$+M<RI&F"N$_W>$,!D'
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M\S2IG6>RUY))>P!SWMT)?Y>'VZTN0$,KV']>^* \-,*BR;+/T?JC0,+K-DY
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MDPYBNT7.!LSI5K=GO6WACCZEM%Z 07K!H!?F-F)B$L=T-,&8T#\698;6T:[
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M[5XP$ A0VK!D^BT;IXMF!?24Z6I,#B4O42IA)1/9(21F0IC7^M&@K)MF*4K
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M"3!98:U!WSW3@(2254116!;A9+FTTC32+IUQHP7;$L'C'J;9_*R:6%:X )B
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MEV DL1V@)@L8#VCE?F$>UQRF#0-MV2B.8+<SRZMKRI4U3<K9VP>O)?ZSBZQ
MQMN($6?4([M>KJ)-;!$L!J15G=:5C9]7T,:IW0.3U0IKY:BWUU^/D@X'<@7:
M6EP($[LP(9)C*G!(YUZ?+K-YU-6IUR:VO1>L.M]=@F.D]S ZD,NK<CI^T)8/
M#S?*6M_X^DRGD$^*])1 KFII8NKK)L+?5?:T^HRX1A\8QE-F_<1Q_4MP+>H+
M)GO:%2>SMQ0!8DC[.PIP44JNM2)V&6(ES[0#:* 0;4!TFH%<:9'CK:&-[6&"
MN<\'8X/LSG8TW1(3AQ'UL.\#=I"(N8-$7C+#/-L5YWD]7U"K<]!["+LQU^%?
M;QI[&WH8^R-.WXXXM9S81A7,M20F#8W6W!XI\#7)EFZQM%8 R@B5Y@2]IS/0
MJX)>#"9-#5F$0*E+>]G/@^0OQ,B!\]WYY]'+16'JD<6TW=43G4*A<C'I#BH)
ME%W2] C8+6":D&K_UQNS$9@-((&!0Y80 U,]SS,$.4C' "=7'.]FJQ=1D]G=
M16\U\@T++5LZVS6N$[NC3L<WP)^':W_'IM*^]GTDJ>["3Q&?@W2,QNCDEB[6
M;O:=8$PU/^5I*,KA[VK@;RAT-ZH(/I(N49<NJ\7HM&)V>CK"S5E5SYE+''XZ
M7M3-W#+.>MO?:U ]M^W1:%7_Z2*M0<1DAK^'^\O7.34$]T2O9&Z'>MH -!+#
M<R[.)"-6O"[<BC^X!EZF(X;AE^/>-X2VJ4H,!"$)0Y:!]9[6OF].'SE!:V!:
M9,.Q1->,TR?KG,2ECTNC8>\8X*XX'LT-..<;>&6=-=KM$W?=)DIXKT<EW&3#
MT>Q3V %=,SP2#OU(:SY\1Z?('/H>-2(7@?O2J"(5Y2:=<%7W;<6'2 ]?EL))
MK@3,C8V#&+3 ,JB2C^"RYT5!1"5>@&'40D/8(MZH)95=$F%/4RWFW')K""0F
M<FK(G.%5\\5,E"F_)_)C35UO:<I+$Y>[QM&5DD!A>F-XOOKDB@,PPH*)Y2W/
M+;4?%KQ"VU+#;7&+@ O%,+E8.@MA;4BK-X\-=J@X[,:4E)N>7S-(B#LVE4[.
M4*A0#UV8D'84.^*PG[X9<[:1APV8D6&%DB#!)3V.0EY^32B*W6#$N;' K%Q,
M%_!;<B&4SSLQ\4?NY^.['O72B3M+$8^6=QS\J6L9+YV -!LTIW4ZA9&(313$
MI*,. Z]Z<X(W8L!<ABRT<]MZB616500"W\A='8(+AU079<!OA9KA! DI!VEW
MQZ;2L8?@\(4T9.UCY[KJI5,LSZR$5XRS\IC'L6>PZ]X6^4E&*.LPK]_#KA_Y
MLX;Q%/SR ?P_6EKT)GC5 ;A2^/O78$[%1D _.'A]V#RTCI.YT/WM><T%[8XE
MPG:?8WBQAAZU$E,B)B8#S@:7NY2RKAXF*!$=K FKRZ#18!//\IE46=%D#_]Z
M\,)?'9IR_C *EK>5\6E)&#63;.,,Z2"8GS\,1MTKD&@J_89=U#:6&CT8<$H(
M4,M=JJ0XH/#VF'J2;(PYDPW/W<FB'+.11'XDVVG2A:1<!O ).([$ZM(K?AR=
M7FA\2EP+UGN:-XW0.Y'QG ET54Q',VIK/6[$A;\V!/+9 (&T$,B= 0(Y0"#O
MRU3 KC?T1&2$OO$:XR.!&TRG4,V]:<GSQG@#&^S?L/F0-=[""#H7.R *EW'3
MCB\:#J50%0[8*!@L*B@?R>X!M\MC8Z"G5:4KEFB3F47LLO!+T&RD%_GG<NZI
M1;QKJ'D#4*B!379:,H-W1*QR:B]8V^-X*3A&MQX\'L'0D(4J UD%EVD%Y(^K
MM)Y05*\_F*5!'4S\AJUMF2*8P!]D&0:FW,,@!':EL1CSKK6Q(*"U?0&,A#&W
M!(/)4%]$]G>47D-0S4@)A-'=FV:>U9CL3%U2?)E;9SL8L::,DQL7U>FII,72
M8@GVJ>)[Y4&Z(L[L=/WA/,FR.:+V")BM_]BWO2N\% ZV-7-:(R,)J4O,A(B.
MM7]P'S)4FT#ZX7G.03VEXH8'^-,^()BI;^:K9:WRD"Y:0M*;:W!^75KW-J N
M['!_7]K;71."N6K*"K-<1@Y%>#/(X(N#?J"@@]RO[*QL(2\:WV\UOC1 ['L!
MDKOD'.:_XAH?R!J_"=?8$D9Z%'*^08?2([-6'#4]6HC!"D^6BO< ,V4%.Y9=
M-O/6MU!*.P(=DV72Y,M<>]/88V?&UD3:R/C8V3,L^]N9M-X2#L*9M6V41,(4
M0@K4"3)XP&E[SA'A3KMX4[R'^$V$1J;ELA5 Z4B$2]:>IBLR@>ZSCWI0' \S
MHZ4+VP6FC].N."+[&K,H8N-8@=(R7Q"6/Q&<"Q..N] B6R &!!29?K=A<TVL
ME#;MW2FPU=.*U@?J*8/'F\5G*>5.N1[_2]N4./N65IB>'DUT 7#MSC%+VMGC
M3C JP/-IN*E,248J?-@3+55U?XYT,Z3B08 I7Z&R>@BV[OO4327<ZLHUNS;1
M5?#VO0;O:L5Z0WA^M Z>']\$GK\5+L$TG62<-,@:QZEKX':6?@;1A'QIFC;D
MO^41F8*Q=.YL%/==;YU<I2) X$J,X\>R-1??WXK^#BMP3M6%URT'2'KFX6L.
MCK.L]&Z(%HY(;/TX9Z'CAQMIX1T+F=6E@.M* ./5)8#DS 15< PLZRT-C*Y1
M&IA<I3;P/HB [UX_< 1[VDB0#UE!8'$WIHI@@X*RG93K:>7YR$V'ZE['282C
M4)N C,'""21VFW21I[9)5$N?K+#%?98TZ<4\8 X-I/4T'\O#FPQ%/\%$\_G"
M1)A4X+:M^RY="Y/8.5,4#G \S?]DDC9*KC9XK#G2XD>$9'4BZHS0<!$E9FA3
M"\Z3](@J660CT,<9SZ H)"O,=<)HW!$S?(UD_E9:DCYH @0(RS[,#4]!)+M4
M*J7!)8HS*K(6RMOD6H.](H.9)^VLSQ$62,*\D17'TPB1INIWNWMVMF?55QZY
M7(T0Y_[\6X)_S%V$QZ^[AQC/5?-<(F1+/GJX)5PM;AFD?3R-O =%#AO*Y7+2
MR]"\N2&QM3G8YT,.UN9@=X<<[)"#O2]3X:"TDNQ&^V/PIAHF13DX2S'U-M#.
MW-&I="PU#SPWN\C>KO,5Q[*IVKB[<*;-T%!EX-T?>/?7PS3>&ZO9,=S['#S'
M"M#8(><V_W4K?F4 F[YJQ#0XP; %YZJ[O"5:_+,R:=M!@NJ8$!$*OL/)2)T,
ME]UWG8&55,1;OOOO#\59Z^!BO=T^]-P8[OX/>?=?&'_?]W#E%F=(^#V:U#EV
MY#">L!$!X@[WEFI8CF'S[58AG,1 )>S@='W@Q_I>MQA6SLOSJK"1RDF(%Z)'
M4+%>FU=7PSDV.Y10]H<"H3I82D4- F$0"#^D0!!TA-Q[=_7:A-JM(*.7"9=D
MP,WU]T7DJZ-\&H[D;WL!%92 <GF(( F,6$@I$?1O>( 8 '82!C_@TM1A8:G-
M,AO!9*KCA\8[=WPJ'\^R2 +;SD5<S//"D:*D\2FI-[>_8<UQ4/@L-/6)*Q%O
MM0<Q\(40N1'HFTCA" Y$8M52!O=FLKD!UWLZ%>E-9K*MM(LO':O[!VNN;%1D
MZ2M2I%T3;!FF3QP$B; $#HH>';=R( ;LS!2U6=-B>%0>S-Z4".4#QW5^C/)B
M49.=>)QA<2-C H0AB@:Y^PL!$)46YDCY"O:M6A$&*69,X7'XADX"T<?']+!
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MC4^[&*DG64VV7^@\.9]2@M[]%8PBE /!B/DQ7:I?P-^2DCMT5Z+@(,C::&^
M@)5#ER%U*\,&*2EDZY;+0_H=:#?]N,8R.%8';JE<V&S#G"@7YAF#K]MXAK^V
M[XP>:8H'0WJN^6!;7XDZ/@S_X$H3WPMO/#__!I<##Y4#WD9=*>Z9<'SQ>LNG
M-_T5E<9>[OU)_J?D:DD"J&S!,T^_5")INN=.\D0D(.A3-B!IX$ :VU$,DY43
M8:2GK_',G)>1L\7(/MM0:RH>!'APBRDZB/P'6Z\:^)U<<>J:2ZNZCDG#3A;C
MS+\)UI@M';FHQQFL8-;X(&LV2?SFZ!*Z$222]::I1T3#B\;9&&.DL;GFN).+
M4@<DT9B3]+RJ^7<H/^__O?HB^<_@,Z6'$+^8JHJ]L,-N*W0DQ#Q%P3A3J@$;
MG/)_(+U(D2"G "C8D)HF#?1,C!C91WARI*UX7^_0.N-_A0%X!7N_>Q4BG;)8
M U0_#6<2Q\;A5R:LA5F $88_EXOI,<9E3HRBFW#"2IHRT>V>89$@%L1MQ;]I
M&*6S;; ).9R#ZB2B)B +4'_E?!5/?#?,(<:R,-:6:/* [9Y/,%9SZ8F(A1=$
MYR7A2*L83>HX/:[HT,BT&NEF_^^J#A8]H*TX:46%62RLC]HJEO$B;X@MEBM$
M,1\<(U%VG2MK&EIICN$?RS!1T%+1).(Q4Z*MBP\1VO!D>^?!\<,'.]L/<90?
MLM,%GYKX:/3/+:NFBT)].A(>ZG;1WO2K#>XD -];S*AZ'S\YR9MQ437*>Y?]
M>0;."-Z[2?8GRD#<)TX"FX4F3Q.O2%ZZZ>A\M[Z%1-F08G:"_Q'(:70D>C4R
M'"T'@7.T43"7[]G(U=0Q!3V6T0U#/$L;@(:!\( I?_]P)([UF%B*<B$:\ODP
M?H7GC;!ETEK9H8$/7R+AJBL<4Y/I?M0RX%!_E%E&.1,5V *^C(EZW)/2$W0N
M[#+TL@] CB]4G\+'MB,+]M;&LP[(85D5V0\2DL@F:'42RB'#5\@A[3Y6SW#
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M[Y@5XU#:^'-97<#TP8%_P'E9.! <]O+''D<[J<8+*9-L@D!FY$["PY@:JOJ
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MFVNXT!Y0 4ON#0W;;FBN=2L5FM_+LHN"U433]OJDAVZWWQ1ZO&@#@$96UV8
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M!6!]&N5^D>LD5)X6)3Z:<V#^+KQ[9=NIY;6<Q\P >G1Y%'8J8EP%#MP6GD5
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M]#S(Q77.I-5=^YVG[V=>>%/.*?!#?>KYL7[K!9G =EZ)/U\$0O=N8B$P-I\
M?<7Z-$NS6.CBK\Q/[YFY;$G*,DRS9S@F=_HZ6432ZG.KK[.B"1M+5\"8:RAA
MG&GB89IPF23.BB1,P^G91K_'4?I3D80][#943L>=OM;Y0*\%Z)$"],UQ-!=Z
MZGWE6/T^L<>1XQI]#J:< ^= ]TY_X'1/=!GLWWF87@:&ZXP,]R0-\YA>UH4/
M>ARL/V-ZL8Q!KV_TK1,YX9A>E@#BV-U3#"QZBO[0GT@A+0Y;5TR9:6Q@&ITC
M8R8W#*S[<]H*?J:',[L0I@>F!Z8'IH?]P/\DW)N?1#D'*X@2]F.R'_.BF 3[
M,<^>7MB/>6;TPG[,LZ87]F.>%[VP'_,0A71KLT3N=[T+:C"<&$X,)X83PZE%
M<&J'2VDU-6XA8AUT83_TXGL]F7FQX-%$3$(,)X83PXGA]*3@=#E&^G81_P\O
M\<>%@*=VQWZ0I6)R.FQX_AB(<-4W^CV[:W'#\+,@EPM&),<P>V[7YI%63Q>1
M&$ZMA=/EF.KL;&<*83@QG!A.#">&4_LL\3?7;_\0"#LQ*>UQ^*YW(_0PFU^C
M[WVZY'X_))7S:6,+PXGAQ'!B.#&<+AM.EV.W7YS__?&P 9M']9AHSH9H+AQ.
MC$Z,3@RG]L+I<BQY]L4SA3"<&$X,)X83PZE]5OF;Z[>_QE%AED^C>.Y1ZP1*
M@2?7^RMVO3,1,9P83@PGAM.3@M/EF.G;A?S[P*O4MKTCYSO]IO]C.<S^][\-
M+=-Z?8W.^JJ37K_*0B^; +PF)TSCY83Y]A'9!2,2)\P_>41B.+463I=CXK.3
MGBF$X<1P8C@QG!A.[;/?#TJ8U[,$S'8_U!=QM-:OKX^C^2)+O=2/0O;Q,PTR
MG!A.#">&T]."T^58^4_$Q_]X.,19U.=%:A<.)T8G1B>&4WOA5&H"WZ7>=2#>
M:MJ;Q<-+&?('0_\L8G_Z6I][\8T?=D"$@]!>I,4/14-\_*VZN_]D2>I/[\',
MA[V%U04[4V_N!_>O'EJ2GDW\_PJYP_)4^$$PZQ=XE/_I=/2/O@@FK_1?O1OQ
M&E[^*Q,A L-RW-?Z_WI!AA_0.QT%Z(E_6VA$ZP9#6(MB,$3UT.Z:0[LT V )
MFB$Z)8*=@%J%UQ@T'Q'O!&A8LW+L_,"O]2_W"SCJN]B[]L>O]4_>7$B@?(KP
M]%9_5'WMN_P]_#<$YIOO #)K8!0+[\_.M9A&,7QN03 ^)EPDEN\&%4^?Q6+Z
M_;._I='XV=LOB.[H0AK#^@#=Y,UWWLI)JQ!!6!&>? .%P%9*1%WL^*FUE+-T
MZ-4CDP?MC?_V-W$KP@Q[2?AOI<-KUW4OA<@;!.&'KUX")HH@ZV'P.M%B!4W$
MFL1/4D2@="9@HT$0W8'E\JI]\"7! !PH")1U]OVSWC/Z.\J5_.]['U>Q5S V
M V^1P [R/X'4\B?I#+_2>_'LN&;JR>8ZPF$0YM\_,^UG6P70 9.)I/ @AO Q
MB@M[&?'V_X07)_H'L*PG^IOK^+NW^K^R4.C]GG$&,X0. 9^U R:N%ZWG/-*S
MW9 X@3OJ]-?C-DGF5L^R+Y2 FX;+88/ 6@Z7CT$V3C.*BC8$GB=)XU:3=_;\
M0A&Y4: <:SKE10&%,84QA3'E[#"E'9E:A;5N#5\0N$J'TP%0RRW_%P>C3_&%
M1_30JV^.7CRFLW[+1A\SOL$P99@R3!FF#%.&Z0E@2HNU(]M,*3;%L:9Q--=]
M4!,#^"0\JW++X8/Z(KK#C',1W_ICT8:$!-,P1WUC-+0X=^,A4(U TV\*2B_:
M "#7<&S7L.P1X]*#N-3O-M:QH16XY!A]QS(L=\"X]!"H;'O8-#*UQ:.QP7>S
M5@% H1^+F0@3_U;H$R_UE._H0/%_B#OML9Q>#Z+<8RV4:Q668YC]AI#RO"/Z
MJT=H[OL$[8T+C)I25S:NN*_D>4HD8;LC$&=,$B<E";?;D#[!)'$ 2?1M&Z1$
M0U4H3!*[D80U<+K'OH(*4;3&C;1Z6+-KT6G?7+_]$J5>4)PW_I9 VJ95]B5;
M"Z]"GT39=2":9A&'K:6X!(#/-/KFR##-PU*\#L35'0#[R/?T;0SC$1?8P#$J
M"&WV>L@UCG\;CQ:V?PIT,S!ZIF,XIL5TPW3#=+,SW3B&.W*-_FC =',F=&/W
MS>[P/.BFIK&VLKBVP;J[7[)82U$9SI5@W0_'L?"PN]?UO?[<Z0YT.$C@1[#U
M*-;IWE\8TB/[W.SV\W_%)F!4Z'0OO%@75.>$%4[R//V>H6.I!*CQ^O-!M[?\
MEK;M+:>K?YGYB2Z^CL4",^=AMV"+W*4S_<Y+]$7LP[D V/HD]N$,N._\,+3-
M*(MWB1X;&B#B>%8'@+=8Q-%76 !>)W#8=7"@J[\"#NL <+A=)W]+V^6M'!R)
MN)G+XX1PVRGU6,$PU@MJUP9GKM\K?GKJ8Y&E_#I^R="SA=P[QE)?P-$U7!T@
M6G_8D X%0"F$FI\"T*/$QZO0X0+PE7$4"PG_.%]>? 443N"9KO[;\G5L].5K
MZC)T+T@BJAB._6LZ&H JQ6/+FS?R:\(-(:+VEFZ&S.CB9L FW/EFM.)F>N7-
M['2?3K=]-:D-\IX_A/Y7YH7PM"\FA'@YZ6%CP1QOO52B -7&PJT4:*7?^8 0
MH<(U/R&*'L/JT1R0\!H_@^V'0MAF\2L*%43;!/%6EA(GK_0K_Z7^(?^LICZ[
M_I.O].=6A<JOZORA/P#F2)7*-=*3*/O2@!\ ZQ- ="*C@L\D"T HA<CY:@D
MQ$MU8%@B]A#_JW3\(&-!%E$'9][1,?\,-FI</6*=GWI)$HU]7)V HL] +2CY
MI0X\-/#_ZZ5$<O!BOD3Q[PG^K3PFD:*- @50:9;LSB*'"'%Z9S<&:=#%TY8]
MW3%?K 4$?1 .F>]V*I TI BX$_JU"'P %<!K&H@Q<+SR'#FTM(F8XT*X)RE3
MBK,GM ,%K[LH_C.(O G]!G"G=IG8\2$6?V5^+)"+)UW 0D##3Q5L!<Q\WJ^P
MH"5D<P$1$=FT79"M)A"+!73"L:D?)X=B&K.\O5@>4J4"KZ94& _4F?O$E^1
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MS#&1'"9*[+YEV ,6)>=S*6;//B61T)IM<"=M[;GT!>O<BO.N%L]Q_Z5=4!4
M"2QDU .-=.0>LV-8Y29?\E7M>%4=TZ: QDFNZ7&2]Y["-5W9ANGTC)[=9XHZ
M\ZOJ."/T*C)!G?4M@2EHV4/#M8_:$I8)ZI#FH]B8XSP(JJ8'<]NT_?O#'-Z
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M4_VYU>W53X4-S/)35<+,VH8P<VXR=/7//GS'BX-[^$X.2GT]*-VN65\42:@
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MQ3G \W4)U[+?_D_7DNK1CL"MP5IP#S4IVLJ68%O;"]C<7J#:7F# [05.T%Z
M,W_;D]VV)O/W$]9.<.(O)_ZV*ZN)$W\Y\9<3?T]^9YS.R4!AH)PG4#CQEQ-_
M*\.*BU$PG$KYF*F4Y:00ANOCP;4R2(+!^HCH*J=!<.8O9_Z>.LET: V OH\6
M(^5\QH<O96B,>I8Q<MLX5/)B+\4Q>J"X.4>??LN7LB6+ /L=<>HOI_Z>%UKB
M #9["%*54W_/\W9,PW6&1M\]ZCQ6OI\][J?7&QDCZQ0IIGP_.]R/XW1/D3C/
MZ;_X/T[_W4-#M+O[>UHO(<_TPJ^%^$<+KX733CG]]_+NH29%6YG^VW"WZ9MJ
MS]IZC^;J6!)LT8R54T6+YEZ]5?2^G:;7#;&EU[6].TW7FNPN]\KNU4Z RE_E
M!*N]LO<8P[O][6W[_RG=8XBQ5DX<Y);,WX3<\I$ZAMA=ZX5$!ZRV>G$ )F,Y
MT![O:0^C\+I]FN4^;1R9NM?@'+7-0?VUAPF-T6WO#N"_+' >%P@N#0=@A$F;
MQR!PUO\Q\[Q,^XAI_SHW^^:<_Y-?#^?\'Q,NG///.?^M2%KF3.XC9G)?-% 8
M4QA3&%/.#E/:D9E$("K] ;EU5?H%#H#=)2:,/_Y&.0F?8<HP99@R3!FF%PY3
M6JP-26#/WGX605!5=,K!VO!K1>W9"\:/EF;P>!D16'HT&!J.V5#G[OWK)LX2
M2!VKU^TW!:%]$Z+.$D)79L\V!E9#0Q):@T;=_4?W/"4LL@9]8]#44(<#-WJ6
M@.H,K*894EL<%S_*>?$U4>Y-YG[H)RFZ,VY%N^2YV>L;9J^AM-ZV,&*GJ73T
MEC#B*]L=&NZHH:+.MF"1:3$:/6!<N([A#%DKW :DOF,W53V]IRP_<[-\8[CE
M-Y$(3.:JR?B)N!5!M)C#)PX5\$^IG/"J/Q@8HQ%/N3N?*VG0Z[!+6P6^CQ75
MVK#ZCF$/N"',^5Q*IV]UC\VTF$BV$,G0&0")\ C;\[D2RW*;\CNVKCW/H:T!
MOD1IQ<<4Y9DRWY8A\^3JT0&0P#]&AFL>M:U%Y1Y?\D7M>%$=V^T>M;%2Y98>
M)UGO*=P2Z*S#'C8R/-55,4'M3E##KL4$=>:W=#6R1X8U/&I++":G0YICF;WC
MSL;=3$XU#;B5?3VX?+J]Y=,\,8VKIT]]/5P]?4RX</4T5T^WHJB/*QVY)I8Q
MA3&%,>5",>5R D=</5WYYKE5IC%,&:8,4X8IPY1A>JXPI<7:D*;]I*JG!Y9K
MC,R&QC:VI,"A8[K=QFHZ6U(G@X.3FRM\;0<:-9;HVQ(LLDW7Z/>Y>OIA3'(&
M7#W-U=/K&+'E#@W3X8+%K>1SR-#TI\2(KT;6T+"<QFJ#VX%%0VZ&LAV+7+=G
M]+@&?RN0++MQVZ(=5CD73S>Q4*$V&*;I&$/GV.6Z7/:V1<#8C6GY7!EZ4(<!
MP^J#=CT\VB18)I*'B:3?.]X(6":2AXG$-$S+:LZ-PT1RP*4X_:8,7JZ?YOKI
M1ZY/ZX,JVC-&!R9Q<X7:\:ZJXXZZAY4@<,'G$0G*QG8F1L\Z56TN$]3.!&5;
MYU+RR;>TF:!,H^^ZTK/)!'765V7W,>1^#O144X);64+]/YV._M$7P>25_JMW
M ]?U6?R5B1#!9;G.:_U_O2###^B=CKJ*B7^[_?9+@Z=Z:'?-H5V"^A(TPRB>
M>\%.0%U7(KL#H&'-RK'S [_6O]POX*CO8N_:'[_6/WES(8'R*<+36_:P^MIW
M^7OX;PC,-]\!9-; *!;>GYUK,8UB^-R"8'Q,N$@ZV TJGCZ+Q?3[9W]+H_&S
MMU^HNCZ:ZF-8'Z +UI"W<M(J1!!6A"??0"$T"#Y'U*8'SO^2Q:715XR;Q_,F
M?I+BT1.94[@AE]#0;V2BPK8$!8/^,5;QCHUQCJZ^.OA>]\,QH$\B)OKUO?Z\
MUQWI0/F!'P'PHEBG7A,O]&D<S6O_")0?4PU]2B/(YQ$5T0LLHM?K!?0ZEB.#
M2:T_-[O#Y=>UG5YWN_H76"K?J7[G)0 I/PSN]4DF\-L10-D/;T62TH']< =@
M['[WE\)H&T3CSSYLTXN#>T-;=6$LX9#9M6LXA+(V1Z%^UUQ!H1#;,.R$07;7
MR=_6]GE['0(M8A^.";#7O32-_>M,=OI(HU?ZE?_R8?PI#ZW)0YOEH>59K<I9
M<??]KE4^<N7#(CN0]@I]NLO+]+K] BBX3(V$@=<&8DRWA32";-8/,X&J#BPD
M;OPQ7,,X2W38HPAG7CC.'_6!(<-';O#,XVB^R.@CB\!+ ?)SVG(BXEL?I-/8
M6X \"_S45ZQ(6WAQ"I"-IM-$I+CQ[4P. %P_I+UZR$$-EI5#,R'O0\B@@.9)
M[)N2UZ_WV 9#E"3\=I B>L,_ W;7I28^O3,+>ZW? %\(\04_UA/0TP(]&7N!
M,/ G8&ICH-X;6.Q.Q$+SYW,@[]@'YJ+$(S"T+$@3U#@4!P<51/+%G/J6^.(D
MI@6!(H,(/JHG,R\6G6LB4^0(<#;Z2GY.I81,LK&H0(%@L@ BCO!9V$\"#Z-M
MU-7_D&QNG-(&<Q910 TV'@N4\_!_ N**L*E$LFG8J*?#,5 E1Y40GDW1T0Z/
MPIXSY/4$6E2)$R'P'6V:I5DLF%WLR2[R1-FM";+,,_;F&3</P[4B_!-8P9_Z
M8R]$P;HD)5'+HF$;+TIYN:IG/:AK:X6BU2L5K?TT?="T2E61R'H_':=V3&U)
MX\%C4EK<BS6ZSP'JY#I[YJ&W-3HD(_L>R%Y5O;6MJK>>>( YH$42ME1E#+SD
M^1.29;GP0E&2+191G*)0F$YU)6BF(DGD/T\%?(EDAZ!7T>@&&9@+)2^;^&E7
M_T$D"S\5=/OY-@V0HOJU"'R0)@]A<2[/E+""I29^,O874N+3"P@Q^/.=G\[H
M:U%X$^$N"M5[Z9/C*$E)5X\CN63%YIH"=?@B'-\S$NXIR(I\T,UYH"S&]A9C
M\4-07;%@AS5^CBW\*_S<_C8/DZ4]DMC:P_[7E^Q_.):&B34OUCD"]I=2%;?!
M7F^[7:U4L"7W(]L_WWAIZ._D-X,O2 >!9(C :$'13VNVO[+N?5#)X4O2WP L
M//61J87 EC6EE4OC@!G8G@SLWQ& D%"JM."89^T)QW=H.4IC6 -;.#<222"3
MV ?RR.*81#<8ODFB+T$<+>B:5HI8CZSG0,Y%C!/I%;UU"5(K6;K2IP^\PZDO
M9*UZT7=D)NO782K<DPK?DY\%6=G4\V/]%J.7%,?QYPOT3-S I2/'3.AZI--!
M%W]E?GK/Q+HGN$& Q6*,(>"))OU;^B%P5R0[6B;9 Y0-;0LI*9+M5WS5](-S
ML/Q_,B2[-4? Y1R!:H[ B',$VI4C $+EDT@U5#980C2FSH4BE?H<"@-S5:UR
M#[4\-P@#TNN>NQ6]D'X8'.!T?&+"H&$KZJ?_[_>??OCIR_]I[S[]H+]_]^M/
M7][]6__MP^=??O_M_8?/3('[@_2-__9'<FB^CT 2Q:'^'M.;)J6-ZK]EL![@
M6Y..\GLMB;)X+(AS!3YHM!/4:6?>K=!G?I)&,18O851(B% ?>\E,N:O1[4W&
M*_*8PH"E"#!\_#I+?'3*$%^9^J'*_?"0KZA4CKN9/Y[)A92K'?1P?/<NBO_$
MA\?>PL>H:RC$!)XOW=3E5Z0K7SU'SC/8/:KF,>KFL5+90:N'PP([A"_XT23I
MZN_HN&O<6O3!?V6A4#_WI$Y.S'[F320 Y*+P!UP$3 5:!'_\O?NYJ_^ PW9B
MP%(_O/K[WX:6U7O]^^<?WM,?S=<O24)4E79BW'8U?:?&@>5>B=_OY: KM@P8
MZHW'V3R3H8J)0!\_)0=ZBT4<??4QF \7_-RJI1EY*_>@WD1)B,_VRF=1^A%
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MKK+$U9JX53QSN291I.8%I ZJ'"Z02M*D4B"_B[( -- L1H%!]14A<*%[E,Y
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MRYS& H252B6L]K)^30(-7E[S]N16%HA$5.@4^%A!&$VUVJB(-6=8FE0AIW_
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MGIQZD<H1D58.$C=3;S(!_L*O\ICR<OUXR,B[A+;:\G/#!JK"7'V7KL(^YF'
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M;->3V;"[1>91*T3"MQ_I:1P'V"/ZL#Z-ET['NUO.HMU,G9?L->P6U%"$N&]
M\-&-[JQ68(1] Q7(HT$%%:BCZW7H6LMA8$_AU56NKDBSZ\\,LT"FLFX/9$W^
M](_A>K2*J#.UGCN$,$5F7!]8];2KP.TJ<+>F9K2] +>KO[WU7CKEMUWU[=96
MTG35MUWU[9K[TE7?=M6WVWU874UEMRG=IFS<ICR5[.QZM2T;]5I[)B_D2I"A
M?X+*.R?;NBMHO-_Z6YT<W>UK5W^[X=OJ)!YW];>WESH+Y&NK %HARMO5LBU(
ME3_<>QD<[;_J2@PWZUCV]U\'KPZZ NE-.Y:#XV#_<'T@D.Y8'O18CEZ\#@Y>
M?.]C65WZ;KS-MZBP2<ION_JS&^@Q.'IY'+RZ!1)35\KY* <$-N7QB_W@\'"_
M.Z$-/:'@$%2@_?WN"FWH ;T,]O:/@^/]1]-1N^+:!\C2XK[WN@6[]\$F\W>-
M[V^7(2T5!5ZCID+ZF%&O=%/J,70[>'.O2-."4!+4AA5F'^M2@_4J-Z5VM!\F
MW"MII%1)Y24P-C8^.=A[<]+R''VU_Z9+=USGY,T5JM7#Y+5&(-3(>*XSIQ!,
MQ 02VJ3421YCAF/F5[HHE IA.*&6"V7:JTBE92AWX]+IEDX#^[;6IX$4[T35
M0-4S9FL4M;1]9HXYF+FT("I'BW+->5]:.MZW]TQ9,;U3&CZ'ICF7N4)S*YF9
M*Q&64NL#ITE=?J002?JTX&AIG'!>\^OCX/#@12-5N67NGC/W-;-:N7O[G9?@
M-98@4^=E'+YX$>R!=5)?1W?7UQ::9UA0HKPR_-8)R]NQ3&SHGI9>3!OITT;Z
M;L*];L0LE2=#7W[)]<)^[3D4I<,XA2N!/?]RI5OV3:I\DA4:*B&,<'J*<\?E
M>2J_X<;T7HQ]\J0ZDA$A2JHG*@HN]\6.8L ARQC_<L: .3AO0BP&:F5,%]1
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MQ7V(OJ5+6#>FM,8K[-'&?_LM30A)6XQ:^)6?H0D[C0NCL:._/TE8:G$2@99
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MD6F%QIB9*@.*0 $.P9)&-Q3*PBL$J]'.ZH*@H8DSH-''2&'X!DPH%41!Z7B
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M[GXS<N?K%R]?KXO<>=.HK'E1IAL[&EV]YMG^\_E0TJ+FS('I=?/LX#G]:NW
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MX[$%C"Y5. ;ABP)DC'8VJ7^54>'(UV&=I8'[*)X660/H@K(GR2]6D7'OBG_
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MU$G28&3UBC;B[QF2HQ8>1@7,7DNBA;K!!^=XB(#&+<&=<Q#\!38'R67D8'O
M^;*QCLP!(O3[NS ?],T7?HH::2BJ)Y:7'7]RZHK^/3LI3FF,PYLE/E"#J)\
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MF^]"[Q(X4@'48WKIM:CWFPJ[E3":Y_G2'U TNF\3U1_:IU3DJJ/9NB3V W0
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M=KA-09VF.+R:MI(EKJP#'Y@-/+#AWF%4IMDL!E[DZ$7H1551<UZ(Q+3;F2W
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MM%)27E/^$>\DC2,?W7>XC6GSI7N/R.#Z.QUJCL=W^5GVKT;?RV<]X"YV 53
MN2NW_:.5)GLA_4D]FG\U]2-H'C+GWH8_-&T)7$=1%PM8@N^J#MJ=; EC\"K
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M-9+,&V"5B',\VZZ9AK3 2*MW5\'QZD('0*]AO0>&I>90V [C#UAW: H28WU
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M1A.X ?J7L,QP)H- 8@#1 AU6D>Z$:#R$*0&3WODAEZPVXS9K<0NF1?6F'VJ
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MWEG+BJ^(K $W8'YEB?DU1+,T987A@Y8[,=A4%58=A=N"(4B&6## 7## (&R
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M]F>@M+\:4]H(8> JW3<<@@%W8P,/TKS7!E-^#61DF:'5E,(.% M2&@!5>16
M?\/.!09&*ZR#Q8^E!?3K:DS]4G@I:.G81-^)?X6RBNW5*MDK8=) GD.!X$ZF
M;:@+VY<GEZ<GCT>FBNH[0(H*ZE-&R>A<SDQ+.)=DAB#Z-AJ!WW"7TL&ESMYF
MJ=WP4DNKK&"P0[N=AEH$Y*G_:%T /*NP8HF%N1)A'M4CWCH&X_+!0#!&#.3J
MFY],9')A3#@!Y9!C ?FMK_]:?3.Q+3+_,"QFINI5[&+697]^_.79^?D9W)O]
M6,\20[%OQ(H46CYZFZ&66X]U1!\Q,+:J.1X/YPGL-VA'6[2;#U*,<5S&^UK&
M)--]?G;^&!4![\%G9!@54+5=K8BB@%W0J:2;PMPQFJ7*YP1V.I\.GYT_FA>V
M^ILM$3XG3@-F_@\F2Q-K^*?>0D<R\2S#^$=7_:>D@4W*V+Y;^X&5^,$L?7Q"
M#KP@N>?@^(U]3;7(0^H1_F%M:!7;V,S'<?0-NK%S*^ ZL,.M$II@]E;!'9TX
M1[U>GL,N! XB"0Z& 9M,@XVB![?UNBSP*.3-@GOMR;/,'.0OVV96>CO>CT!^
MO0"LV[QB'JF+,';94SBH!9=H/SG'Q"HRUX%7R=YFX??W(_.#. @!O&*R[U$P
MZFZ!*"?5HJ68Y\#V$CNZE'ZCCHI<_\E)_5BO)# &-F+/K'!^Q.48^Y-=QDX*
MX0<K..C7N,',TQ#P)[6JHT!*H,]YZUB)&_"?!U-2>X,1T$]I&HED@$->A "H
MR%4E *, K"$ZO=Q(@@#P\V#YIE8JS32="#NDB693%=U_]?VV?6)E;GH<35\"
M@W>'!1G& $5^WT:08%Y/ _@E#)'@BSBYA& J2@ PML*QW\,XG8E7(.@HBFQ=
M(OU_"&.%R@"YE?$_N&JR6A_0@YI$1CPY(B,L,N+I$1GQ(9 1OY/CSRJ:6 E!
MTR2*80QW2/$5[#\.OV&8-E3!AN@!Q!R179;*FK:V%Q$J#J\J_(Q7W36GU[P*
MW\C18-3G#"G$,%&DZ%FJV<-&7!3F*:([ #(8$OI\#L3!.C04L9E-!O4:J-+P
MI"E7U7;E-BGRT9IH>$Y@_M7+^%6#)%8ADXX,AYH:9]B"H!,&[9,>NA$+,1(P
MX1!=:8 < .WB-:E9 S2,89S=S,_T%FXU[X;D6URO-VHW]X]W./D6U%T/\!UP
M/1O-UOKRY]\5MO:!Q_9LZ"%*R.Q 2D@W30F)O>EN2^Q8Q(-#I/88_E6C\&;T
MO&"5,*(]E)3X.*0_#OBMU4^ ^-P]X?M_IX^[,$B3PN)$<!47HH.DKUU5NQ G
MKC84))8FM!;";U/&6>"#LQL3+#,M[-&>BX-(ECQ@RS;R0,X 755(K\OVE[11
MDZ?D3(M-Q>4GF^:**ELQ2&Y^XLB+Y><[S5,GR!]=]29<Z6WK8NE>U\VMUP]7
M$(+ETM.Z])J1$I7-;1T3EGY^]M5?0.-\=?;E7W!C!_3\I>T8?7J0KV")/RT$
MZ9"IN8]=^?O%WT<=<XJ9\V&CD077ZZH][GX!1V9+- 0(_1Y2K+:/JSRI5Z';
MM/P HZA=WX<Q58O5ROM=+6TOJO!5#J?@YPGV(]13)(/+HS<B.V#OP>X@]+SQ
M1A,WRQZW ?6N$U?5U#NY57PGTLCR[V+56/%-)N7,CT6+%)EN7XO:B12/VVEL
M:*?!'TVJ+9UC,@&PSW.H?E$8V.2);>*YH5(#39FB:H7PG]!T*9O!L.R@JMTS
M_\Z&V$01^2F%"A!+:GO@,I*R\M,D),GDJ"83#&5"(?R 1F[*UFS3KY//4L;9
M'FL_5?@HP@D,FJFQ(ZV$TWY7_][Z<XD9U$[>G";)MJG !D( QX:+1/J[T^%U
M/<M^H+AC5SIN2=WA"G" (GU813T$S52]ZR1@AE9X&@2&P9_-FFC_(S81PR!4
M\-;<TTM;9^R4(Z%@YGPL&9F'SO-2N\UFH@/;%'IF!@9P):G;#<% 6LL)RQV1
M3P>V$E7LP&?>-,OM"D*6\&;85?YN\"+5YIX&'4#\"Q11Z.9!6#)O#CP^/\T&
MXK(</FVD\:*YP/H&BZKM-C&3S7YT#!7>A'8)$F=2*$.C%,3F5YH9,.:OMJ#'
M;P%O('73D?G$"^;,6CW@@_Y%K8+%3>GC\D\_Z<LX-XY=!J/:[!J2  1QGF/_
M=6 \P4:9]9S0"Z]+_%-H-1.ZLYLMK*<T=Z"9.HC@@!WNJ3%@P]6Z_^10G[S^
M))@+AMRZMBWW3$B[+6W;%&_3TJUXAD&'JG[,.X>^34H]H^<H8KUEWOP*GLRP
MO15#;5(7<)!?8#\M_ #I--D19%-,]C%ILY/YZ1BU>!0Y</TN6*BDX,\ T8)J
M^KMT-#)<+"-N<K +V$#*@STW8+A/V'MLP;&OP*H6XF_8K[:>_Y439'V%RFBK
M<8EV1"O*+4TF4P01.TT8UT/6-(G#D.UU&%QP&'19R=Z'(Q2"VRP<D:1 [*WM
MRH$03D9,0?"6B"QH6GFT[JU=A[<;9CXP2'V]"Z\_U#*]DX,1)GK8P9#?757O
M7T >P0,6VE_]*I?2M_NP^7;L\P33+$JG#R30)/*8#YX5!R@]#5WZS;':+C?5
M&DMFW,2M<3D5VUQIMQ+<:U*$K;Z GP8P7JD9&9V(:O&.S-* SW?'63I@N'GD
M8OA#M$$>+C-.MV^< [NG:Z*AVH$$(/V'C+].Y@H_.^8*;:[PBV.N\!/.%::^
M"RBHD-4::I@UH(>F&MJ 2RZ-8(#'$_%;$IW8WV)G+YH(XU[^\[TN>4%T%B_%
MXPYQL#]_=?;D?%_H)5>]IXV:LJNVZ3I*I0!P#+$94:\I]-O]' #6!,GF\'U?
M:'LG[N?$82E]D.G$-/1,RG69)IZG.3=8I!X:I#:1K4)!,%P*ZA9;#@SLGSPQ
MO0(EV-U+W[(3J+&-TI[=*;=\_ ]-YS_)P/\?,?"E!&,JNDUYQ[!NS+^D+DP?
M6A?GJ+G./'0I$Q1?6> $@N(\E3IMB5X^?OQ4U^W:^X:AWCKZ!,E$]J4NU]]2
MB*$;RYOVK!5&]S  \.OJF^_P=TTH&PB7X/^T5$/^D)9P]&&$;D\]P)1C-0:H
MA)R&5'OTV\0-+8!+%^#+\W=;@ =L)K_ :(YZP$/^2YPE%T3%P4FC$Q-5(9Q'
M*GH-\]ER=3DQ-#+MK7?;U$5/XC_](^$T-R%"^UG>[+TB-$/DV#'EH7:\Q'@O
MEW;-&G]:<*37?D*1/J)U_'3%K3  CO6:-'.U#R11*C:63A=:HV*YTD'+H$J2
MQ!#2 (>NR.@L09\L#4+O$%4X,B'2$$O9+*7SM+C<X'^6+?V^Q4 S%//Y6]H2
M_MB+"\:_#QS0T<S._5<WRQML4'?=H^C4<">11:FI/Y!0#U112'"*X>$\.#7$
M[8914OD3U5D3ZZ="='HL;[9JUR%)=;D]#.":.BF;!C')UI$)8YUVP3C.J)9"
M.7?XR,L=3=OKJB8\48B4[8FG]&.KC5EJ8UU Q.VT-T@&@,:B#: ;*]CYV&9%
MJ>7R$!( BD>'\F0E@Q-!EE9A>:84)<.$)@1/(/H/3>M4BPB7<5W,#>_&)JY(
M'/=R"0YB2U$NEEZ(P(SQ+WO!QI= YA_P2?)SM/7*T*6VLLPU8#"N!$K<+[3V
MY_+F%KAN?ISOO$K993]KMS<OJ#]C,_OG1&=.:38+/R$[:,M\N_QL%Y[-)!3(
M$< L,Y(C DGCQ"E($2^Y\)RPYR"YY5DH9RZ\17J%1G;#Y!#$A Z_ ?<NA1:U
MPAPZ":[\3!307SAL%[RQQIGA5/:^@G3)L\UC*RUHJ!'Z@(%9 =)]P%=?D_(B
M>EZ&Q^?<ZA3-*4D/FN%9]'R<!,D:DQ\)30?0O5VMJ?'PY<YQ__:ALOP!$@ON
MXCF?,Z$QI@6ULCP,*^4/DC8-"!KW9B#C*LDM#(#5_BP7:H6@MAOC:D3)PIH)
M?V9Y3P6^&6F9NJI5E:TJ2)Y&119$<:S\U,[P4\>)HOVLDICGJ6Y."<A*U)4B
MPDQ8I@?VD!("\N4EZ7CO5<X#&3B6O NSQH104ML, K=Q>GJ#BEC*]>PVDZJ>
MI\'X3AP(\N?8*ASJOQS8/H9D7SK0OEP6,QK?KV:BTG:Q=A(C<7(3G]MG4'O+
MEX:S,]<E*VZ::LZU'6[>;"\Y>>!_7Y05T%7C'H KELN GC&]=^\V"&\7FK5
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M2!/O>89WZYM9%:72Z#SHZWYZ<G_8PFEOD.QNXDM/="?XOPOTKKP)K>Q1/*L
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MY@M$X/R&A2S]:ZQ\C,"+8J.1[87[=&@'2# (S)WACQDYN$A)0ZIT:-OW[WJ
MIA S\X9(@M#@EQG58%VJHW=)"IN29 H7U<U7X1RC,^[MAJY2A2N3N8F]=#2^
MJ-Y)_R8QA"*$*S%2,KLN61^8'R*DK]/3,HF3:".IVU)@6D :Q#XLW+#M3,,/
M#9*;X+-7P:AQ;[$D5_&TVJO=8$/=08@C2(YS-H=*4[WD5N4-QBVQ<$]@L\#2
MSTUVK*W:]V3ZY+' 9<>5FL)^G]-Q[]_F1\YX('K4IFV6N;X<_T!1#SOAB"J
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M&+%L%9*B)9Z7IRYENDO*",=&R01/,+T%= Z0/A,YMD<K<Z6%"-5&T'A7&L5
M_295/GN5\O0<PI8SAB1%>"-AD&HC+JA$RB%(@?4K;&UN.X"D8$[L:@O?"QLG
M-"</Y!E%VU;:0=S$V)'TFH)I7%M+A>%%] U1I9/D6G1TL%4Y<YY23.)ZH;&:
M<QEL]%QH4@QU&#LL!\<J"G*5,9:+:7(BP &F$:(J\W^LRXT<LE+30RV#+[=<
ME!#$I!OI8UBUPBT(VEWL<RD3!;CBK@3^.>T2+^6_9O@Y,_O@9VGW$3M7: X
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M['JB+BCX.IWD&8M>ISB5;VEJOI)<@;I\A!I!4X<<]3.B;4Z#)9@0Q.O4D"+
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MZ663)'14EG6%5\5Z)"T-?ZHCN^2_3IY-Y*P.LB71CXJZCR/7"-2)SAR&""G
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M]\/M2._3!#<[]*(?1O:1&'L5R@5UI+ R:2.$D*FMH"M: AHZ7(TGV*9<?(!
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M-31.MA%2]IXX2Z+ 4ECZF#KC^#Y?MF1^&&$+ZG#*VY@.B?FZ0:-DZ7D=<2V
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MGLZ'JU5J>[NYGQ^D?KYN[6MYJYAN]*Z,8$O9F$IFNNI,"N=-!Y.=<>X4BY;
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MM^1N9#';]]"#2ET*\#XJN8'2LH!/(4AYJ>0B9'YLIQH%TS6K,!&DW36<J ;
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M6%&!,>!R:012;Q/UP?;('A5#VXX539,Z+B=3M7S25U:D\3"8K!WI<8JY/?T
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M+VPOHFO 9 /4DBKH,H+EP+M@3:Y_ X*"OI15H04CJQ)MWD-/B.^PRA0&H$(
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M+[*8KQEB?H1_\7OM_8_6]^KO)_'&6Q+RB':6:S"KI;O )BR)\3F(L6X0(^8
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M4*=GZ?*[^I;X:YP&XD\U$<RNQ^=AT/;ZA$+W.+@8W(>_77P^CW_,Q6/\'!9
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ML]'XQZFL(#U(FUH#0PVEQY+6F@;U4!">-[]*93Q;P#X;GST$1<HJ\3C%7!L
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ME&$*(TS&@28(#0U]HF&!&;7BE $D"EQB7I@#N6"2'X^BP$L]?\\K=EA])P!
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M^]7._\Z%U<Y)K6I-^@VC[615ZPWW=!>,CW9I(>QHTQ!42/,@RU&.0\$3/#3
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MQ]+C7$X>3-(J:/: \PRU#T=LB5[#'("Y6%<NZ]/F3>EG09?#H6SJQ*/@O$G
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M+KQ-)0 -*'<XBSFD+@<>!MXDG(>:7(I!KZVC83&?4\'OT',""MS78(^<OT>
MWX.Y.3U"?\Z./(88I6R#$5\-R="6"'EN0<&KJ9'6)BS]PRP?/'L+G5'P;;CM
M W^;)4H,B%KW0)L/<.')*_37@"A,\7J1@GU<'DH>4&Z??^'"[P>L[P-HZ8W!
M-.R!:8A?-:@183EY<S%03[>8.?*:A_4WX1"G+]&(@K\7+CUC18/07P(3_BC
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MUA[.;CKTG%KE*5H6K!-C^S(^_;/\]][CS=*)9'KU7#W[!)Q @G9),00[YB@
M2U[H;]PT^=FAUB\SY*@X@@^/,4>^!QGY]$$Z^R>=B(MT.+VP*AV(1:X48W;=
M-B_=:2E484 P#(Z 01;K)R)=>A,D:ABEIZBR(5*@QUOI!^>_ZI"O\QQ.O:YG
MS1T=XW;X@G]!MGZ0]OL@[:B+M+TTHYWMH?IVP%)*FL[I XP-62)OBCG $E'J
M0H,;PU-Q8"3@Z$'(,PVX\FW!:_4^QF3UL296S 1MDA]9&2*PO@QF6;%N"BMS
M-"#-KJ;\&1+A@+J&IX-4@2M8S"YB,9OX&V8"M> -ALF;R!P(?#W1D7V;F+4%
MC3K=/<I-BM$<]B XT20,90'1P(.J)F8 B38BZZ6F=FX3:@CXN!O(Z%+0.X6<
M*F#6;@#T,C%Y7QYD@$#<.&? 3P?XRP1;%@-4SBMY#P@0DT$H.?$(C]>KG!2G
M8 3B"1DY2+RPV44.+(D8$&_N'.8,*R<BL;GA8V0L]/P:NJ9#38O@:"Z/3;M&
MDZWYJ/JT^Z;'M.93)?*\59S+OPL;KD\+)/SS33,?KA+-3]\KI(E)*&?FD]@T
M*][@/7BRE->*^DC(YU&BB3*6O\I4+ZWZ[$SU <*@T8M0$E[70<:KV&40GUG:
M.9(*??DF%7K8J&1ONF0?0VUA?3-GERV:04</6-7,J >P=D$/\ )'D 5LTA'F
MG*VI$8K!8]G,%F)/-WF^U<6U=M$BN'S,*N,?I]*"]" W*_&II(;28YEQ38.R
M*PC:FU\#Y9FS\6%&4 ZM$H]3S#4<\'I]K(:PBS9=]2Q44KG@+(P.@5YCU*"@
M+JTW.,^Q.JS92E'%HQ$/GYT%#*VZJ2LK:_& <"Z6S PXR4SI7LB*Z\3DO8.J
M0@4I-PU92INQ%:,HI^O0;O4(>M9]8_3>S@Q;!PJRL$J ]X38"4;"2^M<HU"6
MU=,?0&#O78#/3_=@!&+SI\-NBT9[B/E$']^N3Y7?3YU(:?2SU6[N<:Y'%% 7
M"O_+IWOP?PDS/KY;$J7@B(=3GQCY:6X\2;8^30XG\<E]HYD?.&J/\G=?E2<0
MM->H%V%=59F[ZG&+C:A,L2OO^!D#-O'8Y7=BF-%IZFBS-)G5NJQS0<J--BK>
MO<J/YE6!,PG!T@%!/NB-_BT IKJ"5F2'Z!U#[E-' ,2SS'N 6=D&J[^F)OY7
MJ33W.)3F@@\$9Z9(L0KTT7<A!G6A358YQ7P-D[45B-T$XMFAV7TD4^<:R^>X
MJ<G&9$!XES!'QNE2GQ5G36K(MH6[P[P_K,F G@,C"'X,#*+O8]P8?HE9VZX^
M#K")53J8S5 [HP^-IM.;0%AZ&L])A?R)%:MLEH-WPRRP"&;8[X135%@(!&<$
M8",:1%Z@C-O*UF=+N7NGZW_<U9VJ).(QF,/*O-MZ%8KRZ+=8W23VB%@G,3E-
M<P3QI\RAR#T)1L073C3"-GD8>B*4K&%+G5BVQA(#=IT3EJ=AQY=&YEGJ?.G@
M"8H'.#=9A04S=!$0 ,AEPBM\])5,!,0X\P<LC-A8@GDL^%Q*%YP4J)PC4 BA
MXE-Z!/9(T(L(L@M,4:NM0(:Q=.; #/ >/I9&8 D2U_@?1PZZNA+.%SW I@Q"
M,K-EL;>7Z1$JQ-L*)L>PT(0!EDE$:%Y :"OF*IAB5>FR#W!CG3\<\:]K,-G"
M&4B)KT)>!7ZRYA"1I@PC'&'D#O15:&C4$PW7<C?9MOH9,2\,D5PP!I#'3."E
M7K^W:W9JUJEDU=1MFEL!"N<*(!JH$R K[),$%!,C:+1)#=YU(G<,XOAR_(:,
M4K$2!Q#, SUL(I+S>7AL8]CJD,&J^I9,?3I^&^;-;&AP=;]5A\5.2E82'R4K
MKI*5U$?)RKLO69DK2+6F(&4=T;/:CQ1K5OP]H#Z=AOI**BG_&G;W4K3"7<G8
MBA&15 3U.GTU,E3B:JSQR9G>+QS_U#W+=9H<->E6UH0)L[S.,1A8/7-_?JZ^
MQ,U;S^G_7YASQ'H86 =.QE(2J"/*JHQ]UWRG  S8"O G\1_9GQ<K9-$6IGJZ
M(\%)@M**_01!]ZH!^^?X'##%(;$Z!ET&8VJIKP0]EO14\'#[SJ[U!>(KC:;U
MRNJP(16TI@,GY^?"F+#%1Y'Y82X6'88YK?DW&181$.E.;ICXPJ\+'VN7&//O
M6.?X*I5GQC7.PIL9M5Z\$,">L@;A(3=>2CO6*?F2OOE-^JQ\8:#CO6?0(\!.
M1*R4##;+L(X2?FCHH>#C*/B8"TXT"/<@^R'^G3X1S!<(A_*2*V?Z/ LCLP(I
M:"W@>45Q<%M%. ] B-W;@LN_]/3T^')[P$?)>'\\**#<!@><W[:'K.-;@ ]R
MAQ!.28%@XY!-Z9$7D2&.-L5;BW<0>=-U?IP4,-"IW05A;GN$S*)+"(_T0K1-
M+&<KZW",>*<#WAM.;&'%WXR*+<=\'IA@M\_MD0@Y??H9ZXE9\8'U?C_4FEOV
M% [3O\TI1N&=F3?%K->M1^=0J% Q)GRB@,+W'C,U]>GS\Y_Q\RA\^7S=LC=2
M9+RON&@CA7MF@?=M/BVQ+*R_T:NQ<]=7'=MM<8 ]XFMY1<B]NN+3]W@H% RQ
M_Q8NKA 9Q=8%PLT<4=R7)[R2@>6)Z9& WSPP[T3(H:*_@'D,UJO 5N"RG1J4
M=/%7YOZI0&\V?N5D_2'Z(V93 7 .;T%@F995&TG\76:OE!#=:EE,?#4U:&1L
M9YXX= *S72FVC,6D/DY[FF-_<3H/Z[6"HBEK6\P>,%QY;JO3X>_[W,3!,+Y8
MPC>OQ*U]1L^E,MMA+;[U\IDP;)]9B#2G!4G0H'P\F"G.U#2_2AE6X@S.A;!B
MUT.HNY94L4_;H@#C/)Q(,'@BM$Y9+"4H[2Y1[= \+B\QG-^)IY,LTZ )T455
MY4]GJQEP&H<"K;$0NH%.=W-OI<,L;.%9'S=;/[?VFS<KA?/[_/E2./\G\RRW
MFZF46[A;>NDFVP.=86%GX^):OBU/MNY1\C P ^M#ES /3@ZS^",+0QRER[D6
M.4]&T34XI>@_X@I?EB[$G@I[% ^KWVL+2\*83/=\GVMYG.MC3$ Y_NL?B(3R
M=T.YK(+A]P:?*"#V1,+<:?!?X1SV)UW?][)&V/>=3%]["&Y BS=EVE#C$66^
M,=%]?JNSUO/YUDWP6/0=GQM?I!K1I!SP)62U_H.B^ OWL-C6+RBS]  +S.'$
M+,J87HT^*A+Z@C.0A9[1 Q?_?LBU#[EV4G(M<V"YEO$GUS([DFO+9<W&\B7C
MEB^0A/X<9K+%$2T'*;?>=[ ].C>L#)TP;B_FJ=$ZF$#0>G6\/3GKE?IY1GV:
MBE=SM[%?W=;3/JNWXBM"[I'Z5+X-3=6K7.9'+_+I.T-_EBFY=Q1KGUUP8>]3
M#=C;8*E^.<9BT^MQ)*X]5R8W9NJD%IM&TX=<;'K#_;0%4YA=LA4;M#0$%5;U
M4BD50 D%@43QH:5%BX:#KD(@KEEFT1K>+-I$T1I.8[2)(;AN&@.@BR%6I\D&
M%0D4:3Z#$%8,HM:Y&5?:=\W!6/8DDOW'F9!&PFF'6E9&++P"%C&_ <=M=A*[
MB 78>V!:JR07)=8"/+$6E'!X?']H-+L0&F ]Y/29<TR?F@U#F0RN&.GQ9O6=
M4,)5\_E!CMZHHZI#"677<7T%I+Q.NTPV^,1V(I*,16+QZ S6-PLNNL)4OJ)4
M6&\)[?QV&-X')GU$E5&$.FQNYQ?VPNN9:>CZQY7V\ZW2]L@K]-?#M9_[[)/?
M_08HYQ(,2UB=E5U!:JYI*'TV/8X0''H&S0SVC(<)3!;%(//?-=@L-F_:VAMA
M\R,HIO%ERB[Z3GWZ,M9[H<=RYW:ZGSE(COF:6&&^INK3Z'V\,WAYC:<>D]1\
M=5;?LE/OQ80]P5EG!6OII%5<ZS4\WVWV"!.XQ"XFF"X_8E7U36MI(LO"N[DH
MR!>!6P%[+-M=,L_^:^#2Z?14K#I2]Y%:"MMQPBN_)WQKBHU3?C!AI@LV']DM
M7LXJ2!RHZ_1X68E%#Z!\7<"5 E^$<_7IGU9$C=\W]9L?ZE%F?]$3+JV73'[4
M2[KJ)=,?]9*^ZB5WU$@E/.&B+?<4=?)MU3/PLR;UP=DK'6+GHGK'X0%&=+L\
M+U52CCZBHJ5.G=U/EJJIY,NE2BU0NI(*Q5R^G*?_4ZQ)E?QUH5K+5_(YJ?QP
M>5>@3D@V6WHHU@K%:^FJ4+EG&FI7$#A9[*P8ZN$I'ZUP,36TKR+T:C46,ZT*
M:5ZLNKK485$4E+39'4-Z^Q0.;#F?@055G:=PQMW8+^N?!+FI9&V!MEJ'-51.
M$,0*.'/LJK;JWH4YM\E1MP62)R9\2?TGPE?PL?W9<YU)@:8 ,ZDAJVB5F5U"
M6)>D2QPLHL]%5<=>=5VS9<8XGCQ@1=TL8Y$'W*Q!Z:Y#"AN/7,U408FM#L2"
M#[&6PQHM *V@366P?.%V ,?1,,LU$N)CTC\7K,9Y2*@8V"GD<61G 1,[MH89
MUL^0<+06FM/?62L.=(D7P7+(B)<,>!G$3@4P-=ZADXHO00_R:;@"C#SW0_%-
MXCA51>6#"575Z</GB]?-V37J]LA^=ZQU9K*\)QSL33PX%,A&E5T0M! -D@<:
M C[1X+'QRS4.1*'7ZL.&^P[1H-4/)A0TX<'.:&'W9@#868)&OKR%R-V<AX\G
M/:B(S;_UJ4R0![ UN2P;,K9B8Z5_./RO=*T#2*G<;1)#VTZZGB-\:K-]GBMY
MF$EC[%9F[C?AJ^68&\ZG?EH<AD5H;$'<D&#_L=31^7L XE^E#'0'LY4A2+P8
M! E;Z>&5QYG-:T![(T7W*Q6EA+I[UEY)YC_+K%&1#T-%7AT:?9WM%^030; B
MOL>+U/GX;+[2-<C&? :$Y5761ZP8)93:ZT9'UJQJ&6$DWL*V2]=T,.M3;)BW
M-?AE?D$JE0$PGJ058/O$4>ZQ/D\.;+8T8NB>*L:Z,2F8^]""H0PLR2;NXP)V
M<7;QS>:E[%O Q]@,VCY!%SZ@.U/-56+)V]7MID+5O[B+5FGSJ>FL;[7%:0GK
M%T'J"\*8(H@*/PNI 0&IJD+O1:D')[RS@:EMOAK-D&%L H1:!C+?!ZH/&P-G
MS,_<U85=9DM)VIE,XS1Z(TP5C3=S<_(V82+B8& ->,..6@]F8,A?I1Z=*3C6
M_C4V2L>*#[$@4H -3..K2^SE\_3*N%\$%:1B"NODMEG+=HX2D6J,2YA(A-3$
MS?-SU0N;V_N,5;Q)3MQ-BG72S%#J0W"5<\B"G+8S%>*K!/L.9[ZEL&;O-S#S
M<%6:/NL=N:<G>*HG>[@>KAD$I^&K],3W-UBCO@1CJJT8/7&1M]VWQ"=O62+7
MF2<GE6 B(W(1^MV!SRY;ZXO3M9?-E"X=-P&:[&:&<\&:&LV6G^S=W(:U%*"M
MV=A^8J.%[HU]2EP$VR90!47QXJPFMQ>FH;ODK$LSAJH]M@LFOC#YR=$E;$MG
MO7Y\DSFDW173M%H%$3IPMR.X[\?DB2=D")CN@XNI.751S 2\,.-,&^+092"C
MHAQ4D_-;3@_<0B%,K;*-53@;A&$0WP2%'U@E!UOC3%U#C(+M9<"K TQQC;N$
M3__UXU$!1;9A*Q(]I.U& ;*MCP3M![:834%]/RH887&H04\UMTV+ZI^ 2.)@
M+09QZ_>8;3*A)DU'[K!?\BL&,8&-5^3F"(Z)8],CM(&A4V4_(N)4)GN5#-J/
MD'9&3]K&R1@9WG40#CGZ)ESG95=3PAO]OLV>'N=E/C*QQ98USDBN@#UMCFU=
M]9:.ZUQ:G+4S)K;,U'16X,A?_Y<Q:$G@2;2 ;";"I4.&WB0M3/AAY (G3K'R
M5UBBNX@!+&RMY*45G!(4F7KV/,#[3!ERTQ"("L_U5:H.<?.!_6'[;FP/'$P[
MP^&*%":PCQ!LEZ!$H+ ?Y)$S/&A@[Z"<7>(-NX7]W9&I;09CM%:=P[@''7F'
M*W".+[S;-2/3VL4=Z,DMUHQMFPFN:90SK]!QRI%J!85D,<#CXR)/Q#TMTA8>
M =PRU\*]%(*<;=A&H1"X.DL&V]P>_<?\1[H>4IN@!?,/RH9.4:])V7+&#%R7
MS]% WOS-WF"0_C8P6-%Y&';(AM9Y&>K(5Q@) 9$$,<Z_S*E$:IEV]6%0RG:I
M.#K&&5@H.AQEM2S'. %:P%(A)Q5+7Z5D)!X[@WSOT@J4U$<%BEB!$@E]5*!\
M5*#LLP*%/YUM*J/H_B8-^]2D;LK0#.E1G!*QBU-R7P,K,KV[K$(Y+A1<5027
MF;M,,9N7JC?Y?,T\KV(;?UMVK*+%:"A9AU$8T\="+YJI/84K#\E/U!_NT?-.
M\"/?G$H*Z4)R06:#"L>%?;FN_MU5>WB8@/'J$GWJ*@,RWZN[>)&/54EY$?H:
M9EVP'&P7(..@PI+_&('/]N;" =26]]:>N5;=9>V[OAY@XRJ6C@@]!"VB7%S<
M44]5S>/0K#7;![KA[&AB)A/#Y\XGK^-@?^O2WN.EAV==GRM1N!=,^8,J?Y_U
M#$MGA?L+/D\)#-CL?S]%/BTU5<*.J>(ISQK?W<UFT7#POPWCG^]HXC-1L\$Q
M[2[;@>'02R@G%.IG<-MBIF'BO-BZ<EF.V+^[<_8O9K36?'>J_:VIFE-ZP]\A
MTM9>/ZW/G4:G\3D2B@4CT50P$H]_.1ZC9JK5?*VZ8T;=%QO-HC4UA]8LV[HA
M8C>Z"//37Y54.O$\&M>ZZ0UP>&0)RV\JL4N=*0+%GM&L;'8IT\$?>6?E>&:0
ME0T#JDO06:HKA3F$SN*\)V>G))ZO3XUL];78> J_9EY.E4>YKD^E_L<3QQ06
MGJ"V3(3_68H0^U->S_[/LJ^D9[["D;^BG=H/ G?0-.GNWHK[;9:<:YF+14+!
M:,RK;6Y=6*ZD<W'&<!D*GY16GFUWXL3KIFM_K&#3>40KWK]=/K<*R>9)R;%Y
M1]E3>W. V/NNMC-/-C!)5LK!=1[FBU4\:6#WK+%Q-VDD% V&HS%_K.&!FHV8
M)+1(F]>5FL@=W@S4&S!N *Z(M0OU::K6;Q2OB@^CU_BI2G]?BKZFPT:&)>K>
MY4&+3ULY,6D3-\[G]WVQ@0O+NR?_Y*;DGXA$@[&D3_)?%Y B\9^PL-Z3#W\H
MRS+N3#T&-7I#U%9!JQGT1[P8:XDEZ<B0KO[8*\!JE$C[5&6(3R4+0&#C/R%=
M#W"PTNSO6-VZYT5[T\'NQ8[?04#S6C<5"R:3B6 BDCJ$YOT0/OL2/ODY2X:9
M,"LD$I@P*':NG\9O?VZ;MR^/C5,5.SZTWKPDBGR-]RV+!L\$_[>.1;/PD>M*
M$_P:UNRKQ*<=YNTP;__T-2REG<NJQ,8#[2.I>)":[,%P*+*9K$(8K9]-^!!@
MAQ!@$4& ^8Z)*Y?U:>EWXN;7;^WWQ)#/6')]^GY7R%P6[@JU0KXJ98HYJ7J3
MJ>1O2G>Y?*7**Y-L 9;+7Q6RA=J9HCKEC>JY0'HH3-';3+:NE.>8')LF3CK2
MY(3'5>=*9XJ@J&A,-)O&D+3F\43Q$RF@WU(TDO7I,XGW7RI=N?5#V0L;>AJ>
M>\$CO_&Q@X-K*/]MXH(+\;M[S;]Q<"2:#";"7E-*]Q@:#"\54B"<:@4TGX'Z
M@0O4NVQ]F@B1[.#I5_2M$#LI:;5!V.]N@1@[W]C?(6A\8T]\'1H_J 5[E)#2
MF1NS>6_A 2XYR@R0%:@Y%>IZDVCFA>2G))X^+0MG(W\[/.]MKRU(%CQU"^VZ
MK?39\OGK2J>=BZ7DQD[WUJKW0U:=N*R:G8VOL.D+4 R 0R,Z1&NB[!*3%Z)0
MFSX42[E8]_?O['@3T__814W.E;'5SW7I,T7IE8#2&NG!+E-CPD(G5CU'!CLK
M,X.!H32&6+=<T]D$]IFZD"4486DP^--\S-6GOROIZBC5GQ3RFUB_1V)>:ZT*
M-BC#&ED^IMX<-E[X8(.^;IH*!9&MT@S2HF!E W7FII4G%D/?W\*);>N+\QTY
MW7[LMXQ,T[T.T?-2PF5\[BCP>:G=:S&_#N3&^R[L/1[_SNV:B"S&*GMXQEY8
MLEMLEM3X]<WOMW+Y9_@0V)R]S.ZQN-G6$F>/Z>I%IIR#G14R\^B,KT(G&\F_
M6U2&)L:/%[W?_9-3-T7ES#62JZY1<A9Q"1?IM]9\O[#/:R-Z8M#<.2VEMEM6
MLL%%!'CZ7]23VFYU;R2UA.*]66"&$[PWL^$J%0');'F2UP*.)616L;^_;*_*
MEHPSFK1[[7Y?2[=3:Q)N4/P'VS!B[R)9DP 6W'3W1+V3E<'AY&+:.)!1NQ9T
M5QNFN]=$FQ>KKELV<XX)YN-UW1TCS[4BR]PUGV[#@U=CJH5/U;7QA:^JQYAF
M=MTSQ6'.W>? 9CTC,CVZ=Y8@&9Q8)=7$/PO/T_KTUX^G4:E?Z(X*T9.*:LS#
MR+XV5_<>/NGE0B@=QB7M##K)>%Z[;MX[+JEP[#6W*/J[P<[U17HS:W/W_J?[
M_OMU/^]SC\^OF52B%'M9C+DYAVL]#.[=YTQO9X#'5WF<=F#(A^>Y"I&.X]G2
M=HA'-7E#_K1&J5\1924>%WF;Z15'%YW-79]?_J,8-T\W/VY[\LKSK^&M+L;
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MA$!1(Q0/^HC_M;8 *18@GB9<XOK)I6J<Z'(#<6I9EJNEWU"QWM(1N< "UY^
MG5]R+K"H:S2&] 7%&#U%BY6+(3Y:-&K"DC0$56&Y&+)66BK-%=>QJ3QYV23G
M4C_Z2)C7Z=@.D(AI?%8WD@Q15>JI:YI!EXA=@J'0'5-97B@@[8@1EX4?L2,N
MC%MNH&JH"3.51B/0I[L][+UH@[B>K.!3HS,D>2GOU>&]GR;FZND[H)B[3>4U
MMMN&8@CV5BP7P6[77(J1,--&XQ"Y;I74^L Q7*7U.4@5[T^%5'R*E^9#9<$0
M"UZ U0+1J5HX071)52/9]0Z)DZ@*JS(99"1Q 1\ L3AT&SN08R/%H;!( "5L
MJ.$$,4(RG9./X/RI?0S2SF&LK[9.O;;;//020RT$<<)J+9NP^FZ I6,15?6=
MC <6\X7R9H$=M(BI&O*B0QYZO'.YUL#*!N+29?/=1W2Q''*#%WJQ-130%RA;
M,^*!(X'455<_*OD=^CZ6#W%&51,"E:&E:'JHK6%R;1"+(E^"7$02'$!B%+J^
M.X@=)O%SNQF4(A](+\R-Z:U^8GICF-[:)Z9WU9R"WX>/_G#_\.CDU[MC>HO-
ML1$>G;L_G--;;]V;4[\1IK?>'.^U7//'8#>_5USS)7@72.]><USHW_ZH[CV=
MW]XY:[XB;P/IK37'Q9]']R?E_FWX]*HE6.94'C3'-T<W-U;!VQEX*Q3)_SI(
M+U.>![O/+[6C]L_KN\XGI'?53@G4&_L&-*]46B.+](H("3CHB8*O''W&=I^L
M("2JH<FPHS^!'XP:"^14^B1$$"MEP-2:9TXG6P09Q&NG.MV2I ,=:L&1SFSS
M)VLCIV'X5#6QL3X\QZ?&UA.#,.Q_,2#QW&,/?8K*J4/@+T?&.<E')1"TT+V,
M6== )]/V+>Y(>=@@+<V/T9+Y-$Q#?""S>ZTEOQ%H-O,R,00(Q9+4CPPJR*GI
M,6].I_C<;='(PI[@842. UFC/XOOT43\<9)\21-<C(*W)I5^4= .<$;#!#/2
MF>$RBQ0]7XH0T'A0[^(QM#ILGF$PUSBU]'%RDJA/.5S-@.][MH.]3C+C*0;2
M62!)2J1S!;@$L_.D'IA8NA9\E(FS"/NA;(K0 )&+\1;$O$4$4[6"^H7W 6(.
M/SU<I9M+N1&H_QI1>T#T) "T%H"V4IAL4KZ.(@Y%S7WLWA"C T/-KT6!"^C4
M9,M*]SX$94*(CJL4/G1S*2V.=-,;MD*E>]%$F"B*N<@S@C&76,1(H[@94D5Q
M,E@>_DV+@:>>=UX:@Q&DA.*039&4CAP69U/AFR<76),L9LF9R+.>>7U_C;-=
M*>LN10:I;^?2"P)@'Q&MZ$1\(_XUE5V.KG5X"\1,\$:..E %(D_-+F8/U2JG
MF"-R(A,.(/T9%D/K(_R/JN,CTX-M.)-TGE% EEP1@AM](*W%\T3GPS[[4END
MS/@_5UNFPDP@8P (47]HQ=-=VZ4OR3J:*%(=14HOL2F7%=RR(>TX5&(5F>ZU
M>(G07 ]HCD?;!^V]W:YU;ML?PBDJ;B4JHVK%_>:X>NE5G<[]P<G!]I=O-W=G
M9XWK7^ PW1P?GA\?'.\VSF_UQN[NQ=WY[?'YH7[)7/S=X_T;*0H?"1OX=R2T
MDI30";Y@%*X1_7>&A)95),1\#VB.;_]<G=HE[Z%TL/9N>T(RJX7F^-'M789G
MM^67QX<OWW#*D/*\!"XS-^3(U \HA&MM[&$%;9L[$MS(F'$-H@D(^7EHY\7,
M-<K])KNL&E'2:L",]K8] -)\2@DB/WH;_%U+LO<!&:EE:@@+0R.R@8?6D!FN
MNZV;+?VPT;B4>2YJ2!<G_O&'CB5\$M'.49(MWNSO?J#K=JWE9I?L%RW6EI/Z
M'U,X020<*64"5:""F9=ON.&Z4+8P6]ZF29F4)TW*4[K@14(+ICOPEB-?JM<'
M9M*D&(&?G2I(\69\2=I";@*B9:VL !'^^4H"%$(LQB.9WNH"8M\!.W L U 0
M\YJE1CK8(@I$0R!A0#S*:)&>&7Z[1Y\KY@F4@53IUH :3HC(6CI^@Z8"/+&6
M*9F/O8'M<J>C+SU^=/FTV1.0!C4SXA6#.B<RP%1"0BE@GH'S@?>1L#SJ%Z3K
M$/,4H6>AK\D7"FU 1GH0-8[ )?I(X:SU,,BWOZ0BVO<Y ]JA[SV'/7Y4IIL\
M^Q$4?YYO-\</1[=6Z_?AK_9!^:/9.WO-<=TPN\_/1Y7NN/KEFYBP1C,6NN73
MXGG+!(.-2!]N8%B"LJ]+.R"BJY*-+H9UNR',#U>C4%<GC(P8>6\.OM;'YO)1
MZ>_)L#]@ZL@/M8NA'T4T;N!7PP%^#YY6S!>*L2K DXN=&_BC0K^(9 B8* GA
M1C',)W:+ 08 PG <'&B]2$Y8U/]/!E-T0X3L>CXVC8WU9J ^H[ZE]F: WA#(
MPL=Y5FEM;$OY-%Q>Z4N8(% 5'7:00)5##HE55AF**<EE1Q&LBK.3ZP:[LP/>
M<#O95B*V+^5\66Z+X;<,MLR;%R^.-:*M$<2XT6VMDOMJ0"OC(QZ1R*D10<:&
MQ*P'>C<O0**+@ZT*+:@D?WT9*;<<[55R*^@>BL\ <E)$H\B4>8M:&&EL8VW$
MWV(-)79?21T2MB-*:W3%0ZI=^+4+45:CW1N&LMZ#,@;,U'H"T7!DPZB/%%6?
M&U2U_0FJBH&JZI^@JI6"JJKL;G\\#O*CFVO[Z%5M0I>!;U2:8Z]S<&8WVH6;
MX_]1HL2=YOC@\-=%]^CDYFYOA=':CXNJVFZ.?U=?OA\?'1C??ZV]5+P)JFJ_
M.1X/G_P=^_+ V'E5@'1)K&-P_=P-]E_"=N]AW=T5D4"8/T&P CP5\XE^_QZ/
M#_+.U=!YE4<W;8/6VCLYH)9T.2UFQQ;RQ:^M#:#0X-:L\ 2X01E,L;S1SB1B
M[BS;VF7#\Z#!'+,Q8T&:*):F!;+R@-+/ UX[%;WH*_4X"G(\@H;_I/H++T1^
M R/A'$%H#1I9D>D:!6A,J^U@Q(\XV<'(A=X-F'[5"($ +1<"-)>5%B#T.$NV
M,,.EVA?UJ^R%&^BI3',QYE@*72[%EG:K[@4/. F?2#B0B$*P'-[9SQM LQ$9
MA)(-:K%JC)?26*+GV<3P4APUZ%<#G9Z8L["9+04(/!.]27 P-C6M%>-AKK#M
MLVE[;8EWB+=T<H@='_8R/@UZ))^'-CD/JN;H6X@(P&9KT*#4D,N(K^9,BM'*
M<\\67LV<YXZ%<!'ND1)F"1,%&-LDGQ2;#"6$,J?B6- 7A[W(</1QHPP3II8B
M"G*X'/* N+O)4Y#U?7F 8&EM:LJ+06#\JL^<N\PJOMD15,[2G^*BBQ;$@-RP
M;/B[EKT"V AHRI_I4; E'H;:N0 , P'*FB+-L(EV&U 1@+_LBT9X6LMJ&\-
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M;_A!5R;]:6R\99)7**L  28]N]MS!% _5B@V&/I,4P51TS.FE6PV7J9DF,J
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MIX7$ @//)2=<]9\Q@XQOM@.M"]7M+O$*\&%DD\9.CHQ_ BK7@+ V?(;R(M$
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M[['3W>W1%R<A /CKN7$ "+*8F,%R*(O_DITOKGKG>:QM5?OQD2:]\^Y"^->
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M)XOY6.S39),&D2VJ2?^37"A7];"$$Y=;V*D*AJT #8U0,7;9J(0?S7WN7-(
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MBKP-FK_>')^>7(6[WOY5P7AX[V-9;8[WNF%X<?5KY^C7JQHSO&> 96H 906
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MGP9W.I]-(2JC#%OZ40P!I271-A.MTA*@*$#@8+^"#C9Z #P3/9=Y3%D5ANC
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MUQQRTFOH2<*)>MG(O;;-<TT^A-)$UTDMUKD:7+A&&QN^8&0??-X>)$1U?^C
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MPU<LLI3<AU<<V!R/%O)]XF$E>J+(?K]&'^#?4# PSH.DVL/08]O//-0ND2M
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MFV#P(ABP$-2S(%JL@3YX-D;"FV5K0+NYS,PWDE7*F5'K+,8195\#2Q>VA(F
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MRHE,\67F4D3_=_YO*3\R1+O!N6)&:54J8G=%W[A;WP!MO,=NMP//W[-"2&,
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MP_]\J^G);>UQ""'^_D8P]QP/[C!G2TSQ?(Q;8$>FQJDCA6E+X^F(E(??0BJ
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MY()3A6"^(D,*CB32F+X(7R2A63A2CM$0Q^'OHL4:#$%?0<[(B.".Q %Z$#R
MI J$F:0IZ@+_!I^6)IIKP\^F-";=LDFN '\3,%CHX'1R>K8\FD*H@H@/O>2A
MJ0,DM&K*N"?)Y*(VMPA"^RX($-"6%.&4P2X*,Q!E'(HF2T1G*.'S@H.S"$>V
M!,2DW.:DZT255G^%^[/C_![:T2+5ET8X28*IR>'N#U1FZ.JXP0!BZ#K>%7H&
MYCL0;HM7>E-A .7;( :V7N%*#WV,(Y,*F'/,/83+K(<[."REBK21!/X;^EE0
MQI"\07(-L5JK'\1J)D!7=""4-5G=>6AVZ4>;\"43*?\RD0XB%(PE%(>3.D@$
M'(==A^-,>QH&3>J-&2A,+Q!.P9X(\/I.=UE5?O6>'EFNM(P0O1<C](;-F-B;
MQ[-VX_LCP&\:3P2L]J&0-\7N<CP[YS+26V:L%CTS ^;1,N1LC[B;F ZJ*:?<
M1O@0*$ZY4+"@.*M'0N$ AN&V W(,>V<!<P#58EDU/#8#7!HK[:;T4^*,-A[B
MD-O'\U.5-BRRS0=B\'P@,GNC-]49@IT&M873!QC=X@+Q(:8?&A^)0MH! 8#L
MOP6,0:Z*L0K(+ZB<K)%;A7U58(:F$V/&!UX*_+!]#63P@]VSP"LZ97!-!H/'
MC2!/PO!UTRG[0FV0#4?6&L8#&^="EGY >>Q$2T9+3EUQ\I13%[2I"9DC54PS
M=71D8/L(XMJR?H"X1O;OU$3-G-6J#P9@C0)B##R-Y?8 I(;@O; S1?FJ:O@6
M("BI>\3]($.WHCH 5([M2?17YN?-1_9(3S ..4\#!E:RLG#Z15BQ0J90(:^1
MJ8LC;LYAF3)_3WJ+H0O)"/E2<[CE --)@@13JM&JX.'FGN^GO9IB086L5ZJ\
M\4JD2IBFS%MTLGYO?7'#4K@46<R)UV*(:]QXXW U$'/#]33\0L^G&@LQOF(L
MXY2YGZK0+DTWY'V5W$1*W>X%I!L;#.3!'BGUE.<*8DYQHOW+?):^$,KASZDB
M7%#)BD3#IVZ#\H!-F8ONP649)&! =#6Y"^E*"I.=3C+#/]NF_E",%]*S,VD&
MOYC@VBQT+4,J3D + ]6B+QQL]6!;#VY8A_=MT.4K6CU:OJ6?5SZ>(A]/VT_<
M( >LGW:T,Y=OGE6:(LA@E8@(YA'V1+P1RH6,V\&37=OW8!/-E&/]^+VZ@FXZ
M<#LSO7KW/:?M<NMVT":S^/&W;<XL6T*^4/UR,)NU'DLY-LEU81MKP2K'6C!'
M+1A[K 7S50OV@7T3[_(>D'[D'>:ZZ![\R;S$1%L/Q@2I!XMOJQ'MQU'.A?Y1
M;]RUT4]GU9OJ7:W!M"\;C;62KH3[O?[@CTZ(8MNL5SAQ[MW"2>8RY2[+LMWE
M\.6FJ58N\J\#(;A5"0=7]$_EG;$ X5^U#\B4GY5%\A"_:S.X(U_)6JG#KB!*
M)R<W$#UO8.?/V>Q@2VRONWP5LV?JXX^Q.NR'\%N"P2LC)HCOH?<6X0I N&(F
M%P'AV!S+_:CU"A<%DV[^J+$EZ;^K_+VSF+E"*;WZTT9D6 R"]C;FC D9 '[H
MBQ:NV-A]+CLDYC; %O=?NXQAN"D3POO!3LP;3;SV[1T/VO7D>G:X]"JQB^OO
M#;;</U=5>9]<E'P:*7]$H0AZWSY7353W^^S\W07*@6R/3GY,A\315 ^WU->J
M/0UGZ[O267?Y,)HT'GKGC>]GA1#>693XP8 G'4][Q'8;WQ /Q6'_H.YT)-ZN
M)0*US2)P4:]DM+QZ>_T0YH(2T1WU??D^.A\&[ZX&J4]99PBQMSM@?J0JMC!+
MQ'R?_'4ZD,5)7NC^"/I>FLE>I 2HZJHLP/] Q^,9-X((>56O<:JZ0%*,$R==
M*<,VNV.NNI3*T^YRWK_1E]><G/W%)<)Z[TF!T>!BJ>A:8!8=P\!91,/6MD$=
MR92[C25[T2WYKTA7N[$4,)(;^<82(U\2ZS'T('PM1#9T+40^FTGG\L$F&B2.
M@[8S?<"A.+['@MC8+C[.* *&-BQG9$-7R>1SZ4*IZ,(9ONGK;N#L8W7O57'"
M20(M?Z4^XHI!N\K</[.WN=;][>C]?/%D18<HV4PP_XYBZKLC0Z! 4.17VGA>
M:QB(C<+KRJ?1J_%\:&'-Y-)LSJT]==2,$?#,HF6MG=@CQD/?24/[G72P=NAL
MH8@\[XJ_0]]V$-LO(^3F;NKH#E+1.E'1H*KOA\WN\F91[W&5'X6K[\F('+Y?
M\*3WK8-+D2BY\/*,T,?&L+:ON(?/Y$#(RW5,3S=DKK=%[!Q\%KV.#=T&HYC-
MI?,E-QV[UT,(]Z<-48H(#F0G_5<.W9>D4DF7<V[37;;3)8;$8E)]RL/'(!U3
M&GX"A^RV-A!=J6F9ZL?V??&VQ_^:SHM_DJGVZ='6@G7J.5ZU=K]J^>DG$KDW
MD,O$TT3D>.L*?.L*??Z[.!^Y'9K(E-(YMI(NEDMQ7L#.UBY@YLT+J_%:OWY3
MZ'54OAEFI,@'2%1O:2H;$08/7^;6+G&Q@0CCV((_&*&/CE0[P+QB@.'^];X[
MBCZ]Y.\V%KTES(77A(5T/I-)HZN<QU4L7CE)"-+;2X:W7LFW,JB=SZ-K(K<#
MG^UD<</'N)'%+2&+6\AZ\=DNI[*G@$#"KD.'@55*YJH.A7I'I%="D5YUFV]_
M(W$]&)4KB5I5%MJZPK^2%GX:&77O0*<*X]O+*VZH_7X(4:#Y$9S^*/GBIED]
M:]XT.\U&FZG>U9GV9?6A<=FZJ3<>VK2O'%-OG#=KS<Y1ER5KG4==EAA=EG'7
M931I9&FO#(OTUWPPOI3KU0>E.OR38L^QPE(IO'YDT?ZHK9*USJ.V2HRV<A3
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M!P<ERB>/[4_?FC(_F@KH=-#[N,% %0<<^JK29VC8/66$!AD2&V1X2)F,1J+
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M731]\V,ILOD5^[J6;JG)<A&-&&-'Q= !Q&RZD,^E,P6W/DEVXGS9H!(J#I7
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MYG./TS#W;82IH@4H6.( I:N9.2+$PHC$NJ)J=DPE/&BB0 V&46@TU;:RTQ=
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MC3CU9K8<AVU(:2KU7]$UAD-_DI _#8%#4DZKB>H,T0E. (0!+LHJ.+^0[M/
M!Q3HTVD\,N75R1_FG$Y$/.R4P0/RD)>,+A@&+@0'G7&\'NT<7:7-T /FW_6
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MM1Z@$-FW09>O-(=G#HAS_WC:=N(F.?#026%E^0;AT]2@4+R">81D%!'GQ85
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MR!XYWS'MW(5?  F8!GI.8B)I8-H/CJS94A\*S@U:ZL^FL:S%K']F[!=0D@(
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M+WKPJ0+7 M?+0R-_]AC0*CM;ST1BM%H$3!YB3#F_Z;G6!AS,7V^I7;R/-K$
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MSW2JD#CZ2ZH/0:UBCFC"QNG/T ?'GQ1=T^PB6H1/:!;S2BO.]QB%=!5PF[U
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MHK#A4R;S-77:#8+=!YPN[C8N$HB#XP02>E#,+D,XIQN)4!"202P\[P\EYX<
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MP%PB+"PPN4"%_"@I(B7#58^XVL)S!2#"2YW3<00'IECNKL-!@6?0L@V&3T4
M98UI?#W-(J:]3G:-!KFO9%N1GT%!M!Q$9&Z@A;0W$FV^&#:-"P5CA5"'XWX
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M-RZJM28+9K6DVL_;^LVOCY:;H7V[MH#D,:QALW1B[1L:!<G4WY[(EV8#W-#
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M)JS]1"KY'G.ZU<#/Q5_3GH'\5QJW<X4K9[MX"HL/4PA%YK8#+$D-2+AGT52
M&1X*\YY )T9:QHIKHPXRJA<P3PY<>:-OPC=8;[4+L2SL^]N?9NHOJ;% R;3
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MM5LH-:M<:RJ:;;CB7<9^N'+4HM?PPV7%8B;SZC;BWRAGE_F=5^> 2_Q!2>&
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M8&N:S-I)O;E<7LQEUA:DB> T\=[#1KQF[=S?K)C+Y<1\.8Z;".<V)\OS(M#
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M/(_: #_F,4G[3BIX)PTDQ_F_[XM'IJCVA?0%+_!$!O\0^)ZK8-"(I>G7@42
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M_DS2TV1Y-HU_5'*T#W2F^MD5N3[]>5SY7MJ:D=2=SZS)=Z;CH\;CS^[W]LE
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MRV<1VJS-W0,]0VI$RY98\P%84W'2BGUMW@YI+CJ=:J=.1%_S^YFX"<O1 CT
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MV1_,&TU=U+07+7&FJS(M#OTQ=*X?,'C_%7!UU!ME#/8G#O)E<U28$Q6Q'.#
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MET*!6FO>YSB]/J_]UI[=PG/N[N4[B%W]S9?7U=YR)3%?6%$';JP&ZJ4:\:N
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ML%+3L(,5<'@]X?X<#@>53^?@K&UP6B;H#Y"XXW=9W7\T>'OS&MN.?[>N2B:
MA+X9;.]!_U)K\9VQKSJ-/))R;TOV&/UFRYL)MGQF85,/@>Y/J,W=+W*799F'
MV[K.HQVXSO ]KG"=F\EY;#U77G2A*7:A1[,7>BB<Z:J,HU" +RZ[] 7OX[PG
MUO;?!'BR)@O ]LE3CX!4P/C3@VXYN8T QP=8"I,>V(.'0@/T_@7KHO\%$ .O
MEW(172/X,?*1S2KP7IS=U.R+UB/\-*'OLK,H)M^*I715DJ(CN/#K"_8A60*Z
M@]B@ Q8#&E*@,6-$[Q\NAAR=;67YEV,3OQ: ,\4FR>!R/<7HV2,4XSV\IA/;
MP-4PD"4*DJKZ93QP71R(@H#7:3(*&T\EM&LG#2="[^?'?#=>*%:@7EB3)E[2
M_:46'.AM9666"_/U2%Z:^C5+'<=2GF<RQ6888)0O=*:3/_:I-5 N<VIA:UY;
M>]YKF^E,I^7IQ:6L7ELWU8//E'ND:9)^(-5_UYVW TH00IM1,!"(;,Z,.@!*
M2!'X B5*,L+)*SQMDNT39]*YOPX6!?  !R^!\$&0+\15<2"UY[X;3)A)T:"L
M+^<E6\'L&#].T;+K;/:C0&65X/\37#;<UDQ1N5,9##OM$P7=\LX,E8E :R'8
MR<P%:)!R4] HH^]BRDL/D'K =6OX%'P5"S<B)-XQAK.L6H7FOQ'&U'CM^1^]
M*_1MC4HST/G9%=+;)5OA1R]5M;, X!R%4B$Y-#QMQIF<@[4SFMGGLMO)+9H7
MT$25';%%:ZQU=@'TSTR.B9A#,W12"MS/#T$TFFB6]6B@5(/C\V_RS_$S,0SR
M31 +DX+^<N]P2]5]VB547O^=8FT',#_G(R<6>%R=B&S\I"^G 00[2EL_W&!=
M@T@+1A-9V+EI^79V \,:#C_A1PMC2GB^ ._ASZ;"GO5GD;'R>T9S]!:$OJ0X
MCEM^5;XU@G/IO!36?P5E-"*R A_ E!C+_T&EG])TX8%GJ_OF>K*,/3;"\R/R
MC^Z_/*L-WD9T<MYQT@ U0G-G\+<CJN_X&)_H3<>CWS05:W;"G#-K56'98<[7
MXQOK^,)#9NE=LQ$U*+'HB%ES*/15_=&99PEBT$W@9,E4@=O5;6,)L_*/J<6$
M*X-]X@ZD"WZ!/?4@&0JF6[A-'\!.,.^$OD$(S=X3W?VE\$>6/DV,,:$C^XSM
MY.6]IMY9FB]8&" ,KPG.DJ/MHU%;?+8VUU>?$.']SO1/L99I9>]O?S]N+_WY
M85[G+'>FQ#KN38Z__#:/"UB72W<+1,BWNXO*)FIIN4I&=/K@.(=R[X!G*XO(
MBP#[%9!B9HI*%\HJ475T 8#S"JGE3XFJ"V+(&=1'JWH&+*$1_\9R@9W:A4 B
MWZQTP^$&!E8?Z,9 TOBD0W^"!HX7?01]C%6RSFY@0'3@L>,AMDU%/BP!;+K(
M>XEI>GMB>MP?.(PW515$?&A")AY9YA.6N'8WL^?4W ()X[E+1GOZ^:YM\O1B
MCAS>_$E,M#9TJ3?DZ)%2-#=_GB5N(DJPY+0Y#&":5LC'!*<W$5LU].:Y<'8P
MSC:)/*/(N;?0&RJD[UL?74]T=.Q(N@,!ZB3GUUO'%TY./KU<^#/5_^9>9'B"
M.=VFR>6IVS_(:3A$9^DZ..+ (Q6&V#X8!2$S^R!NT!'E[$SDB?1L:I0X<03^
M)CYID(&MTAGB!GE0R"-W(TW2CP#:E'<J4"5LU7*T'?:DUZX"U2Q00E3=Y"G(
M'"H^6%#ZDE1@RNX'^23AQ6!BBE:*'Y@Y>(:8HADL(\<<81R5[O3OXI'T>9#1
M<QLT<U-T[L#_$7]1A\.-F'8N";@YE:3F/\KW@L!DIR!F*&L*W#^%(H.HWO<&
ME#)^I_GO@!="/)-HC.W_M//?F4F^D?^VB9R+-,=W[03D[#X!.9" G-\G(,>:
M@)SO3(_-A^.3'\>UAY\;E9^NDX'<Z$PSW]JGPV:M6/TA[3.07]"\J&3#,Y"Y
M._I*,IYO#'KL;_.VY+7.=-2ZKQ6+1&N8PZW9%(_S-D6N,VWFNM\>LUK[:QV;
M#/!NBFR7NVA0< !3EX>CSOGJY]CYE#Z-5.$Q)ZDA%]N\7Z+(=1J<\FV #NC\
M)/*8#[K^Z/.LTP[]!JO1(@:H)B1 06 /J(P!NSX3_VN*J]:XFCYM#AFB^AT*
M_I-)JJDO/1[U3//J:CK8G6Z>!G>=,Z ;.6RKS"&8HBI*7QIASZ,1I1:!VEHJ
M]4:+0<\G_$5RE^_I!I8S4F?ZF_(X5/*+&@;[B@;/06-=SA6J_G;!R]_L3/.G
MY_9Q]LP:?>MNC3$\A?8^^-)_THQ*]:QF# \^!S9*M?)=9 [SIZ"3ITF?*N@4
MX[VJ6/1M GN0;8-&6ISB5]JEE@8-6&Z Z6N[A=8+MV@"@6=V+GS3"U[ICQHQ
MV(_<;#ED/X5W#/0/VF)&D6/Q8<8 NAXLQZ0C/M,)#4&,<SN5Q[P\]:VU[*O,
M-3QH2 9:OJ:3X[V<)/VY5,^\V9E>&SGK1KD^+U0VZHJ^E"0GAR$-@7Z,OQS5
M)JU?TGAP\%E =L'@/R;<N;R+-'D$QFC/0UCW+-2*G0V!^5H)I##=)/#W(<_!
M0<>>I/9LU1E0#Y: 0H-1[BJS/0G"/\3].FP>!Y'3$LAP-!^\$I&YJA%?Y,OI
MB\"C'L*5C@8**V66%97Y3]A[(F\'X';Z<QQ[$99V?N5%#E-S\;=@6 KVQ1-<
M>!"(UB\;-% U8;E?3E2#'T'IIWFV"WS%B1$ANQR/@380B&(P/,DZ??-+H'H,
M'I@S)MY3(/)-+[X@ZAABA?6L 0)EYQRV"?-Y+D#_8Q]@9@A@$0Q2<]A.>\4R
M7)=D^FE^JW/XH]E,DYN'>!CJNFC*H8M](U"8.)B<FLGQ0I'Y 'R;NA)YYW5'
MEHG>:[.I8;[77)<\S5)>%#'STPOWD,DI%Y?9E84BM-O)W]W*_\_>ES8GCBUI
M?^=7Z*VY'5$U@;F(G>Z>BL#&:WE?:O$70B !LH5$2<(V_/HW\RS:D$ "@<'%
M1,SML@W26?+D=IY\,N)RW9F]@B Y:A \6^.(-D*KD07)E<2,(XET'-LECJ>Z
MXRJX]Y N$ ;="U@LYL4PD<UFY&@A]BMCMK+$9X'1Z8C2LT@^,M0$M)6.-&*H
M [([%L.RXVBFQ8EKX5?"SD&@-I+.^/CADWM\*^BOZ#[E8':Z0RF1]<OW+$$E
MQ5,LZ\&]PKY/,C)^)E.']$7R9+8][*<?S".K3G,U>MGG<8&::)<57;9F<,;-
M^%9K4GY6+Q\?2NK1V>J"H\ET<'38FHBO-]_[WW\6#^LJZG VHFWTOYS!AW7K
MP/R#)J%PSL2KNUM">K[)1GCKP9+R6"F-VQ?W ]5!G'ME8$:1=O@;IAK+W3V?
MC:K5RF^Q40M]PTSTNOO!M(EU:WZVUSU+Z2 N_174"T1C,^E>EQGR,@2U=7'A
M(5\:B4M893Z/#%&K7.J6;/O@0YO*AD)Q;<PNC'DL+ PUQ.L9V-Z'_-X=#!J;
M@)O$J9(,_+)"7#-/DR#G;42E$Y(BO$7&TP4O,!5*\H3)QA=)U=BW=0;YPN\Q
M$C7'Y4"WCUX:DL2@\C8DT'NP/_R._V.9C7I$B@WT/UG.A@RABR(WG)N).P8%
M>1@B!&Y.YBWOS<<O],#6I#K)OUKV@?W[]_/*;(XDA1*%/#R8U;.7T[*HBIBK
MIQ, CY_,P'M;P_$QPHA.8AOM$GBB[DDOY$56D7C4N-OG6-/&W8/[YSVQF,W
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MXH.2E'90DE2A)! VO@V^%P=/U:.37TLU$U@$2E)H3<[RD\GCM=&L=):BTMN
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MJ6" MJ$DX4.9!D=TZO(/_7?]_$=M]$[$KRNV#<D;Q513 U+74BH^V+YPZ/V
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M2O5$>:C=_UYJ8:,[392G.TV ;UKHW-6/7QY/]N7>IZ]\K,RQ(>*T=6TF0N8
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MYJMYL>6Y=#0&QY<_+PO/O[22@W8*'>(\08WV !@6H.A@ 1909@N#Q*(<OQD
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M1-$5L;A/:$VNM)_ZR\_SR\J%MAIC40\M^C@^- \/;D^DAZ/^IZ^L4X'D[U3
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MYFT@/04KV+ZH :6_;W&SE?/VK9:KSMVXP$DF^[<=3@*J%Q9+$8&3>7VX4XY
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MU>JP0]B1K+[0U8Q76"R[;["7/"MC?-%H,*1@<'B3J5K/X%R ZV$R;1 \NU/
MT*GSX,&[[(^G,"YDSD>P'@2]W7!??PNO/H(WG^+I!C' !M^IJ0&WR?JM;X:+
MG?@49[@NY9%6$_-2KC =;__E /*XS$6*3][U;9KLLRO:Z*9W*%'[['<MO"-:
MU\;$S7W,VQBQ&%(>RC>&%.&!KATJ-A9P1FV.Z&[.-?_PBG;GVC>8>-OC&].Z
M]B=N^#]O?XJY:0/,MV<[H*N?"U^$2T/?4[8L+F\J'6]P1\&QBP3F1.)P[\ [
M2AB9>[[I1.9N2([6.I_+EXOP?VD$YDY0GB^'1^7Y7&VAJ%R@47G&%Y63A>Q+
M6I>%6<P/:@Q-5:-K+K*(@X82//JB'[LT7CR[0S]9B1GJ9Z)C:N*LJ28X0V1D
M/$$2G&9;470>'9)/N,,CWW,^XUGP[3BM$9%@Z&&8$PHZ4K2*6'#1"[\8U@>4
MU<:'@]-CC&^;B@M#2,J%69GIE06$"-X.QH1^-3,[$A1\D6#FO2)!P1\)9I:-
M!-WSE304%#RA8&;MH>#15H2"(5K@@T2#2^F.N-FD^0%A,3KNB!$0'J0<$,[<
M[K7&A$MM3UKQNEC*3?.%_N6M373"PDS4%AVF'1;.W*,U1X9+[5):P7N<X#"*
MEV&_-;F]/7XI6(-.H5A_=UX&<<?+X.-E*.YX&1;B98@2]UIK GY;X\CNMT59
M7H>X>]]>:$W.E*>3[\.V^%)9LI<CHS&(+N \,# U,%+D+YRK8(7D%:O)O5Q(
M[-*Q3B+-HI^#EAP_O%#7&;\<3XW0BUK)Z][B2TF$<8U./+EOQ\Q 1U%?(,+L
M=!0-N?XP3#%9 ,_"!"LGG.HHC@@)8'?^+)RQG(R"Y1\8&8B,9&'4?\>_3;V?
M)1/@/W#"X*/Y7*E0_LLI%(U,TOA)>V#H:"O=HFZ)1Q"^(6<(LQ\;+&$]@^^9
M,@D+R&(U[@Z$JEC+"O^J7[W>*0FT"O_<P>E\%KQ_P'ONK[ZA#!0)BXHM/C-5
MMVQS1#G:6*X+ET3".,[) N)80"))YP/!-T@:14*XXXUY]&!DB2Z(HO= "\@S
M@IO0>RX<C!,MN<_=HQ&K^])5QD#S@9F;$ /=XTI>X]^8%',A_F 1T;QYQG?M
M2G&96>>[=K7I7B\1\5$F1, J*<='"41AK=%2BEL7EVQU;NQ4#F'6#8^=(O5#
M*>W8*<'^K3F22G$'X_856"JN(K;/5&ANS^=Y=0R+Y!,]J6ZPQRPKR"X\\#;(
M1/X9@QIX5>^ TPX>!5I(UE,(8NJAI,I[8"([TE"U)2V+%E 2L-X$P;Q[&EHN
M\/W@9<B9RJX@PJ\[!'EDXILHGI/>*KF20I.;LF)Y7!KZR5?)RI!;*<<90T\,
M'F :HUY?.!MIGE_G!"_=5"2WC-]=\JS35'[?V_ME3ME->'%:&F?"F_:/+A+D
M.SS/Z,V91K+ZB!1/S<(=_6:747CDB.RT*;/4M*IG>G,7DW-=6KPDBSA6C-4;
MW2S\*IX^4^G#Y_&;2/1-3Z?D9,6[(Z07]ETP^J0RXR?DW+8K.A>8'!4-DJ6P
M,L@$ZC DDVL[I(\"P9:= PT;H%M=Q22+I,!!(?<H!C(L2^:8!R=]"+^%]MB]
MG38H?8#EDOUET6[TB5:2=/?Q?27CW#?#&W28/GLF>QR;$]U"@HW6QF%#P+F
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M!EHPEK.%4G2_G5"RU]+,Q9O)\;JJQ5NF(K:\</]*,9_/BN7(0I0 GVM4Q5Q
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M1^EY%1/9\6;O>+,W:(-VO-D[WNSTS1/QJA! ^'?*RGN3#<NJ; 65!L=L^4
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M%6V<@QC! DE2:$2J=KL0.1+V%SPA\%4TDD/C53&SSH!G#%" N/E9 /6FPO^
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M!DT310(*6\(!\VSA-V38:#=<1T::[T==B49O:%]N3A_$.B85T#6X <6$YJX
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M#)N$$/+[%$(X$$,H-1';_<_OD_L?2 R'//(ARWDX<)KRR$6O%A=DUK5L-.W
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M7$[B84PN@3 F2^?Y'%UD=B=%?M\EB1'I) (A)!!2198%FZ.Y7/:S%R3N]<P
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M:B)M^LO@\NIQ76<UC$N,E1]5PGW9>E#;__@ ZD1!??+%0;U^/$#(-WPTO>$
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MS<'S]0$<EO$+;#+CM@\X.1#]IP,X--%S!Z(_$/T7 7!HHD]HD\D!)PGB)'O
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M2BR"+>%I$_M!"-OJ%& _,,4"S7-)SD</(Z9\*Q2:UE V GS>EFQ9*OC#%64
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MUMZ!D3JRS2:_>CLM-V-W1;9Y?^&$;LEFR30G(UEB"=VJ!=YXG/3E^U[:2R&
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MJRKF$+Y,21-1/<(.SH+IE'&I])BZM5T0A',-7=G]R]SA7!%)9KD @4@*&9.
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M0-8W7V_-ESJSI[8L/HR>N=O6TRZQ_J_R0UQ"O)#OS-J"P>;>C.M^^]L/?'
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M((IIX9YYSA/;(.VR>KF6P:MF5+)O9IGM8[LZ#H&"5 9\EN4"PNT2M*20:'V
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M&2G>YT0C.PT*-:B:#"(/?/,ZA*TP_2*L06J1"<@^HSG4&\4]]5!:"RE57H>
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M,;IR$8R6([5R!!SL4@XCUV3YR *RM"R?'B@@O3KJD^VPH2]T4(K<O,O&G*J
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M6W;38-A*M7XVDZV>N-J5Y[77%88MQ)=_$:S5;I>[76[6+G= ;#L@MAT0VPX
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MI'KWOVZ^&Q2-'G: -"\!8_XE2MJ9M'WR' .PV3'*1:UEUVYZKZ"OY,\3K8D
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MOIR$U)?C/$>VY4!K"!MO@DQ$"['XNPU"Q=@Y'G%<&/P$P*6&8PBFXG$4-BH
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M1](TFD&0BM:.P$X^9CX%07$:R4' ]0D94VO(-V!5]!BQ"H"*R#],_FO8\@M
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M%LR>0/['^9I8$ .S1W"&$_IO/]\=O^XIOD$6!8[(_SX$(\@B QCI(( Q'&!
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M"YT_E'Y_;SS>6-]79\@MP[.;GH5RJ45Y=IG][/NQT$8GI XW2 ILH3MWR*5
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MWC1XW&*M_W!Z]?C]XN2D[02CQ9<-CSM,\4NSGG:@K8L";8U]$!$0AB,@"BN
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MPI<-!Q)B;6H=L)$/:OV#@^-\IF&<7U\;"\1&7BE<J$HAV)6NVD-27PYH:"(
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ME\=7]W>BLV;3^FJRM7[GI_.[[O;TWDDQNJ\FJC0O5OAB?/1"ZM616))RLC+
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M6!N+GRDKQD7E2TF)L8>[HP]?TZ5D)I=-EDKO@@T[MX\[,Q=D%\X%XI^GANY
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M0!B7+B04C W$O:N 5(J$SB8_Z6JC/5#TFZ3WW&@3:L(Z3?DK##&[CW1"ONV
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M">!OH9[B^U /R"].-'[#_=,^O_0[J?:BB2:J,'K91(/O6:>>K_$V6H5\& /
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MXXS)Y4,*#"8 MBBZ# UKT&?F:'1^%@28#>O%-AKP,R9W,#NCV9B1J>NJ([K
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MW^[_JE[]T?CP";O#-7DUKVD%:#QC)1K5W,)><U_A9AC/-%,E.;/$Q =^ZNA
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ML^ESJ3@S.T<.CJK:<2E-F<TW?06;/I>*,[.WI5HY KTFY_2?)]YG5W%F=]^
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M4&N]GNL\ZU9J:L; MA?_O=H]']*LPOT]7NA(2DOKUK5^++)8ILAR./G:L?>
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M2A&Q.F2U_MK#>L%TB0!6%5\F B]@0J$S3*^!%="BJ6V+&F4!M:A-)X!'6>H
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MXD$E^6#11'4E-+/Y4\BW@HZ(^$4J)T1087,@V?4ZNEVSFP/)YC21I(DP//9
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MB\L63F6*/:SC?C5FN]>M2Z).1B- (^#"!>R8LZ<3/XS4ARXS.W-_5#4V6%F
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MJ%Q2A=>F#]'R.1'R)P[.,[1%L$V/VB.\*4PW2/*%'/EPMW0JC?K\_*AF?7!
MC0=I%"&&4%7^L2O(#\'_GJ/^8MX&QMGAK=P-&2H42<&!N)?9NJ%Y0GJQ.K$V
MX@WN; I-$@D(N%GVM[=UT%$FT!.L;()#V-=A!<"G79>*3MKU!/'N)"(-Q0CD
MO%&W%3WRH%]S.S[!9WB4*F)[=J^@"72 F;DQX7&QL/+1\H&B"\/!>4!TCW;;
MS1FO&P0(7%.NH84C[440Z G@N/-%!L]G$FW_-L2*SH -2%(9\%:LA9>B1NZ.
MC$<O^-$&<TI\"[348Q1F#L[Y'+!GKCHOE8P%/H@'S6,(.E!A#[*:6[I3'%W<
M9<?[K10LZ1F[SK \4/42?A".G[,@Q1++PWGE?8A>%;6Z$'U"(7HJ*%"RJ3(P
M]HDL;ETYV2>OQWP0'$#*\3*H^_DA O:7>Y!Q8:ZV:"(T!.:CDHOTZ<.'L5N(
M.]J>(=Q2YE\>GC^\P,!:*CV7V)QZ_/#Q;@IKB%Y>7#Q_MI/L/?5H!(@:<YW5
MCNX"^S"!CAV,Z])]8)JC6"Z/'#MFPR\]WS_?.'H]SKC_1$WD.9A1J4%.7=25
MU-F7LD6>6O$08*:H4^E3[U^P)HH*0Y%1+EX#E0<DITV0&-WS46&*,YZY=$^^
M$Z5M51D*#5A%ZM5LUK96ZE0-F.<>8HOB*Y?M/KLX!2%=$/+I*0CY P<A@6G0
M(P9@\R%A@2IH^D(J*HWU.>WLE+8X*AC,C'19T/H\%\TU7.<^]65/@[-B0J_7
MZDPP\_806K/?[=FZ4R&/QPH@Q2@8.'*;%8 CQ'2$ F)KN;'=7C/3!/U3T[@,
M>7'+;"ME@IS[TN<UQAV!>)$,07AQ7)>LB0\Q%*H_MYM.<Z_':C;IEPM&,A1Y
MA18QH[9VHV.ZGI=1D5 ]H<C'KPB(7'65J^[N0ALC)]9^H*QJW/TGOO.LN)V8
M:87]=^?YU"[(!NMJ5M@\Q4W?:RNT4SOG*\Z:A0BR6W&K'$4^1HW/*&P<?%G:
M]VFI6AXS]+A)PJ;^$EH*U]CTDL2ET7'P:' @.+<8U%96#'R6/HK/;J&7<@Y]
MBN&H]]E*X[%YKF=R[]H/BUL\("WM'7<7RV'[?.QA'[CF&FIRL_9EO7'ZSVZM
M_*,#M=NYZNF18)J,JOXXE1$P  Q_])ED68-=5^-Z@! <<7 =0@6.WK@''6($
M^[.O.!.5LC7ER&#>B;T39P @.V2[#T^]@-^,![^5Y8C5/]X5>7I(+?0O#LS@
M@J!O&%T8Y*8.B)8A3O 68!".;4JA!J:D_QF847!K8]"N6&F/% =P.@Q4UWO<
MZ]]6 +.%H@W0U/X[$NSO'*02/"H#_D[O\HB+O"SR!4"0X$>.&[)U TTV*JNV
MEZY12POT?#F>A-A:Q IVB;U; .J!V!B[0/![ Y8O8EY!*3J]R"B0"JGLLM(=
M;!KS-!BV&;D"Y\G0$AZTBLQ0@4;5->U7@I@HSO*=6+#4!9\Y+2GKT![05/SB
MX<79XT<3BAM"/_B+"]$LH03H95=HG46=;<#&7+5T%F\IS%Y3X0>P+AYU;Z6G
MY\_&;_;?BI7]>BMV!N=L2?[*#Q#U>O]%(B3/O/MA= 'JSH*9EC$9FY65,Y3'
MA<PR OKSOE@].S?_:[/BES]^F":/'CYZBB\)_FSLGY^XG O2W^3SZ,D \0=^
MOUG6W"0+Z!1)>:6Z JY/^$_K_S3Z)I\$;69VH$AVTP)O/S5(OQ>6X'*UVEC1
M<D*6=(3,X4$R:8WI9VV:E;@SFYL\;WE^WEM',X<B\&B2B*V3RF_O,])?Z%WF
M/;X+JH+[!O@GSO<_-E;=DWY>F<^8<NAH7Q?+9,><IZ)K"9I\37:HR\S1HB5]
MFN%^<RL2/D(,CECG3,,"R[Z/-8C40D0(1B>$P PF=5I5'TEF*.([H!\078*C
MATM%AM9VW-6\(08'3Z2"G <%F<]+23^Q]R)._QU$/ZRG![P"O02O?[F\?.?B
M^505@V<IXOCK:G/-/47F$#MF+U7&XXR^,]<TCON6N%UNU):P%P$S!6V+JFK!
MXU9D"KHIFD;16),1&J'5 LZ!68%1DS? SP1]]B"'42*#'+V0_$(P20PSN;AI
M@IG 6/B$@P>D];=,\PVA%6]1P)QMJ!,%CX*>[TU3WT ON9SY#'Z-[!>TZM?"
M^"(AJO>O7M(JTF-D#F,?E @>U%O)@,1-W'OP$/4TS_^$ AZ 6JF1&4L@>*97
M:IR5!P'K+#S;=*ZR7W)5\F".%EH;YO[#)U->U$T'U7%Y4('7M+%_%^T*0(C/
M,D&R0V3C[B:@'8J+HS :ATQ-5-"+F1? '7I5B!<Q7LAI3EBPD")W@(NB9YO=
MC[#MV?EC5W%)W1U)2(<VO1_K".F5KAG#DIIX2:6CP3'S:2&/9=^_&:3750)"
M9@P Y(19WR\T4(RVRN/%]_X,5#H&_@L42T#%-M6B1%!YJP&!@"Z> ^][-.Q\
M/ ;K$C[MXBDD[ZN(KN[R3\%,[<PU/3KEFERNZ:=3KNEKY)IZ#2,[.JW$X+$/
M%MFR*+?_MN_!>&U3_$].X_#23UV#OJHE]^4^XFPV,=HF! [+%AE(Q0CL,?O8
M*,1R&NSYZBJ6)=\-NNR,[!JXRAUWPGC/QTU#>@MXPZ#I[,JH^TF#^?% +BJO
MX11'LY0QHSD!(""\KLX(;,%;E<R%Q+U\]4U0#5;CR897@-&KHU:.#4!>SPI[
M\<!>]0 F1-Y&GXW4O#D&T>94\X3,6LZ4C&-6F4?485\ ZJ34.7&-7<&,VO"Z
M6ZE\U9XT34K.:!M &>O<%\7AP=CSB*CZC4S'SF-HL<$B:4P \B?X+QOD01AM
M5 R!:DW]Q-(\"DQ")"5(=2$<KFDD@C<PFU YX<+A S,Z9CIN)]%I.X"@]*]%
MJH1:9ESQ+- JMVR/,.D#PM6QG![V9"'<D[,6K&$&MZ1L!Y(SQG^B[)YW,"B8
M"_+<&*)_@2AE56^C]7/>7"I0U]Z-M(9P]WSC $L00%I240N(--D\9 &79>[8
M&J+QF=[Q818P 89H!PZV>@D0WYGUV<[_9"5ZTOJQUI]/C,)$^7V[W\47+F>)
M+;IC8M">)V(,J:^6C>^ZPINWP"H*NN5EM:F9$*-GYX;\P\UY\KZ WYC/B=@-
M0TI!,*;)9PYM:?2=PE0/QMNID13_U"A5X3,A4.)?;?-<,5U;[Z#"8XAR?W(:
MN2,(,D)JAH?4BOH>L^=[.(E#/#1<'.9ZG/Z7-&_O@ :LIU9R8!C6 #%^^35K
M/=!5M6!ZD8W9>,+7]B;PP+ X!_J^(MD[MG%!'(G3'VFRS*U.G5=E=<V@7OI#
M1YRJFA=P^ R'\F2Q([!H;>P'=(Y?\JY6UW95<>$QU56(1;#G^TXZZFOKJ)QT
ME K>U-4?[.CVH1P\^@?[P>5U'L9/D";?*H.;K%ST (:8990E\DH5P5EE8#HQ
M2.1$6F0PC$W#I_UF2;BKKN1-(5U[FTM@2UNBK0N8(FU9"MGE:>Y([)H67B1V
MK'P_9GJLV7!G=^@#H+WGTG9F-LI\JV9XXV8%A6*P9PHV(%955.:'52M"[EHT
MQ*#F-0!;)XL-/EXAQD[;XBMOBZ?G/YOQ'8^\.^4SIJ?U^JIJ+)M(@1ZF5G;0
M3O?E8]C) P]!^];V2-Q@%J4IR(G-$TX/)CX]*,\7 \NP@>4(@LG#)7LMY7+S
M72\KL 9]Q;:_B[N&Z(FNQ3(0%3!CHP))$!5 0 OK.9=/$;6*<0ET_Z#.*TC.
MQH@^UN5]#00HG^2)!\?4JJK$S&F/?>T]-IV8]_?KAAZ!*7ZVCW+E)@#Q$JI*
M<&UVP6G1:8FB^<.(IK%P)M@_UYL,3N6<[7U-$^ENTB,[2=]7/Y&?CS^17XNG
M<^G]C9?LZ01=70*?I6FMRBFL'H-^R<VV:0'-ONASFXSS.\/&LR-BH-FN6.*X
M4)I0.%6U<7SS$7_ 8*X?2XIW12&3$5'(O@BDH6,++-:BW?IC*]YY]N@!XJL9
M>AKL]77#E1#3BX.6.[YIIH.7[H+/C%CZ:4[ZIYFBAW,)9/I H!HU'K\](PJ#
MF?" WH!F&']W,4W5K4/X\8"7)ON8KWI1 ?-B(1T]CEUQ[4R /CXE0%T"]-DI
M 7I*@'X_I_?%P_'']^6TR9GPY"6%5))?\]N\K-8!+'FHR=#]2<L?.@S--&_O
M(* ]X/,)HB4H/USM1*&,,D-)A:.IBVH=@^5I4BRX)R'[A,@P1)>Z+I3!4,B7
MPLBY\]XX]"9D9;K8ZKZ8HPM7&!+5NG_!*0GB\-=@I/M$@3)$-FN(^*=&95GL
M^;W@0DLNY.BEK_(5),=^-AZC6K@X0"T(&.#*I3Q?).Z/[[(M_.44@?MV$;A+
M(FAB@]YA-WR&.E8%/I0T(DA'65&5W)8,.=G'DM1' "_WQ\N8R\)17-(U#FUZ
MMJ*0%83H:TP<2-!..X,#L2N'?@X@T42% FUEC?@WDV26U35<>49<;M-<_C(1
M7FM*"?>$.UP"P5ZRRJS& UBT]M]XR!#:BR*1G.HU@ITA J!R&T;P^I1P)T$]
MALQ$=#V>5*Y&6J3 *"G@'LQ(:X7(3T^)9(6U6@(%2TVE,^NL:9$K:ED1U&>5
MK*PR *[BYP\G=BS;AHK].3LUG)C%-3?8;\8[9&@L-G;PF,N$,N]%OJ)"9BJP
MAN^![LH+3H_CR8Q?)'6)"%KN%?:X'S4+GY4,Y#]A_E4^V+NWNT*8O9]V=CDA
M(IS>F4\&9][TS?R?NB<2OR<H[B"!7A-%>7EOL^_;)]8T/[],*,N&669JTEWC
M>CB(-<)^_(I;%WTSDUP<E!3@F@A]NL&,7.Q"#R[1?D$^G4/?($K]X89->K=F
M:S(.>.?0C_<\A$"9EF42/YI?6!<-->^=8I'ORA7$SKGA U4YH+I&:W1 JP_(
MO-]6PKG5M&Y/G63MZYNOC\:;KR\C\LO?L[N3L?KMC-7=-2.C7%."O!&@S(/)
MJ!>2?11VO@E8(.W?Y5@A&D>C6R8Y%KK\5EIZ5#-."@/<JJAGFR407<PX6LQG
M\UD_(2H><!L\F )ZS0E'!Q0K)WK(PCV)"71_8/H1QF3*!Y"D+@1&?:,JZX0?
M6;5V,?=?$&RMXPOS7)Z=:7'HE7XI('&3\\RZU'OXA0?0*G17-FR&I9, UDZ.
M>7 S8J6U$HNDM,3_7)606,*JM^&0A;?.8/V1_BJHJNJ93+1F=-,[QYM-W=QJ
M7V GC%&N)QI?ZUGU[!\V)%J*8(I(*IPXZ[X@D(MA9B'RA?89[4CBRCA60&'"
MK08AB0)5Q.]1LUV',WSLRG5GPN/)*>'A$AX_GQ(>IX3'=V-A3,.*+T:NQ#8$
M(-NM,T$$4TU/ZP358[-%VE51Q?E0J^,7'#B8<,LZ:O\B;R#CI+<Q[PM_1.\<
M-3?W56?8_B)C:J-E%-<[!?!6\T*B6.@9O9 Z*<?D"*2\BM[+Z7FJA$'T@)V;
M0./K4]2?/?:5U-"@W!K?9$N=[SQ%,G^W&%EP0[1_<0!Y2M=+-[-N5?<X6GZS
MLP7;V*9Z$S$%AVU'>H_CF8NL14/3F'8YV/$3Z"&<C?/0*'R-6)+#>+V0T;S9
M6+E8-87T\[FMI,_KPG07(E$,;%/H0K<NPD(X$"J5^6N)Y\)!"J&$''; #/N_
MCL(7 L$B8,/MFM\6\PW6;J%]&(:1TU'M,H[:ZC@ZA6M]\<?C??$/2!?6HFW*
MI/@G7_S;^>+WRS_#DBOB\LAU_-71Q222YT><@.N=WI>QQK,RF\]K!I^B K'J
MHI3N"5MNL]SO"RNORJ68X+)#B9+>(NG[%;R7!50H&!T_4@!?9&6M7+^HV336
MT5"E=_TQI[!Z*WL SFY\8Q*\,7'-J WVT,:F[)X(GP_]W^&GZ,[3'OH&UN;]
M42^/%1P;I!:XH]'6 6-O%],=P+9C,FXCT ^0_8+R4L+ *SQ(G]5P!V6QP0ZG
M\I]6Z"%KYSF&@7_8;.0OUH194TG6-MK+R"\*N6)DY80'TG_R W-W>^:3QJEK
MBUKT)T\[NL#5LL^R=38KZ+T[WIKBCTC]3#]6U&B&?B<J4;(-P;(A^F_FO?,S
M#;8S#'BZ#<C M&EC\/,/[^:H=01N_U W!;GY6RJ(I_'>YU4F?-4@72!3>H.5
MV=9($^BU..%S]<)3#3(+T]P+T]RMPKPC3',E3/, /H6G1,^\)&?4 ^7P2>[3
MJN&7F^XLWV>*>UY4=":YBY7'-&EVFQ4E'"7&%W:.XL4$G= S78U]S[Z ((03
MN2.H]P[BF&W?.2S!>"+M]PE^"$%*ZR>M@_K&I]\)!0.?P/UNRFT(/^S5K^<0
M#? N+?AX,!GKFVT#6'CP,T"RMEP9S<6N4$%5U;KM$X^N?]D@"+4?"6'FE7+D
M9"08B\"-(M/2&9L$>Z-A#8\G#7RP-%HRHY1_'&0X61#?@*%H ,,II[@#DLYS
M)/CC7/B<XB,8]H' !J><\!&CE*1GK8"&/X;#4YPP6NVH[8IL7"Q2*>:)%)A[
M&9=>1C TLD#@M[ZQ.)21=00*^//98T$9@;T[O\5X%Y\YQ42V\M:I%VZ* "F?
MQ0*+6)C-G(P/K#5U$\G,]%L_HS#L:$*-8!=VCSSWK5>D,0,6Z'^Y!J!!QK3/
M7X""UIYS"\Y952:?<?,Z%Z>)V/5/6_\;T-3$H6H.'8_([-ZMR+M,R57L=3)3
MUVDAV=UIP<2=%E+Q3UW\6Y% NGASFZVN$05*B<?07#GX<U)R=\59H<_B/W%6
MGU.>E?Q*Q6?!#;XGD'R"RGO/N,XZM7^$=F5Y;4T;T IK%S^FUD#1EXU)$*@)
MVILK2!V<B3H+]PT,+C%J;!3]QX#"755_)(-E3N[00'U>C&*Z QG  #?\!ZF!
M?'[L&W]GHO;I*5'K$K7/3XG:4Z+V>SG]K'_VY.#"<K;//M3@!O^5>FZ]2"Y7
M;?'@E[J8YJCJ)!UY2BQ\N\1"; CL-0"XOJ1$#K[4&P]PZC==*CST6](H'=Y'
MI&>D6T1;D4,%L@*1D8V+1^"?IB0^:1)FF_]V_OX\^<VJ/CN!T!D+;K,&MM3/
M7Y(!</'\V3-J>+?$QA%I<O$4;WUYGL"2/GM!_]\\^WD^?W!A38X6>A&=LQG@
MD[OVM+=6#/M15*I.)0GA1Z$-A'<@%AHG\"R,21W>*,1.PDLW+P9>$T6CV#.T
M]Z^J93%+&COI3&4P7Q8K@$?7\.WY*J,:%_M!*P0[8-HFZ@$T *L+/\,<^AGO
MW9B&/@"^X!-$43P%7]^:OZ)K+OG+Z%7FRC.OXQJ_//_M_"I<X^09M$3YTQ?X
MX)GA#V(VCJ'IN>4=LK0NYS8I,WP H@;#.?HK_OZ[^]W(<]V.^/DG.T,_]^T"
M^^-3^/'YTV>CYV=@4EX@GRUMX&H[L\: J?429:%L2O805_A7H-9P7<1>$FUL
M_L)3TT+O]UKXXQ9H>0>R$J^9?I/1;Z*:% K;_$(VN_716^&!HISXQ7-QE'C*
MX&J2K\^0(O.%U43?.;Q#I$YG[S=(2 X [/<=P>. P<1J GD%3(X!"0_TVQ/F
M6.HC".4WAP\@.<L(&S;(8SGB(9.4N_,"I L?9WP/&&87ATVGWN$Z"TKE.I&P
M<;I#,E9"HM[:]:5"O?"LP7?"JA+I-?>%=6>DP1J\ZJ:88F<M"EZ6!""+-%2&
M=73[3LK>4RO4:019HUZ[+A?Z'BAU,+GP*U*ZHW'TAG>T_11,+>]1DF[F?\U7
M\+$T570SZJI7=AH@0CKT,) .K.U23YIFF"NE>_[SKYV1@Y[QK6E^9^8R52OF
MEN,#+E'C#,_7J]N<&@YA2TI^154C]DVZ/R(56FRO"--WF=]"-'UH)3CH'4G,
MHEC8.5C#A-E[SYX^_'\F6(\ H6X"LP293C9'2O5VYJ^V-UQ7L,Z?J;S?>?E[
MEW6A+2]@2M#$*ROLU@,?ABU^::BUE9>Y-,_A(X7V9%[;>:AJE][%&;F[@5J[
M:S=E^/=P!\'15><W $V\Q3H\>YKX'4/[-MQE2NH[W<A[2J-?UE9=9O9_-U/[
M_U_7H$'?8+[PO^RD9B@A[[=UD0VVLE'YLD&M.:((6JM-7'92G"(Y'?79'8GY
M6NH3BIHQK0,)REFQSH0@#8B$/0#6$),X&D))+%GX';(?@$N\:**EQSQ2M+0\
M&<.2=9=!+JFF0D_K'%)_*8/:OE_F^N](^(X#I#'IET:H@[ZAE+05*VOW*;0R
M=&7/Y_P3[L8);:,'<G7*,B%H5_E7*E3@RVJ."J:I%NT=.L;6:KQ9 ?,XJ1TH
M%4=/U"Z0+GPRD;?58_UCI=;+46L=/YW,3J1*%28US$TSTZD_Y\ ,CCQ+]^YH
MA/LL2WW>,>D,]PG3]X' 6*7<+ F6O<&T1VIF-_D24NHX9],"F=N!">\NS]:P
MF';$9;'@XJMC-UIWQL-_.L7#)1[^^.$I'GZ*AW\WGMOLWIY;2-?%+3-<,3*5
M-X^P49A'QG32F6RL--[-@]#*-?4_JN-F NQ_N3IM*D A& (-9HN]?.RL2G>+
M8@7 C*V*&**3L%8U1&P2#T0-%94_=;(2,ADL6 7SE?]$IWC?D91VSG8Z,TU\
M9NX[J'3!TA3*D>MV@Y-]DZ&U1! ^M <=4%XSUO1_@>$_30YAW1'4FZY@;ZRG
M\Q%Z$]E'7,/JVM,RE_>BC32\.'Y!COV,/#KU\/3\XND!93;9)TF/G;)@WT\6
MK+\0=5& SP\0#EBVJ[S=U"O53'FZC>*ZS-1$MX7U,"\\ID0]B]J[[$ (,X)$
M@",O'#K%/@0<2P'>8XF_-0IOH&T!1[C4>R8(]$,0S1UK/XT0'IX!!T(,H*KT
M<FH6PWQAG>8TTH.;*ANL9OW'!D(!CD/+/UZ1: TU1:"SMJ=[A&>Y.VVC;U//
M#>"G)N2T2*F-E6^(9<]"6"A[2%UC 8(@0/OK73J2V&42L0*8(NB50:9&$6HL
M0L0H[ (4,VK4%=!FB.T"UV0A?TC0P\V^G;JVH5_?MB4]!4"Y)['[)M:XLZ5)
MP)Q)BR9<[ZIB:/2/C;6IY@5S!J/PCI1!D0<^$N#AAI0KAU9;MJZY^$C!>U$"
MV8+3 SB)SC> ]>[IC-+5/9Y_@"UQ6,[F)L/(9>8#VO!G&/ER!6T1*!X7_6S/
M;2[O-YZ,$50*)SK\'Q4 6!6P8?@%50^6K1'JO(<"DK#M[+>LZ\+.>D%N!1[<
MI]SOMV@I^*H+N Z V+T:!PR@F[PD##F6<GC;+^I!Y2[M:9:%[V(N8'P*Y#GN
ME%<KT0-KA=HG%IA!AMD 9BIF2$<9Y!0)"V=1<[KT)%!?6Z 6AVLR,I4"ZAA-
M$HMB\*D5,A+F/ 'Q 7N)RI.AM,>=K8C]-W >QMY&*OE=*+B5D]E:B'<9-,7$
M6))^491N@ 8Z&TH:EE8Q4GZF<4@ ,..:1E2G;PEMO&F8][5['9H62E\5Z&1!
MMYU@@GP>\V5980$B]#HXB?O7%O?K^XG['/"!Q10;25$==#7[2"*GVYFE%!4E
M'YBNT7>B.1E<CVYJD(9S25#,M-6ML"BVB#IE%4W93_9 ;J!Y,S'I@ Z%MP14
M'H^?/H6?P[_]=.$E>WZ2PZ\NAS>3L&B9RK5 -9':V:PY]L+%25TUU)%39>G]
M8&5_.[.=ST[93I?MO#AE.T_9SN]&QQ7W.VLIQN9=98!S6(_#0>9F;$ IG]BZ
MIK<0$RYSR(<D]::$A"(C:0 %8K(Y8&B29;ZL[&$[SQ#72H65B FJE@7EXKHN
MM'-\.F$@%4O<1;L3?Z69^0Y2\EQ/GNR[3K&EN+<)ZX"!O@VM<IX5-6XP=.FT
M8=[@1'?FVG74"%8]F)%C/V6.;X/]<?@& XBSVF1V/TQSUV=E87VP O%AUW6U
M64.(DK!_,PW+19SO(I]C \\"N$%SXWVV(.*4\8.HF'JYK-!$9>PC;9D[YB_B
MP4]\6$ 5/?!P8'NVR!$)X:^28=U8MP4#8&P:XK 1XPH?ZC>6^'W.KU-XWK-^
MQIL^X9\PP$"PRXDJ& J-[(OSBZ</'SWXR9P).SCK%D?5BCUJU!>E^I-^S^XF
M5-Y"#@)0JI.*VF!)/(16IEL7U1L1ZC.?$>I+ R0SO-B.[[3EO_:6_WB_,[4#
M_A1@.4#BP:WT'J@PC7%.#!H)D-_)6);<WUSG"'M%EJKN P*.V"C&*,\*N;[&
M;*F?'EY</'@"K$\GV?O*LE<>+GL8#IN&R\_\AWB/S[Z[AN!PGB0%A5+R3P.7
M@NGBNTU!LQ]K[&6?N*45/D)"D7@R$"0<]+"0:[5$P31)V/3IF%VD>9ED60@7
M[?-<2P8H'D0:'CAO9E;K7B-[QS*W]M <+_$-TGL&0X7)Y';I]Z:*<@]NX;W6
ML7H=(V!C9Z*906TSHA["-J(7CX) 3R)'D3I<E=&K.,1A_ $D9>);J>\<NK7Z
M"?YG#[:R1 NZR>@U=K)60;#+J@$D9X+_QH3KKB??TOS/A7$14>$S%L+KK%BY
M2HM/V*[<WMFHAG(\1;!$O7J&P?^!MK''=^_LK>W[<SJ#]6$^<,J;Z)2/#_E$
M.EL-?3V5P H'%[>Z<V!0>XN;DQJXPP&@,YO5&]"NV!B.D(1&!!OBTM@4JVL*
MI%06:X4[YVAX[[P\_!EV@YZ9?:MW&]'?FQU*0XJKW#FCRJ9DWF851$<S?=Z<
M<8H!WK+,LQ5^ZB(<^?.GS\ZR8.03PYA-?E>SF6(4]3?6(X<]_5'\=+<2N^?&
M;AI^_W593=&N=O1$977WP.HV%%T]HO&9B5%#O[B4?@:!J.^U6;DIS -T"TB<
M6XIX2Y\<K#1AY;Q+$^LI,EH3HSW_:>)E$J5-6P[AM_ST].PF6(:3K?"U;84E
M(2,W*U19AZ;2' $7=Z1=6'/12MH6**U \\P+=%AT>>"R:D@G^LNMN]G>F!RP
MU' D<.J&<8,2:T]*YR &GBN&3_R53L/2I^AVG=B* =L<0J83J\(*['^%2&P.
MJ1AH^XJ.%L$[8"-/%+<I]^E23;?#MHCHSZ(U!8Z:^QQLD4FC1!X$6%[2DOBX
M==8TV;5O/-'>6$?Z^B;87#U 2;ZUM?,/K :$&6!"E#[D01_.CF,'*IE[VH1?
M>Q.N0GAR0<"S[ Y;FM$R8H,3W8)D89?9(R+'IKZSCSG9/V"=XI: /U%"GJKQ
MC:+,'*;+7-?48P7B+LMUSD;*7_/Z&CK20T_/?VSL)"ZV8E2KGU]+CA1D#DP\
M+ <_=JG;F?OZ^93[<KFO1Z?<URGW];VHWJ?G%S\=QGR'Z*--EY+^V/77T2W=
M83US8C[ZGU33'-T0ATMS,FCYE;G2'*[3*9GH!""98-X636-=1@/16K'_)$-'
M?Y/0#$4N5#&B\]*L(.EK)IK3RJ/DJ/JOSJ\=_5DJ;R#B 6N)FM4&<D2 Q?,W
M$<F!OPW9.8AL046- I \? 4B\AKI5PMEE4!G'#PI_%QWC=%?DX[_&O<9R9?Y
M#!-]AOT.>@ F66;5>LL,X?HKW)^3D5_1&5??X,WGK8'KQ$?L"M83F5<(6US9
MD_5?[W+KWJP^RG7VLJ9"OV296Z//=6B';S ^RN\;YNYHY-2;ECR8!) WWCS1
MRM/T]_-(>KJF *ZTNM9=^_ _>U6Q_QP(6SA<'J4R^CYU1W3K?JU$B!)^USGA
M^XE<.DIOXY<IV&)I)(?HPS403)GE.EC4/\FJB56-Y2F-?3+S!_9WOTQQUQ"W
MR;ZB9F3X/AUZWZ $[Y7O<@"RZQH_7=?9BL5]AQBFP5;'Q$V#>XUH[(/D\;I"
MZ'7>8*=PZ,3-Q.S4$4UZ+!"U._XKY8YJ**G<)HU(;.8B4CO&MHLB/]V%FT3W
M>=>#7:\C:6P$@^:P25X'(<K,9^J1ERCH'^XX']S&X)V0J@V&NXC)$T"WGZ.Q
M\&;GL@@KDV=GH/0/!]:JM>1?4JO![?8O2W5P<NA7E41R<'8'38.>3<7MX)FD
M*.J085<@P>UK:V81'VOV@MY/,V?Y^?6Y,UBLZ=-(VUCUYE39&8.7^ -Z\!*8
M^[^M"CNZ9?(K'I0/P 6%5HCK39L_N(+*3KS/O(/N\EM]^V1$QY6!FK&HNT>Q
M^F-#%!8>* -@+B@5L\K"'O0%P$@RQ6E[FQMW*3;O=7'#MBYFQ.]1V+$4=8,C
M< WH_:E! =+4"Q__>T.8.8=Q5W4879GTW<94CY?/GA"19"6D^'GZB2K>1,&F
MQE @2G+*)8W)-3%.J(DQ/@2WH?[:<!*&O]>W;!QJO67\)P>;)4A6(M_=O9MX
M_J3[#[I"^?8&PF,Y51 8KF$^';K?H !Y;U.V76@TZO[GC?V4SMJ1IV8J$!\Z
M:(P_B_6ADT2'3N)/9^Q75I8[CQ_?1Z;"L4O;%!BXYX-W35/.![OE]*F"/FKX
M4G5)D6)#&%%E_9EK/F(0 .5.XR )<V_/_]%3Z_ES*I?E4ADG0^O[N5]1EMK7
M\Z@_=]P:Q%PTU08L<J$8I"8^^[J?NW03P@SM_.?E0K$9HE MT1UL064J74JG
M">704%IZF(('4PG5/G6:A ;JH-+]S3I\7)NJTNV8^WIGI\-*/KI^]AN[_?GR
M3WD]*UB^>9@L^-PJS/Z]?W1N$9R-UX"=@(6*P;'$9Y#7RI(OAP*RSF) YL9U
MG8>YYQ;S3)ZB 5926JFX*Z1+&Y$Z OI#C*L66R&!N;9 SJ^ZVF8E=BT$7S?;
M<INE^$BEL2L\:-X9PM[/./8#9V=JYODI->-2,X]/J9E3:N:[L;KF(ZVNL/N;
MMUSB:WT4MQOKR]!.Z3%TH.+=_X.[WTCGFS@RS)#3?5&.P*3"ILJC [#0N#8G
M[5RL%L!(8HW)9=%8X\(^O2XPLFQO)X9@2NP/'L[<_!9OS%L %]*Y&I1<H WB
MZU^5^V-<%%GBYXXW@+AQA/"Q<RCM=ASYPS!2&7P:_L5]'!L,9N#S@F\X\@/L
M^/9NWNFDV\,(WP;=H%F&PF#4L#RIHJ ],F,"D?'-:<<;NCMC!AR.!>X6UV=V
MH)NL";O)CN*!'?A(_T' 0!5]L;>1!S[4#)"N$09Y7YCDM)N^/O<+D@E)#(V9
M%I>Y:UX0=GW1Y#WCP<<W52H<4]2X"7L5U72F(9<9B:)K7T*O%&*6?'5MS2-?
MB1N]%A^@(R(0T9AA>&ONQBS,'?LS!43T3W4.!EO10P.587ZM$4/B9S!)TKYK
MH]@-!IY-3\H#;]R9C^$6T$1.!V5<P$(,]=33%M*\^ #U>2.Z69N1W:PA)S&4
M'K"3-X-X?#'#$I&BI:AQT..;@E,2AD9&Z:H6(Z(VWD5=0 WD2:U\9VKE^IX<
M980BG5$#(HHD.5$$RIU\C:=FDRVL&LEJZ8<-I1*L7YK<[OS9EO/]JP4U:\H@
M3F^8)!VN*WJLTT8'1C,,?*T>K#?3T@KJ?6+[P5G+Y.E(<Q7I5]]HRU.G<7N8
M>I Y3;IS0&T:IQ=':F.8Y]"NGV,VCUNAP/RU/EL;3"+8">!*ZRR/)C,2)>^5
M.^+(\QKO8H@Q4 ]  &K*S;"CH8--Y;7A:>M^&UJB$836N@""(L'K$D]$;GP^
MIE\2X(36&(@D'T]%O"4<;N!\39,U9%31H4;FWXP;+2)7_=P>:XU''@VI#\J!
M<#EID!U5-"'TU)MM@_]PB@;<8VRD)B!U;.PH00*M90AA9<V'FE.#[X&=#CLL
M_)JU&6\1T#\$@:#$.\ %YEMGK52EXS7>K)A> _IS95CVGYH-U.E!VZ"% [VI
M/@-N[]IM;J^D6/_.!74JU U<VJ82&$0G(Y0.,+Y/4=)LK7I>-H.X+VYZT0V0
M^$ '+/H&:G!O[(Q3(R3?$FF5MW=5_1%O\$K(#\#P %*J$:LKNYS@'V8D(PU6
MNKAK6KC(RLEFY5 '_@7\7]B!<TT.)9I?BVR& FC=(QB!(/SJ8GT#3!@$$3#X
M3M3<?I@PFW9Z<V8R9'\(HN(,-L$_3[=QV ?J-#%Q,W?SZZ0>T3-1K[C[ ,M>
M\JR;]_2&3K]8M[&&=H \(7DO8V39S=HVFWT,X*FW10W0PSL 4<"GV(UCA>I!
MM7C 3:X,WV1?'(F^_<A"TA*T$>0,\N?FC;W5'D7N_*,X%#/SL=WL4Q9.['E2
MW1?!<E]CUS_#^DF@DVICH_G<_78FU=?+K[X_U 83H BL9?VK(;$X-[_Y<BX[
MPKN\M \XNW@TH0JW)NU?!]33R.6_P7*T>5A&SQZ!O1LC[7-(':<HJ\4*"E8A
M!0SLE6!HJ4/<JA^],':N[)(2C-!I'L91)%C+TS"80J2Z?^) S-* ,B*E#YAE
M&,FD.W%$:(M8A2=MK,D:PCTJS5Y<R $F9J,\S?B]SDO2819DK+7B-M_@(8(/
M)UCM]35TH6EE;'LC,0=%<9).%$?I4&K_ ]E6)O#02EF:.@0+;) 4:X;C1ZWD
MI!?AY8WN9,KMX ;O0!;^1C2X1,+S8&\CB^\#8NWRUPO*14_Z9(31W*]9$&_J
M$(.#TQ"7C[I=W$E$]YV'QVYU[DI+_OSPE)9T:<DGI[3D*2WYW;A>Q5C7"WA^
M[0;-G5>DM7#FE#C^NK6&5+TI\XZ_] 5,QW?T(H:[1H:C:M?6!W/N^SK^43%Q
M(^0R52:\=G129H\!N*O]KR871'%JP*P"V56&'<<L!)GM7D;6(1@4]L [X%R2
M,UFAGLAKE6:I</#Q#"4,"$;C,.#4::)IZGRZ_A(A@8,QA<,^\@/K^/;J'ZY:
MX@O9C1W;+T($ZVQX7S-JTY53A?!U78H&VB5U](SN5=@KE^&&$S$UW0UW$M1O
M3A>H&HZ^YX"*+O+:4SSB$2564("LDV]#7U23V]N?AS$G1J6XR-M=>%[=/H@J
M873M-ZY\O0+""QOO1![Z-6UE@'K0;JE9IM*!'.2GZL?44Q.FP><5;H@SH$<"
M=SCE/I^WUI.F&&.+G3AOH-TXE7"R'PS)]1Q<<(S&.=B_$'*LYM05"B[O,+.F
MQ+]* T&OEKJH>[)6BI%2=<C<"I:=8_'<&T>[QH.OZNML5?P/'Y33:K[%<,Q'
MV.S(LHK'[1^H@U3"4]^6G&4'VPKOW7C>JB?%P2;4'STE(:FK"=F9\.P6AQ!$
MF!K)N4QGZJ<SBIWZ$(9A:5M* URIEG'<>/;I_1\%V<^!'7?H?C/WWF])SW[[
MG!TU@(9B,D^]HS(W+<&LX,QR&,I>1=+M4"3]MT#@T0YROH$(J%M*4Y\:IWP3
M0HMGAQ!:V.T$T<(3B<4QDE@\ZS)8:*HUQ-V14DD=LT5OTUD@MC!<;0MI,DR1
M3:O5W Z=N/KQH=0J#"I0FQNT-<$J!K].)X_Q-GSZM)CSOX@H@YL$A(3\493/
M="D'/M\#_@4&$3N^D@)PWCF2K[5(3,N[(C6>= ZG*VNL6L6> G)%LG9G@O];
MMD'Z7/=O!TF.@M_N NL 9,04BUZW^@7.?.\&&U@]JU[9G"^+A1XM'#LR7/57
MHEG%<V@YK:%RV/^:2(< +@?>KBG_YW['_Q*WE[\5<<C4[T:UH6<+1MA!QM#/
M?8G@!J]>QT11:&_-;]V&K!LS0#^!XXZ-Q^SG,%GQM,1PC>;6G0@JA2,V +@J
M%*-'0XP.,B"\&@7/B)G,M3WX&#O1/=4Z :*K+/); EY,<PZ(@)D 07,5V8>,
M"1M_H%CPZ7718!$UM&H[=I6^,TI^<8J2NRCYTU.4_!0E_V[LFNG$]&O#A+5A
M+P'-2$22XU>UBK$%*I!5AG@F9L8@I\M'?$W,%T#>&"E;>?B^*MO071Q;R0)\
MM!D0T^.192AYJ[G;L<K562 US=$++HV@-NO4\'H\1U. JF#(G\0D_3"&W@WV
MHUT JKMPQZ-JM^WBZ'-BU(C;JV,J'UX#?V.4!]I_9$,2D)S?:OP74V^3@V:8
M<NW,KH[%KMPBW(H&,. B#RF"FNS8;[)R(0$!;][,LMH^JO;$&S12_!^$(NG1
M^CG"@QL9X-R3P-M5@$SKOH,'OJ[S9;'!42QRE'L1]#XKW5"5L_UOZG) 7<4%
M2P$%VRM S$,TX8SQ$+Q77-4RT-P,C0D*AZ5;N7^20,?8BK#;I2G:#88)P(YH
M)D3K3;3P&'(HL55$ALC;.E_E=^ ":%8:LO+I!13.\&85$Y8'O_,L<0D*,I]4
M1L%^B/T6&9O=<R8.VCHDR'LF6R E,9HE@(!X@\Q$#+@C(?9';GT=W<%CO>*?
MQWO4OUNM=:U#G-:&[Y<5K9 5A<T7R/406]U QJ<O)]M1]H+CP\T0P]4-=*[/
M;ZIR'E<),7I]2-WN?;7#R,ZR=38KJ+ 5%2;&88/,5%'K:B$&$3;^0GL:0@5)
M7Y7.R.$0<' _3Y&)#^F@9R'R+NT2 O=45X?KV@/J/*#(A5X;76EC@DH;?52?
M-,;7UQC/QVN,7[+5Q^22Z1I?V%/GCNV:2^NJU*O<T0'?GZ'FXCD_PWR)L![<
MA:?;U(X<2-8VT"] 5%*#/54:7>(%.-/J(YE]BZ)>IF:YP6S" O:)-R9<!P1=
M'H8;N-MC4Y<4[=4KW+9>.@)!=BM;Y&:>(P6>W:^?-  ;'@=,J(Q58:SDS-GQ
M8-K0SFH2A8>%/FEU=J<AO;21";*,?VZK%^-7$<UZ:Y[PVJ7C1>K&RI#5#')C
M-RJTS#ZBKK&ZD@N4Z.MB3(H@@C.E6PS1R(JQI,HX0;)ZB'=.^N>KZY]'#\<+
MB[,SWV5U"X67GZ]O'CWLZAN4"'"ESBX>3I(2$N6NS8C*!^Z,[J*+36VNSG#S
M'YZ.=G#ME_SFOB ^#O4&F$//'ONQVA?/JSK W#4;".;"\*D@<;6!)AJ;VOYE
M,N:+S)1X"5?-YW^1?3 -)ORB/L)C&);<UB0R$PTQ9-W[_9'\^$*2(%PN".V+
M1P^PAD'Z0E$#CU^M\PWY89*DQQ>I>?3PT1,L*T9%$[^,JD==P":,TBA61VK2
M1PNPVS[LZW\B(0&CPP'N2'#D$?TC++ Y"94[RD#C<08,E-Q0$)\6C+6B[+T9
M> \9CTU50NU%1++BL06[_(MN6(R_5_D9'*.QHMO3,=KE?BBVTA$-#G-DDV2V
MIQW,&'Y./3D[A].9*X@_3+_,(/A=0#I7JS[$"PBR82514E?6DEGEKHS7NA37
M5GXRIN".6_*R*R.U&DRV)U\@TY]8)\R'+.? 28!#AJ CVDYN(\L=O!\-L=@A
M<TI$&?KHX3@8K'-;IUE3-(XVNC/+@ EI[.< F(-"CLHG-2/"<5,,)VW65;BL
MF "A/!SD?V,:&/%RR:I4$=?DUVJV858[CD<:YH'AGO-2/;(O<GOD%LW.#-BC
M4P;,9<!^.F7 3AFP[\BLOS@@$)G9+0LZN54F_9'KK:-;,@!CO8\9_H;"&'W9
MJ'2PU#&-JDXB0F N,7$A4S3M;XJ:.\!ZC(WX.YIZ:6%]'BL]Y\EGC1WZ8<=C
M]]!:XTACK0]D1\N-;[@I<Z<.(1R>ZP5<M':V5PRL64'-T[B8;>B%>>N87M/X
M-HC6/D!L-D_8/-4T<7<W%0+CP0I;NP828%L C0"C:(,V/(Y_3H5-\!'R_///
MDI?;?(14#!;/HG$N-C$NCH$ <ULL<\8,84O7B'Z_JH4YS*<"]GN^O%"5OPGY
MMQ &CYU*6^6AF%WF:%\&!$9;4U$<&9Y@HW)'6@UX0Y8Q&<#4/F51M $UA?M^
MAEJ=-.@W@'V\.;Q5! !.5V"MM5+AWA5W2!,[ENM*/VU8M!LCWLZ=-7T:"'>7
M+,] *U(T3(@PK5:;1F?**7L6"I\\RB6O&/3JH/V8Y1>0GR;9GN96?1;+*3B,
MGA,N $[JKZONQ(U"PB>.0BCG)M2N+I;A'G@2^V_1($)YVIO5 GCU\5CV#9E1
MUP.HX;"HSNX*090=U;)GC*,NKU=-[M]D3$!/ANB5Q&J27RHH]P@@1?V,@2>A
M^Q;\V$KH2-J@[N@CT$Y%(2BK^\KJ#LAC,*%F'4UP=;^@))I8$D<@N$XR\PUX
MF=^(J&Q69+IS3K$)2)H.84A&VY62D0[NH0^I'E2'&9*('B=F!&^C_B#/4(G6
M[,SGI:7J!,M0L'X-RM3\B7K85P?9U[T?/+@%$K:7S 'VD@1 J9XF +#XBHID
M:D7-;DWFB.Y2XKH9DU#W:3M^ V+GO2%\@)E:$?^O?)N\4N@M1GH=!D@.!4>!
MGPS)3L21Z*G: >J)UG!;4,FGEB)'04H)DS-7,$X>\X1<U3V=W(B[SQYG2"69
MG%U.J-9&5Y:QH>L^O8YFQ0%"(<, (0$PY3?"1M>A-"6<B7J:<HG-R$F%W-0O
MDUY0BV]$H0NC".E,70;'KNK.-K7\&Q:%(^,L/:+;_P(4X[55#*L8)TT7%K7O
M/19D/V/U9F+U1O$7!,3I67/ .,RI4O(U>FZ/*\.C!LOTNOH!\"@[LS>/3]D;
ME[UY=LK>G+(WW\W)?*V9@[Y0Y\$+^U2%\HNUGP9(ZG.A,85#S3!["=9@2&,Y
M+"K*5UB8#(8>A&6)QMLU(13E^K$ "*<05=0._<T'7TTEK,YW;* F8[XA&) <
MCD$-,M5Y<RC6E53?9@*V@6 L0PRK>_L7OO.>G4ZQ&ZQ^P'Z&T#N]!M0C?Q;#
M1JG7GEV7^2BPVK&?,L>WP6YZ<FV1(\E,.<S4A?D;-@>IZ:&+O[J0K,#5]%+#
M;8RV:KG="!E^3J#AK@_9)X<'BFOM=J5Q1OBG9\5DK_RAC!N7#1I,^I!I':6(
M[ EB#;X586SZ&A$$21+Y6G@4E(5@&8M\.11/T6XVEW4-R#;43NYW;[ONB/(K
M3AMI%_*[XU$("B_'KK 97.'.*U-)(4A52LJ=-XLET1>4W/4> (Q8(0B*L)@5
MZTSX[>%NGH5$S4)?LF_?VFN=/JCZ)*G;2<FBSG.CGI7 C00\P*9'0#L/L/<S
MIBS_9%_=,J(,9HS_#DY=^!OW3 WDJX]Y&;*+CK]8^7%1EXB35OT&Y*0=(3VT
M=SNF=M$3G!-FC[)>;4N-(Y3OCVE_II."WFR9H_YH\D_02?XFJZW,NJY,^$?H
M=R M&SEHY7NK]#CC)R'Z!JR9.HE+;;:(@BTO"[O12>-$'6/N#^L,)),B-UQD
M;"1@M1J)]:0;SWCT68D%Y36W[IY*'I4#5#0V)+\''EQHTN,8UBD9FYS=W2 2
MW\ 3@/6HJCWC#X_I-J?:9&#1Y)\F8KYX5*\U5TLA<9<#3]3NF11.@I5/"?%%
MP6F6#W!:;NR47SFX36,"*/#%^:.?'_[EP<4DA(1HF#3BC,%*[J4^[9D:R?7A
MJ'@RT@BQG*V,.V"P:,HNE3WNX">^0W^?^J1@]##VL^GD[$*58,RANEM5@/6S
M,3!GJ9TO ^&EMB1-Q/!_BO[[SMIN1</>':VUA*[KJFD>;-8^ELD73\A "(_:
M?J4)=HYA&>+Q6H,#"M9TXOX3]BJW[\P50L JP6!&GCQ__ES/A=@X^VY[^/PR
M<4S^\Y/>_ :(ST?C$9\NZLN6Y@GU>8P4?(\>V=N[+'Q<O[JI,U>1R^6Y4I(+
M[MW!-'9=SRPJWPKK6KJG<GK?=R;#[S3+/%LU^H-BC![0X*^:,8?!8ZC@8]7G
M-LA5WC(,-7F]LA.9PSW4[^22. 0OGC][8LX._;175Z_?7T;E;Y,TX1,?M"XU
MY7%,M7A#&E'F(78L);:U%NI\ ,F81D1]\)]$P"W!.5=Z#4;5(J]!HX?W4'=O
MF<,T( 7,RP6VV[++W#ZH_?S<Y%G9HI'"EQAW._U$G(%(!#[[F%1K1PMN_V7%
M9G:#%"A"H@NA%?@IE8)QX,NQE\]NJC+#GI]P;5FI[F;LYJ<@_IA+M)<7LX_&
MGJCT7TF99]#+3<)V_$\)&=J!0I(#KE;(-^@RY8.EVHA)])^YTR+R"+/5RAA;
M-ZW "PC6PFVN,8 IG/AU!6R0C-9JX,LX;95*D5^QDHYKG8RHZJH$TI[JY"GQ
M!4KM/931IYC14P$6L3-=:@Z3\_P/7GLJF&SLPC[@?T]<;RRP[#"["7VJ<"Q1
M/]VSJNZ (*BF"D791XK)QN-;?10"]PW"*B:'4%'%S$N^!U@/4XEJE.DF4^KK
MN+Q^*-^M0DXX<W!EU[<(1]J$W8_A8ONY)H"?NKC5L1_+.].03TYI2)>&_/F4
MACRE(;\;VW0Z,7^/M#:&E'O,LF[/&Z$D@;O>9=0Y'NEB0I-T5JVW+I3-1'(^
M! R:&E(8!M\KH$\7!N!>1IQ+Q'!!S]A<9M#NMM6<HS]$L9(Z;KED::T9=-_Q
M!N3/J_-U5?/M,S9" +37L!V.=_/M4@>  2)[$, Y#-TP9W6Q=KG*0+OKWJS!
M@&X'!^1I;X"L&N@C,L[0P$#M4I[UW#O/ Q0_P($*1-X1M[8G,=S;(\#%(UY?
MO8_YB4W(!]-FGQ[XH).G@=FY1F>WQ81V3OP-8IA0C*,1'\:%(V:^%W!+ ;%C
M/S*/3UO,#M$62%_9>@M/=8I.E5W)Z79JQ,PY@8'D9$$ANWKN.D*CG95_ H0Q
M01@H@^@ 9&'WCD64>7JA:2>9&N,^A!A& =<Y?IA2I1G&FLOLKMD@?,'75,0%
MC7W[9=00% &<65B/948VZF+PJ;&1CD%TU]U6]J_R'1IKVW.LWLJ1T%<X3 9]
MY^0%*\I590850-%( A#:@G)I">QE=@TX6]-?_Z$J0BM($,C?!>]HU2*R[7.5
MDPD+I*A#ST['(C#7>9S]B=J4D="4_D9OB*M6=?"W+(/^,HV)?A1,3'@5@0$D
M-('U9%OJ?>):2+MK)\II]QRG%>,LG4N-;8B:B?6.8=NXQ)V"O0",IMS2'+D$
M!"!AV(=&SO=\41(5"E>R:N4-QS6ZU4A]; <-([([/6^A#6'E6O!J:CD3;&>_
M9T/^8IW@[E^*,)D,0_W+Y>6[F'5U2*F<#I%O4%9TY-F_(L[F*4A<E.&Q;['[
M$)F%-]16RO$2(Y@,JSD-!R_B6F2G8_'>O876?3&/Y("8AWFY T#$9R6VL6"P
M.X;PZ)@ML$)[7^0$^SU97922F8Z+Z-#:2M?J /0+9H<.YIQQ>'FICBTT21$.
MN'"3;V_EY&G*8^Y)P<)$;NC0/[,'.52;6X_CVH[ 3J"AF)I,'?2+=\30>,X-
MKAF>($,K3@[Q\&K+W0.3<E):7S_U]OB U-OJMJ@KL6!@-[W/%GGKJ5OWDCKL
M)G,P._J^SZ7_@?>7]J']RI)R#O@.(B4?YKQ'' X9R,9MB<"<A9MNBZIT.Q/M
MU*$Y2:Z4B9X*TLS;XWVDQU^^\>E@UEV^%BY89$6YJ1&#UE0TO]ON6IK[P*%V
MS3@J+HQ2Q*8[V]"0%,QF4G3DG'0,- .Y7D;-^JJ:/L>^)5B>D2O#)'G^8>NJ
MI5(N!;ZT7]2X-A#AD\W@DT/ A'<)*@!;PE7S@M[(M,.0<_$)A6/7A3L#YT]/
M@7,7.']^"IR? N??D4'P9+Q!<,4XUG?H;6B/X@3*.490SI,!4,X8KGPJ/A5B
M=*1Y-G'(S?DST"XQ"F3Y6K&6J.4[B!(ZHLMMWZ7V@P^%L5Q*@VFC!#>"M?P;
M.L48;GDI9=H!Q+N/CW=GT3%="O#:&^S9);D5=G^-=W_=^ ZH^)+'X[3!"U35
M-)C*K^WG3^V.Q?+J,Z@)658K- AE;NT97 .1$@RD1"@GTBH)2T+'2?>C#$L8
M3NPEWY%2 ':QGA9AK^P&;+?4X@;HLU0W!_LK!C^XM91B#L,0J6O:Q,U,?8-3
M-.OISI[NW3L*\D]2\?6/^J?WZ)\@>O!TQ!_E$?_T/N?[4!<=$R4R_/GOI"1(
MLO6!8B?] >UQ?"S*S'#G\Y]C8V#+H/NWX>#!Q>;%:>_LW#L7?T:=GQ=-+/MA
M$1&<BF>3K*5G"=0U,UU,YY*"@-6 ?@FD=Y'\R\7#A^G#AP^Q"4:%L4M50$2[
MPN"N@#Z5<RC=%B Q[K\F S>YQJ,Y,#DY3Q U5)C\V4MSDJ6.+$'1J%TE"._.
MD4&WP8P,] <$V')93:=;_ LU!D,:U1SA9<N*XN/V"S[F((--GMFUES]$U&,S
M)['H+4BRL'&Y8(,]9TB27<_Y+* '4KRM,5P 'L*M[I78AO5NV$V4Y1_[89S$
M[>N+&RJO/IJZ'E8Q=QRZPD3B^F,"OTRJ SA)ES5--2M<SBZZ&ZLT<I2>S ,\
M3/BL[JLI#RO<";/J0<3;<CBE2=HS.-,[N.!#$_WZGM_ZQMT(=_'H<1M.6@3I
MY=,V^=K;Y+9SQ#,>@)BH=7[<%?FXI#LDD22S[CKR."A'7V'8'KB&&8)K1,UX
MN(L@E\JL<D6_J1QO'6(]B=;7%BTE64%F6$?5XA:;UO1KK[-K%*@U9'3Y;/<Y
MYG69S0@-_GL!C0.5O_3.=5N GQHJ[K:*!L,N\!1'7DB!F ,BA9B-;YJ-X)#@
MNB ZV,44=AI*[#<<CEU&=R8Q?SHE,26)^>3A*8EY2F)^/XK:6LI7.?3H$\J1
MWP&H1EK/&P?CRAWCV!-<:=VXAHAS^?BF(+IGK$5*6M35+E9.K!OP'XX'Y6[E
M4RNZE_FQJ\UCE)@@,O1YDD&+3SQLRX()XJW=6,^E%Y(U&D!BO+Q0RN4M"$0H
MN2F)[CP)Y;GRG54'!4N*F<%E'"J1ZOF2D_!] ^$+I ]RSO>30-?BZ]^0"+PL
M9D"@T+$XG5_N0<Y6(C?(0V>\L+*#LO"R:4W$-L<(Q":21B#S'G@=@0![7X=E
M>?$+=:FAZ7UAZJLJB&2/?3,@0R)R/FN"-Q DH2&QYH=*&"EJ;*A@?[G,ZQG3
MJM]F18GG>E,MVCO :2*0>W:SJLKJ>FLPG[F0,A38</ )X;Y*)6(RM[LNJY/;
MK-Q$H5](,^RWG-/D[-$$IR)T.:Q^ !+ZM?44FFI3S]1H,=/_.+II2([4Q#AI
MZE_<_GCS"^. !?<0U1ZJ/!7$0LI1UU47 J&;O ,2)8?%#]C(@$_ZZZN'7#YI
M[14OE$>(G*(7WW*5@D7R'8=V52;Z2(2_4XAD*3\5Q!M<!P=[P$!A7S.D.TYK
M_[77/K O=.RJR6?V?-ZFW28FV+C2GDC-K*R -4<EGO DA=HK.CFQ>$K.]X6]
M:&Y/]2@41:?M.F]SPW5*D"*'JW2[CZ@#"O,LPA^N\^JZSM;VD($*BNPD0E]?
MA 9E:)VUE(ZTO\US2&$VJ2O&XW_B3\DJPY=,[4$PAUKR:KTEL)A<@.+(B4Y2
M/\[-Z3WLDRO"FH72=I*.;R =@7B$J;_K309EAWF.X7$K(BM''Q)6Y/ME1_?X
M)JN7X%"'%ZER;J)IB4QP$]:C5ROLAZ/5UX)JC[*BMO8Z/AM\"N1NR%?,,D?B
MVQVORLO[8IV3.?,-).YV2!^!,-Q6@J+@&(CCDD70JVO9U)<SP<M*3L'9GZ7J
MN'.M1O&0G>/SRE9C^9KM\+X35N?K2TLW*SS+@&3/5VH3_5^7J8$<6W2P2_18
M$0V9)2%I<5^)?:M+[#%3 (UL6^E#$!?^]^=YO12=I.;K2\V@S>.CKRH(EE$6
MUI%2UCF7E'*$UEHY]A@K,'>$823^UP1+>3L!%#@#0=)*B ##/XQH+2SK.')Q
MV)E;?7;*K;K<ZL4IMWK*K7Y/.K&K% EA_T<%3=JA+<2FAF= .'^5(]]QD[+V
MM$<A_!--<+K>0UXU]&56/: ?($)L#TX O\@=\_PV+ZNU[ZDI+2DH:G"J2/D&
M]66OH RD4R1$9'D-I$$*:S=-BQ7S(<R3?&5%8)939[Y^]HH@;;!%LPM-+0 [
M+S-HT)%*DR6TZ* .Q/!ST:BBBR@^17[B-%M]K#?K=H;]KNRQ<4M8[3H/P:S+
M"I/XQ6:IZ(78[0/>.ZL6[[!:SA['V0*X*"&ELUCD"AH&B9J9M1<+<!TX-BJU
M<3 #U[G='&A!6(>U6)<$*"7_)/5UFP6&41<;Z\KBE]'LT:L8H*AJ<LZ3#YU)
M-/LF$4E/75<X=)J]:]M!M&4?N6L+7"C%$&E<:^.?9Z>]X$14:@AW)DFP>;[(
MT(BN$SBPN%7<RJ4/L.S&?D='L%*.3U(7&OR :H;9SSD94IR( \XASS=29NN&
MFA072_R#/8?@2NS\HCJT4-VRC ZGM%:<WAB \.G"F"5VH) *@ET1\YOI5M5A
MO15U9?R,(B]?QWU2AE^_K/*G ^KS7KT$X;92X.HI<0,7*R2)0P<P#FW$W>OB
M[$N T6PV:VJ-&.$_F%RTW')&&Q/FT!2(-,J[NOJT3=ZW5CZ97=/N=2R0"PL!
M*^VWQ#>=L5/KR(L-YG+M@.CWEHB#4<4MBMH> /.BT>3[O*W>W]C_=67*-31R
MU:QH/5>)MOUKG@OM,K"RXF@V*]BDIG'#!$WF_;D%UA!:G0^$<) @:06=$UX2
MEQ:V9 7!)U')]"J'!#]DO?#?D"-'O_$C$::Y]S>&;\)RGE)3SLV*VOK^D&F!
M%HY1GGV+,0G012FNS+)HK*,X/Q$(?Y,]_VS\GO\%J\'(!GB+EL7E_+9H*J4"
MK.<G-6/$&T6<B]9X@3\I+FVZT=LH9 %#X^-<M?8"Z:7GB9+ A\S]O[M6SB+/
M*7HJ=6-]I0EQ30+4AME78N6$CMD;H:F%U^C>%J>&E]],8G\>+[&_0A(X*Y9$
MJ4DR>Y7# 0*0 <_O^W?*I=AS1TER"Y*"-:YB03H^5"L-/K]LG,)/DW=<"0OG
MQ_Q?[65_!7[-&HZV,%):U&(K MI+C^F6S&FX=,X1U"RL]])GK.<P1OR;WV'K
MNOHC9^'V>\2=8?8*>PYF$^>("#RB[IF>.S<]<B )Z[#=K^-Y:ZX^O'[Y^ROS
MWZXE^JK+[9'NM0S</"J]@:<30<*$?!R, VZN''X2INLE=V:8&U!UX;%#+]->
M5NXHT[)KD&ELY(PS>KQQ,V?)59\:KXS_#GRAQ&Y[B+73F/AUH-Q&:^*SP'D*
MQ=4AHQI'<=MXCML&,I*K[!K_Z&H.J;P8_*V.L-=R'#23?UI]RJ'&;J"Q+WC[
M);_BWZ=^8[Y._OU?I_8O];_"GZ]>O;MZ]?[5FP^7'UZ_??,^N7SS:_+WRZNK
MRS<?7K]ZG[S]+7EW>65_MEKO;U<O__/R_:LKO.:OKZ[^8O_S_=]^P:?]DR[H
MMSH@7Z$Z-]!@UC&!B&]$_L:O'ADE#CBF?L \I_XA1%-*V<$:]GV%9R!@@#?+
M*8)?0V7DT0AD>MT"&J%-0&%0_W)Q+S X-)U0H*)7K:7ZM%$/@XY=$,PH*'2;
MWV(!(':;5UAJ;GRFP%]PKDE_1%,M=KQZX".*1O?6S=9KFD6P*XGHE<Q-;"E;
M0V<_2'+,[<'::Q.P00"1K92BPB6=#419C@!J-RQ]^,:'$ 8.^SEL]ASAX'U)
MN <C/";H#A0[RAVJ=^1R\-  KO_]U5Y\[+0P.S-[/Y\R>RZS]^B4V3ME]KZ7
M$^^G\XOQ'N';(%OROZE=EB#Z@!";_3WG![YB%;M+FZ-[5S3&'J5;9%:RQTU-
MR!Q,()7@EA34-![S"*ODNJKFB7,N*4*&97B0HV'5^L>F+IIYX>!<!0+3Y>G4
M.S5K?%>NIH!.[-6=/5Y01SL\/!3>W-FK$8]!6$4NWH-'<@D^.BC8"Q0@\/B+
M0SAC;SD\4LJM7)$S"2ATKX?OKO-K;AB5)JX-F1[(_U!,1\!%ZNE]4P)I*?2U
M@UD(X"8R5)X:C<>&GU<9I'/Y5Z.8'CD"VI I0./FOA7_" 0"/!,>._Z!0MR[
MP'+Y"&FALW]WPJ7(%83+]P7J)G!"+X\Z#?2FW,X3:?+"8S-^;*LP4$&)NX"3
M'N9W\+LQHQ4^/!E\.$@LMI6E"#LNJPE>Y[#TN#Q#;_VG]12_G9H]H-G]I>\&
M]DKRY=B1X)3=^W;DFZ./,CE5?";('6ETOB2=\X6HADCA<)BTSV^ W/&H'E%%
M&[:&<K1#?$QQEKX;FU(  $062.,X.=P([)J;. - NGU,\ZOI=O\,]GM-O91+
MYN"OCU&[HP<4Y3S\N0('N%''-"[O&N#$+@$;SO*TRNIY$V+,D1:\V4S_X)!I
M-6V9YDT%'ZXD^_C?59M3L)=>E G0W31!UG01?5//'4E\A_]NB#'SE'L19JEC
M#(JTLNU,H>F<BGX_0&Y*IBNDVCI4<*(<08>GR_0*3=^6X1/84W2E@^)B_[;L
M$XF36OX&"+0/(Q7%06HRW-NBGN=:/]/6[EJ#H402V7]CQ8>;YH4F<:I(YM2S
MMXSJZB0B%%BIS*\ATX(>$M[+*#NC57CO<16,,.U%Y*$AWM_0LJ N=TV@K' /
M,S:-^&]4'TL-OHL!=QJ,Y\%WJ2ZWPC:8^&R$= P@ZQA5)^% &EH*@5PX7@,C
M*NV.>!<F+SFC'E0E\S9(I@CMZ_#)R,5AYQVZ$'+G7\@D<L<O)$ZC1Q*:Q7[9
M/V_*YML9X@>TOGM3K1X01@_PAKY1R'E"B8(D2!3<'[QG!R5I73/V/#S 2#I(
M]^W7:NE((ZKG< X/S)2A)M+9;^ I1CTEIL:D+ME2%MHXPQ75$ .S $XZKPC'
MANVT&=2&S^+R\VK3]B!&$XT8-9#6@7KYLICYF\GS)JB89Y#ET>T*=NQ5S)#I
MT4\'16@GXRUBRI1^[050C 9/A#T\I+,'4/O,W.O3\+-3+H(SG!DKJ\:!+IA;
M53I^J@/+ 6L9(,@87@W;'5B = =FUSUU8OB585]5J?/C14$J6-_?5?]80VG@
M+"\YCB(M2QU%+)F[:@,Z*"#SQ(>3 DU25<M(8ODDA)27WL%UR(38LR\1%JZM
MZJVJ]T1J(,!7.+!#6-T8D 4YG;#O52%_K=VM"I4X+&*F3\0$I#^M-M0ZEXYX
M"']2/C*5%43(.F0/R@R(EZQ8IIB6Q//7Q;T:+Z, IB"9 'X!O\0P)6J%FS1H
MNHMC0[Y5._EIQ(->NS:]U]=@#<"6(%&D!J,NP3G-L7W C)&LU%7'X]@O@3"^
MR<TKMCQ@66@;*&8WB((OH4J=WLBF!:\M]%R#B0S<\1_.$]F92GQ^2B6Z5.+C
M4RKQE$K\?DSK YI(CH!#4_T-E@WUX:$%*DV09@WP!*6?(U;/2 Z(:WCJG/&7
M!$J& RU(KV547>61RAQXX[(T#]VS1U^5+-&0 )T?H:X[*&J#E(?^88HA3ST3
MS8,^2H$/0Y0"R;TH!8[]>#C"G7% S[67V;IH[?C(;3BE?+Y=R@=R&DH_8*#<
MVJ.X/$HY8,B'.66@\O4I$7LBN>?+TIKRR:5<ZBCQL&P) <!L1#]ZGC[JO<=$
M]U">NFDV'(^TGJM+^_?W:Z."TJ?QH'[9/ZB+1W*/V7W//0;%E:XP,C<P?O@[
M1 *":R4C8JR[\:PLA[SLW#H=O6/ \  ^[N))>A$.@JL:FH$W44UK][:^B0'P
M1WTK-++2?D$W&JEG1:.KVN3E=N10EJL^\/]G[UV;XS:2=.'O]2OP8=\3[ B(
M(TJ6;*\V3D2+HCV<D46]).V9^8CN1I.PF@ 'Z";%_?6G\E:550#Z0LFDZ$'$
M[E@D<2E4967EY<DGH]<8]1J,57MY]? 9^H(4H0UWUN#CB+&=5/ SFX9BOR5Y
M,SH'5<O'QX@&C'9(W[(*T:.I<7XU5?7915PU$*.^AJ/I&KU<O"0-*'G%':=C
M2Z*^]$M)/W:$5M[^=IR\/1R+?^PJ L*0BTH/\@NF/5YOGW/K_XJNZCX;*\A6
M$,.$MQR*ECM(L*G5E=$!%6]G(!^&7><R]1#MF.6YKU9'YN5L*KWM))XFPEC5
M6.<B*DRBT?+PM1_GTY ]'YAL\X$*% 3=AJ]#U#)Y\=A4#1F9\^FJ+B1PP*AC
M)@[4_= "GCBQNY8NTH:?;"? SBO"EL.Z6M3JIJW5*\_TYK<=-.*#'8$)BMQN
M3919GMQY&M:""&U/ D6>,L/\H%F54SD\A@C4#)E@AOSS,6V;<[,NNZ?L$EDW
MB=^-K7@A[ ;R6TR+:Q?3"O93TQVW+KX@;OU*QZW]DC,/V[*VAS6DBGR*.5@X
M.^K/P>HJMC[[.WRO3$RCN!:ZZHOHE3!]B)&;Y]*+(2X6;L2SN._^<XVE[/@:
M; *)T9M/M..\IP)50 PNKZ^HWGA1@>DAPH9O@[IG7: &6WB$(A-7%0TVX*/D
MES?8@"Y6JLW 5Z^44>.N$,-.SFQ[XBJK++[NK;-^[*XV1"G_7\_W[:4'$(>F
MH2AC#4PDH,+O>1\"$W<QF@9I>V!IFXY,%&P/8A-T\%AS4X?D140X?P*BPMT'
M,(??)R/Q$T+A,']ZX5@78/[Q^1!@=@'F[X8 \Q!@_F8TY&QDE(?2!]=,6T8V
MP2PED^=_@K*.BEFGP=IB,!$&@M&'(B-,COO&RL@GMO$9B!NZ*)Y>F%EG!O/M
M4:.N.U R':NNF'2H!LQ,+%V'C.YB+^SV,B]5B*0-EPO!J *UB0(U*+Z;8S7/
M?+!F$*4'%Z4=F'Y 2.#L>./QVF/&7#>; &2Q?_T]8K )&(.^IIGEC?UR@3#8
M(5CWWB,8()<$OC+A=.(2+(JO-"X>)J,23[FG(PPZR@Z]S5PGI@ND1JS'_1BU
MC8V3UP"RI3(M IZ9%FHEW8P\&S;0@V^@'8B'SB%LE(RM-EV5RR$!]G@)L)ZT
M"9M76.ATC3$\0"'9X^J_7OQPD/[X^F7ZXL6!0^#A8F:TF(DUCNP!5C27&C_O
MZ),$/>C#;1]7]NJI";@ ]^!2"$*_L)/\)3*%SSAX,TH9-&ZUSE55"LL#!?+H
M9.>W73C]:+SAQT])]C*NB07X 1;VVF]Q7$]Y<NPA#$)#,2;X^<&/WST?X1@N
MK5>!U^-H[02=S.[LJ8_)%K!/7+33/\S\@G1!^%S^2*]M9P@2(!?^;];J(,E\
M^3Q-7CQ_\2JU$[Z\!5R$,)DR@IC?2BT/@,81<E> 8$ \+ P!_HL?7,D%A%R^
MY[+(B*.%&3;](T4\HV5Q9,Y2;=[-2QP3/'>8Q(!X07SJOM8BA %G(QH+\C&T
MWQA'-\@X;SG)P]&%[,),*<S0;V2;8^#Q,BIIQ"R <Q*19$"1"41OP<Q9&[,,
M5UY0GU/[,H]@)CJ" ,7<1S@L',A^H%XS5K4K5_E[6=TN\ME%;A1ZW*N(8:\\
M0KPV2"0U^75&)9(JQ07N8K+(D>MWRSR7:R2B>/56)?^0=G#TC0SR&;%\(4P:
MS^S<)]E[=HY+6B= 21Q8X1/8OQFP:R/511F2X3JJ[CKQ[S:,@TM4+S]&Q%U;
M!T>-@ZNB7*O(X'2VJJ$NJMH1-!!'4DAX2+DW=US&CS ,+P>NJPRX29FG<:\8
MD>QA_SJB&[EB4@]R2K+/0>+/M2I6R5R\)<]J=;8'+\?JB<*_R7"2?CT6J*?>
M+@+N;YF!'Y3!(X0F V6 _)-2><$5@$"W+S"(MEK714'+2R@?R4'"NG+=T78)
MS73C$%92=XIU!+B3IZKT9"W-6<1QZ8E+%14=.>.Z>DO=8MQQK[>3QV\Q"]W2
MTPRDN]"@W)"2H=(+4E=6$][DI(T\ %97P?#DK>A,)@W2N7]=A1@P?-N1-T#&
M@]$5O,=3R&R\VUWJ:6Y;W )EBPENV+T/'IWX<?OHQ)&0L@Z1B<>+3*@TT!(;
M)TBYUH9XZH][F2.7;!.WW$"<$\A7F'B7LD*.A9>J_%@1@HX3N%!5/_D3=VU&
M_&#(B+N,^*LA(SYDQ+\953@9F9"9KHLQCOJ?>$OF?2%5I;%Q2883<I(333_1
M$SUUY?;TUG4Z:N>U^L\K"F SQP'VPP*N2>YMG0&6%%BHFZIFQ@6&G>8,\G?F
MM!<,B3<;\=\7,&KKRES4&<+-%>9:10"2.83O? P-0^"%>/X<''[+4?ZQ?X3$
MT&<Y%6Q3T+J84XC,/\5XCFB'S"^;99[-(H]ED-B'YY%]OD.&+_O<:H#UD^(:
M=YGC[8'IU*Y#[+R#YPZ83GXBBPU(/(NA#Z6 Y#67(+G6?JRX\5W>N_$&V7H$
M@U]E"^;%@OL5@AB=YLM5C?T*YYJ20S.D ',*133I5L4S T]!':,>E=SFBN2]
M33%KHBP%:5\>3Z[BMU5-%567U2T2YH$DJO>,B! ,8H_(/.^C_IY_# % JD$J
MO6&20ZD#6F22H43^WWE&]#A4:<;!EIF=% CA<A6:9BY4V=A!J!\GU>8JW#^Z
M,*&5I]6LP# R=;&!KJ-VB?'TI<B_BQY&\6 73 Q"B$+KYDY,U6D3_5@K52D:
MCF(M^L&@)&4SBJ%EM.50=@"-5K/P06Z")5AD7/&;@G4 #Z:8&%;A(^O;C*JH
MEE@Y7Y0&DHJ#&#Z"I6D]6TDUD<"%/4\[5Q7)[0)V<>HPHO0TK#?K:J7V2!X<
M_1@G:KCJ%,Q-E##FK]8O&$3C$7(:OOP5Z=,8B<=. :P45)A@F8@'G<"O85!7
MI>H.$/[9'I95_!==KNA_2=W!#1Y^OETN1GM0:T!A3,ED:YQ/.ZRL\^(+FEW!
MYW5=V FU4Y&0E.7_P1VS'DVF\L"4@_@#)G&1W1#!SLZ,BEJMNDL[&E)2NUG(
MOC1L,=5L4[&D2@@W=02BJ8%OA'P<4SAP(-?GZ*W_4<](X <Q>6@QF8?&D2Y(
M [F 1/R<BZWM0/+240, , UDPO>ZH$P_ZZM<4-)Y;(T[OF?=\[NLS&V&=.SV
MKN!%*'+>Q8"^OBMJ^(1]YP4^P$@@@NZ+EIM6BT7N&I.HD?DJ8XRH%.AD0!"G
MIR)O2!H^IHQ>!*J,ZHQ4(VOL]HP%0[#&NA*(BHZR&:;'F3U WXH&5W@#FEM+
MA9@G"8'6,A R 4/<< $2HC5)9Q)>E6WTRVJ1,Y4ALK;;MP1!DY>O7L&?P]^]
M/O"!M=D@8P\N8Y<1K(08*D&MD,IPC*)C80QUH0W5FC:^"V3U+E^Z^ /4;Y20
MR$+UA-&%I!5=,!1=H-!*75EK"CM:*'1+%'A05V& 9$T@ ME2/9Q**5;?D]>W
M3A_$\*'%L&BI.HH!>'\ *7J!RY6]Q2D?3<KPM[)PDRT%#9G4*RQ5 H[6Z65I
MEYL:FT_SY"H'+OAREF&#7&12P4!<75T539Z:B"O(.PO.&&SYJBK@$?#Z3#%K
MX1(@<)]/@F3S)><Q^* -Z%N,HV^A"+.R2OC;HA?3WA,(6 ?TOC7RIR[H:T$%
M+P90@0,5O!Y !0.HX)O1]K\[;0]TAI'&M\IY(MQ*P-I-Y*6SY**N5M=<?VHO
M@S('V+'XMU_WS_:3>3[#)AL,H%810>=R@Y+/:A0.?)Q!HN\E\FU#P&B!SIL5
M=SL=^ "7+V0V01FM4N+B@CD72X'3]U1FA;YXQ,GK<T"6KNH[.\2+%1.&F\ T
M/M@_>/7\Q;/73&?OCZ. JDX//M6CA^8?5%_E^*J(-+993:'2%F+\$T72KH9J
MOGX<+ T9Y";8;>"IGSY/;^-]:IE9GM!-&LIP]GI1H&VN7$+)9$=Q,^[F;7_6
M-81=\IU$\OWZ^<'!L^_V)D.4],$%8>$$0:/)]<H*2 %K4Y;4D(PU:T$!!NO_
MM:Z8Y=#S%703%+98TSO[S$!VO%-":JA:[=BLTP?:38IWN*1NE+ )V[*/29]Q
M!PYFPT7P&4'N[>P45]0- L-@EP#_ :F^RJW!BQ >KA-VB4<:C*'!4-"CFB+"
M:980:1[9/[Y*"$\!N(\W2LL1D7V2-5PA-:&M%4C_]P<O@L@':'GBSO1'E,I7
M1-TU NC!R/</ZQTQ#QFRM-EB@;Y,D]$K[&R5>IL;NZ'MF4>@*LS/!4\-*J;V
MBAMZ\$P(=;&,:<I5'9 6%LI*B!8T#?5RD6+M8'HZ3T0Z+$.]84_%>.:8PM4:
M '2TZ3-RR\.S?7;NV6^SSX1XOZ'@OY6\:5YP8ME],G;86&$%3+V*%T$++\18
MH5JOXQ"ECC@WN$Q)+L';KJ]__@,XR_K[UZ[1H%H?6K5>487SJL1$D;,*/9C"
M68P,I+0V;0,">)=G-6JT68$&5:H"\5=50]+G+[^R;X8&<=S1AB/"'/N"=P#J
M(EDX.U7;HA10<%=Z6:;A:A(%Y .>+Q"_6U"7P6+.8+?&!1DF5?4)#4'*S8*R
M'_E""<,U2%VQ-F]9NY/(?4ZV=*,$Q3^#)626:ZQ<S)HFN_!]M):7UJ:_N SV
M7%#TZ,N][:T 9&V66'UI31<P=XMI'JT45**3PZ$2.<.6>N@M5;9P K=9[=8*
MZ^ISI@/"[AAV+3W<B-J95QS&HR;WPJ5+)UZJ <;]S9:XE9*ANNB<%?EI#N).
MS6O%[N%&]7=B971==RR9%) L./N0;&.0K8>'%1]L#RM^;R7-+JJ#%+-4_EH6
M@-+<4'\->B;F_@<Q9D_+6EX@)Q^R9I;]._EY44VLGOPEJS_E2Z&"J#,TBZVB
MPM8V;P_'I[^F^!]*+L.__I&JUFB+N[#+C8+=K:L4U@00_3 _Z\3S8%G$H<2_
MJ^ #DX;2QI';FBZY,[FUQRZ+28&<_0V,"1_&3=6H#_B")EUEK^\_WWP0=4WR
ML/4>?NN]V'[KG>;H)5HYX J,>!,2D1O2.2WNB+E!_!#5<J)VCU%EXT9'+MC<
M3@Y>R@%S])D]R3&<*U*9OJGSBI;5WKU?YQ>P^VL5/3%^#&SROX!.G1UCV79O
M;X7A52A;WN?&[W/9W>),>5+27,;312, ;8KA^_C("VVK[3:Q-6/C>?/5/^%D
MJ,@6G?EE)<WDD5 @@7J0JVL:G6@8-IK#47:,T.RD9GJ&^,0US-ILV\LAV^:R
M;=\/V;8AV_8-';,[="3_M?3Q?,EQ%8JK.$@?Z"N2O6QB-_4* FH<"4,R6#A1
M&/?CVX\8;%9B]>^JSOOS"8 \2JR!ANPOS66>+U6G7,PVY1@HR1M_RED9DQC#
MF8\Q$&D+T&WKOKNFL^^NHZ#B0VRR:NS,-(UT?L:8#(28,T6**^]T;# =0"EH
M[ZTGC-N\S# )&:3'_!3P\,))X-"\^ZL.#JV;!?^Y;M*BV\V:VZEAN/Z K"XD
MQH*LNW(P3BDOV&:3DJE,['^FN>?]; >YU@R$/Q\-E<4B(=!.4]GWTE<Q7;8O
M=@-[BJJ3*=8T#;_"/F[%H6NA_]78;Q-3^WJ>,*;IV[:5,S=KYE'%/9L3ZMG\
MU&V$IZ@>=^@JVTEFIRS KHTST/@\7E7O&2J:2 TA?3@%_K3/8)]F-[ O_H7+
M4.N#QPA,BTSU _\,P]<469_Y]G2ABLH_8XBCH19FT,\K.O+HG<C_59<Q=[&+
M68/0=3L6+@#C_3)T59?5!1,]^B(6ZQK2( VP#>JSH5E=7R_<@8DCO1\5<M<F
MB8AWWZA-0VT+J&1"JJ7O/??=4PO]('/"'XMKZLX=31]O[O6]8U^]NL6G!S:4
M7W AHV1V.Z@.US7A]K_7S)L'DS0+E(^T [0^[$H9/!"P+JI5 ^&0;$;XJJA
M/90NQ(C6N6?X,*XE'G6IZ%1_4,WNPR(;)B/A'A4II59KS\D;4W\V?;D;7F'7
M?K%3\N,=(L,[R^I)9FV09R>?%_D=1W0:E5%?\Z&S8F8H+[?+M](=2V(9IC25
M?3%2 "#-B<AHL!)[$+HIYAP^=0K+\R0:)DSM>*^O+L+^JI"?+AHNAEY=@ZTQ
MXQJ0!$SHFM_?]:2JWO"-2,I=2EA5-A5M84R<C63(3!*$<NVV,#4M="L_STB7
M68L.-RI>U[H@VN%XT8QT*\$-?"L)_!DU9D4-%*EHQBD03)WSG:D8;@MI,XO6
M8%';+X72*$AWDOKENB^WC/"4%/-2UA)=Y!BDWP=N^Y4SX;^$:>0[81HA$0+R
M=]90L' AOXB=CTE=9=#H!7F@P0TS$9K'GITE8=ZYCL)I$[)>O;052D&E=#XP
M4:7W57 */6,EJS$K(_O)$;!."\43MC/FEA[0D51(H.:]9W"HF@*EUZGDXPBD
M#U^&X=378!ATA5,' ^WA&2I01H1SN0L>L.=L*=R@R&0^S1KNG,6.+%DK(T4C
MBY(L^592=YZCIZ4[7>]D4.U_V:CUB%J VS.A\*5RKG'U,.PAQW_V\WC\T7K_
MLGM*1B]CUMK*9V;_-4H5[,F</?LGGC'^5\G9L[]'!U4J>(=J18<+8=@:]$>G
M\-%T4.&,K1EPP$"#%\^SHK9G/_/W]MQ)%R5\4=I[BJ?1T@JTK"^<@C9/UMA1
M+*I;^*.$ N#CEX)QX?PFGCB-X 9=?5AT46MB1.4/._[1:.>Z7:XI=.863@>2
M!:4*-/N2(UH_=>2K!R^S9P??P<Y7OWLU@]^UW2;#;I/G43_X <L([+D5'A<O
M7SU/]H)?_?C\M;,[6^;DJ#,%WJ5$P-<P]_2M#H.):GD86JMVW@$*(78QGOIN
M6)N>^FY(3[GTU ]#>NH1TU,BND]4@\\DJ%:@AV[/<CC4$79!Q;1HJ2DE+QRA
M8H^XX(+[BWT=9SP@'814*=6B85QF-<UGJSH/M7^D]%^9MM)_U1,K2]GKZ7L-
MH3(<!I"Z(9*GD9<X0$HF:5M'^4Q FF=/L1)B?ZKREB(T73?TI[]\D,:EO# :
MUAGV$M(K.$L1-2&.6Q\8 4X ]-T^E<(>*.<Q6J3BR6GF<SC4P'#%NGD!X=;4
ME2;(>4FHU<"!)RTC_;!97-2BNP^QIR\RLFZ6!U@HBDV!C0=31*//%CD!?**A
M7%O)A$*G18<72H^6OWMC5?Z.X8/-:Z<3<U',F6S08FID$=VM?TZLR--3;)XX
MRNDENR60%">KK1UZUW"-DRHATD!YHJ"XLBJQD9K)5K\=\ 2#^*]3+W"W>Z_)
MU.NPHJ:DW#)M!"!=44+J(&TIE1RYIH"@$1NM)O?FU 60%"3\U(EP:U8@]D5.
M6#1.4WNEB&Q#JYHB8I#BK&?2!*;.?;T!M$!IC]'%3B.]T>G[SYD4"3[?N%+<
MWGF][[G4=RPE7<M@U/*[%?$SEFR8,5+4ODV42BR31I-2KHZOO'*-&)U2N\A+
MK'F&V*[U-\# ;W7D5:VBXK?5X&3,B S;1TWA$P ?M]QJD0H\\]H!#USHRLTF
M4E2Y/ITL)%R;1J/+L"X9/2;BFBD:'@?!HQ=W7VM2N.;D1J;E4L]$,$ J$G3#
MH>(\'9O$X@.J3,2+L&1%EMV@T& #9-0.FK!F*A%6PBIV.8VJT"92&M@-N94T
M<D!N)!);ZEB1R;2[QP&?:75])S43ZL"5W(-J"6<W G1$KN]\B2;3L.@V3S<*
M\]&!.U5\> 8):*NZ\47C_,WNF+VU[@9@16C#MY6@\)F _D2_%NL):1=."=?!
M&%2X@@L=O2B[[>P>J&I ,H)D@#%!C2<1S^'UFO]$$IN4[!+ "-$\V7,%!TAJ
M3^V;6;;,0D6E:D+2N#C;E1O"ASH&55@^V%1(+IU?<":;Z'*YXI%85O&+E@(1
MQEI9R1QTSMH=!Q!,(4UOMCUY--J)ZF/E1:WUE'S%EN\P'>_@N(U]S;RV@H3!
MR:7BPY9W<EU/4=X &W"C5(5GA%"]=]SC;R\K >NH>3)UY3MRW6=J!I/N$4@>
M0[RB-02>A5@ZU6;"*MD/5?<9ITHG[3&BL6U\C'K7%,^^ECM@&%GF*4NZWS/(
MRB.2+;8;W:QOHLC)5*M3ZM3E.5-Q&E-%"LO'7>JL"U)!?8>G 7'5M>8^W0I
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MY['[KOT.J&Z>234Z8//4.+N_S#E5N2**NX+^2+4PTR@"HU.1N=\JHHDT'O9
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M'><MVI0<[@6%6%K[CW>;5?D@V$A*T60+#N!.JG+5P#^:_,;Z'A@^5OED2$R
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M^5^ XDISX:IDCLE0U*X[PP)Y9V/*@6KT<8I=NT(WHIJTCR5=E%/'$TD;:PL
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M/#\^^7"6?#P]/CE-SD^2\[\>)8?O3\Z./_P\ /<>_I ^>+X+<L^Z^6>7U?6
MVGOD&EI76=G!_R9=X#L*91V0CJHR)2T8UV9BLZ)K; VHNLM_U9:<7?:$/3!\
M=]7P3VN.>M-I:5SE5Y.@&#?5M;H^):;K=N&H0?),0 BXPMTT,!%NN ;6W@+N
M'9QQD!"D9R^P 8/X_(!!A&2 /;JJ56UO2#'V-RV6J6.OL.\I+_!/F-6;%M?\
M2U=<,BL::ZRP#U\G97Y1P9WX,ZP!AJ.O!) (ZU8U&1A6J68S4E2X\-OQPCZ_
MS"AVX4F"4J9OEJ<Q;=*4H1=+QSTYRQLK]G2F6RL'J@VI?-L;7I0&-/Q^[/;
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MZ:RB[D)A!69V(?2*&#8<EQLFT0,\=*-2K'5^4WT:$M^/TV'@BUR ;33M&H?
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M0=J-+%_*&JO/+ZAM+^+>4T4C1Y16?,JF\2+)EV!HH 0*::RHKHI9.,]Z4,@
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MC]J@?1U0 \6%O3) SU37&,&%2R\0@BKKJ[9XZI6-WL"8XR0,8[2/$8EA\L\
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MT"6.%:H.BOJ ZLMU0OQXX 5>4KJ;&DG?T"?\FA-1+>@F&UCA.K)K#B*%F"N
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M'7?WK*"&N4$*_88A2KV,T-(3\<W!U:@O.'K)X"7,W!*UILE(E'7P(^!4#4(
MZN)^DQ7$I>,VW)KJ:K/F9Q)JI^9G#2*?69P <XAO.O.W/G>0IS5>C!K\T2OJ
MS51$'$9GN2Y<H/B&+O\'RG%J]N2RN/)0@/>YHHG*VQ8ZG!1.-=B 52/I@-$8
M("'445Q,.%<I^[ <74D\^!3,LW&OONLKKTJ/MEQ:OR+ *1X%KF6$FX@/0!+U
M!FX+GZR!%?#?'VHC@>#7@G^V5DW5^JHTPG^D>A;<^J@7^;65G+A$K'AC3<O
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M<OSR3SJ?6!<U2#D><!V; =<:A+[&<O";C;?VD#UH/1S1RQ/]EKHXYX;0M(K
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MF@O3.2&Q)^-'3YR0F!M,&AC/H'V<')O5LE);62@%(]=>J@/AIXI"F_J4L!H
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M,/("#]\@.$&T#)P@%(2Z/2K!$BP"S;2'\;V"$$2!I=X'"$'4^NX]@A!$/GS
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M8[N+83*6@:GKF$:6IU\W3Q*+'9?S6IHT=UQC\L^3OJ]WCW![7<D[T<XCIY=
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MN6/L U;71;W-T,+,?X(O?]A>C;FAMD%M<E'?RQ"#MK-7UFE/S"569;B9%(
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MS4I/(.Q-YS49$@/A5L[S?U$C$ZRZX>65AS;X'J@QP;(U($2EVIU.Q"2)'%"
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M;E7WTNM2+]J^&IR=D-YG6[4&B\&W<&=I@A@OM O;(F\WEJ GC*XM5#@E9,0
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MG:98 #XYG3D!@F0QD4HW'I?EFP\(M2D3HGD7 2H&,;Q*0/%E75*K:RW[XS)
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M#]&5!OG>ARKR2,<@U5.13C_H]QX/T3\AE+- ^86B<S:KKM$" SJ,!2;>FLQ
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M /J$>7U1A1UDTW_\\!VBAQY:;0!%P&@Y]:KZC\>*1?0&D)UE4 %D0.&]RP7
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M=$./H>$')1I/AS2J8)R"MX_W<E9<Y'"'@,IT,\X)8%C.L:5!@1AS4U5IU]*
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M-.S4KOF-=FY.\PFD+*X*;^R"WC"L2V"&.K5 Q5]UE+C2-;J$26';Y@-CC>=
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M%Y1R)3=3JA!$P4M!@Y\?[(;$:Q'!JXO5%.[NH\N2;A["YLK"'_B53P96_I#
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MY-WQJ_3MNS>_G_[_[;UY5]M8MC?\OSZ%5M;;[X+[*(0QJ23560\!4J$Z!;E
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M[)\D9^1PZ%A%';7NW .\(,A?2A=(U337>" F%*"?:,+Q4O18EJ(/Y_VK,"A
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M++-/H5IE=H#4J82Z"#L&7:/6ZVY-M>SXP0KP@Y_FX <V29V5^X2V,@F+YJB
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MZ9P-(D\A6T%@G[DTMC:.SG\A[/9U;)1")>&5R*_$?)U>.$QN5 ,*1KE&V-<
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M*O>A=\<$@CXDO*[^$$^) ?4$,L A^-)OH:R/C]Y'[#UST'R\D<%62:I;;*W
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MY/?(Z[R_.C/1T&J4X<ENA-)?I]2[U[3];3Q"I^7,RD=KM*+J+B.G0MFJM,?
MNV41%<'*TIE!HIV*M&^ GK^?OQ.(_:<I+(YD$S)'Y*PZ$UMA_^>B7?,^_&FU
MQIE!#L1V/C?U<[3A_*?^V%%2W72+4*GXOK%Y>A->A9H?/<*(Z0J:G;W0V*P/
M^#><;<$OCP96 Q1JP[OVENT'S6.MJ6B[P+2=8+;53)KO-6EZ[E5R@ZVR/"))
MW6&:(B>J(Y;RTE?]TEJ4H^;F*+,<A4)_Z!<9AX>MCE)64IJ*OVFZ'3#7S$V6
M&;6\>Q4D<1@J['LK#+*&HXTMV:Q>X^A;)QEI=6DMT[_%'EGW)(2J.T9/\<5;
M_%*[EQS;O31%(XZ4J C[(?%.;*R#+E>M>')LFON+<J_HQETB<>*7 //?(\=V
M* )%D7S^;@V>QP8-]#-/#Y2DMG0-X?U&2[>;2,!6 %G;(J+N4&-3EZ/%")4E
M/R8_D%*1*AJGBF/9GC': @PM>W:G*<K3@B]P8M=P9>(<5,/A1#\(PA^N)#>0
MX= U?!C#,4K&([^_U.S "D^7[]!ML:$-]Y/P(A\[6:KP99 4O7QF0\C!CMDE
M:ZCL\F+-B_7@&<UH(QO,+ENIVRR\4?'\'J;]*$,VX]"?5K;W(-&"U._+X<.4
M04C&:*)^"_-*VH%R?D@B!=ZY'*S-,O>1+A=R&35[T)DN3B4U -]!5(;*,2G*
M<*+9E31[K/2<,M;-UF9O[^669>"4/*Y6%HS5:*I\M Z<R1#; /NDW)5,4]Y;
MBVJRV^5-1<BRK@FC7G,6!0S ,U^ 3'7(*42'@);G=()NW8 5<K),B_B]W>R"
M>RJXM]T%][K@WJ/[%(^YD[)E^U@I(<#L+H&U4BTCJ0PIJ:SH>0&Y%_J8@,:9
M%Z2>U)O!31>P;-7K7EN6&P!I @P<E /E(90]G$C>CSS($J<:UR =MG':NN.Z
MDG)^ 83J4V'(<.*PJ =UU05V[)-*#,](B<0*L=Z5RWK>GB/K^<SJTYU(;^X_
MR&F$&M4,?;L\L1S*K<&YX@4==5;-RZ1N5WBJJD'W"^<IW/ 4,B74B;3Y*Z$C
M&"<-1-\WSLPH;#)>\$8Z:_XZT[+8#Y)#1SU;R<M"GB2_CZ8N19(+N!R4/%G2
MUSQ=P2-MS-$ASLWHS?+MWG)-*6F>L]9;K\X29]1#E):@@'NCV^)8&\BVB;4(
MBFSS.E13]TH+86LJ.M]6VHU:3P'3\+%IFCWV;0U/JP9BJ'.Z:9!*MVA)*E1>
MA5)FM"]Z''9%Z_GQM[08Y_T)VNJ@J5QC(8SG#E*_@'T1MB9]V^HM"D=(XW!J
MQ<@HL>2BL"V,))57EIQLM"A@<F#!)VGF2(!CR)L,&F;<C\9#)B\.5.A$95W1
M@Z>5D^VH S<2\%_KKXMR*O?",Y?"HB-E79ECT$Z0VTC*Y*;#; :@[^9\9I@4
MR%T]2Z=G>C-:[AR5_T#=(^&@E->8(8-TP"Q1+@F+6#)MF+,FKOW!V'XOS+-*
MT6UIC93.35Z(LNF$%P*9Y#@D3HF7@HJHN%E4Z(R __&QP4Z\@K6\(C=3V.=F
MV_5BO^;:.Q7S,R_&'8RHM3>*\JOP%5AC,#9-"'>8.JX&$D%W_. Z,CF]NLI8
M=8>T("-J;)(*M.!U19R%0X[TF(,!FLBZO.R'%)0[<PC*CZ;N_%15,*CE3QTC
M3O#G%<JN"CVG+/3(55EI?-8@.X$D@R3,Q(&EYH<!OYNX7&2BG)=X0; L(PYU
M$0$KG*3[.56&7^DHO1:LJRG9S@;/I&@7*J\IU2EB62F!+->M5M?9DV4"&:68
M@&.P4$P/8WU!='%)1'@B&44?J&$GQ=)(! N'H=%4A%GB5JCS6LP(KR.' L6O
MERD$?(<0\%5OSE+ZWBT90+-01D,BD$+PG9FN)##ML *.8?"J[Y?W]PK,/ZT\
M*,-$!6HI1HLEH4H@2F[/1KD8KF-!BV=!NW.PH)/$W0\XP #7Y!-<83#G)Q9J
MS6R,Z-2^"I5R9$?N EEP<(G13P[<(-"%S74#0+FK453&B3M C_N8IT77U<RX
M7%LM1BNISUKU3;BZP4%_J1\%2OU7=?6-X>OF.OJ.8A^(8O?FH-@+X\R8BT0O
MZ@4\$D5' 68BM,+VE,\D%+!+?!!)4;I$DR%"*CEI_59=C.0^HDV C>TI"1+,
MQ 8?3 VSL60><=T.SDT4[-1E V^&^$I'L0]-L:_GXK$"1S\'M>X#&XOY=R:(
MF*16;;.J58USI]IJ7CZW8K\>\DS$R6?P,Z.=2/*A"13V$(H4R#%@J-%W1+S1
M .7\%267IP2>=,G >6!FI!$%S%(T6#PTMW??;6ZZ7W_C=/5> 4(?Z]L"?V(F
M$>KX#GS,FAYLMZ=T):6;*G/6PKX@XUX>X[:]]ALDFH8*B:-^_)ZN#:]@X'^G
M.SORHV'Y;:84>22%:5&F;#989SB$2YXF,0LQ3X:;9Z5.>:7S+<C>%-*V9&9$
M-)SIT%^'GX..BJD$\$,56,25H@8&LT4X*SITA\X0BR_)O<";(14%"C5$=YC?
M4-T4K*0$34KU1!\EQPTB"'EQ5$HB[./X"DA<,+4RSS%8) ,%E!5'%%])XB&Z
M.MCVIU6+<X%?S^ \;.SSU)BJ)Q7_7K//"3:=KY?%^=]U;+,II.$NL.3!7]=-
M>!87*!G,$.+'Q)0?!)L&'E7_W:H#@$GCE(7-7J%_.AK]T_VYE[[Z\-/VIOL+
M7-,8:[L2/X 1B@@XV,[.-GW_.0&*PW.Y^(?[YLWF]BY]NI\+/,*[4B-7_.KH
M)3*J=^X5?_Y_P^]^#[2CC>^3_UV=<YT:<M_J0NXJY+[3A=R[D/NCA]Q1.7 D
M21)$RIJ=)2E1$)A%CK![K#RL+U"DT/\U,.P5Z#[2-O5%RYJ_H=;I?,7.QB1B
M=O?<"Q #8-:#TEB$2L1L;VXVB9C-[:J(^5LX!#W!I6%+,N8;??$-/_^_],_Q
M<-C?Z">CU9$T*W;UP$;C51P/'$ET9@>=I]1YI?:;9!6QFJ840)2[SJKD@JD6
M!;R8; H'H\N$=#4 NXAS)VN&A<JL+ML8^!YD)5V8[>'\+V_F\+\<@;&I/,1H
M=W\.*3=6.61F+ZT&]1;4GS%0T=SN1^<"_7:5B5S)1*8E2S6;Q@/C1R<[V7+@
MB*#*TV1HLA+L@D:'!\ORM-!%'U:Q84.MBH4;A,O(L==VIJI:Y2]J:S/C[&7"
ME' K,$B]T,YX$-!4F*%DI$=JXSF:5)[3<3W!K(B'>*$E%H&'8GE;Q)^6O2-H
M*U@ZUC]@JGO;(GAC!0I#!DV1[22<'S,"$ZA $O'<03C"[#AR#<=AD;.K>)29
M>"8&P0I,E:,H!7F5"P*%X#EPV/8Z3'M9PWO'PP(K9.D1=%[ <YG_GN&R)$RH
M*PQ4S?\:Q8'1[T&S'G(L4U6WEGX5ZLY+!!3@M%0KJ)">Y+-(+3'2$-96IM%8
M2@)4<49"+KE^**4:JGE1H]<1=I\R2ZB:A@C#84>2J4ZY 4:K6U_5RRAD#>\5
MD%BT7O^5A)[4%EF?@H#0 ";P>^N;WD0%1@W(!@^*7CG)?XQ&V,W\UE71[65Y
M4KXNF;3R"'6+*)&&Y%CK$^%D'*NRBA&+'I@)40E/JPM?/9XP^FD.870 =QQY
M&1SG?!&!2OQ*DM]T2A]0V,#O$QF&C@!/(]W8S0O,FSTF1UT)=G.%7<62M@S!
M*CEC2Q4IP?7<'MP^B:39!E.>7#+DIF4UH>=7\T$LT/++DJ4,MVEYW2U53C0X
M-M->97UN[X(P[3$":IL'R2MO+=K!7U;N&\4$9-<\C@N8)#_K]:7(P)3=L%Y/
MU;SP7 F<B0BANY$/?B/?SG$CSU$T95DBN<#[&9[AO>ZF(G$*W'J.QGCW;.5*
M.@4H%!"&[C*TI7)O,;!LQ^>BF"\!)^A2@E9.^+\54PC3 @DV0RW.X88&M+CF
MM.O&?#(+&M["J,]4X6EIW?!'J1G30*K\S#1)[:/'3#9QSX;X),Z59]:\76O>
MW<UY>'CSS?FRARXH9_XK$])<E^8D0:B5RVG&CV,*42(R!U0&D*X$UP)+(%-U
MGGD3)$5[)PXA=KYB?4*DH.$XB]O!+"5&0A66#\1-O@%*,-)SJ-,[YR-RUJT@
M9%/VOP!A4?5JJ?A8BO35O_KF(B!XC8G^\X70\6 9I+L?#W\_YL'_/T>8 "E7
MF.MN'+,YI<5%0W%$E#F4@,G&<Q1?PSX$G%EO<U<%*@(TG1%(.*7(ZW$IPY^-
M;T)A"AB3.+R6O $L/(#)Z>P^K-=&"(1HX()6DV%9M.=0HJR@!( $B<)K&^R\
M*FQ\[!LBMYJJVY3L&DEAV30/1 EF@Y1>K+6AY9* DW2LDF5IB](FL;=REV9J
M%'&[BR*J*.)N%T7LHHA/(2/FJ9;<5\#HJE 2+>!%N 8$@0YUJ%$22+K?A&(6
M0!T6 I6M0X6M19FHL(&Q' T+AA("6QW?,]$*3!0K8 RN&13MR=B]DEF+>%&D
M7Y&ORY?J*3)_Z!W\$??U2 72GD%LI><%*$&>,9U(,YLB*+6L2=@K.X)[[: V
MB;&:S*M9\RQ/C8\\E#9P*O.7O\G!#B._J!196^U!ILYOY63-ZEV^>2JP/LFA
M@M%?4!N-^2[>D<$'8C(*$KOTDO#B^@CK)%05* >8/(":%&4N(MTH D.P:'$A
M8'#(-OZ;FO[IWU=*+Q%AFC,^^X@+Z#G&@N+AE0V5>2KP*36"M!YD(JPS4N\B
MR0=U;56O[Z?HJBMR6]DC:[W/[2<R-KNJ]4U.W5/2!!9XF[6V>GK;ZMVE.4N)
MS@D0PCVPHHMS"C+$L(LO"U1,[&"<4ZE)KK+KW/YA'XOQ8A4M4E*,\ ['J80%
MHU1U8&2Z]23>(N6&:%?S6NQ(J:/>3>@_*!BDQ%U['CJ:?'B:G*=8Z!=L.$1&
MY1?_9FY2Y,(;KM5O-TD=K4$8C:$%Z*"&S^A:^(P;;D<\#TX\\]3M'' 6!?E!
M]&G/1T0*/BQGR! #EN!4H2X,9#3Z:("_T.?X5\HXQQ6 "ZW2#])DQ(AQ&!2
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MMMHW<Z?4\!L#IY=7K5!-8T*5#F3_D)IZ$SAHS^XL?9U(0RSLQBI&.0(N! A
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MM=+)E"[%0LU6#A6/X#EUUWG)EK*?.27^7-; -[?7>NMK;]9M/;Q\ZZ?>8/A
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M 7,J"28?X'^O\M'PP_\/4$L! A0#%     @ -W[:7$R<_1H-&0  44X! !H
M             ( !     &-I:S P,#(P-C4W-SDM,C R-C S,S$N>'-D4$L!
M A0#%     @ -W[:7'X:G>>A%0  #QH! !X              ( !11D  &-I
M:S P,#(P-C4W-SDM,C R-C S,S%?8V%L+GAM;%!+ 0(4 Q0    ( #=^VEPX
M4-0XM&$  *"#"  >              "  2(O  !C:6LP,# R,#8U-S<Y+3(P
M,C8P,S,Q7V1E9BYX;6Q02P$"% ,4    "  W?MI<V"_.+AUN  #2308 '@
M            @ $2D0  8VEK,# P,C V-3<W.2TR,#(V,#,S,5]L86(N>&UL
M4$L! A0#%     @ -W[:7#)_H8,J:0  H,4( !X              ( !:_\
M &-I:S P,#(P-C4W-SDM,C R-C S,S%?<')E+GAM;%!+ 0(4 Q0    ( #=^
MVES4"UXY:2,  +6B   7              "  =%H 0!D8F]R86QA<F-A8W%?
M97@Q,"TQ+FAT;5!+ 0(4 Q0    ( #=^VEP,?GCO-@H  '(X   8
M      "  6^, 0!D8F]R86QA<F-A8W%?97@Q,"TQ,"YH=&U02P$"% ,4
M"  W?MI<8()MA*PP  !580$ %P              @ ';E@$ 9&)O<F%L87)C
M86-Q7V5X,3 M,BYH=&U02P$"% ,4    "  W?MI<6<,<H]A%  #&'0( %P
M            @ &\QP$ 9&)O<F%L87)C86-Q7V5X,3 M,RYH=&U02P$"% ,4
M    "  W?MI<.!PT/&@<  #^VP  %P              @ ')#0( 9&)O<F%L
M87)C86-Q7V5X,3 M-"YH=&U02P$"% ,4    "  W?MI<R/L2FDM(  #>F0$
M%P              @ %F*@( 9&)O<F%L87)C86-Q7V5X,3 M-2YH=&U02P$"
M% ,4    "  W?MI<]YC.5QD$   A&@  %P              @ 'F<@( 9&)O
M<F%L87)C86-Q7V5X,3 M-BYH=&U02P$"% ,4    "  W?MI<]>6J&>$=  !9
M5@$ %@              @ $T=P( 9&)O<F%L87)C86-Q7V5X,3 W+FAT;5!+
M 0(4 Q0    ( #=^VESK@%NG-P0  *$3   7              "  4F5 @!D
M8F]R86QA<F-A8W%?97@R,RTQ+FAT;5!+ 0(4 Q0    ( #=^VEQ$9GM1+ 0
M ) 3   7              "  ;69 @!D8F]R86QA<F-A8W%?97@R,RTR+FAT
M;5!+ 0(4 Q0    ( #=^VEPCY)2"CP,  -D.   7              "  1:>
M @!D8F]R86QA<F-A8W%?97@R,RTS+FAT;5!+ 0(4 Q0    ( #=^VERL&!R>
MII\  "23!P 6              "  =JA @!D8F]R86QA<F-A8W%?97@S+3$N
M:'1M4$L! A0#%     @ -W[:7* 9OZR?:@  JAX# !8              ( !
MM$$# &1B;W)A;&%R8V%C<5]E>#0M-"YH=&U02P$"% ,4    "  W?MI<>6SH
MB0D/  #Q1   %@              @ &'K , 9&)O<F%L87)C86-Q7V5X-2TQ
M+FAT;5!+ 0(4 Q0    ( #=^VEP82:DXL!,  '5S   7              "
M <2[ P!D8F]R86QA<F-A8W%?97@Y.2TQ+FAT;5!+ 0(4 Q0    ( #=^VEPU
M?@S:VP(  -T-   7              "  :G/ P!D8F]R86QA<F-A8W%?97@Y
M.2TV+FAT;5!+ 0(4 Q0    ( #=^VEP]8NFI'7T- /F*?  4
M  "  ;G2 P!D8F]R86QA<F-A8W%?<S1A+FAT;5!+!08     %@ 6  <&   (
%4!$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>dboralarcacq_s4a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cik0002065779="http://cik0002065779/20260331"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cik0002065779-20260331.xsd" xlink:type="simple"/>
    <context id="From2026-01-01to2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassAOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassBOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassAOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassBOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassAOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassAOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassBOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassBOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-12-192025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
        </entity>
        <period>
            <startDate>2025-12-19</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-18_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-18</instant>
        </period>
    </context>
    <context id="AsOf2025-12-18_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-18</instant>
        </period>
    </context>
    <context id="AsOf2025-12-18_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-18</instant>
        </period>
    </context>
    <context id="AsOf2025-12-18_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-18</instant>
        </period>
    </context>
    <context id="AsOf2025-12-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
        </entity>
        <period>
            <instant>2025-12-18</instant>
        </period>
    </context>
    <context id="AsOf2025-12-18_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralArcMergerCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-18</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralArcMergerCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-19_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-19</instant>
        </period>
    </context>
    <context id="AsOf2025-03-19_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-19</instant>
        </period>
    </context>
    <context id="AsOf2025-03-19_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-19</instant>
        </period>
    </context>
    <context id="AsOf2025-03-19_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-19</instant>
        </period>
    </context>
    <context id="AsOf2025-03-19_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-19</instant>
        </period>
    </context>
    <context id="AsOf2025-03-19_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-19</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-12-192025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-19</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-12-192025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-19</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-12-192025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-19</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-12-192025-12-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-19</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-12-192025-12-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralArcMergerCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-19</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember62738953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember62738968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738984">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralArcMergerCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:SubscriptionReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:OrdinarySharesClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-01-11_custom_DBoralARCAcquisitionICorp.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cik0002065779:DBoralARCAcquisitionICorp.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-11</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-11_custom_DBoralARCAcquisitionICorp.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cik0002065779:DBoralARCAcquisitionICorp.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-11</instant>
        </period>
    </context>
    <context id="From2025-12-192025-12-31_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-19</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember62742453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-29</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-29</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-29</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-29</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-02</startDate>
            <endDate>2025-08-11</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-11</instant>
        </period>
    </context>
    <context id="From2025-09-052025-09-09_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-05</startDate>
            <endDate>2025-09-09</endDate>
        </period>
    </context>
    <context id="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-29</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_FounderSharesMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-07-292025-08-01_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-29</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_FounderSharesMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-08-022025-12-31_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-02</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-012025-03-25_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-25</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-25_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-25</instant>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_UnsecuredPromissoryNoteMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cik0002065779:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-012025-03-25_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cik0002065779:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-25</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-25_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-25</instant>
        </period>
    </context>
    <context id="From2025-03-012025-03-25_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik0002065779:ClassAOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-25</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-11_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-11</instant>
        </period>
    </context>
    <context id="From2025-03-202025-12-31_custom_CommonStockClassBMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:CommonStockClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cik0002065779:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ClassAOrdinaryShareMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassAOrdinaryShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ConversionOfClassBToClassACommonStockMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cik0002065779:ConversionOfClassBToClassACommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_CommonStockClassBMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:CommonStockClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_WarrantsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cik0002065779:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-08-01_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:SimpleAgreementsForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cik0002065779:OtherPayableRelatedToTheEquityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cik0002065779:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="From2025-07-292025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cik0002065779:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:DBoralARCAcquisitionICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-29</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-01_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="AsOf2022-07-01_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="From2025-12-012025-12-16_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:EvanaAlphaPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-01</startDate>
            <endDate>2025-12-16</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-08_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-08</instant>
        </period>
    </context>
    <context id="AsOf2026-01-08_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassAOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-08</instant>
        </period>
    </context>
    <context id="AsOf2026-01-08_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cik0002065779:ClassBOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-08</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:ReservedCapacityArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:ReservedCapacityArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:OnDemandArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:OnDemandArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:ReservedCapacityArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:ReservedCapacityArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:ReservedCapacityArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:ReservedCapacityArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:OnDemandArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:OnDemandArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:OnDemandArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cik0002065779:OnDemandArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromIntelligentComputingPowerServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromComprehensiveDataCenterServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromComprehensiveDataCenterServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromComprehensiveDataCenterServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromComprehensiveDataCenterServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromComprehensiveDataCenterServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cik0002065779:RevenueFromComprehensiveDataCenterServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerIMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerIMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerIMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:CustomerIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_PurchaseMember_custom_SupplierAMember_us-gaap_CustomerConcentrationRiskMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cik0002065779:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember62755093">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember62755109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_custom_SupplierGMember_us-gaap_CustomerConcentrationRiskMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierGMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cik0002065779:SupplierGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012025-06-30_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-06_us-gaap_SubsequentEventMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-06</endDate>
        </period>
    </context>
    <context id="From2022-10-012026-03-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_DomesticCountryMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_DomesticCountryMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_StateAndLocalJurisdictionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_StateAndLocalJurisdictionMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cik0002065779:EvanaAlphaPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_NonEmployeeMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_ThirdPartyServiceProviderMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:ThirdPartyServiceProviderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_ThirdPartyServiceProviderMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:ThirdPartyServiceProviderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-06_custom_EmployeeMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-06</instant>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_EmployeeMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-02_custom_NonEmployeeMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-02</instant>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_NonEmployeeMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_SellingAndMarketingExpensesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cik0002065779:IncomeStatementLocationsAxis">cik0002065779:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_SellingAndMarketingExpensesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cik0002065779:IncomeStatementLocationsAxis">cik0002065779:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_GeneralAndAdministrativeExpensesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cik0002065779:IncomeStatementLocationsAxis">cik0002065779:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_GeneralAndAdministrativeExpensesMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cik0002065779:IncomeStatementLocationsAxis">cik0002065779:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_country_SG_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_country_SG_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_country_US_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_country_US_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_country_CA_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_country_CA_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_country_HK_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_country_HK_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_country_GB_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_country_GB_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_OthersMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cik0002065779:OthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_OthersMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cik0002065779:OthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_country_US_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_country_US_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_country_US_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_country_US_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_country_CA_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_country_CA_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_country_CA_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_country_CA_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_country_SG_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_country_SG_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_country_SG_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_country_SG_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_country_HK_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_country_HK_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_country_HK_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_country_HK_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_country_GB_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_country_GB_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_country_GB_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_country_GB_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_OthersMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cik0002065779:OthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_OthersMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cik0002065779:OthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_OthersMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cik0002065779:OthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_OthersMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cik0002065779:OthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-02-11_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cik0002065779:EvanaAlphaPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-02-11</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-01-31_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:DigitalAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_USDCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:USDCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:DigitalAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_USDCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:USDCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:DigitalAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_USDCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:USDCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CryptoAssetAxis">cik0002065779:DigitalAssetsAndUSDCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cik0002065779:ExascaleLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2026-01-01to2026-03-31" id="Fact000003">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="From2026-01-01to2026-03-31" id="Fact000004">0002065779</dei:EntityCentralIndexKey>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0039"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0057"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-12-192025-12-31"
      id="xdx2ixbrl0065"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-18_us-gaap_CommonStockMember"
      id="xdx2ixbrl0077"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-18_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0078"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-18_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0079"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-18_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0080"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-18"
      id="xdx2ixbrl0081"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-18_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember"
      id="xdx2ixbrl0083"
      unitRef="Shares"
      xsi:nil="true"/>
    <cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee
      contextRef="From2025-12-192025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0085"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee
      contextRef="From2025-12-192025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0087"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee
      contextRef="From2025-12-192025-12-31"
      id="xdx2ixbrl0089"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-12-192025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0093"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-12-192025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0094"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-12-192025-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0096"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0099"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-12-192025-12-31"
      id="xdx2ixbrl0117"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-12-192025-12-31"
      id="xdx2ixbrl0121"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-12-192025-12-31"
      id="xdx2ixbrl0125"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2025-12-192025-12-31"
      id="xdx2ixbrl0127"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-18"
      id="xdx2ixbrl0129"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0131"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AmountDueToRelatedParty
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0197"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0209"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl0210"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-01-01to2026-03-31"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2026-01-01to2026-03-31"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2026-01-01to2026-03-31"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2026-01-01to2026-03-31"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2026-01-01to2026-03-31"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-19_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0454"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-19_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0456"
      unitRef="Shares"
      xsi:nil="true"/>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:IssuanceOfRepresentativeShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:IssuanceOfRepresentativeShares
      contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:IssuanceOfRepresentativeShares
      contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ReverseOverallotmentOptionLiability
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ReverseOverallotmentOptionLiability
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ReverseOverallotmentOptionLiability
      contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ForfeitureOfFounderShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ForfeitureOfFounderShares
      contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ForfeitureOfFounderShares
      contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ForfeitureOfFounderShares
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AdjustmentOfAccruedOfferingCosts
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AdjustmentOfAccruedOfferingCosts
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0516"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AdjustmentOfAccruedOfferingCosts
      contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0518"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AdjustmentOfAccruedOfferingCosts
      contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0519"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0522"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0524"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0533"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-19_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl0580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1070"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1071"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1121"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1122"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1139"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1142"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1148"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1150"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1182"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1184"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember62738953"
      id="xdx2ixbrl1191"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738953"
      id="xdx2ixbrl1192"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1193"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2026-01-012026-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1195"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember62738953"
      id="xdx2ixbrl1198"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738953"
      id="xdx2ixbrl1199"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1200"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1202"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1207"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1209"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1216"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1217"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1219"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1220"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-19_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1221"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-19_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1223"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-19_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1225"
      unitRef="Shares"
      xsi:nil="true"/>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember62738968"
      id="xdx2ixbrl1227"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1230"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember62738968"
      id="xdx2ixbrl1236"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738984"
      id="xdx2ixbrl1237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1238"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1240"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1243"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1250"
      unitRef="Shares"
      xsi:nil="true"/>
    <cik0002065779:PaymentOfExpensesThroughPromissoryNoteRelatedParty
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1273"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1292"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1294"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-19_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncashOrPartNoncashAcquisitionInventoryAcquired1
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1475"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1477"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1491"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      id="xdx2ixbrl1493"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1848"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1849"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-012024-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1883"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1884"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1888"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1890"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1900"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1901"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1905"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1907"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1995"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1996"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1998"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl1999"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2098"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2217"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2221"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2227"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2231"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2235"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2244"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2248"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2258"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2272"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2278"
      unitRef="Ratio"
      xsi:nil="true"/>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2023-07-012024-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2282"
      unitRef="Ratio"
      xsi:nil="true"/>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2023-07-012024-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2286"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2470"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_custom_SellingAndMarketingExpensesMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2508"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_custom_GeneralAndAdministrativeExpensesMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2514"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ShareBasedCompensations
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2606"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ShareBasedCompensation1
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2619"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2630"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2631"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:U.s.DollarCoin
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2692"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:PrepaidResearchAndDevelopmentExpenses
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2698"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2708"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2762"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-06-30_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2780"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-06-30_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2792"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2863"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2864"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2865"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2866"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2914"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2915"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2919"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2921"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2938"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2939"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2943"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2945"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2956"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2957"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2964"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2966"
      unitRef="Shares"
      xsi:nil="true"/>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2971"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2972"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2973"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2981"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2982"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2983"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2984"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2988"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl2995"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3002"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3003"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3010"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3012"
      unitRef="Shares"
      xsi:nil="true"/>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2025-07-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3017"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2025-07-012026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3018"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3019"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3027"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-07-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3028"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-07-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3029"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-07-012026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3030"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3034"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3041"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3060"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3065"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3077"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ProceedsFromSaleOfDigitalAssetsAndUsdc
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3104"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3108"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:PaymentForDeferredOfferingCosts
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3116"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ProceedsFromSimpleAgreementsForFutureEquity
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3120"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3137"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3138"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3140"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3141"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesAssumed1
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3143"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LoansAssumed1
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3146"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3426"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3430"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3444"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3448"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3450"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3452"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3456"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3458"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3460"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3464"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3468"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3470"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3472"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3572"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3574"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3582"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3591"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3593"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3599"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3601"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetFairValue
      contextRef="AsOf2025-06-30_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3611"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetFairValue
      contextRef="AsOf2025-06-30_custom_USDCMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3613"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetFairValue
      contextRef="AsOf2026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3627"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ShareBasedCompensations
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3876"
      unitRef="USD"
      xsi:nil="true"/>
    <cik0002065779:ShareBasedCompensations
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3878"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3905"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3906"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3907"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3908"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_OthersMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3959"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_OthersMember_custom_ExascaleLabsIncMember"
      id="xdx2ixbrl3963"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:AmendmentDescription contextRef="From2026-01-01to2026-03-31" id="Fact000010">Amendment
No. 1</dei:AmendmentDescription>
    <dei:DocumentType contextRef="From2026-01-01to2026-03-31" id="Fact000011">S-4</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="From2026-01-01to2026-03-31" id="Fact000012">D. Boral ARC Acquisition I Corp.&#160;</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2026-01-01to2026-03-31" id="Fact000013">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2026-01-01to2026-03-31" id="Fact000014">42-3035215</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2026-01-01to2026-03-31" id="Fact000015">10 East 53rd Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2026-01-01to2026-03-31" id="Fact000016">Suite 3001</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2026-01-01to2026-03-31" id="Fact000017">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2026-01-01to2026-03-31" id="Fact000018">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2026-01-01to2026-03-31" id="Fact000019">10022</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2026-01-01to2026-03-31" id="Fact000020">332</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2026-01-01to2026-03-31" id="Fact000021">266-7344</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="From2026-01-01to2026-03-31" id="Fact000022">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2026-01-01to2026-03-31" id="Fact000023">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2026-01-01to2026-03-31" id="Fact000024">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2026-01-01to2026-03-31" id="Fact000025">false</dei:EntityExTransitionPeriod>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000031"
      unitRef="USD">590</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000033"
      unitRef="USD">590</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000035"
      unitRef="USD">590</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000041"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000043"
      unitRef="Shares">100</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000045"
      unitRef="Shares">100</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000047"
      unitRef="Shares">100</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000049"
      unitRef="USD">100</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000051"
      unitRef="USD">-590</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000053"
      unitRef="USD">100</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000055"
      unitRef="USD">-590</us-gaap:StockholdersEquity>
    <us-gaap:OperatingExpenses
      contextRef="From2025-12-192025-12-31"
      decimals="0"
      id="Fact000059"
      unitRef="USD">590</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-12-192025-12-31"
      decimals="0"
      id="Fact000061"
      unitRef="USD">-590</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-12-192025-12-31"
      decimals="0"
      id="Fact000063"
      unitRef="USD">-590</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-12-192025-12-31"
      decimals="0"
      id="Fact000067"
      unitRef="USD">-590</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-12-192025-12-31"
      decimals="INF"
      id="Fact000069"
      unitRef="Shares">100</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-12-192025-12-31"
      decimals="INF"
      id="Fact000071"
      unitRef="Shares">100</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-12-192025-12-31"
      decimals="INF"
      id="Fact000073"
      unitRef="USDPShares">-5.90</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-12-192025-12-31"
      decimals="INF"
      id="Fact000075"
      unitRef="USDPShares">-5.90</us-gaap:EarningsPerShareDiluted>
    <cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFeeShares
      contextRef="From2025-12-192025-12-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember"
      decimals="INF"
      id="Fact000091"
      unitRef="Shares">100</cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFeeShares>
    <cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee
      contextRef="From2025-12-192025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000086"
      unitRef="USD">100</cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee>
    <cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee
      contextRef="From2025-12-192025-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000088"
      unitRef="USD">-100</cik0002065779:CommonStockIssuedToInitialShareholderForSubscriptionFee>
    <us-gaap:ProfitLoss
      contextRef="From2025-12-192025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000095"
      unitRef="USD">-590</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-12-192025-12-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">-590</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember"
      decimals="INF"
      id="Fact000105"
      unitRef="Shares">100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000100"
      unitRef="USD">100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000101"
      unitRef="USD">-590</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000102"
      unitRef="USD">-100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000103"
      unitRef="USD">-590</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-12-192025-12-31"
      decimals="0"
      id="Fact000109"
      unitRef="USD">-590</us-gaap:NetIncomeLoss>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2025-12-192025-12-31"
      decimals="0"
      id="Fact000115"
      unitRef="USD">590</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:StockIssued1
      contextRef="From2025-12-192025-12-31"
      decimals="0"
      id="Fact000135"
      unitRef="USD">100</us-gaap:StockIssued1>
    <us-gaap:NatureOfOperations contextRef="From2025-12-192025-12-31" id="Fact000137">&lt;p id="xdx_80B_eus-gaap--NatureOfOperations_zJC9E8GNL4Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 1 &#x2014; &lt;span id="xdx_821_zu9lUW4uEBC"&gt;Description of Organization and
Business Operations&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Business Operations&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;D. Boral ARC Merger Corporation
(the &#x201c;Company&#x201d; or &#x201c;PubCo&#x201d;) is a Delaware company formed by D. Boral ARC Acquisition I Corp. (the &#x201c;Parent&#x201d;
or &#x201c;BCAR&#x201d;) on December&#160;19, 2025 (inception). The Company has adopted a fiscal year-end of December&#160;31. The Company
is authorized to issue &lt;span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_zZtAwYCwpUPa" title="Common stock, shares authorized"&gt;100&lt;/span&gt; shares of Common Stock of par value $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zHBaoiIxdGw7" title="Common stock, par value"&gt;0.0001&lt;/span&gt; each share. The Company was formed to be the surviving company
in connection with a contemplated business combination between the Parent and a target company. The Company has no principal operations
or revenue producing activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Going Concern&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company was formed by the
Parent. The Parent has until February&#160;1, 2027 to complete its initial business combination (unless further extended). If the Parent
is unable to complete the initial business combination by February&#160;1, 2027, the Parent must cease all operations and dissolve and
liquidate (unless further extended).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The accompanying financial statements
have been prepared assuming that the Company will continue as a going concern. If the Parent is unable to raise additional funds to alleviate
liquidity needs as well as complete a business combination by close of February&#160;1, 2027 (unless further extended), then the Company
will cease all operations except for the purpose of liquidating. The liquidity condition and date for liquidation and subsequent dissolution
raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. The financial statements do not include any
adjustments that might result from the outcome of these uncertainties.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">100</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000141"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-12-192025-12-31" id="Fact000143">&lt;p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_z3Y09X9ArJqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 2 &#x2014; &lt;span id="xdx_827_z1QOLi23x5K2"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zIQgZvNM5Ow6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86F_zJc7JPdBlxC3"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The accompanying financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and
pursuant to the rules and regulations of the SEC. The financial statements as of December&#160;31, 2025 and for the period from December&#160;19,
2025 (inception) through December&#160;31, 2025 respectively, are audited. In the opinion of management, the financial statements include
all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating
results and cash flows for the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--EmergingGrowthCompanyPolicyTextBlock_zIflyZXwhT3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_867_zieh9LOsfqE3"&gt;Emerging Growth Company&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company is an &#x201c;emerging
growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of
2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period
which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company,
as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zfT5mqcHOWl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_867_zE9hBnagYMVa"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--RisksAndUncertaintiesPolicyTextBlock_zOgwh60tmOf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_863_zT2IwjyYxMwg"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zkhtSX54qy75" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86C_ziSLvQsMEBHb"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company complies with the
accounting and reporting requirements of ASC Topic 740, &#x201c;Income Taxes,&#x201d; which requires an asset and liability approach to
financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the
financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;ASC Topic 740 prescribes a recognition
threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be
taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#x2019;s management determined the United States is the Company&#x2019;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The provision for income taxes
was deemed to be immaterial for the period from December&#160;19, 2025 (inception) through December&#160;31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z9GnwSb4VdD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Loss Per Share&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company computes basic loss
per share (&#x201c;EPS&#x201d;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of December&#160;31, 2025 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrqiA2cU5R4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86F_zTUwRw7Nlatj"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Fair value is defined as the
price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants
at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active
        markets;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly
        observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets
        that are not active; and&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity
        to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant
        value drivers are unobservable.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In some circumstances, the inputs
used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value
measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair
value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSNNhvz3V6Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86F_zM7M5EBTVgG3"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In November&#160;2023, the FASB
issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose
information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public
entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment
disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since inception.
Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material
effect on the Company&#x2019;s financial statement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2025-12-192025-12-31" id="Fact000145">&lt;p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zIQgZvNM5Ow6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86F_zJc7JPdBlxC3"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The accompanying financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and
pursuant to the rules and regulations of the SEC. The financial statements as of December&#160;31, 2025 and for the period from December&#160;19,
2025 (inception) through December&#160;31, 2025 respectively, are audited. In the opinion of management, the financial statements include
all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating
results and cash flows for the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <cik0002065779:EmergingGrowthCompanyPolicyTextBlock contextRef="From2025-12-192025-12-31" id="Fact000147">&lt;p id="xdx_844_ecustom--EmergingGrowthCompanyPolicyTextBlock_zIflyZXwhT3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_867_zieh9LOsfqE3"&gt;Emerging Growth Company&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company is an &#x201c;emerging
growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of
2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period
which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company,
as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-12-192025-12-31" id="Fact000150">&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zfT5mqcHOWl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_867_zE9hBnagYMVa"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <cik0002065779:RisksAndUncertaintiesPolicyTextBlock contextRef="From2025-12-192025-12-31" id="Fact000152">&lt;p id="xdx_841_ecustom--RisksAndUncertaintiesPolicyTextBlock_zOgwh60tmOf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_863_zT2IwjyYxMwg"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2025-12-192025-12-31" id="Fact000154">&lt;p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zkhtSX54qy75" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86C_ziSLvQsMEBHb"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company complies with the
accounting and reporting requirements of ASC Topic 740, &#x201c;Income Taxes,&#x201d; which requires an asset and liability approach to
financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the
financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;ASC Topic 740 prescribes a recognition
threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be
taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#x2019;s management determined the United States is the Company&#x2019;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The provision for income taxes
was deemed to be immaterial for the period from December&#160;19, 2025 (inception) through December&#160;31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-12-192025-12-31" id="Fact000156">&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z9GnwSb4VdD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Loss Per Share&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company computes basic loss
per share (&#x201c;EPS&#x201d;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of December&#160;31, 2025 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2025-12-192025-12-31" id="Fact000159">&lt;p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrqiA2cU5R4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86F_zTUwRw7Nlatj"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Fair value is defined as the
price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants
at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active
        markets;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly
        observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets
        that are not active; and&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity
        to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant
        value drivers are unobservable.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In some circumstances, the inputs
used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value
measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair
value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-12-192025-12-31" id="Fact000161">&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSNNhvz3V6Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86F_zM7M5EBTVgG3"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In November&#160;2023, the FASB
issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose
information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public
entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment
disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since inception.
Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material
effect on the Company&#x2019;s financial statement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-12-192025-12-31" id="Fact000163">&lt;p id="xdx_80F_eus-gaap--SegmentReportingDisclosureTextBlock_zWj9pExp7IJj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 3&#x2009;&#x2014;&#x2009;&lt;span&gt;Segment Information&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_823_zBCYtPTrZJgj" style="display: none"&gt;Segment information&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;ASC Topic 280, &#x201c;Segment
Reporting,&#x201d; establishes standards for companies to report in their financial statement information about operating segments, products,
services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial
information is available that is regularly evaluated by the Company&#x2019;s chief operating decision maker, or group, in deciding how
to allocate resources and assess performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s chief operating
decision maker has been identified as directors (&#x201c;CODM&#x201d;), who review the operating results for the Company as a whole to make
decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only
has one operating segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;When evaluating the Company&#x2019;s
performance and making key decisions regarding resource allocation, the CODM reviews several key metrics, formation and operational costs
which includes the accompanying statement of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The key measures of segment profit
or loss reviewed by our CODM is formation and operational costs. Formation and operational costs are reviewed and monitored by the CODM
to manage and forecast cash to ensure enough capital is available to complete a business combination within the business combination period.
The CODM also reviews formation and operational costs to manage, maintain and enforce all contractual agreements to ensure costs are aligned
with all agreements and budget.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2025-12-192025-12-31" id="Fact000166">&lt;p id="xdx_80F_eus-gaap--BusinessCombinationDisclosureTextBlock_zJxmo93c5NE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 4 &#x2014; &lt;span id="xdx_825_zpHDqrU5OLkc"&gt;Business Combination&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On January&#160;11, 2026, D. Boral
ARC Acquisition I Corp. (&#x201c;BCAR&#x201d; or the &#x201c;Company&#x201d;) entered into the Agreement and Plan of Merger (the &#x201c;Merger
Agreement&#x201d;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly owned subsidiary of BCAR (&#x201c;PubCo&#x201d;),
D. Boral Arc Merger Sub Inc. (&#x201c;Merger Sub&#x201d;), a Delaware corporation and a wholly-owned subsidiary of BCAR, and Exascale Labs
Inc.., a Delaware corporation (&#x201c;Exascale&#x201d;). Pursuant to the Merger Agreement, the Business Combination will be effected in
two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into PubCo, with PubCo remaining as the surviving
publicly traded entity (the &#x201c;Reincorporation Merger&#x201d;); (ii) after the Reincorporation Merger, Merger Sub will be merged with
and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#x201c;Acquisition Merger&#x201d; and together with
the Reincorporation Merger, the &#x201c;Business Combination&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The aggregate consideration for
the Acquisition Merger is $&lt;span id="xdx_906_ecustom--AggregateConsideration_c20260101__20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_pp0p" title="Aggregate consideration"&gt;500,000,000&lt;/span&gt; (the &#x201c;Merger Consideration&#x201d;), payable in the form of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_pd" title="New shares issued"&gt;50,000,000&lt;/span&gt; newly issued shares
of common stock of PubCo valued at $&lt;span id="xdx_902_eus-gaap--SharePrice_c20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_pd" title="Share Price"&gt;10.00&lt;/span&gt; per share to Exascale and its shareholders. At the closing of the Acquisition Merger (the &#x201c;Closing&#x201d;),
the issued and outstanding shares in Exascale held by the former Exascale shareholders will be cancelled and cease to exist as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #FFFFFF; text-align: justify"&gt;Each issued and
        outstanding share of Exascale Class B common stock shall be cancelled and converted into the right to receive a number of shares of PubCo
        Class B common stock (the &#x201c;PubCo Class B Shares&#x201d;) equal to the quotient obtained by dividing (a) the quotient equal to the
        Merger Consideration divided by the fully diluted Exascale capitalization (the &#x201c;Per Share Merger Consideration&#x201d;) by (b) Ten
        Dollars ($10.00), with each such PubCo Class B Share having twenty (20) votes per share; and&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #FFFFFF; text-align: justify"&gt;Each issued and
        outstanding share of Exascale Class A common stock shall be cancelled and converted into the right to receive a number of shares of PubCo
        Class A common stock (the &#x201c;PubCo Class A Shares&#x201d;) equal to the quotient obtained by dividing (a) the Per Share Merger Consideration
        by (b) Ten Dollars ($10.00), with each such PubCo Class A Share having one (1) vote per share.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessCombinationDisclosureTextBlock>
    <cik0002065779:AggregateConsideration
      contextRef="From2026-01-012026-01-11_custom_DBoralARCAcquisitionICorp.Member"
      decimals="0"
      id="Fact000168"
      unitRef="USD">500000000</cik0002065779:AggregateConsideration>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-01-012026-01-11_custom_DBoralARCAcquisitionICorp.Member"
      decimals="INF"
      id="Fact000170"
      unitRef="Shares">50000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2026-01-11_custom_DBoralARCAcquisitionICorp.Member"
      decimals="INF"
      id="Fact000172"
      unitRef="USDPShares">10.00</us-gaap:SharePrice>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-12-192025-12-31" id="Fact000174">&lt;p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zhxdEDXzYVGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 5 &#x2014; &lt;span id="xdx_826_z8QPFSfZW7Qi"&gt;Share Capital&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company is authorized to issue
&lt;span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_z5fNqfWf2Exk" title="Common stock, shares authorized"&gt;100&lt;/span&gt; shares of Common Stock of par value $&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zUx4YfEZD1lg" title="Common stock, par value"&gt;0.0001&lt;/span&gt; each share. Holders of the Company&#x2019;s common stock are entitled to one vote for each
share. On December&#160;19, 2025, the Company issued &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zATkjkJr6MK4" title="Common stock issued"&gt;100&lt;/span&gt; shares of common stock to its Parent D. Boral ARC Acquisition I Corp., at a purchase
price of $&lt;span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_z76UKaf0Ad1g" title="Purchase price"&gt;1.00&lt;/span&gt; per share, or an aggregate purchase price of $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0d_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zeyJujuSXK4h" title="Aggregate purchase price"&gt;100&lt;/span&gt;. The subscription fee was not received yet as of December&#160;31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000176"
      unitRef="Shares">100</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000178"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-12-192025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000180"
      unitRef="Shares">100</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember62742453"
      decimals="INF"
      id="Fact000182"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-12-192025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000184"
      unitRef="USD">100</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-12-192025-12-31" id="Fact000186">&lt;p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zdsxE17ClwOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 6 &#x2014; &lt;span id="xdx_827_zf6PwHW1lV13"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In preparing the financial statements,
the Company considered disclosures of events occurring after December&#160;31, 2025, until the issuance of the financial statements. Based
on this review, the Company identified the following subsequent event.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On January&#160;11, 2026, D. Boral
ARC Acquisition I Corp. (&#x201c;BCAR&#x201d; or the &#x201c;Company&#x201d;) entered into the Agreement and Plan of Merger (the &#x201c;Merger
Agreement&#x201d;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly owned subsidiary of BCAR (&#x201c;PubCo&#x201d;),
D. Boral Arc Merger Sub Inc. (&#x201c;Merger Sub&#x201d;), a Delaware corporation and a wholly-owned subsidiary of BCAR, and Exascale Labs
Inc.., a Delaware corporation (&#x201c;Exascale&#x201d;).&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000194"
      unitRef="USD">590</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">590</us-gaap:AccruedLiabilitiesCurrent>
    <cik0002065779:AmountDueToRelatedParty
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">10000</cik0002065779:AmountDueToRelatedParty>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000200"
      unitRef="USD">590</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000201"
      unitRef="USD">10590</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000203"
      unitRef="USD">590</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000204"
      unitRef="USD">10590</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000212"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000214"
      unitRef="Shares">100</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000216"
      unitRef="Shares">100</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000218"
      unitRef="Shares">100</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000220"
      unitRef="USD">100</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000221"
      unitRef="USD">100</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000223"
      unitRef="USD">-590</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000224"
      unitRef="USD">-10590</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000226"
      unitRef="USD">100</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000227"
      unitRef="USD">100</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000229"
      unitRef="USD">-590</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000230"
      unitRef="USD">-10590</us-gaap:StockholdersEquity>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000235"
      unitRef="USD">10000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000237"
      unitRef="USD">-10000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000239"
      unitRef="USD">-10000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000243"
      unitRef="USD">-10000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-01to2026-03-31"
      decimals="INF"
      id="Fact000245"
      unitRef="Shares">100</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-01to2026-03-31"
      decimals="INF"
      id="Fact000246"
      unitRef="Shares">100</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-01to2026-03-31"
      decimals="INF"
      id="Fact000248"
      unitRef="USDPShares">-100.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-01to2026-03-31"
      decimals="INF"
      id="Fact000250"
      unitRef="USDPShares">-100.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember"
      decimals="INF"
      id="Fact000258"
      unitRef="Shares">100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000253"
      unitRef="USD">100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000254"
      unitRef="USD">-590</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000255"
      unitRef="USD">-100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000256"
      unitRef="USD">-590</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000262"
      unitRef="USD">-10000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000264"
      unitRef="USD">-10000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember_custom_DBoralArcMergerCorporationMember"
      decimals="INF"
      id="Fact000272"
      unitRef="Shares">100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000267"
      unitRef="USD">100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000268"
      unitRef="USD">-10590</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000269"
      unitRef="USD">-100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000270"
      unitRef="USD">-10590</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000276"
      unitRef="USD">-10000</us-gaap:NetIncomeLoss>
    <cik0002065779:PaymentOfExpensesThroughRelatedParty
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000282"
      unitRef="USD">10000</cik0002065779:PaymentOfExpensesThroughRelatedParty>
    <us-gaap:NatureOfOperations contextRef="From2026-01-01to2026-03-31" id="Fact000300">&lt;p id="xdx_80C_eus-gaap--NatureOfOperations_zf7kYOkK4Imf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 1 &#x2014; &lt;span&gt;&lt;span id="xdx_824_zEQebogyAwxh"&gt;Description of Organization
and Business Operations&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Business Operations&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;D. Boral ARC Merger Corporation
(the &#x201c;Company&#x201d; or &#x201c;PubCo&#x201d;) is a Delaware company formed by D. Boral ARC Acquisition I Corp. (the &#x201c;Parent&#x201d;
or &#x201c;BCAR&#x201d;) on December&#160;19, 2025 (inception). The Company has adopted a fiscal year-end of December&#160;31. The Company
is authorized to issue &lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_zAlPgdaBLNye" title="Common stock, shares authorized"&gt;100&lt;/span&gt; shares of Common Stock of par value $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zyXoKWlrnUJg" title="Common stock, par value"&gt;0.0001&lt;/span&gt; each share. The Company was formed to be the surviving company
in connection with a contemplated business combination between the Parent and a target company. The Company has no principal operations
or revenue producing activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Going Concern&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company was formed by
the Parent. The Parent has until February&#160;1, 2027 to complete its initial business combination (unless further extended). If the
Parent is unable to complete the initial business combination by February&#160;1, 2027, the Parent must cease all operations and dissolve
and liquidate (unless further extended).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The accompanying financial
statements have been prepared assuming that the Company will continue as a going concern. If the Parent is unable to raise additional
funds to alleviate liquidity needs as well as complete a business combination by close of February&#160;1, 2027 (unless further extended),
then the Company will cease all operations except for the purpose of liquidating. The liquidity condition and date for liquidation and
subsequent dissolution raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. The financial statements
do not include any adjustments that might result from the outcome of these uncertainties.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000302"
      unitRef="Shares">100</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000304"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000306">&lt;p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zhfiwIBnxW47" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 2 &#x2014; &lt;span&gt;&lt;span id="xdx_82F_z8WT7pqmunKd"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoCc0oxIXVye" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86A_zRelC9ayrXw9"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the SEC. The financial statements as of March
31, 2026 and for the three months ended March 31, 2026 respectively, are un audited. In the opinion of management, the financial
statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the
financial position, operating results and cash flows for the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--EmergingGrowthCompanyPolicyTextBlock_zxCuTvrFDI99" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_864_zu39EgO8Buwg"&gt;Emerging Growth Company&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company is an &#x201c;emerging
growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act
of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition
period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging
growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because
of the potential differences in accounting standards used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_zBvkspy1qQI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86E_zvzbCsC8L8Ff"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--RisksAndUncertaintiesPolicyTextBlock_zSX4tZHeTxo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86D_zOSz8DGNyjqf"&gt;Risk and Uncertainties&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zAGgh3xYfpt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_865_zOgsMgqR3B78"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company complies with
the accounting and reporting requirements of ASC Topic 740, &#x201c;Income Taxes,&#x201d; which requires an asset and liability approach
to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between
the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;ASC Topic 740 prescribes a
recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected
to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#x2019;s management determined the United States is the Company&#x2019;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The provision for income
taxes was deemed to be immaterial for the three months ended March 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z6IKhtn0tFHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_866_z5LJmpNKovA1"&gt;Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company computes basic
loss per share (&#x201c;EPS&#x201d;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of March 31, 2026 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zPwok5ETZsz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86E_zAu283mu3nxe"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Fair value is defined
as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market
participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring
fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments
    in active markets;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 2, defined as inputs other than quoted prices in active markets that are either directly
    or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar
    instruments in markets that are not active; and&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring
    an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs
    or significant value drivers are unobservable.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In some circumstances, the
inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair
value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the
fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhxo4ncWR2Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_861_zIe1QxnsUF6c"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In November&#160;2023, the
FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to
disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis.
Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing
segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since
inception. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would
have a material effect on the Company&#x2019;s financial statement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000308">&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoCc0oxIXVye" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86A_zRelC9ayrXw9"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the SEC. The financial statements as of March
31, 2026 and for the three months ended March 31, 2026 respectively, are un audited. In the opinion of management, the financial
statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the
financial position, operating results and cash flows for the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <cik0002065779:EmergingGrowthCompanyPolicyTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000310">&lt;p id="xdx_84E_ecustom--EmergingGrowthCompanyPolicyTextBlock_zxCuTvrFDI99" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_864_zu39EgO8Buwg"&gt;Emerging Growth Company&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company is an &#x201c;emerging
growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act
of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition
period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging
growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because
of the potential differences in accounting standards used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2026-01-01to2026-03-31" id="Fact000313">&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_zBvkspy1qQI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86E_zvzbCsC8L8Ff"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <cik0002065779:RisksAndUncertaintiesPolicyTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000315">&lt;p id="xdx_845_ecustom--RisksAndUncertaintiesPolicyTextBlock_zSX4tZHeTxo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86D_zOSz8DGNyjqf"&gt;Risk and Uncertainties&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000317">&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zAGgh3xYfpt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_865_zOgsMgqR3B78"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company complies with
the accounting and reporting requirements of ASC Topic 740, &#x201c;Income Taxes,&#x201d; which requires an asset and liability approach
to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between
the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;ASC Topic 740 prescribes a
recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected
to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#x2019;s management determined the United States is the Company&#x2019;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The provision for income
taxes was deemed to be immaterial for the three months ended March 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000319">&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z6IKhtn0tFHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_866_z5LJmpNKovA1"&gt;Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company computes basic
loss per share (&#x201c;EPS&#x201d;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of March 31, 2026 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2026-01-01to2026-03-31" id="Fact000322">&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zPwok5ETZsz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86E_zAu283mu3nxe"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Fair value is defined
as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market
participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring
fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments
    in active markets;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 2, defined as inputs other than quoted prices in active markets that are either directly
    or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar
    instruments in markets that are not active; and&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring
    an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs
    or significant value drivers are unobservable.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In some circumstances, the
inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair
value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the
fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000324">&lt;p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhxo4ncWR2Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_861_zIe1QxnsUF6c"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In November&#160;2023, the
FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to
disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis.
Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing
segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since
inception. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would
have a material effect on the Company&#x2019;s financial statement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000326">&lt;p id="xdx_800_eus-gaap--SegmentReportingDisclosureTextBlock_ziZWg2OvQdfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 3&#x2009;&#x2014;&#x2009;&lt;span&gt;&lt;span&gt;Segment Information&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_82C_z7uy5yMbcEtj" style="display: none"&gt;Segment information&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;ASC Topic 280, &#x201c;Segment
Reporting,&#x201d; establishes standards for companies to report in their financial statement information about operating segments, products,
services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial
information is available that is regularly evaluated by the Company&#x2019;s chief operating decision maker, or group, in deciding how
to allocate resources and assess performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s chief
operating decision maker has been identified as directors (&#x201c;CODM&#x201d;), who review the operating results for the Company as a
whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the
Company only has one operating segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;When evaluating the Company&#x2019;s
performance and making key decisions regarding resource allocation, the CODM reviews several key metrics, formation and operational costs
which includes the accompanying statement of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The key measures of segment
profit or loss reviewed by our CODM is formation and operational costs. Formation and operational costs are reviewed and monitored by
the CODM to manage and forecast cash to ensure enough capital is available to complete a business combination within the business combination
period. The CODM also reviews formation and operational costs to manage, maintain and enforce all contractual agreements to ensure costs
are aligned with all agreements and budget.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000329">&lt;p id="xdx_809_eus-gaap--BusinessCombinationDisclosureTextBlock_zz0pi87aYuh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 4 &#x2014; &lt;span&gt;&lt;span id="xdx_82A_zmgpl2ui5l4b"&gt;Business Combination&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On January&#160;11, 2026,
D. Boral ARC Acquisition I Corp. (&#x201c;BCAR&#x201d; or the &#x201c;Company&#x201d;) entered into the Agreement and Plan of Merger (the
&#x201c;Merger Agreement&#x201d;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly owned subsidiary
of BCAR (&#x201c;PubCo&#x201d;), D. Boral Arc Merger Sub Inc. (&#x201c;Merger Sub&#x201d;), a Delaware corporation and a wholly-owned subsidiary
of BCAR, and Exascale Labs Inc.., a Delaware corporation (&#x201c;Exascale&#x201d;). Pursuant to the Merger Agreement, the Business Combination
will be effected in two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into PubCo, with PubCo remaining
as the surviving publicly traded entity (the &#x201c;Reincorporation Merger&#x201d;); (ii) after the Reincorporation Merger, Merger Sub
will be merged with and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#x201c;Acquisition Merger&#x201d;
and together with the Reincorporation Merger, the &#x201c;Business Combination&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The aggregate consideration
for the Acquisition Merger is $&lt;span id="xdx_900_ecustom--AggregateConsideration_pp0d_c20260101__20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_zXXqwXv1BXGd" title="Aggregate consideration"&gt;500,000,000&lt;/span&gt; (the &#x201c;Merger Consideration&#x201d;), payable in the form of &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_zocbYDaoU3K4" title="New shares issued"&gt;50,000,000&lt;/span&gt; newly issued shares
of common stock of PubCo valued at $&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_c20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_zRXflzuZMDy4" title="Share Price"&gt;10.00&lt;/span&gt; per share to Exascale and its shareholders. At the closing of the Acquisition Merger (the &#x201c;Closing&#x201d;),
the issued and outstanding shares in Exascale held by the former Exascale shareholders will be cancelled and cease to exist as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #FFFFFF; text-align: justify"&gt;Each
    issued and outstanding share of Exascale Class B common stock shall be cancelled and converted into the right to receive a number
    of shares of PubCo Class B common stock (the &#x201c;PubCo Class B Shares&#x201d;) equal to the quotient obtained by dividing (a) the
    quotient equal to the Merger Consideration divided by the fully diluted Exascale capitalization (the &#x201c;Per Share Merger Consideration&#x201d;)
    by (b) Ten Dollars ($10.00), with each such PubCo Class B Share having twenty (20) votes per share; and&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #FFFFFF; text-align: justify"&gt;Each
    issued and outstanding share of Exascale Class A common stock shall be cancelled and converted into the right to receive a number
    of shares of PubCo Class A common stock (the &#x201c;PubCo Class A Shares&#x201d;) equal to the quotient obtained by dividing (a) the
    Per Share Merger Consideration by (b) Ten Dollars ($10.00), with each such PubCo Class A Share having one (1) vote per share.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessCombinationDisclosureTextBlock>
    <cik0002065779:AggregateConsideration
      contextRef="From2026-01-012026-01-11_custom_DBoralARCAcquisitionICorp.Member"
      decimals="0"
      id="Fact000331"
      unitRef="USD">500000000</cik0002065779:AggregateConsideration>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-01-012026-01-11_custom_DBoralARCAcquisitionICorp.Member"
      decimals="INF"
      id="Fact000333"
      unitRef="Shares">50000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2026-01-11_custom_DBoralARCAcquisitionICorp.Member"
      decimals="INF"
      id="Fact000335"
      unitRef="USDPShares">10.00</us-gaap:SharePrice>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000337">&lt;p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z85SDJ4YhdWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 5 &#x2014; &lt;span&gt;&lt;span id="xdx_822_zaJ0zlFDAKm2"&gt;Share Capital&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company is authorized
to issue 100 shares of Common Stock of par value $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zGw25nXRyHs8" title="Common stock, par value"&gt;0.0001&lt;/span&gt; each share. Holders of the Company&#x2019;s common stock are entitled to one
vote for each share. On December&#160;19, 2025, the Company issued &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zTgHwRfLctwa" title="Common stock issued"&gt;100&lt;/span&gt; shares of common stock to its Parent D. Boral ARC Acquisition
I Corp., at a purchase price of $&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zFcXUa3HlvSa" title="Purchase price"&gt;1.00&lt;/span&gt; per share, or an aggregate purchase price of $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0d_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zAz0GKFnQxRf" title="Aggregate purchase price"&gt;100&lt;/span&gt;. The subscription fee was not received yet as
of March 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000339"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-12-192025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000341"
      unitRef="Shares">100</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember62742453"
      decimals="INF"
      id="Fact000343"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-12-192025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000345"
      unitRef="USD">100</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000347">&lt;p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zjwom0VPgJzj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 6 &#x2014; &lt;span&gt;&lt;span id="xdx_828_z3M5gtjk58V7"&gt;Subsequent Events&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In preparing the financial
statements, the Company considered disclosures of events occurring after March 31, 2026, until the issuance of the financial statements.
Based on this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial
statements.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000353"
      unitRef="USD">420340</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000355"
      unitRef="USD">203134</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000357"
      unitRef="USD">623474</us-gaap:AssetsCurrent>
    <cik0002065779:CashHeldInTrustAccount
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000359"
      unitRef="USD">284776628</cik0002065779:CashHeldInTrustAccount>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000361"
      unitRef="USD">285400102</us-gaap:Assets>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000367"
      unitRef="USD">37611</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000369"
      unitRef="USD">37611</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000371"
      unitRef="USD">37611</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000377"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000379"
      unitRef="Shares">500000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000381"
      unitRef="Shares">28000000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000383"
      unitRef="Shares">28000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000385"
      unitRef="USDPShares">10.17</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000375"
      unitRef="USD">284776628</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000391"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000393"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000395"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000397"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000399"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000401"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000403"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000405"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesOutstanding>
    <cik0002065779:SharesSubjectToRedemption
      contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000407"
      unitRef="Shares">28000000</cik0002065779:SharesSubjectToRedemption>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000409"
      unitRef="USD">120</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000411"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000413"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000415"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000417"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000419"
      unitRef="USD">1200</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000423"
      unitRef="USD">584543</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000425"
      unitRef="USD">585863</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000427"
      unitRef="USD">285400102</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:OperatingExpenses
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000429"
      unitRef="USD">320658</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000431"
      unitRef="USD">-320658</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000435"
      unitRef="USD">4776628</us-gaap:InterestIncomeOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000437"
      unitRef="USD">4455970</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact000438"
      unitRef="Shares">15393007</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact000439"
      unitRef="Shares">15393007</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact000440"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact000441"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="INF"
      id="Fact000442"
      unitRef="Shares">11935190</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="INF"
      id="Fact000443"
      unitRef="Shares">11935190</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="INF"
      id="Fact000444"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="INF"
      id="Fact000445"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareDiluted>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsorShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000465"
      unitRef="Shares">12321429</cik0002065779:ClassBOrdinarySharesIssuedToSponsorShares>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000459"
      unitRef="USD">1232</cik0002065779:ClassBOrdinarySharesIssuedToSponsor>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000460"
      unitRef="USD">23768</cik0002065779:ClassBOrdinarySharesIssuedToSponsor>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000463"
      unitRef="USD">25000</cik0002065779:ClassBOrdinarySharesIssuedToSponsor>
    <cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCostsShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000474"
      unitRef="Shares">200000</cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCostsShares>
    <cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000467"
      unitRef="USD">20</cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts>
    <cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000469"
      unitRef="USD">1971400</cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts>
    <cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000472"
      unitRef="USD">1971420</cik0002065779:SaleOfPrivateUnitsNetOfIssuanceCosts>
    <cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000478"
      unitRef="USD">8913405</cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts>
    <cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000481"
      unitRef="USD">8913405</cik0002065779:IssuanceOfPublicWarrantsNetOfIssuanceCosts>
    <cik0002065779:IssuanceOfRepresentativeSharesShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000490"
      unitRef="Shares">1000000</cik0002065779:IssuanceOfRepresentativeSharesShares>
    <cik0002065779:IssuanceOfRepresentativeShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000483"
      unitRef="USD">100</cik0002065779:IssuanceOfRepresentativeShares>
    <cik0002065779:IssuanceOfRepresentativeShares
      contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000485"
      unitRef="USD">2419300</cik0002065779:IssuanceOfRepresentativeShares>
    <cik0002065779:IssuanceOfRepresentativeShares
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000488"
      unitRef="USD">2419400</cik0002065779:IssuanceOfRepresentativeShares>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000494"
      unitRef="USD">14233074</cik0002065779:AccretionInValueOfClassOrdinaryShares>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000495"
      unitRef="USD">4301388</cik0002065779:AccretionInValueOfClassOrdinaryShares>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000497"
      unitRef="USD">18534462</cik0002065779:AccretionInValueOfClassOrdinaryShares>
    <cik0002065779:ReverseOverallotmentOptionLiability
      contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000501"
      unitRef="USD">860414</cik0002065779:ReverseOverallotmentOptionLiability>
    <cik0002065779:ReverseOverallotmentOptionLiability
      contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000502"
      unitRef="USD">429961</cik0002065779:ReverseOverallotmentOptionLiability>
    <cik0002065779:ReverseOverallotmentOptionLiability
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000504"
      unitRef="USD">1290375</cik0002065779:ReverseOverallotmentOptionLiability>
    <cik0002065779:ForfeitureOfFounderSharesShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000513"
      unitRef="Shares">-321429</cik0002065779:ForfeitureOfFounderSharesShares>
    <cik0002065779:ForfeitureOfFounderShares
      contextRef="From2025-03-202025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000507"
      unitRef="USD">32</cik0002065779:ForfeitureOfFounderShares>
    <cik0002065779:ForfeitureOfFounderShares
      contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000508"
      unitRef="USD">-32</cik0002065779:ForfeitureOfFounderShares>
    <cik0002065779:AdjustmentOfAccruedOfferingCosts
      contextRef="From2025-03-202025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000517"
      unitRef="USD">44755</cik0002065779:AdjustmentOfAccruedOfferingCosts>
    <cik0002065779:AdjustmentOfAccruedOfferingCosts
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000520"
      unitRef="USD">44755</cik0002065779:AdjustmentOfAccruedOfferingCosts>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000525"
      unitRef="USD">4455970</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000527"
      unitRef="USD">4455970</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact000536"
      unitRef="Shares">1200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="0"
      id="Fact000529"
      unitRef="USD">120</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000538"
      unitRef="Shares">12000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000530"
      unitRef="USD">1200</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000532"
      unitRef="USD">584543</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000534"
      unitRef="USD">585863</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000542"
      unitRef="USD">4455970</us-gaap:NetIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000546"
      unitRef="USD">4776628</us-gaap:InterestIncomeOther>
    <cik0002065779:PaymentOfExpensesThroughPromissoryNoteRelatedParty
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000548"
      unitRef="USD">41420</cik0002065779:PaymentOfExpensesThroughPromissoryNoteRelatedParty>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000552"
      unitRef="USD">203134</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000554"
      unitRef="USD">37611</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000556"
      unitRef="USD">-444761</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000560"
      unitRef="USD">280000000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000562"
      unitRef="USD">-280000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000566"
      unitRef="USD">25000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cik0002065779:ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000568"
      unitRef="USD">280000000</cik0002065779:ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000570"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000572"
      unitRef="USD">225461</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000574"
      unitRef="USD">934438</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000576"
      unitRef="USD">280865101</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000578"
      unitRef="USD">420340</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000582"
      unitRef="USD">420340</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NotesIssued1
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000586"
      unitRef="USD">32</us-gaap:NotesIssued1>
    <us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000588"
      unitRef="USD">4776628</us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionDescription
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000590">2,419,400</us-gaap:NoncashOrPartNoncashAcquisitionDescription>
    <us-gaap:NatureOfOperations
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000592">&lt;p id="xdx_803_eus-gaap--NatureOfOperations_zLLaTa8ZGhCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1. &lt;span id="xdx_82D_zfE85CfSiSl"&gt;DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;D.
BORAL ARC ACQUISITION I CORP. (the &#x201c;Company&#x201d;) is a blank check company incorporated in the British Virgin Islands on March&#160;20,
2025. The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more businesses (&#x201c;Business Combination&#x201d;). While the Company may pursue an acquisition
opportunity in any business, industry, sector or geographical location, the Company intends to focus on industries that complement our
management team&#x2019;s background, and to capitalize on the ability of our management team to identify and acquire a business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December&#160;31, 2025, the Company had not yet commenced any operations. All activity through December&#160;31, 2025 related to the Company&#x2019;s
formation and the Initial Public Offering (as defined below). The Company will not generate any operating revenues until after the completion
of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on
cash and cash equivalents from the proceeds derived from the Initial Public Offering. The Company has selected December&#160;31 as its
fiscal year end. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated
with early stage and emerging growth companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s sponsor is MFH 1, LLC (the &#x201c;Sponsor&#x201d;). The registration statement for the Company&#x2019;s Initial Public Offering
was declared effective on July&#160;30, 2025. On August&#160;1, 2025, the Company consummated its Initial Public Offering of &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zymewYmUk4Hc" title="Sale of units in initial public offering"&gt;25,000,000&lt;/span&gt;
units (the &#x201c;Units&#x201d; and, with respect to the Class A Ordinary Shares included in the Units being offered, the &#x201c;Public
Shares&#x201d;), at $&lt;span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zLpBFIdH2am2" title="Sale of units per share"&gt;10.00&lt;/span&gt; per Unit, generating gross proceeds of $&lt;span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zeMvai1aOgU5" title="Sale of units in initial public offering aggragate amount"&gt;250,000,000&lt;/span&gt; (the &#x201c;Initial Public Offering&#x201d;). The Company
granted the underwriter a 45-day option to purchase up to an additional &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zvvgsX2GXdI2" title="Sale of units in initial public offering"&gt;3,750,000&lt;/span&gt; Units at the Initial Public Offering price to cover
over-allotments, if any.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Simultaneously
with the consummation of the closing of the Offering, the Company consummated the private placement of an aggregate of &lt;span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z1oRfYkYwYg7" title="Sale of units in initial public offering"&gt;200,000&lt;/span&gt; units (the
&#x201c;Placement Units&#x201d;) to the Sponsor at a price of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ztuGwqkmsSn4" title="Sale of units per share"&gt;10.00&lt;/span&gt; per Unit, generating gross proceeds of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z6JLWVjCNLD2" title="Sale of units in initial public offering aggragate amount"&gt;2,000,000&lt;/span&gt; (the &#x201c;Private
Placement&#x201d;). (see Note 4).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transaction
costs amounted to $&lt;span id="xdx_90D_ecustom--TransactionCosts_pp0p0_c20250320__20251231_zWv4AjHSzFBk" title="Transaction costs"&gt;3,582,634&lt;/span&gt;, consisting of $&lt;span id="xdx_900_ecustom--RepresentativeShares_pp0p0_c20250320__20251231_zfnVet6jBnE8" title="Representative shares"&gt;2,419,400&lt;/span&gt; of the Representative Shares (discussed in the below) and $&lt;span id="xdx_900_ecustom--OtherOfferingCosts_pp0p0_c20250320__20251231_zzbsFZ9QoI29" title="Other offering costs"&gt;1,163,234&lt;/span&gt; of other offering
costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
conjunction with the IPO, the Company issued to the underwriter &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_z9JyvNUCifek" title="Number of share issued"&gt;1,000,000&lt;/span&gt; Class A ordinary shares for no consideration (the &#x201c;Representative
Shares&#x201d;). The fair value of the Representative Shares accounted for as compensation under Accounting Standards Codification (&#x201c;ASC&#x201d;)
718, &#x201c;Compensation &#x2013; Stock Compensation&#x201d; (&#x201c;ASC 718&#x201d;) is included in the offering costs. The estimated fair
value of the Representative Shares as of the IPO date totaled $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zkjrdeMbCkic" title="Number of share issued, value"&gt;2,419,400&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the closing of the Initial Public Offering on August&#160;1, 2025, an amount of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zAYQK4eRIMDe" title="proceeds from sale of initial public offering"&gt;250,000,000&lt;/span&gt; ($10.00 per Unit) from the net proceeds of
the sale of the Units in the Initial Public Offering and a portion of the proceeds from the sale of the Placement Units was placed in
a trust account (the &#x201c;Trust Account&#x201d;), located in the United States and held as cash items and will be invested only in U.S.
government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule&#160;2a-7 under
the Investment Company Act, that invest only in direct U.S. government treasury obligations; the holding of these assets in this form
is intended to be temporary and for the sole purpose of facilitating the intended business combination. To mitigate the risk that the
Company might be deemed to be an investment company for purposes of the Investment Company Act, which risk increases the longer that the
Company hold investments in the trust account, the Company may, at any time (based on our management team&#x2019;s ongoing assessment of
all factors related to our potential status under the Investment Company Act), instruct the trustee to liquidate the investments held
in the trust account and instead to hold the funds in the trust account in cash or in an interest bearing demand deposit account at a
bank.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August&#160;11, 2025, the underwriters of the IPO notified the Company of their partial exercise of the over-allotment option and purchased
&lt;span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zDA2VnME7U0b" title="Sale of units in initial public offering"&gt;3,000,000&lt;/span&gt; additional units (the &#x201c;Option Units&#x201d;) at $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zR9U3nh9D7Y8" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit upon the closing of the over-allotment option, generating
gross proceeds of $&lt;span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zlDHmMAY5wM4" title="Sale of units in initial public offering aggragate amount"&gt;30,000,000&lt;/span&gt;. The over-allotment option closed on August&#160;13, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September&#160;9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and
thereby forfeit the option. As a result,&#160;on September&#160;9, 2025,&#160;the Company cancelled a total of &lt;span id="xdx_905_ecustom--CancelledFounderShares_c20250905__20250909_zuJm4Jjl1XIk" title="Cancelled founder shares"&gt;321,429&lt;/span&gt; of the Company&#x2019;s
founder shares, issued to MFH 1, LLC thereby reducing the sponsor&#x2019;s total shares to &lt;span id="xdx_909_ecustom--CancelledFounderShares_c20250729__20250801_z24hspa4c7wl" title="Cancelled founder shares"&gt;12,000,000&lt;/span&gt;, which was effective from August&#160;1,
2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion
of our initial business combination either (i) in connection with a shareholder meeting called to approve the initial business combination
or (ii) by means of a tender offer. In connection with a proposed Business Combination, the Company may seek shareholder approval of a
Business Combination at a meeting called for such purpose at which shareholders may seek to redeem their shares, regardless of how they
vote for the Business Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially
$&lt;span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zi26VOwh3vcj" title="Sale of units per share"&gt;10.00&lt;/span&gt; per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company
to pay its tax obligations). The per-share amount to be distributed to shareholders who redeem their Public Shares will not be reduced
by the deferred underwriting commissions the Company will pay to the underwriter. These ordinary shares was recorded at a redemption value
and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification
(&#x201c;ASC&#x201d;) Topic 480 &#x201c;Distinguishing Liabilities from Equity.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other reasons, the Company
will, pursuant to its amended and restated memorandum and articles of association conduct the redemptions pursuant to Rule&#160;13e-4
and Regulation 14E of the Exchange Act, which regulate issuer tender offers, and file tender offer documents with the SEC prior to completing
our initial business combination which contain substantially the same financial and other information about the initial business combination
and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
sponsor, officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed to (i) waive
their redemption rights with respect to their founder shares, private shares and public shares in connection with the completion of our
initial business combination; (ii) waive their redemption rights with respect to their founder shares, private shares and public shares
in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and articles of association; (iii)
waive their rights to liquidating distributions from the trust account with respect to their founder shares and private shares if the
Company fail to complete our initial business combination within the completion window, although they will be entitled to liquidating
distributions from the trust account with respect to any public shares they hold if the Company fail to complete our initial business
combination within the prescribed time frame and to liquidating distributions from assets outside the trust account; and (iv) vote any
founder shares and private shares held by them and any public shares they may purchase (including in open market and privately-negotiated
transactions) in favor of our initial business combination (except that any public shares such parties may purchase in compliance with
the requirements of Rule&#160;14e-5 under the Exchange Act would not be voted in favor of approving the business combination transaction).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company will have until 18 months from the closing of the Initial Public Offering, with one (1) three-month extension at the option of
the sponsor (as may be extended by shareholder approval to amend our amended and restated memorandum and articles of association to extend
the date by which the Company must consummate our initial business combination) or until such earlier liquidation date as our board of
directors may approve, to consummate a Business Combination (the &#x201c;Combination Period&#x201d;). If the Company is unable to complete
a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up,
(ii) as promptly as reasonably possible but not more than ten business days thereafter (and subject to lawfully available funds therefor),
redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including
interest earned on the funds held in the trust account (which interest shall be net of taxes and less up to $&lt;span id="xdx_900_eus-gaap--LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_iI_c20251231_zMMxKKn8j5Nc" title="Dissolution expenses"&gt;100,000&lt;/span&gt; of interest to pay
dissolution expenses), divided by the number of then-outstanding public shares, which redemption will completely extinguish public shareholders&#x2019;
rights as shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii)
as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors,
liquidate and dissolve, subject in each case to our obligations under British Virgin Islands law to provide for claims of creditors and
the requirements of other applicable law.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
underwriter has agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event the Company
does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds
held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is
possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price
per Unit ($10.00).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Sponsor has agreed that it will be liable to us if and to the extent any claims by a third party for services rendered or products sold
to us (except for the Company&#x2019;s independent auditors), or a prospective target business with which the Company has entered into
a written letter of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in
the trust account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account
as of the date of the liquidation of the trust account, if less than $10.00 per public share due to reductions in the value of the trust
assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business
who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will
it apply to any claims under our indemnity of the underwriters of our IPO against certain liabilities, including liabilities under the
Securities Act. However, the Company has not asked our sponsor to reserve for such indemnification obligations, nor has the Company independently
verified whether our sponsor has sufficient funds to satisfy its indemnity obligations and the Company believe that our sponsor&#x2019;s
only assets are securities of our company. Therefore, the Company cannot assure you that our sponsor would be able to satisfy those obligations.
As a result, if any such claims were successfully made against the trust account, the funds available for our initial business combination
and redemptions could be reduced to less than $10.00 per public share. In such event, the Company may not be able to complete our initial
business combination, and you would receive such lesser amount per share in connection with any redemption of your public shares. None
of our officers or directors will indemnify us for claims by third parties including, without limitation, claims by vendors and prospective
target businesses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January&#160;11, 2026, D. Boral ARC Acquisition I Corp. (&#x201c;BCAR&#x201d; or the &#x201c;Company&#x201d;) entered into the Agreement and
Plan of Merger (the &#x201c;Merger Agreement&#x201d;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly
owned subsidiary of BCAR (&#x201c;PubCo&#x201d;), D. Boral Arc Merger Sub Inc. (&#x201c;Merger Sub&#x201d;), a Delaware corporation and a
wholly-owned subsidiary of BCAR, and Exascale Labs Inc., a Delaware corporation (&#x201c;Exascale&#x201d;). Pursuant to the Merger Agreement,
the Business Combination will be effected in two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into
PubCo, with PubCo remaining as the surviving publicly traded entity (the &#x201c;Reincorporation Merger&#x201d;); (ii) after the Reincorporation
Merger, Merger Sub will be merged with and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#x201c;Acquisition
Merger&#x201d; and together with the Reincorporation Merger, the &#x201c;Business Combination&#x201d;).&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate consideration for the Acquisition Merger is $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250320__20251231_zLQu92JYDcL4" title="Share newly issued of common stock"&gt;500,000,000&lt;/span&gt; (the &#x201c;Merger Consideration&#x201d;), payable in the form of &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250320__20251231_zrpwY2DyvnT9" title="Share newly issued of common stock, shares"&gt;50,000,000&lt;/span&gt;
newly issued shares of common stock of PubCo valued at $10.00 per share to Exascale and its shareholders. At the closing of the Acquisition
Merger (the &#x201c;Closing&#x201d;), the issued and outstanding shares in Exascale held by the former Exascale shareholders will be cancelled
and cease to exist as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each issued and outstanding share
        of Exascale Class B common stock shall be cancelled and converted into the right to receive a number of shares of PubCo Class B common
        stock (the &#x201c;PubCo Class B Shares&#x201d;) equal to the quotient obtained by dividing (a) the quotient equal to the Merger Consideration
        divided by the fully diluted Exascale capitalization (the &#x201c;Per Share Merger Consideration&#x201d;) by (b) Ten Dollars ($10.00), with
        each such PubCo Class B Share having twenty (20) votes per share; and&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each issued and outstanding share
        of Exascale Class A common stock shall be cancelled and converted into the right to receive a number of shares of PubCo Class A common
        stock (the &#x201c;PubCo Class A Shares&#x201d;) equal to the quotient obtained by dividing (a) the Per Share Merger Consideration by (b)
        Ten Dollars ($10.00), with each such PubCo Class A Share having one (1) vote per share.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Liquidity,
Capital Resources and Going Concern Consideration&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December&#160;31, 2025, the Company had $&lt;span id="xdx_901_eus-gaap--Cash_iI_pp0p0_c20251231_zBQBHTAL4Sk4" title="Cash"&gt;420,340&lt;/span&gt; of cash in its operating bank account and working capital of $&lt;span id="xdx_904_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20251231_zaoDT1sVQ0Cb" title="Working capital deficit"&gt;585,863&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through the payment of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--FounderSharesMember_zd9iA0x85lrl"&gt;25,000&lt;/span&gt;
from the Sponsor to cover for certain offering costs on the Company&#x2019;s behalf in exchange for issuance of Founder Shares (as defined
in Note 4), and loan from the Sponsor of $&lt;span id="xdx_900_eus-gaap--LoansPayable_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z97qhlWYqK2h"&gt;225,461&lt;/span&gt; under the Note (as defined in Note 4). On August&#160;1, 2025, the Company has repaid
$&lt;span id="xdx_903_eus-gaap--RepaymentOfNotesReceivableFromRelatedParties_c20250729__20250801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zb9jcZE28Ibk"&gt;225,461&lt;/span&gt; under the promissory note. Subsequent to the consummation of the Initial Public Offering, the Company&#x2019;s liquidity has been
satisfied through the net proceeds from the consummation of the Initial Public Offering and the Private Placement held outside of the
Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate
of the Sponsor, or certain of the Company&#x2019;s officers and directors may, but are not obligated to, provide the Company Working Capital
Loans (as defined in Note 4). As of December&#160;31, 2025, there were no amounts outstanding under any Working Capital Loan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expects to incur significant costs in pursuit of its acquisition plans and will not generate any operating revenues until after
the completion of its initial business combination. In addition, the Company expects to have negative cash flows from operations as it
pursues an initial business combination target. In connection with the Company&#x2019;s assessment of going concern considerations in accordance
with Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-15, &#x201c;Disclosures of Uncertainties about an Entity&#x2019;s Ability to Continue
as a Going Concern&#x201d; the Company does not currently have adequate liquidity to sustain operations, which consist solely of pursuing
a Business Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may raise additional capital through loans or additional investments from the Sponsor or its shareholders, officers, directors,
or third parties. The Company&#x2019;s officers and directors and the Sponsor may, but are not obligated to (except as described above),
loan the Company funds, from time to time, in whatever amount they deem reasonable in their sole discretion, to meet the Company&#x2019;s
working capital needs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
is customary for a special purpose acquisition company, if the Company is not able to consummate a Business Combination during the Combination
Period, it will cease all operations and redeem the Public Shares. Management plans to continue its efforts to consummate a Business Combination
during the Combination Period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;While
the Company expects to have access to additional sources of capital if necessary, there is no current commitment on the part of any financing
source to provide additional capital and no assurances can be provided that such additional capital will ultimately be available. The
liquidity condition and mandatory liquidation raise substantial doubt about the Company&#x2019;s ability to continue as a going concern
until the earlier of the consummation of the Business Combination or the date the Company is required to liquidate. There is no assurance
that the Company&#x2019;s plans to raise additional capital (to the extent ultimately necessary) or to consummate a Business Combination
will be successful or successful within the Combination Period. The consolidated financial statements do not include any adjustments that
might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000594"
      unitRef="Shares">25000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000596"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000598"
      unitRef="USD">250000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000600"
      unitRef="Shares">3750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000602"
      unitRef="Shares">200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000604"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000606"
      unitRef="USD">2000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <cik0002065779:TransactionCosts
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000608"
      unitRef="USD">3582634</cik0002065779:TransactionCosts>
    <cik0002065779:RepresentativeShares
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000610"
      unitRef="USD">2419400</cik0002065779:RepresentativeShares>
    <cik0002065779:OtherOfferingCosts
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000612"
      unitRef="USD">1163234</cik0002065779:OtherOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000614"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000616"
      unitRef="USD">2419400</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000618"
      unitRef="USD">250000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000627"
      unitRef="Shares">3000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000629"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000631"
      unitRef="USD">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <cik0002065779:CancelledFounderShares
      contextRef="From2025-09-052025-09-09_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000633"
      unitRef="Shares">321429</cik0002065779:CancelledFounderShares>
    <cik0002065779:CancelledFounderShares
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000635"
      unitRef="Shares">12000000</cik0002065779:CancelledFounderShares>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000637"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000646"
      unitRef="USD">100000</us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000655"
      unitRef="USD">500000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000657"
      unitRef="Shares">50000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:Cash
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000659"
      unitRef="USD">420340</us-gaap:Cash>
    <cik0002065779:WorkingCapitalDeficit
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000661"
      unitRef="USD">585863</cik0002065779:WorkingCapitalDeficit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-03-202025-12-31_custom_FounderSharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000662"
      unitRef="USD">25000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:LoansPayable
      contextRef="AsOf2025-12-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000663"
      unitRef="USD">225461</us-gaap:LoansPayable>
    <us-gaap:RepaymentOfNotesReceivableFromRelatedParties
      contextRef="From2025-07-292025-08-01_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000664"
      unitRef="USD">225461</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000673">&lt;p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zy7FcDCgeNii" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2. &lt;span id="xdx_82E_z6Po6lfWFJF7"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zTqQLi3oj3F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zknhPtMT4xkj"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the SEC.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
information and note disclosures normally included in the annual consolidated financial statements prepared in accordance with generally
accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although the Company believes that
the disclosures made are adequate to make the information not misleading. The consolidated financial statements as of December&#160;31,
2025 and for period from March&#160;20, 2025 (inception) through December&#160;31, 2025 are audited. In the opinion of management, the
consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary to provide a fair
statement of the results for the periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--EmergingGrowthCompanyPolicyTextBlock_zjHTebZGYcF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_z9adgwwH5gz6"&gt;Emerging
Growth Company&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart
Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being
required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Further,
Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not
have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply
to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended
transition period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#x2019;s consolidated financial statements with another public company which is neither
an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible
because of the potential differences in accounting standards used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--UseOfEstimates_zCSpiRUyiDb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_z9wBQjRDfAXk"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Making
estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of
a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered
in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results
could differ significantly from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zxisgP8Xl37k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zAhdNNso56Nb"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash
equivalents are carried at cost, which approximates fair value. The Company had $&lt;span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20251231_zmXdChwNJcJ4" title="Cash"&gt;420,340&lt;/span&gt; in cash as of December&#160;31, 2025 The Company
had &lt;span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20251231_zyjNNzvKrPke" title="Cash equivalents"&gt;no&lt;/span&gt; cash equivalents as of December&#160;31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--CashHeldInTrustAccountPolicyTextBlock_z4HvK1JPIUmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zTYNKhDkXdT7"&gt;Cash
Held in Trust Account&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had $&lt;span id="xdx_90E_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20251231_z8h7Eqz2G7o8" title="Cash held in trust"&gt;284,776,628&lt;/span&gt; of cash in the trust account held in an interest bearing demand deposit account as of December&#160;31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock_zjYwZgXnflQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zHG5bezvliwj"&gt;Offering
Costs Associated with the Initial Public Offering&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014; &#x201c;Expenses
of Offering.&#x201d; Deferred offering costs consist principally of professional and registration fees that are related to the Initial
Public Offering. Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 470-20, &#x201c;Debt with Conversion and Other Options,&#x201d;
addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this
guidance to allocate Initial Public Offering proceeds from the Public Units between Class A ordinary shares and warrants based on their
relative fair values. Offering costs allocated to the Class A ordinary shares subject to possible redemption were charged to temporary
equity, and offering costs allocated to the warrants included in the Public Units and Private Units were charged to shareholder&#x2019;s
equity as the warrants, after management&#x2019;s evaluation, were accounted for under equity treatment. As of August&#160;1, 2025, the
Company had offering costs of $&lt;span id="xdx_90C_ecustom--OfferingCost_iI_pp0p0_c20250801_zTEBye9LC6Sa" title="Offering costs"&gt;3,582,634&lt;/span&gt;, consisting of $&lt;span id="xdx_901_ecustom--RepresentativeShares_c20250729__20250801_zO3HwvtfCCL3" title="Representative shares"&gt;2,419,400&lt;/span&gt; of the Representative Shares (as discussed in Note 1) and $&lt;span id="xdx_903_ecustom--OtherOfferingCost_pp0p0_c20250729__20250801_zGB9Qx0HWUBg" title="Other offering costs"&gt;1,163,234&lt;/span&gt;
of other offering costs. Approximately $&lt;span id="xdx_90C_eus-gaap--OtherExpenses_pp0p0_c20250729__20250801_z3GNIDiBSqvd" title="other costs"&gt;143,775&lt;/span&gt; of such costs were allocated to the Public Warrants and the Private Placement Units and
the remainder, approximately $&lt;span id="xdx_90D_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_c20250801_zBavxm1BynCj" title="Ordinary shares subject to redemption"&gt;3,438,859&lt;/span&gt; was allocated to Class A ordinary shares subject to redemption. As of December&#160;31, 2025,
the Company had offering costs of $&lt;span id="xdx_900_ecustom--OfferingCost_iI_pp0p0_c20251231_ziNhZdkvYfdf" title="Offering costs"&gt;3,582,634&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z5OSpTZZj5k8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zcqL0aCgOVV7"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with the accounting and reporting requirements of ASC Topic 740, &#x201c;Income Taxes,&#x201d; which requires an asset
and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed
for differences between the consolidated financial statement and tax bases of assets and liabilities that will result in future taxable
or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable
income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
Topic 740 prescribes a recognition threshold and a measurement attribute for the consolidated financial statement recognition and measurement
of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not
to be sustained upon examination by taxing authorities. The Company&#x2019;s management determined the British Virgin Islands is the Company&#x2019;s
only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income
tax expense. There were no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The
Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from
its position. The Company is considered to be an exempted British Virgin Islands company with no connection to any other taxable jurisdiction
and is presently not subject to income taxes or income tax filing requirements in the British Virgin Islands or the United States. As
such, the provision for income taxes was deemed to be &lt;i&gt;de minimis&lt;/i&gt; for the period from March&#160;20, 2025 (inception) to December&#160;31,
2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--DerivativesReportingOfDerivativeActivity_zfMMEAmeHDb5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zun6kxhx1xka"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#x201c;Derivatives and Hedging.&#x201d; For derivative financial instruments that are accounted
for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each
reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative
liabilities are classified in the balance sheet as current or non-current based on whether or not net cash settlement or conversion of
the instrument could be required within 12 months of the balance sheet date. The underwriters&#x2019; over-allotment option is deemed to
be a freestanding financial instrument indexed to the contingently redeemable shares and was accounted for as a liability pursuant to
ASC 480 if not fully exercised at the time of the Initial Public Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ExtendedProductWarrantyPolicy_z0FLSxdwRnzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zDBCwQoAzPGl"&gt;Warrant
Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for Warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#x2019;
specific terms and applicable authoritative guidance in ASC 480 and FASB ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC
815&#x201d;). The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815,
including whether the instruments are indexed to a company&#x2019;s common shares and whether the instrument holders could potentially
require &#x201c;net cash settlement&#x201d; in a circumstance outside of a company&#x2019;s control, among other conditions for equity classification.
This assessment, which requires the use of professional judgment, is conducted at the time of Warrant issuance and as of each subsequent
quarterly period end date while the instruments are outstanding. Upon review of the Warrant Agreement, Management concluded that the&#160;public
warrants and private warrants issued pursuant to such warrant agreement qualify for equity accounting treatment.&#160;Following the closing
of the Initial Public Offering on August&#160;1, 2025 and underwriter&#x2019;s exercise of over-allotment option on August&#160;13, 2025,
the Company accounted for the&#160;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20251231_zdWSGahahNSi" title="Warrants issued"&gt;14,000,000&lt;/span&gt; public warrants and&#160;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zi4ctrzVvrZc" title="Warrants issued"&gt;100,000&lt;/span&gt; private warrants issued under equity treatment at their
assigned values. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p id="xdx_846_ecustom--ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_z39K6VkBlVx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zMsjsksIRMVh"&gt;Class
A Ordinary Shares Subject to Possible Redemption&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
public shares contain a redemption feature which allows for the redemption of such public shares in connection with the Company&#x2019;s
liquidation, or if there is a shareholder vote or tender offer in connection with the Company&#x2019;s initial Business Combination. In
accordance with ASC 480-10-S99, the Company classifies public shares subject to redemption outside of permanent equity as the redemption
provisions are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as they occur
and will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately
upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value.
The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the extent available)
and Retained earnings. Accordingly, Class A ordinary shares subject to possible redemption are presented at redemption value as temporary
equity, outside of the shareholders&#x2019; equity section of the Company&#x2019;s balance sheet. As of December&#160;31, 2025, the 28,000,000
Class A ordinary shares subject to redemption reflected in the balance sheet are reconciled in the following table:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--TemporaryEquityTableTextBlock_zPcXeTqfm8lb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8BD_zLSvphjsOLC3" style="display: none"&gt;Schedule of ordinary shares subject to redemption&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Gross proceeds from IPO, August&#160;1,
        2025&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_pp0d_c20250802__20251231_z2o34efAYZBg" title="Ordinary shares subject to possible redemption, beginning"&gt;280,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Less:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Proceeds allocated to Public Warrants&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ProceedsAllocatedToPublicWarrants_pp0d_c20250802__20251231_znh5ksE756X8" title="Proceeds allocated to Public Warrants"&gt;(9,028,600&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Proceeds allocated to Over-allotment Option&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ProceedsAllocatedToOverallotmentOption_pp0d_c20250802__20251231_zF18AYVY4Fwe" title="Proceeds allocated to Over-allotment Option"&gt;(1,290,375&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Class A ordinary shares issuance costs&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ClassOrdinarySharesIssuanceCosts_pp0d_c20250802__20251231_zFN36aIn6kRf" title="Class A ordinary shares issuance costs"&gt;(3,438,859&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Plus:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Accretion of carrying
        value to redemption value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--TemporaryEquityAccretionToRedemptionValue_pp0d_c20250802__20251231_z1giMb4Fdhpj" title="Ordinary shares subject to possible redemption"&gt;18,534,462&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Class A ordinary shares
        subject to possible redemption, December&#160;31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_pp0d_c20250802__20251231_z92pFQBkwJ85" title="Ordinary shares subject to possible redemption, ending"&gt;284,776,628&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zCe7sjt49b28" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zhFehGf6YTR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zQunJD1xUwzi"&gt;Net
Income per Ordinary Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company complies with accounting and disclosure
requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share.&#x201d; Net income per share of ordinary shares is computed by dividing
net income applicable to ordinary shareholders by the weighted average number of shares of ordinary shares outstanding during the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not considered the effect of the Warrants sold in the Offering and Private Placement to purchase an aggregate of&#160;&lt;span id="xdx_903_eus-gaap--WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_c20250320__20251231_zIYauijVJJe6" title="Weighted average aggregate shares"&gt;14,100,000&lt;/span&gt;&#160;Class
A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock
method and are contingent on future events. As a result, diluted income per share of Class A ordinary shares is the same as basic income
per share of ordinary shares for the period presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has two classes of ordinary shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income are shared
pro rata among the two classes of ordinary shares. Net income per share of ordinary shares is calculated by dividing the net income by
the weighted average number of shares of ordinary shares outstanding during the respective period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables reflect the net income per share after allocating income between the shares based on outstanding shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zK6g7uklULf4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;&lt;i&gt;&lt;span id="xdx_8BF_zaGSXzmsgspk" style="display: none"&gt;Schedule
    of earning per share basic and diluted&lt;/span&gt;&lt;/i&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;Period from &lt;br/&gt;March&#160;20,
        2025&lt;br/&gt;(Inception) through &lt;br/&gt;December&#160;31, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Class A&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Class B&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;Numerator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Basic and diluted net income
        per share:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold; text-align: left"&gt;Allocation
        of income &#x2013; basic and diluted&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z3sCrZfmImf8" title="Allocation of income - basic"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zOP8f6mC3Gdc" title="Allocation of income - diluted"&gt;2,509,890&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z2qJnxTMSxqk"&gt;&lt;span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_ziM4aHJWJMT8" title="Allocation of income - diluted"&gt;1,946,080&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Basic and diluted weighted
        average share of ordinary shares:&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zLS14Lz9LzJi" title="Basic weighted average share of ordinary shares"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z7DNrJH4OfBj" title="Diluted weighted average share of ordinary shares"&gt;15,393,007&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zZ1AoE0JuY4c" title="Basic weighted average share of ordinary shares"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z5EwpZeeFiAi" title="Diluted weighted average share of ordinary shares"&gt;11,935,190&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Basic and diluted net income
        per share&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zWEL5OqBJofa" title="Basic net income per share"&gt;&lt;span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zT2ajwWAS9G6" title="Diluted net income per share"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zjBGNV05rIv" title="Basic net income per share"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zAOQ6qINRSph" title="Diluted net income per share"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zQW6yz6aHTG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zIcrYsjdOnUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zU8Q18WJlnoi"&gt;Concentration
of credit risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution
which, at times may exceed the Federal depository insurance coverage of $&lt;span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_c20251231_zTBZxivW96d5" title="FDIC Insured Amount"&gt;250,000&lt;/span&gt;. At December&#160;31, 2025, the Company had not experienced
losses on this account and management believes the Company is not exposed to significant risks on such account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zD59y9ZVJcWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zbcnfxYlFdrl"&gt;Fair
value of financial instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value
Measurements and Disclosures,&#x201d; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to
their short-term nature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--RisksAndUncertaintiesPolicyTextBlock_zxL0KasiCzxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zjcWV21IYFn1"&gt;Risks
and Uncertainties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the
ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict,
the North Atlantic Treaty Organization (&#x201c;NATO&#x201d;) deployed additional military forces to eastern Europe, and the United States,
the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus
and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank
Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide
military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of
Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken
in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries
have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact
of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity
prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally,
any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity
in capital markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any
of the above-mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting
from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely
affect the Company&#x2019;s search for an initial Business Combination and any target business with which the Company may ultimately consummate
an initial Business Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8qxlOQm7eDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zJUe6H2lTeAa"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which
requires the disclosure of additional segment information. ASU No. 2023-07 is effective for fiscal years beginning after December&#160;15,
2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted ASU 2023-07 as of the inception
of the Company. Adoption of the ASU did not impact the Company&#x2019;s financial position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December&#160;2023, the FASB issued ASU 2023-09, &lt;i&gt;Income taxes&lt;/i&gt; (Topic 740): Improvements to Income Tax Disclosure (&#x201c;ASU 2023-09&#x201d;),
which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 will be effective for fiscal years beginning after
December&#160;15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for
issuance. The Company adopted ASU 2023-09 as of the inception of the Company. Adoption of the ASU did not impact the Company&#x2019;s financial
position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000675">&lt;p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zTqQLi3oj3F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zknhPtMT4xkj"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the SEC.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
information and note disclosures normally included in the annual consolidated financial statements prepared in accordance with generally
accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although the Company believes that
the disclosures made are adequate to make the information not misleading. The consolidated financial statements as of December&#160;31,
2025 and for period from March&#160;20, 2025 (inception) through December&#160;31, 2025 are audited. In the opinion of management, the
consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary to provide a fair
statement of the results for the periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <cik0002065779:EmergingGrowthCompanyPolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000677">&lt;p id="xdx_84E_ecustom--EmergingGrowthCompanyPolicyTextBlock_zjHTebZGYcF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_z9adgwwH5gz6"&gt;Emerging
Growth Company&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart
Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being
required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Further,
Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not
have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply
to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended
transition period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#x2019;s consolidated financial statements with another public company which is neither
an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible
because of the potential differences in accounting standards used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</cik0002065779:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000686">&lt;p id="xdx_849_eus-gaap--UseOfEstimates_zCSpiRUyiDb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_z9wBQjRDfAXk"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Making
estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of
a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered
in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results
could differ significantly from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000688">&lt;p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zxisgP8Xl37k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zAhdNNso56Nb"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash
equivalents are carried at cost, which approximates fair value. The Company had $&lt;span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20251231_zmXdChwNJcJ4" title="Cash"&gt;420,340&lt;/span&gt; in cash as of December&#160;31, 2025 The Company
had &lt;span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20251231_zyjNNzvKrPke" title="Cash equivalents"&gt;no&lt;/span&gt; cash equivalents as of December&#160;31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000690"
      unitRef="USD">420340</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000692"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <cik0002065779:CashHeldInTrustAccountPolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000694">&lt;p id="xdx_843_ecustom--CashHeldInTrustAccountPolicyTextBlock_z4HvK1JPIUmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zTYNKhDkXdT7"&gt;Cash
Held in Trust Account&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had $&lt;span id="xdx_90E_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20251231_z8h7Eqz2G7o8" title="Cash held in trust"&gt;284,776,628&lt;/span&gt; of cash in the trust account held in an interest bearing demand deposit account as of December&#160;31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</cik0002065779:CashHeldInTrustAccountPolicyTextBlock>
    <cik0002065779:CashHeldInTrustAccount
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000696"
      unitRef="USD">284776628</cik0002065779:CashHeldInTrustAccount>
    <cik0002065779:OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000698">&lt;p id="xdx_843_ecustom--OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock_zjYwZgXnflQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zHG5bezvliwj"&gt;Offering
Costs Associated with the Initial Public Offering&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014; &#x201c;Expenses
of Offering.&#x201d; Deferred offering costs consist principally of professional and registration fees that are related to the Initial
Public Offering. Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 470-20, &#x201c;Debt with Conversion and Other Options,&#x201d;
addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this
guidance to allocate Initial Public Offering proceeds from the Public Units between Class A ordinary shares and warrants based on their
relative fair values. Offering costs allocated to the Class A ordinary shares subject to possible redemption were charged to temporary
equity, and offering costs allocated to the warrants included in the Public Units and Private Units were charged to shareholder&#x2019;s
equity as the warrants, after management&#x2019;s evaluation, were accounted for under equity treatment. As of August&#160;1, 2025, the
Company had offering costs of $&lt;span id="xdx_90C_ecustom--OfferingCost_iI_pp0p0_c20250801_zTEBye9LC6Sa" title="Offering costs"&gt;3,582,634&lt;/span&gt;, consisting of $&lt;span id="xdx_901_ecustom--RepresentativeShares_c20250729__20250801_zO3HwvtfCCL3" title="Representative shares"&gt;2,419,400&lt;/span&gt; of the Representative Shares (as discussed in Note 1) and $&lt;span id="xdx_903_ecustom--OtherOfferingCost_pp0p0_c20250729__20250801_zGB9Qx0HWUBg" title="Other offering costs"&gt;1,163,234&lt;/span&gt;
of other offering costs. Approximately $&lt;span id="xdx_90C_eus-gaap--OtherExpenses_pp0p0_c20250729__20250801_z3GNIDiBSqvd" title="other costs"&gt;143,775&lt;/span&gt; of such costs were allocated to the Public Warrants and the Private Placement Units and
the remainder, approximately $&lt;span id="xdx_90D_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_c20250801_zBavxm1BynCj" title="Ordinary shares subject to redemption"&gt;3,438,859&lt;/span&gt; was allocated to Class A ordinary shares subject to redemption. As of December&#160;31, 2025,
the Company had offering costs of $&lt;span id="xdx_900_ecustom--OfferingCost_iI_pp0p0_c20251231_ziNhZdkvYfdf" title="Offering costs"&gt;3,582,634&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















</cik0002065779:OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock>
    <cik0002065779:OfferingCost
      contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000700"
      unitRef="USD">3582634</cik0002065779:OfferingCost>
    <cik0002065779:RepresentativeShares
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000702"
      unitRef="USD">2419400</cik0002065779:RepresentativeShares>
    <cik0002065779:OtherOfferingCost
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000704"
      unitRef="USD">1163234</cik0002065779:OtherOfferingCost>
    <us-gaap:OtherExpenses
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000706"
      unitRef="USD">143775</us-gaap:OtherExpenses>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000708"
      unitRef="USD">3438859</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <cik0002065779:OfferingCost
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000710"
      unitRef="USD">3582634</cik0002065779:OfferingCost>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000719">&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z5OSpTZZj5k8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zcqL0aCgOVV7"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with the accounting and reporting requirements of ASC Topic 740, &#x201c;Income Taxes,&#x201d; which requires an asset
and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed
for differences between the consolidated financial statement and tax bases of assets and liabilities that will result in future taxable
or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable
income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
Topic 740 prescribes a recognition threshold and a measurement attribute for the consolidated financial statement recognition and measurement
of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not
to be sustained upon examination by taxing authorities. The Company&#x2019;s management determined the British Virgin Islands is the Company&#x2019;s
only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income
tax expense. There were no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The
Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from
its position. The Company is considered to be an exempted British Virgin Islands company with no connection to any other taxable jurisdiction
and is presently not subject to income taxes or income tax filing requirements in the British Virgin Islands or the United States. As
such, the provision for income taxes was deemed to be &lt;i&gt;de minimis&lt;/i&gt; for the period from March&#160;20, 2025 (inception) to December&#160;31,
2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DerivativesReportingOfDerivativeActivity
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000721">&lt;p id="xdx_849_eus-gaap--DerivativesReportingOfDerivativeActivity_zfMMEAmeHDb5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zun6kxhx1xka"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#x201c;Derivatives and Hedging.&#x201d; For derivative financial instruments that are accounted
for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each
reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative
liabilities are classified in the balance sheet as current or non-current based on whether or not net cash settlement or conversion of
the instrument could be required within 12 months of the balance sheet date. The underwriters&#x2019; over-allotment option is deemed to
be a freestanding financial instrument indexed to the contingently redeemable shares and was accounted for as a liability pursuant to
ASC 480 if not fully exercised at the time of the Initial Public Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesReportingOfDerivativeActivity>
    <us-gaap:ExtendedProductWarrantyPolicy
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000723">&lt;p id="xdx_845_eus-gaap--ExtendedProductWarrantyPolicy_z0FLSxdwRnzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zDBCwQoAzPGl"&gt;Warrant
Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for Warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#x2019;
specific terms and applicable authoritative guidance in ASC 480 and FASB ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC
815&#x201d;). The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815,
including whether the instruments are indexed to a company&#x2019;s common shares and whether the instrument holders could potentially
require &#x201c;net cash settlement&#x201d; in a circumstance outside of a company&#x2019;s control, among other conditions for equity classification.
This assessment, which requires the use of professional judgment, is conducted at the time of Warrant issuance and as of each subsequent
quarterly period end date while the instruments are outstanding. Upon review of the Warrant Agreement, Management concluded that the&#160;public
warrants and private warrants issued pursuant to such warrant agreement qualify for equity accounting treatment.&#160;Following the closing
of the Initial Public Offering on August&#160;1, 2025 and underwriter&#x2019;s exercise of over-allotment option on August&#160;13, 2025,
the Company accounted for the&#160;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20251231_zdWSGahahNSi" title="Warrants issued"&gt;14,000,000&lt;/span&gt; public warrants and&#160;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zi4ctrzVvrZc" title="Warrants issued"&gt;100,000&lt;/span&gt; private warrants issued under equity treatment at their
assigned values. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















</us-gaap:ExtendedProductWarrantyPolicy>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000725"
      unitRef="Shares">14000000</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2025-12-31_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000727"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightUnissued>
    <cik0002065779:ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000736">&lt;p id="xdx_846_ecustom--ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_z39K6VkBlVx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zMsjsksIRMVh"&gt;Class
A Ordinary Shares Subject to Possible Redemption&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
public shares contain a redemption feature which allows for the redemption of such public shares in connection with the Company&#x2019;s
liquidation, or if there is a shareholder vote or tender offer in connection with the Company&#x2019;s initial Business Combination. In
accordance with ASC 480-10-S99, the Company classifies public shares subject to redemption outside of permanent equity as the redemption
provisions are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as they occur
and will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately
upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value.
The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the extent available)
and Retained earnings. Accordingly, Class A ordinary shares subject to possible redemption are presented at redemption value as temporary
equity, outside of the shareholders&#x2019; equity section of the Company&#x2019;s balance sheet. As of December&#160;31, 2025, the 28,000,000
Class A ordinary shares subject to redemption reflected in the balance sheet are reconciled in the following table:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--TemporaryEquityTableTextBlock_zPcXeTqfm8lb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8BD_zLSvphjsOLC3" style="display: none"&gt;Schedule of ordinary shares subject to redemption&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Gross proceeds from IPO, August&#160;1,
        2025&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_pp0d_c20250802__20251231_z2o34efAYZBg" title="Ordinary shares subject to possible redemption, beginning"&gt;280,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Less:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Proceeds allocated to Public Warrants&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ProceedsAllocatedToPublicWarrants_pp0d_c20250802__20251231_znh5ksE756X8" title="Proceeds allocated to Public Warrants"&gt;(9,028,600&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Proceeds allocated to Over-allotment Option&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ProceedsAllocatedToOverallotmentOption_pp0d_c20250802__20251231_zF18AYVY4Fwe" title="Proceeds allocated to Over-allotment Option"&gt;(1,290,375&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Class A ordinary shares issuance costs&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ClassOrdinarySharesIssuanceCosts_pp0d_c20250802__20251231_zFN36aIn6kRf" title="Class A ordinary shares issuance costs"&gt;(3,438,859&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Plus:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Accretion of carrying
        value to redemption value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--TemporaryEquityAccretionToRedemptionValue_pp0d_c20250802__20251231_z1giMb4Fdhpj" title="Ordinary shares subject to possible redemption"&gt;18,534,462&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Class A ordinary shares
        subject to possible redemption, December&#160;31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_pp0d_c20250802__20251231_z92pFQBkwJ85" title="Ordinary shares subject to possible redemption, ending"&gt;284,776,628&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zCe7sjt49b28" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</cik0002065779:ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000738">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--TemporaryEquityTableTextBlock_zPcXeTqfm8lb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8BD_zLSvphjsOLC3" style="display: none"&gt;Schedule of ordinary shares subject to redemption&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Gross proceeds from IPO, August&#160;1,
        2025&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_pp0d_c20250802__20251231_z2o34efAYZBg" title="Ordinary shares subject to possible redemption, beginning"&gt;280,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Less:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Proceeds allocated to Public Warrants&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ProceedsAllocatedToPublicWarrants_pp0d_c20250802__20251231_znh5ksE756X8" title="Proceeds allocated to Public Warrants"&gt;(9,028,600&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Proceeds allocated to Over-allotment Option&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ProceedsAllocatedToOverallotmentOption_pp0d_c20250802__20251231_zF18AYVY4Fwe" title="Proceeds allocated to Over-allotment Option"&gt;(1,290,375&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Class A ordinary shares issuance costs&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ClassOrdinarySharesIssuanceCosts_pp0d_c20250802__20251231_zFN36aIn6kRf" title="Class A ordinary shares issuance costs"&gt;(3,438,859&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Plus:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Accretion of carrying
        value to redemption value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--TemporaryEquityAccretionToRedemptionValue_pp0d_c20250802__20251231_z1giMb4Fdhpj" title="Ordinary shares subject to possible redemption"&gt;18,534,462&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Class A ordinary shares
        subject to possible redemption, December&#160;31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_pp0d_c20250802__20251231_z92pFQBkwJ85" title="Ordinary shares subject to possible redemption, ending"&gt;284,776,628&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital
      contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000740"
      unitRef="USD">280000000</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <cik0002065779:ProceedsAllocatedToPublicWarrants
      contextRef="From2025-08-022025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000742"
      unitRef="USD">-9028600</cik0002065779:ProceedsAllocatedToPublicWarrants>
    <cik0002065779:ProceedsAllocatedToOverallotmentOption
      contextRef="From2025-08-022025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000744"
      unitRef="USD">-1290375</cik0002065779:ProceedsAllocatedToOverallotmentOption>
    <cik0002065779:ClassOrdinarySharesIssuanceCosts
      contextRef="From2025-08-022025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000746"
      unitRef="USD">-3438859</cik0002065779:ClassOrdinarySharesIssuanceCosts>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="From2025-08-022025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000748"
      unitRef="USD">18534462</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000750"
      unitRef="USD">284776628</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000752">&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zhFehGf6YTR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zQunJD1xUwzi"&gt;Net
Income per Ordinary Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company complies with accounting and disclosure
requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share.&#x201d; Net income per share of ordinary shares is computed by dividing
net income applicable to ordinary shareholders by the weighted average number of shares of ordinary shares outstanding during the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not considered the effect of the Warrants sold in the Offering and Private Placement to purchase an aggregate of&#160;&lt;span id="xdx_903_eus-gaap--WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_c20250320__20251231_zIYauijVJJe6" title="Weighted average aggregate shares"&gt;14,100,000&lt;/span&gt;&#160;Class
A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock
method and are contingent on future events. As a result, diluted income per share of Class A ordinary shares is the same as basic income
per share of ordinary shares for the period presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has two classes of ordinary shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income are shared
pro rata among the two classes of ordinary shares. Net income per share of ordinary shares is calculated by dividing the net income by
the weighted average number of shares of ordinary shares outstanding during the respective period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables reflect the net income per share after allocating income between the shares based on outstanding shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zK6g7uklULf4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;&lt;i&gt;&lt;span id="xdx_8BF_zaGSXzmsgspk" style="display: none"&gt;Schedule
    of earning per share basic and diluted&lt;/span&gt;&lt;/i&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;Period from &lt;br/&gt;March&#160;20,
        2025&lt;br/&gt;(Inception) through &lt;br/&gt;December&#160;31, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Class A&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Class B&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;Numerator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Basic and diluted net income
        per share:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold; text-align: left"&gt;Allocation
        of income &#x2013; basic and diluted&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z3sCrZfmImf8" title="Allocation of income - basic"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zOP8f6mC3Gdc" title="Allocation of income - diluted"&gt;2,509,890&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z2qJnxTMSxqk"&gt;&lt;span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_ziM4aHJWJMT8" title="Allocation of income - diluted"&gt;1,946,080&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Basic and diluted weighted
        average share of ordinary shares:&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zLS14Lz9LzJi" title="Basic weighted average share of ordinary shares"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z7DNrJH4OfBj" title="Diluted weighted average share of ordinary shares"&gt;15,393,007&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zZ1AoE0JuY4c" title="Basic weighted average share of ordinary shares"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z5EwpZeeFiAi" title="Diluted weighted average share of ordinary shares"&gt;11,935,190&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Basic and diluted net income
        per share&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zWEL5OqBJofa" title="Basic net income per share"&gt;&lt;span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zT2ajwWAS9G6" title="Diluted net income per share"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zjBGNV05rIv" title="Basic net income per share"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zAOQ6qINRSph" title="Diluted net income per share"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zQW6yz6aHTG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000754"
      unitRef="Shares">14100000</us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000763">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zK6g7uklULf4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;&lt;i&gt;&lt;span id="xdx_8BF_zaGSXzmsgspk" style="display: none"&gt;Schedule
    of earning per share basic and diluted&lt;/span&gt;&lt;/i&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;Period from &lt;br/&gt;March&#160;20,
        2025&lt;br/&gt;(Inception) through &lt;br/&gt;December&#160;31, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Class A&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Class B&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;Numerator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Basic and diluted net income
        per share:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold; text-align: left"&gt;Allocation
        of income &#x2013; basic and diluted&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z3sCrZfmImf8" title="Allocation of income - basic"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zOP8f6mC3Gdc" title="Allocation of income - diluted"&gt;2,509,890&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z2qJnxTMSxqk"&gt;&lt;span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_ziM4aHJWJMT8" title="Allocation of income - diluted"&gt;1,946,080&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Basic and diluted weighted
        average share of ordinary shares:&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zLS14Lz9LzJi" title="Basic weighted average share of ordinary shares"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z7DNrJH4OfBj" title="Diluted weighted average share of ordinary shares"&gt;15,393,007&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zZ1AoE0JuY4c" title="Basic weighted average share of ordinary shares"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z5EwpZeeFiAi" title="Diluted weighted average share of ordinary shares"&gt;11,935,190&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Basic and diluted net income
        per share&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zWEL5OqBJofa" title="Basic net income per share"&gt;&lt;span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zT2ajwWAS9G6" title="Diluted net income per share"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zjBGNV05rIv" title="Basic net income per share"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zAOQ6qINRSph" title="Diluted net income per share"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="0"
      id="Fact000765"
      unitRef="USD">2509890</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="0"
      id="Fact000767"
      unitRef="USD">2509890</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="0"
      id="Fact000768"
      unitRef="USD">1946080</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="0"
      id="Fact000770"
      unitRef="USD">1946080</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact000772"
      unitRef="Shares">15393007</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact000774"
      unitRef="Shares">15393007</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="INF"
      id="Fact000776"
      unitRef="Shares">11935190</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="INF"
      id="Fact000778"
      unitRef="Shares">11935190</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact000780"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact000782"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="INF"
      id="Fact000784"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassBMember"
      decimals="INF"
      id="Fact000786"
      unitRef="USDPShares">0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000788">&lt;p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zIcrYsjdOnUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zU8Q18WJlnoi"&gt;Concentration
of credit risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution
which, at times may exceed the Federal depository insurance coverage of $&lt;span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_c20251231_zTBZxivW96d5" title="FDIC Insured Amount"&gt;250,000&lt;/span&gt;. At December&#160;31, 2025, the Company had not experienced
losses on this account and management believes the Company is not exposed to significant risks on such account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000790"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000792">&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zD59y9ZVJcWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zbcnfxYlFdrl"&gt;Fair
value of financial instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value
Measurements and Disclosures,&#x201d; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to
their short-term nature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <cik0002065779:RisksAndUncertaintiesPolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000794">&lt;p id="xdx_842_ecustom--RisksAndUncertaintiesPolicyTextBlock_zxL0KasiCzxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zjcWV21IYFn1"&gt;Risks
and Uncertainties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the
ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict,
the North Atlantic Treaty Organization (&#x201c;NATO&#x201d;) deployed additional military forces to eastern Europe, and the United States,
the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus
and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank
Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide
military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of
Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken
in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries
have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact
of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity
prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally,
any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity
in capital markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any
of the above-mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting
from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely
affect the Company&#x2019;s search for an initial Business Combination and any target business with which the Company may ultimately consummate
an initial Business Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</cik0002065779:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000803">&lt;p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8qxlOQm7eDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zJUe6H2lTeAa"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which
requires the disclosure of additional segment information. ASU No. 2023-07 is effective for fiscal years beginning after December&#160;15,
2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted ASU 2023-07 as of the inception
of the Company. Adoption of the ASU did not impact the Company&#x2019;s financial position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December&#160;2023, the FASB issued ASU 2023-09, &lt;i&gt;Income taxes&lt;/i&gt; (Topic 740): Improvements to Income Tax Disclosure (&#x201c;ASU 2023-09&#x201d;),
which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 will be effective for fiscal years beginning after
December&#160;15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for
issuance. The Company adopted ASU 2023-09 as of the inception of the Company. Adoption of the ASU did not impact the Company&#x2019;s financial
position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cik0002065779:InitialPublicOfferingDisclosureTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000805">&lt;p id="xdx_80D_ecustom--InitialPublicOfferingDisclosureTextBlock_zSLJnITYDvT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3. &lt;span id="xdx_82B_z1KbCnrudoXf"&gt;INITIAL PUBLIC OFFERING&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August&#160;1, 2025, the Company consummated its Initial Public Offering of &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z68SWSkXouvl" title="Sale of units in initial public offering"&gt;25,000,000&lt;/span&gt; Units, at $&lt;span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zuYTl7DjGW56" title="Sale of units per share"&gt;10.00&lt;/span&gt; per Unit, generating gross proceeds
of $&lt;span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNsLNzuqxtP2" title="Sale of units in initial public offering aggragate amount"&gt;250,000,000&lt;/span&gt;. The Company granted the underwriter a 45-day option to purchase up to an additional &lt;span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zLyPTOsY05De" title="Sale of units in initial public offering"&gt;3,750,000&lt;/span&gt; Units at the Initial Public
Offering price to cover over-allotments, if any. On August&#160;11, 2025, the underwriters of the IPO notified the Company of their partial
exercise of the over-allotment option and purchased &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z2DvOPHYNdv4" title="Sale of units in initial public offering"&gt;3,000,000&lt;/span&gt; additional units (the &#x201c;Option Units&#x201d;) at $&lt;span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z5FkLaLYZBbb" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit upon
the closing of the over-allotment option, generating gross proceeds of $&lt;span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zF2cRkgObqV" title="Sale of units in initial public offering aggragate amount"&gt;30,000,000&lt;/span&gt;. On September&#160;9, 2025, the Underwriters advised
the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option. Each Unit consists
of one Ordinary Share and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary
share at a price of $&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z5vX2ACUCNo7" title="Share price"&gt;11.50&lt;/span&gt; per share, subject to adjustment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</cik0002065779:InitialPublicOfferingDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000807"
      unitRef="Shares">25000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000809"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000811"
      unitRef="USD">250000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000813"
      unitRef="Shares">3750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000815"
      unitRef="Shares">3000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000817"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000819"
      unitRef="USD">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SharePrice
      contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000821"
      unitRef="USDPShares">11.50</us-gaap:SharePrice>
    <cik0002065779:PrivatePlacementDisclosureTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000823">&lt;p id="xdx_801_ecustom--PrivatePlacementDisclosureTextBlock_zpb49dy82Zdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4. &lt;span id="xdx_82F_zsyzzDUiuM6e"&gt;PRIVATE PLACEMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Simultaneously
with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zock4izgOfti" title="Sale of units in initial public offering"&gt;200,000&lt;/span&gt; Private Units at a price of $&lt;span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zwMvmX5ifFuc" title="Sale of units per share"&gt;10.00&lt;/span&gt; per
Placement Unit raising $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIzdEwofmxtc" title="Sale of units in initial public offering aggragate amount"&gt;2,000,000&lt;/span&gt; in the aggregate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
proceeds from the sale of the Private Units were added to the net proceeds from the Offering held in the Trust Account. The Placement
Units are identical to the Units sold in the Initial Public Offering, as described in Note 7. If the Company does not complete a Business
Combination within the Combination Period, the proceeds from the sale of the Private Units will be used to fund the redemption of the
Public Shares (subject to the requirements of applicable law) and the Private Warrants will expire worthless.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;













</cik0002065779:PrivatePlacementDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000825"
      unitRef="Shares">200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000827"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000829"
      unitRef="USD">2000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000836">&lt;p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrYpFvvjFz9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5. &lt;span id="xdx_825_zCNNFCMF78fe"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Founder
Shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March&#160;25, 2025, the Company issued an aggregate of &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250301__20250325__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zKIH67EkvYIj" title="Shares issued"&gt;12,321,429&lt;/span&gt; founder shares to the Sponsor for an aggregate purchase price of $&lt;span id="xdx_90F_eus-gaap--Cash_iI_c20250325__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zGVXdJ6E6tx1" title="Cash"&gt;25,000&lt;/span&gt;
in cash. The funds were received on May&#160;27, 2025. Following the partial exercise of the over-allotment option on August&#160;11,
2025, on September&#160;9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment
option and thereby forfeit the option. As a result, on September&#160;9, 2025, the Company cancelled a total of &lt;span id="xdx_905_ecustom--CancelledFounderShares_c20250905__20250909_zl4zcqqhZ3uf" title="Cancelled founder shares"&gt;321,429&lt;/span&gt; founder shares.
As of December&#160;31, 2025, sponsor held a total of &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20250320__20251231__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zrz4M0un8z1i" title="Forfeiture shares"&gt;12,000,000&lt;/span&gt; founder shares and none was subject to forfeiture.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
founder shares are designated as Class B ordinary shares and, except as described below, are identical to the Class A ordinary shares
included in the units being sold in the IPO, and holders of founder shares have the same shareholder rights as public shareholders, except
that (i) the founder shares are subject to certain transfer restrictions, as described in more detail below, (ii) the founder shares are
entitled to registration rights; (iii) our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which
they have agreed to (A) waive their redemption rights with respect to their founder shares, private shares and public shares in connection
with the completion of our initial business combination, (B) waive their redemption rights with respect to their founder shares, private
shares and public shares in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and articles
of association (a) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination
or to redeem &lt;span id="xdx_908_ecustom--PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination_dp_c20250320__20251231_zW3TNlBemkUl" title="Percentage of redemption of public shares"&gt;100%&lt;/span&gt; of our public shares if we have not consummated an initial business combination within the completion window or (b)
with respect to any other material provisions relating to shareholders&#x2019; rights or pre-initial business combination activity, (C)
waive their rights to liquidating distributions from the trust account with respect to their founder shares and private shares if we fail
to complete our initial business combination within the completion window, although they will be entitled to liquidating distributions
from the trust account with respect to any public shares they hold if we fail to complete our initial business combination within such
time period and to liquidating distributions from assets outside the trust account and (D) vote any founder shares held by them and any
public shares they may purchase (including in open market and privately-negotiated transactions) in favor of our initial business combination
(except that any public shares such parties may purchase in compliance with the requirements of Rule&#160;14e-5 under the Exchange Act
would not be voted in favor of approving the business combination transaction), (iv) the founder shares are automatically convertible
into Class A ordinary shares concurrently with or immediately following the consummation of our initial business combination or earlier
at the option of the holder on a one-for-one basis, subject to adjustment as described herein and in our amended and restated memorandum
and articles of association, and (v) prior to the closing of our initial business combination, only holders of our Class B ordinary shares
will be entitled to vote on the appointment and removal of directors or continuing the company in a jurisdiction outside the British Virgin
Islands (including any ordinary resolution required to amend our constitutional documents or to adopt new constitutional documents, in
each case, as a result of our approving a transfer by way of continuation in a jurisdiction outside the British Virgin Islands).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
certain limited exceptions, the founder shares are not transferable, assignable or saleable (except to our officers and directors and
other persons or entities affiliated with our sponsor, each of whom will be subject to the same transfer restrictions) until the completion
of our initial business combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Promissory
Note &#x2013; Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March&#160;20, 2025, the Sponsor issued an unsecured promissory note to the Company, pursuant to which the Company may borrow up to an
aggregate principal amount of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20251231__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredPromissoryNoteMember_zilx2XNUQ3Jd" title="Principal amount"&gt;350,000&lt;/span&gt;, to be used for payment of costs related to the Proposed Offering. The note is non-interest bearing
and payable on the earlier of (i) December&#160;31, 2025 or (ii) the consummation of the Initial Public Offering. On August&#160;1, 2025,
the Company has repaid $&lt;span id="xdx_901_eus-gaap--RepaymentOfNotesReceivableFromRelatedParties_c20250729__20250801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zNBRf0ZD3Bcg" title="Repayment of promissory note"&gt;225,461&lt;/span&gt; under the promissory note with the Sponsor out of the $&lt;span id="xdx_90B_eus-gaap--PaymentsForRepurchaseOfInitialPublicOffering_c20250729__20250801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zcDb7GEDXP32" title="Payment of offering expenses"&gt;700,000&lt;/span&gt; of offering proceeds that has been allocated
for the payment of offering expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Administrative
Services Arrangement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
affiliate of our Sponsor has agreed, commencing from the date that the Company&#x2019;s securities are first listed on Nasdaq, through
the earlier of the Company&#x2019;s consummation of a Business Combination and its liquidation, to make available to the Company our Sponsor
certain office space, utilities and secretarial and administrative support as may be reasonably required by the Company. The Company has
agreed to pay to the affiliate of our Sponsor, $&lt;span id="xdx_900_eus-gaap--PaymentsOfDistributionsToAffiliates_c20250320__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zlnaPZbdyeKh" title="Payment to affiliate"&gt;20,000&lt;/span&gt; per month, for up to 18 months, subject to extension to up to 21 months, for such
administrative services. For the period from March&#160;20, 2025 (inception) to December&#160;31, 2025, $&lt;span id="xdx_909_eus-gaap--AdministrativeFeesExpense_c20250320__20251231_zx13woO4Tfnc" title="Administrative services"&gt;100,000&lt;/span&gt; was charged to operations
and no amounts were outstanding at December&#160;31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Related
Party Loans&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
order to finance transaction costs in connection with a Business Combination, the Company&#x2019;s Sponsor or an affiliate of the Sponsor,
or the Company&#x2019;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#x201c;Working
Capital Loans&#x201d;). Up to $&lt;span id="xdx_90D_eus-gaap--DebtConversionOriginalDebtAmount1_c20250320__20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zoSGVPE4L9ll" title="Conversion of debt"&gt;2,500,000&lt;/span&gt; of such loans may be convertible into private units, at a price of $&lt;span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_c20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zoryQ0v2dVwg" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit, at the option
of the applicable lender. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside
the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital
Loans. As of December&#160;31, 2025, no amounts under such loans have been drawn.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Representative
Shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August&#160;1, 2025, the Company issued &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zEnpb1MH6gf7" title="Number of share issued"&gt;1,000,000&lt;/span&gt; representative shares to D. Boral Capital, LLC and/or its designees (whether or not
the over-allotment is exercised) as part of representative compensation (the &#x201c;Representative Shares&#x201d;). The Representative
Shares have been deemed compensation by FINRA and are therefore subject to a lock-up for a period of 180 days immediately following the
commencement of sales of the IPO pursuant to FINRA Rule&#160;5110(e)(1). Pursuant to this FINRA lock-up, these securities cannot be sold,
transferred, assigned, pledged or hypothecated or the subject of any hedging, short sale, derivative, put or call transaction that would
result in the economic disposition of the securities by any person for a period of 180 days from the commencement of sales of the Initial
Public Offering except as permitted under FINRA Rule&#160;5110(e)(2), including to any underwriter and selected dealer participating in
the Initial Public Offering and their officers or partners, registered persons or affiliates. The Representative Shares have resale registration
rights including two demand (one at the Company&#x2019;s expense and one at D. Boral Capital, LLC&#x2019;s expense) and unlimited &#x201c;piggy-back&#x201d;
rights for periods of five and seven years, respectively, from the commencement of sales of the Initial Public Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-012025-03-25_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000838"
      unitRef="Shares">12321429</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:Cash
      contextRef="AsOf2025-03-25_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000840"
      unitRef="USD">25000</us-gaap:Cash>
    <cik0002065779:CancelledFounderShares
      contextRef="From2025-09-052025-09-09_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000842"
      unitRef="Shares">321429</cik0002065779:CancelledFounderShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2025-03-202025-12-31_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000844"
      unitRef="Shares">12000000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <cik0002065779:PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000846"
      unitRef="Ratio">1</cik0002065779:PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-12-31_custom_UnsecuredPromissoryNoteMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000848"
      unitRef="USD">350000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentOfNotesReceivableFromRelatedParties
      contextRef="From2025-07-292025-08-01_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000850"
      unitRef="USD">225461</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="From2025-07-292025-08-01_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000852"
      unitRef="USD">700000</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <us-gaap:PaymentsOfDistributionsToAffiliates
      contextRef="From2025-03-202025-12-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000861"
      unitRef="USD">20000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:AdministrativeFeesExpense
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000863"
      unitRef="USD">100000</us-gaap:AdministrativeFeesExpense>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2025-03-202025-12-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000865"
      unitRef="USD">2500000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-12-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000867"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000869"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000871">&lt;p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zOodEbadoGl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6. &lt;span id="xdx_827_zvnDuwuTDke4"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Registration
Rights&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of the (i) founder shares, which were issued in a private placement prior to the closing of the initial public offering, (ii)
Private Units (including the component securities as well as any securities underlying those component securities), which was issued in
a private placement simultaneously with the closing of the initial public offering and (iii) private units (including the component securities
as well as any securities underlying those component securities) that may be issued upon conversion of working capital loans will have
registration rights to require the Company to register a sale of any of our securities held by them and any other securities of the company
acquired by them prior to the consummation of a Business Combination pursuant to a registration rights agreement to be signed prior to
or on the effective date of the initial public offering. The holders of these securities are entitled to make up to three demands, excluding
short form demands, that the Company register such securities. In addition, the holders have certain &#x201c;piggy-back&#x201d; registration
rights with respect to registration statements filed subsequent to the completion of the Business Combination. The registration rights
granted to the underwriter are limited to two demand (one at the Company&#x2019;s expense and one at D. Boral Capital, LLC&#x2019;s expense)
and unlimited &#x201c;piggy-back&#x201d; rights for periods of five and seven years, respectively, from the commencement of sales of the
Initial Public Offering. The Company will bear the expenses incurred in connection with the filing of any such registration statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Underwriting
Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has granted the underwriters a 45-day option to purchase up to &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250320__20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zFjNTzXClord" title="Option granted"&gt;3,750,000&lt;/span&gt; additional Units to cover over-allotments at the Initial
Public Offering price, less the underwriting discounts and commissions. On August&#160;11, 2025, the underwriters of the IPO notified
the Company of their partial exercise of the over-allotment option and purchased &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zsDsQ7BIzSY4" title="Sale of units in initial public offering"&gt;3,000,000&lt;/span&gt; additional units (the &#x201c;Option Units&#x201d;)
at $&lt;span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z00hlruxNby8" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit upon the closing of the over-allotment option, generating gross proceeds of $&lt;span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zTKQ26a264L8" title="Sale of units in initial public offering aggragate amount"&gt;30,000,000&lt;/span&gt;. On September&#160;9, 2025,
the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
underwriters were not entitled to any cash underwriting fee at closing of the Initial Public Offering. The underwriters were entitled
to &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250320__20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_z7WKxjLfpBE3" title="Number of share issued"&gt;1,000,000&lt;/span&gt; Representative Shares (whether or not the over-allotment is exercised) at closing of the Initial Public Offering. The underwriters
will not be entitled to any deferred underwriting fee upon closing of the Business Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-03-202025-12-31_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000880"
      unitRef="Shares">3750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000882"
      unitRef="Shares">3000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000884"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000886"
      unitRef="USD">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-202025-12-31_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000888"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000890">&lt;p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zLymJvSLjwni" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7. &lt;span id="xdx_829_zo6eGMSSg8H3"&gt;STOCKHOLDER&#x2019;S EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Preference
shares&lt;/i&gt; &#x2014; The Company is authorized to issue &lt;span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_c20251231_zVKs3Ud7A2J1" title="Preferred stock, shares authorized"&gt;5,000,000&lt;/span&gt; preference shares with a par value of $&lt;span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_c20251231_zGdq3Sz7TMP2" title="Preferred stock, par value"&gt;0.0001&lt;/span&gt; per share. Holders of the
Company&#x2019;s ordinary shares are entitled to one vote for each share. On December&#160;31, 2025, there were &lt;span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_do_c20251231_zes6MDUpNOee" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20251231_zggQcNldTD8j" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt; preferred shares issued
or outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Class
A Ordinary shares&lt;/i&gt; &#x2014; The Company is authorized to issue &lt;span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zUIiqFEC1YKa" title="Common stock, shares authorized"&gt;500,000,000&lt;/span&gt; ordinary shares with a par value of $&lt;span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zpG2arjDcUM5" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share. Holders
of the Company&#x2019;s ordinary shares are entitled to one vote for each share. As a result of closing of the IPO and the partial exercise
of the over-allotment option partial exercise of the over-allotment option, there were &lt;span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zX4U9Oph6c9b" title="Common stock, shares outstanding"&gt;1,200,000&lt;/span&gt; Class A ordinary shares issued or outstanding,
excluding &lt;span id="xdx_90D_ecustom--OrdinarySharesSubjectToPossibleRedemption_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zM1hbLvnyh4d" title="Ordinary shares subject to possible redemption"&gt;28,000,000&lt;/span&gt; Class A ordinary shares subject to possible redemption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Class
B Ordinary shares&lt;/i&gt; &#x2014; The Company is authorized to issue &lt;span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zaDu9F4i7evd"&gt;50,000,000&lt;/span&gt; ordinary shares with a par value of $&lt;span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zaOL9jf9dkb3"&gt;0.0001&lt;/span&gt; per share. Holders
of the Company&#x2019;s ordinary shares are entitled to one vote for each share. On March&#160;25, 2025, the Company issued an aggregate
of &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250301__20250325__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zfTMSHKHds0l"&gt;12,321,429&lt;/span&gt; ordinary shares to the Sponsor for an aggregate purchase price of $&lt;span id="xdx_90D_ecustom--AggregatePurchasePrice_iI_pp0p0_c20250325_ztIeXeeDmxNc" title="Aggregate purchase price"&gt;25,000&lt;/span&gt; in cash, of which &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20250301__20250325__us-gaap--StatementEquityComponentsAxis__custom--ClassAOrdinarySharesMember_zxJWaCgaTD7h"&gt;1,607,143&lt;/span&gt; shares held by the
Sponsor are subject to forfeiture to the extent that the underwriter&#x2019;s over-allotment option is not exercised in full. Following
the partial exercise of the over-allotment option on August&#160;11, 2025 and cancellation &lt;span id="xdx_901_ecustom--CancellationOfOrdinaryShares_iI_c20250811_zQ94bGRQlFb7" title="Cancellation of ordinary shares"&gt;321,429&lt;/span&gt; ordinary shares on September&#160;9,
2025, on December&#160;31, 2025, there were &lt;span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zigcy70u45ba" title="Common stock, shares issued"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zX4NnnaGuwf" title="Common stock, shares outstanding"&gt;12,000,000&lt;/span&gt;&lt;/span&gt; ordinary shares issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation
of our initial business combination, or at any time prior thereto at the option of the holder thereof, on a one-for-one basis, subject
to adjustment as provided herein. Because our sponsor acquired the Class B ordinary shares at a nominal price, our public shareholders
will incur an immediate and substantial dilution upon the closing of the IPO, assuming no value is ascribed to the warrants included in
the units. In the case that additional Class A ordinary shares, or equity-linked securities (as described herein), are issued or deemed
issued in excess of the amounts issued in the IPO and related to the closing of our initial business combination, the ratio at which the
Class B ordinary shares will convert into Class A ordinary shares will be adjusted (unless the holders of a majority of the issued and
outstanding Class B ordinary shares agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance)
so that the number of Class A ordinary shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, 30%
of the sum of (i) the total number of all Class A ordinary shares outstanding upon the completion of the IPO (including any Class A ordinary
shares issued pursuant to the underwriters&#x2019; over-allotment option and excluding the Class A ordinary shares that are included within
the private units), plus (ii) all Class A ordinary shares and equity-linked securities issued or deemed issued, in connection with the
closing of the initial business combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in
the initial business combination and any units issued to our sponsor or any of its affiliates or to our officers or directors upon conversion
of working capital loans) minus (iii) any redemptions of Class A ordinary shares by public shareholders in connection with an initial
business combination; provided that such conversion of founder shares will never occur on a less than &lt;span id="xdx_904_eus-gaap--CommonStockConversionBasis_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--CommonStockClassBMember_zwHvTm6YpHfl" title="Conversion basis"&gt;one-for-one basis&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Holders
of record of the Company&#x2019;s Class A ordinary shares and Class B ordinary shares are entitled to one vote for each share held on all
matters to be voted on by shareholders. Unless specified in the amended and restated memorandum and articles of association or as required
by the Companies Act or stock exchange rules, an ordinary resolution under British Virgin Islands law and the amended and restated memorandum
and articles of association, which requires the affirmative vote of at least a majority of the votes cast by such shareholders as, being
entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the company is generally
required to approve any matter voted on by the Company&#x2019;s shareholders. Approval of certain actions require an ordinary resolution
under British Virgin Islands law, which (except as specified below) requires the affirmative vote of in excess of 50 percent of the votes
cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general
meeting, and pursuant to the Company&#x2019;s amended and restated memorandum and articles of association, such actions include amending
the amended and restated memorandum and articles of association and approving a statutory merger or consolidation with another company.
There is no cumulative voting with respect to the appointment of directors, meaning, following the Company&#x2019;s initial Business Combination,
the holders of more than 50% of the ordinary shares voted for the appointment of directors can elect all of the directors. Prior to the
consummation of the initial Business Combination, only holders of the Class B ordinary shares will (i) have the right to vote on the appointment
and removal of directors and (ii) be entitled to vote on continuing the Company in a jurisdiction outside the British Virgin Islands (including
any ordinary resolution required to amend the constitutional documents or to adopt new constitutional documents, in each case, as a result
of approving a transfer by way of continuation in a jurisdiction outside the British Virgin Islands). Holders of the Class A ordinary
shares will not be entitled to vote on these matters during such time. These provisions of our amended and restated memorandum and articles
of association may only be amended if approved by an ordinary resolution passed by the affirmative vote of the holders representing at
least 90% of the issued Class B ordinary shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants
&#x2014; &lt;/i&gt;Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Warrants.
The Warrants will become exercisable &lt;span id="xdx_900_ecustom--PeriodAfterWhichTheWarrantsAreExercisable_dtD_c20250320__20251231_zqmaOpl3oGMf" title="Period of warrants exercisable"&gt;30&lt;/span&gt; days after the completion of our initial business combination, provided that the Company has an
effective registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the warrants
and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the
securities, or blue sky, laws of the state of residence of the holder (or we permit holders to exercise their warrants on a cashless basis
under the circumstances specified in the warrant agreement). If a registration statement covering the Class A ordinary shares issuable
upon exercise of the warrants is not effective by the 60th business day after the closing of our initial business combination, warrant
holders may, until such time as there is an effective registration statement and during any period when we will have failed to maintain
an effective registration statement, exercise warrants on a &#x201c;cashless basis&#x201d; in accordance with Section&#160;3(a)(9) of the
Securities Act or another exemption. Notwithstanding the above, if our Class A ordinary shares are at the time of any exercise of a warrant
not listed on a national securities exchange such that they satisfy the definition of a &#x201c;covered security&#x201d; under Section&#160;18(b)(1)
of the Securities Act, we may, at our option, require holders of public warrants who exercise their warrants to do so on a &#x201c;cashless
basis&#x201d; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event we so elect, we will not be required to file
or maintain in effect a registration statement. The Warrants will expire five years from the consummation of a Business Combination or
earlier upon redemption or liquidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may call the Warrants for redemption:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in
        whole and not in part;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;at
        a price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z0R8vEvtgNEk" title="Warrant price"&gt;0.01&lt;/span&gt; per warrant; upon a minimum of &lt;span id="xdx_908_ecustom--MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants_dtD_c20250320__20251231_zrGTHCbEFza3" title="Holders of warrants"&gt;30&lt;/span&gt; days&#x2019; prior written notice of redemption (the &#x201c;30-day redemption period&#x201d;);
        and&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;if,
        and only if, the closing price of the Class A ordinary shares equals or exceeds $&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zm2Uo06WbIbb" title="Share price"&gt;18.00&lt;/span&gt; per share (as adjusted for adjustments to the number
        of shares issuable upon exercise or the exercise price of a warrant) for any &lt;span id="xdx_904_ecustom--NumberOfTradingDaysForDeterminingTheSharePrice_dtD_c20250320__20251231_z9LF9cWDtqp1" title="Number of trading days"&gt;20&lt;/span&gt; trading days within a &lt;span id="xdx_901_ecustom--NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_dtD_c20250320__20251231_zO5hmy55kbj4" title="Number of consecutive trading days"&gt;30&lt;/span&gt;-trading day period commencing
        at least 30 days after completion of our initial business combination and ending three business days before we send the notice of redemption
        to the warrant holders.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
private warrants are identical to the warrants sold in the IPO except that, so long as they are held by our sponsor or its permitted transferees,
the private warrants (i) are locked-up until the completion of our initial business combination and (ii) will be entitled to registration
rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted for share sub-divisions, share capitalizations,
reorganizations, recapitalizations and the like. Additionally, in no event will the Company be required to net cash settle the warrants.
If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in
the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution
from the Company&#x2019;s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire
worthless.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise price is $11.50 per share, subject to adjustment as described herein. In addition, if (x) we issue additional Class A ordinary
shares or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at
an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price
to be determined in good faith by our board of directors and, in the case of any such issuance to our initial shareholders or their affiliates,
without taking into account any founder shares held by our initial shareholders or such affiliates, as applicable, prior to such issuance)
(the &#x201c;Newly Issued Price&#x201d;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity
proceeds, and interest thereon, available for the funding of our initial business combination on the date of the consummation of our initial
business combination (net of redemptions), and (z) the volume weighted average trading price of our Class A ordinary shares during the
&lt;span id="xdx_90F_ecustom--NumberOfTradingDaysForDeterminingTheSharePrice_dtD_c20250320__20251231_zwi57d75Gbnf" title="Number of trading days"&gt;20&lt;/span&gt; trading day period starting on the trading day prior to the day on which we consummate our initial business combination (such price,
the &#x201c;Market Value&#x201d;) is below $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231_z9oNRy7TT9cb" title="Warrants exercise price"&gt;9.20&lt;/span&gt; per share, then the exercise price of the warrants will be adjusted (to the nearest cent)
to be equal to &lt;span id="xdx_90C_eus-gaap--AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate_iI_dp_c20251231_zqUGRVZptye" title="Market value"&gt;115%&lt;/span&gt; of the higher of the Market Value and the Newly Issued Price, and the $&lt;span id="xdx_90C_eus-gaap--PreferredStockRedemptionPricePerShare_iI_c20251231_zMU6AAn42sQf" title="Redemption price"&gt;18.00&lt;/span&gt; per share redemption trigger prices will
be adjusted (to the nearest cent) to be equal to &lt;span id="xdx_900_ecustom--ShareRedemptionTriggerPrices_iI_dp_c20251231_zSYWzSorZM4l" title="Share redemption trigger prices"&gt;180%&lt;/span&gt; of the higher of the Market Value and the Newly Issued Price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000892"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000894"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000896"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000898"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000900"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000902"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000904"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesOutstanding>
    <cik0002065779:OrdinarySharesSubjectToPossibleRedemption
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000906"
      unitRef="USD">28000000</cik0002065779:OrdinarySharesSubjectToPossibleRedemption>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000907"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000908"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-012025-03-25_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000909"
      unitRef="Shares">12321429</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cik0002065779:AggregatePurchasePrice
      contextRef="AsOf2025-03-25_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000911"
      unitRef="USD">25000</cik0002065779:AggregatePurchasePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2025-03-012025-03-25_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000912"
      unitRef="Shares">1607143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <cik0002065779:CancellationOfOrdinaryShares
      contextRef="AsOf2025-08-11_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000914"
      unitRef="Shares">321429</cik0002065779:CancellationOfOrdinaryShares>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000916"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000918"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockConversionBasis
      contextRef="From2025-03-202025-12-31_custom_CommonStockClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000920">one-for-one basis</us-gaap:CommonStockConversionBasis>
    <cik0002065779:PeriodAfterWhichTheWarrantsAreExercisable
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000929">P30D</cik0002065779:PeriodAfterWhichTheWarrantsAreExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000931"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cik0002065779:MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000933">P30D</cik0002065779:MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants>
    <us-gaap:SharePrice
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000935"
      unitRef="USDPShares">18.00</us-gaap:SharePrice>
    <cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000937">P20D</cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice>
    <cik0002065779:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000939">P30D</cik0002065779:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice>
    <cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000948">P20D</cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000950"
      unitRef="USDPShares">9.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000952"
      unitRef="Ratio">1.15</us-gaap:AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000954"
      unitRef="USDPShares">18.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <cik0002065779:ShareRedemptionTriggerPrices
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000956"
      unitRef="Ratio">1.80</cik0002065779:ShareRedemptionTriggerPrices>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000958">&lt;p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_zhQ9pqoDD5x" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8. &lt;span id="xdx_821_zmhkA80TXS8d"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s financial assets and liabilities reflects management&#x2019;s estimate of amounts that the Company would
have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction
between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company
seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable
inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is
used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which
transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets
or liabilities and quoted prices for identical assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the Company&#x2019;s assets that are measured at fair value as of August&#160;1, 2025 and
December&#160;31, 2025, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair
value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zl5uLowJiXVi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8B6_zXfmlkhV9ysd" style="display: none"&gt;Schedule of fair value assets and liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;August&#160;1, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left"&gt;Liability:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"&gt;Fair value of over-allotment liability&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;3&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20250801__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAcSNoM2bO7g" style="width: 9%; text-align: right" title="Liability"&gt;1,290,375&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left"&gt;Equity:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Fair value of Public Warrants for Class A
        ordinary shares subject to possible redemption allocation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20250801__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSFisT03zLO" style="text-align: right" title="Equity"&gt;8,061,250&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,
        &lt;br/&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Asset:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Cash held in trust&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;1&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zfsfJbWiQ3Yl" style="width: 9%; text-align: right" title="Assets"&gt;284,776,628&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zKnLC9z1gto9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
over-allotment option was accounted for as a liability in accordance with ASC 815-40 and was presented within liabilities on the balance
sheet. The over-allotment option liability is measured at fair value at August&#160;1, 2025 and on a recurring basis, with changes in
fair value presented within change in fair value of over-allotment option liability in the statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company used a Black-Scholes model to value the over-allotment option. The over-allotment option liability was classified within Level
3 of the fair value hierarchy at the measurement dates due to the use of unobservable inputs inherent in pricing models and assumptions
related to expected share-price volatility, expected life and risk-free interest rate. The Company estimates the volatility of its ordinary
share based on historical volatility that matches the expected remaining life of the over-allotment option. The risk-free interest rate
is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the over-allotment
option. The expected life of the over-allotment option is assumed to be equivalent to its remaining contractual term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
key inputs into the Black-Scholes model were as follows at initial measurement of the over-allotment option:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zGeBHNQlGzMa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B7_zoaVPMUgkntk" style="display: none"&gt;Schedule of initial measurement&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;August&#160;1, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250729__20250801_zykgUgOp2FO7" title="Risk-free interest rate"&gt;4.31&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expected term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250729__20250801_zNNkudmOAsxi" title="Expected terms (years)"&gt;0.12&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expected volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250729__20250801_zYdfJmo8Jv1" title="Expected volatility"&gt;22.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Exercise price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20250801_zsPlpHwwdwY4" title="Exercise price"&gt;10.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Fair value of over-allotment option&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--FairValueOfOverallotmentOption_iI_c20250801_zvdduBXteOCb" title="Fair value of over-allotment option"&gt;0.3441&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zhBNM0cZxCt8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of Public Warrants was determined using Monte Carlo Simulation Model. The Public Warrants have been classified within shareholders&#x2019;
equity and will not require remeasurement after issuance. The following table presents the quantitative information regarding market assumptions
used in the valuation of the Public Warrants:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_znIXiw709dNi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8BE_zsvTOTvZXEk3" style="display: none"&gt;Schedule of market assumptions&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;August&#160;1, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Estimated share price&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharePrice_c20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_pd" title="Estimated share price"&gt;9.68&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Exercise price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_pd" title="Exercise Price"&gt;11.50&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zdgGz9zVX1q2" title="Term (years)"&gt;2.75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Annual risk-free rate (term-matched)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zDaikQy4IZnb" title="Annual risk-free rate (term-matched)"&gt;3.75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expected warrant implied volatility based
        on warrants from comparable SPAC securities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zDGNenuK2YQ2" title="Expected warrant implied volatility based on warrants from comparable SPAC securities"&gt;14.44&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zvYcYlSuTAmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000967">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zl5uLowJiXVi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8B6_zXfmlkhV9ysd" style="display: none"&gt;Schedule of fair value assets and liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;August&#160;1, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left"&gt;Liability:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"&gt;Fair value of over-allotment liability&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;3&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20250801__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAcSNoM2bO7g" style="width: 9%; text-align: right" title="Liability"&gt;1,290,375&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left"&gt;Equity:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Fair value of Public Warrants for Class A
        ordinary shares subject to possible redemption allocation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20250801__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSFisT03zLO" style="text-align: right" title="Equity"&gt;8,061,250&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,
        &lt;br/&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Asset:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Cash held in trust&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;1&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zfsfJbWiQ3Yl" style="width: 9%; text-align: right" title="Assets"&gt;284,776,628&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-08-01_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000969"
      unitRef="USD">1290375</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EquityFairValueDisclosure
      contextRef="AsOf2025-08-01_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000971"
      unitRef="USD">8061250</us-gaap:EquityFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact000973"
      unitRef="USD">284776628</us-gaap:AssetsFairValueDisclosure>
    <cik0002065779:OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000975">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zGeBHNQlGzMa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B7_zoaVPMUgkntk" style="display: none"&gt;Schedule of initial measurement&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;August&#160;1, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250729__20250801_zykgUgOp2FO7" title="Risk-free interest rate"&gt;4.31&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expected term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250729__20250801_zNNkudmOAsxi" title="Expected terms (years)"&gt;0.12&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expected volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250729__20250801_zYdfJmo8Jv1" title="Expected volatility"&gt;22.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Exercise price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20250801_zsPlpHwwdwY4" title="Exercise price"&gt;10.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Fair value of over-allotment option&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--FairValueOfOverallotmentOption_iI_c20250801_zvdduBXteOCb" title="Fair value of over-allotment option"&gt;0.3441&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</cik0002065779:OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000977"
      unitRef="Ratio">0.0431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000979">P0Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000981"
      unitRef="Ratio">0.227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000983"
      unitRef="USDPShares">10.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <cik0002065779:FairValueOfOverallotmentOption
      contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000985"
      unitRef="USDPShares">0.3441</cik0002065779:FairValueOfOverallotmentOption>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000987">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_znIXiw709dNi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8BE_zsvTOTvZXEk3" style="display: none"&gt;Schedule of market assumptions&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;August&#160;1, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Estimated share price&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharePrice_c20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_pd" title="Estimated share price"&gt;9.68&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Exercise price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_pd" title="Exercise Price"&gt;11.50&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zdgGz9zVX1q2" title="Term (years)"&gt;2.75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Annual risk-free rate (term-matched)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zDaikQy4IZnb" title="Annual risk-free rate (term-matched)"&gt;3.75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expected warrant implied volatility based
        on warrants from comparable SPAC securities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zDGNenuK2YQ2" title="Expected warrant implied volatility based on warrants from comparable SPAC securities"&gt;14.44&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000989"
      unitRef="USDPShares">9.68</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000991"
      unitRef="USDPShares">11.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-07-292025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember"
      id="Fact000993">P2Y9M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-07-292025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000995"
      unitRef="Ratio">0.0375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-07-292025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact000997"
      unitRef="Ratio">0.1444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001003">&lt;p id="xdx_809_eus-gaap--SegmentReportingDisclosureTextBlock_zlDYq8wDTeqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9. &lt;span&gt;SEGMENT INFORMATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span id="xdx_82A_ziXv0oR4ze67" style="display: none"&gt;Segment information&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
Topic 280, &#x201c;Segment Reporting,&#x201d; establishes standards for companies to report in their financial statement information about
operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise
for which separate financial information is available that is regularly evaluated by the Company&#x2019;s chief operating decision maker,
or group, in deciding how to allocate resources and assess performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s chief operating decision maker has been identified as the Chief Financial Officer (&#x201c;CODM&#x201d;), who reviews the
operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly,
management has determined that the Company only has one operating segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
evaluating the Company&#x2019;s performance and making key decisions regarding resource allocation the CODM reviews several key metrics,
which include the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zV8K2gwOpH16" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span id="xdx_8BC_zWWW3w6SRnKb" style="display: none"&gt;Schedule of segment information&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; Period from &lt;br/&gt;March&#160;20,
        2025&lt;br/&gt;(inception) through&lt;br/&gt;December&#160;31,&lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 2.5pt"&gt;Formation
        and operating costs&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--OperatingExpenses_iNT_pp0d_di_c20250320__20251231_zktdSzpr5NMa" title="Formation and operating costs"&gt;(320,658&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Interest income on
        cash held in trust account&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--InterestIncomeOther_c20250320__20251231_pp0p" title="Interest income on cash held in trust account"&gt;4,776,628&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Cash held in Trust
        Account&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--CashHeldInTrustAccounts_c20250320__20251231_pp0p" title="Cash held in Trust Account"&gt;284,776,628&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
key measures of segment profit or loss reviewed by the CODM are formation and operating costs, interest income on cash held in trust account,
and cash held in trust account. The CODM reviews interest earned on cash or investments held in Trust Account to measure and monitor shareholder
value and determine the most effective strategy of investment with the Trust Account funds while maintaining compliance with the trust
agreement. Within the operating expenses, the CODM specifically reviews professional service fees, which are a significant segment expense,
and include legal fees and advisory fees. These expenses are monitored to manage and forecast cash available to complete a Business Combination
within the required period. Other general and administrative expenses, including accounting expenses, printing expenses, and regulatory
filing fees, are reviewed in the aggregate to ensure alignment with budget and contractual obligations. Funds invested in the Trust Account
represent the predominant portion of the Company&#x2019;s total assets and are monitored by the CODM to determine the most effective strategy
of investment with the Trust Account funds, while maintaining compliance with the trust agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001005">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zV8K2gwOpH16" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span id="xdx_8BC_zWWW3w6SRnKb" style="display: none"&gt;Schedule of segment information&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; Period from &lt;br/&gt;March&#160;20,
        2025&lt;br/&gt;(inception) through&lt;br/&gt;December&#160;31,&lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 2.5pt"&gt;Formation
        and operating costs&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--OperatingExpenses_iNT_pp0d_di_c20250320__20251231_zktdSzpr5NMa" title="Formation and operating costs"&gt;(320,658&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Interest income on
        cash held in trust account&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--InterestIncomeOther_c20250320__20251231_pp0p" title="Interest income on cash held in trust account"&gt;4,776,628&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Cash held in Trust
        Account&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--CashHeldInTrustAccounts_c20250320__20251231_pp0p" title="Cash held in Trust Account"&gt;284,776,628&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:OperatingExpenses
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001007"
      unitRef="USD">320658</us-gaap:OperatingExpenses>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001009"
      unitRef="USD">4776628</us-gaap:InterestIncomeOther>
    <cik0002065779:CashHeldInTrustAccounts
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001011"
      unitRef="USD">284776628</cik0002065779:CashHeldInTrustAccounts>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001013">&lt;p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zAojbVU1a7zi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10. &lt;span&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span id="xdx_826_zmvFa0ix0mr6" style="display: none"&gt;Subsequent Events&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC Topic 855, &#x201c;Subsequent Events&#x201d;, which establishes general standards of accounting for and disclosure of
events that occur after the balance sheet date but before consolidated financial statements are issued, the Company has evaluated all
events or transactions that occurred up to the date the consolidated financial statements were available to issue. Based upon this review,
the Company identified the following subsequent events:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January&#160;11, 2026, D. Boral ARC Acquisition I Corp. (&#x201c;BCAR&#x201d; or the &#x201c;Company&#x201d;) entered into the Agreement and
Plan of Merger (the &#x201c;Merger Agreement&#x201d;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly
owned subsidiary of BCAR (&#x201c;PubCo&#x201d;), D. Boral Arc Merger Sub Inc. (&#x201c;Merger Sub&#x201d;), a Delaware corporation and a
wholly-owned subsidiary of BCAR, and Exascale Labs Inc., a Delaware corporation (&#x201c;Exascale&#x201d;). Pursuant to the Merger Agreement,
the Business Combination will be effected in two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into
PubCo, with PubCo remaining as the surviving publicly traded entity (the &#x201c;Reincorporation Merger&#x201d;); (ii) after the Reincorporation
Merger, Merger Sub will be merged with and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#x201c;Acquisition
Merger&#x201d; and together with the Reincorporation Merger, the &#x201c;Business Combination&#x201d;).&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001021"
      unitRef="USD">420340</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001022"
      unitRef="USD">243576</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001024"
      unitRef="USD">203134</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001025"
      unitRef="USD">156259</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001027"
      unitRef="USD">623474</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001028"
      unitRef="USD">399835</us-gaap:AssetsCurrent>
    <cik0002065779:CashHeldInTrustAccount
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001030"
      unitRef="USD">284776628</cik0002065779:CashHeldInTrustAccount>
    <cik0002065779:CashHeldInTrustAccount
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001031"
      unitRef="USD">287319687</cik0002065779:CashHeldInTrustAccount>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001033"
      unitRef="USD">285400102</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001034"
      unitRef="USD">287719522</us-gaap:Assets>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001042"
      unitRef="USD">37611</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001043"
      unitRef="USD">345713</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001045"
      unitRef="USD">37611</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001046"
      unitRef="USD">345713</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001048"
      unitRef="USD">37611</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001049"
      unitRef="USD">345713</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001056"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001057"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001058"
      unitRef="Shares">500000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001059"
      unitRef="Shares">500000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001060"
      unitRef="Shares">28000000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001061"
      unitRef="Shares">28000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001062"
      unitRef="Shares">28000000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001063"
      unitRef="Shares">28000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001064"
      unitRef="USDPShares">10.26</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001065"
      unitRef="USDPShares">10.17</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001054"
      unitRef="USD">284776628</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001055"
      unitRef="USD">287319687</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001073"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001075"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001077"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001079"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001081"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001083"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001085"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001087"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001089"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001091"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001093"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001095"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001097"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001099"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001101"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001103"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesOutstanding>
    <cik0002065779:SharesSubjectToRedemption
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact001105"
      unitRef="Shares">28000000</cik0002065779:SharesSubjectToRedemption>
    <cik0002065779:SharesSubjectToRedemption
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact001107"
      unitRef="Shares">28000000</cik0002065779:SharesSubjectToRedemption>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001108"
      unitRef="USD">120</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001109"
      unitRef="USD">120</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001110"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001111"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001112"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001113"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001114"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001115"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001116"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001117"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001118"
      unitRef="USD">1200</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001119"
      unitRef="USD">1200</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001124"
      unitRef="USD">584543</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001125"
      unitRef="USD">52802</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001127"
      unitRef="USD">585863</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001128"
      unitRef="USD">54122</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001130"
      unitRef="USD">285400102</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001131"
      unitRef="USD">287719522</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:OperatingExpenses
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001133"
      unitRef="USD">5420</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001134"
      unitRef="USD">531741</us-gaap:OperatingExpenses>
    <us-gaap:InterestIncomeOther
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001140"
      unitRef="USD">2543059</us-gaap:InterestIncomeOther>
    <us-gaap:OtherIncome
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001143"
      unitRef="USD">2543059</us-gaap:OtherIncome>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001145"
      unitRef="USD">5420</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001146"
      unitRef="USD">2011318</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001152"
      unitRef="Shares">29200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001154"
      unitRef="Shares">29200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001156"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001158"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001160"
      unitRef="USDPShares">0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001162"
      unitRef="USDPShares">0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001164"
      unitRef="Shares">10714286</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001166"
      unitRef="Shares">10714286</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001168"
      unitRef="Shares">12000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001170"
      unitRef="Shares">12000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001172"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001174"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001176"
      unitRef="USDPShares">0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001178"
      unitRef="USDPShares">0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact001187"
      unitRef="Shares">1200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="0"
      id="Fact001180"
      unitRef="USD">120</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001189"
      unitRef="Shares">12000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001181"
      unitRef="USD">1200</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001183"
      unitRef="USD">584543</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001185"
      unitRef="USD">585863</us-gaap:StockholdersEquity>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001194"
      unitRef="USD">-2543059</cik0002065779:AccretionInValueOfClassOrdinaryShares>
    <cik0002065779:AccretionInValueOfClassOrdinaryShares
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001196"
      unitRef="USD">-2543059</cik0002065779:AccretionInValueOfClassOrdinaryShares>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001201"
      unitRef="USD">2011318</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001203"
      unitRef="USD">2011318</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="INF"
      id="Fact001212"
      unitRef="Shares">1200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember"
      decimals="0"
      id="Fact001205"
      unitRef="USD">120</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001214"
      unitRef="Shares">12000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001206"
      unitRef="USD">1200</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001208"
      unitRef="USD">52802</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001210"
      unitRef="USD">54122</us-gaap:StockholdersEquity>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsorShares
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738984"
      decimals="INF"
      id="Fact001234"
      unitRef="Shares">12321429</cik0002065779:ClassBOrdinarySharesIssuedToSponsorShares>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember62738984"
      decimals="0"
      id="Fact001228"
      unitRef="USD">1232</cik0002065779:ClassBOrdinarySharesIssuedToSponsor>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001229"
      unitRef="USD">23768</cik0002065779:ClassBOrdinarySharesIssuedToSponsor>
    <cik0002065779:ClassBOrdinarySharesIssuedToSponsor
      contextRef="From2025-03-202025-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001231"
      unitRef="USD">-25000</cik0002065779:ClassBOrdinarySharesIssuedToSponsor>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001239"
      unitRef="USD">-5420</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001241"
      unitRef="USD">-5420</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001252"
      unitRef="Shares">12321429</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001244"
      unitRef="USD">1232</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001245"
      unitRef="USD">23768</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001246"
      unitRef="USD">-5420</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_custom_SubscriptionReceivableMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001247"
      unitRef="USD">-25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001248"
      unitRef="USD">-5420</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001258"
      unitRef="USD">5420</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001259"
      unitRef="USD">2011318</us-gaap:NetIncomeLoss>
    <cik0002065779:PaymentOfExpensesThroughPromissoryNoteRelatedParty
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001264"
      unitRef="USD">5420</cik0002065779:PaymentOfExpensesThroughPromissoryNoteRelatedParty>
    <us-gaap:InterestIncomeOther
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001268"
      unitRef="USD">2543059</us-gaap:InterestIncomeOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001274"
      unitRef="USD">-46875</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001277"
      unitRef="USD">308102</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001280"
      unitRef="USD">-176764</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001310"
      unitRef="USD">-176764</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001313"
      unitRef="USD">420340</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001316"
      unitRef="USD">243576</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="From2025-03-202025-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001321"
      unitRef="USD">48420</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionInventoryAcquired1
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001325"
      unitRef="USD">2543059</us-gaap:NoncashOrPartNoncashAcquisitionInventoryAcquired1>
    <us-gaap:NatureOfOperations
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001327">&lt;p id="xdx_80C_eus-gaap--NatureOfOperations_zygend9e1RRc" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 1. &lt;span id="xdx_82D_zrYalJ697s07"&gt;DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;D. BORAL ARC
ACQUISITION I CORP. (the &#x201c;Company&#x201d;) is a blank check company incorporated in the British Virgin Islands on March&#160;20,
2025. The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase,
reorganization or similar business combination with one or more businesses (&#x201c;Business Combination&#x201d;). While the Company may
pursue an acquisition opportunity in any business, industry, sector or geographical location, the Company intends to focus on industries
that complement our management team&#x2019;s background, and to capitalize on the ability of our management team to identify and acquire
a business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31,
2026, the Company had not yet commenced any operations. All activity through March 31, 2026 related to the Company&#x2019;s formation
and the Initial Public Offering (as defined below). Since the IPO, the Company&#x2019;s activity has been limited to the costs in pursuit
of the consummation of an initial business combination. The Company will not generate any operating revenues until after the completion
of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on
cash and cash equivalents from the proceeds derived from the Initial Public Offering. The Company has selected December&#160;31 as its
fiscal year end. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated
with early stage and emerging growth companies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company&#x2019;s sponsor is MFH 1, LLC (the &#x201c;Sponsor&#x201d;). The registration statement for the Company&#x2019;s Initial Public Offering was declared effective on July&#160;30, 2025. On August&#160;1, 2025, the Company consummated its Initial Public Offering of &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zZC60ip9O139" title="Sale of units in initial public offering"&gt;25,000,000&lt;/span&gt; units (the &#x201c;Units&#x201d; and, with respect to the Class A Ordinary Shares included in the Units being offered, the &#x201c;Public Shares&#x201d;), at $&lt;span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z3ISudk5ZSw6" title="Sale of units per share"&gt;10.00&lt;/span&gt; per Unit, generating gross proceeds of $&lt;span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zjX8VKK92qjd" title="Sale of units in initial public offering aggragate amount"&gt;250,000,000&lt;/span&gt; (the &#x201c;Initial Public Offering&#x201d;). The Company granted the underwriter a 45-day option to purchase up to an additional &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z9eUpL924fa5" title="Sale of units in initial public offering"&gt;3,750,000&lt;/span&gt; Units at the Initial Public Offering price to cover over-allotments, if any. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Simultaneously with the consummation of the closing of the Offering, the Company consummated the private placement of an aggregate of &lt;span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGrtbDdoicDg" title="Sale of units in initial public offering"&gt;200,000&lt;/span&gt; units (the &#x201c;Placement Units&#x201d;) to the Sponsor at a price of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zABeT3cNd0K6" title="Sale of units per share"&gt;10.00&lt;/span&gt; per Unit, generating gross proceeds of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zm3i9GAh1wZ" title="Sale of units in initial public offering aggragate amount"&gt;2,000,000&lt;/span&gt; (the &#x201c;Private Placement&#x201d;). (see Note 4).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Transaction costs amounted to $&lt;span id="xdx_90C_ecustom--TransactionCosts_pp0p0_c20260101__20260331_zlNHw2cetME1" title="Transaction costs"&gt;3,582,634&lt;/span&gt;, consisting of $&lt;span id="xdx_905_ecustom--RepresentativeShares_pp0p0_c20260101__20260331_zpYwsp2Au2o7" title="Representative shares"&gt;2,419,400&lt;/span&gt; of the Representative Shares (discussed in the below) and $&lt;span id="xdx_90B_ecustom--OtherOfferingCosts_pp0p0_c20260101__20260331_z1IYHYmkc8Vf" title="Other offering costs"&gt;1,163,234&lt;/span&gt; of other offering costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;In conjunction with the IPO, the Company issued to the underwriter &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zC8C67MdLPre" title="Number of share issued"&gt;1,000,000&lt;/span&gt; Class A ordinary shares for no consideration (the &#x201c;Representative Shares&#x201d;). The fair value of the Representative Shares accounted for as compensation under Accounting Standards Codification (&#x201c;ASC&#x201d;) 718, &#x201c;Compensation &#x2013; Stock Compensation&#x201d; (&#x201c;ASC 718&#x201d;) is included in the offering costs. The estimated fair value of the Representative Shares as of the IPO date totaled $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zHyEfQAcbCTg" title="Number of share issued, value"&gt;2,419,400&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Following the closing of the Initial Public Offering on August&#160;1, 2025, an amount of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_ziUw4vAAKbAd" title="proceeds from sale of initial public offering"&gt;250,000,000&lt;/span&gt; ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and a portion of the proceeds from the sale of the Placement Units was placed in a trust account (the &#x201c;Trust Account&#x201d;), located in the United States and held as cash items and will be invested only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule&#160;2a-7 under the Investment Company Act, that invest only in direct U.S. government treasury obligations; the holding of these assets in this form is intended to be temporary and for the sole purpose of facilitating the intended business combination. To mitigate the risk that the Company might be deemed to be an investment company for purposes of the Investment Company Act, which risk increases the longer that the Company hold investments in the trust account, the Company may, at any time (based on our management team&#x2019;s ongoing assessment of all factors related to our potential status under the Investment Company Act), instruct the trustee to liquidate the investments held in the trust account and instead to hold the funds in the trust account in cash or in an interest bearing demand deposit account at a bank.&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;On August&#160;11, 2025, the underwriters of the IPO notified the Company of their partial exercise of the over-allotment option and purchased &lt;span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zJQr08Hr1169" title="Sale of units in initial public offering"&gt;3,000,000&lt;/span&gt; additional units (the &#x201c;Option Units&#x201d;) at $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zGc1BiSVx6Wi" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit upon the closing of the over-allotment option, generating gross proceeds of $&lt;span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zwO1mOZUQPp7" title="Sale of units in initial public offering aggragate amount"&gt;30,000,000&lt;/span&gt;. The over-allotment option closed on August&#160;13, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;On September 9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option. As a result,&#160;on September 9, 2025,&#160;the Company cancelled a total of &lt;span id="xdx_90C_ecustom--CancelledFounderShares_c20250905__20250909_zMn2lTaGsGg9" title="Cancelled founder shares"&gt;321,429&lt;/span&gt; of the Company&#x2019;s founder shares, issued to MFH 1, LLC thereby reducing the sponsor&#x2019;s total shares to &lt;span id="xdx_90F_ecustom--CancelledFounderShares_c20250729__20250801_zE8aHeKIinuh" title="Cancelled founder shares"&gt;12,000,000&lt;/span&gt;, which was effective from August 1, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of our initial business combination either (i) in connection with a shareholder meeting called to approve the initial business combination or (ii) by means of a tender offer. In connection with a proposed Business Combination, the Company may seek shareholder approval of a Business Combination at a meeting called for such purpose at which shareholders may seek to redeem their shares, regardless of how they vote for the Business Combination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $&lt;span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zvYo0cYwbk22" title="Sale of units per share"&gt;10.00&lt;/span&gt; per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter. These ordinary shares was recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480 &#x201c;Distinguishing Liabilities from Equity.&#x201d;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its amended and restated memorandum and articles of association conduct the redemptions pursuant to Rule&#160;13e-4 and Regulation 14E of the Exchange Act, which regulate issuer tender offers, and file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The sponsor, officers and directors have entered
into a letter agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to
their founder shares, private shares and public shares in connection with the completion of our initial business combination; (ii)
waive their redemption rights with respect to their founder shares, private shares and public shares in connection with a
shareholder vote to approve an amendment to our amended and restated memorandum and articles of association; (iii) waive their
rights to liquidating distributions from the trust account with respect to their founder shares and private shares if the Company
fail to complete our initial business combination within the completion window, although they will be entitled to liquidating
distributions from the trust account with respect to any public shares they hold if the Company fail to complete our initial
business combination within the prescribed time frame and to liquidating distributions from assets outside the trust account; and
(iv) vote any founder shares and private shares held by them and any public shares they may purchase (including in open market and privately-negotiated transactions) in favor of our initial business combination (except that
any public shares such parties may purchase in compliance with the requirements of Rule&#160;14e-5 under the Exchange Act would not
be voted in favor of approving the business combination transaction).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company will have until 18 months from the closing of the Initial Public Offering, with one (1) three-month extension at the option of the sponsor (as may be extended by shareholder approval to amend our amended and restated memorandum and articles of association to extend the date by which the Company must consummate our initial business combination) or until such earlier liquidation date as our board of directors may approve, to consummate a Business Combination (the &#x201c;Combination Period&#x201d;). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter (and subject to lawfully available funds therefor), redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (which interest shall be net of taxes and less up to $&lt;span id="xdx_901_eus-gaap--LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_iI_c20251231_zW7hO2wBkNSk" title="Dissolution expenses"&gt;100,000&lt;/span&gt; of interest to pay dissolution expenses), divided by the number of then-outstanding public shares, which redemption will completely extinguish public shareholders&#x2019; rights as shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors, liquidate and dissolve, subject in each case to our obligations under British Virgin Islands law to provide for claims of creditors and the requirements of other applicable law.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The underwriter
has agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event the Company does not complete
a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust
Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the
per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Sponsor has
agreed that it will be liable to us if and to the extent any claims by a third party for services rendered or products sold to us (except
for the Company&#x2019;s independent auditors), or a prospective target business with which the Company has entered into a written letter
of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in the trust account
to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account as of the date
of the liquidation of the trust account, if less than $10.00 per public share due to reductions in the value of the trust assets, less
taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed
a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply
to any claims under our indemnity of the underwriters of our IPO against certain liabilities, including liabilities under the Securities
Act. However, the Company has not asked our sponsor to reserve for such indemnification obligations, nor has the Company independently
verified whether our sponsor has sufficient funds to satisfy its indemnity obligations and the Company believe that our sponsor&#x2019;s
only assets are securities of our company. Therefore, the Company cannot assure you that our sponsor would be able to satisfy those obligations.
As a result, if any such claims were successfully made against the trust account, the funds available for our initial business combination
and redemptions could be reduced to less than $10.00 per public share. In such event, the Company may not be able to complete our initial
business combination, and you would receive such lesser amount per share in connection with any redemption of your public shares. None
of our officers or directors will indemnify us for claims by third parties including, without limitation, claims by vendors and prospective
target businesses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January&#160;11,
2026, D. Boral ARC Acquisition I Corp. (&#x201c;BCAR&#x201d; or the &#x201c;Company&#x201d;) entered into the Agreement and Plan of Merger
(the &#x201c;Merger Agreement&#x201d;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly owned subsidiary
of BCAR (&#x201c;PubCo&#x201d;), D. Boral Arc Merger Sub Inc. (&#x201c;Merger Sub&#x201d;), a Delaware corporation and a wholly-owned subsidiary
of BCAR, and Exascale Labs Inc., a Delaware corporation (&#x201c;Exascale&#x201d;). Pursuant to the Merger Agreement, the Business Combination
will be effected in two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into PubCo, with PubCo remaining
as the surviving publicly traded entity (the &#x201c;Reincorporation Merger&#x201d;); (ii) after the Reincorporation Merger, Merger Sub
will be merged with and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#x201c;Acquisition Merger&#x201d;
and together with the Reincorporation Merger, the &#x201c;Business Combination&#x201d;).&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate
consideration for the Acquisition Merger is $500,000,000 (the &#x201c;Merger Consideration&#x201d;), payable in the form of 50,000,000
newly issued shares of common stock of PubCo valued at $10.00 per share to Exascale and its shareholders. At the closing of the Acquisition
Merger (the &#x201c;Closing&#x201d;), the issued and outstanding shares in Exascale held by the former Exascale shareholders will be cancelled
and cease to exist as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt;"&gt;Each issued and outstanding
    share of Exascale Class B common stock shall be cancelled and converted into the right to receive a number of shares of PubCo Class
    B common stock (the &#x201c;PubCo Class B Shares&#x201d;) equal to the quotient obtained by dividing (a) the quotient equal to the
    Merger Consideration divided by the fully diluted Exascale capitalization (the &#x201c;Per Share Merger Consideration&#x201d;) by (b)
    Ten Dollars ($10.00), with each such PubCo Class B Share having twenty (20) votes per share; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt;"&gt;Each issued and outstanding
    share of Exascale Class A common stock shall be cancelled and converted into the right to receive a number of shares of PubCo Class
    A common stock (the &#x201c;PubCo Class A Shares&#x201d;) equal to the quotient obtained by dividing (a) the Per Share Merger Consideration
    by (b) Ten Dollars ($10.00), with each such PubCo Class A Share having one (1) vote per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;Liquidity, Capital Resources and Going Concern
Consideration&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;As of March 31, 2026, the Company had $&lt;span id="xdx_90D_eus-gaap--Cash_iI_pp0p0_c20260331_zcgybPa75Rrh" title="Cash"&gt;243,576&lt;/span&gt; of cash in its operating bank account and working capital of $&lt;span id="xdx_90E_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20260331_z6EhFQhvkWk2" title="Working capital deficit"&gt;54,122&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company&#x2019;s liquidity needs prior to the
consummation of the Initial Public Offering were satisfied through the payment of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--FounderSharesMember_zDESmG0pruoc" title="Proceeds from issuance of common stock"&gt;25,000&lt;/span&gt;
from the Sponsor to cover for certain offering costs on the Company&#x2019;s behalf in exchange for issuance of Founder Shares (as
defined in Note 4), and loan from the Sponsor of $&lt;span id="xdx_90F_eus-gaap--LoansPayable_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zcxmPKgrvA99" title="Loan payable"&gt;225,461&lt;/span&gt;
under the Note (as defined in Note 4). On August&#160;1, 2025, the Company has repaid $&lt;span id="xdx_903_eus-gaap--RepaymentOfNotesReceivableFromRelatedParties_c20250729__20250801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zL71zekeZW5i" title="Repayment of promissory note"&gt;225,461&lt;/span&gt;
under the promissory note. Subsequent to the consummation of the Initial Public Offering, the Company&#x2019;s liquidity has been
satisfied through the net proceeds from the consummation of the Initial Public Offering and the Private Placement held outside of
the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an
affiliate of the Sponsor, or certain of the Company&#x2019;s officers and directors may, but are not obligated to, provide the
Company Working Capital Loans (as defined in Note 4). As of December&#160;31, 2025 and March&#160;31, 2026, there were no amounts
outstanding under any Working Capital Loan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expects
to incur significant costs in pursuit of its acquisition plans and will not generate any operating revenues until after the completion
of its initial business combination. In addition, the Company expects to have negative cash flows from operations as it pursues an initial
business combination target. In connection with the Company&#x2019;s assessment of going concern considerations in accordance with Accounting
Standards Update (&#x201c;ASU&#x201d;) 2014-15, &#x201c;Disclosures of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going
Concern&#x201d; the Company does not currently have adequate liquidity to sustain operations, which consist solely of pursuing a Business
Combination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company may
raise additional capital through loans or additional investments from the Sponsor or its shareholders, officers, directors, or third
parties. The Company&#x2019;s officers and directors and the Sponsor may, but are not obligated to (except as described above), loan the
Company funds, from time to time, in whatever amount they deem reasonable in their sole discretion, to meet the Company&#x2019;s working
capital needs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As is customary
for a special purpose acquisition company, if the Company is not able to consummate a Business Combination during the Combination Period,
it will cease all operations and redeem the Public Shares. Management plans to continue its efforts to consummate a Business Combination
during the Combination Period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;While the Company expects to have access to
additional sources of capital if necessary, there is no current commitment on the part of any financing source to provide additional
capital and no assurances can be provided that such additional capital will ultimately be available. The liquidity condition and
mandatory liquidation raise substantial doubt about the Company&#x2019;s ability to continue as a going concern until the earlier of
the consummation of the Business Combination or the date the Company is required to liquidate. There is no assurance that the
Company&#x2019;s plans to raise additional capital (to the extent ultimately necessary) or to consummate a Business Combination will
be successful or successful within the Combination Period. The consolidated condensed financial statements do not include any
adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;




















</us-gaap:NatureOfOperations>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001329"
      unitRef="Shares">25000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001331"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001333"
      unitRef="USD">250000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001335"
      unitRef="Shares">3750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001337"
      unitRef="Shares">200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001339"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001341"
      unitRef="USD">2000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <cik0002065779:TransactionCosts
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001343"
      unitRef="USD">3582634</cik0002065779:TransactionCosts>
    <cik0002065779:RepresentativeShares
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001345"
      unitRef="USD">2419400</cik0002065779:RepresentativeShares>
    <cik0002065779:OtherOfferingCosts
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001347"
      unitRef="USD">1163234</cik0002065779:OtherOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001349"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001351"
      unitRef="USD">2419400</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001353"
      unitRef="USD">250000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001362"
      unitRef="Shares">3000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001364"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001366"
      unitRef="USD">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <cik0002065779:CancelledFounderShares
      contextRef="From2025-09-052025-09-09_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001368"
      unitRef="Shares">321429</cik0002065779:CancelledFounderShares>
    <cik0002065779:CancelledFounderShares
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001370"
      unitRef="Shares">12000000</cik0002065779:CancelledFounderShares>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001372"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001374"
      unitRef="USD">100000</us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities>
    <us-gaap:Cash
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001388"
      unitRef="USD">243576</us-gaap:Cash>
    <cik0002065779:WorkingCapitalDeficit
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001390"
      unitRef="USD">54122</cik0002065779:WorkingCapitalDeficit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2026-01-012026-03-31_custom_FounderSharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001392"
      unitRef="USD">25000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:LoansPayable
      contextRef="AsOf2026-03-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001394"
      unitRef="USD">225461</us-gaap:LoansPayable>
    <us-gaap:RepaymentOfNotesReceivableFromRelatedParties
      contextRef="From2025-07-292025-08-01_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001396"
      unitRef="USD">225461</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001403">&lt;p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zwMIFdJLnGU" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 2. &lt;span id="xdx_820_zHeBz4zKHT1d"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z0IWy53sD0Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_z1Rf2RuPJR21"&gt;Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The accompanying consolidated condensed financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
and pursuant to the rules and regulations of the SEC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Certain information and note disclosures normally
included in the annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been
condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to
make the information not misleading. The interim financial statements as of March 31, 2026 and for the three months ended March 31, 2026
are unaudited. In the opinion of management, the consolidated condensed financial statements include all adjustments, consisting only of normal
recurring adjustments, necessary to provide a fair statement of the results for the periods. The accompanying balance sheet as of December
31, 2025, is derived from the audited financial statements presented in the Company&#x2019;s Annual Report on Form 10-K for the year ended
December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--EmergingGrowthCompanyPolicyTextBlock_zmhW1kdqSIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86C_zt6czdzfWEih"&gt;Emerging Growth Company&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make
comparison of the Company&#x2019;s consolidated financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--UseOfEstimates_zQYZj3djUeb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_864_zRzz8424e6p3"&gt;Use of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The preparation of consolidated condensed financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the consolidated condensed financial statements and the
reported amounts of revenues and expenses during the reporting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Making estimates requires management to exercise
significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances
that existed at the date of the consolidated condensed financial statements, which management considered in formulating its estimate,
could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly
from those estimates.&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;















&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPzrLcIyQfel" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_860_zu37CGZfznfc"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company considers all highly liquid
investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents are carried at
cost, which approximates fair value. The Company had $&lt;span id="xdx_90E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20251231_zKSiK1lJFQo5"&gt;420,340&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20260331_zBLVCNltQyz5"&gt;243,576&lt;/span&gt;
in cash as of December&#160;31, 2025 and March&#160;31, 2026, respectively. The Company had &lt;span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20251231_zHKchSeuPLR4" title="Cash equivalents"&gt;&lt;span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20260331_zbssSpEVMX26" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;
cash equivalents as of December&#160;31, 2025 and March&#160;31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--CashHeldInTrustAccountPolicyTextBlock_zf23zmDeFAC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_863_zgMHfmHrvZ42"&gt;Cash Held in Trust Account&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company had $&lt;span id="xdx_90F_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20251231_z5sY6BBpp9d4"&gt;284,776,628&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20260331_zKMPpHYYWvXd"&gt;287,319,687&lt;/span&gt;
a of cash in the trust account held in an interest bearing demand deposit account as of December 31, 2025 and March&#160;31,
2026, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock_z7CN7IDO18Rg" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_860_zF0eseXwdsYe"&gt;Offering Costs Associated with the Initial Public Offering&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014;
&#x201c;Expenses of Offering.&#x201d; Deferred offering costs consist principally of professional and registration fees that are related
to the Initial Public Offering. Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 470-20, &#x201c;Debt with Conversion and
Other Options,&#x201d; addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components.
The Company applies this guidance to allocate Initial Public Offering proceeds from the Public Units between Class A ordinary shares and
warrants based on their relative fair values. Offering costs allocated to the Class A ordinary shares subject to possible redemption were
charged to temporary equity, and offering costs allocated to the warrants included in the Public Units and Private Units were charged
to shareholder&#x2019;s equity as the warrants, after management&#x2019;s evaluation, were accounted for under equity treatment. As of August&#160;1,
2025, the Company had offering costs of $&lt;span id="xdx_903_ecustom--OfferingCost_iI_pp0p0_c20250801_z4hgPDFmpaOa" title="Offering costs"&gt;3,582,634&lt;/span&gt;,
consisting of $&lt;span id="xdx_901_ecustom--RepresentativeShares_c20250729__20250801_z17XWIvrJ0Ql" title="Representative shares"&gt;2,419,400&lt;/span&gt;
of the Representative Shares (as discussed in Note 1) and $&lt;span id="xdx_903_ecustom--OtherOfferingCost_pp0p0_c20250729__20250801_z3stLaw1Yk4h" title="Other offering costs"&gt;1,163,234&lt;/span&gt;
of other offering costs. Approximately $&lt;span id="xdx_90C_eus-gaap--OtherExpenses_pp0p0_c20250729__20250801_zacUbSCdNTya" title="other costs"&gt;143,775&lt;/span&gt;
of such costs were allocated to the Public Warrants and the Private Placement Units and the remainder, approximately $&lt;span id="xdx_90D_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_c20250801_z05aQ6gzdoVi" title="Ordinary shares subject to redemption"&gt;3,438,859&lt;/span&gt;
was allocated to Class A ordinary shares subject to redemption. As of December&#160;31, 2025, the Company had offering costs of $&lt;span id="xdx_900_ecustom--OfferingCost_iI_pp0p0_c20251231_zXALNb75mMuc" title="Offering costs"&gt;3,582,634&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_z77b7DWKM4ee" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86A_zVc6ABTVy162"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company complies with the accounting and reporting
requirements of ASC Topic 740, &#x201c;Income Taxes,&#x201d; which requires an asset and liability approach to financial accounting and
reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the consolidated financial
statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws
and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established,
when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;ASC Topic 740 prescribes a recognition threshold and a measurement
attribute for the consolidated financial statement recognition and measurement of tax positions taken or expected to be taken in a tax
return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.
The Company&#x2019;s management determined the British Virgin Islands is the Company&#x2019;s only major tax jurisdiction. The Company recognizes
accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were no unrecognized tax benefits
as of March 31, 2026 and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review
that could result in significant payments, accruals or material deviation from its position. The Company is considered to be an exempted
British Virgin Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income
tax filing requirements in the British Virgin Islands or the United States. As such, the provision for income taxes was deemed to be &lt;i&gt;de
minimis&lt;/i&gt; for the three months ended March 31, 2026.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;















&lt;p id="xdx_840_eus-gaap--ExtendedProductWarrantyPolicy_zIfpp4pkn1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_863_zpXKgEMQKf8"&gt;Warrant Instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;We account for Warrants as either equity-classified
or liability-classified instruments based on an assessment of the instruments&#x2019; specific terms and applicable authoritative guidance
in ASC 480 and FASB ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC 815&#x201d;). The assessment considers whether the
instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to
a company&#x2019;s common shares and whether the instrument holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance
outside of a company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional
judgment, is conducted at the time of Warrant issuance and as of each subsequent quarterly period end date while the instruments are outstanding.
Upon review of the Warrant Agreement, Management concluded that the&#160;public warrants and private warrants issued pursuant to such
warrant agreement qualify for equity accounting treatment.&#160;Following the closing of the Initial Public Offering on August&#160;1,
2025 and underwriter&#x2019;s exercise of over-allotment option on August&#160;13, 2025, the Company accounted for the&#160;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331_zZXCPtdZIUn7" title="Warrants issued"&gt;14,000,000&lt;/span&gt;
public warrants and&#160;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zV9MLoZewlLk" title="Warrants issued"&gt;100,000&lt;/span&gt; private warrants issued under equity treatment at their assigned values.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_zd7Gejgazmwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86B_zNHDcMFMuEE"&gt;Class A Ordinary Shares Subject to Possible Redemption&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The public shares contain
a redemption feature which allows for the redemption of such public shares in connection with the Company&#x2019;s liquidation, or if
there is a shareholder vote or tender offer in connection with the Company&#x2019;s initial Business Combination. In accordance with
ASC 480-10-S99, the Company classifies public shares subject to redemption outside of permanent equity as the redemption provisions
are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as they occur and
will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately
upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount
value. The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the
extent available) and Retained earnings. Accordingly, Class A ordinary shares subject to possible redemption are presented at
redemption value as temporary equity, outside of the shareholders&#x2019; equity section of the Company&#x2019;s balance sheet. As of
March 31, 2026 and December 31, 2025, the 28,000,000 Class A ordinary shares subject to redemption reflected in the balance sheet
are reconciled in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--TemporaryEquityTableTextBlock_zI3yMm7Bm2me" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B8_zvz98VUo83yh" style="display: none"&gt;Schedule of ordinary shares subject to redemption&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Class A ordinary shares subject to possible redemption, December 31, 2025&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_c20260101__20260331_zuYUa9ZjRBt2" style="text-align: right"&gt;284,776,628&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Plus:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top"&gt;Accretion of carrying value to redemption value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20260101__20260331_zjT475ucOqx7" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;2,543,059&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Class A ordinary shares subject to possible redemption, March 31, 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_c20260101__20260331_zXneNCCbjKKh" style="border-bottom: Black 2.5pt double; text-align: right"&gt;287,319,687&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;










&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zWhlay9HXAC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_866_zIRLAGvnsr1d"&gt;Net (Loss)/Income per Ordinary Share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share.&#x201d; Net income per share of ordinary shares is computed by dividing net income applicable to ordinary shareholders by the weighted average number of shares of ordinary shares outstanding during the period.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The Company has not considered the effect of the Warrants sold in the Offering and Private Placement to purchase an aggregate of&#160;&lt;span id="xdx_906_eus-gaap--WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_c20260101__20260331_zLwsCzFCHW3" title="Weighted average aggregate shares"&gt;14,100,000&lt;/span&gt;&#160;Class A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method and are contingent on future events. As a result, diluted income per share of Class A ordinary shares is the same as basic income per share of ordinary shares for the period presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The Company has two classes of ordinary shares,
which are referred to as Class A ordinary shares and Class B ordinary shares. Net income per share of ordinary shares is calculated by
dividing the net income by the weighted average number of shares of ordinary shares outstanding during the respective period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The following tables reflect the net (loss)/income
per share after allocating income between the shares based on outstanding shares:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z9nBryRVgBB1" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_8BC_zW0SKWND27gd" style="display: none"&gt;&#160;Schedule
    of earning per share basic and diluted&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;
Period from &lt;br/&gt;
March&#160;20, 2025
&lt;br/&gt;
(Inception) through &lt;br/&gt;
March&#160;31,&lt;br/&gt;
2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For the&lt;br/&gt;
three months ended &lt;br/&gt;
March&#160;31, &lt;br/&gt;
2026&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class A&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class B&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class A&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class B&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net income per share:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocation of (loss)/income &#x96; basic and diluted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zy8q1CRpivSl" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_900_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z2LX5LzP7HYe" title="Allocation of (loss)/income - diluted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1475"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1477"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zaYIpma7fKI5" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zUhkVNCQNGB4" title="Allocation of (loss)/income - diluted"&gt;(5,420&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0iSNiakF4xg" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zFRQnvemDvP9" title="Allocation of (loss)/income - diluted"&gt;2,011,318&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zTfMrVC9Nq08" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwCyQpQUqFfg" title="Allocation of (loss)/income - diluted"&gt;2,011,318&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted weighted average share of ordinary shares:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zaCBbKkxOUll" title="Weighted average shares of Class A ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zBiG6LXmLI06" title="Weighted average shares of Class A ordinary shares outstanding, diluted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1491"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1493"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwozb4274lpk" title="Weighted average shares of Class B ordinary shares outstanding, basic"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z4aO9n9RdMz2" title="Weighted average shares of Class B ordinary shares outstanding, diluted"&gt;10,714,286&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zngzHuVdEMLb" title="Weighted average shares of Class A ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z4D9HtOcAKq" title="Weighted average shares of Class A ordinary shares outstanding, diluted"&gt;29,200,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMgqLWjjG1Ug" title="Weighted average shares of Class B ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMDCWHjrReMl" title="Weighted average shares of Class B ordinary shares outstanding, diluted"&gt;12,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net income per share&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z38VIFVXOnne" title="Class A ordinary shares - basic net income per share"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zzqpPBahwyhi" title="Class A ordinary shares - diluted net income per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0i8nL2oW9si" title="Class B ordinary shares - basic net income per share"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z3ekJQDEjG8d" title="Class B ordinary shares - diluted net income per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zEF9ZlGITAD2" title="Class A ordinary shares - basic net income per share"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zA6RCCMfP971" title="Class A ordinary shares - diluted net income per share"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zIcku8QW2zV5" title="Class B ordinary shares - basic net income per share"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zBzYlBzAMw96" title="Class B ordinary shares - diluted net income per share"&gt;0.17&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zNWMKWxINBke" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zKmI21KJxxNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_864_zHGfCbGDFHJ"&gt;Concentration of credit risk&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Financial instruments that potentially subject
the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the
Federal depository insurance coverage of $&lt;span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20260331_zpCvUwnIYIca" title="FDIC Insured Amount"&gt;250,000&lt;/span&gt;.
At December&#160;31, 2025 and March&#160;31, 2026, the Company had not experienced losses on this account and management believes the
Company is not exposed to significant risks on such account.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zCslz5Xo6Ob6" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_867_zDDHritlLFyi"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;














&lt;p id="xdx_84D_ecustom--RisksAndUncertaintiesPolicyTextBlock_zrNJxHwjrMDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_869_zOCJzQXdOYs6"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (&#x201c;NATO&#x201d;) deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Any of the above-mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely affect the Company&#x2019;s search for an initial Business Combination and any target business with which the Company may ultimately consummate an initial Business Combination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z2mXSzfQOpif" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_861_zJiXM6UsbELc"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;In November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires the disclosure of additional segment information. ASU No. 2023-07 is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted ASU 2023-07 as of the inception of the Company. Adoption of the ASU did not impact the Company&#x2019;s financial position, results of operations or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;In December&#160;2023, the FASB issued ASU 2023-09, &lt;i&gt;Income taxes&lt;/i&gt; (Topic 740): Improvements to Income Tax Disclosure (&#x201c;ASU 2023-09&#x201d;), which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 will be effective for fiscal years beginning after December&#160;15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company adopted ASU 2023-09 as of the inception of the Company. Adoption of the ASU did not impact the Company&#x2019;s financial position, results of operations or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001405">&lt;p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z0IWy53sD0Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_z1Rf2RuPJR21"&gt;Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The accompanying consolidated condensed financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
and pursuant to the rules and regulations of the SEC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Certain information and note disclosures normally
included in the annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been
condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to
make the information not misleading. The interim financial statements as of March 31, 2026 and for the three months ended March 31, 2026
are unaudited. In the opinion of management, the consolidated condensed financial statements include all adjustments, consisting only of normal
recurring adjustments, necessary to provide a fair statement of the results for the periods. The accompanying balance sheet as of December
31, 2025, is derived from the audited financial statements presented in the Company&#x2019;s Annual Report on Form 10-K for the year ended
December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <cik0002065779:EmergingGrowthCompanyPolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001407">&lt;p id="xdx_845_ecustom--EmergingGrowthCompanyPolicyTextBlock_zmhW1kdqSIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86C_zt6czdzfWEih"&gt;Emerging Growth Company&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make
comparison of the Company&#x2019;s consolidated financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001409">&lt;p id="xdx_84F_eus-gaap--UseOfEstimates_zQYZj3djUeb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_864_zRzz8424e6p3"&gt;Use of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The preparation of consolidated condensed financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the consolidated condensed financial statements and the
reported amounts of revenues and expenses during the reporting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Making estimates requires management to exercise
significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances
that existed at the date of the consolidated condensed financial statements, which management considered in formulating its estimate,
could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly
from those estimates.&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;















</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001417">&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPzrLcIyQfel" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_860_zu37CGZfznfc"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company considers all highly liquid
investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents are carried at
cost, which approximates fair value. The Company had $&lt;span id="xdx_90E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20251231_zKSiK1lJFQo5"&gt;420,340&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20260331_zBLVCNltQyz5"&gt;243,576&lt;/span&gt;
in cash as of December&#160;31, 2025 and March&#160;31, 2026, respectively. The Company had &lt;span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20251231_zHKchSeuPLR4" title="Cash equivalents"&gt;&lt;span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20260331_zbssSpEVMX26" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;
cash equivalents as of December&#160;31, 2025 and March&#160;31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001418"
      unitRef="USD">420340</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001419"
      unitRef="USD">243576</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001421"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001423"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <cik0002065779:CashHeldInTrustAccountPolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001425">&lt;p id="xdx_844_ecustom--CashHeldInTrustAccountPolicyTextBlock_zf23zmDeFAC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_863_zgMHfmHrvZ42"&gt;Cash Held in Trust Account&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company had $&lt;span id="xdx_90F_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20251231_z5sY6BBpp9d4"&gt;284,776,628&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20260331_zKMPpHYYWvXd"&gt;287,319,687&lt;/span&gt;
a of cash in the trust account held in an interest bearing demand deposit account as of December 31, 2025 and March&#160;31,
2026, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:CashHeldInTrustAccountPolicyTextBlock>
    <cik0002065779:CashHeldInTrustAccount
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001426"
      unitRef="USD">284776628</cik0002065779:CashHeldInTrustAccount>
    <cik0002065779:CashHeldInTrustAccount
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001427"
      unitRef="USD">287319687</cik0002065779:CashHeldInTrustAccount>
    <cik0002065779:OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001429">&lt;p id="xdx_84F_ecustom--OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock_z7CN7IDO18Rg" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_860_zF0eseXwdsYe"&gt;Offering Costs Associated with the Initial Public Offering&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014;
&#x201c;Expenses of Offering.&#x201d; Deferred offering costs consist principally of professional and registration fees that are related
to the Initial Public Offering. Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 470-20, &#x201c;Debt with Conversion and
Other Options,&#x201d; addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components.
The Company applies this guidance to allocate Initial Public Offering proceeds from the Public Units between Class A ordinary shares and
warrants based on their relative fair values. Offering costs allocated to the Class A ordinary shares subject to possible redemption were
charged to temporary equity, and offering costs allocated to the warrants included in the Public Units and Private Units were charged
to shareholder&#x2019;s equity as the warrants, after management&#x2019;s evaluation, were accounted for under equity treatment. As of August&#160;1,
2025, the Company had offering costs of $&lt;span id="xdx_903_ecustom--OfferingCost_iI_pp0p0_c20250801_z4hgPDFmpaOa" title="Offering costs"&gt;3,582,634&lt;/span&gt;,
consisting of $&lt;span id="xdx_901_ecustom--RepresentativeShares_c20250729__20250801_z17XWIvrJ0Ql" title="Representative shares"&gt;2,419,400&lt;/span&gt;
of the Representative Shares (as discussed in Note 1) and $&lt;span id="xdx_903_ecustom--OtherOfferingCost_pp0p0_c20250729__20250801_z3stLaw1Yk4h" title="Other offering costs"&gt;1,163,234&lt;/span&gt;
of other offering costs. Approximately $&lt;span id="xdx_90C_eus-gaap--OtherExpenses_pp0p0_c20250729__20250801_zacUbSCdNTya" title="other costs"&gt;143,775&lt;/span&gt;
of such costs were allocated to the Public Warrants and the Private Placement Units and the remainder, approximately $&lt;span id="xdx_90D_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_c20250801_z05aQ6gzdoVi" title="Ordinary shares subject to redemption"&gt;3,438,859&lt;/span&gt;
was allocated to Class A ordinary shares subject to redemption. As of December&#160;31, 2025, the Company had offering costs of $&lt;span id="xdx_900_ecustom--OfferingCost_iI_pp0p0_c20251231_zXALNb75mMuc" title="Offering costs"&gt;3,582,634&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock>
    <cik0002065779:OfferingCost
      contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001431"
      unitRef="USD">3582634</cik0002065779:OfferingCost>
    <cik0002065779:RepresentativeShares
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001433"
      unitRef="USD">2419400</cik0002065779:RepresentativeShares>
    <cik0002065779:OtherOfferingCost
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001435"
      unitRef="USD">1163234</cik0002065779:OtherOfferingCost>
    <us-gaap:OtherExpenses
      contextRef="From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001437"
      unitRef="USD">143775</us-gaap:OtherExpenses>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001439"
      unitRef="USD">3438859</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <cik0002065779:OfferingCost
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001441"
      unitRef="USD">3582634</cik0002065779:OfferingCost>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001443">&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_z77b7DWKM4ee" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86A_zVc6ABTVy162"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company complies with the accounting and reporting
requirements of ASC Topic 740, &#x201c;Income Taxes,&#x201d; which requires an asset and liability approach to financial accounting and
reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the consolidated financial
statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws
and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established,
when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;ASC Topic 740 prescribes a recognition threshold and a measurement
attribute for the consolidated financial statement recognition and measurement of tax positions taken or expected to be taken in a tax
return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.
The Company&#x2019;s management determined the British Virgin Islands is the Company&#x2019;s only major tax jurisdiction. The Company recognizes
accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were no unrecognized tax benefits
as of March 31, 2026 and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review
that could result in significant payments, accruals or material deviation from its position. The Company is considered to be an exempted
British Virgin Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income
tax filing requirements in the British Virgin Islands or the United States. As such, the provision for income taxes was deemed to be &lt;i&gt;de
minimis&lt;/i&gt; for the three months ended March 31, 2026.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;















</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ExtendedProductWarrantyPolicy
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001451">&lt;p id="xdx_840_eus-gaap--ExtendedProductWarrantyPolicy_zIfpp4pkn1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_863_zpXKgEMQKf8"&gt;Warrant Instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;We account for Warrants as either equity-classified
or liability-classified instruments based on an assessment of the instruments&#x2019; specific terms and applicable authoritative guidance
in ASC 480 and FASB ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC 815&#x201d;). The assessment considers whether the
instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to
a company&#x2019;s common shares and whether the instrument holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance
outside of a company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional
judgment, is conducted at the time of Warrant issuance and as of each subsequent quarterly period end date while the instruments are outstanding.
Upon review of the Warrant Agreement, Management concluded that the&#160;public warrants and private warrants issued pursuant to such
warrant agreement qualify for equity accounting treatment.&#160;Following the closing of the Initial Public Offering on August&#160;1,
2025 and underwriter&#x2019;s exercise of over-allotment option on August&#160;13, 2025, the Company accounted for the&#160;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331_zZXCPtdZIUn7" title="Warrants issued"&gt;14,000,000&lt;/span&gt;
public warrants and&#160;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zV9MLoZewlLk" title="Warrants issued"&gt;100,000&lt;/span&gt; private warrants issued under equity treatment at their assigned values.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ExtendedProductWarrantyPolicy>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001453"
      unitRef="Shares">14000000</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2026-03-31_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001455"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightUnissued>
    <cik0002065779:ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001457">&lt;p id="xdx_84F_ecustom--ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_zd7Gejgazmwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86B_zNHDcMFMuEE"&gt;Class A Ordinary Shares Subject to Possible Redemption&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The public shares contain
a redemption feature which allows for the redemption of such public shares in connection with the Company&#x2019;s liquidation, or if
there is a shareholder vote or tender offer in connection with the Company&#x2019;s initial Business Combination. In accordance with
ASC 480-10-S99, the Company classifies public shares subject to redemption outside of permanent equity as the redemption provisions
are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as they occur and
will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately
upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount
value. The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the
extent available) and Retained earnings. Accordingly, Class A ordinary shares subject to possible redemption are presented at
redemption value as temporary equity, outside of the shareholders&#x2019; equity section of the Company&#x2019;s balance sheet. As of
March 31, 2026 and December 31, 2025, the 28,000,000 Class A ordinary shares subject to redemption reflected in the balance sheet
are reconciled in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--TemporaryEquityTableTextBlock_zI3yMm7Bm2me" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B8_zvz98VUo83yh" style="display: none"&gt;Schedule of ordinary shares subject to redemption&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Class A ordinary shares subject to possible redemption, December 31, 2025&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_c20260101__20260331_zuYUa9ZjRBt2" style="text-align: right"&gt;284,776,628&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Plus:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top"&gt;Accretion of carrying value to redemption value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20260101__20260331_zjT475ucOqx7" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;2,543,059&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Class A ordinary shares subject to possible redemption, March 31, 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_c20260101__20260331_zXneNCCbjKKh" style="border-bottom: Black 2.5pt double; text-align: right"&gt;287,319,687&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;










&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zWhlay9HXAC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_866_zIRLAGvnsr1d"&gt;Net (Loss)/Income per Ordinary Share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share.&#x201d; Net income per share of ordinary shares is computed by dividing net income applicable to ordinary shareholders by the weighted average number of shares of ordinary shares outstanding during the period.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The Company has not considered the effect of the Warrants sold in the Offering and Private Placement to purchase an aggregate of&#160;&lt;span id="xdx_906_eus-gaap--WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_c20260101__20260331_zLwsCzFCHW3" title="Weighted average aggregate shares"&gt;14,100,000&lt;/span&gt;&#160;Class A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method and are contingent on future events. As a result, diluted income per share of Class A ordinary shares is the same as basic income per share of ordinary shares for the period presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The Company has two classes of ordinary shares,
which are referred to as Class A ordinary shares and Class B ordinary shares. Net income per share of ordinary shares is calculated by
dividing the net income by the weighted average number of shares of ordinary shares outstanding during the respective period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The following tables reflect the net (loss)/income
per share after allocating income between the shares based on outstanding shares:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z9nBryRVgBB1" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_8BC_zW0SKWND27gd" style="display: none"&gt;&#160;Schedule
    of earning per share basic and diluted&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;
Period from &lt;br/&gt;
March&#160;20, 2025
&lt;br/&gt;
(Inception) through &lt;br/&gt;
March&#160;31,&lt;br/&gt;
2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For the&lt;br/&gt;
three months ended &lt;br/&gt;
March&#160;31, &lt;br/&gt;
2026&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class A&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class B&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class A&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class B&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net income per share:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocation of (loss)/income &#x96; basic and diluted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zy8q1CRpivSl" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_900_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z2LX5LzP7HYe" title="Allocation of (loss)/income - diluted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1475"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1477"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zaYIpma7fKI5" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zUhkVNCQNGB4" title="Allocation of (loss)/income - diluted"&gt;(5,420&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0iSNiakF4xg" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zFRQnvemDvP9" title="Allocation of (loss)/income - diluted"&gt;2,011,318&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zTfMrVC9Nq08" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwCyQpQUqFfg" title="Allocation of (loss)/income - diluted"&gt;2,011,318&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted weighted average share of ordinary shares:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zaCBbKkxOUll" title="Weighted average shares of Class A ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zBiG6LXmLI06" title="Weighted average shares of Class A ordinary shares outstanding, diluted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1491"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1493"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwozb4274lpk" title="Weighted average shares of Class B ordinary shares outstanding, basic"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z4aO9n9RdMz2" title="Weighted average shares of Class B ordinary shares outstanding, diluted"&gt;10,714,286&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zngzHuVdEMLb" title="Weighted average shares of Class A ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z4D9HtOcAKq" title="Weighted average shares of Class A ordinary shares outstanding, diluted"&gt;29,200,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMgqLWjjG1Ug" title="Weighted average shares of Class B ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMDCWHjrReMl" title="Weighted average shares of Class B ordinary shares outstanding, diluted"&gt;12,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net income per share&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z38VIFVXOnne" title="Class A ordinary shares - basic net income per share"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zzqpPBahwyhi" title="Class A ordinary shares - diluted net income per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0i8nL2oW9si" title="Class B ordinary shares - basic net income per share"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z3ekJQDEjG8d" title="Class B ordinary shares - diluted net income per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zEF9ZlGITAD2" title="Class A ordinary shares - basic net income per share"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zA6RCCMfP971" title="Class A ordinary shares - diluted net income per share"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zIcku8QW2zV5" title="Class B ordinary shares - basic net income per share"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zBzYlBzAMw96" title="Class B ordinary shares - diluted net income per share"&gt;0.17&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zNWMKWxINBke" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001459">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--TemporaryEquityTableTextBlock_zI3yMm7Bm2me" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B8_zvz98VUo83yh" style="display: none"&gt;Schedule of ordinary shares subject to redemption&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Class A ordinary shares subject to possible redemption, December 31, 2025&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_c20260101__20260331_zuYUa9ZjRBt2" style="text-align: right"&gt;284,776,628&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Plus:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top"&gt;Accretion of carrying value to redemption value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20260101__20260331_zjT475ucOqx7" style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;2,543,059&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Class A ordinary shares subject to possible redemption, March 31, 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_c20260101__20260331_zXneNCCbjKKh" style="border-bottom: Black 2.5pt double; text-align: right"&gt;287,319,687&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;










</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001460"
      unitRef="USD">284776628</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001461"
      unitRef="USD">2543059</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001462"
      unitRef="USD">287319687</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001469">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zWhlay9HXAC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_866_zIRLAGvnsr1d"&gt;Net (Loss)/Income per Ordinary Share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share.&#x201d; Net income per share of ordinary shares is computed by dividing net income applicable to ordinary shareholders by the weighted average number of shares of ordinary shares outstanding during the period.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The Company has not considered the effect of the Warrants sold in the Offering and Private Placement to purchase an aggregate of&#160;&lt;span id="xdx_906_eus-gaap--WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_c20260101__20260331_zLwsCzFCHW3" title="Weighted average aggregate shares"&gt;14,100,000&lt;/span&gt;&#160;Class A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method and are contingent on future events. As a result, diluted income per share of Class A ordinary shares is the same as basic income per share of ordinary shares for the period presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The Company has two classes of ordinary shares,
which are referred to as Class A ordinary shares and Class B ordinary shares. Net income per share of ordinary shares is calculated by
dividing the net income by the weighted average number of shares of ordinary shares outstanding during the respective period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The following tables reflect the net (loss)/income
per share after allocating income between the shares based on outstanding shares:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z9nBryRVgBB1" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_8BC_zW0SKWND27gd" style="display: none"&gt;&#160;Schedule
    of earning per share basic and diluted&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;
Period from &lt;br/&gt;
March&#160;20, 2025
&lt;br/&gt;
(Inception) through &lt;br/&gt;
March&#160;31,&lt;br/&gt;
2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For the&lt;br/&gt;
three months ended &lt;br/&gt;
March&#160;31, &lt;br/&gt;
2026&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class A&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class B&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class A&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class B&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net income per share:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocation of (loss)/income &#x96; basic and diluted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zy8q1CRpivSl" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_900_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z2LX5LzP7HYe" title="Allocation of (loss)/income - diluted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1475"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1477"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zaYIpma7fKI5" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zUhkVNCQNGB4" title="Allocation of (loss)/income - diluted"&gt;(5,420&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0iSNiakF4xg" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zFRQnvemDvP9" title="Allocation of (loss)/income - diluted"&gt;2,011,318&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zTfMrVC9Nq08" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwCyQpQUqFfg" title="Allocation of (loss)/income - diluted"&gt;2,011,318&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted weighted average share of ordinary shares:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zaCBbKkxOUll" title="Weighted average shares of Class A ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zBiG6LXmLI06" title="Weighted average shares of Class A ordinary shares outstanding, diluted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1491"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1493"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwozb4274lpk" title="Weighted average shares of Class B ordinary shares outstanding, basic"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z4aO9n9RdMz2" title="Weighted average shares of Class B ordinary shares outstanding, diluted"&gt;10,714,286&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zngzHuVdEMLb" title="Weighted average shares of Class A ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z4D9HtOcAKq" title="Weighted average shares of Class A ordinary shares outstanding, diluted"&gt;29,200,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMgqLWjjG1Ug" title="Weighted average shares of Class B ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMDCWHjrReMl" title="Weighted average shares of Class B ordinary shares outstanding, diluted"&gt;12,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net income per share&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z38VIFVXOnne" title="Class A ordinary shares - basic net income per share"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zzqpPBahwyhi" title="Class A ordinary shares - diluted net income per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0i8nL2oW9si" title="Class B ordinary shares - basic net income per share"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z3ekJQDEjG8d" title="Class B ordinary shares - diluted net income per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zEF9ZlGITAD2" title="Class A ordinary shares - basic net income per share"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zA6RCCMfP971" title="Class A ordinary shares - diluted net income per share"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zIcku8QW2zV5" title="Class B ordinary shares - basic net income per share"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zBzYlBzAMw96" title="Class B ordinary shares - diluted net income per share"&gt;0.17&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001471"
      unitRef="Shares">14100000</us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001473">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z9nBryRVgBB1" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_8BC_zW0SKWND27gd" style="display: none"&gt;&#160;Schedule
    of earning per share basic and diluted&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;
Period from &lt;br/&gt;
March&#160;20, 2025
&lt;br/&gt;
(Inception) through &lt;br/&gt;
March&#160;31,&lt;br/&gt;
2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For the&lt;br/&gt;
three months ended &lt;br/&gt;
March&#160;31, &lt;br/&gt;
2026&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class A&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class B&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class A&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Class B&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net income per share:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocation of (loss)/income &#x96; basic and diluted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zy8q1CRpivSl" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_900_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z2LX5LzP7HYe" title="Allocation of (loss)/income - diluted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1475"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1477"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zaYIpma7fKI5" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zUhkVNCQNGB4" title="Allocation of (loss)/income - diluted"&gt;(5,420&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0iSNiakF4xg" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zFRQnvemDvP9" title="Allocation of (loss)/income - diluted"&gt;2,011,318&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zTfMrVC9Nq08" title="Allocation of (loss)/income - basic"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwCyQpQUqFfg" title="Allocation of (loss)/income - diluted"&gt;2,011,318&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted weighted average share of ordinary shares:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zaCBbKkxOUll" title="Weighted average shares of Class A ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zBiG6LXmLI06" title="Weighted average shares of Class A ordinary shares outstanding, diluted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1491"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1493"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwozb4274lpk" title="Weighted average shares of Class B ordinary shares outstanding, basic"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z4aO9n9RdMz2" title="Weighted average shares of Class B ordinary shares outstanding, diluted"&gt;10,714,286&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zngzHuVdEMLb" title="Weighted average shares of Class A ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z4D9HtOcAKq" title="Weighted average shares of Class A ordinary shares outstanding, diluted"&gt;29,200,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMgqLWjjG1Ug" title="Weighted average shares of Class B ordinary shares outstanding, basic"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMDCWHjrReMl" title="Weighted average shares of Class B ordinary shares outstanding, diluted"&gt;12,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net income per share&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z38VIFVXOnne" title="Class A ordinary shares - basic net income per share"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zzqpPBahwyhi" title="Class A ordinary shares - diluted net income per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0i8nL2oW9si" title="Class B ordinary shares - basic net income per share"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z3ekJQDEjG8d" title="Class B ordinary shares - diluted net income per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zEF9ZlGITAD2" title="Class A ordinary shares - basic net income per share"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zA6RCCMfP971" title="Class A ordinary shares - diluted net income per share"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zIcku8QW2zV5" title="Class B ordinary shares - basic net income per share"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zBzYlBzAMw96" title="Class B ordinary shares - diluted net income per share"&gt;0.17&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001479"
      unitRef="USD">-5420</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001481"
      unitRef="USD">-5420</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001483"
      unitRef="USD">2011318</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001485"
      unitRef="USD">2011318</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001487"
      unitRef="USD">2011318</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001489"
      unitRef="USD">2011318</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001495"
      unitRef="Shares">10714286</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001497"
      unitRef="Shares">10714286</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001499"
      unitRef="Shares">29200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001501"
      unitRef="Shares">29200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001503"
      unitRef="Shares">12000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001505"
      unitRef="Shares">12000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001507"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001509"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001511"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-03-202025-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001513"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001515"
      unitRef="USDPShares">0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001517"
      unitRef="USDPShares">0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001519"
      unitRef="USDPShares">0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001521"
      unitRef="USDPShares">0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001523">&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zKmI21KJxxNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_864_zHGfCbGDFHJ"&gt;Concentration of credit risk&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Financial instruments that potentially subject
the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the
Federal depository insurance coverage of $&lt;span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20260331_zpCvUwnIYIca" title="FDIC Insured Amount"&gt;250,000&lt;/span&gt;.
At December&#160;31, 2025 and March&#160;31, 2026, the Company had not experienced losses on this account and management believes the
Company is not exposed to significant risks on such account.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001525"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001527">&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zCslz5Xo6Ob6" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_867_zDDHritlLFyi"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;














</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <cik0002065779:RisksAndUncertaintiesPolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001535">&lt;p id="xdx_84D_ecustom--RisksAndUncertaintiesPolicyTextBlock_zrNJxHwjrMDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_869_zOCJzQXdOYs6"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (&#x201c;NATO&#x201d;) deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Any of the above-mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely affect the Company&#x2019;s search for an initial Business Combination and any target business with which the Company may ultimately consummate an initial Business Combination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001537">&lt;p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z2mXSzfQOpif" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_861_zJiXM6UsbELc"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;In November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires the disclosure of additional segment information. ASU No. 2023-07 is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted ASU 2023-07 as of the inception of the Company. Adoption of the ASU did not impact the Company&#x2019;s financial position, results of operations or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;In December&#160;2023, the FASB issued ASU 2023-09, &lt;i&gt;Income taxes&lt;/i&gt; (Topic 740): Improvements to Income Tax Disclosure (&#x201c;ASU 2023-09&#x201d;), which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 will be effective for fiscal years beginning after December&#160;15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company adopted ASU 2023-09 as of the inception of the Company. Adoption of the ASU did not impact the Company&#x2019;s financial position, results of operations or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cik0002065779:InitialPublicOfferingDisclosureTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001539">&lt;p id="xdx_800_ecustom--InitialPublicOfferingDisclosureTextBlock_zxUzX7SDLfn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 3. &lt;span id="xdx_82D_zIv3avamgFu2"&gt;INITIAL PUBLIC OFFERING&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;On August&#160;1, 2025, the Company consummated its Initial Public Offering of &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_ziiKEuBh8qWg" title="Sale of units in initial public offering"&gt;25,000,000&lt;/span&gt; Units, at $&lt;span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z7BSNxGdjR2d" title="Sale of units per share"&gt;10.00&lt;/span&gt; per Unit, generating gross proceeds of $&lt;span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z7xJdTWIQs8j" title="Sale of units in initial public offering aggragate amount"&gt;250,000,000&lt;/span&gt;. The Company granted the underwriter a 45-day option to purchase up to an additional &lt;span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zi3AGJrNogke" title="Sale of units in initial public offering"&gt;3,750,000&lt;/span&gt; Units at the Initial Public Offering price to cover over-allotments, if any. On August&#160;11, 2025, the underwriters of the IPO notified the Company of their partial exercise of the over-allotment option and purchased &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zaK7CJ35Z6P" title="Sale of units in initial public offering"&gt;3,000,000&lt;/span&gt; additional units (the &#x201c;Option Units&#x201d;) at $&lt;span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zdx2OOuJjDy3" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit upon the closing of the over-allotment option, generating gross proceeds of $&lt;span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zzL7qvdcW5v5" title="Sale of units in initial public offering aggragate amount"&gt;30,000,000&lt;/span&gt;. On September 9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option. Each Unit consists of one Ordinary Share and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zywvxCggRqMi" title="Share price"&gt;11.50&lt;/span&gt; per share, subject to adjustment.&lt;/p&gt;












</cik0002065779:InitialPublicOfferingDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001541"
      unitRef="Shares">25000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001543"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001545"
      unitRef="USD">250000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001547"
      unitRef="Shares">3750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001549"
      unitRef="Shares">3000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001551"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001553"
      unitRef="USD">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SharePrice
      contextRef="AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001555"
      unitRef="USDPShares">11.50</us-gaap:SharePrice>
    <cik0002065779:PrivatePlacementDisclosureTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001562">&lt;p id="xdx_801_ecustom--PrivatePlacementDisclosureTextBlock_zNIFkS0LzBs2" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 4. &lt;span id="xdx_828_zdpqfBsTh2A9"&gt;PRIVATE PLACEMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zWpVriUo9y18" title="Sale of units in initial public offering"&gt;200,000&lt;/span&gt; Private Units at a price of $&lt;span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zF0n5WVwkcP5" title="Sale of units per share"&gt;10.00&lt;/span&gt; per Placement Unit raising $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zld7xUyBfm51" title="Sale of units in initial public offering aggragate amount"&gt;2,000,000&lt;/span&gt; in the aggregate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The proceeds from the sale of the Private Units were added to the net proceeds from the Offering held in the Trust Account. The Placement Units are identical to the Units sold in the Initial Public Offering, as described in Note 7. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Warrants will expire worthless.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:PrivatePlacementDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001564"
      unitRef="Shares">200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001566"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001568"
      unitRef="USD">2000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001570">&lt;p id="xdx_803_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zpNHGTe8sIDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 5. &lt;span id="xdx_82C_z82mcy6I8tZ8"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;Founder Shares&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;On March&#160;25, 2025, the Company issued an aggregate
of &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250301__20250325__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zMVgGcUrVxOe"&gt;12,321,429
&lt;/span&gt;founder shares to the Sponsor for an aggregate purchase price of $&lt;span id="xdx_90F_eus-gaap--Cash_iI_c20250325__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_z6RLEudCp3Uj"&gt;25,000
&lt;/span&gt;in cash. The funds were received on May&#160;27, 2025. Following the partial exercise of the over-allotment option on August 11,
2025, on September 9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option
and thereby forfeit the option. As a result, on September 9, 2025, the Company cancelled a total of &lt;span id="xdx_909_ecustom--CancelledFounderShares_c20250905__20250909_zTcSZxGrsg3e" title="Cancelled founder shares"&gt;321,429
&lt;/span&gt;founder shares. As of March&#160;31, 2026, sponsor held a total of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zF5BsS2pB1Sd"&gt;12,000,000
&lt;/span&gt;founder shares and none was subject to forfeiture.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The founder shares are designated as Class B
ordinary shares and, except as described below, are identical to the Class A ordinary shares included in the units being sold in the
IPO, and holders of founder shares have the same shareholder rights as public shareholders, except that (i) the founder shares are
subject to certain transfer restrictions, as described in more detail below, (ii) the founder shares are entitled to registration
rights; (iii) our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed
to (A) waive their redemption rights with respect to their founder shares, private shares and public shares in connection with the
completion of our initial business combination, (B) waive their redemption rights with respect to their founder shares, private
shares and public shares in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and
articles of association (a) to modify the substance or timing of our obligation to allow redemption in connection with our initial
business combination or to redeem &lt;span id="xdx_90D_ecustom--PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination_dp_c20260101__20260331_zXCLnhDFZiBd" title="Percentage of redemption of public shares"&gt;100&lt;/span&gt;%
of our public shares if we have not consummated an initial business combination within the completion window or (b) with respect to
any other material provisions relating to shareholders&#x2019; rights or pre-initial business combination activity, (C) waive their
rights to liquidating distributions from the trust account with respect to their founder shares and private shares if we fail to
complete our initial business combination within the completion window, although they will be entitled to liquidating distributions
from the trust account with respect to any public shares they hold if we fail to complete our initial business combination within
such time period and to liquidating distributions from assets outside the trust account and (D) vote any founder shares held by them
and any public shares they may purchase (including in open market and privately-negotiated transactions) in favor of our initial
business combination (except that any public shares such parties may purchase in compliance with the requirements of Rule&#160;14e-5
under the Exchange Act would not be voted in favor of approving the business combination transaction), (iv) the founder shares are
automatically convertible into Class A ordinary shares concurrently with or immediately following the consummation of our initial
business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment as described herein and in
our amended and restated memorandum and articles of association, and (v) prior to the closing of our initial business combination,
only holders of our Class B ordinary shares will be entitled to vote on the appointment and removal of directors or continuing the
company in a jurisdiction outside the British Virgin Islands (including any ordinary resolution required to amend our constitutional
documents or to adopt new constitutional documents, in each case, as a result of our approving a transfer by way of continuation in
a jurisdiction outside the British Virgin Islands).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;With certain limited exceptions, the founder shares are not transferable, assignable or saleable (except to our officers and directors and other persons or entities affiliated with our sponsor, each of whom will be subject to the same transfer restrictions) until the completion of our initial business combination.&lt;/p&gt;




















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;Administrative Services Arrangement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;An affiliate of our Sponsor has agreed, commencing
from the date that the Company&#x2019;s securities are first listed on Nasdaq, through the earlier of the Company&#x2019;s consummation
of a Business Combination and its liquidation, to make available to the Company our Sponsor certain office space, utilities and secretarial
and administrative support as may be reasonably required by the Company. The Company has agreed to pay to the affiliate of our Sponsor,
$&lt;span id="xdx_90C_eus-gaap--PaymentsOfDistributionsToAffiliates_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zQldRVTZCDxg"&gt;20,000
&lt;/span&gt;per month, for up to 18 months, subject to extension to up to 21 months, for such administrative services. For the three months ended March&#160;31, 2026, $&lt;span id="xdx_908_eus-gaap--AdministrativeFeesExpense_c20260101__20260331_zjj5mvpwbgkc"&gt;60,000
&lt;/span&gt; was charged to operations and no amounts were outstanding at March 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;Related Party Loans&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;In order to finance transaction costs in connection with a Business Combination, the Company&#x2019;s Sponsor or an affiliate of the Sponsor, or the Company&#x2019;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#x201c;Working Capital Loans&#x201d;). Up to $&lt;span id="xdx_904_eus-gaap--DebtConversionOriginalDebtAmount1_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z58fA98SjFOl" title="Conversion of debt"&gt;2,500,000&lt;/span&gt; of such loans may be convertible into private units, at a price of $&lt;span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zuLJDC7MopX3" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit, at the option of the applicable lender. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of March&#160;31, 2026, no amounts under such loans have been drawn.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;Representative Shares&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;On August&#160;1, 2025, the Company issued &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z6QXz08pyPJ3" title="Number of share issued"&gt;1,000,000&lt;/span&gt;
representative shares to D. Boral Capital, LLC and/or its designees (whether or not the over-allotment is exercised) as part of
representative compensation (the &#x201c;Representative Shares&#x201d;). The Representative Shares have been deemed compensation by
FINRA and are therefore subject to a lock-up for a period of 180 days immediately following the commencement of sales of the IPO
pursuant to FINRA Rule&#160;5110(e)(1). Pursuant to this FINRA lock-up, these securities cannot be sold, transferred, assigned,
pledged or hypothecated or the subject of any hedging, short sale, derivative, put or call transaction that would result in the
economic disposition of the securities by any person for a period of 180 days from the commencement of sales of the Initial Public
Offering except as permitted under FINRA Rule&#160;5110(e)(2), including to any underwriter and selected dealer participating in the
Initial Public Offering and their officers or partners, registered persons or affiliates. The Representative Shares have resale
registration rights including two demand (one at the Company&#x2019;s expense and one at D. Boral Capital, LLC&#x2019;s expense) and
unlimited &#x201c;piggy-back&#x201d; rights for periods of five and seven years, respectively, from the commencement of sales of the
Initial Public Offering.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-012025-03-25_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001571"
      unitRef="Shares">12321429</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:Cash
      contextRef="AsOf2025-03-25_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001572"
      unitRef="USD">25000</us-gaap:Cash>
    <cik0002065779:CancelledFounderShares
      contextRef="From2025-09-052025-09-09_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001574"
      unitRef="Shares">321429</cik0002065779:CancelledFounderShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2026-01-012026-03-31_custom_FounderMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001575"
      unitRef="Shares">12000000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <cik0002065779:PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001577"
      unitRef="Ratio">1</cik0002065779:PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination>
    <us-gaap:PaymentsOfDistributionsToAffiliates
      contextRef="From2026-01-012026-03-31_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001585"
      unitRef="USD">20000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:AdministrativeFeesExpense
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001586"
      unitRef="USD">60000</us-gaap:AdministrativeFeesExpense>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2026-01-012026-03-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001588"
      unitRef="USD">2500000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-03-31_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001590"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-292025-08-01_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001592"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001594">&lt;p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z3K0SX2d4Sw9" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 6. &lt;span id="xdx_82F_zdVOlujD2uBh"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;Registration Rights&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The holders of the (i) founder shares, which were issued in a private placement prior to the closing of the initial public offering, (ii) Private Units (including the component securities as well as any securities underlying those component securities), which was issued in a private placement simultaneously with the closing of the initial public offering and (iii) private units (including the component securities as well as any securities underlying those component securities) that may be issued upon conversion of working capital loans will have registration rights to require the Company to register a sale of any of our securities held by them and any other securities of the company acquired by them prior to the consummation of a Business Combination pursuant to a registration rights agreement to be signed prior to or on the effective date of the initial public offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#x201c;piggy-back&#x201d; registration rights with respect to registration statements filed subsequent to the completion of the Business Combination. The registration rights granted to the underwriter are limited to two demand (one at the Company&#x2019;s expense and one at D. Boral Capital, LLC&#x2019;s expense) and unlimited &#x201c;piggy-back&#x201d; rights for periods of five and seven years, respectively, from the commencement of sales of the Initial Public Offering. The Company will bear the expenses incurred in connection with the filing of any such registration statements.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;Underwriting Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company has granted the underwriters a 45-day option to purchase up to &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zjtEhPvhMXQe" title="Option granted"&gt;3,750,000&lt;/span&gt; additional Units to cover over-allotments at the Initial Public Offering price, less the underwriting discounts and commissions. On August 11, 2025, the underwriters of the IPO notified the Company of their partial exercise of the over-allotment option and purchased &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zR7wbwMpc9wh" title="Sale of units in initial public offering"&gt;3,000,000&lt;/span&gt; additional units (the &#x201c;Option Units&#x201d;) at $&lt;span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zGqMeTvcqykf" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit upon the closing of the over-allotment option, generating gross proceeds of $&lt;span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zbSfvKxgSk01" title="Sale of units in initial public offering aggragate amount"&gt;30,000,000&lt;/span&gt;. On September 9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The underwriters were not entitled to any cash underwriting fee at closing of the Initial Public Offering. The underwriters were entitled to &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zFQcKs3SbWef" title="Number of share issued"&gt;1,000,000&lt;/span&gt; Representative Shares (whether or not the over-allotment is exercised) at closing of the Initial Public Offering. The underwriters will not be entitled to any deferred underwriting fee upon closing of the Business Combination.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2026-01-012026-03-31_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001603"
      unitRef="Shares">3750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001605"
      unitRef="Shares">3000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001607"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-08-022025-08-11_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001609"
      unitRef="USD">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-01-012026-03-31_us-gaap_IPOMember_custom_UnderwriterMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001611"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001613">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwhUP6jv9mqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 7. &lt;span id="xdx_823_zaILIlDlzmsc"&gt;STOCKHOLDER&#x2019;S EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;i&gt;Preference shares&lt;/i&gt; &#x2014; The Company is
authorized to issue &lt;span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331_zFMVgjM8NmY9" title="Preferred stock, shares authorized"&gt;&lt;span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_c20251231_z0Jl6MArvzB9" title="Preferred stock, shares authorized"&gt;5,000,000&lt;/span&gt;&lt;/span&gt;
preference shares with a par value of $&lt;span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260331_zAytd7i2p886" title="Preferred stock, par value"&gt;&lt;span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_c20251231_zfL19UEBgrDa" title="Preferred stock, par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt;
per share. Holders of the Company&#x2019;s ordinary shares are entitled to one vote for each share. On December&#160;31, 2025 and
March&#160;31, 2026, there were &lt;span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_do_c20260331_zroPfs1eRoNk" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20260331_z9d8GSit2B5" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_do_c20251231_zMEOzupxxnI8" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20251231_zyzADJxkUXd2" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
preferred shares issued or outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;i&gt;Class A Ordinary shares&lt;/i&gt; &#x2014; The
Company is authorized to issue &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zKveQpajq4V5"&gt;&lt;span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zskfIMqX190e"&gt;500,000,000&lt;/span&gt; &lt;/span&gt;ordinary
shares with a par value of $&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zdRFWPvGhFOd"&gt;&lt;span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zjY855rQwcpd"&gt;0.0001&lt;/span&gt; &lt;/span&gt;per
share. Holders of the Company&#x2019;s ordinary shares are entitled to one vote for each share. As a result of closing of the IPO and
the partial exercise of the over-allotment option partial exercise of the over-allotment option, on December&#160;31, 2025 and March&#160;31,
2026, there were &lt;span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zxB3PXFsHCU5"&gt;&lt;span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zsLdgforxL9e"&gt;&lt;span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zxt2nAqbsMr9"&gt;&lt;span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_z4vLyiaVVyR6"&gt;1,200,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;Class
A ordinary shares issued or outstanding, excluding &lt;span id="xdx_904_ecustom--OrdinarySharesSubjectToPossibleRedemption_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinaryShareMember_zMl1aYF2ihsk"&gt;&lt;span id="xdx_90C_ecustom--OrdinarySharesSubjectToPossibleRedemption_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zVJMl0G8IzV"&gt;28,000,000&lt;/span&gt; &lt;/span&gt;Class
A ordinary shares subject to possible redemption.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;i&gt;Class B Ordinary shares&lt;/i&gt; &#x2014; The
Company is authorized to issue &lt;span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zXVGRwMjVDql"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zMMZnne8IkL6"&gt;50,000,000&lt;/span&gt; &lt;/span&gt;ordinary
shares with a par value of $&lt;span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_ztG2sNw8sNFl"&gt;&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zED6jktrmjAl"&gt;0.0001&lt;/span&gt; &lt;/span&gt;per
share. Holders of the Company&#x2019;s ordinary shares are entitled to one vote for each share. On March&#160;25, 2025, the Company
issued an aggregate of &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250301__20250325__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zRVwJpN6yZVk"&gt;12,321,429 &lt;/span&gt;ordinary
shares to the Sponsor for an aggregate purchase price of $&lt;span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20250325_zAFxq56sMRg6"&gt;25,000 &lt;/span&gt;in
cash, of which &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20250301__20250325__us-gaap--StatementEquityComponentsAxis__custom--ClassAOrdinarySharesMember_znPFdJkwaY27"&gt;1,607,143 &lt;/span&gt;shares
held by the Sponsor are subject to forfeiture to the extent that the underwriter&#x2019;s over-allotment option is not exercised in
full. Following the partial exercise of the over-allotment option on August 11, 2025 and cancellation &lt;span id="xdx_901_ecustom--CancellationOfOrdinaryShares_iI_c20250811_zKYsRghvexAh" title="Cancellation of ordinary shares"&gt;321,429&lt;/span&gt;
ordinary shares on September 9, 2025, on December&#160;31, 2025 and March&#160;31, 2026, there were &lt;span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zKBpaz3TRFH" title="Common stock, shares issued"&gt;&lt;span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zIOANVibuum3" title="Common stock, shares outstanding"&gt;12,000,000&lt;/span&gt;&lt;/span&gt;
ordinary &lt;span style="display: none"&gt;12,300,000&lt;/span&gt;shares issued and outstanding.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of our initial business combination, or at any time prior thereto at the option of the holder thereof, on a one-for-one basis, subject to adjustment as provided herein. Because our sponsor acquired the Class B ordinary shares at a nominal price, our public shareholders will incur an immediate and substantial dilution upon the closing of the IPO, assuming no value is ascribed to the warrants included in the units. In the case that additional Class A ordinary shares, or equity-linked securities (as described herein), are issued or deemed issued in excess of the amounts issued in the IPO and related to the closing of our initial business combination, the ratio at which the Class B ordinary shares will convert into Class A ordinary shares will be adjusted (unless the holders of a majority of the issued and outstanding Class B ordinary shares agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance) so that the number of Class A ordinary shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, &lt;span id="xdx_909_ecustom--PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion_iI_dp_c20260331__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--ConversionOfClassBToClassACommonStockMember_zszikt6CRcY8" title="Percentage of total number of ordinary shares"&gt;30&lt;/span&gt;% of the sum of (i) the total number of all Class A ordinary shares outstanding upon the completion of the IPO (including any Class A ordinary shares issued pursuant to the underwriters&#x2019; over-allotment option and excluding the Class A ordinary shares that are included within the private units), plus (ii) all Class A ordinary shares and equity-linked securities issued or deemed issued, in connection with the closing of the initial business combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the initial business combination and any units issued to our sponsor or any of its affiliates or to our officers or directors upon conversion of working capital loans) minus (iii) any redemptions of Class A ordinary shares by public shareholders in connection with an initial business combination; provided that such conversion of founder shares will never occur on a less than &lt;span id="xdx_903_eus-gaap--CommonStockConversionBasis_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--CommonStockClassBMember_zkHKuUlOOCQg" title="Conversion basis"&gt;one-for-one basis&lt;/span&gt;.&lt;/p&gt;





















&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;Holders of record of the Company&#x2019;s Class A ordinary shares and Class B ordinary shares are entitled to one vote for each share held on all matters to be voted on by shareholders. Unless specified in the amended and restated memorandum and articles of association or as required by the Companies Act or stock exchange rules, an ordinary resolution under British Virgin Islands law and the amended and restated memorandum and articles of association, which requires the affirmative vote of at least a majority of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the company is generally required to approve any matter voted on by the Company&#x2019;s shareholders. Approval of certain actions require an ordinary resolution under British Virgin Islands law, which (except as specified below) requires the affirmative vote of in excess of 50 percent of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting, and pursuant to the Company&#x2019;s amended and restated memorandum and articles of association, such actions include amending the amended and restated memorandum and articles of association and approving a statutory merger or consolidation with another company. There is no cumulative voting with respect to the appointment of directors, meaning, following the Company&#x2019;s initial Business Combination, the holders of more than 50% of the ordinary shares voted for the appointment of directors can elect all of the directors. Prior to the consummation of the initial Business Combination, only holders of the Class B ordinary shares will (i) have the right to vote on the appointment and removal of directors and (ii) be entitled to vote on continuing the Company in a jurisdiction outside the British Virgin Islands (including any ordinary resolution required to amend the constitutional documents or to adopt new constitutional documents, in each case, as a result of approving a transfer by way of continuation in a jurisdiction outside the British Virgin Islands). Holders of the Class A ordinary shares will not be entitled to vote on these matters during such time. These provisions of our amended and restated memorandum and articles of association may only be amended if approved by an ordinary resolution passed by the affirmative vote of the holders representing at least 90% of the issued Class B ordinary shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;i&gt;Warrants &#x2014; &lt;/i&gt;Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Warrants. The Warrants will become exercisable &lt;span id="xdx_90C_ecustom--PeriodAfterWhichTheWarrantsAreExercisable_dtD_c20260101__20260331_zWeApScMc3eb" title="Period of warrants exercisable"&gt;30&lt;/span&gt; days after the completion of our initial business combination, provided that the Company has an effective registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or we permit holders to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement). If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th business day after the closing of our initial business combination, warrant holders may, until such time as there is an effective registration statement and during any period when we will have failed to maintain an effective registration statement, exercise warrants on a &#x201c;cashless basis&#x201d; in accordance with Section&#160;3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if our Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a &#x201c;covered security&#x201d; under Section&#160;18(b)(1) of the Securities Act, we may, at our option, require holders of public warrants who exercise their warrants to do so on a &#x201c;cashless basis&#x201d; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event we so elect, we will not be required to file or maintain in effect a registration statement. The Warrants will expire five years from the consummation of a Business Combination or earlier upon redemption or liquidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company may call the Warrants for redemption:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;in whole and not in part;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;at a price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zoNP9mOnjT3c" title="Warrant price"&gt;0.01&lt;/span&gt; per warrant; upon a minimum of &lt;span id="xdx_90D_ecustom--MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants_dtD_c20260101__20260331_zOnTLMGfRTZ7" title="Holders of warrants"&gt;30&lt;/span&gt; days&#x2019; prior written notice of redemption (the &#x201c;30-day redemption period&#x201d;); and&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;if, and only if, the closing price of the Class A ordinary shares equals or exceeds $&lt;span id="xdx_909_eus-gaap--SharePrice_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zJ9mqOJX3QCl" title="Share price"&gt;18.00&lt;/span&gt; per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant) for any &lt;span id="xdx_900_ecustom--NumberOfTradingDaysForDeterminingTheSharePrice_dtD_c20260101__20260331_zvrNRerpdBn3" title="Number of trading days"&gt;20&lt;/span&gt; trading days within a &lt;span id="xdx_906_ecustom--NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_dtD_c20260101__20260331_zwbDb1yUTWP9" title="Number of consecutive trading days"&gt;30&lt;/span&gt;-trading day period commencing at least 30 days after completion of our initial business combination and ending three business days before we send the notice of redemption to the warrant holders.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;






















&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The private warrants are identical to the warrants sold in the IPO except that, so long as they are held by our sponsor or its permitted transferees, the private warrants (i) are locked-up until the completion of our initial business combination and (ii) will be entitled to registration rights.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#x2019;s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The exercise price is $11.50 per share, subject to adjustment as described herein. In addition, if (x) we issue additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price to be determined in good faith by our board of directors and, in the case of any such issuance to our initial shareholders or their affiliates, without taking into account any founder shares held by our initial shareholders or such affiliates, as applicable, prior to such issuance) (the &#x201c;Newly Issued Price&#x201d;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination on the date of the consummation of our initial business combination (net of redemptions), and (z) the volume weighted average trading price of our Class A ordinary shares during the &lt;span id="xdx_905_ecustom--NumberOfTradingDaysForDeterminingTheSharePrice_dtD_c20260101__20260331_zc5q1DDThXIl" title="Number of trading days"&gt;20&lt;/span&gt; trading day period starting on the trading day prior to the day on which we consummate our initial business combination (such price, the &#x201c;Market Value&#x201d;) is below $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331_zs54CHaUkD4i" title="Warrants exercise price"&gt;9.20&lt;/span&gt; per share, then the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to &lt;span id="xdx_904_eus-gaap--AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate_iI_dp_c20260331_zv6Vv7qifSKb" title="Market value"&gt;115&lt;/span&gt;% of the higher of the Market Value and the Newly Issued Price, and the $&lt;span id="xdx_90C_eus-gaap--PreferredStockRedemptionPricePerShare_iI_c20260331_zBQoRodwKOZj" title="Redemption price"&gt;18.00&lt;/span&gt; per share redemption trigger prices will be adjusted (to the nearest cent) to be equal to &lt;span id="xdx_900_ecustom--ShareRedemptionTriggerPrices_iI_dp_c20260331_zxXMTxXeNMw5" title="Share redemption trigger prices"&gt;180&lt;/span&gt;% of the higher of the Market Value and the Newly Issued Price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001615"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001617"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001619"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001621"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001623"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001625"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001627"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001629"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001630"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001631"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001632"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001633"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001634"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001635"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001636"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001637"
      unitRef="Shares">1200000</us-gaap:CommonStockSharesOutstanding>
    <cik0002065779:OrdinarySharesSubjectToPossibleRedemption
      contextRef="AsOf2025-12-31_custom_ClassAOrdinaryShareMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001638"
      unitRef="USD">28000000</cik0002065779:OrdinarySharesSubjectToPossibleRedemption>
    <cik0002065779:OrdinarySharesSubjectToPossibleRedemption
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001639"
      unitRef="USD">28000000</cik0002065779:OrdinarySharesSubjectToPossibleRedemption>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001640"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001641"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001642"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001643"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-012025-03-25_custom_SponsorMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001644"
      unitRef="Shares">12321429</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-25_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001645"
      unitRef="USD">25000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2025-03-012025-03-25_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001646"
      unitRef="Shares">1607143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <cik0002065779:CancellationOfOrdinaryShares
      contextRef="AsOf2025-08-11_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001648"
      unitRef="Shares">321429</cik0002065779:CancellationOfOrdinaryShares>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001650"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001652"
      unitRef="Shares">12000000</us-gaap:CommonStockSharesOutstanding>
    <cik0002065779:PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion
      contextRef="AsOf2026-03-31_custom_ConversionOfClassBToClassACommonStockMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001654"
      unitRef="Ratio">0.30</cik0002065779:PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion>
    <us-gaap:CommonStockConversionBasis
      contextRef="From2026-01-012026-03-31_custom_CommonStockClassBMember_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001656">one-for-one basis</us-gaap:CommonStockConversionBasis>
    <cik0002065779:PeriodAfterWhichTheWarrantsAreExercisable
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001665">P30D</cik0002065779:PeriodAfterWhichTheWarrantsAreExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_WarrantsMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001667"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cik0002065779:MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001669">P30D</cik0002065779:MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants>
    <us-gaap:SharePrice
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001671"
      unitRef="USDPShares">18.00</us-gaap:SharePrice>
    <cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001673">P20D</cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice>
    <cik0002065779:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001675">P30D</cik0002065779:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice>
    <cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001683">P20D</cik0002065779:NumberOfTradingDaysForDeterminingTheSharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001685"
      unitRef="USDPShares">9.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001687"
      unitRef="Ratio">1.15</us-gaap:AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001689"
      unitRef="USDPShares">18.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <cik0002065779:ShareRedemptionTriggerPrices
      contextRef="AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="INF"
      id="Fact001691"
      unitRef="Ratio">1.80</cik0002065779:ShareRedemptionTriggerPrices>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001693">&lt;p id="xdx_805_eus-gaap--FairValueDisclosuresTextBlock_zgzIFlKymks6" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 8. &lt;span id="xdx_822_zoFua9dYO0U2"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The fair value of the Company&#x2019;s financial assets and liabilities reflects management&#x2019;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in;text-align: justify"&gt;Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in;text-align: justify"&gt;Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in;text-align: justify"&gt;Level 3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The following table presents information about
the Company&#x2019;s assets that are measured at fair value as of March 31, 2026 and December&#160;31, 2025, and indicates the fair
value hierarchy of the valuation inputs the Company utilized to determine such fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zn8oEnihuBh3" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B4_zvKnFHZJudo8" style="display: none"&gt;Schedule of fair value assets and liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March&#160;31,&lt;br/&gt;
    2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Asset:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left"&gt;Cash held in trust&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;1&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zC6ecbqmxuZ2" style="width: 9%; text-align: right"&gt;284,776,628&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2BhS1HcIrvl" style="text-align: right; width: 9%"&gt;287,319,687&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zgzxRXAizoPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
















&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;


</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001696">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zn8oEnihuBh3" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B4_zvKnFHZJudo8" style="display: none"&gt;Schedule of fair value assets and liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March&#160;31,&lt;br/&gt;
    2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Asset:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left"&gt;Cash held in trust&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;1&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zC6ecbqmxuZ2" style="width: 9%; text-align: right"&gt;284,776,628&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2BhS1HcIrvl" style="text-align: right; width: 9%"&gt;287,319,687&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001697"
      unitRef="USD">284776628</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001698"
      unitRef="USD">287319687</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001703">&lt;p id="xdx_803_eus-gaap--SegmentReportingDisclosureTextBlock_zwZU5ZaBhVlh" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 9. &lt;span&gt;SEGMENT INFORMATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_822_zUpXgs0k561c" style="display: none"&gt;Segment information&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;ASC Topic 280, &#x201c;Segment Reporting,&#x201d; establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated by the Company&#x2019;s chief operating decision maker, or group, in deciding how to allocate resources and assess performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;The Company&#x2019;s chief operating decision maker has been identified as the Chief Financial Officer (&#x201c;CODM&#x201d;), who reviews the operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one operating segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;When evaluating the Company&#x2019;s performance and making key decisions regarding resource allocation the CODM reviews several key metrics, which include the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z8FE3uJgARte" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8BC_zLnzHUlq4rs8" style="display: none"&gt;Schedule of segment information&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20260101__20260331_zAqMewnjj797" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;For the&lt;br/&gt;
Three Months Ended&lt;br/&gt; March&#160;31,&lt;br/&gt;
2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingExpenses_iNT_di_zLbGcDlF4Xxk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left"&gt;Formation and operating costs&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt;(531,741&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestIncomeOther_zZ0f6IcMo791" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 2.5pt"&gt;Interest income on cash held in trust account&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt;2,543,059&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--CashHeldInTrustAccounts_zt3sLmGGM7pf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Cash held in Trust Account&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;287,319,687&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zWjH3W0mD6S6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"&gt;The key measures of segment profit or loss reviewed
by the CODM are formation and operating costs, interest income on cash held in trust account, and cash held in trust account. The CODM
reviews interest earned on cash or investments held in Trust Account to measure and monitor shareholder value and determine the most effective
strategy of investment with the Trust Account funds while maintaining compliance with the trust agreement. Within the operating expenses,
the CODM specifically reviews professional service fees, which are a significant segment expense, and include legal fees and advisory
fees. These expenses are monitored to manage and forecast cash available to complete a Business Combination within the required period.
Other general and administrative expenses, including accounting expenses, printing expenses, and regulatory filing fees, are reviewed
in the aggregate to ensure alignment with budget and contractual obligations. Funds invested in the Trust Account represent the predominant
portion of the Company&#x2019;s total assets and are monitored by the CODM to determine the most effective strategy of investment with
the Trust Account funds, while maintaining compliance with the trust agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001705">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z8FE3uJgARte" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8BC_zLnzHUlq4rs8" style="display: none"&gt;Schedule of segment information&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20260101__20260331_zAqMewnjj797" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;For the&lt;br/&gt;
Three Months Ended&lt;br/&gt; March&#160;31,&lt;br/&gt;
2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingExpenses_iNT_di_zLbGcDlF4Xxk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left"&gt;Formation and operating costs&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt;(531,741&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestIncomeOther_zZ0f6IcMo791" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 2.5pt"&gt;Interest income on cash held in trust account&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"&gt;2,543,059&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--CashHeldInTrustAccounts_zt3sLmGGM7pf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Cash held in Trust Account&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;287,319,687&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001707"
      unitRef="USD">531741</us-gaap:OperatingExpenses>
    <us-gaap:InterestIncomeOther
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001709"
      unitRef="USD">2543059</us-gaap:InterestIncomeOther>
    <cik0002065779:CashHeldInTrustAccounts
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      decimals="0"
      id="Fact001711"
      unitRef="USD">287319687</cik0002065779:CashHeldInTrustAccounts>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember"
      id="Fact001713">&lt;p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zi2Xqda1MaI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;&lt;b&gt;NOTE 10. &lt;span&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_829_zMAhencS9Vr8" style="display: none"&gt;Subsequent Events&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"&gt;In accordance with ASC Topic 855, &#x201c;Subsequent Events&#x201d;, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued, the Company has evaluated all events or transactions that occurred through the date the consolidated condensed financial statements were available to issue. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001721"
      unitRef="USD">969626</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001722"
      unitRef="USD">4231689</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001724"
      unitRef="USD">123332</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001725"
      unitRef="USD">152536</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <cik0002065779:AdvanceToSuppliers
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001727"
      unitRef="USD">280497</cik0002065779:AdvanceToSuppliers>
    <cik0002065779:AdvanceToSuppliers
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001728"
      unitRef="USD">1030761</cik0002065779:AdvanceToSuppliers>
    <cik0002065779:RefundableDepositsReceivable
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001730"
      unitRef="USD">110000</cik0002065779:RefundableDepositsReceivable>
    <cik0002065779:RefundableDepositsReceivable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001731"
      unitRef="USD">681125</cik0002065779:RefundableDepositsReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001733"
      unitRef="USD">2884694</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001734"
      unitRef="USD">1207626</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001736"
      unitRef="USD">4368149</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001737"
      unitRef="USD">7303737</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001742"
      unitRef="USD">23696</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001743"
      unitRef="USD">19600</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001745"
      unitRef="USD">23696</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001746"
      unitRef="USD">19600</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001748"
      unitRef="USD">4391845</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001749"
      unitRef="USD">7323337</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001757"
      unitRef="USD">128040</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001758"
      unitRef="USD">90015</us-gaap:AccountsPayableCurrent>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001760"
      unitRef="USD">9321564</cik0002065779:SimpleAgreementsForFutureEquity>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001761"
      unitRef="USD">18243885</cik0002065779:SimpleAgreementsForFutureEquity>
    <us-gaap:DepositContractsLiabilities
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001763"
      unitRef="USD">95326</us-gaap:DepositContractsLiabilities>
    <us-gaap:DepositContractsLiabilities
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001764"
      unitRef="USD">432760</us-gaap:DepositContractsLiabilities>
    <cik0002065779:RefundableDepositsPayable
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001766"
      unitRef="USD">223205</cik0002065779:RefundableDepositsPayable>
    <cik0002065779:RefundableDepositsPayable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001767"
      unitRef="USD">1445580</cik0002065779:RefundableDepositsPayable>
    <cik0002065779:OtherCurrentLiabilities
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001769"
      unitRef="USD">113693</cik0002065779:OtherCurrentLiabilities>
    <cik0002065779:OtherCurrentLiabilities
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001770"
      unitRef="USD">107481</cik0002065779:OtherCurrentLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001772"
      unitRef="USD">9881828</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001773"
      unitRef="USD">20319721</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001775"
      unitRef="USD">9881828</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001776"
      unitRef="USD">20319721</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001787"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001789"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001791"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001793"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001795"
      unitRef="Shares">1500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001797"
      unitRef="Shares">1500</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001799"
      unitRef="Shares">1500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001801"
      unitRef="Shares">1500</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001784"
      unitRef="USD">15</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001785"
      unitRef="USD">15</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001803"
      unitRef="USD">67370</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001804"
      unitRef="USD">220636</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001806"
      unitRef="USD">-5557368</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001807"
      unitRef="USD">-13217035</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001809"
      unitRef="USD">-5489983</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001810"
      unitRef="USD">-12996384</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001812"
      unitRef="USD">4391845</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001813"
      unitRef="USD">7323337</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001815"
      unitRef="USD">1319115</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001816"
      unitRef="USD">7015512</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001818"
      unitRef="USD">-1263548</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001819"
      unitRef="USD">-5910315</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001821"
      unitRef="USD">55567</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001822"
      unitRef="USD">1105197</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001827"
      unitRef="USD">262614</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001828"
      unitRef="USD">989155</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001830"
      unitRef="USD">273349</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001831"
      unitRef="USD">362982</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001833"
      unitRef="USD">1365433</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001834"
      unitRef="USD">2797906</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001836"
      unitRef="USD">1901396</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001837"
      unitRef="USD">4150043</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001839"
      unitRef="USD">-1845829</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001840"
      unitRef="USD">-3044846</us-gaap:OperatingIncomeLoss>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001842"
      unitRef="USD">3110518</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001843"
      unitRef="USD">4614821</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001845"
      unitRef="USD">-4956347</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001846"
      unitRef="USD">-7659667</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001851"
      unitRef="USD">-4956347</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001852"
      unitRef="USD">-7659667</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001857"
      unitRef="USDPShares">-3304.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001859"
      unitRef="USDPShares">-3304.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001861"
      unitRef="USDPShares">-5106.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001863"
      unitRef="USDPShares">-5106.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001868"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001870"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001872"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001874"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001881"
      unitRef="Shares">1500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001876"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001877"
      unitRef="USD">46266</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001878"
      unitRef="USD">-601021</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001879"
      unitRef="USD">-554740</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001885"
      unitRef="USD">-4956347</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001886"
      unitRef="USD">-4956347</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001889"
      unitRef="USD">21104</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001891"
      unitRef="USD">21104</us-gaap:ShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001898"
      unitRef="Shares">1500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001893"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001894"
      unitRef="USD">67370</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001895"
      unitRef="USD">-5557368</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001896"
      unitRef="USD">-5489983</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001902"
      unitRef="USD">-7659667</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001903"
      unitRef="USD">-7659667</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001906"
      unitRef="USD">153266</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001908"
      unitRef="USD">153266</us-gaap:ShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact001915"
      unitRef="Shares">1500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_custom_OrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001910"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001911"
      unitRef="USD">220636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001912"
      unitRef="USD">-13217035</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001913"
      unitRef="USD">-12996384</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001920"
      unitRef="USD">-4956347</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001921"
      unitRef="USD">-7659667</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001926"
      unitRef="USD">4110</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001927"
      unitRef="USD">6234</us-gaap:Depreciation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001929"
      unitRef="USD">21104</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001930"
      unitRef="USD">153266</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001932"
      unitRef="USD">3110518</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001933"
      unitRef="USD">4614821</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001938"
      unitRef="USD">123332</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001939"
      unitRef="USD">29204</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <cik0002065779:IncreaseDecreaseInAdvanceToSuppliers
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001941"
      unitRef="USD">280497</cik0002065779:IncreaseDecreaseInAdvanceToSuppliers>
    <cik0002065779:IncreaseDecreaseInAdvanceToSuppliers
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001942"
      unitRef="USD">750264</cik0002065779:IncreaseDecreaseInAdvanceToSuppliers>
    <cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001944"
      unitRef="USD">100000</cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable>
    <cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001945"
      unitRef="USD">571125</cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001947"
      unitRef="USD">-1515306</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001948"
      unitRef="USD">-1709568</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001950"
      unitRef="USD">128040</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001951"
      unitRef="USD">-38025</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001953"
      unitRef="USD">95326</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001954"
      unitRef="USD">337434</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <cik0002065779:IncreaseDecreaseInRefundableDepositsPayable
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001956"
      unitRef="USD">223205</cik0002065779:IncreaseDecreaseInRefundableDepositsPayable>
    <cik0002065779:IncreaseDecreaseInRefundableDepositsPayable
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001957"
      unitRef="USD">1222375</cik0002065779:IncreaseDecreaseInRefundableDepositsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001959"
      unitRef="USD">-198342</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001960"
      unitRef="USD">-6212</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001962"
      unitRef="USD">-560909</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001963"
      unitRef="USD">-1010799</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001968"
      unitRef="USD">27806</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001969"
      unitRef="USD">2138</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001971"
      unitRef="USD">-27806</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001972"
      unitRef="USD">-2138</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <cik0002065779:ProceedsFromSimpleAgreementsForFutureEquity
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001977"
      unitRef="USD">1285000</cik0002065779:ProceedsFromSimpleAgreementsForFutureEquity>
    <cik0002065779:ProceedsFromSimpleAgreementsForFutureEquity
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001978"
      unitRef="USD">4275000</cik0002065779:ProceedsFromSimpleAgreementsForFutureEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001980"
      unitRef="USD">1285000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001981"
      unitRef="USD">4275000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001983"
      unitRef="USD">696285</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001984"
      unitRef="USD">3262063</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001986"
      unitRef="USD">273341</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001987"
      unitRef="USD">969626</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001989"
      unitRef="USD">969626</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact001990"
      unitRef="USD">4231689</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NotesAssumed1
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002004"
      unitRef="USD">4400000</us-gaap:NotesAssumed1>
    <us-gaap:NotesAssumed1
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002005"
      unitRef="USD">32500</us-gaap:NotesAssumed1>
    <us-gaap:NatureOfOperations
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002007">&lt;p id="xdx_80E_eus-gaap--NatureOfOperations_zPEtwaHe5HV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;1. &lt;span id="xdx_821_zp6MNea2BKv9"&gt;Organization and principal activities&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June&#160;1, 2022, Exascale Labs Inc. (the &#x201c;Company&#x201d;)
was formally incorporated in the State of Delaware. In accordance with the Company&#x2019;s Certificate of Incorporation, the Company is
authorized to issue &lt;span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20220601_zokPjcfKfLZ4" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt; shares of ordinary shares, with a par value of $&lt;span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220701_zXzvDlrClWQ5" title="Common stock, par value"&gt;0.01&lt;/span&gt; per share, all in a single class. The governance structure
of the Company stipulates that the business and affairs of the Company shall be managed by or under the direction of its board of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is a next-generation AI infrastructure
provider operating an asset-light, software-defined GPU compute platform and related AI infrastructure solutions. Exascale&#x2019;s core
business includes GaaS, through which it provides reserved and on-demand access to high-performance GPU compute capacity sourced from
third-party data centers globally, as well as GPU cluster management and optimization services for AIDC operators. In addition, Exascale
has developed certain modular data center, high-density liquid cooling, HVDC power and energy storage solutions that are designed to address
deployment bottlenecks in AI infrastructure and that Exascale believes are ready for commercial engagement, although these capabilities
have not yet generated revenue as of the date of this proxy statement/prospectus. The platform is purpose-built for large-scale AI workloads,
including LLM training, fine-tuning, and high-concurrency inference.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January&#160;2026, the Company adopted an Amended
and Restated Certificate of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#x2019;s
equity is divided into 303 Class A ordinary shares and 1,197 Class B ordinary shares, which are entitled to one (1) vote and twenty (20)
votes per share, respectively. Despite the differential in voting power, Class A and Class B ordinary shares rank pari passu in all other
respects, sharing ratably in dividends and any distributions upon liquidation. Furthermore, all outstanding Simple Agreements for Future
Equity (&#x201c;SAFEs&#x201d;) are designated to convert or settle exclusively into Class A ordinary shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January&#160;2026, the Company entered into an
Agreement and Plan of Merger (&#x201c;BCA&#x201d;) with D. Boral ARC Acquisition I Corp.(&#x201c;BCAR&#x201d;), a publicly traded special
purpose acquisition company (&#x201c;SPAC&#x201d;), D. Boral ARC Merger Corporation, a Delaware corporation and a direct, wholly owned subsidiary
of BCAR and D. Boral Arc Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary of BCAR. Upon closing of the transaction,
the combined company will be named Exascale Labs Holdings Inc.(such surviving company, &#x201c;PubCo&#x201d;) and is expected to be traded
on a national securities exchange.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-06-01_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002009"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-07-01_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002011"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002013">&lt;p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zly3FShCFXe3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;2. &lt;span id="xdx_826_znoSd0puRsll"&gt;Summary of significant accounting policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--GoingConcernPolicyTextBlock_zorhFCi8emlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;a. &lt;span id="xdx_864_z1YlhGMWNLQ3"&gt;Going concern&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June&#160;30, 2025, the Company had cash
and cash equivalents of $4.2 million &lt;span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20250630_zP8AepDgmXQ1" style="display: none" title="Cash and cash equivalents"&gt;4,231,689&lt;/span&gt;
and current liabilities of $20.3 &lt;span id="xdx_902_eus-gaap--LiabilitiesCurrent_iI_c20250630_z4jwfecaN8A1" style="display: none" title="Current liabilities"&gt;20,319,721&lt;/span&gt;
million. For the years ended June&#160;30, 2024 and 2025, the Company used $0.6 &lt;span title="Net losses"&gt;&lt;span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20230701__20240630_zimEv9wUsnDk" style="display: none" title="Cash for operating activities"&gt;(560,909)&lt;/span&gt;
million and $1.0 &lt;span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20240701__20250630_zVTfCY856dug" style="display: none" title="Cash for operating activities"&gt;(1,010,799)&lt;/span&gt;
million in cash for operating activities, and incurred net losses of $5.0 &lt;span id="xdx_901_eus-gaap--NetIncomeLoss_c20230701__20240630_zVEtJqHinOV8" style="display: none" title="Net losses"&gt;(4,956,347)&lt;/span&gt;
million and $7.7 &lt;span id="xdx_903_eus-gaap--NetIncomeLoss_c20240701__20250630_zUawJwOLj0Yh" style="display: none" title="Net losses"&gt;(7,659,667)&lt;/span&gt;
million, respectively. The Company has incurred recurring net losses from operations and negative cash flows from operating
activities since inception. As of June&#160;30, 2025, the Company had an accumulated deficit of $13.2
&lt;span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20250630_zuIwST4zPt2k" style="display: none" title="Accumulated deficit"&gt;(13,217,035)&lt;/span&gt; million. These factors raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern
within one year of the date these financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management has formulated and is actively pursuing
plans to mitigate these conditions and secure the Company&#x2019;s continued operations. In connection with the Company&#x2019;s contemplated
business combination with a SPAC and related financing activities, the Company expects to access additional capital through external funding
sources. In addition, the Company continues to focus on expanding its market presence and developing client relationships to drive revenue
growth, while managing operating expenses, with the objective of improving cash flows from operations over time.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For purposes of this disclosure, &#x201c;SPAC&#x201d;
refers to a special purpose acquisition company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more operating businesses. &#x201c;De-SPAC&#x201d; refers to the business combination transaction
pursuant to which an operating company combines with a SPAC, following which the combined company becomes publicly listed (or otherwise
succeeds to the SPAC&#x2019;s public company status).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s negative working capital position
is primarily attributable to the classification of SAFEs. Excluding the accounting impact of the SAFEs, which will only be paid in cash
upon Liquidity Events and Dissolution Event (as defined in Note 9) and the SAFE holders choose to claim the invested proceeds back, management
believes the Company&#x2019;s available cash resources are sufficient for near-term operating needs. If additional liquidity is required,
the Company&#x2019;s majority shareholder has entered into a binding support agreement to provide funding to cover anticipated operating
cash flow shortfalls through the completion of the contemplated de-SPAC transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;However, the aforementioned plans, particularly the
de-SPAC transaction (including the SAFEs conversion) and the raising of additional capital, have not been fully implemented as of the
date these financial statements are issued. There can be no assurance that these plans will be successfully completed within the required
time frame, on acceptable terms, or at all. If the primary plans are not successful, the Company&#x2019;s alternative courses of action
would further intensify efforts in market expansion and client development to increase revenue, while diligently controlling costs to
ensure sufficient cash flow from operating activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company may not be able to secure necessary financing
in a timely manner or on favorable terms, or successfully execute its operational turnaround. These circumstances give rise to substantial
doubt that the Company will continue as a going concern and these financial statements do not include any adjustments that might result
from the outcome of this uncertainty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoHPeRGXD8V6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;b. &lt;span id="xdx_863_zpBEwXbVSFgl"&gt;Basis of presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The financial statements have been prepared in accordance
with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the applicable
rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--UseOfEstimates_zm9vWs4Czw0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;c. &lt;span id="xdx_86E_zKFaeK3WfP28"&gt;Use of estimates and assumptions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and
accompanying notes. Management believes that the estimates used in preparing the financial statements are reasonable and prudent; however,
actual results could differ from these estimates under different assumptions or conditions.&#160;Significant accounting estimates include
revenue recognition, recognition and measurement of SAFEs notes, the allowance for expected credit losses, recognition and measurement
of share-based compensation, deferred tax assets and valuation allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zdsq5TZx08Bg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;d. &lt;span id="xdx_86B_zgmcgXMRrdyd"&gt;Fair value measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;In accordance
with FASB ASC 820&#160;&lt;/span&gt;&lt;i&gt;&lt;span style="color: #212529; color: #212529"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;/i&gt;&lt;span style="color: #212529; color: #212529"&gt;,
&lt;/span&gt;fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. &lt;span style="color: #212529; color: #212529"&gt;The Company uses a three-level hierarchy
for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant
assumptions developed from market data obtained from outside sources (observable inputs) and the Company&#x2019;s own assumptions about
market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). &lt;/span&gt;&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The hierarchy requires entities to maximize the use
of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;Level
1: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;Level
2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;Level
3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash
flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment
or estimation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;The fair
value measurements discussed herein are based upon certain market assumptions and pertinent information available to management during
the years ended June&#160;30, 2024 and 2025. The carrying amount of cash and &lt;/span&gt;cash equivalents&lt;span style="color: #212529; color: #212529"&gt;,
accounts receivable, r&lt;/span&gt;efundable deposits receivable, other receivables, &lt;span style="color: #212529; color: #212529"&gt;accounts payable,
r&lt;/span&gt;efundable deposits payable &lt;span style="color: #212529; color: #212529"&gt;and other current liabilities approximated their fair
values as of June&#160;30, 2024 and 2025. For the years ended June&#160;30, 2024 and 2025, the Company carried SAFEs at their fair value
(see&#160;Note 4-Fair Value Measurements&#160;for fair value information).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--FunctionalCurrencyPolicyTextBlock_zlxnMooXoEU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;e. &lt;span id="xdx_865_zAyE0XfHmhD6"&gt;Functional currency&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying financial statements are presented
in the United States dollar (&#x201c;US$&#x201d;). The functional currency of the Company is the US$.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All transactions are measured and recorded in the
Company&#x2019;s functional currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zbK7C7pPqW23" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;f. &lt;span id="xdx_863_zISAmbUCaane"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers all highly liquid debt instruments
purchased with a maturity period of three months or less to be cash or cash equivalents. The carrying amounts reported in the accompanying
balance sheets for cash and cash equivalents approximate their fair value. As of June&#160;30, 2024 and 2025, the Company does &lt;span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20240630_zJxii2H5kkT6" title="Cash equivalents"&gt;&lt;span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zqb5W6PdbHal" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;t have
any cash equivalents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--ExpectedCreditLossAndAccountsReceivablePolicyTextBlock_zSEmIHvv90sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;g. &lt;span id="xdx_867_zsUZxth16ncb"&gt;Expected credit loss and accounts receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company adopted Financial Standards Accounting
Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 326 &#x201c;&lt;i&gt;Financial Instruments&#160;&#x2014;&#160;Credit
Losses&lt;/i&gt;&#x201d; (&#x201c;ASC&#160;326&#x201d;) on January&#160;1, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s accounts receivable is within
the scope of ASC&#160;326. ASC&#160;326 introduces an approach based on expected credit losses on financial assets at amortized cost.
Upon adoption of ASC&#160;326, the Company estimates the expected credit losses for accounts receivable using the roll-rate method on
a collective basis when similar risk characteristics exist. Expected credit losses are included in general and administrative expenses
in the statements of operations and comprehensive loss. After all attempts to collect a receivable have failed, the receivable is written
off against the allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts receivable represents those receivables derived
in the ordinary course of business, net of an allowance for any potentially uncollectible amounts. The Company makes estimates of expected
credit and collectability trends for the allowance for credit losses based upon its assessment of various factors, including historical
experience, the age of the accounts receivable balances, credit quality of its customers, current economic conditions, reasonable and
supportable forecasts of future economic conditions that may vary by geography, customer-type, or industry sub-vertical, and other factors
that may affect its ability to collect from customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Although the Company has historically not experienced
significant credit losses, they may experience increasing credit loss risks from accounts receivable in future periods if its customers
are adversely affected by economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific
factors, and actual experience in the future may differ from their past experiences or current assessment.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--AdvanceToSuppliersPolicyTextBlock_ziKHq9XEjP3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;h. &lt;span id="xdx_86C_zgfztbsMVxIj"&gt;Advance to suppliers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Advance to suppliers represent prepayments made to
vendors in connection with the purchase of services. Advance are recorded at the amount paid and are classified as current assets when
the related services are expected to be received within one year or the normal operating cycle.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--RefundableDepositsReceivablePolicyTextBlock_zHSdExpu5L9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;i. &lt;span id="xdx_86D_z7CffKljqsfj"&gt;Refundable deposits receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Refundable deposits receivable mainly represent security
deposits and refundable cooperation deposits paid to suppliers and business partners that are contractually recoverable upon the completion
of services. These amounts are recorded as assets when paid, generally at the amount paid. Deposits expected to be recovered within one
year are classified as current; otherwise, they are classified as non-current. The Company evaluates the credit risk of refundable deposits
receivable and recognizes an allowance for credit losses based on the current expected credit losses (&#x201c;CECL&#x201d;) model. Specific
balances are written off when they are deemed uncollectible and all collection efforts have been exhausted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June&#160;30, 2024 and 2025, the balances were
$&lt;span id="xdx_90E_ecustom--RefundableDepositsReceivable_iI_c20240630_za7GUMIQ0fl5" title="Refundable deposits receivable"&gt;110,000&lt;/span&gt; and $&lt;span id="xdx_90E_ecustom--RefundableDepositsReceivable_iI_c20250630_z0ReoE3c16C9" title="Refundable deposits receivable"&gt;681,125&lt;/span&gt;, respectively. The increase was primarily driven by revenue growth and business expansion. As of June&#160;30, 2024
and 2025, there was &lt;span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20240630_zLZRW1Dk6Ukj" title="Allowance for expected credit losses"&gt;&lt;span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_z3aW6vPWJeid" title="Allowance for expected credit losses"&gt;no&lt;/span&gt;&lt;/span&gt; allowance for expected credit losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z0zrIdAY4IM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;j. &lt;span id="xdx_86F_zf8ptRHzRO28"&gt;Equipment, net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Equipment, net is stated at cost less accumulated
depreciation and impairment, if any. Depreciation is computed using the straight-line method over the estimated useful lives of three
or five years, depending on the asset category.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z4iWfcQYqTqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;k. &lt;span id="xdx_86E_zLIGi7CATnu7"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reviews its long-lived assets, equipment,
for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability
of assets held and used is measured by comparison of the carrying amount of an asset to the future undiscounted cash flows expected to
be generated from the use of the asset and its eventual disposition. If such assets are considered to be impaired, the impairment to be
recognized is measured by the amount by which the carrying amount exceeds the fair value of the impaired assets. Assets to be disposed
of are reported at the lower of their carrying amount or fair value less cost to sell. There was &lt;span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20230701__20240630_zgA1bYYr7Yec" title="Impairment of long-lived assets"&gt;&lt;span id="xdx_907_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20240701__20250630_zZHdVotNKmAc" title="Impairment of long-lived assets"&gt;no&lt;/span&gt;&lt;/span&gt; impairment of long-lived assets as
of and for the years ended June&#160;30, 2024 and 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--SimpleAgreementsForFutureEquityPolicyTextBlock_zFgYzNF7u2n6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;l. &lt;/i&gt;&lt;i&gt;&lt;span style="color: #212529; color: #212529"&gt;&lt;span id="xdx_867_z4BrJrohRAA9"&gt;Simple
agreements for future equity&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;SAFEs issued by the Company are freestanding financial
instruments. As they contain certain redemption or liquidation features that&#160;may&#160;require the Company to settle the obligation
in cash upon the occurrence of defined events (e.g., a change of control or dissolution), the instruments&#160;create an obligation that
meets the definition of a liability. Accordingly, the SAFEs are classified in their entirety as liabilities on the balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These liabilities are measured at fair value upon
initial recognition and are subsequently remeasured at fair value at each reporting date. All changes in their fair value are recognized
in&#160;the statement of operations and comprehensive loss in the period in which they occur.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--RevenueRecognitionDeferredRevenue_zJ2s2gZGnL58" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;m. &lt;span id="xdx_86E_zA2yNWLqfBFd"&gt;Revenue recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company applied ASC Topic&#160;606 &#x201c;&lt;i&gt;Revenue
from Contracts with Customers&lt;/i&gt;&#x201d; (&#x201c;ASC&#160;606&#x201d;) for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The five-step model defined by ASC&#160;606 requires
the Company to (i)&#160;identify its contracts with clients, (ii)&#160;identify its performance obligations under those contracts, (iii)&#160;determine
the transaction prices of those contracts, (iv)&#160;allocate the transaction prices to its performance obligations in those contracts,
and (v)&#160;recognize revenue when each performance obligation under those contracts is satisfied. Revenue is recognized when promised
goods or services are transferred to the client in an amount that reflects the consideration expected in exchange for those goods or services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reports all of its revenues on a gross
basis.&#160;This determination is based on the Company&#x2019;s assessment that it is the principal in its revenue arrangements. The Company
controls the service delivery platform and infrastructure before the service is provided to the customer. It is primarily responsible
for fulfilling the service promise, has discretion in setting prices, and assumes the credit risk associated with the customer receivable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As a practical expedient, the Company elected to expense
the incremental costs of obtaining a contract when incurred if the amortization period of the asset that the Company otherwise would have
recognized is one year or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to ASC 606, the Company recognizes revenue
based on the transaction price, which is the amount of consideration it expects to be entitled to exchange for transferring services to
customers. For Intelligent Computing Power Services, contract consideration is generally fixed and is typically stated as a fixed monthly
fee determined by (i) the contractually specified number of GPUs (capacity) and (ii) the service period. Accordingly, the transaction
price is generally the fixed contractual amount. The Company recognizes revenue over time as the services are provided throughout the
contract term. The Company offers payment terms ranging from 0 to 6 months, depending on customers&#x2019; credit profiles and service
requirements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company does not provide warranties for its services
and does not offer service-type warranty arrangements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following is a description of the principal activities
of the Company from which the Company generates its revenue under ASC 606.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(i) Revenue for intelligent computing power service&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #0F1115; color: #0F1115"&gt;The Company
leverages its expertise in high-performance computing and cloud-native architectures to build and operate stable, efficient, and scalable
GPU computing platforms through modular data center design and liquid cooling technology. The Company uses these platforms to provide
computing resources for large-scale AI training, model inference, and high-performance scientific computing to commercial enterprise clients
with substantial GPU computing requirements. Supporting services include GPU server environment deployment, cluster scheduling and performance
optimization, high-speed network interconnection, real-time monitoring and intelligent alerting systems, as well as industry-compliant
security and regulatory assurance. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for the above promises as a single
performance obligation because they are highly integrated and not separately identifiable in the context of the contract. The Company
provides an integrated, managed GPU computing platform in which computing capacity, deployment/configuration, scheduling, networking,
monitoring, and security/compliance are interdependent and together deliver a single combined service&#x2014;continuous access to a functioning
and secured platform over the contractual term.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company provides intelligent computing power services
under two pricing models: (i) reserved capacity arrangements and (ii) on-demand (pay-as-you-go) arrangements. The following table presents
revenue recognized during the period by arrangement type:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zRG8fPT8BVR9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BF_zPudrh40sc0l" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of Revenue recognition&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; years ended&lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Reserved capacity arrangements&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;1,193,982&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;6,501,569&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;On-demand arrangements&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2098"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;44,680&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;1,193,982&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;6,546,249&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zqlXSFBPlAkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Reserved capacity arrangements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company enters into reserved capacity arrangements,
which generally provide committed intelligent computing power services for a defined service term ranging from 3 months to 3 years, with
the majority of such arrangements having a one-year term. These contracts typically are non-cancelable, or may be canceled only under
limited conditions with early notifications required. Payment terms generally range from 0-6 months upon the completion of services, and
certain arrangements require prepayments. Any prepayments are recorded as contract liabilities and recognized over the service term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The performance obligation is satisfied over time
because the customer simultaneously receives and consumes the benefits. Revenue is recognized using a time-elapsed output method over
the contractual service period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On-demand (pay-as-you-go) arrangements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company provides customers with on-demand access
to intelligent computing power and GPU resources under pay-as-you-go model which requires advance payment. Customer advances are recorded
as contract liabilities and recognized as revenue over the time during the provision of related services underlying the contract term.
The revenue is recognized over time because the customer can simultaneously receives and consumes the benefits during the service period.
These arrangements generally do not include a fixed contractual term or minimum usage commitments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(ii) Revenue from comprehensive data center service&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company leverages its project experience in infrastructure
management, cluster optimization, and system monitoring to provide full-cycle operational support to data center asset owners. Services
encompass facility environment deployment, network architecture implementation, security and compliance system development, daily operational
monitoring, and emergency fault response. Revenue is recognized over time because the Company&#x2019;s services are performed throughout
the contract term and the customer benefits as the services are provided.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the&#160;years ended June&#160;30, 2024 and 2025,
$&lt;span id="xdx_905_eus-gaap--Revenues_c20230701__20240630_pp0p" title="Revenue"&gt;1,319,115&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250630_pp0p" title="Revenue"&gt;7,015,512&lt;/span&gt; of the revenue of the Company&#x2019;s was recognized over time, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue disaggregated by service lines for the&#160;years
ended June&#160;30, 2024 and 2025 is disclosed in the table below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zC7KRbYjMXPd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BF_zOrqnCzeKVC3" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of Revenue disaggregated&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;years ended&lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Revenue from intelligent computing
        power service&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zLe37nj4DRT9" title="Total"&gt;1,193,982&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--Revenues_pp0d_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z5LhznXQI8B2" title="Total"&gt;6,546,249&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Revenue from comprehensive
        data center services&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;125,133&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;469,263&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630_zw4xoiRMPQs7" title="Total"&gt;1,319,115&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_pp0d_c20240701__20250630_zxIqgXFsjdA6" title="Total"&gt;7,015,512&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zFyS7keq5WFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;









&lt;p id="xdx_845_ecustom--ContractLiabilitiesPolicyTextBlock_zZWQnliQBId8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;n. &lt;span id="xdx_864_zhAHETYm7uU4"&gt;Contract liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company receives advance payments from its customers
for services to be provided in the future. These payments are recorded as&#160;contract liabilities&#160;on the balance sheet within &#x201c;Contract
liabilities&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Contract liabilities are recognized when
consideration is received from a customer prior to the Company satisfying its related performance obligations. For these service
contracts, the Company recognizes revenue, and reduces the contract liabilities,&#160;over time&#160;as the services are rendered
and the performance obligations are satisfied. Revenue recognized that was included in the contract liability balance at the
beginning of the year was nil &lt;span id="xdx_90A_ecustom--RevenueRecognized_c20230701__20240630_pp0p" style="display: none" title="Revenue recognized"&gt;0&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--RevenueRecognized_c20240701__20250630_pp0p" title="Revenue recognized"&gt;95,326&lt;/span&gt; for the years ended June&#160;30, 2024 and 2025, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--CostOfSalesPolicyTextBlock_zd6uOxmwVUC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;o. &lt;span id="xdx_868_zt2YqZ7h4862"&gt;Cost of revenues&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s cost of revenues primarily includes
computing power service and professional service fees. All the cost of revenues are recognized in the period in which the related services
occur or the benefits are received.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--SellingAndMarketingExpensesPolicyTextBlock_zNtKHlQglhzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;p. &lt;span id="xdx_861_z8U06Sm8eK8b"&gt;Selling and marketing expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s selling and marketing expenses
primarily include: (i) advertising and promotion expenses, (ii) compensation and benefits for sales personnel and related share based
compensation, and (iii) travel and other routine office expense. All expenses are recognized in the period in which the related services
occur or the benefits are received. The Company expenses advertising costs as incurred, and for the years ended June&#160;30, 2024 and
2025, the Company incurred advertising and promotion expenses of $&lt;span id="xdx_908_eus-gaap--MarketingAndAdvertisingExpense_c20230701__20240630_pp0p" title="Advertising and promotion expenses"&gt;26,340&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20240701__20250630_pp0p" title="Advertising and promotion expenses"&gt;157,388&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zTShSXVP9mc7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;q. &lt;span id="xdx_864_zLpo4DODnKa5"&gt;Research and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s research and development expenses
mainly consist of &lt;span style="color: #0F1115; color: #0F1115"&gt;software development outsourcing service fees and testing expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zdyBpybY30kg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;r. &lt;span id="xdx_866_z1OzlN0cGTed"&gt;General and administrative expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s general and administrative expenses
mainly consist of &lt;span style="color: #0F1115; color: #0F1115"&gt;software subscription fees, legal and professional service fees, certification
service fees, depreciation expenses and handling charges.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zH16tov7HOHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;s. &lt;span id="xdx_86A_zfzDgxosnhkd"&gt;Income tax&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Income taxes are determined in accordance with the
provisions of ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC Topic 740&#x201d;). Under this method, deferred tax assets and liabilities
are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing
assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates
expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. Any effect
on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC 740 prescribes a comprehensive model for how companies
should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on
a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the
position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as
the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority
assuming full knowledge of the position and relevant facts.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--CapitalStructurePolicyTextBlock_zrhorRvRLTn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;t. &lt;span id="xdx_86F_zOYxMEHi9sP1"&gt;Capital structure&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is authorized to issue &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20240630_pd" title="Common stock, shares authorized"&gt;&lt;span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_c20250630_pd" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt;&lt;/span&gt; ordinary
shares of $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20240630_pd" title="Common stock, par value"&gt;&lt;span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_c20250630_pd" title="Common stock, par value"&gt;0.01&lt;/span&gt;&lt;/span&gt; par value each. As of June&#160;30, 2024 and 2025, there were &lt;span id="xdx_90B_eus-gaap--CommonStockSharesIssued_c20240630_pd" title="Common stock, shares issued"&gt;&lt;span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_c20240630_pd" title="Common stock, shares outstanding"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockSharesIssued_c20250630_pd" title="Common stock, shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_c20250630_pd" title="Common stock, shares outstanding"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares issued and outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the resolution of the board of directors
on January&#160;8, 2026, the authorized share capital of &lt;span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_c20260108_pd" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt; ordinary shares was re-designated to &lt;span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pd" title="Common stock, shares authorized"&gt;303&lt;/span&gt; Class A ordinary shares and &lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pd" title="Common stock, shares authorized"&gt;1,197&lt;/span&gt;
Class B ordinary shares. Holders of Class A ordinary shares and Class B ordinary shares have the same rights, except for voting and conversion
rights. Each Class A ordinary share is entitled to one vote; and each Class B ordinary share is entitled to twenty votes and is convertible
into one Class A ordinary share at any time by the holder thereof. Class A ordinary shares are not convertible into Class B ordinary shares
under any circumstances. Furthermore, all outstanding warrants, options, and SAFEs are designated to convert or settle exclusively into
Class A ordinary shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zyjuGtgiN2l4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;u. &lt;span id="xdx_860_zz7zMNdlRtT9"&gt;Share-based compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company grants Share awards of the Company to
eligible employees and&#160;non-employees. The Company accounts for share-based awards issued to employees and&#160;non-employees in accordance
with ASC Topic 718 &lt;i&gt;Compensation &#x2013; Stock Compensation. &lt;/i&gt;The Company recognizes forfeitures as they occur. The share-based compensation
expenses have been categorized as either general and administrative expenses or selling and marketing expenses, depending on the job functions
of the grantees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s share-based compensation awards
are expected to be settled through transfers of existing ordinary shares held by the controlling shareholder, rather than through the
issuance of new shares by the Company. The underlying ordinary shares are included in issued and outstanding shares as of the balance
sheet date; accordingly, such settlement is not expected to increase the Company&#x2019;s total issued and outstanding shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Employees&#x2019; share-based awards and non-employees&#x2019;
share-based awards are measured at the grant date fair value of the awards and recognized as expenses a) immediately at grant date if
no vesting conditions are required; or b) using graded vesting method, net of estimated forfeitures, over the requisite service period,
which is the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company employs discounted cash flow method to
determine the fair value of our share-based compensation arrangements, where the key valuation variables include risk free rate, discount
rate and perpetual rate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zj5A0O1qUZwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;v. &lt;span id="xdx_867_zetDcyDJZsD4"&gt;Segment reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC 280, &#x201c;Segment Reporting&#x201d;, establishes
standards for reporting information about operating segments on a basis consistent with the Company&#x2019;s internal organizational structure
as well as information about geographical areas, business segments and major customers in financial statements for details on the Company&#x2019;s
business segments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company uses the &#x201c;management approach&#x201d;
in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#x2019;s
chief operating decision maker (&#x201c;CODM&#x201d;) for making operating decisions and assessing performance as the source for determining
the Company&#x2019;s reportable segments. The Company&#x2019;s CODM is the chief executive director. The CODM regularly reviews entity-wide
operating results and reviews revenues and net loss when making decisions about allocating resources and assessing performance of the
segment, and hence, the Company has only&#160;one&#160;reportable segment. Therefore, as the Company has determined it operates as a single
reportable segment, the CODM assesses the Company&#x2019;s performance and results of operations on an entity-wide basis.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_ecustom--RelatedPartiesPolicyTextBlock_zmOqA55enEsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;w. &lt;span id="xdx_862_zI2bQw1nSKC"&gt;Related parties&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Parties are considered to be related if one party
has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial
and operating decisions. Parties are also considered to be related if they are subject to common control or significant influence, such
as a family member or relative, shareholder, or a related corporation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--ComprehensiveLossPolicyTextBlock_z3GLuD1HtmQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;x. &lt;span id="xdx_866_zJfxnr89HArh"&gt;Comprehensive loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Comprehensive loss is defined as a change in equity
during a period from transactions and other events and circumstances&#160;from&#160;non-owner&#160;sources.&#160;The Company&#x2019;s comprehensive
loss was the same as its reported net loss for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zRr2tTiRL483" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;y.&lt;span id="xdx_864_zWpJBAyOYapg"&gt; Loss&#160;per share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per share of ordinary shares attributable
to ordinary shareholders is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average shares of ordinary
shares outstanding for the period. Potentially dilutive shares, which are based on the weighted-average shares of ordinary shares underlying
outstanding share-based awards or options using the treasury stock method or the if-converted method, as applicable, are included when
calculating diluted net income per share of ordinary shares attributable to ordinary shareholders when their effect is dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Diluted net loss per share attributable to ordinary
shareholders is computed by adjusting the weighted-average number of ordinary shares outstanding for the dilutive effect of all potential
ordinary share equivalents. For the Company, potential ordinary share equivalents consisted of share-based compensation, which are assessed
using the&#160;treasury stock method. These potential shares are included in the diluted earnings per share calculation only when their
effect is&#160;dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In periods where the Company reports a&#160;net loss,
diluted net loss per share is calculated in the same manner as basic net loss per share because the inclusion of any potential ordinary
shares would have an&#160;anti-dilutive&#160;effect. Consequently, all potential ordinary share equivalents were excluded from the calculation
for the years in which a net loss was incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--RevenueRecognitionDividends_z5kiNZU4iFJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;z. &lt;span id="xdx_86E_z1wQVhVX3E9i"&gt;Dividends&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Dividends are recognized when declared. &lt;span id="xdx_908_eus-gaap--Dividends_pp0d_do_c20230701__20240630_z4eZ64ybMTmi" title="Dividends"&gt;&lt;span id="xdx_903_eus-gaap--Dividends_pp0d_do_c20240701__20250630_zSkJu776q1A8" title="Dividends"&gt;No&lt;/span&gt;&lt;/span&gt; dividends
were declared for the years ended June&#160;30, 2024 and 2025, respectively. The Company does not have any present plan to pay any dividends
on ordinary shares in the foreseeable future. The Company currently intends to retain the available funds and any future earnings to operate
and expand its business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock_z7z0wstCtqqk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;aa. &lt;span id="xdx_86F_zUUr7JvI51i1"&gt;Recently adopted accounting standard updates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June&#160;2016, the FASB issued ASU&#160;2016-13,
&lt;i&gt;Financial Instruments&#160;&#x2014;&#160;Credit Losses&lt;/i&gt; (Topic&#160;326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU&#160;2016-13&#x201d;).
The new accounting standard introduced the current expected credit losses methodology (&#x201c;CECL&#x201d;) for estimating allowances for
credit losses. The measurement of expected credit losses under the CECL methodology is applicable to financial assets measured at amortized
costs, including loans and trade receivables. ASU&#160;2016-13 is effective for the Company, as an emerging growth company, for annual
and interim reporting periods beginning after December&#160;15, 2022. The Company adopted the standard on July&#160;1, 2023 using the
modified retrospective method for all financial assets in scope. The adoption of the standard did not have a material impact on the Company&#x2019;s
statements of income, or statements of cash flows.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November&#160;2023, the FASB issued ASU&#160;2023-07,
&#x201c;Segment Reporting (Topic&#160;280): &lt;i&gt;Improvements to Reportable Segment Disclosures&lt;/i&gt;.&#x201d; The amendments in this ASU are
intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating decision mark (&#x201c;CODM&#x201d;),
an amount for other segment items by reportable segment and a description of its composition, all annual disclosures required by FASB
ASU Topic&#160;280 in interim periods as well, and the title and position of the CODM and how the CODM uses the reported measures. Additionally,
this ASU requires that at least one of the reported segment profit and loss measures should be the measure that is most consistent with
the measurement principles used in an entity&#x2019;s financial statements. Lastly, this ASU requires public business entities with a single
reportable segment to provide all disclosures required by these amendments in this ASU and all existing segment disclosures in Topic&#160;280.
This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning
after December&#160;15, 2024. The Company has early adopted ASU 2023-07 on July&#160;1, 2023. As a result of adoption, the required disclosures
have been included in Note 2 and Note 14.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--EmergingGrowthCompanyPolicyTextBlock_zXbI2MERplLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;bb. &lt;span id="xdx_860_zodYVIxzme09"&gt;Emerging growth company&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company intends to operate as an &#x201c;emerging
growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). The JOBS Act permits
companies with emerging growth company status to take advantage of an extended transition period to comply with new or revised accounting
standards, delaying the adoption of these accounting standards until such time as those standards would apply to private companies. The
Company elected to use this extended transition period to enable it to comply with new or revised accounting standards that have different
effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company
or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company&#x2019;s
financial statements may not be comparable to companies that comply with the new or revised accounting standards as of public company
effective dates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztzNempdfu57" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;cc. &lt;span id="xdx_86D_z61KGdSvMHp3"&gt;Recently accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December&#160;2023, the FASB issued ASU&#160;No.&#160;2023-09,&#160;&lt;i&gt;Improvements
to Income Tax Disclosures&lt;/i&gt;&#160;(&#x201c;ASU&#160;2023-09&#x201d;),&#160;which requires entities to make incremental income tax disclosures
on an annual basis. The amendments require that public business entities disclose specific categories in the rate reconciliation and provide
additional information for reconciling items meeting a quantitative threshold. The amendments also require disclosure of income taxes
paid to be disaggregated by jurisdiction, and the disclosure of income tax expense disaggregated by federal, state, and foreign. ASU&#160;2023-09&#160;is
effective for the Company&#x2019;s annual reporting periods ending December&#160;31, 2025 and thereafter, with early adoption permitted.
The Company is evaluating adoption timing and the impact ASU&#160;2023-09&#160;will have on its financial statements and related disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March&#160;2024, the FASB issued ASU No. 2024-02,
&lt;i&gt;Codification Improvements-Amendments to Remove References to the Concepts Statements&lt;/i&gt; (&#x201c;ASU 2024-02&#x201d;). The amendments
in this Update affect a variety of Topics in the Codification. The amendments apply to all reporting entities within the scope of the
affected accounting guidance. This update contains amendments to the Codification that remove references to various Concepts Statements.
In most instances, the references are extraneous and not required to understand or apply the guidance. In other instances, references
were used in prior statements to provide guidance in certain topical areas. ASU 2024-02 is effective for public business entities for
fiscal years beginning after December&#160;15, 2024. For all other entities, the amendments are effective for fiscal years beginning after
December&#160;15, 2025. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or
made available for issuance. The adoption did not have a material impact on the Company&#x2019;s financial statement.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November&#160;2024, the FASB issued ASU 2024-03
&#x201c;&lt;i&gt;Income Statement&#x2014;Reporting comprehensive (loss) income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation
of Income Statement Expenses&lt;/i&gt;&#x201d; (&#x201c;ASU 2024-03&#x201d;). The amendments in this update intend to improve the disclosures about
a public business entity&#x2019;s expenses and address requests from investors for more detailed information about the types of expenses
(including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions
(such as cost of sales, selling, general and administrative expenses, and research and development). ASU 2024-03 is effective for fiscal
years beginning after December&#160;15, 2026, and interim periods beginning after December&#160;15, 2027. The Company is currently evaluating
the impact from the adoption of this ASU on its financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January&#160;2025, the FASB issued Accounting Standards
Update (ASU) No. 2025-01, &lt;i&gt;Income Statement &#x2014; Reporting comprehensive (loss) income &#x2014; Expense Disaggregation Disclosures&lt;/i&gt;
(Subtopic 220-40): Clarifying the Effective Date. The amendment clarifies the effective date of ASU No. 2024-03 that all public business
entities are required to adopt the guidance in annual reporting periods beginning after December&#160;15, 2026, and interim periods within
annual reporting periods beginning after December&#160;15, 2027. Early adoption of Update 2024-03 is permitted. The Company is currently
evaluating the impact of the above new accounting pronouncements or guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July&#160;2025, the FASB issued Accounting Standards
Update (ASU) No. 2025-05, &lt;i&gt;Financial Instruments &#x2014; Credit Losses&lt;/i&gt; (Topic 326): Measurement of Credit Losses for Accounts Receivable
and Contract Assets. The amendment provides (1) all entities with a practical expedient to assume that current conditions as of the balance
sheet date do not change for the remaining life of the assets and (2) entities other than public business entities with an accounting
policy election to consider collection activity after the balance sheet date when estimating expected credit losses for current accounts
receivable and current contract assets arising from transactions accounted for under Topic 606. This guidance is effective for annual
reporting periods beginning after December&#160;15, 2025 and interim reporting periods within those annual reporting periods. Early adoption
is permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Except as mentioned above, the Company does not believe
other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the balance sheets,
statements of income and comprehensive loss and cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <cik0002065779:GoingConcernPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002015">&lt;p id="xdx_845_ecustom--GoingConcernPolicyTextBlock_zorhFCi8emlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;a. &lt;span id="xdx_864_z1YlhGMWNLQ3"&gt;Going concern&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June&#160;30, 2025, the Company had cash
and cash equivalents of $4.2 million &lt;span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20250630_zP8AepDgmXQ1" style="display: none" title="Cash and cash equivalents"&gt;4,231,689&lt;/span&gt;
and current liabilities of $20.3 &lt;span id="xdx_902_eus-gaap--LiabilitiesCurrent_iI_c20250630_z4jwfecaN8A1" style="display: none" title="Current liabilities"&gt;20,319,721&lt;/span&gt;
million. For the years ended June&#160;30, 2024 and 2025, the Company used $0.6 &lt;span title="Net losses"&gt;&lt;span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20230701__20240630_zimEv9wUsnDk" style="display: none" title="Cash for operating activities"&gt;(560,909)&lt;/span&gt;
million and $1.0 &lt;span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20240701__20250630_zVTfCY856dug" style="display: none" title="Cash for operating activities"&gt;(1,010,799)&lt;/span&gt;
million in cash for operating activities, and incurred net losses of $5.0 &lt;span id="xdx_901_eus-gaap--NetIncomeLoss_c20230701__20240630_zVEtJqHinOV8" style="display: none" title="Net losses"&gt;(4,956,347)&lt;/span&gt;
million and $7.7 &lt;span id="xdx_903_eus-gaap--NetIncomeLoss_c20240701__20250630_zUawJwOLj0Yh" style="display: none" title="Net losses"&gt;(7,659,667)&lt;/span&gt;
million, respectively. The Company has incurred recurring net losses from operations and negative cash flows from operating
activities since inception. As of June&#160;30, 2025, the Company had an accumulated deficit of $13.2
&lt;span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20250630_zuIwST4zPt2k" style="display: none" title="Accumulated deficit"&gt;(13,217,035)&lt;/span&gt; million. These factors raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern
within one year of the date these financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management has formulated and is actively pursuing
plans to mitigate these conditions and secure the Company&#x2019;s continued operations. In connection with the Company&#x2019;s contemplated
business combination with a SPAC and related financing activities, the Company expects to access additional capital through external funding
sources. In addition, the Company continues to focus on expanding its market presence and developing client relationships to drive revenue
growth, while managing operating expenses, with the objective of improving cash flows from operations over time.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For purposes of this disclosure, &#x201c;SPAC&#x201d;
refers to a special purpose acquisition company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more operating businesses. &#x201c;De-SPAC&#x201d; refers to the business combination transaction
pursuant to which an operating company combines with a SPAC, following which the combined company becomes publicly listed (or otherwise
succeeds to the SPAC&#x2019;s public company status).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s negative working capital position
is primarily attributable to the classification of SAFEs. Excluding the accounting impact of the SAFEs, which will only be paid in cash
upon Liquidity Events and Dissolution Event (as defined in Note 9) and the SAFE holders choose to claim the invested proceeds back, management
believes the Company&#x2019;s available cash resources are sufficient for near-term operating needs. If additional liquidity is required,
the Company&#x2019;s majority shareholder has entered into a binding support agreement to provide funding to cover anticipated operating
cash flow shortfalls through the completion of the contemplated de-SPAC transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;However, the aforementioned plans, particularly the
de-SPAC transaction (including the SAFEs conversion) and the raising of additional capital, have not been fully implemented as of the
date these financial statements are issued. There can be no assurance that these plans will be successfully completed within the required
time frame, on acceptable terms, or at all. If the primary plans are not successful, the Company&#x2019;s alternative courses of action
would further intensify efforts in market expansion and client development to increase revenue, while diligently controlling costs to
ensure sufficient cash flow from operating activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company may not be able to secure necessary financing
in a timely manner or on favorable terms, or successfully execute its operational turnaround. These circumstances give rise to substantial
doubt that the Company will continue as a going concern and these financial statements do not include any adjustments that might result
from the outcome of this uncertainty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:GoingConcernPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002017"
      unitRef="USD">4231689</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002019"
      unitRef="USD">20319721</us-gaap:LiabilitiesCurrent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002021"
      unitRef="USD">-560909</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002023"
      unitRef="USD">-1010799</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002025"
      unitRef="USD">-4956347</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002027"
      unitRef="USD">-7659667</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002029"
      unitRef="USD">-13217035</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002036">&lt;p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoHPeRGXD8V6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;b. &lt;span id="xdx_863_zpBEwXbVSFgl"&gt;Basis of presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The financial statements have been prepared in accordance
with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the applicable
rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002038">&lt;p id="xdx_849_eus-gaap--UseOfEstimates_zm9vWs4Czw0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;c. &lt;span id="xdx_86E_zKFaeK3WfP28"&gt;Use of estimates and assumptions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and
accompanying notes. Management believes that the estimates used in preparing the financial statements are reasonable and prudent; however,
actual results could differ from these estimates under different assumptions or conditions.&#160;Significant accounting estimates include
revenue recognition, recognition and measurement of SAFEs notes, the allowance for expected credit losses, recognition and measurement
of share-based compensation, deferred tax assets and valuation allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002040">&lt;p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zdsq5TZx08Bg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;d. &lt;span id="xdx_86B_zgmcgXMRrdyd"&gt;Fair value measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;In accordance
with FASB ASC 820&#160;&lt;/span&gt;&lt;i&gt;&lt;span style="color: #212529; color: #212529"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;/i&gt;&lt;span style="color: #212529; color: #212529"&gt;,
&lt;/span&gt;fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. &lt;span style="color: #212529; color: #212529"&gt;The Company uses a three-level hierarchy
for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant
assumptions developed from market data obtained from outside sources (observable inputs) and the Company&#x2019;s own assumptions about
market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). &lt;/span&gt;&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The hierarchy requires entities to maximize the use
of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;Level
1: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;Level
2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;Level
3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash
flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment
or estimation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #212529; color: #212529"&gt;The fair
value measurements discussed herein are based upon certain market assumptions and pertinent information available to management during
the years ended June&#160;30, 2024 and 2025. The carrying amount of cash and &lt;/span&gt;cash equivalents&lt;span style="color: #212529; color: #212529"&gt;,
accounts receivable, r&lt;/span&gt;efundable deposits receivable, other receivables, &lt;span style="color: #212529; color: #212529"&gt;accounts payable,
r&lt;/span&gt;efundable deposits payable &lt;span style="color: #212529; color: #212529"&gt;and other current liabilities approximated their fair
values as of June&#160;30, 2024 and 2025. For the years ended June&#160;30, 2024 and 2025, the Company carried SAFEs at their fair value
(see&#160;Note 4-Fair Value Measurements&#160;for fair value information).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <cik0002065779:FunctionalCurrencyPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002047">&lt;p id="xdx_84F_ecustom--FunctionalCurrencyPolicyTextBlock_zlxnMooXoEU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;e. &lt;span id="xdx_865_zAyE0XfHmhD6"&gt;Functional currency&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying financial statements are presented
in the United States dollar (&#x201c;US$&#x201d;). The functional currency of the Company is the US$.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All transactions are measured and recorded in the
Company&#x2019;s functional currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:FunctionalCurrencyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002049">&lt;p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zbK7C7pPqW23" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;f. &lt;span id="xdx_863_zISAmbUCaane"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers all highly liquid debt instruments
purchased with a maturity period of three months or less to be cash or cash equivalents. The carrying amounts reported in the accompanying
balance sheets for cash and cash equivalents approximate their fair value. As of June&#160;30, 2024 and 2025, the Company does &lt;span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20240630_zJxii2H5kkT6" title="Cash equivalents"&gt;&lt;span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zqb5W6PdbHal" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;t have
any cash equivalents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002051"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002053"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <cik0002065779:ExpectedCreditLossAndAccountsReceivablePolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002055">&lt;p id="xdx_84E_ecustom--ExpectedCreditLossAndAccountsReceivablePolicyTextBlock_zSEmIHvv90sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;g. &lt;span id="xdx_867_zsUZxth16ncb"&gt;Expected credit loss and accounts receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company adopted Financial Standards Accounting
Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 326 &#x201c;&lt;i&gt;Financial Instruments&#160;&#x2014;&#160;Credit
Losses&lt;/i&gt;&#x201d; (&#x201c;ASC&#160;326&#x201d;) on January&#160;1, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s accounts receivable is within
the scope of ASC&#160;326. ASC&#160;326 introduces an approach based on expected credit losses on financial assets at amortized cost.
Upon adoption of ASC&#160;326, the Company estimates the expected credit losses for accounts receivable using the roll-rate method on
a collective basis when similar risk characteristics exist. Expected credit losses are included in general and administrative expenses
in the statements of operations and comprehensive loss. After all attempts to collect a receivable have failed, the receivable is written
off against the allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts receivable represents those receivables derived
in the ordinary course of business, net of an allowance for any potentially uncollectible amounts. The Company makes estimates of expected
credit and collectability trends for the allowance for credit losses based upon its assessment of various factors, including historical
experience, the age of the accounts receivable balances, credit quality of its customers, current economic conditions, reasonable and
supportable forecasts of future economic conditions that may vary by geography, customer-type, or industry sub-vertical, and other factors
that may affect its ability to collect from customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Although the Company has historically not experienced
significant credit losses, they may experience increasing credit loss risks from accounts receivable in future periods if its customers
are adversely affected by economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific
factors, and actual experience in the future may differ from their past experiences or current assessment.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:ExpectedCreditLossAndAccountsReceivablePolicyTextBlock>
    <cik0002065779:AdvanceToSuppliersPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002060">&lt;p id="xdx_848_ecustom--AdvanceToSuppliersPolicyTextBlock_ziKHq9XEjP3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;h. &lt;span id="xdx_86C_zgfztbsMVxIj"&gt;Advance to suppliers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Advance to suppliers represent prepayments made to
vendors in connection with the purchase of services. Advance are recorded at the amount paid and are classified as current assets when
the related services are expected to be received within one year or the normal operating cycle.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:AdvanceToSuppliersPolicyTextBlock>
    <cik0002065779:RefundableDepositsReceivablePolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002062">&lt;p id="xdx_844_ecustom--RefundableDepositsReceivablePolicyTextBlock_zHSdExpu5L9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;i. &lt;span id="xdx_86D_z7CffKljqsfj"&gt;Refundable deposits receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Refundable deposits receivable mainly represent security
deposits and refundable cooperation deposits paid to suppliers and business partners that are contractually recoverable upon the completion
of services. These amounts are recorded as assets when paid, generally at the amount paid. Deposits expected to be recovered within one
year are classified as current; otherwise, they are classified as non-current. The Company evaluates the credit risk of refundable deposits
receivable and recognizes an allowance for credit losses based on the current expected credit losses (&#x201c;CECL&#x201d;) model. Specific
balances are written off when they are deemed uncollectible and all collection efforts have been exhausted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June&#160;30, 2024 and 2025, the balances were
$&lt;span id="xdx_90E_ecustom--RefundableDepositsReceivable_iI_c20240630_za7GUMIQ0fl5" title="Refundable deposits receivable"&gt;110,000&lt;/span&gt; and $&lt;span id="xdx_90E_ecustom--RefundableDepositsReceivable_iI_c20250630_z0ReoE3c16C9" title="Refundable deposits receivable"&gt;681,125&lt;/span&gt;, respectively. The increase was primarily driven by revenue growth and business expansion. As of June&#160;30, 2024
and 2025, there was &lt;span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20240630_zLZRW1Dk6Ukj" title="Allowance for expected credit losses"&gt;&lt;span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_z3aW6vPWJeid" title="Allowance for expected credit losses"&gt;no&lt;/span&gt;&lt;/span&gt; allowance for expected credit losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RefundableDepositsReceivablePolicyTextBlock>
    <cik0002065779:RefundableDepositsReceivable
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002064"
      unitRef="USD">110000</cik0002065779:RefundableDepositsReceivable>
    <cik0002065779:RefundableDepositsReceivable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002066"
      unitRef="USD">681125</cik0002065779:RefundableDepositsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002068"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002070"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002072">&lt;p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z0zrIdAY4IM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;j. &lt;span id="xdx_86F_zf8ptRHzRO28"&gt;Equipment, net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Equipment, net is stated at cost less accumulated
depreciation and impairment, if any. Depreciation is computed using the straight-line method over the estimated useful lives of three
or five years, depending on the asset category.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002074">&lt;p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z4iWfcQYqTqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;k. &lt;span id="xdx_86E_zLIGi7CATnu7"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reviews its long-lived assets, equipment,
for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability
of assets held and used is measured by comparison of the carrying amount of an asset to the future undiscounted cash flows expected to
be generated from the use of the asset and its eventual disposition. If such assets are considered to be impaired, the impairment to be
recognized is measured by the amount by which the carrying amount exceeds the fair value of the impaired assets. Assets to be disposed
of are reported at the lower of their carrying amount or fair value less cost to sell. There was &lt;span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20230701__20240630_zgA1bYYr7Yec" title="Impairment of long-lived assets"&gt;&lt;span id="xdx_907_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20240701__20250630_zZHdVotNKmAc" title="Impairment of long-lived assets"&gt;no&lt;/span&gt;&lt;/span&gt; impairment of long-lived assets as
of and for the years ended June&#160;30, 2024 and 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002076"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002078"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <cik0002065779:SimpleAgreementsForFutureEquityPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002080">&lt;p id="xdx_844_ecustom--SimpleAgreementsForFutureEquityPolicyTextBlock_zFgYzNF7u2n6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;l. &lt;/i&gt;&lt;i&gt;&lt;span style="color: #212529; color: #212529"&gt;&lt;span id="xdx_867_z4BrJrohRAA9"&gt;Simple
agreements for future equity&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;SAFEs issued by the Company are freestanding financial
instruments. As they contain certain redemption or liquidation features that&#160;may&#160;require the Company to settle the obligation
in cash upon the occurrence of defined events (e.g., a change of control or dissolution), the instruments&#160;create an obligation that
meets the definition of a liability. Accordingly, the SAFEs are classified in their entirety as liabilities on the balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These liabilities are measured at fair value upon
initial recognition and are subsequently remeasured at fair value at each reporting date. All changes in their fair value are recognized
in&#160;the statement of operations and comprehensive loss in the period in which they occur.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:SimpleAgreementsForFutureEquityPolicyTextBlock>
    <us-gaap:RevenueRecognitionDeferredRevenue
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002085">&lt;p id="xdx_840_eus-gaap--RevenueRecognitionDeferredRevenue_zJ2s2gZGnL58" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;m. &lt;span id="xdx_86E_zA2yNWLqfBFd"&gt;Revenue recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company applied ASC Topic&#160;606 &#x201c;&lt;i&gt;Revenue
from Contracts with Customers&lt;/i&gt;&#x201d; (&#x201c;ASC&#160;606&#x201d;) for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The five-step model defined by ASC&#160;606 requires
the Company to (i)&#160;identify its contracts with clients, (ii)&#160;identify its performance obligations under those contracts, (iii)&#160;determine
the transaction prices of those contracts, (iv)&#160;allocate the transaction prices to its performance obligations in those contracts,
and (v)&#160;recognize revenue when each performance obligation under those contracts is satisfied. Revenue is recognized when promised
goods or services are transferred to the client in an amount that reflects the consideration expected in exchange for those goods or services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reports all of its revenues on a gross
basis.&#160;This determination is based on the Company&#x2019;s assessment that it is the principal in its revenue arrangements. The Company
controls the service delivery platform and infrastructure before the service is provided to the customer. It is primarily responsible
for fulfilling the service promise, has discretion in setting prices, and assumes the credit risk associated with the customer receivable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As a practical expedient, the Company elected to expense
the incremental costs of obtaining a contract when incurred if the amortization period of the asset that the Company otherwise would have
recognized is one year or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to ASC 606, the Company recognizes revenue
based on the transaction price, which is the amount of consideration it expects to be entitled to exchange for transferring services to
customers. For Intelligent Computing Power Services, contract consideration is generally fixed and is typically stated as a fixed monthly
fee determined by (i) the contractually specified number of GPUs (capacity) and (ii) the service period. Accordingly, the transaction
price is generally the fixed contractual amount. The Company recognizes revenue over time as the services are provided throughout the
contract term. The Company offers payment terms ranging from 0 to 6 months, depending on customers&#x2019; credit profiles and service
requirements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company does not provide warranties for its services
and does not offer service-type warranty arrangements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following is a description of the principal activities
of the Company from which the Company generates its revenue under ASC 606.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(i) Revenue for intelligent computing power service&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #0F1115; color: #0F1115"&gt;The Company
leverages its expertise in high-performance computing and cloud-native architectures to build and operate stable, efficient, and scalable
GPU computing platforms through modular data center design and liquid cooling technology. The Company uses these platforms to provide
computing resources for large-scale AI training, model inference, and high-performance scientific computing to commercial enterprise clients
with substantial GPU computing requirements. Supporting services include GPU server environment deployment, cluster scheduling and performance
optimization, high-speed network interconnection, real-time monitoring and intelligent alerting systems, as well as industry-compliant
security and regulatory assurance. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for the above promises as a single
performance obligation because they are highly integrated and not separately identifiable in the context of the contract. The Company
provides an integrated, managed GPU computing platform in which computing capacity, deployment/configuration, scheduling, networking,
monitoring, and security/compliance are interdependent and together deliver a single combined service&#x2014;continuous access to a functioning
and secured platform over the contractual term.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company provides intelligent computing power services
under two pricing models: (i) reserved capacity arrangements and (ii) on-demand (pay-as-you-go) arrangements. The following table presents
revenue recognized during the period by arrangement type:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zRG8fPT8BVR9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BF_zPudrh40sc0l" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of Revenue recognition&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; years ended&lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Reserved capacity arrangements&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;1,193,982&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;6,501,569&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;On-demand arrangements&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2098"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;44,680&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;1,193,982&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;6,546,249&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zqlXSFBPlAkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Reserved capacity arrangements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company enters into reserved capacity arrangements,
which generally provide committed intelligent computing power services for a defined service term ranging from 3 months to 3 years, with
the majority of such arrangements having a one-year term. These contracts typically are non-cancelable, or may be canceled only under
limited conditions with early notifications required. Payment terms generally range from 0-6 months upon the completion of services, and
certain arrangements require prepayments. Any prepayments are recorded as contract liabilities and recognized over the service term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The performance obligation is satisfied over time
because the customer simultaneously receives and consumes the benefits. Revenue is recognized using a time-elapsed output method over
the contractual service period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On-demand (pay-as-you-go) arrangements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company provides customers with on-demand access
to intelligent computing power and GPU resources under pay-as-you-go model which requires advance payment. Customer advances are recorded
as contract liabilities and recognized as revenue over the time during the provision of related services underlying the contract term.
The revenue is recognized over time because the customer can simultaneously receives and consumes the benefits during the service period.
These arrangements generally do not include a fixed contractual term or minimum usage commitments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(ii) Revenue from comprehensive data center service&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company leverages its project experience in infrastructure
management, cluster optimization, and system monitoring to provide full-cycle operational support to data center asset owners. Services
encompass facility environment deployment, network architecture implementation, security and compliance system development, daily operational
monitoring, and emergency fault response. Revenue is recognized over time because the Company&#x2019;s services are performed throughout
the contract term and the customer benefits as the services are provided.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the&#160;years ended June&#160;30, 2024 and 2025,
$&lt;span id="xdx_905_eus-gaap--Revenues_c20230701__20240630_pp0p" title="Revenue"&gt;1,319,115&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250630_pp0p" title="Revenue"&gt;7,015,512&lt;/span&gt; of the revenue of the Company&#x2019;s was recognized over time, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue disaggregated by service lines for the&#160;years
ended June&#160;30, 2024 and 2025 is disclosed in the table below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zC7KRbYjMXPd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BF_zOrqnCzeKVC3" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of Revenue disaggregated&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;years ended&lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Revenue from intelligent computing
        power service&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zLe37nj4DRT9" title="Total"&gt;1,193,982&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--Revenues_pp0d_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z5LhznXQI8B2" title="Total"&gt;6,546,249&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Revenue from comprehensive
        data center services&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;125,133&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;469,263&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630_zw4xoiRMPQs7" title="Total"&gt;1,319,115&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_pp0d_c20240701__20250630_zxIqgXFsjdA6" title="Total"&gt;7,015,512&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zFyS7keq5WFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;









</us-gaap:RevenueRecognitionDeferredRevenue>
    <cik0002065779:ScheduleOfRevenueRecognitionTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002092">&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zRG8fPT8BVR9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BF_zPudrh40sc0l" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of Revenue recognition&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; years ended&lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Reserved capacity arrangements&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;1,193,982&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;6,501,569&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;On-demand arrangements&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2098"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;44,680&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;1,193,982&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;6,546,249&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</cik0002065779:ScheduleOfRevenueRecognitionTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002094"
      unitRef="USD">1193982</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002096"
      unitRef="USD">6501569</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002100"
      unitRef="USD">44680</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002102"
      unitRef="USD">1193982</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002104"
      unitRef="USD">6546249</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002106"
      unitRef="USD">1319115</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002108"
      unitRef="USD">7015512</us-gaap:Revenues>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002110">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zC7KRbYjMXPd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BF_zOrqnCzeKVC3" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of Revenue disaggregated&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;years ended&lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Revenue from intelligent computing
        power service&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zLe37nj4DRT9" title="Total"&gt;1,193,982&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--Revenues_pp0d_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z5LhznXQI8B2" title="Total"&gt;6,546,249&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Revenue from comprehensive
        data center services&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;125,133&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;469,263&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630_zw4xoiRMPQs7" title="Total"&gt;1,319,115&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_pp0d_c20240701__20250630_zxIqgXFsjdA6" title="Total"&gt;7,015,512&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002112"
      unitRef="USD">1193982</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002114"
      unitRef="USD">6546249</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002116"
      unitRef="USD">125133</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002118"
      unitRef="USD">469263</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002120"
      unitRef="USD">1319115</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002122"
      unitRef="USD">7015512</us-gaap:Revenues>
    <cik0002065779:ContractLiabilitiesPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002127">&lt;p id="xdx_845_ecustom--ContractLiabilitiesPolicyTextBlock_zZWQnliQBId8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;n. &lt;span id="xdx_864_zhAHETYm7uU4"&gt;Contract liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company receives advance payments from its customers
for services to be provided in the future. These payments are recorded as&#160;contract liabilities&#160;on the balance sheet within &#x201c;Contract
liabilities&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Contract liabilities are recognized when
consideration is received from a customer prior to the Company satisfying its related performance obligations. For these service
contracts, the Company recognizes revenue, and reduces the contract liabilities,&#160;over time&#160;as the services are rendered
and the performance obligations are satisfied. Revenue recognized that was included in the contract liability balance at the
beginning of the year was nil &lt;span id="xdx_90A_ecustom--RevenueRecognized_c20230701__20240630_pp0p" style="display: none" title="Revenue recognized"&gt;0&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--RevenueRecognized_c20240701__20250630_pp0p" title="Revenue recognized"&gt;95,326&lt;/span&gt; for the years ended June&#160;30, 2024 and 2025, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:ContractLiabilitiesPolicyTextBlock>
    <cik0002065779:RevenueRecognized
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002129"
      unitRef="USD">0</cik0002065779:RevenueRecognized>
    <cik0002065779:RevenueRecognized
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002131"
      unitRef="USD">95326</cik0002065779:RevenueRecognized>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002133">&lt;p id="xdx_847_eus-gaap--CostOfSalesPolicyTextBlock_zd6uOxmwVUC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;o. &lt;span id="xdx_868_zt2YqZ7h4862"&gt;Cost of revenues&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s cost of revenues primarily includes
computing power service and professional service fees. All the cost of revenues are recognized in the period in which the related services
occur or the benefits are received.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CostOfSalesPolicyTextBlock>
    <cik0002065779:SellingAndMarketingExpensesPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002135">&lt;p id="xdx_84E_ecustom--SellingAndMarketingExpensesPolicyTextBlock_zNtKHlQglhzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;p. &lt;span id="xdx_861_z8U06Sm8eK8b"&gt;Selling and marketing expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s selling and marketing expenses
primarily include: (i) advertising and promotion expenses, (ii) compensation and benefits for sales personnel and related share based
compensation, and (iii) travel and other routine office expense. All expenses are recognized in the period in which the related services
occur or the benefits are received. The Company expenses advertising costs as incurred, and for the years ended June&#160;30, 2024 and
2025, the Company incurred advertising and promotion expenses of $&lt;span id="xdx_908_eus-gaap--MarketingAndAdvertisingExpense_c20230701__20240630_pp0p" title="Advertising and promotion expenses"&gt;26,340&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20240701__20250630_pp0p" title="Advertising and promotion expenses"&gt;157,388&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:SellingAndMarketingExpensesPolicyTextBlock>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002137"
      unitRef="USD">26340</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002139"
      unitRef="USD">157388</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002141">&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zTShSXVP9mc7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;q. &lt;span id="xdx_864_zLpo4DODnKa5"&gt;Research and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s research and development expenses
mainly consist of &lt;span style="color: #0F1115; color: #0F1115"&gt;software development outsourcing service fees and testing expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002143">&lt;p id="xdx_844_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zdyBpybY30kg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;r. &lt;span id="xdx_866_z1OzlN0cGTed"&gt;General and administrative expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s general and administrative expenses
mainly consist of &lt;span style="color: #0F1115; color: #0F1115"&gt;software subscription fees, legal and professional service fees, certification
service fees, depreciation expenses and handling charges.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002145">&lt;p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zH16tov7HOHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;s. &lt;span id="xdx_86A_zfzDgxosnhkd"&gt;Income tax&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Income taxes are determined in accordance with the
provisions of ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC Topic 740&#x201d;). Under this method, deferred tax assets and liabilities
are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing
assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates
expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. Any effect
on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC 740 prescribes a comprehensive model for how companies
should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on
a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the
position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as
the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority
assuming full knowledge of the position and relevant facts.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <cik0002065779:CapitalStructurePolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002150">&lt;p id="xdx_842_ecustom--CapitalStructurePolicyTextBlock_zrhorRvRLTn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;t. &lt;span id="xdx_86F_zOYxMEHi9sP1"&gt;Capital structure&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is authorized to issue &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20240630_pd" title="Common stock, shares authorized"&gt;&lt;span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_c20250630_pd" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt;&lt;/span&gt; ordinary
shares of $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20240630_pd" title="Common stock, par value"&gt;&lt;span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_c20250630_pd" title="Common stock, par value"&gt;0.01&lt;/span&gt;&lt;/span&gt; par value each. As of June&#160;30, 2024 and 2025, there were &lt;span id="xdx_90B_eus-gaap--CommonStockSharesIssued_c20240630_pd" title="Common stock, shares issued"&gt;&lt;span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_c20240630_pd" title="Common stock, shares outstanding"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockSharesIssued_c20250630_pd" title="Common stock, shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_c20250630_pd" title="Common stock, shares outstanding"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares issued and outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the resolution of the board of directors
on January&#160;8, 2026, the authorized share capital of &lt;span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_c20260108_pd" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt; ordinary shares was re-designated to &lt;span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pd" title="Common stock, shares authorized"&gt;303&lt;/span&gt; Class A ordinary shares and &lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pd" title="Common stock, shares authorized"&gt;1,197&lt;/span&gt;
Class B ordinary shares. Holders of Class A ordinary shares and Class B ordinary shares have the same rights, except for voting and conversion
rights. Each Class A ordinary share is entitled to one vote; and each Class B ordinary share is entitled to twenty votes and is convertible
into one Class A ordinary share at any time by the holder thereof. Class A ordinary shares are not convertible into Class B ordinary shares
under any circumstances. Furthermore, all outstanding warrants, options, and SAFEs are designated to convert or settle exclusively into
Class A ordinary shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:CapitalStructurePolicyTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002152"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002154"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002156"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002158"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002160"
      unitRef="Shares">1500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002162"
      unitRef="Shares">1500</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002164"
      unitRef="Shares">1500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002166"
      unitRef="Shares">1500</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-01-08_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002168"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-01-08_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002170"
      unitRef="Shares">303</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-01-08_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002172"
      unitRef="Shares">1197</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002174">&lt;p id="xdx_848_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zyjuGtgiN2l4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;u. &lt;span id="xdx_860_zz7zMNdlRtT9"&gt;Share-based compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company grants Share awards of the Company to
eligible employees and&#160;non-employees. The Company accounts for share-based awards issued to employees and&#160;non-employees in accordance
with ASC Topic 718 &lt;i&gt;Compensation &#x2013; Stock Compensation. &lt;/i&gt;The Company recognizes forfeitures as they occur. The share-based compensation
expenses have been categorized as either general and administrative expenses or selling and marketing expenses, depending on the job functions
of the grantees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s share-based compensation awards
are expected to be settled through transfers of existing ordinary shares held by the controlling shareholder, rather than through the
issuance of new shares by the Company. The underlying ordinary shares are included in issued and outstanding shares as of the balance
sheet date; accordingly, such settlement is not expected to increase the Company&#x2019;s total issued and outstanding shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Employees&#x2019; share-based awards and non-employees&#x2019;
share-based awards are measured at the grant date fair value of the awards and recognized as expenses a) immediately at grant date if
no vesting conditions are required; or b) using graded vesting method, net of estimated forfeitures, over the requisite service period,
which is the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company employs discounted cash flow method to
determine the fair value of our share-based compensation arrangements, where the key valuation variables include risk free rate, discount
rate and perpetual rate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002176">&lt;p id="xdx_84E_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zj5A0O1qUZwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;v. &lt;span id="xdx_867_zetDcyDJZsD4"&gt;Segment reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC 280, &#x201c;Segment Reporting&#x201d;, establishes
standards for reporting information about operating segments on a basis consistent with the Company&#x2019;s internal organizational structure
as well as information about geographical areas, business segments and major customers in financial statements for details on the Company&#x2019;s
business segments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company uses the &#x201c;management approach&#x201d;
in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#x2019;s
chief operating decision maker (&#x201c;CODM&#x201d;) for making operating decisions and assessing performance as the source for determining
the Company&#x2019;s reportable segments. The Company&#x2019;s CODM is the chief executive director. The CODM regularly reviews entity-wide
operating results and reviews revenues and net loss when making decisions about allocating resources and assessing performance of the
segment, and hence, the Company has only&#160;one&#160;reportable segment. Therefore, as the Company has determined it operates as a single
reportable segment, the CODM assesses the Company&#x2019;s performance and results of operations on an entity-wide basis.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <cik0002065779:RelatedPartiesPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002181">&lt;p id="xdx_84D_ecustom--RelatedPartiesPolicyTextBlock_zmOqA55enEsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;w. &lt;span id="xdx_862_zI2bQw1nSKC"&gt;Related parties&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Parties are considered to be related if one party
has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial
and operating decisions. Parties are also considered to be related if they are subject to common control or significant influence, such
as a family member or relative, shareholder, or a related corporation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RelatedPartiesPolicyTextBlock>
    <cik0002065779:ComprehensiveLossPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002183">&lt;p id="xdx_849_ecustom--ComprehensiveLossPolicyTextBlock_z3GLuD1HtmQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;x. &lt;span id="xdx_866_zJfxnr89HArh"&gt;Comprehensive loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Comprehensive loss is defined as a change in equity
during a period from transactions and other events and circumstances&#160;from&#160;non-owner&#160;sources.&#160;The Company&#x2019;s comprehensive
loss was the same as its reported net loss for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:ComprehensiveLossPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002185">&lt;p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zRr2tTiRL483" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;y.&lt;span id="xdx_864_zWpJBAyOYapg"&gt; Loss&#160;per share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per share of ordinary shares attributable
to ordinary shareholders is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average shares of ordinary
shares outstanding for the period. Potentially dilutive shares, which are based on the weighted-average shares of ordinary shares underlying
outstanding share-based awards or options using the treasury stock method or the if-converted method, as applicable, are included when
calculating diluted net income per share of ordinary shares attributable to ordinary shareholders when their effect is dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Diluted net loss per share attributable to ordinary
shareholders is computed by adjusting the weighted-average number of ordinary shares outstanding for the dilutive effect of all potential
ordinary share equivalents. For the Company, potential ordinary share equivalents consisted of share-based compensation, which are assessed
using the&#160;treasury stock method. These potential shares are included in the diluted earnings per share calculation only when their
effect is&#160;dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In periods where the Company reports a&#160;net loss,
diluted net loss per share is calculated in the same manner as basic net loss per share because the inclusion of any potential ordinary
shares would have an&#160;anti-dilutive&#160;effect. Consequently, all potential ordinary share equivalents were excluded from the calculation
for the years in which a net loss was incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:RevenueRecognitionDividends
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002187">&lt;p id="xdx_844_eus-gaap--RevenueRecognitionDividends_z5kiNZU4iFJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;z. &lt;span id="xdx_86E_z1wQVhVX3E9i"&gt;Dividends&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Dividends are recognized when declared. &lt;span id="xdx_908_eus-gaap--Dividends_pp0d_do_c20230701__20240630_z4eZ64ybMTmi" title="Dividends"&gt;&lt;span id="xdx_903_eus-gaap--Dividends_pp0d_do_c20240701__20250630_zSkJu776q1A8" title="Dividends"&gt;No&lt;/span&gt;&lt;/span&gt; dividends
were declared for the years ended June&#160;30, 2024 and 2025, respectively. The Company does not have any present plan to pay any dividends
on ordinary shares in the foreseeable future. The Company currently intends to retain the available funds and any future earnings to operate
and expand its business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionDividends>
    <us-gaap:Dividends
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002189"
      unitRef="USD">0</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002191"
      unitRef="USD">0</us-gaap:Dividends>
    <cik0002065779:RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002193">&lt;p id="xdx_840_ecustom--RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock_z7z0wstCtqqk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;aa. &lt;span id="xdx_86F_zUUr7JvI51i1"&gt;Recently adopted accounting standard updates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June&#160;2016, the FASB issued ASU&#160;2016-13,
&lt;i&gt;Financial Instruments&#160;&#x2014;&#160;Credit Losses&lt;/i&gt; (Topic&#160;326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU&#160;2016-13&#x201d;).
The new accounting standard introduced the current expected credit losses methodology (&#x201c;CECL&#x201d;) for estimating allowances for
credit losses. The measurement of expected credit losses under the CECL methodology is applicable to financial assets measured at amortized
costs, including loans and trade receivables. ASU&#160;2016-13 is effective for the Company, as an emerging growth company, for annual
and interim reporting periods beginning after December&#160;15, 2022. The Company adopted the standard on July&#160;1, 2023 using the
modified retrospective method for all financial assets in scope. The adoption of the standard did not have a material impact on the Company&#x2019;s
statements of income, or statements of cash flows.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November&#160;2023, the FASB issued ASU&#160;2023-07,
&#x201c;Segment Reporting (Topic&#160;280): &lt;i&gt;Improvements to Reportable Segment Disclosures&lt;/i&gt;.&#x201d; The amendments in this ASU are
intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating decision mark (&#x201c;CODM&#x201d;),
an amount for other segment items by reportable segment and a description of its composition, all annual disclosures required by FASB
ASU Topic&#160;280 in interim periods as well, and the title and position of the CODM and how the CODM uses the reported measures. Additionally,
this ASU requires that at least one of the reported segment profit and loss measures should be the measure that is most consistent with
the measurement principles used in an entity&#x2019;s financial statements. Lastly, this ASU requires public business entities with a single
reportable segment to provide all disclosures required by these amendments in this ASU and all existing segment disclosures in Topic&#160;280.
This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning
after December&#160;15, 2024. The Company has early adopted ASU 2023-07 on July&#160;1, 2023. As a result of adoption, the required disclosures
have been included in Note 2 and Note 14.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock>
    <cik0002065779:EmergingGrowthCompanyPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002200">&lt;p id="xdx_84B_ecustom--EmergingGrowthCompanyPolicyTextBlock_zXbI2MERplLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;bb. &lt;span id="xdx_860_zodYVIxzme09"&gt;Emerging growth company&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company intends to operate as an &#x201c;emerging
growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). The JOBS Act permits
companies with emerging growth company status to take advantage of an extended transition period to comply with new or revised accounting
standards, delaying the adoption of these accounting standards until such time as those standards would apply to private companies. The
Company elected to use this extended transition period to enable it to comply with new or revised accounting standards that have different
effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company
or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company&#x2019;s
financial statements may not be comparable to companies that comply with the new or revised accounting standards as of public company
effective dates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002202">&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztzNempdfu57" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;cc. &lt;span id="xdx_86D_z61KGdSvMHp3"&gt;Recently accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December&#160;2023, the FASB issued ASU&#160;No.&#160;2023-09,&#160;&lt;i&gt;Improvements
to Income Tax Disclosures&lt;/i&gt;&#160;(&#x201c;ASU&#160;2023-09&#x201d;),&#160;which requires entities to make incremental income tax disclosures
on an annual basis. The amendments require that public business entities disclose specific categories in the rate reconciliation and provide
additional information for reconciling items meeting a quantitative threshold. The amendments also require disclosure of income taxes
paid to be disaggregated by jurisdiction, and the disclosure of income tax expense disaggregated by federal, state, and foreign. ASU&#160;2023-09&#160;is
effective for the Company&#x2019;s annual reporting periods ending December&#160;31, 2025 and thereafter, with early adoption permitted.
The Company is evaluating adoption timing and the impact ASU&#160;2023-09&#160;will have on its financial statements and related disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March&#160;2024, the FASB issued ASU No. 2024-02,
&lt;i&gt;Codification Improvements-Amendments to Remove References to the Concepts Statements&lt;/i&gt; (&#x201c;ASU 2024-02&#x201d;). The amendments
in this Update affect a variety of Topics in the Codification. The amendments apply to all reporting entities within the scope of the
affected accounting guidance. This update contains amendments to the Codification that remove references to various Concepts Statements.
In most instances, the references are extraneous and not required to understand or apply the guidance. In other instances, references
were used in prior statements to provide guidance in certain topical areas. ASU 2024-02 is effective for public business entities for
fiscal years beginning after December&#160;15, 2024. For all other entities, the amendments are effective for fiscal years beginning after
December&#160;15, 2025. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or
made available for issuance. The adoption did not have a material impact on the Company&#x2019;s financial statement.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November&#160;2024, the FASB issued ASU 2024-03
&#x201c;&lt;i&gt;Income Statement&#x2014;Reporting comprehensive (loss) income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation
of Income Statement Expenses&lt;/i&gt;&#x201d; (&#x201c;ASU 2024-03&#x201d;). The amendments in this update intend to improve the disclosures about
a public business entity&#x2019;s expenses and address requests from investors for more detailed information about the types of expenses
(including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions
(such as cost of sales, selling, general and administrative expenses, and research and development). ASU 2024-03 is effective for fiscal
years beginning after December&#160;15, 2026, and interim periods beginning after December&#160;15, 2027. The Company is currently evaluating
the impact from the adoption of this ASU on its financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January&#160;2025, the FASB issued Accounting Standards
Update (ASU) No. 2025-01, &lt;i&gt;Income Statement &#x2014; Reporting comprehensive (loss) income &#x2014; Expense Disaggregation Disclosures&lt;/i&gt;
(Subtopic 220-40): Clarifying the Effective Date. The amendment clarifies the effective date of ASU No. 2024-03 that all public business
entities are required to adopt the guidance in annual reporting periods beginning after December&#160;15, 2026, and interim periods within
annual reporting periods beginning after December&#160;15, 2027. Early adoption of Update 2024-03 is permitted. The Company is currently
evaluating the impact of the above new accounting pronouncements or guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July&#160;2025, the FASB issued Accounting Standards
Update (ASU) No. 2025-05, &lt;i&gt;Financial Instruments &#x2014; Credit Losses&lt;/i&gt; (Topic 326): Measurement of Credit Losses for Accounts Receivable
and Contract Assets. The amendment provides (1) all entities with a practical expedient to assume that current conditions as of the balance
sheet date do not change for the remaining life of the assets and (2) entities other than public business entities with an accounting
policy election to consider collection activity after the balance sheet date when estimating expected credit losses for current accounts
receivable and current contract assets arising from transactions accounted for under Topic 606. This guidance is effective for annual
reporting periods beginning after December&#160;15, 2025 and interim reporting periods within those annual reporting periods. Early adoption
is permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Except as mentioned above, the Company does not believe
other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the balance sheets,
statements of income and comprehensive loss and cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002209">&lt;p id="xdx_80E_eus-gaap--ConcentrationRiskDisclosureTextBlock_zCNDhVCVmNLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;3. &lt;span id="xdx_82C_zFBbZ0r7Zud1"&gt;Concentration and risk&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentration of credit risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject us
to concentrations of credit risk consisted primarily of cash and cash equivalents, and accounts receivable. We perform ongoing credit
evaluations of our customers&#x2019; financial condition and maintain an allowance for potential credit losses. This allowance consisted
of an amount identified for specific customers and an amount based on overall estimated exposure. Our overall estimated exposure excludes
amounts covered by credit insurance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentration of customers&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s revenue was concentrated among
a limited number of customers during the periods presented. The following table summarized customers with greater than 10% of the total
revenue:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfConcentrationOfCustomersTableTextBlock_zed2bAfuUphh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B4_z48bm01L1Eva" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of Concentration of customers&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; years ended&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Customer A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zI3jDRHvmOHb" title="Concentration of credit risk"&gt;12.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zCJR511w04rj" title="Concentration of credit risk"&gt;14.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zJeeMwjQDM02" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2217"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_z2sWdo9WBpLi" title="Concentration of credit risk"&gt;12.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zvX47L5fSCGl" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2221"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_z7lIZvAGakw4" title="Concentration of credit risk"&gt;10.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_ziuVreXhY8Jc" title="Concentration of credit risk"&gt;31.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zsJSn6PWGOta" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2227"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zdcO0AkLU83b" title="Concentration of credit risk"&gt;11.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zapiuLRQgfx9" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2231"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zXQQtM1R6mP3" title="Concentration of credit risk"&gt;11.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zkn4huYfaA16" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2235"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;*:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;nil, new customer for the year ended June&#160;30, 2025&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zXQpMtPkMqqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s account receivable was concentrated
among a limited number of customers during the periods presented. The following table summarized customers with greater than 10% of the
total account receivable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfAccountsReceivableTextBlock_zul5l5RzGYv6" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BD_zHRJbQ5m4O88" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of account receivable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Customer G&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_ztRPBtEWTJi8" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2244"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zfLH42HKXt76" title="Concentration of credit risk"&gt;42.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer H&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zNKBHqTWkrn4" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2248"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zEKpxvmQvgCh" title="Concentration of credit risk"&gt;38.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zGqVCvs69Qf1" title="Concentration of credit risk"&gt;23.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zC5KwJCVT3zf" title="Concentration of credit risk"&gt;19.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_znrResZohiG9" title="Concentration of credit risk"&gt;43.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_z6V3t8cHkLUj" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2258"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer I&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zYzaLovelHqg" title="Concentration of credit risk"&gt;15.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;*:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;nil, new customer for as of June&#160;30, 2025&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zazzTEdf3qC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentration of suppliers&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s purchases was concentrated among
a limited number of suppliers during the periods presented. The following table summarized suppliers with greater than 10% of the total
purchase:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfConcentrationOfSuppliersTableTextBlock_zdj4W8YCipk8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B7_zFinAf9oIFQc" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of Concentration of suppliers&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; years ended&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Supplier A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__srt--MajorCustomersAxis__custom--SupplierAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGIyJJPBbOil" title="Concentration of credit risk"&gt;56.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zXZaKxf02Dlh" title="Concentration of credit risk"&gt;41.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zgOzrD5jGv2g" title="Concentration of credit risk"&gt;14.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_z26lViCdPaY" title="Concentration of credit risk"&gt;31.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zo7uj5B50TF2" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2272"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_z9dWnq9LW8u3" title="Concentration of credit risk"&gt;18.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zG0uIze1Y1Ua" title="Concentration of credit risk"&gt;12.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zPqI0xfZVU09" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2278"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zNVjriFteaE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s account payable was concentrated
among a limited number of suppliers during the periods presented. The following table summarized suppliers with greater than 10% of the
total account payable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zUoSMF44CI8f" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BC_zrFgXmZyLEDl" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of account payable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Supplier E&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zD1SOuo8O6Gl" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2282"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_znsgNbuG5cH8" title="Concentration of credit risk"&gt;54.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_zdOC7T9Z4elg" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2286"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_zoDYy0fMwpSi" title="Concentration of credit risk"&gt;32.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_z0VhqD2tSjGa" title="Concentration of credit risk"&gt;99.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zwMhyEreZMRe" title="Concentration of credit risk"&gt;12.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;*:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;nil, new supplier for the year ended June&#160;30, 2025&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zUoOBb8uOtB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <cik0002065779:ScheduleOfConcentrationOfCustomersTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002211">&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfConcentrationOfCustomersTableTextBlock_zed2bAfuUphh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B4_z48bm01L1Eva" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of Concentration of customers&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; years ended&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Customer A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zI3jDRHvmOHb" title="Concentration of credit risk"&gt;12.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zCJR511w04rj" title="Concentration of credit risk"&gt;14.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zJeeMwjQDM02" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2217"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_z2sWdo9WBpLi" title="Concentration of credit risk"&gt;12.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zvX47L5fSCGl" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2221"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_z7lIZvAGakw4" title="Concentration of credit risk"&gt;10.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_ziuVreXhY8Jc" title="Concentration of credit risk"&gt;31.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zsJSn6PWGOta" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2227"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zdcO0AkLU83b" title="Concentration of credit risk"&gt;11.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zapiuLRQgfx9" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2231"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zXQQtM1R6mP3" title="Concentration of credit risk"&gt;11.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zkn4huYfaA16" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2235"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</cik0002065779:ScheduleOfConcentrationOfCustomersTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002213"
      unitRef="Ratio">0.120</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002215"
      unitRef="Ratio">0.140</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002219"
      unitRef="Ratio">0.125</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002223"
      unitRef="Ratio">0.102</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002225"
      unitRef="Ratio">0.316</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002229"
      unitRef="Ratio">0.119</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002233"
      unitRef="Ratio">0.110</us-gaap:ConcentrationRiskPercentage1>
    <cik0002065779:ScheduleOfAccountsReceivableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002242">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfAccountsReceivableTextBlock_zul5l5RzGYv6" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BD_zHRJbQ5m4O88" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of account receivable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Customer G&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_ztRPBtEWTJi8" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2244"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zfLH42HKXt76" title="Concentration of credit risk"&gt;42.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer H&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zNKBHqTWkrn4" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2248"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zEKpxvmQvgCh" title="Concentration of credit risk"&gt;38.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zGqVCvs69Qf1" title="Concentration of credit risk"&gt;23.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zC5KwJCVT3zf" title="Concentration of credit risk"&gt;19.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_znrResZohiG9" title="Concentration of credit risk"&gt;43.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_z6V3t8cHkLUj" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2258"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Customer I&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zYzaLovelHqg" title="Concentration of credit risk"&gt;15.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;*:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;nil, new customer for as of June&#160;30, 2025&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</cik0002065779:ScheduleOfAccountsReceivableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002246"
      unitRef="Ratio">0.427</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002250"
      unitRef="Ratio">0.383</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002252"
      unitRef="Ratio">0.234</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002254"
      unitRef="Ratio">0.190</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002256"
      unitRef="Ratio">0.435</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerIMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002260"
      unitRef="Ratio">0.153</us-gaap:ConcentrationRiskPercentage1>
    <cik0002065779:ScheduleOfConcentrationOfSuppliersTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002262">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfConcentrationOfSuppliersTableTextBlock_zdj4W8YCipk8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B7_zFinAf9oIFQc" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of Concentration of suppliers&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; years ended&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Supplier A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__srt--MajorCustomersAxis__custom--SupplierAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGIyJJPBbOil" title="Concentration of credit risk"&gt;56.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zXZaKxf02Dlh" title="Concentration of credit risk"&gt;41.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zgOzrD5jGv2g" title="Concentration of credit risk"&gt;14.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_z26lViCdPaY" title="Concentration of credit risk"&gt;31.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zo7uj5B50TF2" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2272"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_z9dWnq9LW8u3" title="Concentration of credit risk"&gt;18.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zG0uIze1Y1Ua" title="Concentration of credit risk"&gt;12.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zPqI0xfZVU09" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2278"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</cik0002065779:ScheduleOfConcentrationOfSuppliersTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_custom_PurchaseMember_custom_SupplierAMember_us-gaap_CustomerConcentrationRiskMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002264"
      unitRef="Ratio">0.566</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002266"
      unitRef="Ratio">0.414</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002268"
      unitRef="Ratio">0.146</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002270"
      unitRef="Ratio">0.317</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002274"
      unitRef="Ratio">0.184</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012024-06-30_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002276"
      unitRef="Ratio">0.128</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002280">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zUoSMF44CI8f" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BC_zrFgXmZyLEDl" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of account payable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Supplier E&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zD1SOuo8O6Gl" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2282"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_znsgNbuG5cH8" title="Concentration of credit risk"&gt;54.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_zdOC7T9Z4elg" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2286"&gt;-&lt;/span&gt;&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_zoDYy0fMwpSi" title="Concentration of credit risk"&gt;32.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Supplier C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_z0VhqD2tSjGa" title="Concentration of credit risk"&gt;99.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zwMhyEreZMRe" title="Concentration of credit risk"&gt;12.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;*:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;nil, new supplier for the year ended June&#160;30, 2025&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002284"
      unitRef="Ratio">0.549</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002288"
      unitRef="Ratio">0.323</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2023-07-012024-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002290"
      unitRef="Ratio">0.994</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002292"
      unitRef="Ratio">0.121</cik0002065779:ConcentrationRiskPercentage>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002295">&lt;p id="xdx_809_eus-gaap--FairValueDisclosuresTextBlock_zZLKhN6jsn7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;4. &lt;span id="xdx_820_zfA52tDeRbgk"&gt;Fair value measurements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June&#160;30, 2024 and 2025, information about
inputs into the fair value measurement of the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis
in periods subsequent to their initial recognition is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zaDKp93MBRA3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BC_zDd0pvvQ169b" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Schedule of fair value assets and liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value measurement at reporting date using&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;Description&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value &lt;br/&gt;as of&lt;br/&gt;June&#160;30,&lt;br/&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in&lt;br/&gt;Active Markets for&lt;br/&gt;Identical
        Assets &lt;br/&gt;(Level 1)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other&lt;br/&gt;Observable Inputs &lt;br/&gt;(Level
        2)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant &lt;br/&gt;Unobservable Inputs &lt;br/&gt;(Level
        3)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left"&gt;Simple agreements for future equity&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zZ4Gbth8BH69" title="Liability"&gt;9,321,564&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zjkwY6IR5PDj" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2301"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zZGm8phKzm75" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2303"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zwGllHMiXKtd" title="Liability"&gt;9,321,564&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Other payable related to the equity option&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zAoKTZ3VLxo3" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zoB0jQpIEfc6" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2309"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_z30wtD4xs1Jf" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2311"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zwMRf4C7bDM6" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value measurement at reporting date using&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;Description&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Fair value &lt;br/&gt;as of&lt;br/&gt;June&#160;30,&lt;/b&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in&lt;br/&gt;Active Markets for&lt;br/&gt;Identical
        Assets &lt;br/&gt;(Level 1)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other&lt;br/&gt;Observable Inputs &lt;br/&gt;(Level
        2)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant &lt;br/&gt;Unobservable Inputs &lt;br/&gt;(Level
        3)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left"&gt;Simple agreements for future equity&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zLQGMKOLzu9g" title="Liability"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zrVTS8w1XDWd" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2317"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zaXQfj4FsIb" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2319"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zchHueBxrDm8" title="Liability"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Other payable related to the equity option&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zqgBO7cAGUw8" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zy2IwQHN8iz8" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2325"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zzWPmd3ZrEEg" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2327"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zaU0cwEh6R2h" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td id="xdx_F02_zz6sJxvOrWkk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"&gt;(1)&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
        &lt;p id="xdx_F12_z2I6TVTCss33" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company classifies its SAFEs as financial liabilities
        measured at fair value. The value of the agreements depends significantly on future financing activities, liquidity events, or other material
        milestones, and their valuation relies on significant inputs that are not observable in the public market. Accordingly, they are classified
        within Level 3 of the fair value hierarchy.&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value measurement is based on an integrated
        framework combining&#160;scenario analysis and financial instrument decomposition (i.e. Bond Plus Call Method). The proceeds from the
        SAFEs on the date of issuance was $10,592,500, Refer to Note 9-Simple Agreements for Future Equity for further details.&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_F06_zXSVw5NzMGUg" style="color: #0F1115; color: #0F1115"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span id="xdx_F1A_z1nxpK5jT4mb" style="color: #0F1115; color: #0F1115"&gt;Equity
        option. On May&#160;9, 2023, the Company entered into an agreement with a third-party service provider (the &#x201c;Service Provider&#x201d;).
        The Service Provider received a freestanding equity-linked right exercisable, at the Service Provider&#x2019;s option, upon the closing
        of the Company&#x2019;s next qualified equity financing. The right provides the ability to subscribe for up to the value of $200,000 at
        a 25% discount price per share on the grant date. The equity option is remeasured at fair value at each reporting date, with changes in
        fair value recognized in earnings. As of June&#160;30, 2024 and June&#160;30, 2025, the fair value of the equity option was $53,333, and
        no gain or loss from changes in fair value was recognized for the periods presented. The fair value measurement of the equity option is
        categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based analysis, which incorporates significant
        unobservable inputs and management judgment regarding the probability and timing of potential future financing outcomes.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zHmdNJR8ytF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002297">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zaDKp93MBRA3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BC_zDd0pvvQ169b" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Schedule of fair value assets and liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value measurement at reporting date using&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;Description&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value &lt;br/&gt;as of&lt;br/&gt;June&#160;30,&lt;br/&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in&lt;br/&gt;Active Markets for&lt;br/&gt;Identical
        Assets &lt;br/&gt;(Level 1)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other&lt;br/&gt;Observable Inputs &lt;br/&gt;(Level
        2)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant &lt;br/&gt;Unobservable Inputs &lt;br/&gt;(Level
        3)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left"&gt;Simple agreements for future equity&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zZ4Gbth8BH69" title="Liability"&gt;9,321,564&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zjkwY6IR5PDj" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2301"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zZGm8phKzm75" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2303"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zwGllHMiXKtd" title="Liability"&gt;9,321,564&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Other payable related to the equity option&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zAoKTZ3VLxo3" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zoB0jQpIEfc6" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2309"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_z30wtD4xs1Jf" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2311"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zwMRf4C7bDM6" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value measurement at reporting date using&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;Description&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Fair value &lt;br/&gt;as of&lt;br/&gt;June&#160;30,&lt;/b&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in&lt;br/&gt;Active Markets for&lt;br/&gt;Identical
        Assets &lt;br/&gt;(Level 1)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other&lt;br/&gt;Observable Inputs &lt;br/&gt;(Level
        2)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant &lt;br/&gt;Unobservable Inputs &lt;br/&gt;(Level
        3)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left"&gt;Simple agreements for future equity&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zLQGMKOLzu9g" title="Liability"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zrVTS8w1XDWd" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2317"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zaXQfj4FsIb" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2319"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zchHueBxrDm8" title="Liability"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Other payable related to the equity option&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zqgBO7cAGUw8" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zy2IwQHN8iz8" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2325"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zzWPmd3ZrEEg" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2327"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zaU0cwEh6R2h" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td id="xdx_F02_zz6sJxvOrWkk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"&gt;(1)&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
        &lt;p id="xdx_F12_z2I6TVTCss33" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company classifies its SAFEs as financial liabilities
        measured at fair value. The value of the agreements depends significantly on future financing activities, liquidity events, or other material
        milestones, and their valuation relies on significant inputs that are not observable in the public market. Accordingly, they are classified
        within Level 3 of the fair value hierarchy.&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value measurement is based on an integrated
        framework combining&#160;scenario analysis and financial instrument decomposition (i.e. Bond Plus Call Method). The proceeds from the
        SAFEs on the date of issuance was $10,592,500, Refer to Note 9-Simple Agreements for Future Equity for further details.&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_F06_zXSVw5NzMGUg" style="color: #0F1115; color: #0F1115"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span id="xdx_F1A_z1nxpK5jT4mb" style="color: #0F1115; color: #0F1115"&gt;Equity
        option. On May&#160;9, 2023, the Company entered into an agreement with a third-party service provider (the &#x201c;Service Provider&#x201d;).
        The Service Provider received a freestanding equity-linked right exercisable, at the Service Provider&#x2019;s option, upon the closing
        of the Company&#x2019;s next qualified equity financing. The right provides the ability to subscribe for up to the value of $200,000 at
        a 25% discount price per share on the grant date. The equity option is remeasured at fair value at each reporting date, with changes in
        fair value recognized in earnings. As of June&#160;30, 2024 and June&#160;30, 2025, the fair value of the equity option was $53,333, and
        no gain or loss from changes in fair value was recognized for the periods presented. The fair value measurement of the equity option is
        categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based analysis, which incorporates significant
        unobservable inputs and management judgment regarding the probability and timing of potential future financing outcomes.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002299"
      unitRef="USD">9321564</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002305"
      unitRef="USD">9321564</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002307"
      unitRef="USD">53333</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002313"
      unitRef="USD">53333</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002315"
      unitRef="USD">18243885</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002321"
      unitRef="USD">18243885</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002323"
      unitRef="USD">53333</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002329"
      unitRef="USD">53333</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AccountsAndNontradeReceivableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002334">&lt;p id="xdx_806_eus-gaap--AccountsAndNontradeReceivableTextBlock_zdje7HeU8Tqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;5. &lt;span id="xdx_826_z2cS9GvZHBdg"&gt;Accounts receivable &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts receivable consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zOSA2JgZjj2j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts receivable (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B0_zVKrFI6QAXc2" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of Accounts receivable&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Accounts receivable&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--AccountsReceivableNetCurrent_c20240630_pp0p" title="Accounts receivable"&gt;123,332&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AccountsReceivableNetCurrent_c20250630_pp0p" title="Accounts receivable"&gt;152,536&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Less: allowance for credit
        losses&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_c20240630_zTKCr1aFiAHe" title="Less: allowance for credit losses"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_c20250630_zo59ljd2r8vk" title="Less: allowance for credit losses"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Accounts
        receivable, net&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AccountsReceivableNet_c20240630_pp0p" title="Accounts receivable, net"&gt;123,332&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AccountsReceivableNet_c20250630_pp0p" title="Accounts receivable, net"&gt;152,536&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts Receivable are recorded at the invoiced amount
and do not bear interest. The Company maintains an allowance for credit losses for expected losses over the life of the accounts receivable
using the current expected credit loss methodology. The Company determines the allowance based on historical loss experience, current
conditions, and reasonable and supportable forecasts. As of June&#160;30, 2024 and 2025, there was &lt;span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20240630_zNwMZQsRvRJ9" title="Allowance for credit losses"&gt;&lt;span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_z7pQLRmnRnl8" title="Allowance for credit losses"&gt;no&lt;/span&gt;&lt;/span&gt; allowance for expected credit losses.&lt;/p&gt;

</us-gaap:AccountsAndNontradeReceivableTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002336">&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zOSA2JgZjj2j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts receivable (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B0_zVKrFI6QAXc2" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of Accounts receivable&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Accounts receivable&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--AccountsReceivableNetCurrent_c20240630_pp0p" title="Accounts receivable"&gt;123,332&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AccountsReceivableNetCurrent_c20250630_pp0p" title="Accounts receivable"&gt;152,536&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Less: allowance for credit
        losses&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_c20240630_zTKCr1aFiAHe" title="Less: allowance for credit losses"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_c20250630_zo59ljd2r8vk" title="Less: allowance for credit losses"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Accounts
        receivable, net&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AccountsReceivableNet_c20240630_pp0p" title="Accounts receivable, net"&gt;123,332&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AccountsReceivableNet_c20250630_pp0p" title="Accounts receivable, net"&gt;152,536&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002338"
      unitRef="USD">123332</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002340"
      unitRef="USD">152536</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002342"
      unitRef="USD">-0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002344"
      unitRef="USD">-0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002346"
      unitRef="USD">123332</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002348"
      unitRef="USD">152536</us-gaap:AccountsReceivableNet>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002350"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002352"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <cik0002065779:OtherReceivablesTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002354">&lt;p id="xdx_80A_ecustom--OtherReceivablesTextBlock_zA37jU1ZOfV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;br/&gt;&lt;b&gt;6. &lt;span id="xdx_821_zYjS7DyznEb5"&gt;Other receivables&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other receivables represent funds temporarily held
in trust by an employee acting as the Company&#x2019;s behalf. As of June&#160;30, 2024 and 2025, the balance were $&lt;span id="xdx_90D_eus-gaap--OtherReceivables_c20240630_pp0p" title="Other receivables"&gt;2,884,694&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--OtherReceivables_c20250630_pp0p" title="Other receivables"&gt;1,207,626&lt;/span&gt;,
respectively, primary comprising proceeds from SAFEs agreements received via the employee &lt;span style="color: #0F1115; color: #0F1115"&gt;and
net of payments made to designated suppliers at the Company&#x2019;s direction. The outstanding balance was fully settled in January&#160;2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:OtherReceivablesTextBlock>
    <us-gaap:OtherReceivables
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002356"
      unitRef="USD">2884694</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002358"
      unitRef="USD">1207626</us-gaap:OtherReceivables>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002360">&lt;p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zLYDRpyLKNhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;7. &lt;span id="xdx_820_z8sx4dTJBxsg"&gt;Equipment, net&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Equipment, net consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--PropertyPlantAndEquipmentTextBlock_zWlZAMPXOKe1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equipment, net (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B5_z96otHUhXDyg" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Schedule of Equipment&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20240630_zIHWu3xL186" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20250630_zYNqMLOHwIRg" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt"&gt;Equipment&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;27,806&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;29,944&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;27,806&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;29,944&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_pp0d_di_zx2ts7Yln7tf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,110&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,344&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net
        carrying amount&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;23,696&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;19,600&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation expenses for the&#160;years ended June&#160;30,
2024 and 2025 were $&lt;span id="xdx_900_eus-gaap--Depreciation_c20230701__20240630_zomGNXN2kYl4" title="Depreciation expenses"&gt;4,110&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--Depreciation_c20240701__20250630_zueTAB6r85N5" title="Depreciation expenses"&gt;6,234&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002362">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--PropertyPlantAndEquipmentTextBlock_zWlZAMPXOKe1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equipment, net (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B5_z96otHUhXDyg" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Schedule of Equipment&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20240630_zIHWu3xL186" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20250630_zYNqMLOHwIRg" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt"&gt;Equipment&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;27,806&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;29,944&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;27,806&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;29,944&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_pp0d_di_zx2ts7Yln7tf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,110&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,344&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net
        carrying amount&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;23,696&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;19,600&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002364"
      unitRef="USD">27806</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002365"
      unitRef="USD">29944</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentOtherNet
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002367"
      unitRef="USD">27806</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002368"
      unitRef="USD">29944</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002370"
      unitRef="USD">4110</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002371"
      unitRef="USD">10344</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002373"
      unitRef="USD">23696</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002374"
      unitRef="USD">19600</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002376"
      unitRef="USD">4110</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002378"
      unitRef="USD">6234</us-gaap:Depreciation>
    <cik0002065779:RefundableDepositsPayableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002380">&lt;p id="xdx_80D_ecustom--RefundableDepositsPayableTextBlock_zdT8v1NNaUXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;8. &lt;span id="xdx_82D_zslWpkq71Jm9"&gt;Refundable deposits payable &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Refundable deposits payable represent security payments
received from a third party and customers, which are required for certain intelligent computing power service arrangements. As of June&#160;30,
2024 and 2025, the balance were $&lt;span id="xdx_908_ecustom--RefundableDepositsPayable_c20240630_pp0p" title="Refundable deposits payable"&gt;223,205&lt;/span&gt; and $&lt;span id="xdx_909_ecustom--RefundableDepositsPayable_c20250630_pp0p" title="Refundable deposits payable"&gt;1,445,580&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RefundableDepositsPayableTextBlock>
    <cik0002065779:RefundableDepositsPayable
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002382"
      unitRef="USD">223205</cik0002065779:RefundableDepositsPayable>
    <cik0002065779:RefundableDepositsPayable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002384"
      unitRef="USD">1445580</cik0002065779:RefundableDepositsPayable>
    <cik0002065779:SimpleAgreementsForFutureEquityTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002386">&lt;p id="xdx_803_ecustom--SimpleAgreementsForFutureEquityTextBlock_zOlXnvXLN6Ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;9. &lt;span id="xdx_821_zGErECRHaUFh"&gt;Simple agreements for future equity&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has entered into SAFEs with various investors
that were classified as liabilities on the Company&#x2019;s balance sheets and accounted for at fair value, subject to remeasurement each
reporting period. Each SAFEs has no maturity date, does not bear any interest and provides the investor with the right to convert into
a variable number of shares of future equity in the Company at the stated conversion amount, if certain events or conditions are triggered.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the period from October&#160;2022 through June&#160;2025,
the Company entered into Simple Agreements for Future Equity with third-party investors, receiving aggregate gross proceeds of $&lt;span id="xdx_909_eus-gaap--ProceedsFromOtherEquity_c20221001__20250630_pp0p" title="Aggregate gross proceeds"&gt;10,592,500&lt;/span&gt;.
Of this amount, $&lt;span id="xdx_900_eus-gaap--ProceedsFromOtherEquity_c20230701__20240630_pp0p" title="Aggregate gross proceeds"&gt;5,685,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--ProceedsFromOtherEquity_c20240701__20250630_pp0p" title="Aggregate gross proceeds"&gt;4,307,500&lt;/span&gt; were recorded in the fiscal years ended June&#160;30, 2024 and 2025, respectively. Subsequent
to June&#160;30, 2025, the Company received additional SAFEs proceeds of $&lt;span id="xdx_905_ecustom--AdditionalSafesProceeds_pp0d_c20240701__20250606__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkdoR94mROG6" title="Additional SAFEs proceeds"&gt;500,000&lt;/span&gt;, resulting in cumulative proceeds of $&lt;span id="xdx_908_ecustom--CumulativeProceeds_pp0d_c20240701__20250606__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVj7nuUFaL8k" title="Cumulative proceeds"&gt;11,092,500&lt;/span&gt; as
of the date of this report. No issuance costs were incurred in connection with these arrangements. As of the date these financial statements
are issued, none of the SAFEs have been settled or converted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The SAFEs agreements grant investors the right to
participate in the Company&#x2019;s future equity financing events. The agreements contain various conversion and redemption provisions,
including conversion upon an equity financing event, as well as settlement in the event of a liquidity event or dissolution of the Company.
Key terms of the SAFEs are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Equity Financing&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; Upon the
occurrence of an equity financing event, each SAFEs automatically converts into a greater of (i)&#160;the number of shares of preferred
stock equal to SAFEs purchase amount divided by &lt;span style="color: #0F1115; color: #0F1115"&gt;the lowest price per share paid for the standard
preferred stock&lt;/span&gt; or (ii)&#160;the number of shares of preferred stock equal to the SAFEs purchase amount divided by the SAFEs price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&#x201c;SAFEs price&#x201d; means &lt;span style="color: #0F1115; color: #0F1115"&gt;is
        calculated by dividing a fixed post-money valuation cap by the Company capitalization, a defined term that includes all outstanding equity
        and convertible instruments.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&#x201c;Equity Financing&#x201d; means a bona
        fide transaction or series of transactions with the principal purpose of raising capital, pursuant to which the Company issues and sells
        preferred share at a fixed valuation, including but not limited to, a pre-money or post-money valuation.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Not all SAFEs agreements contain the equity financing
conversion provision described above. Certain SAFEs are structured without an Equity Financing conversion feature and are generally settled
only upon a Liquidity Event or a Dissolution Event (as defined in the respective SAFEs agreements). The Company considered the contractual
terms of the SAFEs, including whether an Equity Financing conversion feature is present and the settlement provisions upon a Liquidity
Event or a Dissolution Event, in the valuation and measurement of these instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June&#160;30, 2025, &lt;span id="xdx_90D_ecustom--EquityFinancingDescription_pp0d_c20240701__20250630_zpoJJ0lxxOh" title="Equity Financing description"&gt;SAFEs with an aggregate
purchase amount of $10,132,500 include an Equity Financing conversion feature, while SAFEs with an aggregate purchase amount of $460,000
do not include this feature and are generally settled only upon a Liquidity Event or a Dissolution Event, in accordance with their terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #0F1115; color: #0F1115"&gt;The Company
does not have any preferred stock outstanding as of February&#160;11, 2026; therefore, an equity financing event has not been triggered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Liquidity Event&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; If there
is a liquidity event before the conversion of each SAFE, the holder of each SAFEs will automatically be entitled to the greater of (i)
SAFEs purchase amount, or (ii)&#160;the amount payable on the number of shares of ordinary shares equal to the purchase amount divided
by the Liquidity Price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&#x201c;Liquidity Price&#x201d; is calculated
        by dividing the post-money valuation cap by the separately defined capital base, referred to as &#x201c;liquidity capitalization&#x201d;
        in the SAFEs agreements.&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&#x201c;Liquidity Event&#x201d; means a change
        of control, a direct Listing or an initial public offering.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Dissolution Event&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; If there
is a dissolution event before the conversion of each SAFE, the holder of each SAFEs will automatically be entitled to receive a portion
of proceeds equal to SAFEs purchase amount.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company classifies its SAFEs as financial liabilities
measured at fair value. Since the value of these instruments depends on significant unobservable inputs, including future financing activities
and liquidity events, they are classified as Level 3 within the fair value hierarchy.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value measurement utilizes a combined scenario
analysis and financial instrument decomposition approach. Based on management&#x2019;s assessment of the Company&#x2019;s prospects, probability
distributions are assigned to potential settlement-triggering events. Valuation is performed using a &#x201c;debt plus option&#x201d; model:
the debt component is valued using a discounted cash flow method with key assumptions including expected settlement timing, risk-free
interest rate, and credit spread; the embedded conversion right is treated as a call option and valued using the Black-Scholes model,
with key inputs including the fair value of ordinary shares, expected term, and volatility. The overall fair value represents the probability-weighted
sum across all scenarios, supported by an independent third-party valuation specialist.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June&#160;30, 2024 and 2025, the SAFEs liabilities
were measured at fair value using the above Level 3 methodology. Significant unobservable inputs&#x2014;including timing of events, volatility,
and credit spreads&#x2014;are based on management&#x2019;s reasonable estimates as of each valuation date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following tables set forth a summary of the activity
of the SAFEs liabilities, respectively, which represents a recurring fair value measurement at the end of each reporting period:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zfdZKaMA3CCa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Simple agreements for future equity (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BD_z692NbrbQ79l" style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Schedule of fair value measurement&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left; padding-bottom: 1pt"&gt;Balance at
        June&#160;30, 2023&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90A_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20230701__20240630_z3t0Cul6FTGe" title="Balance at beginning"&gt;526,046&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Issuance of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20230701__20240630_z8DBIBOQ2pC6" title="Issuance of simple agreements for future equity"&gt;5,685,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ChangeInFairValue_c20230701__20240630_pp0p" title="Change in fair value"&gt;3,110,518&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Balance at June&#160;30,
        2024&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20240701__20250630_zmXBtU0sSxXj" title="Balance at beginning"&gt;9,321,564&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Issuance of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20240701__20250630_zpOe9NCtkcUa" title="Issuance of simple agreements for future equity"&gt;4,307,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ChangeInFairValue_pp0d_c20240701__20250630_zSYkDe6txhu7" title="Change in fair value"&gt;4,614,821&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Balance at June&#160;30,
        2025&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_901_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20240701__20250630_zgTzyRzot0oc" title="Balance at ending"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: #0F1115; color: #0F1115"&gt;If and
when the SAFEs are converted into equity, management currently expects that such conversion would be settled through transfers of existing
ordinary shares held by the controlling shareholder, rather than through the issuance of new shares by the Company, subject to the final
conversion terms and the relevant agreements. To the extent settled in this manner, the underlying ordinary shares are already included
in the Company&#x2019;s issued and outstanding shares as of the balance sheet date; therefore, such settlement would not be expected to
increase the Company&#x2019;s total issued and outstanding shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Subsequent to June&#160;30, 2025 (see Note 1), in
connection with the proposed business combination, the outstanding SAFEs are expected to be settled upon the closing of the transaction
(the &#x201c;Closing&#x201d;). Pursuant to their terms, if a SPAC transaction occurs prior to the termination of the SAFEs, each SAFE will
automatically convert at the Closing into the right to receive Class A ordinary shares of PubCo.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At the Closing of BCA transaction, each of SAFEs is
expected to convert into the Class A shares of the PubCo without any action required by the SAFE holders.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:SimpleAgreementsForFutureEquityTextBlock>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2022-10-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002391"
      unitRef="USD">10592500</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002393"
      unitRef="USD">5685000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002395"
      unitRef="USD">4307500</us-gaap:ProceedsFromOtherEquity>
    <cik0002065779:AdditionalSafesProceeds
      contextRef="From2024-07-012025-06-06_us-gaap_SubsequentEventMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002397"
      unitRef="USD">500000</cik0002065779:AdditionalSafesProceeds>
    <cik0002065779:CumulativeProceeds
      contextRef="From2024-07-012025-06-06_us-gaap_SubsequentEventMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002399"
      unitRef="USD">11092500</cik0002065779:CumulativeProceeds>
    <cik0002065779:EquityFinancingDescription
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002401">SAFEs with an aggregate
purchase amount of $10,132,500 include an Equity Financing conversion feature, while SAFEs with an aggregate purchase amount of $460,000
do not include this feature and are generally settled only upon a Liquidity Event or a Dissolution Event, in accordance with their terms.</cik0002065779:EquityFinancingDescription>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002406">&lt;table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zfdZKaMA3CCa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Simple agreements for future equity (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BD_z692NbrbQ79l" style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Schedule of fair value measurement&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left; padding-bottom: 1pt"&gt;Balance at
        June&#160;30, 2023&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90A_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20230701__20240630_z3t0Cul6FTGe" title="Balance at beginning"&gt;526,046&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Issuance of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20230701__20240630_z8DBIBOQ2pC6" title="Issuance of simple agreements for future equity"&gt;5,685,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ChangeInFairValue_c20230701__20240630_pp0p" title="Change in fair value"&gt;3,110,518&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Balance at June&#160;30,
        2024&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20240701__20250630_zmXBtU0sSxXj" title="Balance at beginning"&gt;9,321,564&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Issuance of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20240701__20250630_zpOe9NCtkcUa" title="Issuance of simple agreements for future equity"&gt;4,307,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ChangeInFairValue_pp0d_c20240701__20250630_zSYkDe6txhu7" title="Change in fair value"&gt;4,614,821&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Balance at June&#160;30,
        2025&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_901_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20240701__20250630_zgTzyRzot0oc" title="Balance at ending"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2023-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002408"
      unitRef="USD">526046</cik0002065779:SimpleAgreementsForFutureEquity>
    <cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002410"
      unitRef="USD">5685000</cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValue
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002412"
      unitRef="USD">3110518</cik0002065779:ChangeInFairValue>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002414"
      unitRef="USD">9321564</cik0002065779:SimpleAgreementsForFutureEquity>
    <cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002416"
      unitRef="USD">4307500</cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValue
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002418"
      unitRef="USD">4614821</cik0002065779:ChangeInFairValue>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002420"
      unitRef="USD">18243885</cik0002065779:SimpleAgreementsForFutureEquity>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002422">&lt;p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zcy1yoqRg3A8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;10. &lt;span id="xdx_829_zqCnxgL6N714"&gt;Income taxes&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company was incorporated in the State of Delaware
and is subject to income taxes in its primary jurisdictions: U.S. federal income tax and Delaware state corporate income tax. The statutory
tax rates applicable to the Company are &lt;span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c20230701__20240630_pd" title="Federal income tax rate"&gt;21%&lt;/span&gt; at the federal level and &lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c20230701__20240630_pd" title="State income tax rate"&gt;8.7%&lt;/span&gt; at the Delaware state level.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The current and deferred components of income tax
expense reflected in the statements of operations and comprehensive loss were nil for the years ended June&#160;30, 2024 and 2025.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table reconciles the statutory rate
to the Company&#x2019;s effective tax rate. The effective tax rate reconciliation is based on the U.S. federal statutory rate of &lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c20240701__20250630_pd" title="Federal income tax rate"&gt;21%&lt;/span&gt; and
State income tax rate of &lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c20240701__20250630_pd" title="State income tax rate"&gt;8.7%&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zsAoZZYShxpj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B0_zDFQbJEySiid" style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Schedule
    of effective tax rate reconciliation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20230701__20240630_zzRi4Ul5zEh4" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20240701__20250630_z4awAYIlbT9i" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;years ended &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zobXWve4AQQ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"&gt;US Statutory income tax rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zXJf7zZEBnT9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;State income tax rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8.7&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8.7&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_z7RcGEC6ZYGk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Change in fair value of simple agreements
        for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(18.6&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(17.9&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zr3zjXhd2iGj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Changes in valuation
        allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(11.1&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(11.8&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_zoxSlARfz4f7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Effective income tax
        rate&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zEYZ96HGd4s6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s effective income tax rate was&#160;&lt;span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20230701__20240630_pd" title="Effective income tax rate"&gt;&lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20240701__20250630_pd" title="Effective income tax rate"&gt;0%&lt;/span&gt;&lt;/span&gt;&#160;for
both years ended June&#160;30, 2024 and 2025. This is primarily attributable to the&#160;recognition of a full valuation allowance against
the net deferred tax assets, as the Company has concluded that it is not more likely than not that these assets will be realized in the
foreseeable future. Accordingly, no tax benefit has been recognized for the losses incurred during these periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The principal components of deferred tax assets and
deferred tax liabilities were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z7D3h5I8b915" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B9_zttoKTamREFa" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of deferred tax assets liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20240630_za1CYiN8uNR8" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20250630_zzAPMP8qH497" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zBsuAX9Qs0ka" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Deferred tax assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0d_maDTAGzLH3_zHcERxaR5LOi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Net operating loss carry forward&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;748,679&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,652,998&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0d_mtDTAGzLH3_maDTANzse2_zpw9mkr8b4Dl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Total deferred tax assets&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;748,679&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;1,652,998&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0d_di_msDTANzse2_zkDKYZabHnVh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Less: valuation allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(748,679&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,652,998&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_pp0d_mtDTANzse2_zy5BDhrvNfsk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total
        deferred tax assets, net&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2470"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2471"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zuxWXyBw7azl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The changes in valuation allowance for the years ended
June&#160;30, 2024 and 2025 were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--SummaryOfValuationAllowanceTextBlock_zEsllNSptTmj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B0_zZZDDEY0OvS5" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of valuation allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;years ended&lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Balance at the beginning of the
        year&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pp0d_di_c20230701__20240630_zJGpG8QdG3kj" title="Balance at the beginning of the year"&gt;(200,468&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pp0d_di_c20240701__20250630_zQtXy1pEoPm8" title="Balance at the beginning of the year"&gt;(748,679&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Additions&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230701__20240630_pp0p" title="Additions"&gt;(548,211&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20240701__20250630_pp0p" title="Additions"&gt;(904,319&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Balance
        at the end of the year&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pp0d_di_c20230701__20240630_zoH4it63AAy2" title="Balance at the end of the year"&gt;(748,679&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pp0d_di_c20240701__20250630_zU4aB0tVNds8" title="Balance at the end of the year"&gt;(1,652,998&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z8CNIKlnZrV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June&#160;30, 2024 and 2025, the Company had
net operating loss carryforwards (&#x201c;NOLs&#x201d;) of $&lt;span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20240630__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_zpz7739yT5vi" title="Net operating loss carryforwards"&gt;2.5 &lt;/span&gt;million and $&lt;span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20250630__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_zc5tGTGft7Zk" title="Net operating loss carryforwards"&gt;5.6&lt;/span&gt; million for U.S. federal income tax purposes and $&lt;span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20240630__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--StateAndLocalJurisdictionMember_zrcfQglwNFDb" title="Net operating loss carryforwards"&gt;2.5&lt;/span&gt; million
and $&lt;span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20250630__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--StateAndLocalJurisdictionMember_zrvFbn738Xcg" title="Net operating loss carryforwards"&gt;5.6&lt;/span&gt; million for state income tax purposes.&#160;The federal NOLs&#160;do not expire but are subject to an annual deduction limit
of 80% of taxable income.&#160;The Company&#x2019;s NOLs can be carried forward to offset current year profit for Delaware corporate income
tax purposes, subject to certain limitations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes deferred tax assets if it is
more likely than not that those deferred tax assets will be realized. Management reviews deferred tax assets periodically for recoverability
and makes estimates and judgments regarding the expected geographic sources of taxable income in assessing the need for a valuation allowance
to reduce deferred tax assets to their estimated realizable value. Realization of the Company&#x2019;s deferred tax assets is dependent
upon future earnings, if any, the timing and amount of which are uncertain.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company had &lt;span id="xdx_909_eus-gaap--UnrecognizedTaxBenefits_iI_pp0d_do_c20250630_zIwngjxvmio1" title="Unrecognized tax benefits"&gt;&lt;span id="xdx_903_eus-gaap--UnrecognizedTaxBenefits_iI_pp0d_do_c20240630_zXcxlUP6ogpf" title="Unrecognized tax benefits"&gt;no&lt;/span&gt;&lt;/span&gt; unrecognized tax benefits as of
June&#160;30, 2024 and 2025. The Company currently files income tax returns in the U.S., as well as Delaware. All tax years are open for
examination. The Company currently has no federal or state tax examinations in progress.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002424"
      unitRef="Ratio">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002426"
      unitRef="Ratio">0.087</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002431"
      unitRef="Ratio">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002433"
      unitRef="Ratio">0.087</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002435">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zsAoZZYShxpj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B0_zDFQbJEySiid" style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Schedule
    of effective tax rate reconciliation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20230701__20240630_zzRi4Ul5zEh4" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20240701__20250630_z4awAYIlbT9i" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;years ended &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zobXWve4AQQ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"&gt;US Statutory income tax rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zXJf7zZEBnT9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;State income tax rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8.7&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8.7&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_z7RcGEC6ZYGk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Change in fair value of simple agreements
        for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(18.6&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(17.9&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zr3zjXhd2iGj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Changes in valuation
        allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(11.1&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(11.8&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_zoxSlARfz4f7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Effective income tax
        rate&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002437"
      unitRef="Ratio">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002438"
      unitRef="Ratio">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002440"
      unitRef="Ratio">0.087</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002441"
      unitRef="Ratio">0.087</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002443"
      unitRef="Ratio">-0.186</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002444"
      unitRef="Ratio">-0.179</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002446"
      unitRef="Ratio">-0.111</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002447"
      unitRef="Ratio">-0.118</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002449"
      unitRef="Ratio">-0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002450"
      unitRef="Ratio">-0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002452"
      unitRef="Ratio">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002454"
      unitRef="Ratio">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002456">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z7D3h5I8b915" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B9_zttoKTamREFa" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of deferred tax assets liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20240630_za1CYiN8uNR8" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20250630_zzAPMP8qH497" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zBsuAX9Qs0ka" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Deferred tax assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0d_maDTAGzLH3_zHcERxaR5LOi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Net operating loss carry forward&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;748,679&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,652,998&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0d_mtDTAGzLH3_maDTANzse2_zpw9mkr8b4Dl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Total deferred tax assets&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;748,679&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;1,652,998&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0d_di_msDTANzse2_zkDKYZabHnVh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Less: valuation allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(748,679&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,652,998&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_pp0d_mtDTANzse2_zy5BDhrvNfsk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total
        deferred tax assets, net&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2470"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2471"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002461"
      unitRef="USD">748679</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002462"
      unitRef="USD">1652998</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002464"
      unitRef="USD">748679</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002465"
      unitRef="USD">1652998</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002467"
      unitRef="USD">748679</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002468"
      unitRef="USD">1652998</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002473">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--SummaryOfValuationAllowanceTextBlock_zEsllNSptTmj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B0_zZZDDEY0OvS5" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of valuation allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;years ended&lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Balance at the beginning of the
        year&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pp0d_di_c20230701__20240630_zJGpG8QdG3kj" title="Balance at the beginning of the year"&gt;(200,468&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pp0d_di_c20240701__20250630_zQtXy1pEoPm8" title="Balance at the beginning of the year"&gt;(748,679&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Additions&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230701__20240630_pp0p" title="Additions"&gt;(548,211&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20240701__20250630_pp0p" title="Additions"&gt;(904,319&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Balance
        at the end of the year&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pp0d_di_c20230701__20240630_zoH4it63AAy2" title="Balance at the end of the year"&gt;(748,679&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pp0d_di_c20240701__20250630_zU4aB0tVNds8" title="Balance at the end of the year"&gt;(1,652,998&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002475"
      unitRef="USD">200468</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002477"
      unitRef="USD">748679</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002479"
      unitRef="USD">-548211</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002481"
      unitRef="USD">-904319</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002483"
      unitRef="USD">748679</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002485"
      unitRef="USD">1652998</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-06-30_us-gaap_DomesticCountryMember_custom_ExascaleLabsIncMember"
      decimals="-3"
      id="Fact002487"
      unitRef="USD">2500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-06-30_us-gaap_DomesticCountryMember_custom_ExascaleLabsIncMember"
      decimals="-3"
      id="Fact002489"
      unitRef="USD">5600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-06-30_us-gaap_StateAndLocalJurisdictionMember_custom_ExascaleLabsIncMember"
      decimals="-3"
      id="Fact002491"
      unitRef="USD">2500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-06-30_us-gaap_StateAndLocalJurisdictionMember_custom_ExascaleLabsIncMember"
      decimals="-3"
      id="Fact002493"
      unitRef="USD">5600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002495"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002497"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002500">&lt;p id="xdx_80A_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zEMl0kz98Cb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;11. &lt;span id="xdx_82F_zojw0uTLGhUa"&gt;Share-based compensation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the years ended June&#160;30, 2024 and 2025, total
share-based compensation expenses recognized were $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230701__20240630_pp0p" title="Share-based compensation expenses"&gt;21,104&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630_pp0p" title="Share-based compensation expenses"&gt;153,266&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table sets forth the share-based compensation
expenses for the years ended June&#160;30, 2024 and 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock_zYgAKTu1lo7k" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-based compensation (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BB_zwzJiikWfcV4" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of share-based compensation expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;years ended &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Selling and marketing expenses&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_c20230701__20240630__custom--IncomeStatementLocationsAxis__custom--SellingAndMarketingExpensesMember_pp0p" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2508"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20240701__20250630__custom--IncomeStatementLocationsAxis__custom--SellingAndMarketingExpensesMember_pp0p" title="Total"&gt;153,266&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;General and administrative
        expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230701__20240630__custom--IncomeStatementLocationsAxis__custom--GeneralAndAdministrativeExpensesMember_pp0p" title="Total"&gt;21,104&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630__custom--IncomeStatementLocationsAxis__custom--GeneralAndAdministrativeExpensesMember_pp0p" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2514"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0d_c20230701__20240630_zG6MuWsZDbL5" title="Total"&gt;21,104&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0d_c20240701__20250630_zgdo4PX2S2yh" title="Total"&gt;153,266&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(1) Employee&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January&#160;6, 2025, with the approval from the
Board of the Company, an employee was granted equity award from inception of the employment agreement, which represented 0.1% of the Company&#x2019;s
total shares outstanding at issuance date (the &#x201c;0.1% Award&#x201d;, i.e., 1.5 shares). The equity award had a vesting period of 24
months after grant, but with no requisite service period. Alongside with the employee&#x2019;s separation in September&#160;2025, the equity
award remained its vesting pace under the 24-month vesting schedule. As of June&#160;30, 2025, &lt;span id="xdx_907_ecustom--SharesDescription_pp0d_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_ziZsFKTjvi5i" title="Shares description"&gt;0.375 shares of the Company were vested,
with remaining 1.125 shares unvested.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company determined January&#160;6, 2025 to be
the grant date of the 0.1% Award and recognized total share-based compensation expense amounted to $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_pp0p" title="Share-based compensation expenses"&gt;101,000&lt;/span&gt; at the grant date for the
award since the explicit service vesting condition is not the employee&#x2019;s requisite service period, and the vesting condition is
not a service condition but is merely a delayed exercisability provision. The share-based compensation expense was calculated based on
the fair value of the 0.1% Award as of the grant date. The fair value of the 0.1% Award was determined with assistance of an independent
third-party valuation specialist using discounted cash flow method with key assumptions of risk free rate of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Risk free rate"&gt;4.24%&lt;/span&gt;, discount rate of &lt;span id="xdx_900_ecustom--DiscountRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Discount rate"&gt;13.6%&lt;/span&gt;
and perpetual rate of &lt;span id="xdx_901_ecustom--PerpetualRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Perpetual rate"&gt;3.0%&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(2) Non-employee&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December&#160;2, 2024, with the approval from the
Board of the Company, a contractor was granted equity award from inception of the contractor agreement representing 0.053333% of the Company&#x2019;s
total shares outstanding at issuance date (&#x201c;0.05% Award&#x201d;, i.e., 0.8 shares). The equity award had a vesting period of 24 months
after grant, with half vested as of April&#160;1, 2025 and remaining as of November&#160;1, 2026, but with no requisite service period.
As of June&#160;30, 2025, the first half of the equity award had been vested, the remaining half had been outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company determined December&#160;2, 2024 to be
the grant date of the 0.05% Award and recognized total share-based compensation expense amounted to $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pp0p" title="Share-based compensation expenses"&gt;52,266&lt;/span&gt; at the grant date for the
award since the explicit service vesting condition is not the nonemployee&#x2019;s vesting period, and the vesting condition is not a service
condition but is merely a delayed exercisability provision. The share-based compensation expense was calculated based on the fair value
of the 0.1% Award as of the grant date. The fair value of the 0.05% Award was determined with assistance of an independent third-party
valuation specialist using discounted cash flow method with key assumptions of risk free rate of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pd" title="Risk free rate"&gt;4.36%&lt;/span&gt;, discount rate of &lt;span id="xdx_90C_ecustom--DiscountRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pd" title="Discount rate"&gt;14.9%&lt;/span&gt; and perpetual
rate of &lt;span id="xdx_90E_ecustom--PerpetualRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pd" title="Perpetual rate"&gt;3.0%&lt;/span&gt;.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May&#160;9, 2023, the Company entered into an agreement
with a third-party Service Provider to receive accelerator training services. In consideration for these services, the Company agreed
to grant the Service Provider equity equal to 0.425% of shares outstanding at issuance. The Company accounts for the award as consideration
for services in accordance with ASC 718, &lt;i&gt;Compensation&#x2014;Stock Compensation.&lt;/i&gt; The Company measures equity instruments granted
to a non-employee in exchange for services at their fair value on the grant date and engaged an independent third-party valuation specialist
to determine the grant-date fair value using discounted cash flow method with key assumptions of risk free rate of &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--ThirdPartyServiceProviderMember_pd" title="Risk free rate"&gt;3.81%&lt;/span&gt;, discount rate
of &lt;span id="xdx_906_ecustom--DiscountRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--ThirdPartyServiceProviderMember_pd" title="Discount rate"&gt;15.5%&lt;/span&gt; and perpetual rate of &lt;span id="xdx_904_ecustom--PerpetualRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--ThirdPartyServiceProviderMember_pd" title="Perpetual rate"&gt;3.0%&lt;/span&gt;. The related compensation cost is recognized as expense, with a corresponding increase to additional
paid-in capital, on a straight-line basis over the requisite service period during which the counterparty provides services, which was
from May&#160;2023 through July&#160;2023. For the year ended June&#160;30, 2024, the Company recognized $&lt;span id="xdx_908_eus-gaap--GeneralAndAdministrativeExpense_c20230701__20240630__srt--CounterpartyNameAxis__custom--ThirdPartyServiceProviderMember_pp0p" title="General and administrative expense"&gt;21,104&lt;/span&gt;, which was recorded within
general and administrative expense in the statements of operations and comprehensive loss. The award was fully vested as of June&#160;30,
2024 and 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s share-based compensation awards
are expected to be settled through transfers of existing ordinary shares held by the controlling shareholder, rather than through the
issuance of new shares by the Company. The underlying ordinary shares are included in the issued and outstanding shares as of the balance
sheet date; accordingly, such settlement is not expected to increase the Company&#x2019;s total issued and outstanding shares. The vested
shares are not recorded in the individual names of the holders on the Company&#x2019;s stock ledger, but held by the controlling shareholder
on their behalf, mainly due to the plan to a direct register of shares under the listed company during de-SPAC transaction. The Company,
as well as the controlling shareholder deemed the grant as the time when the employee and non-employees are entitled to economic benefits
and risks of the subsequent changes in fair value of the granted shares accordingly to the agreed vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002502"
      unitRef="USD">21104</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002504"
      unitRef="USD">153266</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002506">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock_zYgAKTu1lo7k" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-based compensation (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BB_zwzJiikWfcV4" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Schedule of share-based compensation expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;years ended &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Selling and marketing expenses&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_c20230701__20240630__custom--IncomeStatementLocationsAxis__custom--SellingAndMarketingExpensesMember_pp0p" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2508"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20240701__20250630__custom--IncomeStatementLocationsAxis__custom--SellingAndMarketingExpensesMember_pp0p" title="Total"&gt;153,266&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;General and administrative
        expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230701__20240630__custom--IncomeStatementLocationsAxis__custom--GeneralAndAdministrativeExpensesMember_pp0p" title="Total"&gt;21,104&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630__custom--IncomeStatementLocationsAxis__custom--GeneralAndAdministrativeExpensesMember_pp0p" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2514"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0d_c20230701__20240630_zG6MuWsZDbL5" title="Total"&gt;21,104&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0d_c20240701__20250630_zgdo4PX2S2yh" title="Total"&gt;153,266&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_custom_SellingAndMarketingExpensesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002510"
      unitRef="USD">153266</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_custom_GeneralAndAdministrativeExpensesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002512"
      unitRef="USD">21104</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002516"
      unitRef="USD">21104</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002518"
      unitRef="USD">153266</us-gaap:ShareBasedCompensation>
    <cik0002065779:SharesDescription
      contextRef="From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember"
      id="Fact002520">0.375 shares of the Company were vested,
with remaining 1.125 shares unvested.</cik0002065779:SharesDescription>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002522"
      unitRef="USD">101000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002524"
      unitRef="Ratio">0.0424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <cik0002065779:DiscountRate
      contextRef="From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002526"
      unitRef="Ratio">0.136</cik0002065779:DiscountRate>
    <cik0002065779:PerpetualRate
      contextRef="From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002528"
      unitRef="Ratio">0.030</cik0002065779:PerpetualRate>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_custom_NonEmployeeMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002530"
      unitRef="USD">52266</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-07-012025-06-30_custom_NonEmployeeMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002532"
      unitRef="Ratio">0.0436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <cik0002065779:DiscountRate
      contextRef="From2024-07-012025-06-30_custom_NonEmployeeMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002534"
      unitRef="Ratio">0.149</cik0002065779:DiscountRate>
    <cik0002065779:PerpetualRate
      contextRef="From2024-07-012025-06-30_custom_NonEmployeeMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002536"
      unitRef="Ratio">0.030</cik0002065779:PerpetualRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-07-012025-06-30_custom_ThirdPartyServiceProviderMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002541"
      unitRef="Ratio">0.0381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <cik0002065779:DiscountRate
      contextRef="From2024-07-012025-06-30_custom_ThirdPartyServiceProviderMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002543"
      unitRef="Ratio">0.155</cik0002065779:DiscountRate>
    <cik0002065779:PerpetualRate
      contextRef="From2024-07-012025-06-30_custom_ThirdPartyServiceProviderMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002545"
      unitRef="Ratio">0.030</cik0002065779:PerpetualRate>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-07-012024-06-30_custom_ThirdPartyServiceProviderMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002547"
      unitRef="USD">21104</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002549">&lt;p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zZF2x5NNJfbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;12. &lt;span id="xdx_82E_zervGI5CRFMj"&gt;Related party transactions&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Hoansoo Lee serves as the Company&#x2019;s Chief Executive
Officer and Chief Financial Officer. The Company has entered into a consulting services agreement with Hoansoo Lee, pursuant to which
Hoansoo Lee provides strategic consulting and advisory services to the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the years ended June&#160;30, 2024 and 2025, the
Company incurred and paid consulting fees totaling $&lt;span id="xdx_902_ecustom--ConsultingFees_c20230701__20240630_pp0p" title="Consulting fees"&gt;75,245&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--ConsultingFees_c20240701__20250630_pp0p" title="Consulting fees"&gt;100,150&lt;/span&gt;, respectively. As of June&#160;30, 2024 and 2025, there were &lt;span id="xdx_90B_ecustom--OutstandingBalancesPayable_iI_pp0d_do_c20250630_zv4U4ppRoKV9" title="Outstanding balances payable"&gt;&lt;span id="xdx_906_ecustom--OutstandingBalancesPayable_iI_pp0d_do_c20240630_zJHMH77lauR4" title="Outstanding balances payable"&gt;no&lt;/span&gt;&lt;/span&gt;
outstanding balances payable to Hoansoo Lee as all amounts had been fully settled during the respective periods.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <cik0002065779:ConsultingFees
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002551"
      unitRef="USD">75245</cik0002065779:ConsultingFees>
    <cik0002065779:ConsultingFees
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002553"
      unitRef="USD">100150</cik0002065779:ConsultingFees>
    <cik0002065779:OutstandingBalancesPayable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002555"
      unitRef="USD">0</cik0002065779:OutstandingBalancesPayable>
    <cik0002065779:OutstandingBalancesPayable
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002557"
      unitRef="USD">0</cik0002065779:OutstandingBalancesPayable>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002559">&lt;p id="xdx_80E_eus-gaap--EarningsPerShareTextBlock_zcKacb4NfAse" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;13. &lt;span id="xdx_828_zmptkHzMOqij"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic loss per share and diluted loss per share have
been calculated in accordance with ASC 260, &#x201c;&lt;i&gt;Earnings Per Share&lt;/i&gt;&#x201d; on computation of loss per share for the years ended
June&#160;30, 2024 and 2025 as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zt9m69C0XZ2d" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basic and diluted net loss per share (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B3_z4fVOy9hZcC8" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Schedule of basic share and diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20230701__20240630_zNS6ebSpnWrd" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49D_20240701__20250630_z1q8DgL1dZak" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;years ended &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Numerator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Net loss attributable to ordinary
        shareholders&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(4,956,347&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(7,659,667&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DenominatorForBasicAndDilutedLossPerShareAbstract_iB_zvdjC7dKX30c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Denominator for basic and diluted loss per
        share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Weighted-average ordinary shares outstanding,
        Basic and diluted*&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230701__20240630_fKg_____zQHyzKNbmYni" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230701__20240630_fKg_____znyMMFNDxhuf" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20250630_fKg_____zSHuzJLV0GTl" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20250630_fKg_____zTkjibsim5P6" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Basic and diluted loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230701__20240630_zmSb1V03Vrje" title="Basic loss per share"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20230701__20240630_zyJQB2bVMLV5" title="Diluted loss per share"&gt;(3,304.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20240701__20250630_zD02im0uKoQi" title="Basic loss per share"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20240701__20250630_zN38w6qibdk8" title="Diluted loss per share"&gt;(5,106.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td id="xdx_F08_zym9vF1L9h5a" style="width: 0.25in; text-align: left"&gt;*&lt;/td&gt;
    &lt;td id="xdx_F1F_zWe9J1egNUee" style="text-align: justify"&gt;The Company&#x2019;s share-based compensation awards are expected to be settled through transfers of existing
        ordinary shares held by the controlling shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary
        shares are included in issued and outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase
        the Company&#x2019;s total issued and outstanding shares. During the years ended June&#160;30, 2024 and 2025, diluted net loss per share
        is calculated in the same manner as basic net loss per share.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zykAwSGmR6Q2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002561">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zt9m69C0XZ2d" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basic and diluted net loss per share (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B3_z4fVOy9hZcC8" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Schedule of basic share and diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20230701__20240630_zNS6ebSpnWrd" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49D_20240701__20250630_z1q8DgL1dZak" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;years ended &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Numerator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Net loss attributable to ordinary
        shareholders&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(4,956,347&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(7,659,667&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DenominatorForBasicAndDilutedLossPerShareAbstract_iB_zvdjC7dKX30c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Denominator for basic and diluted loss per
        share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Weighted-average ordinary shares outstanding,
        Basic and diluted*&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230701__20240630_fKg_____zQHyzKNbmYni" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230701__20240630_fKg_____znyMMFNDxhuf" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20250630_fKg_____zSHuzJLV0GTl" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20250630_fKg_____zTkjibsim5P6" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Basic and diluted loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230701__20240630_zmSb1V03Vrje" title="Basic loss per share"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20230701__20240630_zyJQB2bVMLV5" title="Diluted loss per share"&gt;(3,304.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20240701__20250630_zD02im0uKoQi" title="Basic loss per share"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20240701__20250630_zN38w6qibdk8" title="Diluted loss per share"&gt;(5,106.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td id="xdx_F08_zym9vF1L9h5a" style="width: 0.25in; text-align: left"&gt;*&lt;/td&gt;
    &lt;td id="xdx_F1F_zWe9J1egNUee" style="text-align: justify"&gt;The Company&#x2019;s share-based compensation awards are expected to be settled through transfers of existing
        ordinary shares held by the controlling shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary
        shares are included in issued and outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase
        the Company&#x2019;s total issued and outstanding shares. During the years ended June&#160;30, 2024 and 2025, diluted net loss per share
        is calculated in the same manner as basic net loss per share.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002563"
      unitRef="USD">-4956347</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002564"
      unitRef="USD">-7659667</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002569"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002571"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002573"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002575"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002577"
      unitRef="USDPShares">-3304.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002579"
      unitRef="USDPShares">-3304.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002581"
      unitRef="USDPShares">-5106.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002583"
      unitRef="USDPShares">-5106.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002587">&lt;p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_zw6BQqHEgLZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;14. &lt;span id="xdx_821_z4EX1JG2ykx6"&gt;Segment information&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company manages its business in a centralized
manner and operates as a single segment and accordingly has only one operating and reportable segment, the provision of GPU computing
platform services. The Company&#x2019;s Chief Executive Officer serves as the Chief Operating Decision Maker (&#x201c;CODM&#x201d;). The
CODM regularly reviews entity-level operating results, including revenue and net loss as presented in the statement of operations and
comprehensive loss, when making decisions about resource allocation and assessing segment performance. Therefore, the Company has one
reportable segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The primary measures of segment revenue and profitability
for the Company&#x2019;s operating segment&#160;are considered to be&#160;revenue and net loss. The CODM uses revenue to assess market
performance and growth, and net loss to evaluate profitability and cost management. Both measures are used together to allocate resources,
including personnel and capital resources. Significant expense categories regularly provided to and reviewed by the CODM include those
presented in the statements of operations and comprehensive loss as well as disaggregated expenses of staff costs and employee benefits,
professional service expenses, share-based compensation, and other general and administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table presents the segment information
of the Company for the measurement of segment profitability for the years ended June&#160;30, 2024 and 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zaZ6gYRQMRih" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B7_z0szaN7zwBSj" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;b&gt;Schedule
    of segment information&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20230701__20240630_zry6rmEzVCB1" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49D_20240701__20250630_zCZ2bAgyHGX5" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; years ended&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Revenues&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,319,115&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;7,015,512&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CostOfRevenue_zNi1liCsOXci" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Cost of revenues&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,263,548&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(5,910,315&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_iN_di_zkj1o72qnmk8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Research and development expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,365,433&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,797,906&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--SellingAndMarketingExpenseAbstract_i01B_pp0d_zxMJN07A1pXg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Selling and marketing expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--StaffCostsEmployeeBenefitsAndOfficeExpenses_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Staff costs, employee benefits and
        office expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(262,614&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(835,889&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--ShareBasedCompensations_i01_pp0d_z9QrXvmlrCpc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Share-based compensation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2606"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(153,266&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--SellingGeneralAndAdministrativeExpenseAbstract_i01B_pp0d_zDwHZaCWa85" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;General and administrative expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--StaffCostsEmployeeBenefitsAndOthers_i01_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Staff costs, employee benefits and
        Others&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(244,651&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(328,662&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ProfessionalAndContractServicesExpense_i01N_di_zh2ZOZkpFGtk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Professional service expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(7,594&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(34,320&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ShareBasedCompensation1_i01N_pp0d_di_zzVfAlQURxe7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Share-based compensation&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(21,104&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2619"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_i01_pp0d_z65lbRpLFMOh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Loss
        from operations&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(1,845,829&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(3,044,846&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ChangeInFairValueOfSimpleAgreementsForFutureEquity_i01N_di_zLicrVyEo7og" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Change in fair value
        of simple agreements for future equity&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,110,518&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,614,821&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeLossBeforeReclassificationsTax_i01_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Loss
        before income tax expenses&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(4,956,347&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(7,659,667&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Income tax expense&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2630"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2631"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ProfitLoss_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Net
        loss&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(4,956,347&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(7,659,667&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zMAAq6XghBbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Geographic Information&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As substantially all of the Company&#x2019;s long-lived
assets are located in the United States, no geographical segments of assets are presented. The following table presents the Company&#x2019;s
revenue from major geographical areas for the periods indicated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zxaRjvXJPaOg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BE_zWpnQqztGuFi" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of geographic information&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;years ended &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Singapore&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;260,941&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;2,484,905&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;United States of America&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;169,600&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;2,085,579&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Canada&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;574,664&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;1,443,306&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Hong Kong&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;157,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;600,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;United Kingdom&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;145,410&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;391,722&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Others&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;11,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;10,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--Revenues_pp0d_c20230701__20240630_zoK7sngi7uI1" title="Total"&gt;1,319,115&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_pp0d_c20240701__20250630_zJvmNbPZ8VZg" title="Total"&gt;7,015,512&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zSK0DbrUr1O8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002589">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zaZ6gYRQMRih" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8B7_z0szaN7zwBSj" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;b&gt;Schedule
    of segment information&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20230701__20240630_zry6rmEzVCB1" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49D_20240701__20250630_zCZ2bAgyHGX5" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; years ended&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Revenues&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,319,115&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;7,015,512&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CostOfRevenue_zNi1liCsOXci" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Cost of revenues&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,263,548&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(5,910,315&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_iN_di_zkj1o72qnmk8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Research and development expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,365,433&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,797,906&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--SellingAndMarketingExpenseAbstract_i01B_pp0d_zxMJN07A1pXg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Selling and marketing expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--StaffCostsEmployeeBenefitsAndOfficeExpenses_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Staff costs, employee benefits and
        office expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(262,614&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(835,889&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--ShareBasedCompensations_i01_pp0d_z9QrXvmlrCpc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Share-based compensation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2606"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(153,266&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--SellingGeneralAndAdministrativeExpenseAbstract_i01B_pp0d_zDwHZaCWa85" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;General and administrative expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--StaffCostsEmployeeBenefitsAndOthers_i01_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Staff costs, employee benefits and
        Others&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(244,651&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(328,662&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ProfessionalAndContractServicesExpense_i01N_di_zh2ZOZkpFGtk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Professional service expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(7,594&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(34,320&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ShareBasedCompensation1_i01N_pp0d_di_zzVfAlQURxe7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#x2013; Share-based compensation&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(21,104&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2619"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_i01_pp0d_z65lbRpLFMOh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Loss
        from operations&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(1,845,829&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(3,044,846&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ChangeInFairValueOfSimpleAgreementsForFutureEquity_i01N_di_zLicrVyEo7og" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Change in fair value
        of simple agreements for future equity&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,110,518&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,614,821&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeLossBeforeReclassificationsTax_i01_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Loss
        before income tax expenses&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(4,956,347&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(7,659,667&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Income tax expense&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2630"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2631"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ProfitLoss_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Net
        loss&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(4,956,347&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(7,659,667&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002591"
      unitRef="USD">1319115</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002592"
      unitRef="USD">7015512</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002594"
      unitRef="USD">-1263548</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002595"
      unitRef="USD">-5910315</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002597"
      unitRef="USD">1365433</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002598"
      unitRef="USD">2797906</us-gaap:ResearchAndDevelopmentExpense>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002603"
      unitRef="USD">-262614</cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002604"
      unitRef="USD">-835889</cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses>
    <cik0002065779:ShareBasedCompensations
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002607"
      unitRef="USD">-153266</cik0002065779:ShareBasedCompensations>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOthers
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002612"
      unitRef="USD">-244651</cik0002065779:StaffCostsEmployeeBenefitsAndOthers>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOthers
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002613"
      unitRef="USD">-328662</cik0002065779:StaffCostsEmployeeBenefitsAndOthers>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002615"
      unitRef="USD">7594</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002616"
      unitRef="USD">34320</us-gaap:ProfessionalAndContractServicesExpense>
    <cik0002065779:ShareBasedCompensation1
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002618"
      unitRef="USD">21104</cik0002065779:ShareBasedCompensation1>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002621"
      unitRef="USD">-1845829</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002622"
      unitRef="USD">-3044846</us-gaap:OperatingIncomeLoss>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002624"
      unitRef="USD">3110518</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002625"
      unitRef="USD">4614821</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002627"
      unitRef="USD">-4956347</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002628"
      unitRef="USD">-7659667</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002633"
      unitRef="USD">-4956347</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002634"
      unitRef="USD">-7659667</us-gaap:ProfitLoss>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002636">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zxaRjvXJPaOg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_8BE_zWpnQqztGuFi" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Schedule of geographic information&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;years ended &lt;br/&gt;June&#160;30,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Singapore&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;260,941&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;2,484,905&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;United States of America&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;169,600&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;2,085,579&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Canada&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;574,664&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;1,443,306&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Hong Kong&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;157,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;600,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;United Kingdom&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;145,410&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;391,722&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Others&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;11,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;10,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--Revenues_pp0d_c20230701__20240630_zoK7sngi7uI1" title="Total"&gt;1,319,115&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_pp0d_c20240701__20250630_zJvmNbPZ8VZg" title="Total"&gt;7,015,512&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_country_SG_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002638"
      unitRef="USD">260941</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_country_SG_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002640"
      unitRef="USD">2484905</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_country_US_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002642"
      unitRef="USD">169600</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_country_US_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002644"
      unitRef="USD">2085579</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_country_CA_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002646"
      unitRef="USD">574664</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_country_CA_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002648"
      unitRef="USD">1443306</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_country_HK_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002650"
      unitRef="USD">157500</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_country_HK_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002652"
      unitRef="USD">600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_country_GB_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002654"
      unitRef="USD">145410</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_country_GB_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002656"
      unitRef="USD">391722</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_OthersMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002658"
      unitRef="USD">11000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_OthersMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002660"
      unitRef="USD">10000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002662"
      unitRef="USD">1319115</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002664"
      unitRef="USD">7015512</us-gaap:Revenues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002667">&lt;p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zV94gEMyYrl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;15. &lt;span id="xdx_822_zL1TK7zRpema"&gt;Commitments and contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From inception to date, the Company has not been a
party to any legal proceedings, claims, or disputes arising in the ordinary course of business. As of June&#160;30, 2025, the Company
had no outstanding litigation, and there were no commitments or contingencies that management believes would have a material effect on
the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="From2024-07-012025-06-30_custom_ExascaleLabsIncMember"
      id="Fact002669">&lt;p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zFgRhy6z3nKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;16. &lt;span&gt;Subsequent events&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span&gt;&lt;span id="xdx_829_zHJhA3sZiti7" style="display: none"&gt;Subsequent Events&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluated all events and transactions
that occurred after June&#160;30, 2025, up through February&#160;11, 2026, which is the date that these financial statements are issued,
unless as disclosed elsewhere and below, there was no other material subsequent events occurred that would require recognition or disclosure
in the Company&#x2019;s financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Incorporation of a Subsidiary&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December&#160;16, 2025, subsequent to the reporting
period but prior to the authorization of these financial statements for issue, the Company incorporated its wholly-owned subsidiary, Evana
Alpha Pte. Ltd., in Singapore. The Company subscribed for all &lt;span id="xdx_90A_ecustom--OrdinarySharesIssued_c20251201__20251216__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_pd" title="Ordinary shares issued"&gt;1,000&lt;/span&gt; ordinary shares of the subsidiary, with a issued share capital of
Singapore Dollars &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251201__20251216__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_pd" title="Number of shares issued"&gt;1,000&lt;/span&gt;. The subsidiary&#x2019;s principal business activity is information technology consultancy (excluding cybersecurity).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;SAFEs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From October&#160;1, 2025 to &lt;span style="color: #0F1115; color: #0F1115"&gt;February&#160;11,&lt;/span&gt;
2026, certain institutional and accredited investors provided $&lt;span id="xdx_903_eus-gaap--ProceedsFromSaleOfNotesReceivable_pn3n3_dm_c20251001__20260211__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_zobhxoREKnUk" title="Proceeds from safes"&gt;0.5&lt;/span&gt;&#160;million to the Company in the form of SAFEs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Capital Structure and Dual-Class Share Reclassification&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January&#160;2026, the Company adopted an Amended
and Restated Certificate of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#x2019;s
equity is divided into Class A Ordinary Shares and Class B Ordinary Shares, which are entitled to one (1) vote and twenty (20) votes per
share, respectively. Despite the differential in voting power, Class A and Class B Ordinary Shares rank pari passu in all other respects,
sharing ratably in dividends and any distributions upon liquidation. Furthermore, all outstanding warrants, options, and SAFEs are designated
to convert or settle exclusively into Class A Ordinary Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Business combination agreement and related events&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January&#160;2026, the Company entered into an
BCA with BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and a direct, wholly owned subsidiary of BCAR and D. Boral Arc
Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary of BCAR. Upon closing of the transaction, the combined company
will be named Exascale Labs Holdings Inc. and is expected to be traded on a national securities exchange. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate consideration for the Business Combination
is $&lt;span id="xdx_902_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_dm_c20260101__20260131_z970NdDaFbca" title="Business combination payable"&gt;500.0&lt;/span&gt; million, payable by the surviving publicly traded entity in the form of &lt;span id="xdx_90F_ecustom--OrdinarySharesIssued_c20260101__20260131_pd" title="Ordinary shares issued"&gt;50,000,000&lt;/span&gt; newly issued ordinary shares valued at $&lt;span id="xdx_90D_ecustom--OrdinarySharesPerShare_c20260101__20260131_pd" title="ordinary shares per share"&gt;10.00
&lt;/span&gt;per share. At the effective time of the merger of the Company into the surviving publicly traded entity pursuant to the BCA, the Company&#x2019;s
outstanding ordinary shares and outstanding SAFEs are expected to be cancelled and converted into the right to receive shares of the surviving
publicly traded entity in accordance with the terms of the BCA and the applicable SAFE instruments. Class A ordinary shares are expected
to have one vote per share, and Class B ordinary shares are expected to have 20 votes per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of February&#160;11, 2026, the transactions contemplated
by the BCA had not been consummated. Accordingly, the Company has not recorded any amounts in these financial statements related to the
BCA, as it represents a non-recognized subsequent event.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <cik0002065779:OrdinarySharesIssued
      contextRef="From2025-12-012025-12-16_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002671"
      unitRef="Shares">1000</cik0002065779:OrdinarySharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-12-012025-12-16_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002673"
      unitRef="Shares">1000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromSaleOfNotesReceivable
      contextRef="From2025-10-012026-02-11_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember"
      decimals="-3"
      id="Fact002675"
      unitRef="USD">500000</us-gaap:ProceedsFromSaleOfNotesReceivable>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2026-01-012026-01-31_custom_ExascaleLabsIncMember"
      decimals="-3"
      id="Fact002677"
      unitRef="USD">500000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <cik0002065779:OrdinarySharesIssued
      contextRef="From2026-01-012026-01-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002679"
      unitRef="Shares">50000000</cik0002065779:OrdinarySharesIssued>
    <cik0002065779:OrdinarySharesPerShare
      contextRef="From2026-01-012026-01-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002681"
      unitRef="USDPShares">10.00</cik0002065779:OrdinarySharesPerShare>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002689"
      unitRef="USD">4231689</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002690"
      unitRef="USD">984830</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <cik0002065779:U.s.DollarCoin
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002693"
      unitRef="USD">4074415</cik0002065779:U.s.DollarCoin>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002695"
      unitRef="USD">152536</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002696"
      unitRef="USD">1830105</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <cik0002065779:PrepaidResearchAndDevelopmentExpenses
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002699"
      unitRef="USD">625000</cik0002065779:PrepaidResearchAndDevelopmentExpenses>
    <cik0002065779:AdvanceToSuppliers
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002701"
      unitRef="USD">1030761</cik0002065779:AdvanceToSuppliers>
    <cik0002065779:AdvanceToSuppliers
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002702"
      unitRef="USD">106801</cik0002065779:AdvanceToSuppliers>
    <cik0002065779:RefundableDepositsReceivable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002704"
      unitRef="USD">681125</cik0002065779:RefundableDepositsReceivable>
    <cik0002065779:RefundableDepositsReceivable
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002705"
      unitRef="USD">510000</cik0002065779:RefundableDepositsReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002707"
      unitRef="USD">1207626</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002710"
      unitRef="USD">7303737</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002711"
      unitRef="USD">8131151</us-gaap:AssetsCurrent>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002716"
      unitRef="USD">-0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002717"
      unitRef="USD">95000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002719"
      unitRef="USD">19600</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002720"
      unitRef="USD">14406</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002722"
      unitRef="USD">19600</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002723"
      unitRef="USD">109406</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002725"
      unitRef="USD">7323337</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002726"
      unitRef="USD">8240557</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002734"
      unitRef="USD">90015</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002735"
      unitRef="USD">743742</us-gaap:AccountsPayableCurrent>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002737"
      unitRef="USD">18243885</cik0002065779:SimpleAgreementsForFutureEquity>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002738"
      unitRef="USD">26842205</cik0002065779:SimpleAgreementsForFutureEquity>
    <us-gaap:DepositContractsLiabilities
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002740"
      unitRef="USD">432760</us-gaap:DepositContractsLiabilities>
    <us-gaap:DepositContractsLiabilities
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002741"
      unitRef="USD">109657</us-gaap:DepositContractsLiabilities>
    <cik0002065779:RefundableDepositsPayable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002743"
      unitRef="USD">1445580</cik0002065779:RefundableDepositsPayable>
    <cik0002065779:RefundableDepositsPayable
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002744"
      unitRef="USD">1174702</cik0002065779:RefundableDepositsPayable>
    <cik0002065779:OtherCurrentLiabilities
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002746"
      unitRef="USD">107481</cik0002065779:OtherCurrentLiabilities>
    <cik0002065779:OtherCurrentLiabilities
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002747"
      unitRef="USD">283612</cik0002065779:OtherCurrentLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002749"
      unitRef="USD">20319721</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002750"
      unitRef="USD">29153918</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002752"
      unitRef="USD">20319721</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002753"
      unitRef="USD">29153918</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002764"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002766"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002768"
      unitRef="Shares">1500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002770"
      unitRef="Shares">1500</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002761"
      unitRef="USD">15</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002772"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002774"
      unitRef="Shares">303</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002776"
      unitRef="Shares">303</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002778"
      unitRef="Shares">303</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002782"
      unitRef="USD">3</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002784"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002786"
      unitRef="Shares">1197</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002788"
      unitRef="Shares">1197</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002790"
      unitRef="Shares">1197</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002794"
      unitRef="USD">12</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002796"
      unitRef="USD">220636</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002797"
      unitRef="USD">220636</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002799"
      unitRef="USD">-13217035</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002800"
      unitRef="USD">-21134012</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002802"
      unitRef="USD">-12996384</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002803"
      unitRef="USD">-20913361</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002805"
      unitRef="USD">7323337</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002806"
      unitRef="USD">8240557</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002808"
      unitRef="USD">1862158</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002809"
      unitRef="USD">3754586</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002810"
      unitRef="USD">4475885</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002811"
      unitRef="USD">10561331</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002813"
      unitRef="USD">-1649077</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002814"
      unitRef="USD">-3167659</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002815"
      unitRef="USD">-3827444</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002816"
      unitRef="USD">-8902966</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002818"
      unitRef="USD">213081</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002819"
      unitRef="USD">586927</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002820"
      unitRef="USD">648441</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002821"
      unitRef="USD">1658365</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002828"
      unitRef="USD">378511</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002829"
      unitRef="USD">104729</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002830"
      unitRef="USD">726914</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002831"
      unitRef="USD">310582</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002833"
      unitRef="USD">103107</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002834"
      unitRef="USD">468696</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002835"
      unitRef="USD">268159</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002836"
      unitRef="USD">928255</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002838"
      unitRef="USD">377999</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002839"
      unitRef="USD">1235476</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002840"
      unitRef="USD">2115853</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002841"
      unitRef="USD">3238185</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002843"
      unitRef="USD">859617</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002844"
      unitRef="USD">1808901</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002845"
      unitRef="USD">3110926</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002846"
      unitRef="USD">4477022</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002848"
      unitRef="USD">-646536</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002849"
      unitRef="USD">-1221974</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002850"
      unitRef="USD">-2462485</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002851"
      unitRef="USD">-2818657</us-gaap:OperatingIncomeLoss>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002853"
      unitRef="USD">890523</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002854"
      unitRef="USD">1410457</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002855"
      unitRef="USD">3716052</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002856"
      unitRef="USD">5098320</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002858"
      unitRef="USD">-1537059</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002859"
      unitRef="USD">-2632431</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002860"
      unitRef="USD">-6178537</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002861"
      unitRef="USD">-7916977</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002868"
      unitRef="USD">-1537059</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002869"
      unitRef="USD">-2632431</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002870"
      unitRef="USD">-6178537</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002871"
      unitRef="USD">-7916977</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002878"
      unitRef="USDPShares">-1024.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002880"
      unitRef="USDPShares">-1024.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002882"
      unitRef="USDPShares">-1754.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002884"
      unitRef="USDPShares">-1754.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002886"
      unitRef="USDPShares">-4119.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002888"
      unitRef="USDPShares">-4119.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002890"
      unitRef="USDPShares">-5277.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002892"
      unitRef="USDPShares">-5277.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002894"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002896"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002898"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002899"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002901"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002902"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002904"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002905"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002912"
      unitRef="Shares">1500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002907"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002908"
      unitRef="USD">119636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002909"
      unitRef="USD">-10198846</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002910"
      unitRef="USD">-10079195</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002916"
      unitRef="USD">-1537059</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002917"
      unitRef="USD">-1537059</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002920"
      unitRef="USD">101000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002922"
      unitRef="USD">101000</us-gaap:ShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002929"
      unitRef="Shares">1500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002924"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002925"
      unitRef="USD">220636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002926"
      unitRef="USD">-11735905</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002927"
      unitRef="USD">-11515254</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002936"
      unitRef="Shares">1500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002931"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002932"
      unitRef="USD">67370</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002933"
      unitRef="USD">-5557368</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002934"
      unitRef="USD">-5489983</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002940"
      unitRef="USD">-6178537</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002941"
      unitRef="USD">-6178537</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002944"
      unitRef="USD">153266</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002946"
      unitRef="USD">153266</us-gaap:ShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002953"
      unitRef="Shares">1500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002948"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002949"
      unitRef="USD">220636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002950"
      unitRef="USD">-11735905</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002951"
      unitRef="USD">-11515254</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002962"
      unitRef="Shares">1500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002955"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002958"
      unitRef="USD">220636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002959"
      unitRef="USD">-18501581</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002960"
      unitRef="USD">-18280930</us-gaap:StockholdersEquity>
    <cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002975"
      unitRef="Shares">-1500</cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002968"
      unitRef="USD">-15</cik0002065779:RedesignationOfAuthorizedOrdinaryShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002977"
      unitRef="Shares">303</cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002969"
      unitRef="USD">3</cik0002065779:RedesignationOfAuthorizedOrdinaryShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002979"
      unitRef="Shares">1197</cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2026-01-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002970"
      unitRef="USD">12</cik0002065779:RedesignationOfAuthorizedOrdinaryShares>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002985"
      unitRef="USD">-2632431</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002986"
      unitRef="USD">-2632431</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002997"
      unitRef="Shares">303</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002989"
      unitRef="USD">3</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact002999"
      unitRef="Shares">1197</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002990"
      unitRef="USD">12</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002991"
      unitRef="USD">220636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002992"
      unitRef="USD">-21134012</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact002993"
      unitRef="USD">-20913361</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003008"
      unitRef="Shares">1500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003001"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003004"
      unitRef="USD">220636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003005"
      unitRef="USD">-13217035</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003006"
      unitRef="USD">-12996384</us-gaap:StockholdersEquity>
    <cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares
      contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003021"
      unitRef="Shares">-1500</cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003014"
      unitRef="USD">-15</cik0002065779:RedesignationOfAuthorizedOrdinaryShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares
      contextRef="From2025-07-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003023"
      unitRef="Shares">303</cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2025-07-012026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003015"
      unitRef="USD">3</cik0002065779:RedesignationOfAuthorizedOrdinaryShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares
      contextRef="From2025-07-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003025"
      unitRef="Shares">1197</cik0002065779:RedesignationOfAuthorizedOrdinarySharesShares>
    <cik0002065779:RedesignationOfAuthorizedOrdinaryShares
      contextRef="From2025-07-012026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003016"
      unitRef="USD">12</cik0002065779:RedesignationOfAuthorizedOrdinaryShares>
    <us-gaap:ProfitLoss
      contextRef="From2025-07-012026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003031"
      unitRef="USD">-7916977</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003032"
      unitRef="USD">-7916977</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003043"
      unitRef="Shares">303</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassAMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003035"
      unitRef="USD">3</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003045"
      unitRef="Shares">1197</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_OrdinarySharesClassBMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003036"
      unitRef="USD">12</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003037"
      unitRef="USD">220636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003038"
      unitRef="USD">-21134012</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003039"
      unitRef="USD">-20913361</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003050"
      unitRef="USD">-6178537</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003051"
      unitRef="USD">-7916977</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003056"
      unitRef="USD">4633</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003057"
      unitRef="USD">5194</us-gaap:Depreciation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003059"
      unitRef="USD">153266</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003062"
      unitRef="USD">3716052</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003063"
      unitRef="USD">5098320</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquities>
    <cik0002065779:OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003066"
      unitRef="USD">1681167</cik0002065779:OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003071"
      unitRef="USD">10483</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003072"
      unitRef="USD">1677569</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <cik0002065779:IncreaseDecreaseInAdvanceToSuppliers
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003074"
      unitRef="USD">278612</cik0002065779:IncreaseDecreaseInAdvanceToSuppliers>
    <cik0002065779:IncreaseDecreaseInAdvanceToSuppliers
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003075"
      unitRef="USD">-923960</cik0002065779:IncreaseDecreaseInAdvanceToSuppliers>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003078"
      unitRef="USD">625000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003080"
      unitRef="USD">-104717</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003081"
      unitRef="USD">653727</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003083"
      unitRef="USD">-113693</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003084"
      unitRef="USD">176131</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003086"
      unitRef="USD">144082</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003087"
      unitRef="USD">-323103</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003089"
      unitRef="USD">150000</cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable>
    <cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003090"
      unitRef="USD">-171125</cik0002065779:IncreaseDecreaseInRefundableDepositsReceivable>
    <cik0002065779:IncreaseDecreaseInRefundableDepositsPayable
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003092"
      unitRef="USD">224279</cik0002065779:IncreaseDecreaseInRefundableDepositsPayable>
    <cik0002065779:IncreaseDecreaseInRefundableDepositsPayable
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003093"
      unitRef="USD">-270878</cik0002065779:IncreaseDecreaseInRefundableDepositsPayable>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003095"
      unitRef="USD">-1835770</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003096"
      unitRef="USD">-1707626</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003098"
      unitRef="USD">-757960</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003099"
      unitRef="USD">-3758611</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <cik0002065779:ProceedsFromSaleOfDigitalAssetsAndUsdc
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003105"
      unitRef="USD">606752</cik0002065779:ProceedsFromSaleOfDigitalAssetsAndUsdc>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003107"
      unitRef="USD">2138</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003110"
      unitRef="USD">-2138</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003111"
      unitRef="USD">606752</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <cik0002065779:PaymentForDeferredOfferingCosts
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003117"
      unitRef="USD">95000</cik0002065779:PaymentForDeferredOfferingCosts>
    <cik0002065779:ProceedsFromSimpleAgreementsForFutureEquity
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003119"
      unitRef="USD">4275000</cik0002065779:ProceedsFromSimpleAgreementsForFutureEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003122"
      unitRef="USD">4275000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003123"
      unitRef="USD">-95000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003125"
      unitRef="USD">3514902</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003126"
      unitRef="USD">-3246859</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003128"
      unitRef="USD">969626</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003129"
      unitRef="USD">4231689</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003131"
      unitRef="USD">4484528</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003132"
      unitRef="USD">984830</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NotesAssumed1
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003144"
      unitRef="USD">500000</us-gaap:NotesAssumed1>
    <us-gaap:LoansAssumed1
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003147"
      unitRef="USD">3000000</us-gaap:LoansAssumed1>
    <us-gaap:NatureOfOperations
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003149">&lt;p id="xdx_803_eus-gaap--NatureOfOperations_zZfsaWCqvzt2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;1.
&lt;span id="xdx_827_zX0y8kzKCG"&gt;Organization and principal activities&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On
June&#160;1, 2022, Exascale Labs Inc. (the &#x201c;Company&#x201d;) was formally incorporated in the State of Delaware. In accordance with
the Company&#x2019;s Certificate of Incorporation, the total authorized share capital of the Company consists of &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20260331_pd" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt; shares of ordinary
shares, with a par value of $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20260331_pd" title="Common stock, par value"&gt;0.01&lt;/span&gt; per share, all of which are of one class. The governance structure of the Company stipulates that the
business and affairs of the Company shall be managed by or under the direction of its board of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On
December&#160;16, 2025, the Company incorporated its wholly-owned subsidiary, Evana Alpha Pte. Ltd., in Singapore. The Company subscribed
for all &lt;span id="xdx_907_ecustom--OrdinarySharesIssued_c20251201__20251216__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_zM1cMUnQc5T6" title="Ordinary shares issued"&gt;1,000&lt;/span&gt; ordinary shares of the subsidiary, with a total issued share capital of Singapore Dollars &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251201__20251216__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_zTUt0Dx8cvJd" title="Number of shares issued"&gt;1,000&lt;/span&gt;. The subsidiary&#x2019;s
principal business activity is information technology consultancy (excluding cybersecurity).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company is a next-generation artificial intelligence (&#x201c;AI&#x201d;) infrastructure provider operating an asset-light, software-defined
graphics processing unit (&#x201c;GPU&#x201d;) compute platform and related AI infrastructure solutions. Exascale&#x2019;s core business
includes GPU as a Service (&#x201c;GaaS&#x201d;), through which it provides reserved and on-demand access to high-performance GPU compute
capacity sourced from third-party data centers globally, as well as GPU cluster management and optimization services for artificial intelligence
data center (&#x201c;AIDC&#x201d;) operators. In addition, Exascale has developed certain modular data center, high-density liquid cooling,
high-voltage direct current (&#x201c;HVDC&#x201d;) power and energy storage solutions that are designed to address deployment bottlenecks
in AI infrastructure and that Exascale believes are ready for commercial engagement, although these capabilities have not yet generated
revenue as of the date of this proxy statement/prospectus. The platform is purpose-built for large-scale AI workloads, including large
language model (&#x201c;LLM&#x201d;) training, fine-tuning, and high-concurrency inference.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
January&#160;2026, the Company adopted an Amended and Restated Certificate of Incorporation, which established a dual-class ordinary share
structure. Under this new structure, the Company&#x2019;s equity is divided into 303 Class A ordinary shares and 1,197 Class B ordinary
shares, which are entitled to one (1) vote and twenty (20) votes per share, respectively. Despite the differential in voting power, Class
A and Class B ordinary shares rank pari passu in all other respects, sharing ratably in dividends and any distributions upon liquidation.
Furthermore, all outstanding Simple Agreements for Future Equity (&#x201c;SAFEs&#x201d;) are designated to convert or settle exclusively
into Class A ordinary shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
January&#160;2026, the Company entered into an Agreement and Plan of Merger (&#x201c;BCA&#x201d;) with D. Boral ARC Acquisition I Corp.(&#x201c;BCAR&#x201d;),
a publicly traded special purpose acquisition company (&#x201c;SPAC&#x201d;), D. Boral ARC Merger Corporation, a Delaware corporation and
a direct, wholly owned subsidiary of BCAR and D. Boral Arc Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary
of BCAR. Upon closing of the transaction, the combined company will be named Exascale Labs Holdings Inc.(such surviving company, &#x201c;PubCo&#x201d;)
and is expected to be traded on a national securities exchange.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003151"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003153"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <cik0002065779:OrdinarySharesIssued
      contextRef="From2025-12-012025-12-16_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003155"
      unitRef="Shares">1000</cik0002065779:OrdinarySharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-12-012025-12-16_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003157"
      unitRef="Shares">1000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003159">&lt;p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_z3uJvVhT76yk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;2.
&lt;span id="xdx_823_zJDfylZ6eVGa"&gt;Summary of significant accounting policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--GoingConcernPolicyTextBlock_zjTeaYmk2USj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;a.
&lt;span id="xdx_867_zT6r15wrPfT"&gt;Going concern&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As
of March&#160;31, 2026, the Company had cash and cash equivalents and U.S. Dollar Coin (&#x201c;USDC&#x201d;) of $&lt;span id="xdx_90B_ecustom--CashAndCashEquivalentsAndU.s.DollarCoin_iI_pn3n3_dm_c20260331_zOweLGQ0nMmd" title="Cash and cash equivalents and U.S. Dollar Coin"&gt;5.1 &lt;/span&gt;million
and current liabilities of $29.2 &lt;span id="xdx_90B_eus-gaap--LiabilitiesCurrent_iI_c20260331_zx0VQfPseO64" style="display: none" title="Current liabilities"&gt;29,153,918&lt;/span&gt;
million. For the nine months ended March&#160;31, 2025, the Company used $0.8 &lt;span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20240701__20250331_zXrnaRJA6DE6" style="display: none" title="Cash for operating activities"&gt;(757,960)&lt;/span&gt;
million in operating activities, while for the nine months ended March&#160;31, 2026, it used $3.8 &lt;span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20250701__20260331_z0FbPDcDfL21" style="display: none" title="Cash for operating activities"&gt;(3,758,611)&lt;/span&gt;
million. The Company incurred net losses of $6.2 &lt;span id="xdx_90B_eus-gaap--NetIncomeLoss_c20240701__20250331_zVBAnoAbYj2e" style="display: none" title="Net losses"&gt;(6,178,537)&lt;/span&gt;
million and $7.9 &lt;span id="xdx_906_eus-gaap--NetIncomeLoss_c20250701__20260331_zwLqC0GO7Qj2" style="display: none" title="Net losses"&gt;(7,916,977)&lt;/span&gt;
million for these respective periods. Since inception, the Company has incurred recurring net losses from operations and negative
cash flows from operating activities. As of March&#160;31, 2026, the Company had an accumulated deficit of $21.1 &lt;span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20260331_zxZwKyas1Wfb" style="display: none" title="Accumulated deficit"&gt;(21,134,012)&lt;/span&gt;
million. These factors raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern within one year
of the date these unaudited condensed consolidated financial statements are issued.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Management
has formulated and is actively pursuing plans to mitigate these conditions and secure the Company&#x2019;s continued operations. In connection
with the Company&#x2019;s contemplated business combination with a SPAC and related financing activities, the Company expects to access
additional capital through external funding sources. In addition, the Company continues to focus on expanding its market presence and
developing client relationships to drive revenue growth, while managing operating expenses, with the objective of improving cash flows
from operations over time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
purposes of this disclosure, &#x201c;SPAC&#x201d; refers to a special purpose acquisition company formed to effect a merger, share exchange,
asset acquisition, share purchase, reorganization or similar business combination with one or more operating businesses. &#x201c;De-SPAC&#x201d;
refers to the business combination transaction pursuant to which an operating company combines with a SPAC, following which the combined
company becomes publicly listed (or otherwise succeeds to the SPAC&#x2019;s public company status).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s
negative working capital position is primarily attributable to the classification of SAFEs. Excluding the accounting impact of the SAFEs,
which will only be paid in cash upon Liquidity Events and Dissolution Event (as defined in Note 8), management believes the Company&#x2019;s
available cash resources are sufficient for near-term operating needs. If additional liquidity is required, the Company&#x2019;s majority
shareholder has entered into a binding support agreement to provide funding to cover anticipated operating cash flow shortfalls through
the completion of the contemplated de-SPAC transaction. The support agreement is effective for a period of eighteen months from June&#160;10,
2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;However,
the de-SPAC transaction (including the SAFEs conversion) have not been fully implemented as of the date these unaudited condensed consolidated
financial statements are issued. There can be no assurance that these plans will be successfully completed within the required time frame,
on acceptable terms, or at all. If the primary plans are not successful, the Company&#x2019;s alternative courses of action would further
intensify efforts in market expansion and client development to increase revenue, while diligently controlling costs to ensure sufficient
cash flow from operating activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company may not be able to secure necessary financing in a timely manner or on favorable terms, or successfully execute its operational
turnaround. These circumstances give rise to substantial doubt that the Company will continue as a going concern and these unaudited condensed
consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zrDsuQdfyKG2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;b.
&lt;span id="xdx_860_z2ZzsSnntEpd"&gt;Basis of presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally
accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange
Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting. Certain information and note disclosures normally included in
the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP have been condensed consolidated or
omitted pursuant to such rules and regulations. As such, the information included in this interim financial report should be read in
conjunction with the audited financial statements and accompanying notes for the two years ended June&#160;30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
accompanying unaudited condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly
the financial position, operating results and cash flows of the Company for each of the periods presented. The results of operations for
the three and nine months ended March&#160;31, 2026 are not necessarily indicative of results to be expected for any other interim period
or for the year ending June&#160;30, 2026. The condensed consolidated balance sheet as of June&#160;30, 2025 was derived from the audited
financial statements at that date but does not include all of the disclosures required by U.S. GAAP for annual financial statements.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zcUBkLyQ302a" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;c.
&lt;span id="xdx_869_zJzlNRZuupR8"&gt;Use of estimates and assumptions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation
of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported
in the unaudited condensed consolidated financial statements and accompanying notes. Management believes that the estimates used in preparing
the unaudited condensed consolidated financial statements are reasonable and prudent; however, actual results could differ from these
estimates under different assumptions or conditions.&#160;Significant accounting estimates include recognition and measurement of SAFEs
notes, recognition and measurement of share-based compensation, the allowance for expected credit losses, deferred tax assets and valuation
allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z3MfqTrj1Ctg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;d.
&lt;span id="xdx_861_zefs2YE20oYg"&gt;Fair value measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
accordance with FASB ASC 820&#160;&lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, fair value is defined as the price that would be received
to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company
uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes
between market participant assumptions developed from market data obtained from outside sources (observable inputs) and the Company&#x2019;s
own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable
inputs).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of
inputs used to measure fair value are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Level
1: Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Level
2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Level
3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash
flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment
or estimation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management during
the nine months ended March&#160;31, 2025 and 2026. The carrying amount of cash and cash equivalents, accounts receivable, refundable
deposits receivable, other receivables, accounts payable, refundable deposits payable and other current liabilities approximated their
fair values as of June&#160;30, 2025 and March&#160;31, 2026. For the nine months ended March&#160;31, 2025 and 2026, the Company carried
SAFEs and digital assets at their fair value (see&#160;Note 4-Fair Value Measurements for fair value information).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--FunctionalCurrencyPolicyTextBlock_z2nCVmTUVaCh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;e.
&lt;span id="xdx_86D_zpLd8Tfyfj3f"&gt;Functional currency&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
accompanying unaudited condensed consolidated financial statements are presented in the United States dollar (&#x201c;US$&#x201d;).
The functional currency of the Company and its subsidiary is the US$.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;All
transactions are measured and recorded in the Company&#x2019;s functional currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z91JQokNSbAl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;f.
&lt;span id="xdx_867_zTk17b0iUrZg"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company considers all highly liquid investments instruments purchased with a maturity period of three months or less to be cash or cash
equivalents. The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents approximate their fair value.
As of June&#160;30, 2025 and March&#160;31, 2026, the Company does &lt;span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zmHRDKKWlBMg" title="Cash equivalents"&gt;&lt;span id="xdx_908_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20260331_zVbuobGqAgp7" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;t have any cash equivalents.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--CryptoAssets_zZhlCmsQAIQk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;g.
&lt;span id="xdx_862_zW5hKqqXdcS6"&gt;Crypto assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s
crypto assets classified in current assets are held primarily for use in the ordinary course of business which is expected to be actively
utilized or converted within the normal operating cycle and such crypto assets can be sold in a highly liquid marketplace. During the
nine months ended March&#160;31, 2026, the Company only held crypto assets of Tether USD (&#x201c;USDT&#x201d;) and USDC, which are principally
funded by SAFE investors and as a form of payment for transaction revenue. The Company&#x2019;s crypto assets are held with qualified
third-party custodians who provide secure storage and safeguarding of the Company&#x2019;s crypto assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;USDC&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;USDC
is a stablecoin redeemable on a one-to-one basis for U.S. dollars and is accounted for as a financial instrument in the unaudited condensed
consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Crypto
assets other than USDC&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On
December&#160;13, 2023, the FASB issued ASU 2023-08, which addresses the accounting and disclosure requirements for certain cryptocurrencies.
The new guidance requires entities to subsequently measure certain cryptocurrencies at fair value, with changes in fair value recorded
in net income in each reporting period. The Company applied the ASU since its holding of crypto assets in December&#160;2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Digital
assets that are received as noncash consideration in our revenue arrangements and paid in purchases of professional service and others
are presented as cash flows from operating activities in other operating activities settled in digital assets and USDC. Digital assets
that are received in our revenue arrangements and sold for cash within seven days are presented as cash flows from operating activities,
while other digital asset activity held longer than seven days is reflected as cash flows from investing activities under disposal of
digital assets and USDC held in the consolidated statements of cash flows. The Company presents crypto assets other than USDC separately
from other intangible assets and USDC, recorded as digital assets on the unaudited condensed consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
the three months ended March&#160;31, 2026, the Company recorded receipt and disbursement of digital assets amounted to $&lt;span id="xdx_90E_ecustom--ReceiptOfDigitalAssets_c20260101__20260331_pp0p" title="Receipt of digital assets"&gt;644,616&lt;/span&gt; and $&lt;span id="xdx_901_ecustom--DisbursementOfDigitalAssets_c20260101__20260331_pp0p" title="Disbursement of digital assets"&gt;796,781&lt;/span&gt;.&#160;For
the nine months ended March&#160;31, 2026, the Company recorded receipt and disbursement of digital assets amounted to $&lt;span id="xdx_909_ecustom--ReceiptOfDigitalAssets_c20250701__20260331_pp0p" title="Receipt of digital assets"&gt;939,397&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--DisbursementOfDigitalAssets_c20250701__20260331_pp0p" title="Disbursement of digital assets"&gt;939,397&lt;/span&gt;,
respectively, which resulted in an ending balance of nil. The Company&#x2019;s balances related to digital assets and stablecoins during
the period included USDT and USDC, both of which are USD-pegged stablecoins. &lt;span id="xdx_901_ecustom--FairValueGainOrLossOnDigitalAssets_pp0d_do_c20260101__20260331_zi458qVUCNt1" title="Fair value gain or loss on digital assets"&gt;&lt;span id="xdx_905_ecustom--FairValueGainOrLossOnDigitalAssets_pp0d_do_c20250701__20260331_zVXF30cgUVQc" title="Fair value gain or loss on digital assets"&gt;No&lt;/span&gt;&lt;/span&gt; fair value gain or loss on digital assets was recognized
for the three and nine months ended March&#160;31, 2026 considering the low volatility in the fair value of USDT during the three and
nine months ended March&#160;31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--ExpectedCreditLossAndAccountsReceivablePolicyTextBlock_zyxTRes82yL6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;h.
&lt;span id="xdx_863_z4jvYtW2zBHk"&gt;Expected credit loss and accounts receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company adopted Financial Standards Accounting Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 326 &#x201c;&lt;i&gt;Financial
Instruments&#160;&#x2014;&#160;Credit Losses&lt;/i&gt;&#x201d; (&#x201c;ASC&#160;326&#x201d;) on January&#160;1, 2023.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s accounts receivable are within the scope of ASC&#160;326. ASC&#160;326 introduces an approach based on expected credit
losses on financial assets at amortized cost. Upon adoption of ASC&#160;326, the Company estimates the expected credit losses for accounts
receivable using the roll-rate method on a collective basis when similar risk characteristics exist. Expected credit losses are included
in general and administrative expenses in the statements of operations and comprehensive loss. After all attempts to collect a receivable
have failed, the receivable is written off against the allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Accounts
receivable represents those receivables derived in the ordinary course of business, net of an allowance for any potentially uncollectible
amounts. The Company makes estimates of expected credit and collectability trends for the allowance for credit losses based upon its assessment
of various factors, including historical experience, the age of the accounts receivable balances, credit quality of its customers, current
economic conditions, reasonable and supportable forecasts of future economic conditions that may vary by geography, customer-type, or
industry sub-vertical, and other factors that may affect its ability to collect from customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Although
the Company has historically not experienced significant credit losses, they may experience increasing credit loss risks from accounts
receivable in future periods if its customers are adversely affected by economic pressures or uncertainty associated with local or global
economic recessions, or other customer-specific factors, and actual experience in the future may differ from their past experiences or
current assessment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--DeferredOfferingCostsPolicyTextBlock_zampFPTaHJw6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;i.
&lt;span id="xdx_866_zIRNVy8x1Vb6"&gt;Deferred offering costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company follows the requirements of FASB ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014; &#x201c;Expenses
of Offering&#x201d;. Deferred offering costs consist of underwriting, legal, and other professional expenses incurred through the balance
sheet date that are directly related to the intended de-SPAC Transaction. These costs will be charged to shareholders&#x2019; equity, netted
against the proceeds, upon the completion of the Business Combination. Should the transaction prove to be unsuccessful, these deferred
costs, as well as additional expenses to be incurred, will be charged to the statements of operations and comprehensive loss. As of June&#160;30,
2025 and March&#160;31, 2026, the Company deferred nil &lt;span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20250630_z5VXiUJdObX8" style="display: none" title="Deferred offering costs"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--DeferredOfferingCosts_iI_c20260331_zPoYFoMfe149" title="Deferred offering costs"&gt;95,000&lt;/span&gt; of transaction costs, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_ecustom--AdvanceToSuppliersPolicyTextBlock_zZ6KgRaaPBG2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;j.
&lt;span id="xdx_866_zzQ6PbxNF5wb"&gt;Advance to suppliers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Advance
to suppliers represent prepayments made to vendors in connection with the purchase of services. Advance is recorded at the amount paid
and are classified as current assets when the related services are expected to be received within one year or the normal operating cycle.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--RefundableDepositsReceivablePolicyTextBlock_zk0hhYTHhzHb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;k.
&lt;span id="xdx_869_zdl6xUSc9d8g"&gt;Refundable deposits receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Refundable
deposits receivable mainly represents security deposits and refundable cooperation deposits paid to suppliers and business partners that
are contractually recoverable upon the completion of services. These amounts are recorded as assets when paid, generally at the amount
paid. Deposits expected to be recovered within one year are classified as current; otherwise, they are classified as non-current. Allowance
should be assessed under CECL, and write off when not recoverable. The Company evaluates the credit risk of refundable deposits receivable
and recognizes an allowance for credit losses based on the current expected credit losses (&#x201c;CECL&#x201d;) model. Specific balances
are written off when they are deemed uncollectible and all collection efforts have been exhausted. As of June&#160;30, 2025 and March&#160;31,
2026, &lt;span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_zDO4z5wPjGpf" title="Allowance for expected credit losses"&gt;&lt;span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20260331_zQu1ABES8Qma" title="Allowance for expected credit losses"&gt;no&lt;/span&gt;&lt;/span&gt; allowance for credit losses was recorded.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--PrepaidResearchAndDevelopmentExpensesPolicyTextBlock_zj47oP2LEO03" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;l.
&lt;span id="xdx_866_zznJ5p0oZj1b"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Prepaid
research and development expenses represent advance payments to third-party service providers for technical, design, and development services.
These amounts are initially recorded as prepaid assets and are subsequently recognized as research and development expenses in the period
the services are rendered, in accordance with the terms of the respective agreements. The Company periodically reviews the status of these
agreements to ensure the prepaid balance properly reflects the value of services not yet received. For the three and nine months ended
March&#160;31, 2026, the Company recognized&#160;$&lt;span id="xdx_907_ecustom--AmortizationOfPrepaidResearchAndDevelopmentCosts_c20260101__20260331_zCXNiflih5bg" title="Amortization of prepaid research and development costs"&gt;625,000&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--AmortizationOfPrepaidResearchAndDevelopmentCosts_c20250701__20260331_zBFunA6k8NXc" title="Amortization of prepaid research and development costs"&gt;1,875,000&lt;/span&gt;, respectively, of expense related to the amortization of prepaid
research and development costs, which was included in research and development expense.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_ecustom--OtherReceivablesPolicyRextBlock_zhEjVv3wuafj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;m.
&lt;span id="xdx_86D_zATAJPzQnQpl"&gt;Other receivables&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Other
receivables represent funds temporarily held in trust by an employee acting on the Company&#x2019;s behalf. As of June&#160;30, 2025
and March&#160;31, 2026, the balance were $&lt;span id="xdx_90D_eus-gaap--OtherReceivables_iI_pp0d_c20250630_za2VXMC6Mpee" title="Other receivables"&gt;1,207,626&lt;/span&gt;
and &lt;span id="xdx_908_eus-gaap--OtherReceivables_iI_pp0d_c20260331_zA3XBehG7pA7" style="display: none" title="Other receivables"&gt;0&lt;/span&gt; nil, respectively, with the nil balance as of March 31, 2026 resulting from the employee having repaid all outstanding amounts to the Company. The balance
as of June 30, 2025 was primarily comprising proceeds from SAFEs agreements received via the employee and net of payments made to
designated suppliers at the Company&#x2019;s direction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zCXIK2Zay5zh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;n.
&lt;span id="xdx_865_zZTnYmCZy9f7"&gt;Equipment, net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Equipment,
net is stated at cost less accumulated depreciation and impairment, if any. Depreciation is computed using the straight-line method over
the estimated useful lives of three or five years, depending on the asset category.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_ecustom--RefundableDepositsPayablePolicyTextBlock_zPSaUzzvIgEa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;o.
&lt;span id="xdx_86F_zFO7q56sC1Ja"&gt;Refundable deposits payable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Refundable
deposits payable represent security payments received from a third party and customers, which are required for certain intelligent computing
power service arrangements. As of June&#160;30, 2025 and March&#160;31, 2026, the balance were $&lt;span id="xdx_906_ecustom--RefundableDepositsPayable_iI_pp0d_c20250630_zT5OwPspNGaa" title="Refundable deposits payable"&gt;1,445,580&lt;/span&gt; and $&lt;span id="xdx_907_ecustom--RefundableDepositsPayable_iI_pp0d_c20260331_zlF8FJ2gxvTd" title="Refundable deposits payable"&gt;1,174,702&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zVTnprYtqQTc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;p.
&lt;span id="xdx_862_zigYXt8xtSLl"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company reviews its long-lived assets, equipment, for impairment whenever events or changes in circumstances indicate the carrying amount
of an asset may not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset
to the future undiscounted cash flows expected to be generated from the use of the asset and its eventual disposition. If such assets
are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair
value of the impaired assets. Assets to be disposed of are reported at the lower of their carrying amount or fair value less cost to sell.
There was &lt;span id="xdx_905_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20240701__20250331_zrLs0b2fiOF6" title="Impairment of long-lived assets"&gt;&lt;span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20250701__20260331_z8ukRmzY0PX3" title="Impairment of long-lived assets"&gt;no&lt;/span&gt;&lt;/span&gt; impairment of long-lived assets for the nine months ended March&#160;31, 2025 and 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--SimpleAgreementsForFutureEquityPolicyTextBlock_zdOdrfeIirK4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;q.
&lt;span id="xdx_86C_zSfMxlp0w9ih"&gt;Simple agreements for future equity&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;SAFEs
issued by the Company are freestanding financial instruments. As they contain certain redemption or liquidation features that&#160;may&#160;require
the Company to settle the obligation in cash upon the occurrence of defined events (e.g., a change of control or dissolution), the instruments&#160;create
an obligation that meets the definition of a liability. Accordingly, the SAFEs are classified in their entirety as liabilities on the
balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;These
liabilities are measured at fair value upon initial recognition and are subsequently remeasured at fair value at each reporting date.
All changes in their fair value are recognized in&#160;the condensed consolidated statement of operations and comprehensive loss in the
period in which they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--RevenueRecognitionDeferredRevenue_z7voQ64y5MR7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;r.
&lt;span id="xdx_86B_zHHFuv3eFudi"&gt;Revenue recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company applied ASC Topic&#160;606 &#x201c;&lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;&#x201d; (&#x201c;ASC&#160;606&#x201d;) for all periods
presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
five-step model defined by ASC&#160;606 requires the Company to (i)&#160;identify its contracts with clients, (ii)&#160;identify its performance
obligations under those contracts, (iii)&#160;determine the transaction prices of those contracts, (iv)&#160;allocate the transaction
prices to its performance obligations in those contracts, and (v)&#160;recognize revenue when each performance obligation under those
contracts is satisfied. Revenue is recognized when promised goods or services are transferred to the client in an amount that reflects
the consideration expected in exchange for those goods or services.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company reports all of its revenues on a gross basis.&#160;This determination is based on the Company&#x2019;s assessment that it is the
principal in its revenue arrangements. The Company controls the service delivery platform and infrastructure before the service is provided
to the customer. It is primarily responsible for fulfilling the service promise, has discretion in setting prices, and assumes the credit
risk associated with the customer receivable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As
a practical expedient, the Company elected to expense the incremental costs of obtaining a contract when incurred if the amortization
period of the asset that the Company otherwise would have recognized is one year or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Pursuant
to ASC 606, the Company recognizes revenue based on the transaction price, which is the amount of consideration it expects to be entitled
to exchange for transferring services to customers. For Intelligent Computing Power Services, contract consideration is generally fixed
and is typically stated as a fixed monthly fee determined by (i) the contractually specified number of GPUs (capacity) and (ii) the service
period. Accordingly, the transaction price is generally the fixed contractual amount. The Company recognizes revenue over time as the
services are provided throughout the contract term. The Company offers payment terms ranging from 0 to 6 months, depending on customers&#x2019;
credit profiles and service requirements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company does not provide warranties for its services and does not offer service-type warranty arrangements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
following is a description of the principal activities of the Company from which the Company generates its revenue under ASC 606.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;(i)
Revenue for intelligent computing power service&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company leverages its expertise in high-performance computing and cloud-native architectures to build and operate stable, efficient, and
scalable GPU computing platforms through modular data center design and liquid cooling technology. The Company uses these platforms to
provide computing resources for large-scale AI training, model inference, and high-performance scientific computing to commercial enterprise
clients with substantial GPU computing requirements. Supporting services include GPU server environment deployment, cluster scheduling
and performance optimization, high-speed network interconnection, real-time monitoring and intelligent alerting systems, as well as industry-compliant
security and regulatory assurance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company accounts for the above promises as a single performance obligation because they are highly integrated and not separately identifiable
in the context of the contract. The Company provides an integrated, managed GPU computing platform in which computing capacity, deployment/configuration,
scheduling, networking, monitoring, and security/compliance are interdependent and together deliver a single combined service&#x2014;continuous
access to a functioning and secured platform over the contractual term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company provides intelligent computing power services under two pricing models: (i) reserved capacity arrangements and (ii) on-demand
(pay-as-you-go) arrangements. The following table presents revenue recognized during the period by arrangement type:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zd2TxFvdYVol" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BE_zsDAbjhGLAp7" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Schedule of Revenue recognition&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Reserved
        capacity arrangements&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;1,758,921&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;3,725,315&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;4,161,985&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;10,428,983&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;On-demand
        arrangements&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;5,436&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;1,341&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;6,482&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;12,526&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;1,764,357&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;3,726,656&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;4,168,467&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90E_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;10,441,509&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zk9Xg0gC6OZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0px"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Reserved
capacity arrangements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company enters into reserved capacity arrangements, which generally provide committed intelligent computing power services for a defined
service term ranging from 3 months to 3 years, with the majority of such arrangements having a one-year term. These contracts typically
are non-cancelable, or may be canceled only under limited conditions with early notifications required. Payment terms generally range
from 0-6 months upon the completion of services, and certain arrangements require prepayments. Any prepayments are recorded as contract
liabilities and recognized over the service term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
performance obligation is satisfied over time because the customer simultaneously receives and consumes the benefits. Revenue is recognized
using a time-elapsed output method over the contractual service period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On-demand
(pay-as-you-go) arrangements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif;text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company provides customers with on-demand
access to intelligent computing power and GPU resources under pay-as-you-go model which requires advance payment. Customer advances are
recorded as contract liabilities and recognized as revenue over the time during the provision of related services underlying the contract
term. The revenue is recognized over time because the customer can simultaneously receive and consume the benefits during the service
period. These arrangements generally do not include a fixed contractual term or minimum usage commitments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;(ii)
Revenue from comprehensive data center service&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company leverages its project experience in infrastructure management, cluster optimization, and system monitoring to provide full-cycle
operational support to data center asset owners. Services encompass facility environment deployment, network architecture implementation,
security and compliance system development, daily operational monitoring, and emergency fault response. Revenue is recognized over time
because the Company&#x2019;s services are performed throughout the contract term and the customer benefits as the services are provided.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
the three months ended March&#160;31, 2025 and 2026, $&lt;span id="xdx_909_eus-gaap--Revenues_c20250101__20250331_pp0p" title="Revenue"&gt;1,862,158&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--Revenues_c20260101__20260331_pp0p" title="Revenue"&gt;3,754,586&lt;/span&gt; of the revenue of the Company&#x2019;s was recognized over
time, respectively. For the nine months ended March&#160;31, 2025 and 2026, $&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250331_pp0p" title="Revenue"&gt;4,475,885 &lt;/span&gt;and $&lt;span id="xdx_903_eus-gaap--Revenues_c20250701__20260331_pp0p" title="Revenue"&gt;10,561,331&lt;/span&gt; of the revenue of the Company&#x2019;s
was recognized over time, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Revenue
disaggregated by service lines for the three months and the nine months ended March&#160;31, 2025 and 2026 is disclosed in the table below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_z4whYoH0Yw36" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B8_z323FGsdNtth" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Schedule of Revenue disaggregated&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Revenue
        from intelligent computing power service&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z29WimMIRYO5" title="Total"&gt;1,764,357&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--Revenues_pp0d_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z0wPR3mOXwde" title="Total"&gt;3,726,656&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--Revenues_pp0d_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zzqz7UuAay4i" title="Total"&gt;4,168,467&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zh7mCphOG5Ja" title="Total"&gt;10,441,509&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Revenue
        from comprehensive data center service&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;97,801&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;27,930&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;307,418&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;119,822&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90B_eus-gaap--Revenues_pp0d_c20250101__20250331_zwjWXHIVxdh" title="Total"&gt;1,862,158&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_pp0d_c20260101__20260331_zNTOV4dIJ4Sh" title="Total"&gt;3,754,586&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_eus-gaap--Revenues_pp0d_c20240701__20250331_zNWqBnz3BD5a" title="Total"&gt;4,475,885&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_906_eus-gaap--Revenues_pp0d_c20250701__20260331_zdRfOMzRsXv6" title="Total"&gt;10,561,331&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zatc3Yp3kc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--ContractLiabilitiesPolicyTextBlock_z2PT6xnTNlO" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;s.
&lt;span id="xdx_869_z3dd7lxTNbH4"&gt;Contract liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company receives advance payments from its customers for services to be provided in the future. These payments are recorded as&#160;contract
liabilities&#160;on the balance sheet within &#x201c;Contract liabilities&#x201d;.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Contract
liabilities are recognized when consideration is received from a customer prior to the Company satisfying its related performance obligations.
For these service contracts, the Company recognizes revenue, and reduces the contract liabilities,&#160;over time&#160;as the services
are rendered and the performance obligations are satisfied. Revenue recognized during the nine months ended March&#160;31, 2025 and 2026
that was included in the contract liability balance at the beginning of the period was $&lt;span id="xdx_90A_ecustom--RevenueRecognized_c20240701__20250331_pp0p" title="Revenue recognized"&gt;95,326&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--RevenueRecognized_pp0d_c20250701__20260331_z9oT97FjUGcd" title="Revenue recognized"&gt;366,075&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--CostOfSalesPolicyTextBlock_zaoHhLB8Cxzj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;t.
&lt;span id="xdx_863_z6GbgvPwOLFd"&gt;Cost of revenues&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s cost of revenues primarily includes computing power service, professional service fees and staff costs and employee benefits.
All the cost of revenues are recognized in the period in which the related services occur or the benefits are received.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--SellingAndMarketingExpensesPolicyTextBlock_zw8zqwj9sNL3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;u.
&lt;span id="xdx_864_ziTHMzLNeaI4"&gt;Selling and marketing expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s selling and marketing expenses primarily include: (i) advertising and promotion expenses, (ii) staff costs, employee benefits
and share-based compensation, and (iii) travel and other routine office expenses. All expenses are recognized in the period in which the
related services occur or the benefits are received. The Company expenses advertising costs as incurred, and for the nine months ended
March&#160;31, 2025 and 2026, the Company incurred advertising and promotion expenses of $&lt;span id="xdx_908_eus-gaap--MarketingAndAdvertisingExpense_c20240701__20250331_pp0p" title="Advertising and promotion expenses"&gt;76,090&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20250701__20260331_pp0p" title="Advertising and promotion expenses"&gt;32,113&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zPGLlXD14Ag2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;v.
&lt;span id="xdx_86B_zfPkq0yTYPQi"&gt;Research and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s research and development expenses mainly consist of software development outsourcing service fees, staff costs and employee
benefits, and testing expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zXxvFOjeOFW2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;w.
&lt;span id="xdx_866_zkb75BAicCy2"&gt;General and administrative expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s general and administrative expenses mainly consist of staff costs and employee benefits, professional service fees, depreciation
expenses and other operating expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zM8egXJLQ5Fa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;x.
&lt;span id="xdx_863_znTdepZ9jHh1"&gt;Income tax&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Income
taxes are determined in accordance with the provisions of ASC Topic 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC Topic 740&#x201d;). Under
this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities
are measured using enacted income tax rates expected to apply to taxable income in the periods in which those temporary differences are
expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income
in the period that includes the enactment date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;ASC
740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial
statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be
recognized in the unaudited condensed consolidated financial statements when it is more likely than not the position will be
sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest
amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority
assuming full knowledge of the position and relevant facts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_ecustom--CapitalStructurePolicyTextBlock_zj8IHwVClyZk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;y.
&lt;span id="xdx_865_zxrlWlb60CN6"&gt;Capital structure&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company is authorized to issue &lt;span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20250630_zxhDDryref03" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt; ordinary shares of $&lt;span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250630_z9V4hGvU5My3" title="Common stock, par value"&gt;0.01&lt;/span&gt; par value each. As of June&#160;30, 2025, there were &lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20250630_zDM1htk1G69f" title="Common stock, shares issued"&gt;&lt;span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20250630_zYzvDTOvJVAi" title="Common stock, shares outstanding"&gt;1,500&lt;/span&gt;&lt;/span&gt; shares issued
and outstanding.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Pursuant
to the resolution of the board of directors on January&#160;8, 2026, the authorized share capital of &lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20260108_z7MXAFFZzI8i" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt; ordinary shares was re-designated
to &lt;span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zYWtA0wxDxN4" title="Common stock, shares authorized"&gt;303&lt;/span&gt; Class A ordinary shares and &lt;span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_z1Wg9UO1Hwh6" title="Common stock, shares authorized"&gt;1,197&lt;/span&gt; Class B ordinary shares. Holders of Class A ordinary shares and Class B ordinary shares have
the same rights, except for voting and conversion rights. Each Class A ordinary share is entitled to one vote; and each Class B ordinary
share is entitled to twenty votes and is convertible into one Class A ordinary share at any time by the holder thereof. Class A ordinary
shares are not convertible into Class B ordinary shares under any circumstances. Furthermore, all outstanding warrants, options, and SAFEs
are designated to convert or settle exclusively into Class A ordinary shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As
of March&#160;31, 2026, there were &lt;span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pd" title="Common stock, shares authorized"&gt;303&lt;/span&gt; Class A ordinary shares and &lt;span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pd" title="Common stock, shares authorized"&gt;1,197&lt;/span&gt; Class B ordinary shares outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z72hDOJ3JON1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;z.
&lt;span id="xdx_86B_z63uLSARL1W8"&gt;Share-based compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company grants share options of the Company to eligible employees and&#160;non-employees. The Company accounts for share-based awards
issued to employees and&#160;non-employees in accordance with ASC Topic 718 &lt;i&gt;Compensation &#x2013; Stock Compensation. &lt;/i&gt;The Company
recognizes forfeitures as they occur. The share-based compensation expenses have been categorized as either general and administrative
expenses or selling and marketing expenses, depending on the job functions of the grantees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s share-based compensation awards are expected to be settled through transfers of existing ordinary shares held by the controlling
shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary shares are included in issued and
outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase the Company&#x2019;s total issued
and outstanding shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Employees&#x2019;
share-based awards and non-employees&#x2019; share-based awards are measured at the grant date fair value of the awards and recognized
as expenses a) immediately at grant date if no vesting conditions are required; or b) using graded vesting method, net of estimated forfeitures,
over the requisite service period, which is the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company employs discounted cash flow method to determine the fair value of our share-based compensation arrangements, where the key valuation
variables include risk free rate, discount rate, and perpetual rate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zh2bCTq9oe5d" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;aa.
&lt;span id="xdx_864_zR4H5vg2NKs8"&gt;Segment reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;ASC
280, &#x201c;Segment Reporting&#x201d;, establishes standards for reporting information about operating segments on a basis consistent with
the Company&#x2019;s internal organizational structure as well as information about geographical areas, business segments and major customers
in financial statements for details on the Company&#x2019;s business segments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company uses the &#x201c;management approach&#x201d; in determining reportable operating segments. The management approach considers the
internal organization and reporting used by the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) for making operating
decisions and assessing performance as the source for determining the Company&#x2019;s reportable segments. The Company&#x2019;s CODM is
the chief executive officer. The CODM regularly reviews consolidated operating results and reviews consolidated revenues and net loss
when making decisions about allocating resources and assessing performance of the segment, and hence, the Group has only&#160;one&#160;reportable
segment. Therefore, as the Group has determined it operates as a single reportable segment, the CODM assesses the Group&#x2019;s performance
and results of operations on a consolidated basis.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--RelatedPartiesPolicyTextBlock_zrZgPAsibWna" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;bb.
&lt;span id="xdx_86A_zzhxddzLg2h3"&gt;Related parties&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Parties
are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant
influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject
to common control or significant influence, such as a family member or relative, shareholder, or a related corporation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--ComprehensiveLossPolicyTextBlock_zbTFOSz89y33" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;cc.
&lt;span id="xdx_86C_znQfJNLN3lgc"&gt;Comprehensive loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Comprehensive
loss is defined as a change in equity during a period from transactions and other events and circumstances&#160;from&#160;non-owner&#160;sources.&#160;The
Company&#x2019;s comprehensive loss was the same as its reported net loss for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--EarningsPerSharePolicyTextBlock_z0CKE94bvxGf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;dd.
&lt;span id="xdx_869_zTML0LCjGgK"&gt;Loss per share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Basic
net loss per share of ordinary shares attributable to common shareholders is calculated by dividing net loss attributable to common shareholders
by the weighted-average shares of common shares outstanding for the period. Potentially dilutive shares, which are based on the weighted-average
shares of common stock underlying outstanding share-based awards or options using the treasury stock method or the if-converted method,
as applicable, are included when calculating diluted net income per share of common stock attributable to common shareholders when their
effect is dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Diluted
net loss per share attributable to ordinary shareholders is computed by adjusting the weighted-average number of ordinary shares outstanding
for the dilutive effect of all potential ordinary share equivalents. For the Company, potential ordinary share equivalents consist of
share-based compensation, which are assessed using the&#160;treasury stock method. These potential shares are included in the diluted
earnings per share calculation only when their effect is&#160;dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
periods where the Company reports a&#160;net loss, diluted net loss per share is calculated in the same manner as basic net loss per share
because the inclusion of any potential ordinary shares would have an&#160;anti-dilutive&#160;effect. Consequently, all potential ordinary
share equivalents were excluded from the calculation for the years in which a net loss was incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--RevenueRecognitionDividends_zJ8w8TuqR9s" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;ee.
&lt;span id="xdx_860_zcInrRKO5aA2"&gt;Dividends&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Dividends
are recognized when declared. &lt;span id="xdx_907_eus-gaap--Dividends_pp0d_do_c20240701__20250331_zbPIn012EOig" title="Dividends"&gt;&lt;span id="xdx_90C_eus-gaap--Dividends_pp0d_do_c20250701__20260331_zuV7f8fIUas1" title="Dividends"&gt;No&lt;/span&gt;&lt;/span&gt; dividends were declared for the nine months ended March&#160;31, 2025 and 2026, respectively. The Company
does not have any present plan to pay any dividends on ordinary shares in the foreseeable future. The Company currently intends to retain
the available funds and any future earnings to operate and expand its business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--EmergingGrowthCompanyPolicyTextBlock_zX6M59dr8xPl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;ff&lt;/i&gt;&lt;/b&gt;.
&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zwrHCIubN67h"&gt;Emerging growth company&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company intends to operate as an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012
(the &#x201c;JOBS Act&#x201d;). The JOBS Act permits companies with emerging growth company status to take advantage of an extended transition
period to comply with new or revised accounting standards, delaying the adoption of these accounting standards until such time as those
standards would apply to private companies. The Company elected to use this extended transition period to enable it to comply with new
or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that
it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period
provided in the JOBS Act. As a result, the Company&#x2019;s financial statements may not be comparable to companies that comply with the
new or revised accounting standards as of public company effective dates.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock_zt2bjFLbuL9h" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;gg.
&lt;span id="xdx_86D_zcwKuWVskW29"&gt;Recently adopted accounting standard updates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
June&#160;2016, the FASB issued ASU&#160;2016-13, &lt;i&gt;Financial Instruments&#160;&#x2014;&#160;Credit Losses &lt;/i&gt;(Topic&#160;326): Measurement
of Credit Losses on Financial Instruments (&#x201c;ASU&#160;2016-13&#x201d;). The new accounting standard introduced the current expected
credit losses methodology (&#x201c;CECL&#x201d;) for estimating allowances for credit losses. The measurement of expected credit losses
under the CECL methodology is applicable to financial assets measured at amortized costs, including loans and trade receivables. ASU&#160;2016-13
is effective for the Company, as an emerging growth company, for annual and interim reporting periods beginning after December&#160;15,
2022. The Company adopted the standard on July&#160;1, 2023 using the modified retrospective method for all financial assets in scope.
The adoption of the standard did not have a material impact on the Company&#x2019;s statements of income, or statements of cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
November&#160;2023, the FASB issued ASU&#160;2023-07, &#x201c;Segment Reporting (Topic&#160;280): Improvements to Reportable Segment Disclosures.&#x201d;
The amendments in this ASU are intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about
significant segment expenses. This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating
decision mark (&#x201c;CODM&#x201d;), an amount for other segment items by reportable segment and a description of its composition, all
annual disclosures required by FASB ASU Topic&#160;280 in interim periods as well, and the title and position of the CODM and how the
CODM uses the reported measures. Additionally, this ASU requires that at least one of the reported segment profit and loss measures should
be the measure that is most consistent with the measurement principles used in an entity&#x2019;s financial statements. Lastly, this ASU
requires public business entities with a single reportable segment to provide all disclosures required by these amendments in this ASU
and all existing segment disclosures in Topic&#160;280. This ASU is effective for fiscal&#160;years beginning after December&#160;15,
2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. The Company has early adopted ASU&#160;2023-07
on July&#160;1, 2023. As a result of adoption, the required disclosures have been included in Note 2 and Note 13.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOp72ws5iCAh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;hh.
&lt;span id="xdx_86A_z38IxEch0007"&gt;Recently accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
December&#160;2023, the FASB issued ASU&#160;No.&#160;2023-09,&#160;&lt;i&gt;Improvements to Income Tax Disclosures&lt;/i&gt;&#160;(&#x201c;ASU&#160;2023-09&#x201d;),&#160;which
requires entities to make incremental income tax disclosures on an annual basis. The amendments require that public business entities
disclose specific categories in the rate reconciliation and provide additional information for reconciling items meeting a quantitative
threshold. The amendments also require disclosure of income taxes paid to be disaggregated by jurisdiction, and the disclosure of income
tax expense disaggregated by federal, state, and foreign. Amendments are effective for annual periods beginning after December&#160;15,
2025 and thereafter, with early adoption permitted. The Company is evaluating adoption timing and the impact ASU&#160;2023-09&#160;will
have on its financial statements and related disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
March&#160;2024, the FASB issued ASU No. 2024-02, &lt;i&gt;Codification Improvements-Amendments to Remove References to the Concepts Statements&lt;/i&gt;
(&#x201c;ASU 2024-02&#x201d;). The amendments in this Update affect a variety of Topics in the Codification. The amendments apply to all
reporting entities within the scope of the affected accounting guidance. This update contains amendments to the Codification that remove
references to various Concepts Statements. In most instances, the references are extraneous and not required to understand or apply the
guidance. In other instances, references were used in prior statements to provide guidance in certain topical areas. ASU 2024-02 is effective
for public business entities for fiscal years beginning after December&#160;15, 2024. Early adoption is permitted for both interim and
annual financial statements that have not yet been issued or made available for issuance. The adoption did not have a material impact
on the Company&#x2019;s financial statement.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
November&#160;2024, the FASB issued ASU 2024-03 &#x201c;&lt;i&gt;Income Statement&#x2014;Reporting comprehensive (loss) income&#x2014;Expense Disaggregation
Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;&#x201d; (&#x201c;ASU 2024-03&#x201d;). The amendments in this
update intend to improve the disclosures about a public business entity&#x2019;s expenses and address requests from investors for more
detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization,
and depletion) in commonly presented expense captions (such as cost of sales, selling, general and administrative expenses, and research
and development). ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods beginning after
December&#160;15, 2027. The Company is currently evaluating the impact from the adoption of this ASU on its financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
January&#160;2025, the FASB issued Accounting Standards Update (ASU) No. 2025-01, &lt;i&gt;Income Statement &#x2014; Reporting comprehensive
(loss) income &#x2014; Expense Disaggregation Disclosures&lt;/i&gt; (Subtopic 220-40): Clarifying the Effective Date. The amendment clarifies
the effective date of ASU No. 2024-03 that all public business entities are required to adopt the guidance in annual reporting periods
beginning after December&#160;15, 2026, and interim periods within annual reporting periods beginning after December&#160;15, 2027. Early
adoption of Update 2024-03 is permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or
guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
July&#160;2025, the FASB issued Accounting Standards Update (ASU) No. 2025-05, &lt;i&gt;Financial Instruments &#x2014; Credit Losses&lt;/i&gt; (Topic
326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The amendment provides (1) all entities with a practical
expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the assets and (2) entities
other than public business entities with an accounting policy election to consider collection activity after the balance sheet date when
estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for
under Topic 606. This guidance is effective for annual reporting periods beginning after December&#160;15, 2025 and interim reporting
periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of the above
new accounting pronouncements or guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
September&#160;2025, the FASB issued&#160;&lt;i&gt;ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40):
Accounting for and Disclosure of Software Costs&#160;&lt;/i&gt;(&#x201c;ASU 2025-06&#x201d;), which amends certain aspects of the accounting for
and disclosure of internal-use software costs. ASU 2025-06 is effective for annual reporting periods beginning with the year ending December&#160;31,
2028, with early adoption permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or guidance
on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December&#160;2025,
the FASB issued &lt;i&gt;ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements&lt;/i&gt;, which clarifies interim disclosure
requirements resulting in a comprehensive list of interim disclosures that are required by GAAP, and includes a disclosure principle
that requires the disclosure of events since the end of the last annual reporting period that have a material impact on the Company.
ASU 2025-11 is effective for the Company&#x2019;s interim reporting periods within fiscal years beginning after December 15, 2028, with
early adoption permitted. ASU 2025-11 may be applied either prospectively or retrospectively. The Company is currently evaluating the
impact of the above new accounting pronouncements or guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Except
as mentioned above, the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted,
would have a material effect on the balance sheets, statements of income and comprehensive loss and cash flows.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <cik0002065779:GoingConcernPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003161">&lt;p id="xdx_84E_ecustom--GoingConcernPolicyTextBlock_zjTeaYmk2USj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;a.
&lt;span id="xdx_867_zT6r15wrPfT"&gt;Going concern&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As
of March&#160;31, 2026, the Company had cash and cash equivalents and U.S. Dollar Coin (&#x201c;USDC&#x201d;) of $&lt;span id="xdx_90B_ecustom--CashAndCashEquivalentsAndU.s.DollarCoin_iI_pn3n3_dm_c20260331_zOweLGQ0nMmd" title="Cash and cash equivalents and U.S. Dollar Coin"&gt;5.1 &lt;/span&gt;million
and current liabilities of $29.2 &lt;span id="xdx_90B_eus-gaap--LiabilitiesCurrent_iI_c20260331_zx0VQfPseO64" style="display: none" title="Current liabilities"&gt;29,153,918&lt;/span&gt;
million. For the nine months ended March&#160;31, 2025, the Company used $0.8 &lt;span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20240701__20250331_zXrnaRJA6DE6" style="display: none" title="Cash for operating activities"&gt;(757,960)&lt;/span&gt;
million in operating activities, while for the nine months ended March&#160;31, 2026, it used $3.8 &lt;span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20250701__20260331_z0FbPDcDfL21" style="display: none" title="Cash for operating activities"&gt;(3,758,611)&lt;/span&gt;
million. The Company incurred net losses of $6.2 &lt;span id="xdx_90B_eus-gaap--NetIncomeLoss_c20240701__20250331_zVBAnoAbYj2e" style="display: none" title="Net losses"&gt;(6,178,537)&lt;/span&gt;
million and $7.9 &lt;span id="xdx_906_eus-gaap--NetIncomeLoss_c20250701__20260331_zwLqC0GO7Qj2" style="display: none" title="Net losses"&gt;(7,916,977)&lt;/span&gt;
million for these respective periods. Since inception, the Company has incurred recurring net losses from operations and negative
cash flows from operating activities. As of March&#160;31, 2026, the Company had an accumulated deficit of $21.1 &lt;span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20260331_zxZwKyas1Wfb" style="display: none" title="Accumulated deficit"&gt;(21,134,012)&lt;/span&gt;
million. These factors raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern within one year
of the date these unaudited condensed consolidated financial statements are issued.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Management
has formulated and is actively pursuing plans to mitigate these conditions and secure the Company&#x2019;s continued operations. In connection
with the Company&#x2019;s contemplated business combination with a SPAC and related financing activities, the Company expects to access
additional capital through external funding sources. In addition, the Company continues to focus on expanding its market presence and
developing client relationships to drive revenue growth, while managing operating expenses, with the objective of improving cash flows
from operations over time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
purposes of this disclosure, &#x201c;SPAC&#x201d; refers to a special purpose acquisition company formed to effect a merger, share exchange,
asset acquisition, share purchase, reorganization or similar business combination with one or more operating businesses. &#x201c;De-SPAC&#x201d;
refers to the business combination transaction pursuant to which an operating company combines with a SPAC, following which the combined
company becomes publicly listed (or otherwise succeeds to the SPAC&#x2019;s public company status).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s
negative working capital position is primarily attributable to the classification of SAFEs. Excluding the accounting impact of the SAFEs,
which will only be paid in cash upon Liquidity Events and Dissolution Event (as defined in Note 8), management believes the Company&#x2019;s
available cash resources are sufficient for near-term operating needs. If additional liquidity is required, the Company&#x2019;s majority
shareholder has entered into a binding support agreement to provide funding to cover anticipated operating cash flow shortfalls through
the completion of the contemplated de-SPAC transaction. The support agreement is effective for a period of eighteen months from June&#160;10,
2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;However,
the de-SPAC transaction (including the SAFEs conversion) have not been fully implemented as of the date these unaudited condensed consolidated
financial statements are issued. There can be no assurance that these plans will be successfully completed within the required time frame,
on acceptable terms, or at all. If the primary plans are not successful, the Company&#x2019;s alternative courses of action would further
intensify efforts in market expansion and client development to increase revenue, while diligently controlling costs to ensure sufficient
cash flow from operating activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company may not be able to secure necessary financing in a timely manner or on favorable terms, or successfully execute its operational
turnaround. These circumstances give rise to substantial doubt that the Company will continue as a going concern and these unaudited condensed
consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:GoingConcernPolicyTextBlock>
    <cik0002065779:CashAndCashEquivalentsAndU.s.DollarCoin
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="-3"
      id="Fact003163"
      unitRef="USD">5100000</cik0002065779:CashAndCashEquivalentsAndU.s.DollarCoin>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003165"
      unitRef="USD">29153918</us-gaap:LiabilitiesCurrent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003167"
      unitRef="USD">-757960</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003169"
      unitRef="USD">-3758611</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003171"
      unitRef="USD">-6178537</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003173"
      unitRef="USD">-7916977</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003175"
      unitRef="USD">-21134012</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003182">&lt;p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zrDsuQdfyKG2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;b.
&lt;span id="xdx_860_z2ZzsSnntEpd"&gt;Basis of presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally
accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange
Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting. Certain information and note disclosures normally included in
the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP have been condensed consolidated or
omitted pursuant to such rules and regulations. As such, the information included in this interim financial report should be read in
conjunction with the audited financial statements and accompanying notes for the two years ended June&#160;30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
accompanying unaudited condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly
the financial position, operating results and cash flows of the Company for each of the periods presented. The results of operations for
the three and nine months ended March&#160;31, 2026 are not necessarily indicative of results to be expected for any other interim period
or for the year ending June&#160;30, 2026. The condensed consolidated balance sheet as of June&#160;30, 2025 was derived from the audited
financial statements at that date but does not include all of the disclosures required by U.S. GAAP for annual financial statements.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003187">&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zcUBkLyQ302a" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;c.
&lt;span id="xdx_869_zJzlNRZuupR8"&gt;Use of estimates and assumptions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation
of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported
in the unaudited condensed consolidated financial statements and accompanying notes. Management believes that the estimates used in preparing
the unaudited condensed consolidated financial statements are reasonable and prudent; however, actual results could differ from these
estimates under different assumptions or conditions.&#160;Significant accounting estimates include recognition and measurement of SAFEs
notes, recognition and measurement of share-based compensation, the allowance for expected credit losses, deferred tax assets and valuation
allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003189">&lt;p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z3MfqTrj1Ctg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;d.
&lt;span id="xdx_861_zefs2YE20oYg"&gt;Fair value measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
accordance with FASB ASC 820&#160;&lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, fair value is defined as the price that would be received
to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company
uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes
between market participant assumptions developed from market data obtained from outside sources (observable inputs) and the Company&#x2019;s
own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable
inputs).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of
inputs used to measure fair value are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Level
1: Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Level
2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Level
3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash
flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment
or estimation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management during
the nine months ended March&#160;31, 2025 and 2026. The carrying amount of cash and cash equivalents, accounts receivable, refundable
deposits receivable, other receivables, accounts payable, refundable deposits payable and other current liabilities approximated their
fair values as of June&#160;30, 2025 and March&#160;31, 2026. For the nine months ended March&#160;31, 2025 and 2026, the Company carried
SAFEs and digital assets at their fair value (see&#160;Note 4-Fair Value Measurements for fair value information).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <cik0002065779:FunctionalCurrencyPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003191">&lt;p id="xdx_844_ecustom--FunctionalCurrencyPolicyTextBlock_z2nCVmTUVaCh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;e.
&lt;span id="xdx_86D_zpLd8Tfyfj3f"&gt;Functional currency&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
accompanying unaudited condensed consolidated financial statements are presented in the United States dollar (&#x201c;US$&#x201d;).
The functional currency of the Company and its subsidiary is the US$.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;All
transactions are measured and recorded in the Company&#x2019;s functional currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:FunctionalCurrencyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003193">&lt;p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z91JQokNSbAl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;f.
&lt;span id="xdx_867_zTk17b0iUrZg"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company considers all highly liquid investments instruments purchased with a maturity period of three months or less to be cash or cash
equivalents. The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents approximate their fair value.
As of June&#160;30, 2025 and March&#160;31, 2026, the Company does &lt;span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zmHRDKKWlBMg" title="Cash equivalents"&gt;&lt;span id="xdx_908_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20260331_zVbuobGqAgp7" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;t have any cash equivalents.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003195"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003197"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <cik0002065779:CryptoAssets
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003202">&lt;p id="xdx_84A_ecustom--CryptoAssets_zZhlCmsQAIQk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;g.
&lt;span id="xdx_862_zW5hKqqXdcS6"&gt;Crypto assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s
crypto assets classified in current assets are held primarily for use in the ordinary course of business which is expected to be actively
utilized or converted within the normal operating cycle and such crypto assets can be sold in a highly liquid marketplace. During the
nine months ended March&#160;31, 2026, the Company only held crypto assets of Tether USD (&#x201c;USDT&#x201d;) and USDC, which are principally
funded by SAFE investors and as a form of payment for transaction revenue. The Company&#x2019;s crypto assets are held with qualified
third-party custodians who provide secure storage and safeguarding of the Company&#x2019;s crypto assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;USDC&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;USDC
is a stablecoin redeemable on a one-to-one basis for U.S. dollars and is accounted for as a financial instrument in the unaudited condensed
consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Crypto
assets other than USDC&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On
December&#160;13, 2023, the FASB issued ASU 2023-08, which addresses the accounting and disclosure requirements for certain cryptocurrencies.
The new guidance requires entities to subsequently measure certain cryptocurrencies at fair value, with changes in fair value recorded
in net income in each reporting period. The Company applied the ASU since its holding of crypto assets in December&#160;2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Digital
assets that are received as noncash consideration in our revenue arrangements and paid in purchases of professional service and others
are presented as cash flows from operating activities in other operating activities settled in digital assets and USDC. Digital assets
that are received in our revenue arrangements and sold for cash within seven days are presented as cash flows from operating activities,
while other digital asset activity held longer than seven days is reflected as cash flows from investing activities under disposal of
digital assets and USDC held in the consolidated statements of cash flows. The Company presents crypto assets other than USDC separately
from other intangible assets and USDC, recorded as digital assets on the unaudited condensed consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
the three months ended March&#160;31, 2026, the Company recorded receipt and disbursement of digital assets amounted to $&lt;span id="xdx_90E_ecustom--ReceiptOfDigitalAssets_c20260101__20260331_pp0p" title="Receipt of digital assets"&gt;644,616&lt;/span&gt; and $&lt;span id="xdx_901_ecustom--DisbursementOfDigitalAssets_c20260101__20260331_pp0p" title="Disbursement of digital assets"&gt;796,781&lt;/span&gt;.&#160;For
the nine months ended March&#160;31, 2026, the Company recorded receipt and disbursement of digital assets amounted to $&lt;span id="xdx_909_ecustom--ReceiptOfDigitalAssets_c20250701__20260331_pp0p" title="Receipt of digital assets"&gt;939,397&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--DisbursementOfDigitalAssets_c20250701__20260331_pp0p" title="Disbursement of digital assets"&gt;939,397&lt;/span&gt;,
respectively, which resulted in an ending balance of nil. The Company&#x2019;s balances related to digital assets and stablecoins during
the period included USDT and USDC, both of which are USD-pegged stablecoins. &lt;span id="xdx_901_ecustom--FairValueGainOrLossOnDigitalAssets_pp0d_do_c20260101__20260331_zi458qVUCNt1" title="Fair value gain or loss on digital assets"&gt;&lt;span id="xdx_905_ecustom--FairValueGainOrLossOnDigitalAssets_pp0d_do_c20250701__20260331_zVXF30cgUVQc" title="Fair value gain or loss on digital assets"&gt;No&lt;/span&gt;&lt;/span&gt; fair value gain or loss on digital assets was recognized
for the three and nine months ended March&#160;31, 2026 considering the low volatility in the fair value of USDT during the three and
nine months ended March&#160;31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:CryptoAssets>
    <cik0002065779:ReceiptOfDigitalAssets
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003204"
      unitRef="USD">644616</cik0002065779:ReceiptOfDigitalAssets>
    <cik0002065779:DisbursementOfDigitalAssets
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003206"
      unitRef="USD">796781</cik0002065779:DisbursementOfDigitalAssets>
    <cik0002065779:ReceiptOfDigitalAssets
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003208"
      unitRef="USD">939397</cik0002065779:ReceiptOfDigitalAssets>
    <cik0002065779:DisbursementOfDigitalAssets
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003210"
      unitRef="USD">939397</cik0002065779:DisbursementOfDigitalAssets>
    <cik0002065779:FairValueGainOrLossOnDigitalAssets
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003212"
      unitRef="USD">0</cik0002065779:FairValueGainOrLossOnDigitalAssets>
    <cik0002065779:FairValueGainOrLossOnDigitalAssets
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003214"
      unitRef="USD">0</cik0002065779:FairValueGainOrLossOnDigitalAssets>
    <cik0002065779:ExpectedCreditLossAndAccountsReceivablePolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003216">&lt;p id="xdx_843_ecustom--ExpectedCreditLossAndAccountsReceivablePolicyTextBlock_zyxTRes82yL6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;h.
&lt;span id="xdx_863_z4jvYtW2zBHk"&gt;Expected credit loss and accounts receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company adopted Financial Standards Accounting Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 326 &#x201c;&lt;i&gt;Financial
Instruments&#160;&#x2014;&#160;Credit Losses&lt;/i&gt;&#x201d; (&#x201c;ASC&#160;326&#x201d;) on January&#160;1, 2023.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s accounts receivable are within the scope of ASC&#160;326. ASC&#160;326 introduces an approach based on expected credit
losses on financial assets at amortized cost. Upon adoption of ASC&#160;326, the Company estimates the expected credit losses for accounts
receivable using the roll-rate method on a collective basis when similar risk characteristics exist. Expected credit losses are included
in general and administrative expenses in the statements of operations and comprehensive loss. After all attempts to collect a receivable
have failed, the receivable is written off against the allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Accounts
receivable represents those receivables derived in the ordinary course of business, net of an allowance for any potentially uncollectible
amounts. The Company makes estimates of expected credit and collectability trends for the allowance for credit losses based upon its assessment
of various factors, including historical experience, the age of the accounts receivable balances, credit quality of its customers, current
economic conditions, reasonable and supportable forecasts of future economic conditions that may vary by geography, customer-type, or
industry sub-vertical, and other factors that may affect its ability to collect from customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Although
the Company has historically not experienced significant credit losses, they may experience increasing credit loss risks from accounts
receivable in future periods if its customers are adversely affected by economic pressures or uncertainty associated with local or global
economic recessions, or other customer-specific factors, and actual experience in the future may differ from their past experiences or
current assessment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:ExpectedCreditLossAndAccountsReceivablePolicyTextBlock>
    <cik0002065779:DeferredOfferingCostsPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003223">&lt;p id="xdx_849_ecustom--DeferredOfferingCostsPolicyTextBlock_zampFPTaHJw6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;i.
&lt;span id="xdx_866_zIRNVy8x1Vb6"&gt;Deferred offering costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company follows the requirements of FASB ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014; &#x201c;Expenses
of Offering&#x201d;. Deferred offering costs consist of underwriting, legal, and other professional expenses incurred through the balance
sheet date that are directly related to the intended de-SPAC Transaction. These costs will be charged to shareholders&#x2019; equity, netted
against the proceeds, upon the completion of the Business Combination. Should the transaction prove to be unsuccessful, these deferred
costs, as well as additional expenses to be incurred, will be charged to the statements of operations and comprehensive loss. As of June&#160;30,
2025 and March&#160;31, 2026, the Company deferred nil &lt;span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20250630_z5VXiUJdObX8" style="display: none" title="Deferred offering costs"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--DeferredOfferingCosts_iI_c20260331_zPoYFoMfe149" title="Deferred offering costs"&gt;95,000&lt;/span&gt; of transaction costs, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003225"
      unitRef="USD">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003227"
      unitRef="USD">95000</us-gaap:DeferredOfferingCosts>
    <cik0002065779:AdvanceToSuppliersPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003229">&lt;p id="xdx_846_ecustom--AdvanceToSuppliersPolicyTextBlock_zZ6KgRaaPBG2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;j.
&lt;span id="xdx_866_zzQ6PbxNF5wb"&gt;Advance to suppliers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Advance
to suppliers represent prepayments made to vendors in connection with the purchase of services. Advance is recorded at the amount paid
and are classified as current assets when the related services are expected to be received within one year or the normal operating cycle.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:AdvanceToSuppliersPolicyTextBlock>
    <cik0002065779:RefundableDepositsReceivablePolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003231">&lt;p id="xdx_848_ecustom--RefundableDepositsReceivablePolicyTextBlock_zk0hhYTHhzHb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;k.
&lt;span id="xdx_869_zdl6xUSc9d8g"&gt;Refundable deposits receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Refundable
deposits receivable mainly represents security deposits and refundable cooperation deposits paid to suppliers and business partners that
are contractually recoverable upon the completion of services. These amounts are recorded as assets when paid, generally at the amount
paid. Deposits expected to be recovered within one year are classified as current; otherwise, they are classified as non-current. Allowance
should be assessed under CECL, and write off when not recoverable. The Company evaluates the credit risk of refundable deposits receivable
and recognizes an allowance for credit losses based on the current expected credit losses (&#x201c;CECL&#x201d;) model. Specific balances
are written off when they are deemed uncollectible and all collection efforts have been exhausted. As of June&#160;30, 2025 and March&#160;31,
2026, &lt;span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_zDO4z5wPjGpf" title="Allowance for expected credit losses"&gt;&lt;span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20260331_zQu1ABES8Qma" title="Allowance for expected credit losses"&gt;no&lt;/span&gt;&lt;/span&gt; allowance for credit losses was recorded.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RefundableDepositsReceivablePolicyTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003233"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003235"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <cik0002065779:PrepaidResearchAndDevelopmentExpensesPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003237">&lt;p id="xdx_845_ecustom--PrepaidResearchAndDevelopmentExpensesPolicyTextBlock_zj47oP2LEO03" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;l.
&lt;span id="xdx_866_zznJ5p0oZj1b"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Prepaid
research and development expenses represent advance payments to third-party service providers for technical, design, and development services.
These amounts are initially recorded as prepaid assets and are subsequently recognized as research and development expenses in the period
the services are rendered, in accordance with the terms of the respective agreements. The Company periodically reviews the status of these
agreements to ensure the prepaid balance properly reflects the value of services not yet received. For the three and nine months ended
March&#160;31, 2026, the Company recognized&#160;$&lt;span id="xdx_907_ecustom--AmortizationOfPrepaidResearchAndDevelopmentCosts_c20260101__20260331_zCXNiflih5bg" title="Amortization of prepaid research and development costs"&gt;625,000&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--AmortizationOfPrepaidResearchAndDevelopmentCosts_c20250701__20260331_zBFunA6k8NXc" title="Amortization of prepaid research and development costs"&gt;1,875,000&lt;/span&gt;, respectively, of expense related to the amortization of prepaid
research and development costs, which was included in research and development expense.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:PrepaidResearchAndDevelopmentExpensesPolicyTextBlock>
    <cik0002065779:AmortizationOfPrepaidResearchAndDevelopmentCosts
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003239"
      unitRef="USD">625000</cik0002065779:AmortizationOfPrepaidResearchAndDevelopmentCosts>
    <cik0002065779:AmortizationOfPrepaidResearchAndDevelopmentCosts
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003241"
      unitRef="USD">1875000</cik0002065779:AmortizationOfPrepaidResearchAndDevelopmentCosts>
    <cik0002065779:OtherReceivablesPolicyRextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003246">&lt;p id="xdx_84D_ecustom--OtherReceivablesPolicyRextBlock_zhEjVv3wuafj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;m.
&lt;span id="xdx_86D_zATAJPzQnQpl"&gt;Other receivables&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Other
receivables represent funds temporarily held in trust by an employee acting on the Company&#x2019;s behalf. As of June&#160;30, 2025
and March&#160;31, 2026, the balance were $&lt;span id="xdx_90D_eus-gaap--OtherReceivables_iI_pp0d_c20250630_za2VXMC6Mpee" title="Other receivables"&gt;1,207,626&lt;/span&gt;
and &lt;span id="xdx_908_eus-gaap--OtherReceivables_iI_pp0d_c20260331_zA3XBehG7pA7" style="display: none" title="Other receivables"&gt;0&lt;/span&gt; nil, respectively, with the nil balance as of March 31, 2026 resulting from the employee having repaid all outstanding amounts to the Company. The balance
as of June 30, 2025 was primarily comprising proceeds from SAFEs agreements received via the employee and net of payments made to
designated suppliers at the Company&#x2019;s direction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:OtherReceivablesPolicyRextBlock>
    <us-gaap:OtherReceivables
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003248"
      unitRef="USD">1207626</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003250"
      unitRef="USD">0</us-gaap:OtherReceivables>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003252">&lt;p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zCXIK2Zay5zh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;n.
&lt;span id="xdx_865_zZTnYmCZy9f7"&gt;Equipment, net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Equipment,
net is stated at cost less accumulated depreciation and impairment, if any. Depreciation is computed using the straight-line method over
the estimated useful lives of three or five years, depending on the asset category.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <cik0002065779:RefundableDepositsPayablePolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003254">&lt;p id="xdx_847_ecustom--RefundableDepositsPayablePolicyTextBlock_zPSaUzzvIgEa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;o.
&lt;span id="xdx_86F_zFO7q56sC1Ja"&gt;Refundable deposits payable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Refundable
deposits payable represent security payments received from a third party and customers, which are required for certain intelligent computing
power service arrangements. As of June&#160;30, 2025 and March&#160;31, 2026, the balance were $&lt;span id="xdx_906_ecustom--RefundableDepositsPayable_iI_pp0d_c20250630_zT5OwPspNGaa" title="Refundable deposits payable"&gt;1,445,580&lt;/span&gt; and $&lt;span id="xdx_907_ecustom--RefundableDepositsPayable_iI_pp0d_c20260331_zlF8FJ2gxvTd" title="Refundable deposits payable"&gt;1,174,702&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RefundableDepositsPayablePolicyTextBlock>
    <cik0002065779:RefundableDepositsPayable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003256"
      unitRef="USD">1445580</cik0002065779:RefundableDepositsPayable>
    <cik0002065779:RefundableDepositsPayable
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003258"
      unitRef="USD">1174702</cik0002065779:RefundableDepositsPayable>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003260">&lt;p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zVTnprYtqQTc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;p.
&lt;span id="xdx_862_zigYXt8xtSLl"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company reviews its long-lived assets, equipment, for impairment whenever events or changes in circumstances indicate the carrying amount
of an asset may not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset
to the future undiscounted cash flows expected to be generated from the use of the asset and its eventual disposition. If such assets
are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair
value of the impaired assets. Assets to be disposed of are reported at the lower of their carrying amount or fair value less cost to sell.
There was &lt;span id="xdx_905_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20240701__20250331_zrLs0b2fiOF6" title="Impairment of long-lived assets"&gt;&lt;span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20250701__20260331_z8ukRmzY0PX3" title="Impairment of long-lived assets"&gt;no&lt;/span&gt;&lt;/span&gt; impairment of long-lived assets for the nine months ended March&#160;31, 2025 and 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003262"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003264"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <cik0002065779:SimpleAgreementsForFutureEquityPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003266">&lt;p id="xdx_849_ecustom--SimpleAgreementsForFutureEquityPolicyTextBlock_zdOdrfeIirK4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;q.
&lt;span id="xdx_86C_zSfMxlp0w9ih"&gt;Simple agreements for future equity&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;SAFEs
issued by the Company are freestanding financial instruments. As they contain certain redemption or liquidation features that&#160;may&#160;require
the Company to settle the obligation in cash upon the occurrence of defined events (e.g., a change of control or dissolution), the instruments&#160;create
an obligation that meets the definition of a liability. Accordingly, the SAFEs are classified in their entirety as liabilities on the
balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;These
liabilities are measured at fair value upon initial recognition and are subsequently remeasured at fair value at each reporting date.
All changes in their fair value are recognized in&#160;the condensed consolidated statement of operations and comprehensive loss in the
period in which they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:SimpleAgreementsForFutureEquityPolicyTextBlock>
    <us-gaap:RevenueRecognitionDeferredRevenue
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003268">&lt;p id="xdx_84A_eus-gaap--RevenueRecognitionDeferredRevenue_z7voQ64y5MR7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;r.
&lt;span id="xdx_86B_zHHFuv3eFudi"&gt;Revenue recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company applied ASC Topic&#160;606 &#x201c;&lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;&#x201d; (&#x201c;ASC&#160;606&#x201d;) for all periods
presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
five-step model defined by ASC&#160;606 requires the Company to (i)&#160;identify its contracts with clients, (ii)&#160;identify its performance
obligations under those contracts, (iii)&#160;determine the transaction prices of those contracts, (iv)&#160;allocate the transaction
prices to its performance obligations in those contracts, and (v)&#160;recognize revenue when each performance obligation under those
contracts is satisfied. Revenue is recognized when promised goods or services are transferred to the client in an amount that reflects
the consideration expected in exchange for those goods or services.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company reports all of its revenues on a gross basis.&#160;This determination is based on the Company&#x2019;s assessment that it is the
principal in its revenue arrangements. The Company controls the service delivery platform and infrastructure before the service is provided
to the customer. It is primarily responsible for fulfilling the service promise, has discretion in setting prices, and assumes the credit
risk associated with the customer receivable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As
a practical expedient, the Company elected to expense the incremental costs of obtaining a contract when incurred if the amortization
period of the asset that the Company otherwise would have recognized is one year or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Pursuant
to ASC 606, the Company recognizes revenue based on the transaction price, which is the amount of consideration it expects to be entitled
to exchange for transferring services to customers. For Intelligent Computing Power Services, contract consideration is generally fixed
and is typically stated as a fixed monthly fee determined by (i) the contractually specified number of GPUs (capacity) and (ii) the service
period. Accordingly, the transaction price is generally the fixed contractual amount. The Company recognizes revenue over time as the
services are provided throughout the contract term. The Company offers payment terms ranging from 0 to 6 months, depending on customers&#x2019;
credit profiles and service requirements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company does not provide warranties for its services and does not offer service-type warranty arrangements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
following is a description of the principal activities of the Company from which the Company generates its revenue under ASC 606.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;(i)
Revenue for intelligent computing power service&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company leverages its expertise in high-performance computing and cloud-native architectures to build and operate stable, efficient, and
scalable GPU computing platforms through modular data center design and liquid cooling technology. The Company uses these platforms to
provide computing resources for large-scale AI training, model inference, and high-performance scientific computing to commercial enterprise
clients with substantial GPU computing requirements. Supporting services include GPU server environment deployment, cluster scheduling
and performance optimization, high-speed network interconnection, real-time monitoring and intelligent alerting systems, as well as industry-compliant
security and regulatory assurance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company accounts for the above promises as a single performance obligation because they are highly integrated and not separately identifiable
in the context of the contract. The Company provides an integrated, managed GPU computing platform in which computing capacity, deployment/configuration,
scheduling, networking, monitoring, and security/compliance are interdependent and together deliver a single combined service&#x2014;continuous
access to a functioning and secured platform over the contractual term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company provides intelligent computing power services under two pricing models: (i) reserved capacity arrangements and (ii) on-demand
(pay-as-you-go) arrangements. The following table presents revenue recognized during the period by arrangement type:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zd2TxFvdYVol" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BE_zsDAbjhGLAp7" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Schedule of Revenue recognition&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Reserved
        capacity arrangements&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;1,758,921&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;3,725,315&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;4,161,985&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;10,428,983&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;On-demand
        arrangements&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;5,436&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;1,341&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;6,482&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;12,526&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;1,764,357&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;3,726,656&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;4,168,467&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90E_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;10,441,509&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zk9Xg0gC6OZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0px"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Reserved
capacity arrangements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company enters into reserved capacity arrangements, which generally provide committed intelligent computing power services for a defined
service term ranging from 3 months to 3 years, with the majority of such arrangements having a one-year term. These contracts typically
are non-cancelable, or may be canceled only under limited conditions with early notifications required. Payment terms generally range
from 0-6 months upon the completion of services, and certain arrangements require prepayments. Any prepayments are recorded as contract
liabilities and recognized over the service term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
performance obligation is satisfied over time because the customer simultaneously receives and consumes the benefits. Revenue is recognized
using a time-elapsed output method over the contractual service period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On-demand
(pay-as-you-go) arrangements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif;text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The Company provides customers with on-demand
access to intelligent computing power and GPU resources under pay-as-you-go model which requires advance payment. Customer advances are
recorded as contract liabilities and recognized as revenue over the time during the provision of related services underlying the contract
term. The revenue is recognized over time because the customer can simultaneously receive and consume the benefits during the service
period. These arrangements generally do not include a fixed contractual term or minimum usage commitments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;(ii)
Revenue from comprehensive data center service&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company leverages its project experience in infrastructure management, cluster optimization, and system monitoring to provide full-cycle
operational support to data center asset owners. Services encompass facility environment deployment, network architecture implementation,
security and compliance system development, daily operational monitoring, and emergency fault response. Revenue is recognized over time
because the Company&#x2019;s services are performed throughout the contract term and the customer benefits as the services are provided.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
the three months ended March&#160;31, 2025 and 2026, $&lt;span id="xdx_909_eus-gaap--Revenues_c20250101__20250331_pp0p" title="Revenue"&gt;1,862,158&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--Revenues_c20260101__20260331_pp0p" title="Revenue"&gt;3,754,586&lt;/span&gt; of the revenue of the Company&#x2019;s was recognized over
time, respectively. For the nine months ended March&#160;31, 2025 and 2026, $&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250331_pp0p" title="Revenue"&gt;4,475,885 &lt;/span&gt;and $&lt;span id="xdx_903_eus-gaap--Revenues_c20250701__20260331_pp0p" title="Revenue"&gt;10,561,331&lt;/span&gt; of the revenue of the Company&#x2019;s
was recognized over time, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Revenue
disaggregated by service lines for the three months and the nine months ended March&#160;31, 2025 and 2026 is disclosed in the table below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_z4whYoH0Yw36" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B8_z323FGsdNtth" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Schedule of Revenue disaggregated&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Revenue
        from intelligent computing power service&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z29WimMIRYO5" title="Total"&gt;1,764,357&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--Revenues_pp0d_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z0wPR3mOXwde" title="Total"&gt;3,726,656&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--Revenues_pp0d_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zzqz7UuAay4i" title="Total"&gt;4,168,467&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zh7mCphOG5Ja" title="Total"&gt;10,441,509&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Revenue
        from comprehensive data center service&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;97,801&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;27,930&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;307,418&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;119,822&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90B_eus-gaap--Revenues_pp0d_c20250101__20250331_zwjWXHIVxdh" title="Total"&gt;1,862,158&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_pp0d_c20260101__20260331_zNTOV4dIJ4Sh" title="Total"&gt;3,754,586&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_eus-gaap--Revenues_pp0d_c20240701__20250331_zNWqBnz3BD5a" title="Total"&gt;4,475,885&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_906_eus-gaap--Revenues_pp0d_c20250701__20260331_zdRfOMzRsXv6" title="Total"&gt;10,561,331&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zatc3Yp3kc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionDeferredRevenue>
    <cik0002065779:ScheduleOfRevenueRecognitionTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003275">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zd2TxFvdYVol" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BE_zsDAbjhGLAp7" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Schedule of Revenue recognition&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Reserved
        capacity arrangements&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;1,758,921&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;3,725,315&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;4,161,985&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues"&gt;10,428,983&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;On-demand
        arrangements&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;5,436&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;1,341&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;6,482&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"&gt;12,526&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;1,764,357&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;3,726,656&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;4,168,467&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90E_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues"&gt;10,441,509&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</cik0002065779:ScheduleOfRevenueRecognitionTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003277"
      unitRef="USD">1758921</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003279"
      unitRef="USD">3725315</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003281"
      unitRef="USD">4161985</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003283"
      unitRef="USD">10428983</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003285"
      unitRef="USD">5436</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003287"
      unitRef="USD">1341</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003289"
      unitRef="USD">6482</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_OnDemandArrangementsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003291"
      unitRef="USD">12526</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003293"
      unitRef="USD">1764357</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003295"
      unitRef="USD">3726656</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003297"
      unitRef="USD">4168467</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003299"
      unitRef="USD">10441509</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003304"
      unitRef="USD">1862158</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003306"
      unitRef="USD">3754586</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003308"
      unitRef="USD">4475885</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003310"
      unitRef="USD">10561331</us-gaap:Revenues>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003312">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_z4whYoH0Yw36" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B8_z323FGsdNtth" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Schedule of Revenue disaggregated&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Revenue
        from intelligent computing power service&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z29WimMIRYO5" title="Total"&gt;1,764,357&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--Revenues_pp0d_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z0wPR3mOXwde" title="Total"&gt;3,726,656&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--Revenues_pp0d_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zzqz7UuAay4i" title="Total"&gt;4,168,467&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zh7mCphOG5Ja" title="Total"&gt;10,441,509&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Revenue
        from comprehensive data center service&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;97,801&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;27,930&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;307,418&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total"&gt;119,822&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90B_eus-gaap--Revenues_pp0d_c20250101__20250331_zwjWXHIVxdh" title="Total"&gt;1,862,158&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_pp0d_c20260101__20260331_zNTOV4dIJ4Sh" title="Total"&gt;3,754,586&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_eus-gaap--Revenues_pp0d_c20240701__20250331_zNWqBnz3BD5a" title="Total"&gt;4,475,885&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_906_eus-gaap--Revenues_pp0d_c20250701__20260331_zdRfOMzRsXv6" title="Total"&gt;10,561,331&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003314"
      unitRef="USD">1764357</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003316"
      unitRef="USD">3726656</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003318"
      unitRef="USD">4168467</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003320"
      unitRef="USD">10441509</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003322"
      unitRef="USD">97801</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003324"
      unitRef="USD">27930</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003326"
      unitRef="USD">307418</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003328"
      unitRef="USD">119822</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003330"
      unitRef="USD">1862158</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003332"
      unitRef="USD">3754586</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003334"
      unitRef="USD">4475885</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003336"
      unitRef="USD">10561331</us-gaap:Revenues>
    <cik0002065779:ContractLiabilitiesPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003338">&lt;p id="xdx_84C_ecustom--ContractLiabilitiesPolicyTextBlock_z2PT6xnTNlO" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;s.
&lt;span id="xdx_869_z3dd7lxTNbH4"&gt;Contract liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company receives advance payments from its customers for services to be provided in the future. These payments are recorded as&#160;contract
liabilities&#160;on the balance sheet within &#x201c;Contract liabilities&#x201d;.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Contract
liabilities are recognized when consideration is received from a customer prior to the Company satisfying its related performance obligations.
For these service contracts, the Company recognizes revenue, and reduces the contract liabilities,&#160;over time&#160;as the services
are rendered and the performance obligations are satisfied. Revenue recognized during the nine months ended March&#160;31, 2025 and 2026
that was included in the contract liability balance at the beginning of the period was $&lt;span id="xdx_90A_ecustom--RevenueRecognized_c20240701__20250331_pp0p" title="Revenue recognized"&gt;95,326&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--RevenueRecognized_pp0d_c20250701__20260331_z9oT97FjUGcd" title="Revenue recognized"&gt;366,075&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:ContractLiabilitiesPolicyTextBlock>
    <cik0002065779:RevenueRecognized
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003345"
      unitRef="USD">95326</cik0002065779:RevenueRecognized>
    <cik0002065779:RevenueRecognized
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003347"
      unitRef="USD">366075</cik0002065779:RevenueRecognized>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003349">&lt;p id="xdx_84F_eus-gaap--CostOfSalesPolicyTextBlock_zaoHhLB8Cxzj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;t.
&lt;span id="xdx_863_z6GbgvPwOLFd"&gt;Cost of revenues&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s cost of revenues primarily includes computing power service, professional service fees and staff costs and employee benefits.
All the cost of revenues are recognized in the period in which the related services occur or the benefits are received.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CostOfSalesPolicyTextBlock>
    <cik0002065779:SellingAndMarketingExpensesPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003351">&lt;p id="xdx_844_ecustom--SellingAndMarketingExpensesPolicyTextBlock_zw8zqwj9sNL3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;u.
&lt;span id="xdx_864_ziTHMzLNeaI4"&gt;Selling and marketing expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s selling and marketing expenses primarily include: (i) advertising and promotion expenses, (ii) staff costs, employee benefits
and share-based compensation, and (iii) travel and other routine office expenses. All expenses are recognized in the period in which the
related services occur or the benefits are received. The Company expenses advertising costs as incurred, and for the nine months ended
March&#160;31, 2025 and 2026, the Company incurred advertising and promotion expenses of $&lt;span id="xdx_908_eus-gaap--MarketingAndAdvertisingExpense_c20240701__20250331_pp0p" title="Advertising and promotion expenses"&gt;76,090&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20250701__20260331_pp0p" title="Advertising and promotion expenses"&gt;32,113&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:SellingAndMarketingExpensesPolicyTextBlock>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003353"
      unitRef="USD">76090</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003355"
      unitRef="USD">32113</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003357">&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zPGLlXD14Ag2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;v.
&lt;span id="xdx_86B_zfPkq0yTYPQi"&gt;Research and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s research and development expenses mainly consist of software development outsourcing service fees, staff costs and employee
benefits, and testing expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003359">&lt;p id="xdx_841_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zXxvFOjeOFW2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;w.
&lt;span id="xdx_866_zkb75BAicCy2"&gt;General and administrative expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s general and administrative expenses mainly consist of staff costs and employee benefits, professional service fees, depreciation
expenses and other operating expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003361">&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zM8egXJLQ5Fa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;x.
&lt;span id="xdx_863_znTdepZ9jHh1"&gt;Income tax&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Income
taxes are determined in accordance with the provisions of ASC Topic 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC Topic 740&#x201d;). Under
this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities
are measured using enacted income tax rates expected to apply to taxable income in the periods in which those temporary differences are
expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income
in the period that includes the enactment date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;ASC
740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial
statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be
recognized in the unaudited condensed consolidated financial statements when it is more likely than not the position will be
sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest
amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority
assuming full knowledge of the position and relevant facts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <cik0002065779:CapitalStructurePolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003363">&lt;p id="xdx_847_ecustom--CapitalStructurePolicyTextBlock_zj8IHwVClyZk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;y.
&lt;span id="xdx_865_zxrlWlb60CN6"&gt;Capital structure&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company is authorized to issue &lt;span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20250630_zxhDDryref03" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt; ordinary shares of $&lt;span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250630_z9V4hGvU5My3" title="Common stock, par value"&gt;0.01&lt;/span&gt; par value each. As of June&#160;30, 2025, there were &lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20250630_zDM1htk1G69f" title="Common stock, shares issued"&gt;&lt;span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20250630_zYzvDTOvJVAi" title="Common stock, shares outstanding"&gt;1,500&lt;/span&gt;&lt;/span&gt; shares issued
and outstanding.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Pursuant
to the resolution of the board of directors on January&#160;8, 2026, the authorized share capital of &lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20260108_z7MXAFFZzI8i" title="Common stock, shares authorized"&gt;1,500&lt;/span&gt; ordinary shares was re-designated
to &lt;span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zYWtA0wxDxN4" title="Common stock, shares authorized"&gt;303&lt;/span&gt; Class A ordinary shares and &lt;span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_z1Wg9UO1Hwh6" title="Common stock, shares authorized"&gt;1,197&lt;/span&gt; Class B ordinary shares. Holders of Class A ordinary shares and Class B ordinary shares have
the same rights, except for voting and conversion rights. Each Class A ordinary share is entitled to one vote; and each Class B ordinary
share is entitled to twenty votes and is convertible into one Class A ordinary share at any time by the holder thereof. Class A ordinary
shares are not convertible into Class B ordinary shares under any circumstances. Furthermore, all outstanding warrants, options, and SAFEs
are designated to convert or settle exclusively into Class A ordinary shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As
of March&#160;31, 2026, there were &lt;span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pd" title="Common stock, shares authorized"&gt;303&lt;/span&gt; Class A ordinary shares and &lt;span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pd" title="Common stock, shares authorized"&gt;1,197&lt;/span&gt; Class B ordinary shares outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:CapitalStructurePolicyTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003365"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003367"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003369"
      unitRef="Shares">1500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003371"
      unitRef="Shares">1500</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-01-08_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003378"
      unitRef="Shares">1500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-01-08_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003380"
      unitRef="Shares">303</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-01-08_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003382"
      unitRef="Shares">1197</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003384"
      unitRef="Shares">303</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ClassBOrdinarySharesMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003386"
      unitRef="Shares">1197</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003388">&lt;p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z72hDOJ3JON1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;z.
&lt;span id="xdx_86B_z63uLSARL1W8"&gt;Share-based compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company grants share options of the Company to eligible employees and&#160;non-employees. The Company accounts for share-based awards
issued to employees and&#160;non-employees in accordance with ASC Topic 718 &lt;i&gt;Compensation &#x2013; Stock Compensation. &lt;/i&gt;The Company
recognizes forfeitures as they occur. The share-based compensation expenses have been categorized as either general and administrative
expenses or selling and marketing expenses, depending on the job functions of the grantees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s share-based compensation awards are expected to be settled through transfers of existing ordinary shares held by the controlling
shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary shares are included in issued and
outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase the Company&#x2019;s total issued
and outstanding shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Employees&#x2019;
share-based awards and non-employees&#x2019; share-based awards are measured at the grant date fair value of the awards and recognized
as expenses a) immediately at grant date if no vesting conditions are required; or b) using graded vesting method, net of estimated forfeitures,
over the requisite service period, which is the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company employs discounted cash flow method to determine the fair value of our share-based compensation arrangements, where the key valuation
variables include risk free rate, discount rate, and perpetual rate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003390">&lt;p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zh2bCTq9oe5d" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;aa.
&lt;span id="xdx_864_zR4H5vg2NKs8"&gt;Segment reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;ASC
280, &#x201c;Segment Reporting&#x201d;, establishes standards for reporting information about operating segments on a basis consistent with
the Company&#x2019;s internal organizational structure as well as information about geographical areas, business segments and major customers
in financial statements for details on the Company&#x2019;s business segments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company uses the &#x201c;management approach&#x201d; in determining reportable operating segments. The management approach considers the
internal organization and reporting used by the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) for making operating
decisions and assessing performance as the source for determining the Company&#x2019;s reportable segments. The Company&#x2019;s CODM is
the chief executive officer. The CODM regularly reviews consolidated operating results and reviews consolidated revenues and net loss
when making decisions about allocating resources and assessing performance of the segment, and hence, the Group has only&#160;one&#160;reportable
segment. Therefore, as the Group has determined it operates as a single reportable segment, the CODM assesses the Group&#x2019;s performance
and results of operations on a consolidated basis.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <cik0002065779:RelatedPartiesPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003395">&lt;p id="xdx_848_ecustom--RelatedPartiesPolicyTextBlock_zrZgPAsibWna" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;bb.
&lt;span id="xdx_86A_zzhxddzLg2h3"&gt;Related parties&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Parties
are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant
influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject
to common control or significant influence, such as a family member or relative, shareholder, or a related corporation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RelatedPartiesPolicyTextBlock>
    <cik0002065779:ComprehensiveLossPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003397">&lt;p id="xdx_84F_ecustom--ComprehensiveLossPolicyTextBlock_zbTFOSz89y33" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;cc.
&lt;span id="xdx_86C_znQfJNLN3lgc"&gt;Comprehensive loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Comprehensive
loss is defined as a change in equity during a period from transactions and other events and circumstances&#160;from&#160;non-owner&#160;sources.&#160;The
Company&#x2019;s comprehensive loss was the same as its reported net loss for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:ComprehensiveLossPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003399">&lt;p id="xdx_846_eus-gaap--EarningsPerSharePolicyTextBlock_z0CKE94bvxGf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;dd.
&lt;span id="xdx_869_zTML0LCjGgK"&gt;Loss per share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Basic
net loss per share of ordinary shares attributable to common shareholders is calculated by dividing net loss attributable to common shareholders
by the weighted-average shares of common shares outstanding for the period. Potentially dilutive shares, which are based on the weighted-average
shares of common stock underlying outstanding share-based awards or options using the treasury stock method or the if-converted method,
as applicable, are included when calculating diluted net income per share of common stock attributable to common shareholders when their
effect is dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Diluted
net loss per share attributable to ordinary shareholders is computed by adjusting the weighted-average number of ordinary shares outstanding
for the dilutive effect of all potential ordinary share equivalents. For the Company, potential ordinary share equivalents consist of
share-based compensation, which are assessed using the&#160;treasury stock method. These potential shares are included in the diluted
earnings per share calculation only when their effect is&#160;dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
periods where the Company reports a&#160;net loss, diluted net loss per share is calculated in the same manner as basic net loss per share
because the inclusion of any potential ordinary shares would have an&#160;anti-dilutive&#160;effect. Consequently, all potential ordinary
share equivalents were excluded from the calculation for the years in which a net loss was incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:RevenueRecognitionDividends
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003401">&lt;p id="xdx_84E_eus-gaap--RevenueRecognitionDividends_zJ8w8TuqR9s" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;ee.
&lt;span id="xdx_860_zcInrRKO5aA2"&gt;Dividends&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Dividends
are recognized when declared. &lt;span id="xdx_907_eus-gaap--Dividends_pp0d_do_c20240701__20250331_zbPIn012EOig" title="Dividends"&gt;&lt;span id="xdx_90C_eus-gaap--Dividends_pp0d_do_c20250701__20260331_zuV7f8fIUas1" title="Dividends"&gt;No&lt;/span&gt;&lt;/span&gt; dividends were declared for the nine months ended March&#160;31, 2025 and 2026, respectively. The Company
does not have any present plan to pay any dividends on ordinary shares in the foreseeable future. The Company currently intends to retain
the available funds and any future earnings to operate and expand its business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionDividends>
    <us-gaap:Dividends
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003403"
      unitRef="USD">0</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003405"
      unitRef="USD">0</us-gaap:Dividends>
    <cik0002065779:EmergingGrowthCompanyPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003407">&lt;p id="xdx_841_ecustom--EmergingGrowthCompanyPolicyTextBlock_zX6M59dr8xPl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;ff&lt;/i&gt;&lt;/b&gt;.
&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zwrHCIubN67h"&gt;Emerging growth company&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company intends to operate as an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012
(the &#x201c;JOBS Act&#x201d;). The JOBS Act permits companies with emerging growth company status to take advantage of an extended transition
period to comply with new or revised accounting standards, delaying the adoption of these accounting standards until such time as those
standards would apply to private companies. The Company elected to use this extended transition period to enable it to comply with new
or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that
it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period
provided in the JOBS Act. As a result, the Company&#x2019;s financial statements may not be comparable to companies that comply with the
new or revised accounting standards as of public company effective dates.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:EmergingGrowthCompanyPolicyTextBlock>
    <cik0002065779:RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003412">&lt;p id="xdx_842_ecustom--RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock_zt2bjFLbuL9h" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;gg.
&lt;span id="xdx_86D_zcwKuWVskW29"&gt;Recently adopted accounting standard updates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
June&#160;2016, the FASB issued ASU&#160;2016-13, &lt;i&gt;Financial Instruments&#160;&#x2014;&#160;Credit Losses &lt;/i&gt;(Topic&#160;326): Measurement
of Credit Losses on Financial Instruments (&#x201c;ASU&#160;2016-13&#x201d;). The new accounting standard introduced the current expected
credit losses methodology (&#x201c;CECL&#x201d;) for estimating allowances for credit losses. The measurement of expected credit losses
under the CECL methodology is applicable to financial assets measured at amortized costs, including loans and trade receivables. ASU&#160;2016-13
is effective for the Company, as an emerging growth company, for annual and interim reporting periods beginning after December&#160;15,
2022. The Company adopted the standard on July&#160;1, 2023 using the modified retrospective method for all financial assets in scope.
The adoption of the standard did not have a material impact on the Company&#x2019;s statements of income, or statements of cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
November&#160;2023, the FASB issued ASU&#160;2023-07, &#x201c;Segment Reporting (Topic&#160;280): Improvements to Reportable Segment Disclosures.&#x201d;
The amendments in this ASU are intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about
significant segment expenses. This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating
decision mark (&#x201c;CODM&#x201d;), an amount for other segment items by reportable segment and a description of its composition, all
annual disclosures required by FASB ASU Topic&#160;280 in interim periods as well, and the title and position of the CODM and how the
CODM uses the reported measures. Additionally, this ASU requires that at least one of the reported segment profit and loss measures should
be the measure that is most consistent with the measurement principles used in an entity&#x2019;s financial statements. Lastly, this ASU
requires public business entities with a single reportable segment to provide all disclosures required by these amendments in this ASU
and all existing segment disclosures in Topic&#160;280. This ASU is effective for fiscal&#160;years beginning after December&#160;15,
2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. The Company has early adopted ASU&#160;2023-07
on July&#160;1, 2023. As a result of adoption, the required disclosures have been included in Note 2 and Note 13.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003414">&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOp72ws5iCAh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;hh.
&lt;span id="xdx_86A_z38IxEch0007"&gt;Recently accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
December&#160;2023, the FASB issued ASU&#160;No.&#160;2023-09,&#160;&lt;i&gt;Improvements to Income Tax Disclosures&lt;/i&gt;&#160;(&#x201c;ASU&#160;2023-09&#x201d;),&#160;which
requires entities to make incremental income tax disclosures on an annual basis. The amendments require that public business entities
disclose specific categories in the rate reconciliation and provide additional information for reconciling items meeting a quantitative
threshold. The amendments also require disclosure of income taxes paid to be disaggregated by jurisdiction, and the disclosure of income
tax expense disaggregated by federal, state, and foreign. Amendments are effective for annual periods beginning after December&#160;15,
2025 and thereafter, with early adoption permitted. The Company is evaluating adoption timing and the impact ASU&#160;2023-09&#160;will
have on its financial statements and related disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
March&#160;2024, the FASB issued ASU No. 2024-02, &lt;i&gt;Codification Improvements-Amendments to Remove References to the Concepts Statements&lt;/i&gt;
(&#x201c;ASU 2024-02&#x201d;). The amendments in this Update affect a variety of Topics in the Codification. The amendments apply to all
reporting entities within the scope of the affected accounting guidance. This update contains amendments to the Codification that remove
references to various Concepts Statements. In most instances, the references are extraneous and not required to understand or apply the
guidance. In other instances, references were used in prior statements to provide guidance in certain topical areas. ASU 2024-02 is effective
for public business entities for fiscal years beginning after December&#160;15, 2024. Early adoption is permitted for both interim and
annual financial statements that have not yet been issued or made available for issuance. The adoption did not have a material impact
on the Company&#x2019;s financial statement.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
November&#160;2024, the FASB issued ASU 2024-03 &#x201c;&lt;i&gt;Income Statement&#x2014;Reporting comprehensive (loss) income&#x2014;Expense Disaggregation
Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;&#x201d; (&#x201c;ASU 2024-03&#x201d;). The amendments in this
update intend to improve the disclosures about a public business entity&#x2019;s expenses and address requests from investors for more
detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization,
and depletion) in commonly presented expense captions (such as cost of sales, selling, general and administrative expenses, and research
and development). ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods beginning after
December&#160;15, 2027. The Company is currently evaluating the impact from the adoption of this ASU on its financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
January&#160;2025, the FASB issued Accounting Standards Update (ASU) No. 2025-01, &lt;i&gt;Income Statement &#x2014; Reporting comprehensive
(loss) income &#x2014; Expense Disaggregation Disclosures&lt;/i&gt; (Subtopic 220-40): Clarifying the Effective Date. The amendment clarifies
the effective date of ASU No. 2024-03 that all public business entities are required to adopt the guidance in annual reporting periods
beginning after December&#160;15, 2026, and interim periods within annual reporting periods beginning after December&#160;15, 2027. Early
adoption of Update 2024-03 is permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or
guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
July&#160;2025, the FASB issued Accounting Standards Update (ASU) No. 2025-05, &lt;i&gt;Financial Instruments &#x2014; Credit Losses&lt;/i&gt; (Topic
326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The amendment provides (1) all entities with a practical
expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the assets and (2) entities
other than public business entities with an accounting policy election to consider collection activity after the balance sheet date when
estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for
under Topic 606. This guidance is effective for annual reporting periods beginning after December&#160;15, 2025 and interim reporting
periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of the above
new accounting pronouncements or guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;In
September&#160;2025, the FASB issued&#160;&lt;i&gt;ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40):
Accounting for and Disclosure of Software Costs&#160;&lt;/i&gt;(&#x201c;ASU 2025-06&#x201d;), which amends certain aspects of the accounting for
and disclosure of internal-use software costs. ASU 2025-06 is effective for annual reporting periods beginning with the year ending December&#160;31,
2028, with early adoption permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or guidance
on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December&#160;2025,
the FASB issued &lt;i&gt;ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements&lt;/i&gt;, which clarifies interim disclosure
requirements resulting in a comprehensive list of interim disclosures that are required by GAAP, and includes a disclosure principle
that requires the disclosure of events since the end of the last annual reporting period that have a material impact on the Company.
ASU 2025-11 is effective for the Company&#x2019;s interim reporting periods within fiscal years beginning after December 15, 2028, with
early adoption permitted. ASU 2025-11 may be applied either prospectively or retrospectively. The Company is currently evaluating the
impact of the above new accounting pronouncements or guidance on the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Except
as mentioned above, the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted,
would have a material effect on the balance sheets, statements of income and comprehensive loss and cash flows.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003422">&lt;p id="xdx_803_eus-gaap--ConcentrationRiskDisclosureTextBlock_zS5TxZ8a2Pfc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;3.
&lt;span id="xdx_829_zr7ePs3Ws0Bk"&gt;Concentration and risk&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;Concentration
of credit risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Financial
instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.
The Company performs ongoing credit evaluations of the customers&#x2019; financial condition and maintains an allowance for potential credit
losses. This allowance consists of an amount identified for specific customers and an amount based on overall estimated exposure. Our
overall estimated exposure excludes amounts covered by credit insurance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;Concentration
of customers&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s revenue was concentrated among a limited number of customers during the periods presented. The following table summarized
customers with greater than 10% of the total revenue:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfConcentrationOfCustomersTableTextBlock_zdrUY4cApChh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BB_zF0IjA1n3Cgf" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of Concentration of customers&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zxlgA7Wnag01" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3426"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zqH7DAOCXZV8" title="Concentration of credit risk"&gt;24.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_z4iANF7QCG72" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3430"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_z5ok8h33NPNk" title="Concentration of credit risk"&gt;24.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zl0hTdibTWy2" title="Concentration of credit risk"&gt;11.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zr78XgBdGFo5" title="Concentration of credit risk"&gt;11.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zEivBBjP6d54" title="Concentration of credit risk"&gt;10.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zJU8ZQcVPnQ2" title="Concentration of credit risk"&gt;22.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zFn7N05enlt1" title="Concentration of credit risk"&gt;13.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zh9iXLwhZpMf" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3444"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_ziHKyapdTwK3" title="Concentration of credit risk"&gt;17.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zjeLxYJlsrI1" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3448"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_z796I4O4Ft1f" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3450"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zRbhCM2LF7S5" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3452"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zgDdNqfgOq26" title="Concentration of credit risk"&gt;10.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zwowQSBgSD2k" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3456"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zN6m8I45z7m6" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3458"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z7iN0ziOqvYg" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3460"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zyjXbig4uFfc" title="Concentration of credit risk"&gt;10.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z34E1WctisKk" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3464"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zKgQ6gkcige5" title="Concentration of credit risk"&gt;15.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zWsV8sKzzwa8" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3468"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zB7onhtTK1u9" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3470"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zxDehDpeHJYc" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3472"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zpwvFHT7lvqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s account receivable was concentrated among a limited number of customers during the periods presented. The following table
summarized customers with greater than 10% of the total account receivable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfAccountsReceivableTextBlock_zssuHJd4Ga7j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B7_zUHNVQLGGhr4" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of account receivable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;June&#160;30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zZDJYmdTS6e7" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zA8eCEY2tIWj" title="Concentration of credit risk"&gt;29.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zBKTwHAkynJb" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zK6G4BVNOl4d" title="Concentration of credit risk"&gt;19.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_ztBmu7lekrwl" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z4Qc91H8QUS6" title="Concentration of credit risk"&gt;10.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        G&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zL35tipxfmbl" title="Concentration of credit risk"&gt;42.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zqXdvkL42fyj" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        H&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_z8f6t0ucYWmb" title="Concentration of credit risk"&gt;38.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zMd1APLqZ6f8" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        I&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zVQSNFcXuZY3" title="Concentration of credit risk"&gt;19.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zHUH7nofxl86" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zdxUw16dlq13" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;Concentration
of suppliers&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s purchases was concentrated among a limited number of suppliers during the periods presented. The following table summarized
suppliers with greater than 10% of the total purchase:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfConcentrationOfSuppliersTableTextBlock_z3CdJRz1h27f" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 2)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BE_zyVdblECd42c" style="display: none; padding-bottom: 0.5pt"&gt;Schedule of Concentration of suppliers&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zZfZ870bnb8a" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zfZK2HfIukSg" title="Concentration of credit risk"&gt;13.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_fKg_____zoMyxzTZqNtf" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zuAu6Jniu74e" title="Concentration of credit risk"&gt;26.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_z1RvSNaoV0gg" title="Concentration of credit risk"&gt;14.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zmAjaL9pPKIb" title="Concentration of credit risk"&gt;30.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zu3OB7u7IVK3" title="Concentration of credit risk"&gt;21.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zubilSVoZOol" title="Concentration of credit risk"&gt;24.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zlOyPiZv8SE3" title="Concentration of credit risk"&gt;32.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zmj4eUM2HHn1" title="Concentration of credit risk"&gt;33.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zqiSFV5na4Ac" title="Concentration of credit risk"&gt;24.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zougKUG4D7eh" title="Concentration of credit risk"&gt;24.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_z39sRFJ0NCt8" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zMuGucfinjtf" title="Concentration of credit risk"&gt;13.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zGlfi03BgXDb" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zZ6OSrj6FVIa" title="Concentration of credit risk"&gt;11.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zJ08L3iZ3sFe" title="Concentration of credit risk"&gt;45.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zrqGEIvYjMWe" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zHbQGldke1jg" title="Concentration of credit risk"&gt;47.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zd2hl76uQNH" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;*:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;nil, new supplier for the nine months ended March&#160;31, 2026&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zBBE52ciJOOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s account payable was concentrated among a limited number of suppliers during the periods presented. The following table
summarized suppliers with greater than 10% of the total account payable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zRgvFNJVonif" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 3)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B1_z1KfkhgkdJa9" style="display: none"&gt;Schedule of account payable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;June&#160;30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        B&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zoy1O16r6pC2" title="Concentration of credit risk"&gt;12.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zT52WewH3gKf" title="Concentration of credit risk"&gt;74.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ConcentrationRiskPercentage_dp0_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_z49d3JRTVlqf" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zH861vcBqWw8" title="Concentration of credit risk"&gt;12.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--ConcentrationRiskPercentage_dp0_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zbDTqTB9gdUl" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zowygHhsFI98" title="Concentration of credit risk"&gt;13.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_z9tjQJ8njxna" title="Concentration of credit risk"&gt;54.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_ecustom--ConcentrationRiskPercentage_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_z0EDwEhAYvj3" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        G&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--SupplierGMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbgS1YdQk6w3" title="Concentration of credit risk"&gt;32.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ConcentrationRiskPercentage_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierGMember_zx8Qj3Ar38J3" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;*:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;nil, new supplier for the nine months ended March&#160;31, 2026&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <cik0002065779:ScheduleOfConcentrationOfCustomersTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003424">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfConcentrationOfCustomersTableTextBlock_zdrUY4cApChh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BB_zF0IjA1n3Cgf" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of Concentration of customers&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zxlgA7Wnag01" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3426"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zqH7DAOCXZV8" title="Concentration of credit risk"&gt;24.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_z4iANF7QCG72" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3430"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_z5ok8h33NPNk" title="Concentration of credit risk"&gt;24.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zl0hTdibTWy2" title="Concentration of credit risk"&gt;11.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zr78XgBdGFo5" title="Concentration of credit risk"&gt;11.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zEivBBjP6d54" title="Concentration of credit risk"&gt;10.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zJU8ZQcVPnQ2" title="Concentration of credit risk"&gt;22.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zFn7N05enlt1" title="Concentration of credit risk"&gt;13.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zh9iXLwhZpMf" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3444"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_ziHKyapdTwK3" title="Concentration of credit risk"&gt;17.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zjeLxYJlsrI1" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3448"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_z796I4O4Ft1f" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3450"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zRbhCM2LF7S5" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3452"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zgDdNqfgOq26" title="Concentration of credit risk"&gt;10.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zwowQSBgSD2k" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3456"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zN6m8I45z7m6" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3458"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z7iN0ziOqvYg" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3460"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zyjXbig4uFfc" title="Concentration of credit risk"&gt;10.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z34E1WctisKk" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3464"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zKgQ6gkcige5" title="Concentration of credit risk"&gt;15.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zWsV8sKzzwa8" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3468"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zB7onhtTK1u9" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3470"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zxDehDpeHJYc" style="color: White" title="Concentration of credit risk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3472"&gt;-&lt;/span&gt;&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</cik0002065779:ScheduleOfConcentrationOfCustomersTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003428"
      unitRef="Ratio">0.249</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003432"
      unitRef="Ratio">0.246</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003434"
      unitRef="Ratio">0.117</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003436"
      unitRef="Ratio">0.118</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003438"
      unitRef="Ratio">0.100</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003440"
      unitRef="Ratio">0.223</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003442"
      unitRef="Ratio">0.137</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003446"
      unitRef="Ratio">0.170</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003454"
      unitRef="Ratio">0.102</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003462"
      unitRef="Ratio">0.101</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerFMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003466"
      unitRef="Ratio">0.156</us-gaap:ConcentrationRiskPercentage1>
    <cik0002065779:ScheduleOfAccountsReceivableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003474">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfAccountsReceivableTextBlock_zssuHJd4Ga7j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B7_zUHNVQLGGhr4" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of account receivable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;June&#160;30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zZDJYmdTS6e7" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zA8eCEY2tIWj" title="Concentration of credit risk"&gt;29.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zBKTwHAkynJb" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zK6G4BVNOl4d" title="Concentration of credit risk"&gt;19.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_ztBmu7lekrwl" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z4Qc91H8QUS6" title="Concentration of credit risk"&gt;10.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        G&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zL35tipxfmbl" title="Concentration of credit risk"&gt;42.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zqXdvkL42fyj" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        H&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_z8f6t0ucYWmb" title="Concentration of credit risk"&gt;38.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zMd1APLqZ6f8" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Customer
        I&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zVQSNFcXuZY3" title="Concentration of credit risk"&gt;19.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zHUH7nofxl86" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</cik0002065779:ScheduleOfAccountsReceivableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003476"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003478"
      unitRef="Ratio">0.297</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003480"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003482"
      unitRef="Ratio">0.195</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003484"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003486"
      unitRef="Ratio">0.105</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003488"
      unitRef="Ratio">0.427</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003490"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003492"
      unitRef="Ratio">0.383</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerHMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003494"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerIMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003496"
      unitRef="Ratio">0.190</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerIMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003498"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <cik0002065779:ScheduleOfConcentrationOfSuppliersTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003502">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfConcentrationOfSuppliersTableTextBlock_z3CdJRz1h27f" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 2)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BE_zyVdblECd42c" style="display: none; padding-bottom: 0.5pt"&gt;Schedule of Concentration of suppliers&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zZfZ870bnb8a" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zfZK2HfIukSg" title="Concentration of credit risk"&gt;13.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_fKg_____zoMyxzTZqNtf" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zuAu6Jniu74e" title="Concentration of credit risk"&gt;26.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_z1RvSNaoV0gg" title="Concentration of credit risk"&gt;14.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zmAjaL9pPKIb" title="Concentration of credit risk"&gt;30.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zu3OB7u7IVK3" title="Concentration of credit risk"&gt;21.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zubilSVoZOol" title="Concentration of credit risk"&gt;24.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        C&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zlOyPiZv8SE3" title="Concentration of credit risk"&gt;32.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zmj4eUM2HHn1" title="Concentration of credit risk"&gt;33.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zqiSFV5na4Ac" title="Concentration of credit risk"&gt;24.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zougKUG4D7eh" title="Concentration of credit risk"&gt;24.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_z39sRFJ0NCt8" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zMuGucfinjtf" title="Concentration of credit risk"&gt;13.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zGlfi03BgXDb" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zZ6OSrj6FVIa" title="Concentration of credit risk"&gt;11.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zJ08L3iZ3sFe" title="Concentration of credit risk"&gt;45.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zrqGEIvYjMWe" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zHbQGldke1jg" title="Concentration of credit risk"&gt;47.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zd2hl76uQNH" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;*:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;nil, new supplier for the nine months ended March&#160;31, 2026&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</cik0002065779:ScheduleOfConcentrationOfSuppliersTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003504"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003506"
      unitRef="Ratio">0.130</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003508"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003510"
      unitRef="Ratio">0.264</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003512"
      unitRef="Ratio">0.144</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003514"
      unitRef="Ratio">0.302</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003516"
      unitRef="Ratio">0.211</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003518"
      unitRef="Ratio">0.249</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003520"
      unitRef="Ratio">0.329</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003522"
      unitRef="Ratio">0.337</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003524"
      unitRef="Ratio">0.240</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierCMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003526"
      unitRef="Ratio">0.242</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003528"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003530"
      unitRef="Ratio">0.138</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003532"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003534"
      unitRef="Ratio">0.115</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003536"
      unitRef="Ratio">0.455</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003538"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012025-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003540"
      unitRef="Ratio">0.476</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003542"
      unitRef="Ratio">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003544">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zRgvFNJVonif" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 3)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B1_z1KfkhgkdJa9" style="display: none"&gt;Schedule of account payable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;June&#160;30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        B&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zoy1O16r6pC2" title="Concentration of credit risk"&gt;12.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zT52WewH3gKf" title="Concentration of credit risk"&gt;74.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        D&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ConcentrationRiskPercentage_dp0_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_z49d3JRTVlqf" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zH861vcBqWw8" title="Concentration of credit risk"&gt;12.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        E&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--ConcentrationRiskPercentage_dp0_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zbDTqTB9gdUl" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zowygHhsFI98" title="Concentration of credit risk"&gt;13.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        F&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_z9tjQJ8njxna" title="Concentration of credit risk"&gt;54.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_ecustom--ConcentrationRiskPercentage_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_z0EDwEhAYvj3" style="color: White" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Supplier
        G&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--SupplierGMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbgS1YdQk6w3" title="Concentration of credit risk"&gt;32.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ConcentrationRiskPercentage_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierGMember_zx8Qj3Ar38J3" style="color: rgb(204,238,255)" title="Concentration of credit risk"&gt;-&lt;/span&gt;**&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;*:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;nil, new supplier for the nine months ended March&#160;31, 2026&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;**:&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;less than 10%&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003546"
      unitRef="Ratio">0.121</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierBMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003548"
      unitRef="Ratio">0.740</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003550"
      unitRef="Ratio">-0</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierDMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003552"
      unitRef="Ratio">0.126</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember62755093"
      decimals="INF"
      id="Fact003554"
      unitRef="Ratio">-0</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003556"
      unitRef="Ratio">0.134</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember62755109"
      decimals="INF"
      id="Fact003558"
      unitRef="Ratio">0.549</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierFMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003560"
      unitRef="Ratio">-0</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2024-07-012025-06-30_us-gaap_AccountsPayableMember_custom_SupplierGMember_us-gaap_CustomerConcentrationRiskMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003562"
      unitRef="Ratio">0.323</cik0002065779:ConcentrationRiskPercentage>
    <cik0002065779:ConcentrationRiskPercentage
      contextRef="From2025-07-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierGMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003564"
      unitRef="Ratio">-0</cik0002065779:ConcentrationRiskPercentage>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003566">&lt;p id="xdx_80D_eus-gaap--FairValueDisclosuresTextBlock_zhBirMcj7P27" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;4.
&lt;span id="xdx_827_ze9UXnp1dT7e"&gt;Fair value measurements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As
of June&#160;30, 2025 and March&#160;31, 2026, information about inputs into the fair value measurement of the Company&#x2019;s assets
and liabilities that are measured at fair value on a recurring basis in periods subsequent to their initial recognition is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_znXIjy2B1Unc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B3_zmXrZbsyeyG7" style="display: none; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Schedule of fair value assets and liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Fair value measurement
        at reporting date using&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Fair value &lt;br/&gt;as of&lt;br/&gt;June&#160;30,&lt;br/&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Quoted Prices in&lt;br/&gt;Active
        Markets for&lt;br/&gt;Identical Assets &lt;br/&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Significant Other&lt;br/&gt;Observable
        Inputs &lt;br/&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Significant &lt;br/&gt;Unobservable
        Inputs &lt;br/&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Liabilities:&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Simple
        agreements for future equity&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zdI2HsL9LKmf" title="Liability"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_z1nxmlaF6O8" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3572"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zmfS5uxBUmhg" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3574"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zHPcFlOlK9Vi" title="Liability"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Other payable
        related to the equity option&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zShE7VowVnA1" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_z5tNnS5uRuuj" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3580"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zzBB0KU0oEw4" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3582"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zkq0aEofGkY2" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Fair value measurement
        at reporting date using&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Fair value &lt;br/&gt;as of&lt;br/&gt;March&#160;31,
        &lt;br/&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Quoted Prices in&lt;br/&gt;Active
        Markets for&lt;br/&gt;Identical Assets &lt;br/&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Significant Other&lt;br/&gt;Observable
        Inputs &lt;br/&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Significant &lt;br/&gt;Unobservable
        Inputs &lt;br/&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Liabilities:&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Simple
        agreements for future equity&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zuhbr7cQGsg7" title="Liability"&gt;26,842,205&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zkBbNkVaZqr1" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3591"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_z9y0FcYieMIb" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3593"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zc1rFDya6DW8" title="Liability"&gt;26,842,205&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Other payable
        related to the equity option&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zvtu6XUHzxw3" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zmtSvpn5Ftt7" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3599"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zQh5SQC30bZf" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3601"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zbm43rdQGMmd" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span id="xdx_F0A_zChGi8tau4Y2"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;span id="xdx_F10_zFPLD0zjBMIf"&gt;The
        Company classifies its SAFEs as financial liabilities measured at fair value. The value of these agreements depends significantly on future
        financing activities, liquidity events, or other material milestones, and their valuation relies on significant inputs that are not observable
        in the public market. Accordingly, they are classified within Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
        fair value measurement is based on an integrated framework combining&#160;scenario analysis and financial instrument decomposition (i.e.
        Bond Plus Call Method). The proceeds of the SAFEs on the date of issuance were $14,092,500, Refer to Note 8-Simple Agreements for Future
        Equity for further details.&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; color: #0F1115"&gt;&lt;span id="xdx_F00_zI5V4PyahiJg"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F13_z2JSmT6vIOn7"&gt;Equity options. On May&#160;9, 2023, the Company entered into an agreement
        with a third-party service provider (the &#x201c;Service Provider&#x201d;). The Service Provider received a freestanding equity-linked right
        exercisable, at the Service Provider&#x2019;s option, upon the closing of the Company&#x2019;s next qualified equity financing. The right
        provides the ability to subscribe for up to the value of $200,000 at a 25% discount price per share on the grant date. The equity option
        is remeasured at fair value at each reporting date, with changes in fair value recognized in earnings. As of June&#160;30, 2025 and March&#160;31,
        2026, the fair value of the equity option was $53,333, and no gain or loss from changes in fair value was recognized for the periods presented.
        The fair value measurement of the equity option is categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based
        analysis, which incorporates significant unobservable inputs and management judgment regarding the probability and timing of potential
        future financing outcomes.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zAeVWeK19ZUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003568">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_znXIjy2B1Unc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B3_zmXrZbsyeyG7" style="display: none; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Schedule of fair value assets and liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Fair value measurement
        at reporting date using&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Fair value &lt;br/&gt;as of&lt;br/&gt;June&#160;30,&lt;br/&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Quoted Prices in&lt;br/&gt;Active
        Markets for&lt;br/&gt;Identical Assets &lt;br/&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Significant Other&lt;br/&gt;Observable
        Inputs &lt;br/&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Significant &lt;br/&gt;Unobservable
        Inputs &lt;br/&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Liabilities:&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Simple
        agreements for future equity&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zdI2HsL9LKmf" title="Liability"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_z1nxmlaF6O8" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3572"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zmfS5uxBUmhg" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3574"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zHPcFlOlK9Vi" title="Liability"&gt;18,243,885&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Other payable
        related to the equity option&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zShE7VowVnA1" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_z5tNnS5uRuuj" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3580"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zzBB0KU0oEw4" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3582"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zkq0aEofGkY2" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Fair value measurement
        at reporting date using&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Fair value &lt;br/&gt;as of&lt;br/&gt;March&#160;31,
        &lt;br/&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Quoted Prices in&lt;br/&gt;Active
        Markets for&lt;br/&gt;Identical Assets &lt;br/&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Significant Other&lt;br/&gt;Observable
        Inputs &lt;br/&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Significant &lt;br/&gt;Unobservable
        Inputs &lt;br/&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Liabilities:&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Simple
        agreements for future equity&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zuhbr7cQGsg7" title="Liability"&gt;26,842,205&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zkBbNkVaZqr1" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3591"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_z9y0FcYieMIb" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3593"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zc1rFDya6DW8" title="Liability"&gt;26,842,205&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in"&gt;Other payable
        related to the equity option&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zvtu6XUHzxw3" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zmtSvpn5Ftt7" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3599"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zQh5SQC30bZf" title="Liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3601"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zbm43rdQGMmd" title="Liability"&gt;53,333&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span id="xdx_F0A_zChGi8tau4Y2"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;span id="xdx_F10_zFPLD0zjBMIf"&gt;The
        Company classifies its SAFEs as financial liabilities measured at fair value. The value of these agreements depends significantly on future
        financing activities, liquidity events, or other material milestones, and their valuation relies on significant inputs that are not observable
        in the public market. Accordingly, they are classified within Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
        fair value measurement is based on an integrated framework combining&#160;scenario analysis and financial instrument decomposition (i.e.
        Bond Plus Call Method). The proceeds of the SAFEs on the date of issuance were $14,092,500, Refer to Note 8-Simple Agreements for Future
        Equity for further details.&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; color: #0F1115"&gt;&lt;span id="xdx_F00_zI5V4PyahiJg"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F13_z2JSmT6vIOn7"&gt;Equity options. On May&#160;9, 2023, the Company entered into an agreement
        with a third-party service provider (the &#x201c;Service Provider&#x201d;). The Service Provider received a freestanding equity-linked right
        exercisable, at the Service Provider&#x2019;s option, upon the closing of the Company&#x2019;s next qualified equity financing. The right
        provides the ability to subscribe for up to the value of $200,000 at a 25% discount price per share on the grant date. The equity option
        is remeasured at fair value at each reporting date, with changes in fair value recognized in earnings. As of June&#160;30, 2025 and March&#160;31,
        2026, the fair value of the equity option was $53,333, and no gain or loss from changes in fair value was recognized for the periods presented.
        The fair value measurement of the equity option is categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based
        analysis, which incorporates significant unobservable inputs and management judgment regarding the probability and timing of potential
        future financing outcomes.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003570"
      unitRef="USD">18243885</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003576"
      unitRef="USD">18243885</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003578"
      unitRef="USD">53333</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003584"
      unitRef="USD">53333</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003589"
      unitRef="USD">26842205</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003595"
      unitRef="USD">26842205</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003597"
      unitRef="USD">53333</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_OtherPayableRelatedToTheEquityOptionMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003603"
      unitRef="USD">53333</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CryptoAssetTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003607">&lt;p id="xdx_803_eus-gaap--CryptoAssetTextBlock_zi6RMK8i16tg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;5.
&lt;span id="xdx_829_zy7JjRUSo6a6"&gt;Crypto assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company uses crypto assets like USDT and USDC as medium of exchange for collecting and settling business-related payments and for receiving
investment proceeds. As of June&#160;30, 2025 and March&#160;31, 2026, the Company held nil and 4,074,415 units of USDT and USDC, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
the nine months ended March&#160;31, 2026, the movement for digital assets and USDC were as below&#xff1a;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--CryptoAssetActivityTableTextBlock_z6IoVbbXa5M" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Crypto assets (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BB_z5ypZmSGKPI6" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of digital assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Digital assets&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;USDC&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance
        at June&#160;30, 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90B_eus-gaap--CryptoAssetFairValue_iS_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zVU8fnykwyVd" title="Beginning balance, January 1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3611"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_907_eus-gaap--CryptoAssetFairValue_iS_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_zucsqhJMum0h" title="Beginning balance, January 1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3613"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Additions&lt;sup&gt;(i)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--CryptoAssetPurchase_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_fKGkp_zCVR14RVanL4" title="Additions"&gt;939,397&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--CryptoAssetPurchase_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_fKGkp_z7IluYPLL2H6" title="Additions"&gt;4,711,169&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Disposals
        - sold for US dollars&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--CryptoAssetSale_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zFhrH4pyNUOi" title="Disposals - sold for US dollars"&gt;(596,852&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--CryptoAssetSale_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_zZ3TE6pXpuRg" title="Disposals - sold for US dollars"&gt;(9,900&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Disposals - others&lt;sup&gt;(ii)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--CryptoAssetDisposition_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_fKGlpKQ_____z0eXchozqDD5" title="Disposals"&gt;(342,545&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--CryptoAssetDisposition_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_fKGlpKQ_____zih1kjx1tNMl" title="Disposals"&gt;(626,854&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Balance
        at March&#160;31, 2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_905_eus-gaap--CryptoAssetFairValue_iE_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zwakqvuSDr0k" title="Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3627"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_901_eus-gaap--CryptoAssetFairValue_iE_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_z5rCPa9Emov5" title="Ending balance"&gt;4,074,415&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F05_z0wsheXoxiZe"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F13_zlhgBGZ4Kxka"&gt;The Company acquired a total of 939,397 USDT at a cost of $939,397, funded by revenues and collections of other receivables. The Company acquired a total of 4,711,169 USDC at a cost of $4,711,169, funded by revenues, interest income,
        collections of other receivables and investment proceeds from SAFEs.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_F05_zMHGNT0qLCIg"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1F_z3QKCOoBgzb2"&gt;The Company used digital assets and USDC to settle professional service
        fees and other expenditures.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zlzUyMcRzUte" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s balances related to digital assets are USD-pegged stablecoins. No fair value gain or loss on digital assets was recognized
for the three and nine months ended March&#160;31, 2026 considering the low volatility in the fair value of USDT during the three and
nine months ended March&#160;31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
following table summarizes other operating activities settled in digital assets and USDC:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--CashFlowOperatingCapitalTableTextBlock_zvjZLHvPjup5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Crypto assets (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8B8_zB2Vyc1Bo39h"&gt;Schedule of operating activities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        ended March&#160;31,&lt;br/&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Revenue&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--Revenues_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Revenue"&gt;(1,197,326&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Other
        receivables&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--OtherCurrentAssets_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_zgPbcYEBBUwe" title="Other current assets"&gt;(1,452,102&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Cost and
        expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--CostsAndExpenses_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Cost and expenses"&gt;969,399&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Interest
        income&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--InterestIncomeOther_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_zDM56zONgaVd" title="Interest income"&gt;(1,138&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total
        operating activities settled in digital assets and USDC&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_ecustom--TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Total operating activities settled in digital assets and USDC"&gt;(1,681,167&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zJhdLNbXqBJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;During
the three and nine months ended March&#160;31, 2026, the Company received $&lt;span id="xdx_90D_eus-gaap--PaymentsForProceedsFromInvestments_pn3n3_dm_c20250701__20260331_zf0QgnFTWzBf" title="Investment proceeds"&gt;&lt;span id="xdx_907_eus-gaap--PaymentsForProceedsFromInvestments_pn3n3_dm_c20260101__20260331_z5QJhWbmUOj2" title="Investment proceeds"&gt;3.0&lt;/span&gt;&lt;/span&gt; million of investment proceeds from SAFEs in USDC. These
amounts were disclosed as supplemental non-cash financing information and therefore were not included in net cash provided by financing
activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CryptoAssetTextBlock>
    <us-gaap:CryptoAssetActivityTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003609">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--CryptoAssetActivityTableTextBlock_z6IoVbbXa5M" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Crypto assets (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BB_z5ypZmSGKPI6" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of digital assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Digital assets&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;USDC&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance
        at June&#160;30, 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90B_eus-gaap--CryptoAssetFairValue_iS_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zVU8fnykwyVd" title="Beginning balance, January 1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3611"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_907_eus-gaap--CryptoAssetFairValue_iS_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_zucsqhJMum0h" title="Beginning balance, January 1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3613"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Additions&lt;sup&gt;(i)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--CryptoAssetPurchase_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_fKGkp_zCVR14RVanL4" title="Additions"&gt;939,397&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--CryptoAssetPurchase_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_fKGkp_z7IluYPLL2H6" title="Additions"&gt;4,711,169&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Disposals
        - sold for US dollars&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--CryptoAssetSale_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zFhrH4pyNUOi" title="Disposals - sold for US dollars"&gt;(596,852&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--CryptoAssetSale_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_zZ3TE6pXpuRg" title="Disposals - sold for US dollars"&gt;(9,900&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Disposals - others&lt;sup&gt;(ii)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--CryptoAssetDisposition_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_fKGlpKQ_____z0eXchozqDD5" title="Disposals"&gt;(342,545&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--CryptoAssetDisposition_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_fKGlpKQ_____zih1kjx1tNMl" title="Disposals"&gt;(626,854&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Balance
        at March&#160;31, 2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_905_eus-gaap--CryptoAssetFairValue_iE_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zwakqvuSDr0k" title="Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3627"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_901_eus-gaap--CryptoAssetFairValue_iE_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_z5rCPa9Emov5" title="Ending balance"&gt;4,074,415&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%; margin-left: 0; margin-right: auto"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F05_z0wsheXoxiZe"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F13_zlhgBGZ4Kxka"&gt;The Company acquired a total of 939,397 USDT at a cost of $939,397, funded by revenues and collections of other receivables. The Company acquired a total of 4,711,169 USDC at a cost of $4,711,169, funded by revenues, interest income,
        collections of other receivables and investment proceeds from SAFEs.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_F05_zMHGNT0qLCIg"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1F_z3QKCOoBgzb2"&gt;The Company used digital assets and USDC to settle professional service
        fees and other expenditures.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:CryptoAssetActivityTableTextBlock>
    <us-gaap:CryptoAssetPurchase
      contextRef="From2025-07-012026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003615"
      unitRef="USD">939397</us-gaap:CryptoAssetPurchase>
    <us-gaap:CryptoAssetPurchase
      contextRef="From2025-07-012026-03-31_custom_USDCMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003617"
      unitRef="USD">4711169</us-gaap:CryptoAssetPurchase>
    <us-gaap:CryptoAssetSale
      contextRef="From2025-07-012026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003619"
      unitRef="USD">596852</us-gaap:CryptoAssetSale>
    <us-gaap:CryptoAssetSale
      contextRef="From2025-07-012026-03-31_custom_USDCMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003621"
      unitRef="USD">9900</us-gaap:CryptoAssetSale>
    <us-gaap:CryptoAssetDisposition
      contextRef="From2025-07-012026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003623"
      unitRef="USD">342545</us-gaap:CryptoAssetDisposition>
    <us-gaap:CryptoAssetDisposition
      contextRef="From2025-07-012026-03-31_custom_USDCMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003625"
      unitRef="USD">626854</us-gaap:CryptoAssetDisposition>
    <us-gaap:CryptoAssetFairValue
      contextRef="AsOf2026-03-31_custom_USDCMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003629"
      unitRef="USD">4074415</us-gaap:CryptoAssetFairValue>
    <us-gaap:CashFlowOperatingCapitalTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003636">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--CashFlowOperatingCapitalTableTextBlock_zvjZLHvPjup5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Crypto assets (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span id="xdx_8B8_zB2Vyc1Bo39h"&gt;Schedule of operating activities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        ended March&#160;31,&lt;br/&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Revenue&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--Revenues_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Revenue"&gt;(1,197,326&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Other
        receivables&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--OtherCurrentAssets_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_zgPbcYEBBUwe" title="Other current assets"&gt;(1,452,102&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Cost and
        expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--CostsAndExpenses_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Cost and expenses"&gt;969,399&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Interest
        income&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--InterestIncomeOther_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_zDM56zONgaVd" title="Interest income"&gt;(1,138&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total
        operating activities settled in digital assets and USDC&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_ecustom--TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Total operating activities settled in digital assets and USDC"&gt;(1,681,167&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:CashFlowOperatingCapitalTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003638"
      unitRef="USD">-1197326</us-gaap:Revenues>
    <cik0002065779:OtherCurrentAssets
      contextRef="From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003640"
      unitRef="USD">-1452102</cik0002065779:OtherCurrentAssets>
    <us-gaap:CostsAndExpenses
      contextRef="From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003642"
      unitRef="USD">969399</us-gaap:CostsAndExpenses>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003644"
      unitRef="USD">1138</us-gaap:InterestIncomeOther>
    <cik0002065779:TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc
      contextRef="From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003646"
      unitRef="USD">-1681167</cik0002065779:TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="-3"
      id="Fact003648"
      unitRef="USD">3000000.0</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="-3"
      id="Fact003650"
      unitRef="USD">3000000.0</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:AccountsAndNontradeReceivableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003652">&lt;p id="xdx_801_eus-gaap--AccountsAndNontradeReceivableTextBlock_zt83sqIk2p94" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;6.
&lt;span id="xdx_821_zw6NyDc9ffw7"&gt;Accounts receivable&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Accounts
receivable consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zWg6RZJgXvzh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts receivable (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B9_zVJkzX5GW98" style="display: none; padding-bottom: 0.5pt"&gt;Schedule of Accounts receivable&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250630_zm7wuCB6PhW8" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20260331_zS3fEQLzuX3k" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;June&#160;30,&lt;br/&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;March&#160;31,&lt;br/&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccountsReceivableNetCurrent_iI_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Accounts
        receivable&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;152,536&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,830,105&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_zpFjs0QPDHU9" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Less:
        allowance for credit losses&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccountsReceivableNet_iI_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Accounts
        receivable, net&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;152,536&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;1,830,105&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Accounts
receivable are recorded at the invoiced amount and do not bear interest. The Company maintains an allowance for credit losses for expected
losses over the life of the accounts receivable using the current expected credit loss methodology. The Company determines the allowance
based on historical loss experience, current conditions, and reasonable and supportable forecasts. As of June&#160;30, 2025 and March&#160;31,
2026, there was &lt;span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_zYCAUmcH4Uyf" title="Allowance for credit losses"&gt;&lt;span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20260331_zI2AqCult1gj" title="Allowance for credit losses"&gt;no&lt;/span&gt;&lt;/span&gt; allowance for expected credit losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:AccountsAndNontradeReceivableTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003654">&lt;table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zWg6RZJgXvzh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts receivable (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B9_zVJkzX5GW98" style="display: none; padding-bottom: 0.5pt"&gt;Schedule of Accounts receivable&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250630_zm7wuCB6PhW8" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20260331_zS3fEQLzuX3k" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;June&#160;30,&lt;br/&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;March&#160;31,&lt;br/&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccountsReceivableNetCurrent_iI_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Accounts
        receivable&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;152,536&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,830,105&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_zpFjs0QPDHU9" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Less:
        allowance for credit losses&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccountsReceivableNet_iI_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Accounts
        receivable, net&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;152,536&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;1,830,105&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003656"
      unitRef="USD">152536</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003657"
      unitRef="USD">1830105</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003659"
      unitRef="USD">-0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003660"
      unitRef="USD">-0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003662"
      unitRef="USD">152536</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003663"
      unitRef="USD">1830105</us-gaap:AccountsReceivableNet>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003665"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003667"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003669">&lt;p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zdX7g6UQPBw2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;7.
&lt;span id="xdx_822_zmlf6pOH23ii"&gt;Equipment, net&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Equipment,
net consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6SXjtYgd1Rl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equipment, net (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BE_zhFe2H6s0JL3" style="display: none; padding-bottom: 0.5pt"&gt;Schedule of Equipment&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250630_zjhFyVyhBbpc" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20260331_zJzRw9osXoxa" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;June&#160;30,
        &lt;br/&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;March&#160;31,&lt;br/&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_zDy4QedUaU9k" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Equipment&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;29,944&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;29,198&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_pp0d_zz24YPuTInVl" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;29,944&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;29,198&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_pp0d_di_ztschh1CeBb2" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Less:
        accumulated depreciation&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,344&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(14,792&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0d_zJcMcc2HfH0g" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Net
        carrying amount&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;19,600&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;14,406&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Depreciation
expenses for the three months ended March&#160;31, 2025 and 2026 were $&lt;span id="xdx_909_eus-gaap--Depreciation_c20250101__20250331_pp0p" title="Depreciation expenses"&gt;1,601&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--Depreciation_c20260101__20260331_pp0p" title="Depreciation expenses"&gt;1,565&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Depreciation
expenses for the nine months ended March&#160;31, 2025 and 2026 were $&lt;span id="xdx_902_eus-gaap--Depreciation_c20240701__20250331_pp0p" title="Depreciation expenses"&gt;4,633&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--Depreciation_c20250701__20260331_pp0p" title="Depreciation expenses"&gt;5,194&lt;/span&gt; respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003671">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6SXjtYgd1Rl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equipment, net (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8BE_zhFe2H6s0JL3" style="display: none; padding-bottom: 0.5pt"&gt;Schedule of Equipment&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250630_zjhFyVyhBbpc" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20260331_zJzRw9osXoxa" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;June&#160;30,
        &lt;br/&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;March&#160;31,&lt;br/&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_zDy4QedUaU9k" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Equipment&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;29,944&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;29,198&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_pp0d_zz24YPuTInVl" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;29,944&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;29,198&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_pp0d_di_ztschh1CeBb2" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Less:
        accumulated depreciation&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,344&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(14,792&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0d_zJcMcc2HfH0g" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Net
        carrying amount&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;19,600&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;14,406&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003673"
      unitRef="USD">29944</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003674"
      unitRef="USD">29198</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentOtherNet
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003676"
      unitRef="USD">29944</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003677"
      unitRef="USD">29198</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003679"
      unitRef="USD">10344</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003680"
      unitRef="USD">14792</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003682"
      unitRef="USD">19600</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003683"
      unitRef="USD">14406</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003687"
      unitRef="USD">1601</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003689"
      unitRef="USD">1565</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003691"
      unitRef="USD">4633</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003693"
      unitRef="USD">5194</us-gaap:Depreciation>
    <cik0002065779:SimpleAgreementsForFutureEquityTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003695">&lt;p id="xdx_800_ecustom--SimpleAgreementsForFutureEquityTextBlock_zvL0mGPqikAj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;8.
&lt;span id="xdx_826_zuUPRpykS4s9"&gt;Simple agreements for future equity&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company has entered into SAFEs with various investors that were classified as liabilities on the Company&#x2019;s balance sheets and accounted
for at fair value, subject to remeasurement each reporting period. Each SAFEs has no maturity date, does not bear any interest and provides
the investor with the right to convert into a variable number of shares of future equity in the Company at the stated conversion amount,
if certain events or conditions are triggered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;During
the period from October&#160;2022 through March&#160;31, 2026, the Company entered into Simple Agreements for Future Equity with third-party
investors, receiving aggregate gross proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromOtherEquity_c20221001__20260331_pp0p" title="Aggregate gross proceeds"&gt;14,092,500&lt;/span&gt;. For the nine months ended March&#160;31, 2025 and 2026, the Company received
SAFEs proceeds of $&lt;span id="xdx_902_eus-gaap--ProceedsFromOtherEquity_pp0d_c20240701__20250331_zUakL51Li8jh" title="Aggregate gross proceeds"&gt;4,275,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ProceedsFromOtherEquity_pp0d_c20250701__20260331_z2WDlnQfzWRe" title="Aggregate gross proceeds"&gt;3,500,000&lt;/span&gt;, respectively, with nil and $3,000,000 received in USDC, respectively. No issuance costs were incurred in connection with these arrangements. As of
the date these unaudited condensed consolidated financial statements are issued, none of the SAFEs have been settled or converted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
SAFEs agreements grant investors the right to participate in the Company&#x2019;s future equity financing events. The agreements contain
various conversion and redemption provisions, including conversion upon an equity financing event, as well as settlement in the event
of a liquidity event or dissolution of the Company. Key terms of the SAFEs are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;Equity
Financing&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; Upon the occurrence of an equity financing event, each SAFEs automatically converts into a greater of (i)&#160;the
number of shares of preferred stock equal to SAFEs purchase amount divided by the lowest price per share paid for the standard preferred
stock or (ii)&#160;the number of shares of preferred stock equal to the SAFEs purchase amount divided by the SAFEs price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#x201c;SAFEs price&#x201d; means is calculated by dividing a fixed post-money
        valuation cap by the Company capitalization, a defined term that includes all outstanding equity and convertible instruments.&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#x201c;Equity Financing&#x201d; means a bona fide transaction or series
        of transactions with the principal purpose of raising capital, pursuant to which the Company issues and sells preferred share at a fixed
        valuation, including but not limited to, a pre-money or post-money valuation.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Not
all SAFEs agreements contain the equity financing conversion provision described above. Certain SAFEs are structured without an Equity
Financing conversion feature and are generally settled only upon a Liquidity Event or a Dissolution Event (as defined in the respective
SAFEs agreements). The Company considered the contractual terms of the SAFEs, including whether an Equity Financing conversion feature
is present and the settlement provisions upon a Liquidity Event or a Dissolution Event, in the valuation and measurement of these instruments.
As of March&#160;31, 2026, &lt;span id="xdx_90F_ecustom--EquityFinancingDescription_c20240701__20250331_z5HMRpZeny35" title="Equity Financing description"&gt;SAFEs with an aggregate purchase amount of $13,632,500 include an Equity Financing conversion feature, while
SAFEs with an aggregate purchase amount of $460,000 do not include this feature and are generally settled only upon a Liquidity Event
or a Dissolution Event, in accordance with their terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company does not have any preferred stock outstanding as of the date these unaudited condensed consolidated financial statements are issued;
therefore, an equity financing event has not been triggered.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, serif; text-align: justify; margin-top: 0px; margin-bottom: 0px"&gt;&lt;b&gt;&lt;i&gt;Liquidity
Event&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; If there is a liquidity event before the conversion of each SAFE, the holder of each SAFEs will automatically
be entitled to the greater of (i) SAFEs purchase amount, or (ii)&#160;the amount payable on the number of shares of ordinary shares equal
to the purchase amount divided by the Liquidity Price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#x201c;Liquidity Price&#x201d; is calculated by dividing the post-money
        valuation cap by the separately defined capital base, referred to as &#x201c;liquidity capitalization&#x201d; in the SAFEs agreements.&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#x201c;Liquidity Event&#x201d; means a change of control, a direct Listing
        or an initial public offering.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;i&gt;Dissolution
Event&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; If there is a dissolution event before the conversion of each SAFE, the holder of each SAFEs will automatically
be entitled to receive a portion of proceeds equal to SAFEs purchase amount.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company classifies its SAFEs as financial liabilities measured at fair value. Since the value of these instruments depends on significant
unobservable inputs, including future financing activities and liquidity events, they are classified as Level 3 within the fair value
hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
fair value measurement utilizes a combined scenario analysis and financial instrument decomposition approach. Based on management&#x2019;s
assessment of the Company&#x2019;s prospects, probability distributions are assigned to potential settlement-triggering events. Valuation
is performed using a &#x201c;debt plus option&#x201d; model: the debt component is valued using a discounted cash flow method with key assumptions
including expected settlement timing, risk-free interest rate, and credit spread; the embedded conversion right is treated as a call option
and valued using the Black-Scholes model, with key inputs including the fair value of ordinary shares, expected term, and volatility.
The overall fair value represents the probability-weighted sum across all scenarios, supported by an independent third-party valuation
specialist.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As
of June&#160;30, 2025 and March&#160;31, 2026, the SAFE liabilities were measured at fair value using the above Level 3 methodology. Significant
unobservable inputs&#x2014;including timing of events, volatility, and credit spreads&#x2014;are based on management&#x2019;s reasonable
estimates as of each valuation date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
following tables set forth a summary of the activity of the SAFE liabilities, respectively, which represents a recurring fair value measurement
at the end of each reporting period:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zJ7zAKCvB5s" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Simple agreements for future equity (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B0_zlyvnZCHN8oh" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of fair value measurement&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance
        at June&#160;30, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90A_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20240701__20250331_zsdjo0SWVk52" title="Balance at beginning"&gt;9,321,564&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Issuance
        of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20240701__20250331_zNBYySXf6A5j" title="Issuance of simple agreements for future equity"&gt;4,275,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Change
        in fair value&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ChangeInFairValue_c20240701__20250331_pp0p" title="Change in fair value"&gt;3,716,052&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance
        at March&#160;31, 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90C_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20240701__20250331_zHo7SoRKeCab" title="Balance at ending"&gt;17,312,616&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance
        at June&#160;30, 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20250701__20260331_zv833aNiJuE" title="Balance at beginning"&gt;18,243,885&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Issuance
        of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20250701__20260331_zSP3vbHmvvpg" title="Issuance of simple agreements for future equity"&gt;3,500,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Change
        in fair value&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ChangeInFairValue_c20250701__20260331_pp0p" title="Change in fair value"&gt;5,098,320&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Balance
        at March&#160;31, 2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_908_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20250701__20260331_zmoiw9Md1KUg" title="Balance at ending"&gt;26,842,205&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Subsequent
to March&#160;31, 2026 (see Note 1), in connection with the proposed business combination, the outstanding SAFEs are expected to be settled
upon the closing of the transaction (the &#x201c;Closing&#x201d;). Pursuant to their terms, if a SPAC transaction occurs prior to the termination
of the SAFEs, each SAFE will automatically convert at the Closing into the right to receive Class A ordinary shares of PubCo.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;At
the Closing of the BCA transaction, each SAFE is expected to convert into Class A shares of PubCo, if the amount payable of $26,842,205
is greater than the purchase amount.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</cik0002065779:SimpleAgreementsForFutureEquityTextBlock>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2022-10-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003697"
      unitRef="USD">14092500</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003699"
      unitRef="USD">4275000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003701"
      unitRef="USD">3500000</us-gaap:ProceedsFromOtherEquity>
    <cik0002065779:EquityFinancingDescription
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      id="Fact003703">SAFEs with an aggregate purchase amount of $13,632,500 include an Equity Financing conversion feature, while
SAFEs with an aggregate purchase amount of $460,000 do not include this feature and are generally settled only upon a Liquidity Event
or a Dissolution Event, in accordance with their terms.</cik0002065779:EquityFinancingDescription>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003708">&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zJ7zAKCvB5s" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Simple agreements for future equity (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B0_zlyvnZCHN8oh" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of fair value measurement&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance
        at June&#160;30, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90A_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20240701__20250331_zsdjo0SWVk52" title="Balance at beginning"&gt;9,321,564&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Issuance
        of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20240701__20250331_zNBYySXf6A5j" title="Issuance of simple agreements for future equity"&gt;4,275,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Change
        in fair value&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ChangeInFairValue_c20240701__20250331_pp0p" title="Change in fair value"&gt;3,716,052&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance
        at March&#160;31, 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_90C_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20240701__20250331_zHo7SoRKeCab" title="Balance at ending"&gt;17,312,616&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Balance
        at June&#160;30, 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_903_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20250701__20260331_zv833aNiJuE" title="Balance at beginning"&gt;18,243,885&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Issuance
        of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20250701__20260331_zSP3vbHmvvpg" title="Issuance of simple agreements for future equity"&gt;3,500,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Change
        in fair value&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ChangeInFairValue_c20250701__20260331_pp0p" title="Change in fair value"&gt;5,098,320&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Balance
        at March&#160;31, 2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_908_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20250701__20260331_zmoiw9Md1KUg" title="Balance at ending"&gt;26,842,205&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2024-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003710"
      unitRef="USD">9321564</cik0002065779:SimpleAgreementsForFutureEquity>
    <cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003712"
      unitRef="USD">4275000</cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValue
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003714"
      unitRef="USD">3716052</cik0002065779:ChangeInFairValue>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003716"
      unitRef="USD">17312616</cik0002065779:SimpleAgreementsForFutureEquity>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003718"
      unitRef="USD">18243885</cik0002065779:SimpleAgreementsForFutureEquity>
    <cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003720"
      unitRef="USD">3500000</cik0002065779:IssuanceOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValue
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003722"
      unitRef="USD">5098320</cik0002065779:ChangeInFairValue>
    <cik0002065779:SimpleAgreementsForFutureEquity
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003724"
      unitRef="USD">26842205</cik0002065779:SimpleAgreementsForFutureEquity>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003727">&lt;p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zyFahVjLxWI4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;9.
&lt;span id="xdx_82B_ziKKVuFGi2S9"&gt;Income taxes&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Exascale
Labs Inc. is incorporated in the State of Delaware and is subject to income taxes in its primary jurisdictions: U.S. federal income
tax, California state corporate income tax and Delaware state corporate income tax. The statutory tax rates applicable to the
Company are &lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c20250701__20260331_pd" title="Federal income tax rate"&gt;21%&lt;/span&gt;
at the federal level, 8.84% at the California state level and &lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c20250701__20260331_pd" title="State income tax rate"&gt;8.7%&lt;/span&gt;
at the Delaware state level.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Evana
Alpha Pte. Ltd. is incorporated in Singapore and is subject to the statutory corporate income tax rate of &lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20250701__20260331__us-gaap--IncomeTaxAuthorityNameAxis__custom--EvanaAlphaPteLtdMember_pd" title="Effective income tax rate"&gt;17%&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
current and deferred components of income tax expense reflected in the statements of operations and comprehensive loss were nil &lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20250701__20260331_zQiioohpuxS4" title="Effective income tax rate"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20240701__20250331_zur6gJAGXbi2" style="display: none" title="Effective income tax rate"&gt;0&lt;/span&gt;&lt;/span&gt;
for the nine months ended March&#160;31, 2025 and 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s effective income tax rate was&#160;nil&#160;for the nine months ended March&#160;31, 2025 and 2026. This was primarily
attributable to the&#160;recognition of a full valuation allowance against the net deferred tax assets, as the Company has concluded that
it is not more likely than not that these assets will be realized in the foreseeable future. Accordingly, no tax benefit has been recognized
for the losses incurred during these periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company
had no unrecognized tax benefits as of March 31, 2026. The Company currently files income tax returns in the United States, as well as
Delaware and California. All tax years are open for examination. The Company currently has no federal or state tax examinations in progress.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003729"
      unitRef="Ratio">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003731"
      unitRef="Ratio">0.087</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2025-07-012026-03-31_custom_EvanaAlphaPteLtdMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003733"
      unitRef="Ratio">0.17</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003735"
      unitRef="Ratio">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003737"
      unitRef="Ratio">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003739">&lt;p id="xdx_809_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zmD9QmjKORy7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;10.
&lt;span id="xdx_820_zFODMdXSgusi"&gt;Share-based compensation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
the three and nine months ended March&#160;31, 2025, total share-based compensation expenses recognized were $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20250101__20250331_pp0p" title="Share-based compensation expenses"&gt;101,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20240701__20250331_pp0p" title="Share-based compensation expenses"&gt;153,266&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
the three and nine months ended March&#160;31, 2026, total share-based compensation expenses recognized were nil&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20260101__20260331_pp0p" title="Share-based compensation expenses"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20250701__20260331_pp0p" style="display: none" title="Share-based compensation expenses"&gt;0&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;(1)
Employee&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On
January&#160;6, 2025, with the approval from the Board of the Company, an employee was granted equity award from inception of the employment
agreement, which represented &lt;span id="xdx_901_ecustom--GrantedEquityAward_c20250106__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Granted equity award"&gt;0.1%&lt;/span&gt; of the Company&#x2019;s total shares outstanding at issuance date (the &#x201c;0.1% Award&#x201d;, i.e.,
1.5 shares). The equity award had a vesting period of &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20250701__20260331__srt--CounterpartyNameAxis__custom--EmployeeMember_z1Z0diGK94pe" title="Vesting period"&gt;24&lt;/span&gt; months after grant, but with no requisite service period. Alongside the employee&#x2019;s
separation in September&#160;2025, the equity award remained its vesting pace under the 24-month vesting schedule. As of March&#160;31,
2026, &lt;span id="xdx_906_ecustom--SharesDescription_c20250701__20260331__srt--CounterpartyNameAxis__custom--EmployeeMember_zlx0SpyKOQ08" title="Shares description"&gt;0.9375 shares of the Company were vested, with remaining 0.5625 shares unvested.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;(2)
Non-employee&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;On
December&#160;2, 2024, with the approval from the Board of the Company, a contractor was granted equity award from inception of the contractor
agreement representing &lt;span id="xdx_908_ecustom--GrantedEquityAward_c20241202__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pd" title="Granted equity award"&gt;0.053333%&lt;/span&gt; of the Company&#x2019;s total shares outstanding at issuance date (&#x201c;0.05% Award&#x201d;, i.e., 0.8
shares). The equity award had a vesting period of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20250701__20260331__srt--CounterpartyNameAxis__custom--NonEmployeeMember_zQkNCDGTocwl" title="Vesting period"&gt;24&lt;/span&gt; months after grant, with half vested as of April&#160;1, 2025 and remaining as of
November&#160;1, 2026, but with no requisite service period. As of March&#160;31, 2026, &lt;span id="xdx_904_ecustom--SharesDescription_c20250701__20260331__srt--CounterpartyNameAxis__custom--NonEmployeeMember_z3nHrh1RAC13" title="Shares description"&gt;the first half of the equity award had been vested&lt;/span&gt;,
the remaining half had been outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company&#x2019;s share-based compensation awards are expected to be settled through transfers of existing ordinary shares held by the controlling
shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary shares are included in the issued
and outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase the Company&#x2019;s total
issued and outstanding shares. The vested shares are not recorded in the individual names of the holders on the Company&#x2019;s stock
ledger, but held by the controlling shareholder on their behalf, mainly due to the plan to a direct register of shares under the listed
company during de-SPAC transaction. The Company, as well as the controlling shareholder deemed the grant as the time when the employee
and non-employees are entitled to economic benefits and risks of the subsequent changes in fair value of the granted shares accordingly
to the agreed vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003741"
      unitRef="USD">101000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003743"
      unitRef="USD">153266</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003745"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003747"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <cik0002065779:GrantedEquityAward
      contextRef="AsOf2025-01-06_custom_EmployeeMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003749"
      unitRef="Ratio">0.001</cik0002065779:GrantedEquityAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2025-07-012026-03-31_custom_EmployeeMember_custom_ExascaleLabsIncMember"
      id="Fact003751">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cik0002065779:SharesDescription
      contextRef="From2025-07-012026-03-31_custom_EmployeeMember_custom_ExascaleLabsIncMember"
      id="Fact003753">0.9375 shares of the Company were vested, with remaining 0.5625 shares unvested.</cik0002065779:SharesDescription>
    <cik0002065779:GrantedEquityAward
      contextRef="AsOf2024-12-02_custom_NonEmployeeMember_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003755"
      unitRef="Ratio">0.00053333</cik0002065779:GrantedEquityAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2025-07-012026-03-31_custom_NonEmployeeMember_custom_ExascaleLabsIncMember"
      id="Fact003757">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cik0002065779:SharesDescription
      contextRef="From2025-07-012026-03-31_custom_NonEmployeeMember_custom_ExascaleLabsIncMember"
      id="Fact003759">the first half of the equity award had been vested</cik0002065779:SharesDescription>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003761">&lt;p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zW0BXdSt3Dza" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;11.
&lt;span id="xdx_826_zRqJaIvukVIi"&gt;Related party transactions&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Hoansoo
Lee serves as the Company&#x2019;s Chief Executive Officer and Chief Financial Officer. The Company has entered into a consulting services
agreement with Hoansoo Lee, pursuant to which Hoansoo Lee provides strategic consulting and advisory services to the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
the three and nine months ended March&#160;31, 2025, the Company incurred consulting service fees of $&lt;span id="xdx_90F_ecustom--ConsultingFees_c20250101__20250331_pp0p" title="Consulting fees"&gt;27,000&lt;/span&gt; and $&lt;span id="xdx_902_ecustom--ConsultingFees_c20240701__20250331_pp0p" title="Consulting fees"&gt;73,150&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;For
the three and nine months ended March&#160;31, 2026, the Company incurred consulting service fees of nil &lt;span id="xdx_901_ecustom--ConsultingFees_c20260101__20260331_pp0p" style="display: none" title="Consulting fees"&gt;0&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--ConsultingFees_c20250701__20260331_pp0p" title="Consulting fees"&gt;27,000&lt;/span&gt;,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;As
of June&#160;30, 2025 and March&#160;31, 2026, there were &lt;span id="xdx_90A_ecustom--OutstandingBalancesPayable_iI_pp0d_do_c20250630_zypmsCbXcuw1" title="Outstanding balances payable"&gt;&lt;span id="xdx_90D_ecustom--OutstandingBalancesPayable_iI_pp0d_do_c20260331_zGm0xhqAZNP4" title="Outstanding balances payable"&gt;no&lt;/span&gt;&lt;/span&gt; outstanding balances payable to Hoansoo Lee as all amounts had been fully
settled during the respective periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <cik0002065779:ConsultingFees
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003763"
      unitRef="USD">27000</cik0002065779:ConsultingFees>
    <cik0002065779:ConsultingFees
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003765"
      unitRef="USD">73150</cik0002065779:ConsultingFees>
    <cik0002065779:ConsultingFees
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003767"
      unitRef="USD">0</cik0002065779:ConsultingFees>
    <cik0002065779:ConsultingFees
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003769"
      unitRef="USD">27000</cik0002065779:ConsultingFees>
    <cik0002065779:OutstandingBalancesPayable
      contextRef="AsOf2025-06-30_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003771"
      unitRef="USD">0</cik0002065779:OutstandingBalancesPayable>
    <cik0002065779:OutstandingBalancesPayable
      contextRef="AsOf2026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003773"
      unitRef="USD">0</cik0002065779:OutstandingBalancesPayable>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003775">&lt;p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_z4GoZXwnHKv4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;12.
&lt;span id="xdx_829_zB59rzSX6LQb"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Basic
loss per share and diluted loss per share have been calculated in accordance with ASC 260, &#x201c;&lt;i&gt;Earnings Per Share&lt;/i&gt;&#x201d; on
computation of earnings per share for the three and nine months ended March&#160;31, 2025 and 2026 as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z2sxwJ1VHpU" style="font: 10pt Times New Roman; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basic and diluted net loss per share (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B0_z8caDlAsTD0j" style="display: none; padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Schedule of basic share and diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20250101__20250331_zC16hdQy39z7" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20260101__20260331_zlPyFMn73iHk" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20240701__20250331_zCkUO6zYutQ4" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20250701__20260331_zOuUJ3ksGux6" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;th style="text-align: left; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;th style="text-align: left; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--NumeratorAbstract_iB_zNkHTVkijEU3" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;Numerator:&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_z6giu4JTNcaj" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Net loss
        attributable to ordinary shareholders&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,537,059&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,632,431&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(6,178,537&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(7,916,977&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DenominatorAbstract_iB_zgkk1b9Igsvl" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;b&gt;Denominator:&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DenominatorForBasicAndDilutedLossPerShareAbstract_iB_zy2lnWnhwA39" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Denominator
        for basic and diluted loss per share&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Weighted-average
        ordinary shares outstanding&lt;sup&gt;(i)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250331_fKGkp_zDQw4h37Wwsb" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250331_fKGkp_z1Ku37KqqS1c" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331_fKGkp_zx8fH2VBa76l" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331_fKGkp_ztHfVbfGRHOe" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20250331_fKGkp_zdZsZI7uuxig" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20250331_fKGkp_zxdrS9L5B374" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250701__20260331_fKGkp_zxPaAudjLjnd" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250701__20260331_fKGkp_znBJ1PFMXWY8" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--LossPerOrdinaryShareAbstarct_zCAzhDqWJjpb" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Basic
        and diluted&lt;sup&gt;(ii)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Basic
        and diluted loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250101__20250331_fKGlpKQ_____zRg0YrtZsJH6" title="Basic loss per share"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20250101__20250331_fKGlpKQ_____zLTKtVSBtLic" title="Diluted loss per share"&gt;(1,024.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20260101__20260331_fKGlpKQ_____zMOHv6Iu2y06" title="Basic loss per share"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20260101__20260331_fKGlpKQ_____zOAlpfAhDrW7" title="Diluted loss per share"&gt;(1,754.95&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20240701__20250331_fKGlpKQ_____zOMDMotp0PLj" title="Basic loss per share"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240701__20250331_fKGlpKQ_____zcmGyzLnWIBj" title="Diluted loss per share"&gt;(4,119.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20250701__20260331_fKGlpKQ_____zvq1iE1ENBpf" title="Basic loss per share"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20250701__20260331_fKGlpKQ_____zANr2fj6apLe" title="Diluted loss per share"&gt;(5,277.98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span id="xdx_F08_zYCld0TSLmlc"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1E_zckvTnJmQEhg"&gt;In January&#160;2026, the Company adopted an Amended and Restated Certificate
        of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#x2019;s equity is divided
        into 303 Class A ordinary shares and 1,197 Class B ordinary shares, which are entitled to one (1) vote and twenty (20) votes per share,
        respectively. Despite the differential in voting power, Class A and Class B ordinary shares rank pari passu in all other respects, sharing
        ratably in dividends and any distributions upon liquidation.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F07_zMNm9OVFQe92"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1B_zgBQGgyBG4z3"&gt;During the three and nine months ended March&#160;31, 2025 and 2026, diluted
        net loss per share is calculated in the same manner as basic net loss per share, as the Company was in a net loss position and all potential ordinary shares were anti-dilutive.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zRrW0FzXJpr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003777">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z2sxwJ1VHpU" style="font: 10pt Times New Roman; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basic and diluted net loss per share (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B0_z8caDlAsTD0j" style="display: none; padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Schedule of basic share and diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20250101__20250331_zC16hdQy39z7" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20260101__20260331_zlPyFMn73iHk" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20240701__20250331_zCkUO6zYutQ4" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20250701__20260331_zOuUJ3ksGux6" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;th style="text-align: left; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;th style="text-align: left; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt;
    &lt;th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/th&gt;
    &lt;th style="text-align: center; padding-bottom: 0.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/th&gt; &lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--NumeratorAbstract_iB_zNkHTVkijEU3" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;Numerator:&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_z6giu4JTNcaj" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Net loss
        attributable to ordinary shareholders&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,537,059&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,632,431&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(6,178,537&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(7,916,977&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DenominatorAbstract_iB_zgkk1b9Igsvl" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;&lt;b&gt;Denominator:&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DenominatorForBasicAndDilutedLossPerShareAbstract_iB_zy2lnWnhwA39" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Denominator
        for basic and diluted loss per share&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Weighted-average
        ordinary shares outstanding&lt;sup&gt;(i)&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250331_fKGkp_zDQw4h37Wwsb" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250331_fKGkp_z1Ku37KqqS1c" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331_fKGkp_zx8fH2VBa76l" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331_fKGkp_ztHfVbfGRHOe" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20250331_fKGkp_zdZsZI7uuxig" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20250331_fKGkp_zxdrS9L5B374" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250701__20260331_fKGkp_zxPaAudjLjnd" title="Weighted-average ordinary shares outstanding, Basic"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250701__20260331_fKGkp_znBJ1PFMXWY8" title="Weighted-average ordinary shares outstanding, diluted"&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--LossPerOrdinaryShareAbstarct_zCAzhDqWJjpb" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Basic
        and diluted&lt;sup&gt;(ii)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"&gt;Basic
        and diluted loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250101__20250331_fKGlpKQ_____zRg0YrtZsJH6" title="Basic loss per share"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20250101__20250331_fKGlpKQ_____zLTKtVSBtLic" title="Diluted loss per share"&gt;(1,024.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20260101__20260331_fKGlpKQ_____zMOHv6Iu2y06" title="Basic loss per share"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20260101__20260331_fKGlpKQ_____zOAlpfAhDrW7" title="Diluted loss per share"&gt;(1,754.95&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20240701__20250331_fKGlpKQ_____zOMDMotp0PLj" title="Basic loss per share"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240701__20250331_fKGlpKQ_____zcmGyzLnWIBj" title="Diluted loss per share"&gt;(4,119.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20250701__20260331_fKGlpKQ_____zvq1iE1ENBpf" title="Basic loss per share"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20250701__20260331_fKGlpKQ_____zANr2fj6apLe" title="Diluted loss per share"&gt;(5,277.98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span id="xdx_F08_zYCld0TSLmlc"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1E_zckvTnJmQEhg"&gt;In January&#160;2026, the Company adopted an Amended and Restated Certificate
        of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#x2019;s equity is divided
        into 303 Class A ordinary shares and 1,197 Class B ordinary shares, which are entitled to one (1) vote and twenty (20) votes per share,
        respectively. Despite the differential in voting power, Class A and Class B ordinary shares rank pari passu in all other respects, sharing
        ratably in dividends and any distributions upon liquidation.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F07_zMNm9OVFQe92"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1B_zgBQGgyBG4z3"&gt;During the three and nine months ended March&#160;31, 2025 and 2026, diluted
        net loss per share is calculated in the same manner as basic net loss per share, as the Company was in a net loss position and all potential ordinary shares were anti-dilutive.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003784"
      unitRef="USD">-1537059</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003785"
      unitRef="USD">-2632431</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003786"
      unitRef="USD">-6178537</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003787"
      unitRef="USD">-7916977</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003799"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003801"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003803"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003805"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003807"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003809"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003811"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003813"
      unitRef="Shares">1500</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003820"
      unitRef="USDPShares">-1024.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003822"
      unitRef="USDPShares">-1024.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003824"
      unitRef="USDPShares">-1754.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003826"
      unitRef="USDPShares">-1754.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003828"
      unitRef="USDPShares">-4119.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003830"
      unitRef="USDPShares">-4119.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003832"
      unitRef="USDPShares">-5277.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="INF"
      id="Fact003834"
      unitRef="USDPShares">-5277.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003838">&lt;p id="xdx_805_eus-gaap--SegmentReportingDisclosureTextBlock_zEoFgwHUEmak" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;13.
&lt;span id="xdx_82A_zGToUPHTxt3k"&gt;Segment information&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
Company manages its business in a centralized manner and operates as a single segment and accordingly has only one operating and reportable
segment, the provision of GPU computing platform services. The Company&#x2019;s Chief Executive Officer serves as the CODM. The CODM regularly
reviews entity-wide operating results and reviews consolidated revenues and net loss as reported in the statement of operations and comprehensive
loss when making decisions about allocating resources and assessing performance of the segment, and hence, the Group has only&#160;one&#160;reportable
segment.&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
primary measures of segment revenue and profitability for the Group&#x2019;s operating segment&#160;are considered to be&#160;consolidated&#160;revenue
and net loss.&#160;The CODM uses consolidated revenue to assess market performance and growth, and net loss to evaluate segment profitability
and cost management. Both measures are used together to allocate resources, including employee or capital resources. Significant expense
categories regularly provided to and reviewed by the CODM include those presented in the statements of operations and comprehensive loss
as well as disaggregated expenses of staff costs and employee benefits, professional service expenses, share-based compensation, and other
general and administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;The
following table presents the segment information of the Company for the measurement of segment profitability for the three and nine months
ended March&#160;31, 2025 and 2026:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zdn75OK0oi0h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B8_zPb6QMuV4209" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of segment information&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20250101__20250331_zb2RdiMZ4mJg" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20260101__20260331_zSm0FoNHA26" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20240701__20250331_zyMTxSXq4PM5" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20250701__20260331_zadqFxbEPU4i" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_zI3a3deH3fwf" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Revenues&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,862,158&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;3,754,586&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;4,475,885&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;10,561,331&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CostOfRevenue_pp0d_zMTLZ9zSLNl4" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Cost
        of revenues&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,649,077&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,167,659&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,827,444&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(8,902,966&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GrossProfit_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Gross
        profit&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;213,081&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;586,927&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;648,441&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;1,658,365&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_iN_pp0d_di_zn8IOfQoWaoe" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Research
        and development expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(377,999&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,235,476&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,115,853&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,238,185&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--SellingAndMarketingExpenseAbstract_iB_zVd2FY3RkMFc" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Selling
        and marketing expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--StaffCostsEmployeeBenefitsAndOfficeExpenses_i_pp0p" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#x2013;
        Staff costs, employee benefits and office expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(277,511&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(104,729&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(573,648&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(310,582&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--ShareBasedCompensations_zJ7xD2oOp4Ui" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#x2013;
        Share-based compensation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(101,000&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3876"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(153,266&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3878"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;General
        and administrative expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--StaffCostsEmployeeBenefitsAndOthers_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#x2013;
        Staff costs, employee benefits and Others&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,890&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(360,657&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(33,785&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(563,641&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ProfessionalAndContractServicesExpense_iN_di_z78VitJx7Eo3" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&#x2013;
        Professional service expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(99,217&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(108,039&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(234,374&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(364,614&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingIncomeLoss_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Loss
        from operations&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;(646,536&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;(1,221,974&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;(2,462,485&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;(2,818,657&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--ChangeInFairValueOfSimpleAgreementsForFutureEquity_iN_di_z4jz79hEVis9" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Change
        in fair value of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(890,523&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,410,457&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,716,052&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(5,098,320&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Income
        tax expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3905"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3906"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3907"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3908"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProfitLoss_zq0n3eRYdw7k" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Net
        loss&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;(1,537,059&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;(2,632,431&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;(6,178,537&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;(7,916,977&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zZ3FKbItpbC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;Substantially
all of the Company&#x2019;s long-lived assets are located in the United States. The following table presents the Company&#x2019;s revenue
from major geographical areas for the periods indicated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zIPxDBsoGFvj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B4_z6QXFE6MCFp1" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of geographic information&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;United
        States of America&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;581,009&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;1,564,836&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;1,273,279&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;4,560,992&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Canada&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;367,107&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;1,139,055&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;1,089,559&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;3,232,326&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Singapore&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;662,559&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;425,009&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;1,361,844&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;1,237,464&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Hong Kong&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;150,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;417,992&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;450,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;1,118,534&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;United
        Kingdom&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;98,483&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;207,694&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;291,203&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;412,015&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Others&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;3,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3959"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;10,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3963"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_908_eus-gaap--Revenues_pp0d_c20250101__20250331_zUms2zS7QOY6" title="Total"&gt;1,862,158&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_907_eus-gaap--Revenues_pp0d_c20260101__20260331_z3I7DIpNDZGg" title="Total"&gt;3,754,586&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_908_eus-gaap--Revenues_pp0d_c20240701__20250331_zsHyuymBBcp8" title="Total"&gt;4,475,885&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_906_eus-gaap--Revenues_pp0d_c20250701__20260331_zWKBKmLtNdw2" title="Total"&gt;10,561,331&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_z1dwOhMrHlX7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003843">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zdn75OK0oi0h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B8_zPb6QMuV4209" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of segment information&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20250101__20250331_zb2RdiMZ4mJg" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20260101__20260331_zSm0FoNHA26" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20240701__20250331_zyMTxSXq4PM5" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20250701__20260331_zadqFxbEPU4i" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_zI3a3deH3fwf" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Revenues&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,862,158&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;3,754,586&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;4,475,885&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;10,561,331&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CostOfRevenue_pp0d_zMTLZ9zSLNl4" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Cost
        of revenues&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,649,077&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,167,659&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,827,444&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(8,902,966&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GrossProfit_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Gross
        profit&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;213,081&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;586,927&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;648,441&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;1,658,365&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_iN_pp0d_di_zn8IOfQoWaoe" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Research
        and development expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(377,999&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,235,476&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,115,853&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,238,185&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--SellingAndMarketingExpenseAbstract_iB_zVd2FY3RkMFc" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Selling
        and marketing expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--StaffCostsEmployeeBenefitsAndOfficeExpenses_i_pp0p" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#x2013;
        Staff costs, employee benefits and office expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(277,511&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(104,729&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(573,648&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(310,582&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--ShareBasedCompensations_zJ7xD2oOp4Ui" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#x2013;
        Share-based compensation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(101,000&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3876"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(153,266&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3878"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;General
        and administrative expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--StaffCostsEmployeeBenefitsAndOthers_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&#x2013;
        Staff costs, employee benefits and Others&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,890&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(360,657&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(33,785&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(563,641&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ProfessionalAndContractServicesExpense_iN_di_z78VitJx7Eo3" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&#x2013;
        Professional service expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(99,217&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(108,039&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(234,374&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(364,614&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingIncomeLoss_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;&lt;b&gt;Loss
        from operations&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;(646,536&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;(1,221,974&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;(2,462,485&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;(2,818,657&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--ChangeInFairValueOfSimpleAgreementsForFutureEquity_iN_di_z4jz79hEVis9" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Change
        in fair value of simple agreements for future equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(890,523&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,410,457&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,716,052&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(5,098,320&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Income
        tax expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3905"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3906"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3907"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3908"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProfitLoss_zq0n3eRYdw7k" style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Net
        loss&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;(1,537,059&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;(2,632,431&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;(6,178,537&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;(7,916,977&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003845"
      unitRef="USD">1862158</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003846"
      unitRef="USD">3754586</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003847"
      unitRef="USD">4475885</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003848"
      unitRef="USD">10561331</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003850"
      unitRef="USD">-1649077</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003851"
      unitRef="USD">-3167659</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003852"
      unitRef="USD">-3827444</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003853"
      unitRef="USD">-8902966</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003855"
      unitRef="USD">213081</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003856"
      unitRef="USD">586927</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003857"
      unitRef="USD">648441</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003858"
      unitRef="USD">1658365</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003860"
      unitRef="USD">377999</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003861"
      unitRef="USD">1235476</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003862"
      unitRef="USD">2115853</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003863"
      unitRef="USD">3238185</us-gaap:ResearchAndDevelopmentExpense>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003870"
      unitRef="USD">-277511</cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003871"
      unitRef="USD">-104729</cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003872"
      unitRef="USD">-573648</cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003873"
      unitRef="USD">-310582</cik0002065779:StaffCostsEmployeeBenefitsAndOfficeExpenses>
    <cik0002065779:ShareBasedCompensations
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003875"
      unitRef="USD">-101000</cik0002065779:ShareBasedCompensations>
    <cik0002065779:ShareBasedCompensations
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003877"
      unitRef="USD">-153266</cik0002065779:ShareBasedCompensations>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOthers
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003885"
      unitRef="USD">-3890</cik0002065779:StaffCostsEmployeeBenefitsAndOthers>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOthers
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003886"
      unitRef="USD">-360657</cik0002065779:StaffCostsEmployeeBenefitsAndOthers>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOthers
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003887"
      unitRef="USD">-33785</cik0002065779:StaffCostsEmployeeBenefitsAndOthers>
    <cik0002065779:StaffCostsEmployeeBenefitsAndOthers
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003888"
      unitRef="USD">-563641</cik0002065779:StaffCostsEmployeeBenefitsAndOthers>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003890"
      unitRef="USD">99217</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003891"
      unitRef="USD">108039</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003892"
      unitRef="USD">234374</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003893"
      unitRef="USD">364614</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003895"
      unitRef="USD">-646536</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003896"
      unitRef="USD">-1221974</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003897"
      unitRef="USD">-2462485</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003898"
      unitRef="USD">-2818657</us-gaap:OperatingIncomeLoss>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003900"
      unitRef="USD">890523</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003901"
      unitRef="USD">1410457</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003902"
      unitRef="USD">3716052</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003903"
      unitRef="USD">5098320</cik0002065779:ChangeInFairValueOfSimpleAgreementsForFutureEquity>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003910"
      unitRef="USD">-1537059</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003911"
      unitRef="USD">-2632431</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003912"
      unitRef="USD">-6178537</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003913"
      unitRef="USD">-7916977</us-gaap:ProfitLoss>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003915">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zIPxDBsoGFvj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details 1)"&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td id="xdx_8B4_z6QXFE6MCFp1" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Schedule of geographic information&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Three Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For the&lt;br/&gt;Nine Months
        Ended&lt;br/&gt;March&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;United
        States of America&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;581,009&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;1,564,836&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;1,273,279&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total"&gt;4,560,992&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Canada&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;367,107&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;1,139,055&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;1,089,559&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total"&gt;3,232,326&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Singapore&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;662,559&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;425,009&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;1,361,844&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total"&gt;1,237,464&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;Hong Kong&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;150,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;417,992&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;450,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total"&gt;1,118,534&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;United
        Kingdom&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;98,483&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;207,694&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;291,203&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total"&gt;412,015&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #FFFFFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"&gt;Others&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;3,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3959"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;10,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3963"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF; vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_908_eus-gaap--Revenues_pp0d_c20250101__20250331_zUms2zS7QOY6" title="Total"&gt;1,862,158&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_907_eus-gaap--Revenues_pp0d_c20260101__20260331_z3I7DIpNDZGg" title="Total"&gt;3,754,586&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_908_eus-gaap--Revenues_pp0d_c20240701__20250331_zsHyuymBBcp8" title="Total"&gt;4,475,885&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;&lt;span id="xdx_906_eus-gaap--Revenues_pp0d_c20250701__20260331_zWKBKmLtNdw2" title="Total"&gt;10,561,331&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_country_US_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003917"
      unitRef="USD">581009</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_country_US_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003919"
      unitRef="USD">1564836</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_country_US_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003921"
      unitRef="USD">1273279</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_country_US_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003923"
      unitRef="USD">4560992</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_country_CA_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003925"
      unitRef="USD">367107</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_country_CA_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003927"
      unitRef="USD">1139055</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_country_CA_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003929"
      unitRef="USD">1089559</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_country_CA_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003931"
      unitRef="USD">3232326</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_country_SG_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003933"
      unitRef="USD">662559</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_country_SG_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003935"
      unitRef="USD">425009</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_country_SG_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003937"
      unitRef="USD">1361844</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_country_SG_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003939"
      unitRef="USD">1237464</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_country_HK_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003941"
      unitRef="USD">150000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_country_HK_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003943"
      unitRef="USD">417992</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_country_HK_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003945"
      unitRef="USD">450000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_country_HK_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003947"
      unitRef="USD">1118534</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_country_GB_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003949"
      unitRef="USD">98483</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_country_GB_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003951"
      unitRef="USD">207694</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_country_GB_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003953"
      unitRef="USD">291203</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_country_GB_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003955"
      unitRef="USD">412015</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_OthersMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003957"
      unitRef="USD">3000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_OthersMember_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003961"
      unitRef="USD">10000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003965"
      unitRef="USD">1862158</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003967"
      unitRef="USD">3754586</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003969"
      unitRef="USD">4475885</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      decimals="0"
      id="Fact003971"
      unitRef="USD">10561331</us-gaap:Revenues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003974">&lt;p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zLihNGvAxZLg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;14.
&lt;span id="xdx_827_zx6q22XsxzOc"&gt;Commitments and contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;From
inception to date, the Company has not been a party to any legal proceedings, claims, or disputes arising in the ordinary course of business.
As of March&#160;31, 2026, the Company had no outstanding litigation, and there were no commitments or contingencies that management believes
would have a material effect on the unaudited condensed consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="From2025-07-012026-03-31_custom_ExascaleLabsIncMember"
      id="Fact003976">&lt;p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zRLEv2ZbvEdd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;15.
Subsequent events&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_82A_zSew4Do77Ac5" style="display: none"&gt;Subsequent Events&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company
evaluated all events and transactions that occurred after March&#160;31, 2026, up through June&#160;11, 2026, which is the date that
these unaudited condensed consolidated financial statements are issued, unless as disclosed elsewhere, no other material subsequent events
occurred that would require recognition or disclosure in the Company&#x2019;s unaudited condensed consolidated financial statements.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact001118"
          xlink:label="Fact001118"
          xlink:type="locator"/>
        <link:footnote id="Footnote001253" xlink:label="Footnote001253" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes an aggregate of 321,429
Ordinary Shares cancelled on September&#160;9, 2025 to the extent that the underwriters&#x2019; over-allotment was not exercised.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001118"
          xlink:to="Footnote001253"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001119"
          xlink:label="Fact001119"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001119"
          xlink:to="Footnote001253"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1227"
          xlink:label="xdx2ixbrl1227"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1227"
          xlink:to="Footnote001253"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001228"
          xlink:label="Fact001228"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001228"
          xlink:to="Footnote001253"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001229"
          xlink:label="Fact001229"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001229"
          xlink:to="Footnote001253"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1230"
          xlink:label="xdx2ixbrl1230"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1230"
          xlink:to="Footnote001253"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001231"
          xlink:label="Fact001231"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001231"
          xlink:to="Footnote001253"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1232"
          xlink:label="xdx2ixbrl1232"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1232"
          xlink:to="Footnote001253"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002299"
          xlink:label="Fact002299"
          xlink:type="locator"/>
        <link:footnote id="Footnote002330" xlink:label="Footnote002330" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company classifies its SAFEs as financial liabilities
        measured at fair value. The value of the agreements depends significantly on future financing activities, liquidity events, or other material
        milestones, and their valuation relies on significant inputs that are not observable in the public market. Accordingly, they are classified
        within Level 3 of the fair value hierarchy.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002299"
          xlink:to="Footnote002330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl2301"
          xlink:label="xdx2ixbrl2301"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl2301"
          xlink:to="Footnote002330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl2303"
          xlink:label="xdx2ixbrl2303"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl2303"
          xlink:to="Footnote002330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002305"
          xlink:label="Fact002305"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002305"
          xlink:to="Footnote002330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002315"
          xlink:label="Fact002315"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002315"
          xlink:to="Footnote002330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl2317"
          xlink:label="xdx2ixbrl2317"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl2317"
          xlink:to="Footnote002330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl2319"
          xlink:label="xdx2ixbrl2319"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl2319"
          xlink:to="Footnote002330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002321"
          xlink:label="Fact002321"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002321"
          xlink:to="Footnote002330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002307"
          xlink:label="Fact002307"
          xlink:type="locator"/>
        <link:footnote id="Footnote002331" xlink:label="Footnote002331" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Equity
        option. On May&#160;9, 2023, the Company entered into an agreement with a third-party service provider (the &#x201c;Service Provider&#x201d;).
        The Service Provider received a freestanding equity-linked right exercisable, at the Service Provider&#x2019;s option, upon the closing
        of the Company&#x2019;s next qualified equity financing. The right provides the ability to subscribe for up to the value of $200,000 at
        a 25% discount price per share on the grant date. The equity option is remeasured at fair value at each reporting date, with changes in
        fair value recognized in earnings. As of June&#160;30, 2024 and June&#160;30, 2025, the fair value of the equity option was $53,333, and
        no gain or loss from changes in fair value was recognized for the periods presented. The fair value measurement of the equity option is
        categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based analysis, which incorporates significant
        unobservable inputs and management judgment regarding the probability and timing of potential future financing outcomes.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002307"
          xlink:to="Footnote002331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl2309"
          xlink:label="xdx2ixbrl2309"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl2309"
          xlink:to="Footnote002331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl2311"
          xlink:label="xdx2ixbrl2311"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl2311"
          xlink:to="Footnote002331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002313"
          xlink:label="Fact002313"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002313"
          xlink:to="Footnote002331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002323"
          xlink:label="Fact002323"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002323"
          xlink:to="Footnote002331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl2325"
          xlink:label="xdx2ixbrl2325"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl2325"
          xlink:to="Footnote002331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl2327"
          xlink:label="xdx2ixbrl2327"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl2327"
          xlink:to="Footnote002331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002329"
          xlink:label="Fact002329"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002329"
          xlink:to="Footnote002331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002569"
          xlink:label="Fact002569"
          xlink:type="locator"/>
        <link:footnote id="Footnote002584" xlink:label="Footnote002584" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company&#x2019;s share-based compensation awards are expected to be settled through transfers of existing
        ordinary shares held by the controlling shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary
        shares are included in issued and outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase
        the Company&#x2019;s total issued and outstanding shares. During the years ended June&#160;30, 2024 and 2025, diluted net loss per share
        is calculated in the same manner as basic net loss per share.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002569"
          xlink:to="Footnote002584"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002571"
          xlink:label="Fact002571"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002571"
          xlink:to="Footnote002584"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002573"
          xlink:label="Fact002573"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002573"
          xlink:to="Footnote002584"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002575"
          xlink:label="Fact002575"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002575"
          xlink:to="Footnote002584"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003570"
          xlink:label="Fact003570"
          xlink:type="locator"/>
        <link:footnote id="Footnote003604" xlink:label="Footnote003604" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
        Company classifies its SAFEs as financial liabilities measured at fair value. The value of these agreements depends significantly on future
        financing activities, liquidity events, or other material milestones, and their valuation relies on significant inputs that are not observable
        in the public market. Accordingly, they are classified within Level 3 of the fair value hierarchy.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003570"
          xlink:to="Footnote003604"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl3572"
          xlink:label="xdx2ixbrl3572"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl3572"
          xlink:to="Footnote003604"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl3574"
          xlink:label="xdx2ixbrl3574"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl3574"
          xlink:to="Footnote003604"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003576"
          xlink:label="Fact003576"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003576"
          xlink:to="Footnote003604"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003589"
          xlink:label="Fact003589"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003589"
          xlink:to="Footnote003604"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl3591"
          xlink:label="xdx2ixbrl3591"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl3591"
          xlink:to="Footnote003604"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl3593"
          xlink:label="xdx2ixbrl3593"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl3593"
          xlink:to="Footnote003604"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003595"
          xlink:label="Fact003595"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003595"
          xlink:to="Footnote003604"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003578"
          xlink:label="Fact003578"
          xlink:type="locator"/>
        <link:footnote id="Footnote003605" xlink:label="Footnote003605" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Equity options. On May&#160;9, 2023, the Company entered into an agreement
        with a third-party service provider (the &#x201c;Service Provider&#x201d;). The Service Provider received a freestanding equity-linked right
        exercisable, at the Service Provider&#x2019;s option, upon the closing of the Company&#x2019;s next qualified equity financing. The right
        provides the ability to subscribe for up to the value of $200,000 at a 25% discount price per share on the grant date. The equity option
        is remeasured at fair value at each reporting date, with changes in fair value recognized in earnings. As of June&#160;30, 2025 and March&#160;31,
        2026, the fair value of the equity option was $53,333, and no gain or loss from changes in fair value was recognized for the periods presented.
        The fair value measurement of the equity option is categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based
        analysis, which incorporates significant unobservable inputs and management judgment regarding the probability and timing of potential
        future financing outcomes.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003578"
          xlink:to="Footnote003605"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl3580"
          xlink:label="xdx2ixbrl3580"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl3580"
          xlink:to="Footnote003605"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl3582"
          xlink:label="xdx2ixbrl3582"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl3582"
          xlink:to="Footnote003605"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003584"
          xlink:label="Fact003584"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003584"
          xlink:to="Footnote003605"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003597"
          xlink:label="Fact003597"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003597"
          xlink:to="Footnote003605"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl3599"
          xlink:label="xdx2ixbrl3599"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl3599"
          xlink:to="Footnote003605"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl3601"
          xlink:label="xdx2ixbrl3601"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl3601"
          xlink:to="Footnote003605"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003603"
          xlink:label="Fact003603"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003603"
          xlink:to="Footnote003605"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003615"
          xlink:label="Fact003615"
          xlink:type="locator"/>
        <link:footnote id="Footnote003630" xlink:label="Footnote003630" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company acquired a total of 939,397 USDT at a cost of $939,397, funded by revenues and collections of other receivables. The Company acquired a total of 4,711,169 USDC at a cost of $4,711,169, funded by revenues, interest income,
        collections of other receivables and investment proceeds from SAFEs.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003615"
          xlink:to="Footnote003630"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003617"
          xlink:label="Fact003617"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003617"
          xlink:to="Footnote003630"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003623"
          xlink:label="Fact003623"
          xlink:type="locator"/>
        <link:footnote id="Footnote003631" xlink:label="Footnote003631" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company used digital assets and USDC to settle professional service
        fees and other expenditures.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003623"
          xlink:to="Footnote003631"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003625"
          xlink:label="Fact003625"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003625"
          xlink:to="Footnote003631"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003799"
          xlink:label="Fact003799"
          xlink:type="locator"/>
        <link:footnote id="Footnote003835" xlink:label="Footnote003835" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In January&#160;2026, the Company adopted an Amended and Restated Certificate
        of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#x2019;s equity is divided
        into 303 Class A ordinary shares and 1,197 Class B ordinary shares, which are entitled to one (1) vote and twenty (20) votes per share,
        respectively. Despite the differential in voting power, Class A and Class B ordinary shares rank pari passu in all other respects, sharing
        ratably in dividends and any distributions upon liquidation.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003799"
          xlink:to="Footnote003835"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003801"
          xlink:label="Fact003801"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003801"
          xlink:to="Footnote003835"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003803"
          xlink:label="Fact003803"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003803"
          xlink:to="Footnote003835"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003805"
          xlink:label="Fact003805"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003805"
          xlink:to="Footnote003835"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003807"
          xlink:label="Fact003807"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003807"
          xlink:to="Footnote003835"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003809"
          xlink:label="Fact003809"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003809"
          xlink:to="Footnote003835"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003811"
          xlink:label="Fact003811"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003811"
          xlink:to="Footnote003835"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003813"
          xlink:label="Fact003813"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003813"
          xlink:to="Footnote003835"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003820"
          xlink:label="Fact003820"
          xlink:type="locator"/>
        <link:footnote id="Footnote003836" xlink:label="Footnote003836" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During the three and nine months ended March&#160;31, 2025 and 2026, diluted
        net loss per share is calculated in the same manner as basic net loss per share, as the Company was in a net loss position and all potential ordinary shares were anti-dilutive.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003820"
          xlink:to="Footnote003836"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003822"
          xlink:label="Fact003822"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003822"
          xlink:to="Footnote003836"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003824"
          xlink:label="Fact003824"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003824"
          xlink:to="Footnote003836"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003826"
          xlink:label="Fact003826"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003826"
          xlink:to="Footnote003836"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003828"
          xlink:label="Fact003828"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003828"
          xlink:to="Footnote003836"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003830"
          xlink:label="Fact003830"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003830"
          xlink:to="Footnote003836"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003832"
          xlink:label="Fact003832"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003832"
          xlink:to="Footnote003836"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003834"
          xlink:label="Fact003834"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003834"
          xlink:to="Footnote003836"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>dboralarcacq_ex107_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="AsOf2026-06-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
        </entity>
        <period>
            <startDate>2026-06-10</startDate>
            <endDate>2026-06-10</endDate>
        </period>
    </context>
    <context id="From2026-06-102026-06-10_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-10</startDate>
            <endDate>2026-06-10</endDate>
        </period>
    </context>
    <context id="From2026-06-102026-06-10_2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-10</startDate>
            <endDate>2026-06-10</endDate>
        </period>
    </context>
    <context id="From2026-06-102026-06-10_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>3</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-10</startDate>
            <endDate>2026-06-10</endDate>
        </period>
    </context>
    <context id="From2026-06-102026-06-10_4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>4</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-10</startDate>
            <endDate>2026-06-10</endDate>
        </period>
    </context>
    <context id="From2026-06-102026-06-10_5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>5</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-10</startDate>
            <endDate>2026-06-10</endDate>
        </period>
    </context>
    <context id="From2026-06-102026-06-10_24993218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OffsetAxis">
                    <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-10</startDate>
            <endDate>2026-06-10</endDate>
        </period>
    </context>
    <context id="From2026-06-102026-06-10_14993234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002065779</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OffsetAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-10</startDate>
            <endDate>2026-06-10</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-06-10" id="Fact000003">0002065779</dei:EntityCentralIndexKey>
    <ffd:FeeExhibitTp contextRef="AsOf2026-06-10" id="xdx2ixbrl0010">EX-FILING FEES</ffd:FeeExhibitTp>
    <ffd:SubmissnTp contextRef="AsOf2026-06-10" id="xdx2ixbrl0013">S-4/A</ffd:SubmissnTp>
    <ffd:CombinedProspectusTableNa contextRef="AsOf2026-06-10" id="Fact000009">N/A</ffd:CombinedProspectusTableNa>
    <ffd:RegnFileNb contextRef="AsOf2026-06-10" id="Fact000011">333-295869</ffd:RegnFileNb>
    <ffd:FormTp contextRef="AsOf2026-06-10" id="Fact000012">S-4</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="AsOf2026-06-10" id="Fact000014">D. Boral ARC Acquisition I Corp</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="From2026-06-102026-06-10_1" id="Fact000015">true</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="From2026-06-102026-06-10_1" id="Fact000016">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="From2026-06-102026-06-10_1" id="Fact000017">Class A Common Stock, par value $0.0001 per share, to be issued to shareholders</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="From2026-06-102026-06-10_1" id="Fact000018">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="From2026-06-102026-06-10_1"
      decimals="INF"
      id="Fact000019"
      unitRef="Shares">41200000</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="From2026-06-102026-06-10_1"
      decimals="INF"
      id="Fact000020"
      unitRef="USDPShares">10.67</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="From2026-06-102026-06-10_1"
      decimals="2"
      id="Fact000021"
      unitRef="USD">439604000</ffd:MaxAggtOfferingPric>
    <ffd:FeeAmt
      contextRef="From2026-06-102026-06-10_1"
      decimals="2"
      id="Fact000022"
      unitRef="USD">60709.32</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="From2026-06-102026-06-10_2" id="Fact000023">true</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="From2026-06-102026-06-10_2" id="Fact000024">Other</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="From2026-06-102026-06-10_2" id="Fact000025">Warrants of BCAR</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="From2026-06-102026-06-10_2" id="Fact000026">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="From2026-06-102026-06-10_2"
      decimals="INF"
      id="Fact000027"
      unitRef="Shares">14100000</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="From2026-06-102026-06-10_2"
      decimals="INF"
      id="Fact000028"
      unitRef="USDPShares">0.00</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="From2026-06-102026-06-10_2"
      decimals="2"
      id="Fact000029"
      unitRef="USD">0.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeAmt
      contextRef="From2026-06-102026-06-10_2"
      decimals="2"
      id="Fact000030"
      unitRef="USD">0.00</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="From2026-06-102026-06-10_3" id="Fact000031">true</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="From2026-06-102026-06-10_3" id="Fact000032">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="From2026-06-102026-06-10_3" id="Fact000033">Class A Common Stock issuable upon exercise of Warrants of BCAR</ffd:OfferingSctyTitl>
    <ffd:Rule457aFlg contextRef="From2026-06-102026-06-10_3" id="Fact000034">true</ffd:Rule457aFlg>
    <ffd:AmtSctiesRegd
      contextRef="From2026-06-102026-06-10_3"
      decimals="INF"
      id="Fact000035"
      unitRef="Shares">14100000</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="From2026-06-102026-06-10_3"
      decimals="INF"
      id="Fact000036"
      unitRef="USDPShares">1.59</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="From2026-06-102026-06-10_3"
      decimals="2"
      id="Fact000037"
      unitRef="USD">22419000</ffd:MaxAggtOfferingPric>
    <ffd:FeeAmt
      contextRef="From2026-06-102026-06-10_3"
      decimals="2"
      id="Fact000038"
      unitRef="USD">3096.06</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="From2026-06-102026-06-10_4" id="Fact000039">true</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="From2026-06-102026-06-10_4" id="Fact000040">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="From2026-06-102026-06-10_4" id="Fact000041">Class A Common Stock, par value $0.0001 per share, to be issued to shareholders of Exascale Labs</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="From2026-06-102026-06-10_4" id="Fact000042">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="From2026-06-102026-06-10_4"
      decimals="INF"
      id="Fact000043"
      unitRef="Shares">19256000</ffd:AmtSctiesRegd>
    <ffd:MaxAggtOfferingPric
      contextRef="From2026-06-102026-06-10_4"
      decimals="2"
      id="Fact000044"
      unitRef="USD">57768</ffd:MaxAggtOfferingPric>
    <ffd:FeeAmt
      contextRef="From2026-06-102026-06-10_4"
      decimals="2"
      id="Fact000045"
      unitRef="USD">7.98</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="From2026-06-102026-06-10_5" id="Fact000046">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="From2026-06-102026-06-10_5" id="Fact000047">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="From2026-06-102026-06-10_5" id="Fact000048">Class B Common Stock, par value $0.0001 per share, to be issued to certain shareholders</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="From2026-06-102026-06-10_5" id="Fact000049">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="From2026-06-102026-06-10_5"
      decimals="INF"
      id="Fact000050"
      unitRef="Shares">30744000</ffd:AmtSctiesRegd>
    <ffd:MaxAggtOfferingPric
      contextRef="From2026-06-102026-06-10_5"
      decimals="2"
      id="Fact000051"
      unitRef="USD">92232</ffd:MaxAggtOfferingPric>
    <ffd:FeeAmt
      contextRef="From2026-06-102026-06-10_5"
      decimals="2"
      id="Fact000052"
      unitRef="USD">12.74</ffd:FeeAmt>
    <ffd:TtlOfferingAmt
      contextRef="AsOf2026-06-10"
      decimals="2"
      id="Fact000053"
      unitRef="USD">462173000</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt
      contextRef="AsOf2026-06-10"
      decimals="2"
      id="Fact000054"
      unitRef="USD">63826.10</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt
      contextRef="AsOf2026-06-10"
      decimals="2"
      id="Fact000055"
      unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt
      contextRef="AsOf2026-06-10"
      decimals="2"
      id="Fact000056"
      unitRef="USD">63826.10</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt
      contextRef="AsOf2026-06-10"
      decimals="2"
      id="Fact000057"
      unitRef="USD">0.00</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="From2026-06-102026-06-10_1" id="Fact000058">

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Offering Note&lt;/b&gt;&lt;/p&gt;



















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; width: 0.25in"&gt;1&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Represents Common Stock issuable, pursuant to the Business Combination described in the proxy statement/prospectus forming part of this registration statement, to holders of (i) 29,000,000 Class A ordinary shares of BCAR, (ii) 12,000,000 Class B ordinary shares of BCAR, and (iii) 200,000 Class A ordinary shares of BCAR underlying the private units, each consisting of one Class A ordinary share and one -half of one warrant (the &#x201c;Private Units&#x201d;), issued in a private placement that closed concurrently with BCAR&#x2019;s initial public offering. The per unit price is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum aggregate is based on the average of the high and low prices of BCAR Class A Ordinary Shares, as quoted on the Nasdaq Global Market on May&#160;8, 2026, which was approximately $10.67 per share&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;2&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Represents the warrants issuable to holders of 14,000,000 public warrants of BCAR and 100,000 private warrants of BCAR. Consistent with the response to Question 240.06 of the Securities Act Rules Compliance and Disclosure Interpretations and pursuant to Rule&#160;457(g) of the Securities Act, the registration fee with respect to the warrants has been allocated to the Common Stock underlying BCAR&#x2019;s public warrants, and those shares of Class A Common Stock are included in the total registration fee.&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;3&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Represents 14,000,000 shares of Common Stock underlying BCAR&#x2019;s public warrants and 100,000 shares of Common Stock underlying BCAR&#x2019;s private warrants, with the per unit price estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum offering price per share is based on the average of the high and low prices of BCAR&#x2019;s public warrants as quoted on Nasdaq Global Market on May&#160;8, 2026, which was $1.59 per warrant.&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;4&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Rule&#160;457(f) Fee Calculation Details &lt;br/&gt;&lt;br/&gt;The amount to be registered represents the maximum amount of Class A Common Stock issuable to the stockholders of Exascale in connection with the Business Combination described in the proxy statement/prospectus forming part of this registration statement. The value per share of the securities to be received by Exascale upon the issuance of such securities and the proposed maximum offering price per share is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(f)(2) under the Securities Act. Exascale is a private company, no market exists for its securities, and Exascale has an accumulated deficit. Therefore, the proposed maximum offering price per share is one-third of the aggregate par value of the securities expected to be exchanged in the Business Combination. No cash is to be received or paid by BCAR in connection with the securities to be exchanged in the Business Combination.&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Amount of&lt;br/&gt; Securities&lt;br/&gt; to be Received &lt;br/&gt; or Cancelled&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Value per &lt;br/&gt; Share of Securities&lt;br/&gt; to be Received&lt;br/&gt; or Cancelled&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Total Value &lt;br/&gt; of Securities &lt;br/&gt; to be Received &lt;br/&gt; or Cancelled&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Cash Consideration&lt;br/&gt; Received by&lt;br/&gt; the registrant&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Cash Consideration&lt;br/&gt; (Paid) by the&lt;br/&gt; registrant&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Maximum Aggregate &lt;br/&gt; Offering Price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;19,256,000&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;$0.003&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;$57,768&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;$57,768&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="From2026-06-102026-06-10_2" id="Fact000059">

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Offering Note&lt;/b&gt;&lt;/p&gt;



















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; width: 0.25in"&gt;1&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Represents Common Stock issuable, pursuant to the Business Combination described in the proxy statement/prospectus forming part of this registration statement, to holders of (i) 29,000,000 Class A ordinary shares of BCAR, (ii) 12,000,000 Class B ordinary shares of BCAR, and (iii) 200,000 Class A ordinary shares of BCAR underlying the private units, each consisting of one Class A ordinary share and one -half of one warrant (the &#x201c;Private Units&#x201d;), issued in a private placement that closed concurrently with BCAR&#x2019;s initial public offering. The per unit price is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum aggregate is based on the average of the high and low prices of BCAR Class A Ordinary Shares, as quoted on the Nasdaq Global Market on May&#160;8, 2026, which was approximately $10.67 per share&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;2&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Represents the warrants issuable to holders of 14,000,000 public warrants of BCAR and 100,000 private warrants of BCAR. Consistent with the response to Question 240.06 of the Securities Act Rules Compliance and Disclosure Interpretations and pursuant to Rule&#160;457(g) of the Securities Act, the registration fee with respect to the warrants has been allocated to the Common Stock underlying BCAR&#x2019;s public warrants, and those shares of Class A Common Stock are included in the total registration fee.&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;3&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Represents 14,000,000 shares of Common Stock underlying BCAR&#x2019;s public warrants and 100,000 shares of Common Stock underlying BCAR&#x2019;s private warrants, with the per unit price estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum offering price per share is based on the average of the high and low prices of BCAR&#x2019;s public warrants as quoted on Nasdaq Global Market on May&#160;8, 2026, which was $1.59 per warrant.&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;4&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Rule&#160;457(f) Fee Calculation Details &lt;br/&gt;&lt;br/&gt;The amount to be registered represents the maximum amount of Class A Common Stock issuable to the stockholders of Exascale in connection with the Business Combination described in the proxy statement/prospectus forming part of this registration statement. The value per share of the securities to be received by Exascale upon the issuance of such securities and the proposed maximum offering price per share is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(f)(2) under the Securities Act. Exascale is a private company, no market exists for its securities, and Exascale has an accumulated deficit. Therefore, the proposed maximum offering price per share is one-third of the aggregate par value of the securities expected to be exchanged in the Business Combination. No cash is to be received or paid by BCAR in connection with the securities to be exchanged in the Business Combination.&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Amount of&lt;br/&gt; Securities&lt;br/&gt; to be Received &lt;br/&gt; or Cancelled&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Value per &lt;br/&gt; Share of Securities&lt;br/&gt; to be Received&lt;br/&gt; or Cancelled&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Total Value &lt;br/&gt; of Securities &lt;br/&gt; to be Received &lt;br/&gt; or Cancelled&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Cash Consideration&lt;br/&gt; Received by&lt;br/&gt; the registrant&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Cash Consideration&lt;br/&gt; (Paid) by the&lt;br/&gt; registrant&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Maximum Aggregate &lt;br/&gt; Offering Price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;19,256,000&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;$0.003&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;$57,768&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;$57,768&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="From2026-06-102026-06-10_3" id="Fact000060">

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Offering Note&lt;/b&gt;&lt;/p&gt;



















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; width: 0.25in"&gt;1&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Represents Common Stock issuable, pursuant to the Business Combination described in the proxy statement/prospectus forming part of this registration statement, to holders of (i) 29,000,000 Class A ordinary shares of BCAR, (ii) 12,000,000 Class B ordinary shares of BCAR, and (iii) 200,000 Class A ordinary shares of BCAR underlying the private units, each consisting of one Class A ordinary share and one -half of one warrant (the &#x201c;Private Units&#x201d;), issued in a private placement that closed concurrently with BCAR&#x2019;s initial public offering. The per unit price is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum aggregate is based on the average of the high and low prices of BCAR Class A Ordinary Shares, as quoted on the Nasdaq Global Market on May&#160;8, 2026, which was approximately $10.67 per share&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;2&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Represents the warrants issuable to holders of 14,000,000 public warrants of BCAR and 100,000 private warrants of BCAR. Consistent with the response to Question 240.06 of the Securities Act Rules Compliance and Disclosure Interpretations and pursuant to Rule&#160;457(g) of the Securities Act, the registration fee with respect to the warrants has been allocated to the Common Stock underlying BCAR&#x2019;s public warrants, and those shares of Class A Common Stock are included in the total registration fee.&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;3&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Represents 14,000,000 shares of Common Stock underlying BCAR&#x2019;s public warrants and 100,000 shares of Common Stock underlying BCAR&#x2019;s private warrants, with the per unit price estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum offering price per share is based on the average of the high and low prices of BCAR&#x2019;s public warrants as quoted on Nasdaq Global Market on May&#160;8, 2026, which was $1.59 per warrant.&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;4&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Rule&#160;457(f) Fee Calculation Details &lt;br/&gt;&lt;br/&gt;The amount to be registered represents the maximum amount of Class A Common Stock issuable to the stockholders of Exascale in connection with the Business Combination described in the proxy statement/prospectus forming part of this registration statement. The value per share of the securities to be received by Exascale upon the issuance of such securities and the proposed maximum offering price per share is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(f)(2) under the Securities Act. Exascale is a private company, no market exists for its securities, and Exascale has an accumulated deficit. Therefore, the proposed maximum offering price per share is one-third of the aggregate par value of the securities expected to be exchanged in the Business Combination. No cash is to be received or paid by BCAR in connection with the securities to be exchanged in the Business Combination.&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Amount of&lt;br/&gt; Securities&lt;br/&gt; to be Received &lt;br/&gt; or Cancelled&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Value per &lt;br/&gt; Share of Securities&lt;br/&gt; to be Received&lt;br/&gt; or Cancelled&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Total Value &lt;br/&gt; of Securities &lt;br/&gt; to be Received &lt;br/&gt; or Cancelled&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Cash Consideration&lt;br/&gt; Received by&lt;br/&gt; the registrant&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Cash Consideration&lt;br/&gt; (Paid) by the&lt;br/&gt; registrant&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Maximum Aggregate &lt;br/&gt; Offering Price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;19,256,000&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;$0.003&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;$57,768&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;$57,768&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="From2026-06-102026-06-10_4" id="Fact000061">

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Offering Note&lt;/b&gt;&lt;/p&gt;



















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; width: 0.25in"&gt;1&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Represents Common Stock issuable, pursuant to the Business Combination described in the proxy statement/prospectus forming part of this registration statement, to holders of (i) 29,000,000 Class A ordinary shares of BCAR, (ii) 12,000,000 Class B ordinary shares of BCAR, and (iii) 200,000 Class A ordinary shares of BCAR underlying the private units, each consisting of one Class A ordinary share and one -half of one warrant (the &#x201c;Private Units&#x201d;), issued in a private placement that closed concurrently with BCAR&#x2019;s initial public offering. The per unit price is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum aggregate is based on the average of the high and low prices of BCAR Class A Ordinary Shares, as quoted on the Nasdaq Global Market on May&#160;8, 2026, which was approximately $10.67 per share&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;2&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Represents the warrants issuable to holders of 14,000,000 public warrants of BCAR and 100,000 private warrants of BCAR. Consistent with the response to Question 240.06 of the Securities Act Rules Compliance and Disclosure Interpretations and pursuant to Rule&#160;457(g) of the Securities Act, the registration fee with respect to the warrants has been allocated to the Common Stock underlying BCAR&#x2019;s public warrants, and those shares of Class A Common Stock are included in the total registration fee.&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;3&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Represents 14,000,000 shares of Common Stock underlying BCAR&#x2019;s public warrants and 100,000 shares of Common Stock underlying BCAR&#x2019;s private warrants, with the per unit price estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum offering price per share is based on the average of the high and low prices of BCAR&#x2019;s public warrants as quoted on Nasdaq Global Market on May&#160;8, 2026, which was $1.59 per warrant.&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;4&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Rule&#160;457(f) Fee Calculation Details &lt;br/&gt;&lt;br/&gt;The amount to be registered represents the maximum amount of Class A Common Stock issuable to the stockholders of Exascale in connection with the Business Combination described in the proxy statement/prospectus forming part of this registration statement. The value per share of the securities to be received by Exascale upon the issuance of such securities and the proposed maximum offering price per share is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(f)(2) under the Securities Act. Exascale is a private company, no market exists for its securities, and Exascale has an accumulated deficit. Therefore, the proposed maximum offering price per share is one-third of the aggregate par value of the securities expected to be exchanged in the Business Combination. No cash is to be received or paid by BCAR in connection with the securities to be exchanged in the Business Combination.&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Amount of&lt;br/&gt; Securities&lt;br/&gt; to be Received &lt;br/&gt; or Cancelled&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Value per &lt;br/&gt; Share of Securities&lt;br/&gt; to be Received&lt;br/&gt; or Cancelled&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Total Value &lt;br/&gt; of Securities &lt;br/&gt; to be Received &lt;br/&gt; or Cancelled&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Cash Consideration&lt;br/&gt; Received by&lt;br/&gt; the registrant&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Cash Consideration&lt;br/&gt; (Paid) by the&lt;br/&gt; registrant&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Maximum Aggregate &lt;br/&gt; Offering Price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;19,256,000&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;$0.003&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;$57,768&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;$57,768&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="From2026-06-102026-06-10_5" id="Fact000062">

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Offering Note&lt;/b&gt;&lt;/p&gt;



















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; width: 0.25in"&gt;1&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Represents Common Stock issuable, pursuant to the Business Combination described in the proxy statement/prospectus forming part of this registration statement, to holders of (i) 29,000,000 Class A ordinary shares of BCAR, (ii) 12,000,000 Class B ordinary shares of BCAR, and (iii) 200,000 Class A ordinary shares of BCAR underlying the private units, each consisting of one Class A ordinary share and one -half of one warrant (the &#x201c;Private Units&#x201d;), issued in a private placement that closed concurrently with BCAR&#x2019;s initial public offering. The per unit price is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum aggregate is based on the average of the high and low prices of BCAR Class A Ordinary Shares, as quoted on the Nasdaq Global Market on May&#160;8, 2026, which was approximately $10.67 per share&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;2&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Represents the warrants issuable to holders of 14,000,000 public warrants of BCAR and 100,000 private warrants of BCAR. Consistent with the response to Question 240.06 of the Securities Act Rules Compliance and Disclosure Interpretations and pursuant to Rule&#160;457(g) of the Securities Act, the registration fee with respect to the warrants has been allocated to the Common Stock underlying BCAR&#x2019;s public warrants, and those shares of Class A Common Stock are included in the total registration fee.&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;3&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Represents 14,000,000 shares of Common Stock underlying BCAR&#x2019;s public warrants and 100,000 shares of Common Stock underlying BCAR&#x2019;s private warrants, with the per unit price estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum offering price per share is based on the average of the high and low prices of BCAR&#x2019;s public warrants as quoted on Nasdaq Global Market on May&#160;8, 2026, which was $1.59 per warrant.&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;4&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Rule&#160;457(f) Fee Calculation Details &lt;br/&gt;&lt;br/&gt;The amount to be registered represents the maximum amount of Class A Common Stock issuable to the stockholders of Exascale in connection with the Business Combination described in the proxy statement/prospectus forming part of this registration statement. The value per share of the securities to be received by Exascale upon the issuance of such securities and the proposed maximum offering price per share is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(f)(2) under the Securities Act. Exascale is a private company, no market exists for its securities, and Exascale has an accumulated deficit. Therefore, the proposed maximum offering price per share is one-third of the aggregate par value of the securities expected to be exchanged in the Business Combination. No cash is to be received or paid by BCAR in connection with the securities to be exchanged in the Business Combination.&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Amount of&lt;br/&gt; Securities&lt;br/&gt; to be Received &lt;br/&gt; or Cancelled&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Value per &lt;br/&gt; Share of Securities&lt;br/&gt; to be Received&lt;br/&gt; or Cancelled&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Total Value &lt;br/&gt; of Securities &lt;br/&gt; to be Received &lt;br/&gt; or Cancelled&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Cash Consideration&lt;br/&gt; Received by&lt;br/&gt; the registrant&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Cash Consideration&lt;br/&gt; (Paid) by the&lt;br/&gt; registrant&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Maximum Aggregate &lt;br/&gt; Offering Price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;19,256,000&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;$0.003&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;$57,768&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 15%; text-align: center"&gt;$57,768&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</ffd:OfferingNote>
    <ffd:OffsetExpltnForClmdAmt
      contextRef="From2026-06-102026-06-10_24993218"
      id="Fact000063">Offset Claims </ffd:OffsetExpltnForClmdAmt>
    <ffd:Rule457bOffsetFlg
      contextRef="From2026-06-102026-06-10_14993234"
      id="Fact000064">true</ffd:Rule457bOffsetFlg>
    <ffd:OffsetClmdInd
      contextRef="From2026-06-102026-06-10_14993234"
      id="Fact000065">false</ffd:OffsetClmdInd>
    <ffd:OffsetPrrFilerNm
      contextRef="From2026-06-102026-06-10_14993234"
      id="Fact000066">D. Boral ARC Acquisition I Corp.</ffd:OffsetPrrFilerNm>
    <ffd:OffsetPrrFormTp
      contextRef="From2026-06-102026-06-10_14993234"
      id="Fact000067">S-4</ffd:OffsetPrrFormTp>
    <ffd:OffsetPrrFileNb
      contextRef="From2026-06-102026-06-10_14993234"
      id="Fact000068">333-295869</ffd:OffsetPrrFileNb>
    <ffd:OffsetSrcFilgDt
      contextRef="From2026-06-102026-06-10_14993234"
      id="Fact000069">2026-05-14</ffd:OffsetSrcFilgDt>
    <ffd:OffsetPrrFeeAmt
      contextRef="From2026-06-102026-06-10_14993234"
      decimals="2"
      id="Fact000070"
      unitRef="USD">63826.10</ffd:OffsetPrrFeeAmt>
    <ffd:OffsetClmdInd
      contextRef="From2026-06-102026-06-10_24993218"
      id="Fact000071">true</ffd:OffsetClmdInd>
    <ffd:Rule457bOffsetFlg
      contextRef="From2026-06-102026-06-10_24993218"
      id="Fact000072">true</ffd:Rule457bOffsetFlg>
    <ffd:OffsetPrrFormTp
      contextRef="From2026-06-102026-06-10_24993218"
      id="Fact000073">S-4</ffd:OffsetPrrFormTp>
    <ffd:OffsetPrrFileNb
      contextRef="From2026-06-102026-06-10_24993218"
      id="Fact000074">333-295869</ffd:OffsetPrrFileNb>
    <ffd:OffsetClmInitlFilgDt
      contextRef="From2026-06-102026-06-10_24993218"
      id="Fact000075">2026-05-14</ffd:OffsetClmInitlFilgDt>
    <ffd:OffsetClmdAmt
      contextRef="From2026-06-102026-06-10_24993218"
      decimals="2"
      id="Fact000076"
      unitRef="USD">63826.10</ffd:OffsetClmdAmt>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Amendment
No. 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">D. Boral ARC Acquisition I Corp.&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0002065779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">42-3035215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10 East 53rd Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 3001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">266-7344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 590<span></span>
</td>
<td class="nump">$ 590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_AmountDueToRelatedParty', window );">Amount due to related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,590<span></span>
</td>
<td class="nump">590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,590<span></span>
</td>
<td class="nump">590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,590)<span></span>
</td>
<td class="num">(590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders&#8217; Deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,590)<span></span>
</td>
<td class="num">(590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Shareholders&#8217; Deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">243,576<span></span>
</td>
<td class="nump">420,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">156,259<span></span>
</td>
<td class="nump">203,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">399,835<span></span>
</td>
<td class="nump">623,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-Current Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_CashHeldInTrustAccount', window );">Cash held in trust account</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">287,319,687<span></span>
</td>
<td class="nump">284,776,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">287,719,522<span></span>
</td>
<td class="nump">285,400,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">345,713<span></span>
</td>
<td class="nump">37,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">345,713<span></span>
</td>
<td class="nump">37,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">345,713<span></span>
</td>
<td class="nump">37,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A ordinary shares subject to possible redemption, $0.0001 par value; 500,000,000 shares authorized; 28,000,000 shares issued and outstanding, at redemption value of $10.26 on March&#160;31, 2026 and $10.17 on December&#160;31, 2025, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">287,319,687<span></span>
</td>
<td class="nump">284,776,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred shares, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52,802<span></span>
</td>
<td class="nump">584,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders&#8217; Deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">54,122<span></span>
</td>
<td class="nump">585,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Shareholders&#8217; Deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">287,719,522<span></span>
</td>
<td class="nump">285,400,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member] | Class A Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">120<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member] | Class B Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">984,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,231,689<span></span>
</td>
<td class="nump">$ 969,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_U.s.DollarCoin', window );">U.S. Dollar Coin</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,074,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,830,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,536<span></span>
</td>
<td class="nump">123,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_PrepaidResearchAndDevelopmentExpenses', window );">Prepaid research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_AdvanceToSuppliers', window );">Advance to suppliers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">106,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,030,761<span></span>
</td>
<td class="nump">280,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RefundableDepositsReceivable', window );">Refundable deposits receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">681,125<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,207,626<span></span>
</td>
<td class="nump">2,884,694<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,131,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,303,737<span></span>
</td>
<td class="nump">4,368,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-Current Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,600<span></span>
</td>
<td class="nump">23,696<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Non-Current Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">109,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,600<span></span>
</td>
<td class="nump">23,696<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,240,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,323,337<span></span>
</td>
<td class="nump">4,391,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">743,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,015<span></span>
</td>
<td class="nump">128,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_SimpleAgreementsForFutureEquity', window );">Simple agreements for future equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26,842,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,243,885<span></span>
</td>
<td class="nump">9,321,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositContractsLiabilities', window );">Contract liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">109,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,760<span></span>
</td>
<td class="nump">95,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RefundableDepositsPayable', window );">Refundable deposits payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,174,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,445,580<span></span>
</td>
<td class="nump">223,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">283,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,481<span></span>
</td>
<td class="nump">113,693<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,153,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,319,721<span></span>
</td>
<td class="nump">9,881,828<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,153,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,319,721<span></span>
</td>
<td class="nump">9,881,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">220,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,636<span></span>
</td>
<td class="nump">67,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,134,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,217,035)<span></span>
</td>
<td class="num">(5,557,368)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders&#8217; Deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(20,913,361)<span></span>
</td>
<td class="num">$ (18,280,930)<span></span>
</td>
<td class="num">(12,996,384)<span></span>
</td>
<td class="num">(5,489,983)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Shareholders&#8217; Deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,240,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,323,337<span></span>
</td>
<td class="nump">$ 4,391,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member] | Class A Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member] | Class B Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes an aggregate of 321,429
Ordinary Shares cancelled on September&#160;9, 2025 to the extent that the underwriters&#8217; over-allotment was not exercised.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_AdvanceToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_AdvanceToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_AmountDueToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_AmountDueToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_CashHeldInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_CashHeldInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_PrepaidResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_PrepaidResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_RefundableDepositsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_RefundableDepositsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_RefundableDepositsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_RefundableDepositsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_SimpleAgreementsForFutureEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_SimpleAgreementsForFutureEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_U.s.DollarCoin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_U.s.DollarCoin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositContractsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of liabilities as of the balance sheet date pertaining to amounts received by the insurer or reinsurer from the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483081/340-30-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483054/340-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositContractsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479772/718-30-S55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cik0002065779_ClassAOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cik0002065779_ClassAOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cik0002065779_ClassBOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cik0002065779_ClassBOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares subject to possible redemption outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Shares subject to possible redemption issued</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares subject to possible redemption issued</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares subject to possible redemption issued</a></td>
<td class="nump">28,000,000<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares subject to possible redemption outstanding</a></td>
<td class="nump">28,000,000<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Shares subject to possible redemption , redemption price per share</a></td>
<td class="nump">$ 10.26<span></span>
</td>
<td class="nump">$ 10.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member] | Ordinary Shares Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_SharesSubjectToRedemption', window );">Shares subject to redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member] | Ordinary Shares Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_SharesSubjectToRedemption', window );">Shares subject to redemption</a></td>
<td class="nump">28,000,000<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member] | Class A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member] | Class B Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member] | Class A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member] | Class B Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_SharesSubjectToRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_SharesSubjectToRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=cik0002065779_OrdinarySharesClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=cik0002065779_OrdinarySharesClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=cik0002065779_OrdinarySharesClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=cik0002065779_OrdinarySharesClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cik0002065779_ClassAOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cik0002065779_ClassAOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cik0002065779_ClassBOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cik0002065779_ClassBOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENT OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="4">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2026</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2026</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">$ (590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expenses</a></td>
<td class="num">(590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of per ordinary shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of per ordinary shares Basic</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of per ordinary shares Diluted</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic Loss per ordinary share</a></td>
<td class="num">$ (5.90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (100.00)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted Loss per ordinary share</a></td>
<td class="num">$ (5.90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (100.00)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,420)<span></span>
</td>
<td class="num">$ (531,741)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income on cash held in trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,543,059<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Total other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,543,059<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,420<span></span>
</td>
<td class="nump">$ 2,011,318<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member] | Ordinary Shares Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of per ordinary shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of per ordinary shares Basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">29,200,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of per ordinary shares Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">29,200,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic Loss per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted Loss per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member] | Ordinary Shares Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of per ordinary shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of per ordinary shares Basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,714,286<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of per ordinary shares Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,714,286<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic Loss per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted Loss per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,754,586<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,862,158<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 10,561,331<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,475,885<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 7,015,512<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,319,115<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,808,901)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(859,617)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,477,022)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,110,926)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,150,043)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,901,396)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,221,974)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(646,536)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,818,657)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,462,485)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,044,846)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,845,829)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity', window );">Change in fair value of simple agreements for future equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,410,457)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(890,523)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,098,320)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,716,052)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,614,821)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,110,518)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,167,659)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,649,077)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,902,966)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,827,444)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,910,315)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,263,548)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586,927<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">213,081<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,658,365<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">648,441<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,105,197<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">55,567<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104,729)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(378,511)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(310,582)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(726,914)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(989,155)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(262,614)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(468,696)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(103,107)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(928,255)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(268,159)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(362,982)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(273,349)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,235,476)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(377,999)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,238,185)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,115,853)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,797,906)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,365,433)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,632,431)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,537,059)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,916,977)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,178,537)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,659,667)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,956,347)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,632,431)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1,537,059)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (7,916,977)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (6,178,537)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (7,659,667)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (4,956,347)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of per ordinary shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of per ordinary shares Basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of per ordinary shares Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic Loss per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,754.95)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (1,024.70)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (5,277.98)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (4,119.02)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (5,106.44)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (3,304.23)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted Loss per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,754.95)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (1,024.70)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (5,277.98)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (4,119.02)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (5,106.44)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (3,304.23)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="15"></td></tr>
<tr><td colspan="15"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In January&#160;2026, the Company adopted an Amended and Restated Certificate
        of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#8217;s equity is divided
        into 303 Class A ordinary shares and 1,197 Class B ordinary shares, which are entitled to one (1) vote and twenty (20) votes per share,
        respectively. Despite the differential in voting power, Class A and Class B ordinary shares rank pari passu in all other respects, sharing
        ratably in dividends and any distributions upon liquidation.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s share-based compensation awards are expected to be settled through transfers of existing
        ordinary shares held by the controlling shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary
        shares are included in issued and outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase
        the Company&#8217;s total issued and outstanding shares. During the years ended June&#160;30, 2024 and 2025, diluted net loss per share
        is calculated in the same manner as basic net loss per share.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">During the three and nine months ended March&#160;31, 2025 and 2026, diluted
        net loss per share is calculated in the same manner as basic net loss per share, as the Company was in a net loss position and all potential ordinary shares were anti-dilutive.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cik0002065779_OrdinarySharesClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cik0002065779_OrdinarySharesClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cik0002065779_OrdinarySharesClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cik0002065779_OrdinarySharesClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>D. Boral Arc Merger Corporation [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Exascale Labs Inc. [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>D. Boral ARC Acquisition I Corp [Member]</div>
</th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Exascale Labs Inc. [Member]</div>
</th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th">
<div>Retained Earnings [Member] </div>
<div>D. Boral ARC Acquisition I Corp [Member]</div>
</th>
<th class="th">
<div>Retained Earnings [Member] </div>
<div>Exascale Labs Inc. [Member]</div>
</th>
<th class="th"><div>Subscription Receivable [Member]</div></th>
<th class="th">
<div>Subscription Receivable [Member] </div>
<div>D. Boral ARC Acquisition I Corp [Member]</div>
</th>
<th class="th"><div>Total</div></th>
<th class="th"><div>D. Boral ARC Acquisition I Corp [Member]</div></th>
<th class="th"><div>Exascale Labs Inc. [Member]</div></th>
<th class="th">
<div>Ordinary Shares Class A [Member] </div>
<div>D. Boral ARC Acquisition I Corp [Member]</div>
</th>
<th class="th">
<div>Ordinary Shares Class A [Member] </div>
<div>Exascale Labs Inc. [Member]</div>
</th>
<th class="th">
<div>Ordinary Shares Class B [Member] </div>
<div>D. Boral ARC Acquisition I Corp [Member]</div>
</th>
<th class="th">
<div>Ordinary Shares Class B [Member] </div>
<div>Exascale Labs Inc. [Member]</div>
</th>
<th class="th">
<div>Ordinary Shares [Member] </div>
<div>Exascale Labs Inc. [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (601,021)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (554,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,956,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,956,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,557,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,489,983)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,178,537)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,178,537)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,768<span></span>
</td>
<td class="nump">220,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,420)<span></span>
</td>
<td class="num">(11,735,905)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (25,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,420)<span></span>
</td>
<td class="num">(11,515,254)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,557,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,489,983)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,659,667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,659,667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,217,035)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,996,384)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,198,846)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,079,195)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,537,059)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,537,059)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,768<span></span>
</td>
<td class="nump">220,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,420)<span></span>
</td>
<td class="num">(11,735,905)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,420)<span></span>
</td>
<td class="num">(11,515,254)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 19, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 19, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ClassBOrdinarySharesIssuedToSponsor', window );">Class B ordinary shares issued to Sponsor</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ClassBOrdinarySharesIssuedToSponsorShares', window );">Class B ordinary shares issued to Sponsor, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,768<span></span>
</td>
<td class="nump">220,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,420)<span></span>
</td>
<td class="num">(11,735,905)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,420)<span></span>
</td>
<td class="num">(11,515,254)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 19, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 19, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,455,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,455,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ClassBOrdinarySharesIssuedToSponsor', window );">Class B ordinary shares issued to Sponsor</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ClassBOrdinarySharesIssuedToSponsorShares', window );">Class B ordinary shares issued to Sponsor, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCosts', window );">Sale of Private Units, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,971,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,971,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCostsShares', window );">Sale of Private Units, net of issuance costs, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_IssuanceOfPublicWarrantsNetOfIssuanceCosts', window );">Issuance of Public Warrants, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,913,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,913,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_IssuanceOfRepresentativeShares', window );">Issuance of Representative Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,419,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,419,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_IssuanceOfRepresentativeSharesShares', window );">Issuance of Representative Shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_AccretionInValueOfClassOrdinaryShares', window );">Accretion in value of Class A ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,233,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,301,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,534,462)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ReverseOverallotmentOptionLiability', window );">reverse over-allotment option liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">860,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,290,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ForfeitureOfFounderShares', window );">Forfeiture of founder shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ForfeitureOfFounderSharesShares', window );">Forfeiture of founder shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(321,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_AdjustmentOfAccruedOfferingCosts', window );">Adjustment of accrued offering costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_AccretionInValueOfClassOrdinaryShares', window );">Accretion in value of Class A ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,233,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,301,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,534,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">220,636<span></span>
</td>
<td class="num">$ (590)<span></span>
</td>
<td class="nump">584,543<span></span>
</td>
<td class="num">(18,501,581)<span></span>
</td>
<td class="num">$ (100)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (590)<span></span>
</td>
<td class="nump">585,863<span></span>
</td>
<td class="num">(18,280,930)<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,217,035)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,996,384)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,916,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,916,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RedesignationOfAuthorizedOrdinaryShares', window );">Re-designation of authorized ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RedesignationOfAuthorizedOrdinarySharesShares', window );">Re-designation of authorized ordinary shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">220,636<span></span>
</td>
<td class="num">(10,590)<span></span>
</td>
<td class="nump">52,802<span></span>
</td>
<td class="num">(21,134,012)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,590)<span></span>
</td>
<td class="nump">54,122<span></span>
</td>
<td class="num">(20,913,361)<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 18, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 18, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFee', window );">Common stock issued to initial shareholder for subscription fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFeeShares', window );">Common stock issued to initial shareholder for subscription fee, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">220,636<span></span>
</td>
<td class="num">(590)<span></span>
</td>
<td class="nump">584,543<span></span>
</td>
<td class="num">(18,501,581)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(590)<span></span>
</td>
<td class="nump">585,863<span></span>
</td>
<td class="num">(18,280,930)<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">2,011,318<span></span>
</td>
<td class="num">(2,632,431)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">2,011,318<span></span>
</td>
<td class="num">(2,632,431)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RedesignationOfAuthorizedOrdinaryShares', window );">Re-designation of authorized ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_AccretionInValueOfClassOrdinaryShares', window );">Accretion in value of Class A ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,543,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,543,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_AccretionInValueOfClassOrdinaryShares', window );">Accretion in value of Class A ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,543,059)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,543,059)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RedesignationOfAuthorizedOrdinarySharesShares', window );">Re-designation of authorized ordinary shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 220,636<span></span>
</td>
<td class="num">$ (10,590)<span></span>
</td>
<td class="nump">$ 52,802<span></span>
</td>
<td class="num">$ (21,134,012)<span></span>
</td>
<td class="num">$ (100)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (10,590)<span></span>
</td>
<td class="nump">$ 54,122<span></span>
</td>
<td class="num">$ (20,913,361)<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="20"></td></tr>
<tr><td colspan="20"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes an aggregate of 321,429
Ordinary Shares cancelled on September&#160;9, 2025 to the extent that the underwriters&#8217; over-allotment was not exercised.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_AccretionInValueOfClassOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_AccretionInValueOfClassOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_AdjustmentOfAccruedOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_AdjustmentOfAccruedOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ClassBOrdinarySharesIssuedToSponsor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ClassBOrdinarySharesIssuedToSponsor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ClassBOrdinarySharesIssuedToSponsorShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ClassBOrdinarySharesIssuedToSponsorShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFeeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFeeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ForfeitureOfFounderShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ForfeitureOfFounderShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ForfeitureOfFounderSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ForfeitureOfFounderSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_IssuanceOfPublicWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_IssuanceOfPublicWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_IssuanceOfRepresentativeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_IssuanceOfRepresentativeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_IssuanceOfRepresentativeSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_IssuanceOfRepresentativeSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_RedesignationOfAuthorizedOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_RedesignationOfAuthorizedOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_RedesignationOfAuthorizedOrdinarySharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_RedesignationOfAuthorizedOrdinarySharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ReverseOverallotmentOptionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ReverseOverallotmentOptionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENT OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued Expenses</a></td>
<td class="nump">590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_PaymentOfExpensesThroughRelatedParty', window );">Payment of expenses through related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the beginning of the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the end of period</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued to initial shareholder for subscription fee</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,420<span></span>
</td>
<td class="nump">2,011,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,455,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">308,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Investment income in trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,543,059)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,776,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_PaymentOfExpensesThroughPromissoryNoteRelatedParty', window );">Payment of expenses through promissory note &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,420<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">46,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(203,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(176,764)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(444,761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Investment of cash in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(280,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(280,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of Class B ordinary shares to Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid', window );">Proceeds from sale of Units, net of underwriting discount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from sale of private placement units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225,461)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering', window );">Payment of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(934,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,865,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(176,764)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">420,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the end of period</a></td>
<td class="nump">$ 420,340<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">243,576<span></span>
</td>
<td class="nump">243,576<span></span>
</td>
<td class="nump">420,340<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Forfeiture of founder shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1', window );">Re-measurement of ordinary shares subject to redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,776,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionDescription', window );">Issuance of representative shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2,419,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Deferred offering costs included in promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,420<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1', window );">Accretion of carrying value of redeemable shares to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,543,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,632,431)<span></span>
</td>
<td class="num">(7,916,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,178,537)<span></span>
</td>
<td class="num">$ (7,659,667)<span></span>
</td>
<td class="num">$ (4,956,347)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,565<span></span>
</td>
<td class="nump">5,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,633<span></span>
</td>
<td class="nump">6,234<span></span>
</td>
<td class="nump">4,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,266<span></span>
</td>
<td class="nump">153,266<span></span>
</td>
<td class="nump">21,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquities', window );">Change in fair value of simple agreements for future equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,098,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,716,052<span></span>
</td>
<td class="nump">4,614,821<span></span>
</td>
<td class="nump">3,110,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin', window );">Other operating activities settled in digital assets and U.S. Dollar Coin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,681,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,677,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,483)<span></span>
</td>
<td class="num">(29,204)<span></span>
</td>
<td class="num">(123,332)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_IncreaseDecreaseInAdvanceToSuppliers', window );">Advance to suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">923,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(278,612)<span></span>
</td>
<td class="num">(750,264)<span></span>
</td>
<td class="num">(280,497)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(625,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_IncreaseDecreaseInRefundableDepositsReceivable', window );">Refundable deposits receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150,000)<span></span>
</td>
<td class="num">(571,125)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,707,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,835,770<span></span>
</td>
<td class="nump">1,709,568<span></span>
</td>
<td class="nump">1,515,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">653,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104,717)<span></span>
</td>
<td class="num">(38,025)<span></span>
</td>
<td class="nump">128,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(323,103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,082<span></span>
</td>
<td class="nump">337,434<span></span>
</td>
<td class="nump">95,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_IncreaseDecreaseInRefundableDepositsPayable', window );">Refundable deposits payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(270,878)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,279<span></span>
</td>
<td class="nump">1,222,375<span></span>
</td>
<td class="nump">223,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113,693)<span></span>
</td>
<td class="num">(6,212)<span></span>
</td>
<td class="num">(198,342)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,758,611)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(757,960)<span></span>
</td>
<td class="num">(1,010,799)<span></span>
</td>
<td class="num">(560,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ProceedsFromSaleOfDigitalAssetsAndUsdc', window );">Disposal of digital assets and U.S. Dollar Coin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">606,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,138)<span></span>
</td>
<td class="num">(2,138)<span></span>
</td>
<td class="num">(27,806)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">606,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,138)<span></span>
</td>
<td class="num">(2,138)<span></span>
</td>
<td class="num">(27,806)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_PaymentForDeferredOfferingCosts', window );">Payment for deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ProceedsFromSimpleAgreementsForFutureEquity', window );">Proceeds from Simple agreements for future equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,275,000<span></span>
</td>
<td class="nump">4,275,000<span></span>
</td>
<td class="nump">1,285,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,275,000<span></span>
</td>
<td class="nump">4,275,000<span></span>
</td>
<td class="nump">1,285,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,246,859)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,514,902<span></span>
</td>
<td class="nump">3,262,063<span></span>
</td>
<td class="nump">696,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,231,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">969,626<span></span>
</td>
<td class="nump">969,626<span></span>
</td>
<td class="nump">273,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,484,528<span></span>
</td>
<td class="nump">$ 984,830<span></span>
</td>
<td class="nump">984,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,484,528<span></span>
</td>
<td class="nump">4,231,689<span></span>
</td>
<td class="nump">969,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAssumed1', window );">Investment proceeds received by an employee on behalf of the Company from SAFEs investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">32,500<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income tax paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest expense paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansAssumed1', window );">Investment proceeds received through USDC from SAFEs investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_IncreaseDecreaseInAdvanceToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_IncreaseDecreaseInAdvanceToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_IncreaseDecreaseInRefundableDepositsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_IncreaseDecreaseInRefundableDepositsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_IncreaseDecreaseInRefundableDepositsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_IncreaseDecreaseInRefundableDepositsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_PaymentForDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_PaymentForDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_PaymentOfExpensesThroughPromissoryNoteRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_PaymentOfExpensesThroughPromissoryNoteRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_PaymentOfExpensesThroughRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_PaymentOfExpensesThroughRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ProceedsFromSaleOfDigitalAssetsAndUsdc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ProceedsFromSaleOfDigitalAssetsAndUsdc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ProceedsFromSimpleAgreementsForFutureEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ProceedsFromSimpleAgreementsForFutureEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of loans assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A textual description of the purchase or acquisition through business combination of an asset or business through a noncash (or part noncash) transaction. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the purchase or business combination, as well as the asset acquired and the noncash consideration given (that is, debt, stock, and so forth). Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Organization and Business Operations<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Organization and Business Operations</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--NatureOfOperations_zJC9E8GNL4Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1 &#8212; <span id="xdx_821_zu9lUW4uEBC">Description of Organization and
Business Operations</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Business Operations</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">D. Boral ARC Merger Corporation
(the &#8220;Company&#8221; or &#8220;PubCo&#8221;) is a Delaware company formed by D. Boral ARC Acquisition I Corp. (the &#8220;Parent&#8221;
or &#8220;BCAR&#8221;) on December&#160;19, 2025 (inception). The Company has adopted a fiscal year-end of December&#160;31. The Company
is authorized to issue <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_zZtAwYCwpUPa" title="Common stock, shares authorized">100</span> shares of Common Stock of par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zHBaoiIxdGw7" title="Common stock, par value">0.0001</span> each share. The Company was formed to be the surviving company
in connection with a contemplated business combination between the Parent and a target company. The Company has no principal operations
or revenue producing activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Going Concern</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company was formed by the
Parent. The Parent has until February&#160;1, 2027 to complete its initial business combination (unless further extended). If the Parent
is unable to complete the initial business combination by February&#160;1, 2027, the Parent must cease all operations and dissolve and
liquidate (unless further extended).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The accompanying financial statements
have been prepared assuming that the Company will continue as a going concern. If the Parent is unable to raise additional funds to alleviate
liquidity needs as well as complete a business combination by close of February&#160;1, 2027 (unless further extended), then the Company
will cease all operations except for the purpose of liquidating. The liquidity condition and date for liquidation and subsequent dissolution
raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any
adjustments that might result from the outcome of these uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_80C_eus-gaap--NatureOfOperations_zf7kYOkK4Imf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1 &#8212; <span><span id="xdx_824_zEQebogyAwxh">Description of Organization
and Business Operations</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Business Operations</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">D. Boral ARC Merger Corporation
(the &#8220;Company&#8221; or &#8220;PubCo&#8221;) is a Delaware company formed by D. Boral ARC Acquisition I Corp. (the &#8220;Parent&#8221;
or &#8220;BCAR&#8221;) on December&#160;19, 2025 (inception). The Company has adopted a fiscal year-end of December&#160;31. The Company
is authorized to issue <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_zAlPgdaBLNye" title="Common stock, shares authorized">100</span> shares of Common Stock of par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zyXoKWlrnUJg" title="Common stock, par value">0.0001</span> each share. The Company was formed to be the surviving company
in connection with a contemplated business combination between the Parent and a target company. The Company has no principal operations
or revenue producing activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Going Concern</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company was formed by
the Parent. The Parent has until February&#160;1, 2027 to complete its initial business combination (unless further extended). If the
Parent is unable to complete the initial business combination by February&#160;1, 2027, the Parent must cease all operations and dissolve
and liquidate (unless further extended).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The accompanying financial
statements have been prepared assuming that the Company will continue as a going concern. If the Parent is unable to raise additional
funds to alleviate liquidity needs as well as complete a business combination by close of February&#160;1, 2027 (unless further extended),
then the Company will cease all operations except for the purpose of liquidating. The liquidity condition and date for liquidation and
subsequent dissolution raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements
do not include any adjustments that might result from the outcome of these uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_z3Y09X9ArJqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 &#8212; <span id="xdx_827_z1QOLi23x5K2">Significant Accounting Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zIQgZvNM5Ow6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zJc7JPdBlxC3">Basis of Presentation</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and
pursuant to the rules and regulations of the SEC. The financial statements as of December&#160;31, 2025 and for the period from December&#160;19,
2025 (inception) through December&#160;31, 2025 respectively, are audited. In the opinion of management, the financial statements include
all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating
results and cash flows for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_844_ecustom--EmergingGrowthCompanyPolicyTextBlock_zIflyZXwhT3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zieh9LOsfqE3">Emerging Growth Company</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is an &#8220;emerging
growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of
2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period
which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company,
as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84C_eus-gaap--UseOfEstimates_zfT5mqcHOWl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zE9hBnagYMVa">Use of Estimates</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_841_ecustom--RisksAndUncertaintiesPolicyTextBlock_zOgwh60tmOf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_863_zT2IwjyYxMwg">Risks and Uncertainties</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zkhtSX54qy75" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86C_ziSLvQsMEBHb">Income Taxes</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company complies with the
accounting and reporting requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach to
financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the
financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 740 prescribes a recognition
threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be
taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#8217;s management determined the United States is the Company&#8217;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The provision for income taxes
was deemed to be immaterial for the period from December&#160;19, 2025 (inception) through December&#160;31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z9GnwSb4VdD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Loss Per Share</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company computes basic loss
per share (&#8220;EPS&#8221;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of December&#160;31, 2025 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrqiA2cU5R4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zTUwRw7Nlatj">Fair Value of Financial Instruments</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Fair value is defined as the
price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants
at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active
        markets;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly
        observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets
        that are not active; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity
        to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant
        value drivers are unobservable.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In some circumstances, the inputs
used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value
measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair
value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSNNhvz3V6Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zM7M5EBTVgG3">Recently adopted accounting pronouncements</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November&#160;2023, the FASB
issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose
information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public
entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment
disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since inception.
Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material
effect on the Company&#8217;s financial statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zhfiwIBnxW47" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 &#8212; <span><span id="xdx_82F_z8WT7pqmunKd">Significant Accounting Policies</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoCc0oxIXVye" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86A_zRelC9ayrXw9">Basis of Presentation</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. The financial statements as of March
31, 2026 and for the three months ended March 31, 2026 respectively, are un audited. In the opinion of management, the financial
statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the
financial position, operating results and cash flows for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84E_ecustom--EmergingGrowthCompanyPolicyTextBlock_zxCuTvrFDI99" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_864_zu39EgO8Buwg">Emerging Growth Company</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is an &#8220;emerging
growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act
of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition
period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging
growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because
of the potential differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84A_eus-gaap--UseOfEstimates_zBvkspy1qQI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86E_zvzbCsC8L8Ff">Use of Estimates</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_845_ecustom--RisksAndUncertaintiesPolicyTextBlock_zSX4tZHeTxo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86D_zOSz8DGNyjqf">Risk and Uncertainties</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zAGgh3xYfpt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_865_zOgsMgqR3B78">Income Taxes</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company complies with
the accounting and reporting requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach
to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between
the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 740 prescribes a
recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected
to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#8217;s management determined the United States is the Company&#8217;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provision for income
taxes was deemed to be immaterial for the three months ended March 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z6IKhtn0tFHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_866_z5LJmpNKovA1">Loss Per Share</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company computes basic
loss per share (&#8220;EPS&#8221;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of March 31, 2026 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zPwok5ETZsz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86E_zAu283mu3nxe">Fair Value of Financial Instruments</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Fair value is defined
as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market
participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring
fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments
    in active markets;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly
    or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar
    instruments in markets that are not active; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring
    an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs
    or significant value drivers are unobservable.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In some circumstances, the
inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair
value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the
fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhxo4ncWR2Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zIe1QxnsUF6c">Recently adopted accounting pronouncements</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November&#160;2023, the
FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to
disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis.
Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing
segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since
inception. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would
have a material effect on the Company&#8217;s financial statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment information</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--SegmentReportingDisclosureTextBlock_zWj9pExp7IJj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3&#8201;&#8212;&#8201;<span>Segment Information</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span>&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_823_zBCYtPTrZJgj" style="display: none">Segment information</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 280, &#8220;Segment
Reporting,&#8221; establishes standards for companies to report in their financial statement information about operating segments, products,
services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial
information is available that is regularly evaluated by the Company&#8217;s chief operating decision maker, or group, in deciding how
to allocate resources and assess performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s chief operating
decision maker has been identified as directors (&#8220;CODM&#8221;), who review the operating results for the Company as a whole to make
decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only
has one operating segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">When evaluating the Company&#8217;s
performance and making key decisions regarding resource allocation, the CODM reviews several key metrics, formation and operational costs
which includes the accompanying statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The key measures of segment profit
or loss reviewed by our CODM is formation and operational costs. Formation and operational costs are reviewed and monitored by the CODM
to manage and forecast cash to ensure enough capital is available to complete a business combination within the business combination period.
The CODM also reviews formation and operational costs to manage, maintain and enforce all contractual agreements to ensure costs are aligned
with all agreements and budget.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_800_eus-gaap--SegmentReportingDisclosureTextBlock_ziZWg2OvQdfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3&#8201;&#8212;&#8201;<span><span>Segment Information</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_82C_z7uy5yMbcEtj" style="display: none">Segment information</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 280, &#8220;Segment
Reporting,&#8221; establishes standards for companies to report in their financial statement information about operating segments, products,
services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial
information is available that is regularly evaluated by the Company&#8217;s chief operating decision maker, or group, in deciding how
to allocate resources and assess performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s chief
operating decision maker has been identified as directors (&#8220;CODM&#8221;), who review the operating results for the Company as a
whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the
Company only has one operating segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">When evaluating the Company&#8217;s
performance and making key decisions regarding resource allocation, the CODM reviews several key metrics, formation and operational costs
which includes the accompanying statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The key measures of segment
profit or loss reviewed by our CODM is formation and operational costs. Formation and operational costs are reviewed and monitored by
the CODM to manage and forecast cash to ensure enough capital is available to complete a business combination within the business combination
period. The CODM also reviews formation and operational costs to manage, maintain and enforce all contractual agreements to ensure costs
are aligned with all agreements and budget.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment information</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_803_eus-gaap--SegmentReportingDisclosureTextBlock_zwZU5ZaBhVlh" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 9. <span>SEGMENT INFORMATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_822_zUpXgs0k561c" style="display: none">Segment information</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">ASC Topic 280, &#8220;Segment Reporting,&#8221; establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated by the Company&#8217;s chief operating decision maker, or group, in deciding how to allocate resources and assess performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company&#8217;s chief operating decision maker has been identified as the Chief Financial Officer (&#8220;CODM&#8221;), who reviews the operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one operating segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">When evaluating the Company&#8217;s performance and making key decisions regarding resource allocation the CODM reviews several key metrics, which include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z8FE3uJgARte" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8BC_zLnzHUlq4rs8" style="display: none">Schedule of segment information</span></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_499_20260101__20260331_zAqMewnjj797" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>For the<br/>
Three Months Ended<br/> March&#160;31,<br/>
2026</b></p></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpenses_iNT_di_zLbGcDlF4Xxk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left">Formation and operating costs</td>
    <td style="padding-bottom: 2.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right">(531,741</td>
    <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--InterestIncomeOther_zZ0f6IcMo791" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 2.5pt">Interest income on cash held in trust account</td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right">2,543,059</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--CashHeldInTrustAccounts_zt3sLmGGM7pf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Cash held in Trust Account</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">287,319,687</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zWjH3W0mD6S6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The key measures of segment profit or loss reviewed
by the CODM are formation and operating costs, interest income on cash held in trust account, and cash held in trust account. The CODM
reviews interest earned on cash or investments held in Trust Account to measure and monitor shareholder value and determine the most effective
strategy of investment with the Trust Account funds while maintaining compliance with the trust agreement. Within the operating expenses,
the CODM specifically reviews professional service fees, which are a significant segment expense, and include legal fees and advisory
fees. These expenses are monitored to manage and forecast cash available to complete a Business Combination within the required period.
Other general and administrative expenses, including accounting expenses, printing expenses, and regulatory filing fees, are reviewed
in the aggregate to ensure alignment with budget and contractual obligations. Funds invested in the Trust Account represent the predominant
portion of the Company&#8217;s total assets and are monitored by the CODM to determine the most effective strategy of investment with
the Trust Account funds, while maintaining compliance with the trust agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_809_eus-gaap--SegmentReportingDisclosureTextBlock_zlDYq8wDTeqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. <span>SEGMENT INFORMATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_82A_ziXv0oR4ze67" style="display: none">Segment information</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 280, &#8220;Segment Reporting,&#8221; establishes standards for companies to report in their financial statement information about
operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise
for which separate financial information is available that is regularly evaluated by the Company&#8217;s chief operating decision maker,
or group, in deciding how to allocate resources and assess performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s chief operating decision maker has been identified as the Chief Financial Officer (&#8220;CODM&#8221;), who reviews the
operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly,
management has determined that the Company only has one operating segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
evaluating the Company&#8217;s performance and making key decisions regarding resource allocation the CODM reviews several key metrics,
which include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zV8K2gwOpH16" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span id="xdx_8BC_zWWW3w6SRnKb" style="display: none">Schedule of segment information</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/> Period from <br/>March&#160;20,
        2025<br/>(inception) through<br/>December&#160;31,<br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 2.5pt">Formation
        and operating costs</td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"><span id="xdx_902_eus-gaap--OperatingExpenses_iNT_pp0d_di_c20250320__20251231_zktdSzpr5NMa" title="Formation and operating costs">(320,658</span></td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Interest income on
        cash held in trust account</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--InterestIncomeOther_c20250320__20251231_pp0p" title="Interest income on cash held in trust account">4,776,628</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Cash held in Trust
        Account</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--CashHeldInTrustAccounts_c20250320__20251231_pp0p" title="Cash held in Trust Account">284,776,628</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key measures of segment profit or loss reviewed by the CODM are formation and operating costs, interest income on cash held in trust account,
and cash held in trust account. The CODM reviews interest earned on cash or investments held in Trust Account to measure and monitor shareholder
value and determine the most effective strategy of investment with the Trust Account funds while maintaining compliance with the trust
agreement. Within the operating expenses, the CODM specifically reviews professional service fees, which are a significant segment expense,
and include legal fees and advisory fees. These expenses are monitored to manage and forecast cash available to complete a Business Combination
within the required period. Other general and administrative expenses, including accounting expenses, printing expenses, and regulatory
filing fees, are reviewed in the aggregate to ensure alignment with budget and contractual obligations. Funds invested in the Trust Account
represent the predominant portion of the Company&#8217;s total assets and are monitored by the CODM to determine the most effective strategy
of investment with the Trust Account funds, while maintaining compliance with the trust agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment information</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_805_eus-gaap--SegmentReportingDisclosureTextBlock_zEoFgwHUEmak" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>13.
<span id="xdx_82A_zGToUPHTxt3k">Segment information</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company manages its business in a centralized manner and operates as a single segment and accordingly has only one operating and reportable
segment, the provision of GPU computing platform services. The Company&#8217;s Chief Executive Officer serves as the CODM. The CODM regularly
reviews entity-wide operating results and reviews consolidated revenues and net loss as reported in the statement of operations and comprehensive
loss when making decisions about allocating resources and assessing performance of the segment, and hence, the Group has only&#160;one&#160;reportable
segment.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
primary measures of segment revenue and profitability for the Group&#8217;s operating segment&#160;are considered to be&#160;consolidated&#160;revenue
and net loss.&#160;The CODM uses consolidated revenue to assess market performance and growth, and net loss to evaluate segment profitability
and cost management. Both measures are used together to allocate resources, including employee or capital resources. Significant expense
categories regularly provided to and reviewed by the CODM include those presented in the statements of operations and comprehensive loss
as well as disaggregated expenses of staff costs and employee benefits, professional service expenses, share-based compensation, and other
general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
following table presents the segment information of the Company for the measurement of segment profitability for the three and nine months
ended March&#160;31, 2025 and 2026:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zdn75OK0oi0h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B8_zPb6QMuV4209" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of segment information</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_495_20250101__20250331_zb2RdiMZ4mJg" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_496_20260101__20260331_zSm0FoNHA26" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_495_20240701__20250331_zyMTxSXq4PM5" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_491_20250701__20260331_zadqFxbEPU4i" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td> </tr>
  <tr id="xdx_401_eus-gaap--Revenues_zI3a3deH3fwf" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenues</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">1,862,158</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">3,754,586</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">4,475,885</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">10,561,331</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_407_eus-gaap--CostOfRevenue_pp0d_zMTLZ9zSLNl4" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Cost
        of revenues</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(1,649,077</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(3,167,659</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(3,827,444</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(8,902,966</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr id="xdx_40C_eus-gaap--GrossProfit_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Gross
        profit</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>213,081</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>586,927</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>648,441</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>1,658,365</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_iN_pp0d_di_zn8IOfQoWaoe" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Research
        and development expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(377,999</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,235,476</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(2,115,853</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(3,238,185</td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_408_eus-gaap--SellingAndMarketingExpenseAbstract_iB_zVd2FY3RkMFc" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Selling
        and marketing expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_407_ecustom--StaffCostsEmployeeBenefitsAndOfficeExpenses_i_pp0p" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#8211;
        Staff costs, employee benefits and office expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(277,511</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(104,729</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(573,648</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(310,582</td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_407_ecustom--ShareBasedCompensations_zJ7xD2oOp4Ui" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#8211;
        Share-based compensation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(101,000</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3876">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(153,266</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3878">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">General
        and administrative expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40A_ecustom--StaffCostsEmployeeBenefitsAndOthers_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#8211;
        Staff costs, employee benefits and Others</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(3,890</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(360,657</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(33,785</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(563,641</td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_40B_eus-gaap--ProfessionalAndContractServicesExpense_iN_di_z78VitJx7Eo3" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">&#8211;
        Professional service expenses</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(99,217</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(108,039</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(234,374</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(364,614</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Loss
        from operations</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(646,536</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(1,221,974</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(2,462,485</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(2,818,657</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td> </tr>
  <tr id="xdx_40D_ecustom--ChangeInFairValueOfSimpleAgreementsForFutureEquity_iN_di_z4jz79hEVis9" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Change
        in fair value of simple agreements for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(890,523</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,410,457</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(3,716,052</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(5,098,320</td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Income
        tax expenses</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3905">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3906">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3907">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3908">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_400_eus-gaap--ProfitLoss_zq0n3eRYdw7k" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Net
        loss</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(1,537,059</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(2,632,431</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(6,178,537</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(7,916,977</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td> </tr>
  </table>

<p id="xdx_8A0_zZ3FKbItpbC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Substantially
all of the Company&#8217;s long-lived assets are located in the United States. The following table presents the Company&#8217;s revenue
from major geographical areas for the periods indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zIPxDBsoGFvj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details 1)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B4_z6QXFE6MCFp1" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of geographic information</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">United
        States of America</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90A_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total">581,009</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total">1,564,836</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total">1,273,279</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_901_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total">4,560,992</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Canada</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total">367,107</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total">1,139,055</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total">1,089,559</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total">3,232,326</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Singapore</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total">662,559</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total">425,009</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total">1,361,844</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total">1,237,464</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Hong Kong</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total">150,000</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total">417,992</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total">450,000</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total">1,118,534</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">United
        Kingdom</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total">98,483</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total">207,694</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total">291,203</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total">412,015</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Others</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total">3,000</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl3959">-</span></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total">10,000</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl3963">-</span></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_908_eus-gaap--Revenues_pp0d_c20250101__20250331_zUms2zS7QOY6" title="Total">1,862,158</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_907_eus-gaap--Revenues_pp0d_c20260101__20260331_z3I7DIpNDZGg" title="Total">3,754,586</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_908_eus-gaap--Revenues_pp0d_c20240701__20250331_zsHyuymBBcp8" title="Total">4,475,885</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_906_eus-gaap--Revenues_pp0d_c20250701__20260331_zWKBKmLtNdw2" title="Total">10,561,331</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

<p id="xdx_8AB_z1dwOhMrHlX7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_zw6BQqHEgLZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>14. <span id="xdx_821_z4EX1JG2ykx6">Segment information</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company manages its business in a centralized
manner and operates as a single segment and accordingly has only one operating and reportable segment, the provision of GPU computing
platform services. The Company&#8217;s Chief Executive Officer serves as the Chief Operating Decision Maker (&#8220;CODM&#8221;). The
CODM regularly reviews entity-level operating results, including revenue and net loss as presented in the statement of operations and
comprehensive loss, when making decisions about resource allocation and assessing segment performance. Therefore, the Company has one
reportable segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary measures of segment revenue and profitability
for the Company&#8217;s operating segment&#160;are considered to be&#160;revenue and net loss. The CODM uses revenue to assess market
performance and growth, and net loss to evaluate profitability and cost management. Both measures are used together to allocate resources,
including personnel and capital resources. Significant expense categories regularly provided to and reviewed by the CODM include those
presented in the statements of operations and comprehensive loss as well as disaggregated expenses of staff costs and employee benefits,
professional service expenses, share-based compensation, and other general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents the segment information
of the Company for the measurement of segment profitability for the years ended June&#160;30, 2024 and 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zaZ6gYRQMRih" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B7_z0szaN7zwBSj" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b>Schedule
    of segment information</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_490_20230701__20240630_zry6rmEzVCB1" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_49D_20240701__20250630_zCZ2bAgyHGX5" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the<br/> years ended</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Revenues_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Revenues</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">1,319,115</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">7,015,512</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CostOfRevenue_zNi1liCsOXci" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cost of revenues</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,263,548</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(5,910,315</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_iN_di_zkj1o72qnmk8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Research and development expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,365,433</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(2,797,906</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--SellingAndMarketingExpenseAbstract_i01B_pp0d_zxMJN07A1pXg" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Selling and marketing expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--StaffCostsEmployeeBenefitsAndOfficeExpenses_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#8211; Staff costs, employee benefits and
        office expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(262,614</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(835,889</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--ShareBasedCompensations_i01_pp0d_z9QrXvmlrCpc" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#8211; Share-based compensation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2606">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(153,266</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--SellingGeneralAndAdministrativeExpenseAbstract_i01B_pp0d_zDwHZaCWa85" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">General and administrative expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StaffCostsEmployeeBenefitsAndOthers_i01_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#8211; Staff costs, employee benefits and
        Others</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(244,651</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(328,662</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--ProfessionalAndContractServicesExpense_i01N_di_zh2ZOZkpFGtk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#8211; Professional service expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(7,594</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(34,320</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--ShareBasedCompensation1_i01N_pp0d_di_zzVfAlQURxe7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#8211; Share-based compensation</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(21,104</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2619">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_i01_pp0d_z65lbRpLFMOh" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Loss
        from operations</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,845,829</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,044,846</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--ChangeInFairValueOfSimpleAgreementsForFutureEquity_i01N_di_zLicrVyEo7og" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Change in fair value
        of simple agreements for future equity</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(3,110,518</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(4,614,821</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeLossBeforeReclassificationsTax_i01_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Loss
        before income tax expenses</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(4,956,347</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(7,659,667</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Income tax expense</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2630">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2631">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProfitLoss_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Net
        loss</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(4,956,347</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(7,659,667</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A8_zMAAq6XghBbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Geographic Information</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As substantially all of the Company&#8217;s long-lived
assets are located in the United States, no geographical segments of assets are presented. The following table presents the Company&#8217;s
revenue from major geographical areas for the periods indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zxaRjvXJPaOg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BE_zWpnQqztGuFi" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Schedule of geographic information</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <br/>years ended <br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Singapore</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total">260,941</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total">2,484,905</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">United States of America</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--US_pp0p" title="Total">169,600</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--US_pp0p" title="Total">2,085,579</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Canada</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total">574,664</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total">1,443,306</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Hong Kong</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total">157,500</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total">600,000</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">United Kingdom</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total">145,410</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total">391,722</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Others</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total">11,000</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total">10,000</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90E_eus-gaap--Revenues_pp0d_c20230701__20240630_zoK7sngi7uI1" title="Total">1,319,115</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90F_eus-gaap--Revenues_pp0d_c20240701__20250630_zJvmNbPZ8VZg" title="Total">7,015,512</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zSK0DbrUr1O8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--BusinessCombinationDisclosureTextBlock_zJxmo93c5NE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4 &#8212; <span id="xdx_825_zpHDqrU5OLkc">Business Combination</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January&#160;11, 2026, D. Boral
ARC Acquisition I Corp. (&#8220;BCAR&#8221; or the &#8220;Company&#8221;) entered into the Agreement and Plan of Merger (the &#8220;Merger
Agreement&#8221;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly owned subsidiary of BCAR (&#8220;PubCo&#8221;),
D. Boral Arc Merger Sub Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and a wholly-owned subsidiary of BCAR, and Exascale Labs
Inc.., a Delaware corporation (&#8220;Exascale&#8221;). Pursuant to the Merger Agreement, the Business Combination will be effected in
two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into PubCo, with PubCo remaining as the surviving
publicly traded entity (the &#8220;Reincorporation Merger&#8221;); (ii) after the Reincorporation Merger, Merger Sub will be merged with
and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#8220;Acquisition Merger&#8221; and together with
the Reincorporation Merger, the &#8220;Business Combination&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The aggregate consideration for
the Acquisition Merger is $<span id="xdx_906_ecustom--AggregateConsideration_c20260101__20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_pp0p" title="Aggregate consideration">500,000,000</span> (the &#8220;Merger Consideration&#8221;), payable in the form of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_pd" title="New shares issued">50,000,000</span> newly issued shares
of common stock of PubCo valued at $<span id="xdx_902_eus-gaap--SharePrice_c20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_pd" title="Share Price">10.00</span> per share to Exascale and its shareholders. At the closing of the Acquisition Merger (the &#8220;Closing&#8221;),
the issued and outstanding shares in Exascale held by the former Exascale shareholders will be cancelled and cease to exist as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #FFFFFF; text-align: justify">Each issued and
        outstanding share of Exascale Class B common stock shall be cancelled and converted into the right to receive a number of shares of PubCo
        Class B common stock (the &#8220;PubCo Class B Shares&#8221;) equal to the quotient obtained by dividing (a) the quotient equal to the
        Merger Consideration divided by the fully diluted Exascale capitalization (the &#8220;Per Share Merger Consideration&#8221;) by (b) Ten
        Dollars ($10.00), with each such PubCo Class B Share having twenty (20) votes per share; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #FFFFFF; text-align: justify">Each issued and
        outstanding share of Exascale Class A common stock shall be cancelled and converted into the right to receive a number of shares of PubCo
        Class A common stock (the &#8220;PubCo Class A Shares&#8221;) equal to the quotient obtained by dividing (a) the Per Share Merger Consideration
        by (b) Ten Dollars ($10.00), with each such PubCo Class A Share having one (1) vote per share.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_809_eus-gaap--BusinessCombinationDisclosureTextBlock_zz0pi87aYuh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4 &#8212; <span><span id="xdx_82A_zmgpl2ui5l4b">Business Combination</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January&#160;11, 2026,
D. Boral ARC Acquisition I Corp. (&#8220;BCAR&#8221; or the &#8220;Company&#8221;) entered into the Agreement and Plan of Merger (the
&#8220;Merger Agreement&#8221;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly owned subsidiary
of BCAR (&#8220;PubCo&#8221;), D. Boral Arc Merger Sub Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and a wholly-owned subsidiary
of BCAR, and Exascale Labs Inc.., a Delaware corporation (&#8220;Exascale&#8221;). Pursuant to the Merger Agreement, the Business Combination
will be effected in two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into PubCo, with PubCo remaining
as the surviving publicly traded entity (the &#8220;Reincorporation Merger&#8221;); (ii) after the Reincorporation Merger, Merger Sub
will be merged with and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#8220;Acquisition Merger&#8221;
and together with the Reincorporation Merger, the &#8220;Business Combination&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The aggregate consideration
for the Acquisition Merger is $<span id="xdx_900_ecustom--AggregateConsideration_pp0d_c20260101__20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_zXXqwXv1BXGd" title="Aggregate consideration">500,000,000</span> (the &#8220;Merger Consideration&#8221;), payable in the form of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_zocbYDaoU3K4" title="New shares issued">50,000,000</span> newly issued shares
of common stock of PubCo valued at $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20260111__us-gaap--BusinessAcquisitionAxis__custom--DBoralARCAcquisitionICorp.Member_zRXflzuZMDy4" title="Share Price">10.00</span> per share to Exascale and its shareholders. At the closing of the Acquisition Merger (the &#8220;Closing&#8221;),
the issued and outstanding shares in Exascale held by the former Exascale shareholders will be cancelled and cease to exist as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #FFFFFF; text-align: justify">Each
    issued and outstanding share of Exascale Class B common stock shall be cancelled and converted into the right to receive a number
    of shares of PubCo Class B common stock (the &#8220;PubCo Class B Shares&#8221;) equal to the quotient obtained by dividing (a) the
    quotient equal to the Merger Consideration divided by the fully diluted Exascale capitalization (the &#8220;Per Share Merger Consideration&#8221;)
    by (b) Ten Dollars ($10.00), with each such PubCo Class B Share having twenty (20) votes per share; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; background-color: #FFFFFF; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #FFFFFF; text-align: justify">Each
    issued and outstanding share of Exascale Class A common stock shall be cancelled and converted into the right to receive a number
    of shares of PubCo Class A common stock (the &#8220;PubCo Class A Shares&#8221;) equal to the quotient obtained by dividing (a) the
    Per Share Merger Consideration by (b) Ten Dollars ($10.00), with each such PubCo Class A Share having one (1) vote per share.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 46<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-46<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 45<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-45<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479326/805-40-45-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-30/tableOfContent<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-20/tableOfContent<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-10/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Share Capital</a></td>
<td class="text"><p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zhxdEDXzYVGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 5 &#8212; <span id="xdx_826_z8QPFSfZW7Qi">Share Capital</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company is authorized to issue
<span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_z5fNqfWf2Exk" title="Common stock, shares authorized">100</span> shares of Common Stock of par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zUx4YfEZD1lg" title="Common stock, par value">0.0001</span> each share. Holders of the Company&#8217;s common stock are entitled to one vote for each
share. On December&#160;19, 2025, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zATkjkJr6MK4" title="Common stock issued">100</span> shares of common stock to its Parent D. Boral ARC Acquisition I Corp., at a purchase
price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_z76UKaf0Ad1g" title="Purchase price">1.00</span> per share, or an aggregate purchase price of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0d_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zeyJujuSXK4h" title="Aggregate purchase price">100</span>. The subscription fee was not received yet as of December&#160;31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z85SDJ4YhdWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 5 &#8212; <span><span id="xdx_822_zaJ0zlFDAKm2">Share Capital</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company is authorized
to issue 100 shares of Common Stock of par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zGw25nXRyHs8" title="Common stock, par value">0.0001</span> each share. Holders of the Company&#8217;s common stock are entitled to one
vote for each share. On December&#160;19, 2025, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zTgHwRfLctwa" title="Common stock issued">100</span> shares of common stock to its Parent D. Boral ARC Acquisition
I Corp., at a purchase price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zFcXUa3HlvSa" title="Purchase price">1.00</span> per share, or an aggregate purchase price of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0d_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zAz0GKFnQxRf" title="Aggregate purchase price">100</span>. The subscription fee was not received yet as
of March 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zdsxE17ClwOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 6 &#8212; <span id="xdx_827_zf6PwHW1lV13">Subsequent Events</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In preparing the financial statements,
the Company considered disclosures of events occurring after December&#160;31, 2025, until the issuance of the financial statements. Based
on this review, the Company identified the following subsequent event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January&#160;11, 2026, D. Boral
ARC Acquisition I Corp. (&#8220;BCAR&#8221; or the &#8220;Company&#8221;) entered into the Agreement and Plan of Merger (the &#8220;Merger
Agreement&#8221;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly owned subsidiary of BCAR (&#8220;PubCo&#8221;),
D. Boral Arc Merger Sub Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and a wholly-owned subsidiary of BCAR, and Exascale Labs
Inc.., a Delaware corporation (&#8220;Exascale&#8221;).</p>

<span></span>
</td>
<td class="text"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zjwom0VPgJzj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 6 &#8212; <span><span id="xdx_828_z3M5gtjk58V7">Subsequent Events</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In preparing the financial
statements, the Company considered disclosures of events occurring after March 31, 2026, until the issuance of the financial statements.
Based on this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial
statements.</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zi2Xqda1MaI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 10. <span>SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_829_zMAhencS9Vr8" style="display: none">Subsequent Events</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">In accordance with ASC Topic 855, &#8220;Subsequent Events&#8221;, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued, the Company has evaluated all events or transactions that occurred through the date the consolidated condensed financial statements were available to issue. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zAojbVU1a7zi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. <span>SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_826_zmvFa0ix0mr6" style="display: none">Subsequent Events</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC Topic 855, &#8220;Subsequent Events&#8221;, which establishes general standards of accounting for and disclosure of
events that occur after the balance sheet date but before consolidated financial statements are issued, the Company has evaluated all
events or transactions that occurred up to the date the consolidated financial statements were available to issue. Based upon this review,
the Company identified the following subsequent events:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January&#160;11, 2026, D. Boral ARC Acquisition I Corp. (&#8220;BCAR&#8221; or the &#8220;Company&#8221;) entered into the Agreement and
Plan of Merger (the &#8220;Merger Agreement&#8221;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly
owned subsidiary of BCAR (&#8220;PubCo&#8221;), D. Boral Arc Merger Sub Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and a
wholly-owned subsidiary of BCAR, and Exascale Labs Inc., a Delaware corporation (&#8220;Exascale&#8221;). Pursuant to the Merger Agreement,
the Business Combination will be effected in two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into
PubCo, with PubCo remaining as the surviving publicly traded entity (the &#8220;Reincorporation Merger&#8221;); (ii) after the Reincorporation
Merger, Merger Sub will be merged with and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#8220;Acquisition
Merger&#8221; and together with the Reincorporation Merger, the &#8220;Business Combination&#8221;).&#160;</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zRLEv2ZbvEdd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>15.
Subsequent events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_82A_zSew4Do77Ac5" style="display: none">Subsequent Events</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company
evaluated all events and transactions that occurred after March&#160;31, 2026, up through June&#160;11, 2026, which is the date that
these unaudited condensed consolidated financial statements are issued, unless as disclosed elsewhere, no other material subsequent events
occurred that would require recognition or disclosure in the Company&#8217;s unaudited condensed consolidated financial statements.</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zFgRhy6z3nKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>16. <span>Subsequent events</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span><span id="xdx_829_zHJhA3sZiti7" style="display: none">Subsequent Events</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluated all events and transactions
that occurred after June&#160;30, 2025, up through February&#160;11, 2026, which is the date that these financial statements are issued,
unless as disclosed elsewhere and below, there was no other material subsequent events occurred that would require recognition or disclosure
in the Company&#8217;s financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Incorporation of a Subsidiary</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December&#160;16, 2025, subsequent to the reporting
period but prior to the authorization of these financial statements for issue, the Company incorporated its wholly-owned subsidiary, Evana
Alpha Pte. Ltd., in Singapore. The Company subscribed for all <span id="xdx_90A_ecustom--OrdinarySharesIssued_c20251201__20251216__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_pd" title="Ordinary shares issued">1,000</span> ordinary shares of the subsidiary, with a issued share capital of
Singapore Dollars <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251201__20251216__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_pd" title="Number of shares issued">1,000</span>. The subsidiary&#8217;s principal business activity is information technology consultancy (excluding cybersecurity).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>SAFEs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From October&#160;1, 2025 to <span style="color: #0F1115; color: #0F1115">February&#160;11,</span>
2026, certain institutional and accredited investors provided $<span id="xdx_903_eus-gaap--ProceedsFromSaleOfNotesReceivable_pn3n3_dm_c20251001__20260211__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_zobhxoREKnUk" title="Proceeds from safes">0.5</span>&#160;million to the Company in the form of SAFEs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Capital Structure and Dual-Class Share Reclassification</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January&#160;2026, the Company adopted an Amended
and Restated Certificate of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#8217;s
equity is divided into Class A Ordinary Shares and Class B Ordinary Shares, which are entitled to one (1) vote and twenty (20) votes per
share, respectively. Despite the differential in voting power, Class A and Class B Ordinary Shares rank pari passu in all other respects,
sharing ratably in dividends and any distributions upon liquidation. Furthermore, all outstanding warrants, options, and SAFEs are designated
to convert or settle exclusively into Class A Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Business combination agreement and related events</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January&#160;2026, the Company entered into an
BCA with BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and a direct, wholly owned subsidiary of BCAR and D. Boral Arc
Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary of BCAR. Upon closing of the transaction, the combined company
will be named Exascale Labs Holdings Inc. and is expected to be traded on a national securities exchange. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate consideration for the Business Combination
is $<span id="xdx_902_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_dm_c20260101__20260131_z970NdDaFbca" title="Business combination payable">500.0</span> million, payable by the surviving publicly traded entity in the form of <span id="xdx_90F_ecustom--OrdinarySharesIssued_c20260101__20260131_pd" title="Ordinary shares issued">50,000,000</span> newly issued ordinary shares valued at $<span id="xdx_90D_ecustom--OrdinarySharesPerShare_c20260101__20260131_pd" title="ordinary shares per share">10.00
</span>per share. At the effective time of the merger of the Company into the surviving publicly traded entity pursuant to the BCA, the Company&#8217;s
outstanding ordinary shares and outstanding SAFEs are expected to be cancelled and converted into the right to receive shares of the surviving
publicly traded entity in accordance with the terms of the BCA and the applicable SAFE instruments. Class A ordinary shares are expected
to have one vote per share, and Class B ordinary shares are expected to have 20 votes per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of February&#160;11, 2026, the transactions contemplated
by the BCA had not been consummated. Accordingly, the Company has not recorded any amounts in these financial statements related to the
BCA, as it represents a non-recognized subsequent event.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--NatureOfOperations_zJC9E8GNL4Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1 &#8212; <span id="xdx_821_zu9lUW4uEBC">Description of Organization and
Business Operations</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Business Operations</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">D. Boral ARC Merger Corporation
(the &#8220;Company&#8221; or &#8220;PubCo&#8221;) is a Delaware company formed by D. Boral ARC Acquisition I Corp. (the &#8220;Parent&#8221;
or &#8220;BCAR&#8221;) on December&#160;19, 2025 (inception). The Company has adopted a fiscal year-end of December&#160;31. The Company
is authorized to issue <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_zZtAwYCwpUPa" title="Common stock, shares authorized">100</span> shares of Common Stock of par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zHBaoiIxdGw7" title="Common stock, par value">0.0001</span> each share. The Company was formed to be the surviving company
in connection with a contemplated business combination between the Parent and a target company. The Company has no principal operations
or revenue producing activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Going Concern</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company was formed by the
Parent. The Parent has until February&#160;1, 2027 to complete its initial business combination (unless further extended). If the Parent
is unable to complete the initial business combination by February&#160;1, 2027, the Parent must cease all operations and dissolve and
liquidate (unless further extended).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The accompanying financial statements
have been prepared assuming that the Company will continue as a going concern. If the Parent is unable to raise additional funds to alleviate
liquidity needs as well as complete a business combination by close of February&#160;1, 2027 (unless further extended), then the Company
will cease all operations except for the purpose of liquidating. The liquidity condition and date for liquidation and subsequent dissolution
raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any
adjustments that might result from the outcome of these uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_80C_eus-gaap--NatureOfOperations_zf7kYOkK4Imf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1 &#8212; <span><span id="xdx_824_zEQebogyAwxh">Description of Organization
and Business Operations</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Business Operations</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">D. Boral ARC Merger Corporation
(the &#8220;Company&#8221; or &#8220;PubCo&#8221;) is a Delaware company formed by D. Boral ARC Acquisition I Corp. (the &#8220;Parent&#8221;
or &#8220;BCAR&#8221;) on December&#160;19, 2025 (inception). The Company has adopted a fiscal year-end of December&#160;31. The Company
is authorized to issue <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_zAlPgdaBLNye" title="Common stock, shares authorized">100</span> shares of Common Stock of par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zyXoKWlrnUJg" title="Common stock, par value">0.0001</span> each share. The Company was formed to be the surviving company
in connection with a contemplated business combination between the Parent and a target company. The Company has no principal operations
or revenue producing activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Going Concern</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company was formed by
the Parent. The Parent has until February&#160;1, 2027 to complete its initial business combination (unless further extended). If the
Parent is unable to complete the initial business combination by February&#160;1, 2027, the Parent must cease all operations and dissolve
and liquidate (unless further extended).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The accompanying financial
statements have been prepared assuming that the Company will continue as a going concern. If the Parent is unable to raise additional
funds to alleviate liquidity needs as well as complete a business combination by close of February&#160;1, 2027 (unless further extended),
then the Company will cease all operations except for the purpose of liquidating. The liquidity condition and date for liquidation and
subsequent dissolution raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements
do not include any adjustments that might result from the outcome of these uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_80C_eus-gaap--NatureOfOperations_zygend9e1RRc" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 1. <span id="xdx_82D_zrYalJ697s07">DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">D. BORAL ARC
ACQUISITION I CORP. (the &#8220;Company&#8221;) is a blank check company incorporated in the British Virgin Islands on March&#160;20,
2025. The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase,
reorganization or similar business combination with one or more businesses (&#8220;Business Combination&#8221;). While the Company may
pursue an acquisition opportunity in any business, industry, sector or geographical location, the Company intends to focus on industries
that complement our management team&#8217;s background, and to capitalize on the ability of our management team to identify and acquire
a business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31,
2026, the Company had not yet commenced any operations. All activity through March 31, 2026 related to the Company&#8217;s formation
and the Initial Public Offering (as defined below). Since the IPO, the Company&#8217;s activity has been limited to the costs in pursuit
of the consummation of an initial business combination. The Company will not generate any operating revenues until after the completion
of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on
cash and cash equivalents from the proceeds derived from the Initial Public Offering. The Company has selected December&#160;31 as its
fiscal year end. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated
with early stage and emerging growth companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company&#8217;s sponsor is MFH 1, LLC (the &#8220;Sponsor&#8221;). The registration statement for the Company&#8217;s Initial Public Offering was declared effective on July&#160;30, 2025. On August&#160;1, 2025, the Company consummated its Initial Public Offering of <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zZC60ip9O139" title="Sale of units in initial public offering">25,000,000</span> units (the &#8220;Units&#8221; and, with respect to the Class A Ordinary Shares included in the Units being offered, the &#8220;Public Shares&#8221;), at $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z3ISudk5ZSw6" title="Sale of units per share">10.00</span> per Unit, generating gross proceeds of $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zjX8VKK92qjd" title="Sale of units in initial public offering aggragate amount">250,000,000</span> (the &#8220;Initial Public Offering&#8221;). The Company granted the underwriter a 45-day option to purchase up to an additional <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z9eUpL924fa5" title="Sale of units in initial public offering">3,750,000</span> Units at the Initial Public Offering price to cover over-allotments, if any. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Simultaneously with the consummation of the closing of the Offering, the Company consummated the private placement of an aggregate of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGrtbDdoicDg" title="Sale of units in initial public offering">200,000</span> units (the &#8220;Placement Units&#8221;) to the Sponsor at a price of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zABeT3cNd0K6" title="Sale of units per share">10.00</span> per Unit, generating gross proceeds of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zm3i9GAh1wZ" title="Sale of units in initial public offering aggragate amount">2,000,000</span> (the &#8220;Private Placement&#8221;). (see Note 4).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Transaction costs amounted to $<span id="xdx_90C_ecustom--TransactionCosts_pp0p0_c20260101__20260331_zlNHw2cetME1" title="Transaction costs">3,582,634</span>, consisting of $<span id="xdx_905_ecustom--RepresentativeShares_pp0p0_c20260101__20260331_zpYwsp2Au2o7" title="Representative shares">2,419,400</span> of the Representative Shares (discussed in the below) and $<span id="xdx_90B_ecustom--OtherOfferingCosts_pp0p0_c20260101__20260331_z1IYHYmkc8Vf" title="Other offering costs">1,163,234</span> of other offering costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">In conjunction with the IPO, the Company issued to the underwriter <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zC8C67MdLPre" title="Number of share issued">1,000,000</span> Class A ordinary shares for no consideration (the &#8220;Representative Shares&#8221;). The fair value of the Representative Shares accounted for as compensation under Accounting Standards Codification (&#8220;ASC&#8221;) 718, &#8220;Compensation &#8211; Stock Compensation&#8221; (&#8220;ASC 718&#8221;) is included in the offering costs. The estimated fair value of the Representative Shares as of the IPO date totaled $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zHyEfQAcbCTg" title="Number of share issued, value">2,419,400</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Following the closing of the Initial Public Offering on August&#160;1, 2025, an amount of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_ziUw4vAAKbAd" title="proceeds from sale of initial public offering">250,000,000</span> ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and a portion of the proceeds from the sale of the Placement Units was placed in a trust account (the &#8220;Trust Account&#8221;), located in the United States and held as cash items and will be invested only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule&#160;2a-7 under the Investment Company Act, that invest only in direct U.S. government treasury obligations; the holding of these assets in this form is intended to be temporary and for the sole purpose of facilitating the intended business combination. To mitigate the risk that the Company might be deemed to be an investment company for purposes of the Investment Company Act, which risk increases the longer that the Company hold investments in the trust account, the Company may, at any time (based on our management team&#8217;s ongoing assessment of all factors related to our potential status under the Investment Company Act), instruct the trustee to liquidate the investments held in the trust account and instead to hold the funds in the trust account in cash or in an interest bearing demand deposit account at a bank.</p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">On August&#160;11, 2025, the underwriters of the IPO notified the Company of their partial exercise of the over-allotment option and purchased <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zJQr08Hr1169" title="Sale of units in initial public offering">3,000,000</span> additional units (the &#8220;Option Units&#8221;) at $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zGc1BiSVx6Wi" title="Sale of units per share">10.00</span> per unit upon the closing of the over-allotment option, generating gross proceeds of $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zwO1mOZUQPp7" title="Sale of units in initial public offering aggragate amount">30,000,000</span>. The over-allotment option closed on August&#160;13, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">On September 9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option. As a result,&#160;on September 9, 2025,&#160;the Company cancelled a total of <span id="xdx_90C_ecustom--CancelledFounderShares_c20250905__20250909_zMn2lTaGsGg9" title="Cancelled founder shares">321,429</span> of the Company&#8217;s founder shares, issued to MFH 1, LLC thereby reducing the sponsor&#8217;s total shares to <span id="xdx_90F_ecustom--CancelledFounderShares_c20250729__20250801_zE8aHeKIinuh" title="Cancelled founder shares">12,000,000</span>, which was effective from August 1, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of our initial business combination either (i) in connection with a shareholder meeting called to approve the initial business combination or (ii) by means of a tender offer. In connection with a proposed Business Combination, the Company may seek shareholder approval of a Business Combination at a meeting called for such purpose at which shareholders may seek to redeem their shares, regardless of how they vote for the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zvYo0cYwbk22" title="Sale of units per share">10.00</span> per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter. These ordinary shares was recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its amended and restated memorandum and articles of association conduct the redemptions pursuant to Rule&#160;13e-4 and Regulation 14E of the Exchange Act, which regulate issuer tender offers, and file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The sponsor, officers and directors have entered
into a letter agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to
their founder shares, private shares and public shares in connection with the completion of our initial business combination; (ii)
waive their redemption rights with respect to their founder shares, private shares and public shares in connection with a
shareholder vote to approve an amendment to our amended and restated memorandum and articles of association; (iii) waive their
rights to liquidating distributions from the trust account with respect to their founder shares and private shares if the Company
fail to complete our initial business combination within the completion window, although they will be entitled to liquidating
distributions from the trust account with respect to any public shares they hold if the Company fail to complete our initial
business combination within the prescribed time frame and to liquidating distributions from assets outside the trust account; and
(iv) vote any founder shares and private shares held by them and any public shares they may purchase (including in open market and privately-negotiated transactions) in favor of our initial business combination (except that
any public shares such parties may purchase in compliance with the requirements of Rule&#160;14e-5 under the Exchange Act would not
be voted in favor of approving the business combination transaction).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company will have until 18 months from the closing of the Initial Public Offering, with one (1) three-month extension at the option of the sponsor (as may be extended by shareholder approval to amend our amended and restated memorandum and articles of association to extend the date by which the Company must consummate our initial business combination) or until such earlier liquidation date as our board of directors may approve, to consummate a Business Combination (the &#8220;Combination Period&#8221;). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter (and subject to lawfully available funds therefor), redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (which interest shall be net of taxes and less up to $<span id="xdx_901_eus-gaap--LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_iI_c20251231_zW7hO2wBkNSk" title="Dissolution expenses">100,000</span> of interest to pay dissolution expenses), divided by the number of then-outstanding public shares, which redemption will completely extinguish public shareholders&#8217; rights as shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors, liquidate and dissolve, subject in each case to our obligations under British Virgin Islands law to provide for claims of creditors and the requirements of other applicable law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The underwriter
has agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event the Company does not complete
a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust
Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the
per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Sponsor has
agreed that it will be liable to us if and to the extent any claims by a third party for services rendered or products sold to us (except
for the Company&#8217;s independent auditors), or a prospective target business with which the Company has entered into a written letter
of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in the trust account
to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account as of the date
of the liquidation of the trust account, if less than $10.00 per public share due to reductions in the value of the trust assets, less
taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed
a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply
to any claims under our indemnity of the underwriters of our IPO against certain liabilities, including liabilities under the Securities
Act. However, the Company has not asked our sponsor to reserve for such indemnification obligations, nor has the Company independently
verified whether our sponsor has sufficient funds to satisfy its indemnity obligations and the Company believe that our sponsor&#8217;s
only assets are securities of our company. Therefore, the Company cannot assure you that our sponsor would be able to satisfy those obligations.
As a result, if any such claims were successfully made against the trust account, the funds available for our initial business combination
and redemptions could be reduced to less than $10.00 per public share. In such event, the Company may not be able to complete our initial
business combination, and you would receive such lesser amount per share in connection with any redemption of your public shares. None
of our officers or directors will indemnify us for claims by third parties including, without limitation, claims by vendors and prospective
target businesses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January&#160;11,
2026, D. Boral ARC Acquisition I Corp. (&#8220;BCAR&#8221; or the &#8220;Company&#8221;) entered into the Agreement and Plan of Merger
(the &#8220;Merger Agreement&#8221;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly owned subsidiary
of BCAR (&#8220;PubCo&#8221;), D. Boral Arc Merger Sub Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and a wholly-owned subsidiary
of BCAR, and Exascale Labs Inc., a Delaware corporation (&#8220;Exascale&#8221;). Pursuant to the Merger Agreement, the Business Combination
will be effected in two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into PubCo, with PubCo remaining
as the surviving publicly traded entity (the &#8220;Reincorporation Merger&#8221;); (ii) after the Reincorporation Merger, Merger Sub
will be merged with and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#8220;Acquisition Merger&#8221;
and together with the Reincorporation Merger, the &#8220;Business Combination&#8221;).&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate
consideration for the Acquisition Merger is $500,000,000 (the &#8220;Merger Consideration&#8221;), payable in the form of 50,000,000
newly issued shares of common stock of PubCo valued at $10.00 per share to Exascale and its shareholders. At the closing of the Acquisition
Merger (the &#8220;Closing&#8221;), the issued and outstanding shares in Exascale held by the former Exascale shareholders will be cancelled
and cease to exist as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt;">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt;">Each issued and outstanding
    share of Exascale Class B common stock shall be cancelled and converted into the right to receive a number of shares of PubCo Class
    B common stock (the &#8220;PubCo Class B Shares&#8221;) equal to the quotient obtained by dividing (a) the quotient equal to the
    Merger Consideration divided by the fully diluted Exascale capitalization (the &#8220;Per Share Merger Consideration&#8221;) by (b)
    Ten Dollars ($10.00), with each such PubCo Class B Share having twenty (20) votes per share; and</span></td></tr>
  </table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt;">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt;">Each issued and outstanding
    share of Exascale Class A common stock shall be cancelled and converted into the right to receive a number of shares of PubCo Class
    A common stock (the &#8220;PubCo Class A Shares&#8221;) equal to the quotient obtained by dividing (a) the Per Share Merger Consideration
    by (b) Ten Dollars ($10.00), with each such PubCo Class A Share having one (1) vote per share.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>Liquidity, Capital Resources and Going Concern
Consideration</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">As of March 31, 2026, the Company had $<span id="xdx_90D_eus-gaap--Cash_iI_pp0p0_c20260331_zcgybPa75Rrh" title="Cash">243,576</span> of cash in its operating bank account and working capital of $<span id="xdx_90E_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20260331_z6EhFQhvkWk2" title="Working capital deficit">54,122</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company&#8217;s liquidity needs prior to the
consummation of the Initial Public Offering were satisfied through the payment of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--FounderSharesMember_zDESmG0pruoc" title="Proceeds from issuance of common stock">25,000</span>
from the Sponsor to cover for certain offering costs on the Company&#8217;s behalf in exchange for issuance of Founder Shares (as
defined in Note 4), and loan from the Sponsor of $<span id="xdx_90F_eus-gaap--LoansPayable_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zcxmPKgrvA99" title="Loan payable">225,461</span>
under the Note (as defined in Note 4). On August&#160;1, 2025, the Company has repaid $<span id="xdx_903_eus-gaap--RepaymentOfNotesReceivableFromRelatedParties_c20250729__20250801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zL71zekeZW5i" title="Repayment of promissory note">225,461</span>
under the promissory note. Subsequent to the consummation of the Initial Public Offering, the Company&#8217;s liquidity has been
satisfied through the net proceeds from the consummation of the Initial Public Offering and the Private Placement held outside of
the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an
affiliate of the Sponsor, or certain of the Company&#8217;s officers and directors may, but are not obligated to, provide the
Company Working Capital Loans (as defined in Note 4). As of December&#160;31, 2025 and March&#160;31, 2026, there were no amounts
outstanding under any Working Capital Loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expects
to incur significant costs in pursuit of its acquisition plans and will not generate any operating revenues until after the completion
of its initial business combination. In addition, the Company expects to have negative cash flows from operations as it pursues an initial
business combination target. In connection with the Company&#8217;s assessment of going concern considerations in accordance with Accounting
Standards Update (&#8220;ASU&#8221;) 2014-15, &#8220;Disclosures of Uncertainties about an Entity&#8217;s Ability to Continue as a Going
Concern&#8221; the Company does not currently have adequate liquidity to sustain operations, which consist solely of pursuing a Business
Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company may
raise additional capital through loans or additional investments from the Sponsor or its shareholders, officers, directors, or third
parties. The Company&#8217;s officers and directors and the Sponsor may, but are not obligated to (except as described above), loan the
Company funds, from time to time, in whatever amount they deem reasonable in their sole discretion, to meet the Company&#8217;s working
capital needs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As is customary
for a special purpose acquisition company, if the Company is not able to consummate a Business Combination during the Combination Period,
it will cease all operations and redeem the Public Shares. Management plans to continue its efforts to consummate a Business Combination
during the Combination Period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">While the Company expects to have access to
additional sources of capital if necessary, there is no current commitment on the part of any financing source to provide additional
capital and no assurances can be provided that such additional capital will ultimately be available. The liquidity condition and
mandatory liquidation raise substantial doubt about the Company&#8217;s ability to continue as a going concern until the earlier of
the consummation of the Business Combination or the date the Company is required to liquidate. There is no assurance that the
Company&#8217;s plans to raise additional capital (to the extent ultimately necessary) or to consummate a Business Combination will
be successful or successful within the Combination Period. The consolidated condensed financial statements do not include any
adjustments that might result from the outcome of this uncertainty.</p>




















<span></span>
</td>
<td class="text"><p id="xdx_803_eus-gaap--NatureOfOperations_zLLaTa8ZGhCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. <span id="xdx_82D_zfE85CfSiSl">DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
BORAL ARC ACQUISITION I CORP. (the &#8220;Company&#8221;) is a blank check company incorporated in the British Virgin Islands on March&#160;20,
2025. The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more businesses (&#8220;Business Combination&#8221;). While the Company may pursue an acquisition
opportunity in any business, industry, sector or geographical location, the Company intends to focus on industries that complement our
management team&#8217;s background, and to capitalize on the ability of our management team to identify and acquire a business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December&#160;31, 2025, the Company had not yet commenced any operations. All activity through December&#160;31, 2025 related to the Company&#8217;s
formation and the Initial Public Offering (as defined below). The Company will not generate any operating revenues until after the completion
of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on
cash and cash equivalents from the proceeds derived from the Initial Public Offering. The Company has selected December&#160;31 as its
fiscal year end. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated
with early stage and emerging growth companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s sponsor is MFH 1, LLC (the &#8220;Sponsor&#8221;). The registration statement for the Company&#8217;s Initial Public Offering
was declared effective on July&#160;30, 2025. On August&#160;1, 2025, the Company consummated its Initial Public Offering of <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zymewYmUk4Hc" title="Sale of units in initial public offering">25,000,000</span>
units (the &#8220;Units&#8221; and, with respect to the Class A Ordinary Shares included in the Units being offered, the &#8220;Public
Shares&#8221;), at $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zLpBFIdH2am2" title="Sale of units per share">10.00</span> per Unit, generating gross proceeds of $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zeMvai1aOgU5" title="Sale of units in initial public offering aggragate amount">250,000,000</span> (the &#8220;Initial Public Offering&#8221;). The Company
granted the underwriter a 45-day option to purchase up to an additional <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zvvgsX2GXdI2" title="Sale of units in initial public offering">3,750,000</span> Units at the Initial Public Offering price to cover
over-allotments, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously
with the consummation of the closing of the Offering, the Company consummated the private placement of an aggregate of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z1oRfYkYwYg7" title="Sale of units in initial public offering">200,000</span> units (the
&#8220;Placement Units&#8221;) to the Sponsor at a price of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ztuGwqkmsSn4" title="Sale of units per share">10.00</span> per Unit, generating gross proceeds of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z6JLWVjCNLD2" title="Sale of units in initial public offering aggragate amount">2,000,000</span> (the &#8220;Private
Placement&#8221;). (see Note 4).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction
costs amounted to $<span id="xdx_90D_ecustom--TransactionCosts_pp0p0_c20250320__20251231_zWv4AjHSzFBk" title="Transaction costs">3,582,634</span>, consisting of $<span id="xdx_900_ecustom--RepresentativeShares_pp0p0_c20250320__20251231_zfnVet6jBnE8" title="Representative shares">2,419,400</span> of the Representative Shares (discussed in the below) and $<span id="xdx_900_ecustom--OtherOfferingCosts_pp0p0_c20250320__20251231_zzbsFZ9QoI29" title="Other offering costs">1,163,234</span> of other offering
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with the IPO, the Company issued to the underwriter <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_z9JyvNUCifek" title="Number of share issued">1,000,000</span> Class A ordinary shares for no consideration (the &#8220;Representative
Shares&#8221;). The fair value of the Representative Shares accounted for as compensation under Accounting Standards Codification (&#8220;ASC&#8221;)
718, &#8220;Compensation &#8211; Stock Compensation&#8221; (&#8220;ASC 718&#8221;) is included in the offering costs. The estimated fair
value of the Representative Shares as of the IPO date totaled $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zkjrdeMbCkic" title="Number of share issued, value">2,419,400</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the closing of the Initial Public Offering on August&#160;1, 2025, an amount of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zAYQK4eRIMDe" title="proceeds from sale of initial public offering">250,000,000</span> ($10.00 per Unit) from the net proceeds of
the sale of the Units in the Initial Public Offering and a portion of the proceeds from the sale of the Placement Units was placed in
a trust account (the &#8220;Trust Account&#8221;), located in the United States and held as cash items and will be invested only in U.S.
government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule&#160;2a-7 under
the Investment Company Act, that invest only in direct U.S. government treasury obligations; the holding of these assets in this form
is intended to be temporary and for the sole purpose of facilitating the intended business combination. To mitigate the risk that the
Company might be deemed to be an investment company for purposes of the Investment Company Act, which risk increases the longer that the
Company hold investments in the trust account, the Company may, at any time (based on our management team&#8217;s ongoing assessment of
all factors related to our potential status under the Investment Company Act), instruct the trustee to liquidate the investments held
in the trust account and instead to hold the funds in the trust account in cash or in an interest bearing demand deposit account at a
bank.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August&#160;11, 2025, the underwriters of the IPO notified the Company of their partial exercise of the over-allotment option and purchased
<span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zDA2VnME7U0b" title="Sale of units in initial public offering">3,000,000</span> additional units (the &#8220;Option Units&#8221;) at $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zR9U3nh9D7Y8" title="Sale of units per share">10.00</span> per unit upon the closing of the over-allotment option, generating
gross proceeds of $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zlDHmMAY5wM4" title="Sale of units in initial public offering aggragate amount">30,000,000</span>. The over-allotment option closed on August&#160;13, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September&#160;9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and
thereby forfeit the option. As a result,&#160;on September&#160;9, 2025,&#160;the Company cancelled a total of <span id="xdx_905_ecustom--CancelledFounderShares_c20250905__20250909_zuJm4Jjl1XIk" title="Cancelled founder shares">321,429</span> of the Company&#8217;s
founder shares, issued to MFH 1, LLC thereby reducing the sponsor&#8217;s total shares to <span id="xdx_909_ecustom--CancelledFounderShares_c20250729__20250801_z24hspa4c7wl" title="Cancelled founder shares">12,000,000</span>, which was effective from August&#160;1,
2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion
of our initial business combination either (i) in connection with a shareholder meeting called to approve the initial business combination
or (ii) by means of a tender offer. In connection with a proposed Business Combination, the Company may seek shareholder approval of a
Business Combination at a meeting called for such purpose at which shareholders may seek to redeem their shares, regardless of how they
vote for the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially
$<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zi26VOwh3vcj" title="Sale of units per share">10.00</span> per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company
to pay its tax obligations). The per-share amount to be distributed to shareholders who redeem their Public Shares will not be reduced
by the deferred underwriting commissions the Company will pay to the underwriter. These ordinary shares was recorded at a redemption value
and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification
(&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other reasons, the Company
will, pursuant to its amended and restated memorandum and articles of association conduct the redemptions pursuant to Rule&#160;13e-4
and Regulation 14E of the Exchange Act, which regulate issuer tender offers, and file tender offer documents with the SEC prior to completing
our initial business combination which contain substantially the same financial and other information about the initial business combination
and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sponsor, officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed to (i) waive
their redemption rights with respect to their founder shares, private shares and public shares in connection with the completion of our
initial business combination; (ii) waive their redemption rights with respect to their founder shares, private shares and public shares
in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and articles of association; (iii)
waive their rights to liquidating distributions from the trust account with respect to their founder shares and private shares if the
Company fail to complete our initial business combination within the completion window, although they will be entitled to liquidating
distributions from the trust account with respect to any public shares they hold if the Company fail to complete our initial business
combination within the prescribed time frame and to liquidating distributions from assets outside the trust account; and (iv) vote any
founder shares and private shares held by them and any public shares they may purchase (including in open market and privately-negotiated
transactions) in favor of our initial business combination (except that any public shares such parties may purchase in compliance with
the requirements of Rule&#160;14e-5 under the Exchange Act would not be voted in favor of approving the business combination transaction).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will have until 18 months from the closing of the Initial Public Offering, with one (1) three-month extension at the option of
the sponsor (as may be extended by shareholder approval to amend our amended and restated memorandum and articles of association to extend
the date by which the Company must consummate our initial business combination) or until such earlier liquidation date as our board of
directors may approve, to consummate a Business Combination (the &#8220;Combination Period&#8221;). If the Company is unable to complete
a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up,
(ii) as promptly as reasonably possible but not more than ten business days thereafter (and subject to lawfully available funds therefor),
redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including
interest earned on the funds held in the trust account (which interest shall be net of taxes and less up to $<span id="xdx_900_eus-gaap--LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_iI_c20251231_zMMxKKn8j5Nc" title="Dissolution expenses">100,000</span> of interest to pay
dissolution expenses), divided by the number of then-outstanding public shares, which redemption will completely extinguish public shareholders&#8217;
rights as shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii)
as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors,
liquidate and dissolve, subject in each case to our obligations under British Virgin Islands law to provide for claims of creditors and
the requirements of other applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriter has agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event the Company
does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds
held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is
possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price
per Unit ($10.00).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sponsor has agreed that it will be liable to us if and to the extent any claims by a third party for services rendered or products sold
to us (except for the Company&#8217;s independent auditors), or a prospective target business with which the Company has entered into
a written letter of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in
the trust account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account
as of the date of the liquidation of the trust account, if less than $10.00 per public share due to reductions in the value of the trust
assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business
who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will
it apply to any claims under our indemnity of the underwriters of our IPO against certain liabilities, including liabilities under the
Securities Act. However, the Company has not asked our sponsor to reserve for such indemnification obligations, nor has the Company independently
verified whether our sponsor has sufficient funds to satisfy its indemnity obligations and the Company believe that our sponsor&#8217;s
only assets are securities of our company. Therefore, the Company cannot assure you that our sponsor would be able to satisfy those obligations.
As a result, if any such claims were successfully made against the trust account, the funds available for our initial business combination
and redemptions could be reduced to less than $10.00 per public share. In such event, the Company may not be able to complete our initial
business combination, and you would receive such lesser amount per share in connection with any redemption of your public shares. None
of our officers or directors will indemnify us for claims by third parties including, without limitation, claims by vendors and prospective
target businesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January&#160;11, 2026, D. Boral ARC Acquisition I Corp. (&#8220;BCAR&#8221; or the &#8220;Company&#8221;) entered into the Agreement and
Plan of Merger (the &#8220;Merger Agreement&#8221;) by and among BCAR, D. Boral ARC Merger Corporation, a Delaware corporation and wholly
owned subsidiary of BCAR (&#8220;PubCo&#8221;), D. Boral Arc Merger Sub Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and a
wholly-owned subsidiary of BCAR, and Exascale Labs Inc., a Delaware corporation (&#8220;Exascale&#8221;). Pursuant to the Merger Agreement,
the Business Combination will be effected in two steps: (i) BCAR will reincorporate in the State of Delaware by merging with and into
PubCo, with PubCo remaining as the surviving publicly traded entity (the &#8220;Reincorporation Merger&#8221;); (ii) after the Reincorporation
Merger, Merger Sub will be merged with and into Exascale, resulting in Exascale being a wholly owned subsidiary of PubCo (the &#8220;Acquisition
Merger&#8221; and together with the Reincorporation Merger, the &#8220;Business Combination&#8221;).&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate consideration for the Acquisition Merger is $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250320__20251231_zLQu92JYDcL4" title="Share newly issued of common stock">500,000,000</span> (the &#8220;Merger Consideration&#8221;), payable in the form of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250320__20251231_zrpwY2DyvnT9" title="Share newly issued of common stock, shares">50,000,000</span>
newly issued shares of common stock of PubCo valued at $10.00 per share to Exascale and its shareholders. At the closing of the Acquisition
Merger (the &#8220;Closing&#8221;), the issued and outstanding shares in Exascale held by the former Exascale shareholders will be cancelled
and cease to exist as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each issued and outstanding share
        of Exascale Class B common stock shall be cancelled and converted into the right to receive a number of shares of PubCo Class B common
        stock (the &#8220;PubCo Class B Shares&#8221;) equal to the quotient obtained by dividing (a) the quotient equal to the Merger Consideration
        divided by the fully diluted Exascale capitalization (the &#8220;Per Share Merger Consideration&#8221;) by (b) Ten Dollars ($10.00), with
        each such PubCo Class B Share having twenty (20) votes per share; and</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each issued and outstanding share
        of Exascale Class A common stock shall be cancelled and converted into the right to receive a number of shares of PubCo Class A common
        stock (the &#8220;PubCo Class A Shares&#8221;) equal to the quotient obtained by dividing (a) the Per Share Merger Consideration by (b)
        Ten Dollars ($10.00), with each such PubCo Class A Share having one (1) vote per share.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity,
Capital Resources and Going Concern Consideration</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December&#160;31, 2025, the Company had $<span id="xdx_901_eus-gaap--Cash_iI_pp0p0_c20251231_zBQBHTAL4Sk4" title="Cash">420,340</span> of cash in its operating bank account and working capital of $<span id="xdx_904_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20251231_zaoDT1sVQ0Cb" title="Working capital deficit">585,863</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through the payment of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--FounderSharesMember_zd9iA0x85lrl">25,000</span>
from the Sponsor to cover for certain offering costs on the Company&#8217;s behalf in exchange for issuance of Founder Shares (as defined
in Note 4), and loan from the Sponsor of $<span id="xdx_900_eus-gaap--LoansPayable_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z97qhlWYqK2h">225,461</span> under the Note (as defined in Note 4). On August&#160;1, 2025, the Company has repaid
$<span id="xdx_903_eus-gaap--RepaymentOfNotesReceivableFromRelatedParties_c20250729__20250801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zb9jcZE28Ibk">225,461</span> under the promissory note. Subsequent to the consummation of the Initial Public Offering, the Company&#8217;s liquidity has been
satisfied through the net proceeds from the consummation of the Initial Public Offering and the Private Placement held outside of the
Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate
of the Sponsor, or certain of the Company&#8217;s officers and directors may, but are not obligated to, provide the Company Working Capital
Loans (as defined in Note 4). As of December&#160;31, 2025, there were no amounts outstanding under any Working Capital Loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to incur significant costs in pursuit of its acquisition plans and will not generate any operating revenues until after
the completion of its initial business combination. In addition, the Company expects to have negative cash flows from operations as it
pursues an initial business combination target. In connection with the Company&#8217;s assessment of going concern considerations in accordance
with Accounting Standards Update (&#8220;ASU&#8221;) 2014-15, &#8220;Disclosures of Uncertainties about an Entity&#8217;s Ability to Continue
as a Going Concern&#8221; the Company does not currently have adequate liquidity to sustain operations, which consist solely of pursuing
a Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may raise additional capital through loans or additional investments from the Sponsor or its shareholders, officers, directors,
or third parties. The Company&#8217;s officers and directors and the Sponsor may, but are not obligated to (except as described above),
loan the Company funds, from time to time, in whatever amount they deem reasonable in their sole discretion, to meet the Company&#8217;s
working capital needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is customary for a special purpose acquisition company, if the Company is not able to consummate a Business Combination during the Combination
Period, it will cease all operations and redeem the Public Shares. Management plans to continue its efforts to consummate a Business Combination
during the Combination Period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company expects to have access to additional sources of capital if necessary, there is no current commitment on the part of any financing
source to provide additional capital and no assurances can be provided that such additional capital will ultimately be available. The
liquidity condition and mandatory liquidation raise substantial doubt about the Company&#8217;s ability to continue as a going concern
until the earlier of the consummation of the Business Combination or the date the Company is required to liquidate. There is no assurance
that the Company&#8217;s plans to raise additional capital (to the extent ultimately necessary) or to consummate a Business Combination
will be successful or successful within the Combination Period. The consolidated financial statements do not include any adjustments that
might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_z3Y09X9ArJqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 &#8212; <span id="xdx_827_z1QOLi23x5K2">Significant Accounting Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zIQgZvNM5Ow6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zJc7JPdBlxC3">Basis of Presentation</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and
pursuant to the rules and regulations of the SEC. The financial statements as of December&#160;31, 2025 and for the period from December&#160;19,
2025 (inception) through December&#160;31, 2025 respectively, are audited. In the opinion of management, the financial statements include
all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating
results and cash flows for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_844_ecustom--EmergingGrowthCompanyPolicyTextBlock_zIflyZXwhT3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zieh9LOsfqE3">Emerging Growth Company</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is an &#8220;emerging
growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of
2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period
which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company,
as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84C_eus-gaap--UseOfEstimates_zfT5mqcHOWl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zE9hBnagYMVa">Use of Estimates</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_841_ecustom--RisksAndUncertaintiesPolicyTextBlock_zOgwh60tmOf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_863_zT2IwjyYxMwg">Risks and Uncertainties</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zkhtSX54qy75" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86C_ziSLvQsMEBHb">Income Taxes</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company complies with the
accounting and reporting requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach to
financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the
financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 740 prescribes a recognition
threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be
taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#8217;s management determined the United States is the Company&#8217;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The provision for income taxes
was deemed to be immaterial for the period from December&#160;19, 2025 (inception) through December&#160;31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z9GnwSb4VdD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Loss Per Share</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company computes basic loss
per share (&#8220;EPS&#8221;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of December&#160;31, 2025 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrqiA2cU5R4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zTUwRw7Nlatj">Fair Value of Financial Instruments</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Fair value is defined as the
price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants
at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active
        markets;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly
        observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets
        that are not active; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity
        to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant
        value drivers are unobservable.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In some circumstances, the inputs
used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value
measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair
value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSNNhvz3V6Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zM7M5EBTVgG3">Recently adopted accounting pronouncements</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November&#160;2023, the FASB
issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose
information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public
entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment
disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since inception.
Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material
effect on the Company&#8217;s financial statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zhfiwIBnxW47" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 &#8212; <span><span id="xdx_82F_z8WT7pqmunKd">Significant Accounting Policies</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoCc0oxIXVye" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86A_zRelC9ayrXw9">Basis of Presentation</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. The financial statements as of March
31, 2026 and for the three months ended March 31, 2026 respectively, are un audited. In the opinion of management, the financial
statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the
financial position, operating results and cash flows for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84E_ecustom--EmergingGrowthCompanyPolicyTextBlock_zxCuTvrFDI99" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_864_zu39EgO8Buwg">Emerging Growth Company</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is an &#8220;emerging
growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act
of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition
period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging
growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because
of the potential differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84A_eus-gaap--UseOfEstimates_zBvkspy1qQI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86E_zvzbCsC8L8Ff">Use of Estimates</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_845_ecustom--RisksAndUncertaintiesPolicyTextBlock_zSX4tZHeTxo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86D_zOSz8DGNyjqf">Risk and Uncertainties</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zAGgh3xYfpt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_865_zOgsMgqR3B78">Income Taxes</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company complies with
the accounting and reporting requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach
to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between
the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 740 prescribes a
recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected
to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#8217;s management determined the United States is the Company&#8217;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provision for income
taxes was deemed to be immaterial for the three months ended March 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z6IKhtn0tFHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_866_z5LJmpNKovA1">Loss Per Share</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company computes basic
loss per share (&#8220;EPS&#8221;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of March 31, 2026 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zPwok5ETZsz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86E_zAu283mu3nxe">Fair Value of Financial Instruments</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Fair value is defined
as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market
participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring
fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments
    in active markets;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly
    or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar
    instruments in markets that are not active; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring
    an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs
    or significant value drivers are unobservable.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In some circumstances, the
inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair
value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the
fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhxo4ncWR2Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zIe1QxnsUF6c">Recently adopted accounting pronouncements</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November&#160;2023, the
FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to
disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis.
Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing
segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since
inception. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would
have a material effect on the Company&#8217;s financial statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zwMIFdJLnGU" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 2. <span id="xdx_820_zHeBz4zKHT1d">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z0IWy53sD0Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_865_z1Rf2RuPJR21">Basis of Presentation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The accompanying consolidated condensed financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
and pursuant to the rules and regulations of the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Certain information and note disclosures normally
included in the annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been
condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to
make the information not misleading. The interim financial statements as of March 31, 2026 and for the three months ended March 31, 2026
are unaudited. In the opinion of management, the consolidated condensed financial statements include all adjustments, consisting only of normal
recurring adjustments, necessary to provide a fair statement of the results for the periods. The accompanying balance sheet as of December
31, 2025, is derived from the audited financial statements presented in the Company&#8217;s Annual Report on Form 10-K for the year ended
December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_845_ecustom--EmergingGrowthCompanyPolicyTextBlock_zmhW1kdqSIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_86C_zt6czdzfWEih">Emerging Growth Company</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Further, Section&#160;102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make
comparison of the Company&#8217;s consolidated financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--UseOfEstimates_zQYZj3djUeb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_864_zRzz8424e6p3">Use of Estimates</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The preparation of consolidated condensed financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the consolidated condensed financial statements and the
reported amounts of revenues and expenses during the reporting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Making estimates requires management to exercise
significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances
that existed at the date of the consolidated condensed financial statements, which management considered in formulating its estimate,
could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly
from those estimates.</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>















<p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPzrLcIyQfel" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_860_zu37CGZfznfc">Cash and Cash Equivalents</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company considers all highly liquid
investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents are carried at
cost, which approximates fair value. The Company had $<span id="xdx_90E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20251231_zKSiK1lJFQo5">420,340</span> and $<span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20260331_zBLVCNltQyz5">243,576</span>
in cash as of December&#160;31, 2025 and March&#160;31, 2026, respectively. The Company had <span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20251231_zHKchSeuPLR4" title="Cash equivalents"><span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20260331_zbssSpEVMX26" title="Cash equivalents">no</span></span>
cash equivalents as of December&#160;31, 2025 and March&#160;31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_844_ecustom--CashHeldInTrustAccountPolicyTextBlock_zf23zmDeFAC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"><b><span id="xdx_863_zgMHfmHrvZ42">Cash Held in Trust Account</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company had $<span id="xdx_90F_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20251231_z5sY6BBpp9d4">284,776,628</span> and $<span id="xdx_905_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20260331_zKMPpHYYWvXd">287,319,687</span>
a of cash in the trust account held in an interest bearing demand deposit account as of December 31, 2025 and March&#160;31,
2026, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84F_ecustom--OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock_z7CN7IDO18Rg" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_860_zF0eseXwdsYe">Offering Costs Associated with the Initial Public Offering</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212;
&#8220;Expenses of Offering.&#8221; Deferred offering costs consist principally of professional and registration fees that are related
to the Initial Public Offering. Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 470-20, &#8220;Debt with Conversion and
Other Options,&#8221; addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components.
The Company applies this guidance to allocate Initial Public Offering proceeds from the Public Units between Class A ordinary shares and
warrants based on their relative fair values. Offering costs allocated to the Class A ordinary shares subject to possible redemption were
charged to temporary equity, and offering costs allocated to the warrants included in the Public Units and Private Units were charged
to shareholder&#8217;s equity as the warrants, after management&#8217;s evaluation, were accounted for under equity treatment. As of August&#160;1,
2025, the Company had offering costs of $<span id="xdx_903_ecustom--OfferingCost_iI_pp0p0_c20250801_z4hgPDFmpaOa" title="Offering costs">3,582,634</span>,
consisting of $<span id="xdx_901_ecustom--RepresentativeShares_c20250729__20250801_z17XWIvrJ0Ql" title="Representative shares">2,419,400</span>
of the Representative Shares (as discussed in Note 1) and $<span id="xdx_903_ecustom--OtherOfferingCost_pp0p0_c20250729__20250801_z3stLaw1Yk4h" title="Other offering costs">1,163,234</span>
of other offering costs. Approximately $<span id="xdx_90C_eus-gaap--OtherExpenses_pp0p0_c20250729__20250801_zacUbSCdNTya" title="other costs">143,775</span>
of such costs were allocated to the Public Warrants and the Private Placement Units and the remainder, approximately $<span id="xdx_90D_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_c20250801_z05aQ6gzdoVi" title="Ordinary shares subject to redemption">3,438,859</span>
was allocated to Class A ordinary shares subject to redemption. As of December&#160;31, 2025, the Company had offering costs of $<span id="xdx_900_ecustom--OfferingCost_iI_pp0p0_c20251231_zXALNb75mMuc" title="Offering costs">3,582,634</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_z77b7DWKM4ee" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_86A_zVc6ABTVy162">Income Taxes</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company complies with the accounting and reporting
requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach to financial accounting and
reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the consolidated financial
statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws
and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established,
when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">ASC Topic 740 prescribes a recognition threshold and a measurement
attribute for the consolidated financial statement recognition and measurement of tax positions taken or expected to be taken in a tax
return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.
The Company&#8217;s management determined the British Virgin Islands is the Company&#8217;s only major tax jurisdiction. The Company recognizes
accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were no unrecognized tax benefits
as of March 31, 2026 and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review
that could result in significant payments, accruals or material deviation from its position. The Company is considered to be an exempted
British Virgin Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income
tax filing requirements in the British Virgin Islands or the United States. As such, the provision for income taxes was deemed to be <i>de
minimis</i> for the three months ended March 31, 2026.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>















<p id="xdx_840_eus-gaap--ExtendedProductWarrantyPolicy_zIfpp4pkn1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_863_zpXKgEMQKf8">Warrant Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">We account for Warrants as either equity-classified
or liability-classified instruments based on an assessment of the instruments&#8217; specific terms and applicable authoritative guidance
in ASC 480 and FASB ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;). The assessment considers whether the
instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to
a company&#8217;s common shares and whether the instrument holders could potentially require &#8220;net cash settlement&#8221; in a circumstance
outside of a company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional
judgment, is conducted at the time of Warrant issuance and as of each subsequent quarterly period end date while the instruments are outstanding.
Upon review of the Warrant Agreement, Management concluded that the&#160;public warrants and private warrants issued pursuant to such
warrant agreement qualify for equity accounting treatment.&#160;Following the closing of the Initial Public Offering on August&#160;1,
2025 and underwriter&#8217;s exercise of over-allotment option on August&#160;13, 2025, the Company accounted for the&#160;<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331_zZXCPtdZIUn7" title="Warrants issued">14,000,000</span>
public warrants and&#160;<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zV9MLoZewlLk" title="Warrants issued">100,000</span> private warrants issued under equity treatment at their assigned values.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84F_ecustom--ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_zd7Gejgazmwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_86B_zNHDcMFMuEE">Class A Ordinary Shares Subject to Possible Redemption</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The public shares contain
a redemption feature which allows for the redemption of such public shares in connection with the Company&#8217;s liquidation, or if
there is a shareholder vote or tender offer in connection with the Company&#8217;s initial Business Combination. In accordance with
ASC 480-10-S99, the Company classifies public shares subject to redemption outside of permanent equity as the redemption provisions
are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as they occur and
will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately
upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount
value. The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the
extent available) and Retained earnings. Accordingly, Class A ordinary shares subject to possible redemption are presented at
redemption value as temporary equity, outside of the shareholders&#8217; equity section of the Company&#8217;s balance sheet. As of
March 31, 2026 and December 31, 2025, the 28,000,000 Class A ordinary shares subject to redemption reflected in the balance sheet
are reconciled in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--TemporaryEquityTableTextBlock_zI3yMm7Bm2me" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B8_zvz98VUo83yh" style="display: none">Schedule of ordinary shares subject to redemption</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Class A ordinary shares subject to possible redemption, December 31, 2025</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_c20260101__20260331_zuYUa9ZjRBt2" style="text-align: right">284,776,628</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Plus:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top">Accretion of carrying value to redemption value</td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td>
    <td id="xdx_98D_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20260101__20260331_zjT475ucOqx7" style="border-bottom: Black 1pt solid; width: 9%; text-align: right">2,543,059</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Class A ordinary shares subject to possible redemption, March 31, 2026</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_c20260101__20260331_zXneNCCbjKKh" style="border-bottom: Black 2.5pt double; text-align: right">287,319,687</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>










<p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zWhlay9HXAC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_866_zIRLAGvnsr1d">Net (Loss)/Income per Ordinary Share</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share.&#8221; Net income per share of ordinary shares is computed by dividing net income applicable to ordinary shareholders by the weighted average number of shares of ordinary shares outstanding during the period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The Company has not considered the effect of the Warrants sold in the Offering and Private Placement to purchase an aggregate of&#160;<span id="xdx_906_eus-gaap--WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_c20260101__20260331_zLwsCzFCHW3" title="Weighted average aggregate shares">14,100,000</span>&#160;Class A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method and are contingent on future events. As a result, diluted income per share of Class A ordinary shares is the same as basic income per share of ordinary shares for the period presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The Company has two classes of ordinary shares,
which are referred to as Class A ordinary shares and Class B ordinary shares. Net income per share of ordinary shares is calculated by
dividing the net income by the weighted average number of shares of ordinary shares outstanding during the respective period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The following tables reflect the net (loss)/income
per share after allocating income between the shares based on outstanding shares:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z9nBryRVgBB1" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"><b><i><span id="xdx_8BC_zW0SKWND27gd" style="display: none">&#160;Schedule
    of earning per share basic and diluted</span></i></b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <br/>
Period from <br/>
March&#160;20, 2025
<br/>
(Inception) through <br/>
March&#160;31,<br/>
2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the<br/>
three months ended <br/>
March&#160;31, <br/>
2026</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class A</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class B</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class A</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class B</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerator:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net income per share:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation of (loss)/income &#150; basic and diluted</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zy8q1CRpivSl" title="Allocation of (loss)/income - basic"><span id="xdx_900_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z2LX5LzP7HYe" title="Allocation of (loss)/income - diluted"><span style="-sec-ix-hidden: xdx2ixbrl1475"><span style="-sec-ix-hidden: xdx2ixbrl1477">-</span></span></span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zaYIpma7fKI5" title="Allocation of (loss)/income - basic"><span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zUhkVNCQNGB4" title="Allocation of (loss)/income - diluted">(5,420</span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0iSNiakF4xg" title="Allocation of (loss)/income - basic"><span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zFRQnvemDvP9" title="Allocation of (loss)/income - diluted">2,011,318</span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zTfMrVC9Nq08" title="Allocation of (loss)/income - basic"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwCyQpQUqFfg" title="Allocation of (loss)/income - diluted">2,011,318</span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominator:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted weighted average share of ordinary shares:</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zaCBbKkxOUll" title="Weighted average shares of Class A ordinary shares outstanding, basic"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zBiG6LXmLI06" title="Weighted average shares of Class A ordinary shares outstanding, diluted"><span style="-sec-ix-hidden: xdx2ixbrl1491"><span style="-sec-ix-hidden: xdx2ixbrl1493">-</span></span></span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwozb4274lpk" title="Weighted average shares of Class B ordinary shares outstanding, basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z4aO9n9RdMz2" title="Weighted average shares of Class B ordinary shares outstanding, diluted">10,714,286</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zngzHuVdEMLb" title="Weighted average shares of Class A ordinary shares outstanding, basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z4D9HtOcAKq" title="Weighted average shares of Class A ordinary shares outstanding, diluted">29,200,000</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMgqLWjjG1Ug" title="Weighted average shares of Class B ordinary shares outstanding, basic"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMDCWHjrReMl" title="Weighted average shares of Class B ordinary shares outstanding, diluted">12,000,000</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net income per share</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z38VIFVXOnne" title="Class A ordinary shares - basic net income per share"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zzqpPBahwyhi" title="Class A ordinary shares - diluted net income per share">0.00</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0i8nL2oW9si" title="Class B ordinary shares - basic net income per share"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z3ekJQDEjG8d" title="Class B ordinary shares - diluted net income per share">0.00</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zEF9ZlGITAD2" title="Class A ordinary shares - basic net income per share"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zA6RCCMfP971" title="Class A ordinary shares - diluted net income per share">0.07</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zIcku8QW2zV5" title="Class B ordinary shares - basic net income per share"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zBzYlBzAMw96" title="Class B ordinary shares - diluted net income per share">0.17</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8AC_zNWMKWxINBke" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zKmI21KJxxNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_864_zHGfCbGDFHJ">Concentration of credit risk</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Financial instruments that potentially subject
the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the
Federal depository insurance coverage of $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20260331_zpCvUwnIYIca" title="FDIC Insured Amount">250,000</span>.
At December&#160;31, 2025 and March&#160;31, 2026, the Company had not experienced losses on this account and management believes the
Company is not exposed to significant risks on such account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zCslz5Xo6Ob6" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_867_zDDHritlLFyi">Fair value of financial instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>














<p id="xdx_84D_ecustom--RisksAndUncertaintiesPolicyTextBlock_zrNJxHwjrMDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_869_zOCJzQXdOYs6">Risks and Uncertainties</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (&#8220;NATO&#8221;) deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Any of the above-mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely affect the Company&#8217;s search for an initial Business Combination and any target business with which the Company may ultimately consummate an initial Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z2mXSzfQOpif" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_861_zJiXM6UsbELc">Recent Accounting Pronouncements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">In November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires the disclosure of additional segment information. ASU No. 2023-07 is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted ASU 2023-07 as of the inception of the Company. Adoption of the ASU did not impact the Company&#8217;s financial position, results of operations or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">In December&#160;2023, the FASB issued ASU 2023-09, <i>Income taxes</i> (Topic 740): Improvements to Income Tax Disclosure (&#8220;ASU 2023-09&#8221;), which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 will be effective for fiscal years beginning after December&#160;15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company adopted ASU 2023-09 as of the inception of the Company. Adoption of the ASU did not impact the Company&#8217;s financial position, results of operations or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zy7FcDCgeNii" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. <span id="xdx_82E_z6Po6lfWFJF7">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zTqQLi3oj3F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zknhPtMT4xkj">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
information and note disclosures normally included in the annual consolidated financial statements prepared in accordance with generally
accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although the Company believes that
the disclosures made are adequate to make the information not misleading. The consolidated financial statements as of December&#160;31,
2025 and for period from March&#160;20, 2025 (inception) through December&#160;31, 2025 are audited. In the opinion of management, the
consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary to provide a fair
statement of the results for the periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_ecustom--EmergingGrowthCompanyPolicyTextBlock_zjHTebZGYcF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z9adgwwH5gz6">Emerging
Growth Company</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart
Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being
required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not
have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply
to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended
transition period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#8217;s consolidated financial statements with another public company which is neither
an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible
because of the potential differences in accounting standards used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--UseOfEstimates_zCSpiRUyiDb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z9wBQjRDfAXk">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making
estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of
a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered
in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results
could differ significantly from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zxisgP8Xl37k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zAhdNNso56Nb">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash
equivalents are carried at cost, which approximates fair value. The Company had $<span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20251231_zmXdChwNJcJ4" title="Cash">420,340</span> in cash as of December&#160;31, 2025 The Company
had <span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20251231_zyjNNzvKrPke" title="Cash equivalents">no</span> cash equivalents as of December&#160;31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_ecustom--CashHeldInTrustAccountPolicyTextBlock_z4HvK1JPIUmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zTYNKhDkXdT7">Cash
Held in Trust Account</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had $<span id="xdx_90E_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20251231_z8h7Eqz2G7o8" title="Cash held in trust">284,776,628</span> of cash in the trust account held in an interest bearing demand deposit account as of December&#160;31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_ecustom--OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock_zjYwZgXnflQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zHG5bezvliwj">Offering
Costs Associated with the Initial Public Offering</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212; &#8220;Expenses
of Offering.&#8221; Deferred offering costs consist principally of professional and registration fees that are related to the Initial
Public Offering. Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 470-20, &#8220;Debt with Conversion and Other Options,&#8221;
addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this
guidance to allocate Initial Public Offering proceeds from the Public Units between Class A ordinary shares and warrants based on their
relative fair values. Offering costs allocated to the Class A ordinary shares subject to possible redemption were charged to temporary
equity, and offering costs allocated to the warrants included in the Public Units and Private Units were charged to shareholder&#8217;s
equity as the warrants, after management&#8217;s evaluation, were accounted for under equity treatment. As of August&#160;1, 2025, the
Company had offering costs of $<span id="xdx_90C_ecustom--OfferingCost_iI_pp0p0_c20250801_zTEBye9LC6Sa" title="Offering costs">3,582,634</span>, consisting of $<span id="xdx_901_ecustom--RepresentativeShares_c20250729__20250801_zO3HwvtfCCL3" title="Representative shares">2,419,400</span> of the Representative Shares (as discussed in Note 1) and $<span id="xdx_903_ecustom--OtherOfferingCost_pp0p0_c20250729__20250801_zGB9Qx0HWUBg" title="Other offering costs">1,163,234</span>
of other offering costs. Approximately $<span id="xdx_90C_eus-gaap--OtherExpenses_pp0p0_c20250729__20250801_z3GNIDiBSqvd" title="other costs">143,775</span> of such costs were allocated to the Public Warrants and the Private Placement Units and
the remainder, approximately $<span id="xdx_90D_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_c20250801_zBavxm1BynCj" title="Ordinary shares subject to redemption">3,438,859</span> was allocated to Class A ordinary shares subject to redemption. As of December&#160;31, 2025,
the Company had offering costs of $<span id="xdx_900_ecustom--OfferingCost_iI_pp0p0_c20251231_ziNhZdkvYfdf" title="Offering costs">3,582,634</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z5OSpTZZj5k8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zcqL0aCgOVV7">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the accounting and reporting requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset
and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed
for differences between the consolidated financial statement and tax bases of assets and liabilities that will result in future taxable
or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable
income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 740 prescribes a recognition threshold and a measurement attribute for the consolidated financial statement recognition and measurement
of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not
to be sustained upon examination by taxing authorities. The Company&#8217;s management determined the British Virgin Islands is the Company&#8217;s
only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income
tax expense. There were no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The
Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from
its position. The Company is considered to be an exempted British Virgin Islands company with no connection to any other taxable jurisdiction
and is presently not subject to income taxes or income tax filing requirements in the British Virgin Islands or the United States. As
such, the provision for income taxes was deemed to be <i>de minimis</i> for the period from March&#160;20, 2025 (inception) to December&#160;31,
2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--DerivativesReportingOfDerivativeActivity_zfMMEAmeHDb5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zun6kxhx1xka">Derivative
Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#8220;Derivatives and Hedging.&#8221; For derivative financial instruments that are accounted
for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each
reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative
liabilities are classified in the balance sheet as current or non-current based on whether or not net cash settlement or conversion of
the instrument could be required within 12 months of the balance sheet date. The underwriters&#8217; over-allotment option is deemed to
be a freestanding financial instrument indexed to the contingently redeemable shares and was accounted for as a liability pursuant to
ASC 480 if not fully exercised at the time of the Initial Public Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--ExtendedProductWarrantyPolicy_z0FLSxdwRnzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zDBCwQoAzPGl">Warrant
Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for Warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#8217;
specific terms and applicable authoritative guidance in ASC 480 and FASB ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC
815&#8221;). The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815,
including whether the instruments are indexed to a company&#8217;s common shares and whether the instrument holders could potentially
require &#8220;net cash settlement&#8221; in a circumstance outside of a company&#8217;s control, among other conditions for equity classification.
This assessment, which requires the use of professional judgment, is conducted at the time of Warrant issuance and as of each subsequent
quarterly period end date while the instruments are outstanding. Upon review of the Warrant Agreement, Management concluded that the&#160;public
warrants and private warrants issued pursuant to such warrant agreement qualify for equity accounting treatment.&#160;Following the closing
of the Initial Public Offering on August&#160;1, 2025 and underwriter&#8217;s exercise of over-allotment option on August&#160;13, 2025,
the Company accounted for the&#160;<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20251231_zdWSGahahNSi" title="Warrants issued">14,000,000</span> public warrants and&#160;<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zi4ctrzVvrZc" title="Warrants issued">100,000</span> private warrants issued under equity treatment at their
assigned values. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<p id="xdx_846_ecustom--ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_z39K6VkBlVx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zMsjsksIRMVh">Class
A Ordinary Shares Subject to Possible Redemption</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public shares contain a redemption feature which allows for the redemption of such public shares in connection with the Company&#8217;s
liquidation, or if there is a shareholder vote or tender offer in connection with the Company&#8217;s initial Business Combination. In
accordance with ASC 480-10-S99, the Company classifies public shares subject to redemption outside of permanent equity as the redemption
provisions are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as they occur
and will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately
upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value.
The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the extent available)
and Retained earnings. Accordingly, Class A ordinary shares subject to possible redemption are presented at redemption value as temporary
equity, outside of the shareholders&#8217; equity section of the Company&#8217;s balance sheet. As of December&#160;31, 2025, the 28,000,000
Class A ordinary shares subject to redemption reflected in the balance sheet are reconciled in the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--TemporaryEquityTableTextBlock_zPcXeTqfm8lb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BD_zLSvphjsOLC3" style="display: none">Schedule of ordinary shares subject to redemption</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Gross proceeds from IPO, August&#160;1,
        2025</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_904_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_pp0d_c20250802__20251231_z2o34efAYZBg" title="Ordinary shares subject to possible redemption, beginning">280,000,000</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Less:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Proceeds allocated to Public Warrants</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_ecustom--ProceedsAllocatedToPublicWarrants_pp0d_c20250802__20251231_znh5ksE756X8" title="Proceeds allocated to Public Warrants">(9,028,600</span></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Proceeds allocated to Over-allotment Option</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_ecustom--ProceedsAllocatedToOverallotmentOption_pp0d_c20250802__20251231_zF18AYVY4Fwe" title="Proceeds allocated to Over-allotment Option">(1,290,375</span></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Class A ordinary shares issuance costs</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_ecustom--ClassOrdinarySharesIssuanceCosts_pp0d_c20250802__20251231_zFN36aIn6kRf" title="Class A ordinary shares issuance costs">(3,438,859</span></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Plus:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Accretion of carrying
        value to redemption value</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--TemporaryEquityAccretionToRedemptionValue_pp0d_c20250802__20251231_z1giMb4Fdhpj" title="Ordinary shares subject to possible redemption">18,534,462</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Class A ordinary shares
        subject to possible redemption, December&#160;31, 2025</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_pp0d_c20250802__20251231_z92pFQBkwJ85" title="Ordinary shares subject to possible redemption, ending">284,776,628</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zCe7sjt49b28" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zhFehGf6YTR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zQunJD1xUwzi">Net
Income per Ordinary Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company complies with accounting and disclosure
requirements of FASB ASC Topic 260, &#8220;Earnings Per Share.&#8221; Net income per share of ordinary shares is computed by dividing
net income applicable to ordinary shareholders by the weighted average number of shares of ordinary shares outstanding during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not considered the effect of the Warrants sold in the Offering and Private Placement to purchase an aggregate of&#160;<span id="xdx_903_eus-gaap--WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_c20250320__20251231_zIYauijVJJe6" title="Weighted average aggregate shares">14,100,000</span>&#160;Class
A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock
method and are contingent on future events. As a result, diluted income per share of Class A ordinary shares is the same as basic income
per share of ordinary shares for the period presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two classes of ordinary shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income are shared
pro rata among the two classes of ordinary shares. Net income per share of ordinary shares is calculated by dividing the net income by
the weighted average number of shares of ordinary shares outstanding during the respective period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables reflect the net income per share after allocating income between the shares based on outstanding shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zK6g7uklULf4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"><i><span id="xdx_8BF_zaGSXzmsgspk" style="display: none">Schedule
    of earning per share basic and diluted</span></i></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/>Period from <br/>March&#160;20,
        2025<br/>(Inception) through <br/>December&#160;31, <br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Class A</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Class B</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left">Numerator:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Basic and diluted net income
        per share:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold; text-align: left">Allocation
        of income &#8211; basic and diluted</td>
    <td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z3sCrZfmImf8" title="Allocation of income - basic"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zOP8f6mC3Gdc" title="Allocation of income - diluted">2,509,890</span></span></td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z2qJnxTMSxqk"><span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_ziM4aHJWJMT8" title="Allocation of income - diluted">1,946,080</span></span></td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Basic and diluted weighted
        average share of ordinary shares:</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zLS14Lz9LzJi" title="Basic weighted average share of ordinary shares"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z7DNrJH4OfBj" title="Diluted weighted average share of ordinary shares">15,393,007</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zZ1AoE0JuY4c" title="Basic weighted average share of ordinary shares"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z5EwpZeeFiAi" title="Diluted weighted average share of ordinary shares">11,935,190</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Basic and diluted net income
        per share</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td>
    <td style="font-weight: bold; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zWEL5OqBJofa" title="Basic net income per share"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zT2ajwWAS9G6" title="Diluted net income per share">0.16</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td>
    <td style="font-weight: bold; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zjBGNV05rIv" title="Basic net income per share"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zAOQ6qINRSph" title="Diluted net income per share">0.16</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zQW6yz6aHTG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zIcrYsjdOnUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zU8Q18WJlnoi">Concentration
of credit risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution
which, at times may exceed the Federal depository insurance coverage of $<span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_c20251231_zTBZxivW96d5" title="FDIC Insured Amount">250,000</span>. At December&#160;31, 2025, the Company had not experienced
losses on this account and management believes the Company is not exposed to significant risks on such account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zD59y9ZVJcWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zbcnfxYlFdrl">Fair
value of financial instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value
Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to
their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_ecustom--RisksAndUncertaintiesPolicyTextBlock_zxL0KasiCzxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zjcWV21IYFn1">Risks
and Uncertainties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the
ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict,
the North Atlantic Treaty Organization (&#8220;NATO&#8221;) deployed additional military forces to eastern Europe, and the United States,
the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus
and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank
Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide
military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of
Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken
in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries
have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact
of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity
prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally,
any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity
in capital markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the above-mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting
from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely
affect the Company&#8217;s search for an initial Business Combination and any target business with which the Company may ultimately consummate
an initial Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8qxlOQm7eDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zJUe6H2lTeAa">Recent
Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which
requires the disclosure of additional segment information. ASU No. 2023-07 is effective for fiscal years beginning after December&#160;15,
2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted ASU 2023-07 as of the inception
of the Company. Adoption of the ASU did not impact the Company&#8217;s financial position, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December&#160;2023, the FASB issued ASU 2023-09, <i>Income taxes</i> (Topic 740): Improvements to Income Tax Disclosure (&#8220;ASU 2023-09&#8221;),
which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 will be effective for fiscal years beginning after
December&#160;15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for
issuance. The Company adopted ASU 2023-09 as of the inception of the Company. Adoption of the ASU did not impact the Company&#8217;s financial
position, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INITIAL PUBLIC OFFERING<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_InitialPublicOfferingDisclosureTextBlock', window );">INITIAL PUBLIC OFFERING</a></td>
<td class="text"><p id="xdx_800_ecustom--InitialPublicOfferingDisclosureTextBlock_zxUzX7SDLfn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 3. <span id="xdx_82D_zIv3avamgFu2">INITIAL PUBLIC OFFERING</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">On August&#160;1, 2025, the Company consummated its Initial Public Offering of <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_ziiKEuBh8qWg" title="Sale of units in initial public offering">25,000,000</span> Units, at $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z7BSNxGdjR2d" title="Sale of units per share">10.00</span> per Unit, generating gross proceeds of $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z7xJdTWIQs8j" title="Sale of units in initial public offering aggragate amount">250,000,000</span>. The Company granted the underwriter a 45-day option to purchase up to an additional <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zi3AGJrNogke" title="Sale of units in initial public offering">3,750,000</span> Units at the Initial Public Offering price to cover over-allotments, if any. On August&#160;11, 2025, the underwriters of the IPO notified the Company of their partial exercise of the over-allotment option and purchased <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zaK7CJ35Z6P" title="Sale of units in initial public offering">3,000,000</span> additional units (the &#8220;Option Units&#8221;) at $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zdx2OOuJjDy3" title="Sale of units per share">10.00</span> per unit upon the closing of the over-allotment option, generating gross proceeds of $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zzL7qvdcW5v5" title="Sale of units in initial public offering aggragate amount">30,000,000</span>. On September 9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option. Each Unit consists of one Ordinary Share and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zywvxCggRqMi" title="Share price">11.50</span> per share, subject to adjustment.</p>












<span></span>
</td>
<td class="text"><p id="xdx_80D_ecustom--InitialPublicOfferingDisclosureTextBlock_zSLJnITYDvT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3. <span id="xdx_82B_z1KbCnrudoXf">INITIAL PUBLIC OFFERING</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August&#160;1, 2025, the Company consummated its Initial Public Offering of <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z68SWSkXouvl" title="Sale of units in initial public offering">25,000,000</span> Units, at $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zuYTl7DjGW56" title="Sale of units per share">10.00</span> per Unit, generating gross proceeds
of $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNsLNzuqxtP2" title="Sale of units in initial public offering aggragate amount">250,000,000</span>. The Company granted the underwriter a 45-day option to purchase up to an additional <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zLyPTOsY05De" title="Sale of units in initial public offering">3,750,000</span> Units at the Initial Public
Offering price to cover over-allotments, if any. On August&#160;11, 2025, the underwriters of the IPO notified the Company of their partial
exercise of the over-allotment option and purchased <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z2DvOPHYNdv4" title="Sale of units in initial public offering">3,000,000</span> additional units (the &#8220;Option Units&#8221;) at $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z5FkLaLYZBbb" title="Sale of units per share">10.00</span> per unit upon
the closing of the over-allotment option, generating gross proceeds of $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zF2cRkgObqV" title="Sale of units in initial public offering aggragate amount">30,000,000</span>. On September&#160;9, 2025, the Underwriters advised
the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option. Each Unit consists
of one Ordinary Share and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary
share at a price of $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z5vX2ACUCNo7" title="Share price">11.50</span> per share, subject to adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_InitialPublicOfferingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_InitialPublicOfferingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRIVATE PLACEMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_PrivatePlacementDisclosureTextBlock', window );">PRIVATE PLACEMENT</a></td>
<td class="text"><p id="xdx_801_ecustom--PrivatePlacementDisclosureTextBlock_zNIFkS0LzBs2" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 4. <span id="xdx_828_zdpqfBsTh2A9">PRIVATE PLACEMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zWpVriUo9y18" title="Sale of units in initial public offering">200,000</span> Private Units at a price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zF0n5WVwkcP5" title="Sale of units per share">10.00</span> per Placement Unit raising $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zld7xUyBfm51" title="Sale of units in initial public offering aggragate amount">2,000,000</span> in the aggregate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The proceeds from the sale of the Private Units were added to the net proceeds from the Offering held in the Trust Account. The Placement Units are identical to the Units sold in the Initial Public Offering, as described in Note 7. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Warrants will expire worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_801_ecustom--PrivatePlacementDisclosureTextBlock_zpb49dy82Zdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4. <span id="xdx_82F_zsyzzDUiuM6e">PRIVATE PLACEMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously
with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zock4izgOfti" title="Sale of units in initial public offering">200,000</span> Private Units at a price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zwMvmX5ifFuc" title="Sale of units per share">10.00</span> per
Placement Unit raising $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIzdEwofmxtc" title="Sale of units in initial public offering aggragate amount">2,000,000</span> in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proceeds from the sale of the Private Units were added to the net proceeds from the Offering held in the Trust Account. The Placement
Units are identical to the Units sold in the Initial Public Offering, as described in Note 7. If the Company does not complete a Business
Combination within the Combination Period, the proceeds from the sale of the Private Units will be used to fund the redemption of the
Public Shares (subject to the requirements of applicable law) and the Private Warrants will expire worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>













<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_PrivatePlacementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_PrivatePlacementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_803_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zpNHGTe8sIDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 5. <span id="xdx_82C_z82mcy6I8tZ8">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>Founder Shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">On March&#160;25, 2025, the Company issued an aggregate
of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250301__20250325__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zMVgGcUrVxOe">12,321,429
</span>founder shares to the Sponsor for an aggregate purchase price of $<span id="xdx_90F_eus-gaap--Cash_iI_c20250325__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_z6RLEudCp3Uj">25,000
</span>in cash. The funds were received on May&#160;27, 2025. Following the partial exercise of the over-allotment option on August 11,
2025, on September 9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option
and thereby forfeit the option. As a result, on September 9, 2025, the Company cancelled a total of <span id="xdx_909_ecustom--CancelledFounderShares_c20250905__20250909_zTcSZxGrsg3e" title="Cancelled founder shares">321,429
</span>founder shares. As of March&#160;31, 2026, sponsor held a total of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zF5BsS2pB1Sd">12,000,000
</span>founder shares and none was subject to forfeiture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The founder shares are designated as Class B
ordinary shares and, except as described below, are identical to the Class A ordinary shares included in the units being sold in the
IPO, and holders of founder shares have the same shareholder rights as public shareholders, except that (i) the founder shares are
subject to certain transfer restrictions, as described in more detail below, (ii) the founder shares are entitled to registration
rights; (iii) our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed
to (A) waive their redemption rights with respect to their founder shares, private shares and public shares in connection with the
completion of our initial business combination, (B) waive their redemption rights with respect to their founder shares, private
shares and public shares in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and
articles of association (a) to modify the substance or timing of our obligation to allow redemption in connection with our initial
business combination or to redeem <span id="xdx_90D_ecustom--PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination_dp_c20260101__20260331_zXCLnhDFZiBd" title="Percentage of redemption of public shares">100</span>%
of our public shares if we have not consummated an initial business combination within the completion window or (b) with respect to
any other material provisions relating to shareholders&#8217; rights or pre-initial business combination activity, (C) waive their
rights to liquidating distributions from the trust account with respect to their founder shares and private shares if we fail to
complete our initial business combination within the completion window, although they will be entitled to liquidating distributions
from the trust account with respect to any public shares they hold if we fail to complete our initial business combination within
such time period and to liquidating distributions from assets outside the trust account and (D) vote any founder shares held by them
and any public shares they may purchase (including in open market and privately-negotiated transactions) in favor of our initial
business combination (except that any public shares such parties may purchase in compliance with the requirements of Rule&#160;14e-5
under the Exchange Act would not be voted in favor of approving the business combination transaction), (iv) the founder shares are
automatically convertible into Class A ordinary shares concurrently with or immediately following the consummation of our initial
business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment as described herein and in
our amended and restated memorandum and articles of association, and (v) prior to the closing of our initial business combination,
only holders of our Class B ordinary shares will be entitled to vote on the appointment and removal of directors or continuing the
company in a jurisdiction outside the British Virgin Islands (including any ordinary resolution required to amend our constitutional
documents or to adopt new constitutional documents, in each case, as a result of our approving a transfer by way of continuation in
a jurisdiction outside the British Virgin Islands).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">With certain limited exceptions, the founder shares are not transferable, assignable or saleable (except to our officers and directors and other persons or entities affiliated with our sponsor, each of whom will be subject to the same transfer restrictions) until the completion of our initial business combination.</p>




















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>Administrative Services Arrangement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">An affiliate of our Sponsor has agreed, commencing
from the date that the Company&#8217;s securities are first listed on Nasdaq, through the earlier of the Company&#8217;s consummation
of a Business Combination and its liquidation, to make available to the Company our Sponsor certain office space, utilities and secretarial
and administrative support as may be reasonably required by the Company. The Company has agreed to pay to the affiliate of our Sponsor,
$<span id="xdx_90C_eus-gaap--PaymentsOfDistributionsToAffiliates_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zQldRVTZCDxg">20,000
</span>per month, for up to 18 months, subject to extension to up to 21 months, for such administrative services. For the three months ended March&#160;31, 2026, $<span id="xdx_908_eus-gaap--AdministrativeFeesExpense_c20260101__20260331_zjj5mvpwbgkc">60,000
</span> was charged to operations and no amounts were outstanding at March 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>Related Party Loans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">In order to finance transaction costs in connection with a Business Combination, the Company&#8217;s Sponsor or an affiliate of the Sponsor, or the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). Up to $<span id="xdx_904_eus-gaap--DebtConversionOriginalDebtAmount1_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z58fA98SjFOl" title="Conversion of debt">2,500,000</span> of such loans may be convertible into private units, at a price of $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zuLJDC7MopX3" title="Sale of units per share">10.00</span> per unit, at the option of the applicable lender. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of March&#160;31, 2026, no amounts under such loans have been drawn.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>Representative Shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">On August&#160;1, 2025, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z6QXz08pyPJ3" title="Number of share issued">1,000,000</span>
representative shares to D. Boral Capital, LLC and/or its designees (whether or not the over-allotment is exercised) as part of
representative compensation (the &#8220;Representative Shares&#8221;). The Representative Shares have been deemed compensation by
FINRA and are therefore subject to a lock-up for a period of 180 days immediately following the commencement of sales of the IPO
pursuant to FINRA Rule&#160;5110(e)(1). Pursuant to this FINRA lock-up, these securities cannot be sold, transferred, assigned,
pledged or hypothecated or the subject of any hedging, short sale, derivative, put or call transaction that would result in the
economic disposition of the securities by any person for a period of 180 days from the commencement of sales of the Initial Public
Offering except as permitted under FINRA Rule&#160;5110(e)(2), including to any underwriter and selected dealer participating in the
Initial Public Offering and their officers or partners, registered persons or affiliates. The Representative Shares have resale
registration rights including two demand (one at the Company&#8217;s expense and one at D. Boral Capital, LLC&#8217;s expense) and
unlimited &#8220;piggy-back&#8221; rights for periods of five and seven years, respectively, from the commencement of sales of the
Initial Public Offering.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrYpFvvjFz9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5. <span id="xdx_825_zCNNFCMF78fe">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Founder
Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March&#160;25, 2025, the Company issued an aggregate of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250301__20250325__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zKIH67EkvYIj" title="Shares issued">12,321,429</span> founder shares to the Sponsor for an aggregate purchase price of $<span id="xdx_90F_eus-gaap--Cash_iI_c20250325__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zGVXdJ6E6tx1" title="Cash">25,000</span>
in cash. The funds were received on May&#160;27, 2025. Following the partial exercise of the over-allotment option on August&#160;11,
2025, on September&#160;9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment
option and thereby forfeit the option. As a result, on September&#160;9, 2025, the Company cancelled a total of <span id="xdx_905_ecustom--CancelledFounderShares_c20250905__20250909_zl4zcqqhZ3uf" title="Cancelled founder shares">321,429</span> founder shares.
As of December&#160;31, 2025, sponsor held a total of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20250320__20251231__us-gaap--StatementEquityComponentsAxis__custom--FounderMember_zrz4M0un8z1i" title="Forfeiture shares">12,000,000</span> founder shares and none was subject to forfeiture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
founder shares are designated as Class B ordinary shares and, except as described below, are identical to the Class A ordinary shares
included in the units being sold in the IPO, and holders of founder shares have the same shareholder rights as public shareholders, except
that (i) the founder shares are subject to certain transfer restrictions, as described in more detail below, (ii) the founder shares are
entitled to registration rights; (iii) our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which
they have agreed to (A) waive their redemption rights with respect to their founder shares, private shares and public shares in connection
with the completion of our initial business combination, (B) waive their redemption rights with respect to their founder shares, private
shares and public shares in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and articles
of association (a) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination
or to redeem <span id="xdx_908_ecustom--PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination_dp_c20250320__20251231_zW3TNlBemkUl" title="Percentage of redemption of public shares">100%</span> of our public shares if we have not consummated an initial business combination within the completion window or (b)
with respect to any other material provisions relating to shareholders&#8217; rights or pre-initial business combination activity, (C)
waive their rights to liquidating distributions from the trust account with respect to their founder shares and private shares if we fail
to complete our initial business combination within the completion window, although they will be entitled to liquidating distributions
from the trust account with respect to any public shares they hold if we fail to complete our initial business combination within such
time period and to liquidating distributions from assets outside the trust account and (D) vote any founder shares held by them and any
public shares they may purchase (including in open market and privately-negotiated transactions) in favor of our initial business combination
(except that any public shares such parties may purchase in compliance with the requirements of Rule&#160;14e-5 under the Exchange Act
would not be voted in favor of approving the business combination transaction), (iv) the founder shares are automatically convertible
into Class A ordinary shares concurrently with or immediately following the consummation of our initial business combination or earlier
at the option of the holder on a one-for-one basis, subject to adjustment as described herein and in our amended and restated memorandum
and articles of association, and (v) prior to the closing of our initial business combination, only holders of our Class B ordinary shares
will be entitled to vote on the appointment and removal of directors or continuing the company in a jurisdiction outside the British Virgin
Islands (including any ordinary resolution required to amend our constitutional documents or to adopt new constitutional documents, in
each case, as a result of our approving a transfer by way of continuation in a jurisdiction outside the British Virgin Islands).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
certain limited exceptions, the founder shares are not transferable, assignable or saleable (except to our officers and directors and
other persons or entities affiliated with our sponsor, each of whom will be subject to the same transfer restrictions) until the completion
of our initial business combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Promissory
Note &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March&#160;20, 2025, the Sponsor issued an unsecured promissory note to the Company, pursuant to which the Company may borrow up to an
aggregate principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20251231__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredPromissoryNoteMember_zilx2XNUQ3Jd" title="Principal amount">350,000</span>, to be used for payment of costs related to the Proposed Offering. The note is non-interest bearing
and payable on the earlier of (i) December&#160;31, 2025 or (ii) the consummation of the Initial Public Offering. On August&#160;1, 2025,
the Company has repaid $<span id="xdx_901_eus-gaap--RepaymentOfNotesReceivableFromRelatedParties_c20250729__20250801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zNBRf0ZD3Bcg" title="Repayment of promissory note">225,461</span> under the promissory note with the Sponsor out of the $<span id="xdx_90B_eus-gaap--PaymentsForRepurchaseOfInitialPublicOffering_c20250729__20250801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zcDb7GEDXP32" title="Payment of offering expenses">700,000</span> of offering proceeds that has been allocated
for the payment of offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Administrative
Services Arrangement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
affiliate of our Sponsor has agreed, commencing from the date that the Company&#8217;s securities are first listed on Nasdaq, through
the earlier of the Company&#8217;s consummation of a Business Combination and its liquidation, to make available to the Company our Sponsor
certain office space, utilities and secretarial and administrative support as may be reasonably required by the Company. The Company has
agreed to pay to the affiliate of our Sponsor, $<span id="xdx_900_eus-gaap--PaymentsOfDistributionsToAffiliates_c20250320__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zlnaPZbdyeKh" title="Payment to affiliate">20,000</span> per month, for up to 18 months, subject to extension to up to 21 months, for such
administrative services. For the period from March&#160;20, 2025 (inception) to December&#160;31, 2025, $<span id="xdx_909_eus-gaap--AdministrativeFeesExpense_c20250320__20251231_zx13woO4Tfnc" title="Administrative services">100,000</span> was charged to operations
and no amounts were outstanding at December&#160;31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Party Loans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to finance transaction costs in connection with a Business Combination, the Company&#8217;s Sponsor or an affiliate of the Sponsor,
or the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working
Capital Loans&#8221;). Up to $<span id="xdx_90D_eus-gaap--DebtConversionOriginalDebtAmount1_c20250320__20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zoSGVPE4L9ll" title="Conversion of debt">2,500,000</span> of such loans may be convertible into private units, at a price of $<span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_c20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zoryQ0v2dVwg" title="Sale of units per share">10.00</span> per unit, at the option
of the applicable lender. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside
the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital
Loans. As of December&#160;31, 2025, no amounts under such loans have been drawn.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Representative
Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August&#160;1, 2025, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250729__20250801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zEnpb1MH6gf7" title="Number of share issued">1,000,000</span> representative shares to D. Boral Capital, LLC and/or its designees (whether or not
the over-allotment is exercised) as part of representative compensation (the &#8220;Representative Shares&#8221;). The Representative
Shares have been deemed compensation by FINRA and are therefore subject to a lock-up for a period of 180 days immediately following the
commencement of sales of the IPO pursuant to FINRA Rule&#160;5110(e)(1). Pursuant to this FINRA lock-up, these securities cannot be sold,
transferred, assigned, pledged or hypothecated or the subject of any hedging, short sale, derivative, put or call transaction that would
result in the economic disposition of the securities by any person for a period of 180 days from the commencement of sales of the Initial
Public Offering except as permitted under FINRA Rule&#160;5110(e)(2), including to any underwriter and selected dealer participating in
the Initial Public Offering and their officers or partners, registered persons or affiliates. The Representative Shares have resale registration
rights including two demand (one at the Company&#8217;s expense and one at D. Boral Capital, LLC&#8217;s expense) and unlimited &#8220;piggy-back&#8221;
rights for periods of five and seven years, respectively, from the commencement of sales of the Initial Public Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z3K0SX2d4Sw9" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 6. <span id="xdx_82F_zdVOlujD2uBh">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>Registration Rights</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The holders of the (i) founder shares, which were issued in a private placement prior to the closing of the initial public offering, (ii) Private Units (including the component securities as well as any securities underlying those component securities), which was issued in a private placement simultaneously with the closing of the initial public offering and (iii) private units (including the component securities as well as any securities underlying those component securities) that may be issued upon conversion of working capital loans will have registration rights to require the Company to register a sale of any of our securities held by them and any other securities of the company acquired by them prior to the consummation of a Business Combination pursuant to a registration rights agreement to be signed prior to or on the effective date of the initial public offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of the Business Combination. The registration rights granted to the underwriter are limited to two demand (one at the Company&#8217;s expense and one at D. Boral Capital, LLC&#8217;s expense) and unlimited &#8220;piggy-back&#8221; rights for periods of five and seven years, respectively, from the commencement of sales of the Initial Public Offering. The Company will bear the expenses incurred in connection with the filing of any such registration statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>Underwriting Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company has granted the underwriters a 45-day option to purchase up to <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zjtEhPvhMXQe" title="Option granted">3,750,000</span> additional Units to cover over-allotments at the Initial Public Offering price, less the underwriting discounts and commissions. On August 11, 2025, the underwriters of the IPO notified the Company of their partial exercise of the over-allotment option and purchased <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zR7wbwMpc9wh" title="Sale of units in initial public offering">3,000,000</span> additional units (the &#8220;Option Units&#8221;) at $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zGqMeTvcqykf" title="Sale of units per share">10.00</span> per unit upon the closing of the over-allotment option, generating gross proceeds of $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zbSfvKxgSk01" title="Sale of units in initial public offering aggragate amount">30,000,000</span>. On September 9, 2025, the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The underwriters were not entitled to any cash underwriting fee at closing of the Initial Public Offering. The underwriters were entitled to <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_zFQcKs3SbWef" title="Number of share issued">1,000,000</span> Representative Shares (whether or not the over-allotment is exercised) at closing of the Initial Public Offering. The underwriters will not be entitled to any deferred underwriting fee upon closing of the Business Combination.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zOodEbadoGl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. <span id="xdx_827_zvnDuwuTDke4">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of the (i) founder shares, which were issued in a private placement prior to the closing of the initial public offering, (ii)
Private Units (including the component securities as well as any securities underlying those component securities), which was issued in
a private placement simultaneously with the closing of the initial public offering and (iii) private units (including the component securities
as well as any securities underlying those component securities) that may be issued upon conversion of working capital loans will have
registration rights to require the Company to register a sale of any of our securities held by them and any other securities of the company
acquired by them prior to the consummation of a Business Combination pursuant to a registration rights agreement to be signed prior to
or on the effective date of the initial public offering. The holders of these securities are entitled to make up to three demands, excluding
short form demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration
rights with respect to registration statements filed subsequent to the completion of the Business Combination. The registration rights
granted to the underwriter are limited to two demand (one at the Company&#8217;s expense and one at D. Boral Capital, LLC&#8217;s expense)
and unlimited &#8220;piggy-back&#8221; rights for periods of five and seven years, respectively, from the commencement of sales of the
Initial Public Offering. The Company will bear the expenses incurred in connection with the filing of any such registration statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underwriting
Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has granted the underwriters a 45-day option to purchase up to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250320__20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zFjNTzXClord" title="Option granted">3,750,000</span> additional Units to cover over-allotments at the Initial
Public Offering price, less the underwriting discounts and commissions. On August&#160;11, 2025, the underwriters of the IPO notified
the Company of their partial exercise of the over-allotment option and purchased <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zsDsQ7BIzSY4" title="Sale of units in initial public offering">3,000,000</span> additional units (the &#8220;Option Units&#8221;)
at $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z00hlruxNby8" title="Sale of units per share">10.00</span> per unit upon the closing of the over-allotment option, generating gross proceeds of $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20250802__20250811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zTKQ26a264L8" title="Sale of units in initial public offering aggragate amount">30,000,000</span>. On September&#160;9, 2025,
the Underwriters advised the Company that it has elected not to exercise the remaining over-allotment option and thereby forfeit the option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters were not entitled to any cash underwriting fee at closing of the Initial Public Offering. The underwriters were entitled
to <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250320__20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwriterMember_z7WKxjLfpBE3" title="Number of share issued">1,000,000</span> Representative Shares (whether or not the over-allotment is exercised) at closing of the Initial Public Offering. The underwriters
will not be entitled to any deferred underwriting fee upon closing of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDER&#8217;S EQUITY<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDER&#8217;S EQUITY</a></td>
<td class="text"><p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zhxdEDXzYVGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 5 &#8212; <span id="xdx_826_z8QPFSfZW7Qi">Share Capital</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company is authorized to issue
<span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_z5fNqfWf2Exk" title="Common stock, shares authorized">100</span> shares of Common Stock of par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zUx4YfEZD1lg" title="Common stock, par value">0.0001</span> each share. Holders of the Company&#8217;s common stock are entitled to one vote for each
share. On December&#160;19, 2025, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zATkjkJr6MK4" title="Common stock issued">100</span> shares of common stock to its Parent D. Boral ARC Acquisition I Corp., at a purchase
price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_z76UKaf0Ad1g" title="Purchase price">1.00</span> per share, or an aggregate purchase price of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0d_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zeyJujuSXK4h" title="Aggregate purchase price">100</span>. The subscription fee was not received yet as of December&#160;31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z85SDJ4YhdWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 5 &#8212; <span><span id="xdx_822_zaJ0zlFDAKm2">Share Capital</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company is authorized
to issue 100 shares of Common Stock of par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zGw25nXRyHs8" title="Common stock, par value">0.0001</span> each share. Holders of the Company&#8217;s common stock are entitled to one
vote for each share. On December&#160;19, 2025, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zTgHwRfLctwa" title="Common stock issued">100</span> shares of common stock to its Parent D. Boral ARC Acquisition
I Corp., at a purchase price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zFcXUa3HlvSa" title="Purchase price">1.00</span> per share, or an aggregate purchase price of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0d_c20251219__20251231__srt--CounterpartyNameAxis__custom--DBoralARCAcquisitionICorpMember_zAz0GKFnQxRf" title="Aggregate purchase price">100</span>. The subscription fee was not received yet as
of March 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDER&#8217;S EQUITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwhUP6jv9mqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 7. <span id="xdx_823_zaILIlDlzmsc">STOCKHOLDER&#8217;S EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><i>Preference shares</i> &#8212; The Company is
authorized to issue <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331_zFMVgjM8NmY9" title="Preferred stock, shares authorized"><span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_c20251231_z0Jl6MArvzB9" title="Preferred stock, shares authorized">5,000,000</span></span>
preference shares with a par value of $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260331_zAytd7i2p886" title="Preferred stock, par value"><span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_c20251231_zfL19UEBgrDa" title="Preferred stock, par value">0.0001</span></span>
per share. Holders of the Company&#8217;s ordinary shares are entitled to one vote for each share. On December&#160;31, 2025 and
March&#160;31, 2026, there were <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_do_c20260331_zroPfs1eRoNk" title="Preferred stock, shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20260331_z9d8GSit2B5" title="Preferred stock, shares outstanding"><span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_do_c20251231_zMEOzupxxnI8" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20251231_zyzADJxkUXd2" title="Preferred stock, shares outstanding">no</span></span></span></span>
preferred shares issued or outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><i>Class A Ordinary shares</i> &#8212; The
Company is authorized to issue <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zKveQpajq4V5"><span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zskfIMqX190e">500,000,000</span> </span>ordinary
shares with a par value of $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zdRFWPvGhFOd"><span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zjY855rQwcpd">0.0001</span> </span>per
share. Holders of the Company&#8217;s ordinary shares are entitled to one vote for each share. As a result of closing of the IPO and
the partial exercise of the over-allotment option partial exercise of the over-allotment option, on December&#160;31, 2025 and March&#160;31,
2026, there were <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zxB3PXFsHCU5"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zsLdgforxL9e"><span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zxt2nAqbsMr9"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_z4vLyiaVVyR6">1,200,000</span></span></span> </span>Class
A ordinary shares issued or outstanding, excluding <span id="xdx_904_ecustom--OrdinarySharesSubjectToPossibleRedemption_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinaryShareMember_zMl1aYF2ihsk"><span id="xdx_90C_ecustom--OrdinarySharesSubjectToPossibleRedemption_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zVJMl0G8IzV">28,000,000</span> </span>Class
A ordinary shares subject to possible redemption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><i>Class B Ordinary shares</i> &#8212; The
Company is authorized to issue <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zXVGRwMjVDql"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zMMZnne8IkL6">50,000,000</span> </span>ordinary
shares with a par value of $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_ztG2sNw8sNFl"><span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zED6jktrmjAl">0.0001</span> </span>per
share. Holders of the Company&#8217;s ordinary shares are entitled to one vote for each share. On March&#160;25, 2025, the Company
issued an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250301__20250325__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zRVwJpN6yZVk">12,321,429 </span>ordinary
shares to the Sponsor for an aggregate purchase price of $<span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20250325_zAFxq56sMRg6">25,000 </span>in
cash, of which <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20250301__20250325__us-gaap--StatementEquityComponentsAxis__custom--ClassAOrdinarySharesMember_znPFdJkwaY27">1,607,143 </span>shares
held by the Sponsor are subject to forfeiture to the extent that the underwriter&#8217;s over-allotment option is not exercised in
full. Following the partial exercise of the over-allotment option on August 11, 2025 and cancellation <span id="xdx_901_ecustom--CancellationOfOrdinaryShares_iI_c20250811_zKYsRghvexAh" title="Cancellation of ordinary shares">321,429</span>
ordinary shares on September 9, 2025, on December&#160;31, 2025 and March&#160;31, 2026, there were <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zKBpaz3TRFH" title="Common stock, shares issued"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zIOANVibuum3" title="Common stock, shares outstanding">12,000,000</span></span>
ordinary <span style="display: none">12,300,000</span>shares issued and outstanding.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of our initial business combination, or at any time prior thereto at the option of the holder thereof, on a one-for-one basis, subject to adjustment as provided herein. Because our sponsor acquired the Class B ordinary shares at a nominal price, our public shareholders will incur an immediate and substantial dilution upon the closing of the IPO, assuming no value is ascribed to the warrants included in the units. In the case that additional Class A ordinary shares, or equity-linked securities (as described herein), are issued or deemed issued in excess of the amounts issued in the IPO and related to the closing of our initial business combination, the ratio at which the Class B ordinary shares will convert into Class A ordinary shares will be adjusted (unless the holders of a majority of the issued and outstanding Class B ordinary shares agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance) so that the number of Class A ordinary shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, <span id="xdx_909_ecustom--PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion_iI_dp_c20260331__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--ConversionOfClassBToClassACommonStockMember_zszikt6CRcY8" title="Percentage of total number of ordinary shares">30</span>% of the sum of (i) the total number of all Class A ordinary shares outstanding upon the completion of the IPO (including any Class A ordinary shares issued pursuant to the underwriters&#8217; over-allotment option and excluding the Class A ordinary shares that are included within the private units), plus (ii) all Class A ordinary shares and equity-linked securities issued or deemed issued, in connection with the closing of the initial business combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the initial business combination and any units issued to our sponsor or any of its affiliates or to our officers or directors upon conversion of working capital loans) minus (iii) any redemptions of Class A ordinary shares by public shareholders in connection with an initial business combination; provided that such conversion of founder shares will never occur on a less than <span id="xdx_903_eus-gaap--CommonStockConversionBasis_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--CommonStockClassBMember_zkHKuUlOOCQg" title="Conversion basis">one-for-one basis</span>.</p>





















<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Holders of record of the Company&#8217;s Class A ordinary shares and Class B ordinary shares are entitled to one vote for each share held on all matters to be voted on by shareholders. Unless specified in the amended and restated memorandum and articles of association or as required by the Companies Act or stock exchange rules, an ordinary resolution under British Virgin Islands law and the amended and restated memorandum and articles of association, which requires the affirmative vote of at least a majority of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the company is generally required to approve any matter voted on by the Company&#8217;s shareholders. Approval of certain actions require an ordinary resolution under British Virgin Islands law, which (except as specified below) requires the affirmative vote of in excess of 50 percent of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting, and pursuant to the Company&#8217;s amended and restated memorandum and articles of association, such actions include amending the amended and restated memorandum and articles of association and approving a statutory merger or consolidation with another company. There is no cumulative voting with respect to the appointment of directors, meaning, following the Company&#8217;s initial Business Combination, the holders of more than 50% of the ordinary shares voted for the appointment of directors can elect all of the directors. Prior to the consummation of the initial Business Combination, only holders of the Class B ordinary shares will (i) have the right to vote on the appointment and removal of directors and (ii) be entitled to vote on continuing the Company in a jurisdiction outside the British Virgin Islands (including any ordinary resolution required to amend the constitutional documents or to adopt new constitutional documents, in each case, as a result of approving a transfer by way of continuation in a jurisdiction outside the British Virgin Islands). Holders of the Class A ordinary shares will not be entitled to vote on these matters during such time. These provisions of our amended and restated memorandum and articles of association may only be amended if approved by an ordinary resolution passed by the affirmative vote of the holders representing at least 90% of the issued Class B ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><i>Warrants &#8212; </i>Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Warrants. The Warrants will become exercisable <span id="xdx_90C_ecustom--PeriodAfterWhichTheWarrantsAreExercisable_dtD_c20260101__20260331_zWeApScMc3eb" title="Period of warrants exercisable">30</span> days after the completion of our initial business combination, provided that the Company has an effective registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or we permit holders to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement). If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th business day after the closing of our initial business combination, warrant holders may, until such time as there is an effective registration statement and during any period when we will have failed to maintain an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if our Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1) of the Securities Act, we may, at our option, require holders of public warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event we so elect, we will not be required to file or maintain in effect a registration statement. The Warrants will expire five years from the consummation of a Business Combination or earlier upon redemption or liquidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company may call the Warrants for redemption:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">in whole and not in part;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">at a price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zoNP9mOnjT3c" title="Warrant price">0.01</span> per warrant; upon a minimum of <span id="xdx_90D_ecustom--MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants_dtD_c20260101__20260331_zOnTLMGfRTZ7" title="Holders of warrants">30</span> days&#8217; prior written notice of redemption (the &#8220;30-day redemption period&#8221;); and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">if, and only if, the closing price of the Class A ordinary shares equals or exceeds $<span id="xdx_909_eus-gaap--SharePrice_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zJ9mqOJX3QCl" title="Share price">18.00</span> per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant) for any <span id="xdx_900_ecustom--NumberOfTradingDaysForDeterminingTheSharePrice_dtD_c20260101__20260331_zvrNRerpdBn3" title="Number of trading days">20</span> trading days within a <span id="xdx_906_ecustom--NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_dtD_c20260101__20260331_zwbDb1yUTWP9" title="Number of consecutive trading days">30</span>-trading day period commencing at least 30 days after completion of our initial business combination and ending three business days before we send the notice of redemption to the warrant holders.</td> </tr>
  </table>






















<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The private warrants are identical to the warrants sold in the IPO except that, so long as they are held by our sponsor or its permitted transferees, the private warrants (i) are locked-up until the completion of our initial business combination and (ii) will be entitled to registration rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The exercise price is $11.50 per share, subject to adjustment as described herein. In addition, if (x) we issue additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price to be determined in good faith by our board of directors and, in the case of any such issuance to our initial shareholders or their affiliates, without taking into account any founder shares held by our initial shareholders or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination on the date of the consummation of our initial business combination (net of redemptions), and (z) the volume weighted average trading price of our Class A ordinary shares during the <span id="xdx_905_ecustom--NumberOfTradingDaysForDeterminingTheSharePrice_dtD_c20260101__20260331_zc5q1DDThXIl" title="Number of trading days">20</span> trading day period starting on the trading day prior to the day on which we consummate our initial business combination (such price, the &#8220;Market Value&#8221;) is below $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331_zs54CHaUkD4i" title="Warrants exercise price">9.20</span> per share, then the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to <span id="xdx_904_eus-gaap--AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate_iI_dp_c20260331_zv6Vv7qifSKb" title="Market value">115</span>% of the higher of the Market Value and the Newly Issued Price, and the $<span id="xdx_90C_eus-gaap--PreferredStockRedemptionPricePerShare_iI_c20260331_zBQoRodwKOZj" title="Redemption price">18.00</span> per share redemption trigger prices will be adjusted (to the nearest cent) to be equal to <span id="xdx_900_ecustom--ShareRedemptionTriggerPrices_iI_dp_c20260331_zxXMTxXeNMw5" title="Share redemption trigger prices">180</span>% of the higher of the Market Value and the Newly Issued Price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zLymJvSLjwni" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. <span id="xdx_829_zo6eGMSSg8H3">STOCKHOLDER&#8217;S EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preference
shares</i> &#8212; The Company is authorized to issue <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_c20251231_zVKs3Ud7A2J1" title="Preferred stock, shares authorized">5,000,000</span> preference shares with a par value of $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_c20251231_zGdq3Sz7TMP2" title="Preferred stock, par value">0.0001</span> per share. Holders of the
Company&#8217;s ordinary shares are entitled to one vote for each share. On December&#160;31, 2025, there were <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_do_c20251231_zes6MDUpNOee" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20251231_zggQcNldTD8j" title="Preferred stock, shares outstanding">no</span></span> preferred shares issued
or outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Class
A Ordinary shares</i> &#8212; The Company is authorized to issue <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zUIiqFEC1YKa" title="Common stock, shares authorized">500,000,000</span> ordinary shares with a par value of $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zpG2arjDcUM5" title="Common stock, par value">0.0001</span> per share. Holders
of the Company&#8217;s ordinary shares are entitled to one vote for each share. As a result of closing of the IPO and the partial exercise
of the over-allotment option partial exercise of the over-allotment option, there were <span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zX4U9Oph6c9b" title="Common stock, shares outstanding">1,200,000</span> Class A ordinary shares issued or outstanding,
excluding <span id="xdx_90D_ecustom--OrdinarySharesSubjectToPossibleRedemption_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zM1hbLvnyh4d" title="Ordinary shares subject to possible redemption">28,000,000</span> Class A ordinary shares subject to possible redemption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Class
B Ordinary shares</i> &#8212; The Company is authorized to issue <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zaDu9F4i7evd">50,000,000</span> ordinary shares with a par value of $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zaOL9jf9dkb3">0.0001</span> per share. Holders
of the Company&#8217;s ordinary shares are entitled to one vote for each share. On March&#160;25, 2025, the Company issued an aggregate
of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250301__20250325__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zfTMSHKHds0l">12,321,429</span> ordinary shares to the Sponsor for an aggregate purchase price of $<span id="xdx_90D_ecustom--AggregatePurchasePrice_iI_pp0p0_c20250325_ztIeXeeDmxNc" title="Aggregate purchase price">25,000</span> in cash, of which <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20250301__20250325__us-gaap--StatementEquityComponentsAxis__custom--ClassAOrdinarySharesMember_zxJWaCgaTD7h">1,607,143</span> shares held by the
Sponsor are subject to forfeiture to the extent that the underwriter&#8217;s over-allotment option is not exercised in full. Following
the partial exercise of the over-allotment option on August&#160;11, 2025 and cancellation <span id="xdx_901_ecustom--CancellationOfOrdinaryShares_iI_c20250811_zQ94bGRQlFb7" title="Cancellation of ordinary shares">321,429</span> ordinary shares on September&#160;9,
2025, on December&#160;31, 2025, there were <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zigcy70u45ba" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zX4NnnaGuwf" title="Common stock, shares outstanding">12,000,000</span></span> ordinary shares issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation
of our initial business combination, or at any time prior thereto at the option of the holder thereof, on a one-for-one basis, subject
to adjustment as provided herein. Because our sponsor acquired the Class B ordinary shares at a nominal price, our public shareholders
will incur an immediate and substantial dilution upon the closing of the IPO, assuming no value is ascribed to the warrants included in
the units. In the case that additional Class A ordinary shares, or equity-linked securities (as described herein), are issued or deemed
issued in excess of the amounts issued in the IPO and related to the closing of our initial business combination, the ratio at which the
Class B ordinary shares will convert into Class A ordinary shares will be adjusted (unless the holders of a majority of the issued and
outstanding Class B ordinary shares agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance)
so that the number of Class A ordinary shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, 30%
of the sum of (i) the total number of all Class A ordinary shares outstanding upon the completion of the IPO (including any Class A ordinary
shares issued pursuant to the underwriters&#8217; over-allotment option and excluding the Class A ordinary shares that are included within
the private units), plus (ii) all Class A ordinary shares and equity-linked securities issued or deemed issued, in connection with the
closing of the initial business combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in
the initial business combination and any units issued to our sponsor or any of its affiliates or to our officers or directors upon conversion
of working capital loans) minus (iii) any redemptions of Class A ordinary shares by public shareholders in connection with an initial
business combination; provided that such conversion of founder shares will never occur on a less than <span id="xdx_904_eus-gaap--CommonStockConversionBasis_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--CommonStockClassBMember_zwHvTm6YpHfl" title="Conversion basis">one-for-one basis</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of record of the Company&#8217;s Class A ordinary shares and Class B ordinary shares are entitled to one vote for each share held on all
matters to be voted on by shareholders. Unless specified in the amended and restated memorandum and articles of association or as required
by the Companies Act or stock exchange rules, an ordinary resolution under British Virgin Islands law and the amended and restated memorandum
and articles of association, which requires the affirmative vote of at least a majority of the votes cast by such shareholders as, being
entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the company is generally
required to approve any matter voted on by the Company&#8217;s shareholders. Approval of certain actions require an ordinary resolution
under British Virgin Islands law, which (except as specified below) requires the affirmative vote of in excess of 50 percent of the votes
cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general
meeting, and pursuant to the Company&#8217;s amended and restated memorandum and articles of association, such actions include amending
the amended and restated memorandum and articles of association and approving a statutory merger or consolidation with another company.
There is no cumulative voting with respect to the appointment of directors, meaning, following the Company&#8217;s initial Business Combination,
the holders of more than 50% of the ordinary shares voted for the appointment of directors can elect all of the directors. Prior to the
consummation of the initial Business Combination, only holders of the Class B ordinary shares will (i) have the right to vote on the appointment
and removal of directors and (ii) be entitled to vote on continuing the Company in a jurisdiction outside the British Virgin Islands (including
any ordinary resolution required to amend the constitutional documents or to adopt new constitutional documents, in each case, as a result
of approving a transfer by way of continuation in a jurisdiction outside the British Virgin Islands). Holders of the Class A ordinary
shares will not be entitled to vote on these matters during such time. These provisions of our amended and restated memorandum and articles
of association may only be amended if approved by an ordinary resolution passed by the affirmative vote of the holders representing at
least 90% of the issued Class B ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants
&#8212; </i>Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Warrants.
The Warrants will become exercisable <span id="xdx_900_ecustom--PeriodAfterWhichTheWarrantsAreExercisable_dtD_c20250320__20251231_zqmaOpl3oGMf" title="Period of warrants exercisable">30</span> days after the completion of our initial business combination, provided that the Company has an
effective registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the warrants
and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the
securities, or blue sky, laws of the state of residence of the holder (or we permit holders to exercise their warrants on a cashless basis
under the circumstances specified in the warrant agreement). If a registration statement covering the Class A ordinary shares issuable
upon exercise of the warrants is not effective by the 60th business day after the closing of our initial business combination, warrant
holders may, until such time as there is an effective registration statement and during any period when we will have failed to maintain
an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the
Securities Act or another exemption. Notwithstanding the above, if our Class A ordinary shares are at the time of any exercise of a warrant
not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1)
of the Securities Act, we may, at our option, require holders of public warrants who exercise their warrants to do so on a &#8220;cashless
basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event we so elect, we will not be required to file
or maintain in effect a registration statement. The Warrants will expire five years from the consummation of a Business Combination or
earlier upon redemption or liquidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may call the Warrants for redemption:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
        whole and not in part;</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
        a price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z0R8vEvtgNEk" title="Warrant price">0.01</span> per warrant; upon a minimum of <span id="xdx_908_ecustom--MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants_dtD_c20250320__20251231_zrGTHCbEFza3" title="Holders of warrants">30</span> days&#8217; prior written notice of redemption (the &#8220;30-day redemption period&#8221;);
        and</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
        and only if, the closing price of the Class A ordinary shares equals or exceeds $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zm2Uo06WbIbb" title="Share price">18.00</span> per share (as adjusted for adjustments to the number
        of shares issuable upon exercise or the exercise price of a warrant) for any <span id="xdx_904_ecustom--NumberOfTradingDaysForDeterminingTheSharePrice_dtD_c20250320__20251231_z9LF9cWDtqp1" title="Number of trading days">20</span> trading days within a <span id="xdx_901_ecustom--NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_dtD_c20250320__20251231_zO5hmy55kbj4" title="Number of consecutive trading days">30</span>-trading day period commencing
        at least 30 days after completion of our initial business combination and ending three business days before we send the notice of redemption
        to the warrant holders.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
private warrants are identical to the warrants sold in the IPO except that, so long as they are held by our sponsor or its permitted transferees,
the private warrants (i) are locked-up until the completion of our initial business combination and (ii) will be entitled to registration
rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted for share sub-divisions, share capitalizations,
reorganizations, recapitalizations and the like. Additionally, in no event will the Company be required to net cash settle the warrants.
If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in
the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution
from the Company&#8217;s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire
worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price is $11.50 per share, subject to adjustment as described herein. In addition, if (x) we issue additional Class A ordinary
shares or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at
an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price
to be determined in good faith by our board of directors and, in the case of any such issuance to our initial shareholders or their affiliates,
without taking into account any founder shares held by our initial shareholders or such affiliates, as applicable, prior to such issuance)
(the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity
proceeds, and interest thereon, available for the funding of our initial business combination on the date of the consummation of our initial
business combination (net of redemptions), and (z) the volume weighted average trading price of our Class A ordinary shares during the
<span id="xdx_90F_ecustom--NumberOfTradingDaysForDeterminingTheSharePrice_dtD_c20250320__20251231_zwi57d75Gbnf" title="Number of trading days">20</span> trading day period starting on the trading day prior to the day on which we consummate our initial business combination (such price,
the &#8220;Market Value&#8221;) is below $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231_z9oNRy7TT9cb" title="Warrants exercise price">9.20</span> per share, then the exercise price of the warrants will be adjusted (to the nearest cent)
to be equal to <span id="xdx_90C_eus-gaap--AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate_iI_dp_c20251231_zqUGRVZptye" title="Market value">115%</span> of the higher of the Market Value and the Newly Issued Price, and the $<span id="xdx_90C_eus-gaap--PreferredStockRedemptionPricePerShare_iI_c20251231_zMU6AAn42sQf" title="Redemption price">18.00</span> per share redemption trigger prices will
be adjusted (to the nearest cent) to be equal to <span id="xdx_900_ecustom--ShareRedemptionTriggerPrices_iI_dp_c20251231_zSYWzSorZM4l" title="Share redemption trigger prices">180%</span> of the higher of the Market Value and the Newly Issued Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p id="xdx_805_eus-gaap--FairValueDisclosuresTextBlock_zgzIFlKymks6" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b>NOTE 8. <span id="xdx_822_zoFua9dYO0U2">FAIR VALUE MEASUREMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in;text-align: justify">Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in;text-align: justify">Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in;text-align: justify">Level 3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The following table presents information about
the Company&#8217;s assets that are measured at fair value as of March 31, 2026 and December&#160;31, 2025, and indicates the fair
value hierarchy of the valuation inputs the Company utilized to determine such fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zn8oEnihuBh3" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B4_zvKnFHZJudo8" style="display: none">Schedule of fair value assets and liabilities</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March&#160;31,<br/>
    2026</b></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Asset:</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Cash held in trust</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center">1</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zC6ecbqmxuZ2" style="width: 9%; text-align: right">284,776,628</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2BhS1HcIrvl" style="text-align: right; width: 9%">287,319,687</td>
    <td style="width: 1%">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zgzxRXAizoPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
















<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>


<span></span>
</td>
<td class="text"><p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_zhQ9pqoDD5x" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8. <span id="xdx_821_zmhkA80TXS8d">FAIR VALUE MEASUREMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would
have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction
between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company
seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable
inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is
used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which
transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets
or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s assets that are measured at fair value as of August&#160;1, 2025 and
December&#160;31, 2025, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair
value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zl5uLowJiXVi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8B6_zXfmlkhV9ysd" style="display: none">Schedule of fair value assets and liabilities</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">August&#160;1, <br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Liability:</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">Fair value of over-allotment liability</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center">3</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20250801__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAcSNoM2bO7g" style="width: 9%; text-align: right" title="Liability">1,290,375</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Equity:</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Fair value of Public Warrants for Class A
        ordinary shares subject to possible redemption allocation</td>
    <td>&#160;</td>
    <td style="text-align: center">3</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_986_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20250801__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSFisT03zLO" style="text-align: right" title="Equity">8,061,250</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
        <br/>2025</b></span></p></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Asset:</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Cash held in trust</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center">1</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zfsfJbWiQ3Yl" style="width: 9%; text-align: right" title="Assets">284,776,628</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zKnLC9z1gto9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
over-allotment option was accounted for as a liability in accordance with ASC 815-40 and was presented within liabilities on the balance
sheet. The over-allotment option liability is measured at fair value at August&#160;1, 2025 and on a recurring basis, with changes in
fair value presented within change in fair value of over-allotment option liability in the statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used a Black-Scholes model to value the over-allotment option. The over-allotment option liability was classified within Level
3 of the fair value hierarchy at the measurement dates due to the use of unobservable inputs inherent in pricing models and assumptions
related to expected share-price volatility, expected life and risk-free interest rate. The Company estimates the volatility of its ordinary
share based on historical volatility that matches the expected remaining life of the over-allotment option. The risk-free interest rate
is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the over-allotment
option. The expected life of the over-allotment option is assumed to be equivalent to its remaining contractual term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs into the Black-Scholes model were as follows at initial measurement of the over-allotment option:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zGeBHNQlGzMa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B7_zoaVPMUgkntk" style="display: none">Schedule of initial measurement</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">August&#160;1, <br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Risk-free interest rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250729__20250801_zykgUgOp2FO7" title="Risk-free interest rate">4.31</span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expected term (years)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250729__20250801_zNNkudmOAsxi" title="Expected terms (years)">0.12</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expected volatility</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250729__20250801_zYdfJmo8Jv1" title="Expected volatility">22.7</span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Exercise price</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20250801_zsPlpHwwdwY4" title="Exercise price">10.00</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Fair value of over-allotment option</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90F_ecustom--FairValueOfOverallotmentOption_iI_c20250801_zvdduBXteOCb" title="Fair value of over-allotment option">0.3441</span></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zhBNM0cZxCt8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of Public Warrants was determined using Monte Carlo Simulation Model. The Public Warrants have been classified within shareholders&#8217;
equity and will not require remeasurement after issuance. The following table presents the quantitative information regarding market assumptions
used in the valuation of the Public Warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_znIXiw709dNi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BE_zsvTOTvZXEk3" style="display: none">Schedule of market assumptions</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">August&#160;1, <br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Estimated share price</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--SharePrice_c20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_pd" title="Estimated share price">9.68</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Exercise price</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_pd" title="Exercise Price">11.50</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Term (years)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zdgGz9zVX1q2" title="Term (years)">2.75</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Annual risk-free rate (term-matched)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zDaikQy4IZnb" title="Annual risk-free rate (term-matched)">3.75</span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expected warrant implied volatility based
        on warrants from comparable SPAC securities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zDGNenuK2YQ2" title="Expected warrant implied volatility based on warrants from comparable SPAC securities">14.44</span></td>
    <td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A6_zvYcYlSuTAmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and principal activities<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and principal activities</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--NatureOfOperations_zJC9E8GNL4Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1 &#8212; <span id="xdx_821_zu9lUW4uEBC">Description of Organization and
Business Operations</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Business Operations</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">D. Boral ARC Merger Corporation
(the &#8220;Company&#8221; or &#8220;PubCo&#8221;) is a Delaware company formed by D. Boral ARC Acquisition I Corp. (the &#8220;Parent&#8221;
or &#8220;BCAR&#8221;) on December&#160;19, 2025 (inception). The Company has adopted a fiscal year-end of December&#160;31. The Company
is authorized to issue <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_zZtAwYCwpUPa" title="Common stock, shares authorized">100</span> shares of Common Stock of par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zHBaoiIxdGw7" title="Common stock, par value">0.0001</span> each share. The Company was formed to be the surviving company
in connection with a contemplated business combination between the Parent and a target company. The Company has no principal operations
or revenue producing activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Going Concern</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company was formed by the
Parent. The Parent has until February&#160;1, 2027 to complete its initial business combination (unless further extended). If the Parent
is unable to complete the initial business combination by February&#160;1, 2027, the Parent must cease all operations and dissolve and
liquidate (unless further extended).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The accompanying financial statements
have been prepared assuming that the Company will continue as a going concern. If the Parent is unable to raise additional funds to alleviate
liquidity needs as well as complete a business combination by close of February&#160;1, 2027 (unless further extended), then the Company
will cease all operations except for the purpose of liquidating. The liquidity condition and date for liquidation and subsequent dissolution
raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any
adjustments that might result from the outcome of these uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_80C_eus-gaap--NatureOfOperations_zf7kYOkK4Imf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1 &#8212; <span><span id="xdx_824_zEQebogyAwxh">Description of Organization
and Business Operations</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Business Operations</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">D. Boral ARC Merger Corporation
(the &#8220;Company&#8221; or &#8220;PubCo&#8221;) is a Delaware company formed by D. Boral ARC Acquisition I Corp. (the &#8220;Parent&#8221;
or &#8220;BCAR&#8221;) on December&#160;19, 2025 (inception). The Company has adopted a fiscal year-end of December&#160;31. The Company
is authorized to issue <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_zAlPgdaBLNye" title="Common stock, shares authorized">100</span> shares of Common Stock of par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zyXoKWlrnUJg" title="Common stock, par value">0.0001</span> each share. The Company was formed to be the surviving company
in connection with a contemplated business combination between the Parent and a target company. The Company has no principal operations
or revenue producing activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Going Concern</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company was formed by
the Parent. The Parent has until February&#160;1, 2027 to complete its initial business combination (unless further extended). If the
Parent is unable to complete the initial business combination by February&#160;1, 2027, the Parent must cease all operations and dissolve
and liquidate (unless further extended).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The accompanying financial
statements have been prepared assuming that the Company will continue as a going concern. If the Parent is unable to raise additional
funds to alleviate liquidity needs as well as complete a business combination by close of February&#160;1, 2027 (unless further extended),
then the Company will cease all operations except for the purpose of liquidating. The liquidity condition and date for liquidation and
subsequent dissolution raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements
do not include any adjustments that might result from the outcome of these uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and principal activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_803_eus-gaap--NatureOfOperations_zZfsaWCqvzt2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>1.
<span id="xdx_827_zX0y8kzKCG">Organization and principal activities</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">On
June&#160;1, 2022, Exascale Labs Inc. (the &#8220;Company&#8221;) was formally incorporated in the State of Delaware. In accordance with
the Company&#8217;s Certificate of Incorporation, the total authorized share capital of the Company consists of <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20260331_pd" title="Common stock, shares authorized">1,500</span> shares of ordinary
shares, with a par value of $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20260331_pd" title="Common stock, par value">0.01</span> per share, all of which are of one class. The governance structure of the Company stipulates that the
business and affairs of the Company shall be managed by or under the direction of its board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">On
December&#160;16, 2025, the Company incorporated its wholly-owned subsidiary, Evana Alpha Pte. Ltd., in Singapore. The Company subscribed
for all <span id="xdx_907_ecustom--OrdinarySharesIssued_c20251201__20251216__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_zM1cMUnQc5T6" title="Ordinary shares issued">1,000</span> ordinary shares of the subsidiary, with a total issued share capital of Singapore Dollars <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251201__20251216__srt--CounterpartyNameAxis__custom--EvanaAlphaPteLtdMember_zTUt0Dx8cvJd" title="Number of shares issued">1,000</span>. The subsidiary&#8217;s
principal business activity is information technology consultancy (excluding cybersecurity).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company is a next-generation artificial intelligence (&#8220;AI&#8221;) infrastructure provider operating an asset-light, software-defined
graphics processing unit (&#8220;GPU&#8221;) compute platform and related AI infrastructure solutions. Exascale&#8217;s core business
includes GPU as a Service (&#8220;GaaS&#8221;), through which it provides reserved and on-demand access to high-performance GPU compute
capacity sourced from third-party data centers globally, as well as GPU cluster management and optimization services for artificial intelligence
data center (&#8220;AIDC&#8221;) operators. In addition, Exascale has developed certain modular data center, high-density liquid cooling,
high-voltage direct current (&#8220;HVDC&#8221;) power and energy storage solutions that are designed to address deployment bottlenecks
in AI infrastructure and that Exascale believes are ready for commercial engagement, although these capabilities have not yet generated
revenue as of the date of this proxy statement/prospectus. The platform is purpose-built for large-scale AI workloads, including large
language model (&#8220;LLM&#8221;) training, fine-tuning, and high-concurrency inference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
January&#160;2026, the Company adopted an Amended and Restated Certificate of Incorporation, which established a dual-class ordinary share
structure. Under this new structure, the Company&#8217;s equity is divided into 303 Class A ordinary shares and 1,197 Class B ordinary
shares, which are entitled to one (1) vote and twenty (20) votes per share, respectively. Despite the differential in voting power, Class
A and Class B ordinary shares rank pari passu in all other respects, sharing ratably in dividends and any distributions upon liquidation.
Furthermore, all outstanding Simple Agreements for Future Equity (&#8220;SAFEs&#8221;) are designated to convert or settle exclusively
into Class A ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
January&#160;2026, the Company entered into an Agreement and Plan of Merger (&#8220;BCA&#8221;) with D. Boral ARC Acquisition I Corp.(&#8220;BCAR&#8221;),
a publicly traded special purpose acquisition company (&#8220;SPAC&#8221;), D. Boral ARC Merger Corporation, a Delaware corporation and
a direct, wholly owned subsidiary of BCAR and D. Boral Arc Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary
of BCAR. Upon closing of the transaction, the combined company will be named Exascale Labs Holdings Inc.(such surviving company, &#8220;PubCo&#8221;)
and is expected to be traded on a national securities exchange.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_80E_eus-gaap--NatureOfOperations_zPEtwaHe5HV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>1. <span id="xdx_821_zp6MNea2BKv9">Organization and principal activities</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June&#160;1, 2022, Exascale Labs Inc. (the &#8220;Company&#8221;)
was formally incorporated in the State of Delaware. In accordance with the Company&#8217;s Certificate of Incorporation, the Company is
authorized to issue <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20220601_zokPjcfKfLZ4" title="Common stock, shares authorized">1,500</span> shares of ordinary shares, with a par value of $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220701_zXzvDlrClWQ5" title="Common stock, par value">0.01</span> per share, all in a single class. The governance structure
of the Company stipulates that the business and affairs of the Company shall be managed by or under the direction of its board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is a next-generation AI infrastructure
provider operating an asset-light, software-defined GPU compute platform and related AI infrastructure solutions. Exascale&#8217;s core
business includes GaaS, through which it provides reserved and on-demand access to high-performance GPU compute capacity sourced from
third-party data centers globally, as well as GPU cluster management and optimization services for AIDC operators. In addition, Exascale
has developed certain modular data center, high-density liquid cooling, HVDC power and energy storage solutions that are designed to address
deployment bottlenecks in AI infrastructure and that Exascale believes are ready for commercial engagement, although these capabilities
have not yet generated revenue as of the date of this proxy statement/prospectus. The platform is purpose-built for large-scale AI workloads,
including LLM training, fine-tuning, and high-concurrency inference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January&#160;2026, the Company adopted an Amended
and Restated Certificate of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#8217;s
equity is divided into 303 Class A ordinary shares and 1,197 Class B ordinary shares, which are entitled to one (1) vote and twenty (20)
votes per share, respectively. Despite the differential in voting power, Class A and Class B ordinary shares rank pari passu in all other
respects, sharing ratably in dividends and any distributions upon liquidation. Furthermore, all outstanding Simple Agreements for Future
Equity (&#8220;SAFEs&#8221;) are designated to convert or settle exclusively into Class A ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January&#160;2026, the Company entered into an
Agreement and Plan of Merger (&#8220;BCA&#8221;) with D. Boral ARC Acquisition I Corp.(&#8220;BCAR&#8221;), a publicly traded special
purpose acquisition company (&#8220;SPAC&#8221;), D. Boral ARC Merger Corporation, a Delaware corporation and a direct, wholly owned subsidiary
of BCAR and D. Boral Arc Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary of BCAR. Upon closing of the transaction,
the combined company will be named Exascale Labs Holdings Inc.(such surviving company, &#8220;PubCo&#8221;) and is expected to be traded
on a national securities exchange.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_z3Y09X9ArJqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 &#8212; <span id="xdx_827_z1QOLi23x5K2">Significant Accounting Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zIQgZvNM5Ow6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zJc7JPdBlxC3">Basis of Presentation</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and
pursuant to the rules and regulations of the SEC. The financial statements as of December&#160;31, 2025 and for the period from December&#160;19,
2025 (inception) through December&#160;31, 2025 respectively, are audited. In the opinion of management, the financial statements include
all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating
results and cash flows for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_844_ecustom--EmergingGrowthCompanyPolicyTextBlock_zIflyZXwhT3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zieh9LOsfqE3">Emerging Growth Company</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is an &#8220;emerging
growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of
2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period
which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company,
as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84C_eus-gaap--UseOfEstimates_zfT5mqcHOWl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zE9hBnagYMVa">Use of Estimates</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_841_ecustom--RisksAndUncertaintiesPolicyTextBlock_zOgwh60tmOf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_863_zT2IwjyYxMwg">Risks and Uncertainties</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zkhtSX54qy75" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86C_ziSLvQsMEBHb">Income Taxes</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company complies with the
accounting and reporting requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach to
financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the
financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 740 prescribes a recognition
threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be
taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#8217;s management determined the United States is the Company&#8217;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The provision for income taxes
was deemed to be immaterial for the period from December&#160;19, 2025 (inception) through December&#160;31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z9GnwSb4VdD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Loss Per Share</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company computes basic loss
per share (&#8220;EPS&#8221;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of December&#160;31, 2025 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrqiA2cU5R4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zTUwRw7Nlatj">Fair Value of Financial Instruments</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Fair value is defined as the
price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants
at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active
        markets;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly
        observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets
        that are not active; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity
        to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant
        value drivers are unobservable.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In some circumstances, the inputs
used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value
measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair
value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSNNhvz3V6Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zM7M5EBTVgG3">Recently adopted accounting pronouncements</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November&#160;2023, the FASB
issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose
information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public
entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment
disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since inception.
Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material
effect on the Company&#8217;s financial statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zhfiwIBnxW47" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 &#8212; <span><span id="xdx_82F_z8WT7pqmunKd">Significant Accounting Policies</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoCc0oxIXVye" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86A_zRelC9ayrXw9">Basis of Presentation</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. The financial statements as of March
31, 2026 and for the three months ended March 31, 2026 respectively, are un audited. In the opinion of management, the financial
statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the
financial position, operating results and cash flows for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84E_ecustom--EmergingGrowthCompanyPolicyTextBlock_zxCuTvrFDI99" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_864_zu39EgO8Buwg">Emerging Growth Company</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is an &#8220;emerging
growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act
of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition
period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging
growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because
of the potential differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84A_eus-gaap--UseOfEstimates_zBvkspy1qQI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86E_zvzbCsC8L8Ff">Use of Estimates</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_845_ecustom--RisksAndUncertaintiesPolicyTextBlock_zSX4tZHeTxo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86D_zOSz8DGNyjqf">Risk and Uncertainties</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zAGgh3xYfpt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_865_zOgsMgqR3B78">Income Taxes</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company complies with
the accounting and reporting requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach
to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between
the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 740 prescribes a
recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected
to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#8217;s management determined the United States is the Company&#8217;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provision for income
taxes was deemed to be immaterial for the three months ended March 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z6IKhtn0tFHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_866_z5LJmpNKovA1">Loss Per Share</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company computes basic
loss per share (&#8220;EPS&#8221;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of March 31, 2026 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zPwok5ETZsz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86E_zAu283mu3nxe">Fair Value of Financial Instruments</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Fair value is defined
as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market
participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring
fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments
    in active markets;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly
    or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar
    instruments in markets that are not active; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring
    an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs
    or significant value drivers are unobservable.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In some circumstances, the
inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair
value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the
fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhxo4ncWR2Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zIe1QxnsUF6c">Recently adopted accounting pronouncements</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November&#160;2023, the
FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to
disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis.
Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing
segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since
inception. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would
have a material effect on the Company&#8217;s financial statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_z3uJvVhT76yk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>2.
<span id="xdx_823_zJDfylZ6eVGa">Summary of significant accounting policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84E_ecustom--GoingConcernPolicyTextBlock_zjTeaYmk2USj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>a.
<span id="xdx_867_zT6r15wrPfT">Going concern</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">As
of March&#160;31, 2026, the Company had cash and cash equivalents and U.S. Dollar Coin (&#8220;USDC&#8221;) of $<span id="xdx_90B_ecustom--CashAndCashEquivalentsAndU.s.DollarCoin_iI_pn3n3_dm_c20260331_zOweLGQ0nMmd" title="Cash and cash equivalents and U.S. Dollar Coin">5.1 </span>million
and current liabilities of $29.2 <span id="xdx_90B_eus-gaap--LiabilitiesCurrent_iI_c20260331_zx0VQfPseO64" style="display: none" title="Current liabilities">29,153,918</span>
million. For the nine months ended March&#160;31, 2025, the Company used $0.8 <span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20240701__20250331_zXrnaRJA6DE6" style="display: none" title="Cash for operating activities">(757,960)</span>
million in operating activities, while for the nine months ended March&#160;31, 2026, it used $3.8 <span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20250701__20260331_z0FbPDcDfL21" style="display: none" title="Cash for operating activities">(3,758,611)</span>
million. The Company incurred net losses of $6.2 <span id="xdx_90B_eus-gaap--NetIncomeLoss_c20240701__20250331_zVBAnoAbYj2e" style="display: none" title="Net losses">(6,178,537)</span>
million and $7.9 <span id="xdx_906_eus-gaap--NetIncomeLoss_c20250701__20260331_zwLqC0GO7Qj2" style="display: none" title="Net losses">(7,916,977)</span>
million for these respective periods. Since inception, the Company has incurred recurring net losses from operations and negative
cash flows from operating activities. As of March&#160;31, 2026, the Company had an accumulated deficit of $21.1 <span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20260331_zxZwKyas1Wfb" style="display: none" title="Accumulated deficit">(21,134,012)</span>
million. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern within one year
of the date these unaudited condensed consolidated financial statements are issued.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Management
has formulated and is actively pursuing plans to mitigate these conditions and secure the Company&#8217;s continued operations. In connection
with the Company&#8217;s contemplated business combination with a SPAC and related financing activities, the Company expects to access
additional capital through external funding sources. In addition, the Company continues to focus on expanding its market presence and
developing client relationships to drive revenue growth, while managing operating expenses, with the objective of improving cash flows
from operations over time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
purposes of this disclosure, &#8220;SPAC&#8221; refers to a special purpose acquisition company formed to effect a merger, share exchange,
asset acquisition, share purchase, reorganization or similar business combination with one or more operating businesses. &#8220;De-SPAC&#8221;
refers to the business combination transaction pursuant to which an operating company combines with a SPAC, following which the combined
company becomes publicly listed (or otherwise succeeds to the SPAC&#8217;s public company status).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s
negative working capital position is primarily attributable to the classification of SAFEs. Excluding the accounting impact of the SAFEs,
which will only be paid in cash upon Liquidity Events and Dissolution Event (as defined in Note 8), management believes the Company&#8217;s
available cash resources are sufficient for near-term operating needs. If additional liquidity is required, the Company&#8217;s majority
shareholder has entered into a binding support agreement to provide funding to cover anticipated operating cash flow shortfalls through
the completion of the contemplated de-SPAC transaction. The support agreement is effective for a period of eighteen months from June&#160;10,
2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However,
the de-SPAC transaction (including the SAFEs conversion) have not been fully implemented as of the date these unaudited condensed consolidated
financial statements are issued. There can be no assurance that these plans will be successfully completed within the required time frame,
on acceptable terms, or at all. If the primary plans are not successful, the Company&#8217;s alternative courses of action would further
intensify efforts in market expansion and client development to increase revenue, while diligently controlling costs to ensure sufficient
cash flow from operating activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company may not be able to secure necessary financing in a timely manner or on favorable terms, or successfully execute its operational
turnaround. These circumstances give rise to substantial doubt that the Company will continue as a going concern and these unaudited condensed
consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zrDsuQdfyKG2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>b.
<span id="xdx_860_z2ZzsSnntEpd">Basis of presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally
accepted accounting principles (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange
Commission (&#8220;SEC&#8221;) regarding interim financial reporting. Certain information and note disclosures normally included in
the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP have been condensed consolidated or
omitted pursuant to such rules and regulations. As such, the information included in this interim financial report should be read in
conjunction with the audited financial statements and accompanying notes for the two years ended June&#160;30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
accompanying unaudited condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly
the financial position, operating results and cash flows of the Company for each of the periods presented. The results of operations for
the three and nine months ended March&#160;31, 2026 are not necessarily indicative of results to be expected for any other interim period
or for the year ending June&#160;30, 2026. The condensed consolidated balance sheet as of June&#160;30, 2025 was derived from the audited
financial statements at that date but does not include all of the disclosures required by U.S. GAAP for annual financial statements.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_841_eus-gaap--UseOfEstimates_zcUBkLyQ302a" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>c.
<span id="xdx_869_zJzlNRZuupR8">Use of estimates and assumptions</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation
of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported
in the unaudited condensed consolidated financial statements and accompanying notes. Management believes that the estimates used in preparing
the unaudited condensed consolidated financial statements are reasonable and prudent; however, actual results could differ from these
estimates under different assumptions or conditions.&#160;Significant accounting estimates include recognition and measurement of SAFEs
notes, recognition and measurement of share-based compensation, the allowance for expected credit losses, deferred tax assets and valuation
allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z3MfqTrj1Ctg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>d.
<span id="xdx_861_zefs2YE20oYg">Fair value measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
accordance with FASB ASC 820&#160;<i>Fair Value Measurements and Disclosures</i>, fair value is defined as the price that would be received
to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company
uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes
between market participant assumptions developed from market data obtained from outside sources (observable inputs) and the Company&#8217;s
own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable
inputs).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of
inputs used to measure fair value are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Level
1: Quoted prices in active markets for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Level
2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Level
3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash
flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment
or estimation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management during
the nine months ended March&#160;31, 2025 and 2026. The carrying amount of cash and cash equivalents, accounts receivable, refundable
deposits receivable, other receivables, accounts payable, refundable deposits payable and other current liabilities approximated their
fair values as of June&#160;30, 2025 and March&#160;31, 2026. For the nine months ended March&#160;31, 2025 and 2026, the Company carried
SAFEs and digital assets at their fair value (see&#160;Note 4-Fair Value Measurements for fair value information).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_844_ecustom--FunctionalCurrencyPolicyTextBlock_z2nCVmTUVaCh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>e.
<span id="xdx_86D_zpLd8Tfyfj3f">Functional currency</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
accompanying unaudited condensed consolidated financial statements are presented in the United States dollar (&#8220;US$&#8221;).
The functional currency of the Company and its subsidiary is the US$.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">All
transactions are measured and recorded in the Company&#8217;s functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z91JQokNSbAl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>f.
<span id="xdx_867_zTk17b0iUrZg">Cash and cash equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company considers all highly liquid investments instruments purchased with a maturity period of three months or less to be cash or cash
equivalents. The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents approximate their fair value.
As of June&#160;30, 2025 and March&#160;31, 2026, the Company does <span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zmHRDKKWlBMg" title="Cash equivalents"><span id="xdx_908_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20260331_zVbuobGqAgp7" title="Cash equivalents">no</span></span>t have any cash equivalents.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84A_ecustom--CryptoAssets_zZhlCmsQAIQk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>g.
<span id="xdx_862_zW5hKqqXdcS6">Crypto assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s
crypto assets classified in current assets are held primarily for use in the ordinary course of business which is expected to be actively
utilized or converted within the normal operating cycle and such crypto assets can be sold in a highly liquid marketplace. During the
nine months ended March&#160;31, 2026, the Company only held crypto assets of Tether USD (&#8220;USDT&#8221;) and USDC, which are principally
funded by SAFE investors and as a form of payment for transaction revenue. The Company&#8217;s crypto assets are held with qualified
third-party custodians who provide secure storage and safeguarding of the Company&#8217;s crypto assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><i><span style="text-decoration: underline">USDC</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">USDC
is a stablecoin redeemable on a one-to-one basis for U.S. dollars and is accounted for as a financial instrument in the unaudited condensed
consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><i><span style="text-decoration: underline">Crypto
assets other than USDC</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">On
December&#160;13, 2023, the FASB issued ASU 2023-08, which addresses the accounting and disclosure requirements for certain cryptocurrencies.
The new guidance requires entities to subsequently measure certain cryptocurrencies at fair value, with changes in fair value recorded
in net income in each reporting period. The Company applied the ASU since its holding of crypto assets in December&#160;2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Digital
assets that are received as noncash consideration in our revenue arrangements and paid in purchases of professional service and others
are presented as cash flows from operating activities in other operating activities settled in digital assets and USDC. Digital assets
that are received in our revenue arrangements and sold for cash within seven days are presented as cash flows from operating activities,
while other digital asset activity held longer than seven days is reflected as cash flows from investing activities under disposal of
digital assets and USDC held in the consolidated statements of cash flows. The Company presents crypto assets other than USDC separately
from other intangible assets and USDC, recorded as digital assets on the unaudited condensed consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
the three months ended March&#160;31, 2026, the Company recorded receipt and disbursement of digital assets amounted to $<span id="xdx_90E_ecustom--ReceiptOfDigitalAssets_c20260101__20260331_pp0p" title="Receipt of digital assets">644,616</span> and $<span id="xdx_901_ecustom--DisbursementOfDigitalAssets_c20260101__20260331_pp0p" title="Disbursement of digital assets">796,781</span>.&#160;For
the nine months ended March&#160;31, 2026, the Company recorded receipt and disbursement of digital assets amounted to $<span id="xdx_909_ecustom--ReceiptOfDigitalAssets_c20250701__20260331_pp0p" title="Receipt of digital assets">939,397</span> and $<span id="xdx_904_ecustom--DisbursementOfDigitalAssets_c20250701__20260331_pp0p" title="Disbursement of digital assets">939,397</span>,
respectively, which resulted in an ending balance of nil. The Company&#8217;s balances related to digital assets and stablecoins during
the period included USDT and USDC, both of which are USD-pegged stablecoins. <span id="xdx_901_ecustom--FairValueGainOrLossOnDigitalAssets_pp0d_do_c20260101__20260331_zi458qVUCNt1" title="Fair value gain or loss on digital assets"><span id="xdx_905_ecustom--FairValueGainOrLossOnDigitalAssets_pp0d_do_c20250701__20260331_zVXF30cgUVQc" title="Fair value gain or loss on digital assets">No</span></span> fair value gain or loss on digital assets was recognized
for the three and nine months ended March&#160;31, 2026 considering the low volatility in the fair value of USDT during the three and
nine months ended March&#160;31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_843_ecustom--ExpectedCreditLossAndAccountsReceivablePolicyTextBlock_zyxTRes82yL6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>h.
<span id="xdx_863_z4jvYtW2zBHk">Expected credit loss and accounts receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company adopted Financial Standards Accounting Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 326 &#8220;<i>Financial
Instruments&#160;&#8212;&#160;Credit Losses</i>&#8221; (&#8220;ASC&#160;326&#8221;) on January&#160;1, 2023.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s accounts receivable are within the scope of ASC&#160;326. ASC&#160;326 introduces an approach based on expected credit
losses on financial assets at amortized cost. Upon adoption of ASC&#160;326, the Company estimates the expected credit losses for accounts
receivable using the roll-rate method on a collective basis when similar risk characteristics exist. Expected credit losses are included
in general and administrative expenses in the statements of operations and comprehensive loss. After all attempts to collect a receivable
have failed, the receivable is written off against the allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Accounts
receivable represents those receivables derived in the ordinary course of business, net of an allowance for any potentially uncollectible
amounts. The Company makes estimates of expected credit and collectability trends for the allowance for credit losses based upon its assessment
of various factors, including historical experience, the age of the accounts receivable balances, credit quality of its customers, current
economic conditions, reasonable and supportable forecasts of future economic conditions that may vary by geography, customer-type, or
industry sub-vertical, and other factors that may affect its ability to collect from customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Although
the Company has historically not experienced significant credit losses, they may experience increasing credit loss risks from accounts
receivable in future periods if its customers are adversely affected by economic pressures or uncertainty associated with local or global
economic recessions, or other customer-specific factors, and actual experience in the future may differ from their past experiences or
current assessment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_849_ecustom--DeferredOfferingCostsPolicyTextBlock_zampFPTaHJw6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>i.
<span id="xdx_866_zIRNVy8x1Vb6">Deferred offering costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company follows the requirements of FASB ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212; &#8220;Expenses
of Offering&#8221;. Deferred offering costs consist of underwriting, legal, and other professional expenses incurred through the balance
sheet date that are directly related to the intended de-SPAC Transaction. These costs will be charged to shareholders&#8217; equity, netted
against the proceeds, upon the completion of the Business Combination. Should the transaction prove to be unsuccessful, these deferred
costs, as well as additional expenses to be incurred, will be charged to the statements of operations and comprehensive loss. As of June&#160;30,
2025 and March&#160;31, 2026, the Company deferred nil <span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20250630_z5VXiUJdObX8" style="display: none" title="Deferred offering costs">0</span> and $<span id="xdx_90C_eus-gaap--DeferredOfferingCosts_iI_c20260331_zPoYFoMfe149" title="Deferred offering costs">95,000</span> of transaction costs, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_846_ecustom--AdvanceToSuppliersPolicyTextBlock_zZ6KgRaaPBG2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>j.
<span id="xdx_866_zzQ6PbxNF5wb">Advance to suppliers</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Advance
to suppliers represent prepayments made to vendors in connection with the purchase of services. Advance is recorded at the amount paid
and are classified as current assets when the related services are expected to be received within one year or the normal operating cycle.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_848_ecustom--RefundableDepositsReceivablePolicyTextBlock_zk0hhYTHhzHb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>k.
<span id="xdx_869_zdl6xUSc9d8g">Refundable deposits receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Refundable
deposits receivable mainly represents security deposits and refundable cooperation deposits paid to suppliers and business partners that
are contractually recoverable upon the completion of services. These amounts are recorded as assets when paid, generally at the amount
paid. Deposits expected to be recovered within one year are classified as current; otherwise, they are classified as non-current. Allowance
should be assessed under CECL, and write off when not recoverable. The Company evaluates the credit risk of refundable deposits receivable
and recognizes an allowance for credit losses based on the current expected credit losses (&#8220;CECL&#8221;) model. Specific balances
are written off when they are deemed uncollectible and all collection efforts have been exhausted. As of June&#160;30, 2025 and March&#160;31,
2026, <span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_zDO4z5wPjGpf" title="Allowance for expected credit losses"><span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20260331_zQu1ABES8Qma" title="Allowance for expected credit losses">no</span></span> allowance for credit losses was recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_845_ecustom--PrepaidResearchAndDevelopmentExpensesPolicyTextBlock_zj47oP2LEO03" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>l.
<span id="xdx_866_zznJ5p0oZj1b">Prepaid research and development expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Prepaid
research and development expenses represent advance payments to third-party service providers for technical, design, and development services.
These amounts are initially recorded as prepaid assets and are subsequently recognized as research and development expenses in the period
the services are rendered, in accordance with the terms of the respective agreements. The Company periodically reviews the status of these
agreements to ensure the prepaid balance properly reflects the value of services not yet received. For the three and nine months ended
March&#160;31, 2026, the Company recognized&#160;$<span id="xdx_907_ecustom--AmortizationOfPrepaidResearchAndDevelopmentCosts_c20260101__20260331_zCXNiflih5bg" title="Amortization of prepaid research and development costs">625,000</span> and $<span id="xdx_90C_ecustom--AmortizationOfPrepaidResearchAndDevelopmentCosts_c20250701__20260331_zBFunA6k8NXc" title="Amortization of prepaid research and development costs">1,875,000</span>, respectively, of expense related to the amortization of prepaid
research and development costs, which was included in research and development expense.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84D_ecustom--OtherReceivablesPolicyRextBlock_zhEjVv3wuafj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>m.
<span id="xdx_86D_zATAJPzQnQpl">Other receivables</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Other
receivables represent funds temporarily held in trust by an employee acting on the Company&#8217;s behalf. As of June&#160;30, 2025
and March&#160;31, 2026, the balance were $<span id="xdx_90D_eus-gaap--OtherReceivables_iI_pp0d_c20250630_za2VXMC6Mpee" title="Other receivables">1,207,626</span>
and <span id="xdx_908_eus-gaap--OtherReceivables_iI_pp0d_c20260331_zA3XBehG7pA7" style="display: none" title="Other receivables">0</span> nil, respectively, with the nil balance as of March 31, 2026 resulting from the employee having repaid all outstanding amounts to the Company. The balance
as of June 30, 2025 was primarily comprising proceeds from SAFEs agreements received via the employee and net of payments made to
designated suppliers at the Company&#8217;s direction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zCXIK2Zay5zh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>n.
<span id="xdx_865_zZTnYmCZy9f7">Equipment, net</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Equipment,
net is stated at cost less accumulated depreciation and impairment, if any. Depreciation is computed using the straight-line method over
the estimated useful lives of three or five years, depending on the asset category.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_847_ecustom--RefundableDepositsPayablePolicyTextBlock_zPSaUzzvIgEa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>o.
<span id="xdx_86F_zFO7q56sC1Ja">Refundable deposits payable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Refundable
deposits payable represent security payments received from a third party and customers, which are required for certain intelligent computing
power service arrangements. As of June&#160;30, 2025 and March&#160;31, 2026, the balance were $<span id="xdx_906_ecustom--RefundableDepositsPayable_iI_pp0d_c20250630_zT5OwPspNGaa" title="Refundable deposits payable">1,445,580</span> and $<span id="xdx_907_ecustom--RefundableDepositsPayable_iI_pp0d_c20260331_zlF8FJ2gxvTd" title="Refundable deposits payable">1,174,702</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zVTnprYtqQTc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>p.
<span id="xdx_862_zigYXt8xtSLl">Impairment of long-lived assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company reviews its long-lived assets, equipment, for impairment whenever events or changes in circumstances indicate the carrying amount
of an asset may not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset
to the future undiscounted cash flows expected to be generated from the use of the asset and its eventual disposition. If such assets
are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair
value of the impaired assets. Assets to be disposed of are reported at the lower of their carrying amount or fair value less cost to sell.
There was <span id="xdx_905_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20240701__20250331_zrLs0b2fiOF6" title="Impairment of long-lived assets"><span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20250701__20260331_z8ukRmzY0PX3" title="Impairment of long-lived assets">no</span></span> impairment of long-lived assets for the nine months ended March&#160;31, 2025 and 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_849_ecustom--SimpleAgreementsForFutureEquityPolicyTextBlock_zdOdrfeIirK4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>q.
<span id="xdx_86C_zSfMxlp0w9ih">Simple agreements for future equity</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">SAFEs
issued by the Company are freestanding financial instruments. As they contain certain redemption or liquidation features that&#160;may&#160;require
the Company to settle the obligation in cash upon the occurrence of defined events (e.g., a change of control or dissolution), the instruments&#160;create
an obligation that meets the definition of a liability. Accordingly, the SAFEs are classified in their entirety as liabilities on the
balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">These
liabilities are measured at fair value upon initial recognition and are subsequently remeasured at fair value at each reporting date.
All changes in their fair value are recognized in&#160;the condensed consolidated statement of operations and comprehensive loss in the
period in which they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84A_eus-gaap--RevenueRecognitionDeferredRevenue_z7voQ64y5MR7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>r.
<span id="xdx_86B_zHHFuv3eFudi">Revenue recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company applied ASC Topic&#160;606 &#8220;<i>Revenue from Contracts with Customers</i>&#8221; (&#8220;ASC&#160;606&#8221;) for all periods
presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
five-step model defined by ASC&#160;606 requires the Company to (i)&#160;identify its contracts with clients, (ii)&#160;identify its performance
obligations under those contracts, (iii)&#160;determine the transaction prices of those contracts, (iv)&#160;allocate the transaction
prices to its performance obligations in those contracts, and (v)&#160;recognize revenue when each performance obligation under those
contracts is satisfied. Revenue is recognized when promised goods or services are transferred to the client in an amount that reflects
the consideration expected in exchange for those goods or services.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company reports all of its revenues on a gross basis.&#160;This determination is based on the Company&#8217;s assessment that it is the
principal in its revenue arrangements. The Company controls the service delivery platform and infrastructure before the service is provided
to the customer. It is primarily responsible for fulfilling the service promise, has discretion in setting prices, and assumes the credit
risk associated with the customer receivable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">As
a practical expedient, the Company elected to expense the incremental costs of obtaining a contract when incurred if the amortization
period of the asset that the Company otherwise would have recognized is one year or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Pursuant
to ASC 606, the Company recognizes revenue based on the transaction price, which is the amount of consideration it expects to be entitled
to exchange for transferring services to customers. For Intelligent Computing Power Services, contract consideration is generally fixed
and is typically stated as a fixed monthly fee determined by (i) the contractually specified number of GPUs (capacity) and (ii) the service
period. Accordingly, the transaction price is generally the fixed contractual amount. The Company recognizes revenue over time as the
services are provided throughout the contract term. The Company offers payment terms ranging from 0 to 6 months, depending on customers&#8217;
credit profiles and service requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company does not provide warranties for its services and does not offer service-type warranty arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
following is a description of the principal activities of the Company from which the Company generates its revenue under ASC 606.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">(i)
Revenue for intelligent computing power service</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company leverages its expertise in high-performance computing and cloud-native architectures to build and operate stable, efficient, and
scalable GPU computing platforms through modular data center design and liquid cooling technology. The Company uses these platforms to
provide computing resources for large-scale AI training, model inference, and high-performance scientific computing to commercial enterprise
clients with substantial GPU computing requirements. Supporting services include GPU server environment deployment, cluster scheduling
and performance optimization, high-speed network interconnection, real-time monitoring and intelligent alerting systems, as well as industry-compliant
security and regulatory assurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company accounts for the above promises as a single performance obligation because they are highly integrated and not separately identifiable
in the context of the contract. The Company provides an integrated, managed GPU computing platform in which computing capacity, deployment/configuration,
scheduling, networking, monitoring, and security/compliance are interdependent and together deliver a single combined service&#8212;continuous
access to a functioning and secured platform over the contractual term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company provides intelligent computing power services under two pricing models: (i) reserved capacity arrangements and (ii) on-demand
(pay-as-you-go) arrangements. The following table presents revenue recognized during the period by arrangement type:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zd2TxFvdYVol" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8BE_zsDAbjhGLAp7" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of Revenue recognition</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Reserved
        capacity arrangements</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90A_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues">1,758,921</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_908_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues">3,725,315</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues">4,161,985</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues">10,428,983</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">On-demand
        arrangements</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues">5,436</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues">1,341</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues">6,482</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues">12,526</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_905_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues">1,764,357</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_903_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues">3,726,656</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_900_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues">4,168,467</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_90E_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues">10,441,509</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

<p id="xdx_8A4_zk9Xg0gC6OZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>







<p style="font: 10pt Times New Roman, Times, serif; margin: 0px"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Reserved
capacity arrangements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company enters into reserved capacity arrangements, which generally provide committed intelligent computing power services for a defined
service term ranging from 3 months to 3 years, with the majority of such arrangements having a one-year term. These contracts typically
are non-cancelable, or may be canceled only under limited conditions with early notifications required. Payment terms generally range
from 0-6 months upon the completion of services, and certain arrangements require prepayments. Any prepayments are recorded as contract
liabilities and recognized over the service term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
performance obligation is satisfied over time because the customer simultaneously receives and consumes the benefits. Revenue is recognized
using a time-elapsed output method over the contractual service period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">On-demand
(pay-as-you-go) arrangements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif;text-align: justify; margin-top: 0; margin-bottom: 0">The Company provides customers with on-demand
access to intelligent computing power and GPU resources under pay-as-you-go model which requires advance payment. Customer advances are
recorded as contract liabilities and recognized as revenue over the time during the provision of related services underlying the contract
term. The revenue is recognized over time because the customer can simultaneously receive and consume the benefits during the service
period. These arrangements generally do not include a fixed contractual term or minimum usage commitments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">(ii)
Revenue from comprehensive data center service</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company leverages its project experience in infrastructure management, cluster optimization, and system monitoring to provide full-cycle
operational support to data center asset owners. Services encompass facility environment deployment, network architecture implementation,
security and compliance system development, daily operational monitoring, and emergency fault response. Revenue is recognized over time
because the Company&#8217;s services are performed throughout the contract term and the customer benefits as the services are provided.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
the three months ended March&#160;31, 2025 and 2026, $<span id="xdx_909_eus-gaap--Revenues_c20250101__20250331_pp0p" title="Revenue">1,862,158</span> and $<span id="xdx_90B_eus-gaap--Revenues_c20260101__20260331_pp0p" title="Revenue">3,754,586</span> of the revenue of the Company&#8217;s was recognized over
time, respectively. For the nine months ended March&#160;31, 2025 and 2026, $<span id="xdx_905_eus-gaap--Revenues_c20240701__20250331_pp0p" title="Revenue">4,475,885 </span>and $<span id="xdx_903_eus-gaap--Revenues_c20250701__20260331_pp0p" title="Revenue">10,561,331</span> of the revenue of the Company&#8217;s
was recognized over time, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Revenue
disaggregated by service lines for the three months and the nine months ended March&#160;31, 2025 and 2026 is disclosed in the table below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_z4whYoH0Yw36" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B8_z323FGsdNtth" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of Revenue disaggregated</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenue
        from intelligent computing power service</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z29WimMIRYO5" title="Total">1,764,357</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--Revenues_pp0d_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z0wPR3mOXwde" title="Total">3,726,656</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_904_eus-gaap--Revenues_pp0d_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zzqz7UuAay4i" title="Total">4,168,467</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zh7mCphOG5Ja" title="Total">10,441,509</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Revenue
        from comprehensive data center service</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total">97,801</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total">27,930</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total">307,418</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total">119,822</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_90B_eus-gaap--Revenues_pp0d_c20250101__20250331_zwjWXHIVxdh" title="Total">1,862,158</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_90D_eus-gaap--Revenues_pp0d_c20260101__20260331_zNTOV4dIJ4Sh" title="Total">3,754,586</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_903_eus-gaap--Revenues_pp0d_c20240701__20250331_zNWqBnz3BD5a" title="Total">4,475,885</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_906_eus-gaap--Revenues_pp0d_c20250701__20260331_zdRfOMzRsXv6" title="Total">10,561,331</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

<p id="xdx_8A4_zatc3Yp3kc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84C_ecustom--ContractLiabilitiesPolicyTextBlock_z2PT6xnTNlO" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>s.
<span id="xdx_869_z3dd7lxTNbH4">Contract liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company receives advance payments from its customers for services to be provided in the future. These payments are recorded as&#160;contract
liabilities&#160;on the balance sheet within &#8220;Contract liabilities&#8221;.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Contract
liabilities are recognized when consideration is received from a customer prior to the Company satisfying its related performance obligations.
For these service contracts, the Company recognizes revenue, and reduces the contract liabilities,&#160;over time&#160;as the services
are rendered and the performance obligations are satisfied. Revenue recognized during the nine months ended March&#160;31, 2025 and 2026
that was included in the contract liability balance at the beginning of the period was $<span id="xdx_90A_ecustom--RevenueRecognized_c20240701__20250331_pp0p" title="Revenue recognized">95,326</span> and $<span id="xdx_90D_ecustom--RevenueRecognized_pp0d_c20250701__20260331_z9oT97FjUGcd" title="Revenue recognized">366,075</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--CostOfSalesPolicyTextBlock_zaoHhLB8Cxzj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>t.
<span id="xdx_863_z6GbgvPwOLFd">Cost of revenues</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s cost of revenues primarily includes computing power service, professional service fees and staff costs and employee benefits.
All the cost of revenues are recognized in the period in which the related services occur or the benefits are received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_844_ecustom--SellingAndMarketingExpensesPolicyTextBlock_zw8zqwj9sNL3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>u.
<span id="xdx_864_ziTHMzLNeaI4">Selling and marketing expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s selling and marketing expenses primarily include: (i) advertising and promotion expenses, (ii) staff costs, employee benefits
and share-based compensation, and (iii) travel and other routine office expenses. All expenses are recognized in the period in which the
related services occur or the benefits are received. The Company expenses advertising costs as incurred, and for the nine months ended
March&#160;31, 2025 and 2026, the Company incurred advertising and promotion expenses of $<span id="xdx_908_eus-gaap--MarketingAndAdvertisingExpense_c20240701__20250331_pp0p" title="Advertising and promotion expenses">76,090</span> and $<span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20250701__20260331_pp0p" title="Advertising and promotion expenses">32,113</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zPGLlXD14Ag2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>v.
<span id="xdx_86B_zfPkq0yTYPQi">Research and development expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s research and development expenses mainly consist of software development outsourcing service fees, staff costs and employee
benefits, and testing expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_841_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zXxvFOjeOFW2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>w.
<span id="xdx_866_zkb75BAicCy2">General and administrative expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s general and administrative expenses mainly consist of staff costs and employee benefits, professional service fees, depreciation
expenses and other operating expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zM8egXJLQ5Fa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>x.
<span id="xdx_863_znTdepZ9jHh1">Income tax</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Income
taxes are determined in accordance with the provisions of ASC Topic 740, &#8220;Income Taxes&#8221; (&#8220;ASC Topic 740&#8221;). Under
this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities
are measured using enacted income tax rates expected to apply to taxable income in the periods in which those temporary differences are
expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income
in the period that includes the enactment date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">ASC
740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial
statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be
recognized in the unaudited condensed consolidated financial statements when it is more likely than not the position will be
sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest
amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority
assuming full knowledge of the position and relevant facts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_847_ecustom--CapitalStructurePolicyTextBlock_zj8IHwVClyZk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>y.
<span id="xdx_865_zxrlWlb60CN6">Capital structure</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company is authorized to issue <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20250630_zxhDDryref03" title="Common stock, shares authorized">1,500</span> ordinary shares of $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250630_z9V4hGvU5My3" title="Common stock, par value">0.01</span> par value each. As of June&#160;30, 2025, there were <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20250630_zDM1htk1G69f" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20250630_zYzvDTOvJVAi" title="Common stock, shares outstanding">1,500</span></span> shares issued
and outstanding.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Pursuant
to the resolution of the board of directors on January&#160;8, 2026, the authorized share capital of <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20260108_z7MXAFFZzI8i" title="Common stock, shares authorized">1,500</span> ordinary shares was re-designated
to <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zYWtA0wxDxN4" title="Common stock, shares authorized">303</span> Class A ordinary shares and <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_z1Wg9UO1Hwh6" title="Common stock, shares authorized">1,197</span> Class B ordinary shares. Holders of Class A ordinary shares and Class B ordinary shares have
the same rights, except for voting and conversion rights. Each Class A ordinary share is entitled to one vote; and each Class B ordinary
share is entitled to twenty votes and is convertible into one Class A ordinary share at any time by the holder thereof. Class A ordinary
shares are not convertible into Class B ordinary shares under any circumstances. Furthermore, all outstanding warrants, options, and SAFEs
are designated to convert or settle exclusively into Class A ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">As
of March&#160;31, 2026, there were <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pd" title="Common stock, shares authorized">303</span> Class A ordinary shares and <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pd" title="Common stock, shares authorized">1,197</span> Class B ordinary shares outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z72hDOJ3JON1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>z.
<span id="xdx_86B_z63uLSARL1W8">Share-based compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company grants share options of the Company to eligible employees and&#160;non-employees. The Company accounts for share-based awards
issued to employees and&#160;non-employees in accordance with ASC Topic 718 <i>Compensation &#8211; Stock Compensation. </i>The Company
recognizes forfeitures as they occur. The share-based compensation expenses have been categorized as either general and administrative
expenses or selling and marketing expenses, depending on the job functions of the grantees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s share-based compensation awards are expected to be settled through transfers of existing ordinary shares held by the controlling
shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary shares are included in issued and
outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase the Company&#8217;s total issued
and outstanding shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Employees&#8217;
share-based awards and non-employees&#8217; share-based awards are measured at the grant date fair value of the awards and recognized
as expenses a) immediately at grant date if no vesting conditions are required; or b) using graded vesting method, net of estimated forfeitures,
over the requisite service period, which is the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company employs discounted cash flow method to determine the fair value of our share-based compensation arrangements, where the key valuation
variables include risk free rate, discount rate, and perpetual rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zh2bCTq9oe5d" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>aa.
<span id="xdx_864_zR4H5vg2NKs8">Segment reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">ASC
280, &#8220;Segment Reporting&#8221;, establishes standards for reporting information about operating segments on a basis consistent with
the Company&#8217;s internal organizational structure as well as information about geographical areas, business segments and major customers
in financial statements for details on the Company&#8217;s business segments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company uses the &#8220;management approach&#8221; in determining reportable operating segments. The management approach considers the
internal organization and reporting used by the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) for making operating
decisions and assessing performance as the source for determining the Company&#8217;s reportable segments. The Company&#8217;s CODM is
the chief executive officer. The CODM regularly reviews consolidated operating results and reviews consolidated revenues and net loss
when making decisions about allocating resources and assessing performance of the segment, and hence, the Group has only&#160;one&#160;reportable
segment. Therefore, as the Group has determined it operates as a single reportable segment, the CODM assesses the Group&#8217;s performance
and results of operations on a consolidated basis.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_848_ecustom--RelatedPartiesPolicyTextBlock_zrZgPAsibWna" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>bb.
<span id="xdx_86A_zzhxddzLg2h3">Related parties</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Parties
are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant
influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject
to common control or significant influence, such as a family member or relative, shareholder, or a related corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84F_ecustom--ComprehensiveLossPolicyTextBlock_zbTFOSz89y33" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>cc.
<span id="xdx_86C_znQfJNLN3lgc">Comprehensive loss</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Comprehensive
loss is defined as a change in equity during a period from transactions and other events and circumstances&#160;from&#160;non-owner&#160;sources.&#160;The
Company&#8217;s comprehensive loss was the same as its reported net loss for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_846_eus-gaap--EarningsPerSharePolicyTextBlock_z0CKE94bvxGf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>dd.
<span id="xdx_869_zTML0LCjGgK">Loss per share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Basic
net loss per share of ordinary shares attributable to common shareholders is calculated by dividing net loss attributable to common shareholders
by the weighted-average shares of common shares outstanding for the period. Potentially dilutive shares, which are based on the weighted-average
shares of common stock underlying outstanding share-based awards or options using the treasury stock method or the if-converted method,
as applicable, are included when calculating diluted net income per share of common stock attributable to common shareholders when their
effect is dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Diluted
net loss per share attributable to ordinary shareholders is computed by adjusting the weighted-average number of ordinary shares outstanding
for the dilutive effect of all potential ordinary share equivalents. For the Company, potential ordinary share equivalents consist of
share-based compensation, which are assessed using the&#160;treasury stock method. These potential shares are included in the diluted
earnings per share calculation only when their effect is&#160;dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
periods where the Company reports a&#160;net loss, diluted net loss per share is calculated in the same manner as basic net loss per share
because the inclusion of any potential ordinary shares would have an&#160;anti-dilutive&#160;effect. Consequently, all potential ordinary
share equivalents were excluded from the calculation for the years in which a net loss was incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84E_eus-gaap--RevenueRecognitionDividends_zJ8w8TuqR9s" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>ee.
<span id="xdx_860_zcInrRKO5aA2">Dividends</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Dividends
are recognized when declared. <span id="xdx_907_eus-gaap--Dividends_pp0d_do_c20240701__20250331_zbPIn012EOig" title="Dividends"><span id="xdx_90C_eus-gaap--Dividends_pp0d_do_c20250701__20260331_zuV7f8fIUas1" title="Dividends">No</span></span> dividends were declared for the nine months ended March&#160;31, 2025 and 2026, respectively. The Company
does not have any present plan to pay any dividends on ordinary shares in the foreseeable future. The Company currently intends to retain
the available funds and any future earnings to operate and expand its business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_841_ecustom--EmergingGrowthCompanyPolicyTextBlock_zX6M59dr8xPl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>ff</i></b>.
<b><i><span id="xdx_86A_zwrHCIubN67h">Emerging growth company</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company intends to operate as an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012
(the &#8220;JOBS Act&#8221;). The JOBS Act permits companies with emerging growth company status to take advantage of an extended transition
period to comply with new or revised accounting standards, delaying the adoption of these accounting standards until such time as those
standards would apply to private companies. The Company elected to use this extended transition period to enable it to comply with new
or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that
it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period
provided in the JOBS Act. As a result, the Company&#8217;s financial statements may not be comparable to companies that comply with the
new or revised accounting standards as of public company effective dates.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_842_ecustom--RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock_zt2bjFLbuL9h" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>gg.
<span id="xdx_86D_zcwKuWVskW29">Recently adopted accounting standard updates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
June&#160;2016, the FASB issued ASU&#160;2016-13, <i>Financial Instruments&#160;&#8212;&#160;Credit Losses </i>(Topic&#160;326): Measurement
of Credit Losses on Financial Instruments (&#8220;ASU&#160;2016-13&#8221;). The new accounting standard introduced the current expected
credit losses methodology (&#8220;CECL&#8221;) for estimating allowances for credit losses. The measurement of expected credit losses
under the CECL methodology is applicable to financial assets measured at amortized costs, including loans and trade receivables. ASU&#160;2016-13
is effective for the Company, as an emerging growth company, for annual and interim reporting periods beginning after December&#160;15,
2022. The Company adopted the standard on July&#160;1, 2023 using the modified retrospective method for all financial assets in scope.
The adoption of the standard did not have a material impact on the Company&#8217;s statements of income, or statements of cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
November&#160;2023, the FASB issued ASU&#160;2023-07, &#8220;Segment Reporting (Topic&#160;280): Improvements to Reportable Segment Disclosures.&#8221;
The amendments in this ASU are intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about
significant segment expenses. This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating
decision mark (&#8220;CODM&#8221;), an amount for other segment items by reportable segment and a description of its composition, all
annual disclosures required by FASB ASU Topic&#160;280 in interim periods as well, and the title and position of the CODM and how the
CODM uses the reported measures. Additionally, this ASU requires that at least one of the reported segment profit and loss measures should
be the measure that is most consistent with the measurement principles used in an entity&#8217;s financial statements. Lastly, this ASU
requires public business entities with a single reportable segment to provide all disclosures required by these amendments in this ASU
and all existing segment disclosures in Topic&#160;280. This ASU is effective for fiscal&#160;years beginning after December&#160;15,
2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. The Company has early adopted ASU&#160;2023-07
on July&#160;1, 2023. As a result of adoption, the required disclosures have been included in Note 2 and Note 13.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOp72ws5iCAh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>hh.
<span id="xdx_86A_z38IxEch0007">Recently accounting pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
December&#160;2023, the FASB issued ASU&#160;No.&#160;2023-09,&#160;<i>Improvements to Income Tax Disclosures</i>&#160;(&#8220;ASU&#160;2023-09&#8221;),&#160;which
requires entities to make incremental income tax disclosures on an annual basis. The amendments require that public business entities
disclose specific categories in the rate reconciliation and provide additional information for reconciling items meeting a quantitative
threshold. The amendments also require disclosure of income taxes paid to be disaggregated by jurisdiction, and the disclosure of income
tax expense disaggregated by federal, state, and foreign. Amendments are effective for annual periods beginning after December&#160;15,
2025 and thereafter, with early adoption permitted. The Company is evaluating adoption timing and the impact ASU&#160;2023-09&#160;will
have on its financial statements and related disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
March&#160;2024, the FASB issued ASU No. 2024-02, <i>Codification Improvements-Amendments to Remove References to the Concepts Statements</i>
(&#8220;ASU 2024-02&#8221;). The amendments in this Update affect a variety of Topics in the Codification. The amendments apply to all
reporting entities within the scope of the affected accounting guidance. This update contains amendments to the Codification that remove
references to various Concepts Statements. In most instances, the references are extraneous and not required to understand or apply the
guidance. In other instances, references were used in prior statements to provide guidance in certain topical areas. ASU 2024-02 is effective
for public business entities for fiscal years beginning after December&#160;15, 2024. Early adoption is permitted for both interim and
annual financial statements that have not yet been issued or made available for issuance. The adoption did not have a material impact
on the Company&#8217;s financial statement.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
November&#160;2024, the FASB issued ASU 2024-03 &#8220;<i>Income Statement&#8212;Reporting comprehensive (loss) income&#8212;Expense Disaggregation
Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i>&#8221; (&#8220;ASU 2024-03&#8221;). The amendments in this
update intend to improve the disclosures about a public business entity&#8217;s expenses and address requests from investors for more
detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization,
and depletion) in commonly presented expense captions (such as cost of sales, selling, general and administrative expenses, and research
and development). ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods beginning after
December&#160;15, 2027. The Company is currently evaluating the impact from the adoption of this ASU on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
January&#160;2025, the FASB issued Accounting Standards Update (ASU) No. 2025-01, <i>Income Statement &#8212; Reporting comprehensive
(loss) income &#8212; Expense Disaggregation Disclosures</i> (Subtopic 220-40): Clarifying the Effective Date. The amendment clarifies
the effective date of ASU No. 2024-03 that all public business entities are required to adopt the guidance in annual reporting periods
beginning after December&#160;15, 2026, and interim periods within annual reporting periods beginning after December&#160;15, 2027. Early
adoption of Update 2024-03 is permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or
guidance on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
July&#160;2025, the FASB issued Accounting Standards Update (ASU) No. 2025-05, <i>Financial Instruments &#8212; Credit Losses</i> (Topic
326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The amendment provides (1) all entities with a practical
expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the assets and (2) entities
other than public business entities with an accounting policy election to consider collection activity after the balance sheet date when
estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for
under Topic 606. This guidance is effective for annual reporting periods beginning after December&#160;15, 2025 and interim reporting
periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of the above
new accounting pronouncements or guidance on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
September&#160;2025, the FASB issued&#160;<i>ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40):
Accounting for and Disclosure of Software Costs&#160;</i>(&#8220;ASU 2025-06&#8221;), which amends certain aspects of the accounting for
and disclosure of internal-use software costs. ASU 2025-06 is effective for annual reporting periods beginning with the year ending December&#160;31,
2028, with early adoption permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or guidance
on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December&#160;2025,
the FASB issued <i>ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements</i>, which clarifies interim disclosure
requirements resulting in a comprehensive list of interim disclosures that are required by GAAP, and includes a disclosure principle
that requires the disclosure of events since the end of the last annual reporting period that have a material impact on the Company.
ASU 2025-11 is effective for the Company&#8217;s interim reporting periods within fiscal years beginning after December 15, 2028, with
early adoption permitted. ASU 2025-11 may be applied either prospectively or retrospectively. The Company is currently evaluating the
impact of the above new accounting pronouncements or guidance on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Except
as mentioned above, the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted,
would have a material effect on the balance sheets, statements of income and comprehensive loss and cash flows.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zly3FShCFXe3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2. <span id="xdx_826_znoSd0puRsll">Summary of significant accounting policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_845_ecustom--GoingConcernPolicyTextBlock_zorhFCi8emlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>a. <span id="xdx_864_z1YlhGMWNLQ3">Going concern</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June&#160;30, 2025, the Company had cash
and cash equivalents of $4.2 million <span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20250630_zP8AepDgmXQ1" style="display: none" title="Cash and cash equivalents">4,231,689</span>
and current liabilities of $20.3 <span id="xdx_902_eus-gaap--LiabilitiesCurrent_iI_c20250630_z4jwfecaN8A1" style="display: none" title="Current liabilities">20,319,721</span>
million. For the years ended June&#160;30, 2024 and 2025, the Company used $0.6 <span title="Net losses"><span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20230701__20240630_zimEv9wUsnDk" style="display: none" title="Cash for operating activities">(560,909)</span>
million and $1.0 <span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20240701__20250630_zVTfCY856dug" style="display: none" title="Cash for operating activities">(1,010,799)</span>
million in cash for operating activities, and incurred net losses of $5.0 <span id="xdx_901_eus-gaap--NetIncomeLoss_c20230701__20240630_zVEtJqHinOV8" style="display: none" title="Net losses">(4,956,347)</span>
million and $7.7 <span id="xdx_903_eus-gaap--NetIncomeLoss_c20240701__20250630_zUawJwOLj0Yh" style="display: none" title="Net losses">(7,659,667)</span>
million, respectively. The Company has incurred recurring net losses from operations and negative cash flows from operating
activities since inception. As of June&#160;30, 2025, the Company had an accumulated deficit of $13.2
<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20250630_zuIwST4zPt2k" style="display: none" title="Accumulated deficit">(13,217,035)</span> million. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern
within one year of the date these financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has formulated and is actively pursuing
plans to mitigate these conditions and secure the Company&#8217;s continued operations. In connection with the Company&#8217;s contemplated
business combination with a SPAC and related financing activities, the Company expects to access additional capital through external funding
sources. In addition, the Company continues to focus on expanding its market presence and developing client relationships to drive revenue
growth, while managing operating expenses, with the objective of improving cash flows from operations over time.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of this disclosure, &#8220;SPAC&#8221;
refers to a special purpose acquisition company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more operating businesses. &#8220;De-SPAC&#8221; refers to the business combination transaction
pursuant to which an operating company combines with a SPAC, following which the combined company becomes publicly listed (or otherwise
succeeds to the SPAC&#8217;s public company status).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s negative working capital position
is primarily attributable to the classification of SAFEs. Excluding the accounting impact of the SAFEs, which will only be paid in cash
upon Liquidity Events and Dissolution Event (as defined in Note 9) and the SAFE holders choose to claim the invested proceeds back, management
believes the Company&#8217;s available cash resources are sufficient for near-term operating needs. If additional liquidity is required,
the Company&#8217;s majority shareholder has entered into a binding support agreement to provide funding to cover anticipated operating
cash flow shortfalls through the completion of the contemplated de-SPAC transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">However, the aforementioned plans, particularly the
de-SPAC transaction (including the SAFEs conversion) and the raising of additional capital, have not been fully implemented as of the
date these financial statements are issued. There can be no assurance that these plans will be successfully completed within the required
time frame, on acceptable terms, or at all. If the primary plans are not successful, the Company&#8217;s alternative courses of action
would further intensify efforts in market expansion and client development to increase revenue, while diligently controlling costs to
ensure sufficient cash flow from operating activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company may not be able to secure necessary financing
in a timely manner or on favorable terms, or successfully execute its operational turnaround. These circumstances give rise to substantial
doubt that the Company will continue as a going concern and these financial statements do not include any adjustments that might result
from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoHPeRGXD8V6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>b. <span id="xdx_863_zpBEwXbVSFgl">Basis of presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The financial statements have been prepared in accordance
with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the applicable
rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_849_eus-gaap--UseOfEstimates_zm9vWs4Czw0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>c. <span id="xdx_86E_zKFaeK3WfP28">Use of estimates and assumptions</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and
accompanying notes. Management believes that the estimates used in preparing the financial statements are reasonable and prudent; however,
actual results could differ from these estimates under different assumptions or conditions.&#160;Significant accounting estimates include
revenue recognition, recognition and measurement of SAFEs notes, the allowance for expected credit losses, recognition and measurement
of share-based compensation, deferred tax assets and valuation allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zdsq5TZx08Bg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>d. <span id="xdx_86B_zgmcgXMRrdyd">Fair value measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #212529; color: #212529">In accordance
with FASB ASC 820&#160;</span><i><span style="color: #212529; color: #212529">Fair Value Measurements and Disclosures</span></i><span style="color: #212529; color: #212529">,
</span>fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. <span style="color: #212529; color: #212529">The Company uses a three-level hierarchy
for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant
assumptions developed from market data obtained from outside sources (observable inputs) and the Company&#8217;s own assumptions about
market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). </span></p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The hierarchy requires entities to maximize the use
of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #212529; color: #212529">Level
1: Quoted prices in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #212529; color: #212529">Level
2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #212529; color: #212529">Level
3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash
flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment
or estimation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #212529; color: #212529">The fair
value measurements discussed herein are based upon certain market assumptions and pertinent information available to management during
the years ended June&#160;30, 2024 and 2025. The carrying amount of cash and </span>cash equivalents<span style="color: #212529; color: #212529">,
accounts receivable, r</span>efundable deposits receivable, other receivables, <span style="color: #212529; color: #212529">accounts payable,
r</span>efundable deposits payable <span style="color: #212529; color: #212529">and other current liabilities approximated their fair
values as of June&#160;30, 2024 and 2025. For the years ended June&#160;30, 2024 and 2025, the Company carried SAFEs at their fair value
(see&#160;Note 4-Fair Value Measurements&#160;for fair value information).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84F_ecustom--FunctionalCurrencyPolicyTextBlock_zlxnMooXoEU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>e. <span id="xdx_865_zAyE0XfHmhD6">Functional currency</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements are presented
in the United States dollar (&#8220;US$&#8221;). The functional currency of the Company is the US$.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All transactions are measured and recorded in the
Company&#8217;s functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zbK7C7pPqW23" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>f. <span id="xdx_863_zISAmbUCaane">Cash and cash equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid debt instruments
purchased with a maturity period of three months or less to be cash or cash equivalents. The carrying amounts reported in the accompanying
balance sheets for cash and cash equivalents approximate their fair value. As of June&#160;30, 2024 and 2025, the Company does <span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20240630_zJxii2H5kkT6" title="Cash equivalents"><span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zqb5W6PdbHal" title="Cash equivalents">no</span></span>t have
any cash equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84E_ecustom--ExpectedCreditLossAndAccountsReceivablePolicyTextBlock_zSEmIHvv90sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>g. <span id="xdx_867_zsUZxth16ncb">Expected credit loss and accounts receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company adopted Financial Standards Accounting
Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 326 &#8220;<i>Financial Instruments&#160;&#8212;&#160;Credit
Losses</i>&#8221; (&#8220;ASC&#160;326&#8221;) on January&#160;1, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s accounts receivable is within
the scope of ASC&#160;326. ASC&#160;326 introduces an approach based on expected credit losses on financial assets at amortized cost.
Upon adoption of ASC&#160;326, the Company estimates the expected credit losses for accounts receivable using the roll-rate method on
a collective basis when similar risk characteristics exist. Expected credit losses are included in general and administrative expenses
in the statements of operations and comprehensive loss. After all attempts to collect a receivable have failed, the receivable is written
off against the allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable represents those receivables derived
in the ordinary course of business, net of an allowance for any potentially uncollectible amounts. The Company makes estimates of expected
credit and collectability trends for the allowance for credit losses based upon its assessment of various factors, including historical
experience, the age of the accounts receivable balances, credit quality of its customers, current economic conditions, reasonable and
supportable forecasts of future economic conditions that may vary by geography, customer-type, or industry sub-vertical, and other factors
that may affect its ability to collect from customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although the Company has historically not experienced
significant credit losses, they may experience increasing credit loss risks from accounts receivable in future periods if its customers
are adversely affected by economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific
factors, and actual experience in the future may differ from their past experiences or current assessment.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_848_ecustom--AdvanceToSuppliersPolicyTextBlock_ziKHq9XEjP3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>h. <span id="xdx_86C_zgfztbsMVxIj">Advance to suppliers</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advance to suppliers represent prepayments made to
vendors in connection with the purchase of services. Advance are recorded at the amount paid and are classified as current assets when
the related services are expected to be received within one year or the normal operating cycle.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_844_ecustom--RefundableDepositsReceivablePolicyTextBlock_zHSdExpu5L9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>i. <span id="xdx_86D_z7CffKljqsfj">Refundable deposits receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Refundable deposits receivable mainly represent security
deposits and refundable cooperation deposits paid to suppliers and business partners that are contractually recoverable upon the completion
of services. These amounts are recorded as assets when paid, generally at the amount paid. Deposits expected to be recovered within one
year are classified as current; otherwise, they are classified as non-current. The Company evaluates the credit risk of refundable deposits
receivable and recognizes an allowance for credit losses based on the current expected credit losses (&#8220;CECL&#8221;) model. Specific
balances are written off when they are deemed uncollectible and all collection efforts have been exhausted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June&#160;30, 2024 and 2025, the balances were
$<span id="xdx_90E_ecustom--RefundableDepositsReceivable_iI_c20240630_za7GUMIQ0fl5" title="Refundable deposits receivable">110,000</span> and $<span id="xdx_90E_ecustom--RefundableDepositsReceivable_iI_c20250630_z0ReoE3c16C9" title="Refundable deposits receivable">681,125</span>, respectively. The increase was primarily driven by revenue growth and business expansion. As of June&#160;30, 2024
and 2025, there was <span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20240630_zLZRW1Dk6Ukj" title="Allowance for expected credit losses"><span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_z3aW6vPWJeid" title="Allowance for expected credit losses">no</span></span> allowance for expected credit losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z0zrIdAY4IM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>j. <span id="xdx_86F_zf8ptRHzRO28">Equipment, net</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equipment, net is stated at cost less accumulated
depreciation and impairment, if any. Depreciation is computed using the straight-line method over the estimated useful lives of three
or five years, depending on the asset category.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z4iWfcQYqTqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>k. <span id="xdx_86E_zLIGi7CATnu7">Impairment of long-lived assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews its long-lived assets, equipment,
for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability
of assets held and used is measured by comparison of the carrying amount of an asset to the future undiscounted cash flows expected to
be generated from the use of the asset and its eventual disposition. If such assets are considered to be impaired, the impairment to be
recognized is measured by the amount by which the carrying amount exceeds the fair value of the impaired assets. Assets to be disposed
of are reported at the lower of their carrying amount or fair value less cost to sell. There was <span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20230701__20240630_zgA1bYYr7Yec" title="Impairment of long-lived assets"><span id="xdx_907_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20240701__20250630_zZHdVotNKmAc" title="Impairment of long-lived assets">no</span></span> impairment of long-lived assets as
of and for the years ended June&#160;30, 2024 and 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_844_ecustom--SimpleAgreementsForFutureEquityPolicyTextBlock_zFgYzNF7u2n6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>l. </i><i><span style="color: #212529; color: #212529"><span id="xdx_867_z4BrJrohRAA9">Simple
agreements for future equity</span></span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">SAFEs issued by the Company are freestanding financial
instruments. As they contain certain redemption or liquidation features that&#160;may&#160;require the Company to settle the obligation
in cash upon the occurrence of defined events (e.g., a change of control or dissolution), the instruments&#160;create an obligation that
meets the definition of a liability. Accordingly, the SAFEs are classified in their entirety as liabilities on the balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These liabilities are measured at fair value upon
initial recognition and are subsequently remeasured at fair value at each reporting date. All changes in their fair value are recognized
in&#160;the statement of operations and comprehensive loss in the period in which they occur.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_840_eus-gaap--RevenueRecognitionDeferredRevenue_zJ2s2gZGnL58" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>m. <span id="xdx_86E_zA2yNWLqfBFd">Revenue recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company applied ASC Topic&#160;606 &#8220;<i>Revenue
from Contracts with Customers</i>&#8221; (&#8220;ASC&#160;606&#8221;) for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The five-step model defined by ASC&#160;606 requires
the Company to (i)&#160;identify its contracts with clients, (ii)&#160;identify its performance obligations under those contracts, (iii)&#160;determine
the transaction prices of those contracts, (iv)&#160;allocate the transaction prices to its performance obligations in those contracts,
and (v)&#160;recognize revenue when each performance obligation under those contracts is satisfied. Revenue is recognized when promised
goods or services are transferred to the client in an amount that reflects the consideration expected in exchange for those goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reports all of its revenues on a gross
basis.&#160;This determination is based on the Company&#8217;s assessment that it is the principal in its revenue arrangements. The Company
controls the service delivery platform and infrastructure before the service is provided to the customer. It is primarily responsible
for fulfilling the service promise, has discretion in setting prices, and assumes the credit risk associated with the customer receivable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a practical expedient, the Company elected to expense
the incremental costs of obtaining a contract when incurred if the amortization period of the asset that the Company otherwise would have
recognized is one year or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to ASC 606, the Company recognizes revenue
based on the transaction price, which is the amount of consideration it expects to be entitled to exchange for transferring services to
customers. For Intelligent Computing Power Services, contract consideration is generally fixed and is typically stated as a fixed monthly
fee determined by (i) the contractually specified number of GPUs (capacity) and (ii) the service period. Accordingly, the transaction
price is generally the fixed contractual amount. The Company recognizes revenue over time as the services are provided throughout the
contract term. The Company offers payment terms ranging from 0 to 6 months, depending on customers&#8217; credit profiles and service
requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company does not provide warranties for its services
and does not offer service-type warranty arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a description of the principal activities
of the Company from which the Company generates its revenue under ASC 606.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(i) Revenue for intelligent computing power service</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #0F1115; color: #0F1115">The Company
leverages its expertise in high-performance computing and cloud-native architectures to build and operate stable, efficient, and scalable
GPU computing platforms through modular data center design and liquid cooling technology. The Company uses these platforms to provide
computing resources for large-scale AI training, model inference, and high-performance scientific computing to commercial enterprise clients
with substantial GPU computing requirements. Supporting services include GPU server environment deployment, cluster scheduling and performance
optimization, high-speed network interconnection, real-time monitoring and intelligent alerting systems, as well as industry-compliant
security and regulatory assurance. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for the above promises as a single
performance obligation because they are highly integrated and not separately identifiable in the context of the contract. The Company
provides an integrated, managed GPU computing platform in which computing capacity, deployment/configuration, scheduling, networking,
monitoring, and security/compliance are interdependent and together deliver a single combined service&#8212;continuous access to a functioning
and secured platform over the contractual term.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company provides intelligent computing power services
under two pricing models: (i) reserved capacity arrangements and (ii) on-demand (pay-as-you-go) arrangements. The following table presents
revenue recognized during the period by arrangement type:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zRG8fPT8BVR9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BF_zPudrh40sc0l" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Schedule of Revenue recognition</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/> years ended<br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Reserved capacity arrangements</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues">1,193,982</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues">6,501,569</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">On-demand arrangements</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl2098">-</span></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues">44,680</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_900_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues">1,193,982</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90E_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues">6,546,249</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zqlXSFBPlAkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reserved capacity arrangements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company enters into reserved capacity arrangements,
which generally provide committed intelligent computing power services for a defined service term ranging from 3 months to 3 years, with
the majority of such arrangements having a one-year term. These contracts typically are non-cancelable, or may be canceled only under
limited conditions with early notifications required. Payment terms generally range from 0-6 months upon the completion of services, and
certain arrangements require prepayments. Any prepayments are recorded as contract liabilities and recognized over the service term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The performance obligation is satisfied over time
because the customer simultaneously receives and consumes the benefits. Revenue is recognized using a time-elapsed output method over
the contractual service period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On-demand (pay-as-you-go) arrangements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company provides customers with on-demand access
to intelligent computing power and GPU resources under pay-as-you-go model which requires advance payment. Customer advances are recorded
as contract liabilities and recognized as revenue over the time during the provision of related services underlying the contract term.
The revenue is recognized over time because the customer can simultaneously receives and consumes the benefits during the service period.
These arrangements generally do not include a fixed contractual term or minimum usage commitments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(ii) Revenue from comprehensive data center service</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leverages its project experience in infrastructure
management, cluster optimization, and system monitoring to provide full-cycle operational support to data center asset owners. Services
encompass facility environment deployment, network architecture implementation, security and compliance system development, daily operational
monitoring, and emergency fault response. Revenue is recognized over time because the Company&#8217;s services are performed throughout
the contract term and the customer benefits as the services are provided.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the&#160;years ended June&#160;30, 2024 and 2025,
$<span id="xdx_905_eus-gaap--Revenues_c20230701__20240630_pp0p" title="Revenue">1,319,115</span> and $<span id="xdx_903_eus-gaap--Revenues_c20240701__20250630_pp0p" title="Revenue">7,015,512</span> of the revenue of the Company&#8217;s was recognized over time, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue disaggregated by service lines for the&#160;years
ended June&#160;30, 2024 and 2025 is disclosed in the table below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zC7KRbYjMXPd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BF_zOrqnCzeKVC3" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Schedule of Revenue disaggregated</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/>years ended<br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Revenue from intelligent computing
        power service</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zLe37nj4DRT9" title="Total">1,193,982</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_907_eus-gaap--Revenues_pp0d_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z5LhznXQI8B2" title="Total">6,546,249</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Revenue from comprehensive
        data center services</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total">125,133</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total">469,263</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630_zw4xoiRMPQs7" title="Total">1,319,115</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90A_eus-gaap--Revenues_pp0d_c20240701__20250630_zxIqgXFsjdA6" title="Total">7,015,512</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zFyS7keq5WFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>









<p id="xdx_845_ecustom--ContractLiabilitiesPolicyTextBlock_zZWQnliQBId8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>n. <span id="xdx_864_zhAHETYm7uU4">Contract liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company receives advance payments from its customers
for services to be provided in the future. These payments are recorded as&#160;contract liabilities&#160;on the balance sheet within &#8220;Contract
liabilities&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Contract liabilities are recognized when
consideration is received from a customer prior to the Company satisfying its related performance obligations. For these service
contracts, the Company recognizes revenue, and reduces the contract liabilities,&#160;over time&#160;as the services are rendered
and the performance obligations are satisfied. Revenue recognized that was included in the contract liability balance at the
beginning of the year was nil <span id="xdx_90A_ecustom--RevenueRecognized_c20230701__20240630_pp0p" style="display: none" title="Revenue recognized">0</span> and $<span id="xdx_904_ecustom--RevenueRecognized_c20240701__20250630_pp0p" title="Revenue recognized">95,326</span> for the years ended June&#160;30, 2024 and 2025, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_847_eus-gaap--CostOfSalesPolicyTextBlock_zd6uOxmwVUC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>o. <span id="xdx_868_zt2YqZ7h4862">Cost of revenues</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s cost of revenues primarily includes
computing power service and professional service fees. All the cost of revenues are recognized in the period in which the related services
occur or the benefits are received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84E_ecustom--SellingAndMarketingExpensesPolicyTextBlock_zNtKHlQglhzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>p. <span id="xdx_861_z8U06Sm8eK8b">Selling and marketing expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s selling and marketing expenses
primarily include: (i) advertising and promotion expenses, (ii) compensation and benefits for sales personnel and related share based
compensation, and (iii) travel and other routine office expense. All expenses are recognized in the period in which the related services
occur or the benefits are received. The Company expenses advertising costs as incurred, and for the years ended June&#160;30, 2024 and
2025, the Company incurred advertising and promotion expenses of $<span id="xdx_908_eus-gaap--MarketingAndAdvertisingExpense_c20230701__20240630_pp0p" title="Advertising and promotion expenses">26,340</span> and $<span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20240701__20250630_pp0p" title="Advertising and promotion expenses">157,388</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zTShSXVP9mc7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>q. <span id="xdx_864_zLpo4DODnKa5">Research and development expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s research and development expenses
mainly consist of <span style="color: #0F1115; color: #0F1115">software development outsourcing service fees and testing expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_844_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zdyBpybY30kg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>r. <span id="xdx_866_z1OzlN0cGTed">General and administrative expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s general and administrative expenses
mainly consist of <span style="color: #0F1115; color: #0F1115">software subscription fees, legal and professional service fees, certification
service fees, depreciation expenses and handling charges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zH16tov7HOHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>s. <span id="xdx_86A_zfzDgxosnhkd">Income tax</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Income taxes are determined in accordance with the
provisions of ASC Topic 740, <i>Income Taxes</i> (&#8220;ASC Topic 740&#8221;). Under this method, deferred tax assets and liabilities
are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing
assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates
expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. Any effect
on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 740 prescribes a comprehensive model for how companies
should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on
a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the
position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as
the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority
assuming full knowledge of the position and relevant facts.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_842_ecustom--CapitalStructurePolicyTextBlock_zrhorRvRLTn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>t. <span id="xdx_86F_zOYxMEHi9sP1">Capital structure</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized to issue <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20240630_pd" title="Common stock, shares authorized"><span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_c20250630_pd" title="Common stock, shares authorized">1,500</span></span> ordinary
shares of $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20240630_pd" title="Common stock, par value"><span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_c20250630_pd" title="Common stock, par value">0.01</span></span> par value each. As of June&#160;30, 2024 and 2025, there were <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_c20240630_pd" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_c20240630_pd" title="Common stock, shares outstanding"><span id="xdx_90A_eus-gaap--CommonStockSharesIssued_c20250630_pd" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_c20250630_pd" title="Common stock, shares outstanding">1,500</span></span></span></span> shares issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the resolution of the board of directors
on January&#160;8, 2026, the authorized share capital of <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_c20260108_pd" title="Common stock, shares authorized">1,500</span> ordinary shares was re-designated to <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pd" title="Common stock, shares authorized">303</span> Class A ordinary shares and <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pd" title="Common stock, shares authorized">1,197</span>
Class B ordinary shares. Holders of Class A ordinary shares and Class B ordinary shares have the same rights, except for voting and conversion
rights. Each Class A ordinary share is entitled to one vote; and each Class B ordinary share is entitled to twenty votes and is convertible
into one Class A ordinary share at any time by the holder thereof. Class A ordinary shares are not convertible into Class B ordinary shares
under any circumstances. Furthermore, all outstanding warrants, options, and SAFEs are designated to convert or settle exclusively into
Class A ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_848_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zyjuGtgiN2l4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>u. <span id="xdx_860_zz7zMNdlRtT9">Share-based compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company grants Share awards of the Company to
eligible employees and&#160;non-employees. The Company accounts for share-based awards issued to employees and&#160;non-employees in accordance
with ASC Topic 718 <i>Compensation &#8211; Stock Compensation. </i>The Company recognizes forfeitures as they occur. The share-based compensation
expenses have been categorized as either general and administrative expenses or selling and marketing expenses, depending on the job functions
of the grantees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s share-based compensation awards
are expected to be settled through transfers of existing ordinary shares held by the controlling shareholder, rather than through the
issuance of new shares by the Company. The underlying ordinary shares are included in issued and outstanding shares as of the balance
sheet date; accordingly, such settlement is not expected to increase the Company&#8217;s total issued and outstanding shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Employees&#8217; share-based awards and non-employees&#8217;
share-based awards are measured at the grant date fair value of the awards and recognized as expenses a) immediately at grant date if
no vesting conditions are required; or b) using graded vesting method, net of estimated forfeitures, over the requisite service period,
which is the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company employs discounted cash flow method to
determine the fair value of our share-based compensation arrangements, where the key valuation variables include risk free rate, discount
rate and perpetual rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84E_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zj5A0O1qUZwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>v. <span id="xdx_867_zetDcyDJZsD4">Segment reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 280, &#8220;Segment Reporting&#8221;, establishes
standards for reporting information about operating segments on a basis consistent with the Company&#8217;s internal organizational structure
as well as information about geographical areas, business segments and major customers in financial statements for details on the Company&#8217;s
business segments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the &#8220;management approach&#8221;
in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#8217;s
chief operating decision maker (&#8220;CODM&#8221;) for making operating decisions and assessing performance as the source for determining
the Company&#8217;s reportable segments. The Company&#8217;s CODM is the chief executive director. The CODM regularly reviews entity-wide
operating results and reviews revenues and net loss when making decisions about allocating resources and assessing performance of the
segment, and hence, the Company has only&#160;one&#160;reportable segment. Therefore, as the Company has determined it operates as a single
reportable segment, the CODM assesses the Company&#8217;s performance and results of operations on an entity-wide basis.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84D_ecustom--RelatedPartiesPolicyTextBlock_zmOqA55enEsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>w. <span id="xdx_862_zI2bQw1nSKC">Related parties</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parties are considered to be related if one party
has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial
and operating decisions. Parties are also considered to be related if they are subject to common control or significant influence, such
as a family member or relative, shareholder, or a related corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_849_ecustom--ComprehensiveLossPolicyTextBlock_z3GLuD1HtmQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>x. <span id="xdx_866_zJfxnr89HArh">Comprehensive loss</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Comprehensive loss is defined as a change in equity
during a period from transactions and other events and circumstances&#160;from&#160;non-owner&#160;sources.&#160;The Company&#8217;s comprehensive
loss was the same as its reported net loss for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zRr2tTiRL483" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>y.<span id="xdx_864_zWpJBAyOYapg"> Loss&#160;per share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per share of ordinary shares attributable
to ordinary shareholders is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average shares of ordinary
shares outstanding for the period. Potentially dilutive shares, which are based on the weighted-average shares of ordinary shares underlying
outstanding share-based awards or options using the treasury stock method or the if-converted method, as applicable, are included when
calculating diluted net income per share of ordinary shares attributable to ordinary shareholders when their effect is dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Diluted net loss per share attributable to ordinary
shareholders is computed by adjusting the weighted-average number of ordinary shares outstanding for the dilutive effect of all potential
ordinary share equivalents. For the Company, potential ordinary share equivalents consisted of share-based compensation, which are assessed
using the&#160;treasury stock method. These potential shares are included in the diluted earnings per share calculation only when their
effect is&#160;dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In periods where the Company reports a&#160;net loss,
diluted net loss per share is calculated in the same manner as basic net loss per share because the inclusion of any potential ordinary
shares would have an&#160;anti-dilutive&#160;effect. Consequently, all potential ordinary share equivalents were excluded from the calculation
for the years in which a net loss was incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_844_eus-gaap--RevenueRecognitionDividends_z5kiNZU4iFJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>z. <span id="xdx_86E_z1wQVhVX3E9i">Dividends</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dividends are recognized when declared. <span id="xdx_908_eus-gaap--Dividends_pp0d_do_c20230701__20240630_z4eZ64ybMTmi" title="Dividends"><span id="xdx_903_eus-gaap--Dividends_pp0d_do_c20240701__20250630_zSkJu776q1A8" title="Dividends">No</span></span> dividends
were declared for the years ended June&#160;30, 2024 and 2025, respectively. The Company does not have any present plan to pay any dividends
on ordinary shares in the foreseeable future. The Company currently intends to retain the available funds and any future earnings to operate
and expand its business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_840_ecustom--RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock_z7z0wstCtqqk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>aa. <span id="xdx_86F_zUUr7JvI51i1">Recently adopted accounting standard updates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June&#160;2016, the FASB issued ASU&#160;2016-13,
<i>Financial Instruments&#160;&#8212;&#160;Credit Losses</i> (Topic&#160;326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU&#160;2016-13&#8221;).
The new accounting standard introduced the current expected credit losses methodology (&#8220;CECL&#8221;) for estimating allowances for
credit losses. The measurement of expected credit losses under the CECL methodology is applicable to financial assets measured at amortized
costs, including loans and trade receivables. ASU&#160;2016-13 is effective for the Company, as an emerging growth company, for annual
and interim reporting periods beginning after December&#160;15, 2022. The Company adopted the standard on July&#160;1, 2023 using the
modified retrospective method for all financial assets in scope. The adoption of the standard did not have a material impact on the Company&#8217;s
statements of income, or statements of cash flows.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November&#160;2023, the FASB issued ASU&#160;2023-07,
&#8220;Segment Reporting (Topic&#160;280): <i>Improvements to Reportable Segment Disclosures</i>.&#8221; The amendments in this ASU are
intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating decision mark (&#8220;CODM&#8221;),
an amount for other segment items by reportable segment and a description of its composition, all annual disclosures required by FASB
ASU Topic&#160;280 in interim periods as well, and the title and position of the CODM and how the CODM uses the reported measures. Additionally,
this ASU requires that at least one of the reported segment profit and loss measures should be the measure that is most consistent with
the measurement principles used in an entity&#8217;s financial statements. Lastly, this ASU requires public business entities with a single
reportable segment to provide all disclosures required by these amendments in this ASU and all existing segment disclosures in Topic&#160;280.
This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning
after December&#160;15, 2024. The Company has early adopted ASU 2023-07 on July&#160;1, 2023. As a result of adoption, the required disclosures
have been included in Note 2 and Note 14.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84B_ecustom--EmergingGrowthCompanyPolicyTextBlock_zXbI2MERplLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>bb. <span id="xdx_860_zodYVIxzme09">Emerging growth company</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company intends to operate as an &#8220;emerging
growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). The JOBS Act permits
companies with emerging growth company status to take advantage of an extended transition period to comply with new or revised accounting
standards, delaying the adoption of these accounting standards until such time as those standards would apply to private companies. The
Company elected to use this extended transition period to enable it to comply with new or revised accounting standards that have different
effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company
or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company&#8217;s
financial statements may not be comparable to companies that comply with the new or revised accounting standards as of public company
effective dates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztzNempdfu57" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>cc. <span id="xdx_86D_z61KGdSvMHp3">Recently accounting pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December&#160;2023, the FASB issued ASU&#160;No.&#160;2023-09,&#160;<i>Improvements
to Income Tax Disclosures</i>&#160;(&#8220;ASU&#160;2023-09&#8221;),&#160;which requires entities to make incremental income tax disclosures
on an annual basis. The amendments require that public business entities disclose specific categories in the rate reconciliation and provide
additional information for reconciling items meeting a quantitative threshold. The amendments also require disclosure of income taxes
paid to be disaggregated by jurisdiction, and the disclosure of income tax expense disaggregated by federal, state, and foreign. ASU&#160;2023-09&#160;is
effective for the Company&#8217;s annual reporting periods ending December&#160;31, 2025 and thereafter, with early adoption permitted.
The Company is evaluating adoption timing and the impact ASU&#160;2023-09&#160;will have on its financial statements and related disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March&#160;2024, the FASB issued ASU No. 2024-02,
<i>Codification Improvements-Amendments to Remove References to the Concepts Statements</i> (&#8220;ASU 2024-02&#8221;). The amendments
in this Update affect a variety of Topics in the Codification. The amendments apply to all reporting entities within the scope of the
affected accounting guidance. This update contains amendments to the Codification that remove references to various Concepts Statements.
In most instances, the references are extraneous and not required to understand or apply the guidance. In other instances, references
were used in prior statements to provide guidance in certain topical areas. ASU 2024-02 is effective for public business entities for
fiscal years beginning after December&#160;15, 2024. For all other entities, the amendments are effective for fiscal years beginning after
December&#160;15, 2025. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or
made available for issuance. The adoption did not have a material impact on the Company&#8217;s financial statement.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November&#160;2024, the FASB issued ASU 2024-03
&#8220;<i>Income Statement&#8212;Reporting comprehensive (loss) income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation
of Income Statement Expenses</i>&#8221; (&#8220;ASU 2024-03&#8221;). The amendments in this update intend to improve the disclosures about
a public business entity&#8217;s expenses and address requests from investors for more detailed information about the types of expenses
(including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions
(such as cost of sales, selling, general and administrative expenses, and research and development). ASU 2024-03 is effective for fiscal
years beginning after December&#160;15, 2026, and interim periods beginning after December&#160;15, 2027. The Company is currently evaluating
the impact from the adoption of this ASU on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January&#160;2025, the FASB issued Accounting Standards
Update (ASU) No. 2025-01, <i>Income Statement &#8212; Reporting comprehensive (loss) income &#8212; Expense Disaggregation Disclosures</i>
(Subtopic 220-40): Clarifying the Effective Date. The amendment clarifies the effective date of ASU No. 2024-03 that all public business
entities are required to adopt the guidance in annual reporting periods beginning after December&#160;15, 2026, and interim periods within
annual reporting periods beginning after December&#160;15, 2027. Early adoption of Update 2024-03 is permitted. The Company is currently
evaluating the impact of the above new accounting pronouncements or guidance on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July&#160;2025, the FASB issued Accounting Standards
Update (ASU) No. 2025-05, <i>Financial Instruments &#8212; Credit Losses</i> (Topic 326): Measurement of Credit Losses for Accounts Receivable
and Contract Assets. The amendment provides (1) all entities with a practical expedient to assume that current conditions as of the balance
sheet date do not change for the remaining life of the assets and (2) entities other than public business entities with an accounting
policy election to consider collection activity after the balance sheet date when estimating expected credit losses for current accounts
receivable and current contract assets arising from transactions accounted for under Topic 606. This guidance is effective for annual
reporting periods beginning after December&#160;15, 2025 and interim reporting periods within those annual reporting periods. Early adoption
is permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or guidance on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except as mentioned above, the Company does not believe
other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the balance sheets,
statements of income and comprehensive loss and cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration and risk<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentration and risk</a></td>
<td class="text"><p id="xdx_803_eus-gaap--ConcentrationRiskDisclosureTextBlock_zS5TxZ8a2Pfc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>3.
<span id="xdx_829_zr7ePs3Ws0Bk">Concentration and risk</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Concentration
of credit risk</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Financial
instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.
The Company performs ongoing credit evaluations of the customers&#8217; financial condition and maintains an allowance for potential credit
losses. This allowance consists of an amount identified for specific customers and an amount based on overall estimated exposure. Our
overall estimated exposure excludes amounts covered by credit insurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Concentration
of customers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s revenue was concentrated among a limited number of customers during the periods presented. The following table summarized
customers with greater than 10% of the total revenue:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfConcentrationOfCustomersTableTextBlock_zdrUY4cApChh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8BB_zF0IjA1n3Cgf" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of Concentration of customers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zxlgA7Wnag01" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3426">-</span></span>**</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zqH7DAOCXZV8" title="Concentration of credit risk">24.9</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_z4iANF7QCG72" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3430">-</span></span>**</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_z5ok8h33NPNk" title="Concentration of credit risk">24.6</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zl0hTdibTWy2" title="Concentration of credit risk">11.7</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zr78XgBdGFo5" title="Concentration of credit risk">11.8</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zEivBBjP6d54" title="Concentration of credit risk">10.0</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zJU8ZQcVPnQ2" title="Concentration of credit risk">22.3</span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        C</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zFn7N05enlt1" title="Concentration of credit risk">13.7</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zh9iXLwhZpMf" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3444">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_ziHKyapdTwK3" title="Concentration of credit risk">17.0</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zjeLxYJlsrI1" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3448">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        D</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_z796I4O4Ft1f" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3450">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zRbhCM2LF7S5" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3452">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zgDdNqfgOq26" title="Concentration of credit risk">10.2</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zwowQSBgSD2k" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3456">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        E</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zN6m8I45z7m6" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3458">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z7iN0ziOqvYg" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3460">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zyjXbig4uFfc" title="Concentration of credit risk">10.1</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z34E1WctisKk" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3464">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        F</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zKgQ6gkcige5" title="Concentration of credit risk">15.6</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zWsV8sKzzwa8" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3468">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zB7onhtTK1u9" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3470">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zxDehDpeHJYc" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3472">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

<p id="xdx_8A0_zpwvFHT7lvqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s account receivable was concentrated among a limited number of customers during the periods presented. The following table
summarized customers with greater than 10% of the total account receivable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfAccountsReceivableTextBlock_zssuHJd4Ga7j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 1)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B7_zUHNVQLGGhr4" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of account receivable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>As of<br/>June&#160;30,</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>As of<br/>March&#160;31,</b></td>
    <td>&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zZDJYmdTS6e7" style="color: rgb(204,238,255)" title="Concentration of credit risk">-</span>**</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zA8eCEY2tIWj" title="Concentration of credit risk">29.7</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zBKTwHAkynJb" style="color: White" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zK6G4BVNOl4d" title="Concentration of credit risk">19.5</span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        E</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_ztBmu7lekrwl" style="color: rgb(204,238,255)" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z4Qc91H8QUS6" title="Concentration of credit risk">10.5</span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        G</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zL35tipxfmbl" title="Concentration of credit risk">42.7</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zqXdvkL42fyj" style="color: White" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        H</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_z8f6t0ucYWmb" title="Concentration of credit risk">38.3</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zMd1APLqZ6f8" style="color: rgb(204,238,255)" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        I</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zVQSNFcXuZY3" title="Concentration of credit risk">19.0</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zHUH7nofxl86" style="color: White" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

<p id="xdx_8A3_zdxUw16dlq13" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Concentration
of suppliers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s purchases was concentrated among a limited number of suppliers during the periods presented. The following table summarized
suppliers with greater than 10% of the total purchase:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfConcentrationOfSuppliersTableTextBlock_z3CdJRz1h27f" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 2)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8BE_zyVdblECd42c" style="display: none; padding-bottom: 0.5pt">Schedule of Concentration of suppliers</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td></tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zZfZ870bnb8a" style="color: rgb(204,238,255)" title="Concentration of credit risk">-</span>*</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zfZK2HfIukSg" title="Concentration of credit risk">13.0</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_fKg_____zoMyxzTZqNtf" style="color: rgb(204,238,255)" title="Concentration of credit risk">-</span>*</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zuAu6Jniu74e" title="Concentration of credit risk">26.4</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_z1RvSNaoV0gg" title="Concentration of credit risk">14.4</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zmAjaL9pPKIb" title="Concentration of credit risk">30.2</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zu3OB7u7IVK3" title="Concentration of credit risk">21.1</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zubilSVoZOol" title="Concentration of credit risk">24.9</span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        C</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zlOyPiZv8SE3" title="Concentration of credit risk">32.9</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zmj4eUM2HHn1" title="Concentration of credit risk">33.7</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zqiSFV5na4Ac" title="Concentration of credit risk">24.0</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zougKUG4D7eh" title="Concentration of credit risk">24.2</span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        D</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_z39sRFJ0NCt8" style="color: White" title="Concentration of credit risk">-</span>*</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zMuGucfinjtf" title="Concentration of credit risk">13.8</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zGlfi03BgXDb" style="color: White" title="Concentration of credit risk">-</span>*</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zZ6OSrj6FVIa" title="Concentration of credit risk">11.5</span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        E</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zJ08L3iZ3sFe" title="Concentration of credit risk">45.5</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zrqGEIvYjMWe" style="color: rgb(204,238,255)" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zHbQGldke1jg" title="Concentration of credit risk">47.6</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zd2hl76uQNH" style="color: rgb(204,238,255)" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">*:</td>
    <td style="text-align: justify">nil, new supplier for the nine months ended March&#160;31, 2026</td>
        </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

<p id="xdx_8AB_zBBE52ciJOOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s account payable was concentrated among a limited number of suppliers during the periods presented. The following table
summarized suppliers with greater than 10% of the total account payable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zRgvFNJVonif" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 3)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B1_z1KfkhgkdJa9" style="display: none">Schedule of account payable</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>As of<br/>June&#160;30,</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>As of<br/>March&#160;31,</b></td>
    <td>&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        B</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90D_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zoy1O16r6pC2" title="Concentration of credit risk">12.1</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90E_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zT52WewH3gKf" title="Concentration of credit risk">74.0</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        D</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_ecustom--ConcentrationRiskPercentage_dp0_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_z49d3JRTVlqf" style="color: White" title="Concentration of credit risk">-</span>*</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zH861vcBqWw8" title="Concentration of credit risk">12.6</span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        E</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_ecustom--ConcentrationRiskPercentage_dp0_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zbDTqTB9gdUl" style="color: rgb(204,238,255)" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zowygHhsFI98" title="Concentration of credit risk">13.4</span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        F</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_z9tjQJ8njxna" title="Concentration of credit risk">54.9</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_ecustom--ConcentrationRiskPercentage_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_z0EDwEhAYvj3" style="color: White" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        G</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--SupplierGMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbgS1YdQk6w3" title="Concentration of credit risk">32.3</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_ecustom--ConcentrationRiskPercentage_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierGMember_zx8Qj3Ar38J3" style="color: rgb(204,238,255)" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">*:</td>
    <td style="text-align: justify">nil, new supplier for the nine months ended March&#160;31, 2026</td>
        </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_80E_eus-gaap--ConcentrationRiskDisclosureTextBlock_zCNDhVCVmNLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>3. <span id="xdx_82C_zFBbZ0r7Zud1">Concentration and risk</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Concentration of credit risk</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject us
to concentrations of credit risk consisted primarily of cash and cash equivalents, and accounts receivable. We perform ongoing credit
evaluations of our customers&#8217; financial condition and maintain an allowance for potential credit losses. This allowance consisted
of an amount identified for specific customers and an amount based on overall estimated exposure. Our overall estimated exposure excludes
amounts covered by credit insurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Concentration of customers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s revenue was concentrated among
a limited number of customers during the periods presented. The following table summarized customers with greater than 10% of the total
revenue:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfConcentrationOfCustomersTableTextBlock_zed2bAfuUphh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B4_z48bm01L1Eva" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Schedule of Concentration of customers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/> years ended<br/> June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Customer A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zI3jDRHvmOHb" title="Concentration of credit risk">12.0</span></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zCJR511w04rj" title="Concentration of credit risk">14.0</span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zJeeMwjQDM02" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2217">-</span></span>*</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_z2sWdo9WBpLi" title="Concentration of credit risk">12.5</span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer C</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zvX47L5fSCGl" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2221">-</span></span>*</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_z7lIZvAGakw4" title="Concentration of credit risk">10.2</span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer D</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_ziuVreXhY8Jc" title="Concentration of credit risk">31.6</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zsJSn6PWGOta" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2227">-</span></span>**</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer E</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zdcO0AkLU83b" title="Concentration of credit risk">11.9</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zapiuLRQgfx9" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2231">-</span></span>**</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer F</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zXQQtM1R6mP3" title="Concentration of credit risk">11.0</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zkn4huYfaA16" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2235">-</span></span>**</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left">*:</td>
    <td style="text-align: justify">nil, new customer for the year ended June&#160;30, 2025</td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

<p id="xdx_8A3_zXQpMtPkMqqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s account receivable was concentrated
among a limited number of customers during the periods presented. The following table summarized customers with greater than 10% of the
total account receivable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfAccountsReceivableTextBlock_zul5l5RzGYv6" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BD_zHRJbQ5m4O88" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Schedule of account receivable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of<br/> June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Customer G</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_ztRPBtEWTJi8" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2244">-</span></span>*</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zfLH42HKXt76" title="Concentration of credit risk">42.7</span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer H</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zNKBHqTWkrn4" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2248">-</span></span>*</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zEKpxvmQvgCh" title="Concentration of credit risk">38.3</span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer F</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zGqVCvs69Qf1" title="Concentration of credit risk">23.4</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zC5KwJCVT3zf" title="Concentration of credit risk">19.0</span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer D</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_znrResZohiG9" title="Concentration of credit risk">43.5</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_z6V3t8cHkLUj" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2258">-</span></span>**</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer I</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zYzaLovelHqg" title="Concentration of credit risk">15.3</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span></span>**</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left">*:</td>
    <td style="text-align: justify">nil, new customer for as of June&#160;30, 2025</td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

<p id="xdx_8A7_zazzTEdf3qC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Concentration of suppliers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s purchases was concentrated among
a limited number of suppliers during the periods presented. The following table summarized suppliers with greater than 10% of the total
purchase:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfConcentrationOfSuppliersTableTextBlock_zdj4W8YCipk8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B7_zFinAf9oIFQc" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Schedule of Concentration of suppliers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/> years ended<br/> June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Supplier A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__srt--MajorCustomersAxis__custom--SupplierAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGIyJJPBbOil" title="Concentration of credit risk">56.6</span></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zXZaKxf02Dlh" title="Concentration of credit risk">41.4</span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplier B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zgOzrD5jGv2g" title="Concentration of credit risk">14.6</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_z26lViCdPaY" title="Concentration of credit risk">31.7</span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplier C</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zo7uj5B50TF2" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2272">-</span></span>**</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_z9dWnq9LW8u3" title="Concentration of credit risk">18.4</span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplier D</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zG0uIze1Y1Ua" title="Concentration of credit risk">12.8</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zPqI0xfZVU09" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2278">-</span></span>**</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

<p id="xdx_8A9_zNVjriFteaE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s account payable was concentrated
among a limited number of suppliers during the periods presented. The following table summarized suppliers with greater than 10% of the
total account payable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zUoSMF44CI8f" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BC_zrFgXmZyLEDl" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Schedule of account payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of<br/> June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Supplier E</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90E_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zD1SOuo8O6Gl" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2282">-</span></span>*</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_909_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_znsgNbuG5cH8" title="Concentration of credit risk">54.9</span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplier F</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_zdOC7T9Z4elg" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2286">-</span></span>*</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_zoDYy0fMwpSi" title="Concentration of credit risk">32.3</span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplier C</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_z0VhqD2tSjGa" title="Concentration of credit risk">99.4</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zwMhyEreZMRe" title="Concentration of credit risk">12.1</span></td>
    <td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left">*:</td>
    <td style="text-align: justify">nil, new supplier for the year ended June&#160;30, 2025</td> </tr>
  </table>

<p id="xdx_8A4_zUoOBb8uOtB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-3A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurements</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--FairValueDisclosuresTextBlock_zhBirMcj7P27" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>4.
<span id="xdx_827_ze9UXnp1dT7e">Fair value measurements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">As
of June&#160;30, 2025 and March&#160;31, 2026, information about inputs into the fair value measurement of the Company&#8217;s assets
and liabilities that are measured at fair value on a recurring basis in periods subsequent to their initial recognition is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_znXIjy2B1Unc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B3_zmXrZbsyeyG7" style="display: none; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Schedule of fair value assets and liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>Fair value measurement
        at reporting date using</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid"><b>Description</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Fair value <br/>as of<br/>June&#160;30,<br/>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Quoted Prices in<br/>Active
        Markets for<br/>Identical Assets <br/>(Level 1)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Significant Other<br/>Observable
        Inputs <br/>(Level 2)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Significant <br/>Unobservable
        Inputs <br/>(Level 3)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Liabilities:</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Simple
        agreements for future equity<sup>(1)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zdI2HsL9LKmf" title="Liability">18,243,885</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_z1nxmlaF6O8" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3572">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zmfS5uxBUmhg" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3574">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zHPcFlOlK9Vi" title="Liability">18,243,885</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Other payable
        related to the equity option<sup>(2)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zShE7VowVnA1" title="Liability">53,333</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_z5tNnS5uRuuj" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3580">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zzBB0KU0oEw4" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3582">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zkq0aEofGkY2" title="Liability">53,333</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>Fair value measurement
        at reporting date using</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid"><b>Description</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Fair value <br/>as of<br/>March&#160;31,
        <br/>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Quoted Prices in<br/>Active
        Markets for<br/>Identical Assets <br/>(Level 1)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Significant Other<br/>Observable
        Inputs <br/>(Level 2)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Significant <br/>Unobservable
        Inputs <br/>(Level 3)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Liabilities:</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%">&#160;</td>
    <td style="text-align: left; white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%">&#160;</td>
    <td style="text-align: left; white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%">&#160;</td>
    <td style="text-align: left; white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%">&#160;</td>
    <td style="text-align: left; white-space: nowrap; width: 1%">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Simple
        agreements for future equity<sup>(1)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zuhbr7cQGsg7" title="Liability">26,842,205</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zkBbNkVaZqr1" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3591">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_z9y0FcYieMIb" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3593">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zc1rFDya6DW8" title="Liability">26,842,205</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Other payable
        related to the equity option<sup>(2)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zvtu6XUHzxw3" title="Liability">53,333</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zmtSvpn5Ftt7" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3599">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zQh5SQC30bZf" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3601">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zbm43rdQGMmd" title="Liability">53,333</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span id="xdx_F0A_zChGi8tau4Y2">(1)</span></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span id="xdx_F10_zFPLD0zjBMIf">The
        Company classifies its SAFEs as financial liabilities measured at fair value. The value of these agreements depends significantly on future
        financing activities, liquidity events, or other material milestones, and their valuation relies on significant inputs that are not observable
        in the public market. Accordingly, they are classified within Level 3 of the fair value hierarchy.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
        fair value measurement is based on an integrated framework combining&#160;scenario analysis and financial instrument decomposition (i.e.
        Bond Plus Call Method). The proceeds of the SAFEs on the date of issuance were $14,092,500, Refer to Note 8-Simple Agreements for Future
        Equity for further details.</p> </td> </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; color: #0F1115"><span id="xdx_F00_zI5V4PyahiJg">(2)</span></td>
    <td style="text-align: justify"><span id="xdx_F13_z2JSmT6vIOn7">Equity options. On May&#160;9, 2023, the Company entered into an agreement
        with a third-party service provider (the &#8220;Service Provider&#8221;). The Service Provider received a freestanding equity-linked right
        exercisable, at the Service Provider&#8217;s option, upon the closing of the Company&#8217;s next qualified equity financing. The right
        provides the ability to subscribe for up to the value of $200,000 at a 25% discount price per share on the grant date. The equity option
        is remeasured at fair value at each reporting date, with changes in fair value recognized in earnings. As of June&#160;30, 2025 and March&#160;31,
        2026, the fair value of the equity option was $53,333, and no gain or loss from changes in fair value was recognized for the periods presented.
        The fair value measurement of the equity option is categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based
        analysis, which incorporates significant unobservable inputs and management judgment regarding the probability and timing of potential
        future financing outcomes.</span></td> </tr>
  </table>

<p id="xdx_8AD_zAeVWeK19ZUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_809_eus-gaap--FairValueDisclosuresTextBlock_zZLKhN6jsn7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>4. <span id="xdx_820_zfA52tDeRbgk">Fair value measurements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June&#160;30, 2024 and 2025, information about
inputs into the fair value measurement of the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis
in periods subsequent to their initial recognition is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zaDKp93MBRA3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BC_zDd0pvvQ169b" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Schedule of fair value assets and liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measurement at reporting date using</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Description</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value <br/>as of<br/>June&#160;30,<br/>2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted Prices in<br/>Active Markets for<br/>Identical
        Assets <br/>(Level 1)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other<br/>Observable Inputs <br/>(Level
        2)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant <br/>Unobservable Inputs <br/>(Level
        3)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left">Simple agreements for future equity<sup>(1)</sup></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zZ4Gbth8BH69" title="Liability">9,321,564</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zjkwY6IR5PDj" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2301">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zZGm8phKzm75" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2303">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zwGllHMiXKtd" title="Liability">9,321,564</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other payable related to the equity option<sup>(2)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zAoKTZ3VLxo3" title="Liability">53,333</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zoB0jQpIEfc6" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2309">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_z30wtD4xs1Jf" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2311">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zwMRf4C7bDM6" title="Liability">53,333</span></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measurement at reporting date using</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Description</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Fair value <br/>as of<br/>June&#160;30,</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2025</b></p></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted Prices in<br/>Active Markets for<br/>Identical
        Assets <br/>(Level 1)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other<br/>Observable Inputs <br/>(Level
        2)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant <br/>Unobservable Inputs <br/>(Level
        3)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left">Simple agreements for future equity<sup>(1)</sup></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zLQGMKOLzu9g" title="Liability">18,243,885</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zrVTS8w1XDWd" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2317">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zaXQfj4FsIb" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2319">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zchHueBxrDm8" title="Liability">18,243,885</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other payable related to the equity option<sup>(2)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zqgBO7cAGUw8" title="Liability">53,333</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zy2IwQHN8iz8" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2325">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zzWPmd3ZrEEg" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2327">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zaU0cwEh6R2h" title="Liability">53,333</span></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td id="xdx_F02_zz6sJxvOrWkk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left">(1)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
        <p id="xdx_F12_z2I6TVTCss33" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company classifies its SAFEs as financial liabilities
        measured at fair value. The value of the agreements depends significantly on future financing activities, liquidity events, or other material
        milestones, and their valuation relies on significant inputs that are not observable in the public market. Accordingly, they are classified
        within Level 3 of the fair value hierarchy.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value measurement is based on an integrated
        framework combining&#160;scenario analysis and financial instrument decomposition (i.e. Bond Plus Call Method). The proceeds from the
        SAFEs on the date of issuance was $10,592,500, Refer to Note 9-Simple Agreements for Future Equity for further details.</p> </td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span id="xdx_F06_zXSVw5NzMGUg" style="color: #0F1115; color: #0F1115">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span id="xdx_F1A_z1nxpK5jT4mb" style="color: #0F1115; color: #0F1115">Equity
        option. On May&#160;9, 2023, the Company entered into an agreement with a third-party service provider (the &#8220;Service Provider&#8221;).
        The Service Provider received a freestanding equity-linked right exercisable, at the Service Provider&#8217;s option, upon the closing
        of the Company&#8217;s next qualified equity financing. The right provides the ability to subscribe for up to the value of $200,000 at
        a 25% discount price per share on the grant date. The equity option is remeasured at fair value at each reporting date, with changes in
        fair value recognized in earnings. As of June&#160;30, 2024 and June&#160;30, 2025, the fair value of the equity option was $53,333, and
        no gain or loss from changes in fair value was recognized for the periods presented. The fair value measurement of the equity option is
        categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based analysis, which incorporates significant
        unobservable inputs and management judgment regarding the probability and timing of potential future financing outcomes.</span></td> </tr>
  </table>

<p id="xdx_8A0_zHmdNJR8ytF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts receivable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndNontradeReceivableTextBlock', window );">Accounts receivable</a></td>
<td class="text"><p id="xdx_801_eus-gaap--AccountsAndNontradeReceivableTextBlock_zt83sqIk2p94" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>6.
<span id="xdx_821_zw6NyDc9ffw7">Accounts receivable</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Accounts
receivable consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zWg6RZJgXvzh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts receivable (Details)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B9_zVJkzX5GW98" style="display: none; padding-bottom: 0.5pt">Schedule of Accounts receivable</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250630_zm7wuCB6PhW8" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20260331_zS3fEQLzuX3k" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td></tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>As of<br/>June&#160;30,<br/>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>As of<br/>March&#160;31,<br/>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableNetCurrent_iI_pp0p" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Accounts
        receivable</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">152,536</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">1,830,105</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_403_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_zpFjs0QPDHU9" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Less:
        allowance for credit losses</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_407_eus-gaap--AccountsReceivableNet_iI_pp0p" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Accounts
        receivable, net</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>152,536</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>1,830,105</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Accounts
receivable are recorded at the invoiced amount and do not bear interest. The Company maintains an allowance for credit losses for expected
losses over the life of the accounts receivable using the current expected credit loss methodology. The Company determines the allowance
based on historical loss experience, current conditions, and reasonable and supportable forecasts. As of June&#160;30, 2025 and March&#160;31,
2026, there was <span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_zYCAUmcH4Uyf" title="Allowance for credit losses"><span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20260331_zI2AqCult1gj" title="Allowance for credit losses">no</span></span> allowance for expected credit losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_806_eus-gaap--AccountsAndNontradeReceivableTextBlock_zdje7HeU8Tqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>5. <span id="xdx_826_z2cS9GvZHBdg">Accounts receivable </span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zOSA2JgZjj2j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts receivable (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B0_zVKrFI6QAXc2" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Schedule of Accounts receivable</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of<br/> June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Accounts receivable</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_903_eus-gaap--AccountsReceivableNetCurrent_c20240630_pp0p" title="Accounts receivable">123,332</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--AccountsReceivableNetCurrent_c20250630_pp0p" title="Accounts receivable">152,536</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less: allowance for credit
        losses</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_c20240630_zTKCr1aFiAHe" title="Less: allowance for credit losses">-</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_c20250630_zo59ljd2r8vk" title="Less: allowance for credit losses">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Accounts
        receivable, net</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_901_eus-gaap--AccountsReceivableNet_c20240630_pp0p" title="Accounts receivable, net">123,332</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_902_eus-gaap--AccountsReceivableNet_c20250630_pp0p" title="Accounts receivable, net">152,536</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts Receivable are recorded at the invoiced amount
and do not bear interest. The Company maintains an allowance for credit losses for expected losses over the life of the accounts receivable
using the current expected credit loss methodology. The Company determines the allowance based on historical loss experience, current
conditions, and reasonable and supportable forecasts. As of June&#160;30, 2024 and 2025, there was <span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20240630_zNwMZQsRvRJ9" title="Allowance for credit losses"><span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_z7pQLRmnRnl8" title="Allowance for credit losses">no</span></span> allowance for expected credit losses.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndNontradeReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/326/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndNontradeReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_OtherReceivablesTextBlock', window );">Other receivables</a></td>
<td class="text"><p id="xdx_80A_ecustom--OtherReceivablesTextBlock_zA37jU1ZOfV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<br/><b>6. <span id="xdx_821_zYjS7DyznEb5">Other receivables</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other receivables represent funds temporarily held
in trust by an employee acting as the Company&#8217;s behalf. As of June&#160;30, 2024 and 2025, the balance were $<span id="xdx_90D_eus-gaap--OtherReceivables_c20240630_pp0p" title="Other receivables">2,884,694</span> and $<span id="xdx_903_eus-gaap--OtherReceivables_c20250630_pp0p" title="Other receivables">1,207,626</span>,
respectively, primary comprising proceeds from SAFEs agreements received via the employee <span style="color: #0F1115; color: #0F1115">and
net of payments made to designated suppliers at the Company&#8217;s direction. The outstanding balance was fully settled in January&#160;2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_OtherReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_OtherReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment, net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Equipment, net</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zdX7g6UQPBw2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>7.
<span id="xdx_822_zmlf6pOH23ii">Equipment, net</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Equipment,
net consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6SXjtYgd1Rl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equipment, net (Details)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8BE_zhFe2H6s0JL3" style="display: none; padding-bottom: 0.5pt">Schedule of Equipment</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250630_zjhFyVyhBbpc" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20260331_zJzRw9osXoxa" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td></tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>As of<br/>June&#160;30,
        <br/>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>As of<br/>March&#160;31,<br/>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_zDy4QedUaU9k" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Equipment</td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right">29,944</td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right">29,198</td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_pp0d_zz24YPuTInVl" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Total</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>29,944</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>29,198</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_pp0d_di_ztschh1CeBb2" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Less:
        accumulated depreciation</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(10,344</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(14,792</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0d_zJcMcc2HfH0g" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Net
        carrying amount</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>19,600</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>14,406</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Depreciation
expenses for the three months ended March&#160;31, 2025 and 2026 were $<span id="xdx_909_eus-gaap--Depreciation_c20250101__20250331_pp0p" title="Depreciation expenses">1,601</span> and $<span id="xdx_907_eus-gaap--Depreciation_c20260101__20260331_pp0p" title="Depreciation expenses">1,565</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Depreciation
expenses for the nine months ended March&#160;31, 2025 and 2026 were $<span id="xdx_902_eus-gaap--Depreciation_c20240701__20250331_pp0p" title="Depreciation expenses">4,633</span> and $<span id="xdx_900_eus-gaap--Depreciation_c20250701__20260331_pp0p" title="Depreciation expenses">5,194</span> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zLYDRpyLKNhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>7. <span id="xdx_820_z8sx4dTJBxsg">Equipment, net</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equipment, net consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--PropertyPlantAndEquipmentTextBlock_zWlZAMPXOKe1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equipment, net (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B5_z96otHUhXDyg" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Schedule of Equipment</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_497_20240630_zIHWu3xL186" style="font-weight: bold; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_492_20250630_zYNqMLOHwIRg" style="font-weight: bold; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of<br/> June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt">Equipment</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right">27,806</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right">29,944</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">27,806</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">29,944</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_pp0d_di_zx2ts7Yln7tf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(4,110</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(10,344</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net
        carrying amount</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">23,696</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">19,600</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expenses for the&#160;years ended June&#160;30,
2024 and 2025 were $<span id="xdx_900_eus-gaap--Depreciation_c20230701__20240630_zomGNXN2kYl4" title="Depreciation expenses">4,110</span> and $<span id="xdx_904_eus-gaap--Depreciation_c20240701__20250630_zueTAB6r85N5" title="Depreciation expenses">6,234</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Refundable deposits payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RefundableDepositsPayableTextBlock', window );">Refundable deposits payable</a></td>
<td class="text"><p id="xdx_80D_ecustom--RefundableDepositsPayableTextBlock_zdT8v1NNaUXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>8. <span id="xdx_82D_zslWpkq71Jm9">Refundable deposits payable </span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Refundable deposits payable represent security payments
received from a third party and customers, which are required for certain intelligent computing power service arrangements. As of June&#160;30,
2024 and 2025, the balance were $<span id="xdx_908_ecustom--RefundableDepositsPayable_c20240630_pp0p" title="Refundable deposits payable">223,205</span> and $<span id="xdx_909_ecustom--RefundableDepositsPayable_c20250630_pp0p" title="Refundable deposits payable">1,445,580</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_RefundableDepositsPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_RefundableDepositsPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Simple agreements for future equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_SimpleAgreementsForFutureEquityTextBlock', window );">Simple agreements for future equity</a></td>
<td class="text"><p id="xdx_800_ecustom--SimpleAgreementsForFutureEquityTextBlock_zvL0mGPqikAj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>8.
<span id="xdx_826_zuUPRpykS4s9">Simple agreements for future equity</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company has entered into SAFEs with various investors that were classified as liabilities on the Company&#8217;s balance sheets and accounted
for at fair value, subject to remeasurement each reporting period. Each SAFEs has no maturity date, does not bear any interest and provides
the investor with the right to convert into a variable number of shares of future equity in the Company at the stated conversion amount,
if certain events or conditions are triggered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">During
the period from October&#160;2022 through March&#160;31, 2026, the Company entered into Simple Agreements for Future Equity with third-party
investors, receiving aggregate gross proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromOtherEquity_c20221001__20260331_pp0p" title="Aggregate gross proceeds">14,092,500</span>. For the nine months ended March&#160;31, 2025 and 2026, the Company received
SAFEs proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromOtherEquity_pp0d_c20240701__20250331_zUakL51Li8jh" title="Aggregate gross proceeds">4,275,000</span> and $<span id="xdx_903_eus-gaap--ProceedsFromOtherEquity_pp0d_c20250701__20260331_z2WDlnQfzWRe" title="Aggregate gross proceeds">3,500,000</span>, respectively, with nil and $3,000,000 received in USDC, respectively. No issuance costs were incurred in connection with these arrangements. As of
the date these unaudited condensed consolidated financial statements are issued, none of the SAFEs have been settled or converted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
SAFEs agreements grant investors the right to participate in the Company&#8217;s future equity financing events. The agreements contain
various conversion and redemption provisions, including conversion upon an equity financing event, as well as settlement in the event
of a liquidity event or dissolution of the Company. Key terms of the SAFEs are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Equity
Financing</i></b>&#160;&#8211; Upon the occurrence of an equity financing event, each SAFEs automatically converts into a greater of (i)&#160;the
number of shares of preferred stock equal to SAFEs purchase amount divided by the lowest price per share paid for the standard preferred
stock or (ii)&#160;the number of shares of preferred stock equal to the SAFEs purchase amount divided by the SAFEs price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">&#8220;SAFEs price&#8221; means is calculated by dividing a fixed post-money
        valuation cap by the Company capitalization, a defined term that includes all outstanding equity and convertible instruments.</td>
        </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#9679;</td>
    <td style="text-align: justify">&#8220;Equity Financing&#8221; means a bona fide transaction or series
        of transactions with the principal purpose of raising capital, pursuant to which the Company issues and sells preferred share at a fixed
        valuation, including but not limited to, a pre-money or post-money valuation.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Not
all SAFEs agreements contain the equity financing conversion provision described above. Certain SAFEs are structured without an Equity
Financing conversion feature and are generally settled only upon a Liquidity Event or a Dissolution Event (as defined in the respective
SAFEs agreements). The Company considered the contractual terms of the SAFEs, including whether an Equity Financing conversion feature
is present and the settlement provisions upon a Liquidity Event or a Dissolution Event, in the valuation and measurement of these instruments.
As of March&#160;31, 2026, <span id="xdx_90F_ecustom--EquityFinancingDescription_c20240701__20250331_z5HMRpZeny35" title="Equity Financing description">SAFEs with an aggregate purchase amount of $13,632,500 include an Equity Financing conversion feature, while
SAFEs with an aggregate purchase amount of $460,000 do not include this feature and are generally settled only upon a Liquidity Event
or a Dissolution Event, in accordance with their terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company does not have any preferred stock outstanding as of the date these unaudited condensed consolidated financial statements are issued;
therefore, an equity financing event has not been triggered.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, serif; text-align: justify; margin-top: 0px; margin-bottom: 0px"><b><i>Liquidity
Event</i></b>&#160;&#8211; If there is a liquidity event before the conversion of each SAFE, the holder of each SAFEs will automatically
be entitled to the greater of (i) SAFEs purchase amount, or (ii)&#160;the amount payable on the number of shares of ordinary shares equal
to the purchase amount divided by the Liquidity Price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">&#8220;Liquidity Price&#8221; is calculated by dividing the post-money
        valuation cap by the separately defined capital base, referred to as &#8220;liquidity capitalization&#8221; in the SAFEs agreements.</td>
        </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#9679;</td>
    <td style="text-align: justify">&#8220;Liquidity Event&#8221; means a change of control, a direct Listing
        or an initial public offering.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>Dissolution
Event</i></b>&#160;&#8211; If there is a dissolution event before the conversion of each SAFE, the holder of each SAFEs will automatically
be entitled to receive a portion of proceeds equal to SAFEs purchase amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company classifies its SAFEs as financial liabilities measured at fair value. Since the value of these instruments depends on significant
unobservable inputs, including future financing activities and liquidity events, they are classified as Level 3 within the fair value
hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
fair value measurement utilizes a combined scenario analysis and financial instrument decomposition approach. Based on management&#8217;s
assessment of the Company&#8217;s prospects, probability distributions are assigned to potential settlement-triggering events. Valuation
is performed using a &#8220;debt plus option&#8221; model: the debt component is valued using a discounted cash flow method with key assumptions
including expected settlement timing, risk-free interest rate, and credit spread; the embedded conversion right is treated as a call option
and valued using the Black-Scholes model, with key inputs including the fair value of ordinary shares, expected term, and volatility.
The overall fair value represents the probability-weighted sum across all scenarios, supported by an independent third-party valuation
specialist.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">As
of June&#160;30, 2025 and March&#160;31, 2026, the SAFE liabilities were measured at fair value using the above Level 3 methodology. Significant
unobservable inputs&#8212;including timing of events, volatility, and credit spreads&#8212;are based on management&#8217;s reasonable
estimates as of each valuation date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
following tables set forth a summary of the activity of the SAFE liabilities, respectively, which represents a recurring fair value measurement
at the end of each reporting period:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zJ7zAKCvB5s" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Simple agreements for future equity (Details)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B0_zlyvnZCHN8oh" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of fair value measurement</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Amount</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Balance
        at June&#160;30, 2024</b></td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b><span id="xdx_90A_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20240701__20250331_zsdjo0SWVk52" title="Balance at beginning">9,321,564</span></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Issuance
        of simple agreements for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20240701__20250331_zNBYySXf6A5j" title="Issuance of simple agreements for future equity">4,275,000</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Change
        in fair value</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--ChangeInFairValue_c20240701__20250331_pp0p" title="Change in fair value">3,716,052</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Balance
        at March&#160;31, 2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><span id="xdx_90C_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20240701__20250331_zHo7SoRKeCab" title="Balance at ending">17,312,616</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Balance
        at June&#160;30, 2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><span id="xdx_903_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20250701__20260331_zv833aNiJuE" title="Balance at beginning">18,243,885</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Issuance
        of simple agreements for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20250701__20260331_zSP3vbHmvvpg" title="Issuance of simple agreements for future equity">3,500,000</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Change
        in fair value</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--ChangeInFairValue_c20250701__20260331_pp0p" title="Change in fair value">5,098,320</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Balance
        at March&#160;31, 2026</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_908_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20250701__20260331_zmoiw9Md1KUg" title="Balance at ending">26,842,205</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Subsequent
to March&#160;31, 2026 (see Note 1), in connection with the proposed business combination, the outstanding SAFEs are expected to be settled
upon the closing of the transaction (the &#8220;Closing&#8221;). Pursuant to their terms, if a SPAC transaction occurs prior to the termination
of the SAFEs, each SAFE will automatically convert at the Closing into the right to receive Class A ordinary shares of PubCo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">At
the Closing of the BCA transaction, each SAFE is expected to convert into Class A shares of PubCo, if the amount payable of $26,842,205
is greater than the purchase amount.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_803_ecustom--SimpleAgreementsForFutureEquityTextBlock_zOlXnvXLN6Ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>9. <span id="xdx_821_zGErECRHaUFh">Simple agreements for future equity</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has entered into SAFEs with various investors
that were classified as liabilities on the Company&#8217;s balance sheets and accounted for at fair value, subject to remeasurement each
reporting period. Each SAFEs has no maturity date, does not bear any interest and provides the investor with the right to convert into
a variable number of shares of future equity in the Company at the stated conversion amount, if certain events or conditions are triggered.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period from October&#160;2022 through June&#160;2025,
the Company entered into Simple Agreements for Future Equity with third-party investors, receiving aggregate gross proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromOtherEquity_c20221001__20250630_pp0p" title="Aggregate gross proceeds">10,592,500</span>.
Of this amount, $<span id="xdx_900_eus-gaap--ProceedsFromOtherEquity_c20230701__20240630_pp0p" title="Aggregate gross proceeds">5,685,000</span> and $<span id="xdx_902_eus-gaap--ProceedsFromOtherEquity_c20240701__20250630_pp0p" title="Aggregate gross proceeds">4,307,500</span> were recorded in the fiscal years ended June&#160;30, 2024 and 2025, respectively. Subsequent
to June&#160;30, 2025, the Company received additional SAFEs proceeds of $<span id="xdx_905_ecustom--AdditionalSafesProceeds_pp0d_c20240701__20250606__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkdoR94mROG6" title="Additional SAFEs proceeds">500,000</span>, resulting in cumulative proceeds of $<span id="xdx_908_ecustom--CumulativeProceeds_pp0d_c20240701__20250606__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVj7nuUFaL8k" title="Cumulative proceeds">11,092,500</span> as
of the date of this report. No issuance costs were incurred in connection with these arrangements. As of the date these financial statements
are issued, none of the SAFEs have been settled or converted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The SAFEs agreements grant investors the right to
participate in the Company&#8217;s future equity financing events. The agreements contain various conversion and redemption provisions,
including conversion upon an equity financing event, as well as settlement in the event of a liquidity event or dissolution of the Company.
Key terms of the SAFEs are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Equity Financing</i></b>&#160;&#8211; Upon the
occurrence of an equity financing event, each SAFEs automatically converts into a greater of (i)&#160;the number of shares of preferred
stock equal to SAFEs purchase amount divided by <span style="color: #0F1115; color: #0F1115">the lowest price per share paid for the standard
preferred stock</span> or (ii)&#160;the number of shares of preferred stock equal to the SAFEs purchase amount divided by the SAFEs price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#8220;SAFEs price&#8221; means <span style="color: #0F1115; color: #0F1115">is
        calculated by dividing a fixed post-money valuation cap by the Company capitalization, a defined term that includes all outstanding equity
        and convertible instruments.</span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#8220;Equity Financing&#8221; means a bona
        fide transaction or series of transactions with the principal purpose of raising capital, pursuant to which the Company issues and sells
        preferred share at a fixed valuation, including but not limited to, a pre-money or post-money valuation.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not all SAFEs agreements contain the equity financing
conversion provision described above. Certain SAFEs are structured without an Equity Financing conversion feature and are generally settled
only upon a Liquidity Event or a Dissolution Event (as defined in the respective SAFEs agreements). The Company considered the contractual
terms of the SAFEs, including whether an Equity Financing conversion feature is present and the settlement provisions upon a Liquidity
Event or a Dissolution Event, in the valuation and measurement of these instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June&#160;30, 2025, <span id="xdx_90D_ecustom--EquityFinancingDescription_pp0d_c20240701__20250630_zpoJJ0lxxOh" title="Equity Financing description">SAFEs with an aggregate
purchase amount of $10,132,500 include an Equity Financing conversion feature, while SAFEs with an aggregate purchase amount of $460,000
do not include this feature and are generally settled only upon a Liquidity Event or a Dissolution Event, in accordance with their terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #0F1115; color: #0F1115">The Company
does not have any preferred stock outstanding as of February&#160;11, 2026; therefore, an equity financing event has not been triggered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Liquidity Event</i></b>&#160;&#8211; If there
is a liquidity event before the conversion of each SAFE, the holder of each SAFEs will automatically be entitled to the greater of (i)
SAFEs purchase amount, or (ii)&#160;the amount payable on the number of shares of ordinary shares equal to the purchase amount divided
by the Liquidity Price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#8220;Liquidity Price&#8221; is calculated
        by dividing the post-money valuation cap by the separately defined capital base, referred to as &#8220;liquidity capitalization&#8221;
        in the SAFEs agreements.</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#8220;Liquidity Event&#8221; means a change
        of control, a direct Listing or an initial public offering.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Dissolution Event</i></b>&#160;&#8211; If there
is a dissolution event before the conversion of each SAFE, the holder of each SAFEs will automatically be entitled to receive a portion
of proceeds equal to SAFEs purchase amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company classifies its SAFEs as financial liabilities
measured at fair value. Since the value of these instruments depends on significant unobservable inputs, including future financing activities
and liquidity events, they are classified as Level 3 within the fair value hierarchy.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value measurement utilizes a combined scenario
analysis and financial instrument decomposition approach. Based on management&#8217;s assessment of the Company&#8217;s prospects, probability
distributions are assigned to potential settlement-triggering events. Valuation is performed using a &#8220;debt plus option&#8221; model:
the debt component is valued using a discounted cash flow method with key assumptions including expected settlement timing, risk-free
interest rate, and credit spread; the embedded conversion right is treated as a call option and valued using the Black-Scholes model,
with key inputs including the fair value of ordinary shares, expected term, and volatility. The overall fair value represents the probability-weighted
sum across all scenarios, supported by an independent third-party valuation specialist.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June&#160;30, 2024 and 2025, the SAFEs liabilities
were measured at fair value using the above Level 3 methodology. Significant unobservable inputs&#8212;including timing of events, volatility,
and credit spreads&#8212;are based on management&#8217;s reasonable estimates as of each valuation date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following tables set forth a summary of the activity
of the SAFEs liabilities, respectively, which represents a recurring fair value measurement at the end of each reporting period:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zfdZKaMA3CCa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Simple agreements for future equity (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BD_z692NbrbQ79l" style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Schedule of fair value measurement</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left; padding-bottom: 1pt">Balance at
        June&#160;30, 2023</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b><span id="xdx_90A_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20230701__20240630_z3t0Cul6FTGe" title="Balance at beginning">526,046</span></b></td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Issuance of simple agreements for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20230701__20240630_z8DBIBOQ2pC6" title="Issuance of simple agreements for future equity">5,685,000</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Change in fair value</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--ChangeInFairValue_c20230701__20240630_pp0p" title="Change in fair value">3,110,518</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Balance at June&#160;30,
        2024</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span id="xdx_90F_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20240701__20250630_zmXBtU0sSxXj" title="Balance at beginning">9,321,564</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Issuance of simple agreements for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20240701__20250630_zpOe9NCtkcUa" title="Issuance of simple agreements for future equity">4,307,500</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Change in fair value</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--ChangeInFairValue_pp0d_c20240701__20250630_zSYkDe6txhu7" title="Change in fair value">4,614,821</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Balance at June&#160;30,
        2025</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span id="xdx_901_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20240701__20250630_zgTzyRzot0oc" title="Balance at ending">18,243,885</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #0F1115; color: #0F1115">If and
when the SAFEs are converted into equity, management currently expects that such conversion would be settled through transfers of existing
ordinary shares held by the controlling shareholder, rather than through the issuance of new shares by the Company, subject to the final
conversion terms and the relevant agreements. To the extent settled in this manner, the underlying ordinary shares are already included
in the Company&#8217;s issued and outstanding shares as of the balance sheet date; therefore, such settlement would not be expected to
increase the Company&#8217;s total issued and outstanding shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to June&#160;30, 2025 (see Note 1), in
connection with the proposed business combination, the outstanding SAFEs are expected to be settled upon the closing of the transaction
(the &#8220;Closing&#8221;). Pursuant to their terms, if a SPAC transaction occurs prior to the termination of the SAFEs, each SAFE will
automatically convert at the Closing into the right to receive Class A ordinary shares of PubCo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At the Closing of BCA transaction, each of SAFEs is
expected to convert into the Class A shares of the PubCo without any action required by the SAFE holders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_SimpleAgreementsForFutureEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_SimpleAgreementsForFutureEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zyFahVjLxWI4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>9.
<span id="xdx_82B_ziKKVuFGi2S9">Income taxes</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Exascale
Labs Inc. is incorporated in the State of Delaware and is subject to income taxes in its primary jurisdictions: U.S. federal income
tax, California state corporate income tax and Delaware state corporate income tax. The statutory tax rates applicable to the
Company are <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c20250701__20260331_pd" title="Federal income tax rate">21%</span>
at the federal level, 8.84% at the California state level and <span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c20250701__20260331_pd" title="State income tax rate">8.7%</span>
at the Delaware state level.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Evana
Alpha Pte. Ltd. is incorporated in Singapore and is subject to the statutory corporate income tax rate of <span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20250701__20260331__us-gaap--IncomeTaxAuthorityNameAxis__custom--EvanaAlphaPteLtdMember_pd" title="Effective income tax rate">17%</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
current and deferred components of income tax expense reflected in the statements of operations and comprehensive loss were nil <span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20250701__20260331_zQiioohpuxS4" title="Effective income tax rate"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20240701__20250331_zur6gJAGXbi2" style="display: none" title="Effective income tax rate">0</span></span>
for the nine months ended March&#160;31, 2025 and 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s effective income tax rate was&#160;nil&#160;for the nine months ended March&#160;31, 2025 and 2026. This was primarily
attributable to the&#160;recognition of a full valuation allowance against the net deferred tax assets, as the Company has concluded that
it is not more likely than not that these assets will be realized in the foreseeable future. Accordingly, no tax benefit has been recognized
for the losses incurred during these periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company
had no unrecognized tax benefits as of March 31, 2026. The Company currently files income tax returns in the United States, as well as
Delaware and California. All tax years are open for examination. The Company currently has no federal or state tax examinations in progress.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<span></span>
</td>
<td class="text"><p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zcy1yoqRg3A8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>10. <span id="xdx_829_zqCnxgL6N714">Income taxes</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company was incorporated in the State of Delaware
and is subject to income taxes in its primary jurisdictions: U.S. federal income tax and Delaware state corporate income tax. The statutory
tax rates applicable to the Company are <span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c20230701__20240630_pd" title="Federal income tax rate">21%</span> at the federal level and <span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c20230701__20240630_pd" title="State income tax rate">8.7%</span> at the Delaware state level.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The current and deferred components of income tax
expense reflected in the statements of operations and comprehensive loss were nil for the years ended June&#160;30, 2024 and 2025.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table reconciles the statutory rate
to the Company&#8217;s effective tax rate. The effective tax rate reconciliation is based on the U.S. federal statutory rate of <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c20240701__20250630_pd" title="Federal income tax rate">21%</span> and
State income tax rate of <span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c20240701__20250630_pd" title="State income tax rate">8.7%</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zsAoZZYShxpj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B0_zDFQbJEySiid" style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Schedule
    of effective tax rate reconciliation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_493_20230701__20240630_zzRi4Ul5zEh4" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_494_20240701__20250630_z4awAYIlbT9i" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/>years ended <br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zobXWve4AQQ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">US Statutory income tax rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">21.0</td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">21.0</td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zXJf7zZEBnT9" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">State income tax rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8.7</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8.7</td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_z7RcGEC6ZYGk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Change in fair value of simple agreements
        for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(18.6</td>
    <td style="text-align: left">)%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(17.9</td>
    <td style="text-align: left">)%</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zr3zjXhd2iGj" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Changes in valuation
        allowance</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(11.1</td>
    <td style="padding-bottom: 1pt; text-align: left">)%</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(11.8</td>
    <td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_zoxSlARfz4f7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Effective income tax
        rate</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">-</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">-</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zEYZ96HGd4s6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s effective income tax rate was&#160;<span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20230701__20240630_pd" title="Effective income tax rate"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_c20240701__20250630_pd" title="Effective income tax rate">0%</span></span>&#160;for
both years ended June&#160;30, 2024 and 2025. This is primarily attributable to the&#160;recognition of a full valuation allowance against
the net deferred tax assets, as the Company has concluded that it is not more likely than not that these assets will be realized in the
foreseeable future. Accordingly, no tax benefit has been recognized for the losses incurred during these periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The principal components of deferred tax assets and
deferred tax liabilities were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z7D3h5I8b915" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B9_zttoKTamREFa" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Schedule of deferred tax assets liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_494_20240630_za1CYiN8uNR8" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_497_20250630_zzAPMP8qH497" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of <br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zBsuAX9Qs0ka" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Deferred tax assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0d_maDTAGzLH3_zHcERxaR5LOi" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net operating loss carry forward</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">748,679</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">1,652,998</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0d_mtDTAGzLH3_maDTANzse2_zpw9mkr8b4Dl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Total deferred tax assets</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">748,679</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">1,652,998</td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0d_di_msDTANzse2_zkDKYZabHnVh" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less: valuation allowance</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(748,679</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(1,652,998</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_pp0d_mtDTANzse2_zy5BDhrvNfsk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total
        deferred tax assets, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2470">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2471">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zuxWXyBw7azl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The changes in valuation allowance for the years ended
June&#160;30, 2024 and 2025 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--SummaryOfValuationAllowanceTextBlock_zEsllNSptTmj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B0_zZZDDEY0OvS5" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Schedule of valuation allowance</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/>years ended<br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Balance at the beginning of the
        year</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pp0d_di_c20230701__20240630_zJGpG8QdG3kj" title="Balance at the beginning of the year">(200,468</span></td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pp0d_di_c20240701__20250630_zQtXy1pEoPm8" title="Balance at the beginning of the year">(748,679</span></td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Additions</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230701__20240630_pp0p" title="Additions">(548,211</span></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20240701__20250630_pp0p" title="Additions">(904,319</span></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance
        at the end of the year</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_908_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pp0d_di_c20230701__20240630_zoH4it63AAy2" title="Balance at the end of the year">(748,679</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_907_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pp0d_di_c20240701__20250630_zU4aB0tVNds8" title="Balance at the end of the year">(1,652,998</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A5_z8CNIKlnZrV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June&#160;30, 2024 and 2025, the Company had
net operating loss carryforwards (&#8220;NOLs&#8221;) of $<span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20240630__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_zpz7739yT5vi" title="Net operating loss carryforwards">2.5 </span>million and $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20250630__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_zc5tGTGft7Zk" title="Net operating loss carryforwards">5.6</span> million for U.S. federal income tax purposes and $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20240630__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--StateAndLocalJurisdictionMember_zrcfQglwNFDb" title="Net operating loss carryforwards">2.5</span> million
and $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20250630__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--StateAndLocalJurisdictionMember_zrvFbn738Xcg" title="Net operating loss carryforwards">5.6</span> million for state income tax purposes.&#160;The federal NOLs&#160;do not expire but are subject to an annual deduction limit
of 80% of taxable income.&#160;The Company&#8217;s NOLs can be carried forward to offset current year profit for Delaware corporate income
tax purposes, subject to certain limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes deferred tax assets if it is
more likely than not that those deferred tax assets will be realized. Management reviews deferred tax assets periodically for recoverability
and makes estimates and judgments regarding the expected geographic sources of taxable income in assessing the need for a valuation allowance
to reduce deferred tax assets to their estimated realizable value. Realization of the Company&#8217;s deferred tax assets is dependent
upon future earnings, if any, the timing and amount of which are uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company had <span id="xdx_909_eus-gaap--UnrecognizedTaxBenefits_iI_pp0d_do_c20250630_zIwngjxvmio1" title="Unrecognized tax benefits"><span id="xdx_903_eus-gaap--UnrecognizedTaxBenefits_iI_pp0d_do_c20240630_zXcxlUP6ogpf" title="Unrecognized tax benefits">no</span></span> unrecognized tax benefits as of
June&#160;30, 2024 and 2025. The Company currently files income tax returns in the U.S., as well as Delaware. All tax years are open for
examination. The Company currently has no federal or state tax examinations in progress.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Share-based compensation</a></td>
<td class="text"><p id="xdx_809_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zmD9QmjKORy7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>10.
<span id="xdx_820_zFODMdXSgusi">Share-based compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
the three and nine months ended March&#160;31, 2025, total share-based compensation expenses recognized were $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20250101__20250331_pp0p" title="Share-based compensation expenses">101,000</span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20240701__20250331_pp0p" title="Share-based compensation expenses">153,266</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
the three and nine months ended March&#160;31, 2026, total share-based compensation expenses recognized were nil<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20260101__20260331_pp0p" title="Share-based compensation expenses"><span id="xdx_900_eus-gaap--ShareBasedCompensation_c20250701__20260331_pp0p" style="display: none" title="Share-based compensation expenses">0</span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">(1)
Employee</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">On
January&#160;6, 2025, with the approval from the Board of the Company, an employee was granted equity award from inception of the employment
agreement, which represented <span id="xdx_901_ecustom--GrantedEquityAward_c20250106__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Granted equity award">0.1%</span> of the Company&#8217;s total shares outstanding at issuance date (the &#8220;0.1% Award&#8221;, i.e.,
1.5 shares). The equity award had a vesting period of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20250701__20260331__srt--CounterpartyNameAxis__custom--EmployeeMember_z1Z0diGK94pe" title="Vesting period">24</span> months after grant, but with no requisite service period. Alongside the employee&#8217;s
separation in September&#160;2025, the equity award remained its vesting pace under the 24-month vesting schedule. As of March&#160;31,
2026, <span id="xdx_906_ecustom--SharesDescription_c20250701__20260331__srt--CounterpartyNameAxis__custom--EmployeeMember_zlx0SpyKOQ08" title="Shares description">0.9375 shares of the Company were vested, with remaining 0.5625 shares unvested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">(2)
Non-employee</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">On
December&#160;2, 2024, with the approval from the Board of the Company, a contractor was granted equity award from inception of the contractor
agreement representing <span id="xdx_908_ecustom--GrantedEquityAward_c20241202__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pd" title="Granted equity award">0.053333%</span> of the Company&#8217;s total shares outstanding at issuance date (&#8220;0.05% Award&#8221;, i.e., 0.8
shares). The equity award had a vesting period of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20250701__20260331__srt--CounterpartyNameAxis__custom--NonEmployeeMember_zQkNCDGTocwl" title="Vesting period">24</span> months after grant, with half vested as of April&#160;1, 2025 and remaining as of
November&#160;1, 2026, but with no requisite service period. As of March&#160;31, 2026, <span id="xdx_904_ecustom--SharesDescription_c20250701__20260331__srt--CounterpartyNameAxis__custom--NonEmployeeMember_z3nHrh1RAC13" title="Shares description">the first half of the equity award had been vested</span>,
the remaining half had been outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s share-based compensation awards are expected to be settled through transfers of existing ordinary shares held by the controlling
shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary shares are included in the issued
and outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase the Company&#8217;s total
issued and outstanding shares. The vested shares are not recorded in the individual names of the holders on the Company&#8217;s stock
ledger, but held by the controlling shareholder on their behalf, mainly due to the plan to a direct register of shares under the listed
company during de-SPAC transaction. The Company, as well as the controlling shareholder deemed the grant as the time when the employee
and non-employees are entitled to economic benefits and risks of the subsequent changes in fair value of the granted shares accordingly
to the agreed vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_80A_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zEMl0kz98Cb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>11. <span id="xdx_82F_zojw0uTLGhUa">Share-based compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended June&#160;30, 2024 and 2025, total
share-based compensation expenses recognized were $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230701__20240630_pp0p" title="Share-based compensation expenses">21,104</span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630_pp0p" title="Share-based compensation expenses">153,266</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the share-based compensation
expenses for the years ended June&#160;30, 2024 and 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock_zYgAKTu1lo7k" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-based compensation (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BB_zwzJiikWfcV4" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Schedule of share-based compensation expenses</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <br/>years ended <br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Selling and marketing expenses</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensation_c20230701__20240630__custom--IncomeStatementLocationsAxis__custom--SellingAndMarketingExpensesMember_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2508">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20240701__20250630__custom--IncomeStatementLocationsAxis__custom--SellingAndMarketingExpensesMember_pp0p" title="Total">153,266</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">General and administrative
        expenses</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230701__20240630__custom--IncomeStatementLocationsAxis__custom--GeneralAndAdministrativeExpensesMember_pp0p" title="Total">21,104</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630__custom--IncomeStatementLocationsAxis__custom--GeneralAndAdministrativeExpensesMember_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2514">-</span></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0d_c20230701__20240630_zG6MuWsZDbL5" title="Total">21,104</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0d_c20240701__20250630_zgdo4PX2S2yh" title="Total">153,266</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Employee</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January&#160;6, 2025, with the approval from the
Board of the Company, an employee was granted equity award from inception of the employment agreement, which represented 0.1% of the Company&#8217;s
total shares outstanding at issuance date (the &#8220;0.1% Award&#8221;, i.e., 1.5 shares). The equity award had a vesting period of 24
months after grant, but with no requisite service period. Alongside with the employee&#8217;s separation in September&#160;2025, the equity
award remained its vesting pace under the 24-month vesting schedule. As of June&#160;30, 2025, <span id="xdx_907_ecustom--SharesDescription_pp0d_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_ziZsFKTjvi5i" title="Shares description">0.375 shares of the Company were vested,
with remaining 1.125 shares unvested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determined January&#160;6, 2025 to be
the grant date of the 0.1% Award and recognized total share-based compensation expense amounted to $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_pp0p" title="Share-based compensation expenses">101,000</span> at the grant date for the
award since the explicit service vesting condition is not the employee&#8217;s requisite service period, and the vesting condition is
not a service condition but is merely a delayed exercisability provision. The share-based compensation expense was calculated based on
the fair value of the 0.1% Award as of the grant date. The fair value of the 0.1% Award was determined with assistance of an independent
third-party valuation specialist using discounted cash flow method with key assumptions of risk free rate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Risk free rate">4.24%</span>, discount rate of <span id="xdx_900_ecustom--DiscountRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Discount rate">13.6%</span>
and perpetual rate of <span id="xdx_901_ecustom--PerpetualRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Perpetual rate">3.0%</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) Non-employee</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December&#160;2, 2024, with the approval from the
Board of the Company, a contractor was granted equity award from inception of the contractor agreement representing 0.053333% of the Company&#8217;s
total shares outstanding at issuance date (&#8220;0.05% Award&#8221;, i.e., 0.8 shares). The equity award had a vesting period of 24 months
after grant, with half vested as of April&#160;1, 2025 and remaining as of November&#160;1, 2026, but with no requisite service period.
As of June&#160;30, 2025, the first half of the equity award had been vested, the remaining half had been outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determined December&#160;2, 2024 to be
the grant date of the 0.05% Award and recognized total share-based compensation expense amounted to $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pp0p" title="Share-based compensation expenses">52,266</span> at the grant date for the
award since the explicit service vesting condition is not the nonemployee&#8217;s vesting period, and the vesting condition is not a service
condition but is merely a delayed exercisability provision. The share-based compensation expense was calculated based on the fair value
of the 0.1% Award as of the grant date. The fair value of the 0.05% Award was determined with assistance of an independent third-party
valuation specialist using discounted cash flow method with key assumptions of risk free rate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pd" title="Risk free rate">4.36%</span>, discount rate of <span id="xdx_90C_ecustom--DiscountRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pd" title="Discount rate">14.9%</span> and perpetual
rate of <span id="xdx_90E_ecustom--PerpetualRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--NonEmployeeMember_pd" title="Perpetual rate">3.0%</span>.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May&#160;9, 2023, the Company entered into an agreement
with a third-party Service Provider to receive accelerator training services. In consideration for these services, the Company agreed
to grant the Service Provider equity equal to 0.425% of shares outstanding at issuance. The Company accounts for the award as consideration
for services in accordance with ASC 718, <i>Compensation&#8212;Stock Compensation.</i> The Company measures equity instruments granted
to a non-employee in exchange for services at their fair value on the grant date and engaged an independent third-party valuation specialist
to determine the grant-date fair value using discounted cash flow method with key assumptions of risk free rate of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--ThirdPartyServiceProviderMember_pd" title="Risk free rate">3.81%</span>, discount rate
of <span id="xdx_906_ecustom--DiscountRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--ThirdPartyServiceProviderMember_pd" title="Discount rate">15.5%</span> and perpetual rate of <span id="xdx_904_ecustom--PerpetualRate_c20240701__20250630__srt--CounterpartyNameAxis__custom--ThirdPartyServiceProviderMember_pd" title="Perpetual rate">3.0%</span>. The related compensation cost is recognized as expense, with a corresponding increase to additional
paid-in capital, on a straight-line basis over the requisite service period during which the counterparty provides services, which was
from May&#160;2023 through July&#160;2023. For the year ended June&#160;30, 2024, the Company recognized $<span id="xdx_908_eus-gaap--GeneralAndAdministrativeExpense_c20230701__20240630__srt--CounterpartyNameAxis__custom--ThirdPartyServiceProviderMember_pp0p" title="General and administrative expense">21,104</span>, which was recorded within
general and administrative expense in the statements of operations and comprehensive loss. The award was fully vested as of June&#160;30,
2024 and 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s share-based compensation awards
are expected to be settled through transfers of existing ordinary shares held by the controlling shareholder, rather than through the
issuance of new shares by the Company. The underlying ordinary shares are included in the issued and outstanding shares as of the balance
sheet date; accordingly, such settlement is not expected to increase the Company&#8217;s total issued and outstanding shares. The vested
shares are not recorded in the individual names of the holders on the Company&#8217;s stock ledger, but held by the controlling shareholder
on their behalf, mainly due to the plan to a direct register of shares under the listed company during de-SPAC transaction. The Company,
as well as the controlling shareholder deemed the grant as the time when the employee and non-employees are entitled to economic benefits
and risks of the subsequent changes in fair value of the granted shares accordingly to the agreed vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related party transactions</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zW0BXdSt3Dza" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>11.
<span id="xdx_826_zRqJaIvukVIi">Related party transactions</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Hoansoo
Lee serves as the Company&#8217;s Chief Executive Officer and Chief Financial Officer. The Company has entered into a consulting services
agreement with Hoansoo Lee, pursuant to which Hoansoo Lee provides strategic consulting and advisory services to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
the three and nine months ended March&#160;31, 2025, the Company incurred consulting service fees of $<span id="xdx_90F_ecustom--ConsultingFees_c20250101__20250331_pp0p" title="Consulting fees">27,000</span> and $<span id="xdx_902_ecustom--ConsultingFees_c20240701__20250331_pp0p" title="Consulting fees">73,150</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
the three and nine months ended March&#160;31, 2026, the Company incurred consulting service fees of nil <span id="xdx_901_ecustom--ConsultingFees_c20260101__20260331_pp0p" style="display: none" title="Consulting fees">0</span> and $<span id="xdx_904_ecustom--ConsultingFees_c20250701__20260331_pp0p" title="Consulting fees">27,000</span>,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">As
of June&#160;30, 2025 and March&#160;31, 2026, there were <span id="xdx_90A_ecustom--OutstandingBalancesPayable_iI_pp0d_do_c20250630_zypmsCbXcuw1" title="Outstanding balances payable"><span id="xdx_90D_ecustom--OutstandingBalancesPayable_iI_pp0d_do_c20260331_zGm0xhqAZNP4" title="Outstanding balances payable">no</span></span> outstanding balances payable to Hoansoo Lee as all amounts had been fully
settled during the respective periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zZF2x5NNJfbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>12. <span id="xdx_82E_zervGI5CRFMj">Related party transactions</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Hoansoo Lee serves as the Company&#8217;s Chief Executive
Officer and Chief Financial Officer. The Company has entered into a consulting services agreement with Hoansoo Lee, pursuant to which
Hoansoo Lee provides strategic consulting and advisory services to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended June&#160;30, 2024 and 2025, the
Company incurred and paid consulting fees totaling $<span id="xdx_902_ecustom--ConsultingFees_c20230701__20240630_pp0p" title="Consulting fees">75,245</span> and $<span id="xdx_904_ecustom--ConsultingFees_c20240701__20250630_pp0p" title="Consulting fees">100,150</span>, respectively. As of June&#160;30, 2024 and 2025, there were <span id="xdx_90B_ecustom--OutstandingBalancesPayable_iI_pp0d_do_c20250630_zv4U4ppRoKV9" title="Outstanding balances payable"><span id="xdx_906_ecustom--OutstandingBalancesPayable_iI_pp0d_do_c20240630_zJHMH77lauR4" title="Outstanding balances payable">no</span></span>
outstanding balances payable to Hoansoo Lee as all amounts had been fully settled during the respective periods.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and diluted net loss per share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Basic and diluted net loss per share</a></td>
<td class="text"><p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_z4GoZXwnHKv4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>12.
<span id="xdx_829_zB59rzSX6LQb">Basic and diluted net loss per share</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Basic
loss per share and diluted loss per share have been calculated in accordance with ASC 260, &#8220;<i>Earnings Per Share</i>&#8221; on
computation of earnings per share for the three and nine months ended March&#160;31, 2025 and 2026 as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z2sxwJ1VHpU" style="font: 10pt Times New Roman; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basic and diluted net loss per share (Details)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B0_z8caDlAsTD0j" style="display: none; padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Schedule of basic share and diluted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_497_20250101__20250331_zC16hdQy39z7" style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_490_20260101__20260331_zlPyFMn73iHk" style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_491_20240701__20250331_zCkUO6zYutQ4" style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_496_20250701__20260331_zOuUJ3ksGux6" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <th style="text-align: left; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th> </tr>
  <tr style="vertical-align: bottom">
    <th style="text-align: left; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th> </tr>
  <tr id="xdx_406_ecustom--NumeratorAbstract_iB_zNkHTVkijEU3" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Numerator:</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td> </tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_z6giu4JTNcaj" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Net loss
        attributable to ordinary shareholders</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(1,537,059</td>
    <td style="white-space: nowrap; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(2,632,431</td>
    <td style="white-space: nowrap; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(6,178,537</td>
    <td style="white-space: nowrap; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(7,916,977</td>
    <td style="text-align: left">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td> </tr>
  <tr id="xdx_40E_ecustom--DenominatorAbstract_iB_zgkk1b9Igsvl" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"><b>Denominator:</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td> </tr>
  <tr id="xdx_406_ecustom--DenominatorForBasicAndDilutedLossPerShareAbstract_iB_zy2lnWnhwA39" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Denominator
        for basic and diluted loss per share</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Weighted-average
        ordinary shares outstanding<sup>(i)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250331_fKGkp_zDQw4h37Wwsb" title="Weighted-average ordinary shares outstanding, Basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250331_fKGkp_z1Ku37KqqS1c" title="Weighted-average ordinary shares outstanding, diluted">1,500</span></span></td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331_fKGkp_zx8fH2VBa76l" title="Weighted-average ordinary shares outstanding, Basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331_fKGkp_ztHfVbfGRHOe" title="Weighted-average ordinary shares outstanding, diluted">1,500</span></span></td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20250331_fKGkp_zdZsZI7uuxig" title="Weighted-average ordinary shares outstanding, Basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20250331_fKGkp_zxdrS9L5B374" title="Weighted-average ordinary shares outstanding, diluted">1,500</span></span></td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250701__20260331_fKGkp_zxPaAudjLjnd" title="Weighted-average ordinary shares outstanding, Basic"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250701__20260331_fKGkp_znBJ1PFMXWY8" title="Weighted-average ordinary shares outstanding, diluted">1,500</span></span></td>
    <td style="text-align: left">&#160;</td> </tr>
  <tr id="xdx_404_ecustom--LossPerOrdinaryShareAbstarct_zCAzhDqWJjpb" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Basic
        and diluted<sup>(ii)</sup></td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Basic
        and diluted loss per share</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250101__20250331_fKGlpKQ_____zRg0YrtZsJH6" title="Basic loss per share"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20250101__20250331_fKGlpKQ_____zLTKtVSBtLic" title="Diluted loss per share">(1,024.70</span></span></td>
    <td style="white-space: nowrap; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20260101__20260331_fKGlpKQ_____zMOHv6Iu2y06" title="Basic loss per share"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20260101__20260331_fKGlpKQ_____zOAlpfAhDrW7" title="Diluted loss per share">(1,754.95</span></span></td>
    <td style="white-space: nowrap; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20240701__20250331_fKGlpKQ_____zOMDMotp0PLj" title="Basic loss per share"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240701__20250331_fKGlpKQ_____zcmGyzLnWIBj" title="Diluted loss per share">(4,119.02</span></span></td>
    <td style="white-space: nowrap; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20250701__20260331_fKGlpKQ_____zvq1iE1ENBpf" title="Basic loss per share"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20250701__20260331_fKGlpKQ_____zANr2fj6apLe" title="Diluted loss per share">(5,277.98</span></span></td>
    <td style="text-align: left">)</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span id="xdx_F08_zYCld0TSLmlc">(i)</span></td>
    <td style="text-align: justify"><span id="xdx_F1E_zckvTnJmQEhg">In January&#160;2026, the Company adopted an Amended and Restated Certificate
        of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#8217;s equity is divided
        into 303 Class A ordinary shares and 1,197 Class B ordinary shares, which are entitled to one (1) vote and twenty (20) votes per share,
        respectively. Despite the differential in voting power, Class A and Class B ordinary shares rank pari passu in all other respects, sharing
        ratably in dividends and any distributions upon liquidation.</span></td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span id="xdx_F07_zMNm9OVFQe92">(ii)</span></td>
    <td style="text-align: justify"><span id="xdx_F1B_zgBQGgyBG4z3">During the three and nine months ended March&#160;31, 2025 and 2026, diluted
        net loss per share is calculated in the same manner as basic net loss per share, as the Company was in a net loss position and all potential ordinary shares were anti-dilutive.</span></td> </tr>
  </table>

<p id="xdx_8A0_zRrW0FzXJpr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_80E_eus-gaap--EarningsPerShareTextBlock_zcKacb4NfAse" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>13. <span id="xdx_828_zmptkHzMOqij">Basic and diluted net loss per share</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic loss per share and diluted loss per share have
been calculated in accordance with ASC 260, &#8220;<i>Earnings Per Share</i>&#8221; on computation of loss per share for the years ended
June&#160;30, 2024 and 2025 as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zt9m69C0XZ2d" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basic and diluted net loss per share (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B3_z4fVOy9hZcC8" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Schedule of basic share and diluted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_490_20230701__20240630_zNS6ebSpnWrd" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_49D_20240701__20250630_z1q8DgL1dZak" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <br/>years ended <br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Numerator:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net loss attributable to ordinary
        shareholders</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(4,956,347</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(7,659,667</td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DenominatorForBasicAndDilutedLossPerShareAbstract_iB_zvdjC7dKX30c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Denominator for basic and diluted loss per
        share</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted-average ordinary shares outstanding,
        Basic and diluted*</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230701__20240630_fKg_____zQHyzKNbmYni" title="Weighted-average ordinary shares outstanding, Basic"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230701__20240630_fKg_____znyMMFNDxhuf" title="Weighted-average ordinary shares outstanding, diluted">1,500</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20250630_fKg_____zSHuzJLV0GTl" title="Weighted-average ordinary shares outstanding, Basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20250630_fKg_____zTkjibsim5P6" title="Weighted-average ordinary shares outstanding, diluted">1,500</span></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Basic and diluted loss per share</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230701__20240630_zmSb1V03Vrje" title="Basic loss per share"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20230701__20240630_zyJQB2bVMLV5" title="Diluted loss per share">(3,304.23</span></span></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20240701__20250630_zD02im0uKoQi" title="Basic loss per share"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20240701__20250630_zN38w6qibdk8" title="Diluted loss per share">(5,106.44</span></span></td>
    <td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td id="xdx_F08_zym9vF1L9h5a" style="width: 0.25in; text-align: left">*</td>
    <td id="xdx_F1F_zWe9J1egNUee" style="text-align: justify">The Company&#8217;s share-based compensation awards are expected to be settled through transfers of existing
        ordinary shares held by the controlling shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary
        shares are included in issued and outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase
        the Company&#8217;s total issued and outstanding shares. During the years ended June&#160;30, 2024 and 2025, diluted net loss per share
        is calculated in the same manner as basic net loss per share.</td> </tr>
  </table>

<p id="xdx_8A5_zykAwSGmR6Q2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zLihNGvAxZLg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>14.
<span id="xdx_827_zx6q22XsxzOc">Commitments and contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">From
inception to date, the Company has not been a party to any legal proceedings, claims, or disputes arising in the ordinary course of business.
As of March&#160;31, 2026, the Company had no outstanding litigation, and there were no commitments or contingencies that management believes
would have a material effect on the unaudited condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zV94gEMyYrl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>15. <span id="xdx_822_zL1TK7zRpema">Commitments and contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From inception to date, the Company has not been a
party to any legal proceedings, claims, or disputes arising in the ordinary course of business. As of June&#160;30, 2025, the Company
had no outstanding litigation, and there were no commitments or contingencies that management believes would have a material effect on
the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Crypto assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CryptoAssetTextBlock', window );">Crypto assets</a></td>
<td class="text"><p id="xdx_803_eus-gaap--CryptoAssetTextBlock_zi6RMK8i16tg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b>5.
<span id="xdx_829_zy7JjRUSo6a6">Crypto assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company uses crypto assets like USDT and USDC as medium of exchange for collecting and settling business-related payments and for receiving
investment proceeds. As of June&#160;30, 2025 and March&#160;31, 2026, the Company held nil and 4,074,415 units of USDT and USDC, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
the nine months ended March&#160;31, 2026, the movement for digital assets and USDC were as below&#65306;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--CryptoAssetActivityTableTextBlock_z6IoVbbXa5M" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Crypto assets (Details)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8BB_z5ypZmSGKPI6" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of digital assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Digital assets</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>USDC</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Balance
        at June&#160;30, 2025</b></td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b><span id="xdx_90B_eus-gaap--CryptoAssetFairValue_iS_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zVU8fnykwyVd" title="Beginning balance, January 1"><span style="-sec-ix-hidden: xdx2ixbrl3611">-</span></span></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b><span id="xdx_907_eus-gaap--CryptoAssetFairValue_iS_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_zucsqhJMum0h" title="Beginning balance, January 1"><span style="-sec-ix-hidden: xdx2ixbrl3613">-</span></span></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Additions<sup>(i)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--CryptoAssetPurchase_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_fKGkp_zCVR14RVanL4" title="Additions">939,397</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--CryptoAssetPurchase_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_fKGkp_z7IluYPLL2H6" title="Additions">4,711,169</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Disposals
        - sold for US dollars</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--CryptoAssetSale_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zFhrH4pyNUOi" title="Disposals - sold for US dollars">(596,852</span></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--CryptoAssetSale_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_zZ3TE6pXpuRg" title="Disposals - sold for US dollars">(9,900</span></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Disposals - others<sup>(ii)</sup></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--CryptoAssetDisposition_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_fKGlpKQ_____z0eXchozqDD5" title="Disposals">(342,545</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--CryptoAssetDisposition_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_fKGlpKQ_____zih1kjx1tNMl" title="Disposals">(626,854</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Balance
        at March&#160;31, 2026</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_905_eus-gaap--CryptoAssetFairValue_iE_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zwakqvuSDr0k" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl3627">-</span></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_901_eus-gaap--CryptoAssetFairValue_iE_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_z5rCPa9Emov5" title="Ending balance">4,074,415</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: left"><span id="xdx_F05_z0wsheXoxiZe">(i)</span></td>
    <td style="text-align: justify"><span id="xdx_F13_zlhgBGZ4Kxka">The Company acquired a total of 939,397 USDT at a cost of $939,397, funded by revenues and collections of other receivables. The Company acquired a total of 4,711,169 USDC at a cost of $4,711,169, funded by revenues, interest income,
        collections of other receivables and investment proceeds from SAFEs.</span></td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><span id="xdx_F05_zMHGNT0qLCIg">(ii)</span></td>
    <td style="text-align: justify"><span id="xdx_F1F_z3QKCOoBgzb2">The Company used digital assets and USDC to settle professional service
        fees and other expenditures.</span></td> </tr>
  </table>

<p id="xdx_8A8_zlzUyMcRzUte" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>









<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s balances related to digital assets are USD-pegged stablecoins. No fair value gain or loss on digital assets was recognized
for the three and nine months ended March&#160;31, 2026 considering the low volatility in the fair value of USDT during the three and
nine months ended March&#160;31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
following table summarizes other operating activities settled in digital assets and USDC:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--CashFlowOperatingCapitalTableTextBlock_zvjZLHvPjup5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Crypto assets (Details 1)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span id="xdx_8B8_zB2Vyc1Bo39h">Schedule of operating activities</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        ended March&#160;31,<br/>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenue</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--Revenues_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Revenue">(1,197,326</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">)</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Other
        receivables</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_ecustom--OtherCurrentAssets_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_zgPbcYEBBUwe" title="Other current assets">(1,452,102</span></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Cost and
        expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--CostsAndExpenses_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Cost and expenses">969,399</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Interest
        income</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--InterestIncomeOther_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_zDM56zONgaVd" title="Interest income">(1,138</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total
        operating activities settled in digital assets and USDC</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_903_ecustom--TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Total operating activities settled in digital assets and USDC">(1,681,167</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td> </tr>
  </table>

<p id="xdx_8A2_zJhdLNbXqBJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">During
the three and nine months ended March&#160;31, 2026, the Company received $<span id="xdx_90D_eus-gaap--PaymentsForProceedsFromInvestments_pn3n3_dm_c20250701__20260331_zf0QgnFTWzBf" title="Investment proceeds"><span id="xdx_907_eus-gaap--PaymentsForProceedsFromInvestments_pn3n3_dm_c20260101__20260331_z5QJhWbmUOj2" title="Investment proceeds">3.0</span></span> million of investment proceeds from SAFEs in USDC. These
amounts were disclosed as supplemental non-cash financing information and therefore were not included in net cash provided by financing
activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for crypto asset. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zIQgZvNM5Ow6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zJc7JPdBlxC3">Basis of Presentation</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and
pursuant to the rules and regulations of the SEC. The financial statements as of December&#160;31, 2025 and for the period from December&#160;19,
2025 (inception) through December&#160;31, 2025 respectively, are audited. In the opinion of management, the financial statements include
all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating
results and cash flows for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoCc0oxIXVye" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86A_zRelC9ayrXw9">Basis of Presentation</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. The financial statements as of March
31, 2026 and for the three months ended March 31, 2026 respectively, are un audited. In the opinion of management, the financial
statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the
financial position, operating results and cash flows for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging Growth Company</a></td>
<td class="text"><p id="xdx_844_ecustom--EmergingGrowthCompanyPolicyTextBlock_zIflyZXwhT3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zieh9LOsfqE3">Emerging Growth Company</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is an &#8220;emerging
growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of
2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period
which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company,
as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_ecustom--EmergingGrowthCompanyPolicyTextBlock_zxCuTvrFDI99" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_864_zu39EgO8Buwg">Emerging Growth Company</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is an &#8220;emerging
growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act
of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition
period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging
growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because
of the potential differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--UseOfEstimates_zfT5mqcHOWl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zE9hBnagYMVa">Use of Estimates</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84A_eus-gaap--UseOfEstimates_zBvkspy1qQI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86E_zvzbCsC8L8Ff">Use of Estimates</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RisksAndUncertaintiesPolicyTextBlock', window );">Risk and Uncertainties</a></td>
<td class="text"><p id="xdx_841_ecustom--RisksAndUncertaintiesPolicyTextBlock_zOgwh60tmOf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_863_zT2IwjyYxMwg">Risks and Uncertainties</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_845_ecustom--RisksAndUncertaintiesPolicyTextBlock_zSX4tZHeTxo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86D_zOSz8DGNyjqf">Risk and Uncertainties</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zkhtSX54qy75" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86C_ziSLvQsMEBHb">Income Taxes</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company complies with the
accounting and reporting requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach to
financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the
financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 740 prescribes a recognition
threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be
taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#8217;s management determined the United States is the Company&#8217;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The provision for income taxes
was deemed to be immaterial for the period from December&#160;19, 2025 (inception) through December&#160;31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zAGgh3xYfpt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_865_zOgsMgqR3B78">Income Taxes</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company complies with
the accounting and reporting requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach
to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between
the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 740 prescribes a
recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected
to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#8217;s management determined the United States is the Company&#8217;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provision for income
taxes was deemed to be immaterial for the three months ended March 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z9GnwSb4VdD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Loss Per Share</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company computes basic loss
per share (&#8220;EPS&#8221;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of December&#160;31, 2025 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z6IKhtn0tFHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_866_z5LJmpNKovA1">Loss Per Share</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company computes basic
loss per share (&#8220;EPS&#8221;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of March 31, 2026 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrqiA2cU5R4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zTUwRw7Nlatj">Fair Value of Financial Instruments</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Fair value is defined as the
price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants
at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active
        markets;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly
        observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets
        that are not active; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity
        to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant
        value drivers are unobservable.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In some circumstances, the inputs
used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value
measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair
value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zPwok5ETZsz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86E_zAu283mu3nxe">Fair Value of Financial Instruments</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Fair value is defined
as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market
participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring
fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments
    in active markets;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly
    or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar
    instruments in markets that are not active; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring
    an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs
    or significant value drivers are unobservable.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In some circumstances, the
inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair
value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the
fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements</a></td>
<td class="text"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSNNhvz3V6Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zM7M5EBTVgG3">Recently adopted accounting pronouncements</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November&#160;2023, the FASB
issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose
information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public
entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment
disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since inception.
Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material
effect on the Company&#8217;s financial statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhxo4ncWR2Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zIe1QxnsUF6c">Recently adopted accounting pronouncements</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November&#160;2023, the
FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to
disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis.
Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing
segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since
inception. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would
have a material effect on the Company&#8217;s financial statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_EmergingGrowthCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_EmergingGrowthCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zIQgZvNM5Ow6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zJc7JPdBlxC3">Basis of Presentation</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and
pursuant to the rules and regulations of the SEC. The financial statements as of December&#160;31, 2025 and for the period from December&#160;19,
2025 (inception) through December&#160;31, 2025 respectively, are audited. In the opinion of management, the financial statements include
all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating
results and cash flows for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoCc0oxIXVye" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86A_zRelC9ayrXw9">Basis of Presentation</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. The financial statements as of March
31, 2026 and for the three months ended March 31, 2026 respectively, are un audited. In the opinion of management, the financial
statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the
financial position, operating results and cash flows for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging Growth Company</a></td>
<td class="text"><p id="xdx_844_ecustom--EmergingGrowthCompanyPolicyTextBlock_zIflyZXwhT3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zieh9LOsfqE3">Emerging Growth Company</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is an &#8220;emerging
growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of
2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period
which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company,
as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_ecustom--EmergingGrowthCompanyPolicyTextBlock_zxCuTvrFDI99" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_864_zu39EgO8Buwg">Emerging Growth Company</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is an &#8220;emerging
growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act
of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition
period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging
growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because
of the potential differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--UseOfEstimates_zfT5mqcHOWl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zE9hBnagYMVa">Use of Estimates</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84A_eus-gaap--UseOfEstimates_zBvkspy1qQI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86E_zvzbCsC8L8Ff">Use of Estimates</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zkhtSX54qy75" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86C_ziSLvQsMEBHb">Income Taxes</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company complies with the
accounting and reporting requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach to
financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the
financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 740 prescribes a recognition
threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be
taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#8217;s management determined the United States is the Company&#8217;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The provision for income taxes
was deemed to be immaterial for the period from December&#160;19, 2025 (inception) through December&#160;31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zAGgh3xYfpt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_865_zOgsMgqR3B78">Income Taxes</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company complies with
the accounting and reporting requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach
to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between
the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 740 prescribes a
recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected
to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#8217;s management determined the United States is the Company&#8217;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provision for income
taxes was deemed to be immaterial for the three months ended March 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net (Loss)/Income per Ordinary Share</a></td>
<td class="text"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z9GnwSb4VdD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Loss Per Share</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company computes basic loss
per share (&#8220;EPS&#8221;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of December&#160;31, 2025 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z6IKhtn0tFHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_866_z5LJmpNKovA1">Loss Per Share</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company computes basic
loss per share (&#8220;EPS&#8221;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of March 31, 2026 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrqiA2cU5R4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zTUwRw7Nlatj">Fair Value of Financial Instruments</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Fair value is defined as the
price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants
at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active
        markets;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly
        observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets
        that are not active; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity
        to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant
        value drivers are unobservable.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In some circumstances, the inputs
used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value
measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair
value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zPwok5ETZsz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86E_zAu283mu3nxe">Fair Value of Financial Instruments</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Fair value is defined
as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market
participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring
fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments
    in active markets;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly
    or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar
    instruments in markets that are not active; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring
    an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs
    or significant value drivers are unobservable.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In some circumstances, the
inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair
value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the
fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p id="xdx_841_ecustom--RisksAndUncertaintiesPolicyTextBlock_zOgwh60tmOf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_863_zT2IwjyYxMwg">Risks and Uncertainties</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_845_ecustom--RisksAndUncertaintiesPolicyTextBlock_zSX4tZHeTxo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86D_zOSz8DGNyjqf">Risk and Uncertainties</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future results of operations
involve a number of risks and uncertainties. Factors that could affect our business or future results and cause actual results to vary
materially from historical results include our ability to execute our acquisition strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSNNhvz3V6Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zM7M5EBTVgG3">Recently adopted accounting pronouncements</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November&#160;2023, the FASB
issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose
information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public
entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment
disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since inception.
Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material
effect on the Company&#8217;s financial statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhxo4ncWR2Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zIe1QxnsUF6c">Recently adopted accounting pronouncements</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November&#160;2023, the
FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to
disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis.
Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing
segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since
inception. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would
have a material effect on the Company&#8217;s financial statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z0IWy53sD0Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_865_z1Rf2RuPJR21">Basis of Presentation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The accompanying consolidated condensed financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
and pursuant to the rules and regulations of the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Certain information and note disclosures normally
included in the annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been
condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to
make the information not misleading. The interim financial statements as of March 31, 2026 and for the three months ended March 31, 2026
are unaudited. In the opinion of management, the consolidated condensed financial statements include all adjustments, consisting only of normal
recurring adjustments, necessary to provide a fair statement of the results for the periods. The accompanying balance sheet as of December
31, 2025, is derived from the audited financial statements presented in the Company&#8217;s Annual Report on Form 10-K for the year ended
December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zTqQLi3oj3F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zknhPtMT4xkj">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
information and note disclosures normally included in the annual consolidated financial statements prepared in accordance with generally
accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although the Company believes that
the disclosures made are adequate to make the information not misleading. The consolidated financial statements as of December&#160;31,
2025 and for period from March&#160;20, 2025 (inception) through December&#160;31, 2025 are audited. In the opinion of management, the
consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary to provide a fair
statement of the results for the periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging Growth Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_845_ecustom--EmergingGrowthCompanyPolicyTextBlock_zmhW1kdqSIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_86C_zt6czdzfWEih">Emerging Growth Company</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Further, Section&#160;102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make
comparison of the Company&#8217;s consolidated financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_ecustom--EmergingGrowthCompanyPolicyTextBlock_zjHTebZGYcF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z9adgwwH5gz6">Emerging
Growth Company</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart
Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being
required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not
have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply
to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended
transition period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#8217;s consolidated financial statements with another public company which is neither
an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible
because of the potential differences in accounting standards used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84F_eus-gaap--UseOfEstimates_zQYZj3djUeb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_864_zRzz8424e6p3">Use of Estimates</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The preparation of consolidated condensed financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the consolidated condensed financial statements and the
reported amounts of revenues and expenses during the reporting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Making estimates requires management to exercise
significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances
that existed at the date of the consolidated condensed financial statements, which management considered in formulating its estimate,
could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly
from those estimates.</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>















<span></span>
</td>
<td class="text"><p id="xdx_849_eus-gaap--UseOfEstimates_zCSpiRUyiDb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z9wBQjRDfAXk">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making
estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of
a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered
in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results
could differ significantly from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPzrLcIyQfel" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_860_zu37CGZfznfc">Cash and Cash Equivalents</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company considers all highly liquid
investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents are carried at
cost, which approximates fair value. The Company had $<span id="xdx_90E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20251231_zKSiK1lJFQo5">420,340</span> and $<span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20260331_zBLVCNltQyz5">243,576</span>
in cash as of December&#160;31, 2025 and March&#160;31, 2026, respectively. The Company had <span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20251231_zHKchSeuPLR4" title="Cash equivalents"><span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20260331_zbssSpEVMX26" title="Cash equivalents">no</span></span>
cash equivalents as of December&#160;31, 2025 and March&#160;31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zxisgP8Xl37k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zAhdNNso56Nb">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash
equivalents are carried at cost, which approximates fair value. The Company had $<span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20251231_zmXdChwNJcJ4" title="Cash">420,340</span> in cash as of December&#160;31, 2025 The Company
had <span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20251231_zyjNNzvKrPke" title="Cash equivalents">no</span> cash equivalents as of December&#160;31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_CashHeldInTrustAccountPolicyTextBlock', window );">Cash Held in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_844_ecustom--CashHeldInTrustAccountPolicyTextBlock_zf23zmDeFAC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify"><b><span id="xdx_863_zgMHfmHrvZ42">Cash Held in Trust Account</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company had $<span id="xdx_90F_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20251231_z5sY6BBpp9d4">284,776,628</span> and $<span id="xdx_905_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20260331_zKMPpHYYWvXd">287,319,687</span>
a of cash in the trust account held in an interest bearing demand deposit account as of December 31, 2025 and March&#160;31,
2026, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_843_ecustom--CashHeldInTrustAccountPolicyTextBlock_z4HvK1JPIUmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zTYNKhDkXdT7">Cash
Held in Trust Account</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had $<span id="xdx_90E_ecustom--CashHeldInTrustAccount_iI_pp0p0_c20251231_z8h7Eqz2G7o8" title="Cash held in trust">284,776,628</span> of cash in the trust account held in an interest bearing demand deposit account as of December&#160;31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock', window );">Offering Costs Associated with the Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84F_ecustom--OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock_z7CN7IDO18Rg" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_860_zF0eseXwdsYe">Offering Costs Associated with the Initial Public Offering</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212;
&#8220;Expenses of Offering.&#8221; Deferred offering costs consist principally of professional and registration fees that are related
to the Initial Public Offering. Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 470-20, &#8220;Debt with Conversion and
Other Options,&#8221; addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components.
The Company applies this guidance to allocate Initial Public Offering proceeds from the Public Units between Class A ordinary shares and
warrants based on their relative fair values. Offering costs allocated to the Class A ordinary shares subject to possible redemption were
charged to temporary equity, and offering costs allocated to the warrants included in the Public Units and Private Units were charged
to shareholder&#8217;s equity as the warrants, after management&#8217;s evaluation, were accounted for under equity treatment. As of August&#160;1,
2025, the Company had offering costs of $<span id="xdx_903_ecustom--OfferingCost_iI_pp0p0_c20250801_z4hgPDFmpaOa" title="Offering costs">3,582,634</span>,
consisting of $<span id="xdx_901_ecustom--RepresentativeShares_c20250729__20250801_z17XWIvrJ0Ql" title="Representative shares">2,419,400</span>
of the Representative Shares (as discussed in Note 1) and $<span id="xdx_903_ecustom--OtherOfferingCost_pp0p0_c20250729__20250801_z3stLaw1Yk4h" title="Other offering costs">1,163,234</span>
of other offering costs. Approximately $<span id="xdx_90C_eus-gaap--OtherExpenses_pp0p0_c20250729__20250801_zacUbSCdNTya" title="other costs">143,775</span>
of such costs were allocated to the Public Warrants and the Private Placement Units and the remainder, approximately $<span id="xdx_90D_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_c20250801_z05aQ6gzdoVi" title="Ordinary shares subject to redemption">3,438,859</span>
was allocated to Class A ordinary shares subject to redemption. As of December&#160;31, 2025, the Company had offering costs of $<span id="xdx_900_ecustom--OfferingCost_iI_pp0p0_c20251231_zXALNb75mMuc" title="Offering costs">3,582,634</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_843_ecustom--OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock_zjYwZgXnflQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zHG5bezvliwj">Offering
Costs Associated with the Initial Public Offering</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212; &#8220;Expenses
of Offering.&#8221; Deferred offering costs consist principally of professional and registration fees that are related to the Initial
Public Offering. Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 470-20, &#8220;Debt with Conversion and Other Options,&#8221;
addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this
guidance to allocate Initial Public Offering proceeds from the Public Units between Class A ordinary shares and warrants based on their
relative fair values. Offering costs allocated to the Class A ordinary shares subject to possible redemption were charged to temporary
equity, and offering costs allocated to the warrants included in the Public Units and Private Units were charged to shareholder&#8217;s
equity as the warrants, after management&#8217;s evaluation, were accounted for under equity treatment. As of August&#160;1, 2025, the
Company had offering costs of $<span id="xdx_90C_ecustom--OfferingCost_iI_pp0p0_c20250801_zTEBye9LC6Sa" title="Offering costs">3,582,634</span>, consisting of $<span id="xdx_901_ecustom--RepresentativeShares_c20250729__20250801_zO3HwvtfCCL3" title="Representative shares">2,419,400</span> of the Representative Shares (as discussed in Note 1) and $<span id="xdx_903_ecustom--OtherOfferingCost_pp0p0_c20250729__20250801_zGB9Qx0HWUBg" title="Other offering costs">1,163,234</span>
of other offering costs. Approximately $<span id="xdx_90C_eus-gaap--OtherExpenses_pp0p0_c20250729__20250801_z3GNIDiBSqvd" title="other costs">143,775</span> of such costs were allocated to the Public Warrants and the Private Placement Units and
the remainder, approximately $<span id="xdx_90D_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_c20250801_zBavxm1BynCj" title="Ordinary shares subject to redemption">3,438,859</span> was allocated to Class A ordinary shares subject to redemption. As of December&#160;31, 2025,
the Company had offering costs of $<span id="xdx_900_ecustom--OfferingCost_iI_pp0p0_c20251231_ziNhZdkvYfdf" title="Offering costs">3,582,634</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_z77b7DWKM4ee" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_86A_zVc6ABTVy162">Income Taxes</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The Company complies with the accounting and reporting
requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach to financial accounting and
reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the consolidated financial
statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws
and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established,
when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">ASC Topic 740 prescribes a recognition threshold and a measurement
attribute for the consolidated financial statement recognition and measurement of tax positions taken or expected to be taken in a tax
return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.
The Company&#8217;s management determined the British Virgin Islands is the Company&#8217;s only major tax jurisdiction. The Company recognizes
accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were no unrecognized tax benefits
as of March 31, 2026 and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review
that could result in significant payments, accruals or material deviation from its position. The Company is considered to be an exempted
British Virgin Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income
tax filing requirements in the British Virgin Islands or the United States. As such, the provision for income taxes was deemed to be <i>de
minimis</i> for the three months ended March 31, 2026.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>















<span></span>
</td>
<td class="text"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z5OSpTZZj5k8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zcqL0aCgOVV7">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the accounting and reporting requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset
and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed
for differences between the consolidated financial statement and tax bases of assets and liabilities that will result in future taxable
or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable
income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 740 prescribes a recognition threshold and a measurement attribute for the consolidated financial statement recognition and measurement
of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not
to be sustained upon examination by taxing authorities. The Company&#8217;s management determined the British Virgin Islands is the Company&#8217;s
only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income
tax expense. There were no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The
Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from
its position. The Company is considered to be an exempted British Virgin Islands company with no connection to any other taxable jurisdiction
and is presently not subject to income taxes or income tax filing requirements in the British Virgin Islands or the United States. As
such, the provision for income taxes was deemed to be <i>de minimis</i> for the period from March&#160;20, 2025 (inception) to December&#160;31,
2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesReportingOfDerivativeActivity', window );">Derivative Financial Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_849_eus-gaap--DerivativesReportingOfDerivativeActivity_zfMMEAmeHDb5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zun6kxhx1xka">Derivative
Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#8220;Derivatives and Hedging.&#8221; For derivative financial instruments that are accounted
for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each
reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative
liabilities are classified in the balance sheet as current or non-current based on whether or not net cash settlement or conversion of
the instrument could be required within 12 months of the balance sheet date. The underwriters&#8217; over-allotment option is deemed to
be a freestanding financial instrument indexed to the contingently redeemable shares and was accounted for as a liability pursuant to
ASC 480 if not fully exercised at the time of the Initial Public Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtendedProductWarrantyPolicy', window );">Warrant Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--ExtendedProductWarrantyPolicy_zIfpp4pkn1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_863_zpXKgEMQKf8">Warrant Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">We account for Warrants as either equity-classified
or liability-classified instruments based on an assessment of the instruments&#8217; specific terms and applicable authoritative guidance
in ASC 480 and FASB ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;). The assessment considers whether the
instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to
a company&#8217;s common shares and whether the instrument holders could potentially require &#8220;net cash settlement&#8221; in a circumstance
outside of a company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional
judgment, is conducted at the time of Warrant issuance and as of each subsequent quarterly period end date while the instruments are outstanding.
Upon review of the Warrant Agreement, Management concluded that the&#160;public warrants and private warrants issued pursuant to such
warrant agreement qualify for equity accounting treatment.&#160;Following the closing of the Initial Public Offering on August&#160;1,
2025 and underwriter&#8217;s exercise of over-allotment option on August&#160;13, 2025, the Company accounted for the&#160;<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331_zZXCPtdZIUn7" title="Warrants issued">14,000,000</span>
public warrants and&#160;<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zV9MLoZewlLk" title="Warrants issued">100,000</span> private warrants issued under equity treatment at their assigned values.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_845_eus-gaap--ExtendedProductWarrantyPolicy_z0FLSxdwRnzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zDBCwQoAzPGl">Warrant
Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for Warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#8217;
specific terms and applicable authoritative guidance in ASC 480 and FASB ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC
815&#8221;). The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815,
including whether the instruments are indexed to a company&#8217;s common shares and whether the instrument holders could potentially
require &#8220;net cash settlement&#8221; in a circumstance outside of a company&#8217;s control, among other conditions for equity classification.
This assessment, which requires the use of professional judgment, is conducted at the time of Warrant issuance and as of each subsequent
quarterly period end date while the instruments are outstanding. Upon review of the Warrant Agreement, Management concluded that the&#160;public
warrants and private warrants issued pursuant to such warrant agreement qualify for equity accounting treatment.&#160;Following the closing
of the Initial Public Offering on August&#160;1, 2025 and underwriter&#8217;s exercise of over-allotment option on August&#160;13, 2025,
the Company accounted for the&#160;<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20251231_zdWSGahahNSi" title="Warrants issued">14,000,000</span> public warrants and&#160;<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zi4ctrzVvrZc" title="Warrants issued">100,000</span> private warrants issued under equity treatment at their
assigned values. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock', window );">Class A Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84F_ecustom--ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_zd7Gejgazmwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_86B_zNHDcMFMuEE">Class A Ordinary Shares Subject to Possible Redemption</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The public shares contain
a redemption feature which allows for the redemption of such public shares in connection with the Company&#8217;s liquidation, or if
there is a shareholder vote or tender offer in connection with the Company&#8217;s initial Business Combination. In accordance with
ASC 480-10-S99, the Company classifies public shares subject to redemption outside of permanent equity as the redemption provisions
are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as they occur and
will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately
upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount
value. The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the
extent available) and Retained earnings. Accordingly, Class A ordinary shares subject to possible redemption are presented at
redemption value as temporary equity, outside of the shareholders&#8217; equity section of the Company&#8217;s balance sheet. As of
March 31, 2026 and December 31, 2025, the 28,000,000 Class A ordinary shares subject to redemption reflected in the balance sheet
are reconciled in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--TemporaryEquityTableTextBlock_zI3yMm7Bm2me" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B8_zvz98VUo83yh" style="display: none">Schedule of ordinary shares subject to redemption</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Class A ordinary shares subject to possible redemption, December 31, 2025</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_c20260101__20260331_zuYUa9ZjRBt2" style="text-align: right">284,776,628</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Plus:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top">Accretion of carrying value to redemption value</td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td>
    <td id="xdx_98D_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20260101__20260331_zjT475ucOqx7" style="border-bottom: Black 1pt solid; width: 9%; text-align: right">2,543,059</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Class A ordinary shares subject to possible redemption, March 31, 2026</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_c20260101__20260331_zXneNCCbjKKh" style="border-bottom: Black 2.5pt double; text-align: right">287,319,687</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>










<p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zWhlay9HXAC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_866_zIRLAGvnsr1d">Net (Loss)/Income per Ordinary Share</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share.&#8221; Net income per share of ordinary shares is computed by dividing net income applicable to ordinary shareholders by the weighted average number of shares of ordinary shares outstanding during the period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The Company has not considered the effect of the Warrants sold in the Offering and Private Placement to purchase an aggregate of&#160;<span id="xdx_906_eus-gaap--WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_c20260101__20260331_zLwsCzFCHW3" title="Weighted average aggregate shares">14,100,000</span>&#160;Class A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method and are contingent on future events. As a result, diluted income per share of Class A ordinary shares is the same as basic income per share of ordinary shares for the period presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The Company has two classes of ordinary shares,
which are referred to as Class A ordinary shares and Class B ordinary shares. Net income per share of ordinary shares is calculated by
dividing the net income by the weighted average number of shares of ordinary shares outstanding during the respective period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The following tables reflect the net (loss)/income
per share after allocating income between the shares based on outstanding shares:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z9nBryRVgBB1" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"><b><i><span id="xdx_8BC_zW0SKWND27gd" style="display: none">&#160;Schedule
    of earning per share basic and diluted</span></i></b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <br/>
Period from <br/>
March&#160;20, 2025
<br/>
(Inception) through <br/>
March&#160;31,<br/>
2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the<br/>
three months ended <br/>
March&#160;31, <br/>
2026</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class A</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class B</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class A</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class B</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerator:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net income per share:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation of (loss)/income &#150; basic and diluted</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zy8q1CRpivSl" title="Allocation of (loss)/income - basic"><span id="xdx_900_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z2LX5LzP7HYe" title="Allocation of (loss)/income - diluted"><span style="-sec-ix-hidden: xdx2ixbrl1475"><span style="-sec-ix-hidden: xdx2ixbrl1477">-</span></span></span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zaYIpma7fKI5" title="Allocation of (loss)/income - basic"><span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zUhkVNCQNGB4" title="Allocation of (loss)/income - diluted">(5,420</span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0iSNiakF4xg" title="Allocation of (loss)/income - basic"><span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zFRQnvemDvP9" title="Allocation of (loss)/income - diluted">2,011,318</span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zTfMrVC9Nq08" title="Allocation of (loss)/income - basic"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwCyQpQUqFfg" title="Allocation of (loss)/income - diluted">2,011,318</span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominator:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted weighted average share of ordinary shares:</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zaCBbKkxOUll" title="Weighted average shares of Class A ordinary shares outstanding, basic"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zBiG6LXmLI06" title="Weighted average shares of Class A ordinary shares outstanding, diluted"><span style="-sec-ix-hidden: xdx2ixbrl1491"><span style="-sec-ix-hidden: xdx2ixbrl1493">-</span></span></span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwozb4274lpk" title="Weighted average shares of Class B ordinary shares outstanding, basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z4aO9n9RdMz2" title="Weighted average shares of Class B ordinary shares outstanding, diluted">10,714,286</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zngzHuVdEMLb" title="Weighted average shares of Class A ordinary shares outstanding, basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z4D9HtOcAKq" title="Weighted average shares of Class A ordinary shares outstanding, diluted">29,200,000</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMgqLWjjG1Ug" title="Weighted average shares of Class B ordinary shares outstanding, basic"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMDCWHjrReMl" title="Weighted average shares of Class B ordinary shares outstanding, diluted">12,000,000</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net income per share</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z38VIFVXOnne" title="Class A ordinary shares - basic net income per share"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zzqpPBahwyhi" title="Class A ordinary shares - diluted net income per share">0.00</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0i8nL2oW9si" title="Class B ordinary shares - basic net income per share"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z3ekJQDEjG8d" title="Class B ordinary shares - diluted net income per share">0.00</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zEF9ZlGITAD2" title="Class A ordinary shares - basic net income per share"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zA6RCCMfP971" title="Class A ordinary shares - diluted net income per share">0.07</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zIcku8QW2zV5" title="Class B ordinary shares - basic net income per share"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zBzYlBzAMw96" title="Class B ordinary shares - diluted net income per share">0.17</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8AC_zNWMKWxINBke" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_846_ecustom--ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_z39K6VkBlVx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zMsjsksIRMVh">Class
A Ordinary Shares Subject to Possible Redemption</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public shares contain a redemption feature which allows for the redemption of such public shares in connection with the Company&#8217;s
liquidation, or if there is a shareholder vote or tender offer in connection with the Company&#8217;s initial Business Combination. In
accordance with ASC 480-10-S99, the Company classifies public shares subject to redemption outside of permanent equity as the redemption
provisions are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as they occur
and will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately
upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value.
The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the extent available)
and Retained earnings. Accordingly, Class A ordinary shares subject to possible redemption are presented at redemption value as temporary
equity, outside of the shareholders&#8217; equity section of the Company&#8217;s balance sheet. As of December&#160;31, 2025, the 28,000,000
Class A ordinary shares subject to redemption reflected in the balance sheet are reconciled in the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--TemporaryEquityTableTextBlock_zPcXeTqfm8lb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BD_zLSvphjsOLC3" style="display: none">Schedule of ordinary shares subject to redemption</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Gross proceeds from IPO, August&#160;1,
        2025</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_904_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_pp0d_c20250802__20251231_z2o34efAYZBg" title="Ordinary shares subject to possible redemption, beginning">280,000,000</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Less:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Proceeds allocated to Public Warrants</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_ecustom--ProceedsAllocatedToPublicWarrants_pp0d_c20250802__20251231_znh5ksE756X8" title="Proceeds allocated to Public Warrants">(9,028,600</span></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Proceeds allocated to Over-allotment Option</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_ecustom--ProceedsAllocatedToOverallotmentOption_pp0d_c20250802__20251231_zF18AYVY4Fwe" title="Proceeds allocated to Over-allotment Option">(1,290,375</span></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Class A ordinary shares issuance costs</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_ecustom--ClassOrdinarySharesIssuanceCosts_pp0d_c20250802__20251231_zFN36aIn6kRf" title="Class A ordinary shares issuance costs">(3,438,859</span></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Plus:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Accretion of carrying
        value to redemption value</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--TemporaryEquityAccretionToRedemptionValue_pp0d_c20250802__20251231_z1giMb4Fdhpj" title="Ordinary shares subject to possible redemption">18,534,462</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Class A ordinary shares
        subject to possible redemption, December&#160;31, 2025</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_pp0d_c20250802__20251231_z92pFQBkwJ85" title="Ordinary shares subject to possible redemption, ending">284,776,628</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zCe7sjt49b28" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net (Loss)/Income per Ordinary Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zWhlay9HXAC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_866_zIRLAGvnsr1d">Net (Loss)/Income per Ordinary Share</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share.&#8221; Net income per share of ordinary shares is computed by dividing net income applicable to ordinary shareholders by the weighted average number of shares of ordinary shares outstanding during the period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The Company has not considered the effect of the Warrants sold in the Offering and Private Placement to purchase an aggregate of&#160;<span id="xdx_906_eus-gaap--WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_c20260101__20260331_zLwsCzFCHW3" title="Weighted average aggregate shares">14,100,000</span>&#160;Class A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method and are contingent on future events. As a result, diluted income per share of Class A ordinary shares is the same as basic income per share of ordinary shares for the period presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The Company has two classes of ordinary shares,
which are referred to as Class A ordinary shares and Class B ordinary shares. Net income per share of ordinary shares is calculated by
dividing the net income by the weighted average number of shares of ordinary shares outstanding during the respective period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The following tables reflect the net (loss)/income
per share after allocating income between the shares based on outstanding shares:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z9nBryRVgBB1" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"><b><i><span id="xdx_8BC_zW0SKWND27gd" style="display: none">&#160;Schedule
    of earning per share basic and diluted</span></i></b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <br/>
Period from <br/>
March&#160;20, 2025
<br/>
(Inception) through <br/>
March&#160;31,<br/>
2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the<br/>
three months ended <br/>
March&#160;31, <br/>
2026</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class A</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class B</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class A</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class B</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerator:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net income per share:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation of (loss)/income &#150; basic and diluted</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zy8q1CRpivSl" title="Allocation of (loss)/income - basic"><span id="xdx_900_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z2LX5LzP7HYe" title="Allocation of (loss)/income - diluted"><span style="-sec-ix-hidden: xdx2ixbrl1475"><span style="-sec-ix-hidden: xdx2ixbrl1477">-</span></span></span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zaYIpma7fKI5" title="Allocation of (loss)/income - basic"><span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zUhkVNCQNGB4" title="Allocation of (loss)/income - diluted">(5,420</span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0iSNiakF4xg" title="Allocation of (loss)/income - basic"><span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zFRQnvemDvP9" title="Allocation of (loss)/income - diluted">2,011,318</span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zTfMrVC9Nq08" title="Allocation of (loss)/income - basic"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwCyQpQUqFfg" title="Allocation of (loss)/income - diluted">2,011,318</span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominator:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted weighted average share of ordinary shares:</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zaCBbKkxOUll" title="Weighted average shares of Class A ordinary shares outstanding, basic"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zBiG6LXmLI06" title="Weighted average shares of Class A ordinary shares outstanding, diluted"><span style="-sec-ix-hidden: xdx2ixbrl1491"><span style="-sec-ix-hidden: xdx2ixbrl1493">-</span></span></span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwozb4274lpk" title="Weighted average shares of Class B ordinary shares outstanding, basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z4aO9n9RdMz2" title="Weighted average shares of Class B ordinary shares outstanding, diluted">10,714,286</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zngzHuVdEMLb" title="Weighted average shares of Class A ordinary shares outstanding, basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z4D9HtOcAKq" title="Weighted average shares of Class A ordinary shares outstanding, diluted">29,200,000</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMgqLWjjG1Ug" title="Weighted average shares of Class B ordinary shares outstanding, basic"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMDCWHjrReMl" title="Weighted average shares of Class B ordinary shares outstanding, diluted">12,000,000</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net income per share</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z38VIFVXOnne" title="Class A ordinary shares - basic net income per share"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zzqpPBahwyhi" title="Class A ordinary shares - diluted net income per share">0.00</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0i8nL2oW9si" title="Class B ordinary shares - basic net income per share"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z3ekJQDEjG8d" title="Class B ordinary shares - diluted net income per share">0.00</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zEF9ZlGITAD2" title="Class A ordinary shares - basic net income per share"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zA6RCCMfP971" title="Class A ordinary shares - diluted net income per share">0.07</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zIcku8QW2zV5" title="Class B ordinary shares - basic net income per share"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zBzYlBzAMw96" title="Class B ordinary shares - diluted net income per share">0.17</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zhFehGf6YTR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zQunJD1xUwzi">Net
Income per Ordinary Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company complies with accounting and disclosure
requirements of FASB ASC Topic 260, &#8220;Earnings Per Share.&#8221; Net income per share of ordinary shares is computed by dividing
net income applicable to ordinary shareholders by the weighted average number of shares of ordinary shares outstanding during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not considered the effect of the Warrants sold in the Offering and Private Placement to purchase an aggregate of&#160;<span id="xdx_903_eus-gaap--WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_c20250320__20251231_zIYauijVJJe6" title="Weighted average aggregate shares">14,100,000</span>&#160;Class
A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock
method and are contingent on future events. As a result, diluted income per share of Class A ordinary shares is the same as basic income
per share of ordinary shares for the period presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two classes of ordinary shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income are shared
pro rata among the two classes of ordinary shares. Net income per share of ordinary shares is calculated by dividing the net income by
the weighted average number of shares of ordinary shares outstanding during the respective period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables reflect the net income per share after allocating income between the shares based on outstanding shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zK6g7uklULf4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"><i><span id="xdx_8BF_zaGSXzmsgspk" style="display: none">Schedule
    of earning per share basic and diluted</span></i></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/>Period from <br/>March&#160;20,
        2025<br/>(Inception) through <br/>December&#160;31, <br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Class A</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Class B</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left">Numerator:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Basic and diluted net income
        per share:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold; text-align: left">Allocation
        of income &#8211; basic and diluted</td>
    <td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z3sCrZfmImf8" title="Allocation of income - basic"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zOP8f6mC3Gdc" title="Allocation of income - diluted">2,509,890</span></span></td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z2qJnxTMSxqk"><span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_ziM4aHJWJMT8" title="Allocation of income - diluted">1,946,080</span></span></td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Basic and diluted weighted
        average share of ordinary shares:</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zLS14Lz9LzJi" title="Basic weighted average share of ordinary shares"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z7DNrJH4OfBj" title="Diluted weighted average share of ordinary shares">15,393,007</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zZ1AoE0JuY4c" title="Basic weighted average share of ordinary shares"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z5EwpZeeFiAi" title="Diluted weighted average share of ordinary shares">11,935,190</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Basic and diluted net income
        per share</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td>
    <td style="font-weight: bold; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zWEL5OqBJofa" title="Basic net income per share"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zT2ajwWAS9G6" title="Diluted net income per share">0.16</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td>
    <td style="font-weight: bold; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zjBGNV05rIv" title="Basic net income per share"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zAOQ6qINRSph" title="Diluted net income per share">0.16</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zQW6yz6aHTG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zKmI21KJxxNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_864_zHGfCbGDFHJ">Concentration of credit risk</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Financial instruments that potentially subject
the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the
Federal depository insurance coverage of $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20260331_zpCvUwnIYIca" title="FDIC Insured Amount">250,000</span>.
At December&#160;31, 2025 and March&#160;31, 2026, the Company had not experienced losses on this account and management believes the
Company is not exposed to significant risks on such account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zIcrYsjdOnUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zU8Q18WJlnoi">Concentration
of credit risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution
which, at times may exceed the Federal depository insurance coverage of $<span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_c20251231_zTBZxivW96d5" title="FDIC Insured Amount">250,000</span>. At December&#160;31, 2025, the Company had not experienced
losses on this account and management believes the Company is not exposed to significant risks on such account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zCslz5Xo6Ob6" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_867_zDDHritlLFyi">Fair value of financial instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>














<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zD59y9ZVJcWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zbcnfxYlFdrl">Fair
value of financial instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value
Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to
their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84D_ecustom--RisksAndUncertaintiesPolicyTextBlock_zrNJxHwjrMDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_869_zOCJzQXdOYs6">Risks and Uncertainties</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">The United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (&#8220;NATO&#8221;) deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">Any of the above-mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely affect the Company&#8217;s search for an initial Business Combination and any target business with which the Company may ultimately consummate an initial Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_842_ecustom--RisksAndUncertaintiesPolicyTextBlock_zxL0KasiCzxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zjcWV21IYFn1">Risks
and Uncertainties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the
ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict,
the North Atlantic Treaty Organization (&#8220;NATO&#8221;) deployed additional military forces to eastern Europe, and the United States,
the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus
and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank
Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide
military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of
Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken
in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries
have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact
of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity
prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally,
any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity
in capital markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the above-mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting
from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely
affect the Company&#8217;s search for an initial Business Combination and any target business with which the Company may ultimately consummate
an initial Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z2mXSzfQOpif" style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify"><b><span id="xdx_861_zJiXM6UsbELc">Recent Accounting Pronouncements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">In November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires the disclosure of additional segment information. ASU No. 2023-07 is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted ASU 2023-07 as of the inception of the Company. Adoption of the ASU did not impact the Company&#8217;s financial position, results of operations or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;text-align: justify">In December&#160;2023, the FASB issued ASU 2023-09, <i>Income taxes</i> (Topic 740): Improvements to Income Tax Disclosure (&#8220;ASU 2023-09&#8221;), which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 will be effective for fiscal years beginning after December&#160;15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company adopted ASU 2023-09 as of the inception of the Company. Adoption of the ASU did not impact the Company&#8217;s financial position, results of operations or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8qxlOQm7eDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zJUe6H2lTeAa">Recent
Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which
requires the disclosure of additional segment information. ASU No. 2023-07 is effective for fiscal years beginning after December&#160;15,
2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted ASU 2023-07 as of the inception
of the Company. Adoption of the ASU did not impact the Company&#8217;s financial position, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December&#160;2023, the FASB issued ASU 2023-09, <i>Income taxes</i> (Topic 740): Improvements to Income Tax Disclosure (&#8220;ASU 2023-09&#8221;),
which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 will be effective for fiscal years beginning after
December&#160;15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for
issuance. The Company adopted ASU 2023-09 as of the inception of the Company. Adoption of the ASU did not impact the Company&#8217;s financial
position, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_CashHeldInTrustAccountPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_CashHeldInTrustAccountPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_EmergingGrowthCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_EmergingGrowthCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesReportingOfDerivativeActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesReportingOfDerivativeActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtendedProductWarrantyPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for extended product warranties and other guarantee contracts including the methodology for measuring the liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtendedProductWarrantyPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zIQgZvNM5Ow6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zJc7JPdBlxC3">Basis of Presentation</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and
pursuant to the rules and regulations of the SEC. The financial statements as of December&#160;31, 2025 and for the period from December&#160;19,
2025 (inception) through December&#160;31, 2025 respectively, are audited. In the opinion of management, the financial statements include
all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating
results and cash flows for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoCc0oxIXVye" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86A_zRelC9ayrXw9">Basis of Presentation</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. The financial statements as of March
31, 2026 and for the three months ended March 31, 2026 respectively, are un audited. In the opinion of management, the financial
statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the
financial position, operating results and cash flows for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates and assumptions</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--UseOfEstimates_zfT5mqcHOWl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zE9hBnagYMVa">Use of Estimates</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84A_eus-gaap--UseOfEstimates_zBvkspy1qQI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86E_zvzbCsC8L8Ff">Use of Estimates</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income tax</a></td>
<td class="text"><p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zkhtSX54qy75" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86C_ziSLvQsMEBHb">Income Taxes</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company complies with the
accounting and reporting requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach to
financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the
financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 740 prescribes a recognition
threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be
taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#8217;s management determined the United States is the Company&#8217;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The provision for income taxes
was deemed to be immaterial for the period from December&#160;19, 2025 (inception) through December&#160;31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zAGgh3xYfpt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_865_zOgsMgqR3B78">Income Taxes</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company complies with
the accounting and reporting requirements of ASC Topic 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach
to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between
the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted
tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 740 prescribes a
recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected
to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. The Company&#8217;s management determined the United States is the Company&#8217;s only major tax jurisdiction.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were
no unrecognized tax benefits as of December&#160;31, 2025 and no amounts accrued for interest and penalties. The Company is currently
not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The
Company is subject to income tax examinations by major taxing authorities since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provision for income
taxes was deemed to be immaterial for the three months ended March 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z9GnwSb4VdD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Loss Per Share</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company computes basic loss
per share (&#8220;EPS&#8221;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of December&#160;31, 2025 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_z6IKhtn0tFHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_866_z5LJmpNKovA1">Loss Per Share</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company computes basic
loss per share (&#8220;EPS&#8221;) by dividing net loss by the weighted average number of common stock shares outstanding for the reporting
period. Diluted earnings per share is calculated by dividing net loss by the weighted average number of common stock shares equivalents
outstanding. During the periods when there are anti-dilutive, common stock share equivalents, if any, are not considered in the computation.
As of March 31, 2026 there were no anti-dilutive common stock shares or common stock share equivalents outstanding.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging growth company</a></td>
<td class="text"><p id="xdx_844_ecustom--EmergingGrowthCompanyPolicyTextBlock_zIflyZXwhT3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zieh9LOsfqE3">Emerging Growth Company</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is an &#8220;emerging
growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of
2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period
which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company,
as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_ecustom--EmergingGrowthCompanyPolicyTextBlock_zxCuTvrFDI99" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_864_zu39EgO8Buwg">Emerging Growth Company</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is an &#8220;emerging
growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act
of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Further, Section&#160;102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition
period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging
growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because
of the potential differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently accounting pronouncements</a></td>
<td class="text"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSNNhvz3V6Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_zM7M5EBTVgG3">Recently adopted accounting pronouncements</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November&#160;2023, the FASB
issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose
information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public
entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment
disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since inception.
Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material
effect on the Company&#8217;s financial statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhxo4ncWR2Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zIe1QxnsUF6c">Recently adopted accounting pronouncements</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November&#160;2023, the
FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to
disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis.
Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing
segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The Company adopted ASU 2023-07 since
inception. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would
have a material effect on the Company&#8217;s financial statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_GoingConcernPolicyTextBlock', window );">Going concern</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84E_ecustom--GoingConcernPolicyTextBlock_zjTeaYmk2USj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>a.
<span id="xdx_867_zT6r15wrPfT">Going concern</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">As
of March&#160;31, 2026, the Company had cash and cash equivalents and U.S. Dollar Coin (&#8220;USDC&#8221;) of $<span id="xdx_90B_ecustom--CashAndCashEquivalentsAndU.s.DollarCoin_iI_pn3n3_dm_c20260331_zOweLGQ0nMmd" title="Cash and cash equivalents and U.S. Dollar Coin">5.1 </span>million
and current liabilities of $29.2 <span id="xdx_90B_eus-gaap--LiabilitiesCurrent_iI_c20260331_zx0VQfPseO64" style="display: none" title="Current liabilities">29,153,918</span>
million. For the nine months ended March&#160;31, 2025, the Company used $0.8 <span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20240701__20250331_zXrnaRJA6DE6" style="display: none" title="Cash for operating activities">(757,960)</span>
million in operating activities, while for the nine months ended March&#160;31, 2026, it used $3.8 <span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20250701__20260331_z0FbPDcDfL21" style="display: none" title="Cash for operating activities">(3,758,611)</span>
million. The Company incurred net losses of $6.2 <span id="xdx_90B_eus-gaap--NetIncomeLoss_c20240701__20250331_zVBAnoAbYj2e" style="display: none" title="Net losses">(6,178,537)</span>
million and $7.9 <span id="xdx_906_eus-gaap--NetIncomeLoss_c20250701__20260331_zwLqC0GO7Qj2" style="display: none" title="Net losses">(7,916,977)</span>
million for these respective periods. Since inception, the Company has incurred recurring net losses from operations and negative
cash flows from operating activities. As of March&#160;31, 2026, the Company had an accumulated deficit of $21.1 <span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20260331_zxZwKyas1Wfb" style="display: none" title="Accumulated deficit">(21,134,012)</span>
million. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern within one year
of the date these unaudited condensed consolidated financial statements are issued.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Management
has formulated and is actively pursuing plans to mitigate these conditions and secure the Company&#8217;s continued operations. In connection
with the Company&#8217;s contemplated business combination with a SPAC and related financing activities, the Company expects to access
additional capital through external funding sources. In addition, the Company continues to focus on expanding its market presence and
developing client relationships to drive revenue growth, while managing operating expenses, with the objective of improving cash flows
from operations over time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
purposes of this disclosure, &#8220;SPAC&#8221; refers to a special purpose acquisition company formed to effect a merger, share exchange,
asset acquisition, share purchase, reorganization or similar business combination with one or more operating businesses. &#8220;De-SPAC&#8221;
refers to the business combination transaction pursuant to which an operating company combines with a SPAC, following which the combined
company becomes publicly listed (or otherwise succeeds to the SPAC&#8217;s public company status).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s
negative working capital position is primarily attributable to the classification of SAFEs. Excluding the accounting impact of the SAFEs,
which will only be paid in cash upon Liquidity Events and Dissolution Event (as defined in Note 8), management believes the Company&#8217;s
available cash resources are sufficient for near-term operating needs. If additional liquidity is required, the Company&#8217;s majority
shareholder has entered into a binding support agreement to provide funding to cover anticipated operating cash flow shortfalls through
the completion of the contemplated de-SPAC transaction. The support agreement is effective for a period of eighteen months from June&#160;10,
2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However,
the de-SPAC transaction (including the SAFEs conversion) have not been fully implemented as of the date these unaudited condensed consolidated
financial statements are issued. There can be no assurance that these plans will be successfully completed within the required time frame,
on acceptable terms, or at all. If the primary plans are not successful, the Company&#8217;s alternative courses of action would further
intensify efforts in market expansion and client development to increase revenue, while diligently controlling costs to ensure sufficient
cash flow from operating activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company may not be able to secure necessary financing in a timely manner or on favorable terms, or successfully execute its operational
turnaround. These circumstances give rise to substantial doubt that the Company will continue as a going concern and these unaudited condensed
consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_845_ecustom--GoingConcernPolicyTextBlock_zorhFCi8emlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>a. <span id="xdx_864_z1YlhGMWNLQ3">Going concern</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June&#160;30, 2025, the Company had cash
and cash equivalents of $4.2 million <span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20250630_zP8AepDgmXQ1" style="display: none" title="Cash and cash equivalents">4,231,689</span>
and current liabilities of $20.3 <span id="xdx_902_eus-gaap--LiabilitiesCurrent_iI_c20250630_z4jwfecaN8A1" style="display: none" title="Current liabilities">20,319,721</span>
million. For the years ended June&#160;30, 2024 and 2025, the Company used $0.6 <span title="Net losses"><span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20230701__20240630_zimEv9wUsnDk" style="display: none" title="Cash for operating activities">(560,909)</span>
million and $1.0 <span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20240701__20250630_zVTfCY856dug" style="display: none" title="Cash for operating activities">(1,010,799)</span>
million in cash for operating activities, and incurred net losses of $5.0 <span id="xdx_901_eus-gaap--NetIncomeLoss_c20230701__20240630_zVEtJqHinOV8" style="display: none" title="Net losses">(4,956,347)</span>
million and $7.7 <span id="xdx_903_eus-gaap--NetIncomeLoss_c20240701__20250630_zUawJwOLj0Yh" style="display: none" title="Net losses">(7,659,667)</span>
million, respectively. The Company has incurred recurring net losses from operations and negative cash flows from operating
activities since inception. As of June&#160;30, 2025, the Company had an accumulated deficit of $13.2
<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20250630_zuIwST4zPt2k" style="display: none" title="Accumulated deficit">(13,217,035)</span> million. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern
within one year of the date these financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has formulated and is actively pursuing
plans to mitigate these conditions and secure the Company&#8217;s continued operations. In connection with the Company&#8217;s contemplated
business combination with a SPAC and related financing activities, the Company expects to access additional capital through external funding
sources. In addition, the Company continues to focus on expanding its market presence and developing client relationships to drive revenue
growth, while managing operating expenses, with the objective of improving cash flows from operations over time.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of this disclosure, &#8220;SPAC&#8221;
refers to a special purpose acquisition company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more operating businesses. &#8220;De-SPAC&#8221; refers to the business combination transaction
pursuant to which an operating company combines with a SPAC, following which the combined company becomes publicly listed (or otherwise
succeeds to the SPAC&#8217;s public company status).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s negative working capital position
is primarily attributable to the classification of SAFEs. Excluding the accounting impact of the SAFEs, which will only be paid in cash
upon Liquidity Events and Dissolution Event (as defined in Note 9) and the SAFE holders choose to claim the invested proceeds back, management
believes the Company&#8217;s available cash resources are sufficient for near-term operating needs. If additional liquidity is required,
the Company&#8217;s majority shareholder has entered into a binding support agreement to provide funding to cover anticipated operating
cash flow shortfalls through the completion of the contemplated de-SPAC transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">However, the aforementioned plans, particularly the
de-SPAC transaction (including the SAFEs conversion) and the raising of additional capital, have not been fully implemented as of the
date these financial statements are issued. There can be no assurance that these plans will be successfully completed within the required
time frame, on acceptable terms, or at all. If the primary plans are not successful, the Company&#8217;s alternative courses of action
would further intensify efforts in market expansion and client development to increase revenue, while diligently controlling costs to
ensure sufficient cash flow from operating activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company may not be able to secure necessary financing
in a timely manner or on favorable terms, or successfully execute its operational turnaround. These circumstances give rise to substantial
doubt that the Company will continue as a going concern and these financial statements do not include any adjustments that might result
from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zrDsuQdfyKG2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>b.
<span id="xdx_860_z2ZzsSnntEpd">Basis of presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally
accepted accounting principles (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange
Commission (&#8220;SEC&#8221;) regarding interim financial reporting. Certain information and note disclosures normally included in
the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP have been condensed consolidated or
omitted pursuant to such rules and regulations. As such, the information included in this interim financial report should be read in
conjunction with the audited financial statements and accompanying notes for the two years ended June&#160;30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
accompanying unaudited condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly
the financial position, operating results and cash flows of the Company for each of the periods presented. The results of operations for
the three and nine months ended March&#160;31, 2026 are not necessarily indicative of results to be expected for any other interim period
or for the year ending June&#160;30, 2026. The condensed consolidated balance sheet as of June&#160;30, 2025 was derived from the audited
financial statements at that date but does not include all of the disclosures required by U.S. GAAP for annual financial statements.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoHPeRGXD8V6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>b. <span id="xdx_863_zpBEwXbVSFgl">Basis of presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The financial statements have been prepared in accordance
with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the applicable
rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates and assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--UseOfEstimates_zcUBkLyQ302a" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>c.
<span id="xdx_869_zJzlNRZuupR8">Use of estimates and assumptions</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation
of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported
in the unaudited condensed consolidated financial statements and accompanying notes. Management believes that the estimates used in preparing
the unaudited condensed consolidated financial statements are reasonable and prudent; however, actual results could differ from these
estimates under different assumptions or conditions.&#160;Significant accounting estimates include recognition and measurement of SAFEs
notes, recognition and measurement of share-based compensation, the allowance for expected credit losses, deferred tax assets and valuation
allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_849_eus-gaap--UseOfEstimates_zm9vWs4Czw0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>c. <span id="xdx_86E_zKFaeK3WfP28">Use of estimates and assumptions</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and
accompanying notes. Management believes that the estimates used in preparing the financial statements are reasonable and prudent; however,
actual results could differ from these estimates under different assumptions or conditions.&#160;Significant accounting estimates include
revenue recognition, recognition and measurement of SAFEs notes, the allowance for expected credit losses, recognition and measurement
of share-based compensation, deferred tax assets and valuation allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z3MfqTrj1Ctg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>d.
<span id="xdx_861_zefs2YE20oYg">Fair value measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
accordance with FASB ASC 820&#160;<i>Fair Value Measurements and Disclosures</i>, fair value is defined as the price that would be received
to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company
uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes
between market participant assumptions developed from market data obtained from outside sources (observable inputs) and the Company&#8217;s
own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable
inputs).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of
inputs used to measure fair value are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Level
1: Quoted prices in active markets for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Level
2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Level
3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash
flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment
or estimation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management during
the nine months ended March&#160;31, 2025 and 2026. The carrying amount of cash and cash equivalents, accounts receivable, refundable
deposits receivable, other receivables, accounts payable, refundable deposits payable and other current liabilities approximated their
fair values as of June&#160;30, 2025 and March&#160;31, 2026. For the nine months ended March&#160;31, 2025 and 2026, the Company carried
SAFEs and digital assets at their fair value (see&#160;Note 4-Fair Value Measurements for fair value information).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zdsq5TZx08Bg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>d. <span id="xdx_86B_zgmcgXMRrdyd">Fair value measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #212529; color: #212529">In accordance
with FASB ASC 820&#160;</span><i><span style="color: #212529; color: #212529">Fair Value Measurements and Disclosures</span></i><span style="color: #212529; color: #212529">,
</span>fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. <span style="color: #212529; color: #212529">The Company uses a three-level hierarchy
for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant
assumptions developed from market data obtained from outside sources (observable inputs) and the Company&#8217;s own assumptions about
market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). </span></p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The hierarchy requires entities to maximize the use
of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #212529; color: #212529">Level
1: Quoted prices in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #212529; color: #212529">Level
2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #212529; color: #212529">Level
3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash
flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment
or estimation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #212529; color: #212529">The fair
value measurements discussed herein are based upon certain market assumptions and pertinent information available to management during
the years ended June&#160;30, 2024 and 2025. The carrying amount of cash and </span>cash equivalents<span style="color: #212529; color: #212529">,
accounts receivable, r</span>efundable deposits receivable, other receivables, <span style="color: #212529; color: #212529">accounts payable,
r</span>efundable deposits payable <span style="color: #212529; color: #212529">and other current liabilities approximated their fair
values as of June&#160;30, 2024 and 2025. For the years ended June&#160;30, 2024 and 2025, the Company carried SAFEs at their fair value
(see&#160;Note 4-Fair Value Measurements&#160;for fair value information).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_FunctionalCurrencyPolicyTextBlock', window );">Functional currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_844_ecustom--FunctionalCurrencyPolicyTextBlock_z2nCVmTUVaCh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>e.
<span id="xdx_86D_zpLd8Tfyfj3f">Functional currency</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
accompanying unaudited condensed consolidated financial statements are presented in the United States dollar (&#8220;US$&#8221;).
The functional currency of the Company and its subsidiary is the US$.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">All
transactions are measured and recorded in the Company&#8217;s functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84F_ecustom--FunctionalCurrencyPolicyTextBlock_zlxnMooXoEU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>e. <span id="xdx_865_zAyE0XfHmhD6">Functional currency</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements are presented
in the United States dollar (&#8220;US$&#8221;). The functional currency of the Company is the US$.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All transactions are measured and recorded in the
Company&#8217;s functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z91JQokNSbAl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>f.
<span id="xdx_867_zTk17b0iUrZg">Cash and cash equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company considers all highly liquid investments instruments purchased with a maturity period of three months or less to be cash or cash
equivalents. The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents approximate their fair value.
As of June&#160;30, 2025 and March&#160;31, 2026, the Company does <span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zmHRDKKWlBMg" title="Cash equivalents"><span id="xdx_908_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20260331_zVbuobGqAgp7" title="Cash equivalents">no</span></span>t have any cash equivalents.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zbK7C7pPqW23" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>f. <span id="xdx_863_zISAmbUCaane">Cash and cash equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid debt instruments
purchased with a maturity period of three months or less to be cash or cash equivalents. The carrying amounts reported in the accompanying
balance sheets for cash and cash equivalents approximate their fair value. As of June&#160;30, 2024 and 2025, the Company does <span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20240630_zJxii2H5kkT6" title="Cash equivalents"><span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zqb5W6PdbHal" title="Cash equivalents">no</span></span>t have
any cash equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ExpectedCreditLossAndAccountsReceivablePolicyTextBlock', window );">Expected credit loss and accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_843_ecustom--ExpectedCreditLossAndAccountsReceivablePolicyTextBlock_zyxTRes82yL6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>h.
<span id="xdx_863_z4jvYtW2zBHk">Expected credit loss and accounts receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company adopted Financial Standards Accounting Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 326 &#8220;<i>Financial
Instruments&#160;&#8212;&#160;Credit Losses</i>&#8221; (&#8220;ASC&#160;326&#8221;) on January&#160;1, 2023.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s accounts receivable are within the scope of ASC&#160;326. ASC&#160;326 introduces an approach based on expected credit
losses on financial assets at amortized cost. Upon adoption of ASC&#160;326, the Company estimates the expected credit losses for accounts
receivable using the roll-rate method on a collective basis when similar risk characteristics exist. Expected credit losses are included
in general and administrative expenses in the statements of operations and comprehensive loss. After all attempts to collect a receivable
have failed, the receivable is written off against the allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Accounts
receivable represents those receivables derived in the ordinary course of business, net of an allowance for any potentially uncollectible
amounts. The Company makes estimates of expected credit and collectability trends for the allowance for credit losses based upon its assessment
of various factors, including historical experience, the age of the accounts receivable balances, credit quality of its customers, current
economic conditions, reasonable and supportable forecasts of future economic conditions that may vary by geography, customer-type, or
industry sub-vertical, and other factors that may affect its ability to collect from customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Although
the Company has historically not experienced significant credit losses, they may experience increasing credit loss risks from accounts
receivable in future periods if its customers are adversely affected by economic pressures or uncertainty associated with local or global
economic recessions, or other customer-specific factors, and actual experience in the future may differ from their past experiences or
current assessment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_ecustom--ExpectedCreditLossAndAccountsReceivablePolicyTextBlock_zSEmIHvv90sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>g. <span id="xdx_867_zsUZxth16ncb">Expected credit loss and accounts receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company adopted Financial Standards Accounting
Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 326 &#8220;<i>Financial Instruments&#160;&#8212;&#160;Credit
Losses</i>&#8221; (&#8220;ASC&#160;326&#8221;) on January&#160;1, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s accounts receivable is within
the scope of ASC&#160;326. ASC&#160;326 introduces an approach based on expected credit losses on financial assets at amortized cost.
Upon adoption of ASC&#160;326, the Company estimates the expected credit losses for accounts receivable using the roll-rate method on
a collective basis when similar risk characteristics exist. Expected credit losses are included in general and administrative expenses
in the statements of operations and comprehensive loss. After all attempts to collect a receivable have failed, the receivable is written
off against the allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable represents those receivables derived
in the ordinary course of business, net of an allowance for any potentially uncollectible amounts. The Company makes estimates of expected
credit and collectability trends for the allowance for credit losses based upon its assessment of various factors, including historical
experience, the age of the accounts receivable balances, credit quality of its customers, current economic conditions, reasonable and
supportable forecasts of future economic conditions that may vary by geography, customer-type, or industry sub-vertical, and other factors
that may affect its ability to collect from customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although the Company has historically not experienced
significant credit losses, they may experience increasing credit loss risks from accounts receivable in future periods if its customers
are adversely affected by economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific
factors, and actual experience in the future may differ from their past experiences or current assessment.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_AdvanceToSuppliersPolicyTextBlock', window );">Advance to suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_846_ecustom--AdvanceToSuppliersPolicyTextBlock_zZ6KgRaaPBG2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>j.
<span id="xdx_866_zzQ6PbxNF5wb">Advance to suppliers</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Advance
to suppliers represent prepayments made to vendors in connection with the purchase of services. Advance is recorded at the amount paid
and are classified as current assets when the related services are expected to be received within one year or the normal operating cycle.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_848_ecustom--AdvanceToSuppliersPolicyTextBlock_ziKHq9XEjP3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>h. <span id="xdx_86C_zgfztbsMVxIj">Advance to suppliers</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advance to suppliers represent prepayments made to
vendors in connection with the purchase of services. Advance are recorded at the amount paid and are classified as current assets when
the related services are expected to be received within one year or the normal operating cycle.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RefundableDepositsReceivablePolicyTextBlock', window );">Refundable deposits receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_848_ecustom--RefundableDepositsReceivablePolicyTextBlock_zk0hhYTHhzHb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>k.
<span id="xdx_869_zdl6xUSc9d8g">Refundable deposits receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Refundable
deposits receivable mainly represents security deposits and refundable cooperation deposits paid to suppliers and business partners that
are contractually recoverable upon the completion of services. These amounts are recorded as assets when paid, generally at the amount
paid. Deposits expected to be recovered within one year are classified as current; otherwise, they are classified as non-current. Allowance
should be assessed under CECL, and write off when not recoverable. The Company evaluates the credit risk of refundable deposits receivable
and recognizes an allowance for credit losses based on the current expected credit losses (&#8220;CECL&#8221;) model. Specific balances
are written off when they are deemed uncollectible and all collection efforts have been exhausted. As of June&#160;30, 2025 and March&#160;31,
2026, <span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_zDO4z5wPjGpf" title="Allowance for expected credit losses"><span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20260331_zQu1ABES8Qma" title="Allowance for expected credit losses">no</span></span> allowance for credit losses was recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_844_ecustom--RefundableDepositsReceivablePolicyTextBlock_zHSdExpu5L9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>i. <span id="xdx_86D_z7CffKljqsfj">Refundable deposits receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Refundable deposits receivable mainly represent security
deposits and refundable cooperation deposits paid to suppliers and business partners that are contractually recoverable upon the completion
of services. These amounts are recorded as assets when paid, generally at the amount paid. Deposits expected to be recovered within one
year are classified as current; otherwise, they are classified as non-current. The Company evaluates the credit risk of refundable deposits
receivable and recognizes an allowance for credit losses based on the current expected credit losses (&#8220;CECL&#8221;) model. Specific
balances are written off when they are deemed uncollectible and all collection efforts have been exhausted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June&#160;30, 2024 and 2025, the balances were
$<span id="xdx_90E_ecustom--RefundableDepositsReceivable_iI_c20240630_za7GUMIQ0fl5" title="Refundable deposits receivable">110,000</span> and $<span id="xdx_90E_ecustom--RefundableDepositsReceivable_iI_c20250630_z0ReoE3c16C9" title="Refundable deposits receivable">681,125</span>, respectively. The increase was primarily driven by revenue growth and business expansion. As of June&#160;30, 2024
and 2025, there was <span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20240630_zLZRW1Dk6Ukj" title="Allowance for expected credit losses"><span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_do_c20250630_z3aW6vPWJeid" title="Allowance for expected credit losses">no</span></span> allowance for expected credit losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zCXIK2Zay5zh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>n.
<span id="xdx_865_zZTnYmCZy9f7">Equipment, net</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Equipment,
net is stated at cost less accumulated depreciation and impairment, if any. Depreciation is computed using the straight-line method over
the estimated useful lives of three or five years, depending on the asset category.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z0zrIdAY4IM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>j. <span id="xdx_86F_zf8ptRHzRO28">Equipment, net</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equipment, net is stated at cost less accumulated
depreciation and impairment, if any. Depreciation is computed using the straight-line method over the estimated useful lives of three
or five years, depending on the asset category.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zVTnprYtqQTc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>p.
<span id="xdx_862_zigYXt8xtSLl">Impairment of long-lived assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company reviews its long-lived assets, equipment, for impairment whenever events or changes in circumstances indicate the carrying amount
of an asset may not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset
to the future undiscounted cash flows expected to be generated from the use of the asset and its eventual disposition. If such assets
are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair
value of the impaired assets. Assets to be disposed of are reported at the lower of their carrying amount or fair value less cost to sell.
There was <span id="xdx_905_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20240701__20250331_zrLs0b2fiOF6" title="Impairment of long-lived assets"><span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20250701__20260331_z8ukRmzY0PX3" title="Impairment of long-lived assets">no</span></span> impairment of long-lived assets for the nine months ended March&#160;31, 2025 and 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z4iWfcQYqTqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>k. <span id="xdx_86E_zLIGi7CATnu7">Impairment of long-lived assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews its long-lived assets, equipment,
for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability
of assets held and used is measured by comparison of the carrying amount of an asset to the future undiscounted cash flows expected to
be generated from the use of the asset and its eventual disposition. If such assets are considered to be impaired, the impairment to be
recognized is measured by the amount by which the carrying amount exceeds the fair value of the impaired assets. Assets to be disposed
of are reported at the lower of their carrying amount or fair value less cost to sell. There was <span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20230701__20240630_zgA1bYYr7Yec" title="Impairment of long-lived assets"><span id="xdx_907_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0d_do_c20240701__20250630_zZHdVotNKmAc" title="Impairment of long-lived assets">no</span></span> impairment of long-lived assets as
of and for the years ended June&#160;30, 2024 and 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_SimpleAgreementsForFutureEquityPolicyTextBlock', window );">Simple agreements for future equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_849_ecustom--SimpleAgreementsForFutureEquityPolicyTextBlock_zdOdrfeIirK4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>q.
<span id="xdx_86C_zSfMxlp0w9ih">Simple agreements for future equity</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">SAFEs
issued by the Company are freestanding financial instruments. As they contain certain redemption or liquidation features that&#160;may&#160;require
the Company to settle the obligation in cash upon the occurrence of defined events (e.g., a change of control or dissolution), the instruments&#160;create
an obligation that meets the definition of a liability. Accordingly, the SAFEs are classified in their entirety as liabilities on the
balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">These
liabilities are measured at fair value upon initial recognition and are subsequently remeasured at fair value at each reporting date.
All changes in their fair value are recognized in&#160;the condensed consolidated statement of operations and comprehensive loss in the
period in which they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_844_ecustom--SimpleAgreementsForFutureEquityPolicyTextBlock_zFgYzNF7u2n6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>l. </i><i><span style="color: #212529; color: #212529"><span id="xdx_867_z4BrJrohRAA9">Simple
agreements for future equity</span></span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">SAFEs issued by the Company are freestanding financial
instruments. As they contain certain redemption or liquidation features that&#160;may&#160;require the Company to settle the obligation
in cash upon the occurrence of defined events (e.g., a change of control or dissolution), the instruments&#160;create an obligation that
meets the definition of a liability. Accordingly, the SAFEs are classified in their entirety as liabilities on the balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These liabilities are measured at fair value upon
initial recognition and are subsequently remeasured at fair value at each reporting date. All changes in their fair value are recognized
in&#160;the statement of operations and comprehensive loss in the period in which they occur.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionDeferredRevenue', window );">Revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84A_eus-gaap--RevenueRecognitionDeferredRevenue_z7voQ64y5MR7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>r.
<span id="xdx_86B_zHHFuv3eFudi">Revenue recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company applied ASC Topic&#160;606 &#8220;<i>Revenue from Contracts with Customers</i>&#8221; (&#8220;ASC&#160;606&#8221;) for all periods
presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
five-step model defined by ASC&#160;606 requires the Company to (i)&#160;identify its contracts with clients, (ii)&#160;identify its performance
obligations under those contracts, (iii)&#160;determine the transaction prices of those contracts, (iv)&#160;allocate the transaction
prices to its performance obligations in those contracts, and (v)&#160;recognize revenue when each performance obligation under those
contracts is satisfied. Revenue is recognized when promised goods or services are transferred to the client in an amount that reflects
the consideration expected in exchange for those goods or services.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company reports all of its revenues on a gross basis.&#160;This determination is based on the Company&#8217;s assessment that it is the
principal in its revenue arrangements. The Company controls the service delivery platform and infrastructure before the service is provided
to the customer. It is primarily responsible for fulfilling the service promise, has discretion in setting prices, and assumes the credit
risk associated with the customer receivable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">As
a practical expedient, the Company elected to expense the incremental costs of obtaining a contract when incurred if the amortization
period of the asset that the Company otherwise would have recognized is one year or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Pursuant
to ASC 606, the Company recognizes revenue based on the transaction price, which is the amount of consideration it expects to be entitled
to exchange for transferring services to customers. For Intelligent Computing Power Services, contract consideration is generally fixed
and is typically stated as a fixed monthly fee determined by (i) the contractually specified number of GPUs (capacity) and (ii) the service
period. Accordingly, the transaction price is generally the fixed contractual amount. The Company recognizes revenue over time as the
services are provided throughout the contract term. The Company offers payment terms ranging from 0 to 6 months, depending on customers&#8217;
credit profiles and service requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company does not provide warranties for its services and does not offer service-type warranty arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
following is a description of the principal activities of the Company from which the Company generates its revenue under ASC 606.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">(i)
Revenue for intelligent computing power service</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company leverages its expertise in high-performance computing and cloud-native architectures to build and operate stable, efficient, and
scalable GPU computing platforms through modular data center design and liquid cooling technology. The Company uses these platforms to
provide computing resources for large-scale AI training, model inference, and high-performance scientific computing to commercial enterprise
clients with substantial GPU computing requirements. Supporting services include GPU server environment deployment, cluster scheduling
and performance optimization, high-speed network interconnection, real-time monitoring and intelligent alerting systems, as well as industry-compliant
security and regulatory assurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company accounts for the above promises as a single performance obligation because they are highly integrated and not separately identifiable
in the context of the contract. The Company provides an integrated, managed GPU computing platform in which computing capacity, deployment/configuration,
scheduling, networking, monitoring, and security/compliance are interdependent and together deliver a single combined service&#8212;continuous
access to a functioning and secured platform over the contractual term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company provides intelligent computing power services under two pricing models: (i) reserved capacity arrangements and (ii) on-demand
(pay-as-you-go) arrangements. The following table presents revenue recognized during the period by arrangement type:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zd2TxFvdYVol" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8BE_zsDAbjhGLAp7" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of Revenue recognition</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Reserved
        capacity arrangements</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90A_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues">1,758,921</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_908_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues">3,725,315</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues">4,161,985</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues">10,428,983</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">On-demand
        arrangements</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues">5,436</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues">1,341</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues">6,482</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues">12,526</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_905_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues">1,764,357</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_903_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues">3,726,656</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_900_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues">4,168,467</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_90E_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues">10,441,509</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

<p id="xdx_8A4_zk9Xg0gC6OZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>







<p style="font: 10pt Times New Roman, Times, serif; margin: 0px"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Reserved
capacity arrangements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company enters into reserved capacity arrangements, which generally provide committed intelligent computing power services for a defined
service term ranging from 3 months to 3 years, with the majority of such arrangements having a one-year term. These contracts typically
are non-cancelable, or may be canceled only under limited conditions with early notifications required. Payment terms generally range
from 0-6 months upon the completion of services, and certain arrangements require prepayments. Any prepayments are recorded as contract
liabilities and recognized over the service term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
performance obligation is satisfied over time because the customer simultaneously receives and consumes the benefits. Revenue is recognized
using a time-elapsed output method over the contractual service period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">On-demand
(pay-as-you-go) arrangements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif;text-align: justify; margin-top: 0; margin-bottom: 0">The Company provides customers with on-demand
access to intelligent computing power and GPU resources under pay-as-you-go model which requires advance payment. Customer advances are
recorded as contract liabilities and recognized as revenue over the time during the provision of related services underlying the contract
term. The revenue is recognized over time because the customer can simultaneously receive and consume the benefits during the service
period. These arrangements generally do not include a fixed contractual term or minimum usage commitments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">(ii)
Revenue from comprehensive data center service</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company leverages its project experience in infrastructure management, cluster optimization, and system monitoring to provide full-cycle
operational support to data center asset owners. Services encompass facility environment deployment, network architecture implementation,
security and compliance system development, daily operational monitoring, and emergency fault response. Revenue is recognized over time
because the Company&#8217;s services are performed throughout the contract term and the customer benefits as the services are provided.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
the three months ended March&#160;31, 2025 and 2026, $<span id="xdx_909_eus-gaap--Revenues_c20250101__20250331_pp0p" title="Revenue">1,862,158</span> and $<span id="xdx_90B_eus-gaap--Revenues_c20260101__20260331_pp0p" title="Revenue">3,754,586</span> of the revenue of the Company&#8217;s was recognized over
time, respectively. For the nine months ended March&#160;31, 2025 and 2026, $<span id="xdx_905_eus-gaap--Revenues_c20240701__20250331_pp0p" title="Revenue">4,475,885 </span>and $<span id="xdx_903_eus-gaap--Revenues_c20250701__20260331_pp0p" title="Revenue">10,561,331</span> of the revenue of the Company&#8217;s
was recognized over time, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Revenue
disaggregated by service lines for the three months and the nine months ended March&#160;31, 2025 and 2026 is disclosed in the table below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_z4whYoH0Yw36" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B8_z323FGsdNtth" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of Revenue disaggregated</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenue
        from intelligent computing power service</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z29WimMIRYO5" title="Total">1,764,357</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--Revenues_pp0d_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z0wPR3mOXwde" title="Total">3,726,656</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_904_eus-gaap--Revenues_pp0d_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zzqz7UuAay4i" title="Total">4,168,467</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zh7mCphOG5Ja" title="Total">10,441,509</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Revenue
        from comprehensive data center service</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total">97,801</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total">27,930</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total">307,418</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total">119,822</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_90B_eus-gaap--Revenues_pp0d_c20250101__20250331_zwjWXHIVxdh" title="Total">1,862,158</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_90D_eus-gaap--Revenues_pp0d_c20260101__20260331_zNTOV4dIJ4Sh" title="Total">3,754,586</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_903_eus-gaap--Revenues_pp0d_c20240701__20250331_zNWqBnz3BD5a" title="Total">4,475,885</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_906_eus-gaap--Revenues_pp0d_c20250701__20260331_zdRfOMzRsXv6" title="Total">10,561,331</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

<p id="xdx_8A4_zatc3Yp3kc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--RevenueRecognitionDeferredRevenue_zJ2s2gZGnL58" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>m. <span id="xdx_86E_zA2yNWLqfBFd">Revenue recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company applied ASC Topic&#160;606 &#8220;<i>Revenue
from Contracts with Customers</i>&#8221; (&#8220;ASC&#160;606&#8221;) for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The five-step model defined by ASC&#160;606 requires
the Company to (i)&#160;identify its contracts with clients, (ii)&#160;identify its performance obligations under those contracts, (iii)&#160;determine
the transaction prices of those contracts, (iv)&#160;allocate the transaction prices to its performance obligations in those contracts,
and (v)&#160;recognize revenue when each performance obligation under those contracts is satisfied. Revenue is recognized when promised
goods or services are transferred to the client in an amount that reflects the consideration expected in exchange for those goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reports all of its revenues on a gross
basis.&#160;This determination is based on the Company&#8217;s assessment that it is the principal in its revenue arrangements. The Company
controls the service delivery platform and infrastructure before the service is provided to the customer. It is primarily responsible
for fulfilling the service promise, has discretion in setting prices, and assumes the credit risk associated with the customer receivable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a practical expedient, the Company elected to expense
the incremental costs of obtaining a contract when incurred if the amortization period of the asset that the Company otherwise would have
recognized is one year or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to ASC 606, the Company recognizes revenue
based on the transaction price, which is the amount of consideration it expects to be entitled to exchange for transferring services to
customers. For Intelligent Computing Power Services, contract consideration is generally fixed and is typically stated as a fixed monthly
fee determined by (i) the contractually specified number of GPUs (capacity) and (ii) the service period. Accordingly, the transaction
price is generally the fixed contractual amount. The Company recognizes revenue over time as the services are provided throughout the
contract term. The Company offers payment terms ranging from 0 to 6 months, depending on customers&#8217; credit profiles and service
requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company does not provide warranties for its services
and does not offer service-type warranty arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a description of the principal activities
of the Company from which the Company generates its revenue under ASC 606.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(i) Revenue for intelligent computing power service</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #0F1115; color: #0F1115">The Company
leverages its expertise in high-performance computing and cloud-native architectures to build and operate stable, efficient, and scalable
GPU computing platforms through modular data center design and liquid cooling technology. The Company uses these platforms to provide
computing resources for large-scale AI training, model inference, and high-performance scientific computing to commercial enterprise clients
with substantial GPU computing requirements. Supporting services include GPU server environment deployment, cluster scheduling and performance
optimization, high-speed network interconnection, real-time monitoring and intelligent alerting systems, as well as industry-compliant
security and regulatory assurance. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for the above promises as a single
performance obligation because they are highly integrated and not separately identifiable in the context of the contract. The Company
provides an integrated, managed GPU computing platform in which computing capacity, deployment/configuration, scheduling, networking,
monitoring, and security/compliance are interdependent and together deliver a single combined service&#8212;continuous access to a functioning
and secured platform over the contractual term.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company provides intelligent computing power services
under two pricing models: (i) reserved capacity arrangements and (ii) on-demand (pay-as-you-go) arrangements. The following table presents
revenue recognized during the period by arrangement type:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zRG8fPT8BVR9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BF_zPudrh40sc0l" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Schedule of Revenue recognition</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/> years ended<br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Reserved capacity arrangements</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues">1,193,982</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues">6,501,569</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">On-demand arrangements</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl2098">-</span></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues">44,680</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_900_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues">1,193,982</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90E_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues">6,546,249</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zqlXSFBPlAkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reserved capacity arrangements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company enters into reserved capacity arrangements,
which generally provide committed intelligent computing power services for a defined service term ranging from 3 months to 3 years, with
the majority of such arrangements having a one-year term. These contracts typically are non-cancelable, or may be canceled only under
limited conditions with early notifications required. Payment terms generally range from 0-6 months upon the completion of services, and
certain arrangements require prepayments. Any prepayments are recorded as contract liabilities and recognized over the service term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The performance obligation is satisfied over time
because the customer simultaneously receives and consumes the benefits. Revenue is recognized using a time-elapsed output method over
the contractual service period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On-demand (pay-as-you-go) arrangements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company provides customers with on-demand access
to intelligent computing power and GPU resources under pay-as-you-go model which requires advance payment. Customer advances are recorded
as contract liabilities and recognized as revenue over the time during the provision of related services underlying the contract term.
The revenue is recognized over time because the customer can simultaneously receives and consumes the benefits during the service period.
These arrangements generally do not include a fixed contractual term or minimum usage commitments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(ii) Revenue from comprehensive data center service</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leverages its project experience in infrastructure
management, cluster optimization, and system monitoring to provide full-cycle operational support to data center asset owners. Services
encompass facility environment deployment, network architecture implementation, security and compliance system development, daily operational
monitoring, and emergency fault response. Revenue is recognized over time because the Company&#8217;s services are performed throughout
the contract term and the customer benefits as the services are provided.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the&#160;years ended June&#160;30, 2024 and 2025,
$<span id="xdx_905_eus-gaap--Revenues_c20230701__20240630_pp0p" title="Revenue">1,319,115</span> and $<span id="xdx_903_eus-gaap--Revenues_c20240701__20250630_pp0p" title="Revenue">7,015,512</span> of the revenue of the Company&#8217;s was recognized over time, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue disaggregated by service lines for the&#160;years
ended June&#160;30, 2024 and 2025 is disclosed in the table below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zC7KRbYjMXPd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BF_zOrqnCzeKVC3" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Schedule of Revenue disaggregated</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/>years ended<br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Revenue from intelligent computing
        power service</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zLe37nj4DRT9" title="Total">1,193,982</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_907_eus-gaap--Revenues_pp0d_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z5LhznXQI8B2" title="Total">6,546,249</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Revenue from comprehensive
        data center services</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total">125,133</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total">469,263</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630_zw4xoiRMPQs7" title="Total">1,319,115</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90A_eus-gaap--Revenues_pp0d_c20240701__20250630_zxIqgXFsjdA6" title="Total">7,015,512</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zFyS7keq5WFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>









<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ContractLiabilitiesPolicyTextBlock', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84C_ecustom--ContractLiabilitiesPolicyTextBlock_z2PT6xnTNlO" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>s.
<span id="xdx_869_z3dd7lxTNbH4">Contract liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company receives advance payments from its customers for services to be provided in the future. These payments are recorded as&#160;contract
liabilities&#160;on the balance sheet within &#8220;Contract liabilities&#8221;.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Contract
liabilities are recognized when consideration is received from a customer prior to the Company satisfying its related performance obligations.
For these service contracts, the Company recognizes revenue, and reduces the contract liabilities,&#160;over time&#160;as the services
are rendered and the performance obligations are satisfied. Revenue recognized during the nine months ended March&#160;31, 2025 and 2026
that was included in the contract liability balance at the beginning of the period was $<span id="xdx_90A_ecustom--RevenueRecognized_c20240701__20250331_pp0p" title="Revenue recognized">95,326</span> and $<span id="xdx_90D_ecustom--RevenueRecognized_pp0d_c20250701__20260331_z9oT97FjUGcd" title="Revenue recognized">366,075</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_845_ecustom--ContractLiabilitiesPolicyTextBlock_zZWQnliQBId8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>n. <span id="xdx_864_zhAHETYm7uU4">Contract liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company receives advance payments from its customers
for services to be provided in the future. These payments are recorded as&#160;contract liabilities&#160;on the balance sheet within &#8220;Contract
liabilities&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Contract liabilities are recognized when
consideration is received from a customer prior to the Company satisfying its related performance obligations. For these service
contracts, the Company recognizes revenue, and reduces the contract liabilities,&#160;over time&#160;as the services are rendered
and the performance obligations are satisfied. Revenue recognized that was included in the contract liability balance at the
beginning of the year was nil <span id="xdx_90A_ecustom--RevenueRecognized_c20230701__20240630_pp0p" style="display: none" title="Revenue recognized">0</span> and $<span id="xdx_904_ecustom--RevenueRecognized_c20240701__20250630_pp0p" title="Revenue recognized">95,326</span> for the years ended June&#160;30, 2024 and 2025, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84F_eus-gaap--CostOfSalesPolicyTextBlock_zaoHhLB8Cxzj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>t.
<span id="xdx_863_z6GbgvPwOLFd">Cost of revenues</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s cost of revenues primarily includes computing power service, professional service fees and staff costs and employee benefits.
All the cost of revenues are recognized in the period in which the related services occur or the benefits are received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--CostOfSalesPolicyTextBlock_zd6uOxmwVUC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>o. <span id="xdx_868_zt2YqZ7h4862">Cost of revenues</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s cost of revenues primarily includes
computing power service and professional service fees. All the cost of revenues are recognized in the period in which the related services
occur or the benefits are received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_SellingAndMarketingExpensesPolicyTextBlock', window );">Selling and marketing expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_844_ecustom--SellingAndMarketingExpensesPolicyTextBlock_zw8zqwj9sNL3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>u.
<span id="xdx_864_ziTHMzLNeaI4">Selling and marketing expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s selling and marketing expenses primarily include: (i) advertising and promotion expenses, (ii) staff costs, employee benefits
and share-based compensation, and (iii) travel and other routine office expenses. All expenses are recognized in the period in which the
related services occur or the benefits are received. The Company expenses advertising costs as incurred, and for the nine months ended
March&#160;31, 2025 and 2026, the Company incurred advertising and promotion expenses of $<span id="xdx_908_eus-gaap--MarketingAndAdvertisingExpense_c20240701__20250331_pp0p" title="Advertising and promotion expenses">76,090</span> and $<span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20250701__20260331_pp0p" title="Advertising and promotion expenses">32,113</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_ecustom--SellingAndMarketingExpensesPolicyTextBlock_zNtKHlQglhzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>p. <span id="xdx_861_z8U06Sm8eK8b">Selling and marketing expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s selling and marketing expenses
primarily include: (i) advertising and promotion expenses, (ii) compensation and benefits for sales personnel and related share based
compensation, and (iii) travel and other routine office expense. All expenses are recognized in the period in which the related services
occur or the benefits are received. The Company expenses advertising costs as incurred, and for the years ended June&#160;30, 2024 and
2025, the Company incurred advertising and promotion expenses of $<span id="xdx_908_eus-gaap--MarketingAndAdvertisingExpense_c20230701__20240630_pp0p" title="Advertising and promotion expenses">26,340</span> and $<span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20240701__20250630_pp0p" title="Advertising and promotion expenses">157,388</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zPGLlXD14Ag2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>v.
<span id="xdx_86B_zfPkq0yTYPQi">Research and development expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s research and development expenses mainly consist of software development outsourcing service fees, staff costs and employee
benefits, and testing expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zTShSXVP9mc7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>q. <span id="xdx_864_zLpo4DODnKa5">Research and development expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s research and development expenses
mainly consist of <span style="color: #0F1115; color: #0F1115">software development outsourcing service fees and testing expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zXxvFOjeOFW2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>w.
<span id="xdx_866_zkb75BAicCy2">General and administrative expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s general and administrative expenses mainly consist of staff costs and employee benefits, professional service fees, depreciation
expenses and other operating expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_844_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zdyBpybY30kg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>r. <span id="xdx_866_z1OzlN0cGTed">General and administrative expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s general and administrative expenses
mainly consist of <span style="color: #0F1115; color: #0F1115">software subscription fees, legal and professional service fees, certification
service fees, depreciation expenses and handling charges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zM8egXJLQ5Fa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>x.
<span id="xdx_863_znTdepZ9jHh1">Income tax</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Income
taxes are determined in accordance with the provisions of ASC Topic 740, &#8220;Income Taxes&#8221; (&#8220;ASC Topic 740&#8221;). Under
this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities
are measured using enacted income tax rates expected to apply to taxable income in the periods in which those temporary differences are
expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income
in the period that includes the enactment date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">ASC
740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial
statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be
recognized in the unaudited condensed consolidated financial statements when it is more likely than not the position will be
sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest
amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority
assuming full knowledge of the position and relevant facts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zH16tov7HOHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>s. <span id="xdx_86A_zfzDgxosnhkd">Income tax</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Income taxes are determined in accordance with the
provisions of ASC Topic 740, <i>Income Taxes</i> (&#8220;ASC Topic 740&#8221;). Under this method, deferred tax assets and liabilities
are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing
assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates
expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. Any effect
on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 740 prescribes a comprehensive model for how companies
should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on
a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the
position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as
the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority
assuming full knowledge of the position and relevant facts.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_CapitalStructurePolicyTextBlock', window );">Capital structure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_847_ecustom--CapitalStructurePolicyTextBlock_zj8IHwVClyZk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>y.
<span id="xdx_865_zxrlWlb60CN6">Capital structure</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company is authorized to issue <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20250630_zxhDDryref03" title="Common stock, shares authorized">1,500</span> ordinary shares of $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250630_z9V4hGvU5My3" title="Common stock, par value">0.01</span> par value each. As of June&#160;30, 2025, there were <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20250630_zDM1htk1G69f" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20250630_zYzvDTOvJVAi" title="Common stock, shares outstanding">1,500</span></span> shares issued
and outstanding.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Pursuant
to the resolution of the board of directors on January&#160;8, 2026, the authorized share capital of <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20260108_z7MXAFFZzI8i" title="Common stock, shares authorized">1,500</span> ordinary shares was re-designated
to <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zYWtA0wxDxN4" title="Common stock, shares authorized">303</span> Class A ordinary shares and <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_z1Wg9UO1Hwh6" title="Common stock, shares authorized">1,197</span> Class B ordinary shares. Holders of Class A ordinary shares and Class B ordinary shares have
the same rights, except for voting and conversion rights. Each Class A ordinary share is entitled to one vote; and each Class B ordinary
share is entitled to twenty votes and is convertible into one Class A ordinary share at any time by the holder thereof. Class A ordinary
shares are not convertible into Class B ordinary shares under any circumstances. Furthermore, all outstanding warrants, options, and SAFEs
are designated to convert or settle exclusively into Class A ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">As
of March&#160;31, 2026, there were <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pd" title="Common stock, shares authorized">303</span> Class A ordinary shares and <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pd" title="Common stock, shares authorized">1,197</span> Class B ordinary shares outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_842_ecustom--CapitalStructurePolicyTextBlock_zrhorRvRLTn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>t. <span id="xdx_86F_zOYxMEHi9sP1">Capital structure</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized to issue <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20240630_pd" title="Common stock, shares authorized"><span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_c20250630_pd" title="Common stock, shares authorized">1,500</span></span> ordinary
shares of $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20240630_pd" title="Common stock, par value"><span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_c20250630_pd" title="Common stock, par value">0.01</span></span> par value each. As of June&#160;30, 2024 and 2025, there were <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_c20240630_pd" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_c20240630_pd" title="Common stock, shares outstanding"><span id="xdx_90A_eus-gaap--CommonStockSharesIssued_c20250630_pd" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_c20250630_pd" title="Common stock, shares outstanding">1,500</span></span></span></span> shares issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the resolution of the board of directors
on January&#160;8, 2026, the authorized share capital of <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_c20260108_pd" title="Common stock, shares authorized">1,500</span> ordinary shares was re-designated to <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pd" title="Common stock, shares authorized">303</span> Class A ordinary shares and <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20260108__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pd" title="Common stock, shares authorized">1,197</span>
Class B ordinary shares. Holders of Class A ordinary shares and Class B ordinary shares have the same rights, except for voting and conversion
rights. Each Class A ordinary share is entitled to one vote; and each Class B ordinary share is entitled to twenty votes and is convertible
into one Class A ordinary share at any time by the holder thereof. Class A ordinary shares are not convertible into Class B ordinary shares
under any circumstances. Furthermore, all outstanding warrants, options, and SAFEs are designated to convert or settle exclusively into
Class A ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z72hDOJ3JON1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>z.
<span id="xdx_86B_z63uLSARL1W8">Share-based compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company grants share options of the Company to eligible employees and&#160;non-employees. The Company accounts for share-based awards
issued to employees and&#160;non-employees in accordance with ASC Topic 718 <i>Compensation &#8211; Stock Compensation. </i>The Company
recognizes forfeitures as they occur. The share-based compensation expenses have been categorized as either general and administrative
expenses or selling and marketing expenses, depending on the job functions of the grantees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company&#8217;s share-based compensation awards are expected to be settled through transfers of existing ordinary shares held by the controlling
shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary shares are included in issued and
outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase the Company&#8217;s total issued
and outstanding shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Employees&#8217;
share-based awards and non-employees&#8217; share-based awards are measured at the grant date fair value of the awards and recognized
as expenses a) immediately at grant date if no vesting conditions are required; or b) using graded vesting method, net of estimated forfeitures,
over the requisite service period, which is the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company employs discounted cash flow method to determine the fair value of our share-based compensation arrangements, where the key valuation
variables include risk free rate, discount rate, and perpetual rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zyjuGtgiN2l4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>u. <span id="xdx_860_zz7zMNdlRtT9">Share-based compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company grants Share awards of the Company to
eligible employees and&#160;non-employees. The Company accounts for share-based awards issued to employees and&#160;non-employees in accordance
with ASC Topic 718 <i>Compensation &#8211; Stock Compensation. </i>The Company recognizes forfeitures as they occur. The share-based compensation
expenses have been categorized as either general and administrative expenses or selling and marketing expenses, depending on the job functions
of the grantees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s share-based compensation awards
are expected to be settled through transfers of existing ordinary shares held by the controlling shareholder, rather than through the
issuance of new shares by the Company. The underlying ordinary shares are included in issued and outstanding shares as of the balance
sheet date; accordingly, such settlement is not expected to increase the Company&#8217;s total issued and outstanding shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Employees&#8217; share-based awards and non-employees&#8217;
share-based awards are measured at the grant date fair value of the awards and recognized as expenses a) immediately at grant date if
no vesting conditions are required; or b) using graded vesting method, net of estimated forfeitures, over the requisite service period,
which is the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company employs discounted cash flow method to
determine the fair value of our share-based compensation arrangements, where the key valuation variables include risk free rate, discount
rate and perpetual rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment reporting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zh2bCTq9oe5d" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>aa.
<span id="xdx_864_zR4H5vg2NKs8">Segment reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">ASC
280, &#8220;Segment Reporting&#8221;, establishes standards for reporting information about operating segments on a basis consistent with
the Company&#8217;s internal organizational structure as well as information about geographical areas, business segments and major customers
in financial statements for details on the Company&#8217;s business segments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company uses the &#8220;management approach&#8221; in determining reportable operating segments. The management approach considers the
internal organization and reporting used by the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) for making operating
decisions and assessing performance as the source for determining the Company&#8217;s reportable segments. The Company&#8217;s CODM is
the chief executive officer. The CODM regularly reviews consolidated operating results and reviews consolidated revenues and net loss
when making decisions about allocating resources and assessing performance of the segment, and hence, the Group has only&#160;one&#160;reportable
segment. Therefore, as the Group has determined it operates as a single reportable segment, the CODM assesses the Group&#8217;s performance
and results of operations on a consolidated basis.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zj5A0O1qUZwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>v. <span id="xdx_867_zetDcyDJZsD4">Segment reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 280, &#8220;Segment Reporting&#8221;, establishes
standards for reporting information about operating segments on a basis consistent with the Company&#8217;s internal organizational structure
as well as information about geographical areas, business segments and major customers in financial statements for details on the Company&#8217;s
business segments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the &#8220;management approach&#8221;
in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#8217;s
chief operating decision maker (&#8220;CODM&#8221;) for making operating decisions and assessing performance as the source for determining
the Company&#8217;s reportable segments. The Company&#8217;s CODM is the chief executive director. The CODM regularly reviews entity-wide
operating results and reviews revenues and net loss when making decisions about allocating resources and assessing performance of the
segment, and hence, the Company has only&#160;one&#160;reportable segment. Therefore, as the Company has determined it operates as a single
reportable segment, the CODM assesses the Company&#8217;s performance and results of operations on an entity-wide basis.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RelatedPartiesPolicyTextBlock', window );">Related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_848_ecustom--RelatedPartiesPolicyTextBlock_zrZgPAsibWna" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>bb.
<span id="xdx_86A_zzhxddzLg2h3">Related parties</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Parties
are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant
influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject
to common control or significant influence, such as a family member or relative, shareholder, or a related corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84D_ecustom--RelatedPartiesPolicyTextBlock_zmOqA55enEsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>w. <span id="xdx_862_zI2bQw1nSKC">Related parties</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parties are considered to be related if one party
has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial
and operating decisions. Parties are also considered to be related if they are subject to common control or significant influence, such
as a family member or relative, shareholder, or a related corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ComprehensiveLossPolicyTextBlock', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84F_ecustom--ComprehensiveLossPolicyTextBlock_zbTFOSz89y33" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>cc.
<span id="xdx_86C_znQfJNLN3lgc">Comprehensive loss</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Comprehensive
loss is defined as a change in equity during a period from transactions and other events and circumstances&#160;from&#160;non-owner&#160;sources.&#160;The
Company&#8217;s comprehensive loss was the same as its reported net loss for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_849_ecustom--ComprehensiveLossPolicyTextBlock_z3GLuD1HtmQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>x. <span id="xdx_866_zJfxnr89HArh">Comprehensive loss</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Comprehensive loss is defined as a change in equity
during a period from transactions and other events and circumstances&#160;from&#160;non-owner&#160;sources.&#160;The Company&#8217;s comprehensive
loss was the same as its reported net loss for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_846_eus-gaap--EarningsPerSharePolicyTextBlock_z0CKE94bvxGf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>dd.
<span id="xdx_869_zTML0LCjGgK">Loss per share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Basic
net loss per share of ordinary shares attributable to common shareholders is calculated by dividing net loss attributable to common shareholders
by the weighted-average shares of common shares outstanding for the period. Potentially dilutive shares, which are based on the weighted-average
shares of common stock underlying outstanding share-based awards or options using the treasury stock method or the if-converted method,
as applicable, are included when calculating diluted net income per share of common stock attributable to common shareholders when their
effect is dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Diluted
net loss per share attributable to ordinary shareholders is computed by adjusting the weighted-average number of ordinary shares outstanding
for the dilutive effect of all potential ordinary share equivalents. For the Company, potential ordinary share equivalents consist of
share-based compensation, which are assessed using the&#160;treasury stock method. These potential shares are included in the diluted
earnings per share calculation only when their effect is&#160;dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
periods where the Company reports a&#160;net loss, diluted net loss per share is calculated in the same manner as basic net loss per share
because the inclusion of any potential ordinary shares would have an&#160;anti-dilutive&#160;effect. Consequently, all potential ordinary
share equivalents were excluded from the calculation for the years in which a net loss was incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zRr2tTiRL483" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>y.<span id="xdx_864_zWpJBAyOYapg"> Loss&#160;per share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per share of ordinary shares attributable
to ordinary shareholders is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average shares of ordinary
shares outstanding for the period. Potentially dilutive shares, which are based on the weighted-average shares of ordinary shares underlying
outstanding share-based awards or options using the treasury stock method or the if-converted method, as applicable, are included when
calculating diluted net income per share of ordinary shares attributable to ordinary shareholders when their effect is dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Diluted net loss per share attributable to ordinary
shareholders is computed by adjusting the weighted-average number of ordinary shares outstanding for the dilutive effect of all potential
ordinary share equivalents. For the Company, potential ordinary share equivalents consisted of share-based compensation, which are assessed
using the&#160;treasury stock method. These potential shares are included in the diluted earnings per share calculation only when their
effect is&#160;dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In periods where the Company reports a&#160;net loss,
diluted net loss per share is calculated in the same manner as basic net loss per share because the inclusion of any potential ordinary
shares would have an&#160;anti-dilutive&#160;effect. Consequently, all potential ordinary share equivalents were excluded from the calculation
for the years in which a net loss was incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionDividends', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84E_eus-gaap--RevenueRecognitionDividends_zJ8w8TuqR9s" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>ee.
<span id="xdx_860_zcInrRKO5aA2">Dividends</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Dividends
are recognized when declared. <span id="xdx_907_eus-gaap--Dividends_pp0d_do_c20240701__20250331_zbPIn012EOig" title="Dividends"><span id="xdx_90C_eus-gaap--Dividends_pp0d_do_c20250701__20260331_zuV7f8fIUas1" title="Dividends">No</span></span> dividends were declared for the nine months ended March&#160;31, 2025 and 2026, respectively. The Company
does not have any present plan to pay any dividends on ordinary shares in the foreseeable future. The Company currently intends to retain
the available funds and any future earnings to operate and expand its business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_844_eus-gaap--RevenueRecognitionDividends_z5kiNZU4iFJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>z. <span id="xdx_86E_z1wQVhVX3E9i">Dividends</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dividends are recognized when declared. <span id="xdx_908_eus-gaap--Dividends_pp0d_do_c20230701__20240630_z4eZ64ybMTmi" title="Dividends"><span id="xdx_903_eus-gaap--Dividends_pp0d_do_c20240701__20250630_zSkJu776q1A8" title="Dividends">No</span></span> dividends
were declared for the years ended June&#160;30, 2024 and 2025, respectively. The Company does not have any present plan to pay any dividends
on ordinary shares in the foreseeable future. The Company currently intends to retain the available funds and any future earnings to operate
and expand its business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock', window );">Recently adopted accounting standard updates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_842_ecustom--RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock_zt2bjFLbuL9h" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>gg.
<span id="xdx_86D_zcwKuWVskW29">Recently adopted accounting standard updates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
June&#160;2016, the FASB issued ASU&#160;2016-13, <i>Financial Instruments&#160;&#8212;&#160;Credit Losses </i>(Topic&#160;326): Measurement
of Credit Losses on Financial Instruments (&#8220;ASU&#160;2016-13&#8221;). The new accounting standard introduced the current expected
credit losses methodology (&#8220;CECL&#8221;) for estimating allowances for credit losses. The measurement of expected credit losses
under the CECL methodology is applicable to financial assets measured at amortized costs, including loans and trade receivables. ASU&#160;2016-13
is effective for the Company, as an emerging growth company, for annual and interim reporting periods beginning after December&#160;15,
2022. The Company adopted the standard on July&#160;1, 2023 using the modified retrospective method for all financial assets in scope.
The adoption of the standard did not have a material impact on the Company&#8217;s statements of income, or statements of cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
November&#160;2023, the FASB issued ASU&#160;2023-07, &#8220;Segment Reporting (Topic&#160;280): Improvements to Reportable Segment Disclosures.&#8221;
The amendments in this ASU are intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about
significant segment expenses. This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating
decision mark (&#8220;CODM&#8221;), an amount for other segment items by reportable segment and a description of its composition, all
annual disclosures required by FASB ASU Topic&#160;280 in interim periods as well, and the title and position of the CODM and how the
CODM uses the reported measures. Additionally, this ASU requires that at least one of the reported segment profit and loss measures should
be the measure that is most consistent with the measurement principles used in an entity&#8217;s financial statements. Lastly, this ASU
requires public business entities with a single reportable segment to provide all disclosures required by these amendments in this ASU
and all existing segment disclosures in Topic&#160;280. This ASU is effective for fiscal&#160;years beginning after December&#160;15,
2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. The Company has early adopted ASU&#160;2023-07
on July&#160;1, 2023. As a result of adoption, the required disclosures have been included in Note 2 and Note 13.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_840_ecustom--RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock_z7z0wstCtqqk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>aa. <span id="xdx_86F_zUUr7JvI51i1">Recently adopted accounting standard updates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June&#160;2016, the FASB issued ASU&#160;2016-13,
<i>Financial Instruments&#160;&#8212;&#160;Credit Losses</i> (Topic&#160;326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU&#160;2016-13&#8221;).
The new accounting standard introduced the current expected credit losses methodology (&#8220;CECL&#8221;) for estimating allowances for
credit losses. The measurement of expected credit losses under the CECL methodology is applicable to financial assets measured at amortized
costs, including loans and trade receivables. ASU&#160;2016-13 is effective for the Company, as an emerging growth company, for annual
and interim reporting periods beginning after December&#160;15, 2022. The Company adopted the standard on July&#160;1, 2023 using the
modified retrospective method for all financial assets in scope. The adoption of the standard did not have a material impact on the Company&#8217;s
statements of income, or statements of cash flows.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November&#160;2023, the FASB issued ASU&#160;2023-07,
&#8220;Segment Reporting (Topic&#160;280): <i>Improvements to Reportable Segment Disclosures</i>.&#8221; The amendments in this ASU are
intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating decision mark (&#8220;CODM&#8221;),
an amount for other segment items by reportable segment and a description of its composition, all annual disclosures required by FASB
ASU Topic&#160;280 in interim periods as well, and the title and position of the CODM and how the CODM uses the reported measures. Additionally,
this ASU requires that at least one of the reported segment profit and loss measures should be the measure that is most consistent with
the measurement principles used in an entity&#8217;s financial statements. Lastly, this ASU requires public business entities with a single
reportable segment to provide all disclosures required by these amendments in this ASU and all existing segment disclosures in Topic&#160;280.
This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning
after December&#160;15, 2024. The Company has early adopted ASU 2023-07 on July&#160;1, 2023. As a result of adoption, the required disclosures
have been included in Note 2 and Note 14.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging growth company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_841_ecustom--EmergingGrowthCompanyPolicyTextBlock_zX6M59dr8xPl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>ff</i></b>.
<b><i><span id="xdx_86A_zwrHCIubN67h">Emerging growth company</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company intends to operate as an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012
(the &#8220;JOBS Act&#8221;). The JOBS Act permits companies with emerging growth company status to take advantage of an extended transition
period to comply with new or revised accounting standards, delaying the adoption of these accounting standards until such time as those
standards would apply to private companies. The Company elected to use this extended transition period to enable it to comply with new
or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that
it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period
provided in the JOBS Act. As a result, the Company&#8217;s financial statements may not be comparable to companies that comply with the
new or revised accounting standards as of public company effective dates.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84B_ecustom--EmergingGrowthCompanyPolicyTextBlock_zXbI2MERplLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>bb. <span id="xdx_860_zodYVIxzme09">Emerging growth company</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company intends to operate as an &#8220;emerging
growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). The JOBS Act permits
companies with emerging growth company status to take advantage of an extended transition period to comply with new or revised accounting
standards, delaying the adoption of these accounting standards until such time as those standards would apply to private companies. The
Company elected to use this extended transition period to enable it to comply with new or revised accounting standards that have different
effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company
or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company&#8217;s
financial statements may not be comparable to companies that comply with the new or revised accounting standards as of public company
effective dates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently accounting pronouncements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOp72ws5iCAh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>hh.
<span id="xdx_86A_z38IxEch0007">Recently accounting pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
December&#160;2023, the FASB issued ASU&#160;No.&#160;2023-09,&#160;<i>Improvements to Income Tax Disclosures</i>&#160;(&#8220;ASU&#160;2023-09&#8221;),&#160;which
requires entities to make incremental income tax disclosures on an annual basis. The amendments require that public business entities
disclose specific categories in the rate reconciliation and provide additional information for reconciling items meeting a quantitative
threshold. The amendments also require disclosure of income taxes paid to be disaggregated by jurisdiction, and the disclosure of income
tax expense disaggregated by federal, state, and foreign. Amendments are effective for annual periods beginning after December&#160;15,
2025 and thereafter, with early adoption permitted. The Company is evaluating adoption timing and the impact ASU&#160;2023-09&#160;will
have on its financial statements and related disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
March&#160;2024, the FASB issued ASU No. 2024-02, <i>Codification Improvements-Amendments to Remove References to the Concepts Statements</i>
(&#8220;ASU 2024-02&#8221;). The amendments in this Update affect a variety of Topics in the Codification. The amendments apply to all
reporting entities within the scope of the affected accounting guidance. This update contains amendments to the Codification that remove
references to various Concepts Statements. In most instances, the references are extraneous and not required to understand or apply the
guidance. In other instances, references were used in prior statements to provide guidance in certain topical areas. ASU 2024-02 is effective
for public business entities for fiscal years beginning after December&#160;15, 2024. Early adoption is permitted for both interim and
annual financial statements that have not yet been issued or made available for issuance. The adoption did not have a material impact
on the Company&#8217;s financial statement.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
November&#160;2024, the FASB issued ASU 2024-03 &#8220;<i>Income Statement&#8212;Reporting comprehensive (loss) income&#8212;Expense Disaggregation
Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i>&#8221; (&#8220;ASU 2024-03&#8221;). The amendments in this
update intend to improve the disclosures about a public business entity&#8217;s expenses and address requests from investors for more
detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization,
and depletion) in commonly presented expense captions (such as cost of sales, selling, general and administrative expenses, and research
and development). ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods beginning after
December&#160;15, 2027. The Company is currently evaluating the impact from the adoption of this ASU on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
January&#160;2025, the FASB issued Accounting Standards Update (ASU) No. 2025-01, <i>Income Statement &#8212; Reporting comprehensive
(loss) income &#8212; Expense Disaggregation Disclosures</i> (Subtopic 220-40): Clarifying the Effective Date. The amendment clarifies
the effective date of ASU No. 2024-03 that all public business entities are required to adopt the guidance in annual reporting periods
beginning after December&#160;15, 2026, and interim periods within annual reporting periods beginning after December&#160;15, 2027. Early
adoption of Update 2024-03 is permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or
guidance on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
July&#160;2025, the FASB issued Accounting Standards Update (ASU) No. 2025-05, <i>Financial Instruments &#8212; Credit Losses</i> (Topic
326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The amendment provides (1) all entities with a practical
expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the assets and (2) entities
other than public business entities with an accounting policy election to consider collection activity after the balance sheet date when
estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for
under Topic 606. This guidance is effective for annual reporting periods beginning after December&#160;15, 2025 and interim reporting
periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of the above
new accounting pronouncements or guidance on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">In
September&#160;2025, the FASB issued&#160;<i>ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40):
Accounting for and Disclosure of Software Costs&#160;</i>(&#8220;ASU 2025-06&#8221;), which amends certain aspects of the accounting for
and disclosure of internal-use software costs. ASU 2025-06 is effective for annual reporting periods beginning with the year ending December&#160;31,
2028, with early adoption permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or guidance
on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December&#160;2025,
the FASB issued <i>ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements</i>, which clarifies interim disclosure
requirements resulting in a comprehensive list of interim disclosures that are required by GAAP, and includes a disclosure principle
that requires the disclosure of events since the end of the last annual reporting period that have a material impact on the Company.
ASU 2025-11 is effective for the Company&#8217;s interim reporting periods within fiscal years beginning after December 15, 2028, with
early adoption permitted. ASU 2025-11 may be applied either prospectively or retrospectively. The Company is currently evaluating the
impact of the above new accounting pronouncements or guidance on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Except
as mentioned above, the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted,
would have a material effect on the balance sheets, statements of income and comprehensive loss and cash flows.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztzNempdfu57" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>cc. <span id="xdx_86D_z61KGdSvMHp3">Recently accounting pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December&#160;2023, the FASB issued ASU&#160;No.&#160;2023-09,&#160;<i>Improvements
to Income Tax Disclosures</i>&#160;(&#8220;ASU&#160;2023-09&#8221;),&#160;which requires entities to make incremental income tax disclosures
on an annual basis. The amendments require that public business entities disclose specific categories in the rate reconciliation and provide
additional information for reconciling items meeting a quantitative threshold. The amendments also require disclosure of income taxes
paid to be disaggregated by jurisdiction, and the disclosure of income tax expense disaggregated by federal, state, and foreign. ASU&#160;2023-09&#160;is
effective for the Company&#8217;s annual reporting periods ending December&#160;31, 2025 and thereafter, with early adoption permitted.
The Company is evaluating adoption timing and the impact ASU&#160;2023-09&#160;will have on its financial statements and related disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March&#160;2024, the FASB issued ASU No. 2024-02,
<i>Codification Improvements-Amendments to Remove References to the Concepts Statements</i> (&#8220;ASU 2024-02&#8221;). The amendments
in this Update affect a variety of Topics in the Codification. The amendments apply to all reporting entities within the scope of the
affected accounting guidance. This update contains amendments to the Codification that remove references to various Concepts Statements.
In most instances, the references are extraneous and not required to understand or apply the guidance. In other instances, references
were used in prior statements to provide guidance in certain topical areas. ASU 2024-02 is effective for public business entities for
fiscal years beginning after December&#160;15, 2024. For all other entities, the amendments are effective for fiscal years beginning after
December&#160;15, 2025. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or
made available for issuance. The adoption did not have a material impact on the Company&#8217;s financial statement.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November&#160;2024, the FASB issued ASU 2024-03
&#8220;<i>Income Statement&#8212;Reporting comprehensive (loss) income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation
of Income Statement Expenses</i>&#8221; (&#8220;ASU 2024-03&#8221;). The amendments in this update intend to improve the disclosures about
a public business entity&#8217;s expenses and address requests from investors for more detailed information about the types of expenses
(including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions
(such as cost of sales, selling, general and administrative expenses, and research and development). ASU 2024-03 is effective for fiscal
years beginning after December&#160;15, 2026, and interim periods beginning after December&#160;15, 2027. The Company is currently evaluating
the impact from the adoption of this ASU on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January&#160;2025, the FASB issued Accounting Standards
Update (ASU) No. 2025-01, <i>Income Statement &#8212; Reporting comprehensive (loss) income &#8212; Expense Disaggregation Disclosures</i>
(Subtopic 220-40): Clarifying the Effective Date. The amendment clarifies the effective date of ASU No. 2024-03 that all public business
entities are required to adopt the guidance in annual reporting periods beginning after December&#160;15, 2026, and interim periods within
annual reporting periods beginning after December&#160;15, 2027. Early adoption of Update 2024-03 is permitted. The Company is currently
evaluating the impact of the above new accounting pronouncements or guidance on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July&#160;2025, the FASB issued Accounting Standards
Update (ASU) No. 2025-05, <i>Financial Instruments &#8212; Credit Losses</i> (Topic 326): Measurement of Credit Losses for Accounts Receivable
and Contract Assets. The amendment provides (1) all entities with a practical expedient to assume that current conditions as of the balance
sheet date do not change for the remaining life of the assets and (2) entities other than public business entities with an accounting
policy election to consider collection activity after the balance sheet date when estimating expected credit losses for current accounts
receivable and current contract assets arising from transactions accounted for under Topic 606. This guidance is effective for annual
reporting periods beginning after December&#160;15, 2025 and interim reporting periods within those annual reporting periods. Early adoption
is permitted. The Company is currently evaluating the impact of the above new accounting pronouncements or guidance on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except as mentioned above, the Company does not believe
other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the balance sheets,
statements of income and comprehensive loss and cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_CryptoAssets', window );">Crypto assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84A_ecustom--CryptoAssets_zZhlCmsQAIQk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>g.
<span id="xdx_862_zW5hKqqXdcS6">Crypto assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s
crypto assets classified in current assets are held primarily for use in the ordinary course of business which is expected to be actively
utilized or converted within the normal operating cycle and such crypto assets can be sold in a highly liquid marketplace. During the
nine months ended March&#160;31, 2026, the Company only held crypto assets of Tether USD (&#8220;USDT&#8221;) and USDC, which are principally
funded by SAFE investors and as a form of payment for transaction revenue. The Company&#8217;s crypto assets are held with qualified
third-party custodians who provide secure storage and safeguarding of the Company&#8217;s crypto assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><i><span style="text-decoration: underline">USDC</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">USDC
is a stablecoin redeemable on a one-to-one basis for U.S. dollars and is accounted for as a financial instrument in the unaudited condensed
consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><i><span style="text-decoration: underline">Crypto
assets other than USDC</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">On
December&#160;13, 2023, the FASB issued ASU 2023-08, which addresses the accounting and disclosure requirements for certain cryptocurrencies.
The new guidance requires entities to subsequently measure certain cryptocurrencies at fair value, with changes in fair value recorded
in net income in each reporting period. The Company applied the ASU since its holding of crypto assets in December&#160;2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Digital
assets that are received as noncash consideration in our revenue arrangements and paid in purchases of professional service and others
are presented as cash flows from operating activities in other operating activities settled in digital assets and USDC. Digital assets
that are received in our revenue arrangements and sold for cash within seven days are presented as cash flows from operating activities,
while other digital asset activity held longer than seven days is reflected as cash flows from investing activities under disposal of
digital assets and USDC held in the consolidated statements of cash flows. The Company presents crypto assets other than USDC separately
from other intangible assets and USDC, recorded as digital assets on the unaudited condensed consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">For
the three months ended March&#160;31, 2026, the Company recorded receipt and disbursement of digital assets amounted to $<span id="xdx_90E_ecustom--ReceiptOfDigitalAssets_c20260101__20260331_pp0p" title="Receipt of digital assets">644,616</span> and $<span id="xdx_901_ecustom--DisbursementOfDigitalAssets_c20260101__20260331_pp0p" title="Disbursement of digital assets">796,781</span>.&#160;For
the nine months ended March&#160;31, 2026, the Company recorded receipt and disbursement of digital assets amounted to $<span id="xdx_909_ecustom--ReceiptOfDigitalAssets_c20250701__20260331_pp0p" title="Receipt of digital assets">939,397</span> and $<span id="xdx_904_ecustom--DisbursementOfDigitalAssets_c20250701__20260331_pp0p" title="Disbursement of digital assets">939,397</span>,
respectively, which resulted in an ending balance of nil. The Company&#8217;s balances related to digital assets and stablecoins during
the period included USDT and USDC, both of which are USD-pegged stablecoins. <span id="xdx_901_ecustom--FairValueGainOrLossOnDigitalAssets_pp0d_do_c20260101__20260331_zi458qVUCNt1" title="Fair value gain or loss on digital assets"><span id="xdx_905_ecustom--FairValueGainOrLossOnDigitalAssets_pp0d_do_c20250701__20260331_zVXF30cgUVQc" title="Fair value gain or loss on digital assets">No</span></span> fair value gain or loss on digital assets was recognized
for the three and nine months ended March&#160;31, 2026 considering the low volatility in the fair value of USDT during the three and
nine months ended March&#160;31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_DeferredOfferingCostsPolicyTextBlock', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_849_ecustom--DeferredOfferingCostsPolicyTextBlock_zampFPTaHJw6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>i.
<span id="xdx_866_zIRNVy8x1Vb6">Deferred offering costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
Company follows the requirements of FASB ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212; &#8220;Expenses
of Offering&#8221;. Deferred offering costs consist of underwriting, legal, and other professional expenses incurred through the balance
sheet date that are directly related to the intended de-SPAC Transaction. These costs will be charged to shareholders&#8217; equity, netted
against the proceeds, upon the completion of the Business Combination. Should the transaction prove to be unsuccessful, these deferred
costs, as well as additional expenses to be incurred, will be charged to the statements of operations and comprehensive loss. As of June&#160;30,
2025 and March&#160;31, 2026, the Company deferred nil <span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20250630_z5VXiUJdObX8" style="display: none" title="Deferred offering costs">0</span> and $<span id="xdx_90C_eus-gaap--DeferredOfferingCosts_iI_c20260331_zPoYFoMfe149" title="Deferred offering costs">95,000</span> of transaction costs, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_PrepaidResearchAndDevelopmentExpensesPolicyTextBlock', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_845_ecustom--PrepaidResearchAndDevelopmentExpensesPolicyTextBlock_zj47oP2LEO03" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>l.
<span id="xdx_866_zznJ5p0oZj1b">Prepaid research and development expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Prepaid
research and development expenses represent advance payments to third-party service providers for technical, design, and development services.
These amounts are initially recorded as prepaid assets and are subsequently recognized as research and development expenses in the period
the services are rendered, in accordance with the terms of the respective agreements. The Company periodically reviews the status of these
agreements to ensure the prepaid balance properly reflects the value of services not yet received. For the three and nine months ended
March&#160;31, 2026, the Company recognized&#160;$<span id="xdx_907_ecustom--AmortizationOfPrepaidResearchAndDevelopmentCosts_c20260101__20260331_zCXNiflih5bg" title="Amortization of prepaid research and development costs">625,000</span> and $<span id="xdx_90C_ecustom--AmortizationOfPrepaidResearchAndDevelopmentCosts_c20250701__20260331_zBFunA6k8NXc" title="Amortization of prepaid research and development costs">1,875,000</span>, respectively, of expense related to the amortization of prepaid
research and development costs, which was included in research and development expense.</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_OtherReceivablesPolicyRextBlock', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84D_ecustom--OtherReceivablesPolicyRextBlock_zhEjVv3wuafj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>m.
<span id="xdx_86D_zATAJPzQnQpl">Other receivables</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Other
receivables represent funds temporarily held in trust by an employee acting on the Company&#8217;s behalf. As of June&#160;30, 2025
and March&#160;31, 2026, the balance were $<span id="xdx_90D_eus-gaap--OtherReceivables_iI_pp0d_c20250630_za2VXMC6Mpee" title="Other receivables">1,207,626</span>
and <span id="xdx_908_eus-gaap--OtherReceivables_iI_pp0d_c20260331_zA3XBehG7pA7" style="display: none" title="Other receivables">0</span> nil, respectively, with the nil balance as of March 31, 2026 resulting from the employee having repaid all outstanding amounts to the Company. The balance
as of June 30, 2025 was primarily comprising proceeds from SAFEs agreements received via the employee and net of payments made to
designated suppliers at the Company&#8217;s direction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RefundableDepositsPayablePolicyTextBlock', window );">Refundable deposits payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_847_ecustom--RefundableDepositsPayablePolicyTextBlock_zPSaUzzvIgEa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b><i>o.
<span id="xdx_86F_zFO7q56sC1Ja">Refundable deposits payable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Refundable
deposits payable represent security payments received from a third party and customers, which are required for certain intelligent computing
power service arrangements. As of June&#160;30, 2025 and March&#160;31, 2026, the balance were $<span id="xdx_906_ecustom--RefundableDepositsPayable_iI_pp0d_c20250630_zT5OwPspNGaa" title="Refundable deposits payable">1,445,580</span> and $<span id="xdx_907_ecustom--RefundableDepositsPayable_iI_pp0d_c20260331_zlF8FJ2gxvTd" title="Refundable deposits payable">1,174,702</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_AdvanceToSuppliersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_AdvanceToSuppliersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_CapitalStructurePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_CapitalStructurePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ComprehensiveLossPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ComprehensiveLossPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ContractLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ContractLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_CryptoAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_CryptoAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_EmergingGrowthCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_EmergingGrowthCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ExpectedCreditLossAndAccountsReceivablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ExpectedCreditLossAndAccountsReceivablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_FunctionalCurrencyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_FunctionalCurrencyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_OtherReceivablesPolicyRextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_OtherReceivablesPolicyRextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_PrepaidResearchAndDevelopmentExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_PrepaidResearchAndDevelopmentExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_RefundableDepositsPayablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_RefundableDepositsPayablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_RefundableDepositsReceivablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_RefundableDepositsReceivablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_RelatedPartiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_RelatedPartiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_SellingAndMarketingExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_SellingAndMarketingExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_SimpleAgreementsForFutureEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_SimpleAgreementsForFutureEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition for dividend revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) - D. Boral ARC Acquisition I Corp [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of earning per share basic and diluted</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--TemporaryEquityTableTextBlock_zI3yMm7Bm2me" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B8_zvz98VUo83yh" style="display: none">Schedule of ordinary shares subject to redemption</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Class A ordinary shares subject to possible redemption, December 31, 2025</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_c20260101__20260331_zuYUa9ZjRBt2" style="text-align: right">284,776,628</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Plus:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top">Accretion of carrying value to redemption value</td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td>
    <td id="xdx_98D_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20260101__20260331_zjT475ucOqx7" style="border-bottom: Black 1pt solid; width: 9%; text-align: right">2,543,059</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Class A ordinary shares subject to possible redemption, March 31, 2026</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_985_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_c20260101__20260331_zXneNCCbjKKh" style="border-bottom: Black 2.5pt double; text-align: right">287,319,687</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>










<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--TemporaryEquityTableTextBlock_zPcXeTqfm8lb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BD_zLSvphjsOLC3" style="display: none">Schedule of ordinary shares subject to redemption</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Gross proceeds from IPO, August&#160;1,
        2025</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_904_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iS_pp0d_c20250802__20251231_z2o34efAYZBg" title="Ordinary shares subject to possible redemption, beginning">280,000,000</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Less:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Proceeds allocated to Public Warrants</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_ecustom--ProceedsAllocatedToPublicWarrants_pp0d_c20250802__20251231_znh5ksE756X8" title="Proceeds allocated to Public Warrants">(9,028,600</span></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Proceeds allocated to Over-allotment Option</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_ecustom--ProceedsAllocatedToOverallotmentOption_pp0d_c20250802__20251231_zF18AYVY4Fwe" title="Proceeds allocated to Over-allotment Option">(1,290,375</span></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Class A ordinary shares issuance costs</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_ecustom--ClassOrdinarySharesIssuanceCosts_pp0d_c20250802__20251231_zFN36aIn6kRf" title="Class A ordinary shares issuance costs">(3,438,859</span></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Plus:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Accretion of carrying
        value to redemption value</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--TemporaryEquityAccretionToRedemptionValue_pp0d_c20250802__20251231_z1giMb4Fdhpj" title="Ordinary shares subject to possible redemption">18,534,462</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Class A ordinary shares
        subject to possible redemption, December&#160;31, 2025</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iE_pp0d_c20250802__20251231_z92pFQBkwJ85" title="Ordinary shares subject to possible redemption, ending">284,776,628</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of earning per share basic and diluted</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z9nBryRVgBB1" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"><b><i><span id="xdx_8BC_zW0SKWND27gd" style="display: none">&#160;Schedule
    of earning per share basic and diluted</span></i></b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <br/>
Period from <br/>
March&#160;20, 2025
<br/>
(Inception) through <br/>
March&#160;31,<br/>
2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the<br/>
three months ended <br/>
March&#160;31, <br/>
2026</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class A</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class B</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class A</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class B</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerator:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net income per share:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation of (loss)/income &#150; basic and diluted</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zy8q1CRpivSl" title="Allocation of (loss)/income - basic"><span id="xdx_900_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z2LX5LzP7HYe" title="Allocation of (loss)/income - diluted"><span style="-sec-ix-hidden: xdx2ixbrl1475"><span style="-sec-ix-hidden: xdx2ixbrl1477">-</span></span></span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zaYIpma7fKI5" title="Allocation of (loss)/income - basic"><span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zUhkVNCQNGB4" title="Allocation of (loss)/income - diluted">(5,420</span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0iSNiakF4xg" title="Allocation of (loss)/income - basic"><span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zFRQnvemDvP9" title="Allocation of (loss)/income - diluted">2,011,318</span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zTfMrVC9Nq08" title="Allocation of (loss)/income - basic"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwCyQpQUqFfg" title="Allocation of (loss)/income - diluted">2,011,318</span></span></span></td>
    <td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominator:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted weighted average share of ordinary shares:</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zaCBbKkxOUll" title="Weighted average shares of Class A ordinary shares outstanding, basic"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zBiG6LXmLI06" title="Weighted average shares of Class A ordinary shares outstanding, diluted"><span style="-sec-ix-hidden: xdx2ixbrl1491"><span style="-sec-ix-hidden: xdx2ixbrl1493">-</span></span></span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zwozb4274lpk" title="Weighted average shares of Class B ordinary shares outstanding, basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z4aO9n9RdMz2" title="Weighted average shares of Class B ordinary shares outstanding, diluted">10,714,286</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zngzHuVdEMLb" title="Weighted average shares of Class A ordinary shares outstanding, basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z4D9HtOcAKq" title="Weighted average shares of Class A ordinary shares outstanding, diluted">29,200,000</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMgqLWjjG1Ug" title="Weighted average shares of Class B ordinary shares outstanding, basic"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zMDCWHjrReMl" title="Weighted average shares of Class B ordinary shares outstanding, diluted">12,000,000</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net income per share</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z38VIFVXOnne" title="Class A ordinary shares - basic net income per share"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zzqpPBahwyhi" title="Class A ordinary shares - diluted net income per share">0.00</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z0i8nL2oW9si" title="Class B ordinary shares - basic net income per share"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20250320__20250331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z3ekJQDEjG8d" title="Class B ordinary shares - diluted net income per share">0.00</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zEF9ZlGITAD2" title="Class A ordinary shares - basic net income per share"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zA6RCCMfP971" title="Class A ordinary shares - diluted net income per share">0.07</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zIcku8QW2zV5" title="Class B ordinary shares - basic net income per share"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zBzYlBzAMw96" title="Class B ordinary shares - diluted net income per share">0.17</span></span></span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zK6g7uklULf4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left"><i><span id="xdx_8BF_zaGSXzmsgspk" style="display: none">Schedule
    of earning per share basic and diluted</span></i></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/>Period from <br/>March&#160;20,
        2025<br/>(Inception) through <br/>December&#160;31, <br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Class A</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Class B</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left">Numerator:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Basic and diluted net income
        per share:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold; text-align: left">Allocation
        of income &#8211; basic and diluted</td>
    <td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z3sCrZfmImf8" title="Allocation of income - basic"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zOP8f6mC3Gdc" title="Allocation of income - diluted">2,509,890</span></span></td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td>
    <td style="width: 9%; font-weight: bold; text-align: right"><span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z2qJnxTMSxqk"><span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_ziM4aHJWJMT8" title="Allocation of income - diluted">1,946,080</span></span></td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Basic and diluted weighted
        average share of ordinary shares:</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zLS14Lz9LzJi" title="Basic weighted average share of ordinary shares"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_z7DNrJH4OfBj" title="Diluted weighted average share of ordinary shares">15,393,007</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zZ1AoE0JuY4c" title="Basic weighted average share of ordinary shares"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_z5EwpZeeFiAi" title="Diluted weighted average share of ordinary shares">11,935,190</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Basic and diluted net income
        per share</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td>
    <td style="font-weight: bold; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zWEL5OqBJofa" title="Basic net income per share"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassAMember_zT2ajwWAS9G6" title="Diluted net income per share">0.16</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td>
    <td style="font-weight: bold; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zjBGNV05rIv" title="Basic net income per share"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20250320__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesClassBMember_zAOQ6qINRSph" title="Diluted net income per share">0.16</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of fair value assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zn8oEnihuBh3" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B4_zvKnFHZJudo8" style="display: none">Schedule of fair value assets and liabilities</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>March&#160;31,<br/>
    2026</b></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Asset:</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Cash held in trust</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center">1</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zC6ecbqmxuZ2" style="width: 9%; text-align: right">284,776,628</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2BhS1HcIrvl" style="text-align: right; width: 9%">287,319,687</td>
    <td style="width: 1%">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zl5uLowJiXVi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8B6_zXfmlkhV9ysd" style="display: none">Schedule of fair value assets and liabilities</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">August&#160;1, <br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Liability:</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">Fair value of over-allotment liability</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center">3</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20250801__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAcSNoM2bO7g" style="width: 9%; text-align: right" title="Liability">1,290,375</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Equity:</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Fair value of Public Warrants for Class A
        ordinary shares subject to possible redemption allocation</td>
    <td>&#160;</td>
    <td style="text-align: center">3</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_986_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20250801__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSFisT03zLO" style="text-align: right" title="Equity">8,061,250</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
        <br/>2025</b></span></p></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Asset:</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Cash held in trust</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center">1</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zfsfJbWiQ3Yl" style="width: 9%; text-align: right" title="Assets">284,776,628</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of initial measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zGeBHNQlGzMa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B7_zoaVPMUgkntk" style="display: none">Schedule of initial measurement</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">August&#160;1, <br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Risk-free interest rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250729__20250801_zykgUgOp2FO7" title="Risk-free interest rate">4.31</span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expected term (years)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250729__20250801_zNNkudmOAsxi" title="Expected terms (years)">0.12</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expected volatility</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250729__20250801_zYdfJmo8Jv1" title="Expected volatility">22.7</span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Exercise price</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20250801_zsPlpHwwdwY4" title="Exercise price">10.00</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Fair value of over-allotment option</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90F_ecustom--FairValueOfOverallotmentOption_iI_c20250801_zvdduBXteOCb" title="Fair value of over-allotment option">0.3441</span></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Schedule of market assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_znIXiw709dNi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BE_zsvTOTvZXEk3" style="display: none">Schedule of market assumptions</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">August&#160;1, <br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Estimated share price</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--SharePrice_c20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_pd" title="Estimated share price">9.68</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Exercise price</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_pd" title="Exercise Price">11.50</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Term (years)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zdgGz9zVX1q2" title="Term (years)">2.75</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Annual risk-free rate (term-matched)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zDaikQy4IZnb" title="Annual risk-free rate (term-matched)">3.75</span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expected warrant implied volatility based
        on warrants from comparable SPAC securities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250729__20250801__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zDGNenuK2YQ2" title="Expected warrant implied volatility based on warrants from comparable SPAC securities">14.44</span></td>
    <td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z8FE3uJgARte" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8BC_zLnzHUlq4rs8" style="display: none">Schedule of segment information</span></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_499_20260101__20260331_zAqMewnjj797" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>For the<br/>
Three Months Ended<br/> March&#160;31,<br/>
2026</b></p></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpenses_iNT_di_zLbGcDlF4Xxk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left">Formation and operating costs</td>
    <td style="padding-bottom: 2.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right">(531,741</td>
    <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--InterestIncomeOther_zZ0f6IcMo791" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 2.5pt">Interest income on cash held in trust account</td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right">2,543,059</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--CashHeldInTrustAccounts_zt3sLmGGM7pf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Cash held in Trust Account</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">287,319,687</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zV8K2gwOpH16" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span id="xdx_8BC_zWWW3w6SRnKb" style="display: none">Schedule of segment information</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/> Period from <br/>March&#160;20,
        2025<br/>(inception) through<br/>December&#160;31,<br/>2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 2.5pt">Formation
        and operating costs</td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; width: 9%; text-align: right"><span id="xdx_902_eus-gaap--OperatingExpenses_iNT_pp0d_di_c20250320__20251231_zktdSzpr5NMa" title="Formation and operating costs">(320,658</span></td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Interest income on
        cash held in trust account</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--InterestIncomeOther_c20250320__20251231_pp0p" title="Interest income on cash held in trust account">4,776,628</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Cash held in Trust
        Account</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--CashHeldInTrustAccounts_c20250320__20251231_pp0p" title="Cash held in Trust Account">284,776,628</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of fair value assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_znXIjy2B1Unc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B3_zmXrZbsyeyG7" style="display: none; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Schedule of fair value assets and liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>Fair value measurement
        at reporting date using</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid"><b>Description</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Fair value <br/>as of<br/>June&#160;30,<br/>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Quoted Prices in<br/>Active
        Markets for<br/>Identical Assets <br/>(Level 1)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Significant Other<br/>Observable
        Inputs <br/>(Level 2)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Significant <br/>Unobservable
        Inputs <br/>(Level 3)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Liabilities:</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Simple
        agreements for future equity<sup>(1)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zdI2HsL9LKmf" title="Liability">18,243,885</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_z1nxmlaF6O8" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3572">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zmfS5uxBUmhg" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3574">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zHPcFlOlK9Vi" title="Liability">18,243,885</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Other payable
        related to the equity option<sup>(2)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zShE7VowVnA1" title="Liability">53,333</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_z5tNnS5uRuuj" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3580">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zzBB0KU0oEw4" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3582">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zkq0aEofGkY2" title="Liability">53,333</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>Fair value measurement
        at reporting date using</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid"><b>Description</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Fair value <br/>as of<br/>March&#160;31,
        <br/>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Quoted Prices in<br/>Active
        Markets for<br/>Identical Assets <br/>(Level 1)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Significant Other<br/>Observable
        Inputs <br/>(Level 2)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Significant <br/>Unobservable
        Inputs <br/>(Level 3)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Liabilities:</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%">&#160;</td>
    <td style="text-align: left; white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%">&#160;</td>
    <td style="text-align: left; white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%">&#160;</td>
    <td style="text-align: left; white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%">&#160;</td>
    <td style="text-align: left; white-space: nowrap; width: 1%">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Simple
        agreements for future equity<sup>(1)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zuhbr7cQGsg7" title="Liability">26,842,205</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zkBbNkVaZqr1" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3591">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_z9y0FcYieMIb" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3593">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zc1rFDya6DW8" title="Liability">26,842,205</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Other payable
        related to the equity option<sup>(2)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zvtu6XUHzxw3" title="Liability">53,333</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zmtSvpn5Ftt7" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3599">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zQh5SQC30bZf" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3601">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zbm43rdQGMmd" title="Liability">53,333</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span id="xdx_F0A_zChGi8tau4Y2">(1)</span></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span id="xdx_F10_zFPLD0zjBMIf">The
        Company classifies its SAFEs as financial liabilities measured at fair value. The value of these agreements depends significantly on future
        financing activities, liquidity events, or other material milestones, and their valuation relies on significant inputs that are not observable
        in the public market. Accordingly, they are classified within Level 3 of the fair value hierarchy.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
        fair value measurement is based on an integrated framework combining&#160;scenario analysis and financial instrument decomposition (i.e.
        Bond Plus Call Method). The proceeds of the SAFEs on the date of issuance were $14,092,500, Refer to Note 8-Simple Agreements for Future
        Equity for further details.</p> </td> </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; color: #0F1115"><span id="xdx_F00_zI5V4PyahiJg">(2)</span></td>
    <td style="text-align: justify"><span id="xdx_F13_z2JSmT6vIOn7">Equity options. On May&#160;9, 2023, the Company entered into an agreement
        with a third-party service provider (the &#8220;Service Provider&#8221;). The Service Provider received a freestanding equity-linked right
        exercisable, at the Service Provider&#8217;s option, upon the closing of the Company&#8217;s next qualified equity financing. The right
        provides the ability to subscribe for up to the value of $200,000 at a 25% discount price per share on the grant date. The equity option
        is remeasured at fair value at each reporting date, with changes in fair value recognized in earnings. As of June&#160;30, 2025 and March&#160;31,
        2026, the fair value of the equity option was $53,333, and no gain or loss from changes in fair value was recognized for the periods presented.
        The fair value measurement of the equity option is categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based
        analysis, which incorporates significant unobservable inputs and management judgment regarding the probability and timing of potential
        future financing outcomes.</span></td> </tr>
  </table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zaDKp93MBRA3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BC_zDd0pvvQ169b" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Schedule of fair value assets and liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measurement at reporting date using</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Description</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value <br/>as of<br/>June&#160;30,<br/>2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted Prices in<br/>Active Markets for<br/>Identical
        Assets <br/>(Level 1)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other<br/>Observable Inputs <br/>(Level
        2)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant <br/>Unobservable Inputs <br/>(Level
        3)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left">Simple agreements for future equity<sup>(1)</sup></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zZ4Gbth8BH69" title="Liability">9,321,564</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zjkwY6IR5PDj" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2301">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zZGm8phKzm75" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2303">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zwGllHMiXKtd" title="Liability">9,321,564</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other payable related to the equity option<sup>(2)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zAoKTZ3VLxo3" title="Liability">53,333</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zoB0jQpIEfc6" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2309">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_z30wtD4xs1Jf" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2311">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zwMRf4C7bDM6" title="Liability">53,333</span></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measurement at reporting date using</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Description</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Fair value <br/>as of<br/>June&#160;30,</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2025</b></p></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted Prices in<br/>Active Markets for<br/>Identical
        Assets <br/>(Level 1)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other<br/>Observable Inputs <br/>(Level
        2)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant <br/>Unobservable Inputs <br/>(Level
        3)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left">Simple agreements for future equity<sup>(1)</sup></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zLQGMKOLzu9g" title="Liability">18,243,885</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zrVTS8w1XDWd" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2317">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zaXQfj4FsIb" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2319">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zchHueBxrDm8" title="Liability">18,243,885</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other payable related to the equity option<sup>(2)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zqgBO7cAGUw8" title="Liability">53,333</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zy2IwQHN8iz8" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2325">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zzWPmd3ZrEEg" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2327">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zaU0cwEh6R2h" title="Liability">53,333</span></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td id="xdx_F02_zz6sJxvOrWkk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left">(1)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
        <p id="xdx_F12_z2I6TVTCss33" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company classifies its SAFEs as financial liabilities
        measured at fair value. The value of the agreements depends significantly on future financing activities, liquidity events, or other material
        milestones, and their valuation relies on significant inputs that are not observable in the public market. Accordingly, they are classified
        within Level 3 of the fair value hierarchy.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value measurement is based on an integrated
        framework combining&#160;scenario analysis and financial instrument decomposition (i.e. Bond Plus Call Method). The proceeds from the
        SAFEs on the date of issuance was $10,592,500, Refer to Note 9-Simple Agreements for Future Equity for further details.</p> </td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span id="xdx_F06_zXSVw5NzMGUg" style="color: #0F1115; color: #0F1115">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span id="xdx_F1A_z1nxpK5jT4mb" style="color: #0F1115; color: #0F1115">Equity
        option. On May&#160;9, 2023, the Company entered into an agreement with a third-party service provider (the &#8220;Service Provider&#8221;).
        The Service Provider received a freestanding equity-linked right exercisable, at the Service Provider&#8217;s option, upon the closing
        of the Company&#8217;s next qualified equity financing. The right provides the ability to subscribe for up to the value of $200,000 at
        a 25% discount price per share on the grant date. The equity option is remeasured at fair value at each reporting date, with changes in
        fair value recognized in earnings. As of June&#160;30, 2024 and June&#160;30, 2025, the fair value of the equity option was $53,333, and
        no gain or loss from changes in fair value was recognized for the periods presented. The fair value measurement of the equity option is
        categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based analysis, which incorporates significant
        unobservable inputs and management judgment regarding the probability and timing of potential future financing outcomes.</span></td> </tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment information</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zdn75OK0oi0h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B8_zPb6QMuV4209" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of segment information</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_495_20250101__20250331_zb2RdiMZ4mJg" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_496_20260101__20260331_zSm0FoNHA26" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_495_20240701__20250331_zyMTxSXq4PM5" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_491_20250701__20260331_zadqFxbEPU4i" style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td> </tr>
  <tr id="xdx_401_eus-gaap--Revenues_zI3a3deH3fwf" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenues</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">1,862,158</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">3,754,586</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">4,475,885</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">10,561,331</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_407_eus-gaap--CostOfRevenue_pp0d_zMTLZ9zSLNl4" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Cost
        of revenues</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(1,649,077</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(3,167,659</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(3,827,444</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(8,902,966</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr id="xdx_40C_eus-gaap--GrossProfit_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Gross
        profit</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>213,081</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>586,927</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>648,441</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>1,658,365</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_iN_pp0d_di_zn8IOfQoWaoe" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Research
        and development expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(377,999</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,235,476</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(2,115,853</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(3,238,185</td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_408_eus-gaap--SellingAndMarketingExpenseAbstract_iB_zVd2FY3RkMFc" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Selling
        and marketing expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_407_ecustom--StaffCostsEmployeeBenefitsAndOfficeExpenses_i_pp0p" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#8211;
        Staff costs, employee benefits and office expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(277,511</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(104,729</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(573,648</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(310,582</td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_407_ecustom--ShareBasedCompensations_zJ7xD2oOp4Ui" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#8211;
        Share-based compensation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(101,000</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3876">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(153,266</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3878">-</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">General
        and administrative expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_40A_ecustom--StaffCostsEmployeeBenefitsAndOthers_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#8211;
        Staff costs, employee benefits and Others</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(3,890</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(360,657</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(33,785</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(563,641</td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_40B_eus-gaap--ProfessionalAndContractServicesExpense_iN_di_z78VitJx7Eo3" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">&#8211;
        Professional service expenses</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(99,217</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(108,039</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(234,374</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(364,614</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Loss
        from operations</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(646,536</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(1,221,974</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(2,462,485</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>(2,818,657</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"><b>)</b></td> </tr>
  <tr id="xdx_40D_ecustom--ChangeInFairValueOfSimpleAgreementsForFutureEquity_iN_di_z4jz79hEVis9" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Change
        in fair value of simple agreements for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(890,523</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,410,457</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(3,716,052</td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(5,098,320</td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Income
        tax expenses</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3905">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3906">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3907">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3908">-</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_400_eus-gaap--ProfitLoss_zq0n3eRYdw7k" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Net
        loss</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(1,537,059</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(2,632,431</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(6,178,537</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>(7,916,977</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td> </tr>
  </table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zaZ6gYRQMRih" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B7_z0szaN7zwBSj" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b>Schedule
    of segment information</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_490_20230701__20240630_zry6rmEzVCB1" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_49D_20240701__20250630_zCZ2bAgyHGX5" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the<br/> years ended</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Revenues_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Revenues</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">1,319,115</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">7,015,512</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CostOfRevenue_zNi1liCsOXci" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cost of revenues</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,263,548</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(5,910,315</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_iN_di_zkj1o72qnmk8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Research and development expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,365,433</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(2,797,906</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--SellingAndMarketingExpenseAbstract_i01B_pp0d_zxMJN07A1pXg" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Selling and marketing expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--StaffCostsEmployeeBenefitsAndOfficeExpenses_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#8211; Staff costs, employee benefits and
        office expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(262,614</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(835,889</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--ShareBasedCompensations_i01_pp0d_z9QrXvmlrCpc" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#8211; Share-based compensation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2606">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(153,266</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--SellingGeneralAndAdministrativeExpenseAbstract_i01B_pp0d_zDwHZaCWa85" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">General and administrative expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StaffCostsEmployeeBenefitsAndOthers_i01_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#8211; Staff costs, employee benefits and
        Others</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(244,651</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(328,662</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--ProfessionalAndContractServicesExpense_i01N_di_zh2ZOZkpFGtk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#8211; Professional service expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(7,594</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(34,320</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--ShareBasedCompensation1_i01N_pp0d_di_zzVfAlQURxe7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#8211; Share-based compensation</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(21,104</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2619">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_i01_pp0d_z65lbRpLFMOh" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Loss
        from operations</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,845,829</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,044,846</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--ChangeInFairValueOfSimpleAgreementsForFutureEquity_i01N_di_zLicrVyEo7og" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Change in fair value
        of simple agreements for future equity</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(3,110,518</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(4,614,821</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeLossBeforeReclassificationsTax_i01_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Loss
        before income tax expenses</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(4,956,347</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(7,659,667</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Income tax expense</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2630">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2631">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProfitLoss_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Net
        loss</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(4,956,347</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(7,659,667</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of geographic information</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zIPxDBsoGFvj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details 1)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B4_z6QXFE6MCFp1" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of geographic information</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">United
        States of America</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90A_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total">581,009</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total">1,564,836</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total">1,273,279</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_901_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--US_pp0p" title="Total">4,560,992</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Canada</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total">367,107</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total">1,139,055</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total">1,089,559</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total">3,232,326</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Singapore</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total">662,559</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total">425,009</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total">1,361,844</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total">1,237,464</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Hong Kong</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total">150,000</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total">417,992</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total">450,000</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total">1,118,534</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">United
        Kingdom</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total">98,483</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total">207,694</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total">291,203</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total">412,015</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Others</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--Revenues_c20250101__20250331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total">3,000</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--Revenues_c20260101__20260331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl3959">-</span></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--Revenues_c20240701__20250331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total">10,000</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--Revenues_c20250701__20260331__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl3963">-</span></span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_908_eus-gaap--Revenues_pp0d_c20250101__20250331_zUms2zS7QOY6" title="Total">1,862,158</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_907_eus-gaap--Revenues_pp0d_c20260101__20260331_z3I7DIpNDZGg" title="Total">3,754,586</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_908_eus-gaap--Revenues_pp0d_c20240701__20250331_zsHyuymBBcp8" title="Total">4,475,885</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_906_eus-gaap--Revenues_pp0d_c20250701__20260331_zWKBKmLtNdw2" title="Total">10,561,331</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zxaRjvXJPaOg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment information (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BE_zWpnQqztGuFi" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Schedule of geographic information</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <br/>years ended <br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Singapore</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total">260,941</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--SG_pp0p" title="Total">2,484,905</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">United States of America</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--US_pp0p" title="Total">169,600</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--US_pp0p" title="Total">2,085,579</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Canada</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total">574,664</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--CA_pp0p" title="Total">1,443,306</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Hong Kong</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total">157,500</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--HK_pp0p" title="Total">600,000</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">United Kingdom</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total">145,410</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__country--GB_pp0p" title="Total">391,722</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Others</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--Revenues_c20230701__20240630__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total">11,000</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--Revenues_c20240701__20250630__srt--StatementGeographicalAxis__custom--OthersMember_pp0p" title="Total">10,000</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90E_eus-gaap--Revenues_pp0d_c20230701__20240630_zoK7sngi7uI1" title="Total">1,319,115</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90F_eus-gaap--Revenues_pp0d_c20240701__20250630_zJvmNbPZ8VZg" title="Total">7,015,512</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Tables) - Exascale Labs Inc. [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ScheduleOfRevenueRecognitionTableTextBlock', window );">Schedule of Revenue recognition</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zd2TxFvdYVol" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8BE_zsDAbjhGLAp7" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of Revenue recognition</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Reserved
        capacity arrangements</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90A_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues">1,758,921</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_908_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues">3,725,315</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues">4,161,985</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues">10,428,983</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">On-demand
        arrangements</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues">5,436</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues">1,341</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues">6,482</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues">12,526</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_905_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues">1,764,357</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_903_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues">3,726,656</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_900_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues">4,168,467</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_90E_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues">10,441,509</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfRevenueRecognitionTableTextBlock_zRG8fPT8BVR9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BF_zPudrh40sc0l" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Schedule of Revenue recognition</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/> years ended<br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Reserved capacity arrangements</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues">1,193,982</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--ReservedCapacityArrangementsMember_pp0p" title="Revenues">6,501,569</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">On-demand arrangements</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl2098">-</span></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember__us-gaap--TransactionTypeAxis__custom--OnDemandArrangementsMember_pp0p" title="Revenues">44,680</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_900_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues">1,193,982</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90E_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_pp0p" title="Revenues">6,546,249</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue disaggregated</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_z4whYoH0Yw36" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B8_z323FGsdNtth" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of Revenue disaggregated</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenue
        from intelligent computing power service</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z29WimMIRYO5" title="Total">1,764,357</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--Revenues_pp0d_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z0wPR3mOXwde" title="Total">3,726,656</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_904_eus-gaap--Revenues_pp0d_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zzqz7UuAay4i" title="Total">4,168,467</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--Revenues_pp0d_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zh7mCphOG5Ja" title="Total">10,441,509</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Revenue
        from comprehensive data center service</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--Revenues_c20250101__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total">97,801</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--Revenues_c20260101__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total">27,930</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20240701__20250331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total">307,418</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20250701__20260331__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total">119,822</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_90B_eus-gaap--Revenues_pp0d_c20250101__20250331_zwjWXHIVxdh" title="Total">1,862,158</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_90D_eus-gaap--Revenues_pp0d_c20260101__20260331_zNTOV4dIJ4Sh" title="Total">3,754,586</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_903_eus-gaap--Revenues_pp0d_c20240701__20250331_zNWqBnz3BD5a" title="Total">4,475,885</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_906_eus-gaap--Revenues_pp0d_c20250701__20260331_zdRfOMzRsXv6" title="Total">10,561,331</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zC7KRbYjMXPd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BF_zOrqnCzeKVC3" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Schedule of Revenue disaggregated</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/>years ended<br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Revenue from intelligent computing
        power service</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_zLe37nj4DRT9" title="Total">1,193,982</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_907_eus-gaap--Revenues_pp0d_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromIntelligentComputingPowerServiceMember_z5LhznXQI8B2" title="Total">6,546,249</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Revenue from comprehensive
        data center services</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--Revenues_c20230701__20240630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total">125,133</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--Revenues_c20240701__20250630__srt--ProductOrServiceAxis__custom--RevenueFromComprehensiveDataCenterServicesMember_pp0p" title="Total">469,263</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90F_eus-gaap--Revenues_pp0d_c20230701__20240630_zw4xoiRMPQs7" title="Total">1,319,115</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90A_eus-gaap--Revenues_pp0d_c20240701__20250630_zxIqgXFsjdA6" title="Total">7,015,512</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ScheduleOfRevenueRecognitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ScheduleOfRevenueRecognitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration and risk (Tables) - Exascale Labs Inc. [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ScheduleOfConcentrationOfCustomersTableTextBlock', window );">Schedule of Concentration of customers</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfConcentrationOfCustomersTableTextBlock_zdrUY4cApChh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8BB_zF0IjA1n3Cgf" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of Concentration of customers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zxlgA7Wnag01" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3426">-</span></span>**</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zqH7DAOCXZV8" title="Concentration of credit risk">24.9</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_z4iANF7QCG72" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3430">-</span></span>**</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_z5ok8h33NPNk" title="Concentration of credit risk">24.6</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zl0hTdibTWy2" title="Concentration of credit risk">11.7</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zr78XgBdGFo5" title="Concentration of credit risk">11.8</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zEivBBjP6d54" title="Concentration of credit risk">10.0</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zJU8ZQcVPnQ2" title="Concentration of credit risk">22.3</span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        C</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zFn7N05enlt1" title="Concentration of credit risk">13.7</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zh9iXLwhZpMf" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3444">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_ziHKyapdTwK3" title="Concentration of credit risk">17.0</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zjeLxYJlsrI1" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3448">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        D</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_z796I4O4Ft1f" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3450">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zRbhCM2LF7S5" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3452">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zgDdNqfgOq26" title="Concentration of credit risk">10.2</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zwowQSBgSD2k" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3456">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        E</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zN6m8I45z7m6" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3458">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z7iN0ziOqvYg" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3460">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zyjXbig4uFfc" title="Concentration of credit risk">10.1</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z34E1WctisKk" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3464">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        F</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zKgQ6gkcige5" title="Concentration of credit risk">15.6</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zWsV8sKzzwa8" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3468">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zB7onhtTK1u9" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3470">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zxDehDpeHJYc" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl3472">-</span></span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfConcentrationOfCustomersTableTextBlock_zed2bAfuUphh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B4_z48bm01L1Eva" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Schedule of Concentration of customers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/> years ended<br/> June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Customer A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zI3jDRHvmOHb" title="Concentration of credit risk">12.0</span></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zCJR511w04rj" title="Concentration of credit risk">14.0</span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zJeeMwjQDM02" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2217">-</span></span>*</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_z2sWdo9WBpLi" title="Concentration of credit risk">12.5</span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer C</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zvX47L5fSCGl" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2221">-</span></span>*</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_z7lIZvAGakw4" title="Concentration of credit risk">10.2</span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer D</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_ziuVreXhY8Jc" title="Concentration of credit risk">31.6</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zsJSn6PWGOta" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2227">-</span></span>**</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer E</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zdcO0AkLU83b" title="Concentration of credit risk">11.9</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zapiuLRQgfx9" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2231">-</span></span>**</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer F</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zXQQtM1R6mP3" title="Concentration of credit risk">11.0</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zkn4huYfaA16" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2235">-</span></span>**</td>
    <td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ScheduleOfAccountsReceivableTextBlock', window );">Schedule of account receivable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfAccountsReceivableTextBlock_zssuHJd4Ga7j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 1)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B7_zUHNVQLGGhr4" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of account receivable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>As of<br/>June&#160;30,</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>As of<br/>March&#160;31,</b></td>
    <td>&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zZDJYmdTS6e7" style="color: rgb(204,238,255)" title="Concentration of credit risk">-</span>**</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zA8eCEY2tIWj" title="Concentration of credit risk">29.7</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zBKTwHAkynJb" style="color: White" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zK6G4BVNOl4d" title="Concentration of credit risk">19.5</span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        E</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_ztBmu7lekrwl" style="color: rgb(204,238,255)" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_z4Qc91H8QUS6" title="Concentration of credit risk">10.5</span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        G</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zL35tipxfmbl" title="Concentration of credit risk">42.7</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zqXdvkL42fyj" style="color: White" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        H</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_z8f6t0ucYWmb" title="Concentration of credit risk">38.3</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zMd1APLqZ6f8" style="color: rgb(204,238,255)" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Customer
        I</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zVQSNFcXuZY3" title="Concentration of credit risk">19.0</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zHUH7nofxl86" style="color: White" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfAccountsReceivableTextBlock_zul5l5RzGYv6" style="font: 10pt Times New Roman, Times, Serif;border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BD_zHRJbQ5m4O88" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Schedule of account receivable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of<br/> June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Customer G</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_ztRPBtEWTJi8" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2244">-</span></span>*</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerGMember_zfLH42HKXt76" title="Concentration of credit risk">42.7</span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer H</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zNKBHqTWkrn4" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2248">-</span></span>*</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerHMember_zEKpxvmQvgCh" title="Concentration of credit risk">38.3</span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer F</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zGqVCvs69Qf1" title="Concentration of credit risk">23.4</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFMember_zC5KwJCVT3zf" title="Concentration of credit risk">19.0</span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer D</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_znrResZohiG9" title="Concentration of credit risk">43.5</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_z6V3t8cHkLUj" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2258">-</span></span>**</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Customer I</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerIMember_zYzaLovelHqg" title="Concentration of credit risk">15.3</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span></span>**</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left">*:</td>
    <td style="text-align: justify">nil, new customer for as of June&#160;30, 2025</td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ScheduleOfConcentrationOfSuppliersTableTextBlock', window );">Schedule of Concentration of suppliers</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfConcentrationOfSuppliersTableTextBlock_z3CdJRz1h27f" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 2)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8BE_zyVdblECd42c" style="display: none; padding-bottom: 0.5pt">Schedule of Concentration of suppliers</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td></tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zZfZ870bnb8a" style="color: rgb(204,238,255)" title="Concentration of credit risk">-</span>*</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zfZK2HfIukSg" title="Concentration of credit risk">13.0</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_fKg_____zoMyxzTZqNtf" style="color: rgb(204,238,255)" title="Concentration of credit risk">-</span>*</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zuAu6Jniu74e" title="Concentration of credit risk">26.4</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_z1RvSNaoV0gg" title="Concentration of credit risk">14.4</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zmAjaL9pPKIb" title="Concentration of credit risk">30.2</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zu3OB7u7IVK3" title="Concentration of credit risk">21.1</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zubilSVoZOol" title="Concentration of credit risk">24.9</span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        C</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zlOyPiZv8SE3" title="Concentration of credit risk">32.9</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zmj4eUM2HHn1" title="Concentration of credit risk">33.7</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zqiSFV5na4Ac" title="Concentration of credit risk">24.0</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zougKUG4D7eh" title="Concentration of credit risk">24.2</span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        D</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_z39sRFJ0NCt8" style="color: White" title="Concentration of credit risk">-</span>*</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zMuGucfinjtf" title="Concentration of credit risk">13.8</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zGlfi03BgXDb" style="color: White" title="Concentration of credit risk">-</span>*</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zZ6OSrj6FVIa" title="Concentration of credit risk">11.5</span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        E</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zJ08L3iZ3sFe" title="Concentration of credit risk">45.5</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp0_c20260101__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zrqGEIvYjMWe" style="color: rgb(204,238,255)" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zHbQGldke1jg" title="Concentration of credit risk">47.6</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zd2hl76uQNH" style="color: rgb(204,238,255)" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">*:</td>
    <td style="text-align: justify">nil, new supplier for the nine months ended March&#160;31, 2026</td>
        </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfConcentrationOfSuppliersTableTextBlock_zdj4W8YCipk8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B7_zFinAf9oIFQc" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Schedule of Concentration of suppliers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/> years ended<br/> June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Supplier A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__srt--MajorCustomersAxis__custom--SupplierAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGIyJJPBbOil" title="Concentration of credit risk">56.6</span></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zXZaKxf02Dlh" title="Concentration of credit risk">41.4</span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplier B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zgOzrD5jGv2g" title="Concentration of credit risk">14.6</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_z26lViCdPaY" title="Concentration of credit risk">31.7</span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplier C</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zo7uj5B50TF2" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2272">-</span></span>**</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_z9dWnq9LW8u3" title="Concentration of credit risk">18.4</span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplier D</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zG0uIze1Y1Ua" title="Concentration of credit risk">12.8</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchaseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zPqI0xfZVU09" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2278">-</span></span>**</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of account payable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zRgvFNJVonif" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 3)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B1_z1KfkhgkdJa9" style="display: none">Schedule of account payable</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>As of<br/>June&#160;30,</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>As of<br/>March&#160;31,</b></td>
    <td>&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        B</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90D_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zoy1O16r6pC2" title="Concentration of credit risk">12.1</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90E_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zT52WewH3gKf" title="Concentration of credit risk">74.0</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        D</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_ecustom--ConcentrationRiskPercentage_dp0_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_z49d3JRTVlqf" style="color: White" title="Concentration of credit risk">-</span>*</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierDMember_zH861vcBqWw8" title="Concentration of credit risk">12.6</span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        E</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_ecustom--ConcentrationRiskPercentage_dp0_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zbDTqTB9gdUl" style="color: rgb(204,238,255)" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_ecustom--ConcentrationRiskPercentage_dp_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zowygHhsFI98" title="Concentration of credit risk">13.4</span></td>
    <td style="text-align: left; white-space: nowrap">%</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        F</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_z9tjQJ8njxna" title="Concentration of credit risk">54.9</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_ecustom--ConcentrationRiskPercentage_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_z0EDwEhAYvj3" style="color: White" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Supplier
        G</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--SupplierGMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbgS1YdQk6w3" title="Concentration of credit risk">32.3</span></td>
    <td style="text-align: left; white-space: nowrap">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_ecustom--ConcentrationRiskPercentage_dp0_c20250701__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierGMember_zx8Qj3Ar38J3" style="color: rgb(204,238,255)" title="Concentration of credit risk">-</span>**</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">*:</td>
    <td style="text-align: justify">nil, new supplier for the nine months ended March&#160;31, 2026</td>
        </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">**:</td>
    <td style="text-align: justify">less than 10%</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zUoSMF44CI8f" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentration and risk (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BC_zrFgXmZyLEDl" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Schedule of account payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of<br/> June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Supplier E</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90E_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_zD1SOuo8O6Gl" style="color: rgb(204,238,255)" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2282">-</span></span>*</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_909_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierEMember_znsgNbuG5cH8" title="Concentration of credit risk">54.9</span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplier F</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_zdOC7T9Z4elg" style="color: White" title="Concentration of credit risk"><span style="-sec-ix-hidden: xdx2ixbrl2286">-</span></span>*</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierFMember_zoDYy0fMwpSi" title="Concentration of credit risk">32.3</span></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplier C</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_ecustom--ConcentrationRiskPercentage_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_z0VhqD2tSjGa" title="Concentration of credit risk">99.4</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_ecustom--ConcentrationRiskPercentage_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_zwMhyEreZMRe" title="Concentration of credit risk">12.1</span></td>
    <td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left">*:</td>
    <td style="text-align: justify">nil, new supplier for the year ended June&#160;30, 2025</td> </tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ScheduleOfAccountsReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ScheduleOfAccountsReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ScheduleOfConcentrationOfCustomersTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ScheduleOfConcentrationOfCustomersTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ScheduleOfConcentrationOfSuppliersTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ScheduleOfConcentrationOfSuppliersTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of fair value assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_znXIjy2B1Unc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B3_zmXrZbsyeyG7" style="display: none; text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Schedule of fair value assets and liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>Fair value measurement
        at reporting date using</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid"><b>Description</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Fair value <br/>as of<br/>June&#160;30,<br/>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Quoted Prices in<br/>Active
        Markets for<br/>Identical Assets <br/>(Level 1)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Significant Other<br/>Observable
        Inputs <br/>(Level 2)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Significant <br/>Unobservable
        Inputs <br/>(Level 3)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Liabilities:</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Simple
        agreements for future equity<sup>(1)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zdI2HsL9LKmf" title="Liability">18,243,885</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_z1nxmlaF6O8" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3572">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zmfS5uxBUmhg" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3574">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zHPcFlOlK9Vi" title="Liability">18,243,885</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Other payable
        related to the equity option<sup>(2)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zShE7VowVnA1" title="Liability">53,333</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_z5tNnS5uRuuj" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3580">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zzBB0KU0oEw4" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3582">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zkq0aEofGkY2" title="Liability">53,333</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>Fair value measurement
        at reporting date using</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid"><b>Description</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Fair value <br/>as of<br/>March&#160;31,
        <br/>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Quoted Prices in<br/>Active
        Markets for<br/>Identical Assets <br/>(Level 1)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Significant Other<br/>Observable
        Inputs <br/>(Level 2)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Significant <br/>Unobservable
        Inputs <br/>(Level 3)</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Liabilities:</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%">&#160;</td>
    <td style="text-align: left; white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%">&#160;</td>
    <td style="text-align: left; white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%">&#160;</td>
    <td style="text-align: left; white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%">&#160;</td>
    <td style="text-align: left; white-space: nowrap; width: 1%">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Simple
        agreements for future equity<sup>(1)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zuhbr7cQGsg7" title="Liability">26,842,205</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zkBbNkVaZqr1" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3591">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_z9y0FcYieMIb" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3593">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zc1rFDya6DW8" title="Liability">26,842,205</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Other payable
        related to the equity option<sup>(2)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zvtu6XUHzxw3" title="Liability">53,333</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zmtSvpn5Ftt7" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3599">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zQh5SQC30bZf" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl3601">-</span></span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zbm43rdQGMmd" title="Liability">53,333</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span id="xdx_F0A_zChGi8tau4Y2">(1)</span></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span id="xdx_F10_zFPLD0zjBMIf">The
        Company classifies its SAFEs as financial liabilities measured at fair value. The value of these agreements depends significantly on future
        financing activities, liquidity events, or other material milestones, and their valuation relies on significant inputs that are not observable
        in the public market. Accordingly, they are classified within Level 3 of the fair value hierarchy.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
        fair value measurement is based on an integrated framework combining&#160;scenario analysis and financial instrument decomposition (i.e.
        Bond Plus Call Method). The proceeds of the SAFEs on the date of issuance were $14,092,500, Refer to Note 8-Simple Agreements for Future
        Equity for further details.</p> </td> </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; color: #0F1115"><span id="xdx_F00_zI5V4PyahiJg">(2)</span></td>
    <td style="text-align: justify"><span id="xdx_F13_z2JSmT6vIOn7">Equity options. On May&#160;9, 2023, the Company entered into an agreement
        with a third-party service provider (the &#8220;Service Provider&#8221;). The Service Provider received a freestanding equity-linked right
        exercisable, at the Service Provider&#8217;s option, upon the closing of the Company&#8217;s next qualified equity financing. The right
        provides the ability to subscribe for up to the value of $200,000 at a 25% discount price per share on the grant date. The equity option
        is remeasured at fair value at each reporting date, with changes in fair value recognized in earnings. As of June&#160;30, 2025 and March&#160;31,
        2026, the fair value of the equity option was $53,333, and no gain or loss from changes in fair value was recognized for the periods presented.
        The fair value measurement of the equity option is categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based
        analysis, which incorporates significant unobservable inputs and management judgment regarding the probability and timing of potential
        future financing outcomes.</span></td> </tr>
  </table>

<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zaDKp93MBRA3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BC_zDd0pvvQ169b" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Schedule of fair value assets and liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measurement at reporting date using</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Description</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value <br/>as of<br/>June&#160;30,<br/>2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted Prices in<br/>Active Markets for<br/>Identical
        Assets <br/>(Level 1)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other<br/>Observable Inputs <br/>(Level
        2)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant <br/>Unobservable Inputs <br/>(Level
        3)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left">Simple agreements for future equity<sup>(1)</sup></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zZ4Gbth8BH69" title="Liability">9,321,564</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zjkwY6IR5PDj" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2301">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zZGm8phKzm75" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2303">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zwGllHMiXKtd" title="Liability">9,321,564</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other payable related to the equity option<sup>(2)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zAoKTZ3VLxo3" title="Liability">53,333</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zoB0jQpIEfc6" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2309">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_z30wtD4xs1Jf" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2311">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zwMRf4C7bDM6" title="Liability">53,333</span></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measurement at reporting date using</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Description</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Fair value <br/>as of<br/>June&#160;30,</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2025</b></p></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted Prices in<br/>Active Markets for<br/>Identical
        Assets <br/>(Level 1)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other<br/>Observable Inputs <br/>(Level
        2)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant <br/>Unobservable Inputs <br/>(Level
        3)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left">Simple agreements for future equity<sup>(1)</sup></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zLQGMKOLzu9g" title="Liability">18,243,885</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zrVTS8w1XDWd" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2317">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zaXQfj4FsIb" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2319">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SimpleAgreementsForFutureEquityMember_fKDEp_zchHueBxrDm8" title="Liability">18,243,885</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other payable related to the equity option<sup>(2)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zqgBO7cAGUw8" title="Liability">53,333</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zy2IwQHN8iz8" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2325">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zzWPmd3ZrEEg" title="Liability"><span style="-sec-ix-hidden: xdx2ixbrl2327">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--OtherPayableRelatedToTheEquityOptionMember_fKDIp_zaU0cwEh6R2h" title="Liability">53,333</span></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td id="xdx_F02_zz6sJxvOrWkk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left">(1)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
        <p id="xdx_F12_z2I6TVTCss33" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company classifies its SAFEs as financial liabilities
        measured at fair value. The value of the agreements depends significantly on future financing activities, liquidity events, or other material
        milestones, and their valuation relies on significant inputs that are not observable in the public market. Accordingly, they are classified
        within Level 3 of the fair value hierarchy.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value measurement is based on an integrated
        framework combining&#160;scenario analysis and financial instrument decomposition (i.e. Bond Plus Call Method). The proceeds from the
        SAFEs on the date of issuance was $10,592,500, Refer to Note 9-Simple Agreements for Future Equity for further details.</p> </td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span id="xdx_F06_zXSVw5NzMGUg" style="color: #0F1115; color: #0F1115">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span id="xdx_F1A_z1nxpK5jT4mb" style="color: #0F1115; color: #0F1115">Equity
        option. On May&#160;9, 2023, the Company entered into an agreement with a third-party service provider (the &#8220;Service Provider&#8221;).
        The Service Provider received a freestanding equity-linked right exercisable, at the Service Provider&#8217;s option, upon the closing
        of the Company&#8217;s next qualified equity financing. The right provides the ability to subscribe for up to the value of $200,000 at
        a 25% discount price per share on the grant date. The equity option is remeasured at fair value at each reporting date, with changes in
        fair value recognized in earnings. As of June&#160;30, 2024 and June&#160;30, 2025, the fair value of the equity option was $53,333, and
        no gain or loss from changes in fair value was recognized for the periods presented. The fair value measurement of the equity option is
        categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based analysis, which incorporates significant
        unobservable inputs and management judgment regarding the probability and timing of potential future financing outcomes.</span></td> </tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts receivable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zWg6RZJgXvzh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts receivable (Details)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B9_zVJkzX5GW98" style="display: none; padding-bottom: 0.5pt">Schedule of Accounts receivable</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250630_zm7wuCB6PhW8" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20260331_zS3fEQLzuX3k" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td></tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>As of<br/>June&#160;30,<br/>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>As of<br/>March&#160;31,<br/>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableNetCurrent_iI_pp0p" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Accounts
        receivable</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">152,536</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">1,830,105</td>
    <td style="width: 1%; text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr id="xdx_403_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_zpFjs0QPDHU9" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Less:
        allowance for credit losses</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_407_eus-gaap--AccountsReceivableNet_iI_pp0p" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Accounts
        receivable, net</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>152,536</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>1,830,105</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zOSA2JgZjj2j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts receivable (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B0_zVKrFI6QAXc2" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Schedule of Accounts receivable</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of<br/> June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Accounts receivable</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_903_eus-gaap--AccountsReceivableNetCurrent_c20240630_pp0p" title="Accounts receivable">123,332</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--AccountsReceivableNetCurrent_c20250630_pp0p" title="Accounts receivable">152,536</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less: allowance for credit
        losses</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_c20240630_zTKCr1aFiAHe" title="Less: allowance for credit losses">-</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0d_d0_c20250630_zo59ljd2r8vk" title="Less: allowance for credit losses">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Accounts
        receivable, net</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_901_eus-gaap--AccountsReceivableNet_c20240630_pp0p" title="Accounts receivable, net">123,332</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_902_eus-gaap--AccountsReceivableNet_c20250630_pp0p" title="Accounts receivable, net">152,536</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6SXjtYgd1Rl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equipment, net (Details)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8BE_zhFe2H6s0JL3" style="display: none; padding-bottom: 0.5pt">Schedule of Equipment</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250630_zjhFyVyhBbpc" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20260331_zJzRw9osXoxa" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td></tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>As of<br/>June&#160;30,
        <br/>2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>As of<br/>March&#160;31,<br/>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_zDy4QedUaU9k" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Equipment</td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right">29,944</td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right">29,198</td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_pp0d_zz24YPuTInVl" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Total</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>29,944</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b>29,198</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_pp0d_di_ztschh1CeBb2" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Less:
        accumulated depreciation</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(10,344</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(14,792</td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0d_zJcMcc2HfH0g" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Net
        carrying amount</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>19,600</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b>14,406</b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--PropertyPlantAndEquipmentTextBlock_zWlZAMPXOKe1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equipment, net (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B5_z96otHUhXDyg" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Schedule of Equipment</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_497_20240630_zIHWu3xL186" style="font-weight: bold; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_492_20250630_zYNqMLOHwIRg" style="font-weight: bold; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of<br/> June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt">Equipment</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right">27,806</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right">29,944</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">27,806</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">29,944</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iNI_pp0d_di_zx2ts7Yln7tf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(4,110</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(10,344</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net
        carrying amount</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">23,696</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">19,600</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Simple agreements for future equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of fair value measurement</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zJ7zAKCvB5s" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Simple agreements for future equity (Details)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B0_zlyvnZCHN8oh" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of fair value measurement</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Amount</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Balance
        at June&#160;30, 2024</b></td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b><span id="xdx_90A_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20240701__20250331_zsdjo0SWVk52" title="Balance at beginning">9,321,564</span></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Issuance
        of simple agreements for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20240701__20250331_zNBYySXf6A5j" title="Issuance of simple agreements for future equity">4,275,000</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Change
        in fair value</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--ChangeInFairValue_c20240701__20250331_pp0p" title="Change in fair value">3,716,052</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Balance
        at March&#160;31, 2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><span id="xdx_90C_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20240701__20250331_zHo7SoRKeCab" title="Balance at ending">17,312,616</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Balance
        at June&#160;30, 2025</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><b><span id="xdx_903_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20250701__20260331_zv833aNiJuE" title="Balance at beginning">18,243,885</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Issuance
        of simple agreements for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20250701__20260331_zSP3vbHmvvpg" title="Issuance of simple agreements for future equity">3,500,000</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Change
        in fair value</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--ChangeInFairValue_c20250701__20260331_pp0p" title="Change in fair value">5,098,320</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Balance
        at March&#160;31, 2026</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_908_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20250701__20260331_zmoiw9Md1KUg" title="Balance at ending">26,842,205</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zfdZKaMA3CCa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Simple agreements for future equity (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BD_z692NbrbQ79l" style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Schedule of fair value measurement</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left; padding-bottom: 1pt">Balance at
        June&#160;30, 2023</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b><span id="xdx_90A_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20230701__20240630_z3t0Cul6FTGe" title="Balance at beginning">526,046</span></b></td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Issuance of simple agreements for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20230701__20240630_z8DBIBOQ2pC6" title="Issuance of simple agreements for future equity">5,685,000</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Change in fair value</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--ChangeInFairValue_c20230701__20240630_pp0p" title="Change in fair value">3,110,518</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Balance at June&#160;30,
        2024</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span id="xdx_90F_ecustom--SimpleAgreementsForFutureEquity_iS_pp0d_c20240701__20250630_zmXBtU0sSxXj" title="Balance at beginning">9,321,564</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Issuance of simple agreements for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_ecustom--IssuanceOfSimpleAgreementsForFutureEquity_pp0d_c20240701__20250630_zpOe9NCtkcUa" title="Issuance of simple agreements for future equity">4,307,500</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Change in fair value</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--ChangeInFairValue_pp0d_c20240701__20250630_zSYkDe6txhu7" title="Change in fair value">4,614,821</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Balance at June&#160;30,
        2025</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span id="xdx_901_ecustom--SimpleAgreementsForFutureEquity_iE_pp0d_c20240701__20250630_zgTzyRzot0oc" title="Balance at ending">18,243,885</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables) - Exascale Labs Inc. [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective tax rate reconciliation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zsAoZZYShxpj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B0_zDFQbJEySiid" style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Schedule
    of effective tax rate reconciliation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_493_20230701__20240630_zzRi4Ul5zEh4" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_494_20240701__20250630_z4awAYIlbT9i" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/>years ended <br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zobXWve4AQQ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">US Statutory income tax rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">21.0</td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">21.0</td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zXJf7zZEBnT9" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">State income tax rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8.7</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8.7</td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_z7RcGEC6ZYGk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Change in fair value of simple agreements
        for future equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(18.6</td>
    <td style="text-align: left">)%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(17.9</td>
    <td style="text-align: left">)%</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zr3zjXhd2iGj" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Changes in valuation
        allowance</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(11.1</td>
    <td style="padding-bottom: 1pt; text-align: left">)%</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(11.8</td>
    <td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_zoxSlARfz4f7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Effective income tax
        rate</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">-</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">-</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z7D3h5I8b915" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B9_zttoKTamREFa" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Schedule of deferred tax assets liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_494_20240630_za1CYiN8uNR8" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_497_20250630_zzAPMP8qH497" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of <br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zBsuAX9Qs0ka" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Deferred tax assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0d_maDTAGzLH3_zHcERxaR5LOi" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net operating loss carry forward</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">748,679</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">1,652,998</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0d_mtDTAGzLH3_maDTANzse2_zpw9mkr8b4Dl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Total deferred tax assets</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">748,679</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">1,652,998</td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0d_di_msDTANzse2_zkDKYZabHnVh" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less: valuation allowance</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(748,679</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(1,652,998</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_pp0d_mtDTANzse2_zy5BDhrvNfsk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total
        deferred tax assets, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2470">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2471">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of valuation allowance</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--SummaryOfValuationAllowanceTextBlock_zEsllNSptTmj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B0_zZZDDEY0OvS5" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Schedule of valuation allowance</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/>years ended<br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Balance at the beginning of the
        year</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pp0d_di_c20230701__20240630_zJGpG8QdG3kj" title="Balance at the beginning of the year">(200,468</span></td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pp0d_di_c20240701__20250630_zQtXy1pEoPm8" title="Balance at the beginning of the year">(748,679</span></td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Additions</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230701__20240630_pp0p" title="Additions">(548,211</span></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20240701__20250630_pp0p" title="Additions">(904,319</span></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance
        at the end of the year</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_908_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pp0d_di_c20230701__20240630_zoH4it63AAy2" title="Balance at the end of the year">(748,679</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_907_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pp0d_di_c20240701__20250630_zU4aB0tVNds8" title="Balance at the end of the year">(1,652,998</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock', window );">Schedule of share-based compensation expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock_zYgAKTu1lo7k" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-based compensation (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8BB_zwzJiikWfcV4" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Schedule of share-based compensation expenses</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <br/>years ended <br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Selling and marketing expenses</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensation_c20230701__20240630__custom--IncomeStatementLocationsAxis__custom--SellingAndMarketingExpensesMember_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2508">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20240701__20250630__custom--IncomeStatementLocationsAxis__custom--SellingAndMarketingExpensesMember_pp0p" title="Total">153,266</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">General and administrative
        expenses</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230701__20240630__custom--IncomeStatementLocationsAxis__custom--GeneralAndAdministrativeExpensesMember_pp0p" title="Total">21,104</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630__custom--IncomeStatementLocationsAxis__custom--GeneralAndAdministrativeExpensesMember_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2514">-</span></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0d_c20230701__20240630_zG6MuWsZDbL5" title="Total">21,104</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0d_c20240701__20250630_zgdo4PX2S2yh" title="Total">153,266</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an equity-based arrangement (such as stock or unit options and stock or unit awards) with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain equity-based awards at future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares or units issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483043/710-10-30-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482943/710-10-55-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and diluted net loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic share and diluted</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z2sxwJ1VHpU" style="font: 10pt Times New Roman; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basic and diluted net loss per share (Details)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8B0_z8caDlAsTD0j" style="display: none; padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Schedule of basic share and diluted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_497_20250101__20250331_zC16hdQy39z7" style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_490_20260101__20260331_zlPyFMn73iHk" style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_491_20240701__20250331_zCkUO6zYutQ4" style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_496_20250701__20260331_zOuUJ3ksGux6" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <th style="text-align: left; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Three Months
        Ended<br/>March&#160;31,</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        Ended<br/>March&#160;31,</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th> </tr>
  <tr style="vertical-align: bottom">
    <th style="text-align: left; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th>
    <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></th>
    <th style="text-align: center; padding-bottom: 0.5pt"><b>&#160;</b></th> </tr>
  <tr id="xdx_406_ecustom--NumeratorAbstract_iB_zNkHTVkijEU3" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><b>Numerator:</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td> </tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_z6giu4JTNcaj" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Net loss
        attributable to ordinary shareholders</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(1,537,059</td>
    <td style="white-space: nowrap; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(2,632,431</td>
    <td style="white-space: nowrap; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(6,178,537</td>
    <td style="white-space: nowrap; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(7,916,977</td>
    <td style="text-align: left">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td> </tr>
  <tr id="xdx_40E_ecustom--DenominatorAbstract_iB_zgkk1b9Igsvl" style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"><b>Denominator:</b></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td> </tr>
  <tr id="xdx_406_ecustom--DenominatorForBasicAndDilutedLossPerShareAbstract_iB_zy2lnWnhwA39" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Denominator
        for basic and diluted loss per share</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Weighted-average
        ordinary shares outstanding<sup>(i)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250331_fKGkp_zDQw4h37Wwsb" title="Weighted-average ordinary shares outstanding, Basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250331_fKGkp_z1Ku37KqqS1c" title="Weighted-average ordinary shares outstanding, diluted">1,500</span></span></td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331_fKGkp_zx8fH2VBa76l" title="Weighted-average ordinary shares outstanding, Basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331_fKGkp_ztHfVbfGRHOe" title="Weighted-average ordinary shares outstanding, diluted">1,500</span></span></td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20250331_fKGkp_zdZsZI7uuxig" title="Weighted-average ordinary shares outstanding, Basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20250331_fKGkp_zxdrS9L5B374" title="Weighted-average ordinary shares outstanding, diluted">1,500</span></span></td>
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250701__20260331_fKGkp_zxPaAudjLjnd" title="Weighted-average ordinary shares outstanding, Basic"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250701__20260331_fKGkp_znBJ1PFMXWY8" title="Weighted-average ordinary shares outstanding, diluted">1,500</span></span></td>
    <td style="text-align: left">&#160;</td> </tr>
  <tr id="xdx_404_ecustom--LossPerOrdinaryShareAbstarct_zCAzhDqWJjpb" style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Basic
        and diluted<sup>(ii)</sup></td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Basic
        and diluted loss per share</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250101__20250331_fKGlpKQ_____zRg0YrtZsJH6" title="Basic loss per share"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20250101__20250331_fKGlpKQ_____zLTKtVSBtLic" title="Diluted loss per share">(1,024.70</span></span></td>
    <td style="white-space: nowrap; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20260101__20260331_fKGlpKQ_____zMOHv6Iu2y06" title="Basic loss per share"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20260101__20260331_fKGlpKQ_____zOAlpfAhDrW7" title="Diluted loss per share">(1,754.95</span></span></td>
    <td style="white-space: nowrap; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20240701__20250331_fKGlpKQ_____zOMDMotp0PLj" title="Basic loss per share"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240701__20250331_fKGlpKQ_____zcmGyzLnWIBj" title="Diluted loss per share">(4,119.02</span></span></td>
    <td style="white-space: nowrap; text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20250701__20260331_fKGlpKQ_____zvq1iE1ENBpf" title="Basic loss per share"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20250701__20260331_fKGlpKQ_____zANr2fj6apLe" title="Diluted loss per share">(5,277.98</span></span></td>
    <td style="text-align: left">)</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span id="xdx_F08_zYCld0TSLmlc">(i)</span></td>
    <td style="text-align: justify"><span id="xdx_F1E_zckvTnJmQEhg">In January&#160;2026, the Company adopted an Amended and Restated Certificate
        of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#8217;s equity is divided
        into 303 Class A ordinary shares and 1,197 Class B ordinary shares, which are entitled to one (1) vote and twenty (20) votes per share,
        respectively. Despite the differential in voting power, Class A and Class B ordinary shares rank pari passu in all other respects, sharing
        ratably in dividends and any distributions upon liquidation.</span></td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span id="xdx_F07_zMNm9OVFQe92">(ii)</span></td>
    <td style="text-align: justify"><span id="xdx_F1B_zgBQGgyBG4z3">During the three and nine months ended March&#160;31, 2025 and 2026, diluted
        net loss per share is calculated in the same manner as basic net loss per share, as the Company was in a net loss position and all potential ordinary shares were anti-dilutive.</span></td> </tr>
  </table>

<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zt9m69C0XZ2d" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basic and diluted net loss per share (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_8B3_z4fVOy9hZcC8" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Schedule of basic share and diluted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_490_20230701__20240630_zNS6ebSpnWrd" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_49D_20240701__20250630_z1q8DgL1dZak" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <br/>years ended <br/>June&#160;30,</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Numerator:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net loss attributable to ordinary
        shareholders</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(4,956,347</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(7,659,667</td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DenominatorForBasicAndDilutedLossPerShareAbstract_iB_zvdjC7dKX30c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Denominator for basic and diluted loss per
        share</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted-average ordinary shares outstanding,
        Basic and diluted*</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230701__20240630_fKg_____zQHyzKNbmYni" title="Weighted-average ordinary shares outstanding, Basic"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230701__20240630_fKg_____znyMMFNDxhuf" title="Weighted-average ordinary shares outstanding, diluted">1,500</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20250630_fKg_____zSHuzJLV0GTl" title="Weighted-average ordinary shares outstanding, Basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20250630_fKg_____zTkjibsim5P6" title="Weighted-average ordinary shares outstanding, diluted">1,500</span></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Basic and diluted loss per share</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230701__20240630_zmSb1V03Vrje" title="Basic loss per share"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20230701__20240630_zyJQB2bVMLV5" title="Diluted loss per share">(3,304.23</span></span></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20240701__20250630_zD02im0uKoQi" title="Basic loss per share"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20240701__20250630_zN38w6qibdk8" title="Diluted loss per share">(5,106.44</span></span></td>
    <td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td id="xdx_F08_zym9vF1L9h5a" style="width: 0.25in; text-align: left">*</td>
    <td id="xdx_F1F_zWe9J1egNUee" style="text-align: justify">The Company&#8217;s share-based compensation awards are expected to be settled through transfers of existing
        ordinary shares held by the controlling shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary
        shares are included in issued and outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase
        the Company&#8217;s total issued and outstanding shares. During the years ended June&#160;30, 2024 and 2025, diluted net loss per share
        is calculated in the same manner as basic net loss per share.</td> </tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Crypto assets (Tables) - Exascale Labs Inc. [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CryptoAssetActivityTableTextBlock', window );">Schedule of digital assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--CryptoAssetActivityTableTextBlock_z6IoVbbXa5M" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Crypto assets (Details)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td id="xdx_8BB_z5ypZmSGKPI6" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of digital assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Digital assets</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>USDC</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt"><b>Balance
        at June&#160;30, 2025</b></td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b><span id="xdx_90B_eus-gaap--CryptoAssetFairValue_iS_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zVU8fnykwyVd" title="Beginning balance, January 1"><span style="-sec-ix-hidden: xdx2ixbrl3611">-</span></span></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><b><span id="xdx_907_eus-gaap--CryptoAssetFairValue_iS_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_zucsqhJMum0h" title="Beginning balance, January 1"><span style="-sec-ix-hidden: xdx2ixbrl3613">-</span></span></b></td>
    <td style="width: 1%; text-align: left; white-space: nowrap; padding-bottom: 0.5pt">&#160;</td>
        </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Additions<sup>(i)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--CryptoAssetPurchase_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_fKGkp_zCVR14RVanL4" title="Additions">939,397</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--CryptoAssetPurchase_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_fKGkp_z7IluYPLL2H6" title="Additions">4,711,169</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Disposals
        - sold for US dollars</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--CryptoAssetSale_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zFhrH4pyNUOi" title="Disposals - sold for US dollars">(596,852</span></td>
    <td style="text-align: left; white-space: nowrap">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--CryptoAssetSale_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_zZ3TE6pXpuRg" title="Disposals - sold for US dollars">(9,900</span></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Disposals - others<sup>(ii)</sup></td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--CryptoAssetDisposition_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_fKGlpKQ_____z0eXchozqDD5" title="Disposals">(342,545</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--CryptoAssetDisposition_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_fKGlpKQ_____zih1kjx1tNMl" title="Disposals">(626,854</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Balance
        at March&#160;31, 2026</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_905_eus-gaap--CryptoAssetFairValue_iE_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsMember_zwakqvuSDr0k" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl3627">-</span></span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_901_eus-gaap--CryptoAssetFairValue_iE_c20250701__20260331__srt--CryptoAssetAxis__custom--USDCMember_z5rCPa9Emov5" title="Ending balance">4,074,415</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">&#160;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%; margin-left: 0; margin-right: auto"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: left"><span id="xdx_F05_z0wsheXoxiZe">(i)</span></td>
    <td style="text-align: justify"><span id="xdx_F13_zlhgBGZ4Kxka">The Company acquired a total of 939,397 USDT at a cost of $939,397, funded by revenues and collections of other receivables. The Company acquired a total of 4,711,169 USDC at a cost of $4,711,169, funded by revenues, interest income,
        collections of other receivables and investment proceeds from SAFEs.</span></td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><span id="xdx_F05_zMHGNT0qLCIg">(ii)</span></td>
    <td style="text-align: justify"><span id="xdx_F1F_z3QKCOoBgzb2">The Company used digital assets and USDC to settle professional service
        fees and other expenditures.</span></td> </tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowOperatingCapitalTableTextBlock', window );">Schedule of operating activities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--CashFlowOperatingCapitalTableTextBlock_zvjZLHvPjup5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Crypto assets (Details 1)">
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span id="xdx_8B8_zB2Vyc1Bo39h">Schedule of operating activities</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; white-space: nowrap">&#160;</td></tr>
<tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>For the<br/>Nine Months
        ended March&#160;31,<br/>2026</b></td>
    <td style="padding-bottom: 0.5pt">&#160;</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenue</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--Revenues_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Revenue">(1,197,326</span></td>
    <td style="width: 1%; text-align: left; white-space: nowrap">)</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Other
        receivables</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_ecustom--OtherCurrentAssets_pp0d_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_zgPbcYEBBUwe" title="Other current assets">(1,452,102</span></td>
    <td style="text-align: left; white-space: nowrap">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Cost and
        expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--CostsAndExpenses_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Cost and expenses">969,399</span></td>
    <td style="text-align: left; white-space: nowrap">&#160;</td> </tr>
  <tr style="background-color: #FFFFFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Interest
        income</td>
    <td style="padding-bottom: 0.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--InterestIncomeOther_iN_pp0d_di_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_zDM56zONgaVd" title="Interest income">(1,138</span></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr>
  <tr style="background-color: #CCEEFF; vertical-align: bottom">
    <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt"><b>Total
        operating activities settled in digital assets and USDC</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><b><span id="xdx_903_ecustom--TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc_c20250701__20260331__srt--CryptoAssetAxis__custom--DigitalAssetsAndUSDCMember_pp0p" title="Total operating activities settled in digital assets and USDC">(1,681,167</span></b></td>
    <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"><b>)</b></td> </tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingCapitalTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the net increase (decrease) in operating capital in the operating section of the statement of cash flows, represents the entire footnote disclosure that provides details regarding the net change during the reporting period of all assets and liabilities used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingCapitalTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about activity for crypto asset. Excludes information about crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Organization and Business Operations (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>193
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination (Details Narrative) - D. Boral ARC Acquisition I Corp. [Member]<br></strong></div></th>
<th class="th">
<div>Jan. 11, 2026 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_AggregateConsideration', window );">Aggregate consideration | $</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">New shares issued | shares</a></td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_AggregateConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_AggregateConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cik0002065779_DBoralARCAcquisitionICorp.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cik0002065779_DBoralARCAcquisitionICorp.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>194
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Capital (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued | shares</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price | $</a></td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>195
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS (Details Narrative) - D. Boral ARC Acquisition I Corp [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 09, 2025</div></th>
<th class="th"><div>Aug. 11, 2025</div></th>
<th class="th"><div>Aug. 01, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 25, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_TransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,582,634<span></span>
</td>
<td class="nump">$ 3,582,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RepresentativeShares', window );">Representative shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,419,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,419,400<span></span>
</td>
<td class="nump">2,419,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_OtherOfferingCosts', window );">Other offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,163,234<span></span>
</td>
<td class="nump">$ 1,163,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of share issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_CancelledFounderShares', window );">Cancelled founder shares</a></td>
<td class="nump">321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities', window );">Dissolution expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,576<span></span>
</td>
<td class="nump">420,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_WorkingCapitalDeficit', window );">Working capital deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,122<span></span>
</td>
<td class="nump">585,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">Founder Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,461<span></span>
</td>
<td class="nump">$ 225,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties', window );">Repayment of promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of units in initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of units per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of units in initial public offering aggragate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Underwriter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of share issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,419,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">proceeds from sale of initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of units in initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of units per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of units in initial public offering aggragate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of units in initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of units per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of units in initial public offering aggragate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_CancelledFounderShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_CancelledFounderShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_OtherOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_OtherOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_RepresentativeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_RepresentativeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated accrued costs to dispose of assets or other items expected to be sold in liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -SubTopic 30<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480034/205-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentOfNotesReceivableFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cik0002065779_FounderSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cik0002065779_FounderSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0002065779_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0002065779_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0002065779_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0002065779_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>196
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - D. Boral ARC Acquisition I Corp [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital', window );">Ordinary shares subject to possible redemption, beginning</a></td>
<td class="nump">$ 284,776,628<span></span>
</td>
<td class="nump">$ 280,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ProceedsAllocatedToPublicWarrants', window );">Proceeds allocated to Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,028,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ProceedsAllocatedToOverallotmentOption', window );">Proceeds allocated to Over-allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,290,375)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ClassOrdinarySharesIssuanceCosts', window );">Class A ordinary shares issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,438,859)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Ordinary shares subject to possible redemption</a></td>
<td class="nump">2,543,059<span></span>
</td>
<td class="nump">18,534,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital', window );">Ordinary shares subject to possible redemption, ending</a></td>
<td class="nump">$ 287,319,687<span></span>
</td>
<td class="nump">$ 284,776,628<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ClassOrdinarySharesIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ClassOrdinarySharesIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ProceedsAllocatedToOverallotmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ProceedsAllocatedToOverallotmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ProceedsAllocatedToPublicWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ProceedsAllocatedToPublicWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>197
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of Class B ordinary shares outstanding, basic</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of Class B ordinary shares outstanding, diluted</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Class B ordinary shares - basic net income per share</a></td>
<td class="num">$ (5.90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (100.00)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Class B ordinary shares - diluted net income per share</a></td>
<td class="num">$ (5.90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (100.00)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member] | Ordinary Shares Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Allocation of (loss)/income - basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,509,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Allocation of (loss)/income - diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,509,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of Class B ordinary shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">29,200,000<span></span>
</td>
<td class="nump">15,393,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of Class B ordinary shares outstanding, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">29,200,000<span></span>
</td>
<td class="nump">15,393,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Class B ordinary shares - basic net income per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Class B ordinary shares - diluted net income per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member] | Ordinary Shares Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Allocation of (loss)/income - basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,420)<span></span>
</td>
<td class="nump">$ 2,011,318<span></span>
</td>
<td class="nump">$ 1,946,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Allocation of (loss)/income - diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,420)<span></span>
</td>
<td class="nump">$ 2,011,318<span></span>
</td>
<td class="nump">$ 1,946,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of Class B ordinary shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,714,286<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">11,935,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of Class B ordinary shares outstanding, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,714,286<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">11,935,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Class B ordinary shares - basic net income per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Class B ordinary shares - diluted net income per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cik0002065779_OrdinarySharesClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cik0002065779_OrdinarySharesClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cik0002065779_OrdinarySharesClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cik0002065779_OrdinarySharesClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>198
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - D. Boral ARC Acquisition I Corp [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 25, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243,576<span></span>
</td>
<td class="nump">$ 420,340<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_CashHeldInTrustAccount', window );">Cash held in trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,319,687<span></span>
</td>
<td class="nump">284,776,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_OfferingCost', window );">Offering costs</a></td>
<td class="nump">$ 3,582,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,582,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RepresentativeShares', window );">Representative shares</a></td>
<td class="nump">2,419,400<span></span>
</td>
<td class="nump">2,419,400<span></span>
</td>
<td class="nump">2,419,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_OtherOfferingCost', window );">Other offering costs</a></td>
<td class="nump">1,163,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">other costs</a></td>
<td class="nump">143,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ordinary shares subject to redemption</a></td>
<td class="nump">$ 3,438,859<span></span>
</td>
<td class="nump">$ 287,319,687<span></span>
</td>
<td class="nump">$ 284,776,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted', window );">Weighted average aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,100,000<span></span>
</td>
<td class="nump">14,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">FDIC Insured Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_CashHeldInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_CashHeldInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_OfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_OfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_OtherOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_OtherOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_RepresentativeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_RepresentativeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479772/718-30-S55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of limited partnership units outstanding determined by relating the portion of time within a reporting period that limited partnership units have been outstanding to the total time in that period. Used in the calculation of diluted net income or loss per limited partnership unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>199
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INITIAL PUBLIC OFFERING (Details Narrative) - D. Boral ARC Acquisition I Corp [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 11, 2025</div></th>
<th class="th"><div>Aug. 01, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of units in initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of units per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of units in initial public offering aggragate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of units in initial public offering</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of units per share</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of units in initial public offering aggragate amount</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>200
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PRIVATE PLACEMENT (Details Narrative) - Private Placement [Member] - D. Boral ARC Acquisition I Corp [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 01, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of units in initial public offering</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of units per share</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of units in initial public offering aggragate amount</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>201
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - D. Boral ARC Acquisition I Corp [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 09, 2025</div></th>
<th class="th"><div>Aug. 01, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 25, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Aug. 11, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243,576<span></span>
</td>
<td class="nump">$ 420,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_CancelledFounderShares', window );">Cancelled founder shares</a></td>
<td class="nump">321,429<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination', window );">Percentage of redemption of public shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering', window );">Payment of offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 934,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdministrativeFeesExpense', window );">Administrative services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of units per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of units per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties', window );">Repayment of promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering', window );">Payment of offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDistributionsToAffiliates', window );">Payment to affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">Unsecured promissory note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=cik0002065779_FounderMember', window );">Founder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Forfeiture shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_CancelledFounderShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_CancelledFounderShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdministrativeFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for administrative fee from service provided, including, but not limited to, salary, rent, or overhead cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 850<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdministrativeFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDistributionsToAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDistributionsToAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentOfNotesReceivableFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0002065779_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0002065779_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cik0002065779_UnsecuredPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cik0002065779_UnsecuredPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=cik0002065779_FounderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=cik0002065779_FounderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>202
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - D. Boral ARC Acquisition I Corp [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2025</div></th>
<th class="th"><div>Aug. 01, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750,000<span></span>
</td>
<td class="nump">3,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of units in initial public offering</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of units per share</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of units in initial public offering aggragate amount</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of units in initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of units per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of units in initial public offering aggragate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Underwriter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0002065779_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0002065779_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>203
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDER&#8217;S EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 25, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Aug. 11, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">New shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_AggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_CancellationOfOrdinaryShares', window );">Cancellation of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_PeriodAfterWhichTheWarrantsAreExercisable', window );">Period of warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.20<span></span>
</td>
<td class="nump">$ 9.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants', window );">Holders of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_NumberOfTradingDaysForDeterminingTheSharePrice', window );">Number of trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice', window );">Number of consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate', window );">Market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ShareRedemptionTriggerPrices', window );">Share redemption trigger prices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180.00%<span></span>
</td>
<td class="nump">180.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalent</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 243,576<span></span>
</td>
<td class="nump">$ 420,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member] | Conversion of class B to class A common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion', window );">Percentage of total number of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member] | Class A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</a></td>
<td class="nump">1,607,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">New shares issued</a></td>
<td class="nump">12,321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member] | Class A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_OrdinarySharesSubjectToPossibleRedemption', window );">Ordinary shares subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member] | Class B Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member] | Common Stock Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConversionBasis', window );">Conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-one basis<span></span>
</td>
<td class="text">one-for-one basis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member] | Class A Ordinary Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_OrdinarySharesSubjectToPossibleRedemption', window );">Ordinary shares subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_AggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_AggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_CancellationOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_CancellationOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_NumberOfTradingDaysForDeterminingTheSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_NumberOfTradingDaysForDeterminingTheSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_OrdinarySharesSubjectToPossibleRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_OrdinarySharesSubjectToPossibleRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_PeriodAfterWhichTheWarrantsAreExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_PeriodAfterWhichTheWarrantsAreExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ShareRedemptionTriggerPrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ShareRedemptionTriggerPrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current weighted-average discount rate used to measure present value of total expected payment to policyholder in excess of present value of total expected assessment. Excludes benefit classified as market risk benefit or under provisions of Topic 815 on derivative and hedging.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of basis for conversion of convertible common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=cik0002065779_ConversionOfClassBToClassACommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=cik0002065779_ConversionOfClassBToClassACommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cik0002065779_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cik0002065779_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=cik0002065779_ClassAOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=cik0002065779_ClassAOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0002065779_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0002065779_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cik0002065779_ClassAOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cik0002065779_ClassAOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cik0002065779_ClassBOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cik0002065779_ClassBOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cik0002065779_CommonStockClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cik0002065779_CommonStockClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cik0002065779_ClassAOrdinaryShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cik0002065779_ClassAOrdinaryShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>204
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Aug. 01, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member] | Fair Value, Recurring [Member] | Simple agreements for future equity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liability</a></td>
<td class="nump">$ 26,842,205<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,243,885<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 9,321,564<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member] | Fair Value, Recurring [Member] | Other payable related to the equity option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liability</a></td>
<td class="nump">53,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
<td class="nump">53,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liability</a></td>
<td class="nump">287,319,687<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 284,776,628<span></span>
</td>
<td class="nump">$ 1,290,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,061,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Exascale Labs Inc. [Member] | Fair Value, Recurring [Member] | Simple agreements for future equity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liability</a></td>
<td class="nump">26,842,205<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,243,885<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">9,321,564<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Exascale Labs Inc. [Member] | Fair Value, Recurring [Member] | Other payable related to the equity option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liability</a></td>
<td class="nump">53,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
<td class="nump">53,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 284,776,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Exascale Labs Inc. [Member] | Fair Value, Recurring [Member] | Simple agreements for future equity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liability</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Exascale Labs Inc. [Member] | Fair Value, Recurring [Member] | Other payable related to the equity option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liability</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Exascale Labs Inc. [Member] | Fair Value, Recurring [Member] | Simple agreements for future equity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liability</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Exascale Labs Inc. [Member] | Fair Value, Recurring [Member] | Other payable related to the equity option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liability</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
        Company classifies its SAFEs as financial liabilities measured at fair value. The value of these agreements depends significantly on future
        financing activities, liquidity events, or other material milestones, and their valuation relies on significant inputs that are not observable
        in the public market. Accordingly, they are classified within Level 3 of the fair value hierarchy.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The Company classifies its SAFEs as financial liabilities
        measured at fair value. The value of the agreements depends significantly on future financing activities, liquidity events, or other material
        milestones, and their valuation relies on significant inputs that are not observable in the public market. Accordingly, they are classified
        within Level 3 of the fair value hierarchy.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Equity options. On May&#160;9, 2023, the Company entered into an agreement
        with a third-party service provider (the &#8220;Service Provider&#8221;). The Service Provider received a freestanding equity-linked right
        exercisable, at the Service Provider&#8217;s option, upon the closing of the Company&#8217;s next qualified equity financing. The right
        provides the ability to subscribe for up to the value of $200,000 at a 25% discount price per share on the grant date. The equity option
        is remeasured at fair value at each reporting date, with changes in fair value recognized in earnings. As of June&#160;30, 2025 and March&#160;31,
        2026, the fair value of the equity option was $53,333, and no gain or loss from changes in fair value was recognized for the periods presented.
        The fair value measurement of the equity option is categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based
        analysis, which incorporates significant unobservable inputs and management judgment regarding the probability and timing of potential
        future financing outcomes.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Equity
        option. On May&#160;9, 2023, the Company entered into an agreement with a third-party service provider (the &#8220;Service Provider&#8221;).
        The Service Provider received a freestanding equity-linked right exercisable, at the Service Provider&#8217;s option, upon the closing
        of the Company&#8217;s next qualified equity financing. The right provides the ability to subscribe for up to the value of $200,000 at
        a 25% discount price per share on the grant date. The equity option is remeasured at fair value at each reporting date, with changes in
        fair value recognized in earnings. As of June&#160;30, 2024 and June&#160;30, 2025, the fair value of the equity option was $53,333, and
        no gain or loss from changes in fair value was recognized for the periods presented. The fair value measurement of the equity option is
        categorized within Level 3 of the fair value hierarchy and was determined using a scenario-based analysis, which incorporates significant
        unobservable inputs and management judgment regarding the probability and timing of potential future financing outcomes.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=cik0002065779_SimpleAgreementsForFutureEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=cik0002065779_SimpleAgreementsForFutureEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=cik0002065779_OtherPayableRelatedToTheEquityOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=cik0002065779_OtherPayableRelatedToTheEquityOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>205
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details 1) - D. Boral ARC Acquisition I Corp [Member]<br></strong></div></th>
<th class="th">
<div>Aug. 01, 2025 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.31%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected terms (years)</a></td>
<td class="text">1 month 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">22.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_FairValueOfOverallotmentOption', window );">Fair value of over-allotment option</a></td>
<td class="nump">$ 0.3441<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_FairValueOfOverallotmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_FairValueOfOverallotmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>206
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details 2) - D. Boral ARC Acquisition I Corp [Member]<br></strong></div></th>
<th class="th">
<div>Aug. 01, 2025 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Annual risk-free rate (term-matched)</a></td>
<td class="nump">4.31%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected warrant implied volatility based on warrants from comparable SPAC securities</a></td>
<td class="nump">22.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cik0002065779_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Estimated share price</a></td>
<td class="nump">$ 9.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Term (years)</a></td>
<td class="text">2 years 9 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Annual risk-free rate (term-matched)</a></td>
<td class="nump">3.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected warrant implied volatility based on warrants from comparable SPAC securities</a></td>
<td class="nump">14.44%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cik0002065779_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cik0002065779_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>207
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">$ (590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember', window );">D. Boral ARC Acquisition I Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,420)<span></span>
</td>
<td class="num">(531,741)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (320,658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income on cash held in trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,543,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,776,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_CashHeldInTrustAccounts', window );">Cash held in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,319,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,776,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(320,658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,420)<span></span>
</td>
<td class="nump">2,011,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,455,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,808,901)<span></span>
</td>
<td class="num">$ (859,617)<span></span>
</td>
<td class="num">$ (4,477,022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,110,926)<span></span>
</td>
<td class="num">$ (4,150,043)<span></span>
</td>
<td class="num">$ (1,901,396)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,754,586<span></span>
</td>
<td class="nump">1,862,158<span></span>
</td>
<td class="nump">10,561,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,475,885<span></span>
</td>
<td class="nump">7,015,512<span></span>
</td>
<td class="nump">1,319,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,167,659)<span></span>
</td>
<td class="num">(1,649,077)<span></span>
</td>
<td class="num">(8,902,966)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,827,444)<span></span>
</td>
<td class="num">(5,910,315)<span></span>
</td>
<td class="num">(1,263,548)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,235,476)<span></span>
</td>
<td class="num">(377,999)<span></span>
</td>
<td class="num">(3,238,185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,115,853)<span></span>
</td>
<td class="num">(2,797,906)<span></span>
</td>
<td class="num">(1,365,433)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpenseAbstract', window );"><strong>Selling and marketing expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_StaffCostsEmployeeBenefitsAndOfficeExpenses', window );">&#8211; Staff costs, employee benefits and office expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104,729)<span></span>
</td>
<td class="num">(277,511)<span></span>
</td>
<td class="num">(310,582)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(573,648)<span></span>
</td>
<td class="num">(835,889)<span></span>
</td>
<td class="num">(262,614)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ShareBasedCompensations', window );">&#8211; Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(101,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(153,266)<span></span>
</td>
<td class="num">(153,266)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_StaffCostsEmployeeBenefitsAndOthers', window );">&#8211; Staff costs, employee benefits and Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(360,657)<span></span>
</td>
<td class="num">(3,890)<span></span>
</td>
<td class="num">(563,641)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,785)<span></span>
</td>
<td class="num">(328,662)<span></span>
</td>
<td class="num">(244,651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">&#8211; Professional service expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(108,039)<span></span>
</td>
<td class="num">(99,217)<span></span>
</td>
<td class="num">(364,614)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(234,374)<span></span>
</td>
<td class="num">(34,320)<span></span>
</td>
<td class="num">(7,594)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ShareBasedCompensation1', window );">&#8211; Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(21,104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,221,974)<span></span>
</td>
<td class="num">(646,536)<span></span>
</td>
<td class="num">(2,818,657)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,462,485)<span></span>
</td>
<td class="num">(3,044,846)<span></span>
</td>
<td class="num">(1,845,829)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity', window );">Change in fair value of simple agreements for future equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,410,457)<span></span>
</td>
<td class="num">(890,523)<span></span>
</td>
<td class="num">(5,098,320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,716,052)<span></span>
</td>
<td class="num">(4,614,821)<span></span>
</td>
<td class="num">(3,110,518)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Loss before income tax expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,659,667)<span></span>
</td>
<td class="num">(4,956,347)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,632,431)<span></span>
</td>
<td class="num">(1,537,059)<span></span>
</td>
<td class="num">(7,916,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,178,537)<span></span>
</td>
<td class="num">(7,659,667)<span></span>
</td>
<td class="num">(4,956,347)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 586,927<span></span>
</td>
<td class="nump">$ 213,081<span></span>
</td>
<td class="nump">$ 1,658,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 648,441<span></span>
</td>
<td class="nump">$ 1,105,197<span></span>
</td>
<td class="nump">$ 55,567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_CashHeldInTrustAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_CashHeldInTrustAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ShareBasedCompensation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ShareBasedCompensation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ShareBasedCompensations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ShareBasedCompensations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_StaffCostsEmployeeBenefitsAndOfficeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_StaffCostsEmployeeBenefitsAndOfficeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_StaffCostsEmployeeBenefitsAndOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_StaffCostsEmployeeBenefitsAndOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_DBoralARCAcquisitionICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>208
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and principal activities (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Dec. 16, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jan. 08, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_OrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member] | Evana Alpha Pte. Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_OrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">New shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_OrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_OrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cik0002065779_EvanaAlphaPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cik0002065779_EvanaAlphaPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>209
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) - Exascale Labs Inc. [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 3,754,586<span></span>
</td>
<td class="nump">$ 1,862,158<span></span>
</td>
<td class="nump">$ 10,561,331<span></span>
</td>
<td class="nump">$ 4,475,885<span></span>
</td>
<td class="nump">$ 7,015,512<span></span>
</td>
<td class="nump">$ 1,319,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cik0002065779_RevenueFromIntelligentComputingPowerServiceMember', window );">Revenue from intelligent computing power service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,726,656<span></span>
</td>
<td class="nump">1,764,357<span></span>
</td>
<td class="nump">10,441,509<span></span>
</td>
<td class="nump">4,168,467<span></span>
</td>
<td class="nump">6,546,249<span></span>
</td>
<td class="nump">1,193,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cik0002065779_RevenueFromIntelligentComputingPowerServiceMember', window );">Revenue from intelligent computing power service [Member] | Reserved Capacity Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,725,315<span></span>
</td>
<td class="nump">1,758,921<span></span>
</td>
<td class="nump">10,428,983<span></span>
</td>
<td class="nump">4,161,985<span></span>
</td>
<td class="nump">6,501,569<span></span>
</td>
<td class="nump">1,193,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cik0002065779_RevenueFromIntelligentComputingPowerServiceMember', window );">Revenue from intelligent computing power service [Member] | On demand arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,341<span></span>
</td>
<td class="nump">$ 5,436<span></span>
</td>
<td class="nump">$ 12,526<span></span>
</td>
<td class="nump">$ 6,482<span></span>
</td>
<td class="nump">$ 44,680<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cik0002065779_RevenueFromIntelligentComputingPowerServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cik0002065779_RevenueFromIntelligentComputingPowerServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=cik0002065779_ReservedCapacityArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=cik0002065779_ReservedCapacityArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=cik0002065779_OnDemandArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=cik0002065779_OnDemandArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>210
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3) - Exascale Labs Inc. [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">$ 3,754,586<span></span>
</td>
<td class="nump">$ 1,862,158<span></span>
</td>
<td class="nump">$ 10,561,331<span></span>
</td>
<td class="nump">$ 4,475,885<span></span>
</td>
<td class="nump">$ 7,015,512<span></span>
</td>
<td class="nump">$ 1,319,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cik0002065779_RevenueFromIntelligentComputingPowerServiceMember', window );">Revenue from intelligent computing power service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">3,726,656<span></span>
</td>
<td class="nump">1,764,357<span></span>
</td>
<td class="nump">10,441,509<span></span>
</td>
<td class="nump">4,168,467<span></span>
</td>
<td class="nump">6,546,249<span></span>
</td>
<td class="nump">1,193,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cik0002065779_RevenueFromComprehensiveDataCenterServicesMember', window );">Revenue from comprehensive data center services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">$ 27,930<span></span>
</td>
<td class="nump">$ 97,801<span></span>
</td>
<td class="nump">$ 119,822<span></span>
</td>
<td class="nump">$ 307,418<span></span>
</td>
<td class="nump">$ 469,263<span></span>
</td>
<td class="nump">$ 125,133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cik0002065779_RevenueFromIntelligentComputingPowerServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cik0002065779_RevenueFromIntelligentComputingPowerServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cik0002065779_RevenueFromComprehensiveDataCenterServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cik0002065779_RevenueFromComprehensiveDataCenterServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>211
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jan. 08, 2026</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">$ 590<span></span>
</td>
<td class="nump">$ 10,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash for operating activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net losses</a></td>
<td class="num">(590)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (590)<span></span>
</td>
<td class="num">(10,590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">984,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">984,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,231,689<span></span>
</td>
<td class="nump">$ 969,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,153,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,153,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,319,721<span></span>
</td>
<td class="nump">9,881,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash for operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,758,611)<span></span>
</td>
<td class="num">$ (757,960)<span></span>
</td>
<td class="num">(1,010,799)<span></span>
</td>
<td class="num">(560,909)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,632,431)<span></span>
</td>
<td class="num">$ (1,537,059)<span></span>
</td>
<td class="num">(7,916,977)<span></span>
</td>
<td class="num">(6,178,537)<span></span>
</td>
<td class="num">(7,659,667)<span></span>
</td>
<td class="num">(4,956,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,134,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,134,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,217,035)<span></span>
</td>
<td class="num">(5,557,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RefundableDepositsReceivable', window );">Refundable deposits receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">681,125<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for expected credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,754,586<span></span>
</td>
<td class="nump">$ 1,862,158<span></span>
</td>
<td class="nump">10,561,331<span></span>
</td>
<td class="nump">4,475,885<span></span>
</td>
<td class="nump">7,015,512<span></span>
</td>
<td class="nump">1,319,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366,075<span></span>
</td>
<td class="nump">95,326<span></span>
</td>
<td class="nump">95,326<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketingAndAdvertisingExpense', window );">Advertising and promotion expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,113<span></span>
</td>
<td class="nump">76,090<span></span>
</td>
<td class="nump">$ 157,388<span></span>
</td>
<td class="nump">$ 26,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_CashAndCashEquivalentsAndU.s.DollarCoin', window );">Cash and cash equivalents and U.S. Dollar Coin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ReceiptOfDigitalAssets', window );">Receipt of digital assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">939,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_DisbursementOfDigitalAssets', window );">Disbursement of digital assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">796,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">939,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_FairValueGainOrLossOnDigitalAssets', window );">Fair value gain or loss on digital assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_AmortizationOfPrepaidResearchAndDevelopmentCosts', window );">Amortization of prepaid research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,207,626<span></span>
</td>
<td class="nump">2,884,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RefundableDepositsPayable', window );">Refundable deposits payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,174,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,174,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,445,580<span></span>
</td>
<td class="nump">$ 223,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member] | Class A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member] | Class B Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_AmortizationOfPrepaidResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_AmortizationOfPrepaidResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_CashAndCashEquivalentsAndU.s.DollarCoin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_CashAndCashEquivalentsAndU.s.DollarCoin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_DisbursementOfDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_DisbursementOfDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_FairValueGainOrLossOnDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_FairValueGainOrLossOnDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ReceiptOfDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ReceiptOfDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_RefundableDepositsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_RefundableDepositsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_RefundableDepositsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_RefundableDepositsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_RevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_RevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingAndAdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total expense recognized in the period for promotion, public relations, and brand or product advertising.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingAndAdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cik0002065779_ClassAOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cik0002065779_ClassAOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cik0002065779_ClassBOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cik0002065779_ClassBOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>212
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration and risk (Details) - Revenue Benchmark [Member] - Customer Concentration Risk [Member] - Exascale Labs Inc. [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="nump">24.90%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24.60%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="nump">11.80%<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
<td class="nump">22.30%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customer C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">10.20%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customer D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10.20%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">31.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customer E [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10.10%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customer F [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_CustomerEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_CustomerEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_CustomerFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_CustomerFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>213
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration and risk (Details 1) - Accounts Receivable [Member] - Customer Concentration Risk [Member] - Exascale Labs Inc. [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Customer G [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">42.70%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Customer H [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">38.30%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Customer F [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">23.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Customer D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">43.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Customer I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">15.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="nump">29.70%<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="nump">19.50%<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Customer E [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="nump">10.50%<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_CustomerGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_CustomerGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_CustomerHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_CustomerHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_CustomerFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_CustomerFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_CustomerIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_CustomerIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_CustomerEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_CustomerEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>214
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration and risk (Details 2) - Purchase [Member] - Customer Concentration Risk [Member] - Exascale Labs Inc. [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cik0002065779_PurchaseMember', window );">Supplier A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">26.40%<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">41.40%<span></span>
</td>
<td class="nump">56.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cik0002065779_PurchaseMember', window );">Supplier B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="nump">30.20%<span></span>
</td>
<td class="nump">14.40%<span></span>
</td>
<td class="nump">24.90%<span></span>
</td>
<td class="nump">21.10%<span></span>
</td>
<td class="nump">31.70%<span></span>
</td>
<td class="nump">14.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cik0002065779_PurchaseMember', window );">Supplier C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="nump">33.70%<span></span>
</td>
<td class="nump">32.90%<span></span>
</td>
<td class="nump">24.20%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">18.40%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cik0002065779_PurchaseMember', window );">Supplier D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="nump">13.80%<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cik0002065779_PurchaseMember', window );">Supplier E [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">45.50%<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">47.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cik0002065779_PurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=cik0002065779_PurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_SupplierAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_SupplierAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_SupplierBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_SupplierBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_SupplierCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_SupplierCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_SupplierDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_SupplierDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_SupplierEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_SupplierEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>215
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration and risk (Details 3) - Customer Concentration Risk [Member] - Exascale Labs Inc. [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Supplier E [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ConcentrationRiskPercentage', window );">Concentration of credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Supplier F [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ConcentrationRiskPercentage', window );">Concentration of credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Supplier B [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ConcentrationRiskPercentage', window );">Concentration of credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Supplier D [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ConcentrationRiskPercentage', window );">Concentration of credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Supplier G [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ConcentrationRiskPercentage', window );">Concentration of credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable [Member] | Supplier E [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ConcentrationRiskPercentage', window );">Concentration of credit risk</a></td>
<td class="nump">13.40%<span></span>
</td>
<td class="nump">54.90%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable [Member] | Supplier F [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ConcentrationRiskPercentage', window );">Concentration of credit risk</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">32.30%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable [Member] | Supplier C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ConcentrationRiskPercentage', window );">Concentration of credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.10%<span></span>
</td>
<td class="nump">99.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable [Member] | Supplier B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ConcentrationRiskPercentage', window );">Concentration of credit risk</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable [Member] | Supplier D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ConcentrationRiskPercentage', window );">Concentration of credit risk</a></td>
<td class="nump">12.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable [Member] | Supplier G [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ConcentrationRiskPercentage', window );">Concentration of credit risk</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ConcentrationRiskPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ConcentrationRiskPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_SupplierEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_SupplierEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_SupplierFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_SupplierFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_SupplierBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_SupplierBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_SupplierDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_SupplierDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_SupplierGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_SupplierGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cik0002065779_SupplierCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cik0002065779_SupplierCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>216
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts receivable (Details) - Exascale Labs Inc. [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 1,830,105<span></span>
</td>
<td class="nump">$ 152,536<span></span>
</td>
<td class="nump">$ 123,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Less: allowance for credit losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">$ 1,830,105<span></span>
</td>
<td class="nump">$ 152,536<span></span>
</td>
<td class="nump">$ 123,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>217
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts receivable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>218
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other receivables (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,207,626<span></span>
</td>
<td class="nump">$ 2,884,694<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>219
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equipment, net (Details) - Exascale Labs Inc. [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Equipment</a></td>
<td class="nump">$ 29,198<span></span>
</td>
<td class="nump">$ 29,944<span></span>
</td>
<td class="nump">$ 27,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherNet', window );">Total</a></td>
<td class="nump">29,198<span></span>
</td>
<td class="nump">29,944<span></span>
</td>
<td class="nump">27,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation', window );">Less: accumulated depreciation</a></td>
<td class="num">(14,792)<span></span>
</td>
<td class="num">(10,344)<span></span>
</td>
<td class="num">(4,110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net carrying amount</a></td>
<td class="nump">$ 14,406<span></span>
</td>
<td class="nump">$ 19,600<span></span>
</td>
<td class="nump">$ 23,696<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>220
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment, net (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="nump">$ 1,565<span></span>
</td>
<td class="nump">$ 1,601<span></span>
</td>
<td class="nump">$ 5,194<span></span>
</td>
<td class="nump">$ 4,633<span></span>
</td>
<td class="nump">$ 6,234<span></span>
</td>
<td class="nump">$ 4,110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>221
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Refundable deposits payable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_RefundableDepositsPayable', window );">Refundable deposits payable</a></td>
<td class="nump">$ 1,174,702<span></span>
</td>
<td class="nump">$ 1,445,580<span></span>
</td>
<td class="nump">$ 223,205<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_RefundableDepositsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_RefundableDepositsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>222
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Simple agreements for future equity (Details) - Exascale Labs Inc. [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_SimpleAgreementsForFutureEquity', window );">Balance at beginning</a></td>
<td class="nump">$ 18,243,885<span></span>
</td>
<td class="nump">$ 9,321,564<span></span>
</td>
<td class="nump">$ 9,321,564<span></span>
</td>
<td class="nump">$ 526,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_IssuanceOfSimpleAgreementsForFutureEquity', window );">Issuance of simple agreements for future equity</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">4,275,000<span></span>
</td>
<td class="nump">4,307,500<span></span>
</td>
<td class="nump">5,685,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ChangeInFairValue', window );">Change in fair value</a></td>
<td class="nump">5,098,320<span></span>
</td>
<td class="nump">3,716,052<span></span>
</td>
<td class="nump">4,614,821<span></span>
</td>
<td class="nump">3,110,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_SimpleAgreementsForFutureEquity', window );">Balance at ending</a></td>
<td class="nump">$ 26,842,205<span></span>
</td>
<td class="nump">$ 17,312,616<span></span>
</td>
<td class="nump">$ 18,243,885<span></span>
</td>
<td class="nump">$ 9,321,564<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_IssuanceOfSimpleAgreementsForFutureEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_IssuanceOfSimpleAgreementsForFutureEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_SimpleAgreementsForFutureEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_SimpleAgreementsForFutureEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>223
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Simple agreements for future equity (Details Narrative) - Exascale Labs Inc. [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">33 Months Ended</th>
<th class="th" colspan="1">42 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 06, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Aggregate gross proceeds</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 4,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,307,500<span></span>
</td>
<td class="nump">$ 5,685,000<span></span>
</td>
<td class="nump">$ 10,592,500<span></span>
</td>
<td class="nump">$ 14,092,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_EquityFinancingDescription', window );">Equity Financing description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">SAFEs with an aggregate purchase amount of $13,632,500 include an Equity Financing conversion feature, while
SAFEs with an aggregate purchase amount of $460,000 do not include this feature and are generally settled only upon a Liquidity Event
or a Dissolution Event, in accordance with their terms.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">SAFEs with an aggregate
purchase amount of $10,132,500 include an Equity Financing conversion feature, while SAFEs with an aggregate purchase amount of $460,000
do not include this feature and are generally settled only upon a Liquidity Event or a Dissolution Event, in accordance with their terms.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_AdditionalSafesProceeds', window );">Additional SAFEs proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_CumulativeProceeds', window );">Cumulative proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,092,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_AdditionalSafesProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_AdditionalSafesProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_CumulativeProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_CumulativeProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_EquityFinancingDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_EquityFinancingDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>224
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details) - Exascale Labs Inc. [Member]<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">US Statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax rate</a></td>
<td class="nump">8.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.70%<span></span>
</td>
<td class="nump">8.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Change in fair value of simple agreements for future equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.90%)<span></span>
</td>
<td class="num">(18.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.80%)<span></span>
</td>
<td class="num">(11.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>225
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income taxes (Details 1) - Exascale Labs Inc. [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 1,652,998<span></span>
</td>
<td class="nump">$ 748,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">1,652,998<span></span>
</td>
<td class="nump">748,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(1,652,998)<span></span>
</td>
<td class="num">(748,679)<span></span>
</td>
<td class="num">$ (200,468)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>226
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details 2) - Exascale Labs Inc. [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at the beginning of the year</a></td>
<td class="num">$ (748,679)<span></span>
</td>
<td class="num">$ (200,468)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Additions</a></td>
<td class="num">(904,319)<span></span>
</td>
<td class="num">(548,211)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at the end of the year</a></td>
<td class="num">$ (1,652,998)<span></span>
</td>
<td class="num">$ (748,679)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>227
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details Narrative) - Exascale Labs Inc. [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax rate</a></td>
<td class="nump">8.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.70%<span></span>
</td>
<td class="nump">8.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Evana Alpha Pte. Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=cik0002065779_EvanaAlphaPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=cik0002065779_EvanaAlphaPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>228
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation (Details) - Exascale Labs Inc. [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 153,266<span></span>
</td>
<td class="nump">$ 153,266<span></span>
</td>
<td class="nump">$ 21,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_IncomeStatementLocationsAxis=cik0002065779_SellingAndMarketingExpensesMember', window );">Selling and marketing expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,266<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_IncomeStatementLocationsAxis=cik0002065779_GeneralAndAdministrativeExpensesMember', window );">General and administrative expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 21,104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_IncomeStatementLocationsAxis=cik0002065779_SellingAndMarketingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_IncomeStatementLocationsAxis=cik0002065779_SellingAndMarketingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_IncomeStatementLocationsAxis=cik0002065779_GeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_IncomeStatementLocationsAxis=cik0002065779_GeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>229
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation (Details Narrative) - Exascale Labs Inc. [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jan. 06, 2025</div></th>
<th class="th"><div>Dec. 02, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 153,266<span></span>
</td>
<td class="nump">$ 153,266<span></span>
</td>
<td class="nump">$ 21,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">$ 468,696<span></span>
</td>
<td class="nump">$ 103,107<span></span>
</td>
<td class="nump">$ 928,255<span></span>
</td>
<td class="nump">$ 268,159<span></span>
</td>
<td class="nump">362,982<span></span>
</td>
<td class="nump">273,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_SharesDescription', window );">Shares description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0.9375 shares of the Company were vested, with remaining 0.5625 shares unvested.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0.375 shares of the Company were vested,
with remaining 1.125 shares unvested.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_DiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_PerpetualRate', window );">Perpetual rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_GrantedEquityAward', window );">Granted equity award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Non employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_SharesDescription', window );">Shares description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the first half of the equity award had been vested<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_DiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_PerpetualRate', window );">Perpetual rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_GrantedEquityAward', window );">Granted equity award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05333%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Third party service provider [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_DiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_PerpetualRate', window );">Perpetual rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_DiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_DiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_GrantedEquityAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_GrantedEquityAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_PerpetualRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_PerpetualRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_SharesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_SharesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cik0002065779_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cik0002065779_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cik0002065779_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cik0002065779_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cik0002065779_ThirdPartyServiceProviderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cik0002065779_ThirdPartyServiceProviderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>230
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions (Details Narrative) - Exascale Labs Inc. [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_ConsultingFees', window );">Consulting fees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="nump">$ 73,150<span></span>
</td>
<td class="nump">$ 100,150<span></span>
</td>
<td class="nump">$ 75,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_OutstandingBalancesPayable', window );">Outstanding balances payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_ConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_ConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_OutstandingBalancesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_OutstandingBalancesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>231
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and diluted net loss per share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="4">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2026</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2026</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_DenominatorForBasicAndDilutedLossPerShareAbstract', window );"><strong>Denominator for basic and diluted loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average ordinary shares outstanding, Basic</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average ordinary shares outstanding, diluted</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share</a></td>
<td class="num">$ (5.90)<span></span>
</td>
<td class="num">$ (100.00)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share</a></td>
<td class="num">$ (5.90)<span></span>
</td>
<td class="num">$ (100.00)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to ordinary shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,632,431)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1,537,059)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (7,916,977)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (6,178,537)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (7,659,667)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (4,956,347)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_DenominatorForBasicAndDilutedLossPerShareAbstract', window );"><strong>Denominator for basic and diluted loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average ordinary shares outstanding, Basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average ordinary shares outstanding, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,754.95)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (1,024.70)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (5,277.98)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (4,119.02)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (5,106.44)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (3,304.23)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,754.95)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (1,024.70)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (5,277.98)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (4,119.02)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (5,106.44)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (3,304.23)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="14"></td></tr>
<tr><td colspan="14"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In January&#160;2026, the Company adopted an Amended and Restated Certificate
        of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company&#8217;s equity is divided
        into 303 Class A ordinary shares and 1,197 Class B ordinary shares, which are entitled to one (1) vote and twenty (20) votes per share,
        respectively. Despite the differential in voting power, Class A and Class B ordinary shares rank pari passu in all other respects, sharing
        ratably in dividends and any distributions upon liquidation.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s share-based compensation awards are expected to be settled through transfers of existing
        ordinary shares held by the controlling shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary
        shares are included in issued and outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase
        the Company&#8217;s total issued and outstanding shares. During the years ended June&#160;30, 2024 and 2025, diluted net loss per share
        is calculated in the same manner as basic net loss per share.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">During the three and nine months ended March&#160;31, 2025 and 2026, diluted
        net loss per share is calculated in the same manner as basic net loss per share, as the Company was in a net loss position and all potential ordinary shares were anti-dilutive.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_DenominatorForBasicAndDilutedLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_DenominatorForBasicAndDilutedLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>232
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information (Details 1) - Exascale Labs Inc. [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">$ 3,754,586<span></span>
</td>
<td class="nump">$ 1,862,158<span></span>
</td>
<td class="nump">$ 10,561,331<span></span>
</td>
<td class="nump">$ 4,475,885<span></span>
</td>
<td class="nump">$ 7,015,512<span></span>
</td>
<td class="nump">$ 1,319,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_SG', window );">SINGAPORE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">425,009<span></span>
</td>
<td class="nump">662,559<span></span>
</td>
<td class="nump">1,237,464<span></span>
</td>
<td class="nump">1,361,844<span></span>
</td>
<td class="nump">2,484,905<span></span>
</td>
<td class="nump">260,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">1,564,836<span></span>
</td>
<td class="nump">581,009<span></span>
</td>
<td class="nump">4,560,992<span></span>
</td>
<td class="nump">1,273,279<span></span>
</td>
<td class="nump">2,085,579<span></span>
</td>
<td class="nump">169,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">1,139,055<span></span>
</td>
<td class="nump">367,107<span></span>
</td>
<td class="nump">3,232,326<span></span>
</td>
<td class="nump">1,089,559<span></span>
</td>
<td class="nump">1,443,306<span></span>
</td>
<td class="nump">574,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">HONG KONG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">417,992<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">1,118,534<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">157,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">UNITED KINGDOM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">207,694<span></span>
</td>
<td class="nump">98,483<span></span>
</td>
<td class="nump">412,015<span></span>
</td>
<td class="nump">291,203<span></span>
</td>
<td class="nump">391,722<span></span>
</td>
<td class="nump">145,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cik0002065779_OthersMember', window );">Others [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_SG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_SG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cik0002065779_OthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cik0002065779_OthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>233
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies (Details Narrative) - Exascale Labs Inc. [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Dec. 16, 2025</div></th>
<th class="th"><div>Feb. 11, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_OrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination payable</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_OrdinarySharesPerShare', window );">ordinary shares per share</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cik0002065779_EvanaAlphaPteLtdMember', window );">Evana Alpha Pte. Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_OrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">New shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfNotesReceivable', window );">Proceeds from safes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_OrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_OrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_OrdinarySharesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_OrdinarySharesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cik0002065779_EvanaAlphaPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cik0002065779_EvanaAlphaPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>234
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Crypto assets (Details) - Exascale Labs Inc. [Member]<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CryptoAssetAxis=cik0002065779_DigitalAssetsMember', window );">Digital Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CryptoAssetHoldingLineItems', window );"><strong>Crypto Asset, Holding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CryptoAssetFairValue', window );">Beginning balance, January 1</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CryptoAssetPurchase', window );">Additions</a></td>
<td class="nump">939,397<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CryptoAssetSale', window );">Disposals - sold for US dollars</a></td>
<td class="num">(596,852)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CryptoAssetDisposition', window );">Disposals</a></td>
<td class="num">(342,545)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CryptoAssetFairValue', window );">Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CryptoAssetAxis=cik0002065779_USDCMember', window );">USDC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CryptoAssetHoldingLineItems', window );"><strong>Crypto Asset, Holding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CryptoAssetFairValue', window );">Beginning balance, January 1</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CryptoAssetPurchase', window );">Additions</a></td>
<td class="nump">4,711,169<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CryptoAssetSale', window );">Disposals - sold for US dollars</a></td>
<td class="num">(9,900)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CryptoAssetDisposition', window );">Disposals</a></td>
<td class="num">(626,854)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CryptoAssetFairValue', window );">Ending balance</a></td>
<td class="nump">$ 4,074,415<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company acquired a total of 939,397 USDT at a cost of $939,397, funded by revenues and collections of other receivables. The Company acquired a total of 4,711,169 USDC at a cost of $4,711,169, funded by revenues, interest income,
        collections of other receivables and investment proceeds from SAFEs.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The Company used digital assets and USDC to settle professional service
        fees and other expenditures.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetDisposition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in crypto asset from disposition. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetDisposition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of crypto asset. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476163/350-60-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetHoldingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetHoldingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in crypto asset from purchase. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in crypto asset from sale. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CryptoAssetAxis=cik0002065779_DigitalAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CryptoAssetAxis=cik0002065779_DigitalAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CryptoAssetAxis=cik0002065779_USDCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CryptoAssetAxis=cik0002065779_USDCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>235
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Crypto assets (Details 1) - Exascale Labs Inc. [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CryptoAssetHoldingLineItems', window );"><strong>Crypto Asset, Holding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 3,754,586<span></span>
</td>
<td class="nump">$ 1,862,158<span></span>
</td>
<td class="nump">$ 10,561,331<span></span>
</td>
<td class="nump">$ 4,475,885<span></span>
</td>
<td class="nump">$ 7,015,512<span></span>
</td>
<td class="nump">$ 1,319,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CryptoAssetAxis=cik0002065779_DigitalAssetsAndUSDCMember', window );">Digital assets and USDC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CryptoAssetHoldingLineItems', window );"><strong>Crypto Asset, Holding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,197,326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,452,102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Cost and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">969,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,138)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cik0002065779_TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc', window );">Total operating activities settled in digital assets and USDC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,681,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cik0002065779_TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cik0002065779_TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cik0002065779_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetHoldingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetHoldingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CryptoAssetAxis=cik0002065779_DigitalAssetsAndUSDCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CryptoAssetAxis=cik0002065779_DigitalAssetsAndUSDCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>236
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Crypto assets (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember', window );">Exascale Labs Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Investment proceeds</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cik0002065779_ExascaleLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>237
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Jun. 10, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0002065779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">D. Boral ARC Acquisition I Corp<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_RegnFileNb', window );">Registration File Number</a></td>
<td class="text">333-295869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-4/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_RegnFileNb">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_RegnFileNb</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>238
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings<br></strong></div></th>
<th class="th">
<div>Jun. 10, 2026 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingAxis=1', window );">Offering: 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Class A Common Stock, par value $0.0001 per share, to be issued to shareholders<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">41,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit | $ / shares</a></td>
<td class="nump">10.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 439,604,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 60,709.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Offering Note</b></p>



















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">1</td>
    <td style="text-align: justify">Represents Common Stock issuable, pursuant to the Business Combination described in the proxy statement/prospectus forming part of this registration statement, to holders of (i) 29,000,000 Class A ordinary shares of BCAR, (ii) 12,000,000 Class B ordinary shares of BCAR, and (iii) 200,000 Class A ordinary shares of BCAR underlying the private units, each consisting of one Class A ordinary share and one -half of one warrant (the &#8220;Private Units&#8221;), issued in a private placement that closed concurrently with BCAR&#8217;s initial public offering. The per unit price is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum aggregate is based on the average of the high and low prices of BCAR Class A Ordinary Shares, as quoted on the Nasdaq Global Market on May&#160;8, 2026, which was approximately $10.67 per share&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">2</td>
    <td style="text-align: justify">Represents the warrants issuable to holders of 14,000,000 public warrants of BCAR and 100,000 private warrants of BCAR. Consistent with the response to Question 240.06 of the Securities Act Rules Compliance and Disclosure Interpretations and pursuant to Rule&#160;457(g) of the Securities Act, the registration fee with respect to the warrants has been allocated to the Common Stock underlying BCAR&#8217;s public warrants, and those shares of Class A Common Stock are included in the total registration fee.&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">3</td>
    <td style="text-align: justify">Represents 14,000,000 shares of Common Stock underlying BCAR&#8217;s public warrants and 100,000 shares of Common Stock underlying BCAR&#8217;s private warrants, with the per unit price estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum offering price per share is based on the average of the high and low prices of BCAR&#8217;s public warrants as quoted on Nasdaq Global Market on May&#160;8, 2026, which was $1.59 per warrant.&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">4</td>
    <td style="text-align: justify">Rule&#160;457(f) Fee Calculation Details <br/><br/>The amount to be registered represents the maximum amount of Class A Common Stock issuable to the stockholders of Exascale in connection with the Business Combination described in the proxy statement/prospectus forming part of this registration statement. The value per share of the securities to be received by Exascale upon the issuance of such securities and the proposed maximum offering price per share is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(f)(2) under the Securities Act. Exascale is a private company, no market exists for its securities, and Exascale has an accumulated deficit. Therefore, the proposed maximum offering price per share is one-third of the aggregate par value of the securities expected to be exchanged in the Business Combination. No cash is to be received or paid by BCAR in connection with the securities to be exchanged in the Business Combination.&#160;</td> </tr>
  </table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount of<br/> Securities<br/> to be Received <br/> or Cancelled</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Value per <br/> Share of Securities<br/> to be Received<br/> or Cancelled</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Total Value <br/> of Securities <br/> to be Received <br/> or Cancelled</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cash Consideration<br/> Received by<br/> the registrant</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cash Consideration<br/> (Paid) by the<br/> registrant</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maximum Aggregate <br/> Offering Price</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: middle; width: 15%; text-align: center">19,256,000</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">$0.003</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">$57,768</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">$57,768</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingAxis=2', window );">Offering: 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Other<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Warrants of BCAR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">14,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit | $ / shares</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Offering Note</b></p>



















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">1</td>
    <td style="text-align: justify">Represents Common Stock issuable, pursuant to the Business Combination described in the proxy statement/prospectus forming part of this registration statement, to holders of (i) 29,000,000 Class A ordinary shares of BCAR, (ii) 12,000,000 Class B ordinary shares of BCAR, and (iii) 200,000 Class A ordinary shares of BCAR underlying the private units, each consisting of one Class A ordinary share and one -half of one warrant (the &#8220;Private Units&#8221;), issued in a private placement that closed concurrently with BCAR&#8217;s initial public offering. The per unit price is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum aggregate is based on the average of the high and low prices of BCAR Class A Ordinary Shares, as quoted on the Nasdaq Global Market on May&#160;8, 2026, which was approximately $10.67 per share&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">2</td>
    <td style="text-align: justify">Represents the warrants issuable to holders of 14,000,000 public warrants of BCAR and 100,000 private warrants of BCAR. Consistent with the response to Question 240.06 of the Securities Act Rules Compliance and Disclosure Interpretations and pursuant to Rule&#160;457(g) of the Securities Act, the registration fee with respect to the warrants has been allocated to the Common Stock underlying BCAR&#8217;s public warrants, and those shares of Class A Common Stock are included in the total registration fee.&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">3</td>
    <td style="text-align: justify">Represents 14,000,000 shares of Common Stock underlying BCAR&#8217;s public warrants and 100,000 shares of Common Stock underlying BCAR&#8217;s private warrants, with the per unit price estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum offering price per share is based on the average of the high and low prices of BCAR&#8217;s public warrants as quoted on Nasdaq Global Market on May&#160;8, 2026, which was $1.59 per warrant.&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">4</td>
    <td style="text-align: justify">Rule&#160;457(f) Fee Calculation Details <br/><br/>The amount to be registered represents the maximum amount of Class A Common Stock issuable to the stockholders of Exascale in connection with the Business Combination described in the proxy statement/prospectus forming part of this registration statement. The value per share of the securities to be received by Exascale upon the issuance of such securities and the proposed maximum offering price per share is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(f)(2) under the Securities Act. Exascale is a private company, no market exists for its securities, and Exascale has an accumulated deficit. Therefore, the proposed maximum offering price per share is one-third of the aggregate par value of the securities expected to be exchanged in the Business Combination. No cash is to be received or paid by BCAR in connection with the securities to be exchanged in the Business Combination.&#160;</td> </tr>
  </table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount of<br/> Securities<br/> to be Received <br/> or Cancelled</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Value per <br/> Share of Securities<br/> to be Received<br/> or Cancelled</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Total Value <br/> of Securities <br/> to be Received <br/> or Cancelled</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cash Consideration<br/> Received by<br/> the registrant</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cash Consideration<br/> (Paid) by the<br/> registrant</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maximum Aggregate <br/> Offering Price</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: middle; width: 15%; text-align: center">19,256,000</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">$0.003</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">$57,768</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">$57,768</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingAxis=3', window );">Offering: 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_Rule457aFlg', window );">Rule 457(a)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Class A Common Stock issuable upon exercise of Warrants of BCAR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">14,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit | $ / shares</a></td>
<td class="nump">1.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 22,419,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 3,096.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Offering Note</b></p>



















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">1</td>
    <td style="text-align: justify">Represents Common Stock issuable, pursuant to the Business Combination described in the proxy statement/prospectus forming part of this registration statement, to holders of (i) 29,000,000 Class A ordinary shares of BCAR, (ii) 12,000,000 Class B ordinary shares of BCAR, and (iii) 200,000 Class A ordinary shares of BCAR underlying the private units, each consisting of one Class A ordinary share and one -half of one warrant (the &#8220;Private Units&#8221;), issued in a private placement that closed concurrently with BCAR&#8217;s initial public offering. The per unit price is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum aggregate is based on the average of the high and low prices of BCAR Class A Ordinary Shares, as quoted on the Nasdaq Global Market on May&#160;8, 2026, which was approximately $10.67 per share&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">2</td>
    <td style="text-align: justify">Represents the warrants issuable to holders of 14,000,000 public warrants of BCAR and 100,000 private warrants of BCAR. Consistent with the response to Question 240.06 of the Securities Act Rules Compliance and Disclosure Interpretations and pursuant to Rule&#160;457(g) of the Securities Act, the registration fee with respect to the warrants has been allocated to the Common Stock underlying BCAR&#8217;s public warrants, and those shares of Class A Common Stock are included in the total registration fee.&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">3</td>
    <td style="text-align: justify">Represents 14,000,000 shares of Common Stock underlying BCAR&#8217;s public warrants and 100,000 shares of Common Stock underlying BCAR&#8217;s private warrants, with the per unit price estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum offering price per share is based on the average of the high and low prices of BCAR&#8217;s public warrants as quoted on Nasdaq Global Market on May&#160;8, 2026, which was $1.59 per warrant.&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">4</td>
    <td style="text-align: justify">Rule&#160;457(f) Fee Calculation Details <br/><br/>The amount to be registered represents the maximum amount of Class A Common Stock issuable to the stockholders of Exascale in connection with the Business Combination described in the proxy statement/prospectus forming part of this registration statement. The value per share of the securities to be received by Exascale upon the issuance of such securities and the proposed maximum offering price per share is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(f)(2) under the Securities Act. Exascale is a private company, no market exists for its securities, and Exascale has an accumulated deficit. Therefore, the proposed maximum offering price per share is one-third of the aggregate par value of the securities expected to be exchanged in the Business Combination. No cash is to be received or paid by BCAR in connection with the securities to be exchanged in the Business Combination.&#160;</td> </tr>
  </table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount of<br/> Securities<br/> to be Received <br/> or Cancelled</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Value per <br/> Share of Securities<br/> to be Received<br/> or Cancelled</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Total Value <br/> of Securities <br/> to be Received <br/> or Cancelled</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cash Consideration<br/> Received by<br/> the registrant</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cash Consideration<br/> (Paid) by the<br/> registrant</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maximum Aggregate <br/> Offering Price</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: middle; width: 15%; text-align: center">19,256,000</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">$0.003</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">$57,768</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">$57,768</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingAxis=4', window );">Offering: 4</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Class A Common Stock, par value $0.0001 per share, to be issued to shareholders of Exascale Labs<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">19,256,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 57,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 7.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Offering Note</b></p>



















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">1</td>
    <td style="text-align: justify">Represents Common Stock issuable, pursuant to the Business Combination described in the proxy statement/prospectus forming part of this registration statement, to holders of (i) 29,000,000 Class A ordinary shares of BCAR, (ii) 12,000,000 Class B ordinary shares of BCAR, and (iii) 200,000 Class A ordinary shares of BCAR underlying the private units, each consisting of one Class A ordinary share and one -half of one warrant (the &#8220;Private Units&#8221;), issued in a private placement that closed concurrently with BCAR&#8217;s initial public offering. The per unit price is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum aggregate is based on the average of the high and low prices of BCAR Class A Ordinary Shares, as quoted on the Nasdaq Global Market on May&#160;8, 2026, which was approximately $10.67 per share&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">2</td>
    <td style="text-align: justify">Represents the warrants issuable to holders of 14,000,000 public warrants of BCAR and 100,000 private warrants of BCAR. Consistent with the response to Question 240.06 of the Securities Act Rules Compliance and Disclosure Interpretations and pursuant to Rule&#160;457(g) of the Securities Act, the registration fee with respect to the warrants has been allocated to the Common Stock underlying BCAR&#8217;s public warrants, and those shares of Class A Common Stock are included in the total registration fee.&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">3</td>
    <td style="text-align: justify">Represents 14,000,000 shares of Common Stock underlying BCAR&#8217;s public warrants and 100,000 shares of Common Stock underlying BCAR&#8217;s private warrants, with the per unit price estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum offering price per share is based on the average of the high and low prices of BCAR&#8217;s public warrants as quoted on Nasdaq Global Market on May&#160;8, 2026, which was $1.59 per warrant.&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">4</td>
    <td style="text-align: justify">Rule&#160;457(f) Fee Calculation Details <br/><br/>The amount to be registered represents the maximum amount of Class A Common Stock issuable to the stockholders of Exascale in connection with the Business Combination described in the proxy statement/prospectus forming part of this registration statement. The value per share of the securities to be received by Exascale upon the issuance of such securities and the proposed maximum offering price per share is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(f)(2) under the Securities Act. Exascale is a private company, no market exists for its securities, and Exascale has an accumulated deficit. Therefore, the proposed maximum offering price per share is one-third of the aggregate par value of the securities expected to be exchanged in the Business Combination. No cash is to be received or paid by BCAR in connection with the securities to be exchanged in the Business Combination.&#160;</td> </tr>
  </table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount of<br/> Securities<br/> to be Received <br/> or Cancelled</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Value per <br/> Share of Securities<br/> to be Received<br/> or Cancelled</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Total Value <br/> of Securities <br/> to be Received <br/> or Cancelled</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cash Consideration<br/> Received by<br/> the registrant</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cash Consideration<br/> (Paid) by the<br/> registrant</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maximum Aggregate <br/> Offering Price</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: middle; width: 15%; text-align: center">19,256,000</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">$0.003</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">$57,768</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">$57,768</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingAxis=5', window );">Offering: 5</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Class B Common Stock, par value $0.0001 per share, to be issued to certain shareholders<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">30,744,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 92,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 12.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Offering Note</b></p>



















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">1</td>
    <td style="text-align: justify">Represents Common Stock issuable, pursuant to the Business Combination described in the proxy statement/prospectus forming part of this registration statement, to holders of (i) 29,000,000 Class A ordinary shares of BCAR, (ii) 12,000,000 Class B ordinary shares of BCAR, and (iii) 200,000 Class A ordinary shares of BCAR underlying the private units, each consisting of one Class A ordinary share and one -half of one warrant (the &#8220;Private Units&#8221;), issued in a private placement that closed concurrently with BCAR&#8217;s initial public offering. The per unit price is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum aggregate is based on the average of the high and low prices of BCAR Class A Ordinary Shares, as quoted on the Nasdaq Global Market on May&#160;8, 2026, which was approximately $10.67 per share&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">2</td>
    <td style="text-align: justify">Represents the warrants issuable to holders of 14,000,000 public warrants of BCAR and 100,000 private warrants of BCAR. Consistent with the response to Question 240.06 of the Securities Act Rules Compliance and Disclosure Interpretations and pursuant to Rule&#160;457(g) of the Securities Act, the registration fee with respect to the warrants has been allocated to the Common Stock underlying BCAR&#8217;s public warrants, and those shares of Class A Common Stock are included in the total registration fee.&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">3</td>
    <td style="text-align: justify">Represents 14,000,000 shares of Common Stock underlying BCAR&#8217;s public warrants and 100,000 shares of Common Stock underlying BCAR&#8217;s private warrants, with the per unit price estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(c) under the Securities Act. The proposed maximum offering price per share is based on the average of the high and low prices of BCAR&#8217;s public warrants as quoted on Nasdaq Global Market on May&#160;8, 2026, which was $1.59 per warrant.&#160;</td> </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">4</td>
    <td style="text-align: justify">Rule&#160;457(f) Fee Calculation Details <br/><br/>The amount to be registered represents the maximum amount of Class A Common Stock issuable to the stockholders of Exascale in connection with the Business Combination described in the proxy statement/prospectus forming part of this registration statement. The value per share of the securities to be received by Exascale upon the issuance of such securities and the proposed maximum offering price per share is estimated solely for purposes of calculating the registration fee in accordance with Rule&#160;457(f)(2) under the Securities Act. Exascale is a private company, no market exists for its securities, and Exascale has an accumulated deficit. Therefore, the proposed maximum offering price per share is one-third of the aggregate par value of the securities expected to be exchanged in the Business Combination. No cash is to be received or paid by BCAR in connection with the securities to be exchanged in the Business Combination.&#160;</td> </tr>
  </table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount of<br/> Securities<br/> to be Received <br/> or Cancelled</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Value per <br/> Share of Securities<br/> to be Received<br/> or Cancelled</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Total Value <br/> of Securities <br/> to be Received <br/> or Cancelled</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cash Consideration<br/> Received by<br/> the registrant</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cash Consideration<br/> (Paid) by the<br/> registrant</td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maximum Aggregate <br/> Offering Price</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: middle; width: 15%; text-align: center">19,256,000</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">$0.003</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">$57,768</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: middle; width: 15%; text-align: center">$57,768</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesOthrRuleFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesOthrRuleFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule457aFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule457aFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>239
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offsets<br></strong></div></th>
<th class="th">
<div>Jun. 10, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OffsetAxis=1', window );">Offset: 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OffsetTable', window );"><strong>Offset Payment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OffsetClmdInd', window );">Offset Claimed</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_Rule457bOffsetFlg', window );">Rule 457(b) Offset</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OffsetPrrFilerNm', window );">Registrant or Filer Name</a></td>
<td class="text">D. Boral ARC Acquisition I Corp.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OffsetPrrFormTp', window );">Form or Filing Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OffsetPrrFileNb', window );">File Number</a></td>
<td class="text">333-295869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OffsetSrcFilgDt', window );">Filing Date</a></td>
<td class="text">May 14,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OffsetPrrFeeAmt', window );">Fee Paid with Fee Offset Source</a></td>
<td class="nump">$ 63,826.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OffsetAxis=2', window );">Offset: 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OffsetTable', window );"><strong>Offset Payment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OffsetClmdInd', window );">Offset Claimed</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_Rule457bOffsetFlg', window );">Rule 457(b) Offset</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OffsetPrrFormTp', window );">Form or Filing Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OffsetPrrFileNb', window );">File Number</a></td>
<td class="text">333-295869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OffsetClmInitlFilgDt', window );">Initial Filing Date</a></td>
<td class="text">May 14,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OffsetClmdAmt', window );">Fee Offset Claimed</a></td>
<td class="nump">$ 63,826.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_OffsetExpltnForClmdAmt', window );">Explanation for Claimed Amount</a></td>
<td class="text">Offset Claims <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetClmInitlFilgDt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the "parent" filing) .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection p<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetClmInitlFilgDt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetClmdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of offsetting fees being claimed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection p<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetClmdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetClmdInd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetClmdInd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetExpltnForClmdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetExpltnForClmdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetPrrFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee previously paid from which an offset is being derived.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection p<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetPrrFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetPrrFileNb">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection p<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetPrrFileNb</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetPrrFilerNm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection p<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetPrrFilerNm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:filerNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetPrrFormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Form Type of the offset filing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection p<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetPrrFormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:formTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetSrcFilgDt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection p<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetSrcFilgDt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule457bOffsetFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule457bOffsetFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetAxis=2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetAxis=2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>240
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Jun. 10, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 462,173,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">63,826.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">63,826.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>241
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>429</ContextCount>
  <ElementCount>383</ElementCount>
  <EntityCount>2</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>83</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - BALANCE SHEET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/BalanceSheet</Role>
      <ShortName>BALANCE SHEET</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - BALANCE SHEET (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/BalanceSheetParenthetical</Role>
      <ShortName>BALANCE SHEET (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - STATEMENT OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/StatementOfOperations</Role>
      <ShortName>STATEMENT OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/StatementOfChangesInStockholdersDeficit</Role>
      <ShortName>STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - STATEMENT OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/StatementOfCashFlows</Role>
      <ShortName>STATEMENT OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>999007 - Disclosure - Description of Organization and Business Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperations</Role>
      <ShortName>Description of Organization and Business Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>999008 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>999009 - Disclosure - Segment information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SegmentInformation</Role>
      <ShortName>Segment information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999010 - Disclosure - Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/BusinessCombination</Role>
      <ShortName>Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999011 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999012 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999013 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/DescriptionOfOrganizationBusinessOperations</Role>
      <ShortName>DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999015 - Disclosure - INITIAL PUBLIC OFFERING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/InitialPublicOffering</Role>
      <ShortName>INITIAL PUBLIC OFFERING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999016 - Disclosure - PRIVATE PLACEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/PrivatePlacement</Role>
      <ShortName>PRIVATE PLACEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999017 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999018 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999019 - Disclosure - STOCKHOLDER’S EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDER’S EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999020 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Organization and principal activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/OrganizationAndPrincipalActivities</Role>
      <ShortName>Organization and principal activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDisclosure</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Concentration and risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/ConcentrationAndRisk</Role>
      <ShortName>Concentration and risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Fair value measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/FairValueMeasurementsDisclosure</Role>
      <ShortName>Fair value measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Accounts receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/AccountsReceivable</Role>
      <ShortName>Accounts receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Other receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/OtherReceivables</Role>
      <ShortName>Other receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/EquipmentNet</Role>
      <ShortName>Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Refundable deposits payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/RefundableDepositsPayable</Role>
      <ShortName>Refundable deposits payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Simple agreements for future equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SimpleAgreementsForFutureEquity</Role>
      <ShortName>Simple agreements for future equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/IncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Share-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/Share-basedCompensation</Role>
      <ShortName>Share-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Related party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/RelatedPartyTransactionsDisclosure</Role>
      <ShortName>Related party transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Basic and diluted net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/BasicAndDilutedNetLossPerShare</Role>
      <ShortName>Basic and diluted net loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/CommitmentsAndContingenciesDisclosure</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Crypto assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/CryptoAssets</Role>
      <ShortName>Crypto assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://cik0002065779/role/SignificantAccountingPolicies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999037 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://cik0002065779/role/SignificantAccountingPolicies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://cik0002065779/role/SignificantAccountingPolicies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cik0002065779/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999040 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cik0002065779/role/FairValueMeasurements</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Summary of significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure</Role>
      <ShortName>Summary of significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDisclosure</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Concentration and risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/ConcentrationAndRiskTables</Role>
      <ShortName>Concentration and risk (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cik0002065779/role/ConcentrationAndRisk</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Fair value measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/FairValueMeasurementsTablesDisclosure</Role>
      <ShortName>Fair value measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cik0002065779/role/FairValueMeasurementsDisclosure</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Accounts receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/AccountsReceivableTables</Role>
      <ShortName>Accounts receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cik0002065779/role/AccountsReceivable</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/EquipmentNetTables</Role>
      <ShortName>Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cik0002065779/role/EquipmentNet</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Simple agreements for future equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SimpleAgreementsForFutureEquityTables</Role>
      <ShortName>Simple agreements for future equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cik0002065779/role/SimpleAgreementsForFutureEquity</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/IncomeTaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cik0002065779/role/IncomeTaxes</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Share-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/Share-basedCompensationTables</Role>
      <ShortName>Share-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cik0002065779/role/Share-basedCompensation</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Basic and diluted net loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/BasicAndDilutedNetLossPerShareTables</Role>
      <ShortName>Basic and diluted net loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cik0002065779/role/BasicAndDilutedNetLossPerShare</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999050 - Disclosure - Crypto assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/CryptoAssetsTables</Role>
      <ShortName>Crypto assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cik0002065779/role/CryptoAssets</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999051 - Disclosure - Description of Organization and Business Operations (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperationsDetailsNarrative</Role>
      <ShortName>Description of Organization and Business Operations (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperations</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999052 - Disclosure - Business Combination (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/BusinessCombinationDetailsNarrative</Role>
      <ShortName>Business Combination (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/BusinessCombination</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999053 - Disclosure - Share Capital (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/ShareCapitalDetailsNarrative</Role>
      <ShortName>Share Capital (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/ShareCapital</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999054 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative</Role>
      <ShortName>DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/DescriptionOfOrganizationBusinessOperations</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999055 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999056 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999057 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999058 - Disclosure - INITIAL PUBLIC OFFERING (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/InitialPublicOfferingDetailsNarrative</Role>
      <ShortName>INITIAL PUBLIC OFFERING (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/InitialPublicOffering</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999059 - Disclosure - PRIVATE PLACEMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/PrivatePlacementDetailsNarrative</Role>
      <ShortName>PRIVATE PLACEMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/PrivatePlacement</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999060 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/RelatedPartyTransactions</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/CommitmentsAndContingencies</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999062 - Disclosure - STOCKHOLDER’S EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDER’S EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/StockholdersEquity</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999063 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/FairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/FairValueMeasurementsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999064 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/FairValueMeasurementsDetails1</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/FairValueMeasurementsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999065 - Disclosure - FAIR VALUE MEASUREMENTS (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/FairValueMeasurementsDetails2</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/FairValueMeasurementsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999066 - Disclosure - Segment information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SegmentInformationDetails</Role>
      <ShortName>Segment information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/SegmentInformation</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>999067 - Disclosure - Organization and principal activities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative</Role>
      <ShortName>Organization and principal activities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/OrganizationAndPrincipalActivities</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>999068 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>999069 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>999070 - Disclosure - Summary of significant accounting policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure</Role>
      <ShortName>Summary of significant accounting policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>999071 - Disclosure - Concentration and risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/ConcentrationAndRiskDetails</Role>
      <ShortName>Concentration and risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/ConcentrationAndRiskTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>999072 - Disclosure - Concentration and risk (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/ConcentrationAndRiskDetails1</Role>
      <ShortName>Concentration and risk (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/ConcentrationAndRiskTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>999073 - Disclosure - Concentration and risk (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/ConcentrationAndRiskDetails2</Role>
      <ShortName>Concentration and risk (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/ConcentrationAndRiskTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>999074 - Disclosure - Concentration and risk (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/ConcentrationAndRiskDetails3</Role>
      <ShortName>Concentration and risk (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/ConcentrationAndRiskTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>999075 - Disclosure - Accounts receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/AccountsReceivableDetails</Role>
      <ShortName>Accounts receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/AccountsReceivableTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>999076 - Disclosure - Accounts receivable (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/AccountsReceivableDetailsNarrative</Role>
      <ShortName>Accounts receivable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/AccountsReceivableTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>999077 - Disclosure - Other receivables (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/OtherReceivablesDetailsNarrative</Role>
      <ShortName>Other receivables (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/OtherReceivables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>999078 - Disclosure - Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/EquipmentNetDetails</Role>
      <ShortName>Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/EquipmentNetTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>999079 - Disclosure - Equipment, net (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/EquipmentNetDetailsNarrative</Role>
      <ShortName>Equipment, net (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/EquipmentNetTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>999080 - Disclosure - Refundable deposits payable (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/RefundableDepositsPayableDetailsNarrative</Role>
      <ShortName>Refundable deposits payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/RefundableDepositsPayable</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>999081 - Disclosure - Simple agreements for future equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SimpleAgreementsForFutureEquityDetails</Role>
      <ShortName>Simple agreements for future equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/SimpleAgreementsForFutureEquityTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>999082 - Disclosure - Simple agreements for future equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative</Role>
      <ShortName>Simple agreements for future equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/SimpleAgreementsForFutureEquityTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>999083 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/IncomeTaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/IncomeTaxesTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>999084 - Disclosure - Income taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/IncomeTaxesDetails1</Role>
      <ShortName>Income taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/IncomeTaxesTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>999085 - Disclosure - Income taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/IncomeTaxesDetails2</Role>
      <ShortName>Income taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/IncomeTaxesTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>999086 - Disclosure - Income taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/IncomeTaxesTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>999087 - Disclosure - Share-based compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/Share-basedCompensationDetails</Role>
      <ShortName>Share-based compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/Share-basedCompensationTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>999088 - Disclosure - Share-based compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/Share-basedCompensationDetailsNarrative</Role>
      <ShortName>Share-based compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/Share-basedCompensationTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>999089 - Disclosure - Related party transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrativeDisclosure</Role>
      <ShortName>Related party transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/RelatedPartyTransactionsDisclosure</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>999090 - Disclosure - Basic and diluted net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Basic and diluted net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/BasicAndDilutedNetLossPerShareTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>999091 - Disclosure - Segment information (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/SegmentInformationDetails1</Role>
      <ShortName>Segment information (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/SegmentInformation</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>999092 - Disclosure - Commitments and contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure</Role>
      <ShortName>Commitments and contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/CommitmentsAndContingenciesDisclosure</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>999093 - Disclosure - Crypto assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/CryptoAssetsDetails</Role>
      <ShortName>Crypto assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/CryptoAssetsTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>999094 - Disclosure - Crypto assets (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/CryptoAssetsDetails1</Role>
      <ShortName>Crypto assets (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/CryptoAssetsTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="dboralarcacq_s4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>999095 - Disclosure - Crypto assets (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cik0002065779/role/CryptoAssetsDetailsNarrative</Role>
      <ShortName>Crypto assets (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cik0002065779/role/CryptoAssetsTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="dboralarcacq_ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="dboralarcacq_ex107.htm">
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="dboralarcacq_ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>995212 - Document - Offsets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOffsetTable</Role>
      <ShortName>Offsets</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="dboralarcacq_ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cik0002065779-20260331.xsd</File>
    <File>cik0002065779-20260331_cal.xml</File>
    <File>cik0002065779-20260331_def.xml</File>
    <File>cik0002065779-20260331_lab.xml</File>
    <File>cik0002065779-20260331_pre.xml</File>
    <File doctype="S-4/A" isDefinitelyFs="true" isUsgaap="true" original="dboralarcacq_s4a.htm">dboralarcacq_s4a.htm</File>
    <File doctype="EX-FILING FEES" original="dboralarcacq_ex107.htm">dboralarcacq_ex107.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1575">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="20">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="67">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>243
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "dboralarcacq_s4a.htm": {
   "nsprefix": "cik0002065779",
   "nsuri": "http://cik0002065779/20260331",
   "dts": {
    "schema": {
     "local": [
      "cik0002065779-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cik0002065779-20260331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cik0002065779-20260331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cik0002065779-20260331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cik0002065779-20260331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "dboralarcacq_s4a.htm"
     ]
    }
   },
   "keyStandard": 232,
   "keyCustom": 119,
   "axisStandard": 22,
   "axisCustom": 1,
   "memberStandard": 22,
   "memberCustom": 53,
   "hidden": {
    "total": 282,
    "http://fasb.org/us-gaap/2025": 221,
    "http://cik0002065779/20260331": 59,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 421,
   "entityCount": 1,
   "segmentCount": 81,
   "elementCount": 587,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 1575,
    "http://xbrl.sec.gov/dei/2025": 18
   },
   "report": {
    "R1": {
     "role": "http://cik0002065779/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cik0002065779/role/BalanceSheet",
     "longName": "00000002 - Statement - BALANCE SHEET",
     "shortName": "BALANCE SHEET",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://cik0002065779/role/BalanceSheetParenthetical",
     "longName": "00000003 - Statement - BALANCE SHEET (Parenthetical)",
     "shortName": "BALANCE SHEET (Parenthetical)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:TemporaryEquitySharesIssued",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://cik0002065779/role/StatementOfOperations",
     "longName": "00000004 - Statement - STATEMENT OF OPERATIONS",
     "shortName": "STATEMENT OF OPERATIONS",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit",
     "longName": "00000005 - Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT",
     "shortName": "STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ExascaleLabsIncMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://cik0002065779/role/StatementOfCashFlows",
     "longName": "00000006 - Statement - STATEMENT OF CASH FLOWS",
     "shortName": "STATEMENT OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:IncreaseDecreaseInAccruedLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperations",
     "longName": "999007 - Disclosure - Description of Organization and Business Operations",
     "shortName": "Description of Organization and Business Operations",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://cik0002065779/role/SignificantAccountingPolicies",
     "longName": "999008 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://cik0002065779/role/SegmentInformation",
     "longName": "999009 - Disclosure - Segment information",
     "shortName": "Segment information",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cik0002065779/role/BusinessCombination",
     "longName": "999010 - Disclosure - Business Combination",
     "shortName": "Business Combination",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cik0002065779/role/ShareCapital",
     "longName": "999011 - Disclosure - Share Capital",
     "shortName": "Share Capital",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R12": {
     "role": "http://cik0002065779/role/SubsequentEvents",
     "longName": "999012 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperations",
     "longName": "999013 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS",
     "shortName": "DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R14": {
     "role": "http://cik0002065779/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R15": {
     "role": "http://cik0002065779/role/InitialPublicOffering",
     "longName": "999015 - Disclosure - INITIAL PUBLIC OFFERING",
     "shortName": "INITIAL PUBLIC OFFERING",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "cik0002065779:InitialPublicOfferingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "cik0002065779:InitialPublicOfferingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cik0002065779/role/PrivatePlacement",
     "longName": "999016 - Disclosure - PRIVATE PLACEMENT",
     "shortName": "PRIVATE PLACEMENT",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "cik0002065779:PrivatePlacementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "cik0002065779:PrivatePlacementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://cik0002065779/role/RelatedPartyTransactions",
     "longName": "999017 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://cik0002065779/role/CommitmentsAndContingencies",
     "longName": "999018 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cik0002065779/role/StockholdersEquity",
     "longName": "999019 - Disclosure - STOCKHOLDER\u2019S EQUITY",
     "shortName": "STOCKHOLDER\u2019S EQUITY",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R20": {
     "role": "http://cik0002065779/role/FairValueMeasurements",
     "longName": "999020 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://cik0002065779/role/OrganizationAndPrincipalActivities",
     "longName": "999021 - Disclosure - Organization and principal activities",
     "shortName": "Organization and principal activities",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R22": {
     "role": "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDisclosure",
     "longName": "999022 - Disclosure - Summary of significant accounting policies",
     "shortName": "Summary of significant accounting policies",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R23": {
     "role": "http://cik0002065779/role/ConcentrationAndRisk",
     "longName": "999023 - Disclosure - Concentration and risk",
     "shortName": "Concentration and risk",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://cik0002065779/role/FairValueMeasurementsDisclosure",
     "longName": "999024 - Disclosure - Fair value measurements",
     "shortName": "Fair value measurements",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://cik0002065779/role/AccountsReceivable",
     "longName": "999025 - Disclosure - Accounts receivable",
     "shortName": "Accounts receivable",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:AccountsAndNontradeReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:AccountsAndNontradeReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://cik0002065779/role/OtherReceivables",
     "longName": "999026 - Disclosure - Other receivables",
     "shortName": "Other receivables",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_ExascaleLabsIncMember",
      "name": "cik0002065779:OtherReceivablesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_ExascaleLabsIncMember",
      "name": "cik0002065779:OtherReceivablesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://cik0002065779/role/EquipmentNet",
     "longName": "999027 - Disclosure - Equipment, net",
     "shortName": "Equipment, net",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://cik0002065779/role/RefundableDepositsPayable",
     "longName": "999028 - Disclosure - Refundable deposits payable",
     "shortName": "Refundable deposits payable",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_ExascaleLabsIncMember",
      "name": "cik0002065779:RefundableDepositsPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_ExascaleLabsIncMember",
      "name": "cik0002065779:RefundableDepositsPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://cik0002065779/role/SimpleAgreementsForFutureEquity",
     "longName": "999029 - Disclosure - Simple agreements for future equity",
     "shortName": "Simple agreements for future equity",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "cik0002065779:SimpleAgreementsForFutureEquityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "cik0002065779:SimpleAgreementsForFutureEquityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://cik0002065779/role/IncomeTaxes",
     "longName": "999030 - Disclosure - Income taxes",
     "shortName": "Income taxes",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://cik0002065779/role/Share-basedCompensation",
     "longName": "999031 - Disclosure - Share-based compensation",
     "shortName": "Share-based compensation",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://cik0002065779/role/RelatedPartyTransactionsDisclosure",
     "longName": "999032 - Disclosure - Related party transactions",
     "shortName": "Related party transactions",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://cik0002065779/role/BasicAndDilutedNetLossPerShare",
     "longName": "999033 - Disclosure - Basic and diluted net loss per share",
     "shortName": "Basic and diluted net loss per share",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://cik0002065779/role/CommitmentsAndContingenciesDisclosure",
     "longName": "999034 - Disclosure - Commitments and contingencies",
     "shortName": "Commitments and contingencies",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://cik0002065779/role/CryptoAssets",
     "longName": "999035 - Disclosure - Crypto assets",
     "shortName": "Crypto assets",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:CryptoAssetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:CryptoAssetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://cik0002065779/role/SignificantAccountingPoliciesPolicies",
     "longName": "999036 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999037 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure",
     "longName": "999038 - Disclosure - Summary of significant accounting policies (Policies)",
     "shortName": "Summary of significant accounting policies (Policies)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "cik0002065779:GoingConcernPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cik0002065779:ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cik0002065779:ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://cik0002065779/role/FairValueMeasurementsTables",
     "longName": "999040 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure",
     "longName": "999041 - Disclosure - Summary of significant accounting policies (Tables)",
     "shortName": "Summary of significant accounting policies (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "cik0002065779:ScheduleOfRevenueRecognitionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueRecognitionDeferredRevenue",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "cik0002065779:ScheduleOfRevenueRecognitionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueRecognitionDeferredRevenue",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://cik0002065779/role/ConcentrationAndRiskTables",
     "longName": "999042 - Disclosure - Concentration and risk (Tables)",
     "shortName": "Concentration and risk (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "cik0002065779:ScheduleOfConcentrationOfCustomersTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "cik0002065779:ScheduleOfConcentrationOfCustomersTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://cik0002065779/role/FairValueMeasurementsTablesDisclosure",
     "longName": "999043 - Disclosure - Fair value measurements (Tables)",
     "shortName": "Fair value measurements (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://cik0002065779/role/AccountsReceivableTables",
     "longName": "999044 - Disclosure - Accounts receivable (Tables)",
     "shortName": "Accounts receivable (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://cik0002065779/role/EquipmentNetTables",
     "longName": "999045 - Disclosure - Equipment, net (Tables)",
     "shortName": "Equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://cik0002065779/role/SimpleAgreementsForFutureEquityTables",
     "longName": "999046 - Disclosure - Simple agreements for future equity (Tables)",
     "shortName": "Simple agreements for future equity (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cik0002065779:SimpleAgreementsForFutureEquityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cik0002065779:SimpleAgreementsForFutureEquityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://cik0002065779/role/IncomeTaxesTables",
     "longName": "999047 - Disclosure - Income taxes (Tables)",
     "shortName": "Income taxes (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://cik0002065779/role/Share-basedCompensationTables",
     "longName": "999048 - Disclosure - Share-based compensation (Tables)",
     "shortName": "Share-based compensation (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://cik0002065779/role/BasicAndDilutedNetLossPerShareTables",
     "longName": "999049 - Disclosure - Basic and diluted net loss per share (Tables)",
     "shortName": "Basic and diluted net loss per share (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://cik0002065779/role/CryptoAssetsTables",
     "longName": "999050 - Disclosure - Crypto assets (Tables)",
     "shortName": "Crypto assets (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:CryptoAssetActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CryptoAssetTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:CryptoAssetActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CryptoAssetTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperationsDetailsNarrative",
     "longName": "999051 - Disclosure - Description of Organization and Business Operations (Details Narrative)",
     "shortName": "Description of Organization and Business Operations (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R52": {
     "role": "http://cik0002065779/role/BusinessCombinationDetailsNarrative",
     "longName": "999052 - Disclosure - Business Combination (Details Narrative)",
     "shortName": "Business Combination (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-01-11_custom_DBoralARCAcquisitionICorp.Member",
      "name": "cik0002065779:AggregateConsideration",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-01-11_custom_DBoralARCAcquisitionICorp.Member",
      "name": "cik0002065779:AggregateConsideration",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://cik0002065779/role/ShareCapitalDetailsNarrative",
     "longName": "999053 - Disclosure - Share Capital (Details Narrative)",
     "shortName": "Share Capital (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-12-192025-12-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
     "longName": "999054 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS (Details Narrative)",
     "shortName": "DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "cik0002065779:TransactionCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "cik0002065779:TransactionCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails",
     "longName": "999055 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "cik0002065779:ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "cik0002065779:ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1",
     "longName": "999056 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember_custom_OrdinarySharesClassAMember",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999057 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:CashEquivalentsAtCarryingValue",
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://cik0002065779/role/InitialPublicOfferingDetailsNarrative",
     "longName": "999058 - Disclosure - INITIAL PUBLIC OFFERING (Details Narrative)",
     "shortName": "INITIAL PUBLIC OFFERING (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2025-07-292025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-08-01_us-gaap_IPOMember_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "cik0002065779:InitialPublicOfferingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://cik0002065779/role/PrivatePlacementDetailsNarrative",
     "longName": "999059 - Disclosure - PRIVATE PLACEMENT (Details Narrative)",
     "shortName": "PRIVATE PLACEMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2025-07-292025-08-01_us-gaap_PrivatePlacementMember_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R60": {
     "role": "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "999060 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "cik0002065779:PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_us-gaap_OverAllotmentOptionMember_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://cik0002065779/role/StockholdersEquityDetailsNarrative",
     "longName": "999062 - Disclosure - STOCKHOLDER\u2019S EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDER\u2019S EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-25_custom_DBoralARCAcquisitionICorpMember",
      "name": "cik0002065779:AggregatePurchasePrice",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://cik0002065779/role/FairValueMeasurementsDetails",
     "longName": "999063 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_us-gaap_FairValueMeasurementsRecurringMember_custom_SimpleAgreementsForFutureEquityMember_custom_ExascaleLabsIncMember",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://cik0002065779/role/FairValueMeasurementsDetails1",
     "longName": "999064 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details 1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cik0002065779:OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-292025-08-01_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cik0002065779:OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://cik0002065779/role/FairValueMeasurementsDetails2",
     "longName": "999065 - Disclosure - FAIR VALUE MEASUREMENTS (Details 2)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details 2)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "AsOf2025-08-01_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cik0002065779:OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-08-01_custom_PublicWarrantsMember_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://cik0002065779/role/SegmentInformationDetails",
     "longName": "999066 - Disclosure - Segment information (Details)",
     "shortName": "Segment information (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-03-202025-12-31_custom_DBoralARCAcquisitionICorpMember",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
     "longName": "999067 - Disclosure - Organization and principal activities (Details Narrative)",
     "shortName": "Organization and principal activities (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R68": {
     "role": "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2",
     "longName": "999068 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_RevenueFromIntelligentComputingPowerServiceMember_custom_ReservedCapacityArrangementsMember_custom_ExascaleLabsIncMember",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cik0002065779:ScheduleOfRevenueRecognitionTableTextBlock",
       "us-gaap:RevenueRecognitionDeferredRevenue",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3",
     "longName": "999069 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_RevenueFromComprehensiveDataCenterServicesMember_custom_ExascaleLabsIncMember",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueRecognitionDeferredRevenue",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure",
     "longName": "999070 - Disclosure - Summary of significant accounting policies (Details Narrative)",
     "shortName": "Summary of significant accounting policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_custom_ExascaleLabsIncMember",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:CashEquivalentsAtCarryingValue",
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://cik0002065779/role/ConcentrationAndRiskDetails",
     "longName": "999071 - Disclosure - Concentration and risk (Details)",
     "shortName": "Concentration and risk (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cik0002065779:ScheduleOfConcentrationOfCustomersTableTextBlock",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerAMember_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cik0002065779:ScheduleOfConcentrationOfCustomersTableTextBlock",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://cik0002065779/role/ConcentrationAndRiskDetails1",
     "longName": "999072 - Disclosure - Concentration and risk (Details 1)",
     "shortName": "Concentration and risk (Details 1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cik0002065779:ScheduleOfAccountsReceivableTextBlock",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerGMember_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cik0002065779:ScheduleOfAccountsReceivableTextBlock",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://cik0002065779/role/ConcentrationAndRiskDetails2",
     "longName": "999073 - Disclosure - Concentration and risk (Details 2)",
     "shortName": "Concentration and risk (Details 2)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cik0002065779:ScheduleOfConcentrationOfSuppliersTableTextBlock",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_PurchaseMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierAMember_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cik0002065779:ScheduleOfConcentrationOfSuppliersTableTextBlock",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://cik0002065779/role/ConcentrationAndRiskDetails3",
     "longName": "999074 - Disclosure - Concentration and risk (Details 3)",
     "shortName": "Concentration and risk (Details 3)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember62755093",
      "name": "cik0002065779:ConcentrationRiskPercentage",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SupplierEMember_custom_ExascaleLabsIncMember62755093",
      "name": "cik0002065779:ConcentrationRiskPercentage",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://cik0002065779/role/AccountsReceivableDetails",
     "longName": "999075 - Disclosure - Accounts receivable (Details)",
     "shortName": "Accounts receivable (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://cik0002065779/role/AccountsReceivableDetailsNarrative",
     "longName": "999076 - Disclosure - Accounts receivable (Details Narrative)",
     "shortName": "Accounts receivable (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:AllowanceForDoubtfulAccountsReceivable",
       "span",
       "span",
       "p",
       "cik0002065779:RefundableDepositsReceivablePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R77": {
     "role": "http://cik0002065779/role/OtherReceivablesDetailsNarrative",
     "longName": "999077 - Disclosure - Other receivables (Details Narrative)",
     "shortName": "Other receivables (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:OtherReceivables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "cik0002065779:OtherReceivablesPolicyRextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R78": {
     "role": "http://cik0002065779/role/EquipmentNetDetails",
     "longName": "999078 - Disclosure - Equipment, net (Details)",
     "shortName": "Equipment, net (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://cik0002065779/role/EquipmentNetDetailsNarrative",
     "longName": "999079 - Disclosure - Equipment, net (Details Narrative)",
     "shortName": "Equipment, net (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R80": {
     "role": "http://cik0002065779/role/RefundableDepositsPayableDetailsNarrative",
     "longName": "999080 - Disclosure - Refundable deposits payable (Details Narrative)",
     "shortName": "Refundable deposits payable (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31_custom_ExascaleLabsIncMember",
      "name": "cik0002065779:RefundableDepositsPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R81": {
     "role": "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetails",
     "longName": "999081 - Disclosure - Simple agreements for future equity (Details)",
     "shortName": "Simple agreements for future equity (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30_custom_ExascaleLabsIncMember",
      "name": "cik0002065779:SimpleAgreementsForFutureEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-06-30_custom_ExascaleLabsIncMember",
      "name": "cik0002065779:SimpleAgreementsForFutureEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "b",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "cik0002065779:SimpleAgreementsForFutureEquityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative",
     "longName": "999082 - Disclosure - Simple agreements for future equity (Details Narrative)",
     "shortName": "Simple agreements for future equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ProceedsFromOtherEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "cik0002065779:SimpleAgreementsForFutureEquityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ProceedsFromOtherEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "cik0002065779:SimpleAgreementsForFutureEquityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://cik0002065779/role/IncomeTaxesDetails",
     "longName": "999083 - Disclosure - Income taxes (Details)",
     "shortName": "Income taxes (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_ExascaleLabsIncMember",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://cik0002065779/role/IncomeTaxesDetails1",
     "longName": "999084 - Disclosure - Income taxes (Details 1)",
     "shortName": "Income taxes (Details 1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30_custom_ExascaleLabsIncMember",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_custom_ExascaleLabsIncMember",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://cik0002065779/role/IncomeTaxesDetails2",
     "longName": "999085 - Disclosure - Income taxes (Details 2)",
     "shortName": "Income taxes (Details 2)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ExascaleLabsIncMember",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://cik0002065779/role/IncomeTaxesDetailsNarrative",
     "longName": "999086 - Disclosure - Income taxes (Details Narrative)",
     "shortName": "Income taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_custom_ExascaleLabsIncMember",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://cik0002065779/role/Share-basedCompensationDetails",
     "longName": "999087 - Disclosure - Share-based compensation (Details)",
     "shortName": "Share-based compensation (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_SellingAndMarketingExpensesMember_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://cik0002065779/role/Share-basedCompensationDetailsNarrative",
     "longName": "999088 - Disclosure - Share-based compensation (Details Narrative)",
     "shortName": "Share-based compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_EmployeeMember_custom_ExascaleLabsIncMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrativeDisclosure",
     "longName": "999089 - Disclosure - Related party transactions (Details Narrative)",
     "shortName": "Related party transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "cik0002065779:ConsultingFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "cik0002065779:ConsultingFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails",
     "longName": "999090 - Disclosure - Basic and diluted net loss per share (Details)",
     "shortName": "Basic and diluted net loss per share (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "From2025-12-192025-12-31",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://cik0002065779/role/SegmentInformationDetails1",
     "longName": "999091 - Disclosure - Segment information (Details 1)",
     "shortName": "Segment information (Details 1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_country_SG_custom_ExascaleLabsIncMember",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure",
     "longName": "999092 - Disclosure - Commitments and contingencies (Details Narrative)",
     "shortName": "Commitments and contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-01-31_custom_ExascaleLabsIncMember",
      "name": "cik0002065779:OrdinarySharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-01-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://cik0002065779/role/CryptoAssetsDetails",
     "longName": "999093 - Disclosure - Crypto assets (Details)",
     "shortName": "Crypto assets (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember",
      "name": "us-gaap:CryptoAssetPurchase",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:CryptoAssetActivityTableTextBlock",
       "us-gaap:CryptoAssetTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_DigitalAssetsMember_custom_ExascaleLabsIncMember",
      "name": "us-gaap:CryptoAssetPurchase",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:CryptoAssetActivityTableTextBlock",
       "us-gaap:CryptoAssetTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://cik0002065779/role/CryptoAssetsDetails1",
     "longName": "999094 - Disclosure - Crypto assets (Details 1)",
     "shortName": "Crypto assets (Details 1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012026-03-31_custom_DigitalAssetsAndUSDCMember_custom_ExascaleLabsIncMember",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:CashFlowOperatingCapitalTableTextBlock",
       "us-gaap:CryptoAssetTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://cik0002065779/role/CryptoAssetsDetailsNarrative",
     "longName": "999095 - Disclosure - Crypto assets (Details Narrative)",
     "shortName": "Crypto assets (Details Narrative)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:PaymentsForProceedsFromInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:PaymentsForProceedsFromInvestments",
       "span",
       "span",
       "p",
       "us-gaap:CryptoAssetTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_custom_ExascaleLabsIncMember",
      "name": "us-gaap:PaymentsForProceedsFromInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:PaymentsForProceedsFromInvestments",
       "span",
       "span",
       "p",
       "us-gaap:CryptoAssetTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_s4a.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsAndNontradeReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsAndNontradeReceivableTextBlock",
     "presentation": [
      "http://cik0002065779/role/AccountsReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable",
        "documentation": "The entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r231"
     ]
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, net",
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r783"
     ]
    },
    "us-gaap_AccountsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable [Member]",
        "documentation": "Obligations incurred and payable to vendors for goods and services received."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r701",
      "r920"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/AccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r700",
      "r805",
      "r997",
      "r998"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/AccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "cik0002065779_AccretionInValueOfClassOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "AccretionInValueOfClassOrdinaryShares",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion in value of Class A ordinary shares",
        "label": "Accretion in value of Class A ordinary shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalLiabilityLongDurationInsuranceCurrentWeightedAverageDiscountRate",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market value",
        "documentation": "Current weighted-average discount rate used to measure present value of total expected payment to policyholder in excess of present value of total expected assessment. Excludes benefit classified as market risk benefit or under provisions of Topic 815 on derivative and hedging."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r783",
      "r1029"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r911",
      "r912",
      "r913",
      "r914",
      "r979",
      "r1032"
     ]
    },
    "cik0002065779_AdditionalSafesProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "AdditionalSafesProceeds",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional SAFEs proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_AdjustmentOfAccruedOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "AdjustmentOfAccruedOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment of accrued offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdministrativeFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdministrativeFeesExpense",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Administrative services",
        "documentation": "Amount of expense for administrative fee from service provided, including, but not limited to, salary, rent, or overhead cost."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r1030",
      "r1031"
     ]
    },
    "cik0002065779_AdvanceToSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "AdvanceToSuppliers",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance to suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_AdvanceToSuppliersPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "AdvanceToSuppliersPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Advance to suppliers",
        "label": "AdvanceToSuppliersPolicyTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_AggregateConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "AggregateConsideration",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate consideration"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_AggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "AggregatePurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate purchase price",
        "label": "AggregatePurchasePrice"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/AccountsReceivableDetails",
      "http://cik0002065779/role/AccountsReceivableDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for expected credit losses",
        "verboseLabel": "Less: allowance for credit losses",
        "terseLabel": "Allowance for credit losses",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r229",
      "r234",
      "r235",
      "r236",
      "r998"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_AmortizationOfPrepaidResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "AmortizationOfPrepaidResearchAndDevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of prepaid research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_AmountDueToRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "AmountDueToRelatedParty",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount due to related party"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r95",
      "r114",
      "r138",
      "r139",
      "r140",
      "r183",
      "r200",
      "r215",
      "r218",
      "r230",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r429",
      "r433",
      "r481",
      "r547",
      "r548",
      "r555",
      "r643",
      "r741",
      "r742",
      "r749",
      "r783",
      "r799",
      "r800",
      "r812",
      "r948",
      "r949",
      "r992"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r121",
      "r138",
      "r139",
      "r140",
      "r230",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r429",
      "r433",
      "r481",
      "r783",
      "r948",
      "r949",
      "r992"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r452",
      "r777"
     ]
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Non-Current Assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r230",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r429",
      "r433",
      "r481",
      "r948",
      "r949",
      "r992"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "verboseLabel": "Basis of presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://cik0002065779/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r423",
      "r588",
      "r760",
      "r761",
      "r970",
      "r971",
      "r972"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://cik0002065779/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r423",
      "r588",
      "r760",
      "r761",
      "r970",
      "r971",
      "r972"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://cik0002065779/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r363",
      "r364",
      "r365",
      "r366",
      "r372",
      "r373",
      "r374",
      "r375",
      "r381",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r417",
      "r418",
      "r419",
      "r423",
      "r765",
      "r773",
      "r970",
      "r971",
      "r972"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business combination payable",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r419",
      "r765",
      "r769"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://cik0002065779/role/BusinessCombination"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination",
        "documentation": "The entire disclosure for business combination."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r367",
      "r376",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r394",
      "r397",
      "r398",
      "r404",
      "r405",
      "r406",
      "r414",
      "r418",
      "r419",
      "r420",
      "r422",
      "r424",
      "r765",
      "r766",
      "r767",
      "r768",
      "r770",
      "r771",
      "r772"
     ]
    },
    "country_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "CA",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_CancellationOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CancellationOfOrdinaryShares",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancellation of ordinary shares"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_CancelledFounderShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CancelledFounderShares",
     "presentation": [
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancelled founder shares"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_CapitalStructurePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CapitalStructurePolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital structure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r558",
      "r615",
      "r636",
      "r783",
      "r799",
      "r800",
      "r812",
      "r848"
     ]
    },
    "cik0002065779_CashAndCashEquivalentsAndU.s.DollarCoin": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CashAndCashEquivalentsAndU.s.DollarCoin",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents and U.S. Dollar Coin"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "verboseLabel": "Cash",
        "terseLabel": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r112",
      "r716"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at the beginning of the period",
        "periodEndLabel": "Cash and cash equivalents at the end of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r67",
      "r135"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r67"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r848",
      "r996"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FDIC Insured Amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental schedule of non-cash financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowOperatingCapitalTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowOperatingCapitalTableTextBlock",
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of operating activities",
        "documentation": "Tabular disclosure of the net increase (decrease) in operating capital in the operating section of the statement of cash flows, represents the entire footnote disclosure that provides details regarding the net change during the reporting period of all assets and liabilities used in operating activities."
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_CashHeldInTrustAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CashHeldInTrustAccount",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash held in trust account",
        "verboseLabel": "Cash held in trust"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_CashHeldInTrustAccountPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CashHeldInTrustAccountPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Held in Trust Account"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_CashHeldInTrustAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CashHeldInTrustAccounts",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash held in Trust Account"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ChangeInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ChangeInFairValue",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ChangeInFairValueOfSimpleAgreementsForFutureEquities",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of simple agreements for future equity"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ChangeInFairValueOfSimpleAgreementsForFutureEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ChangeInFairValueOfSimpleAgreementsForFutureEquity",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails",
      "http://cik0002065779/role/StatementOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of simple agreements for future equity",
        "label": "ChangeInFairValueOfSimpleAgreementsForFutureEquity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ClassAOrdinaryShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ClassAOrdinaryShareMember",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A Ordinary Share [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ClassAOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ClassAOrdinarySharesMember",
     "presentation": [
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A Ordinary Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A Ordinary Shares Subject to Possible Redemption"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ClassBOrdinarySharesIssuedToSponsor": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ClassBOrdinarySharesIssuedToSponsor",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class B ordinary shares issued to Sponsor"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ClassBOrdinarySharesIssuedToSponsorShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ClassBOrdinarySharesIssuedToSponsorShares",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class B ordinary shares issued to Sponsor, shares"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ClassBOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ClassBOrdinarySharesMember",
     "presentation": [
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class B Ordinary Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/StatementOfOperations",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r115",
      "r116",
      "r117",
      "r138",
      "r140",
      "r167",
      "r168",
      "r175",
      "r177",
      "r185",
      "r186",
      "r230",
      "r262",
      "r264",
      "r265",
      "r266",
      "r269",
      "r270",
      "r276",
      "r277",
      "r279",
      "r280",
      "r282",
      "r286",
      "r289",
      "r290",
      "r293",
      "r296",
      "r303",
      "r481",
      "r593",
      "r594",
      "r595",
      "r596",
      "r603",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r616",
      "r628",
      "r651",
      "r674",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r845",
      "r907",
      "r908",
      "r915"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r185",
      "r279",
      "r289",
      "r290",
      "r291",
      "r293",
      "r296",
      "r301",
      "r303",
      "r435",
      "r593",
      "r594",
      "r595",
      "r596",
      "r750",
      "r845",
      "r906",
      "r907"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails2",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails2",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r142",
      "r304"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightUnissued",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued",
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ClassOrdinarySharesIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ClassOrdinarySharesIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A ordinary shares issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure",
      "http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
      "http://cik0002065779/role/ShareCapitalDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 14)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r88",
      "r557",
      "r627"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingencies",
      "http://cik0002065779/role/CommitmentsAndContingenciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "verboseLabel": "Commitments and contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r260",
      "r261",
      "r702",
      "r940",
      "r944"
     ]
    },
    "cik0002065779_CommonStockClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CommonStockClassBMember",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Class B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockConversionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockConversionBasis",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion basis",
        "documentation": "Description of basis for conversion of convertible common stock."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CommonStockIssuedToInitialShareholderForSubscriptionFee",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued to initial shareholder for subscription fee"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_CommonStockIssuedToInitialShareholderForSubscriptionFeeShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CommonStockIssuedToInitialShareholderForSubscriptionFeeShares",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued to initial shareholder for subscription fee, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r803",
      "r804",
      "r806",
      "r807",
      "r808",
      "r809",
      "r911",
      "r912",
      "r914",
      "r979",
      "r1028",
      "r1032"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
      "http://cik0002065779/role/ShareCapitalDetailsNarrative",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
      "http://cik0002065779/role/ShareCapitalDetailsNarrative",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r628"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r49",
      "r628",
      "r649",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r277",
      "r285",
      "r560",
      "r783"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84"
     ]
    },
    "cik0002065779_ComprehensiveLossPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ComprehensiveLossPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails",
      "http://cik0002065779/role/ConcentrationAndRiskDetails1",
      "http://cik0002065779/role/ConcentrationAndRiskDetails2",
      "http://cik0002065779/role/ConcentrationAndRiskDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r226",
      "r589",
      "r590",
      "r701",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails",
      "http://cik0002065779/role/ConcentrationAndRiskDetails1",
      "http://cik0002065779/role/ConcentrationAndRiskDetails2",
      "http://cik0002065779/role/ConcentrationAndRiskDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r226",
      "r589",
      "r590",
      "r701",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails",
      "http://cik0002065779/role/ConcentrationAndRiskDetails1",
      "http://cik0002065779/role/ConcentrationAndRiskDetails2",
      "http://cik0002065779/role/ConcentrationAndRiskDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r226",
      "r589",
      "r590",
      "r701",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of credit risk",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r478"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRisk"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration and risk",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r192",
      "r474",
      "r476",
      "r477",
      "r479",
      "r480",
      "r731",
      "r918"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails",
      "http://cik0002065779/role/ConcentrationAndRiskDetails1",
      "http://cik0002065779/role/ConcentrationAndRiskDetails2",
      "http://cik0002065779/role/ConcentrationAndRiskDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r701",
      "r729",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "cik0002065779_ConcentrationRiskPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ConcentrationRiskPercentage",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Concentration of credit risk",
        "label": "ConcentrationRiskPercentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails",
      "http://cik0002065779/role/ConcentrationAndRiskDetails1",
      "http://cik0002065779/role/ConcentrationAndRiskDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Concentration of credit risk",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r226",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails",
      "http://cik0002065779/role/ConcentrationAndRiskDetails1",
      "http://cik0002065779/role/ConcentrationAndRiskDetails2",
      "http://cik0002065779/role/ConcentrationAndRiskDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r701",
      "r729",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails",
      "http://cik0002065779/role/ConcentrationAndRiskDetails1",
      "http://cik0002065779/role/ConcentrationAndRiskDetails2",
      "http://cik0002065779/role/ConcentrationAndRiskDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r226",
      "r589",
      "r590",
      "r701",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "cik0002065779_ConsultingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ConsultingFees",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting fees"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ContractLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ContractLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contract liabilities",
        "label": "ContractLiabilitiesPolicyTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ConversionOfClassBToClassACommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ConversionOfClassBToClassACommonStockMember",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of class B to class A common stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Conversion Description [Axis]",
        "documentation": "Information by description of stock conversions."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19"
     ]
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockNameDomain",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The unique name of a noncash or part noncash stock conversion."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails",
      "http://cik0002065779/role/StatementOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of revenues",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r138",
      "r139",
      "r140",
      "r230",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r481",
      "r741",
      "r948"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost of revenues",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost and expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure",
      "http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
      "http://cik0002065779/role/Share-basedCompensationDetailsNarrative",
      "http://cik0002065779/role/ShareCapitalDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r145",
      "r146",
      "r272",
      "r291",
      "r500",
      "r508",
      "r554",
      "r718",
      "r719",
      "r720",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r974",
      "r976",
      "r977",
      "r978"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditLossAbstract",
     "auth_ref": []
    },
    "us-gaap_CryptoAssetActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetActivityTableTextBlock",
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of digital assets",
        "documentation": "Tabular disclosure of information about activity for crypto asset. Excludes information about crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "srt_CryptoAssetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CryptoAssetAxis",
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsDetails",
      "http://cik0002065779/role/CryptoAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Crypto Asset [Axis]"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r259",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939"
     ]
    },
    "us-gaap_CryptoAssetDisposition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetDisposition",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Disposals",
        "label": "Crypto Asset, Disposition",
        "documentation": "Amount of decrease in crypto asset from disposition. Excludes crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "srt_CryptoAssetDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CryptoAssetDomain",
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsDetails",
      "http://cik0002065779/role/CryptoAssetsDetails1"
     ],
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r259",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939"
     ]
    },
    "us-gaap_CryptoAssetFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetFairValue",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, January 1",
        "periodEndLabel": "Ending balance",
        "label": "Crypto Asset, Fair Value",
        "documentation": "Fair value of crypto asset. Excludes crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r251",
      "r253"
     ]
    },
    "us-gaap_CryptoAssetHoldingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetHoldingLineItems",
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsDetails",
      "http://cik0002065779/role/CryptoAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Crypto Asset, Holding [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252"
     ]
    },
    "us-gaap_CryptoAssetHoldingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetHoldingTable",
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsDetails",
      "http://cik0002065779/role/CryptoAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Crypto Asset, Holding [Table]",
        "documentation": "Disclosure of information about crypto asset. Includes, but is not limited to, name, cost basis, fair value, and number of units held. Excludes information about crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252"
     ]
    },
    "us-gaap_CryptoAssetPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetPurchase",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additions",
        "label": "Crypto Asset, Purchase",
        "documentation": "Amount of increase in crypto asset from purchase. Excludes crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_CryptoAssetSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetSale",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Disposals - sold for US dollars",
        "label": "Crypto Asset, Sale",
        "documentation": "Amount of decrease in crypto asset from sale. Excludes crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_CryptoAssetTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetTextBlock",
     "presentation": [
      "http://cik0002065779/role/CryptoAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Crypto assets",
        "documentation": "The entire disclosure for crypto asset. Excludes crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257"
     ]
    },
    "cik0002065779_CryptoAssets": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CryptoAssets",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Crypto assets",
        "label": "CryptoAssets"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_CumulativeProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CumulativeProceeds",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_CustomerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CustomerAMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails",
      "http://cik0002065779/role/ConcentrationAndRiskDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_CustomerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CustomerBMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails",
      "http://cik0002065779/role/ConcentrationAndRiskDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_CustomerCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CustomerCMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails",
      "http://cik0002065779/role/ConcentrationAndRiskDetails1",
      "http://cik0002065779/role/ConcentrationAndRiskDetails2",
      "http://cik0002065779/role/ConcentrationAndRiskDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r920"
     ]
    },
    "cik0002065779_CustomerDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CustomerDMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails",
      "http://cik0002065779/role/ConcentrationAndRiskDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer D [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_CustomerEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CustomerEMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails",
      "http://cik0002065779/role/ConcentrationAndRiskDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer E [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_CustomerFMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CustomerFMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails",
      "http://cik0002065779/role/ConcentrationAndRiskDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer F [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_CustomerGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CustomerGMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer G [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_CustomerHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CustomerHMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer H [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_CustomerIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "CustomerIMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer I [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_DBoralARCAcquisitionICorp.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "DBoralARCAcquisitionICorp.Member",
     "presentation": [
      "http://cik0002065779/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "D. Boral ARC Acquisition I Corp. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_DBoralARCAcquisitionICorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "DBoralARCAcquisitionICorpMember",
     "presentation": [
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/CommitmentsAndContingencies",
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperations",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/FairValueMeasurements",
      "http://cik0002065779/role/FairValueMeasurementsDetails",
      "http://cik0002065779/role/FairValueMeasurementsDetails1",
      "http://cik0002065779/role/FairValueMeasurementsDetails2",
      "http://cik0002065779/role/FairValueMeasurementsTables",
      "http://cik0002065779/role/InitialPublicOffering",
      "http://cik0002065779/role/InitialPublicOfferingDetailsNarrative",
      "http://cik0002065779/role/PrivatePlacement",
      "http://cik0002065779/role/PrivatePlacementDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactions",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cik0002065779/role/SegmentInformation",
      "http://cik0002065779/role/SegmentInformationDetails",
      "http://cik0002065779/role/ShareCapitalDetailsNarrative",
      "http://cik0002065779/role/StatementOfCashFlows",
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit",
      "http://cik0002065779/role/StatementOfOperations",
      "http://cik0002065779/role/StockholdersEquity",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative",
      "http://cik0002065779/role/SubsequentEvents",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "D. Boral ARC Acquisition I Corp [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_DBoralArcMergerCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "DBoralArcMergerCorporationMember",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "D. Boral Arc Merger Corporation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of debt",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r19"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r489",
      "r490",
      "r747",
      "r748",
      "r782"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "cik0002065779_DeferredOfferingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred offering costs",
        "label": "DeferredOfferingCostsPolicyTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/IncomeTaxesDetails1": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/IncomeTaxesDetails1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets, net",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/IncomeTaxesDetails1": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carry forward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/IncomeTaxesDetails1": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetails1",
      "http://cik0002065779/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "negatedPeriodStartLabel": "Balance at the beginning of the year",
        "negatedPeriodEndLabel": "Balance at the end of the year",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "cik0002065779_DenominatorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "DenominatorAbstract",
     "presentation": [
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_DenominatorForBasicAndDilutedLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "DenominatorForBasicAndDilutedLossPerShareAbstract",
     "presentation": [
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denominator for basic and diluted loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositContractsLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositContractsLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract liabilities",
        "documentation": "Carrying amount of liabilities as of the balance sheet date pertaining to amounts received by the insurer or reinsurer from the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/EquipmentNetDetailsNarrative",
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation of equipment",
        "verboseLabel": "Depreciation expenses",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r27",
      "r132",
      "r721",
      "r722",
      "r724",
      "r726"
     ]
    },
    "us-gaap_DerivativesReportingOfDerivativeActivity": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativesReportingOfDerivativeActivity",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Instruments",
        "documentation": "Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations."
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "cik0002065779_DigitalAssetsAndUSDCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "DigitalAssetsAndUSDCMember",
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital assets and USDC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_DigitalAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "DigitalAssetsMember",
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital Assets [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenue disaggregated",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "cik0002065779_DisbursementOfDigitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "DisbursementOfDigitalAssets",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disbursement of digital assets"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_DisclosureInitialPublicOfferingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "DisclosureInitialPublicOfferingAbstract",
     "auth_ref": []
    },
    "cik0002065779_DisclosureOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "DisclosureOtherReceivablesAbstract",
     "auth_ref": []
    },
    "cik0002065779_DisclosurePrivatePlacementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "DisclosurePrivatePlacementAbstract",
     "auth_ref": []
    },
    "cik0002065779_DisclosureRefundableDepositsPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "DisclosureRefundableDepositsPayableAbstract",
     "auth_ref": []
    },
    "cik0002065779_DisclosureSimpleAgreementsForFutureEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "DisclosureSimpleAgreementsForFutureEquityAbstract",
     "auth_ref": []
    },
    "cik0002065779_DiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "DiscountRate",
     "presentation": [
      "http://cik0002065779/role/Share-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Dividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Dividends",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Dividends",
        "label": "Dividends [Default Label]",
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r80"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r826",
      "r827"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails",
      "http://cik0002065779/role/StatementOfOperations",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic Loss per ordinary share",
        "verboseLabel": "Class B ordinary shares - basic net income per share",
        "terseLabel": "Basic loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r129",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r164",
      "r167",
      "r175",
      "r176",
      "r177",
      "r182",
      "r275",
      "r321",
      "r360",
      "r426",
      "r448",
      "r449",
      "r546",
      "r571",
      "r728"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails",
      "http://cik0002065779/role/StatementOfOperations",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted Loss per ordinary share",
        "verboseLabel": "Class B ordinary shares - diluted net income per share",
        "terseLabel": "Diluted loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r129",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r167",
      "r175",
      "r176",
      "r177",
      "r182",
      "r275",
      "r321",
      "r360",
      "r426",
      "r448",
      "r449",
      "r546",
      "r571",
      "r728"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share",
        "verboseLabel": "Net (Loss)/Income per Ordinary Share",
        "terseLabel": "Loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r179"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted net loss per share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r178",
      "r180",
      "r181"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetails",
      "http://cik0002065779/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r764"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetails",
      "http://cik0002065779/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Statutory income tax rate",
        "verboseLabel": "Federal income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r141",
      "r331",
      "r351",
      "r764"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r764",
      "r906",
      "r910",
      "r962"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in fair value of simple agreements for future equity",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r764",
      "r906",
      "r910",
      "r962",
      "r963"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetails",
      "http://cik0002065779/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income tax rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r764",
      "r906",
      "r910",
      "r962"
     ]
    },
    "cik0002065779_EmergingGrowthCompanyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "EmergingGrowthCompanyPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company",
        "verboseLabel": "Emerging growth company"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Employee Benefits and Share-Based Compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "cik0002065779_EmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "EmployeeMember",
     "presentation": [
      "http://cik0002065779/role/Share-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://cik0002065779/role/AccountsReceivable",
      "http://cik0002065779/role/AccountsReceivableDetails",
      "http://cik0002065779/role/AccountsReceivableDetailsNarrative",
      "http://cik0002065779/role/AccountsReceivableTables",
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShare",
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails",
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareTables",
      "http://cik0002065779/role/CommitmentsAndContingencies",
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure",
      "http://cik0002065779/role/CommitmentsAndContingenciesDisclosure",
      "http://cik0002065779/role/ConcentrationAndRisk",
      "http://cik0002065779/role/ConcentrationAndRiskDetails",
      "http://cik0002065779/role/ConcentrationAndRiskDetails1",
      "http://cik0002065779/role/ConcentrationAndRiskDetails2",
      "http://cik0002065779/role/ConcentrationAndRiskDetails3",
      "http://cik0002065779/role/ConcentrationAndRiskTables",
      "http://cik0002065779/role/CryptoAssets",
      "http://cik0002065779/role/CryptoAssetsDetails",
      "http://cik0002065779/role/CryptoAssetsDetails1",
      "http://cik0002065779/role/CryptoAssetsDetailsNarrative",
      "http://cik0002065779/role/CryptoAssetsTables",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperations",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/EquipmentNet",
      "http://cik0002065779/role/EquipmentNetDetails",
      "http://cik0002065779/role/EquipmentNetDetailsNarrative",
      "http://cik0002065779/role/EquipmentNetTables",
      "http://cik0002065779/role/FairValueMeasurements",
      "http://cik0002065779/role/FairValueMeasurementsDetails",
      "http://cik0002065779/role/FairValueMeasurementsDetails1",
      "http://cik0002065779/role/FairValueMeasurementsDetails2",
      "http://cik0002065779/role/FairValueMeasurementsDisclosure",
      "http://cik0002065779/role/FairValueMeasurementsTables",
      "http://cik0002065779/role/FairValueMeasurementsTablesDisclosure",
      "http://cik0002065779/role/IncomeTaxes",
      "http://cik0002065779/role/IncomeTaxesDetails",
      "http://cik0002065779/role/IncomeTaxesDetails1",
      "http://cik0002065779/role/IncomeTaxesDetails2",
      "http://cik0002065779/role/IncomeTaxesDetailsNarrative",
      "http://cik0002065779/role/IncomeTaxesTables",
      "http://cik0002065779/role/InitialPublicOffering",
      "http://cik0002065779/role/InitialPublicOfferingDetailsNarrative",
      "http://cik0002065779/role/OrganizationAndPrincipalActivities",
      "http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
      "http://cik0002065779/role/OtherReceivables",
      "http://cik0002065779/role/OtherReceivablesDetailsNarrative",
      "http://cik0002065779/role/PrivatePlacement",
      "http://cik0002065779/role/PrivatePlacementDetailsNarrative",
      "http://cik0002065779/role/RefundableDepositsPayable",
      "http://cik0002065779/role/RefundableDepositsPayableDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactions",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrativeDisclosure",
      "http://cik0002065779/role/RelatedPartyTransactionsDisclosure",
      "http://cik0002065779/role/SegmentInformation",
      "http://cik0002065779/role/SegmentInformationDetails",
      "http://cik0002065779/role/SegmentInformationDetails1",
      "http://cik0002065779/role/Share-basedCompensation",
      "http://cik0002065779/role/Share-basedCompensationDetails",
      "http://cik0002065779/role/Share-basedCompensationDetailsNarrative",
      "http://cik0002065779/role/Share-basedCompensationTables",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquity",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetails",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityTables",
      "http://cik0002065779/role/StatementOfCashFlows",
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit",
      "http://cik0002065779/role/StatementOfOperations",
      "http://cik0002065779/role/StockholdersEquity",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative",
      "http://cik0002065779/role/SubsequentEvents",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDisclosure",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r106",
      "r107",
      "r108",
      "r125",
      "r126",
      "r127",
      "r147",
      "r148",
      "r149",
      "r151",
      "r158",
      "r160",
      "r162",
      "r184",
      "r232",
      "r233",
      "r258",
      "r274",
      "r305",
      "r321",
      "r349",
      "r350",
      "r357",
      "r358",
      "r359",
      "r361",
      "r425",
      "r426",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r491",
      "r492",
      "r494",
      "r570",
      "r582",
      "r583",
      "r584",
      "r603",
      "r674"
     ]
    },
    "us-gaap_EquityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity",
        "documentation": "Fair value of the entity's equity."
       }
      }
     },
     "auth_ref": [
      "r980",
      "r981",
      "r985"
     ]
    },
    "cik0002065779_EquityFinancingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "EquityFinancingDescription",
     "presentation": [
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Financing description"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_EvanaAlphaPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "EvanaAlphaPteLtdMember",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure",
      "http://cik0002065779/role/IncomeTaxesDetailsNarrative",
      "http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Evana Alpha Pte. Ltd. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ExascaleLabsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ExascaleLabsIncMember",
     "presentation": [
      "http://cik0002065779/role/AccountsReceivable",
      "http://cik0002065779/role/AccountsReceivableDetails",
      "http://cik0002065779/role/AccountsReceivableDetailsNarrative",
      "http://cik0002065779/role/AccountsReceivableTables",
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShare",
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails",
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareTables",
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure",
      "http://cik0002065779/role/CommitmentsAndContingenciesDisclosure",
      "http://cik0002065779/role/ConcentrationAndRisk",
      "http://cik0002065779/role/ConcentrationAndRiskDetails",
      "http://cik0002065779/role/ConcentrationAndRiskDetails1",
      "http://cik0002065779/role/ConcentrationAndRiskDetails2",
      "http://cik0002065779/role/ConcentrationAndRiskDetails3",
      "http://cik0002065779/role/ConcentrationAndRiskTables",
      "http://cik0002065779/role/CryptoAssets",
      "http://cik0002065779/role/CryptoAssetsDetails",
      "http://cik0002065779/role/CryptoAssetsDetails1",
      "http://cik0002065779/role/CryptoAssetsDetailsNarrative",
      "http://cik0002065779/role/CryptoAssetsTables",
      "http://cik0002065779/role/EquipmentNet",
      "http://cik0002065779/role/EquipmentNetDetails",
      "http://cik0002065779/role/EquipmentNetDetailsNarrative",
      "http://cik0002065779/role/EquipmentNetTables",
      "http://cik0002065779/role/FairValueMeasurementsDetails",
      "http://cik0002065779/role/FairValueMeasurementsDisclosure",
      "http://cik0002065779/role/FairValueMeasurementsTables",
      "http://cik0002065779/role/FairValueMeasurementsTablesDisclosure",
      "http://cik0002065779/role/IncomeTaxes",
      "http://cik0002065779/role/IncomeTaxesDetails",
      "http://cik0002065779/role/IncomeTaxesDetails1",
      "http://cik0002065779/role/IncomeTaxesDetails2",
      "http://cik0002065779/role/IncomeTaxesDetailsNarrative",
      "http://cik0002065779/role/IncomeTaxesTables",
      "http://cik0002065779/role/OrganizationAndPrincipalActivities",
      "http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
      "http://cik0002065779/role/OtherReceivables",
      "http://cik0002065779/role/OtherReceivablesDetailsNarrative",
      "http://cik0002065779/role/RefundableDepositsPayable",
      "http://cik0002065779/role/RefundableDepositsPayableDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrativeDisclosure",
      "http://cik0002065779/role/RelatedPartyTransactionsDisclosure",
      "http://cik0002065779/role/SegmentInformation",
      "http://cik0002065779/role/SegmentInformationDetails",
      "http://cik0002065779/role/SegmentInformationDetails1",
      "http://cik0002065779/role/Share-basedCompensation",
      "http://cik0002065779/role/Share-basedCompensationDetails",
      "http://cik0002065779/role/Share-basedCompensationDetailsNarrative",
      "http://cik0002065779/role/Share-basedCompensationTables",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquity",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetails",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityTables",
      "http://cik0002065779/role/StatementOfCashFlows",
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit",
      "http://cik0002065779/role/StatementOfOperations",
      "http://cik0002065779/role/SubsequentEvents",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDisclosure",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exascale Labs Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ExpectedCreditLossAndAccountsReceivablePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ExpectedCreditLossAndAccountsReceivablePolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected credit loss and accounts receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExtendedProductWarrantyPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ExtendedProductWarrantyPolicy",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Instruments",
        "documentation": "Disclosure of accounting policy for extended product warranties and other guarantee contracts including the methodology for measuring the liability."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsTables",
      "http://cik0002065779/role/FairValueMeasurementsTablesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value assets and liabilities",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r980",
      "r981",
      "r986"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r450",
      "r452",
      "r453",
      "r454",
      "r455",
      "r464",
      "r465",
      "r467",
      "r472",
      "r505",
      "r506",
      "r507",
      "r713",
      "r747",
      "r748",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r777",
      "r779",
      "r781"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails3",
      "http://cik0002065779/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r466"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r452",
      "r453",
      "r455",
      "r777",
      "r983",
      "r987"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurements",
      "http://cik0002065779/role/FairValueMeasurementsDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS",
        "verboseLabel": "Fair value measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r460",
      "r462",
      "r463",
      "r464",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r545",
      "r777",
      "r780"
     ]
    },
    "cik0002065779_FairValueGainOrLossOnDigitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "FairValueGainOrLossOnDigitalAssets",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value gain or loss on digital assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r306",
      "r311",
      "r313",
      "r452",
      "r465",
      "r472",
      "r505",
      "r713",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r777",
      "r781"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r306",
      "r311",
      "r313",
      "r315",
      "r452",
      "r453",
      "r465",
      "r472",
      "r506",
      "r713",
      "r747",
      "r748",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r777",
      "r781"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r452",
      "r453",
      "r454",
      "r455",
      "r465",
      "r472",
      "r507",
      "r713",
      "r747",
      "r748",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r777",
      "r779",
      "r781"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails3",
      "http://cik0002065779/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r466"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r452",
      "r453",
      "r455",
      "r777",
      "r983",
      "r987"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r450",
      "r452",
      "r453",
      "r454",
      "r455",
      "r464",
      "r465",
      "r467",
      "r472",
      "r505",
      "r506",
      "r507",
      "r713",
      "r747",
      "r748",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r777",
      "r779",
      "r781"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r987"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of market assumptions",
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r461",
      "r466"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://cik0002065779/role/SignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "verboseLabel": "Fair value of financial instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "cik0002065779_FairValueOfOverallotmentOption": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "FairValueOfOverallotmentOption",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of over-allotment option"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r553"
     ]
    },
    "cik0002065779_ForfeitureOfFounderShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ForfeitureOfFounderShares",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeiture of founder shares",
        "label": "ForfeitureOfFounderShares"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ForfeitureOfFounderSharesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ForfeitureOfFounderSharesShares",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeiture of founder shares, shares"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_FounderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "FounderMember",
     "presentation": [
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Founder [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_FounderSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "FounderSharesMember",
     "presentation": [
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Founder Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_FunctionalCurrencyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "FunctionalCurrencyPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Functional currency"
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "GB",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/Share-basedCompensationDetailsNarrative",
      "http://cik0002065779/role/StatementOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "General and administrative expenses",
        "label": "General and administrative expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r654"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_GeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "GeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://cik0002065779/role/Share-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_GoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "GoingConcernPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going concern"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "auth_ref": []
    },
    "cik0002065779_GrantedEquityAward": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "GrantedEquityAward",
     "presentation": [
      "http://cik0002065779/role/Share-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted equity award"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails",
      "http://cik0002065779/role/StatementOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r59",
      "r94",
      "r138",
      "r139",
      "r140",
      "r230",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r481",
      "r735",
      "r741",
      "r917",
      "r924",
      "r925",
      "r926",
      "r927",
      "r948"
     ]
    },
    "country_HK": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "HK",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "HONG KONG"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/InitialPublicOfferingDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r26",
      "r74",
      "r131",
      "r722",
      "r778"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r75"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax expenses",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r90",
      "r94",
      "r547",
      "r549",
      "r567",
      "r723",
      "r725",
      "r727",
      "r735",
      "r741",
      "r917",
      "r924",
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "auth_ref": []
    },
    "cik0002065779_IncomeStatementLocationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "IncomeStatementLocationsAxis",
     "presentation": [
      "http://cik0002065779/role/Share-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Locations [Axis]",
        "verboseLabel": "IncomeStatementLocationsAxis [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_IncomeStatementLocationsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "IncomeStatementLocationsDomain",
     "presentation": [
      "http://cik0002065779/role/Share-basedCompensationDetails"
     ],
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r968"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r968"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r141",
      "r326",
      "r331",
      "r335",
      "r336",
      "r337",
      "r340",
      "r346",
      "r352",
      "r354",
      "r355",
      "r356",
      "r552",
      "r587",
      "r598",
      "r764"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails",
      "http://cik0002065779/role/StatementOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax expenses",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r104",
      "r138",
      "r161",
      "r162",
      "r183",
      "r203",
      "r218",
      "r330",
      "r331",
      "r353",
      "r573",
      "r723",
      "r725",
      "r727",
      "r764"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "verboseLabel": "Income tax",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r328",
      "r329",
      "r340",
      "r341",
      "r345",
      "r348",
      "r592"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r69",
      "r904",
      "r966",
      "r967"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other receivables",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "cik0002065779_IncreaseDecreaseInAdvanceToSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "IncreaseDecreaseInAdvanceToSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Advance to suppliers",
        "label": "IncreaseDecreaseInAdvanceToSuppliers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contract liabilities",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r902"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current liabilities",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid research and development expenses",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "cik0002065779_IncreaseDecreaseInRefundableDepositsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "IncreaseDecreaseInRefundableDepositsPayable",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Refundable deposits payable",
        "label": "IncreaseDecreaseInRefundableDepositsPayable"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_IncreaseDecreaseInRefundableDepositsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "IncreaseDecreaseInRefundableDepositsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Refundable deposits receivable",
        "label": "IncreaseDecreaseInRefundableDepositsReceivable"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_InitialPublicOfferingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "InitialPublicOfferingDisclosureTextBlock",
     "presentation": [
      "http://cik0002065779/role/InitialPublicOffering"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INITIAL PUBLIC OFFERING"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      },
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsDetails1",
      "http://cik0002065779/role/SegmentInformationDetails",
      "http://cik0002065779/role/StatementOfCashFlows",
      "http://cik0002065779/role/StatementOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income on cash held in trust account",
        "negatedLabel": "Investment income in trust account",
        "negatedTerseLabel": "Interest income",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense paid",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "cik0002065779_IssuanceOfPublicWarrantsNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "IssuanceOfPublicWarrantsNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Public Warrants, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_IssuanceOfRepresentativeShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "IssuanceOfRepresentativeShares",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Representative Shares"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_IssuanceOfRepresentativeSharesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "IssuanceOfRepresentativeSharesShares",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Representative Shares, shares"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_IssuanceOfSimpleAgreementsForFutureEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "IssuanceOfSimpleAgreementsForFutureEquity",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of simple agreements for future equity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://cik0002065779/role/AccountsReceivable",
      "http://cik0002065779/role/AccountsReceivableDetails",
      "http://cik0002065779/role/AccountsReceivableDetailsNarrative",
      "http://cik0002065779/role/AccountsReceivableTables",
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShare",
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails",
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareTables",
      "http://cik0002065779/role/CommitmentsAndContingencies",
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure",
      "http://cik0002065779/role/CommitmentsAndContingenciesDisclosure",
      "http://cik0002065779/role/ConcentrationAndRisk",
      "http://cik0002065779/role/ConcentrationAndRiskDetails",
      "http://cik0002065779/role/ConcentrationAndRiskDetails1",
      "http://cik0002065779/role/ConcentrationAndRiskDetails2",
      "http://cik0002065779/role/ConcentrationAndRiskDetails3",
      "http://cik0002065779/role/ConcentrationAndRiskTables",
      "http://cik0002065779/role/CryptoAssets",
      "http://cik0002065779/role/CryptoAssetsDetails",
      "http://cik0002065779/role/CryptoAssetsDetails1",
      "http://cik0002065779/role/CryptoAssetsDetailsNarrative",
      "http://cik0002065779/role/CryptoAssetsTables",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperations",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/EquipmentNet",
      "http://cik0002065779/role/EquipmentNetDetails",
      "http://cik0002065779/role/EquipmentNetDetailsNarrative",
      "http://cik0002065779/role/EquipmentNetTables",
      "http://cik0002065779/role/FairValueMeasurements",
      "http://cik0002065779/role/FairValueMeasurementsDetails",
      "http://cik0002065779/role/FairValueMeasurementsDetails1",
      "http://cik0002065779/role/FairValueMeasurementsDetails2",
      "http://cik0002065779/role/FairValueMeasurementsDisclosure",
      "http://cik0002065779/role/FairValueMeasurementsTables",
      "http://cik0002065779/role/FairValueMeasurementsTablesDisclosure",
      "http://cik0002065779/role/IncomeTaxes",
      "http://cik0002065779/role/IncomeTaxesDetails",
      "http://cik0002065779/role/IncomeTaxesDetails1",
      "http://cik0002065779/role/IncomeTaxesDetails2",
      "http://cik0002065779/role/IncomeTaxesDetailsNarrative",
      "http://cik0002065779/role/IncomeTaxesTables",
      "http://cik0002065779/role/InitialPublicOffering",
      "http://cik0002065779/role/InitialPublicOfferingDetailsNarrative",
      "http://cik0002065779/role/OrganizationAndPrincipalActivities",
      "http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
      "http://cik0002065779/role/OtherReceivables",
      "http://cik0002065779/role/OtherReceivablesDetailsNarrative",
      "http://cik0002065779/role/PrivatePlacement",
      "http://cik0002065779/role/PrivatePlacementDetailsNarrative",
      "http://cik0002065779/role/RefundableDepositsPayable",
      "http://cik0002065779/role/RefundableDepositsPayableDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactions",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrativeDisclosure",
      "http://cik0002065779/role/RelatedPartyTransactionsDisclosure",
      "http://cik0002065779/role/SegmentInformation",
      "http://cik0002065779/role/SegmentInformationDetails",
      "http://cik0002065779/role/SegmentInformationDetails1",
      "http://cik0002065779/role/Share-basedCompensation",
      "http://cik0002065779/role/Share-basedCompensationDetails",
      "http://cik0002065779/role/Share-basedCompensationDetailsNarrative",
      "http://cik0002065779/role/Share-basedCompensationTables",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquity",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetails",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityTables",
      "http://cik0002065779/role/StatementOfCashFlows",
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit",
      "http://cik0002065779/role/StatementOfOperations",
      "http://cik0002065779/role/StockholdersEquity",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative",
      "http://cik0002065779/role/SubsequentEvents",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDisclosure",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r138",
      "r139",
      "r140",
      "r230",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r430",
      "r433",
      "r434",
      "r481",
      "r626",
      "r734",
      "r749",
      "r812",
      "r948",
      "r992",
      "r993"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Shareholders\u2019 Deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r89",
      "r563",
      "r783",
      "r799",
      "r800",
      "r906",
      "r909",
      "r929",
      "r990"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS\u2019 DEFICIT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r111",
      "r138",
      "r139",
      "r140",
      "r230",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r430",
      "r433",
      "r434",
      "r481",
      "r783",
      "r948",
      "r992",
      "r993"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r980"
     ]
    },
    "us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dissolution expenses",
        "documentation": "Amount of estimated accrued costs to dispose of assets or other items expected to be sold in liquidation."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_LoansAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment proceeds received through USDC from SAFEs investors",
        "documentation": "The fair value of loans assumed in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19"
     ]
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r87",
      "r995"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r941",
      "r942",
      "r943"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r28",
      "r941",
      "r942",
      "r943"
     ]
    },
    "cik0002065779_LossPerOrdinaryShareAbstarct": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "LossPerOrdinaryShareAbstarct",
     "presentation": [
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails",
      "http://cik0002065779/role/StatementOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per ordinary share",
        "verboseLabel": "Basic and diluted(ii)"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails",
      "http://cik0002065779/role/ConcentrationAndRiskDetails1",
      "http://cik0002065779/role/ConcentrationAndRiskDetails2",
      "http://cik0002065779/role/ConcentrationAndRiskDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r226",
      "r751",
      "r754",
      "r793",
      "r797",
      "r999",
      "r1000",
      "r1001",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "us-gaap_MarketingAndAdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketingAndAdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising and promotion expenses",
        "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r725"
     ]
    },
    "cik0002065779_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Holders of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails",
      "http://cik0002065779/role/ConcentrationAndRiskDetails1",
      "http://cik0002065779/role/ConcentrationAndRiskDetails2",
      "http://cik0002065779/role/ConcentrationAndRiskDetails3"
     ],
     "auth_ref": [
      "r226",
      "r751",
      "r754",
      "r793",
      "r797",
      "r999",
      "r1000",
      "r1001",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://cik0002065779/role/DescriptionOfOrganizationAndBusinessOperations",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperations",
      "http://cik0002065779/role/OrganizationAndPrincipalActivities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Organization and Business Operations",
        "verboseLabel": "DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS",
        "terseLabel": "Organization and principal activities",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r189",
      "r730",
      "r732"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash for operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r70"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cik0002065779/role/StatementOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows",
      "http://cik0002065779/role/StatementOfOperations",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss and comprehensive loss",
        "verboseLabel": "Net loss",
        "label": "Net losses",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r70",
      "r91",
      "r108",
      "r109",
      "r122",
      "r123",
      "r127",
      "r138",
      "r139",
      "r140",
      "r144",
      "r150",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r161",
      "r162",
      "r173",
      "r230",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r275",
      "r278",
      "r281",
      "r287",
      "r321",
      "r360",
      "r426",
      "r449",
      "r481",
      "r569",
      "r650",
      "r672",
      "r673",
      "r723",
      "r725",
      "r727",
      "r810",
      "r948"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocation of (loss)/income - basic",
        "verboseLabel": "Net loss attributable to ordinary shareholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r130",
      "r154",
      "r155",
      "r156",
      "r157",
      "r164",
      "r165",
      "r174",
      "r177",
      "r278",
      "r281",
      "r287",
      "r426"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocation of (loss)/income - diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r166",
      "r169",
      "r170",
      "r171",
      "r172",
      "r174",
      "r177"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently adopted accounting pronouncements",
        "verboseLabel": "Recent Accounting Pronouncements",
        "terseLabel": "Recently accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_NonEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "NonEmployeeMember",
     "presentation": [
      "http://cik0002065779/role/Share-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non employee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashOrPartNoncashAcquisitionDebtAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Re-measurement of ordinary shares subject to redemption",
        "documentation": "The amount of debt that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashOrPartNoncashAcquisitionDescription",
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of representative shares",
        "documentation": "A textual description of the purchase or acquisition through business combination of an asset or business through a noncash (or part noncash) transaction. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the purchase or business combination, as well as the asset acquired and the noncash consideration given (that is, debt, stock, and so forth). Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs included in promissory note",
        "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashOrPartNoncashAcquisitionInventoryAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion of carrying value of redeemable shares to redemption value",
        "documentation": "The amount of inventory that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19"
     ]
    },
    "us-gaap_NotesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment proceeds received by an employee on behalf of the Company from SAFEs investors",
        "documentation": "The fair value of notes assumed in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19"
     ]
    },
    "us-gaap_NotesIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesIssued1",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeiture of founder shares",
        "documentation": "The fair value of notes issued in noncash investing and financing activities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19"
     ]
    },
    "cik0002065779_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of consecutive trading days"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_NumberOfTradingDaysForDeterminingTheSharePrice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "NumberOfTradingDaysForDeterminingTheSharePrice",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of trading days"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_NumeratorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "NumeratorAbstract",
     "presentation": [
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_OfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OfferingCost",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Costs Associated with the Initial Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_OnDemandArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OnDemandArrangementsMember",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "On demand arrangements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of initial measurement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails",
      "http://cik0002065779/role/StatementOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://cik0002065779/role/StatementOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails",
      "http://cik0002065779/role/StatementOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r723",
      "r727",
      "r735",
      "r917",
      "r924",
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "cik0002065779_OrdinarySharesClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OrdinarySharesClassAMember",
     "presentation": [
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit",
      "http://cik0002065779/role/StatementOfOperations",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Shares Class A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_OrdinarySharesClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OrdinarySharesClassBMember",
     "presentation": [
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit",
      "http://cik0002065779/role/StatementOfOperations",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Shares Class B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_OrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OrdinarySharesIssued",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure",
      "http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_OrdinarySharesPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OrdinarySharesPerShare",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ordinary shares per share"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_OrdinarySharesSubjectToPossibleRedemption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OrdinarySharesSubjectToPossibleRedemption",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Ordinary shares subject to possible redemption",
        "label": "OrdinarySharesSubjectToPossibleRedemption"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss before income tax expenses",
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r125",
      "r570"
     ]
    },
    "cik0002065779_OtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OtherCurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "other costs",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r799",
      "r800"
     ]
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r652",
      "r686",
      "r687",
      "r688",
      "r799",
      "r800"
     ]
    },
    "us-gaap_OtherIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncomeAbstract",
     "presentation": [
      "http://cik0002065779/role/StatementOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income:"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_OtherOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OtherOfferingCost",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other offering costs",
        "label": "OtherOfferingCost"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_OtherOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OtherOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other operating activities settled in digital assets and U.S. Dollar Coin",
        "label": "OtherOperatingActivitiesSettledInDigitalAssetsAndU.s.DollarCoin"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_OtherPayableRelatedToTheEquityOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OtherPayableRelatedToTheEquityOptionMember",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other payable related to the equity option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/OtherReceivablesDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other receivables",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r637",
      "r742",
      "r799",
      "r800",
      "r997"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_OtherReceivablesPolicyRextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OtherReceivablesPolicyRextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other receivables",
        "label": "OtherReceivablesPolicyRextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_OtherReceivablesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OtherReceivablesTextBlock",
     "presentation": [
      "http://cik0002065779/role/OtherReceivables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other receivables",
        "label": "OtherReceivablesTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "cik0002065779_OthersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OthersMember",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Others [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_OutstandingBalancesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "OutstandingBalancesPayable",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding balances payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/InitialPublicOfferingDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_PaymentForDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "PaymentForDeferredOfferingCosts",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment for deferred offering costs",
        "label": "PaymentForDeferredOfferingCosts"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_PaymentOfExpensesThroughPromissoryNoteRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "PaymentOfExpensesThroughPromissoryNoteRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of expenses through promissory note \u2013 related party"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_PaymentOfExpensesThroughRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "PaymentOfExpensesThroughRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of expenses through related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForProceedsFromInvestments",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment proceeds",
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfInitialPublicOffering",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of offering costs",
        "label": "Payment of offering expenses",
        "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_PaymentsOfDistributionsToAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDistributionsToAffiliates",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment to affiliate",
        "documentation": "The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_PaymentsToAcquireRestrictedInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireRestrictedInvestments",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment of cash in Trust Account",
        "label": "Payments to Acquire Restricted Investments",
        "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "cik0002065779_PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "PercentageOfRedemptionOfPublicSharesIncaseOfNonCompletionOfInitialBusinessCombination",
     "presentation": [
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of redemption of public shares"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "PercentageOfTheTotalNumberOfOrdinarySharesOutstandingAfterConversion",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of total number of ordinary shares"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_PeriodAfterWhichTheWarrantsAreExercisable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "PeriodAfterWhichTheWarrantsAreExercisable",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period of warrants exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_PerpetualRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "PerpetualRate",
     "presentation": [
      "http://cik0002065779/role/Share-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Perpetual rate"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r289"
     ]
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockRedemptionPricePerShare",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption price",
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r35"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r628"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r289"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r628",
      "r649",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred shares, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r277",
      "r284",
      "r559",
      "r783"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r237",
      "r238",
      "r717"
     ]
    },
    "cik0002065779_PrepaidResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "PrepaidResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_PrepaidResearchAndDevelopmentExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "PrepaidResearchAndDevelopmentExpensesPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid research and development expenses",
        "label": "PrepaidResearchAndDevelopmentExpensesPolicyTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_PrivatePlacementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "PrivatePlacementDisclosureTextBlock",
     "presentation": [
      "http://cik0002065779/role/PrivatePlacement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PRIVATE PLACEMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/PrivatePlacementDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ProceedsAllocatedToOverallotmentOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ProceedsAllocatedToOverallotmentOption",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds allocated to Over-allotment Option"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ProceedsAllocatedToPublicWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ProceedsAllocatedToPublicWarrants",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds allocated to Public Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "proceeds from sale of initial public offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of Class B ordinary shares to Sponsor",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of private placement units",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate gross proceeds",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "cik0002065779_ProceedsFromSaleOfDigitalAssetsAndUsdc": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ProceedsFromSaleOfDigitalAssetsAndUsdc",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal of digital assets and U.S. Dollar Coin"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfNotesReceivable",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from safes",
        "documentation": "The cash inflow associated with the sale of a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "cik0002065779_ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountPaid",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of Units, net of underwriting discount paid"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ProceedsFromSimpleAgreementsForFutureEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ProceedsFromSimpleAgreementsForFutureEquity",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Simple agreements for future equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductInformationLineItems",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r222",
      "r510",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r714",
      "r722",
      "r725",
      "r727",
      "r751",
      "r752",
      "r792",
      "r794",
      "r795",
      "r798",
      "r801",
      "r846",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r945",
      "r946",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "auth_ref": [
      "r222",
      "r510",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r714",
      "r722",
      "r725",
      "r727",
      "r751",
      "r752",
      "r792",
      "r794",
      "r795",
      "r798",
      "r801",
      "r846",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r945",
      "r946",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalAndContractServicesExpense",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "\u2013 Professional service expenses",
        "label": "Professional and Contract Services Expense",
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails",
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r122",
      "r123",
      "r133",
      "r138",
      "r139",
      "r140",
      "r144",
      "r150",
      "r158",
      "r161",
      "r162",
      "r230",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r275",
      "r321",
      "r360",
      "r426",
      "r428",
      "r431",
      "r432",
      "r449",
      "r481",
      "r547",
      "r549",
      "r568",
      "r602",
      "r650",
      "r672",
      "r673",
      "r774",
      "r775",
      "r811",
      "r858",
      "r948"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://cik0002065779/role/EquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equipment, net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r101",
      "r102",
      "r103"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/EquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r113",
      "r566"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/EquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment, net",
        "verboseLabel": "Net carrying amount",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r493",
      "r551",
      "r566",
      "r783"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentOtherAccumulatedDepreciation",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/EquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Property, Plant and Equipment, Other, Accumulated Depreciation",
        "documentation": "Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentOtherNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentOtherNet",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/EquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equipment, net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r101",
      "r102",
      "r565"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://cik0002065779/role/EquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "cik0002065779_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_PurchaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "PurchaseMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ReceiptOfDigitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ReceiptOfDigitalAssets",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receipt of digital assets"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "RecentlyAdoptedAccountingStandardUpdatesPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently adopted accounting standard updates"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_RedesignationOfAuthorizedOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "RedesignationOfAuthorizedOrdinaryShares",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Re-designation of authorized ordinary shares"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_RedesignationOfAuthorizedOrdinarySharesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "RedesignationOfAuthorizedOrdinarySharesShares",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Re-designation of authorized ordinary shares, shares"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_RefundableDepositsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "RefundableDepositsPayable",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/RefundableDepositsPayableDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Refundable deposits payable"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_RefundableDepositsPayablePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "RefundableDepositsPayablePolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Refundable deposits payable",
        "label": "RefundableDepositsPayablePolicyTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_RefundableDepositsPayableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "RefundableDepositsPayableTextBlock",
     "presentation": [
      "http://cik0002065779/role/RefundableDepositsPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Refundable deposits payable",
        "label": "RefundableDepositsPayableTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_RefundableDepositsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "RefundableDepositsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Refundable deposits receivable"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_RefundableDepositsReceivablePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "RefundableDepositsReceivablePolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Refundable deposits receivable",
        "label": "RefundableDepositsReceivablePolicyTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_RelatedPartiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "RelatedPartiesPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related parties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r143",
      "r144",
      "r228",
      "r312",
      "r316",
      "r498",
      "r499",
      "r556",
      "r564",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r648",
      "r682",
      "r1030"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r143",
      "r144",
      "r228",
      "r498",
      "r499",
      "r500",
      "r655",
      "r656",
      "r659"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r143",
      "r144",
      "r228",
      "r312",
      "r316",
      "r498",
      "r499",
      "r556",
      "r564",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r648",
      "r682",
      "r991",
      "r1030"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://cik0002065779/role/RelatedPartyTransactions",
      "http://cik0002065779/role/RelatedPartyTransactionsDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS",
        "verboseLabel": "Related party transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r496",
      "r497",
      "r499",
      "r501",
      "r599",
      "r600",
      "r601",
      "r657",
      "r658",
      "r659",
      "r678",
      "r680"
     ]
    },
    "us-gaap_RepaymentOfNotesReceivableFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentOfNotesReceivableFromRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of promissory note",
        "documentation": "The cash inflow from a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of promissory note",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "cik0002065779_RepresentativeShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "RepresentativeShares",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Representative shares"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure",
      "http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
      "http://cik0002065779/role/Share-basedCompensationDetailsNarrative",
      "http://cik0002065779/role/ShareCapitalDetailsNarrative"
     ],
     "auth_ref": [
      "r138",
      "r145",
      "r146",
      "r272",
      "r291",
      "r500",
      "r508",
      "r554",
      "r718",
      "r719",
      "r720",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r974",
      "r976",
      "r977",
      "r978"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails",
      "http://cik0002065779/role/StatementOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r712",
      "r723",
      "r724",
      "r741",
      "r994"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "cik0002065779_ReservedCapacityArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ReservedCapacityArrangementsMember",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserved Capacity Arrangements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r80",
      "r562",
      "r585",
      "r586",
      "r597",
      "r629",
      "r783"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r147",
      "r148",
      "r149",
      "r151",
      "r158",
      "r160",
      "r162",
      "r232",
      "r233",
      "r258",
      "r274",
      "r321",
      "r349",
      "r350",
      "r357",
      "r358",
      "r359",
      "r361",
      "r425",
      "r426",
      "r436",
      "r438",
      "r439",
      "r441",
      "r447",
      "r491",
      "r492",
      "r582",
      "r584",
      "r603",
      "r1032"
     ]
    },
    "cik0002065779_RevenueFromComprehensiveDataCenterServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "RevenueFromComprehensiveDataCenterServicesMember",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from comprehensive data center services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_RevenueFromIntelligentComputingPowerServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "RevenueFromIntelligentComputingPowerServiceMember",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from intelligent computing power service [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionDeferredRevenue": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionDeferredRevenue",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue recognition",
        "documentation": "Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionDividends": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionDividends",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends",
        "documentation": "Disclosure of accounting policy for revenue recognition for dividend revenue."
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_RevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "RevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue recognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/StatementOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsDetails1",
      "http://cik0002065779/role/SegmentInformationDetails",
      "http://cik0002065779/role/SegmentInformationDetails1",
      "http://cik0002065779/role/StatementOfOperations",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "verboseLabel": "Total",
        "terseLabel": "Revenue",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r128",
      "r138",
      "r139",
      "r140",
      "r183",
      "r201",
      "r202",
      "r214",
      "r218",
      "r222",
      "r224",
      "r226",
      "r230",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r481",
      "r547",
      "r549",
      "r741",
      "r776",
      "r799",
      "r800",
      "r948"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://cik0002065779/role/StatementOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ReverseOverallotmentOptionLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ReverseOverallotmentOptionLiability",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "reverse over-allotment option liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RisksAndUncertaintiesAbstract",
     "auth_ref": []
    },
    "cik0002065779_RisksAndUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk and Uncertainties",
        "verboseLabel": "Risks and Uncertainties"
       }
      }
     },
     "auth_ref": []
    },
    "country_SG": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "SG",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SINGAPORE"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SaleOfPrivateUnitsNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Private Units, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_SaleOfPrivateUnitsNetOfIssuanceCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SaleOfPrivateUnitsNetOfIssuanceCostsShares",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Private Units, net of issuance costs, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/InitialPublicOfferingDetailsNarrative",
      "http://cik0002065779/role/PrivatePlacementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of units in initial public offering aggragate amount",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/InitialPublicOfferingDetailsNarrative",
      "http://cik0002065779/role/PrivatePlacementDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/InitialPublicOfferingDetailsNarrative",
      "http://cik0002065779/role/PrivatePlacementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of units in initial public offering",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/InitialPublicOfferingDetailsNarrative",
      "http://cik0002065779/role/PrivatePlacementDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of units per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r920",
      "r921"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://cik0002065779/role/AccountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts receivable",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r56"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of account payable",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ScheduleOfAccountsReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ScheduleOfAccountsReceivableTextBlock",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of account receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://cik0002065779/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r363",
      "r364",
      "r365",
      "r366",
      "r372",
      "r373",
      "r374",
      "r375",
      "r381",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r417",
      "r418",
      "r419",
      "r423",
      "r765",
      "r773",
      "r970",
      "r971",
      "r972"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure",
      "http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
      "http://cik0002065779/role/ShareCapitalDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "cik0002065779_ScheduleOfConcentrationOfCustomersTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ScheduleOfConcentrationOfCustomersTableTextBlock",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Concentration of customers"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ScheduleOfConcentrationOfSuppliersTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ScheduleOfConcentrationOfSuppliersTableTextBlock",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Concentration of suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock",
     "presentation": [
      "http://cik0002065779/role/Share-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share-based compensation expenses",
        "documentation": "Tabular disclosure of an equity-based arrangement (such as stock or unit options and stock or unit awards) with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain equity-based awards at future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares or units issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r82"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of deferred tax assets liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareTables",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of earning per share basic and diluted",
        "label": "Schedule of basic share and diluted",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of effective tax rate reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r764",
      "r962"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value measurement",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r980",
      "r981"
     ]
    },
    "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, off-Balance-Sheet Risk [Table]",
        "documentation": "Disclosure of information about fair value of financial asset and liability not recognized in financial statement because of failure to meet criterion for recognition."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r553",
      "r989"
     ]
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operation, Product Information, Concentration of Risk [Table]",
        "documentation": "Disclosure of information about concentration risk of product within nature of operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r143",
      "r144",
      "r498",
      "r499",
      "r500",
      "r655",
      "r656",
      "r659"
     ]
    },
    "cik0002065779_ScheduleOfRevenueRecognitionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ScheduleOfRevenueRecognitionTableTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenue recognition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of geographic information",
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r57"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of segment information",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r32",
      "r33",
      "r34",
      "r36",
      "r78",
      "r79",
      "r80",
      "r115",
      "r116",
      "r117",
      "r185",
      "r289",
      "r290",
      "r291",
      "r293",
      "r296",
      "r301",
      "r303",
      "r435",
      "r593",
      "r594",
      "r595",
      "r596",
      "r750",
      "r845",
      "r906",
      "r907"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails1"
     ],
     "auth_ref": [
      "r191",
      "r224",
      "r225",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r547",
      "r548",
      "r549",
      "r550",
      "r617",
      "r618",
      "r619",
      "r683",
      "r684",
      "r685",
      "r689",
      "r696",
      "r697",
      "r698",
      "r699",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r715",
      "r729",
      "r751",
      "r753",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r796",
      "r804",
      "r999",
      "r1000",
      "r1001",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://cik0002065779/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r183",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r204",
      "r205",
      "r206",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r226",
      "r736",
      "r739",
      "r740",
      "r741",
      "r743",
      "r745",
      "r746"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r221",
      "r224",
      "r737",
      "r738",
      "r744"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/StatementOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/StatementOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Selling and marketing expenses",
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingAndMarketingExpenseAbstract",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Selling and marketing expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_SellingAndMarketingExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SellingAndMarketingExpensesMember",
     "presentation": [
      "http://cik0002065779/role/Share-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and marketing expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_SellingAndMarketingExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SellingAndMarketingExpensesPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and marketing expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/Share-basedCompensationDetails",
      "http://cik0002065779/role/Share-basedCompensationDetailsNarrative",
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation",
        "verboseLabel": "Total",
        "terseLabel": "Share-based compensation expenses",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "cik0002065779_ShareBasedCompensation1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ShareBasedCompensation1",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "\u2013 Share-based compensation",
        "label": "ShareBasedCompensation1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://cik0002065779/role/Share-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term (years)",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails1",
      "http://cik0002065779/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "verboseLabel": "Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails1",
      "http://cik0002065779/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "verboseLabel": "Expected warrant implied volatility based on warrants from comparable SPAC securities",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails1",
      "http://cik0002065779/role/FairValueMeasurementsDetails2",
      "http://cik0002065779/role/Share-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "verboseLabel": "Annual risk-free rate (term-matched)",
        "terseLabel": "Risk free rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "cik0002065779_ShareBasedCompensations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ShareBasedCompensations",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "\u2013 Share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://cik0002065779/role/BusinessCombinationDetailsNarrative",
      "http://cik0002065779/role/FairValueMeasurementsDetails2",
      "http://cik0002065779/role/InitialPublicOfferingDetailsNarrative",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "verboseLabel": "Share price",
        "terseLabel": "Estimated share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_ShareRedemptionTriggerPrices": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ShareRedemptionTriggerPrices",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share redemption trigger prices"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected terms (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://cik0002065779/role/Share-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r955",
      "r958"
     ]
    },
    "cik0002065779_SharesDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SharesDescription",
     "presentation": [
      "http://cik0002065779/role/Share-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://cik0002065779/role/ShareCapitalDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_SharesSubjectToRedemption": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SharesSubjectToRedemption",
     "presentation": [
      "http://cik0002065779/role/BalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares subject to redemption"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://cik0002065779/role/SignificantAccountingPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies",
        "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "terseLabel": "Summary of significant accounting policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137"
     ]
    },
    "cik0002065779_SimpleAgreementsForFutureEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SimpleAgreementsForFutureEquity",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Simple agreements for future equity",
        "periodStartLabel": "Balance at beginning",
        "periodEndLabel": "Balance at ending"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_SimpleAgreementsForFutureEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SimpleAgreementsForFutureEquityMember",
     "presentation": [
      "http://cik0002065779/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Simple agreements for future equity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_SimpleAgreementsForFutureEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SimpleAgreementsForFutureEquityPolicyTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Simple agreements for future equity",
        "label": "SimpleAgreementsForFutureEquityPolicyTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_SimpleAgreementsForFutureEquityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SimpleAgreementsForFutureEquityTextBlock",
     "presentation": [
      "http://cik0002065779/role/SimpleAgreementsForFutureEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Simple agreements for future equity",
        "label": "SimpleAgreementsForFutureEquityTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "cik0002065779_SponsorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SponsorMember",
     "presentation": [
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_StaffCostsEmployeeBenefitsAndOfficeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "StaffCostsEmployeeBenefitsAndOfficeExpenses",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "\u2013 Staff costs, employee benefits and office expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_StaffCostsEmployeeBenefitsAndOthers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "StaffCostsEmployeeBenefitsAndOthers",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "\u2013 Staff costs, employee benefits and Others"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/StatementOfOperations",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r115",
      "r116",
      "r117",
      "r138",
      "r140",
      "r167",
      "r168",
      "r175",
      "r177",
      "r185",
      "r186",
      "r230",
      "r262",
      "r264",
      "r265",
      "r266",
      "r269",
      "r270",
      "r276",
      "r277",
      "r279",
      "r280",
      "r282",
      "r286",
      "r289",
      "r290",
      "r293",
      "r296",
      "r303",
      "r481",
      "r593",
      "r594",
      "r595",
      "r596",
      "r603",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r616",
      "r628",
      "r651",
      "r674",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r845",
      "r907",
      "r908",
      "r915"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r49",
      "r53",
      "r54",
      "r106",
      "r107",
      "r108",
      "r125",
      "r126",
      "r127",
      "r147",
      "r148",
      "r149",
      "r151",
      "r158",
      "r160",
      "r162",
      "r184",
      "r232",
      "r233",
      "r258",
      "r274",
      "r305",
      "r321",
      "r349",
      "r350",
      "r357",
      "r358",
      "r359",
      "r361",
      "r425",
      "r426",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r491",
      "r492",
      "r494",
      "r570",
      "r582",
      "r583",
      "r584",
      "r603",
      "r674"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r191",
      "r224",
      "r225",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r547",
      "r548",
      "r549",
      "r550",
      "r617",
      "r618",
      "r619",
      "r683",
      "r684",
      "r685",
      "r689",
      "r696",
      "r697",
      "r698",
      "r699",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r715",
      "r729",
      "r751",
      "r753",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r796",
      "r804",
      "r999",
      "r1000",
      "r1001",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://cik0002065779/role/AccountsReceivable",
      "http://cik0002065779/role/AccountsReceivableDetails",
      "http://cik0002065779/role/AccountsReceivableDetailsNarrative",
      "http://cik0002065779/role/AccountsReceivableTables",
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShare",
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails",
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareTables",
      "http://cik0002065779/role/CommitmentsAndContingencies",
      "http://cik0002065779/role/CommitmentsAndContingenciesDisclosure",
      "http://cik0002065779/role/ConcentrationAndRisk",
      "http://cik0002065779/role/ConcentrationAndRiskTables",
      "http://cik0002065779/role/CryptoAssets",
      "http://cik0002065779/role/CryptoAssetsDetailsNarrative",
      "http://cik0002065779/role/CryptoAssetsTables",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperations",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/EquipmentNet",
      "http://cik0002065779/role/EquipmentNetDetails",
      "http://cik0002065779/role/EquipmentNetDetailsNarrative",
      "http://cik0002065779/role/EquipmentNetTables",
      "http://cik0002065779/role/FairValueMeasurements",
      "http://cik0002065779/role/FairValueMeasurementsDetails1",
      "http://cik0002065779/role/FairValueMeasurementsDisclosure",
      "http://cik0002065779/role/FairValueMeasurementsTables",
      "http://cik0002065779/role/FairValueMeasurementsTablesDisclosure",
      "http://cik0002065779/role/IncomeTaxes",
      "http://cik0002065779/role/IncomeTaxesDetails",
      "http://cik0002065779/role/IncomeTaxesDetails1",
      "http://cik0002065779/role/IncomeTaxesDetails2",
      "http://cik0002065779/role/IncomeTaxesTables",
      "http://cik0002065779/role/InitialPublicOffering",
      "http://cik0002065779/role/OrganizationAndPrincipalActivities",
      "http://cik0002065779/role/OtherReceivables",
      "http://cik0002065779/role/OtherReceivablesDetailsNarrative",
      "http://cik0002065779/role/PrivatePlacement",
      "http://cik0002065779/role/RefundableDepositsPayable",
      "http://cik0002065779/role/RefundableDepositsPayableDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactions",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrativeDisclosure",
      "http://cik0002065779/role/RelatedPartyTransactionsDisclosure",
      "http://cik0002065779/role/SegmentInformation",
      "http://cik0002065779/role/SegmentInformationDetails",
      "http://cik0002065779/role/SegmentInformationDetails1",
      "http://cik0002065779/role/Share-basedCompensation",
      "http://cik0002065779/role/Share-basedCompensationDetails",
      "http://cik0002065779/role/Share-basedCompensationDetailsNarrative",
      "http://cik0002065779/role/Share-basedCompensationTables",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquity",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetails",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityTables",
      "http://cik0002065779/role/StatementOfCashFlows",
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit",
      "http://cik0002065779/role/StatementOfOperations",
      "http://cik0002065779/role/StockholdersEquity",
      "http://cik0002065779/role/SubsequentEvents",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDisclosure",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r184",
      "r276",
      "r277",
      "r279",
      "r282",
      "r492",
      "r510",
      "r591",
      "r604",
      "r616",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r628",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r639",
      "r640",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r653",
      "r654",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r674",
      "r725",
      "r727",
      "r805",
      "r1030"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://cik0002065779/role/AccountsReceivable",
      "http://cik0002065779/role/AccountsReceivableDetails",
      "http://cik0002065779/role/AccountsReceivableDetailsNarrative",
      "http://cik0002065779/role/AccountsReceivableTables",
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/BalanceSheetParenthetical",
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShare",
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails",
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareTables",
      "http://cik0002065779/role/CommitmentsAndContingencies",
      "http://cik0002065779/role/CommitmentsAndContingenciesDisclosure",
      "http://cik0002065779/role/ConcentrationAndRisk",
      "http://cik0002065779/role/ConcentrationAndRiskTables",
      "http://cik0002065779/role/CryptoAssets",
      "http://cik0002065779/role/CryptoAssetsDetailsNarrative",
      "http://cik0002065779/role/CryptoAssetsTables",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperations",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/EquipmentNet",
      "http://cik0002065779/role/EquipmentNetDetails",
      "http://cik0002065779/role/EquipmentNetDetailsNarrative",
      "http://cik0002065779/role/EquipmentNetTables",
      "http://cik0002065779/role/FairValueMeasurements",
      "http://cik0002065779/role/FairValueMeasurementsDetails1",
      "http://cik0002065779/role/FairValueMeasurementsDisclosure",
      "http://cik0002065779/role/FairValueMeasurementsTables",
      "http://cik0002065779/role/FairValueMeasurementsTablesDisclosure",
      "http://cik0002065779/role/IncomeTaxes",
      "http://cik0002065779/role/IncomeTaxesDetails",
      "http://cik0002065779/role/IncomeTaxesDetails1",
      "http://cik0002065779/role/IncomeTaxesDetails2",
      "http://cik0002065779/role/IncomeTaxesTables",
      "http://cik0002065779/role/InitialPublicOffering",
      "http://cik0002065779/role/OrganizationAndPrincipalActivities",
      "http://cik0002065779/role/OtherReceivables",
      "http://cik0002065779/role/OtherReceivablesDetailsNarrative",
      "http://cik0002065779/role/PrivatePlacement",
      "http://cik0002065779/role/RefundableDepositsPayable",
      "http://cik0002065779/role/RefundableDepositsPayableDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactions",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrativeDisclosure",
      "http://cik0002065779/role/RelatedPartyTransactionsDisclosure",
      "http://cik0002065779/role/SegmentInformation",
      "http://cik0002065779/role/SegmentInformationDetails",
      "http://cik0002065779/role/SegmentInformationDetails1",
      "http://cik0002065779/role/Share-basedCompensation",
      "http://cik0002065779/role/Share-basedCompensationDetails",
      "http://cik0002065779/role/Share-basedCompensationDetailsNarrative",
      "http://cik0002065779/role/Share-basedCompensationTables",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquity",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetails",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative",
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityTables",
      "http://cik0002065779/role/StatementOfCashFlows",
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit",
      "http://cik0002065779/role/StatementOfOperations",
      "http://cik0002065779/role/StockholdersEquity",
      "http://cik0002065779/role/SubsequentEvents",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDisclosure",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r184",
      "r228",
      "r276",
      "r277",
      "r279",
      "r282",
      "r492",
      "r510",
      "r591",
      "r604",
      "r616",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r628",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r639",
      "r640",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r653",
      "r654",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r674",
      "r725",
      "r727",
      "r805",
      "r1030"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued to initial shareholder for subscription fee",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://cik0002065779/role/BusinessCombinationDetailsNarrative",
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrativeDisclosure",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cik0002065779/role/ShareCapitalDetailsNarrative",
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New shares issued",
        "verboseLabel": "Common stock issued",
        "terseLabel": "Number of share issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r48",
      "r49",
      "r80",
      "r593",
      "r674",
      "r691"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeiture shares",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r48",
      "r49",
      "r80"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/ShareCapitalDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate purchase price",
        "verboseLabel": "Number of share issued, value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r48",
      "r49",
      "r80",
      "r603",
      "r674",
      "r691",
      "r811"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Shareholders\u2019 Deficit",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r53",
      "r54",
      "r71",
      "r630",
      "r649",
      "r675",
      "r676",
      "r783",
      "r812",
      "r906",
      "r908",
      "r909",
      "r929",
      "r990",
      "r1032"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://cik0002065779/role/ShareCapital",
      "http://cik0002065779/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital",
        "verboseLabel": "STOCKHOLDER\u2019S EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r288",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r305",
      "r435",
      "r446",
      "r677",
      "r679",
      "r695"
     ]
    },
    "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteSubscriptionsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Subscription receivable",
        "label": "Stockholders' Equity Note, Subscriptions Receivable",
        "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r48",
      "r49",
      "r53",
      "r681"
     ]
    },
    "cik0002065779_SubscriptionReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SubscriptionReceivableMember",
     "presentation": [
      "http://cik0002065779/role/StatementOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Receivable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r503"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r503"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://cik0002065779/role/SimpleAgreementsForFutureEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r503"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://cik0002065779/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r504"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cik0002065779/role/InitialPublicOfferingDetailsNarrative",
      "http://cik0002065779/role/PrivatePlacementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative",
      "http://cik0002065779/role/InitialPublicOfferingDetailsNarrative",
      "http://cik0002065779/role/PrivatePlacementDetailsNarrative",
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cik0002065779/role/InitialPublicOfferingDetailsNarrative",
      "http://cik0002065779/role/PrivatePlacementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of valuation allowance",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://cik0002065779/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplementary Information:"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_SupplierAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SupplierAMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_SupplierBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SupplierBMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails2",
      "http://cik0002065779/role/ConcentrationAndRiskDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_SupplierCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SupplierCMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails2",
      "http://cik0002065779/role/ConcentrationAndRiskDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_SupplierDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SupplierDMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails2",
      "http://cik0002065779/role/ConcentrationAndRiskDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier D [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_SupplierEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SupplierEMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails2",
      "http://cik0002065779/role/ConcentrationAndRiskDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier E [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_SupplierFMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SupplierFMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier F [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_SupplierGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "SupplierGMember",
     "presentation": [
      "http://cik0002065779/role/ConcentrationAndRiskDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier G [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares subject to possible redemption",
        "documentation": "Value of accretion of temporary equity to its redemption value during the period."
       }
      }
     },
     "auth_ref": [
      "r950",
      "r952",
      "r953",
      "r954"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A ordinary shares subject to possible redemption, $0.0001 par value; 500,000,000 shares authorized; 28,000,000 shares issued and outstanding, at redemption value of $10.26 on March\u00a031, 2026 and $10.17 on December\u00a031, 2025, respectively",
        "verboseLabel": "Ordinary shares subject to redemption",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r264",
      "r265",
      "r266",
      "r269",
      "r270",
      "r276",
      "r277",
      "r279",
      "r283",
      "r322",
      "r323",
      "r561"
     ]
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://cik0002065779/role/BalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares subject to possible redemption issued",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_TemporaryEquityRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityRedemptionPricePerShare",
     "presentation": [
      "http://cik0002065779/role/BalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares subject to possible redemption , redemption price per share",
        "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://cik0002065779/role/BalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares subject to possible redemption issued",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r279"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://cik0002065779/role/BalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares subject to possible redemption issued",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r279"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://cik0002065779/role/BalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares subject to possible redemption outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r279"
     ]
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityTableTextBlock",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of earning per share basic and diluted",
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954"
     ]
    },
    "us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityValueExcludingAdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Ordinary shares subject to possible redemption, beginning",
        "periodEndLabel": "Ordinary shares subject to possible redemption, ending",
        "label": "Temporary Equity, Par Value",
        "documentation": "Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "cik0002065779_ThirdPartyServiceProviderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "ThirdPartyServiceProviderMember",
     "presentation": [
      "http://cik0002065779/role/Share-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third party service provider [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "TotalOperatingActivitiesSettledInDigitalAssetsAndUsdc",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total operating activities settled in digital assets and USDC"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_TransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "TransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransactionDomain",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r974",
      "r976",
      "r977",
      "r978"
     ]
    },
    "us-gaap_TransactionTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransactionTypeAxis",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Type [Axis]",
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r975",
      "r976",
      "r977",
      "r978"
     ]
    },
    "cik0002065779_U.s.DollarCoin": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "U.s.DollarCoin",
     "crdr": "debit",
     "calculation": {
      "http://cik0002065779/role/BalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cik0002065779/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. Dollar Coin"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://cik0002065779/role/SegmentInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_USDCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "USDCMember",
     "presentation": [
      "http://cik0002065779/role/CryptoAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "USDC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cik0002065779_UnderwriterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "UnderwriterMember",
     "presentation": [
      "http://cik0002065779/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriter [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r339",
      "r763"
     ]
    },
    "cik0002065779_UnsecuredPromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "UnsecuredPromissoryNoteMember",
     "presentation": [
      "http://cik0002065779/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured promissory note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://cik0002065779/role/SignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "verboseLabel": "Use of estimates and assumptions",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r188",
      "r193",
      "r194",
      "r195",
      "r547",
      "r549",
      "r733"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "cik0002065779_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "WarrantsMember",
     "presentation": [
      "http://cik0002065779/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageLimitedPartnershipUnitsOutstandingDiluted",
     "presentation": [
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average aggregate shares",
        "documentation": "Weighted average number of limited partnership units outstanding determined by relating the portion of time within a reporting period that limited partnership units have been outstanding to the total time in that period. Used in the calculation of diluted net income or loss per limited partnership unit."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails",
      "http://cik0002065779/role/StatementOfOperations",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of per ordinary shares Diluted",
        "verboseLabel": "Weighted average shares of Class B ordinary shares outstanding, diluted",
        "terseLabel": "Weighted-average ordinary shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r177"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://cik0002065779/role/StatementOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of per ordinary shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://cik0002065779/role/BasicAndDilutedNetLossPerShareDetails",
      "http://cik0002065779/role/StatementOfOperations",
      "http://cik0002065779/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of per ordinary shares Basic",
        "verboseLabel": "Weighted average shares of Class B ordinary shares outstanding, basic",
        "terseLabel": "Weighted-average ordinary shares outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r177"
     ]
    },
    "cik0002065779_WorkingCapitalDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cik0002065779/20260331",
     "localname": "WorkingCapitalDeficit",
     "crdr": "credit",
     "presentation": [
      "http://cik0002065779/role/DescriptionOfOrganizationBusinessOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital deficit"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cik0002065779/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    }
   }
  },
  "dboralarcacq_ex107.htm": {
   "dts": {
    "inline": {
     "local": [
      "dboralarcacq_ex107.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 32,
   "keyCustom": 0,
   "axisStandard": 2,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/ffd/2025": 2,
    "http://xbrl.sec.gov/dei/2025": 1
   },
   "contextCount": 8,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 67,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "report": {
    "R96": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "96",
     "firstAnchor": {
      "contextRef": "AsOf2026-06-10",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-06-10",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_ex107.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "97",
     "firstAnchor": {
      "contextRef": "From2026-06-102026-06-10_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-06-102026-06-10_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_ex107.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable",
     "longName": "995212 - Document - Offsets",
     "shortName": "Offsets",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "98",
     "firstAnchor": {
      "contextRef": "From2026-06-102026-06-10_14993234",
      "name": "ffd:OffsetClmdInd",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ffd:Rule457bOffsetFlg",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-06-102026-06-10_14993234",
      "name": "ffd:OffsetClmdInd",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ffd:Rule457bOffsetFlg",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_ex107.htm",
      "first": true,
      "unique": true
     }
    },
    "R99": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "99",
     "firstAnchor": {
      "contextRef": "AsOf2026-06-10",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-06-10",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dboralarcacq_ex107.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r839"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r839"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r839"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r839"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r839"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r839"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r839"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r839"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r836",
      "r839"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r839"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r839"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "SubTopic": "30",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480034/205-30-25-6"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "850",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482943/710-10-55-8"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2A"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310/tableOfContent"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/326/tableOfContent"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483081/340-30-45-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483054/340-30-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476163/350-60-45-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-4"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-6"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-6"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.FF.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479772/718-30-S55-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-10/tableOfContent"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-4"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-5"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-7"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-20/tableOfContent"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-3"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-30/tableOfContent"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-3"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479326/805-40-45-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-3A"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-29"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-29"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-38"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "45",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-45"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "46",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-46"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476163/350-60-45-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-4"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-6"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-6"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
